FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Ma, CH
   Lv, Q
   Cao, Y
   Wang, Q
   Zhou, XK
   Ye, BW
   Yi, CQ
AF Ma, C.  H.
   Lv, Q.
   Cao, Y.
   Wang, Q.
   Zhou, X.  K.
   Ye, B.  W.
   Yi, C.  Q.
TI Genes relevant with osteoarthritis by comparison gene expression
   profiles of synovial membrane of osteoarthritis patients at different
   stages
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteoarthritis; Gene therapy; Differentially expressed genes
ID RHEUMATOID ARTHRITIS; KNEE OSTEOARTHRITIS; ARTICULAR CARTILAGE; BONE;
   PROGRESSION; MICROARRAY; OSTEOCLASTOGENESIS; OSTEOIMMUNOLOGY;
   IDENTIFICATION; POLYMORPHISM
AB BACKGROUND: This study aimed to identify biological markers about osteoarthritis (OA) which is a polygenic disease by investigating the gene expression profiles of the synovium samples from early stage and end stage OA patients for the diagnosis and treatment of OA.
   METHODS: The gene expression profile of GSE32317 was downloaded from Gene Expression Omnibus (GEO) database, including 10 samples from early stage OA patients and 9 samples from end stage OA patients. The differentially expressed genes (DEGs) were identified by Significance Analysis of Microarrays. The co expression network of DEGs was constructed by Pearson correlation test. Then, modules in the constructed co expression network were selected by MCODE Plugin. What's more, EASE (Expression Analysis Systematic Explorer) was used to define the significant functions and pathways in the identified modules.
   RESULTS: Total 419 DEGs were identified, among which 112 were up regulated and 307 down regulated. We selected 7 statistically significant modules with gene number above 10 and phenotypic correlation test of modules showed that all the modules had significant correlation with OA (p < 0.05). The genes of module 1, module 2 and module 7 were significantly related to immune system functions, protein glycosylation functions, bone, chondrocytes and cartilage functions, respectively. The most significant pathway in module 3 and module 5 was Wnt signal pathway, and in module 4 was Toll like receptor signal pathway.
   CONCLUSIONS: DEGs related to immune response, cartilage development, protein glycosylation, muscle development, and DEGs participated in the Wnt signaling pathway and Toll like receptor (TLR) signaling pathway might be the potential target genes for the OA treatment.
C1 [Ma, C.  H.; Cao, Y.; Wang, Q.; Zhou, X.  K.; Ye, B.  W.; Yi, C.  Q.] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Orthoped Surg, Shanghai 200030, Peoples R China.
   Tongji Univ, Tong Ji Hosp, Dept Radiol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Tongji University
RP Yi, CQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Orthoped Surg, Shanghai 200030, Peoples R China.
EM chengqingyichqy@hotmail.com
RI LI, LI QING/GRR 8855 2022; zhou, xiaokun/HHZ 4705 2022
FU National Natural Science Foundation of China [30700853]
FX This study was supported by National Natural Science Foundation of China
   (30700853).
CR Allocco DJ, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471 2105 5 18
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Blom AB, 2009, ARTHRITIS RHEUM, V60, P501, DOI 10.1002/art.24247
   Chung EY, 2012, J CLIN INVEST, V122, P2257, DOI 10.1172/JCI45851
   Dell'Accio F, 2008, ARTHRITIS RHEUM US, V58, P1410, DOI 10.1002/art.23444
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gillam MH, 2013, OSTEOARTHR CARTILAGE, V21, P405, DOI 10.1016/j.joca.2012.12.008
   Goldring MB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2592
   Gravallese EM, 2001, ARTHRITIS RES, V3, P6, DOI 10.1186/ar134
   Hopwood B, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2301
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004 1343
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Kusaoi M, 2012, THER APHER DIAL, V16, P456, DOI 10.1111/j.1744 9987.2012.01111.x
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Luo XY, 2012, LUPUS, V21, P53, DOI 10.1177/0961203311422709
   Matsuhashi T, 2008, OSTEOARTHR CARTILAGE, V16, P772, DOI 10.1016/j.joca.2007.11.004
   Pelletier JP, 2013, ANN RHEUM DIS, V72, P250, DOI 10.1136/annrheumdis 2012 201710
   Ritchlin C. T., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P276
   Roos EM, 2011, NAT REV RHEUMATOL, V7, P57, DOI 10.1038/nrrheum.2010.195
   Segal NA, 2009, ARTHRIT RHEUM ARTHR, V61, P1210, DOI 10.1002/art.24541
   Seto H, 2004, J CLIN INVEST, V113, P718, DOI 10.1172/JCI200419899
   Sharan R, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100129
   Slemenda C, 1998, ARTHRITIS RHEUM, V41, P1951, DOI 10.1002/1529 0131(199811)41:11<1951::AID ART9>3.0.CO;2 9
   Suurmond J, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3466
   Takahashi D, 2009, ARTHRITIS RHEUM US, V60, P2372, DOI 10.1002/art.24718
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Townsend MJ, 2010, IMMUNOL REV, V237, P264, DOI 10.1111/j.1600 065X.2010.00945.x
   Tsuneyoshi Y, 2012, SCAND J RHEUMATOL, V41, P132, DOI 10.3109/03009742.2011.605391
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Urita A, 2011, ARTHRITIS RHEUM US, V63, P3428, DOI 10.1002/art.30584
   Vandooren B, 2008, ARTHRITIS RHEUM US, V58, P718, DOI 10.1002/art.23290
   Velasco J, 2010, OSTEOPOROSIS INT, V21, P109, DOI 10.1007/s00198 009 0931 0
   Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543
   Wang XB, 2004, OSTEOARTHR CARTILAGE, V12, P963, DOI 10.1016/j.joca.2004.08.008
   Yang HY, 2013, J ORTHOP RES, V31, P680, DOI 10.1002/jor.22291
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang B, 2013, EUR REV MED PHARMACO, V17, P2097
   Zhang Q, 2014, EUR REV MED PHARMACO, V18, P179
   Zhao C, 2008, ONCOGENE, V27, P63, DOI 10.1038/sj.onc.1210637
NR 42
TC 23
Z9 24
U1 0
U2 9
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD FEB
PY 2014
VL 18
IS 3
BP 431
EP 439
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AP3HZ
UT WOS:000341967500021
PM 24563447
DA 2025 08 17
ER

PT J
AU Fang, HM
   Zhou, LJ
   Shen, LR
   Zhou, HY
   Fang, YZ
   Fan, H
AF Fang, Hongmei
   Zhou, Lijuan
   Shen, Lirong
   Zhou, Haiyan
   Fang, Yingzhi
   Fan, Hui
TI Effects of icariin on the proliferation and differentiation of MC3T3 E1
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Osteoporosis; icariin; MC3T3 E1 cells; proliferation; differentiation;
   mineralization
ID POSTMENOPAUSAL WOMEN; BONE RESORPTION; STEM CELLS; IN VITRO;
   OSTEOPOROSIS; OSTEOPROTEGERIN; OSTEOBLAST; PREVENTION; PROMOTES; DENSITY
AB Icariin (ICA), the main active flavonoid glucoside isolated from Herbaepimedii (HEF), is an anabolic agent in bone that has been reported to prevent bone loss in ovariectomized rats and postmenopausal women. However, the understanding of its mechanism of this anabolic action of ICA in osteogenesis remains incomplete. Here, we found that Icariin could promote MC3T3 E1 osteoblastic cell proliferation, associated with increased protein levels of the proliferation markergene cyclin D1 and, CDK4. Icariin also enhanced MC3T3 E1 cell differentiation and mineralization demonstrated by increased the expression of differentiation markers, alkaline phosphatase (ALP) and collagen type I (Col I), osteocalcin (OCN) and bone nodule formation via Alizarin red S staining. In addition, the ratio of OPG/RANKL also could be enhanced by ICA. Therefore, in the present study, we investigate the effects of ICA on osteoblast differentiation from at least three perspectives, so as to obtain an understanding of its mechanism of action and elucidate the molecular mechanisms of this drug, which might provide an insight into the rationality and in depth theoretical basis for the clinical application of ICA in preventing osteoporosis.
C1 [Fang, Hongmei; Zhou, Lijuan; Shen, Lirong; Fan, Hui] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Pharm, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China.
   [Zhou, Haiyan] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Anesthesiolongy, Hangzhou, Zhejiang, Peoples R China.
   [Fang, Yingzhi] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Clin Trial Inst, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University
RP Fan, H (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Pharm, 3 East Qingchun Rd, Hangzhou 310016, Zhejiang, Peoples R China.
EM huifang569lp@126.com
CR AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Bardyn T, 2009, INT J ORAL MAX IMPL, V24, P1006
   Cao H, 2012, INT J MOL MED, V29, P435, DOI 10.3892/ijmm.2011.845
   Compston J, 2010, RADIOL CLIN N AM, V48, P477, DOI 10.1016/j.rcl.2010.02.010
   Dell'Agli M, 2008, J NAT PROD, V71, P1513, DOI 10.1021/np800049y
   Fan JJ, 2011, MOLECULES, V16, P10123, DOI 10.3390/molecules161210123
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   HORIGUCHI Y, 1991, INFECT IMMUN, V59, P1112, DOI 10.1128/IAI.59.3.1112 1116.1991
   Jia M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/364604
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Li B, 2014, INT IMMUNOPHARMACOL, V19, P381, DOI 10.1016/j.intimp.2014.01.009
   Li SG, 2010, CANCER LETT, V298, P222, DOI 10.1016/j.canlet.2010.07.009
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   Lindsay R, 2004, ENDOCRINE, V24, P223, DOI 10.1385/ENDO:24:3:223
   Lucinda LMF, 2010, FITOTERAPIA, V81, P982, DOI 10.1016/j.fitote.2010.06.014
   Ma XN, 2013, PLANTA MED, V79, P1501, DOI 10.1055/s 0033 1350802
   Sanders S, 2013, SOUTH MED J, V106, P698, DOI 10.1097/SMJ.0b013e3182a0df8b
   Wang JP, 2007, J PHARMACOL SCI, V104, P82, DOI 10.1254/jphs.FP0061549
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Yang LJ, 2013, J ETHNOPHARMACOL, V145, P715, DOI 10.1016/j.jep.2012.11.031
   Yin YX, 2007, CHINESE MED J PEKING, V120, P204, DOI 10.1097/00029330 200702010 00006
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhang ZB, 2006, ASIAN J ANDROL, V8, P601, DOI 10.1111/j.1745 7262.2006.00197.x
   Zheng D, 2012, BONE, V51, P85, DOI 10.1016/j.bone.2012.04.006
   Zhou LM, 2013, EXP CELL RES, V319, P1505, DOI 10.1016/j.yexcr.2013.03.017
NR 26
TC 2
Z9 2
U1 0
U2 10
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2017
VL 10
IS 10
BP 14876
EP 14882
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FL5QD
UT WOS:000414299700091
DA 2025 08 17
ER

PT J
AU Wang, K
   Xu, C
   Xie, X
   Jing, Y
   Chen, PJ
   Yadav, S
   Wang, Z
   Taylor, RW
   Wang, J
   Feng, JQ
AF Wang, K.
   Xu, C.
   Xie, X.
   Jing, Y.
   Chen, P. J.
   Yadav, S.
   Wang, Z.
   Taylor, R. W.
   Wang, J.
   Feng, J. Q.
TI Axin2+PDL Cells Directly Contribute to New Alveolar Bone Formation in
   Response to Orthodontic Tension Force
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE periodontal ligament; Wnt signaling pathway; osteogenesis; cellular
   mechanotransduction; orthodontics; cell lineage
ID LIGAMENT STEM CELLS; PERIODONTAL LIGAMENT; OSTEOGENIC DIFFERENTIATION;
   TOOTH MOVEMENT; TRANSCRIPTION; EXPRESSION; PERIOSTIN; YAP
AB Wnt beta catenin signaling plays a key role in orthodontic tooth movement (OTM), a common clinical practice for malocclusion correction. However, its targeted periodontal ligament (PDL) progenitor cells remain largely unclear. In this study, we first showed a synchronized increase in Wnt beta catenin levels and Axin2(+) PDL progenitor cell numbers during OTM using immunostaining of beta catenin in wild type mice and X gal staining in the Axin2 LacZ knock in line. Next, we demonstrated time dependent increases in Axin2(+) PDL progenitors and their progeny cell numbers within PDL and alveolar bones during OTM using a one time tamoxifen induced Axin2 tracing line (Axin2(CreERT2/+); R26R(tdTomato/+)). Coimmunostaining images displayed both early and late bone markers (such as RUNX2 and DMP1) in the Axin2(Lin) PDL cells. Conversely, ablation of Axin2(+) PDL cells via one time tamoxifen induced diphtheria toxin subunit A (DTA) led to a drastic decrease in osteogenic activity (as reflected by alkaline phosphatase) in PDL and alveolar bone. There was also a decrease in new bone mass and a significant reduction in the mineral apposition rate on both the control side (to a moderate degree) and the OTM side (to a severe degree). Thus, we conclude that the Axin2(+) PDL cells (the Wnt targeted key cells) are highly sensitive to orthodontic tension force and play a critical role in OTM induced PDL expansion and alveolar bone formation. Future drug development targeting the Axin2(+) PDL progenitor cells may accelerate alveolar bone formation during orthodontic treatment.
C1 [Wang, K.; Xu, C.; Xie, X.; Wang, Z.; Wang, J.; Feng, J. Q.] Texas A&M Univ, Dept Biomed Sci, Coll Dent, 3302 Gaston Ave, Dallas, TX 75246 USA.
   [Wang, K.; Chen, P. J.; Yadav, S.] Univ Connecticut, Div Orthodont, Hlth Ctr, Farmington, CT USA.
   [Xu, C.; Xie, X.; Wang, J.] Sichuan Univ, West China Hosp Stomatol, Dept Periodont, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis, 14,Sect 3,South Renmin Rd, Chengdu 610041, Peoples R China.
   [Jing, Y.; Taylor, R. W.] Texas A&M Univ, Dept Orthodont, Coll Dent, Dallas, TX 75246 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; University of Connecticut; Sichuan
   University; Texas A&M University System
RP Wang, J; Feng, JQ (通讯作者)，Texas A&M Univ, Dept Biomed Sci, Coll Dent, 3302 Gaston Ave, Dallas, TX 75246 USA.; Wang, J (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Periodont, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis, 14,Sect 3,South Renmin Rd, Chengdu 610041, Peoples R China.
EM junwang@scu.edu.cn; jfeng@tamu.edu
RI ; jing, yan/KIJ 2322 2024
OI CHEN, PO JUNG/0000 0002 8875 432X; Wang, Jun/0000 0002 5314 8442; FENG,
   JIAN/0000 0003 1508 5038; Wang, Ke/0000 0002 1866 0678
FU US National Institutes of Health [DE030643, DE025659]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This study was
   supported by US National Institutes of Health grants DE030643 and
   DE025659 to J.Q. Feng.
CR Bowman AN, 2013, P NATL ACAD SCI USA, V110, P7324, DOI 10.1073/pnas.1305411110
   Chang ML, 2017, J CELL PHYSIOL, V232, P3762, DOI 10.1002/jcp.25856
   Feng F, 2010, ORAL DIS, V16, P20, DOI 10.1111/j.1601 0825.2009.01593.x
   Feng L, 2016, J DENT RES, V95, P1049, DOI 10.1177/0022034516648604
   Fu HD, 2016, J MOL HISTOL, V47, P455, DOI 10.1007/s10735 016 9687 y
   Huelter Hassler D, 2017, EUR J ORTHODONT, V39, P251, DOI 10.1093/ejo/cjx012
   Xu HY, 2017, MOL MED REP, V15, P1800, DOI 10.3892/mmr.2017.6200
   Ivanova A, 2005, GENESIS, V43, P129, DOI 10.1002/gene.20162
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Kawarizadeh A, 2005, J DENT RES, V84, P902, DOI 10.1177/154405910508401006
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lim XH, 2013, SCIENCE, V342, P1226, DOI 10.1126/science.1239730
   Odagaki N, 2018, J DENT RES, V97, P1374, DOI 10.1177/0022034518771331
   Rangiani A, 2016, EUR J ORTHODONT, V38, P373, DOI 10.1093/ejo/cjv071
   REITAN K., 1957, AMER JOUR ORTHODONT, V43, P32, DOI 10.1016/0002 9416(57)90114 8
   Ren YS, 2015, FASEB J, V29, P2702, DOI 10.1096/fj.14 265496
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shen T, 2014, INT J CLIN EXP PATHO, V7, P7872
   Sonoyama W, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000079
   Sun BY, 2018, J MOL HISTOL, V49, P123, DOI 10.1007/s10735 017 9752 1
   Takimoto A, 2015, DEVELOPMENT, V142, P787, DOI 10.1242/dev.116228
   Tang N, 2012, ARCH MED SCI, V8, P422, DOI 10.5114/aoms.2012.28810
   van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023
   Wang B, 2015, NATURE, V524, P180, DOI 10.1038/nature14863
   Xie X, 2019, J DENT RES, V98, P1262, DOI 10.1177/0022034519871021
   Xu Q, 2019, J DENT RES, V98, P689, DOI 10.1177/0022034519839438
   Yuan X, 2018, J DENT RES, V97, P803, DOI 10.1177/0022034518755719
   Zhang LQ, 2016, BBA GEN SUBJECTS, V1860, P2211, DOI 10.1016/j.bbagen.2016.05.003
   Zhang X, 2019, J DENT RES, V98, P331, DOI 10.1177/0022034518817305
NR 30
TC 25
Z9 28
U1 1
U2 36
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JUN
PY 2022
VL 101
IS 6
BP 695
EP 703
AR 00220345211062585
DI 10.1177/00220345211062585
EA JAN 2022
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 1K1EC
UT WOS:000748478000001
PM 35001706
OA Green Published
DA 2025 08 17
ER

PT J
AU Wu, XW
   Chen, XL
   Zhang, SJ
   Zhang, X
   Sun, H
   Peng, XY
AF Wu Xiang wei
   Chen Xue ling
   Zhang Shi jie
   Zhang Xi
   Sun Hong
   Peng Xin yu
TI Pericyst may be a new pharmacological and therapeutic target for hydatid
   disease
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE pericyst; hydatid cysts; transforming growth factor beta 1;
   calcification; therapy
ID TRANSFORMING GROWTH FACTOR BETA 1; OSTEOBLAST DIFFERENTIATION;
   SURGICAL TREATMENT; MANAGEMENT; LIVER; ECHINOCOCCOSIS; EXPRESSION;
   CELLS; BONE
AB Background Most hydatid cysts with calcified walls are biologically and clinically silent and inactive. Transforming growth factor beta 1 (TGF beta 1) plays a critical role in the calcification process of cells. The aim of this study was to assess the effect of modulating TGF beta 1 signaling on the calcification of hydatid cysts.
   Methods Pericyst cells isolated from hepatic hydatid cysts were cultured with osteogenic media. These cells were assessed for alkaline phosphatase activity and mineralization capacity using Alizarin Red staining. Cells were also treated with recombinant human TGF beta 1 and TGF beta inhibitor, and the expression profiles of osteoblast markers (RUNX2, osterix, and osteocalcin) were analyzed using Western blotting. The effects of inhibiting TGF beta 1 signaling on calcification of pericyst walls were assessed using different doses of TGF beta inhibitor for 7 weeks in a preclinical disease model of liver cystic echinococcosis.
   Results Cells within the pericyst displayed high levels of alkaline phosphatase activity and mineralized nodule formation, as induced by osteogenic media. These activities, as well as expression profiles of osteoblast markers (RUNX2, osterix, and osteocalcin) could be inhibited by addition of recombinant human TGF beta 1 (rhTGF beta 1) and enhanced by TGF beta inhibitor. In the animal model of cystic echinococcosis, inhibition of TGF beta 1 signaling increased calcification of the pericyst wall, which was associated with decreased cyst load index and lower viability of protoscoleces.
   Conclusions Cells within the pericysts adopt an osteoblast like phenotype and have osteogenic potential. Inhibition of TGF beta 1 signaling increases hydatid cyst calcification. Pharmacological modulation of calcification in pericysts may be a new therapeutic target in the treatment of hydatid disease. Chin Med J 2011;124(18):2857 2862
C1 [Wu Xiang wei; Zhang Shi jie; Peng Xin yu] Shihezi Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Key Lab Xinjiang Endem & Ethn Dis,Sch Med, Shihezi 832000, Xinjiang, Peoples R China.
   [Zhang Xi] Shihezi Univ, Dept Phys Examinat, Affiliated Hosp 1, Sch Med, Shihezi 832000, Xinjiang, Peoples R China.
   [Chen Xue ling] Shihezi Univ, Dept Immunol, Affiliated Hosp 1, Sch Med, Shihezi 832000, Xinjiang, Peoples R China.
C3 Shihezi University; Shihezi University; Shihezi University
RP Peng, XY (通讯作者)，Shihezi Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Key Lab Xinjiang Endem & Ethn Dis,Sch Med, Shihezi 832000, Xinjiang, Peoples R China.
EM pengxy2000@yahoo.com
RI zhang, shijie/HGF 0836 2022
FU National Natural Science Foundation of China [81060227, 30760244];
   Xinjiang Production and Construction Corps Medicine Special [2009GG48]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81060227 and No. 30760244), and Xinjiang
   Production and Construction Corps Medicine Special (No. 2009GG48).
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Buttenschoen K, 2003, LANGENBECK ARCH SURG, V388, P218, DOI 10.1007/s00423 003 0397 z
   Czermak BV, 2008, ABDOM IMAGING, V33, P133, DOI 10.1007/s00261 007 9331 0
   Dervenis C, 2005, J GASTROINTEST SURG, V9, P869, DOI 10.1016/j.gassur.2004.10.016
   Hansman MF, 2001, AM J SURG, V181, P404, DOI 10.1016/S0002 9610(01)00611 0
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   McFall B, 2004, INT J CLIN PRACT, V58, P479, DOI 10.1111/j.1368 5031.2004.00174.x
   Mondragón De la Peña C, 2002, PARASITE, V9, P351, DOI 10.1051/parasite/2002094351
   Nepalia S, 2006, J Assoc Physicians India, V54, P458
   Prousalidis J, 1999, HPB Surg, V11, P253, DOI 10.1155/1999/20148
   Sahin M, 1997, EUR J CLIN INVEST, V27, P537, DOI 10.1046/j.1365 2362.1997.1530690.x
   Sayek I, 2004, SURG TODAY, V34, P987, DOI 10.1007/s00595 004 2830 5
   SHAH DS, 2006, IND J RADIOL IMAG, V16, P533
   Shaw JM, 2006, S AFR J SURG, V44, P70
   Simionescu A, 2007, AM J PATHOL, V171, P116, DOI 10.2353/ajpath.2007.060930
   Smego RA, 2005, INT J INFECT DIS, V9, P69, DOI 10.1016/j.ijid.2004.08.001
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Voros Dionysios, 2007, Surg Infect (Larchmt), V8, P621, DOI 10.1089/sur.2006.0070
   WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205
   Wen Hao, 2010, Front Med China, V4, P394, DOI 10.1007/s11684 010 0180 9
   Wu Xiang wei, 2004, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V22, P1
   Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0
NR 24
TC 13
Z9 17
U1 0
U2 11
PU CHINESE MEDICAL ASSOC
PI BEIJING
PA 42 DONGSI XIDAJIE, BEIJING 100710, PEOPLES R CHINA
SN 0366 6999
J9 CHINESE MED J PEKING
JI Chin. Med. J.
PD SEP 20
PY 2011
VL 124
IS 18
BP 2857
EP 2862
DI 10.3760/cma.j.issn.0366 6999.2011.18.011
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 825QP
UT WOS:000295297500012
PM 22040492
DA 2025 08 17
ER

PT J
AU Liu, J
   Zhou, L
   Fu, XM
   Xu, C
   Huang, S
   Li, Y
   Gao, HH
   Guan, W
   LanYang
   Lv, N
AF Liu, Jing
   Zhou, Lei
   Fu, Xiaomin
   Xu, Chen
   Huang, Sai
   Li, Yan
   Gao, Honghao
   Guan, Wei
   LanYang
   Lv, Na
TI MicroRNAs and regulated interaction networks reveal differences between
   adult and pediatric acute myeloid leukemia
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Pediatric acute myeloid leukemia; microRNA; differential expression;
   interaction network; miRNA targeted therapy
ID POOR PROGNOSIS; CELL PROLIFERATION; UP REGULATION; EXPRESSION; PREDICTS;
   DATABASE; CHILDREN; SURVIVAL; BIOMARKER; RELAPSE
AB Objectives: The purpose of this study was to identify featured microRNAs and their regulated network between adult and pediatric acute myeloid leukemia (AML) and find potential utility as biomarkers for diagnosis and treatment of pediatric AML. Methods: We downloaded the microRNA expression dataset GSE35320 from Gene Expression Omnibus database and selected expression chips from bone marrow of 71 pediatric AML samples and 6 adulthood AML samples. Differentially expressed microRNAs were identified by Wilcox test. The target genes of these microRNAs were predicted using an integrative method and their functional enrichment analysis was performed using DAVID. Finally, STRING database and Cytoscape software was used to construct and analyze the interaction network. Results: A total of 7 differentially expressed microRNAs were identified and the remarkably up regulated and down regulated microRNAs were miR 16 and miR 142 5p which included 323 and 22 predicted target genes, respectively. The target genes of 7 microRNAs were most associated with regulation of cell cycle, p53 signaling pathway, Wnt signaling pathway and neurotrophin signaling pathway. The interaction network of miR 16 target genes was constructed among 354 high confidence interaction pairs. The core genes of the network, such as TP53, BCL2, VEGFA, had a role in prognosis of children with AML. Conclusions: The featured microRNAs and their target genes are significant in the occurrence and development of pediatric AML, which is likely to be important for the identification of therapeutic targets and biomarkers for these patients.
C1 [Liu, Jing; Zhou, Lei; Huang, Sai; Li, Yan; Gao, Honghao; Guan, Wei; LanYang; Lv, Na] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, 28 Fuxin Rd, Beijing 100853, Peoples R China.
   [Fu, Xiaomin] Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Endocrinol, Beijing 100853, Peoples R China.
   [Xu, Chen] Affiliated Hosp Mil Med Sci, Dept Hematopoiet Stem Cell Transplantat, Beijing 100071, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital
RP Lv, N (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, 28 Fuxin Rd, Beijing 100853, Peoples R China.
EM youying3457658@sohu.com
RI zhou, lei/D 5281 2013
FU Doctorial Innovation Foundation of People's Liberation Army Medical
   University [B14009]
FX This study was supported by the Doctorial Innovation Foundation of
   People's Liberation Army Medical University (No. B14009).
CR Bai J, 2012, ONCOTARGETS THER, V5, P213, DOI 10.2147/OTT.S36017
   Cheng CK, 2011, BLOOD, V118, P6638, DOI 10.1182/blood 2011 05 354712
   Creutzig U, 2012, BLOOD, V120, P3187, DOI 10.1182/blood 2012 03 362608
   Damm F, 2012, BLOOD, V119, P3211, DOI 10.1182/blood 2011 12 400994
   Daschkey S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056334
   de Bont ESJM, 2002, CLIN CANCER RES, V8, P2856
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355
   Emmrich S, 2016, ONCOGENE, V35, P1822, DOI 10.1038/onc.2015.247
   Emmrich S, 2014, LEUKEMIA, V28, P1022, DOI 10.1038/leu.2013.357
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gamazon ER, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013534
   Gao XN, 2011, LEUKEMIA RES, V35, P1226, DOI 10.1016/j.leukres.2011.06.010
   Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood 2007 07 098749
   Gennarino VA, 2009, GENOME RES, V19, P481, DOI 10.1101/gr.084129.108
   Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821
   Gong JN, 2014, CELL DEATH DIFFER, V21, P100, DOI 10.1038/cdd.2013.133
   Hou HA, 2016, ONCOTARGET, V7, P9084, DOI 10.18632/oncotarget.7000
   Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jiang QH, 2009, NUCLEIC ACIDS RES, V37, pD98, DOI 10.1093/nar/gkn714
   Lee YS, 2009, ANNU REV PATHOL MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
   Lin X, 2015, CLIN TRANSL ONCOL, V17, P358, DOI 10.1007/s12094 014 1237 z
   Lin XF, 2015, INT J CLIN EXP PATHO, V8, P14658
   Liu XD, 2016, J CANCER RES CLIN, V142, P77, DOI 10.1007/s00432 015 1995 1
   Mattsson K, 2015, PEDIATR TRANSPLANT, V19, P767, DOI 10.1111/petr.12585
   MAUNG ZT, 1994, BRIT J HAEMATOL, V88, P105, DOI 10.1111/j.1365 2141.1994.tb04984.x
   Megonigal MD, 1998, ONCOGENE, V16, P1351, DOI 10.1038/sj.onc.1201637
   Mi SL, 2007, P NATL ACAD SCI USA, V104, P19971, DOI 10.1073/pnas.0709313104
   Santos SCR, 2004, BLOOD, V103, P3883, DOI 10.1182/BLOOD 2003 05 1634
   Seth R, 2015, INDIAN J PEDIATR, V82, P817, DOI 10.1007/s12098 015 1695 5
   Sethupathy P, 2006, RNA, V12, P192, DOI 10.1261/rna.2239606
   Sharawat SK, 2015, BLOOD CELL MOL DIS, V54, P56, DOI 10.1016/j.bcmd.2014.07.019
   Shi JL, 2016, ONCOTARGET, V7, P2585, DOI 10.18632/oncotarget.6226
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Taga T, 2016, PEDIATR INT, V58, P71, DOI 10.1111/ped.12865
   Tao YF, 2013, BMC MED GENET, V14, DOI 10.1186/1471 2350 14 74
   Wang ZY, 2013, MOL CELL BIOCHEM, V383, P59, DOI 10.1007/s11010 013 1754 z
   Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851
   Xu LH, 2015, EUR REV MED PHARMACO, V19, P4841
   Yan WY, 2015, ONCOTARGET, V6, P26424, DOI 10.18632/oncotarget.4459
   Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056
   Zhang H, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 108
   Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007826
   Zhang LD, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 110
   Zhang WY, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 66
NR 46
TC 1
Z9 1
U1 0
U2 4
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 10
BP 10576
EP 10583
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA FO5IL
UT WOS:000416887200051
PM 31966399
DA 2025 08 17
ER

PT J
AU Kim, H
   Oh, J
   Kim, MK
   Lee, KH
   Jeong, D
AF Kim, Hyunsoo
   Oh, Jiin
   Kim, Min Kyoung
   Lee, Kyung Hee
   Jeong, Daewon
TI Selenoprotein W engages in overactive osteoclast differentiation in
   multiple myeloma
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Selenoprotein W; Osteoclast differentiation; Multiple myeloma; Bone
   disease
ID BONE; CELLS; EXPRESSION; CYTOKINES; THERAPY; GROWTH
AB BackgroundPatients with multiple myeloma exhibit malignant osteolytic bone disease due to excessive osteoclast formation and function. We recently identified that osteoclastogenic stimulator selenoprotein W (SELENOW) is upregulated via ERK signaling and downregulated via p38 signaling during receptor activator of nuclear factor (NF) kappa Beta ligand (RANKL) induced osteoclast differentiation. In the intrinsic physiological process, RANKL induced downregulation of SELENOW maintains proper osteoclast differentiation; in contrast, forced overexpression of SELENOW leads to overactive osteoclast formation and function.Methods and resultsWe observed that SELENOW is highly expressed in multiple myeloma derived peripheral blood mononuclear cells (PBMCs) and mature osteoclasts when compared to healthy controls. Also, the level of tumor necrosis factor alpha (TNF alpha), a pathological osteoclastogenic factor, is increased in the PBMCs and serum of patients with multiple myeloma. ERK activation by TNF alpha was more marked and sustained than that by RANKL, allowing SELENOW upregulation. Excessive expression of SELENOW in osteoclast progenitors and mature osteoclasts derived from multiple myeloma facilitated efficient nuclear translocation of osteoclastogenic transcription factors NF kappa B and NFATc1, which are favorable for osteoclast formation.ConclusionOur findings suggest a possibility that feedforward signaling of osteoclastogenic SELENOW by TNF alpha derived from multiple myeloma induces overactive osteoclast differentiation, leading to bone loss during multiple myeloma.
C1 [Kim, Hyunsoo; Oh, Jiin; Jeong, Daewon] Yeungnam Univ, Coll Med, Dept Microbiol, Lab Bone Metab & Control, Daegu 42415, South Korea.
   [Kim, Hyunsoo] Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA.
   [Kim, Min Kyoung; Lee, Kyung Hee] Yeungnam Univ, Coll Med, Dept Hematol Oncol, Daegu 42415, South Korea.
   [Jeong, Daewon] Yeungnam Univ, Co Bone Sci, Coll Med, Daegu 42415, South Korea.
C3 Yeungnam University; University of Pennsylvania; Yeungnam University;
   Yeungnam University
RP Jeong, D (通讯作者)，Yeungnam Univ, Coll Med, Dept Microbiol, Lab Bone Metab & Control, Daegu 42415, South Korea.; Jeong, D (通讯作者)，Yeungnam Univ, Co Bone Sci, Coll Med, Daegu 42415, South Korea.
EM dwjeong@ynu.ac.kr
RI Kim, Hyunsoo/AAP 1689 2021; Lee, Kyung Hee/KVZ 1947 2024
OI Kim, Hyunsoo/0009 0003 4777 5735; 
FU National Research Foundation of Korea [2022R1A2C1002736,
   2022R1A5A2018865]; National Research Foundation of Korea
FX This research was funded by grants from the National Research Foundation
   of Korea (Nos. 2022R1A2C1002736 and 2022R1A5A2018865 to D. J.).
CR Anderson K, 2018, J CLIN ONCOL, V36, P812, DOI 10.1200/JCO.2017.76.6402
   BAROUKH B, 1991, J PERIODONTAL RES, V26, P161, DOI 10.1111/j.1600 0765.1991.tb01640.x
   Cao YR, 2010, EXP HEMATOL, V38, P860, DOI 10.1016/j.exphem.2010.06.012
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Choi SJ, 2000, BLOOD, V96, P671
   Feldmann M, 2001, CURR DIRECT AUTOIMMU, V3, P188
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kim H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22565 7
   Kim H, 2018, BMB REP, V51, P468, DOI 10.5483/BMBRep.2018.51.9.126
   Kim H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00139 2
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Komano Y, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2046
   Kröpil P, 2008, EUR RADIOL, V18, P51, DOI 10.1007/s00330 007 0738 3
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Lam J, 2002, ANN RHEUM DIS, V61, P82
   Lee J, 2006, BLOOD, V107, P2686, DOI 10.1182/blood 2005 07 2798
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Lim Hyun Sook, 2022, J Bone Metab, V29, P265, DOI 10.11005/jbm.2022.29.4.265
   Lu SY, 2010, MOL BIOL CELL, V21, P1763, DOI 10.1091/mbc.E09 07 0584
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Neale SD, 2002, QJM INT J MED, V95, P233, DOI 10.1093/qjmed/95.4.233
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Reguera Ortega JL, 2021, HEMATO BASEL, V2, P660, DOI 10.3390/hemato2040043
   Ria R, 2009, CLIN CANCER RES, V15, P5369, DOI 10.1158/1078 0432.CCR 09 0040
   Robbiani DF, 2007, HEMATOL ONCOL, V25, P16, DOI 10.1002/hon.803
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   Takegahara N, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116353
   Walsh MC, 2018, NAT REV RHEUMATOL, V14, P146, DOI 10.1038/nrrheum.2017.213
   Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590 020 00816 x
   Wu C, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0823 5
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   ZHANG XG, 1992, CANCER, V69, P1373, DOI 10.1002/1097 0142(19920315)69:6<1373::AID CNCR2820690612>3.0.CO;2 1
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 36
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 4851
EI 1573 4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD DEC
PY 2024
VL 51
IS 1
AR 587
DI 10.1007/s11033 024 09517 2
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA J2Z9E
UT WOS:001335809700004
PM 38683225
OA Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Li, G
   Wang, J
   Ren, GY
   Hao, FL
   Zhang, YN
   Shi, PK
   Liu, X
   Dong, FS
AF Li, Gang
   Wang, Jie
   Ren, Guiyun
   Hao, Fuliang
   Zhang, Yanning
   Shi, Peikai
   Liu, Xiao
   Dong, Fusheng
TI Morphological Observation on Critical Sized Cranial Defect Repaired by
   Icariin and Autologous Concentrate Growth Factors in Rabbits
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Critical Pathways; Drugs; Chinese Herbal; Morpholines; Transplantation;
   Autologous
ID BONE DEFECT; DIFFERENTIATION; RICH; ANGIOGENESIS; CELLS; MODEL
AB Background: Morphological changes repaired by icariin and autologous concentrate growth factors (ACGF) in critical sized cranial defect were observed and their promoting effects were investigated.
   Material/Methods: Seventy two New Zealand white rabbits weighing 1.8 similar to 2.0kg were used to build a critical sized cranial defect model and were randomly divided into 3 groups. X ray, HE staining, general and histological observation, and immunohistochemistry were used to describe the changes caused by normal saline, icariin, and ACGF.
   Results: Cranial defects were covered with newly formed bone tissue at the 12th week in icariin and ACGF groups, with red color, hard surface, and no obvious boundary. Densities were the same in 2 groups at 4 timepoints. HE staining showed defects filled with a large amount of fibrous connective tissue, thick collagen fibers, and abundant osteoclasts. No new bone matrix appeared in any of the 3 groups. Trabecular area, trabeculae width, and osteoblast number in 2 groups were more than that of the control group, and osteoclast number was lower. However, osteoclast number among the 3 groups at the 12th week had no significant difference, which was the same with 4 indicators between the icariin and ACGF groups. From the 4th to 12th week, regenerated cartilage was formed and showed positive reaction with BMP 2 and TGFb1 from primary bone, which also was demonstrated by granulation tissue and uniform dyeing.
   Conclusions: ACGF and icariin both can increase new bone quantity and improve bone quality, which can also promote healing. The effects and mechanisms of icariin and ACGF on the expression of gene are not exactly the same.
C1 [Li, Gang; Dong, Fusheng] Hebei Med Univ, Stomatol Hosp, Dept Prosthodont, Shijiazhuang, Hebei, Peoples R China.
   [Wang, Jie; Zhang, Yanning] Hebei Med Univ, Stomatol Hosp, Dept Oral Pathol, Shijiazhuang, Hebei, Peoples R China.
   [Hao, Fuliang; Shi, Peikai; Liu, Xiao] Hebei Med Univ, Stomatol Hosp, Dept Oral & Maxillofacial Surg, Shijiazhuang, Hebei, Peoples R China.
C3 Hebei Medical University; Hebei Medical University; Hebei Medical
   University
RP Dong, FS (通讯作者)，Hebei Med Univ, Stomatol Hosp, Dept Prosthodont, Shijiazhuang, Hebei, Peoples R China.
EM fusheng_dong0129@sina.com
CR Alford PW, 2008, BIOMECH MODEL MECHAN, V7, P245, DOI 10.1007/s10237 007 0101 2
   Anitua E, 1999, INT J ORAL MAX IMPL, V14, P529
   Bosch C, 1998, J CRANIOFAC SURG, V9, P310, DOI 10.1097/00001665 199807000 00004
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Choukroun J, 2006, ORAL SURG ORAL MED O, V101, P299, DOI 10.1016/j.tripleo.2005.07.012
   Chung BH, 2008, BIOCHEM BIOPH RES CO, V376, P404, DOI 10.1016/j.bbrc.2008.09.001
   Drosse I, 2008, INJURY, V39, pS9, DOI 10.1016/S0020 1383(08)70011 1
   Ehrenfest DMD, 2009, TRENDS BIOTECHNOL, V27, P158, DOI 10.1016/j.tibtech.2008.11.009
   Einhorn TA, 1999, CLIN ORTHOP RELAT R, pS59, DOI 10.1097/00003086 199910001 00007
   Fennis JPM, 2002, INT J ORAL MAX SURG, V31, P281, DOI 10.1054/ijom.2002.0151
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Landesberg R, 2005, J ORAL MAXIL SURG, V63, P529, DOI 10.1016/j.joms.2004.12.007
   Li SG, 2010, CANCER LETT, V298, P222, DOI 10.1016/j.canlet.2010.07.009
   Ma HP, 2011, J CELL BIOCHEM, V112, P916, DOI 10.1002/jcb.23007
   Miriyala S, 2006, CIRCULATION, V113, P2818, DOI 10.1161/CIRCULATIONAHA.106.611822
   Pan Min, 2010, Zhongguo Zhong Yao Za Zhi, V35, P1892
   Pekic S, 2014, HAND CLINIC, V124, P271, DOI 10.1016/B978 0 444 59602 4.00018 6
   Rodella LF, 2011, MICROSC RES TECHNIQ, V74, P772, DOI 10.1002/jemt.20968
   Sacco L., 2006, Lecture, V12, P4
   Schlegel KA, 2006, ORAL SURG ORAL MED O, V102, P7, DOI 10.1016/j.tripleo.2005.09.011
   SCHMITZ JP, 1986, CLIN ORTHOP RELAT R, P299, DOI 10.1097/00003086 198604000 00036
   Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005
   ten Dijke P, 2003, J BONE JOINT SURG AM, V85A, P34
   van den Berg WB, 2001, CLIN ORTHOP RELAT R, pS244
   Worster AA, 2000, AM J VET RES, V61, P1003, DOI 10.2460/ajvr.2000.61.1003
   Wu YQ, 2015, CELL PROLIFERAT, V48, P375, DOI 10.1111/cpr.12185
   Xie XW, 2015, J BIOMATER APPL, V30, P290, DOI 10.1177/0885328215581551
NR 28
TC 0
Z9 1
U1 0
U2 19
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD MAY 19
PY 2017
VL 23
BP 2373
EP 2381
DI 10.12659/MSM.900098
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EV5UM
UT WOS:000401833100003
PM 28525525
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Lodberg, A
   van der Eerden, BCJ
   Boers Sijmons, B
   Thomsen, JS
   Brüel, A
   van Leeuwen, JPTM
   Eijken, M
AF Lodberg, Andreas
   van der Eerden, Bram C. J.
   Boers Sijmons, Bianca
   Thomsen, Jesper Skovhus
   Bruel, Annemarie
   van Leeuwen, Johannes P. T. M.
   Eijken, Marco
TI A follistatin based molecule increases muscle and bone mass without
   affecting the red blood cell count in mice
SO FASEB JOURNAL
LA English
DT Article
DE IASP; therapeutic; erythropoiesis; muscle anabolic; osteoporosis
ID ACTIVIN A; PARATHYROID HORMONE; ERYTHROID DIFFERENTIATION; ANDROGEN
   DEPRIVATION; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; II RECEPTORS; MOUSE
   MODEL; MYOSTATIN; PROTEIN
AB Inhibitors of the activin receptor signaling pathway (IASPs) have become candidate therapeutics for sarcopenia and bone remodeling disorders because of their ability to increase muscle and bone mass. However, IASPs utilizing activin type IIA and IIB receptors are also potent stimulators of erythropoiesis, a feature that may restrict their usage to anemic patients because of increased risk of venous thromboembolism. Based on the endogenous TGF  superfamily antagonist follistatin (FST), a molecule in the IASP class, FSTHBS mFc, was generated and tested in both ovariectomized and naive BALB/c and C57BL/6 mice. In ovariectomized mice, FSTHBS mFc therapy dose dependently increased cancellous bone mass up to 42% and improved bone microstructural indices. For the highest dosage of FSTHBS mFc (30 mg/kg, 2 times/wk), the increase in cancellous bone mass was similar to that observed with parathyroid hormone therapy (1 34, 80 mu g/kg, 5 times/wk). Musculus quadriceps femoris mass dose dependently increased up to 21% in ovariectomized mice. In both ovariectomized and naive mice, FSTHBS mFc therapy did not influence red blood cell count or hematocrit or hemoglobin levels. If the results are reproduced, a human FSTHBS mFc version could be applicable in patients with musculoskeletal conditions irrespective of hematocrit status.Lodberg, A., van der Eerden, B. C. J., Boers Sijmons, B., Thomsen, J. S., Bruel, A., van Leeuwen, J. P. T. M., Eijken, M. A follistatin based molecule increases muscle and bone mass without affecting the red blood cell count in mice.
C1 [Lodberg, Andreas] Aarhus Univ Hosp, Dept Pulm Med, Aarhus, Denmark.
   [Lodberg, Andreas; Thomsen, Jesper Skovhus; Bruel, Annemarie] Aarhus Univ Hosp, Dept Biomed, Aarhus, Denmark.
   [Eijken, Marco] Aarhus Univ Hosp, Dept Renal Med, Aarhus, Denmark.
   [Eijken, Marco] Aarhus Univ Hosp, Dept Clin Immunol, Aarhus, Denmark.
   [van der Eerden, Bram C. J.; Boers Sijmons, Bianca; van Leeuwen, Johannes P. T. M.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
C3 Aarhus University; Aarhus University; Aarhus University; Aarhus
   University; Erasmus University Rotterdam; Erasmus MC
RP Lodberg, A (通讯作者)，Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 3, DK 8000 Aarhus C, Denmark.
EM andreaslodberg@gmail.com
RI ; van der Eerden, Bram/I 7496 2012; van Leeuwen, Johannes/D 5015 2014;
   Lodberg, Andreas/ABB 2541 2021; Bruel, Annemarie/AAT 2310 2020; Thomsen,
   Jesper/HKN 2794 2023
OI Bruel, Annemarie/0000 0003 4833 0888; van der Eerden,
   Bram/0000 0003 4403 6497; van Leeuwen, Johannes/0000 0002 2282 4006;
   Eijken, Marco/0000 0002 9043 3971; Lodberg, Andreas/0000 0001 9261 8753;
   Thomsen, Jesper Skovhus/0000 0001 9386 6679; 
CR Attie KM, 2014, AM J HEMATOL, V89, P766, DOI 10.1002/ajh.23732
   ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092 8674(92)90209 U
   Bhattacharya I, 2018, CLIN PHARM DRUG DEV, V7, P484, DOI 10.1002/cpdd.386
   Bialek P, 2014, BONE, V60, P162, DOI 10.1016/j.bone.2013.12.002
   Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brækkan SK, 2010, HAEMATOL HEMATOL J, V95, P270, DOI 10.3324/haematol.2009.008417
   Burton LA, 2010, CLIN INTERV AGING, V5, P217
   Carrancio S, 2014, BRIT J HAEMATOL, V165, P870, DOI 10.1111/bjh.12838
   Cash JN, 2009, EMBO J, V28, P2662, DOI 10.1038/emboj.2009.205
   Chiu CS, 2013, J GERONTOL A BIOL, V68, P1181, DOI 10.1093/gerona/glt030
   Cruz Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034
   Datta Mannan A, 2013, J PHARMACOL EXP THER, V344, P616, DOI 10.1124/jpet.112.201491
   Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091
   Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003
   Dussiot M, 2014, NAT MED, V20, P398, DOI 10.1038/nm.3468
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Fajardo RJ, 2010, BONE, V46, P64, DOI 10.1016/j.bone.2009.09.018
   Fuller K, 2000, BIOCHEM BIOPH RES CO, V268, P2, DOI 10.1006/bbrc.2000.2075
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   Goh BC, 2017, J BIOL CHEM, V292, P13809, DOI 10.1074/jbc.M117.782128
   Hammers DW, 2017, EMBO MOL MED, V9, P531, DOI 10.15252/emmm.201607231
   Hirotani H, 2002, CALCIFIED TISSUE INT, V70, P330, DOI 10.1007/s00223 001 2037 3
   Ikenoue T, 1999, J CELL BIOCHEM, V75, P206, DOI 10.1002/(SICI)1097 4644(19991101)75:2<206::AID JCB3>3.3.CO;2 K
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kalyani RR, 2014, LANCET DIABETES ENDO, V2, P819, DOI 10.1016/S2213 8587(14)70034 8
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Koncarevic A, 2010, ENDOCRINOLOGY, V151, P4289, DOI 10.1210/en.2010 0134
   Lach Trifilieff E, 2014, MOL CELL BIOL, V34, P606, DOI 10.1128/MCB.01307 13
   Latres E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15153
   Latres E, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395 015 0060 8
   Lee SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000789
   Lee SJ, 2010, MOL ENDOCRINOL, V24, P1998, DOI 10.1210/me.2010 0127
   Lee SJ, 2005, P NATL ACAD SCI USA, V102, P18117, DOI 10.1073/pnas.0505996102
   Lee YS, 2013, P NATL ACAD SCI USA, V110, pE3713, DOI 10.1073/pnas.1309907110
   Liu LK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136968
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Lodberg A, 2018, BONE, V110, P326, DOI 10.1016/j.bone.2018.02.026
   Lodberg Andreas, 2015, Bone Rep, V2, P59, DOI 10.1016/j.bonr.2015.04.001
   Lotinun S, 2010, BONE, V46, P1082, DOI 10.1016/j.bone.2010.01.370
   Massagué J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051
   MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092 8674(91)90549 E
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   McPherron AC, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471 213X 9 24
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Morvan F, 2017, P NATL ACAD SCI USA, V114, P12448, DOI 10.1073/pnas.1707925114
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Padhi D, 2014, J CLIN ENDOCR METAB, V99, pE1967, DOI 10.1210/jc.2014 1271
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Pistilli EE, 2011, AM J PATHOL, V178, P1287, DOI 10.1016/j.ajpath.2010.11.071
   Platzbecker U, 2017, LANCET ONCOL, V18, P1338, DOI 10.1016/S1470 2045(17)30615 0
   Polkey MI, 2019, AM J RESP CRIT CARE, V199, P313, DOI 10.1164/rccm.201802 0286OC
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Rooks D, 2017, J AM GERIATR SOC, V65, P1988, DOI 10.1111/jgs.14927
   Rooks DS, 2017, J CACHEXIA SARCOPENI, V8, P727, DOI 10.1002/jcsm.12205
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   SAKAI R, 1993, BIOCHEM BIOPH RES CO, V195, P39, DOI 10.1006/bbrc.1993.2006
   Shen C, 2018, J PHARMACOL EXP THER, V366, P291, DOI 10.1124/jpet.118.248195
   SHIMONAKA M, 1991, ENDOCRINOLOGY, V128, P3313, DOI 10.1210/endo 128 6 3313
   SHIOZAKI M, 1992, P NATL ACAD SCI USA, V89, P1553, DOI 10.1073/pnas.89.5.1553
   Sidis Y, 2005, ENDOCRINOLOGY, V146, P130, DOI 10.1210/en.2004 1041
   Sidis Y, 2006, ENDOCRINOLOGY, V147, P3586, DOI 10.1210/en.2006 0089
   Souza TA, 2008, MOL ENDOCRINOL, V22, P2689, DOI 10.1210/me.2008 0290
   SUGINO K, 1993, J BIOL CHEM, V268, P15579
   Suragani RNVS, 2014, NAT MED, V20, P408, DOI 10.1038/nm.3512
   Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008
   Thomsen JS, 2012, CALCIFIED TISSUE INT, V90, P294, DOI 10.1007/s00223 012 9576 7
   Trendelenburg AU, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044 5040 2 3
   UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282
   VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Vegger JB, 2014, BONE, V66, P287, DOI 10.1016/j.bone.2014.06.020
   Virchow R. L. K., 1910, THROMBOSE EMBOLIE 18, V7
   Wagner KR, 2008, ANN NEUROL, V63, P561, DOI 10.1002/ana.21338
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001155.pub2
   Westbroek I, 2007, J CELL BIOCHEM, V101, P360, DOI 10.1002/jcb.21177
   Whittemore LA, 2003, BIOCHEM BIOPH RES CO, V300, P965, DOI 10.1016/S0006 291X(02)02953 4
   Woodhouse L, 2016, J FRALITY AGING, V5, P62, DOI 10.14283/jfa.2016.81
   Yaden BC, 2014, J PHARMACOL EXP THER, V349, P355, DOI 10.1124/jpet.113.211169
   Yamawaki K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078076
   Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014 5793(00)01570 2
   Zhu YX, 2016, BIOANALYSIS, V8, P193, DOI 10.4155/bio.15.238
NR 82
TC 21
Z9 23
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2019
VL 33
IS 5
BP 6001
EP 6010
DI 10.1096/fj.201801969RR
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA HW8IK
UT WOS:000466932600017
PM 30759349
OA Bronze
DA 2025 08 17
ER

PT J
AU Anitua, E
   Zalduendo, M
   Troya, M
   Orive, G
AF Anitua, Eduardo
   Zalduendo, Mar
   Troya, Maria
   Orive, Gorka
TI PRGF exerts a cytoprotective role in zoledronic acid treated oral cells
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Zoledronic acid; Bisphosphonates; Oral cells; Apoptosis; Inflammation;
   Plasma rich in growth factors
ID BISPHOSPHONATE RELATED OSTEONECROSIS; PLATELET RICH PLASMA;
   GROWTH FACTORS PRGF; IN VITRO; TISSUE REGENERATION; JAW; PROLIFERATION;
   INHIBITION; INFLAMMATION; FIBROBLASTS
AB Bisphosphonates related osteonecrosis of the jaw (BRONJ) is a common problem in patients undergoing long term administration of highly potent nitrogen containing bisphosphonates (N BPs). This pathology occurs via bone and soft tissue mechanism. Zoledronic acid (ZA) is the most potent intravenous N BP used to prevent bone loss in patients with bone dysfunction. The objective of this in vitro study was to evaluate the role of different ZA concentrations on the cells from human oral cavity, as well as the potential of plasma rich in growth factors (PRGF) to overcome the negative effects of this BP.
   Primary human gingival fibroblasts and primary human alveolar osteoblasts were used. Cell proliferation was evaluated by means of a fluorescence based method. A colorimetric assay to detect DNA fragmentation undergoing apoptosis was used to determine cell death, and the expression of both NF kappa B and pNF kappa B were quantified by Western blot analysis.
   ZA had a cytotoxic effect on both human gingival fibroblasts and human alveolar osteoblasts. This BP inhibits cell proliferation, stimulates apoptosis, and induces inflammation. However, the addition of PRGF suppresses all these negative effects of the ZA.
   PRGF shows a cytoprotective role against the negative effects of ZA on primary oral cells.
   At present, there is no definitive treatment for bisphosphonates related osteonecrosis of the jaw (BRONJ), being mainly palliatives. Our results revealed that PRGF has a cytoprotective role in cells exposed to zoledronic acid, thus providing a reliable adjunctive therapy for the treatment of BRONJ pathology.
C1 [Anitua, Eduardo; Orive, Gorka] Fdn Eduardo Anitua, Jacinto Quincoces 39, Vitoria 01007, Spain.
   [Anitua, Eduardo; Zalduendo, Mar; Troya, Maria; Orive, Gorka] Biotechnol Inst BTI, Lab Regenerat Med, Vitoria, Spain.
RP Orive, G (通讯作者)，Fdn Eduardo Anitua, Jacinto Quincoces 39, Vitoria 01007, Spain.; Orive, G (通讯作者)，Biotechnol Inst BTI, Lab Regenerat Med, Vitoria, Spain.
EM gorka.orive@ehu.es
RI Zalduendo, Mar/N 7896 2018; , Mar/N 7896 2018; Anitua,
   Eduardo/O 1154 2018; Troya, María/N 7897 2018; Troya, Maria/N 7897 2018
OI , Mar/0000 0001 8458 6042; Anitua, Eduardo/0000 0002 8386 5303; Troya,
   Maria Isabel/0000 0002 9742 9094; Troya, Maria/0000 0002 5308 0505;
   ORIVE, GORKA/0000 0002 0773 300X
FU Pharmascreen Saiotek project (Basque Government)
FX This study was funded by Pharmascreen Saiotek project (Basque
   Government).
CR Açil Y, 2012, J CRANIO MAXILL SURG, V40, pE229, DOI 10.1016/j.jcms.2011.10.024
   Agis H, 2010, J DENT RES, V89, P40, DOI 10.1177/0022034509354298
   Albanese A, 2013, IMMUN AGEING, V10, DOI 10.1186/1742 4933 10 23
   Alessandri AL, 2013, PHARMACOL THERAPEUT, V139, P189, DOI 10.1016/j.pharmthera.2013.04.006
   Anitua E, 2013, BRIT J ORAL MAX SURG, V51, pE272, DOI 10.1016/j.bjoms.2012.08.018
   Anitua E, 2007, BIOMATERIALS, V28, P4551, DOI 10.1016/j.biomaterials.2007.06.037
   Anitua E, 2014, NEUROBIOL AGING, V35, P1582, DOI 10.1016/j.neurobiolaging.2014.01.009
   Anitua E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073118
   Anitua E, 2013, J PERIODONTOL, V84, P1180, DOI 10.1902/jop.2012.120292
   Anitua E, 2012, J PERIODONTOL, V83, P1028, DOI 10.1902/jop.2011.110505
   Anitua E, 2012, J CONTROL RELEASE, V157, P317, DOI 10.1016/j.jconrel.2011.11.011
   Anitua E, 2012, J CONTROL RELEASE, V157, P29, DOI 10.1016/j.jconrel.2011.07.004
   Anitua E, 2011, J BIOMED MATER RES A, V97A, P536, DOI 10.1002/jbm.a.33053
   Bendinelli P, 2010, J CELL PHYSIOL, V225, P757, DOI 10.1002/jcp.22274
   Cartsos VM, 2008, J AM DENT ASSOC, V139, P23, DOI 10.14219/jada.archive.2008.0016
   Chen FM, 2011, J CONTROL RELEASE, V149, P92, DOI 10.1016/j.jconrel.2010.10.021
   Colella AD, 2012, ANAL BIOCHEM, V430, P108, DOI 10.1016/j.ab.2012.08.015
   Hinchy NV, 2013, ORAL ONCOL, V49, P878, DOI 10.1016/j.oraloncology.2013.06.008
   Koch FP, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 12
   Lesclous P, 2009, BONE, V45, P843, DOI 10.1016/j.bone.2009.07.011
   Martins MAT, 2012, ORAL ONCOL, V48, P79, DOI 10.1016/j.oraloncology.2011.08.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Montaseri A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028663
   Mozzati M, 2013, SUR CURR RES, V01, DOI [10.4172/2161 1076.s12 011, DOI 10.4172/2161 1076.S12 011]
   Mozzati M, 2012, ORAL ONCOL, V48, P817, DOI 10.1016/j.oraloncology.2012.03.009
   Mozzati M, 2012, ORAL ONCOL, V48, P469, DOI 10.1016/j.oraloncology.2011.12.004
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   Okada S, 2013, TOHOKU J EXP MED, V231, P145, DOI 10.1620/tjem.231.145
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Pabst AM, 2015, CLIN ORAL INVEST, V19, P1625, DOI 10.1007/s00784 014 1394 z
   Raja S, 2009, INT J DENT HYG, V7, P82, DOI 10.1111/j.1601 5037.2009.00380.x
   Rasmusson L, 2014, INT J DENT, V2014, DOI 10.1155/2014/471035
   Ravosa MJ, 2011, ARCH ORAL BIOL, V56, P491, DOI 10.1016/j.archoralbio.2010.11.003
   Scheper MA, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755 1536 3 6
   Scoletta M, 2013, J ORAL MAXIL SURG, V71, P994, DOI 10.1016/j.joms.2013.01.006
   Tanaka Y, 2013, ARCH ORAL BIOL, V58, P628, DOI 10.1016/j.archoralbio.2012.11.010
   Tipton DA, 2011, J PERIODONTAL RES, V46, P39, DOI 10.1111/j.1600 0765.2010.01306.x
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 303
   Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003
   Zhang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067303
NR 41
TC 17
Z9 19
U1 0
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD APR
PY 2016
VL 20
IS 3
BP 513
EP 521
DI 10.1007/s00784 015 1528 y
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA DH7HC
UT WOS:000372962300011
PM 26201455
DA 2025 08 17
ER

PT J
AU Ziebart, T
   Koch, F
   Klein, MO
   Guth, J
   Adler, J
   Pabst, A
   Al Nawas, B
   Walter, C
AF Ziebart, T.
   Koch, F.
   Klein, M. O.
   Guth, J.
   Adler, J.
   Pabst, A.
   Al Nawas, B.
   Walter, C.
TI Geranylgeraniol   A new potential therapeutic approach to bisphosphonate
   associated osteonecrosis of the jaw
SO ORAL ONCOLOGY
LA English
DT Article
DE Bisphosphonate associated osteonecrosis of the jaws; Geranylgeraniol;
   Wound healing; Therapy; Prevention
ID PROSTATE CANCER CELLS; NITROGEN CONTAINING BISPHOSPHONATES; MEVALONATE
   PATHWAY; ENDOTHELIAL CELLS; ZOLEDRONIC ACID; IN VITRO;
   HYPERBARIC OXYGEN; INDUCE APOPTOSIS; BONE RESORPTION; ALENDRONATE
AB Bisphosphonate associated osteonecrosis of the jaw (BP ONJ) is one of the main side effects of bisphosphonate therapy (BPT). To date, there is no effective therapy of the BP ONJ.
   Nitrogen containing bisphosphonates (N BPs) are particularly able to inhibit pyrophosphate synthase (FPPS) in the mevalonate pathway (MVP). Consequent of decreased synthesis of the metabolite Geranylgeraniol (GGOH) is believed to largely account for the development of BP ONJ. Negative effect of N BPs could be shown, resulting in decreased viability and migration capacity of different cell types of hard and soft tissues such as osteoblasts, fibroblast und endothelial cells. Aim of our in vitro study was to demonstrate that the mevalonate pathway metabolite GGOH could reverse the negative biological effect of N BPs. Biological effect of GGOH on bisphosphonate treated human umbilicord vein endothelial cells (HUVEC), fibroblast and osteogenic cells was analyzed by a viability test and measuring the migration capacity in a scratch wound assay as well as a migration assay using Boyden chambers. The morphological cell architecture of the treated cells was analyzed by phallacidin staining. GGOH cell treatment can rescue the negative effect of bisphosphonates. These results underline the hypothesis that systemic or local treatment with GGOH could lead to new therapeutic strategies for BP ONJ. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Ziebart, T.; Koch, F.; Klein, M. O.; Guth, J.; Adler, J.; Pabst, A.; Al Nawas, B.; Walter, C.] Johannes Gutenberg Univ Mainz, Univ Med, Klin Mund Kiefer & Gesichtschirurg Plast Operatio, Mainz, Germany.
C3 Johannes Gutenberg University of Mainz
RP Ziebart, T (通讯作者)，Univ Med Ctr Mainz, Dept Oral & Maxillofacial Surg, Augustuspl 2, D 55131 Mainz, Germany.
EM ziebart@mkg.klinik.uni mainz.de
RI Walter, Christian/GZG 8888 2022; Ziebart, Thomas/C 7048 2017; Al Nawas,
   Bilal/C 8885 2013
OI Walter, Christian/0000 0003 1491 8077; 
FU Novartis
FX Walter has given speeches for Roche and has received research funding
   from Novartis.
CR Abu Id MH, 2008, J CRANIO MAXILL SURG, V36, P95, DOI 10.1016/j.jcms.2007.06.008
   Allegra A, 2010, ACTA HAEMATOL BASEL, V124, P79, DOI 10.1159/000313787
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Edwards BJ, 2008, J AM DENT ASSOC, V139, P1674, DOI 10.14219/jada.archive.2008.0110
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Freiberger JJ, 2007, J ORAL MAXIL SURG, V65, P1321, DOI 10.1016/j.joms.2007.03.019
   Freiberger JJ, 2009, J ORAL MAXIL SURG, V67, P96, DOI 10.1016/j.joms.2008.12.003
   Groetz KA, 2006, J ORAL MAXIL SURG, V64, P1571, DOI 10.1016/j.joms.2006.05.041
   Hashimoto K, 2007, BIOCHEM BIOPH RES CO, V354, P478, DOI 10.1016/j.bbrc.2007.01.014
   Iguchi K, 2006, CANCER LETT, V237, P223, DOI 10.1016/j.canlet.2005.06.006
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   KOCH FP, 2010, J CRANIOMAXILLOFAC S
   Moreira MS, 2005, DENT TRAUMATOL, V21, P329, DOI 10.1111/j.1600 9657.2005.00370.x
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Otto S, 2010, J ORAL MAXIL SURG, V68, P2837, DOI 10.1016/j.joms.2010.07.017
   Correia VDP, 2006, DENT TRAUMATOL, V22, P312, DOI 10.1111/j.1600 9657.2005.00434.x
   RABKIN SW, 1987, J MOL CELL CARDIOL, V19, P1073, DOI 10.1016/S0022 2828(87)80352 8
   Reed SD, 2004, J UROLOGY, V171, P1537, DOI 10.1097/01.ju.0000116777.94426.60
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Ruggiero SL, 2009, ANNU REV MED, V60, P85, DOI 10.1146/annurev.med.60.063007.134350
   Saad F, 2002, SEMIN ONCOL, V29, P19, DOI 10.1053/sonc.2002.37418
   Shipman CM, 1998, CANCER RES, V58, P5294
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630
   Vescovi P, 2010, LASER MED SCI, V25, P101, DOI 10.1007/s10103 009 0687 y
   Virtanen SS, 2002, CANCER RES, V62, P2708
   Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
   Walter C, 2010, ORAL DIS
   Williamson RA, 2010, INT J ORAL MAX SURG, V39, P251, DOI 10.1016/j.ijom.2009.11.014
   Ziebart T, 2009, CLIN ORAL INVESTIG
NR 35
TC 51
Z9 59
U1 0
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368 8375
J9 ORAL ONCOL
JI Oral Oncol.
PD MAR
PY 2011
VL 47
IS 3
BP 195
EP 201
DI 10.1016/j.oraloncology.2010.12.003
PG 7
WC Oncology; Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 739TR
UT WOS:000288741500008
PM 21247791
DA 2025 08 17
ER

PT J
AU Wilcox, CV
   Knych, HK
   Katzman, SA
   Arthur, RM
   Rodriguez, V
   Finno, CJ
AF Wilcox, Callie V.
   Knych, Heather K.
   Katzman, Scott A.
   Arthur, Rick M.
   Rodriguez, Veronika
   Finno, Carrie J.
TI Effect of clodronate on gene expression in the peripheral blood of
   horses
SO JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE bisphosphonate; blood; bone; clodronate; gene; horse
ID RESISTANT ACID PHOSPHATASE; BONE; TILUDRONATE; BISPHOSPHONATES; FIGHT
AB There are two FDA approved bisphosphonate products, clodronate (Osphos (R)) and tiludronate (Tildren (R)), for use in horses. It is hypothesized that bisphosphonates can produce analgesic effects and prevent proper healing of microcracks in bone. Therefore, bisphosphonate use is banned in racehorses. However, bisphosphonates have a short detection window in the blood before sequestration in the skeleton, making the reliability of current drug tests questionable. Seven exercising Thoroughbred horses were administered clodronate (1.8 mg/kg i.m.), and four were administered saline. RNA was isolated from peripheral blood mononuclear cells (PBMCs) collected immediately before a single dose of clodronate or saline and then on Days 1, 6, 28, 56 and 182 post dose. mRNA was sequenced and analysed for differentially expressed transcripts. While no single transcripts were differentially expressed, pathway analysis revealed that p38 MAPK (p = .04) and Ras (p = .04) pathways were upregulated, and cadherin signalling (p = .02) was downregulated on Day 1. Previously investigated biomarkers, cathepsin K (CTSK) and type 5 acid phosphatase (ACP5), were analysed with RT qPCR in a targeted gene approach, with no significant difference observed. A significant effect of time on gene expression for ACP5 (p = .03) and CTSK (p < .0001) was observed. Thus, these genes warrant further investigation for detecting clodronate use over time.
C1 [Wilcox, Callie V.; Rodriguez, Veronika; Finno, Carrie J.] Univ Calif Davis, Sch Vet Med, Dept Populat Hlth & Reprod, Davis, CA 95616 USA.
   [Knych, Heather K.] Univ Calif Davis, Sch Vet Med, K L Maddy Equine Analyt Pharmacol Lab, Davis, CA USA.
   [Knych, Heather K.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA USA.
   [Katzman, Scott A.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA USA.
   [Arthur, Rick M.] Univ Calif Davis, Sch Vet Med, Davis, CA USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis
RP Finno, CJ (通讯作者)，Univ Calif Davis, Sch Vet Med, Dept Populat Hlth & Reprod, Davis, CA 95616 USA.
EM cjfinno@ucdavis.edu
RI Finno, Carrie/W 4701 2019
OI Finno, Carrie/0000 0001 5924 0234; Wilcox, Callie/0000 0001 6963 8043
FU Grayson Jockey Club Research Foundation; Viola Foundation
FX The authors would like to thank the Grayson Jockey Club Research
   Foundation and The Viola Foundation for providing funding for this
   study.
CR Adams S., 2002, LAMENESS IN HORSES, P183
   Anon, 1999, Guide to veterinary Services for Horses Shows, V7th edition
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Chu PL, 2003, AM J KIDNEY DIS, V41, P1052, DOI 10.1016/S0272 6386(03)00203 8
   Coudry V, 2007, AM J VET RES, V68, P329, DOI 10.2460/ajvr.68.3.329
   Dahlgren AR, 2021, GENES BASEL, V12, DOI 10.3390/genes12121874
   Delguste C, 2007, BONE, V41, P414, DOI 10.1016/j.bone.2007.05.005
   Denoix JM, 2003, EQUINE VET J, V35, P407, DOI 10.2746/042516403776014226
   Düsterdieck Zellmer KF, 2018, TIERAERZTL PRAX G N, V46, P323, DOI 10.15653/TPG 170804
   Evans E, 1972, Midwives Chron, V86, P118
   Finno CJ, 2016, FREE RADICAL BIO MED, V101, P261, DOI 10.1016/j.freeradbiomed.2016.10.009
   Gough MR, 2010, EQUINE VET J, V42, P381, DOI 10.1111/j.2042 3306.2010.00120.x
   Kidd LJ, 2011, J ORTHOP RES, V29, P1827, DOI 10.1002/jor.21464
   Knych HK, 2023, EQUINE VET J, V55, P696, DOI 10.1111/evj.13866
   Knych HK, 2022, J VET DIAGN INVEST, V34, P23, DOI 10.1177/10406387211050049
   Kocijan R, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115104
   Krueger CR, 2020, EQUINE VET J, V52, P725, DOI 10.1111/evj.13244
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 2 r29
   Lee Seung Hun, 2015, J Bone Metab, V22, P167, DOI 10.11005/jbm.2015.22.4.167
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Marini JC, 2003, NEW ENGL J MED, V349, P423, DOI 10.1056/NEJMp038103
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Nwosu LN, 2017, OSTEOARTHR CARTILAGE, V25, P858, DOI 10.1016/j.joca.2017.01.002
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   Reichel C, 2011, FORENSIC SCI INT, V213, P20, DOI 10.1016/j.forsciint.2011.07.031
   Riggs CM, 2021, EQUINE VET J, V53, P1287, DOI 10.1111/evj.13395
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Suva LJ, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115711
   Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Wang G, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864 017 4191 7
   Wang G, 2017, MED SPORT SCI, V62, P119, DOI 10.1159/000470919
NR 32
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0140 7783
EI 1365 2885
J9 J VET PHARMACOL THER
JI J. Vet. Pharmacol. Ther.
PD MAY
PY 2024
VL 47
IS 3
BP 187
EP 192
DI 10.1111/jvp.13424
EA JAN 2024
PG 6
WC Pharmacology & Pharmacy; Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Veterinary Sciences
GA OR4Q7
UT WOS:001139594400001
PM 38197553
OA hybrid
DA 2025 08 17
ER

PT J
AU Weber, AJ
   Li, G
   Kalak, R
   Street, J
   Buttgereit, F
   Dunstan, CR
   Seibel, MJ
   Zhou, H
AF Weber, Agnes J.
   Li, Gang
   Kalak, Robert
   Street, Janie
   Buttgereit, Frank
   Dunstan, Colin R.
   Seibel, Markus J.
   Zhou, Hong
TI Osteoblast targeted disruption of glucocorticoid signalling does not
   delay intramembranous bone healing
SO STEROIDS
LA English
DT Article
DE Glucocorticoids; Osteoblast; Hydroxysteroid dehydrogenase (HSD);
   Intramembranous bone healing
ID 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 2; FRACTURE REPAIR; CELLS;
   DIFFERENTIATION; TRANSGENES; EXPRESSION; LINEAGE; GROWTH; MICE
AB Objective: Glucocorticoids at pharmacological doses have been shown to interfere with fracture repair. The role of endogenous glucocorticoids in fracture healing is not well understood. We examined whether endogenous glucocorticoids affect bone healing in an in vivo model of cortical defect repair. Methods: Experiments were performed using a well characterised mouse model in which intracellular glucocorticoid signalling was disrupted in osteoblasts through transgenic overexpression of 11 beta hydroxysteroid dehydrogenase type 2 (11 beta HSD2) under the control of a collagen type 1 promoter (Col2.3 11 beta HSD2). Unicortical bone defects (empty set 0.8 mm) were created in the tibiae of 7 week old male transgenic mice and their wild type littermates. Repair was assessed via histomorphometry, immunohistochemistry and microcomputed tomography (micro CT) analysis at 1 3 weeks after defect creation. Results: At week 1, micro CT images of the defect demonstrated formation of mineralized intramembranous bone which increased in volume and density by week 2. At week 3, healing of the defect was nearly complete in all animals. Analysis by histomorphometry and micro CT revealed that repair of the bony defect was similar in Col2.3 11 beta HSD2 transgenic animals and their wild type littermates at all time points. Conclusion: Disrupting endogenous glucocorticoid signalling in mature osteoblasts did not affect intramembranous fracture healing in a tibia defect repair model. It remains to be shown whether glucocorticoid signalling has a role in endochondral fracture healing. (C) 2010 Elsevier Inc. All Fights reserved.
C1 [Weber, Agnes J.; Li, Gang; Kalak, Robert; Street, Janie; Dunstan, Colin R.; Seibel, Markus J.; Zhou, Hong] Univ Sydney, Bone Res Program, ANZAC Res Inst, Sydney, NSW 2139, Australia.
   [Weber, Agnes J.; Buttgereit, Frank] Charite, Dept Rheumatol & Clin Immunol, Berlin, Germany.
   [Li, Gang] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [Seibel, Markus J.] Univ Sydney, Dept Endocrinol & Metab, Concord Repatriat Hosp, Sydney, NSW 2139, Australia.
C3 University of Sydney; ANZAC Research Institute; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Chinese University of Hong Kong; University of Sydney
RP Zhou, H (通讯作者)，Univ Sydney, Bone Res Program, ANZAC Res Inst, Hosp Rd, Sydney, NSW 2139, Australia.
EM hzhou@med.usyd.edu.au
RI Dunstan, Colin/G 6214 2013; Li, Gang/J 7830 2018
OI Dunstan, Colin/0000 0001 7586 4071; Buttgereit,
   Frank/0000 0003 2534 550X; Zhou, Hong/0000 0001 5899 9660; Seibel,
   Markus J/0000 0002 2701 378X; Li, Gang/0000 0002 3981 2239
FU National Health and Medical Research Council, Australia [402462,
   570946]; Charite University Hospital, Berlin, Germany; University of
   Sydney, Australia; Berlin Brandenburg Center of Regenerative Therapies
   (BCRT)
FX We thank Mamdouh Khalil and his staff for excellent animal care. The
   authors also acknowledge the scientific and technical assistance from
   staff at the NANO Major National Research Facility at the Electron
   Microscope Unit, The University of Sydney. We thank Professor Barbara
   Kream, The University of Connecticut, USA, for providing the Col2.3 11
   beta HSD2 tg mice. This work was supported by the National Health and
   Medical Research Council, Australia, Project Grants 402462 and 570946 to
   HZ, MJS and CRD. AW was supported by an educational grant from the
   Charite University Hospital, Berlin, Germany. GL was the recipient of an
   International Visiting Research Fellowship Award from the University of
   Sydney, Australia. The Berlin Brandenburg Center of Regenerative
   Therapies (BCRT) supported this work by a research grant to FB.
CR Aspenberg P, 2005, ACTA ORTHOP, V76, P741, DOI 10.1080/17453670510045318
   BELLOWS CG, 1987, ENDOCRINOLOGY, V121, P1985, DOI 10.1210/endo 121 6 1985
   Campbell TM, 2003, CALCIFIED TISSUE INT, V73, P49, DOI 10.1007/s00223 002 2120 4
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955 0674(00)00276 3
   Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Li G, 2005, CALCIFIED TISSUE INT, V76, P299, DOI 10.1007/s00223 004 0145 6
   Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003 0655
   Smith RE, 1997, ENDOCRINOLOGY, V138, P540, DOI 10.1210/en.138.2.540
   Stewart PM, 1999, VITAM HORM, V57, P249
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Woitge HW, 2001, ENDOCRINOLOGY, V142, P1341, DOI 10.1210/en.142.3.1341
   Zheng Y, 2007, CANCER RES, V67, P9542, DOI 10.1158/0008 5472.CAN 07 1046
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
   Zhou H, 2009, DEVELOPMENT, V136, P427, DOI 10.1242/dev.027706
NR 21
TC 12
Z9 14
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0039 128X
EI 1878 5867
J9 STEROIDS
JI Steroids
PD MAR
PY 2010
VL 75
IS 3
BP 282
EP 286
DI 10.1016/j.steroids.2010.01.005
PG 5
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 571TZ
UT WOS:000275780000012
PM 20096296
DA 2025 08 17
ER

PT J
AU Ikeda, R
   Mizoguchi, K
AF Ikeda, Ryuji
   Mizoguchi, Kazushige
TI Hachimijiogan
   (Ba Wei Di Huang Wan), a herbal
   medicine, improves unbalance of calcium metabolism in aged rats
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Hachimijiogan; Kampo drug; Herbal medicine; Calcium metabolism; Aging;
   Rat
ID TRADITIONAL CHINESE MEDICINE; PARATHYROID HORMONE; JIO GAN; VITAMIN D;
   INTESTINAL RESISTANCE; BONE LOSS; SECONDARY HYPERPARATHYROIDISM;
   RENAL FAILURE; DIABETIC RATS; ELDERLY WOMEN
AB Aim of the study: Aged animals as well as elderly humans commonly exhibit calcium (Ca) shortage because of increased Ca excretion into urine and decreased intestinal Ca absorption, which induce elevation of serum PTH levels to maintain serum Ca levels between a normal physiological range. The most important organ that regulates this Ca homeostasis is the kidney. Hachimijiogan (HJG), a traditional herbal medicine in Japan and China, has been used for treating clinical diseases associated with kidney dysfunctions in elderly humans. However, the mechanisms of its pharmacological actions remain to be understood poorly. The present study was designed to examine whether HJG improves age related unbalance of Ca metabolism at the systemic level using aged rats.
   Materials and methods: HJG was administered to 21 month old aged rats for 3 months, and several parameters associated with Ca metabolism in serum and urine were measured.
   Results: Although HJG as well as aging itself did not affect serum Ca levels compared to young (11 week old) rats, HJG improved increase in urinary Ca excretion and elevation of serum parathyroid hormone (PTH) levels in aged rats. However, HJG did not improve marked reduction of intestinal Ca absorption in aged rats.
   Conclusion: HJG showed regulating action for age related unbalance of Ca metabolism at the systemic level. This finding would provide useful information for treating age related several disorders associated with Ca unbalance. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
C1 [Ikeda, Ryuji; Mizoguchi, Kazushige] NCGG, Natl Inst Longev Sci, Dept Geriatr Med, Sect Oriental Med, Aichi 4748522, Japan.
RP Mizoguchi, K (通讯作者)，NCGG, Natl Inst Longev Sci, Dept Geriatr Med, Sect Oriental Med, 36 3 Gengo, Aichi 4748522, Japan.
EM k mizo@nils.go.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [18590663, 21590781]; Ministry of Health, Labor and Welfare of Japan
   [18C 8]; Grants in Aid for Scientific Research [21590781, 18590663]
   Funding Source: KAKEN
FX We thank all members of our department, particularly Dr. W. Maruyama,
   Dr. H. Shoji and Ms. Y. Tanaka for their experimental supports and
   helpful advice. This work was supported by grants from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (18590663
   and 21590781), and a Research Grant for Longevity Sciences (18C 8) from
   the Ministry of Health, Labor and Welfare of Japan.
CR Ambrose Z, 2007, TRENDS BIOTECHNOL, V25, P333, DOI 10.1016/j.tibtech.2007.05.004
   Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143 4160(03)00141 6
   Björkman MP, 2008, EUR J ENDOCRINOL, V158, P749, DOI 10.1530/EJE 07 0849
   Chen HY, 2005, BIOL PHARM BULL, V28, P865, DOI 10.1248/bpb.28.865
   COSTA EM, 1986, BIOCHEM BIOPH RES CO, V137, P742, DOI 10.1016/0006 291X(86)91141 1
   EASTELL R, 1991, J BONE MINER RES, V6, P125
   FORERO MS, 1987, J BONE MINER RES, V2, P363
   Halloran B, 2002, AM J PHYSIOL ENDOC M, V282, pE557, DOI 10.1152/ajpendo.00261.2001
   Healy KD, 2003, P NATL ACAD SCI USA, V100, P9733, DOI 10.1073/pnas.1633774100
   Hirawa N, 1996, AM J CHINESE MED, V24, P241, DOI 10.1142/S0192415X9600030X
   Hirokawa S, 1996, J ETHNOPHARMACOL, V50, P77, DOI 10.1016/0378 8741(95)01332 6
   Hirotani Y, 2007, BIOL PHARM BULL, V30, P1015, DOI 10.1248/bpb.30.1015
   Honda Hirokazu, 2007, Clin Calcium, V17, P654
   KAMEI A, 1987, J OCUL PHARMACOL, V3, P239, DOI 10.1089/jop.1987.3.239
   Kanehara Masayuki, 2006, J Tradit Chin Med, V26, P72
   Kinsella K., 2001, An Aging World: 2001, US Bureau of the Census
   Lanske B, 2007, J NUTR BIOCHEM, V18, P771, DOI 10.1016/j.jnutbio.2007.02.002
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   MARCUS R, 1984, J CLIN ENDOCR METAB, V58, P223, DOI 10.1210/jcem 58 2 223
   MCCARRON DA, 1980, HYPERTENSION, V2, P162, DOI 10.1161/01.HYP.2.2.162
   MCCARRON DA, 1982, SCIENCE, V217, P267, DOI 10.1126/science.7089566
   McKane WR, 1996, J CLIN ENDOCR METAB, V81, P1699, DOI 10.1210/jc.81.5.1699
   Nakagawa T, 2005, J PHARM PHARMACOL, V57, P1205, DOI 10.1211/jpp.57.9.0016
   Nasri H, 2004, ACTA MED AUST, V31, P67
   Ogirima Takeshi, 2005, J Tradit Chin Med, V25, P226
   ORWOLL ES, 1986, J CLIN ENDOCR METAB, V63, P1262, DOI 10.1210/jcem 63 6 1262
   Pattanaungkul S, 2000, J CLIN ENDOCR METAB, V85, P4023, DOI 10.1210/jc.85.11.4023
   Randon RB, 2005, BRAZ J MED BIOL RES, V38, P1409, DOI 10.1590/S0100 879X2005000900016
   Raza M, 2007, NEUROSCI LETT, V418, P77, DOI 10.1016/j.neulet.2007.03.005
   Riggs BL, 1998, J BONE MINER RES, V13, P168, DOI 10.1359/jbmr.1998.13.2.168
   ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702
   SEEMAN TE, 1994, ENDOCR REV, V15, P233, DOI 10.1210/er.15.2.233
   Tanaka S, 2000, ARCH GERONTOL GERIAT, V30, P215, DOI 10.1016/S0167 4943(00)00053 4
   WISKE PS, 1979, NEW ENGL J MED, V300, P1419, DOI 10.1056/NEJM197906213002506
   Wood RJ, 1998, ENDOCRINOLOGY, V139, P3843, DOI 10.1210/en.139.9.3843
   Yamabe N, 2006, J PHARM PHARMACOL, V58, P535, DOI 10.1211/jpp.58.4.0014
   Yamabe N, 2005, J PHARM PHARMACOL, V57, P1637, DOI 10.1211/jpp.57.12.0014
   Yamabe N, 2007, BIOL PHARM BULL, V30, P520, DOI 10.1248/bpb.30.520
   YOUNG G, 1987, J BONE MINER RES, V2, P367
NR 39
TC 6
Z9 7
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUL 15
PY 2009
VL 124
IS 2
BP 176
EP 181
DI 10.1016/j.jep.2009.04.044
PG 6
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 474LZ
UT WOS:000268286700002
PM 19409475
DA 2025 08 17
ER

PT J
AU Shi, SF
   Jia, JF
   Guo, XK
   Zhao, YP
   Chen, DS
   Guo, YY
   Cheng, T
   Zhang, XL
AF Shi, Si Feng
   Jia, Jing Fu
   Guo, Xiao Kui
   Zhao, Ya Ping
   Chen, De Sheng
   Guo, Yong Yuan
   Cheng, Tao
   Zhang, Xian Long
TI Biocompatibility of chitosan coated iron oxide nanoparticles with
   osteoblast cells
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE chitosan coated iron oxide; magnetic nanoparticles; osteoblasts
ID CELLULAR UPTAKE; OSTEOPOROSIS; ADHESION; TITANIUM; DIFFERENTIATION;
   MICROSTRUCTURE; SCAFFOLDS; NANOMETER; CANCER
AB Background: Bone disorders ( including osteoporosis, loosening of a prosthesis, and bone infections) are of great concern to the medical community and are difficult to cure. Therapies are available to treat such diseases, but all have drawbacks and are not specifically targeted to the site of disease. Chitosan is widely used in the biomedical community, including for orthopedic applications. The aim of the present study was to coat chitosan onto iron oxide nanoparticles and to determine its effect on the proliferation and differentiation of osteoblasts.
   Methods: Nanoparticles were characterized using transmission electron microscopy, dynamic light scattering, x ray diffraction, zeta potential, and vibrating sample magnetometry. Uptake of nanoparticles by osteoblasts was studied by transmission electron microscopy and Prussian blue staining. Viability and proliferation of osteoblasts were measured in the presence of uncoated iron oxide magnetic nanoparticles or those coated with chitosan. Lactate dehydrogenase, alkaline phosphatase, total protein synthesis, and extracellular calcium deposition was studied in the presence of the nanoparticles.
   Results: Chitosan coated iron oxide nanoparticles enhanced osteoblast proliferation, decreased cell membrane damage, and promoted cell differentiation, as indicated by an increase in alkaline phosphatase and extracellular calcium deposition. Chitosan coated iron oxide nanoparticles showed good compatibility with osteoblasts.
   Conclusion: Further research is necessary to optimize magnetic nanoparticles for the treatment of bone disease.
C1 [Shi, Si Feng; Chen, De Sheng; Guo, Yong Yuan; Cheng, Tao; Zhang, Xian Long] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Dept Orthoped Surg, Shanghai 200233, Peoples R China.
   [Jia, Jing Fu; Zhao, Ya Ping] Shanghai Jiao Tong Univ, Sch Chem & Chem Technol, Shanghai 200233, Peoples R China.
   [Guo, Xiao Kui] Shanghai Jiao Tong Univ, Sch Med, Dept Med Microbiol & Parasitol, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Zhang, XL (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Dept Orthoped Surg, 600 Yi Shan Rd, Shanghai 200233, Peoples R China.
EM zhangxianlong20101@163.com
RI Zhang, Xianlong/AAL 8407 2020; Jia, Jingfu/ISU 7795 2023
FU Interdisciplinary (Medical Engineering) Research Fund of Shanghai Jiao
   Tong University [YG2011MS30]
FX This work was supported by the Interdisciplinary (Medical Engineering)
   Research Fund of Shanghai Jiao Tong University (YG2011MS30).
CR Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   Alexiou C, 2003, J DRUG TARGET, V11, P139, DOI 10.3109/1061186031000150791
   Ascenzi MG, 2012, J BONE MINER RES, V27, P702, DOI 10.1002/jbmr.1497
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   Cai KY, 2008, J MATER SCI MATER M, V19, P499, DOI 10.1007/s10856 007 3184 5
   Chen R, 2011, INT J NANOMED, V6, P511, DOI 10.2147/IJN.S16934
   Dempster David W, 2011, Am J Manag Care, V17 Suppl 6, pS164
   Haidar ZS, 2009, J BIOMED MATER RES A, V91A, P919, DOI 10.1002/jbm.a.32292
   Heinemann C, 2008, BIOMACROMOLECULES, V9, P2913, DOI 10.1021/bm800693d
   Jones GL, 2009, BIOMATERIALS, V30, P5376, DOI 10.1016/j.biomaterials.2009.07.028
   Khang D, 2008, BIOMATERIALS, V29, P970, DOI 10.1016/j.biomaterials.2007.11.009
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Li YF, 2011, INT J NANOMED, V6, P815, DOI 10.2147/IJN.S17611
   Ma JB, 2001, BIOMATERIALS, V22, P331, DOI 10.1016/S0142 9612(00)00188 5
   Mathews S, 2011, CELL PROLIFERAT, V44, P537, DOI 10.1111/j.1365 2184.2011.00788.x
   Mou YB, 2011, INT J NANOMED, V6, P2633, DOI 10.2147/IJN.S24307
   Nam HY, 2009, J CONTROL RELEASE, V135, P259, DOI 10.1016/j.jconrel.2009.01.018
   Nhiem T, 2011, ACTA BIOMATER, V7, P1298, DOI 10.1016/j.actbio.2010.10.004
   Ortega D, 2010, PHILOS T R SOC A, V368, P4407, DOI 10.1098/rsta.2010.0172
   Osaka T, 2009, COLLOID SURFACE B, V71, P325, DOI 10.1016/j.colsurfb.2009.03.004
   Pareta RA, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957 4484/19/26/265101
   Polyak B, 2009, EXPERT OPIN DRUG DEL, V6, P53, DOI [10.1517/17425240802662795 , 10.1517/17425240802662795]
   Price RL, 2004, J BIOMED MATER RES A, V70A, P129, DOI 10.1002/jbm.a.30073
   Sànchez Riera L, 2010, BEST PRACT RES CL RH, V24, P793, DOI 10.1016/j.berh.2010.10.003
   Seeman E, 2004, MED J AUSTRALIA, V180, P298, DOI 10.5694/j.1326 5377.2004.tb05931.x
   Selvan ST, 2010, BIOINTERPHASES, V5, pFA110, DOI 10.1116/1.3516492
   Shen LX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026267
   Shi CM, 2006, J SURG RES, V133, P185, DOI 10.1016/j.jss.2005.12.013
   Voltairas PA, 2002, J BIOMECH, V35, P813, DOI 10.1016/S0021 9290(02)00034 9
   Wang L, 2010, BIOMATERIALS, V31, P1691, DOI 10.1016/j.biomaterials.2009.11.053
   Webster TJ, 2000, J BIOMED MATER RES, V51, P475, DOI 10.1002/1097 4636(20000905)51:3<475::AID JBM23>3.0.CO;2 9
   Webster TJ, 2001, TISSUE ENG, V7, P291, DOI 10.1089/10763270152044152
   Zhang YF, 2009, J CONTROL RELEASE, V136, P172, DOI 10.1016/j.jconrel.2009.02.016
   Zhao G, 2005, J BIOMED MATER RES A, V74A, P49, DOI 10.1002/jbm.a.30320
   Zhu XM, 2012, INT J NANOMED, V7, P953, DOI 10.2147/IJN.S28316
NR 35
TC 97
Z9 102
U1 4
U2 70
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2012
VL 7
BP 5593
EP 5602
DI 10.2147/IJN.S34348
PG 10
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA 025MX
UT WOS:000310194600001
PM 23118539
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Dai, J
   Rabie, ABM
AF Dai, Juan
   Rabie, A. Bakr M.
TI Recombinant adeno associated virus vector hybrids efficiently target
   different skeletal cells
SO FRONTIERS IN BIOSCIENCE
LA English
DT Article
DE AAV; eGFP; VEGF; chondrocyte; UMR106; BMSC
ID FIBROBLAST GROWTH FACTOR; MESENCHYMAL STEM CELLS; ACTIVATED GENE
   TRANSDUCTION; ADENO ASSOCIATED VIRUS; IN VIVO; BONE FORMATION;
   OSTEOGENIC DIFFERENTIATION; 2 MEDIATED TRANSDUCTION; TRANSGENE
   EXPRESSION; SUSTAINED EXPRESSION
AB Finding the optimal recombinant adenoassociated virus (rAAV) serotypes for efficient as well as tissue specific transduction has become imperative for successful gene therapy. We used rat condylar chondrocytes, osteoblast like cell line UMR106 and bone marrow stromal cells (BMSCs) to evaluate the transduction efficiency of different rAAV serotypes in vitro; hoping to establish an efficient in vivo rAAV mediated delivery system for gene therapy in craniofacial region. All of the selected rAAV serotypes were able to infect target cells and gave rise to eGFP expression and VEGF secretion. Quantified by fluorescence activated cell sorter (FACS) and ELISA analysis, rAAV2 was superior for efficient transduction of rat chondrocytes, rAAV1 was most efficient when introduced into UMR 106 cell line and rAAV5 yielded the highest infection efficiency in BMSCs. Hence, differences in receptor binding in different oral tissues and transduction pathways suggest rAAV based hybrids have various transduction efficiencies and can efficiently target different oral tissues.
C1 Univ Hong Kong, Fac Dent, Biomed & Tissue Engn Grp, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong
RP Rabie, ABM (通讯作者)，Univ Hong Kong, Fac Dent, Biomed & Tissue Engn Grp, 34 Hosp Rd, Hong Kong, Hong Kong, Peoples R China.
EM rabie@hkusua.hku.hk
RI Rabie, Abou Bakr/B 2169 2009; Dai, Juan/A 4575 2012
CR Arai Y, 2000, J RHEUMATOL, V27, P979
   Berns KI, 1996, CURR TOP MICROBIOL, V218, P1
   Bonadio J, 2002, ANN NY ACAD SCI, V961, P48, DOI 10.1111/j.1749 6632.2002.tb03047.x
   Chen M, 2005, WORLD J GASTROENTERO, V11, P4045, DOI 10.3748/wjg.v11.i26.4045
   Chen Y, 2003, GENE THER, V10, P1345, DOI 10.1038/sj.gt.3301999
   Conway JE, 1997, J VIROL, V71, P8780, DOI 10.1128/JVI.71.11.8780 8789.1997
   Crystal RG, 2004, HUM GENE THER, V15, P1131
   Dai J, 2004, CURR GENE THER, V4, P469
   Dai J, 2007, FRONT BIOSCI LANDMRK, V12, P2212, DOI 10.2741/2224
   Douar AM, 2001, J VIROL, V75, P1824, DOI 10.1128/JVI.75.4.1824 1833.2001
   Flotte TR, 2004, GENE THER, V11, P805, DOI 10.1038/sj.gt.3302233
   Gafni Y, 2004, MOL THER, V9, P587, DOI 10.1016/j.ymthe.2003.12.009
   Gao GP, 2003, P NATL ACAD SCI USA, V100, P6081, DOI 10.1073/pnas.0937739100
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Grimm D., 2003, Current Gene Therapy, V3, P281, DOI 10.2174/1566523034578285
   Grimm D, 2003, MOL THER, V7, P839, DOI 10.1016/S1525 0016(03)00095 9
   Grossin L, 2003, FASEB J, V17, P829, DOI 10.1096/fj.02 0518com
   Hermens WTJMC, 1999, HUM GENE THER, V10, P1885, DOI 10.1089/10430349950017563
   Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983
   Inoue N, 1998, J VIROL, V72, P7024, DOI 10.1128/JVI.72.9.7024 7031.1998
   Ito H, 2004, GENE THER, V11, P34, DOI 10.1038/sj.gt.3302102
   Ju XD, 2004, ACTA PHARMACOL SIN, V25, P196
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kügler S, 2003, VIROLOGY, V311, P89, DOI 10.1016/S0042 6822(03)00162 4
   Kumar S, 2004, HUM GENE THER, V15, P1197, DOI 10.1089/hum.2004.15.1197
   Lotery AJ, 2003, HUM GENE THER, V14, P1663, DOI 10.1089/104303403322542301
   Luk KDK, 2003, BIOCHEM BIOPH RES CO, V308, P636, DOI 10.1016/S0006 291X(03)01429 3
   Madry H, 2003, HUM GENE THER, V14, P393, DOI 10.1089/104303403321208998
   McMahon JM, 2006, STEM CELLS DEV, V15, P87, DOI 10.1089/scd.2006.15.87
   Molténi A, 1999, BONE, V24, P337, DOI 10.1016/S8756 3282(98)00191 4
   Monahan PE, 2000, MOL MED TODAY, V6, P433, DOI 10.1016/S1357 4310(00)01810 4
   MUZYCZKA N, 1984, ADV EXP MED BIOL, V179, P151
   Natsu K, 2004, TISSUE ENG, V10, P1093, DOI 10.1089/1076327041887754
   Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923
   Ohashi S, 2002, BIOCHEM BIOPH RES CO, V293, P1530, DOI 10.1016/S0006 291X(02)00386 8
   Oligino TJ, 2000, CLIN ORTHOP RELAT R, pS17
   Pan RY, 2000, ARTHRITIS RHEUM, V43, P289, DOI 10.1002/1529 0131(200002)43:2<289::AID ANR8>3.0.CO;2 H
   Ponnazhagan S, 1997, J VIROL, V71, P3098, DOI 10.1128/JVI.71.4.3098 3104.1997
   Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758
   Rabie ABM, 2002, AM J ORTHOD DENTOFAC, V122, P401, DOI 10.1067/mod.2002.125713
   Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791 801.2002
   Reiter I, 2002, BONE, V31, P333, DOI 10.1016/S8756 3282(02)00823 2
   Salvetti A, 1998, HUM GENE THER, V9, P695, DOI 10.1089/hum.1998.9.5 695
   Smith AD, 2003, J VIROL, V77, P6394, DOI 10.1128/JVI.77.11.6394 6404.2003
   Smith Arica JR, 2003, CLONING STEM CELLS, V5, P51, DOI 10.1089/153623003321512166
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768
   Tajima Y, 1998, ARCH ORAL BIOL, V43, P873, DOI 10.1016/S0003 9969(98)00070 3
   Tamayose K, 1996, HUM GENE THER, V7, P507, DOI 10.1089/hum.1996.7.4 507
   Tan MQ, 2001, MOL THER, V3, P940, DOI 10.1006/mthe.2001.0346
   Tarkka T, 2003, J GENE MED, V5, P560, DOI 10.1002/jgm.392
   Ulrich Vinther M, 2005, Eur Cell Mater, V10, P40
   Ulrich Vinther M, 2004, J ORTHOP RES, V22, P726, DOI 10.1016/j.orthres.2003.12.003
   Ulrich Vinther M, 2002, ARTHRITIS RHEUM US, V46, P2095, DOI 10.1002/art.10433
   Visnapuu V, 2002, Orthod Craniofac Res, V5, P147, DOI 10.1034/j.1600 0544.2002.02205.x
   Weber JM, 2006, BONE, V39, P485, DOI 10.1016/j.bone.2006.03.002
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224 2232.1998
   YOVANDICH J, 1995, HUM GENE THER, V6, P603, DOI 10.1089/hum.1995.6.5 603
NR 59
TC 10
Z9 13
U1 0
U2 5
PU FRONTIERS IN BIOSCIENCE INC
PI MANHASSET
PA C/O NORTH SHORE UNIV HOSPITAL, BIOMEDICAL RESEARCH CENTER, 350 COMMUNITY
   DR, MANHASSET, NY 11030 USA
SN 1093 9946
J9 FRONT BIOSCI
JI Front. Biosci.
PD MAY 1
PY 2007
VL 12
BP 4280
EP 4287
DI 10.2741/2387
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 163KG
UT WOS:000246157900117
PM 17485374
OA Bronze
DA 2025 08 17
ER

PT J
AU Yu, W
   Chen, FC
   Xu, WN
   Ding, SL
   Chen, PB
   Yang, L
   Jiang, SD
   Pan, XY
AF Yu, Wei
   Chen, Fan Cheng
   Xu, Wen Ning
   Ding, Sheng Long
   Chen, Peng Bo
   Yang, Lei
   Jiang, Sheng Dan
   Pan, Xiao Yun
TI Inhibition of Y1 Receptor Promotes Osteogenesis in Bone Marrow Stromal
   Cells via cAMP/PKA/CREB Pathway
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE neuropeptide Y1 receptor; RUNX2; osteogenesis; bone marrow stromal cells
   (BMSCs); protein kinase A
ID MESENCHYMAL STEM CELLS; NEUROPEPTIDE Y; OSTEOBLAST DIFFERENTIATION;
   TRANSCRIPTION FACTOR; ADENYLATE CYCLASE; SIGNALING PATHWAY; RUNX2; ZINC;
   ACTIVATION; CREB
AB Inhibition of neuropeptide Y1 receptor stimulates osteogenesis in vitro and in vivo. However, the underlying mechanisms involved in these effects remain poorly understood. Here we identify the effects of Y1 receptor deficiency on osteogenic differentiation in human bone marrow stromal cells (BMSCs) by using genetic and pharmacological regulation, and to explore the pathways mediating these effects. In BMSCs, inhibition of Y1 receptor stimulates osteogenesis and upregulates the expression levels of the master transcriptional factor RUNX2. Mechanistically, Y1 receptor deficiency increases the levels of intracellular cAMP, which via protein kinase A (PKA) mediated pathways results in activation of phospho CREB (p CREB). We find RUNX2 activation induced by Y1 receptor deficiency is reversed by H 89, a PKA inhibitor. These results indicate Y1 receptor deficiency activates PKA mediated phosphorylation of CREB, leading to activation of RUNX2 and enhances osteogenic differentiation in BMSCs. In conclusion, these data indicate that Y1 receptor deficiency promotes osteogenic differentiation by RUNX2 stimulation through cAMP/PKA/CREB pathway.
C1 [Yu, Wei; Yang, Lei; Pan, Xiao Yun] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.
   [Yu, Wei; Yang, Lei; Pan, Xiao Yun] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
   [Yu, Wei; Xu, Wen Ning; Chen, Peng Bo; Jiang, Sheng Dan] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Clin,Spine Ctr, Shanghai, Peoples R China.
   [Chen, Fan Cheng] Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China.
   [Ding, Sheng Long] Fudan Univ, Zhongshan Hosp, Dept Orthopaed, Qingpu Branch, Shanghai, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Shanghai Jiao
   Tong University; Fudan University; Fudan University
RP Pan, XY (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Peoples R China.; Pan, XY (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.; Jiang, SD (通讯作者)，Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Clin,Spine Ctr, Shanghai, Peoples R China.
EM jiangshengdan@xinhuamed.com.cn; wzfeygk@163.com
RI Ding, Shenglong/AAM 5776 2020
FU National Natural Science Foundation of China [81672206]; Zhejiang
   Province Technology Project [2015C33209]; Wenzhou Technology Project
   [Y20150243]
FX This work was supported by National Natural Science Foundation of China
   (Grant No.: 81672206); Zhejiang Province Technology Project (grant
   number 2015C33209); and Wenzhou Technology Project (grant number
   Y20150243).
CR Adhami MD, 2015, J BONE MINER RES, V30, P71, DOI 10.1002/jbmr.2321
   Bai JL, 2010, ENVIRON MOL MUTAGEN, V51, P112, DOI 10.1002/em.20517
   Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200
   BJURHOLM A, 1992, J BONE MINER RES, V7, P1011
   Cheng AX, 2010, J BONE MINER RES, V25, P2404, DOI 10.1002/jbmr.174
   Czarnecka M, 2019, NEUROPEPTIDES, V73, P11, DOI 10.1016/j.npep.2018.11.008
   Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003
   Derghal A, 2017, FRONT NEUROSCI SWITZ, V11, DOI 10.3389/fnins.2017.00181
   Doorn J, 2011, BIOMATERIALS, V32, P6089, DOI 10.1016/j.biomaterials.2011.05.010
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Harrell CR, 2019, BIOMED PHARMACOTHER, V109, P2318, DOI 10.1016/j.biopha.2018.11.099
   HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083
   Igwe JC, 2009, J CELL BIOCHEM, V108, P621, DOI 10.1002/jcb.22294
   KASSIS S, 1987, J BIOL CHEM, V262, P3429
   Kim JM, 2013, J CELL PHYSIOL, V228, P617, DOI 10.1002/jcp.24171
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lee NJ, 2010, J BONE MINER RES, V25, P1736, DOI 10.1002/jbmr.61
   Li TF, 2004, EXP CELL RES, V299, P128, DOI 10.1016/j.yexcr.2004.05.025
   Loh K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00624 2
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Park KH, 2018, STEM CELLS DEV, V27, P1125, DOI 10.1089/scd.2018.0023
   Pedrazzini T, 2004, NEUROPEPTIDES, V38, P267, DOI 10.1016/j.npep.2004.05.007
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   SELBIE LA, 1993, J BIOL CHEM, V268, P24296
   Shi WG, 2017, J BIOL CHEM, V292, P20883, DOI 10.1074/jbc.M117.809517
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Sousa DM, 2009, CURR DRUG TARGETS, V10, P9, DOI 10.2174/138945009787122888
   Sousa DM, 2012, BONE, V51, P8, DOI 10.1016/j.bone.2012.03.020
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Stevenson AS, 2001, EXP CELL RES, V263, P118, DOI 10.1006/excr.2000.5107
   von Bülow V, 2005, J IMMUNOL, V175, P4697, DOI 10.4049/jimmunol.175.7.4697
   Wellinghausen N, 1996, CYTOKINE, V8, P767, DOI 10.1006/cyto.1996.0102
   Yahara M, 2017, MOL MED REP, V16, P2779, DOI 10.3892/mmr.2017.6866
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Ying XZ, 2015, EUR J PHARMACOL, V765, P394, DOI 10.1016/j.ejphar.2015.09.005
   Yu W, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122150
   Yulyaningsih E, 2011, BRIT J PHARMACOL, V163, P1170, DOI 10.1111/j.1476 5381.2011.01363.x
   Zhang L, 2011, PHARMACOL THERAPEUT, V131, P91, DOI 10.1016/j.pharmthera.2011.03.011
   Zhang ZR, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060588
NR 41
TC 12
Z9 15
U1 2
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD NOV 10
PY 2020
VL 11
AR 583105
DI 10.3389/fendo.2020.583105
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OU6OG
UT WOS:000591645200001
PM 33240219
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mace, ML
   Egstrand, S
   Morevati, M
   Olgaard, K
   Lewin, E
AF Mace, Maria L.
   Egstrand, Soren
   Morevati, Marya
   Olgaard, Klaus
   Lewin, Ewa
TI New Insights to the Crosstalk between Vascular and Bone Tissue in
   Chronic Kidney Disease Mineral and Bone Disorder
SO METABOLITES
LA English
DT Article
DE uremic vasculopathy; vascular calcification; renal osteodystrophy;
   tissue crosstalk; Wnt pathway; sclerostin; dickkopf 1; TGF beta
   signaling; activin A
ID MICROVASCULAR ENDOTHELIAL CELLS; SERUM SCLEROSTIN LEVELS; NITRIC OXIDE
   SYNTHASE; CARDIOVASCULAR DISEASE; ACTIVIN A; OSTEOPROGENITOR
   PROLIFERATION; ARTERIAL CALCIFICATION; CIRCADIAN CLOCK; MORTALITY RISK;
   SMOOTH MUSCLE
AB Vasculature plays a key role in bone development and the maintenance of bone tissue throughout life. The two organ systems are not only linked in normal physiology, but also in pathophysiological conditions. The chronic kidney disease mineral and bone disorder (CKD MBD) is still the most serious complication to CKD, resulting in increased morbidity and mortality. Current treatment therapies aimed at the phosphate retention and parathyroid hormone disturbances fail to reduce the high cardiovascular mortality in CKD patients, underlining the importance of other factors in the complex syndrome. This review will focus on vascular disease and its interplay with bone disorders in CKD. It will present the very late data showing a direct effect of vascular calcification on bone metabolism, indicating a vascular bone tissue crosstalk in CKD. The calcified vasculature not only suffers from the systemic effects of CKD but seems to be an active player in the CKD MBD syndrome impairing bone metabolism and might be a novel target for treatment and prevention.
C1 [Mace, Maria L.; Egstrand, Soren; Morevati, Marya; Olgaard, Klaus; Lewin, Ewa] Univ Copenhagen, Rigshosp, Dept Nephrol, DK 2100 Copenhagen, Denmark.
   [Egstrand, Soren; Lewin, Ewa] Univ Copenhagen, Herlev Hosp, Dept Nephrol, DK 2100 Copenhagen, Denmark.
C3 University of Copenhagen; Copenhagen University Hospital;
   Rigshospitalet; University of Copenhagen; Herlev & Gentofte Hospital
RP Mace, ML (通讯作者)，Univ Copenhagen, Rigshosp, Dept Nephrol, DK 2100 Copenhagen, Denmark.
EM marya.morevati@regionh.dk; ewa.lewin@regionh.dk
RI Egstrand, Søren/HNO 9853 2023
OI Egstrand, Soren/0000 0001 7159 2857; Morevati, Marya/0000 0001 9166 0319
FU Danish Heart Association [19 R132 A9209 22141, 16 R107 A6720 22012];
   Augustinus Foundation [19 2370]
FX The original studies on vascular bone crosstalk referred to in the
   review received unrestricted grants from the Danish Heart Association,
   grant numbers 19 R132 A9209 22141 and 16 R107 A6720 22012; and the
   Augustinus Foundation, grant number 19 2370 to M.L.M.
CR Abbasian N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113534
   Agapova OA, 2016, KIDNEY INT, V89, P1231, DOI 10.1016/j.kint.2016.02.002
   Ahmed SF, 2013, J OSTEOPOROS, V2013, DOI 10.1155/2013/460210
   Andrukhova O, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00311
   Arasu A, 2012, J CLIN ENDOCR METAB, V97, P2027, DOI 10.1210/jc.2011 3419
   Asci G, 2011, NEPHROL DIAL TRANSPL, V26, P1010, DOI 10.1093/ndt/gfq491
   Bäck M, 2019, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00196
   Badimon L, 2017, CURR OPIN HEMATOL, V24, P230, DOI 10.1097/MOH.0000000000000336
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Behets GJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176411
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Block GA, 2013, CLIN J AM SOC NEPHRO, V8, P2132, DOI 10.2215/CJN.04260413
   Bloise E, 2019, PHYSIOL REV, V99, P739, DOI 10.1152/physrev.00002.2018
   BOUKHRIS R, 1972, J AMER MED ASSOC, V219, P1307, DOI 10.1001/jama.219.10.1307
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534 200206000 00033
   Brandenburg VM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 219
   Butler JS, 2011, J ORTHOP RES, V29, P414, DOI 10.1002/jor.21260
   Cantatore FP, 2005, CELL BIOL INT, V29, P583, DOI 10.1016/j.cellbi.2005.03.011
   Carrillo López N, 2016, KIDNEY INT, V90, P77, DOI 10.1016/j.kint.2016.01.024
   Carulli Christian, 2013, Front Endocrinol (Lausanne), V4, P106, DOI 10.3389/fendo.2013.00106
   Cejka D, 2012, NEPHROL DIAL TRANSPL, V27, P226, DOI 10.1093/ndt/gfr270
   Cejka D, 2011, CLIN J AM SOC NEPHRO, V6, P877, DOI 10.2215/CJN.06550810
   Chen M, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00138 0
   Clarkin CE, 2008, J CELL PHYSIOL, V214, P537, DOI 10.1002/jcp.21234
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   Dai L, 2020, NEPHROL DIAL TRANSPL, V35, P31, DOI 10.1093/ndt/gfaa006
   Davies MR, 2005, J AM SOC NEPHROL, V16, P917, DOI 10.1681/ASN.2004100835
   Davies MR, 2003, J AM SOC NEPHROL, V14, P1559, DOI 10.1097/01.ASN.0000068404.57780.DD
   De Maré A, 2019, TOXINS, V11, DOI 10.3390/toxins11070428
   Dhingra R, 2007, ARCH INTERN MED, V167, P879, DOI 10.1001/archinte.167.9.879
   Dou JX, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475 2840 13 74
   Dreyer T, 2021, J ORTHOP TRANSL, V29, P134, DOI 10.1016/j.jot.2021.05.005
   Drüeke TB, 2010, NAT REV NEPHROL, V6, P723, DOI 10.1038/nrneph.2010.143
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Edmonds ME, 2000, Z KARDIOL, V89, P101
   Egstrand S, 2021, CELLS BASEL, V10, DOI 10.3390/cells10071769
   Egstrand S, 2020, KIDNEY INT, V98, P1461, DOI 10.1016/j.kint.2020.06.034
   Egstrand S, 2020, CURR OPIN NEPHROL HY, V29, P367, DOI 10.1097/MNH.0000000000000611
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Epsley S, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.511799
   Fang YF, 2014, J AM SOC NEPHROL, V25, P1760, DOI 10.1681/ASN.2013080818
   Fields GB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01278
   FRYE MA, 1992, BONE MINER, V19, P185, DOI 10.1016/0169 6009(92)90925 4
   FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Graciolli FG, 2017, KIDNEY INT, V91, P1436, DOI 10.1016/j.kint.2016.12.029
   Gravesen E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201936
   Gravesen E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190820
   Hak AE, 2000, ARTERIOSCL THROM VAS, V20, P1926, DOI 10.1161/01.ATV.20.8.1926
   Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108
   Hruska KA, 2017, BONE, V100, P80, DOI 10.1016/j.bone.2017.01.023
   Hyder JA, 2007, CALCIFIED TISSUE INT, V80, P301, DOI 10.1007/s00223 007 9004 6
   Ishimura E, 2014, J CLIN ENDOCR METAB, V99, P4315, DOI 10.1210/jc.2014 2372
   Ito N, 2021, CALCIFIED TISSUE INT, V109, P66, DOI 10.1007/s00223 021 00823 6
   Jahng JWS, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.20
   Jankowski J, 2021, CIRCULATION, V143, P1157, DOI 10.1161/CIRCULATIONAHA.120.050686
   Jorgensen HS, 2021, CALCIFIED TISSUE INT, V108, P496, DOI 10.1007/s00223 020 00786 0
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Kiran S, 2021, CELLS BASEL, V10, DOI 10.3390/cells10051004
   Krüger Genge A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184411
   Kuo TH, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882 019 1452 5
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Kyriakidis NC, 2021, TOXINS, V13, DOI 10.3390/toxins13010026
   Laroche M, 2005, CALCIFIED TISSUE INT, V77, P129, DOI 10.1007/s00223 005 0250 1
   Lewin E, 1997, KIDNEY INT, V52, P1232, DOI 10.1038/ki.1997.448
   LEWIN E, 1993, SCAND J UROL NEPHROL, V27, P115, DOI 10.3109/00365599309180425
   Lewin E, 2015, KIDNEY INT, V87, P1089, DOI 10.1038/ki.2015.80
   Li DS, 2021, THER ADV ENDOCRINOL, V12, DOI 10.1177/20420188211025161
   Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7
   Lin IC, 2008, PLAST RECONSTR SURG, V121, P1554, DOI 10.1097/PRS.0b013e31816c3bd7
   LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0
   Liu P, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00883
   Lodberg A, 2021, CYTOKINE GROWTH F R, V60, P1, DOI 10.1016/j.cytogfr.2021.04.001
   Luo ZL, 2019, AM J PATHOL, V189, P1495, DOI 10.1016/j.ajpath.2019.05.005
   Lv W, 2016, INT UROL NEPHROL, V48, P2043, DOI 10.1007/s11255 016 1379 8
   Mace ML, 2021, J BONE MINER RES, V36, P510, DOI 10.1002/jbmr.4203
   Mace ML, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228810
   Mace ML, 2017, KIDNEY INT, V92, P165, DOI 10.1016/j.kint.2017.01.015
   Malyszko J, 2010, CLIN CHIM ACTA, V411, P1412, DOI 10.1016/j.cca.2010.06.019
   Martin A, 2012, PHYSIOL REV, V92, P131, DOI 10.1152/physrev.00002.2011
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2015, J BONE MINER RES, V30, P539, DOI 10.1002/jbmr.2372
   Morena M, 2015, NEPHROL DIAL TRANSPL, V30, P1345, DOI 10.1093/ndt/gfv081
   Murali SK, 2016, J BONE MINER RES, V31, P129, DOI 10.1002/jbmr.2606
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Naveh Many T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124332
   Nordholm A, 2019, PFLUG ARCH EUR J PHY, V471, P1079, DOI 10.1007/s00424 019 02291 2
   Nordholm A, 2018, AM J PHYSIOL RENAL, V314, pF753, DOI 10.1152/ajprenal.00528.2017
   PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0
   Pasch A, 2018, INT J NEPHROL, V2018, DOI 10.1155/2018/9182078
   Pelletier S, 2015, OSTEOPOROSIS INT, V26, P2165, DOI 10.1007/s00198 015 3127 9
   Persy V, 2009, TRENDS MOL MED, V15, P405, DOI 10.1016/j.molmed.2009.07.001
   Rehman A, 2021, TRENDS ENDOCRIN MET, V32, P238, DOI 10.1016/j.tem.2020.12.001
   RIANCHO JA, 1995, J BONE MINER RES, V10, P439
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Romero A, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082082
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Rowe PSN, 2012, CRIT REV EUKAR GENE, V22, P61, DOI 10.1615/CritRevEukarGeneExpr.v22.i1.50
   Rukov JL, 2016, AM J PHYSIOL RENAL, V310, pF477, DOI 10.1152/ajprenal.00472.2015
   Ryan ZC, 2013, P NATL ACAD SCI USA, V110, P6199, DOI 10.1073/pnas.1221255110
   Sabbagh Y, 2012, J BONE MINER RES, V27, P1757, DOI 10.1002/jbmr.1630
   Sanchis P, 2019, KIDNEY INT, V95, P958, DOI 10.1016/j.kint.2018.12.014
   Sang Q X, 1998, Cell Res, V8, P171
   Santhanam L, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI147116
   Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80
   Shalhoub V, 2012, J CLIN INVEST, V122, P2543, DOI 10.1172/JCI61405
   Shan C, 2021, J ENDOCRINOL, V249, pR43, DOI 10.1530/JOE 20 0203
   Shan C, 2019, MOL BRAIN, V12, DOI 10.1186/s13041 019 0444 5
   Shanahan CM, 2000, Z KARDIOL, V89, P63
   Sheng ZF, 2012, CLIN ENDOCRINOL, V76, P797, DOI 10.1111/j.1365 2265.2011.04315.x
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sivaraj KK, 2016, DEVELOPMENT, V143, P2706, DOI 10.1242/dev.136861
   Slatopolsky E, 1999, AM J MED SCI, V317, P370, DOI 10.1097/00000441 199906000 00004
   Sorensen IMH, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882 020 02192 y
   Stegen S, 2018, BONE, V115, P50, DOI 10.1016/j.bone.2017.08.022
   Szulc P, 2013, J BONE MINER RES, V28, P1760, DOI 10.1002/jbmr.1888
   Thambiah S, 2012, CALCIFIED TISSUE INT, V90, P473, DOI 10.1007/s00223 012 9595 4
   Tonelli M, 2005, CIRCULATION, V112, P2627, DOI 10.1161/CIRCULATIONAHA.105.553198
   Toussain ND, 2008, NEPHROL DIAL TRANSPL, V23, P586, DOI 10.1093/ndt/gfm660
   Valdivielso JM, 2019, ARTERIOSCL THROM VAS, V39, P1938, DOI 10.1161/ATVBAHA.119.312705
   VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0
   Van den Bergh G, 2019, TRENDS MOL MED, V25, P1133, DOI 10.1016/j.molmed.2019.08.006
   Veeriah V, 2016, SCI REP UK, V6, DOI 10.1038/srep29880
   Veillette CJH, 2004, BONE, V34, P288, DOI 10.1016/j.bone.2003.10.009
   von Schroeder HP, 2003, BONE, V33, P673, DOI 10.1016/S8756 3282(03)00215 1
   Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030503
   Wang ZH, 2021, ADV EXP MED BIOL, V1303, P333, DOI 10.1007/978 3 030 63046 1_18
   Williams J, 2020, MICROCIRCULATION, V27, DOI 10.1111/micc.12613
   Williams MJ, 2018, KIDNEY INT, V93, P147, DOI 10.1016/j.kint.2017.06.016
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yang XB, 2003, J BONE MINER RES, V18, P47, DOI 10.1359/jbmr.2003.18.1.47
   Zelt JGE, 2019, J BONE MINER RES, V34, P270, DOI 10.1002/jbmr.3572
   Zschiedrich S, 2016, NEPHROL DIAL TRANSPL, V31, P284, DOI 10.1093/ndt/gfv077
NR 139
TC 16
Z9 16
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 1989
J9 METABOLITES
JI Metabolites
PD DEC
PY 2021
VL 11
IS 12
AR 849
DI 10.3390/metabo11120849
PG 18
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA XX5KM
UT WOS:000736334300001
PM 34940607
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xiao, HXZ
   Qi, RJ
   Wang, ZL
   Xiao, MH
   Xiang, Y
   Wang, YP
   Wang, L
AF Xiao, Hanxianzhi
   Qi, Rongjia
   Wang, Ziling
   Xiao, Minghe
   Xiang, Yue
   Wang, Yaping
   Wang, Lu
TI Angelica sinensis polysaccharides ameliorate
   5 flourouracil induced bone marrow stromal cell proliferation inhibition
   via regulating Wnt/β catenin signaling
SO BIOCELL
LA English
DT Article
DE Angelica sinensis polysaccharides; 5 Fluorouracil; Wnt/beta catenin
   signaling pathway; Oxidative stress; Cell proliferation; FoxO1
ID HEMATOPOIETIC STEM CELL; FORKHEAD TRANSCRIPTION FACTORS; BETA CATENIN;
   OXIDATIVE STRESS; SELF RENEWAL; STRUCTURAL CHARACTERIZATION; FUNCTIONAL
   INTERACTION; IN VITRO; WNT; FOXO
AB Chemotherapy may cause cellular oxidative stress to bone marrow. Oxidative damage of bone marrow hematopoietic microenvironment is closely related to chronic myelosuppression after chemotherapeutic treatment. Angelica sinensis polysaccharides (ASP) are major effective ingredients of traditional Chinese medicine Angelica with multi target anti oxidative stress features. In the current study, we investigated the protective roles and mechanisms of ASP on chemotherapy induced bone marrow stromal cell (BMSC) damage. The human bone marrow stromal cell line HS 5 cells were divided into control group, 5 FU group, 5 FU + ASP group, and 5 FU + LiCl group to investigate the mechanism of ASP to alleviate 5 FU induced BMSC proliferation inhibition. The results showed that 5 FU inhibits the growth of HS 5 cells in a time and dose dependent manner; however, ASP partially counteracted the 5 FU induced decrease in cell viability, whereas Wnt signaling inhibitor Dkk1 antagonized the effect of ASP on HS 5 cells. ASP reversed the decrease in total cytoplasmic beta catenin, p GSK 3 beta, and CyclinD1 following 5 FU treatment and modulated nuclear expression of beta catenin, Lef 1, and C myc proteins. Furthermore, ASP also enhanced the antioxidant capacity of cells and reduced 5 FU induced oxidative stress, attenuated FoxO1 expression, thus weakened its downstream apoptosis related proteins and G0/G1 checkpoint associated p27(Kip1) expression to alleviate 5 FU induced apoptosis and to promote cell cycle progression. All the results above suggest that the protective role of ASP in 5 FU treated BMSCs proliferation for the chemotherapy may be related to its activating Wnt/beta catenin signaling and keeping homeostasis between beta catenin and FoxO1 under oxidative stress. The study provides a potential therapeutic strategy for alleviating chemotherapeutic damage on BMSCs.
C1 [Xiao, Hanxianzhi; Qi, Rongjia; Wang, Ziling; Xiao, Minghe; Xiang, Yue; Wang, Yaping; Wang, Lu] Chongqing Med Univ, Dept Histol & Embryol, Lab Stem Cell & Tissue Engn, Chongqing 40012, Peoples R China.
C3 Chongqing Medical University
RP Wang, L (通讯作者)，Chongqing Med Univ, Dept Histol & Embryol, Lab Stem Cell & Tissue Engn, Chongqing 40012, Peoples R China.
EM luwang@cqmu.edu.cn
RI xiao, ming/KHT 1774 2024; 王, 璐/HTO 2844 2023; Xiang, Yue/JVO 8485 2024
FU National Natural Science Foundation of China [81873103]; Foundation and
   Frontier Research Project of Chongqing Science and Technology Commission
   [cstc2014jcyjA10001]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81873103), the Foundation and Frontier Research Project
   of Chongqing Science and Technology Commission (Grant No.
   cstc2014jcyjA10001).
CR Ai ST, 2013, CARBOHYD POLYM, V94, P731, DOI 10.1016/j.carbpol.2013.02.007
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Beauséjour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bradley RR, 1999, AM J KIDNEY DIS, V34, P349, DOI 10.1016/S0272 6386(99)70367 7
   Braunschweig L, 2015, MOL CELL NEUROSCI, V67, P84, DOI 10.1016/j.mcn.2015.06.006
   Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629
   Cao W, 2010, INT J BIOL MACROMOL, V46, P115, DOI 10.1016/j.ijbiomac.2009.11.005
   Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200
   Crawford J, 2004, CANCER AM CANCER SOC, V100, P228, DOI 10.1002/cncr.11882
   Danciu TE, 2004, J DENT RES, V83, P596, DOI 10.1177/154405910408300803
   Deng SX, 2006, J NAT PROD, V69, P536, DOI 10.1021/np050301s
   Dietz BM, 2016, PHARMACOL REV, V68, P1026, DOI 10.1124/pr.115.010843
   Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960 9822(00)00728 4
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140 6736(00)02034 1
   DRITSCHILO A, 1981, ENVIRON HEALTH PERSP, V39, P59, DOI 10.2307/3429279
   Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507
   Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083
   Famili F, 2016, STEM CELL REP, V6, P652, DOI 10.1016/j.stemcr.2016.04.009
   Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003
   Galotto M, 1999, EXP HEMATOL, V27, P1460, DOI 10.1016/S0301 472X(99)00076 4
   Gomes AR, 2008, CELL CYCLE, V7, P3133, DOI 10.4161/cc.7.20.6920
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   Han JL, 2015, J NEUROCHEM, V134, P879, DOI 10.1111/jnc.13199
   Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200
   Hu WY, 2016, CLIN CANCER RES, V22, P2000, DOI 10.1158/1078 0432.CCR 15 1421
   Huang J, 2012, NAT MED, V18, P1778, DOI 10.1038/nm.2984
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388
   Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365 2443.2003.00620.x
   Iyer S, 2013, J CLIN INVEST, V123, P3409, DOI 10.1172/JCI68049
   Ji P, 2014, INT J BIOL MACROMOL, V67, P195, DOI 10.1016/j.ijbiomac.2014.03.025
   Jin ML, 2012, CARBOHYD POLYM, V89, P713, DOI 10.1016/j.carbpol.2012.04.049
   Kemp K, 2010, ANN HEMATOL, V89, P701, DOI 10.1007/s00277 009 0896 2
   Kim JA, 2009, STEM CELLS, V27, P1318, DOI 10.1002/stem.52
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025 2036.2002
   Kuter DJ, 2015, ONCOLOGY NY, V29, P282
   Lai P, 2015, PHARM BIOL, V53, P1842, DOI 10.3109/13880209.2015.1027779
   Lei T, 2014, NEURAL REGEN RES, V9, P260, DOI 10.4103/1673 5374.128218
   Lento W, 2014, GENE DEV, V28, P995, DOI 10.1101/gad.231944.113
   Li J, 2004, BRIT J HAEMATOL, V127, P326, DOI 10.1111/j.1365 2141.2004.05200.x
   Lin CL, 2008, ENDOCRINOLOGY, V149, P2934, DOI 10.1210/en.2007 1372
   Liu C, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472 6882 10 79
   Liu PJ, 2010, EXP HEMATOL, V38, P437, DOI 10.1016/j.exphem.2010.03.012
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Losick VP, 2011, DEV CELL, V21, P159, DOI 10.1016/j.devcel.2011.06.018
   Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017
   Ma YY, 2012, CELL BIOL INT, V36, P923, DOI 10.1042/CBI20120078
   Malhotra S, 2009, CELL STEM CELL, V4, P27, DOI 10.1016/j.stem.2008.12.004
   MARSH JC, 1976, CANCER RES, V36, P1853
   Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115
   Meng AM, 2003, CANCER RES, V63, P5414
   Ming M, 2012, J BIOL CHEM, V287, P22683, DOI 10.1074/jbc.M112.342089
   Mohammed MK, 2016, GENES DIS, V3, P11, DOI 10.1016/j.gendis.2015.12.004
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003
   Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038
   Mu XY, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3508907
   Nakae J, 2008, FEBS LETT, V582, P54, DOI 10.1016/j.febslet.2007.11.025
   Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969 8982.2000
   Nemeth MJ, 2009, STEM CELLS, V27, P1109, DOI 10.1002/stem.32
   Nicolay NH, 2016, SCI REP UK, V6, DOI 10.1038/srep26645
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Oh IH, 2010, EXPERT OPIN BIOL TH, V10, P1315, DOI 10.1517/14712598.2010.504705
   Oliveira MS, 2014, TOXICOL LETT, V224, P380, DOI 10.1016/j.toxlet.2013.11.023
   Owusu Ansah E, 2009, NATURE, V461, P537, DOI 10.1038/nature08313
   Papac Rose J., 2001, Yale Journal of Biology and Medicine, V74, P391
   Petersen CP, 2009, CELL, V139, P1056, DOI 10.1016/j.cell.2009.11.035
   Prata KD, 2010, EXP HEMATOL, V38, P292, DOI 10.1016/j.exphem.2010.01.006
   Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535 6108(02)00086 7
   Richter J, 2017, CRIT REV BIOCHEM MOL, V52, P414, DOI 10.1080/10409238.2017.1325828
   Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723
   Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387
   Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842 7852.2002
   Schreck C, 2014, ANN NY ACAD SCI, V1310, P32, DOI 10.1111/nyas.12384
   Shang P, 2003, WORLD J GASTROENTERO, V9, P1963, DOI 10.3748/wjg.v9.i9.1963
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Somaiah C, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0407 7
   Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024
   Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200
   TESTA NG, 1985, ANTICANCER RES, V5, P101
   Tsai NM, 2005, CLIN CANCER RES, V11, P3475, DOI 10.1158/1078 0432.CCR 04 1827
   Wang KP, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/7601592
   Wang SS, 2015, LIFE SCI, V123, P86, DOI 10.1016/j.lfs.2015.01.002
   Wang Y, 2010, FREE RADICAL BIO MED, V48, P348, DOI 10.1016/j.freeradbiomed.2009.11.005
   Wei WL, 2016, J ETHNOPHARMACOL, V190, P116, DOI 10.1016/j.jep.2016.05.023
   Wilson PM, 2014, NAT REV CLIN ONCOL, V11, P282, DOI 10.1038/nrclinonc.2014.51
   Xiao HXZ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112265
   Xie X, 2019, BONE JOINT RES, V8, P323, DOI [10.1302/2046 3758.87.BJR 2018 0223.R2, 10.1302/2046 3758.87BJR 2018 0223.R2]
   Yang TH, 2006, INT J BIOL MACROMOL, V39, P179, DOI 10.1016/j.ijbiomac.2006.02.013
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhang KY, 2020, AGING US, V12, P8029, DOI 10.18632/aging.103121
   Zhang S, 2010, INT J BIOL MACROMOL, V47, P546, DOI 10.1016/j.ijbiomac.2010.07.012
   Zhang Y, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111869
   Zhang Y, 2016, CARBOHYD POLYM, V147, P401, DOI 10.1016/j.carbpol.2016.04.002
   Zhang Y, 2014, FOOD FUNCT, V5, P1381, DOI 10.1039/c4fo00006d
   Zhao KJ, 2003, J AGR FOOD CHEM, V51, P2576, DOI 10.1021/jf026178h
   Zhao L, 2012, FITOTERAPIA, V83, P1712, DOI 10.1016/j.fitote.2012.09.029
   Zhuang C, 2018, INT J BIOL MACROMOL, V115, P281, DOI 10.1016/j.ijbiomac.2018.04.083
NR 101
TC 3
Z9 3
U1 2
U2 22
PU TECH SCIENCE PRESS
PI HENDERSON
PA 871 CORONADO CENTER DR, SUTE 200, HENDERSON, NV 89052 USA
SN 0327 9545
EI 1667 5746
J9 BIOCELL
JI Biocell
PY 2021
VL 45
IS 4
BP 1045
EP 1058
DI 10.32604/biocell.2021.015039
PG 14
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA RT5FA
UT WOS:000644484100022
OA Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Kim, JM
   Lee, JH
   Lee, GS
   Noh, EM
   Song, HK
   Gu, DR
   Kim, SC
   Lee, SH
   Kwon, KB
   Lee, YR
AF Kim, Jeong Mi
   Lee, Jung Han
   Lee, Guem San
   Noh, Eun Mi
   Song, Hyun Kyung
   Gu, Dong Ryun
   Kim, Seong Cheol
   Lee, Seoung Hoon
   Kwon, Kang Beom
   Lee, Young Rae
TI Sophorae Flos extract inhibits RANKLinduced osteoclast differentiation
   by suppressing the NF B/NFATc1 pathway in mouse bone marrow cells
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Sophorae Flos (SF); Osteoclast; NF kappa B; NFATc1; PLC gamma 2
ID NF KAPPA B; RECEPTOR ACTIVATOR; IMMUNE SYSTEM; JAPONICA L.; NFATC1;
   RANKL; OSTEOIMMUNOLOGY; HOMEOSTASIS; INDUCTION; BINDING
AB Background: Sophorae Flos (SF) is a composite of flowers and buds of Styphnolobium japonicum (L.) Schott and has been used in traditional Korean and Chinese medicine for the treatment of hemostasis and inflammation. Previous studies reported that SF possesses anti obesity properties, as well as anti allergic, anti proliferative, and anti inflammatory activities. However, the effect of SF in bone resorption has not been studies. In this study, we examined the potential of SF extract (SFE) to inhibit receptor activator of NF .B ligand (RANKL) induced osteoclast differentiation in cultured mouse derived bone marrow macrophages (BMMs).
   Methods: BMMs, that act as osteoclast precursors, were cultured with M CSF (50 ng/ml) and RANKL (100 ng/ml) for 4 days to generate osteoclasts. Osteoclast differentiation was measured by tartrate resistant acidic phosphatase (TRAP) staining and the TRAP solution assay. Osteoclast differentiation marker genes were analyzed by the quantitative real time polymerase chain reaction analysis. RANKLs signaling pathways were confirmed through western blotting.
   Results: SFE significantly decreased osteoclast differentiation in a dose dependent manner. SFE inhibited RANKL induced osteoclastogenesis by suppressing NF .B activation. By contrast, SFE did not affect phospholipase C gamma 2 or subsequent cAMP response element binding activation. SFE inhibited the RANKL induced expression of nuclear factor of activated T cells c1 (NFATc1).
   Conclusions: SFE attenuated the RANKL mediated induction of NF .B through inhibition of I kappa Ba phosphorylation, which contributed to inhibiting of RANKL induced osteoclast differentiation through downregulation of NFATc1.
C1 [Kim, Jeong Mi; Noh, Eun Mi; Song, Hyun Kyung; Gu, Dong Ryun; Kim, Seong Cheol; Lee, Seoung Hoon; Kwon, Kang Beom; Lee, Young Rae] Wonkwang Univ, Sch Med, CMFR, Iksan 570749, South Korea.
   [Lee, Jung Han] Wonkwang Univ, Sch Korean Med, Dept Rehabil Med Korean Med, Iksan 570749, South Korea.
   [Lee, Guem San] Wonkwang Univ, Sch Korean Med, Dept Herbol, Iksan 570749, South Korea.
   [Gu, Dong Ryun; Lee, Seoung Hoon] Wonkwang Univ, Coll Dent, Dept Oral Microbiol & Immunol, Iksan 570749, South Korea.
   [Kim, Seong Cheol; Kwon, Kang Beom] Wonkwang Univ, Sch Korean Med, Dept Korean Physiol Wonkwang, Iksan 570749, South Korea.
   [Lee, Young Rae] Wonkwang Univ, Coll Dent, Dept Oral Biochem, Iksan 570749, South Korea.
   [Lee, Young Rae] Wonkwang Univ, Coll Dent, Inst Biomat Implant, Iksan 570749, South Korea.
   [Lee, Seoung Hoon; Lee, Young Rae] Wonkwang Univ, Integrated Omics Inst, Iksan 570749, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University
RP Kwon, KB; Lee, YR (通讯作者)，Wonkwang Univ, Sch Med, CMFR, Iksan 570749, South Korea.; Kwon, KB (通讯作者)，Wonkwang Univ, Sch Korean Med, Dept Korean Physiol Wonkwang, Iksan 570749, South Korea.; Lee, YR (通讯作者)，Wonkwang Univ, Coll Dent, Dept Oral Biochem, Iksan 570749, South Korea.; Lee, YR (通讯作者)，Wonkwang Univ, Coll Dent, Inst Biomat Implant, Iksan 570749, South Korea.; Lee, YR (通讯作者)，Wonkwang Univ, Integrated Omics Inst, Iksan 570749, South Korea.
EM desson@wku.ac.kr; mindyr@wku.ac.kr
RI Kim, Jae Hong/B 2530 2009
OI Lee, Young Rae/0000 0002 2119 2609
FU Wonkwang University
FX The present study was supported by Wonkwang University in 2014.
CR Abe M, 1996, PATHOL INT, V46, P977, DOI 10.1111/j.1440 1827.1996.tb03577.x
   Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   ISHIDA H, 1989, CHEM PHARM BULL, V37, P1616, DOI 10.1248/cpb.37.1616
   Kim BH, 2003, PLANTA MED, V69, P474, DOI 10.1055/s 2003 39712
   Kim JM, 2008, ARCH PHARM RES, V31, P886, DOI 10.1007/s12272 001 1242 1
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kite GC, 2009, PHYTOCHEMISTRY, V70, P785, DOI 10.1016/j.phytochem.2009.04.003
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lee J, 2010, ARCH PHARM RES, V33, P523, DOI 10.1007/s12272 010 0405 0
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074 7613(00)80390 8
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Liu R, 2007, J SEP SCI, V30, P1870, DOI 10.1002/jssc.200600528
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Park KW, NUTR RES
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tang YP, 2002, J ASIAN NAT PROD RES, V4, P123, DOI 10.1080/10286020290027407
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092 8674(95)90506 5
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoon HJ, 2013, NUTR RES, V33, P1053, DOI 10.1016/j.nutres.2013.08.004
NR 37
TC 16
Z9 16
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD MAR 23
PY 2017
VL 17
AR 164
DI 10.1186/s12906 016 1550 x
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA EQ0RO
UT WOS:000397778500002
PM 28335757
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, J
   Zhang, N
   Huang, X
   Xu, J
   Fernandes, JC
   Dai, K
   Zhang, X
AF Li, J.
   Zhang, N.
   Huang, X.
   Xu, J.
   Fernandes, J. C.
   Dai, K.
   Zhang, X.
TI Dexamethasone shifts bone marrow stromal cells from osteoblasts to
   adipocytes by C/EBPalpha promoter methylation
SO CELL DEATH & DISEASE
LA English
DT Article
DE osteoporosis; BMSC differentiation; Wnt/beta catenin; C/EBPalpha; DNA
   methylation
ID MESENCHYMAL STEM CELLS; INDUCED OSTEOPOROSIS; DIFFERENTIATION;
   TRANSCRIPTION; GLUCOCORTICOIDS; OSTEOGENESIS; ACTIVATION; EXPRESSION;
   TISSUE
AB Dexamethasone (Dex) induced osteoporosis has been described as the most severe side effect in long term glucocorticoid therapy. The decreased bone mass and the increased marrow fat suggest that Dex possibly shifts the differentiation of bone marrow stromal cells (BMSCs) to favor adipocyte over osteoblast, but the underlying mechanisms are still unknown. In this paper, we established a Dex induced osteoporotic mouse model, and found that BMSCs from Dex treated mice are more likely to differentiate into adipocyte than those from control mice, even under the induction of bone morphogenetic protein 2 (BMP2). We also discovered both in vitro and in vivo that the expression level of adipocyte regulator CCAAT/enhancer binding protein alpha (C/EBPalpha) is significantly upregulated in Dex induced osteoporotic BMSCs during osteoblastogenesis by a mechanism that involves inhibited DNA hypermethylation of its promoter. Knockdown of C/EBPalpha in Dex induced osteoporotic cells rescues their differentiation potential, suggesting that Dex shifts BMSC differentiation by inhibiting C/EBPalpha promoter methylation and upregulating its expression level. We further found that the Wnt/beta catenin pathway is involved in Dex induced osteoporosis and C/EBPalpha promoter methylation, and its activation by LiCl rescues the effect of Dex on C/EBPalpha promoter methylation and osteoblast/adipocyte balance. This study revealed the C/EBPalpha promoter methylation mechanism and evaluated the function of Wnt/beta catenin pathway in Dex induced osteoporosis, providing a useful therapeutic target for this type of osteoporosis.
C1 [Li, J.; Zhang, N.; Huang, X.; Dai, K.; Zhang, X.] Shanghai Jiao Tong Univ, Sch Med, Key Lab Stem Cell Biol, Inst Hlth Sci,SIBS,CAS, Shanghai 200030, Peoples R China.
   [Zhang, N.; Dai, K.; Zhang, X.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthopaed Implant, Dept Orthopaed Surg,Shanghai Peoples Hosp 9, Shanghai 200030, Peoples R China.
   [Xu, J.] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA 6009, Australia.
   [Fernandes, J. C.] Univ Montreal, Hop Sacre Coeur, Orthopaed Res Lab, Res Ctr, Montreal, PQ H4J 1C5, Canada.
C3 Chinese Academy of Sciences; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; University of Western Australia; Universite de
   Montreal
RP Dai, K (通讯作者)，Inst Hlth Sci, Key Lab Stem Cell Biol, Room 101,225 South Chongqing Rd, Shanghai 200025, Peoples R China.
EM krdai@sibs.ac.cn; xlzhang@sibs.ac.cn
RI Fernandes, Julio C/B 6916 2014; Fernandes, Julio/B 6916 2014; Zhang,
   Xiaoling/J 1666 2016; Zhang, Ning/AHA 3443 2022
OI Fernandes, Julio C/0000 0002 3888 832X; Zhang, Ning/0000 0002 9513 9288;
   Xu, Jiake/0000 0003 2021 8309; Zhang, Xiaoling/0000 0002 0134 1347
FU Ministry of Science and Technology of China [2011DFA30790,
   2010CB945600]; National Natural Science Foundation of China [81190133,
   31101056]; Chinese Academy of Sciences [XDA01030404, KSCX2 EW Q 1 07];
   Science and Technology Commission of Shanghai Municipality [12411951100,
   12410708600, 13430710700]; Shanghai Municipal Education Commission
   [J50206]
FX This work was supported by grants from The Ministry of Science and
   Technology of China (No. 2011DFA30790, 2010CB945600), National Natural
   Science Foundation of China (No. 81190133, 31101056), Chinese Academy of
   Sciences (No. XDA01030404, KSCX2 EW Q 1 07), Science and Technology
   Commission of Shanghai Municipality (No. 12411951100, 12410708600,
   13430710700), Shanghai Municipal Education Commission (No. J50206).
CR Abdallah BM, 2012, BONE, V50, P540, DOI 10.1016/j.bone.2011.06.030
   Azuma K, 2010, ENDOCR J, V57, P455, DOI 10.1507/endocrj.K09E 290
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034
   Fan QM, 2009, J CELL MOL MED, V13, P2489, DOI 10.1111/j.1582 4934.2008.00606.x
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Kalak R, 2009, BONE, V45, P61, DOI 10.1016/j.bone.2009.03.673
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Rodríguez JP, 2008, CURR STEM CELL RES T, V3, P208, DOI 10.2174/157488808785740325
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Rodríguez JP, 2000, J CELL BIOCHEM, V79, P557, DOI 10.1002/1097 4644(20001215)79:4<557::AID JCB40>3.0.CO;2 H
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen ED, 2000, GENE DEV, V14, P1293
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
NR 27
TC 143
Z9 157
U1 2
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT
PY 2013
VL 4
AR e832
DI 10.1038/cddis.2013.348
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 251XK
UT WOS:000326967100018
PM 24091675
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sun, LX
   Peng, RC
AF Sun, Lixin
   Peng, Ruchen
TI The value of integration of bone scan and targeted SPECT/CT in diagnosis
   of primary hyperparathyroidism with multiple bone brown tumor
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Bone scan; SPECT; CT; Primary hyperparathyroidism; Bone brown tumor
ID METASTASES; SCINTIGRAPHY; MANAGEMENT; PATIENT
AB Although parathyroid bone disease is rarely seen nowadays, skeletal manifestation can be the first sign of hyperparathyroidism (HPT) in some clinical practice. Nevertheless, the diagnosis of HPT is often overlooked. We describe three cases of multiple brown tumors (BT) in which bone pain and destruction were the first symptoms that masqueraded as a malignancy. However, according to the results of bone scan and targeted single photon emission computed tomography/computed tomography (SPECT/CT), we considered BTs as the diagnosis in all of three cases. The final diagnoses were confirmed by laboratory tests and post parathyroidectomy pathology. Parathyroid hormone (PTH) is significantly elevated in primary hyperparathyroidism (PHPT) as we know. However, such elevation is virtually never seen in malignancies. Diffuse or multiple foci of tracer uptakes in the bone scan were always seen in bone metastasis, multiple myeloma, and other bone neoplasm. When patients visited nuclear medicine for first consultation without biochemical results, radiological evidence from planar bone scan and targeted SPECT/CT can help in distinguishing the skeletal diseases. Lytic bone lesions with sclerosis, intra focal or ectopic ossification and calcification, fluid fluid level, and distribution of the lesions may be helpful in the differential diagnosis in these reported cases. In conclusion, when patients present with multiple foci of uptake on bone scan, targeted SPECT/CT is acquired for suspicious lesions, which can increase the diagnostic sensitivity and reduce unnecessary interventions and treatment. Moreover, BTs should be always kept in differential diagnosis of multiple lesions without a conclusive primary tumor.
C1 [Sun, Lixin] Capital Med Univ, Beijing Luhe Hosp, Dept Nucl Med, Xinhua Rd 82, Beijing 101149, Peoples R China.
   [Peng, Ruchen] Capital Med Univ, Beijing Luhe Hosp, Dept Radiol, Xinhua Rd 82, Beijing 101149, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Peng, RC (通讯作者)，Capital Med Univ, Beijing Luhe Hosp, Dept Radiol, Xinhua Rd 82, Beijing 101149, Peoples R China.
EM pengruchen@ccmu.edu.cn
RI Sun, Lixin/AAT 1932 2020
OI Peng, Ruchen/0000 0001 5705 0453
CR [Anonymous], 2016, ANN ITAL CHIR, V87
   Bilezikian JP, 2018, LANCET, V391, P168, DOI 10.1016/S0140 6736(17)31430 7
   Bransky Natalie, 2020, J Bone Metab, V27, P217, DOI 10.11005/jbm.2020.27.3.217
   Buckley O, 2007, NUCL MED COMMUN, V28, P521, DOI 10.1097/MNM.0b013e3281744440
   CHEW FS, 1993, AM J ROENTGENOL, V160, P752, DOI 10.2214/ajr.160.4.8456657
   CHOI CW, 1995, CLIN NUCL MED, V20, P310, DOI 10.1097/00003072 199504000 00005
   Engur CO, 2022, INDIAN J NUCL MED, V37, P288, DOI 10.4103/ijnm.ijnm_195_21
   Fang Yijie, 2015, Zhonghua Yi Xue Za Zhi, V95, P3691
   García Talavera P, 2016, REV ESP MED NUCL IMA, V35, P351, DOI 10.1016/j.remn.2016.03.001
   Hong WS, 2011, SKELETAL RADIOL, V40, P205, DOI 10.1007/s00256 010 0979 0
   Khan A A, 2017, Osteoporos Int, V28, P1, DOI 10.1007/s00198 016 3716 2
   Messina Laura, 2021, Radiol Case Rep, V16, P2482, DOI 10.1016/j.radcr.2021.06.015
   Misiorowski W, 2017, ENDOCRINE, V58, P380, DOI 10.1007/s12020 017 1414 2
   Ngo QX, 2021, INT J SURG CASE REP, V79, P375, DOI [10.1016/j.ijscr.2020.01.002, 10.1016/j.ijscr.2021.01.002]
   O'Donnell P, 2004, SKELETAL RADIOL, V33, P330, DOI 10.1007/s00256 004 0779 5
   Penhoat MG, 2017, JOINT BONE SPINE, V84, P209, DOI 10.1016/j.jbspin.2016.06.007
   Phulsunga Rohit Kumar, 2016, World J Nucl Med, V15, P56, DOI 10.4103/1450 1147.167598
   Pinto LP, 2006, PEDIATR DENT, V28, P543
   Rossi B, 2014, SKELETAL RADIOL, V43, P693, DOI 10.1007/s00256 013 1770 9
   Sager Sait, 2012, Indian J Endocrinol Metab, V16, P850, DOI 10.4103/2230 8210.100682
   SCUTELLARI PN, 1985, HAEMATOLOGICA, V70, P136
   Silverberg SJ, 1996, J CLIN ENDOCR METAB, V81, P2036, DOI 10.1210/jc.81.6.2036
   Su AW, 2010, J CHIN MED ASSOC, V73, P177, DOI 10.1016/S1726 4901(10)70035 6
   VANHEERDEN JA, 1977, SURG CLIN N AM, V57, P557
   Yamaga E, 2022, CLIN NUCL MED, V47, P236, DOI 10.1097/RLU.0000000000003897
   Yuen N.K., 2016, Perm. J, V20, P78, DOI [10.7812/tpp/15 127, DOI 10.7812/TPP/15 127]
   Zanglis A, 2006, CLIN NUCL MED, V31, P640, DOI 10.1097/01.rlu.0000237968.88074.fb
NR 27
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0364 2348
EI 1432 2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD DEC
PY 2023
VL 52
IS 12
BP 2505
EP 2511
DI 10.1007/s00256 023 04361 0
EA MAY 2023
PG 7
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA X1SL0
UT WOS:000994717800002
PM 37227482
DA 2025 08 17
ER

PT J
AU Mukhtar, O
   Jackson, SHD
AF Mukhtar, Omar
   Jackson, Stephen H. D.
TI Drug therapies in older adults (part 1)
SO CLINICAL MEDICINE
LA English
DT Article
DE Pharmacology; elderly; geriatrics; physiology of ageing; prescribing;
   osteoporosis; Alzheimer's disease; guidelines
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; ALZHEIMERS DISEASE;
   CHOLINESTERASE INHIBITORS; ESTABLISHED OSTEOPOROSIS; ORAL
   BISPHOSPHONATES; RISK; FRACTURES; GALANTAMINE; SAFETY
AB Prescribing for older adults represents a significant challenge as the UK population ages. Physiological decline and the rising prevalence of frailty increase the likelihood of altered pharmacodynamics and pharmacokinetics, suboptimal prescribing and adverse effects among this growing cohort of the population. In the first of two articles, we begin by considering these issues and posit four key questions which should be considered when prescribing for older adults. Does this agent reflect the priorities of the patient? Are there alternatives   with greater efficacy, effectiveness or tolerability   that might be considered? Are the dose, frequency and formulation appropriate? How does this prescription relate to concurrent medication? We also describe current drug therapies in two disease states with a predilection for older adults: Alzheimer's disease (AD) and osteoporosis. Using these examples we highlight the limitations of evidence based medicine and guidelines in this cohort of the population, illustrating the reliance on sub group analysis to demonstrate the efficacy of drug therapies for older adults in osteoporosis and the underutilisation of appropriate treatments for patients with AD as a result of flawed guidelines.
C1 [Mukhtar, Omar] Kings Coll Hosp London, Kings Hlth Partners, London SE5 9RS, England.
   [Jackson, Stephen H. D.] Kings Coll Hosp London, Kings Hlth Partners, Dept Clin Gerontol, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London; University of London;
   King's College London; King's College Hospital NHS Foundation Trust;
   King's College Hospital
RP Mukhtar, O (通讯作者)，Kings Coll Hosp London, Denmark Hill, London SE5 9RS, England.
EM o.mukhtar@nhs.net
OI Mukhtar, Omar/0000 0002 9671 7457
CR [Anonymous], 2001, NAT SERV FRAM OLD PE
   [Anonymous], 2009, COCHRANE DATABASE SY
   [Anonymous], 2008, Knowl. Inf. Systeme., DOI DOI 10.1002/14651858.CD001155.PUB2
   [Anonymous], 2012, NATL STAT
   [Anonymous], 2011, DON GAL RIV MEM TREA
   BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051
   Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub2, 10.1002/14651858.CD001190.pub3]
   Birks J., 2009, COCHRANE DB SYST REV, V1
   Boonen S, 2006, J AM GERIATR SOC, V54, P782, DOI 10.1111/j.1532 5415.2006.00695.x
   BRUN A, 1981, HISTOPATHOLOGY, V5, P549, DOI 10.1111/j.1365 2559.1981.tb01818.x
   Burger H, 1998, AM J EPIDEMIOL, V147, P871, DOI 10.1093/oxfordjournals.aje.a009541
   Burn D, 2006, MOVEMENT DISORD, V21, P1899, DOI 10.1002/mds.21077
   Campbell SE, 2004, AGE AGEING, V33, P110, DOI 10.1093/ageing/afh036
   Cardwell CR, 2010, JAMA J AM MED ASSOC, V304, P657, DOI 10.1001/jama.2010.1098
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Cummings J, 2007, NEUROLOGY, V69, pS10, DOI 10.1212/01.wnl.0000281846.40390.50
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curtis JR, 2008, J BONE MINER RES, V23, P1061, DOI [10.1359/jbmr.080232, 10.1359/JBMR.080232]
   Curtis JR, 2012, DRUG AGING, V29, P549, DOI 10.2165/11599620 000000000 00000
   Danysz W, 2000, NEUROTOX RES, V2, P85, DOI 10.1007/BF03033787
   del Ser T, 2013, J ALZHEIMERS DIS, V33, P205, DOI 10.3233/JAD 2012 120805
   Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951
   Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474 4422(10)70223 4
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Farrimond LE, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen 2012 000917
   Franklin BD., 2007, INT J PHARM PRACT, V15, P133, DOI DOI 10.1211/ijpp.15.2.0009
   Frazier Susan C, 2005, J Gerontol Nurs, V31, P4
   Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72
   Green Jacqueline L, 2007, Am J Geriatr Pharmacother, V5, P31, DOI 10.1016/j.amjopharm.2007.03.004
   Green J, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4444
   Hager K, 2014, NEUROPSYCH DIS TREAT, V10, P391, DOI 10.2147/NDT.S57909
   Hochberg MC, 2005, J BONE MINER RES, V20, P971, DOI 10.1359/JBMR.050104
   Howard R, 2012, NEW ENGL J MED, V366, P893, DOI 10.1056/NEJMoa1106668
   Inglis F, 2002, INT J CLIN PRACT, P45
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   LIPSITZ LA, 1989, J GERONTOL, V44, pM179, DOI 10.1093/geronj/44.6.M179
   Loke YK, 2011, THER ADV DRUG SAF, V2, P59, DOI 10.1177/2042098611401129
   Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365 2125.2003.02007.x
   Masoudi FA, 2003, AM HEART J, V146, P250, DOI 10.1016/S0002 8703(03)00189 3
   McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536
   McMurdo MET, 2011, AGE AGEING, V40, P659, DOI 10.1093/ageing/afr115
   Meier RPH, 2012, ARCH INTERN MED, V172, P930, DOI 10.1001/archinternmed.2012.1796
   Morimoto BH, 2013, DEMENT GERIATR COGN, V35, P325, DOI 10.1159/000348347
   National Institute for Health and Care Excellence, 2006, DEM SUPP PEOPL DEM T
   OBRIEN T, 2000, COCHRANE DB SYST REV, V2
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Parsons CG, 2013, NEUROTOX RES, V24, P358, DOI 10.1007/s12640 013 9398 z
   Payne RA, 2014, EUR J CLIN PHARMACOL, V70, P575, DOI 10.1007/s00228 013 1639 9
   Raskind MA, 2000, NEUROLOGY, V54, P2261, DOI 10.1212/WNL.54.12.2261
   Reid IR, 2014, LANCET, V383, P146, DOI 10.1016/S0140 6736(13)61647 5
   Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI [10.1038/nrneurol.2011.2, 10.1101/cshperspect.a006239]
   Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839
   Sanders S, 2013, SOUTH MED J, V106, P698, DOI 10.1097/SMJ.0b013e3182a0df8b
   Schneider Lon S, 2013, Continuum (Minneap Minn), V19, P339, DOI 10.1212/01.CON.0000429180.60095.d0
   Schneider LS, 2011, ARCH NEUROL CHICAGO, V68, P991, DOI 10.1001/archneurol.2011.69
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Seegers V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063677
   Sellmeyer DE, 2010, JAMA J AM MED ASSOC, V304, P1480, DOI 10.1001/jama.2010.1360
   Solomon DH, 2009, NEW ENGL J MED, V360, P1789
   Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532 5415.2006.00889.x
   Touchon J, 2006, CURR MED RES OPIN, V22, P49, DOI 10.1185/030079906x80279
   Traynor K, 2013, AM J HEALTH SYST PH, V70, P648, DOI 10.2146/news130028
   Walston J, 2006, J AM GERIATR SOC, V54, P991, DOI 10.1111/j.1532 5415.2006.00745.x
   Wilcock GK, 2000, BRIT MED J, V321, P1445, DOI 10.1136/bmj.321.7274.1445
   Woodruff Pak DS, 2001, P NATL ACAD SCI USA, V98, P2089, DOI 10.1073/pnas.031584398
   Wynne HA, 2010, MATURITAS, V66, P246, DOI 10.1016/j.maturitas.2010.03.004
   Yeaw J, 2009, J MANAGE CARE PHARM, V15, P728, DOI 10.18553/jmcp.2009.15.9.728
NR 70
TC 12
Z9 12
U1 0
U2 24
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470 2118
EI 1473 4893
J9 CLIN MED
JI Clin. Med.
PD FEB
PY 2015
VL 15
IS 1
BP 47
EP 53
DI 10.7861/clinmedicine.15 1 47
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA CA8VZ
UT WOS:000349200300012
PM 25650198
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gong, WY
   Zhu, Y
   Wang, LM
AF Gong, Weiyue
   Zhu, Yao
   Wang, Limin
TI Qiang Jin Mixture Promotes Osteogenic Differentiation of MC3T3 E1 Cells
   via BMP2/Smads Pathway and its Network Pharmacology Study
SO MOLECULAR BIOTECHNOLOGY
LA English
DT Article; Early Access
DE BMP2/Smads/RUNX2 pathway; Network pharmacology; Osteoporosis; QiangJin
   mixture; Traditional Chinese Medicine
ID OSTEOPOROSIS; MECHANISM
AB The study aimed to explore the potential of QiangJin mixture (QJM), a Chinese herbal compound prescription, in regulating MC3T3 E1 cell differentiation and to analyze the ingredients and therapeutic targets of QJM against osteoporosis based on network pharmacology. MC3T3 E1 cells were incubated with different concentrations of QJM contained rat serum (5, 10, or 20%). After 14 days of cell culture, Alizarin Red staining was performed to assess the mineralization ability of osteoblasts. RT qPCR was used to measure mRNA levels of osteogenesis related genes. Western blot was conducted to measure protein levels of factors related to the BMP2/Smads pathway. Functional and pathway enrichment of overlapping targets for QJM and osteoporosis were analyzed using gene ontology and KEGG analyses. As shown by experimental results, QJM contained serum led to calcium deposition, increased expression levels of osteogenesis related genes, and activated BMP2/Smad/Runx2 signaling in MC3T3 E1 cells. A total of 125 active compounds and 162 disease related targets were identified. The core targets were MAPK8, TP53, ESR1, STAT3, MAPK3, IL6, NFKB1, JUN, MAPK1 and AKT1. In conclusion, QJM promotes the osteogenic differentiation of MC3T3 E1 cells by activating the BMP2/Smads signaling. Additionally, QJM is an anti osteoporotic mixture by regulating diverse therapeutic targets and signaling pathways.
C1 [Gong, Weiyue; Zhu, Yao; Wang, Limin] Zhejiang Chinese Med Univ, Huzhou Tradit Chinese Med Hosp, Dept Pharm, 315 South St, Huzhou 313000, Peoples R China.
C3 Zhejiang Chinese Medical University
RP Wang, LM (通讯作者)，Zhejiang Chinese Med Univ, Huzhou Tradit Chinese Med Hosp, Dept Pharm, 315 South St, Huzhou 313000, Peoples R China.
EM wanglimin20191@hotmail.com
FU Zhejiang Traditional Chinese Medicine Science and Technology Plan
   Project
FX The authors appreciate all the participants providing supports for this
   study.
CR Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Bai L, 2023, BIOMATERIALS, V297, DOI 10.1016/j.biomaterials.2023.122125
   Chai S, 2024, PHYTOMEDICINE, V128, DOI 10.1016/j.phymed.2024.155516
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Choi H, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929 016 0260 5
   DeSelm CJ, 2012, J CELL BIOCHEM, V113, P2895, DOI 10.1002/jcb.24165
   Durbano HW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186909
   Gera S, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14071449
   Gold LS, 2022, OSTEOPOROSIS INT, V33, P1925, DOI 10.1007/s00198 022 06450 7
   Goldstajn MS, 2023, ARCH GYNECOL OBSTET, V307, P1727, DOI 10.1007/s00404 022 06647 5
   Gu Chonghao, 2024, Altern Ther Health Med, V30, P263
   Jiang X, 2022, CLIMACTERIC, V25, P50, DOI 10.1080/13697137.2021.1957818
   Wu JS, 2022, J TRADIT CHIN MED, V42, P479, DOI 10.19852/j.cnki.jtcm.20220408.003
   Kaunitz AM, 2015, OBSTET GYNECOL, V126, P859, DOI 10.1097/AOG.0000000000001058
   Khired ZA, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00865 7
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Komori T, 2020, MOL CELLS, V43, P168, DOI 10.14348/molcells.2019.0244
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Li Bo, 2022, Phytomedicine, V102, P154198, DOI 10.1016/j.phymed.2022.154198
   Li CX, 2024, PHYTOMEDICINE, V122, DOI 10.1016/j.phymed.2023.155137
   Li K, 2023, AM J CHINESE MED, V51, P1957, DOI 10.1142/S0192415X23500866
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Liu H, 2021, MOL CELL ENDOCRINOL, V520, DOI 10.1016/j.mce.2020.111074
   Miller PD, 2022, J BONE MINER RES, V37, P1437, DOI 10.1002/jbmr.4563
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Piao M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169244
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Shen K, 2021, J BIOMAT SCI POLYM E, V32, P1865, DOI 10.1080/09205063.2021.1949098
   Shibata S, 2008, J ANAT, V213, P274, DOI 10.1111/j.1469 7580.2008.00934.x
   Strecker SE, 2019, ADV BIOSYST, V3, DOI 10.1002/adbi.201900184
   Sun Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12866
   Tang JL, 2008, LANCET, V372, P1938, DOI 10.1016/S0140 6736(08)61354 9
   Trefts E, 2017, CURR BIOL, V27, pR1147, DOI 10.1016/j.cub.2017.09.019
   Wang D, 2023, PHYTOMEDICINE, V119, DOI 10.1016/j.phymed.2023.154998
   Wang SJ, 2016, CURR PHARM DESIGN, V22, P312
   Wang YM, 2018, BIOCHEM BIOPH RES CO, V498, P981, DOI 10.1016/j.bbrc.2018.03.093
   Wu Y, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1109296
   Wu ZB, 2024, MEDCOMM, V5, DOI 10.1002/mco2.657
   Xi XY, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1198475
   Xiao JC, 2023, LIFE SCI, V322, DOI 10.1016/j.lfs.2022.121326
   Yan CP, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.883228
   Yang LY, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6623464
   Yang YJ, 2023, PHYTOMEDICINE, V116, DOI 10.1016/j.phymed.2023.154875
   Yao N, 2021, J TRADIT CHIN MED, V41, P935, DOI 10.19852/j.cnki.jtcm.2021.06.010
   Yoshida G, 2022, AUTOPHAGY, V18, P2323, DOI 10.1080/15548627.2021.2017587
   Zhang WT, 2022, J ORTHOP TRANSL, V33, P41, DOI 10.1016/j.jot.2022.01.002
   Zhao P, 2018, EUR REV MED PHARMACO, V22, P3962, DOI 10.26355/eurrev_201806_15280
   Zhu ZG, 2018, MOL MED REP, V18, P2561, DOI 10.3892/mmr.2018.9286
NR 49
TC 1
Z9 1
U1 2
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1073 6085
EI 1559 0305
J9 MOL BIOTECHNOL
JI Mol. Biotechnol.
PD 2024 NOV 11
PY 2024
DI 10.1007/s12033 024 01313 4
EA NOV 2024
PG 17
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA L7N3M
UT WOS:001352544100001
PM 39527391
DA 2025 08 17
ER

PT J
AU Moriceau, G
   Ory, B
   Mitrofan, L
   Riganti, C
   Blanchard, F
   Brion, R
   Charrier, C
   Battaglia, S
   Pilet, P
   Denis, MG
   Shultz, LD
   Mönkkönen, J
   Rédini, F
   Heymann, D
AF Moriceau, Gatien
   Ory, Benjamin
   Mitrofan, Laura
   Riganti, Chiara
   Blanchard, Frederic
   Brion, Regis
   Charrier, Celine
   Battaglia, Severine
   Pilet, Paul
   Denis, Marc G.
   Shultz, Leonard D.
   Monkkonen, Jukka
   Redini, Francoise
   Heymann, Dominique
TI Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance
   of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the
   Prenylation Process
SO CANCER RESEARCH
LA English
DT Article
ID MAMMALIAN TARGET; RAPAMYCIN INHIBITION; SOFT TISSUE; BONE;
   BISPHOSPHONATES; GROWTH; CHEMOTHERAPY; SURVIVAL; THERAPY; UPDATE
AB Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants new strategies still needed to improve overall patient survival. In this study, we investigated in vivo the effects of RAD001 (Everolimus), a new orally available mTOR inhibitor, on the growth of human and mouse osteosarcoma cells either alone or in combination with zoledronate (ZOL), an anti osteoporotic drug used to treat bone metastases. RAD001 inhibited osteosarcoma cell proliferation in a dose and time dependent manner with no modification of cell cycle distribution. Combination with ZOL augmented this inhibition of cell proliferation, decreasing PI3K/mTOR signaling compared with single treatments. Notably, in contrast to RAD001, ZOL downregulated isoprenylated membrane bound Ras concomitantly with an increase of nonisoprenylated cytosolic Ras in sensitive and resistant osteosarcoma cell lines to both drugs. Moreover, ZOL and RAD001 synergized to decrease Ras isoprenylation and GTP bound Ras levels. Further, the drug combination reduced tumor development in two murine models of osteoblastic or osteolytic osteosarcoma. We found that ZOL could reverse RAD001 resistance in osteosarcoma, limiting osteosarcoma cell growth in combination with RAD001. Our findings rationalize further study of the applications of mTOR and mevalonate pathway inhibitors that can limit protein prenylation pathways. Cancer Res; 70(24); 10329 39. (C)2010 AACR.
C1 [Heymann, Dominique] INSERM, Fac Med, UMR 957, F 44035 Nantes 1, France.
   [Moriceau, Gatien; Ory, Benjamin; Blanchard, Frederic; Brion, Regis; Charrier, Celine; Battaglia, Severine; Redini, Francoise; Heymann, Dominique] Univ Nantes, Nantes Atlantique Univ, Nantes, France.
   [Ory, Benjamin] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   [Ory, Benjamin] Harvard Univ, Sch Med, Boston, MA USA.
   [Mitrofan, Laura; Monkkonen, Jukka] Univ Kuopio, Dept Pharmaceut, FIN 70211 Kuopio, Finland.
   [Riganti, Chiara] Univ Turin, Dept Genet Biol & Biochem, Turin, Italy.
   [Pilet, Paul] INSERM, UMR 791, F 44035 Nantes 1, France.
   [Denis, Marc G.] INSERM, UMR 913, F 44035 Nantes 1, France.
   [Shultz, Leonard D.] Jackson Lab, Bar Harbor, ME 04609 USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Nantes Universite; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   Medical School; University of Eastern Finland; University of Turin;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Jackson Laboratory
RP Heymann, D (通讯作者)，INSERM, Fac Med, UMR 957, 1 Rue Gaston Veil, F 44035 Nantes 1, France.
EM dominique.heymann@univ nantes.fr
RI REDINI, Francoise/K 7981 2015; Charrier, Céline/K 9198 2015; BATTAGLIA,
   Severine/K 8715 2015; Blanchard, Frederic/K 8018 2015; ory,
   benjamin/K 8231 2015; Heymann, Dominique/AAC 6014 2019; Denis,
   Marc/K 8049 2015
OI ory, benjamin/0000 0002 2622 7356; Blanchard,
   Frederic/0000 0003 1055 2573; Heymann, Dominique/0000 0001 7777 0669;
   Riganti, Chiara/0000 0001 9787 4836; Denis, Marc/0000 0001 5865 3248
FU Pharma Novartis (Rueil Malmaison, France); NIH [CA34196]
FX This work was supported by a grant from Pharma Novartis
   (Rueil Malmaison, France) and by a NIH Cancer Core grant CA34196.
CR Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Chawla SP, 2007, J CLIN ONCOL, V25
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Cutler C, 2004, CANCER, V101, P1478, DOI 10.1002/cncr.20495
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802
   Foster DA, 2009, CELL CYCLE, V8, P1026, DOI 10.4161/cc.8.7.8044
   Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143
   Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484
   Haritunians T, 2007, LEUKEMIA, V21, P333, DOI 10.1038/sj.leu.2404471
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Houghton PJ, 2008, PEDIATR BLOOD CANCER, V50, P799, DOI 10.1002/pbc.21296
   Jiang BH, 2008, DRUG RESIST UPDATE, V11, P63, DOI 10.1016/j.drup.2008.03.001
   Joliat MJ, 2002, IN VIVO, V16, P223
   Kamijo A, 2002, CANCER LETT, V188, P213, DOI 10.1016/S0304 3835(02)00433 0
   Kauffman HM, 2005, TRANSPLANTATION, V80, P883, DOI 10.1097/01.TP.0000184006.43152.8D
   Khariwala SS, 2006, LARYNGOSCOPE, V116, P814, DOI 10.1097/01.mlg.0000210544.64659.35
   Kiel C, 2009, J BIOL CHEM, V284, P31893, DOI 10.1074/jbc.M109.031153
   Kim SH, 2009, ANTICANCER RES, V29, P1143
   KLEIN B, 1977, INT J CANCER, V20, P112, DOI 10.1002/ijc.2910200118
   Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221
   Kruh GD, 2003, ONCOGENE, V22, P7262, DOI 10.1038/sj.onc.1206932
   Laezza C, 2008, J MOL MED, V86, P1341, DOI 10.1007/s00109 008 0396 1
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Liu WM, 2008, CURR CLIN PHARMACOL, V3, P108, DOI 10.2174/157488408784293714
   MacKenzie AR, 2007, EXPERT REV ANTICANC, V7, P1145, DOI 10.1586/14737140.7.8.1145
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008 5472.CAN 05 2925
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Ory B, 2007, CURR MED CHEM, V14, P1381, DOI 10.2174/092986707780831159
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Petiot A, 2002, CELL STRUCT FUNCT, V27, P431, DOI 10.1247/csf.27.431
   Provisor AJ, 1997, J CLIN ONCOL, V15, P76, DOI 10.1200/JCO.1997.15.1.76
   Reddy GK, 2006, CLIN GENITOURIN CANC, V5, P110, DOI 10.3816/CGC.2006.n.026
   Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889
   ROSEN G, 1976, CANCER AM CANCER SOC, V37, P1, DOI 10.1002/1097 0142(197601)37:1<1::AID CNCR2820370102>3.0.CO;2 3
   Sánchez Fructuoso AI, 2008, EXPERT OPIN DRUG MET, V4, P807, DOI 10.1517/17425255.4.6.807 
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721
   Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008 5472.CAN 04 3135
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Wullschleger S, 2006, CELL, V127, P5
   Zhou QA, 2010, MED ONCOL, V27, P1239, DOI 10.1007/s12032 009 9365 y
NR 44
TC 77
Z9 82
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2010
VL 70
IS 24
BP 10329
EP 10339
DI 10.1158/0008 5472.CAN 10 0578
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 694XD
UT WOS:000285334200034
PM 20971812
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Bimonte, VM
   Catanzaro, G
   Spinello, Z
   Massari, MC
   Curreli, M
   Terrana, G
   Defeudis, G
   Halupczok Zyla, J
   Mantovani, G
   Ferretti, E
   Migliaccio, S
AF Bimonte, V. M.
   Catanzaro, G.
   Spinello, Z.
   Massari, M. C.
   Curreli, M.
   Terrana, G.
   Defeudis, G.
   Halupczok Zyla, J.
   Mantovani, G.
   Ferretti, E.
   Migliaccio, S.
TI Hypocalcemia in combination with hyperphosphatemia impairs muscle cell
   differentiation in vitro
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE Hypoparathyroidism; Hyperphosphatemia; Hypocalcemia; Skeletal muscle
   cells; Myotube; Insulin like growth factor 1
ID QUALITY OF LIFE; SKELETAL MUSCLE; HYPERTROPHY; HYPOPARATHYROIDISM;
   DIAGNOSIS; CALCIUM; PATHWAY
AB PurposeHypoparathyroidism is a rare endocrine disorder characterized by low or absent secretion of parathyroid hormone (PTH), which leads to decreased calcium and increased phosphorus levels in the serum. The diagnosis of hypoparathyroidism is based on the identification of the aforementioned biochemical abnormalities, which may be accompanied by clinical manifestations. Symptoms of hypoparathyroidism, primarily attributed to hypocalcemia, include muscle cramps or spasms, facial, leg, and foot pain, seizures, and tingling in the lips or fingers. The treatment of hypoparathyroidism depends on the severity of symptoms and the underlying pathology. Over the long term, calcium supplements, active vitamin D analogs, and thiazide diuretics may be needed. In fact, in patient cohorts in which optimal disease control still remains elusive, replacement therapy with recombinant parathyroid hormone analogs may be contemplated. Despite the predominantly neuromuscular symptoms of hypoparathyroidism, further effects of parathyroid hormone deficiency at the muscle cell level remain poorly understood. Thus, the aim of our study was to evaluate the effects of hypocalcemia in combination with hyperphosphatemia on muscle cells differentiation in vitro.MethodsC2C12 cells, an in vitro model of muscle cells, were differentiated for 2 or 6 days in the presence of hypocalcemia (CaCl2 0.9 mmol/l) and moderate (PO4 1.4 mmol/l) or severe (PO4 2.9 mmol/l) hyperphosphatemia, or combinations of both conditions. Cell differentiation and expression of genes linked to muscle differentiation were evaluated.ResultsThe combination of hypocalcemia with hyperphosphatemia induced a significant reduction (50%) in differentiation marker levels, such as MyoD (protein 1 for myoblast determination) and myogenin on the 1st day of differentiation, and MHC (myosin heavy chains) after 6 days of differentiation compared to control. Furthermore, this condition induced a statistically significant reduction of insulin like growth factor 1 (IGF 1) mRNA expression and inhibition of IGF signaling and decrease in ERK phosphorylation compared to control cells.ConclusionsOur results showed that a condition of hypocalcemia with hyperphosphatemia induced an alteration of muscle cell differentiation in vitro. In particular, we observed the reduction of myogenic differentiation markers, IGF 1 signaling pathway, and ERK phosphorylation in differentiated skeletal myoblasts. These data suggest that this altered extracellular condition might contribute to the mechanisms causing persistence of symptoms in patients affected by hypoparathyroidism.
C1 [Bimonte, V. M.; Curreli, M.; Defeudis, G.; Migliaccio, S.] Univ Foro Italico, Dept Movement Human & Hlth Sci, Largo Lauro De Bosis 6, I 00195 Rome, Italy.
   [Catanzaro, G.; Spinello, Z.; Massari, M. C.; Terrana, G.; Ferretti, E.] Sapienza Univ Rome, Dept Expt Med, I 00161 Rome, Italy.
   [Halupczok Zyla, J.] Wroclaw Med Univ, Dept Endocrinol Diabet & Isotope Therapy, 50004, PL 50004 Wroclaw, Poland.
   [Mantovani, G.] Univ Milan, Dept Clin Sci & Community Hlth, I 20122 Milan, Italy.
   [Mantovani, G.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Endocrinol Unit, I 20122 Milan, Italy.
C3 Foro Italico University of Rome; Sapienza University Rome; Wroclaw
   Medical University; University of Milan; IRCCS Ca Granda Ospedale
   Maggiore Policlinico
RP Migliaccio, S (通讯作者)，Univ Foro Italico, Dept Movement Human & Hlth Sci, Largo Lauro De Bosis 6, I 00195 Rome, Italy.
EM silvia.migliaccio@uniroma4.it
RI Spinello, Zaira/AIB 7587 2022; Mantovani, Giovanna/A 2378 2014;
   Defeudis, Giuseppe/AAP 9167 2020
OI Defeudis, Giuseppe/0000 0003 2425 5609; Bimonte, Viviana
   Maria/0000 0003 4345 9033; Spinello, Zaira/0000 0002 7016 6538; 
FU The authors would like to acknowledge all the support staff at the
   participating institutions for their contributions to this study.
FX The authors would like to acknowledge all the support staff at the
   participating institutions for their contributions to this study.
CR Ahmad SS, 2020, CELLS BASEL, V9, DOI 10.3390/cells9081773
   Armstrong DD, 2005, AM J PHYSIOL CELL PH, V289, pC853, DOI 10.1152/ajpcell.00093.2005
   Aventaggiato M, 2023, CELLS BASEL, V12, DOI 10.3390/cells12050691
   Aversa A, 2017, ENDOCRINE, V56, P639, DOI 10.1007/s12020 016 1208 y
   Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215
   Bimonte VM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020754
   Bimonte VM, 2017, ENDOCRINE, V58, P340, DOI 10.1007/s12020 016 1193 1
   Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101 1014
   Clarke BL, 2016, J CLIN ENDOCR METAB, V101, P2284, DOI 10.1210/jc.2015 3908
   Cusano NE, 2013, J ENDOCRINOL INVEST, V36, P1121, DOI 10.1007/BF03346763
   De Sanctis V, 2012, CURR OPIN ENDOCRINOL, V19, P435, DOI 10.1097/MED.0b013e3283591502
   Desbois Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064
   Dumont NA, 2015, COMPR PHYSIOL, V5, P1027, DOI 10.1002/cphy.c140068
   Giusti F, 2019, FRONT HORM RES, V51, P139, DOI 10.1159/000491044
   Glass DJ, 2003, TRENDS MOL MED, V9, P344, DOI 10.1016/S1471 4914(03)00138 2
   Harslof T, 2016, INT J ENDOCRINOL MET, V14, DOI 10.5812/ijem.38440
   Hernández Hernández M, 2017, SEMIN CELL DEV BIOL, V72, P10, DOI 10.1016/j.semcdb.2017.11.010
   Kimura S, 2014, SCI REP UK, V4, DOI 10.1038/srep05066
   Lee J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222559
   Li J, 2006, BIOCHEM BIOPH RES CO, V345, P1425, DOI 10.1016/j.bbrc.2006.05.051
   Marks KH, 1996, PEDIATR NEPHROL, V10, P364
   Muñoz Cánoves P, 2013, FEBS J, V280, P4131, DOI 10.1111/febs.12338
   Pepe J, 2020, ENDOCRINE, V69, P485, DOI 10.1007/s12020 020 02324 2
   Qiu T, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0002 7
   Raimann A, 2020, CELL TISSUE RES, V382, P427, DOI 10.1007/s00441 020 03254 1
   Rejnmark L, 2018, ENDOCRINE, V59, P237, DOI 10.1007/s12020 017 1479 y
   Reza MM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01131 0
   Romagnoli C, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11041017
   Romagnoli C, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.764346
   Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101 1009
   Rubin MR, 2008, J BONE MINER RES, V23, P2018, DOI 10.1359/JBMR.080803
   Sato C, 2021, J BONE MINER METAB, V39, P385, DOI 10.1007/s00774 020 01184 0
   Sikjaer T, 2014, OSTEOPOROSIS INT, V25, P1717, DOI 10.1007/s00198 014 2677 6
   Silva BC, 2021, REV ENDOCR METAB DIS, V22, P789, DOI 10.1007/s11154 020 09614 0
   Tapscott SJ, 2005, DEVELOPMENT, V132, P2685, DOI 10.1242/dev.01874
   Wang YM, 2013, BONE RES, V1, P249, DOI 10.4248/BR201303003
   Waseem R, 2022, MOLECULES, V27, DOI 10.3390/molecules27031118
   Yoshida T, 2020, CELLS BASEL, V9, DOI 10.3390/cells9091970
   Yoshiko Y, 2002, AM J PHYSIOL CELL PH, V283, pC1278, DOI 10.1152/ajpcell.00168.2002
NR 39
TC 1
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0391 4097
EI 1720 8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD APR
PY 2024
VL 47
IS 4
BP 947
EP 957
DI 10.1007/s40618 023 02212 2
EA OCT 2023
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA MC0D7
UT WOS:001082124500001
PM 37819413
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Gregson, CL
   Bergen, DJM
   Leo, P
   Sessions, RB
   Wheeler, L
   Hartley, A
   Youlten, S
   Croucher, P
   McInerney Leo, AM
   Fraser, W
   Tang, JCY
   Anderson, L
   Marshall, M
   Sergot, L
   Paternoster, L
   Smith, GD
   Brown, MA
   Hammond, C
   Kemp, JP
   Tobias, JH
   Duncan, EL
AF Gregson, Celia L.
   Bergen, Dylan J. M.
   Leo, Paul
   Sessions, Richard B.
   Wheeler, Lawrie
   Hartley, April
   Youlten, Scott
   Croucher, Peter, I
   McInerney Leo, Aideen M.
   Fraser, William
   Tang, Jonathan C. Y.
   Anderson, Lisa
   Marshall, Mhairi
   Sergot, Leon
   Paternoster, Lavinia
   Smith, George Davey
   Brown, Matthew A.
   Hammond, Chrissy
   Kemp, John P.
   Tobias, Jon H.
   Duncan, Emma L.
CA AOGC Consortium
TI A Rare Mutation in SMAD9 Associated With High Bone Mass
   Identifies the SMAD Dependent BMP Signaling Pathway as a Potential
   Anabolic Target for Osteoporosis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE DXA; EXON SEQUENCING; HIGH BONE MASS; MONOGENIC; OSTEOANABOLIC; SMAD9;
   ZEBRAFISH
ID MINERAL DENSITY; BUCHEM DISEASE; LOCI; PHENOTYPE; POLYMORPHISMS;
   INDIVIDUALS; REGION; AGE
AB Novel anabolic drug targets are needed to treat osteoporosis. Having established a large national cohort with unexplained high bone mass (HBM), we aimed to identify a novel monogenic cause of HBM and provide insight into a regulatory pathway potentially amenable to therapeutic intervention. We investigated a pedigree with unexplained HBM in whom previous sequencing had excluded known causes of monogenic HBM. Whole exome sequencing identified a rare (minor allele frequency 0.0023), highly evolutionarily conserved missense mutation in SMAD9 (c.65T>C, p.Leu22Pro) segregating with HBM in this autosomal dominant family. The same mutation was identified in another two unrelated individuals both with HBM. In silico protein modeling predicts the mutation severely disrupts the MH1 DNA binding domain of SMAD9. Affected individuals have bone mineral density (BMD) Z scores +3 to +5, mandible enlargement, a broad frame, torus palatinus/mandibularis, pes planus, increased shoe size, and a tendency to sink when swimming. Peripheral quantitative computed tomography (pQCT) measurement demonstrates increased trabecular volumetric BMD and increased cortical thickness conferring greater predicted bone strength; bone turnover markers are low/normal. Notably, fractures and nerve compression are not found. Both genome wide and gene based association testing involving estimated BMD measured at the heel in 362,924 white British subjects from the UK Biobank Study showed strong associations with SMAD9 (P GWAS = 6 x 10( 16); P GENE = 8 x 10( 17)). Furthermore, we found Smad9 to be highly expressed in both murine cortical bone derived osteocytes and skeletal elements of zebrafish larvae. Our findings support SMAD9 as a novel HBM gene and a potential novel osteoanabolic target for osteoporosis therapeutics. SMAD9 is thought to inhibit bone morphogenetic protein (BMP) dependent target gene transcription to reduce osteoblast activity. Thus, we hypothesize SMAD9 c.65T>C is a loss of function mutation reducing BMP inhibition. Lowering SMAD9 as a potential novel anabolic mechanism for osteoporosis therapeutics warrants further investigation. (c) 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
C1 [Gregson, Celia L.; Bergen, Dylan J. M.; Hartley, April; Tobias, Jon H.] Univ Bristol, Bristol Med Sch, Musculoskeletal Res Unit, Translat Hlth Sci, Bristol, Avon, England.
   [Bergen, Dylan J. M.; Hammond, Chrissy] Univ Bristol, Fac Life Sci, Sch Physiol Pharmacol & Neurosci, Bristol, Avon, England.
   [Leo, Paul; Wheeler, Lawrie; McInerney Leo, Aideen M.; Anderson, Lisa; Marshall, Mhairi; Brown, Matthew A.; Duncan, Emma L.; AOGC Consortium] Queensland Univ Technol, Princess Alexandra Hosp, Inst Hlth & Biomed Innovat, Translat Res Inst,Fac Hlth,Translat Genom Grp, Woolloongabba, Qld, Australia.
   [Sessions, Richard B.] Univ Bristol, Fac Life Sci, Sch Biochem, Bristol, Avon, England.
   [Hartley, April; Paternoster, Lavinia; Smith, George Davey; Kemp, John P.] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, MRC,Integrat Epidemiol Unit, Bristol, Avon, England.
   [Youlten, Scott; Croucher, Peter, I] Garvan Inst Med Res, Div Bone Biol, Sydney, NSW, Australia.
   [Croucher, Peter, I] UNSW Sydney, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia.
   [Croucher, Peter, I] UNSW Sydney, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.
   [McInerney Leo, Aideen M.] Univ Queensland, Diamantina Inst, Dermatol Res Ctr, Brisbane, Qld, Australia.
   [Fraser, William; Tang, Jonathan C. Y.] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England.
   [Fraser, William] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Dept Diabet Endocrinol & Clin Biochem, Norwich, Norfolk, England.
   [Sergot, Leon] Severn Deanery, Severn Sch Radiol, Bristol, Avon, England.
   [Kemp, John P.] Univ Queensland, Diamantina Inst, Fac Med, Woolloongabba, Qld, Australia.
   [Duncan, Emma L.] Royal Brisbane & Womens Hosp, Dept Endocrinol & Diabet, Herston, Qld, Australia.
   [Duncan, Emma L.] Univ Queensland, Fac Med, Herston, Qld, Australia.
C3 University of Bristol; University of Bristol; Princess Alexandra
   Hospital; Queensland University of Technology (QUT); University of
   Queensland; University of Bristol; University of Bristol; Garvan
   Institute of Medical Research; University of New South Wales Sydney;
   University of New South Wales Sydney; University of Queensland;
   University of East Anglia; Norfolk & Norwich University Hospitals NHS
   Foundation Trust; University of Queensland; Royal Brisbane & Women's
   Hospital; University of Queensland
RP Gregson, CL (通讯作者)，Univ Bristol, Musculoskeletal Res Unit, Translat Hlth Sci, Bristol Med Sch,Southmead Hosp, Learning & Res Bldg,Level 1, Bristol BS10 5NB, Avon, England.
EM celia.gregson@bristol.ac.uk
RI Tang, Jonathan/G 3090 2011; Kemp, John/R 3091 2018; Gregson,
   Celia/AAE 1216 2021; McInerney Leo, Aideen/D 8302 2016; Tobias,
   Jon/E 2832 2014; Duncan, Emma/L 1224 2013; Brown, Matthew A/E 5749 2010;
   Paternoster, Lavinia/C 1292 2015; Leo, Paul/B 3470 2011; Davey Smith,
   George/A 7407 2013; Bergen, Dylan/AAU 4547 2020; Hammond,
   Chrissy/D 6568 2013; Brown, Matthew/E 5749 2010
OI Tang, Jonathan/0000 0001 6305 6333; Tobias, Jon/0000 0002 7475 3932;
   Croucher, Peter/0000 0002 7102 2413; Duncan, Emma/0000 0002 8143 4403;
   Gregson, Celia/0000 0001 6414 0529; Brown, Matthew
   A/0000 0003 0538 8211; Hartley, April/0000 0003 4932 1588; Paternoster,
   Lavinia/0000 0003 2514 0889; Bergen, Dylan/0000 0001 7808 6121; Davey
   Smith, George/0000 0002 1407 8314; Hammond, Chrissy/0000 0002 4935 6724;
   Sessions, Richard/0000 0003 0320 0895; McInerney Leo,
   Aideen/0000 0002 0059 5732
FU Wellcome Trust [20378/Z/16/Z, 101123, 080280/Z/06/Z]; EU [247642];
   British Geriatric Society; NIHR CRN [5163]; Harold Hyam Wingate
   Foundation [DMMTF 180208]; Elizabeth Blackwell Institute for Health
   Research (University of Bristol) discipline hopping fellowship via a
   Wellcome Trust [204813/Z/16/Z]; UK Medical Research Council
   [MC_UU_12013/4, MC_UU_00011/1]; University of Queensland Development
   Fellowship [UQFEL1718945]; National Health and Medical Research Council
   (Australia) [511132, 1032571, GNT1158758]; Versus Arthritis [21211,
   21937, 19476, 20000]; NHMRC Early Career Fellowship; NHMRC Senior
   Principal Research Fellowship; Medical Research Council [MC_UU_00011/1,
   MC_UU_12013/4] Funding Source: researchfish; Versus Arthritis [19476,
   21937] Funding Source: researchfish; Versus Arthritis; Cancer Research
   UK [20000] Funding Source: researchfish; Versus Arthritis; Cancer
   Research UK [21211] Funding Source: researchfish; MRC [MC_UU_00011/1,
   MC_UU_12013/4] Funding Source: UKRI; Wellcome Trust [080280/Z/06/Z]
   Funding Source: Wellcome Trust
FX CLG was funded by the Wellcome Trust (080280/Z/06/Z), the EU 7th
   Framework Programme ref 247642 (GEoCoDE), a British Geriatric Society
   travel grant, and Versus Arthritis (formerly Arthritis Research UK)
   (grant ref 20000). This study was supported by the NIHR CRN (no. 5163).
   DB received travel grants from The Harold Hyam Wingate Foundation
   (DMMTF 180208) and an Elizabeth Blackwell Institute for Health Research
   (University of Bristol) discipline hopping fellowship via a Wellcome
   Trust Institutional Strategic Support Grant (204813/Z/16/Z). AH is
   funded by the Wellcome Trust (20378/Z/16/Z). LP, AH, and GDS work in a
   unit that receives UK Medical Research Council funding (MC_UU_12013/4,
   MC_UU_00011/1). CH and DB were funded by Versus Arthritis (21211, 21937,
   19476). AML is supported by an NHMRC Early Career Fellowship. JPK is
   funded by a University of Queensland Development Fellowship
   (UQFEL1718945); his contribution is supported by a National Health and
   Medical Research Council (Australia) project grant (GNT1158758). MAB is
   supported by an NHMRC Senior Principal Research Fellowship. PIC is
   funded by a Wellcome Trust Strategic Award (101123). The AOGC was funded
   by the National Health and Medical Research Council (Australia) (511132
   and 1032571). Funders had no role in study design, analysis, or
   manuscript preparation.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410 248
   Alexander C, 2011, DEVELOPMENT, V138, P5135, DOI 10.1242/dev.067801
   Arnold SJ, 2006, DEV BIOL, V296, P104, DOI 10.1016/j.ydbio.2006.04.442
   Barruet E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122958
   Bergen DJM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00006
   Bergen DJM, 2017, BIOL OPEN, V6, P1180, DOI 10.1242/bio.025502
   Bonewald L, 2019, BONE, V120, P212, DOI 10.1016/j.bone.2018.11.002
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   BUTLER WT, 1977, J DENT RES, V56, P228, DOI 10.1177/00220345770560030601
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   de Leeuw CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004219
   Drake KM, 2011, AM J RESP CRIT CARE, V184, P1400, DOI 10.1164/rccm.201106 1130OC
   Duncan EL, 2003, J BONE MINER RES, V18, P1531, DOI 10.1359/jbmr.2003.18.8.1531
   Duncan EL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001372
   Eswar Narayanan, 2006, Curr Protoc Bioinformatics, VChapter 5, pUnit, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s47, 10.1002/cpps.20, 10.1002/cpbi.3, 10.1002/0471250953.bi0506s15]
   Ferrer Costa C, 2005, BIOINFORMATICS, V21, P3176, DOI 10.1093/bioinformatics/bti486
   Frost M, 2011, J BONE MINER RES, V26, P1721, DOI 10.1002/jbmr.376
   Gregson CL, 2012, OSTEOPOROSIS INT, V23, P643, DOI 10.1007/s00198 011 1603 4
   Gregson CL, 2018, BONE, V114, P62, DOI 10.1016/j.bone.2018.06.001
   Gregson CL, 2016, J BONE MINER RES, V31, P640, DOI 10.1002/jbmr.2706
   Gregson CL, 2014, J CLIN ENDOCR METAB, V99, P2897, DOI 10.1210/jc.2013 3958
   Gregson CL, 2013, BONE, V52, P380, DOI 10.1016/j.bone.2012.10.021
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Hammond CL, 2009, DEVELOPMENT, V136, P3991, DOI 10.1242/dev.042150
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hart T, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 778
   Huang Z, 2009, HUM MOL GENET, V18, P2791, DOI 10.1093/hmg/ddp214
   Kemp JP, 2017, NAT GENET, V49, P1468, DOI 10.1038/ng.3949
   Koay MA, 2004, J BONE MINER RES, V19, P1619, DOI 10.1359/JBMR.040704
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Le Goff C, 2011, AM J HUM GENET, V89, P7, DOI 10.1016/j.ajhg.2011.05.012
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Loeys BL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000488
   Lowery JW, 2018, PHYSIOL REV, V98, P2431, DOI 10.1152/physrev.00028.2017
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McInerney Leo AM, 2013, AM J HUM GENET, V93, P515, DOI 10.1016/j.ajhg.2013.06.022
   Medina Gomez C, 2018, AM J HUM GENET, V102, P88, DOI 10.1016/j.ajhg.2017.12.005
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Nelson CP, 2017, NAT GENET, V49, P1385, DOI 10.1038/ng.3913
   Ngeow J, 2015, GASTROENTEROLOGY, V149, P886, DOI 10.1053/j.gastro.2015.06.027
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rommel K, 2005, HUM MUTAT, V26, P529, DOI 10.1002/humu.20239
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810 575
   Sheu TJ, 2014, MOL CELL BIOCHEM, V397, P67, DOI 10.1007/s11010 014 2173 5
   Shintani M, 2009, J MED GENET, V46, P331, DOI 10.1136/jmg.2008.062703
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Spoorendonk KM, 2008, DEVELOPMENT, V135, P3765, DOI 10.1242/dev.024034
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Stitziel NO, 2016, NEW ENGL J MED, V374, P1134, DOI 10.1056/NEJMoa1507652
   Timberlake AT, 2016, ELIFE, V5, DOI 10.7554/eLife.20125
   Tosca L, 2011, EUR J MED GENET, V54, pE489, DOI 10.1016/j.ejmg.2011.06.004
   TSUKAMOTO S, 2014, SCI REP UK, V4
   Uitterlinden AG, 2004, AM J HUM GENET, V75, P1032, DOI 10.1086/426458
   Walcott BP, 2018, HUM GENOME VAR, V5, DOI 10.1038/hgv.2018.1
   Watanabe K, 2019, NAT GENET, V51, P1339, DOI 10.1038/s41588 019 0481 0
   Webb TR, 2017, J AM COLL CARDIOL, V69, P823, DOI 10.1016/j.jacc.2016.11.056
   WESTERFIELD M, 2000, ZEBRAFISH BOOK GUIDE
   Whyte MP, 2019, BONE, V127, P228, DOI 10.1016/j.bone.2019.05.003
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xiao J, 2018, CLIN NUTR, V37, P2284, DOI 10.1016/j.clnu.2017.09.021
   YOULTEN S, 2017, AM SOC BON MIN RES A
   Zheng HF, 2015, NATURE, V526, P112, DOI 10.1038/nature14878
   Zimmermann L, 2018, J MOL BIOL, V430, P2237, DOI 10.1016/j.jmb.2017.12.007
NR 68
TC 32
Z9 31
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2020
VL 35
IS 1
BP 92
EP 105
DI 10.1002/jbmr.3875
EA NOV 2019
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KC8SX
UT WOS:000496351000001
PM 31525280
OA Green Published, Green Accepted, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Tautzenberger, A
   Förtsch, C
   Zwerger, C
   Dmochewitz, L
   Kreja, L
   Ignatius, A
   Barth, H
AF Tautzenberger, Andrea
   Foertsch, Christina
   Zwerger, Christian
   Dmochewitz, Lydia
   Kreja, Ludwika
   Ignatius, Anita
   Barth, Holger
TI C3 Rho Inhibitor for Targeted Pharmacological Manipulation of
   Osteoclast Like Cells
SO PLOS ONE
LA English
DT Article
ID ADP RIBOSYLATING TOXINS; BOTULINUM C2 TOXIN; CYTOSKELETAL ORGANIZATION;
   DELIVERY; RIBOSYLTRANSFERASE; MACROPHAGES; EXOENZYMES; INSIGHTS; PROTEIN
AB The C3 toxins from Clostridium botulinum (C3bot) and Clostridium limosum (C3lim) as well as C3 derived fusion proteins are selectively taken up into the cytosol of monocytes/macrophages where the C3 catalyzed ADP ribosylation of Rho results in inhibition of Rho signalling and characteristic morphological changes. Since the fusion toxin C2IN C3lim was efficiently taken up into and inhibited proliferation of murine macrophage like RAW 264.7 cells, its effects on RAW 264.7 derived osteoclasts were investigated. C2IN C3lim was taken up into differentiated osteoclasts and decreased their resorption activity. In undifferentiated RAW 264.7 cells, C2IN C3lim treatment significantly decreased their differentiation into osteoclasts as determined by counting the multi nucleated, TRAP positive cells. This inhibitory effect was concentration and time dependent and most efficient when C2IN C3lim was applied in the early stage of osteoclast formation. A single dose application of C2IN C3lim at day 0 and its subsequent removal at day 1 reduced the number of osteoclasts in a comparable manner while C2IN C3lim application at later time points did not reduce the number of osteoclasts to a comparable degree. Control experiments with an enzymatically inactive C3 protein revealed that the ADP ribosylation of Rho was essential for the observed effects. In conclusion, the results indicate that Rho activity is crucial during the early phase of osteoclast differentiation. Other bone cell types such as pre osteoblastic cells were not affected by C2IN C3lim. Due to their cell type selective and specific mode of action, C3 proteins and C3 fusions might be valuable tools for targeted pharmacological manipulation of osteoclast formation and activity, which could lead to development of novel therapeutic strategies against osteoclast associated diseases.
C1 [Tautzenberger, Andrea; Kreja, Ludwika; Ignatius, Anita] Univ Ulm, Inst Orthopaed Res & Biomech, Ctr Musculoskeletal Res, D 89069 Ulm, Germany.
   [Foertsch, Christina; Zwerger, Christian; Dmochewitz, Lydia; Barth, Holger] Univ Ulm, Med Ctr, Inst Pharmacol & Toxicol, D 89069 Ulm, Germany.
C3 Ulm University; Ulm University
RP Ignatius, A (通讯作者)，Univ Ulm, Inst Orthopaed Res & Biomech, Ctr Musculoskeletal Res, D 89069 Ulm, Germany.
EM anita.ignatius@uni ulm.de; holger.barth@uni ulm.de
RI Ignatius, Anita/M 6012 2013
FU Medical Faculty of the University of Ulm; International Graduate School
   in Molecular Medicine Ulm (IGradU)
FX The work was supported by the Medical Faculty of the University of Ulm
   and the International Graduate School in Molecular Medicine Ulm
   (IGradU). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agholme F, 2012, J MATER SCI MATER M, V23, P743, DOI 10.1007/s10856 011 4539 5
   Aktories K, 2005, REV PHYSIOL BIOCH P, V152, P1, DOI 10.1007/s10254 004 0034 4
   AKTORIES K, 1987, BIOCHEM J, V247, P363, DOI 10.1042/bj2470363
   AKTORIES K, 1995, BIOCHIMIE, V77, P326, DOI 10.1016/0300 9084(96)88142 9
   ALLEY MC, 1988, CANCER RES, V48, P589
   Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364 1369.1998
   Barth H, 2008, CURR MED CHEM, V15, P459, DOI 10.2174/092986708783503195
   Barth H, 2011, EUR J CELL BIOL, V90, P944, DOI 10.1016/j.ejcb.2010.11.007
   Brazier H, 2006, J BONE MINER RES, V21, P1387, DOI 10.1359/JBMR.060613
   Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200
   Christow H, 2013, TOXICON, V75, P144, DOI 10.1016/j.toxicon.2013.02.002
   Dmochewitz L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054517
   Fahrer J, 2010, CELL MICROBIOL, V12, P233, DOI 10.1111/j.1462 5822.2009.01393.x
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hu YW, 2005, FEBS LETT, V579, P4937, DOI 10.1016/j.febslet.2005.07.078
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   JUST I, 1992, J BIOL CHEM, V267, P10274
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lillich M, 2012, BIOCONJUGATE CHEM, V23, P1426, DOI 10.1021/bc300041z
   Saltel F, 2008, EUR J CELL BIOL, V87, P459, DOI 10.1016/j.ejcb.2008.01.001
   Vogelsgesang M, 2007, N S ARCH PHARMACOL, V374, P347, DOI 10.1007/s00210 006 0113 y
   Wang YW, 2012, BIOMATERIALS, V33, P8540, DOI 10.1016/j.biomaterials.2012.07.039
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   ZHANG D, 1995, J CELL SCI, V108, P2285
NR 24
TC 14
Z9 15
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2013
VL 8
IS 12
AR e85695
DI 10.1371/journal.pone.0085695
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 281RE
UT WOS:000329117900133
PM 24386487
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Hao, DD
   Wang, SY
   Feng, L
   Zhu, SY
   Zhong, Y
   Zhang, FY
   Chen, YL
   Fu, YX
   Shi, ZY
   Tang, F
   Wu, YH
AF Hao, Doudou
   Wang, Suyuan
   Feng, Lin
   Zhu, Suying
   Zhong, Yang
   Zhang, Fengying
   Chen, Yanli
   Fu, Yongxing
   Shi, Zhiyou
   Tang, Feng
   Wu, Yunhong
TI Therapeutic effect of bloodletting on bone deterioration induced by
   hypobaric hypoxia in young rats
SO BONE
LA English
DT Article
DE Hypobaric hypoxia; Bloodletting; Bone deterioration; Bone
   microarchitecture; Gene expression profile
ID RESIDENCY; RECEPTOR
AB Objectives: High altitude regions, comprising hypoxic condition, are associated with different altitude induced pathologies, including a reduction in bone density. Elucidating the mechanisms underlying bone degradation in such environments and developing targeted interventions and therapeutics is important. Bloodletting therapy has promising clinical applications, but its effects on the skeletal system and bone homeostasis are not well understood. The aim of this study was to investigate the effects of a hypobaric hypoxia environment on specific femoral morphological and structural properties, including the bone volume, cortical thickness, and trabecular microarchitecture, in juvenile Sprague Dawley (SD) rats, and to explore the potential modulating effects of a bloodletting intervention on these parameters. Methods: Male SD rats, 6 weeks of age, were subjected to a simulated hypobaric hypoxia environment, replicating a 5000 m altitude, for 12 weeks. For the bloodletting intervention group, rats were subjected to a weekly 500 mu L tail vein blood withdrawal. Micro CT technology, hematoxylin and eosin staining, and tartrate resistant acid phosphatase staining were employed to comprehensively assess the femoral microstructure, tissue architecture, and cellular morphology. Additionally, immunofluorescence analysis was conducted to quantify the expression of key proteins, and transcriptome analysis was performed to identify differentially expressed genes. Results: Exposing rats to hypobaric hypoxia led to a significant reduction in the bone mineral content, trabecular bone number, and cortical bone thickness, suggesting a deterioration of bone microstructure. Additionally, the hypoxic environment upregulated the expression of RANKL and HIF 1 alpha, while downregulating RUNX2 expression. Notably, although bloodletting intervention did not significantly reverse these bone structural changes, transcriptome analysis revealed its regulatory influence on the expression of key genes, particularly Mmp2, Fosl2, and URS0000B2A65A, which are implicated in pathways governing the hypoxic response, osteoclast differentiation, and PI3K Akt signaling. Conclusion: This study highlights the detrimental effect of hypobaric hypoxia on the bone microstructure of juvenile rats and underscores the therapeutic potential of bloodletting to ameliorate this condition. Additionally, our study on the regulatory mechanisms mediating the effects of bloodletting on gene expression offers new perspectives on bone alterations. It suggests promising avenues for the development of novel preventative measures and targeted therapies to address the challenges posed by related bone disorders.
C1 [Hao, Doudou; Wang, Suyuan; Zhong, Yang; Zhang, Fengying] Hosp Chengdu Off Peoples Govt Tibetan Autonomous R, Dept Biobank, Chengdu, Peoples R China.
   [Feng, Lin; Tang, Feng] Qinghai Univ, Res Ctr High Altitude Med, Xining, Peoples R China.
   [Zhu, Suying; Shi, Zhiyou] Tibet Univ, Med Coll, Lhasa, Peoples R China.
   [Chen, Yanli] Xizang Minzu Univ, Med Coll, Xianyang, Peoples R China.
   [Fu, Yongxing] Hosp Chengdu Off Peoples Govt Tibetan Autonomous R, Dept Cardiol, Chengdu, Peoples R China.
   [Tang, Feng] Qinghai Univ, Qinghai Utah Joint Res Key Lab High Altitude Med, Xining, Qinghai, Peoples R China.
   [Tang, Feng] Qinghai Univ, Qinghai Prov Key Lab Plateau Med Applicat, Key Lab Minist Educ, Xining, Peoples R China.
   [Wu, Yunhong] Hosp Chengdu Off Peoples Govt Tibetan Autonomous R, Dept Endocrinol & Metab, Chengdu, Peoples R China.
C3 Qinghai University; Xizang University; Xizang Minzu University; Qinghai
   University; Qinghai University
RP Tang, F (通讯作者)，Qinghai Univ, Res Ctr High Altitude Med, Xining, Peoples R China.; Tang, F (通讯作者)，Qinghai Univ, Qinghai Utah Joint Res Key Lab High Altitude Med, Xining, Qinghai, Peoples R China.; Tang, F (通讯作者)，Qinghai Univ, Qinghai Prov Key Lab Plateau Med Applicat, Key Lab Minist Educ, Xining, Peoples R China.; Wu, YH (通讯作者)，Hosp Chengdu Off Peoples Govt Tibetan Autonomous R, Dept Endocrinol & Metab, Chengdu, Peoples R China.
EM leileitang1984@163.com; wu_yunhong@163.com
RI Zhong, Yang/JDA 0414 2023
FU Science and Technology Department of Tibet; Central Government Guides
   the Local Science and Technology development fund project
   [XZ202102YD0026C, XZ202202YD0011C]; Science and technology department of
   Tibet, "Unveiling and Commanding" project [XZ202303ZY0011G]; Natural
   Science Foundation of Tibet Autonomous Region [XZ202401ZR0029]
FX This work was financially sponsored by the Science and Technology
   Department of Tibet, the Central Government Guides the Local Science and
   Technology development fund project [grant number XZ202102YD0026C,
   XZ202202YD0011C]; the science and technology department of Tibet,
   "Unveiling and Commanding" project [grant number XZ202303ZY0011G], and
   the Natural Science Foundation of Tibet Autonomous Region [grant number
   XZ202401ZR0029].
CR Basu M, 2014, HIGH ALT MED BIOL, V15, P170, DOI 10.1089/ham.2013.1098
   Basu M, 2013, HIGH ALT MED BIOL, V14, P150, DOI 10.1089/ham.2012.1042
   Brent MB, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.831369
   Brent MB, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116258
   Brent MB, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116203
   Chen H, 2022, CHIN J INTEGR MED, V28, P1096, DOI 10.1007/s11655 022 3581 0
   Chen JF, 2024, J IMMUNOL, V212, DOI 10.4049/jimmunol.2300592
   Chen J, 2013, EXP MOL PATHOL, V95, P364, DOI 10.1016/j.yexmp.2013.10.010
   Chen P, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.842800
   Chen YX, 2017, GIGASCIENCE, V7, DOI 10.1093/gigascience/gix120
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Dai ZQ, 2023, J TRADIT CHIN MED, V43, P1259, DOI 10.19852/j.cnki.jtcm.20221006.004
   Gao JL, 2020, EUR J CARDIOVASC NUR, V19, P20, DOI 10.1177/1474515119876778
   Hale AT, 2021, NEUROSURGERY, V89, P435, DOI 10.1093/neuros/nyab184
   Hao XX, 2023, J BONE MINER RES, V38, P597, DOI 10.1002/jbmr.4772
   Hoshi K, 2004, J BONE MINER RES, V19, P214, DOI 10.1359/JBMR.0301221
   Kang JH, 2023, LIFE SCI, V333, DOI 10.1016/j.lfs.2023.122140
   Kim TH, 2013, J ALTERN COMPLEM MED, V19, P921, DOI 10.1089/acm.2012.0752
   Kolomansky A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113817
   Langmead B, 2019, BIOINFORMATICS, V35, P421, DOI 10.1093/bioinformatics/bty648
   Lee SY, 2021, EXP MOL MED, V53, P591, DOI 10.1038/s12276 021 00594 y
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 323
   Li SH, 2022, COMPLEMENT THER CLIN, V46, DOI 10.1016/j.ctcp.2021.101503
   Loots GG, 2018, BONE, V116, P307, DOI 10.1016/j.bone.2018.08.022
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Pae EK, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0282937
   Rauner M, 2016, J BONE MINER RES, V31, P1877, DOI 10.1002/jbmr.2857
   Rodríguez AJ, 2023, BONE, V168, DOI 10.1016/j.bone.2022.116647
   Schaper Gerhardt K, 2024, EUR J CANCER, V202, DOI 10.1016/j.ejca.2024.113984
   Seda M, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 33589 y
   Sies NS, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 82605 6
   Tang F, 2019, HIGH ALT MED BIOL, V20, P112, DOI 10.1089/ham.2017.0159
   Usategui Martín R, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232112742
   Wang AF, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.961903
   Wang C, 2023, CHIN J INTEGR MED, V29, P170, DOI 10.1007/s11655 022 3626 4
   Wang LH, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.21106
   Wang ZY, 2023, PLATELETS, V34, DOI 10.1080/09537104.2022.2157381
   Yan CQ, 2022, MOLECULES, V27, DOI 10.3390/molecules27175538
   Yazdani M, 2023, BIOL TRACE ELEM RES, V201, P3193, DOI 10.1007/s12011 022 03424 y
   Zhang F, 2022, EXP MOL MED, V54, P1991, DOI 10.1038/s12276 022 00875 0
   Zhang L, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.582670
   Zhang RF, 2019, EUR REV MED PHARMACO, V23, P6774, DOI 10.26355/eurrev_201908_18715
   Zhang WF, 2023, EUR J PHARMACOL, V950, DOI 10.1016/j.ejphar.2023.175753
   Zhao JM, 2022, BMC MUSCULOSKEL DIS, V23, DOI 10.1186/s12891 022 05644 8
   Zhao Q, 2012, CHIN J INTEGR MED, V18, P230, DOI 10.1007/s11655 012 1002 5
   Zhong R, 2023, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.1062778
   Zuo HJ, 2022, ENVIRON RES, V215, DOI 10.1016/j.envres.2022.114206
NR 47
TC 0
Z9 0
U1 4
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2025
VL 190
AR 117281
DI 10.1016/j.bone.2024.117281
EA NOV 2024
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA L4J2E
UT WOS:001350390100001
PM 39395656
OA hybrid
DA 2025 08 17
ER

PT J
AU Moon, HH
   Clines, KL
   Cooks, MA
   Cialek, CA
   Esvelt, MA
   Clines, GA
AF Moon, Henry H.
   Clines, Katrina L.
   Cooks, Mark A.
   Cialek, Charlotte A.
   Esvelt, Marian A.
   Clines, Gregory A.
TI Castration Determines the Efficacy of ETAR Blockade in a
   Mouse Model of Prostate Cancer Bone Metastasis
SO ENDOCRINOLOGY
LA English
DT Article
ID ENDOTHELIN A RECEPTOR; MALE MICE; ZIBOTENTAN ZD4054; ANIMAL MODELS;
   CAUSAL ROLE; GROWTH; MEN; ANTAGONIST; ATRASENTAN; PLACEBO
AB Bone metastasis is a painful complication of advanced prostate cancer. Endothelin 1 is a tumor secreted factor that plays a central role in osteoblast activation and the osteosclerotic response of prostate cancer metastatic to bone. Antagonists that block the activation of the endothelin A receptor (ETAR), located on osteoblasts, reduce osteoblastic bone lesions in animal models of bone metastasis. However, ETAR antagonists demonstrated limited efficacy in clinical trials of men with advanced prostate cancer who also received standard androgen deprivation therapy (ADT). Previous data from our group suggested that, in a mouse model, ETAR antagonists might only be efficacious when androgen signaling in the osteoblast is lowered beyond the ability of standard ADT. This notion was tested in a mouse model of prostate cancer bone metastasis. Castrated and sham operated male athymic nude mice underwent intracardiac inoculation of the ARCaP(M) castration resistant prostate cancer cell line. The mice were then treated with either the ETAR antagonist zibotentan or a vehicle control to generate four experimental groups: vehicle+sham (Veh+Sham), vehicle+castrate (Veh+Castr), zibotentan+sham (Zibo+Sham), and zibotentan+castrate (Zibo+Castr). The mice were monitored radiographically for the development of skeletal lesions. The Zibo+Castr group had significantly longer survival and a single incidental lesion. Mice in the Zibo+Sham group had the shortest survival and the largest number of skeletal lesions. Survival and skeletal lesions of the Veh+Sham and Veh+Castr groups were intermediate compared with the zibotentan treated groups. We report a complex interaction between ETAR and androgen signaling, whereby ETAR blockade was most efficacious when combined with complete androgen deprivation.
C1 [Moon, Henry H.; Clines, Katrina L.; Cooks, Mark A.; Cialek, Charlotte A.; Clines, Gregory A.] Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA.
   [Esvelt, Marian A.] Univ Michigan, Unit Lab Med, Ann Arbor, MI 48109 USA.
   [Clines, Gregory A.] Vet Affairs Med Ctr, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; US Department of Veterans
   Affairs; Veterans Health Administration (VHA)
RP Clines, GA (通讯作者)，Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA.; Clines, GA (通讯作者)，Vet Affairs Med Ctr, Ann Arbor, MI 48105 USA.
EM clines@umich.edu
RI ; Esvelt, Marian/W 7464 2019
OI Cialek, Charlotte/0000 0002 6615 4585; Clines,
   Gregory/0000 0002 3755 7529; 
FU Department of Veterans Affairs Grant [1I01BX001370]; Michigan
   Integrative Musculoskeletal Health Core Center (National Institutes of
   Health) [P30 AR069620]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [P30AR069620] Funding Source: NIH
   RePORTER
FX This work was supported by Department of Veterans Affairs Grant
   1I01BX001370 (to G.A.C.) and by histology services support from the
   Michigan Integrative Musculoskeletal Health Core Center (National
   Institutes of Health Grant P30 AR069620).
CR Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176
   Carducci MA, 2007, CANCER AM CANCER SOC, V110, P1959, DOI 10.1002/cncr.22996
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Clines GA, 2011, J BONE MINER RES, V26, P2523, DOI 10.1002/jbmr.450
   Dai JL, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.4
   Dillard PR, 2008, MOL CELL ENDOCRINOL, V295, P115, DOI 10.1016/j.mce.2008.08.013
   Drake JM, 2010, CANCER BIOL THER, V9, P607, DOI 10.4161/cbt.9.8.11112
   Esvelt MA, 2019, TOXICOL PATHOL, V47, P150, DOI 10.1177/0192623318816295
   Gelman IH, 2016, CANCER RES, V76, P6137, DOI 10.1158/0008 5472.CAN 16 2636
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Growcott JW, 2009, ANTI CANCER DRUG, V20, P83, DOI 10.1097/CAD.0b013e328320791c
   Grunda JM, 2013, CLIN EXP METASTAS, V30, P769, DOI 10.1007/s10585 013 9577 6
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Haque SU, 2013, MOL CANCER THER, V12, P1556, DOI 10.1158/1535 7163.MCT 12 0975
   Hewitson TD, 2012, ENDOCRINOLOGY, V153, P188, DOI 10.1210/en.2011 1311
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   James ND, 2009, EUR UROL, V55, P1112, DOI 10.1016/j.eururo.2008.11.002
   KLEIN H, 1988, AM J CLIN ONCOL CANC, V11, pS30, DOI 10.1097/00000421 198801102 00008
   Lara PN, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju013
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu XH, 2007, CANCER RES, V67, P5747, DOI 10.1158/0008 5472.CAN 07 0478
   Morris CD, 2005, BRIT J CANCER, V92, P2148, DOI 10.1038/sj.bjc.6602676
   Nelson JB, 2003, J UROLOGY, V169, P1143, DOI 10.1097/01.ju.0000042162.08938.27
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   Nelson JB, 2012, CANCER AM CANCER SOC, V118, P5709, DOI 10.1002/cncr.27674
   Quinn DI, 2013, LANCET ONCOL, V14, P893, DOI 10.1016/S1470 2045(13)70294 8
   Rosano L, 2007, MOL CANCER THER, V6, P2003, DOI 10.1158/1535 7163.MCT 07 0151
   Rosol TJ, 2003, CANCER AM CANCER SOC, V97, P748, DOI 10.1002/cncr.11150
   Sedelaar JPM, 2013, PROSTATE, V73, P1316, DOI 10.1002/pros.22677
   Simmons JK, 2015, VET PATHOL, V52, P827, DOI 10.1177/0300985815586223
   Singh R, 2009, ENDOCRINOLOGY, V150, P1259, DOI 10.1210/en.2008 0858
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Stuchbery R, 2017, NAT REV UROL, V14, P49, DOI 10.1038/nrurol.2016.221
   VANWEERDEN WM, 1992, LIFE SCI, V50, P857, DOI 10.1016/0024 3205(92)90204 3
   Wei AH, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003896
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xiang LS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040999
   Xu JC, 2006, PROSTATE, V66, P1664, DOI 10.1002/pros.20488
   YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0
   Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Zhang X, 2015, J VASC SURG, V61, P767, DOI 10.1016/j.jvs.2013.11.004
   Zhau Haiyen E., 2000, Cancer, V88, P2995, DOI 10.1002/1097 0142(20000615)88:12+<2995::AID CNCR15>3.3.CO;2 P
NR 45
TC 6
Z9 6
U1 0
U2 8
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD AUG
PY 2019
VL 160
IS 8
BP 1786
EP 1796
DI 10.1210/en.2019 00261
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IN4NY
UT WOS:000478653000002
PM 31173072
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Kuroshima, S
   Sasaki, M
   Nakajima, K
   Tamaki, S
   Hayano, H
   Sawase, T
AF Kuroshima, Shinichiro
   Sasaki, Muneteru
   Nakajima, Kazunori
   Tamaki, Saki
   Hayano, Hiroki
   Sawase, Takashi
TI Transplantation of Noncultured Stromal Vascular Fraction Cells of
   Adipose Tissue Ameliorates Osteonecrosis of the Jaw Like Lesions in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEONECROSIS OF THE JAW; STROMAL VASCULAR FRACTION; TRANSPLANTATION;
   TRAP POSITIVE MONONUCLEAR CELLS; NONATTACHED OSTEOCLASTS
ID BISPHOSPHONATE RELATED OSTEONECROSIS; REGENERATIVE CELLS; OSTEOCLAST
   FORMATION; BONE; THERAPY; INHIBITION; OSTEOGENESIS; PAMIDRONATE;
   MECHANISMS; APOPTOSIS
AB The precise pathoetiology and effective treatment strategies for bisphosphonate related osteonecrosis of the jaw (BRONJ) remain unknown. Transplantation of noncultured stromal vascular fraction (SVF) cells has been shown to be a useful method for regenerative medicine in place of stem cell therapy. This study investigated the effects of noncultured SVF transplantation on tooth extraction socket healing in mice. Both chemotherapeutic/bisphosphonate combination therapy for 7 weeks and tooth extraction of maxillary first molars at 3 weeks after drug administration were performed using female C57BL/6J mice. Osseous and soft tissue wound healing were validated at 4 weeks postextraction using gross wound healing and histomorphometry. Here, we created a new animal model of high prevalence ONJ like lesions that mimic human progression, because human ONJ mainly occurs in female patients taking both chemotherapeutic and bisphosphonate following tooth extraction. Moreover, mice with chemotherapeutic and bisphosphonate combination therapy for 5 weeks received SVF transplantation just after tooth extraction at 3 weeks post drug administration. Euthanasia was performed at 2 weeks postextraction to assess the transplantation effects on wound healing using gross wound healing, histomorphometry, immunohistomorphometry, quantitative real time polymerase chain reaction, and microcomputed tomography. We showed that systemic transplantation of noncultured SVF cells ameliorates ONJ like lesions by improving both osseous and soft tissue healing of tooth extraction sockets. SVF therapy significantly increased blood vessels and the ratio of M2/M1 macrophages. In addition, SVF transplantation reduced the increases in tartrate resistant acid phosphatase positive (TRAP(+)) mononuclear cells (MNCs) and nonattached osteoclasts from the bone surface, which were significantly detected in the connective tissue of tooth extraction sockets and bone marrow by chemotherapeutic/bisphosphonate combination therapy. Our findings suggest that transplantation of noncultured SVF cells is a suitable treatment for BRONJ. Abnormal TRAP(+) MNCs and nonattached osteoclasts in systemic and local environments may contribute to the development of BRONJ. (c) 2017 American Society for Bone and Mineral Research.
C1 [Kuroshima, Shinichiro; Sasaki, Muneteru; Nakajima, Kazunori; Tamaki, Saki; Hayano, Hiroki; Sawase, Takashi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Appl Prosthodont, Nagasaki, Japan.
C3 Nagasaki University
RP Kuroshima, S (通讯作者)，1 7 1 Sakamoto, Nagasaki 8528588, Japan.
EM kuroshima@nagasaki u.ac.jp
OI Kuroshima, Shinichiro/0000 0001 9891 9987
FU JSPS [25870523, 15K11258]; Grants in Aid for Scientific Research
   [15K11258, 15K11166, 16K20510, 25870523, 16H05534] Funding Source: KAKEN
FX This work was supported by JSPS KAKENHI (Grant Nos. 25870523 and
   15K11258).
CR Aghaloo TL, 2010, J ORAL MAXIL SURG, V68, P959, DOI 10.1016/j.joms.2009.10.010
   AMLER M H, 1960, J Am Dent Assoc, V61, P32
   Atalay S, 2014, BURNS, V40, P1375, DOI 10.1016/j.burns.2014.01.023
   Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040
   Bourin P, 2013, CYTOTHERAPY, V15, P641, DOI 10.1016/j.jcyt.2013.02.006
   Castro Govea Y, 2012, ARCH PLAST SURG APS, V39, P659, DOI 10.5999/aps.2012.39.6.659
   Chae DS, 2017, CYTOTHERAPY, V19, P543, DOI 10.1016/j.jcyt.2017.01.006
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491
   Egan KP, 2012, HISTOPATHOLOGY, V61, P1168, DOI 10.1111/j.1365 2559.2012.04333.x
   Fondi C, 2007, CLIN CASES MINER BON, V4, P21
   Gibson Corley KN, 2013, VET PATHOL, V50, P1007, DOI 10.1177/0300985813485099
   Gillooly JF, 2001, SCIENCE, V293, P2248, DOI 10.1126/science.1061967
   Gotoh M, 2014, INT J UROL, V21, P294, DOI 10.1111/iju.12266
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Hokugo A, 2013, BONE, V53, P59, DOI 10.1016/j.bone.2012.11.030
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Kuroshima S, 2016, CLIN ORAL INVEST, V20, P727, DOI 10.1007/s00784 015 1550 0
   Kuroshima S, 2013, BONE, V56, P101, DOI 10.1016/j.bone.2013.05.013
   Kuroshima S, 2012, ENDOCRINOLOGY, V153, P17, DOI 10.1210/en.2011 1439
   Lin K, 2008, CYTOTHERAPY, V10, P417, DOI 10.1080/14653240801982979
   Marino G, 2013, J SURG RES, V185, P36, DOI 10.1016/j.jss.2013.05.024
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Miksad RA, 2011, ONCOLOGIST, V16, P121, DOI 10.1634/theoncologist.2010 0183
   Nomura I, 2014, CLIN ORTHOP RELAT R, V472, P3798, DOI 10.1007/s11999 014 3608 8
   Parfitt AM, 1997, J BONE MINER RES, V12, P1864, DOI 10.1359/jbmr.1997.12.11.1864
   Perin EC, 2014, AM HEART J, V168, P88, DOI 10.1016/j.ahj.2014.03.022
   RADDEN H G, 1959, Ann R Coll Surg Engl, V24, P366
   Rauch F, 2002, J CLIN INVEST, V110, P1293, DOI 10.1172/JCI200215952
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saxer F, 2016, STEM CELLS, V34, P2956, DOI 10.1002/stem.2478
   Shimizu Y, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.000877
   Vieira AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128021
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yamashita J, 2011, CLIN CANCER RES, V17, P1405, DOI 10.1158/1078 0432.CCR 10 1614
   Yoshimura K, 2010, BREAST J, V16, P169, DOI 10.1111/j.1524 4741.2009.00873.x
   Zhang QZ, 2013, CLIN CANCER RES, V19, P3176, DOI 10.1158/1078 0432.CCR 13 0042
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 42
TC 49
Z9 53
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2018
VL 33
IS 1
BP 154
EP 166
DI 10.1002/jbmr.3292
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FS9FX
UT WOS:000422723400018
PM 28902422
DA 2025 08 17
ER

PT J
AU Zhang, D
   Iwabuchi, S
   Baba, T
   Hashimoto, SI
   Mukaida, N
   Sasaki, SI
AF Zhang, Di
   Iwabuchi, Sadahiro
   Baba, Tomohisa
   Hashimoto, Shin ichi
   Mukaida, Naofumi
   Sasaki, So ichiro
TI Involvement of a Transcription factor, Nfe2, in Breast Cancer
   Metastasis to Bone
SO CANCERS
LA English
DT Article
DE bone metastasis; breast cancer; transcription factor; Wnt pathway
ID FACTOR NF E2; ERYTHROID PROMOTER; GENE EXPRESSION; MICE LACKING; NRF2;
   RUNX2; ANTIOXIDANT; INDUCTION; SUBUNIT; PATHWAY
AB Simple Summary
   Breast cancer patients are frequently complicated by bone metastasis, which deteriorates their life expectancy. Bone metastasis is treated with the drugs targeting osteoclast activation, which is mostly observed at the metastasis sites. However, these drugs cannot directly inhibit cancer cell growth and therefore, a novel therapeutic strategy is required to impede cancer cell proliferation at bone metastasis sites. Here, we proved that a transcription factor, NFE2, was expressed selectively in breast cancer cells at bone metastasis sites and contributed crucially to their enhanced proliferation therein, by activating Wnt pathway. Thus, NFE2 can be a novel molecular target to treat breast cancer bone metastasis.
   Patients with triple negative breast cancer (TNBC) is frequently complicated by bone metastasis, which deteriorates the life expectancy of this patient cohort. In order to develop a novel type of therapy for bone metastasis, we established 4T1.3 clone with a high capacity to metastasize to bone after orthotopic injection, from a murine TNBC cell line, 4T1.0. To elucidate the molecular mechanism underlying a high growth ability of 4T1.3 in a bone cavity, we searched for a novel candidate molecule with a focus on a transcription factor whose expression was selectively enhanced in a bone cavity. Comprehensive gene expression analysis detected enhanced Nfe2 mRNA expression in 4T1.3 grown in a bone cavity, compared with in vitro culture conditions. Moreover, Nfe2 gene transduction into 4T1.0 cells enhanced their capability to form intraosseous tumors. Moreover, Nfe2 shRNA treatment reduced tumor formation arising from intraosseous injection of 4T1.3 clone as well as another mouse TNBC derived TS/A.3 clone with an augmented intraosseous tumor formation ability. Furthermore, NFE2 expression was associated with in vitro growth advantages of these TNBC cell lines under hypoxic condition, which mimics the bone microenvironment, as well as Wnt pathway activation. These observations suggest that NFE2 can potentially contribute to breast cancer cell survival in the bone microenvironment.
C1 [Zhang, Di; Baba, Tomohisa; Mukaida, Naofumi; Sasaki, So ichiro] Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.
   [Iwabuchi, Sadahiro; Hashimoto, Shin ichi] Wakayama Med Univ, Inst Adv Med, Dept Mol Pathophysiol, 811 1 Kimiidera, Wakayama 6418509, Japan.
C3 Kanazawa University; Wakayama Medical University
RP Sasaki, SI (通讯作者)，Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.
EM zddione@stu.kanazawa u.ac.jp; iwabuchi@wakayama med.ac.jp;
   sergenti@staff.kanazawa u.ac.jp; hashimot@wakayama med.ac.jp;
   mukaida@staff.kanazawa u.ac.jp; s_sasaki@staff.kanazawa u.ac.jp
RI Iwabuchi, Sadahiro/AAD 4455 2022; SASAKI, Soichiro/D 8452 2015; Mukaida,
   Naofumi/D 7623 2011
OI Iwabuchi, Sadahiro/0000 0003 0434 3054; Sasaki,
   Soichiro/0000 0001 9092 7181; Mukaida, Naofumi/0000 0002 4193 1851
FU Japan Society for the Promotion of Science [20K07567]; Grants in Aid for
   Scientific Research [20K07567] Funding Source: KAKEN
FX This work is partially supported by Grant in Aid for Scientific Research
   (C) (20K07567) from the Japan Society for the Promotion of Science
   (So ichiro Sasaki and Naofumi Mukaida).
CR ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0
   ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488
   Baba T, 2013, J EXP MED, V210, P2661, DOI 10.1084/jem.20130112
   Body JJ, 2017, CRIT REV ONCOL HEMAT, V115, P67, DOI 10.1016/j.critrevonc.2017.04.008
   Chui CMY, 2003, CYTOKINE, V21, P51, DOI 10.1016/S1043 4666(02)00499 4
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Cosphiadi I, 2018, CLIN BREAST CANCER, V18, pE1117, DOI 10.1016/j.clbc.2018.03.001
   Dafni U, 2019, BREAST CARE, V14, P344, DOI 10.1159/000503219
   Davudian S, 2016, GENE, V588, P30, DOI 10.1016/j.gene.2016.04.040
   FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092 8674(94)90187 2
   Gasiorek JJ, 2015, CELL MOL LIFE SCI, V72, P2323, DOI 10.1007/s00018 015 1866 6
   Glembotsky AC, 2014, J THROMB HAEMOST, V12, P761, DOI 10.1111/jth.12550
   Gong X, 2015, ONCOGENE, V34, P4692, DOI 10.1038/onc.2014.417
   Hirotsu Y, 2012, NUCLEIC ACIDS RES, V40, P10228, DOI 10.1093/nar/gks827
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Jutzi JS, 2013, J EXP MED, V210, P1003, DOI 10.1084/jem.20120521
   Jutzi JS, 2019, BLOOD, V133, P1766, DOI 10.1182/blood 2018 09 875047
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kaufmann KB, 2012, J EXP MED, V209, P35, DOI 10.1084/jem.20110540
   Kim B, 2020, J BONE MINER RES, V35, P155, DOI 10.1002/jbmr.3869
   Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031
   Lecine P, 1998, BLOOD, V92, P1608, DOI 10.1182/blood.V92.5.1608.417k27_1608_1616
   Lee WH, 2014, AM J PHYSIOL CELL PH, V306, pC407, DOI 10.1152/ajpcell.00312.2013
   Li XQ, 2016, CANCER LETT, V380, P78, DOI 10.1016/j.canlet.2016.06.007
   LOLLINI PL, 1984, CLIN EXP METASTAS, V2, P251, DOI 10.1007/BF00132932
   Loyd MR, 2003, BLOOD, V102, P4223, DOI 10.1182/blood 2003 02 0574
   Manigandan K, 2015, BIOCHIMIE, V119, P103, DOI 10.1016/j.biochi.2015.10.014
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37
   MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548
   MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090
   MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604
   Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008 5472.CAN 07 5003
   Onishi Y, 2003, J BIOL CHEM, V278, P8163, DOI 10.1074/jbc.M209612200
   Peeken JC, 2018, BLOOD, V131, P2065, DOI 10.1182/blood 2017 10 810622
   Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008 5472.CAN 08 1078
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506 500
   Sasaki S, 2016, CANCER LETT, V378, P23, DOI 10.1016/j.canlet.2016.05.005
   Sasaki S, 2014, INT J CANCER, V135, P1297, DOI 10.1002/ijc.28779
   SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651
   Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Taguchi K, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00085
   Toki T, 1996, BIOCHEM BIOPH RES CO, V219, P760, DOI 10.1006/bbrc.1996.0307
   Vishal M, 2017, INT J BIOL MACROMOL, V99, P608, DOI 10.1016/j.ijbiomac.2017.03.021
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xia TS, 2010, ONCOL REP, V24, P203, DOI 10.3892/or_00000847
   Zhong Z, 2020, CANCER METAST REV, V39, P625, DOI 10.1007/s10555 020 09887 6
NR 52
TC 13
Z9 14
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD OCT
PY 2020
VL 12
IS 10
AR 3003
DI 10.3390/cancers12103003
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA OK3FL
UT WOS:000584538600001
PM 33081224
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Moran, JM
   Roncero Martin, R
   Rodriguez Velasco, FJ
   Calderon Garcia, JF
   Rey Sanchez, P
   Vera, V
   Canal Macias, ML
   Pedrera Zamorano, JD
AF Moran, Jose M.
   Roncero Martin, Raul
   Rodriguez Velasco, Francisco J.
   Calderon Garcia, Julian F.
   Rey Sanchez, Purificacion
   Vera, Vicente
   Canal Macias, Maria L.
   Pedrera Zamorano, Juan D.
TI Effects of Curcumin on the Proliferation and Mineralization of Human
   Osteoblast Like Cells: Implications of Nitric Oxide
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoblast; nitric oxide synthase; nitric oxide
ID FUNCTIONAL ROLE; IN VITRO; ACTIVATION; SYNTHASE; DIFFERENTIATION;
   OSTEOCLASTOGENESIS; ANTICANCER; MODULATION; EXPRESSION; APOPTOSIS
AB Curcumin (diferuloylmethane) is found in the rhizomes of the turmeric plant (Curcuma longa L.) and has been used for centuries as a dietary spice and as a traditional Indian medicine used to treat different conditions. At the cellular level, curcumin modulates important molecular targets: transcription factors, enzymes, cell cycle proteins, cytokines, receptors and cell surface adhesion molecules. Because many of the curcumin targets mentioned above participate in the regulation of bone remodeling, curcumin may affect the skeletal system. Nitric oxide (NO) is a gaseous molecule generated from L arginine during the catalization of nitric oxide synthase (NOS), and it plays crucial roles in catalization and in the nervous, cardiovascular and immune systems. Human osteoblasts have been shown to express NOS isoforms, and the exact mechanism(s) by which NO regulates bone formation remain unclear. Curcumin has been widely described to inhibit inducible nitric oxide synthase expression and nitric oxide production, at least in part via direct interference in NF kappa B activation. In the present study, after exposure of human osteoblast like cells (MG 63), we have observed that curcumin abrogated inducible NOS expression and decreased NO levels, inhibiting also cell prolifieration. This effect was prevented by the NO donor sodium nitroprusside. Under osteogenic conditions, curcumin also decreased the level of mineralization. Our results indicate that NO plays a role in the osteoblastic profile of MG 63 cells.
C1 [Moran, Jose M.; Roncero Martin, Raul; Rodriguez Velasco, Francisco J.; Calderon Garcia, Julian F.; Rey Sanchez, Purificacion; Vera, Vicente; Canal Macias, Maria L.; Pedrera Zamorano, Juan D.] Univ Extremadura, Sch Nursing & Occupat Therapy, Metab Bone Dis Res Grp, Caceres 10003, Spain.
C3 Universidad de Extremadura
RP Pedrera Zamorano, JD (通讯作者)，Univ Extremadura, Sch Nursing & Occupat Therapy, Metab Bone Dis Res Grp, Caceres 10003, Spain.
EM jmmorang@unex.es; rronmar@unex.es; fcorodriguezv@unex.es;
   jfcalgar@unex.es; prey@unex.es; viventevera@odon.ucm.es;
   luzcanal@unex.es; jpedrera@unex.es
RI ; Moran, Jose M./N 9636 2013; Velasco, Francisco/O 8177 2017; Moran,
   Jose/N 9636 2013
OI VERA GONZALEZ, VICENTE/0000 0001 9456 9203; Roncero Martin,
   Raul/0000 0002 1113 8967; Moran, Jose M./0000 0002 5538 182X; Calderon
   Garcia, Julian Fernando/0000 0002 0844 0479; Rey Sanchez,
   Purificacion/0000 0001 5854 0454; Rodriguez Velasco, Francisco
   Jose/0000 0003 0610 3839
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Bar Sela G, 2011, EVIDENCE BASED ANTIC, P225
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Biswas S, 2008, MOL NUTR FOOD RES, V52, P987, DOI 10.1002/mnfr.200700259
   Bonthius DJ, 2008, NEUROTOXICOLOGY, V29, P1080, DOI 10.1016/j.neuro.2008.08.007
   Chakravarti N, 2006, INT J CANCER, V119, P1268, DOI 10.1002/ijc.21967
   Chan WH, 2006, FOOD CHEM TOXICOL, V44, P1362, DOI 10.1016/j.fct.2006.03.001
   Chen HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038378
   Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914
   Chen RM, 2005, J ORTHOP RES, V23, P462, DOI 10.1016/j.orthres.2004.08.011
   Cheng GZ, 2011, NITRIC OXIDE BIOL CH, V25, P316, DOI 10.1016/j.niox.2011.05.009
   Epstein J, 2010, BRIT J NUTR, V103, P1545, DOI 10.1017/S0007114509993667
   Folwarczna J, 2010, PHARMACOL REP, V62, P900, DOI 10.1016/S1734 1140(10)70350 9
   Goel A, 2008, MOL NUTR FOOD RES, V52, P1010, DOI 10.1002/mnfr.200700354
   Guimaraes MR, 2011, J PERIODONTAL RES, V46, P269, DOI 10.1111/j.1600 0765.2010.01342.x
   Hikiji H, 1997, FEBS LETT, V410, P238, DOI 10.1016/S0014 5793(97)00597 8
   Hussan F., 2012, EVID BASED COMPL ALT, V2012, P1
   Koyama A, 2000, EUR J PHARMACOL, V391, P225, DOI 10.1016/S0014 2999(00)00100 X
   Leow PC, 2010, INVEST NEW DRUG, V28, P766, DOI 10.1007/s10637 009 9311 z
   Li Y, 2011, CELL BIOL INT, V35, P757, DOI 10.1042/CBI20100832
   López Lázaro M, 2008, MOL NUTR FOOD RES, V52, pS103, DOI 10.1002/mnfr.200700238
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   Milacic V, 2008, CANCER RES, V68, P7283, DOI 10.1158/0008 5472.CAN 07 6246
   Mori M, 2000, BIOCHEM BIOPH RES CO, V275, P715, DOI 10.1006/bbrc.2000.3169
   Mungrue IN, 2003, ACTA PHYSIOL SCAND, V179, P123, DOI 10.1046/j.1365 201X.2003.01182.x
   Notoya M, 2006, EUR J PHARMACOL, V534, P55, DOI 10.1016/j.ejphar.2006.01.028
   Ortiz Ortiz MA, 2009, NEUROTOXICOLOGY, V30, P1008, DOI 10.1016/j.neuro.2009.07.016
   Otsuka E, 1998, EUR J PHARMACOL, V349, P345, DOI 10.1016/S0014 2999(98)00190 3
   Pan MH, 2000, BIOCHEM PHARMACOL, V60, P1665, DOI 10.1016/S0006 2952(00)00489 5
   RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330
   Reuter S, 2008, BIOCHEM PHARMACOL, V76, P1340, DOI 10.1016/j.bcp.2008.07.031
   RIANCHO JA, 1995, J BONE MINER RES, V10, P439
   Saura M, 2010, THESCIENTIFICWORLDJO, V10, P624, DOI 10.1100/tsw.2010.58
   Singh S, 2007, CELL, V130, P765, DOI 10.1016/j.cell.2007.08.024
   Son MJ, 2010, J BIOCHEM MOL TOXIC, V24, P313, DOI 10.1002/jbt.20340
   von Metzler I, 2009, J CANCER RES CLIN, V135, P173, DOI 10.1007/s00432 008 0461 8
   Walters DK, 2008, INVEST NEW DRUG, V26, P289, DOI 10.1007/s10637 007 9099 7
   Wang JP, 2007, J PHARMACOL SCI, V104, P82, DOI 10.1254/jphs.FP0061549
   Yamaguchi M, 2007, MOL CELL BIOCHEM, V303, P83, DOI 10.1007/s11010 007 9458 x
   Yamaguchi M, 2012, INTEGR BIOL UK, V4, P905, DOI 10.1039/c2ib20045g
   Zhou T, 2013, ACTA ODONTOL SCAND, V71, P349, DOI 10.3109/00016357.2012.682092
NR 41
TC 39
Z9 42
U1 0
U2 30
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2012
VL 13
IS 12
BP 16104
EP 16118
DI 10.3390/ijms131216104
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 058BC
UT WOS:000312608100037
PM 23443113
OA Green Accepted, Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Wang, XL
   Zhang, C
   Ma, Q
   Xiao, WJ
   Guo, L
   Wu, Y
AF Wang, Xiaolong
   Zhang, Chen
   Ma, Qiang
   Xiao, Wenjiao
   Guo, Li
   Wu, Yong
TI An effective method for bisphosphonate moiety inserting into O H bond of
   carboxylic acids by Cu (II) catalyst
SO TETRAHEDRON LETTERS
LA English
DT Article
DE Bone targeting; Bisphosphonates; Naproxen; Prod rug; Insertion
ID DRUG DELIVERY; IN VITRO; OSTEOMYELITIS; CONJUGATE; PRODRUGS; CELLS
AB In this study we developed a novel copper catalyzed O H insertion of tetraethyl diphosphonodia zomethane into carboxylic acids, providing a simple method to link bisphosphonates to compounds containing carboxyl group. Moreover, a novel bone targeting prodrug of naproxen was synthesized according to this new methodology, and the preliminary evaluation indicated that the prodrug exhibited excellent bone affinity in vitro. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Wang, Xiaolong; Zhang, Chen; Ma, Qiang; Xiao, Wenjiao; Guo, Li; Wu, Yong] Sichuan Univ, West China Sch Pharm, Dept Med Chem, Key Lab Drug Targeting & Drug Delivery Syst,Educ, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University
RP Guo, L; Wu, Y (通讯作者)，Sichuan Univ, West China Sch Pharm, Dept Med Chem, Key Lab Drug Targeting & Drug Delivery Syst,Educ, Chengdu 610041, Sichuan, Peoples R China.
EM guoli@scu.edu.cn; wyong@scu.edu.cn
RI Xiao, Wenjiao/A 2762 2010; Ma, Qiang/AAD 2446 2021
FU National Natural Science Foundation of China [81573286, 81773577,
   21472130]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81573286, No. 81773577 & No. 21472130).
CR Fazil M, 2015, DRUG DELIV, V22, P1, DOI 10.3109/10717544.2013.870259
   Gillingham D, 2013, CHEM SOC REV, V42, P4918, DOI 10.1039/c3cs35496b
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Hosain F, 1996, J NUCL MED, V37, P105
   Hunter AC, 2016, EUR J ORG CHEM, V2016, P2260, DOI 10.1002/ejoc.201600064
   Jiang QL, 2008, LETT ORG CHEM, V5, P229, DOI 10.2174/157017808783955862
   Leung GJ, 2014, J PHARM PHARMACOL, V66, P347, DOI 10.1111/jphp.12165
   Liu CL, 2016, ACS APPL MATER INTER, V8, P29997, DOI 10.1021/acsami.6b10374
   Maelle M, 2005, TETRAHEDRON, V61, P7528
   Paolino D, 2015, J MATER CHEM B, V3, P250, DOI 10.1039/c4tb00955j
   Pettaway CA, 2017, ANN SURG ONCOL, V24, P3115, DOI 10.1245/s10434 017 5949 5
   Pirrung MC, 2002, J AM CHEM SOC, V124, P1014, DOI 10.1021/ja011599l
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Spina A, 2013, J CELL PHYSIOL, V228, P198, DOI 10.1002/jcp.24124
   Tanaka KSE, 2010, BIOORG MED CHEM LETT, V20, P1355, DOI 10.1016/j.bmcl.2010.01.006
   Wang ZK, 2014, CHEM COMMUN, V50, P3976, DOI 10.1039/c4cc00402g
   Zhao Y, 2015, LETT DRUG DES DISCOV, V12, P585, DOI 10.2174/1570180812999150217171229
NR 18
TC 8
Z9 8
U1 0
U2 20
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040 4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD JAN 17
PY 2018
VL 59
IS 3
BP 280
EP 283
DI 10.1016/j.tetlet.2017.12.038
PG 4
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR EXPANDED)
SC Chemistry
GA FV1GH
UT WOS:000424308900020
DA 2025 08 17
ER

PT J
AU Yu, ZT
   Jiang, XJ
   Yin, JJ
   Han, L
   Xiong, CW
   Huo, ZN
   Xu, J
   Shang, JJ
   Xi, K
   Nong, LM
   Huang, Y
   Zhou, XD
AF Yu, Zhentang
   Jiang, Xijia
   Yin, Jianjian
   Han, Lei
   Xiong, Chengwei
   Huo, Zhennan
   Xu, Jie
   Shang, Jingjing
   Xi, Kun
   Nong, Luming
   Huang, Yong
   Zhou, Xindie
TI CK1ε drives osteogenic differentiation of bone marrow mesenchymal stem
   cells via activating Wnt/β catenin pathway
SO AGING US
LA English
DT Article
DE bone defect; bone regeneration; osteogenic differentiation; mesenchymal
   stem cells; Wnt/beta catenin; CK1 epsilon
ID TUMOR GROWTH; REGENERATION; SCAFFOLDS; FAMILY
AB The treatment of bone defects is a difficult problem in orthopedics. At present, the treatment mainly relies on autologous or allogeneic bone transplantation, which may lead to some complications such as foreign body rejection, local infection, pain, or numbness at the bone donor site. Local injection of conservative therapy to treat bone defects is one of the research hotspots at present. Bone marrow mesenchymal stem cells (BMSCs) can self renew, significantly proliferate, and differentiate into various types of cells. Although it has been reported that CK1 epsilon could mediate the Wnt/beta catenin pathway, leading to the development of the diseases, whether CK1 epsilon plays a role in bone regeneration through the Wnt/beta catenin pathway has rarely been reported. The purpose of this study was to investigate whether CK1 epsilon was involved in the osteogenic differentiation (OD) of BMSCs through the Wnt/beta catenin pathway and explore the mechanism. We used quantitative reverse transcription polymerase chain reaction (qRT qPCR), Western blots, immunofluorescence, alkaline phosphatase, and alizarin red staining to detect the effect of CK1 epsilon on the OD of BMSCs and the Wnt/beta catenin signaling pathway. CK1 epsilon was highly expressed in BMSCs with OD, and our study further demonstrated that CK1 epsilon might promote the OD of BMSCs by activating DLV2 phosphorylation, initiating Wnt signaling downstream, and activating beta catenin nuclear transfer. In addition, by locally injecting a CK1 epsilon carrying adeno associated virus (AAV5 CK1 epsilon) into a femoral condyle defect rat model, the overexpression of CK1 epsilon significantly promoted bone repair. Our data show that CK1 epsilon was involved in the regulation of OD by mediating Wnt/beta catenin. This may provide a new strategy for the treatment of bone defects.
C1 [Yu, Zhentang; Jiang, Xijia; Yin, Jianjian; Han, Lei; Xiong, Chengwei; Huo, Zhennan; Xu, Jie; Nong, Luming; Huang, Yong; Zhou, Xindie] Nanjing Med Univ, Dept Orthoped, Affiliated Changzhou Peoples Hosp 2, Changzhou 213000, Jiangsu, Peoples R China.
   [Yu, Zhentang] Yibin Integrated Tradit Chinese & Western Med Hos, Dept Orthoped, Yibin 644104, Peoples R China.
   [Yu, Zhentang; Han, Lei; Xiong, Chengwei; Huo, Zhennan] Dalian Med Univ, Dept Grad Sch, Dalian 116000, Peoples R China.
   [Shang, Jingjing] Nanjing Med Univ, Dept Pharm, Affiliated Changzhou Peoples Hosp 2, Changzhou 213000, Jiangsu, Peoples R China.
   [Xi, Kun] Soochow Univ, Inst Orthoped, Affiliated Hosp 1, Dept Orthoped, Suzhou 215006, Peoples R China.
   [Zhou, Xindie] Gonghe Cty Hosp Tradit Chinese Med, Dept Orthoped, Xining 811800, Qinghai, Peoples R China.
   [Zhou, Xindie] Nanjing Med Univ, Changzhou Med Ctr, Changzhou 213000, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Dalian Medical University; Nanjing Medical
   University; Soochow University   China; Nanjing Medical University
RP Huang, Y; Zhou, XD (通讯作者)，Nanjing Med Univ, Dept Orthoped, Affiliated Changzhou Peoples Hosp 2, Changzhou 213000, Jiangsu, Peoples R China.; Zhou, XD (通讯作者)，Gonghe Cty Hosp Tradit Chinese Med, Dept Orthoped, Xining 811800, Qinghai, Peoples R China.; Zhou, XD (通讯作者)，Nanjing Med Univ, Changzhou Med Ctr, Changzhou 213000, Jiangsu, Peoples R China.
EM huangyong@njmu.edu.cn; zhouxindie@njmu.edu.cn
RI Xi, Kun/JMQ 1169 2023; Yin, Jianjian/KIJ 2252 2024; Yu,
   Zhentang/IYT 3258 2023
OI Xi, Kun/0000 0002 0458 9866; 
FU Changzhou Sci and Tech Program [CJ20220120]; Qinghai Province Health
   System Guidance Plan Project [2022 wjzdx 106]; Young Talent Development
   Plan of Changzhou Health commission [CZQM2020059]; Changzhou High Level
   Medical Talents Training Project [2022CZBJ059, 2022CZBJ061]
FX This study was supported by Changzhou Sci and Tech Program (Grant No.
   CJ20220120), Qinghai Province Health System Guidance Plan Project
   (2022 wjzdx 106), and Funding from Young Talent Development Plan of
   Changzhou Health commission (CZQM2020059), and Changzhou High Level
   Medical Talents Training Project (2022CZBJ059 and 2022CZBJ061).
CR Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Baetta R, 2019, ARTERIOSCL THROM VAS, V39, P1330, DOI 10.1161/ATVBAHA.119.312612
   Bernatik O, 2011, J BIOL CHEM, V286, P10396, DOI 10.1074/jbc.M110.169870
   Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen Q, 2016, DRUG DES DEV THER, V10, P2311, DOI 10.2147/DDDT.S91321
   Chen XJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108746
   Cheng YY, 2020, MOL CELL ENDOCRINOL, V506, DOI 10.1016/j.mce.2020.110763
   Cheong JK, 2011, INT J BIOCHEM CELL B, V43, P465, DOI 10.1016/j.biocel.2010.12.004
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Esaki N, 2020, BIOCHEM BIOPH RES CO, V532, P406, DOI 10.1016/j.bbrc.2020.08.066
   Foldynová Trantírková S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2581
   Guo YY, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101915
   Guo YX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0031 x
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Jiang J, 2017, CURR TOP DEV BIOL, V123, P303, DOI 10.1016/bs.ctdb.2016.09.002
   Jo S, 2018, J BONE MINER METAB, V36, P307, DOI 10.1007/s00774 017 0846 3
   Kaigler D, 2013, CELL TRANSPLANT, V22, P767, DOI 10.3727/096368912X652968
   Knippschild U, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00096
   Kuang ZH, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106960
   Lee YC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205015
   Li J, 2022, INT IMMUNOPHARMACOL, V102, DOI 10.1016/j.intimp.2021.108416
   Li YX, 2015, J ATHEROSCLER THROMB, V22, P424, DOI 10.5551/jat.27839
   Lin SH, 2016, TUMOR BIOL, V37, P3997, DOI 10.1007/s13277 015 4225 1
   Liu RF, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3658798
   Liu SY, 2015, CELL METAB, V22, P606, DOI 10.1016/j.cmet.2015.08.018
   Liu Y, 2020, INT J BIOL MACROMOL, V148, P153, DOI 10.1016/j.ijbiomac.2020.01.109
   Liu YH, 2013, BIOMATERIALS, V34, P9998, DOI 10.1016/j.biomaterials.2013.09.040
   Lu TL, 2022, BIOMATER ADV, V141, DOI 10.1016/j.bioadv.2022.213120
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   McGovern JA, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.033084
   McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308
   Morgenstern Y, 2017, EMBO J, V36, P3046, DOI 10.15252/embj.201696253
   Nauth A, 2018, J ORTHOP TRAUMA, V32, pS7, DOI 10.1097/BOT.0000000000001115
   Peng ZY, 2021, J MATER CHEM B, V9, P5698, DOI 10.1039/d1tb00178g
   Saranya I, 2022, DIFFERENTIATION, V128, P57, DOI 10.1016/j.diff.2022.10.003
   Shang JJ, 2023, ISCIENCE, V26, DOI 10.1016/j.isci.2023.107025
   Su ZJ, 2018, P NATL ACAD SCI USA, V115, pE7522, DOI 10.1073/pnas.1802422115
   Tang Y, 2019, J CELL BIOCHEM, V120, P13403, DOI 10.1002/jcb.28615
   Wang CL, 2022, CELLS BASEL, V11, DOI 10.3390/cells11162491
   Wang Q, 2018, INT J EXP PATHOL, V99, P113, DOI 10.1111/iep.12275
   Watson EC, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031559
   Wei QS, 2016, BIOMED PHARMACOTHER, V84, P931, DOI 10.1016/j.biopha.2016.09.107
   Wu SB, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.665931
   Xu B, 2012, PROSTATE, V72, P1171, DOI 10.1002/pros.22466
   Xu F, 2014, BIOCHEM J, V458, P159, DOI 10.1042/BJ20130986
   Xu ZH, 2023, WORLD J STEM CELLS, V15, P502, DOI 10.4252/wjsc.v15.i6.502
   Xu ZH, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110593
   Yang N, 2021, INT J MED SCI, V18, P3697, DOI 10.7150/ijms.61080
   Yang Y, 2017, CELL SIGNAL, V31, P58, DOI 10.1016/j.cellsig.2016.12.010
   You L, 2016, BIOORG MED CHEM LETT, V26, P5891, DOI 10.1016/j.bmcl.2016.11.012
   Yu K, 2022, MOL THER, V30, P3226, DOI 10.1016/j.ymthe.2022.05.020
   Yuan ZY, 2016, CURR STEM CELL RES T, V11, P216, DOI 10.2174/1574888X10666150519093429
   Zhang L, 2006, DEV BIOL, V299, P221, DOI 10.1016/j.ydbio.2006.07.025
   Zheng CX, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0060 3
   Zhou XD, 2023, CHEM ENG J, V462, DOI 10.1016/j.cej.2023.142158
   Zhu GQ, 2023, J BIOMAT SCI POLYM E, V34, P2000, DOI 10.1080/09205063.2023.2204779
NR 58
TC 1
Z9 1
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD OCT 15
PY 2023
VL 15
IS 19
BP 10196
EP 10219
PG 24
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA CN4K4
UT WOS:001125913100013
DA 2025 08 17
ER

PT J
AU Wang, X
   Zhao, D
   Zhu, YZ
   Dong, Y
   Liu, YJ
AF Wang, Xue
   Zhao, Ding
   Zhu, Yuzhu
   Dong, Ying
   Liu, Yijun
TI Long non coding RNA GAS5 promotes osteogenic differentiation of bone
   marrow mesenchymal stem cells by regulating the miR 135a 5p/FOXO1
   pathway
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Long non coding RNA GAS5; Osteoblast differentiation; Bone marrow
   mesenchymal stem cells; miR 135a 5p; FOXO1
ID CELLULAR PROLIFERATION; LINEAGE PROGRESSION; GROWTH ARREST; EXPRESSION;
   MICRORNA; MIR 21; FOXO1
AB Studies have shown that promoting the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts could protect against osteoporosis. Increasing evidence demonstrates that long non coding RNAs (lncRNAs) participate in BMSC osteogenic differentiation. This study aimed to investigate the role and underlying mechanism of growth arrest specific transcript 5 (GAS5) in osteogenic differentiation. The mechanism was mainly focused on miR 135a 5p/FOXO1 pathway by gain  and loss of function tests. GAS5 and FOXO1 expression was decreased, whereas miR 135a 5p expression was increased, in the BMSCs from osteoporotic mice. Levels of GAS5 and FOXO1 were increased and miR 135a 5p expression was decreased during osteogenic differentiation of BMSCs. Overexpression of GAS5 promoted, whereas knockdown of GAS5 suppressed, BMSC osteogenic differentiation. As for the mechanism, GAS5 functioned as a competing endogenous RNA for miR 135a 5p to regulate FOXO1 expression. In conclusion, GAS5 promoted osteogenesis of BMSCs by regulating the miR 135a 5p/FOXO1 axis. This finding suggests that targeting GAS5 may be a useful therapy for treating postmenopausal osteoporosis.
C1 [Wang, Xue] Jilin Univ, Hosp 1, Dept Anesthesiol, Changchun 130000, Jilin, Peoples R China.
   [Zhao, Ding; Liu, Yijun] Jilin Univ, Hosp 1, Dept Orthopaed, 3302 Jilin Rd, Changchun 130000, Jilin, Peoples R China.
   [Zhu, Yuzhu] Changchun Matern Hosp, Dept Anesthesiol, Changchun 130000, Jilin, Peoples R China.
   [Dong, Ying] Jilin Prov Tumor Hosp, Dept Radiotherapy 3, Changchun 130012, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Liu, YJ (通讯作者)，Jilin Univ, Hosp 1, Dept Orthopaed, 3302 Jilin Rd, Changchun 130000, Jilin, Peoples R China.
EM yj_liujl@163.com
CR Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Caldwell KK, 2018, NEUROTOXICOL TERATOL, V66, P102, DOI 10.1016/j.ntt.2017.11.003
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.382
   Cui BZ, 2017, J CELL BIOCHEM, V118, P4548, DOI 10.1002/jcb.26116
   Feng L, 2018, MOL THER NUCL ACIDS, V11, P345, DOI 10.1016/j.omtn.2018.03.004
   Huang Y, 2018, J CELL MOL MED, V22, P5768, DOI 10.1111/jcmm.13866
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Imamura K, 2018, J BIOMATER APPL, V32, P1382, DOI 10.1177/0885328218763318
   Iyer S, 2013, J CLIN INVEST, V123, P3409, DOI 10.1172/JCI68049
   Jin FY, 2017, CELL PHYSIOL BIOCHEM, V43, P2062, DOI 10.1159/000484191
   Kim KM, 2012, J BONE MINER RES, V27, P1669, DOI 10.1002/jbmr.1604
   Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0627 5
   Liu X, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0424 6
   Lu YJ, 2016, BLOOD, V128, P1424, DOI 10.1182/blood 2016 05 714535
   Luo G, 2017, MOL CANCER RES, V15, P789, DOI 10.1158/1541 7786.MCR 16 0331
   Mao XP, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0438 8
   Moritoki Y, 2014, J UROLOGY, V191, P1174, DOI 10.1016/j.juro.2013.10.137
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092 8674(88)91065 3
   Shang GW, 2018, J CELL PHYSIOL, V233, P6041, DOI 10.1002/jcp.26424
   Singh PB, 2017, J EXP MED, V214, P3627, DOI 10.1084/jem.20170545
   Siqueira MF, 2011, BONE, V48, P1043, DOI 10.1016/j.bone.2011.01.019
   Tang R, 2017, J BIOL CHEM, V292, P14270, DOI 10.1074/jbc.M117.790030
   Tang SA, 2019, STEM CELLS, V37, P270, DOI 10.1002/stem.2937
   Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962
   Tu JJ, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0813 5
   Wang CD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.238
   Wang QJ, 2017, BIOMED PHARMACOTHER, V89, P1178, DOI 10.1016/j.biopha.2017.02.090
   Wang XY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0014 7
   Wu QY, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00587
   Xiao JJ, 2015, MOL CELL BIOCHEM, V409, P113, DOI 10.1007/s11010 015 2517 9
   Yang KN, 2013, NANOSCALE, V5, P1205, DOI 10.1039/c2nr33575a
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Zeng BH, 2019, EXP CELL RES, V374, P365, DOI 10.1016/j.yexcr.2018.12.014
   Zeng WF, 2013, PROTEIN CELL, V4, P539, DOI 10.1007/s13238 013 3003 3
   Zhang Y, 2012, J BIOL CHEM, V287, P21926, DOI 10.1074/jbc.M112.340398
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zou WG, 2013, J EXP MED, V210, P1793, DOI 10.1084/jem.20111790
NR 40
TC 36
Z9 42
U1 0
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD OCT 1
PY 2019
VL 496
AR 110534
DI 10.1016/j.mce.2019.110534
PG 8
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA IZ8BV
UT WOS:000487328200010
PM 31398367
DA 2025 08 17
ER

PT J
AU Wan, XH
   Corn, PG
   Yang, J
   Palanisamy, N
   Starbuck, MW
   Efstathiou, E
   Tapia, EMLN
   Zurita, AJ
   Aparicio, A
   Ravoori, MK
   Vazquez, ES
   Robinson, DR
   Wu, YM
   Cao, XH
   Iyer, MK
   McKeehan, W
   Kundra, V
   Wang, F
   Troncoso, P
   Chinnaiyan, AM
   Logothetis, CJ
   Navone, NM
AF Wan, Xinhai
   Corn, Paul G.
   Yang, Jun
   Palanisamy, Nallasivam
   Starbuck, Michael W.
   Efstathiou, Eleni
   Tapia, Elsa M. Li Ning
   Zurita, Amado J.
   Aparicio, Ana
   Ravoori, Murali K.
   Vazquez, Elba S.
   Robinson, Dan R.
   Wu, Yi Mi
   Cao, Xuhong
   Iyer, Matthew K.
   McKeehan, Wallace
   Kundra, Vikas
   Wang, Fen
   Troncoso, Patricia
   Chinnaiyan, Arul M.
   Logothetis, Christopher J.
   Navone, Nora M.
TI Prostate cancer cell stromal cell crosstalk via FGFR1 mediates antitumor
   activity of dovitinib in bone metastases
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID ANDROGEN RECEPTOR; HEPARAN SULFATE; EXPRESSION; TUMORS; ADENOCARCINOMA;
   IDENTIFICATION; INHIBITOR; CARCINOMA; PATHWAYS; FAMILY
AB Bone is the most common site of prostate cancer (PCa) progression to a therapy resistant, lethal phenotype. We found that blockade of fibroblast growth factor receptors (FGFRs) with the receptor tyrosine kinase inhibitor dovitinib has clinical activity in a subset of men with castration resistant PCa and bone metastases. Our integrated analyses suggest that FGF signaling mediates a positive feedback loop between PCa cells and bone cells and that blockade of FGFR1 in osteoblasts partially mediates the antitumor activity of dovitinib by improving bone quality and by blocking PCa cell bone cell interaction. These findings account for clinical observations such as reductions in lesion size and intensity on bone scans, lymph node size, and tumor specific symptoms without proportional declines in serum prostate specific antigen concentration. Our findings suggest that targeting FGFR has therapeutic activity in advanced PCa and provide direction for the development of therapies with FGFR inhibitors.
C1 [Wan, Xinhai; Corn, Paul G.; Yang, Jun; Starbuck, Michael W.; Efstathiou, Eleni; Tapia, Elsa M. Li Ning; Zurita, Amado J.; Aparicio, Ana; Logothetis, Christopher J.; Navone, Nora M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Wan, Xinhai; Corn, Paul G.; Yang, Jun; Starbuck, Michael W.; Efstathiou, Eleni; Tapia, Elsa M. Li Ning; Zurita, Amado J.; Aparicio, Ana; Logothetis, Christopher J.; Navone, Nora M.] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA.
   [Palanisamy, Nallasivam; Robinson, Dan R.; Wu, Yi Mi; Cao, Xuhong; Iyer, Matthew K.; Chinnaiyan, Arul M.] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA.
   [Starbuck, Michael W.] Rolanette & Berdon Lawrence Bone Dis Program, Houston, TX 77030 USA.
   [Efstathiou, Eleni] Univ Athens Greece Sch Med, Athens 11528, Greece.
   [Ravoori, Murali K.; Kundra, Vikas] Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77030 USA.
   [Vazquez, Elba S.] Univ Buenos Aires, Dept Biol Chem, Natl Res Council Argentina CONICET IQUIBICEN, Buenos Aires, DF, Argentina.
   [McKeehan, Wallace; Wang, Fen] IBT Texas A&M Hlth Sci Ctr, Ctr Canc & Stem Cell Biol, Houston, TX 77030 USA.
   [Kundra, Vikas] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA.
   [Troncoso, Patricia] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Michigan
   System; University of Michigan; University of Texas System; UTMD
   Anderson Cancer Center; University of Buenos Aires; University of Texas
   System; UTMD Anderson Cancer Center; University of Texas System; UTMD
   Anderson Cancer Center
RP Navone, NM (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
EM nnavone@mdanderson.org
RI ; Yao, Jun/JAC 5608 2023; Vazquez, Elba/D 5134 2019; Chinnaiyan,
   Arul/LCE 5288 2024; Zurita, Amado/MXK 6131 2025; Palanisamy,
   Nallasivam/ABC 8844 2020; Iyer, Matthew/JMA 9808 2023
OI /0000 0002 0217 7390; Corn, Paul/0000 0002 4106 6335; Vazquez,
   Elba/0000 0002 0460 0236; Palanisamy, Nallasivam/0000 0002 0633 9772
FU Prostate Cancer Foundation; Cancer Center Support (Core) Grant [P30
   CA016672]; Prostate SPORE grant [5P50 CA140388]; Cancer Prevention &
   Research Institute of Texas [RP110555]; NIH [CA96824]; David H. Koch
   Center for Applied Research in Genitourinary Cancers at MD Anderson,
   Houston, TX; National Institute of General Medical Sciences
   [T32GM007863] Funding Source: NIH RePORTER
FX Funding: This work was supported in part by the Prostate Cancer
   Foundation, generous philanthropic contributions to The University of
   Texas MD Anderson Moon Shots Program, Cancer Center Support (Core) Grant
   P30 CA016672 and Prostate SPORE grant 5P50 CA140388, and the Cancer
   Prevention & Research Institute of Texas grant RP110555, NIH CA96824,
   and the David H. Koch Center for Applied Research in Genitourinary
   Cancers at MD Anderson, Houston, TX.
CR Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004
   Angevin E, 2013, CLIN CANCER RES, V19, P1257, DOI 10.1158/1078 0432.CCR 12 2885
   Antonarakis ES, 2012, EXPERT OPIN THER TAR, V16, P365, DOI 10.1517/14728222.2012.668887
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097 0142(20000615)88:12+<2989::AID CNCR14>3.0.CO;2 Q
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Corn PG, 2013, CLIN CANCER RES, V19, P5856, DOI 10.1158/1078 0432.CCR 13 1550
   Efstathiou E, 2012, J CLIN ONCOL, V30, P637, DOI 10.1200/JCO.2010.33.7675
   Gotoh N, 2008, CANCER SCI, V99, P1319, DOI 10.1111/j.1349 7006.2008.00840.x
   Han B, 2008, CANCER RES, V68, P7629, DOI 10.1158/0008 5472.CAN 08 2014
   Jacob AL, 2006, DEV BIOL, V296, P315, DOI 10.1016/j.ydbio.2006.05.031
   Kerbel RS, 2005, CANCER CELL, V8, P269, DOI 10.1016/j.ccr.2005.09.016
   Kim KB, 2011, CLIN CANCER RES, V17, P7451, DOI 10.1158/1078 0432.CCR 11 1747
   Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093
   Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841
   Lonigro RJ, 2011, NEOPLASIA, V13, P1019, DOI 10.1593/neo.111252
   Martin A, 2012, PHYSIOL REV, V92, P131, DOI 10.1152/physrev.00002.2011
   Mathew P, 2007, CLIN CANCER RES, V13, P5816, DOI 10.1158/1078 0432.CCR 07 1269
   McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135
   Memarzadeh S, 2007, CANCER CELL, V12, P572, DOI 10.1016/j.ccr.2007.11.002
   Michaelson MD, 2009, ANN ONCOL, V20, P913, DOI 10.1093/annonc/mdp111
   Murakami M, 2008, CURR OPIN HEMATOL, V15, P215, DOI 10.1097/MOH.0b013e3282f97d98
   Murukesh N, 2010, BRIT J CANCER, V102, P8, DOI 10.1038/sj.bjc.6605483
   Navone NM, 1997, CLIN CANCER RES, V3, P2493
   O'Connor JPB, 2012, NAT REV CLIN ONCOL, V9, P167, DOI 10.1038/nrclinonc.2012.2
   Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521 1878(200002)22:2<108::AID BIES2>3.0.CO;2 M
   Powers CJ, 2000, ENDOCR RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165
   Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509
   Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Valta MP, 2008, INT J CANCER, V123, P22, DOI 10.1002/ijc.23422
   Wöhrle S, 2011, J BONE MINER RES, V26, P2486, DOI 10.1002/jbmr.478
   Yang D, 2005, RADIOLOGY, V235, P950, DOI 10.1148/radiol.2353040108
   Yang J, 2001, CANCER RES, V61, P5652
   Zhang YY, 2008, DEVELOPMENT, V135, P775, DOI 10.1242/dev.009910
   Zurita AJ, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mdr047
NR 35
TC 83
Z9 92
U1 0
U2 21
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD SEP 3
PY 2014
VL 6
IS 252
AR 252ra122
DI 10.1126/scitranslmed.3009332
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA AO4KD
UT WOS:000341305400006
PM 25186177
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Akens, MK
   Wise Milestone, L
   Won, E
   Schwock, J
   Yee, AJM
   Wilson, BC
   Whyne, CM
AF Akens, Margarete K.
   Wise Milestone, Lisa
   Won, Emily
   Schwock, Joerg
   Yee, Albert J. M.
   Wilson, Brian C.
   Whyne, Can M.
TI In vitro and in vivo effects of photodynamic therapy on metastatic
   breast cancer cells pre treated with zoledronic acid
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Bone metastasis; Photodynamic therapy; Breast cancer; Zoledronic acid;
   Spine
ID VERTEBRAL METASTASES; BONE METASTASES; BISPHOSPHONATES; MECHANISM;
   EFFICACY; IMPACT; MODEL; LINES; RAT
AB Background: Photodynamic therapy (PDT), a non ionizing, minimally invasive drug light treatment, has recently been shown to successfully ablate tumor within rat vertebrae with concurrent improvements in bone strength and architecture. The bisphosphonate zoledronic acid (zoo, a current drug for patients with skeletal metastases, primarily works by inhibiting osteoclast activity, but direct anti tumor effects have also been reported. However, it is unknown if or how pre treatment with zol may alter the tumorcidal effect of PDT. The aim of this study was to evaluate the effect of PDT, both in vitro and in vivo, on zol pretreated cancer cells.
   Materials and methods: Human metastatic breast cancer cells (MT 1) were cultured in vitro and treated with zol (10 mu M) for 24 h, followed by PDT treatment. Cell viability was assessed by fluorescence microscopy and flow cytometry. In vivo, MT 1 cells were injected (intracardiac) into athymic rats. On day 7, zol (60 mu g/kg) was administered subcutaneously. On day 14, PDT was applied (1 mg/kg verteporfin; 75 J; 690 nm) to lumbar vertebrae. Histomorphometric assessment of tumor burden was evaluated on day 21.
   Results: The cell viability measured in vitro after PDT treatment decreased in cells pre incubated with zol up to 20% compared to treatment with PDT alone. Zol alone had no influence on the MT 1 cell viability. In vivo, all treatments, either alone or combined, had a tumorcidal effect.
   Conclusions: Pre treatment with zol in vivo did not yield a synergistic effect on tumor ablation in contrast to the in vitro results, but neither did it abrogate the positive tumorcidal effect of PDT, so that those therapies may be applied in combination. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Akens, Margarete K.; Wise Milestone, Lisa; Won, Emily; Yee, Albert J. M.; Whyne, Can M.] Sunnybrook Res Inst, Orthopaed Biomech Lab, Toronto, ON M4N 3M5, Canada.
   [Schwock, Joerg; Wilson, Brian C.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada.
C3 University of Toronto; Sunnybrook Health Science Center; Sunnybrook
   Research Institute; University of Toronto; University Health Network
   Toronto; Princess Margaret Cancer Centre
RP Akens, MK (通讯作者)，Univ Hlth Network, Techna Inst, Room 211,100 Coll St, Toronto, ON M5G 1P5, Canada.
EM margarete.akens@rmp.uhn.ca; lwisemil@gmail.com; emily.won85@gmail.com;
   joerg.schwock@gmail.com; albert.yee@sunnybrook.ca;
   wilson@uhnres.utoronto.ca; cari.whyne@sunnybrook.ca
RI ; Akens, Margarete/K 5502 2013
OI Schwock, Joerg/0000 0001 8889 5600; Akens,
   Margarete/0000 0003 3523 2381; Wilson, Brian C./0000 0001 5543 666X
FU Ontario Institute for Cancer Research (OICR)
FX Funding for this study was provided by the Ontario Institute for Cancer
   Research (OICR).
CR Akens MK, 2007, PHOTOCHEM PHOTOBIOL, V83, P1034, DOI 10.1111/j.1751 1097.2007.00172.x
   Akens MK, 2010, BREAST CANCER RES TR, V119, P325, DOI 10.1007/s10549 009 0356 7
   Benassi MS, 2007, CANCER LETT, V250, P194, DOI 10.1016/j.canlet.2006.10.004
   Berenson JR, 2005, ONCOLOGIST, V10, P52, DOI 10.1634/theoncologist.10 1 52
   Biel MA, 2007, PHOTOCHEM PHOTOBIOL, V83, P1063, DOI 10.1111/j.1751 1097.2007.00153.x
   Broom R, 2009, J PAIN SYMPTOM MANAG, V38, P244, DOI 10.1016/j.jpainsymman.2008.08.005
   Burch S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1921887
   Burch S, 2005, J ORTHOP RES, V23, P995, DOI 10.1016/j.orthres.2004.12.014
   Clemons M, 2006, ONCOLOGIST, V11, P227, DOI 10.1634/theoncologist.11 3 227
   Clézardin P, 2005, CANCER TREAT REV, V31, pS1, DOI 10.1016/j.ctrv.2005.09.002
   Coleman R, 2011, CANCER AM CANCER SOC, V117, P11, DOI 10.1002/cncr.25529
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Dimitroff CJ, 1999, INVEST NEW DRUG, V17, P121, DOI 10.1023/A:1006367032156
   Engebraaten O, 1999, INT J CANCER, V82, P219, DOI 10.1002/(SICI)1097 0215(19990719)82:2<219::AID IJC12>3.0.CO;2 #
   Ferro Elisa, 2012, J Signal Transduct, V2012, P365769, DOI 10.1155/2012/365769
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a
   Hambly RJ, 1997, BREAST CANCER RES TR, V43, P247, DOI 10.1023/A:1005756632293
   Henderson BW, 2004, CANCER RES, V64, P2120, DOI 10.1158/0008 5472.CAN 03 3513
   Hernández Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499
   Ibbotson SH, 2002, BRIT J DERMATOL, V146, P178, DOI 10.1046/j.0007 0963.2001.04689.x
   Keramaris NC, 2008, INJURY, V39, pS45, DOI 10.1016/S0020 1383(08)70015 9
   LAM S, 1994, SEMIN ONCOL, V21, P15
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   NAUNDORF H, 1992, BREAST CANCER RES TR, V23, P87, DOI 10.1007/BF01831480
   Niedre M, 2002, PHOTOCHEM PHOTOBIOL, V75, P382, DOI 10.1562/0031 8655(2002)075<0382:DNILDO>2.0.CO;2
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002 9394(02)01566 0
   SASAKI A, 1995, CANCER RES, V55, P3551
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Tatsui H, 1996, SPINE, V21, P2143, DOI 10.1097/00007632 199609150 00017
   van der Meel R, 2011, DRUG DISCOV TODAY, V16, P219, DOI 10.1016/j.drudis.2011.01.005
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
   Won E, 2010, BREAST CANCER RES TR, V124, P111, DOI 10.1007/s10549 009 0712 7
   Won E, 2010, SPINE, V35, P272, DOI 10.1097/BRS.0b013e3181af8360
NR 40
TC 6
Z9 8
U1 0
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572 1000
EI 1873 1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2014
VL 11
IS 3
BP 426
EP 433
DI 10.1016/j.pdpdt.2014.04.002
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AP2JZ
UT WOS:000341899800022
PM 25176573
DA 2025 08 17
ER

PT J
AU Ma, Y
   Zhu, Y
   Wang, F
   Zhao, GY
   Huang, LL
   Lu, RZ
   Wang, DX
   Tian, XY
   Ye, Y
AF Ma, Ying
   Zhu, Yin
   Wang, Feng
   Zhao, Guoyang
   Huang, Lianlian
   Lu, Rongzhu
   Wang, Dongxu
   Tian, Xinyu
   Ye, Yang
TI 3,3′ Diindolylmethane promotes bone formation   A assessment in MC3T3 E1
   cells and zebrafish
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE 3,3 '  Diindolylmethane; Osteoporosis; BAP1; IP3R; Store operated
   calcium entry
ID TUMOR SUPPRESSOR; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST; OSTEOPOROSIS;
   RECEPTOR; PATHWAY; ORAI1; STIM1
AB Osteoporosis is a common degenerative bone disease in middle aged and elderly people. The current drugs used to treat osteoporosis have many side effects and low patient compliance. Phytochemotherapy may be safer and more effective. 3,3 ' diindolemethane (DIM) is the digestive product of indole 3 methanol in cruciferous vegetables in the stomach, which is a kind of anti tumor and anti oxidation phytochemical. However, the effects of DIM on osteoblasts and the mechanism by which DIM regulates bone formation are not fully understood. The aim of this study was to investigate the effects of DIM on the bone formation of mouse preosteoblasts MC3T3 E1 and zebrafish. DIM promotes proliferation and osteogenic differentiation of MC3T3 E1 cells in vitro, and also plays a bone promoting role by increasing the interaction between BRCA1 Associated Protein 1(BAP1) and Inositol 1,4,5 Trisphosphate Receptor(IP3R), up regulating the expression of BAP1 and IP3R and downstream storage operation calcium entry (SOCE) related protein Recombinant Stromal Interaction Molecule 1(STIM1). The effect of DIM on osteoporosis was confirmed in zebrafish osteoporosis model, and its molecular mechanism may be related to BAP1/IP3R/SOCE signaling pathway. These findings highlight the potential therapeutic value of DIM in the prevention and treatment of osteoporosis.
C1 [Ma, Ying; Huang, Lianlian; Lu, Rongzhu; Ye, Yang] Jiangsu Univ, Sch Med, Dept Prevent Med & Publ Hlth Lab Sci, 301 Xuefu Rd, Zhenjiang 212013, Peoples R China.
   [Zhu, Yin] Jiangsu Univ, Dept Oncol, Jurong Hosp, Zhenjiang, Peoples R China.
   [Wang, Feng] Southeast Univ, Zhongda Hosp, Sch Med, Dept Spine Surg, Nanjing, Peoples R China.
   [Zhao, Guoyang] Jiangsu Univ, Affiliated Hosp, Orthoped Dept, Zhenjiang, Peoples R China.
   [Lu, Rongzhu] Jiangsu Univ, Affiliated Kunshan Hosp, Ctr Expt Res, Suzhou, Peoples R China.
   [Wang, Dongxu] Jiangsu Univ Sci & Technol, Sch Grain Sci & Technol, Zhenjiang, Peoples R China.
   [Tian, Xinyu] Jiangsu Univ, Nanjing Drum Tower Hosp, Nanjing Drum Tower Hosp Clin Coll, Dept Clin Lab, Nanjing, Peoples R China.
C3 Jiangsu University; Jiangsu University; Southeast University   China;
   Jiangsu University; Jiangsu University; Jiangsu University of Science &
   Technology; Jiangsu University; Nanjing University
RP Ye, Y (通讯作者)，Jiangsu Univ, Sch Med, Dept Prevent Med & Publ Hlth Lab Sci, 301 Xuefu Rd, Zhenjiang 212013, Peoples R China.
EM jamesnone@ujs.edu.cn
OI Wang, Dongxu/0000 0001 7377 6190
FU National Natural Science Foundation of China [82073543, 82272403];
   Guiding Science and Technology Program for Social Development of
   Zhenjiang [FZ2022028]; Jiangsu Association for Science & Technology
   Youth Science & Technology Talents Lifting Project [JSTJ 2023 XH014]
FX The present study was supported by the National Natural Science
   Foundation of China (82073543, 82272403) , Guiding Science and
   Technology Program for Social Development of Zhenjiang (FZ2022028) and
   Jiangsu Association for Science & Technology Youth Science & Technology
   Talents Lifting Project (JSTJ 2023 XH014) .
CR Adhikary S, 2018, NUTRITION, V53, P64, DOI 10.1016/j.nut.2017.12.003
   Ahmad A, 2016, MOL NUTR FOOD RES, V60, P1251, DOI 10.1002/mnfr.201500867
   Ahmed AI, 2022, AM J PHYSIOL CELL PH, V322, pC977, DOI 10.1152/ajpcell.00413.2021
   Baughman JM, 2016, CELL REP, V16, P583, DOI 10.1016/j.celrep.2016.05.096
   Blick SKA, 2008, DRUGS, V68, P2709, DOI 10.2165/0003495 200868180 00012
   Bononi A, 2017, NATURE, V546, P549, DOI 10.1038/nature22798
   Cao LL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.851663
   Carbone M, 2020, CANCER DISCOV, V10, P1103, DOI 10.1158/2159 8290.CD 19 1220
   Carnovali M, 2016, PHARMACOL RES, V104, P1, DOI 10.1016/j.phrs.2015.12.009
   Chen K, 2019, J BIOL CHEM, V294, P11445, DOI 10.1074/jbc.RA119.007813
   Chen YH, 2018, CONNECT TISSUE RES, V59, P6, DOI 10.1080/03008207.2017.1408601
   Cheng ZP, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00448 x
   Conte E, 2021, CELLS BASEL, V10, DOI 10.3390/cells10102722
   Dai LP, 2021, BIOCHEM BIOPH RES CO, V554, P33, DOI 10.1016/j.bbrc.2021.02.100
   Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711
   Dong L, 2010, BIOCHEM PHARMACOL, V79, P715, DOI 10.1016/j.bcp.2009.10.010
   Goltzman D, 2015, NAT REV ENDOCRINOL, V11, P298, DOI 10.1038/nrendo.2015.30
   Han A, 2021, CANCER RES, V81, P2807, DOI 10.1158/0008 5472.CAN 20 3430
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Hedgepeth SC, 2015, J BIOL CHEM, V290, P7304, DOI 10.1074/jbc.M114.611186
   Hu F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107217
   IJzerman AP, 2019, TRENDS BIOCHEM SCI, V44, P861, DOI 10.1016/j.tibs.2019.04.004
   Jarmoskaite I, 2020, ELIFE, V9, DOI 10.7554/eLife.57264
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee GA, 2017, FOOD CHEM TOXICOL, V109, P284, DOI 10.1016/j.fct.2017.08.037
   Lee SH, 2016, BIOCHEM BIOPH RES CO, V473, P1309, DOI 10.1016/j.bbrc.2016.04.068
   Li YW, 2014, CANCER METAST REV, V33, P629, DOI 10.1007/s10555 013 9478 9
   Liang M, 2007, ASSAY DRUG DEV TECHN, V5, P655, DOI 10.1089/adt.2007.089
   Liu Y, 2022, J AGR FOOD CHEM, DOI 10.1021/acs.jafc.2c07005
   Louie BH, 2020, CANCER TREAT REV, V90, DOI 10.1016/j.ctrv.2020.102091
   Luo SY, 2016, J ORTHOP TRANSL, V4, P35, DOI 10.1016/j.jot.2015.07.002
   Maria CS, 2016, SEMIN CELL DEV BIOL, V49, P11, DOI 10.1016/j.semcdb.2015.12.004
   Mishra R, 2020, DEV CELL, V52, P167, DOI 10.1016/j.devcel.2019.11.016
   Niu YB, 2015, MOL MED REP, V11, P4468, DOI 10.3892/mmr.2015.3249
   Ong H.L., 2020, Cold Spring Harb. Perspect. Biol., V12
   Qian NC, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw4847
   Sampieri A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31621 0
   Sohn S, 2015, J DENT RES, V94, P1560, DOI 10.1177/0022034515608128
   Tang H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.999851
   Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467
   Wharton B, 2003, LANCET, V362, P1389, DOI 10.1016/S0140 6736(03)14636 3
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Wu LZ, 2020, BIOCHEM BIOPH RES CO, V527, P200, DOI 10.1016/j.bbrc.2020.04.048
   Wu XX, 2021, MOL IMMUNOL, V130, P104, DOI 10.1016/j.molimm.2020.11.013
   Yang ZF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00293
   Ye Y, 2021, INT J BIOL SCI, V17, P1217, DOI 10.7150/ijbs.56833
   Yu TY, 2015, J PHARMACOL SCI, V127, P75, DOI 10.1016/j.jphs.2014.11.006
   Zhang ZG, 2016, FITOTERAPIA, V110, P166, DOI 10.1016/j.fitote.2016.03.013
   Zhuang Q, 2023, J AGR FOOD CHEM, V71, P411, DOI 10.1021/acs.jafc.2c05954
NR 51
TC 1
Z9 1
U1 3
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD DEC
PY 2024
VL 230
AR 116618
DI 10.1016/j.bcp.2024.116618
EA NOV 2024
PN 3
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA M4J3V
UT WOS:001357218200001
PM 39528071
DA 2025 08 17
ER

PT J
AU Khajuria, DK
   Vasireddi, R
   Trebbin, M
   Karasik, D
   Razdan, R
AF Khajuria, Deepak Kumar
   Vasireddi, Ramakrishna
   Trebbin, Martin
   Karasik, David
   Razdan, Rema
TI Novel therapeutic intervention for osteoporosis prepared with strontium
   hydroxyapatite and zoledronic acid: In vitro and pharmacodynamic
   evaluation
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Strontium; Hydroxyapatite; Zoledronic acid; Rat model; Osteoporosis
ID OSTEOBLAST LIKE CELLS; DOPED HYDROXYAPATITE; OVARIECTOMIZED RATS;
   RANELATE TREATMENT; BONE LOSS; PROPRANOLOL; OSTEOCLAST; DIFFERENTIATION;
   BISPHOSPHONATE; NANOPARTICLES
AB Osteoporosis therapeutics has been monopolized mainly by bisphosphonates, which are potent anti osteoporotic drugs, while they do not promote bone formation or replenish the already resorbed bone. Although strontium substituted hydroxyapatite (SrHA) has been proclaimed to improve bone properties in an osteoporotic animal model, there is no published data on direct delivery of SrHA nanoparticles by bisphosphonate like zoledronic acid (ZOL) to the bone. Therefore, this study was designed to investigate the potential of using SrHA/ZOL nano particle  based drug formulation in an ovariectomized rat model of postmenopausal osteoporosis. SrHA and SrHA/ZOL nanoparticles were prepared and characterized by field emission scanning electron microscopy (FESEM), X ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR). Twelve weeks after ovariectomy, rats were treated with either single intravenous dose of SrHA/ZOL (100, 50 or 25 mu g/kg); ZOL (100 mu g/ kg); or SrHA (100 mu g/kg). Saline treated OVX and SHAM OVX groups served as controls. The energy dispersive X ray (EDX) microanalysis of bone specimen obtained from SrHA/ZOL groups yielded range between 64.3 +/  6.7 to 66.9 +/  6.8 of calcium weight (wt) % and 1.64 +/  0.6 to 1.74 +/  0.8 of calcium/phosphorus (Ca/P) ratio which was significantly higher when compared with 39.7 +/  9.3 calcium and 1.30 +/  0.2 Ca/P ratio for OVX group. Moreover, the strontium wt% in SrHA/ZOL group (between 3.1 +/  0.5 and 6.8 +/  0.4) was significantly higher than SrHA group (1.8 +/  0.9). These results confirmed targeted delivery of SrHA nanoparticles by ZOL to the bone. Therapy with SrHA/ZOL showed significant improvements in trabecular bone microarchitecture and mechanical strength as compared to ZOL or SrHA (p < 0.05). Moreover, treatment with SrHA/ZOL significantly precluded an increase in serum bone specific alkaline phosphatase and tartrate resistant acid phosphatase than either ZOL or SrHA (p < 0.05). These results strongly implicate that SrHA/ZOL nanoparticle based drug formulation showed better efficacy at a much lower dose of ZOL SrHA/ZOL drug formulation has a therapeutic advantage over ZOL or SrHA monotherapy for experimental osteoporosis. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Khajuria, Deepak Kumar; Karasik, David] Bar Ilan Univ, Fac Med Galilee, Musculoskeletal Genet Lab, H Szold St 14,POB 1589, IL 1311502 Safed, Israel.
   [Khajuria, Deepak Kumar; Razdan, Rema] Al Ameen Coll Pharm, Dept Pharmacol, Bangalore, Karnataka, India.
   [Vasireddi, Ramakrishna; Trebbin, Martin] Univ Hamburg, Hamburg Ctr Ultrafast Imaging, Hamburg, Germany.
C3 Bar Ilan University; University of Hamburg
RP Khajuria, DK (通讯作者)，Bar Ilan Univ, Fac Med Galilee, Musculoskeletal Genet Lab, H Szold St 14,POB 1589, IL 1311502 Safed, Israel.
EM deepak_kumarkhajuria@yahoo.co.in
RI Khajuria, Deepak Kumar/A 5993 2019; Trebbin, Martin/A 5281 2015;
   Khajuria, Deepak/A 5993 2019
OI Khajuria, Deepak Kumar/0000 0002 3737 8504; Trebbin,
   Martin/0000 0001 8278 5865; Vasireddi, Ramakrishna/0000 0002 7298 7436;
   Karasik, David/0000 0002 8826 0530
FU Indian Council of Medical Research (ICMR), Govt. of India, New Delhi
   [45/35/2010 PHA/BMS]
FX Authors gratefully acknowledge financial support and research fellowship
   (File No: 45/35/2010 PHA/BMS) from Indian Council of Medical Research
   (ICMR), Govt. of India, New Delhi.
CR Atkins GJ, 2009, OSTEOPOROSIS INT, V20, P653, DOI 10.1007/s00198 008 0728 6
   Bawa HS, 2015, J BONE JOINT SURG AM, V97A, P1555, DOI 10.2106/JBJS.N.01275
   Bitto A, 2008, BRIT J PHARMACOL, V155, P896, DOI 10.1038/bjp.2008.305
   Boanini E, 2011, J MATER SCI MATER M, V22, P2079, DOI 10.1007/s10856 011 4379 3
   Boanini E, 2014, BIOMATERIALS, V35, P5619, DOI 10.1016/j.biomaterials.2014.03.053
   Boanini E, 2012, BIOMATERIALS, V33, P722, DOI 10.1016/j.biomaterials.2011.09.092
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Bonnet N, 2006, J PHARMACOL EXP THER, V318, P1118, DOI 10.1124/jpet.106.105437
   Capuccini C, 2009, J BIOMED MATER RES A, V89A, P594, DOI 10.1002/jbm.a.31975
   Favia G, 2009, BONE, V45, P406, DOI 10.1016/j.bone.2009.05.008
   Geng Z, 2015, J MATER CHEM B, V3, P3738, DOI 10.1039/c4tb02148g
   Gomes AJ, 2007, INT J PHARMACEUT, V332, P153, DOI 10.1016/j.ijpharm.2006.09.035
   Hadjipanteli A, 2014, X RAY SPECTROM, V43, P286, DOI 10.1002/xrs.2551
   Iafisco M, 2014, MAT SCI ENG C MATER, V35, P212, DOI 10.1016/j.msec.2013.11.009
   Janckila AJ, 2001, CLIN CHEM, V47, P74
   Kaufman JM, 2013, J CLIN ENDOCR METAB, V98, P592, DOI 10.1210/jc.2012 3048
   Kettenberger U., 2015, J TISSUE ENG REGEN M, V9
   Khajuria DK, 2015, EUR J PHARM SCI, V66, P173, DOI 10.1016/j.ejps.2014.10.015
   Khajuria DK, 2014, SCI PHARM, V82, P357, DOI 10.3797/scipharm.1310 06
   Khajuria DK, 2013, J ORTHOP SCI, V18, P832, DOI 10.1007/s00776 013 0433 y
   Khajuria DK, 2012, REV BRAS REUMATOL, V52, P462
   Khajuria DK, 2011, REV BRAS REUMATOL, V51, P365
   Kimachi K, 2011, N S ARCH PHARMACOL, V383, P297, DOI 10.1007/s00210 010 0596 4
   Li YF, 2016, J BIOMED MATER RES B, V104, P476, DOI 10.1002/jbm.b.33417
   Lin LW, 2009, J BIOMED MATER RES A, V89A, P326, DOI 10.1002/jbm.a.31994
   Meunier PJ, 2009, OSTEOPOROSIS INT, V20, P1663, DOI 10.1007/s00198 008 0825 6
   Moreau M, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3373
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Prakash D, 2009, INT J NANOMED, V4, P133
   Rao BM, 2005, J PHARMACEUT BIOMED, V39, P781, DOI 10.1016/j.jpba.2005.04.012
   Reginster JY, 2015, OSTEOPOROSIS INT, V26, P1667, DOI 10.1007/s00198 015 3109 y
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Sahana H, 2013, J BIOMED NANOTECHNOL, V9, P193, DOI 10.1166/jbn.2013.1482
   Shirke SS, 2008, EXP BIOL MED, V233, P1403, DOI 10.3181/0803 RM 93
   Vermeer JAF, 2013, BONE, V57, P242, DOI 10.1016/j.bone.2013.08.007
   Yu NYC, 2013, EUR CELLS MATER, V25, P190, DOI 10.22203/eCM.v025a14
   Yu NYC, 2010, EUR CELLS MATER, V20, P431
NR 37
TC 40
Z9 41
U1 1
U2 55
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD FEB 1
PY 2017
VL 71
BP 698
EP 708
DI 10.1016/j.msec.2016.10.066
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA EG3TI
UT WOS:000390967200083
PM 27987763
DA 2025 08 17
ER

PT J
AU Wang, PH
   Yang, R
   Liu, S
   Ren, YH
   Liu, X
   Wang, XX
   Zhang, WJ
   Chi, B
AF Wang, Penghui
   Yang, Rong
   Liu, Shuai
   Ren, Yanhan
   Liu, Xin
   Wang, Xiaoxue
   Zhang, Wenjie
   Chi, Bo
TI Thermosensitive nanoparticle of mPEG PTMC for oligopeptide delivery into
   osteoclast precursors
SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS
LA English
DT Article
DE Thermosensitive; monomethoxy polyethylene glycol block polytrimethylene
   carbonate; nanoparticle; oligopeptide; osteoclast precursors
ID DRUG DELIVERY; CYCLODEXTRIN; INHIBITORS; RELEASE
AB Transmembrane delivery of biomolecules through nanoparticles plays an important role in targeted therapy. Here, we designed a simple nanoparticle for the delivery of model peptide drug into primary osteoclast precursor cells (bone marrow macrophages) by thermosensitive and biodegradable diblock copolymer monomethoxy poly(ethylene glycol) block poly(trimethylene carbonate). The model peptide drug was encapsulated into the nanoparticle by dropping the drug carrier dissolved in dimethylsulfoxide solvent into water containing poly(vinyl alcohol) to achieve temperature response nanoparticles. Through size analysis, we found that the nanoparticles possessed a temperature sensitive property between 30 degrees C and 40 degrees C. Moreover, flow cytometry and spectrofluorimetry analysis indicated that nanoparticle systems underwent significant cellular uptake. In addition, the evaluation of cell biology showed that nanoparticles have excellent biocompatibility. Thus, the results indicated that the temperature sensitive nanoparticles have potential application value for targeted delivery of oligopeptide in the treatment process of osteoarthritis.
C1 [Wang, Penghui; Yang, Rong; Liu, Xin; Wang, Xiaoxue; Zhang, Wenjie; Chi, Bo] Nanjing Tech Univ, Coll Food Sci & Light Ind, State Key Lab Mat Oriented Chem Engn, 30 South Puzhu Rd, Nanjing 211816, Jiangsu, Peoples R China.
   [Liu, Shuai] Nanjing Univ Sci & Technol, Sch Chem Engn, Nanjing, Peoples R China.
   [Ren, Yanhan] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, N Chicago, IL USA.
   [Chi, Bo] Nanjing Tech Univ, Jiangsu Natl Synerget Innovat Ctr Adv Mat, Nanjing, Peoples R China.
C3 Nanjing Tech University; Nanjing University of Science & Technology;
   Chicago Medical School; Rosalind Franklin University of Medicine &
   Science; Nanjing Tech University
RP Chi, B (通讯作者)，Nanjing Tech Univ, Coll Food Sci & Light Ind, State Key Lab Mat Oriented Chem Engn, 30 South Puzhu Rd, Nanjing 211816, Jiangsu, Peoples R China.
EM chibo@njtech.edu.cn
RI Yang, Rong/J 3718 2014; Chi, Bo/G 4256 2013; Ren, Yanhan/U 4597 2019
OI WANG, Penghui/0000 0002 8466 0617; CHI, BO/0000 0002 4101 1860; Ren,
   Yanhan/0000 0002 8588 9114
FU National Natural Science Foundation of China [31771049]; Foundation of
   key R&D Project of Jiangsu Province [BE2018731]; Research Foundation of
   State Key Laboratory of MaterialsOriented Chemical Engineering
   [ZK201806, KL1806, ZK201606]; Six Talent Peaks Project of Jiangsu
   Province [SWYY 046]; Postgraduate Research & Practice Innovation Program
   of Jiangsu Province [SJCX20_0408]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by the National Natural Science Foundation of China
   (31771049), Foundation of key R&D Project of Jiangsu Province
   (BE2018731), Research Foundation of State Key Laboratory of
   MaterialsOriented Chemical Engineering (ZK201806, KL1806 and ZK201606),
   The Six Talent Peaks Project of Jiangsu Province (SWYY 046), and
   Postgraduate Research & Practice Innovation Program of Jiangsu Province
   (SJCX20_0408).
CR Behravesh E, 2002, BIOMACROMOLECULES, V3, P153, DOI 10.1021/bm010137x
   Bunchongprasert K, 2020, J PHARM SCI US, V109, P1145, DOI 10.1016/j.xphs.2019.11.009
   Chen CL, 2016, EUR J MED CHEM, V117, P70, DOI 10.1016/j.ejmech.2016.04.007
   Chen ZW, 2018, ACCOUNTS CHEM RES, V51, P668, DOI 10.1021/acs.accounts.7b00526
   Cheng H, 2019, BIOMATERIALS, V195, P75, DOI 10.1016/j.biomaterials.2019.01.003
   Dan K, 2011, CHEM COMMUN, V47, P12491, DOI 10.1039/c1cc15663b
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Erdogar N, 2017, CURR TOP MED CHEM, V17, P1521, DOI 10.2174/1568026616666161222101104
   Francia V, 2019, NANOMEDICINE UK, V14, P1533, DOI 10.2217/nnm 2018 0446
   Gao Y, 2019, BIOMECH MODEL MECHAN, V18, P1731, DOI 10.1007/s10237 019 01171 z
   Goda T, 2019, LANGMUIR, V35, P8167, DOI 10.1021/acs.langmuir.9b00856
   Hambli R, 2016, J MECH BEHAV BIOMED, V60, P492, DOI 10.1016/j.jmbbm.2016.03.010
   Jennings CL, 2016, J BIOACT COMPAT POL, V31, P323, DOI 10.1177/0883911515627178
   Kang QQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190690
   Kim EN, 2019, PHYTOTHER RES, V33, P2948, DOI 10.1002/ptr.6468
   Kim SY, 2007, MACROMOLECULES, V40, P5519, DOI 10.1021/ma070190z
   Klouda L, 2015, EUR J PHARM BIOPHARM, V97, P338, DOI 10.1016/j.ejpb.2015.05.017
   Kuang Y, 2019, COLLOID SURFACE B, V181, P461, DOI 10.1016/j.colsurfb.2019.05.078
   Lin WF, 2019, LANGMUIR, V35, P1273, DOI 10.1021/acs.langmuir.8b00851
   Liu W, 2016, J BIOMAT SCI POLYM E, V27, P490, DOI 10.1080/09205063.2016.1140612
   Ma ZZ, 2019, INFLAMM RES, V68, P157, DOI 10.1007/s00011 018 1209 9
   Mura P, 2018, EUR J PHARM BIOPHARM, V122, P54, DOI 10.1016/j.ejpb.2017.10.008
   Putaux JL, 2017, LANGMUIR, V33, P7917, DOI 10.1021/acs.langmuir.7b01136
   Rosenblum D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03705 y
   Sharma K, 2012, J BIOACT COMPAT POL, V27, P525, DOI 10.1177/0883911512461470
   Socka M, 2018, LANGMUIR, V34, P3701, DOI 10.1021/acs.langmuir.8b00440
   Takahashi Y, 2003, MACROMOLECULES, V36, P5139, DOI 10.1021/ma030076q
   Toumi H, 2016, J YOGA PHYS THER, V6, P2
   Vanparijs N, 2017, CHEM SOC REV, V46, P1193, DOI 10.1039/c6cs00748a
   Wang B, 2019, J BONE MINER RES, V34, P939, DOI 10.1002/jbmr.3667
   Wang PH, 2020, J BIOMAT SCI POLYM E, V31, P277, DOI 10.1080/09205063.2019.1687132
   Xu CN, 2019, J CONTROL RELEASE, V295, P153, DOI 10.1016/j.jconrel.2018.12.013
   Yeon JT, 2015, J CELL SCI, V128, P3411, DOI 10.1242/jcs.170738
   Yoon KD, 2007, J NAT PROD, V70, P2029, DOI 10.1021/np070327e
   Yuan Y, 2018, NANO LETT, V18, P921, DOI 10.1021/acs.nanolett.7b04307
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang Y, 2005, BIOMATERIALS, V26, P2089, DOI 10.1016/j.biomaterials.2004.06.004
   Zhang Z, 2006, J CONTROL RELEASE, V111, P263, DOI 10.1016/j.jconrel.2005.12.001
   Zhao Y, 2018, BIOMACROMOLECULES, V19, P2944, DOI 10.1021/acs.biomac.8b00501
   Zhu PP, 2018, CURR PROTEIN PEPT SC, V19, P211, DOI 10.2174/1389203718666170710115240
NR 40
TC 3
Z9 3
U1 3
U2 39
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0883 9115
EI 1530 8030
J9 J BIOACT COMPAT POL
JI J. Bioact. Compat. Polym.
PD JUL
PY 2020
VL 35
IS 4 5
BP 426
EP 434
AR 0883911520933916
DI 10.1177/0883911520933916
EA JUL 2020
PG 9
WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Materials Science; Polymer Science
GA NF1BL
UT WOS:000549953000001
DA 2025 08 17
ER

PT J
AU Gao, FP
   Yuan, Q
   Cai, PJ
   Gao, L
   Zhao, LN
   Liu, MQ
   Yao, YW
   Chai, ZF
   Gao, XY
AF Gao, Fuping
   Yuan, Qing
   Cai, Pengju
   Gao, Liang
   Zhao, Lina
   Liu, Meiqing
   Yao, Yawen
   Chai, Zhifang
   Gao, Xueyun
TI Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing
   Cartilage/Bone Destruction
SO ADVANCED SCIENCE
LA English
DT Article
DE Au clusters; bone destruction; inflammation; rheumatoid arthritis
ID NF KAPPA B; ACTIVATED PROTEIN KINASE; MODIFYING ANTIRHEUMATIC DRUGS;
   INHIBITS OSTEOCLASTOGENESIS; THERAPEUTIC STRATEGIES; COLLAGEN ARTHRITIS;
   EXPRESSION; RANKL; GOLD; PATHOGENESIS
AB Super small nanoclusters may intrinsically trigger specific molecular pathway for disease treatment in vitro/vivo. To prove the hypothesis the super small nanoclusters, e.g., Au clusters, are directly used to treat rheumatoid arthritis (RA) in vitro/vivo. RA is a chronic autoimmune disease that is characterized by the inflammation of joints and the unreversible destruction of the cartilage/bone. Au clusters significantly suppress lipopolysaccharide (LPS) induced proinflammatory mediator production in the murine macrophage cell line by inhibiting the signaling pathways that regulate the major proinflammatory mediator genes. In preclinical rat RA studies, Au clusters strongly prevent type II collagen induced rat RA without systemic side effects. Compared with the clinical first line anchored anti RA drug, methotrexate, Au clusters equally inhibit inflammation in vivo. Type II collagen induced rat RA is characterized with the destruction of cartilage/bone; treatment with Au clusters reverses the destruction of cartilage/bone to its normal state. This is because Au clusters directly inhibit receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation and function through the downregulation of osteoclast specific genetic marker expression. However the methotrexate almost has no positive effect for this key issue in rat RA therapy. These data prove that the super small nanoclusters, e.g., Au clusters, could be a novel candidate nanodrug for RA treatment.
C1 [Gao, Fuping; Yuan, Qing; Cai, Pengju; Gao, Liang; Zhao, Lina; Liu, Meiqing; Yao, Yawen; Chai, Zhifang; Gao, Xueyun] Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
   [Yuan, Qing; Gao, Liang; Gao, Xueyun] Beijing Univ Technol, Dept Chem & Chem Engn, Beijing 100124, Peoples R China.
   [Chai, Zhifang] Soochow Univ, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China.
C3 Chinese Academy of Sciences; Key Laboratory for Biological Effects of
   Nanomaterials & Nanosafety, CAS; Institute of High Energy Physics, CAS;
   Beijing University of Technology; Soochow University   China
RP Gao, XY (通讯作者)，Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biol Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.; Gao, XY (通讯作者)，Beijing Univ Technol, Dept Chem & Chem Engn, Beijing 100124, Peoples R China.
EM gaoxy@ihep.ac.cn
RI ; Yuan, Qing/ABF 3033 2020; Gao, Liang/G 1454 2010; Chai,
   Zhi/KIG 1970 2024; Yawen, Yao/HTO 6339 2023
OI Gao, Xueyun/0000 0002 2267 9945; Gao, Liang/0000 0002 9337 345X; Zhao,
   Lina/0000 0002 9796 0221; Liu, Meiqing/0000 0001 5862 931X; Chai,
   Zhifang/0000 0003 0680 6067; Gao, Fuping/0000 0002 0287 9763
FU National Natural Science Foundation of China [21425522, 21727817,
   31670976, 21390414, 81472851]
FX This work was supported by grants from the National Natural Science
   Foundation of China (21425522, 21727817, 31670976, 21390414, and
   81472851). The authors thank Wenjie Wang, Lianqiu Wu, Haijing Zhang, and
   Huachen Song in Institute of Materia Medica, Chinese Academy of Medical
   Sciences & Peking Union Medical College for establishing the
   collagen induced precinical arthritis (CIA) rat model.
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014 5793(95)00956 A
   Billiau A, 2011, CYTOKINE GROWTH F R, V22, P339, DOI 10.1016/j.cytogfr.2011.11.003
   Bingham CO, 2002, J RHEUMATOL, V29, P3
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown C. L., 2008, Inflammopharmacology, V16, P133, DOI 10.1007/s10787 007 0017 6
   Eisler R, 2003, INFLAMM RES, V52, P487, DOI 10.1007/s00011 003 1208 2
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Goswami N, 2017, MATER HORIZ, V4, P817, DOI 10.1039/c7mh00451f
   Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898 6568(00)00149 2
   Herman S, 2008, TRENDS MOL MED, V14, P245, DOI 10.1016/j.molmed.2008.04.001
   Hochberg MC, 2005, SEMIN ARTHRITIS RHEU, V34, P819, DOI 10.1016/j.semarthrit.2004.11.006
   Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105 2896.2006.00375.x
   Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006 2952(97)00154 8
   Jeong HJ, 2014, INT IMMUNOPHARMACOL, V23, P426, DOI 10.1016/j.intimp.2014.09.008
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jin RC, 2016, CHEM REV, V116, P10346, DOI 10.1021/acs.chemrev.5b00703
   Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850
   Lovinger SP, 2003, JAMA J AM MED ASSOC, V289, P3229, DOI 10.1001/jama.289.24.3229
   Luo ZT, 2012, J AM CHEM SOC, V134, P16662, DOI 10.1021/ja306199p
   Mancarella L, 2007, J RHEUMATOL, V34, P1670
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Naidu VGM, 2013, CHEM BIOL INTERACT, V203, P467, DOI 10.1016/j.cbi.2012.12.016
   O'Dell JR, 2004, NEW ENGL J MED, V350, P2591, DOI 10.1056/NEJMra040226
   O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Olsen NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMra032906
   Palladino MA, 2003, NAT REV DRUG DISCOV, V2, P736, DOI 10.1038/nrd1175
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Saag KG, 2008, ARTHRIT RHEUM ARTHR, V59, P762, DOI 10.1002/art.23721
   SCHNABEL A, 1994, SEMIN ARTHRITIS RHEU, V23, P310, DOI 10.1016/0049 0172(94)90027 2
   Scott DL, 2006, NEW ENGL J MED, V355, P704, DOI 10.1056/NEJMct055183
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis 2016 210715
   Smolen JS, 2003, NAT REV DRUG DISCOV, V2, P473, DOI 10.1038/nrd1109
   STAINES NA, 1994, BRIT J RHEUMATOL, V33, P798
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Toro EJ, 2012, J BIOL CHEM, V287, P17894, DOI 10.1074/jbc.M111.280511
   TRENTHAM DE, 1982, ARTHRITIS RHEUM, V25, P911, DOI 10.1002/art.1780250801
   Tunyogi Csapo M, 2008, ARTHRITIS RHEUM US, V58, P2397, DOI 10.1002/art.23653
   van Ede AE, 1998, SEMIN ARTHRITIS RHEU, V27, P277, DOI 10.1016/S0049 0172(98)80049 8
   van Heerden B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050441
   Visser K, 2009, ANN RHEUM DIS, V68, P1094, DOI 10.1136/ard.2008.092668
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200
   Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003
   Yao QF, 2018, ACCOUNTS CHEM RES, V51, P1338, DOI 10.1021/acs.accounts.8b00065
   Yuan Q, 2016, NANOSCALE, V8, P12095, DOI 10.1039/c6nr02750d
   Zheng KY, 2018, COORDIN CHEM REV, V357, P1, DOI 10.1016/j.ccr.2017.11.019
   Zou J, 1999, J INORG BIOCHEM, V74, P352
NR 53
TC 74
Z9 75
U1 2
U2 90
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD APR 3
PY 2019
VL 6
IS 7
AR 1801671
DI 10.1002/advs.201801671
PG 13
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA HR4YI
UT WOS:000463153100004
PM 30989021
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hu, XH
   Ji, X
   Yang, MT
   Fan, SH
   Wang, JR
   Lu, MP
   Shi, W
   Mei, L
   Xu, CY
   Fan, XY
   Hussain, M
   Du, JY
   Wu, JS
   Wu, XM
AF Hu, Xinhua
   Ji, Xing
   Yang, Mengting
   Fan, Shihao
   Wang, Jirong
   Lu, Meiping
   Shi, Wei
   Mei, Liu
   Xu, Chengyun
   Fan, Xueying
   Hussain, Musaddique
   Du, Jingyu
   Wu, Junsong
   Wu, Ximei
TI Cdc42 Is Essential for Both Articular Cartilage Degeneration and
   Subchondral Bone Deterioration in Experimental Osteoarthritis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOARTHRITIS; CDC42; ARTICULAR CARTILAGE; SUBCHONDRAL BONE
ID ENDOTHELIAL GROWTH FACTOR; INHIBITION; CELLS; RAC1; DIFFERENTIATION;
   ALENDRONATE; REDUCTION; JAK/STAT
AB Cdc42, a member of Rho family small guanosine triphosphatases (GTPases), is critical for cartilage development. We investigated the roles of Cdc42 in osteoarthritis and explored the potential mechanism underlying Cdc42 mediated articular cartilage degeneration and subchondral bone deterioration. Cdc42 is highly expressed in both articular cartilage and subchondral bone in a mouse osteoarthritis model with surgical destabilization of the medial meniscus (DMM) in the knee joints. Specifically, genetic disruption of Cdc42, knockdown of Cdc42 expression, or inhibition of Cdc42 activity robustly attenuates the DMM induced destruction, hypertrophy, high expression of matrix metallopeptidase 13 and collagen X, and activation of Stat3 in articular cartilages. Notably, genetic disruption of Cdc42, knockdown of Cdc42 expression or inhibition of Cdc42 activity significantly restored the increased numbers of mesenchymal stem cells, osteoprogenitors, osteoblasts, osteoclasts, and neovascularized vessels, the increased bone mass, and the activated Erk1/2, Smad1/5 and Smad2 in subchondral bone of DMM operated mice. Mechanistically, Cdc42 mediates interleukin 1 induced interleukin 6 production and subsequent Jak/Stat3 activation to regulate chondrocytic inflammation, and also lies upstream of Erk/Smads to regulate subchondral bone remodeling during transform growth factor 1 signaling. Cdc42 is apparently required for both articular cartilage degeneration and subchondral bone deterioration of osteoarthritis, thus, interventions targeting Cdc42 have potential in osteoarthritic therapy. (C) 2018 American Society for Bone and Mineral Research.
C1 [Hu, Xinhua; Ji, Xing; Yang, Mengting; Fan, Shihao; Wang, Jirong; Shi, Wei; Mei, Liu; Xu, Chengyun; Fan, Xueying; Hussain, Musaddique; Wu, Ximei] Zhejiang Univ, Sch Med, Dept Pharmacol, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
   [Lu, Meiping] Zhejiang Univ, Sch Med, Childrens Hosp, Dept Rheumatol, Hangzhou, Zhejiang, Peoples R China.
   [Du, Jingyu; Wu, Junsong] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University
RP Wu, XM (通讯作者)，Zhejiang Univ, Sch Med, Dept Pharmacol, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
EM xiwu@zju.edu.cn
RI Mei, Liu/ITU 2228 2023; Hussain, Musaddique/NDT 5042 2025; Fan,
   Shihao/LFV 7725 2024; Shi, Wei/AFH 1126 2022
OI hu, xinhua/0000 0002 3536 6534; Shi, Wei/0000 0002 8177 2920; Shi,
   Wei/0009 0001 2085 0323; Wu, Junsong/0009 0002 5500 1492
FU National Natural Science Foundation of China [31571493, 31271561,
   31071292, 81171748, 81571928]; Department of Education of Zhejiang
   Province [Y201328229]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 31571493, 31271561, 31071292, 81171748, 81571928) and
   Department of Education of Zhejiang Province (Y201328229). We thank Dr.
   Yi Zheng (Department of Experimental Hematology and Cancer Biology,
   Cincinnati Children's Hospital Medical Center) for
   Cdc42<SUP>flox/flox</SUP> mice and Dr. Jianquan Chen (Orthopaedic
   Institute of Soochow University, China) for technical support.
CR Abraham S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8286
   Aizawa R, 2012, MECH DEVELOP, V129, P38, DOI 10.1016/j.mod.2012.02.002
   Blasioli DJ, 2014, TISSUE ENG PART B RE, V20, P355, DOI [10.1089/ten.teb.2013.0377, 10.1089/ten.TEB.2013.0377]
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Calich ALG, 2010, CLIN RHEUMATOL, V29, P451, DOI 10.1007/s10067 009 1352 3
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   Enomoto H, 2003, AM J PATHOL, V162, P171, DOI 10.1016/S0002 9440(10)63808 4
   Exton JH, 1998, J BIOL CHEM, V273, P19923, DOI 10.1074/jbc.273.32.19923
   Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Gong Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.510
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Ito Y, 2010, J CLIN INVEST, V120, P1981, DOI 10.1172/JCI39650
   Jin G, 2000, J ORTHOPAED RES, V18, P899, DOI 10.1002/jor.1100180608
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kurgonaite K, 2015, J CELL SCI, V128, P3781, DOI 10.1242/jcs.170969
   Legendre F, 2003, J BIOL CHEM, V278, P2903, DOI 10.1074/jbc.M110773200
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   McNary SM, 2014, TISSUE ENG PT A, V20, P921, DOI [10.1089/ten.tea.2013.0043, 10.1089/ten.TEA.2013.0043]
   MILGRAM JW, 1983, CLIN ORTHOP RELAT R, P293
   Moon PM, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926 015 0524 1
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Novakofski KD, 2012, J ORTHOP RES, V30, P246, DOI 10.1002/jor.21515
   Ono N, 2014, DEV CELL, V29, P330, DOI 10.1016/j.devcel.2014.03.014
   Pan J, 2012, BONE, V51, P212, DOI 10.1016/j.bone.2011.11.030
   Pfander D, 2001, ANN RHEUM DIS, V60, P1070, DOI 10.1136/ard.60.11.1070
   Suzuki W, 2015, ENDOCRINOLOGY, V156, P314, DOI 10.1210/en.2014 1032
   Wang GY, 2005, J BONE MINER RES, V20, P1022, DOI 10.1359/JBMR.050113
   Wang JR, 2016, GENETICS, V202, P1055, DOI 10.1534/genetics.115.180109
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Woods A, 2007, J BIOL CHEM, V282, P23500, DOI 10.1074/jbc.M700680200
   Woods A, 2007, J CELL PHYSIOL, V213, P1, DOI 10.1002/jcp.21110
   Yang L, 2007, P NATL ACAD SCI USA, V104, P5091, DOI 10.1073/pnas.0610819104
   Yao HY, 2015, ONCOTARGET, V6, P17501, DOI 10.18632/oncotarget.3766
   Zhang L, 2011, CLIN EXP MED, V11, P235, DOI 10.1007/s10238 011 0131 z
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhu SA, 2015, ANN RHEUM DIS, V74, P285, DOI 10.1136/annrheumdis 2013 203901
NR 40
TC 37
Z9 46
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2018
VL 33
IS 5
BP 945
EP 958
DI 10.1002/jbmr.3380
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GF5KU
UT WOS:000432006800021
PM 29314205
OA Bronze
DA 2025 08 17
ER

PT J
AU Cui, YZ
   Guo, YY
   Kong, L
   Shi, JY
   Liu, P
   Li, R
   Geng, YT
   Gao, WH
   Zhang, ZP
   Fu, DH
AF Cui, Yongzhi
   Guo, Yuanyuan
   Kong, Li
   Shi, Jingyu
   Liu, Ping
   Li, Rui
   Geng, Yongtao
   Gao, Weihang
   Zhang, Zhiping
   Fu, Dehao
TI A bone targeted engineered exosome platform delivering siRNA to treat
   osteoporosis
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Exosomes; MSCs; siRNA; Bone targeting peptide; Osteoporosis therapy
ID MESENCHYMAL STEM CELLS; PROMOTES OSTEOGENIC DIFFERENTIATION;
   EXTRACELLULAR VESICLES; ANGIOGENESIS; EXPRESSION; OSTEOCYTE
AB The complex pathogenesis of osteoporosis includes excessive bone resorption, insufficient bone formation and inadequate vascularization, a combination which is difficult to completely address with conventional therapies. Engineered exosomes carrying curative molecules show promise as alternative osteoporosis therapies, but depend on specifically functionalized vesicles and appropriate engineering strategies. Here, we developed an exosome delivery system based on exosomes secreted by mesenchymal stem cells (MSCs) derived from human induced pluripotent stem cells (iPSCs). The engineered exosomes BT Exo siShn3, took advantage of the intrinsic anti osteoporosis function of these special MSC derived exosomes and collaborated with the loaded siRNA of the Shn3 gene to enhance the therapeutic effects. Modification of a bone targeting peptide endowed the BT Exo siShn3 an ability to deliver siRNA to osteoblasts specifically. Silencing of the osteoblastic Shn3 gene enhanced osteogenic differentiation, decreased autologous RANKL expression and thereby inhibited osteoclast formation. Furthermore, Shn3 gene silencing increased production of SLIT3 and consequently facilitated vascularization, especially formation of type H vessels. Our study demonstrated that BT Exo siShn3 could serve as a promising therapy to kill three birds with one stone and implement comprehensive anti osteoporosis effects.
C1 [Cui, Yongzhi; Fu, Dehao] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai 200080, Peoples R China.
   [Cui, Yongzhi; Li, Rui; Geng, Yongtao; Fu, Dehao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan 430022, Hubei, Peoples R China.
   [Guo, Yuanyuan; Shi, Jingyu] Huazhong Univ Sci & Technol, Liyuan Hosp, Tongji Med Sch, Dept Pharm, Wuhan 430077, Hubei, Peoples R China.
   [Kong, Li; Zhang, Zhiping] Huazhong Univ Sci & Technol, Tongji Sch Pharm, Wuhan 430030, Hubei, Peoples R China.
   [Liu, Ping; Gao, Weihang] Huazhong Univ Sci & Technol, Liyuan Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan 430077, Hubei, Peoples R China.
C3 Shanghai Jiao Tong University; Huazhong University of Science &
   Technology; Huazhong University of Science & Technology; Huazhong
   University of Science & Technology; Huazhong University of Science &
   Technology
RP Fu, DH (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Orthoped, Sch Med, Shanghai 200080, Peoples R China.
EM fudehao@sjtu.edu.cn
RI guo, yuanyuan/GXM 6237 2022; Fu, Dehao/AAM 4137 2020; zhang,
   zhiping/H 1786 2011; Gao, Weihang/AAR 9477 2020
OI Gao, Weihang/0000 0002 9205 6401; Fu, Dehao/0000 0002 9295 1692; 
FU National Nat ural Science Foundation of China [81874026, 82070911]
FX We thank Shanghai CloudSeq Biotech Company for conducting the small RNA
   NGS assay and Dr Lin Zeng (BioDataStudio, Shanghai) for bioinformatics
   analysis. This study was supported by the National Nat ural Science
   Foundation of China (Grant No: 81874026 and 82070911) .
CR Alvarez Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Bellera N, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000946
   Beltrami C, 2017, MOL THER, V25, P679, DOI 10.1016/j.ymthe.2016.12.022
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Brennan MA, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909125
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Ching HS, 2017, CURR STEM CELL RES T, V12, P71, DOI 10.2174/1574888X11666160815095733
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Fan JB, 2020, ACS NANO, V14, P11973, DOI 10.1021/acsnano.0c05122
   Guo LJ, 2014, EXP CELL RES, V321, P142, DOI 10.1016/j.yexcr.2013.12.001
   Guo YY, 2015, ACS NANO, V9, P6918, DOI 10.1021/acsnano.5b01042
   He SF, 2018, NANO LETT, V18, P2411, DOI 10.1021/acs.nanolett.7b05430
   Hu GW, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt546
   Hu Y, 2021, BIOACT MATER, V6, P2905, DOI 10.1016/j.bioactmat.2021.02.014
   Huang S, 2012, STEM CELLS DEV, V21, P2531, DOI 10.1089/scd.2012.0014
   Jiang MJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01178 6
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Kim K, 2015, MOL CELLS, V38, P75, DOI 10.14348/molcells.2015.2241
   Kimbrel EA, 2020, NAT REV DRUG DISCOV, V19, P463, DOI 10.1038/s41573 020 0064 x
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li KC, 2017, J TISSUE ENG REGEN M, V11, P3068, DOI 10.1002/term.2208
   Li N, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0086 3
   Liu SY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00619
   Lu M, 2020, BIOMATERIALS, V242, DOI 10.1016/j.biomaterials.2020.119925
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Luo ZW, 2019, NANOSCALE, V11, P20884, DOI 10.1039/c9nr02791b
   Nakasa T, 2011, ARTHRITIS RHEUM US, V63, P1582, DOI 10.1002/art.30321
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   PECK WA, 1993, AM J MED, V94, P646
   Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575
   Qi X, 2016, INT J BIOL SCI, V12, P836, DOI 10.7150/ijbs.14809
   Qiao L, 2019, J CLIN INVEST, V129, P2237, DOI 10.1172/JCI123135
   Roeder E, 2016, BONE, V92, P189, DOI 10.1016/j.bone.2016.09.004
   Sabapathy V, 2016, J CELL MOL MED, V20, P1571, DOI 10.1111/jcmm.12839
   Shim JH, 2013, J CLIN INVEST, V123, P4010, DOI 10.1172/JCI69443
   Song CC, 2020, FASEB J, V34, P4798, DOI 10.1096/fj.201902551R
   Sun L, 2019, MOL CELL BIOCHEM, V460, P165, DOI 10.1007/s11010 019 03578 9
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Sun YX, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/412327
   Tao SC, 2018, ADV SCI, V5, DOI 10.1002/advs.201700449
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   Wang YY, 2020, INT J NANOMED, V15, P7967, DOI 10.2147/IJN.S263756
   Wang YY, 2017, THERANOSTICS, V7, P1360, DOI 10.7150/thno.16532
   Wein MN, 2012, P NATL ACAD SCI USA, V109, P8173, DOI 10.1073/pnas.1205848109
   Xia YG, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01834 0
   Xu F, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1196 y
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yan YF, 2019, BIOMATERIALS, V190, P97, DOI 10.1016/j.biomaterials.2018.10.033
   Yang M, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12784
   Yang M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16003
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Yao XD, 2019, BIOMATERIALS, V224, DOI 10.1016/j.biomaterials.2019.119492
   Zhai MM, 2020, ADV SCI, V7, DOI 10.1002/advs.202001334
   Zhang JY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0417 0
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zhou L, 2019, INT J MOL MED, V43, P727, DOI 10.3892/ijmm.2018.4017
   Zou JM, 2019, ANAL CHEM, V91, P2425, DOI 10.1021/acs.analchem.8b05204
NR 60
TC 167
Z9 177
U1 23
U2 405
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD APR
PY 2022
VL 10
BP 207
EP 221
DI 10.1016/j.bioactmat.2021.09.015
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA YH6DD
UT WOS:000743255000002
PM 34901540
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU da Silva, ACE
   Batista, FRD
   Hassumi, JS
   Palin, LP
   Monteiro, NG
   Frigério, PB
   Okamoto, R
AF Ervolino da Silva, Ana Claudia
   de Souza Batista, Fabio Roberto
   Hassumi, Jaqueline Suemi
   Pitol Palin, Leticia
   Monteiro, Naara Gabriela
   Frigerio, Paula Buzo
   Okamoto, Roberta
TI Improvement of Peri Implant Repair in Estrogen Deficient Rats Fed a
   Cafeteria Diet and Treated with Risedronate Sodium
SO BIOLOGY BASEL
LA English
DT Article
DE osteoporosis; ovariectomy; metabolic syndrome; risedronic acid
ID METABOLIC SYNDROME; OSTEONECROSIS; OSTEOPOROSIS; ASSOCIATION; MODEL;
   INFLAMMATION; PREVENTION; DIAGNOSIS
AB Simple Summary Postmenopausal osteoporosis, characterized by an imbalance in the remodeling cycle in which bone resorption exceeds bone formation, affects a large part of the population seeking rehabilitation with osseointegrated implants, making the prognosis of these patients unfavorable. It is estimated that approximately 99 million people over the age of 50 were diagnosed with osteoporosis in the United States in 2010. A range of drugs are used for the treatment of postmenopausal osteoporosis, aiming to prevent skeletal fractures in individuals with this osteometabolic disorder. Bisphosphonates are widely prescribed drugs to increase bone mineral density (BMD) and decrease the risk of skeletal fractures in patients with osteoporosis, with good results in this regard. However, little attention has been paid to the impact that the mechanism of action of this drug generates on the bone repair process, and more scientific evidence is needed to better understand the role of this drug in the peri implant repair process. (1) Background: Postmenopausal osteoporosis combined with an unhealthy lifestyle can lead to the development of metabolic syndrome, a common condition in individuals requiring oral rehabilitation. Bisphosphonates are used to increase bone mineral density. However, further studies are needed to evaluate the action of this drug on the bone repair process in the jaws. The aim of this study was to evaluate the peri implant repair of rats with estrogen deficiency and metabolic syndrome treated with risedronate sodium. (2) Methods: Twenty four female Wistar rats were divided into three groups: SHAM: sham surgery; OVX/SM: ovariectomy combined with a cafeteria diet; OVX/SM/RIS: ovariectomy associated with a cafeteria diet and treatment with sodium risedronate. After 30 days, the animals underwent extraction of the upper first molars. Thirty days after the extraction, an implant was installed in the same region. Sixty days after the implant was installed, the animals were euthanized for biomechanical analysis and confocal microscopic analysis. After confirming the normal distribution of the sample data, a one way ANOVA test was performed, followed by Tukey's post test, with a 5% significance level. (3) Results: Significant bone preservation was observed in the risedronate treated group. Higher removal torque values were obtained by the risedronate treated group. (4) Conclusions: Better biomechanical performance of the implants installed in the animals treated with risedronate sodium was observed.
C1 [Ervolino da Silva, Ana Claudia; de Souza Batista, Fabio Roberto; Hassumi, Jaqueline Suemi; Pitol Palin, Leticia; Monteiro, Naara Gabriela; Frigerio, Paula Buzo] Sao Paulo State Univ Julio de Mesquita Filho UNES, Aracatuba Dent Sch, Dept Diag & Surg, BR 16015050 Aracatuba, SP, Brazil.
   [Okamoto, Roberta] Sao Paulo State Univ Julio de Mesquita Filho UNES, Aracatuba Dent Sch, Dept Basic Sci, BR 16015050 Aracatuba, SP, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista
RP da Silva, ACE (通讯作者)，Sao Paulo State Univ Julio de Mesquita Filho UNES, Aracatuba Dent Sch, Dept Diag & Surg, BR 16015050 Aracatuba, SP, Brazil.
EM ana.ervolino@unesp.br; fabiorsbatista@gmail.com;
   jaquelinehassumi@hotmail.com; leticiappalin@gmail.com;
   naaragmonteiro@gmail.com; paula.frigerio@outlook.com;
   roberta.okamoto@unesp.br
RI ; da Silva, Ana/GXH 4851 2022; Palin, Letícia/AAY 4320 2020; Okamoto,
   Roberta/C 4562 2012
OI Pitol Palin, Leticia/0000 0003 4765 3765; Monteiro,
   Naara/0000 0002 2857 9195; Okamoto, Roberta/0000 0002 6773 6966;
   Ervolino da Silva, Ana Claudia/0000 0002 6592 0460; Buzo Frigerio,
   Paula/0000 0002 5012 5093
FU SAo Paulo Research Foundation FAPESP [2019/09946 0, 2018/03114 0];
   Vinnova [2018 03114] Funding Source: Vinnova
FX This study was financially supported by the SAo Paulo Research
   Foundation FAPESP (2019/09946 0; 2018/03114 0).
CR Abtahi J, 2013, J DENT RES, V92, P279, DOI 10.1177/0022034512472335
   [Anonymous], FACTS STAT OST ITS I
   Baccaro LF, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S54614
   BERNARDIS LL, 1968, J ENDOCRINOL, V40, P527, DOI 10.1677/joe.0.0400527
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boccaccio A, 2018, INT J MED SCI, V15, P16, DOI 10.7150/ijms.20522
   Brügger OE, 2015, INT J ORAL MAX IMPL, V30, P151, DOI 10.11607/jomi.3769
   Carillon J, 2013, FREE RADICAL BIO MED, V65, P254, DOI 10.1016/j.freeradbiomed.2013.06.022
   Conde J, 2011, BIOFACTORS, V37, P413, DOI 10.1002/biof.185
   DEVLIN H, 1990, ARCH ORAL BIOL, V35, P29, DOI 10.1016/0003 9969(90)90110 V
   Ferreira GZ, 2020, J APPL ORAL SCI, V28, DOI 10.1590/1678 7757 2020 0204
   Furuse C, 2018, BONE, V114, P226, DOI 10.1016/j.bone.2018.06.017
   Gomez Smith M, 2016, PHYSIOL BEHAV, V167, P382, DOI 10.1016/j.physbeh.2016.09.029
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hou J, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.600181
   IOF, Facts and statistics
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Ko SH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010202
   Langdahl B, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115516
   Lewis JW, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00122 0
   Miller PD, 2010, OSTEOPOROSIS INT, V21, P1793, DOI 10.1007/s00198 010 1208 3
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ramalho Ferreira G, 2015, INT J ORAL MAX SURG, V44, P798, DOI 10.1016/j.ijom.2015.02.018
   Ramalho Ferreira G, 2017, CLIN ORAL INVEST, V21, P1485, DOI 10.1007/s00784 016 1909 x
   Razmjou S, 2018, MENOPAUSE, V25, P89, DOI 10.1097/GME.0000000000000951
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Wells G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004523.pub3
   Wong SK, 2018, BIOMED PHARMACOTHER, V98, P191, DOI 10.1016/j.biopha.2017.12.042
   Wong SK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060347
   Xue P, 2012, ENDOCRINE, V42, P546, DOI 10.1007/s12020 012 9684 1
   Zhou JJ, 2013, BONE, V57, P30, DOI 10.1016/j.bone.2013.07.013
NR 34
TC 5
Z9 5
U1 0
U2 5
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2079 7737
J9 BIOLOGY BASEL
JI Biology Basel
PD APR
PY 2022
VL 11
IS 4
AR 578
DI 10.3390/biology11040578
PG 13
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 0Q8YV
UT WOS:000785197700001
PM 35453776
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Abdallah, BM
   Alzahrani, AM
AF Abdallah, Basem M.
   Alzahrani, Abdullah M.
TI A 769662 stimulates the differentiation of bone marrow  derived
   mesenchymal stem cells into osteoblasts via AMP activated protein
   kinase dependent mechanism
SO JOURNAL OF APPLIED BIOMEDICINE
LA English
DT Article
DE A 769662; Adipocyte; AMPK; BMSC; Osteoblast; Stem cells
ID IN VIVO; METFORMIN; INHIBITION; SURVIVAL; PATHWAY
AB AMP activated protein kinase (AMPK) signaling shows an important role in energy metabolism and has recently been involved in osteogenic and adipogenic differentiation. In this study we aimed to investigate the role of AMPK activator, A 769662, in regulating the differentiation of mesenchymal stem cells derived from bone marrow (BMSCs) into osteoblastic and adipocytic cell lineage. The effect of A 769662 on osteogenesis was assessed by quantitative alkaline phosphatase (ALP) activity, matrix mineralization stained with Alizarin red, and gene expression analysis by quantitative polymerase chain reaction (qPCR). Adipogenesis was determined by Oil Red O staining for fat droplets and qPCR analysis of adipogenic markers. A 769662 activated the phosphorylation of AMPK alpha 1 during the osteogenesis of mBMSCs as revealed by western blot analysis. A 769662 promoted the early stage of the commitment of mouse (m) BMSCs differentiation into osteoblasts, while inhibiting their differentiation into adipocytes in a dose dependent manner. The effects of A 769662 on stimulating osteogenesis and inhibiting adipogenesis of mBMSCs were significantly eliminated in the presence of either AMPK alpha 1 siRNA or Compound C, an inhibitor of AMPK pathway. In conclusion, we identified A 769662 as a new compound that promotes the commitment of BMSCs into osteoblasts versus adipocytes via AMPK dependent mechanism. Thus our data show A 769662 as a potential osteo anabolic drug for treatment of osteoporosis.
C1 [Abdallah, Basem M.; Alzahrani, Abdullah M.] King Faisal Univ, Coll Sci, Dept Biol Sci, POB 380, Al Hasa 31982, Saudi Arabia.
C3 King Faisal University
RP Abdallah, BM (通讯作者)，King Faisal Univ, Coll Sci, Dept Biol Sci, POB 380, Al Hasa 31982, Saudi Arabia.
EM babdallallah@kfu.edu.sa
RI Alzahrani, Abdullah/H 8384 2016; Abdallah, Basem/G 5667 2017
FU Deanship of Scientific Research at King Faisal University, Saudi Arabia
   [180076]
FX This work was funded by the Deanship of Scientific Research at King
   Faisal University, Saudi Arabia (Grant No. 180076).
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Abdallah BM, 2018, BONE, V110, P221, DOI 10.1016/j.bone.2018.02.018
   Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Amantea CM, 2008, J CELL BIOCHEM, V105, P424, DOI 10.1002/jcb.21840
   Babkov DA, 2019, BIOORG MED CHEM LETT, V29, P2443, DOI 10.1016/j.bmcl.2019.07.035
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bianco P, 2015, DEVELOPMENT, V142, P1023, DOI 10.1242/dev.102210
   Chava S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0791 7
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen SC, 2017, MOL CELL ENDOCRINOL, V440, P57, DOI 10.1016/j.mce.2016.11.011
   Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005
   CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432 1033.1995.tb20498.x
   Day EA, 2017, TRENDS ENDOCRIN MET, V28, P545, DOI 10.1016/j.tem.2017.05.004
   de Meester C, 2014, CARDIOVASC RES, V101, P20, DOI 10.1093/cvr/cvt227
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Göransson O, 2007, J BIOL CHEM, V282, P32549, DOI 10.1074/jbc.M706536200
   Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304
   Hardie DG, 2014, ANNU REV NUTR, V34, P31, DOI 10.1146/annurev nutr 071812 161148
   Hardouin P, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00085
   Jafari A, 2015, STEM CELLS, V33, P2219, DOI 10.1002/stem.2013
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Kanno T, 2007, J CELL BIOCHEM, V101, P1266, DOI 10.1002/jcb.21249
   Kim EK, 2012, J CELL PHYSIOL, V227, P1680, DOI 10.1002/jcp.22892
   Kim J, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.16
   Li Y, 2018, CURR STEM CELL RES T, V13, P185, DOI 10.2174/1574888X12666171012141908
   Luby AO, 2019, J CRANIOFAC SURG, V30, P730, DOI 10.1097/SCS.0000000000005250
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Rharass T, 2018, EUR J ENDOCRINOL, V179, pR165, DOI 10.1530/EJE 18 0182
   Sanders MJ, 2007, J BIOL CHEM, V282, P32539, DOI 10.1074/jbc.M706543200
   Scott JW, 2014, CHEM BIOL, V21, P619, DOI 10.1016/j.chembiol.2014.03.006
   Sedlinsky C, 2011, EUR J PHARMACOL, V668, P477, DOI 10.1016/j.ejphar.2011.07.033
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Shen W, 2012, OSTEOPOROSIS INT, V23, P2293, DOI 10.1007/s00198 011 1873 x
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Suh JM, 2006, CELL METAB, V3, P25, DOI 10.1016/j.cmet.2005.11.012
   Taipaleenmäki H, 2011, EXP CELL RES, V317, P745, DOI 10.1016/j.yexcr.2010.12.015
   Tamargo Gómez I, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123812
   Thirupathi A, 2019, LIFE SCI, V227, P30, DOI 10.1016/j.lfs.2019.04.039
   Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05
   Wang SB, 2012, CLIN SCI, V122, P555, DOI 10.1042/CS20110625
   Wu LY, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00122
   Zhao LM, 2011, VITAM HORM, V87, P127, DOI 10.1016/B978 0 12 386015 6.00042 1
   Zheng CX, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0060 3
   Zhou Y, 2009, BIOL PHARM BULL, V32, P993, DOI 10.1248/bpb.32.993
   Zhu YL, 2014, INT J MOL SCI, V15, P11190, DOI 10.3390/ijms150611190
NR 46
TC 2
Z9 3
U1 0
U2 4
PU UNIV SOUTH BOHEMIA
PI CESKA BUDEJOVICE
PA FAC HEALTH & SOCIAL STUD, JIROVCOVA, CESKA BUDEJOVICE, 370 04, CZECH
   REPUBLIC
SN 1214 021X
EI 1214 0287
J9 J APPL BIOMED
JI J. Appl. Biomed.
PY 2021
VL 19
IS 3
BP 158
EP 169
DI 10.32725/jab.2021.016
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA WE0RQ
UT WOS:000705337500005
PM 34907759
OA gold
DA 2025 08 17
ER

PT J
AU Dai, LF
   Xu, M
   Wu, HY
   Xue, LJ
   Yuan, DK
   Wang, Y
   Shen, ZQ
   Zhao, HB
   Hu, M
AF Dai, Lifen
   Xu, Ming
   Wu, Haiying
   Xue, Lanjie
   Yuan, Dekai
   Wang, Yuan
   Shen, Zhiqiang
   Zhao, Hongbin
   Hu, Min
TI The functional mechanism of simvastatin in experimental osteoporosis
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Simvastatin; Osteoporosis; Osteoblast; Bone mineral density; Animal
   model
ID BONE MORPHOGENETIC PROTEIN 2; COA REDUCTASE INHIBITORS; OSTEOBLAST
   DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; ANABOLIC THERAPIES;
   PROLIFERATION; EXPRESSION; STATINS; RISK; MICROARCHITECTURE
AB Osteoporosis is a systemic and metabolic bone disease. New drugs with good curative effect, fewer side effects, and high safety need to be developed urgently. Recently, simvastatin has been used to treat osteoporosis more frequently; however, its clinical effect and treatment mechanism are still unknown. With the use of animal models, the treatment effectiveness of simvastatin on experimental osteoporosis was investigated and the functional mechanism was preliminarily explored. The results show that simvastatin significantly increased the mechanical parameters such as maximum load, stiffness, and energy absorbing capacity, and improved the microarchitecture. They indicated that the antiosteoporosis activity of simvastatin may be due to the promotion of proliferation and differentiation of osteoblasts. Simvastatin was effective in treating experimental osteoporosis. This study provides necessary experimental evidence for the clinical application of simvastatin in osteoporosis treatment.
C1 [Dai, Lifen; Xu, Ming; Yuan, Dekai; Wang, Yuan; Hu, Min] Kunming Univ, Kunming Res Ctr Mol Med, Kunming 650214, Peoples R China.
   [Dai, Lifen] Kunming Med Univ, Affiliated Hosp 2, Dept Endocrinol, Kunming 650500, Peoples R China.
   [Dai, Lifen; Shen, Zhiqiang] Kunming Med Univ, Sch Pharmaceut Sci, Kunming 650500, Peoples R China.
   [Dai, Lifen; Shen, Zhiqiang] Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, Kunming 650500, Peoples R China.
   [Wu, Haiying; Zhao, Hongbin] Kunming Med Univ, Affiliated Hosp 1, Dept Emergency Med, Kunming 650032, Peoples R China.
   [Wu, Haiying; Zhao, Hongbin] Kunming Med Univ, Affiliated Hosp 1, Intens Care Unit, Kunming 650032, Peoples R China.
   [Xue, Lanjie] Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming 650500, Peoples R China.
C3 Kunming University; Kunming Medical University; Kunming Medical
   University; Kunming Medical University; Kunming Medical University;
   Kunming Medical University; Kunming University of Science & Technology
RP Hu, M (通讯作者)，Kunming Univ, Kunming Res Ctr Mol Med, Kunming 650214, Peoples R China.
EM 596829191@qq.com; humin999@aliyun.com
RI Hu, Min/HLH 2112 2023
FU National Natural Science Foundation of China [81060361]; Natural Science
   Foundation of Yunnan Province, China [2012FA002, 2010ZC169, 2012HB043];
   Department of Education, Yunnan province, China [ZD2012006]; Natural
   Science Foundation of Kunming City, China [10S090202,
   2012 01 01 A R 07 0006, 2014 05 06 A R 07 0005]
FX This work was supported by the National Natural Science Foundation of
   China (grant 81060361), the Natural Science Foundation of Yunnan
   Province, China (grants 2012FA002, 2010ZC169, 2012HB043), the Department
   of Education, Yunnan province, China (grant ZD2012006), and the Natural
   Science Foundation of Kunming City, China (grants 10S090202,
   2012 01 01 A R 07 0006, 2014 05 06 A R 07 0005).
CR Akhter MP, 2001, BONE, V29, P121, DOI 10.1016/S8756 3282(01)00486 0
   Alam S, 2009, ORAL SURG ORAL MED O, V107, P22, DOI 10.1016/j.tripleo.2008.06.025
   Baek KH, 2005, J KOREAN MED SCI, V20, P438, DOI 10.3346/jkms.2005.20.3.438
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Castañeda S, 2006, SKELETAL RADIOL, V35, P34, DOI 10.1007/s00256 005 0022 z
   Chen HY, 2012, J ETHNOPHARMACOL, V142, P80, DOI 10.1016/j.jep.2012.04.017
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chuang SC, 2013, EUR J PHARMACOL, V714, P74, DOI 10.1016/j.ejphar.2013.05.044
   Dominguez Ligia J, 2010, Acta Biomed, V81 Suppl 1, P55
   Du ZB, 2009, CLIN ORAL IMPLAN RES, V20, P145, DOI 10.1111/j.1600 0501.2008.01630.x
   Emmanuele L, 2003, BIOCHEM BIOPH RES CO, V302, P67, DOI 10.1016/S0006 291X(03)00109 8
   Grey A, 2005, EXPERT OPIN INV DRUG, V14, P265, DOI 10.1517/13543784.14.3.265
   Hatano Hiroshi, 2003, J Orthop Sci, V8, P842, DOI 10.1007/s00776 003 0724 9
   Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365 2362.2009.02092.x
   Hordon LD, 2006, BONE, V38, P444, DOI 10.1016/j.bone.2005.09.020
   Hwang R, 2004, J BIOL CHEM, V279, P21239, DOI 10.1074/jbc.M312771200
   Izumo N, 2001, METHOD FIND EXP CLIN, V23, P389, DOI 10.1358/mf.2001.23.7.662123
   Kim T, 2013, J ETHNOPHARMACOL, V146, P83, DOI 10.1016/j.jep.2012.11.037
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   Lasota A, 2004, Rocz Akad Med Bialymst, V49 Suppl 1, P129
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li BF, 2010, ACTA ORTHOP, V81, P396, DOI 10.3109/17453674.2010.483986
   Li GW, 2012, EUR RADIOL, V22, P923, DOI 10.1007/s00330 011 2325 x
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756 3282(03)00239 4
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Liu XL, 2012, MED ENG PHYS, V34, P2, DOI 10.1016/j.medengphy.2011.06.010
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Oxlund H, 2004, BONE, V34, P609, DOI 10.1016/j.bone.2003.12.014
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Reginster Jean Yves, 2006, Treat Endocrinol, V5, P15, DOI 10.2165/00024677 200605010 00003
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Rizzo M, 2006, AM J MED SCI, V332, P55, DOI 10.1097/00000441 200608000 00001
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Scholz Ahrens KE, 2007, AM J PHYSIOL ENDOC M, V293, pE385, DOI 10.1152/ajpendo.00627.2006
   Schorlemmer S, 2005, BONE, V37, P491, DOI 10.1016/j.bone.2005.05.002
   Sharif PS, 2011, RHEUMATOL INT, V31, P289, DOI 10.1007/s00296 010 1586 z
   Shirke SS, 2008, EXP BIOL MED, V233, P1403, DOI 10.3181/0803 RM 93
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   von Stechow D, 2003, BMC MUSCULOSKEL DIS, V4, DOI 10.1186/1471 2474 4 8
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Wong RWK, 2005, BRIT J ORAL MAX SURG, V43, P46, DOI 10.1016/j.bjoms.2004.08.014
   Yazawa H, 2005, J PERIODONTOL, V76, P295, DOI 10.1902/jop.2005.76.2.295
   Yin H, 2012, EUR J PHARMACOL, V674, P200, DOI 10.1016/j.ejphar.2011.11.024
   Zhang YZ, 2006, J ETHNOPHARMACOL, V105, P274, DOI 10.1016/j.jep.2005.12.013
   Zhao FD, 2009, BONE, V44, P372, DOI 10.1016/j.bone.2008.10.048
NR 51
TC 19
Z9 21
U1 0
U2 19
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JAN
PY 2016
VL 34
IS 1
BP 23
EP 32
DI 10.1007/s00774 014 0638 y
PG 10
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA CZ8ER
UT WOS:000367333500003
PM 25511080
DA 2025 08 17
ER

PT J
AU Cui, JC
   Li, ZH
   Wang, WC
   Zeng, L
AF Cui, Juncheng
   Li, Zhihong
   Wang, Wanchun
   Zeng, Li
TI Adiponectin: A new therapeutic option for periprosthetic osteolysis
SO AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE Adiponectin; periprosthetic osteolysis; wear debris
ID TOTAL HIP ARTHROPLASTY; HUMAN OSTEOBLASTS; OSTEOCLAST DIFFERENTIATION;
   PROTEIN ACRP30; BONE FORMATION; WEAR RATE; PARTICLES; PATHWAYS; LIGAND;
   RANKL
AB Periprosthetic osteolysis is the most prevalent complication after total joint arthroplasty. It often results in aseptic loosening of the implant, which is required for revision surgery. Wear debris has been recognized as a key factor in the initiation and development of periprosthetic osteolysis, and yet there is no approved treatment available to it. Adiponectin is a hormone secreted by adipose tissue. Many researchers have reported that adiponectin can block osteoclastogenesis and promote osteoblast proliferation. We then hypothesize that adiponectin may play an efficient role in the therapy of periprosthetic osteolysis, which may offer new therapeutic options for the management of periprosthetic osteolysis after total joint arthroplasty.
C1 [Zeng, Li] Nanhua Univ, Dept Med Cosmetol, Affiliate Hosp 1, Hengyang 421001, Hunan, Peoples R China.
   [Cui, Juncheng; Li, Zhihong; Wang, Wanchun] Cent S Univ, Dept Orthoped, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
C3 University of South China; Central South University
RP Wang, WC (通讯作者)，Cent S Univ, Dept Orthoped, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
EM xyeyygk3@hotmail.com
RI Li, Zhihong/M 4989 2019; Zeng, Zheng/W 4263 2017
CR Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992
   Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120
   Dumbleton JH, 2002, J ARTHROPLASTY, V17, P649, DOI 10.1054/arth.2002.33664
   Greenfield EM, 2002, J ORTHOPAED RES, V20, P1, DOI 10.1016/S0736 0266(01)00070 5
   Hallab NJ, 2005, J ORTHOP RES, V23, P384, DOI 10.1016/j.orthres.2004.09.001
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Mitsui Y, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 18
   Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Pearle AD, 2007, CLIN ORTHOP RELAT R, P194, DOI 10.1097/BLO.0b013e3180320ae8
   Pioletti DP, 2002, J BIOMED MATER RES, V61, P408, DOI 10.1002/jbm.10218
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Ritchlin C. T., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P276
   Schwarz E. M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P390
   Shinoda Y, 2006, J CELL BIOCHEM, V99, P196, DOI 10.1002/jcb.20890
   Vermes C, 2000, J BONE MINER RES, V15, P1756, DOI 10.1359/jbmr.2000.15.9.1756
   Wilkinson JM, 2005, J ORTHOP RES, V23, P520, DOI 10.1016/j.orthres.2004.11.005
   Yamaguchi N, 2007, FEMS IMMUNOL MED MIC, V49, P28, DOI 10.1111/j.1574 695X.2006.00164.x
   Zambonin G, 1998, CALCIFIED TISSUE INT, V62, P362, DOI 10.1007/s002239900445
NR 22
TC 1
Z9 1
U1 0
U2 5
PU ACADEMIC JOURNALS
PI VICTORIA ISLAND
PA P O BOX 5170 00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA
SN 1996 0816
J9 AFR J PHARM PHARMACO
JI Afr. J. Pharm. Pharmacol.
PD NOV
PY 2011
VL 5
IS 18
BP 2115
EP 2117
DI 10.5897/AJPP11.426
PG 3
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 883ZR
UT WOS:000299675000013
DA 2025 08 17
ER

PT J
AU Johansson, MK
   de Vries, TJ
   Schoenmaker, T
   Ehinger, M
   Brun, ACM
   Fasth, A
   Karisson, S
   Everts, V
   Richter, J
AF Johansson, Maria K.
   de Vries, Teun J.
   Schoenmaker, Ton
   Ehinger, Mats
   Brun, Ann C. M.
   Fasth, Anders
   Karisson, Stefan
   Everts, Vincent
   Richter, Johan
TI Hematopoietic stem cell targeted neonatal gene therapy reverses lethally
   progressive osteopetrosis in oc/oc mice
SO BLOOD
LA English
DT Article
ID AUTOSOMAL RECESSIVE OSTEOPETROSIS; VACUOLAR PROTON PUMP; BONE MARROW;
   TRANSPLANTATION; EXPRESSION; MOUSE; OSTEOCLASTS; MUTATIONS; DIAGNOSIS;
   DEFECTS
AB Infantile malignant osteopetrosis (IMO) is a fatal disease caused by lack of functional osteoclasts, and the only available treatment is hematopoietic stem cell (HSC) transplantation. In the majority of patients, the TCIRG1 gene, coding for a subunit of a proton pump essential for bone resorption, is mutated. Oc/oc mice have a deletion in the homologue gene (tcirg 1) and die at 3 to 4 weeks, but can be rescued by neonatal transplantation of HSCs. Here, HSC targeted gene therapy of osteopetrosis in the oc/oc mouse model was developed. oc/oc fetal liver cells depleted of Ter119 expressing erythroid cells were transduced with a retroviral vector expressing tcirgl and GFP, and subsequently transplanted intraperitoneally to irradiated neonatal oc/oc mice. Eight of 15 mice survived past the normal life span of oc/oc mice. In vitro osteoclastogenesis revealed formation of GFPpositive osteoclasts and bone resorption, albeit at a lower level than from wild type cells. The skeletal phenotype was analyzed by X ray and histopathology and showed partial correction at 8 weeks and almost normalization after 18 weeks. In summary, osteopetrosis in oc/oc mice can be reversed by neonatal transplantation of gene modified HSCs leading to long term survival. This represents a significant step toward the development of gene therapy for osteopetrosis.
C1 Lund Univ, Dept Mol Med & Gene Therapy, Lund, Sweden.
   Vrije Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Periodontol & Oral Cell Biol, Amsterdam, Netherlands.
   Lund Univ, Dept Pathol, Lund, Sweden.
   Univ Gothenburg, Dept Pediat, Gothenburg, Sweden.
C3 Lund University; Vrije Universiteit Amsterdam; Academic Center for
   Dentistry Amsterdam; Lund University; University of Gothenburg
RP Richter, J (通讯作者)，Lund Univ, Dept Mol Med & Gene Therapy, Lund, Sweden.
EM johan.richter@med.lu.se
RI ; Fasth, Anders/I 1109 2019; Ehinger, Mats/H 8457 2016
OI Fasth, Anders/0000 0002 0033 740X; Schoenmaker, Ton/0000 0001 6649 374X;
   de Vries, Teun/0000 0001 6464 5172; 
CR Blin Wakkach C, 2004, LEUKEMIA, V18, P1505, DOI 10.1038/sj.leu.2403449
   Blin Wakkach C, 2006, EXP HEMATOL, V34, P851, DOI 10.1016/j.exphem.2006.04.003
   Boissy P, 2002, ENDOCRINOLOGY, V143, P1913, DOI 10.1210/en.143.5.1913
   Cavazzana Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669
   Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842
   COCCIA PF, 1980, NEW ENGL J MED, V302, P701, DOI 10.1056/NEJM198003273021301
   de Vries TJ, 2005, J CELL BIOCHEM, V94, P954, DOI 10.1002/jcb.20326
   Driessen GJA, 2003, BONE MARROW TRANSPL, V32, P657, DOI 10.1038/sj.bmt.1704194
   Fasth A, 1999, Pediatr Transplant, V3 Suppl 1, P102
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Frattini A, 2005, P NATL ACAD SCI USA, V102, P14629, DOI 10.1073/pnas.0507637102
   Frattini A, 2003, J BONE MINER RES, V18, P1740, DOI 10.1359/jbmr.2003.18.10.1740
   GERRITSEN EJA, 1994, PEDIATRICS, V93, P247
   Johansson M, 2006, EXP HEMATOL, V34, P242, DOI 10.1016/j.exphem.2005.11.010
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145
   Lindemann C, 2002, EXP HEMATOL, V30, P150, DOI 10.1016/S0301 472X(01)00778 0
   Mortellaro A, 2006, BLOOD, V108, P2979, DOI 10.1182/blood 2006 05 023507
   Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393
   Rajapurohitam V, 2001, BONE, V28, P513, DOI 10.1016/S8756 3282(01)00416 1
   Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191
   SEIFERT MF, 1987, TISSUE CELL, V19, P29, DOI 10.1016/0040 8166(87)90054 1
   Selski DJ, 2006, J CELL BIOCHEM, V97, P641, DOI 10.1002/jcb.20679
   Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767
   Steward CG, 2005, BIOL BLOOD MARROW TR, V11, P115, DOI 10.1016/j.bbmt.2004.11.001
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760
   Van Wesenbeeck L, 2005, CRIT REV EUKAR GENE, V15, P133, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.40
   Wilson CJ, 2000, ARCH DIS CHILD, V83, P449, DOI 10.1136/adc.83.5.449
NR 31
TC 36
Z9 41
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD JUN 15
PY 2007
VL 109
IS 12
BP 5178
EP 5185
DI 10.1182/blood 2006 12 061382
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 180JW
UT WOS:000247360200027
PM 17332244
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Neog, MK
   Rasool, M
AF Neog, Manoj Kumar
   Rasool, Mahaboobkhan
TI Targeted delivery of p coumaric acid encapsulated mannosylated liposomes
   to the synovial macrophages inhibits osteoclast formation and bone
   resorption in the rheumatoid arthritis animal model
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Mannosylated liposomes; p Coumaric acid; Rheumatoid arthritis;
   Osteoclastogenesis; Bone erosion
ID INFLAMMATION
AB The current study aimed to target the delivery of p coumaric acid (CA), a dietary polyphenol to the synovial macrophages of AIA rats via mannose incorporated liposomal delivery system (ML) with reference to osteoclastogenesis and bone resorption. In vivo imaging and in vitro drug release study indicated the efficiency of mannosylated liposomes to localize at the site of inflammation and increased sustain drug release respectively. Morphological assessment of isolated synovial macrophages with respect to CD86 (synovial macrophages) and CD51 (pre /osteoclast) indicated that p coumaric acid encapsulated mannosylated liposomes (ML CA) inhibited the osteoclasts differentiation. ML CA treatment inhibited the TRAP staining, downregulated the expression of MMP 9 and NFATcl and inflammatory cytokines. The ex vivo study specified the ability of CA to induce the OPG production in bone marrow stromal cell triggered macrophage osteoclasts differentiation and to preserve the calcium content. Taken together, our results demonstrated that ML CA could intervene in the osteoclast formation.
C1 [Neog, Manoj Kumar; Rasool, Mahaboobkhan] VIT, Sch Bio Sci & Technol, Immunopathol Lab, SMV 240, Vellore 632014, Tamil Nadu, India.
C3 Vellore Institute of Technology (VIT); VIT Vellore
RP Rasool, M (通讯作者)，VIT, Sch Bio Sci & Technol, Immunopathol Lab, SMV 240, Vellore 632014, Tamil Nadu, India.
EM mkr474@gmail.com
RI ; Neog, Manoj/GLR 7933 2022; Rasool, Mahaboobkhan/KOC 4395 2024
OI Neog, Manoj/0000 0002 3017 0030; Rasool,
   Mahaboobkhan/0000 0003 4980 5355
CR Aziz MH, 2017, J IMMUNOL, V198, P4855, DOI 10.4049/jimmunol.1602175
   Burmester GR, 1997, ARTHRITIS RHEUM, V40, P5, DOI 10.1002/art.1780400104
   Chang J, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.14
   Danks L, 2002, ANN RHEUM DIS, V61, P916, DOI 10.1136/ard.61.10.916
   Davignon JL, 2013, RHEUMATOLOGY, V52, P590, DOI 10.1093/rheumatology/kes304
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Hattori Y, 2006, J PHARMACOL EXP THER, V318, P828, DOI 10.1124/jpet.106.105098
   Horwood NJ, 2016, CLIN REV ALLERG IMMU, V51, P79, DOI 10.1007/s12016 015 8519 2
   Jeganathan S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104498
   Kapoor B, 2014, SCI WORLD J, DOI 10.1155/2014/978351
   Kennedy A, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00052
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kundu S, 2012, FREE RADICAL RES, V46, P1482, DOI 10.3109/10715762.2012.727991
   Lee NK, 2010, ENDOCRINOL METAB, V25, P264, DOI 10.3803/EnM.2010.25.4.264
   Marino S., 2014, BONEKEY REP, V3, P1
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409
   Neog MK, 2017, BIOFACTORS, V43, P698, DOI 10.1002/biof.1377
   Prasad LK, 2015, NANOMEDICINE UK, V10, P2063, DOI [10.2217/nnm.15.45, 10.2217/NNM.15.45]
   Quinn JMW, 2005, BIOCHEM BIOPH RES CO, V328, P739, DOI 10.1016/j.bbrc.2004.11.076
   Richards PJ, 1999, RHEUMATOLOGY, V38, P818, DOI 10.1093/rheumatology/38.9.818
   Sultana F, 2017, COLLOID SURFACE B, V155, P349, DOI 10.1016/j.colsurfb.2017.04.046
   Sultana F, 2017, EUR J PHARM BIOPHARM, V115, P229, DOI 10.1016/j.ejpb.2017.03.009
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   TANAKA T, 1987, ACTA HISTOCHEM CYTOC, V20, P693, DOI 10.1267/ahc.20.693
   Taylor K. E. S., 2012, OXIDATIVE STRESS RHE, P145
   Väänänen HK, 1998, MAT SCI ENG C BIO S, V6, P205, DOI 10.1016/S0928 4931(98)00052 6
   Van Lent PLEM, 1998, ANN RHEUM DIS, V57, P408, DOI 10.1136/ard.57.7.408
   van Rooijen N, 2002, J LIPOSOME RES, V12, P81, DOI 10.1081/LPR 120004780
   Wijagkanalan W, 2008, J CONTROL RELEASE, V125, P121, DOI 10.1016/j.jconrel.2007.10.011
NR 32
TC 48
Z9 50
U1 0
U2 32
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939 6411
EI 1873 3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD DEC
PY 2018
VL 133
BP 162
EP 175
DI 10.1016/j.ejpb.2018.10.010
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HC0LI
UT WOS:000451489400018
PM 30339889
DA 2025 08 17
ER

PT J
AU Yeon, JT
   Kim, KJ
   Choi, SW
   Moon, SH
   Park, YS
   Ryu, BJ
   Oh, J
   Kim, MS
   Erkhembaatar, M
   Son, YJ
   Kim, SH
AF Yeon, Jeong Tae
   Kim, Kwang Jin
   Choi, Sik Won
   Moon, Seong Hee
   Park, Young Sik
   Ryu, Byung Jun
   Oh, Jaemin
   Kim, Min Seuk
   Erkhembaatar, Munkhsoyol
   Son, Young Jin
   Kim, Seong Hwan
TI Anti Osteoclastogenic Activity of Praeruptorin A via Inhibition of
   p38/Akt c Fos NFATc1 Signaling and PLCγ Independent Ca<SUP>2+</SUP>
   Oscillation
SO PLOS ONE
LA English
DT Article
ID MULTIDRUG RESISTANCE; CANCER CELLS; BONE LOSS; C FOS; DIFFERENTIATION;
   PATHWAY; RANKL; ACTIVATION; NFATC1; OSTEOIMMUNOLOGY
AB Background: A decrease of bone mass is a major risk factor for fracture. Several natural products have traditionally been used as herbal medicines to prevent and/or treat bone disorders including osteoporosis. Praeruptorin A is isolated from the dry root extract of Peucedanum praeruptorum Dunn and has several biological activities, but its anti osteoporotic activity has not been studied yet.
   Materials and Methods: The effect of praeruptorin A on the differentiation of bone marrow derived macrophages into osteoclasts was examined by phenotype assay and confirmed by real time PCR and immunoblotting. The involvement of NFATc1 in the anti osteoclastogenic action of praeruptorin A was evaluated by its lentiviral ectopic expression. Intracellular Ca2+ levels were also measured.
   Results: Praeruptorin A inhibited the RANKL stimulated osteoclast differentiation accompanied by inhibition of p38 and Akt signaling, which could be the reason for praeruptorin A downregulated expression levels of c Fos and NFATc1, transcription factors that regulate osteoclast specific genes, as well as osteoclast fusion related molecules. The anti osteoclastogenic effect of praeruptorin A was rescued by overexpression of NFATc1. Praeruptorin A strongly prevented the RANKL induced Ca2+ oscillation without any changes in the phosphorylation of PLCc.
   Conclusion: Praeruptorin A could exhibit its anti osteoclastogenic activity by inhibiting p38/Akt c Fos NFATc1 signaling and PLCc independent Ca2+ oscillation.
C1 [Yeon, Jeong Tae; Kim, Kwang Jin; Son, Young Jin] Sunchon Natl Univ, Res Inst Basic Sci, Sunchon, South Korea.
   [Choi, Sik Won; Moon, Seong Hee; Ryu, Byung Jun; Kim, Seong Hwan] Korea Res Inst Chem Technol, Div Drug Discovery Res, Pharmacol Res Ctr, Lab Translat Therapeut, Taejon 305606, South Korea.
   [Moon, Seong Hee] Chungnam Natl Univ, Dept Biol, Taejon, South Korea.
   [Park, Young Sik] Natl Inst Food & Drug Safety Evaluat, Herbal Med Res Div, Cheongwon, South Korea.
   [Park, Young Sik; Kim, Seong Hwan] Chungnam Natl Univ, Grad Sch New Drug Discovery & Dev, Taejon, South Korea.
   [Oh, Jaemin] Wongkwang Univ, Sch Med, Dept Anat, Iksan, South Korea.
   [Oh, Jaemin] Wongkwang Univ, Sch Med, Inst Skeletal Dis, Iksan, South Korea.
   [Kim, Min Seuk; Erkhembaatar, Munkhsoyol] Wongkwang Univ, Sch Dent, Dept Oral Physiol, Iksan, South Korea.
C3 Sunchon National University; Korea Research Institute of Chemical
   Technology (KRICT); Chungnam National University; Ministry of Food &
   Drug Safety (MFDS), Republic of Korea; National Institute of Food & Drug
   Safety Evaluation; Chungnam National University; Wonkwang University;
   Wonkwang University; Wonkwang University
RP Son, YJ (通讯作者)，Sunchon Natl Univ, Res Inst Basic Sci, Sunchon, South Korea.
EM sony@sunchon.ac.kr; hwan@krict.re.kr
RI ; Kim, Seong/AAA 6086 2021; Park, Jin Young/HDN 0483 2022; Jin Ho,
   Seo/B 3621 2014
OI Erkhembaatar, Munkhsoyol/0009 0006 0855 9636; Choi,
   Sik Won/0000 0003 1726 2536; 
FU Korea Research Institute of Chemical Technology [SI 1304]; Korea
   Institute for Advancement of Technology [R0002019]; Korea Ministry of
   Knowledge Economy; Basic Science Research Program through the National
   Research Foundation of Korea [NRF 2012R1A1A1038381]; Ministry of
   Education, Science and Technology (MEST)
FX This work was supported by the Korea Research Institute of Chemical
   Technology project's grant (SI 1304) and the Inter ER Cooperation
   Projects (R0002019) of Korea Institute for Advancement of Technology,
   which were funded by the Korea Ministry of Knowledge Economy. MSK was
   supported by the Basic Science Research Program through the National
   Research Foundation of Korea (NRF 2012R1A1A1038381), funded by the
   Ministry of Education, Science and Technology (MEST). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi SW, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/748687
   Choi SW, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/810563
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Del Fattore A, 2008, ARCH BIOCHEM BIOPHYS, V473, P147, DOI 10.1016/j.abb.2008.01.011
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Fleisch H, 2003, EUR SPINE J, V12, pS142, DOI 10.1007/s00586 003 0622 z
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Inada M, 2006, J IMMUNOL, V177, P1879, DOI 10.4049/jimmunol.177.3.1879
   Ji Y, 1996, Zhongguo Zhong Xi Yi Jie He Za Zhi, V16, P676
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim MH, 2009, J CELL PHYSIOL, V221, P618, DOI 10.1002/jcp.21892
   Koide M, 1999, ARCH ORAL BIOL, V44, P711, DOI 10.1016/S0003 9969(99)00067 9
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Lee SU, 2010, INT IMMUNOPHARMACOL, V10, P298, DOI 10.1016/j.intimp.2009.11.014
   LI JM, 1994, ACTA PHARM SINIC, V15, P525
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lippuner K, 1997, OSTEOPOROSIS INT, V7, P414, DOI 10.1007/PL00004149
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Shen XL, 2006, BIOORGAN MED CHEM, V14, P7138, DOI 10.1016/j.bmc.2006.06.066
   Song YL, 2012, XENOBIOTICA, V42, P221, DOI 10.3109/00498254.2011.609250
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wu JYC, 2003, EUR J PHARMACOL, V473, P9, DOI 10.1016/S0014 2999(03)01946 0
   Yeon JT, 2012, BMB REP, V45, P171, DOI 10.5483/BMBRep.2012.45.3.171
   Yu PJ, 2011, PHYTOTHER RES, V25, P550, DOI 10.1002/ptr.3295
   Zhang Cun, 2005, Zhongguo Zhong Yao Za Zhi, V30, P1356
NR 45
TC 27
Z9 29
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2014
VL 9
IS 2
AR e88974
DI 10.1371/journal.pone.0088974
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AB3VI
UT WOS:000331717900042
PM 24586466
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Torreggiani, E
   Bianchini, C
   Penolazzi, L
   Lambertini, E
   Vecchiatini, R
   Canella, A
   Gambari, R
   Magri, E
   Pelucchi, S
   Pastore, A
   Piva, R
AF Torreggiani, Elena
   Bianchini, Chiara
   Penolazzi, Letizia
   Lambertini, Elisabetta
   Vecchiatini, Renata
   Canella, Alessandro
   Gambari, Roberto
   Magri, Eros
   Pelucchi, Stefano
   Pastore, Antonio
   Piva, Roberta
TI Osteogenic potential of cells derived from nasal septum
SO RHINOLOGY
LA English
DT Article
DE human primary osteoblasts; nasal septum; chromatin immunoprecipitation;
   bone repair
ID MESENCHYMAL STEM CELLS; BONE REGENERATION; DRUG DELIVERY; TISSUE;
   DIFFERENTIATION; RECONSTRUCTION; DEFECTS; GROWTH; GENE; HEAD
AB Background: The research addressed to detect new molecular targets in the development of therapeutic strategies aimed to repair bone tissues.
   The aim of this study was to determine the potential osteogenic activity of bone cells from the nasal septum and their use to perform accurate molecular analysis from a single sample.
   Methodology: The cells, after nasal septum surgery, were subjected to gene silencing, Reverse Transcriptase   Polymerase Chain reactions, immunocytochemistry and chromatin immunoprecipitation.
   Results: Cells from the nasal septum can give rise to mature osteoblasts that express osteogenic markers (ALP, Runx2, Slug) and are able to mineralize. We demonstrated that Runx2, a transcription factor critical in early osteospecific differentiation, interacts in vivo with the promoter of the SLUG gene, a marker of osteoblast maturation.
   Conclusions: We demonstrated that nasal septum derived osteoblasts represent an interesting alternative source for bone forming cells, and a promising material to be utilized in bone cellular therapy.
C1 [Torreggiani, Elena; Penolazzi, Letizia; Lambertini, Elisabetta; Vecchiatini, Renata; Canella, Alessandro; Gambari, Roberto; Piva, Roberta] Univ Ferrara, Dept Biochem & Mol Biol, Mol Biol Sect, I 44121 Ferrara, Italy.
   [Bianchini, Chiara; Pelucchi, Stefano; Pastore, Antonio] Univ Hosp Ferrara, Otorhinolaryngol Unit, Dept Med & Surg Special, Ferrara, Italy.
   [Magri, Eros] Univ Ferrara, Dept Expt & Diagnost Med, Sect Anat Pathol, I 44121 Ferrara, Italy.
C3 University of Ferrara; University of Ferrara; Arcispedale Sant'Anna;
   University of Ferrara
RP Piva, R (通讯作者)，Univ Ferrara, Dept Biochem & Mol Biol, Mol Biol Sect, Via Fossato Mortara 74, I 44121 Ferrara, Italy.
EM piv@unife.it
RI Torreggiani, Elena/J 6404 2016; Vecchiatini, Renata/J 1829 2015;
   Gambari, Roberto/F 9555 2015; pelucchi, stefano/AAB 9721 2019; Canella,
   Alessandro/O 7704 2017
OI Torreggiani, Elena/0000 0001 7874 2002; Vecchiatini,
   Renata/0000 0001 7055 9502; Penolazzi, Letizia/0000 0002 1293 5087;
   Gambari, Roberto/0000 0001 9205 6033; Piva, Roberta/0000 0003 2663 6210;
   Canella, Alessandro/0000 0002 0141 7399; Bianchini,
   Chiara/0000 0002 5115 6107
FU Regione Emilia Romagna, Programma di Ricerca Regione Universita;
   Fondazione Cassa di Risparmio di Cento
FX This research was supported by grants from Regione Emilia Romagna,
   Programma di Ricerca Regione Universita' 2007 2009. E.L. is a recipient
   of a fellowship from the Fondazione Cassa di Risparmio di Cento.
CR Bücheler M, 2003, DNA CELL BIOL, V22, P549, DOI 10.1089/104454903322405446
   Bueno EM, 2009, NAT REV RHEUMATOL, V5, P685, DOI 10.1038/nrrheum.2009.228
   Byers RJ, 1999, J PATHOL, V187, P374, DOI 10.1002/(SICI)1096 9896(199902)187:3<374::AID PATH257>3.0.CO;2 V
   Chen XD, 1999, J BONE MINER RES, V14, P362, DOI 10.1359/jbmr.1999.14.3.362
   Cordeiro PG, 2008, J SURG ONCOL, V97, P669, DOI 10.1002/jso.21017
   DOGLIOLI P, 1991, CYTOTECHNOLOGY, V7, P39, DOI 10.1007/BF00135637
   Gerressen M, 2009, CLIN ORAL IMPLAN RES, V20, P109, DOI 10.1111/j.1600 0501.2008.01619.x
   Goessler UR, 2007, EUR ARCH OTO RHINO L, V264, P1343, DOI 10.1007/s00405 007 0369 y
   Grayson WL, 2010, P NATL ACAD SCI USA, V107, P3299, DOI 10.1073/pnas.0905439106
   Khan SN, 2005, J AM ACAD ORTHOP SUR, V13, P77, DOI 10.5435/00124635 200501000 00010
   Kuriakose MA, 2003, HEAD NECK J SCI SPEC, V25, P816, DOI 10.1002/hed.10294
   Lambertini E, 2008, J CELL PHYSIOL, V216, P101, DOI 10.1002/jcp.21379
   Lambertini E, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471 2199 11 13
   Lambertini E, 2009, CELL MOL LIFE SCI, V66, P3641, DOI 10.1007/s00018 009 0149 5
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269, DOI 10.1177/10454411920030030501
   Malard O, 2007, EXPERT REV MED DEVIC, V4, P729, DOI 10.1586/17434440.4.5.729
   Moioli EK, 2007, ADV DRUG DELIVER REV, V59, P308, DOI 10.1016/j.addr.2007.03.019
   Nicole R, 2005, EUR ARCH OTO RHINO L, V262, P539, DOI 10.1007/s00405 004 0866 1
   Nussenbaum B, 2005, LARYNGOSCOPE, V115, P1170, DOI 10.1097/01.MLG.0000166513.74247.CC
   Panetta NJ, 2010, CURR STEM CELL RES T, V5, P122
   Pellegrini G, 2009, J DENT RES, V88, P1065, DOI 10.1177/0022034509349748
   Penolazzi L, 2010, TISSUE ENG PART C ME, V16, P141, DOI [10.1089/ten.tec.2008.0582, 10.1089/ten.TEC.2008.0582]
   Porter JR, 2009, BIOTECHNOL PROGR, V25, P1539, DOI 10.1002/btpr.246
   Richmon JD, 2005, LARYNGOSCOPE, V115, P1553, DOI 10.1097/01.MLG.0000175541.31131.A5
   Risbud M V, 2005, Orthod Craniofac Res, V8, P54
   ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826
   Scheller EL, 2009, J ORAL REHABIL, V36, P368, DOI 10.1111/j.1365 2842.2009.01939.x
   Scheller EL, 2009, J DENT RES, V88, P585, DOI 10.1177/0022034509337480
   Shanti RM, 2007, J ORAL MAXIL SURG, V65, P1640, DOI 10.1016/j.joms.2007.04.008
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Sundelacruz S, 2009, SEMIN CELL DEV BIOL, V20, P646, DOI 10.1016/j.semcdb.2009.03.017
   Zaky SH, 2009, J DENT RES, V88, P1077, DOI 10.1177/0022034509349926
NR 33
TC 2
Z9 2
U1 0
U2 0
PU INT RHINOLOGIC SOC
PI UTRECHT
PA UNIV MEDICAL CENTER UTRECHT, RM G05 127, DEPT OTORHINOL, HEIDELBERGLAAN
   100, 3584 CX UTRECHT, NETHERLANDS
SN 0300 0729
J9 RHINOLOGY
JI Rhinology
PD JUN
PY 2011
VL 49
IS 2
BP 148
EP 154
DI 10.4193/Rhino10.087
PG 7
WC Otorhinolaryngology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Otorhinolaryngology
GA 780XQ
UT WOS:000291894900005
PM 21743868
OA Bronze
DA 2025 08 17
ER

PT J
AU Bihani, A
   Thiagarajan, S
   Chaukar, D
   D'Cruz, AK
AF Bihani, Ameya
   Thiagarajan, Shivakumar
   Chaukar, Devendra
   D'Cruz, Anil K.
TI Giant cell tumor of hyoid bone: Diagnostic dilemma with a novel
   management
SO JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
LA English
DT Article
DE Denosumab; giant cell tumor of bone; hyoid; RANK RANK ligand; targeted
   therapy
ID MYOTONIC DYSTROPHY; OPEN LABEL; DENOSUMAB; SAFETY
AB Giant cell tumor of bone (GCTB) is locally aggressive tumor occurring in the epiphysis of long bones. GCTBs are uncommon tumors in the head and neck region and rarely involve hyoid bone. We report a case of GCTB of hyoid bone. The patient presented with swelling in left submandibular region. The tumor was surgically excised after initial denosumab therapy. Despite adequate resection and rehabilitation, he was tube dependent. Subsequently it was found that the patient had a coexisting myotonic dystrophy, unknown to exist with GCTB of hyoid. Eventually, the patient succumbed to respiratory failure secondary to myotonic dystrophy. GCTB hyoid is a rare presentation posing a diagnostic dilemma. Ours is the first case to report the use of denosumab for GCT in head and neck region. Myotonic dystrophy Type I and GCTB are both known to result from abnormality of closely situated foci on chromosome 19.
C1 [Bihani, Ameya] Medicare Hosp, Dept ENT & Head & Neck Surg, Indore, Madhya Pradesh, India.
   [Thiagarajan, Shivakumar; Chaukar, Devendra; D'Cruz, Anil K.] Tata Mem Hosp, Dept Head & Neck Surg Oncol, Mumbai, Maharashtra, India.
C3 Tata Memorial Centre (TMC); Tata Memorial Hospital
RP Thiagarajan, S (通讯作者)，Tata Mem Hosp, Dept Head & Neck Surg Oncol, Mumbai, Maharashtra, India.
EM drshiva78in@gmail.com
RI Thiagarajan, Suraj/O 3519 2019
CR Balke M, 2010, LANCET ONCOL, V11, P218, DOI 10.1016/S1470 2045(10)70027 9
   BARDI G, 1991, CANCER GENET CYTOGEN, V57, P161, DOI 10.1016/0165 4608(91)90147 M
   BERTONI F, 1992, CANCER, V70, P1124, DOI 10.1002/1097 0142(19920901)70:5<1124::AID CNCR2820700517>3.0.CO;2 P
   BORIANI S, 1986, Italian Journal of Orthopaedics and Traumatology, V12, P191
   Brien EW, 1997, SKELETAL RADIOL, V26, P246, DOI 10.1007/s002560050230
   BURNAM JA, 1979, LARYNGOSCOPE, V89, P1415, DOI 10.1002/lary.5540890906
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Caudell JJ, 2003, INT J RADIAT ONCOL, V57, P158, DOI 10.1016/S0360 3016(03)00416 4
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Commins DJ, 1999, J LARYNGOL OTOL, V113, P566, DOI 10.1017/S0022215100144500
   de Die Smulders CEM, 1998, BRAIN, V121, P1557, DOI 10.1093/brain/121.8.1557
   Iype EM, 2000, BRIT J ORAL MAX SURG, V38, P610, DOI 10.1054/bjom.2000.0483
   Jaffe HL, 1940, ARCH PATHOL, V30, P993
   Kalkman JS, 2005, J NEUROL NEUROSUR PS, V76, P1406, DOI 10.1136/jnnp.2004.050005
   Lau JK, 2015, INT J CARDIOL, V184, P600, DOI 10.1016/j.ijcard.2015.03.069
   Martin Broto J, 2014, ACTA ONCOL, V53, P1173, DOI 10.3109/0284186X.2014.910313
   Martorell L, 2001, NEUROLOGY, V56, P328, DOI 10.1212/WNL.56.3.328
   Matcuk GR, 2015, SKELETAL RADIOL, V44, P1027, DOI 10.1007/s00256 015 2117 5
   Qureshi SS, 2005, SKELETAL RADIOL, V34, P225, DOI 10.1007/s00256 004 0824 4
   Ruka W, 2010, INT J RADIAT ONCOL, V78, P494, DOI 10.1016/j.ijrobp.2009.07.1704
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   Theadom A, 2014, NEUROEPIDEMIOLOGY, V43, P259, DOI 10.1159/000369343
   Thomas D, 2010, LANCET ONCOL, V11, P815, DOI 10.1016/S1470 2045(10)70170 4
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Wieneke JA, 2001, MODERN PATHOL, V14, P1209, DOI 10.1038/modpathol.3880462
   Win AK, 2012, MAYO CLIN PROC, V87, P130, DOI 10.1016/j.mayocp.2011.09.005
   Wülling M, 2001, J CANCER RES CLIN, V127, P467, DOI 10.1007/s004320100234
NR 27
TC 1
Z9 2
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0973 1482
EI 1998 4138
J9 J CANCER RES THER
JI J. Canc. Res. Ther.
PD JAN MAR
PY 2022
VL 18
IS 1
BP 282
EP 285
DI 10.4103/jcrt.JCRT_205_19
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 0V1BR
UT WOS:000788081000048
PM 35381802
OA gold
DA 2025 08 17
ER

PT J
AU Hong, IS
   Lee, HY
   Choi, SW
   Kim, HS
   Yu, KR
   Seo, Y
   Jung, JW
   Kang, KS
AF Hong, In Sun
   Lee, Hwa Yong
   Choi, Soon Won
   Kim, Hyung Sik
   Yu, Kyung Rok
   Seo, Yoojin
   Jung, Ji Won
   Kang, Kyung Sun
TI The effects of hedgehog on RNA binding protein Msi1 during the
   osteogenic differentiation of human cord blood derived mesenchymal stem
   cells
SO BONE
LA English
DT Article
DE hedgehog (Hh); RNA binding Msi1; osteogenic differentiation; Wnt1;
   miR 148
ID SONIC HEDGEHOG; STROMAL CELLS; BONE MARROW; OSTEOBLAST DIFFERENTIATION;
   SIGNALING PATHWAY; PROGENITOR CELLS; GENE EXPRESSION; TISSUE REPAIR;
   MUSASHI; ACTIVATION
AB Human umbilical cord blood (UCB) derived mesenchymal stem cells (MSCs) are useful tools for regenerative medicine due to their capacity for self renewal and multi lineage differentiation. The appropriate clinical application of MSCs for regenerative medicine requires an integrated understanding of multiple signaling pathways that regulate cell proliferation, stemness and differentiation. However, the potential molecular mechanisms mediating these functions are not completely understood.
   The effects of hedgehog (Hh) signaling on the osteogenic differentiation of MSCs are still controversial, and the underlying mechanisms are unclear. In the present study, we evaluated the direct effects of Hh signaling on the osteogenic differentiation of hUCB MSCs and investigated potential downstream regulatory mechanisms responsible for Hh signaling. We observed that Hh signaling acts as a negative regulator of osteogenic differentiation through the suppression of RNA binding Msi1, which in turn suppresses the expression of Wnt1 and the miR 148 family, especially miR 148b. Moreover, Hh and Msi1 are considered to be potential stemness markers of hUCB MSCs due to their differentiation dependent expression profiles. This study provides new insights into mechanisms regulating MSC differentiation and may have implications for a variety of therapeutic applications in the clinic. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Hong, In Sun; Lee, Hwa Yong; Choi, Soon Won; Kim, Hyung Sik; Yu, Kyung Rok; Seo, Yoojin; Kang, Kyung Sun] Seoul Natl Univ, Adult Stem Cell Res Ctr, Seoul 151742, South Korea.
   [Hong, In Sun; Lee, Hwa Yong; Choi, Soon Won; Kim, Hyung Sik; Yu, Kyung Rok; Seo, Yoojin; Kang, Kyung Sun] Seoul Natl Univ, Dept Vet Publ Hlth, Lab Stem Cell & Tumor Biol, Seoul 151742, South Korea.
   [Jung, Ji Won] Natl Inst Hlth, Ctr Biomed Sci, Div Intractable Dis, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Korea
   Disease Control & Prevention Agency (KDCA); Korea National Institute of
   Health (KNIH); Korea CDC Center for Biomedical Science
RP Kang, KS (通讯作者)，Seoul Natl Univ, Coll Vet Med, Sch Med, Adult Stem Cell Res Ctr, Seoul 151742, South Korea.
EM kangpub@snu.ac.kr
RI Choi, Soon/S 3052 2017; Kim, HyungSik/NRB 0078 2025; Yu,
   Kyung Rok/AAR 6227 2021; Lee, Ho jeong/S 4934 2019; Kang,
   Kyung Sun/G 6205 2013
OI Hong, In Sun/0000 0002 3267 0127; Kang, Kyung Sun/0000 0002 9322 741X
FU Bio & Medical Technology Development Program of the National Research
   Foundation (NRF); Korean government (MEST) [2012M3A9C6049716]
FX This research was supported by the Bio & Medical Technology Development
   Program of the National Research Foundation (NRF) funded by the Korean
   government (MEST. No. 2012M3A9C6049716). The finders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript
CR Akasaka Y, 2005, HISTOPATHOLOGY, V47, P348, DOI 10.1111/j.1365 2559.2005.02223.x
   Alvarez Medina R, 2009, DEVELOPMENT, V136, P3301, DOI 10.1242/dev.041772
   Baron MH, 2001, DIFFERENTIATION, V68, P175, DOI 10.1046/j.1432 0436.2001.680405.x
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100
   Bhandari DR, 2011, DIFFERENTIATION, V82, P144, DOI 10.1016/j.diff.2011.06.003
   Blasi A, 2011, VASC CELL, V3, DOI 10.1186/2045 824X 3 5
   Brownell I, 2011, CELL STEM CELL, V8, P552, DOI 10.1016/j.stem.2011.02.021
   Cai JQ, 2012, CELL BIOL INT, V36, P349, DOI 10.1042/CBI20110284
   Chen GK, 2004, DEVELOPMENT, V131, P2619, DOI 10.1242/dev.01151
   Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044
   Copeland N, 2009, CLIN MED, V9, P342, DOI 10.7861/clinmedicine.9 4 342
   D'Ippolito G, 2006, REJUV RES, V9, P10, DOI 10.1089/rej.2006.9.10
   Gao J, 2011, J CELL BIOCHEM, V112, P1844, DOI 10.1002/jcb.23106
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glass DA, 2006, ANN NY ACAD SCI, V1068, P117, DOI 10.1196/annals.1346.015
   Goff LA, 2008, EXP HEMATOL, V36, P1354, DOI 10.1016/j.exphem.2008.05.004
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Ingham PW, 2011, NAT REV GENET, V12, P393, DOI 10.1038/nrg2984
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   James AW, 2010, TISSUE ENG PT A, V16, P2605, DOI [10.1089/ten.tea.2010.0048, 10.1089/ten.TEA.2010.0048]
   James AW, 2012, STEM CELLS DEV, V21, P2170, DOI 10.1089/scd.2011.0461
   Kaneko Y, 2000, DEV NEUROSCI BASEL, V22, P139, DOI 10.1159/000017435
   Kang KS, 2005, CYTOTHERAPY, V7, P368, DOI 10.1080/14653240500238160
   Kawahara H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199166
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim WK, 2010, J CELL BIOCHEM, V111, P1199, DOI 10.1002/jcb.22846
   Küspert M, 2012, J NEUROSCI, V32, P5472, DOI 10.1523/JNEUROSCI.5759 11.2012
   Laine SK, 2012, J CELL BIOCHEM, V113, P2687, DOI 10.1002/jcb.24144
   Liao XY, 2009, MODERN PATHOL, V22, P839, DOI 10.1038/modpathol.2009.45
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Mak SK, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/140427
   Mizuno Hiroshi, 2009, Journal of Nippon Medical School, V76, P56
   Moodley Y, 2010, AM J RESP CRIT CARE, V182, P643, DOI 10.1164/rccm.201001 0014OC
   Muto J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033431
   Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079
   Ohyama T, 2012, NUCLEIC ACIDS RES, V40, P3218, DOI 10.1093/nar/gkr1139
   Okano H, 2002, J CELL SCI, V115, P1355
   Oliveira FS, 2012, J CELL BIOCHEM, V113, P204, DOI 10.1002/jcb.23345
   Palmieri A, 2008, BIO MED MATER ENG, V18, P91, DOI 10.3233/BME 2008 0512
   Plaisant M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016798
   Plaisant M, 2009, STEM CELLS, V27, P703, DOI 10.1634/stemcells.2008 0888
   Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432 0436.2003.700603.x
   Raji B, 2007, MOL VIS, V13, P1412
   Sakakibara S, 2002, P NATL ACAD SCI USA, V99, P15194, DOI 10.1073/pnas.232087499
   Sakakibara S, 2001, J NEUROSCI, V21, P8091, DOI 10.1523/JNEUROSCI.21 20 08091.2001
   Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130
   Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004 0166
   Schoolmeesters A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005605
   Scott RE, 2002, ANTICANCER RES, V22, P3837
   Seo Y, 2011, CELL TRANSPLANT, V20, P1033, DOI 10.3727/096368910X545086
   Shindo K, 2003, EXP CELL RES, V290, P370, DOI 10.1016/S0014 4827(03)00349 5
   Sicklick JK, 2006, AM J PHYSIOL GASTR L, V290, pG859, DOI 10.1152/ajpgi.00456.2005
   Siddall NA, 2006, P NATL ACAD SCI USA, V103, P8402, DOI 10.1073/pnas.0600906103
   Sugiyama Nakagiri Y, 2006, AM J PATHOL, V168, P80, DOI 10.2353/ajpath.2006.050469
   Sun B, 2007, BIOCHEM BIOPH RES CO, V354, P919, DOI 10.1016/j.bbrc.2007.01.069
   Torroja C, 2004, DEVELOPMENT, V131, P2395, DOI 10.1242/dev.01102
   van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304
   Wu SM, 2010, STEM CELL RES, V4, P38, DOI 10.1016/j.scr.2009.09.002
   Xin HQ, 2011, J CEREBR BLOOD F MET, V31, P2181, DOI 10.1038/jcbfm.2011.116
   Zhang ZJ, 2012, J CELL BIOCHEM, V113, P888, DOI 10.1002/jcb.23418
NR 64
TC 17
Z9 19
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2013
VL 56
IS 2
BP 416
EP 425
DI 10.1016/j.bone.2013.07.016
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 210VX
UT WOS:000323864000027
PM 23880227
DA 2025 08 17
ER

PT J
AU Yun, HM
   Kim, B
   Park, JE
   Park, KR
AF Yun, Hyung Mun
   Kim, Bomi
   Park, Ji Eun
   Park, Kyung Ran
TI Trifloroside Induces Bioactive Effects on Differentiation, Adhesion,
   Migration, and Mineralization in Pre Osteoblast MC3T3E 1 Cells
SO CELLS
LA English
DT Article
DE autophagy; necroptosis; Gentianae Scabrae Radix; osteoblast
   differentiation; RUNX2; trifluoroside
ID GENTIANAE SCABRAE RADIX; STEM CELLS; SECOIRIDOID GLYCOSIDES;
   ALKALINE PHOSPHATASE; BONE FORMATION; EXPRESSION; METALLOPROTEINASE 13;
   AUTOPHAGY; ROOT
AB Gentianae Scabrae Radix is used in traditional medicine and is known to possess bioactive compounds, including secoiridoid glycosides, flavonoids, lignans, and triterpenes. Trifloroside (TriFs) is a secoiridoid glycoside known for its antioxidant activity; however, its other effects have not been studied. In the present study, we investigated the biological effects of TriFs isolated from the roots of Gentianae Scabrae Radix using pre osteoblast MC3T3E 1 cells. No cellular toxicity was observed with 1 mu M TriFs, whereas 5 100 mu M TriFs showed a gradual increase in cell viability. Alkaline phosphatase staining and microscopic observations revealed that 1 10 mu M TriFs stimulated osteogenic activity during early osteoblast differentiation. Trifloroside also increased mineral apposition during osteoblast maturation. Biochemical analyses revealed that TriFs promoted nuclear RUNX2 expression and localization by stimulating the major osteogenic BMP2 Smad1/5/8 RUNX2 pathway. Trifloroside also increased p GSK3 beta, beta catenin, p JNK, and p p38, but not Wnt3a, p AKT, and p ERK. Moreover, TriFs increased the MMP13 levels and promoted cell migration and adhesion. In contrast, TriFs induced osteoblast differentiation and maturation had negligible effects on autophagy and necrosis. Our findings suggest that TriFs induces osteogenic effects through differentiation, adhesion, migration, and mineral apposition. Therefore, TriFs is suggested as a potential drug target in osteoblast mediated bone diseases.
C1 [Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
   [Kim, Bomi; Park, Ji Eun] Natl Dev Inst Korean Med, Gyongsan 38540, South Korea.
   [Park, Kyung Ran] Korea Basic Sci Inst KBSI, Gwangju Ctr, Gwangju 61751, South Korea.
C3 Kyung Hee University; Korea Basic Science Institute (KBSI)
RP Park, KR (通讯作者)，Korea Basic Sci Inst KBSI, Gwangju Ctr, Gwangju 61751, South Korea.
EM krpark83@kbsi.re.kr
FU National Research Foundation of Korea (NRF)   Korea government (MSIT); 
   [2022R1C1C1003491]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (2022R1C1C1003491).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Bergeron C, 1997, PHYTOCHEMISTRY, V44, P633, DOI 10.1016/S0031 9422(96)00636 X
   Bernardini S, 2018, NAT PROD RES, V32, P1926, DOI 10.1080/14786419.2017.1356838
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Deng T, 2021, BMC ENDOCR DISORD, V21, DOI 10.1186/s12902 021 00715 8
   Di YY, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.100753
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   He YM, 2015, J NAT MED TOKYO, V69, P303, DOI 10.1007/s11418 015 0894 8
   Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Jiang RW, 2005, PHYTOCHEMISTRY, V66, P2674, DOI 10.1016/j.phytochem.2005.09.028
   Khotib J, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14070615
   Kim IR, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1320 9
   Kobayashi T, 2021, METHODS MOL BIOL, V2230, P3, DOI 10.1007/978 1 0716 1028 2_1
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Li Min, 2020, Zhongguo Gu Shang, V33, P933, DOI 10.12200/j.issn.1003 0034.2020.10.009
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Liang J, 2022, PEERJ, V10, DOI 10.7717/peerj.13939
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111362
   Park KR, 2021, AM J CANCER RES, V11, P4919
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136899
   Park KR, 2022, AM J CHINESE MED, V50, P295, DOI 10.1142/S0192415X22500112
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052483
   Park KR, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153347
   Park KR, 2019, ANTIOXID REDOX SIGN, V30, P1969, DOI 10.1089/ars.2018.7530
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Shalehin N, 2020, J DENT SCI, V15, P437, DOI 10.1016/j.jds.2019.09.009
   Soelaiman IN, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/764701
   Suh HW, 2015, J ETHNOPHARMACOL, V172, P219, DOI 10.1016/j.jep.2015.06.042
   Toriseva M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042596
   Uusitalo H, 2000, CALCIFIED TISSUE INT, V67, P382, DOI 10.1007/s002230001152
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Xue C, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13740
   Yamagiwa H, 1999, BONE, V25, P197, DOI 10.1016/S8756 3282(99)00157 X
   Yang EJ, 2017, J MED FOOD, V20, P951, DOI 10.1089/jmf.2017.3938
   Yang Y, 2021, J BIOMED MATER RES A, V109, P1429, DOI 10.1002/jbm.a.37134
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zaragoza C, 2006, J CELL SCI, V119, P1896, DOI 10.1242/jcs.02895
NR 48
TC 5
Z9 5
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD DEC
PY 2022
VL 11
IS 23
AR 3887
DI 10.3390/cells11233887
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 6Y9VX
UT WOS:000897434700001
PM 36497145
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Acikgoz, E
   Mukhtarova, G
   Alpay, A
   Avci, CB
   Bagca, BG
   Oktem, G
AF Acikgoz, Eda
   Mukhtarova, Gunel
   Alpay, Araz
   Avci, Cigir Biray
   Bagca, Bakiye Goker
   Oktem, Gulperi
TI Sonic hedgehog signaling is associated with resistance to zoledronic
   acid in CD133high/CD44high prostate cancer stem cells
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Cancer stem cell; Sonic hedgehog; Zoledronic acid; Drug resistance;
   Three dimensional culture
AB Cancer stem cells (CSCs) are a unique population that has been linked to drug resistance and metastasis and recurrence of prostate cancer. The sonic hedgehog (SHH) signal regulates stem cells in normal prostate epithelium by affecting cell behavior, survival, proliferation, and maintenance. Aberrant SHH pathway activation leads to an unsuitable expansion of stem cell lineages in the prostate epithelium and the transformation of prostate CSCs (PCSCs). Zoledronic acid (ZOL), one of the third generation bisphosphonates, effectively prevented bone metastasis and treated advanced prostate cancer despite androgen deprivation therapy. Despite strong evidence for the involvement of the SHH in human PCSCs survival and drug resistance, the roles of SHH in the PCSCs related resistance to ZOL remain to be fully elucidated. The present study aimed to investigate the role of the SHH pathway in ZOL resistance of PCSCs in 2D and three 3D cell culture conditions. For this purpose, we isolated CD133(high)/ CD44(high) PCSCs using a flow cytometer. Following ZOL treatment, mRNA and protein expressions of the components of the SHH signaling pathway in PCSCs and non CSCs were analyzed using qRT PCR and Immunofluorescence staining, respectively. Our finding suggested that SHH signaling may be activated by different mechanisms that lead to avoidance of the inhibition effect of ZOL. Thereby, SHH pathways may be associated with the resistance to ZOL developed by prostate CSCs. Inhibition of CSCs related SHH signaling along with ZOL treatment should be considered to achieve improvement in survival or delayed treatment failure and prevention of the CSCs related drug resistance.
C1 [Acikgoz, Eda] Van Yuzuncu Yil Univ, Fac Med, Dept Histol & Embryol, TR 65080 Van, Turkey.
   [Mukhtarova, Gunel] Ege Univ, Dept Med Genet, Med Sch, TR 35080 Izmir, Turkey.
   [Mukhtarova, Gunel] Ege Univ, Grad Sch Hlth Sci, Dept Basic Oncol, TR 35080 Izmir, Turkey.
   [Alpay, Araz] Ege Univ, Grad Sch Hlth Sci, Dept Hlth Bioinformat, TR 35080 Izmir, Turkey.
   [Avci, Cigir Biray; Bagca, Bakiye Goker] Ege Univ, Fac Med, Dept Med Biol, TR 35080 Izmir, Turkey.
   [Oktem, Gulperi] Ege Univ, Fac Med, Dept Histol & Embryol, TR 35080 Izmir, Turkey.
   [Oktem, Gulperi] Ege Univ, Inst Hlth Sci, Dept Stem Cell, TR 35080 Izmir, Turkey.
C3 Yuzuncu Yil University; Ege University; Ege University; Ege University;
   Ege University; Ege University; Ege University
RP Acikgoz, E (通讯作者)，Van Yuzuncu Yil Univ, Fac Med, Dept Histol & Embryol, TR 65080 Van, Turkey.
EM acikgozedaa@gmail.com
RI Goker Bagca, Bakiye/KBQ 4243 2024; Acikgoz, eda/W 2171 2017; oktem,
   gulperi/LZE 5121 2025; Biray Avcı, Çığır/GWV 1665 2022
OI Acikgoz, Eda/0000 0002 6772 3081; ALPAY, ARAZ/0000 0001 5680 5455;
   Mukhtarova, Gunel/0000 0003 3374 9272; 
FU Ege University Research Foundation [2016 TIP 079]
FX This work was supported by Ege University Research Foundation (Project
   no: 2016 TIP 079).
CR Acikgoz E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141090
   Bidet M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023834
   Bizzarro V, 2015, ONCOTARGET, V6, P25074, DOI 10.18632/oncotarget.4725
   Bühler H, 2016, IN VIVO, V30, P761, DOI 10.21873/invivo.10992
   Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571 019 0293 2
   Coscia M, 2010, J CELL MOL MED, V14, P2803, DOI 10.1111/j.1582 4934.2009.00926.x
   Di Vito A, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720948497
   Di Zazzo E, 2016, ONCOTARGET, V7, P193, DOI 10.18632/oncotarget.6220
   Erdogan S, 2018, BIOMED PHARMACOTHER, V107, P793, DOI 10.1016/j.biopha.2018.08.061
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   Gokalp C, 2020, MOL BIOL REP, V47, P7675, DOI 10.1007/s11033 020 05840 6
   Gonnissen A, 2013, INT J MOL SCI, V14, P13979, DOI 10.3390/ijms140713979
   Han SJ, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935 021 01853 8
   Huang PX, 2016, CELL, V166, P1176, DOI 10.1016/j.cell.2016.08.003
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140 6736(15)01037 5
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jensen C, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00033
   Jeong J, 2002, J CLIN INVEST, V110, P591, DOI 10.1172/JCI200216506
   Kamba T, 2017, INT J CLIN ONCOL, V22, P166, DOI 10.1007/s10147 016 1037 2
   Karlsson H, 2012, EXP CELL RES, V318, P1577, DOI 10.1016/j.yexcr.2012.03.026
   Kars MD, 2007, ANTICANCER RES, V27, P4031
   Kattan J, 2016, INVEST NEW DRUG, V34, P474, DOI 10.1007/s10637 016 0357 4
   KWOK TT, 1985, INT J CANCER, V35, P675, DOI 10.1002/ijc.2910350517
   Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923
   Leao R, 2017, UROL INT, V99, P125, DOI 10.1159/000455160
   Lee SH, 2013, CANCER RES, V73, DOI 10.1158/1538 7445.AM2013 3715
   Lin JF, 2011, J UROLOGY, V185, P1490, DOI 10.1016/j.juro.2010.11.045
   Liou GY, 2019, INT J BIOCHEM CELL B, V106, P1, DOI 10.1016/j.biocel.2018.10.013
   MARKER P, 2007, ONCOGENE, V25, P277, DOI DOI 10.1016/J.UROLONC.2007.02.003
   Mei WJ, 2019, CANCERS, V11, DOI 10.3390/cancers11040434
   Merseburger AS, 2013, ONCOLOGIST, V18, P558, DOI 10.1634/theoncologist.2012 0478
   Milone MR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.165
   Morii T, 2010, ANTICANCER RES, V30, P3565
   Ni J, 2014, CURR CANCER DRUG TAR, V14, P225, DOI 10.2174/1568009614666140328152459
   Niyaz M, 2019, TRANSL ONCOL, V12, P1334, DOI 10.1016/j.tranon.2019.07.004
   Park SH, 2019, THERANOSTICS, V9, P2235, DOI 10.7150/thno.30678
   Perry CM, 2004, DRUGS, V64, P1197, DOI 10.2165/00003495 200464110 00004
   Ray A, 2011, INT J ONCOL, V39, P797, DOI 10.3892/ijo.2011.1093
   Regan JL, 2017, CELL REP, V21, P2813, DOI 10.1016/j.celrep.2017.11.025
   Riedl A, 2017, J CELL SCI, V130, P203, DOI 10.1242/jcs.188102
   Riobo NA, 2012, CURR OPIN PHARMACOL, V12, P736, DOI 10.1016/j.coph.2012.07.002
   Rouhrazi H, 2018, BIOTECH HISTOCHEM, V93, P77, DOI 10.1080/10520295.2017.1387286
   Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101
   Sari IN, 2018, CELLS BASEL, V7, DOI 10.3390/cells7110208
   Seshacharyulu P, 2019, ONCOGENE, V38, P5265, DOI 10.1038/s41388 019 0791 9
   Sims Mourtada J, 2007, ONCOGENE, V26, P5674, DOI 10.1038/sj.onc.1210356
   Singh S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040021
   Skoda AM, 2018, BOSNIAN J BASIC MED, V18, P8, DOI 10.17305/bjbms.2018.2756
   Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470 2045(15)00489 1
   Wang GC, 2012, DISCOV MED, V13, P135
   Wang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1109 z
   Wilson C, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1066 7
NR 52
TC 18
Z9 20
U1 0
U2 52
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 4851
EI 1573 4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD APR
PY 2021
VL 48
IS 4
BP 3567
EP 3578
DI 10.1007/s11033 021 06387 w
EA MAY 2021
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA SM1SG
UT WOS:000647013800002
PM 33948856
DA 2025 08 17
ER

PT J
AU Li, BE
   Lee, WC
   Song, C
   Ye, L
   Abel, ED
   Long, FX
AF Li, Boer
   Lee, Wen Chih
   Song, Chao
   Ye, Ling
   Abel, E. Dale
   Long, Fanxin
TI Both aerobic glycolysis and mitochondrial respiration are required for
   osteoclast differentiation
SO FASEB JOURNAL
LA English
DT Article
DE aerobic glycolysis; bone; metabolism; osteoclast; oxidative
   phosphorylation
ID BONE RESORPTION; BIOGENESIS
AB Excessive bone resorption over bone formation is the root cause for bone loss leading to osteoporotic fractures. Development of new antiresorptive therapies calls for a holistic understanding of osteoclast differentiation and function. Although much has been learned about the molecular regulation of osteoclast biology, little is known about the metabolic requirement and bioenergetics during osteoclastogenesis. Here, we report that glucose metabolism through oxidative phosphorylation (OXPHOS) is the predominant bioenergetic pathway to support osteoclast differentiation. Meanwhile, increased lactate production from glucose, known as aerobic glycolysis when oxygen is abundant, is also critical for osteoclastogenesis. Genetic deletion of Glut1 in osteoclast progenitors reduces aerobic glycolysis without compromising OXPHOS, but nonetheless diminishes osteoclast differentiation in vitro. Glut1 deficiency in the progenitors leads to osteopetrosis due to fewer osteoclasts specifically in the female mice. Thus, Glut1 mediated glucose metabolism through both lactate production and OXPHOS is necessary for normal osteoclastogenesis.
C1 [Li, Boer; Ye, Ling] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Li, Boer; Lee, Wen Chih; Long, Fanxin] Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO USA.
   [Lee, Wen Chih; Song, Chao; Long, Fanxin] Childrens Hosp Philadelphia, Translat Res Program Pediat Orthopaed, Philadelphia, PA 19104 USA.
   [Abel, E. Dale] Univ Iowa, Carver Coll Med, Div Endocrinol & Metab, Fraternal Order Eagles Diabet Res Ctr, Iowa City, IA USA.
   [Long, Fanxin] Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
C3 Sichuan University; Washington University (WUSTL); University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   University of Iowa; University of Pennsylvania
RP Long, FX (通讯作者)，Childrens Hosp Philadelphia, Translat Res Program Pediat Orthopaed, Philadelphia, PA 19104 USA.
EM longf1@email.chop.edu
RI ; ye, ling/AFP 0048 2022
OI Abel, E. Dale/0000 0001 5290 0738; CHAO, SONG/0000 0002 1209 1056; 
FU China Scholarship Council [201506240134]; NIH [R01 DK111212, P30
   AR057235]; Washington University Musculoskeletal Research Center
FX China Scholarship Council, Grant/Award Number: 201506240134; NIH,
   Grant/Award Number: R01 DK111212 and P30 AR057235; Washington University
   Musculoskeletal Research Center
CR Ahn H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153886
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Arnett TR, 2018, BONE, V115, P25, DOI 10.1016/j.bone.2017.12.021
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011
   Karner CM, 2018, BONE, V115, P2, DOI 10.1016/j.bone.2017.08.008
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Mai V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020647
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Ramchand SK, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00505
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Williams JP, 1997, BIOCHEM BIOPH RES CO, V235, P646, DOI 10.1006/bbrc.1997.6795
   Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584
   Zhang Y, 2018, J BONE MINER RES, V33, P1114, DOI 10.1002/jbmr.3398
NR 21
TC 67
Z9 76
U1 1
U2 88
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2020
VL 34
IS 8
BP 11058
EP 11067
DI 10.1096/fj.202000771R
EA JUL 2020
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA NE3EW
UT WOS:000547605500001
PM 32627870
DA 2025 08 17
ER

PT J
AU Hao, XQ
   Zhang, XW
   Hu, Y
   Ren, CX
   Liu, CW
   Wang, L
   Zhou, YJ
   Wang, SS
   Luo, HY
   Yan, GX
   Wang, X
   Wang, XM
   Ren, FL
   Shi, C
   Song, WL
   Sun, HC
AF Hao, Xinqing
   Zhang, Xuewei
   Hu, Yue
   Ren, Chunxia
   Liu, Cangwei
   Wang, Lu
   Zhou, Yijun
   Wang, Shuangshuang
   Luo, Huanyu
   Yan, Guangxing
   Wang, Xiao
   Wang, Xiaomeng
   Ren, Feilong
   Shi, Ce
   Song, Wenlong
   Sun, Hongchen
TI Brasenia inspired hydrogel with sustained and sequential release of BMP
   and WNT activators for improved bone regeneration
SO CHINESE CHEMICAL LETTERS
LA English
DT Article
DE Bone regeneration; FK506; BIO; Heterogeneous hydrogels; Osteogenic
   differentiation
ID OSTEOBLASTIC DIFFERENTIATION; CHITOSAN NANOPARTICLES; TISSUE; DELIVERY;
   SCAFFOLD; FK506; VEGF; MASS
AB Although bone morphogenetic protein (BMP) and WNT signaling play pivotal roles in bone development, homeostasis, and regeneration, the applications of proteins to stimulate corresponding signaling pathways showed limited outcomes in the repair and regeneration of bone defects that might be attributed to the reciprocal interventions of these pathways. In order to satisfy the combinational and sequential activation of BMP and WNT pathways, inspired by the heterogeneous hydrogel liked structures of Brasenia, hetero geneous alginate/chitosan hydrogels were fabricated and spatially loaded with FK506 and BIO to achieve sustained and sequential release of the activators. Alkaline phosphatase staining, alizarin red staining and qRT PCR results suggested that FK506 and BIO enhanced osteoblastic differentiation in vitro when used separately. Besides, by mixing and matching the activators and the hydrogel layers, a superior releasing mode that a combination of early FK506 release and following BIO release was identified via both in vitro and in vivo explorations for most efficient bone regeneration. These results suggested that drug loaded heterogeneous hydrogels possess great potentials in treating bone loss defects for future clinical practice.(c) 2023 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.
C1 [Hao, Xinqing; Ren, Chunxia; Wang, Lu; Luo, Huanyu; Yan, Guangxing; Wang, Xiao; Wang, Xiaomeng; Ren, Feilong; Shi, Ce; Sun, Hongchen] Jilin Univ, Hosp Stomatol, Changchun 130021, Peoples R China.
   [Zhang, Xuewei] Hainan Univ, Sch Mat Sci & Engn, Haikou 570228, Peoples R China.
   [Zhang, Xuewei; Song, Wenlong] Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
   [Hu, Yue; Liu, Cangwei; Zhou, Yijun; Wang, Shuangshuang] China Med Univ, Sch Stomatol, Shenyang 110001, Peoples R China.
   [Luo, Huanyu; Yan, Guangxing; Wang, Xiao; Wang, Xiaomeng; Ren, Feilong; Shi, Ce; Sun, Hongchen] Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Peoples R China.
C3 Jilin University; Hainan University; Jilin University; China Medical
   University
RP Shi, C; Sun, HC (通讯作者)，Jilin Univ, Hosp Stomatol, Changchun 130021, Peoples R China.; Song, WL (通讯作者)，Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.; Shi, C; Sun, HC (通讯作者)，Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Peoples R China.
EM ceshi@jlu.edu.cn; songwenlong@jlu.edu.cn; hcsun@jlu.edu.cn
RI zhou, yijun/JMP 2684 2023; Wang, Xiaomeng/F 9504 2015; Sun,
   Hongchen/X 7152 2019; Song, Wenlong/C 2799 2013
FU National Natural Science Foun  dation of China [81970903, 81920108012];
   Fundamental Research Funds for the Central Universities; Jilin
   Provincial Science & Technology Department [20200201527JC]; Jilin
   Department of Health [2019Q013]; Department of Finance of Jilin Province
   [JCSZ2019378 6]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 81970903 and 81920108012) , Fundamental Research Funds for
   the Central Universities, Jilin Provincial Science & Technology
   Department (No. 20200201527JC), Jilin Department of Health (No.
   2019Q013) , and Department of Finance of Jilin Province (No.
   JCSZ2019378 6).
CR Annett S, 2020, PHARMACOL THERAPEUT, V215, DOI 10.1016/j.pharmthera.2020.107623
   Cheng PF, 2016, BIOMATERIALS, V81, P14, DOI 10.1016/j.biomaterials.2015.12.005
   Chim H, 2012, CELL TISSUE RES, V350, P89, DOI 10.1007/s00441 012 1449 x
   Darcy A, 2012, BONE, V50, P1294, DOI 10.1016/j.bone.2012.03.001
   Feng SM, 2019, INT J BIOL MACROMOL, V135, P141, DOI 10.1016/j.ijbiomac.2019.05.129
   Fu BF, 2022, CHINESE CHEM LETT, V33, P4577, DOI 10.1016/j.cclet.2022.03.048
   Fuji T, 2009, TISSUE ENG PT A, V15, P3525, DOI [10.1089/ten.tea.2009.0048, 10.1089/ten.TEA.2009.0048]
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Itasaki N, 2010, DEV DYNAM, V239, P16, DOI 10.1002/dvdy.22009
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Kim Hyunsook, 2015, J Tradit Complement Med, V5, P56, DOI 10.1016/j.jtcme.2014.10.003
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Kugimiya F, 2005, BIOCHEM BIOPH RES CO, V338, P872, DOI 10.1016/j.bbrc.2005.10.024
   Lee M, 2009, BIOMATERIALS, V30, P6094, DOI 10.1016/j.biomaterials.2009.07.046
   Leena R.S., 2017, BIOINTERFACES, V158, P308
   Li H, 2017, J BIOMED MATER RES A, V105, P265, DOI 10.1002/jbm.a.35900
   Liu ZY, 2006, J BIOL CHEM, V281, P17156, DOI 10.1074/jbc.M513812200
   Lopes D, 2018, BIOMATERIALS, V185, P240, DOI 10.1016/j.biomaterials.2018.09.028
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Martino MM, 2014, SCIENCE, V343, P885, DOI 10.1126/science.1247663
   Nie L, 2019, J BIOMAT SCI POLYM E, V30, P1636, DOI 10.1080/09205063.2019.1654210
   Ranganathan S, 2019, INT J BIOL MACROMOL, V133, P354, DOI 10.1016/j.ijbiomac.2019.04.115
   Santos LF, 2018, EUR J PHARM SCI, V118, P49, DOI 10.1016/j.ejps.2018.03.020
   Scarpa E, 2018, NANOMED NANOTECHNOL, V14, P1267, DOI 10.1016/j.nano.2018.02.014
   Shi C, 2016, SCI REP UK, V6, DOI 10.1038/srep24256
   Song DY, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 90324 1
   Stewart E, 2014, CELL REP, V9, P829, DOI 10.1016/j.celrep.2014.09.028
   Tang L, 2002, CELL BIOL INT, V26, P75, DOI 10.1006/cbir.2001.0812
   Venkatesan J, 2015, INT J BIOL MACROMOL, V72, P269, DOI 10.1016/j.ijbiomac.2014.07.008
   Vicenti F, 2002, TRANSPLANTATION, V73, P775, DOI 10.1097/00007890 200203150 00021
   Vlacic Zischke J, 2011, BIOMATERIALS, V32, P665, DOI 10.1016/j.biomaterials.2010.09.025
   Wang LL, 2022, CHINESE CHEM LETT, V33, P1956, DOI 10.1016/j.cclet.2021.10.070
   Wang L, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00132 6
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Xie WB, 2022, CHINESE CHEM LETT, V33, P1951, DOI 10.1016/j.cclet.2021.11.058
   Yaszemski MJ, 1996, BIOMATERIALS, V17, P175, DOI 10.1016/0142 9612(96)85762 0
   Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968
   Zhang WJ, 2014, EUR CELLS MATER, V27, P1
NR 39
TC 12
Z9 17
U1 4
U2 48
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1001 8417
EI 1878 5964
J9 CHINESE CHEM LETT
JI Chin. Chem. Lett.
PD JUL
PY 2023
VL 34
IS 7
AR 107965
DI 10.1016/j.cclet.2022.107965
EA APR 2023
PG 7
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA H3MG7
UT WOS:000995035600001
DA 2025 08 17
ER

PT J
AU Fontani, F
   Marcucci, G
   Iantomasi, T
   Brandi, ML
   Vincenzini, MT
AF Fontani, Filippo
   Marcucci, Gemma
   Iantomasi, Teresa
   Brandi, Maria Luisa
   Vincenzini, Maria Teresa
TI Glutathione, N acetylcysteine and Lipoic Acid Down Regulate
   Starvation Induced Apoptosis, RANKL/OPG Ratio and Sclerostin in
   Osteocytes: Involvement of JNK and ERK1/2 Signalling
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Osteocytes; Antioxidants; Apoptosis; Bone remodelling
ID MARROW STROMAL CELLS; BONE MINERAL DENSITY; FATIGUE IN VIVO; OXIDATIVE
   STRESS; OSTEOBLASTIC DIFFERENTIATION; HYDROGEN PEROXIDE; KAPPA B;
   EXPRESSION; SUPPLEMENTATION; RECRUITMENT
AB Osteocyte apoptosis due to microdamage and/or oxidative stress is related to increased local bone turnover and resorption observed in various bone diseases. Previous data on osteoblasts and osteoclasts have linked reactive oxygen species and antioxidants to bone remodelling. This study performs a comprehensive analysis on the effect of antioxidants such as glutathione (GSH), N acetylcysteine and lipoic acid (LA) on starvation induced osteocyte apoptosis and on cytokines involved in bone remodelling such as the receptor activator kB ligand (RANKL), osteoprotegerin (OPG) and sclerostin. For this study, apoptosis was induced by serum starvation in a murine osteocyte like cell line MLO Y4; this condition mimics in part osteocyte apoptosis due to microdamage. The results show that starvation induced apoptosis and expression of RANKL, OPG and sclerostin are redox regulated processes. All antioxidants are able to inhibit the apoptosis due to starvation. They down regulate the expression and the release of RANKL, the expression of sclerostin and RANKL/OPG ratio, whereas they only in part up regulate OPG expression. Antioxidants mediate their effect on starvation induced apoptosis by JNK signalling and on cytokine expression by both JNK and ERK1/2 activities. This study shows the possible involvement of biological antioxidants such as GSH and LA on redox regulated mechanisms related to apoptosis and expression of cytokines involved in bone remodelling. Moreover, it suggests that both JNK and ERK1/2 may be useful biological targets for drugs affecting bone diseases associated with increased oxidative stress.
C1 [Fontani, Filippo; Iantomasi, Teresa; Vincenzini, Maria Teresa] Univ Florence, Dept Biomed Expt & Clin Sci, I 50134 Florence, Italy.
   [Marcucci, Gemma; Brandi, Maria Luisa] Univ Florence, Dept Surg & Translat Med, Bone Metab Dis Unit, I 50139 Florence, Italy.
C3 University of Florence; University of Florence
RP Vincenzini, MT (通讯作者)，Univ Florence, Dept Biomed Expt & Clin Sci, Viale Morgagni 50, I 50134 Florence, Italy.
EM vincenzini@unifi.it
RI Marcucci, Gemma/K 5205 2016
OI Marcucci, Gemma/0000 0003 0579 0542; brandi, maria
   luisa/0000 0002 8741 0592
FU Ministero dell'Istruzione, dell'Universita e della Ricerca; Fondazione
   Cassa di Risparmio di Firenze
FX We would like to thank Dr. Lynda Bonewald for the MLO Y4 cells and the
   careful reading and review of the manuscript. This study was supported
   by grants from the Ministero dell'Istruzione, dell'Universita e della
   Ricerca and Fondazione Cassa di Risparmio di Firenze.
CR Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Al Dujaili SA, 2011, J CELL BIOCHEM, V112, P2412, DOI 10.1002/jcb.23164
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Bakker A, 2004, BIOCHEM BIOPH RES CO, V320, P1163, DOI 10.1016/j.bbrc.2004.06.056
   Ballatori N, 2009, BIOL CHEM, V390, P191, DOI 10.1515/BC.2009.033
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bjelakovic G, 2007, J Basic Clin Physiol Pharmacol, V18, P115
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Byun CH, 2005, J BONE MINER RES, V20, P1125, DOI 10.1359/JBMR.050302
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Circu ML, 2012, BBA MOL CELL RES, V1823, P1767, DOI 10.1016/j.bbamcr.2012.06.019
   Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Hall SL, 1998, CALCIFIED TISSUE INT, V63, P183, DOI 10.1007/s002239900512
   Hedgecock NL, 2007, BONE, V40, P627, DOI 10.1016/j.bone.2006.10.006
   Henriksen K, 2009, BONE, V44, P1026, DOI 10.1016/j.bone.2009.03.671
   Jilka RL, 2013, BONE, V54, P264, DOI 10.1016/j.bone.2012.11.038
   Jun JH, 2008, J CELL BIOCHEM, V103, P1246, DOI 10.1002/jcb.21508
   Kalajzic I, 2013, BONE, V54, P296, DOI 10.1016/j.bone.2012.09.040
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kennedy OD, 2014, BONE, V64, P132, DOI 10.1016/j.bone.2014.03.049
   Kikuyama A, 2002, CALCIFIED TISSUE INT, V71, P243, DOI 10.1007/s00223 001 1110 2
   Kogianni G, 2004, LIFE SCI, V75, P2879, DOI 10.1016/j.lfs.2004.04.048
   Koh JM, 2005, J ENDOCRINOL, V185, P401, DOI 10.1677/joe.1.05995
   Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004 1021
   Mainini G, 2012, CLIN EXP OBSTET GYN, V39, P489
   Mulcahy LE, 2011, BONE, V48, P182, DOI 10.1016/j.bone.2010.09.014
   Nicks KM, 2012, J BONE MINER RES, V27, P637, DOI 10.1002/jbmr.1468
   Noble Brendon, 2005, European Journal of Morphology, V42, P91, DOI 10.1080/09243860500096248
   Papanicolaou SE, 2009, BIORHEOLOGY, V46, P389, DOI 10.3233/BIR 2009 0550
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Rochefort GY, 2010, OSTEOPOROSIS INT, V21, P1457, DOI 10.1007/s00198 010 1194 5
   Romagnoli C, 2013, FEBS J, V280, P867, DOI 10.1111/febs.12075
   Sanders KM, 2007, TRANSL RES, V150, P215, DOI 10.1016/j.trsl.2007.03.012
   Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005
   Tami AE, 2002, J BONE MINER RES, V17, P2030, DOI 10.1359/jbmr.2002.17.11.2030
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Yan WL, 2013, INT J CARDIOL, V167, P602, DOI 10.1016/j.ijcard.2012.09.232
   Yang WC, 2009, BONE, V44, P32, DOI 10.1016/j.bone.2008.08.133
NR 43
TC 72
Z9 80
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD APR
PY 2015
VL 96
IS 4
BP 335
EP 346
DI 10.1007/s00223 015 9961 0
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CD6KS
UT WOS:000351198600008
PM 25660312
DA 2025 08 17
ER

PT J
AU Middlemiss, T
   Laird, BJA
   Fallon, MT
AF Middlemiss, T.
   Laird, B. J. A.
   Fallon, M. T.
TI Mechanisms of Cancer induced Bone Pain
SO CLINICAL ONCOLOGY
LA English
DT Article
DE Bone pain; cancer; nociception; OPG; RANK
ID RAT MODEL; SPINAL CORD; NEURONAL RESPONSES; BREAKTHROUGH PAIN; SKELETAL
   PAIN; MANAGEMENT; PATHOPHYSIOLOGY; MORPHINE; RECEPTOR; MARKERS
AB Cancer induced bone pain (CIBP) is common and challenging to treat. Common therapies, such as opioids, radiotherapy and bisphosphonates, are often only partially effective. CIBP is a different entity to inflammatory or neuropathic pain and needs to be considered as such. This overview examines the mechanisms of CIBP; the imbalance of bone turnover, peripheral and central nervous involvement and key neurochemical mediators. The current understanding of the underlying pathophysiology of CIBP is discussed. (C) 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
C1 [Middlemiss, T.; Laird, B. J. A.; Fallon, M. T.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
   [Middlemiss, T.] St Andrews Hosp, Airdrie, Scotland.
C3 University of Edinburgh
RP Middlemiss, T (通讯作者)，Western Gen Hosp, Edinburgh Canc Res Ctr CRUK, Crewe Rd S, Edinburgh EH4 2XR, Midlothian, Scotland.
EM tommiddlemiss@hotmail.com
OI Fallon, Marie/0000 0001 9214 0091
CR [Anonymous], WHAT IS KEY QUESTION
   Bailey F, 2006, CANC RELATED BREAKTH, P43
   BANNING A, 1991, PAIN, V45, P45, DOI 10.1016/0304 3959(91)90163 R
   Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Chow E, 2007, CLIN ONCOL UK, V19, pS26, DOI 10.1016/j.clon.2007.01.347
   Clohisy DR, 1996, J ORTHOPAED RES, V14, P2, DOI 10.1002/jor.1100140103
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Colvin L, 2008, EUR J CANCER, V44, P1083, DOI 10.1016/j.ejca.2008.03.001
   de Wit R, 2001, PAIN, V91, P339, DOI 10.1016/S0304 3959(00)00455 3
   Donovan Rodriguez T, 2006, NEUROSCI LETT, V393, P237, DOI 10.1016/j.neulet.2005.09.073
   Donovan Rodriguez T, 2005, ANESTHESIOLOGY, V102, P132, DOI 10.1097/00000542 200501000 00022
   Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165 3806(01)00303 0
   Garnero P, 2000, BRIT J CANCER, V82, P858, DOI 10.1054/bjoc.1999.1012
   Gordon Williams Richard M, 2007, Curr Opin Support Palliat Care, V1, P6, DOI 10.1097/SPC.0b013e328133f5e9
   Grond S, 1996, PAIN, V64, P107, DOI 10.1016/0304 3959(95)00076 3
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306 4522(00)00110 X
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Honore P, 2000, Prog Brain Res, V129, P389
   Lassiter LK, 2003, SEMIN ONCOL, V30, P678, DOI 10.1016/S0093 7754(03)00353 1
   Luger NM, 2001, CANCER RES, V61, P4038
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304 3959(02)00102 1
   Mach DB, 2002, NEUROSCIENCE, V113, P155, DOI 10.1016/S0306 4522(02)00165 3
   MANTYH PW, 1995, P NATL ACAD SCI USA, V92, P2622, DOI 10.1073/pnas.92.7.2622
   MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937
   Martin CD, 2007, NEUROSCI LETT, V427, P148, DOI 10.1016/j.neulet.2007.08.055
   Matthews EA, 2002, ANESTHESIOLOGY, V96, P633, DOI 10.1097/00000542 200203000 00020
   Mcquay H.J., 2013, Cochrane Database Syst Rev., DOI [DOI 10.1002/14651858.CD001793, 10.1002/14651858.CD001793.PUB2]
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305 7372(98)90005 6
   Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304 3959(01)00324 4
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Neville Webbe HL, 2003, PALLIATIVE MED, V17, P539, DOI 10.1191/0269216303pm800ra
   NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509
   OSTER MW, 1978, ARCH INTERN MED, V138, P1801, DOI 10.1001/archinte.138.12.1801
   Payne R, 1997, CANCER, V80, P1608, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1608::AID CNCR11>3.0.CO;2 3
   Portenoy R.K., 2004, Oxford textbook of palliative medicine, V3rd, P438
   Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304 3959(99)00006 8
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140 6736(99)01310 0
   ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204
   Rustoen T, 2005, J PAIN SYMPTOM MANAG, V30, P234, DOI 10.1016/j.jpainsymman.2005.04.002
   Sabino M. C., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P561
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Sabino Mary Ann C, 2005, J Support Oncol, V3, P15
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Seibel MJ, 2005, NAT CLIN PRACT ONCOL, V2, P504, DOI 10.1038/ncponc0320
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Suzuki R, 2002, NAT NEUROSCI, V5, P1319, DOI 10.1038/nn966
   TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304 3959(82)90137 3
   Urch C, 2004, PALLIATIVE MED, V18, P267, DOI 10.1191/0269216304pm887ra
   Urch CE, 2005, J PAIN, V6, P837, DOI 10.1016/j.jpain.2005.08.005
   Urch CE, 2003, PAIN, V106, P347, DOI 10.1016/j.pain.2003.08.002
   Vega JA, 2003, J ANAT, V203, P1, DOI 10.1046/j.1469 7580.2003.00203.x
   Wong R, 2002, Cochrane Database Syst Rev, pCD002068
NR 56
TC 72
Z9 83
U1 1
U2 11
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0936 6555
EI 1433 2981
J9 CLIN ONCOL UK
JI Clin. Oncol.
PD AUG
PY 2011
VL 23
IS 6
SI SI
BP 387
EP 392
DI 10.1016/j.clon.2011.03.003
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 797DE
UT WOS:000293103900003
PM 21683564
DA 2025 08 17
ER

PT J
AU Qiu, ZC
   Dong, XL
   Dai, Y
   Xiao, GK
   Wang, XL
   Wong, KC
   Wong, MS
   Yao, XS
AF Qiu, Zuo Cheng
   Dong, Xiao Li
   Dai, Yi
   Xiao, Gao Keng
   Wang, Xin Luan
   Wong, Ka Chun
   Wong, Man Sau
   Yao, Xin Sheng
TI Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma
   Drynariae as Potential Candidates for the Treatment of Osteoporosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE in silico target fishing; osteoporosis; Cathepsin K; Rhizoma Drynariae;
   Kushennol F; Sophoraflavanone G; RAW264.7 cells; osteoclasts; bone
   resorption
ID ESTROGEN RECEPTOR ALPHA; BONE RESORPTION; OSTEOPROTECTIVE FRACTION;
   LIGAND; IDENTIFICATION; CELLS; DIFFERENTIATION; PROLIFERATION;
   PHARMACOLOGY; FLAVONOIDS
AB Rhizoma Drynariae (RD), as one of the most common clinically used folk medicines, has been reported to exert potent anti osteoporotic activity. The bioactive ingredients and mechanisms that account for its bone protective effects are under active investigation. Here we adopt a novel in silico target fishing method to reveal the target profile of RD. Cathepsin K (Ctsk) is one of the cysteine proteases that is over expressed in osteoclasts and accounts for the increase in bone resorption in metabolic bone disorders such as postmenopausal osteoporosis. It has been the focus of target based drug discovery in recent years. We have identified two components in RD, Kushennol F and Sophoraflavanone G, that can potentially interact with Ctsk. Biological studies were performed to verify the effects of these compounds on Ctsk and its related bone resorption process, which include the use of in vitro fluorescence based Ctsk enzyme assay, bone resorption pit formation assay, as well as Receptor Activator of Nuclear factor kappa B (NF kappa B) ligand (RANKL) induced osteoclastogenesis using murine RAW264.7 cells. Finally, the binding mode and stability of these two compounds that interact with Ctsk were determined by molecular docking and dynamics methods. The results showed that the in silico target fishing method could successfully identify two components from RD that show inhibitory effects on the bone resorption process related to protease Ctsk.
C1 [Qiu, Zuo Cheng; Dai, Yi; Xiao, Gao Keng; Yao, Xin Sheng] Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China.
   [Dong, Xiao Li; Wong, Ka Chun; Wong, Man Sau] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
   [Dong, Xiao Li] Shenzhen Key Lab Food Biol Safety Control, Shenzhen 518057, Peoples R China.
   [Wang, Xin Luan] Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Hlth Engn, Translat Med R&D Ctr, Shenzhen 518000, Peoples R China.
   [Wong, Man Sau] State Key Lab Chinese Med & Mol Pharmacol Incubat, Shenzhen 518057, Peoples R China.
C3 Jinan University; Hong Kong Polytechnic University; Chinese Academy of
   Sciences; Shenzhen Institute of Advanced Technology, CAS
RP Yao, XS (通讯作者)，Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China.; Wong, MS (通讯作者)，Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.; Wong, MS (通讯作者)，State Key Lab Chinese Med & Mol Pharmacol Incubat, Shenzhen 518057, Peoples R China.
EM qiu666@stu2014.jnu.edu.cn; bcxldong@polyu.edu.hk; daiyi1004@163.com;
   xiaogk@yaolab.org; xl.wang@siat.ac.cn; aguesses@yahoo.com.hk;
   bcmswong@polyu.edu.hk; tyaoxs@jnu.edu.cn
RI ; Dai, Yi/AAC 1336 2019; Wong, Man Sau/F 2059 2015; Dong,
   Xiaoli/ACK 2017 2022
OI Qiu, Zuo cheng/0000 0002 9161 5435; Wong, Man Sau/0000 0002 0729 8618;
   DONG, XIAOLI/0000 0002 7372 0450; 
FU Shenzhen Key Laboratory of Food Biological Safety; State Key Laboratory
   of Chinese Medicine and Molecular Pharmacology (Incubation); National
   Natural Science Foundation of China [81220108028]; Shenzhen Basic
   Research Program [JCYJ20140819153305697, JCYJ20140819153305696];
   National Major Scientific and Program of Introducing Talents of
   Discipline to Universities [B13038]
FX We thank the Shenzhen Key Laboratory of Food Biological Safety and the
   State Key Laboratory of Chinese Medicine and Molecular Pharmacology
   (Incubation) for their support. This work was supported by National
   Natural Science Foundation of China (81220108028), Shenzhen Basic
   Research Program (JCYJ20140819153305697, JCYJ20140819153305696) as well
   as the National Major Scientific and Program of Introducing Talents of
   Discipline to Universities (B13038).
CR Antolín AA, 2012, ACS CHEM BIOL, V7, P1962, DOI 10.1021/cb300317y
   Appelman Dijkstra NM, 2015, DRUGS, V75, P1049, DOI 10.1007/s40265 015 0417 7
   Boonen S, 2012, CURR OSTEOPOROS REP, V10, P73, DOI 10.1007/s11914 011 0085 9
   Boran ADW, 2010, CURR OPIN DRUG DISC, V13, P297
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Cereto Massagué A, 2015, METHODS, V71, P98, DOI 10.1016/j.ymeth.2014.09.006
   Chen LL, 2011, ARCH ORAL BIOL, V56, P1655, DOI 10.1016/j.archoralbio.2011.06.008
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Duong LT, 2016, CALCIFIED TISSUE INT, V98, P381, DOI 10.1007/s00223 015 0051 0
   Eastell R, 2011, J BONE MINER RES, V26, P1303, DOI 10.1002/jbmr.341
   Engin HB, 2014, CURR PHARM DESIGN, V20, P1201, DOI 10.2174/13816128113199990066
   Fonovic M, 2014, PROTEOM CLIN APPL, V8, P416, DOI 10.1002/prca.201300085
   [高颖 GAO Ying], 2008, [中国药物化学杂志, Chinese Journal of Medicinal Chemistry], V18, P284
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Guo DY, 2011, J ETHNOPHARMACOL, V138, P451, DOI 10.1016/j.jep.2011.09.034
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Jenkins J. L., 2006, Drug Discov. Today Technol, V3, P413, DOI [10.1016/j.ddtec.2006.12.008. 5.2, DOI 10.1016/J.DDTEC.2006.12.008.5.2, 10.1016/j.ddtec.2006.12.008, DOI 10.1016/J.DDTEC.2006.12.008]
   Jeong JC, 2005, PHARMACOL RES, V51, P125, DOI 10.1016/j.phrs.2004.06.005
   Jeong JC, 2004, TOXICOL IN VITRO, V18, P829, DOI 10.1016/j.tiv.2004.05.002
   Jeong JC, 2003, INT IMMUNOPHARMACOL, V3, P1685, DOI 10.1016/j.intimp.2003.08.003
   Jerome C, 2011, OSTEOPOROSIS INT, V22, P3001, DOI 10.1007/s00198 011 1529 x
   Komm BS, 2012, MATURITAS, V71, P221, DOI 10.1016/j.maturitas.2011.11.018
   Koutsoukas A, 2011, J PROTEOMICS, V74, P2554, DOI 10.1016/j.jprot.2011.05.011
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Li CS, 2006, BIOORG MED CHEM LETT, V16, P1985, DOI 10.1016/j.bmcl.2005.12.071
   Lim SH, 2011, PHYTOMEDICINE, V18, P425, DOI 10.1016/j.phymed.2011.02.002
   Lindberg MK, 2001, J ENDOCRINOL, V171, P425, DOI 10.1677/joe.0.1710425
   Lounkine E, 2012, NATURE, V486, P361, DOI 10.1038/nature11159
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Mestres J, 2006, J CHEM INF MODEL, V46, P2725, DOI 10.1021/ci600300k
   Montolio M, 2012, J MED CHEM, V55, P9838, DOI 10.1021/jm301055g
   Mukwaya E, 2014, PHARM BIOL, V52, P1223, DOI 10.3109/13880209.2014.884606
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Muller P, 2006, J MED CHEM, V49, P6768, DOI 10.1021/jm0606589
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nomura T, 2002, PURE APPL CHEM, V74, P1199, DOI 10.1351/pac200274071199
   Park J, 2012, BIOMOL THER, V20, P183, DOI 10.4062/biomolther.2012.20.2.183
   Patil AD, 2002, J NAT PROD, V65, P624, DOI 10.1021/np0105634
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sharma V, 2015, BIOCHEM J, V465, P163, DOI 10.1042/BJ20140809
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Spitzmüller A, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003257
   Stoch SA, 2013, BRIT J CLIN PHARMACO, V75, P1240, DOI 10.1111/j.1365 2125.2012.04471.x
   Sun JS, 2002, BIOMATERIALS, V23, P3377, DOI 10.1016/S0142 9612(02)00038 8
   Vidal D, 2011, METHODS MOL BIOL, V672, P489, DOI 10.1007/978 1 60761 839 3_19
   Vidal D, 2010, MOL INFORM, V29, P543, DOI 10.1002/minf.201000055
   Wang XL, 2008, CHEM PHARM BULL, V56, P46, DOI 10.1248/cpb.56.46
   Wang XL, 2010, NAT PROD RES, V24, P1206, DOI 10.1080/14786410902991860
   Wang XL, 2011, PHYTOMEDICINE, V18, P868, DOI 10.1016/j.phymed.2011.01.022
   Wang Z, 2013, EVID BASED COMPLEMEN, V2013
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005
   Wu Xin an, 2005, Zhongguo Zhongyao Zazhi, V30, P443
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
   [赵平 Zhao Ping], 2004, [天然产物研究与开发, Natural Product R & D], V16, P172
NR 55
TC 22
Z9 24
U1 0
U2 36
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2016
VL 17
IS 12
AR 2116
DI 10.3390/ijms17122116
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EI1XR
UT WOS:000392280500160
PM 27999266
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Dong, H
   Liu, RH
   Zou, K
   Jin, ZX
   Kang, JN
   Zhang, Y
   Zhang, XD
   Sun, ZF
   Yu, GL
   Huang, NN
   Bretches, M
   Yang, SY
   Ning, B
AF Dong, Hui
   Liu, Ronghan
   Zou, Ke
   Jin, Zhengxin
   Kang, Jianning
   Zhang, Ying
   Zhang, Xiaodi
   Sun, Zhengfang
   Yu, Guilian
   Huang, Nana
   Bretches, Morgan
   Yang, Shang You
   Ning, Bin
TI Higenamine Promotes Osteogenesis Via IQGAP1/SMAD4 Signaling Pathway and
   Prevents Age  and Estrogen Dependent Bone Loss in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE Osteoporosis; Osteoblast; Higenamine; SMAD family; IQGAP1
ID MURINE MODEL; POSTMENOPAUSAL WOMEN; OSTEOBLASTOGENESIS; DIFFERENTIATION;
   IDENTIFICATION; ROMOSOZUMAB; SUPPRESSES; FRACTURES; MARROW; CELLS
AB Osteoporosis is a common bone disease caused by an imbalance of bone resorption and formation that results in a loss of total bone density. SMAD2/3 signal transduction is known to play a crucial role in osteogenic differentiation through transforming growth factor beta (TGF beta). By screening a library of small molecule compounds, the current study identifies higenamine (HG) as an active osteogenic agent that could be a therapeutic candidate for osteoporosis. In vitro data demonstrated that HG effectively induced expressions of osteogenic markers in mouse bone marrow stromal cell (BMSCs) and preosteoblastic cell cultures. Further, HG treatment resulted in enhanced bone formation and prevented accelerated bone loss on two animal models that mimic spontaneous senile osteoporosis and postmenopausal osteoporosis. IQ motif containing GTPase activating protein 1 (IQGAP1) was confirmed as a novel target of HG, where HG appears to bind to the Glu 1019 site of IQGAP1 to exert its osteogenic effects. Data subsequently suggested that HG promoted phosphorylation of SMAD2/3 and regulated the SMAD2/3 pathway by inhibiting SMAD4 ubiquitination. Overall, the findings highlight HG as a new small molecule drug to promote bone formation through SMAD2/3 pathway in osteoporosis. (c) 2023 American Society for Bone and Mineral Research (ASBMR).
C1 [Dong, Hui; Liu, Ronghan; Zou, Ke; Zhang, Ying; Yu, Guilian; Ning, Bin] Shandong Univ, Jinan Cent Hosp, Jinan, Peoples R China.
   [Liu, Ronghan; Jin, Zhengxin; Kang, Jianning; Zhang, Ying; Sun, Zhengfang; Huang, Nana; Ning, Bin] Shandong First Med Univ, Cent Hosp, Shandong Med Univ 1, Jinan, Peoples R China.
   [Liu, Ronghan; Jin, Zhengxin; Kang, Jianning; Zhang, Ying; Sun, Zhengfang; Huang, Nana; Ning, Bin] Shandong Acad Med Sci, Jinan, Peoples R China.
   [Zhang, Xiaodi] Weifang Med Univ, Weifang, Peoples R China.
   [Huang, Nana] Univ Kansas, Sch Med Wichita, Dept Orthoped Surg, Wichita, KS USA.
   [Bretches, Morgan; Yang, Shang You] Wichita State Univ, Dept Biol Sci, Wichita, KS USA.
   [Yang, Shang You] Univ Kansas, Sch Med Wichita, Dept Orthoped Surg, Wichita, KS 67214 USA.
   [Ning, Bin] Shandong Univ, Jinan Cent Hosp, 105 Jiefang Rd, Jinan 250013, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Shandong First Medical University
   & Shandong Academy of Medical Sciences; University of Jinan; Shandong
   Second Medical University; University of Kansas; University of Kansas
   Medical Center; Wichita State University; University of Kansas;
   University of Kansas Medical Center; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Shandong University
RP Yang, SY (通讯作者)，Univ Kansas, Sch Med Wichita, Dept Orthoped Surg, Wichita, KS 67214 USA.; Ning, B (通讯作者)，Shandong Univ, Jinan Cent Hosp, 105 Jiefang Rd, Jinan 250013, Shandong, Peoples R China.
EM syang6@kumc.edu; ningbin@sdu.edu.cn
RI Liu, Ronghan/ABH 1619 2021; Yang, Shang You/ADX 1056 2022; Zhang,
   Xiaodi/KIB 3120 2024; Kang, Jianning/JFB 0278 2023; Bretches,
   Morgan/ABF 7376 2021; Jin, Zhengxin/GPK 2894 2022
OI Yang, Shang You/0000 0002 8835 5302; Dong, Hui/0000 0002 0239 1020; 
FU National Natural Science Foundation of China [81771346, 82071383];
   Natural Science Foundation of Shandong Province [ZR2020KH007,
   ZR2020QH070]; Taishan Scholar Foundation of Shandong Province
   [tsqn201812156]; Academic Promotion Program of Shandong First Medical
   University [2019QL025, 2019RC021]; Spring Industry Leader Talent Support
   Plan [201984]; Rongxiang Regenerative Medicine Fund [2019SDRX 23]; China
   Postdoctoral Science Foundation [2021M691225]
FX The authors wish to acknowledge the following funding sources: National
   Natural Science Foundation of China (Nos. 81771346 and 82071383),
   Natural Science Foundation of Shandong Province (Key Project No.
   ZR2020KH007; Youth Program No. ZR2020QH070), Taishan Scholar Foundation
   of Shandong Province (tsqn201812156), Academic Promotion Program of
   Shandong First Medical University (2019QL025 and 2019RC021), Spring
   Industry Leader Talent Support Plan (201984), Rongxiang Regenerative
   Medicine Fund (2019SDRX 23), and China Postdoctoral Science Foundation
   (Project 2021M691225).
CR Bai G, 2008, ACTA PHARMACOL SIN, V29, P1187, DOI 10.1111/j.1745 7254.2008.00859.x
   Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102
   Bharatham N, 2014, J CHEM INF MODEL, V54, P648, DOI 10.1021/ci4004656
   Chen JN, 2022, NEURAL REGEN RES, V17, P144, DOI 10.4103/1673 5374.314114
   Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Dai LY, 2019, ANNU REV BIOCHEM, V88, P383, DOI 10.1146/annurev biochem 062917 012837
   Dai XP, 2017, NAT MED, V23, DOI 10.1038/nm.4378
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Grafe I, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022202
   Hao ZC, 2023, BIOACT MATER, V23, P206, DOI 10.1016/j.bioactmat.2022.10.018
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hong D, 2010, EXP CELL RES, V316, P2291, DOI 10.1016/j.yexcr.2010.05.011
   Hu W, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44048 y
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138
   Jiang Y, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1299 5
   Jiang YP, 2013, J BIOMED MATER RES A, V101, P2817, DOI 10.1002/jbm.a.34595
   Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600
   Jing H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0231 0
   Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368
   Lee CC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158320
   Li T, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12548
   Li ZY, 2019, NATURE, V575, P203, DOI 10.1038/s41586 019 1722 1
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Liu C, 2015, INFLAMM RES, V64, P395, DOI 10.1007/s00011 015 0817 x
   Liu CS, 2013, J CLIN INVEST, V123, P1138, DOI 10.1172/JCI63836
   Liu DW, 2018, CELL RES, V28, P918, DOI 10.1038/s41422 018 0070 2
   Liu RH, 2019, ANN RHEUM DIS, V78, P1524, DOI 10.1136/annrheumdis 2019 215543
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Mizokami A, 2017, BIOCHEM PHARMACOL, V132, P1, DOI 10.1016/j.bcp.2017.02.001
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Morimoto A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22402 x
   Mullin BH, 2020, GENOME BIOL, V21, DOI 10.1186/s13059 020 01997 2
   Muramatsu H, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 81669 8
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Smith JM, 2015, TRENDS CELL BIOL, V25, P171, DOI 10.1016/j.tcb.2014.12.005
   STUART AJ, 1992, AVIAN DIS, V36, P447, DOI 10.2307/1591527
   Sun L, 2021, BIOSENS BIOELECTRON, V29, P6
   TAKEDA T, 1981, MECH AGEING DEV, V17, P183, DOI 10.1016/0047 6374(81)90084 1
   Varshavsky A, 2017, ANNU REV BIOCHEM, V86, P123, DOI 10.1146/annurev biochem 061516 044859
   Wang J, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12051
   Wang KD, 2022, ANN RHEUM DIS, V81, P544, DOI 10.1136/annrheumdis 2021 221380
   Wang QL, 2019, EUR REV MED PHARMACO, V23, P7224, DOI 10.26355/eurrev_201909_18825
   Wei XH, 2021, PHYTOMEDICINE, V86, DOI 10.1016/j.phymed.2021.153565
   Wu DM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0975 1
   Xu JJ, 2016, CELL DEATH DIFFER, V23, P1941, DOI 10.1038/cdd.2016.72
   Yang SY, 2002, ARTHRITIS RHEUM, V46, P2514, DOI 10.1002/art.10527
   Zhang NN, 2017, J ETHNOPHARMACOL, V196, P242, DOI 10.1016/j.jep.2016.12.033
   Zhang X, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.196
NR 60
TC 7
Z9 8
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2023
VL 38
IS 5
BP 775
EP 791
DI 10.1002/jbmr.4800
EA MAR 2023
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AS3B8
UT WOS:000967842600001
PM 36907987
DA 2025 08 17
ER

PT J
AU Shen, ZH
   Hu, XQ
   Hu, MJ
   Pan, XK
   Lu, HG
   Chen, B
   Wu, B
   Chen, G
AF Shen, Zhong Hai
   Hu, Xu Qi
   Hu, Min Jie
   Pan, Xue Kang
   Lu, Hui Gen
   Chen, Bao
   Wu, Bin
   Chen, Gang
TI Activation of AKT signaling via small molecule natural compound prevents
   against osteoblast apoptosis and osteonecrosis of the femoral head
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Vinpocetine; osteoblast; apoptosis; Akt; ONFH
ID INDUCED AVASCULAR NECROSIS; VINPOCETINE; INHIBITION; EXPRESSION;
   CASPASE 3; PATHWAY; BCL 2
AB Vinpocetine (Vinp), a natural compound extracted from the leaves of Phyllostachys pubescens with apoptosis modulatory properties in variety of disorders. In the present study, we investigated the possible mechanism of Vinp in alleviating of the progress of osteonecrosis of the femoral head (ONFH) both in vitro and in vivo experiments. The results showed that treatment with Vinp suppressed the dexamethasone (Dex) induced over regulation of ROS level and apoptotic factors. Mechanistically, the Vinp activated Akt signaling pathway in osteoblast. Moreover, Vinp exerted a protective role in animal ONFH model. To summarize, this work illustrated Vinp possessed a new potential therapeutic drug in ONFH.
C1 [Shen, Zhong Hai; Hu, Xu Qi; Hu, Min Jie; Pan, Xue Kang; Lu, Hui Gen; Chen, Bao; Wu, Bin; Chen, Gang] Jiaxing Univ Jiaxing, Dept Orthopaed, Affiliated Hosp 2, 1518 Huancheng Rd, Jiaxing 314000, Zhejiang, Peoples R China.
RP Chen, G (通讯作者)，Jiaxing Univ Jiaxing, Dept Orthopaed, Affiliated Hosp 2, 1518 Huancheng Rd, Jiaxing 314000, Zhejiang, Peoples R China.
EM drjxchengang@sina.com
OI Chen, Gang/0000 0001 6219 5243
FU Jiaxing Public Welfare Science and Technology Project, Zhejiang
   Province, China [2019AD32194]
FX The study was supported by Jiaxing Public Welfare Science and Technology
   Project, Zhejiang Province, China (Grant No. 2019AD32194).
CR Cakir E, 2011, APMIS, V119, P574, DOI 10.1111/j.1600 0463.2011.02778.x
   Dai WW, 2017, PLANTA MED, V83, P888, DOI 10.1055/s 0043 107808
   Deng S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01787
   Dong YL, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0589 z
   Fattori V, 2017, PHARMACOL RES, V120, P10, DOI 10.1016/j.phrs.2016.12.039
   Feng ZH, 2017, APOPTOSIS, V22, P1001, DOI 10.1007/s10495 017 1383 1
   Gao YC, 2020, INT J BIOL SCI, V16, P543, DOI 10.7150/ijbs.35256
   Himburg HA, 2010, NAT MED, V16, P475, DOI 10.1038/nm.2119
   Hinz N, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0450 3
   Huang EW, 2012, APOPTOSIS, V17, P1120, DOI 10.1007/s10495 012 0743 0
   Kim HJ, 2010, BMB REP, V43, P524, DOI 10.5483/BMBRep.2010.43.8.524
   Li HG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034566
   Ma YY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162295
   Nie ZG, 2019, MOL MED REP, V20, P401, DOI 10.3892/mmr.2019.10267
   Oksvold MP, 2002, J HISTOCHEM CYTOCHEM, V50, P289, DOI 10.1177/002215540205000301
   Petek D, 2019, EFORT OPEN REV, V4, P85, DOI 10.1302/2058 5241.4.180036
   Ravindran J, 2011, APOPTOSIS, V16, P145, DOI 10.1007/s10495 010 0554 0
   Sönmez MF, 2017, BIOTECH HISTOCHEM, V92, P92, DOI 10.1080/10520295.2016.1259499
   Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097 4652(2001)9999:9999<00::AID JCP1051>3.0.CO;2 F
   Tints K, 2014, INT J MOL SCI, V15, P5680, DOI 10.3390/ijms15045680
   van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028
   Wang K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096894
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Xu XX, 2014, J MOL HISTOL, V45, P473, DOI 10.1007/s10735 014 9571 6
   Xue XH, 2018, MOL MED REP, V17, P3751, DOI 10.3892/mmr.2017.8349
   Zhang F, 2018, TRANSL STROKE RES, V9, P174, DOI 10.1007/s12975 017 0549 z
   Zhang PP, 2021, PUBLIC HEALTH NUTR, V24, P2205, DOI 10.1017/S1368980020000324
   Zhao MM, 2020, FRONT NEUROSCI SWITZ, V14, DOI 10.3389/fnins.2020.00223
   Zhu MP, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109769
NR 29
TC 7
Z9 7
U1 0
U2 1
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2020
VL 12
IS 11
BP 7211
EP 7222
PG 12
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA PD5ZO
UT WOS:000597762400017
PM 33312361
DA 2025 08 17
ER

PT J
AU Huang, H
   Chang, EJ
   Ryu, J
   Lee, ZH
   Lee, Y
   Kim, HH
AF Huang, Hao
   Chang, Eun Ju
   Ryu, Jiyoon
   Lee, Zang Hee
   Lee, Youngkyun
   Kim, Hong Hee
TI Induction of c Fos and NFATc1 during RANKL stimulated osteoclast
   differentiation is mediated by the p38 signaling pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE osteoclasts; RANKL; p38; c Fos; NFATc1
ID ACTIVATED PROTEIN KINASE; NECROSIS FACTOR RECEPTOR; NF KAPPA B; MAP
   KINASE; RESPONSE ELEMENT; NUCLEAR FACTOR; TRANSDUCTION; REGULATOR;
   MEMBERS; FAMILY
AB The crucial role of p38 mitogen activated protein kinase for osteoclast differentiation has been suggested from studies with specific pharmacological inhibitors and dominant negative forms of p38. However, the targets through which p38 regulates osteoclast differentiation have not been clearly revealed. Here, we show that inhibition of p38 activity with SB203580 reduced osteoclastogenesis from primary precursor cells, with concomitant suppression in the induction of both c Fos and nuclear factor of activated T cells (NFAT) cl by receptor activator of nuclear factor KB ligand (RANKL),, the key osteoclast differentiation factor. Overexpression of dominant negative forms of p38 upstream kinases MKK3 and MKK6 elicited similar reduction in RANKL stimulated elevation of c Fos and NFATc1. Interestingly, overexpression of c Fos restored RANKL induced osteoclast differentiation from and NFATc1 expression in SB203580 treated precursor cells. Our results demonstrate a previously unknown function of the p38 pathway in up regulating c Fos and NFATcl expression during RANKL induced osteoclastogenesis. (c) 2006 Elsevier Inc. All rights reserved.
C1 Seoul Natl Univ, Program BK21, Seoul 110749, South Korea.
   Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, Seoul 110749, South Korea.
   Seoul Natl Univ, Dent Res Inst, Seoul 110749, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU)
RP Lee, Y (通讯作者)，Seoul Natl Univ, Program BK21, Seoul 110749, South Korea.
EM yklee@snu.ac.kr; hhbkim@snu.ac.kr
RI Sun, Hao/T 5576 2019; Ryu, Jiyoon/M 8573 2019
OI HUANG, HAO/0000 0002 6687 6967; 
CR DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886
   Ichiki T, 2003, HYPERTENSION, V42, P177, DOI 10.1161/01.HYP.0000079791.26014.04
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jimi E, 1999, J IMMUNOL, V163, P434
   Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162 3109(00)00206 X
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Li XT, 2003, ENDOCRINOLOGY, V144, P4999, DOI 10.1210/en.2003 0166
   LOTSOVA V, 1997, NAT MED, V3, P1285
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Shin JN, 2002, J BIOL CHEM, V277, P8346, DOI 10.1074/jbc.M110964200
   Simi A, 2005, J NEUROCHEM, V92, P915, DOI 10.1111/j.1471 4159.2004.02938.x
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
NR 22
TC 144
Z9 162
U1 0
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 8
PY 2006
VL 351
IS 1
BP 99
EP 105
DI 10.1016/j.bbrc.2006.10.011
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 103VG
UT WOS:000241914400016
PM 17052691
DA 2025 08 17
ER

PT J
AU Wang, ZD
   Tao, HQ
   Chu, M
   Yu, L
   Yang, P
   Wang, QF
   Lu, J
   Yang, HL
   Wang, ZH
   Zhang, HL
   Geng, DC
AF Wang, Zhidong
   Tao, Huaqiang
   Chu, Miao
   Yu, Lei
   Yang, Peng
   Wang, Qiufei
   Lu, Jun
   Yang, Huilin
   Wang, Zhenheng
   Zhang, Hailin
   Geng, Dechun
TI Byakangelicol suppresses TiPs stimulated osteoclastogenesis and bone
   destruction via COX 2/NF κB signaling pathway
SO REGENERATIVE BIOMATERIALS
LA English
DT Article
DE COX 2; TiPs; inflammation; byakangelicol; NF kappa B
ID TOTAL JOINT REPLACEMENT; ANGELICA DAHURICA; COX 2 INHIBITORS; WEAR
   DEBRIS; MACROPHAGE; PARTICLES; FURANOCOUMARINS; FIBROBLASTS; EXPRESSION;
   OSTEOLYSIS
AB Aseptic loosening (AL) is considered a significant cause of prosthesis revision after arthroplasty and a crucial factor in the longevity of an artificial joint prosthesis. The development of AL is primarily attributed to a series of biological reactions, such as peri prosthetic osteolysis (PPO) induced by wear particles around the prosthesis. Chronic inflammation of the peri prosthetic border tissue and hyperactivation of osteoclasts are key factors in this process, which are induced by metallic wear particles like Ti particles (TiPs). In our in vitro study, we observed that TiPs significantly enhanced the expression of inflammation related genes, including COX 2, IL 1 beta and IL 6. Through screening a traditional Chinese medicine database, we identified byakangelicol, a traditional Chinese medicine molecule that targets COX 2. Our results demonstrated that byakangelicol effectively inhibited TiPs stimulated osteoclast activation. Mechanistically, we found that byakangelicol suppressed the expression of COX 2 and related pro inflammatory factors by modulating macrophage polarization status and NF kappa B signaling pathway. The in vivo results also demonstrated that byakangelicol effectively inhibited the expression of inflammation related factors, thereby significantly alleviating TiPs induced cranial osteolysis. These findings suggested that byakangelicol could potentially be a promising therapeutic approach for preventing PPO.{Graphical abstract}
C1 [Wang, Zhidong; Tao, Huaqiang; Chu, Miao; Yu, Lei; Yang, Peng; Yang, Huilin; Wang, Zhenheng; Geng, Dechun] Soochow Univ, Dept Orthoped, Affiliated Hosp 1, 188 Shizi St, Suzhou, Peoples R China.
   [Wang, Qiufei] Soochow Univ, Peoples Hosp Changshu City 1, Dept Orthoped, Changshu Hosp, Changshu 215500, Peoples R China.
   [Lu, Jun] Nanjing Univ, Div Sports Med & Adult Reconstruct Surg, Dept Orthoped Surg, Nanjing Drum Tower Hosp,Affiliated Hosp,Med Sch, 321 Zhongshan Rd, Nanjing 210000, Peoples R China.
   [Zhang, Hailin] Nantong Univ, Dept Orthoped, Jiangyin Peoples Hosp, 163 Shoushan Rd, Jiangyin 214400, Peoples R China.
C3 Soochow University   China; Soochow University   China; Nanjing
   University; Nantong University
RP Yang, HL; Wang, ZH; Geng, DC (通讯作者)，Soochow Univ, Dept Orthoped, Affiliated Hosp 1, 188 Shizi St, Suzhou, Peoples R China.; Zhang, HL (通讯作者)，Nantong Univ, Dept Orthoped, Jiangyin Peoples Hosp, 163 Shoushan Rd, Jiangyin 214400, Peoples R China.
EM suzhouspine@163.com; wangzhenheng1987@163.com;
   jasonzhang0520@outlook.com; szgengdc@suda.edu.cn
RI Yang, Peng/B 3819 2012; Geng, Dechun/LMO 1733 2024; zhang,
   hailin/HMP 1435 2023
FU National Natural Science Foundation of China [82272157, 82072425,
   82072498]; Natural Science Foundation of Jiangsu Province [BE2021650];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD); Program of Suzhou Health Commission [GSWS2022002,
   GSWS2020121]; Jiangsu Medical Research Project [ZD2022014]; National and
   Local Engineering Laboratory of New Functional Polymer Materials
   [SDGC2205]; Special Project of Diagnosis and Treatment Technology for
   Key Clinical Diseases in Suzhou [LCZX202003]
FX This work was supported by the National Natural Science Foundation of
   China. (82272157, 82072425, 82072498), the Natural Science Foundation of
   Jiangsu Province (BE2021650), the Priority Academic Program Development
   of Jiangsu Higher Education Institutions (PAPD), the Program of Suzhou
   Health Commission (GSWS2022002, GSWS2020121), Jiangsu Medical Research
   Project (ZD2022014), National and Local Engineering Laboratory of New
   Functional Polymer Materials (SDGC2205) and Special Project of Diagnosis
   and Treatment Technology for Key Clinical Diseases in Suzhou
   (LCZX202003).
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Arcângelo J, 2019, FOOT ANKLE SURG, V25, P96, DOI 10.1016/j.fas.2017.11.002
   Bertolini A, 2002, CURR MED CHEM, V9, P1033, DOI 10.2174/0929867024606650
   Borghi SM, 2018, J NUTR BIOCHEM, V53, P81, DOI 10.1016/j.jnutbio.2017.10.010
   Bukata SV, 2004, J ORTHOP RES, V22, P6, DOI 10.1016/S0736 0266(03)00153 0
   Cherian JJ, 2015, CLIN ORTHOP RELAT R, V473, P2700, DOI 10.1007/s11999 015 4220 2
   Cong YH, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1122057
   Connors JP, 2022, BIOENGINEERING BASEL, V9, DOI 10.3390/bioengineering9120764
   Cutolo M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.867260
   de Haan K, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25221 2
   Feng X, 2022, AM J TRANSL RES, V14, P7080
   Funes SC, 2018, IMMUNOLOGY, V154, P186, DOI 10.1111/imm.12910
   Gao XR, 2018, CELL CYCLE, V17, P2134, DOI 10.1080/15384101.2018.1515549
   Geng DC, 2011, ACTA BIOMATER, V7, P3216, DOI 10.1016/j.actbio.2011.05.007
   Goodman SB, 2003, INT J IMMUNOPATH PH, V16, P201, DOI 10.1177/039463200301600303
   Holding CA, 2006, BIOMATERIALS, V27, P5212, DOI 10.1016/j.biomaterials.2006.05.054
   HOROWITZ SM, 1994, CALCIFIED TISSUE INT, V54, P320, DOI 10.1007/BF00295957
   Hu TY, 2019, PHYTOMEDICINE, V55, P214, DOI 10.1016/j.phymed.2018.08.001
   Im GI, 2004, BIOMATERIALS, V25, P269, DOI 10.1016/S0142 9612(03)00523 4
   Katz JN, 2006, BEST PRACT RES CL RH, V20, P145, DOI 10.1016/j.berh.2005.09.003
   Kim YK, 2007, PHYTOTHER RES, V21, P288, DOI 10.1002/ptr.2043
   Li D, 2017, EXP THER MED, V14, P874, DOI 10.3892/etm.2017.4569
   Lin CH, 2002, J PHARM PHARMACOL, V54, P1271, DOI 10.1211/002235702320402125
   Lin SP, 2022, ACTA BIOMATER, V142, P345, DOI 10.1016/j.actbio.2022.02.007
   Liu Y, 2019, J CELL PHYSIOL, V234, P13832, DOI 10.1002/jcp.28063
   Marjoribanks J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001751.pub3
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Oh H, 2002, PLANTA MED, V68, P463, DOI 10.1055/s 2002 32075
   Pajarinen J, 2021, J BIOMED MATER RES A, V109, P1512, DOI 10.1002/jbm.a.37142
   Piao XL, 2004, J ETHNOPHARMACOL, V93, P243, DOI 10.1016/j.jep.2004.03.054
   Shapouri Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Sharma AR, 2020, MATERIALS, V13, DOI 10.3390/ma13163628
   Stiller CO, 2022, J INTERN MED, V292, P557, DOI 10.1111/joim.13505
   Talmo CT, 2010, CLIN GERIATR MED, V26, P517, DOI 10.1016/j.cger.2010.04.002
   Tang KY, 2022, ASIAN J SURG, V45, P535, DOI 10.1016/j.asjsur.2021.09.041
   Wei XC, 2009, AM J PHYSIOL CELL PH, V297, pC310, DOI 10.1152/ajpcell.00597.2008
   Wen ZK, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420 022 00999 2
   Zaveri TD, 2017, BIOMATERIALS, V115, P128, DOI 10.1016/j.biomaterials.2016.10.038
   Zhang J, 2020, CELL METAB, V31, P1136, DOI 10.1016/j.cmet.2020.05.004
   Zhang LW, 2020, THERANOSTICS, V10, P6638, DOI 10.7150/thno.44793
   Zhao FC, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 2945
   Zhu FB, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/5707242
NR 43
TC 1
Z9 1
U1 6
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2056 3418
EI 2056 3426
J9 REGEN BIOMATER
JI Regen. Biomater.
PD JAN 2
PY 2024
VL 11
AR rbad092
DI 10.1093/rb/rbad092
EA JAN 2024
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA DU7D6
UT WOS:001134650800001
PM 38173778
OA gold
DA 2025 08 17
ER

PT J
AU Lv, DM
   Ding, SR
   Zhong, L
   Tu, J
   Li, HB
   Yao, H
   Zou, YT
   Zeng, ZL
   Liao, Y
   Wan, XS
   Wen, LL
   Xie, XB
AF Lv, Dongming
   Ding, Shirong
   Zhong, Li
   Tu, Jian
   Li, Hongbo
   Yao, Hao
   Zou, Yutong
   Zeng, Ziliang
   Liao, Yan
   Wan, Xuesi
   Wen, Lili
   Xie, Xianbiao
TI M<SUP>6</SUP>A demethylase FTO mediated downregulation of DACT1 mRNA
   stability promotes Wnt signaling to facilitate osteosarcoma progression
SO ONCOGENE
LA English
DT Article
ID GENE; SUPPRESSES; PROTEIN
AB Despite advances in clinical diagnosis and treatment, the prognosis of patients with osteosarcoma (OS) remains poor, and the treatment efficacy has plateaued. Therefore, it is important to identify new therapeutic targets for OS. N 6 methyladenosine (m(6)A) modification has been reported to participate in tumor malignancy. In this study, functional screening showed that the m(6)A demethylase FTO could be a candidate therapeutic target for OS. Upregulated FTO in OS could predict a poorer prognosis. FTO promoted the growth and metastasis of OS in vitro and in vivo. Methylated RNA immunoprecipitation sequencing (MeRIP seq) and RNA sequencing (RNA seq) were performed to identify DACT1 as a potential target of FTO. In vitro assays demonstrated that FTO could reduce the mRNA stability of DACT1 via m(6)A demethylation, which decreased DACT1 expression and further activated the Wnt signaling pathway. The oncogenic effect of FTO on OS was dependent on DACT1. In addition, the m(6)A reader IGF2BP1 was validated to participate in the regulation of DACT1. Entacapone, a conventional drug for Parkinson's disease, was confirmed to suppress OS via m(6)A mediated regulation through the FTO/DACT1 axis. Our findings demonstrate that FTO may be a novel therapeutic target and that entacapone has preclinical value to be repurposed for OS.
C1 [Lv, Dongming; Tu, Jian; Li, Hongbo; Yao, Hao; Zou, Yutong; Zeng, Ziliang; Liao, Yan; Xie, Xianbiao] Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Lv, Dongming; Tu, Jian; Li, Hongbo; Yao, Hao; Zou, Yutong; Zeng, Ziliang; Liao, Yan; Xie, Xianbiao] Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Peoples R China.
   [Ding, Shirong] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, Guangzhou, Peoples R China.
   [Zhong, Li] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China.
   [Zhong, Li] Sun Yat Sen Univ, Affiliated Hosp 7, Sci Res Ctr, Shenzhen, Peoples R China.
   [Wan, Xuesi] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Wan, Xuesi] Sun Yat Sen Univ, Diabet Ctr, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Wen, Lili] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology
   South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen
   University; Sun Yat Sen University; State Key Lab Oncology South China;
   Sun Yat Sen University
RP Xie, XB (通讯作者)，Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China.; Xie, XB (通讯作者)，Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Peoples R China.; Wen, LL (通讯作者)，Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.
EM wenll@sysucc.org.cn; xiexbiao@mail.sysu.edu.cn
RI ; Zou, Yutong/JSL 1539 2023; Li, Hongbo/HTQ 5200 2023; Wang,
   Bo/KEH 0105 2024
OI Lv, Dongming/0000 0001 9642 0410; Zeng, Ziliang/0000 0002 0095 8396
FU National Natural Science Foundation of China [81972510, 81772864,
   81572638]; Natural Science Foundation of Guangdong Province
   [2016A030313239]; Medical Scientific Research Foundation of Guangdong
   Province [A2020483]
FX This study was supported by National Natural Science Foundation of China
   (Grants 81972510, 81772864 and 81572638), Natural Science Foundation of
   Guangdong Province (No.2016A030313239), and Medical Scientific Research
   Foundation of Guangdong Province (A2020483).
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1
   Barbieri I, 2020, NAT REV CANCER, V20, P303, DOI 10.1038/s41568 020 0253 2
   Berulava T, 2020, EUR J HEART FAIL, V22, P54, DOI 10.1002/ejhf.1672
   Cacabelos R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030551
   Chen CYA, 2008, METHOD ENZYMOL, V448, P335, DOI 10.1016/S0076 6879(08)02617 7
   Chen HR, 2021, GASTROENTEROLOGY, V160, P1284, DOI 10.1053/j.gastro.2020.11.013
   Chen SJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02847 6
   Chen XX, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01220 7
   Chen YB, 2021, AUTOPHAGY, V17, P457, DOI 10.1080/15548627.2020.1720431
   Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626
   Eaton BR, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28352
   Esposito M, 2021, NAT CELL BIOL, V23, P257, DOI 10.1038/s41556 021 00641 w
   Fischer J, 2009, NATURE, V458, P894, DOI 10.1038/nature07848
   Fisher DA, 2006, DEV DYNAM, V235, P2620, DOI 10.1002/dvdy.20917
   Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634
   Gao X, 2008, J BIOL CHEM, V283, P35679, DOI 10.1074/jbc.M804088200
   Gilbert WV, 2016, SCIENCE, V352, P1408, DOI 10.1126/science.aad8711
   Gordin A, 2004, J NEURAL TRANSM, V111, P1343, DOI 10.1007/s00702 004 0190 3
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004
   Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556 018 0045 z
   Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006
   Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]
   Li HY, 2020, THERANOSTICS, V10, P9477, DOI 10.7150/thno.45763
   Li JH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00769
   Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017
   Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078 0432.CCR 15 0198
   Lin ZY, 2020, EMBO J, V39, DOI 10.15252/embj.2019103181
   Liu H, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02422 5
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Lv DM, 2020, METABOLOMICS, V16, DOI 10.1007/s11306 020 01745 4
   Matsuoka K, 2020, CELL RES, V30, P885, DOI 10.1038/s41422 020 0370 1
   Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1004 4
   Okerlund ND, 2010, J NEUROSCI, V30, P4362, DOI 10.1523/JNEUROSCI.0354 10.2010
   Peng SM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7116
   Simpson E, 2018, JAAPA J AM ACAD PHYS, V31, P15, DOI 10.1097/01.JAA.0000541477.24116.8d
   Stojic L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14978 7
   Su R, 2020, CANCER CELL, V38, P79, DOI 10.1016/j.ccell.2020.04.017
   Sun T, 2020, ONCOGENE, V39, P5358, DOI 10.1038/s41388 020 1338 9
   Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014
   Wang XR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15304 x
   Wang YJ, 2019, EPIGENOMICS UK, V11, P1693, DOI 10.2217/epi 2019 0262
   Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012
   Xiao YR, 2020, P NATL ACAD SCI USA, V117, P21441, DOI 10.1073/pnas.2000516117
   Yang CF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21196985
   Yang JH, 2019, BIOL RES, V52, DOI 10.1186/s40659 019 0238 3
   Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10669 0
   Yin XD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3399
   Zhang CZ, 2020, ONCOGENE, V39, P4507, DOI 10.1038/s41388 020 1303 7
   Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200
   Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132
   Zhong L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 020 00414 1
   Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006
   Zhou B, 2021, HEPATOLOGY, V73, P91, DOI 10.1002/hep.31220
   Zhou L, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109964
   Zhou ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01216 3
   Zhu ST, 2020, MOL THER NUCL ACIDS, V22, P957, DOI 10.1016/j.omtn.2020.10.010
   Zhuang CS, 2019, J CELL MOL MED, V23, P2163, DOI 10.1111/jcmm.14128
NR 58
TC 46
Z9 47
U1 0
U2 19
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD MAR 18
PY 2022
VL 41
IS 12
BP 1727
EP 1741
DI 10.1038/s41388 022 02214 z
EA FEB 2022
PG 15
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA ZV6UV
UT WOS:000751251500003
PM 35121825
DA 2025 08 17
ER

PT J
AU Kósa, JP
   Kis, A
   Bácsi, K
   Balla, B
   Nagy, Z
   Takács, I
   Speer, G
   Lakatos, P
AF Kosa, Janos P.
   Kis, Adrian
   Bacsi, Krisztian
   Balla, Bernadett
   Nagy, Zsolt
   Takacs, Istvan
   Speer, Gabor
   Lakatos, Peter
TI The protective role of bone morphogenetic protein 8 in the
   glucocorticoid induced apoptosis on bone cells
SO BONE
LA English
DT Article
DE Glucocorticoid induced osteoporosis; Transcriptional profiling; BMP 8;
   Calvarial osteoblast; siRNA; MC3T3 E1
ID INDUCED OSTEOPOROSIS; TRABECULAR BONE; OSTEOBLASTS; EXPRESSION;
   SPERMATOGENESIS; MECHANISMS; MOUSE; DIFFERENTIATION; MAINTENANCE;
   OSTEOCLASTS
AB One of the side effects associated with glucocorticoid therapy is glucocorticoid induced bone loss. Glucocorticoids partly detain bone formation via the inhibition of osteoblastic function, however, the exact mechanism of this inhibition remains elusive. In this study, we examined the effect of dexamethasone, an active glucocorticoid analogue, on cell viability and expression of bone remodelling related genes in primary mouse calvarial and cloned MC3T3 E1 osteoblasts. Using sensitive biochemical assays, we demonstrated the apoptotic effect of dexamethasone on osteoblastic cells. Then, utilizing Taqman probe based quantitative RT PCR technology, gene expression profiles of 111 bone metabolism related genes were determined. As a result of dexamethasone treatment we have detected significant apoptotic cell death, and six genes, including Smad3, type 2 collagen alpha 1, type 9 collagen alpha 1, matrix metalloproteinase 2, bone morphogenetic protein 4 and bone morphogenetic protein 8 showed (BMP 8) significant changes in their expression on a time  and concentration dependent manner. BMP 8, (a novel player in bone metabolism) exhibited a two orders of magnitude elevation in its mRNA level and highly elevated protein concentration by Western blot in response to dexamethasone treatment. The knockdown of BMP 8 by RNA interference significantly increased dexamethasone induced cell death, confirming a protective role for BMP 8 in the glucocorticoid induced apoptosis of osteoblasts. Our results suggest that BMP 8 might be an essential player in bone metabolism, especially in response to glucocorticoids. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Kosa, Janos P.; Kis, Adrian; Bacsi, Krisztian; Balla, Bernadett; Nagy, Zsolt; Takacs, Istvan; Speer, Gabor; Lakatos, Peter] Semmelweis Univ, Dept Internal Med 1, H 1083 Budapest, Hungary.
C3 Semmelweis University
RP Kósa, JP (通讯作者)，Semmelweis Univ, Dept Internal Med 1, Koranyi 2 A, H 1083 Budapest, Hungary.
EM jkosa@bel1.sote.hu; kisadrian@gmail.com; bacsi@bel1.sote.hu;
   betti@bel1.sote.hu; zsolt@bel1.sote.hu; takist@bel1.sote.hu;
   speerga@bel1.sote.hu; lakpet@bel1.sote.hu
RI Takács, István/O 3018 2017; Podani, Janos/G 3074 2014; Nagy,
   Zsolt/AAC 2331 2019
FU National Research and Technological Office (NKTH) of Hungary
   [NKFP 1A/007/2004, NKFP 1A/002/2004]; Ministry of Health, Hungary [ETT
   022/2006, ETT 151/2009]
FX This work was supported by grants NKFP 1A/007/2004 and NKFP 1A/002/2004
   from the National Research and Technological Office (NKTH) of Hungary,
   as well as by research grant ETT 022/2006 and ETT 151/2009 from the
   Ministry of Health, Hungary.
CR ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502
   Andrieux J, 2007, CANCER GENET CYTOGEN, V178, P11, DOI 10.1016/j.cancergencyto.2007.06.001
   Beavan S, 2001, J BONE MINER RES, V16, P1496, DOI 10.1359/jbmr.2001.16.8.1496
   Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754
   Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   DEMPSTER DW, 1983, CALCIFIED TISSUE INT, V35, P410, DOI 10.1007/BF02405069
   DYKMAN TR, 1985, ARTHRITIS RHEUM US, V28, P361, DOI 10.1002/art.1780280402
   Furlan F, 2001, CELL COMMUN ADHES, V8, P367, DOI 10.3109/15419060109080755
   Furumatsu T, 2005, J BIOL CHEM, V280, P8343, DOI 10.1074/jbc.M413913200
   Henderson LJ, 2005, BRIT J CANCER, V92, P1553, DOI 10.1038/sj.bjc.6602452
   Iu MF, 2005, J ENDOCRINOL, V185, P131, DOI 10.1677/joe.1.05962
   Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061
   Newman ED, 2006, OSTEOPOROSIS INT, V17, P1428, DOI 10.1007/s00198 006 0149 3
   Okamoto M, 2006, J BONE MINER RES, V21, P1022, DOI 10.1359/JBMR.060411
   Patschan D, 2001, BONE, V29, P498, DOI 10.1016/S8756 3282(01)00610 X
   ROSS EJ, 1982, LANCET, V2, P646
   Shin SS, 2004, J HAND SURG AM, V29A, P809, DOI 10.1016/j.jhsa.2004.02.008
   Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200
   Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190
   Sulzbacher I, 2002, J CLIN PATHOL, V55, P381, DOI 10.1136/jcp.55.5.381
   Wang CJ, 2008, J BONE MINER RES, V23, P837, DOI 10.1359/JBMR.080214
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wu JJ, 2003, J BIOL CHEM, V278, P24521, DOI 10.1074/jbc.M302431200
   Ying Y, 2000, MOL ENDOCRINOL, V14, P1053, DOI 10.1210/me.14.7.1053
   Zhao GQ, 1996, GENE DEV, V10, P1657, DOI 10.1101/gad.10.13.1657
   Zhao GQ, 1998, DEVELOPMENT, V125, P1103
   Zhao GQ, 1996, MECH DEVELOP, V57, P159, DOI 10.1016/0925 4773(96)00543 6
NR 29
TC 27
Z9 31
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD MAY 1
PY 2011
VL 48
IS 5
BP 1052
EP 1057
DI 10.1016/j.bone.2011.01.017
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 754TK
UT WOS:000289879900013
PM 21277400
DA 2025 08 17
ER

PT J
AU Mucci, JM
   Scian, R
   De Francesco, PN
   García, FS
   Ceci, R
   Fossati, CA
   Delpino, MV
   Rozenfeld, PA
AF Mucci, Juan M.
   Scian, Romina
   De Francesco, Pablo N.
   Suqueli Garcia, Florencia
   Ceci, Romina
   Fossati, Carlos A.
   Victoria Delpino, M.
   Rozenfeld, Paula A.
TI Induction of osteoclastogenesis in an in vitro model of Gaucher
   disease is mediated by T cells via TNF α
SO GENE
LA English
DT Article
DE Gaucher disease; Glucocerebrosidase deficiency; Bone disease;
   Macrophages; TNF alpha; T cells
ID RHEUMATOID ARTHRITIS PATIENTS; ENZYME REPLACEMENT THERAPY; BONE
   DESTRUCTION; UP REGULATION; HUMAN BLOOD; MACROPHAGES; DIFFERENTIATION;
   MECHANISM; METALLOPROTEINASES; OSTEOPROTEGERIN
AB Gaucher disease is a lysosomal storage disorder caused by deficiency of glucocerebrosidase enzymatic activity leading to accumulation of its substrate glucocerebrosidase mainly in macrophages. Skeletal disorder of Gaucher disease is the major cause of morbidity and is highly refractory to enzyme replacement therapy. However, pathological mechanisms of bone alterations in Gaucher disease are still poorly understood. We hypothesized that cellular alteration in Gaudier disease produces a proinflammatory milieu leading to bone destruction through enhancement of monocyte differentiation to osteoclasts and osteoclasts resorption activity. Against this background we decided to investigate in an in vitro chemical model of Gaucher disease, the capacity of secreted soluble mediators to induce osteoclastogenesis, and the mechanism responsible for this phenomena. We demonstrated that soluble factors produced by CBE treated PBMC induced differentiation of osteoclasts precursors into mature and active osteoclasts that express chitotriosidase and secrete proinflammatory cytokines. We also showed a role of TNF alpha in promoting osteoclastogenesis in Gaucher disease chemical model. To analyze the biological relevance of T cells in osteoclastogenesis of Gaucher disease, we investigated this process in T cell depleted PBMC cultures. The findings suggest that T cells play a role in osteoclast formation in Gaucher disease. In conclusion, our data suggests that in vitro GCASE deficiency, along with concomitant glucosylceramide accumulation, generates a state of osteoclastogenesis mediated in part by pro resorptive cytokines, especially TNF alpha. Moreover, T cells are involved in osteoclastogenesis in Gaucher disease chemical model. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Mucci, Juan M.; De Francesco, Pablo N.; Suqueli Garcia, Florencia; Ceci, Romina; Fossati, Carlos A.; Rozenfeld, Paula A.] Univ Nacl La Plata, Fac Ciencias Exactas, Dept Ciencias Biol, LISIN, RA 1900 La Plata, Argentina.
   [Scian, Romina; Victoria Delpino, M.] Univ Buenos Aires, Fac Farm & Bioquim, CONICET, Inst Estudios Inmunidad Humoral, RA 1113 Buenos Aires, DF, Argentina.
   [Scian, Romina; Victoria Delpino, M.] Univ Buenos Aires, Hosp Clin Jose de San Martin, Lab Inmunogenet, Fac Med, RA 1113 Buenos Aires, DF, Argentina.
C3 National University of La Plata; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); University of Buenos Aires; University
   of Buenos Aires; University of Buenos Aires Hospital
RP Rozenfeld, PA (通讯作者)，Univ Nacl La Plata, Fac Ciencias Exactas, Dept Ciencias Biol, LISIN, RA 1900 La Plata, Argentina.
EM paurozen@biol.unlp.edu.ar
RI ; De Francesco, Pablo Nicolas/CAF 5119 2022; De Francesco, Pablo
   Nicolás/CAF 5119 2022; Delpino, Victoria/ITV 4318 2023
OI Delpino, M. Victoria/0000 0003 2077 8509; De Francesco, Pablo
   Nicolas/0000 0003 4226 7507; 
FU Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina
   [PICT01070]; Shire HGT
FX This work was supported by the Agencia Nacional de Promocion Cientifica
   y Tecnologica, Argentina [PICT01070 to PR]. The finding source had no
   involvement in study design; in the collection, analysis and
   interpretation of data; in the writing of the report; and in the
   decision to submit the article for publication PR has received research
   grants from Shire HGT and acts as a consultant for Shire HGT. However,
   this arrangement would not have any influence on this work.
CR Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Boven LA, 2004, AM J CLIN PATHOL, V122, P359, DOI 10.1309/BG5VA8JRDQH1M7HN
   Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763
   Burrage PS, 2007, CURR DRUG TARGETS, V8, P293, DOI 10.2174/138945007779940098
   Campeau PM, 2009, BLOOD, V114, P3181, DOI 10.1182/blood 2009 02 205708
   Cox TM, 2010, BIOL TARGETS THER, V4, P299, DOI 10.2147/BTT.S7582
   Deegan PB, 2011, MEDICINE, V90, P52, DOI 10.1097/MD.0b013e3182057be4
   Deegan PB, 2005, BLOOD CELL MOL DIS, V35, P259, DOI 10.1016/j.bcmd.2005.05.005
   FINKELSTEIN R, 1992, CLIN INFECT DIS, V15, P771, DOI 10.1093/clind/15.5.771
   Goker Alpan O, 2011, MOL GENET METAB, V104, P438, DOI 10.1016/j.ymgme.2011.08.004
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   GRABOWSKI GA, 2009, ONLINE METABOLIC MOL
   Haynes DR, 2004, INFLAMM RES, V53, P596, DOI 10.1007/s00011 004 1303 z
   HIBBS MS, 1985, J BIOL CHEM, V260, P2493
   HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084
   Kacher Y, 2009, BLOOD CELL MOL DIS, V43, P134, DOI 10.1016/j.bcmd.2009.03.006
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Kotake S, 1996, J BONE MINER RES, V11, P88
   Lacerda L, 1999, BLOOD CELL MOL DIS, V25, P130, DOI 10.1006/bcmd.1999.0237
   Lecourt S, 2012, STEM CELLS DEV, V21, P239, DOI 10.1089/scd.2011.0365
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Magal I, 2006, BRIT J HAEMATOL, V133, P93, DOI 10.1111/j.1365 2141.2006.05978.x
   Margalit M, 2002, POSTGRAD MED J, V78, P564, DOI 10.1136/pmj.78.923.564
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Mikosch P, 2011, BEST PRACT RES CL RH, V25, P665, DOI 10.1016/j.berh.2011.10.015
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Moran MT, 2000, BLOOD, V96, P1969, DOI 10.1182/blood.V96.5.1969.h8001969_1969_1978
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Okamoto K, 2011, INT IMMUNOPHARMACOL, V11, P543, DOI 10.1016/j.intimp.2010.11.010
   Pavlova EV, 2011, BLOOD CELL MOL DIS, V46, P27, DOI 10.1016/j.bcmd.2010.10.010
   Roggia C, 2004, Minerva Med, V95, P125
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schueler UH, 2004, J INHERIT METAB DIS, V27, P649, DOI 10.1023/B:BOLI.0000042959.44318.7c
   Suda T, 2001, Novartis Found Symp, V232, P235
   Takayanagi H, 2010, ANN NY ACAD SCI, V1192, P117, DOI 10.1111/j.1749 6632.2009.05303.x
   Takayanagi H, 2010, ADV EXP MED BIOL, V658, P61, DOI 10.1007/978 1 4419 1050 9_7
   van Dussen L, 2011, J CLIN ENDOCR METAB, V96, P2194, DOI 10.1210/jc.2011 0162
   VANCE DE, 1967, J LIPID RES, V8, P621
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Weitzmann MN, 2005, IMMUNOL REV, V208, P154, DOI 10.1111/j.0105 2896.2005.00324.x
   YATZIV S, 1988, J LAB CLIN MED, V111, P416
   Yoshino M, 2007, PEDIATR INT, V49, P959, DOI 10.1111/j.1442 200X.2007.02502.x
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 47
TC 31
Z9 33
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 1119
EI 1879 0038
J9 GENE
JI Gene
PD NOV 1
PY 2012
VL 509
IS 1
BP 51
EP 59
DI 10.1016/j.gene.2012.07.071
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 015GW
UT WOS:000309435400006
PM 23010424
OA Green Published
DA 2025 08 17
ER

PT J
AU Mannavola, F
   Mandala, M
   Todisco, A
   Sileni, VC
   Palla, M
   Minisini, AM
   Pala, L
   Morgese, F
   Di Guardo, L
   Stucci, LS
   Guida, M
   Indini, A
   Quaglino, P
   Ferraresi, V
   Marconcini, R
   Tronconi, MC
   Rossi, E
   Nigro, O
   Occelli, M
   Cortellini, A
   Quadrini, S
   Palmieri, G
   Pigozzo, J
   Ascierto, PA
   Vitale, MG
   Strippoli, S
   Ferrucci, PF
   Berardi, R
   Randon, G
   Cardone, P
   Schinzari, G
   Silvestris, F
   Tucci, M
AF Mannavola, Francesco
   Mandala, Mario
   Todisco, Annalisa
   Sileni, Vanna Chiarion
   Palla, Marco
   Minisini, Alessandro Marco
   Pala, Laura
   Morgese, Francesca
   Di Guardo, Lorenza
   Stucci, Luigia Stefania
   Guida, Michele
   Indini, Alice
   Quaglino, Pietro
   Ferraresi, Virginia
   Marconcini, Riccardo
   Tronconi, Maria Chiara
   Rossi, Ernesto
   Nigro, Olga
   Occelli, Marcella
   Cortellini, Alessio
   Quadrini, Silvia
   Palmieri, Giuseppe
   Pigozzo, Jacopo
   Ascierto, Paolo Antonio
   Vitale, Maria Grazia
   Strippoli, Sabino
   Ferrucci, Pier Francesco
   Berardi, Rossana
   Randon, Giovanni
   Cardone, Pietro
   Schinzari, Giovanni
   Silvestris, Franco
   Tucci, Marco
CA Italian Melanoma Intergrp IMI
TI An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact
   of Immunotherapy and Radiotherapy on Survival
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE melanoma; bone metastases; SREs; immunotherapy; bisphosphonates;
   denosumab
ID SKELETAL RELATED EVENTS; CANCER PATIENTS; MALIGNANT MELANOMA;
   CLINICAL OUTCOMES; PROSTATE CANCER; RISK FACTORS; BREAST; DABRAFENIB;
   TRAMETINIB; HEALTH
AB Background We performed a multicenter retrospective observational study to investigate the impact of clinical pathological features and therapeutic strategies on both the complications and survival of patients with bone metastases (BMs) from malignant melanoma. Patients and Methods A total of 305 patients with melanoma and radiological evidence of BMs were retrospectively enrolled from 19 Italian centers. All patients received conventional treatments in accordance with each own treating physician's practice. Both univariate and multivariate models were used to explore the impact of melanoma features, including skeletal related events (SREs), and different treatments on both overall survival (OS) and time to SREs. The chi squared test evaluated the suitability of several parameters to predict the occurrence of SREs. Results Eighty three percent of patients had metachronous BMs. The prevalent (90%) bone metastatic site was the spine, while 45% had involvement of the appendicular skeleton. Forty seven percent experienced at least one SRE, including palliative radiotherapy (RT) in 37% of cases. No melanoma associated factor was predictive of the development of SREs, although patients receiving early treatment with bone targeted agents showed 62% lower risk and delayed time of SRE occurrence. Median OS from the diagnosis of bone metastasis was 10.7 months. The multivariate analysis revealed as independent prognostic factors the number of BMs, number of metastatic organs, baseline lactate dehydrogenase levels, and treatment with targeted therapy or immunotherapy. Subgroup analyses showed the best OS (median = 16.5 months) in the subset of patients receiving both immunotherapy and palliative RT. Conclusion Based on our results, patients undergoing immunotherapy and palliative RT showed an OS benefit suggestive of a possible additive effect. The apparent protective role of bone targeting agent use on SREs observed in our analysis should deserve prospective evaluation.
C1 [Mannavola, Francesco; Todisco, Annalisa; Stucci, Luigia Stefania; Silvestris, Franco; Tucci, Marco] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Bari, Italy.
   [Mandala, Mario; Indini, Alice] Azienda Osped Papa Giovanni XXIII Hosp, Dept Oncol & Hematol, Med Oncol Unit, Bergamo, Italy.
   [Sileni, Vanna Chiarion; Pigozzo, Jacopo] Veneto Inst Oncol, Sci Inst Res Hospitalizat & Healthcare, Melanoma Oncol Unit, Padua, Italy.
   [Palla, Marco; Ascierto, Paolo Antonio] Ist Nazl Tumori IRCCS Fdn Pascale, Melanoma Canc Immunotherapy & Dev Therapeut, Naples, Italy.
   [Minisini, Alessandro Marco; Vitale, Maria Grazia] Azienda Sanitaria Univ Friuli Centrale, Dept Oncol, Udine, Italy.
   [Pala, Laura; Ferrucci, Pier Francesco] European Inst Oncol, Sci Inst Res Hospitalizat & Healthcare, Div Melanoma Sarcoma & Rare Tumors, Milan, Italy.
   [Morgese, Francesca; Berardi, Rossana] Univ Politecn Marche, Oncol Clin, Ancona, Italy.
   [Di Guardo, Lorenza; Randon, Giovanni] Natl Inst Tumori, Dept Med Oncol & Hematol, Melanoma Med Oncol Unit, Milan, Italy.
   [Guida, Michele; Strippoli, Sabino; Tucci, Marco] IRCCS Giovanni Paolo II, Canc Inst, Bari, Italy.
   [Quaglino, Pietro; Cardone, Pietro] Univ Turin, Dept Med Sci, Dermatol Clin, Turin, Italy.
   [Ferraresi, Virginia] IRCCS Regina Elena Natl Canc Inst, Div Med Oncol 1, Rome, Italy.
   [Marconcini, Riccardo] Univ Pisa, Santa Chiara Hosp, Med Oncol Dept, Pisa, Italy.
   [Tronconi, Maria Chiara] Humanitas Clin & Res Ctr, IRCCS, Humanitas Canc Ctr, Med Oncol & Hematol Unit, Rozzano, Italy.
   [Rossi, Ernesto; Schinzari, Giovanni] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol, Rome, Italy.
   [Nigro, Olga] Osped Circolo & Fdn Macchi, ASST Sette Laghi, Med Oncol, Varese, Italy.
   [Occelli, Marcella] Santa Croce & Carle Teaching Hosp, Med Oncol Unit, Cuneo, Italy.
   [Cortellini, Alessio] Univ Aquila, San Salvatore Hosp, Dept Biotechnol & Appl Clin Sci, Laquila, Italy.
   [Quadrini, Silvia] Azienda Sanitaria Locale Frosinone, Med Oncol Unit, Frosinone, Italy.
   [Palmieri, Giuseppe] CNR, Inst Genet & Biomed Res, Unit Canc Genet, Sassari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; ASST Papa Giovanni XXIII;
   IRCCS Istituto Oncologico Veneto (IOV); IRCCS Fondazione Pascale; IRCCS
   European Institute of Oncology (IEO); Marche Polytechnic University;
   Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Turin;
   Santa Chiara Hospital; University of Pisa; IRCCS Humanitas Research
   Hospital; Catholic University of the Sacred Heart; IRCCS Policlinico
   Gemelli; Ospedale Circolo & Fondazione Macchi; ASST dei Sette Laghi;
   University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Ricerca Genetica e Biomedica (IRGB CNR)
RP Tucci, M (通讯作者)，Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Bari, Italy.; Tucci, M (通讯作者)，IRCCS Giovanni Paolo II, Canc Inst, Bari, Italy.
EM marco.tucci@uniba.it
RI Berardi, Rossana/AAC 5758 2022; Vitale, MariaGrazia/LRU 6171 2024; Di
   Guardo, Lorenza/L 6850 2017; Pigozzo, Jacopo/AAD 5994 2021; stucci,
   luigia/I 7465 2018; Pala, Laura/AHD 9154 2022; Quaglino,
   Pietro/AAC 6122 2022; Ascierto, Paolo/J 9106 2016; Ferrucci,
   Pier/AAQ 9002 2020; Tucci, Marco/K 5136 2016; Indini,
   Alice/AAC 2396 2022; Cortellini, Alessio/AAB 8609 2019; ferraresi,
   virginia/ABH 7898 2020; Pigozzo, Jacopo/K 2503 2016; Tronconi, Maria
   Chiara/AAB 8590 2021; Rossi, Ernesto/AAB 7519 2022; Guida,
   Michele/AAG 7017 2020; nigro, olga/NFT 1193 2025; chiarion sileni,
   vanna/B 9042 2018; strippoli, sabino/AAF 6774 2021; Palmieri,
   Giuseppe/AAX 2627 2021; mandala, mario/AAB 8637 2022; Morgese,
   Francesca/AAC 4123 2022
OI Morgese, Francesca/0000 0002 0994 3713; QUAGLINO,
   Pietro/0000 0003 4185 9586; Ferrucci, Pier
   Francesco/0000 0001 6255 5851; Tronconi, Maria
   Chiara/0000 0003 4911 2823; Cortellini, Alessio/0000 0002 1209 5735;
   Pigozzo, Jacopo/0000 0003 2427 8915; Rossi, Ernesto/0000 0002 6442 1707;
   chiarion sileni, vanna/0000 0001 9191 9124; ferraresi,
   virginia/0000 0001 6419 1668; Vitale, Maria Grazia/0000 0003 2331 5315; 
FU "Precision Medicine" project
FX This work was funded by the "Precision Medicine" project.
CR Abdel Rahman O, 2018, J DERMATOL TREAT, V29, P176, DOI 10.1080/09546634.2017.1360987
   Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   Ahern E, 2017, CLIN CANCER RES, V23, P5789, DOI 10.1158/1078 0432.CCR 17 0606
   Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044
   Angela Y, 2019, CANCER IMMUNOL IMMUN, V68, P1187, DOI 10.1007/s00262 019 02353 5
   Ascierto PA, 2019, NAT MED, V25, P941, DOI 10.1038/s41591 019 0448 9
   Bäuerle T, 2011, INT J CANCER, V128, P2453, DOI 10.1002/ijc.25563
   Barnes M, 2015, J BONE ONCOL, V4, P107, DOI 10.1016/j.jbo.2015.10.002
   Bostel T, 2016, TUMORI J, V102, P156, DOI 10.5301/tj.5000382
   Cafforio P, 2014, J BONE MINER RES, V29, P55, DOI 10.1002/jbmr.2022
   Chu GCY, 2014, CANCER METAST REV, V33, P497, DOI 10.1007/s10555 013 9488 7
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   D'Oronzo S, 2015, CANCER TREAT REV, V41, P798, DOI 10.1016/j.ctrv.2015.09.003
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078 0432.CCR 12 1630
   Grassberger C, 2019, NAT REV CLIN ONCOL, V16, P729, DOI 10.1038/s41571 019 0238 9
   James ND, 2016, JAMA ONCOL, V2, P493, DOI 10.1001/jamaoncol.2015.5570
   Kawai AT, 2019, PROSTATE CANCER US, V2019, DOI 10.1155/2019/5971615
   Liu Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0647 8
   LONG GV, 2020, J CLIN ONCOL S, V0038, DOI DOI 10.1200/jco.2020.38.5_suppl.57
   Mannavola F, 2019, J TRANSL MED, V17, DOI 10.1186/s12967 019 1982 4
   Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6
   Oster G, 2013, SUPPORT CARE CANCER, V21, P3279, DOI 10.1007/s00520 013 1887 3
   Petrelli F, 2019, MELANOMA RES, V29, P1, DOI 10.1097/CMR.0000000000000520
   Schadendorf D, 2017, EUR J CANCER, V82, P45, DOI 10.1016/j.ejca.2017.05.033
   SELBY HM, 1956, RADIOLOGY, V67, P224, DOI 10.1148/67.2.224
   Smyth MJ, 2016, J CLIN ONCOL, V34, pE104, DOI 10.1200/JCO.2013.51.3572
   Stucci S, 2015, CRIT REV ONCOL HEMAT, V96, P183, DOI 10.1016/j.critrevonc.2015.05.018
   Sullivan RJ, 2019, NAT MED, V25, P929, DOI 10.1038/s41591 019 0474 7
   Tanaka R, 2016, ONCOLOGIST, V21, P508, DOI 10.1634/theoncologist.2015 0377
   Tas F, 2012, J ONCOL, V2012, DOI 10.1155/2012/647684
   Tucci M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01148
   Tucci Marco, 2018, Oncotarget, V9, P20826, DOI 10.18632/oncotarget.24846
   Tucci M, 2014, LANCET ONCOL, V15, pE584, DOI 10.1016/S1470 2045(14)70462 0
   Ulas A, 2016, TUMOR BIOL, V37, P1131, DOI 10.1007/s13277 015 3907 z
   Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078 0432.CCR 11 2479
   Wong MHF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub3
   Zekri J, 2017, J BONE ONCOL, V8, P13, DOI 10.1016/j.jbo.2017.08.003
   Zhang DX, 2019, MELANOMA RES, V29, P77, DOI 10.1097/CMR.0000000000000538
   2018, NAT REV DRUG DISCOV, V0017, P00854
NR 40
TC 18
Z9 18
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 15
PY 2020
VL 10
AR 1652
DI 10.3389/fonc.2020.01652
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA NY2ZN
UT WOS:000576264400001
PM 33042809
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lovato, C
   Lewiecki, EM
AF Lovato, Christina
   Lewiecki, E. Michael
TI Emerging anabolic agents in the treatment of osteoporosis
SO EXPERT OPINION ON EMERGING DRUGS
LA English
DT Article
DE Abaloparatide; osteoporosis; sclerostin; romosozumab; crisis
ID BONE MINERAL DENSITY; RANDOMIZED CLINICAL TRIAL; POSTMENOPAUSAL WOMEN;
   STRONTIUM RANELATE; ROMOSOZUMAB TREATMENT; VERTEBRAL FRACTURE;
   CYNOMOLGUS MONKEYS; SALMON CALCITONIN; RISK; ABALOPARATIDE
AB Introduction: Osteoporosis is a common skeletal disease with serious consequences due to osteoporotic fractures and high costs to society for post fracture care. Most patients at high risk for fracture are not receiving care to reduce fracture risk. The osteoporosis treatment gap has reached crisis proportions. Strategies to reduce the treatment gap include systematic methods for identifying and treating high risk patients, better education of patients and healthcare providers, better use of currently available drugs, and development of new drugs to treat osteoporosis.
   Areas covered: Two osteoanabolic agents with novel mechanisms of action have recently completed phase 3 clinical trials. The efficacy and safety findings of these studies are reviewed. Abaloparatide, a synthetic analog of parathyroid hormone related protein, has received regulatory approval for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Romosozumab, a humanized monoclonal antibody to sclerostin, an endogenous inhibitor of bone formation, is under regulatory review.
   Expert opinion: Osteoanabolic therapy for osteoporosis can restore, at least in part, the degradation of bone microarchitecture that is a hallmark of this disease. The emergence of new osteoanabolic compounds expands the treatment options for patients at high risk for fracture.
C1 [Lovato, Christina] Univ New Mexico, Hlth Sci Ctr, Div Endocrinol Diabet & Metab, Albuquerque, NM 87131 USA.
   [Lewiecki, E. Michael] New Mexico Clin Res & Osteoporosis Ctr, 300 Oak St NE, Albuquerque, NM 87106 USA.
C3 University of New Mexico; University of New Mexico's Health Sciences
   Center; New Mexico Clinical Research & Osteoporosis Center
RP Lewiecki, EM (通讯作者)，New Mexico Clin Res & Osteoporosis Ctr, 300 Oak St NE, Albuquerque, NM 87106 USA.
EM elewiecki@salud.unm.edu
RI Lewiecki, E./B 3706 2018
CR Agency EM, 2011, EUR MED AG REC LIM L
   American Society for Bone and Mineral Research, 2016, CALL ACT ADD CRIS TR
   Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   [Anonymous], 2016, BON HLTH IND SURV FI
   [Anonymous], Osteoporosis
   [Anonymous], CLIN PHARM
   [Anonymous], PROT OSS REM AV FURT
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   [Anonymous], ARCH OSTEOPOROS
   Bandeira L, 2016, EXPERT OPIN DRUG MET, V12, P681, DOI 10.1080/17425255.2016.1175436
   Baron Roland, 2007, Curr Osteoporos Rep, V5, P73
   BEIGHTON P, 1976, ANN INTERN MED, V84, P393, DOI 10.7326/0003 4819 84 4 393
   Binkley N, 2012, J BONE MINER RES, V27, P1821, DOI 10.1002/jbmr.1602
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Blake GM, 2007, J CLIN DENSITOM, V10, P113, DOI 10.1016/j.jocd.2007.01.002
   Camacho PM, 2016, ENDOCR PRACT, V22, P1111, DOI 10.4158/EP161435.ESGL
   Capriani C, 2012, J BONE MINER RES, V27, P2419, DOI 10.1002/jbmr.1800
   Cauley JA, 2008, OSTEOPOROSIS INT, V19, P1717, DOI 10.1007/s00198 008 0634 y
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   CHESTNUT CH, 1993, OSTEOPOROSIS INT, V3, pS206, DOI 10.1007/BF01621908
   Chouinard L, 2016, REGUL TOXICOL PHARM, V81, P212, DOI 10.1016/j.yrtph.2016.08.010
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cosman F, 2017, MAYO CLIN PROC, V92, P200, DOI 10.1016/j.mayocp.2016.10.009
   Cosman F, 2017, J BONE MINER RES, V32, P17, DOI 10.1002/jbmr.2991
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cranney A, 2002, ENDOCR REV, V23, P517, DOI 10.1210/er.2001 3002
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P313, DOI 10.1007/s00198 004 1689 z
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Feldstein AC, 2005, OSTEOPOROSIS INT, V16, P953, DOI 10.1007/s00198 005 1950 0
   Ferrari S, 2014, BEST PRACT RES CL EN, V28, P859, DOI 10.1016/j.beem.2014.08.002
   Genant HK, 2017, J BONE MINER RES, V32, P181, DOI 10.1002/jbmr.2932
   Hattersley G, 2014, EUR CALC TISS SOC C
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   International Osteoporosis Foundation, CAPT FRACT
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   Kanis JA, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657 016 0278 z
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Lewiecki EM, 2017, OSTEOPOROSIS INT, V28, P407, DOI 10.1007/s00198 016 3708 2
   Lewiecki EM, 2016, WOMENS HEALTH, V12, P79, DOI 10.2217/whe.15.97
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Lewiecki E Michael, 2011, Curr Osteoporos Rep, V9, P141, DOI 10.1007/s11914 011 0056 1
   Lewiecki EM, 2010, J CLIN DENSITOM, V13, P335, DOI 10.1016/j.jocd.2010.06.005
   Lewiecki EM, 2016, J BONE MINER RES S, V31, pS26
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   MARIE PJ, 1993, J BONE MINER RES, V8, P607
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Matheny JB, 2017, CALCIFIED TISSUE INT, V101, P82, DOI 10.1007/s00223 017 0258 3
   McClung MR, 2012, OSTEOPOROSIS INT, V23, P267, DOI 10.1007/s00198 011 1791 y
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Miller Paul D, 2004, Endocr Pract, V10, P139
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P852, DOI 10.1210/jc.2015 3156
   Misof BM, 2003, J CLIN ENDOCR METAB, V88, P1150, DOI 10.1210/jc.2002 021988
   Moreira CA, 2017, BONE, V97, P314, DOI 10.1016/j.bone.2016.11.004
   National Bone Health Alliance, FRACT PREV CENTR
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Odén A, 2015, OSTEOPOROSIS INT, V26, P2243, DOI 10.1007/s00198 015 3154 6
   Ominsky MS, 2017, J BONE MINER RES, V32, P788, DOI 10.1002/jbmr.3036
   Overman RA, 2013, ANN PHARMACOTHER, V47, P1675, DOI 10.1177/1060028013509233
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Panneman MJM, 2004, OSTEOPOROSIS INT, V15, P120, DOI 10.1007/s00198 003 1544 7
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Rotondi NK, 2016, J RHEUMATOL, V43, P1593, DOI 10.3899/jrheum.151409
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   Solomon DH, 2014, J BONE MINER RES, V29, P1929, DOI 10.1002/jbmr.2202
   Solomon DH, 2003, AM J MED, V115, P398, DOI 10.1016/S0002 9343(03)00357 7
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Tosi LL, 2008, J BONE JOINT SURG AM, V90A, P163, DOI 10.2106/JBJS.G.00682
   Wright NC, 2017, OSTEOPOROSIS INT, V28, P1225, DOI 10.1007/s00198 016 3865 3
NR 85
TC 12
Z9 13
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472 8214
EI 1744 7623
J9 EXPERT OPIN EMERG DR
JI Expert Opin Emerg. Drugs
PY 2017
VL 22
IS 3
BP 247
EP 257
DI 10.1080/14728214.2017.1362389
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FH1OS
UT WOS:000410909900005
PM 28756709
DA 2025 08 17
ER

PT J
AU Hildebrandt, S
   Baschant, U
   Thiele, S
   Tuckermann, J
   Hofbauer, LC
   Rauner, M
AF Hildebrandt, Susanne
   Baschant, Ulrike
   Thiele, Sylvia
   Tuckermann, Jan
   Hofbauer, Lorenz C.
   Rauner, Martina
TI Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro
   and in vivo
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BONE MINERAL DENSITY; INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY;
   RHEUMATOID ARTHRITIS; RESPONSE ELEMENTS; RECEPTOR; GROWTH; MASS;
   DIFFERENTIATION; TRANSCRIPTION
AB Glucocorticoid induced osteoporosis is a frequent complication of systemic glucocorticoid (GC) therapy and mainly characterized by suppressed osteoblast activity. Wnt16 derived from osteogenic cells is a key determinant of bone mass. Here, we assessed whether GC suppress bone formation via inhibiting Wnt16 expression. GC treatment with dexamethasone (DEX) decreased Wnt16 mRNA levels in murine bone marrow stromal cells (mBMSCs) time  and dose dependently. Similarly, Wnt16 expression was also suppressed after DEX treatment in calvarial organ cultures. Consistently, mice receiving GC containing slow release prednisolone pellets showed lower skeletal Wnt16 mRNA levels and bone mineral density than placebo treated mice. The suppression of Wnt16 by GCs was GC receptor dependent as co treatment of mBMSCs with DEX and the GR antagonist RU 486 abrogated the GC mediated suppression of Wnt16. Likewise, DEX failed to suppress Wnt16 expression in GR knockout mBMSCs. In addition, Wnt16 mRNA levels were unaltered in bone tissue of GC treated GR dimerization defective GR(dim) mice, suggesting that GCs suppress Wnt16 via direct DNA binding mechanisms. Consistently, DEX treatment reduced Wnt16 promoter activity in MC3T3 E1 cells. Finally, recombinant Wnt16 restored DEX induced suppression of bone formation in mouse calvaria. Thus, this study identifies Wnt16 as a novel target of GC action in GC induced suppression of bone formation.
C1 [Hildebrandt, Susanne; Baschant, Ulrike; Thiele, Sylvia; Hofbauer, Lorenz C.; Rauner, Martina] Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Dresden, Germany.
   [Hildebrandt, Susanne; Baschant, Ulrike; Thiele, Sylvia; Hofbauer, Lorenz C.; Rauner, Martina] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany.
   [Tuckermann, Jan] Univ Ulm, Inst Comparat Mol Endocrinol CME, Ulm, Germany.
   [Hildebrandt, Susanne] Free Univ Berlin, Inst Chem & Biochem, Berlin, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden; Ulm
   University; Free University of Berlin
RP Rauner, M (通讯作者)，Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Dresden, Germany.; Rauner, M (通讯作者)，Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany.
EM martina.rauner@uniklinikum dresden.de
RI ; Hofbauer, Lorenz/G 2490 2010; Rauner, Martina/A 1665 2015; Baschant,
   Ulrike/ABX 3545 2022; Hofbauer, Lorenz C./G 2490 2010
OI Tuckermann, Jan/0000 0003 3691 275X; Baschant,
   Ulrike/0000 0002 6862 1650; Rauner, Martina/0000 0002 4067 6799;
   Hofbauer, Lorenz C./0000 0002 8691 8423
FU Medical Faculty of the TU Dresden (MedDrive); German Research Foundation
   [SPP1468]; Excellence Initiative by the German Federal and State
   Governments; Deutsche Forschungsgemeinschaft [RA1923/1 1]; Deutsche
   Forschungsgemeinschaft ("IMMUNOBONE" priority program) [1468]; 
   [CRC1149]
FX This work was supported by start up grants from the Medical Faculty of
   the TU Dresden (MedDrive) to MR, UB and ST, the German Research
   Foundation (SPP1468 "Immunobone" to LCH and MR and JT), the Excellence
   Initiative by the German Federal and State Governments" (Institutional
   Strategy, measure "Support the best") to MR and LCH and CRC1149 to JT.
   This work was supported by grants from Deutsche Forschungsgemeinschaft
   (RA1923/1 1 and the "IMMUNOBONE" priority program 1468) to MR and LCH.
CR Alam I, 2017, ASBMR ANN M 2017
   Alam I, 2017, CALCIFIED TISSUE INT, V100, P361, DOI 10.1007/s00223 016 0225 4
   Alam I, 2016, ENDOCRINOLOGY, V157, P722, DOI 10.1210/en.2015 1281
   Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baschant U, 2013, MOL CELL ENDOCRINOL, V380, P108, DOI 10.1016/j.mce.2013.06.009
   Baschant U, 2012, NAT REV RHEUMATOL, V8, P645, DOI 10.1038/nrrheum.2012.166
   Baschant U, 2011, P NATL ACAD SCI USA, V108, P19317, DOI 10.1073/pnas.1105857108
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892
   Chen ZG, 2016, INT J MOL MED, V37, P329, DOI 10.3892/ijmm.2015.2432
   COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49
   Curtis JR, 2006, ARTHRIT RHEUM ARTHR, V55, P420, DOI 10.1002/art.21984
   DELANY AM, 1994, J CELL BIOCHEM, V56, P295, DOI 10.1002/jcb.240560304
   DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607
   García Ibarbia C, 2013, OSTEOPOROSIS INT, V24, P2449, DOI 10.1007/s00198 013 2302 0
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gori F, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.36
   Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704
   Hansen KE, 2014, SEMIN ARTHRITIS RHEU, V44, P47, DOI 10.1016/j.semarthrit.2014.02.002
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   Hendrickx G, 2014, BONE, V59, P57, DOI 10.1016/j.bone.2013.10.022
   Hofbauer LC, 2009, MOL ENDOCRINOL, V23, P1525, DOI 10.1210/me.2009 0069
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Kemp JP, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004423
   Koller DL, 2013, J BONE MINER RES, V28, P547, DOI 10.1002/jbmr.1796
   KRUSE NJ, 1978, BIOCHIM BIOPHYS ACTA, V540, P101, DOI 10.1016/0304 4165(78)90439 7
   LAAN RFJM, 1993, ANN INTERN MED, V119, P963, DOI 10.7326/0003 4819 119 10 199311150 00001
   Leclerc N, 2005, ARTHRITIS RHEUM US, V52, P929, DOI 10.1002/art.20872
   Lim HW, 2015, GENOME RES, V25, P836, DOI 10.1101/gr.188581.114
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Medina Gomez C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002718
   MEISLER N, 1995, J CELL BIOCHEM, V59, P376, DOI 10.1002/jcb.240590309
   Morimoto E, 2017, J CELL PHYSIOL, V232, P145, DOI 10.1002/jcp.25399
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Naganathan V, 2000, ARCH INTERN MED, V160, P2917, DOI 10.1001/archinte.160.19.2917
   Nilsson K., 2017, ASBMR ANN M 2017
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Olkku A, 2009, BONE, V44, P555, DOI 10.1016/j.bone.2008.11.013
   Oshagbemi OA, 2017, OSTEOPOROSIS INT, V28, P2859, DOI 10.1007/s00198 017 4115 z
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092 8674(00)81183 6
   SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411
   Surjit M, 2011, CELL, V145, P224, DOI 10.1016/j.cell.2011.03.027
   Thiele S, 2012, J BONE MINER RES, V27, P2242, DOI 10.1002/jbmr.1688
   Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034
   Vettorazzi S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8796
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Witte F, 2009, GENE EXPR PATTERNS, V9, P215, DOI 10.1016/j.gep.2008.12.009
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
NR 55
TC 38
Z9 42
U1 1
U2 12
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUN 7
PY 2018
VL 8
AR 8711
DI 10.1038/s41598 018 26300 z
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GI4YG
UT WOS:000434376700013
PM 29880826
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Centola, M
   Tonnarelli, B
   Schären, S
   Glaser, N
   Barbero, A
   Martin, I
AF Centola, Matteo
   Tonnarelli, Beatrice
   Schaeren, Stefan
   Glaser, Nicolas
   Barbero, Andrea
   Martin, Ivan
TI Priming 3D Cultures of Human Mesenchymal Stromal Cells Toward Cartilage
   Formation Via Developmental Pathways
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID HUMAN BONE MARROW; STEM CELLS; PROMOTES PROLIFERATION; WNT;
   DIFFERENTIATION; GROWTH; PROGENITORS; CHONDROGENESIS; SPECIFICATION;
   PLASTICITY
AB The field of regenerative medicine has increasingly recognized the importance to be inspired by developmental processes to identify signaling pathways crucial for 3D organogenesis and tissue regeneration. Here, we aimed at recapitulating the first events occurring during limb development (ie, cell condensation and expansion of an undifferentiated mesenchymal cell population) to prime 3D cultures of human bone marrow derived mesenchymal stromal/stem cells (hBM MSC) toward the chondrogenic route. Based on embryonic development studies, we hypothesized that Wnt3a and fibroblast growth factor 2 (FGF2) induce hBM MSC to proliferate in 3D culture as an undifferentiated pool of progenitors (defined by clonogenic capacity and expression of typical markers), retaining chondrogenic potential upon induction by suitable morphogens. hBM MSC were responsive to Wnt signaling in 3D pellet culture, as assessed by significant upregulation of main target genes and increase of unphosphorylated  catenin levels. Wnt3a was able to induce a five fold increase in the number of proliferating hBM MSC (6.4% vs. 1.3% in the vehicle condition), although total DNA content of the 3D construct was decreasing over time. Preconditioning with Wnt3a improved transforming growth factor 1 mediated chondrogenesis (30% more glycosaminoglycans/cell in average). In contrast to developmental and 2D MSC culture models, FGF2 antagonized the Wnt mediated effects. Interestingly, the CD146(+) subpopulation was found to be more responsive to Wnt3a. The presented data indicate a possible strategy to prime 3D cultures of hBM MSC by invoking a developmental engineering approach. The study also identifies some opportunities and challenges to cross fertilize skeletal development models and 3D hBM MSC culture systems.
C1 Univ Basel, Univ Basel Hosp, Dept Surg, Basel, Switzerland.
   Univ Basel, Univ Basel Hosp, Dept Biomed, Basel, Switzerland.
C3 University of Basel; University of Basel
RP Martin, I (通讯作者)，Univ Basel Hosp, Dept Surg, Hebelstr 20, CH 4031 Basel, Switzerland.
EM ivan.martin@usb.ch
RI ; Martin, Ivan/K 9286 2016
OI Barbero, Andrea/0000 0001 5252 789X; Martin, Ivan/0000 0001 6493 0432; 
FU Swiss National Science Foundation program "Sinergia" (SNF)
   [CRSII3_136179/1]
FX This work was partially funded by the Swiss National Science Foundation
   program "Sinergia" (SNF grant no. CRSII3_136179/1).
CR Abo A, 2012, NAT BIOTECHNOL, V30, P835, DOI 10.1038/nbt.2361
   Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Bénazet JD, 2009, SCIENCE, V323, P1050, DOI 10.1126/science.1168755
   Bianchi G, 2003, EXP CELL RES, V287, P98, DOI 10.1016/S0014 4827(03)00138 1
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Bianco P, 2011, J CELL BIOCHEM, V112, P1713, DOI 10.1002/jcb.23103
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Chen X, 2012, TISSUE ENG PT A, V18, P2528, DOI [10.1089/ten.tea.2012.0094, 10.1089/ten.TEA.2012.0094]
   Churchman SM, 2012, ARTHRITIS RHEUM US, V64, P2632, DOI 10.1002/art.34434
   Coutu DL, 2011, BLOOD, V117, P6801, DOI 10.1182/blood 2010 12 321539
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Delorme B, 2009, STEM CELLS, V27, P1142, DOI 10.1002/stem.34
   Di Maggio N, 2012, STEM CELLS, V30, P1455, DOI 10.1002/stem.1106
   Dickhut A, 2009, J CELL PHYSIOL, V219, P219, DOI 10.1002/jcp.21673
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304 4165(86)90306 5
   Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200
   Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035
   Grayson WL, 2006, J CELL PHYSIOL, V207, P331, DOI 10.1002/jcp.20571
   Inoue T, 2006, STEM CELLS, V24, P95, DOI 10.1634/stemcells.2005 0124
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Jukes JM, 2008, P NATL ACAD SCI USA, V105, P6840, DOI 10.1073/pnas.0711662105
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Lenas P, 2009, TISSUE ENG PART B RE, V15, P381, DOI [10.1089/ten.teb.2008.0575, 10.1089/ten.TEB.2008.0575]
   Leucht P, 2008, SEMIN CELL DEV BIOL, V19, P434, DOI 10.1016/j.semcdb.2008.09.002
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456
   Maruyama T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000727
   Oldershaw RA, 2011, NAT BIOTECHNOL, V28, P1187
   Russell KC, 2010, STEM CELLS, V28, P788, DOI 10.1002/stem.312
   Sabatino MA., 2012, J TISSUE ENG REGEN M
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sasai Y, 2013, NATURE, V493, P318, DOI 10.1038/nature11859
   Sasai Y, 2012, DEVELOPMENT, V139, P4111, DOI 10.1242/dev.079590
   Scotti C, 2013, P NATL ACAD SCI USA, V110, P3997, DOI 10.1073/pnas.1220108110
   Scotti C, 2010, P NATL ACAD SCI USA, V107, P7251, DOI 10.1073/pnas.1000302107
   Ströbel S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2942
   ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176
   Yu K, 2008, DEVELOPMENT, V135, P483, DOI 10.1242/dev.013268
NR 42
TC 35
Z9 38
U1 0
U2 25
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD NOV 1
PY 2013
VL 22
IS 21
BP 2849
EP 2858
DI 10.1089/scd.2013.0216
PG 10
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 234JN
UT WOS:000325639500004
PM 23777290
OA Green Published
DA 2025 08 17
ER

PT J
AU Butler, AM
   Cetin, K
   Hernandez, RK
   Reams, BD
   Overman, RA
   Kim, JI
   Hirsch, BR
   Abernethy, AP
   Liede, A
   Brookhart, MA
AF Butler, Anne M.
   Cetin, Karynsa
   Hernandez, Rohini K.
   Reams, B. Diane
   Overman, Robert A.
   Kim, Jung I.
   Hirsch, Bradford R.
   Abernethy, Amy P.
   Liede, Alexander
   Brookhart, M. Alan
TI Treatment dynamics of bone targeting agents among men with bone
   metastases from prostate cancer in the United States
SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
LA English
DT Article
DE bone targeting agents; competing risks; electronic health record data;
   patterns of use; pharmacoepidemiology; prostate cancer
ID SKELETAL RELATED EVENTS; QUALITY OF LIFE; ANDROGEN DEPRIVATION THERAPY;
   ZOLEDRONIC ACID; BREAST CANCER; CLINICAL FEATURES; SOLID TUMORS;
   ELDERLY MEN; RISK; DISEASE
AB PurposeTo examine the dynamics of treatment with 2 bone targeting agents (BTAs)denosumab and zoledronic acidamong men with bone metastases from prostate cancer.
   MethodsUsing electronic health record data from oncology practices across the US, we identified prostate cancer patients diagnosed with bone metastasis in 2012/2013 without evidence of BTA use within 6months prior to diagnosis. We examined the risk and predictors of BTA initiation, interruption, and re initiation.
   ResultsAmong 897 men diagnosed with prostate cancer, the cumulative incidence of BTA initiation after bone metastasis diagnosis was 34% (95% confidence interval [CI], 31 37%) at 30days, 64% (95% CI, 61 68%) at 180days, and 88% (95% CI, 85 91%) at 2years. Denosumab was initiated more frequently than zoledronic acid. Men with diabetes, more bone lesions, history of androgen deprivation therapy, or no hospice enrollment were more likely to initiate treatment. Following initiation, the cumulative incidence of treatment interruption was 17% (95% CI, 14 19%) at 60days and 70% (95% CI, 66 74%) at 2years, with interruption more likely among patients receiving emerging therapies for prostate cancer or enrolling in hospice. The cumulative incidence of re initiation following interruption was 36.3% (95% CI, 32.7 40.2%) at 15days, 49.8% (95% CI, 45.9 54.1%) at 30days, and 81.0% (95% CI, 77.5 84.7%) at 1year.
   ConclusionsBone targeting agent therapy is initiated by the majority of men living with bone metastases following a prostate cancer diagnosis; however, the timing of initiation is highly variable. Once on treatment, gaps or interruptions in therapy are common.
C1 [Butler, Anne M.; Reams, B. Diane; Brookhart, M. Alan] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Cetin, Karynsa; Hernandez, Rohini K.; Liede, Alexander] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Cetin, Karynsa; Hernandez, Rohini K.; Liede, Alexander] Amgen Inc, San Francisco, CA USA.
   [Overman, Robert A.] UNC Eshelman Sch Pharm, Div Pharmaceut Outcomes & Policy, Chapel Hill, NC USA.
   [Kim, Jung I.] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
   [Hirsch, Bradford R.; Abernethy, Amy P.] Flatiron Hlth, New York, NY USA.
   [Butler, Anne M.] Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63110 USA.
   [Butler, Anne M.] Washington Univ, Sch Med, Dept Surg, Div Publ Hlth Sci, St Louis, MO 63110 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   Amgen; Amgen; University of North Carolina; University of North Carolina
   Chapel Hill; Washington University (WUSTL); Washington University
   (WUSTL)
RP Brookhart, MA (通讯作者)，Univ North Carolina Chapel Hill, UNC Gillings Sch Global Publ Hlth, CB 7435, Chapel Hill, NC 27599 USA.
EM mabrook@email.unc.edu
RI Overman, Robert/C 4593 2015
OI Overman, Robert/0000 0001 9082 4625
FU Amgen, Inc.
FX Amgen, Inc.
CR Abernethy AP, 2017, J ONCOL PRACT, V13, P530, DOI 10.1200/JOP.2017.024224
   [Anonymous], XGEVA DEN
   [Anonymous], PROL DEN
   [Anonymous], ZOM ZOL AC
   [Anonymous], NCCN GUID PAT PROST
   Basch E, 2014, J CLIN ONCOL, V32, P3436, DOI 10.1200/JCO.2013.54.8404
   Beebe Dimmer JL, 2012, PHARMACOEPIDEM DR S, V21, P70, DOI 10.1002/pds.2258
   Cathomas R, 2014, UROL INT, V92, P377, DOI 10.1159/000358258
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cookson MS, 2013, J UROLOGY, V190, P429, DOI 10.1016/j.juro.2013.05.005
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Hatoum HT, 2008, CANCER, V113, P1438, DOI 10.1002/cncr.23775
   Hatoum HT, 2011, CLIN BREAST CANCER, V11, P177, DOI 10.1016/j.clbc.2011.03.015
   Heidenreich A, 2012, UROL INT, V89, P30, DOI 10.1159/000338810
   Hernandez RK, 2015, CLIN EPIDEMIOL, V7, P335, DOI 10.2147/CLEP.S85496
   Hernandez RK, 2014, SUPPORT CARE CANCER, V22, P2697, DOI 10.1007/s00520 014 2251 y
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Idota A, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064 016 2741 0
   Jayasekera J, 2014, PHARMACOECONOMICS, V32, P173, DOI 10.1007/s40273 013 0121 y
   Krupski TL, 2007, J UROLOGY, V178, P1423, DOI 10.1016/j.juro.2007.05.135
   Li Shuling, 2012, Clin Epidemiol, V4, P87, DOI 10.2147/CLEP.S28339
   Liede A, 2015, CLIN EPIDEMIOL, V7, P441, DOI 10.2147/CLEP.S92209
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   Parker C, 2015, ANN ONCOL, V26, pV69, DOI 10.1093/annonc/mdv222
   Raats M. M., 1992, Food Quality and Preference, V3, P89, DOI 10.1016/0950 3293(91)90028 D
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saad F, 2010, UROLOGY, V76, P1175, DOI 10.1016/j.urology.2010.05.026
   So A, 2012, CUAJ CAN UROL ASSOC, V6, P465, DOI [10.5489/cuaj.12149, 10.5489/cuaj.117]
   Tanaka R, 2016, ONCOLOGIST, V21, P508, DOI 10.1634/theoncologist.2015 0377
   Wardley A, 2005, BRIT J CANCER, V92, P1869, DOI 10.1038/sj.bjc.6602551
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Weinfurt KP, 2004, MED CARE, V42, P164, DOI 10.1097/01.mlr.0000108746.69256.45
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
NR 34
TC 8
Z9 9
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1053 8569
EI 1099 1557
J9 PHARMACOEPIDEM DR S
JI Pharmacoepidemiol. Drug Saf.
PD FEB
PY 2018
VL 27
IS 2
BP 229
EP 238
DI 10.1002/pds.4360
PG 10
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy
GA FU9UY
UT WOS:000424203800014
PM 29316026
DA 2025 08 17
ER

PT J
AU Gadi, J
   Jung, SH
   Lee, MJ
   Jami, A
   Ruthala, K
   Kim, KM
   Cho, NH
   Jung, HS
   Kim, CH
   Lim, SK
AF Gadi, Jogeswar
   Jung, Seung Hyun
   Lee, Min Jung
   Jami, Ajita
   Ruthala, Kalyani
   Kim, Kyoung Min
   Cho, Nam Hoon
   Jung, Han Sung
   Kim, Cheol Hee
   Lim, Sung Kil
TI The Transcription Factor Protein Sox11 Enhances Early Osteoblast
   Differentiation by Facilitating Proliferation and the Survival of
   Mesenchymal and Osteoblast Progenitors
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BONE FORMATION; EXPRESSION PATTERNS; GENE EXPRESSION; RUNX2; ZEBRAFISH;
   REPAIR; SUGGESTS; DEFECTS; THERAPY; OSTERIX
AB Sox11 deletion mice are known to exhibit developmental defects of craniofacial skeletal malformations, asplenia, and hypoplasia of the lung, stomach, and pancreas. Despite the importance of Sox11 in the developing skeleton, the role of Sox11 in osteogenesis has not been studied yet. In this study, we identified that Sox11 is an important transcription factor for regulating the proliferation and survival of osteoblast precursor cells as well as the self renewal potency of mesenchymal progenitor cells via up regulation of Tead2. Furthermore, Sox11 also plays an important role in the segregation of functional osteoblast lineage progenitors from osteochondrogenic progenitors. Facilitation of osteoblast differentiation from mesenchymal cells was achieved by enhanced expression of the osteoblast lineage specific transcription factors Runx2 and Osterix. Morpholino targeted disruption of Sox11 in zebrafish impaired organogenesis, including the bones, which were under mineralized. These results indicated that Sox11 plays a crucial role in the proliferation and survival of mesenchymal and osteoblast precursors by Tead2, and osteogenic differentiation by regulating Runx2 and Osterix.
C1 [Gadi, Jogeswar; Jami, Ajita; Kim, Kyoung Min; Lim, Sung Kil] Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol, Seoul 120752, South Korea.
   [Gadi, Jogeswar; Jami, Ajita; Kim, Kyoung Min; Lim, Sung Kil] Yonsei Univ, Coll Med, Dept Internal Med, Endocrine Res Inst, Seoul 120752, South Korea.
   [Lee, Min Jung; Jami, Ajita; Ruthala, Kalyani; Kim, Kyoung Min; Lim, Sung Kil] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea.
   [Cho, Nam Hoon] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea.
   [Ruthala, Kalyani] Yonsei Univ, Coll Med, Dept Anat, Embryol Lab, Seoul 120752, South Korea.
   [Jung, Seung Hyun; Kim, Cheol Hee] Chungnam Natl Univ, Dept Biol, Lab Dev Genet, Taejon 305764, South Korea.
   [Lee, Min Jung; Jung, Han Sung] Yonsei Univ, Coll Dent, Res Ctr Orofacial Hard Tissue Regenerat, Div Anat & Dev Biol,Dept Oral Biol, Seoul 120752, South Korea.
   [Jung, Seung Hyun] KIOM, Diabet Complicat Res Ctr, Div Tradit Korean Med TKM, Taejon 305811, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; Yonsei University; Yonsei University
   Health System; Yonsei University; Yonsei University Health System;
   Yonsei University; Yonsei University Health System; Chungnam National
   University; Yonsei University; Yonsei University Health System; Korea
   Institute of Oriental Medicine (KIOM)
RP Lim, SK (通讯作者)，Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol, 50 Yonsei Ro, Seoul 120752, South Korea.
EM lsk@yuhs.ac
RI Kim, Ji/AAN 5655 2021; Jung, Han Sung/I 3848 2012; Kim,
   Cheol Hee/F 6278 2013; Lee, Min/B 9579 2013
OI Jung, Han Sung/0000 0002 5563 7039; Jung, Han Sung/0000 0003 2795 531X;
   Kim, Cheol Hee/0000 0002 3019 0699; jo, namhun/0000 0002 0045 6441
FU National Research Foundation of Korea (NRF) [20120000486]; Korean
   government (MEST)
FX This work was supported by a National Research Foundation of Korea (NRF)
   Grant No. 20120000486 funded by the Korean government (MEST).
CR Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008
   Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792
   Chen F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024638
   De Martino S, 2000, DEV DYNAM, V217, P279, DOI 10.1002/(SICI)1097 0177(200003)217:3<279::AID DVDY6>3.0.CO;2 S
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162
   Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005
   Fu HH, 2007, J BIOMED MATER RES A, V83A, P770, DOI 10.1002/jbm.a.31356
   Gelse K, 2003, ARTHRITIS RHEUM US, V48, P430, DOI 10.1002/art.10759
   Hargrave M, 1997, DEV DYNAM, V210, P79, DOI 10.1002/(SICI)1097 0177(199710)210:2<79::AID AJA1>3.0.CO;2 6
   Hartmann C, 2009, CURR OPIN GENET DEV, V19, P437, DOI 10.1016/j.gde.2009.09.001
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   Hauptmann G, 2000, METH MOL B, V137, P139
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Koopman P, 2004, GENE, V328, P177, DOI 10.1016/j.gene.2003.12.008
   Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019
   Lengner CJ, 2005, J BIOL CHEM, V280, P15872, DOI 10.1074/jbc.M411144200
   Li N, 2009, DEV DYNAM, V238, P459, DOI 10.1002/dvdy.21838
   Lieberman JR, 1999, J BONE JOINT SURG AM, V81A, P905, DOI 10.2106/00004623 199907000 00002
   Lou Y, 2009, HUM MOL GENET, V18, P556, DOI 10.1093/hmg/ddn383
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nissen Meyer LSH, 2007, J CELL SCI, V120, P2785, DOI 10.1242/jcs.003855
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Park SJ, 2010, BONE, V46, P1498, DOI 10.1016/j.bone.2010.02.027
   Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534 5807(02)00223 X
   Sock E, 2004, MOL CELL BIOL, V24, P6635, DOI 10.1128/mcb.24.15.6635 6644.2004
   van der Meulen T, 2005, BBA GENE STRUCT EXPR, V1729, P105, DOI 10.1016/j.bbaexp.2005.03.008
   Zhou GD, 2006, TISSUE ENG, V12, P3209, DOI 10.1089/ten.2006.12.3209
NR 32
TC 47
Z9 50
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 30
PY 2013
VL 288
IS 35
BP 25400
EP 25413
DI 10.1074/jbc.M112.413377
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 302QC
UT WOS:000330619000037
PM 23888050
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Carter, PH
   Liu, RQ
   Foster, WR
   Tamasi, JA
   Tebben, AJ
   Favata, M
   Staal, A
   Cvijic, ME
   French, MH
   Dell, V
   Apanovitch, D
   Lei, M
   Zhao, QH
   Cunningham, M
   Decicco, CP
   Trzaskos, JM
   Feyen, JHM
AF Carter, Percy H.
   Liu, Rui Qin
   Foster, William R.
   Tamasi, Joseph A.
   Tebben, Andrew J.
   Favata, Margaret
   Staal, Ada
   Cvijic, Mary Ellen
   French, Michele H.
   Dell, Vanessa
   Apanovitch, Donald
   Lei, Ming
   Zhao, Qihong
   Cunningham, Mark
   Decicco, Carl P.
   Trzaskos, James M.
   Feyen, Jean H. M.
TI Discovery of a small molecule antagonist of the parathyroid hormone
   receptor by using an N terminal parathyroid hormone peptide probe
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE gene microarray; homology model; osteoporosis; bone
ID PHOTOAFFINITY CROSS LINKING; PROTEIN RECEPTOR; BINDING; ACTIVATION;
   MECHANISMS; AGONIST; ANALOGS; SWITCH
AB Once daily s.c. administration of either human parathyroid hormone (PTH) (1 84) or recombinant human PTH (1 34) provides for dramatic increases in bone mass in women with postmenopausal osteoporosis. We initiated a program to discover orally bioavailable small molecule equivalents of these peptides. A traditional high throughput screening approach using cAMP activation of the PTH/PTH related peptide receptor (PPR) as a readout failed to provide any lead compounds. Accordingly, we designed a new screen for this receptor that used a modified N terminal fragment of PTH as a probe for small molecule binding to the transmembrane region of the PPR, driven by the assumption that the pharmacological properties (agonist/antagonist) of compounds that bound to this putative signaling domain of the PPR could be altered by chemical modification. We developed DPC AJ1951, a 14 amino acid peptide that acts as a potent agonist of the PPR, and characterized its activity in ex vivo and in vivo assays of bone resorption. In addition, we studied its ability to initiate gene transcription by using microarray technology. Together, these experiments indicated that the highly modified 14 amino acid peptide induces qualitatively similar biological responses to those produced by PTH (1 34), albeit with lower potency relative to the parent peptide. Encouraged by these data, we performed a screen of a small compound collection by using DPC AJ1951 as the ligand. These studies led to the identification of the benzoxazepinone SW106, a previously unrecognized small molecule antagonist for the PPR. The binding of SW106 to the PPR was rationalized by using a homology receptor model.
C1 Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA.
C3 Bristol Myers Squibb
RP Carter, PH (通讯作者)，Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA.
EM percy.carter@bms.com
OI Foster, William/0000 0002 5594 0791
CR Beeley NRA, 2000, DRUG DISCOV TODAY, V5, P354, DOI 10.1016/S1359 6446(00)01528 2
   Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9
   Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498
   Carter Percy H., 2006, Endocrine Metabolic & Immune Disorders Drug Targets, V6, P59
   Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102
   Cocuzza AJ, 2001, BIOORG MED CHEM LETT, V11, P1389, DOI 10.1016/S0960 894X(01)00239 6
   Dean T, 2006, MOL ENDOCRINOL, V20, P931, DOI 10.1210/me.2005 0349
   Gensure RC, 2001, J BIOL CHEM, V276, P42692, DOI 10.1074/jbc.M106215200
   Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200
   Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033
   Shimizu M, 2001, ENDOCRINOLOGY, V142, P3068, DOI 10.1210/en.142.7.3068
   Shimizu N, 2005, J BIOL CHEM, V280, P1797, DOI 10.1074/jbc.M408270200
   Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Vilardaga JP, 2001, MOL ENDOCRINOL, V15, P1186, DOI 10.1210/me.15.7.1186
NR 15
TC 30
Z9 35
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 17
PY 2007
VL 104
IS 16
BP 6846
EP 6851
DI 10.1073/pnas.0605125104
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 159ME
UT WOS:000245869200064
PM 17428923
OA Green Published
DA 2025 08 17
ER

PT J
AU Lu, J
   Wang, ML
   Wang, ZY
   Fu, ZQ
   Lu, AP
   Zhang, G
AF Lu, Jun
   Wang, Maolin
   Wang, Ziyue
   Fu, Zhongqi
   Lu, Aiping
   Zhang, Ge
TI Advances in the discovery of cathepsin K inhibitors on bone resorption
SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
LA English
DT Article
DE Cathepsin K; osteoclast; bone resorption; osteoporosis; cathepsin K
   inhibitors
ID BETA SUBSTITUTED CYCLOHEXANECARBOXAMIDE; CHINESE HERBAL MEDICINE;
   CYSTEINE PROTEASE; POSTMENOPAUSAL WOMEN; SELECTIVE INHIBITORS; MINERAL
   DENSITY; 3,4 DISUBSTITUTED AZETIDINONES; ARYLAMINOETHYL AMIDES;
   OSTEOPOROSIS THERAPY; BIOCHEMICAL MARKERS
AB Cathepsin K (Cat K), highly expressed in osteoclasts, is a cysteine protease member of the cathepsin lysosomal protease family and has been of increasing interest as a target of medicinal chemistry efforts for its role in bone matrix degradation. Inhibition of the Cat K enzyme reduces bone resorption and thus, has rendered the enzyme as an attractive target for anti resorptive osteoporosis therapy. Over the past decades, considerable efforts have been made to design and develop highly potent, excellently selective and orally applicable Cat K inhibitors. These inhibitors are derived from synthetic compounds or natural products, some of which have passed preclinical studies and are presently in clinical trials at different stages of advancement. In this review, we briefly summarised the historic development of Cat K inhibitors and discussed the relationship between structures of inhibitors and active sites in Cat K for the purpose of guiding future development of inhibitors.
C1 [Lu, Jun; Wang, Maolin; Wang, Ziyue; Fu, Zhongqi; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Hong Kong, Peoples R China.
   [Lu, Jun; Wang, Maolin; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Inst Integrated Bioinfomed & Translat Sci IBTS, Hong Kong, Hong Kong, Peoples R China.
C3 Hong Kong Baptist University; Hong Kong Baptist University
RP Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Hong Kong, Peoples R China.
EM aipinglu@hkbu.edu.hk; zhangge@hkbu.edu.hk
RI Zhang, Ge/N 4150 2013; Lu, Jun/JBJ 8742 2023; LU, Aiping/JDX 0577 2023
OI Lu, Jun/0000 0003 1625 8682; FU, Zhongqi/0000 0003 0426 6263; Wang,
   Ziyue/0000 0002 4121 4799
CR Adami S, 2006, J BONE MINER RES, V21, pS24
   Allen JG, 2010, J MED CHEM, V53, P4332, DOI 10.1021/jm9018756
   Altmann E, 2006, BIOORG MED CHEM LETT, V16, P2549, DOI 10.1016/j.bmcl.2006.01.104
   Altmann E, 2003, BIOORG MED CHEM LETT, V13, P1997, DOI 10.1016/S0960 894X(03)00344 5
   Altmann E, 2002, J MED CHEM, V45, P2352, DOI 10.1021/jm010801s
   Altmann E, 2007, J MED CHEM, V50, P591, DOI 10.1021/jm0613525
   [Anonymous], INT J MOL SCI
   Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110
   Black WC, 2005, BIOORG MED CHEM LETT, V15, P4741, DOI 10.1016/j.bmcl.2005.07.071
   Borisek J, 2015, J MED CHEM, V58, P6928, DOI 10.1021/acs.jmedchem.5b00746
   Boros EE, 2004, BIOORG MED CHEM LETT, V14, P3425, DOI 10.1016/j.bmcl.2004.04.084
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Boyd MJ, 2009, BIOORG MED CHEM LETT, V19, P675, DOI 10.1016/j.bmcl.2008.12.053
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Bühling F, 2004, AM J PATHOL, V164, P2203, DOI 10.1016/S0002 9440(10)63777 7
   Cabal Antonio, 2017, Bone Rep, V6, P26, DOI 10.1016/j.bonr.2017.01.001
   Cai JQ, 2010, BIOORG MED CHEM LETT, V20, P4350, DOI 10.1016/j.bmcl.2010.06.072
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Chen LL, 2011, ARCH ORAL BIOL, V56, P1655, DOI 10.1016/j.archoralbio.2011.06.008
   Crane SN, 2006, J MED CHEM, V49, P1066, DOI 10.1021/jm051059p
   Dean JH, 1985, IMMUNOTOXICOLOGY IMM
   DesJarlais RL, 1998, J AM CHEM SOC, V120, P9114, DOI 10.1021/ja981171v
   Dossetter AG, 2012, J MED CHEM, V55, P6363, DOI 10.1021/jm3007257
   Duong LT, 2016, CALCIFIED TISSUE INT, V98, P381, DOI 10.1007/s00223 015 0051 0
   Eastell R, 2014, J BONE MINER RES, V29, P458, DOI 10.1002/jbmr.2047
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Falgueyret JP, 2005, J MED CHEM, V48, P7535, DOI 10.1021/jm0504961
   Falgueyret JP, 2004, ANAL BIOCHEM, V335, P218, DOI 10.1016/j.ab.2004.09.005
   Falgueyret JP, 2001, J MED CHEM, V44, P94, DOI 10.1021/jm0003440
   Fuller K, 2008, BONE, V42, P200, DOI 10.1016/j.bone.2007.09.044
   GANTE J, 1994, ANGEW CHEM INT EDIT, V33, P1699, DOI 10.1002/anie.199416991
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Gauthier JY, BIOORG MED CHEM LETT
   Grabowska UB, 2005, CURR OPIN DRUG DISC, V8, P619
   Greenspan PD, 2001, J MED CHEM, V44, P4524, DOI 10.1021/jm010206q
   Guay J, 1999, BONE, V25, P205, DOI 10.1016/S8756 3282(99)00160 X
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   Harslof T, 2016, CURR OPIN PHARMACOL, V28, P38, DOI 10.1016/j.coph.2016.02.012
   Helali AM, 2013, CURR DRUG TARGETS, V14, P1591, DOI 10.2174/13894501113149990202
   Hirsch HD, 2017, CLIN REPROD MED SURG, P195
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Hussein H, 2017, J VET PHARMACOL THER, V40, P327, DOI 10.1111/jvp.12368
   Isabel E, 2010, BIOORG MED CHEM LETT, V20, P887, DOI 10.1016/j.bmcl.2009.12.083
   Jeong JC, 2005, PHARMACOL RES, V51, P125, DOI 10.1016/j.phrs.2004.06.005
   Kim TS, 2006, CURR TOP MED CHEM, V6, P355, DOI 10.2174/156802606776287036
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   Law S, 2017, BIOCHEM J, V474, P851, DOI 10.1042/BCJ20160985
   Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656
   LEWIS CA, 1977, BIOCHEMISTRY US, V16, P4890, DOI 10.1021/bi00641a023
   Li CS, 2006, BIOORG MED CHEM LETT, V16, P1985, DOI 10.1016/j.bmcl.2005.12.071
   Marquis RW, 2001, J MED CHEM, V44, P1380, DOI 10.1021/jm000481x
   Marquis RW, 2001, J MED CHEM, V44, P725, DOI 10.1021/jm000320t
   McClung MR, 2014, ARTHRITIS RHEUMATOL, V66, pS987
   McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297 105
   MOON JB, 1986, J AM CHEM SOC, V108, P1350, DOI 10.1021/ja00266a066
   Mukwaya E, 2014, PHARM BIOL, V52, P1223, DOI 10.3109/13880209.2014.884606
   Novartis A, 2005, Patent No. [WO05049028, 05049028]
   Novinec M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4287
   Ochi Y, 2011, BONE, V49, P1351, DOI 10.1016/j.bone.2011.09.041
   Organon N, 2007, Patent No. [WO07080191, 07080191]
   Organon N., 2005, Patent No. [WO05011703, 05011703]
   Palmer JT, 2005, J MED CHEM, V48, P7520, DOI 10.1021/jm058198r
   Panwar P, 2016, BRIT J PHARMACOL, V173, P396, DOI 10.1111/bph.13383
   Papanastasiou P, 2006, J BONE MINER RES, V21, pS59
   Patil AD, 2002, J NAT PROD, V65, P628, DOI 10.1021/np010500l
   Patil AD, 2002, J NAT PROD, V65, P624, DOI 10.1021/np0105634
   PECK WA, 1993, AM J MED, V94, P646
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Qiu ZC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122116
   Quibell M, 2004, BIOORGAN MED CHEM, V12, P5689, DOI 10.1016/j.bmc.2004.07.054
   Rankovic Z, 2010, BIOORG MED CHEM LETT, V20, P1524, DOI 10.1016/j.bmcl.2010.01.100
   Robichaud J, 2004, BIOORG MED CHEM LETT, V14, P4291, DOI 10.1016/j.bmcl.2004.05.087
   Robichaud J, 2003, J MED CHEM, V46, P3709, DOI 10.1021/jm0301078
   Robichaud J, 2008, J MED CHEM, V51, P6410, DOI 10.1021/jm800610j
   Robichaud J, 2007, BIOORG MED CHEM LETT, V17, P3146, DOI 10.1016/j.bmcl.2007.03.028
   Setti EL, 2005, BIOORG MED CHEM LETT, V15, P1529, DOI 10.1016/j.bmcl.2004.12.088
   Setti EL, 2003, BIOORG MED CHEM LETT, V13, P2051, DOI 10.1016/S0960 894X(03)00304 4
   Sharma V, 2015, BIOCHEM J, V465, P163, DOI 10.1042/BJ20140809
   SHI GP, 1992, J BIOL CHEM, V267, P7258
   Shinozuka T, 2006, BIOORG MED CHEM LETT, V16, P1502, DOI 10.1016/j.bmcl.2005.12.053
   Shinozuka T, 2006, BIOORGAN MED CHEM, V14, P6789, DOI 10.1016/j.bmc.2006.06.032
   Shinozuka T, 2006, BIOORGAN MED CHEM, V14, P6807, DOI 10.1016/j.bmc.2006.06.031
   Soung DY, 2013, BONE, V55, P248, DOI 10.1016/j.bone.2013.02.010
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Sun JS, 2002, BIOMATERIALS, V23, P3377, DOI 10.1016/S0142 9612(02)00038 8
   Sun PJ, 2013, PHYTOMEDICINE, V20, P975, DOI 10.1016/j.phymed.2013.04.019
   SUZUE S, 1968, CHEM PHARM BULL, V16, P1417
   Tanaka M, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1625 y
   Teno N, 2008, J MED CHEM, V51, P5459, DOI 10.1021/jm800626a
   Teno N, 2007, BIOORG MED CHEM LETT, V17, P6096, DOI 10.1016/j.bmcl.2007.09.047
   Tu LY, 2017, INT J CLIN EXP MED, V10, P5977
   Volonterio A, 2003, CHEM EUR J, V9, P4510, DOI 10.1002/chem.200304881
   Wang D, 2004, INT J PHARM, V277, P73, DOI 10.1016/j.ijpharm.2003.03.003
   Wang D, 2002, BIOCHEMISTRY US, V41, P8849, DOI 10.1021/bi0257080
   Wang ZQ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/356260
   Ward YD, 2002, J MED CHEM, V45, P5471, DOI 10.1021/jm020209i
   Wijkmans J, 2011, EXPERT OPIN THER PAT, V21, P1611, DOI 10.1517/13543776.2011.616283
   Yamashita DS, 2000, CURR PHARM DESIGN, V6, P1, DOI 10.2174/1381612003401569
   Yamashita DS, 2006, J MED CHEM, V49, P1597, DOI 10.1021/jm050915u
   Yamashita DS, 1997, J AM CHEM SOC, V119, P11351, DOI 10.1021/ja972204u
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
   Yu NYC, 2017, J BIOMED MATER RES B, V105, P136, DOI 10.1002/jbm.b.33481
   Yuan XY, 2013, ORG BIOMOL CHEM, V11, P5847, DOI 10.1039/c3ob41165f
   Zaidi M, 2001, J BONE MINER RES, V16, P1747, DOI 10.1359/jbmr.2001.16.10.1747
NR 106
TC 59
Z9 65
U1 0
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1475 6366
EI 1475 6374
J9 J ENZYM INHIB MED CH
JI J. Enzym. Inhib. Med. Chem.
PY 2018
VL 33
IS 1
BP 890
EP 904
DI 10.1080/14756366.2018.1465417
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA GE9XH
UT WOS:000431583900003
PM 29723068
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hadaya, D
   Soundia, A
   Gkouveris, I
   Bezouglaia, O
   Dry, SM
   Pirih, FQ
   Aghaloo, TL
   Tetradis, S
AF Hadaya, D.
   Soundia, A.
   Gkouveris, I
   Bezouglaia, O.
   Dry, S. M.
   Pirih, F. Q.
   Aghaloo, T. L.
   Tetradis, S.
TI Antiresorptive Type and Discontinuation Timing Affect ONJ Burden
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE bone biology; bone remodeling; regeneration; oral and maxillofacial
   surgery; osteoclasts; osteonecrosis; osteoporosis
ID BISPHOSPHONATE RELATED OSTEONECROSIS; MEDICATION RELATED OSTEONECROSIS;
   RANKL INHIBITION; VERTEBRAL FRACTURES; TUMOR BURDEN; JAWS ONJ;
   DENOSUMAB; MECHANISM; THERAPY; MANAGEMENT
AB Osteonecrosis of the jaws (ONJ), a severe side effect of antiresorptive medications, is characterized by exposed, nonhealing bone in the oral cavity. Treatment options for ONJ range from management of symptomology to surgical resection of the affected area. Antiresorptive discontinuation, often termed a "drug holiday," has been used for managing ONJ patients. Antiresorptives can be discontinued prior to oral surgical procedures, such as tooth extraction, to prevent ONJ development or in patients with established ONJ to accelerate healing. Here, our objective was to test these clinical scenarios using the potent bisphosphonate, zoledronic acid (ZA), and the denosumab surrogate for rodents, OPG Fc, in a rat model of ONJ. Animals were pretreated with antiresorptives or saline, after which we induced ONJ using periapical disease and tooth extraction. In our first experimental design, antiresorptives were discontinued 1 wk prior to tooth extraction, and animals were evaluated 4 wk later for clinical, radiographic, and histologic features of ONJ. In the second experiment, ONJ was established and antiresorptives were discontinued for 4 wk. Discontinuation of OPG Fc, but not ZA, prior to tooth extraction ameliorated subsequent ONJ development. In contrast, discontinuation of either ZA or OPG Fc in rats with established ONJ did not lead to ONJ resolution. In conclusion, our findings suggest that antiresorptive discontinuation is dependent on both the type of antiresorptive and the timing of discontinuation.
C1 [Hadaya, D.; Soundia, A.; Gkouveris, I; Bezouglaia, O.; Aghaloo, T. L.; Tetradis, S.] UCLA, Div Diagnost & Surg Sci, Sch Dent, Los Angeles, CA 90095 USA.
   [Dry, S. M.] UCLA, David Geffen Sch Med Ucla, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
   [Pirih, F. Q.] UCLA, Div Constitut & Regenerat Sci, Sch Dent, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles
RP Aghaloo, TL; Tetradis, S (通讯作者)，UCLA, Sch Dent, 10833 Le Conte Ave,CHS Rm 53 068, Los Angeles, CA 90095 USA.
EM taghaloo@dentistry.ucla.edu; stetradis@dentistry.ucla.edu
FU Amgen; National Institutes of Health (NIH)/National Institute of Dental
   and Craniofacial Research (NIDCR) [R01 DE019465];  [T90/R90 DE007296]; 
   [F30 DE028171]; National Institute of Dental and Craniofacial Research
   [R01DE019465] Funding Source: NIH RePORTER
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by grants from Amgen and by National Institutes of Health
   (NIH)/National Institute of Dental and Craniofacial Research (NIDCR) R01
   DE019465 (ST). D. Hadaya was supported by T90/R90 DE007296 and F30
   DE028171.
CR Aghaloo TL, 2011, J BONE MINER RES, V26, P1871, DOI 10.1002/jbmr.379
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Anastasilakis AD, 2012, THER CLIN RISK MANAG, V8, P295, DOI 10.2147/TCRM.S24239
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Canon J, 2012, BREAST CANCER RES TR, V135, P771, DOI 10.1007/s10549 012 2222 2
   Canon J, 2010, BONE, V46, P1613, DOI 10.1016/j.bone.2010.03.001
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Carlson ER, 2009, J ORAL MAXIL SURG, V67, P85, DOI 10.1016/j.joms.2009.01.006
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Curtis JR, 2008, OSTEOPOROSIS INT, V19, P1613, DOI 10.1007/s00198 008 0604 4
   de Molon RS, 2015, J BONE MINER RES, V30, P1627, DOI 10.1002/jbmr.2490
   de Molon RS, 2014, BONE, V68, P11, DOI 10.1016/j.bone.2014.07.027
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Hadaya D, 2019, J ORAL MAXIL SURG, V77, P71, DOI 10.1016/j.joms.2018.08.010
   Hadaya D, 2018, J ORAL MAXIL SURG, V76, P2332, DOI 10.1016/j.joms.2018.05.025
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Lewiecki EM, 2008, BIOL TARGETS THER, V2, P645
   Miller PD, 2011, BONE, V49, P77, DOI 10.1016/j.bone.2010.12.024
   Miller RE, 2014, J THORAC ONCOL, V9, P345, DOI 10.1097/JTO.0000000000000070
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Ominsky MS, 2008, J BONE MINER RES, V23, P672, DOI 10.1359/JBMR.080109
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Ruggiero SL, 2015, J ORAL MAXIL SURG, V73, pS94, DOI 10.1016/j.joms.2015.09.024
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Schieferdecker A, 2014, ONCOTARGET, V5, P6647, DOI 10.18632/oncotarget.2160
   Soundia A, 2016, BONE, V90, P133, DOI 10.1016/j.bone.2016.06.011
   Watts NB, 2019, J CLIN ENDOCR METAB, V104, P2443, DOI 10.1210/jc.2018 01965
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Yang G, 2019, BONE, V124, P75, DOI 10.1016/j.bone.2019.04.010
   Yonemori K, 2008, CANCER SCI, V99, P1237, DOI 10.1111/j.1349 7006.2008.00803.x
   Zandi M, 2015, J CRANIO MAXILL SURG, V43, P1823, DOI 10.1016/j.jcms.2015.08.008
NR 40
TC 12
Z9 12
U1 2
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JUL
PY 2021
VL 100
IS 7
BP 746
EP 753
DI 10.1177/0022034520986804
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA SW0NM
UT WOS:000664214600012
PM 33478337
OA Green Published
DA 2025 08 17
ER

PT J
AU Hein, CD
   Liu, XM
   Chen, F
   Cullen, DM
   Wang, D
AF Hein, Christopher D.
   Liu, Xin Ming
   Chen, Fu
   Cullen, Diane M.
   Wang, Dong
TI The Synthesis of a Multiblock Osteotropic Polyrotaxane by
   Copper(I) Catalyzed Huisgen 1,3 Dipolar Cycloaddition
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE bisphosphonates; bone targeting; click chemistry; drug delivery systems;
   polyrotaxanes
ID TARGETED DRUG DELIVERY; PROSPECTIVE RANDOMIZED TRIAL; METASTATIC
   BREAST CANCER; POLY(ETHYLENE GLYCOL); CLICK CHEMISTRY; BONE;
   CYCLODEXTRIN; DOCETAXEL; OSTEOPOROSIS; MECHANISM
AB The design and synthesis of a novel bone targeting polyrotaxane delivery system that utilizes alendronate (ALN) as targeting moiety is presented in this manuscript. For the introduction of ALN, it is first conjugated to alpha cyclodextrin (alpha CD) and subsequently threaded onto a short poly(ethylene glycol) (PEG) chain, forming a pseudopolyrotaxane. Using click chemistry, this assembly is copolymerized with bulky monomers that bear imaging and/or therapeutic agent(s) to prevent ALN functionalized alpha CD from dethreading. Overall bone affinity of this novel polymer conjugate can be easily controlled by changing the number of ALN alpha CD incorporated. The osteotropicity of the delivery system was also confirmed in vivo.
C1 [Hein, Christopher D.; Liu, Xin Ming; Chen, Fu; Wang, Dong] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm, Omaha, NE 68198 USA.
   [Cullen, Diane M.] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68131 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   Creighton University
RP Wang, D (通讯作者)，Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm, 986025 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM dwang@unmc.edu
FU NIH [AR053325]; College of Pharmacy, University of Nebraska Medical
   Center
FX We acknowledge financial support from NIH (AR053325 to D.W.) and the
   College of Pharmacy, University of Nebraska Medical Center (teaching
   assistantship to C. D. H.).
CR [Anonymous], 1980, Enzym. Basis Detoxication
   Bock VD, 2006, EUR J ORG CHEM, V2006, P51, DOI 10.1002/ejoc.200500483
   BROWN SE, 1993, AUST J CHEM, V46, P953, DOI 10.1071/CH9930953
   Ceccato M, 1997, LANGMUIR, V13, P2436, DOI 10.1021/la9609231
   Chan S, 1999, J CLIN ONCOL, V17, P2341, DOI 10.1200/JCO.1999.17.8.2341
   Chan TR, 2004, ORG LETT, V6, P2853, DOI 10.1021/ol0493094
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Cisternas MG, 2009, J RHEUMATOL, V36, P2531, DOI 10.3899/jrheum.081068
   COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401
   DUTT MC, 1980, J CHROMATOGR, V195, P133
   EASTON CJ, 1999, MODIFIED CYCLODEXTRI, P252
   Fossella F, 2003, J CLIN ONCOL, V21, P3016, DOI 10.1200/JCO.2003.12.046
   Harada A, 1997, POLYM ADVAN TECHNOL, V8, P241, DOI 10.1002/(SICI)1099 1581(199704)8:4<241::AID PAT641>3.0.CO;2 L
   HARADA A, 1990, MACROMOLECULES, V23, P2821, DOI 10.1021/ma00212a039
   Heaney RP, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1697, DOI 10.1016/B978 0 12 373884 4.00010 0
   Hein CD, 2008, PHARM RES DORDR, V25, P2216, DOI 10.1007/s11095 008 9616 1
   Iqbal MM, 2000, SOUTH MED J, V93, P2
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521 3773(20010601)40:11<2004::AID ANIE2004>3.3.CO;2 X
   Li J, 2008, ADV DRUG DELIVER REV, V60, P1000, DOI 10.1016/j.addr.2008.02.011
   Liu XM, 2007, J CONTROL RELEASE, V122, P54, DOI 10.1016/j.jconrel.2007.06.021
   Liu XM, 2007, BIOMACROMOLECULES, V8, P2653, DOI 10.1021/bm070430i
   MELTON LD, 1971, CARBOHYD RES, V18, P29, DOI 10.1016/S0008 6215(00)80256 6
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Moon C, 2007, J CONTROL RELEASE, V124, P43, DOI 10.1016/j.jconrel.2007.08.029
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nabholtz JM, 1999, J CLIN ONCOL, V17, P1413, DOI 10.1200/JCO.1999.17.5.1413
   Ooya T, 2000, POLYM ADVAN TECHNOL, V11, P642, DOI 10.1002/1099 1581(200008/12)11:8/12<642::AID PAT15>3.0.CO;2 8
   ORME MW, 1994, BIOORG MED CHEM LETT, V4, P1375, DOI 10.1016/S0960 894X(01)80365 6
   Pan HZ, 2008, MOL PHARMACEUT, V5, P548, DOI 10.1021/mp800003u
   Raisz LG, 1997, ANN INTERN MED, V126, P458, DOI 10.7326/0003 4819 126 6 199703150 00007
   Ramos M, 2003, J CHEMOTHERAPY, V15, P192, DOI 10.1179/joc.2003.15.2.192
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Rodionov VO, 2005, ANGEW CHEM INT EDIT, V44, P2210, DOI 10.1002/anie.200461496
   SIMMONS MG, 1980, J CHEM SOC DALTON, P1827, DOI 10.1039/dt9800001827
   Uludag H, 2002, BIOTECHNOL PROGR, V18, P604, DOI 10.1021/bp0200447
   VANDALEN JP, 1974, J IMMUNOL METHODS, V5, P103, DOI 10.1016/0022 1759(74)90052 0
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P935, DOI 10.1016/j.addr.2004.12.012
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang J, 2010, J PHYS CHEM B, V114, P5342, DOI 10.1021/jp101068b
   WILLIAMS FM, 1987, PHARMACOL THERAPEUT, V34, P99, DOI 10.1016/0163 7258(87)90094 5
   Willson TM, 1996, BIOORG MED CHEM LETT, V6, P1043, DOI 10.1016/0960 894X(96)00164 3
   Yamashita A, 2008, J CONTROL RELEASE, V131, P137, DOI 10.1016/j.jconrel.2008.07.011
   ZHANG B, 1993, HUAXI YAOXUE ZAZHI, V8, P26
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhang XH, 2009, J HEPATOL, V50, pS147, DOI 10.1016/S0168 8278(09)60389 5
   Zhang XW, 2008, J POLYM SCI POL CHEM, V46, P5283, DOI 10.1002/pola.22856
NR 48
TC 16
Z9 25
U1 0
U2 32
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 5187
EI 1616 5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD DEC 8
PY 2010
VL 10
IS 12
BP 1544
EP 1556
DI 10.1002/mabi.201000205
PG 13
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA 694QP
UT WOS:000285313000017
PM 20954201
DA 2025 08 17
ER

PT J
AU Ehnert, S
   van Griensven, M
   Unger, M
   Scheffler, H
   Falldorf, K
   Fentz, AK
   Seeliger, C
   Schröter, S
   Nussler, AK
   Balmayor, ER
AF Ehnert, Sabrina
   van Griensven, Martijn
   Unger, Marina
   Scheffler, Hanna
   Falldorf, Karsten
   Fentz, Anne Kristin
   Seeliger, Claudine
   Schroeter, Steffen
   Nussler, Andreas K.
   Balmayor, Elizabeth R.
TI Co Culture with Human Osteoblasts and Exposure to Extremely Low
   Frequency Pulsed Electromagnetic Fields Improve Osteogenic
   Differentiation of Human Adipose Derived Mesenchymal Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE extremely low frequency pulsed electromagnetic fields (ELF PEMF);
   primary human osteoblasts (OBs); primary human adipose derived
   mesenchymal stem cells (Ad MSCs); primary human osteoclasts (OCs)
ID BONE; PROLIFERATION; MINERALIZATION; MECHANISMS; PHOSPHATASE
AB Human adipose derived mesenchymal stem cells (Ad MSCs) have been proposed as suitable option for cell based therapies to support bone regeneration. In the bone environment, Ad MSCs will receive stimuli from resident cells that may favor their osteogenic differentiation. There is recent evidence that this process can be further improved by extremely low frequency pulsed electromagnetic fields (ELF PEMFs). Thus, the project aimed at (i) investigating whether co culture conditions of human osteoblasts (OBs) and Ad MSCs have an impact on their proliferation and osteogenic differentiation; (ii) whether this effect can be further improved by repetitive exposure to two specific ELF PEMFs (16 and 26 Hz); (iii) and the effect of these ELF PEMFs on human osteoclasts (OCs). Osteogenic differentiation was improved by co culturing OBs and Ad MSCs when compared to the individual mono cultures. An OB to Ad MSC ratio of 3:1 had best effects on total protein content, alkaline phosphatase (AP) activity, and matrix mineralization. Osteogenic differentiation was further improved by both ELF PEMFs investigated. Interestingly, only repetitive exposure to 26 Hz ELF PEMF increased Trap5B activity in OCs. Considering this result, a treatment with gradually increasing frequency might be of interest, as the lower frequency (16 Hz) could enhance bone formation, while the higher frequency (26 Hz) could enhance bone remodeling.
C1 [Ehnert, Sabrina; Scheffler, Hanna; Schroeter, Steffen; Nussler, Andreas K.] Eberhard Karls Univ Tubingen, Siegfried Weller Inst Trauma Res, D 72076 Tubingen, Germany.
   [van Griensven, Martijn; Unger, Marina; Seeliger, Claudine; Balmayor, Elizabeth R.] Tech Univ Munich, Klinikum Rechts Isar, Expt Trauma Surg, D 81675 Munich, Germany.
   [Falldorf, Karsten; Fentz, Anne Kristin] Sachtleben GmbH, D 20251 Hamburg, Germany.
C3 Eberhard Karls University of Tubingen; Technical University of Munich
RP Balmayor, ER (通讯作者)，Tech Univ Munich, Klinikum Rechts Isar, Expt Trauma Surg, D 81675 Munich, Germany.
EM sabrina.ehnert@med.uni tuebingen.de; martijn.vangriensven@tum.de;
   marina.unger@tum.de; hscheffler@bgu tuebingen.de;
   falldorf@citresearch.de; fentz@citresearch.de; claudine.seeliger@tum.de;
   sschroeter@bgu tuebingen.de; andreas.nuessler@med.uni tuebingen.de;
   elizabeth.rosado balmayor@tum.de
RI ; Balmayor, E./N 9283 2015; Rosado Balmayor, Elizabeth/N 9283 2015; van
   Griensven, Martijn/F 5808 2012; Ehnert, Sabrina/AAE 8163 2019; Nussler,
   Andreas/H 3557 2019; Falldorf, Karsten/AAJ 1118 2020
OI Seeliger, Claudine/0000 0002 7631 444X; Falldorf,
   Karsten/0000 0001 9487 7097; Rosado Balmayor,
   Elizabeth/0000 0002 0484 4847; van Griensven,
   Martijn/0000 0001 5104 9881; Ehnert, Sabrina/0000 0003 4347 1702; 
FU Sachtleben GmbH (Hamburg); German Research Foundation (DFG); Technical
   University of Munich (TUM)
FX Sachtleben GmbH (Hamburg) supported the study by providing 4 Somagen
   devices and chip cards for application, as well as financial support for
   the required assay material. This work was supported by the German
   Research Foundation (DFG) and the Technical University of Munich (TUM)
   in the framework of the Open Access Publishing Program.
CR BASSETT CAL, 1974, SCIENCE, V184, P575
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Bulnheim U, 2014, J TISSUE ENG REGEN M, V8, P831, DOI 10.1002/term.1590
   Ciombor Deborah McK, 2005, Foot Ankle Clin, V10, P579, DOI 10.1016/j.fcl.2005.06.006
   Dawson JI, 2008, ARCH BIOCHEM BIOPHYS, V473, P124, DOI 10.1016/j.abb.2008.03.024
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Ehnert S, 2011, CELL TRANSPLANT, V20, P1465, DOI 10.3727/096368910X550224
   Ehnert S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14983 9
   Ehnert Sabrina, 2015, Bone Rep, V3, P48, DOI 10.1016/j.bonr.2015.08.002
   Gershovich JG, 2013, TISSUE ENG PT A, V19, P2565, DOI [10.1089/ten.tea.2013.0256, 10.1089/ten.TEA.2013.0256]
   Glueck M, 2015, BIORESEARCH OPEN ACC, V4, P121, DOI 10.1089/biores.2015.0002
   Granero Molto F, 2008, EXPERT OPIN BIOL TH, V8, P255, DOI 10.1517/14712598.8.3.255 
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Halleen JM, 2001, CLIN CHEM, V47, P597
   Hannouche D, 2001, J BONE JOINT SURG BR, V83B, P157, DOI 10.1302/0301 620X.83B2.12106
   Heino TJ, 2004, EXP CELL RES, V294, P458, DOI 10.1016/j.yexcr.2003.11.016
   Hong JM, 2014, BONE, V62, P99, DOI 10.1016/j.bone.2014.02.005
   Kelch S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16113 x
   Li ZL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020526
   Liu L, 2011, J CELL BIOL, V193, P257, DOI 10.1083/jcb.201010131
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Niemeyer P, 2010, BIOMATERIALS, V31, P3572, DOI 10.1016/j.biomaterials.2010.01.085
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Poh P. S. P., 2016, EUR CELLS MATER, V31, P122
   Prause M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/413097
   Prause M, 2014, INJURY, V45, P1156, DOI 10.1016/j.injury.2014.05.005
   Rubin J, 1996, J ORTHOPAED RES, V14, P7, DOI 10.1002/jor.1100140104
   Santos TS, 2015, J CELL BIOCHEM, V116, P2896, DOI 10.1002/jcb.25237
   Schmitt A, 2012, SCI WORLD J, DOI 10.1100/2012/384936
   Schneider S, 2017, EUR J MED RES, V22, DOI 10.1186/s40001 017 0258 9
   Shetty Sahana, 2016, Indian J Endocrinol Metab, V20, P846
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Smith JO, 2011, TISSUE ENG PART B RE, V17, P307, DOI [10.1089/ten.teb.2011.0143, 10.1089/ten.TEB.2011.0143]
   Spees JL, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0363 7
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Watanabe Y, 2016, INJURY, V47, pS47, DOI 10.1016/S0020 1383(16)30012 2
   Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50
   Yan XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090846
   Yumoto H, 2015, CELL PHYSIOL BIOCHEM, V35, P601, DOI 10.1159/000369722
   Zhang X, 2010, BIOCHEM BIOPH RES CO, V396, P662, DOI 10.1016/j.bbrc.2010.04.154
   Zhou J, 2014, BIOELECTROMAGNETICS, V35, P30, DOI 10.1002/bem.21794
   Zhou J, 2011, BONE, V49, P753, DOI 10.1016/j.bone.2011.06.026
NR 42
TC 37
Z9 39
U1 0
U2 18
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2018
VL 19
IS 4
AR 994
DI 10.3390/ijms19040994
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GJ0XU
UT WOS:000434978700073
PM 29584629
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gu, ZM
   Wang, H
   Xia, JL
   Yang, Y
   Jin, ZD
   Xu, HW
   Shi, JM
   De Domenico, I
   Tricot, G
   Zhan, FH
AF Gu, Zhimin
   Wang, He
   Xia, Jiliang
   Yang, Ye
   Jin, Zhendong
   Xu, Hongwei
   Shi, Jumei
   De Domenico, Ivana
   Tricot, Guido
   Zhan, Fenghuang
TI Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast
   Differentiation
SO CANCER RESEARCH
LA English
DT Article
ID MULTIPLE MYELOMA; HEPCIDIN EXPRESSION; IRON HOMEOSTASIS;
   DRUG RESISTANCE; CANCER; ACTIVATION; STAT3; INTERNALIZATION; METABOLISM;
   INDUCTION
AB Iron homeostasis is disrupted in multiple myeloma, a difficult to cure plasma cell malignancy with lytic bone lesions. Here, we systematically analyzed iron gene expression signature and demonstrated that mRNA expression of iron exporter ferroportin (FPN1) is significantly downregulated in myeloma cells and correlates negatively with clinic outcome. Restoring expression of FPN1 reduces intracellular liable iron pool, inhibits STAT3 MCL 1 signaling, and suppresses myeloma cells growth. Furthermore, we demonstrated that mRNA of FPN1 is also downregulated at the initial stages of osteoclast differentiation and suppresses myeloma cell induced osteoclast differentiation through regulating iron regulator TFRC, NF kappa B, and JNK pathways. Altogether, we demonstrated that down regulation of FPN1 plays critical roles in promoting myeloma cell growth and bone resorption in multiple myeloma. (C) 2015 AACR.
C1 [Gu, Zhimin; Wang, He; Xia, Jiliang; Yang, Ye; Xu, Hongwei; Tricot, Guido; Zhan, Fenghuang] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA.
   [Jin, Zhendong] Univ Iowa, Coll Pharm, Dept Pharmaceut Sci & Expt Therapeut, Iowa City, IA 52242 USA.
   [Shi, Jumei] Tongji Univ, Sch Med, Dept Hematol, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.
   [De Domenico, Ivana] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
C3 University of Iowa; University of Iowa; Tongji University; Utah System
   of Higher Education; University of Utah
RP Zhan, FH (通讯作者)，Univ Iowa, 285 Newton Rd,3257 CBRB, Iowa City, IA 52242 USA.
EM guido tricot@uiowa.edu; fenghuang zhan@uiowa.edu
RI YANG, YE/B 8740 2014; YANG, YE/F 4987 2015
OI Zhan, Fenghuang/0000 0001 6208 1676; YANG, YE/0000 0003 0228 5102
FU NIH [R01CA115399, R01CA152105, R21CA143887]; MMRF; Leukemia and Lymphoma
   Society TRP; Department of Internal Medicine, Carver College of
   Medicine, University of Iowa; National Natural Science Foundation of
   China, China [81228016]; NCI [P30CA086862]
FX This work was supported by NIH grants R01CA115399 (G. Tricot),
   R01CA152105 (F. Zhan), R21CA143887 (F. Zhan), the MMRF Senior (F. Zhan,
   2008 and 2010), the Leukemia and Lymphoma Society TRP (F. Zhan, 2010 and
   2011), and institutional start up funds from the Department of Internal
   Medicine, Carver College of Medicine, University of Iowa (F. Zhan and G.
   Tricot), and the National Natural Science Foundation of China, China
   (no. 81228016). The project described was supported by Award Number
   P30CA086862 from the NCI.
CR Andrews NC, 2008, BLOOD, V112, P219, DOI 10.1182/blood 2007 12 077388
   Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777
   Bennett CL, 2008, JAMA J AM MED ASSOC, V299, P914, DOI 10.1001/jama.299.8.914
   Campbell J A, 1940, Br Med J, V2, P275
   Catlett Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074 7613(00)80011 4
   Deicher R, 2006, EUR J CLIN INVEST, V36, P301, DOI 10.1111/j.1365 2362.2006.01633.x
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood 2009 03 209965
   Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104
   Gu ZM, 2010, BLOOD, V116, P5289, DOI 10.1182/blood 2010 02 267963
   Hetet G, 2003, BLOOD, V102, P1904, DOI 10.1182/blood 2003 02 0439
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Kakhlon O, 2002, BIOCHEM J, V363, P431, DOI 10.1042/0264 6021:3630431
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kristinsson SY, 2011, EXPERT REV MOL DIAGN, V11, P593, DOI [10.1586/erm.11.44, 10.1586/ERM.11.44]
   Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008 5472.CAN 11 1870
   Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood 2006 09 044974
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Peperzak V, 2013, NAT IMMUNOL, V14, P290, DOI 10.1038/ni.2527
   Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]
   Qiao B, 2012, CELL METAB, V15, P918, DOI 10.1016/j.cmet.2012.03.018
   Radulescu S, 2012, CELL REP, V2, P270, DOI 10.1016/j.celrep.2012.07.003
   Rice AE, 2009, J MOL BIOL, V386, P717, DOI 10.1016/j.jmb.2008.12.063
   RICHMOND HG, 1959, BMJ BRIT MED J, V1, P947, DOI 10.1136/bmj.1.5127.947
   Ross SL, 2012, CELL METAB, V15, P905, DOI 10.1016/j.cmet.2012.03.017
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Sharma S, 2008, CLIN CANCER RES, V14, P3262, DOI 10.1158/1078 0432.CCR 07 4153
   Shaughnessy JD, 2007, BLOOD, V109, P2276, DOI 10.1182/blood 2006 07 038430
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   VanderWall Kristina, 2013, Critical Reviews in Oncogenesis, V18, P449
   Waheed A, 2002, P NATL ACAD SCI USA, V99, P3117, DOI 10.1073/pnas.042701499
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Wrighting DM, 2006, BLOOD, V108, P3204, DOI 10.1182/blood 2006 06 027631
   Yang Y, 2014, ONCOTARGET, V5, P11986, DOI 10.18632/oncotarget.2388
   Yang Y, 2013, BLOOD, V122, P1437, DOI 10.1182/blood 2013 02 482919
   Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547
   Zhan FH, 2007, BLOOD, V109, P1692, DOI 10.1182/blood 2006 07 037077
   Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood 2005 11 013458
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001
   Zohn IE, 2007, BLOOD, V109, P4174, DOI 10.1182/blood 2007 01 066068
NR 47
TC 87
Z9 97
U1 2
U2 23
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2015
VL 75
IS 11
BP 2211
EP 2221
DI 10.1158/0008 5472.CAN 14 3804
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CL9XX
UT WOS:000357333500010
PM 25855377
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Rinotas, V
   Liepouri, F
   Ouzouni, MD
   Chalkidi, N
   Papaneophytou, C
   Lampropoulou, M
   Vidali, VP
   Kontopidis, G
   Couladouros, E
   Eliopoulos, E
   Papakyriakou, A
   Douni, E
AF Rinotas, Vagelis
   Liepouri, Fotini
   Ouzouni, Maria Dimitra
   Chalkidi, Niki
   Papaneophytou, Christos
   Lampropoulou, Mariza
   Vidali, Veroniki P.
   Kontopidis, George
   Couladouros, Elias
   Eliopoulos, Elias
   Papakyriakou, Athanasios
   Douni, Eleni
TI Structure Based Discovery of Receptor Activator of Nuclear Factor κB
   Ligand (RANKL) Induced Osteoclastogenesis Inhibitors
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE virtual screening; computer aided drug discovery; small molecule
   inhibitor; cell based assay; toxicity evaluation; synthesis; compound
   solubility
ID KAPPA B LIGAND; BONE RESORPTION; OSTEOPROTEGERIN LIGAND; RANKL;
   DIFFERENTIATION; DERIVATIVES; DENOSUMAB; OPTIMIZATION; OSTEOBLAST;
   CHEMISTRY
AB Receptor activator of nuclear factor & kappa;B ligand (RANKL) has been actively pursued as a therapeutic target for osteoporosis, given that RANKL is the master mediator of bone resorption as it promotes osteoclast differentiation, activity and survival. We employed a structure based virtual screening approach comprising two stages of experimental evaluation and identified 11 commercially available compounds that displayed dose dependent inhibition of osteoclastogenesis. Their inhibitory effects were quantified through TRAP activity at the low micromolar range (IC50 < 5 & mu;M), but more importantly, 3 compounds displayed very low toxicity (LC50 > 100 & mu;M). We also assessed the potential of an N (1 aryl 1H indol 5 yl)aryl sulfonamide scaffold that was based on the structure of a hit compound, through synthesis of 30 derivatives. Their evaluation revealed 4 additional hits that inhibited osteoclastogenesis at low micromolar concentrations; however, cellular toxicity concerns preclude their further development. Taken together with the structure activity relationships provided by the hit compounds, our study revealed potent inhibitors of RANKL induced osteoclastogenesis of high therapeutic index, which bear diverse scaffolds that can be employed in hit to lead optimization for the development of therapeutics against osteolytic diseases.
C1 [Rinotas, Vagelis; Chalkidi, Niki; Douni, Eleni] Biomed Sci Res Ctr Alexander Fleming, Inst Bioinnovat, 34 Fleming St, Vari 16672, Greece.
   [Liepouri, Fotini; Lampropoulou, Mariza; Couladouros, Elias] ProACTINA SA, 20 Delfon St, Athens 15125, Greece.
   [Ouzouni, Maria Dimitra; Couladouros, Elias] Agr Univ Athens, Dept Food Sci & Human Nutr, Lab Gen Chem, 75 Iera Odos, Athens 11855, Greece.
   [Papaneophytou, Christos; Kontopidis, George] Univ Thessaly, Vet Sch, Dept Biochem, 224 Trikalon, Kardhitsa 43131, Greece.
   [Papaneophytou, Christos] Univ Nicosia, Sch Life & Hlth Sci, Dept Life Sci, 46 Makedonitissas Ave, CY 2417 Nicosia, Cyprus.
   [Vidali, Veroniki P.] Natl Ctr Sci Res Demokritos, Inst Nanosci & Nanotechnol, Patr Gregoriou E & 27 Neapoleos Str, Athens 15341, Greece.
   [Eliopoulos, Elias; Douni, Eleni] Agr Univ Athens, Dept Biotechnol, Lab Genet, 75 Iera Odos, Athens 11855, Greece.
   [Papakyriakou, Athanasios] Natl Ctr Sci Res Demokritos, Inst Biosci & Applicat, Patr Gregoriou E & 27 Neapoleos Str, Athens 15341, Greece.
C3 Alexander Fleming Biomedical Sciences Research Center; Agricultural
   University of Athens; University of Thessaly; University of Nicosia;
   National Centre of Scientific Research "Demokritos"; Agricultural
   University of Athens; National Centre of Scientific Research
   "Demokritos"
RP Douni, E (通讯作者)，Biomed Sci Res Ctr Alexander Fleming, Inst Bioinnovat, 34 Fleming St, Vari 16672, Greece.; Douni, E (通讯作者)，Agr Univ Athens, Dept Biotechnol, Lab Genet, 75 Iera Odos, Athens 11855, Greece.; Papakyriakou, A (通讯作者)，Natl Ctr Sci Res Demokritos, Inst Biosci & Applicat, Patr Gregoriou E & 27 Neapoleos Str, Athens 15341, Greece.
EM thpap@bio.demokritos.gr; douni@aua.gr
RI ; Papakyriakou, Athanasios/K 7033 2012; Vidali, Veroniki/ADE 9531 2022;
   Papaneophytou, Christos/Y 3821 2019; Eliopoulos, Elias/HTM 7046 2023;
   Rinotas, Vagelis/KFA 6328 2024
OI Rinotas, Vagelis/0000 0002 2390 3136; 
FU project TheRAlead [09SYN 21 784]; European Union; Greek national funds
   through the Operational Program "Competitiveness & Entrepreneurship"
   [NSRF 2007 2013]
FX This work was funded by the project TheRAlead (09SYN 21 784),
   co financed by the European Union (European Regional Development
   Fund ERDF) and Greek national funds through the Operational Program
   "Competitiveness & Entrepreneurship", NSRF 2007 2013, in the context of
   GSRT National action "Cooperation".
CR Bender BJ, 2021, NAT PROTOC, V16, P4799, DOI 10.1038/s41596 021 00597 z
   Beroza P, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33981 8
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476 5381.2009.00190.x
   Chen CL, 2014, J MED CHEM, V57, P8072, DOI 10.1021/jm5007897
   Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Douni E, 2012, HUM MOL GENET, V21, P784, DOI 10.1093/hmg/ddr510
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Ferrari S, 2023, NAT REV RHEUMATOL, V19, P307, DOI 10.1038/s41584 023 00935 3
   Fischer A, 2021, J MED CHEM, V64, P2489, DOI 10.1021/acs.jmedchem.0c02227
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   He MM, 2005, SCIENCE, V310, P1022, DOI 10.1126/science.1116304
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263 7855(96)00018 5
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Jiang M, 2019, J MED CHEM, V62, P5370, DOI 10.1021/acs.jmedchem.8b02027
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee CC, 2015, EUR J MED CHEM, V98, P115, DOI 10.1016/j.ejmech.2015.05.015
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Luan XD, 2012, J IMMUNOL, V189, P245, DOI 10.4049/jimmunol.1103387
   Melagraki G, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00800
   Mettou A, 2018, SLAS DISCOV, V23, P84, DOI 10.1177/2472555217712507
   Miyata J, 2012, BIOORG MED CHEM LETT, V22, P5681, DOI 10.1016/j.bmcl.2012.06.087
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Ng KW, 2014, CURR OPIN PHARMACOL, V16, P58, DOI 10.1016/j.coph.2014.03.004
   Papaneophytou CP, 2013, PROTEIN EXPRES PURIF, V90, P9, DOI 10.1016/j.pep.2013.04.005
   Rinotas V, 2020, J MED CHEM, V63, P12043, DOI 10.1021/acs.jmedchem.0c01316
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Sisay M, 2017, ONCOTARGETS THER, V10, P3801, DOI 10.2147/OTT.S135867
   SOEKANTO A, 1994, CALCIFIED TISSUE INT, V54, P290, DOI 10.1007/BF00295953
   Stein RM, 2020, NATURE, V579, P609, DOI 10.1038/s41586 020 2027 0
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Ta HM, 2010, P NATL ACAD SCI USA, V107, P20281, DOI 10.1073/pnas.1011686107
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tseng CH, 2011, J MED CHEM, V54, P3103, DOI 10.1021/jm1016494
   Villoutreix BO, 2012, CURR PHARM DESIGN, V18, P4648
   Watts NB, 2017, J BONE MINER RES, V32, P1481, DOI 10.1002/jbmr.3119
   Yang K, 2022, J MED CHEM, V65, P10992, DOI 10.1021/acs.jmedchem.2c00081
   Zhu M, 2010, J MED CHEM, V53, P8760, DOI 10.1021/jm1011269
NR 49
TC 5
Z9 5
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2023
VL 24
IS 14
AR 11290
DI 10.3390/ijms241411290
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA N6QP4
UT WOS:001038237000001
PM 37511048
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Huang, ZB
   Li, GH
   Zhang, ZS
   Gu, RN
   Wang, WY
   Lai, XJ
   Cui, ZK
   Zeng, FY
   Xu, SY
   Deng, F
AF Huang, Zhibin
   Li, Guihuan
   Zhang, Zhishuai
   Gu, Ruonan
   Wang, Wenyang
   Lai, Xiaoju
   Cui, Zhong Kai
   Zeng, Fangyin
   Xu, Shiyuan
   Deng, Fan
TI 被撤回的出版物: β2AR HIF 1α CXCL12 signaling of osteoblasts activated by
   isoproterenol promotes migration and invasion of prostate cancer cells
   (Retracted article. See vol. 25, 2025)
SO BMC CANCER
LA English
DT Article; Retracted Publication
DE Chronic stress; Cancer; Bone metastasis; Sympathetic nerve
ID SYMPATHETIC NERVOUS SYSTEM; BETA BLOCKERS; MESENCHYMAL TRANSITION;
   DRUG USE; METASTASIS; EXPRESSION; EMT; COLONIZATION; GROWTH; AXIS
AB Background Chronic stress is well known to promote tumor progression, however, little is known whether chronic stress mediated regulation of osteoblasts contributes to the migration and invasion of metastatic cancer cells. Methods The proliferation, migration and invasion of prostate cancer cells were assessed by CCK 8 and transwell assay. HIF 1 alpha expression of osteoblasts and epithelial mesenchymal transition (EMT) markers of prostate cancer cells were examined by Western blot. The mRNA level of cytokines associated with bone metastasis in osteoblasts and EMT markers in PC 3 and DU145 cells were performed by qRT PCR. Functional rescue experiment of cells were performed by using siRNA, plasmid transfection and inhibitor treatment. Results Isoproterenol (ISO), a pharmacological surrogate of sympathetic nerve activation induced by chronic stress, exhibited no direct effect on migration and invasion of PC 3 and DU145 prostate cancer cells. Whereas, osteoblasts pretreated with ISO promoted EMT, migration and invasion of PC 3 and DU145 cells, which could be inhibited by beta 2AR inhibitor. Mechanistically, ISO increased the secretion of CXCL12 via the beta 2AR HIF 1 alpha signaling in osteoblasts. Moreover, overexpression of HIF 1 alpha osteoblasts promoted migration and invasion of PC 3 and DU145 cells, which was inhibited by addition of recombinant knockdown of CXCR4 in PC 3 and DU145 cells, and inhibiting CXCL12 CXCR4 signaling with LY2510924 blunted the effects of osteoblasts in response to ISO on EMT and migration as well as invasion of PC 3 and DU145 cells. Conclusions These findings demonstrated that beta 2AR HIF 1 alpha CXCL12 signaling in osteoblasts facilitates migration and invasion as well as EMT of prostate cancer cells, and may play a potential role in affecting bone metastasis of prostate cancer.
C1 [Huang, Zhibin; Gu, Ruonan; Xu, Shiyuan] Southern Med Univ, Zhujiang Hosp, Dept Anesthesiol, Guangzhou 510280, Guangdong, Peoples R China.
   [Huang, Zhibin; Li, Guihuan; Zhang, Zhishuai; Gu, Ruonan; Wang, Wenyang; Lai, Xiaoju; Cui, Zhong Kai; Deng, Fan] Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangzhou 510515, Guangdong, Peoples R China.
   [Zeng, Fangyin] Southern Med Univ, Affiliated Hosp 5, Dept Clin Lab, Guangzhou 510900, Guangdong, Peoples R China.
   [Huang, Zhibin] Fujian Med Univ, Fujian Prov Hosp, Dept Anesthesiol, Fuzhou 350001, Fujian, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China; Fujian Provincial Hospital;
   Fujian Medical University
RP Xu, SY (通讯作者)，Southern Med Univ, Zhujiang Hosp, Dept Anesthesiol, Guangzhou 510280, Guangdong, Peoples R China.; Deng, F (通讯作者)，Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangzhou 510515, Guangdong, Peoples R China.; Zeng, FY (通讯作者)，Southern Med Univ, Affiliated Hosp 5, Dept Clin Lab, Guangzhou 510900, Guangdong, Peoples R China.
EM zengfy@126.com; xsy998@smu.edu.cn; fandeng@smu.edu.cn
RI Cui, Zhong Kai/K 2051 2019; Wang, Wenyang/AAQ 2759 2021
FU National Natural Science Foundation of China [81772761, 81672540,
   81472407]; Science and Technology Foundation of Guangzhou in China
   [201607010351, 210707010303]; President Foundation of The Fifth
   Affiliated Hospital, Southern Medical University [YZ2017ZD002]
FX This work was supported financially by the National Natural Science
   Foundation of China (Grant No. 81772761, 81672540, 81472407); Science
   and Technology Foundation of Guangzhou in China (Grant No.
   201607010351,210707010303). President Foundation of The Fifth Affiliated
   Hospital, Southern Medical University (YZ2017ZD002). Funding bodies did
   not have any influence in the design of the study and data collection,
   analysis and interpretation of data or in writing the manuscript.
CR Armer JS, 2018, CANCER AM CANCER SOC, V124, P3401, DOI 10.1002/cncr.31570
   Assayag J, 2014, EUR J CANCER, V50, P2838, DOI 10.1016/j.ejca.2014.08.006
   Barbieri A, 2015, INT J ONCOL, V47, P527, DOI 10.3892/ijo.2015.3038
   Benslimane Ahmim Z, 2017, CANCER LETT, V395, P11, DOI 10.1016/j.canlet.2017.02.032
   Blanc Lapierre A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00269
   Braadland PR, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00375
   Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chen HY, 2018, J PATHOL, V244, P49, DOI 10.1002/path.4988
   Cole SW, 2015, NAT REV CANCER, V15, P563, DOI 10.1038/nrc3978
   Conley LaComb MK, 2013, MOL CANCER, V12, DOI 10.1186/1476 4598 12 85
   Darash Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03 0935fje
   DeSantis CE, 2016, CA CANCER J CLIN, V66, P290, DOI 10.3322/caac.21340
   Devignes CS, 2018, P NATL ACAD SCI USA, V115, pE992, DOI 10.1073/pnas.1718009115
   Elefteriou F, 2005, CELL MOL LIFE SCI, V62, P2339, DOI 10.1007/s00018 005 5175 3
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Elmquist JK, 2005, NATURE, V434, P447, DOI 10.1038/434447a
   Fox JP, 2013, BREAST J, V19, P276, DOI 10.1111/tbj.12096
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   Kan C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101674
   Kawai M, 2014, J BIOL CHEM, V289, P1457, DOI 10.1074/jbc.M113.500850
   Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Lu H, 2015, ONCOTARGETS THER, V8, P985, DOI 10.2147/OTT.S78836
   Mulcrone PL, 2017, J BONE MINER RES, V32, P1442, DOI 10.1002/jbmr.3133
   Park SY, 2011, INT J CANCER, V128, P2306, DOI 10.1002/ijc.25589
   Perron L, 2004, CANCER CAUSE CONTROL, V15, P535, DOI 10.1023/B:CACO.0000036152.58271.5e
   Pietilä M, 2016, CANCER LETT, V380, P359, DOI 10.1016/j.canlet.2015.12.033
   Saha A, 2017, CANCER RES, V77, P5158, DOI [10.1158/0008 5472.CAN 17 0284, 10.1158/0008 5472.can 17 0284]
   Shan MH, 2017, FREE RADICAL BIO MED, V110, P432, DOI 10.1016/j.freeradbiomed.2017.05.021
   Shen PF, 2014, PROSTATE, V74, P756, DOI 10.1002/pros.22795
   Shi M, 2013, CANCER METAST REV, V32, P603, DOI 10.1007/s10555 013 9440 x
   Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182
   Sleightholm RL, 2017, PHARMACOL THERAPEUT, V179, P158, DOI 10.1016/j.pharmthera.2017.05.012
   Su FJ, 2014, EXP THER MED, V8, P1677, DOI 10.3892/etm.2014.1989
   Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555 010 9256 x
   Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Udumyan R, 2017, CANCER RES, V77, P3700, DOI 10.1158/0008 5472.CAN 17 0108
   Ullrich PM, 2003, J UROLOGY, V169, P1449, DOI 10.1097/01.ju.0000053243.87457.60
   Wang LL, 2017, CANCER LETT, V398, P24, DOI 10.1016/j.canlet.2017.04.001
   Wang N, 2014, J BONE MINER RES, V29, P2688, DOI 10.1002/jbmr.2300
   Xiang J, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.83
   Yamada T, 2015, J CELL BIOCHEM, V116, P1144, DOI 10.1002/jcb.25071
   Yap A, 2018, BRIT J ANAESTH, V121, P45, DOI 10.1016/j.bja.2018.03.024
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
   Zhang PH, 2011, ONCOL REP, V26, P1471, DOI 10.3892/or.2011.1417
   Zhang XF, 2018, CANCER GENE THER, V25, DOI 10.1038/s41417 017 0008 8
NR 49
TC 29
Z9 32
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD NOV 26
PY 2019
VL 19
IS 1
AR 1142
DI 10.1186/s12885 019 6301 1
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA JR1WK
UT WOS:000499423900002
PM 31771535
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Cao, Q
   Zhang, JY
   Liu, HT
   Wu, Q
   Chen, JC
   Chen, GQ
AF Cao, Qian
   Zhang, Junyu
   Liu, Haitao
   Wu, Qiong
   Chen, Jinchun
   Chen, Guo Qiang
TI The mechanism of anti osteoporosis effects of 3 hydroxybutyrate and
   derivatives under simulated microgravity
SO BIOMATERIALS
LA English
DT Article
DE Osteoporosis; Microgravity; PHB; 3 Hydroxybutyrate acid;
   3 Hydroxybutyrate methyl ester; NFATc1
ID BONE FORMATION; RESISTANCE EXERCISE; METHYL ESTER; STRENGTH; GROWTH;
   WOMEN; BISPHOSPHONATES; DIFFERENTIATION; SENSITIVITY; METABOLISM
AB Skeletons have significant bone loss (osteoporosis) under microgravity environment. This study showed that microbial polyhydroxyalkanoates (PHA) degradation product, and also ketone body 3 hydroxybutyrate acid (3HB) and its derivative 3 hydroxybutyrate methyl ester (3HBME) inhibit the development of osteoporosis in mice maintained under simulated microgravity, helping preserve bone microstructure and mechanical property. Mice orally administrated with 3HB or 3HBME recovered much more quickly from osteoporosis resulted from simulated microgravity compared with the controls without 3HB or 3HBME treatments due to less calcium loss to the sera. It was known that abnormal activation of osteoclasts induced by microgravity led to bone tissue absorption and thus osteoporosis. In this study, it was found that 3HB or 3HBME down regulated the nuclear factor of activated T cells cytoplasmic 1 (NFATc1), which is the transcription factor of pre osteoclast differentiation. When NFATc1 activation and downstream functions were inhibited, 3HB or 3HBME was able to strongly reduce pre osteoclast differentiation. As a result, bone absorption was prevented. It was demonstrated that 100 mg/kg 3HB resulted in the most obvious effect on osteoporosis prevention. Based on these results, 3HB and 3HBME should be further developed as novel drug candidates against osteoporosis induced by microgravity. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Cao, Qian; Zhang, Junyu; Wu, Qiong; Chen, Jinchun; Chen, Guo Qiang] Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Dept Biol Sci & Biotechnol, MOE Key Lab Bioinformat,Sch Life Sci, Beijing 100084, Peoples R China.
   [Liu, Haitao] Tsinghua Univ, State Key Lab Automot Safety & Energy, Beijing 100084, Peoples R China.
   [Chen, Guo Qiang] Tsinghua Univ, Ctr Nano & Micro Mech, Beijing 100084, Peoples R China.
C3 Tsinghua University; Tsinghua University; Tsinghua University
RP Chen, GQ (通讯作者)，Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China.
EM chengq@mail.tsinghua.edu.cn
RI Liu, Haitao/AAB 9506 2021; wu, qiong/GRY 4672 2022; Chen,
   Guo Qiang/M 3777 2016
FU State Basic Science Foundation 973 [2012CB725201]; 863 project
   [2012AA02A702]; State Industrialization Grant [2012BAD32B02]; China
   National Nature Science Foundation [31170099]
FX We are grateful to Professor Peng Shang of Northwest Polytechnic
   University for assistances on optimization of pre osteoclast culture.
   Professor Yulin Deng of Beijing Institute of Technology allowed us to
   use his three dimensional clinostat. We are also thankful to the School
   of Biological Science and Medical Engineering, Beihang University for
   doing the micro CT scanning for us. This work was supported by the State
   Basic Science Foundation 973 (Grant No. 2012CB725201 to GQC). QW was
   grateful to an 863 project (No. 2012AA02A702) for developing synthetic
   biology techniques for novel PHA and monomer production. JCC received
   support from State Industrialization Grant (Zhicheng Grant No.
   2012BAD32B02) to develop process for large scale production of this
   family of new polymers and monomers as well as applications. A China
   National Nature Science Foundation Grant (No. 31170099) was awarded to
   JCC for developing this platform.
CR Amin Shreyasee, 2010, Curr Rheumatol Rep, V12, P170, DOI 10.1007/s11926 010 0096 z
   [Anonymous], 2009, FEBS LETT, V583, P2435
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brown M, 2008, ADV PHYSIOL EDUC, V32, P120, DOI 10.1152/advan.90111.2008
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   Carvil P., 2013, Aviat. Focus, V4, P10
   Chen YB, 2008, J BIOL CHEM, V283, P29593, DOI 10.1074/jbc.M802493200
   Cheng S, 2005, BIOMACROMOLECULES, V6, P593, DOI 10.1021/bm049465y
   COOK DJ, 1993, ARTHRITIS RHEUM, V36, P750, DOI 10.1002/art.1780360603
   Fazeli PK, 2013, OSTEOPOROSIS INT, V24, P2433, DOI 10.1007/s00198 013 2353 2
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fujimura R, 1997, J BONE MINER RES, V12, P656, DOI 10.1359/jbmr.1997.12.4.656
   Gesty Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   HEANEY RP, 1978, J LAB CLIN MED, V92, P964
   Host HH, 2007, PHYS THER, V87, P292, DOI 10.2522/ptj.20050396
   Iwamoto J, 2004, J BONE MINER METAB, V22, P26, DOI 10.1007/s00774 003 0443 5
   Iwamoto J, 2000, J BONE MINER RES, V15, P1842, DOI 10.1359/jbmr.2000.15.9.1842
   Iwamoto Jun, 2005, Keio Journal of Medicine, V54, P55, DOI 10.2302/kjm.54.55
   Jämsä T, 1998, BONE, V23, P155, DOI 10.1016/S8756 3282(98)00076 3
   LeBlanc A, 2000, J APPL PHYSIOL, V89, P2158, DOI 10.1152/jappl.2000.89.6.2158
   LeBlanc A, 2013, OSTEOPOROSIS INT, V24, P2105, DOI 10.1007/s00198 012 2243 z
   LeBlanc A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P157
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Martin DP, 2005, BIOPOLYMERS
   Martínez V, 2012, APPL ENVIRON MICROB, V78, P6017, DOI 10.1128/AEM.01099 12
   MCCLOSKEY EV, 1987, BONE, V8, pS35
   Morey Holton ER, 1998, BONE, V22, p83S, DOI 10.1016/S8756 3282(98)00019 2
   Morey Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001
   Nawathe S, 2014, J BONE MINER RES, V29, P507, DOI 10.1002/jbmr.2033
   Nishikawa M, 2005, CELL TRANSPLANT, V14, P829, DOI 10.3727/000000005783982477
   O'Connor S, 2013, BIOMATERIALS, V34, P2710, DOI 10.1016/j.biomaterials.2012.12.032
   Oganov V. S., 1992, Aviakosmicheskaya i Ekologicheskaya Meditsina, V26, P20
   Park KH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478 811X 11 74
   Puttapitakpong P, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472 6874 14 35
   Rozental TD, 2013, J BONE JOINT SURG AM, V95A, P633, DOI 10.2106/JBJS.L.00588
   Saxena R, 2011, J BONE MINER METAB, V29, P111, DOI 10.1007/s00774 010 0201 4
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shackelford LC, 2004, J APPL PHYSIOL, V97, P119, DOI 10.1152/japplphysiol.00741.2003
   Shibli Rahhal A, 2013, EAT WEIGHT DISORD ST, V18, P229, DOI 10.1007/s40519 013 0034 y
   Smith SM, 1999, AM J PHYSIOL REG I, V277, pR1
   Sudesh K, 2008, CLEAN SOIL AIR WATER, V36, P433, DOI 10.1002/clen.200700183
   Sun LW, 2011, CALCIFIED TISSUE INT, V88, P48, DOI 10.1007/s00223 010 9422 8
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tian G, 2001, APPL SPECTROSC, V55, P888, DOI 10.1366/0003702011952686
   Tortajada M, 2013, INT MICROBIOL, V16, P1, DOI 10.2436/20.1501.01.175
   Vermeer C, 1998, J Gravit Physiol, V5, P65
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140 6736(00)02217 0
   Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wu Q, 2009, ARTIF CELL BLOOD SUB, V37, P1, DOI 10.1080/10731190802664429
   Xiao XQ, 2007, BIOMATERIALS, V28, P3608, DOI 10.1016/j.biomaterials.2007.04.046
   Yeo HJ, 2007, J BIOL CHEM, V282, P35318, DOI 10.1074/jbc.M702435200
   Zhang JY, 2013, BIOMATERIALS, V34, P7552, DOI 10.1016/j.biomaterials.2013.06.043
   Zhang ZM, 2010, OSTEOPOROSIS INT, V21, P1383, DOI 10.1007/s00198 009 1071 2
   Zhao Y, 2007, BIOMATERIALS, V28, P3063, DOI 10.1016/j.biomaterials.2007.03.003
   Zhu ED, 2014, ENDOCRINOLOGY, V155, P1188, DOI 10.1210/en.2013 1993
   Zinn M, 2001, ADV DRUG DELIVER REV, V53, P5, DOI 10.1016/S0169 409X(01)00218 6
   Zinn M, 2011, BIOTECHNOL J, V6, P1240, DOI 10.1002/biot.201100219
   Zou XH, 2009, BIOMATERIALS, V30, P1532, DOI 10.1016/j.biomaterials.2008.12.012
NR 64
TC 64
Z9 69
U1 1
U2 77
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD SEP
PY 2014
VL 35
IS 28
BP 8273
EP 8283
DI 10.1016/j.biomaterials.2014.06.020
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AM3TC
UT WOS:000339774700021
PM 24976243
DA 2025 08 17
ER

PT J
AU Takito, J
   Otsuka, H
   Yanagisawa, N
   Arai, H
   Shiga, M
   Inoue, M
   Nonaka, N
   Nakamura, M
AF Takito, Jiro
   Otsuka, Hirotada
   Yanagisawa, Nobuaki
   Arai, Hiroshi
   Shiga, Masayasu
   Inoue, Mitsuko
   Nonaka, Naoko
   Nakamura, Masanori
TI Regulation of Osteoclast Multinucleation by the Actin Cytoskeleton
   Signaling Network
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID C SRC; CELL FUSION; RHO GTPASES; DC STAMP; KAPPA B; PODOSOMES; BONE;
   LIPOPOLYSACCHARIDE; DIFFERENTIATION; INVADOPODIA
AB Although it is known that osteoclasts are multinucleated cells that are responsible for bone resorption, the mechanism by which their size is regulated is unclear. We previously reported that an actin rich superstructure, termed the zipper like structure, specifically appears during the fusion of large osteoclast like cells (OCLs). Actin cytoskeleton reorganization in osteoclasts is regulated by a signaling network that includes the macrophage colony stimulating factor (M CSF) receptor, a proto oncogene, Src, and small GTPases. Here, we examined the role of actin reorganization in the multinucleation of OCLs differentiated from RAW 264.7 cells using various pharmacological agents. Jasplakinolide, which stabilizes actin stress fibers, induced the development of small OCLs, and the Src inhibitor SU6656 and the dynamin inhibitor dynasore impaired the maintenance of the podosome belt and the zipper like structure. These inhibitors decreased the formation of large OCLs but increased the number of small OCLs. M CSF is known to stimulate osteoclast fusion. M CSF signaling via Src up regulated Rac1 activity but down regulated Rho activity. Rac1 and Rho localized to the center of the zipper like structure. Rho activator II promoted the formation of small OCLs, whereas the Rho inhibitor Y27632 promoted the generation of large OCLs. These results suggest that the status of the actin cytoskeleton signaling network determines the size of OCLs during cell fusion. (C) 2014 Wiley Periodicals, Inc.
C1 [Takito, Jiro; Otsuka, Hirotada; Yanagisawa, Nobuaki; Arai, Hiroshi; Nonaka, Naoko; Nakamura, Masanori] Showa Univ, Dept Oral Anat & Dev Biol, Sch Dent, Tokyo 1428555, Japan.
   [Takito, Jiro] Tohoku Univ, Res Ctr Supercrit Fluid Technol, Grad Sch Engn, Sendai, Miyagi 980, Japan.
   [Shiga, Masayasu; Inoue, Mitsuko] Showa Univ, Dept Pediat Dent, Sch Dent, Tokyo 1428555, Japan.
C3 Showa University; Tohoku University; Showa University
RP Takito, J (通讯作者)，Showa Univ, Dept Oral Anat & Dev Biol, Sch Dent, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
EM takito@dent.showa u.ac.jp
RI Arai, Hiroshi/MIN 1891 2025
FU Japan Society for the Promotion of Science [25462873]; Grants in Aid for
   Scientific Research [24592777, 15K11022, 25462873] Funding Source: KAKEN
FX Contract grant sponsor: Japan Society for the Promotion of Science
   (Grant in Aid for Scientific Research (C));Contract grant number:
   25462873.
CR Akisaka T, 2003, J ELECTRON MICROSC, V52, P535, DOI 10.1093/jmicro/52.6.535
   Albiges Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704
   AMANO H, 1995, CALCIFIED TISSUE INT, V57, P367, DOI 10.1007/BF00302072
   Amano H, 1998, J BONE MINER RES, V13, P846, DOI 10.1359/jbmr.1998.13.5.846
   Arias Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100
   Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960 9822(00)00537 6
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brazier H, 2006, J BONE MINER RES, V21, P1387, DOI 10.1359/JBMR.060613
   Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.E04 12 1117
   Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163
   BUBB MR, 1994, J BIOL CHEM, V269, P14869
   Cao H, 2010, MOL CELL BIOL, V30, P781, DOI 10.1128/MCB.00330 09
   Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993
   Collin O, 2008, CURR BIOL, V18, P1288, DOI 10.1016/j.cub.2008.07.046
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Goldberg SR, 2012, BONE, V51, P145, DOI 10.1016/j.bone.2012.04.018
   Granot Attas S, 2009, MOL BIOL CELL, V20, P4324, DOI 10.1091/mbc.E08 11 1158
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Heckel T, 2009, P NATL ACAD SCI USA, V106, P1451, DOI 10.1073/pnas.0804464106
   Hoshino D, 2013, J CELL SCI, V126, P2979, DOI 10.1242/jcs.079475
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Islam S, 2008, MICROBIOL IMMUNOL, V52, P585, DOI 10.1111/j.1348 0421.2008.00076.x
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756 3282(90)90082 A
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Kumagai N, 2004, BIOCHEM BIOPH RES CO, V325, P758, DOI 10.1016/j.bbrc.2004.10.094
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002
   MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696
   Nakanishi Matsui M, 2013, BIOCHEM BIOPH RES CO, V440, P611, DOI 10.1016/j.bbrc.2013.09.109
   Nakanishi Matsui M, 2012, BIOCHEM BIOPH RES CO, V425, P144, DOI 10.1016/j.bbrc.2012.07.050
   Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377
   Oikawa T, 2012, J CELL BIOL, V197, P553, DOI 10.1083/jcb.201111116
   Ory S, 2000, J CELL SCI, V113, P1177
   Ory S, 2008, EUR J CELL BIOL, V87, P469, DOI 10.1016/j.ejcb.2008.03.002
   Sakai H, 2010, AM J PHYSIOL CELL PH, V299, pC570, DOI 10.1152/ajpcell.00486.2009
   SCHENK RK, 1967, J CELL BIOL, V34, P275, DOI 10.1083/jcb.34.1.275
   Schramp M, 2008, J CELL BIOL, V181, P1195, DOI 10.1083/jcb.200801078
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takahashi A, 2013, J CELL BIOCHEM, V114, P1238, DOI 10.1002/jcb.24433
   Takegahara N, 2010, FASEB J, V24, P4782, DOI 10.1096/fj.10 158212
   Takito Jiro, 2012, Commun Integr Biol, V5, P453, DOI 10.4161/cib.20980
   Takito J, 2012, J CELL SCI, V125, P662, DOI 10.1242/jcs.090886
   TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014 4827(85)80044 6
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Touaitahuata H, 2013, EUR J CELL BIOL, V92, P139, DOI 10.1016/j.ejcb.2013.03.001
   Wang YQ, 2008, J BONE MINER RES, V23, P260, DOI 10.1359/JBMR.071013
   Winograd Katz SE, 2011, EUR J CELL BIOL, V90, P143, DOI 10.1016/j.ejcb.2010.07.006
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 57
TC 32
Z9 36
U1 0
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2015
VL 230
IS 2
BP 395
EP 405
DI 10.1002/jcp.24723
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA AS6LE
UT WOS:000344374300017
PM 25056912
OA Bronze
DA 2025 08 17
ER

PT J
AU Ochiai, N
   Nakachi, Y
   Yokoo, T
   Ichihara, T
   Eriksson, T
   Yonemoto, Y
   Kato, T
   Ogata, H
   Fujimoto, N
   Kobayashi, Y
   Udagawa, N
   Kaku, S
   Ueki, T
   Okazaki, Y
   Takahashi, N
   Suda, T
AF Ochiai, Nagahiro
   Nakachi, Yutaka
   Yokoo, Tomotaka
   Ichihara, Takahiro
   Eriksson, Tore
   Yonemoto, Yuki
   Kato, Takehiko
   Ogata, Hitoshi
   Fujimoto, Natsuko
   Kobayashi, Yasuhiro
   Udagawa, Nobuyuki
   Kaku, Shinsuke
   Ueki, Tomokazu
   Okazaki, Yasushi
   Takahashi, Naoyuki
   Suda, Tatsuo
TI Murine osteoclasts secrete serine protease HtrA1 capable of degrading
   osteoprotegerin in the bone microenvironment
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID NECROSIS FACTOR RECEPTOR; MESENCHYMAL STEM CELLS; INHIBITORY FACTOR;
   DIFFERENTIATION; LIGAND; MICE; OPG; OSTEOPOROSIS; ASSOCIATION;
   MODULATION
AB Osteoclasts are multinucleated cells responsible for bone resorption. The differentiation of osteoclasts from bone marrow macrophages (BMMs) is induced by receptor activator of NF.B ligand (RANKL). Osteoprotegerin (OPG), a decoy receptor of RANKL, inhibits osteoclastogenesis by blocking RANKL signaling. Here we investigated the degradation of OPG in vitro. Osteoclasts, but not BMMs, secreted OPG degrading enzymes. Using mass spectrometry and RNA sequencing analysis, we identified high temperature requirement A serine peptidase 1 (HtrA1) as an OPG degrading enzyme. HtrA1 did not degrade OPG pre reduced by dithiothreitol, suggesting that HtrA1 recognizes the three dimensional structure of OPG. HtrA1 initially cleaved the amide bond between leucine 90 and glutamine 91 of OPG, then degraded OPG into small fragments. Inhibitory activity of OPG on RANKL induced osteoclastogenesis was suppressed by adding HtrA1 in RAW 264.7 cell cultures. These results suggest that osteoclasts potentially prepare a microenvironment suitable for osteoclastogenesis. HtrA1 may be a novel drug target for osteoporosis.
C1 [Ochiai, Nagahiro; Nakachi, Yutaka; Yokoo, Tomotaka; Okazaki, Yasushi; Suda, Tatsuo] Saitama Med Univ, Res Ctr Genom Med, Saitama 3501298, Japan.
   [Ochiai, Nagahiro; Ichihara, Takahiro; Yonemoto, Yuki; Kato, Takehiko; Ogata, Hitoshi; Fujimoto, Natsuko; Kaku, Shinsuke; Ueki, Tomokazu] Taisho Pharmaceut Co Ltd, Pharmacol Labs, Saitama 3319530, Japan.
   [Eriksson, Tore] Taisho Pharmaceut Co Ltd, Chem Labs, Saitama 3319530, Japan.
   [Kobayashi, Yasuhiro; Takahashi, Naoyuki] Matsumoto Dent Univ, Inst Oral Sci, Nagano 3990781, Japan.
   [Udagawa, Nobuyuki] Matsumoto Dent Univ, Dept Biochem, Nagano 3990781, Japan.
   [Okazaki, Yasushi] Juntendo Univ, Ctr Genom & Regenerat Med, Tokyo 1138421, Japan.
C3 Saitama Medical University; Taisho Pharmaceutical Holdings Co Ltd;
   Taisho Pharmaceutical Holdings Co Ltd; Matsumoto Dental University;
   Matsumoto Dental University; Juntendo University
RP Suda, T (通讯作者)，Saitama Med Univ, Res Ctr Genom Med, Saitama 3501298, Japan.
EM tasuda@saitama med.ac.jp
RI KOBAYASHI, YASUHIRO/AAU 4931 2021; ochiai, nagahiro/MGB 5431 2025;
   Okazaki, Yasushi/KSM 2364 2024; Nakachi, Yutaka/M 2446 2013
OI Ochiai, Nagahiro/0000 0001 7834 539X; Okazaki,
   Yasushi/0000 0003 3241 5502; Nakachi, Yutaka/0000 0003 1964 2495; 
CR Akiyama T, 2014, J BIOL CHEM, V289, P15621, DOI 10.1074/jbc.M113.520510
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Cabrera AC, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14208 z
   Chamberlain JJ, 2017, ANN INTERN MED, V166, P572, DOI 10.7326/M16 2937
   Chamberland A, 2009, J BIOL CHEM, V284, P27352, DOI 10.1074/jbc.M109.037051
   Chambers TJ, 2011, ANN NY ACAD SCI, V1240, P1, DOI 10.1111/j.1749 6632.2011.06249.x
   Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140 6736(06)69705 5
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315
   Filliat G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181600
   Frochaux V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109483
   Graham JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063884
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hadfield KD, 2008, J BIOL CHEM, V283, P5928, DOI 10.1074/jbc.M709299200
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hou S, 2007, DEV CELL, V13, P226, DOI 10.1016/j.devcel.2007.07.001
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 4 r36
   Koide M, 2013, ENDOCRINOLOGY, V154, P773, DOI 10.1210/en.2012 1928
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698, 10.1093/bioinformatics/btp352]
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luan XD, 2012, J IMMUNOL, V189, P245, DOI 10.4049/jimmunol.1103387
   Martin TJ, 2015, J BONE MINER RES, V30, P212, DOI 10.1002/jbmr.2449
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Nakamura H, 2002, J HISTOCHEM CYTOCHEM, V50, P945, DOI 10.1177/002215540205000708
   Neumann U, 2004, ANAL BIOCHEM, V328, P166, DOI 10.1016/j.ab.2003.12.035
   Nozawa S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.89624
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Okuda S, 2017, NUCLEIC ACIDS RES, V45, pD1107, DOI 10.1093/nar/gkw1080
   Pazianas M, 2011, ANN NY ACAD SCI, V1240, pE19, DOI 10.1111/j.1749 6632.2011.06372.x
   R Core Team, 2016, R LANG ENV STAT COMP
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Tiaden AN, 2016, STEM CELLS, V34, P1601, DOI 10.1002/stem.2297
   Tiaden AN, 2012, STEM CELLS, V30, P2271, DOI 10.1002/stem.1190
   Tomoyasu A, 1998, BIOCHEM BIOPH RES CO, V245, P382, DOI 10.1006/bbrc.1998.8443
   Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450
   VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044
   Wu XH, 2014, FEBS LETT, V588, P143, DOI 10.1016/j.febslet.2013.11.022
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yasuhara R, 2009, BIOCHEM J, V419, P159, DOI 10.1042/BJ20081469
NR 53
TC 17
Z9 17
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2399 3642
J9 COMMUN BIOL
JI Commun. Biol.
PD MAR 1
PY 2019
VL 2
AR 86
DI 10.1038/s42003 019 0334 5
PG 13
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Science & Technology   Other
   Topics
GA HO7VT
UT WOS:000461158800002
PM 30854478
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, Q
   Wu, TJ
   Luo, CY
   Xie, H
   Wang, DH
   Peng, JJ
   Wu, KS
   Huang, WL
AF Zhang, Qiong
   Wu, Tianjie
   Luo, Congying
   Xie, Han
   Wang, Dinghui
   Peng, Jiajun
   Wu, Kusheng
   Huang, Wenlong
TI Ecotoxicological risk assessment of the novel psychoactive substance
   Esketamine: Emphasis on fish skeletal, behavioral, and vascular
   development
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article
DE Esketamine (Esket); Novel psychoactive substances; Skeleton development;
   Behavioral disorders; Vascular Toxicity
ID ILLICIT DRUGS; WASTE WATER; IN VIVO; KETAMINE; TOXICITY; ZEBRAFISH;
   EXPOSURE; ENVIRONMENT; EXPRESSION; RESPONSES
AB Novel psychoactive substances (NPS), such as Esketamine (Esket), often contaminate the aquatic ecosystems following human consumption, raising concerns about the residues and potential ecological hazards to non  target organisms. The study used zebrafish as a model organism to investigate the developmental toxicity and ecotoxicological effects of acute Esket exposure. Our findings demonstrate that exposure to Esket significantly affected the early development and angiogenesis of zebrafish embryos/larvae. The mandible length was significantly decreased, and the angles between the pharyngeal arch cartilages were narrowed compared to the control group (all P < 0.05). Additionally, Esket resulted in a decrease of 47.6 89.8 % in the number of neural crest cells (NCC). Transcriptome analysis indicated altered expression of genes associated with cartilage and osteoblast growth. Moreover, Esket significantly inhibited swimming ability in zebrafish larvae and was accompanied by behavioral abnormalities and molecular alterations in the brain. Potential mechanisms underlying Esket induced behavioral disorders involve neurotransmitter system impairment, abnormal cartilage development and function, aberrant vascular development, as well as perturbations in oxidative stress and apoptosis signaling pathways. Notably, the dysregulation of skeleton development through the bone morphogenetic protein (BMP) signaling pathway is identified as the primary mechanistic behind Esket induced behavioral disorder. This study enhances our understanding of Esket's ecotoxicology profile and provides a comprehensive assessment of the environmental risks associated with NPS.
C1 [Zhang, Qiong; Luo, Congying; Xie, Han; Wang, Dinghui; Peng, Jiajun; Wu, Kusheng] Shantou Univ, Dept Prevent Med, Med Coll, 22, Xinling Rd, Shantou 515041, Guangdong, Peoples R China.
   [Wu, Tianjie] Sun Yat Sen Univ, Shantou Cent Hosp, Dept Anaesthesiol, Affiliated Shantou Hosp, Shantou 515041, Guangdong, Peoples R China.
   [Huang, Wenlong] Shantou Univ, Dept Forens Med, Med Coll, Shantou 515041, Guangdong, Peoples R China.
C3 Shantou University; Sun Yat Sen University; Shantou University
RP Wu, KS (通讯作者)，Shantou Univ, Dept Prevent Med, Med Coll, 22, Xinling Rd, Shantou 515041, Guangdong, Peoples R China.; Huang, WL (通讯作者)，Shantou Univ, Dept Forens Med, Med Coll, Shantou 515041, Guangdong, Peoples R China.
EM kswu@stu.edu.cn; 12wlhuang1@stu.edu.cn
RI Zhang, Qiong/IXD 5405 2023; Wang, Dinghui/AAQ 8034 2020; wu,
   tianjie/I 2596 2013; Wu, Kusheng/O 5141 2019
FU Guangdong Basic and Applied Basic Research Foundation [2023A1515011878,
   2021A1515111093, 2023A1515012357]
FX This study received financial support from the Guangdong Basic and
   Applied Basic Research Foundation (grant no.: 2023A1515011878,
   2021A1515111093, 2023A1515012357) . The authors wish to thank all the
   people who participated in this project.
CR ADAMS JD, 1978, P W PHARMACOL SOC, V21, P471
   Aguilar AG, 2024, J PSYCHOACTIVE DRUGS, V56, P33, DOI 10.1080/02791072.2023.2178558
   Baker DR, 2013, SCI TOTAL ENVIRON, V454, P442, DOI 10.1016/j.scitotenv.2013.03.043
   Bobo WV, 2002, AM J ADDICTION, V11, P332, DOI 10.1080/10550490290088126
   Bonilla Claudio M, 2012, DEVELOPMENT, V139, P709, DOI 10.1242/dev.073197
   Brown DD, 1997, P NATL ACAD SCI USA, V94, P13011, DOI 10.1073/pnas.94.24.13011
   Chen XM, 2023, SCI TOTAL ENVIRON, V892, DOI 10.1016/j.scitotenv.2023.164396
   Daston GP, 2007, BIRTH DEFECTS RES B, V80, P421, DOI 10.1002/bdrb.20135
   DeLaurier A, 2019, WIRES DEV BIOL, V8, DOI 10.1002/wdev.337
   Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1097/00000539 200302000 00041
   Félix LM, 2018, CHEMOSPHERE, V201, P730, DOI 10.1016/j.chemosphere.2018.03.049
   Félix LM, 2016, CHEM RES TOXICOL, V29, P1298, DOI 10.1021/acs.chemrestox.6b00122
   Fernández I, 2018, AQUAT TOXICOL, V194, P208, DOI 10.1016/j.aquatox.2017.11.015
   Flint RB, 2017, PEDIATR ANESTH, V27, P1098, DOI 10.1111/pan.13239
   Gaschler MM, 2017, BIOCHEM BIOPH RES CO, V482, P419, DOI 10.1016/j.bbrc.2016.10.086
   Gill JS, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00441
   Gomes LMRS, 2011, PAIN PHYSICIAN, V14, P83
   Guo XQ, 2017, J APPL TOXICOL, V37, P192, DOI 10.1002/jat.3340
   Hanson MG, 2004, NEURON, V43, P687, DOI 10.1016/j.neuron.2004.08.018
   Horzmann KA, 2018, TOXICOL SCI, V163, P5, DOI 10.1093/toxsci/kfy044
   Hu JJ, 2021, J HAZARD MATER, V405, DOI 10.1016/j.jhazmat.2020.124150
   Huang JJ, 2023, BMC ANESTHESIOL, V23, DOI 10.1186/s12871 023 02077 1
   Huang RH, 2023, CELL MOL NEUROBIOL, V43, P3005, DOI 10.1007/s10571 023 01354 4
   Huang S, 2024, TOXICS, V12, DOI 10.3390/toxics12060427
   Huang Wenlong, 2023, Chemosphere, V344, P140401, DOI 10.1016/j.chemosphere.2023.140401
   Huang WL, 2023, SCI TOTAL ENVIRON, V868, DOI 10.1016/j.scitotenv.2023.161702
   Huang WL, 2022, CHEMOSPHERE, V291, DOI 10.1016/j.chemosphere.2021.133033
   Huang WL, 2021, ECOTOX ENVIRON SAFE, V212, DOI 10.1016/j.ecoenv.2021.111991
   Igoshina E, 2023, LANCET CHILD ADOLESC, V7, P577, DOI 10.1016/S2352 4642(23)00079 2
   Jiang JJ, 2015, ENVIRON SCI TECHNOL, V49, P792, DOI 10.1021/es503944e
   Kim Y, 2007, ENVIRON INT, V33, P370, DOI 10.1016/j.envint.2006.11.017
   Knogler LD, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00121
   Komoike Y, 2019, J HAZARD MATER, V365, P430, DOI 10.1016/j.jhazmat.2018.11.023
   Langova V, 2023, J NEUROSCI RES, V101, P1098, DOI 10.1002/jnr.25186
   Lazcano I, 2023, GEN COMP ENDOCR, V334, DOI 10.1016/j.ygcen.2023.114225
   Le Douarin NM, 2007, BRAIN RES REV, V55, P237, DOI 10.1016/j.brainresrev.2007.06.023
   Li SW, 2017, ECOTOX ENVIRON SAFE, V143, P173, DOI 10.1016/j.ecoenv.2017.05.040
   Li SY, 2024, B ENVIRON CONTAM TOX, V112, DOI 10.1007/s00128 024 03883 0
   Liao PH, 2015, AQUAT TOXICOL, V165, P84, DOI 10.1016/j.aquatox.2015.05.010
   Lin AYC, 2014, WATER RES, V53, P351, DOI 10.1016/j.watres.2014.01.022
   Lin WT, 2024, J HAZARD MATER, V465, DOI 10.1016/j.jhazmat.2023.133113
   Liu PW, 2024, BIOTECHNOL GENET ENG, V40, P1202, DOI 10.1080/02648725.2023.2193058
   Liu SJ, 2023, TOXICOL SCI, V196, P38, DOI 10.1093/toxsci/kfad078
   Liu SJ, 2020, DEV DYNAM, V249, P794, DOI 10.1002/dvdy.179
   Liu Y, 2022, NUCLEIC ACIDS RES, V50, pW159, DOI 10.1093/nar/gkac394
   McCall AK, 2016, WATER RES, V88, P933, DOI 10.1016/j.watres.2015.10.040
   Mu XY, 2023, ENVIRON SCI TECHNOL, V57, P14138, DOI 10.1021/acs.est.3c03626
   Myers CP, 2005, NEURON, V46, P37, DOI 10.1016/j.neuron.2005.02.022
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Paulissen E, 2022, ELIFE, V11, DOI [10.7554/eLife.74821, 10.7554/eLife.74821.sa0, 10.7554/eLife.74821.sa1, 10.7554/eLife.74821.sa2]
   Peacock A, 2019, LANCET, V394, P1668, DOI 10.1016/S0140 6736(19)32231 7
   Perez Pereira A, 2022, ENVIRON TOXICOL CHEM, V41, P569, DOI 10.1002/etc.4955
   Popova V, 2019, AM J PSYCHIAT, V176, P428, DOI 10.1176/appi.ajp.2019.19020172
   Power DM, 2001, COMP BIOCHEM PHYS C, V130, P447, DOI 10.1016/S1532 0456(01)00271 X
   Quadros VA, 2016, BEHAV PROCESS, V122, P1, DOI 10.1016/j.beproc.2015.10.014
   Riehl R, 2011, NEUROTOXICOL TERATOL, V33, P658, DOI 10.1016/j.ntt.2011.05.011
   Robinson B, 2018, NEUROSCI LETT, V682, P56, DOI 10.1016/j.neulet.2018.06.014
   Robinson BL, 2018, NEUROTOXICOL TERATOL, V69, P63, DOI 10.1016/j.ntt.2017.12.005
   Saili KS, 2012, TOXICOLOGY, V291, P83, DOI 10.1016/j.tox.2011.11.001
   Smith Apeldoorn SY, 2021, BJPSYCH OPEN, V8, DOI 10.1192/bjo.2021.1059
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Ueharu H, 2023, FRONT PHYSIOL, V14, DOI 10.3389/fphys.2023.1170511
   Vazquez Roig P, 2012, ENVIRON SCI POLLUT R, V19, P971, DOI 10.1007/s11356 011 0617 y
   Wang WW, 2022, SCI TOTAL ENVIRON, V850, DOI 10.1016/j.scitotenv.2022.158040
   Wang X, 2022, SCI TOTAL ENVIRON, V848, DOI 10.1016/j.scitotenv.2022.157816
   Wang ZL, 2020, WATER RES, V174, DOI 10.1016/j.watres.2020.115585
   Wang ZL, 2019, J HAZARD MATER, V363, P268, DOI 10.1016/j.jhazmat.2018.09.020
   Wang Z, 2023, SCI TOTAL ENVIRON, V858, DOI 10.1016/j.scitotenv.2022.160078
   Wen XX, 2011, ACTA HISTOCHEM, V113, P382, DOI 10.1016/j.acthis.2009.12.004
   Wozniak JR, 2019, LANCET NEUROL, V18, P760, DOI 10.1016/S1474 4422(19)30150 4
   Xia M, 2021, SCI TOTAL ENVIRON, V758, DOI 10.1016/j.scitotenv.2020.143694
   Yan Y, 2020, ECOTOX ENVIRON SAFE, V194, DOI 10.1016/j.ecoenv.2020.110415
   Yin XX, 2021, SCI TOTAL ENVIRON, V792, DOI 10.1016/j.scitotenv.2021.148153
   Yuan WJ, 2024, TOXICOL APPL PHARM, V482, DOI 10.1016/j.taap.2023.116789
   Zanos P, 2018, PHARMACOL REV, V70, P621, DOI 10.1124/pr.117.015198
   Zhang L, 2024, MOL NEUROBIOL, V61, P10072, DOI 10.1007/s12035 024 04245 x
   Zhang LM, 2022, BEHAV BRAIN RES, V433, DOI 10.1016/j.bbr.2022.113996
   Zhang Q, 2024, J HAZARD MATER, V465, DOI 10.1016/j.jhazmat.2023.133332
   Zhang Q, 2023, ENVIRON INT, V172, DOI 10.1016/j.envint.2023.107745
   Zhang XF, 2022, ENVIRON SCI TECHNOL, V56, P2519, DOI 10.1021/acs.est.1c07767
   Zhornitsky S, 2022, PROG NEURO PSYCHOPH, V118, DOI 10.1016/j.pnpbp.2022.110575
   Zhu Z, 2022, ECOTOX ENVIRON SAFE, V245, DOI 10.1016/j.ecoenv.2022.114082
NR 82
TC 5
Z9 5
U1 11
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304 3894
EI 1873 3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD DEC 5
PY 2024
VL 480
AR 135823
DI 10.1016/j.jhazmat.2024.135823
EA SEP 2024
PG 19
WC Engineering, Environmental; Environmental Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Environmental Sciences & Ecology
GA G6E3N
UT WOS:001317543400001
PM 39278034
DA 2025 08 17
ER

PT J
AU Gluz, E
   Mizrahi, DM
   Margel, S
AF Gluz, Eran
   Mizrahi, Dana M.
   Margel, Shlomo
TI Synthesis and characterization of new poly(ethylene
   glycol)bisphosphonate vinylic monomer and non fluorescent and
   NIR fluorescent bisphosphonate micrometer sized particles
SO POLYMER
LA English
DT Article
DE Bisphosphonate; Bisphosphonate vinylic monomer; NIR bisphosphonates
   particles
ID CYANINE DYES; SPECTRAL PROPERTIES; CANCER; BIODISTRIBUTION; MECHANISMS;
   RELEASE; INVITRO; MODEL
AB Bisphosphonates (BPs) are non hydrolysable pyrophosphate analogs with high affinity to hydroxyapatite (HAP, the main inorganic ingredient in bones) and are mainly used for bone diseases treatments.
   A new stable PEG BP monomer and particles have been prepared for enhanced long term bone targeted imaging and therapy applications. The new formed BP particles possess dual functionalities: chelation to the bone mineral, HAP, through the BP groups and covalent attachment of a dye or drug through primary amine groups.
   The BP particles showed no cytotoxic effect on human osteosarcoma cell lines and minor toxicity on mouse macrophage cells, indicating that these BP particles are good candidates for in vivo testing. The BP monomer and particles exhibited inhibition of HAP formation and dissolution, similar to a commercial Alendronate. Near IR (NIR) fluorescent BP particles were obtained by conjugation of Cy7 NHS ester to the primary amine groups of the BP particles. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Gluz, Eran; Margel, Shlomo] Bar Ilan Univ, Dept Chem, Inst Nanotechnol & Adv Mat, IL 52900 Ramat Gan, Israel.
   [Mizrahi, Dana M.] Israel Inst Biol Res, Dept Organ Chem, IL 74100 Ness Ziona, Israel.
C3 Bar Ilan University
RP Margel, S (通讯作者)，Bar Ilan Univ, Dept Chem, Inst Nanotechnol & Adv Mat, IL 52900 Ramat Gan, Israel.
EM erangz@hotmail.com; danami@iibr.gov.il; shlomo.margel@mail.biu.ac.il
CR Akgun B, 2012, J POLYM SCI POL CHEM, V50, P801, DOI 10.1002/pola.25835
   Balas F, 2006, J AM CHEM SOC, V128, P8116, DOI 10.1021/ja062286z
   BRISMAR H, 1995, J HISTOCHEM CYTOCHEM, V43, P699, DOI 10.1177/43.7.7608524
   Budini M, 2012, J BIOL CHEM, V287, P7512, DOI 10.1074/jbc.M111.288720
   Clézardin P, 2011, BONE, V49, P66, DOI 10.1016/j.bone.2010.11.017
   COXON FP, 2008, CALCIFIED TISSUE S1, V82, pS127
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022 1759(88)90310 9
   Deligeorgiev T, 2006, DYES PIGMENTS, V70, P185, DOI 10.1016/j.dyepig.2005.05.010
   Deligeorgiev TG, 2000, DYES PIGMENTS, V44, P131, DOI 10.1016/S0143 7208(99)00084 4
   Dufrane D, 2003, J MATER SCI MATER M, V14, P33, DOI 10.1023/A:1021545302732
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603
   FRANCIS MD, 1969, CALC TISS RES, V3, P151, DOI 10.1007/BF02058658
   Fu YL, 2009, DYES PIGMENTS, V82, P409, DOI 10.1016/j.dyepig.2009.03.005
   GOLOMB G, 1991, BIOMATERIALS, V12, P397, DOI 10.1016/0142 9612(91)90008 X
   GOLOMB G, 1992, PHARMACEUT RES, V9, P143, DOI 10.1023/A:1018956516640
   He XX, 2010, WIRES NANOMED NANOBI, V2, P349, DOI 10.1002/wnan.85
   Jiang S, 2010, J R SOC INTERFACE, V7, P3, DOI 10.1098/rsif.2009.0243
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Miller PD, 2011, BONE, V49, P77, DOI 10.1016/j.bone.2010.12.024
   Mizrahi DM, 2011, EUR J MED CHEM, V46, P5175, DOI 10.1016/j.ejmech.2011.08.040
   Mizrahi DM, 2010, J POLYM SCI POL CHEM, V48, P5468, DOI 10.1002/pola.24355
   Owens G, 2007, AM J MANAG CARE, V13, pS290
   Pan HZ, 2008, MOL PHARMACEUT, V5, P548, DOI 10.1021/mp800003u
   Park JW, 2012, BIOCONJUGATE CHEM, V23, P350, DOI 10.1021/bc200232d
   Reid IR, 2011, BONE, V49, P89, DOI 10.1016/j.bone.2010.09.002
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sanders JM, 2005, J MED CHEM, V48, P2957, DOI 10.1021/jm040209d
   Santra S, 2005, TECHNOL CANCER RES T, V4, P593, DOI 10.1177/153303460500400603
   SHEN S, 1994, J POLYM SCI POL CHEM, V32, P1087, DOI 10.1002/pola.1994.080320611
   Shibata K, 2007, IND HEALTH, V45, P426, DOI 10.2486/indhealth.45.426
   VANGELDER JM, 1995, BONE, V16, P511, DOI 10.1016/8756 3282(95)00081 N
   Veronese FM, 2008, BIODRUGS, V22, P315, DOI 10.2165/00063030 200822050 00004
   Wang L, 2006, CHEM COMMUN, P2795, DOI 10.1039/b605365c
   Xu RX, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3147424
   Yarmoluk SM, 2001, DYES PIGMENTS, V50, P21, DOI 10.1016/S0143 7208(01)00023 7
NR 41
TC 14
Z9 23
U1 1
U2 65
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032 3861
EI 1873 2291
J9 POLYMER
JI Polymer
PD JAN 24
PY 2013
VL 54
IS 2
BP 565
EP 571
DI 10.1016/j.polymer.2012.11.071
PG 7
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA 078FV
UT WOS:000314085000013
DA 2025 08 17
ER

PT J
AU Williams, JN
   Kambrath, AV
   Patel, RB
   Kang, KS
   Mével, E
   Li, Y
   Cheng, YH
   Pucylowski, AJ
   Hassert, MA
   Voor, MJ
   Kacena, MA
   Thompson, WR
   Warden, SJ
   Burr, DB
   Allen, MR
   Robling, AG
   Sankar, U
AF Williams, Justin N.
   Kambrath, Anuradha Valiya
   Patel, Roshni B.
   Kang, Kyung Shin
   Mevel, Elsa
   Li, Yong
   Cheng, Ying Hua
   Pucylowski, Austin J.
   Hassert, Mariah A.
   Voor, Michael J.
   Kacena, Melissa A.
   Thompson, William R.
   Warden, Stuart J.
   Burr, David B.
   Allen, Matthew R.
   Robling, Alexander G.
   Sankar, Uma
TI Inhibition of CaMKK2 Enhances Fracture Healing by Stimulating Indian
   Hedgehog Signaling and Accelerating Endochondral Ossification
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PRECLINICAL STUDIES; ANIMAL MODELS; INJURY/FRACTURE HEALING;
   ORTHOPAEDICS; ANABOLICS; THERAPEUTICS
ID PROTEIN KINASE KINASE; INTENSITY PULSED ULTRASOUND; BONE FORMATION;
   MOLECULAR ASPECTS; PERIOSTEAL CELLS; MICE; OSTEOBLAST; BETA;
   DIFFERENTIATION; STO 609
AB Approximately 10% of all bone fractures do not heal, resulting in patient morbidity and healthcare costs. However, no pharmacological treatments are currently available to promote efficient bone healing. Inhibition of Ca2+/calmodulin (CaM) dependent protein kinase kinase 2 (CaMKK2) reverses age associated loss of trabecular and cortical bone volume and strength in mice. In the current study, we investigated the role of CaMKK2 in bone fracture healing and show that its pharmacological inhibition using STO 609 accelerates early cellular and molecular events associated with endochondral ossification, resulting in a more rapid and efficient healing of the fracture. Within 7 days postfracture, treatment with STO 609 resulted in enhanced Indian hedgehog signaling, paired related homeobox (PRX1) positive mesenchymal stem cell (MSC) recruitment, and chondrocyte differentiation and hypertrophy, along with elevated expression of osterix, vascular endothelial growth factor, and type 1 collagen at the fracture callus. Early deposition of primary bone by osteoblasts resulted in STO 609 treated mice possessing significantly higher callus bone volume by 14 days following fracture. Subsequent rapid maturation of the bone matrix bestowed fractured bones in STO 609 treated animals with significantly higher torsional strength and stiffness by 28 days postinjury, indicating accelerated healing of the fracture. Previous studies indicate that fixed and closed femoral fractures in the mice take 35 days to fully heal without treatment. Therefore, our data suggest that STO 609 potentiates a 20% acceleration of the bone healing process. Moreover, inhibiting CaMKK2 also imparted higher mechanical strength and stiffness at the contralateral cortical bone within 4 weeks of treatment. Taken together, the data presented here underscore the therapeutic potential of targeting CaMKK2 to promote efficacious and rapid healing of bone fractures and as a mechanism to strengthen normal bones. (C) 2018 American Society for Bone and Mineral Research.
C1 [Williams, Justin N.; Kambrath, Anuradha Valiya; Patel, Roshni B.; Kang, Kyung Shin; Mevel, Elsa; Li, Yong; Pucylowski, Austin J.; Kacena, Melissa A.; Warden, Stuart J.; Burr, David B.; Allen, Matthew R.; Robling, Alexander G.; Sankar, Uma] Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5055, Indianapolis, IN 46202 USA.
   [Cheng, Ying Hua; Allen, Matthew R.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
   [Hassert, Mariah A.] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO USA.
   [Voor, Michael J.] Univ Louisville, Sch Med, Dept Orthopaed Surg, Louisville, KY 40292 USA.
   [Voor, Michael J.] Univ Louisville, Speed Sch Engn, Dept Bioengn, Louisville, KY 40292 USA.
   [Kacena, Melissa A.; Allen, Matthew R.] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
   [Thompson, William R.; Warden, Stuart J.] Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Indianapolis, IN 46204 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Saint Louis
   University; University of Louisville; University of Louisville; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Indianapolis
RP Sankar, U (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5055, Indianapolis, IN 46202 USA.
EM usankar@iupui.edu
RI ; Thompson, William/G 6027 2016; Allen, Matthew/A 8799 2015; Warden,
   Stuart/C 5287 2012; Li, Yongguang/ACM 0755 2022; Sankar,
   Uma/AHE 2383 2022
OI Warden, Stuart/0000 0002 6415 4936; Williams,
   Justin/0000 0003 2341 2596; 
FU Department of Defense (DoD) US Army Medical Research and Materiel
   Command (USAMRMC) Congressionally Directed Medical Research Programs
   (CDMRP) [PR121604]; NIH National Institutes of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS) [R01 AR068332, AR053237];
   Comprehensive Musculoskeletal T32 Training Program from the NIH NIAMS
   [AR065971]; S10 grant [NIH OD016208]
FX This work was supported by grants from the Department of Defense (DoD)
   US Army Medical Research and Materiel Command (USAMRMC) Congressionally
   Directed Medical Research Programs (CDMRP) (PR121604) to US, and the NIH
   National Institutes of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) (R01 AR068332 to US; AR053237 to AGR). JNW is supported through
   a Comprehensive Musculoskeletal T32 Training Program from the NIH NIAMS
   (AR065971 to DBB). The 1176 mu CT system was supported by an S10 grant
   (NIH OD016208 to MRA). We thank Dr. Keith W. Condon for help with
   histology and guidance on immunohistochemistry, and Drs. Ushashi Dadwal
   and Mavis Irwin for technical assistance.
CR Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880
   Anderson KA, 2008, CELL METAB, V7, P377, DOI 10.1016/j.cmet.2008.02.011
   Anderson KA, 2012, MOL ENDOCRINOL, V26, P281, DOI 10.1210/me.2011 1299
   Anderson Kristin A, 2009, F1000 Biol Rep, V1, P10, DOI 10.3410/B1 10
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Busse JW, 2016, BMJ BRIT MED J, V355, DOI 10.1136/bmj.i5351
   Cary RL, 2013, J BONE MINER RES, V28, P1599, DOI 10.1002/jbmr.1890
   Chesterman ES, 2002, ANAT REC, V266, P1, DOI 10.1002/ar.10028
   Colomer J., 2007, V45, P169
   Covey Dana C, 2008, Instr Course Lect, V57, P65
   Cunningham BP, 2017, INJURY, V48, pS69, DOI 10.1016/j.injury.2017.04.020
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Einhorn TA, 2011, CLIN CASES MINER BON, V8, P17
   Gerstenfeld LC, 2006, J HISTOCHEM CYTOCHEM, V54, P1215, DOI 10.1369/jhc.6A6959.2006
   Green MF, 2011, CELL SIGNAL, V23, P2005, DOI 10.1016/j.cellsig.2011.07.014
   Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534 5807(02)00218 6
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002
   Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009
   Hilton MJ, 2005, DEVELOPMENT, V132, P4339, DOI 10.1242/dev.02025
   Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471
   Hu DP, 2017, DEVELOPMENT, V144, P221, DOI 10.1242/dev.130807
   Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200
   Kahanov L, 2015, OPEN ACCESS J SPORTS, V6, P87, DOI 10.2147/OAJSM.S39512
   Kawanami A, 2009, BIOCHEM BIOPH RES CO, V386, P477, DOI 10.1016/j.bbrc.2009.06.059
   Kitsos CM, 2005, J BIOL CHEM, V280, P33101, DOI 10.1074/jbc.M505208200
   Kokubo M, 2009, J NEUROSCI, V29, P8901, DOI 10.1523/JNEUROSCI.0040 09.2009
   Kostenuik P, 2017, J ORTHOP RES, V35, P213, DOI 10.1002/jor.23460
   Kukimoto Niino M, 2011, J BIOL CHEM, V286, P22570, DOI 10.1074/jbc.M111.251710
   Le AX, 2001, J ORTHOPAED RES, V19, P78, DOI 10.1016/S0736 0266(00)00006 1
   Li YW, 2011, DEVELOPMENT, V138, P359, DOI 10.1242/dev.052324
   Liu XC, 2017, BONE, V103, P241, DOI 10.1016/j.bone.2017.07.017
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   MACEY LR, 1989, J BONE JOINT SURG AM, V71A, P722, DOI 10.2106/00004623 198971050 00014
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Marcelo KL, 2016, MOL ENDOCRINOL, V30, P557, DOI 10.1210/me.2016 1021
   Marsell R, 2010, J ORTHOP TRAUMA, V24, pS4, DOI 10.1097/BOT.0b013e3181ca3fab
   Martin JF, 2000, GENESIS, V26, P225, DOI 10.1002/(SICI)1526 968X(200004)26:4<225::AID GENE10>3.3.CO;2 6
   McBride Gagyi SH, 2015, BONE, V81, P533, DOI 10.1016/j.bone.2015.09.003
   Means AR, 2008, MOL ENDOCRINOL, V22, P2759, DOI 10.1210/me.2008 0312
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Monaco S, 2015, CELL SIGNAL, V27, P204, DOI 10.1016/j.cellsig.2014.11.007
   Moseley KF, 2012, CURR OPIN ENDOCRINOL, V19, P128, DOI 10.1097/MED.0b013e328350a6e1
   Murakami S, 2000, CALCIFIED TISSUE INT, V66, P272, DOI 10.1007/PL00005843
   Murao H, 2013, J BONE MINER METAB, V31, P390, DOI 10.1007/s00774 013 0429 x
   Ono N, 2014, DEV CELL, V29, P330, DOI 10.1016/j.devcel.2014.03.014
   Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008 5472.CAN 08 1078
   Pritchard ZJ, 2015, BONE, V75, P120, DOI 10.1016/j.bone.2015.01.021
   Racioppi L, 2012, J BIOL CHEM, V287, P31658, DOI 10.1074/jbc.R112.356485
   Racioppi L, 2012, J BIOL CHEM, V287, P11579, DOI 10.1074/jbc.M111.336032
   Rostovskaya M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051221
   Sankar U, 2016, J BIOMECH, V49, P1233, DOI 10.1016/j.jbiomech.2016.02.040
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Schnell S, 2010, GERIATR ORTHOP SURG, V1, P6, DOI 10.1177/2151458510378105
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Taschner MJ, 2008, DEV BIOL, V317, P132, DOI 10.1016/j.ydbio.2008.02.007
   Tevlin R, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2809
   Tokumitsu H, 2003, J BIOL CHEM, V278, P10908, DOI 10.1074/jbc.M213183200
   Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200
   van Geel Tineke A C M, 2010, Curr Osteoporos Rep, V8, P118, DOI 10.1007/s11914 010 0023 2
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Warden SJ, 2009, BONE, V44, P485, DOI 10.1016/j.bone.2008.11.007
   Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14
   York B, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12139 3
NR 66
TC 31
Z9 36
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2018
VL 33
IS 5
BP 930
EP 944
DI 10.1002/jbmr.3379
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GF5KU
UT WOS:000432006800020
PM 29314250
OA Green Published, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Chen, YJ
   Wu, JY
   Leung, WC
   Liu, YX
   Fu, XQ
   Zhu, JQ
   Wu, Y
   Chou, JY
   Yin, CL
   Wang, YP
   Wang, XQ
   Bai, JX
   Wu, ZZ
   Yu, ZL
AF Chen, Ying Jie
   Wu, Jia Ying
   Leung, Wai Chung
   Liu, Yu Xi
   Fu, Xiu Qiong
   Zhu, Jia Qian
   Wu, Ying
   Chou, Ji Yao
   Yin, Cheng Le
   Wang, Ya Ping
   Wang, Xiao Qi
   Bai, Jing Xuan
   Wu, Zheng Zhi
   Yu, Zhi Ling
TI An herbal formula inhibits STAT3 signaling and attenuates bone erosion
   in collagen induced arthritis rats
SO PHYTOMEDICINE
LA English
DT Article
DE Rheumatoid arthritis; Bone erosion; Osteoclastogenesis; Rosa multiflora;
   Lonicera japonica; STAT3 signaling
ID ADJUVANT INDUCED ARTHRITIS; RHEUMATOID ARTHRITIS; KAPPA B; OSTEOCLAST
   DIFFERENTIATION; RECEPTOR ACTIVATOR; DOWN REGULATION; NUCLEAR FACTOR;
   RANKL; CELLS; INFLAMMATION
AB Background: Receptor activator of NF kappa B ligand (RANKL) facilitates differentiation of osteoclast precursors into osteoclasts, resulting in bone erosion in rheumatoid arthritis (RA) patients. Fibroblast like synoviocytes (FLS) are the main cells for producing RANKL. Signal transducer and activator of transcription 3 (STAT3) signaling is activated in FLS of RA patients (RA FLS), which has been linked to RANKL production. A two herb formula (RL) comprising Rosae Multiflorae Fructus and Lonicerae Japonicae Flos is traditionally used for treating RA in China. We have found that a standardized ethanolic extract of RL (RLE for short) alleviates bone erosion in collagen induced arthritis (CIA) rats.
   Purpose: This study aimed to determine whether RLE inhibits RANKL production and osteoclastogenesis in cell and rat models, and to explore the involvement of the STAT3 pathway in this inhibition.
   Study Design and Methods: A CIA rat model, interleukin 6/soluble interleukin 6 receptor (IL 6/sIL 6R) stimulated RA FLS and a co culture system (IL 6/sIL 6R stimulated RA FLS/peripheral blood mononuclear cells) were used to evaluate the effects of RLE. Micro computed tomography analysis was used to observe bone erosion in CIA rats. Tartrateresistant acid phosphatase staining was used to evaluate osteoclastogenesis. Western blotting and ELISA assays were employed to examine protein levels. RT qPCR was used to detect mRNA levels. STAT3 over activated RA FLS were used to investigate the involvement of STAT3 signaling in the anti osteoclastogenic effects of RLE.
   Results: RLE alleviated bone erosion in joints of CIA rats. In both synovial tissues of CIA rats and IL 6/sIL 6R stimulated RA FLS, RLE downregulated the protein level of RANKL. In the co culture system, RLE significantly and dose dependently inhibited IL 6/sIL 6R induced osteoclastogenesis. Mechanistic studies revealed that RLE lowered the protein level of phospho STAT3 (Tyr705) in synovial tissues of CIA rats. In IL 6/sIL 6R stimulated RA FLS, RLE inhibited the activation/phosphorylation of a STAT3 upstream kinase Janus kinase 2 (Tyr1007/1008) and STAT3 (Tyr705), decreased the nuclear localization of STAT3, lowered mRNA levels of STAT3 transcriptionally regulated genes IL 1 beta and TNF alpha. RLE's inhibitory effects on RANKL production in RA FLS gradually decreased when IL 6/sIL 6R doses increased. Over activation of STAT3 diminished the inhibitory effects of RLE on RANKL production in IL 6/sIL 6R stimulated RA FLS, and attenuated the anti osteoclastogenic effects of RLE in the co culture system.
   Conclusion: We, for the first time, demonstrated that suppressing STAT3 signaling contributes to the inhibition of RANKL production and osteoclastogenesis, and thereby supports the mechanisms responsible for the reduction in bone erosion in RLE treated CIA rats. This study provides further pharmacological groundwork for developing RLE as a modern anti arthritic drug, and supports the notion that targeting STAT3 signaling is a viable strategy for managing bone erosion.
C1 [Chen, Ying Jie; Wu, Jia Ying; Leung, Wai Chung; Liu, Yu Xi; Fu, Xiu Qiong; Wu, Ying; Chou, Ji Yao; Yin, Cheng Le; Wang, Ya Ping; Wang, Xiao Qi; Bai, Jing Xuan; Yu, Zhi Ling] HKBU Shenzhen Res Inst & Continuing Educ, Res & Dev Ctr Nat Hlth Prod, Shenzhen, Peoples R China.
   [Chen, Ying Jie; Wu, Jia Ying; Leung, Wai Chung; Liu, Yu Xi; Fu, Xiu Qiong; Zhu, Jia Qian; Wu, Ying; Chou, Ji Yao; Yin, Cheng Le; Wang, Ya Ping; Wang, Xiao Qi; Bai, Jing Xuan; Yu, Zhi Ling] Hong Kong Baptist Univ, Ctr Canc & Inflammat Res, Sch Chinese Med, Kowloon Tong, Hong Kong, Peoples R China.
   [Chen, Ying Jie; Wu, Jia Ying; Leung, Wai Chung; Liu, Yu Xi; Fu, Xiu Qiong; Wu, Ying; Chou, Ji Yao; Yin, Cheng Le; Wang, Ya Ping; Wang, Xiao Qi; Bai, Jing Xuan; Yu, Zhi Ling] Hong Kong Baptist Univ, Consun Chinese Med Res Ctr Renal Dis, Sch Chinese Med, Kowloon Tong, Hong Kong, Peoples R China.
   [Wu, Zheng Zhi] Shenzhen Inst Geriatr, Shenzhen, Peoples R China.
   [Wu, Ying; Yu, Zhi Ling] Hong Kong Baptist Univ, JaneClare Transdermal TCM Therapy Lab, Kowloon Tong, Hong Kong, Peoples R China.
C3 Hong Kong Baptist University; Hong Kong Baptist University; Hong Kong
   Baptist University
RP Yu, ZL (通讯作者)，HKBU Shenzhen Res Inst & Continuing Educ, Res & Dev Ctr Nat Hlth Prod, Shenzhen, Peoples R China.; Yu, ZL (通讯作者)，Hong Kong Baptist Univ, Ctr Canc & Inflammat Res, Sch Chinese Med, Kowloon Tong, Hong Kong, Peoples R China.; Yu, ZL (通讯作者)，Hong Kong Baptist Univ, Consun Chinese Med Res Ctr Renal Dis, Sch Chinese Med, Kowloon Tong, Hong Kong, Peoples R China.; Yu, ZL (通讯作者)，Hong Kong Baptist Univ, JaneClare Transdermal TCM Therapy Lab, Kowloon Tong, Hong Kong, Peoples R China.
EM zlyu@hkbu.edu.hk
RI Liu, Yuxi/LRT 6257 2024; WU, Ying/HCH 0078 2022; Wu,
   Jiaying/AAM 8347 2021
OI Chen, Yingjie/0000 0002 4604 3896; Fu, Xiu Qiong/0000 0002 1458 9720
FU Shenzhen Science and Technology Innovation Commission
   [JCYJ20160229210327924, JCYJ20170817173608483]; National Natural Science
   Foundation of China [81673649, 8187141799, 81803788]; Food and Health
   Bureau of Hong Kong [14150571, 15163441]; Research Grants Council of
   Hong Kong [12125116, 12102918, 12101519]; Guangdong Provincial
   Department of Science and Technology [2016A030313007]; Hong Kong Baptist
   University [FRG2/17 18/032]
FX This work is supported by Shenzhen Science and Technology Innovation
   Commission (JCYJ20160229210327924 and JCYJ20170817173608483), National
   Natural Science Foundation of China (81673649, 8187141799 and 81803788),
   Food and Health Bureau of Hong Kong (14150571 and 15163441), Research
   Grants Council of Hong Kong (12125116, 12102918 and 12101519), Guangdong
   Provincial Department of Science and Technology (2016A030313007) and
   Hong Kong Baptist University (FRG2/17 18/032).
CR Ban JO, 2014, BRIT J PHARMACOL, V171, P2900, DOI 10.1111/bph.12619
   Bandyopadhyay S, 2006, BIOCHEM PHARMACOL, V72, P184, DOI 10.1016/j.bcp.2006.04.018
   Bode JG, 2012, CELL SIGNAL, V24, P1185, DOI 10.1016/j.cellsig.2012.01.018
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092 8674(00)81959 5
   Cao HH, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0367 4
   Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897
   Chang XY, 2015, CHEM BIOL INTERACT, V236, P41, DOI 10.1016/j.cbi.2015.04.021
   Chen YJ, 2020, J ETHNOPHARMACOL, V252, DOI 10.1016/j.jep.2020.112625
   Cheng BCY, 2016, SCI REP UK, V6, DOI 10.1038/srep20042
   Choe JY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4162
   Ding HM, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22373
   Eldahshan OA, 2012, J APPL PHARM SCI, V2, P74
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005
   Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363
   Hashizume M, 2011, ARTHRITIS, DOI 10.1155/2011/765624
   He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Kwak SC, 2013, BIOL PHARM BULL, V36, P1779
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Li CH, 2016, INFLAMM RES, V65, P193, DOI 10.1007/s00011 015 0905 y
   Li CH, 2013, BIOCHEM BIOPH RES CO, V435, P533, DOI 10.1016/j.bbrc.2013.04.084
   Lou LX, 2016, EXP THER MED, V11, P2054, DOI 10.3892/etm.2016.3136
   MADSON KL, 1994, J RHEUMATOL, V21, P2359
   Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Nanjing University of Chinese Medicine, 1977, CHIN MAT MED GRAND D
   Oike T, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11233 w
   Ramiro S, 2017, ANN RHEUM DIS, V76, P1093, DOI 10.1136/annrheumdis 2016 210708
   Reynolds JM, 2012, P NATL ACAD SCI USA, V109, P13064, DOI 10.1073/pnas.1120585109
   Saravanan S, 2014, EUR J PHARM SCI, V56, P70, DOI 10.1016/j.ejps.2014.02.005
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Shi FC, 2015, CHEM BIOL INTERACT, V226, P82, DOI 10.1016/j.cbi.2014.10.031
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140 6736(07)60784 3
   Song FM, 2018, J CELL PHYSIOL, V233, P1723, DOI 10.1002/jcp.26084
   Su T, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00227
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Tu LN, 2012, INT IMMUNOPHARMACOL, V13, P417, DOI 10.1016/j.intimp.2012.04.001
   Tunyogi Csapo M, 2008, ARTHRITIS RHEUM US, V58, P2397, DOI 10.1002/art.23653
   Umar S., 2012, INDIAN J RHEUMATOLOG, V7, P191
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang K, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1547 6
   Wasserman A, 2018, AM FAM PHYSICIAN, V97, P455
   Yang CLH, 2013, CLIN REV ALLERG IMMU, V44, P284, DOI 10.1007/s12016 012 8329 8
   Ye J.Q., 2002, XIANDAI SHIYONG ZHON
   Yoon CH, 2013, JOINT BONE SPINE, V80, P274, DOI 10.1016/j.jbspin.2012.08.010
   Yuan FL, 2012, MOL BIOL REP, V39, P771, DOI 10.1007/s11033 011 0797 z
   Zhang CQ, 2018, J BIOMATER TISS ENG, V8, P1512, DOI 10.1166/jbt.2018.1885
NR 50
TC 16
Z9 17
U1 1
U2 22
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD SEP
PY 2020
VL 76
AR 153254
DI 10.1016/j.phymed.2020.153254
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA MV7YZ
UT WOS:000556569600012
PM 32531698
DA 2025 08 17
ER

PT J
AU Kim, MJ
   Kim, HS
   Lee, S
   Min, KY
   Choi, WS
   You, JS
AF Kim, Myoung Jun
   Kim, Hyuk Soon
   Lee, Sangyong
   Min, Keun Young
   Choi, Wahn Soo
   You, Jueng Soo
TI Hexosamine Biosynthetic Pathway Derived O GlcNAcylation Is Critical for
   RANKL Mediated Osteoclast Differentiation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE O GlcNAc transferase; O GlcNAcylation; osteoclastogenesis; osteoclast;
   NFATc1; p65
ID N ACETYLGLUCOSAMINE MODIFICATION; KAPPA B ACTIVATION; GLCNAC
   MODIFICATION; CYTOSOLIC PROTEINS; GLUCOSE METABOLISM; IN VITRO;
   GLYCOSYLATION; NUCLEAR; TRANSFERASE; RECEPTOR
AB O linked N acetylglucosaminylation (O GlcNAcylation) performed by O GlcNAc transferase (OGT) is a nutrient responsive post translational modification (PTM) via the hexosamine biosynthetic pathway (HBP). Various transcription factors (TFs) are O GlcNAcylated, affecting their activities and significantly contributing to cellular processes ranging from survival to cellular differentiation. Given the pleiotropic functions of O GlcNAc modification, it has been studied in various fields; however, the role of O GlcNAcylation during osteoclast differentiation remains to be explored. Kinetic transcriptome analysis during receptor activator of nuclear factor kappaB (NF kappa B) ligand (RANKL) mediated osteoclast differentiation revealed that the nexus of major nutrient metabolism, HBP was critical for this process. We observed that the critical genes related to HBP activation, including Nagk, Gfpt1, and Ogt, were upregulated, while the global O GlcNAcylation was increased concomitantly during osteoclast differentiation. The O GlcNAcylation inhibition by the small molecule inhibitor OSMI 1 reduced osteoclast differentiation in vitro and in vivo by disrupting the translocation of NF kappa B p65 and nuclear factor of activated T cells c1 (NFATc1) into the nucleus by controlling their PTM O GlcNAcylation. Furthermore, OSMI 1 had a synergistic effect with bone target therapy on osteoclastogenesis. Lastly, knocking down Ogt with shRNA (shOgt) mimicked OSMI 1's effect on osteoclastogenesis. Targeting O GlcNAcylation during osteoclast differentiation may be a valuable therapeutic approach for osteoclast activated bone diseases.
C1 [Kim, Myoung Jun; Lee, Sangyong; Min, Keun Young; Choi, Wahn Soo; You, Jueng Soo] Konkuk Univ, Sch Med, Seoul 05029, South Korea.
   [Kim, Hyuk Soon] Dong A Univ, Dept Biomed Sci, Coll Nat Sci, Busan 49315, South Korea.
   [Kim, Hyuk Soon] Dong A Univ, Dept Hlth Sci, Grad Sch, Busan 49315, South Korea.
   [Choi, Wahn Soo; You, Jueng Soo] Konkuk Univ, KU Open Innovat Ctr, Res Inst Med Sci, Chungju 27478, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Dong A University;
   Dong A University; Konkuk University
RP You, JS (通讯作者)，Konkuk Univ, Sch Med, Seoul 05029, South Korea.; You, JS (通讯作者)，Konkuk Univ, KU Open Innovat Ctr, Res Inst Med Sci, Chungju 27478, South Korea.
EM wns798@naver.com; hskimxo@dau.ac.kr; sangyong@konkuk.ac.kr;
   m.m1203@hanmail.net; wahnchoi@kku.ac.kr; jsyou@kku.ac.kr
RI Kim, Myoung Jun/JMQ 4109 2023; Kim, Hyuk Soon/IQW 9348 2023
OI Kim, Hyuk Soon/0000 0002 0566 0142
FU National Research Foundation of Korea (NRF)   Ministry of Science, ICT,
   and Future Planning [2021R1A2C4001833, 2016R1A5A2012284]
FX The Basic Science Research Program supported this research through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Science, ICT, and Future Planning (2021R1A2C4001833 and
   2016R1A5A2012284).
CR Allison DF, 2012, P NATL ACAD SCI USA, V109, P16888, DOI 10.1073/pnas.1208468109
   Andres LM, 2017, ACS CHEM BIOL, V12, P2030, DOI 10.1021/acschembio.7b00232
   Andrés Bergós J, 2012, J BIOL CHEM, V287, P33615, DOI 10.1074/jbc.M112.354241
   Berrabah W, 2014, HEPATOLOGY, V59, P2022, DOI 10.1002/hep.26710
   Bond MR, 2013, ANNU REV NUTR, V33, P205, DOI 10.1146/annurev nutr 071812 161240
   Chiaradonna F, 2018, CELLS BASEL, V7, DOI 10.3390/cells7060053
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dentin R, 2008, SCIENCE, V319, P1402, DOI 10.1126/science.1151363
   Dong W, 2018, BIOCHEM BIOPH RES CO, V505, P1195, DOI 10.1016/j.bbrc.2018.10.059
   Esposito M, 2021, NAT CANCER, V2, P258, DOI 10.1038/s43018 021 00181 0
   Golks A, 2007, EMBO J, V26, P4368, DOI 10.1038/sj.emboj.7601845
   Gu H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010202
   Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815
   Hsieh TJ, 2012, J CELL PHYSIOL, V227, P108, DOI 10.1002/jcp.22707
   Ishihara K, 2010, BIOCHEM BIOPH RES CO, V398, P489, DOI 10.1016/j.bbrc.2010.06.105
   Khidekel N, 2007, NAT CHEM BIOL, V3, P339, DOI 10.1038/nchembio881
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kim JH, 2011, BIOCHEM J, V436, P253, DOI 10.1042/BJ20110062
   Kim SH, 2007, BIOCHEM BIOPH RES CO, V362, P325, DOI 10.1016/j.bbrc.2007.07.149
   Koyama T, 2015, EXP CELL RES, V338, P194, DOI 10.1016/j.yexcr.2015.08.009
   Kreppel LK, 1997, J BIOL CHEM, V272, P9308
   Li X, 2009, J BIOL CHEM, V284, P19248, DOI 10.1074/jbc.M109.005678
   Liu YB, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12522 0
   Lothrop AP, 2013, FEBS LETT, V587, P1247, DOI 10.1016/j.febslet.2013.01.047
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Ma ZY, 2017, J BIOL CHEM, V292, P9150, DOI 10.1074/jbc.M116.766568
   McColgan NM, 2020, GLYCOBIOLOGY, V30, P872, DOI 10.1093/glycob/cwaa033
   Mercatali L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081655
   Mercatali L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111827
   Nagel AK, 2014, MOL CELL PROTEOMICS, V13, P3381, DOI 10.1074/mcp.M114.040691
   Nagel AK, 2013, MOL CELL PROTEOMICS, V12, P945, DOI 10.1074/mcp.M112.026633
   Ogawa M, 2012, BBA GEN SUBJECTS, V1820, P24, DOI 10.1016/j.bbagen.2011.10.011
   Ramakrishnan P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004097
   Rexach JE, 2012, NAT CHEM BIOL, V8, P253, DOI [10.1038/NCHEMBIO.770, 10.1038/nchembio.770]
   Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922
   Ruan HB, 2013, TRENDS ENDOCRIN MET, V24, P301, DOI 10.1016/j.tem.2013.02.002
   Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114
   Sohn KC, 2014, J DERMATOL SCI, V75, P10, DOI 10.1016/j.jdermsci.2014.04.010
   Su C, 2017, J NEUROSCI, V37, P2125, DOI 10.1523/JNEUROSCI.3384 16.2017
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Swamy M, 2016, NAT IMMUNOL, V17, P712, DOI 10.1038/ni.3439
   Takeuchi T, 2020, BIOL PHARM BULL, V43, P1501, DOI 10.1248/bpb.b20 00221
   Takeuchi Tomoharu, 2016, Bone Rep, V5, P15, DOI 10.1016/j.bonr.2016.02.001
   Takeuchi T, 2017, BIOL PHARM BULL, V40, P352, DOI 10.1248/bpb.b16 00877
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wells L, 2002, J BIOL CHEM, V277, P1755, DOI 10.1074/jbc.M109656200
   Wittrant Y, 2008, BONE, V42, P1122, DOI 10.1016/j.bone.2008.02.006
   Wu DL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.585288
   Xu J, 2015, MOL MED REP, V11, P865, DOI 10.3892/mmr.2014.2807
   Yang WH, 2008, P NATL ACAD SCI USA, V105, P17345, DOI 10.1073/pnas.0806198105
   Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668
   Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22
   Yuzwa SA, 2012, NAT CHEM BIOL, V8, P393, DOI [10.1038/NCHEMBIO.797, 10.1038/nchembio.797]
   Zhang DM, 2015, INFLAMM RES, V64, P943, DOI 10.1007/s00011 015 0877 y
   Zhang Z, 2019, J BIOL CHEM, V294, P1363, DOI 10.1074/jbc.RA118.005993
   Zhang Z, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00206
NR 58
TC 24
Z9 25
U1 2
U2 15
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2021
VL 22
IS 16
AR 8888
DI 10.3390/ijms22168888
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UI2SN
UT WOS:000690463900001
PM 34445596
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Fouque, D
   Roth, H
   Pelletier, S
   London, GM
   Hannedouche, T
   Jean, G
   Bouchet, JL
   Drüeke, T
AF Fouque, Denis
   Roth, Hubert
   Pelletier, Solenne
   London, Gerard M.
   Hannedouche, Thierry
   Jean, Guillaume
   Bouchet, Jean Louis
   Drueeke, Tilman
TI Control of mineral metabolism and bone disease in haemodialysis
   patients: which optimal targets?
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE calcium; haemodialysis; parathyroid hormone; phosphate; survival
ID STAGE RENAL DISEASE; CHRONIC KIDNEY DISEASE; PRACTICE PATTERNS; DIALYSIS
   OUTCOMES; MAINTENANCE HEMODIALYSIS; MORTALITY RISK; PARATHYROID HORMONE;
   PREDICTORS; PHOSPHORUS; CALCIUM
AB Background. There is a high drug treatment burden on patients receiving long term dialysis therapy. Abnormalities of calcium and phosphate metabolism are associated with increased mortality, and attempts to correct these disturbances may improve survival.
   Methods. We prospectively evaluated the targets of the currently used Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in 8377 prevalent patients receiving intermittent haemodialysis therapy in France from July 2007 to December 2009.
   Results. Adjusted Cox analyses showed that only one among six targets was predictive of mortality, i.e. a serum intact parathyroid hormone (iPTH) <130 pg/mL. A continuous risk analysis using fractional polynomials showed a 10% increase in hazard ratio (HR) for mortality for a serum phosphate <0.71 (2.2) and >1.98 (6.14) mmol/L (mg/dL), a non corrected serum calcium <1.59 (6.37) and >2.41 (9.66) mmol/L (mg/dL) and a serum iPTH < 100 and > 1090 pg/mL.
   Conclusion. The findings of our observational study confirm the existence of a grey zone, in which precise biochemical targets are difficult to define, with the exception of avoiding extreme values. Given the absence of intervention trials proving the clinical usefulness of phosphorus control, and pending the results of large clinical trials on the effect of optimal PTH and calcium control on hard outcomes, the present findings may help to refine future recommendations for the treatment of chronic haemodialysis patients.
C1 [Fouque, Denis; Pelletier, Solenne] Univ Lyon, Hop Edouard Herriot, Dept Nephrol, CENS, Lyon, France.
   [Roth, Hubert] CHU Grenoble, Ctr Rech Nutr Humaine Rhone Alpes, Grenoble, France.
   [London, Gerard M.] Hop Manhes, Fleury Merogis, France.
   [Hannedouche, Thierry] Hop Univ Strasbourg, Serv Nephrol, Strasbourg, France.
   [Hannedouche, Thierry] Fac Med Strasbourg, Strasbourg, France.
   [Jean, Guillaume] Ctr Rein Artificiel, Tassin La Demi Lune, France.
   [Bouchet, Jean Louis] Ctr Traitement Malad Renales St Augustin, Bordeaux, France.
   [Drueeke, Tilman] Univ Picardie Jules Verne, Inserm Unit ERI 12, UFR Med & Pharm, Amiens, France.
C3 CHU Lyon; Communaute Universite Grenoble Alpes; Universite Grenoble
   Alpes (UGA); CHU Grenoble Alpes; Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; CHU Strasbourg;
   Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Picardie Jules Verne (UPJV)
RP Fouque, D (通讯作者)，Univ Lyon, Hop Edouard Herriot, Dept Nephrol, CENS, Lyon, France.
EM denis.fouque@chu lyon.fr
RI ; DRUEKE, Tilman/B 4958 2010; Fouque, Denis/C 5338 2014; fouque,
   denis/C 5338 2014
OI ROTH, Hubert/0000 0002 1980 3220; fouque, denis/0000 0002 9707 7199;
   Drueke, Tilman B./0000 0002 0700 7681; Jean,
   guillaume/0000 0003 4757 9956
FU Genzyme; Amgen; Fresenius; Shire; Novartis; Roche
FX Genzyme, the sponsor of this observational study secured the funding
   required throughout study implementation and managed the development of
   the protocol, the electronic case report form, the regulatory
   submissions and logistics. The results presented in this paper have not
   been published previously in whole or part, except in abstract format.
   D. F. received honoraria and lecture fees from Amgen, Fresenius, Genzyme
   and Shire. H. R. received honoraria from Genzyme. S. P. received a
   consulting fee from Amgen. G. M. L. received honoraria for lecture fees
   from Amgen, Fresenius and Shire. T. H. received honoraria and lecture
   fees from Amgen, Fresenius, Genzyme, Novartis and Roche. G. J. received
   honoraria from Amgen, Fresenius, Genzyme and Shire. J. L. B. received
   honoraria from Bellco, Fresenius, Genzyme and Merck Sharpe Dohme. T. D.:
   Advisor/Consultant: Amgen; Fresenius; Genzyme; Leo; Mitsubishi; Roche;
   Theraclion. Speaker: Amgen; Chugai; Genzyme; Kirin; Roche; Takeda
   Grant/Research Support: Amgen; Genzyme; Shire.
CR [Anonymous], 2008, THERAP APHER DIAL, V12, P514
   [Anonymous], 2003, AM J KIDNEY DIS S3, V42, pS1
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905
   Canaud B, 2008, NEPHROL THER, V4, P256, DOI 10.1016/j.nephro.2008.01.003
   Couchoud C, 2012, REIN REGISTRY ANN RE
   Couchoud C, 2012, NEPHROL DIAL TRANSPL, V27, P2312, DOI 10.1093/ndt/gfr639
   Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219
   Foley RN, 1996, J AM SOC NEPHROL, V7, P728
   Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Johansen KL, 2007, J RENAL NUTR, V17, P305, DOI 10.1053/j.jrn.2007.06.005
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD  MBD Work Group, 2009, KIDNEY INT S113, V76, pS1
   Lopes AA, 2012, AM J KIDNEY DIS, V60, P90, DOI 10.1053/j.ajkd.2011.12.025
   Moe SM, 2008, CLIN J AM SOC NEPHRO, V3, pS127, DOI 10.2215/CJN.04331206
   Nigwekar SU, 2011, NEPHROL DIAL TRANSPL, V26, P764, DOI 10.1093/ndt/gfq799
   Parekh RS, 2008, KIDNEY INT, V74, P1335, DOI 10.1038/ki.2008.449
   Pelletier S, 2011, NEPHROL DIAL TRANSPL, V26, P7, DOI 10.1093/ndt/gfq713
   Pelletier S, 2010, NEPHROL THER, V6, P11, DOI 10.1016/j.nephro.2009.09.001
   Pérez García R, 2009, NEPHROL DIAL TRANSPL, V24, P578, DOI 10.1093/ndt/gfn464
   Phelan PJ, 2008, RENAL FAILURE, V30, P423, DOI 10.1080/08860220801964236
   Portolés J, 2007, NEPHROL DIAL TRANSPL, V22, P500, DOI 10.1093/ndt/gfl558
   Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331
   Royston P, 2005, METHOD INFORM MED, V44, P561
   Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275
   Snaedal S, 2009, AM J KIDNEY DIS, V53, P1024, DOI 10.1053/j.ajkd.2009.02.008
   Souberbielle JCP, 2010, KIDNEY INT, V77, P93, DOI 10.1038/ki.2009.374
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Wald R, 2008, AM J KIDNEY DIS, V52, P531, DOI 10.1053/j.ajkd.2008.05.020
   Wald R, 2007, AM J KIDNEY DIS, V49, P257, DOI 10.1053/j.ajkd.2006.11.027
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 34
TC 74
Z9 76
U1 0
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD FEB
PY 2013
VL 28
IS 2
BP 360
EP 367
DI 10.1093/ndt/gfs404
PG 8
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation; Urology & Nephrology
GA 106CQ
UT WOS:000316119500019
PM 23136211
OA Bronze
DA 2025 08 17
ER

PT J
AU Zeng, YY
   Shen, YD
   Wu, SY
   Cai, L
   Wang, Z
   Cai, KX
   Shen, JT
   Yie, KHR
   Zhang, HL
   Xu, LH
   Liu, JS
AF Zeng, Youyun
   Shen, Yiding
   Wu, Shuyi
   Cai, Lei
   Wang, Zhen
   Cai, Kexin
   Shen, Jiating
   Yie, Kendrick Hii Ru
   Zhang, Hualin
   Xu, Lihua
   Liu, Jinsong
TI Bone targeting PLGA derived lipid drug delivery system ameliorates bone
   loss in osteoporotic ovariectomized rats
SO MATERIALS & DESIGN
LA English
DT Article
DE Bone targeting; Polyaspartic acid peptides; Drug delivery system;
   Osteoporosis; Anti osteoporosis drug
ID CATHEPSIN K INHIBITOR; POLYMER HYBRID NANOPARTICLES; POSTMENOPAUSAL
   OSTEOPOROSIS; ODANACATIB; THERAPY; PEPTIDE; CARRIER; DESIGN;
   PHARMACOKINETICS; BARRIERS
AB The lack of safety, efficacy, and specificity has made the delivery of anti osteoporotic drugs at a proper dose a challenge. In our study, cathepsin K inhibitor loaded poly (D, L lactide co glycolide) derived lipid hybrid nanoparticles (DNPs) were modified with bone specific polyaspartic acid [(Asp)(8) DNPs] to treat osteoporosis. (Asp)(8) DNPs showed its hydroxyapatite binding affinity and achieved a sustained release of cathepsin K inhibitor for up to 5 days. Cathepsin K inhibitor loaded (Asp)8 DNPs significantly decreased the tartrate resistant acid phosphatase (TRAP) activity and resorption related genes in osteoclasts. Animal studies also exhibited high accumulation of (Asp)8 DNPs in the tibia and femur and a greater bone mass in trabecular bone and better organized three dimensional architecture in osteoporotic rat models. Herein, the bone targeting drug delivery system show its potential in treatment of osteoporosis. (C) 2022 The Authors. Published by Elsevier Ltd.
C1 [Zeng, Youyun; Shen, Yiding; Wu, Shuyi; Cai, Lei; Wang, Zhen; Cai, Kexin; Shen, Jiating; Yie, Kendrick Hii Ru; Liu, Jinsong] Wenzhou Med Univ, Sch & Hosp Stomatol, Wenzhou 325027, Peoples R China.
   [Zhang, Hualin] Ningxia Med Univ, Coll Stomatol, Yinchuan 750004, Peoples R China.
   [Xu, Lihua] Wenzhou Med Univ, Affiliated Hosp 1, Gen Med Dept, Wenzhou 325000, Peoples R China.
C3 Wenzhou Medical University; Ningxia Medical University; Wenzhou Medical
   University
RP Liu, JS (通讯作者)，Wenzhou Med Univ, Sch & Hosp Stomatol, Wenzhou 325027, Peoples R China.; Zhang, HL (通讯作者)，Ningxia Med Univ, Coll Stomatol, Yinchuan 750004, Peoples R China.; Xu, LH (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 1, Gen Med Dept, Wenzhou 325000, Peoples R China.
EM hua31415926@163.com; lihuaxusx@163.com; jinsong0719@wmu.edu.cn
RI Zhang, Hualin/A 2318 2008; Xu, Lihua/P 8054 2019
FU National Natural Science Foundation of China [81870810, 82071170];
   Zhejiang Provincial Science and Technology Project for Public Welfare
   [LGF21H140004]; Wen zhou Public Welfare Science and Technology Project
   [Y20180164, ZY2019009, 2021Y0441]
FX This work is supported by the National Natural Science Foundation of
   China (81870810 and 82071170) , Zhejiang Provincial Science and
   Technology Project for Public Welfare (LGF21H140004) , Wen zhou Public
   Welfare Science and Technology Project (Y20180164, ZY2019009 and
   2021Y0441) .
CR Almazrooa SA, 2009, J AM DENT ASSOC, V140, P864, DOI 10.14219/jada.archive.2009.0280
   Anderson MS, 2014, J CLIN ENDOCR METAB, V99, P552, DOI 10.1210/jc.2013 1688
   Askari M, 2021, BIOMATER SCI UK, V9, P535, DOI 10.1039/d0bm00973c
   Beto Judith A, 2015, Clin Nutr Res, V4, P1, DOI 10.7762/cnr.2015.4.1.1
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Bou S, 2020, SOFT MATTER, V16, P4173, DOI 10.1039/d0sm00077a
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chen BL, 2012, J ORTHOP RES, V30, P733, DOI 10.1002/jor.22004
   Chen Z, 2016, ACS NANO, V10, P10049, DOI 10.1021/acsnano.6b04695
   Cheng TL, 2015, J TISSUE ENG, V6, DOI 10.1177/2041731415609448
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dave V, 2019, J MICROBIOL METH, V160, P130, DOI 10.1016/j.mimet.2019.03.017
   Eastell R, 2011, J BONE MINER RES, V26, P1303, DOI 10.1002/jbmr.341
   Fang RH, 2010, LANGMUIR, V26, P16958, DOI 10.1021/la103576a
   Fazil M, 2013, EXPERT OPIN DRUG DEL, V10, P1123, DOI 10.1517/17425247.2013.785518
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fu YC, 2014, ACTA BIOMATER, V10, P4583, DOI 10.1016/j.actbio.2014.07.015
   Ghitman J, 2020, MATER DESIGN, V193, DOI 10.1016/j.matdes.2020.108805
   Gu PF, 2019, CARBOHYD POLYM, V223, DOI 10.1016/j.carbpol.2019.115128
   Hao L, 2015, INFECT IMMUN, V83, P1235, DOI 10.1128/IAI.01713 14
   Hayman AR, 2001, J HISTOCHEM CYTOCHEM, V49, P675, DOI 10.1177/002215540104900601
   Iwamoto J, 2014, BONE, V64, P88, DOI 10.1016/j.bone.2014.04.003
   Jensen PR, 2014, CALCIFIED TISSUE INT, V94, P212, DOI 10.1007/s00223 013 9800 0
   Jiang T, 2014, INT J PHARMACEUT, V475, P547, DOI 10.1016/j.ijpharm.2014.08.067
   Kim Hee Sun, 2019, Restor Dent Endod, V44, pe17, DOI 10.5395/rde.2019.44.e17
   Li MJ, 2019, BIOMATERIALS, V216, DOI 10.1016/j.biomaterials.2019.119269
   Li S, 2021, COMPOS COMMUN, V28, DOI 10.1016/j.coco.2021.100908
   Li S, 2021, POLYM COMPOSITE, V42, P6512, DOI 10.1002/pc.26317
   Li S, 2021, J MECH BEHAV BIOMED, V120, DOI 10.1016/j.jmbbm.2021.104561
   Liu JS, 2017, INT J NANOMED, V12, P3561, DOI 10.2147/IJN.S133787
   Lu J, 2018, J ENZYM INHIB MED CH, V33, P890, DOI 10.1080/14756366.2018.1465417
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   Mohanty A, 2020, MOLECULES, V25, DOI 10.3390/molecules25194377
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Ogawa K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084335
   Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Panwar P, 2019, J BONE MINER RES, V34, P777, DOI 10.1002/jbmr.3687
   Pei LM, 2004, J CLIN INVEST, V113, P805, DOI 10.1172/JCI200421311
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rotman SG, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090885
   Shirzad M, 2021, J MECH BEHAV BIOMED, V120, DOI 10.1016/j.jmbbm.2021.104594
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248 010 9210 4
   Yamashita S, 2018, BIOMATERIALS, V154, P74, DOI 10.1016/j.biomaterials.2017.10.053
   Yang Q, 2021, INT J NANOMED, V16, P185, DOI 10.2147/IJN.S286221
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Yu NYC, 2017, J BIOMED MATER RES B, V105, P136, DOI 10.1002/jbm.b.33481
   Zhang WY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13058
   Zhang ZX, 2021, MATER DESIGN, V204, DOI 10.1016/j.matdes.2021.109648
   Zheng MB, 2015, J NANOSCI NANOTECHNO, V15, P4792, DOI 10.1166/jnn.2015.9604
   Zheng MB, 2013, ACS NANO, V7, P2056, DOI 10.1021/nn400334y
NR 58
TC 5
Z9 5
U1 2
U2 28
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0264 1275
EI 1873 4197
J9 MATER DESIGN
JI Mater. Des.
PD SEP
PY 2022
VL 221
AR 110967
DI 10.1016/j.matdes.2022.110967
EA AUG 2022
PG 12
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 4Y4RX
UT WOS:000861516100003
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, D
   Du, J
   Yu, M
   Suo, L
AF Zhang, Dan
   Du, Jian
   Yu, Min
   Suo, Linna
TI Urine derived stem cells extracellular vesicles ameliorate diabetic
   osteoporosis through HDAC4/HIF 1α/VEGFA axis by delivering
   microRNA 26a 5p
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Article
DE Urine derived stem cells; Extracellular vesicles; microRNA 26a 5p;
   Histone deacetylase; HDAC4; HIF 1 alpha; VEGFA; Diabetes; Osteoporosis
ID ANGIOGENESIS; GUIDELINES; EXOSOMES
AB Critical roles of stem cell extracellular vesicles (EVs) in the management of osteoporosis have been documented. Here, this study was designed to enlarge the research of the specific effects and underlying mechanism of urine derived stem cells EVs (USCs EVs) on osteoporosis in diabetes rats. Firstly, miR 26a 5p and histone deacetylase 4 (HDAC4) expression in USCs of rats after diabetic osteoporosis (DOP) modeling induced by streptozotocin injection was determined, followed by study of their interaction. Then, USCs EVs were co cultured with osteogenic precursor cells, the effects of miRNA 26a 5p (miR 26a 5p) on osteoblasts, osteoclasts, bone mineralization deposition rate were evaluated. Meanwhile, the effect of USCs EVs carrying miR 26a 5p on DOP rats was assessed. Elevated miR 26a 5p was seen in USCs EVs which limited HDAC4 expression. Moreover, USCs EVs delivered miR 26a 5p to osteogenic precursor cells, thereby promoting their differentiation, enhancing the activity of osteoblasts, and inhibiting the activity of osteoclasts, thereby preventing DOP through the activation of hypoxia inducible factor 1 subunit alpha (HIF 1 alpha)/vascular endothelial growth factor A (VEGFA) pathway by repressing HDAC4. In a word, USCs EVsmiR 26a 5p is a promising therapy for DOP by activating HIF 1 alpha/VEGFA pathway through HDAC4 inhibition.
C1 [Zhang, Dan; Du, Jian; Suo, Linna] China Med Univ, Dept Endocrinol, Affiliated Hosp 4, Shenyang 110032, Peoples R China.
   [Yu, Min] China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth,Minist Educ, Shenyang 110122, Peoples R China.
   [Yu, Min] China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Key Lab Med Cell Biol,Minist Educ, Shenyang 110122, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Suo, L (通讯作者)，China Med Univ, Dept Endocrinol, Affiliated Hosp 4, Shenyang 110032, Peoples R China.
EM lnsuo@cmu.edu.cn
CR Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Burdeyron P, 2020, WORLD J STEM CELLS, V12, P1080, DOI 10.4252/wjsc.v12.i10.1080
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Chen CY, 2020, ACTA BIOMATER, V111, P208, DOI 10.1016/j.actbio.2020.05.020
   Chen CY, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0056 9
   Chen RJ, 2019, BIOCHEM BIOPH RES CO, V516, P666, DOI 10.1016/j.bbrc.2019.06.083
   Choi C, 2012, MENOPAUSE, V19, P1043, DOI 10.1097/gme.0b013e31824b1cc5
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   DeShields SC, 2018, J ENDOCRINOL INVEST, V41, P1051, DOI 10.1007/s40618 018 0828 x
   Duan Yu Rui, 2021, J Cell Mol Med, V25, P10798, DOI 10.1111/jcmm.14558
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Faulkner B, 2019, MOLECULES, V24, DOI 10.3390/molecules24071355
   Guan H, 2020, EXP CELL RES, V392, DOI 10.1016/j.yexcr.2020.112007
   Ji XL, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4378947
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI [10.1016/j.joca.2012.02.010, 10.1111/j.1939 165X.2012.00418.x]
   Leidig Bruckner G, 2014, BMC ENDOCR DISORD, V14, DOI 10.1186/1472 6823 14 33
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Li XR, 2020, THERANOSTICS, V10, P9561, DOI 10.7150/thno.42153
   Li Y, 2015, MOL THER, V23, P1349, DOI 10.1038/mt.2015.101
   Ling XZ, 2020, J CELL MOL MED, V24, P640, DOI 10.1111/jcmm.14774
   Liu SG, 2020, BIOSENS BIOELECTRON, V166, DOI 10.1016/j.bios.2020.112461
   Liu XD, 2015, BIOL CHEM, V396, P339, DOI 10.1515/hsz 2014 0268
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Malavkia D, 2020, J CELL PHYSIOL, V235, P7996, DOI 10.1002/jcp.29454
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Muraca M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228682
   Ouyang B, 2019, SEX MED UK, V7, P241, DOI 10.1016/j.esxm.2019.02.001
   Quinlan E, 2015, BIOMATERIALS, V52, P358, DOI 10.1016/j.biomaterials.2015.02.006
   Schoepflin ZR, 2016, J BONE MINER RES, V31, P1287, DOI 10.1002/jbmr.2787
   Trompeter HI, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 111
   Wang CG, 2020, EXP MOL MED, V52, P1310, DOI 10.1038/s12276 020 0475 0
   Wang JLS, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115606
   Wang YY, 2020, INT J NANOMED, V15, P7967, DOI 10.2147/IJN.S263756
   Wei H, 2020, AGING US, V12, P14365, DOI 10.18632/aging.103478
   Xu DH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050977
   Yu LB, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02636 8
   Zhang JY, 2016, INT J BIOL SCI, V12, P1472, DOI 10.7150/ijbs.15514
   Zhang Y, 2017, ONCOGENE, V36, P4171, DOI 10.1038/onc.2017.51
   Zhong FD, 2015, ORG BIOMOL CHEM, V13, P1792, DOI 10.1039/c4ob02247e
   Zhou T, 2011, J AM SOC NEPHROL, V22, P1221, DOI 10.1681/ASN.2011010106
NR 41
TC 26
Z9 29
U1 1
U2 25
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0742 2091
EI 1573 6822
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD OCT
PY 2023
VL 39
IS 5
BP 2243
EP 2257
DI 10.1007/s10565 022 09713 5
EA MAY 2022
PG 15
WC Cell Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Toxicology
GA T7MW5
UT WOS:000795415500001
PM 35554780
DA 2025 08 17
ER

PT J
AU Guenou, H
   Kaabeche, K
   Dufour, C
   Miraoui, H
   Marie, PJ
AF Guenou, Hind
   Kaabeche, Karim
   Dufour, Cecilie
   Miraoui, Hichem
   Marie, Pierre J.
TI Down regulation of ubiquitin ligase Cbl induced by Twist
   haploinsufficiency in Saethre Chotzen syndrome results in increased
   PI3K/Akt signaling and osteoblast proliferation
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID GROWTH FACTOR RECEPTOR 2; PHOSPHOINOSITIDE 3 KINASE;
   PHOSPHATIDYLINOSITOL 3 KINASE; MEDIATED DEGRADATION; PROTEIN KINASE;
   BONE FORMATION; CELL GROWTH; DNA BINDING; DIFFERENTIATION; EXPRESSION
AB Genetic mutations of Twist, a basic helix loop helix transcription factor, induce premature fusion of cranial sutures in Saethre Chotzen syndrome (SCS). We report here a previously undescribed mechanism involved in the altered osteoblastogenesis in SCS. Cranial osteoblasts from an SCS patient with a Twist mutation causing basic helix loop helix deletion exhibited decreased expression of E3 ubiquitin ligase Cb1 compared with wild type osteoblasts. This was associated with decreased ubiquitin mediated degradation of phosphatidyl inositol 3 kinase (PI3K) and increased PI3K expression and PI3K/Akt signaling. Increased PI3K immunoreactivity was also found in osteoblasts in histological sections of affected cranial sutures from SCS patients. Transfection with Twist or Cb1 abolished the increased PI3K/Akt signaling in Twist mutant osteoblasts. Forced overexpression of Cb1 did not correct the altered expression of osteoblast differentiation markers in Twist mutant cells. In contrast, pharmacological inhibition of PI3K/Akt, but not ERK signaling, corrected the increased cell growth in Twist mutant osteoblasts. The results show that Twist haploinsufficiency results in decreased Cb1 mediated PI3K degradation in osteoblasts, causing PI3K accumulation and activation of PI3K/Akt dependent osteoblast growth. This provides genetic and biochemical evidence for a role for Cb1 mediated PI3K signaling in the altered osteoblast phenotype induced by Twist haploinsufficiency in SCS.
C1 Univ Paris 07, INSERM, U606, Lab Osteoblast Biol & Pathol, Paris, France.
C3 Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm)
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@larib.inserm.fr
RI Guenou, Hind/Q 3811 2018
OI Guenou, Hind/0000 0003 3906 2519
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   [Anonymous], SCI STKE
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Borgatti P, 2000, FEBS LETT, V477, P27, DOI 10.1016/S0014 5793(00)01758 0
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Debiais F, 2004, EXP CELL RES, V297, P235, DOI 10.1016/j.yexcr.2004.03.032
   Demontis S, 2006, CELL DEATH DIFFER, V13, P335, DOI 10.1038/sj.cdd.4401744
   Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002
   Drissi H, 1999, CANCER RES, V59, P3705
   Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200
   El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813
   El Ghouzzi V, 1999, EUR J HUM GENET, V7, P27, DOI 10.1038/sj.ejhg.5200240
   El Ghouzzi V, 2001, FEBS LETT, V492, P112, DOI 10.1016/S0014 5793(01)02238 4
   ElGhouzzi V, 1997, NAT GENET, V15, P42
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005
   Gripp KW, 2000, HUM MUTAT, V15, P150, DOI 10.1002/(SICI)1098 1004(200002)15:2<150::AID HUMU3>3.0.CO;2 D
   Guenou H, 2005, HUM MOL GENET, V14, P1429, DOI 10.1093/hmg/ddi152
   Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092 8674(00)80553 X
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197 36
   Kaabeche K, 2005, J CELL SCI, V118, P1223, DOI 10.1242/jcs.01679
   Kaabeche K, 2004, J BIOL CHEM, V279, P36259, DOI 10.1074/jbc.M402469200
   Kim Donghwa, 2005, Curr Opin Investig Drugs, V6, P1250
   Lee YR, 2005, BIOCHEM BIOPH RES CO, V336, P1221, DOI 10.1016/j.bbrc.2005.08.256
   Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Pratap J, 2003, CANCER RES, V63, P5357
   Radcliff K, 2005, CIRC RES, V96, P398, DOI 10.1161/01.RES.0000157671.47477.71
   Roos Mattjus P, 2004, ANN MED, V36, P285, DOI 10.1080/07853890310016324
   Sattler M, 1996, ONCOGENE, V12, P839
   Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762
   Stephens L, 2005, CURR OPIN PHARMACOL, V5, P357, DOI 10.1016/j.coph.2005.03.002
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781
   Viñals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014 5793(01)03236 7
   Wennström S, 1999, MOL CELL BIOL, V19, P4279
   Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647
   Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yousfi M, 2002, HUM MOL GENET, V11, P359, DOI 10.1093/hmg/11.4.359
   Yousfi M, 2002, BIOCHEM BIOPH RES CO, V297, P641, DOI 10.1016/S0006 291X(02)02260 X
   Yousfi M, 2001, J CLIN INVEST, V107, P1153, DOI 10.1172/JCI11846
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
NR 50
TC 38
Z9 47
U1 1
U2 8
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3993 USA
SN 0002 9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD OCT
PY 2006
VL 169
IS 4
BP 1303
EP 1311
DI 10.2353/ajpath.2006.060102
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 089HW
UT WOS:000240872400019
PM 17003487
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Hardy, S
   Choo, YM
   Hamann, M
   Cray, J
AF Hardy, Samantha
   Choo, Yeun Mun
   Hamann, Mark
   Cray, James
TI Manzamine A Alters In Vitro Calvarial Osteoblast Function
SO MARINE DRUGS
LA English
DT Article
DE manzamine; bone; osteoblast; six1; osteogenesis
ID NATURAL PRODUCTS; SIX1 EXPRESSION; CERVICAL CANCER; POOR PROGNOSIS;
   DRUG; ALKALOIDS; PROTEIN; CELL; DISCOVERY; SPONGE
AB Manzamine A is a marine derived alkaloid which has anti viral and anti proliferative properties and is currently being investigated for its efficacy in the treatment of certain viruses (malaria, herpes, HIV 1) and cancers (breast, cervical, colorectal). Manzamine A has been found to exert effects via modulation of SIX1 gene expression, a gene critical to craniofacial development via the WNT, NOTCH, and PI3K/AKT pathways. To date little work has focused on Manzamine A and how its use may affect bone. We hypothesize that Manzamine A, through SIX1, alters bone cell activity. Here, we assessed the effects of Manzamine A on cells that are responsible for the generation of bone, pre osteoblasts and osteoblasts. PCR, qrtPCR, MTS cell viability, Caspase 3/7, and functional assays were used to test the effects of Manzamine A on these cells. Our data suggests Six1 is highly expressed in osteoblasts and their progenitors. Further, osteoblast progenitors and osteoblasts exhibit great sensitivity to Manzamine A treatment exhibited by a significant decrease in cell viability, increase in cellular apoptosis, and decrease in alkaline phosphatase activity. In silico binding experiment showed that manzamine A potential as an inhibitor of cell proliferation and survival proteins, i.e., I kappa b, JAK2, AKT, PKC, FAK, and Bcl 2. Overall, our data suggests Manzamine A may have great effects on bone health overall and may disrupt skeletal development, homeostasis, and repair.
C1 [Hardy, Samantha; Cray, James] Ohio State Univ, Coll Med, Dept Biomed Educ & Anat, Columbus, OH 43210 USA.
   [Choo, Yeun Mun] Univ Malaya, Fac Sci, Chem Dept, Kuala Lumpur 50603, Malaysia.
   [Hamann, Mark] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Coll Pharm, Charleston, SC 29425 USA.
   [Hamann, Mark] Med Univ South Carolina, Dept Publ Hlth, Coll Pharm, Charleston, SC 29425 USA.
   [Hamann, Mark] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Coll Med, Charleston, SC 29425 USA.
   [Hamann, Mark] Med Univ South Carolina, Dept Publ Hlth, Coll Med, Charleston, SC 29425 USA.
   [Cray, James] Ohio State Coll Dent, Div Biosci, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; Universiti Malaya;
   Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina; Medical University of
   South Carolina; University System of Ohio; Ohio State University
RP Cray, J (通讯作者)，Ohio State Univ, Coll Med, Dept Biomed Educ & Anat, Columbus, OH 43210 USA.; Cray, J (通讯作者)，Ohio State Coll Dent, Div Biosci, Columbus, OH 43210 USA.
EM cray.30@osu.edu
RI CHOO, YEUN MUN/B 8402 2010; CHOO, YEUN MUN/B 8402 2010
OI CHOO, YEUN MUN/0000 0001 9891 5898; 
FU Ohio State College of Medicine
FX This research was funded by the Ohio State College of Medicine.
CR Adrados I, 2016, ONCOGENE, V35, P3485, DOI 10.1038/onc.2015.408
   Ang KKH, 2001, PARASITOL RES, V87, P715, DOI 10.1007/s004360000366
   Ang KKH, 2000, ANTIMICROB AGENTS CH, V44, P1645, DOI 10.1128/AAC.44.6.1645 1649.2000
   Barrow P, 2018, REPROD TOXICOL, V80, P117, DOI 10.1016/j.reprotox.2018.04.008
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bessarab DA, 2004, DEV DYNAM, V230, P781, DOI 10.1002/dvdy.20093
   Birkinshaw RW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10363 1
   Bonnet A, 2010, MECH DEVELOP, V127, P120, DOI 10.1016/j.mod.2009.10.001
   Bonnin MA, 2005, MECH DEVELOP, V122, P573, DOI 10.1016/j.mod.2004.11.005
   Brucker MC, 2017, J MIDWIFERY WOM HEAL, V62, P308, DOI 10.1111/jmwh.12611
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Calpena E, 2022, J MED GENET, V59, P165, DOI 10.1136/jmedgenet 2020 107459
   Cassidy C, 2020, INFECT AGENTS CANCER, V15, DOI 10.1186/s13027 020 00338 z
   Chary MA, 2020, J MED TOXICOL, V16, P284, DOI 10.1007/s13181 020 00777 5
   Cheng Q, 2018, CANCER BIOL THER, V19, P381, DOI 10.1080/15384047.2018.1423920
   Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101
   Dauner DG, 2021, J AM PHARM ASSOC, V61, P293, DOI 10.1016/j.japh.2021.01.007
   El Sayed KA, 2008, J NAT PROD, V71, P300, DOI 10.1021/np0703702
   Fabbro D, 2015, BRIT J PHARMACOL, V172, P2675, DOI 10.1111/bph.13096
   Freyer L, 2010, DEV DYNAM, V239, P1708, DOI 10.1002/dvdy.22308
   Funato N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00706
   Gammone MA, 2016, ANTI CANCER AGENT ME, V16, P1549, DOI 10.2174/1871520616666160211123841
   Grifone R, 2004, MOL CELL BIOL, V24, P6253, DOI 10.1128/MCB.24.14.6253 6267.2004
   Grifone R, 2007, DEV BIOL, V302, P602, DOI 10.1016/j.ydbio.2006.08.059
   Guzon Illescas O, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1226 6
   Hamann M, 2007, J NAT PROD, V70, P1397, DOI 10.1021/np060092r
   Hanna GS, 2021, J NAT PROD, V84, P3001, DOI 10.1021/acs.jnatprod.1c00625
   He Z, 2017, ONCOTARGETS THER, V10, P1071, DOI 10.2147/OTT.S125330
   Holliday LS, 2021, EXTRACELL VESICLES C, V2, P18, DOI 10.20517/evcna.2020.02
   Hosseinipour M, 2019, VIROLOGY, V537, P20, DOI 10.1016/j.virol.2019.08.009
   Hu Jin Feng, 2003, Alkaloids Chem Biol, V60, P207, DOI 10.1016/S0099 9598(03)60004 0
   ICHIBA T, 1994, J NAT PROD, V57, P168, DOI 10.1021/np50103a027
   Ikeda K, 2010, INT J DEV BIOL, V54, P1453, DOI 10.1387/ijdb.093041ki
   Indraningrat AAG, 2016, MAR DRUGS, V14, DOI 10.3390/md14050087
   Jänne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871
   Ji Q, 2020, EUR REV MED PHARMACO, V24, P2218, DOI 10.26355/eurrev_202003_20487
   Jin HD, 2014, EXP MOL PATHOL, V97, P247, DOI 10.1016/j.yexmp.2014.07.005
   Karan D, 2020, J NAT PROD, V83, P286, DOI 10.1021/acs.jnatprod.9b00577
   Kato Shumei, 2020, J Immunother Precis Oncol, V3, P52, DOI 10.36401/jipo 20 11
   Knight JDR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000982
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Laclef C, 2003, MECH DEVELOP, V120, P669, DOI 10.1016/S0925 4773(03)00065 0
   Laclef C, 2003, DEVELOPMENT, V130, P2239, DOI 10.1242/dev.00440
   Laport MS, 2009, CURR PHARM BIOTECHNO, V10, P86, DOI 10.2174/138920109787048625
   Li B, 2009, DEVELOPMENT, V136, P3267, DOI 10.1242/dev.036954
   Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002 9440(10)61166 2
   Li DP, 2022, ANNU REV MED, V73, P1, DOI 10.1146/annurev med 042420 113838
   Li WX, 2021, AM J TRANSL RES, V13, P2840
   Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083
   Li YM, 2019, EUR REV MED PHARMACO, V23, P4688, DOI 10.26355/eurrev_201906_18050
   Lisk Radcliffe, 2014, BMJ Qual Improv Rep, V3, DOI 10.1136/bmjquality.u205006.w2103
   Manivannan E, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.584940
   Mayer AMS, 2021, MAR DRUGS, V19, DOI 10.3390/md19090506
   Mioso R, 2017, MOLECULES, V22, DOI 10.3390/molecules22020208
   Mioso R, 2015, REV IBEROAM MICOL, V32, P147, DOI 10.1016/j.riam.2014.01.004
   Morri M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 55196 6
   Mouffak S, 2021, BIOMED PHARMACOTHER, V143, DOI 10.1016/j.biopha.2021.112107
   Nagel S, 2015, ONCOTARGET, V6, P40112, DOI 10.18632/oncotarget.5556
   Nair DG, 2015, ACTA PHARMACOL SIN, V36, P158, DOI 10.1038/aps.2014.114
   National Center for Health Statistics, 2021, OST LOW BON MASS OLD
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Newman DJ, 2002, CURR CANCER DRUG TAR, V2, P279, DOI 10.2174/1568009023333791
   Newman DJ, 2009, DIVING HYPERB MED, V39, P216
   Newman DJ, 2000, NAT PROD REP, V17, P215, DOI 10.1039/a902202c
   Nie XG, 2011, DEV BIOL, V352, P141, DOI 10.1016/j.ydbio.2011.01.027
   Palem JR, 2017, Z NATURFORSCH C, V72, P49, DOI 10.1515/znc 2016 0080
   Palem JR, 2011, PLANTA MED, V77, P46, DOI 10.1055/s 0030 1250093
   Panula J, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 105
   Peng JN, 2010, J MED CHEM, V53, P61, DOI 10.1021/jm900672t
   Peng JN, 2003, J AM CHEM SOC, V125, P13382, DOI 10.1021/ja030087z
   Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200
   Radwan M, 2012, CELL CYCLE, V11, P1765, DOI 10.4161/cc.20135
   Rao KV, 2006, J NAT PROD, V69, P1034, DOI 10.1021/np0601399
   Rao KV, 2004, J NAT PROD, V67, P1314, DOI 10.1021/np0400095
   Rao KV, 2003, J NAT PROD, V66, P823, DOI 10.1021/np020592u
   Relaix F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003425
   Ren ZX, 2021, AM J OBSTET GYNECOL, V225, P33, DOI 10.1016/j.ajog.2021.04.227
   Riddiford N, 2017, DEV BIOL, V431, P152, DOI 10.1016/j.ydbio.2017.09.027
   Rodriguez S, 2008, DEV BIOL, V314, P40, DOI 10.1016/j.ydbio.2007.10.056
   Saleem A, 2021, INFLAMMOPHARMACOLOGY, V29, P1331, DOI 10.1007/s10787 021 00850 7
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Sato S, 2012, DEV BIOL, V368, P95, DOI 10.1016/j.ydbio.2012.05.023
   Schnell S, 2010, GERIATR ORTHOP SURG, V1, P6, DOI 10.1177/2151458510378105
   Shilabin AG, 2008, J NAT PROD, V71, P1218, DOI 10.1021/np800163u
   Shyr ZA, 2020, J PHARMACOL EXP THER, V375, P127, DOI 10.1124/jpet.120.000123
   Song WX, 2019, CANCER SCI, V110, P608, DOI 10.1111/cas.13905
   Sun Yaping, 2020, Antib Ther, V3, P246, DOI 10.1093/abt/tbaa025
   Tavares ALP, 2017, DEVELOPMENT, V144, P2021, DOI 10.1242/dev.145144
   Thompson MJ, 2012, CHEMMEDCHEM, V7, P578, DOI 10.1002/cmdc.201200002
   Towers CG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10077
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsamantioti E.S., 2021, StatPearls
   Wang HH, 2016, GENET MOL BIOL, V39, P151, DOI 10.1590/1678 4685 GMB 2015 0075
   Wang QQ, 2022, BIOMED PHARMACOTHER, V154, DOI 10.1016/j.biopha.2022.113622
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
   Wesley BD, 2021, AM J OBSTET GYNECOL, V225, P21, DOI 10.1016/j.ajog.2021.02.032
   Wilmer E, 2016, CLIN DERMATOL, V34, P401, DOI 10.1016/j.clindermatol.2016.02.013
   Wu WJ, 2014, INT J BIOL SCI, V10, P983, DOI 10.7150/ijbs.9442
   Wu WJ, 2015, INT J CANCER, V136, P1245, DOI 10.1002/ijc.28755
   Xin XC, 2016, ONCOL LETT, V12, P3435, DOI 10.3892/ol.2016.5098
   Xu PX, 2003, DEVELOPMENT, V130, P3085, DOI 10.1242/dev.00536
   Yang LY, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060689
   Yousaf M, 2004, J MED CHEM, V47, P3512, DOI 10.1021/jm030475b
   Yu C, 2018, BIOMED PHARMACOTHER, V105, P10, DOI 10.1016/j.biopha.2018.04.028
   Yu J, 2004, CURR OPIN GENET DEV, V14, P550, DOI 10.1016/j.gde.2004.07.009
   Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471 2105 7 85
   Zarenezhad E, 2021, RUSS J BIOORG CHEM+, V47, P609, DOI 10.1134/S1068162021030183
   Zou D, 2006, DEV BIOL, V293, P499, DOI 10.1016/j.ydbio.2005.12.015
NR 108
TC 3
Z9 3
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1660 3397
J9 MAR DRUGS
JI Mar. Drugs
PD OCT
PY 2022
VL 20
IS 10
AR 647
DI 10.3390/md20100647
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 5S2PD
UT WOS:000875037800001
PM 36286470
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yao, BJ
   Liu, J
   Zhang, M
   Leng, XY
   Zhao, DQ
AF Yao, Baojin
   Liu, Jia
   Zhang, Mei
   Leng, Xiangyang
   Zhao, Daqing
TI Deciphering the potential pharmaceutical mechanism of Guzhi Zengsheng
   Zhitongwan on rat bone and kidney based on the "kidney governing bone"
   theory
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Chinese medicinal formulation; Guzhi Zengsheng Zhitongwan;
   Pharmaceutical mechanism; Osteoarthritis; Kidney governing bone
ID BINDING PROTEINS; TGF BETA; EXPRESSION; OSTEOBLAST; GENES;
   MINERALIZATION; PROLIFERATION; RESORPTION; SKELETAL; COLLAGEN
AB Background Guzhi Zengsheng Zhitongwan (GZZSZTW) is an effective Chinese medicinal formulation for the treatment of osteoarthritis (OA) designed according to the "kidney governing bone" theory, which has been widely used as a golden guide for treating bone and cartilage diseases in traditional Chinese medicine. The aim of this study was to explore the molecular mechanism underlying its effects on the bone and kidney. Methods Preparation and quality control were performed as previously described. Since GZZSZTW is orally administered in the form of pills prepared in boiled water, the Chinese materia medica (CMM) mixture of this formula was extracted with distilled water by a reflux method and was then filtered through a 0.45 mu m Hollow Fiber Cartridge (GE Healthcare, USA). The filtrate was freeze dried by a Heto PowerDry LL3000 Freeze Dryer (Thermo, USA) and stored at   80 degrees C. The effects of GZZSZTW on gene expression and regulation of both kidney and bone tissues were investigated using a state of the art RNA seq technology. Results We demonstrated that GZZSZTW could enhance kidney function and suppress bone formation and resorption by modulating the activities of osteoblast and osteoclast, and might subsequently contribute to the inhibition of osteophyte formation during the process of OA. These effects might be achieved by the synergistic interactions of various herbs and their active components in GZZSZTW, which increased the expression levels of functional genes participating in kidney function, regulation, and repair, and then decreased the expression levels of genes involved in bone formation and resorption. Thus, our findings were consistent with the "kidney governing bone" theory, which has been widely used as a guide in clinical practice for thousands of years. Conclusions This study has deepened the current knowledge about the molecular effects of GZZSZTW on bone and kidney regulation. Furthermore, this study might be able to provide possible strategies to further prevent and treat joint diseases by using traditional Chinese medicinal formulations following the "kidney governing bone" theory.
C1 [Yao, Baojin; Zhao, Daqing] Changchun Univ Chinese Med, Jilin Ginseng Acad, Changchun 130117, Jilin, Peoples R China.
   [Liu, Jia] Changchun Univ Chinese Med, Coll Pharm, Changchun 130117, Jilin, Peoples R China.
   [Zhang, Mei] Changchun Univ Chinese Med, Innovat Practice Ctr, Changchun 130117, Jilin, Peoples R China.
   [Leng, Xiangyang] Changchun Univ Chinese Med, Affiliated Hosp, Changchun 130117, Jilin, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University of
   Chinese Medicine; Changchun University of Chinese Medicine; Changchun
   University of Chinese Medicine
RP Zhao, DQ (通讯作者)，Changchun Univ Chinese Med, Jilin Ginseng Acad, Changchun 130117, Jilin, Peoples R China.; Leng, XY (通讯作者)，Changchun Univ Chinese Med, Affiliated Hosp, Changchun 130117, Jilin, Peoples R China.
EM leng_xiangyang@163.com; zhaodaqing1963@163.com
FU National Key Research and Development Program of China [2018YFC1704700];
   TCM Clinical Research Center for Bone diseases of Jilin Province
   [20180623048TC]
FX This work was supported by the National Key Research and Development
   Program of China (grant no. 2018YFC1704700) and the TCM Clinical
   Research Center for Bone diseases of Jilin Province (grant no.
   20180623048TC). The funding bodies provided financial support, and the
   awardees performed the research. The founding sponsor had no role in the
   design of the study, the collection, analysis, and interpretation of
   data and in writing the manuscript.
CR Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011 2152
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Boban I, 2006, BONE, V39, P1302, DOI 10.1016/j.bone.2006.06.025
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Cheng CW, 2005, KIDNEY INT, V68, P2694, DOI 10.1111/j.1523 1755.2005.00740.x
   Duverger O, 2013, J CELL PHYSIOL, V228, P654, DOI 10.1002/jcp.24175
   Eguchi K, 2018, BIOCHEM BIOPH RES CO, V507, P465, DOI 10.1016/j.bbrc.2018.11.065
   Erlandsson MC, 2013, BBA MOL CELL RES, V1833, P2653, DOI 10.1016/j.bbamcr.2013.06.020
   Fan Y, 2016, FASEB J, V30, P428, DOI 10.1096/fj.15 278184
   Fujie A, 2015, BIOCHEM BIOPH RES CO, V457, P451, DOI 10.1016/j.bbrc.2015.01.012
   Govoni KE, 2005, PEDIATR NEPHROL, V20, P261, DOI 10.1007/s00467 004 1658 y
   Ioan Facsinay A, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4422
   Izu Y, 2016, CELL TISSUE RES, V364, P623, DOI 10.1007/s00441 015 2345 y
   Ju DH, 2014, FRONT MED PRC, V8, P389, DOI 10.1007/s11684 014 0362 y
   Kahai S, 2004, MATRIX BIOL, V23, P445, DOI 10.1016/j.matbio.2004.09.004
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Ker DFE, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1027 6
   Kim BJ, 2018, J CLIN INVEST, V128, P1429, DOI 10.1172/JCI91086
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985
   Lai RE, 2018, J FOOD DRUG ANAL, V26, pS45, DOI 10.1016/j.jfda.2018.03.002
   Lee HL, 2011, BONE, V49, P242, DOI 10.1016/j.bone.2011.04.006
   Lenarczyk M, 2015, J MOL HISTOL, V46, P123, DOI 10.1007/s10735 014 9605 0
   Mosig RA, 2007, HUM MOL GENET, V16, P1113, DOI 10.1093/hmg/ddm060
   Nguan CYC, 2014, AM J PHYSIOL RENAL, V306, pF724, DOI 10.1152/ajprenal.00410.2013
   Nikitovic D, 2012, J BIOL CHEM, V287, P33926, DOI 10.1074/jbc.R112.379602
   Ninomiya K, 2007, BIOCHEM BIOPH RES CO, V362, P460, DOI 10.1016/j.bbrc.2007.07.193
   Pan L, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00519
   Pico Michael J, 2016, Bone Rep, V5, P222, DOI 10.1016/j.bonr.2016.07.006
   Pietschmann N, 2014, METALLOMICS, V6, P1043, DOI 10.1039/c4mt00003j
   Pugh CA, 2019, G3 BETHESDA
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Sasa K, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28605 5
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shu B, 2015, CHIN J INTEGR MED, V21, P656, DOI 10.1007/s11655 015 2306 z
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Upadhyay J, 2015, METABOLISM, V64, P105, DOI 10.1016/j.metabol.2014.10.021
   van der Kraan PM, 2007, OSTEOARTHR CARTILAGE, V15, P237, DOI 10.1016/j.joca.2006.11.006
   Vansthertem D, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/193259
   Volk SW, 2014, CALCIFIED TISSUE INT, V94, P621, DOI 10.1007/s00223 014 9843 x
   Wang LK, 2010, BIOINFORMATICS, V26, P136, DOI 10.1093/bioinformatics/btp612
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yao BJ, 2019, CHIN MED UK, V14, DOI 10.1186/s13020 019 0252 y
   Yao BJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9847286
   Yao BJ, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/7265939
   Zhang H, 2011, CURR MOL MED, V11, P489, DOI 10.2174/156652411796268704
   Zhou ZQ, 2015, HUM MOL GENET, V24, P1764, DOI 10.1093/hmg/ddu594
NR 47
TC 7
Z9 7
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD APR 15
PY 2020
VL 15
IS 1
AR 146
DI 10.1186/s13018 020 01677 8
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA LH7FE
UT WOS:000528950200006
PM 32295616
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Rucci, N
   Susa, M
   Teti, A
AF Rucci, Nadia
   Susa, Maria
   Teti, Anna
TI Inhibition of protein kinase c Src as a therapeutic approach for cancer
   and bone metastases
SO ANTI CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE c Src inhibitor; cancer; bone metastasis
ID RESORPTION IN VITRO; HUMAN BREAST CANCER; TYROSINE KINASE; ZOLEDRONIC
   ACID; GROWTH FACTOR; MURINE MODEL; ACTIVATION; EXPRESSION; CARCINOMA;
   PP60C SRC
AB c Src is a proto oncogene involved in the genesis of and invasion by many cancers. This non receptor tyrosine kinase also plays a crucial role in bone homeostasis, since inhibition or deletion of c Src impairs the function of osteoclasts, the bone resorbing cells. It is thus conceivable that c Src could be a suitable target for the pharmacological treatment of cancers, skeletal metastases and diseases of bone loss, such as osteoporosis. The pyrrolo pyrimidines CGP77675 and CGP76030 proved to be effective in preventing bone loss in animal models, while the effect of AZD0530, a dually active inhibitor of c Src and Bcr ABL, on bone resorption, has been tested in a Phase I clinical trials with promising results. As far as the metastatic bone disease is concerned, c Src inhibitors could potentially have inhibitory effects both on osteoclasts and on tumour cells, and could disrupt the vicious circle established between these cell types in the bone microenvironment. In accord with this idea, CGP76030 is able to reduce the incidence of osteolytic lesions and of visceral metastases, and to suppress morbidity and lethality in a bone metastasis mouse model without obvious adverse effects. The purine based c Src inhibitor AP23451 and the dual c Src/Abl inhibitors AP22408 and AP23236 proved efficacious in reducing bone metastases in preclinical studies. These results open a new avenue for the development of innovative therapies for the treatment of bone metastatic disease.
C1 [Rucci, Nadia; Teti, Anna] Univ Aquila, Dept Expt Med, I 67100 Laquila, Italy.
   [Susa, Maria] Novartis Inst BioMed Res, Basel, Switzerland.
C3 University of L'Aquila; Novartis
RP Teti, A (通讯作者)，Univ Aquila, Dept Expt Med, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
EM teti@univaq.it
OI Teti, Anna Maria/0000 0002 5887 4419; Rucci, Nadia/0000 0002 1371 8252
FU Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom
CR AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247
   Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221
   Alvarez RH, 2006, CANCER AM CANCER SOC, V107, P1918, DOI 10.1002/cncr.22215
   Angelucci A, 2006, EUR J CANCER, V42, P2838, DOI 10.1016/j.ejca.2006.06.024
   ARGUELLO F, 1988, CANCER RES, V48, P6876
   Avraham H, 1999, METHODS, V17, P250, DOI 10.1006/meth.1998.0735
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   Boyce BF, 2003, KIDNEY INT, V63, pS2, DOI 10.1046/j.1523 1755.63.s85.2.x
   Boyce BF, 2002, J BONE MINER RES, V17, pS159
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Boyce BF, 2006, CLIN CANCER RES, V12, p6291S, DOI 10.1158/1078 0432.CCR 06 0991
   Boyd DD, 2004, CLIN CANCER RES, V10, P1545, DOI 10.1158/1078 0432.CCR 1565 02
   Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102
   CHARHON SA, 1983, CANCER AM CANCER SOC, V51, P918, DOI 10.1002/1097 0142(19830301)51:5<918::AID CNCR2820510526>3.0.CO;2 J
   Chong YP, 2005, BBA PROTEINS PROTEOM, V1754, P210, DOI 10.1016/j.bbapap.2005.07.027
   CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863
   Coleman RE, 2001, SEMIN ONCOL, V28, P11, DOI 10.1053/sonc.2001.24155
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706
   Eastell R, 2005, J CLIN ONCOL, V23, p202S
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Fukami Y, 2002, PHARMACOL THERAPEUT, V93, P263, DOI 10.1016/S0163 7258(02)00195 X
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hannon RA, 2005, BONE, V36, pS135
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003
   Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912
   Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006 2952(00)00405 6
   La Rosée P, 2002, CANCER RES, V62, P7149
   Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   LIPTON A, 2006, CLIN CANCER RES, V12, pS635
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756 3282(99)00020 4
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68
   Myoui A, 2003, CANCER RES, V63, P5028
   Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144
   OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Planas Silva MD, 2006, BIOCHEM BIOPH RES CO, V341, P73, DOI 10.1016/j.bbrc.2005.12.164
   Puttini M, 2006, CANCER RES, V66, P11314, DOI 10.1158/0008 5472.CAN 06 1199
   Recchi I, 2003, EUR J CANCER, V39, P1927, DOI 10.1016/S0959 8049(03)00394 0
   Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004
   Salter MW, 1998, BIOCHEM PHARMACOL, V56, P789, DOI 10.1016/S0006 2952(98)00124 5
   Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092 8674(00)80664 9
   Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480
   Shakespeare WC, 2003, CURR OPIN DRUG DISC, V6, P729
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Summy JM, 2005, MOL CANCER THER, V4, P1900, DOI 10.1158/1535 7163.MCT 05 0171
   Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078 0432.CCR 05 2692
   Susa M, 2000, TRENDS PHARMACOL SCI, V21, P489, DOI 10.1016/S0165 6147(00)01567 4
   Susa M, 2005, CANC DRUG DISC DEV, P71
   TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200
   Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229
   Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0
   TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046
   Teti A, 1998, J BONE MINER RES, V13, P50, DOI 10.1359/jbmr.1998.13.1.50
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Tokarski JS, 2004, BLOOD, V104, p160A, DOI 10.1182/blood.V104.11.553.553
   Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   Wang YH, 2003, BIOORG MED CHEM LETT, V13, P3067, DOI 10.1016/S0960 894X(03)00648 6
   Whyte M.P., 2002, CONNECTIVE TISSUE IT, V2nd, P753
   Yezhelyev MV, 2004, CLIN CANCER RES, V10, P8028, DOI 10.1158/1078 0432.CCR 04 0621
   Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435
   YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521
NR 70
TC 62
Z9 72
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871 5206
EI 1875 5992
J9 ANTI CANCER AGENT ME
JI Anti Cancer Agents Med. Chem.
PD APR
PY 2008
VL 8
IS 3
BP 342
EP 349
DI 10.2174/187152008783961905
PG 8
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 300FS
UT WOS:000255810300009
PM 18393792
DA 2025 08 17
ER

PT J
AU Campbell, EJ
   Campbell, GM
   Hanley, DA
AF Campbell, Eric J.
   Campbell, Graeme M.
   Hanley, David A.
TI The effect of parathyroid hormone and teriparatide on fracture healing
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE fracture healing; nonunion; parathyroid hormone; teriparatide
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; FEMORAL FRACTURES;
   STRESS FRACTURES; DELAYED UNION; RISK FACTORS; PTH 1 34; NONUNION;
   OSTEOPOROSIS; RAT
AB Introduction: Daily subcutaneous injections of parathyroid hormone (PTH), and its synthetic peptide fragment, teriparatide (PTH 1 34, TPTD), have a net anabolic effect on bone and prevent osteoporotic fractures. TPTD is currently approved for this indication worldwide. Because of the anabolic effect, there is an interest in a role for TPTD (and, where available, human PTH 1 84) in improving bone healing after a fracture. PTH has been studied in animal fracture healing models and in a limited number of human trials. We have reviewed current literature regarding possible mechanisms and efficacy for PTH and TPTD to improve the healing process in the setting of various types of fractures.
   Areas covered: Our review focuses first on the role of PTH in normal bone. We then discuss mechanisms of normal bone healing as well as delayed and impaired fracture healing. We summarize pertinent animal data and then review human studies utilizing PTH or TPTD for fracture healing. In particular, we examine unique situations including osteoporotic fractures, diabetes, stress fractures, delayed or poor healing and combination with bisphosphonate therapy.
   Expert opinion: Available data indicate there is likely an important role for TPTD and PTH in promoting fracture healing in selected patients, but more clinical trial data are needed.
C1 [Campbell, Eric J.] Univ Calgary, Cumming Sch Med, Calgary, AB T2N 4N1, Canada.
   [Campbell, Graeme M.] Univ Hosp Schleswig Holstein, Dept Diagnost Radiol, Sect Biomed Imaging, D 24118 Kiel, Germany.
   [Hanley, David A.] Univ Calgary, Div Endocrinol & Metab, Calgary Richmond Rd Diagnost & Treatment Ctr, Dept Med,Cumming Sch Med, Calgary, AB T2T 5C7, Canada.
   [Hanley, David A.] Univ Calgary, Div Endocrinol & Metab, Calgary Richmond Rd Diagnost & Treatment Ctr, Dept Community Hlth Sci,Cumming Sch Med, Calgary, AB T2T 5C7, Canada.
   [Hanley, David A.] Univ Calgary, Div Endocrinol & Metab, Calgary Richmond Rd Diagnost & Treatment Ctr, Dept Oncol,Cumming Sch Med, Calgary, AB T2T 5C7, Canada.
C3 University of Calgary; University of Kiel; Schleswig Holstein University
   Hospital; University of Calgary; University of Calgary; University of
   Calgary
RP Hanley, DA (通讯作者)，Univ Calgary, Dept Med, Cumming Sch Med, Calgary, AB, Canada.
EM dahanley@ucalgary.ca
RI Campbell, Graeme/JPX 2238 2023
CR AHO ALLAN J., 1966, ACTA PATHOL MICROBIOL SCAND, V184, P1
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Aspenberg P, 2005, ACTA ORTHOP, V76, P741, DOI 10.1080/17453670510045318
   Aspenberg P, 2008, ACTA ORTHOP, V79, P111, DOI 10.1080/17453670710014851
   Aspenberg P, 2010, ACTA ORTHOP, V81, P236, DOI 10.3109/17453671003761946
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Barnes GL, 1999, J BONE MINER RES, V14, P1805, DOI 10.1359/jbmr.1999.14.11.1805
   Beam HA, 2002, J ORTHOPAED RES, V20, P1210, DOI 10.1016/S0736 0266(02)00066 9
   Borges JLC, 2013, ARQ BRAS ENDOCRINOL, V57, P153, DOI 10.1590/S0004 27302013000200010
   Breer S, 2012, INT ORTHOP, V36, P2581, DOI 10.1007/s00264 012 1708 1
   Burd TA, 2003, J BONE JOINT SURG BR, V85B, P700, DOI 10.1302/0301 620X.85B5.13970
   Chiang CY, 2013, BONE, V52, P360, DOI 10.1016/j.bone.2012.10.006
   Chintamaneni S, 2010, OSTEOPOROSIS INT, V21, P1059, DOI 10.1007/s00198 009 1061 4
   Chung UI, 1998, P NATL ACAD SCI USA, V95, P13030, DOI 10.1073/pnas.95.22.13030
   COZEN L, 1972, CLIN ORTHOP RELAT R, P134
   Dayer R, 2006, J BONE MINER RES, V21, P258, DOI 10.1359/JBMR.051009
   Dayer R, 2010, OSTEOPOROSIS INT, V21, P957, DOI 10.1007/s00198 009 1031 x
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Ellegaard M, 2013, J BONE MINER RES, V28, P2145, DOI 10.1002/jbmr.1957
   Fields KB, 2011, CURR SPORT MED REP, V10, P299, DOI 10.1249/JSR.0b013e31822d403f
   Fransen M, 2004, Cochrane Database Syst Rev, pCD001160, DOI 10.1002/14651858.CD001160.pub2
   Friedl G, 2007, J ORTHOP RES, V25, P1454, DOI 10.1002/jor.20433
   Funk JR, 2000, J ORTHOP RES, V18, P126, DOI 10.1002/jor.1100180118
   Gaston MS, 2007, J BONE JOINT SURG BR, V89B, P1553, DOI 10.1302/0301 620X.89B12
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Habermann B, 2010, CALCIFIED TISSUE INT, V86, P82, DOI 10.1007/s00223 009 9317 8
   Hamann C, 2014, ENDOCRINOLOGY, V155, P1197, DOI 10.1210/en.2013 1960
   Hankenson KD, 2014, INJURY, V45, pS8, DOI 10.1016/j.injury.2014.04.003
   Hanley DA, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1661
   Hansen S, 2013, J BONE MINER RES, V28, P736, DOI 10.1002/jbmr.1784
   Hayda RA, 1998, CLIN ORTHOP RELAT R, pS31
   HERBSMAN H, 1968, J SURG RES, V8, P424, DOI 10.1016/0022 4804(68)90058 9
   Hernandez RK, 2012, ACTA ORTHOP, V83, P653, DOI 10.3109/17453674.2012.747054
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   Holzer G, 1999, CLIN ORTHOP RELAT R, P258, DOI 10.1097/00003086 199909000 00033
   Huang HT, 2012, MENOPAUSE, V19, P1360, DOI 10.1097/gme.0b013e318260143d
   Isaacs JD, 2010, CLIN ORTHOP RELAT R, V468, P3384, DOI 10.1007/s11999 010 1535 x
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kim H W, 1999, Iowa Orthop J, V19, P71
   Kobayashi T, 2005, J CLIN INVEST, V115, P1734, DOI 10.1172/JCI24397
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Komrakova M, 2010, BONE, V47, P480, DOI 10.1016/j.bone.2010.05.013
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Lee YK, 2012, OSTEOPOROSIS INT, V23, P2897, DOI 10.1007/s00198 012 2172 x
   LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502
   Lewiecki EM, 2013, J CLIN DENSITOM, V16, P28, DOI 10.1016/j.jocd.2012.11.013
   Li YF, 2012, OSTEOPOROSIS INT, V23, P1463, DOI 10.1007/s00198 011 1751 6
   Lin EA, 2012, J ORTHOP TRAUMA, V26, P719, DOI 10.1097/BOT.0b013e31826f5b9e
   LODER RT, 1988, CLIN ORTHOP RELAT R, P210
   MACEY LR, 1989, J BONE JOINT SURG AM, V71A, P722, DOI 10.2106/00004623 198971050 00014
   Malhotra R, 2013, CLIN CASES MINER BON, V10, P210, DOI 10.11138/ccmbm/2013.10.3.210
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   Marx RG, 2001, CLIN J SPORT MED, V11, P73, DOI 10.1097/00042752 200104000 00002
   Mattila VM, 2007, MED SCI SPORT EXER, V39, P1061, DOI 10.1249/01.mss.0b013e318053721d
   MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150, DOI 10.1302/0301 620X.60B2.350882
   MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V118, P824, DOI 10.1210/endo 118 2 824
   Meyer RA, 2001, J ORTHOP RES, V19, P428, DOI 10.1016/S0736 0266(00)90034 2
   Mognetti B, 2011, CALCIFIED TISSUE INT, V89, P163, DOI 10.1007/s00223 011 9503 3
   Murnaghan M, 2006, J BONE JOINT SURG AM, V88A, P140, DOI 10.2106/JBJS.F.00454
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Orwoll ES, 2014, J CLIN INVEST, V124, P491, DOI 10.1172/JCI71101
   Oteo Alvaro A., 2010, Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.], V19, pe22, DOI [DOI 10.1016/J.JSE.2010.05.005, 10.1016/j.jse.2010.05.005]
   Oteo Alvaro A, 2011, ORTHOPEDICS, V34, pE574, DOI 10.3928/01477447 20110714 50
   PARFITT AM, 1976, METABOLISM, V25, P1033, DOI 10.1016/0026 0495(76)90133 5
   Pegrum J, 2012, PHYSICIAN SPORTSMED, V40, P32, DOI 10.3810/psm.2012.09.1978
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Pepper M, 2006, CLIN SPORT MED, V25, P1, DOI 10.1016/j.csm.2005.08.010
   Quattrocchi E, 2004, CLIN THER, V26, P841, DOI 10.1016/S0149 2918(04)90128 2
   Raghavan P, 2012, CLIN MED INSIGHTS EN, V5, P39, DOI 10.4137/CMED.S9663
   REEVE J, 1980, BMJ BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340
   Royer M, 2012, JOINT BONE SPINE, V79, pS86, DOI 10.1016/S1297 319X(12)70013 1
   Rubery PT, 2010, J SPINAL DISORD TECH, V23, P151, DOI 10.1097/BSD.0b013e31819a8b7a
   Rubin MR, 2003, ENDOCRIN METAB CLIN, V32, P285, DOI 10.1016/S0889 8529(02)00056 7
   Schürch MA, 1998, ANN INTERN MED, V128, P801, DOI 10.7326/0003 4819 128 10 199805150 00002
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shibuya N, 2013, J FOOT ANKLE SURG, V52, P207, DOI 10.1053/j.jfas.2012.11.012
   SIMMONS DJ, 1985, CLIN ORTHOP RELAT R, P100
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simpson C.M., 2012, EXPERT OPIN DRUG SAF, V11, P215, DOI DOI 10.1517/14740338.2012.639359
   Sloan AV, 2010, BONE, V47, P235, DOI 10.1016/j.bone.2010.05.015
   Snyder RA, 2006, CLIN SPORT MED, V25, P37, DOI 10.1016/j.csm.2005.08.005
   Tachiiri H, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0179 y
   Tägil M, 2010, BONE, V46, P852, DOI 10.1016/j.bone.2009.11.009
   Tamai K, 2013, OSTEOPOROSIS INT, V24, P2729, DOI 10.1007/s00198 013 2367 9
   Tsiridis E, 2007, J ORTHOP RES, V25, P1193, DOI 10.1002/jor.20420
   Warden Stuart J, 2006, Curr Osteoporos Rep, V4, P103
   Whyte MP, 2007, J CLIN ENDOCR METAB, V92, P1203, DOI 10.1210/jc.2006 1902
   Zhang DF, 2014, J ORTHOP TRAUMA, V28, P57, DOI 10.1097/BOT.0b013e31828e13fe
NR 96
TC 33
Z9 44
U1 0
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JAN
PY 2015
VL 15
IS 1
BP 119
EP 129
DI 10.1517/14712598.2015.977249
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AW1XC
UT WOS:000346080900011
PM 25363308
DA 2025 08 17
ER

PT J
AU Lee, CP
   Huang, YN
   Nithiyanantham, S
   Huang, CM
   Ko, YC
AF Lee, Chi Pin
   Huang, Yu Nan
   Nithiyanantham, Srinivasan
   Huang, Chung Ming
   Ko, Ying Chin
TI LncRNA Jak3:Jak3 coexpressed pattern regulates monosodium urate
   crystal induced osteoclast differentiation through Nfatc1/Ctsk
   expression
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE bone erosion; gouty arthritis; LncRNA Jak3; MSU; osteoclast
   differentiation
ID LONG NONCODING RNA; BONE EROSION; ACTIVATION; ARTHRITIS; KINASE; GOUT;
   JAK; PATHOGENESIS; INFLAMMATION; MECHANISMS
AB LncRNA transcripts have been emerged as gene regulators through transcriptional and posttranscriptional regulation. Monosodium urate monohydrate (MSU) elicits inflammatory response and a critical regulator of bone erosion in gout. The aim of this study is to clarify the pro osteogenic role of LncRNA in MSU induced osteoclast differentiation. We performed microarray analysis to identify stage specific expressions of LncRNA and mRNA during osteoclast differentiation in RAW264.7 cells. Among the 314 pairs of LncRNA mRNA coexpressed patterns in the osteoclast lineage, 22 pairs revealed to have inflammatory function. Importantly, LncRNA Jak3 and Jak3 co expression patterns were significantly upregulated in the osteoclasts. In specific, Jak3 contributes to MSU induced osteoclasts differentiation by positively regulating expression of the osteoclast factor, nuclear factor of activated T cells 1 (Nfatc1). Mechanistically, LncRNA Jak3 mediated Nfatc1 activation upregulated cathepsin K (Ctsk) expressions. LncRNA Jak3 knockdown abolished formation of MSU induced mature osteoclasts. In addition, we found that gout patients showed increased levels of LncRNA Jak3 in the mononuclear cells. Our data demonstrate that the critical functional role of LncRNA Jak3 in osteoclast differentiation via Jak3/Nfatc1/Ctsk axis. Finally, characterization of these regulatory networks is likely to reveal novel drug targets and opportunities for therapeutic intervention in bone erosion.
C1 [Lee, Chi Pin; Nithiyanantham, Srinivasan; Ko, Ying Chin] China Med Univ, China Med Univ Hosp, Environm Omics Dis Res Ctr, 2 Yude Rd, Taichung 40447, Taiwan.
   [Huang, Yu Nan] Natl Chung Hsing Univ, Dept Life Sci, Taichung, Taiwan.
   [Huang, Chung Ming] China Med Univ Hosp, Div Rheumatol & Immunol, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital  
   Taiwan; National Chung Hsing University; China Medical University
   Taiwan; China Medical University Hospital   Taiwan
RP Ko, YC (通讯作者)，China Med Univ, China Med Univ Hosp, Environm Omics Dis Res Ctr, 2 Yude Rd, Taichung 40447, Taiwan.
EM ycko0406@gmail.com
RI Chung, Chi Jung/G 4755 2013; Huang, YuNan/KFR 6316 2024
FU Ministry of Science and Technology [MOST106 2314 B 039 017 MY3]; China
   Medical University Hospital [DMR 107 108]
FX Ministry of Science and Technology, Grant/Award Number:
   MOST106 2314 B 039 017 MY3; China Medical University Hospital,
   Grant/Award Number: DMR 107 108
CR Boyle DL, 2015, ANN RHEUM DIS, V74, P1311, DOI 10.1136/annrheumdis 2014 206028
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Castellanos Rubio A, 2016, SCIENCE, V352, P91, DOI 10.1126/science.aad0467
   Choe JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/597512
   Dalbeth N, 2007, RHEUMATOLOGY, V46, P1804, DOI 10.1093/rheumatology/kem246
   Dalbeth N, 2009, ANN RHEUM DIS, V68, P1290, DOI 10.1136/ard.2008.094201
   Dalbeth N, 2008, ARTHRITIS RHEUM US, V58, P1854, DOI 10.1002/art.23488
   Dou C, 2016, SCI REP UK, V6, DOI 10.1038/srep21499
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Gao W, 2016, ANN RHEUM DIS, V75, P311, DOI 10.1136/annrheumdis 2014 207201
   Gong CG, 2015, DEV CELL, V34, P181, DOI 10.1016/j.devcel.2015.05.009
   Jiang W, 2015, CELL REP, V11, P137, DOI 10.1016/j.celrep.2015.03.008
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kitaura H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/181849
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Kuuliala K, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1278 0
   Lee CP, 2016, SCI REP UK, V6, DOI 10.1038/srep25740
   Lopez Pajares V, 2015, DEV CELL, V32, P693, DOI 10.1016/j.devcel.2015.01.028
   Macian F, 2013, NAT IMMUNOL, V14, P116, DOI 10.1038/ni.2522
   Maeshima K, 2012, ARTHRITIS RHEUM US, V64, P1790, DOI 10.1002/art.34329
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Tran NT, 2016, EMBO REP, V17, P887, DOI 10.15252/embr.201541970
   O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Sato K, 2006, CURR OPIN RHEUMATOL, V4, P9
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schlesinger N, 2010, ANN RHEUM DIS, V69, P1907, DOI 10.1136/ard.2010.128454
   Spurlock CF III, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7932
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Vance KW, 2014, TRENDS GENET, V30, P348, DOI 10.1016/j.tig.2014.06.001
   Vijayakrishnan L, 2011, TRENDS PHARMACOL SCI, V32, P25, DOI 10.1016/j.tips.2010.10.004
   Wang SJ, 2011, J MOL MED, V89, P1241, DOI 10.1007/s00109 011 0796 5
   Yarilina A, 2012, ARTHRITIS RHEUM US, V64, P3856, DOI 10.1002/art.37691
   Zamudio Cuevas Y, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1012 3
   Zhang WY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0485 6
NR 37
TC 28
Z9 37
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1520 4081
EI 1522 7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD FEB
PY 2019
VL 34
IS 2
BP 179
EP 187
DI 10.1002/tox.22672
PG 9
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA HH5OD
UT WOS:000455775800009
PM 30387921
DA 2025 08 17
ER

PT J
AU Nanbara, H
   Wara aswapati, N
   Nagasawa, T
   Yoshida, Y
   Yashiro, R
   Bando, Y
   Kobayashi, H
   Khongcharoensuk, J
   Hormdee, D
   Pitiphat, W
   Boch, JA
   Izumi, Y
AF Nanbara, Hiromi
   Wara aswapati, Nawarat
   Nagasawa, Toshiyuki
   Yoshida, Yasuhiro
   Yashiro, Reiko
   Bando, Yukiko
   Kobayashi, Hiroaki
   Khongcharoensuk, Janjura
   Hormdee, Doosadee
   Pitiphat, Waranuch
   Boch, Jason A.
   Izumi, Yuichi
TI Modulation of Wnt5a Expression by Periodontopathic Bacteria
SO PLOS ONE
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; PORPHYROMONAS GINGIVALIS; OSTEOPROTEGERIN
   LIGAND; GENE EXPRESSION; RHEUMATOID ARTHRITIS; STEM CELLS;
   PERIODONTITIS; ACTIVATION; WINGLESS; PROLIFERATION
AB Wingless proteins, termed Wnt, are involved in embryonic development, blood cell differentiation, and tumorigenesis. In mammalian hematopoiesis, Wnt signaling is essential for stem cell homeostasis and lymphocyte differentiation. Recent studies have suggested that these molecules are associated with cardiovascular diseases, rheumatoid arthritis, and osteoarthritis. Furthermore, Wnt5a signaling is essential for the general inflammatory response of human macrophages. Periodontitis is a chronic inflammatory disease caused by gram negative periodontopathic bacteria and the resultant host immune response. Periodontitis is characterized by loss of tooth supporting structures and alveolar bone resorption. There have been no previous reports on Wnt5a expression in periodontitis tissue, and only few study reported the molecular mechanisms of Wnt5a expression in LPS stimulated monocytic cells. Using RT PCR, we demonstrated that Wnt5a mRNA expression was up regulated in chronic periodontitis tissue as compared to healthy control tissue. P. gingivalis LPS induced Wnt5a mRNA in the human monocytic cell line THP 1 with a peak at 4 hrs after stimulation. P. gingivalis LPS induced higher up regulation of Wnt5a mRNA than E. coli LPS. The LPS receptors TLR2 and TLR4 were equally expressed on the surface of THP 1 cells. P. gingivalis LPS induced l kappa B alpha degradation and was able to increase the NF kappa B binding activity to DNA. P. gingivalis LPS induced Wnt5a expression was inhibited by NF kappa B inhibitors, suggesting NF kappa B involvement. Furthermore, IFN gamma synergistically enhanced the P. gingivalis LPS induced production of Wnt5a. Pharmacological investigation and siRNA experiments showed that STAT1 was important for P. gingivalis LPS induced Wnt5a expression. These results suggest that the modulation of Wnt5a expression by P. gingivalis may play an important role in the periodontal inflammatory process and serve a target for the development of new therapies.
C1 [Nanbara, Hiromi; Nagasawa, Toshiyuki; Yashiro, Reiko; Bando, Yukiko; Kobayashi, Hiroaki; Izumi, Yuichi] Tokyo Med & Dent Univ, Dept Periodontol, Tokyo, Japan.
   [Nanbara, Hiromi; Izumi, Yuichi] Tokyo Med & Dent Univ, Global Ctr Excellence Program, Int Res Ctr Mol Sci Tooth & Bone Dis, Tokyo, Japan.
   [Wara aswapati, Nawarat; Khongcharoensuk, Janjura; Hormdee, Doosadee] Khon Kaen Univ, Fac Dent, Dept Periodontol, Khon Kaen, Thailand.
   [Yoshida, Yasuhiro] Univ Occupat & Environm Hlth, Sch Med, Dept Immunol, Fukuoka, Japan.
   [Pitiphat, Waranuch] Khon Kaen Univ, Fac Dent, Dept Community Dent, Khon Kaen, Thailand.
   [Boch, Jason A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Khon Kaen University; University of Occupational & Environmental Health
     Japan; Khon Kaen University; Harvard University; Harvard School of
   Dental Medicine
RP Nanbara, H (通讯作者)，Tokyo Med & Dent Univ, Dept Periodontol, Tokyo, Japan.
EM freude@med.uoeh u.ac.jp
RI Kobayashi, Hiroaki/AAG 6812 2019; Hormdee, Doosadee/JWA 3497 2024
OI Pitiphat, Waranuch/0000 0001 6628 0306; /0000 0003 1658 3119
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [21390553]; National Research Council of Thailand (NRCT); Japan Society
   for the Promotion of Science (JSPS); Khon Kaen University; Grants in Aid
   for Scientific Research [24890066, 21390553] Funding Source: KAKEN
FX This study was supported by Grant in Aid for Scientific Research
   21390553, grant from Global Center of Excellence (GCOE) Program,
   International Research Center for Molecular Science in Tooth and Bone
   Diseases Program, from the Ministry of Education, Culture, Sports,
   Science, and Technology of Japan; the National Research Council of
   Thailand (NRCT); Japan Society for the Promotion of Science (JSPS)
   grant, JSPS Invitation Fellowship for Research in Japan (NW), and Khon
   Kaen University grant. http://www.mext.go.jp/. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Armitage G C, 1999, Ann Periodontol, V4, P1, DOI 10.1902/annals.1999.4.1.1
   Bansal K, 2011, J BIOL CHEM, V286, P37032, DOI 10.1074/jbc.M111.260414
   Bickel M, 2001, J CLIN PERIODONTOL, V28, P840, DOI 10.1034/j.1600 051x.2001.028009840.x
   Blumenthal A, 2006, BLOOD, V108, P965, DOI 10.1182/blood 2005 12 5046
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Cheng CW, 2008, BIOCHEM BIOPH RES CO, V365, P285, DOI 10.1016/j.bbrc.2007.10.166
   Christman MA, 2008, AM J PHYSIOL HEART C, V294, pH2864, DOI 10.1152/ajpheart.00982.2007
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Darveau RP, 2002, INFECT IMMUN, V70, P1867, DOI 10.1128/IAI.70.4.1867 1873.2002
   Dissanayake SK, 2008, CANCER RES, V68, P10205, DOI 10.1158/0008 5472.CAN 08 2149
   Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445
   Fujio Y, 2004, FEBS LETT, V573, P202, DOI 10.1016/j.febslet.2004.07.082
   GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Holt SC, 2005, PERIODONTOL 2000, V38, P72, DOI 10.1111/j.1600 0757.2005.00113.x
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014 5793(94)01130 3
   Kanaya S, 2004, EUR J IMMUNOL, V34, P1451, DOI 10.1002/eji.200324549
   Katoh M, 2007, INT J MOL MED, V19, P273
   KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Loesche WJ, 2001, CLIN MICROBIOL REV, V14, P727, DOI 10.1128/CMR.14.4.727 752.2001
   LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730
   Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06 04 0320
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Ohmori Y, 2001, J LEUKOCYTE BIOL, V69, P598
   Pereira C, 2008, ARTERIOSCL THROM VAS, V28, P504, DOI 10.1161/ATVBAHA.107.157438
   Plosker GL, 2003, DRUGS, V63, P2317, DOI 10.2165/00003495 200363210 00004
   Pulendran B, 2001, J IMMUNOL, V167, P5067, DOI 10.4049/jimmunol.167.9.5067
   Rasmussen L, 2000, J CLIN PERIODONTOL, V27, P41, DOI 10.1034/j.1600 051x.2000.027001041.x
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074 7613(00)00004 2
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012 1606(76)90108 1
   Staal FJT, 2003, CURR OPIN IMMUNOL, V15, P204, DOI 10.1016/S0952 7915(03)00003 7
   Wang D, 2005, ORAL MICROBIOL IMMUN, V20, P172, DOI 10.1111/j.1399 302X.2005.00208.x
   Yang DH, 2009, CIRC RES, V104, P372, DOI 10.1161/CIRCRESAHA.108.185405
   Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200
NR 41
TC 52
Z9 57
U1 0
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2012
VL 7
IS 4
AR e34434
DI 10.1371/journal.pone.0034434
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 952GU
UT WOS:000304780500045
PM 22485170
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Lee, EJ
   Kim, JL
   Gong, JH
   Park, SH
   Kang, YH
AF Lee, Eun Jung
   Kim, Jung Lye
   Gong, Ju Hyun
   Park, Sin Hye
   Kang, Young Hee
TI Inhibition of Osteoclast Activation by Phloretin through Disturbing αvβ3
   Integrin c Src Pathway
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID FACTOR KAPPA B; ACTIN CYTOSKELETON; RECEPTOR ACTIVATOR; BONE;
   OSTEOPOROSIS; DIFFERENTIATION; ADHESION; THERAPY; PYK2
AB This study was to explore the sequential signaling of disorganization of the actin cytoskeletal architecture by phloretin. RAW 264.7 macrophages were incubated with 1 20 mu M phloretin for 5 days in the presence of RANKL. C57BL/6 mice were ovariectomized (OVX) and orally treated with 10mg/kg phloretin once a day for 8 weeks. Phloretin allayed RANKL stimulated formation of actin podosomes with the concomitant retardation of the vinculin activation. Oral administration of phloretin suppressed the induction of femoral gelsolin and vinculin in OVX mice. The RANK RANKL interaction resulted in the alpha v beta 3 integrin induction, which was demoted by phloretin. The RANKL induction of actin rings and vacuolar type H+ ATPase entailed Pyk2 phosphorylation and c Src and c Cbl induction, all of which were blunted by phloretin. Similar inhibition was also observed in phloretin exposed OVX mouse femoral bone tissues with decreased trabecular collagen formation. Phloretin suppressed the paxillin induction in RANKL activated osteoclasts and in OVX epiphyseal bone tissues. Also, phloretin attenuated the Syk phosphorylation and phospholipase C gamma induction by RANKL in osteoclasts. These results suggest that phloretin was an inhibitor of actin podosomes and sealing zone, disrupting alpha v beta 3 integrin c Src Pyk2/Syk signaling pathway for the regulation of actin cytoskeletal organization in osteoclasts.
C1 [Lee, Eun Jung; Kim, Jung Lye; Gong, Ju Hyun; Park, Sin Hye; Kang, Young Hee] Hallym Univ, Dept Food Sci & Nutr, Chunchon 200702, South Korea.
C3 Hallym University
RP Kang, YH (通讯作者)，Hallym Univ, Dept Food Sci & Nutr, Chunchon 200702, South Korea.
EM yhkang@hallym.ac.kr
RI Lee, Eun Hye/KDN 5679 2024; Park, Sin Hye/HNI 5057 2023
OI PARK, SIN HYE/0000 0003 1656 185X; 
FU National Research Foundation of Korea [2012R1A2A2A01012946]; Ministry of
   Education, Science and Technology and National Research Foundation of
   Korea through the Human Resource Training Project for Regional
   Innovation, Korea [2012H1B8A2026122]
FX This work was supported by grant from the National Research Foundation
   of Korea (2012R1A2A2A01012946) and by the Ministry of Education, Science
   and Technology and National Research Foundation of Korea through the
   Human Resource Training Project for Regional Innovation, Korea
   (2012H1B8A2026122).
CR Åkesson K, 2003, B WORLD HEALTH ORGAN, V81, P657
   Al Anazi Abdullah Foraih, 2011, J Nat Sci Biol Med, V2, P154, DOI 10.4103/0976 9668.92322
   Banu J, 2012, NUTR REV, V70, P22, DOI 10.1111/j.1753 4887.2011.00451.x
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Beard MK, 2012, CURR MED RES OPIN, V28, P141, DOI 10.1185/03007995.2011.643296
   Beaulieu V, 2005, J BIOL CHEM, V280, P8452, DOI 10.1074/jbc.M412750200
   Bedell S, 2014, J STEROID BIOCHEM, V139, P225, DOI 10.1016/j.jsbmb.2012.12.004
   Chen JD, 2011, GI MOTILITY TESTING: A LABORATORY AND OFFICE HANDBOOK, P81
   Coury F, 2013, P NATL ACAD SCI USA, V110, P2163, DOI 10.1073/pnas.1206392110
   Dawson Hughes B, 2007, J BONE MINER RES, V22, pV59, DOI 10.1359/JBMR.07S209
   Faienza MF, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/575936
   Fukunaga T, 2014, J BIOL CHEM, V289, P13554, DOI 10.1074/jbc.M114.550731
   Hagiwara K, 2011, EUR J PHARMACOL, V662, P78, DOI 10.1016/j.ejphar.2011.04.023
   Hara K, 2007, J BONE MINER METAB, V25, P345, DOI 10.1007/s00774 007 0781 9
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Izawa T, 2012, MOL CELL BIOL, V32, P2943, DOI 10.1128/MCB.00077 12
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kamon M, 2010, CELL BIOL INT, V34, P109, DOI 10.1042/CBI20090011
   Kim JL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/919374
   Kim JL, 2012, MOL NUTR FOOD RES, V56, P1223, DOI 10.1002/mnfr.201100831
   Knowles HJ, 2008, J PATHOL, V215, P56, DOI 10.1002/path.2319
   Lane NE, 2005, J BONE MINER RES, V20, P58, DOI 10.1359/JBMR.041017
   Lee EJ, 2014, PHYTOMEDICINE, V21, P1208, DOI 10.1016/j.phymed.2014.04.002
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   Qin A, 2012, INT J BIOCHEM CELL B, V44, P1422, DOI 10.1016/j.biocel.2012.05.014
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Sheng MHC, 2009, CELL MOL LIFE SCI, V66, P1946, DOI 10.1007/s00018 009 8811 5
   Stein EM, 2014, J BONE MINER RES, V29, P1101, DOI 10.1002/jbmr.2144
   Szewczyk KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060285
   Takahashi N, 2007, ODONTOLOGY, V95, P1, DOI 10.1007/s10266 007 0071 y
   Taku K, 2012, MENOPAUSE, V19, P776, DOI 10.1097/gme.0b013e3182410159
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Touaitahuata Heiani, 2014, Small GTPases, V5, pe28119, DOI 10.4161/sgtp.28119
   Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659
   Turner JV, 2007, J PHARM SCI US, V96, P1879, DOI 10.1002/jps.20987
   Xiong WC, 2003, FRONT BIOSCI LANDMRK, V8, pD1219, DOI 10.2741/1117
   Zou W, 2013, J CELL BIOCHEM, V114, P1871, DOI 10.1002/jcb.24531
NR 40
TC 20
Z9 22
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 680145
DI 10.1155/2015/680145
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CD8XN
UT WOS:000351380000001
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Lien, YT
   Madrasi, K
   Samant, S
   Kim, MJ
   Li, F
   Li, L
   Wang, YN
   Schmidt, S
AF Lien, Yi Ting (Kayla)
   Madrasi, Kumpal
   Samant, Snehal
   Kim, Myong Jin
   Li, Fang
   Li, Li
   Wang, Yaning
   Schmidt, Stephan
TI Establishment of a Disease Drug Trial Model for Postmenopausal
   Osteoporosis: A Zoledronic Acid Case Study
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE biomarkers; bisphosphonates; bone turnover marker; disease&#8208; drug
   trial model; fracture; postmenopausal osteoporosis
ID BONE MINERAL DENSITY; FRACTURE RISK; SYSTEMS ANALYSIS; PREVENTION;
   TURNOVER; PLACEBO; MARKERS; WOMEN
AB Costly and lengthy clinical trials hinder the development of safe and effective treatments for postmenopausal osteoporosis. To reduce the expense associated with these trials, we established a mechanistic disease drug trial model for postmenopausal osteoporosis that can predict phase 3 trial outcome based on short term bone turnover marker data. To this end, we applied a previously developed model for tibolone to bisphosphonates using zoledronic acid as paradigm compound by (1) linking the mechanistic bone cell interaction model to bone turnover markers as well as bone mineral density in lumbar spine and total hip, (2) employing a mechanistic disease progression function, and (3) accounting for zoledronic acid's mechanism of action. Once developed, we fitted the model to clinical trial data of 581 postmenopausal women receiving (1) 5 mg zoledronic acid in year 1 and saline in year 2, (2) 5 mg zoledronic acid in year 1 and year 2, or (3) placebo (saline), calcium (500 mg), and vitamin D (400 IU). All biomarker data was fitted reasonably well, with no apparent bias or model misspecification. Age, years since menopause, and body mass index at baseline were identified as significant covariates. In the future, the model can be modified to explore the link between short term biomarkers and fracture risk.
C1 [Lien, Yi Ting (Kayla); Madrasi, Kumpal; Samant, Snehal; Schmidt, Stephan] Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol, Dept Pharmaceut, 6550 Sanger Rd, Orlando, FL USA.
   [Lien, Yi Ting (Kayla); Madrasi, Kumpal; Samant, Snehal; Kim, Myong Jin; Li, Fang; Li, Li; Wang, Yaning] US FDA, Ctr Drug Evaluat & Res CDER, Off Translat Sci OTS, Off Clin Pharmacol, Silver Spring, MD USA.
C3 State University System of Florida; University of Florida; US Food &
   Drug Administration (FDA)
RP Schmidt, S (通讯作者)，Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol, Dept Pharmaceut, 6550 Sanger Rd, Orlando, FL USA.
EM sschmidt@cop.ufl.edu
RI wang, yuqi/J 1632 2017
FU US Food and Drug Administration (FDA) Office of Women's Health; US
   Department of Energy; FDA/Center
FX This work was supported by the US Food and Drug Administration (FDA)
   Office of Women's Health. This project was supported in part by an
   appointment to the ORISE Research Participation Program at the
   CDER/OTS/OCP/DCP3 and CDER/OGD/ORS, FDA, administered by the Oak Ridge
   Institute for Science and Education through an interagency agreement
   between the US Department of Energy and FDA/Center.
CR Administration USFaD, GUID PRECL CLIN EV A
   Aspray TJ, 2013, AGE AGEING, V42, P548, DOI 10.1093/ageing/aft095
   Berkhout J, 2016, CPT PHARMACOMET SYST, V5, P656, DOI 10.1002/psp4.12135
   Berkhout J, 2015, CPT PHARMACOMET SYST, V4, P516, DOI 10.1002/psp4.12006
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Cefalu CA, 2004, CURR MED RES OPIN, V20, P341, DOI 10.1185/030079903125003062
   Colman EG, 2003, J BONE MINER RES, V18, P1125, DOI 10.1359/jbmr.2003.18.6.1125
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Foundation NO, 2017, WHAT IS OST WHAT CAU
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Holford N, 2006, POP APPR GROUP EUR 2
   Lambrinoudaki I, 2008, CLIN INTERV AGING, V3, P445, DOI 10.2147/CIA.S2046
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lesko LJ, 2013, CLIN PHARMACOL THER, V93, P413, DOI 10.1038/clpt.2013.29
   Madrasi K, 2018, J CLIN PHARMACOL, V58, P572, DOI 10.1002/jcph.1071
   McClung M, 2009, OBSTET GYNECOL, V114, P999, DOI 10.1097/AOG.0b013e3181bdce0a
   NONMEM, 2009, NONMEM US GUID 1989
   Orozco P, 1997, EUR J EPIDEMIOL, V13, P919, DOI 10.1023/A:1007309722100
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Pillai G, 2004, BRIT J CLIN PHARMACO, V58, P618, DOI 10.1111/j.1365 2125.2004.02224.x
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Plan EL, 2012, POP APPR GROUP EUR 2
   Post TM, 2013, J PHARMACOKINET PHAR, V40, P143, DOI 10.1007/s10928 012 9294 9
   Post TM, 2010, CLIN PHARMACOKINET, V49, P89, DOI 10.2165/11318150 000000000 00000
   Post TM, 2005, PHARM RES DORDR, V22, P1038, DOI 10.1007/s11095 005 5641 5
   Riggs M M, 2010, NAT I GEN MED SCI QU
   Sardiwal S, 2012, KIDNEY INT, V82, P100, DOI 10.1038/ki.2012.77
   Schmidt S, 2011, J PHARMACOKINET PHAR, V38, P873, DOI 10.1007/s10928 011 9224 2
   Sowers MR, 2008, J CLIN ENDOCR METAB, V93, P3847, DOI 10.1210/jc.2008 1056
   Unnanuntana A, 2010, J BONE JOINT SURG AM, V92A, P743, DOI 10.2106/JBJS.I.00919
   Vestergaard P, 2008, OSTEOPOROSIS INT, V19, P257, DOI 10.1007/s00198 007 0437 6
NR 32
TC 6
Z9 6
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0091 2700
EI 1552 4604
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD DEC
PY 2020
VL 60
SU 2
SI SI
BP S86
EP S102
DI 10.1002/jcph.1748
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PA9CY
UT WOS:000595926500010
PM 33274518
DA 2025 08 17
ER

PT J
AU Castillo, AB
   Leucht, P
AF Castillo, Alesha B.
   Leucht, Philipp
TI Bone Homeostasis and Repair: Forced Into Shape
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Bone remodeling; Mechanical adaptation; Mechanobiology; Osteocyte;
   Osteoblast; Stem cell
ID MESENCHYMAL STEM CELLS; MECHANICAL LOADING THRESHOLDS; PROVIDES LIFELONG
   BENEFITS; IN VIVO; WEIGHT BEARING; LONG BONES; FLUID FLOW; TISSUE
   DIFFERENTIATION; OSTEOCYTE APOPTOSIS; TIBIAL COMPRESSION
AB Mechanical loading is a potent anabolic regulator of bone mass, and the first line of defense for bone loss is weight bearing exercise. Likewise, protected weight bearing is the first prescribed physical therapy following orthopedic reconstructive surgery. In both cases, enhancement of new bone formation is the goal. Our understanding of the physical cues, mechanisms of force sensation, and the subsequent cellular response will help identify novel physical and therapeutic treatments for age  and disuse related bone loss, delayed  and nonunion fractures, and significant bony defects. This review highlights important new insights into the principles and mechanisms governing mechanical adaptation of the skeleton during homeostasis and repair and ends with a summary of clinical implications stemming from our current understanding of how bone adapts to biophysical force.
C1 [Castillo, Alesha B.] NYU, Polytech Sch Engn, Dept Mech & Aerosp Engn, New York, NY USA.
   [Castillo, Alesha B.; Leucht, Philipp] NYU, Sch Med, Dept Orthopaed Surg, New York, NY USA.
   [Castillo, Alesha B.] Vet Affairs New York Harbor Healthcare Syst, New York, NY USA.
   [Leucht, Philipp] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.
C3 New York University; New York University; New York University
RP Castillo, AB (通讯作者)，NYU, Polytech Sch Engn, Dept Mech & Aerosp Engn, New York, NY USA.
EM alesha.castillo@nyu.edu
RI Leucht, Philipp/H 7238 2019; Castillo, Alesha/AAC 9961 2019; Castillo,
   Alesha/A 8728 2014
OI Leucht, Philipp/0000 0002 8409 8513; Castillo,
   Alesha/0000 0002 1371 7567
FU RRD VA [I01 RX001500] Funding Source: Medline
CR Ajubi NE, 1999, AM J PHYSIOL ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171
   Alimperti S, 2014, J CELL SCI, V127, P2627, DOI 10.1242/jcs.134833
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013
   Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027
   Baker A H, 1934, Ulster Med J, V3, P277
   Birkhold AI, 2015, BONE, V75, P210, DOI 10.1016/j.bone.2015.02.027
   Birkhold AI, 2014, BIOMATERIALS, V35, P9290, DOI 10.1016/j.biomaterials.2014.07.051
   Birkhold AI, 2014, BONE, V66, P15, DOI 10.1016/j.bone.2014.05.013
   Birmingham E, 2015, ANN BIOMED ENG, V43, P1036, DOI 10.1007/s10439 014 1135 0
   Boerckel JD, 2012, J ORTHOP RES, V30, P1067, DOI 10.1002/jor.22042
   Boerckel JD, 2011, P NATL ACAD SCI USA, V108, pE674, DOI 10.1073/pnas.1107019108
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Carter DR, 1998, CLIN ORTHOP RELAT R, pS41
   Castillo A, 2012, J BONE MINER RES, V27
   Castillo Alesha B, 2010, Curr Osteoporos Rep, V8, P98, DOI 10.1007/s11914 010 0015 2
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Claes LE, 1998, CLIN ORTHOP RELAT R, pS132
   COWIN SC, 1995, J BIOMECH, V28, P1281, DOI 10.1016/0021 9290(95)00058 P
   Currey J.D., 2013, BONES
   De Souza RL, 2005, BONE, V37, P810, DOI 10.1016/j.bone.2005.07.022
   Dickerson DA, 2008, BIOMECH MODEL MECHAN, V7, P191, DOI 10.1007/s10237 007 0085 y
   Dolan EB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119652
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Firoozabadi R, 2015, ADV ORTHOP, V2015, DOI 10.1155/2015/491976
   Frey SP, 2013, SCI WORLD J, DOI 10.1155/2013/341078
   Frost HM, 2004, ANGLE ORTHOD, V74, P3
   FROST HM, 1992, J BONE MINER RES, V7, P253
   Gardner MJ, 2006, J ORTHOP RES, V24, P1679, DOI 10.1002/jor.20230
   González M, 2014, MAT SCI ENG C MATER, V42, P691, DOI 10.1016/j.msec.2014.06.010
   GOODSHIP AE, 1985, J BONE JOINT SURG BR, V67, P650, DOI 10.1302/0301 620X.67B4.4030869
   Govey PM, 2014, J BIOMECH, V47, P1838, DOI 10.1016/j.jbiomech.2014.03.022
   Gunter K, 2008, J BONE MINER RES, V23, P986, DOI 10.1359/JBMR.071201
   Heino TJ, 2004, EXP CELL RES, V294, P458, DOI 10.1016/j.yexcr.2003.11.016
   Hind K, 2007, BONE, V40, P14, DOI 10.1016/j.bone.2006.07.006
   Holguin N, 2014, BONE, V65, P83, DOI 10.1016/j.bone.2014.05.006
   Hsieh YF, 2001, J BONE MINER RES, V16, P2291, DOI 10.1359/jbmr.2001.16.12.2291
   Jacobs CR, 2010, ANNU REV BIOMED ENG, V12, P369, DOI 10.1146/annurev bioeng 070909 105302
   Javaheri B, 2014, J BONE MINER RES, V29, P705, DOI 10.1002/jbmr.2064
   Jing D, 2014, FASEB J, V28, P1582, DOI 10.1096/fj.13 237578
   Kennedy OD, 2014, BONE, V64, P132, DOI 10.1016/j.bone.2014.03.049
   KERSHAW CJ, 1993, CLIN ORTHOP RELAT R, P28
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   Lacroix D, 2002, MED BIOL ENG COMPUT, V40, P14, DOI 10.1007/BF02347690
   Lau KHW, 2013, AM J PHYSIOL ENDOC M, V305, pE271, DOI 10.1152/ajpendo.00092.2013
   Le YY, 2004, CELL MOL IMMUNOL, V1, P95
   Lee KCL, 2002, BONE, V31, P407, DOI 10.1016/S8756 3282(02)00842 6
   Leucht P, 2013, J ORTHOP RES, V31, P1828, DOI 10.1002/jor.22440
   LEWIS OJ, 1956, J BONE JOINT SURG BR, V38, P928, DOI 10.1302/0301 620X.38B4.928
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Low BC, 2014, FEBS LETT, V588, P2663, DOI 10.1016/j.febslet.2014.04.012
   Lynch ME, 2011, BONE, V49, P439, DOI 10.1016/j.bone.2011.05.017
   Martelli S, 2014, CLIN BIOMECH, V29, P869, DOI 10.1016/j.clinbiomech.2014.08.001
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Meakin LB, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00154
   Metzger TA, 2015, J BIOMECH ENG T ASME, V137, DOI 10.1115/1.4028985
   Milgrom C, 2000, BRIT J SPORT MED, V34, P195, DOI 10.1136/bjsm.34.3.195
   NAKAHARA H, 1991, J ORTHOP RES, V9, P465, DOI 10.1002/jor.1100090402
   Norman SC, 2015, J BIOMECH, V48, P53, DOI 10.1016/j.jbiomech.2014.11.004
   Palomares KTS, 2009, J ORTHOP RES, V27, P1123, DOI 10.1002/jor.20863
   Petit MA, 2013, ACSMS RESOURCE MANUA, P699
   PIEKARSKI K, 1977, NATURE, V269, P80, DOI 10.1038/269080a0
   Plotkin LI, 2005, AM J PHYSIOL CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004
   Razi H, 2015, J BONE MINER RES, V30, P1864, DOI 10.1002/jbmr.2528
   Razi H, 2015, ACTA BIOMATER, V13, P301, DOI 10.1016/j.actbio.2014.11.021
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Rodriguez JA, 2011, J ARTHROPLASTY, V26, P1409, DOI 10.1016/j.arth.2011.06.021
   Roosa SMM, 2011, J BONE MINER RES, V26, P100, DOI 10.1002/jbmr.193
   Santos A, 2010, BIOCHEM BIOPH RES CO, V391, P364, DOI 10.1016/j.bbrc.2009.11.064
   Schulte FA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062172
   Simanski CJP, 2006, J ORTHOP TRAUMA, V20, P108, DOI 10.1097/01.bot.0000197701.96954.8c
   Sugiyama T, 2012, J BONE MINER RES, V27, P1784, DOI 10.1002/jbmr.1599
   Sun YX, 2015, BONE, V74, P1, DOI 10.1016/j.bone.2014.12.066
   Thi MM, 2013, P NATL ACAD SCI USA, V110, P21012, DOI 10.1073/pnas.1321210110
   Thompson B, 2012, NAT REV ENDOCRINOL, V8, P529, DOI 10.1038/nrendo.2012.36
   Trüssel A, 2012, ANN BIOMED ENG, V40, P2475, DOI 10.1007/s10439 012 0594 4
   TURNER CH, 1994, J BONE MINER RES, V9, P87
   Turner CH, 1998, BONE, V23, P399, DOI 10.1016/S8756 3282(98)00118 5
   TURNER CH, 1995, J BONE MINER RES, V10, P1544
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Vatsa A, 2007, J BIOMECH, V40, pS89, DOI 10.1016/j.jbiomech.2007.02.015
   Verbruggen SW, 2015, BIOPHYS J, V108, P1587, DOI 10.1016/j.bpj.2015.02.031
   Verbruggen SW, 2012, J R SOC INTERFACE, V9, P2735, DOI 10.1098/rsif.2012.0286
   Wagner E, 2013, FOOT ANKLE INT, V34, P978, DOI 10.1177/1071100713477403
   Warden SJ, 2007, J BONE MINER RES, V22, P251, DOI 10.1359/JBMR.061107
   Warden SJ, 2014, J BONE MINER RES, V29, P1131, DOI 10.1002/jbmr.2143
   Warden SJ, 2014, P NATL ACAD SCI USA, V111, P5337, DOI 10.1073/pnas.1321605111
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Wolff J, 2010, CLIN ORTHOP RELAT R, V468, P1056, DOI 10.1007/s11999 010 1239 2
   Xing WR, 2005, J CELL BIOCHEM, V96, P1049, DOI 10.1002/jcb.20606
   You J, 2000, J BIOMECH ENG T ASME, V122, P387, DOI 10.1115/1.1287161
   Zaman G, 2010, BONE, V46, P628, DOI 10.1016/j.bone.2009.10.021
NR 95
TC 17
Z9 20
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523 3774
EI 1534 6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD SEP
PY 2015
VL 17
IS 9
AR 58
DI 10.1007/s11926 015 0537 9
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CP6QL
UT WOS:000360012800007
PM 26233599
DA 2025 08 17
ER

PT J
AU Dixit, N
   Wu, DJ
   Belgacem, YH
   Borodinsky, LN
   Gershwin, ME
   Adamopoulos, IE
AF Dixit, Neha
   Wu, Dennis J.
   Belgacem, Yesser H.
   Borodinsky, Laura N.
   Gershwin, M. Eric
   Adamopoulos, Iannis E.
TI Leukotriene B4 activates intracellular calcium and augments human
   osteoclastogenesis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID CYTOSOLIC PHOSPHOLIPASE A(2); RHEUMATOID ARTHRITIS; BONE RESORPTION; B 4
   RECEPTORS; BORATE 2 APB; CA2+ RELEASE; IN VITRO; DIFFERENTIATION; CELLS;
   ENTRY
AB Introduction: Bone erosion in inflammatory arthritis depends on the recruitment and activation of bone resorbing cells, the osteoclasts. Interleukin 23 (IL 23) has been primarily implicated in mediating inflammatory bone loss via the differentiation of Th17 receptor activator of nuclear factor kappa B ligand (RANKL) ? producing cells. In this article, we describe a new role of IL 23 in activating the synthesis and production of leukotriene B4 (LTB4) in innate immune cells.
   Methods: We utilized whole blood ? derived human peripheral blood mononuclear cells (PBMCs), differentiated them towards an osteoclast lineage and then performed immunofluorescence and cytochemical staining to detect the expression of LTB4 associated receptors and enzymes such as phospholipase A2, 5 lipoxygenase and leukotriene A4 hydrolase, as well as the presence of tartrate resistant acid phosphatase (TRAP) and F actin rings on fully mature osteoclasts. We used enzyme immunoassays to measure LTB4 levels in culture media derived from IL 23 treated human PBMCs. We used real time calcium imaging to study the effect of leukotrienes and requirements of different calcium sources and signaling proteins in activating intracellular calcium flux using pharmacological inhibitors to phospholipase C (U73122), membrane calcium channels (2 APB) and phosphatidylinositol 3 kinase (Wortmannin) and utilized qPCR for gene expression analysis in macrophages and osteoclasts.
   Results: Our data show that LTB4 engagement of BLT1 and BLT2 receptors on osteoclast precursors leads to activation of phospholipase C and calcium release activated channel mediated intracellular calcium flux, which can activate further LTB4 autocrine production. IL 23 induced synthesis and secretion of LTB4 resulted in the upregulation of osteoclast related genes NFATC1, MMP9, ACP5, CTSK and ITGB3 and the formation of giant, multinucleated TRAP(+) cells capable of F actin ring formation. These effects were dependent on Ca2+ signaling and were completely inhibited by BLT1/BLT2 and/or PLC and CRAC inhibitors.
   Conclusions: In conclusion, IL 23 can initiate osteoclast differentiation independently from the RANK RANKL pathway by utilizing Ca2+ signaling and the LTB4 signaling cascade.
C1 [Dixit, Neha; Wu, Dennis J.; Gershwin, M. Eric; Adamopoulos, Iannis E.] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA.
   [Belgacem, Yesser H.; Borodinsky, Laura N.] Shriners Hosp Children Northern Calif, Dept Physiol & Membrane Biol, Sacramento, CA 95817 USA.
   [Adamopoulos, Iannis E.] Shriners Hosp Children Northern Calif, Inst Pediat Regenerat Med, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis
RP Adamopoulos, IE (通讯作者)，Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, 451 Hlth Sci Dr, Davis, CA 95616 USA.
EM iannis@ucdavis.edu
RI ; Adamopoulos, Iannis/AAE 5624 2022
OI Adamopoulos, Iannis/0000 0002 3708 2965; 
FU NIAMS NIH HHS [R01 AR062173] Funding Source: Medline; NINDS NIH HHS [R01
   NS073055] Funding Source: Medline
CR Adamopoulos IE, 2011, J IMMUNOL, V187, P951, DOI 10.4049/jimmunol.1003986
   Adamopoulos IE, 2006, J PATHOL, V208, P35, DOI 10.1002/path.1891
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02 0037rev
   Chen M, 2006, J EXP MED, V203, P837, DOI 10.1084/jem.20052371
   Csoma Z, 2002, AM J RESP CRIT CARE, V166, P1345, DOI 10.1164/rccm.200203 233OC
   Floss DM, 2013, J BIOL CHEM, V288, P19386, DOI 10.1074/jbc.M112.432153
   Garcia C, 1996, J BONE MINER RES, V11, P1619
   Garg H.G. Hales., 2004, CHEM BIOL HYALURONAN, V1st
   Hein P, 2005, EMBO J, V24, P4106, DOI 10.1038/sj.emboj.7600870
   Hikiji H, 2009, P NATL ACAD SCI USA, V106, P21294, DOI 10.1073/pnas.0905209106
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Hur EM, 2002, CELL SIGNAL, V14, P397, DOI 10.1016/S0898 6568(01)00258 3
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Iversen L, 1997, SKIN PHARMACOL, V10, P169, DOI 10.1159/000211501
   Kajiya H, 2012, ADV EXP MED BIOL, V740, P917, DOI 10.1007/978 94 007 2888 2_41
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lee CW, 2011, J CELL PHYSIOL, V226, P2103, DOI 10.1002/jcp.22537
   Lee IT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072783
   Lee JM, 2012, J IMMUNOL, V189, P5284, DOI 10.4049/jimmunol.1003738
   Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709
   LIN AH, 1988, ANN NY ACAD SCI, V524, P196
   Mandal AK, 2008, P NATL ACAD SCI USA, V105, P20434, DOI 10.1073/pnas.0808211106
   Mathis S, 2007, AUTOIMMUN REV, V7, P12, DOI 10.1016/j.autrev.2007.03.005
   Mathis SP, 2010, J IMMUNOL, V185, P3049, DOI 10.4049/jimmunol.1001031
   Matsunaga Y, 2013, FASEB J, V27, P3306, DOI 10.1096/fj.12 217000
   Mentaverri R, 2003, CELL CALCIUM, V34, P169, DOI 10.1016/S0143 4160(03)00080 0
   Monach PA, 2010, ARTHRITIS RHEUM US, V62, P753, DOI 10.1002/art.27238
   Myou S, 2003, J IMMUNOL, V171, P4399, DOI 10.4049/jimmunol.171.8.4399
   Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361
   Ong EC, 2013, J BIOL CHEM, V288, P22219, DOI 10.1074/jbc.M113.459826
   Prakriya M, 2001, J PHYSIOL LONDON, V536, P3, DOI 10.1111/j.1469 7793.2001.t01 1 00003.x
   Sadik CD, 2012, P NATL ACAD SCI USA, V109, pE3177, DOI 10.1073/pnas.1213797109
   SAMUELSSON B, 1987, DRUGS, V33, P2, DOI 10.2165/00003495 198700331 00003
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Shahrara S, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2477
   Sharma RK, 2013, J IMMUNOL, V191, P3462, DOI 10.4049/jimmunol.1300967
   Shugg RPP, 2013, J BIOL CHEM, V288, P35346, DOI 10.1074/jbc.M113.507525
   SILBAUGH SA, 1992, EUR J PHARMACOL, V223, P57, DOI 10.1016/0014 2999(92)90818 O
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Yago T, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2297
   Yago T, 2009, J CELL BIOCHEM, V108, P947, DOI 10.1002/jcb.22326
   Yokomizo T, 2011, ADV ENZYME REGUL, V51, P59, DOI 10.1016/j.advenzreg.2010.08.002
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhou YD, 2011, J CELL PHYSIOL, V226, P1082, DOI 10.1002/jcp.22423
NR 45
TC 15
Z9 17
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2014
VL 16
IS 6
AR 496
DI 10.1186/s13075 014 0496 y
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CB8ND
UT WOS:000349886000020
PM 25443625
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cordonnier, T
   Langonné, A
   Sohier, J
   Layrolle, P
   Rosset, P
   Sensébé, L
   Deschaseaux, F
AF Cordonnier, Thomas
   Langonne, Alain
   Sohier, Jerome
   Layrolle, Pierre
   Rosset, Philippe
   Sensebe, Luc
   Deschaseaux, Frederic
TI Consistent Osteoblastic Differentiation of Human Mesenchymal Stem Cells
   with Bone Morphogenetic Protein 4 and Low Serum
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
ID CALCIUM PHOSPHATE CERAMICS; MARROW STROMAL CELLS; IN VITRO; PROGENITOR
   CELLS; CHONDROGENIC DIFFERENTIATION; CHONDROBLAST DIFFERENTIATION;
   EXTRACELLULAR MATRIX; SIGNALING PATHWAYS; GENE EXPRESSION; MESSENGER RNA
AB Providing fully mature and functional osteoblasts is challenging for bone tissue engineering and regenerative medicine. Such cells could be obtained from multipotent bone marrow mesenchymal stem cells (MSCs) after induction by different osteogenic factors. However, there are some discrepancies in results, notably due to the use of sera and to the type of osteogenic factor. In this study, we compared the osteogenic differentiation of bone marrow MSCs induced by dexamethasone (Dex) or bone morphogenetic proteins (BMPs) by assessing phenotypes in vitro and functional osteoblasts in vivo. Reducing the content of fetal calf serum from 10% to 2% significantly increased the mineral deposition and expression of osteoblastic markers during osteogenesis. In comparison to Dex condition, the addition of BMP4 greatly improved the differentiation of MSCs into fully mature osteoblasts as seen by high expression of Osterix. These results were confirmed in different supportive matrixes, plastic flasks, or biphasic calcium phosphate biomaterials. In contrast to Dex derived osteoblasts, BMP4 derived osteoblasts from MSCs were significantly able to produce new bone in subcutis of nude mice in accordance with in vitro results. In conclusion, we describe a convenient ex vivo method to produce consistently mature functional osteoblasts from human MSCs with use of BMP4 and low serum.
C1 [Langonne, Alain; Sensebe, Luc; Deschaseaux, Frederic] Etab Francais Sang Ctr Atlantique, Res Dept, F 37000 Tours, France.
   [Cordonnier, Thomas; Sohier, Jerome; Layrolle, Pierre] Fac Med, INSERM, Lab Bone Resorpt Physiopathol & Primary Bone Tumo, U957, Nantes, France.
   [Cordonnier, Thomas; Langonne, Alain; Rosset, Philippe; Sensebe, Luc; Deschaseaux, Frederic] Univ Tours, Lab Hematopoiesis, EA3855, Tours, France.
   [Rosset, Philippe] Trousseau Hosp, Dept Orthoped, Tours, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Tours; CHU Tours
RP Deschaseaux, F (通讯作者)，Etab Francais Sang Ctr Atlantique, Res Dept, 2 Bd Tonnelle, F 37000 Tours, France.
EM frederic.deschaseaux@efs.sante.fr
RI Cordonnier, Thomas/L 1402 2015; Sohier, Jerome/O 1923 2017; Layrolle,
   Pierre/K 9257 2015
OI Layrolle, Pierre/0000 0001 9800 5210; Cordonnier,
   Thomas/0000 0002 0166 6870; Deschaseaux, Frederic/0000 0001 7822 0896;
   Sohier, Jerome/0000 0002 2696 5754
FU Agence Nationale de la Recherche Technologies pour la Sante et
   l'Autonomie, ATOS [024 03]; European Commission [FP7/2007 2013, 241879]
FX This work was funded by the Agence Nationale de la Recherche
   Technologies pour la Sante et l'Autonomie, ATOS project no. 024 03
   (2007 2010). The research leading to these results has also received
   funding from the European Commission Seventh Framework Programme
   (FP7/2007 2013) under the Grant agreement no. 241879, through the
   RE BORNE project. The authors would like to acknowledge Paul Pilet for
   technical assistance in microscopy and micro tomography.
CR AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097 4644(19990301)72:3<396::AID JCB9>3.3.CO;2 Y
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   Blokhuis TJ, 2008, INJURY, V39, pS33, DOI 10.1016/S0020 1383(08)70013 5
   Canalis E, 2005, J Endocrinol Invest, V28, P3
   Chang WH, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159945
   Chase LG, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt8
   Chau JFL, 2009, HISTOL HISTOPATHOL, V24, P1593, DOI 10.14670/HH 24.1593
   Cheung A, 2006, CURR ORTHOPAED, V20, P424, DOI 10.1016/j.cuor.2006.09.003
   da Silva ML, 2006, J CELL SCI, V119, P2204, DOI DOI 10.1242/JCS.02932
   Derfoul A, 2006, STEM CELLS, V24, P1487, DOI 10.1634/stemcells.2005 0415
   Deschaseaux F, 2010, J CELL MOL MED, V14, P103, DOI 10.1111/j.1582 4934.2009.00878.x
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Drissi H, 1999, CANCER RES, V59, P3705
   Felka T, 2010, CYTOTHERAPY, V12, P143, DOI 10.3109/14653240903470647
   Fellah BH, 2008, BIOMATERIALS, V29, P1177, DOI 10.1016/j.biomaterials.2007.11.034
   Fischer EM, 2003, TISSUE ENG, V9, P1179, DOI 10.1089/10763270360728080
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Gronthos S, 2003, J BONE MINER RES, V18, P716, DOI 10.1359/jbmr.2003.18.4.716
   Habibovic P, 2008, J ORTHOP RES, V26, P1363, DOI 10.1002/jor.20648
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Indrawattana N, 2004, BIOCHEM BIOPH RES CO, V320, P914, DOI 10.1016/j.bbrc.2004.06.029
   ISHIDOU Y, 1995, J BONE MINER RES, V10, P1651
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359 6101(97)00036 1
   Kawaguchi J, 2005, BONE, V36, P758, DOI 10.1016/j.bone.2004.07.019
   Kim HJ, 2007, ANN NY ACAD SCI, V1116, P335, DOI 10.1196/annals.1402.057
   LANE NE, ANN NY ACAD SCI, V1192, P81
   Le Nihouannen D, 2005, BONE, V36, P1086, DOI 10.1016/j.bone.2005.02.017
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lennon DP, 1996, IN VITRO CELL DEV AN, V32, P602
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   NAKASE T, 1994, J BONE MINER RES, V9, P651
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nemoto E, 2009, BONE, V44, P805, DOI 10.1016/j.bone.2008.12.029
   Nishimori S, 2001, J BIOL CHEM, V276, P10700, DOI 10.1074/jbc.M007499200
   Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872
   Oshina H, 2007, BONE, V41, P575, DOI 10.1016/j.bone.2007.06.022
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Purpura KA, 2004, STEM CELLS, V22, P39, DOI 10.1634/stemcells.22 1 39
   Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Sato M, 1999, J BONE MINER RES, V14, P1084, DOI 10.1359/jbmr.1999.14.7.1084
   Schallmoser K, 2008, TISSUE ENG PT C METH, V14, P185, DOI 10.1089/ten.tec.2008.0060
   Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007 0554
   Sensebé L, 2010, VOX SANG, V98, P93, DOI 10.1111/j.1423 0410.2009.01227.x
   Shao J, 2009, PHARMAZIE, V64, P674, DOI 10.1691/ph.2009.9561
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Silber JS, 2003, SPINE, V28, P134, DOI 10.1097/00007632 200301150 00008
   Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   STEIN GS, 1992, BIOELECTROMAGNETICS, P247, DOI 10.1002/bem.2250130722
   Tarte K, 2010, BLOOD, V115, P1549, DOI 10.1182/blood 2009 05 219907
   Torii Y, 1996, CELL BIOL INT, V20, P459, DOI 10.1006/cbir.1996.0060
   Tsuji K, 2008, J BONE JOINT SURG AM, V90A, P14, DOI 10.2106/JBJS.G.01109
   Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659
   Warren SM, 2003, NATURE, V422, P625, DOI 10.1038/nature01545
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105
   Wojtowicz AM, 2010, TISSUE ENG PT A, V16, P2795, DOI 10.1089/ten.TEA.2010.0025
   Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092 8674(03)00847 X
   Yoshimura Y, 2001, J BONE MINER RES, V16, P876, DOI 10.1359/jbmr.2001.16.5.876
   Yuan HP, 1999, BIOMATERIALS, V20, P1799, DOI 10.1016/S0142 9612(99)00075 7
   Zhou GD, 2006, TISSUE ENG, V12, P3209, DOI 10.1089/ten.2006.12.3209
NR 73
TC 37
Z9 41
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD MAR
PY 2011
VL 17
IS 3
BP 249
EP 259
DI 10.1089/ten.tec.2010.0387
PG 11
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 727KV
UT WOS:000287799400001
PM 20822481
DA 2025 08 17
ER

PT J
AU Li, X
   Wang, YX
   Li, LP
   Zhou, SJ
   Zhao, FC
AF Li, Xiang
   Wang, Yuxin
   Li, Liangping
   Zhou, Shengji
   Zhao, Fengchao
TI Sclareol inhibits RANKL induced osteoclastogenesis and promotes
   osteoblastogenesis through promoting CCN1 expression via repressing the
   MAPK pathway
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Article
DE Sclareol; Cysteine rich protein 61; Osteoporosis; Receptor activator of
   nuclear factor kappa B ligand; Mitogen activated protein kinase pathway
ID IN VITRO; C FOS; DIFFERENTIATION; CELLS; CYR61; ALPHA(V)BETA(3);
   PROLIFERATION; SUPPRESSION; INDUCTION
AB Osteoclasts are crucial cellular components of bone and are the cause of various bone problems like osteoporosis. Various biological activities such as anti tumorous, anti inflammatory, antibacterial, and immunomodulatory function are influenced by Sclareol, as a natural diterpene compound. However, studies on the effect and mechanism of Sclareol on osteoporosis are rare. In the current research, the influence of Sclareol on osteoclastogenesis and osteoblastogenesis was targeted to be discovered in ovariectomy (OVX) induced animal models and in vitro. The expression levels of osteoclast related genes such as c Fos, NFATc1, and CTSK were detected by RT qPCR and western blotting to understand the inhibition of Sclareol on the creation of osteoclast. The influence of Sclareol on osteoblastogenesis and the expression of osteoblastogenic markers were also examined. Sclareol inhibited the osteoclastogenesis caused by receptor activator of nuclear factor kappa B ligand (RANKL) which promoted osteoblastogenesis through upregulating the expression of cysteine rich protein 61 (CYR61/CCN1), which is a matricellular protein of the CCN family. The p ERK and p P38 protein expression levels were considerably downregulated by Sclareol. Furthermore, CCN1 overexpression partially mimicked the inhibitory effect of Sclareol, while the opposite results were obtained after CCN1 silencing. Additionally, Sclareol protected against loss of bones in an osteoporosis mouse model generated by OVX. The acquired results indicated that Sclareol represses RANKL induced osteoclastogenesis and promotes osteoblastogenesis via promoting the expression of CCN1 by constraining the mitogen activated protein kinase (MAPK) pathway. Our findings proposed that for the avoidance and treatment of osteoclast linked disorders, Sclareol is a potentially effective drug.
C1 [Li, Xiang; Wang, Yuxin; Zhou, Shengji; Zhao, Fengchao] Zhejiang Univ, Sch Med, Dept Orthopaed Surg, Affiliated Hosp 1, 79 Qingchun Rd, Hangzhou 310003, Peoples R China.
   [Li, Liangping] Zhejiang Univ, Sch Med, Dept Surg, Affiliated Hosp 2, Hangzhou 310009, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Zhao, FC (通讯作者)，Zhejiang Univ, Sch Med, Dept Orthopaed Surg, Affiliated Hosp 1, 79 Qingchun Rd, Hangzhou 310003, Peoples R China.
EM zhaofengchao@zju.edu.cn
RI li, liangping/LVR 1411 2024; Lee, Leonard/GOJ 8927 2022
OI Li, Liangping/0000 0002 5809 1940; Zhao, Fengchao/0000 0002 6000 7197
FU Project of Scientific Research Fund of the Zhejiang Provincial Education
   Department [188310 542126/015]
FX This work was supported by A Project of Scientific Research Fund of the
   Zhejiang Provincial Education Department (188310 542126/015). No
   benefits in any form have been or will be received from a commercial
   party related directly or indirectly to the subject of this manuscript.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bharti AC, 2004, APOPTOSIS, V9, P677, DOI 10.1023/B:APPT.0000045780.10463.c6
   Boerckel JD, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt534
   Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169
   Chen CY, 2017, J BONE MINER RES, V32, P34, DOI 10.1002/jbmr.2926
   Crockett JC, 2007, ENDOCRINOLOGY, V148, P5761, DOI 10.1210/en.2007 0473
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dimas K, 2007, APOPTOSIS, V12, P685, DOI 10.1007/s10495 006 0026 8
   Duan GQ, 2018, CANCER BIOMARK, V22, P29, DOI 10.3233/CBM 170698
   Frey SP, 2012, INT ORTHOP, V36, P2387, DOI 10.1007/s00264 012 1659 6
   Gillespie MT, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2141
   Han GH, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010017
   Hatziantoniou S, 2006, PHARMACOL RES, V53, P80, DOI 10.1016/j.phrs.2005.09.008
   Hsieh YH, 2017, INT IMMUNOPHARMACOL, V44, P16, DOI 10.1016/j.intimp.2016.12.026
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Huang GJ, 2012, J NAT PROD, V75, P54, DOI 10.1021/np200512a
   Jahan K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67886 7
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jin HM, 2019, FOOD FUNCT, V10, P6556, DOI 10.1039/c9fo00206e
   Johnson SK, 2014, BLOOD, V124, P2051, DOI 10.1182/blood 2014 02 555813
   Kaushik R, 2010, J FOOD SCI TECH MYS, V47, P27, DOI 10.1007/s13197 010 0011 7
   Kim Y, 2005, J BIOL CHEM, V280, P32905, DOI 10.1074/jbc.M505820200
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Lau LF, 2016, J CELL COMMUN SIGNAL, V10, P121, DOI 10.1007/s12079 016 0324 z
   Lee NK, 2010, ENDOCRINOL METAB, V25, P264, DOI 10.3803/EnM.2010.25.4.264
   Lee S, 2016, CYTOTECHNOLOGY, V68, P1633, DOI 10.1007/s10616 015 9907 4
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Liu H, 2017, INT J ONCOL, V50, P631, DOI 10.3892/ijo.2016.3815
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Löbel M, 2012, CELL MOL LIFE SCI, V69, P3101, DOI 10.1007/s00018 012 0981 x
   Miyazaki T, 2014, PATIENT PREFER ADHER, V8, P463, DOI 10.2147/PPA.S46192
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Noori S, 2013, IRAN J IMMUNOL, V10, P10, DOI IJIv10i1A2
   Roscher Anne, 2016, Bone Rep, V5, P214, DOI 10.1016/j.bonr.2016.07.002
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Su JL, 2010, J BIOL CHEM, V285, P31325, DOI 10.1074/jbc.M109.087122
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsai SW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051351
   Tyagi AK, 2016, ARCH BIOCHEM BIOPHYS, V593, P80, DOI 10.1016/j.abb.2016.02.013
   Wei ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059171
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600 079X.2010.00803.x
   Zhang QY, 2009, ARTHRITIS RHEUM US, V60, P3602, DOI 10.1002/art.24999
   Zhang YC, 2016, J BONE MINER RES, V31, P549, DOI 10.1002/jbmr.2712
   Zhao GX, 2020, J BONE MINER RES, V35, P2289, DOI 10.1002/jbmr.4128
   Zhao GX, 2018, J BONE MINER RES, V33, P1076, DOI 10.1002/jbmr.3394
NR 49
TC 16
Z9 17
U1 2
U2 28
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0742 2091
EI 1573 6822
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD DEC
PY 2021
VL 37
IS 6
BP 849
EP 871
DI 10.1007/s10565 020 09578 6
EA JAN 2021
PG 23
WC Cell Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Toxicology
GA XA6SL
UT WOS:000606347200001
PM 33423118
DA 2025 08 17
ER

PT J
AU Lee, CH
   Huang, YL
   Liao, JF
   Chiou, WF
AF Lee, Chia Hsin
   Huang, Yu Ling
   Liao, Jyh Fei
   Chiou, Wen Fei
TI Ugonin K promotes osteoblastic differentiation and mineralization by
   activation of p38 MAPK  and ERK mediated expression of Runx2 and osterix
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Ugonin K; Osteoblast; MAPK; Runx2; Osterix
ID BONE MORPHOGENETIC PROTEIN 2; ALKALINE PHOSPHATASE; TRANSCRIPTION
   FACTOR; SIGNALING PATHWAYS; KINASE; PHOSPHORYLATION; RHIZOMES; MATRIX;
   GROWTH; BMP 2
AB Ugonin K is a flavonoid isolated from the roots of Helminthostachys zeylanica, a folk medicine used to strengthen bone mass and cure bone fracture. It is of interest to determine whether ugonin K has beneficial effect on osteoblast maturation. In this study, MC3T3 E1 osteoblasts were treated with ugonin K. Cell differentiation and mineralization were identified by alkaline phosphatase (ALP) activity and Alizarin red S staining, respectively. RT PCR and Western blot were used to analyze osteoblast associated gene expression and signaling pathways. Our results showed that ugonin K significantly induced the increase of ALP activity, expressions of bone sialoprotein (BSP) and osteocalcin (OCN), and mineralization. The mRNA expressions of the transcription factors Runx2 and osterix were also up regulated by ugonin K. Ugonin K increased the phosphorylated level of p38 and ERK, respectively. In the presence of SB203580, ugonin K induced expressions of Runx2 and osterix, ALP activity, BSP level and bone nodule formation were all completely inhibited, but ugonin K induced OCN expression was not affected. On the other hand, ugonin K induced ALP activity and mineralization were mildly attenuated by PD98059, but the over expressed Runx2, osterix, BSP and OCN also were significantly repressed by PD98059. These suggested that both p38 and ERK participate in regulating ugonin K evoked osteogenesis but p38 seemed to play a more important role. Take together, the potential anabolic effect of ugonin K on bone might act through activations of p38  and ERK mediated Runx2 and osterix expressions to induce the synthesis of osteoids and formation of bone nodule. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Huang, Yu Ling; Chiou, Wen Fei] Natl Res Inst Chinese Med, Taipei 112, Taiwan.
   [Lee, Chia Hsin; Liao, Jyh Fei] Natl Yang Ming Univ, Dept Pharmacol, Taipei 112, Taiwan.
   [Chiou, Wen Fei] Hungkuang Univ, Dept Biotechnol, Taichung, Taiwan.
   [Chiou, Wen Fei] Natl Yang Ming Univ, Inst Tradit Med, Taipei 112, Taiwan.
C3 National Research Institute of Chinese Medicine; National Yang Ming
   Chiao Tung University; Hungkuang University; National Yang Ming Chiao
   Tung University
RP Chiou, WF (通讯作者)，Natl Res Inst Chinese Med, 155 1,Sect 2,Li Nung St, Taipei 112, Taiwan.
EM wfchiou@nricm.edu.tw
RI Lee, Chang Chun/M 1436 2016
FU National Science Council, Executive Yuan, Republic of China
   [NSC98 2320 B 077 004 MY3]; National Research Institute of Chinese
   Medicine, Taipei, Taiwan, Republic of China [NRICM99 DBCM 2]
FX This research was funded by the National Science Council, Executive
   Yuan, Republic of China (NSC98 2320 B 077 004 MY3) and the National
   Research Institute of Chinese Medicine, Taipei, Taiwan, Republic of
   China (NRICM99 DBCM 2).
CR Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen CC, 2003, PLANTA MED, V69, P964, DOI 10.1055/s 2003 45112
   Chiu R, 2010, J ORTHOP RES, V28, P571, DOI 10.1002/jor.21035
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Franceschi RT, 2007, ANN NY ACAD SCI, V1116, P196, DOI 10.1196/annals.1402.081
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Hsu YL, 2007, BIOCHEM PHARMACOL, V73, P504, DOI 10.1016/j.bcp.2006.10.020
   Hsu YL, 2009, MOL NUTR FOOD RES, V53, P1452, DOI 10.1002/mnfr.200800483
   Huang YC, 2009, J NAT PROD, V72, P1273, DOI 10.1021/np900148a
   Huang YL, 2003, PHYTOCHEMISTRY, V64, P1277, DOI 10.1016/j.phytochem.2003.09.009
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Kono SJ, 2007, BONE, V40, P68, DOI 10.1016/j.bone.2006.07.024
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Leong WF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004135
   Lin YC, 2009, NEUROCHEM RES, V34, P923, DOI 10.1007/s11064 008 9860 0
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827
   Ogata Y, 2008, J PERIODONTAL RES, V43, P127, DOI 10.1111/j.1600 0765.2007.01014.x
   Orimo H, 2008, MOL CELL BIOCHEM, V315, P51, DOI 10.1007/s11010 008 9788 3
   Liao QC, 2007, ACTA PHARMACOL SIN, V28, P1597, DOI 10.1111/j.1745 7254.2007.00632.x
   Suja SR, 2004, J ETHNOPHARMACOL, V92, P61, DOI 10.1016/j.jep.2004.01.019
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
NR 43
TC 65
Z9 68
U1 0
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 15
PY 2011
VL 668
IS 3
BP 383
EP 389
DI 10.1016/j.ejphar.2011.06.059
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 840AV
UT WOS:000296411500004
PM 21806985
DA 2025 08 17
ER

PT J
AU Xu, H
   Wang, YM
   Rong, X
   Wang, D
   Xie, JW
   Huang, ZY
   Zeng, WA
   Fu, XX
   Li, JS
   Zhou, ZK
AF Xu, Hong
   Wang, Yuemin
   Rong, Xiao
   Wang, Duan
   Xie, Jinwei
   Huang, Zeyu
   Zeng, Weinan
   Fu, Xiaoxue
   Li, Jianshu
   Zhou, Zongke
TI Ingenious Synergy of a Pathology Specific Biomimetic Multifunctional
   Nanoplatform for Targeted Therapy in Rheumatoid Arthritis
SO SMALL
LA English
DT Article
DE bone erosion; inflammation; reactive oxygen species; rheumatoid
   arthritis; targeted therapy
ID ROS; NANOPARTICLES; MIGRATION; DELIVERY; DISEASE; STRESS; DESIGN;
   JOINTS; CELLS
AB Based on the pathological characteristics of rheumatoid arthritis, including the overproduction of reactive oxygen species (ROS), inflammatory responses, and osteoclast differentiation, a biomimetic multifunctional nanomedicine (M M@I) is designed. Iguratimod (IGU) is loaded, which inhibits inflammatory responses and osteoclast differentiation, into mesoporous polydopamine (MPDA), which scavenges ROS. Subsequently, the nanoparticles are coated with a cell membrane of macrophages to achieve actively targeted delivery of the nanoparticles to inflamed joints. It is shown that the M M@I nanoparticles are taken up well by lipopolysaccharide induced RAW 264.7 macrophages or bone marrow derived macrophages (BMDMs). In vitro, the M M@I nanoparticles effectively scavenge ROS, downregulate genes related to inflammation promotion and osteoclast differentiation, and reduce the proinflammatory cytokines and osteoclast related enzymes. They also reduce the polarization of macrophages to a pro inflammatory M1 phenotype and inhibit differentiation into osteoclasts. In mice with collagen induced arthritis, the M M@I nanoparticles accumulate at arthritic sites and circulate longer, significantly mitigating arthritis symptoms and bone destruction. These results suggest that the pathology specific biomimetic multifunctional nanoparticles are effective against rheumatoid arthritis, and they validate the approach of developing multifunctional therapies that target various pathological processes simultaneously.
   A pathology specific biomimetic multifunctional nanoplatform (M M@I) is synthesized for targeted therapy in rheumatoid arthritis. The coated cell membranes will deliver M M@I nanoparticles to the inflamed joints and persist in long circulation in CIA mice. The inflammation and bone erosion will be inhibited by the synergistic effect of MPDA for ROS scavenging and iguratimod for inhibiting inflammatory response and osteoclast differentiation.image
C1 [Xu, Hong; Wang, Duan; Xie, Jinwei; Huang, Zeyu; Zeng, Weinan; Fu, Xiaoxue; Zhou, Zongke] Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu 610041, Peoples R China.
   [Xu, Hong; Wang, Duan; Xie, Jinwei; Huang, Zeyu; Zeng, Weinan; Fu, Xiaoxue; Zhou, Zongke] Sichuan Univ, West China Hosp, Orthoped Res Inst, Chengdu 610041, Peoples R China.
   [Wang, Yuemin; Li, Jianshu] Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Peoples R China.
   [Rong, Xiao] Sichuan Univ, West China Hosp, Dept Ultrasound, Chengdu 610041, Peoples R China.
   [Li, Jianshu] Sichuan Univ, West China Hosp Stomatol, Medx Ctr Mat, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University; Sichuan University
RP Zhou, ZK (通讯作者)，Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu 610041, Peoples R China.; Zhou, ZK (通讯作者)，Sichuan Univ, West China Hosp, Orthoped Res Inst, Chengdu 610041, Peoples R China.; Li, JS (通讯作者)，Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Peoples R China.; Li, JS (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Medx Ctr Mat, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
EM jianshu_li@scu.edu.cn; zhouzongke@scu.edu.cn
RI Huang, ZeYu/G 1340 2015; Wang, Yuemin/B 7507 2014; Fu,
   Xiaoxue/AAC 6924 2022
OI Huang, ZeYu/0000 0002 0456 8379; Fu, Xiaoxue/0009 0007 7113 9607; Xie,
   Jinwei/0000 0002 0623 6036; Zeng, Weinan/0000 0002 3952 1968; Zhou,
   Zongke/0000 0002 9037 4756
FU National Natural Science Foundation of China [82172394, U22A20280,
   82102542]
FX The authors thank the financial support from the National Natural
   Science Foundation of China (Grant No. 82172394, U22A20280, 82102542).
   The authors gratefully acknowledge Li Li, Fei Chen, Chunjuan Bao, and
   Yang Deng from the lnstitute of Clinical Pathology, West China Hospital,
   Sichuan University for processing histological staining. The authors
   sincerely appreciate Li Chai, Yi Li, Xing Xu, Li Zhou, Lei Wu, and
   YaPing Wu from the Core Facilities, West China Hospital, Sichuan
   University for their technical assistance and guidance. The authors
   thank Xiaoting Chen from the Animal Experimental Center of West China
   Hospital for technical assistance in animal experiments. The authors
   thank A. C. Rodriguez from Creaducate Enterprises Ltd. for editing the
   English text of a draft of this manuscript.
CR Adami G., 2023, RMD OPEN, V9
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Alivernini S, 2020, NAT MED, V26, P1295, DOI 10.1038/s41591 020 0939 8
   Andersson SE, 1999, J RHEUMATOL, V26, P2018
   Bao XF, 2018, ACS NANO, V12, P8882, DOI 10.1021/acsnano.8b04022
   Bongartz T, 2006, JAMA J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275
   Cao HQ, 2016, ACS NANO, V10, P7738, DOI 10.1021/acsnano.6b03148
   Chen HH, 2022, CARBOHYD POLYM, V284, DOI 10.1016/j.carbpol.2022.119183
   Chen QX, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202201067
   Cutolo M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.867260
   d'Arcy R, 2014, POLYM ADVAN TECHNOL, V25, P478, DOI 10.1002/pat.3264
   De Cicco P., 2023, J Ethnopharmacol, V311
   Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22454 z
   Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]
   Fang HH, 2022, ACS APPL MATER INTER, V14, P8824, DOI 10.1021/acsami.1c23429
   Filippin LI, 2008, CLIN EXP IMMUNOL, V152, P415, DOI 10.1111/j.1365 2249.2008.03634.x
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Gan K, 2016, INT IMMUNOPHARMACOL, V35, P294, DOI 10.1016/j.intimp.2016.03.038
   Gong T, 2020, BIOMATERIALS, V258, DOI 10.1016/j.biomaterials.2020.120296
   Guan BY, 2016, J AM CHEM SOC, V138, P11306, DOI 10.1021/jacs.6b06558
   Guo LN, 2022, SMALL, V18, DOI 10.1002/smll.202202604
   Guo LN, 2021, J CONTROL RELEASE, V330, P119, DOI 10.1016/j.jconrel.2020.10.069
   Hong YH, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113602
   Honzawa T, 2022, INT IMMUNOL, V34, P635, DOI 10.1093/intimm/dxac041
   Jing WY, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1107670
   Kanzaki H, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00351
   Kinne RW, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2333
   Lee JY, 2022, EXPLORATION PRC, V2, DOI 10.1002/EXP.20210086
   Li CH, 2017, J CONTROL RELEASE, V246, P133, DOI 10.1016/j.jconrel.2016.12.027
   Li JM, 2021, BIOACT MATER, V6, P3839, DOI 10.1016/j.bioactmat.2021.03.039
   Li JB, 2017, J BONE MINER RES, V32, P962, DOI 10.1002/jbmr.3059
   Li RX, 2019, NANO LETT, V19, P124, DOI 10.1021/acs.nanolett.8b03439
   Li T, 2021, MBIO, V12, DOI 10.1128/mBio.02231 21
   Lin J, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6929286
   Liu L, 2022, NANO TODAY, V47, DOI 10.1016/j.nantod.2022.101640
   Liu YL, 2017, J AM CHEM SOC, V139, P856, DOI 10.1021/jacs.6b11013
   Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a
   Liu YL, 2013, ADV MATER, V25, P1353, DOI 10.1002/adma.201204683
   Ma BX, 2020, ACS NANO, V14, P5862, DOI 10.1021/acsnano.0c01012
   Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465
   Mateen S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152925
   Myatt SS, 2011, ANTIOXID REDOX SIGN, V14, P675, DOI 10.1089/ars.2010.3383
   Palmer G, 2006, ARTHRITIS RHEUM, V54, P2707, DOI 10.1002/art.22062
   Phull AR, 2018, CHEM BIOL INTERACT, V281, P121, DOI 10.1016/j.cbi.2017.12.024
   Pöllinger B, 2011, J IMMUNOL, V186, P2602, DOI 10.4049/jimmunol.1003370
   Safiri S, 2019, ANN RHEUM DIS, V78, P1463, DOI 10.1136/annrheumdis 2019 215920
   Shen QY, 2023, INT J PHARMACEUT, V635, DOI 10.1016/j.ijpharm.2023.122698
   Smallwood MJ, 2018, FREE RADICAL BIO MED, V125, P3, DOI 10.1016/j.freeradbiomed.2018.05.086
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Su XH, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111382
   Takenaka M, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121160
   VanderHeijde DMFM, 1995, BRIT J RHEUMATOL, V34, P74
   Volin MV, 2005, CURR PHARM DESIGN, V11, P633, DOI 10.2174/1381612053381972
   Walker D, 2022, CLIN RHEUMATOL, V41, P2695, DOI 10.1007/s10067 022 06232 w
   Wang L, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120208
   Wang YM, 2022, ADV MATER, V34, DOI 10.1002/adma.202107406
   Wong XY, 2020, ACS NANO, V14, P2585, DOI 10.1021/acsnano.9b08133
   Xing YX, 2017, NANOSCALE, V9, P8781, DOI 10.1039/c7nr01857f
   Xuan MJ, 2015, ADV HEALTHC MATER, V4, P1645, DOI 10.1002/adhm.201500129
   Yang YH, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120390
   Yilmaz PD, 2023, CLIN EXP HYPERTENS, V45, DOI 10.1080/10641963.2022.2156529
   Yokota K, 2021, ARTHRITIS RHEUMATOL, V73, P1145, DOI 10.1002/art.41666
   Yu HH, 2022, ACS NANO, V16, P502, DOI 10.1021/acsnano.1c07556
   Zhang Fan, 2019, Nat Immunol, V20, P928, DOI 10.1038/s41590 019 0378 1
   Zhu YZ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf6654
NR 65
TC 5
Z9 5
U1 4
U2 81
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD MAR
PY 2024
VL 20
IS 10
DI 10.1002/smll.202305197
EA NOV 2023
PG 15
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA KD4G9
UT WOS:001091898600001
PM 37914665
DA 2025 08 17
ER

PT J
AU Lv, HC
   Yang, TY
   He, AM
   Wang, MB
   Jia, HS
   Ma, M
   Li, SQ
AF Lv, Huicheng
   Yang, Tieyi
   He, Aimin
   Wang, Mingbo
   Jia, Haisheng
   Ma, Min
   Li, Siqin
TI miR 27b attenuates dexamethasone inhibited proliferation and
   osteoblastic differentiation in MC3T3 E1 cells by targeting PPARγ2
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE miR 27b; proliferation; osteoblastic differentiation; PPAR gamma 2
ID PPAR GAMMA; OSTEOGENIC DIFFERENTIATION; OSTEOCLAST FORMATION; PROMOTES;
   OSTEOPOROSIS; PROGRESSION; OVEREXPRESSION; PATHWAYS; RECEPTOR
AB Osteoporosis is a metabolic bone illness characterized by low bone density and a high risk of fracture. It is estimated that there are >60 million individuals in China suffering from this disease, which highlights an urgent requirement for the development of novel and safe drugs for the long term treatment of osteoporosis. MicroRNAs (miRNAs/miRs) have previously been identified as critical regulators in the progression of osteoporosis. As an intronic miRNA, miR 27b enhances the osteoblastic differentiation of stem cells from the bone marrow and the maxillary sinus membrane. However, the mechanism underlying miR 27b in osteoporosis remains to be elucidated. In the present study, MC3T3 E1 pre osteoblasts were treated with dexamethasone (DEX) to establish an in vitro model of osteoporosis. The results of the present study demonstrated that DEX treatment markedly inhibited the viability of MC3T3 E1 cells, and downregulated the expression level of miR 27b. The results of reverse transcription quantitative PCR, western blotting and dual luciferase assays revealed that miR 27b directly regulated and suppressed the expression of peroxisome proliferator activated receptor gamma 2 (PPAR gamma 2) in MC3T3 E1 cells. Furthermore, overexpression of miR 27b by transfection of cells with miR 27b mimic attenuated DEX mediated inhibition of cell viability, alkaline phosphatase (ALP) activity and the expression levels of bone morphogenetic protein 2 (BMP2), runt related protein 2 (Runx2) and osteocalcin (OCN). The results of the present study indicated that miR 27b alleviated DEX inhibited proliferation and osteoblastic differentiation. Moreover, miR 27b knockdown repressed MC3T3 E1 cell viability, ALP activity and protein levels of BMP2, Runx2 and OCN. However, these effects were abrogated by small interfering RNA mediated PPAR gamma 2 silencing. In conclusion, the results of the present study demonstrated that miR 27b attenuated DEX inhibited proliferation and osteoblastic differentiation in MC3T3 E1 pre osteoblasts by targeting PPAR gamma 2.
C1 [Lv, Huicheng; Yang, Tieyi; He, Aimin; Wang, Mingbo; Jia, Haisheng; Ma, Min] Inner Mongolia Med Univ, Dept Trauma 2, Affiliated Hosp 2, Hohhot 010000, Inner Mongolia, Peoples R China.
   [Li, Siqin] Peoples Hosp Inner Mongolia Autonomous Reg, Dept Ultrasound Med, 20 Zhaowuda Rd, Hohhot 010020, Inner Mongolia, Peoples R China.
C3 Inner Mongolia Medical University
RP Li, SQ (通讯作者)，Peoples Hosp Inner Mongolia Autonomous Reg, Dept Ultrasound Med, 20 Zhaowuda Rd, Hohhot 010020, Inner Mongolia, Peoples R China.
EM lisiqin889@sina.com
RI Wang, Zhibo/GSD 3371 2022; ma, min/IWV 2792 2023
FU Inner Mongolia Natural Science Foundation [2017MS08118]; Inner Mongolia
   Medical University `Science and Technology Million Project'
   [YKD2016kjbw010]
FX The present study was approved by the Inner Mongolia Natural Science
   Foundation (grant. no. 2017MS08118) and the Inner Mongolia Medical
   University `Science and Technology Million Project' (grant no.
   YKD2016kjbw010).
CR Calvier L, 2017, CELL METAB, V25, P1118, DOI 10.1016/j.cmet.2017.03.011
   Chen DN, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0211 4
   Chen RJ, 2019, BIOCHEM BIOPH RES CO, V516, P666, DOI 10.1016/j.bbrc.2019.06.083
   Cui ZY, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 019 0670 6
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Gaffney Stomberg E, 2019, BIOL TRACE ELEM RES, V188, P26, DOI 10.1007/s12011 018 1583 8
   Ge DW, 2017, EUR REV MED PHARMACO, V21, P4784
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0893 x
   Guo L, 2019, J CELL PHYSIOL, V234, P581, DOI 10.1002/jcp.26788
   Guo M, 2017, MOL PSYCHIATR, V22, P1056, DOI 10.1038/mp.2016.225
   Han ZW, 2020, J CELL BIOCHEM, V121, P1664, DOI 10.1002/jcb.29401
   Henriksen TI, 2017, MOL METAB, V6, P770, DOI 10.1016/j.molmet.2017.04.006
   Hou Ning, 2012, Yichuan, V34, P326, DOI 10.3724/SP.J.1005.2012.00326
   Jiang N, 2018, OSTEOPOROSIS INT, V29, P1721, DOI 10.1007/s00198 018 4532 7
   Karbiener M, 2009, BIOCHEM BIOPH RES CO, V390, P247, DOI 10.1016/j.bbrc.2009.09.098
   Kida K, 2011, PHARM RES DORDR, V28, P2467, DOI 10.1007/s11095 011 0473 y
   Kini U., 2012, RADIONUCLIDE HYBRID, P29, DOI [DOI 10.1007/978 3 642 02400 9_2, 10.1007/978 3 642 02400 9_2]
   Lee JJ, 2012, ONCOGENE, V31, P3818, DOI 10.1038/onc.2011.543
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Li JY, 2019, EUR REV MED PHARMACO, V23, P6394, DOI 10.26355/eurrev_201908_18519
   Li KQ, 2020, MOL CELL PROBE, V49, DOI 10.1016/j.mcp.2019.101479
   Li P, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9669
   Li QQ, 2019, EUR REV MED PHARMACO, V23, P9207, DOI 10.26355/eurrev_201911_19412
   Li QL, 2017, Int J Nurs Sci, V4, P12, DOI [10.3390/ijms18050977, 10.1016/j.ijnss.2016.12.001]
   Li YF, 2017, CELL PHYSIOL BIOCHEM, V43, P602, DOI 10.1159/000480532
   Lin X, 2015, CLIN INTERV AGING, V10, P1017, DOI 10.2147/CIA.S54613
   Patel JJ, 2014, CELL BIOCHEM FUNCT, V32, P368, DOI 10.1002/cbf.3025
   Peng W, 2017, IMPLANT DENT, V26, P492, DOI 10.1097/ID.0000000000000637
   Seenprachawong K, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00543
   Shen GY, 2019, INT J BIOL SCI, V15, P2182, DOI 10.7150/ijbs.33490
   Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Stralberg F, 2017, J LEUKOCYTE BIOL, V101, P1233, DOI 10.1189/jlb.3A1016 433R
   Takigawa S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020240
   Tang JS, 2020, CELL BIOL INT, V44, P2532, DOI 10.1002/cbin.11460
   Tao JQ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0253 3
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wang HN, 2019, MOL MED REP, V20, P4271, DOI 10.3892/mmr.2019.10676
   Wang J, 2012, CELL RES, V22, P516, DOI 10.1038/cr.2011.132
   Wang YQ, 2019, J INT MED RES, V47, P6268, DOI 10.1177/0300060519870723
   Wu XQ, 2017, BIOMED PHARMACOTHER, V96, P299, DOI 10.1016/j.biopha.2017.08.060
   Xu JY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171109
   Xu WN, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00922
   Yang LY, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6623464
   Ye GZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1135 3
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhu C, 2016, CELL SIGNAL, V28, P989, DOI 10.1016/j.cellsig.2016.04.010
   Zhuang HL, 2016, CURR STEM CELL RES T, V11, P255, DOI 10.2174/1574888X10666150531173309
NR 49
TC 2
Z9 2
U1 0
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD FEB
PY 2022
VL 23
IS 2
DI 10.3892/etm.2021.11050
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA XX0LH
UT WOS:000735998400001
PM 34970350
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Park, JS
   Lim, YG
   Park, K
AF Park, Ji Sun
   Lim, Yong Geun
   Park, Kyeongsoon
TI Novel bidentate β glutamic acid based bone targeting agents for
   in vivo bone imaging
SO JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY
LA English
DT Article
DE beta Glutamic acid; Hydroxyapatite; Bone targeting imaging; Fluorescence
   imaging
ID SELECTIVE DRUG DELIVERY; POLYETHYLENE GLYCOL; CALCIUM; NANOPARTICLES;
   HYDROXYAPATITE; BISPHOSPHONATE; CALCIFICATION; FLUOROPHORES;
   OLIGOPEPTIDE; COMPLEXATION
AB Due to the unique calcium mineral composition of bone, bone targeting agents that coordinate with calcium or recognize hydroxyapatite (HAp) have been used to deliver drugs or as imaging agents for the therapy and diagnosis of bone related diseases. To date, various bisphosphonates or acidic oligopeptide based bone targeting agents have been explored. However, bisphosphonates can induce osteonecrosis, and acidic oligopeptide based molecules have not yet been validated in in vivo bone imaging. In this study, we newly designed beta glutamic acid (beta E) based bone targeting agents by conjugating mono beta E or tri beta E with polyethylene glycol (PEG) labeled with Cy7 dye (termed as beta E PEG Cy7 or beta EEE PEG Cy7). In vitro and in vivo studies showed that beta EEE PEG Cy7 binds more strongly to calcium containing particles and HAp than beta E PEG Cy7, leading to a clearer visualization of bone tissues and knee joints. Compared to alendronate conjugated PEG Cy7 (ALN PEG Cy7) as a positive control, beta EEE PEG Cy7 has lower binding affinity to both HAp and bone tissues, whereas it showed less cytotoxicity toward osteoblastic like cells. Although beta EEE PEG Cy7 has a lower performance of binding affinity to HAp and in vivo bone tissues, we believe that beta EEE PEG Cy7 with less toxicity can be used as a bone targeting agent for in vivo bone tissue imaging. (C) 2022 The Korean Society of Industrial and Engineering Chemistry. Published by Elsevier B.V. All rights reserved.
C1 [Park, Ji Sun; Lim, Yong Geun; Park, Kyeongsoon] Chung Ang Univ, Dept Syst Biotechnol, Anseong 17546, Gyeonggi, South Korea.
C3 Chung Ang University
RP Park, K (通讯作者)，Chung Ang Univ, Dept Syst Biotechnol, Anseong 17546, Gyeonggi, South Korea.
EM kspark1223@cau.ac.kr
RI Park, Kyeongsoon/AGQ 9584 2022
FU National Research Foundation of Korea [NRF 2018R1A2B3002001,
   2019M3A9E2066883]
FX This work was supported by the National Research Foundation of Korea
   [grant numbers NRF 2018R1A2B3002001, 2019M3A9E2066883].
CR Alexopoulos N, 2009, NAT REV CARDIOL, V6, P681, DOI 10.1038/nrcardio.2009.165
   Bao K, 2015, THERANOSTICS, V5, P609, DOI 10.7150/thno.11222
   Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215
   Beto Judith A, 2015, Clin Nutr Res, V4, P1, DOI 10.7762/cnr.2015.4.1.1
   Bhushan KR, 2007, ANGEW CHEM INT EDIT, V46, P7969, DOI 10.1002/anie.200701216
   Carafoli E, 2016, J BIOL CHEM, V291, P20849, DOI 10.1074/jbc.R116.735894
   Chen J, 2005, GREEN CHEM, V7, P64, DOI 10.1039/b413546f
   Chen S, 2012, RSC ADV, V2, P1820, DOI 10.1039/c1ra00527h
   Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338
   Choi E, 2021, J IND ENG CHEM, V94, P282, DOI 10.1016/j.jiec.2020.11.001
   Chu WJ, 2017, INT J PHARMACEUT, V516, P352, DOI 10.1016/j.ijpharm.2016.11.051
   de Miguel L, 2014, INT J PHARMACEUT, V460, P73, DOI 10.1016/j.ijpharm.2013.10.048
   Deiters A, 2003, J AM CHEM SOC, V125, P11782, DOI 10.1021/ja0370037
   Doherty TM, 2003, P NATL ACAD SCI USA, V100, P11201, DOI 10.1073/pnas.1932554100
   Feng Xu, 2009, Curr Chem Biol, V3, P189
   Gartner ZJ, 2009, P NATL ACAD SCI USA, V106, P4606, DOI 10.1073/pnas.0900717106
   Gilbert M, 2000, J BIOL CHEM, V275, P16213, DOI 10.1074/jbc.M001773200
   Harmatys KM, 2013, MOL PHARMACEUT, V10, P4263, DOI 10.1021/mp400357v
   He J, 2021, J IND ENG CHEM, V99, P134, DOI 10.1016/j.jiec.2021.04.021
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hyun H, 2014, ANGEW CHEM INT EDIT, V53, P10668, DOI 10.1002/anie.201404930
   Ishizaki J, 2009, J BONE MINER METAB, V27, P1, DOI 10.1007/s00774 008 0004 z
   Itoh D, 2002, J BIOMED MATER RES, V62, P292, DOI 10.1002/jbm.10338
   Iyer K.M., 2019, ANATOMY BONE FRACTUR, P1, DOI [10.1007/978 3 030 15089 1_1, DOI 10.1007/978 3 030 15089 1_1]
   Jung SY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094614
   KAO JPY, 1989, J BIOL CHEM, V264, P8179
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kawamoto EM, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00061
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim HS, 2021, J IND ENG CHEM, V104, P478, DOI 10.1016/j.jiec.2021.08.041
   Kubícek V, 2010, FUTURE MED CHEM, V2, P521, DOI 10.4155/FMC.09.162
   Kumar S, 2008, TETRAHEDRON, V64, P7097, DOI 10.1016/j.tet.2008.05.083
   Lee S, 2014, ACS NANO, V8, P2048, DOI 10.1021/nn406584y
   Lim YG, 2020, J IND ENG CHEM, V89, P442, DOI 10.1016/j.jiec.2020.06.018
   Min JS, 2021, INT J BIOL MACROMOL, V184, P20, DOI 10.1016/j.ijbiomac.2021.06.036
   Mroczka R, 2020, ELECTROCHIM ACTA, V339, DOI 10.1016/j.electacta.2020.135931
   Murphy MB, 2007, BIOMACROMOLECULES, V8, P2237, DOI 10.1021/bm070121s
   Ngo JT, 2009, NAT CHEM BIOL, V5, P715, DOI 10.1038/nchembio.200
   Ogawa K, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14149 7
   Park DJ, 2016, J MATER CHEM B, V4, P1219, DOI 10.1039/c5tb02338f
   Peacock M, 2010, CLIN J AM SOC NEPHRO, V5, pS23, DOI 10.2215/CJN.05910809
   Pes L, 2017, BIOORG MED CHEM LETT, V27, P1252, DOI 10.1016/j.bmcl.2017.01.059
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Stern PH, 2007, J CELL BIOCHEM, V101, P1087, DOI 10.1002/jcb.21311
   Su J, 2017, NANOMATERIALS BASEL, V7, DOI 10.3390/nano7060121
   Sun ST, 2016, BIOCONJUGATE CHEM, V27, P329, DOI 10.1021/acs.bioconjchem.5b00369
   Tran HDN, 2020, J IND ENG CHEM, V89, P58, DOI 10.1016/j.jiec.2020.06.017
   Weissleder R, 2001, NAT BIOTECHNOL, V19, P316, DOI 10.1038/86684
   Xie GM, 2017, J MATER SCI, V52, P10915, DOI 10.1007/s10853 017 1116 4
   Xu HS, 2013, EXPERT OPIN PHARMACO, V14, P435, DOI 10.1517/14656566.2013.775250
   Yamashita S, 2017, J CONTROL RELEASE, V262, P10, DOI 10.1016/j.jconrel.2017.07.018
   Yeo T, 2021, J IND ENG CHEM, V94, P343, DOI 10.1016/j.jiec.2020.11.004
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Yuan WH, 2020, BIOACT MATER, V5, P819, DOI 10.1016/j.bioactmat.2020.06.002
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
   Zhang KY, 2019, SMALL, V15, DOI 10.1002/smll.201900242
   Zhang YF, 2016, ANN JOINT, V1, DOI 10.21037/aoj.2016.11.04
   Zheng B, 2021, ORG PROCESS RES DEV, V25, P2270, DOI 10.1021/acs.oprd.1c00174
NR 59
TC 1
Z9 1
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1226 086X
EI 1876 794X
J9 J IND ENG CHEM
JI J. Ind. Eng. Chem.
PD JUN 25
PY 2022
VL 110
BP 471
EP 478
DI 10.1016/j.jiec.2022.03.021
EA MAY 2022
PG 8
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering
GA 6E5GE
UT WOS:000883407400001
DA 2025 08 17
ER

PT J
AU Su, H
   Yan, BH
   Wang, RC
   Li, ZC
   Xu, ZW
   Xue, HP
   Tan, GQ
AF Su, Hui
   Yan, Binghan
   Wang, Ruochong
   Li, Zhichao
   Xu, Zhanwang
   Xue, Haipeng
   Tan, Guoqing
TI Proteomic Analysis Based on TMT Regarding the Therapeutic Action of
   Rhizoma Drynariae on Rats in an Osteoporosis Model
SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
LA English
DT Article
DE Rhizoma drynariae; therapeutic action; TMT; rats; osteoporosis;
   proteomic analysis
ID BONE MINERAL DENSITY; OXIDATIVE STRESS; PARAOXONASE 1; SIGNALING
   PATHWAYS; DIFFERENTIATION; METABOLISM; OSTEOBLAST; ESTROGEN; GENE;
   ASSOCIATION
AB Background: Primary osteoporosis has increasingly become one of the risk factors affecting human health, and the clinical effect and action mechanism of traditional Chinese medicine in the treatment of primary osteoporosis have been widely studied. Previous studies have confirmed that in traditional Chinese medicine (TCM), Drynaria rhizome has a role in improving bone density. In this study, a tandem mass tag (TMT) based proteomic analysis was conducted to derive potential targets for Drynaria rhizome treatment in postmenopausal osteoporosis. Methods: The model group (OVX) and experimental group (OVXDF) for menopausal osteoporosis were established using the universally acknowledged ovariectomy method, and the OVXDF group was given 0.48g/kg Rhizoma Drynariae solution by gavage for 12 weeks. After 12 weeks, femurs of rats selected for this study were examined with a bone mineral density (BMD) test, Micro CT, ELISABiochemical testing, hematoxylin and eosin (HE) staining, and immunohistochemistry. A certain portion of the bone tissue was studied with a TMT based proteomic analysis and functional and pathway enrichment analysis. Finally, key target genes were selected for Western blotting for validation. Results: The comparison of the OVXDF and OVX groups indicated that Drynaria rhizome could improve bone density. In the TMT based proteomic analysis, the comparison of these two groups revealed a total of 126 differentially expressed proteins (DEPs), of which 62 were upregulated and 64 were downregulated. Further, by comparing the differential genes between the OVXDF and OVX groups and between the OVX and SHAM groups, we concluded that the 27 differential genes were significantly changed in the rats selected for the osteoporosis model after Drynaria rhizome intragastric administration. The gene ontology (GO) enrichment analysis of DEPs showed that molecular function was mainly involved in biological processes, such as glucose metabolism, carbohydrate metabolism, immune responses, and aging. A Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of DEPs revealed that multiple differential genes were enriched in the estrogen and peroxisome proliferator activated receptor (PPAR) signaling pathways. Relationships with nitrogen metabolism, glycerophospholipid metabolism, secretion systems, and tumor diseases were also observed. Western blotting was consistent with the analysis. Conclusions: We used TMT based proteomics to analyze the positive effects of TCM Drynaria rhizome, which can regulate related proteins through the unique roles of multiple mechanisms, targets, and pathways. This treatment approach can regulate oxidative stress, improve lipid metabolism, reduce the inflammatory response mechanism, and improve bone density. These benefits highlight the unique advantages of TCM in the treatment of primary osteoporosis.
C1 [Su, Hui; Yan, Binghan; Li, Zhichao; Xu, Zhanwang; Tan, Guoqing] Shandong Univ Tradit Chinese Med, Jinan, Shandong, Peoples R China.
   [Xu, Zhanwang; Xue, Haipeng; Tan, Guoqing] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan, Shandong, Peoples R China.
   [Wang, Ruochong] Beijing Univ Tradit Chinese Med, Beijing, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine; Beijing University of Chinese Medicine
RP Xue, HP; Tan, GQ (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan, Shandong, Peoples R China.
EM xzw15690271773@163.com; bonesh1027@163.com
OI Wang, ruochong/0009 0007 1635 0151; su, hui/0000 0003 4458 0193
FU National Natural Science Foundation of China [82174410]; Natural Science
   Foundation of Shandong Province [ZR2020KH011, ZR2020MH362]; Clinical
   Medical Science and Technology Innovation Plan of Jinan [202019148]
FX This study is funded by National Natural Science Foundation of China
   (Grant no. 82174410); Natural Science Foundation of Shandong Province
   (Grant no. ZR2020KH011); Natural Science Foundation of Shandong
   Province, (Grant no. ZR2020MH362) clinical Medical Science and
   Technology Innovation Plan of Jinan (Grant no. 202019148).
CR Andersen TL, 2004, BONE, V35, P1107, DOI 10.1016/j.bone.2004.06.019
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   Bartelt A, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0006 3
   Blanchard OL, 2015, FASEB J, V29, P1629, DOI 10.1096/fj.14 269043
   Bolognese MA, 2010, REV ENDOCR METAB DIS, V11, P253, DOI 10.1007/s11154 010 9137 1
   Chen Shun Qing, 2021, Zhongguo Zhong Yao Za Zhi, V46, P2737, DOI 10.19540/j.cnki.cjcmm.20210222.602
   Cheung CHY, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929 017 0343 y
   Cho E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113436
   Cifani P, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600079
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Cui J, 2013, TRENDS MOL MED, V19, P197, DOI 10.1016/j.molmed.2012.12.007
   Dujsikova H, 2010, Vnitr Lek, V56, P656
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Eren E, 2013, CHOLESTEROL, DOI 10.1155/2013/792090
   Eriksson R, 2019, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00781
   Feng H, 2020, CELL REP, V30, P3411, DOI 10.1016/j.celrep.2020.02.049
   Gambacciani M, 2014, PANMINERVA MED, V56, P115
   Giaginis C, 2007, FUND CLIN PHARMACOL, V21, P231, DOI 10.1111/j.1472 8206.2007.00486.x
   Guo Li juan, 2005, Zhonghua Yi Xue Za Zhi, V85, P734
   Haaber AB, 2000, INT J PANCREATOL, V27, P21, DOI 10.1385/IJGC:27:1:21
   Haas MJ, 2012, FREE RADICAL BIO MED, V52, P2161, DOI 10.1016/j.freeradbiomed.2012.04.009
   Hamel P, 2008, AM J PHYSIOL CELL PH, V294, pC1021, DOI 10.1152/ajpcell.00361.2007
   Han LF, 2015, NAT PROD RES, V29, P1703, DOI 10.1080/14786419.2014.998216
   Hopwood B, 2009, BONE, V44, P87, DOI 10.1016/j.bone.2008.08.120
   Hu LP, 2019, CLIN CANCER RES, V25, P1318, DOI 10.1158/1078 0432.CCR 18 2297
   Hu YM, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02842 3
   Hurley DL, 1997, MAYO CLIN PROC, V72, P943
   Jiang LJ, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.596783
   Lamichhane A. P., 2005, JNMA, Journal of the Nepal Medical Association, V44, P60
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Levine Jeffrey P, 2003, Curr Womens Health Rep, V3, P181
   Li AC, 2004, J LIPID RES, V45, P2161, DOI 10.1194/jlr.R400010 JLR200
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li F, 2006, PHARMAZIE, V61, P962
   Li J, 2019, BMB REP, V52, P572, DOI 10.5483/BMBRep.2019.52.9.076
   Li Y, 2018, CURR STEM CELL RES T, V13, P185, DOI 10.2174/1574888X12666171012141908
   Lin WH, 2001, HUM MOL GENET, V10, P1753, DOI 10.1093/hmg/10.17.1753
   Loomes KM, 2019, HEPATOLOGY, V69, P245, DOI 10.1002/hep.30196
   Mackinnon ES, 2010, J NUTRIGENET NUTRIGE, V3, P1, DOI 10.1159/000316636
   Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100
   Maruyama T, 2017, J BONE MINER RES, V32, P1816, DOI 10.1002/jbmr.3171
   Mazière C, 2013, BBA MOL BASIS DIS, V1832, P1756, DOI 10.1016/j.bbadis.2013.05.033
   Mendes ML, 2022, PROTEOMICS, V22, DOI 10.1002/pmic.202100330
   Moran CE, 1997, AM J GASTROENTEROL, V92, P867
   Mu PY, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.10050
   Niamh Clancy., 2023, The Veterinary Nurses Practical Guide to Small Animal Anaesthesia
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Qin Shucun, 2014, Cardiovascular & Hematological Disorders   Drug Targets, V14, P149
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755 8794 1 13
   Scheideler M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471 2164 9 340
   Shangguan YF, 2021, BIOCHEM PHARMACOL, V185, DOI 10.1016/j.bcp.2021.114414
   Shen Z, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.503524
   Shi SM, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.574151
   Sun B, 2016, HISTOL HISTOPATHOL, V31, P647, DOI 10.14670/HH 11 702
   Toptas B, 2013, MOL BIOL REP, V40, P6519, DOI 10.1007/s11033 013 2770 5
   Townsend SA, 2017, ALIMENT PHARM THER, V46, P494, DOI 10.1111/apt.14210
   Vnnen H. K., 1996, MATURITAS, V23, pS65, DOI [10.1016/0378 5122(96)01015 8, DOI 10.1016/0378 5122(96)01015 8]
   Vundavilli H, 2021, J THEOR BIOL, V519, DOI 10.1016/j.jtbi.2021.110647
   Wang XL, 2011, PHYTOMEDICINE, V18, P868, DOI 10.1016/j.phymed.2011.01.022
   Xu BE, 2019, LIFE SCI, V226, P47, DOI 10.1016/j.lfs.2019.04.013
   Xu WT, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04272 y
   Xu YY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.723759
   Yan L.I., 2019, Chin. J. Trad. Chin. Med. Pharm, V37, P279
   Yang Li, 2013, Zhong Yao Cai, V36, P1287
   Yang WS, 2003, OBES RES, V11, P586, DOI 10.1038/oby.2003.82
   Yilmaz N, 2013, CLIN LAB, V59, P597, DOI 10.7754/Clin.Lab.2012.120629
   Yilmaz N, 2009, AGING CLIN EXP RES, V21, P353
   Yoon WJ, 2013, J CELL PHYSIOL, V228, P2377, DOI 10.1002/jcp.24403
   Zheng XF, 2018, EXP THER MED, V16, P1807, DOI 10.3892/etm.2018.6356
NR 73
TC 2
Z9 2
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1386 2073
EI 1875 5402
J9 COMB CHEM HIGH T SCR
JI Comb. Chem. High Throughput Screen
PY 2024
VL 27
IS 15
BP 2223
EP 2238
DI 10.2174/0113862073261905231110061401
PG 16
WC Biochemical Research Methods; Chemistry, Applied; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA ZY9M8
UT WOS:001278964400014
PM 38099525
OA Green Published
DA 2025 08 17
ER

PT J
AU Lazar, AC
   Lacatus, R
   Pacurar, M
   Campian, RS
AF Lazar, Adela Cristina
   Lacatus, Radu
   Pacurar, Mariana
   Campian, Radu Septimiu
TI Studies Results Regarding Bisphosphonate Therapy in Dental Medicine
SO REVISTA DE CHIMIE
LA English
DT Article
DE bisphosphonates; osteonecrosis of the jaw; osteoporosis; creatinine;
   alkaline phosphatase
ID OSTEONECROSIS; OSTEOPOROSIS; MECHANISMS; JAWS
AB Osteoporosis is a health problem reported worldwide, which predominantly affects women in menopause. Since the percentage level in this population category is quite high, a treatment plan was elaborated to minimize the negative effects of this bone disease, to restore the general state of comfort and allow women to reintegrate in society.
C1 [Lazar, Adela Cristina; Campian, Radu Septimiu] Iuliu Hatieganu Univ Med & Pharm, Dept Oral Rehabil, Oral Hlth & Dent Off Management, 15 Victor Babes Str, Cluj Napoca 400012, Romania.
   [Lacatus, Radu] Univ Agr Sci & Vet Med, Dept Semiol & Med Imaging Ethopathol Radiol & Rad, 3 5 Manastur Str, Cluj Napoca 400372, Romania.
   [Pacurar, Mariana] Univ Med & Pharm, Fac Dent Med, 38 Gh Marinescu Str, Targu Mures 540139, Romania.
C3 Iuliu Hatieganu University of Medicine & Pharmacy; University of
   Agricultural Sciences & Veterinary Medicine Cluj Napoca; George Emil
   Palade University of Medicine, Pharmacy, Science, & Technology of Targu
   Mures
RP Lazar, AC (通讯作者)，Iuliu Hatieganu Univ Med & Pharm, Dept Oral Rehabil, Oral Hlth & Dent Off Management, 15 Victor Babes Str, Cluj Napoca 400012, Romania.
EM lazar_adela@yahoo.ro
RI Pacurar, Mariana/ABR 5190 2022; Lazar, ADELA/AAO 8270 2021; Radu,
   Lacatus/AAY 2055 2021
OI Radu, Lacatus/0000 0003 0491 9180
CR Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   COXON J. P., 2004, PROSTATE CANCER P D, P99
   FLEICH H, 1999, BISPHOSPHONATE BONE
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   GRAHAM R., BISPHOSPHONATES MODE
   Lazar AC, 2016, REV CHIM BUCHAREST, V67, P692
   Malden NJ, 2007, BRIT DENT J, V203, P93, DOI 10.1038/bdj.2007.636
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960 0760(03)00360 1
   Stepaniuk K, 2011, J VET DENT, V28, P277, DOI 10.1177/089875641102800413
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 16
TC 1
Z9 1
U1 0
U2 1
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R 77131, ROMANIA
SN 0034 7752
J9 REV CHIM BUCHAREST
JI Rev. Chim.
PD APR
PY 2018
VL 69
IS 4
BP 1018
EP 1022
PG 5
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering
GA GH2HN
UT WOS:000433223000056
DA 2025 08 17
ER

PT J
AU Zheng, XL
   Wang, WYJ
   Chen, SS
   Zuo, B
   Li, J
AF Zheng, Xueling
   Wang, Wanyuji
   Chen, Sisi
   Zuo, Bin
   Li, Jiao
TI Transplanted mesenchymal stromal cells are unable to migrate to the bone
   surface and subsequently improve osteogenesis in glucocorticoid induced
   osteoporosis
SO CYTOTHERAPY
LA English
DT Article
DE bone formation; MSC migration; osteoporosis; TGF B1
ID STEM CELLS; TGF BETA; EXTRACELLULAR MATRIX; MARROW; OSTEOBLASTOGENESIS;
   DIFFERENTIATION; OSTEOCLASTS; MECHANISMS; EXPRESSION; PREVENTS
AB Long term or high dose use of glucocorticoids causes bone loss and low bone formation. We previously demonstrated that dexamethasone (Dex) administration caused the shifted differentiation balance of mesenchymal stromal cells (MSCs) to favor adipogenic lineage over osteoblastic lineage, which is one of the key mechanisms for Dex induced osteoporosis (DIO). These findings indicate that supplementing functional allogeneic MSCs could be a therapeutic strategy for DIO. Here, we found that transplanting MSCs by intramedullary injection had little effect in promoting new bone formation. Fluorescent labeled lineage tracing revealed that 1 week after transplantation, green fluorescent protein (GFP) MSCs were found to migrate to the bone surface (BS) in control mice but not in DIO mice. As expected, GFP MSCs on the BS were mostly Runx2 positive; however, GFP MSCs located away from the BS failed to differentiate into osteoblasts. We further discovered that the levels of transforming growth factor beta 1 (TGF ,B1), one of the main chemokines for MSC migration, is significantly decreased in the bone marrow fluid of DIO mice, which is insufficient to direct MSC migration. Mechanistically, Dex inhibits TGF ,B1 expression by down regulating its promoter activity, which decreases bone matrix deposited TGF ,B1 as well as active TGF ,B1 released during osteoclast mediated bone resorption. This study indicates that blocking MSC migration in osteoporotic BM contributes to bone loss and suggests that MSC mobilization to the BS may be a promising target for treating osteoporosis.(c) 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
C1 [Zheng, Xueling; Wang, Wanyuji; Li, Jiao] Zunyi Med Univ, Dept Cell Biol, Zunyi, Guizhou, Peoples R China.
   [Chen, Sisi; Zuo, Bin] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Li, Jiao] Zunyi Med Univ, West Xuefu Rd, Zunyi, Guizhou, Peoples R China.
C3 Zunyi Medical University; Shanghai Jiao Tong University; Zunyi Medical
   University
RP Li, J (通讯作者)，Zunyi Med Univ, West Xuefu Rd, Zunyi, Guizhou, Peoples R China.
EM jiaoli@zmu.edu.cn
RI chen, sisi/KMA 2807 2024
FU National Natural Science Founda  tion of China [82060266, 81660376]
FX Funding Supported by grants from the National Natural Science Founda 
   tion of China (No. 82060266, 81660376) .
CR Åkesson K, 2003, B WORLD HEALTH ORGAN, V81, P657
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Bikle Daniel D, 2003, Gravit Space Biol Bull, V16, P45
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Chandra A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073553
   Chen XD, 2007, J BONE MINER RES, V22, P1943, DOI 10.1359/JBMR.070725
   Cosman F, 2009, ENDOCR PRACT, V15, P483, DOI 10.4158/EP08306.ORR1
   DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   De Becker A, 2016, WORLD J STEM CELLS, V8, P73, DOI 10.4252/wjsc.v8.i3.73
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   Fabian C, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0533 2
   Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253
   Götherström C, 2020, CURR OSTEOPOROS REP, V18, P337, DOI 10.1007/s11914 020 00594 3
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Haasters F, 2014, BIOCHEM BIOPH RES CO, V452, P118, DOI 10.1016/j.bbrc.2014.08.055
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Halder SK, 2005, NEOPLASIA, V7, P509, DOI 10.1593/neo.04640
   Halleux C., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P71
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kiernan J, 2017, STEM CELL TRANSL MED, V6, P1930, DOI 10.1002/sctm.17 0054
   Langrzyk A, 2018, ANTIOXID REDOX SIGN, V29, P169, DOI 10.1089/ars.2017.7159
   Li J, 2013, CELL DEATH DIS, V4, P832
   Li J, 2016, AGING DIS, V7, P514, DOI 10.14336/AD.2015.1206
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Nikolaou VS, 2009, INJURY, V40, P663, DOI 10.1016/j.injury.2008.10.035
   Oh JY, 2021, PROG RETIN EYE RES, V85, DOI 10.1016/j.preteyeres.2021.100967
   Ota K, 2013, BONE, V57, P68, DOI 10.1016/j.bone.2013.07.023
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rath D, 2016, THROMB RES, V144, P79, DOI 10.1016/j.thromres.2016.06.006
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Sanghani Kerai A, 2017, BONE JOINT RES, V6, P358, DOI 10.1302/2046 3758.66.BJR 2016 0259.R1
   Shen B, 2021, NATURE, V591, P438, DOI 10.1038/s41586 021 03298 5
   Su PH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082343
   Sui BD, 2019, BIOMATERIALS, V196, P18, DOI 10.1016/j.biomaterials.2017.10.046
   Sui BD, 2016, STEM CELL TRANSL MED, V5, P1238, DOI 10.5966/sctm.2015 0347
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tikhonova AN, 2019, NATURE, V569, P222, DOI 10.1038/s41586 019 1104 8
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   Yagi H, 2010, CELL TRANSPLANT, V19, P667, DOI 10.3727/096368910X508762
   Yao W, 2013, STEM CELLS, V31, P2003, DOI 10.1002/stem.1461
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang SJ, 2016, EUR REV MED PHARMACO, V20, P899
   Zhang T, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12338
   Zheng XL, 2021, EXP GERONTOL, V148, DOI 10.1016/j.exger.2021.111313
NR 52
TC 1
Z9 2
U1 1
U2 3
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1465 3249
EI 1477 2566
J9 CYTOTHERAPY
JI Cytotherapy
PD MAY
PY 2023
VL 25
IS 5
BP 472
EP 482
DI 10.1016/j.jcyt.2023.01.004
EA APR 2023
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA D6MB6
UT WOS:000969841100001
PM 36863932
DA 2025 08 17
ER

PT J
AU Wang, CD
   Yuan, WE
   Xiao, F
   Gan, YK
   Zhao, XT
   Zhai, ZJ
   Zhao, XY
   Zhao, C
   Cui, PL
   Jin, T
   Chen, XD
   Zhang, XL
AF Wang, Chuandong
   Yuan, Weien
   Xiao, Fei
   Gan, Yaokai
   Zhao, Xiaotian
   Zhai, Zhanjing
   Zhao, Xiaoying
   Zhao, Chen
   Cui, Penglei
   Jin, Tuo
   Chen, Xiaodong
   Zhang, Xiaoling
TI Biscarbamate Cross Linked Low Molecular Weight Polyethylenimine for
   Delivering Anti chordin siRNA into Human Mesenchymal Stem Cells for
   Improving Bone Regeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE low molecular weight polyethylenimine; Chordin; human bone mesenchymal
   stem cells; bone morphogenetic protein 2; osteogenesis
ID MORPHOGENETIC PROTEINS; IN VITRO; OSTEOGENIC DIFFERENTIATION; RNA
   INTERFERENCE; GENE DELIVERY; NOGGIN; CYTOTOXICITY; OSTEOBLASTS;
   INHIBITION; EFFICIENCY
AB Small interfering RNA (siRNA) provides a rapid solution for drug design and provides new methods to develop customizable medicines. Polyethyleneimine 25 kDa (PEI25kDa) is an effective transfection agent used in siRNA delivery. However, the lack of degradable linkage causes undesirable toxicity, hindering its clinical application. We designed a low molecular weight cross linked polyethylenimine named PEI Et (Mn: 1220, Mw: 2895) by using degradable ethylene biscarbamate linkage with lower cytotoxicity and higher knockdown efficiency than PEI25kDa in delivery Chordin siRNA to human bone mesenchymal stem cells (hBMSCs). Suppression of Chordin by using anti Chordin siRNA delivered by PEI Et improved bone regeneration in vitro and in vivo associated with the bone morphogenetic protein 2 (BMP 2) mediated smad1/5/8 signaling pathway. Results of this study suggest that Chordin siRNA can be potentially used to improve osteogenesis associated with the BMP 2 mediated Smad1/5/8 signaling pathway and biodegradable biscarbamate cross linked low molecular weight polyethylenimine (PEI Et) is a therapeutically feasible carrier material to deliver anti Chordin siRNA to hBMSCs.
C1 [Wang, Chuandong; Xiao, Fei; Cui, Penglei; Chen, Xiaodong; Zhang, Xiaoling] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Yuan, Weien; Zhao, Xiaotian; Jin, Tuo] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai, Peoples R China.
   [Gan, Yaokai; Zhai, Zhanjing] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implant, Dept Orthopaed Surg,Sch Med, Shanghai, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China.
   [Zhao, Chen] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Orthopaed, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of
   Sciences; Shanghai Jiao Tong University
RP Zhang, XL (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.; Zhang, XL (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China.; Zhang, XL (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China.
EM xlzhang@shsmu.edu.cn
RI Zhang, Xiaoling/J 1666 2016; Chen, Xiao Dong/ADG 8612 2022
OI Zhang, Xiaoling/0000 0002 0134 1347; 
FU National Natural Science Foundation of China [81190133, 81401844];
   Chinese Academy of Sciences [XDA01030502]; Science and Technology
   Commission of Shanghai [14431900900, 15411951100]; Shanghai Municipal
   Commission of Health and Family Planning [2013ZYJB0501]; Shanghai Jiao
   Tong University Medicine engineering cooperation program [YG2014QN04];
   Morning Star Young Scholars Program of Shanghai Jiao Tong University
   SMC Morningstar Young Scholars [2013SMC A 6]; key discipline
   construction fund of Shanghai education commission [J50206]
FX This work was supported by grants from National Natural Science
   Foundation of China (No. 81190133 and 81401844), Chinese Academy of
   Sciences (No. XDA01030502), Science and Technology Commission of
   Shanghai (No. 14431900900 and 15411951100), Shanghai Municipal
   Commission of Health and Family Planning (No. 2013ZYJB0501), Shanghai
   Jiao Tong University Medicine engineering cooperation program
   (YG2014QN04), Morning Star Young Scholars Program of Shanghai Jiao Tong
   University SMC Morningstar Young Scholars (A type) (2013SMC A 6) and key
   discipline construction fund of Shanghai education commission (J50206).
CR Albers CE, 2012, BONE, V51, P401, DOI 10.1016/j.bone.2012.06.020
   Argintar E, 2011, INJURY, V42, P730, DOI 10.1016/j.injury.2010.11.016
   Aspenberg P, 2001, J BONE MINER RES, V16, P497, DOI 10.1359/jbmr.2001.16.3.497
   Axelrad TW, 2009, CYTOKINE GROWTH F R, V20, P481, DOI 10.1016/j.cytogfr.2009.10.003
   Bernatik O, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00047
   Chen C, 2012, J CELL BIOCHEM, V113, P3672, DOI 10.1002/jcb.24240
   Duan SY, 2012, ANGEW CHEM INT EDIT, V51, P7938, DOI 10.1002/anie.201201793
   Dunlap DD, 1997, NUCLEIC ACIDS RES, V25, P3095, DOI 10.1093/nar/25.15.3095
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459
   Hinsenkamp M, 2015, INT ORTHOP, V39, P137, DOI 10.1007/s00264 014 2562 0
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Kloen P, 2012, BONE, V51, P59, DOI 10.1016/j.bone.2012.03.032
   Kwong FNK, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2436
   Larraín J, 2000, DEVELOPMENT, V127, P821
   Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092 8674(00)80132 4
   Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936
   Schneider H, 2014, TISSUE ENG PT A, V20, P335, DOI [10.1089/ten.tea.2012.0563, 10.1089/ten.TEA.2012.0563]
   Takayama K, 2009, J BONE MINER METAB, V27, P402, DOI 10.1007/s00774 009 0054 x
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Wang YQ, 2012, INT J NANOMED, V7, P693, DOI 10.2147/IJN.S27849
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Xiang SN, 2012, BIOMATERIALS, V33, P6520, DOI 10.1016/j.biomaterials.2012.05.044
   Yamamoto K, 2015, P NATL ACAD SCI USA, V112, P6152, DOI 10.1073/pnas.1420713112
NR 24
TC 11
Z9 11
U1 0
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 28
PY 2017
VL 8
AR 572
DI 10.3389/fphar.2017.00572
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FE9NZ
UT WOS:000408531700001
PM 28970797
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ren, MX
   Li, YZ
   Zhang, H
   Li, LJ
   He, P
   Ji, P
   Yang, S
AF Ren, Mingxing
   Li, Yuzhou
   Zhang, He
   Li, Lingjie
   He, Ping
   Ji, Ping
   Yang, Sheng
TI An oligopeptide/aptamer conjugated dendrimer based nanocarrier for
   dual targeting delivery to bone
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
AB Bone targeting is one of the most potentially valuable therapeutic methods for medically treating bone diseases, such as osteoarthritis, osteoporosis, nonunion bone defects, bone cancer, and myeloma related bone disease, but its efficacy remains a challenge due to unfavorable bone biodistribution, off target effects, and the lack of cell specificity. To address these problems, we synthesized a new dual targeting nanocarrier for delivery to bone by covalently modifying the G4.0 PAMAM dendrimer with the C11 peptide and the CH6 aptamer (CH6 PAMAM C11). The molecular structure was confirmed using H 1 NMR and FT IR spectroscopy. CLSM results showed that the novel nanocarrier could successfully accumulate in the targeted cells, mineralized areas and tissues. DLS and TEM demonstrated that CH6 PAMAM C11 was approximately 40 50 nm in diameter. In vitro targeting experiments confirmed that the C11 ligand had a high affinity for HAP, while the CH6 aptamer had a high affinity for osteoblasts. The in vivo biodistribution analysis showed that CH6 PAMAM C11 could rapidly accumulate in bone within 4 h and 12 h and then deliver drugs to sites of osteoblast activity. The components of CH6 PAMAM C11 were well excreted via the kidneys. The accumulation of many more CH6 PAMAM C11 dual targeting nanocarriers than single targeting nanocarriers was observed in the periosteal layer of the rat skull, along with aggregation at sites of osteoblast activity. All of these results indicate that CH6 PAMAM C11 may be a promising nanocarrier for the delivery of drugs to bone, particularly for the treatment of osteoporosis, and our research strategy may serve as a reference for research in targeted drug, small molecule drug and nucleic acid delivery.
C1 [Ren, Mingxing; Li, Yuzhou; Zhang, He; Li, Lingjie; He, Ping; Ji, Ping; Yang, Sheng] Chongqing Med Univ, Coll Stomatol, 426 Songshibei Rd, Chongqing 401147, Peoples R China.
   [Ren, Mingxing; Li, Yuzhou; Zhang, He; Li, Lingjie; He, Ping; Ji, Ping; Yang, Sheng] Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing, Peoples R China.
   [Ren, Mingxing; Li, Yuzhou; Zhang, He; Li, Lingjie; He, Ping; Ji, Ping; Yang, Sheng] Chongqing Municipal Key Lab Oral Biomed Engn High, Chongqing, Peoples R China.
C3 Chongqing Medical University
RP Yang, S (通讯作者)，Chongqing Med Univ, Coll Stomatol, 426 Songshibei Rd, Chongqing 401147, Peoples R China.; Yang, S (通讯作者)，Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing, Peoples R China.; Yang, S (通讯作者)，Chongqing Municipal Key Lab Oral Biomed Engn High, Chongqing, Peoples R China.
EM ysdentist@hospital.cqmu.edu.cn
RI ; He, Ping/NYS 5771 2025; Li, Lingjie/HZL 4635 2023
OI Li, Yuzhou/0000 0003 1768 1140; 
FU National Natural Science Foundation of China [81500894, 81901057]; Basic
   Research and Frontier Exploration Grant of Chongqing Science and
   Technology Commission (the Natural Science Foundation of Chongqing)
   [cstc2019jcyj msxmX0366]; Scientific and Technological Research Program
   of Chongqing Municipal Education Commission [KJQN201900441]; Major
   Program of Chongqing Yuzhong District [20190103]; Chongqing Postgraduate
   Tutor Team Construction Project [dstd201806]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81500894 and 81901057), the Basic Research and Frontier
   Exploration Grant of Chongqing Science and Technology Commission (the
   Natural Science Foundation of Chongqing, Grant No.
   cstc2019jcyj msxmX0366), the Scientific and Technological Research
   Program of Chongqing Municipal Education Commission (Grant No.
   KJQN201900441), the Major Program of Chongqing Yuzhong District (Grant
   No. 20190103), and the Chongqing Postgraduate Tutor Team Construction
   Project (Grant No. dstd201806).
CR Ardjomandi N, 2013, NUCLEIC ACID THER, V23, P44, DOI 10.1089/nat.2012.0349
   Arnsdorf EJ, 2009, TISSUE ENG PT A, V15, P2637, DOI 10.1089/ten.TEA.2008.0244
   Chen QC, 2018, ACS APPL MATER INTER, V10, P23700, DOI 10.1021/acsami.8b08606
   Dorozhkin S. V., 2017, Morphologie, V101, P125, DOI 10.1016/j.morpho.2017.03.007
   Field LD, 2015, ACCOUNTS CHEM RES, V48, P1380, DOI 10.1021/ar500449v
   FLEISCH H, 1987, BONE, V8, pS23
   Fujisawa R, 1996, BBA PROTEIN STRUCT M, V1292, P53, DOI 10.1016/0167 4838(95)00190 5
   Geiger BC, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat8800
   GIBSON CW, 1991, BIOCHEM BIOPH RES CO, V174, P1306, DOI 10.1016/0006 291X(91)91564 S
   Guo Q, 2020, J CONTROL RELEASE, V320, P347, DOI 10.1016/j.jconrel.2020.01.039
   HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hutmacher DW, 2003, TISSUE ENG, V9, pS45, DOI 10.1089/10763270360696978
   Iliuk AB, 2011, ANAL CHEM, V83, P4440, DOI 10.1021/ac201057w
   Itoh D, 2002, J BIOMED MATER RES, V62, P292, DOI 10.1002/jbm.10338
   Jasmine MJ, 2010, J PHYS CHEM B, V114, P7735, DOI 10.1021/jp100837h
   Kamada H, 2003, NAT BIOTECHNOL, V21, P399, DOI 10.1038/nbt798
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kibria G, 2011, J CONTROL RELEASE, V153, P141, DOI 10.1016/j.jconrel.2011.03.012
   Kinghorn AB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122516
   Le Norcy E, 2011, J DENT RES, V90, P1091, DOI 10.1177/0022034511411301
   Lee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/nnano.2012.73, 10.1038/NNANO.2012.73]
   Levine RM, 2017, J CONTROL RELEASE, V251, P24, DOI 10.1016/j.jconrel.2017.02.017
   Li XC, 2020, CANCER LETT, V489, P163, DOI 10.1016/j.canlet.2020.06.017
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Luong D, 2016, ACTA BIOMATER, V43, P14, DOI 10.1016/j.actbio.2016.07.015
   McCarthy I, 2006, J BONE JOINT SURG AM, V88A, P4, DOI 10.2106/JBJS.F.00890
   Mecke A, 2005, LANGMUIR, V21, P10348, DOI 10.1021/la050629l
   Mendes LP, 2017, MOLECULES, V22, DOI 10.3390/molecules22091401
   Nishida H, 2018, HEMATOL REP, V10, P11, DOI 10.4081/hr.2018.7401
   Ogawa K, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14149 7
   Paolino D, 2015, J MATER CHEM B, V3, P250, DOI 10.1039/c4tb00955j
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Saraswathy M, 2015, COLLOID SURFACE B, V126, P590, DOI 10.1016/j.colsurfb.2014.12.042
   Schäfer R, 2007, ROFO FORTSCHR RONTG, V179, P1009, DOI 10.1055/s 2007 963409
   Shaw WJ, 2008, BIOPHYS J, V94, P3247, DOI 10.1529/biophysj.107.119636
   Sun WT, 2016, LANGMUIR, V32, P9237, DOI 10.1021/acs.langmuir.6b02228
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Takara K, 2012, J CONTROL RELEASE, V162, P225, DOI 10.1016/j.jconrel.2012.06.019
   TALMAGE RV, 1970, AM J ANAT, V129, P467, DOI 10.1002/aja.1001290408
   Terpos E, 2018, METABOLISM, V80, P80, DOI 10.1016/j.metabol.2017.11.012
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Wang YC, 2017, ACS NANO, V11, P9445, DOI 10.1021/acsnano.7b05103
   Wartiovaara J, 2004, J CLIN INVEST, V114, P1475, DOI 10.1172/JCI200422562
   Xiong L, 2015, SMALL, V11, P5919, DOI 10.1002/smll.201501056
   Yamamoto Y, 2004, J CONTROL RELEASE, V95, P229, DOI 10.1016/j.jconrel.2003.11.017
   Yamashita S, 2017, J CONTROL RELEASE, V262, P10, DOI 10.1016/j.jconrel.2017.07.018
   Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223 009 9312 0
   Yee AJ, 2018, FUTURE ONCOL, V14, P195, DOI 10.2217/fon 2017 0403
   Yoshimi Y, 2016, J PERIODONTOL, V87, P820, DOI 10.1902/jop.2016.150507
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
NR 53
TC 35
Z9 37
U1 4
U2 66
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD MAR 28
PY 2021
VL 9
IS 12
BP 2831
EP 2844
DI 10.1039/d0tb02926b
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA RG8DQ
UT WOS:000635763800004
PM 33704322
DA 2025 08 17
ER

PT J
AU Thamake, SI
   Raut, SL
   Gryczynski, Z
   Ranjan, AP
   Vishwanatha, JK
AF Thamake, Sanjay I.
   Raut, Sangram L.
   Gryczynski, Zygmunt
   Ranjan, Amalendu P.
   Vishwanatha, Jamboor K.
TI Alendronate coated poly lactic co glycolic acid (PLGA) nanoparticles for
   active targeting of metastatic breast cancer
SO BIOMATERIALS
LA English
DT Article
DE Alendronate; Curcumin; Bortezomib; Breast cancer; Nanoparticles; Bone
   targeting
ID HUMAN MULTIPLE MYELOMA; DRUG DELIVERY; POLY(D,L LACTIDE CO GLYCOLIDE)
   NANOPARTICLES; IN VITRO; NILE RED; BONE; CURCUMIN; BORTEZOMIB; THERAPY;
   BISPHOSPHONATES
AB Delivery of therapeutic agents to bone is crucial in several diseases such as osteoporosis, Paget's disease, myeloproliferative diseases, multiple myeloma as well as skeletal metastasizing cancers. Prevention of cancer growth and lowering the cancer induced bone resorption is important in the treatment of bone metastasizing cancers. Keeping in mind the low diffusivity and availability of cell surface targets on cancer cells, we designed a targeted system to deliver chemotherapeutic agents to the bone microenvironment as an approach to tissue targeting using alendronate (Aln). We co encapsulated curcumin and bortezomib in the PLGA nanoparticles to further enhance the therapeutic efficiency and overall clinical outcome. These multifunctional nanoparticles were characterized for particle size, morphology and drug encapsulation. The particles were spherical with smooth surface and had particle size of 235 +/  70.30 nm. We validated the bone targeting ability of these nanoparticles in vitro. Curcumin and bortezomib are known to have synergistic effect in inhibition of growth of cancer; however there was no synergism in the anti osteoclastogenic activity of these agents. Surprisingly, curcumin by itself had significant inhibition of osteclastogenic activity. In vivo non invasive bioimaging showed higher localization of Aln coated nanoparticles to the bone compared to control groups, which was further confirmed by histological analysis. Aln coated nanoparticles protected bone resorption and decreased the rate of tumor growth as compared to control groups in an intraosseous model of bone metastasis. Our data show efficient attachment of Aln on the surface of nanoparticles which could be used as a drug carrier for preferential delivery of multiple therapeutic agents to bone microenvironment. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Vishwanatha, Jamboor K.] Univ N Texas Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Biomed Sci, Ft Worth, TX 76107 USA.
   [Gryczynski, Zygmunt; Ranjan, Amalendu P.; Vishwanatha, Jamboor K.] Univ N Texas Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA.
   [Vishwanatha, Jamboor K.] Univ N Texas Hlth Sci Ctr, Inst Canc Res, Ft Worth, TX 76107 USA.
C3 University of North Texas System; University of North Texas Health
   Science Center; University of North Texas System; University of North
   Texas Health Science Center; University of North Texas System;
   University of North Texas Health Science Center
RP Vishwanatha, JK (通讯作者)，Univ N Texas Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Biomed Sci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.
EM jamboor.vishwanatha@unthsc.edu
RI ; Raut, Sangram/I 9788 2019; Ranjan, Amalendu/KCL 9296 2024
OI Raut, Sangram/0000 0002 1219 3968; Vishwanatha,
   Jamboor/0000 0002 0266 6020; 
FU Department of Defense (DoD) [W81XWH 10 1 0223]; SignPath Pharma Inc.
FX This research was partially supported by a Department of Defense (DoD)
   Breast Cancer Research Program (BCRP) predoctoral fellowship
   W81XWH 10 1 0223 (SIT) and SignPath Pharma Inc. Authors would like to
   thank A. Brun and I. Chang for technical help.
CR Alexis Frank, 2010, Handb Exp Pharmacol, P55, DOI 10.1007/978 3 642 00477 3_2
   Bachmeier BE, 2007, CELL PHYSIOL BIOCHEM, V19, P137, DOI 10.1159/000099202
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Braden A, 2007, J BIOMED NANOTECHNOL, V3, P148, DOI 10.1166/jbn.2007.010
   Cenni E, 2008, BIOMATERIALS, V29, P1400, DOI 10.1016/j.biomaterials.2007.12.022
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078 0432.CCR 07 1441
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Cocquyt V, 1999, J CLIN PHARMACOL, V39, P385, DOI 10.1177/00912709922007958
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Ferrer ML, 2005, J PHYS CHEM B, V109, P80, DOI 10.1021/jp047550u
   Gonzalez Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Janjan N, 2009, J PALLIAT MED, V12, P417, DOI 10.1089/jpm.2009.9633
   Jones MD, 2010, CLIN CANCER RES, V16, P4978, DOI 10.1158/1078 0432.CCR 09 3293
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kafka EL, 2008, J BIOMED NANOTECHNOL, V4, P196, DOI 10.1166/jbn.2008.018
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Lipton Allan, 2011, Clin Adv Hematol Oncol, V9, P42
   Lipton A, 2010, SEMIN ONCOL, V37, pS15, DOI 10.1053/j.seminoncol.2010.10.002
   Low S, 2012, ADV DRUG DELIV REV
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Mukerjee A, 2009, ANTICANCER RES, V29, P3867
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Okassa LN, 2007, EUR J PHARM BIOPHARM, V67, P31, DOI 10.1016/j.ejpb.2006.12.020
   Park J, 2008, MOL ONCOL, V2, P317, DOI 10.1016/j.molonc.2008.09.006
   Ranjan AP, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/29/295104
   Raut SL, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957 4484/21/39/395102
   Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625
   Russell RGG, 2007, BONE, V40, pS21, DOI 10.1016/j.bone.2007.03.002
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Shaikh J, 2009, EUR J PHARM SCI, V37, P223, DOI 10.1016/j.ejps.2009.02.019
   Sharma RA, 2001, CLIN CANCER RES, V7, P1894
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078 0432.CCR 04 0744
   Sung B, 2009, MOL CANCER THER, V8, P959, DOI 10.1158/1535 7163.MCT 08 0905
   Thamake SI, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/3/035101
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang GL, 2010, J DRUG TARGET, V18, P611, DOI 10.3109/10611861003622560
   Xu PS, 2009, MOL PHARMACEUT, V6, P190, DOI 10.1021/mp800137z
NR 41
TC 164
Z9 184
U1 1
U2 153
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 2012
VL 33
IS 29
BP 7164
EP 7173
DI 10.1016/j.biomaterials.2012.06.026
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 998VX
UT WOS:000308269600026
PM 22795543
DA 2025 08 17
ER

PT J
AU Lovell, S
   Zhang, LR
   Kryza, T
   Neodo, A
   Bock, N
   De Vita, E
   Williams, ED
   Engelsberger, E
   Xu, CY
   Bakker, AT
   Maneiro, M
   Tanaka, RJ
   Bevan, CL
   Clements, JA
   Tate, EW
AF Lovell, Scott
   Zhang, Leran
   Kryza, Thomas
   Neodo, Anna
   Bock, Nathalie
   De Vita, Elena
   Williams, Elizabeth D.
   Engelsberger, Elisabeth
   Xu, Congyi
   Bakker, Alexander T.
   Maneiro, Maria
   Tanaka, Reiko J.
   Bevan, Charlotte L.
   Clements, Judith A.
   Tate, Edward W.
TI A Suite of Activity Based Probes To Dissect the KLK Activome in
   Drug Resistant Prostate Cancer
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID KALLIKREIN RELATED PEPTIDASES; SUBSTRATE SPECIFICITY; ACTIVATION
   PROFILES; SERINE PROTEASES; ANTIGEN PSA; INHIBITORS; BONE; DESIGN;
   CELLS; PROLIFERATION
AB Kallikrein related peptidases (KLKs) are a family of secreted serine proteases, which form a network (the KLK activome) with an important role in proteolysis and signaling. In prostate cancer (PCa), increased KLK activity promotes tumor growth and metastasis through multiple biochemical pathways, and specific quantification and tracking of changes in the KLK activome could contribute to validation of KLKs as potential drug targets. Herein we report a technology platform based on novel activity based probes (ABPs) and inhibitors enabling simultaneous orthogonal analysis of KLK2, KLK3, and KLK14 activity in hormone responsive PCa cell lines and tumor homogenates. Importantly, we identifed a significant decoupling of KLK activity and abundance and suggest that KLK proteolysis should be considered as an additional parameter, along with the PSA blood test, for accurate PCa diagnosis and monitoring. Using selective inhibitors and multiplexed fluorescent activity based protein profiling (ABPP), we dissect the KLK activome in PCa cells and show that increased KLK14 activity leads to a migratory phenotype. Furthermore, using biotinylated ABPs, we show that active KLK molecules are secreted into the bone microenvironment by PCa cells following stimulation by osteoblasts suggesting KLK mediated signaling mechanisms could contribute to PCa metastasis to bone. Together our findings show that ABPP is a powerful approach to dissect dysregulation of the KLK activome as a promising and previously underappreciated therapeutic target in advanced PCa.
C1 [Lovell, Scott; Zhang, Leran; Neodo, Anna; De Vita, Elena; Engelsberger, Elisabeth; Xu, Congyi; Bakker, Alexander T.; Maneiro, Maria; Tate, Edward W.] Imperial Coll London, Dept Chem, London W12 0BZ, England.
   [Kryza, Thomas] Univ Queensland, Translat Res Inst, Mater Res Inst, Woolloongabba, Qld 4102, Australia.
   [Kryza, Thomas; Bock, Nathalie; Williams, Elizabeth D.; Clements, Judith A.] Queensland Univ Technol, Fac Hlth, Australian Prostate Canc Res Ctr Queensland APCRC, Inst Hlth & Biomed Innovat, Woolloongabba, Qld 4102, Australia.
   [Kryza, Thomas] Queensland Univ Technol, Fac Hlth, Sch Biomed Sci, Translat Res Inst, Woolloongabba, Qld 4102, Australia.
   [Tanaka, Reiko J.] Imperial Coll London, Dept Bioengn, London SW7 2AZ, England.
   [Bevan, Charlotte L.] Imperial Coll London, Hammersmith Hosp, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, London W12 0NN, England.
   [Tate, Edward W.] Francis Crick Inst, London NW1 1AT, England.
C3 Imperial College London; University of Queensland; Mater Research;
   Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); University of Queensland; Imperial College London;
   Imperial College London; Francis Crick Institute
RP Tate, EW (通讯作者)，Imperial Coll London, Dept Chem, London W12 0BZ, England.; Tate, EW (通讯作者)，Francis Crick Inst, London NW1 1AT, England.
EM e.tate@imperial.ac.uk
RI ; Kryza, Thomas/AAX 7681 2020; Lovell, Scott/KDO 2062 2024; Williams,
   Elizabeth/B 1538 2008; De Vita, Elena/AAV 3670 2021; Rey,
   Maria/ABH 9364 2020; WILLIAMS, ELIZABETH/NSV 3246 2025; Bevan,
   Charlotte/K 2276 2012; Tate, Edward/B 6654 2008
OI Kryza, Thomas/0000 0003 1668 8551; Zhang, Leran/0000 0002 1051 8132;
   Maneiro Rey, Maria/0000 0001 6229 9157; Williams,
   Elizabeth/0000 0002 3364 6655; Bock, Nathalie/0000 0001 9331 4698;
   Bevan, Charlotte/0000 0002 7533 0552; Lovell, Scott/0000 0002 9627 5679;
   De Vita, Elena/0000 0003 4707 8342; Neodo, Anna/0000 0001 9481 9292
FU EPSRC Centre for Doctoral Training in Physical Sciences Innovation in
   Chemical Biology for Bioindustry and Healthcare [EP/LO15498/1]; EPSRC
   Doctoral Prize fellowship; Xunta de Galicia; H2020 MSCA IF fellowship
   [890900]; Cancer Research UK [C24523/A25192]; Worldwide Cancer Research
   [19 0059]; Swiss National Science Foundation; CRUK Imperial Centre
   [CS24523/A25147]; Marie Curie Actions (MSCA) [890900] Funding Source:
   Marie Curie Actions (MSCA)
FX The authors thank L. Haigh (Department of Chemistry Mass Spectrometry
   Facility, Imperial College London) for assistance in acquiring
   high resolution mass spectrometry (HRMS) data. S.L. was supported by the
   EPSRC Centre for Doctoral Training in Physical Sciences Innovation in
   Chemical Biology for Bioindustry and Healthcare (Grant EP/LO15498/1) and
   an EPSRC Doctoral Prize fellowship. M.M. thanks the Xunta de Galicia for
   a postdoctoral fellowship. E.D.V. is supported by a H2020 MSCA IF
   fellowship (Grant 890900). L.Z. was supported by Cancer Research UK
   (Grant C24523/A25192). E.W.T. thanks Worldwide Cancer Research for
   support (Grant 19 0059). A.N. was supported by a postdoctoral mobility
   fellowship from the Swiss National Science Foundation. C.L.B.
   acknowledges infrastructure support from the CRUK Imperial Centre (Grant
   CS24523/A25147). The table of contents and abstract graphic was created
   with BioRender.com.
CR Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012
   Beaufort N, 2010, BIOL CHEM, V391, P581, DOI 10.1515/BC.2010.055
   Bender KO, 2015, J AM CHEM SOC, V137, P4771, DOI 10.1021/jacs.5b00315
   Bock N, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0049 8
   Body JJ, 2015, NAT REV UROL, V12, P340, DOI 10.1038/nrurol.2015.90
   Costello LC, 2004, PROSTATE CANCER P D, V7, P111, DOI 10.1038/sj.pcan.4500712
   Cumming AP, 2011, PROSTATE CANCER P D, V14, P286, DOI 10.1038/pcan.2011.34
   Dallas SL, 2005, J CELL PHYSIOL, V202, P361, DOI 10.1002/jcp.20147
   Darst BF, 2020, CANCER EPIDEM BIOMAR, V29, P1381, DOI 10.1158/1055 9965.EPI 19 1560
   de Bruin G, 2016, ANGEW CHEM INT EDIT, V55, P4199, DOI 10.1002/anie.201509092
   de Veer SJ, 2017, J INVEST DERMATOL, V137, P430, DOI 10.1016/j.jid.2016.09.017
   de Veer SJ, 2012, BIOL CHEM, V393, P331, DOI [10.1515/BC 2011 250, 10.1515/bc 2011 250]
   Eitelhuber AC, 2015, CHEM BIOL, V22, P129, DOI 10.1016/j.chembiol.2014.10.021
   Emami N, 2010, BIOL CHEM, V391, P85, DOI 10.1515/BC.2010.007
   Fuhrman Luck Ruth A, 2014, EJIFCC, V25, P269
   Furio L, 2014, J EXP MED, V211, P499, DOI 10.1084/jem.20131797
   Goettig P, 2010, BIOCHIMIE, V92, P1546, DOI 10.1016/j.biochi.2010.06.022
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008 5472.CAN 08 3795
   Iwamura M, 1996, UROLOGY, V48, P317, DOI 10.1016/S0090 4295(96)00182 3
   Kasparek P, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006566
   Kasperkiewicz P, 2017, J AM CHEM SOC, V139, P10115, DOI 10.1021/jacs.7b04394
   Kasperkiewicz P, 2017, FEBS J, V284, P1518, DOI 10.1111/febs.14001
   Kasperkiewicz P, 2014, P NATL ACAD SCI USA, V111, P2518, DOI 10.1073/pnas.1318548111
   KILLIAN CS, 1993, BIOCHEM BIOPH RES CO, V192, P940, DOI 10.1006/bbrc.1993.1506
   Kojtari A, 2014, J CHEM INF MODEL, V54, P2967, DOI 10.1021/ci500371c
   Kryza T, 2020, MOL ONCOL, V14, P105, DOI 10.1002/1878 0261.12587
   LeBeau AM, 2008, CHEM BIOL, V15, P665, DOI 10.1016/j.chembiol.2008.05.020
   LeBeau AM, 2009, BIOORGAN MED CHEM, V17, P4888, DOI 10.1016/j.bmc.2009.06.012
   Li N, 2013, NAT PROTOC, V8, P1155, DOI 10.1038/nprot.2013.065
   Lilja H, 2008, NAT REV CANCER, V8, P268, DOI 10.1038/nrc2351
   Lose F, 2012, BIOL CHEM, V393, P403, DOI 10.1515/hsz 2011 0268
   Lu Y, 2004, CLIN EXP METASTAS, V21, P399, DOI 10.1007/s10585 005 0056 6
   Malm J, 2000, PROSTATE, V45, P132, DOI 10.1002/1097 0045(20001001)45:2<132::AID PROS7>3.0.CO;2 3
   Maslanka M, 2019, PHARMACEUTICALS BASE, V12, DOI 10.3390/ph12020086
   Ménez R, 2008, J MOL BIOL, V376, P1021, DOI 10.1016/j.jmb.2007.11.052
   Mize GJ, 2008, MOL CANCER RES, V6, P1043, DOI 10.1158/1541 7786.MCR 08 0096
   Morova T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14644 y
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nadiminty N, 2006, CLIN CANCER RES, V12, P1420, DOI 10.1158/1078 0432.CCR 05 1849
   Nevedomskaya E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051359
   Nguyen DP, 2014, BJU INT, V113, P986, DOI 10.1111/bju.12452
   Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313
   Nguyen QT, 2013, NAT REV CANCER, V13, P653, DOI 10.1038/nrc3566
   Obiezu CV, 2005, CLIN CHEM, V51, P1432, DOI 10.1373/clinchem.2005.049692
   Ohler A, 2010, BIOL CHEM, V391, P455, DOI 10.1515/BC.2010.023
   Pascale M, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3617 6
   Poreba M, 2019, CELL DEATH DIFFER, V26, P229, DOI 10.1038/s41418 018 0110 y
   Poreba M, 2017, NAT PROTOC, V12, P2189, DOI 10.1038/nprot.2017.091
   Prassas I, 2015, NAT REV DRUG DISCOV, V14, P183, DOI 10.1038/nrd4534
   Rawlings ND, 2018, NUCLEIC ACIDS RES, V46, pD624, DOI 10.1093/nar/gkx1134
   Rice MA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00801
   Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470 2045(14)71205 7
   Serim S, 2015, ORG BIOMOL CHEM, V13, P2293, DOI 10.1039/c4ob02444c
   Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008 5472.CAN 04 2442
   Shaw JLV, 2007, CLIN CHEM, V53, P1423, DOI 10.1373/clinchem.2007.088104
   Shokoohmand A, 2019, BIOMATERIALS, V220, DOI 10.1016/j.biomaterials.2019.119402
   Singh P, 2009, PROTEINS, V77, P984, DOI 10.1002/prot.22524
   Skala W, 2014, J BIOL CHEM, V289, P34267, DOI 10.1074/jbc.M114.598201
   Sotiropoulou G, 2012, TRENDS PHARMACOL SCI, V33, P623, DOI 10.1016/j.tips.2012.09.005
   Sung SY, 2008, CANCER RES, V68, P9996, DOI 10.1158/0008 5472.CAN 08 2492
   Tanaka RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019895
   Theodorescu D, 2008, PROTEOM CLIN APPL, V2, P556, DOI 10.1002/prca.200780082
   van de Plassche MAT, 2020, J MED CHEM, V63, P3996, DOI 10.1021/acs.jmedchem.9b01879
   van Soom J, 2015, MEDCHEMCOMM, V6, P1954, DOI 10.1039/c5md00288e
   Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016
   Webb M, 2020, BIOTECHNIQUES, V68, P65, DOI 10.2144/btn 2019 0092
   Williams SA, 2010, PROSTATE, V70, P788, DOI 10.1002/pros.21111
   Wright MH, 2016, NAT PROD REP, V33, P681, DOI 10.1039/c6np00001k
   Yonou H, 2001, BIOCHEM BIOPH RES CO, V289, P1082, DOI 10.1006/bbrc.2001.6129
   Yonou H, 2007, PROSTATE, V67, P840, DOI 10.1002/pros.20574
   Yoon H, 2007, J BIOL CHEM, V282, P31852, DOI 10.1074/jbc.M705190200
   Yoon H, 2009, BIOL CHEM, V390, P373, DOI 10.1515/BC.2009.026
NR 73
TC 22
Z9 23
U1 2
U2 36
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002 7863
EI 1520 5126
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JUN 16
PY 2021
VL 143
IS 23
BP 8911
EP 8924
DI 10.1021/jacs.1c03950
EA JUN 2021
PG 14
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA SW1SF
UT WOS:000664300200048
PM 34085829
OA hybrid, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Dong, X
   He, LH
   Zang, XL
   He, Y
   An, JG
   Wu, BP
   Liu, XH
   Bi, HS
   Zhang, Y
   Xiao, E
AF Dong, Xian
   He, Linhai
   Zang, Xiaolong
   He, Yang
   An, Jingang
   Wu, Baoping
   Liu, Xinhua
   Bi, Hongsen
   Zhang, Yi
   Xiao, E.
TI Adipose Derived Stem Cells Promote Bone Coupling in
   Bisphosphonate Related Osteonecrosis of the Jaw by TGF β1
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE adipose derived mesenchymal stem cells; transforming growth factor
   beta1; zoledronic acid; bone remodeling; osteoclasts;
   bisphosphonate related osteonecrosis of the jaw (BRONJ)
ID GROWTH FACTOR BETA; TGF BETA; RESORPTION; THERAPY; OSTEOBLAST;
   MANAGEMENT; MIGRATION; DISEASE; REPAIR
AB This study aimed to investigate molecularly targeted therapy to revive bone remodeling and prevent BRONJ by local adipose derived stem cells (ADSCs) transplantation. Clinical samples of BRONJ and healthy jawbones were used to examine the bone coupling related cells and TGF beta 1 expression. Bone coupling related cells and TGF beta 1 expression were also assessed in BRONJ like animal model to confirm the results in clinical samples. ADSCs were locally administered in vivo and the therapeutic effects were evaluated by gross observation, radiological imaging, and histological examination. Furthermore, ADSCs conditioned medium (ADSCs CM) and neutralizing antibody were applied to assess the effects of ADSCs derived TGF beta 1 on restoring bone coupling in vivo. Osteoclast formation and resorption assays were performed to evaluate the effects of ADSCs derived TGF beta 1 on ZA treated pre osteoclasts. Cell migration was performed to assess the effects of ADSCs derived TGF beta 1 on patients' bone marrow stem cells (BMSCs). The number of osteoclasts, Runx2 positive bone lining cells (BLCs) and TGF beta 1 expression were decreased in BRONJ and animal model jaw bone samples. These reductions were significantly rescued and necrotic jawbone healing was effectively promoted by local ADSCs administration in BRONJ like animal models. Mechanistically, ADSCs CM mainly contributed to promoting bone coupling, while TGF beta 1 neutralizing antibody in the conditioned medium inhibited these effects. Besides, osteoclastogenesis and patients' BMSCs migration were also rescued by ADSCs derived TGF beta 1. Furthermore, bone resorption released bone matrix TGF beta 1, together with ADSCs derived TGF beta 1, synergistically contributed to rescuing BMSCs migration. Collectively, ADSCs promoted bone healing of BRONJ by TGF beta 1 activated osteoclastogenesis and BMSCs migration capacities.
C1 [Dong, Xian; He, Linhai; Zang, Xiaolong; He, Yang; An, Jingang; Zhang, Yi; Xiao, E.] Peking Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Beijing, Peoples R China.
   [He, Linhai] Peking Univ, Sch & Hosp Stomatol, Clin Div 1, Beijing, Peoples R China.
   [Wu, Baoping; Liu, Xinhua] First Peoples Hosp Jinzhong, Jinzhong, Peoples R China.
   [Bi, Hongsen] Peking Univ, Hosp 3, Dept Plast Surg, Beijing, Peoples R China.
C3 Peking University; Peking University; Shanxi Medical University; Peking
   University
RP Zhang, Y; Xiao, E (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Beijing, Peoples R China.
EM zhangyi2000@263.net; xiaoe1986@vip.163.com
FU National Natural Science Foundation of China [81371117]; Beijing Natural
   Science Foundation [7202234, 7192230]
FX This work was supported by a grant from National Natural Science
   Foundation of China (No. 81371117) and the Beijing Natural Science
   Foundation (Nos. 7202234 and 7192230).
CR Andersen TL, 2013, AM J PATHOL, V183, P235, DOI 10.1016/j.ajpath.2013.03.006
   Bateman ME, 2018, STEM CELLS, V36, P1311, DOI 10.1002/stem.2847
   Boskey AL, 2010, J DENT RES, V89, P1333, DOI 10.1177/0022034510377791
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Crane JL, 2014, J MOL MED, V92, P107, DOI 10.1007/s00109 013 1084 3
   Djouad F, 2003, BLOOD, V102, P3837, DOI 10.1182/blood 2003 04 1193
   Gnecchi Massimiliano, 2009, V482, P281, DOI 10.1007/978 1 59745 060 7_18
   Gong X, 2017, SCI REP UK, V7, DOI 10.1038/srep36129
   He LH, 2017, J DENT RES, V96, P539, DOI 10.1177/0022034517691507
   He LH, 2017, SCI REP UK, V7, DOI 10.1038/srep42385
   Kaibuchi N, 2016, ACTA BIOMATER, V42, P400, DOI 10.1016/j.actbio.2016.06.022
   Kasagi S, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 4
   Katagiri W, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12333
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Kim JS, 2006, BLOOD, V108, P1821, DOI 10.1182/blood 2005 10 009191
   Komatsu Y, 2016, INT J MOL MED, V38, P139, DOI 10.3892/ijmm.2016.2582
   Li YS, 2013, STEM CELLS DEV, V22, P2047, DOI 10.1089/scd.2012.0615
   Liang WN, 2016, MOL MED REP, V14, P3676, DOI 10.3892/mmr.2016.5715
   Liao L, 2017, THERANOSTICS, V7, P106, DOI 10.7150/thno.16911
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Pakyari M, 2013, ADV WOUND CARE, V2, P215, DOI 10.1089/wound.2012.0406
   Park YB, 2017, OSTEOARTHR CARTILAGE, V25, P570, DOI 10.1016/j.joca.2016.10.012
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Silva LF, 2016, ORAL MAXILLOFAC SURG, V20, P9, DOI 10.1007/s10006 015 0538 x
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Valeta Magara A, 2019, CANCER RES, V79, P3360, DOI 10.1158/0008 5472.CAN 17 2158
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yang MY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05401 1
   Zang XL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1277 y
NR 32
TC 10
Z9 14
U1 2
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD MAY 12
PY 2021
VL 9
AR 639590
DI 10.3389/fcell.2021.639590
PG 12
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA SH8HZ
UT WOS:000654374200001
PM 34055774
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Agnihotri, R
   Gaur, S
AF Agnihotri, Rupali
   Gaur, Sumit
TI Chemically modified tetracyclines: Novel therapeutic agents in the
   management of chronic periodontitis
SO INDIAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Chemically modified tetracyclines; host modulation; host response;
   periodontitis
ID RESPIRATORY DISTRESS SYNDROME; BONE RESORPTION; NITRIC OXIDE; RATS;
   COLLAGENASE; DOXYCYCLINE; MECHANISM; PERIODONTOPATHOGENS; COMBINATION;
   MINOCYCLINE
AB Chronic periodontitis is a complex infection initiated by gram negative bacteria which destroy the supporting structures of the tooth. Recently, it has been recognized that it is the host response to bacterial infection which causes greater destruction of the connective tissue elements, periodontal ligament and alveolar bone in periodontitis. This has led to the development of various host modulating approaches to target cells and their destructive mediators involved in tissue degradation. Chemically modified tetracyclines (CMTs) are derivatives of tetracycline group of drugs which lack antimicrobial action but have potent host modulating affects. They inhibit pathologically elevated matrix metal loproteinases, pro inflammtory cytokines and other destructive mediators. Bone resorption is also suppressed due to their combined anti proteinase and apoptotic affects on osteoblasts and osteoclasts, respectively. Development of resistant bacteria and gastrointestinal toxicity seen with parent tetracyclines is not produced by CMTs. Hence, CMTs are viewed as potential therapeutic agents in the management of chronic diseases like periodontitis that involve destruction of connective tissue and bone.
C1 [Agnihotri, Rupali] Manipal Univ, Manipal Coll Dent Sci, Dept Periodont, Manipal, Karnataka, India.
   [Gaur, Sumit] Manipal Univ, Manipal Coll Dent Sci, Dept Pedodont & Prevent Dent, Manipal, Karnataka, India.
C3 Manipal Academy of Higher Education (MAHE); Manipal Academy of Higher
   Education (MAHE)
RP Agnihotri, R (通讯作者)，Manipal Univ, Manipal Coll Dent Sci, Dept Periodont, Manipal, Karnataka, India.
EM get2rupali_agnihotri@yahoo.co.in
OI Gaur, Sumit/0000 0002 9342 5387; Agnihotri, Rupali/0000 0003 1964 2719
CR Amano S, 1997, J CELL PHYSIOL, V173, P301, DOI 10.1002/(SICI)1097 4652(199712)173:3<301::AID JCP1>3.0.CO;2 R
   [Anonymous], 1996, Ann Periodontol, V1, P926
   BIRKEDALHANSEN H, 1993, J PERIODONTOL, V64, P474, DOI 10.1902/jop.1993.64.5s.474
   Bord S, 1996, BONE, V19, P35, DOI 10.1016/8756 3282(96)00106 8
   Cazalis J, 2009, INFLAMMATION, V32, P130, DOI 10.1007/s10753 009 9111 9
   CHANG KM, 1994, J PERIODONTAL RES, V29, P242, DOI 10.1111/j.1600 0765.1994.tb01218.x
   Chapple ILC, 1997, J CLIN PERIODONTOL, V24, P287, DOI 10.1111/j.1600 051X.1997.tb00760.x
   DEWITT DL, 1993, AM J MED S2A, V95, P40, DOI DOI 10.1016/0002 9343(93)90396 7
   Dezube BJ, 2006, J CLIN ONCOL, V24, P1389, DOI 10.1200/JCO.2005.04.2614
   Golub L M, 1998, Adv Dent Res, V12, P12
   Golub L M, 1992, Curr Opin Dent, V2, P80
   GOLUB LM, 1987, J DENT RES, V66, P1310, DOI 10.1177/00220345870660080401
   Golub LM, 1997, INFLAMM RES, V46, P310, DOI 10.1007/s000110050193
   GOLUB LM, 1983, J PERIODONTAL RES, V18, P516, DOI 10.1111/j.1600 0765.1983.tb00388.x
   GOLUB LM, 1991, CRIT REV ORAL BIOL M, V2, P297, DOI 10.1177/10454411910020030201
   Golub LM, 2011, PHARMACOL RES, V63, P99, DOI 10.1016/j.phrs.2010.10.003
   GREENWALD RA, 1992, J RHEUMATOL, V19, P927
   Grenier D, 2002, J PERIODONTOL, V73, P79, DOI 10.1902/jop.2002.73.1.79
   Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053
   Holmes SG, 2004, BONE, V35, P471, DOI 10.1016/j.bone.2004.02.028
   Houde V, 2006, J PERIODONTOL, V77, P1371, DOI 10.1902/jop.2006.050419
   Karimbux NY, 1998, J PERIODONTOL, V69, P34, DOI 10.1902/jop.1998.69.1.34
   Kowashi Y, 1980, ODONTOLOGY, V15, P151
   Liu Y, 2002, ANTIMICROB AGENTS CH, V46, P1447, DOI 10.1128/AAC.46.5.1447 1454.2002
   Llavaneras A, 2001, J PERIODONTOL, V72, P1069, DOI 10.1902/jop.2001.72.8.1069
   Lokeshwar BL, 2011, PHARMACOL RES, V63, P146, DOI 10.1016/j.phrs.2010.11.003
   NATHAN C, 1994, J BIOL CHEM, V269, P13725
   Oringer RJ, 2002, J PERIODONTOL, V73, P835, DOI 10.1902/jop.2002.73.8.835
   Page RC, 1997, PERIODONTOL 2000, V14, P9, DOI 10.1111/j.1600 0757.1997.tb00189.x
   PERRY HD, 1985, ANN OPHTHALMOL, V17, P742
   Ramamurthy NS, 2002, J PERIODONTOL, V73, P726, DOI 10.1902/jop.2002.73.7.726
   RIFKIN BR, 1994, ANN NY ACAD SCI, V732, P165, DOI 10.1111/j.1749 6632.1994.tb24733.x
   Roy SK, 2011, PHARMACOL RES, V64, P580, DOI 10.1016/j.phrs.2011.06.012
   Ryan ME, 1999, ANN NY ACAD SCI, V878, P311, DOI 10.1111/j.1749 6632.1999.tb07692.x
   Ryan ME, 2000, PERIODONTOL 2000, V24, P226, DOI 10.1034/j.1600 0757.2000.2240111.x
   Sandler C, 2005, INFLAMM RES, V54, P304, DOI 10.1007/s00011 005 1358 5
   Sato T, 1997, J CELL SCI, V110, P589
   Steinberg J, 2005, SHOCK, V24, P348, DOI 10.1097/01.shk.0000180619.06317.2c
   Steinsvoll Svein, 2004, Microbial Ecology in Health and Disease, V16, P1, DOI 10.1080/08910600410026355
   Trachtman H, 1996, BIOCHEM BIOPH RES CO, V229, P243, DOI 10.1006/bbrc.1996.1787
   Vernillo A T, 1998, Adv Dent Res, V12, P56
   WHITE JE, 1989, LANCET, V1, P966
   YU Z, 1993, J PERIODONTAL RES, V28, P420, DOI 10.1111/jre.1993.28.6.420
   YU Z, 1992, BIOCHEM MED METAB B, V47, P10, DOI 10.1016/0885 4505(92)90003 H
NR 44
TC 14
Z9 15
U1 0
U2 14
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0253 7613
EI 1998 3751
J9 INDIAN J PHARMACOL
JI Indian J. Pharmacol.
PD MAR APR
PY 2012
VL 44
IS 2
BP 161
EP 167
DI 10.4103/0253 7613.93841
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 913FD
UT WOS:000301859900003
PM 22529468
OA Green Published
DA 2025 08 17
ER

PT J
AU Jiang, Q
   Nagano, K
   Moriishi, T
   Komori, H
   Sakane, C
   Matsuo, Y
   Zhang, ZG
   Nishimura, R
   Ito, K
   Qin, X
   Komori, T
AF Jiang, Qing
   Nagano, Kenichi
   Moriishi, Takeshi
   Komori, Hisato
   Sakane, Chiharu
   Matsuo, Yuki
   Zhang, Zhiguo
   Nishimura, Riko
   Ito, Kosei
   Qin, Xin
   Komori, Toshihisa
TI Roles of Sp7 in osteoblasts for the proliferation, differentiation, and
   osteocyte process formation
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Sp7; Osteoblast differentiation; Osteoblast proliferation; Osteocyte
   apoptosis; Osteocyte processes; Cortical porosity
ID BONE FORMATION; ESTROGEN; OSTERIX; EXPRESSION; RUNX2
AB Background: Zinc finger  containing transcription factor Osterix/Specificity protein  7 (Sp7) is an essential transcription factor for osteoblast differentiation. However, its functions in differentiated osteoblasts remain unclear and the effects of osteoblast specific Sp7 deletion on osteocytes have not been sufficiently studied. Methods: Sp7 floxneo/floxneo mice, in which Sp7 expression was 30 % of that in wild  type mice because of disturbed splicing by neo gene insertion, and osteoblast specific knockout ( Sp7 fl/fl; Col1a1  Cre ) mice using 2.3  kb Col1a1 enhanced green fluorescent protein (EGFP) Cre were examined by micro  computed tomography (micro  CT), bone histomorphometry, serum markers, and histological analyses. The expression of osteoblast and osteocyte marker genes was examined by real time reverse transcription (RT) PCR analysis. Osteoblastogenesis, osteoclastogenesis, and regulation of the expression of collagen type I alpha 1 chain ( Col1a1 ) were examined in primary osteoblasts. Results: Femoral trabecular bone volume was higher in female Sp7 floxneo/floxneo and Sp7 fl/fl; Col1a1  Cre mice than in the respective controls, but not in males. Bromodeoxyuridine (BrdU) positive osteoblastic cells were increased in male Sp7 fl/fl; Col1a1   Cre mice, and osteoblast number and the bone formation rate were increased in tibial trabecular bone in female Sp7 fl/fl; Col1a1  Cre mice, although osteoblast maturation was inhibited in female Sp7 fl/fl; Col1a1  Cre mice as shown by the increased expression of an immature osteoblast marker gene, secreted phosphoprotein 1 ( Spp1 ), and reduced expression of a mature osteoblast marker gene, bone gamma carboxyglutamate protein/bone gamma carboxyglutamate protein 2 ( Bglap/Bglap2 ). Furthermore, alkaline phosphatase activity was increased but mineralization was reduced in the culture of primary osteoblasts from Sp7 fl/fl; Col1a1  Cre mice. Therefore, the accumulated immature osteoblasts in Sp7 fl/fl; Col1a1  Cre mice was likely compensated for the inhibition of osteoblast maturation at different levels in males and females. Vertebral trabecular bone volume was lower in both male and female Sp7 fl/fl; Col1a1  Cre mice than in the controls and the osteoblast parameters and bone formation rate in females were lower in Sp7 fl/fl ; Col1a1  Cre mice than in Sp7 fl/fl mice, suggesting differential regulatory mechanisms in long bones and vertebrae. The femoral cortical bone was thin and porous in Sp7 floxneo/ floxneo and Sp7 fl/fl; Col1a1   Cre mice of both sexes, the number of canaliculi was reduced, and terminal deoxynucleotidyl transferase mediated dUTP nick end labelling (TUNEL) positive lacunae and the osteoclasts were increased, whereas the bone formation rate was similar in Sp7 fl/fl; Col1a1  Cre and Sp7 fl/fl mice. The serum levels of total procollagen type 1 N  terminal propeptide (P1NP), a marker for bone formation, were similar, while those of tartrate  resistant acid phosphatase 5b (TRAP5b), a marker for bone resorption, were higher in Sp7 fl/fl; Col1a1   Cre mice. Osteoblasts were less cuboidal, the expression of Col1a1 and Col1a1  EGFP Cre was lower in Sp7 fl/fl; Col1a1  Cre mice, and overexpression of Sp7 induced Col1a1 expression. Conclusions: Our studies indicated that Sp7 inhibits the proliferation of immature osteoblasts, induces osteoblast maturation and Col1a1 expression, and is required for osteocytes to acquire a sufficient number of processes for their survival, which prevents cortical porosity.
   The translational potential of this article: This study clarified the roles of Sp7 in differentiated osteoblasts in proliferarion, maturation, Col1a1 expression, and osteocyte process formation, which are required for targeting SP7 in the development of therapies for osteoporosis.
C1 [Jiang, Qing; Qin, Xin] Soochow Univ, Inst Orthopaed, Suzhou Med Coll, Suzhou 215006, Peoples R China.
   [Jiang, Qing; Komori, Hisato; Matsuo, Yuki; Ito, Kosei; Qin, Xin; Komori, Toshihisa] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, Nagasaki 8528588, Japan.
   [Nagano, Kenichi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Oral Pathol & Bone Metab, Nagasaki 8528588, Japan.
   [Moriishi, Takeshi; Matsuo, Yuki] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, Nagasaki 8528588, Japan.
   [Sakane, Chiharu] Nagasaki Univ, Res Ctr Biomed Models & Anim Welf, Grad Sch Biomed Sci, Nagasaki 8528588, Japan.
   [Zhang, Zhiguo] China Acad Chinese Med Sci, Inst Basic Theory Chinese Med, Beijing 100700, Peoples R China.
   [Nishimura, Riko] Osaka Univ, Grad Sch Dent, Dept Mol & Cellular Biochem, 1 8 Yamadaoka, Suita, Osaka 5650871, Japan.
C3 Soochow University   China; Nagasaki University; Nagasaki University;
   Nagasaki University; Nagasaki University; Institute of Basic Theory for
   Chinese Medicine, CACMS; China Academy of Chinese Medical Sciences;
   University of Osaka
RP Qin, X (通讯作者)，Soochow Univ, Inst Orthopaed, Suzhou Med Coll, Suzhou 215006, Peoples R China.; Qin, X; Komori, T (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, Nagasaki 8528588, Japan.
EM xqin@suda.edu.cn; komorit@nagasaki u.ac.jp
RI ; Nagano, Kenichi/AAH 3246 2019
OI Nagano, Kenichi/0000 0003 3145 4841; Zhang, Zhiguo/0000 0001 8626 8611;
   Ito, Kosei/0000 0002 8416 2466; Qin, Xin/0009 0009 0036 3972; 
FU Japanese Ministry of Education, Culture, Sports, Science and Technology,
   Japan [23H00440, 19K10056, 23K09120, 23K08591, 22K11805, 24K12356]; Key
   Laboratory of Orthopaedics of Suzhou [SZS2022017]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions (PAPD),
   China
FX This work was supported by grants from the Japanese Ministry of
   Education, Culture, Sports, Science and Technology, Japan to Toshihisa
   Komori (23H00440), Kenichi Nagano (19K10056), Takeshi Moriishi
   (23K09120), Hisato Komori (23K08591), Chiharu Sakane (22K11805), and
   Yuki Matsuo (24K12356), Key Laboratory of Orthopaedics of Suzhou
   (SZS2022017) to Qing Jiang and Xin Qin, and Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD), China to
   Qing Jiang and Xin Qin. We thank B. De Crombrugghe for the 2.3 kb Col1a1
   promoter, H. Kaneko for technical and secretarial assistances.
CR Baek WY, 2010, BONE, V46, P920, DOI 10.1016/j.bone.2009.12.007
   Baek WY, 2009, J BONE MINER RES, V24, P1055, DOI [10.1359/JBMR.081248, 10.1359/jbmr.081248]
   Cheung WY, 2016, J BONE MINER RES, V31, P890, DOI 10.1002/jbmr.2740
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   ERNST M, 1989, J STEROID BIOCHEM, V34, P279, DOI 10.1016/0022 4731(89)90092 7
   Fiscaletti M, 2018, BONE, V110, P66, DOI 10.1016/j.bone.2018.01.031
   Hojo H, 2016, DEV CELL, V37, P238, DOI 10.1016/j.devcel.2016.04.002
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   Kennedy OD, 2014, BONE, V64, P132, DOI 10.1016/j.bone.2014.03.049
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105776
   Komori T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122045
   Kusuzaki K, 2000, BONE, V27, P655, DOI 10.1016/S8756 3282(00)00383 5
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Ludwig K, 2022, BONE, V160, DOI 10.1016/j.bone.2022.116400
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   Moriishi T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063173
   Moriishi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040143
   Moriishi T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027487
   Moustafa A, 2012, OSTEOPOROSIS INT, V23, P1225, DOI 10.1007/s00198 011 1656 4
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishimura R, 2012, J BIOL CHEM, V287, P33179, DOI 10.1074/jbc.M111.337063
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Otani S, 2022, ONCOGENE, V41, P683, DOI 10.1038/s41388 021 02120 w
   Qin X, 2021, J BONE MINER RES, V36, P2081, DOI 10.1002/jbmr.4386
   Qin X, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009169
   Qin X, 2019, HUM MOL GENET, V28, P896, DOI 10.1093/hmg/ddy386
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   SCHEVEN BAA, 1992, BIOCHEM BIOPH RES CO, V186, P54, DOI 10.1016/S0006 291X(05)80774 0
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Sun J, 2023, NATURE, V621, P602, DOI 10.1038/s41586 023 06519 1
   Wang JLS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26571 7
   Wang JLS, 2023, CURR OSTEOPOROS REP, V21, P241, DOI 10.1007/s11914 023 00778 7
   Yoshida CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032364
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
   Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506
NR 38
TC 12
Z9 12
U1 2
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD JUL
PY 2024
VL 47
BP 161
EP 175
DI 10.1016/j.jot.2024.06.005
EA JUN 2024
PG 15
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA XE3S3
UT WOS:001259974300001
PM 39027344
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Song, LS
   Zhang, ZX
   Wang, Y
   Liu, Y
   Zhang, R
   Lu, LJ
AF Song, Liang Song
   Zhang, Zhi Xin
   Wang, Yang
   Liu, Yang
   Zhang, Rui
   Lu, Lai Jin
TI Effects of nano emulsion preparations of tocopherols and tocotrienols on
   oxidative stress and osteoblast differentiation
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article
DE nano emulsion; tocopherol; tocotrienol; osteoblast; oxidative stress
ID DRUG DELIVERY SYSTEM; VITAMIN E; ALPHA TOCOPHEROL; SIGNALING PATHWAYS;
   BONE FORMATION; DISEASE; SUPPLEMENTATION; BIOAVAILABILITY; OSTEOPOROSIS;
   INFLAMMATION
AB Tocopherols and tocotrienols are two groups of compounds in the vitamin E family, of which the tocopherols are widely used as antioxidant dietary supplements. Recent studies have shown mixed observations for tocopherol functions in bone homeostasis. We have evaluated the potency of suspension and nano emulsion formulation based delivery of different vitamin E family members in lipopolysaccharide (LPS) induced oxidative stress and osteoblast differentiation. Our results showed the both tocopherols and tocotrienols could reduce oxidative stress as evaluated by the levels of reactive oxygen species (ROS). Their effects were enhanced when applied in the nano emulsion mode of delivery due to increased bioavailability. In addition, our results showed that tocotrienols increased osteoblast differentiation, while tocopherols showed reduced osteoblast differentiation, which may be due to their differential effects on SMAD and p65 signaling. Together, these findings indicate that tocotrienols delivered through nano emulsion exhibit superior antioxidant properties and osteoblast differentiation, and could serve as a better alternative to tocopherol based vitamin E supplements.
C1 [Song, Liang Song; Zhang, Zhi Xin; Wang, Yang; Liu, Yang; Lu, Lai Jin] Jilin Univ, Hosp 1, Dept Hand & Foot Surg, Changchun 130021, Peoples R China.
   [Zhang, Rui] Gongzhuling City Cent Hosp, Dept Emergency, Jilin 136100, Peoples R China.
C3 Jilin University
RP Lu, LJ (通讯作者)，Jilin Univ, Hosp 1, Dept Hand & Foot Surg, Changchun 130021, Peoples R China.
EM lulaijin11@hotmail.com
RI lu, lu/HGA 0894 2022
CR Abdul Majeed S, 2015, LIFE SCI, V125, P42, DOI 10.1016/j.lfs.2014.12.012
   Abdul Majeed S, 2013, CURR DRUG TARGETS, V14, P1579, DOI 10.2174/13894501113149990193
   Ahsan H, 2014, NUTR METAB, V11, DOI 10.1186/1743 7075 11 52
   Anton N, 2011, PHARM RES DORDR, V28, P978, DOI 10.1007/s11095 010 0309 1
   Brigelius Flohé R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145
   Bunout D, 2000, EXPERT OPIN INV DRUG, V9, P2629, DOI 10.1517/13543784.9.11.2629
   Cerpnjak K, 2013, ACTA PHARMACEUT, V63, P427, DOI 10.2478/acph 2013 0040
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chin KY, 2015, DRUG DES DEV THER, V9, P2049, DOI 10.2147/DDDT.S79660
   Chin KY, 2013, CURR DRUG TARGETS, V14, P1533, DOI 10.2174/13894501113149990178
   Deng L, 2014, BONE, V67, P200, DOI 10.1016/j.bone.2014.07.006
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fujita K, 2012, NAT MED, V18, P589, DOI 10.1038/nm.2659
   Godbout JP, 2004, J NEUROIMMUNOL, V149, P101, DOI 10.1016/j.jneuroim.2003.12.017
   Ha H, 2011, BIOCHEM BIOPH RES CO, V406, P546, DOI 10.1016/j.bbrc.2011.02.085
   Hamidi MS, 2012, J BONE MINER RES, V27, P1368, DOI 10.1002/jbmr.1566
   Hayden RS, 2014, ADV FUNCT MATER, V24, P472, DOI 10.1002/adfm.201302210
   Hercz G, 2001, SEMIN DIALYSIS, V14, P55, DOI 10.1046/j.1525 139x.2001.00015.x
   Hippalgaonkar K, 2010, AAPS PHARMSCITECH, V11, P1526, DOI 10.1208/s12249 010 9526 5
   Hybertson BM, 2005, EXP LUNG RES, V31, P283, DOI 10.1080/01902140590918560
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Kasai S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132059
   Khan I, 2015, IET NANOBIOTECHNOL, V9, P396, DOI 10.1049/iet nbt.2014.0062
   Kontush A, 1996, J LIPID RES, V37, P1436
   Kuo F, 2008, INT J PHARMACEUT, V363, P206, DOI 10.1016/j.ijpharm.2008.07.022
   Li AG, 2015, MOL CELLS, V38, P941, DOI 10.14348/molcells.2015.2353
   Marie PJ, 2012, CURR OSTEOPOROS REP, V10, P190, DOI 10.1007/s11914 012 0109 0
   Mathur P, 2015, CLIN CARDIOL, V38, P570, DOI 10.1002/clc.22422
   Muhammad N, 2013, CLINICS, V68, P1338, DOI 10.6061/clinics/2013(10)08
   Mukherjee B, 2013, CURR PHARM BIOTECHNO, V14, P1221, DOI 10.2174/138920101415140804121008
   Niki E, 2012, ANN NUTR METAB, V61, P207, DOI 10.1159/000343106
   Nishio K, 2013, REDOX BIOL, V1, P97, DOI 10.1016/j.redox.2012.10.002
   Ochi H, 2015, GERONTOLOGY, V61, P319, DOI [10.1159/000366419, 10.115]
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Saremi A, 2010, AM J THER, V17, pE56, DOI 10.1097/MJT.0b013e31819cdc9a
   Shaw AT, 2016, SEMIN CELL DEV BIOL, V49, P2, DOI 10.1016/j.semcdb.2015.10.013
   Siddappa Ramakrishnaiah, 2007, Curr Stem Cell Res Ther, V2, P209, DOI 10.2174/157488807781696267
   Slater BJ, 2008, EXPERT OPIN BIOL TH, V8, P885, DOI 10.1517/14712598.8.7.885 
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Subramanian B, 2008, INT IMMUNOPHARMACOL, V8, P1533, DOI 10.1016/j.intimp.2008.06.009
   Subramanian B, 2012, BIOMATERIALS, V33, P8383, DOI 10.1016/j.biomaterials.2012.08.020
   Subramanian B, 2010, TISSUE ENG PT A, V16, P2821, DOI [10.1089/ten.tea.2009.0595, 10.1089/ten.TEA.2009.0595]
   Suntres ZE, 1996, SHOCK, V6, pS57, DOI 10.1097/00024382 199610001 00011
NR 45
TC 4
Z9 6
U1 1
U2 18
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354 4664
EI 1821 4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2017
VL 69
IS 1
BP 149
EP 156
DI 10.2298/ABS160208090S
PG 8
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA EO4ZN
UT WOS:000396702900016
OA gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Gao, L
   Li, SL
   Li, YK
AF Gao, Liu
   Li, Shi Lun
   Li, Yu Kun
TI Liraglutide Promotes the Osteogenic Differentiation in MC3T3 E1 Cells
   Via Regulating the Expression of Smad2/3 Through PI3K/Akt and
   Wnt/β Catenin Pathways
SO DNA AND CELL BIOLOGY
LA English
DT Article
DE liraglutide; glucagon like peptide 1 receptor; osteoblast
   differentiation; Smad2; 3;  catenin
ID PEPTIDE 1 RECEPTOR AGONIST; TGF BETA/SMAD; GLP 1; PROLIFERATION; TARGETS
AB Diabetes is a worldwide health problem with increasing prevalence. Some reports indicate the interplay between bone and glucose metabolism. The imbalance between bone resorption and formation resulted in the structural integrity and strength of bone. Glucagon like peptide 1 (GLP 1) and its agonists (Liraglutide) have an anabolic action on bone remodeling by stimulating osteoblast differentiation as well as increasing osteoblast longevity. However, the underlying mechanisms remain elusive. We detected the presence of GLP 1 receptor (GLP 1R) in MC3T3 E1 cells via immunocytochemistry assay. Alkaline phosphatase activity assay, alizarin red stain, quantitative real time polymerase chain reaction, and western blot were employed to detect the effect of Liraglutide on osteogenic differentiation. Liraglutide promoted the expression of GLP 1R in a dosage  and time dependent manner, and it enhanced the osteogenic differentiation in MC3T3 E1 cells. Liraglutide application improved the levels of Smad2/3 and p Smad2/3; however, the silencing of Smad2/3 blocked the osteogenic differentiation induced by Liraglutide. What is more, the application of PI3K and Wnt inhibitors inhibited the upregulation of Akt, p Akt,  catenin, Smad2/3, and p Smad2/3 induced by Liraglutide. Liraglutide facilitated the osteogenic differentiation via the regulation of Smad2/3 via PI3K/AKT and Wnt/ catenin pathways. These data revealed a new mechanism of Liraglutide inducing osteogenic differentiation and provided theory evidence to maintain normal bone metabolism during diabetes therapy.
C1 [Gao, Liu; Li, Yu Kun] Hebei Med Univ, Hosp 3, Dept Endocrinol, 139 Ziqiang Rd, Shijiazhuang 050000, Hebei, Peoples R China.
   [Li, Shi Lun] Key Orthopaed Biomech Lab Hebei Prov, Shijiazhuang, Hebei, Peoples R China.
C3 Hebei Medical University
RP Li, YK (通讯作者)，Hebei Med Univ, Hosp 3, Dept Endocrinol, 139 Ziqiang Rd, Shijiazhuang 050000, Hebei, Peoples R China.
EM yu_kun_li@126.com
RI gao, Liu/AAH 5970 2019
CR Aki S, 2015, J BIOL CHEM, V290, P6086, DOI 10.1074/jbc.M114.601484
   Aoyama E, 2014, INT J MOL MED, V34, P475, DOI 10.3892/ijmm.2014.1787
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Boyle JG, 2018, CLIN SCI, V132, P1699, DOI 10.1042/CS20171299
   Budi EH, 2017, TRENDS CELL BIOL, V27, P658, DOI 10.1016/j.tcb.2017.04.005
   Camkurt MA, 2018, HORM MOL BIOL CLIN I, V36, DOI 10.1515/hmbci 2018 0031
   Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008
   Chen L, 2018, BIOMED PHARMACOTHER, V101, P670, DOI 10.1016/j.biopha.2018.02.090
   Coulter AA, 2018, DRUGS, V78, P1113, DOI 10.1007/s40265 018 0946 y
   de Kroon LMG, 2017, SCI REP UK, V7, DOI 10.1038/srep43164
   Gallwitz Baptist, 2015, Eur Endocrinol, V11, P21, DOI 10.17925/EE.2015.11.01.21
   Gu YZ, 2018, J BIOMED MATER RES A, V106, P1851, DOI 10.1002/jbm.a.36388
   Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908
   Heo SY, 2018, CELL BIOCHEM FUNCT, V36, P137, DOI 10.1002/cbf.3325
   Hu B, 2017, PHARMAZIE, V72, P35, DOI 10.1691/ph.2017.6502
   Hu XK, 2016, MOL MED REP, V14, P3662, DOI 10.3892/mmr.2016.5729
   Iepsen EW, 2015, EXPERT REV CARDIOVAS, V13, P753, DOI 10.1586/14779072.2015.1054810
   Kazakos K, 2011, DIABETES RES CLIN PR, V93, pS32, DOI 10.1016/S0168 8227(11)70011 0
   Lambadiari V, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933 017 0646 z
   Li L, 2015, INT J MOL SCI, V16, P3188, DOI 10.3390/ijms16023188
   Liu HZ, 2016, J TOXICOL SCI, V41, P185, DOI 10.2131/jts.41.185
   Lu N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132744
   Luo GJ, 2016, BRIT J CLIN PHARMACO, V81, P78, DOI 10.1111/bcp.12777
   Mannucci E, 2015, CLIN CASES MINER BON, V12, P130, DOI 10.11138/ccmbm/2015.12.2.130
   Mansur SA, 2015, J CELL PHYSIOL, V230, P3009, DOI 10.1002/jcp.25033
   Nauck MA, 2018, DIABETES OBES METAB, V20, P5, DOI 10.1111/dom.13129
   Nuche Berenguer B, 2010, J CELL PHYSIOL, V225, P585, DOI 10.1002/jcp.22243
   Ramsey W, 2017, ADV EXP MED BIOL, V1033, P13, DOI 10.1007/978 3 319 66653 2_2
   Rizzo M, 2015, J CLIN ENDOCR METAB, V100, P603, DOI 10.1210/jc.2014 2291
   Russell Jones D, 2009, MOL CELL ENDOCRINOL, V297, P137, DOI 10.1016/j.mce.2008.11.018
   Ryan GJ, 2011, CLIN THER, V33, P793, DOI 10.1016/j.clinthera.2011.06.004
   Sanghani Kerai A, 2018, CURR STEM CELL RES T, V13, P369, DOI 10.2174/1574888X13666180410160511
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sun HX, 2015, J DIABETES, V7, P584, DOI 10.1111/1753 0407.12282
   Vellucci R, 2018, OSTEOPOROSIS INT, V29, P1477, DOI 10.1007/s00198 018 4476 y
   Vestergaard P, 2014, DIABETOLOGIA, V57, P2007, DOI 10.1007/s00125 014 3338 1
   Wu XL, 2018, MOL CELLS, V41, P234, DOI 10.14348/molcells.2018.2340
   Wu XL, 2017, EXP CELL RES, V360, P281, DOI 10.1016/j.yexcr.2017.09.018
   Yan XH, 2018, ACTA BIOCH BIOPH SIN, V50, P37, DOI 10.1093/abbs/gmx129
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yu JSL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8212
   Yu JM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03661 5
NR 42
TC 24
Z9 26
U1 3
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044 5498
EI 1557 7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD DEC 1
PY 2018
VL 37
IS 12
BP 1031
EP 1043
DI 10.1089/dna.2018.4397
EA NOV 2018
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA HD6BR
UT WOS:000449379300001
PM 30403540
DA 2025 08 17
ER

PT J
AU Chu, M
   Gao, T
   Zhang, X
   Kang, WL
   Feng, Y
   Cai, Z
   Wu, P
AF Chu, Man
   Gao, Ting
   Zhang, Xu
   Kang, Wulin
   Feng, Yu
   Cai, Zhe
   Wu, Ping
TI Elucidation of Potential Targets of San Miao San in the Treatment of
   Osteoarthritis Based on Network Pharmacology and Molecular Docking
   Analysis
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID NF KAPPA B; RHEUMATOID ARTHRITIS; IN VITRO; CHONDROCYTES; ACTIVATION;
   APOPTOSIS; LINGZHI; BONE; PAIN; SUPPLEMENTATION
AB Background. To examine the potential therapeutic targets of Chinese medicine formula San Miao San (SMS) in the treatment of osteoarthritis (OA), we analyzed the active compounds of SMS and key targets of OA and investigated the interacting pathways using network pharmacological approaches and molecular docking analysis. Methods. The active compounds of SMS and OA related targets were searched and screened by TCMSP, DrugBank, Genecards, OMIM, DisGeNet, TTD, and PharmGKB databases. Venn analysis and PPI were performed for evaluating the interaction of the targets. The topological analysis and molecular docking were used to confirm the subnetworks and binding affinity between active compounds and key targets, respectively. The GO and KEGG functional enrichment analysis for all targets of each subnetwork were conducted. Results. A total of 57 active compounds and 203 targets of SMS were identified by the TCMSP and DrugBank database, while 1791 OA related targets were collected from the Genecards, OMIM, DisGeNet, TTD, and PharmGKB databases. By Venn analysis, 108 intersection targets between SMS targets and OA targets were obtained. Most of these intersecting targets involve quercetin, kaempferol, and wogonin. Moreover, intersecting targets identified by PPI analysis were introduced into Cytoscape plug in CytoNCA for topological analysis. Hence, nine key targets of SMS for OA treatment were obtained. Furthermore, the potential binding conformations between active compounds and key targets were found through molecular docking analysis. According to the DAVID enrichment analysis, the main biological processes of SMS in the treatment of OA include oxidative stress, response to reactive oxygen species, and apoptotic signaling pathways. Finally, we found wogonin, the key compound in SMS, might play a pivotal role on Toll like receptor, IL 17, TNF, osteoclast differentiation, and apoptosis signaling pathways through interacting with four key targets. Conclusions. Therefore, this study elucidated the potential active compounds and key targets of SMS in the treatment of OA based on network pharmacology.
C1 [Chu, Man; Zhang, Xu] Shaanxi Univ Chinese Med, Faulty Med Technol, Xianyang, Peoples R China.
   [Chu, Man; Kang, Wulin] Shaanxi Univ Chinese Med, Affiliated Hosp, Xianyang, Peoples R China.
   [Gao, Ting] Ningxia Med Univ, Dept Pharmaceut, Gen Hosp, Yinchuan, Ningxia, Peoples R China.
   [Feng, Yu] Ningxia Med Univ, Gen Hosp, Dept Sports Med & Arthroscopy, Yinchuan, Ningxia, Peoples R China.
   [Cai, Zhe; Wu, Ping] Guangzhou Women & Childrens Med Ctr, Dept Allergy Immunol & Rheumatol, Guangzhou, Peoples R China.
   [Cai, Zhe] Chinese Univ Hong Kong, Inst Chinese Med, Hong Kong, Peoples R China.
   [Cai, Zhe] Chinese Univ Hong Kong, State Key Lab Res Bioactiv & Clin Applicat Med Pl, Hong Kong, Peoples R China.
C3 Shaanxi University of Chinese Medicine; Shaanxi University of Chinese
   Medicine; Ningxia Medical University; Ningxia Medical University;
   Chinese University of Hong Kong; Chinese University of Hong Kong
RP Feng, Y (通讯作者)，Ningxia Med Univ, Gen Hosp, Dept Sports Med & Arthroscopy, Yinchuan, Ningxia, Peoples R China.; Cai, Z; Wu, P (通讯作者)，Guangzhou Women & Childrens Med Ctr, Dept Allergy Immunol & Rheumatol, Guangzhou, Peoples R China.; Cai, Z (通讯作者)，Chinese Univ Hong Kong, Inst Chinese Med, Hong Kong, Peoples R China.; Cai, Z (通讯作者)，Chinese Univ Hong Kong, State Key Lab Res Bioactiv & Clin Applicat Med Pl, Hong Kong, Peoples R China.
EM 2071013@sntcm.edu.cn; gaoting1736@126.com;
   18717241320@email.sntcm.edu.cn; 1553358@sntcm.edu.cn;
   fengyu_7072@163.com; caifranklin@163.com; 13053560626@163.com
RI Yu, Feng/U 9998 2019
OI Gao, Ting/0000 0002 0485 4076
FU Project of Educational Commission of Shaanxi Province of China
   [20JK0608]; Natural Science Foundation of Guangdong Province
   [2020A1515110193]; Guangzhou Science and Technology Plan Project of
   Guangdong Province [202102010290]; Project of Shaanxi University of
   Chinese Medicine [2020GP14]; Natural Science Foundation of Ningxia Hui
   Autonomous Region [2021AAC05021]
FX The authors thank all funding supporters including the Project of
   Educational Commission of Shaanxi Province of China, the Natural Science
   Foundation of Guangdong Province, and the Guangzhou Science and
   Technology Plan Project of Guangdong Province. The authors thank all
   authors contributions to this study. The authors thank Dr. Miranda
   Sin Man Tsang contributions to polish the manuscript. This work was
   supported by the Project of Educational Commission of Shaanxi Province
   of China (ref. 20JK0608), the Project of Shaanxi University of Chinese
   Medicine (ref: 2020GP14), the Natural Science Foundation of Guangdong
   Province (no. 2020A1515110193), the Natural Science Foundation of
   Ningxia Hui Autonomous Region (no. 2021AAC05021), and the Guangzhou
   Science and Technology Plan Project of Guangdong Province (no.
   202102010290).
CR Bao YX, 2006, IMMUNOPHARM IMMUNOT, V28, P197, DOI 10.1080/08923970600815097
   Bergink A., 2014, ARTHRITIS RHEUMATOL, V48, P1922
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   Bertuglia A, 2016, OSTEOARTHR CARTILAGE, V24, P555, DOI 10.1016/j.joca.2015.10.008
   Bettica P, 2002, ARTHRITIS RHEUM, V46, P3178, DOI 10.1002/art.10630
   Branco JC, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen 2015 000166
   Cai Z, 2016, CHIN MED UK, V11, DOI 10.1186/s13020 016 0093 x
   Chu M, 2021, J ORTHOP TRANSL, V26, P132, DOI 10.1016/j.jot.2020.07.008
   Coryell PR, 2021, NAT REV RHEUMATOL, V17, P47, DOI 10.1038/s41584 020 00533 7
   Danks L, 2002, ANN RHEUM DIS, V61, P916, DOI 10.1136/ard.61.10.916
   Feng K, 2019, J CELL PHYSIOL, V234, P18192, DOI 10.1002/jcp.28452
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   Hawker GA, 2011, ARTHRIT CARE RES, V63, P1382, DOI 10.1002/acr.20298
   Henrotin YE, 2003, OSTEOARTHR CARTILAGE, V11, P747, DOI 10.1016/S1063 4584(03)00150 X
   Hewett M, 2002, NUCLEIC ACIDS RES, V30, P163, DOI 10.1093/nar/30.1.163
   Hu Y, 2019, FREE RADICAL BIO MED, V145, P146, DOI 10.1016/j.freeradbiomed.2019.09.024
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jolbäck P, 2018, ACTA ORTHOP, V89, P265, DOI 10.1080/17453674.2018.1444300
   Kang SC, 2007, INT J ORAL MAX SURG, V36, P391, DOI 10.1016/j.ijom.2006.12.004
   Khan NM, 2017, FREE RADICAL BIO MED, V106, P288, DOI 10.1016/j.freeradbiomed.2017.02.041
   Kim SH, 2015, MOL NUTR FOOD RES, V59, P1400, DOI 10.1002/mnfr.201400820
   Lepetsos P, 2016, BBA MOL BASIS DIS, V1862, P576, DOI 10.1016/j.bbadis.2016.01.003
   Li D, 2012, AM J MED SCI, V344, P486, DOI 10.1097/MAJ.0b013e3182579dc6
   Li EK, 2007, ARTHRIT RHEUM ARTHR, V57, P1143, DOI 10.1002/art.22994
   Li ZF, 2015, INFLAMMATION, V38, P1563, DOI 10.1007/s10753 015 0131 3
   Lijnen HR, 2002, BIOCHEMISTRY MOSCOW+, V67, P92, DOI 10.1023/A:1013908332232
   Loef M, 2018, RHEUMATOLOGY, V57, P1917, DOI 10.1093/rheumatology/key016
   Loeser RF, 2008, CURR OPIN RHEUMATOL, V20, P581, DOI 10.1097/BOR.0b013e3283090463
   Lopes CT, 2010, BIOINFORMATICS, V26, P2347, DOI 10.1093/bioinformatics/btq430
   Mandl LA, 2019, OSTEOARTHR CARTILAGE, V27, P359, DOI 10.1016/j.joca.2018.11.001
   Martin G, 2003, INFLAMMATION, V27, P233, DOI 10.1023/A:1025040631514
   Maruotti N, 2017, J CELL PHYSIOL, V232, P2957, DOI 10.1002/jcp.25969
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Park JS, 2015, BIOMOL THER, V23, P442, DOI 10.4062/biomolther.2015.045
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Pisani LP, 2017, ANTICANCER RES, V37, P5389, DOI 10.21873/anticanres.11965
   Prasadam I, 2010, ARTHRITIS RHEUM US, V62, P1349, DOI 10.1002/art.27397
   Qu RZ, 2018, FASEB J, V32, P1044, DOI 10.1096/fj.201700265R
   Rafanan BS, 2018, PAIN MANAG, V8, P115, DOI 10.2217/pmt 2017 0047
   Rakoff Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Safran M, 2010, DATABASE OXFORD, DOI 10.1093/database/baq020
   Shen MY, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758 2946 4 31
   Smith SR, 2016, OSTEOARTHR CARTILAGE, V24, P962, DOI 10.1016/j.joca.2016.01.135
   Suzuki Y, 2001, RHEUMATOLOGY, V40, P673, DOI 10.1093/rheumatology/40.6.673
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Upton AR, 2012, RHEUMATOL INT, V32, P535, DOI 10.1007/s00296 010 1733 6
   Van Spil WE, 2019, BIOCHEM PHARMACOL, V165, P41, DOI 10.1016/j.bcp.2019.02.037
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Watt Fiona E, 2017, Eur Med J Rheumatol, V2, P50
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wong L Y, 2015, East Asian Arch Psychiatry, V25, P150
   Wu ZR, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01134
   Xu LB, 2015, INFLAMM RES, V64, P895, DOI 10.1007/s00011 015 0872 3
   Yang H, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658 018 0072 6
   Ye ZQ, 2014, CAN J PHYSIOL PHARM, V92, P132, DOI 10.1139/cjpp 2013 0228
   Zan PF, 2018, J CELL BIOCHEM, V119, P290, DOI 10.1002/jcb.26172
   Zhang J, 2019, J INT MED RES, DOI 10.1177/0300060519873461
   Zhong M, 2011, CALCIFIED TISSUE INT, V88, P96, DOI 10.1007/s00223 010 9433 5
   Zhou Tao, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P918
   Zhou XD, 2019, INT IMMUNOPHARMACOL, V71, P233, DOI 10.1016/j.intimp.2019.03.037
   Zhuang ZL, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.902491
NR 63
TC 12
Z9 12
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD JAN 18
PY 2022
VL 2022
AR 7663212
DI 10.1155/2022/7663212
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA ZU6YL
UT WOS:000769986800002
PM 35087596
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Onodera, S
   Saito, A
   Hojo, H
   Nakamura, T
   Zujur, D
   Watanabe, K
   Morita, N
   Hasegawa, D
   Masaki, H
   Nakauchi, H
   Nomura, T
   Shibahara, T
   Yamaguchi, A
   Chung, U
   Azuma, T
   Ohba, S
AF Onodera, Shoko
   Saito, Akiko
   Hojo, Hironori
   Nakamura, Takashi
   Zujur, Denise
   Watanabe, Katsuhito
   Morita, Nana
   Hasegawa, Daigo
   Masaki, Hideki
   Nakauchi, Hiromitsu
   Nomura, Takeshi
   Shibahara, Takahiko
   Yamaguchi, Akira
   Chung, Ung il
   Azuma, Toshifumi
   Ohba, Shinsuke
TI Hedgehog Activation Regulates Human Osteoblastogenesis
SO STEM CELL REPORTS
LA English
DT Article
ID BONE FORMATION; OXIDATIVE STRESS; WNT ANTAGONIST; GLI3; DIFFERENTIATION;
   PROTEIN; FOXO1; PROLIFERATION; MUTATIONS; PATHWAYS
AB Two genetic diseases, Gorlin syndrome and McCune Albright syndrome (MAS), show completely opposite symptoms in terms of bone mineral density and hedgehog (Hh) activity. In this study, we utilized human induced pluripotent stem cell (iPSC) based models of the two diseases to understand the roles of Hh signaling in osteogenesis. Gorlin syndrome derived iPSCs showed increased osteoblastogen esis and mineralization with Hh signaling activation and upregulation of a set of transcription factors in an osteogenic culture, compared with the isogenic control. MAS specific iPSCs showed poor mineralization with low Hh signaling activity in the osteogenic culture; impaired osteoblastogenesis was restored to the normal level by treatment with an Hh signaling activating small molecule. These data suggest that Hh signaling is a key controller for differentiation of osteoblasts from precursors. This study may pave a path to new drug therapies for genetic abnormalities in calcification caused by dysregulation of Hh signaling.
C1 [Onodera, Shoko; Saito, Akiko; Nakamura, Takashi; Azuma, Toshifumi] Tokyo Dent Coll, Dept Biochem, Tokyo 1010061, Japan.
   [Onodera, Shoko; Hojo, Hironori; Zujur, Denise; Chung, Ung il; Ohba, Shinsuke] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Tokyo 1138656, Japan.
   [Hojo, Hironori; Chung, Ung il; Ohba, Shinsuke] Univ Tokyo, Grad Sch Engn, Dept Bioengn, Tokyo 1138655, Japan.
   [Watanabe, Katsuhito; Hasegawa, Daigo; Shibahara, Takahiko] Tokyo Dent Coll, Dept Oral & Maxillofacial Surg, Tokyo 1010061, Japan.
   [Morita, Nana; Nomura, Takeshi] Tokyo Dent Coll, Dept Oral Med Oral & Maxillofacial Surg, Chiba 2728513, Japan.
   [Masaki, Hideki; Nakauchi, Hiromitsu] Univ Tokyo, Inst Med Sci, Ctr Stem Cell Biol & Regenerat Med, Tokyo 1088639, Japan.
   [Nakauchi, Hiromitsu] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.
   [Yamaguchi, Akira; Azuma, Toshifumi] Tokyo Dent Coll, Oral Hlth Sci Ctr, Tokyo 1010061, Japan.
   [Ohba, Shinsuke] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, Nagasaki 8528521, Japan.
C3 Tokyo Dental College; University of Tokyo; University of Tokyo; Tokyo
   Dental College; Tokyo Dental College; University of Tokyo; Stanford
   University; Tokyo Dental College; Nagasaki University
RP Azuma, T (通讯作者)，Tokyo Dent Coll, Dept Biochem, Tokyo 1010061, Japan.; Ohba, S (通讯作者)，Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Integrat Med, Tokyo 1138656, Japan.; Ohba, S (通讯作者)，Univ Tokyo, Grad Sch Engn, Dept Bioengn, Tokyo 1138655, Japan.; Azuma, T (通讯作者)，Tokyo Dent Coll, Oral Hlth Sci Ctr, Tokyo 1010061, Japan.; Ohba, S (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, Nagasaki 8528521, Japan.
EM tazuma@tdc.ac.jp; s ohba@nagasaki u.ac.jp
RI ; Yamaguchi, Akira/AAX 9286 2020; AZUMA, TOSHIFUMI/HTQ 4727 2023;
   NAKAMURA, Takashi/I 3248 2014
OI Nakamura, Takashi/0000 0002 6124 061X; Hojo,
   Hironori/0000 0003 2245 6853; Ohba, Shinsuke/0000 0002 6874 8539;
   Onodera, Shoko/0000 0003 0673 3400; Nakauchi,
   Hiromitsu/0000 0002 9841 6973
FU JSPS KAKENHI grant [JP17H04403, JP16K20427, JP18H03007]; American
   Society for Bone and Mineral Research; Tokyo Dental College Research
   Branding Project; JSPS Graduate Program for Leaders in Life Innovation
   (GPLLI); JSPS; Japan Science and Technology Agency (JST) Center of
   Innovation Program (COI); Grants in Aid for Scientific Research
   [20H03885, 20H03894] Funding Source: KAKEN
FX We thank Drs. Mahito Nakanishi (National Institute of Advanced
   Industrial Science and Technology.AIST), Manami Ohtaka (AIST), and Ken
   Nishimura (University of Tsukuba) for providing technical assistance.
   This work utilized the core research facility of the Center for Disease
   Biology and Integrative Medicine, The University of Tokyo, which was
   organized by The University of Tokyo Center for NanoBio Integration
   entrusted by the Ministry of Education, Culture, Sports, Science and
   Technology (MEXT) Japan. This work was supported by a JSPS KAKENHI grant
   (no. JP17H04403, no. JP16K20427, and no. JP18H03007); a Rising Star
   Award Grant from the American Society for Bone and Mineral Research (to
   S.Ohba); Tokyo Dental College Research Branding Project; the JSPS
   Graduate Program for Leaders in Life Innovation (GPLLI); the JSPS
   Core to Core Program (Advanced Research Networks); and the Japan Science
   and Technology Agency (JST) Center of Innovation Program (COI).
CR Albright F, 1937, NEW ENGL J MED, V216, P727, DOI 10.1056/NEJM193704292161701
   Alman BA, 2015, NAT REV RHEUMATOL, V11, P552, DOI 10.1038/nrrheum.2015.84
   Alvarez Medina R, 2008, DEVELOPMENT, V135, P237, DOI 10.1242/dev.012054
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598
   Day TF, 2008, J BONE JOINT SURG AM, V90A, P19, DOI 10.2106/JBJS.G.01174
   Fujii K, 2014, PEDIATR INT, V56, P667, DOI 10.1111/ped.12461
   Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109
   GORLIN RJ, 1960, NEW ENGL J MED, V262, P908, DOI 10.1056/NEJM196005052621803
   GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733 8635(18)30114 1
   Hasegawa D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186879
   He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200
   Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Iyer S, 2013, J CLIN INVEST, V123, P3409, DOI 10.1172/JCI68049
   Joeng KS, 2009, DEVELOPMENT, V136, P4177, DOI 10.1242/dev.041624
   Kanke K, 2014, STEM CELL REP, V2, P751, DOI 10.1016/j.stemcr.2014.04.016
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Katoh Y, 2006, INT J MOL MED, V17, P171
   Khan SK, 2018, P NATL ACAD SCI USA, V115, pE418, DOI 10.1073/pnas.1714313114
   Kode A, 2012, J CLIN INVEST, V122, P3490, DOI 10.1172/JCI64906
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lichtenstein L, 1938, ARCH SURG CHICAGO, V36, P874, DOI 10.1001/archsurg.1938.01190230153012
   Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962 8924(02)02405 4
   Ohba S, 2008, DEV CELL, V14, P689, DOI 10.1016/j.devcel.2008.03.007
   Ohba S, 2007, BIOCHEM BIOPH RES CO, V357, P854, DOI 10.1016/j.bbrc.2007.03.173
   ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Regard JB, 2013, NAT MED, V19, P1505, DOI 10.1038/nm.3314
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962
   Turan S, 2015, CURR OSTEOPOROS REP, V13, P146, DOI 10.1007/s11914 015 0268 x
   Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092 8674(00)80678 9
   Wang CB, 2007, DEV BIOL, V305, P460, DOI 10.1016/j.ydbio.2007.02.029
   WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403
   Wen XH, 2010, MOL CELL BIOL, V30, P1910, DOI 10.1128/MCB.01089 09
   Xu QH, 1998, DEVELOPMENT, V125, P4767
   Xu RS, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0034 7
   Zhang YX, 2018, BIOCHEM BIOPH RES CO, V503, P1401, DOI 10.1016/j.bbrc.2018.07.055
   Zujur D, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602875
NR 44
TC 17
Z9 19
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2213 6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD JUL 14
PY 2020
VL 15
IS 1
BP 125
EP 139
DI 10.1016/j.stemcr.2020.05.008
PG 15
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA MM3CS
UT WOS:000550033500011
PM 32531191
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, W
   Zhang, XJ
   Wang, R
   Xu, H
   Chi, B
AF Liu, Wei
   Zhang, Xuejin
   Wang, Rui
   Xu, Hong
   Chi, Bo
TI Supramolecular assemblies of histidinylated β cyclodextrin for enhanced
   oligopeptide delivery into osteoclast precursors
SO JOURNAL OF BIOMATERIALS SCIENCE POLYMER EDITION
LA English
DT Article
DE membrane; cellular uptake; cell penetration; osteoclast inhibitor;
   macropinocytosis; Cyclodextrins
ID CELL PENETRATING PEPTIDES; ALPHA CYCLODEXTRIN; ANTICANCER DRUGS; BONE
   METASTASIS; RECENT PROGRESS; NANOPARTICLES; SIRNA; INHIBITION;
   ACTIVATION; PACLITAXEL
AB Much attention has been given to the problem of drug delivery through the cell membrane in order to treat and manage bone diseases recently. The aim of this study was to develop nanoparticles made of amino  and histidinyl modified amphiphilic beta cyclodextrins (beta CDs) entrapping osteoclast inhibitor, a hydrophobic oligopeptides drug, across the membrane of bone marrow derived macrophages (BMMs). Drug loaded beta CDs nanoparticles (NPs) were prepared by the emulsion solvent evaporation technique and fully characterized for size, zeta potential, and entrapment efficiency. Spherical NPs displaying a hydrodynamic radius of about 295nm which did not change upon storage as an aqueous dispersion, a positive zeta potential, and entrapment efficiency of drug very close to 98% were produced. Flow cytometry and spectrofluorimetry analysis indicated that the model drug itself was not taken up by the BMMs; however, NP systems underwent significant cellular uptake. In particular, histidinyl group modified CD (beta CD H) NPs were taken up more efficiently than amino group modified (beta CD A) ones. Cellular uptake mechanism study demonstrated that the permeability of drug loaded NPs across the membrane of BMMs is probably due to macropinocytosis pathway. Cell viability studies showed that both beta CD A and beta CD H exhibited no significant cytotoxicity up to 1.0mg/ml against the cells. These results highlight the developed beta CD H NPs have great potential in safely and effectively delivering osteoclast inhibitors and other therapeutic agents toward bone disease.
C1 [Liu, Wei; Zhang, Xuejin; Wang, Rui; Xu, Hong; Chi, Bo] Nanjing Tech Univ, State Key Lab Mat Oriented Chem Engn, Nanjing, Jiangsu, Peoples R China.
   [Xu, Hong; Chi, Bo] Nanjing Tech Univ, Dept Light Ind, Biopolymer Mat Lab, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Tech University; Nanjing Tech University
RP Chi, B (通讯作者)，Nanjing Tech Univ, State Key Lab Mat Oriented Chem Engn, Nanjing, Jiangsu, Peoples R China.; Chi, B (通讯作者)，Nanjing Tech Univ, Dept Light Ind, Biopolymer Mat Lab, Nanjing, Jiangsu, Peoples R China.
EM chibo@njtech.edu.cn
RI wang, rui/JAC 6240 2023; Chi, Bo/G 4256 2013; Zhang,
   Xuejin/LFR 8381 2024
OI CHI, BO/0000 0002 4101 1860; 
FU National Basic Research Program of China [31401588]; Research Nature
   Science Foundation of Jiangsu Province [BK2012428]
FX This research was supported by The National Basic Research Program of
   China [grant number 31401588]; The Research Nature Science Foundation of
   Jiangsu Province [grant number BK2012428].
CR Al Soraj M, 2012, J CONTROL RELEASE, V161, P132, DOI 10.1016/j.jconrel.2012.03.015
   Bennevault Celton V, 2011, BIOCONJUGATE CHEM, V22, P2404, DOI 10.1021/bc200167p
   Bilensoy E, 2008, INT J PHARM, V347, P163, DOI 10.1016/j.ijpharm.2007.06.051
   Böhm I, 2011, ANGEW CHEM INT EDIT, V50, P7896, DOI 10.1002/anie.201101604
   Chi B, 2010, BIOCONJUGATE CHEM, V21, P1473, DOI 10.1021/bc100066k
   Dai JL, 2010, CANCER RES, V70, P5014, DOI 10.1158/0008 5472.CAN 10 0100
   El Sayed A, 2008, J BIOL CHEM, V283, P23450, DOI 10.1074/jbc.M709387200
   Ghosh P, 2010, J AM CHEM SOC, V132, P2642, DOI 10.1021/ja907887z
   Goda T, 2010, BIOMATERIALS, V31, P2380, DOI 10.1016/j.biomaterials.2009.11.095
   Hassane FS, 2011, J CONTROL RELEASE, V153, P163, DOI 10.1016/j.jconrel.2011.04.013
   He B, 2013, BIOMATERIALS, V34, P4309, DOI 10.1016/j.biomaterials.2013.01.100
   He HM, 2013, BIOMATERIALS, V34, P5344, DOI 10.1016/j.biomaterials.2013.03.068
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Kanazawa T, 2013, BIOMATERIALS, V34, P9220, DOI 10.1016/j.biomaterials.2013.08.036
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Li C, 2011, J PHYS CHEM C, V115, P17651, DOI 10.1021/jp203940s
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Patil KM, 2012, J AM CHEM SOC, V134, P7196, DOI 10.1021/ja210026m
   Quaglia F, 2009, BIOMATERIALS, V30, P374, DOI 10.1016/j.biomaterials.2008.09.035
   Ren Y, 2012, ACS NANO, V6, P8620, DOI 10.1021/nn301975s
   SEONG LL, 2008, BIOMATERIALS, V29, P2408
   Tan HN, 2013, CARBOHYD POLYM, V93, P679, DOI 10.1016/j.carbpol.2012.12.016
   Wang FH, 2014, J CONTROL RELEASE, V174, P126, DOI 10.1016/j.jconrel.2013.11.020
   Xiao YL, 2013, P NATL ACAD SCI USA, V110, P12385, DOI 10.1073/pnas.1216082110
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yang C, 2013, CANCER DISCOV, V3, P212, DOI 10.1158/2159 8290.CD 12 0271
   Yang CA, 2007, BIOMATERIALS, V28, P3245, DOI 10.1016/j.biomaterials.2007.03.033
   Yhaya F, 2011, MACROMOLECULES, V44, P8433, DOI 10.1021/ma2013964
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang JX, 2013, ADV DRUG DELIVER REV, V65, P1215, DOI 10.1016/j.addr.2013.05.001
NR 30
TC 6
Z9 6
U1 1
U2 50
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0920 5063
EI 1568 5624
J9 J BIOMAT SCI POLYM E
JI J. Biomater. Sci. Polym. Ed.
PD APR 12
PY 2016
VL 27
IS 6
BP 490
EP 504
DI 10.1080/09205063.2016.1140612
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science; Polymer Science
GA DG0HV
UT WOS:000371746800003
PM 26907470
DA 2025 08 17
ER

PT J
AU Gong, YS
   Chen, J
   Zhang, QZ
   Zhang, JT
AF Gong, Y.  S.
   Chen, J.
   Zhang, Q.  Z.
   Zhang, J.  T.
TI Effect of 17β oestradiol and ginsenoside on osteoporosis in
   ovariectomised rats
SO JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
LA English
DT Article
DE osteoporosis; ovariectomy; 17 beta oestradiol; ginsenoside;
   histomorphometry; osteoblast
ID HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; LONG TERM; BONE;
   ESTROGEN
AB To study the anti osteoporosis effects and mechanism of action of oestradiol (E 2) and ginsenoside (tR), we measured the bone mineral densities (BMD) of lumbar vertebra and tibia and analysed the tibia histological morphological data, as well observed the activity and the number of osteoblasts and the activity of alkaline phosphatase (ALP) and the concentration of cAMP. Results showed that E 2 (400 mu g kg( 1) week( 1)) and tR (10, 20, 30 mg kg( 1)day( )1)were able to countervail the decreasing in BMDs of lumbar vertebra and tibia induced by OVX in rats (P < 0.05); E 2 (0.1 mu mol l( 1)) and ginsenoside Rg(1) (1 mu mol l( 1) and 10 mmol l( 1)) were able to increase the number of osteoblasts, the activity of ALP and the concentration of intercellular cAMP in cultured osteoblast cells. The present findings suggest that E 2 and tR have an anti osteoporosis effect in ovariectomised rats.
C1 Chinese Acad Med Sci, Inst Mat Med, Beijing 100050, Peoples R China.
   Peking Union Med Coll, Beijing 100050, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Materia Medica   CAMS; Chinese Academy of Medical Sciences
     Peking Union Medical College; Peking Union Medical College
RP Zhang, JT (通讯作者)，Chinese Acad Med Sci, Inst Mat Med, Beijing 100050, Peoples R China.
EM zhangjt@imm.ac.cn
CR Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Kelly O, 2004, PROSTAG LEUKOTR ESS, V71, P295, DOI 10.1016/j.plefa.2004.04.003
   Khastgir G, 2001, J CLIN ENDOCR METAB, V86, P289, DOI 10.1210/jc.86.1.289
   Kris Etherton PM, 2002, AM J MED, V113, P71, DOI 10.1016/S0002 9343(01)00995 0
   Mundy GR, 1996, CLIN ORTHOP RELAT R, P24, DOI 10.1097/00003086 199603000 00004
   Ravn P, 2002, DAN MED BULL, V49, P1
   Reid Ian R, 2002, Expert Opin Drug Saf, V1, P93, DOI 10.1517/14740338.1.1.93
   Stepan J J, 2003, Endocr Regul, V37, P225
   Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243
   Vedi S, 1996, BONE, V19, P535, DOI 10.1016/S8756 3282(96)00227 X
   Vedi S, 1999, OSTEOPOROSIS INT, V10, P52, DOI 10.1007/s001980050194
   Vedi S, 2003, BONE, V33, P330, DOI 10.1016/S8756 3282(03)00114 5
NR 12
TC 29
Z9 37
U1 0
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1028 6020
EI 1477 2213
J9 J ASIAN NAT PROD RES
JI J. Asian Nat. Prod. Res.
PD OCT NOV
PY 2006
VL 8
IS 7
BP 649
EP 656
DI 10.1080/10286020500246063
PG 8
WC Plant Sciences; Chemistry, Applied; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Chemistry; Pharmacology & Pharmacy
GA 112UI
UT WOS:000242552400013
PM 17135052
DA 2025 08 17
ER

PT J
AU Su, CM
   Chiang, YC
   Huang, CY
   Hsu, CJ
   Fong, YC
   Tang, CH
AF Su, Chen Ming
   Chiang, Yi Chun
   Huang, Chun Yin
   Hsu, Chin Jung
   Fong, Yi Chin
   Tang, Chih Hsin
TI Osteopontin Promotes Oncostatin M Production in Human Osteoblasts:
   Implication of Rheumatoid Arthritis Therapy
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NF KAPPA B; LEUKEMIA INHIBITORY FACTOR; RECEPTOR TRANSACTIVATION; HUMAN
   MACROPHAGES; MESSENGER RNA; EXPRESSION; CELLS; INFLAMMATION; INTEGRIN;
   BONE
AB Accumulating evidence indicates that subchondral bone might play an essential role in rheumatoid arthritis (RA). Osteopontin (OPN) induces the production of an important proinflammatory cytokine involved in the pathogenesis of RA. This study evaluated the activation of oncostatin M(OSM) by OPN in human primary osteoblasts to understand RA pathogenesis and characterized the intracellular signaling pathways involved in this activation. Quantitative PCR, ELISA, and Western blot results indicated that stimulation of human primary osteoblasts with OPN induces OSM expression through alpha(nu)beta(3) integrin/c Src/platelet derived growth factor receptor transactivation/MEK/ERK. Treatment of osteoblasts with OPN also increased c Jun phosphorylation, AP 1 luciferase activity, and c Jun binding to the AP 1 element on the OSM promoter, as demonstrated using chromatin immunoprecipitation assay. Moreover, inhibition of OPN expression using lentiviral OPN short hairpin RNA resulted in the amelioration of articular swelling, cartilage erosion, and OSM expression in the ankle joint of mice with collagen induced arthritis as shown using microcomputed tomography and immunohistochemistry staining. Our results imply that OSM expression in osteoblasts increases in response to OPN induced inflammation in vitro. Finally, lentiviral OPN short hairpin RNA ameliorates the inflammatory response and bone destruction in mice with collagen induced arthritis. Therefore, OPN may be a potential therapeutic target for RA.
C1 [Su, Chen Ming] Wenzhou Med Univ, Affiliated Dongyang Hosp, Dept Biomed Sci Lab, Dongyang 322100, Zhejiang, Peoples R China.
   [Su, Chen Ming; Chiang, Yi Chun; Tang, Chih Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung 40466, Taiwan.
   [Huang, Chun Yin] China Med Univ, Grad Inst Clin Med Sci, Taichung 40466, Taiwan.
   [Huang, Chun Yin] China Med Univ, Beigang Hosp, Dept Orthoped Surg, Taichung 65142, Yun Lin County, Taiwan.
   [Hsu, Chin Jung; Fong, Yi Chin] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung 40466, Taiwan.
   [Hsu, Chin Jung; Fong, Yi Chin] China Med Univ Hosp, Dept Orthoped Surg, Taichung 40466, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Sch Med, Dept Pharmacol, Taichung 40466, Taiwan.
   [Tang, Chih Hsin] Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung 40466, Taiwan.
C3 Wenzhou Medical University; China Medical University Taiwan; China
   Medical University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; China Medical University Taiwan;
   Asia University Taiwan
RP Tang, CH (通讯作者)，China Med Univ, Grad Inst Basic Med Sci, 91 Hsueh Shih Rd, Taichung 40466, Taiwan.
EM chtang@mail.cmu.edu.tw
RI ; Yen, Ching/A 2771 2013; Tang, Chih/O 5212 2015; Huang,
   Chien Chung/ABH 8727 2020
OI Su, Chen Ming/0000 0002 9336 4668; 
FU Ministry of Science and Technology of Taiwan [103 2628 B 039 002 MY3,
   101 2314 B 039 002 MY3]; China Medical University [CMU102 BC]
FX This work was supported by Ministry of Science and Technology of Taiwan
   Grants 103 2628 B 039 002 MY3 and 101 2314 B 039 002 MY3 and China
   Medical University Grant CMU102 BC.
CR Bäcklund J, 2013, ANN RHEUM DIS, V72, P1225, DOI 10.1136/annrheumdis 2012 202055
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Baum R, 2014, CURR OSTEOPOROS REP, V12, P9, DOI 10.1007/s11914 013 0183 y
   Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432
   Boumans MJH, 2012, ANN RHEUM DIS, V71, P180, DOI 10.1136/annrheumdis 2011 200298
   Brand DD, 2003, SPRINGER SEMIN IMMUN, V25, P3, DOI 10.1007/s00281 003 0127 1
   Caverzasio J, 2013, J BONE MINER RES, V28, P260, DOI 10.1002/jbmr.1748
   Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960
   Chan CM, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0056819, 10.1371/journal.pone.0068504]
   Chen GJ, 2010, ARTHRITIS RHEUM US, V62, P2900, DOI 10.1002/art.27603
   Chen YJ, 2009, J CELL PHYSIOL, V221, P98, DOI 10.1002/jcp.21835
   Felson D, 2012, ANN RHEUM DIS, V71, P86, DOI 10.1136/annrheumdis 2011 200618
   Glinskii OV, 2014, ONCOTARGET, V5, P1382, DOI 10.18632/oncotarget.1837
   Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281
   Grabiec AM, 2012, ANN RHEUM DIS, V71, P424, DOI 10.1136/ard.2011.154211
   Gravallese EM, 2003, J CLIN INVEST, V112, P147, DOI 10.1172/JCI200310109
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Herenius MMJ, 2011, ANN RHEUM DIS, V70, P1160, DOI 10.1136/ard.2010.141549
   Hintzen C, 2009, ARTHRITIS RHEUM US, V60, P1932, DOI 10.1002/art.24602
   Hsieh HL, 2010, NEUROTOX RES, V17, P344, DOI 10.1007/s12640 009 9111 4
   Huang CY, 2012, ARTHRITIS RHEUM US, V64, P3344, DOI 10.1002/art.34557
   Kastl SP, 2008, ARTERIOSCL THROM VAS, V28, P498, DOI 10.1161/ATVBAHA.107.160580
   Kastl SP, 2009, BLOOD, V114, P2812, DOI 10.1182/blood 2009 01 200915
   Lisignoli G, 2000, CLIN EXP IMMUNOL, V119, P346
   Lund SA, 2013, J CELL BIOCHEM, V114, P1194, DOI 10.1002/jcb.24462
   Ma YS, 1999, NUCLEIC ACIDS RES, V27, P4649, DOI 10.1093/nar/27.23.4649
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Morimoto J, 2010, CURR DRUG TARGETS, V11, P494, DOI 10.2174/138945010790980321
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Nemoto E, 2004, J PERIODONTAL RES, V39, P388, DOI 10.1111/j.1600 0765.2004.00750.x
   Petrow PK, 2000, ARTHRITIS RHEUM, V43, P1597, DOI 10.1002/1529 0131(200007)43:7<1597::AID ANR25>3.0.CO;2 0
   Plater Zyberk C, 2001, ARTHRITIS RHEUM, V44, P2697, DOI 10.1002/1529 0131(200111)44:11<2697::AID ART450>3.0.CO;2 #
   Ramaiah SK, 2008, TOXICOL SCI, V103, P4, DOI 10.1093/toxsci/kfm246
   RODAN GA, 1995, ANN NY ACAD SCI, V760, P1, DOI 10.1111/j.1749 6632.1995.tb44614.x
   Schonthaler HB, 2011, ANN RHEUM DIS, V70, pI109, DOI 10.1136/ard.2010.140533
   Sims Natalie A, 2014, Bonekey Rep, V3, P527, DOI 10.1038/bonekey.2014.22
   Staines KA, 2012, J ENDOCRINOL, V214, P241, DOI 10.1530/JOE 12 0143
   Su CM, 2015, STEM CELLS, V33, P2243, DOI 10.1002/stem.2024
   Su CM, 2013, TOXICOL APPL PHARM, V272, P335, DOI 10.1016/j.taap.2013.06.010
   Take Y, 2009, ARTHRITIS RHEUM US, V60, P3591, DOI 10.1002/art.25020
   Tzeng HE, 2013, BIOCHEM PHARMACOL, V85, P531, DOI 10.1016/j.bcp.2012.11.021
   Wahl AF, 2001, ANN RHEUM DIS, V60, pIII75
   Wai PY, 2008, CANCER METAST REV, V27, P103, DOI 10.1007/s10555 007 9104 9
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Wang KX, 2008, CYTOKINE GROWTH F R, V19, P333, DOI 10.1016/j.cytogfr.2008.08.001
   Wilder RL, 2002, ANN RHEUM DIS, V61, P96, DOI 10.1136/ard.61.suppl_2.ii96
   Xu GW, 2005, J CLIN INVEST, V115, P1060
   Yamamoto N, 2003, J CLIN INVEST, V112, P181, DOI 10.1172/JCI200317778
   Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328
   Yumoto K, 2002, P NATL ACAD SCI USA, V99, P4556, DOI 10.1073/pnas.052523599
   Zheng WX, 2009, ARTHRITIS RHEUM US, V60, P1957, DOI 10.1002/art.24625
NR 51
TC 42
Z9 44
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD OCT 1
PY 2015
VL 195
IS 7
BP 3355
EP 3364
DI 10.4049/jimmunol.1403191
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA CS0ID
UT WOS:000361741200041
PM 26304992
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Jia, SY
   Wen, GC
   Xie, SE
   Song, ZQ
   Qi, MC
   Liang, YQ
   Bi, WJ
   Dong, W
AF Zhang, Yan
   Jia, Shunyi
   Wen, Guochen
   Xie, Shanen
   Song, Zhiqiang
   Qi, Mengchun
   Liang, Yongqiang
   Bi, Wenjuan
   Dong, Wei
TI Zoledronate Promotes Peri Implant Osteogenesis in Diabetic Osteoporosis
   by the AMPK Pathway
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Zoledronate; Osteogenesis; Diabetic osteoporosis; AMPK; Oral
   implantology
ID TITANIUM IMPLANTS; MC3T3 E1 CELLS; BONE FORMATION; DIFFERENTIATION;
   ACID; OSSEOINTEGRATION; FIXATION; KINASE; RAT; BISPHOSPHONATES
AB Together with diabetic osteoporosis (DOP), diabetes patients experience poor peri implant osteogenesis following implantation for dentition defects. Zoledronate (ZOL) is widely used to treat osteoporosis clinically. To evaluate the mechanism of ZOL for the treatment of DOP, experiments with DOP rats and high glucose grown MC3T3 E1 cells were used. The DOP rats treated with ZOL and/or ZOL implants underwent a 4 week implant healing interval, and then microcomputed tomography, biomechanical testing, and immunohistochemical staining were performed to elucidate the mechanism. In addition, MC3T3 E1 cells were maintained in an osteogenic medium with or without ZOL to confirm the mechanism. The cell migration, cellular actin content, and osteogenic differentiation were evaluated by a cell activity assay, a cell migration assay, as well as alkaline phosphatase, alizarin red S, and immunofluorescence staining. The mRNA and protein expression of adenosine monophosphate activated protein kinase (AMPK), phosphorylated AMPK (p AMPK), osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), bone morphogenetic protein 2 (BMP2), and collagen type I (Col I) were detected using real time quantitative PCRs and western blot assays, respectively. In the DOP rats, ZOL markedly improved osteogenesis, enhanced bone strength and increased the expression of AMPK, p AMPK, and Col I in peri implant bones. The in vitro findings showed that ZOL reversed the high glucose induced inhibition of osteogenesis via the AMPK signaling pathway. In conclusion, the ability of ZOL to promote osteogenesis in DOP by targeting AMPK signaling suggests that therapy with ZOL, particularly simultaneous local and systemic administration, may be a unique approach for future implant repair in diabetes patients.
C1 [Zhang, Yan; Jia, Shunyi; Wen, Guochen; Xie, Shanen; Qi, Mengchun; Liang, Yongqiang; Bi, Wenjuan; Dong, Wei] North China Univ Sci & Technol, Sch Stomatol, Tangshan 063210, Hebei, Peoples R China.
   [Song, Zhiqiang] TangShan BoChuang Stomatol Hosp, Oral & Maxillofacial Surg, Tangshan 063000, Hebei, Peoples R China.
   [Dong, Wei] Chinese Peoples Liberat Army Gen Hosp, Inst Stomatol, Fuxing Lu 28, Beijing 100853, Peoples R China.
C3 North China University of Science & Technology; Chinese People's
   Liberation Army General Hospital
RP Dong, W (通讯作者)，North China Univ Sci & Technol, Sch Stomatol, Tangshan 063210, Hebei, Peoples R China.; Dong, W (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Inst Stomatol, Fuxing Lu 28, Beijing 100853, Peoples R China.
EM 970484328@qq.com
RI ; dong, wei/KVA 6898 2024; liang, yongqiang/IUP 7337 2023
OI Dong, Wei/0000 0002 0997 8983; 
FU National Natural Science Foundation of China [81600844]; Science and
   Technology Project of Hebei Education Department [QN2020438]; Natural
   Science Foundation of Hebei Province [H2017209114]
FX & nbsp;This study was supported by the National Natural Science
   Foundation of China (Grant No. 81600844); Science and Technology Project
   of Hebei Education Department (Grant No. QN2020438); Natural Science
   Foundation of Hebei Province (Grant No. H2017209114).
CR Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Barale M, 2021, CALCIFIED TISSUE INT, V109, P383, DOI 10.1007/s00223 021 00848 x
   Baron SJ, 2005, CIRC RES, V96, P337, DOI 10.1161/01.RES.0000155723.53868.d2
   Basudan Amani M, 2020, Materials (Basel), V13, DOI 10.3390/ma13225248
   Bonnet N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058726
   Carbonare LD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061261
   Castellani C, 2011, ACTA BIOMATER, V7, P432, DOI 10.1016/j.actbio.2010.08.020
   Chen M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02628 8
   Cui M, 2019, EXP CLIN ENDOCR DIAB, V127, P68, DOI 10.1055/s 0042 105282
   Dodson TB, 2009, J ORAL MAXIL SURG, V67, P44, DOI 10.1016/j.joms.2008.12.004
   Dong W, 2018, BIOCHEM BIOPH RES CO, V505, P1195, DOI 10.1016/j.bbrc.2018.10.059
   Fan YS, 2018, MOLECULES, V23, DOI 10.3390/molecules23092306
   Gao Y, 2009, BIOMATERIALS, V30, P1790, DOI 10.1016/j.biomaterials.2008.12.025
   Gao Y, 2009, BONE, V44, P225, DOI 10.1016/j.bone.2008.10.054
   Gu YY, 2023, CELL BIOL INT, V47, P216, DOI 10.1002/cbin.11921
   Hua YW, 2020, J ORTHOP RES, V38, P2113, DOI 10.1002/jor.24651
   Huang KC, 2019, INT J MED SCI, V16, P751, DOI 10.7150/ijms.32612
   Ikeda H, 2019, J ORAL MAX SURG MED, V31, P333, DOI 10.1016/j.ajoms.2019.03.001
   Jang WG, 2011, BIOCHEM BIOPH RES CO, V404, P1004, DOI 10.1016/j.bbrc.2010.12.099
   Jeyabalan J, 2012, J ENDOCRINOL, V212, P277, DOI 10.1530/JOE 11 0306
   Kajiwara H, 2005, BIOMATERIALS, V26, P581, DOI 10.1016/j.biomaterials.2004.02.072
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kotsovilis S, 2006, CLIN ORAL IMPLAN RES, V17, P587, DOI 10.1111/j.1600 0501.2005.01245.X
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Liu HH, 2018, HUM GENE THER, V29, P1416, DOI 10.1089/hum.2018.003
   Ma LY, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4924
   Manfredi M, 2011, INT J ORAL MAX SURG, V40, P277, DOI 10.1016/j.ijom.2010.11.002
   Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465
   Moy PK, 2005, INT J ORAL MAX IMPL, V20, P569
   Oh SJ, 2016, BIOCHEM BIOPH RES CO, V475, P125, DOI 10.1016/j.bbrc.2016.05.055
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Pyo SW, 2014, INT J ORAL MAX IMPL, V29, P478, DOI 10.11607/jomi.3423
   Qi MC, 2012, BONE, V50, P119, DOI 10.1016/j.bone.2011.10.011
   Shibamoto A, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 018 0009 y
   Sordi MB, 2021, J MATER SCI MATER M, V32, DOI 10.1007/s10856 020 06475 6
   Tatarakis N, 2014, CLIN ORAL IMPLAN RES, V25, P803, DOI 10.1111/clr.12139
   Tong XS, 2019, J CELL BIOCHEM, V120, P1630, DOI 10.1002/jcb.27468
   Tsurushima H, 2013, INT J ORAL MAX SURG, V42, P1481, DOI 10.1016/j.ijom.2013.06.011
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wang CK, 2009, BIOMATERIALS, V30, P4178, DOI 10.1016/j.biomaterials.2009.04.029
   Wang N, 2021, PHYTOTHER RES, V35, P2639, DOI 10.1002/ptr.7010
   Wang YG, 2016, CELL SIGNAL, V28, P1270, DOI 10.1016/j.cellsig.2016.06.004
   Wu L, 2021, DIABETES, V70, P2192, DOI 10.2337/db21 0050
   Xiao J, 2022, HUM CELL, V35, P1045, DOI 10.1007/s13577 022 00704 6
   Yang JS, 2019, MOL MED REP, V20, P5084, DOI 10.3892/mmr.2019.10790
   Yang LC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12071914
   Yang XJ, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/ab8720
   Zhang XN, 2020, DRUG DEVELOP RES, V81, P875, DOI 10.1002/ddr.21705
   Zhou RY, 2020, MOL MED REP, V22, P3387, DOI 10.3892/mmr.2020.11391
   Zou GK, 2012, OR SURG OR MED OR PA, V114, P284, DOI 10.1016/j.tripleo.2011.07.006
NR 51
TC 2
Z9 2
U1 2
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD SEP
PY 2023
VL 113
IS 3
BP 329
EP 343
DI 10.1007/s00223 023 01112 0
EA JUL 2023
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HY3C7
UT WOS:001022082100002
PM 37392365
DA 2025 08 17
ER

PT J
AU Jang, Y
   Sohn, HM
   Ko, YJ
   Hyun, H
   Lim, W
AF Jang, Yuria
   Sohn, Hong Moon
   Ko, Young Jong
   Hyun, Hoon
   Lim, Wonbong
TI Inhibition of RANKL Induced Osteoclastogenesis by Novel Mutant RANKL
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE leucine rich repeat containing G protein coupled receptor 4; receptor
   activator of nuclear factor kappa B ligand; osteoclast; osteoporosis
ID BONE RESORPTION; BISPHOSPHONATE; EXPRESSION; DENOSUMAB
AB Background: Recently, it was reported that leucine rich repeat containing G protein coupled receptor 4 (LGR4, also called GPR48) is another receptor for RANKL and was shown to compete with RANK to bind RANKL and suppress canonical RANK signaling during osteoclast differentiation. The critical role of the protein triad RANK RANKL in osteoclastogenesis has made their binding an important target for the development of drugs against osteoporosis. In this study, point mutations were introduced in the RANKL protein based on the crystal structure of the RANKL complex and its counterpart receptor RANK, and we investigated whether LGR4 signaling in the absence of the RANK signal could lead to the inhibition of osteoclastogenesis.; Methods: The effects of point mutated RANKL (mRANKL MT) on osteoclastogenesis were assessed by tartrate resistant acid phosphatase (TRAP), resorption pit formation, quantitative real time polymerase chain reaction (qPCR), western blot, NFATc1 nuclear translocation, micro CT and histomorphological assay in wild type RANKL (mRANKL WT) induced in vitro and in vivo experimental mice model. Results: As a proof of concept, treatment with the mutant RANKL led to the stimulation of GSK 3 beta phosphorylation, as well as the inhibition of NFATc1 translocation, mRNA expression of TRAP and OSCAR, TRAP activity, and bone resorption, in RANKL induced mouse models; and Conclusions: The results of our study demonstrate that the mutant RANKL can be used as a therapeutic agent for osteoporosis by inhibiting RANKL induced osteoclastogenesis via comparative inhibition of RANKL. Moreover, the mutant RANKL was found to lack the toxic side effects of most osteoporosis treatments.
C1 [Jang, Yuria; Sohn, Hong Moon; Ko, Young Jong; Lim, Wonbong] Chosun Univ Hosp, Lab Orthopaed Res, Gwangju 61452, South Korea.
   [Jang, Yuria; Sohn, Hong Moon; Ko, Young Jong; Lim, Wonbong] Chosun Univ Hosp, Dept Orthopaed Surg, Gwangju 61452, South Korea.
   [Hyun, Hoon] Chonnam Natl Univ, Med Sch, Dept Biomed Sci, Gwangju 61469, South Korea.
   [Lim, Wonbong] Chosun Univ, Dept Premed Sci, Coll Med, Gwangju 61452, South Korea.
C3 Chosun University; Chosun University; Chonnam National University;
   Chosun University
RP Lim, W (通讯作者)，Chosun Univ Hosp, Lab Orthopaed Res, Gwangju 61452, South Korea.; Lim, W (通讯作者)，Chosun Univ Hosp, Dept Orthopaed Surg, Gwangju 61452, South Korea.; Lim, W (通讯作者)，Chosun Univ, Dept Premed Sci, Coll Med, Gwangju 61452, South Korea.
EM youria0526@nate.com; hmsohn@chosun.ac.kr; yeasts@hanmail.net;
   hhyun@chonnam.ac.kr; wonbong@chosun.ac.kr
OI Lim, Wonbong/0000 0001 6337 6599
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2018R1D1A1B07047024,
   NRF 2017R1D1A3B03032725, NRF 2017R1D1A1A02018589]; Chosun University
   Hospital
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF), funded by the Ministry
   of Education (NRF 2018R1D1A1B07047024, NRF 2017R1D1A3B03032725,
   NRF 2017R1D1A1A02018589) and supported by a research grant from Chosun
   University Hospital (2020).
CR Bachrach LK, 2009, J CLIN ENDOCR METAB, V94, P400, DOI 10.1210/jc.2008 1531
   Beest FJAPV, 2008, OSTEOPOROSIS INT, V19, P511, DOI 10.1007/s00198 007 0466 1
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Cao X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0040 9
   CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Jönsson B, 2011, OSTEOPOROSIS INT, V22, P967, DOI 10.1007/s00198 010 1424 x
   Kang IS, 2016, SCI REP UK, V6, DOI 10.1038/srep38014
   Kim TW, 1999, AM J ORTHOD DENTOFAC, V115, P645, DOI 10.1016/S0889 5406(99)70290 8
   Ko Y, 2020, OSTEOPOROSIS INT, V31, P983, DOI 10.1007/s00198 019 05200 6
   Komm BS, 2015, EXPERT REV CLIN PHAR, V8, P769, DOI 10.1586/17512433.2015.1099432
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571
   Manfredi M, 2011, INT J ORAL MAX SURG, V40, P277, DOI 10.1016/j.ijom.2010.11.002
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Matsumoto Y, 2017, J CLIN INVEST, V127, P1303, DOI 10.1172/JCI90527
   Meadows ES, 2012, BMC WOMENS HEALTH, V12, DOI 10.1186/1472 6874 12 1
   MUHLBAUER RC, 1991, J BONE MINER RES, V6, P1003
   Renema N, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160150
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   van Dam PA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092183
   Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022
   Yi H, 2016, Identification and characterisation of LGR4/beta catenin signalling in acute myeloid leukaemic stem cells
NR 26
TC 16
Z9 17
U1 0
U2 12
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2021
VL 22
IS 1
AR 434
DI 10.3390/ijms22010434
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PP8ED
UT WOS:000606088400001
PM 33406741
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Singh, ATK
   Gilchrist, A
   Voyno Yasenetskaya, T
   Radeff Huang, JM
   Stern, PH
AF Singh, ATK
   Gilchrist, A
   Voyno Yasenetskaya, T
   Radeff Huang, JM
   Stern, PH
TI Gα12/Gα13 subunits of heterotrimeric G proteins
   mediate parathyroid hormone activation of phospholipase D in UMR 106
   osteoblastic cells
SO ENDOCRINOLOGY
LA English
DT Article
ID STRESS FIBER FORMATION; GTP BINDING PROTEIN; BETA GAMMA SUBUNITS;
   KINASE C ALPHA; BONE RESORPTION; LYSOPHOSPHATIDIC ACID;
   SIGNAL TRANSDUCTION; P115 RHOGEF; RECEPTOR; G ALPHA(13)
AB PTH, a major regulator of bone remodeling and a therapeutically effective bone anabolic agent, stimulates several signaling pathways in osteoblastic cells. Our recent studies have revealed that PTH activates phospholipase D (PLD)  mediated phospholipid hydrolysis through a RhoA dependent mechanism in osteoblastic cells, raising the question of the upstream link to the PTH receptor. In the current study, we investigated the role of heterotrimeric G proteins in mediating PTH stimulated PLD activity in UMR 106 osteoblastic cells. Transfection with antagonist minigenes coding for small peptide antagonists to G alpha(12) and G alpha(13) subunits of heterotrimeric G proteins prevented PTH stimulated activation of PLD, whereas an antagonist minigene to G alpha s failed to produce this effect. Effects of pharmacological inhibitors (protein kinase inhibitor, Clostridium botulinum exoenzyme C3) were consistent with a role of Rho small G proteins, but not of cAMP, in the effect of PTH on PLD. Expression of constitutively active G alpha(12) and G alpha(13) activated PLD, an effect that was inhibited by dominant negative RhoA. The results identify G alpha(12) and G alpha(13) as upstream transducers of PTH effects on PLD, mediated through RhoA in osteoblastic cells.
C1 Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA.
   Cue BIOtech, Evanston, IL 60201 USA.
   Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA.
C3 Northwestern University; Feinberg School of Medicine; University of
   Illinois System; University of Illinois Chicago; University of Illinois
   Chicago Hospital
RP Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, 303 E Chicago Ave S 215, Chicago, IL 60611 USA.
EM p stern@northwestern.edu
RI Gilchrist, Annette/I 4465 2014; voyno yasenetskaya, tatyana/A 3171 2008
OI Gilchrist, Annette/0000 0003 2386 7646; 
FU NIAMS NIH HHS [AR11262] Funding Source: Medline; NIGMS NIH HHS [GM56159,
   GM65160] Funding Source: Medline
CR BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631
   Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993
   CIVITELLI R, 1988, AM J PHYSIOL, V255, P660
   Dutt P, 2004, CELL SIGNAL, V16, P201, DOI 10.1016/S0898 6568(03)00132 3
   FOLCH L, 1957, J BIOL CHEM, V226, P497
   Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200
   GILCHRIST A, 2002, SCI STKE, V118, pPL1
   Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653
   Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683
   Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112
   Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152
   Huang CF, 2004, AM J PHYSIOL CELL PH, V286, pC22, DOI 10.1152/ajpcell.00229.2003
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109
   Kranenburg O, 1997, J CELL SCI, V110, P2417
   Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851
   Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003
   Lee SY, 2004, EUR J IMMUNOL, V34, P2760, DOI 10.1002/eji.200425117
   Maruyama Y, 2002, CIRC RES, V91, P961, DOI 10.1161/01.RES.0000043282.39776.7C
   McGrew L, 2002, MOL PHARMACOL, V62, P1339, DOI 10.1124/mol.62.6.1339
   Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937
   Nozawa Y, 2002, BBA MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388 1981(02)00327 X
   Oleksy A, 2004, ACTA CRYSTALLOGR D, V60, P740, DOI 10.1107/S0907444904002318
   PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308
   Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823
   Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200
   Radeff JM, 2004, J BONE MINER RES, V19, P1882, DOI 10.1359/JBMR.040806
   Radeff JM, 2004, CELL SIGNAL, V16, P105, DOI 10.1016/S0898 6568(03)00131 1
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   Singh AT, 2003, J BONE MINER RES, V18, P1453, DOI 10.1359/jbmr.2003.18.8.1453
   Singh ATK, 1999, ENDOCRINOLOGY, V140, P131, DOI 10.1210/en.140.1.131
   Stepan V, 2004, AM J PHYSIOL GASTR L, V287, pG715, DOI 10.1152/ajpgi.00169.2003
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Ushio Fukai M, 1999, MOL PHARMACOL, V55, P142, DOI 10.1124/mol.55.1.142
   VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721
   VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081
   ZHANG D, 1995, J CELL SCI, V108, P2285
NR 37
TC 65
Z9 78
U1 1
U2 5
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD MAY
PY 2005
VL 146
IS 5
BP 2171
EP 2175
DI 10.1210/en.2004 1283
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 917GK
UT WOS:000228444300008
PM 15705779
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, Y
   Wang, H
   Yang, QD
   Zhao, WH
   Chen, YY
   Ni, QQ
   Li, WL
   Shi, JL
   Zhang, W
   Li, L
   Xu, Y
   Zhang, HW
   Miao, DS
   Xing, LP
   Sun, W
AF Chen, Yue
   Wang, Hua
   Yang, Qiudong
   Zhao, Wenhua
   Chen, Yuyi
   Ni, Qiaoqi
   Li, Wenlei
   Shi, Jiali
   Zhang, Wei
   Li, Lu
   Xu, Yan
   Zhang, Hengwei
   Miao, Dengshun
   Xing, Lianping
   Sun, Wen
TI Single cell RNA landscape of the osteoimmunology microenvironment in
SO THERANOSTICS
LA English
DT Article
DE Osteoimmunology; Periodontitis; Single cell RNA seq; Mesenchymal stem
   cells; alveolar bone
ID MESENCHYMAL STEM CELLS; ENDOTHELIAL CELLS; MARROW FIBROSIS; BONE;
   REGENERATION; OSTEOBLAST; INNATE; ACTIVATION; MECHANISMS; INHIBITION
AB Single cell RNA sequencing (scRNA seq) enables specific profiling of cell populations at single cell resolution. The osteoimmunology microenvironment in the occurrence and development of periodontitis remains poorly understood at the single cell level. In this study, we used single cell transcriptomics to comprehensively reveal the complexities of the molecular components and differences with counterparts residing in periodontal tissues. Methods: We performed scRNA seq to identify 51248 single cells from healthy controls (n=4), patients with severe chronic periodontitis (n=5), and patients with severe chronic periodontitis after initial periodontal therapy within 1 month (n=3). Uniform manifold approximation and projection (UMAP) were further conducted to explore the cellular composition of periodontal tissues. Pseudotime cell trajectory and RNA velocity analysis, combined with gene enrichment analysis were used to reveal the molecular pathways underlying cell fate decisions. CellPhoneDB were performed to identify ligand receptor pairs among the major cell types in the osteoimmunology microenvironment of Results: A cell atlas of the osteoimmunology microenvironment in periodontal tissues was characterized and included ten major cell types, such as fibroblasts, monocytic cells, endothelial cells, and T and B cells. and IL24 was detected in patients with periodontitis compared to healthy individuals. The fractions of CD55+ mesenchymal stem cells (MSCs), APOE+ pre osteoblasts (pre OBs), and IBSP+ osteoblasts decreased significantly in response to initial periodontal therapy. In addition, CXCL12+ MSC like pericytes could convert their identity into a pre OB state during inflammatory responses even after initial periodontal therapy confirmed by single cell trajectory. Moreover, we portrayed the distinct subtypes of monocytic cells and abundant endothelial cells significantly involved in the immune response. The heterogeneity of T and B cells in periodontal tissues was characterized. Finally, we mapped osteoblast/ osteoclast differentiation mediators to their source cell populations by identifying ligand receptor pairs into the cellular and molecular underpinning of periodontal bone regeneration.
C1 [Chen, Yue; Wang, Hua; Yang, Qiudong; Zhao, Wenhua; Chen, Yuyi; Ni, Qiaoqi; Li, Wenlei; Shi, Jiali; Zhang, Wei; Li, Lu; Xu, Yan; Sun, Wen] Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Basic Sci Stomatol, 140 Hanzhong Rd, Nanjing 210029, Peoples R China.
   [Chen, Yue; Wang, Hua; Yang, Qiudong; Zhao, Wenhua; Chen, Yuyi; Ni, Qiaoqi; Li, Wenlei; Shi, Jiali; Zhang, Wei; Li, Lu; Xu, Yan; Sun, Wen] Jiangsu Prov Key Lab Oral Dis, Nanjing, Peoples R China.
   [Chen, Yue; Wang, Hua; Yang, Qiudong; Zhao, Wenhua; Chen, Yuyi; Ni, Qiaoqi; Li, Wenlei; Shi, Jiali; Zhang, Wei; Li, Lu; Xu, Yan; Sun, Wen] Jiangsu Prov Engn Res Ctr Stomatol Translat Med, Nanjing, Peoples R China.
   [Zhang, Hengwei; Xing, Lianping] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
   [Zhang, Hengwei; Xing, Lianping] Univ Rochester, Med Ctr, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Miao, Dengshun] Nanjing Med Univ, State Key Lab Reprod Med, Res Ctr Bone & Stem Cells, Dept Anat Histol & Embryol, Nanjing, Peoples R China.
C3 Nanjing Medical University; University of Rochester; University of
   Rochester; Nanjing Medical University
RP Sun, W (通讯作者)，Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Basic Sci Stomatol, 140 Hanzhong Rd, Nanjing 210029, Peoples R China.
EM wensun@njmu.edu.cn
RI Li, Wenlei/D 4780 2013; Chen, Yuyi/KZU 5279 2024; Zhang,
   Hongwei/L 5137 2019; Wang, Hua/MHP 9513 2025; ni, qiaoqi/LBI 6724 2024
OI Li, Lu/0000 0002 7302 8528; Sun, Wen/0000 0002 8111 8865
FU National Natural Science Foundation of China [82071086, 81970961];
   National Key Research and Development Program of China [2018YFA0800804];
   Natural Science Foundation of Jiangsu Province in China [BK20180034,
   BK20191346]; Postgraduate Research & Practice Innovation Program of
   Jiangsu Province [KYCX20_1438]; Project of Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD) [2018 87]
FX The research was supported by grants from the National Natural Science
   Foundation of China (82071086 to WS, and 81970961 to HW), from the
   National Key Research and Development Program of China (2018YFA0800804),
   from the Natural Science Foundation of Jiangsu Province in China
   (BK20180034 to WS, and BK20191346 to HW), and from Postgraduate Research
   & Practice Innovation Program of Jiangsu Province (KYCX20_1438). This
   work was also supported by the Project of Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD, 2018 87).
CR Abou Zahr A, 2016, HAEMATOLOGICA, V101, P660, DOI 10.3324/haematol.2015.141283
   Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
   Alvarez C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01664
   Andersson Sjöland A, 2016, LAB INVEST, V96, P206, DOI 10.1038/labinvest.2015.100
   Araujo Pires AC, 2015, J BONE MINER RES, V30, P400, DOI 10.1002/jbmr.2376
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Arthur A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.598612
   Baryawno N, 2019, CELL, V177, P1915, DOI 10.1016/j.cell.2019.04.040
   Belkina AC, 2020, J DENT RES, V99, P855, DOI 10.1177/0022034520912188
   Bian ZL, 2020, NATURE, V582, P571, DOI 10.1038/s41586 020 2316 7
   Blin Wakkach C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02595
   Boland BS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb4432
   Bondjers C, 2006, FASEB J, V20, P1703, DOI 10.1096/fj.05 4944fje
   BONNET JJ, 1989, LIFE SCI, V44, P1759, DOI 10.1016/0024 3205(89)90563 8
   Brulois K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17291 5
   Caetano AJ, 2021, ELIFE, V10, DOI 10.7554/eLife.62810
   Calicchio R, 2013, AM J PATHOL, V183, P1993, DOI 10.1016/j.ajpath.2013.08.020
   Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586 019 0969 x
   Cavalla F, 2021, J DENT RES, V100, P29, DOI 10.1177/0022034520952341
   Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560
   Chen WY, 2021, THERANOSTICS, V11, P2594, DOI 10.7150/thno.51648
   Coelho NM, 2016, CELL TISSUE RES, V365, P521, DOI 10.1007/s00441 016 2440 8
   Condamine T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8943
   Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586 019 1263 7
   Danese S, 2007, J IMMUNOL, V178, P6017, DOI 10.4049/jimmunol.178.10.6017
   Dang T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26143 8
   Barros Fabiana Cervo de, 2014, Braz. Dent. J., V25, P90, DOI 10.1590/0103 6440201302308
   Della Coletta BB, 2021, MOLECULES, V26, DOI 10.3390/molecules26040847
   Deng CC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24110 y
   Dioguardi M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020495
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875
   Feller L, 2014, HEAD FACE MED, V10, DOI 10.1186/1746 160X 10 8
   Gajdzis M, 2020, LIFE BASEL, V10, DOI 10.3390/life10100225
   Gavin C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02249
   Giaginis C, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472 6890 14 8
   Gruber R, 2019, J CLIN PERIODONTOL, V46, P52, DOI 10.1111/jcpe.13056
   Guo YE, 2021, AGING US, V13, P6565, DOI 10.18632/aging.202288
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Harrell CR, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0423 7
   He FZ, 2018, CELL PHYSIOL BIOCHEM, V50, P1178, DOI 10.1159/000494544
   He XT., 2020, Principles of tissue engineering, P1221, DOI [10.1016/B978 0 12 818422 6.00068 X, DOI 10.1016/B978 0 12 818422 6.00068 X]
   HEDIN CA, 1984, J PERIODONTAL RES, V19, P177
   Huang N, 2021, NAT MED, V27, P892, DOI 10.1038/s41591 021 01296 8
   Humbert P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00663
   ISIDOR F, 1985, J CLIN PERIODONTOL, V12, P687, DOI 10.1111/j.1600 051X.1985.tb00940.x
   Jia J, 2016, MICROVASC RES, V105, P103, DOI 10.1016/j.mvr.2016.02.004
   Jones S, 2007, J IMMUNOL, V179, P2824, DOI 10.4049/jimmunol.179.5.2824
   Joshi N, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00646 2019
   Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491
   Kato K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04913 2
   Kisseleva T, 2008, EXP BIOL MED, V233, P109, DOI 10.3181/0707 MR 190
   Knight MN, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0026 7
   Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592 019 0619 0
   Lagares D, 2017, NAT MED, V23, P1405, DOI 10.1038/nm.4419
   Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591 018 0096 5
   Larsson M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742 4690 10 31
   Lei G, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8889731
   Li QY, 2021, THERANOSTICS, V11, P6461, DOI 10.7150/thno.54917
   Li Y, 2012, BLOOD, V120, P3436, DOI 10.1182/blood 2012 03 420612
   Lindsey RC, 2018, J MOL ENDOCRINOL, V61, pT87, DOI 10.1530/JME 17 0284
   Liu L, 2021, TISSUE ENG PT A, V27, P962, DOI [10.1089/ten.tea.2020.0141, 10.1089/ten.TEA.2020.0141]
   Liu ML, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10134 y
   López Camarillo C, 2012, INT J MOL SCI, V13, P142, DOI 10.3390/ijms13010142
   Lorenzo J., 2013, OSTEOPOROSIS, P915
   Lotinun S, 2005, ENDOCRINOLOGY, V146, P4074, DOI 10.1210/en.2005 0480
   Lu EMC, 2020, J PERIODONTAL RES, V55, P859, DOI 10.1111/jre.12778
   Mabuchi Y, 2013, STEM CELL REP, V1, P152, DOI 10.1016/j.stemcr.2013.06.001
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   Mahanonda R, 2016, J IMMUNOL, V197, P715, DOI 10.4049/jimmunol.1600540
   Mai JT, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756 8722 6 61
   Maiuolo J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010081
   Marelli Berg FM, 2004, IMMUNOL LETT, V93, P109, DOI 10.1016/j.imlet.2004.03.014
   Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992
   Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888
   McDonald MM, 2021, CELL
   Mebarki M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02637 7
   Mimche PN, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 20926 9
   Moreno JL, 2003, BLOOD, V102, P1078, DOI 10.1182/blood 2002 11 3437
   Nwadozi E, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00077
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Priglinger E, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12156
   Qian SJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.711337
   Reynolds MA, 2015, J PERIODONTOL, V86, pS105, DOI 10.1902/jop.2015.140378
   Righi A, 2006, INT J SURG PATHOL, V14, P206, DOI 10.1177/1066896906290053
   Saha N, 2018, INT J BIOCHEM CELL B, V105, P123, DOI 10.1016/j.biocel.2018.10.006
   Schaum N, 2018, NATURE, V562, P367, DOI 10.1038/s41586 018 0590 4
   Sculean A, 2015, PERIODONTOL 2000, V68, P7, DOI 10.1111/prd.12091
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   Shao Y, 2020, ARTERIOSCL THROM VAS, V40, pE138, DOI 10.1161/ATVBAHA.120.314330
   Shelby A, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104 020 05376 9
   Smith PC, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00270
   Smith T, 2017, GENOME RES, V27, P491, DOI 10.1101/gr.209601.116
   Smyth LCD, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974 018 1167 8
   Supakul S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051079
   Tompkins KA, 2016, CONNECT TISSUE RES, V57, P69, DOI 10.3109/03008207.2016.1140152
   Tonna S, 2014, CALCIFIED TISSUE INT, V94, P35, DOI 10.1007/s00223 013 9738 2
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tsukasaki M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03147 6
   Turner RT, 2010, J BONE MINER RES, V25, P1637, DOI 10.1002/jbmr.49
   Vegh P, 2018, BRIEF FUNCT GENOMICS, V17, P265, DOI 10.1093/bfgp/ely003
   Vento Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586 018 0698 6
   Walsh MC, 2018, NAT REV RHEUMATOL, V14, P146, DOI 10.1038/nrrheum.2017.213
   Wang H, 2020, J PATHOL, V251, P323, DOI 10.1002/path.5456
   Wang H, 2019, J BONE MINER RES, V34, P1169, DOI 10.1002/jbmr.3677
   Wang N, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17193 5
   Wang YC, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 019 0228 0
   Weng LH, 2016, SCI REP UK, V6, DOI 10.1038/srep38632
   Williams DW, 2021, CELL, V184, P4090, DOI 10.1016/j.cell.2021.05.013
   Xiao L, 2018, J BONE MINER RES, V33, P1090, DOI 10.1002/jbmr.3396
   Xing XD, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd9738
   Xu J., 2020, BONE RES, V8, P22, DOI DOI 10.1038/S41413 020 0097 0
   Yaari G, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt660
   Yang XZ, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6813016
   Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590 019 0378 1
   Zhang F, 2017, SCI REP UK, V7, DOI 10.1038/srep41634
   Zhang JH, 2016, MOL MED REP, V13, P2423, DOI 10.3892/mmr.2016.4824
   Zhang L, 2020, CELL, V181, P442, DOI 10.1016/j.cell.2020.03.048
   Zhang L, 2018, NATURE, V564, P268, DOI 10.1038/s41586 018 0694 x
   Zhang LS, 2021, CELL BIOSCI, V11, DOI [10.1186/s13578 020 00516 x, 10.16505/j.2095 0136.2020.0078]
   Zhang T, 2021, EUR J PHARM SCI, V157, DOI 10.1016/j.ejps.2020.105598
   Zhong LL, 2020, ELIFE, V9, DOI 10.7554/eLife.54695
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhou Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20059 6
   Zhu SP, 2020, THERANOSTICS, V10, P5957, DOI 10.7150/thno.45422
NR 127
TC 110
Z9 120
U1 24
U2 167
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2022
VL 12
IS 3
BP 1074
EP 1096
DI 10.7150/thno.65694
PG 23
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA YI8MZ
UT WOS:000744098300003
PM 35154475
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Smyth, B
   Ong, S
AF Smyth, B.
   Ong, S.
TI Severe hypocalcaemia and hypophosphataemia following intravenous iron
   and denosumab: a novel drug interaction
SO INTERNAL MEDICINE JOURNAL
LA English
DT Article
DE hypocalcaemia; hypophosphataemia; intravenous iron; iron polymaltose;
   denosumab; chronic kidney disease
ID POSTMENOPAUSAL WOMEN; BONE METASTASES; FGF23; HYPERPARATHYROIDISM;
   PHOSPHATE
AB We present the case of a 59 year old woman with chronic kidney disease who suffered severe hypocalcaemia and hypophosphataemia after receiving denosumab and intravenous iron. This potentially life threatening adverse drug interaction has never been reported before. We propose a mechanism to explain it with reference to the physiological derangements caused by both agents on calcium and phosphate homeostasis.
C1 [Smyth, B.; Ong, S.] St George Hosp, Dept Nephrol, Sydney, NSW, Australia.
C3 St George Hospital
RP Smyth, B (通讯作者)，205D 250 Anzac Parade, Kensington, NSW 2033, Australia.
EM brendanjsmyth@gmail.com
CR Blazevic A, 2014, NETH J MED, V72, P49
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Farinola N, 2013, INTERN MED J, V43, P1243, DOI 10.1111/imj.12283
   Fierz YC, 2014, EUR J CLIN NUTR, V68, P531, DOI 10.1038/ejcn.2014.20
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Ikesue H, 2014, ANN PHARMACOTHER, V48, P1159, DOI 10.1177/1060028014539919
   Lanske B, 2014, KIDNEY INT, V86, P1071, DOI 10.1038/ki.2014.316
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Narayanan Prasad, 2013, South Asian J Cancer, V2, P272, DOI 10.4103/2278 330X.119895
   Prats M, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 167
   Recknor C, 2013, OBSTET GYNECOL, V121, P1291, DOI 10.1097/AOG.0b013e318291718c
   Schouten BJ, 2009, J CLIN ENDOCR METAB, V94, P2332, DOI 10.1210/jc.2008 2396
   Shimizu Y, 2009, BONE, V45, P814, DOI 10.1016/j.bone.2009.06.017
   Sirvent AE, 2014, NEFROLOGIA, V34, P542, DOI 10.3265/Nefrologia.pre2014.Mar.12383
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Takeda Y, 2011, AM J NEPHROL, V33, P421, DOI 10.1159/000327019
   Watkins KR, 2015, SUPPORT CARE CANCER, V23, P1657, DOI 10.1007/s00520 014 2521 8
   Yamamoto S, 2012, INTERNAL MED, V51, P2375, DOI 10.2169/internalmedicine.51.7450
NR 20
TC 18
Z9 18
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1444 0903
EI 1445 5994
J9 INTERN MED J
JI Intern. Med. J.
PD MAR
PY 2016
VL 46
IS 3
BP 360
EP 363
DI 10.1111/imj.13001
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA DH8UT
UT WOS:000373073100017
PM 26968599
DA 2025 08 17
ER

PT J
AU Mohamed, AH
   Hassan, AN
   Hay, NHA
   Ahmed, MF
   Sawy, MME
   Sonbol, MM
   Mohamed, RH
AF Mohamed, Amany Helmy
   Hassan, Ahmed Noureldin
   Hay, Nesma Hussein Abdel
   Ahmed, Manar Fouad
   Sawy, Marwa M. El
   Sonbol, Mohamed M.
   Mohamed, Reham Hussein
TI The potential role of SNHG16/ miRNA 146a/ TRAF6 signaling pathway in the
   protective effect of zoledronate against colorectal cancer and
   associated osteoporosis in mouse model
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Colorectal Cancer; Osteoporosis; Zoledronate; TRAF6; SNHG16; miRNA 146a
ID BREAST CANCER; BONE LOSS; ACID; CELLS; INHIBITION; EXPRESSION; PROMOTES;
   BISPHOSPHONATES; OSTEOCLASTS; METASTASIS
AB Bone fracture as a consequence of colorectal cancer (CRC) and associated osteoporosis (OP) is considered a risk factor for increasing the mortality rate among CRC patients. SNHG16/ miRNA 146a/ TRAF6 signaling pathway is a substantial contributor to neoplastic evolution, progression, and metastasis. Here, we investigated the effect of zoledronate (ZOL) on the growth of CRC and associated OP in a mouse model. Thirty Balb/c mice were divided into Na & iuml;ve, azoxymethane (AOM)/dextran sodium sulfate (DSS), and ZOL groups. Body weight and small nucleolar RNA host gene 16 (SNHG16) expression, microRNA 146a, and TRAF6 in bone, colon, and stool were investigated. Samples of colon and bone were collected and processed for light microscopic, immunohistochemical staining for cytokeratin 20 (CK20), nuclear protein Ki67 (pKi 67), and caudal type homeobox transcription factor 2 (CDx2) in colon and receptor activator of nuclear factor kB (RANK) and osteoprotegerin (OPG) in bone. A computerized tomography (CT) scan of the femur and tibia was studied. ZOL produced a significant decrease in the expression of SNHG16 and TRAF6 and an increase in miRNA 146a in the colon and bone. ZOL administration improved the histopathological changes in the colon, produced a significant decrease in CK20 and Ki 67, and increased CDx2 expressions. In bone, ZOL prevented osteoporotic changes and tumour cell invasion produced a significant decrease in RANK and an increase in OPG expressions, alongside improved bone mineral density in CT scans. ZOL could be a promising preventive therapy against colitis induced cancer and associated OP via modulation expression of SNHG16, miRNA 146a, and TRAF6.
C1 [Hassan, Ahmed Noureldin] Galala Univ, Fac Med, Dept Pharmacol, Al Galala, Egypt.
   [Mohamed, Amany Helmy; Hassan, Ahmed Noureldin; Mohamed, Reham Hussein] Ain Shams Univ, Fac Med, Dept Clin Pharmacol, Cairo, Egypt.
   [Hay, Nesma Hussein Abdel; Ahmed, Manar Fouad] Ain Shams Univ, Fac Med, Dept Med Biochem & Mol Biol, Cairo, Egypt.
   [Sawy, Marwa M. El; Sonbol, Mohamed M.] Ain Shams Univ, Fac Med, Dept Anat & Embryol, Cairo, Egypt.
C3 Galala University; Egyptian Knowledge Bank (EKB); Ain Shams University;
   Egyptian Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge
   Bank (EKB); Ain Shams University
RP Mohamed, RH (通讯作者)，Ain Shams Univ, Fac Med, Dept Clin Pharmacol, Cairo, Egypt.
EM rehamhussein@med.asu.edu.eg
CR Abd Elwahab RM, 2023, Zagazig University Medical Journal, V29, P368, DOI [10.21608/zumj.2019.16509.1479, DOI 10.21608/ZUMJ.2019.16509.1479]
   [Anonymous], 2013, Molecular and Cellular Biology
   Asila A, 2021, J GENE MED, V23, DOI 10.1002/jgm.3296
   Barzi A, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 019 0629 7
   Bernstein CN, 2000, ANN INTERN MED, V133, P795, DOI 10.7326/0003 4819 133 10 200011210 00012
   Bishop RT, 2020, CANCER LETT, V488, P27, DOI 10.1016/j.canlet.2020.05.021
   Boissier S, 2000, CANCER RES, V60, P2949
   Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823
   Bonetto A, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00679
   Borghese C, 2017, ONCOTARGET, V8, P42926, DOI 10.18632/oncotarget.17216
   Bruzzese F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.406
   Bürtin F, 2020, WORLD J GASTROENTERO, V26, P1394, DOI 10.3748/wjg.v26.i13.1394
   Buijs JT, 2009, BONE, V44, P380, DOI 10.1016/j.bone.2008.10.047
   Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   Chen ZY, 2022, GENE THER, V29, P193, DOI 10.1038/s41434 020 0176 2
   Cheng W, 2019, EUR REV MED PHARMACO, V23, P9222, DOI 10.26355/eurrev_201911_19414
   Cui PP, 2018, HISTOL HISTOPATHOL, V33, P89, DOI 10.14670/HH 11 893
   Ghafouri Fard S, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.741684
   Greco SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132786
   Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025
   Hong C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190901
   Hsieh YT, 2022, J BIOMED SCI, V29, DOI 10.1186/s12929 022 00849 4
   Hu YL, 2020, J CELL MOL MED, V24, P7637, DOI 10.1111/jcmm.15399
   Huang XL, 2019, INT J MOL MED, V44, P582, DOI 10.3892/ijmm.2019.4207
   Infante M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 018 1001 2
   Kocijan R, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115104
   Konukiewitz B, 2021, BRIT J CANCER, V125, P1632, DOI 10.1038/s41416 021 01553 0
   Lei HT, 2022, ONCOL LETT, V24, DOI 10.3892/ol.2022.13540
   Li HJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 1522 3
   Li JD, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935 020 01517 z
   Li Pengfei, 2017, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V34, P78
   Li TT, 2024, J CANCER, V15, P560, DOI 10.7150/jca.90059
   Li X, 2017, SCI REP UK, V7, DOI 10.1038/srep41358
   Lin PH, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 022 05524 y
   Liu LM, 2018, ENVIRON TOXICOL, V33, P743, DOI 10.1002/tox.22561
   Meng QC, 2020, THERANOSTICS, V10, P3967, DOI 10.7150/thno.40566
   Metzger CE, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 51550 w
   Morgan E, 2023, GUT, V72, P338, DOI 10.1136/gutjnl 2022 327736
   Morii K, 2015, INTERNAL MED, V54, P2609, DOI 10.2169/internalmedicine.54.4430
   Mulyawan IM, 2019, International Journal of Research in Medical Sciences, V7, P644, DOI [10.18203/2320 6012.ijrms20190374, DOI 10.18203/2320 6012.IJRMS20190374]
   Nakasa T, 2011, ARTHRITIS RHEUM US, V63, P1582, DOI 10.1002/art.30321
   Oh HH, 2020, INTEST RES, V18, P168, DOI 10.5217/ir.2019.00080
   Pan JA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1901 x
   Peng HJ, 2007, CANCER RES, V67, P9346, DOI 10.1158/0008 5472.CAN 06 4508
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.11
   Rack B, 2010, ANTICANCER RES, V30, P1807
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Rashid H, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00181
   Singh H, 2012, CANCER AM CANCER SOC, V118, P1236, DOI 10.1002/cncr.26395
   Singh J, 2022, J CANCER RES THER, V18, pS420, DOI 10.4103/jcrt.JCRT_1723_20
   Song G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.649020
   Starczynowski DT, 2011, J CLIN INVEST, V121, P4095, DOI 10.1172/JCI58818
   Suvarna KimS., 2013, Theory and Practice of Histological Techniques, V7
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Thosani N, 2013, J CLIN ONCOL, V31, P623, DOI 10.1200/JCO.2012.42.9530
   Tong GJ, 2020, ONCOL REP, V43, P1187, DOI 10.3892/or.2020.7511
   Vogtmann E, 2017, SCI REP UK, V7, DOI 10.1038/srep44177
   Wang LW, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 07568 9
   Wilson C, 2018, EUR J CANCER, V94, P70, DOI 10.1016/j.ejca.2018.02.004
   Wu H, 2019, INT IMMUNOPHARMACOL, V68, P204, DOI 10.1016/j.intimp.2018.12.043
   Xie YM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00478
   Xu H, 2023, CANCER MED US, V12, P19807, DOI 10.1002/cam4.6552
   Yamakawa Y, 2017, CANCER SCI, V108, P1870, DOI 10.1111/cas.13316
   Yang M, 2019, ONCOTARGETS THER, V12, P11679, DOI 10.2147/OTT.S231630
   Zhang B, 2016, FEBS LETT, V590, P2190, DOI 10.1002/1873 3468.12229
   Zhang L, 2022, CELL MOL BIOENG, V15, P87, DOI 10.1007/s12195 021 00699 4
   Zhang Q, 2015, ONCOTARGET, V6, P26041, DOI 10.18632/oncotarget.4667
   Zhang T, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.23931
   Zhong JH, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160578
   Zhou CF, 2012, IUBMB LIFE, V64, P775, DOI 10.1002/iub.1066
   Zhu GW, 2022, CANCER SCI, V113, P1393, DOI 10.1111/cas.15302
NR 72
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAY 30
PY 2024
VL 133
AR 112125
DI 10.1016/j.intimp.2024.112125
EA APR 2024
PG 11
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA SD4L9
UT WOS:001232506300001
PM 38657499
DA 2025 08 17
ER

PT J
AU Pantovic, A
   Krstic, A
   Janjetovic, K
   Kocic, J
   Harhaji Trajkovic, L
   Bugarski, D
   Trajkovic, V
AF Pantovic, Aleksandar
   Krstic, Aleksandra
   Janjetovic, Kristina
   Kocic, Jelena
   Harhaji Trajkovic, Ljubica
   Bugarski, Diana
   Trajkovic, Vladimir
TI Coordinated time dependent modulation of AMPK/Akt/mTOR signaling and
   autophagy controls osteogenic differentiation of human mesenchymal stem
   cells
SO BONE
LA English
DT Article
DE Mesenchymal stem cells; Osteoblasts; AMPK; Akt; mTOR; Autophagy
ID ACTIVATED PROTEIN KINASE; OSTEOBLASTIC MC3T3 E1 CELLS; BMP 2 EXPRESSION;
   STROMAL CELLS; IN VITRO; AMP KINASE; MTOR; BONE; AKT; RAPAMYCIN
AB We investigated the role of AMP activated protein kinase (AMPK), Akt, mammalian target of rapamycin (mTOR), autophagy and their interplay in osteogenic differentiation of human dental pulp mesenchymal stem cells. The activation of various members of AMPK, Akt and mTOR signaling pathways and autophagy was analyzed by immunoblotting, while osteogenic differentiation was assessed by alkaline phosphatase staining and real time RT PCR/immunoblot quantification of osteocalcin, Runt related transcription factor 2 and bone morphogenetic protein 2 mRNA and/or protein levels. Osteogenic differentiation of mesenchymal stem cells was associated with early (day 1) activation of AMPK and its target Raptor, coinciding with the inhibition of mTOR and its substrate p70S6 kinase. The early induction of autophagy was demonstrated by accumulation of autophagosome bound LC3 11, upregulation of proautophagic,beclin 1 and a decrease in the selective autophagic target p62. This was followed by the late activation of Akt/mTOR at days 3 7 of differentiation. The RNA interference mediated silencing of AMPK, mTOR or autophagy essential LC3 beta, as well as the pharmacological inhibitors of AMPK (compound C), Akt (10 DEBC hydrochloride), mTOR (rapamycin) and autophagy (bafilomycin A1, chloroquine and ammonium chloride), each suppressed mesenchymal stem cell differentiation to osteoblasts. AMPK knockdown prevented early mTOR inhibition and autophagy induction, as well as late activation of Akt/mTOR signaling, while Ala inhibition suppressed mTOR activation without affecting AMPK phosphorylation. Our data indicate that AMPK controls osteogenic differentiation of human mesenchymal stem cells through both early mTOR inhibition mediated autophagy and late activation of Akt/mTOR signaling axis. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Krstic, Aleksandra; Kocic, Jelena; Bugarski, Diana] Univ Belgrade, Inst Med Res, Lab Expt Hematol & Stem Cells, Belgrade 11000, Serbia.
   [Pantovic, Aleksandar; Janjetovic, Kristina; Trajkovic, Vladimir] Univ Belgrade, Inst Microbiol & Immunol, Sch Med, Belgrade 11000, Serbia.
   [Janjetovic, Kristina; Harhaji Trajkovic, Ljubica] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Belgrade 11000, Serbia.
C3 University of Belgrade; University of Belgrade; University of Belgrade
RP Bugarski, D (通讯作者)，Univ Belgrade, Inst Med Res, Lab Expt Hematol & Stem Cells, Dr Subotica 4, Belgrade 11000, Serbia.
EM dianab@imi.bg.ac.rs; vtrajkovic@eunet.rs
RI ; Krstic, Jelena/L 3743 2016; Pantovic, Aleksandar/AFQ 2417 2022;
   Torriglia, Alicia/Q 3509 2019; Janjetovic, Kristina/JPL 1540 2023;
   Trajkovic, Ljubica/AFM 2488 2022; Harhaji Trajkovic,
   Ljubica/AFM 2488 2022
OI Jaukovic, Aleksandra/0000 0003 2686 7481; Krstic,
   Jelena/0000 0002 3423 533X; Pantovic, Aleksandar/0000 0003 4062 8962;
   Janjetovic, Kristina/0000 0003 1387 480X; Trajkovic,
   Vladimir/0000 0002 8061 2968; Harhaji Trajkovic,
   Ljubica/0000 0001 8757 555X
FU Ministry of Education and Science of the Republic of Serbia [41025,
   173053, 175062]; UNESCO L'OREAL National Scholarship Program "For Women
   in Science" [403F]
FX The study was supported by the Ministry of Education and Science of the
   Republic of Serbia (grants 41025, 173053 and 175062 to VT, LHT and DB)
   and the UNESCO L'OREAL National Scholarship Program "For Women in
   Science" (LHT, contract number 403F).
CR Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Chen Y, 2008, INT J BIOCHEM CELL B, V40, P815, DOI 10.1016/j.biocel.2008.01.007
   d'Aquino R, 2008, STEM CELL REV, V4, P21, DOI 10.1007/s12015 008 9013 5
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hardie DG, 2011, EMBO J, V30, P634, DOI 10.1038/emboj.2011.12
   Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008
   Isomoto S, 2007, J ORTHOP SCI, V12, P83, DOI 10.1007/s00776 006 1079 9
   Jang WG, 2011, BIOCHEM BIOPH RES CO, V404, P1004, DOI 10.1016/j.bbrc.2010.12.099
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Janjetovic K, 2011, EUR J PHARMACOL, V651, P41, DOI 10.1016/j.ejphar.2010.11.005
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Kim EK, 2012, J CELL PHYSIOL, V227, P1680, DOI 10.1002/jcp.22892
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Krampera M, 2006, BONE, V39, P678, DOI 10.1016/j.bone.2006.04.020
   Laino G, 2006, J CELL PHYSIOL, V206, P693, DOI 10.1002/jcp.20526
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Leclerc Gilles M, 2010, J Mol Signal, V5, P15, DOI 10.1186/1750 2187 5 15
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Levine YC, 2007, J BIOL CHEM, V282, P20351, DOI 10.1074/jbc.M702182200
   Lieberthal W, 2011, AM J PHYSIOL RENAL, V301, pF1177, DOI 10.1152/ajprenal.00034.2011
   Liu H, 2006, METHOD ENZYMOL, V419, P99, DOI 10.1016/S0076 6879(06)19005 9
   Martin SK, 2010, J BONE MINER RES, V25, P2126, DOI 10.1002/jbmr.114
   Mcgee SL, 2008, FRONT BIOSCI LANDMRK, V13, P3022, DOI 10.2741/2907
   Misirkic M, 2012, PHARMACOL RES, V65, P111, DOI 10.1016/j.phrs.2011.08.003
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mukherjee A, 2010, MOL CELL BIOL, V30, P1018, DOI 10.1128/MCB.01401 09
   Quinn JMW, 2010, FASEB J, V24, P275, DOI 10.1096/fj.09 137158
   ROGERS SW, 1988, J BIOL CHEM, V263, P19843
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748 1716.2009.01972.x
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Takatani T, 2011, MOL CELL ENDOCRINOL, V339, P114, DOI 10.1016/j.mce.2011.04.003
   Tseng WP, 2010, J CELL PHYSIOL, V223, P810, DOI 10.1002/jcp.22104
   Villar V, 2010, FEBS LETT, V584, P4586, DOI 10.1016/j.febslet.2010.10.020
   Vucicevic L, 2011, AUTOPHAGY, V7, P40, DOI 10.4161/auto.7.1.13883
   Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730
   Xiang XX, 2011, ACTA BIOCH BIOPH SIN, V43, P501, DOI 10.1093/abbs/gmr041
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 48
TC 212
Z9 238
U1 6
U2 96
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD JAN
PY 2013
VL 52
IS 1
BP 524
EP 531
DI 10.1016/j.bone.2012.10.024
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 060BK
UT WOS:000312750700062
PM 23111315
DA 2025 08 17
ER

PT J
AU Vermeulen, S
   Knoops, K
   Duimel, H
   Parvizifard, M
   van Beurden, D
   López Iglesias, C
   Giselbrecht, S
   Truckenmüller, R
   Habibovic, P
   Birgani, ZT
AF Vermeulen, Steven
   Knoops, Kevin
   Duimel, Hans
   Parvizifard, Maryam
   van Beurden, Denis
   Lopez Iglesias, Carmen
   Giselbrecht, Stefan
   Truckenmueller, Roman
   Habibovic, Pamela
   Birgani, Zeinab Tahmasebi
TI An in vitro model system based on calcium  and phosphate
   ion induced hMSC spheroid mineralization
SO MATERIALS TODAY BIO
LA English
DT Article
DE Mesenchymal stromal cells; Spheroids; Calcium; Phosphate;
   Mineralization; Bone; Regenerative medicine
ID PROTEIN KINASE; INORGANIC PHOSPHATE; DIFFERENTIATION; CULTURE; CELLS;
   WNT; DISEASE; BMP; OSTEOGENESIS; OSTEOBLASTS
AB A challenge in regenerative medicine is creating the three dimensional organic and inorganic in vitro microenvironment of bone, which would allow the study of musculoskeletal disorders and the generation of building blocks for bone regeneration. This study presents a microwell based platform for creating spheroids of human mesenchymal stromal cells, which are then mineralized using ionic calcium and phosphate supplementation. The resulting mineralized spheroids promote an osteogenic gene expression profile through the influence of the spheroids' biophysical environment and inorganic signaling and require less calcium or phosphate to achieve mineralization compared to a monolayer culture. We found that mineralized spheroids represent an in vitro model for studying small molecule perturbations and extracellular mediated calcification. Furthermore, we demonstrate that understanding pathway signaling elicited by the spheroid environment allows mimicking these pathways in traditional monolayer culture, enabling similar rapid mineralization events. In sum, this study demonstrates the rapid generation and employment of a mineralized cell model system for regenerative medicine applications.
C1 [Vermeulen, Steven; Parvizifard, Maryam; van Beurden, Denis; Giselbrecht, Stefan; Truckenmueller, Roman; Habibovic, Pamela; Birgani, Zeinab Tahmasebi] Maastricht Univ, MERLN Inst Technol Inspired Regenerat Med, Dept Instruct Biomat Engn, Maastricht, Netherlands.
   [Knoops, Kevin; Duimel, Hans; Lopez Iglesias, Carmen] Maastricht Univ, M4I Fac Hlth Med & Life Sci, Microscopy CORE Lab, Maastricht, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Maastricht University
RP Birgani, ZT (通讯作者)，Maastricht Univ, MERLN Inst Technol Inspired Regenerat Med, Dept Instruct Biomat Engn, Maastricht, Netherlands.
EM z.tahmasebibirgani@maastrichtuniversity.nl
RI Vermeulen, Steven/ADS 7474 2022; Giselbrecht, Stefan/H 2174 2013;
   Knoops, Kèvin/F 6247 2012
OI Tahmasebi Birgani, Zeinab (Niloofar)/0000 0003 3899 922X; Habibovic,
   Pamela/0000 0001 8249 5155; Giselbrecht, Stefan/0000 0002 1354 0167;
   Truckenmuller, Roman/0000 0001 7541 525X; Knoops,
   Kevin/0000 0002 7539 1160; Vermeulen, Steven/0000 0001 6797 7084
FU European Union Interreg Vlaanderen Nederland project [0433]; Dutch
   Province of Limburg [SAS 2014 00837, SAS 2018 02477]; Gravitation
   Program of the Netherlands Organization for Scientific Research (NWO)
   [024.003.013]; NWO Incentive Grant for Women in STEM [18748]
FX The authors thank Dr. Pinak Samal and Dr. Philipp Maurer from the MERLN
   institute for the design, fabrication, and provision of the brass molds.
   SV, SG, RT, PH and ZTB acknowledge the financial support of the European
   Union Interreg Vlaanderen Nederland project ("BIOMAT on microfluidic
   chip"; grant no. 0433) , the Dutch Province of Limburg (program "Limburg
   INvesteert in haar Kenniseconomie/LINK"; grant nos. SAS 2014 00837 and
   SAS 2018 02477) and the Gravitation Program of the Netherlands
   Organization for Scientific Research (NWO) (project 'Materials Driven
   Regeneration'; grant no. 024.003.013) . ZTB gratefully acknowledges the
   NWO Incentive Grant for Women in STEM (Project "Biotetris", grant no.
   18748) . Fig. 1 was created with Bio Render.com .
CR An SF, 2015, INT J MOL MED, V36, P215, DOI 10.3892/ijmm.2015.2218
   Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Baptista D, 2022, ACS BIOMATER SCI ENG, V8, P2684, DOI 10.1021/acsbiomaterials.1c01463
   Barradas AMC, 2012, BIOMATERIALS, V33, P3205, DOI 10.1016/j.biomaterials.2012.01.020
   Beck GR, 2003, J BIOL CHEM, V278, P41921, DOI 10.1074/jbc.M304470200
   Belliveau J, 2001, ANAL BIOCHEM, V291, P69, DOI 10.1006/abio.2001.5002
   Blankenship JR, 2005, INFECT IMMUN, V73, P5767, DOI 10.1128/IAI.73.9.5767 5774.2005
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Bussche L, 2016, J BIOL CHEM, V291, P24390, DOI 10.1074/jbc.M116.726117
   Choudhary S, 2004, BIOCHEM BIOPH RES CO, V322, P395, DOI 10.1016/j.bbrc.2004.07.129
   Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082
   Danoux CBSS, 2015, ACTA BIOMATER, V17, P1, DOI 10.1016/j.actbio.2015.02.003
   Darrieutort Laffite C, 2018, JOINT BONE SPINE, V85, P687, DOI 10.1016/j.jbspin.2017.10.004
   Daudon M, 2008, AIP CONF PROC, V1049, P199, DOI 10.1063/1.2998023
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Driehuis E, 2020, NAT PROTOC, V15, P3380, DOI 10.1038/s41596 020 0379 4
   Duchen MR, 2000, J PHYSIOL LONDON, V529, P57, DOI 10.1111/j.1469 7793.2000.00057.x
   Dutta D, 2017, TRENDS MOL MED, V23, P393, DOI 10.1016/j.molmed.2017.02.007
   Evans JT, 2019, LANCET, V393, P647, DOI 10.1016/S0140 6736(18)31665 9
   Faas FGA, 2012, J CELL BIOL, V198, P457, DOI 10.1083/jcb.201201140
   Fois MG, 2022, SMALL, V18, DOI 10.1002/smll.202202112
   FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715
   Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226
   Giselbrecht S, 2006, BIOMED MICRODEVICES, V8, P191, DOI 10.1007/s10544 006 8174 8
   Golub EE, 2009, BBA GEN SUBJECTS, V1790, P1592, DOI 10.1016/j.bbagen.2009.09.006
   Hall GN, 2020, ADV SCI, V7, DOI 10.1002/advs.201902295
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Hao CP, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 93307 4
   He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430
   Holm E, 2014, BIOCHEM J, V464, P355, DOI 10.1042/BJ20140702
   Hsu SH, 2013, BIOMATERIALS, V34, P4725, DOI 10.1016/j.biomaterials.2013.03.031
   Huch M, 2015, DEVELOPMENT, V142, P3113, DOI 10.1242/dev.118570
   Jeger Madiot N, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 87459 6
   Jiang B, 2017, BIOMATERIALS, V133, P275, DOI 10.1016/j.biomaterials.2017.03.050
   Kabiri M, 2012, BIOCHEM BIOPH RES CO, V419, P142, DOI 10.1016/j.bbrc.2012.01.017
   Kakni P, 2020, ADV BIOSYST, V4, DOI 10.1002/adbi.202000126
   Keller A, 2013, NAT GENET, V45, P1077, DOI 10.1038/ng.2723
   Langenbach F, 2011, NAT PROTOC, V6, P1726, DOI 10.1038/nprot.2011.394
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Mahboubi S, 2001, PEDIATR RADIOL, V31, P307, DOI 10.1007/s002470100447
   McQuin C, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005970
   Meleti Z, 2000, BONE, V27, P359, DOI 10.1016/S8756 3282(00)00346 X
   Mohamed Ahmed S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0914 1
   Nahar NN, 2008, J BONE MINER METAB, V26, P514, DOI 10.1007/s00774 008 0859 z
   Pape HC, 2010, J ORTHOP TRAUMA, V24, pS36, DOI 10.1097/BOT.0b013e3181cec4a1
   Passanha FR, 2020, BIOMATERIALS, V254, DOI 10.1016/j.biomaterials.2020.120127
   Pedraza CE, 2008, J CELL BIOCHEM, V103, P1379, DOI 10.1002/jcb.21515
   Penido MGMG, 2012, PEDIATR NEPHROL, V27, P2039, DOI 10.1007/s00467 012 2175 z
   QUELCH KJ, 1983, ARCH ORAL BIOL, V28, P665, DOI 10.1016/0003 9969(83)90100 0
   Rammelt S, 2005, J BIOMED MATER RES A, V73A, P284, DOI 10.1002/jbm.a.30263
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Samal P, 2020, ADV MATER, V32, DOI 10.1002/adma.201907966
   Sato N, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06257 1
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Solchaga LA, 2011, METHODS MOL BIOL, V698, P253, DOI 10.1007/978 1 60761 999 4_20
   Tada H, 2011, BONE, V48, P1409, DOI 10.1016/j.bone.2011.03.675
   Tonk G, 2022, J ORTHOP TRAUMA REHA, V29, DOI 10.1177/22104917221092163
   Truckenmüller R, 2011, ADV MATER, V23, P1311, DOI 10.1002/adma.201003538
   Tsai AC, 2015, TISSUE ENG PT A, V21, P1705, DOI [10.1089/ten.tea.2014.0314, 10.1089/ten.TEA.2014.0314]
   Vadivelu RK, 2017, MICROMACHINES BASEL, V8, DOI 10.3390/mi8040094
   Veldurthy V, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.41
   Vermeulen S, 2022, BIOMATERIALS, V283, DOI 10.1016/j.biomaterials.2022.121431
   Vermeulen S, 2020, BIOMATERIALS, V259, DOI 10.1016/j.biomaterials.2020.120331
   Voorneveld PW, 2015, BRIT J CANCER, V112, P122, DOI 10.1038/bjc.2014.560
   WALEH NS, 1994, CANCER RES, V54, P838
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu LL, 2013, MOL BIOL REP, V40, P2533, DOI 10.1007/s11033 012 2334 0
   Yamamoto M, 2014, ARCH ORAL BIOL, V59, P310, DOI 10.1016/j.archoralbio.2013.12.006
   Yeh HY, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 10
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
   Zujur D, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602875
NR 75
TC 9
Z9 10
U1 1
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2590 0064
J9 MATER TODAY BIO
JI Mater. Today Bio
PD DEC
PY 2023
VL 23
AR 100844
DI 10.1016/j.mtbio.2023.100844
EA NOV 2023
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA Z5TU5
UT WOS:001112704700001
PM 38033367
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU El Hoss, J
   Kolind, M
   Jackson, MT
   Deo, N
   Mikulec, K
   McDonald, MM
   Little, CB
   Little, DG
   Schindeler, A
AF El Hoss, J.
   Kolind, M.
   Jackson, M. T.
   Deo, N.
   Mikulec, K.
   McDonald, M. M.
   Little, C. B.
   Little, D. G.
   Schindeler, A.
TI Modulation of endochondral ossification by MEK inhibitors PD0325901 and
   AZD6244 (Selumetinib)
SO BONE
LA English
DT Article
DE Ras MAPK; Fracture healing; Cancer; Cartilage remodeling; Endochondral
   ossification
ID METALLOPROTEINASE 13 DEFICIENT MICE; KINASE KINASE 1/2 INHIBITOR;
   HYPERTROPHIC CHONDROCYTES; SIGNALING PATHWAY; ADVANCED MELANOMA;
   BONE DEVELOPMENT; FRACTURE REPAIR; BREAST CANCER; MATRIX; GROWTH
AB MEK inhibitors (MEKi) PD0325901 and AZD6244 (Selumetinib) are drugs currently under clinical investigation for cancer treatment, however the Ras MAPK pathway is also an important mediator of normal bone cell differentiation and function. In this study we examined the effects of these compounds on endochondral processes using both in vitro and in vivo models. Treatment with PD0325901 or AZD6244 significantly increased Runx2 and Alkaline phosphate gene expression in calvarial osteoblasts and decreased TRAP + cells in induced osteoclast cultures. To test the effects of these drugs on bone healing, C57/Bl6 mice underwent a closed tibial fracture and were treated with PD0325901 or AZD6244 at 10 mg/kg/day. Animals were culled at day 10 and at day 21 post fracture for analysis of the fracture callus and the femoral growth plate in the contralateral leg. MEKi treatment markedly increased cartilage volume in the soft callus at day 10 post fracture (+ 60% PD0325901, +20% AZD6244) and continued treatment led to a delay in cartilage remodeling. At the growth plate, we observed an increase in the height of the hypertrophic zone relative to the proliferative zone of + 78% in PD0325901 treated mice. Osteoclast surface was significantly decreased both at the terminal end of the growth plate and within the fracture calluses of MEKi treated animals. The mechanistic effects of MEKi on genes encoding cartilage matrix proteins and catabolic enzymes were examined in articular chondrocyte cultures. PD0325901 or AZD6244 led to increased matrix protein expression (Col2a1 and Acan) and decreased expression of catabolic factors (Mmp13 and Adamts 5). Taken together, these data support the hypothesis that MEKi treatment can impact chondrocyte hypertrophy, matrix resorption, and fracture healing. These compounds can also affect bone architecture by expanding the hypertrophic zone of the growth plate and reducing osteoclast surface systemically. Crown Copyright (C) 2013 Published by Elsevier Inc. All rights reserved.
C1 [El Hoss, J.; Kolind, M.; Deo, N.; Mikulec, K.; Little, D. G.; Schindeler, A.] Childrens Hosp Westmead, Orthopaed Res & Biotechnol Unit, Sydney, NSW, Australia.
   [El Hoss, J.; Deo, N.; Little, D. G.; Schindeler, A.] Univ Sydney, Discipline Paediat & Child Hlth, Fac Med, Sydney, NSW 2006, Australia.
   [Jackson, M. T.; Little, C. B.] Univ Sydney, Raymond Purves Bone & Joint Res Labs, Kolling Inst Med Res, Royal N Shore Hosp, Sydney, NSW 2006, Australia.
   [McDonald, M. M.] Garvan Inst Med Res, Bone Biol Grp, Sydney, NSW, Australia.
C3 University of Sydney; NSW Health; The Children's Hospital at Westmead;
   University of Sydney; University of Sydney; Kolling Institute of Medical
   Research; Royal North Shore Hospital; Garvan Institute of Medical
   Research
RP Schindeler, A (通讯作者)，Childrens Hosp Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia.
EM aaron.schindeler@sydney.edu.au
RI ; Deo, Nikita/J 7688 2019; little, christopher/A 9280 2015; Little,
   Christopher/A 9280 2015; McDonald, Michelle/AAD 4760 2019
OI Schindeler, Aaron/0000 0002 7757 6281; Jackson,
   Miriam/0000 0002 6549 1926; Deo, Nikita/0000 0002 3810 488X; little,
   christopher/0000 0002 0353 7634; McDonald, Michelle/0000 0002 3928 2506
FU National Health and Medical Research Council (Australia) [APP1003478];
   University of Sydney (Australia); Children's Tumor Foundation (USA)
FX This work received funding support from the National Health and Medical
   Research Council under Project Grant APP1003478 (Australia), the
   University of Sydney (Australia), and the Children's Tumor Foundation
   (USA).
CR Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956
   Boasberg PD, 2011, CANCER CHEMOTH PHARM, V68, P547, DOI 10.1007/s00280 011 1620 1
   Bobick BE, 2004, J BIOL CHEM, V279, P4588, DOI 10.1074/jbc.M309805200
   Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280 006 0323 5
   Ciuffreda L, 2009, NEOPLASIA, V11, P720, DOI 10.1593/neo.09398
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Denton CL, 2011, CANCER CHEMOTH PHARM, V67, P349, DOI 10.1007/s00280 010 1323 z
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   El Hoss J, 2012, J BONE MINER RES, V27, P68, DOI 10.1002/jbmr.528
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Henderson YC, 2010, MOL CANCER THER, V9, P1968, DOI 10.1158/1535 7163.MCT 10 0062
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Huynh H, 2007, MOL CANCER THER, V6, P2468, DOI 10.1158/1535 7163.MCT 07 0162
   Jackson MT, 2009, ARTHRITIS RHEUM US, V60, P780, DOI 10.1002/art.24303
   Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578
   Kanis JA, 1999, BRIT J CANCER, V79, P1179, DOI 10.1038/sj.bjc.6690188
   Kirkwood JM, 2012, CLIN CANCER RES, V18, P555, DOI 10.1158/1078 0432.CCR 11 1491
   Kosaki N, 2007, BIOCHEM BIOPH RES CO, V354, P846, DOI 10.1016/j.bbrc.2006.12.234
   Koup Jeffrey R., 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P1248
   Lefebvre Veronique, 2005, Birth Defects Research, V75, P200, DOI 10.1002/bdrc.20048
   Little CB, 2009, ARTHRITIS RHEUM US, V60, P3723, DOI 10.1002/art.25002
   Little CB, 1997, OSTEOARTHR CARTILAGE, V5, P49, DOI 10.1016/S1063 4584(97)80031 3
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   McDonald MM, 2013, J BONE MINER RES, V28, P1550, DOI 10.1002/jbmr.1889
   Miedlich SU, 2010, J BIOL CHEM, V285, P18270, DOI 10.1074/jbc.M109.098616
   Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008 5472.CAN 11 2612
   Provot S, 2008, MOL CELL BIOL, V28, P344, DOI 10.1128/MCB.00617 07
   Ranch D, 2011, J BONE MINER RES, V26, P1883, DOI 10.1002/jbmr.401
   Schindeler A, 2008, J ORTHOP RES, V26, P1053, DOI 10.1002/jor.20628
   Schindeler A, 2006, J BONE MINER RES, V21, P1331, DOI 10.1359/JBMR.060603
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461
   Wang J, 2007, CURR TOP MED CHEM, V7, P1364
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078 0432.CCR 06 1150
   Zhang L, 2010, DIABETES OBES METAB, V12, P591, DOI 10.1111/j.1463 1326.2009.01193.x
NR 39
TC 25
Z9 26
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2014
VL 59
BP 151
EP 161
DI 10.1016/j.bone.2013.11.013
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 287QZ
UT WOS:000329558600021
PM 24269278
DA 2025 08 17
ER

PT J
AU Momenzadeh, K
   Yeritsyan, D
   Abbasian, M
   Kheir, N
   Hanna, P
   Wang, JL
   Dosta, P
   Papaioannou, G
   Goldfarb, S
   Tang, CC
   Amar Lewis, E
   Larrea, MNP
   Lozano, EM
   Yousef, M
   Wixted, J
   Wein, M
   Artzi, N
   Nazarian, A
AF Momenzadeh, Kaveh
   Yeritsyan, Diana
   Abbasian, Mohammadreza
   Kheir, Nadim
   Hanna, Philip
   Wang, Jialiang
   Dosta, Pere
   Papaioannou, Garyfallia
   Goldfarb, Sarah
   Tang, Cheng Chia
   Amar Lewis, Eliz
   Nicole Prado Larrea, Michaela
   Martinez Lozano, Edith
   Yousef, Mohamed
   Wixted, John
   Wein, Marc
   Artzi, Natalie
   Nazarian, Ara
TI Stimulation of fracture mineralization by salt inducible kinase
   inhibitors
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE bone; fracture repair; nanoscale drug delivery; SIK2/SIK3 inhibitor;
   PTH; siRNA targeting; microparticle
ID BONE MORPHOGENETIC PROTEINS; ILIAC CREST; POSTMENOPAUSAL WOMEN;
   PARATHYROID HORMONE; POLY(BETA AMINO ESTER)S; GRAFT; ORTHOBIOLOGICS;
   OSTEOPOROSIS; TERIPARATIDE; COMPLICATIONS
AB Introduction Over 6.8 million fractures occur annually in the US, with 10% experiencing delayed  or non union. Anabolic therapeutics like PTH analogs stimulate fracture repair, and small molecule salt inducible kinase (SIK) inhibitors mimic PTH action. This study tests whether the SIK inhibitor YKL 05 099 accelerates fracture callus osteogenesis.Methods 126 female mice underwent femoral shaft pinning and midshaft fracture, receiving daily injections of PBS, YKL 05 099, or PTH. Callus tissues were analyzed via RT qPCR, histology, single cell RNA seq, and mu CT imaging. Biomechanical testing evaluated tissue rigidity. A hydrogel based delivery system for PTH and siRNAs targeting SIK2/SIK3 was developed and tested.Results YKL 05 099 and PTH treated mice showed higher mineralized callus volume fraction and improved structural rigidity. RNA seq indicated YKL 05 099 increased osteoblast subsets and reduced chondrocyte precursors. Hydrogel released siRNAs maintained target knockdown, accelerating callus mineralization.Discussion YKL 05 099 enhances fracture repair, supporting selective SIK inhibitors' development for clinical use. Hydrogel based siRNA delivery offers targeted localized treatment at fracture sites.
C1 [Momenzadeh, Kaveh; Yeritsyan, Diana; Abbasian, Mohammadreza; Kheir, Nadim; Hanna, Philip; Martinez Lozano, Edith; Yousef, Mohamed; Wixted, John; Nazarian, Ara] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Musculoskeletal Translat Innovat Initiat, Boston, MA 02115 USA.
   [Wang, Jialiang] Univ Texas Southwestern Med Ctr, Charles & Jane Pak Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA.
   [Dosta, Pere; Amar Lewis, Eliz; Nicole Prado Larrea, Michaela; Artzi, Natalie] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA.
   [Dosta, Pere; Amar Lewis, Eliz; Nicole Prado Larrea, Michaela; Artzi, Natalie] MIT, Inst Med Engn & Sci, Cambridge, MA USA.
   [Dosta, Pere; Amar Lewis, Eliz; Artzi, Natalie] Harvard Univ, Wyss Inst Biolog Inspired Engn, Boston, MA 02115 USA.
   [Papaioannou, Garyfallia; Goldfarb, Sarah; Tang, Cheng Chia; Wein, Marc] Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02115 USA.
   [Nazarian, Ara] Boston Univ, Dept Mech Engn, Boston, MA 02135 USA.
   [Nazarian, Ara] Yerevan State Med Univ, Dept Orthopaed Surg, Yerevan, Armenia.
C3 Harvard University; Harvard University Medical Affiliates; Beth Israel
   Deaconess Medical Center; Harvard Medical School; University of Texas
   System; University of Texas Southwestern Medical Center; Harvard
   University; Harvard University Medical Affiliates; Brigham & Women's
   Hospital; Harvard Medical School; Massachusetts Institute of Technology
   (MIT); Harvard University; Harvard University; Harvard University
   Medical Affiliates; Massachusetts General Hospital; Harvard Medical
   School; Boston University; Yerevan State Medical University
RP Nazarian, A (通讯作者)，Harvard Med Sch, Beth Israel Deaconess Med Ctr, Musculoskeletal Translat Innovat Initiat, Boston, MA 02115 USA.; Nazarian, A (通讯作者)，Boston Univ, Dept Mech Engn, Boston, MA 02135 USA.; Nazarian, A (通讯作者)，Yerevan State Med Univ, Dept Orthopaed Surg, Yerevan, Armenia.
EM anazaria@bidmc.harvard.edu
RI Papaioannou, Garyfallia/LCE 0610 2024; Dosta, Pere/AGS 5904 2022;
   Momenzadeh, Kaveh/AAB 6270 2021; Amar Lewis, Eliz/LDG 2863 2024
OI Prado, Michaela/0000 0002 1024 7176; Amar Lewis,
   Eliz/0000 0001 9552 9780
FU MGH Endocrine Division T32 NIH [T32DK007028]; Chen Institute
   Massachusetts General Hospital Research Scholar [2024 2029]
FX The authors would like to acknowledge the following funding sources: AN
   received departmental funding for this project from the Carl J. Shapiro
   Department of Orthopaedic Surgery at BIDMC. MW, AN, and NA received
   funding for this project from Tara Ciongoli and the Stepping Strong
   Center at Brigham and Women's Hospital (Innovator and Breakthrough
   awards).
CR Antonova E, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 42
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Babbe H, 2024, P NATL ACAD SCI USA, V121, DOI 10.1073/pnas.2307086120
   BARRETTCONNOR E, 1995, AM J MED, V98, pS3, DOI 10.1016/S0002 9343(05)80037 3
   Bliuc D, 2015, J BONE MINER RES, V30, P637, DOI 10.1002/jbmr.2393
   Bray CC, 2017, ORTHOP CLIN N AM, V48, P333, DOI [10.1016/j.ocl.2017.03.006, 10.1016/j.oc1.2017.03.006]
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Busse JW, 2009, BMJ BRIT MED J, V338, DOI 10.1136/bmj.b351
   Buza JA, 2016, CLIN CASES MINER BON, V13, P101, DOI 10.11138/ccmbm/2016.13.2.101
   Calcei JG, 2019, CLIN SPORT MED, V38, P79, DOI 10.1016/j.csm.2018.08.005
   Clark K, 2012, P NATL ACAD SCI USA, V109, P16986, DOI 10.1073/pnas.1215450109
   Devine John G, 2012, Evid Based Spine Care J, V3, P35, DOI 10.1055/s 0031 1298616
   Dimitriou R, 2011, INJURY, V42, pS3, DOI 10.1016/j.injury.2011.06.015
   Dosta P, 2018, MOL SYST DES ENG, V3, P677, DOI 10.1039/c8me00006a
   Dosta P, 2023, THERANOSTICS, V13, P1, DOI 10.7150/thno.73966
   Dosta P, 2015, ACTA BIOMATER, V20, P82, DOI 10.1016/j.actbio.2015.03.029
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Fong K, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 103
   Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1
   Ghiasi Mohammad S, 2017, Bone Rep, V6, P87, DOI 10.1016/j.bonr.2017.03.002
   Goulet JA, 1997, CLIN ORTHOP RELAT R, P76
   Gross RH, 2012, J PEDIATR ORTHOPED, V32, P100, DOI 10.1097/BPO.0b013e31823d8350
   Guo J, 2017, J BONE MINER RES, V32, P86, DOI 10.1002/jbmr.2917
   Haas AV, 2018, J ENDOCR SOC, V2, P922, DOI 10.1210/js.2018 00118
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002
   Hegde V, 2016, OSTEOPOROSIS INT, V27, P861, DOI 10.1007/s00198 015 3331 7
   Hustedt Joshua W., 2014, Yale Journal of Biology and Medicine, V87, P549
   Jepsen KJ, 2008, J BONE MINER RES, V23, P1204, DOI 10.1359/JBMR.080317
   Khan SN, 2005, J AM ACAD ORTHOP SUR, V13, P77, DOI 10.5435/00124635 200501000 00010
   Lanske B, 2019, J ORTHOP RES, V37, P812, DOI 10.1002/jor.24254
   Li GQ, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 38597 0
   Li XF, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006571
   Long JJJ, 2023, ACS APPL MATER INTER, V15, P35815, DOI 10.1021/acsami.3c03047
   Mancilla EE, 2015, ENDOCR PRACT, V21, P136, DOI 10.4158/EP14315.OR
   Marrinan S, 2015, AGE AGEING, V44, P258, DOI 10.1093/ageing/afu123
   Marsell R, 2010, J ORTHOP TRAUMA, V24, pS4, DOI 10.1097/BOT.0b013e3181ca3fab
   Marturano JE, 2008, J BIOMECH, V41, P1222, DOI 10.1016/j.jbiomech.2008.01.029
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Mujahid N, 2017, CELL REP, V19, P2177, DOI 10.1016/j.celrep.2017.05.042
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nguyen ND, 2007, J BONE MINER RES, V22, P781, DOI 10.1359/JBMR.070315
   Nishimori S, 2019, J CLIN INVEST, V129, P5187, DOI 10.1172/JCI130126
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ozanne J, 2015, BIOCHEM J, V465, P271, DOI 10.1042/BJ20141165
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papakostidis C, 2008, SPINE, V33, pE680, DOI 10.1097/BRS.0b013e3181844eca
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   Ricarte FR, 2018, J BIOL CHEM, V293, P20200, DOI 10.1074/jbc.RA118.004751
   Roberts SJ, 2018, CURR OSTEOPOROS REP, V16, P289, DOI 10.1007/s11914 018 0440 1
   Roberts TT, 2012, ORGANOGENESIS, V8, P114, DOI 10.4161/org.23306
   Sato T, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2214396119
   Sato T, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10441
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Sohn HS, 2019, BIOMATER RES, V23
   Stroup J, 2008, AM J HEALTH SYST PH, V65, P532, DOI 10.2146/ajhp070171
   Sundberg TB, 2016, ACS CHEM BIOL, V11, P2105, DOI 10.1021/acschembio.6b00217
   Sundberg TB, 2014, P NATL ACAD SCI USA, V111, P12468, DOI 10.1073/pnas.1412308111
   Tang CC, 2021, ELIFE, V10, DOI 10.7554/eLife.67772
   Temal Laib T, 2023, J MED CHEM, V67, P380, DOI 10.1021/acs.jmedchem.3c01428
   Vaccaro AR, 2008, SPINE J, V8, P457, DOI 10.1016/j.spinee.2007.03.012
   Wang MD, 2018, BIOCONJUGATE CHEM, V29, P3800, DOI 10.1021/acs.bioconjchem.8b00660
   Wang YH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020337
   Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Wildemann B, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00289 8
   Wixted JJ, 2009, J CELL PHYSIOL, V221, P31, DOI 10.1002/jcp.21809
   Wojda SJ, 2021, TISSUE ENG PT A, V27, P246, DOI [10.1089/ten.tea.2020.0119, 10.1089/ten.TEA.2020.0119]
   Wojda SJ, 2020, J ORTHOP RES, V38, P536, DOI 10.1002/jor.24502
   Wright JG, 2005, J BONE JOINT SURG AM, V87A, P1909, DOI 10.2106/JBJS.8709.edit
   Yoon SH, 2023, J CLIN INVEST, V133, DOI 10.1172/JCI163627
NR 70
TC 1
Z9 1
U1 3
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD SEP 16
PY 2024
VL 12
AR 1450611
DI 10.3389/fbioe.2024.1450611
PG 14
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA H6A4M
UT WOS:001324245300001
PM 39359266
OA gold
DA 2025 08 17
ER

PT J
AU Wang, N
   Docherty, FE
   Brown, HK
   Reeves, KJ
   Fowles, ACM
   Ottewell, PD
   Dear, TN
   Holen, I
   Croucher, PI
   Eaton, CL
AF Wang, Ning
   Docherty, Freyja E.
   Brown, Hannah K.
   Reeves, Kimberley J.
   Fowles, Anne C. M.
   Ottewell, Penelope D.
   Dear, T. Neil
   Holen, Ingunn
   Croucher, Peter I.
   Eaton, Colby L.
TI Prostate Cancer Cells Preferentially Home to Osteoblast rich Areas in
   the Early Stages of Bone Metastasis: Evidence From In Vivo Models
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PROSTATE CANCER; BONE METASTASIS; OSTEOBLAST NICHE; TWO PHOTON
   MICROSCOPY
ID HEMATOPOIETIC STEM CELL; ENDOTHELIAL GROWTH FACTOR; N CADHERIN; NICHE;
   EXPRESSION; ADHESION; RECEPTOR; DIFFERENTIATION; ENGRAFTMENT; INDUCTION
AB It has been suggested that metastasis initiating cells gain a foothold in bone by homing to a metastastatic microenvironment (or niche). Whereas the precise nature of this niche remains to be established, it is likely to contain bone cell populations including osteoblasts and osteoclasts. In the mouse tibia, the distribution of osteoblasts on endocortical bone surfaces is non uniform, and we hypothesize that studying co localization of individual tumor cells with resident cell populations will reveal the identity of critical cellular components of the niche. In this study, we have mapped the distribution of three human prostate cancer cell lines (PC3 NW1, LN CaP, and C4 2B4) colonizing the tibiae of athymic mice following intracardiac injection and evaluated their interaction with potential metastatic niches. Prostate cancer cells labeled with the fluorescent cell membrane dye (Vybrant DiD) were found by two photon microscopy to be engrafted in the tibiae in close proximity (approximate to 40 mu m) to bone surfaces and 70% more cancer cells were detected in the lateral compared to the medial endocortical bone regions. This was associated with a 5 fold higher number of osteoblasts and 7 fold higher bone formation rate on the lateral endocortical bone surface compared to the medial side. By disrupting cellular interactions mediated by the chemokine (C X C motif) receptor 4 (CXCR4)/chemokine ligand 12 (CXCL12) axis with the CXCR4 inhibitor AMD3100, the preferential homing pattern of prostate cancer cells to osteoblast rich bone surfaces was disrupted. In this study, we map the location of prostate cancer cells that home to endocortical regions in bone and our data demonstrate that homing of prostate cancer cells is associated with the presence and activity of osteoblast lineage cells, and suggest that therapies targeting osteoblast niches should be considered to prevent development of incurable prostate cancer bone metastases. (c) 2014 American Society for Bone and Mineral Research.
C1 [Wang, Ning; Docherty, Freyja E.; Brown, Hannah K.; Fowles, Anne C. M.; Eaton, Colby L.] Univ Sheffield, Dept Human Metab, Mellanby Ctr Bone Res, Sheffield S10 2RX, S Yorkshire, England.
   [Reeves, Kimberley J.] Paterson Inst Canc Res Manchester, Break Breast Canc Res Unit, Manchester, Lancs, England.
   [Ottewell, Penelope D.; Holen, Ingunn] Univ Sheffield, Dept Oncol, Sheffield S10 2RX, S Yorkshire, England.
   [Dear, T. Neil] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia.
   [Croucher, Peter I.] Garvan Inst Med Res, Sydney, NSW, Australia.
C3 University of Sheffield; Paterson Institute for Cancer Research;
   University of Sheffield; South Australian Health & Medical Research
   Institute (SAHMRI); Garvan Institute of Medical Research
RP Eaton, CL (通讯作者)，Univ Sheffield, Dept Human Metab, Mellanby Ctr Bone Res, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM c.l.eaton@sheffield.ac.uk; c.l.eaton@sheffield.ac.uk
RI Wang, Ning/HKO 8446 2023
OI Croucher, Peter/0000 0002 7102 2413; Ottewell,
   Penelope/0000 0002 4826 0771; WANG, NING/0000 0002 2663 7515; Holen,
   Ingunn/0000 0002 8759 6913
FU program grant "Defining the Bone Metastasis Niche"   Cancer Research UK
   (CRUK); Mrs Gibson and the Ernest Heine Family Foundation; Cancer
   Research UK [11991] Funding Source: researchfish
FX This project was supported by the program grant "Defining the Bone
   Metastasis Niche" funded by Cancer Research UK (CRUK). PIC is funded by
   Mrs Gibson and the Ernest Heine Family Foundation. We also wish to thank
   the staff at the Bone Analysis Lab, The University of Sheffield, UK, for
   their excellent technical support. We also thank Clare McCartney, Jan
   Bilton, and Ben Woodman from St James's Biological Services, University
   of Leeds for their assistance.
CR Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Arai F, 2012, ANN NY ACAD SCI, V1266, P72, DOI 10.1111/j.1749 6632.2012.06576.x
   Arai F, 2009, ANN NY ACAD SCI, V1176, P36, DOI 10.1111/j.1749 6632.2009.04561.x
   Bianco P, 2011, BLOOD, V117, P5281, DOI 10.1182/blood 2011 01 315069
   Bragado Paloma, 2012, Recent Results Cancer Res, V195, P25, DOI 10.1007/978 3 642 28160 0_3
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726
   Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008 5472.CAN 03 1382
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Frost HM, 2001, ANAT RECORD, V262, P398, DOI 10.1002/ar.1049
   Hosokawa K, 2010, BLOOD, V116, P554, DOI 10.1182/blood 2009 05 224857
   Ibrahim T, 2010, CANCER AM CANCER SOC, V116, P1406, DOI 10.1002/cncr.24896
   JACOBS SC, 1983, UROLOGY, V21, P337, DOI 10.1016/0090 4295(83)90147 4
   Jayakumar P, 2010, P I MECH ENG H, V224, P1415, DOI 10.1243/09544119JEIM821
   Jemal A., 2011, CA: Cancer J. Clin., V61, P69, DOI [DOI 10.3322/CAAC.20107, DOI 10.3322/CAAC.70009]
   Jung YH, 2007, BLOOD, V110, P82, DOI 10.1182/blood 2006 05 021352
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389
   Keller ET, 2011, ASIAN J ANDROL, V13, P622, DOI 10.1038/aja.2011.50
   Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840
   Lehr JE, 1998, J NATL CANCER I, V90, P118, DOI 10.1093/jnci/90.2.118
   Mancini SJC, 2005, BLOOD, V105, P2340, DOI 10.1182/blood 2004 08 3207
   Marlow R, 2013, CANCER RES, V73, P6886, DOI 10.1158/0008 5472.CAN 13 0991
   Matsuura N, 1996, AM J PATHOL, V148, P55
   Miwa S, 2005, CANCER RES, V65, P8818, DOI 10.1158/0008 5472.CAN 05 0540
   Nakasaki M, 2008, BONE, V43, P869, DOI 10.1016/j.bone.2008.07.241
   Paget S., 1889, Cancer Metastasis Rev, V133, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Papayannopoulou T, 2001, BLOOD, V98, P2403, DOI 10.1182/blood.V98.8.2403
   Pedersen EA, 2012, ASIAN J ANDROL, V14, P423, DOI 10.1038/aja.2011.164
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Reeves KJ, 2011, CANCER RES, V71, DOI 10.1158/1538 7445.AM2011 2402
   Reeves KJ, 2009, FASEB J, V23
   Roberts E, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/418340
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Schuettpelz LG, 2011, J CLIN INVEST, V121, P1253, DOI 10.1172/JCI57229
   Shiozawa Y, 2008, J CELL BIOCHEM, V105, P370, DOI 10.1002/jcb.21835
   Shiozawa Y, 2011, CLIN CANCER RES, V17, P5553, DOI 10.1158/1078 0432.CCR 10 2505
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703
   Spector JA, 2001, AM J PHYSIOL CELL PH, V280, pC72, DOI 10.1152/ajpcell.2001.280.1.C72
   Sun YX, 2007, PROSTATE, V67, P61, DOI 10.1002/pros.20500
   Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109
   Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522
   Taichman RS, 2002, CANCER RES, V62, P1832
   Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood 2004 06 2480
   Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200
   Wang N, 2012, MOL ENDOCRINOL, V26, P142, DOI 10.1210/me.2011 1083
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
   Yu CY, 2012, CRIT REV EUKAR GENE, V22, P131, DOI 10.1615/CritRevEukarGeneExpr.v22.i2.50
   Yumoto K, 2014, CYTOM PART A, V85A, P548, DOI 10.1002/cyto.a.22434
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 55
TC 87
Z9 99
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2014
VL 29
IS 12
BP 2688
EP 2696
DI 10.1002/jbmr.2300
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AW4UB
UT WOS:000346274700020
PM 24956445
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Zhou, Y
   Mohan, A
   Moore, DC
   Lin, LJ
   Zhou, FL
   Cao, J
   Wu, Q
   Qin, YX
   Reginato, AM
   Ehrlich, MG
   Yang, WT
AF Zhou, Yi
   Mohan, Aron
   Moore, Douglas C.
   Lin, Liangjun
   Zhou, Frank Li
   Cao, Jay
   Wu, Qian
   Qin, Yi Xian
   Reginato, Anthony M.
   Ehrlich, Michael G.
   Yang, Wentian
TI SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion
SO FASEB JOURNAL
LA English
DT Article
DE M CSF; RANKL; Nfatc1
ID COLONY STIMULATING FACTOR; TYROSINE PHOSPHATASE SHP 2; ACTIVATED
   T CELLS; NOONAN SYNDROME; SIGNALING PATHWAY; NUCLEAR FACTOR; RANK
   LIGAND; DC STAMP; C FOS; DIFFERENTIATION
AB Genes that regulate osteoclast (OC) development and function in both physiologic and disease conditions remain incompletely understood. Shp2 (the Src homology 2 domain containing protein tyrosine phosphatase 2), a ubiquitously expressed cytoplasmic protein tyrosine phosphatase, is implicated in regulating M CSF and receptor activator of nuclear factor B ligand (RANKL) evoked signaling; its role in osteoclastogenesis and bone homeostasis, however, remains unknown. Using a tissue specific gene knockout approach, we inactivated Shp2 expression in murine OCs. Shp2 mutant mice are phenotypically osteopetrotic, featuring a marked increase of bone volume (BV)/total volume (TV) (+42.8%), trabeculae number (Tb.N) (+84.1%), structure model index (+119%), and a decrease of trabecular thickness (Tb.Th) ( 34.1%) and trabecular spacing (Tb.Sp) ( 41.0%). Biochemical analyses demonstrate that Shp2 is required for RANKL induced formation of giant multinucleated OCs by up regulating the expression of nuclear factor of activated T cells, cytoplasmic 1 (Nfatc1), a master transcription factor that is indispensable for terminal OC differentiation. Shp2 deletion, however, has minimal effect on M CSF dependent survival and proliferation of OC precursors. Instead, its deficiency aborts the fusion of OC precursors and formation of multinucleated OCs and decreases bone matrix resorption. Moreover, pharmacological intervention of Shp2 is sufficient to prevent preosteoclast fusion in vitro. These findings uncover a novel mechanism through which Shp2 regulates osteoclastogenesis by promoting preosteoclast fusion. Shp2 or its signaling partners could potentially serve as pharmacological targets to regulate the population of OCs locally and/or systematically, and thus treat OC related diseases, such as periprosthetic osteolysis and osteoporosis.
C1 [Zhou, Yi] Boston Childrens Hosp, Stem Cell Program, Boston, MA USA.
   [Zhou, Yi] Harvard Univ, Sch Med, Boston, MA USA.
   [Mohan, Aron; Moore, Douglas C.; Ehrlich, Michael G.; Yang, Wentian] Brown Univ, Dept Orthopaed, Alpert Med Sch, Providence, RI 02912 USA.
   [Mohan, Aron; Moore, Douglas C.; Ehrlich, Michael G.; Yang, Wentian] Rhode Isl Hosp, Providence, RI USA.
   [Lin, Liangjun; Qin, Yi Xian] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA.
   [Zhou, Frank Li] CALTECH, Engn & Appl Sci, Pasadena, CA 91125 USA.
   [Cao, Jay] USDA, Grand Forks Human Nutr Res Ctr, Grand Forks, ND USA.
   [Wu, Qian] Univ Connecticut, Ctr Hlth, Dept Pathol & Lab Med, Farmington, CT USA.
   [Reginato, Anthony M.] Brown Univ, Alpert Med Sch, Div Rheumatol, Providence, RI 02912 USA.
   [Reginato, Anthony M.] Rhode Isl Hosp, Providence, RI USA.
C3 Harvard University; Harvard University Medical Affiliates; Boston
   Children's Hospital; Harvard University; Harvard Medical School; Brown
   University; Lifespan Health Rhode Island; Rhode Island Hospital; State
   University of New York (SUNY) System; Stony Brook University; California
   Institute of Technology; United States Department of Agriculture (USDA);
   University of Connecticut; Brown University; Lifespan Health Rhode
   Island; Rhode Island Hospital
RP Yang, WT (通讯作者)，1 Hoppin St,Coro 402E, Providence, RI 02903 USA.
EM wyang@lifespan.org
RI Lin, Liangjun/C 9929 2014
FU U.S. National Institutes of Health (NIH) National Institute of Arthritis
   and Musculoskeletal and Skin Diseases [R21AR57156]; NIH National
   Institute of General Medical Sciences [P20 GM103468]; Pediatric
   Orthopaedic Society of North America; Orthopaedic Research and Education
   Foundation; U.S. Department of Agriculture Research Service
   [5450 51000 046 00D]; ARS [ARS 0427566, 813640] Funding Source: Federal
   RePORTER
FX The authors thank Dr. Nhiem Tran for critical reading, Ms. Xiaohong Wang
   for histological section and staining, and Dr. T. Taniguchi for
   pMX IRES GFP and pMX Nfatc1/IRES GFP constructs. The authors are
   grateful to Mr. Howard Yang (Moses Brown High School) for assistance in
   performing experiments and data collection. This work was supported in
   part by the U.S. National Institutes of Health (NIH) National Institute
   of Arthritis and Musculoskeletal and Skin Diseases Grant R21AR57156 (to
   W.Y.) and NIH National Institute of General Medical Sciences Grant P20
   GM103468. This study was also aided by a grant from the Pediatric
   Orthopaedic Society of North America and the Orthopaedic Research and
   Education Foundation (to W.Y.), and the U.S. Department of Agriculture
   Research Service program Grant #5450 51000 046 00D (to J.C.).
CR Aoki K, 1999, BONE, V25, P261, DOI 10.1016/S8756 3282(99)00174 X
   Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Bauler TJ, 2011, DIS MODEL MECH, V4, P228, DOI 10.1242/dmm.006130
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chan G, 2011, BLOOD, V117, P4253, DOI 10.1182/blood 2010 11 319517
   Chan G, 2009, BLOOD, V113, P4414, DOI 10.1182/blood 2008 10 182626
   Chen LW, 2006, MOL PHARMACOL, V70, P562, DOI 10.1124/mol.106.025536
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Fornaro M, 2006, J CELL BIOL, V175, P87, DOI 10.1083/jcb.200602029
   Grossmann KS, 2010, ADV CANCER RES, V106, P53, DOI 10.1016/S0065 230X(10)06002 1
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lee AWM, 2006, CELL DEATH DIFFER, V13, P1900, DOI 10.1038/sj.cdd.4401884
   Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779 6798.2000
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Neel B.G., 2009, Handbook of Cell Signaling, V2nd, P771
   Noonan JA, 2006, REV ENDOCR METAB DIS, V7, P251, DOI 10.1007/s11154 006 9021 1
   Ozcivici Engin, 2008, V455, P323, DOI 10.1007/978 1 59745 104 8_22
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Sweet MG, 2009, AM FAM PHYSICIAN, V79, P193
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Umeda S, 1999, AM J PATHOL, V155, P223, DOI 10.1016/S0002 9440(10)65116 4
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Xu DR, 2004, BIOCHEM J, V383, P219, DOI 10.1042/BJ20040961
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396
   Yang WT, 2006, DEV CELL, V10, P317, DOI 10.1016/j.devcel.2006.01.002
   Yu MJ, 2009, J BIOL CHEM, V284, P32968, DOI 10.1074/jbc.M109.001016
NR 42
TC 26
Z9 29
U1 0
U2 16
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2015
VL 29
IS 5
BP 1635
EP 1645
DI 10.1096/fj.14 260844
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA CH5ZJ
UT WOS:000354114600003
PM 25593124
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Kim, AR
   Kim, HS
   Kim, DK
   Lee, JH
   Yoo, YH
   Kim, JY
   Park, SK
   Nam, ST
   Kim, HW
   Park, YH
   Lee, D
   Lee, MB
   Kim, YM
   Choi, WS
AF Kim, A Ram
   Kim, Hyuk Soon
   Kim, Do Kyun
   Lee, Jun Ho
   Yoo, Young Hyo
   Kim, Jeom Yong
   Park, Sun Kyu
   Nam, Seung Taek
   Kim, Hyun Woo
   Park, Young Hwan
   Lee, Dajeong
   Lee, Min Beom
   Kim, Young Mi
   Choi, Wahn Soo
TI The Extract of Chrysanthemum zawadskii var. latilobum
   Ameliorates Collagen Induced Arthritis in Mice
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID NF KAPPA B; CYTOKINE PRODUCTION; INHIBITION; ACTIVATION; EXPRESSION;
   LINARIN; CELLS; ACID
AB Chrysanthemum zawadskii var. latilobum(CZ) has been used for beverage or tea and also as folk medicine for the remedy of diverse inflammatory diseases. Nevertheless, the therapeutic effect of CZ on arthritis remains to be unknown. In this paper we aim to investigate the CZ's antiarthritic effect and mechanism of action both in vitro and in vivo. To assess CZ's antiarthritic effect, mouse models of type II collagen induced arthritis (CIA) were used. Mice were used to gauge clinical arthritis index and histopathological changes. Reverse transcriptase polymerase chain reaction (RT PCR), western blotting, electrophoretic mobility shift assay (EMSA), and other biological methods were adopted to measure CZ's effect on arthritis and to understand the veiled mechanism of action. CZ greatly suppressed CIA, histopathological score, bone erosion, and osteoclast differentiation. Mechanistically, CZ inhibited the production of various inflammatory and arthritic mediators like inflammatory cytokines, matrix metalloproteinases (MMPs), and chemokines. Of note, CZ significantly suppressed the activation of the NF kappa B pathway in vivo. CZ exerted an antiarthritic effect in CIA mice by curbing the production of crucial inflammatory and arthritis mediators. This study warrants further investigation of CZ for the use in human rheumatoid arthritis (RA).
C1 [Kim, A Ram; Kim, Hyuk Soon; Kim, Do Kyun; Lee, Jun Ho; Nam, Seung Taek; Kim, Hyun Woo; Park, Young Hwan; Lee, Dajeong; Lee, Min Beom; Choi, Wahn Soo] Konkuk Univ, Dept Immunol, Coll Med, Chungju 27478, South Korea.
   [Yoo, Young Hyo; Kim, Jeom Yong; Park, Sun Kyu] Green Cross Wellbeing Co Ltd, Songnam 13595, South Korea.
   [Kim, Young Mi] Duksung Womens Univ, Coll Pharm, Seoul 01369, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Green Cross
   Corporation; Duksung Women's University
RP Choi, WS (通讯作者)，Konkuk Univ, Dept Immunol, Coll Med, Chungju 27478, South Korea.; Kim, YM (通讯作者)，Duksung Womens Univ, Coll Pharm, Seoul 01369, South Korea.
EM kym123@duksung.ac.kr; wahnchoi@kku.ac.kr
RI LEE, JUNHO/MYS 0765 2025; Kim, Hyuk Soon/IQW 9348 2023; Kim,
   Song Yi/JAC 5358 2023; Kim, Woo/D 2733 2015
OI Kim, A Ram/0000 0001 5237 6905; Kim, Hyuk Soon/0000 0002 0566 0142; 
FU Green Cross Wellbeing Co., Ltd.; National Research Foundation of Korea
   (NRF) Grants MSIP; MSIP   Korean government [2012R1A2A1A03670516]; 
   [NRF 2013R1A4A1069575]
FX This work was mostly supported by Green Cross Wellbeing Co., Ltd., and
   in part by the National Research Foundation of Korea (NRF) Grants MSIP;
   NRF 2013R1A4A1069575 and MSIP no. 2012R1A2A1A03670516 funded by the
   Korean government.
CR Bartlett SJ, 2003, ARTHRIT RHEUM ARTHR, V49, P778, DOI 10.1002/art.11456
   Begley CG, 1999, BLOOD, V93, P1443, DOI 10.1182/blood.V93.5.1443.405a31_1443_1447
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Chauhan PS, 2012, PHYTOTHER RES, V26, P1156, DOI 10.1002/ptr.3684
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Fujisawa K, 1996, ARTHRITIS RHEUM US, V39, P197, DOI 10.1002/art.1780390205
   Georganas C, 2000, J IMMUNOL, V165, P7199, DOI 10.4049/jimmunol.165.12.7199
   Gerlag DM, 2000, J IMMUNOL, V165, P1652, DOI 10.4049/jimmunol.165.3.1652
   Han J, 2010, NEUROSCIENCE, V169, P1039, DOI 10.1016/j.neuroscience.2010.05.049
   Han S, 2002, ARCH PHARM RES, V25, P170, DOI 10.1007/BF02976559
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kikuchi H, 1996, CLIN EXP PHARMACOL P, V23, P885, DOI 10.1111/j.1440 1681.1996.tb01138.x
   Kim HS, 2011, J ETHNOPHARMACOL, V136, P392, DOI 10.1016/j.jep.2011.01.016
   Kim SJ, 2014, EUR J PHARMACOL, V738, P66, DOI 10.1016/j.ejphar.2014.05.024
   Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691
   Lee A, 2013, ARTHRITIS RHEUM US, V65, P928, DOI 10.1002/art.37853
   Lee S. J., 1993, BONCHOKANGMOK
   Luo XJ, 2011, INFLAMMATION, V34, P432, DOI 10.1007/s10753 010 9250 z
   Marok R, 1996, ARTHRITIS RHEUM, V39, P583, DOI 10.1002/art.1780390407
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Okamoto H, 2010, ARTHRITIS RHEUM US, V62, P82, DOI 10.1002/art.25063
   Okamoto Hiroshi, 2008, Inflamm Allergy Drug Targets, V7, P53, DOI 10.2174/187152808784165199
   Ono Y, 2004, BIOL PHARM BULL, V27, P1406, DOI 10.1248/bpb.27.1406
   Simmonds RE, 2008, RHEUMATOLOGY, V47, P584, DOI 10.1093/rheumatology/kem298
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Tanaka Eiichi, 2013, Nihon Rinsho, V71, P1199
   Tsao PW, 1997, CLIN IMMUNOL IMMUNOP, V83, P173, DOI 10.1006/clin.1997.4333
   Woolley DE, 2000, ARTHRITIS RES, V2, P65, DOI 10.1186/ar70
NR 30
TC 15
Z9 16
U1 1
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2016
VL 2016
AR 3915013
DI 10.1155/2016/3915013
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA EA8PZ
UT WOS:000386900600001
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Tando, T
   Sato, Y
   Miyamoto, K
   Morita, M
   Kobayashi, T
   Funayama, A
   Kanaji, A
   Hao, W
   Watanabe, R
   Oike, T
   Nakamura, M
   Matsumoto, M
   Toyama, Y
   Miyamoto, T
AF Tando, Toshimi
   Sato, Yuiko
   Miyamoto, Kana
   Morita, Mayu
   Kobayashi, Tami
   Funayama, Atsushi
   Kanaji, Arihiko
   Hao, Wu
   Watanabe, Ryuichi
   Oike, Takatsugu
   Nakamura, Masaya
   Matsumoto, Morio
   Toyama, Yoshiaki
   Miyamoto, Takeshi
TI Hif1α is required for osteoclast activation and bone loss in male
   osteoporosis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Testosterone; Osteoporosis; Hif1 alpha; Male; Osteoclasts; Bone
ID MINERAL DENSITY; ELDERLY MEN; ESTROGEN DEFICIENCY; PROSTATE CANCER;
   TESTOSTERONE; FRACTURES; WOMEN; METAANALYSIS; PREVENTION; RISK
AB The number of osteoporosis patients is increasing not only in women but in men. Male osteoporosis occurs due to aging or androgen depletion therapies, leading to fractures. However, molecular mechanisms underlying male osteoporosis remain unidentified. Here, we show that hypoxia inducible factor 1 alpha (Hif1 alpha) is required for development of testosterone deficiency induced male osteoporosis. We found that in mice Hif1 alpha protein accumulates in osteoclasts following orchidectomy (ORX) in vivo. In vitro, Hif1 alpha protein accumulated in osteoclasts cultured in hypoxic conditions, but Hif1 alpha protein rather than mRNA levels were suppressed by testosterone treatment, even in hypoxia. Administration of a Hif1 alpha inhibitor to ORX mice abrogated testosterone deficiency induced osteoclast activation and bone loss but did not alter osteoclast activities or bone phenotypes in sham operated, testosterone sufficient animals. We conclude that Hif1 alpha protein accumulation due to testosterone deficiency promotes development of male osteoporosis. Thus Hif1 alpha protein could be targeted to inhibit pathologically activated osteoclasts under testosterone deficient conditions to treat male osteoporosis patients. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Tando, Toshimi; Sato, Yuiko; Miyamoto, Kana; Kobayashi, Tami; Funayama, Atsushi; Kanaji, Arihiko; Hao, Wu; Watanabe, Ryuichi; Oike, Takatsugu; Nakamura, Masaya; Matsumoto, Morio; Toyama, Yoshiaki; Miyamoto, Takeshi] Dept Orthoped Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Sato, Yuiko] Dept Musculoskeletal Reconstruct & Regenerat Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Morita, Mayu] Keio Univ, Sch Med, Dept Dent & Oral Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
C3 Keio University
RP Miyamoto, T (通讯作者)，Dept Orthoped Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
EM miyamoto@z5.keio.jp
RI Toyama, Yoshiaki/K 5743 2013; Nakamura, Masaya/K 4111 2013; hao,
   wu/HDM 1705 2022
OI Morita, Mayu/0009 0003 8092 0762
FU Chugai Scientific foundation; Grants in Aid for Scientific Research
   [15H04963, 15K10490] Funding Source: KAKEN
FX We thank Prof. M. Suematsu and Dr. Y.A. Minamishima for technical
   support in performing hypoxic culture. Y. Sato and T. Miyamoto were
   supported by a Grant in aid for Scientific Research, Japan, and Chugai
   Scientific foundation. The authors declare that they have no conflicts
   of interest with the contents of this article.
CR Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485
   Basurto L, 2008, AGING MALE, V11, P140, DOI 10.1080/13685530802273715
   Bauer M, 2012, BREAST CANCER TARGET, V4, P91, DOI 10.2147/BCTT.S29432
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Christmas C, 2002, J GERONTOL A BIOL, V57, pM12, DOI 10.1093/gerona/57.1.M12
   Coleman RE, 2013, NAT REV RHEUMATOL, V9, P365, DOI 10.1038/nrrheum.2013.36
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Edwards BJ, 2013, J BONE JOINT SURG AM, V95A, P297, DOI 10.2106/JBJS.K.01181
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Fink HA, 2006, J CLIN ENDOCR METAB, V91, P3908, DOI 10.1210/jc.2006 0173
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Guitart AV, 2010, EXP HEMATOL, V38, P847, DOI 10.1016/j.exphem.2010.06.002
   Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003 4819 152 6 201003160 00008
   Khosla S, 2001, J CLIN ENDOCR METAB, V86, P3555, DOI 10.1210/jc.86.8.3555
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lassemillante ACM, 2014, ENDOCRINE, V45, P370, DOI 10.1007/s12020 013 0083 z
   Limburg C, 2014, CLIN J ONCOL NURS, V18, P223, DOI 10.1188/14.CJON.223 230
   Miyamoto K, 2011, J EXP MED, V208, P2175, DOI 10.1084/jem.20101890
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Nelson ER, 2013, BONE, V53, P42, DOI 10.1016/j.bone.2012.11.011
   Nguyen ND, 2007, J BONE MINER RES, V22, P781, DOI 10.1359/JBMR.070315
   Ryan CS, 2011, OSTEOPOROSIS INT, V22, P1845, DOI 10.1007/s00198 010 1421 0
   Sato Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111845
   Siris ES, 2004, ARCH INTERN MED, V164, P1108, DOI 10.1001/archinte.164.10.1108
   Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P1966, DOI 10.1210/jc.84.6.1966
   Stathopoulos IP, 2014, HORM INT J ENDOCRINO, V13, P441, DOI 10.14310/horm.2002.1550
   Visekruna M, 2008, J CLIN ENDOCR METAB, V93, P2948, DOI 10.1210/jc.2007 2803
   Walsh JS, 2013, NAT REV ENDOCRINOL, V9, P637, DOI 10.1038/nrendo.2013.171
   Wehren LE, 2004, CURR MED RES OPIN, V20, P525, DOI 10.1185/030079904125003269
   Whyte MP, 2008, J BONE MINER RES, V23, P1698, DOI 10.1359/JBMR.080511
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshimura N, 2010, INT J EPIDEMIOL, V39, P988, DOI 10.1093/ije/dyp276
   Yoshimura N, 2009, J BONE MINER METAB, V27, P620, DOI 10.1007/s00774 009 0080 8
NR 36
TC 29
Z9 35
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 5
PY 2016
VL 470
IS 2
BP 391
EP 396
DI 10.1016/j.bbrc.2016.01.033
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DE4EF
UT WOS:000370581300024
PM 26792721
DA 2025 08 17
ER

PT J
AU Wang, Y
   Chen, SJ
   Du, KZ
   Liang, CX
   Wang, SQ
   Boadi, EO
   Li, J
   Pang, XL
   He, J
   Chang, YX
AF Wang, Yuan
   Chen, Shujing
   Du, Kunze
   Liang, Chunxiao
   Wang, Shuangqi
   Boadi, Evans Owusu
   Li, Jin
   Pang, Xiaoli
   He, Jun
   Chang, Yan xu
TI Traditional herbal medicine: Therapeutic potential in rheumatoid
   arthritis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Traditional herbal medicines; Rheumatoid arthritis; Inflammation and
   immunity
ID NF KAPPA B; FIBROBLAST LIKE SYNOVIOCYTES; COLLAGEN INDUCED ARTHRITIS;
   ADJUVANT INDUCED ARTHRITIS; IN VITRO; SYNOVIAL HYPERPLASIA;
   INFLAMMATION; PROLIFERATION; PATHOGENESIS; RANKL
AB Ethnopharmacological relevance: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease influenced by diverse endogenous and exogenous factors. It is characterized by cartilage and bone destruction. The current conventional allopathic therapy is expensive and carries adverse side effects. Recently, there were some ethnopharmacological studies on RA including anti RA effects and therapeutic targets of distinct dosage forms of traditional herbal medicines (THMs). Aim of the review: This review provides a brief overview of the current understanding of the potential pharmacological mechanisms of THMs (active constituents, extracts and prescriptions) in RA. This study is intended to provide comprehensive information and reference for exploring new therapeutic strategies of THMs in the RA treatment. Materials and methods: This review captured scientific literatures in vivo and vitro experiments on effects of anti RA THMs published between 2016 and 2021 from journals and electronic databases (e.g. PubMed, Elsevier, Science Direct, Web of Science and Google Scholar). Relevant literatures were searched and analyzed by using keywords such as 'rheumatoid arthritis AND traditional herbal medicines', 'rheumatoid arthritis AND immune cells', 'rheumatoid arthritis AND inflammation', 'rheumatoid arthritis AND miRNA', 'rheumatoid arthritis AND Angiogenesis', 'rheumatoid arthritis AND oxidative stress', 'rheumatoid arthritis AND osteoclasts', 'rheumatoid arthritis AND CIA model', 'rheumatoid arthritis AND AA model' AND 'rheumatoid arthritis herbal prescription'. Results: Experiments in vitro and in vivo jointly demonstrated the potential of THMs in the RA treatment. There are plentiful therapeutic targets in RA. THMs and active ingredients could alleviate RA symptoms through different therapeutic targets, such as immunoregulation, inflammation, fibroblast like synoviocytes (FLSs), microRNAs (miRNAs), angiogenesis, oxidative stress, osteoclasts and multiple targets interaction. Anti RA THMs, active ingredients and prescriptions through corresponding therapeutic targets were summarized and classified. Conclusions: Flavonoids, phenolic acids, alkaloids and triterpenes of THMs are identified as the main components to ameliorate RA. Regulation of different and multiple related therapeutic targets by THMs and their active ingredients were associated with greater therapeutic benefits, among which inflammation is the main therapeutic target. Nonetheless, further studies are required to unravel the complexities and in depth mechanisms of THMs in alleviating RA.
C1 [Wang, Yuan; Chen, Shujing; Du, Kunze; Liang, Chunxiao; Wang, Shuangqi; Boadi, Evans Owusu; Li, Jin; He, Jun; Chang, Yan xu] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin 301617, Peoples R China.
   [Pang, Xiaoli] Tianjin Univ Tradit Chinese Med, Acad Nursing, Tianjin 301617, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University
   of Traditional Chinese Medicine
RP Chang, YX (通讯作者)，Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin 301617, Peoples R China.
EM tcmcyx@tjutcm.edu.cn
OI Owusu Boadi, Evans/0000 0002 6043 667X
FU National Key R&D Program of China [2019YFC1711000]; Tianjin Research
   Program of Application Founda tion and Advanced Technology
   [18JCYBJC95000]; National Natural Science Foundation of China
   [81973704]; Special Program of Talents Development for Excellent Youth
   Scholars in Tianjin
FX This study was supported by National Key R&D Program of China
   (2019YFC1711000) , Tianjin Research Program of Application Founda tion
   and Advanced Technology [18JCYBJC95000] , National Natural Science
   Foundation of China [81973704] , Special Program of Talents Development
   for Excellent Youth Scholars in Tianjin.
CR Adefegha SA, 2020, IMMUNOPHARM IMMUNOT, V42, P509, DOI 10.1080/08923973.2020.1814806
   Astry B, 2015, CYTOKINE, V74, P54, DOI 10.1016/j.cyto.2014.11.020
   Thimóteo NSB, 2019, NUTRITION, V60, P112, DOI 10.1016/j.nut.2018.10.010
   Bellezza I, 2018, BBA MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Bindu S, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114147
   Burmester GR, 2020, LANCET, V396, P267, DOI 10.1016/S0140 6736(20)30636 X
   Burska AN, 2021, CLIN EXP RHEUMATOL, V39, P456, DOI 10.55563/clinexprheumatol/jj2bxz
   Bustamante MF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1303 3
   Cai L, 2019, PHARMACOL REP, V71, P1006, DOI 10.1016/j.pharep.2019.05.014
   Cao Y.X., 2021, J TRADIT CHIN MED PH, V36, P983
   Chen JQ, 2016, AUTOIMMUN REV, V15, P1171, DOI 10.1016/j.autrev.2016.09.003
   Chen JF, 2019, INT IMMUNOPHARMACOL, V70, P274, DOI 10.1016/j.intimp.2019.02.029
   Chen QL, 2021, J ETHNOPHARMACOL, V271, DOI 10.1016/j.jep.2021.113849
   Chen SR, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00104
   Chen SJ, 2017, BIOCHEM PHARMACOL, V126, P69, DOI 10.1016/j.bcp.2016.12.006
   Cheng WX, 2020, J ORTHOP TRANSL, V22, P92, DOI 10.1016/j.jot.2019.07.007
   Chiu YG, 2017, EXPERT OPIN BIOL TH, V17, P119, DOI 10.1080/14712598.2017.1263614
   Chuang CH, 2019, J AGR FOOD CHEM, V67, P6773, DOI 10.1021/acs.jafc.9b01163
   Moran Moguel MC, 2018, J IMMUNOL RES, V2018, DOI [10.1155/2018/2474529, 10.1155/2018/6135183]
   Croia C, 2019, CLIN EXP RHEUMATOL, V37, P347
   Cush JJ, 2021, MED CLIN N AM, V105, P355, DOI 10.1016/j.mcna.2020.10.006
   Dai QD, 2018, DRUG DES DEV THER, V12, P4095, DOI 10.2147/DDDT.S175763
   Ding HM, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22373
   Dou YN, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105813
   Edwards JCW, 2006, NAT REV IMMUNOL, V6, P394, DOI 10.1038/nri1838
   Elshabrawy HA, 2015, ANGIOGENESIS, V18, P433, DOI 10.1007/s10456 015 9477 2
   Feng ZT, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108759
   Fikry EM, 2019, BIOMED PHARMACOTHER, V110, P878, DOI 10.1016/j.biopha.2018.12.041
   Gao Qi Long, 2008, Zhongguo Zhong Xi Yi Jie He Za Zhi, V28, P459
   Gao Q, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106527
   Gheorghe KR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016378
   Guan YY, 2018, INT J MOL MED, V42, P1666, DOI 10.3892/ijmm.2018.3723
   Guo K, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201800975
   Guo QQ, 2020, J LEUKOCYTE BIOL, V108, P509, DOI 10.1002/JLB.3MA0320 440RR
   Guo YL, 2019, INT J BIOL MACROMOL, V122, P882, DOI 10.1016/j.ijbiomac.2018.11.015
   Haleagrahara N, 2017, BIOMED PHARMACOTHER, V90, P38, DOI 10.1016/j.biopha.2017.03.026
   Henc I, 2017, INT IMMUNOPHARMACOL, V49, P148, DOI 10.1016/j.intimp.2017.05.034
   Hong BK, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.108
   Hong YH, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113602
   Hu F, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105780
   Hu XX, 2019, INT IMMUNOPHARMACOL, V70, P428, DOI 10.1016/j.intimp.2019.03.008
   Hu YP, 2016, CURR PHARM DESIGN, V22, P6975, DOI 10.2174/1381612822666161025150403
   Huang RY, 2019, PHYTOMEDICINE, V57, P403, DOI 10.1016/j.phymed.2018.12.030
   Jiang SH, 2016, EXP THER MED, V12, P4035, DOI 10.3892/etm.2016.3860
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kongdang P, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2018.11.015
   Li HJ, 2019, CHEM BIODIVERS, V16, DOI 10.1002/cbdv.201900294
   Li JY, 2017, BMC COMPLEM ALTERN M, V17, DOI [10.1186/s12866 016 0911 4, 10.1186/s12906 016 1526 x]
   Li N, 2019, INT IMMUNOPHARMACOL, V67, P186, DOI 10.1016/j.intimp.2018.11.042
   Li X, 2017, BIOSCI BIOTECH BIOCH, V81, P891, DOI 10.1080/09168451.2016.1263145
   Li XH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205035
   Li X, 2019, PHARMACOLOGY, V104, P187, DOI 10.1159/000501163
   Li X, 2016, J CELL MOL MED, V20, P170, DOI 10.1111/jcmm.12717
   Li YX, 2019, INT IMMUNOPHARMACOL, V73, P362, DOI 10.1016/j.intimp.2019.05.024
   Liang J, 2018, INT IMMUNOPHARMACOL, V55, P105, DOI 10.1016/j.intimp.2017.12.006
   Lin YJ, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040880
   Liu C, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113820
   Liu J, 2017, EXP THER MED, V13, P2267, DOI 10.3892/etm.2017.4232
   Liu K., 2020, INT J IMMUNOPATH PH, V34
   Liu M., 2021, J ETHNOPHARMACOL
   Liu N, 2017, INFLAMM RES, V66, P603, DOI 10.1007/s00011 017 1041 7
   Liu WW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02228
   Long H, 2018, CANCER LETT, V428, P90, DOI 10.1016/j.canlet.2018.04.016
   Lu S, 2019, BIOMED PHARMACOTHER, V111, P142, DOI 10.1016/j.biopha.2018.12.043
   Lund FE, 2010, NAT REV IMMUNOL, V10, P236, DOI 10.1038/nri2729
   Luo SS, 2020, CHEM BIOL INTERACT, V319, DOI 10.1016/j.cbi.2020.108984
   Ma AL, 2017, MOL MED REP, V15, P3615, DOI 10.3892/mmr.2017.6484
   Ma JD, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1935 6
   Mateen S, 2019, EUR J PHARMACOL, V852, P14, DOI 10.1016/j.ejphar.2019.02.031
   Mateen S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152925
   Mateen S, 2016, CLIN CHIM ACTA, V455, P161, DOI 10.1016/j.cca.2016.02.010
   McGarry T, 2018, FREE RADICAL BIO MED, V125, P15, DOI 10.1016/j.freeradbiomed.2018.03.042
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   Meng DQ, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108876
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Miller CH, 2016, J IMMUNOL, V196, P4977, DOI 10.4049/jimmunol.1502044
   Mohr T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179065
   Mota CMD, 2020, J ETHNOPHARMACOL, V250, DOI 10.1016/j.jep.2019.112486
   Mussard E, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8120571
   Najm A, 2020, ARTHRITIS RHEUMATOL, V72, P2030, DOI 10.1002/art.41441
   Nho JH, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/3637453
   Ni HD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00436
   Niu DQ, 2019, IN VITRO CELL DEV AN, V55, P243, DOI 10.1007/s11626 019 00325 8
   O'Neil LJ, 2019, TRENDS MOL MED, V25, P215, DOI 10.1016/j.molmed.2018.12.008
   Peng P, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9485
   Bossolani GDP, 2019, LIFE SCI, V238, DOI 10.1016/j.lfs.2019.116956
   Qi WZ, 2019, CHEM BIOL INTERACT, V306, P19, DOI 10.1016/j.cbi.2019.04.002
   Qiao SM, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107047
   Ren W., 2019, NAT PROD RES, V34, P1
   Rengasamy KRR, 2019, PHARMACOL THERAPEUT, V194, P107, DOI 10.1016/j.pharmthera.2018.09.009
   Seo DG, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.153056
   Shen WX, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111861
   Shin JI, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1383697
   Steffen U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01483
   Su JS, 2021, J ETHNOPHARMACOL, V267, DOI 10.1016/j.jep.2020.113514
   Sung S, 2019, MOLECULES, V24, DOI 10.3390/molecules24081589
   Tan SR, 2019, MOL MED REP, V19, P2057, DOI 10.3892/mmr.2019.9854
   Tanaka S, 2019, F1000RES, V8, P1533
   Tanaka S, 2021, J BONE MINER METAB, V39, P106, DOI 10.1007/s00774 020 01159 1
   Tanaka S, 2018, J ORTHOP SCI, V23, P717, DOI 10.1016/j.jos.2018.06.001
   Tanaka S, 2018, MOD RHEUMATOL, V28, P9, DOI 10.1080/14397595.2017.1369491
   Tejada S, 2018, CURR MED CHEM, V25, P4929, DOI 10.2174/0929867324666170718104412
   Trombetta AC, 2018, RESP RES, V19, DOI 10.1186/s12931 018 0891 z
   Tsai SW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051351
   Tu YB, 2019, J FUNCT FOODS, V62, DOI 10.1016/j.jff.2019.103528
   Tu YB, 2019, J ETHNOPHARMACOL, V237, P20, DOI 10.1016/j.jep.2019.03.035
   van der Woude D, 2018, BEST PRACT RES CL RH, V32, P174, DOI 10.1016/j.berh.2018.10.005
   Vasanthi P., 2007, APLAR J RHEUMATOL, V10, P270, DOI DOI 10.1111/J.1479 8077.2007.00305.X
   Venkatesha SH, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw059
   Wang GY, 2020, BIOFACTORS, V46, P441, DOI 10.1002/biof.1599
   Wang JR, 2020, N S ARCH PHARMACOL, V393, P1987, DOI 10.1007/s00210 019 01763 7
   Wang JY, 2016, J ETHNOPHARMACOL, V194, P609, DOI 10.1016/j.jep.2016.10.038
   Wang QR, 2019, INT IMMUNOPHARMACOL, V72, P292, DOI 10.1016/j.intimp.2019.04.027
   Wang SL, 2018, BIOMED PHARMACOTHER, V106, P813, DOI 10.1016/j.biopha.2018.07.021
   Wang WF, 2017, INT IMMUNOPHARMACOL, V48, P61, DOI 10.1016/j.intimp.2017.04.025
   Wang XY, 2017, LIFE SCI, V171, P45, DOI 10.1016/j.lfs.2017.01.004
   Wang Y, 2018, INT IMMUNOPHARMACOL, V65, P284, DOI 10.1016/j.intimp.2018.09.049
   Wang Y, 2017, INT IMMUNOPHARMACOL, V50, P345, DOI 10.1016/j.intimp.2017.07.019
   Wang ZY, 2019, INT IMMUNOPHARMACOL, V73, P370, DOI 10.1016/j.intimp.2019.05.023
   Wehr P, 2019, CLIN EXP IMMUNOL, V196, P12, DOI 10.1111/cei.13256
   Wong VKW, 2019, BRIT J PHARMACOL, V176, P2922, DOI 10.1111/bph.14718
   Wu X, 2017, ONCOTARGET, V8, P44242, DOI 10.18632/oncotarget.17797
   Wu ZM, 2020, AUTOIMMUNITY, V53, P450, DOI 10.1080/08916934.2020.1836488
   Xia ZB, 2018, MED SCI MONITOR, V24, P2524, DOI 10.12659/MSM.907084
   Xie XQ, 2019, INT IMMUNOPHARMACOL, V76, DOI 10.1016/j.intimp.2019.105840
   Xu C.Q., 2016, WORLD SCI TECH, V18, P1883
   Xu L, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8284107
   Xu RG, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658 018 0086 0
   Yang CM, 2017, BIOCHEM PHARMACOL, V132, P77, DOI 10.1016/j.bcp.2017.03.003
   Yang GL, 2021, J AGR FOOD CHEM, V69, P259, DOI 10.1021/acs.jafc.0c06801
   Yang GL, 2018, J AGR FOOD CHEM, V66, P12953, DOI 10.1021/acs.jafc.8b05047
   Yang P, 2020, J ETHNOPHARMACOL, V250, DOI 10.1016/j.jep.2019.112428
   Yao XM, 2019, TROP J PHARM RES, V18, P173, DOI 10.4314/tjpr.v18i1.26
   Yu H, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2019.152876
   Yu WG, 2018, CHIN J NAT MEDICINES, V16, P330, DOI 10.1016/S1875 5364(18)30064 5
   Yuan K, 2020, J NUTR BIOCHEM, V84, DOI 10.1016/j.jnutbio.2020.108454
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhai KF, 2019, J AGR FOOD CHEM, V67, P2856, DOI 10.1021/acs.jafc.9b00185
   Zhai KF, 2018, J AGR FOOD CHEM, V66, P6073, DOI 10.1021/acs.jafc.8b02241
   Zhai KF, 2018, FOOD FUNCT, V9, P2070, DOI [10.1039/c7fo01748k, 10.1039/C7FO01748K]
   Zhai KF, 2017, INFLAMMOPHARMACOLOGY, V25, P523, DOI 10.1007/s10787 017 0385 5
   Zhang C, 2021, CHEM BIOL INTERACT, V341, DOI 10.1016/j.cbi.2021.109451
   Zhang L, 2018, INT J NANOMED, V13, P2051, DOI 10.2147/IJN.S151233
   Zhang P, 2010, RHEUMATOL INT, V30, P713, DOI 10.1007/s00296 010 1370 0
   Zhang Q, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120795
   Zhang Y, 2019, ANN NY ACAD SCI, V1457, P166, DOI 10.1111/nyas.14196
   Zhang YQ, 2019, INFLAMMATION, V42, P506, DOI 10.1007/s10753 018 0908 2
   Zhao HX, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.600867
   Zhao HY, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170302
   Zhu MM, 2019, MOL IMMUNOL, V112, P188, DOI 10.1016/j.molimm.2019.05.010
   Zhuang YY, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00538
   Zou Y, 2019, EXP THER MED, V17, P3999, DOI 10.3892/etm.2019.7425
NR 152
TC 159
Z9 180
U1 33
U2 282
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD OCT 28
PY 2021
VL 279
AR 114368
DI 10.1016/j.jep.2021.114368
EA JUL 2021
PG 21
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA UA2YF
UT WOS:000685028800010
PM 34197960
DA 2025 08 17
ER

PT J
AU Cooke Hubley, S
   Kirby, BJ
   Valcour, JE
   Mugford, G
   Adachi, JD
   Kovacs, CS
AF Cooke Hubley, Sandra
   Kirby, Beth J.
   Valcour, James E.
   Mugford, Gerald
   Adachi, Jonathan D.
   Kovacs, Christopher S.
TI Spine bone mineral density increases after 6 months of exclusive
   lactation, even in women who keep breastfeeding
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Lactation; Calcium; Parathyroid hormone; Estradiol; DXA; Bone formation
ID HORMONE AGONIST TREATMENT; PARATHYROID HORMONE; MATERNAL SKELETON; GNRH
   AGONISTS; UP REGULATION; PREGNANCY; ENDOMETRIOSIS; PROGESTERONE;
   THERAPY; ASSOCIATION
AB This pilot study enrolled 31 women who had breastfed exclusively for 6 months. Lumbar and thoracic BMD increased 4 and 5%, respectively. Femoral neck and total body BMD did not change. Return of menses and progestin only pill use were two potential signals that predicted a greater increase in BMD.
   Purpose/introduction The skeleton is resorbed during lactation to provide much of the calcium content of milk. After lactation ceases, these deficits in skeletal mineral content are largely restored, such that lactation has a neutral or protective effect against the long term risk of low bone mineral density (BMD), osteoporosis, and fragility fractures. We hypothesized that a large observational study may identify the factors that predict a greater increase in BMD after lactation ceases. A pilot study was first needed to test feasibility and the magnitude of expected BMD change.
   Methods We undertook Factors Affecting Bone formation after Breastfeeding Pilot (FABB Pilot), which enrolled women who had breastfed exclusively for 6 months and planned to wean soon. The main outcome was change in BMD between enrolment and 6 months later.
   Results Thirty one women were recruited and completed both time points. Lumbar and thoracic spine BMD increased 4 and 5%, respectively; there was no significant change in femoral neck and total body BMD. Most women did not wean their babies as planned but continued to breastfeed multiple times per day. Despite this, a significant increase in BMD was seen in the subsequent 6 months. Return of spontaneous menses and use of a progestin only pill at recruitment were two potential signals that predicted a greater increase in BMD during the 6 months after exclusive lactation.
   Conclusions Spine BMD increased significantly during 6 months following exclusive lactation and despite continued lactation. The factors that stimulate skeletal recovery remain to be identified.
C1 [Cooke Hubley, Sandra; Kirby, Beth J.; Valcour, James E.; Mugford, Gerald; Kovacs, Christopher S.] Mem Univ Newfoundland, Fac Med, St John, NF, Canada.
   [Adachi, Jonathan D.] McMaster Univ, Fac Hlth Sci, Hamilton, ON, Canada.
   [Kovacs, Christopher S.] Hlth Sci Ctr, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.
C3 Memorial University Newfoundland; McMaster University; Memorial
   University Newfoundland
RP Kovacs, CS (通讯作者)，Mem Univ Newfoundland, Fac Med, St John, NF, Canada.; Kovacs, CS (通讯作者)，Hlth Sci Ctr, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.
EM ckovacs@mun.ca
FU Amgen; Eli Lilly; Merck; Agnovos
FX SCH, BJK, JEV, GM, and CSK report no conflicts of interest with this
   work. JDA reports no conflicts of interest with this work, but financial
   considerations unrelated to this work (grants and/or honoraria from
   Amgen, Eli Lilly, Merck, and Agnovos).
CR [Anonymous], PRIMER METABOLIC BON
   [Anonymous], CAN NUTR FIL
   BARENGOLTS EI, 1990, J BONE MINER RES, V5, P1143
   Bjornerem Å, 2017, J BONE MINER RES, V32, P681, DOI 10.1002/jbmr.3018
   Bowman BM, 1996, J BONE MINER RES, V11, P15
   Brembeck P, 2015, J CLIN ENDOCR METAB, V100, P535, DOI 10.1210/jc.2014 2825
   Collins JN, 2013, ENDOCRINOLOGY, V154, P1400, DOI 10.1210/en.2012 1931
   Cooke Hubley S, 2014, BREASTFEED MED, V9, P273, DOI 10.1089/bfm.2013.0099
   Duan X, 2017, OSTEOPOROSIS INT, V28, P495, DOI 10.1007/s00198 016 3753 x
   FOGELMAN I, 1994, BRIT J OBSTET GYNAEC, V101, P19, DOI 10.1111/j.1471 0528.1994.tb13680.x
   GRILL V, 1991, J CLIN ENDOCR METAB, V73, P1309, DOI 10.1210/jcem 73 6 1309
   Health Canada, 2008, NUTR VAL SOM COMM FO
   HOWELL R, 1995, FERTIL STERIL, V64, P474, DOI 10.1016/S0015 0282(16)57779 6
   Kirby BJ, 2013, J BONE MINER RES, V28, P1987, DOI 10.1002/jbmr.1925
   Kolthoff N, 1998, CLIN SCI, V94, P405, DOI 10.1042/cs0940405
   Kovacs CS, 2015, OSTEOPOROSIS INT, V26, P2223, DOI 10.1007/s00198 015 3149 3
   Kovacs CS, 2016, PHYSIOL REV, V96, P449, DOI 10.1152/physrev.00027.2015
   Liu XS, 2012, J BONE MINER RES, V27, P865, DOI 10.1002/jbmr.1503
   Lopez JM, 1996, OSTEOPOROSIS INT, V6, P153, DOI 10.1007/BF01623940
   Millar WJ, 2009, HLTH REP STAT CANADA, V16, P1
   Miller SC, 2005, BIOL REPROD, V73, P156, DOI 10.1095/biolreprod.105.039610
   Miller SC, 2007, ANAT REC, V290, P65, DOI 10.1002/ar.20403
   Mukherjee T, 1996, AM J OBSTET GYNECOL, V175, P105, DOI 10.1016/S0002 9378(96)70258 2
   NEWHALLPERRY K, 1995, AM J OBSTET GYNECOL, V173, P824, DOI 10.1016/0002 9378(95)90348 8
   ORWOLL ES, 1994, AM J OBSTET GYNECOL, V171, P1221, DOI 10.1016/0002 9378(94)90136 8
   Paoletti AM, 1996, FERTIL STERIL, V65, P707, DOI 10.1016/S0015 0282(16)58200 4
   Public Health Agency of Canada, 2009, WHAT MOTH SAY CAN MA
   Reid I., 2003, PRIMER METABOLIC BON, VFifth, P86
   REVILLA R, 1995, MATURITAS, V22, P145, DOI 10.1016/0378 5122(95)00929 F
   RICO H, 1993, CALCIFIED TISSUE INT, V52, P354, DOI 10.1007/BF00310198
   Ritchie LD, 1998, AM J CLIN NUTR, V67, P693, DOI 10.1093/ajcn/67.4.693
   ROUX C, 1995, OSTEOPOROSIS INT, V5, P185, DOI 10.1007/BF02106098
   Segal E, 2011, OSTEOPOROSIS INT, V22, P2907, DOI 10.1007/s00198 010 1515 8
   Seifert Klauss V, 2012, CLIMACTERIC, V15, P26, DOI 10.3109/13697137.2012.669530
   Taga M, 1996, ACTA OBSTET GYN SCAN, V75, P162, DOI 10.3109/00016349609033310
   TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021 9681(78)90058 9
   UEMURA T, 1994, FERTIL STERIL, V62, P246
   Vajda EG, 2001, BIOL REPROD, V65, P689, DOI 10.1095/biolreprod65.3.689
NR 38
TC 15
Z9 16
U1 0
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD AUG 16
PY 2017
VL 12
IS 1
AR 73
DI 10.1007/s11657 017 0368 6
PG 8
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA FE2TA
UT WOS:000408067400001
PM 28815389
DA 2025 08 17
ER

PT J
AU Mccall, JL
   Geldenhuys, WJ
   Robinson, LJ
   Witt, MR
   Gannett, PM
   Soederberg, BCG
   Blair, HC
   Soboloff, J
   Barnett, JB
AF Mccall, Jamie L.
   Geldenhuys, Werner J.
   Robinson, Lisa J.
   Witt, Michelle R.
   Gannett, Peter M.
   Soederberg, Bjoern C. G.
   Blair, Harry C.
   Soboloff, Jonathan
   Barnett, John B.
TI Preclinical evaluation of ELP 004 in mice
SO PHARMACOLOGY RESEARCH & PERSPECTIVES
LA English
DT Article
DE CYP450; metabolism; mice; osteoclast; pharmacokinetics; preclinical
ID RHEUMATOID ARTHRITIS; INADEQUATE RESPONSE; 3,4 DICHLOROPROPIONANILIDE;
   DOPAMINE; DIFFERENTIATION; OSTEOCLAST; INHIBITOR; PROPANIL; ANTIBODY;
   DRUGS
AB This study provides a detailed understanding of the preclinical pharmacokinetics and metabolism of ELP 004, an osteoclast inhibitor in development for the treatment of bone erosion. Current treatments for arthritis, including biological disease modifying antirheumatic drugs, are not well tolerated in a substantial subset of arthritis patients and are expensive; therefore, new treatments are needed. Pharmacokinetic parameters of ELP 004 were tested with intravenous, oral, and subcutaneous administration and found to be rapidly absorbed and distributed. We found that ELP 004 was non mutagenic, did not induce chromosome aberrations, non cardiotoxic, and had minimal off target effects. Using in vitro hepatic systems, we found that ELP 004 is primarily metabolized by CYP1A2 and CYP2B6 and predicted metabolic pathways were identified. Finally, we show that ELP 004 inhibits osteoclast differentiation without suppressing overall T cell function. These preclinical data will inform future development of an oral compound as well as in vivo efficacy studies in mice.
   In vitro metabolic pathways of ELP 004.image
C1 [Mccall, Jamie L.; Witt, Michelle R.; Barnett, John B.] West Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Morgantown, WV USA.
   [Mccall, Jamie L.; Barnett, John B.] ExesaLibero Pharm Inc, Morgantown, WV USA.
   [Geldenhuys, Werner J.] West Virginia Univ, Sch Pharm, Dept Pharmaceut Sci, Morgantown, WV USA.
   [Robinson, Lisa J.; Witt, Michelle R.] West Virginia, Dept Pathol, Sch Med, Morgantown, WV USA.
   [Gannett, Peter M.] Nova Southeastern Univ, Coll Pharm, Ft Lauderdale, FL USA.
   [Soederberg, Bjoern C. G.] West Virginia Univ, C Eugene Bennett Dept Chem, Morgantown, WV USA.
   [Blair, Harry C.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA USA.
   [Blair, Harry C.] Pittsburgh VA Med Ctr, Dept Cell Biol, Pittsburgh, PA USA.
   [Blair, Harry C.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Soboloff, Jonathan] Temple Univ, Fels Canc Inst Personalized Med, Philadelphia, PA USA.
   [Soboloff, Jonathan] Temple Univ, Lewis Katz Sch Med, Dept Canc & Cellular Biol, Philadelphia, PA USA.
   [Robinson, Lisa J.] Univ Nebraska Med Ctr, Dept Pathol Microbiol & Immunol, Omaha, NE USA.
C3 West Virginia University; West Virginia University; Nova Southeastern
   University; West Virginia University; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University; University of Nebraska System;
   University of Nebraska Medical Center
RP Barnett, JB (通讯作者)，Mylan Pharmaceut Inc, 781 Chestnut Ridge Rd,POB 4310, Morgantown, WV 26505 USA.
EM johnb@exesalibero pharma.com
RI Barnett, John/AAW 6642 2020; McCall, Jamie/K 8085 2019; Gannett,
   Peter/J 3347 2015; Soboloff, Jonathan/I 6995 2012
OI geldenhuys, werner/0000 0002 2405 376X; McCall,
   Jamie/0000 0001 5914 6336; Witt, Michelle/0000 0001 9483 8346; Barnett,
   John/0000 0001 6547 2381; Soboloff, Jonathan/0000 0001 5192 1297;
   Gannett, Peter/0000 0002 7859 5468; Blair, Harry/0000 0002 1152 3718; 
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R42AR074812]; National Institute of General Medical Sciences
   [P20GM103434, P30GM121322]
FX National Institute of Arthritis and Musculoskeletal and Skin Diseases,
   Grant/Award Number: R42AR074812; National Institute of General Medical
   Sciences, Grant/Award Number: P20GM103434 and P30GM121322
CR BARNETT JB, 1992, FUND APPL TOXICOL, V18, P628, DOI 10.1016/0272 0590(92)90124 Z
   Barnett JB., 2023, Method for inhibiting osteoclast development
   Blair HC, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen 2015 000093
   Bongartz T, 2006, JAMA J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275
   Boraschi Diaz I, 2016, CYTOTECHNOLOGY, V68, P105, DOI 10.1007/s10616 014 9759 3
   Brundage KM, 2003, J TOXICOL ENV HEAL A, V66, P2253, DOI 10.1080/713854000
   Buletko AB, 2012, NEUROTOXICOL TERATOL, V34, P336, DOI 10.1016/j.ntt.2012.03.003
   Cerantola S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9050465
   Choy E, 2012, RHEUMATOLOGY, V51, pV3, DOI 10.1093/rheumatology/kes113
   Costello R, 2019, CLIN THER, V41, P1376, DOI 10.1016/j.clinthera.2019.04.030
   Druce KL, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen 2017 018752
   Geldenhuys WJ, 2012, NEUROCHEM INT, V60, P806, DOI 10.1016/j.neuint.2012.03.013
   Geldenhuys WJ, 2009, EUR J PHARMACOL, V619, P38, DOI 10.1016/j.ejphar.2009.08.012
   Genovese MC, 2015, ARTHRITIS RHEUMATOL, V67, P1424, DOI 10.1002/art.39093
   Gritsaenko T, 2018, JOVE J VIS EXP, DOI 10.3791/56499
   Hameed A, 2014, CANCER GROWTH METAST, V7, P33, DOI 10.4137/CGM.S16817
   HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122
   Jones BE, 2018, CURR OPIN IMMUNOL, V55, P9, DOI 10.1016/j.coi.2018.09.002
   Kivitz AJ, 2017, ARTHRITIS RHEUMATOL, V69, P709, DOI 10.1002/art.39955
   Lewis TL, 2008, TOXICOL SCI, V103, P97, DOI 10.1093/toxsci/kfn031
   Lewis TL, 2013, TOXICOL SCI, V131, P395, DOI 10.1093/toxsci/kfs297
   Machold KP, 2007, RHEUMATOLOGY, V46, P342, DOI 10.1093/rheumatology/kel237
   Matcham F, 2014, SEMIN ARTHRITIS RHEU, V44, P123, DOI 10.1016/j.semarthrit.2014.05.001
   McCall JL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249442
   MCMILLAN DC, 1990, TOXICOL APPL PHARM, V103, P102, DOI 10.1016/0041 008X(90)90266 W
   Nishimoto N, 2004, ARTHRITIS RHEUM US, V50, P1761, DOI 10.1002/art.20303
   Robinson LJ, 2021, FASEB J, V35, DOI 10.1096/fj.202001921RR
   Robinson LJ, 2012, LAB INVEST, V92, P1071, DOI 10.1038/labinvest.2012.72
   Salatino Oliveira A, 2018, AM J MED GENET B, V177, P211, DOI 10.1002/ajmg.b.32578
   Saralkar P, 2021, PHARM RES DORDR, V38, P803, DOI 10.1007/s11095 021 03046 4
   Sartori NS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224963
   Sulkowska A, 2002, J MOL STRUCT, V614, P227, DOI 10.1016/S0022 2860(02)00256 9
   Swamydas M, 2013, JOVE J VIS EXP, DOI 10.3791/50586
   Tourkova IL, 2019, LAB INVEST, V99, P1850, DOI 10.1038/s41374 019 0311 0
   Umeda Masataka, 2018, Immunol Med, V41, P181, DOI 10.1080/25785826.2018.1542942
   Vijikumar A, 2022, EXP NEUROL, V355, DOI 10.1016/j.expneurol.2022.114128
   Wanat K, 2020, MOL BIOL REP, V47, P3221, DOI 10.1007/s11033 020 05361 2
   Wang MN, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00105 1
   Yip RML, 2021, JCR J CLIN RHEUMATOL, V27, pE516, DOI 10.1097/RHU.0000000000001293
   Zhou SF, 2008, CURR DRUG METAB, V9, P310, DOI 10.2174/138920008784220664
   Zhou YD, 2011, J CELL PHYSIOL, V226, P1082, DOI 10.1002/jcp.22423
NR 41
TC 1
Z9 1
U1 1
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2052 1707
J9 PHARMACOL RES PERSPE
JI Pharmacol. Res. Perspect.
PD AUG
PY 2024
VL 12
IS 4
AR e1230
DI 10.1002/prp2.1230
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WT7W9
UT WOS:001257201300001
PM 38940379
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yu, H
   Wu, ZN
   Bao, XF
   Tang, XD
   Zhang, JH
   Zhang, Y
   Hu, M
AF Yu, Hang
   Wu, Zhina
   Bao, Xingfu
   Tang, Xiaoduo
   Zhang, Junhu
   Zhang, Yi
   Hu, Min
TI A sustained release Trametinib bio multifunction hydrogel inhibits
   orthodontically induced inflammatory root resorption
SO RSC ADVANCES
LA English
DT Article
ID BONE RESORPTION; OSTEOCLASTOGENESIS
AB Orthodontic tooth movement (OTM) is a bone reconstruction process. In most cases, OTM could induce root resorption as a common side effect, called orthodontically induced inflammatory root resorption (OIIRR). OIIRR affects tooth health and interferes with the stability of orthodontic treatment. Osteoclasts, which perform bone resorption in OTM, attack cementum, causing OIIRR. Many signaling pathways are involved in the maturation and differentiation of osteoclasts, among which the ERK1/2 is one of the important pathways. In this experiment, we added Trametinib (Tra), a specific inhibitor of ERK1/2, to catechol modified chitosan (CHI C) and oxidized dextran (ODex) to form a CCOD Trametinib composite hydrogel (CCOD Tra) to prevent OIIRR. CCOD Tra exhibited good biocompatibility, injectability, strong adhesion, good hemostatic function and sustained release of Tra. We performed local injection of CCOD Tra into the periodontal tissues of rats. CCOD Tra firmly adhered to the periodontal tissues and then released Tra to establish a good biological environment and maintain a drug concentration at a high level around the roots for a long time. H&E, TRAP, immunochemistry staining and micro CT indicated that CCOD Tra had a good effect in terms of preventing OIIRR. Cell experiments showed that CCOD Tra reduced the expression of TRAP, MMP 9 and C FOS in osteoclast cells through the ERK1/2 signaling pathway to inhibit the differentiation and maturation of osteoclasts. Based on the above results, we concluded that CCOD Tra had the ability to prevent OIIRR, the high adhesion and injectability of CCOD may provide better therapeutic ideas for clinical prevention of OIIRR.
C1 [Yu, Hang; Wu, Zhina; Bao, Xingfu; Zhang, Yi; Hu, Min] Jilin Univ, Hosp Stomatol, Dept Orthodont, 1500 Qinghua Rd, Changchun, Jilin, Peoples R China.
   [Yu, Hang; Wu, Zhina; Bao, Xingfu; Zhang, Yi; Hu, Min] Jilin Univ, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Sch & Hosp Stomatol, Changchun, Peoples R China.
   [Tang, Xiaoduo; Zhang, Junhu] Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
   [Tang, Xiaoduo; Zhang, Junhu] First Hosp Jilin Univ, Foint Lab Optofunct Theranost Med & Chem, Changchun 130021, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Jilin University
RP Zhang, Y; Hu, M (通讯作者)，Jilin Univ, Hosp Stomatol, Dept Orthodont, 1500 Qinghua Rd, Changchun, Jilin, Peoples R China.; Zhang, Y; Hu, M (通讯作者)，Jilin Univ, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Sch & Hosp Stomatol, Changchun, Peoples R China.; Zhang, JH (通讯作者)，Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.; Zhang, JH (通讯作者)，First Hosp Jilin Univ, Foint Lab Optofunct Theranost Med & Chem, Changchun 130021, Peoples R China.
EM zhangyi0519@jlu.edu.cn
RI bao, xingfu/D 9619 2017; Zhang, Junhu/O 4850 2017
OI Zhang, Junhu/0000 0001 9100 6608
FU National Natural Science Foundation of China [81801005, 201870795,
   21774043, 21975098, 51905526]; Health Commission of Jilin Province
   [2018 33 05]; Natural Science Foundation of Jilin Province
   [20200201344JC]; Fundamental Research Funds for the Central Universities
   (JLU); Program for JLU Science and Technology Innovation Research Team
   [2017TD 06]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81801005, 201870795, 21774043, 21975098, 51905526), Health
   Commission of Jilin Province No. 2018 33 05 and Natural Science
   Foundation of Jilin Province, No. 20200201344JC, the Fundamental
   Research Funds for the Central Universities (JLU) and the Program for
   JLU Science and Technology Innovation Research Team (No. 2017TD 06).
CR Asefi Sohrab, 2018, Dent Res J (Isfahan), V15, P40
   BRUDVIK P, 1995, EUR J ORTHODONT, V17, P177, DOI 10.1093/ejo/17.3.177
   Chang J, 2019, EUR J ORTHODONT, V41, P601, DOI 10.1093/ejo/cjz006
   Chen SS, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106152
   Feller L, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4864195
   Feng W, 2017, SCI REP UK, V7, DOI 10.1038/srep41411
   He XT, 2019, ACTA BIOMATER, V88, P162, DOI 10.1016/j.actbio.2019.02.004
   Henneman S, 2008, EUR J ORTHODONT, V30, P299, DOI 10.1093/ejo/cjn020
   Huang SH, 2020, CARBOHYD POLYM, V246, DOI 10.1016/j.carbpol.2020.116650
   Huang SY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.678322
   Keklikci HB, 2021, AM J ORTHOD DENTOFAC, V159, pE245, DOI 10.1016/j.ajodo.2020.10.020
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Lian T, 2019, CANCER TREAT REV, V81, DOI 10.1016/j.ctrv.2019.101907
   Lin XX, 2020, J CELL PHYSIOL, V235, P5951, DOI 10.1002/jcp.29520
   dos Santos EJL, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116139
   Lu CZ, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.11.03
   Lu XY, 2013, BONE, V54, P157, DOI 10.1016/j.bone.2013.01.041
   Ma XQ, 2018, LIFE SCI, V209, P140, DOI 10.1016/j.lfs.2018.08.008
   Melsen B, 1999, ANGLE ORTHOD, V69, P151
   Motokawa M, 2012, EUR J ORTHODONT, V34, P350, DOI 10.1093/ejo/cjr018
   Ndong JD, 2015, J BONE MINER RES, V30, P55, DOI 10.1002/jbmr.2316
   Nishida D, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 84354 y
   Ozturk T, 2020, LASER MED SCI, V35, P1419, DOI 10.1007/s10103 020 03014 1
   Peng WZ, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.668428
   Sun KQ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.629968
   Tan JL, 2019, ACS NANO, V13, P5616, DOI 10.1021/acsnano.9b00788
   Tang XD, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202105718
   Tyrovola Joanna B, 2008, J Oral Sci, V50, P367
   Wang B, 2020, ACTA BIOMATER, V116, P259, DOI 10.1016/j.actbio.2020.09.018
   Wang WZ, 2019, J CELL BIOCHEM, V120, P7333, DOI 10.1002/jcb.28008
   Weltman B, 2010, AM J ORTHOD DENTOFAC, V137, P462, DOI 10.1016/j.ajodo.2009.06.021
   Wu MR, 2012, INT J BIOL SCI, V8, P1398, DOI 10.7150/ijbs.5079
   Xing JZ, 2017, ACTA BIOMATER, V49, P306, DOI 10.1016/j.actbio.2016.12.006
   Xu XW, 2019, ACTA BIOMATER, V86, P235, DOI 10.1016/j.actbio.2019.01.001
   Xu XQ, 2020, FASEB J, V34, P8402, DOI 10.1096/fj.201902528RRR
   Yamaguchi T, 2012, INFLAMM RES, V61, P445, DOI 10.1007/s00011 011 0431 5
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Zang SQ, 2019, MAT SCI ENG C MATER, V99, P919, DOI 10.1016/j.msec.2019.02.024
   Zhang XG, 2021, INT IMMUNOPHARMACOL, V100, DOI 10.1016/j.intimp.2021.107991
   Zhou L, 2020, AM J TRANSL RES, V12, P8099
   Zinnia MA, 2021, INT J BIOL MACROMOL, V186, P351, DOI 10.1016/j.ijbiomac.2021.06.197
   Zupancic S, 2019, J CONTROL RELEASE, V316, P223, DOI 10.1016/j.jconrel.2019.10.008
NR 42
TC 2
Z9 2
U1 0
U2 29
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PD JUN 1
PY 2022
VL 12
IS 26
BP 16444
EP 16453
DI 10.1039/d2ra00763k
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 1W0KR
UT WOS:000806471300001
PM 35754868
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cook, B
   Rafiq, R
   Lee, H
   Banks, KM
   El Debs, M
   Chiaravalli, J
   Glickman, JF
   Das, BC
   Chen, SB
   Evans, T
AF Cook, Brandoch
   Rafiq, Ruhina
   Lee, Heejin
   Banks, Kelly M.
   El Debs, Mohammed
   Chiaravalli, Jeanne
   Glickman, J. Fraser
   Das, Bhaskar C.
   Chen, Shuibing
   Evans, Todd
TI Discovery of a Small Molecule Promoting Mouse and Human Osteoblast
   Differentiation via Activation of p38 MAPK β
SO CELL CHEMICAL BIOLOGY
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; POSTMENOPAUSAL WOMEN; BISPHOSPHONATE USE;
   GENE EXPRESSION; CELLS; GROWTH; BMP; WNT; FRACTURE; HEDGEHOG
AB Disorders of bone healing and remodeling are indications with an unmet need for effective pharmacological modulators. We used a high throughput screen to identify activators of the bone marker alkaline phosphatase (ALP), and discovered 6,8 dimethyl 3 (4 phenyl 1H imidazol 5 yl) quinolin 2(1H)one (DIPQUO). DIPQUO markedly promotes osteoblast differentiation, including expression of Runx2, Osterix, and Osteocalcin. Treatment of human mesenchymal stem cells with DIPQUO results in osteogenic differentiation including a significant increase in calcium matrix deposition. DIPQUO stimulates ossification of emerging vertebral primordia in developing zebrafish larvae, and increases caudal fin osteogenic differentiation during adult zebrafish fin regeneration. The stimulatory effect of DIPQUO on osteoblast differentiation and maturation was shown to be dependent on the p38 MAPK pathway. Inhibition of p38 MAPK signaling or specific knockdown of the p38 beta isoform attenuates DIPQUO induction of ALP, suggesting that DIPQUO mediates osteogenesis through activation of p38 b, and is a promising lead candidate for development of bone therapeutics.
C1 [Cook, Brandoch; Rafiq, Ruhina; Lee, Heejin; Banks, Kelly M.; Chen, Shuibing; Evans, Todd] Dept Surg, 1300 York Ave, New York, NY 10065 USA.
   [Rafiq, Ruhina; Lee, Heejin; Banks, Kelly M.] Weill Cornell Med, Grad Sch Med Sci, New York, NY 10065 USA.
   [El Debs, Mohammed] Weill Cornell Med Qatar, Educ City, Qatar.
   [Chiaravalli, Jeanne; Glickman, J. Fraser] Rockefeller Univ, High Throughput & Spect Resource Ctr, New York, NY 10065 USA.
   [Das, Bhaskar C.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Das, Bhaskar C.] Icahn Sch Med Mt Sinai, Dept Nephrol, New York, NY 10029 USA.
C3 Cornell University; Weill Cornell Medicine; Qatar Foundation (QF); Weill
   Cornell Medical College Qatar; Rockefeller University; Icahn School of
   Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai
RP Cook, B; Chen, SB; Evans, T (通讯作者)，Dept Surg, 1300 York Ave, New York, NY 10065 USA.
EM brc2018@med.cornell.edu; shc2034@med.cornell.edu;
   tre2003@med.cornell.edu
RI ; Glickman, Joseph/H 3021 2013
OI Das, Bhaskar/0000 0002 5837 027X; Glickman, Joseph/0000 0002 6706 4039
FU NIH, the National Institute of Diabetes and Digestive and Kidney
   Diseases [K01 DK096031]; NIH, the National Heart, Lung, and Blood
   Institute [R37 HL56182]; New York State Department of Health [NYSTEM
   C029156]
FX We are thankful to Dr. Amitabha Bandyopadhyay (ITT Kanpur) for
   generously providing the BRITER cell line, and to Matthew Greenblatt
   (WCM) for helpful discussions. This work was supported by the NIH, the
   National Institute of Diabetes and Digestive and Kidney Diseases grant
   K01 DK096031 (to B.C.) NIH, the National Heart, Lung, and Blood
   Institute grant R37 HL56182 (to T.E.), and a shared facility contract
   from the New York State Department of Health to T.E. and S.C. (NYSTEM
   C029156).
CR Ando K, 2017, DEV CELL, V43, P643, DOI 10.1016/j.devcel.2017.10.015
   Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Bosnakovski D, 2014, SKELET MUSCLE, V4, DOI 10.1186/2044 5040 4 4
   Cabrera PV, 2012, J BIOL CHEM, V287, P22759, DOI 10.1074/jbc.M111.334581
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen SB, 2004, J AM CHEM SOC, V126, P410, DOI 10.1021/ja037390k
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Darcy A, 2012, BONE, V50, P1294, DOI 10.1016/j.bone.2012.03.001
   Drieling RL, 2016, MENOPAUSE, V23, P1168, DOI 10.1097/GME.0000000000000696
   Feng LL, 2016, CELL REP, V15, P2063, DOI 10.1016/j.celrep.2016.04.066
   Fu RW, 2013, ANN INTERN MED, V158, P890, DOI 10.7326/0003 4819 158 12 201306180 00006
   Fux C, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh001
   Greenblatt MB, 2015, J BIOL CHEM, V290, P284, DOI 10.1074/jbc.M114.599274
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Huang ZN, 2007, TISSUE ENG, V13, P2311, DOI 10.1089/ten.2006.0423
   Huycke TR, 2012, DEVELOPMENT, V139, P2371, DOI 10.1242/dev.079806
   Inohaya K, 2007, DEV DYNAM, V236, P3031, DOI 10.1002/dvdy.21329
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Laue K, 2008, DEVELOPMENT, V135, P3775, DOI 10.1242/dev.021238
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lloyd AA, 2017, P NATL ACAD SCI USA, V114, P8722, DOI 10.1073/pnas.1704460114
   Ma S, 2017, SCI REP UK, V7, DOI 10.1038/srep43399
   Malo N, 2006, NAT BIOTECHNOL, V24, P167, DOI 10.1038/nbt1186
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229
   Moorwood C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026169
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Raingeaud J, 1996, MOL CELL BIOL, V16, P1247
   Rey A, 2007, BONE, V41, P59, DOI 10.1016/j.bone.2007.02.031
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Saita Y, 2015, THER ADV CHRONIC DIS, V6, P185, DOI 10.1177/2040622315584114
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Vaccaro AR, 2008, SPINE J, V8, P457, DOI 10.1016/j.spinee.2007.03.012
   Yadav PS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037134
NR 39
TC 20
Z9 21
U1 0
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2451 9448
J9 CELL CHEM BIOL
JI Cell Chem. Biol.
PD JUL 18
PY 2019
VL 26
IS 7
BP 926
EP +
DI 10.1016/j.chembiol.2019.03.009
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA IK5GK
UT WOS:000476613500004
PM 31031140
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Go, M
   Noguchi, Y
   Masuda, R
   Asano, H
   Kimura, M
   Usami, E
   Yoshimura, T
AF Go, Makiko
   Noguchi, Yoshihiro
   Masuda, Rikuto
   Asano, Hiroki
   Kimura, Michio
   Usami, Eiseki
   Yoshimura, Tomoaki
TI Association between CDK4/6 inhibitors and drug related osteonecrosis of
   the jaw: A pharmacoepidemiological study using the FDA Adverse Events
   Reporting System
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE abemaciclib; CDK4/6 inhibitor; FAERS; osteonecrosis of the jaw;
   palbociclib
ID FOOD
AB The most common toxicities associated with cyclin dependent kinase (CDK) 4/6 inhibitor therapy include decreased leukopenia and neutropenia due to the inhibition of CDK6 of leukocyte and neutrophil precursors in bone marrow. These hematological toxicities are more commonly observed with palbociclib administration than with abemaciclib administration, which is approximately 13 times more selective against CDK4 than CDK6. Thus, even though both successfully inhibit CDK4/6, the side effects of palbociclib and abemaciclib differ due to differences in selectivity. Recent reports have suggested an association between palbociclib and medication related osteonecrosis of the jaw; however, reports on this association are inconsistent. This study investigated the potential association of palbociclib and abemaciclib with MRONJ using the FAERS. Signals of "Osteonecrosis of jaw" were detected only in females using palbociclib (cROR025: 2.08). Other signals detected included stomatitis related adverse events with abemaciclib and intraoral soft tissue damage and infection with palbociclib. As previous exploratory studies have reported MRONJ signals for bisphosphonates and denosumab, we calculated the aROR for palbociclib induced osteonecrosis of the jaw using concomitant bisphosphonates and denosumab as covariates. A signal was detected even after adjusting for sex, age, and concomitant medications as covariates (aROR0025: 5.74). A proper understanding of the differences in CDK selectivity is necessary for the appropriate use of CDK4/6 inhibitors. To the best of our knowledge, this is the first report on CDK4/6 inhibitors and drug related osteonecrosis of the jaw. We believe that these results will offer new insights into adverse events related to the use of CDK4/6 inhibitors, and may aid in the proper use of CDK4/6 inhibitors.
   Recent reports have suggested an association between the cyclin dependent kinase 4/6 inhibitor, palbociclib and medication related osteonecrosis of the jaw; however, reports on this association are inconsistent. This study investigated oral adverse events in patients taking cyclin dependent kinase 4/6 inhibitors, using spontaneous reports submitted to the FAERS, a pharmacovigilance database. The authors detected stomatitis related adverse events for abemaciclib, and signals such as intraoral soft tissue damage including osteonecrosis of the jaw and infection for palbociclib. The results offer new insights into adverse events related to the use of CDK4/6 inhibitors and could help tailor their use. image
C1 [Go, Makiko; Asano, Hiroki; Kimura, Michio; Usami, Eiseki] Ogaki Municipal Hosp, Dept Pharm, Ogaki, Japan.
   [Noguchi, Yoshihiro; Masuda, Rikuto; Kimura, Michio; Yoshimura, Tomoaki] Gifu Pharmaceut Univ, Lab Clin Pharm, Gifu, Japan.
   [Noguchi, Yoshihiro; Usami, Eiseki; Yoshimura, Tomoaki] Gifu Pharmaceut Univ, Lab Med Collaborat Pharm, Gifu, Japan.
C3 Ogaki Municipal Hospital; Gifu Pharmaceutical University; Gifu
   Pharmaceutical University
RP Noguchi, Y (通讯作者)，Gifu Pharmaceut Univ, Lab Clin Pharm, Gifu, Japan.
EM noguchiy@gifu pu.ac.jp
RI ; Noguchi, Yoshihiro/ABI 5618 2020
OI Yoshimura, Tomoaki/0009 0008 2486 8169; Noguchi,
   Yoshihiro/0000 0002 9110 9604
FU Japan Society for the Promotion of Science KAKENHI
FX No Statement Available
CR Ahdi HS, 2023, BMC PHARMACOL TOXICO, V24, DOI 10.1186/s40360 023 00657 y
   Chen P, 2016, MOL CANCER THER, V15, P2273, DOI 10.1158/1535 7163.MCT 16 0300
   EMA, SCREENING ADVERSE RE
   Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303
   Fusco V, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph181910143
   Gao L, 2018, PROTEIN CELL, V9, P488, DOI 10.1007/s13238 018 0548 1
   Im SA, 2019, NEW ENGL J MED, V381, P307, DOI 10.1056/NEJMoa1903765
   Marcianò A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249509
   Noguchi Y, 2024, DRUG SAFETY, V47, P535, DOI 10.1007/s40264 024 01404 w
   Noguchi Y, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab347
   Scully C, 2002, BRIT DENT J, V192, P139, DOI 10.1038/sj.bdj.4801315
   Spring LM, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912 019 0769 3
   Wu C, 2021, MOL CANCER THER, V20, P1680, DOI 10.1158/1535 7163.MCT 20 0848
   Yosofi C, 2023, J ONCOL PHARM PRACT, V29, P1990, DOI 10.1177/10781552231165434
   Zattarin E, 2023, THER ADV MED ONCOL, V15, DOI 10.1177/17588359231204857
   Zhang WD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.606043
   Zhang XY, 2016, J BONE MINER RES, V31, P336, DOI 10.1002/jbmr.2693
NR 17
TC 5
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 1
PY 2024
VL 155
IS 5
BP 849
EP 853
DI 10.1002/ijc.34962
EA APR 2024
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA YF2J2
UT WOS:001202347300001
PM 38619193
DA 2025 08 17
ER

PT J
AU Schmeel, LC
   Schmeel, FC
   Kim, Y
   Blaum Feder, S
   Endo, T
   Schmidt Wolf, IGH
AF Schmeel, Leonard Christopher
   Schmeel, Frederic Carsten
   Kim, Young
   Blaum Feder, Sabine
   Endo, Tomoyuki
   Schmidt Wolf, Ingo G. H.
TI Flunarizine Exhibits In Vitro Efficacy Against Lymphoma and
   Multiple Myeloma Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE Flunarizine; multiple myeloma; lymphoma; cancer therapy; WNT; pathway
ID WNT/BETA CATENIN PATHWAY; VIVO EFFICACY; ETHACRYNIC ACID; WNT
   INHIBITORS; BETA CATENIN; BONE MARROW; TRANSPLANTATION; LENALIDOMIDE;
   ENHANCEMENT; DISEASE
AB Background/Aim: Novel agents such as lenalidomide and bortezomib have significantly improved today's therapy of multiple myeloma. Despite recent innovations, new therapeutic options are needed. The Wingless related integration site (WNT) pathway is aberrantly activated in lymphoma and myeloma and therefore renders WNT signaling molecules attractive for the development of targeted therapies. Flunarizine was used in this study as it has chemical features similar to those of other known WNT inhibitors and already proven proapoptotic properties in leukemia cells. Materials and Methods: The antitumor apoptotic effect of flunarizine at doses ranging from 0.1 200 mu M was investigated on three human lymphoma cell lines, one in urine and four human myeloma cell lines by 3'3 Dihexyloxacarbocyanine iodide and propidium iodide staining in flow cytometry. Results: Flunarizine induced significant apoptotic activity in all tested myeloma and lymphoma cell lines in a dose dependent manner. Conclusion: Our results reveal a significant selective induction of apoptosis by flunarizine and suggest an in vivo effect against lymphoma and myeloma.
C1 [Schmeel, Leonard Christopher; Schmeel, Frederic Carsten; Kim, Young; Blaum Feder, Sabine; Schmidt Wolf, Ingo G. H.] Univ Hosp Bonn, CIO, Dept Internal Med 3, D 53105 Bonn, Germany.
   [Schmeel, Frederic Carsten] Univ Hosp Bonn, Dept Radiol, D 53105 Bonn, Germany.
   [Endo, Tomoyuki] Hokkaido Univ, Grad Sch Med, Dept Hematol, Sapporo, Hokkaido, Japan.
C3 University of Bonn; University of Bonn; Hokkaido University
RP Schmidt Wolf, IGH (通讯作者)，Univ Hosp Bonn, CIO, Sigmund Freud Str 25, D 53105 Bonn, Germany.
EM Ingo.Schmidt Wolf@ukb.uni bonn.de
OI Schmeel, Frederic/0000 0003 0985 1517; Schmeel,
   Christopher/0000 0002 3901 4122
CR Abdul M, 2002, ANTICANCER RES, V22, P1727
   Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Ashihara E, 2009, CLIN CANCER RES, V15, P2731, DOI 10.1158/1078 0432.CCR 08 1350
   BELLELLI A, 1987, ONCOLOGY BASEL, V44, P17, DOI 10.1159/000226436
   Bringhen S, 2006, EXPERT OPIN INV DRUG, V15, P1565, DOI 10.1517/13543784.15.12.1565
   CASTELLINO SM, 1995, BRIT J CANCER, V71, P1181, DOI 10.1038/bjc.1995.230
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Conrad DM, 2010, APOPTOSIS, V15, P597, DOI 10.1007/s10495 010 0454 3
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Dutta Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood 2008 12 194290
   Fink Puches R, 1993, Exp Dermatol, V2, P17, DOI 10.1111/j.1600 0625.1993.tb00194.x
   Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008 5472.CAN 11 2067
   Harousseau JL, 2009, NEW ENGL J MED, V360, P2645, DOI 10.1056/NEJMct0805626
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   HOLMES B, 1984, DRUGS, V27, P6, DOI 10.2165/00003495 198427010 00002
   Kim Y, 2012, LEUKEMIA RES, V36, P598, DOI 10.1016/j.leukres.2012.01.025
   Kim Y, 2011, IN VIVO, V25, P887
   Kim Y, 2011, ANTICANCER RES, V31, P725
   Kim Y, 2011, IN VIVO, V25, P99
   Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359
   Koller CM, 2013, ANTICANCER RES, V33, P2435
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Lu DS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008294
   MICKISCH GH, 1990, CANCER RES, V50, P3670
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Moreau P, 2006, BLOOD, V107, P397, DOI 10.1182/blood 2005 06 2573
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Polakis P, 2000, GENE DEV, V14, P1837
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Rosiñol L, 2008, BLOOD, V112, P3591, DOI 10.1182/blood 2008 02 141598
   Schmeel FC, 2014, HEMATOL ONCOL, V32, P197, DOI 10.1002/hon.2122
   Schmeel LC., 2014, ANTICANCER RES, V34, P835
   Schmeel LC, 2013, ANTICANCER RES, V33, P4719
   Schmidt M, 2011, IN VIVO, V25, P325
   Schmidt M, 2009, BRIT J HAEMATOL, V144, P796, DOI 10.1111/j.1365 2141.2008.07503.x
   SEZZI ML, 1984, ANTICANCER RES, V4, P229
   SILVESTRINI R, 1993, INT J CANCER, V55, P636, DOI 10.1002/ijc.2910550420
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Von Schulz Hausmann SA, 2014, ANTICANCER RES, V34, P4101
   Wall I, 2014, ANTICANCER RES, V34, P5375
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
NR 43
TC 13
Z9 14
U1 0
U2 4
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD MAR
PY 2015
VL 35
IS 3
BP 1369
EP 1376
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CF3QF
UT WOS:000352462900019
PM 25750287
DA 2025 08 17
ER

PT J
AU Zhang, J
   Shao, YR
   He, DK
   Zhang, L
   Xu, GX
   Shen, J
AF Zhang, Jing
   Shao, Yiru
   He, Daikun
   Zhang, Lin
   Xu, Guoxiong
   Shen, Jie
TI Evidence that bone marrow derived mesenchymal stem cells reduce
   epithelial permeability following phosgene induced acute lung injury via
   activation of wnt3a protein induced canonical wnt/ catenin signaling
SO INHALATION TOXICOLOGY
LA English
DT Article
DE Acute lung injury; mesenchymal stem cells; phosgene; wnt signaling
   pathway; wnt3a; wnt5a
ID IDIOPATHIC PULMONARY FIBROSIS; BETA CATENIN; TGF BETA; STROMAL CELLS;
   CYCLIN D1; REPAIR; EXPRESSION; DIFFERENTIATION; MECHANISMS; PATHWAYS
AB An increase in epithelial cell permeability has been proposed to contribute to phosgene induced acute lung injury (ALI). However, no specific and effective means for blocking increases in permeability are currently available. Cell based therapy using bone marrow derived mesenchymal stem cells (MSCs) is an attractive new approach. Canonical wnt/ catenin signaling has been demonstrated to contribute to both epithelial cell injury and repair mechanisms in ALI. The goal of our study was to determine the effects of MSCs on epithelial permeability in phosgene induced ALI in Sprague Dawley (SD) rats and identify changes in major components of the wnt3a/ catenin signaling pathway during this process. Epithelial cell permeability was evaluated by measuring total protein, albumin, keratinocyte growth factor, and occludin in bronchoalveolar lavage fluid and lung tissue. MSCs harboring lentiviral vectors expressing green fluorescent protein (GFP) were used to determine rates of MSC engraftment at injured sites. Lung tissue was excised to evaluate changes in the levels of proteins that function in wnt3a/ catenin signaling, including wnt3a, total  catenin, non phosphorylated Ser33/37/Thr41  catenin, axin2, and cyclin D1 by western blot analysis. Because TGF 1 and wnt5a can inhibit canonical wnt/ catenin signaling, we also measured levels of TGF 1 and wnt5a by western blotting.Conclusions: (1) TGF 1 and wnt5a expression correlated with inhibition of wnt3a/ catenin signaling in our phosgene induced ALI model and (2) exogenously supplied MSCs homed to sites of lung injury and reduced epithelial permeability likely by blocking TGF 1  and wnt5a mediated inhibition of wnt3/ catenin signaling.
C1 [Zhang, Jing; Shao, Yiru; He, Daikun; Zhang, Lin; Shen, Jie] Fudan Univ, Jinshan Hosp, Dept Intens Care Unit, Ctr Emergency, Shanghai, Peoples R China.
   [Zhang, Jing; Shao, Yiru; He, Daikun; Zhang, Lin; Shen, Jie] Fudan Univ, Jinshan Hosp, Dept Intens Care Unit, Intens Care Unit, Shanghai, Peoples R China.
   [Zhang, Jing; Shao, Yiru; He, Daikun; Zhang, Lin; Shen, Jie] Fudan Univ, Jinshan Hosp, Med Res Ctr Chem Injury, Dept Intens Care Unit, Shanghai, Peoples R China.
   [Zhang, Jing; Shao, Yiru; He, Daikun; Zhang, Lin; Shen, Jie] Fudan Univ, Jinshan Hosp, Med Ctr Radiat Injury, Dept Intens Care Unit, Shanghai, Peoples R China.
   [Xu, Guoxiong] Fudan Univ, Jinshan Hosp, Dept Ctr Lab, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Fudan University;
   Fudan University
RP Shen, J (通讯作者)，Fudan Univ, Jinshan Hosp, Ctr Emergency, 1508 Longhang Rd, Shanghai 201508, Peoples R China.; Shen, J (通讯作者)，Fudan Univ, Jinshan Hosp, Intens Care Unit, 1508 Longhang Rd, Shanghai 201508, Peoples R China.
EM j1999sh@163.com
RI shen, jie/JJF 0994 2023; Zhang, Jingxian/B 2253 2010
FU National Natural Science Foundation of China [81471850, 81101412];
   Jinshan District Science and Technology Commission of Shanghai
   [2013 3 05]
FX The authors declare that they have no competing interests related to
   this study. This work was funded by National Natural Science Foundation
   of China (81471850), National Natural Science Foundation of China
   (81101412), and Jinshan District Science and Technology Commission of
   Shanghai (2013 3 05).
CR Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Axelrod A., 2016, THE BATTLE OF VERDUN
   Baarsma H, 2013, EUR RESPIR J, V4257, pP4893
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Beers MF, 2011, J CLIN INVEST, V121, P2065, DOI 10.1172/JCI45961
   Borcherding N, 2015, CANCER RES, V75, P1972, DOI 10.1158/0008 5472.CAN 14 2761
   Cai SX, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0060 y
   Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008
   Chandel NS, 2009, CRIT CARE MED, V37, P1678, DOI 10.1097/CCM.0b013e31819fc81a
   Chilosi M, 2003, AM J PATHOL, V162, P1495, DOI 10.1016/S0002 9440(10)64282 4
   Crosby LM, 2010, AM J PHYSIOL LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009
   Curley GF, 2012, THORAX, V67, P496, DOI 10.1136/thoraxjnl 2011 201059
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   Devine SM, 2003, BLOOD, V101, P2999, DOI 10.1182/blood 2002 06 1830
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Flozak AS, 2010, J BIOL CHEM, V285, P3157, DOI 10.1074/jbc.M109.070326
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Gottardi CJ, 2013, AM J RESP CRIT CARE, V187, P566, DOI 10.1164/rccm.201301 0144ED
   Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710
   Guo Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.254
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Hii HP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134492
   Katoh M, 2009, INT J MOL MED, V23, P763, DOI 10.3892/ijmm_00000190
   Kim JH, 2015, BMB REP, V48, P525, DOI 10.5483/BMBRep.2015.48.9.140
   Kneidinger N, 2011, AM J RESP CRIT CARE, V183, P723, DOI 10.1164/rccm.200910 1560OC
   Königshoff M, 2010, AM J RESP CELL MOL, V42, P21, DOI 10.1165/rcmb.2008 0485TR
   Königshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950
   Königshoff M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002142
   Lee JW, 2011, STEM CELLS, V29, P913, DOI 10.1002/stem.643
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184 1193.2002
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Mora AL, 2008, J CELL BIOCHEM, V105, P641, DOI 10.1002/jcb.21890
   Newman DR, 2016, J HISTOCHEM CYTOCHEM, V64, P99, DOI 10.1369/0022155415617988
   Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100
   Patel SA, 2008, ARCH IMMUNOL THER EX, V56, P1, DOI 10.1007/s00005 008 0001 x
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Piotr F, 2015, TREATMENT LUNG INJUR, V191, pA4358
   Rao R, 2009, ANN NY ACAD SCI, V1165, P62, DOI 10.1111/j.1749 6632.2009.04054.x
   Roarty K, 2007, DEVELOPMENT, V134, P3929, DOI 10.1242/dev.008250
   Roarty K, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2244
   Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200
   Sharma RR, 2014, TRANSFUSION, V54, P1418, DOI 10.1111/trf.12421
   Shen J, 2013, INHAL TOXICOL, V25, P272, DOI 10.3109/08958378.2013.777820
   Shyamsundar M, 2014, AM J RESP CRIT CARE, V189, P1520, DOI 10.1164/rccm.201310 1892OC
   Tanjore H, 2013, AM J RESP CRIT CARE, V187, P630, DOI 10.1164/rccm.201205 0972OC
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Villar J, 2014, CRIT CARE, V18, DOI 10.1186/s13054 014 0568 z
   von Bahr L, 2012, STEM CELLS, V30, P1575, DOI 10.1002/stem.1118
   Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239
NR 53
TC 23
Z9 28
U1 0
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0895 8378
EI 1091 7691
J9 INHAL TOXICOL
JI Inhal. Toxicol.
PD OCT
PY 2016
VL 28
IS 12
BP 572
EP 579
DI 10.1080/08958378.2016.1228720
PG 8
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA EA1ZH
UT WOS:000386390300005
PM 27644345
DA 2025 08 17
ER

PT J
AU Chatterjee, M
   Jain, S
   Stühmer, T
   Andrulis, M
   Ungethüm, U
   Kuban, RJ
   Lorentz, H
   Bommert, K
   Topp, M
   Krämer, D
   Müller Hermelink, HK
   Einsele, H
   Greiner, A
   Bargou, RC
AF Chatterjee, Manik
   Jain, Sarika
   Stuehmer, Thorsten
   Andrulis, Mindaugas
   Ungethuem, Ute
   Kuban, Ralf Juergen
   Lorentz, Heike
   Bommert, Kurt
   Topp, Max
   Kraemer, Doris
   Mueller Hermelink, Hans Konrad
   Einsele, Hermann
   Greiner, Axel
   Bargou, Ralf C.
TI STAT3 and MAPK signaling maintain overexpression of heat shock proteins
   90α and β in multiple myeloma cells, which critically contribute to
   tumor cell survival
SO BLOOD
LA English
DT Article
ID HEAT SHOCK PROTEIN 90; MARROW STROMAL CELLS; BONE MARROW;
   CLINICAL APPLICATIONS; MOLECULAR CHAPERONE; ENDOTHELIAL CELLS;
   PLASMA CELLS; HSP90; KINASE; EXPRESSION
AB The combined blockade of the IL 6R/STAT3 and the MAPK signaling pathways has been shown to inhibit bone marrow microenvironment (BMM) mediated survival of multiple myeloma (MM) cells. Here, we identify the molecular chaperones heat shock proteins (Hsp) 90 alpha and beta as target genes of both pathways. The siRNA mediated knockdown of Hsp90 or treatment with the novel Hsp90 inhibitor 17 DMAG attenuated the levels of STAT3 and phospho ERK and decreased the viability of MM cells. Although knockdown of Hsp90 beta unlike knockdown of Hsp90 alpha was sufficient to induce apoptosis, this effect was strongly increased when both Hsp90s were targeted, indicating a cooperation of both. Given the importance of the BMM for drug resistance and MM cell survival, apoptosis induced by Hsp90 inhibition was not mitigated in the presence of bone marrow stromal cells, osteoclasts, or endothelial cells. These observations suggest that a positive feedback loop consisting of Hsp90 alpha/beta and major signaling pathways supports the survival of MM cells. Finally, in situ overexpression of both Hsp90 proteins was observed in most MMs but not in monoclonal gammopathy of undetermined significance (MGUS) or in normal plasma cells. Our results underpin a role for Hsp90 alpha, and beta in MM pathogenesis. (c) 2007 by The American Society of Hematology
C1 Univ Hosp Wurzburg, Div Hematol, Dept Internal Med 2, D 97080 Wurzburg, Germany.
   Max Delbruck Ctr Mol Med, Robert Rossle Canc Clin, Berlin, Germany.
   Univ Hosp Wurzburg, Inst Pathol, D 97080 Wurzburg, Germany.
   Univ Med Berlin, Charite, Lab Funct Genom, Berlin, Germany.
C3 University of Wurzburg; Helmholtz Association; Max Delbruck Center for
   Molecular Medicine; University of Wurzburg; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin
RP Chatterjee, M (通讯作者)，Univ Hosp Wurzburg, Div Hematol, Dept Internal Med 2, Josef Schneider Str 2, D 97080 Wurzburg, Germany.
EM chatterjee_m@medizin.uni wuerzburg.de
RI Bommert, Kurt/G 9247 2011; Einsele, Hermann/ADP 6603 2022; Topp,
   Max/F 2868 2012; Andrulis, Mindaugas/AAN 5668 2021
OI Andrulis, Mindaugas/0000 0001 9866 4849; 
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Brighenti A, 2005, HISTOPATHOLOGY, V47, P90, DOI 10.1111/j.1365 2559.2005.02173.x
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Buckley Katherine A, 2005, Methods Mol Med, V107, P55
   Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood 2004 04 1670
   Chatterjee M, 2002, BLOOD, V100, P3311, DOI 10.1182/blood 2002 01 0102
   Cohen Saidon C, 2006, BLOOD, V107, P1413, DOI 10.1182/blood 2005 07 2648
   Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163 7258(98)00013 8
   Egorin MJ, 2002, CANCER CHEMOTH PHARM, V49, P7, DOI 10.1007/s00280 001 0380 8
   Eiseman JL, 2005, CANCER CHEMOTH PHARM, V55, P21, DOI 10.1007/s00280 004 0865 3
   Georgakis GV, 2006, CLIN CANCER RES, V12, P584, DOI 10.1158/1078 0432.CCR 05 1194
   Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626
   Kalvakolanu DV, 2005, J INTERF CYTOK RES, V25, P757, DOI 10.1089/jir.2005.25.757
   Kuehl W Michael, 2005, Hematology Am Soc Hematol Educ Program, P346
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Lentzsch S, 2004, LEUKEMIA, V18, P1883, DOI 10.1038/sj.leu.2403486
   Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood 2005 03 1158
   Pellegrino A, 2005, BRIT J HAEMATOL, V129, P248, DOI 10.1111/j.1365 2141.2005.05443.x
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Sato N, 2003, BIOCHEM BIOPH RES CO, V300, P847, DOI 10.1016/S0006 291X(02)02941 8
   Schmidmaier R, 2004, BLOOD, V104, P1825, DOI 10.1182/blood 2003 12 4218
   Schulte TW, 1996, MOL CELL BIOL, V16, P5839
   Shang LM, 2006, J BIOL CHEM, V281, P1876, DOI 10.1074/jbc.M509901200
   Smith V, 2005, CANCER CHEMOTH PHARM, V56, P126, DOI 10.1007/s00280 004 0947 2
   Sreedhar AS, 2004, FEBS LETT, V562, P11
   Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189
   Stephanou A, 1998, J AUTOIMMUN, V11, P249, DOI 10.1006/jaut.1998.0194
   Stephanou A, 1997, BIOCHEM J, V321, P103, DOI 10.1042/bj3210103
   Tian ZQ, 2004, BIOORGAN MED CHEM, V12, P5317, DOI 10.1016/j.bmc.2004.07.053
   Tu YP, 2000, CANCER RES, V60, P6763
   Vacca A, 2006, LEUKEMIA, V20, P193, DOI 10.1038/sj.leu.2404067
   Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood 2003 04 1338
   Valbuena JR, 2005, MODERN PATHOL, V18, P1343, DOI 10.1038/modpathol.3800459
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109 004 0549 9
NR 39
TC 129
Z9 147
U1 0
U2 13
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006 4971
J9 BLOOD
JI Blood
PD JAN 15
PY 2007
VL 109
IS 2
BP 720
EP 728
DI 10.1182/blood 2006 05 024372
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 125BN
UT WOS:000243416600052
PM 17003370
OA Bronze
DA 2025 08 17
ER

PT J
AU Wagner, JM
   Wille, A
   Fueth, M
   Weske, S
   Lotzien, S
   Reinkemeier, F
   Wallner, C
   Sogorski, A
   Dittfeld, S
   Becerikli, M
   Schildhauer, TA
   Lehnhardt, M
   Levkau, B
   Behr, B
AF Wagner, Johannes M.
   Wille, Annalena
   Fueth, Maria
   Weske, Sarah
   Lotzien, Sebastian
   Reinkemeier, Felix
   Wallner, Christoph
   Sogorski, Alexander
   Dittfeld, Stephanie
   Becerikli, Mustafa
   Schildhauer, Thomas A.
   Lehnhardt, Marcus
   Levkau, Bodo
   Behr, Bjorn
TI Pharmacological elevation of sphingosine 1 phosphate by S1P lyase
   inhibition accelerates bone regeneration after post traumatic
   osteomyelitis
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone regeneration; osteomyelitis; sphingosin 1 phosphate
ID COLLAGEN INDUCED ARTHRITIS; SPHINGOSINE 1 PHOSPHATE; GENE EXPRESSION;
   PPAR GAMMA; MANAGEMENT; FTY720; PROMOTES; PROLIFERATION; ANGIOGENESIS;
   OSTEOGENESIS
AB Posttraumatic osteomyelitis and the ensuing bone defects are a debilitating complication after open fractures with little therapeutic options. We have recently identified potent osteoanabolic effects of sphingosine 1 phosphate (S1P) signalling and have now tested whether it may beneficially affect bone regeneration after infection. We employed pharmacological S1P lyase inhibition by 4 deoxypyrodoxin (DOP) to raise S1P levels in vivo in an unicortical long bone defect model of posttraumatic osteomyelitis in mice. In a translational approach, human bone specimens of clinical osteomyelitis patients were treated in organ culture in vitro with DOP. Bone regeneration was assessed by mu CT, histomorphometry, immunohistology and gene expression analysis. The role of S1P receptors was addressed using S1PR3 deficient mice. Here, we present data that DOP treatment markedly enhanced osteogenesis in posttraumatic osteomyelitis. This was accompanied by greatly improved osteoblastogenesis and enhanced angiogenesis in the callus accompanied by osteoclast mediated bone remodelling. We also identified the target of increased S1P to be the S1PR3 as S1PR3( / ) mice showed no improvement of bone regeneration by DOP. In the human bone explants, bone mass significantly increased along with enhanced osteoblastogenesis and angiogenesis. Our data suggest that enhancement of S1P/S1PR3 signalling may be a promising therapeutic target for bone regeneration in posttraumatic osteomyelitis.
C1 [Wagner, Johannes M.; Fueth, Maria; Reinkemeier, Felix; Wallner, Christoph; Sogorski, Alexander; Dittfeld, Stephanie; Becerikli, Mustafa; Lehnhardt, Marcus; Behr, Bjorn] BG Univ Hosp Bergmannsheil Bochum, Dept Plast Surg, Bochum, Germany.
   [Wagner, Johannes M.; Lotzien, Sebastian; Schildhauer, Thomas A.] BG Univ Hosp Bergmannsheil Bochum, Dept Trauma Surg & Gen Surg, Bochum, Germany.
   [Wille, Annalena; Weske, Sarah; Levkau, Bodo] Univ Hosp Dusseldorf, Inst Mol Med 3, Dusseldorf, Germany.
   [Wille, Annalena; Weske, Sarah; Levkau, Bodo] Heinrich Heine Univ Dusseldorf, Dusseldorf, Germany.
   [Behr, Bjorn] BG Univ Hosp Bergmannsheil Bochum, Burkle de la Camp Pl 1, D 44789 Bochum, Germany.
C3 Ruhr University Bochum; Ruhr University Bochum; Heinrich Heine
   University Dusseldorf; Heinrich Heine University Dusseldorf Hospital;
   Heinrich Heine University Dusseldorf; Ruhr University Bochum
RP Behr, B (通讯作者)，BG Univ Hosp Bergmannsheil Bochum, Burkle de la Camp Pl 1, D 44789 Bochum, Germany.
EM bjorn.behr@rub.de
RI Wallner, Christoph/JVO 4067 2024; Reinkemeier, Felix/AAM 8006 2021
OI Schildhauer, Thomas/0000 0002 3232 9869; Wille,
   Annalena/0000 0002 9454 0483; 
FU Deutsche Forschungsgemeinschaft [BE 4169/8 2]; Else Kroener Fresenius
   Stiftung
FX Deutsche Forschungsgemeinschaft, Grant/Award Number: BE 4169/8 2;
   Else Kroener Fresenius Stiftung
CR Aronin CEP, 2010, TISSUE ENG PT A, V16, P1801, DOI [10.1089/ten.tea.2009.0539, 10.1089/ten.TEA.2009.0539]
   Behr B, 2010, P NATL ACAD SCI USA, V107, P11853, DOI 10.1073/pnas.1003317107
   Bonica J, 2020, CELLS BASEL, V9, DOI 10.3390/cells9112437
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brizuela L, 2014, MOL ONCOL, V8, P1181, DOI 10.1016/j.molonc.2014.04.001
   Bury DC, 2021, AM FAM PHYSICIAN, V104, P73
   Calhoun Jason H, 2009, Semin Plast Surg, V23, P59, DOI 10.1055/s 0029 1214158
   Chandra A, 2013, J BIOL CHEM, V288, P20488, DOI 10.1074/jbc.M112.447250
   Duran CL, 2018, METHODS MOL BIOL, V1697, P99, DOI 10.1007/7651_2017_26
   Game F, 2010, NAT REV ENDOCRINOL, V6, P43, DOI 10.1038/nrendo.2009.243
   GUSTILO RB, 1990, J BONE JOINT SURG AM, V72A, P299, DOI 10.2106/00004623 199072020 00023
   Han YP, 2015, J IMMUNOL, V195, P4126, DOI 10.4049/jimmunol.1401842
   Harmer James L, 2011, Foot (Edinb), V21, P149, DOI 10.1016/j.foot.2010.11.005
   Hatzenbuehler J, 2011, AM FAM PHYSICIAN, V84, P1027
   Hernández Preciado MR, 2022, J CLIN MED, V11, DOI 10.3390/jcm11133584
   Higashi K, 2016, BONE, V93, P1, DOI 10.1016/j.bone.2016.09.003
   Huwiler A, 2018, PHARMACOL THERAPEUT, V185, P34, DOI 10.1016/j.pharmthera.2017.11.001
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Kikuta J, 2011, RHEUMATOL INT, V31, P967, DOI 10.1007/s00296 010 1634 8
   Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lai WQ, 2012, FUTURE MED CHEM, V4, P727, DOI [10.4155/FMC.12.28, 10.4155/fmc.12.28]
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Matsuura M, 2000, INT J IMMUNOPHARMACO, V22, P323, DOI 10.1016/S0192 0561(99)00088 0
   Matsuzaki E, 2013, BONE, V55, P315, DOI 10.1016/j.bone.2013.04.008
   Montalban X, 2011, MULT SCLER J, V17, P1341, DOI 10.1177/1352458511411061
   Moritz E, 2021, J INFLAMM RES, V14, P2883, DOI 10.2147/JIR.S302117
   Park JH, 2017, MOL CELLS, V40, P706
   Parsons B, 2004, AM J SURG, V188, p57S, DOI 10.1016/S0002 9610(03)00292 7
   Polzin A, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 38069 5
   Sefcik LS, 2008, BIOMATERIALS, V29, P2869, DOI 10.1016/j.biomaterials.2008.03.017
   Sukocheva O, 2015, STEROIDS, V104, P237, DOI 10.1016/j.steroids.2015.10.009
   Sukocheva OA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020420
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113
   Tantikanlayaporn D, 2018, JBMR PLUS, V2, P217, DOI 10.1002/jbm4.10037
   Wagner JM, 2017, J ORTHOP RES, V35, P2425, DOI 10.1002/jor.23555
   Wagner JM, 2022, J BONE MINER METAB, V40, P20, DOI 10.1007/s00774 021 01269 4
   Wagner JM, 2020, J MOL MED, V98, P897, DOI 10.1007/s00109 020 01924 9
   Wagner JM, 2019, STEM CELL TRANSL MED, V8, P1084, DOI 10.1002/sctm.18 0266
   Wagner JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149389
   Wahli W, 2008, CELL METAB, V7, P188, DOI 10.1016/j.cmet.2008.02.005
   WALDVOGEL FA, 1970, NEW ENGL J MED, V282, P198, DOI 10.1056/NEJM197001222820406
   Wallner C, 2016, STEM CELL TRANSL MED, V5, P836, DOI 10.5966/sctm.2015 0158
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Weske S, 2018, NAT MED, V24, P667, DOI 10.1038/s41591 018 0005 y
   Yang CY, 2022, FASEB J, V36, DOI 10.1096/fj.202200339RRR
NR 50
TC 1
Z9 1
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD DEC
PY 2023
VL 27
IS 23
BP 3786
EP 3795
DI 10.1111/jcmm.17952
EA SEP 2023
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GJ8D5
UT WOS:001067982500001
PM 37710406
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Song, YB
   Meng, ZL
   Zhang, SS
   Li, NG
   Hu, W
   Li, H
AF Song, Yibo
   Meng, Zhaolei
   Zhang, Shanshan
   Li, Nianguo
   Hu, Wei
   Li, Hong
TI miR 4739/ITGA10/PI3K signaling regulates differentiation and apoptosis
   of osteoblast
SO REGENERATIVE THERAPY
LA English
DT Article
DE Osteoblast; Osteoporosis; Luciferase reporter; miR 4739; ITGA10
ID CIRCULATING MIRNAS; OSTEOPOROSIS; EXPRESSION; CELLS
AB Introduction: To probe the impacts and biological roles of miR 4739/ITGA10 on the proliferation, differentiation and apoptosis of osteoblasts.Methods: Bioinformatics analysis was conducted to screen the key genes in osteoporosis. The upstream miRNAs of ITGA10 were predicted by TargetScan. KEGG pathway enrichment analysis was performed by DAVID database. The osteoblast proliferation and apoptosis were measured using CCK 8 and flow cytometry. The differentiation markers were measured by qRT PCR and western blotting. The luciferase reporter assay was conducted to verify the binding of miR 4739 to ITGA10.Results: ITGA10 was down regulated in patients with osteoporosis and identified as the key gene in osteoporosis by the bioinformatics analysis. Then the prediction provided by TargetScan indicated that miR 4739 was the potential upstream miRNA for ITGA10. And the following luciferase reporter assay showed that miR 4739 could bind to ITGA10 30UTR. Furthermore, the miR 4739 inhibitor promoted osteoblasts proliferation, differentiation, and inhibited cell apoptosis by increasing the expression of ITGA10 and subsequently activating the PI3K/AKT signaling pathway.Conclusions: Overall, we proved that the higher expression of miR 4739 participated in the progression of osteoporosis by targeting ITGA10 and modulating PI3K/AKT signaling pathway, and perhaps miR 4739/ ITGA10 axis could be potential diagnostic markers and therapeutic target for osteoporosis.(c) 2022, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/ 4.0/).
C1 [Song, Yibo; Hu, Wei] Jinan Zhangqiu Dist Hosp TCM, Spinal Dept Orthoped, Jinan, Shandong, Peoples R China.
   [Meng, Zhaolei] Jinan Zhangqiu Dist Hosp TCM, Hand & Foot Dept Ward 2, Jinan, Shandong, Peoples R China.
   [Zhang, Shanshan] Jinan Zhangqiu Dist Hosp TCM, Thorac Surg Ward, Jinan, Shandong, Peoples R China.
   [Li, Nianguo] Jinan Zhangqiu Dist Hosp TCM, Med Dept, Jinan, Shandong, Peoples R China.
   [Li, Hong] Fourth Middle Sch Zhangqiu Dist, Jinan, Shandong, Peoples R China.
   [Li, Hong] Fourth Middle Sch Zhangqiu Dist, Zhangqiu Dist,599 Shuangshan North Rd, Jinan, Shandong, Peoples R China.
RP Li, H (通讯作者)，Fourth Middle Sch Zhangqiu Dist, Zhangqiu Dist,599 Shuangshan North Rd, Jinan, Shandong, Peoples R China.
EM smith_james@163.com
RI Zhang, shanshan/HLP 6320 2023
CR Afonso J, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 49089 x
   De Ugarte L, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0149 2
   Dong J, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112137
   Elsafadi M, 2017, STEM CELL RES, V20, P94, DOI 10.1016/j.scr.2017.03.001
   Ge XT, 2021, AM J TRANSL RES, V13, P6330
   Grossman DC, 2017, JAMA J AM MED ASSOC, V318, P2224, DOI 10.1001/jama.2017.18261
   Kanazawa I, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 51
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kim EK, 2012, J CELL PHYSIOL, V227, P1680, DOI 10.1002/jcp.22892
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Kuek V, 2016, SCI REP UK, V6, DOI 10.1038/srep36210
   Lemma SA, 2017, CARCINOGENESIS, V38, P812, DOI 10.1093/carcin/bgx061
   Li HQ, 2014, BIOMARKERS, V19, P553, DOI 10.3109/1354750X.2014.935957
   Li JY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4232794
   Li RK, 2017, J CANCER, V8, P3764, DOI 10.7150/jca.20900
   Liu LL, 2020, ORTHOP SURG, V12, P1304, DOI 10.1111/os.12750
   Lv Hao, 2015, Med Sci Monit, V21, P1527, DOI 10.12659/MSM.894323
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Munch S, 2006, HEALTH SOC WORK, V31, P44, DOI 10.1093/hsw/31.1.44
   Oh JH, 2019, MAR DRUGS, V17, DOI 10.3390/md17100543
   Okada T, 2016, CANCER DISCOV, V6, P1148, DOI 10.1158/2159 8290.CD 15 1481
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Peng CW, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935 019 1060 2
   Rasmusson L, 2014, INT J DENT, V2014, DOI 10.1155/2014/471035
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Rizzo E, 2018, JBMR PLUS, V2, P323, DOI 10.1002/jbm4.10062
   Schepper JD, 2017, ADV EXP MED BIOL, V1033, P225, DOI 10.1007/978 3 319 66653 2_11
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Sharma Sudhaa, 2006, Indian J Med Sci, V60, P183
   Shen JF, 2019, J CANCER RES CLIN, V145, P1681, DOI 10.1007/s00432 019 02907 1
   Song ZQ, 2018, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.02114
   Wang M, 2019, EBIOMEDICINE, V41, P670, DOI 10.1016/j.ebiom.2019.02.057
   Wang XB, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109557
   Weilner S, 2015, BONE, V79, P43, DOI 10.1016/j.bone.2015.05.027
   Wenke AK, 2007, CELL ONCOL, V29, P373
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Yang L, 2012, J BONE MINER RES, V27, P1598, DOI 10.1002/jbmr.1621
   Zhang YQ, 2017, AM J TRANSL RES, V9, P126
   Zhao GX, 2019, J CLIN INVEST, V129, P972, DOI 10.1172/JCI122779
NR 39
TC 7
Z9 8
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC
PY 2022
VL 21
BP 342
EP 350
DI 10.1016/j.reth.2022.08.002
EA SEP 2022
PG 9
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA 4R4AQ
UT WOS:000856709400004
PM 36161100
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhi, X
   Cui, J
   Liu, C
   Zhang, Z
   Cao, LH
   Pan, PP
   Weng, WZ
   Zhai, X
   Zhao, QJ
   Hu, HG
   Qin, LJ
   Chen, X
   Su, JC
AF Zhi Xin
   Cui Jin
   Liu Chao
   Zhang Zheng
   Cao Liehu
   Pan Panpan
   Weng Weizong
   Zhai Xiao
   Zhao Qingjie
   Hu Honggang
   Qin Longjuan
   Chen Xiao
   Su Jiacan
TI 被撤回的出版物: A Matrine Derivative M54 Suppresses Osteoclastogenesis and
   Prevents Ovariectomy Induced Bone Loss by Targeting Ribosomal Protein S5
   (Retracted article. See vol. 16, 2025)
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE RPS5; matrine derivative; RANKL; osteoclasts; AKT pathway
ID NF KAPPA B; OSTEOPOROSIS; INHIBITION; ACID; INFLAMMATION; ACTIVATION;
   EXPRESSION; PATHWAY; CELLS
AB Post menopausal osteoporosis (PMOP) is a metabolic bone disorder characterized by low bone mass and micro architectural deterioration of bone tissue. The over activated osteoclastogenesis, which plays an important role in osteoporosis, has become an important therapeutic target. M54 was a bioactive derivative of the Chinese traditional herb matrine. We found that M54 could suppress RANKL induced osteoclastogenesis in bone marrow mononuclear cells and RAW264.7 cells through suppressing NF kappa B, PI3K/AKT, and MAPKs pathways activity in vitro, and prevent ovariectomy induced bone loss in vivo. Our previous study has proved that ribosomal protein S5 (RPS5) was a direct target of M19, based on which M54 was synthesized. Thus we deduced that M54 also targeted RPS5. During osteoclastogenesis, the RPS5 level in RAW264.7 cells was significantly down regulated while M54 could maintain its level. After RPS5 was silenced, the inhibitory effects of M54 on osteoclastogenesis were partially compromised, indicating that M54 took effects through targeting RPS5. In summary, M54 was a potential clinical medicine for post menopause osteoporosis treatment, and RPS5 is a possible key protein in PMOP.
C1 [Zhi Xin; Cui Jin; Zhang Zheng] Second Mil Med Univ, Shanghai Changhai Hosp, Grad Management Unit, Shanghai, Peoples R China.
   [Liu Chao; Zhao Qingjie; Hu Honggang] Second Mil Med Univ, Sch Pharm, Shanghai, Peoples R China.
   [Cao Liehu; Pan Panpan; Weng Weizong; Zhai Xiao; Chen Xiao; Su Jiacan] Second Mil Med Univ, Shanghai Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Cao Liehu; Pan Panpan; Weng Weizong; Chen Xiao; Su Jiacan] China South Korea Bioengn Ctr, Shanghai, Peoples R China.
   [Qin Longjuan] Orthoped Basic & Translat Res Ctr, Jiangyin, Peoples R China.
C3 Naval Medical University; Naval Medical University; Naval Medical
   University
RP Chen, X; Su, JC (通讯作者)，Second Mil Med Univ, Shanghai Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.; Chen, X; Su, JC (通讯作者)，China South Korea Bioengn Ctr, Shanghai, Peoples R China.
EM sirchenxiao@126.com; drsujiacan@163.com
RI ; Pan, Panpan/GRJ 2514 2022; Wu, Xiaozhi/AAP 3954 2021; Chen,
   Xiao/N 1298 2017; Cui, Jin/HDL 7327 2022
OI Su, Jiacan/0000 0001 7080 263X; 
CR Anastasilakis AD, 2015, OSTEOPOROSIS INT, V26, P2521, DOI 10.1007/s00198 015 3174 2
   Arun MZ, 2016, DRUG DES DEV THER, V10, P1453, DOI 10.2147/DDDT.S103124
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Asati V, 2016, EUR J MED CHEM, V109, P314, DOI 10.1016/j.ejmech.2016.01.012
   Bhat P, 2015, NUCLEIC ACIDS RES, V43, P2888, DOI 10.1093/nar/gkv110
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Del Puente A, 2015, J BIOL REG HOMEOS AG, V29, P527
   Feng J, 2014, ACTA BIOCH BIOPH SIN, V46, P1024, DOI 10.1093/abbs/gmu103
   Feng Q, 2017, ONCOTARGET, V8, P27820, DOI 10.18632/oncotarget.15482
   Feng Y, 2016, PROTEIN CELL, V7, P662, DOI 10.1007/s13238 016 0285 2
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Huang YQ, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00256
   Jakob F, 2015, UNFALLCHIRURG, V118, P925, DOI 10.1007/s00113 015 0085 9
   Jordan SC, 2017, TRANSPLANTATION, V101, P32, DOI 10.1097/TP.0000000000001452
   Joseph AP, 2014, RNA BIOL, V11, P891, DOI 10.4161/rna.29545
   Kaminski A, 2015, PHARMACOL REP, V67, P24, DOI 10.1016/j.pharep.2015.06.074
   Kamiya T, 1998, J BIOCHEM TOKYO, V123, P752
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li JZ, 2016, MOLECULES, V21, DOI 10.3390/molecules21050649
   Li X, 2014, ARTHROSCOPY, V30, P1483, DOI 10.1016/j.arthro.2014.03.020
   Liu J, 2016, MOL MED REP, V13, P2313, DOI 10.3892/mmr.2016.4767
   Liu Q, 2016, SCI REP UK, V6, DOI 10.1038/srep36662
   Mei X, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1736 x
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Qian LQ, 2015, CANCER LETT, V368, P126, DOI 10.1016/j.canlet.2015.07.035
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Silverman SL, 2011, OSTEOPOROSIS INT, V22, P2337, DOI 10.1007/s00198 010 1448 2
   Sun DQ, 2016, BIOCHEM BIOPH RES CO, V477, P83, DOI 10.1016/j.bbrc.2016.06.024
   Tao XF, 2016, PHARMACOL RES, V108, P90, DOI 10.1016/j.phrs.2016.05.003
   Vassalle C, 2016, VASC PHARMACOL, V86, P77, DOI 10.1016/j.vph.2016.07.003
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034641
   Warren JT, 2015, J CELL BIOCHEM, V116, P2476, DOI 10.1002/jcb.25191
   Wu Q, 2015, MED SCI MONITOR, V21
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xu WH, 2014, HEPATOLOGY, V60, P648, DOI 10.1002/hep.27138
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zhang Y, 2015, SCI REP UK, V5, DOI 10.1038/srep13575
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zhu L, 2016, EXP MOL PATHOL, V100, P337, DOI 10.1016/j.yexmp.2015.12.006
NR 43
TC 32
Z9 34
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 30
PY 2018
VL 9
AR 22
DI 10.3389/fphar.2018.00022
PN 1
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA VK5PM
UT WOS:000729630300001
PM 29441015
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Farhat, A
   Jiang, D
   Cui, D
   Keller, ET
   Jackson, TL
AF Farhat, A.
   Jiang, D.
   Cui, D.
   Keller, E. T.
   Jackson, T. L.
TI An integrative model of prostate cancer interaction with the bone
   microenvironment
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
DE Mathematical model; Prostate cancer; Bone metastasis
ID HORMONE RELATED PROTEIN; TGF BETA; IN VITRO; CALCIUM; ANTIGEN;
   METASTASIS; INHIBITION; EXPRESSION; CELLS; TUMOR
AB Despite advanced efforts in early diagnosis, aggressive surgical treatment, and use of targeted chemotherapies, the prognosis for many cancers is still dismal. This emphasizes the necessity to develop new strategies for understanding tumor growth and metastasis. Here we use a systems approach that combines mathematical modeling and numerical simulation to develop a predictive computational model for prostate cancer and its subversion of the bone microenvironment. This model simulates metastatic prostate cancer evolution, progressing from normal bone and hormone levels to quantifiable diseased states. The simulations clearly demonstrate phenomena similar to those found clinically in prostate cancer patients. In addition, the major prediction of this model is the existence of low and high osteogenic states that are markedly different from one another. The existence and potential realization of these steady states appear to be mediated by the Wnt signaling pathway and by the effects of PSA on TGF beta, which encourages the bone microenvironment to evolve. The model is used to explore several potential therapeutic strategies, with some potential drug targets showing more promise than others: in particular, completely blocking Wnt and greatly increasing DKK 1 had significant positive effects, while blocking RANKL did not improve the outcome. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Farhat, A.; Jackson, T. L.] Univ Michigan, Dept Math, Ann Arbor, MI 48109 USA.
   [Jiang, D.] Command Post 1412 Broadway, New York, NY 10018 USA.
   [Cui, D.] Shanghai Gen Hosp, Dept Urol, Shanghai, Peoples R China.
   [Keller, E. T.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Jackson, TL (通讯作者)，Univ Michigan, Dept Math, Ann Arbor, MI 48109 USA.; Keller, ET (通讯作者)，Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
EM etkeller@med.umich.edu; tjacks@umich.edu
RI Keller, Evan/M 1446 2016; Cui, Di/GXM 4204 2022
FU NIH [P01 CA093900]; UM M Cubed; Simon's Foundation; National Cancer
   Institute [P01CA093900] Funding Source: NIH RePORTER
FX We thank Shuichi Takayma for helpful discussions and Beatrix Balogh for
   early efforts on this project. This work was supported by NIH P01
   CA093900 (ETK), UM M Cubed (ETJ, TLJ), and the Simon's Foundation (TLJ).
CR Ahamed J, 2008, BLOOD, V112, P3650, DOI 10.1182/blood 2008 04 151753
   Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008 5472.CAN 13 2652
   Asadi F, 1996, HUM PATHOL, V27, P1319, DOI 10.1016/S0046 8177(96)90344 5
   Blair HC, 2011, BIOFACTORS, V37, P159, DOI 10.1002/biof.143
   BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend 5 6 741
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   BROWN EM, 1981, AM J MED, V71, P565, DOI 10.1016/0002 9343(81)90207 2
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Buenzli PR, 2012, J THEOR BIOL, V307, P42, DOI 10.1016/j.jtbi.2012.04.019
   Cook LM, 2016, SCI REP UK, V6, DOI 10.1038/srep29384
   Cook LM, 2014, CANCER METAST REV, V33, P511, DOI 10.1007/s10555 014 9494 4
   Cramer SD, 1996, J UROLOGY, V156, P526, DOI 10.1016/S0022 5347(01)65919 6
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008 5472.CAN 07 6541
   Dallas SL, 2005, J CELL PHYSIOL, V202, P361, DOI 10.1002/jcp.20147
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Deng XR, 2014, BIOMED ENVIRON SCI, V27, P594, DOI 10.3967/bes2014.091
   Filvaroff E, 1999, DEVELOPMENT, V126, P4267
   Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009
   Friberg S, 1997, J SURG ONCOL, V65, P284, DOI 10.1002/(SICI)1096 9098(199708)65:4<284::AID JSO11>3.0.CO;2 2
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Jurukovski V, 2005, METH MOLEC MED, V117, P161
   Kaminska B, 2005, ACTA BIOCHIM POL, V52, P329
   Kanagal DV, 2014, J CLIN DIAGN RES, V8, pOC1, DOI 10.7860/JCDR/2014/8872.4537
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kypta RM, 2012, NAT REV UROL, V9, P418, DOI 10.1038/nrurol.2012.116
   Langdahl BL, 1997, BONE, V20, P289, DOI 10.1016/S8756 3282(96)00363 8
   Liao JH, 2008, INT J CANCER, V123, P2267, DOI 10.1002/ijc.23602
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Mundy GR, 1999, CLIN CHEM, V45, P1347
   Nielsen PK, 1997, BIOCHEM BIOPH RES CO, V238, P880, DOI 10.1006/bbrc.1997.7207
   Oudard S, 2007, ANN ONCOL, V18, P1828, DOI 10.1093/annonc/mdm332
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Roato I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003627
   Ross A.C., 2011, I MED US COMMITTEE R
   Sanchis Gomar F, 2014, CLIN LAB, V60, P1409, DOI 10.7754/Clin.Lab.2013.130830
   SCHMID HP, 1993, CANCER AM CANCER SOC, V71, P2031, DOI 10.1002/1097 0142(19930315)71:6<2031::AID CNCR2820710618>3.0.CO;2 Q
   Silberstein JL, 2013, TRANSL ANDROL UROL, V2, P122, DOI 10.3978/j.issn.2223 4683.2013.09.03
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Tandon Prabhat K, 2005, Endocr Pract, V11, P254
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Vela I, 2007, BJU INT, V99, P735, DOI 10.1111/j.1464 410X.2006.06670.x
   Wang YJ, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0023495, 10.1371/journal.pone.0020422]
   Welch HG, 2005, J NATL CANCER I, V97, P1132, DOI 10.1093/jnci/dji205
   Werahera PN, 2011, PROSTATE CANCER US, V2011, DOI 10.1155/2011/301850
   Wolff JM, 1998, EUR UROL, V33, P376, DOI 10.1159/000019619
   Xing LP, 2005, BIOCHEM BIOPH RES CO, V328, P709, DOI 10.1016/j.bbrc.2004.11.072
   Yavropoulou Maria P, 2007, Hormones (Athens), V6, P279
   Zhu Y, 2009, LEUKEMIA, V23, P925, DOI 10.1038/leu.2008.384
NR 53
TC 19
Z9 20
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025 5564
EI 1879 3134
J9 MATH BIOSCI
JI Math. Biosci.
PD DEC
PY 2017
VL 294
BP 1
EP 14
DI 10.1016/j.mbs.2017.09.005
PG 14
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA FR9SU
UT WOS:000419414200001
PM 28919575
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yang, CQ
   Ding, PP
   Wang, QK
   Zhang, L
   Zhang, X
   Zhao, JQ
   Xu, EJ
   Wang, N
   Chen, JF
   Yang, G
   Hu, WG
   Zhou, XH
AF Yang, Chaoqun
   Ding, Peipei
   Wang, Qingkai
   Zhang, Long
   Zhang, Xin
   Zhao, Jianquan
   Xu, Enjie
   Wang, Na
   Chen, Jianfeng
   Yang, Guang
   Hu, Weiguo
   Zhou, Xuhui
TI Inhibition of Complement Retards Ankylosing Spondylitis Progression
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RADIOGRAPHIC PROGRESSION; DOUBLE BLIND; CARTILAGE PROTEOGLYCANS;
   MEMBRANE PERMEABILITY; ESTROGEN RECEPTOR; BALB/C MICE; PATHOGENESIS;
   ACTIVATION; ADALIMUMAB; COMPLEXES
AB Ankylosing spondylitis (AS) is a chronic axial spondyloarthritis (SpA) resulting in back pain and progressive spinal ankyloses. Currently, there are no effective therapeutics targeting AS largely due to elusive pathogenesis mechanisms, even as potential candidates such as HLA B27 autoantigen have been identified. Herein, we employed a proteoglycan (PG) induced AS mouse model together with clinical specimens, and found that the complement system was substantially activated in the spinal bone marrow, accompanied by a remarkable proportion alteration of neutrophils and macrophage in bone marrow and spleen, and by the significant increase of TGF beta 1 in serum. The combined treatment with a bacteria derived complement inhibitor Efb C (C terminal of extracellular fibrinogen binding protein of Staphylococcus aureus) remarkably retarded the progression of mouse AS by reducing osteoblast differentiation. Furthermore, we demonstrated that two important modulators involved in AS disease, TGF beta 1 and RANKL, were elevated upon in vitro complement attack in osteoblast and/or osteoclast cells. These findings further unravel that complement activation is closely related with the pathogenesis of AS, and suggest that complement inhibition may hold great potential for AS therapy.
C1 [Yang, Chaoqun; Zhao, Jianquan; Xu, Enjie; Zhou, Xuhui] Second Mil Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai 200003, Peoples R China.
   [Yang, Chaoqun] Fudan Univ, Huashan Hosp, Dept Hand Surg, 12 Wulumuqi Middle Rd, Shanghai 200040, Peoples R China.
   [Ding, Peipei; Wang, Qingkai; Zhang, Long; Zhang, Xin; Wang, Na; Chen, Jianfeng; Hu, Weiguo] Fudan Univ, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
   [Ding, Peipei; Wang, Qingkai; Zhang, Long; Zhang, Xin; Wang, Na; Chen, Jianfeng; Hu, Weiguo] Fudan Univ, Inst Biomed Sci, Collaborat Innovat Ctr Canc Med, Dept Oncol,Shanghai Med Coll, Shanghai 200032, Peoples R China.
   [Yang, Guang] Beijing Inst Basic Med Sci, 27 Taiping Rd, Beijing 100850, Peoples R China.
   [Hu, Weiguo] Fudan Univ, Shanghai Med Coll, Dept Immunol, Shanghai 200032, Peoples R China.
C3 Naval Medical University; Fudan University; Fudan University; Fudan
   University; Academy of Military Medical Sciences   China; Institute of
   Basic Medical Sciences (IBMS); Fudan University
RP Zhou, XH (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai 200003, Peoples R China.; Hu, WG (通讯作者)，Fudan Univ, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Hu, WG (通讯作者)，Fudan Univ, Inst Biomed Sci, Collaborat Innovat Ctr Canc Med, Dept Oncol,Shanghai Med Coll, Shanghai 200032, Peoples R China.; Hu, WG (通讯作者)，Fudan Univ, Shanghai Med Coll, Dept Immunol, Shanghai 200032, Peoples R China.
EM weiguohu@fudan.edu.cn; zhouxuhui@hotmail.com
RI ; Hu, Weiguo/AAP 2239 2021; Chen, Jianfeng/GLR 5748 2022
OI Hu, Weiguo/0000 0002 7397 6800; Chen, Jianfeng/0000 0002 4182 145X; 
FU National Natural Science Foundation of China [81171910, 81372258]; Major
   State Basic Research Development Program of China [2013CB910802];
   Program for Professor of Special Appointment (Eastern Scholar) at
   Shanghai Institutions of Higher Learning [GZ2014002]; Science and
   Technology Commission of Shanghai Municipality [12140903900]
FX This research was supported by the National Natural Science Foundation
   of China (81171910, 81372258), the Major State Basic Research
   Development Program of China (2013CB910802), the Program for Professor
   of Special Appointment (Eastern Scholar, GZ2014002) at Shanghai
   Institutions of Higher Learning to W.H., and Science and Technology
   Commission of Shanghai Municipality (12140903900) to X.Z.
CR Acosta JA, 1996, MOL MED, V2, P755, DOI 10.1007/BF03401659
   Akbulut H, 2010, J RHEUMATOL, V37, P1073, DOI 10.3899/jrheum.091469
   Bárdos T, 2005, ANN RHEUM DIS, V64, P981, DOI 10.1136/ard.2004.029710
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Brandt J, 2003, ARTHRITIS RHEUM US, V48, P1667, DOI 10.1002/art.11017
   BRINCH L, 1982, ANN RHEUM DIS, V41, P86, DOI 10.1136/ard.41.1.86
   COWLING P, 1980, ANN RHEUM DIS, V39, P545, DOI 10.1136/ard.39.6.545
   Daikh David I, 2014, F1000Prime Rep, V6, P78, DOI 10.12703/P6 78
   Dakwar E, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/1/E2
   DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876
   Ebringer A, 2006, CURR RHEUMATOL REV, V2, P55, DOI 10.2174/157339706775697044
   Fuller K, 2000, J CELL SCI, V113, P2445
   Gao YP, 2013, CELL BIOCHEM BIOPHYS, V66, P753, DOI 10.1007/s12013 013 9520 0
   Giant TT, 2004, METH MOLEC MED, V102, P313
   GLANT TT, 1987, ARTHRITIS RHEUM US, V30, P201, DOI 10.1002/art.1780300211
   Gu HM, 2014, FASEB J, V28, P4223, DOI 10.1096/fj.13 247650
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   HALPERIN JA, 1988, J CLIN INVEST, V82, P594, DOI 10.1172/JCI113637
   Haroon N, 2013, ARTHRITIS RHEUM US, V65, P2645, DOI 10.1002/art.38070
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   Howe HS, 2005, RHEUMATOLOGY, V44, P51, DOI 10.1093/rheumatology/keh426
   Ignatius A, 2011, J CELL BIOCHEM, V112, P2594, DOI 10.1002/jcb.23186
   Inman RD, 2008, ARTHRITIS RHEUM US, V58, P3402, DOI 10.1002/art.23969
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   JOBANPUTRA P, 1992, ANN RHEUM DIS, V51, P959, DOI 10.1136/ard.51.8.959
   KINSELLA TD, 1975, J RHEUMATOL, V2, P308
   KRAULEDAT PB, 1985, RHEUMATOL INT, V5, P97, DOI 10.1007/BF00541327
   Landewé R, 2014, ANN RHEUM DIS, V73, P39, DOI 10.1136/annrheumdis 2013 204231
   Li T, 2010, CLIN EXP RHEUMATOL, V28, P201
   MALINSKI JA, 1989, BIOCHEMISTRY US, V28, P61, DOI 10.1021/bi00427a010
   MIKECZ K, 1987, ARTHRITIS RHEUM US, V30, P306, DOI 10.1002/art.1780300310
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Nickerson C. L., 1990, SCAND J RHEUMATOL S, V87, P90
   NICKERSON CL, 1990, SCAND J RHEUMATOL, P85
   PANAYI GS, 1980, ANN RHEUM DIS, V39, P445, DOI 10.1136/ard.39.5.445
   Quinn JMW, 1999, BONE, V25, P1, DOI 10.1016/S8756 3282(99)00094 0
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Ronneberger M, 2011, CURR RHEUMATOL REP, V13, P416, DOI 10.1007/s11926 011 0202 x
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P1324, DOI 10.1002/art.23471
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   van der Heijde D, 2006, ARTHRITIS RHEUM US, V54, P2136, DOI 10.1002/art.21913
   van der Heijde D, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2794
   VINJE O, 1984, CLIN RHEUMATOL, V3, P501, DOI 10.1007/BF02031273
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Yan T, 2001, J CELL BIOCHEM, V83, P320, DOI 10.1002/jcb.1200
   Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357
NR 47
TC 28
Z9 33
U1 0
U2 23
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD OCT 4
PY 2016
VL 6
AR 34643
DI 10.1038/srep34643
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DX7BB
UT WOS:000384539700001
PM 27698377
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hahm, ER
   Kim, SH
   Singh, SV
AF Hahm, Eun Ryeong
   Kim, Su Hyeong
   Singh, Shivendra V.
TI Withaferin A inhibits breast cancer induced osteoclast differentiation
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE breast cancer; osteoclastogenesis; RUNX2; withaferin A
ID BONE METASTASIS; TRANSCRIPTION FACTORS; WITHANIA SOMNIFERA; IN VIVO;
   KAPPA B; CELLS; RUNX2; EXPRESSION; OSTEOLYSIS; GROWTH
AB Bone is the most prone to metastatic spread of breast cancer cells for each subtype of the disease. Bone metastasis related complications including severe pain and pathological fractures affect patients' quality of life. Current treatment options including surgery, radiation, and bone targeted therapies (e.g., bisphosphonates) are costly or have serious adverse effects such as renal toxicity and osteonecrosis of the jaws. Therefore, a safe, inexpensive, and efficacious agent for prevention of breast cancer bone metastasis is urgently needed. Our previously published RNA sequencing analysis revealed that many genes implicated in bone remodeling and breast cancer bone metastasis were significantly downregulated by treatment with withaferin A (WA), which is a promising cancer chemopreventive agent derived from a medicinal plant (Withania somnifera). The present study investigated whether WA inhibits breast cancer induction of osteoclast differentiation. At plasma achievable doses, WA treatment inhibited osteoclast differentiation (osteoclastogenesis) induced by three different subtypes of breast cancer cells (MCF 7, SK BR 3, and MDA MB 231). WA and the root extract of W. somnifera were equally effective for inhibition of breast cancer induction of osteoclast differentiation. This inhibition was accompanied by suppression of interleukin (IL) 6, IL 8, and receptor activator of nuclear factor ?B ligand, which are pivotal osteoclastogenic cytokines. The expression of runt related transcription factor 2, nuclear factor ?B, and SOX9 transcription factors, which positively regulate osteoclastogenesis, was decreased in WA treated breast cancer cells as revealed by confocal microscopy and/or immunoblotting. Taken together, these data suggest that WA could be a promising agent for prevention of breast cancer induced bone metastasis.
C1 [Hahm, Eun Ryeong; Kim, Su Hyeong; Singh, Shivendra V.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA.
   [Singh, Shivendra V.] Univ Pittsburgh, UPMC Hillman Canc Ctr, Sch Med, Pittsburgh, PA USA.
   [Singh, Shivendra V.] UPMC Hillman Canc Ctr, Hillman Canc Ctr Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Singh, SV (通讯作者)，UPMC Hillman Canc Ctr, Hillman Canc Ctr Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
EM singhs@upmc.edu
OI Hahm, Eun Ryeong/0000 0002 3197 4575
FU National Cancer Institute [R01 CA142604]; National Cancer Institute at
   the National Institutes of Health [P30 CA047904]
FX ACKNOWLEDGMENTS This study was supported by the National Cancer
   Institute grant R01 CA142604 (S.V. Singh). This study used the UPMC
   Hillman Cancer Center Cell and Tissue Imaging Facility supported in part
   by the National Cancer Institute at the National Institutes of Health
   grant P30 CA047904. The funders had no role in the design of the study,
   data collection, analysis or interpretation of the data, manuscript
   preparation or decision to submit the manuscript for publication.
CR Antony ML, 2014, J BIOL CHEM, V289, P1852, DOI 10.1074/jbc.M113.496844
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   Barnes GL, 2003, CANCER RES, V63, P2631
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Dai TM, 2019, BIOMED CHROMATOGR, V33, DOI 10.1002/bmc.4573
   Gül G, 2016, CURR MED RES OPIN, V32, P133, DOI 10.1185/03007995.2015.1105795
   Hahm ER, 2021, MOL CARCINOGEN, V60, P3, DOI 10.1002/mc.23266
   Hahm ER, 2020, CANCER PREV RES, V13, P721, DOI 10.1158/1940 6207.CAPR 20 0259
   Hahm ER, 2013, JNCI J NATL CANCER I, V105, P1111, DOI 10.1093/jnci/djt153
   Hahm ER, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023354
   Hahm ER, 2011, MOL CARCINOGEN, V50, P614, DOI 10.1002/mc.20760
   Holen I, 2016, ONCOTARGET, V7, P75571, DOI 10.18632/oncotarget.12289
   Jackson C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246441
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kamalakar A, 2014, BONE, V61, P176, DOI 10.1016/j.bone.2014.01.015
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Kim SH, 2020, J TRADIT COMPL MED, V10, P188, DOI 10.1016/j.jtcme.2020.02.002
   Kim SH, 2014, CANCER PREV RES, V7, P738, DOI 10.1158/1940 6207.CAPR 13 0445
   Kurata T, 2012, JPN J CLIN ONCOL, V42, P663, DOI 10.1093/jjco/hys088
   Lee J, 2015, MOL CARCINOGEN, V54, P417, DOI 10.1002/mc.22110
   Lee J, 2010, CARCINOGENESIS, V31, P1991, DOI 10.1093/carcin/bgq175
   Li XQ, 2016, CANCER LETT, V380, P78, DOI 10.1016/j.canlet.2016.06.007
   Mathew A, 2015, INT J CANCER, V137, P753, DOI 10.1002/ijc.28965
   Nagareddy PR, 2006, J PHARM PHARMACOL, V58, P513, DOI 10.1211/jpp.58.4.0011
   Palliyaguru DL, 2016, MOL NUTR FOOD RES, V60, P1342, DOI 10.1002/mnfr.201500756
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Pore SK, 2020, MOL CANCER THER, V19, P420, DOI 10.1158/1535 7163.MCT 19 0611
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Samanta SK, 2017, JNCI J NATL CANCER I, V109, DOI 10.1093/jnci/djw293
   Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stan SD, 2008, CANCER RES, V68, P7661, DOI 10.1158/0008 5472.CAN 08 1510
   Stan SD, 2008, NUTR CANCER, V60, P51, DOI 10.1080/01635580802381477
   Tahara RK, 2019, ADV EXP MED BIOL, V1152, P105, DOI 10.1007/978 3 030 20301 6_7
   Tawara Ken, 2011, Cancer Manag Res, V3, P177, DOI 10.2147/CMR.S18101
   Tulotta C, 2018, ENDOCR RELAT CANCER, V25, pR421, DOI 10.1530/ERC 17 0309
   Vishal M, 2017, INT J BIOL MACROMOL, V99, P608, DOI 10.1016/j.ijbiomac.2017.03.021
   Vyas AR, 2014, AAPS J, V16, P1, DOI 10.1208/s12248 013 9531 1
   Wang R, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 6311 z
   Wong MH, 2011, BREAST CANCER TARGET, V3, P35, DOI 10.2147/BCTT.S6655
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Yang Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075069
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 47
TC 8
Z9 8
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0899 1987
EI 1098 2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD JUL
PY 2023
VL 62
IS 7
BP 1051
EP 1061
DI 10.1002/mc.23545
EA APR 2023
PG 11
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA I9KR9
UT WOS:000971675600001
PM 37067392
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Norwood, I
   Szondi, D
   Ciocca, M
   Coudert, A
   Cohen Solal, M
   Rucci, N
   Teti, A
   Maurizi, A
AF Norwood, Iona
   Szondi, Denis
   Ciocca, Michela
   Coudert, Amelie
   Cohen Solal, Martine
   Rucci, Nadia
   Teti, Anna
   Maurizi, Antonio
TI Transcriptomic and bioinformatic analysis of Clcn7 dependent
   Autosomal Dominant Osteopetrosis type 2. Preclinical and clinical
   implications
SO BONE
LA English
DT Article
DE RNA deep sequencing; Bioinformatics; Rare bone disease; Osteopetrosis;
   Gene ontology
AB Autosomal Dominant Osteopetrosis type 2 (ADO2) is a rare genetic disease characterized by dense yet fragile bones. To date, the radiological approach remains the gold standard for ADO2 diagnosis. However, recent observations unveiled that ADO2 is a systemic disease affecting various organs beyond bone, including lung, kidney, muscle, and brain. Monitoring disease status and progression would greatly benefit from specific biomarkers shared by the affected organs. In this work, data derived from RNA deep sequencing (RNA dSeq) of bone, lung, kidney, muscle, brain, and osteoclasts isolated from wildtype (WT) and Clcn7(G213R) ADO2 mice were subjected to gene ontology and pathway analyses. Results showed the presence of alterations in gene ontology terms and pathways associated with bone metabolism and osteoclast biology, including JAK STAT, cytokine cytokine receptor, and hematopoietic cell lineage. Furthermore, in line with the multiorgan alterations caused by ADO2, the analysis of soft organs showed an enrichment of PPAR and neuroactive ligand receptor interaction pathways known to be involved in the onset of tissue fibrosis and behavioral alterations, respectively. Finally, we observed the modulations of potential ADO2 biomarkers in organs and cells of ADO2 mice and in the peripheral blood mononuclear cells of patients, using conventional methods. Of note, some of these biomarkers could be possibly responsive to an effective experimental therapy based on a mutation specific siRNA. Overall, the identified gene signature and the soluble forms of the encoded proteins could potentially represent reliable disease biomarkers that could improve the ADO2 diagnosis, the monitoring of both the skeletal and non skeletal dysfunctions, and the assessment of the response to therapy.
C1 [Norwood, Iona; Szondi, Denis; Ciocca, Michela; Rucci, Nadia; Teti, Anna; Maurizi, Antonio] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy.
   [Coudert, Amelie; Cohen Solal, Martine] Univ Paris, INSERM, U 1132 Bioscar, Paris, France.
   [Coudert, Amelie; Cohen Solal, Martine] AP HP, Paris, France.
C3 University of L'Aquila; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite Paris Cite; Assistance Publique Hopitaux
   Paris (APHP)
RP Teti, A (通讯作者)，Dept Biotechnol & Appl Clin Sci, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
EM annamaria.teti@univaq.it
RI Maurizi, Antonio/AAI 7728 2020; Cohen Solal, Martine/P 7808 2017;
   COUDERT, Amélie/AAV 5429 2020
OI Szondi, Denis/0000 0002 1549 7713; Maurizi, Antonio/0000 0002 7027 4694;
   Teti, Anna Maria/0000 0002 5887 4419; Ciocca,
   Michela/0000 0003 1986 7766; Rucci, Nadia/0000 0002 1371 8252
FU Fondazione Telethon [GGP09018, GGP14014]; European Union
   [SYB IL FP7 HEALTH 2013 INNOVATION 602300,
   RUBICON H2020 MSCA RISE 2015_690850]; COST ACTION [CA18139]; "Progetti
   di Rilevante Interesse Nazionale" (PRIN) grant [2015F3JHMB]; Marie
   Sklodowska Curie fellowship from the RUBICON project
FX This work was supported by the Fondazione Telethon grants GGP09018 and
   GGP14014, the European Union funded project
   SYB IL FP7 HEALTH 2013 INNOVATION 602300, the European Union funded
   project RUBICON H2020 MSCA RISE 2015_690850, the COST ACTION funded
   project GEMSTONE CA18139 and the "Progetti di Rilevante Interesse
   Nazionale" (PRIN) grant 2015F3JHMB to A.T. A.M. was recipient of a Marie
   Sklodowska Curie fellowship from the RUBICON project.
CR Abad MA, 2006, J NEUROSCI, V26, P12735, DOI 10.1523/JNEUROSCI.0575 06.2006
   Alam I, 2014, BONE, V59, P66, DOI 10.1016/j.bone.2013.10.021
   Bénichou OD, 2000, BONE, V26, P87, DOI 10.1016/S8756 3282(99)00244 6
   Boini KM, 2012, J CELL MOL MED, V16, P1674, DOI 10.1111/j.1582 4934.2011.01462.x
   Bollerslev J, 2013, EUR J ENDOCRINOL, V169, pR39, DOI 10.1530/EJE 13 0136
   Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014 5793(95)01298 2
   Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286 4579(99)00250 6
   Burri L, 2010, PPAR RES, V2010, DOI 10.1155/2010/542359
   Cappariello A, 2015, BIOMATERIALS, V46, P58, DOI 10.1016/j.biomaterials.2014.12.033
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Capulli M, 2015, MOL THER NUCL ACIDS, V4, P1, DOI 10.1038/mtna.2015.21
   Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861
   Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673
   Del Fattore A, 2008, BONE, V42, P19, DOI 10.1016/j.bone.2007.08.029
   Elbjeirami WM, 2011, KIDNEY INT, V80, P1115, DOI 10.1038/ki.2011.299
   Eser D, 2006, NEUROENDOCRINOLOGY, V84, P244, DOI 10.1159/000097879
   Faiola B, 2008, TOXICOL SCI, V105, P384, DOI 10.1093/toxsci/kfn130
   Fanale D, 2017, PPAR RES, V2017, DOI 10.1155/2017/1830626
   Fedele G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/564687
   Fogo AB, 2011, PEDIATR NEPHROL, V26, P347, DOI 10.1007/s00467 010 1602 2
   Fresard L, 2019, NAT MED, V25, P911, DOI 10.1038/s41591 019 0457 8
   Graves AR, 2008, NATURE, V453, P788, DOI 10.1038/nature06907
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hill B.G., 1965, MED J AUSTRALIA, V2
   Kajiya H, 2009, PFLUG ARCH EUR J PHY, V458, P1049, DOI 10.1007/s00424 009 0689 4
   Kida Y., 2001, HISTOCHEM CELL BIOL, DOI [10.1007/s004180000245, DOI 10.1007/S004180000245]
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824
   Kukurba Kimberly R, 2015, Cold Spring Harb Protoc, V2015, P951, DOI 10.1101/pdb.top084970
   Lakatos HF, 2007, PPAR RES, V2007, DOI 10.1155/2007/71323
   Lee Y, 2011, BIOMOL THER, V19, P141, DOI 10.4062/biomolther.2011.19.2.141
   Li D, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.14
   Lisboa LF, 2015, AM J TRANSPLANT, V15, P1882, DOI 10.1111/ajt.13207
   Maurizi A., 2020, Principles of Bone Biology, P1553
   Maurizi A, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0055 x
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Maurizi A, 2018, BONE, V110, P343, DOI 10.1016/j.bone.2018.02.031
   Moridera K, 2020, J ORTHOP SCI, V25, P331, DOI 10.1016/j.jos.2019.03.023
   Nagalakshmi Ugrappa, 2010, Curr Protoc Mol Biol, VChapter 4, DOI 10.1002/0471142727.mb0411s89
   Neumann D, 2011, HAEMATOL HEMATOL J, V96, DOI 10.3324/haematol.2011.040030
   Ozkan AK, 2015, J BACK MUSCULOSKELET, V28, P197, DOI 10.3233/BMR 140486
   Rajan I, 2011, VET PATHOL, V48, P663, DOI 10.1177/0300985810370164
   Rucci N, 2016, MATRIX BIOL, V52 54, P176, DOI 10.1016/j.matbio.2016.02.009
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Sucur A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1337 6
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Teti A, 2017, BONE, V102, P50, DOI 10.1016/j.bone.2017.02.002
   Villa A, 2009, CALCIFIED TISSUE INT, V84, P1, DOI 10.1007/s00223 008 9196 4
   Waguespack SG, 2002, J CLIN ENDOCR METAB, V87, P2212, DOI 10.1210/jc.87.5.2212
   Waguespack SG, 2007, J CLIN ENDOCR METAB, V92, P771, DOI 10.1210/jc.2006 1986
   Wartosch L, 2009, FASEB J, V23, P4056, DOI 10.1096/fj.09 130880
   Weinert S, 2014, EMBO REP, V15, P784, DOI 10.15252/embr.201438553
   Weinert S, 2010, SCIENCE, V328, P1401, DOI 10.1126/science.1188072
   Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 2 r14
NR 56
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2021
VL 144
AR 115828
DI 10.1016/j.bone.2020.115828
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA QD8FC
UT WOS:000615747100007
PM 33359007
DA 2025 08 17
ER

PT J
AU Zhao, YZ
   Song, T
   Wang, WJ
   Wang, J
   He, JW
   Wu, NN
   Tang, M
   He, BC
   Luo, JY
AF Zhao, Yingze
   Song, Tao
   Wang, Wenjuan
   Wang, Jin
   He, Juanwen
   Wu, Ningning
   Tang, Min
   He, Baicheng
   Luo, Jinyong
TI 被撤回的出版物: P38 and ERK1/2 MAPKs Act in Opposition to Regulate BMP9 Induced
   Osteogenic Differentiation of Mesenchymal Progenitor Cells (Retracted
   Article)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID BONE MORPHOGENETIC PROTEINS; MARROW STROMAL CELLS; STEM CELLS;
   OSTEOBLAST DIFFERENTIATION; GENE THERAPY; BMP 2 GENE; TRANSCRIPTION
   FACTOR; SKELETAL DEVELOPMENT; SIGNALING PATHWAYS; OSTEOCALCIN GENE
AB Although previous studies have demonstrated that BMP9 is highly capable of inducing osteogenic differentiation and bone formation, the precise molecular mechanism involved remains to be fully elucidated. In this current study, we explore the possible involvement and detail effects of p38 and ERK1/2 MAPKs on BMP9 indcued osteogenic differentiation of mesenchymal progenitor cell (MPCs). We find that BMP9 simultaneously stimulates the activation of p38 and ERK1/2 in MPCs. BMP9 induced early osteogenic marker, such as alkaline phosphatase (ALP), and late osteogenic markers, such as matrix mineralization and osteocalcin (OC) are inhibited by p38 inhibitor SB203580, whereas enhanced by ERK1/2 inhibitor PD98059. BMP9 induced activation of Runx2 and Smads signaling are reduced by SB203580, and yet increased by PD98059 in MPCs. The in vitro effects of inhibitors are reproduced with adenoviruses expressing siRNA targeted p38 and ERK1/2, respectively. Using mouse calvarial organ culture and subcutaneous MPCs implantation, we find that inhibition of p38 activity leads to significant decrease in BMP9 induced osteogenic differentiation and bone formation, however, blockage of ERK1/2 results in effective increase in BMP9 indcued osteogenic differentiation in vivo. Together, our results reveal that p38 and ERK1/2 MAPKs are activated in BMP9 induced osteogenic differentiation of MPCs. What is most noteworthy, however, is that p38 and ERK1/2 act in opposition to regulate BMP9 induced osteogenic differentiation of MPCs.
C1 [Zhao, Yingze; Song, Tao; Wang, Wenjuan; Wang, Jin; He, Juanwen; Wu, Ningning; Tang, Min; He, Baicheng; Luo, Jinyong] Chongqing Med Univ, Chinese Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China.
C3 Chongqing Medical University
RP Zhao, YZ (通讯作者)，Chongqing Med Univ, Chinese Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China.
EM luojinyong888@hotmail.com
RI Tang, Min/JPK 7880 2023; Wang, Wenjuan/ABI 4001 2020; Song,
   Tao/HKE 9204 2023
OI Tang, Min/0000 0002 9738 8392; 
FU Natural Science Foundation of China [31071304, 30800658]; Natural
   Science Foundation Project of Chongqing Science and Technology
   Commission [2009BB5060]
FX This work was supported in part by research grants from the Natural
   Science Foundation of China (#31071304 and #30800658 to Dr. Luo), and
   the Natural Science Foundation Project of Chongqing Science and
   Technology Commission (#2009BB5060 to Dr. Luo). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aouadi M, 2006, BIOCHIMIE, V88, P1091, DOI 10.1016/j.biochi.2006.06.003
   Arthur A, 2009, J CELL PHYSIOL, V218, P237, DOI 10.1002/jcp.21592
   Awasthi V, 2000, AM J PHYSIOL LUNG C, V279, pL942, DOI 10.1152/ajplung.2000.279.5.L942
   Bergeron E, 2009, TISSUE ENG PT A, V15, P3341, DOI [10.1089/ten.tea.2009.0189, 10.1089/ten.TEA.2009.0189]
   Boraiah S, 2009, CLIN ORTHOP RELAT R, V467, P3257, DOI 10.1007/s11999 009 1039 8
   Boyle AJ, 2010, METHODS MOL BIOL, V660, P65, DOI 10.1007/978 1 60761 705 1_5
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen C, 2003, NAT BIOTECHNOL, V21, P294, DOI 10.1038/nbt795
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Chen X, 2011, PATHOL ONCOL RES, V17, P257, DOI 10.1007/s12253 010 9307 1
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Cheng SL, 2001, CALCIFIED TISSUE INT, V68, P87, DOI 10.1007/BF02678146
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fan JH, 2009, J CELL PHYSIOL, V220, P72, DOI 10.1002/jcp.21731
   Fan YM, 2007, MOL CELLS, V23, P30
   Frijns E, 2010, J BIOL CHEM, V285, P37650, DOI 10.1074/jbc.M110.138818
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   García Gómez I, 2010, EXPERT OPIN BIOL TH, V10, P1453, DOI 10.1517/14712598.2010.519333
   Garrett IR, 2003, METH MOLEC MED, V80, P183
   Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955 0674(99)80028 3
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gehart H, 2010, EMBO REP, V11, P834, DOI 10.1038/embor.2010.160
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Greenblatt MB, 2010, ANN NY ACAD SCI, V1192, P385, DOI 10.1111/j.1749 6632.2009.05222.x
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Haynes T, 2007, P NATL ACAD SCI USA, V104, P20380, DOI 10.1073/pnas.0708202104
   Heffron DS, 2005, MOL CELL NEUROSCI, V28, P779, DOI 10.1016/j.mcn.2004.12.010
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Huang HY, 2009, P NATL ACAD SCI USA, V106, P12670, DOI 10.1073/pnas.0906266106
   Huang YF, 2012, J BONE MINER RES, V27, P1093, DOI 10.1002/jbmr.1548
   Jensen ED, 2009, J BIOL CHEM, V284, P2225, DOI 10.1074/jbc.M800586200
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Jun JH, 2010, J BIOL CHEM, V285, P36410, DOI 10.1074/jbc.M110.142307
   Kang MH, 2011, EXP CELL RES, V317, P1746, DOI 10.1016/j.yexcr.2011.04.006
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248
   Liu H, 2011, J BONE MINER RES, V26, P1122, DOI 10.1002/jbmr.296
   López Coviella I, 2000, SCIENCE, V289, P313, DOI 10.1126/science.289.5477.313
   Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Myers TJ, 2010, EXPERT OPIN BIOL TH, V10, P1663, DOI 10.1517/14712598.2010.531257
   Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827
   Payne KA, 2010, TISSUE ENG PT A, V16, P3647, DOI [10.1089/ten.tea.2009.0738, 10.1089/ten.TEA.2009.0738]
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ploemacher RE, 1999, LEUKEMIA, V13, P428, DOI 10.1038/sj.leu.2401363
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Qin W, 2012, INT ENDOD J, V45, P224, DOI 10.1111/j.1365 2591.2011.01965.x
   Raida M, 2005, J CANCER RES CLIN, V131, P741, DOI 10.1007/s00432 005 0024 1
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320 344.2004
   Roy Sanjit K, 2010, J Mol Signal, V5, P10, DOI 10.1186/1750 2187 5 10
   Rutherford RB, 2003, DRUG NEWS PERSPECT, V16, P5, DOI 10.1358/dnp.2003.16.1.829301
   Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304 2317.2002
   SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293
   Truksa J, 2006, P NATL ACAD SCI USA, V103, P10289, DOI 10.1073/pnas.0603124103
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Varady P, 2002, ACAD RADIOL, V9, P632, DOI 10.1016/S1076 6332(03)80307 0
   Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919
   Verheyen EM, 2007, DEV CELL, V13, P755, DOI 10.1016/j.devcel.2007.11.006
   Viñals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014 5793(01)03236 7
   Wu NN, 2010, ACTA BIOCH BIOPH SIN, V42, P699, DOI 10.1093/abbs/gmq075
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167
NR 77
TC 53
Z9 66
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 17
PY 2012
VL 7
IS 8
AR e43383
DI 10.1371/journal.pone.0043383
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 996DG
UT WOS:000308063700093
PM 22912865
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Xu, JL
   Lv, Q
   Pan, SM
   Qiu, HH
   Liao, Y
   Zhou, M
   Li, WJ
   Li, CY
   Zhang, P
   Li, YJ
   Xu, GL
   Yu, QF
AF Xu, Jinling
   Lv, Qi
   Pan, Shumin
   Qiu, Huanhuan
   Liao, Yu
   Zhou, Ming
   Li, Weijie
   Li, Caiyan
   Zhang, Pan
   Li, Yujian
   Xu, Guanglin
   Yu, Qingfeng
TI M378 exhibits anti inflammatory activities through NLRP3 signaling
   pathway
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE NSAIDs; NLRP3 inflammasome; Acute liver injury; Acute peritonitis
ID HYDROGEN SULFIDE; INFLAMMASOME; INJURY; LIVER; OSTEOARTHRITIS;
   INTERLEUKIN 8; INHIBITION; EXPRESSION; PROTEIN 1; SECRETION
AB Nonsteroidal anti inflammatory drugs (NSAIDs) are frequently used drugs due to their values in attenuating pain, fever and inflammation. Unfortunately, conspicuous adverse effects, such as gastrointestinal (GI) damage and/or cardiovascular events have impeded their application in clinic. M378 is a novel hydrogen sulfide releasing NSAIDs with uncompromised potency and negligible toxicity compared to the existing NSAIDs. However, its anti inflammatory activity and mechanism are still an enigma. Here we investigated the effect of M378 on the NLRP3 inflammasome signaling pathway and addressed the underlying molecular mechanism. Our data in vitro showed that M378 dose dependently inhibited the cleavage of Caspase 1 and the secretion of active IL 113 and blocked NLRP3 dependent pyroptosis in LPS primed J774A.1 macrophages. Furthermore, M378 remarkably inhibited upstream ASC oligomerization and ROS production regarding the process of NLRP3 inflammasome assembly. Our data in vivo demonstrated that M378 protected mice from acute liver injury, reducing the levels of ALT/AST and IL 113 and improving hepatic pathological damages. Immunoblot analysis revealed that M378 inhibited the expressions of Caspase 1 and IL 113 in liver tissues of ALI mice. We also showed that M378 alleviated IL 113 secretion and peritoneal neutrophils infiltration in MSU elicited acute peritonitis mice.In conclusion, M378 exerted its anti inflammatory effect both in vitro and in vivo and its mechanisms are at least connected to its inhibitory performance on the generation of ASC oligomers and ROS production. These findings give an insight.into the molecular mechanism of hydrogen sulfide releasing NSAIDs and support a potent therapeutic role of M378 in the treatment of NLRP3 driven inflammatory diseases.
C1 [Xu, Jinling; Lv, Qi; Pan, Shumin; Zhou, Ming; Li, Weijie; Li, Caiyan; Zhang, Pan; Li, Yujian; Xu, Guanglin] Nanjing Normal Univ, Coll Life Sci, Nanjing, Peoples R China.
   [Qiu, Huanhuan; Liao, Yu] Nanjing Normal Univ, Sch Food Sci & Pharmaceut Engn, Nanjing, Peoples R China.
   [Yu, Qingfeng] China Pharmaceut Univ, Sch Sci, Nanjing, Peoples R China.
   [Xu, Guanglin] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Peoples R China.
C3 Nanjing Normal University; Nanjing Normal University; China
   Pharmaceutical University; Nanjing Normal University
RP Xu, GL (通讯作者)，Nanjing Normal Univ, Coll Life Sci, Nanjing, Peoples R China.; Yu, QF (通讯作者)，China Pharmaceut Univ, Sch Sci, Nanjing, Peoples R China.
EM xudunlop@126.com; yuqingfeng@cpu.edu.cn
FU National Natural Science Foundation of China [81773948]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD);  [J1103507];  [J1210025]
FX Acknowledgements This work was supported by project 81773948 supported
   by National Natural Science Foundation of China, the Priority Academic
   Program Development of Jiangsu Higher Education Institutions (PAPD) ,
   and NSFC for Talents Training in Basic Science (Grant Nos. J1103507,
   J1210025) .
CR Blackler R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035196
   Blackler RW, 2014, CURR OPIN PHARMACOL, V19, P11, DOI 10.1016/j.coph.2014.05.008
   BROWN Z, 1994, AM J PATHOL, V145, P913
   Camargo CA, 1997, HEPATOLOGY, V26, P1513, DOI 10.1002/hep.510260619
   Dalbeth N, 2016, LANCET, V388, P2039, DOI 10.1016/S0140 6736(16)00346 9
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060
   Giamarellos Bourboulis EJ, 2009, ANN RHEUM DIS, V68, P273, DOI 10.1136/ard.2007.082222
   HACHICHA M, 1995, J EXP MED, V182, P2019, DOI 10.1084/jem.182.6.2019
   Hoque R, 2014, GASTROENTEROLOGY, V146, P1763, DOI 10.1053/j.gastro.2014.03.014
   Hu Q, 2018, BIOFACTORS, V44, P123, DOI 10.1002/biof.1395
   Jiang H, 2017, J EXP MED, V214, P3219, DOI 10.1084/jem.20171419
   Kimura H, 2015, HANDB EXP PHARMACOL, V230, P61, DOI 10.1007/978 3 319 18144 8_3
   Kingsbury SR, 2011, J INFLAMM RES, V4, P39, DOI 10.2147/JIR.S11330
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Shang YL, 2009, HEPATOLOGY, V50, P1204, DOI 10.1002/hep.23121
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Takeuchi K, 2012, CURR MED CHEM, V19, P43, DOI 10.2174/092986712803413962
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462
   Wallace JL, 2020, BRIT J PHARMACOL, V177, P769, DOI 10.1111/bph.14641
   Wallace JL, 2015, NAT REV DRUG DISCOV, V14, P329, DOI 10.1038/nrd4433
   Wallace JL, 2013, DIGEST DIS SCI, V58, P3088, DOI 10.1007/s10620 013 2777 8
   Wallace JL, 2013, WORLD J GASTROENTERO, V19, P1861, DOI 10.3748/wjg.v19.i12.1861
   Wallace JL, 2010, BRIT J PHARMACOL, V159, P1236, DOI 10.1111/j.1476 5381.2009.00611.x
   Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06 6270fje
   Zhang Y., 2013, Patent, Patent No. [CN102579462B, 102579462]
   Zhong ZY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2608
NR 29
TC 1
Z9 1
U1 1
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD OCT 15
PY 2022
VL 933
AR 175261
DI 10.1016/j.ejphar.2022.175261
EA SEP 2022
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 5C9XU
UT WOS:000864606000001
PM 36100126
DA 2025 08 17
ER

PT J
AU Gencheva, M
   Hare, I
   Kurian, S
   Fortney, J
   Piktel, D
   Wysolmerski, R
   Gibson, LF
AF Gencheva, Marieta
   Hare, Ian
   Kurian, Susan
   Fortney, Jim
   Piktel, Debbie
   Wysolmerski, Robert
   Gibson, Laura F.
TI Bone marrow osteoblast vulnerability to chemotherapy
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE bone marrow microenvironment; osteoblast; extracellular matrix;
   hematopoietic stem cell; chemotherapy
ID HEMATOPOIETIC STEM CELLS; EXPRESSION; NICHE; DIFFERENTIATION;
   MECHANISMS; AGENTS; MAINTENANCE; RENEWAL; MICE; P53
AB Osteoblasts are a major component of the bone marrow microenvironment, which provide support for hematopoietic cell development. Functional disruption of any element of the bone marrow niche, including osteoblasts, can potentially impair hematopoiesis. We have studied the effect of two widely used drugs with different mechanisms of action, etoposide (VP16) and melphalan, on murine osteoblasts at distinct stages of maturation. VP16 and melphalan delayed maturation of preosteoblasts and altered CXCL12 protein levels, a key regulator of hematopoietic cell homing to the bone marrow. Sublethal concentrations of VP16 and melphalan also decreased the levels of several transcripts which contribute to the composition of the extracellular matrix (ECM) including osteopontin (OPN), osteocalcin (OCN), and collagen 1A1 (Col1a1). The impact of chemotherapy on message and protein levels for some targets was not always aligned, suggesting differential responses at the transcription and translation or protein stability levels. As one of the main functions of a mature osteoblast is to synthesize ECM of a defined composition, disruption of the ratio of its components may be one mechanism by which chemotherapy affects the ability of osteoblasts to support hematopoietic recovery coincident with altered marrow architecture. Collectively, these observations suggest that the osteoblast compartment of the marrow hematopoietic niche is vulnerable to functional dysregulation by damage imposed by agents frequently used in clinical settings. Understanding the mechanistic underpinning of chemotherapy induced changes on the hematopoietic support capacity of the marrow microenvironment may contribute to improved strategies to optimize patient recovery post transplantation.
C1 [Gencheva, Marieta; Hare, Ian; Fortney, Jim; Piktel, Debbie; Wysolmerski, Robert; Gibson, Laura F.] W Virginia Univ, Sch Med, Alexander B Osborn Hematopoiet Malignancy & Trans, Mary Babb Randolph Canc Ctr,Robert C Byrd Hlth Sc, Morgantown, WV 26506 USA.
   [Hare, Ian; Gibson, Laura F.] W Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.
   [Kurian, Susan] W Virginia Univ, Sch Med, MBRCC Summer Fellowship Program, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.
   [Wysolmerski, Robert] W Virginia Univ, Sch Med, Dept Neurobiol & Anat, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA.
C3 West Virginia University; West Virginia University; West Virginia
   University; West Virginia University
RP Gibson, LF (通讯作者)，W Virginia Univ, Sch Med, Alexander B Osborn Hematopoiet Malignancy & Trans, Mary Babb Randolph Canc Ctr, POB 9300, Morgantown, WV 26506 USA.
EM lgibson@hsc.wvu.edu
OI Gibson, Laura/0000 0002 7291 9046; Piktel, Debra/0000 0001 6706 5923
FU National Institutes of Health (NIH) [R01 HL056888]; NIH [P20 RR016440];
   National Cancer Institute (NCI) [RO1 CA134573]; Alexander B. Osborn
   Hematopoietic Malignancy and Transplantation Program; WV Research Trust
   Fund; Kathy Brundage of the Flow Cytometer Facility at WVU [P30GM103488,
   P30RR032138, P30GM 103488, RR020866, RC P1101809]
FX This work was supported by National Institutes of Health (NIH) R01
   HL056888 (LFG), NIH P20 RR016440 (LFG), National Cancer Institute (NCI)
   RO1 CA134573 (LFG), the Alexander B. Osborn Hematopoietic Malignancy and
   Transplantation Program and the WV Research Trust Fund. We are grateful
   for the support of Kathy Brundage of the Flow Cytometer Facility at WVU
   supported by P30GM103488 and P30RR032138 (FACS Calibur) and P30GM
   103488, P30RR032138, RR020866, and RC P1101809 (FACS Aria). SEM was
   performed at the WVU Shared Research Facilities.
CR Bredemeyer AL, 2008, NATURE, V456, P819, DOI 10.1038/nature07392
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Corazza F, 2004, PEDIATR RES, V55, P152, DOI 10.1203/01.PDR.0000099773.71438.91
   Davies JH, 2003, J CLIN ENDOCR METAB, V88, P6088, DOI 10.1210/jc.2003 030712
   Davies JH, 2002, CALCIFIED TISSUE INT, V70, P408, DOI 10.1007/s002230020039
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Guest I, 2000, IMMUNOPHARMACOLOGY, V46, P103, DOI 10.1016/S0162 3109(99)00168 X
   HALL AG, 1992, BLOOD REV, V6, P163, DOI 10.1016/0268 960X(92)90028 O
   Inomata K, 2009, CELL, V137, P1088, DOI 10.1016/j.cell.2009.03.037
   Kalajzic I, 2005, J BIOL CHEM, V280, P24618, DOI 10.1074/jbc.M413834200
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mercier FE, 2012, NAT REV IMMUNOL, V12, P49, DOI 10.1038/nri3132
   Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038
   Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008 5472.CAN 06 2323
   Nagasawa T, 2011, TRENDS IMMUNOL, V32, P315, DOI 10.1016/j.it.2011.03.009
   Nakamura Y, 2010, BLOOD, V116, P1422, DOI 10.1182/blood 2009 08 239194
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood 2004 11 4422
   Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017
   Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012
   Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Reichert JC., 2008, Protoc Exch
   Rellick SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030758
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   SPANGRUDE GJ, 1993, BLOOD, V82, P3327
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Tauchmanovà L, 2002, J CLIN ENDOCR METAB, V87, P5058, DOI 10.1210/jc.2002 020800
   Thompson DL, 1998, J BONE MINER RES, V13, P195, DOI 10.1359/jbmr.1998.13.2.195
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 37
TC 13
Z9 17
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0902 4441
EI 1600 0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD JUN
PY 2013
VL 90
IS 6
BP 469
EP 478
DI 10.1111/ejh.12109
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 147CN
UT WOS:000319143100002
PM 23551534
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kong, XY
   Li, XM
   Zhang, C
   Zhu, LL
   Liu, CF
   Qin, QX
   Liu, CL
   Wang, QQ
   Zhu, J
   Wu, X
   Wan, HY
   Chen, WH
   Lin, N
AF Kong, Xiangying
   Li, Xiaomin
   Zhang, Cun
   Zhu, Liuluan
   Liu, Chunfang
   Qin, Qingxia
   Liu, Cuiling
   Wang, Qianqian
   Zhu, Jia
   Wu, Xuan
   Wan, Hongye
   Chen, Weiheng
   Lin, Na
TI Ethyl acetate fraction of Huogu formula inhibits adipogenic
   differentiation of bone marrow stromal cells via the BMP and Wnt
   signaling pathways
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Adipogenic differentiation; Osteonecrosis; Bone marrow stromal cells;
   Huogu Formula; Chinese medicine
ID STEROID INDUCED OSTEONECROSIS; GAMMA LIGAND; OSTEOGENESIS; ADIPOCYTES;
   BALANCE
AB Elevated adipogenesis of bone marrow stromal cells (BMSCs) is closely associated with non traumatic osteonecrosis of femoral head (ONFH). Our previous studies have shown that Huogu (HG) formula was effective both in clinic experience and experimental ONFH. How HG impacts the differentiation of BMSCs and what is the underlying molecular mechanism remain largely unknown. Our results showed that ethyl acetate extract of HG (HGE) significantly decreased the adipocyte differentiation as determined by oil red staining, while slightly increased the ALP activity. Investigation of the molecular mechanism revealed that HGE could inhibit the mRNA and protein expression of peroxisome proliferators activated receptor (PPAR)., lipoprotein lipase (LPL) and adipocyteprotein2 (AP2). Interestingly, the inhibition of adipogenic differentiation in BMSCs by HGE could be restored by DKK 1, an inhibitor of Wnts. However, Noggin (an inhibitor of BMPs) displayed an additive role with HGE in suppressing the expression of PPAR., LPL, and AP2. Furthermore, the bone marrow fat formation, as well as the expression of Wnt3a and PPAR., was effectively regulated by HGE in the steroid induced ONFH rats. Our results demonstrated that HGE treatment significantly inhibited adipogenesis and slightly promoted osteogenesis of BMSCs through regulating the BMP and Wnt pathways. The findings shed lights on the molecular mechanism of HGE in the inhibition of adipogenesis and provide scientific rationale for its clinical application of HGE in the treatment of ONFH.
C1 [Kong, Xiangying; Li, Xiaomin; Zhang, Cun; Liu, Chunfang; Qin, Qingxia; Liu, Cuiling; Wang, Qianqian; Wu, Xuan; Wan, Hongye; Lin, Na] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
   [Zhu, Liuluan] Capital Med Univ, Beijing Ditan Hosp, Inst Infect Dis, Beijing, Peoples R China.
   [Zhu, Liuluan] Beijing Key Lab Emerging Infect Dis, Beijing 100015, Peoples R China.
   [Zhu, Jia; Chen, Weiheng] China Acad Chinese Med Sci, Wangjing Hosp, Beijing 100102, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia
   Medica, CACMS; Capital Medical University; Wang Jing Hospital, CACMS;
   China Academy of Chinese Medical Sciences
RP Lin, N (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.; Chen, WH (通讯作者)，China Acad Chinese Med Sci, Wangjing Hosp, Beijing 100102, Peoples R China.
EM drchenweiheng@163.com; nlin@icmm.ac.cn
RI ; wan, ye/AAP 9997 2021; Wang, Qianqian/AHC 6753 2022
OI Wan, Ye/0000 0002 3909 0985; 
FU Beijing Municipal Science and Technology Commission [Z151100003815028];
   National Natural Science Foundation of China [81173417]
FX This study was supported by grants from Beijing Municipal Science and
   Technology Commission (No.Z151100003815028) and National Natural Science
   Foundation of China (No.81173417).
CR [Anonymous], 2015, PHARMACOPOEIA PEOPLE
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bethel M, 2013, CURR OSTEOPOROS REP, V11, P99, DOI 10.1007/s11914 013 0135 6
   Chen Wei heng, 2013, Zhongguo Zhong Xi Yi Jie He Za Zhi, V33, P1054
   Chen WH, 2012, CHIN J INTEGR MED, V18, P378, DOI 10.1007/s11655 012 1086 y
   Dilisio MF, 2014, ORTHOPEDICS, V37, pE631, DOI 10.3928/01477447 20140626 54
   Ge C, 2015, J CELLULAR PHYSL
   Gebhard K L, 2001, Am J Clin Dermatol, V2, P377, DOI 10.2165/00128071 200102060 00004
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jiang YN, 2014, J TRADIT CHIN MED, V34, P342, DOI 10.1016/S0254 6272(14)60100 X
   Kang PD, 2010, INT J EXP PATHOL, V91, P235, DOI 10.1111/j.1365 2613.2010.00705.x
   Kang PD, 2008, JOINT BONE SPINE, V75, P696, DOI 10.1016/j.jbspin.2007.12.008
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Lazarenko OP, 2006, BONE, V38, P74, DOI 10.1016/j.bone.2005.07.008
   Lee SY, 2014, CELL PHYSIOL BIOCHEM, V34, P1339, DOI 10.1159/000366341
   Li JP, 2014, BIOELECTROMAGNETICS, V35, P170, DOI 10.1002/bem.21833
   Li XD, 2005, OSTEOPOROSIS INT, V16, P101, DOI 10.1007/s00198 004 1649 7
   Liu CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151433
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Miyanishi K, 2002, BONE, V30, P185, DOI 10.1016/S8756 3282(01)00663 9
   Muruganandan S., 2014, IUBMB LIFE
   Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099
   Saintier D, 2006, J STEROID BIOCHEM, V99, P165, DOI 10.1016/j.jsbmb.2006.01.009
   Sheng H, 2013, INT J CLIN EXP PATHO, V6, P1046
   Sheng Hui H, 2007, J Orthop Surg Res, V2, P15, DOI 10.1186/1749 799X 2 15
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Sugimura R, 2010, J MOL CELL BIOL, V2, P61, DOI 10.1093/jmcb/mjp030
   Taipaleenmäki H, 2011, EXP CELL RES, V317, P745, DOI 10.1016/j.yexcr.2010.12.015
   Tzameli I, 2004, J BIOL CHEM, V279, P36093, DOI 10.1074/jbc.M405346200
   Wan Rong, 2010, Zhongguo Gu Shang, V23, P915
   Wang GJ, 2000, CLIN ORTHOP RELAT R, P295, DOI 10.1097/00003086 200001000 00030
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Yuan Z, 2015, CURRENT STEM CELL RE
   Zhang X, 2014, TISSUE ENG PART B RE, V20, P84, DOI 10.1089/ten.TEB.2013.0204
NR 35
TC 14
Z9 21
U1 2
U2 14
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2017
VL 13
IS 4
BP 480
EP 491
DI 10.7150/ijbs.18430
PG 12
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA FL7QG
UT WOS:000414442700001
PM 28529456
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Li, CX
   Lin, XQ
   Lin, Q
   Lin, YP
   Lin, HM
AF Li, Chaoxiong
   Lin, Xiangquan
   Lin, Qin
   Lin, Yanping
   Lin, Haiming
TI Jiangu granules ameliorate postmenopausal osteoporosis via rectifying
   bone homeostasis imbalance: A network pharmacology analysis based on
   multi omics validation
SO PHYTOMEDICINE
LA English
DT Article
DE Postmenopausal osteoporotic; Jiangu granules; Monocyte; Notch; Steroid
ID OSTEOCLAST DIFFERENTIATION; BREAST CANCER; MECHANISMS; EPIMEDIUM;
   MIGRATION; MEDICINE; ESTROGEN; WOMEN
AB Background: Postmenopausal osteoporosis (PMOP) is a series of reactions to bone homeostasis dysregulation mediated by estrogen deficiency in elderly women. Jiangu granules, a traditional Chinese medicine formula, has been proven as an effective treatment approach for PMOP, which still needs more research iin its complex regulatory mechanisms. Purpose: Our study aimed to identify the putative targets and regulatory mechanisms of Jiangu granules in PMOP treating. Methods: We utilized the NHANES database to compare the clinical information of normal population and PMOP patients. Associated with transcriptomics and proteomic data, we identified the PMOP related genes, and further studied them with bioinformatic methods including and prognosis model. Network pharmacology was applied for confirming the action targets of Jiangu granules in PMOP. We verified the safety and effectiveness in PMOP treatments of Jiangu granules, and also demonstrated our hypothesis in rats. Results: We discovered that the PMOP patients had higher monocytes than the normal women. Moreover, the transcriptomics and proteomic analysis suggested that the dysregulation of PMOP related genes expression was associated with monocytes, and the Notch pathway were the critical targets representing bone homeostasis imbalance highly involved in the occurrence of PMOP. We also ascertained network pharmacology results further revealing that Jiangu granules might treat PMOP via recovering the bone homeostasis imbalance identified above. In vivo experiments, we confirmed the high efficacy which mainly resulted from function in mitigating the imbalance in bone homeostasis by recovering the normal expression of PMOP related genes associated with monocytes, Notch, and steroid pathway in the rat models. Conclusion: Our finding underscored the clinical potential of Jiangu granules in treating PMOP, and enriched the comprehension of the related pathogenic and therapeutic mechanisms.
C1 [Li, Chaoxiong; Lin, Xiangquan; Lin, Qin] Fuzhou Second Hosp, Dept Orthoped, Fuzhou, Peoples R China.
   [Li, Chaoxiong; Lin, Xiangquan; Lin, Qin] Fujian Prov Clin Med Res Ctr First Aid & Rehabil O, Fuzhou, Peoples R China.
   [Li, Chaoxiong; Lin, Xiangquan; Lin, Qin] Fujian Med Univ, Clin Med Coll 3, Fuzhou, Peoples R China.
   [Lin, Yanping] Fujian Univ Tradit Chinese Med, Coll Acupuncture & Moxibust, Fuzhou, Peoples R China.
   [Lin, Haiming] Fujian Univ Tradit Chinese Med, Coll Integrated Chinese & Western Med, 1st Qiuyang Rd, Fuzhou, Fujian, Peoples R China.
C3 Fujian Medical University; Fujian University of Traditional Chinese
   Medicine; Fujian University of Traditional Chinese Medicine
RP Lin, HM (通讯作者)，Fujian Univ Tradit Chinese Med, Coll Integrated Chinese & Western Med, 1st Qiuyang Rd, Fuzhou, Fujian, Peoples R China.
EM 1998012@fjtcm.edu.cn
CR Al Anazi Abdullah Foraih, 2011, J Nat Sci Biol Med, V2, P154, DOI 10.4103/0976 9668.92322
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Anastasilakis AD, 2020, EXPERT OPIN PHARMACO, V21, P477, DOI 10.1080/14656566.2020.1717468
   Anupama DS, 2020, INT J ORTHOP TRAUMA, V39, DOI 10.1016/j.ijotn.2020.100796
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao RR, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.959417
   D'Amelio P, 2013, IMMUNOL INVEST, V42, P544, DOI 10.3109/08820139.2013.822764
   Deng YR, 2022, ACS NANO, V16, P1051, DOI 10.1021/acsnano.1c08728
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Fagone P, 2012, INFLAMM RES, V61, P1131, DOI 10.1007/s00011 012 0506 y
   Fang YP, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/9661200
   Filipovic M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.902947
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Fu YL, 2023, FRONT PUBLIC HEALTH, V11, DOI 10.3389/fpubh.2023.1204497
   Gamrekelashvili J, 2020, ELIFE, V9, DOI 10.7554/eLife.57007
   Gimble JM, 2012, CLIN BIOCHEM, V45, P874, DOI 10.1016/j.clinbiochem.2012.03.006
   Giordani C., 2023, Int. J. Mol. Sci, P24
   He YF, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04161 1
   Hodis HN, 2016, NEW ENGL J MED, V374, P1221, DOI 10.1056/NEJMoa1505241
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Huang YM, 2017, MOL MED REP, V16, P8420, DOI 10.3892/mmr.2017.7645
   Jarrell JT, 2018, MOLECULES, V23, DOI 10.3390/molecules23051143
   Jiang NN, 2023, BIOMED PHARMACOTHER, V165, DOI 10.1016/j.biopha.2023.115181
   Jiang PL, 2019, THERANOSTICS, V9, P2950, DOI 10.7150/thno.29617
   Ju DH, 2014, FRONT MED PRC, V8, P389, DOI 10.1007/s11684 014 0362 y
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Khandelwal S, 2023, ENDOCRIN METAB CLIN, V52, P259, DOI 10.1016/j.ecl.2022.10.009
   Larabee JL, 2013, J BIOL CHEM, V288, P21526, DOI 10.1074/jbc.M113.465120
   Lee CY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157946
   Li YC, 2015, EXP THER MED, V10, P1089, DOI 10.3892/etm.2015.2616
   Lin HM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1052922
   Lin Yan ping, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P431
   Liu HD, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adg0731
   Liu MJ, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 67
   Luo ZL, 2019, AM J PATHOL, V189, P1495, DOI 10.1016/j.ajpath.2019.05.005
   Ma YS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01316
   Michael H, 2005, J BONE MINER RES, V20, P2224, DOI 10.1359/JBMR.050803
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Mukwaya E, 2014, PHARM BIOL, V52, P1223, DOI 10.3109/13880209.2014.884606
   Nanke Y, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4874195
   Park E, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/4122253
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Richardson DD, 2015, J CELL SCI, V128, P3018, DOI 10.1242/jcs.165365
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Sheng SR, 2023, PHYTOMEDICINE, V114, DOI 10.1016/j.phymed.2023.154739
   Spivakovsky Silvia, 2017, Evid Based Dent, V18, P56, DOI 10.1038/sj.ebd.6401243
   Sun P, 2022, BIOMED PHARMACOTHER, V150, DOI 10.1016/j.biopha.2022.112975
   Tong X, 2023, CHIN MED UK, V18, DOI 10.1186/s13020 023 00788 8
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Wang CC, 2016, J CLIN INVEST, V126, P1471, DOI 10.1172/JCI80672
   Wang W, 2022, CLIN EXP PHARMACOL P, V49, P113, DOI 10.1111/1440 1681.13591
   Wang ZQ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/356260
   Wu AM, 2021, LANCET HEALTH LONGEV, V2, pE580, DOI 10.1016/S2666 7568(21)00172 0
   Xie YM, 2011, CHIN J INTEGR MED, V17, P52, DOI 10.1007/s11655 011 0613 6
   Xu C., 2022, eLife, P11
   Xu Q, 2022, J DRUG TARGET, V30, P394, DOI 10.1080/1061186X.2021.2013488
   Xu YX, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172794
   Xu YT, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.876269
   Yang XW, 2016, CLIN LAB, V62, P2173, DOI 10.7754/Clin.Lab.2016.160408
   Zhang G, 2007, J BONE MINER RES, V22, P1072, DOI 10.1359/JBMR.070405
   Zhao RQ, 2012, INT J MED SCI, V9, P825, DOI 10.7150/ijms.5180
   Zhu HM, 2012, OSTEOPOROSIS INT, V23, P1317, DOI 10.1007/s00198 011 1577 2
NR 66
TC 20
Z9 20
U1 12
U2 95
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JAN
PY 2024
VL 122
AR 155137
DI 10.1016/j.phymed.2023.155137
EA OCT 2023
PG 18
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA HL3Q6
UT WOS:001159625200001
PM 37856991
DA 2025 08 17
ER

PT J
AU Lin, CH
   Jiang, HY
   Lou, C
   Wang, WD
   Cai, TW
   Lin, ZN
   Jiang, LT
   Lin, SD
   Xue, XH
   Pan, XY
AF Lin, Chihao
   Jiang, Hongyi
   Lou, Chao
   Wang, Weidan
   Cai, Tingwen
   Lin, Zhongnan
   Jiang, Liting
   Lin, Shida
   Xue, Xinghe
   Pan, Xiaoyun
TI Asiatic acid prevents glucocorticoid induced femoral head osteonecrosis
   via PI3K/AKT pathway
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
ID CCL4 INDUCED LIVER FIBROSIS; MESENCHYMAL STEM CELLS; CENTELLA ASIATICA;
   INDUCED OSTEOPOROSIS; APOPTOSIS; STRESS; RATS; GENE
AB Glucocorticoid induced osteonecrosis of the femoral head (GIONFH) represents a predominant etiology of non  traumatic osteonecrosis, imposing substantial pain, restricting hip mobility, and diminishing overall quality of life for affected individuals. Centella asiatica (L.) Urb. (CA), an herbal remedy deeply rooted in traditional oriental medicine, has exhibited noteworthy therapeutic efficacy in addressing inflammation and facilitating wound healing. Drawing from CA 's historical applications, its anti inflammatory, anti apoptotic, and antioxidant attributes may hold promise for managing GIONFH. Asiatic acid (AA), a primary constituent of CA, has been substantiated as a key contributor to its anti apoptotic, antioxidant, and anti inflammatory capabilities, showcasing a close association with orthopedic conditions. For the investigation of whether AA could alleviate GIONFH through suppressing oxidative stress, apoptosis, and to delve into its potential cellular and molecular mechanisms, the connection between AA and disease was analyzed through network pharmacology. DEX induced apoptosis in rat osteoblasts and GIONFH in rat models, got utilized for the verification in vitro/vivo, on underlying mechanism of AA in GIONFH. Network pharmacology analysis reveals a robust correlation between AA and GIONFH in multiple target genes. AA has demonstrated the inhibition of DEX induced osteoblast apoptosis by modulating apoptotic factors like BAX, BCL 2, Cleaved caspase3, and cleaved caspase9. Furthermore, it effectively diminishes the ROS overexpression and regulates oxidative stress through mitochondrial pathway. Mechanistic insights suggest that AA 's therapeutic effects involve phosphatidylinositol 3 kinase/Protein kinase B (PI3K/AKT) pathway activation. Additionally, AA has exhibited its potential to ameliorate GIONFH progression in rat models. Our findings revealed that AA mitigated DEX induced osteoblast apoptosis and oxidative stress through triggering PI3K/AKT pathway. Also, AA can effectively thwart GIONFH occurrence and development in rats.
C1 [Lin, Chihao; Jiang, Hongyi; Lou, Chao; Wang, Weidan; Cai, Tingwen; Lin, Zhongnan; Jiang, Liting; Lin, Shida; Xue, Xinghe; Pan, Xiaoyun] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou, Zhejiang Provin, Peoples R China.
   [Lin, Chihao; Jiang, Hongyi; Lou, Chao; Wang, Weidan; Cai, Tingwen; Lin, Zhongnan; Jiang, Liting; Lin, Shida; Xue, Xinghe; Pan, Xiaoyun] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang Provin, Peoples R China.
   [Lin, Chihao; Jiang, Hongyi; Lou, Chao; Wang, Weidan; Cai, Tingwen; Lin, Zhongnan; Jiang, Liting; Lin, Shida; Xue, Xinghe; Pan, Xiaoyun] Key Lab Orthoped Zhejiang Prov, Wenzhou, Zhejiang Provin, Peoples R China.
   [Lin, Chihao; Jiang, Hongyi; Lou, Chao; Wang, Weidan; Cai, Tingwen; Lin, Zhongnan; Jiang, Liting; Lin, Shida; Xue, Xinghe; Pan, Xiaoyun] Wenzhou Med Univ, Clin Sch Med 2, Wenzhou, Zhejiang Provin, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University
RP Xue, XH; Pan, XY (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou, Zhejiang Provin, Peoples R China.; Xue, XH; Pan, XY (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang Provin, Peoples R China.; Xue, XH; Pan, XY (通讯作者)，Key Lab Orthoped Zhejiang Prov, Wenzhou, Zhejiang Provin, Peoples R China.; Xue, XH; Pan, XY (通讯作者)，Wenzhou Med Univ, Clin Sch Med 2, Wenzhou, Zhejiang Provin, Peoples R China.
EM 213205@wzhealth.com; xiaoyunpan@126.com
RI Lin, ChiHao/HZK 8189 2023; Jiang, Liting/MBI 1801 2025; Lou,
   Chao/JPL 0980 2023; Jiang, Hongyi/GLR 0971 2022
FU Wenzhou Municipal Science and Technology Bureau [Y20210400]; Zhejiang
   Province Medical and Health Technology Program [2020KY187]; Wenzhou
   Medical University Second Affiliated Hospital Yuying Program [813386]
FX The research received support from Wenzhou Municipal Science and
   Technology Bureau (Y20210400) , Zhejiang Province Medical and Health
   Technology Program (No. 2020KY187) , Wenzhou Medical University Second
   Affiliated Hospital Yuying Program (No. 813386) .
CR Bai X, 2018, BIOACT MATER, V3, P401, DOI 10.1016/j.bioactmat.2018.05.006
   Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012
   Brinkhaus B, 2000, PHYTOMEDICINE, V7, P427, DOI 10.1016/S0944 7113(00)80065 3
   Bylka W, 2014, PHYTOTHER RES, V28, P1117, DOI 10.1002/ptr.5110
   Chen DJ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12540
   Chen ZG, 2016, INT J MOL MED, V37, P329, DOI 10.3892/ijmm.2015.2432
   Chughtai M, 2017, BONE JOINT J, V99B, P1267, DOI 10.1302/0301 620X.99B10.BJJ 2017 0233.R2
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Dianat M, 2018, RESP RES, V19, DOI 10.1186/s12931 018 0766 3
   Dong L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2599 5
   Dong MM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829741
   Fan J, 2018, DRUG DES DEV THER, V12, P3595, DOI 10.2147/DDDT.S179876
   Han DC, 2019, SAUDI J BIOL SCI, V26, P1027, DOI 10.1016/j.sjbs.2019.04.010
   He LL, 2019, J CELL PHYSIOL, V234, P4267, DOI 10.1002/jcp.27195
   Hong GJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00331
   Idrus RBH, 2012, J ETHNOPHARMACOL, V140, P333, DOI 10.1016/j.jep.2012.01.023
   Jiang HY, 2024, PHYTOTHER RES, V38, P156, DOI 10.1002/ptr.8031
   Jiang HY, 2023, CHEM ENG J, V472, DOI 10.1016/j.cej.2023.144729
   Kawedia JD, 2011, BLOOD, V117, P2340, DOI 10.1182/blood 2010 10 311969
   Ke K, 2014, AM J PHYSIOL ENDOC M, V307, pE61, DOI 10.1152/ajpendo.00044.2014
   Kuang MJ, 2019, INT J BIOL SCI, V15, P1861, DOI 10.7150/ijbs.32262
   Lim JA, 2009, BMB REP, V42, P421, DOI 10.5483/BMBRep.2009.42.7.421
   Lin P, 2023, J ETHNOPHARMACOL, V317, DOI 10.1016/j.jep.2023.116746
   Liu N, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02193 0
   Masola B, 2018, BIOMED PHARMACOTHER, V101, P447, DOI 10.1016/j.biopha.2018.02.115
   Okkay IF, 2022, ENVIRON SCI POLLUT R, V29, P33774, DOI 10.1007/s11356 022 18626 z
   Parajuli A, 2015, BONE, V81, P152, DOI 10.1016/j.bone.2015.07.012
   Park JH, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974 017 1009 0
   Qiu F, 2022, ACTA PHARMACOL SIN, V43, P1395, DOI 10.1038/s41401 021 00763 9
   Qiu WY, 2022, FOOD CHEM TOXICOL, V170, DOI 10.1016/j.fct.2022.113468
   Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400
   Sun BJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.568032
   Sun HY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04313 3
   Tao SC, 2017, THERANOSTICS, V7, P733, DOI 10.7150/thno.17450
   Tian MM, 2021, PHYTOTHER RES, V35, P6389, DOI 10.1002/ptr.7292
   Wang A, 2018, MED SCI MONITOR, V24, P1813, DOI 10.12659/MSM.909655
   Wang XY, 2020, EUR J PHARMACOL, V880, DOI 10.1016/j.ejphar.2020.173212
   Wang Z, 2019, INT J SURG, V69, P23, DOI 10.1016/j.ijsu.2019.06.016
   Wei LW, 2018, INT IMMUNOPHARMACOL, V60, P1, DOI 10.1016/j.intimp.2018.04.016
   Yang N, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.447
   Yuan HF, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/165679
   Zhan JD, 2020, FOOD FUNCT, V11, P7830, DOI [10.1039/d0fo00837k, 10.1039/D0FO00837K]
   Zhan XQ, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755 8794 3 13
   Zhang GH, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431x20187579, 10.1590/1414 431X20187579]
   Zhao MQ, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01448
   Zhao R, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118044
   Zhu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092125
NR 47
TC 4
Z9 5
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAR 30
PY 2024
VL 130
AR 111758
DI 10.1016/j.intimp.2024.111758
EA FEB 2024
PG 12
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA QK1Z6
UT WOS:001220689700001
PM 38422771
DA 2025 08 17
ER

PT J
AU Hart, DA
AF Hart, David A.
TI Towards understanding how bisphosphonate dependent alterations to
   nutrient canal integrity can contribute to risk for atypical femoral
   fractures: Biomechanical considerations and potential relationship to a
   real world analogy
SO BIOESSAYS
LA English
DT Article
DE altered bone matrix; atypical femoral fractures; bisphosphonates;
   mechanistic analogy; nutrient canals; vascular alterations
ID FEMUR; OSTEOPOROSIS; THERAPY
AB Bisphosphonates are a class of drugs which have shown good efficacy in the treatment of post menopausal osteoporosis, as well as a good safety profile. However, side effects such as risk for atypical femoral fractures (AFF) have appeared, leading to a decline in use of the drugs by many patients who would benefit from the treatment. While patient characteristics have contributed to improved understanding of risk factors, the mechanisms involved that explain AFF risk have not appeared. Recently, the possibility that the mechanism(s) involved drug induced modification of cells of the nutrient canals of the femur and subsequent compromise in the bone matrix has been published. The present Hypothesis article builds on the concept presented earlier and expands into biomechanical considerations. An analogy of the mechanisms involved to a real life scenario is also presented. While this analogy has limitations, consideration of the biomechanical implications of progressive alterations to defects presented by compromised nutrient canal bone matrix also presents potential relationships with AFF risk.
   The hypothesis raised is that prolonged use of bisphosphonates (BP) in a rare subset of osteoporosis patients leads to disruption of paracrine regulation in nutrient canal cells leading to mechanically compromised bone matrix and increased risk for an atypical femoral fracture (AFF). This model accounts for many characteristics of such patients.image
C1 [Hart, David A.] Univ Calgary, Fac Kinesiol, McCaig Inst Bone & Joint Hlth, Dept Surg, Calgary, AB, Canada.
C3 University of Calgary
RP Hart, DA (通讯作者)，Univ Calgary, Fac Kinesiol, McCaig Inst Bone & Joint Hlth, Dept Surg, Calgary, AB, Canada.
EM hartd@ucalgary.ca
CR Adler RA, 2021, ENDOCRIN METAB CLIN, V50, P193, DOI 10.1016/j.ecl.2021.03.003
   Akid I, 2021, CLIN GERIATR MED, V37, P683, DOI 10.1016/j.cger.2021.05.012
   Andreasen CM, 2023, BONE, V173, DOI 10.1016/j.bone.2023.116787
   Asghar A, 2020, ANAT REC, V303, P2774, DOI 10.1002/ar.24461
   Black DM, 2022, BONE, V156, DOI 10.1016/j.bone.2021.116297
   Carey John J, 2018, Clin Exp Rheumatol, V36 Suppl 114, P115
   Chang B, 2022, TISSUE ENG PART B RE, V28, P261, DOI [10.1089/ten.teb.2020.0322, 10.1089/ten.TEB.2020.0322]
   Chesnut CH, 2012, CURR OSTEOPOROS REP, V10, P42, DOI 10.1007/s11914 011 0088 6
   Dandinoglu T, 2014, OSTEOPOROSIS INT, V25, P773, DOI 10.1007/s00198 013 2428 0
   Divan V, 2019, CURR OPIN ENDOCRINOL, V26, P283, DOI 10.1097/MED.0000000000000505
   Donnelly E, 2012, CURR OPIN SUPPORT PA, V6, P348, DOI 10.1097/SPC.0b013e3283552d7d
   Ebrahimpour A, 2021, ARCH BONE JT SURG AB, V9, P283, DOI 10.22038/abjs.2020.52698.2608
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   Furukawa H, 2022, J CLIN ENDOCR METAB, V107, pE1890, DOI 10.1210/clinem/dgac022
   Gopinath V, 2023, MED CLIN N AM, V107, P213, DOI 10.1016/j.mcna.2022.10.013
   Götzen N, 2003, J BIOMECH, V36, P1511, DOI 10.1016/S0021 9290(03)00130 1
   Goulet GC, 2008, J BIOMECH, V41, P2169, DOI 10.1016/j.jbiomech.2008.04.022
   Hart DA, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13071136
   Hart DA, 2023, BIOESSAYS, V45, DOI 10.1002/bies.202200206
   Hart DA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23084119
   Hart DA, 2023, FRONT PHYSIOL, V14, DOI 10.3389/fphys.2023.1127689
   Hayes KN, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051140
   Houssaye A, 2020, J ANAT, V236, P510, DOI 10.1111/joa.13121
   Hwang D, 2022, OSTEOPOROSIS INT, V33, P1285, DOI 10.1007/s00198 021 06173 1
   Imre N, 2012, SURG RADIOL ANAT, V34, P427, DOI 10.1007/s00276 011 0930 7
   Iwata K, 2019, J BONE MINER METAB, V37, P206, DOI 10.1007/s00774 018 0940 1
   Joo YB, 2023, MEDICINA LITHUANIA, V59, DOI 10.3390/medicina59040735
   Jung IJ, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 03603 2
   Keen CE, 2021, J CLIN DENSITOM, V24, P651, DOI 10.1016/j.jocd.2021.01.004
   Kizilkanat E, 2007, ANN ANAT, V189, P87, DOI 10.1016/j.aanat.2006.07.004
   Li SS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.717065
   Lim Eic Ju, 2019, Hip Pelvis, V31, P75
   Loundagin LL, 2020, J MECH BEHAV BIOMED, V111, DOI 10.1016/j.jmbbm.2020.104002
   Lu LQ, 2020, J CLIN PHARM THER, V45, P45, DOI 10.1111/jcpt.13056
   Marini F, 2023, EUR J ENDOCRINOL, V188, DOI 10.1093/ejendo/lvad001
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02678 x
   Mitchell A, 2019, BMC VET RES, V15, DOI 10.1186/s12917 019 1966 x
   Nguyen HH, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115319
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Park JH, 2016, INJURY, V47, P1318, DOI 10.1016/j.injury.2016.02.026
   Probyn L, 2015, SKELETAL RADIOL, V44, P1579, DOI 10.1007/s00256 015 2212 7
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Severyns M, 2022, J ORTHOP SURG RES, V17, DOI 10.1186/s13018 022 03060 1
   Tang TT, 2015, BONE, V71, P25, DOI 10.1016/j.bone.2014.10.001
   Tano A, 2019, INJURY, V50, P1876, DOI 10.1016/j.injury.2019.09.004
   Tsuchie H, 2021, MED PRIN PRACT, V30, P430, DOI 10.1159/000517484
   Tyler W, 2014, CLIN GERIATR MED, V30, P349, DOI 10.1016/j.cger.2014.01.010
   Ugartondo N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147395
   Walker LE, 2021, BRIT J CLIN PHARMACO, V87, P4877, DOI 10.1111/bcp.15110
   Wang M, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10629
   Xiong Z, 2023, MATERIALS, V16, DOI 10.3390/ma16093349
   Zebaze R, 2023, JBMR PLUS, V7, DOI 10.1002/jbm4.10713
   Zhou W, 2023, J BONE MINER RES, V38, P896, DOI 10.1002/jbmr.4801
   Zhou W, 2021, CURR OSTEOPOROS REP, V19, P123, DOI 10.1007/s11914 021 00658 y
NR 54
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0265 9247
EI 1521 1878
J9 BIOESSAYS
JI Bioessays
PD FEB
PY 2024
VL 46
IS 2
DI 10.1002/bies.202300117
EA DEC 2023
PG 10
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA FP6P9
UT WOS:001114980300001
PM 38059881
OA hybrid
DA 2025 08 17
ER

PT J
AU Xiang, W
   Jiang, T
   Guo, FJ
   Gong, C
   Yang, KX
   Wu, YX
   Huang, X
   Cheng, WT
   Xu, K
AF Xiang, Wei
   Jiang, Ting
   Guo, Fengjing
   Gong, Chen
   Yang, Kaixiang
   Wu, Yingxing
   Huang, Xin
   Cheng, Weiting
   Xu, Kai
TI Hedgehog pathway inhibitor 4 suppresses malignant properties of
   chondrosarcoma cells by disturbing tumor ciliogenesis
SO ONCOLOGY REPORTS
LA English
DT Article
DE chondrosarcoma; Hedgehog pathway inhibitor 4; proliferation; invasion;
   migration; primary cilia
ID PRIMARY CILIA; SIGNALING PATHWAY; GROWTH; PROLIFERATION; PROGRESSION;
   EXPRESSION; MIGRATION; BLOCKING; INVASION
AB Chondrosarcoma is a type of malignant bone tumor secreting cartilage like matrix. In clinical treatment, there is no frequently used drug treatment option except for surgical resection. Hedgehog (HH) pathway is a classical signaling pathway that regulates normal cartilage cell development. In order to detect the role that HH pathway plays in chondrosarcoma, we used immunohistochemistry and found this tumor clearly expressed HH pathway related proteins. Treatment with HH pathway inhibitor 4 (HPI 4) could significantly decrease human chondrosarcoma cell proliferation, invasion and migration ability. Furthermore, HPI 4 could distinctly disturb HH pathway mediated ciliogenesis and suppress primary cilia related protein intraflagellar transport protein IFT88 expression. HH downstream effect molecular GLI2 was restrained to block parathyroid hormone related protein and affect MAPK/ERK regulated matrix metalloproteinases (MMP2 and MMP9). These results indicated that activated HH pathway existed in chondrosarcoma. and HPI 4 could be a new therapeutic option specific to chondrosarcoma expressing elevated levels of HH pathway.
C1 [Xiang, Wei; Guo, Fengjing; Yang, Kaixiang; Wu, Yingxing; Huang, Xin; Xu, Kai] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthoped, Wuhan 430030, Hubei, Peoples R China.
   [Jiang, Ting] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Rehabil, Wuhan 430030, Hubei, Peoples R China.
   [Gong, Chen] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan 430030, Hubei, Peoples R China.
   [Cheng, Weiting] Wuhan 1 Hosp, Wuhan Integrated Tradit Chinese Med & Western Med, Dept Oncol, Wuhan 430030, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Huazhong University of Science & Technology
RP Xu, K (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthoped, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM kaixutjh@163.com
RI ; vt, cheng/HKE 0837 2023; Jiang, Ting/AFT 8115 2022; GONG,
   CHEN/JDW 5727 2023
OI Xiang, Wei/0000 0002 4443 3620; Guo, Fengjing/0000 0002 5968 4836; 
FU National Natural Science Foundation of China [81202121]; Hubei
   Provincial Health Department of Young Scientists Fund [QJX2012 05]
FX This study was supported by the National Natural Science Foundation of
   China (Grant no. 81202121) and the Hubei Provincial Health Department of
   Young Scientists Fund (Grant no. QJX2012 05).
CR Bartsch JE, 2003, J SURG RES, V110, P383, DOI 10.1016/S0022 4804(03)00007 6
   Basten Sander G, 2013, Cilia, V2, P2, DOI 10.1186/2046 2530 2 2
   Björnsson J, 1998, CANCER, V83, P2105
   Che J, 2013, ONCOL LETT, V5, P1417, DOI 10.3892/ol.2013.1195
   Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03 1429fje
   Das S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034374
   Goto H, 2013, CELL MOL LIFE SCI, V70, P3893, DOI 10.1007/s00018 013 1302 8
   Hassounah NB, 2012, CLIN CANCER RES, V18, P2429, DOI 10.1158/1078 0432.CCR 11 0755
   Ho L, 2013, ONCOGENE, V32, P5388, DOI 10.1038/onc.2012.588
   Irigoín F, 2011, CURR GENOMICS, V12, P285, DOI 10.2174/138920211795860134
   Johnson RW, 2011, ANTICANCER RES, V31, P2705
   Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008 5472.CAN 10 2993
   Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104
   Mak IWY, 2013, BONE, V55, P198, DOI 10.1016/j.bone.2013.02.020
   McGlashan SR, 2007, MATRIX BIOL, V26, P234, DOI 10.1016/j.matbio.2006.12.003
   Oue T, 2013, PEDIATR SURG INT, V29, P1153, DOI 10.1007/s00383 013 3369 6
   Proulx Bonneau S, 2011, BIOMARK INSIGHTS, V6, P107, DOI 10.4137/BMI.S8247
   Rich DR, 2012, OSTEOARTHR CARTILAGE, V20, P923, DOI 10.1016/j.joca.2012.04.017
   Tiet TD, 2006, AM J PATHOL, V168, P321, DOI 10.2353/ajpath.2006.050001
   Wu VM, 2012, P NATL ACAD SCI USA, V109, P13644, DOI 10.1073/pnas.1207170109
   Xu K, 2009, J HUAZHONG U SCI MED, V29, P39, DOI 10.1007/s11596 009 0108 2
   Yan RW, 2013, CELL ONCOL, V36, P421, DOI 10.1007/s13402 013 0149 1
   Zhuang ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067431
NR 23
TC 26
Z9 30
U1 0
U2 20
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD OCT
PY 2014
VL 32
IS 4
BP 1622
EP 1630
DI 10.3892/or.2014.3372
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AQ1FV
UT WOS:000342528200041
PM 25110171
OA Bronze
DA 2025 08 17
ER

PT J
AU Yu, K
   Wang, YH
   Yu, CX
   Han, L
   Li, K
   Miao, K
   Ni, L
   Wen, Z
   Chen, C
   Rao, XQ
   Wang, DW
   Zhou, L
   Zhao, CX
AF Yu, Kun
   Wang, Yinhui
   Yu, Chengxin
   Han, Liang
   Li, Ke
   Miao, Kun
   Ni, Li
   Wen, Zheng
   Chen, Chen
   Rao, Xiaoquan
   Wang, Dao Wen
   Zhou, Ling
   Zhao, Chunxia
TI Regulatory effect of rapamycin on recruitment and function of
   myeloid derived suppressor cells in heart failure
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Heart failure; Inflammation; Immunosuppression; MDSCs; Rapamycin
ID EPIDEMIOLOGY; INFLAMMATION; PROGNOSIS; RESPONSES; THERAPY; DISEASE
AB Background: Immune response and inflammation play important roles in the physiological and pathophysiological processes of heart failure (HF). In our previous study, myeloid derived suppressor cells (MDSCs), a heterogeneous group of immature myeloid cells with anti inflammatory and immunosuppressive functions, were shown to exert cardioprotective effects in HF. The pharmacological targeting of MDSCs using rapamycin may emerge as a promising strategy for the prevention and treatment of HF. However, the specific mechanisms underlying rapamycin induced MDSC accumulation remain unclear. Our study aimed to clarify the effects of rapamycin on the recruitment and function of MDSCs in HF, exploring new therapeutic options for the prevention and treatment of HF. Methods: We used transverse aortic constriction surgery and isoproterenol injection to establish HF models. Flow cytometry, reverse transcription polymerase chain reaction, transcriptomics and western blot were used to explore the regulation of rapamycin on recruitment and function of MDSCs in HF. Furthermore, rapamycin and granulocyte macrophage colony stimulating factor (GM CSF) were combined to induce exogenous MDSCs from bone marrow cells. Results: Rapamycin promotes the recruitment of MDSCs by inhibiting their maturation and differentiation via suppression of the Wnt signaling in HF mice and enhanced the immunosuppressive function of MDSCs via the NF kappa B signaling. Furthermore, exogenous MDSCs induced by rapamycin and GM CSF can significantly alleviate transverse aortic constriction induced cardiac dysfunction. Conclusions: The pharmacological targeting of MDSCs using rapamycin is a promising strategy for the prevention and treatment of HF.
C1 [Yu, Kun; Wang, Yinhui; Li, Ke; Miao, Kun; Ni, Li; Wen, Zheng; Chen, Chen; Rao, Xiaoquan; Wang, Dao Wen; Zhou, Ling; Zhao, Chunxia] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med,Div Cardiol, Wuhan 430030, Peoples R China.
   [Yu, Kun; Wang, Yinhui; Li, Ke; Miao, Kun; Ni, Li; Wen, Zheng; Chen, Chen; Rao, Xiaoquan; Wang, Dao Wen; Zhou, Ling; Zhao, Chunxia] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Peoples R China.
   [Yu, Chengxin] Huazhong Univ Sci & Technol, Tongji Hosp, GI Canc Res Inst, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Han, Liang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Integrated Tradit Chinese & Western Med, Wuhan 430030, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Huazhong University of Science & Technology;
   Huazhong University of Science & Technology
RP Zhou, L; Zhao, CX (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hubei Key Lab Genet & Mol Mech Cardiol Disorders, Wuhan 430030, Peoples R China.
EM zhouling_tjh@163.com; zhaocx2001@126.com
RI Han, Liang/JZD 1497 2024; Zhao, Chunxia/KBB 4190 2024; miao,
   kun/KSM 2486 2024; Wang, Chenwei/HCI 8930 2022; Li, Ke/AAI 6577 2021
FU National Natural Science Founda tion of China [81800355, 81873506];
   Program for Huazhong University of Science and Technology Academic
   Frontier Youth Team [2019QYTD08]; Fundamental Research Funds for the
   Central Universities [YCJJ20230225]
FX This study was supported by the National Natural Science Founda tion of
   China (81800355, 81873506) , Program for Huazhong University of Science
   and Technology Academic Frontier Youth Team (2019QYTD08) and the
   Fundamental Research Funds for the Central Universities (YCJJ20230225) .
CR Baman Jayson R, 2020, JAMA, V324, P1015, DOI 10.1001/jama.2020.13310
   Bolli R, 2022, CARDIOVASC RES, V118, P951, DOI 10.1093/cvr/cvab135
   Burgy O, 2018, MATRIX BIOL, V68 69, P67, DOI 10.1016/j.matbio.2018.03.017
   Chae WJ, 2018, TRENDS IMMUNOL, V39, P830, DOI 10.1016/j.it.2018.08.006
   Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002
   Crespo Leiro MG, 2021, HEART FAIL CLIN, V17, P533, DOI 10.1016/j.hfc.2021.06.002
   Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326 6066.CIR 16 0297
   Gieseck RL, 2018, NAT REV IMMUNOL, V18, P62, DOI 10.1038/nri.2017.90
   Gtif I, 2021, ARCH CARDIOVASC DIS, V114, P680, DOI 10.1016/j.acvd.2021.07.001
   Jiang XW, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1211219
   Karin M, 2016, NATURE, V529, P307, DOI 10.1038/nature17039
   Kong YY, 2013, CURR MED CHEM, V20, P1437, DOI 10.2174/0929867311320110006
   Li BH, 2020, MOL IMMUNOL, V117, P201, DOI 10.1016/j.molimm.2019.11.014
   Nakamura T, 2015, AM J TRANSPLANT, V15, P2364, DOI 10.1111/ajt.13276
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Ostrand Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740
   Park HB, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113904
   Park MY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00183
   Ponikowski Piotr, 2016, Rev Esp Cardiol (Engl Ed), V69, P1167, DOI 10.1016/j.rec.2016.11.005
   Raval AN, 2021, INT J CARDIOL, V326, P131, DOI 10.1016/j.ijcard.2020.10.043
   Raval AN, 2018, AM HEART J, V201, P141, DOI 10.1016/j.ahj.2018.03.016
   Rössner S, 2005, EUR J IMMUNOL, V35, P3533, DOI 10.1002/eji.200526172
   Schwinger RHG, 2021, CARDIOVASC DIAGN THE, V11, P263, DOI 10.21037/cdt 20 302
   Shirakabe A, 2016, CIRCULATION, V133, P1249, DOI 10.1161/CIRCULATIONAHA.115.020502
   Tran FH, 2017, PROTEIN SCI, V26, P650, DOI 10.1002/pro.3122
   Tribouilloy C, 2008, EUR HEART J, V29, P339, DOI 10.1093/eurheartj/ehm554
   WRITING COMMITTEE MEMBERS, 2013, Circulation, V128, pe240, DOI 10.1161/CIR.0b013e31829e8776
   Wu JA, 2010, J ULTRAS MED, V29, P1771, DOI 10.7863/jum.2010.29.12.1771
   Yang JZ, 2023, FRONT MICROBIOL, V14, DOI 10.3389/fmicb.2023.1255971
   Zacchigna S, 2021, CARDIOVASC RES, V117, P43, DOI 10.1093/cvr/cvaa110
   Zhang H, 2017, ONCOGENE, V36, P2095, DOI 10.1038/onc.2016.367
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zhang Y, 2014, J LEUKOCYTE BIOL, V95, P961, DOI 10.1189/jlb.0913473
   Zhang YY, 2017, EUR J HEART FAIL, V19, P1379, DOI 10.1002/ejhf.942
   Zhou L, 2018, CIRCULATION, V138, P181, DOI 10.1161/CIRCULATIONAHA.117.030811
   Ziaeian B, 2016, NAT REV CARDIOL, V13, P368, DOI 10.1038/nrcardio.2016.25
NR 36
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV 15
PY 2024
VL 141
AR 112965
DI 10.1016/j.intimp.2024.112965
EA AUG 2024
PG 14
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA E4F4T
UT WOS:001302576300001
PM 39186836
OA hybrid
DA 2025 08 17
ER

PT J
AU Song, JF
   Jing, ZZ
   Hu, W
   Yu, JP
   Cui, XP
AF Song, Jiefu
   Jing, Zhizhen
   Hu, Wei
   Yu, Jianping
   Cui, Xiaoping
TI α Linolenic Acid Inhibits Receptor Activator of NF κB Ligand Induced
   (RANKL Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss
   via Downregulation of Nuclear Factor KappaB Inducible Nitric Oxide
   Synthases (NF κB iNOS) Signaling Pathways
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE alpha Linolenic Acid; Anti Inflammatory Agents; Apoptosis; Bone
   Diseases; NF kappa B; Nitric Oxide Synthase Type II
ID POLYUNSATURATED FATTY ACIDS; RAW264.7 CELLS; C FOS; EICOSAPENTAENOIC
   ACID; COLORECTAL CANCER; MC3T3 E1 CELLS; TNF ALPHA; EXPRESSION;
   DIFFERENTIATION; RESORPTION
AB Background: Inflammation is a major cellular strain causing increased risk of osteo degenerative diseases. Omega 3 fatty acids have been great source in suppressing inflammation. We investigated the effect of a linolenic acid (ALA) on RANKL stimulated osteoclast differentiation, LPS induced and ovariectomized bone loss in mice models.
   Material/Methods: The bone marrow macrophages (BMMs) were isolated from femurs of ICR mice, stimulated with RANKL, and treated with ALA (100, 200, 300 mu M). Major analytical methods include histological analysis, osteoclasts viability assay, serum cytokines and chemokines ELISA, and gene expression by qPCR.
   Results: ALA intervention inhibited RANKL induced osteoclasts proliferation and differentiation. ALA inhibited bone resorption activity as measured by materialization of F actin ring structures as well. ALA suppressed the RANKLinduced osteoclast markers c Fos, c Jun and NFATc1 together with transcription factor proteins TRAP, OSCAR, cathepsin K and beta 3 integrin. ALA also suppressed the RANKL stimulated phosphorylation of JNK, ERK, and AKT as well as NF kappa B and BCL 2 proteins. ALA intervention (100 and 300 mg/kg) to LPS challenged mice showed annulled morphometric changes induced by LPS by suppressing the levels of proinflammatory cytokines and chemokines. ALA (100 and 300 mg/kg) intervention to estrogen deficiency induced bone loss mice (ovariectomized) showed reductions in TRAP+ osteoclasts count, CTX I expression, levels of IL 1 beta, IL 2, IL 6, IL10, TNF alpha and MCP 1 and iNOS and COX 2.
   Conclusions: ALA suppresses RANKL induced osteoclast differentiation and prevents inflammatory bone loss via downregulation of NF kappa B iNOS COX 2 signaling. ALA is suggested to be a preventive herbal medicine against inflammatory bone disorders.
C1 [Song, Jiefu; Jing, Zhizhen; Hu, Wei; Yu, Jianping; Cui, Xiaoping] Shan Xi Prov Peoples Hosp, Dept Orthoped, Taiyuan, Shanxi, Peoples R China.
RP Song, JF (通讯作者)，Shan Xi Prov Peoples Hosp, Dept Orthoped, Taiyuan, Shanxi, Peoples R China.
EM solorzano.okere9218@hotmail.com
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   AGARWAL S, 1995, J DENT RES, V74, P1057, DOI 10.1177/00220345950740040501
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   AZNAR C, 1990, Cytokine, V2, P259, DOI 10.1016/1043 4666(90)90026 P
   Calder PC, 2013, BRIT J CLIN PHARMACO, V75, P645, DOI 10.1111/j.1365 2125.2012.04374.x
   Calder PC, 2011, EUR J PHARMACOL, V668, pS50, DOI 10.1016/j.ejphar.2011.05.085
   Cohen S, 2006, ARTHRIT RHEUM ARTHR, V55, P15, DOI 10.1002/art.21706
   Coon D, 2007, J ENDODONT, V33, P432, DOI 10.1016/j.joen.2006.12.001
   Ganesan R, 2016, CYTOKINE, V77, P115, DOI 10.1016/j.cyto.2015.11.002
   Ghayor C, 2015, INFLAMM RES, V64, P527, DOI 10.1007/s00011 015 0833 x
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   HAKEDA Y, 1985, BIOCHEM BIOPH RES CO, V126, P340, DOI 10.1016/0006 291X(85)90611 4
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   HUKKANEN M, 1995, ENDOCRINOLOGY, V136, P5445, DOI 10.1210/en.136.12.5445
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jang JY, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1633 3
   Kanazawa K, 2003, J BONE MINER RES, V18, P443, DOI 10.1359/jbmr.2003.18.3.443
   Kanematsu M, 1997, J BONE MINER RES, V12, P1789, DOI 10.1359/jbmr.1997.12.11.1789
   Khal J, 2008, BIOCHEM BIOPH RES CO, V375, P238, DOI 10.1016/j.bbrc.2008.08.004
   Kim JB, 2007, BIOL PHARM BULL, V30, P2345, DOI 10.1248/bpb.30.2345
   Kim JY, 2014, BONE, V60, P104, DOI 10.1016/j.bone.2013.12.013
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li L, 2015, EUR J PHARMACOL, V765, P115, DOI 10.1016/j.ejphar.2015.08.032
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Milde Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71
   Mishra SK, 2013, EUR J INFLAMM, V11, P615, DOI 10.1177/1721727X1301100306
   Mishra SK, 2012, J ETHNOPHARMACOL, V143, P524, DOI 10.1016/j.jep.2012.07.008
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Ono K, 2005, J BONE MINER RES, V20, P23, DOI 10.1359/JBMR.041027
   Oursler MJ, 2010, J CELL BIOCHEM, V110, P1058, DOI 10.1002/jcb.22640
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   RALSTON SH, 1995, J BONE MINER RES, V10, P1040
   Shen CL, 2006, BRIT J NUTR, V95, P462, DOI 10.1079/BJN20051664
   Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248
   Smith GI, 2011, CLIN SCI, V121, P267, DOI 10.1042/CS20100597
   Smith GI, 2011, AM J CLIN NUTR, V93, P402, DOI 10.3945/ajcn.110.005611
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Taraballi F, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731415624667
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43
   Watkins BA, 2000, J NUTR, V130, P2274, DOI 10.1093/jn/130.9.2274
   Whitehouse AS, 2001, CANCER RES, V61, P3604
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
   Zheng WH, 2017, INT IMMUNOPHARMACOL, V42, P1, DOI 10.1016/j.intimp.2016.11.009
NR 48
TC 28
Z9 31
U1 0
U2 19
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD OCT 24
PY 2017
VL 23
BP 5056
EP 5069
DI 10.12659/MSM.904795
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FK7AR
UT WOS:000413656800001
PM 29061958
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhu, ZG
   Xie, QP
   Huang, YZ
   Zhang, SJ
   Chen, Y
AF Zhu, Ziguan
   Xie, Qingping
   Huang, Yazeng
   Zhang, Shuijun
   Chen, Yu
TI Aucubin suppresses Titanium particles mediated apoptosis of MC3T3 E1
   cells and facilitates osteogenesis by affecting the BMP2/Smads/RunX2
   signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE aucubin; Titanium particles; MC3T3 E1; bone morphogenetic protein 2;
   Smads; runt related transcription factor 2
ID BONE MORPHOGENETIC PROTEINS; STRESS INDUCED INHIBITION; MESENCHYMAL
   STEM CELLS; TOTAL HIP ARTHROPLASTY; OXIDATIVE STRESS; EUCOMMIA ULMOIDES;
   OSTEOBLAST DIFFERENTIATION; PROTECTIVE ACTIVITIES; TGF BETA; ANTIOXIDANT
AB Aucubin represents an iridoid glucoside separated from multiple Chinese herbs, which has been demonstrated to possess numerous pharmacological activities. In the present study, the aim was to investigate the roles and mechanisms of aucubin in the suppression of mouse MC3T3 E1 osteoblast apoptosis induced by Titanium particles and the promotion of bone formation. MTT assay and flow cytometry were performed to analyze cell viability and apoptosis, respectively. ELISA and para nitrophenyl phosphate colorimetry were carried out to evaluate the oxidative stress markers and alkaline phosphatase (ALP). Western blotting and reverse transcription quantitative polymerase chain reaction assays were used to evaluate the associated mRNA and protein expression. The results revealed that aucubin enhanced the cell activity of MC3T3 E1 cells treated with Ti particles. Aucubin suppressed the apoptosis of Ti particles induced MC3T3 E1 cells and facilitated osteogenesis by affecting the B cell lymphoma 2 (Bcl 2), Bcl 2 associated X protein, ALP and associated osteogenic factors expression. Aucubin reduced the oxidative stress in Ti particles induced MC3T3 E1 cells. In addition, aucubin upregulated the bone morphogenetic protein 2 (BMP2)/Smads/runt related transcription factor 2 (RunX2) pathway in Ti particles induced MC3T3 E1 cells. In conclusion, the present study confirmed that aucubin suppressed the Ti particles mediated apoptosis of MC3T3 E1 cells and facilitated osteogenesis by affecting the BMP2/Smads/RunX2 signaling pathway.
C1 [Zhu, Ziguan; Xie, Qingping] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Hand Surg & Reconstruct Surg, Hangzhou 310014, Zhejiang, Peoples R China.
   [Huang, Yazeng; Zhang, Shuijun; Chen, Yu] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Orthopaed, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.
C3 Hangzhou Medical College; Zhejiang Provincial People's Hospital;
   Hangzhou Medical College; Zhejiang Provincial People's Hospital
RP Chen, Y (通讯作者)，Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Orthopaed, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.
EM yuchenmy25@163.com
FU Zhejiang Provincial Medical Science and Technology on General Item
   [2015KYA014, 2017KY011]
FX This work was supported by Zhejiang Provincial Medical Science and
   Technology on General Item (grant nos. 2015KYA014 and 2017KY011).
CR Akopova O V, 2012, Fiziol Zh, V58, P3
   Aubin JE, 1996, MICROSC RES TECHNIQ, V33, P128, DOI 10.1002/(SICI)1097 0029(19960201)33:2<128::AID JEMT4>3.0.CO;2 P
   Axelrad TW, 2009, CYTOKINE GROWTH F R, V20, P481, DOI 10.1016/j.cytogfr.2009.10.003
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891 5849(00)00317 8
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   CHANG IM, 1983, DRUG CHEM TOXICOL, V6, P443, DOI 10.3109/01480548309014166
   CHANG IM, 1984, J TOXICOL CLIN TOXIC, V22, P77, DOI 10.3109/00099308409035083
   Chang IM, 1998, RES COMMUN MOL PATH, V102, P189
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chenard KE, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/601549
   Conidi A, 2011, CYTOKINE GROWTH F R, V22, P287, DOI 10.1016/j.cytogfr.2011.11.006
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   De Caestecker M, 2001, RESPIR RES, V2, P193
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Eliseev RA, 2008, ONCOGENE, V27, P3605, DOI 10.1038/sj.onc.1211020
   Galetz MC, 2010, J BIOMED MATER RES B, V93B, P244, DOI 10.1002/jbm.b.31581
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gowri AM, 2013, INDIAN J MED RES, V137, P308
   Gronthos S, 2003, J BONE MINER RES, V18, P716, DOI 10.1359/jbmr.2003.18.4.716
   Grübl A, 2002, J BONE JOINT SURG AM, V84A, P425
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1
   Ho JN, 2005, BIOSCI BIOTECH BIOCH, V69, P2227, DOI 10.1271/bbb.69.2227
   Ho JN, 2005, BIOL PHARM BULL, V28, P1244, DOI 10.1248/bpb.28.1244
   Jin L, 2008, EUR J PHARMACOL, V582, P162, DOI 10.1016/j.ejphar.2007.12.011
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Lenaz G, 1999, ACTA BIOCHIM POL, V46, P1
   Li YM, 1998, BIOL PHARM BULL, V21, P1306, DOI 10.1248/bpb.21.1306
   Lin J, 2011, J ZHEJIANG UNIV SC B, V12, P47, DOI 10.1631/jzus.B1000057
   LOMBARDI AV, 1989, J BONE JOINT SURG AM, V71A, P1337, DOI 10.2106/00004623 198971090 00009
   Marchi Saverio, 2012, J Signal Transduct, V2012, P329635, DOI 10.1155/2012/329635
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Matsumoto A, 1995, Nihon Yakurigaku Zasshi, V105, P273
   Nishimura R, 2012, J BIOCHEM, V151, P247, DOI 10.1093/jb/mvs004
   O'Connor DT, 2004, J ORTHOP RES, V22, P229, DOI 10.1016/S0736 0266(03)00167 0
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Rajamannan NM, 2012, J CELL BIOCHEM, V113, P1623, DOI 10.1002/jcb.24031
   Ruff CB, 2013, AM J PHYS ANTHROPOL, V150, P29, DOI 10.1002/ajpa.22120
   Saito T, 2004, J ENDODONT, V30, P205, DOI 10.1097/00004770 200404000 00005
   Simic P, 2007, EMBO REP, V8, P327, DOI 10.1038/sj.embor.7400943
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Wang F, 2015, ONCOTARGET, V6, P35496, DOI 10.18632/oncotarget.6072
   Wang ML, 2003, J ORTHOPAED RES, V21, P697, DOI 10.1016/S0736 0266(02)00241 3
   Wang ML, 2002, J ORTHOP RES, V20, P1175, DOI 10.1016/S0736 0266(02)00076 1
   Wang N, 2016, J PHARMACOL SCI, V132, P192, DOI 10.1016/j.jphs.2016.10.005
   Xue HY, 2012, PHYTOTHER RES, V26, P369, DOI 10.1002/ptr.3562
   Xue HY, 2008, SCI CHINA SER C, V51, P495, DOI 10.1007/s11427 008 0069 x
   Zreiqat H, 2003, BIOMATERIALS, V24, P337, DOI 10.1016/S0142 9612(02)00324 1
NR 49
TC 19
Z9 21
U1 2
U2 28
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2018
VL 18
IS 3
BP 2561
EP 2570
DI 10.3892/mmr.2018.9286
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GR7RK
UT WOS:000442890400005
PM 30015916
OA hybrid, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Huang, JL
   Ma, ZL
   Peng, XP
   Yang, ZC
   Wu, YH
   Zhong, GH
   Ouyang, TF
   Chen, Z
   Liu, Y
   Wang, QR
   Chen, JJ
   Chen, T
   Zeng, ZH
AF Huang, Junli
   Ma, Zeli
   Peng, Xiaopeng
   Yang, Zichao
   Wu, Yuhao
   Zhong, Guanghong
   Ouyang, Tianfeng
   Chen, Zhen
   Liu, Yao
   Wang, Qirui
   Chen, Jianjun
   Chen, Ting
   Zeng, Zhenhua
TI Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of
   Osteoclasts Related Inflammatory Diseases
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID CHRONIC LYMPHOCYTIC LEUKEMIA; TYROSINE KINASE INHIBITORS; CHEMISTRY
AB Bruton's tyrosine kinase (BTK) is an attractive target in inflammatory and autoimmune diseases. However, the effectiveness of BTK inhibitors is limited by side effects and drug resistance. In this study, we report the development of novel BTK proteolysis targeting chimeras (PROTACs) with different classes of BTK targeting ligands (e.g., spebrutinib) other than ibrutinib. Compound 23 was identified as a potent and fast BTK PROTAC degrader, exhibiting outstanding degradation potency and efficiency in Mino cells (DC50, 4 h = 1.29 +/  0.3 nM, t(1/2, 20 nM) = 0.59 +/  0.20 h). Furthermore, compound 23 forms a stable ternary complex, as confirmed by the HTRF assay. Notably, 23 down regulated the BTK PLC gamma 2 Ca2+ NFATc1 signaling pathway activated by RANKL, thus inhibiting osteo clasto genesis and attenuating alveolar bone resorption in a mouse periodontitis model. These findings suggest that compound 23 is a potent and promising candidate for osteoclast related inflammatory diseases, expanding the potential of BTK PROTACs.
   [GRAPHICS]
C1 [Huang, Junli] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Pharm, Nanning 530021, Guangxi, Peoples R China.
   [Huang, Junli] Guangxi Acad Med Sci, Nanning 530021, Guangxi, Peoples R China.
   [Ma, Zeli; Chen, Ting] Southern Med Univ, Nanfang Hosp, Dept Stomatol, Guangzhou 510515, Peoples R China.
   [Peng, Xiaopeng] Gannan Med Univ, Sch Pharm, Key Lab Prevent & Treatment Cardiovasc & Cerebrova, Jiangxi Prov Key Lab Biomat & Biofabricat Tissue E, Ganzhou 314000, Peoples R China.
   [Yang, Zichao; Zhong, Guanghong; Ouyang, Tianfeng; Chen, Zhen; Chen, Jianjun] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, NMPA Key Lab Res & Evaluat Drug Metab, Guangzhou 510515, Peoples R China.
   [Wu, Yuhao; Zeng, Zhenhua] Southern Med Univ, Nanfang Hosp, Dept Crit Care Med, Guangzhou 510515, Guangdong, Peoples R China.
   [Liu, Yao] Shanghai Jiao Tong Univ, Instrumental Anal Ctr, Shanghai 200240, Peoples R China.
   [Wang, Qirui] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Peoples R China.
C3 Southern Medical University   China; Gannan Medical University; Southern
   Medical University   China; Southern Medical University   China;
   Shanghai Jiao Tong University; Southern Medical University   China
RP Chen, T (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Stomatol, Guangzhou 510515, Peoples R China.; Chen, JJ (通讯作者)，Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, NMPA Key Lab Res & Evaluat Drug Metab, Guangzhou 510515, Peoples R China.; Zeng, ZH (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Crit Care Med, Guangzhou 510515, Guangdong, Peoples R China.
EM jchen21@smu.edu.cn; chent@smu.edu.cn; zhenhuazeng.2008@163.com
RI Wang, Qirui/ITT 7665 2023
OI Wang, Qirui/0000 0002 0460 8860
FU National Natural Science Foundation of China [82173668, 82003598,
   82260676]; National Natural Science Foundation of China
   [20232BAB216131]; Jiangxi Provincial Natural Science Foundation
   [202101094462, 2023PNS26854]; Science and Technology Projects of Ganzhou
FX This work was supported by the National Natural Science Foundation of
   China (No. 82173668 to C.J., 82003598 to L.Y., and 82260676 to P.X.),
   Jiangxi Provincial Natural Science Foundation (20232BAB216131 to P.X.),
   and the Science and Technology Projects of Ganzhou (202101094462 and
   2023PNS26854 to P.X.).
CR Ariza Y, 2019, BONE REP, V10, DOI 10.1016/j.bonr.2019.100201
   Arnason JE, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912 017 0620 7
   Arneson LC, 2021, IMMUNOTARGETS THER, V10, P333, DOI 10.2147/ITT.S288550
   Baek JM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030581
   Bam R, 2010, BLOOD, V116, P200, DOI 10.1182/blood.V116.21.447.447
   Barf T, 2017, J PHARMACOL EXP THER, V363, P240, DOI 10.1124/jpet.117.242909
   Békés M, 2022, NAT REV DRUG DISCOV, V21, P181, DOI 10.1038/s41573 021 00371 6
   Bender AT, 2017, MOL PHARMACOL, V91, P208, DOI 10.1124/mol.116.107037
   Bond MJ, 2020, ACS CENTRAL SCI, V6, P1367, DOI 10.1021/acscentsci.0c00411
   Buhimschi AD, 2018, BIOCHEMISTRY US, V57, P3564, DOI 10.1021/acs.biochem.8b00391
   Chen T, 2021, PHYTOTHER RES, V35, P932, DOI 10.1002/ptr.6846
   Danks L, 2007, J BONE MINER RES, V22, pS255
   Dhillon S, 2021, DRUGS, V81, P503, DOI 10.1007/s40265 021 01482 5
   Dhillon S, 2020, DRUGS, V80, P835, DOI 10.1007/s40265 020 01318 8
   Estupiñan HY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.630942
   Estupiñán HY, 2021, LEUKEMIA, V35, P1317, DOI 10.1038/s41375 021 01123 6
   Foluso O, 2016, CL LYMPH MYELOM LEUK, V16, P63, DOI 10.1016/j.clml.2015.11.011
   Gabizon R, 2020, J AM CHEM SOC, V142, P11734, DOI 10.1021/jacs.9b13907
   Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/NCHEMBIO.2329, 10.1038/nchembio.2329]
   Guo YH, 2019, J MED CHEM, V62, P7923, DOI 10.1021/acs.jmedchem.9b00687
   Hornberger KR, 2023, J MED CHEM, V66, P8281, DOI 10.1021/acs.jmedchem.3c00740
   Huang JL, 2023, EUR J MED CHEM, V259, DOI 10.1016/j.ejmech.2023.115664
   Kiely Collins H, 2021, CELL CHEM BIOL, V28, P952, DOI 10.1016/j.chembiol.2021.03.005
   Liang XY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.702916
   Lipsky AH, 2015, HAEMATOLOGICA, V100, P1571, DOI 10.3324/haematol.2015.126672
   Liu SD, 2020, MED CHEM RES, V29, P802, DOI 10.1007/s00044 020 02526 3
   Liu XG, 2022, J AM CHEM SOC, V144, P16930, DOI 10.1021/jacs.2c05499
   Liu YT, 2021, ACTA PHARMACOL SIN, V42, P1653, DOI 10.1038/s41401 020 00578 0
   Luo GS, 2021, ACTA PHARM SIN B, V11, P1300, DOI 10.1016/j.apsb.2020.11.001
   Ma QY, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00121 1
   Martín Acosta P, 2021, EUR J MED CHEM, V210, DOI 10.1016/j.ejmech.2020.112993
   Munshi M, 2021, BLOOD, V138, DOI 10.1182/blood 2021 153856
   Nowak RP, 2018, NAT CHEM BIOL, V14, P706, DOI 10.1038/s41589 018 0055 y
   Pokhrel NK, 2019, J PERIODONTOL, V90, P546, DOI 10.1002/JPER.18 0334
   Robbins DW, 2021, BLOOD, V138, DOI 10.1182/blood 2021 147473
   Robbins DW, 2020, BLOOD, V136, DOI 10.1182/blood 2020 141461
   Roy MJ, 2019, ACS CHEM BIOL, V14, P361, DOI 10.1021/acschembio.9b00092
   Schafer PH, 2020, RHEUMATOL THER, V7, P101, DOI 10.1007/s40744 019 00182 7
   Schiemer J, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 36738 z
   Schiemer J, 2021, NAT CHEM BIOL, V17, P152, DOI 10.1038/s41589 020 00686 2
   Singh SP, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0779 z
   Sun SL, 2022, J MED CHEM, V65, P7415, DOI 10.1021/acs.jmedchem.2c00030
   Sun YH, 2018, CELL RES, V28, P779, DOI 10.1038/s41422 018 0055 1
   Troup Robert I, 2020, Explor Target Antitumor Ther, V1, P273, DOI 10.37349/etat.2020.00018
   Wang LN, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8767529
   Wurz RP, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 39904 5
   Xiang WG, 2021, J MED CHEM, V64, P13487, DOI 10.1021/acs.jmedchem.1c00900
   Zaidman D, 2020, J CHEM INF MODEL, V60, P4894, DOI 10.1021/acs.jcim.0c00589
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zhang DY, 2023, BLOOD, V141, P1584, DOI 10.1182/blood.2022016934
   Zhang JY, 2022, J MED CHEM, DOI 10.1021/acs.jmedchem.2c00324
NR 51
TC 3
Z9 4
U1 4
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 7
PY 2024
VL 67
IS 4
BP 2438
EP 2465
DI 10.1021/acs.jmedchem.3c01414
PG 28
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA JP7O3
UT WOS:001174436500001
PM 38321747
DA 2025 08 17
ER

PT J
AU Dai, CY
   Zhu, LH
   Chen, GY
   Haddleton, DM
AF Dai, Chunyan
   Zhu, Linhua
   Chen, Guangying
   Haddleton, David M.
TI Defect related luminescent nanostructured hydroxyapatite promotes
   mineralization through both intracellular and extracellular pathways
SO RSC ADVANCES
LA English
DT Article
ID BONE; DIFFERENTIATION; NANOPARTICLES; REGENERATION; COMPOSITE; DRUG
AB Hydroxyapatite (HAP) is a widely used biomaterial for bone tissue substitution due to its chemical similarity with the natural bone. Defect related luminescent HAP materials have the same chemical composition as normal HAP and excellent biocompatibility. However, only few works have focused on the defect related luminescent HAP materials on bone regeneration. In this work, we systematically investigated the bone regeneration pathway induced by nanostructured particles using defect related luminescent hydroxyapatite (S2) materials. We monitored the subcellular distribution and location of S2 during osteoblast differentiation with the property of defect related luminescence. Nano scale S2 could be internalized by osteoblasts (OBs) via caveolae mediated endocytosis and macropinocytosis. S2 incorporated into the lysosomes dissolved and released calcium ions for the formation of mineralized nodules. Extracellular S2 also promoted bone regeneration as a nucleation site. Taken together, the physical properties of hydroxyapatite control the bone regeneration pathway in osteoblasts.
C1 [Dai, Chunyan; Zhu, Linhua; Chen, Guangying] Hainan Normal Univ, Minist Educ, Key Lab Trop Med Plant Chem, Haikou 571158, Hainan, Peoples R China.
   [Dai, Chunyan; Zhu, Linhua; Haddleton, David M.] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
C3 Hainan Normal University; University of Warwick
RP Zhu, LH; Chen, GY (通讯作者)，Hainan Normal Univ, Minist Educ, Key Lab Trop Med Plant Chem, Haikou 571158, Hainan, Peoples R China.; Zhu, LH; Haddleton, DM (通讯作者)，Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
EM chgying123@163.com; zhulinhua1981@163.com; d.m.haddleton@warwick.ac.uk
RI ; Haddleton, David/A 6233 2009
OI Haddleton, David/0000 0002 4965 0827; 
FU Key Research and Development Plan of Hainan Province [ZDYF2018160];
   National Natural Science Foundation of China [21766007]; Program for
   Innovative Research Team in University [IRT 16R19]; Hainan Natural
   Science Foundation of China [217114]; China Scholarship Council (CSC)
   [201808460066, 201808460067]
FX This research was supported by the Key Research and Development Plan of
   Hainan Province (Grant No. ZDYF2018160), National Natural Science
   Foundation of China (Grant No. 21766007), the Program for Innovative
   Research Team in University (Grant No. IRT 16R19), Hainan Natural
   Science Foundation of China (Grant No. 217114), and the.nancial support
   from China Scholarship Council (CSC, Grant No. 201808460066, and
   201808460067).
CR Amornwachirabodee K, 2012, J PHARM SCI US, V101, P3779, DOI 10.1002/jps.23263
   ANGELOV S, 1986, J PHYS CHEM SOLIDS, V47, P409, DOI 10.1016/0022 3697(86)90032 6
   Ashokan A, 2010, BIOMATERIALS, V31, P2606, DOI 10.1016/j.biomaterials.2009.11.113
   Bauer IW, 2008, J MATER SCI MATER M, V19, P1091, DOI 10.1007/s10856 007 3124 4
   Bernhardt A, 2009, J BIOMED MATER RES A, V90A, P852, DOI 10.1002/jbm.a.32144
   Bilic Curcic I, 2005, GENESIS, V43, P87, DOI 10.1002/gene.20156
   Bloebaum RD, 1998, J BIOMED MATER RES, V40, P104, DOI 10.1002/(SICI)1097 4636(199804)40:1<104::AID JBM12>3.0.CO;2 O
   Brankova T, 2003, CHEM MATER, V15, P1855, DOI 10.1021/cm0212055
   Cai YR, 2007, J MATER CHEM, V17, P3780, DOI 10.1039/b705129h
   Dai CY, 2014, BIOL TRACE ELEM RES, V162, P158, DOI 10.1007/s12011 014 0151 0
   Green WH, 1997, SCIENCE, V276, P1826, DOI 10.1126/science.276.5320.1826
   Greulich C, 2011, ACTA BIOMATER, V7, P347, DOI 10.1016/j.actbio.2010.08.003
   Itoh S, 2006, ARTIF ORGANS, V30, P863, DOI 10.1111/j.1525 1594.2006.00313.x
   Kaur T, 2017, J MATER SCI TECHNOL, V33, P734, DOI 10.1016/j.jmst.2016.06.020
   Khajuria DK, 2018, ACS APPL MATER INTER, V10, P19373, DOI 10.1021/acsami.8b02792
   Kim HW, 2004, J BIOMED MATER RES B, V71B, P66, DOI 10.1002/jbm.b.30064
   Lee MN, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0170 6
   Li DD, 2013, DALTON T, V42, P9877, DOI 10.1039/c3dt50243k
   Li YX, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604 018 2978 0
   Maeno S, 2005, BIOMATERIALS, V26, P4847, DOI 10.1016/j.biomaterials.2005.01.006
   Mirza S, 2018, INT J BIOL MACROMOL, V119, P215, DOI 10.1016/j.ijbiomac.2018.07.128
   Pallela R, 2012, J BIOMED MATER RES A, V100A, P486, DOI 10.1002/jbm.a.33292
   Rammelt S, 2005, J BIOMED MATER RES A, V73A, P284, DOI 10.1002/jbm.a.30263
   Rossi AL, 2012, BONE, V50, P301, DOI 10.1016/j.bone.2011.10.022
   Schmidt SM, 2008, J BIOMED MATER RES A, V87A, P418, DOI 10.1002/jbm.a.31761
   Walter MNM, 2016, BIOMATER SCI UK, V4, P346, DOI 10.1039/c5bm00428d
   Wang WN, 2011, J MATER CHEM, V21, P5183, DOI 10.1039/c0jm02215b
   Yu HS, 2009, J BIOMED MATER RES A, V88A, P747, DOI 10.1002/jbm.a.31709
   Zhang CM, 2012, CHEM SOC REV, V41, P7938, DOI 10.1039/c2cs35215j
NR 29
TC 4
Z9 4
U1 0
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PD NOV 7
PY 2019
VL 9
IS 62
BP 35939
EP 35947
DI 10.1039/c9ra06629b
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA JO8LB
UT WOS:000497825500002
PM 35540564
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, CF
   Liu, DY
   Yang, SH
   Mao, TY
AF Huang, Chun Feng
   Liu, De Yen
   Yang, Shung Hour
   Mao, Tso Yen
TI The Effects of Polypharmacy on Bone Mineral Density in Middle Aged and
   Elderly Men
SO INTERNATIONAL JOURNAL OF GERONTOLOGY
LA English
DT Article
DE bone mineral density; CYP450; polypharmacy; vitamin D
ID DRUG; OSTEOPOROSIS; PATHOPHYSIOLOGY; METABOLISM; MECHANISM; FRACTURE;
   CALCIUM
AB Background: Osteoporosis is a loss of bone density among aging adults that can cause fractures and disability. Drug induced osteoporosis is a noteworthy health problem, but many physicians are unaware that many commonly prescribed medications contribute to significant bone loss and fractures. This study investigated the cumulative effects of concurrent polydrug use (>= 5 medications) on bone mineral density (BMD) with inhibited and induced cytochrome P450 (CYP450) enzyme activity.
   Methods: This study enrolled 207 middle aged and elderly male subjects who underwent two dual energy X ray absorptiometry (DXA) scans to measure lumbar vertebrae BMD between 2012 and 2018 and analyzed their prescribed medicines metabolized via the CYP450 system.
   Results: The inhibitory group (n = 66) included patients prescribed more drugs that inhibit CYP450 than those that induce CYP450, the inductive group (n = 72) included patients prescribed more medications that induce CYP450 than those that inhibit CYP450, and the reference group (n = 69) included patients administered with the equal number of prescription drugs that inhibit and induce CYP450 or used neither. The results indicated a significant increase in the risk of BMD loss in the inductive group compared to the reference group (OR = 3.63, 95% CI = 1.43 5.84) (p = 0.013).
   Conclusions: The prescription of drugs that induce CYP450 decreases the BMD in middle aged and elderly males. A possible mechanism is that more CYP450 inducers in number would accelerate the metabolic rate of vitamin D and will eventually affect the function of parathyroid hormone in bone remodeling. Copyright (C) 2019, Taiwan Society of Geriatric Emergency & Critical Care Medicine.
C1 [Huang, Chun Feng] Natl Yang Ming Univ Hosp, Dept Family Med, Yilan, Taiwan.
   [Liu, De Yen] St Marys Jr Coll Med, Dept Hlth & Leisure Management, Nursing & Management, Yilan, Taiwan.
   [Yang, Shung Hour] Natl Yang Ming Univ Hosp, Dept Surg, Yilan, Taiwan.
   [Mao, Tso Yen] Chaoyang Univ Technol, Dept Leisure Serv Management, 168 Jifeng E Rd, Taichung 41349, Taiwan.
C3 Chaoyang University of Technology
RP Mao, TY (通讯作者)，Chaoyang Univ Technol, Dept Leisure Serv Management, 168 Jifeng E Rd, Taichung 41349, Taiwan.
EM tymao.research@gmail.com
RI ; Huang, Chun Feng/KAO 3236 2024
OI Mao, Tso Yen/0000 0001 7133 3257; 
CR Babacan O, 2012, J CLIN NEUROL, V8, P65, DOI 10.3988/jcn.2012.8.1.65
   Berger C, 2009, J BONE MINER RES, V24, P361, DOI 10.1359/JBMR.081004
   Bernard S, 2006, ONCOLOGIST, V11, P126, DOI 10.1634/theoncologist.11 2 126
   Chen LR, 2014, INT J GERONTOL, V8, P183, DOI 10.1016/j.ijge.2014.06.001
   Cooper MS, 2011, BEST PRACT RES CL EN, V25, P975, DOI 10.1016/j.beem.2011.07.001
   Emkey GR, 2014, BEST PRACT RES CL EN, V28, P911, DOI 10.1016/j.beem.2014.07.002
   Feng S, 2013, CURR DRUG METAB, V14, P921
   Fitzpatrick LA, 2004, EPILEPSY BEHAV, V5, pS3, DOI 10.1016/j.yebeh.2003.11.026
   Flockhart, 2007, DRUG INTERACTIONS FL
   HEIMARK LD, 1992, CLIN PHARMACOL THER, V51, P398, DOI 10.1038/clpt.1992.39
   KAZMIER FJ, 1976, MAYO CLIN PROC, V51, P782
   Meyer UA, 2000, LANCET, V356, P1667, DOI 10.1016/S0140 6736(00)03167 6
   Michalets EL, 1998, PHARMACOTHERAPY, V18, P84
   Pascussi JM, 2005, J CLIN INVEST, V115, P177, DOI 10.1172/JCI200521867
   Robien K, 2013, NUTR CLIN PRACT, V28, P194, DOI 10.1177/0884533612467824
   Sattui SE, 2014, NAT REV ENDOCRINOL, V10, P592, DOI 10.1038/nrendo.2014.125
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   SLAUGHTER RL, 1995, ANN PHARMACOTHER, V29, P619, DOI 10.1177/106002809502900612
   Soriano R, 2014, BEST PRACT RES CL EN, V28, P885, DOI 10.1016/j.beem.2014.09.004
   Wang ZC, 2013, J BONE MINER RES, V28, P1101, DOI 10.1002/jbmr.1839
   Wilkinson GR, 2005, NEW ENGL J MED, V352, P2211, DOI 10.1056/NEJMra032424
   Zhou SF, 2009, CURR MED CHEM, V16, P3480, DOI 10.2174/092986709789057635
NR 22
TC 0
Z9 0
U1 0
U2 1
PU TAIWAN SOC GERIATRIC EMERGENCY & CRITICAL CARE MEDICINE TSGECM
PI TAIPEI
PA 12F 14, NO 42, SEC 1, MINSHENG E RD, ZHONGSHAN DIST, TAIPEI, 104, TAIWAN
SN 1873 9598
EI 1873 958X
J9 INT J GERONTOL
JI Int. J. Gerontol.
PD OCT
PY 2019
SI SI
BP S29
EP S32
DI 10.6890/IJGE.201910/SP.0004
PG 4
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA JP6UB
UT WOS:000498397200014
DA 2025 08 17
ER

PT J
AU Liu, XL
   Li, F
   Dong, ZL
   Gu, C
   Mao, DS
   Chen, JQ
   Luo, L
   Huang, YT
   Xiao, J
   Li, ZC
   Liu, Z
   Yang, Y
AF Liu, Xueliang
   Li, Fan
   Dong, Ziliang
   Gu, Chao
   Mao, Dongsheng
   Chen, Jingqi
   Luo, Lei
   Huang, Yuting
   Xiao, Jie
   Li, Zhanchun
   Liu, Zhuang
   Yang, Yu
TI Metal polyDNA nanoparticles reconstruct osteoporotic microenvironment
   for enhanced osteoporosis treatment
SO SCIENCE ADVANCES
LA English
DT Article
ID HERRING SPERM DNA; BONE; OSTEOCLASTOGENESIS; APTAMERS; DELIVERY; CELLS
AB Current clinical approaches to osteoporosis primarily target osteoclast biology, overlooking the synergistic role of bone cells, immune cells, cytokines, and inorganic components in creating an abnormal osteoporotic microenvironment. Here, metal polyDNA nanoparticles (Ca polyCpG MDNs) composed of Ca2+ and ultralong single stranded CpG sequences were developed to reconstruct the osteoporotic microenvironment and suppress osteoporosis. Ca polyCpG MDNs can neutralize osteoclast secreted hydrogen ions, provide calcium repletion, promote remineralization, and repair bone defects. Besides, the immune adjuvant polyCpG in MDNs could induce the secretion of osteoclastogenesis inhibitor interleukin 12 and reduce the expression of osteoclast function effector protein to inhibit osteoclast differentiation, further reducing osteoclast mediated bone resorption. PPi(4 ) generated during the rolling circle amplification reaction acts as bisphosphonate analog and enhances bone targeting of Ca polyCpG MDNs. In ovariectomized mouse and rabbit models, Ca polyCpG MDNs prevented bone resorption and promoted bone repair by restoring the osteoporotic microenvironment, providing valuable insights into osteoporosis therapy.
C1 [Liu, Xueliang; Gu, Chao; Mao, Dongsheng; Chen, Jingqi; Luo, Lei; Huang, Yuting; Yang, Yu] Shanghai Jiao Tong Univ, Renji Hosp, Inst Mol Med IMM, Sch Med, Shanghai 200240, Peoples R China.
   [Li, Fan; Li, Zhanchun] Soochow Univ, Inst Funct Nano & Soft Mat Lab FUNSOM, Suzhou 215123, Jiangsu, Peoples R China.
   [Dong, Ziliang; Liu, Zhuang] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Orthopaed Surg, Shanghai 200127, Peoples R China.
   [Gu, Chao] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Anesthesiol, Shanghai 200127, Peoples R China.
   [Xiao, Jie] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai 200433, Peoples R China.
C3 Shanghai Jiao Tong University; Soochow University   China; Shanghai Jiao
   Tong University; Shanghai Jiao Tong University; Tongji University
RP Yang, Y (通讯作者)，Shanghai Jiao Tong Univ, Renji Hosp, Inst Mol Med IMM, Sch Med, Shanghai 200240, Peoples R China.; Li, ZC (通讯作者)，Soochow Univ, Inst Funct Nano & Soft Mat Lab FUNSOM, Suzhou 215123, Jiangsu, Peoples R China.; Liu, Z (通讯作者)，Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Orthopaed Surg, Shanghai 200127, Peoples R China.; Xiao, J (通讯作者)，Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai 200433, Peoples R China.
EM yuyang@shsmu.edu.cn; zliu@suda.edu.cn; lzctgzyyx@163.com;
   applexiaomz@163.com
RI Yang, Yu/GYJ 1931 2022; Dong, Ziliang/AEH 7615 2022; Liu,
   Zhuang/H 4352 2011
OI Yang, Yu/0000 0002 4518 3299; Mao, Dongsheng/0000 0002 3881 0418; Xiao,
   Jie/0000 0001 5416 4754; Gu, Chao/0009 0000 3537 5089; Jingqi,
   Chen/0000 0002 5099 8978
FU National Research Programs of China [2022YFA1206500]; National Natural
   Science Foundation of China [22277072, 22107065]; Shanghai Key
   Laboratory for Nucleic Acid Chemistry and Nanomedicine, and Innovative
   research team of high level local universities in Shanghai [2021ZYB009,
   2021ZYB003]
FX This work was supported by grants from the National Research Programs of
   China (no. 2022YFA1206500), the National Natural Science Foundation of
   China (nos. 22277072 and 22107065) and "Clinic Plus" Outstanding Project
   (nos. 2021ZYB009 and 2021ZYB003) from Shanghai Key Laboratory for
   Nucleic Acid Chemistry and Nanomedicine, and Innovative research team of
   high level local universities in Shanghai.& nbsp;
CR Amcheslavsky A, 2006, J CELL PHYSIOL, V207, P244, DOI 10.1002/jcp.20563
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bunka DHJ, 2006, NAT REV MICROBIOL, V4, P588, DOI 10.1038/nrmicro1458
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0193 z
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Dou C, 2018, ADV SCI, V5, DOI 10.1002/advs.201700578
   Farokhi M, 2018, BIOTECHNOL ADV, V36, P68, DOI 10.1016/j.biotechadv.2017.10.001
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Fernandes TJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073266
   Fonseca H, 2014, SPORTS MED, V44, P37, DOI 10.1007/s40279 013 0100 7
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Guo YX, 2021, ADV MATER, V33, DOI 10.1002/adma.202007356
   Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915
   Jin FJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 23642 7
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim HD, 2017, BIOMATERIALS, V112, P31, DOI 10.1016/j.biomaterials.2016.10.009
   Kim H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22565 7
   Kitao T, 2017, CHEM SOC REV, V46, P3108, DOI 10.1039/c7cs00041c
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Lee JW, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00134 w
   Li BE, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 28205 3
   Li MY, 2019, ANGEW CHEM INT EDIT, V58, P1350, DOI 10.1002/anie.201810735
   Li SP, 2018, NAT BIOTECHNOL, V36, P258, DOI 10.1038/nbt.4071
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Mendes RF, 2020, CHEM SOC REV, V49, P9121, DOI 10.1039/d0cs00883d
   Michalski MN, 2017, PHARMACOL THERAPEUT, V174, P43, DOI 10.1016/j.pharmthera.2017.02.017
   Mora Raimundo P, 2019, ACS NANO, V13, P5451, DOI 10.1021/acsnano.9b00241
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Nair AK, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2720
   Pang YC, 2020, NANO LETT, V20, P829, DOI 10.1021/acs.nanolett.9b02916
   Patel MN, 2012, SPECTROCHIM ACTA A, V97, P66, DOI 10.1016/j.saa.2012.05.037
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Sun WJ, 2015, ANGEW CHEM INT EDIT, V54, P12029, DOI 10.1002/anie.201506030
   Thirukonda GJ, 2016, J BONE MINER METAB, V34, P395, DOI 10.1007/s00774 015 0683 1
   Tian LL, 2018, ACS NANO, V12, P11541, DOI 10.1021/acsnano.8b06699
   Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584 021 00682 3
   Wang W, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01277 0
   Wu Andy C, 2013, Bonekey Rep, V2, P373, DOI 10.1038/bonekey.2013.107
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Xiong L, 2015, P NATL ACAD SCI USA, V112, P3487, DOI 10.1073/pnas.1419714112
   Xue LL, 2022, J AM CHEM SOC, V144, P9926, DOI 10.1021/jacs.2c02706
   Yang J, 2020, SMALL, V16, DOI 10.1002/smll.201906846
   Yang Y, 2022, NANO LETT, V22, P2826, DOI 10.1021/acs.nanolett.1c04888
   Yang Y, 2018, NANO LETT, V18, P6867, DOI 10.1021/acs.nanolett.8b02732
   Yao M, 2009, J IMMUNOL, V183, P1751, DOI 10.4049/jimmunol.0900249
   Yao SS, 2019, ADV SCI, V6, DOI 10.1002/advs.201900683
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
   Yu P, 2021, J CONTROL RELEASE, V338, P486, DOI 10.1016/j.jconrel.2021.08.056
   Yu WW, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01844 x
   Zannetti C, 2014, J IMMUNOL, V193, P3398, DOI 10.4049/jimmunol.1400249
   Zeng YZ, 2019, ACTA BIOMATER, V93, P152, DOI 10.1016/j.actbio.2019.01.060
   Zhang DW, 2018, BIOACT MATER, V3, P129, DOI 10.1016/j.bioactmat.2017.08.004
   Zhao HX, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120591
   Zhao R, 2022, BIOACT MATER, V17, P379, DOI 10.1016/j.bioactmat.2022.01.007
   Zhong WY, 2003, SPECTROCHIM ACTA A, V59, P1281, DOI 10.1016/S1386 1425(02)00301 3
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
   Zhou Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abl6432
   Zou Z, 2021, ANGEW CHEM INT EDIT, V60, P22970, DOI 10.1002/anie.202110404
NR 68
TC 49
Z9 54
U1 23
U2 195
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375 2548
J9 SCI ADV
JI Sci. Adv.
PD AUG
PY 2023
VL 9
IS 31
AR eadf3329
DI 10.1126/sciadv.adf3329
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA O1QK9
UT WOS:001041633500014
PM 37531423
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, PQ
   Tan, S
   Mendel, M
   Murrills, R
   Bhat, B
   Schlag, B
   Samuel, R
   Matteo, J
   de la Rosa, R
   Howes, K
   Reik, A
   Case, C
   Bex, F
   Young, K
   Gregory, P
AF Liu, PQ
   Tan, S
   Mendel, M
   Murrills, R
   Bhat, B
   Schlag, B
   Samuel, R
   Matteo, J
   de la Rosa, R
   Howes, K
   Reik, A
   Case, C
   Bex, F
   Young, K
   Gregory, P
TI Isogenic human cell lines for drug discovery: Regulation of target gene
   expression by engineered zinc finger protein transcription factors
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Article
DE zinc finger protein; high throughput screening; G protein coupled
   receptors; isogenic cell lines
ID HORMONE RELATED PROTEIN; OSTEOBLAST LIKE CELLS; PEPTIDE RECEPTOR GENE;
   PARATHYROID HORMONE; CRYSTAL STRUCTURE; COUPLED RECEPTOR;
   MAMMALIAN CELLS; DNA RECOGNITION; AGONIST; IDENTIFICATION
AB Isogenic cell lines differing only in the expression of the protein of interest provide the ideal platform for cell based screening. However, related natural lines differentially expressing the therapeutic target of choice are rare. Here the authors report a strategy for drug screening employing isogenic human cell lines in which the expression of the target protein is regulated by a gene specific engineered zinc finger protein (ZFP) transcription factor (TF). To demonstrate this approach, a ZFP TF activator of the human parathyroid hormone receptor 1 (PTHR1) gene was identified and introduced into HEK293 cells ( negative for PTHR1). Following induction of ZFP TF expression, this cell line produced functional PTHR1 protein, resulting in a robust and ligand specific cyclic adenosine monophosphate ( cAMP) response. Reciprocally, the natural expression of PTHR1 observed in SAOS2 cells was dramatically reduced by the introduction of the appropriate PTHR1 specific ZFP TF repressor. Moreover, this ZFP driven PTHR1 repression selectively eliminated the functional cAMP response invoked by known ligands of PTHR1. These data establish ZFP TF generated isogenic lines as a general approach for the identification of therapeutic agents specific for the target gene of interest.
C1 Sangamo Biosci Inc, Point Richmond Tech Ctr, Richmond, CA 94804 USA.
   Wyeth Ayerst Res, Womens Hlth & Bone, Collegeville, PA USA.
   Wyeth Ayerst Res, Neurosci, Princeton, NJ 08543 USA.
C3 Sangamo Therapeutics, Inc.; Pfizer; Wyeth; Pfizer USA; Pfizer; Pfizer
   USA; Wyeth
RP Sangamo Biosci Inc, Point Richmond Tech Ctr, 501 Canal Blvd,Suite A100, Richmond, CA 94804 USA.
EM pgregory@sangamo.com
RI ; Bhat, Badekai/H 6910 2017; Gregory, Philip/AEI 6119 2022
OI Gregory, Philip/0000 0001 9249 2468; Howes,
   Katherine/0009 0004 8804 6907
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202 135
   Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081
   Bettoun JD, 1998, J CLIN INVEST, V102, P958, DOI 10.1172/JCI3678
   Bettoun JD, 1997, J CLIN ENDOCR METAB, V82, P1031, DOI 10.1210/jc.82.4.1031
   Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500
   COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460 2075.1989.tb08361.x
   FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0
   Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043 2760(01)00409 X
   Hoare SRJ, 2000, J PHARMACOL EXP THER, V295, P761
   Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323
   Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087
   Jobert AS, 1996, MOL ENDOCRINOL, V10, P1066, DOI 10.1210/me.10.9.1066
   JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941
   Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200
   Liu PQ, 2004, J BIOMOL SCREEN, V9, P44, DOI 10.1177/1087057103260115
   Liu Q, 2002, J BIOL CHEM, V277, P3850, DOI 10.1074/jbc.M110669200
   Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846
   Manen D, 1998, GENE, V218, P49, DOI 10.1016/S0378 1119(98)00386 2
   Manen D, 2000, J CLIN ENDOCR METAB, V85, P3376, DOI 10.1210/jc.85.9.3376
   MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nemeth EF, 2002, CURR PHARM DESIGN, V8, P2077, DOI 10.2174/1381612023393387
   NISSENSON RA, 1993, RECEPTOR, V3, P193
   Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313
   PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256
   Rankin W, 1997, CANCER, V80, P1564, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1564::AID CNCR6>3.3.CO;2 H
   REBAR EJ, 2002, NAT MED, V4, P4
   Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802
   RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293 56
   RUBEN SM, 1991, SCIENCE, V254, P11, DOI 10.1126/science.1925549
   SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0
   SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349
   SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014 5793(94)00878 7
   Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960 9822(02)01391 X
   Sullivan E, 1999, METH MOL B, V114, P125
   Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100
   Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241
   USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455
   Yao F, 1998, HUM GENE THER, V9, P1939, DOI 10.1089/hum.1998.9.13 1939
   Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041 5049.2001
NR 41
TC 12
Z9 14
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087 0571
EI 1552 454X
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD JUN
PY 2005
VL 10
IS 4
BP 304
EP 313
DI 10.1177/1087057104272663
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA 930FD
UT WOS:000229400300002
PM 15964931
OA hybrid
DA 2025 08 17
ER

PT J
AU Pepe, J
   Cipriani, C
   Cantatore, FP
   Fabbri, A
   Pola, E
   Vinicola, V
   Raimo, O
   Biamonte, F
   Pascone, R
   Ferrara, C
   Minisola, S
AF Pepe, J.
   Cipriani, C.
   Cantatore, F. P.
   Fabbri, A.
   Pola, E.
   Vinicola, V.
   Raimo, O.
   Biamonte, F.
   Pascone, R.
   Ferrara, C.
   Minisola, S.
TI The effect of parathyroid hormone (1 84) treatment on serum bone
   morphogenetic protein 4 and vascular endothelial growth factor in
   postmenopausal women with established osteoporosis
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE Parathyroid hormone 1 84; Bone morphogenetic protein 4; Vessel
   endothelial growth factor; Osteoporosis
ID DIFFERENTIATION; OSTEOBLASTS; THERAPY; TARGETS; CELLS; VEGF; PTH
AB Purpose To investigate the effect of 18 months' parathyroid hormone 1 84 (PTH 1 84) treatment on serum levels of bone morphogenetic protein 4 (BMP4) and vascular endothelial growth factor (VEGF), in postmenopausal women with established osteoporosis.
   Methods Thirty seven postmenopausal women with osteoporosis (mean age 72.9 +/  8.1 years old) and 23 healthy controls (mean age 68.9 +/  9.9 years old) were enrolled. Patients were treated with daily subcutaneous injections of PTH (1 84) 100 mcg for 18 months, plus calcium 1 gr and vitamin D 800 IU per os daily. Blood samples were taken every 6 months during the study.
   Results At baseline, there were no differences considering anthropometric parameters, co morbidities, current medications used between patients and controls. Mean serum VEGF levels were significantly higher in osteoporotic patients compared to controls (436.7 +/  259.7 vs. 260.3 +/  184.3 pg/ml, p = 0.006), while there were no differences in mean serum values of BMP4 (5.3 +/  1.7 vs. 5.7 +/  1.6 pg/ml, p = 0.40). Serum VEGF levels increased by approximately 20% after 12 months of PTH (1 84) treatment compared to baseline (p = 0.03) and by 22% after 18 months (p = 0.01). A significant increase of 10% in mean serum BMP4 levels was observed after 18 months of PTH (1 84) treatment compared to baseline (p = 0.02). In the control group we found no differences after 18 months compared to baseline in BMP4 (5.7 +/  1.6 vs. 6.0 +/  1.5 pg/ml, p = 0.53) and VEGF (260.3 +/  184.3 vs. 257.4 +/  107.1 pg/ ml, p = 0.94).
   Conclusions PTH (1 84) treatment increased serum levels of VEGF and BMP4 in postmenopausal women with severe osteoporosis.
C1 [Pepe, J.; Cipriani, C.; Raimo, O.; Biamonte, F.; Minisola, S.] Sapienza Univ Rome, Dept Internal Med & Med Disciplines, Viale Policlin 155, I 00161 Rome, Italy.
   [Cantatore, F. P.] Univ Foggia, Rheumatol Unit, Foggia, Italy.
   [Fabbri, A.] Univ Roma Tor Vergata, ASL Roma 2, CTO Andrea Alesini Hosp, Rome, Italy.
   [Pola, E.] Policlin Gemelli Hosp, Rome, Italy.
   [Vinicola, V.] IRCCS Santa Lucia Fdn, Rehabil Hosp, Rome, Italy.
   [Pascone, R.] Sapienza Univ, Dept Pediat, Rome, Italy.
   [Ferrara, C.] Sapienza Univ Rome, Sect Hlth Stat, Dept Publ Hlth & Infect Dis, Rome, Italy.
C3 Sapienza University Rome; University of Foggia; University of Rome Tor
   Vergata; Ospedale Sandro Pertini; Catholic University of the Sacred
   Heart; IRCCS Policlinico Gemelli; IRCCS Santa Lucia; Sapienza University
   Rome; Sapienza University Rome
RP Pepe, J (通讯作者)，Sapienza Univ Rome, Dept Internal Med & Med Disciplines, Viale Policlin 155, I 00161 Rome, Italy.
EM jessica.pepe@uniroma1.it
RI FERRARA, CARLA/Q 4641 2016; Cipriani, Cristiana/K 9497 2016; Ferrara,
   Carla/Q 4641 2016; Fortunato, Francesca/S 1322 2018
OI FERRARA, CARLA/0000 0002 8628 829X; Cipriani,
   Cristiana/0000 0002 0141 1202; Cipriani, Chiara/0000 0001 7085 4966; 
CR Adler RA, 2016, J ENDOCRINOL INVEST, V39, P719, DOI 10.1007/s40618 016 0437 5
   Biver E, 2013, CYTOKINE GROWTH F R, V24, P69, DOI 10.1016/j.cytogfr.2012.06.003
   Brunner S, 2007, AM J PHYSIOL ENDOC M, V293, pE1670, DOI 10.1152/ajpendo.00287.2007
   Çebi H, 2010, EKLEM HAST CERRAHISI, V21, P91
   Christodoulakos G, 2004, EUR J ENDOCRINOL, V151, P187, DOI 10.1530/eje.0.1510187
   Costa N, 2009, CYTOKINE, V46, P376, DOI 10.1016/j.cyto.2009.03.012
   Cusano NE, 2014, J CLIN ENDOCR METAB, V99, pE2025, DOI 10.1210/jc.2014 1500
   Dincel VE, 2014, ACTA ORTHOP BELG, V80, P216
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5056, DOI 10.1210/jc.2010 0720
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Lasco A, 2011, OSTEOPOROSIS INT, V22, P299, DOI 10.1007/s00198 010 1222 5
   Lewiecki EM, 2016, J ENDOCRINOL INVEST, V39, P491, DOI 10.1007/s40618 016 0442 8
   Luppen CA, 2008, GROWTH FACTORS, V26, P226, DOI 10.1080/08977190802277880
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Paglia F, 2001, CLIN CHEM, V47, P1314
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Piemonte S, 2012, J ENDOCRINOL INVEST, V35, P866, DOI 10.3275/8522
   Prisby R, 2013, BONE, V54, P68, DOI 10.1016/j.bone.2013.01.028
   Pufe T, 2003, BONE, V33, P869, DOI 10.1016/j.bone.2003.08.002
   Russo S, 2011, CALCIFIED TISSUE INT, V89, P252, DOI 10.1007/s00223 011 9513 1
   Senel K, 2013, ARCH MED SCI, V9, P709, DOI 10.5114/aoms.2013.36896
   Street, 2009, J ORTHOP SURG RES, V16, P4, DOI [10.1186/1749 799X 4 19, DOI 10.1186/1749 799X 4 19]
   Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125
NR 27
TC 11
Z9 12
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1720 8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD JUN
PY 2017
VL 40
IS 6
BP 663
EP 667
DI 10.1007/s40618 017 0636 8
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EV8ZI
UT WOS:000402073400012
PM 28238166
DA 2025 08 17
ER

PT J
AU Wang, LQ
   Li, Y
   Xie, SH
   Huang, JM
   Song, KP
   He, CQ
AF Wang, Liqiong
   Li, Yi
   Xie, Suhang
   Huang, Jinming
   Song, Kangping
   He, Chengqi
TI Effects of Pulsed Electromagnetic Field Therapy at Different Frequencies
   on Bone Mass and Microarchitecture in Osteoporotic Mice
SO BIOELECTROMAGNETICS
LA English
DT Article
DE animal model; frequency; osteoporosis; pulsed electromagnetic field
ID POSTMENOPAUSAL OSTEOPOROSIS; STRONTIUM RANELATE; SIGNALING PATHWAY;
   TNF ALPHA; STIMULATION; EXPRESSION; STRENGTH; REPAIR
AB A pulsed electromagnetic field (PEMF) can promote osteogenesis. However, studies have shown variation in the signal characteristics in terms of waveform type, intensity, frequency, and treatment duration. Among the factors that affect electromagnetic fields, frequency plays a major role. However, few studies have investigated the effects of PEMF at different frequencies in osteoporotic mice. Therefore, our objective was to determine the effect of PEMF frequency in osteoporotic mice. Forty 3 month old female mice were randomly divided into the following five groups: sham, OVX, and OVX followed by 1.6 mT PEMF exposure groups (8 Hz, 50 Hz, and 75 Hz, 1.6 mT). The PEMF was applied for 1 h/day, 7 days/week, for 4 weeks. After 4 weeks, the micro computed tomography showed that PEMF with (50 and 75 Hz) ameliorated the deterioration of bone microarchitecture. Improvements in the bone histological analysis were identified for PEMF with 50 and 75 Hz groups compared with the ovariectomy (OVX) controls. Osteoclast numbers were decreased in PEMF with (50 and 75 Hz). Moreover, the real time PCR demonstrated PEMF with (50 and 75 Hz) significantly promoted the expression of the osteoblast related genes (ALP, OCN, Runx2), and increased the serum PINP. PEMF with (50 and 75 Hz) exerted significant inhibitory effects on the osteoclast related mRNA expression (CTSK, NFATc1, TRAP) and bone resorption markers CTX I and IL 1 beta. Taken together, our results showed that PEMF at 50 and 75 Hz with 1.6 mT significantly ameliorate the deterioration of bone microarchitecture in OVX mice. The inhibitory effect of PEMF may be associated with IL 1 beta inhibition.
C1 [Wang, Liqiong; Li, Yi; Xie, Suhang; Huang, Jinming; Song, Kangping; He, Chengqi] Sichuan Univ, West China Hosp, Rehabil Med Ctr, 37 Guoxue Xiang, Chengdu 610041, Peoples R China.
   [Wang, Liqiong; Li, Yi; Xie, Suhang; Huang, Jinming; Song, Kangping; He, Chengqi] Sichuan Univ, West China Hosp, Rehabil Key Lab Sichuan Prov, Chengdu, Peoples R China.
   [Wang, Liqiong; He, Chengqi] Sichuan Univ, Inst Disaster Management & Reconstruct, Hong Kong Polytech Univ, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Hong Kong Polytechnic
   University; Sichuan University
RP He, CQ (通讯作者)，Sichuan Univ, West China Hosp, Rehabil Med Ctr, 37 Guoxue Xiang, Chengdu 610041, Peoples R China.
EM hxkfhcq2015@126.com
RI ; xie, suhang/KGQ 4191 2024
OI Jinming, Huang/0000 0003 1597 7976; He, Chengqi/0000 0002 5349 0571;
   XIE, Su hang/0000 0001 7724 5936
FU National Natural Science Foundation of China [81572236]
FX National Natural Science Foundation of China, grant number: 81572236.
CR Albus U., 2012, Guide for the care and use of laboratory animals, V46, P267, DOI DOI 10.1258/LA.2012.150312
   Ardawi MSM, 2016, BONE, V83, P127, DOI 10.1016/j.bone.2015.10.017
   Assiotis A, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749 799X 7 24
   Barak S, 2016, CLIN ORAL IMPLAN RES, V27, P935, DOI 10.1111/clr.12661
   BASSETT CAL, 1977, CLIN ORTHOP RELAT R, P128
   BASSETT CAL, 1974, SCIENCE, V184, P575
   CANE V, 1993, J ORTHOPAED RES, V11, P664, DOI 10.1002/jor.1100110508
   Catalano A, 2018, BONE, V116, P42, DOI 10.1016/j.bone.2018.07.010
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P431, DOI 10.1002/bem.10118
   Chaugule S, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00608
   Crocetti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072944
   Crowe MJ, 2003, SPINE, V28, P2660, DOI 10.1097/01.BRS.0000099385.46102.0D
   Gallacher SJ, 2010, CALCIFIED TISSUE INT, V87, P469, DOI 10.1007/s00223 010 9420 x
   Ganesan K, 2009, INDIAN J EXP BIOL, V47, P939
   Hannay G, 2005, BIOELECTROMAGNETICS, V26, P670, DOI 10.1002/bem.20166
   Hwang YH, 2016, MOLECULES, V21, DOI 10.3390/molecules21010074
   Jing D, 2014, J BONE MINER RES, V29, P2250, DOI 10.1002/jbmr.2260
   Jing D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079377
   KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Lewiecki EM, 2009, J WOMENS HEALTH, V18, P1615, DOI 10.1089/jwh.2008.1086
   Li JJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11090 7
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Liu HF, 2013, BIOELECTROMAGNETICS, V34, P323, DOI 10.1002/bem.21770
   Luo F, 2012, ORTHOPEDICS, V35, pE526, DOI 10.3928/01477447 20120327 11
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   Massari L, 2006, J BONE JOINT SURG AM, V88A, P56, DOI 10.2106/JBJS.F.00536
   Mattei MD., 2010, BIOELECTROMAGNETICS, V20, P177
   Miyamoto H, 2019, BIOELECTROMAGNETICS, V40, P412, DOI 10.1002/bem.22207
   Osti L, 2015, ORTHOPEDICS, V38, pE223, DOI 10.3928/01477447 20150305 61
   Peng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112744
   RIGGS BL, 1992, NEW ENGL J MED, V327, P620
   RODAN GA, 1992, BONE, V13, pS3, DOI 10.1016/S8756 3282(09)80003 3
   Shen WW, 2010, BIOELECTROMAGNETICS, V31, P113, DOI 10.1002/bem.20535
   Song ZH, 2018, INT J CLIN EXP PATHO, V11, P1784
   Su Shu Jem, 2013, Evid Based Complement Alternat Med, V2013, P594857, DOI 10.1155/2013/594857
   Tchernof A, 1998, OBES RES, V6, P246, DOI 10.1002/j.1550 8528.1998.tb00344.x
   Tsai MT, 2007, BIOELECTROMAGNETICS, V28, P519, DOI 10.1002/bem.20336
   Tsuji M, 2009, J BONE MINER METAB, V27, P673, DOI 10.1007/s00774 009 0088 0
   Unnanuntana A, 2010, J BONE JOINT SURG AM, V92A, P743, DOI 10.2106/JBJS.I.00919
   Uzunca K, 2007, CLIN RHEUMATOL, V26, P69, DOI 10.1007/s10067 006 0247 9
   Veronesi F, 2014, J ORTHOP RES, V32, P677, DOI 10.1002/jor.22584
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Wang P, 2017, BIOELECTROMAGNETICS, V38, P602, DOI 10.1002/bem.22070
   Wang QS, 2018, J ORTHOP RES, V36, P1415, DOI 10.1002/jor.23777
   Willson T, 2015, CLIN EPIDEMIOL, V7, P65, DOI 10.2147/CLEP.S40966
   Xia CJ, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110170
   Zhang Y, 2006, J BIOL PHYS, V32, P1, DOI 10.1007/s10867 006 6901 2
   Zhou J, 2017, BIOELECTROMAGNETICS, V38, P31, DOI 10.1002/bem.22012
   Zhou J, 2013, RHEUMATOL INT, V33, P1135, DOI 10.1007/s00296 012 2499 9
   Zhou J, 2012, ARCH MED RES, V43, P274, DOI 10.1016/j.arcmed.2012.06.002
   Zhou XD, 2019, PHYTOMEDICINE, V63, DOI 10.1016/j.phymed.2019.153012
   Zhu SY, 2018, J MOL ENDOCRINOL, V60, P185, DOI 10.1530/JME 17 0218
NR 53
TC 13
Z9 15
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0197 8462
EI 1521 186X
J9 BIOELECTROMAGNETICS
JI Bioelectromagnetics
PD SEP
PY 2021
VL 42
IS 6
BP 441
EP 454
DI 10.1002/bem.22344
EA JUN 2021
PG 14
WC Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Biophysics
GA UC4AB
UT WOS:000657463600001
PM 34082467
DA 2025 08 17
ER

PT J
AU Gabelli, SB
   McLellan, JS
   Montalvetti, A
   Oldfield, E
   Docampo, R
   Amzel, LM
AF Gabelli, SB
   McLellan, JS
   Montalvetti, A
   Oldfield, E
   Docampo, R
   Amzel, LM
TI Structure and mechanism of the farnesyl diphosphate synthase from
   Trypanosoma cruza:: Implications for drug design
SO PROTEINS STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE farnesyl diphosphate synthase; geranyl diphosphate; mevalonate pathway;
   bisphosphonate; risedronate; alendronate; conformational change;
   Trypanosoma cruzi; Chagas disease
ID X RAY DIFFRACTION; SUBSTRATE BINDING; POTENT INHIBITORS; IN VITRO;
   BISPHOSPHONATES; CRYSTALLIZATION; RISEDRONATE; GROWTH
AB Typanosoma cruzi, the causative agent of Chagas disease, has recently been shown to be sensitive to the action of the bisphosphonates currently used in bone resorption therapy. These compounds target the mevalonate pathway by inhibiting farnesyl diphosphate synthase (farnesyl pyrophosphate synthase, FPPS), the enzyme that condenses the diphosphates of C 5 alcohols (isopentenyl and dimethylallyl) to form C 10 and C 15 diphosphates (geranyl and farnesyl). The structures of the T. cruzi FPPS (TcFPPS) alone and in two complexes with substrates and inhibitors reveal that following binding of the two substrates and three Mg2+ ions, the enzyme undergoes a conformational change consisting of a hinge like closure of the binding site. In this conformation, it would be possible for the enzyme to bind a bisphosphonate inhibitor that spans the sites usually occupied by dimethylallyl diphosphate (DMAPP) and the homoallyl moiety of isopentenyl diphosphate. This observation may lead to the design of new, more potent anti trypanosomal bisphosphonates, because existing FPPS inhibitors occupy only the DMAPP site. In addition, the structures provide an important mechanistic insight: after its formation, geranyl diphosphate can swing without leaving the enzyme, from the product site to the substrate site to participate in the synthesis of farnesyl diphosphate.
C1 Johns Hopkins Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.
   Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA.
   Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA.
   Univ Georgia, Dept Cellular Biol, Athens, GA 30606 USA.
   Univ Georgia, Ctr Trop & Global Emerging Dis, Athens, GA 30606 USA.
   Funcac Inst Leloir, Buenos Aires, DF, Argentina.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Illinois
   System; University of Illinois Urbana Champaign; University of Illinois
   System; University of Illinois Urbana Champaign; University of Illinois
   System; University of Illinois Urbana Champaign; University System of
   Georgia; University of Georgia; University System of Georgia; University
   of Georgia; Leloir Institute
RP Johns Hopkins Sch Med, Dept Biophys & Biophys Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.
EM mario@neruda.med.jhmi.edu
RI ; McLellan, Jason/A 6874 2010; Gabelli, Sandra/A 3705 2008
OI McLellan, Jason/0000 0003 3991 542X; Gabelli,
   Sandra/0000 0003 1205 5204; Amzel, L. Mario/0000 0002 0129 9572
FU NIGMS NIH HHS [GM65307, GM066895] Funding Source: Medline
CR BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112
   Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140 6736(03)14694 6
   BRENER Z, 1979, PHARMACOL THERAPEUT, V7, P71, DOI 10.1016/0163 7258(79)90025 1
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
   CORNFORTH JW, 1966, J BIOL CHEM, V241, P3970
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   KING HL, 1977, BIOCHEMISTRY US, V16, P3815, DOI 10.1021/bi00636a015
   Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Mao JH, 2004, ACTA CRYSTALLOGR D, V60, P1863, DOI 10.1107/S0907444904020633
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   POULTER CD, 1977, BIOCHEMISTRY US, V16, P5470, DOI 10.1021/bi00644a012
   REED BC, 1976, BIOCHEMISTRY US, V15, P3739, DOI 10.1021/bi00662a015
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Szajnman SH, 2003, BIOORG MED CHEM LETT, V13, P3231, DOI 10.1016/S0960 894X(03)00663 2
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018
   Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076 6879(03)74002 6
   Thompson K, 2002, BIOCHEM BIOPH RES CO, V290, P869, DOI 10.1006/bbrc.2001.6289
   Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609
   *WHO, TDR TROP DIS RES
NR 30
TC 130
Z9 147
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0887 3585
EI 1097 0134
J9 PROTEINS
JI Proteins
PD JAN 1
PY 2006
VL 62
IS 1
BP 80
EP 88
DI 10.1002/prot.20754
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 000CN
UT WOS:000234438600008
PM 16288456
DA 2025 08 17
ER

PT J
AU Kang, BK
   Zhu, Z
   Wang, J
   Zhou, J
   Yu, S
   Zhou, XY
   Zhao, ZM
   Xie, AG
   Lu, L
   Yang, J
AF Kang, Bo Kyoung
   Zhu, Zhu
   Wang, Jian
   Zhou, Jia
   Yu, Shun
   Zhou, Xianyu
   Zhao, Zhenmin
   Xie, Aiguo
   Lu, Lin
   Yang, Jun
TI Maintenance of adult stem cells from human minor salivary glands via the
   Wnt signaling pathway
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Human minor salivary gland stem cells; Salivary gland regeneration; Stem
   cell therapy; Organoids
ID SPEMANN ORGANIZER; PROGENITOR CELLS; EXPRESSION; DIFFERENTIATION;
   PROLIFERATION; LOCALIZATION; COMPONENTS; MURINE; NOGGIN
AB Background Xerostomia is a salivary gland dysfunction that negatively impacts the life quality of patients; however, there is no effective treatment for xerostomia. Bioengineered organs, generated using stem cells obtained from newborn salivary glands and ligated injury models, are a new organ transplantation strategy that could be feasible for xerostomia treatment. Reconstruction of salivary gland organoids by seed cells obtained from human minor salivary glands will offer theoretical fundaments and technology support for clinical application and organ regeneration research. Herein, we aimed to propose a new method for culturing and enriching adult human minor salivary gland stem cells in vitro in a three dimensional (3D) environment via Wnt signaling activation.
   Methods Obtained and characterized human minor salivary gland stem cells (hMSGSCs) with self organization ability were 3D cultured to generate organoids. We examined hMSGSCs proliferation and colony formation using MTT (3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide) assays. Telomerase reverse transcriptase staining, flow cytometry, immunofluorescence assay, RNA isolation, RT PCR, and qPCR were performed to assess hMSGSCs structure and the function of reconstructive organoids in vitro.
   Results hMSGSCs showed typical epithelial like characteristics, such as positive for CD49f and cell KRT expression. hMSGSCs served as adult stem cells in salivary glands and could differentiate into acinar and duct cells. Upon the addition of Noggin, CHIR99021, and Wnt3A to the 3D culture system, hMSGSCs showed higher LGR5 expression and decreased AMY1B and MUC5B expression. Therefore, the Wnt and bone morphogenetic protein (BMP) pathways are important in regulating hMSGSCs self organization and differentiation.
   Conclusions We showed that the stem cell properties of hMSGSCs in a 3D culture system can be maintained by activating the Wnt signaling pathway and inhibiting the BMP signaling pathway. Our findings contribute new insights on salivary gland organoid generation in vitro.
C1 [Kang, Bo Kyoung; Zhu, Zhu; Wang, Jian; Zhou, Jia; Zhou, Xianyu; Xie, Aiguo; Lu, Lin; Yang, Jun] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Sch Med, Shanghai 200011, Peoples R China.
   [Kang, Bo Kyoung; Zhu, Zhu] Shanghai Key Lab Tissue Engn, Shanghai 200011, Peoples R China.
   [Yu, Shun] Jiangnan Univ, Affiliated Hosp, Dept Burns & Plast Surg, Wuxi 214041, Peoples R China.
   [Zhao, Zhenmin] Peking Univ 3Rd Hosp, Dept Plast Surg, 49 North Huayuan Rd, Beijing 100191, Peoples R China.
C3 Shanghai Jiao Tong University; Jiangnan University
RP Xie, AG; Lu, L; Yang, J (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Sch Med, Shanghai 200011, Peoples R China.
EM dr.aigo@aliyun.com; lulin_12345@163.com; yj55569@sina.com
RI ; Lu, Lin/KBB 9125 2024
OI Zhou, Xianyu/0000 0003 0959 0011; 
FU Not applicable.
FX Not applicable.
CR Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Chien SY, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040927
   Clark CEJ, 2012, NEUROSIGNALS, V20, P202, DOI 10.1159/000332153
   DARDICK I, 1987, ORAL SURG ORAL MED O, V64, P703, DOI 10.1016/0030 4220(87)90173 3
   Dardick I, 1998, EUR J MORPHOL, V36, P257
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Futaki S, 2003, J BIOL CHEM, V278, P50691, DOI 10.1074/jbc.M304985200
   Gámez B, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00087
   Gomez Puerto MC, 2019, J PATHOL, V247, P9, DOI 10.1002/path.5170
   Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602
   Hai B, 2010, STEM CELLS DEV, V19, P1793, DOI 10.1089/scd.2009.0499
   Hisatomi Y, 2004, HEPATOLOGY, V39, P667, DOI 10.1002/hep.20063
   Holmberg K, 2014, SCIENTOMETRICS, V101, P1027, DOI [10.1007/s11192 014 1229 3, 10.1159/000358776]
   Kaleagasioglu F, 2014, ONCOL REP, V31, P1407, DOI 10.3892/or.2013.2942
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978 0 12 386035 4.00002 1
   Kishi T, 2006, BIOCHEM BIOPH RES CO, V340, P544, DOI 10.1016/j.bbrc.2005.12.031
   Kleinman HK, 2003, CURR OPIN BIOTECH, V14, P526, DOI 10.1016/j.copbio.2003.08.002
   Krause C, 2011, INT J BIOCHEM CELL B, V43, P478, DOI 10.1016/j.biocel.2011.01.007
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Matsumoto S, 2016, DEVELOPMENT, V143, P2311, DOI 10.1242/dev.134486
   Nagle PW, 2020, CELLS BASEL, V9, DOI 10.3390/cells9122649
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Okumura K, 2003, HEPATOLOGY, V38, P104, DOI 10.1053/jhep.2003.50259
   Patel N, 2011, DEV BIOL, V358, P156, DOI 10.1016/j.ydbio.2011.07.023
   Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970
   Plikus M, 2004, AM J PATHOL, V164, P1099, DOI 10.1016/S0002 9440(10)63197 5
   Sato A, 2007, CLONING STEM CELLS, V9, P191, DOI 10.1089/clo.2006.0054
   Sconocchia T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.802346
   Sepúlveda DE, 2008, TISSUE ENG PT A, V14, P1603, DOI [10.1089/ten.tea.2007.0331, 10.1089/tea.2007.0331]
   SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092 8674(92)90316 5
   Sun P, 2010, HISTOCHEM CELL BIOL, V133, P213, DOI 10.1007/s00418 009 0662 5
   Suzuki A, 2021, CELL MOL LIFE SCI, V78, P3299, DOI 10.1007/s00018 020 03741 2
   Whitton A, 2016, J NEUROSURG PEDIATR, V18, P83, DOI 10.3171/2015.12.PEDS15414
   Yin XL, 2014, NAT METHODS, V11, P106, DOI 10.1038/nmeth.2737
   Yoon YJ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30934 z
   Zeng S, 2010, CELL SIGNAL, V22, P888, DOI 10.1016/j.cellsig.2009.12.007
   Zhang C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11880 z
   Zhang HJ, 2014, STEM CELLS, V32, P2267, DOI 10.1002/stem.1715
   Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092 8674(00)80133 6
NR 40
TC 6
Z9 6
U1 7
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD AUG 25
PY 2023
VL 14
IS 1
AR 220
DI 10.1186/s13287 023 03445 x
PG 15
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA Q0DX0
UT WOS:001054309900001
PM 37620905
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Thulin, MH
   Määttä, J
   Linder, A
   Sterbova, S
   Ohlsson, C
   Damber, JE
   Widmark, A
   Persson, E
AF Thulin, Malin Hagberg
   Maatta, Jorma
   Linder, Anna
   Sterbova, Simona
   Ohlsson, Claes
   Damber, Jan Erik
   Widmark, Anders
   Persson, Emma
TI Inhibition of STAT3 prevents bone metastatic progression of prostate
   cancer in vivo
SO PROSTATE
LA English
DT Article
DE bone metastasis; CRPC; Napabucasin; prostate cancer; STAT3
ID MESENCHYMAL STEM CELLS; OSTEOBLASTS; EXPRESSION; MODEL
AB Background Prostate cancer (PC) metastasizes to the skeleton forming predominantly sclerotic lesions, and there is currently no cure for bone metastatic disease. The transcription factor signal transducer and activator of transcription 3 (STAT3) is implicated as a metastatic driver, but its potential as therapeutic target in bone metastasis has not been investigated. In this study, we evaluated for the first time a STAT3 inhibitor, Napabucasin, as a therapeutic option for bone metastatic PC.
   Methods Effects of STAT3 inhibitors, Stattic and Napabucasin, on metastatic potential in PC cells were studied in vitro by assessment of migration capacity, self renewal potential, and tumorsphere formation. For evaluation of the role of STAT3 in initial skeletal establishment of PC cells as well as in progressed castration resistant PC (CRPC) in bone, human VCaP prostate cancer cells were inoculated in the tibia of mice which subsequently were treated with the STAT3 inhibitor Napabucasin. Bone specimens were analyzed using computed tomography (CT), immunohistochemistry, and quantitative polymerase chain reaction.
   Results The small molecule STAT3 inhibitors Stattic and Napabucasin both effectively impaired metastatic potential of PC cells in vitro. Furthermore, treatment with Napabucasin prevented metastatic establishment in tibial bones in vivo and thereby also the tumor induced sclerotic bone response seen in vehicle treated VCaP xenografts. In addition, treatment with Napabucasin of established bone CRPC significantly decreased both tumor burden and tumor induced trabecular bone volume compared with effects seen in vehicle treated animals. Anti mitotic effects were confirmed by decreased Ki67 staining in Napabucasin treated xenografts compared with vehicle treated xenografts. Alterations of gene expression in the femoral bone marrow (BM) niche toward the maintenance of hematopoietic stem cells and the myeloid lineage were demonstrated by quantitative real time polymerase chain reaction and were further reflected by a substantial increase in the number of erythrocytes in BM of Napabucasin treated mice. Furthermore, a unique pattern of STAT3 phosphorylation in osteoblasts/stromal cells surrounding the areas of tumor cells was demonstrated immunohistochemically in bone xenograft models using several different PC cell lines.
   Conclusion Inhibition of STAT3 activity disrupts the bone metastatic niche and targets both the skeletal establishment of PC and advanced bone metastatic CRPC in mice, suggesting STAT3 as a candidate for molecular targeted therapies of skeletal metastatic disease.
C1 [Thulin, Malin Hagberg; Sterbova, Simona; Widmark, Anders; Persson, Emma] Umea Univ, Dept Radiat Sci, Sect Oncol, NUS M31, SE 90185 Umea, Sweden.
   [Thulin, Malin Hagberg; Ohlsson, Claes] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden.
   [Maatta, Jorma] Univ Turku, Inst Biomed, Turku, Finland.
   [Linder, Anna; Damber, Jan Erik] Univ Gothenburg, Sahlgrenska Canc Ctr, Inst Clin Sci, Gothenburg, Sweden.
C3 Umea University; University of Gothenburg; University of Turku;
   University of Gothenburg
RP Persson, E (通讯作者)，Umea Univ, Dept Radiat Sci, Sect Oncol, NUS M31, SE 90185 Umea, Sweden.
EM emma.e.persson@umu.se
RI ; Ohlsson, Claes/AGP 3544 2022; Ohlsson, Claes/HIR 6959 2022; MÃ¤Ã¤ttÃ¤,
   Jorma/HNS 1621 2023
OI Hagberg Thulin, Malin/0000 0002 8673 1247; Linder,
   Anna/0000 0002 9444 1346; Ohlsson, Claes/0000 0002 9633 2805; Persson,
   Emma/0000 0003 4020 1694; Maatta, Jorma/0000 0001 8752 6862
FU Swedish Cancer Foundation [CAN 2015/732]; Lion's Cancer Research
   Foundation [LP 15 2097]; Cancer Research Foundation in Northern Sweden
   [AMP 17 854]; Percy Falk's Foundation for Breast and Prostate Cancer
   Research (MHT); Novo Nordisk Fonden [NNF13OC0005785, NNF14OC0010513,
   NNF18OC0033898, NNF19OC0055250] Funding Source: researchfish
FX The authors acknowledge the late Anette Hansevi at the Centre for Bone
   and Arthritis Research, University of Gothenburg, for excellent
   technical assistance with pQCT measurements. This study was supported by
   grants from The Swedish Cancer Foundation (CAN 2015/732; AW), The Lion's
   Cancer Research Foundation (LP 15 2097; EP), The Cancer Research
   Foundation in Northern Sweden (AMP 17 854; MHT), and the Percy Falk's
   Foundation for Breast and Prostate Cancer Research (MHT2015).
CR Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054
   Azare J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027851
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008 5472.CAN 09 0395
   Chung YJ, 2006, BLOOD, V108, P1208, DOI 10.1182/blood 2006 01 010199
   Cojoc Monica, 2013, Onco Targets Ther, V6, P1347, DOI 10.2147/OTT.S36109
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039
   Don Doncow N, 2017, EUR UROL, V71, P313, DOI 10.1016/j.eururo.2016.06.018
   Gustavsson H, 2005, PROSTATE, V62, P364, DOI 10.1002/pros.20145
   Han ZQ, 2014, ONCOTARGET, V5, P8416, DOI 10.18632/oncotarget.2314
   Horinaga M, 2005, UROLOGY, V66, P671, DOI 10.1016/j.urology.2005.03.066
   Kamran MZ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/421821
   Korenchuk S, 2001, IN VIVO, V15, P163
   Li Jiliang, 2013, JAKSTAT, V2, pe23930, DOI 10.4161/jkst.23930
   Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112
   Masuda M, 2002, CANCER RES, V62, P3351
   Mora LB, 2002, CANCER RES, V62, P6659
   Persson E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01164
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Schulze J, 2010, BONE, V46, P524, DOI 10.1016/j.bone.2009.09.024
   Shiozawa Y, 2012, EXP HEMATOL, V40, P685, DOI 10.1016/j.exphem.2012.05.004
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Taichman RS, 2002, CANCER RES, V62, P1832
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Thulin MH, 2016, MOL CELL ENDOCRINOL, V422, P182, DOI 10.1016/j.mce.2015.11.013
   Thulin MH, 2014, CLIN EXP METASTAS, V31, P269, DOI 10.1007/s10585 013 9626 1
   Zuo DQ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0914 0
NR 29
TC 11
Z9 12
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0270 4137
EI 1097 0045
J9 PROSTATE
JI Prostate
PD JUN
PY 2021
VL 81
IS 8
BP 452
EP 462
DI 10.1002/pros.24125
EA APR 2021
PG 11
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA RP1GG
UT WOS:000637068200001
PM 33822400
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Bosch Barrera, J
   Merajver, SD
   Menéndez, JA
   Van Poznak, C
AF Bosch Barrera, Joaquim
   Merajver, Sofia D.
   Menendez, Javier A.
   Van Poznak, Catherine
TI Direct antitumour activity of zoledronic acid: preclinical and clinical
   data
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Bisphosphonate; Zoledronic acid; Bone metastasis; Mevalonate pathway;
   Translational oncology
ID BREAST CANCER CELLS; NITROGEN CONTAINING BISPHOSPHONATES; LONG TERM
   EFFICACY; IN VITRO; PROSTATE CANCER; BONE METASTASES; LUNG CANCER;
   TUMOR GROWTH; ANTICANCER AGENTS; 3RD GENERATION BISPHOSPHONATE
AB Bisphosphonates (BPs) are widely used in the management of metastatic bone disease to reduce skeletal morbidity. Zoledronic acid (ZA), the most potent BP in clinical use, has demonstrated clinical utility in multiple tumour types. Preclinical data indicate that ZA may have direct antitumour activity, as has been demonstrated preclinically in both in vitro and in vivo experiments. The majority of preclinical studies showing antitumour effects have used high doses of ZA, making it difficult to translate these data to the clinical setting. This review summarises the published data on antitumour effects of ZA in tumour cell lines, mice experiments, and human clinical trials. Translational questions regarding drug dose, dose interval, and sequence with chemotherapy treatment are also addressed.
C1 [Bosch Barrera, Joaquim; Menendez, Javier A.] Dr Josep Trueta Univ Hosp, Catalan Inst Oncol, ES 17007 Girona, Spain.
   [Merajver, Sofia D.; Van Poznak, Catherine] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
C3 Institut Catala d'Oncologia; Universitat de Girona; Girona University
   Hospital Dr. Josep Trueta; University of Michigan System; University of
   Michigan
RP Bosch Barrera, J (通讯作者)，Dr Josep Trueta Univ Hosp, Catalan Inst Oncol, Avda Franca,S N, ES 17007 Girona, Spain.
EM jbosch@iconcologia.net
RI ; MENENDEZ MENENDEZ, JAVIER ABEL/C 6148 2016; MENENDEZ,
   JAVIER/C 6148 2016
OI Bosch Barrera, Joaquim/0000 0002 0893 7821; MENENDEZ MENENDEZ, JAVIER
   ABEL/0000 0001 8733 4561; 
FU Spanish Society of Medical Oncology (Sociedad Espanola de Oncologia
   Medica, Madrid, Spain); Roses against Cancer Foundation (Fundacio Roses
   contra el cancer, Girona, Spain); NIDCR [5K23DE20197 2]; Avon
   Foundation; Breast Cancer Research Foundation
FX Joaquim Bosch Barrera was supported by a grant from the Spanish Society
   of Medical Oncology (Sociedad Espanola de Oncologia Medica, Madrid,
   Spain). Joaquim Bosch Barrera and Javier A. Menendez are supported by a
   grant from the Roses against Cancer Foundation (Fundacio Roses contra el
   cancer, Girona, Spain). Catherine Van Poznak is supported by NIDCR grant
   5K23DE20197 2. Work supported in part by the Avon Foundation (SDM) and
   the Breast Cancer Research Foundation (SDM).
CR BARGINEAR MF, 2010, ONCOLOGY WILLISTON P, V24, P478
   BARGINEAR MF, 2010, ONCOLOGY WILLISTON P, V24, P480
   Barginear MF, 2010, ONCOLOGY NY, V24, P475
   Benassi MS, 2007, CANCER LETT, V250, P194, DOI 10.1016/j.canlet.2006.10.004
   Brubaker KD, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 15
   Budman DR, 2006, ONCOLOGY BASEL, V70, P147, DOI 10.1159/000093006
   Caccamo N, 2008, EXPERT OPIN BIOL TH, V8, P875, DOI [10.1517/14712598.8.7.875, 10.1517/14712598.8.7.875 ]
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chuah C, 2005, LEUKEMIA, V19, P1896, DOI 10.1038/sj.leu.2403949
   Clézardin P, 2005, CANCER TREAT REV, V31, pS1, DOI 10.1016/j.ctrv.2005.09.002
   Clyburn RD, 2010, CANCER CHEMOTH PHARM, V65, P969, DOI 10.1007/s00280 009 1106 6
   COLEMAN RE, 2010, 33 ANN M SAN ANT BRE
   Costa Luis, 2006, Support Cancer Ther, V3, P143, DOI 10.3816/SCT.2006.n.012
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Devitt Bianca, 2008, Ther Clin Risk Manag, V4, P453
   Dong Mei, 2008, Zhonghua Zhongliu Zazhi, V30, P215
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Facchini G, 2010, CANCER BIOL THER, V10, P543, DOI 10.4161/cbt.10.6.12611
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Fromigue O, 2003, BRIT J CANCER, V89, P178, DOI 10.1038/sj.bjc.6601009
   Gao L, 2005, BLOOD, V106, P4294, DOI 10.1182/blood 2005 04 1730
   Gennari L, 2009, MINI REV MED CHEM, V9, P1052, DOI 10.2174/138955709788922683
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gnant M, 2009, CURR CANCER DRUG TAR, V9, P824, DOI 10.2174/156800909789760267
   Gnant Michael, 2010, Crit Rev Oncol Hematol, V74 Suppl 1, pS2, DOI 10.1016/S1040 8428(10)70003 2
   Gouin F, 2006, INT J CANCER, V119, P980, DOI 10.1002/ijc.21951
   Haque I, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 8
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Horie N, 2007, BRIT J CANCER, V96, P255, DOI 10.1038/sj.bjc.6603548
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Koto K, 2010, ONCOL REP, V24, P233, DOI 10.3892/or_00000851
   Lamoureux F, 2008, INT J CANCER, V122, P751, DOI 10.1002/ijc.23187
   Langer C, 2010, LUNG CANCER, V67, P4, DOI 10.1016/j.lungcan.2009.08.020
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Lu S, 2008, ONCOL REP, V20, P581, DOI 10.3892/or_00000045
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Marra M, 2009, INT J CANCER, V125, P2004, DOI 10.1002/ijc.24648
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Meraviglia S, 2010, CLIN EXP IMMUNOL, V161, P290, DOI 10.1111/j.1365 2249.2010.04167.x
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2007, LIFE SCI, V81, P1066, DOI 10.1016/j.lfs.2007.08.007
   Morgan C, 2007, ACTA ONCOL, V46, P669, DOI 10.1080/02841860600996447
   Neville Webbe HL, 2010, EUR J CANCER, V46, P1211, DOI 10.1016/j.ejca.2010.02.041
   Neville Webbe HL, 2010, SEMIN ONCOL, V37, pS53, DOI 10.1053/j.seminoncol.2010.06.008
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2008, CLIN CANCER RES, V14, P4658, DOI 10.1158/1078 0432.CCR 07 1545
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   Ozturk OH, 2007, CELL BIOL INT, V31, P1069, DOI 10.1016/j.cellbi.2007.02.004
   Pandya KJ, 2010, LUNG CANCER, V67, P330, DOI 10.1016/j.lungcan.2009.04.020
   Peng HJ, 2007, CANCER RES, V67, P9346, DOI 10.1158/0008 5472.CAN 06 4508
   Phillipi CA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub2
   Rachner TD, 2010, CANCER LETT, V287, P109, DOI 10.1016/j.canlet.2009.06.003
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Reeder JG, 2010, ONCOLOGY NY, V24, P462
   REEDER JG, 2010, ONCOLOGY WILLISTON P, V24, P475
   Ricciardi S, 2009, REV RECENT CLIN TRIA, V4, P205, DOI 10.2174/157488709789957718
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Santini D, 2010, CURR CANCER DRUG TAR, V10, P46, DOI 10.2174/156800910790980223
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Verdijk R, 2007, CANCER LETT, V246, P308, DOI 10.1016/j.canlet.2006.03.011
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Vogt U, 2004, ONCOL REP, V12, P1109
   Wakchoure S, 2006, CLIN CANCER RES, V12, P2862, DOI 10.1158/1078 0432.CCR 05 2766
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Winter MC, 2010, 33 ANN SAN ANT BREAS
   Woodward JKL, 2005, ANTI CANCER DRUG, V16, P845, DOI 10.1097/01.cad.0000175582.01446.6f
   Zaghloul MS, 2010, INT J CLIN ONCOL, V15, P382, DOI 10.1007/s10147 010 0074 5
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
   Zhao XM, 2010, BREAST CANCER RES TR, V124, P733, DOI 10.1007/s10549 010 1183 6
   Zhou ZC, 2005, CANCER AM CANCER SOC, V104, P1713, DOI 10.1002/cncr.21383
NR 97
TC 15
Z9 15
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1699 048X
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD MAR
PY 2011
VL 13
IS 3
BP 148
EP 155
DI 10.1007/s12094 011 0634 9
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 746ZF
UT WOS:000289289100004
PM 21421459
DA 2025 08 17
ER

PT J
AU Long, ZY
   Xiang, W
   Li, J
   Yang, TJ
   Yu, GP
AF Long, Zhiyong
   Xiang, Wang
   Li, Jun
   Yang, Tiejun
   Yu, Ganpeng
TI Exploring the Mechanism of Resveratrol in Reducing the Soft Tissue
   Damage of Osteoarthritis Based on Network Pharmacology and Experimental
   Pharmacology
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID SIGNALING PATHWAY; CHONDROCYTES; GENE; EPIDEMIOLOGY; PATHOGENESIS;
   INFLAMMATION; PROTECTS; PAIN
AB Aim. To explore the mechanism of resveratrol in reducing the soft tissue damage of osteoarthritis (OA) based on network pharmacology. Methods. Pharmmapper was used to predict the target of resveratrol, OMIM and Genecards were used to collect OA related disease genes, and David ver 6.8 was used for enrichment analysis. Then, animal experiments were carried out for verification. The rat OA model was established and the rats were randomly divided into 4 groups: model group, resveratrol low dose group, resveratrol high dose group, and blank control group for follow up experiments. Hematoxylin eosin (HE) staining was used to detect the degree of pathological damage of rat bones and joints. Enzyme linked immunosorbent assay (ELISA) was used for the content of inflammatory factors. Western blot was used to detect the expression of Toll like receptor 4 (TLR4), Myeloid differentiation factor 88 (MyD88), nuclear factor kappa B protein (NF kappa B), cysteine protease 9 (CASP 9), Bcl 2 protein, and Bax protein. Results. Through network pharmacological analysis, this study found that resveratrol may regulate the TLR4 signaling pathway, PI3K Akt signaling pathway, FoxO signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, etc. Animal experiments showed that compared with the model group, the pathological damage of bone and joint in the resveratrol low dose and high dose groups was significantly improved. Compared with the model group, the serum levels of IL 1beta, IL 6, IL 17, TNF alpha, and MCP 1 in the resveratrol low dose and high dose groups were significantly reduced (P < 0.05); protein levels of TLR 4, MyD88, and NF kappa B p65 were significantly reduced (P < 0.05); caspase 9 and Bax protein levels were significantly reduced (P < 0.05), and Bcl 2 was significantly increased (P < 0.05). Conclusion. Resveratrol may inhibit the activation of the TLR4 mediated NF kappa B signaling pathway and has a repairing effect on soft tissue damage in OA.
C1 [Long, Zhiyong] Shantou Univ, Shantou Univ Med Coll, Shantou, Guangdong, Peoples R China.
   [Xiang, Wang] Guilin Med Univ, Affiliated Hosp, Guilin, Guangxi, Peoples R China.
   [Li, Jun; Yang, Tiejun; Yu, Ganpeng] Peoples Hosp Ningxiang City, Ningxiang, Hunan, Peoples R China.
C3 Shantou University; Guilin Medical University
RP Li, J; Yang, TJ; Yu, GP (通讯作者)，Peoples Hosp Ningxiang City, Ningxiang, Hunan, Peoples R China.
EM 2212471438@qq.com; 609834551@qq.com; lijun.guke@hotmail.com;
   yangtiejun321@outlook.com; yuganpeng.guke@hotmail.com
RI 李, 绍纯/GVR 8874 2022; xiang, wang/JKH 6962 2023
FU Hunan Province Clinical Medical Technology Innovation Guidance Project
   [2018SK50235]
FX AcknowledgmentsThis research was supported by Hunan Province Clinical
   Medical Technology Innovation Guidance Project (No. 2018SK50235).
CR Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609
   [Anonymous], 2014, NUCLEIC ACIDS RES, V33, pD517
   Atkins RJ, 2012, J CLIN NEUROSCI, V19, P1558, DOI 10.1016/j.jocn.2012.07.002
   Atukorala I, 2016, ANN RHEUM DIS, V75, P390, DOI 10.1136/annrheumdis 2014 205894
   Bobacz K, 2007, ARTHRITIS RHEUM US, V56, P1880, DOI 10.1002/art.22637
   Bruyère O, 2015, DRUG AGING, V32, P179, DOI 10.1007/s40266 015 0243 3
   Burlacu A., 2010, J CELL MOL MED, V7, P257
   Busija L, 2010, BEST PRACT RES CL RH, V24, P757, DOI 10.1016/j.berh.2010.11.001
   Chen LX, 2008, OSTEOARTHR CARTILAGE, V16, P174, DOI 10.1016/j.joca.2007.06.006
   Csali C., 2008, BIOCHEMICAL PHAIAOLO, V75, P677
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140 6736(05)71086 2
   Ding YZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112207
   FELSON DT, 1987, ARTHRITIS RHEUM US, V30, P914, DOI 10.1002/art.1780300811
   Gao XH, 2003, BIOCHEM PHARMACOL, V66, P2427, DOI 10.1016/j.bcp.2003.08.008
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Gu HL, 2017, INT J MOL MED, V39, P734, DOI 10.3892/ijmm.2017.2885
   Gu J, 2012, MOL BIOSYST, V8, P2041, DOI 10.1039/c2mb25065a
   Hawker GA, 2019, CLIN EXP RHEUMATOL, V37, P3
   Hua F, 2005, BIOCHEM BIOPH RES CO, V338, P1118, DOI 10.1016/j.bbrc.2005.10.068
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DG, 2016, J MOL NEUROSCI, V59, P544, DOI 10.1007/s12031 016 0775 y
   Ismail HM, 2015, ARTHRITIS RHEUMATOL, V67, P1826, DOI 10.1002/art.39099
   Jorgensen AE, 2017, J RHEUMATOL, V44, P410, DOI 10.3899/jrheum.160226
   Kanehisa M, 2022, PROTEIN SCI, V31, P47, DOI 10.1002/pro.4172
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Kim S., 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI [DOI 10.1093/NAR/GKY1033, 10.1093/NAR/GKY1033]
   Kühn K, 2004, OSTEOARTHR CARTILAGE, V12, P1, DOI 10.1016/j.joca.2003.09.015
   Kuhn M, 2010, NUCLEIC ACIDS RES, V38, pD552, DOI 10.1093/nar/gkp937
   Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200
   Li H, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1454 2
   Li S, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/138460
   Liang XJ, 2014, MOL BIOSYST, V10, P1014, DOI 10.1039/c3mb70507b
   Limagne E, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050280
   Little CB, 2009, ARTHRITIS RHEUM US, V60, P3723, DOI 10.1002/art.25002
   Liu J., 2019, CHINESE TISSUE ENG R, V19, P3024
   Liu L, 2014, INT J MOL SCI, V15, P6925, DOI 10.3390/ijms15046925
   Liu X.F., 2017, NUCLEIC ACIDS RES, V38, pW614
   Martin JA, 2002, BIOGERONTOLOGY, V3, P257, DOI 10.1023/A:1020185404126
   Nielsen FK, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1871 z
   Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91
   Philipot D, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4494
   Pulsatelli L, 2013, THER ADV CHRONIC DIS, V4, P23, DOI 10.1177/2040622312462734
   Sato T, 2006, ARTHRITIS RHEUM US, V54, P808, DOI 10.1002/art.21638
   Shakibaei M, 2008, BIOCHEM PHARMACOL, V76, P1426, DOI 10.1016/j.bcp.2008.05.029
   Snelling SJB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175109
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Sun YL, 2016, EXP CELL RES, V347, P274, DOI 10.1016/j.yexcr.2016.07.009
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Thompson AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085495
   VANSAASE JLCM, 1989, ANN RHEUM DIS, V48, P271, DOI 10.1136/ard.48.4.271
   Wan YC, 2020, CURR MED CHEM, V27, P3753, DOI 10.2174/0929867326666181217153118
   Watanabe Hideto, 2008, Seikagaku, V80, P28
   Wei YL, 2018, MOL MED REP, V17, P1493, DOI 10.3892/mmr.2017.8036
   Xu DQ, 2016, INT J MED SCI, V13, P942, DOI 10.7150/ijms.16810
   Zhu Ming Yue, 2014, Zhonghua Gan Zang Bing Za Zhi, V22, P837, DOI 10.3760/cma.j.issn.1007 3418.2014.11.008
   Zong Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044107
NR 58
TC 9
Z9 10
U1 1
U2 27
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD OCT 4
PY 2021
VL 2021
AR 9931957
DI 10.1155/2021/9931957
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA YQ8BX
UT WOS:000749530600004
PM 34646331
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Orapiriyakul, W
   Tsimbouri, MP
   Childs, P
   Campsie, P
   Wells, J
   Fernandez Yague, MA
   Burgess, K
   Tanner, KE
   Tassieri, M
   Meek, D
   Vassalli, M
   Biggs, MJP
   Salmeron Sanchez, M
   Oreffo, ROC
   Reid, S
   Dalby, MJ
AF Orapiriyakul, Wich
   Tsimbouri, Monica P.
   Childs, Peter
   Campsie, Paul
   Wells, Julia
   Fernandez Yague, Marc A.
   Burgess, Karl
   Tanner, K. Elizabeth
   Tassieri, Manlio
   Meek, Dominic
   Vassalli, Massimo
   Biggs, Manus J. P.
   Salmeron Sanchez, Manuel
   Oreffo, Richard O. C.
   Reid, Stuart
   Dalby, Matthew J.
TI Nanovibrational Stimulation of Mesenchymal Stem Cells Induces
   Therapeutic Reactive Oxygen Species and Inflammation for
   Three Dimensional Bone Tissue Engineering
SO ACS NANO
LA English
DT Article
DE mesenchymal stem cells; nanovibration; mechanotransduction; bioreactor;
   bone tissue engineering
ID OSTEOGENIC DIFFERENTIATION; TRP CHANNELS; METABOLOMICS ANALYSIS;
   OXIDATIVE STRESS; PIEZO1; PROLIFERATION; MITOCHONDRIA; EXPRESSION;
   INTERPLAY; RELEASE
AB There is a pressing clinical need to develop cell  Na based bone therapies due to a lack of viable, autologous bone grafts and a growing demand for bone grafts in musculoskeletal surgery. Such therapies can be tissue engineered and cellular, such as osteoblasts, combined with a material scaffold. Because mesenchymal stem cells (MSCs) are both available and fast growing compared to mature osteoblasts, therapies that utilize these progenitor cells are particularly promising. We have developed a nanovibrational bioreactor that can convert MSCs into bone forming osteoblasts in two  and three dimensional, but the mechanisms involved in this osteoinduction process remain unclear. Here, to elucidate this mechanism, we use increasing vibrational amplitude, from 30 nm (N30) to 90 nm (N90) amplitudes at 1000 Hz and assess MSC metabolite, gene, and protein changes. These approaches reveal that dose dependent changes occur in MSCs' responses to increased vibrational amplitude, particularly in adhesion and mechanosensitive ion channel expression and that energetic metabolic pathways are activated, leading to low level reactive oxygen species (ROS) production and to low level inflammation as well as to ROS  and inflammation balancing pathways. These events are analogous to those that occur in the natural bone healing processes. We have also developed a tissue engineered MSC laden scaffold designed using cells' mechanical memory, driven by the stronger N90 stimulation. These mechanistic insights and cell scaffold design are underpinned by a process that is free of inductive chemicals.
C1 [Orapiriyakul, Wich; Tsimbouri, Monica P.; Dalby, Matthew J.] Univ Glasgow, Ctr Cellular Microenvironm, Inst Mol Cell & Syst Biol, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.
   [Orapiriyakul, Wich] Prince Songkla Univ, Fac Med, Dept Orthoped, Hat Yai 90110, Thailand.
   [Childs, Peter; Tanner, K. Elizabeth; Tassieri, Manlio; Vassalli, Massimo; Salmeron Sanchez, Manuel] Univ Glasgow, Ctr Cellular Microenvironm, Div Biomed Engn, Sch Engn, Glasgow G12 8LT, Lanark, Scotland.
   [Campsie, Paul; Reid, Stuart] Univ Strathclyde, SUPA Dept Biomed Engn, Glasgow G1 1QE, Lanark, Scotland.
   [Wells, Julia; Oreffo, Richard O. C.] Univ Southampton, Ctr Human Dev Stem Cells & Regenerat, Inst Dev Sci, Bone & Joint Res Grp, Southampton SO16 6YD, Hants, England.
   [Fernandez Yague, Marc A.; Biggs, Manus J. P.] Natl Univ Ireland Galway, Ctr Res Med Devices CURAM, Galway, Ireland.
   [Burgess, Karl] Univ Glasgow, Glasgow Poly, Coll Med Vet & Life Sci, Glasgow G61 1BD, Lanark, Scotland.
   [Tanner, K. Elizabeth] Queen Mary Univ London, Sch Engn & Mat Sci, London E1 4NS, England.
   [Meek, Dominic] Queen Elizabeth II Univ Hosp, Dept Orthoped, Glasgow G51 4TF, Lanark, Scotland.
C3 University of Glasgow; Prince of Songkla University; University of
   Glasgow; University of Strathclyde; University of Southampton; Ollscoil
   na Gaillimhe University of Galway; University of Glasgow; University of
   London; Queen Mary University London
RP Dalby, MJ (通讯作者)，Univ Glasgow, Ctr Cellular Microenvironm, Inst Mol Cell & Syst Biol, Coll Med Vet & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.
EM matthew.dalby@glasgow.ac.uk
RI Tanner, Elizabeth/E 9242 2010; Dalby, Matthew/G 2426 2012; Vassalli,
   Massimo/F 6762 2011; Oreffo, Richard/A 4615 2011; Tassieri,
   Manlio/E 9139 2010; Biggs, Manus/N 8542 2013; Tsimbouri,
   Penelope/F 4373 2010; Yagüe, Marc/A 5533 2018; Salmeron Sanchez,
   Manuel/E 4680 2010
OI Tanner, Elizabeth/0000 0003 2257 0218; Reid, Stuart/0000 0002 9728 3507;
   Childs, Peter/0000 0001 7603 9911; Oreffo, Richard/0000 0001 5995 6726;
   Tassieri, Manlio/0000 0002 6807 0385; Campsie, Paul/0000 0003 4570 7133
FU Royal Thai Government; Faculty of medicine, Prince of Songkla
   University; BBSRC [BB/P00220X/1, BB/S018808/1]; EPSRC [EP/N013905/1,
   EP/P001114/1]; Sir Bobby Charlton Foundation; Science Foundation Ireland
   [16/BBSRC/3317]; Biotechnology and Biological Sciences Research Council
   [BB/N012690/1, BB/P00220X/1, BB/M028259/1] Funding Source: researchfish;
   Engineering and Physical Sciences Research Council [EP/P001114/1,
   EP/N013905/1] Funding Source: researchfish; BBSRC [BB/S018808/1,
   BB/N012690/1, BB/M028259/1, BB/P00220X/1] Funding Source: UKRI; EPSRC
   [EP/P001114/1, EP/N013905/1] Funding Source: UKRI; Science Foundation
   Ireland (SFI) [16/BBSRC/3317] Funding Source: Science Foundation Ireland
   (SFI)
FX W.O. was supported by a scholarship from the Royal Thai Government and
   Faculty of medicine, Prince of Songkla University. The work was
   supported by grants to M.J.D. from BBSRC (BB/P00220X/1, BB/S018808/1),
   EPSRC (EP/N013905/1, EP/P001114/1) and the Sir Bobby Charlton Foundation
   and to M.J.P.B from Science Foundation Ireland (16/BBSRC/3317). We thank
   Mrs. Carol Anne Smith for technical assistance. We thank Jane Alfred,
   Ph.D., from Catalyst Editorial (www.catalyst editorial.co.uk) for
   editing a draft of this manuscript.
CR Alberts B., 2002, Molecular Biology of the Cell
   [Anonymous], 2011, INJURY S2, DOI DOI 10.1016/J.INJURY.2011.06.001
   Atashi F, 2015, STEM CELLS DEV, V24, P1150, DOI 10.1089/scd.2014.0484
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Byon CH, 2008, J BIOL CHEM, V283, P15319, DOI 10.1074/jbc.M800021200
   Campsie P, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 49422 4
   CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196
   Cortright DN, 2007, BBA MOL BASIS DIS, V1772, P978, DOI 10.1016/j.bbadis.2007.03.003
   Coulthard LR, 2009, TRENDS MOL MED, V15, P369, DOI 10.1016/j.molmed.2009.06.005
   Creek DJ, 2011, ANAL CHEM, V83, P8703, DOI 10.1021/ac2021823
   Dalby MJ, 2018, NAT REV MATER, V3, DOI 10.1038/natrevmats.2017.91
   Dimitriou R, 2011, INJURY, V42, pS3, DOI 10.1016/j.injury.2011.06.015
   Elosegui Artola A, 2017, CELL, V171, P1397, DOI 10.1016/j.cell.2017.10.008
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Hamanaka RB, 2011, SCIENCE, V334, P1219, DOI 10.1126/science.1215637
   Henstock JR, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418808695
   Hou JM, 2016, MICROSC RES TECHNIQ, V79, P304, DOI 10.1002/jemt.22631
   Jin P, 2020, ANNU REV NEUROSCI, V43, P207, DOI 10.1146/annurev neuro 070918 050509
   Kanczler J, 2019, METHODS MOL BIOL, V1914, P53, DOI 10.1007/978 1 4939 8997 3_4
   KELL GS, 1965, PHILOS T R SOC S A, V258, P565, DOI 10.1098/rsta.1965.0051
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Klontzas ME, 2017, STEM CELLS DEV, V26, P723, DOI 10.1089/scd.2016.0315
   Lee W, 2014, P NATL ACAD SCI USA, V111, pE5114, DOI 10.1073/pnas.1414298111
   Lewis AH, 2017, CELL REP, V19, P2572, DOI 10.1016/j.celrep.2017.05.079
   Lin CH, 2018, J CELL MOL MED, V22, P786, DOI 10.1111/jcmm.13356
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loeser RF, 2000, BIORHEOLOGY, V37, P109
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Maksimovic S, 2014, NATURE, V509, P617, DOI 10.1038/nature13250
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064
   Miyamoto T, 2014, J BIOL CHEM, V289, P16565, DOI 10.1074/jbc.M113.528638
   Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Myeroff C, 2011, J BONE JOINT SURG AM, V93A, P2227, DOI 10.2106/JBJS.J.01513
   Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830
   Nikukar H, 2013, ACS NANO, V7, P2758, DOI 10.1021/nn400202j
   Nourse JL, 2017, SEMIN CELL DEV BIOL, V71, P3, DOI 10.1016/j.semcdb.2017.06.018
   Pattappa G, 2011, J CELL PHYSIOL, V226, P2562, DOI 10.1002/jcp.22605
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Sugimoto A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 18089 0
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tare RS, 2008, MOL CELL ENDOCRINOL, V288, P11, DOI 10.1016/j.mce.2008.02.017
   Tsimbouri PM, 2017, NAT BIOMED ENG, V1, P758, DOI 10.1038/s41551 017 0127 4
   VANDORPE DH, 1992, J MEMBRANE BIOL, V127, P205
   Wang L, 2015, BIOCHIMIE, V108, P85, DOI 10.1016/j.biochi.2014.10.004
   Wei LY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01304
   Wen JH, 2014, NAT MATER, V13, P979, DOI [10.1038/NMAT4051, 10.1038/nmat4051]
   Yang C, 2014, NAT MATER, V13, P645, DOI [10.1038/NMAT3889, 10.1038/nmat3889]
   Yang JL, 2014, ACS NANO, V8, P9941, DOI 10.1021/nn504767g
   Zhang W, 2013, P NATL ACAD SCI USA, V110, P13612, DOI 10.1073/pnas.1312477110
NR 56
TC 46
Z9 48
U1 0
U2 55
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD AUG 25
PY 2020
VL 14
IS 8
BP 10027
EP 10044
DI 10.1021/acsnano.0c03130
PG 18
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA NJ9CF
UT WOS:000566341000066
PM 32658450
OA Green Published, hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Ma, XY
   Feng, YF
   Wang, TS
   Lei, W
   Li, X
   Zhou, DP
   Wen, XX
   Yu, HL
   Xiang, LB
   Wang, L
AF Ma, Xiang Yu
   Feng, Ya Fei
   Wang, Tian Sheng
   Lei, Wei
   Li, Xiang
   Zhou, Da Peng
   Wen, Xin Xin
   Yu, Hai Long
   Xiang, Liang Bi
   Wang, Lin
TI Involvement of FAK mediated BMP 2/Smad pathway in mediating osteoblast
   adhesion and differentiation on nano HA/chitosan composite coated
   titanium implant under diabetic conditions
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; BONE MORPHOGENETIC PROTEIN; IN VITRO; OXIDATIVE
   STRESS; REGENERATIVE MEDICINE; SIGNALING PATHWAY; KINASE ACTIVITY; TIO2
   NANOTUBES; CHITOSAN; INTEGRINS
AB Chitosan (CS)   based hydroxyapatite (HA) composites have emerged as a novel strategy for promoting bone regeneration. Here nanophase HA/CS composite coated porous titanium implants (nCT) were fabricated and their biological behavior under diabetic conditions was investigated. We proposed that the focal adhesion kinase (FAK)   mediated BMP 2/Smad pathway played a role in mediating the promotive effect of nCTs on osteoblast adhesion and differentiation under diabetes   induced high reactive oxygen species (ROS) condition. To confirm the hypothesis, rat osteoblasts on bare titanium implants (Ti) and nCT were subjected to normal serum (NS), diabetic serum (DS), DS + NAC (a potent ROS inhibitor) and DS + cytochalasin D (an actin polymerization inhibitor). In vivo on diabetic sheep implanted with Ti or nCT showed that diabetes  induced ROS overproduction impaired osteoblast adhesion, evidenced by immunostaining of F   actin and vinculin and morphological observation through inhibition of FAK phosphorylation, which contributed to suppressed BMP 2 dependent Smad1/5/8 phosphorylation. nCT substrate reactivated the FAK BMP 2/Smad pathway, thus reversing osteoblast dysfunction, which exerted a similar effect to NAC treatment on Ti. These effects were further confirmed by improved osteointegration within nCT in diabetic sheep, evidenced by micro CT and histological examinations. Our study demonstrated that reactivation of the FAK BMP 2/Smad pathway was involved in improving osteoblast adhesion and differentiation by nano HA/CS composite coating, potentially directing biomaterial modification and biofunctionalization under diabetic conditions.
C1 [Ma, Xiang Yu; Zhou, Da Peng; Yu, Hai Long; Xiang, Liang Bi] Chinese PIA, Dept Orthoped, Gen Hosp, Shenyang Mil Area Command, Shenyang 110016, Liaoning, Peoples R China.
   [Ma, Xiang Yu; Wang, Tian Sheng; Wen, Xin Xin] PLA, Dept Orthoped, Hosp 463, Shenyang 1100, Liaoning, Peoples R China.
   [Ma, Xiang Yu; Feng, Ya Fei; Lei, Wei; Wen, Xin Xin; Wang, Lin] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710031, Shaanxi, Peoples R China.
   [Li, Xiang] Shanghai Jiao Tong Univ, Slate Key Lab Mech Syst & Vibrat, Sch Mech Engn, Shanghai 200240, Peoples R China.
   [Wang, Lin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Orthoped, Xian 710061, Shaanxi, Peoples R China.
C3 Air Force Medical University; Shanghai Jiao Tong University; Xi'an
   Jiaotong University
RP Xiang, LB (通讯作者)，Chinese PIA, Dept Orthoped, Gen Hosp, Shenyang Mil Area Command, Shenyang 110016, Liaoning, Peoples R China.; Wang, L (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710031, Shaanxi, Peoples R China.; Wang, L (通讯作者)，Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Orthoped, Xian 710061, Shaanxi, Peoples R China.
EM xiangliangbi1963@sina.com; wanglinxj@fmmu.edu.cn
RI ; MA, XIANGYU/AAS 6485 2021; Wang, Lin/J 8805 2018
OI Lei, Wei/0000 0002 7346 6915; Dapeng, Zhou/0000 0001 7455 5699; Wang,
   Lin/0000 0002 5995 8446; Wang, Lin/0000 0001 5937 6318
FU Liao Ning Province Natural Science Foundation of China [201601411];
   National Natural Science Foundation of China [81401769]; Research Fund
   for the National Natural Science Foundation of China [81702131]
FX This work was supported by grants from the Liao Ning Province Natural
   Science Foundation of China (No. 201601411) to Xiang Yu Ma, National
   Natural Science Foundation of China (No. 81401769) to Ya Fei Feng, and
   Research Fund for the National Natural Science Foundation of China (No.
   81702131) to Xiang Yu Ma.
CR Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Aquino Martínez R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178158
   Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959 437X(00)00155 6
   Blokhuis TJ, 2000, J TRAUMA, V48, P179, DOI 10.1097/00005373 200001000 00037
   Botolin S, 2005, ENDOCRINOLOGY, V146, P3622, DOI 10.1210/en.2004 1677
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264 6021:3390481
   Bumgardner JD, 2003, J BIOMAT SCI POLYM E, V14, P423, DOI 10.1163/156856203766652048
   Carradò A, 2017, DENT MATER, V33, P321, DOI 10.1016/j.dental.2016.12.013
   Chen J, 2014, COLLOID SURFACE B, V122, P709, DOI 10.1016/j.colsurfb.2014.08.004
   Chen WQ, 2012, ACS NANO, V6, P4094, DOI 10.1021/nn3004923
   Choung HW, 2016, TISSUE ENG PT A, V22, P93, DOI [10.1089/ten.tea.2015.0272, 10.1089/ten.TEA.2015.0272]
   Dejaeger M, 2017, J BONE MINER RES, V32, P2087, DOI 10.1002/jbmr.3190
   Di Martino A, 2005, BIOMATERIALS, V26, P5983, DOI 10.1016/j.biomaterials.2005.03.016
   Di Silvio L, 2002, BIOMATERIALS, V23, P101, DOI 10.1016/S0142 9612(01)00084 9
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Feng YF, 2013, BIOMATERIALS, V34, P2234, DOI 10.1016/j.biomaterials.2012.12.023
   Gopalakrishnan V, 2006, BIOCHEM CELL BIOL, V84, P93, DOI 10.1139/O05 163
   Guan CC, 2009, BONE, V45, P1146, DOI 10.1016/j.bone.2009.08.009
   Gullón B, 2016, CARBOHYD POLYM, V137, P382, DOI 10.1016/j.carbpol.2015.10.075
   Hamada Y, 2009, BONE, V45, pS35, DOI 10.1016/j.bone.2009.02.004
   Hie M, 2011, INT J MOL MED, V28, P455, DOI 10.3892/ijmm.2011.697
   Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959 437X(01)00260 X
   Hu XF, 2017, ACTA BIOMATER, V61, P233, DOI 10.1016/j.actbio.2017.06.020
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Irrcher I, 2009, AM J PHYSIOL CELL PH, V296, pC116, DOI 10.1152/ajpcell.00267.2007
   Javed F, 2009, J PERIODONTOL, V80, P1719, DOI 10.1902/jop.2009.090283
   Kiliç Ç, 2013, COLLOID SURFACE B, V112, P499, DOI 10.1016/j.colsurfb.2013.08.050
   Kilpadi KL, 2001, J BIOMED MATER RES, V57, P258, DOI 10.1002/1097 4636(200111)57:2<258::AID JBM1166>3.0.CO;2 R
   Lai M, 2017, J BIOMAT SCI POLYM E, V28, P1651, DOI 10.1080/09205063.2017.1342334
   Lai M, 2011, BIOMACROMOLECULES, V12, P1097, DOI 10.1021/bm1014365
   Lee JY, 2002, J CONTROL RELEASE, V78, P187, DOI 10.1016/S0168 3659(01)00498 9
   Li X, 2009, P I MECH ENG H, V223, P173, DOI 10.1243/09544119JEIM466
   Li X, 2015, BIOMATERIALS, V36, P44, DOI 10.1016/j.biomaterials.2014.09.012
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Liu HH, 2013, BIOMATERIALS, V34, P4404, DOI 10.1016/j.biomaterials.2013.02.048
   Ma XY, 2014, BIOMATERIALS, V35, P7259, DOI 10.1016/j.biomaterials.2014.05.028
   Matsuura T, 2000, BIOMATERIALS, V21, P1121, DOI 10.1016/S0142 9612(99)00264 1
   Morris H F, 2000, Ann Periodontol, V5, P157, DOI 10.1902/annals.2000.5.1.157
   Motyl KJ, 2011, AM J PHYSIOL REG I, V300, pR1250, DOI 10.1152/ajpregu.00764.2010
   Olivares Navarrete R, 2008, P NATL ACAD SCI USA, V105, P15767, DOI 10.1073/pnas.0805420105
   Carreira ACO, 2015, VITAM HORM, V99, P293, DOI 10.1016/bs.vh.2015.06.002
   Oliveira JM, 2006, BIOMATERIALS, V27, P6123, DOI 10.1016/j.biomaterials.2006.07.034
   Pan HA, 2013, BIOMATERIALS, V34, P841, DOI 10.1016/j.biomaterials.2012.09.078
   Pina S, 2015, ADV MATER, V27, P1143, DOI 10.1002/adma.201403354
   Ramanathan T, 2002, CARDIOVASC RES, V55, P749, DOI 10.1016/S0008 6363(02)00497 2
   Rao Shreyas S, 2009, Front Neuroeng, V2, P6, DOI 10.3389/neuro.16.006.2009
   Sawhney RS, 2006, J BIOL CHEM, V281, P8497, DOI 10.1074/jbc.M600787200
   Shakir M, 2015, INT J BIOL MACROMOL, V80, P282, DOI 10.1016/j.ijbiomac.2015.05.009
   Sinha RK, 1996, BONE, V18, P451, DOI 10.1016/8756 3282(96)00044 0
   Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309
   Tamura Y, 2001, J BONE MINER RES, V16, P1772, DOI 10.1359/jbmr.2001.16.10.1772
   Tomida H, 2009, CARBOHYD RES, V344, P1690, DOI 10.1016/j.carres.2009.05.006
   Waddington RJ, 2011, CELLS TISSUES ORGANS, V194, P307, DOI 10.1159/000324251
   Wang BG, 2011, BRIT J ORAL MAX SURG, V49, P225, DOI 10.1016/j.bjoms.2010.03.006
   Wang X, 2012, BIOCHIMIE, V94, P1705, DOI 10.1016/j.biochi.2012.03.024
   Wang YK, 2012, STEM CELLS DEV, V21, P1176, DOI 10.1089/scd.2011.0293
   Webster TJ, 2000, J BIOMED MATER RES, V51, P475, DOI 10.1002/1097 4636(20000905)51:3<475::AID JBM23>3.0.CO;2 9
   Wittrant Y, 2008, BONE, V42, P1122, DOI 10.1016/j.bone.2008.02.006
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Xie WM, 2001, BIOORG MED CHEM LETT, V11, P1699, DOI 10.1016/S0960 894X(01)00285 2
   Yang JL, 2014, J BIOMED MATER RES A, V102, P1202, DOI 10.1002/jbm.a.34756
   Yonezawa T, 2011, BIOCHEM BIOPH RES CO, V409, P260, DOI 10.1016/j.bbrc.2011.05.001
   Yu M, 2011, BONE, V49, P387, DOI 10.1016/j.bone.2011.05.025
   Zaidel Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792
   Zhang Xiao, 2016, Beijing Da Xue Xue Bao Yi Xue Ban, V48, P37
   Zhang Y, 2013, J CELL BIOCHEM, V114, P2595, DOI 10.1002/jcb.24607
   Zhao LZ, 2010, J BIOMED MATER RES A, V92A, P432, DOI 10.1002/jbm.a.32348
NR 68
TC 48
Z9 50
U1 4
U2 60
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD JAN 1
PY 2017
VL 6
IS 1
BP 225
EP 238
DI 10.1039/c7bm00652g
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA FQ4RX
UT WOS:000418346500020
PM 29231215
DA 2025 08 17
ER

PT J
AU Terashima, A
   Okamoto, K
   Nakashima, T
   Akira, S
   Ikuta, K
   Takayanagi, H
AF Terashima, Asuka
   Okamoto, Kazuo
   Nakashima, Tomoki
   Akira, Shizuo
   Ikuta, Koichi
   Takayanagi, Hiroshi
TI Sepsis Induced Osteoblast Ablation Causes Immunodeficiency
SO IMMUNITY
LA English
DT Article
ID HEMATOPOIETIC STEM CELLS; BONE FORMATION; DIFFERENTIATION; PROGENITORS;
   MAINTENANCE; NICHE; MICE; IL 7; IMMUNOSUPPRESSION; IDENTIFICATION
AB Sepsis is a host inflammatory response to severe infection associated with high mortality that is caused by lymphopenia associated immunodeficiency. However, it is unknown how lymphopenia persists after the accelerated lymphocyte apoptosis subsides. Here we show that sepsis rapidly ablated osteoblasts, which reduced the number of common lymphoid progenitors (CLPs). Osteoblast ablation or inducible deletion of interleukin 7 (IL 7) in osteoblasts recapitulated the lymphopenic phenotype together with a lower CLP number without affecting hematopoietic stem cells (HSCs). Pharmacological activation of osteoblasts improved sepsis induced lymphopenia. This study demonstrates a reciprocal interaction between the immune and bone systems, in which acute inflammation induces a defect in bone cells resulting in lymphopenia associated immunodeficiency, indicating that bone cells comprise a therapeutic target in certain life threatening immune reactions.
C1 [Terashima, Asuka; Okamoto, Kazuo; Takayanagi, Hiroshi] Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7 3 1, Tokyo 1130033, Japan.
   [Terashima, Asuka; Okamoto, Kazuo; Takayanagi, Hiroshi] Univ Tokyo, Fac Med, Bunkyo Ku, Hongo 7 3 1, Tokyo 1130033, Japan.
   [Terashima, Asuka; Okamoto, Kazuo] Univ Tokyo, Grad Sch Med, Dept Osteoimmunol, Bunkyo Ku, Hongo 7 3 1, Tokyo 1130033, Japan.
   [Nakashima, Tomoki] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Bunkyo Ku, Yushima 1 5 45, Tokyo 1138549, Japan.
   [Nakashima, Tomoki] JST, Precursory Res Embryon Sci & Technol PRESTO, Bunkyo Ku, Yushima 1 5 45, Tokyo 1138549, Japan.
   [Nakashima, Tomoki] Japan Agcy Med Res & Dev, Core Res Evolut Sci & Technol AMED CREST, Bunkyo Ku, Yushima 1 5 45, Tokyo 1138549, Japan.
   [Akira, Shizuo] Osaka Univ, WPI Immunol Frontier Res Ctr IFReC, Host Def Lab, Yamada Oka 3 1, Suita, Osaka 5650871, Japan.
   [Ikuta, Koichi] Kyoto Univ, Inst Virus Res, Dept Biol Responses, Lab Biol Protect,Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
C3 University of Tokyo; University of Tokyo; University of Tokyo; Institute
   of Science Tokyo; Tokyo Medical & Dental University (TMDU); Japan
   Science & Technology Agency (JST); University of Osaka; Kyoto University
RP Takayanagi, H (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7 3 1, Tokyo 1130033, Japan.; Takayanagi, H (通讯作者)，Univ Tokyo, Fac Med, Bunkyo Ku, Hongo 7 3 1, Tokyo 1130033, Japan.
EM takayana@m.u tokyo.ac.jp
RI Akira, Shizuo/C 3134 2009; Terashima, Angelica/ABD 7759 2021
OI Ikuta, Koichi/0000 0003 1319 1021
FU Japan Society for Promotion of Science(JSPS) [15H05703]; JSPS
   [15H05653]; JST; Japan Agency for Medical Research and Development
   [15ek0109106]; Chugai Pharmaceutical Co., LTD.; AYUMI Pharmaceutical
   Corporation; Noevir Co., Ltd.; JSPS Research Fellowship for Young
   Scientists;  [23.2656]; Grants in Aid for Scientific Research [15H05703,
   16H05172, 16K15288, 15H01153, 24111001, 15H05653] Funding Source: KAKEN
FX We are grateful to T. Nagasawa(Kyoto University) for discussion and
   advice. We are also grateful to J. Miyazaki (Osaka University) for
   providing CAG CAT EGFP transgenic mice. We thank T. Negishi Koga, M.
   Shinohara, M. Oh hora, S. Sawa, M. Hayashi, N. Komatsu, M. Guerrini, L.
   Danks, E. Sumiya, C. Tsuda, Y. Ogiwara, N. Otsuka, A. Suematsu, Y.
   Kunisawa, T. Ando, and K. Kusubata for discussion and assistance. This
   work was supported in part by Grant in Aid for Specially Promoted
   Research from the Japan Society for Promotion of Science(JSPS)
   (15H05703); Grant in Aid for Young Scientists A from JSPS (15H05653);
   Grant in Aid for JSPS Fellows (23 center dot 2656); grants for the
   ERATO, Takayanagi Osteonetwork Project and PRESTO from JST; and a grant
   for Practical Research Project for Rare/Intractable Diseases
   (15ek0109106) from Japan Agency for Medical Research and Development.
   Department of Osteoimmunology is an endowment department, supported with
   an unrestricted grant from Chugai Pharmaceutical Co., LTD., AYUMI
   Pharmaceutical Corporation and Noevir Co., Ltd. A. T. was supported by
   JSPS Research Fellowship for Young Scientists.
CR Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074 7613(00)80596 8
   Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599
   Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chen YT, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh158
   Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798
   Delano MJ, 2007, J EXP MED, V204, P1463, DOI 10.1084/jem.20062602
   Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Gentile LF, 2012, J TRAUMA ACUTE CARE, V72, P1491, DOI 10.1097/TA.0b013e318256e000
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Hara T, 2012, J IMMUNOL, V189, P1577, DOI 10.4049/jimmunol.1200586
   Hotchkiss RS, 2006, NAT REV IMMUNOL, V6, P813, DOI 10.1038/nri1943
   Hotchkiss RS, 2013, LANCET INFECT DIS, V13, P260, DOI 10.1016/S1473 3099(13)70001 X
   Karsunky H, 2008, BLOOD, V111, P5562, DOI 10.1182/blood 2007 11 126219
   Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014 5793(00)01338 7
   Kawamoto T, 2014, METHODS MOL BIOL, V1130, P149, DOI 10.1007/978 1 62703 989 5_11
   Kiel MJ, 2007, CELL STEM CELL, V1, P204, DOI 10.1016/j.stem.2007.06.001
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kikuchi K, 2005, J EXP MED, V201, P1197, DOI 10.1084/jem.20050158
   KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0
   Liang BF, 2012, J IMMUNOL, V189, P4444, DOI 10.4049/jimmunol.1201181
   Martin T John, 2014, J Bone Metab, V21, P8, DOI 10.11005/jbm.2014.21.1.8
   Mercier FE, 2012, NAT REV IMMUNOL, V12, P49, DOI 10.1038/nri3132
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Nagasawa T, 2011, TRENDS IMMUNOL, V32, P315, DOI 10.1016/j.it.2011.03.009
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017
   Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242
   Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Scumpia PO, 2010, J IMMUNOL, V184, P2247, DOI 10.4049/jimmunol.0903652
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   Unsinger J, 2010, J IMMUNOL, V184, P3768, DOI 10.4049/jimmunol.0903151
   Venet F, 2012, J IMMUNOL, V189, P5073, DOI 10.4049/jimmunol.1202062
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048
   Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 47
TC 110
Z9 123
U1 1
U2 26
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074 7613
EI 1097 4180
J9 IMMUNITY
JI Immunity
PD JUN 21
PY 2016
VL 44
IS 6
BP 1434
EP 1443
DI 10.1016/j.immuni.2016.05.012
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA DP2SE
UT WOS:000378341200020
PM 27317262
OA Bronze
DA 2025 08 17
ER

PT J
AU Xu, YX
   Chen, SC
   Huang, LX
   Han, WC
   Shao, YY
   Chen, MY
   Zhang, YS
   He, RR
   Xie, BC
AF Xu, Yongxiang
   Chen, Shichun
   Huang, Linxuan
   Han, Weichao
   Shao, Yingying
   Chen, Minyi
   Zhang, Yusheng
   He, Ruirong
   Xie, Baocheng
TI Epimedin C Alleviates Glucocorticoid Induced Suppression of Osteogenic
   Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE epimedin C; PI3K; and AKT signaling pathways; osteoporosis;
   dexamethasone; osteogenic differentiation
ID OSTEOBLAST DIFFERENTIATION; HERBA EPIMEDII; OSTEOPOROSIS; PROMOTES;
   RUNX2; ACTIVATION; MECHANISMS; MC3T3 E1; EXTRACT; CELLS
AB Secondary osteoporosis is triggered mostly by glucocorticoid (GC) therapy. Dexamethasone (DEX) was reported to inhibit osteogenic differentiation in zebrafish larvae and MC3T3 E1 cells in prior research. In this research, we primarily examined the protective impacts of epimedin C on the osteogenic inhibition impact of MC3T3 E1 cells and zebrafish larvae mediated by DEX. The findings illustrated no apparent toxicity for MC3T3 E1 cells after administering epimedin C at increasing dosages from 1 to 60 mu M and no remarkable proliferation in MC3T3 E1 cells treated using DEX. In MC3T3 E1 cells that had been treated using DEX, we discovered that epimedin C enhanced alkaline phosphatase activities and mineralization. Epimedin C could substantially enhance the protein expression of osterix (OSX), Runt related transcription factor 2 (RUNX2), and alkaline phosphatase (ALPL) in MC3T3 E1 cells subjected to DEX treatment. Additionally, epimedin C stimulated PI3K and AKT signaling pathways in MC3T3 E1 cells that had been treated using DEX. Furthermore, in a zebrafish larvae model, epimedin C was shown to enhance bone mineralization in DEX mediated bone impairment. We also found that epimedin C enhanced ALPL activity and mineralization in MC3T3 E1 cells treated using DEX, which may be reversed by PI3K inhibitor (LY294002). LY294002 can also reverse the protective impact of epimedin C on DEX mediated bone impairment in zebrafish larval. These findings suggested that epimedin C alleviated the suppressive impact of DEX on the osteogenesis of zebrafish larval and MC3T3 E1 cells via triggering the PI3K and AKT signaling pathways. Epimedin C has significant potential in the development of innovative drugs for the treatment of glucocorticoid mediated osteoporosis.
C1 [Xu, Yongxiang; Chen, Shichun; Han, Weichao; Shao, Yingying; Chen, Minyi; He, Ruirong; Xie, Baocheng] Southern Med Univ, Affiliated Dongguan Hosp, Dept Pharm, Dongguan, Peoples R China.
   [Huang, Linxuan] Southern Med Univ, Affiliated Dongguan Hosp, Dongguan Inst Clin Canc Res, Dongguan, Peoples R China.
   [Zhang, Yusheng] Affiliated Foshan Hosp Sun Yat Sen Univ, Peoples Hosp Foshan 1, Dept Pharm, Foshan, Peoples R China.
C3 Southern Medical University   China; Southern Medical University   China
RP He, RR; Xie, BC (通讯作者)，Southern Med Univ, Affiliated Dongguan Hosp, Dept Pharm, Dongguan, Peoples R China.
EM 2335941795@qq.com; baochengxie@126.com
RI Xie, Baocheng/GQQ 8354 2022; Xu, Yongxiang/ABF 3668 2021
FU Dongguan Science and technology of social development Program
   [202050715001197, 2019507163147]; Guangdong Basic and Applied Basic
   Research Foundation [2021A1515010151, 2021B1515140054]; National Natural
   Science Foundation of China [82000842]; Project of Administration of
   Traditional Chinese Medicine of Guangdong Province of China [20211403];
   Research and Development Foundation of Dongguan People's Hospital
   [K202012]
FX The project was supported by Dongguan Science and technology of social
   development Program (202050715001197 and 2019507163147); Guangdong Basic
   and Applied Basic Research Foundation (2021A1515010151 and
   2021B1515140054); National Natural Science Foundation of China
   (82000842); Project of Administration of Traditional Chinese Medicine of
   Guangdong Province of China (20211403); Research and Development
   Foundation of Dongguan People's Hospital (K202012).
CR Adler RA, 2016, J BONE MINER RES, V31, P1910, DOI 10.1002/jbmr.2918
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Barnes PJ, 2014, CHEM IMMUNOL ALLERGY, V100, P311, DOI 10.1159/000359984
   Carnovali M, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1253710
   Choi YH, 2018, J CELL BIOCHEM, V119, P748, DOI 10.1002/jcb.26238
   Choi YH, 2016, INT J MOL MED, V38, P610, DOI 10.3892/ijmm.2016.2655
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Cui J, 2020, J CELL MOL MED, V24, P6149, DOI 10.1111/jcmm.15229
   Ersahin T, 2015, MOL BIOSYST, V11, P1946, DOI 10.1039/c5mb00101c
   Fait Tomas, 2019, Drugs Context, V8, P212551, DOI 10.7573/dic.212551
   Guo YN, 2018, CHEM BIODIVERS, V15, DOI 10.1002/cbdv.201700578
   Han JW, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.772944
   HARRISON G, 1995, J BONE MINER RES, V10, P568, DOI 10.1002/jbmr.5650100409
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Huang XW, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109345
   Jing WB, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02690 1
   Kim DH, 2017, MOLECULES, V22, DOI 10.3390/molecules22060986
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Komori T, 2017, ADV EXP MED BIOL, V962, P83, DOI 10.1007/978 981 10 3233 2_6
   Lee CJ, 2014, BIOMED CHROMATOGR, V28, P630, DOI 10.1002/bmc.3081
   Li Y, 2022, DRUG DES DEV THER, V16, P165, DOI 10.2147/DDDT.S335024
   Liu J, 2014, BONE, V67, P81, DOI 10.1016/j.bone.2014.06.040
   Liu TZ, 2006, FOOD CHEM TOXICOL, V44, P227, DOI 10.1016/j.fct.2005.07.003
   Liu YQ, 2014, PHYTOMEDICINE, V21, P1633, DOI 10.1016/j.phymed.2014.07.016
   Luo Q, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00195
   Marí Beffa M, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.675331
   Millán JL, 2016, CALCIFIED TISSUE INT, V98, P398, DOI 10.1007/s00223 015 0079 1
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Nakamura T, 2020, BIOCHEM BIOPH RES CO, V524, P702, DOI 10.1016/j.bbrc.2020.01.136
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Pan JM, 2019, J RECEPT SIG TRANSD, V39, P80, DOI 10.1080/10799893.2019.1625061
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   SATOMURA K, 1991, ACTA ANAT, V142, P97
   Sheng CX, 2020, NEURAL PLAST, V2020, DOI 10.1155/2020/8874885
   Shui YM, 2017, AM J CHINESE MED, V45, P1093, DOI [10.1142/S0192415X17500598, 10.1142/s0192415x17500598]
   Wang Y, 2017, BIOMED PHARMACOTHER, V96, P993, DOI 10.1016/j.biopha.2017.11.136
   Whittier X, 2016, RHEUM DIS CLIN N AM, V42, P177, DOI 10.1016/j.rdc.2015.08.005
   Xie BC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.739326
   Xie BC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00411
   Yeon JT, 2019, ARCH PHARM RES, V42, P712, DOI 10.1007/s12272 019 01163 8
   Zhang LM, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.744647
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhao Yan, 2015, Zhongguo Zhong Xi Yi Jie He Za Zhi, V35, P343
NR 45
TC 18
Z9 19
U1 4
U2 53
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 4
PY 2022
VL 13
AR 894832
DI 10.3389/fphar.2022.894832
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 3B9AK
UT WOS:000828227200001
PM 35860032
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, XD
   Chen, LL
   Tan, JL
   Zhang, LP
   Xia, J
   Cheng, B
   Zhang, WZ
AF Chen, Xiaodan
   Chen, Lingling
   Tan, Jiali
   Zhang, Liping
   Xia, Juan
   Cheng, Bin
   Zhang, Weizhen
TI Rspo1 LGR4 axis in BMSCs protects bone against radiation induced injury
   through the mTOR dependent autophagy pathway
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE autophagy; bone homeostasis; bone mesenchymal stem cells; LGR4; Rspo1
AB While mesenchymal stem cells (MSCs) have been widely used to repair radiation induced bone damage, the molecular mechanism underlying the effects of MSCs in the maintenance of bone homeostasis under radiation stress remains largely unknown. In this study, the role and mechanisms of R spondin 1 (Rspo1) leucine rich repeat containing G protein coupled receptor 4 (LGR4) axis on the initiation of self defense of bone mesenchymal stem cells (BMSCs) and maintenance of bone homeostasis under radiation stress were investigated. Interestingly, radiation increased levels of Rspo1 and LGR4 in BMSCs. siRNA knockdown of Rspo1 or LGR4 aggravated radiation induced impairment of self renewal ability and osteogenic differentiation potential of BMSCs. However, exogenous Rspo1 significantly attenuated radiation induced depletion of BMSCs, and promoted the lineage shift towards osteoblasts. This alteration was associated with the reversal of mammalian target of rapamycin (mTOR) activation and autophagy decrement. Pharmacological and genetic blockade of autophagy attenuated the radio protective effects of Rspo1, rendering BMSCs more vulnerable to radiation induced injury. Then bone radiation injury was induced in C57BL6J mice to further determine the radio protective effects of Rspo1. In mice, administration of Rspo1 recombinant protein alleviated radiation induced bone loss. Our results uncover that Rspo1 LGR4 mTOR autophagy axis are key mechanisms by which BMSCs initiate self defense against radiation and maintain bone homeostasis. Targeting Rspo1 LGR4 may provide a novel strategy for the intervention of radiation induced bone damage.
C1 [Chen, Xiaodan; Chen, Lingling; Tan, Jiali; Xia, Juan; Cheng, Bin] Sun Yat Sen Univ, Hosp Stomatol, Guangzhou, Guangdong, Peoples R China.
   [Chen, Xiaodan; Chen, Lingling; Tan, Jiali; Xia, Juan; Cheng, Bin] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China.
   [Chen, Xiaodan; Chen, Lingling; Tan, Jiali; Xia, Juan; Cheng, Bin] Sun Yat Sen Univ, Guanghua Sch Stomatol, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Liping; Zhang, Weizhen] Univ Michigan, Dept Surg, Med Ctr, Ann Arbor, MI 48109 USA.
   [Zhang, Weizhen] Peking Univ, Hlth Sci Ctr, Sch Basic Sci, Dept Physiol & Pathophysiol, Beijing, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   University of Michigan System; University of Michigan; Peking University
RP Xia, J; Cheng, B (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guangzhou, Guangdong, Peoples R China.; Zhang, WZ (通讯作者)，Peking Univ, Hlth Sci Ctr, Sch Basic Sci, Dept Physiol & Pathophysiol, Beijing, Peoples R China.
EM xiajuan@mail.sysu.edu.cn; chengbin@mail.sysu.edu.cn;
   weizhenz@med.umich.edu
RI ; Chen, Lingling/JCD 4631 2023; zhang, weizhen/K 1484 2018; Bin,
   CHENG/KFQ 9943 2024; Zhang, Weizhen/K 1484 2018
OI Xia, Juan/0000 0002 4966 7119; Zhang, Weizhen/0000 0001 8791 2798
FU National Natural Science Foundation of China [81900976, 81630025,
   81730020, 81930015]; National Key R&D Program of China [2017YFC0908900];
   Guangdong Basic and Applied Basic Research Foundation [2020A151501025];
   Science and Technology Planning Project of Guangzhou, China
   [201704020063]; Fundamental Research Funds for the Central Universities
   [19ykpy80]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81900976, 81630025, 81730020, 81930015; National Key R&D Program of
   China, Grant/Award Number: 2017YFC0908900; Guangdong Basic and Applied
   Basic Research Foundation, Grant/Award Number: 2020A151501025; Science
   and Technology Planning Project of Guangzhou, China, Grant/Award Number:
   201704020063; Fundamental Research Funds for the Central Universities,
   Grant/Award Number: 19ykpy80
CR Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Bhanja P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008014
   Bo T, 2016, J BONE MINER RES, V31, P1979, DOI 10.1002/jbmr.2885
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Carbonneau CL, 2012, BLOOD, V119, P717, DOI 10.1182/blood 2011 06 361626
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chen W, 2017, CYTOKINE, V95, P27, DOI 10.1016/j.cyto.2017.02.004
   Chen X, 2022, J AM STAT ASSOC, V117, P1858, DOI 10.1080/01621459.2021.1891925
   Choi HK, 2018, J BONE MINER RES, V33, P2021, DOI 10.1002/jbmr.3530
   Chun Y, 2018, CELLS BASEL, V7, DOI 10.3390/cells7120278
   Damek Poprawa M, 2010, ARCH ORAL BIOL, V55, P358, DOI 10.1016/j.archoralbio.2010.03.010
   Deshpande SS, 2013, STEM CELLS DEV, V22, P1625, DOI 10.1089/scd.2012.0472
   Gong W, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.276
   Gronhoj C, 2018, INT J RADIAT ONCOL, V101, P581, DOI 10.1016/j.ijrobp.2018.02.034
   Hou J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.338
   Kang S, 2005, MOL CELL BIOL, V25, P1272, DOI 10.1128/MCB.25.4.1272 1282.2005
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Knight MN, 2014, MATRIX BIOL, V37, P157, DOI 10.1016/j.matbio.2014.06.003
   Krönke G, 2010, ARTHRITIS RHEUM US, V62, P2303, DOI 10.1002/art.27496
   Li ZR, 2019, AM J PHYSIOL GASTR L, V316, pG123, DOI 10.1152/ajpgi.00056.2018
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Liu SJ, 2017, MOL MED REP, V16, P4029, DOI 10.3892/mmr.2017.7120
   Liu SY, 2018, BIOCHEM BIOPH RES CO, V499, P59, DOI 10.1016/j.bbrc.2018.03.126
   Nicolay NH, 2015, CANCER LETT, V366, P133, DOI 10.1016/j.canlet.2015.06.012
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Shi GX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030564
   Shin HS, 2018, STEM CELLS, V36, P1020, DOI 10.1002/stem.2818
   Singh S, 2012, J CELL MOL MED, V16, P877, DOI 10.1111/j.1582 4934.2011.01383.x
   Sun P, 2019, J CELL PHYSIOL, V234, P10855, DOI 10.1002/jcp.27927
   Takegami Y, 2016, BIOCHEM BIOPH RES CO, V473, P255, DOI 10.1016/j.bbrc.2016.03.089
   Wang HT, 2013, J MOL MED, V91, P1421, DOI 10.1007/s00109 013 1068 3
   Wright LE, 2015, J BONE MINER RES, V30, P1268, DOI 10.1002/jbmr.2458
   Xu J, 2012, J DENT RES, V91, P702, DOI 10.1177/0022034512448661
   Xu JJ, 2012, CELL TRANSPLANT, V21, P1679, DOI 10.3727/096368911X637434
   Xu XY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0527 0
   Zhang YP, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00165
   Zhao JS, 2007, GASTROENTEROLOGY, V132, P1331, DOI 10.1053/j.gastro.2007.02.001
   Zhao JS, 2009, P NATL ACAD SCI USA, V106, P2331, DOI 10.1073/pnas.0805159106
   Zhou WJ, 2013, NATURE, V501, P107, DOI 10.1038/nature12416
NR 40
TC 13
Z9 12
U1 1
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2021
VL 236
IS 6
BP 4273
EP 4289
DI 10.1002/jcp.30051
EA JAN 2021
PG 17
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA RA5YF
UT WOS:000607843700001
PM 33452710
DA 2025 08 17
ER

PT J
AU Guo, Y
   Xue, YM
   Niu, W
   Chen, M
   Wang, M
   Ma, PX
   Lei, B
AF Guo, Yi
   Xue, Yumeng
   Niu, Wen
   Chen, Mi
   Wang, Min
   Ma, Peter X.
   Lei, Bo
TI Monodispersed Bioactive Glass Nanoparticles Enhance the Osteogenic
   Differentiation of Adipose Derived Stem Cells through Activating
   TGF Beta/Smad3 Signaling Pathway
SO PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION
LA English
DT Article
DE adipose derived stem cells; monodispersed bioactive glass nanoparticles;
   osteogenic differentiation; signaling pathway
ID GOLD NANOPARTICLES; MAPK PATHWAY; TGF BETA; REGENERATIVE MEDICINE;
   STROMAL CELLS; PROLIFERATION; DELIVERY; GROWTH; EXPRESSION; PROTEIN
AB It is important to understand the interaction mechanisms between nanomaterials and adipose derived stem cells for biomedical application. Nanoscale bioactive glass has positive effects on guiding osteoblasts differentiation and bone regeneration. However, the effects and molecular mechanism of monodispersed bioactive glass nanoparticles on the osteogenic differentiation of adipose derived stem cells are still not clear up to now. In this study, the effects and underlying molecular mechanism of monodispersed bioactive glass nanoparticles on the osteogenic differentiation of adipose derived stem cells are investigated in minute detail. The results show that nanoparticles (100 200 nm) can be absorbed by stem cells and is distributed in cytoplasm and nucleus. In both culture conditions (normal and osteoinductive), nanoparticles (80 mu g mL( 1)) can significantly enhance the osteogenic differentiation of stem cells through upregulating the alkaline phosphatase activity, osteogenic genes and protein expressions, as well as calcium deposition. Further study suggests that the activation of transforming growth factor beta/Smad3 signaling pathway plays an important role in the osteogenic differentiation of adipose derived stem cells enhanced by monodispersed nanoparticles. This study may have important implications for better understanding of stem cells fate induced by monodispersed nanoparticles and provide a promising approach toward stem cells based bone regeneration.
C1 [Guo, Yi; Xue, Yumeng; Niu, Wen; Chen, Mi; Wang, Min; Ma, Peter X.; Lei, Bo] Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian 710054, Shaanxi, Peoples R China.
   [Ma, Peter X.] Univ Michigan, Macromol Sci & Engn Ctr, Dept Mat Sci & Engn, Dept Biol & Mat Sci,Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Lei, Bo] Xi An Jiao Tong Univ, State Key Lab Mech Behav Mat, Xian 710054, Shaanxi, Peoples R China.
   [Lei, Bo] Xi An Jiao Tong Univ, State Key Lab Mfg Syst Engn, Xian 710054, Shaanxi, Peoples R China.
   [Lei, Bo] Xi An Jiao Tong Univ, Instrument Anal Ctr, Xian 710054, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; University of Michigan System; University of
   Michigan; Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an
   Jiaotong University
RP Lei, B (通讯作者)，Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian 710054, Shaanxi, Peoples R China.; Lei, B (通讯作者)，Xi An Jiao Tong Univ, State Key Lab Mech Behav Mat, Xian 710054, Shaanxi, Peoples R China.; Lei, B (通讯作者)，Xi An Jiao Tong Univ, State Key Lab Mfg Syst Engn, Xian 710054, Shaanxi, Peoples R China.; Lei, B (通讯作者)，Xi An Jiao Tong Univ, Instrument Anal Ctr, Xian 710054, Shaanxi, Peoples R China.
EM rayboo@xjtu.edu.cn
RI X, Peter/E 4895 2011; Lei, Bo/B 9463 2009
FU China Postdoctoral Science Foundation [2017M613148]; State Key
   Laboratory for Mechanical Behavior of Materials [20161801]; Natural
   Science Basic Research Plan in Shaanxi Province of China [2015JQ5165];
   National Natural Science Foundation of China [51502237]
FX The authors acknowledge the valuable comments of potential reviewers.
   This work was supported by the China Postdoctoral Science Foundation
   (Grant No. 2017M613148), State Key Laboratory for Mechanical Behavior of
   Materials (No 20161801), the Natural Science Basic Research Plan in
   Shaanxi Province of China (Grant No. 2015JQ5165), and the National
   Natural Science Foundation of China (Grant No. 51502237).
CR Banks JM, 2014, BIOMATERIALS, V35, P8951, DOI 10.1016/j.biomaterials.2014.07.012
   Choi SY, 2015, INT J NANOMED, V10, P4383, DOI 10.2147/IJN.S78775
   Dobbenga S, 2016, ACTA BIOMATER, V46, P3, DOI 10.1016/j.actbio.2016.09.031
   Du YZ, 2018, BIOMATERIALS, V157, P40, DOI 10.1016/j.biomaterials.2017.12.005
   Gong WY, 2012, CHIN J DENT RES, V15, P145
   Gong WY, 2017, RSC ADV, V7, P13760, DOI 10.1039/c6ra26713k
   González Cruz RD, 2012, P NATL ACAD SCI USA, V109, pE1523, DOI 10.1073/pnas.1120349109
   Guo X, 2010, ACTA BIOMATER, V6, P2920, DOI 10.1016/j.actbio.2010.02.046
   Haimi S, 2009, ACTA BIOMATER, V5, P3122, DOI 10.1016/j.actbio.2009.04.006
   Han PP, 2013, BIOMATER SCI UK, V1, P379, DOI 10.1039/c2bm00108j
   Henkel J, 2013, BONE RES, V1, P216, DOI 10.4248/BR201303002
   Hwang NS, 2009, WIRES SYST BIOL MED, V1, P97, DOI 10.1002/wsbm.26
   Isaac J, 2011, EUR CELLS MATER, V21, P130, DOI 10.22203/eCM.v021a11
   Jiao K, 2015, ACTA BIOMATER, V19, P23, DOI 10.1016/j.actbio.2015.03.012
   Koli K, 2008, BONE, V43, P679, DOI 10.1016/j.bone.2008.06.016
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lei B, 2012, J MATER CHEM, V22, P16906, DOI 10.1039/c2jm31384g
   Lei B, 2011, J MATER CHEM, V21, P12725, DOI 10.1039/c1jm11547b
   Li JC, 2017, J MATER CHEM B, V5, P1353, DOI 10.1039/c6tb03276a
   Liu Y, 2016, J MATER CHEM B, V4, P4389, DOI 10.1039/c5tb01898f
   Mizuno H, 2012, STEM CELLS, V30, P804, DOI 10.1002/stem.1076
   Ng F, 2008, BLOOD, V112, P295, DOI 10.1182/blood 2007 07 103697
   Oedayrajsingh Varma MJ, 2006, CYTOTHERAPY, V8, P166, DOI 10.1080/14653240600621125
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Quarto N, 2012, STEM CELLS, V30, P2709, DOI 10.1002/stem.1250
   Ravichandran R, 2012, BIOMATERIALS, V33, P846, DOI 10.1016/j.biomaterials.2011.10.030
   Rhyu DY, 2005, J AM SOC NEPHROL, V16, P667, DOI 10.1681/ASN.2004050425
   Russo V, 2014, STEM CELL TRANSL MED, V3, P206, DOI 10.5966/sctm.2013 0125
   Santo VE, 2012, J CONTROL RELEASE, V162, P19, DOI 10.1016/j.jconrel.2012.06.001
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Uccelli A, 2011, LANCET NEUROL, V10, P649, DOI 10.1016/S1474 4422(11)70121 1
   Wang QW, 2016, BIOMATERIALS, V86, P11, DOI 10.1016/j.biomaterials.2016.02.004
   Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147
   Woodruff MA, 2012, MATER TODAY, V15, P430, DOI 10.1016/S1369 7021(12)70194 3
   Xia LG, 2014, BIOMATERIALS, V35, P8514, DOI 10.1016/j.biomaterials.2014.06.028
   Xue YM, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700630
   Xue YM, 2015, J MATER CHEM B, V3, P3831, DOI 10.1039/c5tb00204d
   Yang KN, 2013, NANOSCALE, V5, P1205, DOI 10.1039/c2nr33575a
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Yu M, 2017, ACS APPL MATER INTER, V9, P8460, DOI 10.1021/acsami.6b13874
   Yu M, 2017, NANO RES, V10, P49, DOI 10.1007/s12274 016 1265 9
   Zhou XJ, 2015, ACS APPL MATER INTER, V7, P15777, DOI 10.1021/acsami.5b02636
   Zhu YX, 2008, CELL BIOCHEM FUNCT, V26, P664, DOI 10.1002/cbf.1488
NR 44
TC 23
Z9 23
U1 0
U2 47
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0934 0866
EI 1521 4117
J9 PART PART SYST CHAR
JI Part. Part. Syst. Charact.
PD JUL
PY 2018
VL 35
IS 7
AR 1800087
DI 10.1002/ppsc.201800087
PG 10
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA GN9KF
UT WOS:000439516100009
OA Green Published
DA 2025 08 17
ER

PT J
AU Xie, XD
   Hu, LC
   Mi, BB
   Xue, H
   Hu, YQ
   Panayi, AC
   Endo, Y
   Chen, L
   Yan, CC
   Lin, Z
   Li, H
   Zhou, W
   Liu, GH
AF Xie, Xudong
   Hu, Liangcong
   Mi, Bobin
   Xue, Hang
   Hu, Yiqiang
   Panayi, Adriana C.
   Endo, Yori
   Chen, Lang
   Yan, Chenchen
   Lin, Ze
   Li, Hui
   Zhou, Wu
   Liu, Guohui
TI Metformin alleviates bone loss in ovariectomized mice through inhibition
   of autophagy of osteoclast precursors mediated by E2F1
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE Metformin; Osteoclast precursors; Bone loss; Autophagy; E2F1; BECN1;
   BNIP3
ID REGULATES AUTOPHAGY; ANABOLIC THERAPY; BECLIN 1; DIFFERENTIATION;
   OSTEOPROTEGERIN; TRANSCRIPTION; OSTEOPOROSIS; MACROPHAGES; ACTIVATION;
   PREVENTION
AB Background: Postmenopausal bone loss, mainly caused by excessive bone resorption mediated by osteoclasts, has become a global public health burden. Metformin, a hypoglycemic drug, has been reported to have beneficial effects on maintaining bone health. However, the role and underlying mechanism of metformin in ovariectomized (OVX)induced bone loss is still vague.
   Results: In this study, we demonstrated for the first time that metformin administration alleviated bone loss in postmenopausal women and ovariectomized mice, based on reduced bone resorption markers, increased bone mineral density (BMD) and improvement of bone microstructure. Then, osteoclast precursors administered metformin in vitro and in vivo were collected to examine the differentiation potential and autophagical level. The mechanism was investigated by infection with lentivirus mediated BNIP3 or E2F1 overexpression. We observed a dramatical inhibition of autophagosome synthesis and osteoclast formation and activity. Treatment with RAPA, an autophagy activator, abrogated the metformin mediated autophagy downregulation and inhibition of osteoclastogenesis. Additionally, overexpression of E2F1 demonstrated that reduction of OVX upregulated autophagy mediated by metformin was E2F1 dependent. Mechanistically, metformin mediated downregulation of E2F1 in ovariectomized mice could downregulate BECN1 and BNIP3 levels, which subsequently perturbed the binding of BECN1 to BCL2. Furthermore, the disconnect between BECN1 and BCL2 was shown by BNIP3 overexpression.
   Conclusion: In summary, we demonstrated the effect and underlying mechanism of metformin on OVX induced bone loss, which could be, at least in part, ascribed to its role in downregulating autophagy during osteoclastogenesis via E2F1 dependent BECN1 and BCL2 downregulation, suggesting that metformin or E2F1 inhibitor is a potential agent against postmenopausal bone loss.
C1 [Xie, Xudong; Hu, Liangcong; Mi, Bobin; Xue, Hang; Hu, Yiqiang; Chen, Lang; Yan, Chenchen; Lin, Ze; Li, Hui; Zhou, Wu; Liu, Guohui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430022, Peoples R China.
   [Xie, Xudong; Hu, Liangcong; Mi, Bobin; Xue, Hang; Hu, Yiqiang; Chen, Lang; Yan, Chenchen; Li, Hui; Zhou, Wu; Liu, Guohui] Hubei Prov Key Lab Oral & Maxillofacial Dev & Reg, Wuhan 430022, Peoples R China.
   [Panayi, Adriana C.; Endo, Yori] Harvard Med Sch, Brigham & Womens Hosp, Div Plast Surg, Boston, MA 02215 USA.
C3 Huazhong University of Science & Technology; Harvard University; Harvard
   Medical School; Harvard University Medical Affiliates; Brigham & Women's
   Hospital
RP Li, H; Zhou, W; Liu, GH (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430022, Peoples R China.; Li, H; Zhou, W; Liu, GH (通讯作者)，Hubei Prov Key Lab Oral & Maxillofacial Dev & Reg, Wuhan 430022, Peoples R China.
EM lihuiunion@163.com; 2016XH0120@hust.edu.cn; liuguohui@hust.edu.cn
RI Panayi, Adriana/AAF 1817 2020; chou, wu/AAI 1145 2019; Mi,
   Bobin/LTD 1938 2024; Yan, chenchen/HJY 0642 2023; Endo,
   Yori/AAY 8962 2020
OI Mi, Bobin/0000 0002 6994 4363; 
FU National Science Foundation of China [82002313, 82072444]; National Key
   Research & Development Program of China [2018YFC2001502,
   2018YFB1105705]; Hubei Province Key Laboratory of Oral and Maxillofacial
   Development and Regeneration [2020kqhm008]
FX This work was supported by the National Science Foundation of China (No.
   82002313, No. 82072444), the National Key Research & Development Program
   of China (No. 2018YFC2001502, 2018YFB1105705); Hubei Province Key
   Laboratory of Oral and Maxillofacial Development and Regeneration (No.
   2020kqhm008).
CR Arai A, 2019, J BONE MINER RES, V34, P1753, DOI 10.1002/jbmr.3756
   BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092 8674(91)90558 G
   Bahrambeigi S, 2019, BIOMED PHARMACOTHER, V109, P1593, DOI 10.1016/j.biopha.2018.11.032
   Bian F, 2021, PHARMAZIE, V76, P244, DOI 10.1691/ph.2021.1378
   Blümel JE, 2020, GYNECOL ENDOCRINOL, V36, P421, DOI 10.1080/09513590.2020.1718092
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen QC, 2018, ACS APPL MATER INTER, V10, P23700, DOI 10.1021/acsami.8b08606
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   de Araújo AA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183506
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Dyson NJ, 2016, GENE DEV, V30, P1492, DOI 10.1101/gad.282145.116
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Fu LJ, 2020, CALCIFIED TISSUE INT, V107, P60, DOI 10.1007/s00223 020 00687 2
   Guo HH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0261127
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Hidayat K, 2019, OBES REV, V20, P1494, DOI 10.1111/obr.12885
   Hu Y, 2021, BIOACT MATER, V6, P2905, DOI 10.1016/j.bioactmat.2021.02.014
   Jiang H, 2010, CANCER RES, V70, P7882, DOI 10.1158/0008 5472.CAN 10 1604
   Jung YY, 2016, EXPERT OPIN THER TAR, V20, P167, DOI 10.1517/14728222.2016.1085971
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Khan MP, 2015, DIABETES, V64, P2609, DOI 10.2337/db14 1611
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kuma A, 2017, AUTOPHAGY, V13, P1619, DOI 10.1080/15548627.2017.1343770
   Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092 8674(00)80290 1
   Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li JZ, 2016, SCI REP UK, V6, DOI 10.1038/srep23975
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Liu LS, 2012, J ENDODONT, V38, P943, DOI 10.1016/j.joen.2012.03.010
   Liu W, 2020, EXP THER MED, V20, P1889, DOI 10.3892/etm.2020.8903
   Ma J, 2018, EUR REV MED PHARMACO, V22, P7962, DOI 10.26355/eurrev_201811_16424
   Ma XC, 2012, AUTOPHAGY, V8, P297, DOI 10.4161/auto.18658
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Marycz K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9785890
   Matsuoka Y, 2021, CLIN EXP RHEUMATOL, V39, P763, DOI 10.55563/clinexprheumatol/zn2u9h
   Meijer WH, 2007, AUTOPHAGY, V3, P106, DOI 10.4161/auto.3595
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Murata K, 2017, IMMUNITY, V47, P66, DOI 10.1016/j.immuni.2017.06.018
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Niu C, 2019, AUTOPHAGY, V15, P843, DOI 10.1080/15548627.2019.1569913
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pernicova I, 2020, LANCET DIABETES ENDO, V8, P278, DOI 10.1016/S2213 8587(20)30021 8
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Ruan C, 2021, AUTOPHAGY, V17, P1426, DOI 10.1080/15548627.2020.1763019
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Shapiro IM, 2014, AUTOPHAGY, V10, P7, DOI 10.4161/auto.26679
   Shi J, 2015, BONE, V79, P222, DOI 10.1016/j.bone.2015.06.014
   Sofer E, 2016, HEPATOL INT, V10, P169, DOI 10.1007/s12072 015 9649 6
   Son HJ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/973986
   Son SM, 2016, J ALZHEIMERS DIS, V51, P1197, DOI 10.3233/JAD 151200
   Tao LY., 2021, FRONT CELL DEV BIOL, V9
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021
   Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0731 5
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xie ZL, 2011, DIABETES, V60, P1770, DOI 10.2337/db10 0351
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Xu XQ, 2020, FASEB J, V34, P8402, DOI 10.1096/fj.201902528RRR
   Yan Z, 2018, MOL MED, V24, DOI 10.1186/s10020 018 0013 x
   Zhang Y, 2012, BLOOD, V119, P2895, DOI 10.1182/blood 2011 08 372383
   Zhao HY, 2020, J CELL PHYSIOL, V235, P2997, DOI 10.1002/jcp.29205
   Zhou X, 2021, NANO LETT, V21, P7998, DOI 10.1021/acs.nanolett.1c02150
   Zhou Y, 2018, CALCIFIED TISSUE INT, V103, P581, DOI 10.1007/s00223 018 0457 6
NR 75
TC 22
Z9 22
U1 1
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1478 811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD OCT 25
PY 2022
VL 20
IS 1
AR 165
DI 10.1186/s12964 022 00966 5
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 5N9EQ
UT WOS:000872089700001
PM 36284303
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Riddle, RC
   Taylor, AF
   Rogers, JR
   Donahue, HJ
AF Riddle, Ryan C.
   Taylor, Amanda F.
   Rogers, Jennifer R.
   Donahue, Henry J.
TI ATP release mediates fluid flow induced proliferation of human bone
   marrow stromal cells
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE bone marrow stromal cells; fluid flow; ATP; calcium; calcineurin
ID MESENCHYMAL STEM CELLS; INTRACELLULAR CALCIUM MOBILIZATION;
   GAP JUNCTIONAL HEMICHANNELS; ACTIVATED PROTEIN KINASE; OSTEOBLAST LIKE
   CELLS; SHEAR STRESS; MECHANICAL STRAIN; IN VIVO; EXTRACELLULAR
   NUCLEOTIDES; INTRAMEDULLARY PRESSURE
AB Introduction: Regulation of bone cell activity by autocrine/paracrine factors is a well established mechanism by which skeletal homeostasis is regulated by mechanical signals. The release of extracellular nucleotides in particular has been shown to induce many of the responses thought to be necessary for load induced bone formation. In these studies, we examined the effect of oscillatory fluid flow on the release of ATP from bone marrow stromal cells (BMSCs) and the effect of ATP release on BMSC proliferation and intracellular calcium signaling pathways.
   Materials and Methods: BMSCs were exposed to oscillatory fluid flow, and the concentration of ATP in conditioned media samples was determined using a luciferin:luciferase based reaction. Western blot analysis was used to examine the expression of purinergic receptors. Using pharmacological antagonists of gap junction hemichannels and vesicular trafficking, we studied the mechanism of ATP release from BMSCs. Apyrase was used to study the effect of extracellular nucleotides on intracellular calcium concentration, calcineurin activity, and nuclear factor of activated T cells (NFAT) nuclear translocation.
   Results and Conclusions: Fluid flow exposure induced the flow rate dependent release of ATP from BMSCs that was attenuated by treatment with monensin and N ethylmaleimide, suggesting a vesicular mechanism. Treating BMSCs with ATP, but not other nucleotides, increased cellular proliferation. Moreover, extracellular ATP was a prerequisite for fluid flow induced increases in intracellular calcium concentration, activation of calcineurin, the nuclear translocation of NFATc1, and proliferation. These data indicate that ATP regulates not only osteoblastic and osteocytic cell behavior but also that of mesenchymal precursors and support our hypothesis that similar mechanotransduction mechanisms are activated by fluid flow in these cell types.
C1 Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Milton S Hershey Med Ctr,Div Musculoskeletal Sci, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health
RP Donahue, HJ (通讯作者)，Penn State Univ, Coll Med, Dept Orthopaed & Rehabil, Milton S Hershey Med Ctr,Div Musculoskeletal Sci, Hershey, PA 17033 USA.
EM hdonahue@psu.edu
FU NIA NIH HHS [AG13087] Funding Source: Medline
CR Ajubi NE, 1999, AM J PHYSIOL ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171
   Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021 9290(00)00231 1
   Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097 2765(02)00701 3
   Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852
   Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344 200112000 00012
   Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315
   CECCHELLI R, 1986, BIOSCIENCE REP, V6, P227, DOI 10.1007/BF01115011
   Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04 10 0912
   Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100
   Costessi A, 2005, BONE, V36, P418, DOI 10.1016/j.bone.2004.10.016
   Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735
   COWIN SC, 1991, J BIOMECH ENG T ASME, V113, P191, DOI 10.1115/1.2891234
   Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092 8674(00)80571 1
   DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006 291X(86)90522 X
   Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960
   Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0
   Donahue HJ, 2000, AM J PHYSIOL CELL PH, V278, pC315, DOI 10.1152/ajpcell.2000.278.2.C315
   Donahue TLH, 2003, J BIOMECH, V36, P1363, DOI 10.1016/S0021 9290(03)00118 0
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812
   Gallagher J. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P432
   Genetos DC, 2005, J BONE MINER RES, V20, P41, DOI 10.1359/jbmr.041009
   Hazama A, 1998, PFLUG ARCH EUR J PHY, V437, P31, DOI 10.1007/s004240050742
   HILLAM RA, 1995, J BONE MINER RES, V10, P683
   Holtorf HL, 2005, J BIOMED MATER RES A, V72A, P326, DOI 10.1002/jbm.a.30251
   IRVIN JL, 1954, J BIOL CHEM, V210, P45
   Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021 9290(98)00114 6
   Jiang JX, 2003, CELL COMMUN ADHES, V10, P259, DOI 10.1080/15419060390262994
   Johnson EN, 2003, J BIOL CHEM, V278, P1686, DOI 10.1074/jbc.M210250200
   Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497
   Kahl CR, 2004, MOL BIOL CELL, V15, P1833, DOI 10.1091/mbc.E03 10 0730
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   KEPHART CJ, 2005, 51 ANN M ORTH RES SO
   KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45
   Knight GE, 2002, AM J PHYSIOL RENAL, V282, pF281, DOI 10.1152/ajprenal.00293.2000
   KUFAHL RH, 1990, J BIOMECH, V23, P171, DOI 10.1016/0021 9290(90)90350 C
   Lambrecht G, 2000, N S ARCH PHARMACOL, V362, P340, DOI 10.1007/s002100000312
   Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002
   MACHWATE M, 1993, AM J PHYSIOL, V264, pE790, DOI 10.1152/ajpendo.1993.264.5.E790
   MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304 4157(90)90008 Z
   Nakamura E, 2000, AM J PHYSIOL CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510
   Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200
   PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Qin YX, 2003, J BIOMECH, V36, P1427, DOI 10.1016/S0021 9290(03)00127 1
   Qin YX, 2002, ANN BIOMED ENG, V30, P693, DOI 10.1114/1.1483863
   Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063
   REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113
   REICH KM, 1991, AM J PHYSIOL, V261, pC428, DOI 10.1152/ajpcell.1991.261.3.C428
   Riddle RC, 2006, AM J PHYSIOL CELL PH, V290, pC776, DOI 10.1152/ajpcell.00082.2005
   Romanello M, 2005, BIOCHEM BIOPH RES CO, V331, P1429, DOI 10.1016/j.bbrc.2005.03.246
   Romanello M, 2001, BIOCHEM BIOPH RES CO, V289, P1275, DOI 10.1006/bbrc.2001.6124
   RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711
   Saunders MM, 2001, AM J PHYSIOL CELL PH, V281, pC1917, DOI 10.1152/ajpcell.2001.281.6.C1917
   SCHOFL C, 1992, J BONE MINER RES, V7, P485
   Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732
   Sikavitsas VI, 2005, ANN BIOMED ENG, V33, P63, DOI 10.1007/s10439 005 8963 x
   Sikavitsas VI, 2003, P NATL ACAD SCI USA, V100, P14683, DOI 10.1073/pnas.2434367100
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200
   Swan CC, 2003, J BIOMECH ENG T ASME, V125, P25, DOI 10.1115/1.1535191
   Tate MLK, 2000, J EXP BIOL, V203, P2737
   Terai K, 1999, J BONE MINER RES, V14, P839, DOI 10.1359/jbmr.1999.14.6.839
   Thomas GP, 1996, CALCIFIED TISSUE INT, V58, P101, DOI 10.1007/s002239900018
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   von Kügelgen I, 2000, N S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   WRONSKI TJ, 1983, AM J PHYSIOL, V244, pR305, DOI 10.1152/ajpregu.1983.244.3.R305
   Yellowley CE, 2000, J BONE MINER RES, V15, P209, DOI 10.1359/jbmr.2000.15.2.209
   You J, 2002, J BIOL CHEM, V277, P48724, DOI 10.1074/jbc.M209245200
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   ZHANG RW, 1995, J BONE MINER RES, V10, P415
NR 77
TC 80
Z9 102
U1 2
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2007
VL 22
IS 4
BP 589
EP 600
DI 10.1359/JBMR.070113
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 150RK
UT WOS:000245234000013
PM 17243863
DA 2025 08 17
ER

PT J
AU Li, MY
   Wang, W
   Wang, P
   Yang, K
   Sun, H
   Wang, XJ
AF Li, Manyu
   Wang, Wei
   Wang, Ping
   Yang, Kun
   Sun, Hui
   Wang, Xijun
TI The Pharmacological Effects of Morroniside and Loganin Isolated from
   Liuweidihuang Wan, on MC3T3 E1 Cells
SO MOLECULES
LA English
DT Article
DE Liuweidihuang Wan; morroniside; loganin; osteoporosis; MC3T3 E1
ID OSTEOBLAST DIFFERENTIATION; BONE FORMATION; APOPTOSIS; OSTEOPOROSIS;
   EPIDEMIOLOGY; PREVENTION; FAMILY
AB Liuweidihuang Wan (LW), initially a well known formula for curing "wu chi wu ruan", is commonly used nowadays for clinical treatment of Postmenopausal Osteoporosis (PO), but the identity of the effective substance(s) remains unclear. The present study was designed to evaluate the effects of morroniside and loganin isolated from LW on the proliferation, differentiation and apoptosis of MC3T3 E1 cells, as well as the possible mechanism of action. Morroniside and loganin had no effects on the proliferation of MC3T3 E1 cells, but both susbtances could improve the activity of alkaline phosphatase (ALP), and increase the contents of collagen type I and osteocalcin. Simultaneously, the mRNA expression of caspase 3, capase 9, RANKL was down regulated and that of bcl 2 was up regulated, which partially explains the anti osteoporosis mechanism in MC3T3 E1 cells. In conclusion, morroniside and loganin may directly promote the differentiation and inhibit the apoptosis of MC3T3 E1 cells, and accordingly indirectly reduce bone resorption, which makes them promising natural drugs leads for treating PO in the near future.
C1 [Li, Manyu; Wang, Wei; Wang, Ping; Yang, Kun; Sun, Hui; Wang, Xijun] Heilongjiang Univ Chinese Med, Natl TCM Key Lab Serum Pharmacochem, Harbin 150040, Peoples R China.
C3 Heilongjiang University of Chinese Medicine
RP Wang, XJ (通讯作者)，Heilongjiang Univ Chinese Med, Natl TCM Key Lab Serum Pharmacochem, Heping Rd 24, Harbin 150040, Peoples R China.
EM phar_research@hotmail.com
RI Lu, Xiao Yun/V 6699 2019; Wang, Xijun/C 4477 2014
OI Wang, Xijun/0000 0002 0949 3492
FU National Natural Science Foundation of China [30572300]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No: 30572300).
CR AMUDESWARI S, 1987, COLLAGEN REL RES, V7, P215
   BOYLE WJ, 1998, BONE, V23, P189
   Chen T., 2003, TIANJIN PHARM, V15, P5
   Chua CC, 2003, BBA MOL CELL RES, V1642, P79, DOI 10.1016/S0167 4889(03)00100 9
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dennison E, 2006, RHEUM DIS CLIN N AM, V32, P617, DOI 10.1016/j.rdc.2006.08.003
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Guan J., 2009, Hainan Med J, V20, P79, DOI [10.3969/j.issn.1003 6350.2009.05.035, DOI 10.3969/J.ISSN.1003 6350.2009.05.035]
   [韩旭华 Han Xuhua], 2002, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V18, P1
   Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200
   Israels LG, 1999, STEM CELLS, V17, P306, DOI 10.1002/stem.170306
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Jin UH, 2006, J ETHNOPHARMACOL, V106, P333, DOI 10.1016/j.jep.2006.01.012
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188
   KNOTT L, 1995, BIOCHEM J, V310, P1045, DOI 10.1042/bj3101045
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   LINDSAY R, 1980, LANCET, V2, P1151
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   *PHARM COMM, 2005, PHARM PEOPL REP CHIN, P401
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Ross PD, 1996, ARCH INTERN MED, V156, P1399, DOI 10.1001/archinte.156.13.1399
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   TURNER RT, 1992, ENDOCRINOLOGY, V131, P883, DOI 10.1210/en.131.2.883
   Wang Xi Jun, 2007, Chinese Journal of Natural Medicines, V5, P277
   Wang XiJun Wang XiJun, 2004, Chinese Journal of Natural Medicines, V2, P219
   Wang XJ, 2008, CHIN J EXP TRADIT ME, V14, P33
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
NR 38
TC 55
Z9 62
U1 3
U2 33
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2010
VL 15
IS 10
BP 7403
EP 7414
DI 10.3390/molecules15107403
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 672MG
UT WOS:000283587400049
PM 20966881
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Ruscitto, A
   Scarpa, V
   Morel, M
   Pylawka, S
   Shawber, CJ
   Embree, MC
AF Ruscitto, A.
   Scarpa, V.
   Morel, M.
   Pylawka, S.
   Shawber, C. J.
   Embree, M. C.
TI Notch Regulates Fibrocartilage Stem Cell Fate and Is Upregulated in
   Inflammatory TMJ Arthritis
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE cartilage; temporomandibular disorders; regenerative medicine; bone
   biology; cell signaling; joint disease
ID ENDOCHONDRAL OSSIFICATION; TEMPOROMANDIBULAR JOINT; ARTICULAR CARTILAGE;
   MANDIBULAR CONDYLE; OSTEOARTHRITIS; CHONDROCYTES; RECEPTORS; LIGANDS;
   BONE; OSTEOBLASTS
AB The Notch pathway is critical for the development of the extracellular matrix in cartilage by regulating both anabolic and catabolic cellular activities. Similarly, Notch signaling plays a biphasic role in adult cartilage health and osteoarthritis by maintaining homeostasis and contributing to degeneration, respectively. The temporomandibular joint (TMJ) is the synovial joint of the craniofacial complex and is subject to injury and osteoarthritis. While Notch has been studied in axial skeletal joints, little is known about the role of Notch in TMJ development and disease. We identified fibrocartilage stem cells (FCSCs) localized within the TMJ condyle superficial zone niche that regenerate cartilage and repair joint injury. Here we investigate the role of Notch in regulating TMJ development and FCSC fate. Using a Notch reporter mouse, we discovered FCSCs localized within the TMJ superficial niche exhibit Notch activity during TMJ morphogenesis. We further showed that constitutively activating Notch promotes FCSC differentiation toward both cartilage and bone lineages, but inhibits adipogenesis. Using a TNF alpha induced TMJ inflammatory arthritis mouse model, we found that the expression of Notch receptors and ligands are upregulated and coupled with cells undergoing cartilage to bone transdifferentiation, which may contribute to TMJ pathogenesis. We also discovered that global Notch inhibition reduces osteogenic and chondrogenic differentiation of FCSCs. Together, these findings suggest that Notch is critical for FCSC fate specification and TMJ homeostasis, and reveal that inhibition of the Notch pathway may be a new therapeutic target for treating TMJ osteoarthritis.
C1 [Ruscitto, A.; Scarpa, V.; Morel, M.; Pylawka, S.; Embree, M. C.] Columbia Univ, Cartilage Biol & Regenerat Med Lab, Coll Dent Med, Irving Med Ctr, 630 W 168 St,P&S 16 440, New York, NY 10032 USA.
   [Shawber, C. J.] Columbia Univ, Vagelos Coll Phys & Surg, Irving Med Ctr, Dept OB GYN,Div Reprod Sci, New York, NY USA.
C3 Columbia University; NewYork Presbyterian Hospital; NewYork Presbyterian
   Hospital; Columbia University
RP Embree, MC (通讯作者)，Columbia Univ, Cartilage Biol & Regenerat Med Lab, Coll Dent Med, Irving Med Ctr, 630 W 168 St,P&S 16 440, New York, NY 10032 USA.
EM mce2123@cumc.columbia.edu
OI Pylawka, Serhiy/0000 0002 4054 1456
FU National Institutes of Health (NIH)/National Institute of Dental and
   Craniofacial Research (NIDCR) [5R00DE0220660]; NIH/NIDCR [1R01DE
   029068 01A1]
FX This investigation was supported by National Institutes of Health
   (NIH)/National Institute of Dental and Craniofacial Research (NIDCR)
   5R00DE0220660 (M.C.E.) and NIH/NIDCR 1R01DE 029068 01A1 (M.C.E.). The
   authors declare no potential conflicts of interest with respect to the
   authorship and/or publication of this article.
CR [Anonymous], 2014, Management of Temporomandibular Disorder and Occlusion
   Artavanis Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   BENJAMIN M, 1990, J ANAT, V171, P1
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Canalis E, 2018, OSTEOPOROSIS INT, V29, P2611, DOI 10.1007/s00198 018 4694 3
   Chai Y, 2000, DEVELOPMENT, V127, P1671
   Choi S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48190 5
   D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070 2153(10)92003 6
   Embree MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13073
   Englund M, 2003, ARTHRITIS RHEUM US, V48, P2178, DOI 10.1002/art.11088
   Grogan SP, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2719
   Hayes AJ, 2003, J ANAT, V202, P495, DOI 10.1046/j.1469 7580.2003.00185.x
   Hosaka Y, 2013, P NATL ACAD SCI USA, V110, P1875, DOI 10.1073/pnas.1207458110
   Huey DJ, 2012, SCIENCE, V338, P917, DOI 10.1126/science.1222454
   Jing Y, 2015, J DENT RES, V94, P1668, DOI 10.1177/0022034515598135
   Karlsson C, 2009, INT REV CEL MOL BIO, V275, P65, DOI 10.1016/S1937 6448(09)75003 8
   KNEELAND JB, 1987, RADIOLOGY, V165, P179, DOI 10.1148/radiology.165.1.3628767
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Liang WN, 2016, EXP THER MED, V11, P481, DOI 10.3892/etm.2015.2937
   Liu ZY, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa3792
   Luo XT, 2018, J CRANIO MAXILL SURG, V46, P1132, DOI 10.1016/j.jcms.2018.04.026
   Mahjoub M, 2012, TISSUE CELL, V44, P182, DOI 10.1016/j.tice.2012.03.001
   Morel M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223244
   Murtomaki A, 2013, DEVELOPMENT, V140, P2365, DOI 10.1242/dev.083865
   Nathan J, 2018, J DENT RES, V97, P329, DOI 10.1177/0022034517735094
   Nowotschin S, 2013, BMC DEV BIOL, V13, DOI 10.1186/1471 213X 13 15
   Owtad P, 2013, J DENT RES, V92, P315, DOI 10.1177/0022034513476302
   Park J, 2015, BIOL OPEN, V4, P608, DOI 10.1242/bio.201411031
   Saito T, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1296 y
   Scrivani SJ, 2008, NEW ENGL J MED, V359, P2693, DOI 10.1056/NEJMra0802472
   Shao S, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0295 3
   Shawber CJ, 2007, J CLIN INVEST, V117, P3369, DOI 10.1172/JCI24311
   Shibata S, 1996, ARCH ORAL BIOL, V41, P47, DOI 10.1016/0003 9969(95)00105 0
   SILBERMANN M, 1972, ANAT RECORD, V172, P659, DOI 10.1002/ar.1091720406
   Singh M, 2009, J BIOMECH, V42, P405, DOI 10.1016/j.jbiomech.2008.12.012
   Stoustrup P, 2015, NAT REV RHEUMATOL, V11, P565, DOI 10.1038/nrrheum.2015.97
   Ustunel I, 2008, ACTA HISTOCHEM, V110, P397, DOI 10.1016/j.acthis.2007.12.005
   Yamaki Yuji, 2005, Odontology, V93, P30, DOI 10.1007/s10266 005 0046 9
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
NR 40
TC 31
Z9 38
U1 1
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD SEP
PY 2020
VL 99
IS 10
BP 1174
EP 1181
AR 0022034520924656
DI 10.1177/0022034520924656
EA MAY 2020
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA ND3WL
UT WOS:000534924300001
PM 32442041
OA Green Published
DA 2025 08 17
ER

PT J
AU Gu, CH
   Chen, PF
   Tian, HS
   Yang, Y
   Huang, ZX
   Yan, HG
   Tang, CX
   Xiang, JJ
   Shangguan, LQ
   Pan, KF
   Chen, PY
   Huang, Y
   Liu, ZM
   Tang, RK
   Fan, SW
   Lin, XF
AF Gu, Chenhui
   Chen, Pengfei
   Tian, Hongsen
   Yang, Yang
   Huang, Zhenxiang
   Yan, Huige
   Tang, Chenxi
   Xiang, Jiajia
   Shangguan, Liqing
   Pan, Kaifeng
   Chen, Pengyu
   Huang, Yue
   Liu, Zhaoming
   Tang, Ruikang
   Fan, Shunwu
   Lin, Xianfeng
TI Targeting initial tumour osteoclast spatiotemporal interaction to
   prevent bone metastasis
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID BREAST CANCER; HETEROGENEITY; COLONIZATION; MIGRASOME; BINDING; SEEDS
AB Bone is the most common site of metastasis, and although low proliferation and immunoediting at the early stage make existing treatment modalities less effective, the microenvironment inducing behaviour could be a target for early intervention. Here we report on a spatiotemporal coupling interaction between tumour cells and osteoclasts, and named the tumour associated osteoclast 'tumasteoclast' a subtype of osteoclasts in bone metastases induced by tumour migrasome mediated cytoplasmic transfer. We subsequently propose an in situ decoupling killing strategy in which tetracycline modified nanoliposomes encapsulating sodium bicarbonate and sodium hydrogen phosphate are designed to specifically release high concentrations of hydrogen phosphate ions triggered by tumasteoclasts, which depletes calcium ions and forms calcium phosphorus crystals. This can inhibit the formation of migrasomes for decoupling and disrupt cell membrane for killing, thereby achieving early prevention of bone metastasis. This study provides a research model for exploring tumour cell behaviour in detail and a proof of concept for behaviour targeting strategy.
   Tumour cell behaviour is an underdeveloped target for cancer intervention. Here the authors report on a spatiotemporal interaction between tumour cells and osteoclasts in initial bone metastases and propose a behaviour targeting therapy with an in situ physical killing strategy.
C1 [Gu, Chenhui; Chen, Pengfei; Tian, Hongsen; Yang, Yang; Huang, Zhenxiang; Yan, Huige; Shangguan, Liqing; Pan, Kaifeng; Chen, Pengyu; Huang, Yue; Fan, Shunwu; Lin, Xianfeng] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed Surg, Hangzhou, Peoples R China.
   [Gu, Chenhui; Chen, Pengfei; Tian, Hongsen; Yang, Yang; Huang, Zhenxiang; Yan, Huige; Shangguan, Liqing; Pan, Kaifeng; Chen, Pengyu; Huang, Yue; Fan, Shunwu; Lin, Xianfeng] Key Lab Mech Res & Precis Repair Orthopaed Trauma, Hangzhou, Peoples R China.
   [Tang, Chenxi] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Gastroenterol, Hangzhou, Peoples R China.
   [Xiang, Jiajia] Zhejiang Univ, Coll Chem & Biol Engn, Hangzhou, Peoples R China.
   [Liu, Zhaoming; Tang, Ruikang] Zhejiang Univ, Dept Chem, Hangzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang
   University
RP Fan, SW; Lin, XF (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed Surg, Hangzhou, Peoples R China.; Fan, SW; Lin, XF (通讯作者)，Key Lab Mech Res & Precis Repair Orthopaed Trauma, Hangzhou, Peoples R China.
EM shunwu_fan@zju.edu.cn; xianfeng_lin@zju.edu.cn
RI Xiang, Jiajia/HKE 7116 2023; tian, hongsen/GLU 3656 2022; Chen,
   Pengyu/JZE 2192 2024; Lin, Xianfeng/ABA 2917 2020; Gu,
   Chenhui/KHT 4806 2024
OI Chen, Pengfei/0000 0003 1484 2850; Gu, Chenhui/0000 0002 8698 9395;
   hongsen, tian/0000 0002 9888 6617; Xiang, Jiajia/0000 0001 5404 0735
FU National Natural Science Foundation of China (National Science
   Foundation of China) [82322043, 92268113, 82072414, 82372454, 82330077];
   National Nature Science Fund of China [LGF21H060005]; Natural Science
   Fund of Zhejiang Province [2023C03091]; Zhejiang Provincial Department
   of Science and Technology "Leading Geese" research and development
   project
FX This work was supported by grants from the National Nature Science Fund
   of China (grant nos. 82322043, 92268113 and 82072414 to XF.L., 82372454
   to PF.C. and 82330077 to S.F.), the Natural Science Fund of Zhejiang
   Province (grant no. LGF21H060005 to Y.H.), and the Zhejiang Provincial
   Department of Science and Technology "Leading Geese" research and
   development project (grant no. 2023C03091 to S.F.). We thank H. Jiao at
   the School of Life Sciences of Tsinghua University for his theoretical
   support on migrasome formation. We thank Q. Bian and Y. Zhou at the
   Zhejiang Province Key Laboratory of Anti Cancer Drug Research for their
   technical support on animal experiments. We thank K. Kong at the
   Department of Chemistry of Zhejiang University for his theoretical
   support on CaP crystals. We thank L. Wu, P. Yang, D. Song and G. Zhu at
   the Center of Cryo Electron Microscopy (CCEM), Zhejiang University for
   their technical assistance on cryo TEM, TEM and SEM.
CR Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573 019 0044 1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Dagogo Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Ell B, 2012, CELL, V151, DOI 10.1016/j.cell.2012.10.005
   Ganesh K, 2021, NAT MED, V27, P34, DOI 10.1038/s41591 020 01195 4
   Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590 019 0526 7
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785
   Jardine L, 2021, NATURE, V598, P327, DOI 10.1038/s41586 021 03929 x
   Jiao HF, 2021, CELL, V184, P2896, DOI 10.1016/j.cell.2021.04.027
   Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Li ZL, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29315 3
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0760 3
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Ma L, 2015, CELL RES, V25, P24, DOI 10.1038/cr.2014.135
   Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007
   Massagué J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Miyazaki T, 2011, ANAL BIOCHEM, V410, P7, DOI 10.1016/j.ab.2010.11.014
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Morel AP, 2017, NAT MED, V23, P568, DOI 10.1038/nm.4323
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Satcher RL, 2022, NAT REV CANCER, V22, P85, DOI 10.1038/s41568 021 00406 5
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sevenich L, 2014, NAT CELL BIOL, V16, P876, DOI 10.1038/ncb3011
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tang R, 2013, BREAST CANCER RES TR, V139, P311, DOI 10.1007/s10549 013 2554 6
   Tsilimigras DI, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00261 6
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Wang H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15045
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wu KR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25473 y
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zhang WJ, 2021, CELL, V184, P2471, DOI 10.1016/j.cell.2021.03.011
NR 46
TC 26
Z9 27
U1 30
U2 128
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1748 3387
EI 1748 3395
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD JUL
PY 2024
VL 19
IS 7
BP 1044
EP 1054
DI 10.1038/s41565 024 01613 5
EA MAR 2024
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA A0Q7Z
UT WOS:001187315400004
PM 38499860
DA 2025 08 17
ER

PT J
AU Naviglio, S
   Spina, A
   Chiosi, E
   Fusco, A
   Illiano, F
   Pagano, M
   Romano, M
   Senatore, G
   Sorrentino, A
   Sorvillo, L
   Illiano, G
AF Naviglio, Silvio
   Spina, Annamaria
   Chiosi, Emilio
   Fusco, Anna
   Illiano, Fausto
   Pagano, Mario
   Romano, Maria
   Senatore, Giovanna
   Sorrentino, Annunziata
   Sorvillo, Luca
   Illiano, Gennaro
TI Inorganic phosphate inhibits growth of human osteosarcoma U2OS cells via
   adenylate cyclase/cAMP pathway
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE phosphate; adenylate cyclase; cAMP; growth inhibition; osteosarcoma
   cells
ID OSTEOBLAST LIKE CELLS; TRANSPORTER RETROVIRUS RECEPTOR; PROTEIN COUPLED
   RECEPTORS; CYCLIC AMP; ALKALINE PHOSPHATASE; PARATHYROID HORMONE;
   MESSENGER RNA; KINASE; RAT; IDENTIFICATION
AB In order to elucidate how phosphate regulates cellular functions, we investigated the effects of inorganic phosphate (Pi) on adenylate cyclase (AC)/cyclic AMP (cAMP) axis. Here we describe that Pi treatment of human osteosarcoma U2OS cells results in a decrease of both intracellular cAMP levels and AC activity, and in a cell growth inhibition. The phosphate triggered effects observed in U2OS cells are not a widespread phenomenon regarding all cell lines, since other cell lines screened respond differently to parallel Pi treatments. In U2OS cell line, the AC activity/cAMP downregulation is accompanied by significant variations in the levels of some membrane proteins belonging to the AC system. Remarkably, the above effects are blunted by pharmacological inhibition of sodium dependent phosphate transport. Moreover, 8 Br cAMP and other cAMP elevating agents, such as IBMX and forskolin, interestingly, prevent the cell growth inhibition in response to phosphate. Our results enforce the increasing evidences of phosphate as a signaling molecule, identifying in U2OS cell line the AC/cAMP axis, as a novel signaling pathway modulated by phosphate to ultimately affect cell growth.
C1 Univ Naples 2, Dept Biochem & Biophys, Sch Med, I 80138 Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Naviglio, S (通讯作者)，Univ Naples 2, Dept Biochem & Biophys, Sch Med, Via Crecchio 7, I 80138 Naples, Italy.
EM silvio.naviglio@unina2.it
RI ; Pagano, Mario/G 9395 2012
OI SPINA, Annamaria/0000 0002 2877 3158; NAVIGLIO,
   Silvio/0000 0003 1771 8265; Chiosi, Emilio/0000 0002 8325 9143
CR Adams CS, 2001, J BIOL CHEM, V276, P20316, DOI 10.1074/jbc.M006492200
   Beck GR, 2003, J CELL BIOCHEM, V90, P234, DOI 10.1002/jcb.10622
   Beck GR, 2003, J BIOL CHEM, V278, P41921, DOI 10.1074/jbc.M304470200
   Beck GR, 2003, EXP CELL RES, V288, P288, DOI 10.1016/S0014 4827(03)00213 1
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   BELLOWS CG, 1992, BONE MINER, V17, P15, DOI 10.1016/0169 6009(92)90707 K
   BJURHOLM A, 1992, J BONE MINER RES, V7, P1011
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Brodde OE, 1999, PHARMACOL REV, V51, P651
   Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050
   Caverzasio J, 1996, NEWS PHYSIOL SCI, V11, P119
   Cheung R, 2005, J CELL BIOCHEM, V94, P1017, DOI 10.1002/jcb.20366
   Conradas KA, 2005, MOL CELL PROTEOMICS, V4, P1284, DOI 10.1074/mcp.M500082 MCP200
   Dhanasekaran N, 2001, ONCOGENE, V20, P1530, DOI 10.1038/sj.onc.1204273
   Dhanasekaran N, 1998, BIOL SIGNAL RECEPT, V7, P109
   DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968 0004(89)90046 7
   Fujita T, 2002, J BIOL CHEM, V277, P22191, DOI 10.1074/jbc.M110364200
   Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108
   GRAY PN, 1976, J CELL PHYSIOL, V89, P225, DOI 10.1002/jcp.1040890206
   Hanoune J, 1997, MOL CELL ENDOCRINOL, V128, P179, DOI 10.1016/S0303 7207(97)04013 6
   Heubach JF, 2004, MOL PHARMACOL, V65, P1313, DOI 10.1124/mol.65.5.1313
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kanatani M, 2002, J CELL PHYSIOL, V190, P306, DOI 10.1002/jcp.10067
   Kavanaugh MP, 1996, KIDNEY INT, V49, P959, DOI 10.1038/ki.1996.135
   Kido S, 1999, J BIOL CHEM, V274, P28256, DOI 10.1074/jbc.274.40.28256
   Krützfeldt M, 2005, MOL CELL, V18, P213, DOI 10.1016/j.molcel.2005.03.009
   Kudlacek O, 2001, J BIOL CHEM, V276, P3010, DOI 10.1074/jbc.M007910200
   LoghmanAdham M, 1996, GEN PHARMACOL VASC S, V27, P305, DOI 10.1016/0306 3623(95)02017 9
   Mansfield K, 2001, BONE, V28, P1, DOI 10.1016/S8756 3282(00)00409 9
   Meleti Z, 2000, BONE, V27, P359, DOI 10.1016/S8756 3282(00)00346 X
   MOORE RE, 1993, BONE MINER, V23, P301, DOI 10.1016/S0169 6009(08)80105 5
   Naviglio S, 2004, CELL SIGNAL, V16, P1229, DOI 10.1016/j.cellsig.2004.03.012
   Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241
   NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092 8674(95)90407 7
   Novy M, 2005, MOL BIOL CELL, V16, P2181, DOI 10.1091/mbc.E04 11 0975
   Pagano M, 2004, J CELL PHYSIOL, V198, P408, DOI 10.1002/jcp.10420
   Palmer G, 1997, ENDOCRINOLOGY, V138, P5202, DOI 10.1210/en.138.12.5202
   Rangel LBA, 2003, ONCOGENE, V22, P7225, DOI 10.1038/sj.onc.1207008
   SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003 2697(74)90222 X
   SILVER J, 2002, PRINCIPLES BONE BIOL
   Smit MJ, 1998, P NATL ACAD SCI USA, V95, P15084, DOI 10.1073/pnas.95.25.15084
   Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017
   Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962 8924(02)02294 8
   Suzuki A, 2001, BONE, V28, P589, DOI 10.1016/S8756 3282(01)00459 8
   Takeda E, 2000, ADV ENZYME REGUL, V40, P285, DOI 10.1016/S0065 2571(99)00036 9
   TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1
   Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875
   Wada K, 2004, J CELL PHYSIOL, V198, P40, DOI 10.1002/jcp.10383
   WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439
   WUTHIER RE, 1993, J NUTR, V123, P301, DOI 10.1093/jn/123.suppl_2.301
   Zoidis E, 2004, J ENDOCRINOL, V181, P531, DOI 10.1677/joe.0.1810531
   Zucchini C, 2004, BONE, V34, P672, DOI 10.1016/j.bone.2003.12.008
NR 52
TC 27
Z9 28
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG 15
PY 2006
VL 98
IS 6
BP 1584
EP 1596
DI 10.1002/jcb.20892
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 069SZ
UT WOS:000239469800019
PM 16552724
DA 2025 08 17
ER

PT J
AU Li, Z
   Li, YN
   Liu, CR
   Gu, YQ
   Han, GH
AF Li, Ze
   Li, Yanan
   Liu, Chaoran
   Gu, Yuqing
   Han, Guanghong
TI Research progress of the mechanisms and applications of ginsenosides in
   promoting bone formation
SO PHYTOMEDICINE
LA English
DT Article
DE Ginsenoside; Herbal medicine; Bone formation; Bone microenvironment;
   Bone deficiency related diseases; Bone tissue engineering
ID STEM CELLS; PANAX GINSENG; RG1; DIFFERENTIATION; PHARMACOKINETICS;
   MINERALIZATION; REGENERATION; OSTEOPOROSIS; GROWTH; ROLES
AB Background: Bone deficiency related diseases caused by various factors have disrupted the normal function of the skeleton and imposed a heavy burden globally, urgently requiring potential new treatments. The multi faceted role of compounds like ginsenosides and their interaction with the bone microenvironment, particularly osteoblasts can promote bone formation and exhibit anti inflammatory, vascular remodeling, and antibacterial properties, holding potential value in the treatment of bone deficiency related diseases and bone tissue engineering. Purpose: This review summarizes the interaction between ginsenosides and osteoblasts and the bone microenvironment in bone formation, including vascular remodeling and immune regulation, as well as their therapeutic potential and toxicity in the broad treatment applications of bone deficiency related diseases and bone tissue engineering, to provide novel insights and treatment strategies. Methods: The literature focusing on the mechanisms and applications of ginsenosides in promoting bone formation before March 2024 was searched in PubMed, Web of Science, Google Scholar, Scopus, and Science Direct databases. Keywords such as "phytochemicals", "ginsenosides", "biomaterials", "bone", "diseases", "bone formation", "microenvironment", "bone tissue engineering", "rheumatoid arthritis", "periodontitis", "osteoarthritis", "osteoporosis", "fracture", "toxicology", "pharmacology", and combinations of these keywords were used. Results: Ginsenoside monomers regulate signaling pathways such as WNT/beta catenin, FGF, and BMP/TGF beta, stimulating osteoblast generation and differentiation. It exerts angiogenic and anti inflammatory effects by regulating the bone surrounding microenvironment through signaling such as WNT/beta catenin, NF kappa B, MAPK, PI3K/Akt, and Notch. It shows therapeutic effects and biological safety in the treatment of bone deficiencyrelated diseases, including rheumatoid arthritis, osteoarthritis, periodontitis, osteoporosis, and fractures, and bone tissue engineering by promoting osteogenesis and improving the microenvironment of bone formation. Conclusion: The functions of ginsenosides are diverse and promising in treating bone deficiency related diseases and bone tissue engineering. Moreover, potential exists in regulating the bone microenvironment, modifying biomaterials, and treating inflammatory related bone diseases and dental material applications. However, the mechanisms and effects of some ginsenoside monomers are still unclear, and the lack of clinical research limits their clinical application. Further exploration and evaluation of the potential of ginsenosides in these areas are expected to provide more effective methods for treating bone defects.
C1 [Li, Ze; Li, Yanan; Liu, Chaoran; Gu, Yuqing; Han, Guanghong] Jilin Univ, Hosp Stomatol, Dept Oral Geriatr, Changchun 130021, Peoples R China.
   [Han, Guanghong] 1500 Qinghua Rd, Changchun, Peoples R China.
C3 Jilin University
RP Han, GH (通讯作者)，1500 Qinghua Rd, Changchun, Peoples R China.
EM hangh@jlu.edu.cn
RI Liu, Chaoran/AAG 9471 2020
FU Bethune Project of Jilin University [2020B23]
FX This work was supported by the Bethune Project of Jilin University
   (Grant No. 2020B23) .
CR Ambrosi TH, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00189
   Amiryaghoubi N, 2020, MED RES REV, V40, P1833, DOI 10.1002/med.21672
   Arampatzis AS, 2023, MOLECULES, V28, DOI 10.3390/molecules28237720
   Aravinthan A, 2021, J GINSENG RES, V45, P287, DOI 10.1016/j.jgr.2020.01.004
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bei JX, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202885
   Cao J, 2019, INT J MED SCI, V16, P831, DOI 10.7150/ijms.31883
   Chen CY, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9080907
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen WH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1010937
   Chen YN, 2020, EUR J PHARMACOL, V877, DOI 10.1016/j.ejphar.2020.173090
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Chu CY, 2022, J BIOMED MATER RES B, V110, P7, DOI 10.1002/jbm.b.34891
   Chu CY, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5615647
   Chu CY, 2019, MAT SCI ENG C MATER, V100, P505, DOI 10.1016/j.msec.2019.03.007
   Chu CY, 2019, MAT SCI ENG C MATER, V99, P73, DOI 10.1016/j.msec.2019.01.083
   Chung TH, 2021, NUTRIENTS, V13, DOI 10.3390/nu13093090
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Croes M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132781
   Ding LL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.855393
   Fiedler J, 2006, BIOCHEM BIOPH RES CO, V345, P1177, DOI 10.1016/j.bbrc.2006.05.034
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fu XR, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080784
   Gadomski S, 2022, CELL STEM CELL, V29, P528, DOI 10.1016/j.stem.2022.02.008
   Gao YL, 2011, FOOD CHEM TOXICOL, V49, P1857, DOI 10.1016/j.fct.2011.05.003
   Goerke SM, 2015, MICROVASC RES, V98, P40, DOI 10.1016/j.mvr.2014.12.001
   Golub LM, 2020, PERIODONTOL 2000, V82, P186, DOI 10.1111/prd.12315
   Graziani F, 2017, PERIODONTOL 2000, V75, P152, DOI 10.1111/prd.12201
   Guo L, 2022, INT J IMMUNOPATH PH, V36, DOI 10.1177/03946320221107239
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   He F, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01565
   Hong H, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/8858006
   Hossain MA, 2022, PHYTOMEDICINE, V100, DOI 10.1016/j.phymed.2022.154039
   Hou MQ, 2021, ACTA PHARM SIN B, V11, P1813, DOI 10.1016/j.apsb.2020.12.017
   Hu JZ, 2016, MOL MED REP, V14, P406, DOI 10.3892/mmr.2016.5238
   Hu QR, 2023, J GINSENG RES, V47, P694, DOI 10.1016/j.jgr.2023.07.005
   Huang GD, 2016, FOOD FUNCT, V7, P2451, DOI 10.1039/c6fo00123h
   Huang YC, 2005, PHARM RES, V22, P636, DOI 10.1007/s11095 005 2500 3
   Huang YM, 2014, MOL CELL BIOCHEM, V392, P249, DOI 10.1007/s11010 014 2035 1
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Im DS, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030444
   Jang S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020905
   Jang WY, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24076119
   Jiang J, 2020, J ETHNOPHARMACOL, V251, DOI 10.1016/j.jep.2020.112564
   Jie J, 2021, INFLAMM RES, V70, P789, DOI 10.1007/s00011 021 01452 3
   Jones RE, 2019, CELL REP, V28, P2757, DOI 10.1016/j.celrep.2019.08.021
   Jung SJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103352
   Kang H, 2023, NUTRIENTS, V15, DOI 10.3390/nu15071626
   Kang S, 2016, IN VITRO CELL DEV AN, V52, P895, DOI 10.1007/s11626 016 0062 9
   Karra AG, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010094
   Khoshroo A, 2023, INFLAMMOPHARMACOLOGY, V31, P689, DOI 10.1007/s10787 022 01088 7
   Kim DY, 2012, FITOTERAPIA, V83, P215, DOI 10.1016/j.fitote.2011.10.017
   Kim DY, 2011, INT J MOL MED, V28, P753, DOI 10.3892/ijmm.2011.750
   Kim EN, 2021, MOLECULES, V26, DOI 10.3390/molecules26072092
   Kim HM, 2017, MOLECULES, V22, DOI 10.3390/molecules22010042
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim YR, 2018, MICROB CELL, V5, P472, DOI 10.15698/mic2018.11.654
   Kumar L, 2023, INDIAN J ORTHOP, V57, P127, DOI 10.1007/s43465 023 01064 5
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Langen UH, 2017, NAT CELL BIOL, V19, P189, DOI 10.1038/ncb3476
   Li JX, 2024, J NANOBIOTECHNOL, V22, DOI 10.1186/s12951 023 02261 y
   Li Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09793 y
   Liao SN, 2020, J BIOMED MATER RES A, V108, P2395, DOI 10.1002/jbm.a.36991
   Liu HB, 2020, PHARMACOL RES, V161, DOI 10.1016/j.phrs.2020.105263
   Liu Q, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.593820
   Liu T, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm 22 501
   Liu YM, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/5196682
   Liu Y, 2020, CHEM BIOL INTERACT, V332, DOI 10.1016/j.cbi.2020.109285
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Luan JJ, 2022, J FOOD BIOCHEM, V46, DOI 10.1111/jfbc.14340
   Luo P, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00888
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Metzger CE, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00285
   Misof BM, 2017, BONE, V105, P50, DOI 10.1016/j.bone.2017.07.011
   Moldoveanu T, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a036319
   Murphy MP, 2020, NAT MED, V26, P1583, DOI 10.1038/s41591 020 1013 2
   Murphy MP, 2017, J CRANIOFAC SURG, V28, P1136, DOI 10.1097/SCS.0000000000003893
   Muthukumar T, 2016, CARBOHYD POLYM, V152, P566, DOI 10.1016/j.carbpol.2016.07.003
   Nguyen NH, 2019, INFLAMMOPHARMACOLOGY, V27, P871, DOI 10.1007/s10787 019 00630 4
   Niu ZQ, 2024, PHYTOMEDICINE, V127, DOI 10.1016/j.phymed.2024.155474
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Olczyk M, 2022, LIFE BASEL, V12, DOI 10.3390/life12030423
   Park BW, 2006, INT J ORAL MAX SURG, V35, P624, DOI 10.1016/j.ijom.2006.02.019
   Piao XM, 2020, MOLECULES, V25, DOI 10.3390/molecules25153452
   Ramanathan MR, 2017, EUR J DRUG METAB PH, V42, P545, DOI 10.1007/s13318 016 0387 5
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02821 8
   Salarian M, 2016, ACS BIOMATER SCI ENG, V2, P1872, DOI 10.1021/acsbiomaterials.6b00222
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   SHADER RI, 1988, J CLIN PSYCHOPHARM, V8, P235
   Siddiqi MH, 2014, J PHARM PHARMACOL, V66, P1763, DOI 10.1111/jphp.12306
   Siddiqi MZ, 2015, J MED FOOD, V18, P542, DOI 10.1089/jmf.2014.3251
   Song M, 2021, J AGR FOOD CHEM, V69, P12634, DOI 10.1021/acs.jafc.1c04695
   Song M, 2020, BIOL TRACE ELEM RES, V198, P557, DOI 10.1007/s12011 020 02089 9
   Su F, 2015, ANTIMICROB AGENTS CH, V59, P5654, DOI 10.1128/AAC.01381 15
   Suliman S, 2022, INFLAMM REGEN, V42, DOI 10.1186/s41232 022 00196 9
   Sun MM, 2023, ORAL DIS, V29, P3460, DOI 10.1111/odi.14352
   Tang MS, 2021, PHARMACOL RES, V166, DOI 10.1016/j.phrs.2021.105498
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Terkawi MA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031786
   Thangavelu M, 2020, INT J BIOL MACROMOL, V146, P1024, DOI 10.1016/j.ijbiomac.2019.09.228
   Uenaka M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28673 2
   Verborgt O, 2002, J BONE MINER RES, V17, P907, DOI 10.1359/jbmr.2002.17.5.907
   Wan QQ, 2021, ADV SCI, V8, DOI 10.1002/advs.202003390
   Wang HY, 2022, MOLECULES, V27, DOI 10.3390/molecules27113403
   Wang LJ, 2020, PHYTOTHER RES, V34, P1226, DOI 10.1002/ptr.6605
   Wang P, 2012, AUST DENT J, V57, P157, DOI 10.1111/j.1834 7819.2012.01672.x
   Wang P, 2014, PHYTOMEDICINE, V21, P177, DOI 10.1016/j.phymed.2013.08.021
   Wang Y, 2016, EUR J PHARMACOL, V771, P48, DOI 10.1016/j.ejphar.2015.12.019
   Wang ZL, 2021, FREE RADICAL BIO MED, V174, P182, DOI 10.1016/j.freeradbiomed.2021.08.007
   Wildemann B, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00289 8
   Wu YQ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.955983
   Wu YQ, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00157 5
   Xiao WL, 2023, BIOMED MATER, V18, DOI 10.1088/1748 605X/aca946
   Xu HL, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.714554
   Xu RJ, 2014, J ETHNOPHARMACOL, V158, P338, DOI 10.1016/j.jep.2014.10.054
   Xu Y, 2022, BIOMATERIALS, V280, DOI 10.1016/j.biomaterials.2021.121077
   Yang N, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23116187
   Yang N, 2020, CHIN MED UK, V15, DOI 10.1186/s13020 020 00323 z
   Yang S, 2022, J ETHNOPHARMACOL, V283, DOI 10.1016/j.jep.2021.114739
   Yi YS, 2019, J GINSENG RES, V43, P172, DOI 10.1016/j.jgr.2017.11.005
   Yi YS, 2019, J GINSENG RES, V43, P335, DOI 10.1016/j.jgr.2018.04.004
   Zadeh BSM, 2018, MOLECULES, V23, DOI 10.3390/molecules23081904
   Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016 1002
   Zarneshan SN, 2022, PHARMACOL RES, V177, DOI 10.1016/j.phrs.2022.106099
   Zeng X, 2010, J CLIN PHARMACOL, V50, P285, DOI 10.1177/0091270009344334
   Zhang D, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154205
   Zhang LM, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.744647
   Zhang M, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906 021 03302 5
   Zhang XN, 2016, CHEM BIOL INTERACT, V256, P188, DOI 10.1016/j.cbi.2016.07.003
   Zhao Q, 2016, EUR J DRUG METAB PH, V41, P845, DOI 10.1007/s13318 015 0304 3
   Zheng MM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8174345
   Zhong ZY, 2023, REDOX BIOL, V63, DOI 10.1016/j.redox.2023.102711
   Zhou P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00464
   Zhou SH, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.813953
   Zhu GX, 2021, PHARMACOL RES, V169, DOI 10.1016/j.phrs.2021.105647
   Zhu T, 2022, BIOMED PHARMACOTHER, V148, DOI 10.1016/j.biopha.2022.112719
   Zhu YZ, 2016, TOXICOLOGY, V368, P183, DOI 10.1016/j.tox.2016.07.014
   Zou ML, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.593310
NR 141
TC 12
Z9 13
U1 11
U2 30
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUL
PY 2024
VL 129
AR 155604
DI 10.1016/j.phymed.2024.155604
EA APR 2024
PG 23
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA RR5J2
UT WOS:001229398700001
PM 38614042
DA 2025 08 17
ER

PT J
AU Ehnert, S
   Aspera Werz, RH
   Freude, T
   Reumann, MK
   Ochs, BG
   Bahrs, C
   Schröter, S
   Wintermeyer, E
   Nussler, AK
   Pscherer, S
AF Ehnert, Sabrina
   Aspera Werz, Romina Haydee
   Freude, Thomas
   Reumann, Marie Karolina
   Ochs, Bjoern Gunnar
   Bahrs, Christian
   Schroeter, Steffen
   Wintermeyer, Elke
   Nussler, Andreas Klaus
   Pscherer, Stefan
TI Distinct Gene Expression Patterns Defining Human Osteoblasts' Response
   to BMP2 Treatment: Is the Therapeutic Success All a Matter of Timing?
SO EUROPEAN SURGICAL RESEARCH
LA English
DT Article
DE Alkaline phosphatase activity; Mitochondrial activity;
   Osteoclastogenesis; Primary human osteoblasts; Recombinant human BMP2
ID BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL STEM CELLS; DIFFERENTIATION;
   MECHANISM; FUSION; INHIBITORS; FRACTURES; RHBMP 2; SOST
AB Background: Bone morphogenetic proteins (BMPs) play a key role in bone formation. Local application of BMP2 (Dibotermin alfa) supports bone formation when applied to complex fractures. However, up to 33% of patients do not respond to this therapy. Purpose: Aiming to investigate whether inter individual responses to BMP2 treatment can be predicted by gene expression patterns, we investigated the effect of BMP2 on primary human osteoblasts and THP 1 cell derived osteoclasts from 110 donors. Methods: Osteoblasts were obtained by collagenase digestion of spongy bone tissues. Osteoclasts were differentiated from THP 1 cells using the conditioned media of the osteoblasts. Viability was determined by resazurin conversion. As functional characteristics AP and Trap5B activity were measured. Gene expression levels were determined by RT PCR in 21 of the 110 evaluated donors and visualized by electrophoresis. Results: Based on our data, we could classify three response groups: (i) In 51.8% of all donors, BMP2 treatment induced osteoblast function. These donors strongly expressed the BMP2 inhibitor Noggin (NOG), the alternative BMP2 receptors repulsive guidance molecule B (RGMb) and activin receptor like kinase 6 (Alk6), as well as the Wnt inhibitor sclerostin (SOST). (ii) In 17.3% of all donors, BMP2 treatment induced viability. In these donors, the initial high SOST expression significantly dropped with BMP2 treatment. (iii) 30.9% of all donors were not directly affected by BMP2 treatment. These donors expressed high levels of the pseudoreceptor BMP and activin membrane bound inhibitor (BAMBI) and lacked SOST expression. In all donors, SOST expression correlated directly with receptor activator of NF kappa B ligand (RANKL) expression, defining the cells' potential to stimulate osteoclastogenesis. Conclusions: Our data identified three donor groups profiting from BMP2 treatment either directly via stimulation of osteoblast function or viability and/or indirectly via inhibition of osteoclastogenesis, depending on their expression of BAMBI, SOST, NOG, and RANKL. On the basis of patients' respective expression profiles, the clinical application of BMP2 as well as its timing might be modified in order to better fit the patients' needs to promote bone formation or to inhibit bone resorption. (C) 2016 S. Karger AG, Basel
C1 [Ehnert, Sabrina; Aspera Werz, Romina Haydee; Freude, Thomas; Reumann, Marie Karolina; Ochs, Bjoern Gunnar; Bahrs, Christian; Schroeter, Steffen; Wintermeyer, Elke; Nussler, Andreas Klaus; Pscherer, Stefan] Eberhard Karls Univ Tubingen, BG Trauma Ctr, Tubingen, Germany.
C3 Eberhard Karls University of Tubingen
RP Ehnert, S (通讯作者)，Eberhard Karls Univ Tubingen, Siegfried Weller Inst Unfallmed Forsch, Schnarrenbergstr 95, DE 72076 Tubingen, Germany.
EM sabrina.ehnert@med.uni tuebingen.de
RI Ehnert, Sabrina/AAE 8163 2019; Nussler, Andreas/H 3557 2019
OI Ehnert, Sabrina/0000 0003 4347 1702
FU Eberhard Karls University Tubingen [2174 0 0]
FX The authors would like to thank Rebecca Haupt, Bianca Braun and Patrysya
   Lacorte for their excellent technical assistance. This work was
   supported by intramural funding of the Eberhard Karls University
   Tubingen (fortune Junior 2174 0 0).
CR Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baskin DS, 2003, SPINE, V28, P1219, DOI 10.1097/00007632 200306150 00003
   Baud'huin M, 2012, P NATL ACAD SCI USA, V109, P12207, DOI 10.1073/pnas.1204929109
   Boden SD, 2002, SPINE, V27, P2662
   Burkus JK, 2009, J BONE JOINT SURG AM, V91A, P1181, DOI 10.2106/JBJS.G.01485
   Burkus JK, 2002, J SPINAL DISORD TECH, V15, P337, DOI 10.1097/00024720 200210000 00001
   Canan LW Jr, 2012, J CRANIOFAC SURG, V23, P1627, DOI 10.1097/SCS.0b013e31825c75ba
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Dean DB, 2010, J ANAT, V216, P625, DOI 10.1111/j.1469 7580.2010.01214.x
   Ehnert S, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 101
   Ehnert S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014073
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358
   Jäger M, 2008, J ORTHOP RES, V26, P1440, DOI 10.1002/jor.20565
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Kloen P, 2012, BONE, V51, P59, DOI 10.1016/j.bone.2012.03.032
   Lissenberg Thunnissen SN, 2011, INT ORTHOP, V35, P1271, DOI 10.1007/s00264 011 1301 z
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794
   Papathanasiou I, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0674 6
   Qiang YW, 2008, BONE, V42, P669, DOI 10.1016/j.bone.2007.12.006
   Shen BJ, 2009, INT J BIOL SCI, V5, P192
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Shimer Adam L, 2009, Injury, V40 Suppl 3, pS32, DOI 10.1016/S0020 1383(09)70009 9
   Soares Schanoski A, 2007, J LEUKOCYTE BIOL, V82, P700, DOI 10.1189/jlb.1106673
   Wei SJ, 2012, ORTHOPEDICS, V35, pE847, DOI 10.3928/01477447 20120525 23
   Wu LD, 2007, INT ORTHOP, V31, P605, DOI 10.1007/s00264 006 0235 3
   Wu QF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046307
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Yan XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090846
   Yuasa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116462
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zhang M, 2009, J CELL BIOCHEM, V108, P896, DOI 10.1002/jcb.22319
NR 35
TC 5
Z9 6
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0014 312X
EI 1421 9921
J9 EUR SURG RES
JI Eur. Surg. Res.
PY 2016
VL 57
IS 3 4
BP 197
EP 210
DI 10.1159/000447089
PG 14
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA EA8LZ
UT WOS:000386887600005
PM 27441597
DA 2025 08 17
ER

PT J
AU Niu, Q
   Gao, JF
   Wang, L
   Liu, JX
   Zhang, LY
AF Niu, Qing
   Gao, Jinfang
   Wang, Lei
   Liu, Jiaxi
   Zhang, Liyun
TI Regulation of differentiation and generation of osteoclasts in
   rheumatoid arthritis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE osteoclasts; rheumatoid arthritis; bone destruction; regulation of
   formation and differentiation; targeted therapy
ID RECEPTOR TYROSINE KINASE; BONE MINERAL DENSITY; CITRULLINATED PROTEIN
   ANTIBODIES; ARYL HYDROCARBON RECEPTOR; TRANSCRIPTION FACTOR;
   INFLAMMATORY ARTHRITIS; NEGATIVE REGULATION; MICRORNAS MODULATE;
   STRUCTURAL DAMAGE; RAW264.7 CELLS
AB Introduction: Rheumatoid arthritis (RA), which affects nearly 1% of the world's population, is a debilitating autoimmune disease. Bone erosion caused by periarticular osteopenia and synovial pannus formation is the most destructive pathological changes of RA, also leads to joint deformity and loss of function, and ultimately affects the quality of life of patients. Osteoclasts (OCs) are the only known bone resorption cells and their abnormal differentiation and production play an important role in the occurrence and development of RA bone destruction; this remains the main culprit behind RA. Method: Based on the latest published literature and research progress at home and abroad, this paper reviews the abnormal regulation mechanism of OC generation and differentiation in RA and the possible targeted therapy. Result: OC mediated bone destruction is achieved through the regulation of a variety of cytokines and cell to cell interactions, including gene transcription, epigenetics and environmental factors. At present, most methods for the treatment of RA are based on the regulation of inflammation, the inhibition of bone injury and joint deformities remains unexplored. Discussion: This article will review the mechanism of abnormal differentiation of OC in RA, and summarise the current treatment oftargeting cytokines in the process of OC generation and differentiation to reduce bone destruction in patients with RA, which isexpected to become a valuable treatment choice to inhibit bone destruction in RA.
C1 [Niu, Qing] Shanxi Med Univ, Sch Basic Med Sci, Taiyuan, Peoples R China.
   [Gao, Jinfang; Wang, Lei; Liu, Jiaxi; Zhang, Liyun] Shanxi Med Univ, Hosp 3, Tongji Shanxi Hosp, Shanxi Bethune Hosp,Shanxi Acad Med Sci, Taiyuan, Peoples R China.
C3 Shanxi Medical University; Shanxi Medical University
RP Zhang, LY (通讯作者)，Shanxi Med Univ, Hosp 3, Tongji Shanxi Hosp, Shanxi Bethune Hosp,Shanxi Acad Med Sci, Taiyuan, Peoples R China.
EM 1315710223@qq.com
FU National Natural Science Foundation of China; Shanxi Provincial Key
   Research and Development Project; applied basic research project of
   Shanxi Science and Technology Department;  [81202356];  [81771768]; 
   [81771292];  [201803D31136];  [201901D111416]
FX Funding Financial support for this research was provided by the National
   Natural Science Foundation of China (81202356, 81771768 and 81771292),
   Shanxi Provincial Key Research and Development Project (201803D31136),
   and the applied basic research project of Shanxi Science and Technology
   Department (201901D111416).
CR Abdollahi Roodsaz S, 2008, ARTHRITIS RHEUM, V58, P3753, DOI 10.1002/art.24127
   Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198
   Al Bogami M, 2021, RHEUMATOLOGY, V60, P947, DOI 10.1093/rheumatology/keaa551
   Alzabin S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3875
   Andersen M, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4557
   Andersson A, 2016, ENDOCRINOLOGY, V157, P1013, DOI 10.1210/en.2015 1820
   Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Brzustewicz E, 2015, CYTOKINE, V76, P527, DOI 10.1016/j.cyto.2015.08.260
   Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267
   Carey HA, 2019, ISCIENCE, V11, P238, DOI 10.1016/j.isci.2018.12.018
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Chiou WF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089159
   Chiplunkar AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054891
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Coxon FP, 2008, SEMIN CELL DEV BIOL, V19, P424, DOI 10.1016/j.semcdb.2008.08.004
   Cuda CM, 2016, NAT REV RHEUMATOL, V12, P543, DOI 10.1038/nrrheum.2016.132
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   Das H, 2006, P NATL ACAD SCI USA, V103, P6653, DOI 10.1073/pnas.0508235103
   Das M, 2012, CURR MOL MED, V12, P113, DOI 10.2174/156652412798889090
   Das M, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080908
   Das M, 2019, J CELL MOL MED, V23, P1386, DOI 10.1111/jcmm.14041
   Degboé Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00003
   Delgado Calle J, 2012, EPIGENETICS US, V7, P83, DOI 10.4161/epi.7.1.18753
   Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood 2003 09 3131
   Deodhar A, 2010, ARTHRIT CARE RES, V62, P569, DOI 10.1002/acr.20004
   Donate PB, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017120118
   Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807
   Du NC, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106387
   Duffau P, 2015, ARTHRITIS RHEUMATOL, V67, P3146, DOI 10.1002/art.39321
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000
   Gigliotti CL, 2016, J IMMUNOL, V197, P3905, DOI 10.4049/jimmunol.1600424
   Gosselin D, 2014, CELL, V159, P1327, DOI 10.1016/j.cell.2014.11.023
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Guo LJ, 2014, EXP CELL RES, V321, P142, DOI 10.1016/j.yexcr.2013.12.001
   Guo YY, 2015, J THORAC DIS, V7, P471, DOI 10.3978/j.issn.2072 1439.2015.02.11
   Guo YC, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3712083
   Hafström I, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1833 y
   Hah YS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087733
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   Harre U, 2012, AUTOIMMUNITY, V45, P612, DOI 10.3109/08916934.2012.719950
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hong MH, 2000, J BONE MINER RES, V15, P911, DOI 10.1359/jbmr.2000.15.5.911
   Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915
   Ilvesaro J, 2005, LIFE SCI, V77, P1351, DOI 10.1016/j.lfs.2005.01.027
   Iqbal J, 2013, P NATL ACAD SCI USA, V110, P11115, DOI 10.1073/pnas.1220919110
   Izawa N, 2019, J BONE MINER RES, V34, P1143, DOI 10.1002/jbmr.3689
   Ji JD, 2009, J IMMUNOL, V183, P7223, DOI 10.4049/jimmunol.0900072
   Joosten LAB, 2000, J IMMUNOL, V165, P6553, DOI 10.4049/jimmunol.165.11.6553
   Joosten LAB, 2008, ARTHRITIS RHEUM US, V58, P98, DOI 10.1002/art.23152
   Jung YH, 2007, BLOOD, V110, P82, DOI 10.1182/blood 2006 05 021352
   Kagiya T, 2013, J PERIODONTAL RES, V48, P373, DOI 10.1111/jre.12017
   Katagiri M, 2001, J BIOL CHEM, V276, P7376, DOI 10.1074/jbc.M007393200
   Kawaguchi Hiroshi, 2004, Mod Rheumatol, V14, P1, DOI 10.1007/s10165 003 0257 2
   Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357 2725(03)00211 5
   Kim HB, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0762 7
   Kim JH, 2018, BONE, V107, P188, DOI 10.1016/j.bone.2017.12.005
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim JH, 2011, BIOCHEM J, V436, P253, DOI 10.1042/BJ20110062
   Kim KW, 2019, J BIOCHEM, V166, P259, DOI 10.1093/jb/mvz033
   Kim MJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168888
   Kim SJ, 2014, J IMMUNOL, V193, P3902, DOI 10.4049/jimmunol.1302998
   Komano Y, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2046
   Komatsu N, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143060
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Krishnamurthy A, 2016, ANN RHEUM DIS, V75, P721, DOI 10.1136/annrheumdis 2015 208093
   Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996
   Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471
   Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040
   Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Lemke G, 2017, TRENDS BIOCHEM SCI, V42, P738, DOI 10.1016/j.tibs.2017.06.004
   Li CW, 2022, CELL DEATH DIFFER, V29, P1123, DOI 10.1038/s41418 021 00904 x
   Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood 2009 11 255026
   Li QW, 2020, J BONE MINER RES, V35, P1597, DOI 10.1002/jbmr.4015
   Li T, 2010, NAT IMMUNOL, V11, P799, DOI 10.1038/ni.1918
   Li XN, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420 018 0134 6
   Li YN, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00218 9
   Li YT, 2012, ARTHRITIS RHEUM US, V64, P3240, DOI 10.1002/art.34550
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   Liu X, 2019, INT J MOL MED, V43, P2329, DOI 10.3892/ijmm.2019.4171
   Lu DZ, 2020, MOL CELL ENDOCRINOL, V508, DOI 10.1016/j.mce.2020.110791
   Lu Q, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.684976
   Lu SY, 2014, EXP CELL RES, V328, P32, DOI 10.1016/j.yexcr.2014.08.018
   Lu SY, 2010, MOL BIOL CELL, V21, P1763, DOI 10.1091/mbc.E09 07 0584
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Mizoguchi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4282
   Moura RA, 2013, J RHEUMATOL, V40, P1293, DOI 10.3899/jrheum.121110
   Mukherjee PM, 2010, AM J ORTHOD DENTOFAC, V138, P140, DOI 10.1016/j.ajodo.2010.04.004
   Mulari M, 2003, MICROSC RES TECHNIQ, V61, P496, DOI 10.1002/jemt.10371
   Nakamura YS, 1998, STEM CELLS, V16, P229, DOI 10.1002/stem.160229
   Nanke Y, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4874195
   Negishi Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Nomura K, 2008, BIOCHEM BIOPH RES CO, V367, P881, DOI 10.1016/j.bbrc.2008.01.023
   O'Donnell K, 1999, AM J PATHOL, V154, P1171, DOI 10.1016/S0002 9440(10)65369 2
   Occhi G, 2015, ONCOTARGET, V6, P32104, DOI 10.18632/oncotarget.5194
   Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Onuora Sarah, 2012, Nat Rev Rheumatol, V8, P633, DOI 10.1038/nrrheum.2012.171
   Orsolini G, 2017, CALCIFIED TISSUE INT, V101, P17, DOI 10.1007/s00223 017 0253 8
   Ospelt C, 2008, ARTHRITIS RHEUM US, V58, P3684, DOI 10.1002/art.24140
   Ovrevik J, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964 014 0048 8
   Pagani S, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/1614627
   Palacios BS, 2015, J PATHOL, V235, P515, DOI 10.1002/path.4466
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Park KH, 2017, AM J CHINESE MED, V45, P1725, DOI 10.1142/S0192415X17500938
   Park R, 2020, CELLS BASEL, V9, DOI 10.3390/cells9102294
   Parmar KM, 2005, J BIOL CHEM, V280, P26714, DOI 10.1074/jbc.C500144200
   Peeters MJW, 2020, CANCER IMMUNOL IMMUN, V69, P237, DOI 10.1007/s00262 019 02421 w
   Perpétuo IP, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2690402
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Présumey J, 2013, ANN RHEUM DIS, V72, P1717, DOI 10.1136/annrheumdis 2012 202403
   Qin JC, 2020, PATHOL ONCOL RES, V26, P2023, DOI 10.1007/s12253 019 00663 8
   Qu B, 2015, EXP CELL RES, V338, P89, DOI 10.1016/j.yexcr.2015.07.023
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Rietjens IMCM, 2013, MOL NUTR FOOD RES, V57, P100, DOI 10.1002/mnfr.201200439
   Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood 2004 01 0041
   Rolph D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00937
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Rothlin CV, 2015, ANNU REV IMMUNOL, V33, P355, DOI 10.1146/annurev immunol 032414 112103
   Rothlin CV, 2010, CURR OPIN IMMUNOL, V22, P740, DOI 10.1016/j.coi.2010.10.001
   Ruiz Heiland G, 2014, ANN RHEUM DIS, V73, P771, DOI 10.1136/annrheumdis 2012 202907
   Sargin G, 2019, EUR J RHEUMATOL, V6, P29, DOI 10.5152/eurjrheum.2018.18099
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Scherer HU, 2010, ARTHRITIS RHEUM US, V62, P1620, DOI 10.1002/art.27414
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schneider AJ, 2014, INT J MOL SCI, V15, P17852, DOI 10.3390/ijms151017852
   Seeling M, 2013, P NATL ACAD SCI USA, V110, P10729, DOI 10.1073/pnas.1301001110
   Seibl R, 2003, AM J PATHOL, V162, P1221, DOI 10.1016/S0002 9440(10)63918 1
   Self Fordham JB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01062
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Shalev M, 2021, FEBS J, V288, P4702, DOI 10.1111/febs.15778
   Smart SK, 2018, CANCERS, V10, DOI 10.3390/cancers10120474
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Sugatani T, 2009, J BIOL CHEM, V284, P4667, DOI 10.1074/jbc.M805777200
   Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516
   Takeuchi T, 2017, BIOL PHARM BULL, V40, P352, DOI 10.1248/bpb.b16 00877
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P899, DOI 10.1136/annrheumdis 2018 214827
   Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0
   van de Laar L, 2016, IMMUNITY, V44, P755, DOI 10.1016/j.immuni.2016.02.017
   Vomero M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01577
   Voronov I, 2008, BIOCHEM PHARMACOL, V75, P2034, DOI 10.1016/j.bcp.2008.02.025
   Voronov I, 2005, BIOCHEM PHARMACOL, V70, P300, DOI 10.1016/j.bcp.2005.04.028
   Wang LF, 2021, CELL SIGNAL, V78, DOI 10.1016/j.cellsig.2020.109847
   Wang Q, 2016, TOXICOL SCI, V149, P346, DOI 10.1093/toxsci/kfv246
   Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/NCHEMBIO.1403, 10.1038/nchembio.1403]
   Xu J, 2007, HISTOL HISTOPATHOL, V22, P443, DOI 10.14670/HH 22.443
   Xue JM, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02308 7
   Yamakawa T, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115494
   Yamanaka S, 2020, BIOCHEM BIOPH RES CO, V524, P1, DOI 10.1016/j.bbrc.2019.12.049
   Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Yoon SH, 2011, J BONE MINER RES, V26, P1217, DOI 10.1002/jbmr.310
   Yudoh K, 2000, ARTHRITIS RHEUM, V43, P617, DOI 10.1002/1529 0131(200003)43:3<617::AID ANR19>3.0.CO;2 B
   Zhang LQ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.132
   Zhang Li Qin, 2011, J Bioanal Biomed, V3, P13
   Zhang X, 2019, CLIN CHIM ACTA, V496, P76, DOI 10.1016/j.cca.2019.06.026
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zhao GJ, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/6848430
   Zizzo G, 2012, J IMMUNOL, V189, P3508, DOI 10.4049/jimmunol.1200662
NR 175
TC 29
Z9 30
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 18
PY 2022
VL 13
AR 1034050
DI 10.3389/fimmu.2022.1034050
PG 17
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 6S7KD
UT WOS:000893160700001
PM 36466887
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Heilmann, A
   Schinke, T
   Bindl, R
   Wehner, T
   Rapp, A
   Haffner Luntzer, M
   Liedert, A
   Amling, M
   Ignatius, A
AF Heilmann, Aline
   Schinke, Thorsten
   Bindl, Ronny
   Wehner, Tim
   Rapp, Anna
   Haffner Luntzer, Melanie
   Liedert, Astrid
   Amling, Michael
   Ignatius, Anita
TI Systemic Treatment with the Sphingosine 1 Phosphate Analog FTY720 Does
   Not Improve Fracture Healing in Mice
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE fracture healing; sphingosine 1 phosphate; FTY720
ID SPHINGOSINE 1 PHOSPHATE; ALLOGRAFT INCORPORATION; LOCAL DELIVERY; BONE;
   OSTEOCLASTS; PROMOTES; FINGOLIMOD; ACTIVATION; IMMUNE; DRUG
AB Sphingosine 1 phosphate (S1P) has recently been recognized as a crucial coupling molecule of osteoclast and osteoblast activity provoking osteoanabolic effects. Targeting S1P receptors could, therefore, be a potential strategy to support bone formation in osteopenic diseases or in fracture repair. Here we investigated whether systemic treatment with the S1P analog FTY720 (Fingolimod) could improve fracture healing. Twelve week old, female C57BL/6 mice received an osteotomy of the femur, which was stabilized using an external fixator. The mice received a daily subcutaneous injection of either FTY720 (6mg/kg) or vehicle from the third postoperative day. Fracture healing was evaluated after 10 and 21 days using biomechanical testing, mu computed tomography, and histomorphometry. Because FTY720 is supposed to influence osteoclast recruitment, osteoclasts were identified in the fracture callus by staining for tartrate resistant acid phosphatase (TRAP). There were no significant differences in callus mechanical properties, tissue composition and osteoclast number between the groups, suggesting that systemically applied FTY720 did not influence bone regeneration in this model of regular fracture healing. Even if further studies should test the potency of FTY720 under unfavorable healing conditions, we conclude that the effect of systemically applied FTY720 on fracture healing might be inferior compared to other anabolic treatments. (c) 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31:1845 1850, 2013
C1 [Heilmann, Aline; Bindl, Ronny; Wehner, Tim; Rapp, Anna; Haffner Luntzer, Melanie; Liedert, Astrid; Ignatius, Anita] Univ Ulm, Ctr Musculoskeletal Res, Inst Orthopaed Res & Biomech, D 89069 Ulm, Germany.
   [Schinke, Thorsten; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Hamburg, Germany.
C3 Ulm University; University of Hamburg; University Medical Center
   Hamburg Eppendorf
RP Ignatius, A (通讯作者)，Univ Ulm, Ctr Musculoskeletal Res, Inst Orthopaed Res & Biomech, D 89069 Ulm, Germany.
EM anita.ignatius@uni ulm.de
RI Rapp, Anna/L 8807 2016; Haffner Luntzer, Melanie/L 3562 2019; Ignatius,
   Anita/M 6012 2013; Rapp, Anna Elise/L 8807 2016
OI Ignatius, Anita/0000 0002 4782 1979; Rapp, Anna
   Elise/0000 0001 5122 765X; Haffner Luntzer, Melanie/0000 0002 3333 2613
FU German Research Foundation (DFG) [IG18/7 2, SCHI 504/5 2]
FX Grant sponsor: German Research Foundation (DFG) (Research Unit FOR793);
   Grant numbers: IG18/7 2, SCHI 504/5 2.
CR Aronin CEP, 2010, BIOMATERIALS, V31, P6417, DOI 10.1016/j.biomaterials.2010.04.061
   Aronin CEP, 2010, TISSUE ENG PT A, V16, P1801, DOI [10.1089/ten.tea.2009.0539, 10.1089/ten.TEA.2009.0539]
   Beil FT, 2010, J TRAUMA, V69, P1259, DOI 10.1097/TA.0b013e3181c4544d
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce BF, 2009, DEV CELL, V16, P323, DOI 10.1016/j.devcel.2009.03.002
   Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248
   Brinkmann V, 2009, BRIT J PHARMACOL, V158, P1173, DOI 10.1111/j.1476 5381.2009.00451.x
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Histing T, 2011, J ORTHOP RES, V29, P867, DOI 10.1002/jor.21324
   Huang C, 2012, CELL TISSUE RES, V347, P553, DOI 10.1007/s00441 011 1217 3
   Ishii M, 2013, BBA MOL CELL BIOL L, V1831, P223, DOI 10.1016/j.bbalip.2012.06.002
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kollet O, 2007, ANNU REV IMMUNOL, V25, P51, DOI 10.1146/annurev.immunol.25.022106.141631
   Kumagai K, 2012, J ORTHOP RES, V30, P1516, DOI 10.1002/jor.22103
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Matsuzaki E, 2013, BONE, V55, P315, DOI 10.1016/j.bone.2013.04.008
   Morgan EF, 2009, BONE, V44, P335, DOI 10.1016/j.bone.2008.10.039
   Nam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040044
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Recknagel S, 2013, J TRAUMA ACUTE CARE, V74, P531, DOI 10.1097/TA.0b013e318278956d
   Röntgen V, 2010, J ORTHOP RES, V28, P1456, DOI 10.1002/jor.21148
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Sato C, 2012, BIOCHEM BIOPH RES CO, V423, P200, DOI 10.1016/j.bbrc.2012.05.130
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   Sefcik LS, 2011, TISSUE ENG PT A, V17, P617, DOI 10.1089/ten.TEA.2010.0404
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185
   Wamhoff BR, 2008, ARTERIOSCL THROM VAS, V28, P1454, DOI 10.1161/ATVBAHA.107.159392
NR 32
TC 30
Z9 31
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD NOV
PY 2013
VL 31
IS 11
BP 1845
EP 1850
DI 10.1002/jor.22426
PG 6
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 224YX
UT WOS:000324930500024
PM 23818033
OA Bronze
DA 2025 08 17
ER

PT J
AU Schreuder, WH
   Coumou, AW
   Kessler, PAHW
   de Lange, J
AF Schreuder, Willem H.
   Coumou, Annet W.
   Kessler, Peter A. H. W.
   de lange, Jan
TI Alternative Pharmacologic Therapy for Aggressive Central Giant Cell
   Granuloma: Denosumab
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID SKELETAL
AB In the search for new pharmacologic therapies for central giant cell granuloma (CGCG), proteins that are essential to osteoclastogenesis are intriguing potential targets. In the present case report, we describe a 25 year old patient with an aggressive CGCG of the maxilla, who was successfully treated with the antiresorptive agent denosumab, after other pharmacologic treatment had failed to achieve regression or stabilization of the tumor. Denosumab could be a promising alternative to potentially mutilating surgery for CGCG. However, more research is needed before definite conclusions can be drawn about the potential role of this agent in the treatment of CGCG. (C) 2014 American Association of Oral and Maxillofacial Surgeons
C1 [Schreuder, Willem H.; de lange, Jan] Univ Amsterdam, Acad Ctr Dent Amsterdam, Acad Med Ctr, Dept Oral & Maxillofacial Surg, NL 1100 DD Amsterdam, Netherlands.
   [Schreuder, Willem H.] Antoni van Leeuwenhoek Netherlands Canc Inst, Dept Head & Neck Surg, Amsterdam, Netherlands.
   [Coumou, Annet W.] Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL 1100 DD Amsterdam, Netherlands.
   [Kessler, Peter A. H. W.] Maastricht Univ, Univ Hosp Maastricht, Dept Craniomaxillofacial Surg, Maastricht, Netherlands.
C3 Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam;
   University of Amsterdam; Academic Medical Center Amsterdam; Netherlands
   Cancer Institute; University of Amsterdam; Academic Medical Center
   Amsterdam; Maastricht University; Maastricht University Medical Centre
   (MUMC)
RP Schreuder, WH (通讯作者)，Univ Amsterdam, Acad Ctr Dent Amsterdam, Acad Med Ctr, Dept Oral & Maxillofacial Surg, POB 22660, NL 1100 DD Amsterdam, Netherlands.
EM w.h.schreuder@amc.uva.nl
CR de Lange J, 2004, HEAD NECK J SCI SPEC, V26, P792, DOI 10.1002/hed.20069
   De Lange J, 2007, ORAL SURG ORAL MED O, V104, P603, DOI 10.1016/j.tripleo.2007.04.003
   HARRIS M, 1993, BRIT J ORAL MAX SURG, V31, P89, DOI 10.1016/0266 4356(93)90168 V
   JAFFE HL, 1953, ORAL SURG ORAL MED O, V6, P159, DOI 10.1016/0030 4220(53)90151 0
   Kaban LB, 2007, J ORAL MAXIL SURG, V65, P2018, DOI 10.1016/j.joms.2007.03.030
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600 0714.2003.00126.x
   Peddi P, 2013, CANCER TREAT REV, V39, P97, DOI 10.1016/j.ctrv.2012.07.002
   Qi W X., 2014, Int J Clin Oncol
   Sinningen K, 2012, ENDOCRINE, V42, P52, DOI 10.1007/s12020 012 9696 x
   Terry BC, 1994, ORAL MAXILLOFAC SURG, V6, P579, DOI DOI 10.1016/S1042 3699(20)30771 8
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   WHITAKER SB, 1993, ORAL SURG ORAL MED O, V75, P199, DOI 10.1016/0030 4220(93)90094 K
NR 13
TC 47
Z9 47
U1 0
U2 4
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 2391
EI 1531 5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD JUL
PY 2014
VL 72
IS 7
BP 1301
EP 1309
DI 10.1016/j.joms.2014.02.017
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AK4WI
UT WOS:000338424500014
PM 24835517
DA 2025 08 17
ER

PT J
AU Tosi, P
   Gamberi, B
   Giuliani, N
AF Tosi, P
   Gamberi, B
   Giuliani, N
TI Biology and treatment of multiple myeloma
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE myeloma; oncogenes; microenvironment; stem cell transplantation
ID BONE MARROW TRANSPLANTATION; STEM CELL TRANSPLANTATION; ENDOTHELIAL
   GROWTH FACTOR; HIGH DOSE CHEMOTHERAPY; AUTOLOGOUS TRANSPLANTATION;
   EUROPEAN GROUP; EXPRESSION; DEXAMETHASONE; THALIDOMIDE; BORTEZOMIB
AB Multiple myeloma (AIM) is a B cell malignancy that accounts for 10% of all hematologic cancers. In recent years much has been learned regarding the biology of the myeloma clone; specifically on the chromosomal alterations that can be more frequently found and on the involved oncogenes. It has been also demonstrated that, in MM, bone marrow microenvironment, both in its cellular (stromal cells, osteoblasts, osteoclasts, endothelia) and protein (extracellular matrix) components, plays an important role in promoting growth and survival of malignant plasma cells. Much of this knowledge will be translated into a better patients treatment; although high dose therapy programs can be considered the treatment of choice for patients aged 70 or younger, novel drugs, targeting AIM clone in its microenvironment can be incorporated into these therapeutic programs improving response rate and patients survival. (C) 2006 American Society for Blood and Marrow Transplantation.
C1 Univ Bologna, Policlin S Orsola, Ist Ematol & Oncol Med Seragnoli, I 40138 Bologna, Italy.
   Santa Maria Nuova Hosp, Dept Oncohematol, Reggio Emilia, Italy.
   Univ Parma, Chair Hematol, I 43100 Parma, Italy.
   Univ Parma, BMT Ctr, I 43100 Parma, Italy.
C3 University of Bologna; IRCCS Azienda Ospedaliero Universitaria di
   Bologna; IRCCS Arcispedale S. Maria Nuova; University of Parma;
   University of Parma
RP Univ Bologna, Policlin S Orsola, Ist Ematol & Oncol Med Seragnoli, Via Massarenti 9, I 40138 Bologna, Italy.
EM ptosi@med.unibo.it
RI Giuliani, Nicola/AAT 7968 2020; Gamberi, Barbara/AAA 7508 2019
OI Gamberi, Barbara/0000 0003 3616 5838; Giuliani,
   Nicola/0000 0003 3457 3774
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Attal M, 2003, NEW ENGL J MED, V349, P2495, DOI 10.1056/NEJMoa032290
   Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204
   Badros A, 2001, BRIT J HAEMATOL, V114, P822, DOI 10.1046/j.1365 2141.2001.03033.x
   Barlogie B, 2004, BLOOD, V103, P20, DOI 10.1182/blood 2003 04 1045
   Barosi G, 2004, HAEMATOLOGICA, V89, P717
   Bellamy WT, 1999, CANCER RES, V59, P728
   Bensinger WI, 1996, BLOOD, V88, P2787, DOI 10.1182/blood.V88.7.2787.bloodjournal8872787
   Bjorkstrand B, 1996, BLOOD, V88, P4711, DOI 10.1182/blood.V88.12.4711.bloodjournal88124711
   Cavo M, 1998, BONE MARROW TRANSPL, V22, P27, DOI 10.1038/sj.bmt.1701280
   Cavo M, 2000, BLOOD, V96, P355, DOI 10.1182/blood.V96.1.355.013k02_355_357
   Cavo M, 2002, BLOOD, V100, p179A
   Cavo M, 2005, BLOOD, V106, P35, DOI 10.1182/blood 2005 02 0522
   Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340
   Crawley C, 2005, BLOOD, V105, P4532, DOI 10.1182/blood 2004 06 2387
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   Dispenzieri A, 2005, BEST PRACT RES CL HA, V18, P553, DOI 10.1016/j.beha.2005.01.008
   Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008 5472.CAN 03 2876
   Gahrton G, 2001, BRIT J HAEMATOL, V113, P209, DOI 10.1046/j.1365 2141.2001.02726.x
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Martinelli G, 2000, J CLIN ONCOL, V18, P2273, DOI 10.1200/JCO.2000.18.11.2273
   Rajkumar SV, 2004, BLOOD, V104, p63A, DOI 10.1182/blood.V104.11.205.205
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   RICHARDSON PG, 2005, HAEMATOLOGICA S1, V1, P154
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Shaughnessy JD, 2003, IMMUNOL REV, V194, P140, DOI 10.1034/j.1600 065X.2003.00054.x
   Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102
   Soverini S, 2003, BLOOD, V102, P1588, DOI 10.1182/blood 2002 12 3789
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vacca A, 1999, BLOOD, V93, P3064
   Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745
NR 37
TC 10
Z9 11
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1083 8791
EI 1523 6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JAN
PY 2006
VL 12
IS 1
SU 1
BP 81
EP 86
DI 10.1016/j.bbmt.2005.09.008
PG 6
WC Hematology; Immunology; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Immunology; Transplantation
GA 010FB
UT WOS:000235171200015
PM 16399590
OA hybrid
DA 2025 08 17
ER

PT J
AU Pang, YC
   Qiu, XT
   Liu, SM
   Huo, YL
   Yang, XL
   Ma, C
   Qi, M
   Chen, XJ
   Zhou, ZH
   Lv, ZW
AF Pang, Yi Chuan
   Qiu, Xiaotong
   Liu, Simin
   Huo, Yanlei
   Yang, Xiaoli
   Ma, Chao
   Qi, Min
   Chen, Xiaojun
   Zhou, Zhi Hang
   Lv, Zhongwei
TI Golgi triggered radiation sensitizer retention enhances the
   efferocytosis and immunotherapy in breast cancer with skeleton
   metastases
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Radiotherapy sensibilization; Efferocytosis; Breast cancer; Golgi
   response; Skeletal metastasis
ID BONE METASTASES; NANOPARTICLES; FURIN
AB Radiotherapy with higher precision and better efficiency is required for breast cancer bone metastasis therapy. In this study, we synthesized a golgi triggered radiation sensitizer, Furin Activated Iron Oxide nanoparticles (FAIOs), which could suppress breast cancer bone metastasis by targeting tumor micro environment (TME) and enhancing immune response. As a multi functional theranostic mediator, FAIOs enabled tumor specific MRI and accurate radiation therapy in TMEs with enriched FURIN. The increased efferocytosis triggered by FAIOsmediated tumor cell apoptosis offered remarkable benefits. Moreover, the osteoclast mediated bone destruction was markedly alleviated. These encouraging findings provided insights into therapeutic and diagnostic value of these multifunctional FAIOs for bone metastatic breast cancer. (Scheme)
C1 [Pang, Yi Chuan; Qiu, Xiaotong; Liu, Simin; Huo, Yanlei; Yang, Xiaoli; Ma, Chao; Chen, Xiaojun; Zhou, Zhi Hang; Lv, Zhongwei] Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Sch Med, Shanghai 200072, Peoples R China.
   [Qi, Min] Fudan Univ, Dept Nucl Med, Shanghai Canc Ctr, Shanghai, Peoples R China.
   [Chen, Xiaojun] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Sch Med, Shanghai, Peoples R China.
   [Zhou, Zhi Hang] Natl Clin Res Ctr Stomatol, Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Zhou, Zhi Hang] Natl Clin Res Ctr Stomatol, Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Zhou, Zhi Hang] Shanghai Jiao Tong Univ, Peoples Hosp 9, Coll Stomatol, Dept Oral & Maxillofacial Head & Neck Oncol,Sch Me, Shanghai, Peoples R China.
C3 Tongji University; Fudan University; Shanghai Jiao Tong University;
   Shanghai Jiao Tong University
RP Chen, XJ; Zhou, ZH; Lv, ZW (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Sch Med, Shanghai 200072, Peoples R China.
EM chenxiaojun1993@sjtu.edu.cn; zhihangz@126.com; Lvzwjs2020@163.com
RI Chen, Xiaojun/JRX 0041 2023; , 童昕/GNH 3040 2022
OI Chen, Xiaojun/0000 0002 7796 1315; 
FU National Natural Science Foundation of China [82202202, 82071964];
   Shanghai Sailing Program [23YF1421700]
FX <B>Funding</B> This work was supported by the National Natural Science
   Foundation of China [grant numbers 82202202 & 82071964) ; Shanghai
   Sailing Program (23YF1421700) .
CR Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958
   Berg TJ, 2022, SEMIN CANCER BIOL, V86, P846, DOI 10.1016/j.semcancer.2022.02.011
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bulte JWM, 2019, ADV DRUG DELIVER REV, V138, P293, DOI 10.1016/j.addr.2018.12.007
   Chung AW, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abj5070
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   De Felice F, 2017, ONCOTARGET, V8, P25691, DOI 10.18632/oncotarget.14823
   Dong JL, 2021, TECHNOL CANCER RES T, V20, DOI 10.1177/15330338211064719
   Goodfellow FT, 2016, ADV FUNCT MATER, V26, P3899, DOI 10.1002/adfm.201504444
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kuchuk I, 2013, J BONE ONCOL, V2, P137, DOI 10.1016/j.jbo.2013.09.001
   Lei G, 2020, CELL RES, V30, P146, DOI 10.1038/s41422 019 0263 3
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Liu YL, 2015, THERANOSTICS, V5, P1058, DOI 10.7150/thno.11758
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Ma L, 2021, CLIN CANCER RES, V27, P1778, DOI 10.1158/1078 0432.CCR 20 3215
   Pang YC, 2021, BIOACT MATER, V6, P712, DOI 10.1016/j.bioactmat.2020.09.006
   Pang YC, 2020, NANO LETT, V20, P829, DOI 10.1021/acs.nanolett.9b02916
   Rusk N, 2019, NAT METHODS, V16, P577, DOI 10.1038/s41592 019 0486 8
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sun LJ, 2021, CANCER CELL, V39, P1361, DOI 10.1016/j.ccell.2021.08.005
   Tahara RK, 2019, ADV EXP MED BIOL, V1152, P105, DOI 10.1007/978 3 030 20301 6_7
   Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934
   Vu VP, 2019, NAT NANOTECHNOL, V14, P260, DOI 10.1038/s41565 018 0344 3
   Wang R, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 6311 z
   Ward J, 2008, J CLIN ONCOL, V26, P4304, DOI 10.1200/JCO.2008.16.1893
NR 28
TC 1
Z9 1
U1 2
U2 28
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD JAN 15
PY 2024
VL 480
AR 147818
DI 10.1016/j.cej.2023.147818
EA DEC 2023
PG 10
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA FI6C4
UT WOS:001145161600001
DA 2025 08 17
ER

PT J
AU Lee, YA
   Yang, HI
   Park, EK
   Bang, JS
   Choi, HM
   Oh, DH
   Lee, SH
   Hong, SJ
   Jo, YJ
   Yoo, MC
   Kim, KS
AF Lee, Yeon Ah
   Yang, Hyung In
   Park, Eun Kyung
   Bang, Jun Soo
   Choi, Hyun Mi
   Oh, Da Hee
   Lee, Sang Hoon
   Hong, Seung Jae
   Jo, Yoon Je
   Yoo, Myung Chul
   Kim, Kyoung Soo
TI Mizoribine may suppress bone erosion in patients with rheumatoid
   arthritis by inhibiting osteoclastogenesis
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Mizoribine; DMARD; Osteoclastogenesis; Bone resorption; Rheumatoid
   arthritis
ID DIFFERENTIATION; OSTEOPROTEGERIN; BREDININ; LIGAND
AB Mizoribine is a disease modifying anti rheumatic drug (DMARD) that is used in the treatment of rheumatoid arthritis. However, clinical use of the drug is restricted to a few Asian countries due to a lack of comprehensive evidence on its effectiveness. The inhibitory effect of the drug on human osteoclastogenesis was investigated in the hopes of providing some clear evidence. Mizoribine was found to inhibit in vitro osteoclastogenesis in a dose dependent manner. In addition, the size of the pit area was closely related to the number of osteoclasts in a bone resorption assay. However, mizoribine did not affect the phosphorylation of MAP kinase (p38, JNK, ERK), the degradation of I kappa B alpha, or receptor activator of NF kappa B ligand (RANKL) expression in fibroblast like synoviocytes stimulated with IL 1beta. These results suggested that mizoribine may partially suppress osteoclastogenesis, leading to progressive bone erosion by inhibiting the growth or the signaling pathway of precursor cells to form osteoclasts rather than fibroblast like synoviocytes. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Yang, Hyung In; Park, Eun Kyung; Bang, Jun Soo; Choi, Hyun Mi; Oh, Da Hee; Yoo, Myung Chul; Kim, Kyoung Soo] Kyung Hee Univ, East West Bone & Joint Res Inst, East West Neo Med Ctr, Seoul, South Korea.
   [Yang, Hyung In; Lee, Sang Hoon] Kyung Hee Univ, Dept Internal Med, East West Neo Med Ctr, Seoul, South Korea.
   [Lee, Yeon Ah; Hong, Seung Jae] Kyung Hee Univ, Dept Internal Med, Coll Med, Seoul, South Korea.
   [Jo, Yoon Je] Kyung Hee Univ, Dept Orthoped Surg, Coll Med, Seoul, South Korea.
   [Yoo, Myung Chul] Kyung Hee Univ, Dept Orthoped Surg, East West Neo Med Ctr, Seoul, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung
   Hee University; Kyung Hee University
RP Yoo, MC (通讯作者)，Kyung Hee Univ, East West Bone & Joint Res Inst, East West Neo Med Ctr, 149 Sangil Dong, Seoul, South Korea.
EM mcyookhu@chol.com; labrea46@yahoo.co.kr
FU Ministry of Health & Welfare, Republic of Korea [03 PJ9 PG6 S001 002]
FX This work was supported by a research grant from the Ministry of Health
   & Welfare, Republic of Korea (03 PJ9 PG6 S001 002). The authors thank
   Mr. Aldo Kobayashi from the Asahi Kasei Pharma Corporation for the kind
   provision of mizoribine.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Imaizumi Yasuhiko, 2001, Kobe Journal of Medical Sciences, V47, P13
   Kim KS, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2279
   KUSABA R, 1981, P EUR DIAL TRANS, V18, P420
   Lee CK, 2004, ARTHRITIS RHEUM US, V50, P3831, DOI 10.1002/art.20637
   MIZUNO K, 1974, J ANTIBIOT, V27, P775, DOI 10.7164/antibiotics.27.775
   SASAGAWA K, 1989, INT J IMMUNOPHARMACO, V11, P953
   Seo KW, 2005, TRANSPL P, V37, P155, DOI 10.1016/j.transproceed.2005.01.020
   Takei S, 2002, PEDIATR INT, V44, P205, DOI 10.1046/j.1328 8067.2002.01535.x
   Tanaka H, 2005, CLIN NEPHROL, V63, P417
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   YOSHIZAWA M, 1982, CLIN IMMUNOL, V14, P561
   Zhong Binbin, 2005, Mod Rheumatol, V15, P264, DOI 10.1007/s10165 005 0406 x
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAR 1
PY 2009
VL 605
IS 1 3
BP 46
EP 48
DI 10.1016/j.ejphar.2008.12.048
PG 3
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 422DL
UT WOS:000264407300007
PM 19171130
DA 2025 08 17
ER

PT J
AU Pierce, JL
   Sharma, AK
   Roberts, RL
   Yu, KL
   Irsik, DL
   Choudhary, V
   Dorn, JS
   Bensreti, H
   Benson, RD 
   Kaiser, H
   Khayrullin, A
   Davis, C
   Wehrle, CJ
   Johnson, MH
   Bollag, WB
   Hamrick, MW
   Shi, XM
   Isales, CM
   McGee Lawrence, ME
AF Pierce, Jessica L.
   Sharma, Anuj K.
   Roberts, Rachel L.
   Yu, Kanglun
   Irsik, Debra L.
   Choudhary, Vivek
   Dorn, Jennifer S.
   Bensreti, Husam
   Benson, Reginald D., Jr.
   Kaiser, Helen
   Khayrullin, Andrew
   Davis, Colleen
   Wehrle, Chase J.
   Johnson, Maribeth H.
   Bollag, Wendy B.
   Hamrick, Mark W.
   Shi, Xingming
   Isales, Carlos M.
   McGee Lawrence, Meghan E.
TI The Glucocorticoid Receptor in Osterix Expressing Cells Regulates Bone
   Mass, Bone Marrow Adipose Tissue, and Systemic Metabolism in Female Mice
   During Aging
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE AGING; OSTEOBLASTS; OSTEOPOROSIS; GLUCOCORTICOIDS; BONE MARROW ADIPOSE
   TISSUE (BMAT)
ID PPAR GAMMA; OBESITY; DIFFERENTIATION; OSTEOPOROSIS; OSTEOBLASTS; GR;
   SUMOYLATION; MECHANISMS; OSTEOCYTES; INHIBITION
AB Hallmarks of aging associated osteoporosis include bone loss, bone marrow adipose tissue (BMAT) expansion, and impaired osteoblast function. Endogenous glucocorticoid levels increase with age, and elevated glucocorticoid signaling, associated with chronic stress and dysregulated metabolism, can have a deleterious effect on bone mass. Canonical glucocorticoid signaling through the glucocorticoid receptor (GR) was recently investigated as a mediator of osteoporosis during the stress of chronic caloric restriction. To address the role of the GR in an aging associated osteoporotic phenotype, the current study utilized female GR conditional knockout (GR CKO; GR(fl/fl):Osx Cre+) mice and control littermates on the C57BL/6 background aged to 21 months and studied in comparison to young (3  and 6 month old) mice. GR deficiency in Osx expressing cells led to low bone mass and BMAT accumulation that persisted with aging. Surprisingly, however, GR CKO mice also exhibited alterations in muscle mass (reduced % lean mass and soleus fiber size), accompanied by reduced voluntary physical activity, and also exhibited higher whole body metabolic rate and elevated blood pressure. Moreover, increased lipid storage was observed in GR CKO osteoblastic cultures in a glucocorticoid dependent fashion despite genetic deletion of the GR, and could be reversed via pharmacological inhibition of the mineralocorticoid receptor (MR). These findings provide evidence of a role for the GR (and possibly the MR) in facilitating healthy bone maintenance with aging in females. The effects of GR deficient bone on whole body physiology also demonstrate the importance of bone as an endocrine organ and suggest evidence for compensatory mechanisms that facilitate glucocorticoid signaling in the absence of osteoblastic GR function; these represent new avenues of research that may improve understanding of glucocorticoid signaling in bone toward the development of novel osteogenic agents. (c) 2021 American Society for Bone and Mineral Research (ASBMR).
C1 [Pierce, Jessica L.; Sharma, Anuj K.; Roberts, Rachel L.; Yu, Kanglun; Dorn, Jennifer S.; Bensreti, Husam; Benson, Reginald D., Jr.; Kaiser, Helen; Khayrullin, Andrew; Davis, Colleen; Wehrle, Chase J.; Hamrick, Mark W.; McGee Lawrence, Meghan E.] Augusta Univ, Dept Cellular Biol & Anat, 1120 15th St, Augusta, GA 30912 USA.
   [Irsik, Debra L.; Johnson, Maribeth H.; Shi, Xingming; Isales, Carlos M.] Augusta Univ, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA.
   [Irsik, Debra L.; Bollag, Wendy B.] Charlie Norwood VA Med Ctr, Augusta, GA USA.
   [Choudhary, Vivek; Bollag, Wendy B.] Augusta Univ, Dept Physiol, Augusta, GA 30912 USA.
   [McGee Lawrence, Meghan E.] Augusta Univ, Dept Orthopaed Surg, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Charlie Norwood VA Medical Center;
   University System of Georgia; Augusta University; University System of
   Georgia; Augusta University
RP McGee Lawrence, ME (通讯作者)，Augusta Univ, Dept Cellular Biol & Anat, 1120 15th St, Augusta, GA 30912 USA.
EM mmcgeelawrence@augusta.edu
RI Isales, Carlos/ABF 2983 2021; Choudhary, Vivek/M 3167 2015; Hamrick,
   Mark/K 1131 2016; Isales, Carlos/J 9902 2013; Sharma,
   Anuj/JTS 4887 2023; Kaiser, Helen/HZH 2697 2023
OI Wehrle, Chase/0000 0002 9275 4744; Isales, Carlos/0000 0002 4480 3484;
   Irsik, Debra/0000 0001 6209 3351; Sharma, Anuj/0009 0001 5882 709X;
   Bollag, Wendy/0000 0003 3146 162X
FU NIH [P01AG036675, S10 OD025177]; American Diabetes Association
   [1 16 JDF 062]
FX This work was supported by the NIH (grant number P01AG036675 Project 4
   and S10 OD025177) and the American Diabetes Association (grant number
   1 16 JDF 062). The authors thank Dr. Louis Muglia for providing the
   GR floxed mouse model. We thank Dr. Ismail Kaddour Djebbar of the
   Charlie Norwood VA Medical Center for assistance with coordinating the
   Seahorse metabolic assays, and Dr. David Stepp and James Mintz for
   assistance with operating the CLAMS cages and obtaining metabolic
   measurements. We acknowledge the Augusta University Electron Microscopy
   and Histology Core for tissue embedding and histological sectioning
   services. The contents of this article do not represent the views of the
   Department of Veterans Affairs or the United States Government. The data
   that support the findings of this study are available from the
   corresponding author upon reasonable request. Authors' roles: Study
   design: MEML and JLP. Study conduct: JLP, AKS, RLR, DLI, and HB. Data
   collection: JLP, AKS, RLR, DLI, VC, HB, RDB, HK, and AK. Data analysis:
   JLP, AKS, KY, DLI, JD, HK, AK, CD, HB, CJW, MHJ, and MEML. Data
   interpretation: JLP, HB, DLI, MHJ, and MEML. Drafting manuscript: JLP
   and MEML. Revising manuscript content: JLP, DLI, WBB, XMS, and MEML.
   Approving final version of manuscript: JLP, AKS, RLR, KY, DLI, VC, JSD,
   HB, RDB, HK, AK, CD, CJW, MHJ, WBB, MWH, XMS, CMI, and MEML. JLP and
   MEML take responsibility for the integrity of the data analysis.
CR Ackert Bicknell Cheryl L, 2015, Curr Protoc Mouse Biol, V5, P95, DOI 10.1002/9780470942390.mo140195
   Ahasan MM, 2012, ARTHRITIS RHEUM US, V64, P2404, DOI 10.1002/art.34414
   Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   Almeida M, 2020, AGING CELL, V19, DOI 10.1111/acel.13247
   Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Boivin GP, 2017, J AM ASSOC LAB ANIM, V56, P491
   Brewer JA, 2003, NAT MED, V9, P1318, DOI 10.1038/nm895
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Cao J, 2020, J GERONTOL A BIOL, V75, P826, DOI 10.1093/gerona/glaa049
   Cawthorn WP, 2016, ENDOCRINOLOGY, V157, P508, DOI 10.1210/en.2015 1477
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Cooper MS, 2001, J BONE MINER RES, V16, P1037, DOI 10.1359/jbmr.2001.16.6.1037
   Dalle H, 2019, DIABETES, V68, P305, DOI 10.2337/db17 1577
   Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248 011 9581 z
   Theije CC, 2018, ENDOCRINOLOGY, V159, P519, DOI 10.1210/en.2017 00603
   Deuschle M, 1997, LIFE SCI, V61, P2239, DOI 10.1016/S0024 3205(97)00926 0
   Fazeli PK, 2013, J CLIN ENDOCR METAB, V98, P935, DOI 10.1210/jc.2012 3634
   Fumoto T, 2014, BIOCHEM BIOPH RES CO, V447, P407, DOI 10.1016/j.bbrc.2014.03.149
   Gorgey AS, 2013, PM&R, V5, P939, DOI 10.1016/j.pmrj.2013.05.006
   Guntur AR, 2018, J BONE MINER RES, V33, P1052, DOI 10.1002/jbmr.3390
   HALBERG F, 1959, AM J PHYSIOL, V197, P1083, DOI 10.1152/ajplegacy.1959.197.5.1083
   Henneicke H, 2020, MOL METAB, V42, DOI 10.1016/j.molmet.2020.101098
   Hirata A, 2012, BIOCHEM BIOPH RES CO, V419, P182, DOI 10.1016/j.bbrc.2012.01.139
   Hirata A, 2009, CARDIOVASC RES, V84, P164, DOI 10.1093/cvr/cvp191
   Hua GQ, 2016, P NATL ACAD SCI USA, V113, pE626, DOI 10.1073/pnas.1522821113
   Hua GQ, 2016, P NATL ACAD SCI USA, V113, pE635, DOI 10.1073/pnas.1522826113
   Huang W, 2015, TRANSGENIC RES, V24, P167, DOI 10.1007/s11248 014 9828 6
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Iwaniec UT, 2009, BONE, V44, P404, DOI 10.1016/j.bone.2008.10.058
   Iwaniec UT, 2013, BONE, V53, P145, DOI 10.1016/j.bone.2012.11.034
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kappel S, 2017, ANIMALS, V7, DOI 10.3390/ani7120088
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kino T, 2011, MOL CELL ENDOCRINOL, V336, P23, DOI 10.1016/j.mce.2010.12.001
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Lim HW, 2015, GENOME RES, V25, P836, DOI 10.1101/gr.188581.114
   Marquardt N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203793
   McGee Lawrence ME, 2018, J CELL PHYSIOL, V233, P2671, DOI 10.1002/jcp.26148
   McGee Lawrence ME, 2016, J BONE MINER RES, V31, P116, DOI 10.1002/jbmr.2602
   McGee Lawrence ME, 2015, MOL CELL ENDOCRINOL, V410, P42, DOI 10.1016/j.mce.2015.02.001
   Mittelstadt PR, 2003, MOL ENDOCRINOL, V17, P1534, DOI 10.1210/me.2002 0429
   Mueller KM, 2017, DIABETES, V66, P272, DOI 10.2337/db16 0381
   Nasabian PJ, 2017, J ENDOCRINOL, V234, pR37, DOI 10.1530/JOE 16 0603
   Nehlin JO, 2019, BONE, V123, P265, DOI 10.1016/j.bone.2019.03.041
   Nixon M, 2013, STEROIDS, V78, P59, DOI 10.1016/j.steroids.2012.09.013
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Pierce JL, 2019, BONE, V118, P2, DOI 10.1016/j.bone.2018.05.019
   Pierce JL, 2020, EXP GERONTOL, V130, DOI 10.1016/j.exger.2019.110818
   Pierce JL, 2019, J ENDOCRINOL, V243, P27, DOI 10.1530/JOE 19 0230
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Razidlo DF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011492
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen CJ, 2000, BEST PRACT RES CL EN, V14, P181, DOI 10.1053/beem.2000.0068
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Rotolin S, 2006, J CELL PHYSIOL, V209, P967, DOI 10.1002/jcp.20804
   Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55
   Scheller EL, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00102
   Scheller EL, 2014, ANN NY ACAD SCI, V1311, P14, DOI 10.1111/nyas.12327
   Shen LJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0077515, 10.1371/journal.pone.0077077, 10.1371/journal.pone.0059070]
   Shen W, 2012, EUR J CLIN NUTR, V66, P983, DOI 10.1038/ejcn.2012.35
   Shimizu N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7693
   Wang L, 2015, CALCIFIED TISSUE INT, V96, P129, DOI 10.1007/s00223 014 9945 5
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Weinstein RS, 2010, AGING CELL, V9, P147, DOI 10.1111/j.1474 9726.2009.00545.x
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
NR 70
TC 16
Z9 19
U1 1
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2022
VL 37
IS 2
BP 285
EP 302
DI 10.1002/jbmr.4468
EA NOV 2021
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA YV6WQ
UT WOS:000722066300001
PM 34747055
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Hou, JH
   Qian, JJ
   Li, ZL
   Gong, AX
   Zhong, SX
   Qiao, L
   Qian, SH
   Zhang, YX
   Dou, RJ
   Li, R
   Yang, Y
   Gu, CY
AF Hou, Jianhao
   Qian, Jinjun
   Li, Zhenlin
   Gong, Aixiu
   Zhong, Sixia
   Qiao, Li
   Qian, Shihui
   Zhang, Yanxin
   Dou, Renjie
   Li, Rui
   Yang, Ye
   Gu, Chunyan
TI Bioactive Compounds from Abelmoschus manihot L. Alleviate the
   Progression of Multiple Myeloma in Mouse Model and Improve Bone Marrow
   Microenvironment
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE Abelmoschus manihot L.; Huangkui capsule; flavonoid extracts; multiple
   myeloma; osteoclast; osteoblast
ID HUANGKUI CAPSULE; BETA CATENIN; IN VITRO; EXTRACT; FLOWERS; CELLS;
   FLAVONOIDS; DISEASE; PLASMA; GROWTH
AB Purpose: Abelmoschus manihot (L.) Medik. (Malvaceae) derived Huangkui capsules (HKC) represent a traditional Chinese medicine that has been widely applied to the clinical therapy of kidney and inflammatory diseases. The present study aimed to determine the potential therapeutic effects and underlying mechanisms of the ingredients on Multiple Myeloma (MM), an incurable disease that exhibits malignant plasma cell clonal expansion in the bone marrow.
   Methods: A 5TMM3VT syngeneic MM prone model was established and treated with HKC. Murine pre osteoblast MC3T3 E1 and pre osteoclast Raw264.7 cells were treated with nine flavonoid compounds extracted from the flowers of Abelmoschus manihot. MC3T3 E1 and Raw264.7 cells were then examined by alizarin red staining and tartrate resistant acid phosphatase activity staining, respectively. The proliferation of two human MM cells (ARP1, H929) was examined by performing an MTT assay following treatment with flavonoid compounds. Additionally, the cell cycle was analyzed via staining and flow cytometry. The differential expressions of certain proteins were detected via Western blotting, transcriptomic RNA sequencing as well as RT qPCR.
   Results: The results revealed that MM prone animals appeared to be protected following HKC treatment, as evidenced by a prolonged survival rate. Furthermore, four of the nine flavonoid compounds [Hyperin/Hyperoside, HK 2; Cannabiscitrin, HK 3; 3 O kaempferol 3 O acetyl 6 O (p coumaroyl) beta D glucopyrano side, HK 11; 8 (2 '' pyrrolidione 5 ''  yl)quercetin, HK B10] induced the differentiation of murine pre osteoblast MC3T3 E1 cells. In addition, two compounds [Isomyricitrin, HK 8; quercetin 8 (2 '' pyrrolidione 5 '' yl) 3' O beta D glucopyranosid, HK E3] suppressed osteoclastogenesis in murine Raw264.7 cells. HK 11 directly inhibited MM cells (ARP1 and H929) proliferation and induced G0/G1 cell cycle arrest, which may have involved the suppressing beta catenin protein, increasing expressions of IL 6 and TNF alpha, as well as activating mature TGF beta 1 and some other metabolic pathways.
   Conclusion: These results of the present study indicated that the bio active ingredients of HKC exerted protective effects on MM mouse survival through promoting osteoblastogenesis and suppressing osteoclastogenesis, thus improving the bone marrow microenvironment to inhibit MM cell proliferation.
C1 [Hou, Jianhao; Gu, Chunyan] Nanjing Univ Chinese Med, Affiliated Hosp 3, Nanjing 210001, Peoples R China.
   [Hou, Jianhao; Qian, Jinjun; Zhong, Sixia; Qiao, Li; Zhang, Yanxin; Dou, Renjie; Li, Rui; Yang, Ye; Gu, Chunyan] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing 210023, Peoples R China.
   [Li, Zhenlin; Qian, Shihui] Jiangsu Prov Acad Tradit Chinese Med, Shizi St Hongshan Rd, Nanjing 210028, Peoples R China.
   [Li, Zhenlin; Qian, Shihui] Jiangsu Prov Platform Conservat & Utilizat Agr Ge, Nanjing 210028, Peoples R China.
   [Gong, Aixiu] Nanjing Med Univ, Dept Stomatol, Childrens Hosp, Nanjing 210009, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Nanjing Medical
   University
RP Yang, Y (通讯作者)，Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing 210023, Peoples R China.; Qian, SH (通讯作者)，Jiangsu Prov Acad Tradit Chinese Med, Shizi St Hongshan Rd, Nanjing 210028, Peoples R China.
EM njqsh2005@126.com; yangye876@sina.com
RI YANG, YE/F 4987 2015; Dou, Renjie/KIA 7089 2024; Zhang,
   Yanxin/ABF 2518 2020
OI YANG, YE/0000 0003 0228 5102; 
FU National Natural Science Foundation of China [81970196, 81670200];
   Innovation Team of Six Talent Peaks Project in Jiangsu Province
   [TD SWYY 015]; National Key Research and Development Program Precision
   Medicine Sub program [2016YFC0905900]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions (Integration of
   Chinese and Western Medicine)
FX This work was supported by National Natural Science Foundation of China
   81970196, 81670200 (to CG & YY); Innovation Team of Six Talent Peaks
   Project in Jiangsu Province (TD SWYY 015); National Key Research and
   Development Program Precision Medicine Sub program 2016YFC0905900 (to
   YY); A Project Funded by the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (Integration of Chinese and
   Western Medicine).
CR Ai G, 2013, J ETHNOPHARMACOL, V146, P794, DOI 10.1016/j.jep.2013.02.005
   Chen Ping, 2012, Zhongguo Zhong Yao Za Zhi, V37, P2252
   Chen YZ, 2016, CLIN EXP PHARMACOL P, V43, P145, DOI 10.1111/1440 1681.12528
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Ge J, 2016, J ETHNOPHARMACOL, V189, P238, DOI 10.1016/j.jep.2016.05.033
   Guo JM, 2016, PHARM BIOL, V54, P595, DOI 10.3109/13880209.2015.1068337
   Guo JM, 2010, RAPID COMMUN MASS SP, V24, P443, DOI 10.1002/rcm.4416
   Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623
   Houben A, 2016, DEVELOPMENT, V143, P3826, DOI 10.1242/dev.137489
   Kang H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03720 z
   KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0
   Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233
   Lai Xian Yin, 2006, Zhongguo Zhong Yao Za Zhi, V31, P1597
   Lai XY, 2007, J CHROMATOGR B, V852, P108, DOI 10.1016/j.jchromb.2006.12.043
   Lai XY, 2009, J CHROMATOGR SCI, V47, P206, DOI 10.1093/chromsci/47.3.206
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Manier S, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/157496
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Matthes T, 2015, LEUKEMIA, V29, P1882, DOI 10.1038/leu.2015.145
   Qiang YW, 2010, BRIT J HAEMATOL, V148, P726, DOI 10.1111/j.1365 2141.2009.08009.x
   Rajkumar SV, 2016, AM J HEMATOL, V91, P90, DOI 10.1002/ajh.24236
   Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456
   Rosean TR, 2015, LEUKEMIA, V29, P233, DOI 10.1038/leu.2014.260
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960 9822(02)70790 2
   Sukhdeo K, 2012, LEUKEMIA, V26, P1116, DOI 10.1038/leu.2011.303
   Sun SY, 2018, INT J IMMUNOPATH PH, V32, DOI 10.1177/2058738418787991
   Tu Y, 2013, J ETHNOPHARMACOL, V147, P311, DOI 10.1016/j.jep.2013.03.006
   Urashima M, 1997, BLOOD, V90, P754, DOI 10.1182/blood.V90.2.754.754_754_765
   van Andel H, 2019, LEUKEMIA, V33, P1063, DOI 10.1038/s41375 019 0404 1
   WANG X R, 1981, Acta Botanica Sinica, V23, P222
   Wu LL, 2007, ACTA PHARMACOL SIN, V28, P404, DOI 10.1111/j.1745 7254.2007.00510.x
   Xue CF, 2011, J CHROMATOGR B, V879, P317, DOI 10.1016/j.jchromb.2010.12.016
   Yang SY, 2018, CHEM NAT COMPD+, V54, P257, DOI 10.1007/s10600 018 2317 z
   Yao RS, 2018, AM J TRANSL RES, V10, P2610
   Yuan X, 2014, FOOD CHEM TOXICOL, V65, P242, DOI 10.1016/j.fct.2013.12.030
   Zhang L, 2014, AM J KIDNEY DIS, V64, P57, DOI 10.1053/j.ajkd.2014.01.431
NR 39
TC 17
Z9 19
U1 1
U2 14
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 959
EP 973
DI 10.2147/OTT.S235944
PG 15
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA KG8EP
UT WOS:000510181300001
PM 32099399
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, K
   Qiu, PC
   Yuan, Y
   Zheng, L
   He, JB
   Wang, C
   Guo, Q
   Kenny, J
   Liu, Q
   Zhao, JM
   Chen, JH
   Tickner, J
   Fan, SW
   Lin, XF
   Xu, JK
AF Chen, Kai
   Qiu, Pengcheng
   Yuan, Yu
   Zheng, Lin
   He, Jianbo
   Wang, Chao
   Guo, Qiang
   Kenny, Jacob
   Liu, Qian
   Zhao, Jinmin
   Chen, Junhao
   Tickner, Jennifer
   Fan, Shunwu
   Lin, Xianfeng
   Xu, Jiake
TI Pseurotin A Inhibits Osteoclastogenesis and Prevents
   Ovariectomized Induced Bone Loss by Suppressing Reactive Oxygen Species
SO THERANOSTICS
LA English
DT Article
DE Pseurotin A; reactive oxygen species; osteoclast; osteoporosis
ID NF KAPPA B; OXIDATIVE STRESS; RECEPTOR ACTIVATOR; PHOSPHATIDYLINOSITOL
   3 KINASE; MODULATES OSTEOCLASTOGENESIS; CRUCIAL ROLE; RANKL;
   DIFFERENTIATION; NFATC1; OSTEOPOROSIS
AB Rationale: Growing evidence indicates that intracellular reactive oxygen species (ROS) accumulation is a critical factor in the development of osteoporosis by triggering osteoclast formation and function. Pseurotin A (Pse) is a secondary metabolite isolated from Aspergillus fumigatus with antioxidant properties, recently shown to exhibit a wide range of potential therapeutic applications. However, its effects on osteoporosis remain unknown. This study aimed to explore whether Pse, by suppressing ROS level, is able to inhibit osteoclastogenesis and prevent the bone loss induced by estrogen deficiency in ovariectomized (OVX) mice.
   Methods: The effects of Pse on receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) induced osteoclastogenesis and bone resorptive function were examined by tartrate resistant acid phosphatase (TRAcP) staining and hydroxyapatite resorption assay. 2', 7' dichlorodihydrofluorescein diacetate (H(2)DCFDA) was used to detect intracellular ROS production in vitro. Western blot assay was used to identify proteins associated with ROS generation and scavenging as well as ROS mediated signaling cascades including mitogen activated protein kinases (MAPKs), NF kappa B pathways, and nuclear factor of activated T cells 1 (NFATc1) signaling. The expression of osteoclast specific genes was assessed by qPCR. The in vivo potential of Pse was determined using an OVX mouse model administered with Pse or vehicle for 6 weeks. In vivo ROS production was assessed by intravenous injection of dihydroethidium (DHE) into OVX mice 24h prior to killing. After sacrifice, the bone samples were analyzed using micro CT and histomorphometry to determine bone volume, osteoclast activity, and ROS level ex vivo.
   Results: Pse was demonstrated to inhibit osteoclastogenesis and bone resorptive function in vitro, as well as the downregulation of osteoclast specific genes including Acp5 (encoding TRAcP), Ctsk (encoding cathepsin K), and Mmp9 (encoding matrix metalloproteinase 9). Mechanistically, Pse suppressed intracellular ROS level by inhibiting RANKL induced ROS production and enhancing ROS scavenging enzymes, subsequently suppressing MAPK pathway (ERK, P38, and JNK) and NF kappa B pathways, leading to the inhibition of NFATc1 signaling. Micro CT and histological data indicated that OVX procedure resulted in a significant bone loss, with dramatically increased the number of osteoclasts on the bone surface as well as increased ROS level in the bone marrow microenvironment; whereas Pse supplementation was capable of effectively preventing these OVX induced changes.
   Conclusion: Pse was demonstrated for the first time as a novel alternative therapy for osteoclast related bone diseases such as osteoporosis through suppressing ROS level.
C1 [Chen, Kai; Yuan, Yu; He, Jianbo; Wang, Chao; Guo, Qiang; Kenny, Jacob; Chen, Junhao; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Qiu, Pengcheng; Zheng, Lin; Fan, Shunwu; Lin, Xianfeng] Zhejiang Univ, Dept Orthoped Surg, Sir Run Run Shaw Hosp, Med Coll, Hangzhou 310000, Zhejiang, Peoples R China.
   [Qiu, Pengcheng; Zheng, Lin; Fan, Shunwu; Lin, Xianfeng] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou 310000, Zhejiang, Peoples R China.
   [Yuan, Yu] South China Normal Univ, Sch Phys Educ & Sports Sci, Guangzhou 510631, Guangdong, Peoples R China.
   [He, Jianbo] Guangzhou Univ Chinese Med, Guangzhou 510000, Guangdong, Peoples R China.
   [Guo, Qiang] Cent S Univ, Dept Spine Surg, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Liu, Qian; Zhao, Jinmin] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   [Liu, Qian; Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   [Liu, Qian; Zhao, Jinmin] Guangxi Med Univ, Int Joint Lab Regenerat Bone & Soft Tissues, Nanning 530021, Guangxi, Peoples R China.
C3 University of Western Australia; Zhejiang University; South China Normal
   University; Guangzhou University of Chinese Medicine; Central South
   University; Guangxi Medical University; Guangxi Medical University;
   Guangxi Medical University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.; Lin, XF (通讯作者)，Zhejiang Univ, Dept Orthoped Surg, Sir Run Run Shaw Hosp, Med Coll, Hangzhou 310000, Zhejiang, Peoples R China.; Lin, XF (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou 310000, Zhejiang, Peoples R China.
EM xianfeng_lin@zju.edu.cn; jiake.xu@uwa.au
RI guo, qiang/IXD 7450 2023; Chen, KaiJie/A 1743 2016; Tickner,
   Jennifer/H 5965 2014; Lin, Xianfeng/ABA 2917 2020; zhao,
   jin/LBH 0351 2024; Zheng, Lin/AAE 8093 2021; Yuan, Yu/HKN 3214 2023;
   Chen, Junhao/LCD 2351 2024
OI Chen, Kai/0000 0001 6850 1723; Tickner, Jennifer/0000 0002 5020 0671;
   Xu, Jiake/0000 0003 2021 8309; Kenny, Jacob/0000 0001 8169 9842; Zheng,
   Lin/0000 0002 7585 6968; Yuan, Yu/0000 0003 1032 6330; 
FU Australian Health and Medical Research Council (NHMRC) [1107828,
   1127156, 1163933]; National Nature Science Fund of China [81702143];
   Australian Government Research Training Program Scholarship; National
   Health and Medical Research Council of Australia [1127156, 1163933]
   Funding Source: NHMRC
FX This study was supported by grants from the Australian Health and
   Medical Research Council (NHMRC, No. 1107828, 1127156, 1163933). This
   study was also supported by the National Nature Science Fund of China
   (81702143). Kai Chen is supported by Australian Government Research
   Training Program Scholarship. We acknowledge the facilities and
   technical assistance of the Centre for Microscopy, Characterization &
   Analysis, the University of Western Australia.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Altindag O, 2008, RHEUMATOL INT, V28, P317, DOI 10.1007/s00296 007 0452 0
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006 291X(05)80311 0
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   BLOCH P, 1976, HELV CHIM ACTA, V59, P133, DOI 10.1002/hlca.19760590114
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cha JY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 016 0014 9
   Chen K, 2019, J CELL PHYSIOL, V234, P6477, DOI 10.1002/jcp.27385
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092 8674(00)00116 1
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Glorieux C, 2017, BIOL CHEM, V398, P1095, DOI 10.1515/hsz 2017 0131
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hayashi A, 2007, BIOSCI BIOTECH BIOCH, V71, P1697, DOI 10.1271/bbb.70110
   Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Igarashi Y, 2004, J ANTIBIOT, V57, P748, DOI 10.7164/antibiotics.57.748
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ishikawa M, 2009, BIOORG MED CHEM LETT, V19, P1457, DOI 10.1016/j.bmcl.2009.01.029
   Jung YY, 2008, J BIOL CHEM, V283, P23863, DOI 10.1074/jbc.M803072200
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Kusumbe AP, 2015, NAT PROTOC, V10, P1904, DOI 10.1038/nprot.2015.125
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200
   Li JB, 2017, J BONE MINER RES, V32, P962, DOI 10.1002/jbmr.3059
   Lu QQ, 2014, NAT PROD RES, V28, P1288, DOI 10.1080/14786419.2014.898145
   Maiya S, 2007, CHEMBIOCHEM, V8, P1736, DOI 10.1002/cbic.200700202
   Martínez Luis S, 2012, NAT PROD COMMUN, V7, P165
   Muthusami S, 2005, CLIN CHIM ACTA, V360, P81, DOI 10.1016/j.cccn.2005.04.014
   Myers RR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176702
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Pinheiro EAA, 2013, NAT PROD RES, V27, P1633, DOI 10.1080/14786419.2012.750316
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092 8674(00)80344 X
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodríguez Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Sasaki H, 2009, J MED INVESTIG, V56, P33, DOI 10.2152/jmi.56.33
   Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005
   Shaaban M, 2014, NAT PROD RES, V28, P86, DOI 10.1080/14786419.2013.841687
   Song DZ, 2018, J CELL PHYSIOL, V233, P9674, DOI 10.1002/jcp.26882
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Vödisch M, 2011, J PROTEOME RES, V10, P2508, DOI 10.1021/pr1012812
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yamaguchi Y, 2017, J CELL MOL MED
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 62
TC 211
Z9 221
U1 9
U2 120
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2019
VL 9
IS 6
BP 1634
EP 1650
DI 10.7150/thno.30206
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA HN4DJ
UT WOS:000460134200008
PM 31037128
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Dong, R
   Du, J
   Wang, LP
   Wang, JS
   Ding, G
   Wang, SL
   Fan, ZP
AF Dong, Rui
   Du, Juan
   Wang, Liping
   Wang, Jinsong
   Ding, Gang
   Wang, Songlin
   Fan, Zhipeng
TI Comparison of Long Noncoding RNA and mRNA Expression Profiles in
   Mesenchymal Stem Cells Derived from Human Periodontal Ligament and Bone
   Marrow
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID HUMAN DENTAL PULP; DIFFERENTIAL GENE EXPRESSION; TISSUE;
   TRANSPLANTATION; REGENERATION; BARX1; PROLIFERATION; MIGRATION; THERAPY;
   PATHWAY
AB Mesenchymal stem cells (MSCs) in different anatomic locations possess diverse biological activities. Maintaining the pluripotent state and differentiation depend on the expression and regulation of thousands of genes, but it remains unclear which molecular mechanisms underlie MSC diversity. Thus, potential MSC applications are restricted. Long noncoding RNAs (lncRNAs) are implicated in the complex molecular circuitry of cellular processes. We investigated differences in lncRNA and mRNA expression profiles between bone marrow stem cells (BMSCs) and periodontal ligament stem cells (PDLSCs) with lncRNA microarray assays and bioinformatics analysis. In PDLSCs, numerous lncRNAs were significantly upregulated (n = 457) or downregulated (n = 513) compared to BMSCs. Furthermore, 1,578 mRNAs were differentially expressed. These genes implicated cellular pathways that may be associated with MSC characteristics, including apoptosis, MAPK, cell cycle, and Wnt signaling pathway. Signal net analysis indicated that phospholipase C beta 4, filamin B beta, calcium/calmodulin dependent protein kinase II gamma, and the ionotropic glutamate receptor, AMPA 1, had the highest betweenness centrality among significant genes in the differential gene profile network. A comparison between the coding noncoding gene coexpression networks of PDLSCs and BMSCs identified chemokine (C X C motif) ligand 12 as a core regulatory factor in MSC biology. These results provided insight into the mechanisms underlying MSC biology.
C1 [Dong, Rui; Du, Juan; Wang, Liping; Fan, Zhipeng] Capital Med Univ, Sch Stomatol, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Lab Mol Signaling & Stem Cells Therapy, Beijing 100050, Peoples R China.
   [Wang, Jinsong; Wang, Songlin] Capital Med Univ, Sch Stomatol, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Mol Lab Gene Therapy & Tooth Regenerat, Beijing 100050, Peoples R China.
   [Wang, Jinsong; Wang, Songlin] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100069, Peoples R China.
   [Ding, Gang] Weifang Med Univ, Yidu Cent Hosp, Dept Stomatol, Qinzhou 262500, Peoples R China.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University; Shandong Second Medical University
RP Fan, ZP (通讯作者)，Capital Med Univ, Sch Stomatol, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Lab Mol Signaling & Stem Cells Therapy, Beijing 100050, Peoples R China.
EM zpfan@ccmu.edu.cn
FU National Natural Science Foundation of China [81271101, 81271100,
   81170931]; Program for New Century Excellent Talents in the University
   [NCET 12 0611]; High Level Talents of the Beijing Health System
   [2013 3 035, 2013 3 034]; Beijing Natural Science Foundation [7112057];
   Beijing Nova Program [2011083]
FX This work was supported by Grants from the National Natural Science
   Foundation of China (81271101 to Zhipeng Fan, 81271100 to Rui Dong, and
   81170931 to Juan Du), the Program for New Century Excellent Talents in
   the University (NCET 12 0611 to Zhipeng Fan), High Level Talents of the
   Beijing Health System (2013 3 035 to Zhipeng Fan and 2013 3 034 to Rui
   Dong), the Beijing Natural Science Foundation (7112057 to Rui Dong), and
   the Beijing Nova Program (2011083 to Rui Dong).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Batouli S, 2003, J DENT RES, V82, P976, DOI 10.1177/154405910308201208
   Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462
   Bruder SP, 1998, J BONE JOINT SURG AM, V80A, P985, DOI 10.2106/00004623 199807000 00007
   Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169
   Cai JL, 2004, EXP HEMATOL, V32, P585, DOI 10.1016/j.exphem.2004.03.013
   Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198
   Carlson MRJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471 2164 7 40
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Clarke R, 2008, NAT REV CANCER, V8, P37, DOI 10.1038/nrc2294
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434
   Feng JF, 2011, P NATL ACAD SCI USA, V108, P6503, DOI 10.1073/pnas.1015449108
   Gao H, 2009, STEM CELLS, V27, P857, DOI 10.1002/stem.23
   Ghosal S, 2013, STEM CELLS DEV, V22, P2240, DOI 10.1089/scd.2013.0014
   Giuliani A, 2013, STEM CELL TRANSL MED, V2, P316, DOI 10.5966/sctm.2012 0136
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hayashi O, 2008, CALCIFIED TISSUE INT, V82, P238, DOI 10.1007/s00223 008 9112 y
   Hsieh JY, 2013, NUCLEIC ACIDS RES, V41, P9753, DOI 10.1093/nar/gkt666
   Hu B, 2006, J DENT RES, V85, P416, DOI 10.1177/154405910608500504
   Hu WQ, 2012, EMBO REP, V13, P971, DOI 10.1038/embor.2012.145
   Hung T, 2010, RNA BIOL, V7, P582, DOI 10.4161/rna.7.5.13216
   Inomata N, 2005, IMMUNOL LETT, V98, P265, DOI 10.1016/j.imlet.2004.12.001
   Jahagirdar BN, 2005, STEM CELL REV, V1, P53, DOI 10.1385/SCR:1:1:053
   Jing W, 2008, MED HYPOTHESES, V70, P540, DOI 10.1016/j.mehy.2007.07.010
   Kawaguchi H, 2004, J PERIODONTOL, V75, P1281, DOI 10.1902/jop.2004.75.9.1281
   Kido Y, 2013, AM J MED GENET A, V161, P2339, DOI 10.1002/ajmg.a.36066
   Kim SH, 2009, J PERIODONTOL, V80, P1815, DOI 10.1902/jop.2009.090249
   Kretz M, 2012, GENE DEV, V26, P338, DOI 10.1101/gad.182121.111
   Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704
   Laino G, 2005, J BONE MINER RES, V20, P1394, DOI 10.1359/JBMR.050325
   Lee YM, 2001, J BIOMED MATER RES, V54, P216, DOI 10.1002/1097 4636(200102)54:2<216::AID JBM8>3.0.CO;2 C
   Li CY, 2008, BIOINFORMATICS, V24, P1175, DOI 10.1093/bioinformatics/btn081
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Lu J, 2007, HUM MOL GENET, V16, P1661, DOI 10.1093/hmg/ddm114
   Lyon AM, 2013, MOL PHARMACOL, V84, P488, DOI 10.1124/mol.113.087403
   Ma HD, 2012, SCI WORLD J, DOI 10.1100/2012/541786
   Mattingsdal M, 2013, NEUROIMAGE, V70, P143, DOI 10.1016/j.neuroimage.2012.12.035
   Mauron A, 2007, CLIN PHARMACOL THER, V82, P330, DOI 10.1038/sj.clpt.6100295
   Miletich I, 2005, J ANAT, V207, P619, DOI 10.1111/j.1469 7580.2005.00486.x
   Mitsiadis TA, 1998, EUR J ORAL SCI, V106, P112, DOI 10.1111/j.1600 0722.1998.tb02161.x
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Morsczeck C, 2008, CLIN ORAL INVEST, V12, P113, DOI 10.1007/s00784 007 0170 8
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Prieto C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003911
   Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2
   Rimondini L, 2009, Minerva Stomatol, V58, P483
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   Schilling T, 2008, J CELL BIOCHEM, V103, P413, DOI 10.1002/jcb.21415
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shi S, 2001, BONE, V29, P532, DOI 10.1016/S8756 3282(01)00612 3
   Silvério KG, 2008, STEM CELL REV, V4, P13, DOI 10.1007/s12015 008 9011 7
   Sonoyama W, 2008, J ENDODONT, V34, P166, DOI 10.1016/j.joen.2007.11.021
   Sperber SM, 2008, DEV BIOL, V321, P101, DOI 10.1016/j.ydbio.2008.06.004
   Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082
   Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092 8674(02)01197 2
   Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092 8674(04)00208 9
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
   Yang H, 2013, BIOMATERIALS, V34, P7033, DOI 10.1016/j.biomaterials.2013.05.025
   Yu S, 2013, CELLS TISSUES ORGANS, V197, P209, DOI 10.1159/000343740
   Zhang JD, 2009, BIOINFORMATICS, V25, P1470, DOI 10.1093/bioinformatics/btp167
   Zhang WB, 2006, TISSUE ENG, V12, P2813, DOI 10.1089/ten.2006.12.2813
   Zhang Y, 2004, CHINESE MED J PEKING, V117, P882
NR 66
TC 24
Z9 26
U1 0
U2 29
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 317853
DI 10.1155/2014/317853
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AE3UV
UT WOS:000333904800001
PM 24790996
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, Q
   Zhao, B
   Li, JQ
   Zhao, JW
   Wang, CY
   Li, QY
   Yang, WX
   Xu, L
   Gong, YB
AF Wang, Qin
   Zhao, Bei
   Li, Jiaqi
   Zhao, Jingwen
   Wang, Chengyan
   Li, Quanyao
   Yang, Wenxiao
   Xu, Ling
   Gong, Yabin
TI Qilian Formula Inhibits Tumor Cell Growth in a Bone Metastasis Model of
   Lung Cancer
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE Astragalus membranaceus and Ampelopsis japonica; Traditional Chinese
   Medicine; non small cell lung cancer (NSCLC); bone metastasis;
   osteoclast formation
ID DENOSUMAB; MEDICINE; EXTRACT; PHASE 3
AB Background: Bone metastasis is frequently common in advanced lung cancer with the major issue of a pathological fracture. Previous studies suggested that Astragalus membranaceus (Qi) and Ampelopsis japonica (Lian), which are used as folk medicine in China, have potential effects on inhibiting tumor growth and protecting bones, respectively. In this study, an experiment on the inhibitory effect of the Qilian formula (AAF) in vivo was designed to examine tumor growth in bone and osteoclast formation.Materials and Methods: The bone metastasis xenograft models were established by implanting NCI H460 luc2 lung cancer cells into the right tibiae bones of mice. After confirming the model's viability through optical imaging 7 days post implantation, 2 groups, namely the AAF group and the control group, were administered 0.3 mL of AAF extract (9 g/kg/day) or normal saline via intragastric delivery for a duration of 4 weeks. Throughout the study, we longitudinally assessed tumor burden, bone destruction, and weight bearing capacity in vivo using reporter gene bioluminescence imaging (BLI), micro CT, and dynamic weight bearing (DWB) tests. Mechanistic insights were gained through Hematoxylin eosin (H&E) staining, immunohistochemical (IHC) analysis, western blotting, and flow cytometry.Results: Qilian formula produced significant inhibition to the progress of bone destruction and tumor burden in the right tibiae bone in the treatment group. It was further evidenced by molecular imaging in vivo via small animal micro CT and BLI with parametric quantification, characterizing significantly lower uptake of BLI signal in the treated tumor lesions and improving the pathological changes in the microstructure of bone. Furthermore, DWB tests revealed that Qilian formula treatment significantly maintained the weight bearing capacity. According to immunohistochemical analysis, the effect of the Qilian formula appeared to involve the suppression of osteoclast formation by lower expression of the tartrate resistant acid phosphatase. Cell apoptosis and death induction were evidenced by a higher percentage of Bal2,BAX and caspase 3 expressions of Qilian formula treated tumor tissues.Conclusions: Our study demonstrated a significant inhibitory effect of the Qilian formula on the progression of osteolytic invasion in vivo by suppressing osteoclastogenesis and promoting apoptotic cell death.
C1 [Wang, Qin; Li, Jiaqi; Zhao, Jingwen; Wang, Chengyan; Li, Quanyao; Yang, Wenxiao; Xu, Ling; Gong, Yabin] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai 200437, Peoples R China.
   [Zhao, Bei] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China.
   [Xu, Ling] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Tumor Inst Tradit Chinese Med, Shanghai, Peoples R China.
   [Xu, Ling; Gong, Yabin] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese Med & Weste, Dept Oncol, 110 Ganhe Rd, Shanghai 200437, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Shanghai University of Traditional
   Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Xu, L; Gong, YB (通讯作者)，Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese Med & Weste, Dept Oncol, 110 Ganhe Rd, Shanghai 200437, Peoples R China.
EM xulq67@aliyun.com; gongyabin@hotmail.com
RI ; qianglong, wang/HIK 3742 2022; Gong, Yabin/MTG 1222 2025
OI Li, Quanyao/0000 0002 1496 9221; 
FU science and technology commission of shanghai municipality; East China
   University of Science and Technology
FX The authors would like to thank Prof. Yu Jin and Jianfeng Cai from East
   China University of Science and Technology, for the pharmacology part.
CR Bozzo A, 2021, CLIN ORTHOP RELAT R, V479, P2047, DOI 10.1097/CORR.0000000000001749
   Clézardin P, 2009, CURR CANCER DRUG TAR, V9, P801, DOI 10.2174/156800909789760348
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Coleman R, 2020, LANCET ONCOL, V21, P60, DOI 10.1016/S1470 2045(19)30687 4
   Duivenvoorden WCM, 1999, CLIN EXP METASTAS, V17, P27
   Engblom C, 2017, SCIENCE, V358, DOI 10.1126/science.aal5081
   Gan ZY, 2015, EUR J HAEMATOL, V94, P343, DOI 10.1111/ejh.12436
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Hofbauer LC, 2014, LANCET DIABETES ENDO, V2, P500, DOI 10.1016/S2213 8587(13)70203 1
   Jiaxiang L., 2003, Bull Med Res, V03
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Koo HJ, 2014, J ETHNOPHARMACOL, V151, P951, DOI 10.1016/j.jep.2013.12.008
   Lee CL, 2022, NAT PROD RES, V36, P3133, DOI 10.1080/14786419.2021.1939335
   Nho KJ, 2015, MOL MED REP, V11, P3722, DOI 10.3892/mmr.2015.3179
   Price TT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4059
   Riihimäki M, 2018, CANCER MED US, V7, P5534, DOI 10.1002/cam4.1697
   Sheik A, 2021, PHYTOMEDICINE, V91, DOI 10.1016/j.phymed.2021.153698
   Siegel RL, 2023, CA CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Su T, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00227
   Tao S, 2019, J TRADIT CHIN MED, V39, P339
   Tulotta C, 2019, CLIN CANCER RES, V25, P2769, DOI 10.1158/1078 0432.CCR 18 2202
   Wang SF, 2016, CURR ONCOL, V23, pE188, DOI 10.3747/co.23.2920
   Wang SF, 2019, ONCOL REP, V41, P2636, DOI 10.3892/or.2019.7080
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
NR 26
TC 4
Z9 4
U1 1
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534 7354
EI 1552 695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PY 2023
VL 22
AR 15347354231217274
DI 10.1177/15347354231217274
PG 12
WC Oncology; Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Integrative & Complementary Medicine
GA DB9K6
UT WOS:001129688200001
PM 38130184
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, QQ
   Liu, MC
   Zhang, D
   Lin, BB
   Fu, X
   Zhang, ZQ
   Zhang, BT
   Dong, JT
AF Huang, Qingqing
   Liu, Mingcheng
   Zhang, Duo
   Lin, Bing Biao
   Fu, Xing
   Zhang, Zhiqian
   Zhang, Baotong
   Dong, Jin Tang
TI Nitazoxanide inhibits acetylated KLF5 induced bone metastasis by
   modulating KLF5 function in prostate cancer
SO BMC MEDICINE
LA English
DT Article
DE Prostate cancer; Bone metastasis; TGF beta; Acetylated KLF5;
   Nitazoxanide; MYBL2
ID TGF BETA; INDUCTION; PATHWAY; CELLS; MICROENVIRONMENT; TRANSCRIPTION;
   MECHANISMS; RESISTANCE; SURVIVAL; PROMOTE
AB Background Castration resistant prostate cancer often metastasizes to the bone, and such bone metastases eventually become resistant to available therapies, leading to the death of patients. Enriched in the bone, TGF beta plays a pivotal role in bone metastasis development. However, directly targeting TGF beta or its receptors has been challenging for the treatment of bone metastasis. We previously found that TGF beta induces and then depends on the acetylation of transcription factor KLF5 at K369 to regulate multiple biological processes, including the induction of EMT, cellular invasiveness, and bone metastasis. Acetylated KLF5 (Ac KLF5) and its downstream effectors are thus potential therapeutic targets for treating TGF beta induced bone metastasis in prostate cancer. Methods A spheroid invasion assay was applied to prostate cancer cells expressing KLF5(K369Q), which mimics Ac KLF5, to screen 1987 FDA approved drugs for invasion suppression. Luciferase  and KLF5(K369Q) expressing cells were injected into nude mice via the tail artery to model bone metastasis. Bioluminescence imaging, micro CT), and histological analyses were applied to monitor and evaluate bone metastases. RNA sequencing, bioinformatic, and biochemical analyses were used to understand nitazoxanide (NTZ) regulated genes, signaling pathways, and the underlying mechanisms. The binding of NTZ to KLF5 proteins was evaluated using fluorescence titration, high performance liquid chromatography (HPLC), and circular dichroism (CD) analysis. Results NTZ, an anthelmintic agent, was identified as a potent invasion inhibitor in the screening and validation assays. In KLF5(K369Q) induced bone metastasis, NTZ exerted a potent inhibitory effect in preventive and therapeutic modes. NTZ also inhibited osteoclast differentiation, a cellular process responsible for bone metastasis induced by KLF5(K369Q). NTZ attenuated the function of KLF5(K369Q) in 127 genes' upregulation and 114 genes' downregulation. Some genes' expression changes were significantly associated with worse overall survival in patients with prostate cancer. One such change was the upregulation of MYBL2, which functionally promotes bone metastasis in prostate cancer. Additional analyses demonstrated that NTZ bound to the KLF5 protein, KLF5(K369Q) bound to the promoter of MYBL2 to activate its transcription, and NTZ attenuated the binding of KLF5(K369Q) to the MYBL2 promoter. Conclusions NTZ is a potential therapeutic agent for bone metastasis induced by the TGF beta/Ac KLF5 signaling axis in prostate cancer and likely other cancers.
C1 [Huang, Qingqing; Liu, Mingcheng; Zhang, Duo; Lin, Bing Biao; Fu, Xing; Zhang, Zhiqian; Zhang, Baotong; Dong, Jin Tang] Southern Univ Sci & Technol, Sch Med, Dept Human Cell Biol & Genet, 1088 Xueyuan Blvd, Shenzhen 518055, Peoples R China.
   [Lin, Bing Biao] Sun Yat sen Univ, Affiliated Hosp 7, Kidney & Urol Ctr, Pelv Floor Disorders Ctr,Dept Urol, Shenzhen 518000, Peoples R China.
C3 Southern University of Science & Technology; Sun Yat Sen University
RP Dong, JT (通讯作者)，Southern Univ Sci & Technol, Sch Med, Dept Human Cell Biol & Genet, 1088 Xueyuan Blvd, Shenzhen 518055, Peoples R China.
EM dongjt@sustech.edu.cn
RI Fu, Xing/IRZ 6186 2023; Zhang, Zhiqian/P 7746 2018; Zhang,
   Baotong/H 3482 2019
FU Science, Technology and Innovation Commission of Shenzhen Municipality
   [JCYJ20200109141229255]
FX This study is supported by grant JCYJ20200109141229255 from the Science,
   Technology and Innovation Commission of Shenzhen Municipality.
CR Abd El Fadeal NM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105213
   Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116
   Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810
   Anderton MJ, 2011, TOXICOL PATHOL, V39, P916, DOI 10.1177/0192623311416259
   Berens EB, 2015, JOVE J VIS EXP, DOI 10.3791/53409
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008
   Cribbes S, 2017, SLAS DISCOV, V22, P547, DOI 10.1177/2472555217689884
   Di Santo N, 2014, MUTAT RES FUND MOL M, V768, P16, DOI 10.1016/j.mrfmmm.2014.05.005
   Di Santo Nicola, 2013, Cancers (Basel), V5, P1163, DOI 10.3390/cancers5031163
   Díaz Díaz CJ, 2016, ANN SURG, V264, P429, DOI 10.1097/SLA.0000000000001874
   DiNatale A, 2019, ADV EXP MED BIOL, V1210, P171, DOI 10.1007/978 3 030 32656 2_9
   Ek F, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 12519 4
   Fan Minogue H, 2013, MOL CANCER THER, V12, P1896, DOI 10.1158/1535 7163.MCT 12 1243
   Furesi G, 2021, TRENDS CANCER, V7, P112, DOI 10.1016/j.trecan.2020.09.006
   Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017
   Gandaglia G, 2015, EUR UROL, V68, P325, DOI 10.1016/j.eururo.2014.07.020
   Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202
   Guo P, 2009, J BIOL CHEM, V284, P28243, DOI 10.1074/jbc.M109.036160
   Guo P, 2009, J BIOL CHEM, V284, P18184, DOI 10.1074/jbc.M109.007096
   Guo P, 2009, J BIOL CHEM, V284, P6071, DOI 10.1074/jbc.M806270200
   Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Huang S, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.895573
   Javelaud D, 2011, CANCER RES, V71, P5606, DOI 10.1158/0008 5472.CAN 11 1194
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Khan SA, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.968148
   Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742 1241.2011.02799.x
   Kuchimaru T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05366 3
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li CH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.781640
   Li J, 2020, CANCERS, V12, DOI 10.3390/cancers12030748
   Li QJ, 2021, THERANOSTICS, V11, P5794, DOI 10.7150/thno.56604
   Li X, 2015, INT J CANCER, V136, P536, DOI 10.1002/ijc.29028
   Li YX, 2020, THERANOSTICS, V10, P7656, DOI 10.7150/thno.44567
   Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065
   Liu MC, 2021, CANCERS, V13, DOI 10.3390/cancers13225809
   Liu T, 2022, HEAD NECK J SCI SPEC, V44, P518, DOI 10.1002/hed.26932
   Lu ZR, 2022, BIOCHEM PHARMACOL, V197, DOI 10.1016/j.bcp.2022.114913
   Lü ZR, 2021, ACS MED CHEM LETT, V12, P696, DOI 10.1021/acsmedchemlett.0c00544
   Lv XR, 2013, BIOCHEM J, V456, P35, DOI 10.1042/BJ20130418
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Morris JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090353
   Musa J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.244
   Pal AK, 2020, 3 BIOTECH, V10, DOI 10.1007/s13205 020 02332 z
   Qu Y, 2018, NAT CHEM BIOL, V14, P94, DOI [10.1038/nchembio.2510, 10.1038/NCHEMBIO.2510]
   Ripani P, 2020, ONCOGENE, V39, P2345, DOI 10.1038/s41388 019 1142 6
   Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014
   Pego ER, 2018, UROL ONCOL SEMIN ORI, V36, P272, DOI 10.1016/j.urolonc.2018.03.009
   Senkowski W, 2015, MOL CANCER THER, V14, P1504, DOI 10.1158/1535 7163.MCT 14 0792
   Siegel RL, 2021, CA CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Smith MR, 2013, J CLIN ONCOL, V31, P3800, DOI 10.1200/JCO.2012.44.6716
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Thompson Elliott B, 2021, AM J CLIN EXP UROL, V9, P318
   Wang XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1058 z
   Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961
   White Clinton A Jr, 2004, Expert Rev Anti Infect Ther, V2, P43
   Yurttas C, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120567
   Zhang BT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21976 w
   Zhang BT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14737 8
   Zhang BT, 2013, MOL CELL BIOL, V33, P4919, DOI 10.1128/MCB.00787 13
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
NR 64
TC 13
Z9 13
U1 1
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741 7015
J9 BMC MED
JI BMC Med.
PD FEB 21
PY 2023
VL 21
IS 1
AR 68
DI 10.1186/s12916 023 02763 4
PG 24
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 9E8PX
UT WOS:000937042700003
PM 36810084
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, YW
   Tran, KK
   Shen, H
   Grainger, DW
AF Wang, Yuwei
   Tran, Kenny K.
   Shen, Hong
   Grainger, David W.
TI Selective local delivery of RANK siRNA to bone phagocytes using bone
   augmentation biomaterials
SO BIOMATERIALS
LA English
DT Article
DE siRNA; PLGA microparticles; Calcium phosphate bone cement; Bone
   augmentation
ID CALCIUM PHOSPHATE CEMENT; OSTEOCLASTOGENESIS INHIBITORY FACTOR;
   OSTEOPROTEGERIN LIGAND; DIFFERENTIATION FACTOR; PLASMID DNA;
   MICROSPHERES; GENE; RELEASE; NANOPARTICLES; DRUG
AB Fracture healing and fracture fixation in the context of osteoporosis is extremely difficult. To inhibit osteoclast induced bone resorption and associated implant loosening in this pathology, we describe a local delivery strategy to delivery RNA interfering technology to bone sites to target and down regulate osteoclast formation and function. Resorbable polymer, poly(lactic co glycolic acid) (PLGA) microparticles were exploited as a passive phagocyte targeting carrier to deliver RANK siRNA to both osteoclast precursors and osteoclasts   the professional phagocytes in bone. These natural phagocytes internalize micron sized particles while most other non targeted cells in bone cannot. PLGA siRNA microparticles were dispersed within biomedical grade calcium based injectable bone cement clinically used in osteoporosis as a bone augmentation biomaterial for fragility fracture prevention and fixation. siRNA released from this formulation in vitro retains bioactivity against the cell target. RANK, in cultured osteoclast precursor cells, inhibiting their progression toward the osteoclastic phenotype. These data support the proof of concept to utilize a clinically relevant approach to locally deliver siRNA to phagocytes in bone and improve fragility fracture healing in the context of osteoporosis. This local delivery system delivers siRNA therapeutics directly to osteoporosis sites from clinically familiar injected bone augmentation materials but could be extended to other injectable biomaterials for local siRNA delivery. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Wang, Yuwei; Grainger, David W.] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA.
   [Tran, Kenny K.; Shen, Hong] Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA.
   [Grainger, David W.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; University of
   Washington; University of Washington Seattle; Utah System of Higher
   Education; University of Utah
RP Grainger, DW (通讯作者)，Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA.
EM Yuwei.wang@utah.edu; kynam@u.washington.edu; hs24@u.washington.edu;
   david.grainger@utah.edu
OI Grainger, David/0000 0003 1506 7286
FU NIH [EB00894]; University of Utah
FX The authors appreciate the generous gift of the RANKL plasmid expression
   construct from Professor M. F. Manolson, University of Toronto, Canada
   and donated CPC samples from BioMet. We thank I. Zharov, University of
   Utah, for access to a ceramic oven, and J. Wolchok for his assistance
   with mechanical testing. This work was partially supported by NIH grant
   EB00894 and a SEED grant from the University of Utah.
CR Abbas AO, 2008, J PHARM SCI US, V97, P2448, DOI 10.1002/jps.21215
   Achenbach TV, 2003, CHEMBIOCHEM, V4, P928, DOI 10.1002/cbic.200300708
   ALONSO MJ, 1993, PHARMACEUT RES, V10, P945, DOI 10.1023/A:1018942118148
   Blom EJ, 2000, J BIOMED MATER RES, V50, P67, DOI 10.1002/(SICI)1097 4636(200004)50:1<67::AID JBM10>3.0.CO;2 E
   Bohner M, 2005, BIOMATERIALS, V26, P1553, DOI 10.1016/j.biomaterials.2004.05.010
   Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839
   Capan Y, 1999, PHARMACEUT RES, V16, P509, DOI 10.1023/A:1018862827426
   Cejka D, 2006, CLIN SCI, V110, P47, DOI 10.1042/CS20050162
   Choung S, 2006, BIOCHEM BIOPH RES CO, V342, P919, DOI 10.1016/j.bbrc.2006.02.049
   Cook SD, 2002, J ARTHROPLASTY, V17, P402, DOI 10.1054/arth.2002.32169
   Dong L, 2011, PHARM RES DORDR, V28, P1349, DOI 10.1007/s11095 010 0334 0
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Ginebra MP, 2006, BIOMATERIALS, V27, P2171, DOI 10.1016/j.biomaterials.2005.11.023
   Habraken WJEM, 2006, J BIOMAT SCI POLYM E, V17, P1057, DOI 10.1163/156856206778366004
   Habraken WJEM, 2008, BIOMATERIALS, V29, P2464, DOI 10.1016/j.biomaterials.2008.02.012
   Hirota K, 2007, J CONTROL RELEASE, V119, P69, DOI 10.1016/j.jconrel.2007.01.013
   JARCHO M, 1981, CLIN ORTHOP RELAT R, P259
   Jiang G, 2008, BIOPOLYMERS, V89, P635, DOI 10.1002/bip.20978
   KADOYA Y, 1994, BONE MINER, V27, P85, DOI 10.1016/S0169 6009(08)80211 5
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Larsson S, 2002, Scand J Surg, V91, P140
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Link DP, 2008, J BIOMED MATER RES A, V87A, P760, DOI 10.1002/jbm.a.31831
   Link DP, 2006, BIOMATERIALS, V27, P4941, DOI 10.1016/j.biomaterials.2006.05.022
   Majling J, 1997, J MATER RES, V12, P198, DOI 10.1557/JMR.1997.0026
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   OTSUKA M, 1995, J PHARM SCI, V84, P733, DOI 10.1002/jps.2600840614
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169 409X(02)00228 4
   Patil Y, 2009, INT J PHARMACEUT, V367, P195, DOI 10.1016/j.ijpharm.2008.09.039
   Ratier A, 2001, BIOMATERIALS, V22, P897, DOI 10.1016/S0142 9612(00)00252 0
   Ruhe PQ, 2003, J BONE JOINT SURG AM, V85A, P75
   Sabokbar A, 1997, ANN RHEUM DIS, V56, P414, DOI 10.1136/ard.56.7.414
   Sebba A, 2008, CURR OPIN ENDOCRINOL, V15, P502, DOI 10.1097/MED.0b013e328317ca83
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   SUMNER DR, 1995, J BONE JOINT SURG AM, V77A, P1135, DOI 10.2106/00004623 199508000 00001
   Takechi M, 1998, J BIOMED MATER RES, V39, P308, DOI 10.1002/(SICI)1097 4636(199802)39:2<308::AID JBM19>3.3.CO;2 F
   Tanzer M, 2005, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000194728.62996.2d
   Tanzer M, 1996, J ORTHOPAED RES, V14, P901, DOI 10.1002/jor.1100140609
   von der Linden P, 2006, J ORTHOP RES, V24, P2230, DOI 10.1002/jor.20299
   Walter E, 2001, J CONTROL RELEASE, V76, P149, DOI 10.1016/S0168 3659(01)00413 8
   Wang DA, 2002, BIOMACROMOLECULES, V3, P1197, DOI 10.1021/bm025563c
   Wang DQ, 1999, J CONTROL RELEASE, V57, P9, DOI 10.1016/S0168 3659(98)00099 6
   Wang Y, 2012, ADV DRUG DELIV REV
   Wang Y, 2011, MOL PHARMACEUT, V8, P1016, DOI 10.1021/mp100374n
   Wang YW, 2010, PHARM RES DORDR, V27, P1273, DOI 10.1007/s11095 010 0099 5
   Woodard JR, 2007, BIOMATERIALS, V28, P45, DOI 10.1016/j.biomaterials.2006.08.021
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu F, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/4/044105
   Yang KY, 2007, YONSEI MED J, V48, P653, DOI 10.3349/ymj.2007.48.4.653
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
NR 55
TC 37
Z9 44
U1 1
U2 71
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2012
VL 33
IS 33
BP 8540
EP 8547
DI 10.1016/j.biomaterials.2012.07.039
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 028CS
UT WOS:000310401000033
PM 22951320
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Gu, Y
   Gao, YQ
   Yang, ZH
   Ni, JD
   He, GX
AF Gu, Yuan
   Gao, Yongquan
   Yang, Zhanghuan
   Ni, Jiangdong
   He, Guangxu
TI Overexpression of Wnt7b antagonizes the inhibitory effect of
   dexamethasone on osteoblastogenesis of ST2 cells
SO ENDOKRYNOLOGIA POLSKA
LA English
DT Article
DE Wnt7b; osteoblast; dexamethasone
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; BONE; SCLEROSTIN; ALENDRONATE;
   DICKKOPF 1; ACTIVATION; EXPRESSION
AB Introduction: It is well established that glucocorticoid induced osteoporosis is highly associated with preosteoblast differentiation and function. This study is based on the premise that Wnt7b can promote bone formation through Wnt signalling pathway because it can stimulate preosteoblast differentiation and increase its activity. However, it is unknown whether Wnt7b can rescue the inhibited osteoblast differentiation and function caused by exogenous glucocorticoid.
   Material and methods: In this study we used Wnt7b overexpression ST2 cells to explore whether Wnt7bcan rescue the inhibited osteoblast differentiation and function, which can provide strong proof to investigate a new drug for curing the glucocorticoid induced osteoporosis.
   Results/Conclusion: We found that Wnt7b can rescue the suppressed osteoblast differentiation and function without cell viability caused by dexamethasone. (Endokrynol Pol 2023; 74 (1): 83 88)
C1 [Gu, Yuan; Ni, Jiangdong; He, Guangxu] Cent South Univ, Dept Orthopaed, Xiangya Hosp 2, Changsha, Hunan, Peoples R China.
   [Gao, Yongquan] Cent South Univ, Xiangya Hosp, Xiangya Canc Ctr, Changsha, Peoples R China.
   [Gao, Yongquan] Key Lab Mol Radiat Oncol Hunan Prov, Changsha, Peoples R China.
C3 Central South University; Central South University
RP He, GX (通讯作者)，Cent South Univ, Dept Orthopaed, Xiangya Hosp 2, Changsha, Hunan, Peoples R China.
EM heguangxu1987@csu.edu.cn
FU Youth Program of the National Natural Science Foundation of China
   [81802207]
FX This work was supported by the Youth Program of the National Natural
   Science Foundation of China (grant number 81802207).
CR Butler JS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 210
   Chen H, 2021, FASEB J, V35, DOI 10.1096/fj.202100151RR
   Chen H, 2019, FASEB J, V33, P7810, DOI 10.1096/fj.201900201RR
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Colditz J, 2019, J BONE MINER RES, V34, P1314, DOI 10.1002/jbmr.3702
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Cruciat CM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015081
   Fixen C, 2021, CURR OSTEOPOROS REP, V19, P15, DOI 10.1007/s11914 020 00652 w
   Guañabens N, 2014, CURR OSTEOPOROS REP, V12, P90, DOI 10.1007/s11914 014 0197 0
   Güler Yüksel M, 2018, CALCIFIED TISSUE INT, V102, P592, DOI 10.1007/s00223 017 0335 7
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Lane NE, 2019, CURR OSTEOPOROS REP, V17, P1, DOI 10.1007/s11914 019 00498 x
   Lee P, 2015, CLIN ENDOCRINOL, V83, P157, DOI 10.1111/cen.12730
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Semënov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960 9822(01)00290 1
   Shen LX, 2009, J CELL BIOCHEM, V106, P337, DOI 10.1002/jcb.22010
   Song DY, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0081 8
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Yang YJ, 2021, J ORTHOP TRANSL, V26, P92, DOI 10.1016/j.jot.2020.03.001
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
   Yu FY, 2020, STEM CELLS, V38, P1020, DOI 10.1002/stem.3192
   Zhang LW, 2021, EUR J PHARMACOL, V904, DOI 10.1016/j.ejphar.2021.174176
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
NR 34
TC 1
Z9 1
U1 1
U2 10
PU VIA MEDICA
PI GDANSK
PA UL SWIETOKRZYSKA 73, 80 180 GDANSK, POLAND
SN 0423 104X
J9 ENDOKRYNOL POL
JI Endokrynol. Pol.
PY 2023
VL 74
IS 1
BP 83
EP 88
DI 10.5603/EP.a2022.0035
EA DEC 2022
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EI0T5
UT WOS:000934638100001
PM 36704983
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, AG
   Zhang, X
   Tan, XL
   Cai, B
   Ge, WJ
   Dai, GD
   Cai, JP
AF Zhang, Aiguo
   Zhang, Xian
   Tan, Xiangling
   Cai, Bin
   Ge, Wenjie
   Dai, Guoda
   Cai, Jianping
TI 被撤回的出版物: Resveratrol rescued the TNF α induced impairments of
   osteogenesis of bone marrow derived mesenchymal stem cells and inhibited
   the TNF α activated NP κB signaling pathway (Retracted article. See vol.
   29, pg. 974, 2015)
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Resveratrol; Bone marrow derived mesenchymal stem cells; TNF alpha;
   NE kappa B signaling; Inflammatory bone disease
ID OSTEOBLAST DIFFERENTIATION; INFLAMMATION; EXPRESSION; RECEPTORS; TISSUE
AB Resveratrol, trans 3,4' trihydroxystilbene, is a natural phytoalexin. Its anti inflammatory activity has attracted more and more attention in clinic over the years for the treatment of inflammatory diseases. However, its effect on bone repair and new bone formation in an inflammatory microenvironment is quite little understood, especially when bone marrow derived mesenchymal stem cells (MSCs) are used in stem cell therapy for the treatment of inflammatory bone diseases. In the present study, we investigated the effect of resveratrol on osteogenic differentiation of primary mouse bone marrow derived MSCs and potential mechanism involved when cells were exposed to TNF alpha treatment. We found that resveratrol reversed the apoptotic effect of TNF alpha and abrogated its inhibitory effect on osteogenic differentiation of bone marrow derived MSCs. Mechanistic studies demonstrated that resveratrol rescued the TNF alpha induced impairments of osteogenesis, and inhibited TNF alpha activated NF kappa B signaling. Our study may help understand the mechanism involved in the inhibitory effect of inflammatory cytokines on osteogenic differentiation, and highlights the role of resveratrol as a potential therapeutic agent for bone repair and especially in MSC based cell therapy for the treatment of inflammation associated bone diseases. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhang, Xian; Ge, Wenjie; Dai, Guoda; Cai, Jianping] Wuxi Tradit Chinese Med Hosp, Wuxi 214071, Jiangsu, Peoples R China.
   [Zhang, Aiguo] Wuxi Peoples Hosp, Wuxi 214194, Jiangsu, Peoples R China.
   [Tan, Xiangling] Nantong Univ, Sch Life Sci, Nantong 226019, Jiangsu, Peoples R China.
   [Cai, Bin] Guangxi Med Univ, Nanning 530021, Guangxi, Peoples R China.
C3 Jiangnan University; Nantong University; Guangxi Medical University
RP Cai, JP (通讯作者)，Wuxi Tradit Chinese Med Hosp, Wuxi 214071, Jiangsu, Peoples R China.
EM jpcai123@163.com
RI Zeng, Xiao/ABG 5938 2021
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Ahn J, 2007, BIOCHEM BIOPH RES CO, V364, P972, DOI 10.1016/j.bbrc.2007.10.109
   Alexander NS, 2011, LARYNGOSCOPE, V121, P1313, DOI 10.1002/lary.21798
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bereswill S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015099
   Bertelli AAE, 2001, THERAPIE, V56, P613
   Cerqueira AM, 2013, CAN J PHYSIOL PHARM, V91, P248, DOI 10.1139/cjpp 2012 0268
   Ehnert S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014073
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gómez Zorita S, 2013, NUTRITION, V29, P1374, DOI 10.1016/j.nut.2013.04.014
   Gorbunov N, 2012, J CELL MOL MED, V16, P174, DOI 10.1111/j.1582 4934.2011.01281.x
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359 6101(00)00030 7
   Konyalioglu S, 2013, NEURAL REGEN RES, V8, P485, DOI 10.3969/j.issn.1673 5374.2013.06.001
   Kristjansson B, 2014, STEM CELLS INT, V2014, DOI 10.1155/2014/194318
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Larrosa M, 2011, EUR J NUTR, V50, P673, DOI 10.1007/s00394 011 0178 3
   Larrosa M, 2009, J AGR FOOD CHEM, V57, P2211, DOI 10.1021/jf803638d
   Losso JN, 2010, J AGR FOOD CHEM, V58, P8246, DOI 10.1021/jf1012067
   MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549
   Marino A, 2013, PATHOG DIS, V68, P61, DOI 10.1111/2049 632X.12046
   Martín AR, 2006, BRIT J PHARMACOL, V147, P873, DOI 10.1038/sj.bjp.0706469
   Moon SJ, 2013, INT J MOL MED, V31, P769, DOI 10.3892/ijmm.2013.1269
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Palmieri D, 2011, J SURG RES, V171, pE237, DOI 10.1016/j.jss.2011.07.041
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sánchez Fidalgo S, 2010, EUR J PHARMACOL, V633, P78, DOI 10.1016/j.ejphar.2010.01.025
   Tian J, 2013, RHEUMATOL INT, V33, P1829, DOI 10.1007/s00296 012 2657 0
   Tili E, 2011, J NUCLEIC ACIDS, V2011, DOI 10.4061/2011/102431
   Uguralp S, 2008, PEDIATR SURG INT, V24, P425, DOI 10.1007/s00383 008 2116 x
   Wang DT, 2014, INT IMMUNOPHARMACOL, V19, P206, DOI 10.1016/j.intimp.2014.02.002
   Xiao J, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/185172
   Zhu XX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027081
NR 36
TC 10
Z9 13
U1 0
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2015
VL 26
IS 2
BP 409
EP 415
DI 10.1016/j.intimp.2015.04.026
PG 7
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA CK3JW
UT WOS:000356113400016
PM 25921029
DA 2025 08 17
ER

PT J
AU Mitchell, A
   Watts, AE
   Ebetino, FH
   Suva, LJ
AF Mitchell, Alexis
   Watts, Ashlee E.
   Ebetino, Frank H.
   Suva, Larry J.
TI Bisphosphonate use in the horse: what is good and what is not?
SO BMC VETERINARY RESEARCH
LA English
DT Article
DE Bisphosphonate; Bone resorption; Endocrinology equine; Navicular
   syndrome
ID ADJUVANT ZOLEDRONIC ACID; AMERICAN SOCIETY; TASK FORCE; IN VITRO; BONE;
   TILUDRONATE; ALENDRONATE; CHILDREN; CLODRONATE; FRACTURES
AB BackgroundBisphosphonates (BPs) are a family of molecules characterized by two key properties: their ability to bind strongly to bone mineral and their inhibitory effects on mature osteoclasts and thus bone resorption. Chemically two groups of BPs are recognized, non nitrogen containing and nitrogen containing BPs. Non nitrogen containing BPs incorporate into the energy pathways of the osteoclast, resulting in disrupted cellular energy metabolism leading to cytotoxic effects and osteoclast apoptosis. Nitrogen containing BPs primarily inhibit cholesterol biosynthesis resulting in the disruption of intracellular signaling, and other cellular processes in the osteoclast.BodyBPs also exert a wide range of physiologic activities beyond merely the inhibition of bone resorption. Indeed, the breadth of reported activities include inhibition of cancer cell metastases, proliferation and apoptosis in vitro. In addition, the inhibition of angiogenesis, matrix metalloproteinase activity, altered cytokine and growth factor expression, and reductions in pain have been reported. In humans, clinical BP use has transformed the treatment of both post menopausal osteoporosis and metastatic breast and prostate cancer. However, BP use has also resulted in significant adverse events including acute phase reactions, esophagitis, gastritis, and an association with very infrequent atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ).ConclusionDespite the well characterized health benefits of BP use in humans, little is known regarding the effects of BPs in the horse. In the equine setting, only non nitrogen containing BPs are FDA approved primarily for the treatment of navicular syndrome. The focus here is to discuss the current understanding of the strengths and weaknesses of BPs in equine veterinary medicine and highlight the future utility of these potentially highly beneficial drugs.
C1 [Mitchell, Alexis; Suva, Larry J.] Coll Vet Med & Biomed Sci, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.
   [Watts, Ashlee E.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Large Anim Clin Sci, College Stn, TX USA.
   [Ebetino, Frank H.] Univ Rochester, Dept Chem, Rochester, NY USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M University System; Texas A&M University College Station; University
   of Rochester
RP Suva, LJ (通讯作者)，Coll Vet Med & Biomed Sci, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.
EM lsuva@cvm.tamu.edu
FU Texas A&M University, College of Veterinary Medicine and Biomedical
   Sciences
FX Our efforts in this area were supported by funds provided by Texas A&M
   University, College of Veterinary Medicine and Biomedical Sciences. The
   College funding had no role in the design of the study, collection,
   analysis, and interpretation of any of the literature or in writing or
   conceiving any aspect of the manuscript.
CR Abrahamsen B, 2010, CURR OPIN RHEUMATOL, V22, P404, DOI 10.1097/BOR.0b013e32833ad677
   ADAMI S, 1993, OSTEOPOROSIS INT, V3, pS21
   Adler R, 2018, EUR J ENDOCRINOL
   Adler RA, 2016, CURR OPIN ENDOCRINOL, V23, P430, DOI 10.1097/MED.0000000000000287
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Brown JE, 2010, BREAST CANCER RES TR, V123, P767, DOI 10.1007/s10549 010 0981 1
   Buza JA, 2016, CLIN CASES MINER BON, V13, P101, DOI 10.11138/ccmbm/2016.13.2.101
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coudry V, 2007, AM J VET RES, V68, P329, DOI 10.2460/ajvr.68.3.329
   Delguste C, 2007, BONE, V41, P414, DOI 10.1016/j.bone.2007.05.005
   Denoix JM, 2003, EQUINE VET J, V35, P407, DOI 10.2746/042516403776014226
   Duckworth AD, 2019, J BONE MINER RES
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Escudero N. D., 2012, BONE MARROW RES, V2012, DOI DOI 10.1155/2012/526236
   Falcini F, 2003, J RHEUMATOL, V30, P179
   Fan TM, 2008, J VET INTERN MED, V22, P380, DOI 10.1111/j.1939 1676.2008.0046.x
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Freundlich M, 2008, PEDIATR NEPHROL, V23, P2215, DOI 10.1007/s00467 008 0940 9
   Garganta MD, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 2252 y
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Goodship A, 1994, ANN ONCOL, V5, P53, DOI DOI 10.1080/1025584021000025014
   Gough MR, 2010, EQUINE VET J, V42, P381, DOI 10.1111/j.2042 3306.2010.00120.x
   Henderson RC, 2002, J PEDIATR US, V141, P644, DOI 10.1067/mpd.2002.128207
   Ishchenko Y, 2017, J PHARMACOL EXP THER, V361, P472, DOI 10.1124/jpet.116.238840
   Kakar S, 2009, J ORTHOP TRAUMA, V23, P413, DOI 10.1097/BOT.0b013e3181ac64a0
   Kamm L, 2008, J EQUINE VET SCI, V28, P209, DOI 10.1016/j.jevs.2008.02.007
   Kato Y., 2017, P NATL ACAD SCI US
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim S, 2013, EUR J PHARMACOL, V699, P14, DOI 10.1016/j.ejphar.2012.11.031
   Koivukangas A, 2001, CALCIFIED TISSUE INT, V69, P350, DOI 10.1007/s00223 001 2036 4
   Lepola VT, 1996, BONE, V18, P191, DOI 10.1016/8756 3282(95)00439 4
   Liepe K, 2000, CLIN NUCL MED, V25, P901, DOI 10.1097/00003072 200011000 00009
   López Posadas R, 2016, INFLAMM BOWEL DIS, V22, P2549, DOI 10.1097/MIB.0000000000000920
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Makhoul I, 2016, NAT REV ENDOCRINOL, V12, P29, DOI 10.1038/nrendo.2015.185
   Mitchell A., 2018, Equine Vet J
   Nieto JE, 2013, AM J VET RES, V74, P550, DOI 10.2460/ajvr.74.4.550
   Pazianas M, 2010, THER CLIN RISK MANAG, V6, P325
   Peter CP, 1996, J ORTHOP RES, V14, P74, DOI 10.1002/jor.1100140113
   Porta Sales J, 2017, PALLIATIVE MED, V31, P5, DOI 10.1177/0269216316639793
   Recker RR, 2009, AM J MED, V122, P22, DOI 10.1016/j.amjmed.2008.12.004
   Richbourg HA, 2018, BMC VET RES, V14, DOI 10.1186/s12917 018 1423 2
   ROGERS MJ, 1994, BIOCHEM J, V303, P303, DOI 10.1042/bj3030303
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   RUSSELL RGG, 1970, CLIN ORTHOP RELAT R, P101
   Russell RGG, 2016, ANTIRESORPTIVES
   Saviola G, 2017, CLIN RHEUMATOL, V36, P2343, DOI 10.1007/s10067 017 3681 y
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389
   Suva Larry J, 2005, Curr Osteoporos Rep, V3, P46, DOI 10.1007/s11914 005 0003 0
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   Van Lieshout M, 2017, ACTA ORTHOP BELG, V83, P558
   Waguespack R Wayne, 2010, Compend Contin Educ Vet, V32, pE7
   Whitfield CT, 2016, AM J VET RES, V77, P167, DOI 10.2460/ajvr.77.2.167
   Wilson C, 2018, EUR J CANCER, V94, P70, DOI 10.1016/j.ejca.2018.02.004
NR 64
TC 13
Z9 16
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1746 6148
J9 BMC VET RES
JI BMC Vet. Res.
PD JUN 24
PY 2019
VL 15
AR 211
DI 10.1186/s12917 019 1966 x
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA IF2CX
UT WOS:000472886100002
PM 31234844
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, MJ
   Jin, FJ
   Zhang, S
   Li, S
   Zhu, DQ
   Cui, Y
   Cai, MX
   Liu, XN
   Zhang, YB
   Sun, Y
   Liu, CH
   Wang, XG
AF Liu, Meijing
   Jin, Fujun
   Zhang, Shuai
   Li, Shuang
   Zhu, Danqi
   Cui, Yi
   Cai, Mingxiang
   Liu, Xiangning
   Zhang, Yongbiao
   Sun, Yao
   Liu, Changhui
   Wang, Xiaogang
TI Activation of farnesoid X receptor signaling by geniposidic acid
   promotes osteogenesis
SO PHYTOMEDICINE
LA English
DT Article
DE FXR; Geniposidic acid; Bone formation; Osteoporosis
ID OBETICHOLIC ACID; BILE ACID; KAPPA B; FXR; DIFFERENTIATION; METABOLISM;
   CELLS; LIVER; SHP
AB Background: New targets and strategies are urgently needed for the identification and development of anabolic drugs for osteoporosis. Farnesoid X receptor (FXR) is a promising novel therapeutic target for bone metabolism diseases. Although used clinically, FXR agonists have obvious side effects; therefore, the development of new FXR agonists for the treatment of osteoporosis would be welcomed. Geniposidic acid (GPA) is a bioactive compound extracted from Eucommiae cortex, which is used for treating arthritis, osteoporotic fractures, and hypertension. However, the therapeutic effects of GPA against osteoporosis remain underexplored. Purpose: This study aims to reveal the potential osteogenic effects of FXR and to explore the effect of GPA on bone formation, osteoporosis treatment, and FXR signaling. Study design & methods: The role of FXR in promoting bone formation was evaluated in Fxr knockout (Fxr / ) mice and cell models. GPA activation of FXR was evaluated by molecular docking and luciferase reporter gene assays. Thirty female C57BL/6J mice were randomly assigned into a sham operation group (Sham) and four ovariectomized (OVX) groups (n=6 each) and were treated with vehicle or different doses of GPA (25, 50, and 100 mg/kg/day). The therapeutic effect of GPA on osteoporosis was systematically analyzed by performing bone histomorphometry and measuring serum biochemical parameters, and the molecular mechanism was also evaluated. Furthermore, the action of GPA in Fxr  /  mice was evaluated to investigate its dependency on FXR in promoting bone formation and treating osteoporosis. Results: We found that FXR was highly expressed in bone tissues and enriched in osteoblasts. Notably, deletion of FXR significantly reduced the bone formation rate and bone mass of the Fxr /  mice compared with wild type mice. Furthermore, using a high throughput drug screening strategy based on fluorescent reporter genes, we found that GPA functions as a natural agonist of FXR. We confirmed the activities of GPA on FXR activation and osteogenesis in both osteoblast differentiation models and OVX induced osteoporosis models. We revealed that GPA strongly promotes bone formation by activating FXR/RUNX2 signaling. Moreover, the osteoporotic therapeutic effect of GPA was abolished in Fxr /  mice. Conclusion: This study demonstrated that FXR is a promising target for treating osteoporosis and that GPA promotes bone formation in OVX induced osteoporosis by activating FXR signaling. These findings provide novel insight into the mechanism by which GPA promotes bone formation and more evidence for its application in the treatment of osteoporosis.
C1 [Liu, Meijing; Jin, Fujun; Li, Shuang; Zhu, Danqi; Cui, Yi; Zhang, Yongbiao; Wang, Xiaogang] Beihang Univ, Sch Engn Med, Key Lab Big Data Based Precis Med, Beijing 100191, Peoples R China.
   [Liu, Meijing; Cai, Mingxiang; Liu, Xiangning; Wang, Xiaogang] Jinan Univ, Affiliated Hosp 1 Jinan Univ, Clin Res Platform Interdiscipline Stomatol, Dept Stomatol, Guangzhou 510632, Peoples R China.
   [Liu, Meijing; Liu, Changhui] Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China.
   [Zhang, Shuai; Sun, Yao] Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Sch Stomatol, Dept Oral Implantol, Shanghai 200072, Peoples R China.
C3 Beihang University; Jinan University; Guangzhou University of Chinese
   Medicine; Tongji University
RP Wang, XG (通讯作者)，Beihang Univ, Sch Engn Med, Key Lab Big Data Based Precis Med, Beijing 100191, Peoples R China.; Wang, XG (通讯作者)，Jinan Univ, Affiliated Hosp 1 Jinan Univ, Clin Res Platform Interdiscipline Stomatol, Dept Stomatol, Guangzhou 510632, Peoples R China.; Liu, CH (通讯作者)，Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China.; Sun, Y (通讯作者)，Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Sch Stomatol, Dept Oral Implantol, Shanghai 200072, Peoples R China.
EM yaosun@tongji.edu.cn; liuchanghui@gzucm.edu.cn; xiaogangwang@buaa.edu.cn
RI wang, Xiaogang/J 5003 2017; Zhang, Yongbiao/KLB 9206 2024; Zhang,
   Shuai/HOA 5050 2023; sun, yao/MEP 9275 2025; cai,
   mingxiang/IYT 1913 2023
OI Liu, Meijing/0000 0002 9785 8614; 
FU National Natural Science Foundation of China [82002362, 92049201,
   81773969, 9204920005, 81722031, 81770873, 81802193]; Science and
   Technology Program of Guangzhou [202002020032]; General Financial Grant
   from the China Postdoctoral Science Foundation [2020M680303]
FX This work was supported by the National Natural Science Foundation of
   China (No. 82002362, 92049201, 81773969, 9204920005, 81722031, 81770873,
   81802193), Science and Technology Program of Guangzhou (No.
   202002020032), General Financial Grant from the China Postdoctoral
   Science Foundation (No. 2020M680303).
CR Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Binkley N, 2014, CURR OSTEOPOROS REP, V12, P403, DOI 10.1007/s11914 014 0242 z
   Boufker HI, 2011, BONE, V49, P1219, DOI 10.1016/j.bone.2011.08.013
   Cao Y, 2019, AM J PHYSIOL GASTR L, V317, pG108, DOI 10.1152/ajpgi.00356.2017
   Chen H, 2016, J ETHNOPHARMACOL, V179, P197, DOI 10.1016/j.jep.2015.12.033
   Chiang JYL, 2013, COMPR PHYSIOL, V3, P1191, DOI 10.1002/cphy.c120023
   Cho SW, 2013, J BONE MINER RES, V28, P2109, DOI 10.1002/jbmr.1961
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   El Kasmi KC, 2022, HEPATOLOGY, V75, P252, DOI 10.1002/hep.32101
   Fujimori K, 2019, MOLECULES, V24, DOI 10.3390/molecules24224155
   Guañabens N, 2018, LIVER INT, V38, P776, DOI 10.1111/liv.13730
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   Hiebl V, 2018, BIOTECHNOL ADV, V36, P1657, DOI 10.1016/j.biotechadv.2018.03.003
   Jeong BC, 2010, J BONE MINER RES, V25, P262, DOI 10.1359/jbmr.090718
   KAUR G, 2017, JOVE J VIS EXP, V120, P55234
   Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624
   Liu JJ, 2018, PHYTOMEDICINE, V42, P43, DOI 10.1016/j.phymed.2018.03.020
   Markham A, 2016, DRUGS, V76, P1221, DOI 10.1007/s40265 016 0616 x
   Massafra V, 2018, PHARMACOL THERAPEUT, V191, P162, DOI 10.1016/j.pharmthera.2018.06.009
   Neuschwander Tetri BA, 2015, LANCET, V385, P956, DOI 10.1016/S0140 6736(14)61933 4
   Nevens F, 2016, NEW ENGL J MED, V375, P631, DOI 10.1056/NEJMoa1509840
   Pencek R, 2016, DIABETES OBES METAB, V18, P936, DOI 10.1111/dom.12681
   Plass JRM, 2002, HEPATOLOGY, V35, P589, DOI 10.1053/jhep.2002.31724
   Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269
   Prins HJ, 2014, STEM CELL RES, V12, P428, DOI 10.1016/j.scr.2013.12.001
   Remen KMR, 2011, J BIOL CHEM, V286, P33084, DOI 10.1074/jbc.M111.235937
   Ruiz Gaspà S, 2010, EUR J CLIN INVEST, V40, P25, DOI 10.1111/j.1365 2362.2009.02230.x
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Sun LL, 2021, NAT REV GASTRO HEPAT, V18, P335, DOI 10.1038/s41575 020 00404 2
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Sun Y, 2019, NAT METAB, V1, P485, DOI 10.1038/s42255 019 0053 8
   [王娟娟 Wang Juanjuan], 2017, [中草药, Chinese Traditional and Herbal Drugs], V48, P3228
   Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025
   Xu Y, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13005
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang YL, 2021, PHARMACOL RES, V164, DOI 10.1016/j.phrs.2020.105376
   Zhou ZJZ, 2020, EUR J PHARMACOL, V869, DOI 10.1016/j.ejphar.2019.172857
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 40
TC 8
Z9 11
U1 3
U2 40
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD AUG
PY 2022
VL 103
AR 154258
DI 10.1016/j.phymed.2022.154258
EA JUN 2022
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 2U1YC
UT WOS:000822957200001
PM 35716540
DA 2025 08 17
ER

PT J
AU Ko, CH
   Yue, GGL
   Gao, S
   Luo, KW
   Siu, WS
   Shum, WT
   Shiu, HT
   Lee, JKM
   Li, G
   Leung, PC
   Evdokiou, A
   Lau, CBS
AF Ko, Chun Hay
   Yue, Grace Gar Lee
   Gao, Si
   Luo, Ke Wang
   Siu, Wing Sum
   Shum, Wai Ting
   Shiu, Hoi Ting
   Lee, Julia Kin Ming
   Li, Gang
   Leung, Ping Chung
   Evdokiou, Andreas
   Lau, Clara Bik San
TI Evaluation of the combined use of metronomic zoledronic acid and
   Coriolus versicolor in intratibial breast cancer mouse model
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Breast tumor; Traditional Chinese medicines; Coriolus versicolor;
   Zoledronic acid; Combination therapy
ID ANTICANCER ACTIVITY; CAMELLIA SINENSIS; BONE DISEASE; IN VITRO;
   BISPHOSPHONATES; CHEMOTHERAPY; METASTASIS; ANTITUMOR; GROWTH; CARCINOMA
AB Ethnopharmacological relevance: Coriolus versicolor (CV) is a mushroom traditionally used for strengthening the immune system and nowadays used as immunomodulatory adjuvant in anticancer therapy. Breast cancer usually metastasizes to the skeleton, interrupts the normal bone remodeling process and causes osteolytic bone lesions. The aims of the present study were to evaluate its herb drug interaction with metronomic zoledronate in preventing cancer propagation, metastasis and bone destruction.
   Materials and methods: Mice inoculated with human breast cancer cells tagged with a luciferase (MDA MB 231 TXSA) in tibia were treated with CV aqueous extract, mZOL, or the combination of both for 4 weeks. Alteration of the luciferase signals in tibia, liver and lung were quantified using the IVIS imaging system. The skeletal response was evaluated using micro computed tomography (micro CT). In vitro experiments were carried out to confirm the in vivo findings.
   Results: Results showed that combination of CV and mZOL diminished tumor growth without increasing the incidence of lung and liver metastasis in intratibial breast tumor model. The combination therapy also reserved the integrity of bones. In vitro studies demonstrated that combined use of CV and mZOL inhibited cancer cell proliferation and osteoclastogenesis.
   Conclusions: These findings suggested that combination treatment of CV and mZOL attenuated breast tumor propagation, protected against osteolytic bone lesion without significant metastases. This study provides scientific evidences on the beneficial outcome of using CV together with mZOL in the management of breast cancer and metastasis, which may lead to the development of CV as adjuvant health supplement for the control of breast cancer.
C1 [Ko, Chun Hay; Yue, Grace Gar Lee; Gao, Si; Luo, Ke Wang; Siu, Wing Sum; Shum, Wai Ting; Shiu, Hoi Ting; Lee, Julia Kin Ming; Leung, Ping Chung; Lau, Clara Bik San] Chinese Univ Hong Kong, Inst Chinese Med, Shatin, Hong Kong, Peoples R China.
   [Ko, Chun Hay; Yue, Grace Gar Lee; Gao, Si; Luo, Ke Wang; Siu, Wing Sum; Shum, Wai Ting; Shiu, Hoi Ting; Lee, Julia Kin Ming; Leung, Ping Chung; Lau, Clara Bik San] Chinese Univ Hong Kong, State Key Lab Phytochem & Plant Resources West Ch, Shatin, Hong Kong, Peoples R China.
   [Li, Gang] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Shatin, Hong Kong, Peoples R China.
   [Evdokiou, Andreas] Univ Adelaide, Basil Hetzel Inst, Breast Canc Res Unit, Discipline Surg, Adelaide, SA, Australia.
   [Evdokiou, Andreas] Univ Adelaide, Ctr Personalised Canc Med, Adelaide, SA, Australia.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; University of Adelaide; Basil Hetzel
   Institute; University of Adelaide
RP Lau, CBS (通讯作者)，Chinese Univ Hong Kong, Inst Chinese Med, Shatin, Hong Kong, Peoples R China.
EM gohey@cuhk.edu.hk; graceyue@cuhk.edu.hk; shirleygao@cuhk.edu.hk;
   kewangluo@gmail.com; sammysiu@cuhk.edu.hk; awtshum@cuhk.edu.hk;
   hoitingshiu@cuhk.edu.hk; julialee@cuhk.edu.hk; gangli@ort.cuhk.edu.hk;
   pingcleung@cuhk.edu.hk; andreas.evdokiou@adelaide.edu.au;
   claralau@cuhk.edulk
RI Siu, Sammy/AAR 1168 2021; Lau, Clara/AAF 3989 2020; Li,
   Gang/J 7830 2018; Lau, Clara Bik San/AAF 3989 2020; Yue, Grace
   Gar Lee/JTU 8811 2023; Yue, Grace Gar Lee/AAY 3945 2020; Ko,
   Chun/H 9652 2013
OI Lau, Clara/0000 0002 7409 1270; Li, Gang/0000 0002 3981 2239; Yue, Grace
   Gar Lee/0000 0002 1726 3566; 
FU Food and Health Bureau, Hong Kong Special Administration Region, Health
   and Medical Research Fund [10110891]
FX This research was financially supported by the Food and Health Bureau,
   Hong Kong Special Administration Region, Health and Medical Research
   Fund (no. 10110891).
CR Bocci G, 2012, MED HYPOTHESES, V78, P646, DOI 10.1016/j.mehy.2012.02.001
   Buijs JT, 2009, BONE, V44, P380, DOI 10.1016/j.bone.2008.10.047
   Chu KKW, 2002, J CLIN PHARMACOL, V42, P976
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman R, 2011, CANCER AM CANCER SOC, V117, P11, DOI 10.1002/cncr.25529
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Diaby V, 2015, BREAST CANCER RES TR, V151, P27, DOI 10.1007/s10549 015 3383 6
   Dong Y, 1996, RES COMMUN MOL PATH, V92, P140
   Eliza WLY, 2012, RECENT PATENTS INFLA, V6, P78, DOI [10.2174/187221312798889275, 10.2174/187221312798889310]
   Fan JP, 2006, J PHARMACEUT BIOMED, V41, P950, DOI 10.1016/j.jpba.2006.01.044
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Gnant M, 2012, ANTI CANCER AGENT ME, V12, P114, DOI 10.2174/187152012799014931
   Ho CY, 2006, ONCOL REP, V16, P609
   Labrinidis A, 2009, CLIN EXP METASTAS, V26, P872
   Lam Yuen chi, 2009, Chin Med, V4, P25, DOI 10.1186/1749 8546 4 25
   Lien K, 2013, EUR J CANCER, V49, P3387, DOI 10.1016/j.ejca.2013.06.038
   Luo KW, 2015, ONCOL REP, V34, P477, DOI 10.3892/or.2015.4001
   Luo KW, 2015, J CANCER RES CLIN, V141, P1025, DOI 10.1007/s00432 014 1882 1
   Luo KW, 2014, PHYTOMEDICINE, V21, P1078, DOI 10.1016/j.phymed.2014.04.020
   Luo KW, 2013, CANCER LETT, V339, P42, DOI 10.1016/j.canlet.2013.07.024
   Mahtani R, 2010, CLIN BREAST CANCER, V10, P359, DOI 10.3816/CBC.2010.n.047
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Munzone E., 2015, Nat Rev Clin Oncol
   Nielsen JS, 2008, J CELL SCI, V121, P3683, DOI 10.1242/jcs.037507
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Somasiri A, 2004, CANCER RES, V64, P5068, DOI 10.1158/0008 5472.CAN 04 0240
   Syddall SP, 2010, CURR PHARM DESIGN, V16, P2988
   Luu T, 2011, ONCOLOGIST, V16, P760, DOI 10.1634/theoncologist.2010 0345
   Zhao XM, 2010, BREAST CANCER RES TR, V124, P733, DOI 10.1007/s10549 010 1183 6
   Zinonos I, 2009, MOL CANCER THER, V8, P2969, DOI 10.1158/1535 7163.MCT 09 0745
NR 32
TC 16
Z9 17
U1 0
U2 23
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAY 23
PY 2017
VL 204
BP 77
EP 85
DI 10.1016/j.jep.2017.04.007
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA EW2UB
UT WOS:000402350400009
PM 28412218
DA 2025 08 17
ER

PT J
AU Wu, CL
   Liu, XQ
   Sun, RX
   Qin, YH
   Liu, ZQ
   Yang, SB
   Tang, TT
   Zhu, ZN
   Yu, DG
   Liu, FX
AF Wu, Chuanlong
   Liu, Xuqiang
   Sun, Ruixin
   Qin, Yunhao
   Liu, Zhiqing
   Yang, Shengbing
   Tang, Tingting
   Zhu, Zhenan
   Yu, Degang
   Liu, Fengxiang
TI Targeting Anion Exchange of Osteoclast, a New Strategy for Preventing
   Wear Particles Induced Osteolysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE bone resorption; wear particle; osteoclast; SLC4A2; actin
ID NF KAPPA B; CHITOSAN MICROSPHERES; POLYETHYLENE WEAR; TIALV WEAR; TOTAL
   HIP; IN VIVO; BONE; RANKL; DIDS; DIFFERENTIATION
AB Joint replacement is essential for the treatment of serious joint disease. However, prosthetic failure remains an important clinical issue, with periprosthesis osteolysis (PO), caused by osteoclastic bone resorption induced by wear particles, being the leading cause of failure. Nuclear factor of activated T cells c1 (NFATc1) appears to play an important role in wear particle induced osteoclastogenesis, with bicarbonate/chloride exchanger, solute carrier family 4, anion exchanger, member 2, (SLC4A2) being upregulated during osteoclastogenesis in an NFATc1 dependent manner. Anion exchange mediated by SLC4A2 in osteoclasts could affect the bone resorption activity by regulating pHi. This study investigated the role and mechanism of SLC4A2 in wear particle induced osteoclast differentiation and function in vitro. The use of 4, 4' diisothiocyano 2,2' stilbenedisulfonic acid (DIDS), an anion exchange inhibitor, suppressed wear particle induced PO in vivo. Furthermore, controlled release of DIDS from chitosan microspheres can strengthen the PO therapy effect. Therefore, anion exchange mediated by osteoclastic SLC4A2 may be a potential therapeutic target for the treatment of aseptic loosening of artificial joints.
C1 [Wu, Chuanlong; Liu, Zhiqing; Yang, Shengbing; Tang, Tingting; Zhu, Zhenan; Yu, Degang; Liu, Fengxiang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthopaed Implants, Dept Orthopaed,Peoples Hosp 9, Shanghai, Peoples R China.
   [Wu, Chuanlong] Shanghai Jiao Tong Univ, Dept Orthopaed, Ruijin Hosp, Sch Med, Shanghai, Peoples R China.
   [Liu, Xuqiang] Nanchang Univ, Affiliated Hosp 1, Dept Orthopaed, Nanchang, Jiangxi, Peoples R China.
   [Sun, Ruixin] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai, Peoples R China.
   [Qin, Yunhao] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Orthopaed, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Nanchang
   University; Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Yu, DG; Liu, FX (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthopaed Implants, Dept Orthopaed,Peoples Hosp 9, Shanghai, Peoples R China.
EM ydg163@126.com; liu_fengxiang@126.com
RI li, yan/ITU 9719 2023; ydg, nam/GNP 5078 2022; Tang,
   Tingting/B 1361 2013
FU National Natural Science Foundation of China [81171729, 81802169]; Fund
   for Key Disciplines of Shanghai Municipal Education Commission [J50206];
   Clinical Research Program of Ninth People's Hospital affiliated to
   Shanghai Jiao Tong University School of Medicine [JYLJ029]; Shanghai
   Sailing Program [18YF1413900]; China Scholarship Council (CSC); Natural
   Science Foundation of Shanghai [18ZR1422000]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant Nos. 81171729 and 81802169), the Fund for Key
   Disciplines of Shanghai Municipal Education Commission (Grant No.
   J50206), Clinical Research Program of Ninth People's Hospital affiliated
   to Shanghai Jiao Tong University School of Medicine (Grant No. JYLJ029),
   Shanghai Sailing Program (Grant No. 18YF1413900), the fund by China
   Scholarship Council (CSC), and the Natural Science Foundation of
   Shanghai (Grant No. 18ZR1422000).
CR Abbas S, 2003, J ORTHOPAED RES, V21, P1041, DOI 10.1016/S0736 0266(03)00081 0
   Aliprantis AO, 2010, ADV EXP MED BIOL, V658, P69, DOI 10.1007/978 1 4419 1050 9_8
   Alper SL, 2009, J EXP BIOL, V212, P1672, DOI 10.1242/jeb.029454
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Baumann B, 2005, J ORTHOP RES, V23, P1241, DOI 10.1016/j.orthres.2005.02.017
   Baumann B, 2004, ACTA ORTHOP SCAND, V75, P295, DOI 10.1080/00016470410001222
   Bonar PT, 2008, CHANNELS, V2, P337, DOI 10.4161/chan.2.5.6899
   Broomfield JAJ, 2017, J ARTHROPLASTY, V32, P1186, DOI 10.1016/j.arth.2016.10.037
   Coury F, 2013, P NATL ACAD SCI USA, V110, P2163, DOI 10.1073/pnas.1206392110
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Fric J, 2012, BLOOD, V120, P1380, DOI 10.1182/blood 2012 02 404475
   Goodman SB, 2010, BIOMATERIALS, V31, P5045, DOI 10.1016/j.biomaterials.2010.03.046
   Greenfield EM, 2002, J ORTHOPAED RES, V20, P1, DOI 10.1016/S0736 0266(01)00070 5
   Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092 8674(01)00222 7
   Hirakawa K, 1996, J BIOMED MATER RES, V31, P257, DOI 10.1002/(SICI)1097 4636(199606)31:2<257::AID JBM13>3.0.CO;2 I
   Hua SM, 1997, BIOPHYS J, V73, P2149, DOI 10.1016/S0006 3495(97)78245 6
   Islam MA, 2012, INT J NANOMED, V7, P6077, DOI 10.2147/IJN.S38330
   Jain SK, 2004, DRUG DELIV, V11, P113, DOI 10.1080/10717540490280750
   Kang ML, 2006, EUR J PHARM BIOPHARM, V63, P215, DOI 10.1016/j.ejpb.2006.01.010
   Lee SS, 2003, CELL SIGNAL, V15, P339, DOI 10.1016/S0898 6568(02)00118 3
   Liu FX, 2013, ACTA PHARMACOL SIN, V34, P1457, DOI 10.1038/aps.2013.99
   Liu FX, 2009, BIOMATERIALS, V30, P1756, DOI 10.1016/j.biomaterials.2008.12.018
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Müller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818
   Parker MD, 2018, AM J PHYSIOL CELL PH, V314, pC569, DOI 10.1152/ajpcell.00301.2017
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Ramasamy R, 2001, CARDIOVASC RES, V51, P275, DOI 10.1016/S0008 6363(01)00301 7
   Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756 3282(02)00672 5
   Sartori M, 2017, J BIOMED MATER RES A, V105, P510, DOI 10.1002/jbm.a.35912
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Supanchart C, 2008, ARCH BIOCHEM BIOPHYS, V473, P161, DOI 10.1016/j.abb.2008.03.029
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang XM, 2015, CELL PHYSIOL BIOCHEM, V35, P676, DOI 10.1159/000369728
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Wu J, 2008, P NATL ACAD SCI USA, V105, P16934, DOI 10.1073/pnas.0808763105
   Yang SY, 2004, GENE THER, V11, P483, DOI 10.1038/sj.gt.3302192
NR 41
TC 7
Z9 8
U1 2
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 6
PY 2018
VL 9
AR 1291
DI 10.3389/fphar.2018.01291
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GZ3YH
UT WOS:000449324500001
PM 30459624
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ottewell, PD
   Wang, N
   Meek, J
   Fowles, CA
   Croucher, PI
   Eaton, CL
   Holen, I
AF Ottewell, Penelope D.
   Wang, Ning
   Meek, Joshua
   Fowles, C. Anne
   Croucher, Peter I.
   Eaton, Colby L.
   Holen, Ingunn
TI Castration induced bone loss triggers growth of disseminated prostate
   cancer cells in bone
SO ENDOCRINE RELATED CANCER
LA English
DT Article
DE prostate cancer; castration; bone; metastasis
ID ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED TRIAL; ZOLEDRONIC
   ACID; SKELETAL COMPLICATIONS; MOUSE MODEL; MEN; METASTASIS;
   BISPHOSPHONATES; DORMANCY; MITOXANTRONE
AB Up to 90% of patients with castrate resistant prostate cancer develop bone metastases, and the majority of these men have received androgen deprivation therapy known to cause bone loss. Whether this treatment induced change to the bone microenvironment affects disseminated tumour cells, potentially stimulating development of bone metastasis, remains to be determined. The objective of this study was to use an in vivo model mimicking androgen ablation to establish the effects of this intervention on disseminated prostate cancer cells in bone. We mimicked the effects of androgen deprivation on bone metastasis by castrating 12 week old BALB/c nude mice that had disseminated, hormone insensitive PC3 prostate cancer cells present in the long bones. Castration caused increased bone resorption and loss of bone volume, compared with sham operation. In addition, castration triggered growth of disseminated PC3 cells to form bone metastasis in 70% of animals. In contrast, only 10% of sham operated animals had detectable long bone tumours. Weekly administration of 100 mg/kg zoledronic acid (ZOL) prevented castration induced tumour growth in bone and increased bone volume, but did not eliminate the disseminated tumour cells. ZOL had no effect on tumour growth in the sham operated animals, despite causing a significant increase in bone volume. This is the first demonstration that, in a model of prostate cancer bone metastasis, mimicking androgen ablation results in growth of disseminated tumour cells in bone through osteoclast mediated mechanisms. We provide the first biological evidence supporting the administration of ZOL to prostate cancer patients at the time of androgen ablation to prevent subsequent relapse in bone.
C1 [Ottewell, Penelope D.; Meek, Joshua; Holen, Ingunn] Univ Sheffield, Sch Med, Dept Oncol, Acad Unit Clin Oncol, Sheffield S10 2RX, S Yorkshire, England.
   [Wang, Ning; Fowles, C. Anne; Eaton, Colby L.] Univ Sheffield, Sch Med, Dept Human Metab, Sheffield S10 2RX, S Yorkshire, England.
   [Croucher, Peter I.] Garvan Inst Med Res, Musculoskeletal Med Div, Sydney, NSW, Australia.
C3 University of Sheffield; University of Sheffield; Garvan Institute of
   Medical Research
RP Ottewell, PD (通讯作者)，Univ Sheffield, Sch Med, Dept Oncol, Acad Unit Clin Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM p.d.ottewell@sheffield.ac.uk
RI ; Wang, Ning/HKO 8446 2023
OI Croucher, Peter/0000 0002 7102 2413; Ottewell,
   Penelope/0000 0002 4826 0771; WANG, NING/0000 0002 2663 7515; Holen,
   Ingunn/0000 0002 8759 6913
FU Cancer Research UK; Mrs Janice Gibson and the Ernest Heine Family
   Foundation; Yorkshire Cancer Research; Cancer Research UK [11991]
   Funding Source: researchfish
FX This study was supported by a programme grant from Cancer Research UK
   (to C L Eaton, P I Croucher and I Holen). P I Croucher is supported by
   Mrs Janice Gibson and the Ernest Heine Family Foundation. IVIS luminol
   imaging system was funded by an equipment grant from Yorkshire Cancer
   Research.
CR Aguirre Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   [Anonymous], 2013, SURV RAT PROST CANC
   Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027
   Brown HK, 2009, CURR CANCER DRUG TAR, V9, P807, DOI 10.2174/156800909789760339
   Chu GCY, 2014, ENDOCR RELAT CANCER, V21, P311, DOI 10.1530/ERC 13 0548
   COLE AA, 1987, J HISTOCHEM CYTOCHEM, V35, P203, DOI 10.1177/35.2.3540104
   Coleman RE, 2013, NAT REV RHEUMATOL, V9, P365, DOI 10.1038/nrrheum.2013.36
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Cook LM, 2014, CANCER METAST REV, V33, P511, DOI 10.1007/s10555 014 9494 4
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Das K, 2010, ENDOCR RELAT CANCER, V17, P757, DOI 10.1677/ERC 10 0022
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304 3835(02)00413 5
   El Amm J, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/210686
   Ellis SL, 2011, BLOOD, V118, P1516, DOI 10.1182/blood 2010 08 303800
   Garnero P, 2000, BRIT J CANCER, V82, P858, DOI 10.1054/bjoc.1999.1012
   Graham TJ, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju033
   Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007
   Han M, 2003, J UROLOGY, V169, P517, DOI 10.1016/S0022 5347(05)63946 8
   Hansen AG, 2014, CANCER RES, V74, P1404, DOI 10.1158/0008 5472.CAN 13 1296
   Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296
   Herroon MK, 2013, ONCOTARGET, V4, P2108, DOI 10.18632/oncotarget.1482
   Hung TT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019389
   Kim JK, 2013, NEOPLASIA, V15, P1064, DOI 10.1593/neo.13402
   Kollet O, 2007, ANNU REV IMMUNOL, V25, P51, DOI 10.1146/annurev.immunol.25.022106.141631
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Lee YC, 2013, MOL CANCER RES, V11, P1401, DOI 10.1158/1541 7786.MCR 13 0108
   Matsushima H, 1999, CANCER AM CANCER SOC, V85, P1822, DOI 10.1002/(SICI)1097 0142(19990415)85:8<1822::AID CNCR24>3.0.CO;2 1
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Morgans AK, 2012, UROL CLIN N AM, V39, P533, DOI 10.1016/j.ucl.2012.07.009
   Morrissey C, 2013, J BONE MINER RES, V28, P333, DOI 10.1002/jbmr.1749
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Ottewell PD, 2012, BREAST CANCER RES TR, V133, P523, DOI 10.1007/s10549 011 1782 x
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Reim NS, 2008, J BONE MINER RES, V23, P694, DOI 10.1359/JBMR.080202
   Renström J, 2010, CHEM BIOL INTERACT, V184, P7, DOI 10.1016/j.cbi.2009.11.012
   Saylor PJ, 2014, ASIAN J ANDROL, V16, P341, DOI 10.4103/1008 682X.122591
   Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Shiozawa Y, 2013, J CELL BIOCHEM, V114, P2471, DOI 10.1002/jcb.24592
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Smith MR, 2014, J CLIN ONCOL, V32, P1143, DOI 10.1200/JCO.2013.51.6500
   Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Smith MR, 2003, J UROLOGY, V170, pS55, DOI 10.1097/01.ju.0000095102.34708.bc
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Thudi NK, 2008, PROSTATE, V68, P1116, DOI 10.1002/pros.20776
   Townson JL, 2006, CELL CYCLE, V5, P1744, DOI 10.4161/cc.5.16.2864
   van der Horst G, 2011, NEOPLASIA, V13, P516, DOI 10.1593/neo.11122
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   VELDSCHOLTE J, 1990, BIOCHIM BIOPHYS ACTA, V1052, P187, DOI 10.1016/0167 4889(90)90075 O
   VERHAS M, 1986, CALCIFIED TISSUE INT, V39, P74, DOI 10.1007/BF02553294
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
NR 58
TC 73
Z9 79
U1 1
U2 7
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 1351 0088
EI 1479 6821
J9 ENDOCR RELAT CANCER
JI Endocr. Relat. Cancer
PD OCT
PY 2014
VL 21
IS 5
BP 769
EP 781
DI 10.1530/ERC 14 0199
PG 13
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA AT2TG
UT WOS:000344788400021
PM 25052474
OA Bronze
DA 2025 08 17
ER

PT J
AU Ma, ZP
   Liao, JC
   Zhao, C
   Cai, DZ
AF Ma, Zhong ping
   Liao, Jia cheng
   Zhao, Chang
   Cai, Dao zhang
TI Effects of the 1, 4 dihydropyridine L type calcium channel blocker
   benidipine on bone marrow stromal cells
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Osteoblast; Benidipine; WNT signal pathway; Bone metabolism;
   Osteoporosis
ID RECEPTOR RELATED PROTEIN 5; ESSENTIAL HYPERTENSION; BLOOD PRESSURE;
   STEM CELLS; OSTEOBLAST; OSTEOPOROSIS; DIFFERENTIATION; OSTEOGENESIS;
   METABOLISM; MUTATION
AB Osteoporosis (OP) often increases the risk of bone fracture and other complications and is a major clinical problem. Previous studies have found that high blood pressure is associated with bone formation abnormalities, resulting in increased calcium loss. We have investigated the effect of the antihypertensive drug benidipine on bone marrow stromal cell (BMSC) differentiation into osteoblasts and bone formation under osteoporotic conditions. We used a combination of in vitro and in vivo approaches to test the hypothesis that benidipine promotes murine BMSC differentiation into osteoblasts. Alkaline phosphatase (ALP), osteocalcin (OCN), runt related transcription factor 2 (RUNX2), beta catenin, and low density lipoprotein receptor related protein 5 (LRP5) protein expression was evaluated in primary femoral BMSCs from C57/BL6 mice cultured under osteogenic conditions for 2 weeks to examine the effects of benidipine. An ovariectomized (OVX) mouse model was used to investigate the effect of benidipine treatment for 3 months in vivo. We found that ALP, OCN, and RUNX2 expression was up regulated and WNT/beta catenin signaling was enhanced in vitro and in vivo. In OVX mice that were intragastrically administered benidipine, bone parameters (trabecular thickness, bone mineral density, and trabecular number) in the distal femoral metaphysis were significantly increased compared with control OVX mice. Consistently, benidipine promoted BMSC differentiation into osteoblasts and protected against bone loss in OVX mice. Therefore, benidipine might be a suitable candidate for the treatment of patients with postmenopausal osteoporosis and hypertension.
C1 [Ma, Zhong ping; Liao, Jia cheng; Zhao, Chang; Cai, Dao zhang] Southern Med Univ, Affiliated Hosp 3, Dept Orthoped, Guangzhou 510630, Guangdong, Peoples R China.
   [Ma, Zhong ping; Liao, Jia cheng; Zhao, Chang; Cai, Dao zhang] Acad Orthoped, Guangzhou, Guangdong, Peoples R China.
   [Ma, Zhong ping] Inner Mongolia Med Univ, Affiliated Hosp 2, Dept Orthoped, Hohhot, Inner Mongolia, Peoples R China.
   [Liao, Jia cheng] Southern Med Univ, Dept Orthoped Surg, Affiliated Longhua Peoples Hosp, Shenzhen, Guangdong, Peoples R China.
C3 Southern Medical University   China; Inner Mongolia Medical University;
   Southern Medical University   China
RP Cai, DZ (通讯作者)，Southern Med Univ, Affiliated Hosp 3, Dept Orthoped, 183 West Zhongshan Rd, Guangzhou 510630, Guangdong, Peoples R China.
EM daozhang@medmail.com
FU Inner Mongolia Medical University Science and Technology Project
   [YKD2012KJBW003]
FX This project was funded by the Inner Mongolia Medical University Science
   and Technology Project (YKD2012KJBW003).
CR Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bianco P, 2006, METHOD ENZYMOL, V419, P117, DOI 10.1016/S0076 6879(06)19006 0
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   BRICKMAN AS, 1990, HYPERTENSION, V16, P515, DOI 10.1161/01.HYP.16.5.515
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cappuccio FP, 1999, LANCET, V354, P971, DOI 10.1016/S0140 6736(99)01437 3
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   CIRILLO M, 1989, AM J HYPERTENS, V2, P741, DOI 10.1093/ajh/2.10.741
   Danks L, 2013, J BIOCHEM, V154, P29, DOI 10.1093/jb/mvt049
   Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248 011 9581 z
   GADALLAH M, 1991, AM J HYPERTENS, V4, P404, DOI 10.1093/ajh/4.5.404
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   GROBBEE DE, 1988, BMJ BRIT MED J, V296, P814, DOI 10.1136/bmj.296.6625.814
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   HVARFNER A, 1987, J HYPERTENS, V5, P451
   IZAWA Y, 1985, CALCIFIED TISSUE INT, V37, P605, DOI 10.1007/BF02554916
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   KATZ AM, 1984, AM J MED, V77, P2, DOI 10.1016/S0002 9343(84)80078 9
   Kosaka N, 1998, CALCIFIED TISSUE INT, V62, P554, DOI 10.1007/s002239900478
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   MCCARRON DA, 1980, HYPERTENSION, V2, P162, DOI 10.1161/01.HYP.2.2.162
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Nishiya Y, 2002, CALCIFIED TISSUE INT, V70, P30, DOI 10.1007/s00223 001 1010 5
   Nishiya Y, 2001, BIOL PHARM BULL, V24, P628, DOI 10.1248/bpb.24.628
   OWEN M, 1988, J CELL SCI, P63
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   STRAZZULLO P, 1983, CLIN SCI, V65, P137, DOI 10.1042/cs0650137
   Sun HL, 2013, STEM CELLS, V31, P2183, DOI 10.1002/stem.1455
   Wang BX, 2014, EXP THER MED, V7, P649, DOI 10.3892/etm.2014.1475
   YOUNG EW, 1992, J LAB CLIN MED, V120, P624
NR 33
TC 20
Z9 25
U1 0
U2 27
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302 766X
EI 1432 0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD AUG
PY 2015
VL 361
IS 2
BP 467
EP 476
DI 10.1007/s00441 015 2115 x
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CO6KK
UT WOS:000359265400006
PM 25743688
DA 2025 08 17
ER

PT J
AU Wu, S
   Zhao, F
   Zhao, J
   Li, H
   Chen, JY
   Xia, Y
   Wang, JW
   Zhao, BZ
   Zhao, SH
   Li, N
AF Wu, Shan
   Zhao, Fan
   Zhao, Jing
   Li, Hui
   Chen, Junyu
   Xia, Yang
   Wang, Junwei
   Zhao, Benzheng
   Zhao, Shuhua
   Li, Na
TI Dioscin improves postmenopausal osteoporosis through inducing bone
   formation and inhibiting apoptosis in ovariectomized rats
SO BIOSCIENCE TRENDS
LA English
DT Article
DE Dioscin; postmenopausal osteoporosis; PI3K/P38/AKT pathway; apoptosis
ID OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; SIGNALING
   PATHWAY; PREVENTION; DAMAGE; MASS
AB Postmenopausal osteoporosis (PMO) has become a public health problem worldwide. Hormonal replacement therapy (HRT) is the most popular treatment for PMO at present, but the side effects, including increased risk of endometrial cancer and breast cancer, limit its clinical use. Therefore, finding a new medication with high efficiency and less side effects is urgently required. Dioscin is the main ingredient of some medicinal plants such as Dioscorea nipponica Makino and Dioscorea zingiberensis Wrigh. It is reported that dioscin has anti tumoral and anti atherosclerotic activity as well as an inhibitory effect on hepatic fibrosis. In this study, the effects of dioscin on PMO were examined and the mechanisms were analyzed. The results indicated that the bone mineral density and ultimate load of PMO rats were increased after being treated with dioscin. H&E staining and immunohistochemical staining showed the bone trabeculae formation and bone differentiation of PMO rats were promoted by dioscin. Western blots revealed that dioscin could activate the PI3K/P38/AKT signaling pathway and inhibit the apoptosis signaling pathway in bone tissue cells of PMO rats. In addition, MTT assays showed that MC3T3 E1 cell viability could be improved by dioscin. These results suggest dioscin is a potential therapeutic reagent for osteoporosis and deserves further investigation.
C1 [Wu, Shan; Zhao, Jing; Chen, Junyu; Xia, Yang; Wang, Junwei; Zhao, Benzheng; Zhao, Shuhua] Second Hosp Jilin Univ, Changchun, Jilin, Peoples R China.
   [Zhao, Fan] Jilin Univ, China Japan Union Hosp, Changchun, Jilin, Peoples R China.
   [Li, Hui] Qian Wei Hosp Jilin Prov, Changchun, Jilin, Peoples R China.
   [Li, Na] Changchun Univ Chinese Med, Jilin Ginseng Acad, Changchun, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Changchun University of Chinese
   Medicine
RP Zhao, SH (通讯作者)，Second Hosp Jilin Univ, Dept Gynecol & Obstet, Changchun 130041, Jilin, Peoples R China.
EM zhaoshuhua 1966@163.com
FU Jilin Province Development and Reform Commission [2016C048 2]
FX This work was financially supported by the Jilin Province Development
   and Reform Commission (2016C048 2).
CR Adapala NS, 2014, J CELL BIOCHEM, V115, P1277, DOI 10.1002/jcb.24779
   [Anonymous], 2015, SCI REP UK
   Bahia PK, 2012, J NEUROCHEM, V123, P182, DOI 10.1111/j.1471 4159.2012.07877.x
   Chen ATY, 2013, AGING CELL, V12, P932, DOI 10.1111/acel.12120
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JF, 2012, J BONE MINER RES, V27, P1659, DOI 10.1002/jbmr.1607
   Choi SW, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/810563
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Hamann I, 2014, ARCH BIOCHEM BIOPHYS, V558, P42, DOI 10.1016/j.abb.2014.06.004
   Han XS, 2018, IUBMB LIFE, V70, P633, DOI 10.1002/iub.1757
   Hou JM, 2012, ACTA PHARMACOL SIN, V33, P1277, DOI 10.1038/aps.2012.83
   Huang Q, 2004, ARCH ORAL BIOL, V49, P143, DOI 10.1016/j.archoralbio.2003.07.003
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kita K, 2008, GENES CELLS, V13, P839, DOI 10.1111/j.1365 2443.2008.01209.x
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee YS, 2011, INT IMMUNOPHARMACOL, V11, P712, DOI 10.1016/j.intimp.2011.01.018
   Liu LT, 2016, CURR OSTEOPOROS REP, V14, P386, DOI 10.1007/s11914 016 0339 7
   Liu M, 2018, INT J BIOL MACROMOL, V107, P137, DOI 10.1016/j.ijbiomac.2017.08.151
   Lu BN, 2012, ENVIRON TOXICOL PHAR, V34, P127, DOI 10.1016/j.etap.2012.03.010
   Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Pan CH, 2013, J SCI FOOD AGR, V93, P1278, DOI 10.1002/jsfa.5882
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sample SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043215
   Shi XD, 2014, PSYCHOPHARMACOLOGY, V231, P3109, DOI 10.1007/s00213 014 3491 8
   Song CL, 2008, J BONE MINER METAB, V26, P213, DOI 10.1007/s00774 007 0820 6
   Suzuki E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112566
   Tandon M, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3611
   Tao XF, 2016, PHARMACOL RES, V108, P90, DOI 10.1016/j.phrs.2016.05.003
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Tsukahara S, 2006, NEUROIMMUNOMODULAT, V13, P63, DOI 10.1159/000094829
   Wei YL, 2013, FOOD CHEM TOXICOL, V59, P118, DOI 10.1016/j.fct.2013.05.054
   Wu CM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 277
   Wu SS, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/368970
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xu JH, 2016, MENOPAUSE, V23, P1152, DOI 10.1097/GME.0000000000000673
   Zhang CF, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 30
   Zhao XW, 2016, MOLECULES, V21, DOI 10.3390/molecules21060730
   Zheng JY, 2017, THERANOSTICS, V7, P1373, DOI 10.7150/thno.17826
NR 41
TC 24
Z9 27
U1 1
U2 16
PU IRCA BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2 4 5 KASUGA, BUNKYO KU, TOKYO, 112 0003,
   JAPAN
SN 1881 7815
EI 1881 7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD OCT
PY 2019
VL 13
IS 5
BP 394
EP 401
DI 10.5582/bst.2019.01186
PG 8
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA JK6LB
UT WOS:000494952600004
PM 31611520
OA gold
DA 2025 08 17
ER

PT J
AU Fan, HJ
   Xu, ZA
   Yao, K
   Zheng, BX
   Zhang, Y
   Wang, XX
   Zhang, TJ
   Li, X
   Hu, HT
   Yue, B
   Hu, ZP
   Zheng, HQ
AF Fan, Huijuan
   Xu, Zhanao
   Yao, Ke
   Zheng, Bingxin
   Zhang, Yuan
   Wang, Xuxiang
   Zhang, Tengjiang
   Li, Xuan
   Hu, Haitian
   Yue, Bin
   Hu, Zeping
   Zheng, Hanqiu
TI Osteoclast Cancer Cell Metabolic Cross talk Confers PARP Inhibitor
   Resistance in Bone Metastatic Breast Cancer
SO CANCER RESEARCH
LA English
DT Article
ID MUSCLE GLUTAMINE METABOLISM; OVARIAN CANCER; DNA DAMAGE;
   MOLECULAR MECHANISMS; TRANSCRIPTION FACTOR; MAINTENANCE THERAPY;
   GENE EXPRESSION; TUMOR; STRESS; MICROENVIRONMENT
AB The majority of patients with late stage breast cancer develop distal bone metastases. The bone microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating bone metastatic breast cancer. Here, we observed that osteoclasts reduced the sensitivity of breast cancer cells to DNA damaging agents, including cisplatin and the PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation enhanced the survival of breast cancer cells treated with DNA damaging agents, while blocking glutamine uptake increased sensitivity and suppressed bone metastasis. GPX4, the critical enzyme responsible for glutathione oxidation, was upregulated in cancer cells following PARPi treatment through stress induced ATF4 dependent transcriptional programming. Increased glutamine uptake and GPX4 upregulation concertedly enhanced glutathione metabolism in cancer cells to help neutralize oxidative stress and generate PARPi resistance. Analysis of paired patient samples of primary breast tumors and bone metastases revealed significant induction of GPX4 in bone metastases. Combination therapy utilizing PARPi and zoledronate, which blocks osteoclast activity and thereby reduces the microenvironmental glutamine supply, generated a synergistic effect in reducing bone metastasis. These results identify a role for glutamine production by bone resident cells in supporting metastatic cancer cells to overcome oxidative stress and develop resistance to DNA damaging therapies.
   Significance: Metabolic interaction between osteoclasts and tumor cells contributes to resistance to DNA damaging agents, which can be blocked by combination treatment with PARP and osteoclast inhibitors to reduce bone metastatic burden.
   [GRAPHICS]
   .
C1 [Fan, Huijuan; Xu, Zhanao; Zhang, Yuan; Wang, Xuxiang; Zhang, Tengjiang; Li, Xuan; Hu, Haitian; Zheng, Hanqiu] Tsinghua Univ, State Key Lab Mol Oncol, Beijing 100084, Peoples R China.
   [Yao, Ke; Hu, Zeping] Tsinghua Univ, Sch Pharmaceut Sci, Beijing, Peoples R China.
   [Zheng, Bingxin; Yue, Bin] Qingdao Univ, Affiliated Hosp, Dept Orthoped Oncol, Qingdao, Shandong, Peoples R China.
   [Zheng, Hanqiu] Tsinghua Univ, Sch Med, Dept Basic Med Sci, A308,Med Sci Bldg, Beijing 100084, Peoples R China.
   [Hu, Zeping] Tsinghua Univ, Sch Pharmaceut Sci, Beijing 100084, Peoples R China.
   [Yue, Bin] Qingdao Univ, Affiliated Hosp, Dept Orthoped Oncol, 59 Haier Rd, Qingdao 266000, Peoples R China.
C3 Tsinghua University; Tsinghua University; Qingdao University; Tsinghua
   University; Tsinghua University; Qingdao University
RP Zheng, HQ (通讯作者)，Tsinghua Univ, Sch Med, Dept Basic Med Sci, A308,Med Sci Bldg, Beijing 100084, Peoples R China.; Hu, ZP (通讯作者)，Tsinghua Univ, Sch Pharmaceut Sci, Beijing 100084, Peoples R China.; Yue, B (通讯作者)，Qingdao Univ, Affiliated Hosp, Dept Orthoped Oncol, 59 Haier Rd, Qingdao 266000, Peoples R China.
EM hanzheng@tsinghua.edu.cn; zeping_hu@tsinghua.edu.cn;
   bonetumoryb@qdu.edu.cn
RI ; Hu, Zeping/MBG 4392 2025
OI Hu, Haitian/0009 0000 0794 5718; Yue, Bin/0000 0002 6604 823X; Wang,
   Xuxiang/0000 0002 9816 2096; Fan, Huijuan/0009 0006 1551 3740; Xu,
   Zhanao/0009 0000 1766 6122; Yao, Ke/0000 0003 2638 2978; Zheng, Bing
   Xin/0000 0001 8009 1499; Zheng, Hanqiu/0000 0002 8062 1215
FU National Natural Science Foundation of China (NSFC); Laboratory Animal
   Research Center [2020YFA0509400]; National Key Research and Development
   Program of China [81973355, 81772981, 81972462]; National Science
   Foundation of China; Tsinghua University Initiative Scientific Research
   Program; Tsinghua Peking Center for Life Sciences
FX We thank Z. Chang for helping with IHC staining, and Y. Kang, Y. Fu, and
   P. Jiang for their helpful discussions. We thank C.J. David for
   proofreading this manuscript. We thank all the members of the Zheng
   Laboratory for their helpful discussions and technical assistance. We
   thank the Technology Center for Protein Sciences at Tsinghua University
   for mass spectrometry support, the Laboratory Animal Research Center,
   and the Center of Biomedical Analysis at Tsinghua University for animal
   research support. This study was partially supported by the National Key
   Research and Development Program of China (2020YFA0509400 to H. Zheng),
   National Science Foundation of China (81973355 to Z. Hu; 81772981 and
   81972462 to H. Zheng), Tsinghua University Initiative Scientific
   Research Program, and the Tsinghua Peking Center for Life Sciences.
CR Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020
   BANNAI S, 1986, J BIOL CHEM, V261, P2256
   Chen FF, 2021, BRIT J CANCER, V124, P1912, DOI 10.1038/s41416 021 01329 6
   Costa Mattioli M, 2020, SCIENCE, V368, P384, DOI 10.1126/science.aat5314
   Crist SB, 2022, NAT CELL BIOL, V24, P538, DOI 10.1038/s41556 022 00881 4
   de Weger VA, 2014, ANTI CANCER DRUG, V25, P488, DOI 10.1097/CAD.0000000000000093
   DEBRABANDER M, 1981, P NATL ACAD SCI BIOL, V78, P5608
   Dhyani P, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935 022 02624 9
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Domchek SM, 2016, GYNECOL ONCOL, V140, P199, DOI 10.1016/j.ygyno.2015.12.020
   Duan CW, 2014, CANCER CELL, V25, P778, DOI 10.1016/j.ccr.2014.04.015
   Elia I, 2019, NATURE, V568, P117, DOI 10.1038/s41586 019 0977 x
   Fan HJ, 2020, GENE DEV, V34, P1359, DOI 10.1101/gad.339796.120
   Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Go M, 2022, EXP MOL MED, V54, P825, DOI 10.1038/s12276 022 00775 3
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   HAMBERGER A, 1991, EPILEPSY RES, V9, P32, DOI 10.1016/0920 1211(91)90044 G
   Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738
   Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097 2765(00)00108 8
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097 2765(03)00105 9
   Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973
   Jeong SM, 2013, CANCER CELL, V23, P450, DOI 10.1016/j.ccr.2013.02.024
   Johnson RW, 2017, CURR OSTEOPOROS REP, V15, P231, DOI 10.1007/s11914 017 0378 8
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kang YB, 2016, ENDOCRINOL METAB, V31, P206, DOI 10.3803/EnM.2016.31.2.206
   KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820
   Kim J, 2017, NATURE, V546, P168, DOI 10.1038/nature22359
   Kleih M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2081 4
   KLIMBERG VS, 1990, J SURG RES, V48, P319, DOI 10.1016/0022 4804(90)90066 B
   Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470 2045(14)70228 1
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Martinez Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60
   Martínez Reyes I, 2021, NAT REV CANCER, V21, P669, DOI 10.1038/s41568 021 00378 6
   Mittendorfer B, 2001, AM J PHYSIOL ENDOC M, V280, pE323, DOI 10.1152/ajpendo.2001.280.2.E323
   Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858
   Nguyen A, 2016, J CLIN INVEST, V126, P681, DOI 10.1172/JCI83587
   Nie M, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI160152
   Pakos Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Pujade Lauraine E, 2017, LANCET ONCOL, V18, P1274, DOI 10.1016/S1470 2045(17)30469 2
   R Core Team, 2017, A Language and Environment for Statistical Computing
   Reinfeld BI, 2021, NATURE, V593, P282, DOI 10.1038/s41586 021 03442 1
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Robson, 2017, NEW ENGL J MED, V377, P1700
   Sankar N, 2009, J BIOL CHEM, V284, P15193, DOI 10.1074/jbc.M900776200
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Shi YL, 2016, J CEREBR BLOOD F MET, V36, P1653, DOI 10.1177/0271678X16662891
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Stirling C, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472 6963 10 122
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tafani M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3907147
   Tameire F, 2015, SEMIN CANCER BIOL, V33, P3, DOI 10.1016/j.semcancer.2015.04.002
   VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Yang LF, 2017, ANNU REV BIOMED ENG, V19, P163, DOI 10.1146/annurev bioeng 071516 044546
   Yang LF, 2016, CELL METAB, V24, P685, DOI 10.1016/j.cmet.2016.10.011
   Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097 2765(03)00037 6
   Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004
   Zhang WJ, 2021, CELL, V184, P2471, DOI 10.1016/j.cell.2021.03.011
   Zheng HQ, 2017, CANCER CELL, V32, P731, DOI 10.1016/j.ccell.2017.11.002
   Zheng HQ, 2016, COLD SH Q B, V81, P151, DOI 10.1101/sqb.2016.81.030775
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zuo H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15429 z
NR 71
TC 13
Z9 14
U1 6
U2 26
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2024
VL 84
IS 3
BP 449
EP 467
DI 10.1158/0008 5472.CAN 23 1443
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GW3I6
UT WOS:001155666500010
PM 38038966
DA 2025 08 17
ER

PT J
AU Man, K
   Brunet, MY
   Fernandez Rhodes, M
   Williams, S
   Heaney, LM
   Gethings, LA
   Federici, A
   Davies, OG
   Hoey, D
   Cox, SC
AF Man, Kenny
   Brunet, Mathieu Y.
   Fernandez Rhodes, Maria
   Williams, Soraya
   Heaney, Liam M.
   Gethings, Lee A.
   Federici, Angelica
   Davies, Owen G.
   Hoey, David
   Cox, Sophie C.
TI Epigenetic reprogramming enhances the therapeutic efficacy of
   osteoblast derived extracellular vesicles to promote human bone marrow
   stem cell osteogenic differentiation
SO JOURNAL OF EXTRACELLULAR VESICLES
LA English
DT Article
DE bone; epigenetics; extracellular vesicles; histone deacetylase;
   microRNAs; tissue engineering; trichostatin A
ID HISTONE DEACETYLASE INHIBITORS; GENE EXPRESSION; EXOSOMES; TRICHOSTATIN;
   MICRORNAS; RUNX2; PROLIFERATION; SUPPRESSES; REPRESSION; DEFECTS
AB Extracellular vesicles (EVs) are emerging in tissue engineering as promising acellular tools, circumventing many of the limitations associated with cell based therapies. Epigenetic regulation through histone deacetylase (HDAC) inhibition has been shown to increase differentiation capacity. Therefore, this study aimed to investigate the potential of augmenting osteoblast epigenetic functionality using the HDAC inhibitor Trichostatin A (TSA) to enhance the therapeutic efficacy of osteoblast derived EVs for bone regeneration. TSA was found to substantially alter osteoblast epigenetic function through reduced HDAC activity and increased histone acetylation. Treatment with TSA also significantly enhanced osteoblast alkaline phosphatase activity (1.35 fold), collagen production (2.8 fold) and calcium deposition (1.55 fold) during osteogenic culture (P <= 0.001). EVs derived from TSA treated osteoblasts (TSA EVs) exhibited reduced particle size (1 05 fold) (P > 0.05), concentration (1.4 fold) (P > 0.05) and protein content (1.16 fold) (P <= 0.001) when compared to untreated EVs. TSA EVs significantly enhanced the proliferation (1.13 fold) and migration (1.3 fold) of human bone marrow stem cells (hBMSCs) when compared to untreated EVs (P <= 0.05). Moreover, TSA EVs upregulated hBMSCs osteoblast related gene and protein expression (ALP, Col1a, BSP1 and OCN) when compared to cells cultured with untreated EVs. Importantly, TSA EVs elicited a time dose dependent increase in hBMSCs extracellular matrix mineralisation. MicroRNA profiling revealed a set of differentially expressed microRNAs from TSA EVs, which were osteogenic related. Target prediction demonstrated these microRNAs were involved in regulating pathways such as 'endocytosis' and 'Wnt signalling pathway'. Moreover, proteomics analysis identified the enrichment of proteins involved in transcriptional regulation within TSA EVs. Taken together, our findings suggest that altering osteoblasts' epigenome accelerates their mineralisation and promotes the osteoinductive potency of secreted EVs partly due to the delivery of pro osteogenic microRNAs and transcriptional regulating proteins. As such, for the first time we demonstrate the potential to harness epigenetic regulation as a novel engineering approach to enhance EVs therapeutic efficacy for bone repair.
C1 [Man, Kenny; Brunet, Mathieu Y.; Cox, Sophie C.] Univ Birmingham, Sch Chem Engn, Birmingham, W Midlands, England.
   [Fernandez Rhodes, Maria; Williams, Soraya; Heaney, Liam M.; Davies, Owen G.] Loughborough Univ, Sch Sport Exercise & Hlth Sci, Loughborough, Leics, England.
   [Gethings, Lee A.] Waters Corp, Stamford Ave, Wilmslow, Cheshire, England.
   [Gethings, Lee A.] Univ Manchester, Manchester Inst Biotechnol, Fac Biol Med & Hlth, Div Infect Immun & Resp Med, Manchester, Lancs, England.
   [Federici, Angelica; Hoey, David] Trinity Coll Dublin, Trinity Ctr Biomed Engn, Trinity Biomed Sci Inst, Dublin, Ireland.
   [Federici, Angelica; Hoey, David] Trinity Coll Dublin, Sch Engn, Dept Mech Mfg & Biomed Engn, Dublin, Ireland.
   [Federici, Angelica; Hoey, David] Trinity Coll Dublin, Dublin, Ireland.
   [Federici, Angelica; Hoey, David] RCSI, Adv Mat & Bioengn Res Ctr, Dublin, Ireland.
C3 University of Birmingham; Loughborough University; Waters UK; University
   of Manchester; Trinity College Dublin; Trinity College Dublin; Trinity
   College Dublin; Royal College of Surgeons   Ireland
RP Cox, SC (通讯作者)，Univ Birmingham, Sch Chem Engn, Birmingham, W Midlands, England.
EM s.c.cox@bharm.ac.uk
RI ; Man, Kenny/HDN 3784 2022; Hoey, David/G 3301 2013; Heaney,
   Liam/B 5514 2015; Fernandez Rhodes, María/NOF 9389 2025; Brunet,
   Mathieu/KEJ 6117 2024; Hoey, David/X 9231 2019
OI Brunet, Mathieu/0000 0001 6556 0285; Williams,
   Soraya/0000 0003 1005 7679; Hoey, David/0000 0001 5898 0409;
   Fernandez Rhodes, Maria/0000 0002 9262 7147; Cox,
   Sophie/0000 0003 4746 0322; Man, Kenny/0000 0002 7946 9375; Davies,
   Owen/0000 0003 0808 8695
FU EPSRC [EP/S016589/1]; Science Foundation Ireland [19/FFP/6533]; Academy
   of Medical Sciences; WellcomeTrust; Government Department of Business,
   Energy and Industrial Strategy; British Heart Foundation; Diabetes UK
   [SBF004\1090]; University Of Birmingham; EPSRC/MRC Doctoral Training
   Centre in Regenerative Medicine; EPSRC [EP/S016589/1] Funding Source:
   UKRI
FX EPSRC, Grant/AwardNumber: EP/S016589/1; School ofChemical Engineering;
   University Of Birmingham; Science Foundation Ireland, Grant/AwardNumber:
   19/FFP/6533; Academy of Medical Sciences; WellcomeTrust; Government
   Department of Business, Energy and Industrial Strategy; BritishHeart
   Foundation; Diabetes UK, Grant/AwardNumber: SBF004\1090; EPSRC/MRC
   DoctoralTrainingCentre inRegenerativeMedicine
CR AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968 0004(00)88957 4
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   [Anonymous], 2016, J MARKET ACCESS HLTH
   Barbaric I, 2008, PHYSIOL GENOMICS, V32, P311, DOI 10.1152/physiolgenomics.00116.2007
   Baroli B, 2009, J PHARM SCI US, V98, P1317, DOI 10.1002/jps.21528
   Bhushan R, 2013, INT J BIOCHEM CELL B, V45, P696, DOI 10.1016/j.biocel.2012.12.008
   Bolden JE, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.9
   Brennan MA, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909125
   Burdick JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3003997
   Buzás EI, 2018, SEMIN IMMUNOPATHOL, V40, P453, DOI 10.1007/s00281 018 0682 0
   Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981
   Calori GM, 2011, INJURY, V42, pS56, DOI 10.1016/j.injury.2011.06.011
   Chance Larsen K, 2019, RHEUMATOL ADV PRACT, V3, DOI 10.1093/rap/rkz036
   Chen S, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12669
   Choo MK, 2009, BONE, V45, P579, DOI 10.1016/j.bone.2009.05.009
   Collas P, 2008, TRANSFUS MED HEMOTH, V35, P205, DOI 10.1159/000127449
   Cui YZ, 2016, FEBS LETT, V590, P185, DOI 10.1002/1873 3468.12024
   Davies OG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13027 6
   Davies O.G., 2019, FRONT BIOENG BIOTECH, V7
   Di CX, 2019, CELL DEATH DIFFER, V26, P1181, DOI 10.1038/s41418 018 0231 3
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Distler U, 2016, NAT PROTOC, V11, P795, DOI 10.1038/nprot.2016.042
   Djouad F, 2012, J BIOMATER TISS ENG, V2, P14, DOI 10.1166/jbt.2012.1022
   Dompe C, 2020, CANCERS, V12, DOI 10.3390/cancers12041016
   Driscoll J, 2019, J GASTROENTEROL, V54, P763, DOI 10.1007/s00535 019 01599 1
   Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732
   Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414
   Eichholz KF, 2020, STEM CELL TRANSL MED, V9, P1431, DOI 10.1002/sctm.19 0405
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   Gallagher D, 2015, DEV CELL, V32, P31, DOI 10.1016/j.devcel.2014.11.031
   Gilleron J, 2019, TRAFFIC, V20, P552, DOI 10.1111/tra.12670
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405 367
   Haertinger M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9010163
   Heathman TRJ, 2015, REGEN MED, V10, P49, DOI [10.2217/RME.14.73, 10.2217/rme.14.73]
   Hu Q, 2020, PRECIS CLIN MED, V3, P54, DOI 10.1093/pcmedi/pbaa007
   Hu XQ, 2013, STEM CELLS DEV, V22, P248, DOI 10.1089/scd.2012.0105
   Huang S, 2012, STEM CELLS DEV, V21, P2531, DOI 10.1089/scd.2012.0014
   Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 319
   Huynh Nam Cong Nhat, 2017, Bone Rep, V7, P33, DOI 10.1016/j.bonr.2017.08.001
   Huynh NCN, 2016, J CELL BIOCHEM, V117, P1384, DOI 10.1002/jcb.25429
   Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jin H, 2013, TISSUE ENG PT A, V19, P613, DOI [10.1089/ten.tea.2012.0163, 10.1089/ten.TEA.2012.0163]
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Kang K, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/659890
   Kim H, 2020, METHODS, V177, P80, DOI 10.1016/j.ymeth.2019.10.005
   Kim KM, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1413
   Kooijmans SAA, 2016, PHARMACOL RES, V111, P487, DOI 10.1016/j.phrs.2016.07.006
   Krohn JB, 2016, J PHYSIOL LONDON, V594, P2895, DOI 10.1113/JP271338
   Lawlor L, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0053 2
   Lee JH, 2010, J CELL BIOCHEM, V111, P195, DOI 10.1002/jcb.22689
   Li DQ, 2015, J INVEST DERMATOL, V135, P1676, DOI 10.1038/jid.2015.48
   Li GZ, 2009, PROTEOMICS, V9, P1696, DOI 10.1002/pmic.200800564
   Li HQ, 2015, MOL MED REP, V12, P1561, DOI 10.3892/mmr.2015.3497
   Li XD, 2005, OSTEOPOROSIS INT, V16, P101, DOI 10.1007/s00198 004 1649 7
   Liu Z, 2018, MOL MED REP, V18, P5317, DOI 10.3892/mmr.2018.9596
   Ma JF, 2015, MOL MED REP, V11, P4525, DOI 10.3892/mmr.2015.3268
   Man K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105224
   Man K, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10091838
   Marks PA, 2010, EXPERT OPIN INV DRUG, V19, P1049, DOI 10.1517/13543784.2010.510514
   Meng YB, 2015, J ORTHOP RES, V33, P957, DOI 10.1002/jor.22884
   Minamizaki T, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 0754 2
   Minetti GC, 2006, NAT MED, V12, P1147, DOI 10.1038/nm1479
   Musselman CA, 2011, NUCLEIC ACIDS RES, V39, P9061, DOI 10.1093/nar/gkr613
   Nikravesh N, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801604
   O'Brien K, 2020, NAT REV MOL CELL BIO, V21, P585, DOI 10.1038/s41580 020 0251 y
   Paino F, 2014, STEM CELLS, V32, P279, DOI 10.1002/stem.1544
   Qin YH, 2016, SCI REP UK, V6, DOI 10.1038/srep21961
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Rodríguez Suárez E, 2013, CURR ANAL CHEM, V9, P199
   Rohde E, 2019, CYTOTHERAPY, V21, P581, DOI 10.1016/j.jcyt.2018.12.006
   Sahoo S, 2014, CIRC RES, V114, P333, DOI 10.1161/CIRCRESAHA.114.300639
   Sainitya R, 2015, INT J BIOL MACROMOL, V80, P481, DOI 10.1016/j.ijbiomac.2015.07.016
   Sandonà M, 2020, EMBO REP, V21, DOI 10.15252/embr.202050863
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   Sharma A, 2014, GENE, V538, P366, DOI 10.1016/j.gene.2014.01.051
   Shimazu J, 2016, CELL REP, V15, P27, DOI 10.1016/j.celrep.2016.03.003
   Su PH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082343
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Sun DZ, 2019, NAT REV UROL, V16, P363, DOI 10.1038/s41585 019 0169 3
   Tan SHS, 2020, MATER TODAY BIO, V7, DOI 10.1016/j.mtbio.2020.100067
   Tang XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179860
   Tao SC, 2017, STEM CELL TRANSL MED, V6, P736, DOI 10.5966/sctm.2016 0275
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   van Wijnen AJ, 2019, J ORTHOP RES, V37, P1465, DOI 10.1002/jor.24305
   Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   Wang C. A., 2020, RES SQUARE
   Wang RK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2377 4
   Wang XQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193059
   Wei Y, 2019, BIOCHEM BIOPH RES CO, V514, P252, DOI 10.1016/j.bbrc.2019.04.029
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Woolf AD, 2007, CURR OPIN RHEUMATOL, V19, P370
   Xin HQ, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00377
   Xu J, 2019, ELIFE, V8
   Xu SS, 2019, J CELL PHYSIOL, V234, P15167, DOI 10.1002/jcp.28157
   Yang JW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 08868 0
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Yoshiko Y, 2020, J ORAL BIOSCI, V62, P228, DOI 10.1016/j.job.2020.05.006
   Zhao J.W., 2017, SCI REP UK, V7
   Zhao RB, 2016, BIOCHEM BIOPH RES CO, V477, P749, DOI 10.1016/j.bbrc.2016.06.130
   Zheng HJ, 2019, BONE, V123, P92, DOI 10.1016/j.bone.2019.03.020
NR 104
TC 52
Z9 57
U1 2
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2001 3078
J9 J EXTRACELL VESICLES
JI J. Extracell. Vesicles
PD JUL
PY 2021
VL 10
IS 9
AR e12118
DI 10.1002/jev2.12118
PG 24
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA TF0XB
UT WOS:000670435600001
PM 34262674
OA Green Published
DA 2025 08 17
ER

PT J
AU Shin, MK
   Kim, MK
   Bae, YS
   Jo, I
   Lee, SJ
   Chung, CP
   Park, YJ
   Min, DS
AF Shin, Min Kyoung
   Kim, Mi Kyoung
   Bae, Yoe Sik
   Jo, Inho
   Lee, Seung Jin
   Chung, Chong Pyoung
   Park, Yoon Jeong
   Min, Do Sik
TI A novel collagen binding peptide promotes osteogenic differentiation via
   Ca<SUP>2+</SUP>/calmodulin dependent protein kinase II/ERK/AP 1
   signaling pathway in human bone marrow derived mesenchymal stem cells
SO CELLULAR SIGNALLING
LA English
DT Article
DE mesenchymal stem cells; collagen binding peptide; osteogenesis; Ca2+;
   ERK; CaMKII
ID GROWTH FACTOR I; OSTEOBLAST PHENOTYPE; TRANSCRIPTION; EXPRESSION;
   OSTEOPONTIN; VITRO; CREB; F2L
AB The intracellular signaling events controlling human mesenchymal stem cell (hMSC) differentiation into osteoblasts are poorly understood. Collagen binding domain is considered an essential component of bone mineralization. In the present study, we investigated the regulatory mechanism of osteoblastic differentiation of hMSC by the peptide with a novel collagen binding motif derived from osteopontin. The peptide induced influx of extracellular Ca2+ via calcium channels and increased intracellular Ca2+ concentration ([Ca2+](i)) independent of both pertussis toxin and phospholipase C, and activated ERK, which was inhibited by Ca2+/calmodulin dependent protein kinase (CaMKII) antagonist, KN93. The peptide induced increase of [Ca2+](i) is correlated with ERK activation in a various cell types. The peptide stimulated the migration of hMSC but suppressed cell proliferation. Furthermore, the peptide increased the phosphorylation of cAMP response element binding protein, leading to a significant increase in the transactivation of cAMP response element and serum response element. Ultimately, the peptide increased AP 1 transactivation, c jun expression, and bone mineralization, which are suppressed by KN93. Taken together, these results indicate that the novel collagen binding peptide promotes osteogenic differentiation via Ca2+/CaMKII/ERK/AP 1 signaling pathway in hMSC, suggesting the potential application in cell therapy for bone regeneration. (C) 2007 Elsevier Inc. All rights reserved.
C1 [Shin, Min Kyoung; Min, Do Sik] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.
   [Kim, Mi Kyoung; Bae, Yoe Sik] Dong A Univ, Coll Med, Dept Biochem, Pusan, South Korea.
   [Jo, Inho] Ewha Womans Univ, Sch Med, Dept Mol Med, Seoul, South Korea.
   [Lee, Seung Jin] Ewha Womans Univ, Coll Pharm, Dept Ind Pharm, Seoul, South Korea.
   [Chung, Chong Pyoung] Seoul Natl Univ, Sch Dent, Dept Periodontol, Seoul, South Korea.
   [Park, Yoon Jeong] Seoul Natl Univ, Sch Dent, Dept Craniomaxillofacial Reconstruct Sci, Seoul, South Korea.
C3 Pusan National University; Dong A University; Ewha Womans University;
   Ewha Womans University; Seoul National University (SNU); Seoul National
   University (SNU)
RP Min, DS (通讯作者)，Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, 30 Jangjeon Dong, Pusan 609735, South Korea.
EM minds@pusan.ac.kr
RI Jo, Inho/R 3581 2019; KIM, JUNGMO/ABE 2472 2021
CR Barry ELR, 2000, CALCIFIED TISSUE INT, V66, P145, DOI 10.1007/s002230010029
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Boskey AL, 1996, CONNECT TISSUE RES, V35, P357, DOI 10.3109/03008209609029212
   BUTLER WT, 1995, INT J DEV BIOL, V39, P169
   Canalis E, 2005, NEW ENGL J MED, V352, P2014, DOI 10.1056/NEJMe058080
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332
   FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235
   Francis MJO, 2002, INT J BIOCHEM CELL B, V34, P459, DOI 10.1016/S1357 2725(01)00142 X
   Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092 8674(04)00255 7
   Gao JL, 2007, J IMMUNOL, V178, P1450, DOI 10.4049/jimmunol.178.3.1450
   Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378 1119(01)00551 0
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jin JK, 2007, NEUROBIOL AGING, V28, P1015, DOI 10.1016/j.neurobiolaging.2006.05.022
   Kim H, 2005, BIOCHEM BIOPH RES CO, V332, P1053, DOI 10.1016/j.bbrc.2005.05.051
   Kim MK, 2007, FEBS LETT, V581, P1917, DOI 10.1016/j.febslet.2007.03.078
   Lee HY, 2007, BIOCHEM BIOPH RES CO, V359, P985, DOI 10.1016/j.bbrc.2007.06.001
   Lee JY, 2007, BIOCHEM BIOPH RES CO, V357, P68, DOI 10.1016/j.bbrc.2007.03.106
   Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006 291X(03)00124 4
   LYNCH MP, 1995, EXP CELL RES, V216, P35, DOI 10.1006/excr.1995.1005
   MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo 124 1 301
   Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373
   New LG, 2001, J CELL BIOCHEM, V83, P585, DOI 10.1002/jcb.1253
   Noda T, 2005, HORM METAB RES, V37, P270, DOI 10.1055/s 2005 861468
   Pampena DA, 2004, BIOCHEM J, V378, P1083, DOI 10.1042/BJ20031150
   PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Salasznyk RM, 2004, CELL COMMUN ADHES, V11, P137, DOI 10.1080/15419060500242836
   Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101 1020
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200
   Ter Brugge PJ, 2002, TISSUE ENG, V8, P321, DOI 10.1089/107632702753725076
   Tye CE, 2005, J BIOL CHEM, V280, P13487, DOI 10.1074/jbc.M408923200
   Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40
   Weathington NM, 2006, NAT MED, V12, P317, DOI 10.1038/nm1361
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
NR 40
TC 65
Z9 74
U1 2
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD APR
PY 2008
VL 20
IS 4
BP 613
EP 624
DI 10.1016/j.cellsig.2007.11.012
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 284SE
UT WOS:000254725300004
PM 18248957
DA 2025 08 17
ER

PT J
AU Shigematsu, T
   Shimazaki, R
   Fukagawa, M
   Akizawa, T
AF Shigematsu, Takashi
   Shimazaki, Ryutaro
   Fukagawa, Masafumi
   Akizawa, Tadao
CA Evocalcet Study Grp
TI Pharmacodynamics of evocalcet for secondary hyperparathyroidism in
   Japanese hemodialysis patients
SO CLINICAL AND EXPERIMENTAL NEPHROLOGY
LA English
DT Article
DE Calcimimetics; Evocalcet; Hemodialysis; Parathyroid hormone;
   Pharmacodynamics; Secondary hyperparathyroidism
ID CINACALCET HYDROCHLORIDE; BONE DISEASE
AB BackgroundThis study investigated the pharmacokinetics, pharmacodynamics, and safety of multiple doses of evocalcet in Japanese secondary hyperparathyroidism (SHPT) patients receiving hemodialysis.MethodsIn this multicenter, open label study, conducted between August 2013 and March 2014, 27 patients received multiple doses of 1 and 4mg evocalcet for 14 days, followed by an extension period of multiple doses of 8 and 12mg evocalcet for 7days using an intra patient dose escalation protocol. Pharmacodynamic parameters consisted of measurement of intact parathyroid hormone (PTH), serum corrected calcium, serum phosphorus and intact fibroblast growth factor 23 concentrations. Safety was assessed by analysis of adverse events.ResultsPlasma evocalcet levels reached steady state 3 days after the first day of administration. Pharmacodynamic analyses showed that evocalcet effectively reduced intact PTH and serum corrected calcium levels. Adverse events (AEs) occurred in 29.6 and 62.5% of patients receiving multiple doses of 1 or 4mg, respectively. The AE blood calcium decreased' occurred in eight patients (33.0%) after multiple doses of 4mg. All events were mild, except for one patient with a moderate AE (abnormal liver function) and one patient with a severe adverse drug reaction (blood calcium decreased).ConclusionMultiple doses of evocalcet reduced intact PTH levels with a concomitant decrease in serum calcium levels. Evocalcet was well tolerated in SHPT patients receiving hemodialysis.
C1 [Shigematsu, Takashi] Wakayama Med Univ, Dept Nephrol, 811 1 Kimiidera, Wakayama, Wakayama 6418509, Japan.
   [Shimazaki, Ryutaro] Kyowa Hakko Kirin Co Ltd, R&D Div, Chiyoda Ku, 1 9 2 Otemachi, Tokyo 1000004, Japan.
   [Fukagawa, Masafumi] Tokai Univ, Sch Med, Dept Internal Med, Div Nephrol Endocrinol & Metab, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.
   [Akizawa, Tadao] Showa Univ, Sch Med, Dept Med, Div Nephrol,Minato Ku, Namics 301,4 24 51 Takanawa, Tokyo 1080074, Japan.
C3 Wakayama Medical University; Kyowa Kirin Ltd; Tokai University; Showa
   University
RP Shigematsu, T (通讯作者)，Wakayama Med Univ, Dept Nephrol, 811 1 Kimiidera, Wakayama, Wakayama 6418509, Japan.
EM taki@wakayama med.ac.jp
OI Fukagawa, Masafumi/0000 0002 7832 2339
FU Kyowa Hakko Kirin Co., Ltd.
FX This work was sponsored by Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin
   Co., Ltd. was involved in the study design, data collection, data
   analysis, preparation of the manuscript, and the decision to submit the
   manuscript for publication. This clinical trial was registered at
   ClinicalTrials.gov (NCT01935856) and JAPIC (JapicCTI 132255). The
   authors wish to thank James Graham, PhD, of Edanz Medical Writing for
   providing medical writing support, which was funded by Kyowa Hakko Kirin
   Co., Ltd.
CR Akiba T, 2008, THER APHER DIAL, V12, P117, DOI 10.1111/j.1744 9987.2008.00556.x
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Borrego Utiel FJ, 2013, NEFROLOGIA, V33, P272, DOI 10.3265/Nefrologia.pre2012.Oct.11679
   Charytan C, 2005, AM J KIDNEY DIS, V46, P58, DOI 10.1053/j.ajkd.2005.04.013
   Chonchol M, 2009, AM J KIDNEY DIS, V53, P197, DOI 10.1053/j.ajkd.2008.09.021
   Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710
   Drüeke TB, 2000, J AM SOC NEPHROL, V11, P1141, DOI 10.1681/ASN.V1161141
   Elder G, 2002, J BONE MINER RES, V17, P2094, DOI 10.1359/jbmr.2002.17.12.2094
   Kawata T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195316
   Komaba H, 2011, CLIN EXP NEPHROL, V15, P797, DOI 10.1007/s10157 011 0502 5
   Komaba H, 2008, THER APHER DIAL, V12, pS44, DOI 10.1111/j.1744 9987.2008.00631.x
   Martin KJ, 2007, J AM SOC NEPHROL, V18, P875, DOI 10.1681/ASN.2006070771
   Ohashi N, 2004, BRIT J CLIN PHARMACO, V57, P726, DOI 10.1111/j.1365 2125.2004.02088.x
   Palmer SC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001436
   Shigematsu T, 2018, ADV CLIN PHARM APPL
   Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523 1755.1999.07304.x
   Temiz G, 2016, ANATOL J CARDIOL, V16, P520, DOI 10.5152/AnatolJCardiol.2015.6284
   TORRES A, 1995, KIDNEY INT, V47, P1434, DOI 10.1038/ki.1995.201
   Yokoyama K, 2017, CLIN NEPHROL, V88, P68, DOI 10.5414/CN108974
NR 19
TC 9
Z9 9
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1342 1751
EI 1437 7799
J9 CLIN EXP NEPHROL
JI Clin. Exp. Nephrol.
PD FEB
PY 2019
VL 23
IS 2
BP 258
EP 267
DI 10.1007/s10157 018 1635 6
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA HJ9AO
UT WOS:000457491400013
PM 30159688
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Yun, HM
   Kim, B
   Jeong, YH
   Hong, JT
   Park, KR
AF Yun, Hyung Mun
   Kim, Bomi
   Jeong, Yun Hee
   Hong, Jin Tae
   Park, Kyung Ran
TI Suffruticosol A elevates osteoblast differentiation targeting
   BMP2 Smad/1/5/8 RUNX2 in pre osteoblasts
SO BIOFACTORS
LA English
DT Article
DE P; suffruticosa; pre osteoblasts; RUNX2; Suffruticosol A
ID MESENCHYMAL STEM CELLS; PAEONIA SUFFRUTICOSA; AUTOPHAGY PATHWAY; BONE;
   MICE; TRANSCRIPTION; CONSTITUENTS; RUNX2; NECROSTATIN 1; OSTEOPOROSIS
AB The Paeonia suffruticosa ANDR. (P. suffruticosa) is commonly used in traditional medicine for various purposes. Suffruticosol A (Suf A), isolated from P. suffruticosa, is a beneficial compound with antibiofilm, antivirulence, and anti inflammatory properties. The aim of the present study was to investigate the biological effects of Suf A on osteogenic processes in pre osteoblasts. It was determined here in that Suf A (>98.02%), isolated from P. suffruticosa, showed no cytotoxicity at 0.1 30 mu M; however, it induced cytotoxicity at 50 100 mu M in pre osteoblasts. Suf A increased osteogenic alkaline phosphatase activity and expression levels of noncollagenous proteins. Adhesion and trans migration on the extracellular matrix were potentiated by Suf A, but not by wound healing migration. Suf A did not affect autophagy or necroptosis during osteoblast differentiation. We found that Suf A increased runt related transcription factor 2 (RUNX2) levels and mineralized matrix formation. RUNX2 expression was mediated by Suf A induced BMP2 Smad1/5/8 and mitogen activated protein kinase signaling, as demonstrated by Noggin, a BMP2 inhibitor. These results suggest that Suf A is a potential natural osteogenic compound.
C1 [Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul, South Korea.
   [Kim, Bomi; Jeong, Yun Hee] Natl Dev Inst Korean Med, Gyongsan, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Med Res Ctr, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.
   [Park, Kyung Ran] Korea Basic Sci Inst KBSI, Gwangju Ctr, 49 Dosicheomdansanup Ro, Gwangju 61751, South Korea.
C3 Kyung Hee University; Chungbuk National University; Chungbuk National
   University; Korea Basic Science Institute (KBSI)
RP Hong, JT (通讯作者)，Chungbuk Natl Univ, Coll Pharm, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.; Hong, JT (通讯作者)，Chungbuk Natl Univ, Med Res Ctr, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.; Park, KR (通讯作者)，Korea Basic Sci Inst KBSI, Gwangju Ctr, 49 Dosicheomdansanup Ro, Gwangju 61751, South Korea.
EM jinthong@chungbuk.ac.kr; krpark83@kbsi.re.kr
OI Yun, Hyung Mun/0000 0001 6504 1610
FU National Research Foundation of Korea (NRF), Korea government (MSIP)
   [MRC 2017R1A5A2015541, NRF2022R1C1C1003491]
FX National Research Foundation of Korea (NRF), Korea government (MSIP),
   Grant/Award Numbers: MRC 2017R1A5A2015541, NRF2022R1C1C1003491
CR Almosnid NM, 2016, INT J ONCOL, V48, P646, DOI 10.3892/ijo.2015.3269
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Aryaei A, 2014, J BIOMED MATER RES A, V102, P3282, DOI 10.1002/jbm.a.34993
   Broz A, 2017, J BIOMED MATER RES A, V105, P1469, DOI 10.1002/jbm.a.35969
   Cai TG, 2011, BIOL PHARM BULL, V34, P1501, DOI 10.1248/bpb.34.1501
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen LL, 2020, TISSUE CELL, V67, DOI 10.1016/j.tice.2020.101401
   Darcy A, 2012, BONE, V50, P1294, DOI 10.1016/j.bone.2012.03.001
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Donsante S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22083989
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Feng JS, 2011, CELLS TISSUES ORGANS, V194, P216, DOI 10.1159/000324644
   Feng M, 2018, INT J CLIN EXP PATHO, V11, P675
   Feng M, 2014, J STEROID BIOCHEM, V144, P455, DOI 10.1016/j.jsbmb.2014.09.005
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Guo M, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3027954
   Histing T, 2012, J SURG RES, V175, P271, DOI 10.1016/j.jss.2011.03.052
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Islam R, 2017, J CELL PHYSIOL, V232, P2339, DOI 10.1002/jcp.25442
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Kalbacova M, 2010, CARBON, V48, P4323, DOI 10.1016/j.carbon.2010.07.045
   Kanno S, 2001, BIOL TRACE ELEM RES, V83, P49, DOI 10.1385/BTER:83:1:49
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim IR, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1320 9
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Lai PL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.249
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li G, 2004, ARCH PHARM RES, V27, P1123, DOI 10.1007/BF02975116
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   McBride SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096862
   Ogata Y, 2008, J PERIODONTAL RES, V43, P127, DOI 10.1111/j.1600 0765.2007.01014.x
   Park KR, 2021, AM J CHINESE MED, V49, P883, DOI 10.1142/S0192415X21500427
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052483
   Park KR, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153347
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103700
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Ren J, 2017, CARBON LETT, V22, P42, DOI 10.5714/CL.2017.22.042
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Ryu G, 2001, ARCH PHARM RES, V24, P105, DOI 10.1007/BF02976476
   Ryu HW, 2015, J FUNCT FOODS, V17, P774, DOI 10.1016/j.jff.2015.06.036
   Sarker SD, 1999, TETRAHEDRON, V55, P513, DOI 10.1016/S0040 4020(98)01049 7
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Sen B, 2014, J BONE MINER RES, V29, P78, DOI 10.1002/jbmr.2031
   Shi G, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20187844, 10.1590/1414 431x20187844]
   Simoni D, 2009, BIOORGAN MED CHEM, V17, P512, DOI 10.1016/j.bmc.2008.12.002
   Smriti AAC, 2015, P NATL ACAD SCI USA, V112, P15432, DOI 10.1073/pnas.1518253112
   Soelaiman IN, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/764701
   Thomas S, 2022, J CELL COMMUN SIGNAL, V16, P47, DOI 10.1007/s12079 021 00635 1
   Tian Q, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1295382
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Wang X, 2005, J CHROMATOGR A, V1075, P127, DOI 10.1016/j.chroma.2005.04.017
   Yang Y, 2021, J BIOMED MATER RES A, V109, P1429, DOI 10.1002/jbm.a.37134
   Yoshikawa M, 2000, CHEM PHARM BULL, V48, P1327, DOI 10.1248/cpb.48.1327
   Yu ST, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03480 7
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhang JJ, 2019, PHYTOTHER RES, V33, P442, DOI 10.1002/ptr.6240
   Zhang LS, 2010, J BONE MINER RES, V25, P1572, DOI 10.1002/jbmr.36
   Zhao X, 2021, AM J TRANSL RES, V13, P4233
   Zheng LW, 2017, J INVEST MED, V65, P1014, DOI 10.1136/jim 2017 000426
NR 68
TC 8
Z9 8
U1 2
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 6433
EI 1872 8081
J9 BIOFACTORS
JI Biofactors
PD JAN
PY 2023
VL 49
IS 1
BP 127
EP 139
DI 10.1002/biof.1878
EA JUL 2022
PG 13
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA X4KH5
UT WOS:000827017400001
PM 35852295
OA hybrid
DA 2025 08 17
ER

PT J
AU Duan, K
   Fan, YW
   Wang, RZ
AF Duan, K
   Fan, YW
   Wang, RZ
TI Electrolytic deposition of calcium etidronate drug coating on titanium
   substrate
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE drug delivery/release; coating(s); osteolysis; titanium (alloys);
   electrolytic deposition
ID INDUCED BONE RESORPTION; HUMAN OSTEOBLASTS; BISPHOSPHONATES;
   ELECTRODEPOSITION; HYDROXYAPATITE; ALENDRONATE; OSTEOLYSIS; ACID;
   PROLIFERATION; INHIBITION
AB Wear debris induced osteolysis is the major cause of aseptic loosening and failure of hip implants. One of the promising therapeutic interventions to improve the longevity of hip implants is to administrate bisphosphonate drug to inhibit osteoclastic bone resorption. This study aimed at developing new techniques of directly combining bisphosphonate with implants to achieve local delivery and controlled release of the drug. Instead of using soluble sodium salt, we proposed to apply sparingly soluble calcium salt of bisphosphonate as a potential long term antiosteolysis coating on hip implants. Calcium salt of etidronate, a member of the bisphosphonate family of potent osteoclast inhibitors, was used in this pilot study. By adopting the electrolytic deposition (ELD) technique, which was developed for ceramic coatings including calcium phosphates, we demonstrated that a thin layer of calcium bisphosphonate could be deposited onto titanium surface. The drug coating is amorphous as characterized with X ray diffraction, and has globular morphology under the scanning electron microscope. Electrospray ionization mass spectrometry (ESI MS) and Fourier transformed infrared spectroscopy confirmed that the molecular structure of the etidronate (m/z 205, H3L , the single dissociated form of parent etidronic acid, denoted as H4L) was preserved after the ELD process. In vitro release into a "physiological" buffer solution confirmed that the etidronate concentration was limited by its low solubility. The etidronate concentration was 8 x 10( 5) M at day 1 and kept relatively stable at similar to6 x 10( 5) M from day 2 to day 8. The deposition mechanisms of the drug coating and its potential efficacy as an antiosteolytic release source were discussed. (C) 2004 Wiley Periodicals, Inc.
C1 Univ British Columbia, Dept Mat Engn, Vancouver, BC V6T 1Z4, Canada.
C3 University of British Columbia
RP Univ British Columbia, Dept Mat Engn, 309 6350 Stores Rd, Vancouver, BC V6T 1Z4, Canada.
EM rzwang@interchange.ubc.ca
RI Fan, Yuwei/A 2951 2009
OI Fan, Yuwei/0000 0001 8477 8458
CR BROWNING FH, 1995, EFFECT PRECIPITATING, V12, P5231
   Denissen H, 2000, J PERIODONTOL, V71, P272, DOI 10.1902/jop.2000.71.2.272
   FLEISCH H, 2000, BIOPHOSPHONATES BONE
   Ganguli A, 2002, J MATER SCI MATER M, V13, P923, DOI 10.1023/A:1019892109411
   García Moreno C, 1998, BONE, V22, P233, DOI 10.1016/S8756 3282(97)00270 6
   HARRIS WH, 1995, CLIN ORTHOP RELAT R, P46
   Horowitz SM, 1996, J BIOMED MATER RES, V31, P91, DOI 10.1002/(SICI)1097 4636(199605)31:1<91::AID JBM11>3.0.CO;2 P
   Huikko K, 2000, J CHROMATOGR A, V872, P289, DOI 10.1016/S0021 9673(99)01291 1
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   JOHNSTON TP, 1988, J PHARM SCI, V77, P740, DOI 10.1002/jps.2600770903
   Kuo MC, 2002, MAT SCI ENG C BIO S, V20, P153, DOI 10.1016/S0928 4931(02)00026 7
   LIGGETT SJ, 1973, BIOCHEM MED METAB B, V7, P68, DOI 10.1016/0006 2944(73)90100 2
   Little DG, 2003, J BONE MINER RES, V18, P1300, DOI 10.1359/jbmr.2003.18.7.1300
   Meraw SJ, 1999, J PERIODONTOL, V70, P1228, DOI 10.1902/jop.1999.70.10.1228
   Muratoglu OK, 2002, HIP REPLACEMENT: CURRENT TRENDS AND CONTROVERSIES, P1
   NIH Consensus Statement, 1994, TOT HIP REPL, V12, P1
   Osterman T, 1997, J PHARMACOL EXP THER, V280, P1001
   OSTOVIC D, 1995, DRUG DEV IND PHARM, V21, P1157, DOI 10.3109/03639049509026665
   QING XZ, 1994, J CHROMATOGR A, V686, P204
   REDEPENNING J, 1990, CHEM MATER, V2, P625, DOI 10.1021/cm00012a001
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Sabokbar A, 1998, ANN RHEUM DIS, V57, P614, DOI 10.1136/ard.57.10.614
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P849, DOI 10.1002/jor.1100180602
   Shanbhag AS, 1997, CLIN ORTHOP RELAT R, P33
   SHIRKHANZADEH M, 1991, J MATER SCI LETT, V10, P1415, DOI 10.1007/BF00735695
   THOMAS LC, 1974, INTERPRETATION INFRE
   Wright T M., 2001, American Academy of Orthopaedic Surgeons, P3
   Yoshinari M, 2002, BIOMATERIALS, V23, P2879, DOI 10.1016/S0142 9612(01)00415 X
   ZAKI MT, 1984, MICROCHEM J, V30, P6, DOI 10.1016/0026 265X(84)90130 9
   Zhang JM, 1998, J ELECTROANAL CHEM, V452, P235, DOI 10.1016/S0022 0728(98)00107 7
   Zhitomirsky I, 2002, ADV COLLOID INTERFAC, V97, P279, DOI 10.1016/S0001 8686(01)00068 9
NR 31
TC 15
Z9 19
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD JAN 15
PY 2005
VL 72B
IS 1
BP 43
EP 51
DI 10.1002/jbm.b.30112
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 883KU
UT WOS:000226011300006
PM 15389503
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, QY
   Liu, S
   Wang, YH
   Tong, MC
   Sun, HB
   Dong, M
   Lu, Y
   Niu, WD
   Wang, LA
AF Chen, QianYang
   Liu, Shuo
   Wang, Yuhan
   Tong, MeiChen
   Sun, HaiBo
   Dong, Ming
   Lu, Yun
   Niu, WeiDong
   Wang, LiNa
TI Yam Carbon Dots Promote Bone Defect Repair by Modulating Histone
   Demethylase 4B
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE traditional Chinese medicine; carbon dots; YAM; bone defect; KDM4B
ID PARTICLE SIZE; KDM4B; DIFFERENTIATION; EFFICACY; DELIVERY
AB Introduction: Chronic apical periodontitis is a typical inflammatory disease of the oral cavity, the pathology is characterized by an inflammatory reaction with bone defects in the periapical area. Chinese medicine is our traditional medicine, Carbon Dots (CDs) are a new type of nanomaterials. The purpose of this study was to prepare Yam Carbon Dots (YAM CDs) to investigate the mechanism of action of YAM CDs on bone differentiation in vivo and in vitro. Methods: We characterized YAM CDs using transmission electron microscopy (TEM), Fourier Transform Infrared Spectrometer (FTIR), X Ray Diffraction (XRD) and photoluminescence (PL). CCK 8 assay, Real time qPCR, and Western Blot were conducted using bone marrow mesenchymal stem cells (BMSCs) to verify that YAM CDs promote osteoblast differentiation. In addition, we investigated the role of YAM CDs in promoting bone formation in an inflammatory setting in an in vivo mouse model of cranial defects. Results: The results of TEM and PL showed that the YAM CDs mostly consisted of the components C1s, O1s, and N1s. Additionally the average sizes of YAM CDs were 2 6 nm. The quantum yield was 4.44%, with good fluorescence stability and biosafety. Real time qPCR and Western blot analysis showed that YAM CDs promoted osteoblast differentiation under an inflammatory environment by regulating expression of histone demethylase 4B (KDM4B). In vivo, results showed that YAM CDs effectively repaired cranial bone defects in a mouse model and reduced the expression of inflammatory factors under the action of lipopolysaccharides (LPS). Conclusion: YAM CDs promoted the proliferation and differentiation of osteoblasts by regulating the expression of KDM4B to repair cranial bone defects in mice under an LPS induced inflammatory milieu, which will provide a new idea for the treatment of clinical periapical inflammation and other bone defect diseases.
C1 [Chen, QianYang; Liu, Shuo; Wang, Yuhan; Dong, Ming; Lu, Yun; Niu, WeiDong; Wang, LiNa] Dalian Med Univ, Coll Stomatol, Dept Endodont & Periodont, Dalian 116044, Liaoning, Peoples R China.
   [Tong, MeiChen; Sun, HaiBo] Dalian Med Univ, Academician Lab Immune & Oral Dev & Regenerat, Dalian 116044, Liaoning, Peoples R China.
C3 Dalian Medical University; Dalian Medical University
RP Niu, WD; Wang, LA (通讯作者)，Dalian Med Univ, Coll Stomatol, Dept Endodont & Periodont, Dalian 116044, Liaoning, Peoples R China.
EM 13840886663@139.com; wanglina@dmu.edu.cn
FU National Natural Science Foundation of China [82100998, 82270971];
   Liaoning Provincial Natural Science Foundation Joint Fund
   [2023 MSLH 026]; Provincial Basic Scientific Research Project of
   Liaoning Education Department [LJKZ0841]; Liaoning Province Doctor
   Startup Fund [2022 BS 237]; Dalian Science and Technology Innovation
   Fund [2022JJ13SN063]
FX This work was supported by the National Natural Science Foundation of
   China (82100998, 82270971) ; Liaoning Provincial Natural Science
   Foundation Joint Fund (2023 MSLH 026) ; Provincial Basic Scientific
   Research Project of Liaoning Education Department (LJKZ0841) ; Liaoning
   Province Doctor Startup Fund Funded (2022 BS 237) ; Dalian Science and
   Technology Innovation Fund (2022JJ13SN063) . The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ali H, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1617
   Asada Y, 2022, EXP ANIM TOKYO, V71, P161, DOI 10.1538/expanim.21 0049
   Bordukalo Niksic T, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.869422
   Champion JA, 2007, J CONTROL RELEASE, V121, P3, DOI 10.1016/j.jconrel.2007.03.022
   Chen R, 2023, MOLECULES, V28, DOI 10.3390/molecules28062720
   Chen XH, 2023, MOL PHARMACEUT, V21, P173, DOI 10.1021/acs.molpharmaceut.3c00703
   Dehvari K, 2020, ACTA BIOMATER, V114, P343, DOI 10.1016/j.actbio.2020.07.022
   Deng P, 2021, CELL STEM CELL, V28, P1057, DOI 10.1016/j.stem.2021.01.010
   Epping J, 2020, PLANTA, V252, DOI 10.1007/s00425 020 03458 3
   Fu CC, 2024, ORAL DIS, V30, P1861, DOI 10.1111/odi.14702
   Giordano MG, 2023, MOLECULES, V28, DOI 10.3390/molecules28062772
   Gogoi S, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201600271
   Gong QM, 2024, J ADV RES, V66, P349, DOI 10.1016/j.jare.2024.01.018
   Guo ZY, 2023, ACS APPL MATER INTER, V15, P20726, DOI 10.1021/acsami.3c01322
   Hirai K, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 018 0015 0
   Hwang JH, 2023, J CONTROL RELEASE, V355, P184, DOI 10.1016/j.jconrel.2023.01.071
   Javed N, 2021, NANOSCALE ADV, V3, P182, DOI 10.1039/d0na00479k
   Ji YX, 2023, GELS BASEL, V9, DOI 10.3390/gels9090700
   Kanwal A, 2022, BEILSTEIN J NANOTECH, V13, P1068, DOI 10.3762/bjnano.13.93
   Kim Suji, 2014, Prev Nutr Food Sci, V19, P194, DOI 10.3746/pnf.2014.19.3.194
   Lee HL, 2016, STEM CELLS, V34, P711, DOI 10.1002/stem.2231
   Lee KK, 2023, ACTA BIOMATER, V159, P382, DOI 10.1016/j.actbio.2023.01.028
   Li D, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.815479
   Li YZ, 2022, BIOACT MATER, V18, P213, DOI 10.1016/j.bioactmat.2022.03.021
   Liu S, 2024, INT J BIOL MACROMOL, V259, DOI 10.1016/j.ijbiomac.2023.128200
   Liu YB, 2024, WIRES NANOMED NANOBI, V16, DOI 10.1002/wnan.1954
   Liu ZT, 2023, METABOLISM, V138, DOI 10.1016/j.metabol.2022.155337
   Luo JX, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202301366
   Lyu P, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12121737
   Mamidi N, 2023, BIOMACROMOLECULES, V25, P2075, DOI 10.1021/acs.biomac.3c00279
   Ni FJ, 2024, CANCER SCI, V115, P8, DOI 10.1111/cas.16005
   Obidiegwu JE, 2020, FOODS, V9, DOI 10.3390/foods9091304
   Ran Z, 2024, SMALL METHODS, V8, DOI 10.1002/smtd.202301013
   Riekötter J, 2023, FRONT NUTR, V10, DOI 10.3389/fnut.2023.1112793
   Shat JJ, 2020, J CELL PHYSIOL, V235, P2129, DOI 10.1002/jcp.29117
   Shen YZ, 2023, ACTA BIOMATER, V168, P580, DOI 10.1016/j.actbio.2023.07.006
   Sun BH, 2021, J COLLOID INTERF SCI, V584, P505, DOI 10.1016/j.jcis.2020.10.015
   Sun L, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1308004
   Szpalski C, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10201
   Wang HN, 2013, J CONTROL RELEASE, V166, P172, DOI 10.1016/j.jconrel.2012.12.015
   Wang XK, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 01795 5
   Wang ZZ, 2023, CLIN EPIGENETICS, V15, DOI 10.1186/s13148 023 01608 4
   Wang ZZ, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.790129
   Wen FZ, 2023, CARBOHYD POLYM, V311, DOI 10.1016/j.carbpol.2023.120784
   Yang HQ, 2019, EXP CELL RES, V374, P221, DOI 10.1016/j.yexcr.2018.11.027
   Yang MM, 2023, FREE RADICAL BIO MED, V208, P334, DOI 10.1016/j.freeradbiomed.2023.08.020
   Yang YW, 2019, DRUG DISCOV TODAY, V24, P575, DOI 10.1016/j.drudis.2018.10.006
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   Yu DG, 2024, WIRES NANOMED NANOBI, V16, DOI 10.1002/wnan.1964
   Zeng MT, 2023, INT J NANOMED, V18, P6503, DOI 10.2147/IJN.S431061
   Zhang GX, 2020, BIOFACTORS, V46, P788, DOI 10.1002/biof.1670
   Zhang ML, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1118550
   Zhang N, 2019, FOOD RES INT, V122, P191, DOI 10.1016/j.foodres.2019.04.016
   Zhang X, 2021, BIOCHEM GENET, V59, P1427, DOI 10.1007/s10528 021 10042 1
   Zhang Y, 2023, MOLECULES, V28, DOI 10.3390/molecules28041830
   Zhao YS, 2024, ARTIF CELL NANOMED B, V52, P23, DOI 10.1080/21691401.2023.2239522
   Zhao YS, 2020, INT J NANOMED, V15, P9049, DOI 10.2147/IJN.S281976
   Zhu PD, 2022, ACS APPL BIO MATER, V5, P2031, DOI 10.1021/acsabm.1c01215
   Zhu XF, 2024, ACS APPL MATER INTER, V16, P8527, DOI 10.1021/acsami.3c18418
NR 59
TC 6
Z9 7
U1 15
U2 30
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2024
VL 19
BP 10415
EP 10434
DI 10.2147/IJN.S477587
PG 20
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA J2V9X
UT WOS:001335707300001
PM 39430312
OA gold
DA 2025 08 17
ER

PT J
AU Wang, NN
   Xu, PC
   Wang, XP
   Ya, WX
   Yu, ZM
   Wu, RJ
   Huang, XW
   Si, YY
   Shou, D
AF Wang, Nani
   Xu, Pingcui
   Wang, Xuping
   Ya, Weixuan
   Yu, Zhongming
   Wu, Renjie
   Huang, Xiaowen
   Si, Yuyang
   Shou, Dan
TI Integrated pathological cell fishing and network pharmacology approach
   to investigate main active components of Er Xian decotion for treating
   osteoporosis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Traditional Chinese herbal prescription; Osteoblast; Osteoporosis;
   Oxidative stress; Network pharmacology
ID OXIDATIVE STRESS
AB Ethnopharmacological relevance: Oxidative damage to osteoblasts was a key factor in the development of osteoporosis. Er Xian Decotion (EXD) is widely used in China for the treatment of osteoporosis, which has a variety of antioxidant active ingredients. EXD may be an important source of protection against oxidative damage in osteoblasts, but the anti osteoporotic active components of EXD is currently unclear.
   Aim of the study: This work established an effective and reliable drug screening method to find main active ingredients in EXD (M EXD) that can protect osteoblasts against oxidative stress and achieve anti osteoporosis effects.
   Materials and methods: H2O2 induced osteoblast cell fishing with UHPLC QTOF/MS was firstly used to discover the potential active components from EXD. Afterword, the EXD compound osteoporosis target network was constructed using network pharmacology, thus potentially anti osteoporosis ingredients were founded, and their combination were defined as the M EXD. Finally, pharmacology effects of M EXD was evaluated by ovariectomized rats, prednisolone induced zebrafish and H2O2 induced osteoblasts.
   Results: 40 candidate active ingredients in EXD were initially screened out via pathological cell fishing. According to network pharmacology result, M EXD consisted of 13 ingredients since they had a close relationship with 65 osteoporosis related targets. Pharmacological evaluation showed that M EXD significantly ameliorated oxidative stress in H2O2 induced osteoblast model, evidently reversed the activity of ALP, ROS, GSH px, NO and MDA compared with the model group. M EXD showed better anti oxidative activities than individual ingredients, presenting obvious synergetic effects. In osteoporosis rat and zebrafish models, M EXD also demonstrated good anti osteoporotic properties by mitigating the osteoporosis bone loss and increasing serum bone morphogenetic protein 2, and reversing osteocalcin expression in bone tissue. It significantly ameliorated oxidative stress in the in vivo models. Moreover, M EXD and EXD showed similar anti osteoporotic and anti oxidative properties, while the rest components of EXD had no satisfactory anti osteoporotic efficacy.
   Conclusions: Our work successfully identified the main active components in EXD, which could represent the efficacy of EXD on treating osteoporosis, and meanwhile, it also provided an effective strategy to investigate active ingredients from natural medicines, which might be helpful for drug development and application.
C1 [Wang, Nani; Xu, Pingcui; Wang, Xuping; Yu, Zhongming; Wu, Renjie; Huang, Xiaowen; Shou, Dan] Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Zhejiang, Peoples R China.
   [Wang, Nani; Xu, Pingcui] Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou 310053, Zhejiang, Peoples R China.
   [Ya, Weixuan] Zhejiang Police Coll, Dept Criminal Sci & Technol, Key Lab Drug Prevent & Control Technol Zhejiang P, Hangzhou 310053, Zhejiang, Peoples R China.
   [Si, Yuyang] Guerin Coll Preparatory High Sch, Chicago, IL 60171 USA.
C3 Zhejiang Chinese Medical University; Zhejiang Police College
RP Wang, NN; Shou, D (通讯作者)，Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Zhejiang, Peoples R China.
EM wnn8511@163.com; xpc123ok@163.com; 13958147737@163.com;
   yaoweixuan82@163.com; yzm5266@163.com; wurenjie9904122@163.com;
   bowen8883@126.com; Ysi@guerinprep.org; shoudanok@163.com
FU National Natural Science Foundation of China [81603252, 81873062];
   Zhejiang Provincial Natural Science Foundation of China [LQ17H280002];
   National Key Research and Development Program of China [2016YFC080090,
   2018YFC0807201]; Zhejiang Provincial Science and Technology Plan of TCM
   [2019ZA032]; Open Fund Project of First Class Discipline for Science of
   Chinese Pharmacy, Zhejiang Chinese Medical University [Ya2017008]
FX The work was supported by the National Natural Science Foundation of
   China (No. 81603252, 81873062), Zhejiang Provincial Natural Science
   Foundation of China (No. LQ17H280002), National Key Research and
   Development Program of China (No. 2016YFC080090; No. 2018YFC0807201),
   Zhejiang Provincial Science and Technology Plan of TCM (No. 2019ZA032)
   and the Open Fund Project of First Class Discipline for Science of
   Chinese Pharmacy, Zhejiang Chinese Medical University (Ya2017008).
CR Al Daghri NM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005780
   Bergen DJM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00006
   Cao XX, 2018, MOLECULES, V23, DOI 10.3390/molecules23092307
   Chen JH, 2018, NUTR METAB, V15, DOI 10.1186/s12986 018 0306 7
   Di Nardo P, 2017, METHODS MOL BIOL, V1553, P145, DOI 10.1007/978 1 4939 6756 8_11
   Geng QH, 2019, INT J BIOL SCI, V15, P58, DOI 10.7150/ijbs.25783
   Gong X, 2017, SCI REP UK, V7, DOI 10.1038/srep36129
   Guo J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013077
   Ilaria L., 2018, CLIN INTERV AGING, V13, P757
   Kim J, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090585
   Lewiecki EM, 2019, J DRUG ASSESS, V8, P25, DOI 10.1080/21556660.2019.1579728
   Lin YP, 2019, BIOMED OPT EXPRESS, V10, P1184, DOI 10.1364/BOE.10.001184
   Lu XZ, 2017, EUR REV MED PHARMACO, V21, P4762
   Negoro R, 2018, STEM CELL REP, V11, P1539, DOI 10.1016/j.stemcr.2018.10.019
   Ning K, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7573904
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shin H, 2018, J PHARMACEUT BIOMED, V148, P355, DOI 10.1016/j.jpba.2017.10.018
   Tarantino U, 2017, J ORTHOP TRAUMATOL, V18, pS3, DOI 10.1007/s10195 017 0474 7
   Wang S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00174
   Wang Y, 2012, ACTA BIOCH BIOPH SIN, V44, P431, DOI 10.1093/abbs/gms014
   Wang ZY, 2018, MOLECULES, V23, DOI 10.3390/molecules23102631
   Wu D, 2019, MOLECULES, V24, DOI 10.3390/molecules24010021
   Yoon Byung Ho, 2019, J Bone Metab, V26, P51, DOI 10.11005/jbm.2019.26.1.51
   Zhang HM, 2018, MOLECULES, V23, DOI 10.3390/molecules23071656
   Zhang W., 2019, EVID BAS COMPL ALTER, P1
   Zhang ZG, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906 018 2311 9
NR 27
TC 30
Z9 36
U1 3
U2 82
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD SEP 15
PY 2019
VL 241
AR 111977
DI 10.1016/j.jep.2019.111977
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA IP9MS
UT WOS:000480374900010
PM 31136804
DA 2025 08 17
ER

PT J
AU Lin, XF
   Wang, QQ
   Gu, CH
   Li, MB
   Chen, K
   Chen, PF
   Tang, ZB
   Liu, X
   Pan, HH
   Liu, ZM
   Tang, RK
   Fan, SW
AF Lin, Xianfeng
   Wang, Qingqing
   Gu, Chenhui
   Li, Mobai
   Chen, Kai
   Chen, Pengfei
   Tang, Zhibin
   Liu, Xin
   Pan, Haihua
   Liu, Zhaoming
   Tang, Ruikang
   Fan, Shunwu
TI Smart Nanosacrificial Layer on the Bone Surface Prevents Osteoporosis
   through Acid Base Neutralization Regulated Biocascade Effects
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID DRUG DELIVERY; ATTACHMENT; CALCIUM; PH
AB Osteoporosis is a global chronic disease characterized by severe bone loss and high susceptibility to fragile fracture. It is widely accepted that the origin acidified micro environment created by excessive osteoclasts causes irreversible bone mineral dissolution and organic degradation during osteoclastic resorption. However, current clinically available approaches are mainly developed from the perspective of osteoclast biology rather than the critical acidified niche. Here, we developed a smart "nanosacrificial layer" consisting of sodium bicarbonate (NaHCO3) containing and tetracycline functionalized nanoliposomes (NaHCO3 TNLs) that can target bone surfaces and respond to external secreted acidification from osteoclasts, preventing osteoporosis. In vitro and in vivo results prove that this nanosacrificial layer precisely inhibits the initial acidification of osteoclasts and initiates a chemically regulated biocascade to remodel the bone microenvironment and realize bone protection: extracellular acid base neutralization first inhibits osteoclast function and also promotes its apoptosis, in which the apoptosis derived extracellular vesicles containing RANK (receptor activator of nuclear factor kappa B) further consume RANKL (RANK ligand) in serum, achieving comprehensive osteoclast inhibition. Our therapeutic strategy for osteoporosis is based on original and precise acid base neutralization, aiming to reestablish bone homeostasis by using a smart nanosacrificial layer that is able to induce chemically regulated biocascade effects. This study also provides a novel understanding of osteoporosis therapy in biomedicine and clinical treatments.
C1 [Lin, Xianfeng; Wang, Qingqing; Gu, Chenhui; Li, Mobai; Chen, Pengfei; Tang, Zhibin; Liu, Xin; Fan, Shunwu] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Med Coll, Hangzhou 310016, Zhejiang, Peoples R China.
   [Lin, Xianfeng; Wang, Qingqing; Gu, Chenhui; Li, Mobai; Chen, Pengfei; Tang, Zhibin; Liu, Xin; Fan, Shunwu] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou 310016, Zhejiang, Peoples R China.
   [Chen, Kai] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Pan, Haihua; Liu, Zhaoming; Tang, Ruikang] Zhejiang Univ, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.
   [Pan, Haihua; Liu, Zhaoming; Tang, Ruikang] Zhejiang Univ, Ctr Biomat & Biopathways, Hangzhou 310027, Zhejiang, Peoples R China.
C3 Zhejiang University; University of Western Australia; Zhejiang
   University; Zhejiang University
RP Fan, SW (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Med Coll, Hangzhou 310016, Zhejiang, Peoples R China.; Fan, SW (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou 310016, Zhejiang, Peoples R China.; Liu, ZM; Tang, RK (通讯作者)，Zhejiang Univ, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.; Liu, ZM; Tang, RK (通讯作者)，Zhejiang Univ, Ctr Biomat & Biopathways, Hangzhou 310027, Zhejiang, Peoples R China.
EM oldliu@zju.edu.cn; rtang@zju.edu.cn; shunwu_fan@zju.edu.cn
RI ; Chen, KaiJie/A 1743 2016; Pan, Haihua/O 7512 2018; Lin,
   Xianfeng/ABA 2917 2020; Gu, Chenhui/KHT 4806 2024; Wang,
   Qingqing/E 7972 2014
OI Gu, Chenhui/0000 0002 8698 9395; Chen, Pengfei/0000 0003 1484 2850; Lin,
   xianfeng/0000 0003 1871 774X; Chen, Kai/0000 0001 6850 1723; 
FU National Key R&D Program of China [2018YFC1105203]; National Nature
   Science Fund of China [81702143]
FX The study was supported by the National Key R&D Program of China (Grant
   No. 2018YFC1105203) and the National Nature Science Fund of China (Grant
   No. 81702143). We thank Wu Lingyun and Yang Ping in the Center of
   CryoElectron Microscopy (CCEM), Zhejiang University for their technical
   assistance on cryo TEM.
CR ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3582
   Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Bab I. A., 2012, PRINCIPLES BONE REGE
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022 2836(65)80093 6
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen KJ, 2014, ACS NANO, V8, P5105, DOI 10.1021/nn501162x
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Fink HA, 2019, ANN INTERN MED, V171, P37, DOI 10.7326/M19 0533
   Gartrell BA, 2014, EUR UROL, V65, P278, DOI 10.1016/j.eururo.2013.05.015
   Gerry AB, 2014, ATHEROSCLEROSIS, V233, P537, DOI 10.1016/j.atherosclerosis.2014.01.014
   He CB, 2014, J AM CHEM SOC, V136, P12253, DOI 10.1021/ja507333c
   Jaber S, 2018, LANCET, V392, P31, DOI 10.1016/S0140 6736(18)31080 8
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   Kuyper CL, 2006, J AM CHEM SOC, V128, P3233, DOI 10.1021/ja057349c
   Lee NK, 2010, ENDOCRINOL METAB, V25, P264, DOI 10.3803/EnM.2010.25.4.264
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Meyerhoff A, 1999, CLIN INFECT DIS, V28, P42, DOI 10.1086/515085
   Mo R, 2016, MATER TODAY, V19, P274, DOI 10.1016/j.mattod.2015.11.025
   Nilsson Cathrine, 2003, Methods Cell Sci, V25, P185
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Pick H, 2018, CHEM REV, V118, P8598, DOI 10.1021/acs.chemrev.7b00777
   Poon IKH, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1608786
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Stenbeck G, 2004, J CELL SCI, V117, P827, DOI 10.1242/jcs.00935
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   TETI A, 1989, J CLIN INVEST, V84, P773, DOI 10.1172/JCI114235
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Veerman RE, 2019, TRENDS MOL MED, V25, P382, DOI 10.1016/j.molmed.2019.02.003
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wesson DE, 2019, LANCET, V393, P1417, DOI 10.1016/S0140 6736(18)32562 5
   Wu MH, 2019, J AMB INTEL HUM COMP, V10, P439, DOI 10.1007/s12652 017 0660 8
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Yamaki M, 2005, ARCH BIOCHEM BIOPHYS, V440, P10, DOI 10.1016/j.abb.2005.05.021
   Zhang ZH, 2018, INTENS CARE MED, V44, P1888, DOI 10.1007/s00134 018 5379 2
   Zhao JY, 2019, J BONE MINER RES, V34, P2149, DOI 10.1002/jbmr.3832
   Zhao WN, 2019, MAR DRUGS, V17, DOI 10.3390/md17060342
NR 41
TC 64
Z9 70
U1 10
U2 178
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002 7863
EI 1520 5126
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD OCT 14
PY 2020
VL 142
IS 41
BP 17543
EP 17556
DI 10.1021/jacs.0c07309
PG 14
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA OC8IO
UT WOS:000579400400042
PM 32960592
DA 2025 08 17
ER

PT J
AU Zhao, XD
   Pathak, JL
   Huang, WY
   Zhu, CD
   Li, YY
   Guan, HB
   Zeng, SJ
   Ge, LH
   Shu, Y
AF Zhao, Xuedan
   Pathak, Janak L.
   Huang, Wenyan
   Zhu, Chuandong
   Li, Yunyang
   Guan, Hongbing
   Zeng, Sujuan
   Ge, Linhu
   Shu, Yan
TI Metformin enhances osteogenic differentiation of stem cells from human
   exfoliated deciduous teeth through AMPK pathway
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE AMPK signaling; metformin; osteogenesis; SHEDs; tissue engineering
ID ANTIDIABETIC DRUG METFORMIN; SKELETAL DEVELOPMENT; FRACTURE RISK; BONE
   MASS; OSTEOBLAST
AB Stem cells from human exfoliated deciduous teeth (SHEDs) are ideal seed cells in bone tissue engineering. As a first line antidiabetic drug, metformin has recently been found to promote bone formation. The purpose of this study was to investigate the effect of metformin on the osteogenic differentiation of SHEDs and its underlying mechanism. SHEDs were isolated from the dental pulp of deciduous teeth from healthy children aged 6 to 12, and their surface antigen markers of stem cells were detected by flow cytometry. The effect of metformin (10 200 mu M) treatment on SHEDs cell viability, proliferation, and osteogenic differentiation was analyzed. The activation of adenosine 5 ' monophosphate activated protein kinase (AMPK) phosphorylation Thr172 (p AMPK) was determined by western blot assay. SHEDs were confirmed as mesenchymal stem cells (MSCs) on the basis of the expression of characteristic surface antigens. Metformin (10 200 mu M) did not affect the viability and proliferation of SHEDs but significantly increased the expression of osteogenic genes, alkaline phosphatase activity, matrix mineralization, and p AMPK level expression in SHEDs. Compound C, a specific inhibitor of the AMPK pathway, abolished metformin induced osteogenic differentiation of SHEDs. Moreover, metformin treatment enhanced the expression of proangiogenic/osteogenic growth factors BMP2 and VEGF but reduced the osteoclastogenic factor RANKL/OPG expression in SHEDs. In conclusion, metformin could induce the osteogenic differentiation of SHEDs by activating the AMPK pathway and regulates the expression of proangiogenic/osteogenic growth factors and osteoclastogenic factors in SHEDs. Therefore, metformin pretreated SHEDs could be a potential source of seed cells during stem cell based bone tissue engineering.
C1 [Zhao, Xuedan; Pathak, Janak L.; Huang, Wenyan; Zhu, Chuandong; Li, Yunyang; Guan, Hongbing; Zeng, Sujuan; Ge, Linhu; Shu, Yan] Guangzhou Med Univ, Affiliated Stomatol Hosp, Dept Pediat Dent, Guangzhou Key Lab Basic & Appl Res Oral Regenerat, Guangzhou 510182, Peoples R China.
   [Pathak, Janak L.; Ge, Linhu] Guangzhou Med Univ, Inst Oral Dis, Guangzhou, Peoples R China.
   [Shu, Yan] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
C3 Guangzhou Medical University; Guangzhou Medical University; University
   System of Maryland; University of Maryland Baltimore
RP Zeng, SJ; Ge, LH (通讯作者)，Guangzhou Med Univ, Affiliated Stomatol Hosp, Dept Pediat Dent, Guangzhou Key Lab Basic & Appl Res Oral Regenerat, Guangzhou 510182, Peoples R China.; Shu, Y (通讯作者)，Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
EM 785327008@qq.com; gelinhu@yeah.net; yshu@rx.umaryland.edu
RI ; Pathak, Janak Lal/ACU 7302 2022; zhu, chuandong/JSK 3835 2023
OI ge, linhu/0000 0001 9315 3740; 
FU Guangzhou Science Technology and Innovation Commission [201707010026];
   Guangdong Science and Technology Department [2017A020215141]
FX Guangzhou Science Technology and Innovation Commission, Grant/Award
   Number: 201707010026; Guangdong Science and Technology Department,
   Grant/Award Number: 2017A020215141
CR Akpinar G, 2014, STEM CELLS INT, V2014, DOI 10.1155/2014/457059
   Al Jofi FE, 2018, CYTOTHERAPY, V20, P650, DOI 10.1016/j.jcyt.2018.02.369
   Al Rifai O, 2017, J CLIN INVEST, V127, P4104, DOI 10.1172/JCI93437
   Aljofi F., 2017, METFORMIN MESENCHYMA
   Bailey CJ., 2004, Pract Diab Int, V21, P115, DOI [10.1002/pdi.606, DOI 10.1002/PDI.606]
   Bigham Sadegh A, 2015, CONNECT TISSUE RES, V56, P175, DOI 10.3109/03008207.2015.1027341
   Carnevale V, 2004, DIABETES METAB RES, V20, P196, DOI 10.1002/dmrr.449
   Chava S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0791 7
   Ching HS, 2017, CURR STEM CELL RES T, V12, P71, DOI 10.2174/1574888X11666160815095733
   Claesson Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Gay IC, 2007, ORTHOD CRANIOFAC RES, V10, P149, DOI 10.1111/j.1601 6343.2007.00399.x
   Gu QL, 2017, TOHOKU J EXP MED, V241, P13, DOI 10.1620/tjem.241.13
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Jeyabalan J, 2013, OSTEOPOROSIS INT, V24, P2659, DOI 10.1007/s00198 013 2371 0
   Kanazawa I, 2018, ENDOCRINOLOGY, V159, P597, DOI 10.1210/en.2017 00357
   Khojasteh A, 2015, WORLD J STEM CELLS, V7, P1215, DOI 10.4252/wjsc.v7.i10.1215
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Lin H, 2017, BBA MOL CELL RES, V1864, P2369, DOI 10.1016/j.bbamcr.2017.08.009
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535 7163.MCT 13 0579
   Ma L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051777
   Ma WQ, 2019, MOL CELL ENDOCRINOL, V479, P39, DOI 10.1016/j.mce.2018.08.012
   Martin MJ, 2012, CANCER DISCOV, V2, P344, DOI 10.1158/2159 8290.CD 11 0280
   Marycz K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4710326
   Melton LJ, 2008, J BONE MINER RES, V23, P1334, DOI 10.1359/JBMR.080323
   Orciani M, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00017
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Pierotti MA, 2013, ONCOGENE, V32, P1475, DOI 10.1038/onc.2012.181
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Shu Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558
   Smolders EJ, 2017, BRIT J CLIN PHARMACO, V83, P2225, DOI 10.1111/bcp.13323
   Tan MH, 2016, ENDOCRIN METAB CLIN, V45, P819, DOI 10.1016/j.ecl.2016.06.008
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Xiao CW, 2011, BIOMED MATER, V6, DOI 10.1088/1748 6041/6/1/015013
   Xie J, 2019, Beijing Da Xue Xue Bao Yi Xue Ban, V51, P900
   Yamaguchi N, 2008, FEBS LETT, V582, P451, DOI 10.1016/j.febslet.2007.12.037
NR 45
TC 28
Z9 31
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD DEC
PY 2020
VL 14
IS 12
BP 1869
EP 1879
DI 10.1002/term.3142
EA OCT 2020
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA PF5JX
UT WOS:000583607900001
PM 33049108
OA gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Kurucu, N
   Akyuz, C
   Ergen, FB
   Yalcin, B
   Kosemehmetoglu, K
   Ayvaz, M
   Varan, A
   Aydin, B
   Kutluk, T
AF Kurucu, Nilgun
   Akyuz, Canan
   Ergen, Fatma Bilge
   Yalcin, Bilgehan
   Kosemehmetoglu, Kemal
   Ayvaz, Mehmet
   Varan, Ali
   Aydin, Burca
   Kutluk, Tezer
TI Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE aneurysmal bone cyst; benign bone tumors; denosumab
ID GIANT CELL TUMOR; THERAPY; HYPERCALCEMIA
AB Background: Aneurysmal bone cyst (ABC) is a benign bone tumor. Curettage and bone grafting is the common treatment. Here, we retrospectively evaluate nine patients treated with denosumab.
   Procedure: Nine patients with ABC, mostly pelvic and vertebral, treated with denosumab were analyzed retrospectively. A 70 mg/m(2) denosumab dose was used weekly in the first month, and then monthly. Clinical and radiological responses to treatment were evaluated.
   Results: In all patients, clinical symptoms including pain and limping regressed completely within 3 months. Radiological evaluation revealed changes in lesion size and content. In six patients, overall volume reduction in the range of 18 82% was detected. Decreases in the size and number of cysts were detected in eight patients. In five patients, fat signal appeared on follow up imaging. No major side effects were observed during treatment. Median follow up time after treatment was 15 months. At 5 months, severe hypercalcemia was observed in two patients due to rebound increase in osteoclastic activity. Subsequent to denosumab treatment, three patients underwent surgery for clinical or radiological recurrence.
   Conclusions: Our results showed that denosumab provided a meaningful clinical and radiological improvement in ABC. It may be a treatment option, especially in spinal and pelvic tumors with potentially high surgical morbidity. However, late rebound hypercalcemia may restrict its use. Studies with more cases are required for routine use of denosumab in ABC.
C1 [Kurucu, Nilgun; Akyuz, Canan; Yalcin, Bilgehan; Varan, Ali; Aydin, Burca; Kutluk, Tezer] Hacettepe Univ, Dept Pediat Oncol, Fac Med, Ankara, Turkey.
   [Ergen, Fatma Bilge] Hacettepe Univ, Dept Radiol, Fac Med, Ankara, Turkey.
   [Kosemehmetoglu, Kemal] Hacettepe Univ, Dept Pathol, Fac Med, Ankara, Turkey.
   [Ayvaz, Mehmet] Hacettepe Univ, Dept Orthopedia, Fac Med, Ankara, Turkey.
C3 Hacettepe University; Hacettepe University; Hacettepe University;
   Hacettepe University
RP Kurucu, N (通讯作者)，Hacettepe Univ, Dept Pediat Oncol, Fac Med, Ankara, Turkey.
EM nkurucu@hacettepe.edu.tr
RI Aydin, Burca/K 5807 2012; Kutluk, Tezer/AGM 2157 2022; Kosemehmetoglu,
   Kemal/A 2423 2016; ERGEN, FATMA/I 9176 2013
CR Boyce AM, 2017, CURR OSTEOPOROS REP, V15, P283, DOI 10.1007/s11914 017 0380 1
   Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chang CY, 2017, SKELETAL RADIOL, V46, P35, DOI 10.1007/s00256 016 2503 7
   Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397
   Dubory A, 2016, SPINE, V41, pE654, DOI 10.1097/BRS.0000000000001350
   Ghermandi R, 2016, EUR REV MED PHARMACO, V20, P3692
   Hakim DN, 2015, J BONE ONCOL, V4, P37, DOI 10.1016/j.jbo.2015.02.001
   Lange J, 2006, INT J ORAL MAXILLOF, V35, P865
   Lange T, 2013, EUR SPINE J, V22, P1417, DOI 10.1007/s00586 013 2715 7
   Mahnken AH, 2003, EUR RADIOL, V13, P1118, DOI 10.1007/s00330 002 1668 8
   Mascard E, 2015, ORTHOP TRAUMATOL SUR, V101, pS119, DOI 10.1016/j.otsr.2014.06.031
   Mohanty S, 2009, MED ORAL PATOL ORAL, V14, pE98
   Park HY, 2016, CURR REV MUSCULOSKE, V9, P435, DOI 10.1007/s12178 016 9371 6
   Pauli C, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477 7819 12 17
   Pelle DW, 2014, TRANSL RES, V164, P139, DOI 10.1016/j.trsl.2014.03.005
   Rapp TB, 2012, J AM ACAD ORTHOP SUR, V20, P233, DOI 10.5435/JAAOS 20 04 233
   Rasgoti S, 2006, J BONE JOINT SURG BR, V88, P12
   Schreuder WH, 2017, J CRANIO MAXILL SURG, V45, P232, DOI 10.1016/j.jcms.2016.11.011
   Setsu N, 2016, J BONE MINER METAB, V34, P118, DOI 10.1007/s00774 015 0677 z
   Skubitz KM, 2015, SPINE, V40, pE1201, DOI 10.1097/BRS.0000000000001027
   Solling ASK, 2016, OSTEOPOROSIS INT, V27, P2383, DOI 10.1007/s00198 016 3535 5
   Wang HD, 2014, J CLIN ENDOCR METAB, V99, P891, DOI 10.1210/jc.2013 3081
   Won KY, 2011, PATHOLOGY, V43, P318, DOI 10.1097/PAT.0b013e3283463536
   Wu PF, 2015, TUMOR BIOL, V36, P495, DOI 10.1007/s13277 015 3094 y
   Wülling M, 2001, J CANCER RES CLIN, V127, P467, DOI 10.1007/s004320100234
   Yamagishi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154680
   Zeitlin L, 2003, PEDIATRICS, V111, P1030, DOI 10.1542/peds.111.5.1030
NR 28
TC 63
Z9 64
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1545 5009
EI 1545 5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD APR
PY 2018
VL 65
IS 4
AR e26926
DI 10.1002/pbc.26926
PG 7
WC Oncology; Hematology; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology; Pediatrics
GA FW9FW
UT WOS:000425642100027
PM 29286564
DA 2025 08 17
ER

PT J
AU Zaugg, LK
   Banu, A
   Walther, AR
   Chandrasekaran, D
   Babb, RC
   Salzlechner, C
   Hedegaard, MAB
   Gentleman, E
   Sharpe, PT
AF Zaugg, L. K.
   Banu, A.
   Walther, A. R.
   Chandrasekaran, D.
   Babb, R. C.
   Salzlechner, C.
   Hedegaard, M. A. B.
   Gentleman, E.
   Sharpe, P. T.
TI Translation Approach for Dentine Regeneration Using GSK 3 Antagonists
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE repair; stem cells; mineralization; Raman microspectroscopy; pulp; Wnt
   signaling
ID TIDEGLUSIB; TRIAL
AB The canonical Wnt/beta catenin signaling pathway is crucial for reparative dentinogenesis following tooth damage, and the modulation of this pathway affects the rate and extent of reparative dentine formation in damaged mice molars by triggering the natural process of dentinogenesis. Pharmacological stimulation of Wnt/beta catenin signaling activity by small molecule GSK 3 inhibitor drugs following pulp exposure in mouse molars results in reparative dentinogenesis. The creation of similar but larger lesions in rat molars shows that the adenosine triphosphate (ATP) competitive GSK 3 inhibitor, CHIR99021 (CHIR), and the ATP noncompetitive inhibitor, Tideglusib (TG), can equally enhance reparative dentine formation to fully repair an area of dentine damage up to 10 times larger, mimicking the size of small lesions in humans. To assess the chemical composition of this newly formed dentine and to compare its structure with surrounding native dentine and alveolar bone, Raman microspectroscopy analysis is used. We show that the newly formed dentine comprises equal carbonate to phosphate ratios and mineral to matrix ratios to that of native dentine, both being significantly different from bone. For an effective dentine repair, the activity of the drugs needs to be restricted to the region of damage. To investigate the range of drug induced Wnt activity within the dental pulp, RNA of short term induced (24 h) molars is extracted from separated roots and crowns, and quantitative Axin2 expression is assayed. We show that the activation of Wnt/beta catenin signaling is highly restricted to pulp cells in the immediate location of the damage in the coronal pulp tissue with no drug action detected in the root pulp. These results provide further evidence that this simple method of enhancement of natural reparative dentinogenesis has the potential to be translated into a clinical direct capping approach.
C1 [Zaugg, L. K.; Banu, A.; Walther, A. R.; Chandrasekaran, D.; Babb, R. C.; Salzlechner, C.; Gentleman, E.; Sharpe, P. T.] Kings Coll London, Ctr Craniofacial & Regenerat Biol, Floor 28, London SE1 9RT, England.
   [Zaugg, L. K.] Univ Basel, Univ Ctr Dent Med, Dept Reconstruct Dent, Basel, Switzerland.
   [Walther, A. R.; Hedegaard, M. A. B.] Univ Southern Denmark, Dept Chem Engn Biotechnol & Environm Technol, Odense, Denmark.
C3 University of London; King's College London; University of Basel;
   University of Southern Denmark
RP Sharpe, PT (通讯作者)，Kings Coll London, Ctr Craniofacial & Regenerat Biol, Floor 28, London SE1 9RT, England.
EM paul.sharpe@kcl.ac.uk
RI ; Hedegaard, Martin/X 9953 2018; Walther, Anders Runge/O 7999 2018;
   Walther, Anders/O 7999 2018; Hedegaard, Martin A.B./X 9953 2018
OI Gentleman, Eileen/0000 0003 0447 5137; Zaugg, Lucia/0000 0002 4640 7274;
   Banu, Arshiya/0000 0003 1987 5774; Walther, Anders
   Runge/0000 0003 4940 2644; Hedegaard, Martin A.B./0000 0003 2972 0899;
   Salzlechner, Christoph/0000 0002 1124 513X
FU Swiss National Science Foundation [P300PB_167807]; National Institute
   for Health Research's Biomedical Research Centre based at Guy's and St
   Thomas's NHS Foundation Trust and King's College London; Swiss National
   Science Foundation (SNF) [P300PB_167807] Funding Source: Swiss National
   Science Foundation (SNF)
FX We thank all the CCRB laboratory technicians for their support,
   especially Chris Healy for mCT imaging, Alasdair Edgar for tissue
   processing, and Susmitha Rao for supporting tissue culture. This
   research was supported by the Swiss National Science Foundation (Ref
   P300PB_167807) and the National Institute for Health Research's
   Biomedical Research Centre based at Guy's and St Thomas's NHS Foundation
   Trust and King's College London. The views expressed are those of the
   authors and not necessarily those of the NHS, the National Institute for
   Health Research, or the Department of Health. The authors declare no
   potential conflicts of interest with respect to the authorship and/or
   publication of this article.
CR Babb RC, 2019, METHODS MOL BIOL, V1922, P111, DOI 10.1007/978 1 4939 9012 2_11
   Babb R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03145 6
   Bakhtiar H, 2017, J ENDODONT, V43, P1786, DOI 10.1016/j.joen.2017.06.025
   Chailertvanitkul P, 2014, INT ENDOD J, V47, P835, DOI 10.1111/iej.12225
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   Cvek M, 1978, J Endod, V4, P232, DOI 10.1016/S0099 2399(78)80153 8
   del Ser T, 2013, J ALZHEIMERS DIS, V33, P205, DOI 10.3233/JAD 2012 120805
   Eilers PHC, 2003, ANAL CHEM, V75, P3631, DOI 10.1021/ac034173t
   Leone A, 2012, CELL TISSUE RES, V348, P465, DOI 10.1007/s00441 012 1379 7
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Lovestone S, 2015, J ALZHEIMERS DIS, V45, P75, DOI 10.3233/JAD 141959
   Mandair GS, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2014.115
   Morris MD, 2011, CLIN ORTHOP RELAT R, V469, P2160, DOI 10.1007/s11999 010 1692 y
   National Center for the Replacement Refinement and Reduction of Animals in Research, 2019, MUCH BLOOD DOES RAT
   Neves VCM, 2017, SCI REP UK, V7, DOI 10.1038/srep39654
   Peng JT, 2010, ANAL CHIM ACTA, V683, P63, DOI 10.1016/j.aca.2010.08.033
   Ricucci D, 2019, J DENT, V86, P41, DOI 10.1016/j.jdent.2019.05.022
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Tarnowski CP, 2002, J BONE MINER RES, V17, P1118, DOI 10.1359/jbmr.2002.17.6.1118
   Wallace JM, 2009, J BONE MINER RES, V24, P1002, DOI [10.1359/JBMR.081259, 10.1359/jbmr.081259]
   Wang RZ, 2005, DENT MATER, V21, P429, DOI 10.1016/j.dental.2004.07.008
   Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185
   Zhang YR, 2014, INT J ORAL SCI, V6, P61, DOI 10.1038/ijos.2014.21
   Ziskind D, 2011, J STRUCT BIOL, V174, P23, DOI 10.1016/j.jsb.2010.09.010
NR 25
TC 45
Z9 45
U1 0
U2 22
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD MAY
PY 2020
VL 99
IS 5
BP 544
EP 551
AR 0022034520908593
DI 10.1177/0022034520908593
EA MAR 2020
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA LG0AY
UT WOS:000524562300001
PM 32156176
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Tang, L
   Lu, WJ
   Huang, J
   Tang, X
   Zhang, HY
   Liu, SJ
AF Tang, Ling
   Lu, Wenjun
   Huang, Jian
   Tang, Xu
   Zhang, Huiyun
   Liu, Shujiao
TI miR 144 promotes the proliferation and differentiation of bone
   mesenchymal stem cells by downregulating the expression of SFRP1
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE microRNA 144; proliferation; differentiation; bone mesenchymal stem
   cells; secreted frizzled related protein 1
ID SIGNALING PATHWAY; SUPPRESSES PROLIFERATION; THERAPEUTIC TARGET;
   UP REGULATION; CANCER CELLS; TGF BETA; OSTEOBLASTS; OSTEOPOROSIS;
   HOMEOSTASIS; MIGRATION
AB Osteoporosis (OP) seriously affects the health and quality of life of elderly individuals and postmenopausal women, and the need to identify drugs that can prevent or treat OP remains urgent. Recently, several miRNAs have been reported to be involved in the differentiation of mesenchymal stem cells and osteoblasts; however, the role of miRNA (miR) 144 in regulating OP remains to be elucidated. In the present study, the expression levels of miR 144, secreted frizzled related protein 1 (Sfrp1) and TNF alpha in clinical samples were detected by the reverse transcription quantitative polymerase chain reaction analysis and ELISA, respectively. 5 Ethynyl 2 ' deoxyuridine staining, Hoechst 33258 staining, flow cytometry, a clone formation assay and Alizarin red staining were used to assess the effects of miR 144 combined with or without Sfrp1 small interfering RNA on the proliferation, apoptosis and osteoblastic differentiation of primary mesenchymal stem cells isolated from rats. Western blot assays were performed to assess the relevant mechanisms, and a dual luciferase reporter assay was used to detect the interaction between miR 144 and Sfrp1. The results showed that the levels of miR 144, Sfrp1 and TNF alpha in clinical serum samples obtained from patients with postmenopausal OP were higher than those in serum samples obtained from postmenopausal women with normal bone density. There was a significant positive correlation between miR 144 and Sfrp1. Functional experiments demonstrated that miR 144 promoted proliferation, inhibited apoptosis and induced the osteoblastic differentiation of bone marrow derived mesenchymal stem cells by targeting Sfrp1. It was also shown that miR 144 may help regulate OP by activating the Wnt/beta catenin pathway. These data suggest miR 144 as a novel target for preventing and treating OP.
C1 [Tang, Ling; Lu, Wenjun; Liu, Shujiao] Guilin Med Univ, Dept Geriatr, Affiliated Hosp, 15 Lequn Rd, Guilin 541001, Guangxi, Peoples R China.
   [Huang, Jian] Guilin Med Univ, Dept Cell Biol & Genet, Guilin 541001, Guangxi, Peoples R China.
   [Tang, Xu] Guangxi Med Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Nanning 530021, Guangxi, Peoples R China.
   [Zhang, Huiyun] Guilin Med Univ, Dept Endocrinol, Grad Sch, Guilin 541001, Guangxi, Peoples R China.
C3 Guilin Medical University; Guilin Medical University; Guangxi Medical
   University; Guilin Medical University
RP Liu, SJ (通讯作者)，Guilin Med Univ, Dept Geriatr, Affiliated Hosp, 15 Lequn Rd, Guilin 541001, Guangxi, Peoples R China.
EM lsj1817@163.com
FU Health and Family Planning Commission of Guangxi Zhuang autonomous
   region [Z2016387]; Guilin Scientific Research and Technological
   Development Project [20180106 4 5]
FX The present study was supported by the Health and Family Planning
   Commission of Guangxi Zhuang autonomous region (grant no. Z2016387) and
   the Guilin Scientific Research and Technological Development Project
   (grant no. 20180106 4 5).
CR Abdi J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096608
   Amjadi Moheb F, 2018, GENE, V677, P132, DOI 10.1016/j.gene.2018.07.061
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Cao FD, 2017, MOL MED REP, V16, P9301, DOI 10.3892/mmr.2017.7821
   Casciaro Marco, 2018, Clin Mol Allergy, V16, P11, DOI 10.1186/s12948 018 0089 4
   Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939
   Dai FJ, 2018, MED SCI MONITOR, V24, P2700, DOI 10.12659/MSM.907441
   Dejaeger M, 2017, J BONE MINER RES, V32, P2087, DOI 10.1002/jbmr.3190
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Fan JZ, 2014, MOL CELL BIOCHEM, V392, P85, DOI 10.1007/s11010 014 2021 7
   Feichtinger X, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 22844 2
   Fujita M, 2002, BIOCHEM BIOPH RES CO, V299, P222, DOI 10.1016/S0006 291X(02)02640 2
   Gómez Cerezo N, 2018, J COLLOID INTERF SCI, V528, P309, DOI 10.1016/j.jcis.2018.05.099
   Han SC, 2018, MED SCI MONIT BASIC, V24, P40, DOI 10.12659/MSMBR.907333
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Holdsworth G, 2018, BONE, V107, P93, DOI 10.1016/j.bone.2017.11.003
   Hou QK, 2017, CELL PHYSIOL BIOCHEM, V44, P2256, DOI 10.1159/000486059
   Hu XM, 2018, CELL PHYSIOL BIOCHEM, V47, P545, DOI 10.1159/000489988
   Huang CZ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen 2017 018070
   Janiszewska M, 2017, MENOPAUSE REV, V16, P86, DOI 10.5114/pm.2017.70584
   Li XF, 2018, BIOMED PHARMACOTHER, V99, P622, DOI 10.1016/j.biopha.2018.01.103
   Liu J, 2018, CANCER BIOL THER, V19, P484, DOI 10.1080/15384047.2018.1433502
   Liu Y, 2016, SCI REP UK, V6, DOI 10.1038/srep25578
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez Santillan Maria, 2018, Oncotarget, V9, P22850, DOI 10.18632/oncotarget.25230
   Modinger Y, 2018, SEMIN IMMUNOL, V37, P53, DOI 10.1016/j.smim.2018.01.001
   Nakajima K, 2014, NEOPLASIA, V16, P939, DOI 10.1016/j.neo.2014.09.005
   Nguyen BNT, 2018, CLIN ORTHOP SURG, V10, P149, DOI 10.4055/cios.2018.10.2.149
   Pan Y, 2018, DOMEST ANIM ENDOCRIN, V65, P17, DOI 10.1016/j.domaniend.2018.05.002
   Qiu J, 2018, MOL MED REP, V17, P6301, DOI 10.3892/mmr.2018.8713
   Ren YF, 2018, ONCOL LETT, V15, P1163, DOI 10.3892/ol.2017.7364
   Rizou S, 2018, J MUSCULOSKEL NEURON, V18, P208
   Sarkozy Marta, 2018, Oncotarget, V9, P21580, DOI 10.18632/oncotarget.24662
   Shen GY, 2018, J CELL PHYSIOL, V233, P3929, DOI 10.1002/jcp.26161
   Stewart S, 2014, CELL REP, V6, P482, DOI 10.1016/j.celrep.2014.01.010
   Tang XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179860
   Tao PP, 2018, EXP THER MED, V15, P562, DOI 10.3892/etm.2017.5392
   Teng ZW, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3274641
   Wang C, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.896742
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Wang R, 2017, CELL PHYSIOL BIOCHEM, V41, P213, DOI 10.1159/000456046
   Warrier S, 2016, INT J BIOCHEM CELL B, V75, P104, DOI 10.1016/j.biocel.2016.04.002
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xiang C, 2016, J HUAZHONG U SCI MED, V36, P186, DOI 10.1007/s11596 016 1564 0
   Xu RY, 2018, J TISSUE ENG REGEN M, V12, P1209, DOI 10.1002/term.2652
   Zhang RF, 2018, EUR REV MED PHARMACO, V22, P2860, DOI 10.26355/eurrev_201805_14988
NR 47
TC 25
Z9 28
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL
PY 2019
VL 20
IS 1
BP 270
EP 280
DI 10.3892/mmr.2019.10252
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA II0DR
UT WOS:000474876100031
PM 31115543
OA hybrid, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Park, BK
   Zhang, HL
   Zeng, QH
   Dai, JL
   Keller, ET
   Giordano, T
   Gu, KN
   Shah, V
   Pei, L
   Zarbo, RJ
   McCauley, L
   Shi, ST
   Chen, SQ
   Wang, CY
AF Park, Bae Keun
   Zhang, Honglai
   Zeng, Qinghua
   Dai, Jinlu
   Keller, Evan T.
   Giordano, Thomas
   Gu, Keni
   Shah, Veena
   Pei, Lei
   Zarbo, Richard J.
   McCauley, Laurie
   Shi, Songtao
   Chen, Shaoqiong
   Wang, Cun Yu
TI NF κB in breast cancer cells promotes osteolytic bone metastasis by
   inducing osteoclastogenesis via GM CSF
SO NATURE MEDICINE
LA English
DT Article
ID COLONY STIMULATING FACTOR; MARROW CULTURES; TUMOR GROWTH; IN VIVO;
   INFLAMMATION; INHIBITION; PATHOGENESIS; ACTIVATION; EXPRESSION; THERAPY
AB Advanced breast cancers frequently metastasize to bone, resulting in osteolytic lesions, yet the underlying mechanisms are poorly understood. Here we report that nuclear factor kappa B (NF kappa B) plays a crucial role in the osteolytic bone metastasis of breast cancer by stimulating osteoclastogenesis. Using an in vivo bone metastasis model, we found that constitutive NF kappa B activity in breast cancer cells is crucial for the bone resorption characteristic of osteolytic bone metastasis. We identified the gene encoding granulocyte macrophage colony stimulating factor (GM CSF) as a key target of NF kappa B and found that it mediates osteolytic bone metastasis of breast cancer by stimulating osteoclast development. Moreover, we observed that the expression of GM CSF correlated with NF kappa B activation in bone metastatic tumor tissues from individuals with breast cancer. These results uncover a new and specific role of NF kappa B in osteolytic bone metastasis through GM CSF induction, suggesting that NF kappa B is a potential target for the treatment of breast cancer and the prevention of skeletal metastasis.
C1 Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   Henry Ford Hlth Syst, Dept Pathol, Detroit, MI 48202 USA.
   Univ Michigan, Sch Med & Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; Henry Ford Health System; Henry Ford Hospital; University of
   Michigan System; University of Michigan; University of Southern
   California
RP Wang, CY (通讯作者)，Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM cunywang@umich.edu
RI Dai, Jin/GVT 2414 2022; McCauley, Laurie/G 4041 2012; Thomas,
   George/HSI 4053 2023; Zeng, Qinghua/AAA 6365 2021; Keller,
   Evan/M 1446 2016; Wang, Chunlei/F 3593 2012
OI Giordano, Thomas/0000 0003 0641 8873; 
FU National Cancer Institute [P01CA093900] Funding Source: NIH RePORTER;
   NCI NIH HHS [CA100849, P01 CA093900, CA093900] Funding Source: Medline;
   NIDCR NIH HHS [DE015618] Funding Source: Medline
CR [Anonymous], 2005, CELL, DOI DOI 10.1016/j.cell.2005.07.002
   Baxter A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI 10.1016/j.bmcl.2004.03.058
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805 758
   Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252
   Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008 5472.CAN 05 1602
   Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416
   Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hamilton JA, 2002, TRENDS IMMUNOL, V23, P403, DOI 10.1016/S1471 4906(02)02260 3
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Hodge JM, 2004, J BONE MINER RES, V19, P190, DOI 10.1359/JBMR.0301232
   Horak CE, 2005, CANCER CELL, V8, P93, DOI 10.1016/j.ccr.2005.07.013
   Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092 8674(04)00302 2
   Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535
   Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Li FH, 2005, J BONE MINER RES, V20, P1161, DOI 10.1359/JBMR.050207
   Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910
   Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044 579X(02)00128 1
   Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012
   MACDONALD BR, 1986, J BONE MINER RES, V1, P227
   Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243
   Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374
   Morgan H, 2004, INT J CANCER, V109, P653, DOI 10.1002/ijc.20056
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Myint YY, 1999, AM J PATHOL, V154, P553, DOI 10.1016/S0002 9440(10)65301 1
   Queen MM, 2005, CANCER RES, V65, P8896, DOI 10.1158/0008 5472.CAN 05 1734
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848
   Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410
   Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784
   Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 46
TC 288
Z9 324
U1 1
U2 18
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD JAN
PY 2007
VL 13
IS 1
BP 62
EP 69
DI 10.1038/nm1519
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 123NE
UT WOS:000243301800037
PM 17159986
DA 2025 08 17
ER

PT J
AU Perpétuo, IP
   Caetano Lopes, J
   Rodrigues, AM
   Campanilho Marques, R
   Ponte, C
   Canhao, H
   Ainola, M
   Fonseca, JE
AF Perpetuo, Ines P.
   Caetano Lopes, Joana
   Rodrigues, Ana Maria
   Campanilho Marques, Raquel
   Ponte, Cristina
   Canhao, Helena
   Ainola, Mari
   Fonseca, Joao E.
TI Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts
   Precursors in Rheumatoid Arthritis
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID BLOOD MONONUCLEAR CELLS; PERIPHERAL BLOOD; TNF ALPHA; SYNOVIAL
   INFLAMMATION; RECEPTOR ACTIVATOR; IMMUNE CELLS; IN VITRO; T CELLS; BONE;
   INFLIXIMAB
AB Objective. Tumor necrosis factor (TNF) increases circulating osteoclast (OC) precursors numbers by promoting their proliferation and differentiation. The aim of this study was to assess the effect of TNF inhibitors (TNFi) on the differentiation and activity of OC in rheumatoid arthritis (RA) patients. Methods. Seventeen RA patients treated with TNFi were analyzed at baseline and after a minimum follow up period of 6 months. Blood samples were collected to assess receptor activator of nuclear factor kappa B ligand (RANKL) surface expression on circulating leukocytes and frequency and phenotype of monocyte subpopulations. Quantification of serum levels of bone turnover markers, in vitro OC differentiation assays, and qRT PCR for OC specific genes was performed. Results. After TNFi therapy, patients had reduced RANKL surface expression in B lymphocytes and the frequency of circulating classical CD14(bright) CD16 monocytes was decreased. Serum levels of sRANKL, sRANKL/OPG ratio, and CTX I were reduced in RA patients after TNFi treatment. Moreover, after exposure to TNFi, osteoclast differentiation and activity were decreased, as well as the expression of TRAF6 and cathepsin K. Conclusion. We propose that TNFi arrests bone loss and erosion, through two pathways: direct reduction of osteoclast precursor numbers and inhibition of intracellular signaling pathways acting through TRAF6.
C1 [Perpetuo, Ines P.; Caetano Lopes, Joana; Rodrigues, Ana Maria; Campanilho Marques, Raquel; Ponte, Cristina; Fonseca, Joao E.] Univ Lisbon, Inst Med Mol, Rheumatol Res Unit, Fac Med, Lisbon, Portugal.
   [Campanilho Marques, Raquel; Ponte, Cristina; Fonseca, Joao E.] Hosp Santa Maria, Lisbon Acad Med Ctr, Ctr Hosp Lisboa Norte, Rheumatol Dept,EPE, Lisbon, Portugal.
   [Canhao, Helena] Univ Nova Lisboa, NOVA Med Sch, EpiDoC Unit, CEDOC, Lisbon, Portugal.
   [Ainola, Mari] Univ Helsinki, Inst Clin Med, Musculoskeletal Dis Inflammat Res Grp, Biomedicum Helsinki 1,Fac Med, Helsinki, Finland.
C3 Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria;
   Universidade Nova de Lisboa; University of Helsinki
RP Perpétuo, IP (通讯作者)，Univ Lisbon, Inst Med Mol, Rheumatol Res Unit, Fac Med, Lisbon, Portugal.
EM ines.perpetuo@gmail.com
RI Ainola, Mari Mia/T 8035 2017; Ainola, Mari/T 8035 2017; Rodrigues,
   Melissa/GYQ 6273 2022; Fonseca, Joao/KHW 7048 2024; Canhao,
   Helena/C 9611 2018; Caetano Lopes, Joana/J 9345 2012; Perpétuo,
   Inês/F 3643 2011; Ponte, Cristina/AEU 0624 2022
OI Ainola, Mari/0000 0003 2853 5851; Canhao, Helena/0000 0003 1894 4870;
   Fonseca, Joao/0000 0003 1432 3671; Rodrigues, Ana
   Maria/0000 0003 2046 8017; Ponte, Cristina/0000 0002 3989 1192;
   Caetano Lopes, Joana/0000 0003 0310 4641; Marques Ruivo,
   Raquel/0000 0002 1894 8516; 
FU Fundacao, para a Ciencia e Tecnologia [SFRH/BD/70533/2010];
   Investigator Initiated Studies Program of Merck Sharp Dohme Corp.
   [Merck P08574]; Fundação para a Ciência e a Tecnologia
   [SFRH/BD/70533/2010] Funding Source: FCT
FX This work was supported by Fundacao, para a Ciencia e Tecnologia
   (SFRH/BD/70533/2010 to Ines P. Perpetuo) and by a research grant from
   Investigator Initiated Studies Program of Merck Sharp & Dohme Corp.
   (Merck P08574 to Joao E. Fonseca). The authors would like to thank
   Biobanco IMM, Lisbon Academic Medical Center, Lisbon, Portugal, for
   samples collection and storage. The authors would also like to thank
   Monica Medina and Soraia Silva for their valuable help in image
   analysis.
CR Aeberli D, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen 2015 000079
   Ainola M, 2008, ARTHRITIS RHEUM US, V58, P3394, DOI 10.1002/art.23996
   Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Appel H, 2009, CLIN EXP RHEUMATOL, V27, pS15
   ARNETT TR, 1987, ENDOCRINOLOGY, V120, P602, DOI 10.1210/endo 120 2 602
   Binder NB, 2013, ARTHRITIS RHEUM US, V65, P608, DOI 10.1002/art.37797
   Blache C, 2011, RHEUMATOLOGY, V50, P1814, DOI 10.1093/rheumatology/ker183
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Caetano Lopes J, 2014, CLIN REV ALLERG IMMU, V47, P38, DOI 10.1007/s12016 013 8366 y
   Cascao R, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3168
   Catrina AI, 2006, ARTHRITIS RHEUM US, V54, P76, DOI 10.1002/art.21528
   Catrina AI, 2005, ARTHRITIS RHEUM US, V52, P61, DOI 10.1002/art.20764
   Childs LM, 2001, J BONE MINER RES, V16, P338, DOI 10.1359/jbmr.2001.16.2.338
   Chopin F, 2008, ANN RHEUM DIS, V67, P353, DOI 10.1136/ard.2007.076604
   Costa Rodrigues J, 2011, CELL PROLIFERAT, V44, P410, DOI 10.1111/j.1365 2184.2011.00768.x
   Coulthard LR, 2012, CLIN EXP IMMUNOL, V170, P36, DOI 10.1111/j.1365 2249.2012.04626.x
   de Vries TJ, 2016, J PERIODONTAL RES, V51, P186, DOI 10.1111/jre.12297
   Eng GP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162316
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Fransen J, 2005, CLIN EXP RHEUMATOL, V23, pS93
   Furneri G, 2012, CLIN EXP RHEUMATOL, V30, pS72
   Gengenbacher M, 2008, ANN RHEUM DIS, V67, P620, DOI 10.1136/ard.2007.076711
   González Alvaro I, 2007, ANN RHEUM DIS, V66, P1675, DOI 10.1136/ard.2007.071910
   HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502
   Hoff M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 54
   Huang ZC, 2012, CELL IMMUNOL, V279, P25, DOI 10.1016/j.cellimm.2012.09.001
   Husheem M, 2005, CALCIFIED TISSUE INT, V76, P222, DOI 10.1007/s00223 004 0123 z
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   KURIHARA N, 1989, BLOOD, V74, P1295
   Lee CK, 2004, ARTHRITIS RHEUM US, V50, P3831, DOI 10.1002/art.20637
   Lim MJ, 2014, KOREAN J INTERN MED, V29, P807, DOI 10.3904/kjim.2014.29.6.807
   Matsuno H, 2007, J RHEUMATOL, V34, P2326
   Miao CG, 2013, CELL SIGNAL, V25, P2069, DOI 10.1016/j.cellsig.2013.04.002
   Moreland LW, 2002, CLIN IMMUNOL, V103, P13, DOI 10.1006/clim.2001.5183
   OSIER LK, 1987, BONE MINER, V3, P35
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Perpétuo IP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144655
   PIPER K, 1992, ANAT EMBRYOL, V186, P291
   Schett G, 2005, NAT CLIN PRACT RHEUM, V1, P47, DOI 10.1038/ncprheum0036
   Schett G, 2008, AUTOIMMUNITY, V41, P224, DOI 10.1080/08916930701694717
   Seriolo B, 2006, REUMATISMO, V58, P199, DOI 10.4081/reumatismo.2006.199
   Smeets TJM, 2003, ARTHRITIS RHEUM US, V48, P2155, DOI 10.1002/art.11098
   Sprangers S, 2016, J CELL PHYSIOL, V231, P1249, DOI 10.1002/jcp.25220
   Takeshita M, 2015, CYTOKINE, V75, P222, DOI 10.1016/j.cyto.2015.04.011
   Takita Chikahiro, 2005, Mod Rheumatol, V15, P97, DOI 10.1007/s10165 004 0373 7
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Terry SYA, 2016, J NUCL MED, V57, P467, DOI 10.2967/jnumed.115.162628
   Toubi E, 2005, ANN NY ACAD SCI, V1051, P506, DOI 10.1196/annals.1361.095
   van der Heijde D, 2009, ANN RHEUM DIS, V68, P1113, DOI 10.1136/ard.2008.094375
   Wang SY, 2011, J RHEUMATOL, V38, P821, DOI 10.3899/jrheum.100089
   Wijbrandts CA, 2008, ARTHRITIS RHEUM, V58, P3330, DOI 10.1002/art.23989
   Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026 012 8297 3
   Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01
   Yago T, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2297
   Yago T, 2009, J CELL BIOCHEM, V108, P947, DOI 10.1002/jcb.22326
   Yasunori K, 2008, CLIN RHEUMATOL, V27, P1093, DOI 10.1007/s10067 008 0870 8
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 134
   Ziolkowska M., ARTHRITIS RHEUMATISM, V46
   Zivojinovic SM, 2012, J RHEUMATOL, V39, P18, DOI 10.3899/jrheum.110697
NR 59
TC 25
Z9 27
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2017
VL 2017
AR 2690402
DI 10.1155/2017/2690402
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA EM2ND
UT WOS:000395151900001
PM 28286757
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU McDonald, MM
   Morse, A
   Mikulec, K
   Peacock, L
   Baldock, PA
   Kostenuik, PJ
   Little, DG
AF McDonald, Michelle M.
   Morse, Alyson
   Mikulec, Kathy
   Peacock, Lauren
   Baldock, Paul A.
   Kostenuik, Paul J.
   Little, David G.
TI Matrix Metalloproteinase Driven Endochondral Fracture Union Proceeds
   Independently of Osteoclast Activity
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCLAST; FRACTURE REPAIR; MATRIX METALLOPROTEINASES; ENDOCHONDRAL
   OSSIFICATION; REMODELING
ID ZOLEDRONIC ACID; BISPHOSPHONATE TREATMENT; REPAIR; ANGIOGENESIS;
   PAMIDRONATE; INCADRONATE; ALENDRONATE; INHIBITION; EXPRESSION; STRENGTH
AB As new insights into the complexities of endochondral fracture repair emerge, the temporal role of osteoclast activity remains ambiguous. With numerous antiresorptive agents available to treat bone disease, understanding their impact on bone repair is vital. Further, in light of recent work suggesting osteoclast activity may not be necessary during early endochondral fracture union, we hypothesize instead a pivotal role of matrix metalloproteinase (MMP) secreting cells in driving this process. Although the role of MMPs in fracture healing has been examined, no directly comparative experiments exist. We examined a number of antiresorptive treatments to either block osteoclast activity, including the potent bisphosphonates zoledronic acid (ZA) and clodronate (CLOD), which work via differing mechanisms, or antagonize osteoclastogenesis with recombinant OPG (HuOPG Fc), comparing these directly to an inhibitor of MMP activity (MMI270). Endochondral ossification to union occurred normally in all antiresorptive groups. In contrast, MMP inhibition greatly impaired endochondral union, significantly delaying cartilage callus removal. MMP inhibition also produced smaller, denser hard calluses. Hard callus remodeling was, as expected, delayed with ZA, CLOD, and OPG treatment at 4 and 6 weeks, resulting in larger, more mineralized calluses at 6 weeks. As a result of reduced hard callus turnover, bone formation was reduced with antiresorptive agents at these time points. These results confirm that the achievement of endochondral fracture union occurs independently of osteoclast activity. Alternatively, MMP secretion by invading cells is obligatory to endochondral union. This study provides new insight into cellular contributions to bone repair and may abate concerns regarding antiresorptive therapies impeding initial fracture union.
C1 [McDonald, Michelle M.; Morse, Alyson; Mikulec, Kathy; Peacock, Lauren; Little, David G.] Childrens Hosp Westmead, Westmead, NSW, Australia.
   [McDonald, Michelle M.; Baldock, Paul A.] Garvan Inst Med Res, Bone Biol Program, Sydney, NSW 2010, Australia.
   [Kostenuik, Paul J.] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 NSW Health; Sydney Childrens Hospitals Network; The Children's Hospital
   at Westmead; University of Sydney; Garvan Institute of Medical Research;
   Amgen
RP McDonald, MM (通讯作者)，Garvan Inst Med Res, Bone Biol Program, 384 Victoria Rd, Sydney, NSW 2010, Australia.
EM m.mcdonald@garvan.org.au
RI ; McDonald, Michelle/AAD 4760 2019; Baldock, Paul/B 3840 2012
OI McDonald, Michelle/0000 0002 3928 2506; 
FU Amgen; Novartis; Celgene; Lilly; N8 Medical
FX PJK is an Amgen employee. DGL has received research support from Amgen,
   Novartis, Celgene, Lilly, and N8 Medical. All of the other authors state
   that they have no conflicts of interest.
CR ADAMI S, 2012, JBJS, V24
   Amanat N, 2005, J ORTHOP RES, V23, P1029, DOI 10.1016/j.orthres.2005.03.004
   Amanat N, 2007, J BONE MINER RES, V22, P867, DOI 10.1359/JBMR.070318
   Behonick DJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001150
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Bukata SV, 2011, INJURY, V42, P605, DOI 10.1016/j.injury.2011.03.061
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559
   Einhorn TA, 2005, J ORTHOP TRAUMA, V19, pS4, DOI 10.1097/00005131 200511101 00002
   Everts V, 2006, J BONE MINER RES, V21, P1399, DOI 10.1359/JBMR.060614
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736 0266(03)00011 1
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Harding AK, 2011, ACTA ORTHOP, V82, P465, DOI 10.3109/17453674.2011.594231
   Kellinsalmi M, 2005, BASIC CLIN PHARMACOL, V97, P382, DOI 10.1111/j.1742 7843.2005.pto_176.x
   Kidd LJ, 2011, J ORTHOP RES, V29, P1827, DOI 10.1002/jor.21464
   Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797
   Kosaki N, 2007, BIOCHEM BIOPH RES CO, V354, P846, DOI 10.1016/j.bbrc.2006.12.234
   Li CY, 2001, J BONE MINER RES, V16, P429, DOI 10.1359/jbmr.2001.16.3.429
   Li JL, 1999, J BONE MINER RES, V14, P969, DOI 10.1359/jbmr.1999.14.6.969
   Lieu S, 2011, DIS MODEL MECH, V4, P203, DOI 10.1242/dmm.006304
   Manabe T, 2012, CALCIFIED TISSUE INT, V90, P193, DOI 10.1007/s00223 011 9563 4
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   McDonald MM, 2011, J ORTHOP RES, V29, P726, DOI 10.1002/jor.21293
   Mori S., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P314
   Ortega N, 2010, DIS MODEL MECH, V3, P224, DOI 10.1242/dmm.004226
   Ota N, 2009, ENDOCRINOLOGY, V150, P4823, DOI 10.1210/en.2009 0452
   Pelletier JP, 2004, BONE, V34, P527, DOI 10.1016/j.bone.2003.11.021
   Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582 4934.2005.tb00355.x
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Sawae Y, 2003, J ELECTRON MICROSC, V52, P493, DOI 10.1093/jmicro/52.6.493
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Smith EJ, 2004, J BONE MINER RES, V19, P1698, DOI 10.1359/JBMR.040709
   Sorsa T, 1998, J RHEUMATOL, V25, P975
   Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400
   Ulrich Vinther M, 2005, CALCIFIED TISSUE INT, V76, P280, DOI 10.1007/s00223 004 0126 9
   Uusitalo H, 2000, CALCIFIED TISSUE INT, V67, P382, DOI 10.1007/s002230001152
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092 8674(00)81169 1
   Wigner NA, 2012, INJURY, V43, P274, DOI 10.1016/j.injury.2011.05.038
   Yamagiwa H, 1999, BONE, V25, P197, DOI 10.1016/S8756 3282(99)00157 X
   Zijlstra A, 2004, J BIOL CHEM, V279, P27633, DOI 10.1074/jbc.M313617200
NR 41
TC 25
Z9 29
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2013
VL 28
IS 7
BP 1550
EP 1560
DI 10.1002/jbmr.1889
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 166NM
UT WOS:000320561900006
PM 23408642
OA Bronze
DA 2025 08 17
ER

PT J
AU Kingma, SDK
   Wagemans, T
   Ijlst, L
   Wijburg, FA
   van Vlies, N
AF Kingma, Sandra D. K.
   Wagemans, Tom
   IJlst, Lodewijk
   Wijburg, Frits A.
   van Vlies, Naomi
TI Genistein increases glycosaminoglycan levels in mucopolysaccharidosis
   type I cell models
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID GROWTH FACTOR BETA; TARGETED ISOFLAVONE THERAPY; SANFILIPPO DISEASE
   PATIENTS; ENZYME REPLACEMENT THERAPY; HURLER SYNDROME; FOLLOW UP;
   MEDIATED INHIBITION; TRANSPLANTATION; BONE; EXTRACT
AB Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder characterized by diminished degradation of the glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate, which results in the accumulation of these GAGs and subsequent cellular dysfunction. Patients present with a variety of symptoms, including severe skeletal disease. Genistein has been shown previously to inhibit GAG synthesis in MPS fibroblasts, presumably through inhibition of tyrosine kinase activity of the epidermal growth factor receptor (EGFR). To determine the potentials of genistein for the treatment of skeletal disease, MPS I fibroblasts were induced into chondrocytes and osteoblasts and treated with genistein. Surprisingly, whereas tyrosine phosphorylation levels (as a measure for tyrosine kinase inhibition) were decreased in all treated cell lines, there was a 1.3 and 1.6 fold increase in GAG levels in MPS I chondrocytes and fibroblast, respectively (p < 0.05). Sulfate incorporation in treated MPS I fibroblasts was 2.6 fold increased (p < 0.05), indicating increased GAG synthesis despite tyrosine kinase inhibition. This suggests that GAG synthesis is not exclusively regulated through the tyrosine kinase activity of the EGFR. We hypothesize that the differences in outcomes between studies on the effect of genistein in MPS are caused by the different effects of genistein on different growth factor signaling pathways, which regulate GAG synthesis. More studies are needed to elucidate the precise signaling pathways which are affected by genistein and alter GAG metabolism in order to evaluate the therapeutic potential of genistein for MPS patients.
C1 [Kingma, Sandra D. K.; Wagemans, Tom; Wijburg, Frits A.; van Vlies, Naomi] Univ Amsterdam, Acad Med Ctr, Dept Pediat, NL 1105 AZ Amsterdam, Netherlands.
   [Kingma, Sandra D. K.; Wagemans, Tom; Wijburg, Frits A.; van Vlies, Naomi] Univ Amsterdam, Acad Med Ctr, Amsterdam Lysosome Ctr Sphinx, NL 1105 AZ Amsterdam, Netherlands.
   [Kingma, Sandra D. K.; Wagemans, Tom; IJlst, Lodewijk; van Vlies, Naomi] Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, Dept Clin Chem & Pediat, NL 1105 AZ Amsterdam, Netherlands.
   [Wijburg, Frits A.] Univ Amsterdam, Acad Med Ctr, Dept Pediat, Div Metab Dis H7 270, NL 1105 AZ Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Amsterdam; Academic Medical Center Amsterdam; University of
   Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam;
   Academic Medical Center Amsterdam
RP Wijburg, FA (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Pediat, Div Metab Dis H7 270, Meibergdreef 9, NL 1105 AZ Amsterdam, Netherlands.
EM s.d.kingma@amc.uva.nl; a.h.wagemans@amc.uva.nl; l.ijlst@amc.uva.nl;
   f.a.wijburg@amc.uva.nl; n.vanvlies@amc.uva.nl
OI Kingma, Sandra/0000 0002 5606 2257; Wijburg, Frits/0000 0002 0950 1368
FU WE foundation; foundation 'Steun Emma Kinderziekenhuis AMC'
FX We thank Rene Leen, Vincent Everts, Henk van Lenthe, Wim Kulik and
   Ronald Wanders for technical assistance and helpful discussions. We
   thank Gregorz Wegrzyn for kindly providing the protocol for sulfate
   incorporation and helpful discussions and Axcentua for providing
   genistein. This work was funded by the WE foundation and the foundation
   'Steun Emma Kinderziekenhuis AMC'.
CR AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   Aldenboven M, 2008, BIOL BLOOD MARROW TR, V14, P485, DOI 10.1016/j.bbmt.2008.01.009
   Arfi A, 2010, J INHERIT METAB DIS, V33, P61, DOI 10.1007/s10545 009 9029 2
   Baldo G, 2013, MOL GENET METAB, V109, P33, DOI 10.1016/j.ymgme.2013.03.005
   Blunk T, 2003, GROWTH FACTORS, V21, P71, DOI 10.1080/0897719031000148822
   Blunk T, 2002, TISSUE ENG, V8, P73, DOI 10.1089/107632702753503072
   Coldham NG, 2000, TOXICOL APPL PHARM, V164, P206, DOI 10.1006/taap.2000.8902
   de Ruijter J, 2012, ANN NEUROL, V71, P110, DOI 10.1002/ana.22643
   Delgadillo V, 2011, J INHERIT METAB DIS, V34, P1039, DOI 10.1007/s10545 011 9342 4
   Ferdinandusse S, 2009, MOL GENET METAB, V96, P121, DOI 10.1016/j.ymgme.2008.11.165
   HIRAKI Y, 1988, BIOCHIM BIOPHYS ACTA, V969, P91, DOI 10.1016/0167 4889(88)90092 4
   Hwang KA, 2013, TOXICOL APPL PHARM, V272, P637, DOI 10.1016/j.taap.2013.07.027
   Jakóbkiewicz Banecka J, 2009, J BIOMED SCI, V16, DOI 10.1186/1423 0127 16 26
   Junker JPE, 2010, CELLS TISSUES ORGANS, V191, P105, DOI 10.1159/000232157
   Kim H, 2001, BIOCHEM SOC T, V29, P216, DOI 10.1042/BST0290216
   Kim KH, 2013, MOL GENET METAB, V109, P382, DOI 10.1016/j.ymgme.2013.06.012
   Kingma SDK, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 99
   Kloska A, 2012, J TRANSL MED, V10, DOI 10.1186/1479 5876 10 153
   Kloska A, 2011, METAB BRAIN DIS, V26, P1, DOI 10.1007/s11011 011 9233 2
   Koç ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mackie EJ, 2011, J ENDOCRINOL, V211, P109, DOI 10.1530/JOE 11 0048
   Malinová V, 2012, JIMD REP, V5, P21, DOI 10.1007/8904_2011_87
   Malinowska M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014192
   Muenzer J, 2011, RHEUMATOLOGY, V50, pV4, DOI 10.1093/rheumatology/ker394
   Oussoren E, 2011, BBA MOL BASIS DIS, V1812, P1542, DOI 10.1016/j.bbadis.2011.07.013
   Piotrowska E, 2006, EUR J HUM GENET, V14, P846, DOI 10.1038/sj.ejhg.5201623
   Piotrowska E, 2011, MED SCI MONITOR, V17, pCR196, DOI 10.12659/MSM.881715
   Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304 3940(02)01423 4
   Sifuentes M, 2007, MOL GENET METAB, V90, P171, DOI 10.1016/j.ymgme.2006.08.007
   Simonaro CM, 2008, AM J PATHOL, V172, P112, DOI 10.2353/ajpath.2008.070564
   Tirone E, 1997, J BIOL CHEM, V272, P4787, DOI 10.1074/jbc.272.8.4787
   van der Linden MH, 2011, J INHERIT METAB DIS, V34, P657, DOI 10.1007/s10545 011 9304 x
   Weisstein JS, 2004, J PEDIATR ORTHOPED, V24, P97, DOI 10.1097/01241398 200401000 00019
   White KK, 2011, RHEUMATOLOGY, V50, pV26, DOI 10.1093/rheumatology/ker393
   Yuan WJ, 2009, J ARTIF ORGANS, V12, P242, DOI 10.1007/s10047 009 0479 y
NR 36
TC 17
Z9 18
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141 8955
EI 1573 2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD SEP
PY 2014
VL 37
IS 5
BP 813
EP 821
DI 10.1007/s10545 014 9703 x
PG 9
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA AP1XE
UT WOS:000341864800014
PM 24699889
DA 2025 08 17
ER

PT J
AU Khan, AA
AF Khan, Aliya A.
TI Medical Management of Primary Hyperparathyroidism
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article
DE Bisphosphonates; cinacalcet; estrogen; medical management; primary
   hyperparathyroidism; raloxifene
ID ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; 3RD INTERNATIONAL WORKSHOP;
   MILD PRIMARY HYPERPARATHYROIDISM; BONE MINERAL DENSITY; POSTMENOPAUSAL
   WOMEN; SERUM CALCIUM; ORAL ALENDRONATE; CONTROLLED TRIAL; VITAMIN D;
   DIAGNOSIS
AB Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient population. It is diagnosed in most individuals in the Western world at an asymptomatic stage without signs or symptoms of parathyroid hormone (PTH) calcium excess. Nonspecific symptoms include weakness, malaise, fatigue, and possible mood disturbances, which may be present at the time of diagnosis. The diagnosis of PHPT is confirmed in the presence of hypercalcemia and a normal or elevated PTH level in the absence of conditions that mimic PHPT. Indications for surgery have recently been revised based on international consensus, and surgery is advised in the presence of significant hypercalcemia, impaired renal function, and osteoporosis and in individuals younger than 50 yr. The classical complications of PHPT are skeletal fragility, nephrolithiasis, and nephrocalcinosis. Surgery is always appropriate in an individual with confirmed PHPT after excluding conditions that can mimic PHPT and in the absence of contraindications. Individuals with asymptomatic PHPT not meeting the guidelines for surgery or those with contraindications for surgery may be followed and considered for medical management. For those at an increased risk of fragility fracture, antiresorptive therapy may be considered with close monitoring of biochemical data and bone densitometry. Targeted therapy with a calcimimetic agent may be of value in lowering serum calcium and PTH. There are currently no fracture data for the medical options available, and prospective randomized controlled trials are required to confirm the effects of medical therapy on fracture risk reduction in those with asymptomatic PHPT.
C1 [Khan, Aliya A.] McMaster Univ, Hamilton, ON, Canada.
C3 McMaster University
RP Khan, AA (通讯作者)，McMaster Univ, 209 331 Sheddon Ave, Oakville, ON L6J 1X8, Canada.
EM aliya@mcmaster.ca
CR Beyer TD, 2007, J SURG RES, V143, P145, DOI 10.1016/j.jss.2007.06.009
   Bilezikian JP, 2009, J CLIN ENDOCR METAB, V94, P335, DOI 10.1210/jc.2008 1763
   Chow CC, 2003, J CLIN ENDOCR METAB, V88, P581, DOI 10.1210/jc.2002 020890
   Eastell R, 2009, J CLIN ENDOCR METAB, V94, P340, DOI 10.1210/jc.2008 1758
   Grey A, 2005, J CLIN ENDOCR METAB, V90, P2122, DOI 10.1210/jc.2004 1772
   Grey AB, 1996, ANN INTERN MED, V125, P360, DOI 10.7326/0003 4819 125 5 199609010 00002
   Khan AA, 2004, J CLIN ENDOCR METAB, V89, P3319, DOI 10.1210/jc.2003 030908
   Khan A, 2009, J CLIN ENDOCR METAB, V94, P373, DOI 10.1210/jc.2008 1762
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Marcocci C, 2009, J CLIN ENDOCR METAB, V94, P2766, DOI 10.1210/jc.2008 2640
   Pallan S, 2012, BMJ BRIT MED J, V344, DOI 10.1136/bmj.e1013
   Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004 0842
   Rao DS, 2002, J BONE MINER RES, V17, pN75
   REASNER CA, 1993, J CLIN ENDOCR METAB, V77, P1067, DOI 10.1210/jc.77.4.1067
   Rossini M, 2001, J BONE MINER RES, V16, P113, DOI 10.1359/jbmr.2001.16.1.113
   Rubin MR, 2003, J CLIN ENDOCR METAB, V88, P1174, DOI 10.1210/jc.2002 020667
   SCHMIDLI RS, 1990, CLIN ENDOCRINOL, V32, P293, DOI 10.1111/j.1365 2265.1990.tb00869.x
   Silverberg SJ, 2007, J CLIN ENDOCR METAB, V92, P3803, DOI 10.1210/jc.2007 0585
   Silverberg SJ, 2009, J CLIN ENDOCR METAB, V94, P351, DOI 10.1210/jc.2008 1760
   Udelsman R, 2009, J CLIN ENDOCR METAB, V94, P366, DOI 10.1210/jc.2008 1761
   Zanchetta JR, 2001, J BONE MINER RES, V16, P189, DOI 10.1359/jbmr.2001.16.1.189
NR 21
TC 19
Z9 20
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1094 6950
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD JAN MAR
PY 2013
VL 16
IS 1
BP 60
EP 63
DI 10.1016/j.jocd.2012.11.010
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 093GA
UT WOS:000315178500013
PM 23374743
DA 2025 08 17
ER

PT J
AU Xian, GP
   Huang, R
   Xu, MH
   Zhao, HL
   Xu, XB
   Chen, YC
   Ren, H
   Xu, DL
   Zeng, QC
AF Xian, Gaopeng
   Huang, Rong
   Xu, Minhui
   Zhao, Hengli
   Xu, Xingbo
   Chen, Yangchao
   Ren, Hao
   Xu, Dingli
   Zeng, Qingchun
TI Noncoding RNA regulates the expression of Krm1 and Dkk2 to
   synergistically affect aortic valve lesions
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; INTERSTITIAL CELLS; KREMEN PROTEINS;
   CALCIFICATION; INFLAMMATION; ACTIVATION; RECEPTOR; PATHWAY
AB Calcific aortic valve disease (CAVD) is becoming an increasingly important global medical problem, but effective pharmacological treatments are lacking. Noncoding RNAs play a pivotal role in the progression of cardiovascular diseases, but their relationship with CAVD remains unclear. Sequencing data revealed differential expression of many noncoding RNAs in normal and calcified aortic valves, with significant differences in circHIPK3 and miR 182 5p expression. Overexpression of circHIPK3 ameliorated aortic valve lesions in a CAVD mouse model. In vitro experiments demonstrated that circHIPK3 inhibits the osteogenic response of aortic valve interstitial cells. Mechanistically, DEAD box helicase 5 (DDX5) recruits methyltransferase 3 (METTL3) to promote the N6 methyladenosine (m6A) modification of circHIPK3. Furthermore, m6A modified circHIPK3 increases the stability of Kremen1 (Krm1) mRNA, and Krm1 is a negative regulator of the Wnt/beta catenin pathway. Additionally, miR 182 5p suppresses the expression of Dickkopf2 (Dkk2), the ligand of Krm1, and attenuates the Krm1 mediated inhibition of Wnt signaling. Activation of the Wnt signaling pathway significantly contributes to the promotion of aortic valve calcification. Our study describes the role of the Krm1 Dkk2 axis in inhibiting Wnt signaling in aortic valves and suggests that noncoding RNAs are upstream regulators of this process.
   Calcific aortic valve disease (CAVD, a common heart condition) currently has no effective treatments. This research aimed to examine the role of non coding RNAs (molecules that control gene activity) in CAVD, particularly circHIPK3 and miR 182 5p. Experiments were conducted on human heart valve cells and mice, showing that circHIPK3 can prevent heart valve hardening, while miR 182 5p can trigger a process that encourages hardening. The research also discovered a protein, Krm1, that can stop this hardening process. These results suggest that focusing on these non coding RNAs and proteins could offer a new way to treat CAVD. However, more research is needed to fully comprehend these processes and their potential treatment implications.This summary was initially drafted using artificial intelligence, then revised and fact checked by the author.
C1 [Xian, Gaopeng; Xu, Minhui; Zhao, Hengli; Xu, Dingli; Zeng, Qingchun] Southern Med Univ, Nanfang Hosp, Dept Cardiol, State Key Lab Organ Failure Res, Guangzhou 510515, Peoples R China.
   [Xian, Gaopeng; Xu, Minhui; Zhao, Hengli; Ren, Hao; Xu, Dingli; Zeng, Qingchun] Southern Med Univ, Guangdong Prov Key Lab Cardiac Funct & Microcircul, Guangzhou 510515, Peoples R China.
   [Xian, Gaopeng; Xu, Minhui; Zhao, Hengli; Xu, Dingli; Zeng, Qingchun] Guangzhou Regenerat Med & Hlth Guangdong Lab, Bioland Lab, Guangzhou, Peoples R China.
   [Huang, Rong] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA.
   [Xu, Xingbo] Univ Med Ctr Goettingen, Dept Cardiol, Robert Koch Str 40, D 37075 Gottingen, Germany.
   [Chen, Yangchao] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [Ren, Hao] Southern Med Univ, Nanfang Hosp, Dept Rheumatol, Guangzhou, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Bioland Lab; Boston University; University of Gottingen;
   UNIVERSITY GOTTINGEN HOSPITAL; Chinese University of Hong Kong; Southern
   Medical University   China
RP Xu, DL; Zeng, QC (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Cardiol, State Key Lab Organ Failure Res, Guangzhou 510515, Peoples R China.; Xu, DL; Zeng, QC (通讯作者)，Southern Med Univ, Guangdong Prov Key Lab Cardiac Funct & Microcircul, Guangzhou 510515, Peoples R China.; Xu, DL; Zeng, QC (通讯作者)，Guangzhou Regenerat Med & Hlth Guangdong Lab, Bioland Lab, Guangzhou, Peoples R China.
EM dlxugz@163.com; qingchunzeng@smu.edu.cn
RI Xu, Dingli/AAA 6176 2019; Xian, Gaopeng/NNY 6433 2025
OI Zeng, Qingchun/0000 0001 7665 8237
FU National Natural Science Foundation of China [82070403, 82270374];
   Science and Technology Program of Guangdong Province [2021A0505030031];
   Guangzhou Science and Technology Plan Project [2023B01J1011,
   2023B03J1243]; Youth Science and Technology Innovation Talent of
   Guangdong TeZhi Plan [2019TQ05Y136]
FX This work was supported by the National Natural Science Foundation of
   China(82070403, 82270374), the Science and Technology Program of
   Guangdong Province(2021A0505030031), the Guangzhou Science and
   Technology Plan Project(2023B01J1011, 2023B03J1243), and the Youth
   Science and Technology Innovation Talent of Guangdong TeZhi Plan
   (2019TQ05Y136).
CR Bian WK, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.765419
   Cao MQ, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0555 y
   Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757
   Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154
   El Nakamura R, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 52
   Glazar P, 2014, RNA, V20, P1666, DOI 10.1261/rna.043687.113
   Gu GJ, 2014, J HUAZHONG U SCI MED, V34, P33, DOI 10.1007/s11596 014 1228 x
   Gu YQ, 2022, CELL RES, V32, P24, DOI 10.1038/s41422 021 00595 6
   Honda S, 2014, ARTERIOSCL THROM VAS, V34, P270, DOI 10.1161/ATVBAHA.113.302610
   Hong FS, 2015, J AGR FOOD CHEM, V63, P1639, DOI 10.1021/jf5034834
   Huang Y, 2018, J CELL PHYSIOL, V233, P6693, DOI 10.1002/jcp.26469
   Ji Y, 2022, CANCERS, V14, DOI 10.3390/cancers14225582
   Jiang XK, 2022, CANCER RES, V82, P831, DOI 10.1158/0008 5472.CAN 21 2988
   Kikuchi A, 2022, SEMIN CELL DEV BIOL, V125, P55, DOI 10.1016/j.semcdb.2021.11.003
   Kim C, 2016, BIOMATERIALS, V83, P93, DOI 10.1016/j.biomaterials.2015.12.029
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Lu DC, 2022, EUR HEART J, V43, P4496, DOI 10.1093/eurheartj/ehac337
   Lu DC, 2019, NAT REV CARDIOL, V16, P661, DOI 10.1038/s41569 019 0218 x
   Lu HQ, 2013, DEV CELL, V24, P543, DOI 10.1016/j.devcel.2013.01.021
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Meng XZ, 2008, AM J PHYSIOL CELL PH, V294, pC29, DOI 10.1152/ajpcell.00137.2007
   Nasir K, 2008, ATHEROSCLEROSIS, V198, P104, DOI 10.1016/j.atherosclerosis.2007.09.008
   Peeters FECM, 2018, EUR HEART J, V39, P2618, DOI 10.1093/eurheartj/ehx653
   Rajamannan NM, 2012, J CELL BIOCHEM, V113, P1623, DOI 10.1002/jcb.24031
   Rajamannan NM, 2005, CIRCULATION, V112, pI229, DOI 10.1161/01.CIRCULATIONAHA.104.524306
   Rossebo AB, 2008, NEW ENGL J MED, V359, P1343, DOI 10.1056/NEJMoa0804602
   Seok H, 2020, NATURE, V584, P279, DOI 10.1038/s41586 020 2586 0
   Si XY, 2020, MOL THER NUCL ACIDS, V21, P636, DOI 10.1016/j.omtn.2020.06.024
   Sikura KÉ, 2021, J ADV RES, V27, P165, DOI 10.1016/j.jare.2020.07.005
   Song R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010076
   Song R, 2017, J BIOL CHEM, V292, P8657, DOI 10.1074/jbc.M117.783308
   Song R, 2012, ARTERIOSCL THROM VAS, V32, P2711, DOI 10.1161/ATVBAHA.112.300116
   Sun T, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108613
   Wang YJ, 2021, EUR HEART J, V42, P2935, DOI 10.1093/eurheartj/ehab316
   Xu J, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009530
   Xu K, 2020, ARTERIOSCL THROM VAS, V40, P2910, DOI 10.1161/ATVBAHA.120.314789
   Xuan JJ, 2018, NUCLEIC ACIDS RES, V46, pD327, DOI 10.1093/nar/gkx934
   Yadgir S, 2020, CIRCULATION, V141, P1670, DOI 10.1161/CIRCULATIONAHA.119.043391
   Yan F, 2022, BMC CARDIOVASC DISOR, V22, DOI 10.1186/s12872 022 02471 6
   Zhang F, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.722564
   Zhang L, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.733248
   Zhang LL, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01224 3
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang WB, 2022, J CARDIOVASC TRANSL, V15, P1315, DOI 10.1007/s12265 022 10247 8
   Zhao J, 2020, CANCER SCI, V111, P994, DOI 10.1111/cas.14243
   Zhao LC, 2022, MICROBIOL SPECTR, V10, DOI 10.1128/spectrum.01098 22
   Zhou B, 2020, INT J MOL MED, V46, P1571, DOI 10.3892/ijmm.2020.4694
   Zhou C, 2017, CELL REP, V20, P2262, DOI 10.1016/j.celrep.2017.08.027
   Zhou Y, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw104
NR 50
TC 3
Z9 3
U1 3
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JUL
PY 2024
VL 56
IS 7
BP 1560
EP 1573
DI 10.1038/s12276 024 01256 5
EA JUL 2024
PG 14
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA A5G4X
UT WOS:001258256500005
PM 38945954
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tan, W
   Rossi, NA
   Haroun, KB
   Conner, GR
   McKinnon, B
   Ranasinghe, V
   Shabani, S
   Coblens, OM
AF Tan, Wilhelmina
   Rossi, Nicholas A.
   Haroun, Kareem B.
   Conner, Grant R.
   McKinnon, Brian
   Ranasinghe, Viran
   Shabani, Sepehr
   Coblens, Orly M.
TI Denosumab Induced Maxillary Osteonecrosis: A Case Study on Long Term
   Complications in Multiple Myeloma Treatment
SO ENT EAR NOSE & THROAT JOURNAL
LA English
DT Article; Early Access
DE osteonecrosis; denosumab; maxilla; multiple myeloma; bone metabolism
ID MEDICATION RELATED OSTEONECROSIS; CANCER PATIENTS; JAW; ASSOCIATION;
   RISK
AB Background: Targeted therapies like denosumab have revolutionized multiple myeloma (MM) treatment, improved patient outcomes while introducing long term complications. This study explores a rare instance of delayed maxillary osteonecrosis post denosumab therapy, delving into its pathophysiology and management. Methods: A 40 year old male MM patient who developed a painful palatal lesion post denosumab treatment and diagnosed of maxillary osteonecrosis by computed tomography scan and surgical biopsy is presented. Treatment history, symptom progression, and response to the PENTOCLO protocol were analyzed. Results: Post denosumab discontinuation osteonecrosis highlights its prolonged impact on bone metabolism. PENTOCLO treatment protocol led to significant improvement. Genetic factors influencing osteonecrosis susceptibility have been discussed and considered. Conclusions: This case underscores the need for vigilance regarding long term complications in MM survivors, preventive strategies, including regular dental evaluations and reducing invasive dental procedures, are crucial. We advocate for an interdisciplinary approach and further research into tailored prevention and management of osteonecrosis in cancer survivors.
C1 [Tan, Wilhelmina] Univ Texas Med Branch, Sch Med, Galveston, TX USA.
   [Rossi, Nicholas A.; McKinnon, Brian; Ranasinghe, Viran; Shabani, Sepehr; Coblens, Orly M.] Univ Texas Med Branch, Dept Otolaryngol, Galveston, TX USA.
   [Haroun, Kareem B.] Texas Ear Nose & Throat Specialists, Bedford, TX USA.
   [Conner, Grant R.] Cent Coast Head & Neck Surg, Salinas, CA USA.
   [Tan, Wilhelmina] Univ Texas Med Branch, Dept Otolaryngol Head & Neck Surg, 301 Univ Blvd, Galveston, TX 77555 USA.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; University of Texas System; University of Texas Medical
   Branch Galveston; University of Texas System; University of Texas
   Medical Branch Galveston
RP Tan, W (通讯作者)，Univ Texas Med Branch, Dept Otolaryngol Head & Neck Surg, 301 Univ Blvd, Galveston, TX 77555 USA.
EM witan@utmb.edu
CR Aghaloo TL, 2010, J ORAL MAXIL SURG, V68, P959, DOI 10.1016/j.joms.2009.10.010
   Alsalih A, 2021, DENT J BASEL, V9, DOI 10.3390/dj9080085
   Banjar A, 2023, ORAL DIS, V29, P29, DOI 10.1111/odi.14058
   Borrás Blasco J, 2007, J CLIN PHARM THER, V32, P651, DOI 10.1111/j.1365 2710.2007.00845.x
   Chang HJ, 2023, MAX PLAST RECONSTR S, V45, DOI 10.1186/s40902 023 00377 7
   da Silva JSP, 2019, INT J ORAL MAX SURG, V48, P1289, DOI 10.1016/j.ijom.2019.04.014
   Dalle Carbonare L, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020561
   de Oliveira CC, 2016, MED ORAL PATOL ORAL, V21, pE431, DOI 10.4317/medoral.21044
   Dempster DW, 2018, J CLIN ENDOCR METAB, V103, P2498, DOI 10.1210/jc.2017 02669
   Freiberger JJ, 2012, J ORAL MAXIL SURG, V70, P1573, DOI 10.1016/j.joms.2012.04.001
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hildebrand G.K., 2022, DENOSUMAB
   Jung S, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 11615 9
   Kajizono M, 2015, BIOL PHARM BULL, V38, P1850, DOI 10.1248/bpb.b15 00385
   Kalita F, 2023, J MAXILLOFAC ORAL SU, V22, P344, DOI 10.1007/s12663 023 01876 w
   Kendler DL, 2022, ADV THER, V39, P58, DOI 10.1007/s12325 021 01936 y
   Kim AS, 2022, CURR OSTEOPOROS REP, DOI 10.1007/s11914 022 00756 5
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Peng J, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1017391
   Qi WX, 2014, INT J CLIN ONCOL, V19, P403, DOI 10.1007/s10147 013 0561 6
   Robard L, 2014, EUR ANN OTORHINOLARY, V131, P333, DOI 10.1016/j.anorl.2013.11.006
   Ruggiero S, 2006, J ONCOL PRACT, V2, P7, DOI 10.1200/JOP.2.1.7
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Uyanne Jettie, 2014, Dent Clin North Am, V58, P369, DOI 10.1016/j.cden.2013.12.006
   Venkatasatya SRM, 2017, AM J DENT, V30, P350
   Wang HD, 2014, J CLIN ENDOCR METAB, V99, P891, DOI 10.1210/jc.2013 3081
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
NR 28
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145 5613
EI 1942 7522
J9 ENT EAR NOSE THROAT
JI ENT Ear Nose Throat J.
PD 2024 JUN 16
PY 2024
DI 10.1177/01455613241263181
EA JUN 2024
PG 5
WC Otorhinolaryngology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Otorhinolaryngology
GA UO9E6
UT WOS:001249109000001
PM 38880987
OA gold
DA 2025 08 17
ER

PT J
AU Bauler, TJ
   Kamiya, N
   Lapinski, PE
   Langewisch, E
   Mishina, Y
   Wilkinson, JE
   Feng, GS
   King, PD
AF Bauler, Timothy J.
   Kamiya, Nobuhiro
   Lapinski, Philip E.
   Langewisch, Eric
   Mishina, Yuji
   Wilkinson, John E.
   Feng, Gen Sheng
   King, Philip D.
TI Development of severe skeletal defects in induced SHP 2 deficient adult
   mice: a model of skeletal malformation in humans with SHP 2 mutations
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
ID TYROSINE PHOSPHATASE SHP 2; ACTIVATED PROTEIN KINASE; COLONY STIMULATING
   FACTOR; FACIO CUTANEOUS SYNDROME; NOONAN SYNDROME; DILATED
   CARDIOMYOPATHY; CONDITIONAL DELETION; SIGNAL TRANSDUCTION;
   COSTELLO SYNDROME; LEOPARD SYNDROME
AB SHP 2 (encoded by PTPN11) is a ubiquitously expressed protein tyrosine phosphatase required for signal transduction by multiple different cell surface receptors. Humans with germline SHP 2 mutations develop Noonan syndrome or LEOPARD syndrome, which are characterized by cardiovascular, neurological and skeletal abnormalities. To study how SHP 2 regulates tissue homeostasis in normal adults, we used a conditional SHP 2 mouse mutant in which loss of expression of SHP 2 was induced in multiple tissues in response to drug administration. Induced deletion of SHP 2 resulted in impaired hematopoiesis, weight loss and lethality. Most strikingly, induced SHP 2 deficient mice developed severe skeletal abnormalities, including kyphoses and scolioses of the spine. Skeletal malformations were associated with alterations in cartilage and a marked increase in trabecular bone mass. Osteoclasts were essentially absent from the bones of SHP 2 deficient mice, thus accounting for the osteopetrotic phenotype. Studies in vitro revealed that osteoclastogenesis that was stimulated by macrophage colony stimulating factor (M CSF) and receptor activator of nuclear factor kappa B ligand (RANKL) was defective in SHP 2 deficient mice. At least in part, this was explained by a requirement for SHP 2 in M CSF induced activation of the pro survival protein kinase AKT in hematopoietic precursor cells. These findings illustrate an essential role for SHP 2 in skeletal growth and remodeling in adults, and reveal some of the cellular and molecular mechanisms involved. The model is predicted to be of further use in understanding how SHP 2 regulates skeletal morphogenesis, which could lead to the development of novel therapies for the treatment of skeletal malformations in human patients with SHP 2 mutations.
C1 [Bauler, Timothy J.; Lapinski, Philip E.; Langewisch, Eric; King, Philip D.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.
   [Kamiya, Nobuhiro; Mishina, Yuji] Univ Michigan, Sch Med, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   [Kamiya, Nobuhiro] Texas Scottish Rite Hosp Children, Ctr Excellence Hip Disorders, Dallas, TX 75219 USA.
   [Wilkinson, John E.] Univ Michigan, Sch Med, Unit Lab Anim Med, Ann Arbor, MI 48109 USA.
   [Feng, Gen Sheng] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Texas Scottish Rite Hospital
   for Children; University of Michigan System; University of Michigan;
   University of California System; University of California San Diego
RP King, PD (通讯作者)，Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.
EM kingp@umich.edu
RI Wilkinson, John/JTV 0835 2023; King, Phil/C 7104 2013
OI Bauler, Timothy/0000 0002 5170 0125
FU National Institutes of Health [AI050699]
FX We thank Eric Brown (University of Pennsylvania) for providing ubiquitin
   ert2 cre mice. This work was supported by National Institutes of Health
   grant AI050699 to P.D.K.
CR Bard Chapeau EA, 2006, MOL CELL BIOL, V26, P4664, DOI 10.1128/MCB.02253 05
   Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017
   Chan RJ, 2006, EXP HEMATOL, V34, P1230, DOI 10.1016/j.exphem.2006.04.017
   Chan RJ, 2003, BLOOD, V102, P2074, DOI 10.1182/blood 2003 04 1171
   Chong ZZ, 2007, HISTOL HISTOPATHOL, V22, P1251, DOI 10.14670/HH 22.1251
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002
   Digilio MC, 2002, AM J HUM GENET, V71, P389, DOI 10.1086/341528
   Edouard T, 2007, CELL MOL LIFE SCI, V64, P1585, DOI 10.1007/s00018 007 6509 0
   Estep AL, 2006, AM J MED GENET A, V140A, P8, DOI 10.1002/ajmg.a.31078
   Feng GS, 2007, CELL RES, V17, P37, DOI 10.1038/sj.cr.7310140
   Fornaro M, 2006, J CELL BIOL, V175, P87, DOI 10.1083/jcb.200602029
   Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005
   Gelb BD, 2006, HUM MOL GENET, V15, pR220, DOI 10.1093/hmg/ddl197
   GORLIN RJ, 1969, AM J DIS CHILD, V117, P652, DOI 10.1001/archpedi.1969.02100030654006
   Gripp KW, 2006, AM J MED GENET A, V140A, P1, DOI 10.1002/ajmg.a.31047
   Hagihara K, 2009, DEV BIOL, V334, P276, DOI 10.1016/j.ydbio.2009.07.029
   Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655
   Hanna N, 2006, FEBS LETT, V580, P2477, DOI 10.1016/j.febslet.2006.03.088
   Ke YH, 2007, MOL CELL BIOL, V27, P6706, DOI 10.1128/MCB.01225 07
   Ke YH, 2006, J BIOL CHEM, V281, P34374, DOI 10.1074/jbc.M607325200
   Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200
   Kolanczyk M, 2007, HUM MOL GENET, V16, P874, DOI 10.1093/hmg/ddm032
   Kontaridis MI, 2008, CIRCULATION, V117, P1423, DOI 10.1161/CIRCULATIONAHA.107.728865
   Kontaridis MI, 2006, J BIOL CHEM, V281, P6785, DOI 10.1074/jbc.M513068200
   Krajewska M, 2008, AM J PATHOL, V172, P1312, DOI 10.2353/ajpath.2008.070594
   Lee CK, 2001, J BONE JOINT SURG AM, V83A, P1495, DOI 10.2106/00004623 200110000 00006
   Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298
   MARSHALL MJ, 1991, HISTOCHEM J, V23, P402, DOI 10.1007/BF01042296
   Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349 7006.2009.01257.x
   Menaa C, 2000, BIOCHEM BIOPH RES CO, V267, P943, DOI 10.1006/bbrc.1999.2042
   Murphy J, 2008, AM J RESP CELL MOL, V38, P380, DOI 10.1165/rcmb.2007 0224RC
   Nguyen TV, 2006, J IMMUNOL, V177, P5990, DOI 10.4049/jimmunol.177.9.5990
   Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749
   NOONAN JA, 1968, AM J DIS CHILD, V116, P373, DOI 10.1001/archpedi.1968.02100020377005
   Noonan JA, 2006, REV ENDOCR METAB DIS, V7, P251, DOI 10.1007/s11154 006 9021 1
   PAPADIMITRIOU JM, 1989, ULTRASTRUCT PATHOL, V13, P343, DOI 10.3109/01913128909048488
   Princen F, 2009, MOL CELL BIOL, V29, P378, DOI 10.1128/MCB.01661 08
   Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911
   Rodriguez Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642
   Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo reports/kve020
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002
   Sarkozy A, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750 1172 3 13
   Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352
   Schindeler A, 2008, BONE, V42, P616, DOI 10.1016/j.bone.2007.11.006
   Schindeler A, 2006, J BONE MINER RES, V21, P1331, DOI 10.1359/JBMR.060603
   SHARLAND M, 1992, ARCH DIS CHILD, V67, P178, DOI 10.1136/adc.67.2.178
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tartaglia M, 2006, AM J HUM GENET, V78, P279, DOI 10.1086/499925
   Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772
   Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156
   Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068
   WIKTORJEDRZEJCZAK W, 1982, J EXP MED, V156, P1516, DOI 10.1084/jem.156.5.1516
   Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673
   Yan JC, 2008, HUM MOL GENET, V17, P936, DOI 10.1093/hmg/ddm366
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Yu X, 2005, BONE, V36, P793, DOI 10.1016/j.bone.2005.01.022
   Zhang EE, 2004, P NATL ACAD SCI USA, V101, P16064, DOI 10.1073/pnas.0405041101
   Zhang SS, 2009, P NATL ACAD SCI USA, V106, P7531, DOI 10.1073/pnas.0811715106
   Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446
   Zou GM, 2006, STEM CELLS, V24, P587, DOI 10.1634/stemcells.2005 0272
NR 64
TC 48
Z9 52
U1 1
U2 6
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 1754 8403
EI 1754 8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD MAR
PY 2011
VL 4
IS 2
BP 228
EP U112
DI 10.1242/dmm.006130
PG 13
WC Cell Biology; Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Pathology
GA 727NG
UT WOS:000287807000011
PM 21068439
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jiang, YY
   Luo, XG
   Zheng, ZP
   Wen, S
   Gao, HW
   Xu, C
   Jiang, M
   Wang, SY
AF Jiang, Yingying
   Luo, Xiaogang
   Zheng, Zhanpeng
   Wen, Shun
   Gao, Hongwei
   Xu, Cheng
   Jiang, Min
   Wang, Siyuan
TI Identification of novel RANKL inhibitors through in silico
   analysis
SO BIOORGANIC CHEMISTRY
LA English
DT Article
DE Osteoporosis; RANKL; 3D QSAR pharmacophore modeling; Virtual screening;
   Molecular docking; In vitro test; MD simulations
ID KAPPA B LIGAND; RECEPTOR ACTIVATOR; DRUG DISCOVERY; OSTEOCLASTOGENESIS;
   DIFFERENTIATION; PREDICTION
AB Receptor activator of nuclear factor kappa B ligand (RANKL) is considered the principal regulator of osteoclast differentiation. Therefore, strategies interfering with the RANKL RANK signaling pathway may effectively inhibit osteoclast differentiation and mitigate bone resorption. Consequently, RANKL has become a promising target for new drug design strategies. Despite extensive research on specific drugs and antibodies, only a few have shown efficacy in treating osteoporosis. To address this challenge, we aimed to explore new approaches for designing drugs for osteoporosis. In this study, a 3D quantitative structure activity relationship (QSAR) pharmacophore model was built for RANKL with reference to known inhibitor IC50 values. The optimal pharmacophore model was then employed as a 3D query to screen databases for novel lead compounds. The obtained compounds were subjected to ADMET and TOPKAT analyses to predict drug pharmacokinetics and toxicity. Molecular docking and de novo evolution approaches were applied to verify the docking binding affinities of the compounds. Five candidate compounds were subjected to further in vitro analyses to assess their anti osteoporotic effects, among which compound 4 demonstrated significant inhibitory activity, achieving an inhibitory rate of 92.6 % on osteoclastogenesis at a concentration of 10 mu M. Subsequent molecular dynamics (MD) simulations to assess the stability and behavior of compound 4 and its evolved variant, ZINC00059014397_Evo, within the RANKL binding site revealed that the variant is a potential therapeutic agent for targeting osteoclasts. This study offers valuable insights for developing next generation RANKL inhibitors for osteoporosis treatments.
C1 [Jiang, Yingying; Luo, Xiaogang; Zheng, Zhanpeng; Wen, Shun; Wang, Siyuan] Shenzhen Technol Univ, Coll Pharm, Shenzhen 518118, Peoples R China.
   [Jiang, Yingying] Shenzhen Univ, Sch Biomed Engn, Guangdong Key Lab Biomed Measurements & Ultrasound, Med Sch,Natl Reg Key Technol Engn Lab Med Ultrasou, Shenzhen 518060, Peoples R China.
   [Gao, Hongwei] Ludong Univ, China Sch Life Sci, Yantai 264025, Shandong, Peoples R China.
   [Xu, Cheng] Jianghan Univ, Sch Life Sci, Inst Microalgae Synthet Biol & Green Mfg, Wuhan 430056, Hubei, Peoples R China.
   [Jiang, Min] Shanghai Jiao Tong Univ, Shanghai Inst Traumatol & Orthopaed, Ruijin Hosp, Sch Med,Dept Orthopaed,Shanghai Key Lab Prevent &, Shanghai 200025, Peoples R China.
C3 Shenzhen Technology University; Shenzhen University; Ludong University;
   Jianghan University; Shanghai Jiao Tong University
RP Wang, SY (通讯作者)，Shenzhen Technol Univ, Coll Pharm, Shenzhen 518118, Peoples R China.; Xu, C (通讯作者)，Jianghan Univ, Sch Life Sci, Inst Microalgae Synthet Biol & Green Mfg, Wuhan 430056, Hubei, Peoples R China.; Jiang, M (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Inst Traumatol & Orthopaed, Ruijin Hosp, Sch Med,Dept Orthopaed,Shanghai Key Lab Prevent &, Shanghai 200025, Peoples R China.
EM xucheng_2007@jhun.edu.cn; jiangm263@163.com; wangsiyuan@sztu.edu.cn
RI jiang, yingying/HPO 9902 2023
FU Natural Science Foundation of Top Talent of SZTU [GDRC202122]; Featured
   Innovation Foundation of Ordinary Higher Education Institutions of
   Guangdong Province [2021KTSCX112]
FX This work was supported by the the Natural Science Foundation of Top
   Talent of SZTU (grant No. GDRC202122) , Featured Innovation Foundation
   of Ordinary Higher Education Institutions of Guangdong Province (grant
   No.2021KTSCX112) .
CR Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   Bakhtyari NG, 2013, J ENVIRON SCI HEAL C, V31, P45, DOI 10.1080/10590501.2013.763576
   BIOVIA, 2022, Dassault Syste'mes
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyce BF, 2023, ENDOCRINOL METAB, V38, P504, DOI 10.3803/EnM.2023.501
   Case D.A., 2023, Amber 2023
   Cerchia C, 2024, EUR J MED CHEM, V263, DOI 10.1016/j.ejmech.2023.115932
   Chen H, 2023, J MED CHEM, V66, P752, DOI 10.1021/acs.jmedchem.2c01661
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Doh KE, 2016, ARCH PHARM RES, V39, P178, DOI 10.1007/s12272 015 0672 x
   El Desoky AH, 2016, J NAT PROD, V79, P1922, DOI 10.1021/acs.jnatprod.6b00158
   Gao HW, 2021, BIOORG CHEM, V114, DOI 10.1016/j.bioorg.2021.105149
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Goracci L, 2023, EUR J MED CHEM, V248, DOI 10.1016/j.ejmech.2022.115070
   Gupta S, 2023, EUR J MED CHEM, V261, DOI 10.1016/j.ejmech.2023.115826
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Huang D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33006 4
   Huang DN, 2020, BIOORG CHEM, V94, DOI 10.1016/j.bioorg.2019.103453
   Huang XL, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2021.12575
   Irwin JJ, 2020, J CHEM INF MODEL, V60, P6065, DOI 10.1021/acs.jcim.0c00675
   Jiang YY, 2019, PHYTOMEDICINE, V54, P278, DOI 10.1016/j.phymed.2018.09.199
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Karasik D, 2016, NAT REV RHEUMATOL, V12, P323, DOI 10.1038/nrrheum.2016.48
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lanka G, 2023, COMPUT BIOL MED, V166, DOI 10.1016/j.compbiomed.2023.107481
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169 409X(00)00129 0
   Liu CZ, 2010, J IMMUNOL, V184, P6910, DOI 10.4049/jimmunol.0904033
   Liu ZH, 2021, EUR J MED CHEM, V210, DOI 10.1016/j.ejmech.2020.112982
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Nardone V, 2014, CLINICS, V69, P438, DOI 10.6061/clinics/2014(06)12
   Nelson CA, 2012, STRUCTURE, V20, P1971, DOI 10.1016/j.str.2012.08.030
   Park JH, 2017, MOL CELLS, V40, P706
   Park Min KH, 2018, CELL MOL LIFE SCI, V75, P2519, DOI 10.1007/s00018 018 2817 9
   Rinotas V, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241411290
   Rinotas V, 2020, J MED CHEM, V63, P12043, DOI 10.1021/acs.jmedchem.0c01316
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Roney M, 2023, J BIOMOL STRUCT DYN, V41, P12186, DOI 10.1080/07391102.2023.2166123
   Scott DE, 2016, NAT REV DRUG DISCOV, V15, P533, DOI 10.1038/nrd.2016.29
   Sun ZJ, 2022, J NAT PROD, V85, P866, DOI 10.1021/acs.jnatprod.1c00997
   Sun ZJ, 2021, BIOORG CHEM, V107, DOI 10.1016/j.bioorg.2020.104537
   Ta HM, 2010, P NATL ACAD SCI USA, V107, P20281, DOI 10.1073/pnas.1011686107
   Tseng CH, 2011, J MED CHEM, V54, P3103, DOI 10.1021/jm1016494
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wang EC, 2019, CHEM REV, V119, P9478, DOI 10.1021/acs.chemrev.9b00055
   Yadav PK, 2023, COMPUT BIOL MED, V166, DOI 10.1016/j.compbiomed.2023.107557
   Yang SY, 2010, DRUG DISCOV TODAY, V15, P444, DOI 10.1016/j.drudis.2010.03.013
   Yayan J, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820934822
   Yuan SH, 2020, FITOTERAPIA, V146, DOI 10.1016/j.fitote.2020.104718
   Yuan SH, 2020, J NAT PROD, V83, P1005, DOI 10.1021/acs.jnatprod.9b00929
   Zhang SX, 2021, EUR J MED CHEM, V213, DOI 10.1016/j.ejmech.2021.113185
   Zhang YT, 2022, BIOORG CHEM, V119, DOI 10.1016/j.bioorg.2021.105511
   Zhang YT, 2022, FITOTERAPIA, V161, DOI 10.1016/j.fitote.2022.105233
   Zhao C, 2019, J MED CHEM, V62, P5885, DOI 10.1021/acs.jmedchem.9b00517
   Zhao C, 2019, BIOORG CHEM, V87, P638, DOI 10.1016/j.bioorg.2019.03.066
   Zheng H, 2024, MOL MED, V30, DOI 10.1186/s10020 024 00788 w
   Zhu M, 2010, J MED CHEM, V53, P8760, DOI 10.1021/jm1011269
NR 58
TC 2
Z9 2
U1 6
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0045 2068
EI 1090 2120
J9 BIOORG CHEM
JI Bioorganic Chem.
PD DEC
PY 2024
VL 153
AR 107826
DI 10.1016/j.bioorg.2024.107826
EA SEP 2024
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Chemistry
GA G7H7B
UT WOS:001318308600001
PM 39299177
DA 2025 08 17
ER

PT J
AU Tan, YY
   Yang, YQ
   Chai, L
   Wong, RWK
   Rabie, ABM
AF Tan, Y. Y.
   Yang, Y Q
   Chai, L.
   Wong, R. W. K.
   Rabie, A. B. M.
TI Effects of vascular endothelial growth factor (VEGF) on MC3T3 E1
SO ORTHODONTICS & CRANIOFACIAL RESEARCH
LA English
DT Article
DE bone remodeling; osteoblast; VEGF
ID MANDIBULAR CONDYLAR GROWTH; OSTEOCLAST DIFFERENTIATION; MATRIX
   METALLOPROTEINASES; CHEMOTACTIC MIGRATION; BONE RESORPTION;
   GENE THERAPY; LONG BONES; MATRIX METALLOPROTEINASE 9; CELLS; MODULATION
AB Structured Abstract
   Osteogenesis and angiogenesis are closely correlated. Vascular endothelial growth factor (VEGF) is believed to play a critical role in skeletal development.
   Authors  
   Tan YY, Yang Y Q, Chai L, Wong RWK, Rabie ABM
   Objective  
   To investigate whether VEGF has direct effects on bone cells activities and to better understand how VEGF promotes bone remodeling.
   Materials and Methods  
   MC3T3 E1 cell line was cultured with and without VEGF in vitro. The cells in both control and test groups were collected at different culture time points of 24, 48 and 72 h. Real time polymerase chain reaction (qPCR) was carried out to quantify the mRNA expression of VEGF receptor (VEGFR2), alkaline phosphatase (ALP) and osteocalcin (OCN), osteoprotegerin (OPG) and receptor activator of nuclear factor kappa beta ligand (RANKL).
   Results  
   The expression of VEGFR2 significantly increased by 53% at 24 h and remained increased by 8% at 72 h compared to control (p < 0.05). ALP showed an early increase by 73% at 24 h (p < 0.001), but dropped by 14 and 41% at 48 and 72 h, respectively (p < 0.05). OCN was down regulated by 41% at 24 h but then up regulated by 149% at 72 h (p < 0.001). The expression of OPG significantly decreased by 7% at 24 h (p < 0.001) while dramatically increased by 133% at 72 h (p < 0.001). RANKL remained unchanged at all three time points (p > 0.05).
   Conclusion  
   VEGF promotes bone remodeling by direct effects on osteoblastic cells via regulating gene expression of ALP, OCN, and OPG through VEGFR2 signaling pathway.
C1 [Tan, Y. Y.; Yang, Y Q; Chai, L.; Wong, R. W. K.; Rabie, A. B. M.] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong
RP Yang, YQ (通讯作者)，Univ Hong Kong, Fac Dent, 34 Hosp Rd, Hong Kong, Hong Kong, Peoples R China.
EM yangyanq@hkucc.hku.hk
RI Wong, Ricky/B 2180 2009; Chai, Lei/F 2767 2010; Yue, Yang/AAE 1652 2019;
   Rabie, Abou Bakr/B 2169 2009
OI Yue, Yang/0000 0001 6934 2357; Yang, Yanqi/0000 0002 3582 1277; 
FU Basic Research HKU [200803159006]
FX This work is supported by Seed Funding Programme for Basic Research HKU
   (200803159006). We thank Mr. Raymond Tong and Mr. Shadow Yeung for their
   technical assistance.
CR AUBIN JE, 1996, PRINCIPLES BONE BIOL, P85
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   BLAVIER L, 1995, J CELL SCI, V108, P3649
   Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009 9120(97)00113 6
   EMAD B, 2006, ARCH ORAL BIOL, V4, P160
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006 291X(89)92678 8
   Fiedler J, 2005, BIOCHEM BIOPH RES CO, V334, P561, DOI 10.1016/j.bbrc.2005.06.116
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Lee AJ, 2000, ANN CLIN BIOCHEM, V37, P432, DOI 10.1258/0004563001899573
   Li R, 2009, J ORTHOP RES, V27, P8, DOI 10.1002/jor.20658
   Lu M, 2006, ANGLE ORTHOD, V76, P598
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   Min JK, 2003, J BIOL CHEM, V278, P39548, DOI 10.1074/jbc.M300539200
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   Rabie ABM, 2007, GENE THER, V14, P972, DOI 10.1038/sj.gt.3302943
   Rabie ABM, 1997, CONNECT TISSUE RES, V36, P337, DOI 10.3109/03008209709160232
   Rabie ABM, 2002, AM J ORTHOD DENTOFAC, V122, P401, DOI 10.1067/mod.2002.125713
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756 3282(95)00185 G
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Wong R W K, 2008, Open Orthop J, V2, P27, DOI 10.2174/1874325000802010027
   Yao SM, 2006, ARCH ORAL BIOL, V51, P596, DOI 10.1016/j.archoralbio.2005.12.006
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
NR 26
TC 26
Z9 29
U1 0
U2 8
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1601 6335
J9 ORTHOD CRANIOFAC RES
JI Orthod. Craniofac. Res.
PD NOV
PY 2010
VL 13
IS 4
BP 223
EP 228
DI 10.1111/j.1601 6343.2010.01498.x
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 659LY
UT WOS:000282569200005
PM 21040465
DA 2025 08 17
ER

PT J
AU Park, D
   Park, CW
   Choi, Y
   Lin, J
   Seo, DH
   Kim, HS
   Lee, SY
   Kang, IC
AF Park, Doori
   Park, Chan Won
   Choi, YoungJin
   Lin, Jingjing
   Seo, Dong Hyun
   Kim, Han Sung
   Lee, Soo Young
   Kang, In Cheol
TI A novel small molecule PPI inhibitor targeting integrin
   αvβ3 osteopontin interface blocks bone resorption
   in vitro and prevents bone loss in mice
SO BIOMATERIALS
LA English
DT Article
DE Small molecule PPI inhibitor; ProteoChip; In silico molecular docking
   simulation; Osteoclast inhibition; Bone resorption; Integrin
   alpha(v)beta(3) OPN interface
ID PROTEIN PROTEIN INTERACTIONS; SRC KINASE; OSTEOCLAST DIFFERENTIATION;
   VITRONECTIN RECEPTOR; SCREENING SYSTEM; BETA 3 INTEGRIN; SEALING ZONE;
   ASSAY SYSTEM; CHIP SYSTEM; RANK LIGAND
AB Small molecule inhibition targeting protein protein interaction (PPI) is now recognized as an emerging and challenging area in drug design. We developed a novel interactive drug discovery methodology known as Protein Chip technology (ProteoChip) as a cutting edge PPI assay system applicable for unique PPI targeting therapeutics integrated with computer aided drug design (CADD). Here, we describe a novel small molecular PPI inhibitor, IPS 02001, which the blocks integrin alpha(v)beta(3) osteopontin interface a novel PPI inhibitor identified by the interactive methodology of both ProteoChip  and CADD based PPI assay. IPS 02001 (6,7 Dichloro 2,3,5,8 tetrahydroxy 1,4 naphthoquinone) was screened from different compound libraries (InterBioScreen, Commercial libraries) using an in silica structure based molecular docking simulation method and a protein chip based protein protein interaction assay system. Additionally, integrin alpha(v)beta(3), an adhesion receptor expressed in osteoclasts (OCs), was implicated in the regulation of OC function via regulation of the cytoskeletal organization of OCs. IPS 02001 blocked OC maturation from murine bone marrow derived macrophages, as well as the resorptive function of OCs. Moreover, treatment with IPS 02001 impaired downstream signaling of integrin alpha(v)beta(3) linked to Pyk2, c Src, PLC gamma 2, and Vav3 and disrupted the actin cytoskeleton in mature OCs. Furthermore, IPS 02001 blocked RANKL induced bone destruction by reducing the number of OCs and protected against ovariectomy induced bone loss in mice. Thus, IPS 02001 may represent a promising new class of anti resorptive drugs for treatment of bone diseases associated with increased OC function. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Park, Doori; Lin, Jingjing; Lee, Soo Young] Ewha Womans Univ, Dept Life Sci, Seoul 120750, South Korea.
   [Park, Doori; Lin, Jingjing; Lee, Soo Young] Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 120750, South Korea.
   [Park, Chan Won; Choi, YoungJin; Kang, In Cheol] Hoseo Univ, BioChip Res Ctr, Asan 336795, South Korea.
   [Kang, In Cheol] Coll Nat Sci, Dept Biol Sci, Asan 336795, South Korea.
   [Kang, In Cheol] Hoseo Univ, Asan 336795, South Korea.
   [Kang, In Cheol] InnoPharmaScreen Inc, Asan 336795, South Korea.
   [Seo, Dong Hyun; Kim, Han Sung] Yonsei Univ, Dept Biomed Engn, Wonju 220710, South Korea.
C3 Ewha Womans University; Ewha Womans University; Hoseo University; Hoseo
   University; Yonsei University
RP Lee, SY (通讯作者)，Ewha Womans Univ, Dept Life Sci, Seoul 120750, South Korea.; Lee, SY (通讯作者)，Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 120750, South Korea.; Kang, IC (通讯作者)，Hoseo Univ, BioChip Res Ctr, Asan 336795, South Korea.
EM leesy@ewha.ac.kr; ickang@hoseo.edu
OI Lin, Jingjing/0000 0002 9194 6154
FU National Research Foundation of Korea (NRF)   Korea Government (MSIP)
   [2013R1A1A2010577, 2013R1A2A1A05005153]; NRF   Ministry of Education
   [NRF 2013R1A1A2010577]
FX This study was supported, in part, by the National Research Foundation
   of Korea (NRF) grant funded by the Korea Government (MSIP) (No.
   2013R1A1A2010577; No. 2013R1A2A1A05005153) and by the Basic Science
   Research Program through the NRF funded by the Ministry of Education
   (NRF 2013R1A1A2010577).
CR Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Arias Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100
   Arkin MR, 2014, CHEM BIOL, V21, P1102, DOI 10.1016/j.chembiol.2014.09.001
   Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi HK, 2011, CELL SIGNAL, V23, P1633, DOI 10.1016/j.cellsig.2011.05.017
   Choi Y, 2010, PROTEOMICS, V10, P72, DOI 10.1002/pmic.200900146
   Cohen S, 2006, ARTHRIT RHEUM ARTHR, V55, P15, DOI 10.1002/art.21706
   DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959 440X(02)00283 X
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404
   Epple H, 2008, MOL CELL BIOL, V28, P3610, DOI 10.1128/MCB.00259 08
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Falchi F, 2014, FUTURE MED CHEM, V6, P343, DOI 10.4155/fmc.13.204
   Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040
   FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   GAN ZR, 1988, J BIOL CHEM, V263, P19827
   GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727 195 43129B
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014 4827(91)90386 9
   Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357 2725(96)00155 0
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768
   Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345
   Kim EY, 2009, BIOCHEM BIOPH RES CO, V389, P415, DOI 10.1016/j.bbrc.2009.08.141
   Kim EY, 2009, BIOCHIP J, V3, P249
   Kim EY, 2008, BIOCHEM BIOPH RES CO, V377, P1288, DOI 10.1016/j.bbrc.2008.10.166
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900
   Lee JK, 2013, BIOCHIP J, V7, P151, DOI 10.1007/s13206 013 7208 6
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lee SK, 2006, J BONE MINER RES, V21, P695, DOI 10.1359/JBMR.060117
   Lin YL, 2007, J BIOL CHEM, V282, P4653, DOI 10.1074/jbc.M608552200
   Lo Conte L, 1999, J MOL BIOL, V285, P2177
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Park CW, 2012, BIOCHIP J, V6, P133, DOI 10.1007/s13206 012 6205 5
   Park CW, 2011, BIOCHIP J, V5, P299, DOI 10.1007/s13206 011 5402 y
   Park C, 2014, BIOCHIP J, V8, P234, DOI 10.1007/s13206 014 8310 0
   REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473
   Rieman DJ, 2001, BONE, V28, P282, DOI 10.1016/S8756 3282(00)00445 2
   Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756 3282(02)00672 5
   Rudolph J, 2007, NAT REV CANCER, V7, P202, DOI 10.1038/nrc2087
   Saltel F, 2008, EUR J CELL BIOL, V87, P459, DOI 10.1016/j.ejcb.2008.01.001
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713
   Sidhu SS, 2003, CHEMBIOCHEM, V4, P14, DOI 10.1002/cbic.200390008
   Suda T, 1997, METHOD ENZYMOL, V282, P223
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   White Alex W., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000641
   Yamamoto M, 1998, ENDOCRINOLOGY, V139, P1411, DOI 10.1210/endo.139.3.5831
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 62
TC 33
Z9 36
U1 1
U2 55
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2016
VL 98
BP 131
EP 142
DI 10.1016/j.biomaterials.2016.05.007
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DQ5XK
UT WOS:000379278400012
PM 27187277
DA 2025 08 17
ER

PT J
AU Barkin, J
   Folia, C
AF Barkin, Jack
   Folia, Christine
TI Emerging therapies: what's new is old and what's old is new
SO CANADIAN JOURNAL OF UROLOGY
LA English
DT Article
DE indications; ED/LUTS; silodosin; cialis; abiraterone; denosumab;
   enzalutamide; fesoterodine
ID URINARY TRACT SYMPTOMS; BENIGN PROSTATIC HYPERPLASIA; PELVIC PAIN
   SYNDROME; MANAGEMENT; TAMSULOSIN; PHYSICIAN; EFFICACY; CANCER
AB Researchers are constantly seeking ways to improve existing drugs, drug mechanisms of activity, find new indications for old drugs or to develop new drugs to treat urological diseases and conditions. In Canada, tadalafil in a 5 mg daily dosage (old drug), and a new drug, silodosin, have recently become available to treat patients who have benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS). In clinical studies, silodosin has shown promise as a treatment for ureteral stones, whereas it has shown conflicting results as a potential treatment for prostatitis. Two new therapies have emerged for treating overactive bladder (OAB): Mirabegron (not yet available in Canada) and fesoterodine (newly introduced in the marketplace). New therapies denosumab (to prevent skeletal events) and abiraterone acetate and enzalutamide were recently approved to treat certain patients with advanced prostate cancer. With the advent of new therapies to treat urological diseases, in many cases, primary management of the patient is often shifted from the urologist to the family physician, and sometimes moved from the oncologist to the urologist.
C1 [Barkin, Jack] Univ Toronto, Humber River Reg Hosp, Dept Surg, Toronto, ON M6A 3B5, Canada.
   [Folia, Christine] Agro Hlth Associates In, Burlington, ON, Canada.
C3 University of Toronto
RP Barkin, J (通讯作者)，Univ Toronto, Dept Surg, 404 960 Lawrence Ave W, Toronto, ON M6A 3B5, Canada.
CR Barkin J, 1993, PERSPECTIVES CARDI S, P25
   Barkin J, 2011, CAN J UROL, V18, P14
   Barkin J, 2011, CAN J UROL, V18, P20
   Chapple Christopher R., 2011, EUR UROL, V59, P342
   Collins MM, 2003, WORLD J UROL, V21, P86, DOI 10.1007/s00345 003 0331 6
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   Dellabella M, 2003, J UROLOGY, V170, P2202, DOI 10.1097/01.ju.0000096050.22281.a7
   Donatucci CF, 2011, BJU INT, V107, P1110, DOI 10.1111/j.1464 410X.2010.09687.x
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gomella LG, 2010, CAN J UROL, V17, P35
   Greenspan MB, 2012, CAN J UROL, V19, P18
   HATANO A, 1994, BRIT J PHARMACOL, V113, P723, DOI 10.1111/j.1476 5381.1994.tb17053.x
   Itoh Y, 2011, INT J UROL, V18, P672, DOI 10.1111/j.1442 2042.2011.02810.x
   Kapoor A, 2012, CAN J UROL, V19, P10
   Liu XS, 2011, CAN J UROL, V18, P24
   Nickel JC, 2011, J UROLOGY, V186, P125, DOI 10.1016/j.juro.2011.03.028
   Nickel JC, 2004, J UROLOGY, V171, P1594, DOI 10.1097/01.ju.0000117811.40279.19
   Nickel JC, 2010, UPDATE GUIDELINES MA
   PERCIVAL RC, 1987, EUR J SURG ONCOL, V13, P41
   Radomski SB, 2012, CAN J UROL, V19, P2
   Rehsia S, 2012, CAN J UROL, V19, P28
   Rosen R, 2003, EUR UROL, V44, P637, DOI 10.1016/j.eururo.2003.08.015
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Sther HI, 2012, NEW ENGL J MED, DOI [10.1056/NEJM0a1207506., DOI 10.1056/NEJMOA.1207506]
   Takasu T, 2007, J PHARMACOL EXP THER, V321, P642, DOI 10.1124/jpet.106.115840
   Tatemichi S, 2006, YAKUGAKU ZASSHI, V126, P209, DOI 10.1248/yakushi.126.209
NR 26
TC 5
Z9 7
U1 0
U2 3
PU CANADIAN J UROLOGY
PI ST LAURENT
PA 2330 WARD ST, STE 604, ST LAURENT, QUEBEC H4M 2V6, CANADA
SN 1195 9479
J9 CAN J UROL
JI Can. J. Urol.
PD OCT
PY 2012
VL 19
SU 1
BP 49
EP 53
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 024MI
UT WOS:000310112900008
PM 23089348
DA 2025 08 17
ER

PT J
AU Liu, MJ
   Zhu, DQ
   Jin, FJ
   Li, S
   Liu, XN
   Wang, XG
AF Liu, Meijing
   Zhu, Danqi
   Jin, Fujun
   Li, Shuang
   Liu, Xiangning
   Wang, Xiaogang
TI Peptide modified geniposidic acid targets bone and effectively promotes
   osteogenesis
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Geniposidic acid; SDSSD; Bone targeting; Osteogenesis
ID EUCOMMIAE CORTEX; DIFFERENTIATION; PHARMACOKINETICS; NANOPARTICLES;
   OSTEOPOROSIS; DELIVERY
AB Background: Geniposidic acid (GPA), one of the active components of Eucommia ulmoides, promote bone for mation and treat osteoporosis by activating farnesoid X receptor (FXR). However, GPA has low oral availability and lack of bone targeting in the treatment of bone related diseases. With the development of modern technology, small molecules, amino acids, or aptamers are used for biological modification of drugs and target cells in bone tissue, which has become the trend of bone targeted research. Methods: In this study, SDSSD (an osteoblast targeting peptide) were modified in GPA using Fmoc solid phase synthesis technique to form a new SDSSD GPA conjugate (SGPA). The bone targeting of SGPA was evaluated using in vivo imaging and cell co culture. In vitro, the effect of SGPA on cytotoxicity, osteoblastic activity, and mineralization ability were studied in mouse primary osteoblasts (OBs). In vivo, the therapeutic effect of SGPA on osteoporosis using an ovariectomized (OVX) mouse model. The bone mass, histomorphometry, serum biochem ical parameters, and the molecular mechanism were evaluated. Results: SGPA was enriched in OBs and tends to accumulate in bone tissue. In vitro, SGPA significantly enhanced the osteogenic activity and mineralization of OBs compared with GPA. In vivo, SGPA enhanced serum BALP and P1NP levels, increased the trabecular bone mass of the mice, and SGPA administration have a higher bone mineralization deposition rate than the GPA treated mice. Moreover, SGPA significantly activated FXR and Runt  related transcription factor 2 (RUNX2). Conclusions: Collectively, SGPA is enriched into OBs, and promotes bone formation by activating FXR RUNX2 signalling, effectively treating osteoporosis at relatively low doses. The translational potential of this article: This study demonstrates a more efficient and safe application of GPA in treating osteoporosis, provide a new concept for the bone targeted application of natural compounds.
C1 [Liu, Meijing; Zhu, Danqi; Jin, Fujun; Li, Shuang; Wang, Xiaogang] Beihang Univ, Sch Engn Med, Key Lab Big Data Based Precis Med, Beijing 100191, Peoples R China.
   [Liu, Meijing; Liu, Xiangning] Jinan Univ, Affiliated Hosp 1, Clin Res Platform Interdiscipline Stomatol, Guangzhou 510632, Peoples R China.
   [Liu, Meijing; Liu, Xiangning] Jinan Univ, Dept Stomatol, Guangzhou 510632, Peoples R China.
C3 Beihang University; Jinan University; Jinan University
RP Wang, XG (通讯作者)，Beihang Univ, Sch Engn Med, Key Lab Big Data Based Precis Med, Beijing 100191, Peoples R China.
EM xiaogangwang@buaa.edu.cn
RI Liu, Xiangning/GON 7899 2022; wang, Xiaogang/J 5003 2017
OI Liu, Meijing/0000 0002 9785 8614
FU National Natural Science Foundation of China [82002362, 92049201];
   General Financial Grant from the China Postdoctoral Science Foundation
   [2021M701421]
FX This work was supported by the National Natural Science Foundation of
   China (No. 82002362, 92049201), General Financial Grant from the China
   Postdoctoral Science Foundation (No. 2021M701421).
CR An J, 2016, XENOBIOTICA, V46, P793, DOI 10.3109/00498254.2015.1129470
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Carbone EJ, 2017, NANOMED NANOTECHNOL, V13, P37, DOI 10.1016/j.nano.2016.08.015
   Chen H, 2016, J ETHNOPHARMACOL, V179, P197, DOI 10.1016/j.jep.2015.12.033
   Cheng C, 2016, DRUG METAB DISPOS, V44, P1853, DOI 10.1124/dmd.116.071647
   Cho SW, 2013, J BONE MINER RES, V28, P2109, DOI 10.1002/jbmr.1961
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Curry SJ, 2018, JAMA J AM MED ASSOC, V319, P2521, DOI 10.1001/jama.2018.7498
   FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092 8674(95)90530 8
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hu B, 2014, J AGR FOOD CHEM, V62, P12443, DOI 10.1021/jf5046766
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liu M, 2022, PHYTOMEDICINE, V102
   Liu YG, 2015, INT J NANOMED, V10, P1387, DOI 10.2147/IJN.S76123
   Maridas DE, 2018, JOVE J VIS EXP, DOI 10.3791/56750
   Pillinger G, 2016, ONCOTARGET, V7, P39784, DOI 10.18632/oncotarget.9289
   Pontikoglou C, 2011, STEM CELL REV REP, V7, P569, DOI 10.1007/s12015 011 9228 8
   Qin X, 2021, J BONE MINER RES, V36, P2081, DOI 10.1002/jbmr.4386
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Sekiya I, 2004, J BONE MINER RES, V19, P256, DOI 10.1359/JBMR.0301220
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Sun Y, 2019, NAT METAB, V1, P485, DOI 10.1038/s42255 019 0053 8
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wu L, 2017, CURR TOP MED CHEM, V17, P1670, DOI 10.2174/1568026617666161116141033
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
NR 34
TC 10
Z9 11
U1 3
U2 38
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD JAN
PY 2023
VL 38
BP 23
EP 31
DI 10.1016/j.jot.2022.07.007
EA OCT 2022
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 5V8FP
UT WOS:000877460200002
PM 36313979
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Birnbaum, MJ
   Picco, J
   Clements, M
   Witwicka, H
   Yang, MH
   Hoey, MT
   Odgren, PR
AF Birnbaum, Mark J.
   Picco, Jenna
   Clements, Meghan
   Witwicka, Hanna
   Yang, Meiheng
   Hoey, Margaret T.
   Odgren, Paul R.
TI Using Osteoclast Differentiation as a Model for Gene Discovery in an
   Undergraduate Cell Biology Laboratory
SO BIOCHEMISTRY AND MOLECULAR BIOLOGY EDUCATION
LA English
DT Article
DE Active learning; biotechnology education; cellular biology;
   computational biology; computers in research and teaching; gene
   expression; genomics proteomics bioinformatics; integration of research
   into undergraduate teaching; molecular biology
ID EXPRESSION
AB A key goal of molecular/cell biology/biotechnology is to identify essential genes in virtually every physiological process to uncover basic mechanisms of cell function and to establish potential targets of drug therapy combating human disease. This article describes a semester long, project oriented molecular/cellular/biotechnology laboratory providing students, within a framework of bone cell biology, with a modern approach to gene discovery. Students are introduced to the topics of bone cells, bone synthesis, bone resorption, and osteoporosis. They then review the theory of microchip gene arrays, and study microchip array data generated during the differentiation of bone resorbing osteoclasts in vitro. The class selects genes whose expression increases during osteoclastogenesis, and researches them in small groups using web based bioinformatics tools. Students then go to a biotechnology company website to find and order small inhibitory RNAs (siRNAs) designed to "knockdown'' expression of the gene of interest. Students then learn to transfect these siRNAs into osteoclasts, stimulate the cells to differentiate, assay osteoclast differentiation in vitro, and measure specific gene expression using real time PCR and immunoblotting. Specific siRNA knockdown resulting in a decrease in osteoclastogenesis is indicative of a gene's physiological relevance. The results are analyzed statistically and presented to the class in groups. In the past 2 years, students identified several genes essential for optimal osteoclast differentiation, including Myo1d. The students hypothesize that the myo1d protein functions in osteoclasts to deliver important proteins to the cell surface via vesicular transport along microfilaments. Student response to the new course was overwhelmingly positive.
C1 [Birnbaum, Mark J.; Picco, Jenna; Clements, Meghan] Merrimack Coll, Dept Biol, N Andover, MA 01845 USA.
   [Witwicka, Hanna; Yang, Meiheng; Odgren, Paul R.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.
   [Hoey, Margaret T.] Fitchburg State Coll, Dept Biol, Fitchburg, MA 01420 USA.
C3 Merrimack College; University of Massachusetts System; University of
   Massachusetts Worcester; Massachusetts System of Public Higher
   Education; Fitchburg State College
RP Birnbaum, MJ (通讯作者)，Merrimack Coll, Dept Biol, N Andover, MA 01845 USA.
EM mark.birnbaum@merrimack.edu
FU Merrimack College; U.S. National Institute of Dental and Craniofacial
   Research [DE 007444]
FX This work was supported by Merrimack College Sabbatical Leave and
   Faculty Development grants to M.J.B., and grant DE 007444 from the U.S.
   National Institute of Dental and Craniofacial Research to P.R.O.
CR Ausubel F.M., 2008, CURRENT PROTOCOLS MO
   Balemans W, 2005, CALCIFIED TISSUE INT, V77, P263, DOI 10.1007/s00223 005 0027 6
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Huber LA, 2000, TRAFFIC, V1, P494, DOI 10.1034/j.1600 0854.2000.010607.x
   Marks S., 2002, PRINCIPLES BONE BIOL, VSecond, P3, DOI DOI 10.1016/B978 012098652 1.50103 7
   ODGREN PR, 2006, BIOL MECH TOOTH ERUP
   Saltel F, 2008, EUR J CELL BIOL, V87, P459, DOI 10.1016/j.ejcb.2008.01.001
   Seabra MC, 2004, TRAFFIC, V5, P393, DOI 10.1111/j.1398 9219.2004.00190.x
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Yang M, 2008, J CELL PHYSIOL, V215, P497, DOI 10.1002/jcp.21331
   Yang MH, 2006, J BIOL CHEM, V281, P23598, DOI 10.1074/jbc.M602191200
   Yang MH, 2006, BLOOD, V107, P2262, DOI 10.1182/blood 2005 08 3365
NR 13
TC 6
Z9 6
U1 0
U2 8
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1470 8175
J9 BIOCHEM MOL BIOL EDU
JI Biochem. Mol. Biol. Educ.
PD NOV DEC
PY 2010
VL 38
IS 6
BP 385
EP 392
DI 10.1002/bmb.20433
PG 8
WC Biochemistry & Molecular Biology; Education, Scientific Disciplines
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Education & Educational Research
GA 693VT
UT WOS:000285254200005
PM 21567867
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhu, W
   Yang, ML
   Yang, GY
   Boden, G
   Li, L
AF Zhu, W.
   Yang, M. L.
   Yang, G. Y.
   Boden, G.
   Li, L.
TI Changes in serum runt related transcription factor 2 levels after a
   6 month treatment with recombinant human parathyroid hormone in patients
   with osteoporosis
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article
DE Bone mineral density; matrix metalloproteinase 13; osteoporosis;
   recombinant human parathyroid hormone; Runt related transcription factor
   2
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; COLLAGENASE 3; OSTEOBLASTS;
   CBFA1; EXPRESSION; INDUCTION; ACTIVATOR; MASS; OVEREXPRESSION
AB Background: The mechanisms regulating the anabolic response of the skeleton for recombinant human PTH (1 34) [rhPTH (1 34)] administration has not been fully elucidated. Aim: The aim of this study was to evaluate the effect of rhPTH (1 34) on serum levels of runt related transcription factor 2 (Runx2) in women with osteoporosis. Methods: Sixty postmenopausal women with osteoporosis (EO group) and 45 control subjects (NC group) were enrolled in this study. The EO group received daily injection of 20 mu g rhPTH (1 34) plus oral 500 mg elemental calcium and 400 IU vitamin D3 for 6 months. Runx2 and Matrix metalloproteinase 13 (MMP 13) were measured with commercially available enzyme linked immunosorbent assay kits. Bone mineral density (BMD) was also measured before and 6 months after rhPTH (1 34) treatment. Results: Serum total Ca2+, phosphate, and bone specific alkaline phosphatase were significantly increased (p<0.05 or p<0.01), and the lumbar spine BMD (LS BMD) was also increased by 4% in patients with osteoporosis after treatment with rhPTH (1 34) (p<0.05). On the contrary, serum Runx2 and MMP 13 were significantly decreased at post treatment (13.1% and 36.6%, respectively, p<0.05 and p<0.01). At baseline, serum Runx2 positively correlated with MMP 13 (r=0.74, p<0.01), the correction remained after adjusting for age and body mass index. Conclusion: The daily injection of rhPTH (1 34) was able to stimulate bone formation. The therapy of 20 mu g rhPTH (1 34) for 6 months resulted in decrease of serum Runx2 and MMP 13. These changes might reflect the increase of active osteoblasts and the better bone homeostasis. (J. Endocrinol. Invest. 35: 602 606, 2012) (C) 2012, Editrice Kurtis
C1 [Zhu, W.; Li, L.] Chongqing Med Univ, Dept Clin Biochem, Coll Lab Med, Chongqing, Peoples R China.
   [Zhu, W.; Li, L.] Chongqing Med Univ, Key Lab Lab Med Diagnost, Coll Lab Med, Minist Educ, Chongqing, Peoples R China.
   [Yang, M. L.; Yang, G. Y.] Chongqing Med Univ, Dept Endocrinol, Affiliated Hosp 2, Chongqing, Peoples R China.
   [Boden, G.] Temple Univ, Sch Med, Div Endocrinol Diabet Metab, Philadelphia, PA 19122 USA.
   [Boden, G.] Temple Univ, Sch Med, Clin Res Ctr, Philadelphia, PA 19122 USA.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University
RP Li, L (通讯作者)，Chongqing Med Univ, Dept Clin Biochem, Coll Lab Med, Chongqing, Peoples R China.
EM lingli31@yahoo.com.cn
RI LIU, YULU/C 4121 2018; Liu, Ying/I 2050 2016; huang,
   yizhou/KPA 7194 2024
FU National Natural Science Foundation of China [30871199, 81070640,
   30971388, 30771037]; Ministry of Education of China [20105503110002]
FX This work was supported by research grants from the National Natural
   Science Foundation of China (30871199, 81070640, 30971388 and 30771037)
   and Doctoral Fund of Ministry of Education of China (20105503110002).
CR Albala C, 1996, INT J OBESITY, V20, P1027
   Anastasilakis AD, 2008, EUR J ENDOCRINOL, V158, P411, DOI 10.1530/EJE 07 0528
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092 8674(95)90487 5
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144
   Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hodsman AB, 1997, J CLIN ENDOCR METAB, V82, P620, DOI 10.1210/jc.82.2.620
   Hwang JS, 2006, OSTEOPOROSIS INT, V17, P373, DOI 10.1007/s00198 005 2002 5
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jiménez MJG, 1999, MOL CELL BIOL, V19, P4431
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002 0225
   Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Liang JD, 1999, CALCIFIED TISSUE INT, V65, P369, DOI 10.1007/s002239900715
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Merciris D, 2007, AM J PATHOL, V170, P1676, DOI 10.2353/ajpath.2007.061069
   Miles RR, 2000, ENDOCRINOLOGY, V141, P28, DOI 10.1210/en.141.1.28
   Miles RR, 2000, ENDOCRINOLOGY, V141, P4533, DOI 10.1210/en.141.12.4533
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Perinpanayagam H, 2004, J ORTHOP RES, V22, P404, DOI 10.1016/S0736 0266(03)00196 7
   Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333
   RIBOT C, 1994, ADV NUTR RES, V9, P257
   Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129
   SCHMIDT IU, 1995, ENDOCRINOLOGY, V136, P5127, DOI 10.1210/en.136.11.5127
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3 4.60
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Winchester SK, 2000, J BIOL CHEM, V275, P23310, DOI 10.1074/jbc.M003004200
   Winchester SK, 1999, J CELL PHYSIOL, V181, P479, DOI 10.1002/(SICI)1097 4652(199912)181:3<479::AID JCP12>3.0.CO;2 D
NR 38
TC 4
Z9 6
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0391 4097
EI 1720 8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD JUN
PY 2012
VL 35
IS 6
BP 602
EP 606
DI 10.3275/8110
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 032YV
UT WOS:000310758400012
PM 22104703
DA 2025 08 17
ER

PT J
AU Xie, X
   Liu, M
   Meng, Q
AF Xie, X.
   Liu, M.
   Meng, Q.
TI Angelica polysaccharide promotes proliferation and osteoblast
   differentiation of mesenchymal stem cells by regulation of long
   non coding RNA H19
SO BONE & JOINT RESEARCH
LA English
DT Article
DE Osteoporosis; Angelica polysaccharide; Long non coding RNA H19;
   Phosphatidylinositol 3 kinase/protein kinase B; Wnt/beta catenin
ID TRADITIONAL CHINESE MEDICINE; GENE EXPRESSION; BONE LOSS; OSTEOPOROSIS;
   MIR 675
AB Objectives
   Osteoporosis is a systemic bone metabolic disease, which often occurs among the elderly. Angelica polysaccharide (AP) is the main component of angelica sinensis, and is widely used for treating various diseases. However, the effects of AP on osteoporosis have not been investigated. This study aimed to uncover the functions of AP in mesenchymal stem cell (MSC) proliferation and osteoblast differentiation.
   Methods
   MSCs were treated with different concentrations of AP, and then cell viability, Cyclin D1 protein level, and the osteogenic markers of runt related transcription factor 2 (RUNX2), osteocalcin (OCN), alkaline phosphatase (ALP), bone morphogenetic protein 2 (BMP 2) were examined by Cell Counting Kit 8 (CCK 8) and western blot assays, respectively. The effect of AP on the main signalling pathways of phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) and Wnt/beta catenin was determined by western blot. Following this, si H19#1 and si H19#2 were transfected into MSCs, and the effects of H19 on cell proliferation and osteoblast differentiation in MSCs were studied. Finally, in vivo experimentation explored bone mineral density, bone mineral content, and the ash weight and dry weight of femoral bone.
   Results
   The results revealed that AP significantly promoted cell viability, upregulated cyclin D1 and increased RUNX2, OCN, ALP, and BMP 2 protein levels in MSCs. Moreover, we found that AP notably activated PI3K/AKT and Wnt/beta catenin signalling pathways in MSCs. Additionally, the relative expression level of H19 was upregulated by AP in a dose dependent manner. The promoting effects of AP on cell proliferation and osteoblast differentiation were reversed by H19 knockdown. Moreover, in vivo experimentation further confirmed the promoting effect of AP on bone formation.
   Conclusion
   These data indicate that AP could promote MSC proliferation and osteoblast differentiation by regulating H19.
C1 [Xie, X.; Liu, M.; Meng, Q.] Jining Med Univ, Dept Endocrinol, Affiliated Hosp, Jining, Peoples R China.
C3 Jining Medical University
RP Meng, Q (通讯作者)，Jining Med Univ, Dept Endocrinol, Affiliated Hosp, Jining, Peoples R China.
EM mengqiang0156@sina.com
CR Berasi SP, 2011, GROWTH FACTORS, V29, P128, DOI 10.3109/08977194.2011.593178
   Cao W, 2010, PHYTOMEDICINE, V17, P598, DOI 10.1016/j.phymed.2009.12.014
   Cappariello A, 2016, HORM MOL BIOL CLIN I, V28, P5, DOI 10.1515/hmbci 2016 0009
   Chen HY, 2005, BIOL PHARM BULL, V28, P865, DOI 10.1248/bpb.28.865
   Dey BK, 2014, GENE DEV, V28, P491, DOI 10.1101/gad.234419.113
   Doyard M, 2012, OSTEOPOROSIS INT, V23, P2435, DOI 10.1007/s00198 011 1871 z
   Du L, 2016, SCI REP UK, V6, DOI 10.1038/srep32261
   Ezzat Zadeh Zahra, 2017, J Aging Res, V2017, P1454103, DOI 10.1155/2017/1454103
   Fathilah SN, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/948080
   Hua YL, 2014, J ETHNOPHARMACOL, V151, P1090, DOI 10.1016/j.jep.2013.12.011
   Huang YP, 2016, SCI REP UK, V6, DOI 10.1038/srep28897
   Huo G, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15038998
   Keniry A, 2012, NAT CELL BIOL, V14, P659, DOI 10.1038/ncb2521
   Lacativa Paulo Gustavo S., 2006, Arq Bras Endocrinol Metab, V50, P674, DOI 10.1590/S0004 27302006000400013
   Li Y, 2017, J CELL PHYSIOL, V232, P2427, DOI 10.1002/jcp.25517
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Liao JY, 2017, ONCOTARGET, V8, P53581, DOI 10.18632/oncotarget.18655
   Lim DW, 2014, NUTRIENTS, V6, P4362, DOI 10.3390/nu6104362
   Liu G., 2017, British Biomedical Bulletin, V5, P301
   Liu G, 2016, ONCOL RES, V23, P99, DOI 10.3727/096504015X14496932933575
   Liu YZ, 2014, INT J ONCOL, V45, P104, DOI 10.3892/ijo.2014.2392
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Okazaki Ryo, 2016, J Bone Metab, V23, P111, DOI 10.11005/jbm.2016.23.3.111
   Peng X, 2018, BONE JOINT RES, V7, P173, DOI 10.1302/2046 3758.72.BJR 2017 0172.R1
   Relation T, 2018, STEM CELLS, V36, P915, DOI 10.1002/stem.2801
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Sanghani Kerai A, 2018, BONE JOINT RES, V7, P289, DOI 10.1302/2046 3758.74.BJR 2017 0302.R1
   Sanghani Kerai A, 2017, BONE JOINT RES, V6, P358, DOI 10.1302/2046 3758.66.BJR 2016 0259.R1
   Shang P, 2003, WORLD J GASTROENTERO, V9, P1963, DOI 10.3748/wjg.v9.i9.1963
   Shao BM, 2004, BIOCHEM BIOPH RES CO, V320, P1103, DOI 10.1016/j.bbrc.2004.06.065
   Sharma S, 2013, BIOCHEM BIOPH RES CO, V436, P607, DOI 10.1016/j.bbrc.2013.05.136
   Su JL, 2010, J BIOL CHEM, V285, P31325, DOI 10.1074/jbc.M109.087122
   Su ZR, 2016, FEBS LETT, V590, P1354, DOI 10.1002/1873 3468.12171
   Tao Y, 2012, ONCOL LETT, V3, P1283, DOI 10.3892/ol.2012.667
   Wang L, 2015, NEOPLASMA, V62, P412, DOI 10.4149/neo_2015_049
   Wang SJ, 2016, CURR PHARM DESIGN, V22, P312
   Wehner D, 2014, CELL REP, V6, P467, DOI 10.1016/j.celrep.2013.12.036
   Xia B, 2017, BONE JOINT RES, V6, P640, DOI 10.1302/2046 3758.612.BJR 2017 0102.R1
   Xu ML, 2017, J BIOL CHEM, V292, P12667, DOI 10.1074/jbc.M117.777581
   Yan B, 2009, INT J ORAL MAXILLOF, V38, P593
   Yang J, 2018, CELL BIOL INT, V42, P867, DOI 10.1002/cbin.10954
   Yang XB, 2005, ANAL SCI, V21, P1177, DOI 10.2116/analsci.21.1177
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang S, 2010, INT J BIOL MACROMOL, V47, P546, DOI 10.1016/j.ijbiomac.2010.07.012
   Zhang Y, 2018, ARTIF CELL NANOMED B, V46, pS254, DOI 10.1080/21691401.2017.1421210
   Zhang Y, 2016, CARBOHYD POLYM, V147, P401, DOI 10.1016/j.carbpol.2016.04.002
   Zhao W, 2012, WORLD J GASTROENTERO, V18, P1048, DOI 10.3748/wjg.v18.i10.1048
   Zhou CH, 2014, AMINO ACIDS, V46, P1673, DOI 10.1007/s00726 014 1729 8
   Zhou XY, 2015, SCI REP UK, V5, DOI 10.1038/srep11516
   Zhu MY, 2008, INT J BIOL MACROMOL, V43, P276, DOI 10.1016/j.ijbiomac.2008.06.008
NR 51
TC 46
Z9 51
U1 4
U2 47
PU BRITISH EDITORIAL SOC BONE JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2046 3758
J9 BONE JOINT RES
JI Bone Jt. Res.
PD JUL
PY 2019
VL 8
IS 7
BP 323
EP 332
DI 10.1302/2046 3758.87BJR 2018 0223.R2
PG 10
WC Cell & Tissue Engineering; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA IN6BY
UT WOS:000478762300005
PM 31463041
DA 2025 08 17
ER

PT J
AU Rotman, SG
   Thompson, K
   Grijpma, DW
   Richards, RG
   Moriarty, TF
   Eglin, D
   Guillaume, O
AF Rotman, Stijn G.
   Thompson, Keith
   Grijpma, Dirk W.
   Richards, Robert G.
   Moriarty, Thomas F.
   Eglin, David
   Guillaume, Olivier
TI Development of bone seeker ?functionalised microspheres as a targeted
   local antibiotic delivery system for bone infections
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Alendronate; Bone infection; Bone targeting; Drug delivery;
   Microparticle; Osteomyelitis
ID DRUG DELIVERY; IN VITRO; NANOPARTICLES; GENTAMICIN; RELEASE; VIVO;
   MANAGEMENT; MECHANISM
AB Objective: Bone infections are challenging to treat because of limited capability of systemic antibiotics to accumulate at the bone site. To enhance therapeutic action, systemic treatments are commonly combined with local antibiotic loaded materials. Nevertheless, available drug carriers have undesirable properties, including inappropriate antibiotic release profiles and nonbiodegradability. To alleviate such limitations, we aim to develop a drug delivery system (DDS) for local administration that can interact strongly with bone mineral, releasing antibiotics at the infected bone site.
   Methods: Biodegradable polyesters (poly (e caprolactone) or poly (D,L lactic acid)) were selected to fabricate antibiotic loaded microspheres by oil in water emulsion. Antibiotic release and antimicrobial effects on Staphylococcus aureus were assessed by zone of inhibition measurements. Microsphere bone affinity was increased by functionalising the bisphosphonate drug alendronate to the microsphere surface using carbodiimide chemistry. Effect of bone targeting microspheres on bone homeostasis was tested by looking at the resorption potential of osteoclasts exposed to the developed microspheres.
   Results: In vitro, the antibiotic release profile from the microspheres was shown to be dependent on the polymer used and the microsphere preparation method. Mineral binding assays revealed that microsphere surface modification with alendronate significantly enhanced interaction with bone like materials. Additionally, alendronate functionalised microspheres did not differentially affect osteoclast mineral resorption in vitro, compared with nonfunctionalised microspheres.
   Conclusion: We report the development and characterisation of a DDS which can release antibiotics in a sustained manner. Surface grafted alendronate groups enhanced bone affinity of the microsphere construct, resulting in a bone targeting DDS.
   The Translational Potential of this Article: The DDS presented can be loaded with hydrophobic antibiotics, representing a potential, versatile and biodegradable candidate to locally treat bone infection.
C1 [Rotman, Stijn G.; Thompson, Keith; Richards, Robert G.; Moriarty, Thomas F.; Eglin, David; Guillaume, Olivier] AO Res Inst Davos, Musculoskeletal Regenerat Program, Davos, Switzerland.
   [Rotman, Stijn G.; Grijpma, Dirk W.] Univ Twente, Tech Med Ctr, Fac Sci & Technol, Dept Biomat Sci & Technol, Enschede, Netherlands.
C3 AO Foundation; University of Twente
RP Guillaume, O (通讯作者)，AO Res Inst Davos, Clavadelerstr 8, CH 7270 Davos, Switzerland.
EM olivier.guillaume@tuwien.ac.at
RI Richards, Robert/I 8235 2015; Guillaume, Olivier/ABF 1855 2020
OI Thompson, Keith/0000 0002 9167 5147; Guillaume,
   Olivier/0000 0003 0735 113X; 
FU AO Foundation; AOTrauma Clinical Priority Program Bone Infection
   [AR2015 04]
FX This work was supported by the AO Foundation and AOTrauma Clinical
   Priority Program Bone Infection. Grant number: AR2015 04. Issued in
   Switzerland.
CR Bistolfi A, 2011, ANTIBIOTIC LOADED CE, V2011
   Boo G J, 2015, PREPARATION GENTAMIC, V60
   Bosworth LA, 2019, J NANOMATER, V2019, DOI 10.1155/2019/4605092
   Cenni E, 2012, J BIOMAT SCI POLYM E, V23, P1285, DOI 10.1163/092050611X580373
   CHA Y, 1990, BIOMATERIALS, V11, P108, DOI 10.1016/0142 9612(90)90124 9
   Chang HI, 2006, J CONTROL RELEASE, V110, P414, DOI 10.1016/j.jconrel.2005.10.028
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Darley ESR, 2004, J ANTIMICROB CHEMOTH, V53, P928, DOI 10.1093/jac/dkh191
   de Miguel L, 2014, INT J PHARMACEUT, V460, P73, DOI 10.1016/j.ijpharm.2013.10.048
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fleisch H., 1995, BISPHOSPHONATES BONE
   Geurts JAP, 2017, WOODH PUBL SER BIOM, P219, DOI 10.1016/B978 0 08 100205 6.00010 0
   Guillaume O, 2017, POLYM ADVAN TECHNOL, V28, P1219, DOI 10.1002/pat.3892
   Guillaume O, 2017, ACTA BIOMATER, V54, P386, DOI 10.1016/j.actbio.2017.03.006
   Guillaume O, 2011, ACTA BIOMATER, V7, P3390, DOI 10.1016/j.actbio.2011.05.009
   Hatzenbuehler J, 2011, AM FAM PHYSICIAN, V84, P1027
   Imbuluzqueta E, 2011, ACTA BIOMATER, V7, P1599, DOI 10.1016/j.actbio.2010.11.031
   Isefuku S, 2003, J ORTHOP TRAUMA, V17, P212, DOI 10.1097/00005131 200303000 00010
   Korzhikov V, 2016, J MICROENCAPSUL, V33, P199, DOI 10.3109/02652048.2016.1144818
   Liggins RT, 2004, INT J PHARMACEUT, V281, P103, DOI 10.1016/j.ijpharm.2004.05.027
   Moshiri A, 2016, CLIN EXP PHARMACOL P, V43, P659, DOI 10.1111/1440 1681.12577
   Neut D, 2009, ACTA ORTHOP, V80, P514, DOI 10.3109/17453670903350040
   Patzakis MJ, 2005, J AM ACAD ORTHOP SUR, V13, P417, DOI 10.5435/00124635 200510000 00006
   Pranatharthiharan S, 2017, DRUG DELIV, V24, P20, DOI 10.1080/10717544.2016.1225856
   Ribeiro CAS, 2017, COLLOID POLYM SCI, V295, P1271, DOI 10.1007/s00396 016 4007 3
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   SAMPATH SS, 1990, J PHARM SCI US, V79, P428, DOI 10.1002/jps.2600790514
   Sánchez E, 2001, EUR J PHARM BIOPHARM, V52, P151, DOI 10.1016/S0939 6411(01)00169 2
   Schmidmaier G, 2013, BIOMATERIALS ASS INF, P435
   Schnieders J, 2006, BIOMATERIALS, V27, P4239, DOI 10.1016/j.biomaterials.2006.03.032
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   Sinha VR, 2004, INT J PHARMACEUT, V278, P1, DOI 10.1016/j.ijpharm.2004.01.044
   SORENSEN TS, 1990, ACTA ORTHOP SCAND, V61, P353, DOI 10.3109/17453679008993535
   Spiridonova TI, 2019, J PHARM SCI US, V108, P2690, DOI 10.1016/j.xphs.2019.03.036
   Sunoqrot S, 2017, COLLOID POLYM SCI, V295, P2051, DOI 10.1007/s00396 017 4183 9
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Ungaro F, 2012, J CONTROL RELEASE, V157, P149, DOI 10.1016/j.jconrel.2011.08.010
   Yan JL, 2011, BIOMACROMOLECULES, V12, P2562, DOI 10.1021/bm200375x
   Yewle JN, 2012, THESIS
   Yin Q, 2016, P NATL ACAD SCI USA, V113, pE4601, DOI 10.1073/pnas.1603316113
   Ze Liu H, 2011, EFFECTS HYDROPHILICI, P675
NR 42
TC 27
Z9 29
U1 0
U2 38
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD MAR
PY 2020
VL 21
BP 136
EP 145
DI 10.1016/j.jot.2019.07.006
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA LH5WR
UT WOS:000528855800019
PM 32309139
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bevilacqua, M
   Dominguez, LJ
   Rosini, S
   Barbagallo, M
AF Bevilacqua, M
   Dominguez, LJ
   Rosini, S
   Barbagallo, M
TI Bisphosphonates and atherosclerosis: why?
SO LUPUS
LA English
DT Article
DE atherosclerosis; bisphosphonates; osteoporosis; vascular calcifications
ID MACROPHAGE LIKE; IN VITRO; CALCIFICATION; MECHANISMS; ACCUMULATION;
   IBANDRONATE; SUPPRESSION; ALENDRONATE; INHIBITION; ETIDRONATE
AB The increasing knowledge on bone calcification processes has revealed some similarities with vascular tissue, where calcifications of arteries and cardiac valves contribute to several cardiovascular problems, such as heart failure, systolic hypertension, and myocardial and peripheral ischemic disease. Bisphosphonates have been used extensively for over two decades for the treatment of diseases associated with excessive bone resorption, i.e., osteoporosis, osteolytic bone metastasis, hypercalcemia and Paget's disease, by blocking osteoclastic function. Etidronate, pamidronate and clodronate has been shown to inhibit the development of experimental atherosclerosis, and proposed mechanisms for this action include inhibition of arterial calcification and lipid accumulation, degradation of atherogenic LDL cholesterol and reduced foam cell formation. Bisphosphonates inhibit various enzymes involved in cholesterol biosynthesis and suppress macrophages in atheromatous lesions. The possibility of pharmacological agents that effectively treat both osteoporosis and atherosclerosis is attractive, however, current evidence is not conclusive and further research is necessary to confirm these actions in the clinical setting.
C1 Univ Milan, Endocrine & Diabet Unit, Osped L Sacco, Milan, Italy.
   Univ Palermo, Dept Internal Med, Geriatr Unit, Palermo, Italy.
C3 University of Milan; Luigi Sacco Hospital; University of Palermo
RP Bevilacqua, M (通讯作者)，Serv Endocrinol & Diabetol, Osped L Sacco,Via GB Grassi 74, I 20157 Milan, Italy.
EM mauriziobevilacqua@fastwebnet.it
RI BARBAGALLO, MARIO/K 4794 2017; Bevilacqua, Maurizio/B 4816 2012
OI BARBAGALLO, MARIO/0000 0002 1349 6530; dominguez, ligia
   j/0000 0003 1466 8610; 
CR ACIERNO LJ, 1994, HIST CARDIOLOGY, P109
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Bukowski JF, 2005, BIOCHEM BIOPH RES CO, V328, P746, DOI 10.1016/j.bbrc.2004.11.075
   CRAM RL, 1971, NEW ENGL J MED, V285, P1012, DOI 10.1056/NEJM197110282851808
   Demer LL, 2003, ARTERIOSCL THROM VAS, V23, P1739, DOI 10.1161/01.ATV.0000093547.63630.0F
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   Hayden MR, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475 2840 4 4
   Ikehira H, 1999, J Nucl Med Technol, V27, P41
   Koshiyama H, 2000, J CLIN ENDOCR METAB, V85, P2793, DOI 10.1210/jc.85.8.2793
   KRAMSCH DM, 1981, SCIENCE, V213, P1511, DOI 10.1126/science.6792706
   KRAMSCH DM, 1978, CIRC RES, V42, P562, DOI 10.1161/01.RES.42.4.562
   MERADJI M, 1978, J PEDIATR US, V92, P401, DOI 10.1016/S0022 3476(78)80427 2
   MONKKONEN J, 1994, J DRUG TARGET, V2, P299, DOI 10.3109/10611869409015910
   Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers MJ, 1997, PHARMACEUT RES, V14, P625, DOI 10.1023/A:1012157212793
   ROSENBLUM IY, 1975, ATHEROSCLEROSIS, V22, P411, DOI 10.1016/0021 9150(75)90021 0
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   RUSSELL RGG, 1972, LANCET, V1, P10
   Shimshi M, 2005, BIOCHEM BIOPH RES CO, V328, P790, DOI 10.1016/j.bbrc.2004.12.091
   Tankó LB, 2005, OSTEOPOROSIS INT, V16, P184, DOI 10.1007/s00198 004 1662 x
   Tuominen OM, 2002, METHOD FIND EXP CLIN, V24, P487, DOI 10.1358/mf.2002.24.8.705068
   Ylitalo R, 1996, J LAB CLIN MED, V127, P200, DOI 10.1016/S0022 2143(96)90079 7
   YLITALO R, 1994, J LAB CLIN MED, V123, P769
   Ylitalo R, 1998, PHARMACOL TOXICOL, V83, P125, DOI 10.1111/j.1600 0773.1998.tb01455.x
   Ylitalo R, 2002, PHARMACOL TOXICOL, V90, P139, DOI 10.1034/j.1600 0773.2002.900305.x
   Ylitalo R, 1997, LIFE SCI, V62, P413, DOI 10.1016/S0024 3205(97)01134 X
   ZHU BQ, 1994, CARDIOLOGY, V85, P370, DOI 10.1159/000176738
NR 31
TC 36
Z9 42
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0961 2033
EI 1477 0962
J9 LUPUS
JI Lupus
PY 2005
VL 14
IS 9
BP 773
EP 779
DI 10.1191/0961203305lu2219oa
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 971VJ
UT WOS:000232412600029
PM 16218486
DA 2025 08 17
ER

PT J
AU Wang, LP
   Guo, TZ
   Wei, TP
   Li, WW
   Shi, XY
   Clark, JD
   Kingery, WS
AF Wang, Liping
   Guo, Tian Zhi
   Wei, Tzuping
   Li, Wen Wu
   Shi, Xiaoyou
   Clark, J. David
   Kingery, Wade S.
TI Bisphosphonates Inhibit Pain, Bone Loss, and Inflammation in a Rat Tibia
   Fracture Model of Complex Regional Pain Syndrome
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID SYMPATHETIC DYSTROPHY SYNDROME; SYNDROME TYPE I; NOCICEPTIVE
   SENSITIZATION; SIGNALING CONTRIBUTES; MINERAL DENSITY; DOUBLE BLIND;
   TNF ALPHA; ALENDRONATE; ACTIVATION; CELLS
AB BACKGROUND: Bisphosphonates are used to prevent the bone loss and fractures associated with osteoporosis, bone metastases, multiple myeloma, and osteogenesis deformans. Distal limb fractures cause regional bone loss with cutaneous inflammation and pain in the injured limb that can develop into complex regional pain syndrome (CRPS). Clinical trials have reported that antiresorptive bisphosphonates can prevent fracture induced bone loss, inhibit serum inflammatory cytokine levels, and alleviate CRPS pain. Previously, we observed that the inhibition of inflammatory cytokines or adaptive immune responses attenuated the development of pain behavior in a rat fracture model of CRPS, and we hypothesized that bisphosphonates could prevent pain behavior, trabecular bone loss, postfracture cutaneous cytokine upregulation, and adaptive immune responses in this CRPS model.
   METHODS: Rats underwent tibia fracture and cast immobilization for 4 weeks and were chronically administered either subcutaneously perfused alendronate or oral zoledronate. Behavioral measurements included hindpaw von Frey allodynia, unweighting, warmth, and edema. Bone microarchitecture was measured by microcomputed tomography, and bone cellular activity was evaluated by static and dynamic histomorphometry. Spinal cord Fos immunostaining was performed, and skin cytokine (tumor necrosis factor, interleukin [IL] 1, IL 6) and nerve growth factor (NGF) levels were determined by enzyme immunoassay. Skin and sciatic nerve immunoglobulin levels were determined by enzyme immunoassay.
   RESULTS: Rats with tibia fractures developed hindpaw allodynia, unweighting, warmth, and edema, increased spinal Fos expression and trabecular bone loss in the lumbar vertebra and bilateral distal femurs as measured by microcomputed tomography, increased trabecular bone resorption and osteoclast surface with decreased bone formation rates, increased cutaneous inflammatory cytokine and NGF expression, and elevated immunocomplex deposition in skin and nerve. Alendronate (60 mu g/kg/d subcutaneously [s.c.]) or zoledronate (3 mg/kg/d orally) treatment for 28 days, started at the time of fracture, completely inhibited the development of hindpaw allodynia and reduced hindpaw unweighting by 44% +/  13% and 58% +/  5%, respectively. Orally administered zoledronate (3 mg/kg/d for 21 days) treatment also completely reversed established allodynia and unweighting when started at 4 weeks postfracture. Histomorphometric and microcomputed tomography analysis demonstrated that both the 3 and 60 mu g/kg/d alendronate treatments reversed trabecular bone loss (an 88% +/  25% and 188% +/  39% increase in the ipsilateral distal femur BV/TV, respectively) and blocked the increase in osteoclast numbers and erosion surface observed in bilateral distal femurs and in L5 vertebra of the fracture rats. Alendronate treatment inhibited fracture induced increases in hindpaw inflammatory mediators, reducing postfracture levels of tumor necrosis factor by 43% +/  9%, IL 1 by 60% +/  9%, IL 6 by 56% +/  14%, and NGF by 37% +/  14%, but had no effect on increased spinal cord Fos expression, or skin and sciatic nerve immunocomplex deposition.
   CONCLUSIONS: Collectively, these results indicate that bisphosphonate therapy inhibits pain, osteoclast activation, trabecular bone loss, and cutaneous inflammation in the rat fracture model of CRPS, data supporting the hypothesis that bisphosphonate therapy can provide effective multimodal treatment for CRPS.
C1 [Wang, Liping; Guo, Tian Zhi; Wei, Tzuping; Kingery, Wade S.] Vet Affairs Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv, Palo Alto, CA USA.
   [Li, Wen Wu; Shi, Xiaoyou; Clark, J. David] Stanford Univ, Dept Anesthesiol, Sch Med, Stanford, CA 94305 USA.
   [Li, Wen Wu; Shi, Xiaoyou; Clark, J. David] Vet Affairs Palo Alto Hlth Care Syst, Anesthesiol Serv, Palo Alto, CA USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Palo Alto Health Care System; Stanford University; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto
   Health Care System
RP Kingery, WS (通讯作者)，Vet Affairs Palo Alto Hlth Care Syst, Phys Med & Rehabil Serv 117, 3801 Miranda Ave, Palo Alto, CA 94304 USA.
EM wkingery@stan ford.edu
RI Li, Wen Wu/G 7259 2011; Wang, Liping/JRY 1318 2023; Clark,
   J/JGD 6932 2023
FU Rehabilitation Research and Development Service, Veterans Health
   Administration, Department of Veteran Affairs [A4265R, F7137R]; National
   Institute of Health [DK067197, NS072168]
FX Rehabilitation Research and Development Service, Veterans Health
   Administration, Department of Veteran Affairs (A4265R, F7137R), and the
   National Institute of Health (DK067197, NS072168).
CR Adami S, 1997, ANN RHEUM DIS, V56, P201, DOI 10.1136/ard.56.3.201
   Amelio PD, 2008, J BONE MINER RES, V23, P373, DOI 10.1359/JBMR.071031
   BASLE MF, 1983, METAB BONE DIS RELAT, V4, P305, DOI 10.1016/S0221 8747(83)80004 6
   Bean DJ, 2016, EUR J PAIN, V20, P884, DOI 10.1002/ejp.813
   BICKERSTAFF DR, 1993, BRIT J RHEUMATOL, V32, P46
   Bilezikian JP, 2009, AM J MED, V122, P14, DOI 10.1016/j.amjmed.2008.12.003
   Birklein F, 2014, J PAIN, V15, P485, DOI 10.1016/j.jpain.2014.01.490
   CECCHINI MG, 1990, J BONE MINER RES, V5, P1019
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Clement EV, 1999, BONE, V24, P131
   Clement EV, 2000, J BONE MINER RES, V15, P586
   Clement EVP, 2002, J BONE MINER RES, V17, P2247, DOI 10.1359/jbmr.2002.17.12.2247
   Cossins L, 2013, EUR J PAIN, V17, P158, DOI 10.1002/j.1532 2149.2012.00217.x
   de Mos M, 2007, PAIN, V129, P12, DOI 10.1016/j.pain.2006.09.008
   de Mos M, 2009, CLIN J PAIN, V25, P590, DOI 10.1097/AJP.0b013e3181a11623
   Dirckx M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/718201
   Dirschl DR, 1997, BONE, V21, P79, DOI 10.1016/S8756 3282(97)00082 3
   GENANT HK, 1975, RADIOLOGY, V117, P21, DOI 10.1148/117.1.21
   Goebel A, 2010, ANN INTERN MED, V152, P152, DOI 10.7326/0003 4819 152 3 201002020 00006
   Green JR, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.24154
   Groeneweg JG, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 91
   Guo TZ, 2012, MOL PAIN, V8, DOI 10.1186/1744 8069 8 85
   Guo TZ, 2006, PAIN, V121, P158, DOI 10.1016/j.pain.2005.12.022
   Guo TZ, 2004, PAIN, V108, P95, DOI 10.1016/j.pain.2003.12.010
   Gür A, 2003, YONSEI MED J, V44, P99
   Harris JA, 1998, BRAIN RES BULL, V45, P1, DOI 10.1016/S0361 9230(97)00277 3
   Huygen FJPM, 2002, MEDIAT INFLAMM, V11, P47, DOI 10.1080/09629350210307
   Karacan I, 2004, J BONE MINER METAB, V22, P44, DOI 10.1007/s00774 003 0447 1
   Karlsson M, 1996, BONE, V18, P19, DOI 10.1016/8756 3282(95)00422 X
   KOZIN F, 1976, AM J MED, V60, P321, DOI 10.1016/0002 9343(76)90747 6
   Li WW, 2014, PAIN, V155, P2377, DOI 10.1016/j.pain.2014.09.007
   Li WW, 2012, ANESTHESIOLOGY, V116, P882, DOI 10.1097/ALN.0b013e31824bb303
   Li WW, 2010, PAIN, V151, P843, DOI 10.1016/j.pain.2010.09.026
   Li WW, 2009, PAIN, V144, P303, DOI 10.1016/j.pain.2009.04.033
   Li WW, 2013, PAIN, V154, P1224, DOI 10.1016/j.pain.2013.03.033
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Manicourt DH, 2004, ARTHRITIS RHEUM US, V50, P3690, DOI 10.1002/art.20591
   Miwa A, 2012, AM J HEMATOL, V87, P1084, DOI 10.1002/ajh.23328
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   Munnikes RJM, 2005, MEDIAT INFLAMM, P366, DOI 10.1155/MI.2005.366
   Papadaki HA, 2004, J BONE MINER METAB, V22, P577, DOI 10.1007/s00774 004 0526 y
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Robinson JN, 2004, PAIN MED, V5, P276, DOI 10.1111/j.1526 4637.2004.04038.x
   Sabsovich I, 2008, PAIN, V138, P47, DOI 10.1016/j.pain.2007.11.004
   Sabsovich I, 2008, PAIN, V137, P507, DOI 10.1016/j.pain.2007.10.013
   Sandroni P, 2003, PAIN, V103, P199, DOI 10.1016/S0304 3959(03)00065 4
   SANSONI P, 1995, J BONE MINER RES, V10, P1719
   SARANGI PP, 1993, J BONE JOINT SURG BR, V75, P450, DOI 10.1302/0301 620X.75B3.8496220
   Shi XY, 2013, REGUL PEPTIDES, V186, P92, DOI 10.1016/j.regpep.2013.08.001
   Varenna M, 2000, J RHEUMATOL, V27, P1477
   Varenna M, 2013, RHEUMATOLOGY, V52, P534, DOI 10.1093/rheumatology/kes312
   Wei TP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974 015 0472 8
   Wei TP, 2009, PAIN, V144, P278, DOI 10.1016/j.pain.2009.04.020
   Wei TP, 2009, EUR J PAIN, V13, P253, DOI 10.1016/j.ejpain.2008.04.014
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Wolf AM, 2006, HAEMATOLOGICA, V91, P1165
   Wong R, 2002, Cochrane Database Syst Rev, pCD002068
NR 61
TC 35
Z9 41
U1 1
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003 2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD OCT
PY 2016
VL 123
IS 4
BP 1033
EP 1045
DI 10.1213/ANE.0000000000001518
PG 13
WC Anesthesiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anesthesiology
GA DW8RT
UT WOS:000383923900031
PM 27636578
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Mulcrone, PL
   Campbell, JP
   Clément Demange, L
   Anbinder, AL
   Merkel, AR
   Brekken, RA
   Sterling, JA
   Elefteriou, F
AF Mulcrone, Patrick L.
   Campbell, J. Preston
   Clement Demange, Lise
   Anbinder, Ana Lia
   Merkel, Alyssa R.
   Brekken, Rolf A.
   Sterling, Julie A.
   Elefteriou, Florent
TI Skeletal Colonization by Breast Cancer Cells Is Stimulated by an
   Osteoblast and β2AR Dependent Neo Angiogenic Switch
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BREAST CANCER; OSTEOBLAST; VEGF; beta 2AR; BONE VASCULATURE
ID SYMPATHETIC NERVOUS SYSTEM; CHRONIC STRESS; IN VITRO; BONE; METASTASIS;
   TUMOR; GROWTH; ACTIVATION; EXPRESSION; SURVIVAL
AB The skeleton is a common site for breast cancer metastasis. Although significant progress has been made to manage osteolytic bone lesions, the mechanisms driving the early steps of the bone metastatic process are still not sufficiently understood to design efficacious strategies needed to inhibit this process and offer preventative therapeutic options. Progression and recurrence of breast cancer, as well as reduced survival of patients with breast cancer, are associated with chronic stress, a condition known to stimulate sympathetic nerve outflow. In this study, we show that stimulation of the beta 2 adrenergic receptor (beta 2AR) by isoproterenol, used as a pharmacological surrogate of sympathetic nerve activation, led to increased blood vessel density and Vegf a expression in bone. It also raised levels of secreted Vegf a in osteoblast cultures, and accordingly, the conditioned media from isoproterenol treated osteoblast cultures promoted new vessel formation in two ex vivo models of angiogenesis. Blocking the interaction between Vegf a and its receptor, Vegfr2, blunted the increase in vessel density induced by isoproterenol. Genetic loss of the b2AR globally, or specifically in type 1 collagen expressing osteoblasts, diminished the increase in Vegf positive osteoblast number and bone vessel density induced by isoproterenol, and reduced the higher incidence of bone metastatic lesions induced by isoproterenol after intracardiac injection of an osteotropic variant of MDA MB 231 breast cancer cells. Inhibition of the interaction between Vegf a and Vegfr2 with the blocking antibody mcr84 also prevented the increase in bone vascular density and bone metastasis triggered by isoproterenol. Together, these results indicate that stimulation of the b2AR in osteoblasts triggers a Vegf dependent neo angiogenic switch that promotes bone vascular density and the colonization of the bone microenvironment by metastatic breast cancer cells. (C) 2017 American Society for Bone and Mineral Research.
C1 [Mulcrone, Patrick L.; Campbell, J. Preston; Sterling, Julie A.] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Mulcrone, Patrick L.; Merkel, Alyssa R.; Sterling, Julie A.] Vanderbilt Univ, Vanderbilt Ctr Bone Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Clement Demange, Lise; Elefteriou, Florent] Baylor Coll Med, Dept Orthoped Surg, 1 Baylor Plaza, Houston, TX 77030 USA.
   [Anbinder, Ana Lia] Univ Estadual Paulista UNESP, Dept Biosci & Oral Diag, Sao Jose Dos Campos Sch Dent, Sao Jose Dos Campos, Brazil.
   [Merkel, Alyssa R.; Sterling, Julie A.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA.
   [Merkel, Alyssa R.; Sterling, Julie A.; Elefteriou, Florent] Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Nashville, TN USA.
   [Brekken, Rolf A.] UT Southwestern, Dept Surg, Dallas, TX USA.
   [Brekken, Rolf A.] UT Southwestern, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA.
   [Elefteriou, Florent] Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.
C3 Vanderbilt University; Vanderbilt University; Baylor College of
   Medicine; Universidade Estadual Paulista; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Tennessee Valley
   Healthcare System; Vanderbilt University; University of Texas System;
   University of Texas Southwestern Medical Center; University of Texas
   System; University of Texas Southwestern Medical Center; Baylor College
   of Medicine
RP Elefteriou, F (通讯作者)，Baylor Coll Med, Dept Orthoped Surg, 1 Baylor Plaza, Houston, TX 77030 USA.; Elefteriou, F (通讯作者)，Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.
RI ; Elefteriou, Florent/P 2586 2017; Anbinder, Ana/B 8816 2012
OI Merkel, Alyssa/0000 0001 6498 4211; Anbinder, Ana
   Lia/0000 0003 3930 4274; Elefteriou, Florent/0000 0002 2972 5633; 
FU NCI [R01CA 168 717, R01 CA163 199, F31 CA192 748]; Department of
   Veterans Affairs [1 I01 BX 001 957]
FX This work was supported by the following grants: NCI (R01CA 168 717 to
   FE; R01 CA163 199 to JAS; F31 CA192 748 to PLM) and the Department of
   Veterans Affairs (1 I01 BX 001 957 to JAS).
CR American Cancer Society, 2016, CANC FACTS FIG 2016
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Asada N, 2013, CELL STEM CELL, V12, P737, DOI 10.1016/j.stem.2013.05.001
   Barron TI, 2012, THER ADV MED ONCOL, V4, P113, DOI 10.1177/1758834012439738
   Campbell JP, 2015, SCI REP UK, V5, DOI 10.1038/srep12635
   Campbell JP, 2012, JOVE J VIS EXP, DOI 10.3791/4260
   Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Chida Y, 2008, NAT CLIN PRACT ONCOL, V5, P466, DOI 10.1038/ncponc1134
   Costa L, 2008, SUPPORT CARE CANCER, V16, P879, DOI 10.1007/s00520 008 0418 0
   Creed SJ, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0655 3
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Deckers MML, 2001, BONE, V28, P14, DOI 10.1016/S8756 3282(00)00428 2
   Dy GK, 2013, CA CANCER J CLIN, V63, P249, DOI 10.3322/caac.21184
   Elefteriou F, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.61
   Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224
   Golbidi S, 2015, AM J PHYSIOL HEART C, V308, pH1476, DOI 10.1152/ajpheart.00859.2014
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324
   HILL EL, 1991, CELL TISSUE RES, V264, P469, DOI 10.1007/BF00319037
   Hulsurkar M, 2017, ONCOGENE, V36, P1525, DOI 10.1038/onc.2016.319
   Itoh Y, 1998, J NEUROL SCI, V157, P73, DOI 10.1016/S0022 510X(98)00050 1
   Ji Y, 2013, CELL DIV, V8, DOI 10.1186/1747 1028 8 1
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Le CP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10634
   Ma Y, 2011, ENDOCRINOLOGY, V152, P1412, DOI 10.1210/en.2010 0881
   Madden KS, 2011, BREAST CANCER RES TR, V130, P747, DOI 10.1007/s10549 011 1348 y
   Melhem Bertrandt A, 2011, J CLIN ONCOL, V29, P2645, DOI 10.1200/JCO.2010.33.4441
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nagaraja AS, 2016, ONCOGENE, V35, P2390, DOI 10.1038/onc.2015.302
   Palesh O, 2007, J PSYCHOSOM RES, V63, P233, DOI 10.1016/j.jpsychores.2007.05.012
   Pasic L, 2011, GENE DEV, V25, P1641, DOI 10.1101/gad.2025611
   Pasquier E, 2011, ONCOTARGET, V2, P797
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Roland CL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007669
   Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535 7163.MCT 09 0280
   Saito T, 2010, NAT MED, V16, P678, DOI 10.1038/nm.2146
   Santini D, 2011, J CELL PHYSIOL, V226, P780, DOI 10.1002/jcp.22402
   Sastry KSR, 2007, J BIOL CHEM, V282, P14094, DOI 10.1074/jbc.M611370200
   Sekiguchi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028639
   Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008 5472.CAN 10 0522
   Song FN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108507
   Stiles JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060021
   Sullivan LA, 2010, MABS AUSTIN, V2, P165, DOI 10.4161/mabs.2.2.11360
   Sullivan LA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012031
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447
   Wang HM, 2013, ANN ONCOL, V24, P1312, DOI 10.1093/annonc/mds616
   Yang L, 2014, GASTROENTEROLOGY, V146, P1339, DOI 10.1053/j.gastro.2014.01.061
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   Yu LL, 2008, INVEST OPHTH VIS SCI, V49, P522, DOI 10.1167/iovs.07 1175
   Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085
NR 54
TC 58
Z9 68
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2017
VL 32
IS 7
BP 1442
EP 1454
DI 10.1002/jbmr.3133
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EZ0FB
UT WOS:000404375300007
PM 28300321
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Matsumoto, K
   Hayashi, K
   Murata Hirai, K
   Iwasaki, M
   Okamura, H
   Minato, N
   Morita, CT
   Tanaka, Y
AF Matsumoto, Kenji
   Hayashi, Kosuke
   Murata Hirai, Kaoru
   Iwasaki, Masashi
   Okamura, Haruki
   Minato, Nagahiro
   Morita, Craig T.
   Tanaka, Yoshimasa
TI Targeting Cancer Cells with a Bisphosphonate Prodrug
SO CHEMMEDCHEM
LA English
DT Article
DE anticancer agents; bisphosphonates; farnesyl diphosphate synthase;
   lipophilicity; prodrugs
ID GERANYLGERANYL DIPHOSPHATE SYNTHASE; TRANSCRIPTASE INHIBITOR TENOFOVIR;
   PLUS ZOLEDRONIC ACID; BONE RESORPTION; ISOPRENOID BISPHOSPHONATES;
   IN VITRO; THERAPY; DIPHOSPHONATES; PYROPHOSPHATE; ALAFENAMIDE
AB Nitrogen containing bisphosphonates have antitumor activity in certain breast cancer and myeloma patients. However, these drugs have limited oral absorption, tumor cell entry and activity, and cause bone side effects. The potencies of phosphorylated antiviral drugs have been increased by administering them as prodrugs, in which the negative charges on the phosphate moieties are masked to make them lipophilic. We synthesized heterocyclic bisphosphonate (BP) prodrugs in which the phosphonate moieties are derivatized with pivaloyloxymethyl (pivoxil) groups and that lack the hydroxy "bone hook" on the geminal carbon. When the lipophilic BP prodrugs enter tumor cells, they are converted into their active forms by intracellular esterases. The most active BP prodrug, tetrakispivaloyloxymethyl 2 (thiazole 2 ylamino)ethylidene 1,1 bisphosphonate (7), was found to potently inhibit the in vitro growth of a variety of tumor cell lines, especially hematopoietic cells, at nanomolar concentrations. Consistent with this fact, compound 7 inhibited the prenylation of the RAP1A small GTPase signaling protein at concentrations as low as 1 10 nm. In preclinical studies, 7 slowed the growth of human bladder cancer cells in an immunodeficient mouse model. Thus, 7 is significantly more active than zoledronic acid, the most active FDA approved BP, and a potential anticancer therapeutic.
C1 [Matsumoto, Kenji; Hayashi, Kosuke; Murata Hirai, Kaoru; Iwasaki, Masashi; Minato, Nagahiro; Tanaka, Yoshimasa] Kyoto Univ, Grad Sch Med, Ctr Innovat Immunoregulat Technol & Therapeut, Kyoto 6068501, Japan.
   [Matsumoto, Kenji; Hayashi, Kosuke; Murata Hirai, Kaoru; Iwasaki, Masashi; Minato, Nagahiro; Tanaka, Yoshimasa] Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Kyoto 6068501, Japan.
   [Okamura, Haruki] Hyogo Coll Med, Dept Tumor Immunol & Cell Therapy, Nishinomiya, Hyogo 6638501, Japan.
   [Morita, Craig T.] Univ Iowa, Carver Coll Med, Iowa City Vet Affairs Hlth Care Syst, Dept Internal Med, 601 Highway 6 West,Res 151, Iowa City, IA 52246 USA.
   [Morita, Craig T.] Univ Iowa, Carver Coll Med, Iowa City Vet Affairs Hlth Care Syst, Interdisciplinary Grad Program Immunol, 601 Highway 6 West,Res 151, Iowa City, IA 52246 USA.
   [Tanaka, Yoshimasa] Nagasaki Univ, Grad Sch Biomed Sci, Ctr Bioinformat & Mol Med, 1 12 4 Sakamoto, Nagasaki 8528523, Japan.
C3 Kyoto University; Kyoto University; Hyogo Medical University; University
   of Iowa; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Iowa City VA Health Care System; University of
   Iowa; US Department of Veterans Affairs; Veterans Health Administration
   (VHA); Iowa City VA Health Care System; Nagasaki University
RP Tanaka, Y (通讯作者)，Kyoto Univ, Grad Sch Med, Ctr Innovat Immunoregulat Technol & Therapeut, Kyoto 6068501, Japan.; Tanaka, Y (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Immunol & Cell Biol, Kyoto 6068501, Japan.; Tanaka, Y (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Ctr Bioinformat & Mol Med, 1 12 4 Sakamoto, Nagasaki 8528523, Japan.
EM ystanaka@nagasaki u.ac.jp
RI Morita, Craig/C 1365 2011
OI Tanaka, Yoshimasa/0000 0002 5024 0614; Morita, Craig/0000 0001 8496 8294
FU Ministry of Education, Science, Culture, Sports, and Technology of Japan
   (MEXT); "Special Coordination Funds for Promoting Science and
   Technology" from MEXT; Astellas Pharma Inc. through the "Formation of
   Center for Innovation by Fusion of Advanced Technologies" program;
   "Platform for Drug Discovery, Informatics, and Structural Life Science"
   from MEXT; Kyoto University; Japan Agency for Medical Research and
   Development (AMED); US Department of Veterans Affairs (Veterans Health
   Administration, Office of Research and Development, Biomedical
   Laboratory Research and Development) [1 I01 BX000972 01A1]; US National
   Cancer Institute [CA097274, P30A086862]; University of Iowa Carver
   College of Medicine Carver Medical Research Initiative Grant;
   Grants in Aid for Scientific Research [24111008] Funding Source: KAKEN
FX The authors thank Ms. Chiyomi Inoue for technical assistance. This work
   was supported by Grants in Aid for Scientific Research from the Ministry
   of Education, Science, Culture, Sports, and Technology of Japan (MEXT),
   by "Special Coordination Funds for Promoting Science and Technology"
   from MEXT and Astellas Pharma Inc. through the "Formation of Center for
   Innovation by Fusion of Advanced Technologies" program, by "Platform for
   Drug Discovery, Informatics, and Structural Life Science" from MEXT, by
   a Grant in Aid for Translational Research from Kyoto University and
   Japan Agency for Medical Research and Development (AMED) (to Y.T.), and
   by the US Department of Veterans Affairs (Veterans Health
   Administration, Office of Research and Development, Biomedical
   Laboratory Research and Development) Grant 1 I01 BX000972 01A1, US
   National Cancer Institute Grants CA097274 (University of Iowa/Mayo
   Clinic Lymphoma Specialized Program of Research Excellence) and
   P30A086862 (Core Support), and the University of Iowa Carver College of
   Medicine Carver Medical Research Initiative Grant (to C.T.M.). C.T.M. is
   the Kelting Family Scholar in Rheumatology.
CR Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Chen CKM, 2008, J MED CHEM, V51, P5594, DOI 10.1021/jm800325y
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   DEGENHARDT CR, 1986, J ORG CHEM, V51, P3488, DOI 10.1021/jo00368a017
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Gao LJ, 2016, BIOORG MED CHEM LETT, V26, P2142, DOI 10.1016/j.bmcl.2016.03.076
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Hecker SJ, 2008, J MED CHEM, V51, P2328, DOI 10.1021/jm701260b
   Idrees ASM, 2013, CANCER SCI, V104, P536, DOI 10.1111/cas.12124
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Lee WA, 2005, ANTIMICROB AGENTS CH, V49, P1898, DOI 10.1128/AAC.49.5.1898 1906.2005
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Markowitz M, 2014, J ANTIMICROB CHEMOTH, V69, P1362, DOI 10.1093/jac/dkt532
   Mehellou Y, 2016, CHEMMEDCHEM, V11, P1114, DOI 10.1002/cmdc.201600156
   Mehellou Y, 2009, CHEMMEDCHEM, V4, P1779, DOI 10.1002/cmdc.200900289
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   ROGERS MJ, 1995, MOL PHARMACOL, V47, P398
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Sax PE, 2015, LANCET, V385, P2606, DOI 10.1016/S0140 6736(15)60616 X
   Stachnik A, 2014, P NATL ACAD SCI USA, V111, P17995, DOI 10.1073/pnas.1421422111
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Wiemer AJ, 2008, BIOORGAN MED CHEM, V16, P3652, DOI 10.1016/j.bmc.2008.02.016
   Wiemer AJ, 2008, BIOORGAN MED CHEM, V16, P390, DOI 10.1016/j.bmc.2007.09.029
   Wiemer AJ, 2015, TOP CURR CHEM, V360, P115, DOI 10.1007/128_2014_561
   Yuen T, 2014, P NATL ACAD SCI USA, V111, P17989, DOI 10.1073/pnas.1421410111
   Zhang Y, 2006, J MED CHEM, V49, P5804, DOI 10.1021/jm060280e
   Zhang YH, 2010, ANGEW CHEM INT EDIT, V49, P1136, DOI 10.1002/anie.200905933
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
   Zhang YD, 2013, SCI WORLD J, DOI 10.1155/2013/130134
NR 39
TC 36
Z9 39
U1 0
U2 46
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860 7179
EI 1860 7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD DEC 16
PY 2016
VL 11
IS 24
BP 2656
EP 2663
DI 10.1002/cmdc.201600465
PG 8
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA EG8GB
UT WOS:000391292900003
PM 27786425
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhang, P
   Liu, YS
   Jin, CY
   Zhang, M
   Tang, FC
   Zhou, YS
AF Zhang, Ping
   Liu, Yunsong
   Jin, Chanyuan
   Zhang, Min
   Tang, Fuchou
   Zhou, Yongsheng
TI Histone Acetyltransferase GCN5 Regulates Osteogenic Differentiation of
   Mesenchymal Stem Cells by Inhibiting NF κB
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE GCN5; MSCS; NF B; OSTEOGENIC DIFFERENTIATION; OSTEOPOROSIS
ID BONE FORMATION; IN VIVO; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTIONAL
   REGULATION; STROMAL CELLS; YEAST GCN5P; ACETYLATION; GROWTH; ACTIVATION;
   MICE
AB As the most well studied histone acetyltransferase (HAT) in yeast and mammals, general control nonderepressible 5 (GCN5) was documented to play essential roles in various developmental processes. However, little is known about its role in osteogenic differentiation of mesenchymal stem cells (MSCs). Here, we detected the critical function of GCN5 in osteogenic commitment of MSCs. In this role, the HAT activity of GCN5 was not required. Mechanistically, GCN5 repressed nuclear factor kappa B (NF B) dependent transcription and inhibited the NF B signaling pathway. The impaired osteogenic differentiation by GCN5 knockdown was blocked by inhibition of NF B. Most importantly, the expression of GCN5 was decreased significantly in the bone tissue sections of ovariectomized mice or aged mice. Collectively, these results may point to the GCN5 NF B pathway as a novel potential molecular target for stem cell mediated regenerative medicine and the treatment of metabolic bone diseases such as osteoporosis. (c) 2015 American Society for Bone and Mineral Research.
C1 [Zhang, Ping; Liu, Yunsong; Jin, Chanyuan; Zhang, Min; Zhou, Yongsheng] Peking Univ, Sch & Hosp Stomatol, Dept Prosthodont, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
   [Tang, Fuchou] Peking Univ, Coll Life Sci, Biodynam Opt Imaging Ctr, Beijing 100871, Peoples R China.
   [Zhou, Yongsheng] Peking Univ, Sch & Hosp Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100871, Peoples R China.
C3 Peking University; Peking University; Peking University
RP Zhou, YS (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Prosthodont, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
EM kqzhouysh@hsc.pku.edu.cn
RI Zhou, Yanheng/AFX 1820 2022; Zhang, Ping/IYJ 1806 2023; Liu,
   Yunsong/AAS 6801 2020
OI Zhang, Ping/0000 0001 9163 6191; Liu, Yunsong/0000 0001 8364 1898
FU National Natural Science Foundation of China [81570953, 81500822];
   Program for New Century Excellent Talents in University from Ministry of
   Education [NCET 11 0026]; PKU School of Stomatology for Talented Young
   Investigators [PKUSS20140109]; Construction Program for National Key
   Clinical Specialty from National Health and Family Planning Commission
   of China
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81570953, No. 81500822), the Program for New
   Century Excellent Talents in University from Ministry of Education
   (NCET 11 0026), the PKU School of Stomatology for Talented Young
   Investigators (PKUSS20140109), and the Construction Program for National
   Key Clinical Specialty from National Health and Family Planning
   Commission of China (2011).
CR ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786
   ALLIS CD, 1985, P NATL ACAD SCI USA, V82, P8048, DOI 10.1073/pnas.82.23.8048
   Ambrosetti D, 2008, MOL CELL BIOL, V28, P4759, DOI 10.1128/MCB.01849 07
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092 8674(00)81063 6
   Bu P, 2007, MOL CELL BIOL, V27, P3405, DOI 10.1128/MCB.00066 07
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368
   Chen Q, 2013, J BONE MINER RES, V28, P1214, DOI 10.1002/jbmr.1851
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Fuentealba LC, 2007, CELL, V131, P980, DOI 10.1016/j.cell.2007.09.027
   Ge WS, 2011, STEM CELLS, V29, P1112, DOI 10.1002/stem.663
   Govind CK, 2007, MOL CELL, V25, P31, DOI 10.1016/j.molcel.2006.11.020
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401
   Imoberdorf RM, 2006, MOL CELL BIOL, V26, P1610, DOI 10.1128/MCB.26.5.1610 1616.2006
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jin QH, 2014, EMBO REP, V15, P1192, DOI 10.15252/embr.201438990
   Kahata K, 2004, GENES CELLS, V9, P143, DOI 10.1111/j.1365 2443.2004.00706.x
   Kennedy J, 1999, BONE, V24, P9, DOI 10.1016/S8756 3282(98)00148 3
   Kim JH, 2010, GENE DEV, V24, P2766, DOI 10.1101/gad.1979710
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627
   Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Lerin C, 2006, CELL METAB, V3, P429, DOI 10.1016/j.cmet.2006.04.013
   Lin WC, 2008, DEV GROWTH DIFFER, V50, P321, DOI [10.1111/j.1440 169x.2008.01041.x, 10.1111/j.1440 169X.2008.01041.x]
   Liu Yang, 2013, Biomed Res Int, V2013, P839683, DOI 10.1155/2013/839683
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Mao XC, 2009, GENE DEV, V23, P849, DOI 10.1101/gad.1748409
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905
   Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097 2765(00)80211 7
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   WEISS A, 1991, BONE, V12, P165, DOI 10.1016/8756 3282(91)90039 L
   Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060
   Wong R W K, 2010, Open Biomed Eng J, V4, P71, DOI 10.2174/1874120701004010071
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Zhang HW, 2014, J CLIN INVEST, V124, P3200, DOI 10.1172/JCI68901
   Zhang P, 2014, P NATL ACAD SCI USA, V111, P10684, DOI 10.1073/pnas.1411026111
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
NR 54
TC 49
Z9 54
U1 1
U2 25
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2016
VL 31
IS 2
BP 391
EP 402
DI 10.1002/jbmr.2704
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DD8NE
UT WOS:000370182900017
PM 26420353
OA Bronze
DA 2025 08 17
ER

PT J
AU Matsushita, Y
   Sakamoto, K
   Tamamura, Y
   Shibata, Y
   Minamizato, T
   Kihara, T
   Ito, M
   Katsube, K
   Hiraoka, S
   Koseki, H
   Harada, K
   Yamaguchi, A
AF Matsushita, Yuki
   Sakamoto, Kei
   Tamamura, Yoshihiro
   Shibata, Yasuaki
   Minamizato, Tokutaro
   Kihara, Tasuku
   Ito, Masako
   Katsube, Ken ichi
   Hiraoka, Shuichi
   Koseki, Haruhiko
   Harada, Kiyoshi
   Yamaguchi, Akira
TI CCN3 Protein Participates in Bone Regeneration as an Inhibitory Factor
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DRILL HOLE INJURY; MORPHOGENETIC PROTEINS; OSTEOBLAST DIFFERENTIATION;
   NOV CCN3; SIGNALING PATHWAYS; CAUSES OSTEOPENIA; HUMAN FRACTURES;
   WILMS TUMORS; IN VITRO; EXPRESSION
AB CCN3, a member of the CCN protein family, inhibits osteoblast differentiation in vitro. However, the role of CCN3 in bone regeneration has not been well elucidated. In this study, we investigated the role of CCN3 in bone regeneration. We identified the Ccn3 gene by microarray analysis as a highly expressed gene at the early phase of bone regeneration in a mouse bone regeneration model. We confirmed the up regulation of Ccn3 at the early phase of bone regeneration by RT PCR, Western blot, and immunofluorescence analyses. Ccn3 transgenic mice, in which Ccn3 expression was driven by 2.3 kb Col1a1 promoter, showed osteopenia compared with wild type mice, but Ccn3 knock out mice showed no skeletal changes compared with wild type mice. We analyzed the bone regeneration process in Ccn3 transgenic mice and Ccn3 knock out mice by microcomputed tomography and histological analyses. Bone regeneration in Ccn3 knock out mice was accelerated compared with that in wild type mice. The mRNA expression levels of osteoblast related genes (Runx2, Sp7, Col1a1, Alpl, and Bglap) in Ccn3 knock out mice were up regulated earlier than those in wildtype mice, as demonstrated by RT PCR. Bone regeneration in Ccn3 transgenic mice showed no significant changes compared with that in wild type mice. Phosphorylation of Smad1/5 was highly up regulated at bone regeneration sites in Ccn3 KO mice compared with wild type mice. These results indicate that CCN3 is up regulated in the early phase of bone regeneration and acts as a negative regulator for bone regeneration. This study may contribute to the development of new strategies for bone regeneration therapy.
C1 [Matsushita, Yuki; Sakamoto, Kei; Tamamura, Yoshihiro; Katsube, Ken ichi; Yamaguchi, Akira] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Sect Oral Pathol, Tokyo 1138549, Japan.
   [Matsushita, Yuki; Kihara, Tasuku; Harada, Kiyoshi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Sect Maxillofacial Surg, Tokyo 1138549, Japan.
   [Matsushita, Yuki; Yamaguchi, Akira] Tokyo Med & Dent Univ, Global Ctr Excellence Program, Int Res Ctr Mol Sci Tooth & Bone Dis, Tokyo 1138549, Japan.
   [Tamamura, Yoshihiro] Mukogawa Womens Univ, Dept Hlth & Sports Sci, Nishinomiya, Hyogo 6638137, Japan.
   [Shibata, Yasuaki] Nagasaki Univ, Grad Sch Biomed Sci, Dept Oral Pathol, Nagasaki 8528588, Japan.
   [Minamizato, Tokutaro] Nagasaki Univ, Grad Sch Biomed Sci, Dept Regenerat Oral Surg, Nagasaki 8528588, Japan.
   [Ito, Masako] Nagasaki Univ Hosp, Med Work Life Balance Ctr, Nagasaki 8528588, Japan.
   [Hiraoka, Shuichi] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo 200045, Japan.
   [Koseki, Haruhiko] RIKEN Res Ctr Allergy & Immunol, Lab Dev Genet, Yokohama, Kanagawa 1578535, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Mukogawa Women's University; Nagasaki University; Nagasaki University;
   Nagasaki University; National Center for Child Health & Development  
   Japan; RIKEN
RP Yamaguchi, A (通讯作者)，Tokyo Med & Dent Univ, Grad Sch, Sect Oral Pathol, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138549, Japan.
EM akira.mpa@tmd.ac.jp
RI Koseki, Haruhiko/I 3825 2014; Yamaguchi, Akira/AAX 9286 2020;
   Matsushita, Yuki/H 3188 2015; 勝部, 憲一/JNS 0658 2023
OI Koseki, Haruhiko/0000 0001 8424 5854; Matsushita,
   Yuki/0000 0001 9577 3249; 
FU Japan Society for the Promotion of Science [21659420, 22249061,
   23659854]; Ministry of Health, Labor, and Welfare [21040101]; Global
   Center of Excellence Program, International Research Center for
   Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental
   University; Grants in Aid for Scientific Research [23249015, 23659854,
   23592696, 21659420, 22249061] Funding Source: KAKEN
FX This work was supported by Grants in aid for Scientific Research
   21659420, 22249061, and 23659854 from the Japan Society for the
   Promotion of Science and Health and Labor Sciences Research Grant
   21040101 from the Ministry of Health, Labor, and Welfare (to A. Y.) and
   by the Global Center of Excellence Program, International Research
   Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical
   and Dental University.
CR BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309
   Burren CP, 1999, J CLIN ENDOCR METAB, V84, P1096
   Canalis E, 2010, ENDOCRINOLOGY, V151, P221, DOI 10.1210/en.2009 0574
   Chevalier G, 1998, AM J PATHOL, V152, P1563
   Dean DB, 2010, J ANAT, V216, P625, DOI 10.1111/j.1469 7580.2010.01214.x
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912
   Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459
   Gupta R, 2007, SCIENCE, V316, P590, DOI 10.1126/science.1136031
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Haque T, 2008, BONE, V42, P1144, DOI 10.1016/j.bone.2008.01.028
   Heath E, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 18
   Ito M, 2005, J BONE MINER RES, V20, P1828, DOI 10.1359/JBMR.050610
   Janune D, 2011, FEBS LETT, V585, P3033, DOI 10.1016/j.febslet.2011.08.024
   Katae Y, 2009, J ORTHOP RES, V27, P1652, DOI 10.1002/jor.20920
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Katsube K, 2001, Brain Res Gene Expr Patterns, V1, P61
   Katsube K, 2009, J CELL COMMUN SIGNAL, V3, P135, DOI 10.1007/s12079 009 0059 1
   Katsuki Y, 2008, BIOCHEM BIOPH RES CO, V368, P808, DOI 10.1016/j.bbrc.2008.02.010
   Kawaki H, 2011, BONE, V49, P975, DOI 10.1016/j.bone.2011.06.033
   Kloen P, 2012, BONE, V51, P59, DOI 10.1016/j.bone.2012.03.032
   Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981
   KREBSBACH PH, 1993, MOL CELL BIOL, V13, P5168, DOI 10.1128/MCB.13.9.5168
   Kubota S, 2012, JPN DENT SCI REV, V48, P101, DOI 10.1016/j.jdsr.2012.02.002
   Kwong FNK, 2009, INT ORTHOP, V33, P281, DOI 10.1007/s00264 008 0691 z
   Lafont J, 2005, J BONE MINER RES, V20, P2213, DOI 10.1359/JBMR.050818
   Lin CG, 2005, J BIOL CHEM, V280, P8229, DOI 10.1074/jbc.M404903200
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Macsai CE, 2012, BONE, V50, P1081, DOI 10.1016/j.bone.2012.02.013
   Minamizato T, 2007, BIOCHEM BIOPH RES CO, V354, P567, DOI 10.1016/j.bbrc.2007.01.029
   Monfoulet L, 2010, CALCIFIED TISSUE INT, V86, P72, DOI 10.1007/s00223 009 9314 y
   Nakase T, 2006, J BONE MINER METAB, V24, P425, DOI 10.1007/s00774 006 0718 8
   Natarajan D, 2000, DEV DYNAM, V219, P417, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1058>3.0.CO;2 2
   Ouellet V, 2012, J CELL COMMUN SIGNAL, V6, P73, DOI 10.1007/s12079 012 0161 7
   Ouellet V, 2011, AM J PATHOL, V178, P2377, DOI 10.1016/j.ajpath.2011.01.033
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140 6736(03)15172 0
   Pereira RC, 2000, ENDOCRINOLOGY, V141, P4558, DOI 10.1210/en.141.12.4558
   Rydziel S, 2007, J BIOL CHEM, V282, P19762, DOI 10.1074/jbc.M700212200
   Shimoyama T, 2010, ARTERIOSCL THROM VAS, V30, P675, DOI 10.1161/ATVBAHA.110.203356
   SORET J, 1989, J VIROL, V63, P1803, DOI 10.1128/JVI.63.4.1803 1807.1989
   Su BY, 1998, CR ACAD SCI III VIE, V321, P883, DOI 10.1016/S0764 4469(99)80002 X
   Subramaniam MM, 2008, VIRCHOWS ARCH, V452, P33, DOI 10.1007/s00428 007 0523 3
   Tanaka K, 2010, BONE, V47, P1006, DOI 10.1016/j.bone.2010.08.016
   Uchida S, 2000, BONE, V27, P81, DOI 10.1016/S8756 3282(00)00293 3
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yamaguchi A, 2008, JPN DENT SCI REV, V44, P48, DOI 10.1016/j.jdsr.2007.11.003
   Yeger H, 2007, J CELL COMMUN SIGNAL, V1, P159, DOI 10.1007/s12079 008 0022 6
   Yoshimura Y, 2001, J BONE MINER RES, V16, P876, DOI 10.1359/jbmr.2001.16.5.876
NR 50
TC 49
Z9 52
U1 1
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 5
PY 2013
VL 288
IS 27
BP 19973
EP 19985
DI 10.1074/jbc.M113.454652
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 179JG
UT WOS:000321515800062
PM 23653360
OA Green Published
DA 2025 08 17
ER

PT J
AU Park, SH
   Lee, J
   Kang, MA
   Moon, YJ
   Wang, SI
   Kim, KM
   Park, BH
   Jang, KY
   Kim, JR
AF Park, See Hyoung
   Lee, Jongsung
   Kang, Mi Ae
   Moon, Young Jae
   Wang, Sung Il
   Kim, Kyoung Min
   Park, Byung Hyun
   Jang, Kyu Yun
   Kim, Jung Ryul
TI Potential of L thyroxine to differentiate osteoblast like cells via
   Angiopoietin1
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE L Thyroxine; Differentiation; Osteoblast; Angiopoietin1
ID OSTEOPROGENITOR CELLS; ARTERIOLAR GROWTH; DRUG DEVELOPMENT; IN VITRO;
   ANGIOGENESIS; PROLIFERATION; PROGRESSION
AB Angiogenesis is closely associated with osteoblast differentiation. Previously, we demonstrated that bone formation can be accelerated by treatment with COMP Angiopoietin1, a known angiogenic factor. Angiopoietin1 (Ang1) is a specific growth factor that generates stable and mature vasculature through the Tie2 receptor. In this study, we aimed to identify a novel drug that can activate endogenous Ang1 expression as a pharmacological treatment for bone formation. Therefore, Ang1 expression was examined in U2OS osteoblast like cells treated with 770 drugs from a library of Food and Drug Administration (FDA) approved drugs by using ELISA for Ang1. L thyroxine was selected as a novel drug candidate. LThyroxine is a synthetic form of the hormone thyroxine, which is used to treat patients with hypothyroidism. Enzyme linked immunosorbent assays (ELISAs) were performed to test whether Ang1 is induced in a dose dependent manner in human osteoblast like cell lines, U2OS and MG63. The effects of L thyroxine on osteoblast differentiation and mineralization were evaluated by alkaline phosphatase (ALP) activity and Alizarin red s staining. To determine the molecular mechanism, the expression of proteins related to bone formation and differentiation, such as type I collagen (COL1A1), osteocalcin (OC), bone sialoprotein (BSP), distal less homeobox 5 (Dlx5), Runt related transcription factor 2 (Runx2), osterix (OSX), and ALP, was tested by Western blotting analysis. Consequently, L thyroxine induced Ang1 expression in a dose dependent manner in both U2OS and M63 cells, which was confirmed by ELISA and Western blotting. Also, L thyroxine activated ALP activity in U2OS and MG63 cells as well as ALP expression. Furthermore, L thyroxine enhanced the expression of COL1A1, Runx2, OC, BSP, Dlx5, and OSX mRNA and proteins. Taken together, we demonstrated that L thyroxine increased Ang1 expression and induces bone formation, differentiation, and mineralization in U2OS and MG63 cell lines, which suggests that L thyroxine could be a potential bone production agent. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Park, See Hyoung] Hongik Univ, Dept Bio & Chem Engn, 2639 Sejong Ro, Sejong 30016, South Korea.
   [Lee, Jongsung] Sungkyunkwan Univ, Dept Genet Engn, Suwon, South Korea.
   [Kang, Mi Ae; Wang, Sung Il; Kim, Jung Ryul] Chonbuk Natl Univ, Dept Orthopaed Surg, Res Inst Clin Med, Chonbuk Natl Univ Hosp,Med Sch,Biomed Res Inst, Jeonju 54896, South Korea.
   [Kang, Mi Ae; Kim, Kyoung Min; Jang, Kyu Yun; Kim, Jung Ryul] Res Inst Endocrine Sci, 567 Baekje Daero, Jeonju 54896, South Korea.
   [Moon, Young Jae; Park, Byung Hyun] Chonbuk Natl Univ, Res Inst Endocrine Sci, Dept Biochem, Sch Med, 567 Baekje Daero, Jeonju 54896, South Korea.
   [Kim, Kyoung Min; Jang, Kyu Yun] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Dept Pathol,Biomed Res Inst,Med Sch, Jeonju 54896, South Korea.
C3 Hongik University; Sungkyunkwan University (SKKU); Jeonbuk National
   University; Jeonbuk National University Hospital; Jeonbuk National
   University; Jeonbuk National University; Jeonbuk National University
   Hospital
RP Kim, JR (通讯作者)，Chonbuk Natl Univ, Dept Orthopaed Surg, Res Inst Clin Med, Chonbuk Natl Univ Hosp,Med Sch,Biomed Res Inst, Jeonju 54896, South Korea.; Jang, KY; Kim, JR (通讯作者)，Res Inst Endocrine Sci, 567 Baekje Daero, Jeonju 54896, South Korea.; Jang, KY (通讯作者)，Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Dept Pathol,Biomed Res Inst,Med Sch, Jeonju 54896, South Korea.
EM kyjang@chonbuk.ac.kr; jrkeem@jbnu.ac.kr
FU National Research Foundation of Korea (NRF)   Korean government
   [NRF 2014R1A2A1A11052707]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (NRF 2014R1A2A1A11052707).
CR Aoki T, 2015, ENDOCRINOLOGY, V156, P4312, DOI 10.1210/en.2014 1988
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Chow WA, 2009, LANCET ONCOL, V10, P61, DOI 10.1016/S1470 2045(08)70334 6
   Dacic S, 2001, J BONE MINER RES, V16, P1228, DOI 10.1359/jbmr.2001.16.7.1228
   Danzi S, 2008, CURR OPIN INVEST DR, V9, P357
   DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167 6296(02)00126 1
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Eligar V, 2016, ANN CLIN BIOCHEM, V53, P421, DOI 10.1177/0004563216642255
   Fagan SC, 2010, PHARMACOTHERAPY, V30, p51S, DOI 10.1592/phco.30.pt2.51S
   Feric NT, 2014, BIOMATER SCI UK, V2, P1384, DOI 10.1039/c4bm00073k
   KASPERK C, 1995, J CLIN ENDOCR METAB, V80, P2511, DOI 10.1210/jc.80.8.2511
   Kostenuik PJ, 1999, J BONE MINER RES, V14, P21, DOI 10.1359/jbmr.1999.14.1.21
   Kostenuik PJ, 1997, AM J PHYSIOL ENDOC M, V273, pE1133
   Malaval L, 1999, J CELL BIOCHEM, V74, P616
   Ongaro A, 2016, J CELL PHYSIOL, V231, P2652, DOI 10.1002/jcp.25366
   Park BH, 2010, BONE, V46, P1442, DOI 10.1016/j.bone.2010.02.004
   PATRONO C, 1994, NEW ENGL J MED, V330, P1287
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092 8674(00)81813 9
   Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468
   Suzuki T, 2007, BIOCHEM BIOPH RES CO, V362, P1019, DOI 10.1016/j.bbrc.2007.08.099
   Wang XG, 2003, AM J PHYSIOL HEART C, V284, pH613, DOI 10.1152/ajpheart.00449.2002
   Zhang HF, 2016, STEM CELLS, V34, P2040, DOI 10.1002/stem.2395
   Zheng W, 2004, AM J PHYSIOL HEART C, V286, pH1994, DOI 10.1152/ajpheart.00991.2003
   Zhou L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110593
NR 27
TC 9
Z9 9
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 23
PY 2016
VL 478
IS 3
BP 1409
EP 1415
DI 10.1016/j.bbrc.2016.08.137
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EP9TH
UT WOS:000397715400062
PM 27569283
DA 2025 08 17
ER

PT J
AU Tang, YF
   Sun, YQ
   Zeng, JK
   Yuan, B
   Zhao, Y
   Geng, XW
   Jia, LS
   Zhou, SY
   Chen, XS
AF Tang, Yifan
   Sun, Yanqing
   Zeng, Junkai
   Yuan, Bo
   Zhao, Yin
   Geng, Xiangwu
   Jia, Lianshun
   Zhou, Shengyuan
   Chen, Xiongsheng
TI Exosomal miR 140 5p inhibits osteogenesis by targeting IGF1R and
   regulating the mTOR pathway in ossification of the posterior
   longitudinal ligament
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE OPLL; miR 140 5p; MSC; Exosome
ID INSULIN; ACTIVATION; BIOLOGY; LINKAGE; SPINE; CELLS; OPLL
AB Background Ossification of the posterior longitudinal ligament (OPLL) is a disabling disease whose pathogenesis is still unclear, and there are no effective cures or prevention methods. Exosomal miRNA plays an important role in the osteogenesis of ectopic bone. Therefore, we focused on the downregulation of miR 140 5p in OPLL cell derived exosomes to explore the mechanism by which exosomal miR 140 5p inhibits osteogenesis in OPLL. Results Exosomes were isolated by differential centrifugation and identified by transmission electron microscopy, nanoparticle tracking analysis, and exosomal markers. Exosomal RNA was extracted to perform miRNA sequencing and disclose the differentially expressed miRNAs, among which miR 140 5p was significantly downregulated. Confocal microscopy was used to trace the exosomal miR 140 5p delivered from OPLL cells to human mesenchymal stem cells (hMSCs). In vitro, we verified that exosomal miR 140 5p inhibited the osteoblast differentiation of hMSCs by targeting IGF1R and suppressing the phosphorylation of the IRS1/PI3K/Akt/mTOR pathway. In vivo, we verified that exosomal miR 140 5p inhibited ectopic bone formation in mice as assessed by micro CT and immunohistochemistry. Conclusions We found that exosomal miR 140 5p could inhibit the osteogenic differentiation of hMSCs by targeting IGF1R and regulating the mTOR pathway, prompting a further potential means of drug treatment and a possible target for molecular therapy of OPLL.
C1 [Tang, Yifan; Sun, Yanqing; Zeng, Junkai; Yuan, Bo; Zhao, Yin; Geng, Xiangwu; Jia, Lianshun; Zhou, Shengyuan; Chen, Xiongsheng] Second Mil Med Univ, Spine Ctr, Dept Orthoped, Shanghai Changzheng Hosp, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
C3 Naval Medical University
RP Zhou, SY; Chen, XS (通讯作者)，Second Mil Med Univ, Spine Ctr, Dept Orthoped, Shanghai Changzheng Hosp, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
EM zsy32@163.com; cxspine@smmu.edu.cn
FU National Natural Science Foundation of China [81873764, 82172472]
FX This work is supported by the National Natural Science Foundation of
   China (No. 81873764 and No. 82172472).
CR Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744
   Asari T, 2012, BIOCHEM BIOPH RES CO, V417, P1193, DOI 10.1016/j.bbrc.2011.12.106
   Boody BS, 2019, INT ORTHOP, V43, P797, DOI 10.1007/s00264 018 4106 5
   Bouland C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.674084
   Chakrabortty SK, 2015, RNA, V21, P1966, DOI 10.1261/rna.053629.115
   Choi BW, 2011, ASIAN SPINE J, V5, P267, DOI 10.4184/asj.2011.5.4.267
   de Voogt WS, 2021, ADV DRUG DELIVER REV, V174, P250, DOI 10.1016/j.addr.2021.04.017
   Fang YY, 2019, CELL BIOL INT, V43, P323, DOI 10.1002/cbin.11102
   Fukutake K, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000 015 0440 8
   Goto K, 1998, CALCIFIED TISSUE INT, V62, P158, DOI 10.1007/s002239900410
   Gualerzi A, 2021, ADV DRUG DELIVER REV, V174, P229, DOI 10.1016/j.addr.2021.04.014
   Harris L, 2018, SPINE, V43, pE545, DOI 10.1097/BRS.0000000000002401
   Huang Xiaoyao, 2021, Front Physiol, V12, P656588, DOI 10.3389/fphys.2021.656588
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Inamasu J, 2006, NEUROSURGERY, V58, P1027, DOI 10.1227/01.NEU.0000215867.87770.73
   ISHII Y, 1993, BIOMED RES TOKYO, V14, P85, DOI 10.1016/8756 3282(93)90232 Y
   Jokoji G, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100994
   Kim TJ, 2008, JOINT BONE SPINE, V75, P471, DOI 10.1016/j.jbspin.2007.07.019
   Kristjánsson B, 2016, SPINE, V41, pE1, DOI 10.1097/BRS.0000000000001178
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Marar C, 2021, NAT IMMUNOL, V22, P560, DOI 10.1038/s41590 021 00899 0
   Meng FG, 2018, THERANOSTICS, V8, P2862, DOI 10.7150/thno.23547
   Nakajima H, 2020, SPINE, V45, pE1460, DOI 10.1097/BRS.0000000000003648
   Nam DC, 2019, BIOMOL THER, V27, P342, DOI 10.4062/biomolther.2019.043
   Okawa A, 1998, NAT GENET, V19, P271, DOI 10.1038/956
   Ren Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040587
   Ren Y, 2012, J ORTHOP RES, V30, P748, DOI 10.1002/jor.21586
   Riedemann J, 2006, ENDOCR RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280
   Salem ESB, 2017, ADV EXP MED BIOL, V998, P113, DOI 10.1007/978 981 10 4397 0_8
   Michaela S, 2021, ADV DRUG DELIVER REV, V173, P89, DOI 10.1016/j.addr.2021.03.005
   Shin E, 2020, EMBO J, V39, DOI 10.15252/embj.2020104719
   Siddle K, 2011, J MOL ENDOCRINOL, V47, pR1, DOI 10.1530/JME 11 0022
   Smith ZA, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.1.FOCUS10256
   Stapleton CJ, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10271
   Sun H, 2019, J CELL BIOCHEM, V120, P171, DOI 10.1002/jcb.27289
   Sung BH, 2021, DEV CELL, V56, P1861, DOI 10.1016/j.devcel.2021.03.020
   Tanaka T, 2003, AM J HUM GENET, V73, P812, DOI 10.1086/378593
   Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Xi G, 2016, ENDOCRINOLOGY, V157, P268, DOI 10.1210/en.2015 1690
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yan L, 2017, AGING DIS, V8, P570, DOI 10.14336/AD.2017.0201
   Yan L, 2010, CHINESE MED J PEKING, V123, P2341, DOI 10.3760/cma.j.issn.0366 6999.2010.17.011
NR 43
TC 20
Z9 25
U1 3
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD OCT 15
PY 2022
VL 20
IS 1
AR 452
DI 10.1186/s12951 022 01655 8
PG 15
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA 5J7IM
UT WOS:000869213000002
PM 36243800
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Blangy, A
   Touaitahuata, H
   Cres, G
   Pawlak, G
AF Blangy, Anne
   Touaitahuata, Heiani
   Cres, Gaelle
   Pawlak, Geraldine
TI Cofilin Activation during Podosome Belt Formation in Osteoclasts
SO PLOS ONE
LA English
DT Article
ID ACTIN DYNAMICS; REGULATES COFILIN; PHOSPHATASE SLINGSHOT; CULTURED
   OSTEOCLASTS; LIM KINASE; PATHWAY; CORTACTIN; ORGANIZATION; INVADOPODIA;
   ADF/COFILIN
AB Podosomes are dynamic actin based structures found constitutively in cells of monocytic origin such as macrophages, dendritic cells and osteoclasts. They have been involved in osteoclast cell adhesion, motility and matrix degradation, and all these functions rely on the ability of podosomes to form supra molecular structures called podosome belts or sealing zones on mineralized substrates. Podosomes contain two distinct domains, an actin rich core enriched in actin polymerization regulators, surrounded by a ring of signaling and plaque molecules. The organization of podosome arrays into belts is linked to actin dynamics. Cofilin is an actin severing protein that is known to regulate cytoskeleton architecture and cell migration. Cofilin is present in lamellipodia and invadopodia where it regulates actin polymerization. In this report, we show that cofilin is a novel component of the podosome belt, the mature osteoclast adhesion structure. Time course analysis demonstrated that cofilin is activated during primary osteoclast differentiation, at the time of podosome belt assembly. Immunofluorescence studies reveal a localization of active cofilin in the podosome core structure, whereas phosphorylated, inactive cofilin is concentrated in the podosome cloud. Pharmacological studies unraveled the role of a specific cofilin phosphatase to achieve cofilin activation during osteoclast differentiation. We ruled out the implication of PP1/PP2A and PTEN in this process, and rather provided evidence for the involvement of SSH1. In summary, our data involve cofilin as a regulator of podosome organization that is activated during osteoclast differentiation by a RANKL mediated signaling pathway targeting the SSH1 phosphatase.
C1 [Blangy, Anne; Touaitahuata, Heiani; Cres, Gaelle; Pawlak, Geraldine] Univ Montpellier, CNRS UMR 5237, Ctr Rech Biochim Macromol, F 34059 Montpellier, France.
   [Pawlak, Geraldine] Univ Grenoble 1, Grenoble, France.
C3 Universite de Montpellier; Centre National de la Recherche Scientifique
   (CNRS); CNRS   National Institute for Biology (INSB); Communaute
   Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)
RP Blangy, A (通讯作者)，Univ Montpellier, CNRS UMR 5237, Ctr Rech Biochim Macromol, F 34059 Montpellier, France.
EM anne.blangy@crbm.cnrs.fr
OI BLANGY, Anne/0000 0001 7043 0784
FU Fondation pour la Recherche Medicale (FRM) [DVO20081013473]; Institut
   National du Cancer [INCa 4361]; Agence Nationale de la Recherche (ANR)
   [ANR 2011 BLAN 006]; Grants in Aid for Scientific Research [24592816]
   Funding Source: KAKEN
FX This work was supported by research grants from the Fondation pour la
   Recherche Medicale (FRM grant # DVO20081013473 to AB), the Institut
   National du Cancer (grant # INCa 4361 to AB) and the Agence Nationale de
   la Recherche (ANR grant # ANR 2011 BLAN 006 to AB). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521 4141(2000012)30:12<3422::AID IMMU3422>3.0.CO;2 J
   Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729
   Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001
   Bravo Cordero JJ, 2011, CURR BIOL, V21, P635, DOI 10.1016/j.cub.2011.03.039
   Brazier H, 2006, J BONE MINER RES, V21, P1387, DOI 10.1359/JBMR.060613
   Brazier H, 2009, INT J BIOCHEM CELL B, V41, P1391, DOI 10.1016/j.biocel.2008.12.007
   Burgstaller G, 2004, J CELL SCI, V117, P223, DOI 10.1242/jcs.00839
   Chabadel A, 2007, MOL BIOL CELL, V18, P4899, DOI 10.1091/mbc.E07 04 0378
   Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665
   Crimaldi L, 2009, EXP CELL RES, V315, P2581, DOI 10.1016/j.yexcr.2009.06.012
   Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201
   Granot Attas S, 2009, MOL BIOL CELL, V20, P4324, DOI 10.1091/mbc.E08 11 1158
   Hammarfjord O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021615
   Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005
   Kim JS, 2009, MOL BIOL CELL, V20, P2650, DOI 10.1091/mbc.E09 02 0131
   Kurita S, 2008, J BIOL CHEM, V283, P32542, DOI 10.1074/jbc.M804627200
   Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962 8924(03)00128 4
   Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002
   Luxenburg C, 2006, EUR J CELL BIOL, V85, P203, DOI 10.1016/j.ejcb.2005.11.002
   Luxenburg C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000179
   Luxenburg C, 2012, J CELL SCI, V125, P1666, DOI 10.1242/jcs.075903
   Luxenburg C, 2006, J CELL SCI, V119, P4878, DOI 10.1242/jcs.03271
   McMichael BK, 2010, J BIOL CHEM, V285, P9506, DOI 10.1074/jbc.M109.017269
   Mooren OL, 2009, J BIOL CHEM, V284, P23995, DOI 10.1074/jbc.M109.024398
   Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141
   Nagata Ohashi K, 2004, J CELL BIOL, V165, P465, DOI 10.1083/jcb.200401136
   Nishita M, 2004, J BIOL CHEM, V279, P7193, DOI 10.1074/jbc.M312591200
   Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092 8674(01)00638 9
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377
   Ory S, 2008, EUR J CELL BIOL, V87, P469, DOI 10.1016/j.ejcb.2008.03.002
   Oser M, 2009, J CELL BIOCHEM, V108, P1252, DOI 10.1002/jcb.22372
   Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   Saltel F, 2011, EUR J CELL BIOL, V90, P100, DOI 10.1016/j.ejcb.2010.05.011
   Serezani CH, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002448
   Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519
   Tang WW, 2011, DEV CELL, V21, P1038, DOI 10.1016/j.devcel.2011.10.023
   Van Troys M, 2008, EUR J CELL BIOL, V87, P649, DOI 10.1016/j.ejcb.2008.04.001
   Vitolo MI, 2013, ONCOGENE, V32, P2200, DOI 10.1038/onc.2012.234
   Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008 5472.CAN 10 1246
   Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076
NR 46
TC 29
Z9 31
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 25
PY 2012
VL 7
IS 9
AR e45909
DI 10.1371/journal.pone.0045909
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 016YP
UT WOS:000309556100098
PM 23049890
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, S
   Grover, M
   Sibai, T
   Black, J
   Rianon, N
   Rajagopal, A
   Munivez, E
   Bertin, T
   Dawson, B
   Chen, YQ
   Jiang, MM
   Lee, B
   Yang, T
   Bae, Y
AF Chen, Shan
   Grover, Monica
   Sibai, Tarek
   Black, Jennifer
   Rianon, Nahid
   Rajagopal, Abbhirami
   Munivez, Elda
   Bertin, Terry
   Dawson, Brian
   Chen, Yuqing
   Jiang, Ming Ming
   Lee, Brendan
   Yang, Tao
   Bae, Yangjin
TI Losartan increases bone mass and accelerates chondrocyte hypertrophy in
   developing skeleton
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE ARB; Osteoclasts; Chondrocyte; ERK phosphorylation; RANKL; Losartan
ID RENIN ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; RECEPTOR BLOCKER;
   MARFAN SYNDROME; TGF BETA; DIFFERENTIATION; RANKL; OSTEOCLASTOGENESIS;
   OSTEOPOROSIS; INHIBITION
AB Angiotensin receptor blockers (ARBs) are a group of anti hypertensive drugs that are widely used to treat pediatric hypertension. Recent application of ARBs to treat diseases such as Marfan syndrome or Alport syndrome has shown positive outcomes in animal and human studies, suggesting a broader therapeutic potential for this class of drugs. Multiple studies have reported a benefit of ARBs on adult bone homeostasis; however, its effect on the growing skeleton in children is unknown. We investigated the effect of Losartan, an ARB, in regulating bone mass and cartilage during development in mice. Wild type mice were treated with Losartan from birth until 6 weeks of age, after which bones were collected for microCT and histomorphometric analyses. Losartan increased trabecular bone volume vs. tissue volume (a 98% increase) and cortical thickness (a 9% increase) in 6 weeks old wild type mice. The bone changes were attributed to decreased osteoclastogenesis as demonstrated by reduced osteoclast number per bone surface in vivo and suppressed osteodast differentiation in vitro. At the molecular level, Angiotensin II induced ERK1/2 phosphorylation in RAW cells was attenuated by Losartan. Similarly, RANKL induced ERK1/2 phosphorylation was suppressed by Losartan, suggesting a convergence of RANKL and angiotensin signaling at the level of ERK1/2 regulation. To assess the effect of Losartan on cartilage development, we examined the cartilage phenotype of wild type mice treated with Losartan in utero from conception to 1 day of age. Growth plates of these mice showed an elongated hypertrophic chondrocyte zone and increased CollOal expression level, with minimal changes in chondrocyte proliferation. Altogether, inhibition of the angiotensin pathway by Losartan increases bone mass and accelerates chondrocyte hypertrophy in growth plate during skeletal development. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Grover, Monica; Rajagopal, Abbhirami; Munivez, Elda; Bertin, Terry; Dawson, Brian; Chen, Yuqing; Jiang, Ming Ming; Lee, Brendan; Bae, Yangjin] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Sibai, Tarek] Boston Univ, Sch Med Orthoped Surg, Boston, MA 02215 USA.
   [Black, Jennifer] Univ Colorado, Sch Med, Dept Pathol & Lab Med, Childrens Hosp Colorado, Aurora, CO USA.
   [Rianon, Nahid] Univ Texas Med Sch, Dept Internal Med, Houston, TX USA.
   [Yang, Tao] Van Andel Res Inst, Ctr Canc & Cell Biol, Lab Skeletal Biol, Program Skeletal Dis & Tumor Metastasis, Grand Rapids, MI USA.
   [Chen, Shan] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Biostat, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Boston University; Children's Hospital
   Colorado; University of Colorado System; University of Colorado Anschutz
   Medical Campus; University of Texas System; University of Texas Health
   Science Center Houston; Van Andel Institute; Van Andel Research
   Institute; University of Texas System; University of Texas Health
   Science Center Houston; University of Texas School Public Health
RP Lee, B (通讯作者)，1 Baylor Plaza Rm R814, Houston, TX 77030 USA.
EM blee@bcm.edu
RI Yang, Tao/ITU 1429 2023
FU NIH/NICHD [P01 HD070394]; Rolanette and Berdon Lawrence Disease Program
   of Texas; BCM Intellectual and Developmental Disabilities Research
   Center from the Eunice Kennedy Shriver National Institute of Child
   Health & Human Development [HD024064]
FX This study was funded by NIH/NICHD P01 HD070394 (BL), the Rolanette and
   Berdon Lawrence Disease Program of Texas, and the BCM Intellectual and
   Developmental Disabilities Research Center (HD024064) from the Eunice
   Kennedy Shriver National Institute of Child Health & Human Development.
CR Asaba Y, 2009, J BONE MINER RES, V24, P241, DOI [10.1359/jbmr.081006, 10.1359/JBMR.081006]
   Chiu HH, 2013, MAYO CLIN PROC, V88, P271, DOI 10.1016/j.mayocp.2012.11.005
   Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536
   Cortez Retamozo V, 2013, IMMUNITY, V38, P296, DOI 10.1016/j.immuni.2012.10.015
   Dagenais NJ, 2005, PHARMACOTHERAPY, V25, P1213, DOI 10.1592/phco.2005.25.9.1213
   de Lange Brokaar BJE, 2012, OSTEOARTHR CARTILAGE, V20, P1484, DOI 10.1016/j.joca.2012.08.027
   Donmez BO, 2012, PHARMACOL REP, V64, P878, DOI 10.1016/S1734 1140(12)70882 4
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Fukuda D, 2008, PHARMACOL THERAPEUT, V118, P268, DOI 10.1016/j.pharmthera.2008.02.007
   Garcia P, 2010, BRIT J PHARMACOL, V159, P1672, DOI 10.1111/j.1476 5381.2010.00651.x
   Giampietro Philip F, 2007, HSS J, V3, P89, DOI 10.1007/s11420 006 9030 3
   Gross O, 2009, KIDNEY INT, V76, P599, DOI 10.1038/ki.2009.223
   Grover M, 2012, AM J MED GENET A, V158A, P2221, DOI 10.1002/ajmg.a.35540
   Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287
   Haznedaroglu IC, 2003, INT J BIOCHEM CELL B, V35, P867, DOI 10.1016/S1357 2725(02)00278 9
   Higuchi S, 2007, CLIN SCI, V112, P417, DOI 10.1042/CS20060342
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Izu Y, 2009, J BIOL CHEM, V284, P4857, DOI 10.1074/jbc.M807610200
   Kaneko K, 2011, J BONE MINER RES, V26, P2959, DOI 10.1002/jbmr.501
   Kawakami Y, 2012, ARTHRITIS, DOI 10.1155/2012/648537
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Luft FC, 2012, ANN MED, V44, pS49, DOI 10.3109/07853890.2011.653396
   Ma L, 2010, BONE, V47, P5, DOI 10.1016/j.bone.2010.03.016
   Männistö TK, 2001, J HYPERTENS, V19, P1835, DOI 10.1097/00004872 200110000 00018
   Moura B, 2006, JOINT BONE SPINE, V73, P733, DOI 10.1016/j.jbspin.2006.01.026
   Nagasawa A, 2013, J SURG RES, V183, P472, DOI 10.1016/j.jss.2012.12.012
   Napierala D, 2008, HUM MOL GENET, V17, P2244, DOI 10.1093/hmg/ddn125
   Odenbach J, 2011, HYPERTENSION, V57, P123, DOI 10.1161/HYPERTENSIONAHA.110.159525
   Reuter S, 2012, BRIT J PHARMACOL, V165, P2127, DOI 10.1111/j.1476 5381.2011.01702.x
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Sukumaran V, 2010, HYPERTENS RES, V33, P695, DOI 10.1038/hr.2010.67
   Tsubakimoto Y, 2009, ARTERIOSCL THROM VAS, V29, P1529, DOI 10.1161/ATVBAHA.109.187732
   Tsukamoto I, 2013, FEBS OPEN BIO, V3, P279, DOI 10.1016/j.fob.2013.07.001
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Yang T, 2013, P NATL ACAD SCI USA, V110, P7336, DOI 10.1073/pnas.1219748110
   Zaman MA, 2002, NAT REV DRUG DISCOV, V1, P621, DOI 10.1038/nrd873
   Zhang Y, 2013, J MATER CHEM B, V1, P132, DOI 10.1039/c2tb00071g
NR 38
TC 26
Z9 27
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1096 7192
EI 1096 7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD MAY
PY 2015
VL 115
IS 1
BP 53
EP 60
DI 10.1016/j.ymgme.2015.02.006
PG 8
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA CI8OO
UT WOS:000355031800009
PM 25779879
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Simmons, AD
   Baumann, C
   Zhang, XY
   Kamp, TJ
   de la Fuente, R
   Palecek, SP
AF Simmons, Aaron D.
   Baumann, Claudia
   Zhang, Xiangyu
   Kamp, Timothy J.
   de la Fuente, Rabindranath
   Palecek, Sean P.
TI Integrated multi omics analysis identifies features that predict human
   pluripotent stem cell derived progenitor differentiation to
   cardiomyocytes
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE Human pluripotent stem cells; Cardiomyocytes; Cardiac progenitor cells;
   Differentiation; Transcriptomics; Epigenomics; Multi omics
ID DEPENDENT INSULINOTROPIC POLYPEPTIDE; DIACYLGLYCEROL KINASE;
   CARDIAC HYPERTROPHY; GENE EXPRESSION; PROTEIN KINASES; REGULATOR;
   PATHWAYS; RNAS
AB Human pluripotent stem cell derived cardiomyocytes (hPSC CMs) are advancing cardiovascular development and disease modeling, drug testing, and regenerative therapies. However, hPSC CM production is hindered by significant variability in the differentiation process. Establishment of early quality markers to monitor lineage progression and predict terminal differentiation outcomes would address this robustness and reproducibility roadblock in hPSC CM production. An integrated transcriptomic and epigenomic analysis assesses how attributes of the cardiac progenitor cell (CPC) affect CM differentiation outcome. Resulting analysis identifies predictive markers of CPCs that give rise to high purity CM batches, including TTN, TRIM55, DGKI, MEF2C, MAB21L2, MYL7, LDB3, SLC7A11, and CALD1. Predictive models developed from these genes provide high accuracy in determining terminal CM purities at the CPC stage. Further, insights into mechanisms of batch failure and dominant non CM cell types generated in failed batches are elucidated. Namely EMT, MAPK, and WNT signaling emerge as significant drivers of batch divergence, giving rise to off target populations of fibroblasts/mural cells, skeletal myocytes, epicardial cells, and a non CPC SLC7A11+ subpopulation. This study demonstrates how integrated multi omic analysis of progenitor cells can identify quality attributes of that progenitor and predict differentiation outcomes, thereby improving differentiation protocols and increasing process robustness.
C1 [Simmons, Aaron D.; Palecek, Sean P.] Univ Wisconsin Madison, Dept Chem & Biol Engn, 1415 Engn Dr, Madison, WI 53706 USA.
   [Baumann, Claudia; Zhang, Xiangyu; de la Fuente, Rabindranath] Univ Georgia, Dept Physiol & Pharmacol, Athens, GA 30602 USA.
   [Baumann, Claudia; Zhang, Xiangyu; de la Fuente, Rabindranath] Univ Georgia, Regenerat Biosci Ctr, Athens, GA 30602 USA.
   [Kamp, Timothy J.] Univ Wisconsin Madison, Dept Cell & Regenerat Biol, Madison, WI 53705 USA.
   [Kamp, Timothy J.] Univ Wisconsin Madison, Dept Med, Madison, WI 53705 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University System of Georgia; University of Georgia; University System
   of Georgia; University of Georgia; University of Wisconsin System;
   University of Wisconsin Madison; University of Wisconsin System;
   University of Wisconsin Madison
RP Palecek, SP (通讯作者)，Univ Wisconsin Madison, Dept Chem & Biol Engn, 1415 Engn Dr, Madison, WI 53706 USA.
EM sppalecek@wisc.edu
RI Kamp, Timothy/ABD 1343 2020
FU National Heart, Lung, and Blood Institute (NHLBI) [5R01HL148059];
   National Institute for General Medical Sciences [NIH 5 T32 GM135066];
   National Institute of Child Health and Human Development [NICHD:
   HD093383]; U.S. Department of Agriculture National Institute of Food and
   Agriculture National Institutes of Health dual purpose grant
   [2020 67105 30882]; National Science Foundation Center for Cell
   Manufacturing Technologies (NSF) [CMaT EEC 1648035]
FX This work was supported research grants awarded by the National Heart,
   Lung, and Blood Institute (NHLBI; 5R01HL148059) , the National Institute
   for General Medical Sciences (NIH 5 T32 GM135066) , the National
   Institute of Child Health and Human Development (NICHD: HD093383) , the
   U.S. Department of Agriculture National Institute of Food and
   Agriculture National Institutes of Health dual purpose grant
   (2020 67105 30882) and the National Science Foundation Center for Cell
   Manufacturing Technologies (NSF; CMaT EEC 1648035) . The authors
   utilized the University of Wisconsin   Madison Biotechnology Center Gene
   Expression Center (Research Resource Identifier   RRID: SCR_017757) .
   The authors would also like to thank Austin K. Feeney for his assistance
   and input on this project, as well as Theresa and Mark Kotanchek for
   assistance in modeling efforts and generous providing of access to the
   Evolved Analytics DataModeler software package.
CR Arimoto T, 2006, CIRCULATION, V113, P60, DOI 10.1161/CIRCULATIONAHA.105.560771
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Barreto S, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121536
   Bilim O., Differential regulation of diacylglycerol kinase isoform in 1749 8090 6 65
   Brade T, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a013847
   Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Bylund JB, 2017, STEM CELLS DEV, V26, P678, DOI 10.1089/scd.2016.0226
   Carbon S, 2021, NUCLEIC ACIDS RES, V49, pD325, DOI 10.1093/nar/gkaa1113
   Chae YK, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21061 1
   Chen Y, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420 023 01548 1
   den Hartogh SC, 2016, SCI REP UK, V6, DOI 10.1038/srep19386
   Derrick CJ, 2021, DEVELOPMENT, V148, DOI 10.1242/dev.191320
   Divate M, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00250
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Ebert A, 2019, CIRC RES, V125, P90, DOI 10.1161/CIRCRESAHA.118.313973
   Elorbany R, 2022, PLOS GENET, V18, DOI 10.1371/journal.pgen.1009666
   Fagg WS, 2022, NUCLEIC ACIDS RES, V50, P5313, DOI 10.1093/nar/gkac327
   Fakhry CT, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859 016 1181 8
   Fang XX, 2020, CIRC RES, V127, P486, DOI 10.1161/CIRCRESAHA.120.316509
   Friedman CE, 2018, CELL STEM CELL, V23, P586, DOI 10.1016/j.stem.2018.09.009
   Galdos FX, 2023, ELIFE, V12, DOI 10.7554/eLife.80075
   Ghafouri Fard S, 2023, J CELL MOL MED, V27, P2278, DOI 10.1111/jcmm.17875
   Ghobrial G, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00136
   Gong WM, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859 015 0460 0
   Grancharova T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 94732 1
   Greenwell AA, 2020, PEPTIDES, V125, DOI 10.1016/j.peptides.2019.170228
   Hiromura M, 2016, CIRC J, V80, P1988, DOI 10.1253/circj.CJ 16 0152
   Houweling AC, 2005, CARDIOVASC RES, V67, P583, DOI 10.1016/j.cardiores.2005.06.013
   Huang XD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 23904 4
   Jia GS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07307 6
   Kelly RG, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015750
   Klewer SE, 2006, GENE EXPR PATTERNS, V6, P462, DOI 10.1016/j.modgep.2005.11.005
   Kolahdouzmohammadi M, 2023, J CELL COMMUN SIGNAL, V17, P939, DOI 10.1007/s12079 023 00744 z
   Kotanchek M., 2023, Genetic Programming Theory and Practice, P91, DOI [10.1007/978 981 19 8460 05, DOI 10.1007/978 981 19 8460 05]
   Kurian L, 2015, CIRCULATION, V131, P1278, DOI 10.1161/CIRCULATIONAHA.114.013303
   Lam YY, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e18243
   Lee J, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/1569740
   Li MY, 2018, FEBS J, V285, P220, DOI 10.1111/febs.14191
   Li SM, 2023, STEM CELL RES THER, V14, DOI 10.1186/s13287 023 03442 0
   Li Y, 2015, SCI REP UK, V5, DOI 10.1038/srep09758
   Lian XJ, 2013, NAT PROTOC, V8, P162, DOI 10.1038/nprot.2012.150
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   LINTS TJ, 1993, DEVELOPMENT, V119, P419
   Liu D, 2023, EXP MOL MED, V55, P2025, DOI 10.1038/s12276 023 01081 2
   Liu J, 2016, STEM CELLS, V34, P2648, DOI 10.1002/stem.2434
   Lo EK, 2022, bioRxiv, DOI [10.1101/2022.09.07.506886, 10.1101/2022.09.07.506886, DOI 10.1101/2022.09.07.506886]
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Ma WJ, 2021, NAR GENOM BIOINFORM, V3, DOI 10.1093/nargab/lqab022
   Menasché P, 2018, J AM COLL CARDIOL, V71, P429, DOI 10.1016/j.jacc.2017.11.047
   Miao YX, 2015, INT J MOL SCI, V16, P7976, DOI 10.3390/ijms16047976
   Muraoka N, 2014, EMBO J, V33, P1565, DOI 10.15252/embj.201387605
   Murata M, 2023, BIOMED REP, V18, DOI 10.3892/br.2023.1601
   Pereira IT, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.287
   Ramos S, 2002, GENE, V298, P147, DOI 10.1016/S0378 1119(02)00980 0
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Ruan H, 2019, BMC BIOL, V17, DOI 10.1186/s12915 019 0709 6
   Sahara M, 2019, DEV CELL, V48, P475, DOI 10.1016/j.devcel.2019.01.005
   Saito Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032991
   Sarzani R, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232214415
   Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192
   Shoni M, 2014, CURR STEM CELL RES T, V9, P366, DOI 10.2174/1574888X09666140616130217
   Simmons AD, 2021, TISSUE ENG PART C ME, V27, P322, DOI [10.1089/ten.tec.2021.0023, 10.1089/ten.TEC.2021.0023]
   Smith KA, 2008, DEV CELL, V14, P287, DOI 10.1016/j.devcel.2007.11.015
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Strober BJ, 2019, SCIENCE, V364, P1287, DOI 10.1126/science.aaw0040
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Takeishi Y, 2007, PHARMACOL THERAPEUT, V115, P352, DOI 10.1016/j.pharmthera.2007.04.010
   Tyser RCV, 2023, CURR CARDIOL REP, V25, P495, DOI 10.1007/s11886 023 01880 z
   Tyser RCV, 2021, SCIENCE, V371, P1011, DOI 10.1126/science.abb2986
   Ussher JR, 2018, CELL METAB, V27, P450, DOI 10.1016/j.cmet.2017.11.003
   Vahdat S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 52516 8
   Velichkova G, 2023, CELLS DEV, V175, DOI 10.1016/j.cdev.2023.203857
   Wang D, 2014, HYPERTENSION, V63, P514, DOI 10.1161/HYPERTENSIONAHA.113.02164
   Wang FF, 2021, FEBS LETT, V595, P2271, DOI 10.1002/1873 3468.14168
   Wang LY, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109364
   Wang XL, 2022, BIOENGINEERED, V13, P10707, DOI 10.1080/21655979.2022.2051259
   Wang YB, 2007, CIRCULATION, V116, P1413, DOI 10.1161/CIRCULATIONAHA.106.679589
   Wang ZJ, 2018, BIOINFORMATICS, V34, P2867, DOI 10.1093/bioinformatics/bty194
   Watanabe Y, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2307658120
   Wei TC, 2011, GENE EXPR PATTERNS, V11, P384, DOI 10.1016/j.gep.2011.05.001
   Weng GH, 2021, J MOL HISTOL, V52, P943, DOI 10.1007/s10735 021 10010 4
   Wu SM, 2008, CELL, V132, P537, DOI 10.1016/j.cell.2008.02.002
   Wu TZ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Xu L, 2004, J HYPERTENS, V22, P1579, DOI 10.1097/01.hjh.0000133717.48334.cf
   Xu Y., 2023, Frontiers in Cardiovascular Medicine, V10
   Yap L, 2023, NPJ REGEN MED, V8, DOI 10.1038/s41536 023 00302 6
   Ye HK, 2020, EUR REV MED PHARMACO, V24, P3315, DOI 10.26355/eurrev_202003_20699
   Ye SQ, 2023, CIRC RES, V132, P187, DOI 10.1161/CIRCRESAHA.122.321398
   Zeidler S, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00033
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zhang RN, 2020, J CELL MOL MED, V24, P8368, DOI 10.1111/jcmm.15292
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 9 r137
   Zhong H, 2023, LIFE SCI ALLIANCE, V6, DOI 10.26508/lsa.202302121
   Ziegler N, 2020, J BIOL CHEM, V295, P17659, DOI 10.1074/jbc.RA120.013990
NR 95
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0022 2828
EI 1095 8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD NOV
PY 2024
VL 196
BP 52
EP 70
DI 10.1016/j.yjmcc.2024.08.007
EA SEP 2024
PG 19
WC Cardiac & Cardiovascular Systems; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Cell Biology
GA G5A5Q
UT WOS:001316764700001
PM 39222876
DA 2025 08 17
ER

PT J
AU Miyaoka, D
   Inaba, M
   Imanishi, Y
   Hayashi, N
   Ohara, M
   Nagata, Y
   Kurajoh, M
   Yamada, S
   Mori, K
   Emoto, M
AF Miyaoka, Daichi
   Inaba, Masaaki
   Imanishi, Yasuo
   Hayashi, Noriyuki
   Ohara, Masaya
   Nagata, Yuki
   Kurajoh, Masafumi
   Yamada, Shinsuke
   Mori, Katsuhito
   Emoto, Masanori
TI Denosumab Improves Glomerular Filtration Rate in Osteoporotic Patients
   With Normal Kidney Function by Lowering Serum Phosphorus
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; DISORDERS OF CALCIUM; PHOSPHATE METABOLISM;
   ANTIRESORPTIVES
ID BONE MINERAL DENSITY; ESTROGEN RECEPTOR MODULATOR; CYSTATIN C;
   GENERAL POPULATION; TURNOVER MARKERS; RENAL FUNCTION; PHOSPHATE;
   ASSOCIATION; CREATININE; RALOXIFENE
AB Higher serum phosphorus (Pi) increases the risk for chronic kidney disease (CKD). It was reported that a single administration of denosumab or zoledronate significantly suppressed serum Pi levels as well as those of bone resorption markers in serum. Also, previous evidences suggest a link between bone anti resorptive therapy and vasoprotective/renoprotective effects through mechanisms that remain unexplored. The aim of this study is to assess the renoprotective effect of denosumab and involvement of denosumab induced reduction in serum Pi in osteoporotic patients. Osteoporotic patients (n = 73) without overt proteinuria in dipstick test results were treated with denosumab (60 mg) every 6 months during the study period (24 months). Estimated glomerular filtration rate based on serum cystatin C (eGFRcys) was used as a filtration marker and tartrate resistant acid phosphatase 5b (TRACP 5b) as a bone resorption marker. For analysis of non CKD patients (n = 56), those with eGFRcys <60 mL/min/1.73 m(2) were excluded. A single injection of denosumab suppressed serum Pi as well as TRACP 5b during the first 6 months, whereas age related decline in eGFRcys was significantly reversed, with an increase of 2.75 +/  1.2 mL/min/1.73 m(2) after 24 months noted. Multivariate analysis showed that serum Pi reduction following the initial denosumab injection was positively associated with serum TRACP 5b suppression during that same period (beta = 0.241, p = 0.049). In addition, a positive association of serum Pi suppression, but not of corrected calcium or TRACP 5b, with eGFRcys increase after 24 months (beta = 0.321, p = 0.014) was found after adjustments for gender, age, BMI, antihypertensive drug use, albumin, and eGFRcys. The same was observed in osteoporotic cases restricted to non CKD patients. In conclusion, serum Pi reduction resulting from phosphorus load decrement from bone induced by denosumab is a determinant for eGFRcys increase. Early introduction of bone antiresorptive therapy can retain glomerular filtration in osteoporosis cases, including non CKD patients. (c) 2019 American Society for Bone and Mineral Research.
C1 [Miyaoka, Daichi; Inaba, Masaaki; Imanishi, Yasuo; Hayashi, Noriyuki; Ohara, Masaya; Nagata, Yuki; Kurajoh, Masafumi; Yamada, Shinsuke; Mori, Katsuhito; Emoto, Masanori] Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Osaka, Japan.
C3 Osaka Metropolitan University
RP Inaba, M (通讯作者)，Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Abeno Ku, 1 4 3 Asahi Machi, Osaka 5458585, Japan.
EM m1356849@med.osaka cu.ac.jp
OI Miyaoka, Daichi/0000 0003 0505 107X
CR Anagnostis P, 2009, OSTEOPOROSIS INT, V20, P197, DOI 10.1007/s00198 008 0648 5
   Anastasilakis AD, 2012, BONE, V50, P1130, DOI 10.1016/j.bone.2012.02.006
   Baxmann AC, 2008, CLIN J AM SOC NEPHRO, V3, P348, DOI 10.2215/CJN.02870707
   BRODEHL J, 1988, PEDIATR NEPHROL, V2, P183, DOI 10.1007/BF00862587
   Burger D, 2013, KIDNEY INT, V83, P187, DOI 10.1038/ki.2012.416
   Chen CL, 2015, J CLIN ENDOCR METAB, V100, P2784, DOI 10.1210/jc.2015 1259
   Chue CD, 2011, NEPHROL DIAL TRANSPL, V26, P2576, DOI 10.1093/ndt/gfq787
   Dharnidharka VR, 2002, AM J KIDNEY DIS, V40, P221, DOI 10.1053/ajkd.2002.34487
   Di Iorio BR, 2013, NEPHROL DIAL TRANSPL, V28, P632, DOI 10.1093/ndt/gfs477
   Dixon A, 2007, AM J NEPHROL, V27, P120, DOI 10.1159/000099837
   Fekedulegn DB, 2007, PSYCHOSOM MED, V69, P651, DOI 10.1097/PSY.0b013e31814c405c
   Filler G, 2005, CLIN BIOCHEM, V38, P1, DOI 10.1016/j.clinbiochem.2004.09.025
   Fried LF, 2007, J AM SOC NEPHROL, V18, P282, DOI 10.1681/ASN.2006050546
   Gao P, 2001, J BONE MINER RES, V16, P605, DOI 10.1359/jbmr.2001.16.4.605
   Hayashi K, 2017, J ATHEROSCLER THROMB, V24, P863, DOI 10.5551/jat.38612
   Helmersson Karlqvist J, 2013, CLIN BIOCHEM, V46, P1761, DOI 10.1016/j.clinbiochem.2013.07.007
   Horio M, 2013, AM J KIDNEY DIS, V61, P197, DOI 10.1053/j.ajkd.2012.07.007
   Imai E, 2008, HYPERTENS RES, V31, P433, DOI 10.1291/hypres.31.433
   Kang JH, 2013, OSTEOPOROSIS INT, V24, P271, DOI 10.1007/s00198 012 2213 5
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   Klawansky S, 2003, OSTEOPOROSIS INT, V14, P570, DOI 10.1007/s00198 003 1435 y
   Kulak CAM, 2012, CALCIFIED TISSUE INT, V90, P263, DOI 10.1007/s00223 012 9572 y
   Lee H, 2012, NEPHROL DIAL TRANSPL, V27, P2799, DOI 10.1093/ndt/gfr762
   Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523 1755.2005.00365.x
   McGovern AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074996
   Melamed ML, 2011, KIDNEY INT, V79, P241, DOI 10.1038/ki.2010.378
   Miyaoka D, 2019, OSTEOPOROSIS INT, V30, P241, DOI 10.1007/s00198 018 4688 1
   Miyauchi A, 2010, BONE, V47, P493, DOI 10.1016/j.bone.2010.05.022
   Nishizawa Y, 2008, J BONE MINER METAB, V26, P265, DOI 10.1007/s00774 007 0826 0
   Okamoto K, 2010, LIFE SCI, V87, P686, DOI 10.1016/j.lfs.2010.10.006
   Okuno S, 2005, OSTEOPOROSIS INT, V16, P501, DOI 10.1007/s00198 004 1712 4
   Orimo Hajime, 2012, Arch Osteoporos, V7, P3
   Ozaki E, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18473 w
   Shidara K, 2008, CALCIFIED TISSUE INT, V82, P278, DOI 10.1007/s00223 008 9127 4
   Tangri N, 2011, KIDNEY INT, V79, P471, DOI 10.1038/ki.2010.431
   Ueda M, 2005, LIFE SCI, V77, P1130, DOI 10.1016/j.lfs.2005.02.007
   Yamashita T, 2011, CLIN EXP NEPHROL, V15, P831, DOI 10.1007/s10157 011 0501 6
   Yoda K, 2012, J CLIN ENDOCR METAB, V97, pE2036, DOI 10.1210/jc.2012 2024
   Yoda M, 2012, BIOMED PHARMACOTHER, V66, P266, DOI 10.1016/j.biopha.2011.11.001
   Zoccali C, 2011, J AM SOC NEPHROL, V22, P1923, DOI 10.1681/ASN.2011020175
NR 40
TC 11
Z9 11
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2019
VL 34
IS 11
BP 2028
EP 2035
DI 10.1002/jbmr.3821
EA AUG 2019
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA JM2FN
UT WOS:000480323100001
PM 31273841
OA Bronze
DA 2025 08 17
ER

PT J
AU Musacchio, E
   Valvason, C
   Botsios, C
   Ostuni, F
   Furlan, A
   Ramonda, R
   Modesti, V
   Sartori, L
   Punzi, L
AF Musacchio, Estella
   Valvason, Chiara
   Botsios, Constantin
   Ostuni, Francesca
   Furlan, Antonio
   Ramonda, Roberta
   Modesti, Valentina
   Sartori, Leonardo
   Punzi, Leonardo
TI The Tumor Necrosis Factor α blocking Agent Infliximab Inhibits
   Interleukin 1β (IL 1β) and IL 6 Gene Expression in Human Osteoblastic
   Cells
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE ANTI TUMOR NECROSIS FACTOR alpha; INFLIXIMAB; OSTEOBLASTS; INTERLEUKIN 1
   beta; INTERLEUKIN 6; OSTEOPROTEGERIN
ID SYSTEMIC BONE LOSS; RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS;
   SYNOVIAL FLUID; CYTOKINES; THERAPY; MECHANISMS; OSTEOPOROSIS;
   INFLAMMATION; DESTRUCTION
AB Objective. Tumor necrosis factor alpha (TNF alpha) is a proinflammatory cytokine involved in the pathogenesis of several rheumatic diseases, including rheumatoid arthritis (RA), associated with systemic bone loss and subchondral bone erosions. TNF alpha blocking agents Such as infliximab have been successful in treatment of disease modifying antirheumatic drug resistant rheumatic diseases. Infliximab therapy in RA also had beneficial effects on local bone destruction and bone mineral density. We assessed effects of infliximab treatment on the bone tissue compartment and cytokine profile expression in vitro.
   Methods. Osteoblast like cells were exposed for 24 h to sera of RA patients collected at baseline and after I month (T1) and 3 years (T2) of infliximab treatment. Total RNA was extracted, and expression of interleukin 1 beta (IL 1 beta), IL 6, and osteoprotegerin (OPG) was measured by RT PCR.
   Results. IL 1 beta gene expression was significantly reduced by the T1 serum, and the same decrease was elicited by the T2 serum. IL 6 downregulation was evident with the T2 serum. OPG was unaffected.
   Conclusion. The finding of downregulation of inflammatory cytokines was interesting, particularly IL 6, which plays a crucial role in arthritis related bone loss due to its involvement in osteoclast recruitment and activation. These results may represent a biological explanation and a link for the clinical observation of the beneficial effects of anti TNF alpha. agents on the progression of rheumatic diseases at the bone level. (First Release July 1 2009; J Rheumatol 2009;36:1575 9 doi: 10.3899/jrheum.081321)
C1 [Punzi, Leonardo] Univ Padua, Rheumatol Unit, Dept Clin & Expt Med, Div Rheumatol, I 35128 Padua, Italy.
   [Musacchio, Estella; Sartori, Leonardo] Univ Padua, Dept Med & Surg Sci, Med Clin 1, I 35128 Padua, Italy.
C3 University of Padua; University of Padua
RP Punzi, L (通讯作者)，Univ Padua, Rheumatol Unit, Dept Clin & Expt Med, Div Rheumatol, Via Giustiniani 2, I 35128 Padua, Italy.
EM punzireu@unipd.it
RI ; Furlan, Antonio/B 4420 2011
OI Musacchio, Estella/0000 0001 9811 9103; PUNZI,
   LEONARDO/0000 0002 8853 516X; Furlan, Antonio/0000 0002 8409 5603
CR Acosta Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496
   AREND WP, 1990, ARTHRITIS RHEUM US, V33, P305, DOI 10.1002/art.1780330302
   Arenzana Seisdedos F, 1987, Scand J Rheumatol Suppl, V66, P13
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Baugh J A, 2001, Curr Opin Drug Discov Devel, V4, P635
   BERTAZZOLO N, 1994, AGENTS ACTIONS, V41, P90, DOI 10.1007/BF01986402
   Bilbe G, 1996, BONE, V19, P437, DOI 10.1016/S8756 3282(96)00254 2
   Boissier MC, 2009, JOINT BONE SPINE, V76, P10, DOI 10.1016/j.jbspin.2008.08.002
   Catrina AI, 2006, ARTHRITIS RHEUM US, V54, P76, DOI 10.1002/art.21528
   Chopin F, 2008, ANN RHEUM DIS, V67, P353, DOI 10.1136/ard.2007.076604
   CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756 3282(94)90305 0
   Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163
   Gengenbacher M, 2008, ANN RHEUM DIS, V67, P620, DOI 10.1136/ard.2007.076711
   Goldring SR, 2002, J RHEUMATOL, V29, P44
   Goldring SR, 2002, J RHEUMATOL, V29, P2471
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Hofbauer LC, 2006, RHEUMATOLOGY, V45, P1218, DOI 10.1093/rheumatology/kel108
   Jackson JM, 2007, DERMATOL THER, V20, P251, DOI 10.1111/j.1529 8019.2007.00138.x
   Manolagas SC, 1998, ANN NY ACAD SCI, V840, P194, DOI 10.1111/j.1749 6632.1998.tb09563.x
   MARTELPELLETIER J, 1994, LAB INVEST, V70, P807
   NEALE ML, 1989, BRIT J RHEUMATOL, V28, P104
   Olivieri I, 2008, RHEUMATOLOGY, V47, P1664, DOI 10.1093/rheumatology/ken320
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Park JY, 2007, BULL HOSP JT DIS, V65, pS4
   Punzi L, 1996, ANN RHEUM DIS, V55, P642, DOI 10.1136/ard.55.9.642
   Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407
   Saidenberg Kermanac'h N, 2004, BONE, V35, P1200, DOI 10.1016/j.bone.2004.07.004
   Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471 2199 7 3
   Seriolo B, 2006, ANN NY ACAD SCI, V1069, P420, DOI 10.1196/annals.1351.040
   Sinigaglia L, 2006, RHEUM DIS CLIN N AM, V32, P631, DOI 10.1016/j.rdc.2006.07.002
   Stolina M, 2005, J BONE MINER RES, V20, P1756, DOI 10.1359/JBMR.050601
   Tracey D, 2008, PHARMACOL THERAPEUT, V117, P244, DOI 10.1016/j.pharmthera.2007.10.001
   Valvason C, 2008, RHEUMATOLOGY, V47, P31, DOI 10.1093/rheumatology/kem289
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 34
TC 36
Z9 41
U1 0
U2 3
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315 162X
EI 1499 2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD AUG
PY 2009
VL 36
IS 8
BP 1575
EP 1579
DI 10.3899/jrheum.081321
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 485ZI
UT WOS:000269164700007
PM 19567627
OA Bronze
DA 2025 08 17
ER

PT J
AU Miraoui, H
   Severe, N
   Vaudin, P
   Pagès, JC
   Marie, PJ
AF Miraoui, Hichem
   Severe, Nicolas
   Vaudin, Pascal
   Pages, Jean Christophe
   Marie, Pierre J.
TI Molecular Silencing of Twist1 Enhances Osteogenic Differentiation of
   Murine Mesenchymal Stem Cells: Implication of FGFR2 Signaling
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE TWIST1; OSTEOGENIC DIFFERENTIATION; MESENCHYMAL STEM CELLS; FGF RECEPTOR
   SIGNALING
ID HELIX TRANSCRIPTION FACTOR; GROWTH FACTOR RECEPTOR 2; OSTEOBLAST
   PROGENITORS; BONE; EXPRESSION; MUTATIONS; CBL; HAPLOINSUFFICIENCY;
   PROTEINS; FAMILY
AB The capacity of mesenchymal stem cells (MSCs) to differentiate into functional osteoblasts is tightly controlled by transcription factors that trigger osteoblast commitment and differentiation. The role of Twist1, a basic helix loop helix (bHLH) transcription factor, in osteogenic differentiation of MSCs remains unclear Het e we investigated the role of Twist1 in the osteogenic differentiation program of murine C3H10T1/2 mesenchymal cells We showed that molecular silencing of Twist1 using short hairpin RNA (shRNA) expression moderately increased C3H10T1/2 cell proliferation and had no effect on cell survival In contrast, Twist1 silencing enhanced osteoblast gene expression and matrix mineralization in vitro Biochemical analyses revealed that Twist1 silencing increased the expression of FGFR2 protein level, which was reduced by a mutant Runx2 Consistent with this finding, Twist1 silencing increased ERK1/2 and PI3K signaling Moreover, molecular or pharmacological inhibition of FGFR2 or of ERK1/2 and PI3K signaling partly abolished the increased osteoblast gene expression induced by Twist1 silencing in C3H10T1/2 cells These results reveal that Twist1 silencing upregulates osteoblast differentiation of murine mesenchymal cells in part via activation of FGFR2 expression and downstream signaling pathways, which provides novel insights into the molecular signals by which this transcription factor regulates the osteogenic differentiation program in MSCs. J Cell Biochem. 110 1147 1154, 2010 (C) 2010 Wiley Liss, Inc
C1 [Miraoui, Hichem; Severe, Nicolas; Marie, Pierre J.] Univ Paris Diderot, Hop Lariboisiere, INSERM, Lab Osteoblast Biol & Pathol,U606, F 75475 Paris 10, France.
   [Vaudin, Pascal; Pages, Jean Christophe] Univ Tours, INSERM, U966, Tours, France.
C3 Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere Fernand Widal   APHP; Universite de Tours;
   Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Marie, PJ (通讯作者)，Univ Paris Diderot, Hop Lariboisiere, INSERM, Lab Osteoblast Biol & Pathol,U606, 2 rue Ambroise Pare, F 75475 Paris 10, France.
RI Pagès, Jean Christophe/IAM 2849 2023; Vaudin, Pascal/J 1870 2014
OI Pages, Jean Christophe/0000 0002 6852 5546; 
FU Inserm Programme National de Recherche (Pro A Inserm, France); la
   Fondation de l'Avenir (Paris, France) [ER6 417]; Association Rhumatisme
   & Travail (Hopital Lariboisiere, Paris, France); Ministere de la
   Recherche (Paris, France)
FX Grant sponsor Inserm Programme National de Recherche (Pro A Inserm,
   France). Grant sponsor la Fondation de l'Avenir (Paris, France), Grant
   number ER6 417: Grant sponsor Association Rhumatisme & Travail (Hopital
   Lariboisiere, Paris, France)Tins work was funded in part by Inserm
   Programme National de Recherche (Pro A Inserm, France). la Emulation de
   l'Avenir (ER6 417, Paris, France) and Association Rhumatisme & Travail
   (Hopital Lariboisiere, Paris, France) Hichem Miraoui is a recipient of a
   Ph D. Award from the Ministere de la Recherche (Paris, France).
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Castanon I, 2002, GENE, V287, P11, DOI 10.1016/S0378 1119(01)00893 9
   CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686
   Connerney J, 2008, DEV BIOL, V318, P323, DOI 10.1016/j.ydbio.2008.03.037
   Connerney J, 2006, DEV DYNAM, V235, P1345, DOI 10.1002/dvdy.20717
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955 0674(03)00004 8
   Dufour C, 2008, BONE, V42, P1032, DOI 10.1016/j.bone.2008.02.009
   ElGhouzzi V, 1997, NAT GENET, V15, P42
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Franceschi RT, 2007, ANN NY ACAD SCI, V1116, P196, DOI 10.1196/annals.1402.081
   Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416 7428.2001
   Guenou H, 2005, HUM MOL GENET, V14, P1429, DOI 10.1093/hmg/ddi152
   Guenou H, 2006, AM J PATHOL, V169, P1303, DOI 10.2353/ajpath.2006.060102
   Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067
   Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197 36
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Johnson D, 2000, MECH DEVELOP, V91, P341, DOI 10.1016/S0925 4773(99)00278 6
   Kaabeche K, 2004, J BIOL CHEM, V279, P36259, DOI 10.1074/jbc.M402469200
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Komaki M, 2007, J CELL BIOCHEM, V100, P303, DOI 10.1002/jcb.21038
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097 4644(19991215)75:4<566::AID JCB3>3.0.CO;2 0
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Ling L, 2006, J CELL PHYSIOL, V209, P811, DOI 10.1002/jcp.20760
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Marie Pierre J., 2008, V12, P144, DOI 10.1159/000115036
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   O'Rourke MP, 2002, DEV BIOL, V248, P143, DOI 10.1006/dbio.2002.0730
   Oram KF, 2005, GENETICS, V170, P971, DOI 10.1534/genetics.105.041277
   Oshima A, 2002, J CELL BIOCHEM, V86, P792, DOI 10.1002/jcb.10272
   Oyajobi BO, 1999, J BONE MINER RES, V14, P351, DOI 10.1359/jbmr.1999.14.3.351
   PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rice DPC, 2000, DEVELOPMENT, V127, P1845
   Rice R, 2005, DEV DYNAM, V234, P28, DOI 10.1002/dvdy.20501
   Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694
   Tang CH, 2007, J CELL PHYSIOL, V211, P45, DOI 10.1002/jcp.20896
   Teplyuk NM, 2009, J CELL BIOCHEM, V107, P144, DOI 10.1002/jcb.22108
   Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100
   Yousfi M, 2003, BIOCHEM BIOPH RES CO, V305, P209, DOI 10.1016/S0006 291X(03)00642 9
   Yousfi M, 2002, HUM MOL GENET, V11, P359, DOI 10.1093/hmg/11.4.359
   Zhang Y, 2008, J CELL BIOCHEM, V105, P487, DOI 10.1002/jcb.21844
NR 49
TC 47
Z9 49
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG 1
PY 2010
VL 110
IS 5
BP 1147
EP 1154
DI 10.1002/jcb.22628
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 632PE
UT WOS:000280435900013
PM 20564211
DA 2025 08 17
ER

PT J
AU Jin, JK
   Dayyani, F
   Gallick, GE
AF Jin, Jung Kang
   Dayyani, Farshid
   Gallick, Gary E.
TI Steps in prostate cancer progression that lead to bone metastasis
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE prostate cancer; bone; metastasis; invasion; migration; osteoblast;
   osteoclast
ID FOCAL ADHESION KINASE; PLASMINOGEN ACTIVATOR SYSTEM; HORMONE RELATED
   PROTEIN; SRC FAMILY KINASES; ANDROGEN DEPRIVATION THERAPY; MARROW
   ENDOTHELIAL CELLS; N CADHERIN EXPRESSION; FACTOR I RECEPTOR; MATRIX
   METALLOPROTEINASES; BREAST CANCER
AB Prostate cancer is a complex disease in which metastasis to the bone is the main cause of death. Initial stages of metastasis are generally similar to those for most solid tumors; however, the mechanisms that underlie the homing of prostate tumor cells to the bone are not completely understood. Prostate cancer bone metastasis is also a microenvironment driven disease, involving bidirectional interactions between the tumor and the bone microenvironment. In this review, we discuss the current understanding of the biologic processes and regulatory factors involved in the metastasis of prostate cancer cells, and their specific properties that promote growth in bone. Although many of these processes still need to be fully elucidated, a better understanding of the complex tumor/microenvironment interplay is slowly leading to more effective therapies for patients with prostate cancer bone metastases.
C1 [Gallick, Gary E.] Univ Texas MD Anderson Canc Ctr, Unit 0018 4, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Jin, Jung Kang; Gallick, Gary E.] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; University of Texas Health Science Center Houston;
   University of Texas Graduate School of Biomedical Sciences
RP Gallick, GE (通讯作者)，Univ Texas MD Anderson Canc Ctr, Unit 0018 4, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM ggallick@mdanderson.org
RI Dayyani, Farshid/CAF 8867 2022; Jin, Jungkang/H 6285 2011
OI Dayyani, Farshid/0000 0002 4970 5189; 
FU NIH/NCI [T32 CA009666, P50 CA140388]
FX Grant sponsor: NIH/NCI; Grant numbers: T32 CA009666, P50 CA140388
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022 5347(01)62092 5
   [Anonymous], 2010, GLOBOCAN 2008 CANC I
   [Anonymous], ASCO M ABSTR
   Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015
   Arya M, 2006, SURG ONCOL, V15, P117, DOI 10.1016/j.suronc.2006.10.002
   Arya Manit, 2004, J Exp Ther Oncol, V4, P291
   Attar RM, 2009, CLIN CANCER RES, V15, P3251, DOI 10.1158/1078 0432.CCR 08 1171
   Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658
   Barrett JM, 2005, PROSTATE, V64, P75, DOI 10.1002/pros.20206
   Bartsch R, 2009, EXPERT OPIN BIOL TH, V9, P1225, DOI 10.1517/14712590903146877
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bello DeOcampo D, 2003, CURR DRUG TARGETS, V4, P197, DOI 10.2174/1389450033491118
   Bonkhoff H, 2010, PROSTATE, V70, P100, DOI 10.1002/pros.21042
   Boxler S, 2010, AM J PATHOL, V177, P2216, DOI 10.2353/ajpath.2010.091190
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brehmer B, 2003, PROSTATE CANCER P D, V6, P217, DOI 10.1038/sj.pcan.4500657
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097 0215(20000201)85:3<446::AID IJC23>3.0.CO;2 B
   BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Chen TS, 2000, CANCER RES, V60, P2132
   Chiao JW, 2000, BRIT J CANCER, V83, P360, DOI 10.1054/bjoc.2000.1261
   CHRISTENSSON A, 1994, EUR J BIOCHEM, V220, P45, DOI 10.1111/j.1432 1033.1994.tb18597.x
   CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432 1033.1990.tb19466.x
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Clarke NW, 2009, ASIAN J ANDROL, V11, P57, DOI 10.1038/aja.2008.29
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   COHEN P, 1994, J ENDOCRINOL, V142, P407, DOI 10.1677/joe.0.1420407
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Cooper CR, 2000, CLIN CANCER RES, V6, P4839
   Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Cramer SD, 1996, J UROLOGY, V156, P526, DOI 10.1016/S0022 5347(01)65919 6
   CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008 5472.CAN 07 6541
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Dallas SL, 2005, J CELL PHYSIOL, V202, P361, DOI 10.1002/jcp.20147
   Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027
   Davis TL, 2001, PROSTATE, V46, P240
   Dong Z, 2008, NEOPLASIA, V10, P439, DOI 10.1593/neo.08106
   Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097 0045(19991001)41:2<127::AID PROS7>3.0.CO;2 H
   Dutt SS, 2009, FUTURE ONCOL, V5, P1403, DOI [10.2217/fon.09.117, 10.2217/FON.09.117]
   Efstathiou E, 2010, CLIN CANCER RES, V16, P1100, DOI 10.1158/1078 0432.CCR 09 1215
   Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802
   Festuccia C, 1998, CLIN EXP METASTAS, V16, P513, DOI 10.1023/A:1006590217724
   Fizazi K, 2007, ANN ONCOL, V18, P1765, DOI 10.1093/annonc/mdm086
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111
   Goldenberg Furmanov M, 2004, CANCER RES, V64, P1058, DOI 10.1158/0008 5472.CAN 03 2420
   Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522
   Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078 0432.CCR 07 1263
   Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011
   Guise TA, 2003, CANCER AM CANCER SOC, V97, P779, DOI 10.1002/cncr.11129
   Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490
   Haapala K, 2007, HUM PATHOL, V38, P474, DOI 10.1016/j.humpath.2006.09.008
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Hall CL, 2008, NEOPLASIA, V10, P797, DOI 10.1593/neo.08380
   Hall CL, 2006, CANCER RES, V66, P8648, DOI 10.1158/0008 5472.CAN 06 1544
   Hall CL, 2006, J CELL BIOCHEM, V97, P661, DOI 10.1002/jcb.20735
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Hannon RA, 2010, J BONE MINER RES, V25, P463, DOI 10.1359/jbmr.090830
   Hao JS, 1996, AM J PATHOL, V149, P1341
   Hart CA, 2005, BRIT J CANCER, V92, P503, DOI 10.1038/sj.bjc.6602325
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   He H, 2010, PROSTATE, V70, P518, DOI 10.1002/pros.21086
   Hirbe AC, 2010, CURR PHARM DESIGN, V16, P1284, DOI 10.2174/138161210791034012
   Hobisch A, 2000, J PATHOL, V191, P239, DOI 10.1002/1096 9896(2000)9999:9999<::AID PATH633>3.0.CO;2 X
   Hobisch A, 1998, CANCER RES, V58, P4640
   Holen I, 2002, CANCER RES, V62, P1619
   HONN KV, 1992, CANCER METAST REV, V11, P353, DOI 10.1007/BF01307187
   Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008 5472.CAN 09 3016
   Huang L, 2002, J CLIN PATHOL, V55, P877, DOI 10.1136/jcp.55.11.877
   Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Ibrahim T, 2010, CANCER AM CANCER SOC, V116, P1406, DOI 10.1002/cncr.24896
   Ide H, 1997, CANCER RES, V57, P5022
   Iwamura M, 1996, UROLOGY, V48, P317, DOI 10.1016/S0090 4295(96)00182 3
   Jacob K, 1999, CANCER RES, V59, P4453
   Jaggi M, 2005, UROL ONCOL SEMIN ORI, V23, P402, DOI 10.1016/j.urolonc.2005.03.024
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Josson S, 2010, SEMIN CELL DEV BIOL, V21, P26, DOI 10.1016/j.semcdb.2009.11.016
   KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kanis JA, 1997, CANCER, V80, P1538, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1538::AID CNCR3>3.0.CO;2 G
   Kim MP, 2009, CELL TISSUE RES, V335, P249, DOI 10.1007/s00441 008 0682 9
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002
   Koch H, 2005, STEM CELLS DEV, V14, P621, DOI 10.1089/scd.2005.14.621
   Kopetz ES, 2002, INVEST NEW DRUG, V20, P173, DOI 10.1023/A:1015630513908
   Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008 5472.CAN 05 1293
   Kumano M, 2009, UROL ONCOL SEMIN ORI, V27, P180, DOI 10.1016/j.urolonc.2008.01.012
   Lai TH, 2008, PROSTATE, V68, P1341, DOI 10.1002/pros.20799
   Lattouf JB, 2010, CURR OPIN UROL, V20, P247, DOI 10.1097/MOU.0b013e32833835be
   Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344
   Lee RJ, 2011, BONE, V48, P88, DOI 10.1016/j.bone.2010.05.038
   Lee SO, 2003, CLIN CANCER RES, V9, P370
   Lee SO, 2004, PROSTATE, V60, P178, DOI 10.1002/pros.20045
   Lee Y, 2003, J ORTHOP RES, V21, P62, DOI 10.1016/S0736 0266(02)00095 5
   Lee YC, 2010, ONCOGENE, V29, P3196, DOI 10.1038/onc.2010.73
   Lehr JE, 1998, J NATL CANCER I, V90, P118, DOI 10.1093/jnci/90.2.118
   Li Y, 2007, CANCER TREAT REV, V33, P521, DOI 10.1016/j.ctrv.2007.06.003
   Liao JH, 2008, INT J CANCER, V123, P2267, DOI 10.1002/ijc.23602
   Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555 006 9033 z
   Lichtinghagen R, 2002, EUR UROL, V42, P398, DOI 10.1016/S0302 2838(02)00324 X
   LILJA H, 1987, J CLIN INVEST, V80, P281, DOI 10.1172/JCI113070
   Littlepage LE, 2010, CANCER RES, V70, P2224, DOI 10.1158/0008 5472.CAN 09 3515
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   LOKESHWAR BL, 1993, CANCER RES, V53, P4493
   Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097 0045(20000215)42:3<239::AID PROS10>3.0.CO;2 G
   MARTENSSON S, 1995, HUM PATHOL, V26, P735, DOI 10.1016/0046 8177(95)90220 1
   Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193
   Mazo IB, 1999, J LEUKOCYTE BIOL, V66, P25, DOI 10.1002/jlb.66.1.25
   McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429
   Mellado B, 2009, CLIN TRANSL ONCOL, V11, P5, DOI 10.1007/s12094 009 0304 3
   Miller RE, 2008, MOL CANCER THER, V7, P2160, DOI 10.1158/1535 7163.MCT 08 0046
   Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549
   Mol AJM, 2007, J CANCER RES CLIN, V133, P687, DOI 10.1007/s00432 007 0235 8
   Morgia G, 2005, UROL RES, V33, P44, DOI 10.1007/s00240 004 0440 8
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Nabha SM, 2008, INT J CANCER, V122, P2482, DOI 10.1002/ijc.23431
   Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008 5472.CAN 05 1731
   Nelson JB, 2003, J UROLOGY, V170, pS65, DOI 10.1097/01.ju.0000096372.07687.86
   Nelson JB, 1996, CANCER RES, V56, P663
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   NESBITT S, 1993, J BIOL CHEM, V268, P16737
   Nyambo R, 2004, J BONE MINER RES, V19, P1712, DOI 10.1359/JBMR.040703
   Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884
   Paget S., 1889, Cancer Metastasis Rev, V133, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008 5472.CAN 07 2997
   Paronetto MP, 2004, AM J PATHOL, V164, P1243, DOI 10.1016/S0002 9440(10)63212 9
   Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 23
   PINERO GJ, 1995, ARCH ORAL BIOL, V40, P145, DOI 10.1016/0003 9969(94)00144 Z
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Recchi I, 2003, EUR J CANCER, V39, P1927, DOI 10.1016/S0959 8049(03)00394 0
   Reutsch CA, 2009, SWISS MED WKLY, V139, P220, DOI smw 12284
   Ritchie CK, 1997, ENDOCRINOLOGY, V138, P1145, DOI 10.1210/en.138.3.1145
   Romanov VI, 1999, PROSTATE, V39, P108
   ROMANOWSKI R, 1990, CALCIFIED TISSUE INT, V46, P353, DOI 10.1007/BF02554964
   Rovin JD, 2002, PROSTATE, V53, P124, DOI 10.1002/pros.10114
   Rubin J, 2004, PROSTATE, V58, P41, DOI 10.1002/pros.10299
   Rubin J, 2006, PROSTATE, V66, P789, DOI 10.1002/pros.20379
   Russo A, 2010, EXPERT OPIN EMERG DR, V15, P27, DOI 10.1517/14728210903571667
   Ryan CJ, 2007, UROL ONCOL SEMIN ORI, V25, P134, DOI 10.1016/j.urolonc.2006.07.019
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2010, CANCER TREAT REV, V36, P177, DOI 10.1016/j.ctrv.2009.11.005
   Saha B, 2008, PROSTATE, V68, P78, DOI 10.1002/pros.20670
   Schmelz M, 2002, NEOPLASIA, V4, P243, DOI 10.1038/sj.neo.7900223
   Scott LJ, 2001, BRIT J CANCER, V84, P1417, DOI 10.1054/bjoc.2001.1804
   Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810
   Sheng SJ, 2001, CANCER METAST REV, V20, P287, DOI 10.1023/A:1015539612576
   SIEGALL CB, 1990, CANCER RES, V50, P7786
   SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022 5347(17)35267 9
   Sikes RA, 2004, INT J CANCER, V110, P497, DOI 10.1002/ijc.20153
   Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208
   Slack Davis JK, 2004, J CELL BIOCHEM, V91, P41, DOI 10.1002/jcb.10665
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Sommerfeldt DW, 2001, EUR SPINE J, V10, pS86, DOI 10.1007/s005860100283
   SORIANO P, 1991, Cell, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Stewart Delisha A, 2004, Reprod Biol Endocrinol, V2, P2, DOI 10.1186/1477 7827 2 2
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078 0432.CCR 05 2692
   Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750
   Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109
   Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522
   Taichman RS, 2002, CANCER RES, V62, P1832
   Taichman RS, 2007, J CLIN INVEST, V117, P2351, DOI 10.1172/JCI31791
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Tatarov O, 2009, CLIN CANCER RES, V15, P3540, DOI 10.1158/1078 0432.CCR 08 1857
   TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Thudi NK, 2011, PROSTATE, V71, P615, DOI 10.1002/pros.21277
   Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002 9440(10)65177 2
   Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097 0215(19961009)68:2<169::AID IJC4>3.0.CO;2 W
   Trevino Jose G., 2006, Angiogenesis, V9, P101, DOI 10.1007/s10456 006 9038 9
   Trudel D, 2003, CANCER RES, V63, P8511
   Tsingotjidou AS, 2001, ANTICANCER RES, V21, P971
   Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008 5472.CAN 09 1618
   UMBAS R, 1994, CANCER RES, V54, P3929
   UMBAS R, 1992, CANCER RES, V52, P5104
   URWIN GH, 1985, BRIT J UROL, V57, P721, DOI 10.1111/j.1464 410X.1985.tb07040.x
   van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018 008 8281 1
   Vela I, 2007, BJU INT, V99, P735, DOI 10.1111/j.1464 410X.2006.06670.x
   Vij R, 2009, AM J HEMATOL, V84, P650, DOI 10.1002/ajh.21509
   Virk MS, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2169
   Virk MS, 2009, BONE, V44, P160, DOI 10.1016/j.bone.2008.09.009
   Wahdan Alaswad RS, 2010, CANCER RES, V70, P9106, DOI 10.1158/0008 5472.CAN 10 1119
   WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166
   Webber MM, 1995, CLIN CANCER RES, V1, P1089
   Whang PG, 2005, J ORTHOP RES, V23, P1475, DOI 10.1016/j.orthres.2005.05.004
   Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078 0432.CCR 09 1691
   Zhang J, 2003, CANCER RES, V63, P7883
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zheng DQ, 1999, CANCER RES, V59, P1655
   Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200
   Zhong WD, 2008, ONCOLOGY BASEL, V75, P230, DOI 10.1159/000163852
NR 207
TC 129
Z9 169
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 1
PY 2011
VL 128
IS 11
BP 2545
EP 2561
DI 10.1002/ijc.26024
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 748EE
UT WOS:000289372000005
PM 21365645
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Chen, Q
   Massagué, J
AF Chen, Qing
   Massague, Joan
TI Molecular Pathways: VCAM 1 as a Potential Therapeutic Target in
   Metastasis
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; MYELOMA CELL LINES;
   MULTIPLE MYELOMA; BREAST CANCER; ALPHA 4 BETA 1 INTEGRIN;
   MONOCLONAL ANTIBODY; ENDOTHELIAL CELLS; IN VIVO; ADHESION; NATALIZUMAB
AB Interactions between disseminated tumor cells (DTC) and stromal cells in the microenvironment are critical for tumor colonization of distal organs. Recent studies have shown that vascular cell adhesion molecule 1 (VCAM 1) is aberrantly expressed in breast cancer cells and mediates prometastatic tumor stromal interactions. Moreover, the usefulness of VCAM 1 to DTCs in 2 different organs lung and bone is based on distinct mechanisms. In the lungs, VCAM 1 on the surface of cancer cells binds to its counter receptor, the alpha 4 beta 1 integrin (also known as very late antigen, VLA 4), on metastasis associated macrophages, triggering VCAM 1 mediated activation of the phosphoinositide 3 kinase growth and survival pathway in the cancer cells. In the bone marrow, cancer cell VCAM 1 attracts and tethers alpha 4 integrin expressing osteoclast progenitors to facilitate their maturation into multinucleated osteoclasts that mediate osteolytic metastasis. These findings highlight the importance of direct interactions between DTCs and stromal cells during tumor dissemination and draw attention to the possibility of targeting the alpha 4 integrin VCAM 1 interactions in metastatic breast cancer. Anti alpha 4 integrin inhibitors have been developed to treat various diseases driven by massive leukocyte infiltrates and have gained U. S. Food and Drug Administration approval or are undergoing clinical trials. Testing these drugs against tumor stromal leukocyte interactions may provide a new strategy to suppress lung and bone relapse of breast cancer. Clin Cancer Res; 18(20); 5520 5. (C) 2012 AACR.
C1 [Chen, Qing; Massague, Joan] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA.
   [Massague, Joan] Howard Hughes Med Inst, Chevy Chase, MD USA.
C3 Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute
RP Massagué, J (通讯作者)，Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Box 116,1275 York Ave, New York, NY 10065 USA.
EM j massague@ski.mskcc.org
RI CHEN, QING/IXN 5937 2023; Massague, Joan/C 4216 2008
OI Massague, Joan/0000 0001 9324 8408
FU Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS
   [R37 CA034610, P30 CA008748] Funding Source: Medline
CR Bloomgren G, 2012, NEW ENGL J MED, V366, P1870, DOI 10.1056/NEJMoa1107829
   Cardones AR, 2003, CANCER RES, V63, P6751
   Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025
   Comi G, 2009, NEUROL SCI, V30, P155, DOI 10.1007/s10072 009 0147 2
   CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859
   de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275
   Ding YB, 2003, WORLD J GASTROENTERO, V9, P1409, DOI 10.3748/wjg.v9.i7.1409
   ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092 8674(90)90661 W
   Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866
   Fidler IJ, 2002, LANCET ONCOL, V3, P53, DOI 10.1016/S1470 2045(01)00622 2
   Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732
   HAMANN A, 1994, J IMMUNOL, V152, P3282
   HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600 065X.1990.tb00561.x
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   KENT SJ, 1995, J NEUROIMMUNOL, V58, P1, DOI 10.1016/0165 5728(94)00165 K
   Kibler C, 1998, CELL ADHES COMMUN, V5, P307, DOI 10.3109/15419069809040300
   Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031
   Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165 5728(99)00084 3
   Leger Olivier J. P., 1997, Human Antibodies, V8, P3
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275
   Major EO, 2010, ANNU REV MED, V61, P35, DOI 10.1146/annurev.med.080708.082655
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood 2004 01 0236
   Mountain A, 1992, Biotechnol Genet Eng Rev, V10, P1
   Olson DL, 2005, MOL CANCER THER, V4, P91
   OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092 8674(89)90775 7
   Podar K, 2011, BRIT J HAEMATOL, V155, P438, DOI 10.1111/j.1365 2141.2011.08864.x
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562
   Ruco LP, 1996, J PATHOL, V179, P266
   Schmidt Klaus J, 2009, Curr Drug Discov Technol, V6, P290
   Shin J, 2006, CELL PHYSIOL BIOCHEM, V17, P211, DOI 10.1159/000094126
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Sugiura T., 2012, J PHARM EXP THER
   TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347
   Takazoe M, 2009, DIGESTIVE DIS WEEK
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   UCHIYAMA H, 1992, BLOOD, V80, P2306
   van Wetering S, 2003, AM J PHYSIOL CELL PH, V285, pC343, DOI 10.1152/ajpcell.00048.2003
   VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0
   Zhao J, 2008, EUR J PHARMACOL, V589, P127, DOI 10.1016/j.ejphar.2008.04.063
NR 47
TC 132
Z9 149
U1 1
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2012
VL 18
IS 20
BP 5520
EP 5525
DI 10.1158/1078 0432.CCR 11 2904
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 048JW
UT WOS:000311908500002
PM 22879387
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Toegel, S
   Hoffmann, O
   Wadsak, W
   Ettlinger, D
   Mien, LK
   Wiesner, K
   Nguemo, J
   Viernstein, H
   Kletter, K
   Dudczak, R
   Mitterhauser, M
AF Toegel, S
   Hoffmann, O
   Wadsak, W
   Ettlinger, D
   Mien, LK
   Wiesner, K
   Nguemo, J
   Viernstein, H
   Kletter, K
   Dudczak, R
   Mitterhauser, M
TI Uptake of bone seekers is solely associated with mineralisation!: A
   study with <SUP>99m</SUP>Tc MDP, <SUP>153</SUP>Sm EDTMP and
   <SUP>18</SUP>F fluoride on osteoblasts
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article
DE polyphosphonates; binding studies; osteoblasts; technetium 99m;
   fluorine 18; bone
ID COMPARTMENTS; IN 111; RE 188
AB Purpose: Although polyphosphonates (PPs) were introduced as bone imaging agents in nuclear medicine in the early 1970s, the mechanisms involved in their uptake still remain unclear. Suggested mechanisms range from mineral adsorption with disputed binding to the organic phase, over incorporation into the mineralisation process to a combination of both mechanisms. Thus, our investigations aimed to: (1) evaluate adsorption parameters of Tc 99m MDP, Sm 153 EDTMP and F 18 fluoride on mineralising osteoblast cultures, (2) correlate the radiotracer binding measured in the cell cultures with binding values from our previously presented mineral model and (3) compare binding with cell number.
   Methods: Primary osteoblasts were obtained by sequential digestion of foetal mice calvariae. The cells were incubated with 0.3 mu mol of radiolabelled PPs or 25 MBq F 18 fluoride for 120 min. Gamma signals from labelled samples were detected with a Millennium Hawkeye SPECT camera or with a dedicated Advance full ring PET scanner and the binding percentages were calculated.
   Results: From days 8 to 15 of culture, the percent binding of all evaluated tracers increased significantly, whereas the protein concentration showed insignificant changes. Additional comparisons of the binding values with our recently published pre vivo model revealed remarkable agreement, suggesting solely bone forming minerals to be responsible for radiotracer binding.
   Conclusion: This study provides evidence that binding of the evaluated radiotracers is not associated with osteoblast numbers but only with the concentration of bone forming minerals. The presented correlations substantiate our recently presented pre vivo model for the evaluation of bone seekers: mechanisms associated with the uptake of bone seekers are irreversible and mineral associated processes.
C1 Med Univ Vienna, AKH Wien, Dept Nucl Med, A 1090 Vienna, Austria.
   Gen Hosp Vienna, Hosp Pharm, Vienna, Austria.
   Ludwig Boltzmann Inst Nucl Med & Endocrinol, Vienna, Austria.
   Univ Vienna, Dept Inorgan Chem, Vienna, Austria.
   Univ Vienna, Dept Pharmacol & Toxicol, Vienna, Austria.
   Univ Vienna, Dept Pharmaceut Technol & Biopharmaceut, Vienna, Austria.
C3 University Hospital Vienna; Medical University of Vienna; Ludwig
   Boltzmann Institute; University of Vienna; University of Vienna;
   University of Vienna
RP Med Univ Vienna, AKH Wien, Dept Nucl Med, Waehringer Guertel 18 20, A 1090 Vienna, Austria.
RI ; Wadsak, Wolfgang/K 7408 2019; Toegel, Stefan/J 6548 2019
OI Mitterhauser, Markus/0000 0003 3173 5272; Wadsak,
   Wolfgang/0000 0003 4479 8053; Toegel, Stefan/0000 0003 4317 1769
CR FRANCIS MD, 1980, J NUCL MED, V21, P1185
   Fueger BJ, 2004, NUCL MED COMMUN, V25, P361, DOI 10.1097/00006231 200404000 00008
   Horiuchi Suzuki K, 2004, EUR J NUCL MED MOL I, V31, P388, DOI 10.1007/s00259 003 1364 1
   KANISHI D, 1993, ORAL SURG ORAL MED O, V75, P239, DOI 10.1016/0030 4220(93)90100 I
   MARSH ME, 1995, J BONE MINER RES, V10, P1635
   Mitterhauser M, 2005, BONE, V37, P404, DOI 10.1016/j.bone.2005.04.027
   Mitterhauser M, 2004, BONE, V34, P835, DOI 10.1016/j.bone.2004.01.011
   SCHWARTZ Z, 1993, J NUCL MED, V34, P104
   SUBRAMANIAN G, 1975, J NUCL MED, V16, P1080
   Wang H, 2005, BONE, V36, P84, DOI 10.1016/j.bone.2004.08.021
NR 10
TC 66
Z9 72
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1619 7070
EI 1619 7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD APR
PY 2006
VL 33
IS 4
BP 491
EP 494
DI 10.1007/s00259 005 0026 x
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 034EZ
UT WOS:000236913100013
PM 16416330
DA 2025 08 17
ER

PT J
AU Li, YX
   Liu, C
   Luo, J
   Zeng, Y
   Meng, XL
   Wang, SH
   Zhang, Y
AF Li, Yangxin
   Liu, Chuan
   Luo, Jie
   Zeng, Yong
   Meng, Xianli
   Wang, Shaohui
   Zhang, Yi
TI Ershiwuwei Lvxue Pill alleviates rheumatoid arthritis by different
   pathways and produces changes in the gut microbiota
SO PHYTOMEDICINE
LA English
DT Article
DE Tibetan medicine; Ershiwuwei Lvxue Pill; Rheumatoid arthritis;
   Systematic pharmacology; Gut microbiota; Metabolites
ID KINASE; BONE
AB Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease that often results in joint destruction. Ershiwuwei Lvxue Pill (ELP), a prescription of Tibetan medicine, has been used for centuries for the clinical treatment of RA in Tibet, China. In a previous study, we reported that ELP could ameliorate RA symptoms in CIA rats by inhibiting the inflammatory response and inducing apoptosis in synovial tissues. It is still needed further to clarify the mechanisms of action of ELP in mitigating RA.
   Purpose: In this study, we aim to elucidate the mechanism of action of ELP to improve RA joint damage and explore the changes in the intestinal flora and host metabolites.
   Methods: Firstly, we analyzed the main absorbed constituents of ELP in the serum of rats by ultra performance liquid chromatography quadrupole time flight mass spectrometry (UPLC Q TOF/MS). Then, we verified the alleviating effects of ELP on cartilage injury and bone erosion as well as the inflammatory response in CIA rats by microCT, H&E staining, safranin O staining, and ELISA. Moreover, we investigated the main factors that mediate joint damage, including the production of matrix metalloproteinases (MMPs) and osteoclast activity in the ankle of rats by immunohistochemistry and tartrate resistant acid phosphatase (TRAP) staining. Further, we explored the molecular mechanisms of the MMPs production and osteoclast activity in CIA rats treated with ELP through various experiments such as ELISA, qRT PCR, western blotting, and immunofluorescence assay. Besides, we investigated gut microbiota composition by 16S rDNA sequencing and serum metabolites through untargeted metabolomics. In addition, we analyzed the correlation between gut microbiota and metabolites by Spearman correlation analysis.
   Results: In this study, we identified 20 compounds from rat serum samples, which could be the ELP components that improve RA. Moreover, we found that ELP could alleviate cartilage and bone injury by reducing MMP 1, MMP 3, and MMP 13 expression and osteoclast activity in CIA rats. Further studies demonstrated that ELP could reduce joint damage by inhibiting osteoprotegerin (OPG)/receptor activator for nuclear factor KB ligand (RANKL) /nuclear factor KB (NF KB) and extracellular signal regulated kinase (ERK)/c Jun N terminal kinases (JNK) signal pathways. The 16S rDNA sequencing analysis indicated that there was a significant difference in the gut microbiota composition between the normal and CIA rats, and these differences were changed after ELP administration. ELP could alter the gut microbiota by increasing the abundance of the genus Lactobacillus and decreasing the abundance of Dorea, [Eubacterium]_ventriosum_group, Anaerostipes, Collinsella, Coprococcus_1, Ruminiclostridium_5, Ruminococcus_1, Family_XIII_UCG 001, Butyricicoccus, Erysipelotrichaceae_UCG 003, Lachno clostridium, Faecalibacterium, Lachnospiraceae_UCG 010, Roseburia, Rs E47_termite_group_norank, Treponema_2 genera. Non targeted metabolomics analysis showed that ELP reduced arachidonic acid levels. The serum arachidonic acid level was significantly correlated with the abundance of 41 genera, particularly Collinsella and Lactobacillus.
   Conclusion: Our study shows that ELP can improve RA joint damage by inhibiting MMPs production and oste oclast activity, and regulating intestinal flora and host metabolites, which provides a novel insight into the ELP alleviating RA.
C1 [Li, Yangxin; Zeng, Yong] Chengdu Univ Tradit Chinese Med, Sch Pharm, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China.
   [Liu, Chuan; Luo, Jie; Wang, Shaohui; Zhang, Yi] Chengdu Univ Tradit Chinese Med, Sch Ethn Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China.
   [Meng, Xianli] Chengdu Univ Tradit Chinese Med, Innovat Inst Chinese Med & Pharm, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China.
   [Wang, Shaohui; Zhang, Yi] Chengdu Univ Tradit Chinese Med, Sch Ethn Med, State Key Lab Southwestern Chinese Med Resources, 1166 Liutai Ave, Chengdu 611137, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine; Chengdu University of Traditional
   Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Wang, SH; Zhang, Y (通讯作者)，Chengdu Univ Tradit Chinese Med, Sch Ethn Med, State Key Lab Southwestern Chinese Med Resources, 1166 Liutai Ave, Chengdu 611137, Peoples R China.
EM zhangyi@cdutcm.edu.cn; winter9091@163.com
RI Liu, Chuan/HOF 8470 2023; Wang, Shengpeng/JOZ 1627 2023; Wang,
   Shaohui/HKO 6774 2023
OI Liu, Haibo/0000 0002 4213 2883; Liu, Chuan/0000 0002 4652 8949
FU National Natural Science Founda tion of China; National Key R&D Program
   of China; Regional Innovation and Cooperation Project of the Science &
   Technology Department of Sichuan Province; Key R&D and Transformation
   Program of the Sci ence & Technology Department of Qinghai Province; 
   [82130113];  [2017YFC1703904];  [2020YFQ0032];  [2020 SF C33]
FX Acknowledgments This study was supported by the National Natural Science
   Founda tion of China (82130113) ; the National Key R&D Program of China
   (2017YFC1703904) ; the Regional Innovation and Cooperation Project of
   the Science & Technology Department of Sichuan Province (2020YFQ0032) ;
   the Key R&D and Transformation Program of the Sci ence & Technology
   Department of Qinghai Province (2020 SF C33) .
CR Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Bécède M, 2019, SEMIN ARTHRITIS RHEU, V49, P211, DOI 10.1016/j.semarthrit.2019.02.004
   Chen J, 2016, GENOME MED, V8, DOI 10.1186/s13073 016 0299 7
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   Gao FP, 2019, ADV SCI, V6, DOI 10.1002/advs.201801671
   Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466
   He M, 2019, INT J RHEUM DIS, V22, P38, DOI 10.1111/1756 185X.13062
   Holmdahl R, 2014, EUR J IMMUNOL, V44, P1593, DOI 10.1002/eji.201444486
   [胡华刚 Hu Huagang], 2016, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V22, P1053
   Jing ZW, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.692893
   Kyriachenko Y, 2019, WORLD J DIABETES, V10, P154, DOI 10.4239/wjd.v10.i3.154
   Lin H., 2015, J HUBEI U CHIN MED, V17, P24, DOI [DOI 10.3969/J.ISSN.1008 987X.2015.02.07, 10.3969/j.issn.1008 987x.2015.02.07]
   Liu C, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0262469
   Liu C, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113820
   Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266
   Nelson J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102991
   Rehaume LM, 2014, ARTHRITIS RHEUMATOL, V66, P2780, DOI 10.1002/art.38773
   Ruiz Quezada SL, 2013, Ann Rheum Dis, V71, P673, DOI [10.1136/annrheumdis 2012 eular.607, DOI 10.1136/ANNRHEUMDIS 2012 EULAR.607]
   Ryu JH, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001881
   Sabeh F, 2010, J IMMUNOL, V184, P6396, DOI 10.4049/jimmunol.0904068
   Safiri S, 2019, ANN RHEUM DIS, V78, P1463, DOI 10.1136/annrheumdis 2019 215920
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Sun Y, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00369
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Westra J, 2004, ANN RHEUM DIS, V63, P1453, DOI 10.1136/ard.2003.013011
   Xu YJ, 2021, EMBO J, V40, DOI 10.15252/embj.2021108069
   Yadav M, 2018, ARCH MICROBIOL, V200, P203, DOI 10.1007/s00203 017 1459 x
   Ye ZD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21242 z
   Zaiss MM, 2021, NAT REV RHEUMATOL, V17, P224, DOI 10.1038/s41584 021 00585 3
NR 30
TC 27
Z9 30
U1 4
U2 111
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD DEC
PY 2022
VL 107
AR 154462
DI 10.1016/j.phymed.2022.154462
EA SEP 2022
PG 16
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 4Z9EX
UT WOS:000862503500002
PM 36162242
DA 2025 08 17
ER

PT J
AU Yang, YX
   Zhang, YW
   Kuang, SS
   Zhang, Y
   Zhou, LD
   Mao, BY
   Xie, JS
AF Yang, Yi xin
   Zhang, Yao wen
   Kuang, Shan shan
   Zhang, Yang
   Zhou, Lan dao
   Mao, Bao yu
   Xie, Ji sheng
TI Studies on the Anti inflammatory Effect of Xiaoyao Pills in The
   Treatment of Postmenopausal Osteoporosis in Mice
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
ID IL 17; THERAPY
AB Osteoporosis is a common metabolic disease of elderly and postmenopausal women, with no obvious symptoms during its early stages. In the latter stages of this condition, the patients are prone to fractures, and this can seriously affect their health and quality of life. The worldwide increase in life expectancy has made osteoporosis a global concern. The Xiaoyao pills were previously used in the treatment of depression. In addition, the drug appeared to have estrogen  like activity, which affected the expression of ALP, an early osteoblast specific marker, and COL 1, a major component of bone extracellular matrix. Xiaoyao pills were assessed for their effects on postmenopausal osteoporosis (PMOM) in mice. The target information of each herbal component ofXiaoyao pills was accessed through the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Information from GeneCards, OMIM, PharmGkb, TTD, DrugBank, and other websites was used to construct the regulatory network of the herbal complex through Cytoscape and String network to assess the protein interactions. Mice were ovariectomized, and treated with high and low doses of Xiaoyao pills and these were compared to controls. Their symptoms were assessed by immunocytochemistry of bone tissues. The results suggested that Xiaoyao pills had the ability to alleviate the symptoms of PMOM in ovariectomized mice through the IL 17 signaling pathway. This drug has the potential to become a novel therapeutic agent for the treatment of osteoporosis.
C1 [Yang, Yi xin; Zhang, Yao wen; Kuang, Shan shan; Zhang, Yang; Xie, Ji sheng] Youjiang Med Univ Nationalities, Dept Histol & Embryol, Baise, Peoples R China.
   [Zhou, Lan dao] Youjiang Med Univ Nationalities, Affiliated Hosp, Dept Geriatr Orthoped, Baise, Peoples R China.
   [Mao, Bao yu] Youjiang Med Univ Nationalities, Dept Pathophysiol, Baise, Peoples R China.
C3 Youjiang Medical University for Nationalities; Youjiang Medical
   University for Nationalities; Youjiang Medical University for
   Nationalities
RP Xie, JS (通讯作者)，Youjiang Med Univ Nationalities, Dept Histol & Embryol, Baise, Peoples R China.
EM jjs1968@163.com
RI ; Zhang, Yaowen/JAZ 0324 2023; Yixin, Yang/LFU 8035 2024
OI Yang, Yixin/0009 0006 5750 9109; 
FU Baise City Scientific Research and Technology Development Program
   [20224128]
FX The Baise City Scientific Research and Technology Development Program
   (20224128) supported this work. The authors thank Dr. Dev Sooranna of
   Imperial College London and YMUN for editing the manuscript. YYX and ZYW
   contributed equally to this study.
CR ACOG Committee on Clinical Practice Guidelines Gynecology, 2022, Obstet Gynecol, V139, P698, DOI 10.1097/AOG.0000000000004730
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Amatya N, 2017, TRENDS IMMUNOL, V38, P310, DOI 10.1016/j.it.2017.01.006
   Amberger JS, 2019, NUCLEIC ACIDS RES, V47, pD1038, DOI 10.1093/nar/gky1151
   Amin U, 2023, WOMENS HEALTH, V19, DOI 10.1177/17455057231176655
   Barshir R, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2021.166913
   Bateman A, 2023, NUCLEIC ACIDS RES, V51, pD523, DOI 10.1093/nar/gkac1052
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Chen S. X. R. B. X., 2002, Pharmacology experimental methodology
   Commission NP., 2020, Pharmacopoeia of the People's Republic of China
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Daoussis D, 2010, SEMIN ARTHRITIS RHEU, V39, P369, DOI 10.1016/j.semarthrit.2008.10.008
   Fang Y, 2020, NEURAL PLAST, V2020, DOI 10.1155/2020/8841332
   Hu TH, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114612
   Huangfu LJ, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01620 3
   Hwang YH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051383
   Ji YF, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.643456
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Knox C, 2023, NUCLEIC ACIDS RES, V52, pD1265, DOI 10.1093/nar/gkad976
   Le Goff B, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8659302
   Lencel P, 2011, MED HYPOTHESES, V76, P317, DOI 10.1016/j.mehy.2010.09.023
   Li BL, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/7732508
   Li J, 2022, CLIMACTERIC, V25, P562, DOI 10.1080/13697137.2022.2102894
   Ling XP, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/7795527
   MACKIE TT, 1946, T ROY SOC TROP MED H, V40, P15, DOI 10.1016/0035 9203(46)90061 2
   Majumder S, 2021, ANNU REV IMMUNOL, V39, P537, DOI 10.1146/annurev immunol 101819 092536
   McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021
   Patel D, 2023, ANN JOINT, V8, DOI 10.21037/aoj 23 2
   Peng RP, 2024, CELL DEATH DIS, V15, DOI 10.1038/s41419 024 06475 2
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Ramchand SK, 2024, J CLIN ENDOCR METAB, V109, P303, DOI 10.1210/clinem/dgad496
   Ren P, 2024, J TRADIT CHIN MED, V44, P212, DOI 10.19852/j.cnki.jtcm.20230904.006
   Rendi MH, 2011, COMPARATIVE ANATOMY AND HISTOLOGY: A MOUSE AND HUMAN ATLAS, P253
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Selvaraj V, 2024, DIFFERENTIATION, V136, DOI 10.1016/j.diff.2024.100757
   Sharma A, 2023, BIOMED PHARMACOTHER, V163, DOI 10.1016/j.biopha.2023.114850
   Shi BY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01324
   Slupski W, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051609
   Walker MD, 2023, NEW ENGL J MED, V389, P1979, DOI 10.1056/NEJMcp2307353
   Wang TY, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 41101 9
   Wang Tianyue, 2023, Aging (Albany NY), V15, P1543, DOI 10.18632/aging.204561
   Whirl Carrillo M, 2021, CLIN PHARMACOL THER, V110, P563, DOI 10.1002/cpt.2350
   Xiao J, 2023, OPEN LIFE SCI, V18, DOI 10.1515/biol 2022 0747
   Zhang JR, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5950395
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang X., 2024, J Shanxi Med University, V55, P36
   Zhou LP, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00779
   Zhou Y, 2024, NUCLEIC ACIDS RES, V52, pD1465, DOI 10.1093/nar/gkad751
NR 49
TC 0
Z9 0
U1 2
U2 5
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD AUG
PY 2024
IS 210
AR e67051
DI 10.3791/67051
PG 26
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA O0G2W
UT WOS:001368007600005
PM 39248484
DA 2025 08 17
ER

PT J
AU Li, F
   Yao, JH
   Yan, YL
   Lin, W
   Ning, XR
   Cao, JJ
AF Li, Fang
   Yao, Jianhua
   Yan, Yonglong
   Lin, Wei
   Ning, Xiaoran
   Cao, Jingjing
TI Study on the Protective Mechanism of Futoxide on Subchondral Bone in
   Osteoarthritic Mice Model
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Futoxide; Osteoarthritis; BMSCs; Molecular Mechanism
ID DIFFERENTIATION; ICARIIN
AB Background: The present research investigated the effects of Futoxide on the osteogenic differentiation potential, mineralization and collagen synthesis capabilities of Bone Marrow Stromal Cells (BMSCs) which were isolated from mouse tibial subchondral bone and cultured in vitro. Material and methods: Vonkossa's staining was performed on BMSCs. The proportion of Nestin and Osterix positive cells was detected by flow cytometry. BMP 2 was used to induce the proliferation of BMSCs, which were treated with Futoxide, TGF beta 1 and DKK2. The cells were respectively differentiated into osteoblasts for alizarin red staining and then quantified by a spectrophotometer. The mRNA and protein expressions of CollAl and CollA2 were detected by RT PCR. Results The experiment found that the expressions of Nestin and Osterix in BMSCs increased, but were inhibited by the drug. The synthesis of collagen type I by BMSCs was inhibited, the expressions of CollAl and CollA2 were reduced, and tibial bone mineralization was improved. Conclusion: It is concluded that osteoarthritis (OA) in mice impaired the subchondral bone mineralization and Futoxide decreased the secretion of TGF beta 1 in BMSCs, subsequently decreased the expression of DKK2, which was the Wnt/beta catenin signaling pathway inhibitory factor. Therefore, the activity of Wnt/beta catenin signaling pathway was increased to a certain extent, the OA subchondral bone mineralization was repaired, and the subchondral bone were thus protected.
C1 [Li, Fang; Yan, Yonglong; Lin, Wei; Ning, Xiaoran; Cao, Jingjing] Hebei Gen Hosp, Dept Rheumatism & Immunol, Shijiazhuang 050051, Hebei, Peoples R China.
   [Yao, Jianhua] Hebei Med Univ, Hosp 2, Dept Geratol, Shijiazhuang 050000, Hebei, Peoples R China.
C3 Hebei Medical University
RP Yao, JH (通讯作者)，Hebei Med Univ, Hosp 2, Dept Geratol, Shijiazhuang 050000, Hebei, Peoples R China.
RI Lin, Wei/KFQ 5381 2024; Ning, Xiaoran/AAW 8177 2020; Huang,
   Jianzhong/KEI 1516 2024
FU Hebei province administration of traditional Chinese medicine scientific
   research projects [2015136]
FX Hebei province administration of traditional Chinese medicine scientific
   research projects (2015136).
CR Aref Eshghi E, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0788 x
   Chan TF, 2011, J BONE MINER RES, V26, P1399, DOI 10.1002/jbmr.358
   Fan JJ, 2011, MOLECULES, V16, P10123, DOI 10.3390/molecules161210123
   Henrotin Y, 2012, OSTEOPOROSIS INT, V23, pS847, DOI 10.1007/s00198 012 2162 z
   Hunter DJ, 2008, RHEUM DIS CLIN N AM, V34, P789, DOI 10.1016/j.rdc.2008.05.003
   Li D, 2012, OSTEOARTHR CARTILAGE, V20, P1647, DOI 10.1016/j.joca.2012.08.009
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Ma HP, 2011, J CELL BIOCHEM, V112, P916, DOI 10.1002/jcb.23007
   Madry H, 2010, KNEE SURG SPORT TR A, V18, P419, DOI 10.1007/s00167 010 1054 z
   RADIN EL, 1972, LANCET, V1, P519
   Wang ZC, 2014, EXP THER MED, V8, P1528, DOI 10.3892/etm.2014.1950
   Zhang YQ, 2010, CLIN GERIATR MED, V26, P355, DOI [10.1016/j.rdc.2012.10.004, 10.1016/j.cger.2010.03.001]
   Zhem G., 2015, TRENDS PHARMACOL SCI, V35, P227
NR 13
TC 2
Z9 2
U1 0
U2 6
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD OCT
PY 2018
VL 8
IS 10
BP 1490
EP 1497
DI 10.1166/jbt.2018.1900
PG 8
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HD5GE
UT WOS:000452555700014
DA 2025 08 17
ER

PT J
AU Yang, Z
   Chen, JQ
   Liu, TJ
   Chen, YL
   Ma, ZK
   Fan, YZ
   Wang, ZX
   Xu, S
   Wang, K
   Wang, XY
   Li, L
   Xie, HJ
AF Yang, Zhao
   Chen, Jia Qi
   Liu, Tian Jie
   Chen, Yu Le
   Ma, Zhen Kun
   Fan, Yi Zeng
   Wang, Zi Xi
   Xu, Shan
   Wang, Ke
   Wang, Xin Yang
   Li, Lei
   Xie, Hong Jun
TI Knocking down AR promotes osteoblasts to recruit prostate cancer cells
   by altering exosomal circ DHPS/miR 214 3p/CCL5 pathway
SO ASIAN JOURNAL OF ANDROLOGY
LA English
DT Article
DE androgen receptor; circRNA; exosome; prostate cancer
ID ANDROGEN RECEPTOR; CIRCULAR RNA; ENDOTHELIAL CELLS; T CELLS; BONE;
   METASTASIS; BIOMARKER; THERAPY; DISEASE
AB Tumor derived exosomes have been shown to play a key role in organ specific metastasis, and the androgen receptor regulates prostate cancer (PCa) progression. It is unclear whether the androgen receptor regulates the recruitment of prostate cancer cells to the bone microenvironment, even bone metastases, through exosomes. Here, we found that exosomes isolated from PCa cells after knocking down androgen receptor (AR) or enzalutamide treatment can facilitate the migration of prostate cancer cells to osteoblasts. In addition, AR silencing or treatment with the AR antagonist enzalutamide may increase the expression of circular RNA deoxyhypusine synthase (circ DHPS) in PCa cells, which can be transported to osteoblasts by exosomes. Circ DHPS acts as a competitive endogenous RNA (ceRNA) against endogenous miR 214 3p to promote C C chemokine ligand 5 (CCL5) levels in osteoblasts. Increasing the level of CCL5 in osteoblasts could recruit more PCa cells into the bone microenvironment. Thus, blocking the circ DHPS/miR 214 3p/CCL5 signal may decrease exosome mediated migration of prostate cancer cells to osteoblasts.
C1 [Yang, Zhao; Chen, Jia Qi; Liu, Tian Jie; Chen, Yu Le; Ma, Zhen Kun; Fan, Yi Zeng; Wang, Zi Xi; Xu, Shan; Wang, Ke; Wang, Xin Yang; Li, Lei; Xie, Hong Jun] Xi An Jiao Tong Univ, Dept Oncol, Affiliated Hosp 1, Xian 710061, Peoples R China.
C3 Xi'an Jiaotong University
RP Xie, HJ (通讯作者)，Xi An Jiao Tong Univ, Dept Oncol, Affiliated Hosp 1, Xian 710061, Peoples R China.
EM xiehongjun0@163.com
RI Xu, Shan/X 5227 2019; Wang, Zixi/KEI 0077 2024; Li, Lei/E 4677 2017
OI Liu, Tianjie/0000 0002 2321 1869
FU Urology at Xi'an Jiaotong University (Xi'an, China); National Natural
   Science Foundation of China [82002693, 81803022]; Natural Science
   Foundation of Shaanxi Province [2022JQ 903, 2020JQ 519]
FX We thank all members of the Institute of Urology at Xi'an Jiaotong
   University (Xi'an, China). This work was supported by grant from the
   National Natural Science Foundation of China (No. 82002693 and No.
   81803022), and the Natural Science Foundation of Shaanxi Province (No.
   2022JQ 903 and No. 2020JQ 519).
CR Aga M, 2014, ONCOGENE, V33, P4613, DOI 10.1038/onc.2014.66
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Barton VN, 2015, MOL CANCER THER, V14, P769, DOI 10.1158/1535 7163.MCT 14 0926
   Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235
   Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051
   Borel M, 2020, BBA MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165919
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Corrado C, 2014, CANCER LETT, V348, P71, DOI 10.1016/j.canlet.2014.03.009
   Coughlan Christina, 2020, Curr Protoc Cell Biol, V88, pe110, DOI 10.1002/cpcb.110
   Fu W, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109374
   Gurunathan S, 2019, CELLS BASEL, V8, DOI 10.3390/cells8040307
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002 0032
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Huang CK, 2019, J CELL MOL MED, V23, P6112, DOI 10.1111/jcmm.14477
   Izumi K, 2013, EMBO MOL MED, V5, P1383, DOI 10.1002/emmm.201202367
   Kershaw MH, 2013, NAT REV CANCER, V13, P525, DOI 10.1038/nrc3565
   Kosaka N, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020022
   Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361
   Lee E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5715
   Li PF, 2015, CLIN CHIM ACTA, V444, P132, DOI 10.1016/j.cca.2015.02.018
   Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82
   Lin TH, 2013, J BIOL CHEM, V288, P19359, DOI 10.1074/jbc.M113.477216
   Lobb RJ, 2017, SEMIN CELL DEV BIOL, V67, P3, DOI 10.1016/j.semcdb.2017.01.004
   Luga V, 2013, CANCER RES, V73, P6843, DOI 10.1158/0008 5472.CAN 13 1791
   Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876
   Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159 8290.CD 12 0206
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Niu Y, 2010, ONCOGENE, V29, P3593, DOI 10.1038/onc.2010.121
   Parkin DM, 2005, CA CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Qin J, 2014, J CLIN INVEST, V124, P5013, DOI 10.1172/JCI76412
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rybak Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027
   Scott Eggener, 2017, Urol Oncol, V35, P123, DOI 10.1016/j.urolonc.2016.12.021
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Siegel RL., 2020, CA CANCER J CLIN, V70, P7
   Soekmadji Carolina, 2013, Cancers (Basel), V5, P1522, DOI 10.3390/cancers5041522
   Sumazin P, 2011, CELL, V147, P370, DOI 10.1016/j.cell.2011.09.041
   Tian Y, 2015, ONCOL LETT, V9, P1983, DOI 10.3892/ol.2015.3025
   van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263
   Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021
   Wang XH, 2013, MOL CANCER THER, V12, P1026, DOI 10.1158/1535 7163.MCT 12 0895
   Zhang X, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045 015 0181 x
   Zhao ZJ, 2017, RNA BIOL, V14, P514, DOI 10.1080/15476286.2015.1122162
NR 47
TC 6
Z9 7
U1 0
U2 4
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 1008 682X
EI 1745 7262
J9 ASIAN J ANDROL
JI Asian J. Androl.
PD MAR APR
PY 2024
VL 26
IS 2
DI 10.4103/aja202351
PG 11
WC Andrology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA HJ2E1
UT WOS:001159058700004
PM 37966336
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kim, MM
   Mendis, E
   Rajapakse, N
   Lee, SH
   Kim, SK
AF Kim, Moon Moo
   Mendis, Eresha
   Rajapakse, Niranjan
   Lee, Sang Hoon
   Kim, Se Kwon
TI Effect of Spongin Derived From Hymeniacidon sinapium on Bone
   Mineralization
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B APPLIED BIOMATERIALS
LA English
DT Article
DE Spongin; Hymeniacidon sinapium; osteocalcin; collagen; mineralization;
   anti inflammatory
ID MARINE NATURAL PRODUCTS; CYCLIC HEPTAPEPTIDES; CELLS; DIFFERENTIATION;
   ALKALOIDS; CYTOKINES; MC3T3 E1
AB Marine sponges have been known to provide a source of novel bone and cartilage replacements because of their secondary metabolites and specific skeleton structures. In particular, it has been reported that spongin as a component of fibrous skeleton, pseudokeratin, neurokeratin, horny protein, and collagen like protein in sponges can be used in several biomedical applications including osteoarthritis (OA). However, the pharmacological mechanism of action of spongin remains obscure. In this study, it was investigated whether spongin derived from Hymeniacidon sinapium can promote bone mineralization of osteoblast like MG 63 cells. Our present study provides the first evidence that spongin is effective in activating bone mineralization. Furthermore, spongin increased ALP activity, collagen synthesis, and osteocalcin secretion in addition to bone mineralization in osteoblastic cells in vitro. In addition, it was demonstrated that spongin exerted the inhibitory effect on production of inflammatory mediators such as TNF alpha, IL 1 beta, and PGE(2) in macrophage, RAW264.7 cells. These results suggest that the anti inflammatory effect of spongin derived from Hymeniacidon sinapium can play a critical role in bone mineralization of osteoblast like MG 63 cells. (C) 2009 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 90B: 540 546, 2009
C1 [Lee, Sang Hoon; Kim, Se Kwon] Pukyong Natl Univ, Dept Chem, Pusan 608737, South Korea.
   [Kim, Moon Moo] Dong Eui Univ, Dept Chem, Pusan 614714, South Korea.
   [Mendis, Eresha; Rajapakse, Niranjan] Univ Peradeniya, Dept Food Sci & Technol, Peradeniya, Sri Lanka.
C3 Pukyong National University; Dong Eui University; University of
   Peradeniya
RP Kim, SK (通讯作者)，Pukyong Natl Univ, Dept Chem, Pusan 608737, South Korea.
EM mmkim@deu.ac.kr; sknkim@pknu.ac.kr
RI Kim, Se Kwon/B 8848 2012; Rajapakse, Niranjan/AAM 7694 2020; lee,
   wj/JNR 4926 2023
OI Kim, Se Kwon/0000 0001 6507 9539
FU Ministry of Maritime Affairs and Fisheries, Republic of Korea
FX The authors acknowledge Marine Bioprocess Research Center of Marine Bin
   21 Project, funded by the Ministry of Maritime Affairs and Fisheries,
   Republic of Korea.
CR ABRAMSON SB, 2003, OSTEOARTHRITIS, P251
   Aouacheria A, 2006, MOL BIOL EVOL, V23, P2288, DOI 10.1093/molbev/msl100
   BENTON HP, 1988, BIOCHEM BIOPH RES CO, V154, P421, DOI 10.1016/0006 291X(88)90703 6
   Blunt JW, 2003, NAT PROD REP, V20, P1, DOI 10.1039/b207130b
   DINARELLO CA, 1988, ANN NY ACAD SCI, V546, P122, DOI 10.1111/j.1749 6632.1988.tb21627.x
   Faulkner DJ, 2002, NAT PROD REP, V19, P1, DOI 10.1039/b009029h
   Green D, 2003, TISSUE ENG, V9, P1159, DOI 10.1089/10763270360728062
   GROSS J, 1956, J HISTOCHEM CYTOCHEM, V4, P227, DOI 10.1177/4.3.227
   Kajii T, 1999, ARCH ORAL BIOL, V44, P233, DOI 10.1016/S0003 9969(98)00120 4
   Kim MM, 2007, BIOORG MED CHEM LETT, V17, P1938, DOI 10.1016/j.bmcl.2007.01.030
   KOBAYASHI J, 1993, TETRAHEDRON, V49, P2391, DOI 10.1016/S0040 4020(01)86318 3
   Kobayashi J, 1997, TETRAHEDRON, V53, P16679, DOI 10.1016/S0040 4020(97)10097 7
   KOBAYASHI J, 1991, J ORG CHEM, V56, P4574, DOI 10.1021/jo00014a052
   Lysek N, 2003, Z NATURFORSCH C, V58, P568
   MIZUTANI K, 1988, BIOCHEM BIOPH RES CO, V253, P859
   PELLETIER JP, 1993, RHEUM DIS CLIN N AM, V19, P545
   PETTIT GR, 1990, CAN J CHEM, V68, P708, DOI 10.1139/v90 110
   Shlopov BV, 2000, ARTHRITIS RHEUM US, V43, P195, DOI 10.1002/1529 0131(200001)43:1<195::AID ANR24>3.0.CO;2 G
   Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469
   TSUDA M, 1994, TETRAHEDRON, V50, P4667, DOI 10.1016/S0040 4020(01)85006 7
   TSUDA M, 1993, TETRAHEDRON, V49, P6785, DOI 10.1016/S0040 4020(01)80422 1
   VAN KL, 2004, IMMUNOL CELL BIOL, V82, P315
   Vincenti MP, 2001, ARTHRITIS RES, V3, P381, DOI 10.1186/ar331
   WOOD DD, 1983, ARTHRITIS RHEUM US, V26, P975, DOI 10.1002/art.1780260806
   Yelin E., 2003, OSTEOARTHRITIS, V2nd, P17
   Zheng L, 2006, BIOTECHNOL APPL BIOC, V44, P135, DOI 10.1042/BA20050176
NR 26
TC 20
Z9 22
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1552 4973
EI 1552 4981
J9 J BIOMED MATER RES B
JI J. Biomed. Mater. Res. Part B
PD AUG
PY 2009
VL 90B
IS 2
BP 540
EP 546
DI 10.1002/jbm.b.31315
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 472FD
UT WOS:000268114200007
PM 19165732
DA 2025 08 17
ER

PT J
AU Xiao, ZS
   Baudry, J
   Cao, L
   Huang, JS
   Chen, H
   Yates, CR
   Li, W
   Dong, B
   Waters, CM
   Smith, JC
   Quarles, LD
AF Xiao, Zhousheng
   Baudry, Jerome
   Cao, Li
   Huang, Jinsong
   Chen, Hao
   Yates, Charles R.
   Li, Wei
   Dong, Brittany
   Waters, Christopher M.
   Smith, Jeremy C.
   Quarles, L. Darryl
TI Polycystin 1 interacts with TAZ to stimulate osteoblastogenesis and
   inhibit adipogenesis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; KIDNEY DISEASE;
   TRANSCRIPTION FACTOR; GENE EXPRESSION; BONE MARROW; OSTEOGENIC
   DIFFERENTIATION; MECHANICAL STIMULATION; CAUSES CYSTOGENESIS; RUNX2
   EXPRESSION
AB The molecular mechanisms that transduce the osteoblast response to physical forces in the bone microenvironment are poorly understood. Here, we used genetic and pharmacological experiments to determine whether the polycystins PC1 and PC2 (encoded by Pkd1 and Pkd2) and the transcriptional coactivator TAZ form a mechanosensing complex in osteoblasts. Compound heterozygous mice lacking 1 copy of Pkd1 and Taz exhibited additive decrements in bone mass, impaired osteoblast mediated bone formation, and enhanced bone marrow fat accumulation. Bone marrow stromal cells and osteoblasts derived from these mice showed impaired osteoblastogenesis and enhanced adipogenesis. Increased extracellular matrix stiffness and application of mechanical stretch to multipotent mesenchymal cells stimulated the nuclear translocation of the PC1 C terminal tail/TAZ (PC1 CTT/TAZ) complex, leading to increased runt related transcription factor 2 mediated (Runx2 mediated) osteogenic and decreased PPAR gamma dependent adipogenic gene expression. Using structure based virtual screening, we identified a compound predicted to bind to PC2 in the PC1: PC2 C terminal tail region with helix: helix interaction. This molecule stimulated polycystin and TAZ dependent osteoblastogenesis and inhibited adipogenesis. Thus, we show that polycystins and TAZ integrate at the molecular level to reciprocally regulate osteoblast and adipocyte differentiation, indicating that the polycystins/TAZ complex may be a potential therapeutic target to increase bone mass.
C1 [Xiao, Zhousheng; Cao, Li; Huang, Jinsong; Quarles, L. Darryl] Univ Tennessee, Dept Med, Hlth Sci Ctr, Memphis, TN 38163 USA.
   [Baudry, Jerome; Smith, Jeremy C.] Oak Ridge Natl Lab, UT ORNL Ctr Mol Biophys, Oak Ridge, TN USA.
   [Baudry, Jerome; Smith, Jeremy C.] Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN USA.
   [Chen, Hao; Yates, Charles R.; Li, Wei] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA.
   [Dong, Brittany; Waters, Christopher M.] Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN 38163 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; United States Department of Energy (DOE); Oak Ridge National
   Laboratory; University of Tennessee System; University of Tennessee
   Knoxville; University of Tennessee System; University of Tennessee
   Knoxville; University of Tennessee System; University of Tennessee
   Health Science Center; University of Tennessee System; University of
   Tennessee Health Science Center
RP Quarles, LD (通讯作者)，Univ Tennessee, Hlth Sci Ctr, Coleman Coll Med Bldg,Suite B216,956 Court Ave, Memphis, TN 38163 USA.
EM dquarles@uthsc.edu
RI Li, Wei/A 2671 2011; smith, jeremy/B 7287 2012; Waters,
   Christopher/V 2759 2019; Chen, Hao/AAJ 7107 2020; Huang,
   Jinsong/MBH 6212 2025
OI xiao, zhousheng/0000 0002 3363 5673; Smith, Jeremy/0000 0002 2978 3227;
   Quarles, L. Darryl/0000 0002 5082 7896; 
FU NIH [R01 DK083303, R01 AR045955, R01 AR37308, HL123540, HL131526]
FX This work was supported by NIH grants R01 DK083303, R01 AR045955, and
   R01 AR37308 to LDQ and HL123540 and HL131526 to CMW.
CR Araç D, 2012, EMBO J, V31, P1364, DOI 10.1038/emboj.2012.26
   Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042
   Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027
   Bertuccio CA, 2013, MEDICINA BUENOS AIRE, V73, P155
   Bertuccio CA, 2009, J BIOL CHEM, V284, P21011, DOI 10.1074/jbc.M109.017756
   Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chauvet V, 2004, J CLIN INVEST, V114, P1433, DOI 10.1172/JCI200421753
   Chauvet V, 2002, AM J PATHOL, V160, P973, DOI 10.1016/S0002 9440(10)64919 X
   Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004 1013.2003
   Dalagiorgou G, 2017, CELL MOL LIFE SCI, V74, P921, DOI 10.1007/s00018 016 2394 8
   Dalagiorgou G, 2013, CELL MOL LIFE SCI, V70, P167, DOI 10.1007/s00018 012 1164 5
   David V, 2007, ENDOCRINOLOGY, V148, P2553, DOI 10.1210/en.2006 1704
   Du LL, 2014, BIOELECTROMAGNETICS, V35, P519, DOI 10.1002/bem.21873
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Evangelista W, 2016, BIOORGAN MED CHEM, V24, P4928, DOI 10.1016/j.bmc.2016.07.064
   Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200
   Forman JR, 2005, J MOL BIOL, V349, P861, DOI 10.1016/j.jmb.2005.04.008
   Gao J, 2016, MOL MED REP, V14, P218, DOI 10.3892/mmr.2016.5239
   Gordon WR, 2015, DEV CELL, V33, P729, DOI 10.1016/j.devcel.2015.05.004
   GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202
   Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Hossain Z, 2007, P NATL ACAD SCI USA, V104, P1631, DOI 10.1073/pnas.0605266104
   Jung H, 2009, BIOCHEM PHARMACOL, V78, P1323, DOI 10.1016/j.bcp.2009.07.001
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778
   Khonsari RH, 2013, HUM MOL GENET, V22, P1873, DOI 10.1093/hmg/ddt041
   Kim I, 2009, J AM SOC NEPHROL, V20, P2556, DOI 10.1681/ASN.2009030271
   Koptides M, 2000, HUM MOL GENET, V9, P447, DOI 10.1093/hmg/9.3.447
   Li R, 2015, J BIOMECH, V48, P3665, DOI [10.1016/j.ibiomech.2015.08.013, DOI 10.1016/J.JBIOMECH.2015.08.013]
   Low SH, 2006, DEV CELL, V10, P57, DOI 10.1016/j.devcel.2005.12.005
   Lu WN, 2001, HUM MOL GENET, V10, P2385, DOI 10.1093/hmg/10.21.2385
   Makita R, 2008, AM J PHYSIOL RENAL, V294, pF542, DOI 10.1152/ajprenal.00201.2007
   Merrick D, 2014, PEDIATR NEPHROL, V29, P505, DOI 10.1007/s00467 013 2548 y
   Merrick D, 2012, DEV CELL, V22, P197, DOI 10.1016/j.devcel.2011.10.028
   Merrick DM, 2012, FASEB J S, V26, plb811
   Mesner LD, 2014, J CLIN INVEST, V124, P2736, DOI 10.1172/JCI73072
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076
   Osagie Clouard L, 2017, BONE JOINT RES, V6, P14, DOI 10.1302/2046 3758.61.BJR 2016 0085.R1
   Piontek K, 2007, NAT MED, V13, P1490, DOI 10.1038/nm1675
   Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092 8674(00)81793 6
   Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697 179
   Qiu N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015240
   Reginensi A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003380
   Rubin CT, 2007, P NATL ACAD SCI USA, V104, P17879, DOI 10.1073/pnas.0708467104
   Sen B, 2008, ENDOCRINOLOGY, V149, P6065, DOI 10.1210/en.2008 0687
   Speight P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11642
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Talbot JJ, 2014, J AM SOC NEPHROL, V25, P1737, DOI 10.1681/ASN.2013091026
   Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254 07
   Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965
   Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376
   Wang CD, 2017, EXP CELL RES, V352, P346, DOI 10.1016/j.yexcr.2017.02.021
   Watnick TJ, 1998, MOL CELL, V2, P247, DOI 10.1016/S1097 2765(00)80135 5
   Wu YQ, 2012, CONNECT TISSUE RES, V53, P451, DOI 10.3109/03008207.2012.702815
   Xiao ZS, 2008, J BIOL CHEM, V283, P12624, DOI 10.1074/jbc.M710407200
   Xiao ZS, 2006, J BIOL CHEM, V281, P30884, DOI 10.1074/jbc.M604772200
   Xiao ZS, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf5034
   Xiao ZS, 2015, REV ENDOCR METAB DIS, V16, P115, DOI 10.1007/s11154 015 9313 4
   Xiao ZS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114198
   Xiao ZS, 2011, FASEB J, V25, P2418, DOI 10.1096/fj.10 180299
   Xiao ZS, 2010, J BIOL CHEM, V285, P1177, DOI 10.1074/jbc.M109.050906
   Xiao ZS, 2001, KIDNEY INT, V60, P1699, DOI 10.1046/j.1523 1755.2001.00011.x
   Yang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056585
   Yin QX, 2014, INT J NANOMED, V9, P17, DOI 10.2147/IJN.S52005
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
   Zhang SQ, 2009, J BONE MINER RES, V24, P1889, DOI [10.1359/JBMR.090502, 10.1359/jbmr.090502]
   Zhu J, 2011, P NATL ACAD SCI USA, V108, P10133, DOI 10.1073/pnas.1017669108
NR 72
TC 55
Z9 61
U1 1
U2 13
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN 2
PY 2018
VL 128
IS 1
BP 157
EP 174
DI 10.1172/JCI93725
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FR7KX
UT WOS:000419248000019
PM 29202470
OA Bronze, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Xue, Y
   Zhang, L
   Liu, FW
   Zhao, YW
   Zhou, JH
   Hou, Y
   Bao, H
   Kong, L
   Ma, F
   Han, Y
AF Xue, Yang
   Zhang, Lan
   Liu, Fuwei
   Zhao, Yiwei
   Zhou, Jianhong
   Hou, Yan
   Bao, Han
   Kong, Liang
   Ma, Fei
   Han, Yong
TI Surface Bandgap Engineering of Nanostructured Implants for Rapid
   Photothermal Ion Therapy of Bone Defects
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE photothermal therapy; signaling pathways; surface bandgap engineering;
   implants; bone regeneration
ID HYDROXYAPATITE NANORODS; IN VITRO; TIO2; REGENERATION; SCAFFOLDS
AB Bone defects are seriously threatening the health of orthopedics patients and it is difficult for implants to accelerate bone regeneration without using bone growth factors. Herein, a fast photothermal ion therapeutic strategy is developed based on the bandgap engineering of nanostructured TiO2 through (Si/P) dual elemental doping by micro arc oxidation treatment of titanium implants. The (Si/P) dual doping can tune the surface bandgap structure of TiO2 by decreasing bandgap and broadening valence band simultaneously, which is confirmed by density functional theory calculations. It not only endows the implants with a mildly photothermal effect under near infrared (NIR) light irradiation, but also creates an (Si/P) ion rich microenvironment around the implants. This photothermal ion microenvironment can tune the behaviors of osteoblasts by promoting p38/Smad and ERK signaling pathways of osteoblasts, thus significantly upregulating the expression of osteogenesis genes by the synergistic action of mild photothermal stimulation and increased release of Si/P ions. The in vivo results are also in good agreement with in vitro tests, i.e., under NIR light irradiation, the photothermally responsive TiO2 enhances the bone formation and osteointegration with implants. Therefore, this kind of photothermal ion strategy is a promising remote and noninvasive therapeutic mode for promoting bone regeneration of Ti implants.
C1 [Xue, Yang; Zhang, Lan; Zhao, Yiwei; Ma, Fei; Han, Yong] Xi An Jiao Tong Univ, State Key Lab Mech Behav Mat, Xian 710049, Peoples R China.
   [Liu, Fuwei; Hou, Yan; Bao, Han; Kong, Liang] Fourth Mil Med Univ, State Key Lab Mil Stomatol, Dept Oral & Maxillofacial Surg, Sch Stomatol, Xian 710032, Peoples R China.
   [Liu, Fuwei; Hou, Yan; Bao, Han; Kong, Liang] Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Dept Oral & Maxillofacial Surg, Sch Stomatol, Xian 710032, Peoples R China.
   [Liu, Fuwei; Hou, Yan; Bao, Han; Kong, Liang] Fourth Mil Med Univ, Shaanxi Clin Res Ctr Oral Dis, Dept Oral & Maxillofacial Surg, Sch Stomatol, Xian 710032, Peoples R China.
   [Zhou, Jianhong] Baoji Univ Arts & Sci, Adv Titanium Alloys & Funct Coatings Cooperat Inn, Inst Phys & Optoelect Technol, Baoji 721016, Peoples R China.
C3 Xi'an Jiaotong University; Air Force Medical University; Air Force
   Medical University; Air Force Medical University; Baoji University of
   Arts & Sciences
RP Zhang, L; Han, Y (通讯作者)，Xi An Jiao Tong Univ, State Key Lab Mech Behav Mat, Xian 710049, Peoples R China.
EM lan.zhang@mail.xjtu.edu.cn; yonghan@mail.xjtu.edu.cn
RI ; zhao, yiwei/HTL 2193 2023; Bao, Han/KGK 9452 2024
OI Zhang, Lan/0000 0002 2162 3333; Zhao, Yiwei/0000 0003 4442 2267; 
FU Research Fund for the National Natural Science Foundation of China
   [51771142, 51971171, 82072075]; Natural Science Foundation of Shaanxi
   Province [2021JC 07, 2019TD 020]
FX The authors appreciate Research Fund for the National Natural Science
   Foundation of China (Grant No. 51771142, 51971171, and 82072075) and
   Natural Science Foundation of Shaanxi Province (No. 2021JC 07,
   2019TD 020) for financially supporting this work.
CR Baur WH, 2019, CHEM MATER, V31, P2401, DOI 10.1021/acs.chemmater.8b04919
   BLOCHL PE, 1994, PHYS REV B, V49, P16223, DOI 10.1103/PhysRevB.49.16223
   Cao CY, 2021, NANO TODAY, V39, DOI 10.1016/j.nantod.2021.101165
   Chen MW, 2022, CHEM ENG J, V427, DOI 10.1016/j.cej.2021.130982
   Clyne Trevor William, 2019, International Materials Reviews, V64, P127, DOI 10.1080/09506608.2018.1466492
   Ding ZH, 2017, COLLOID SURFACE B, V159, P493, DOI 10.1016/j.colsurfb.2017.08.010
   Fu JN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27217 4
   Gao XY, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202106700
   Ha YJ, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202200011
   He YD, 2022, BIOACT MATER, V8, P109, DOI 10.1016/j.bioactmat.2021.06.033
   He YY, 2021, ADV SCI, V8, DOI 10.1002/advs.202100719
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Hu K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16513 0
   Jena KK, 2019, ACS APPL MATER INTER, V11, P30247, DOI 10.1021/acsami.9b09140
   Jia ZJ, 2019, ACS APPL MATER INTER, V11, P4447, DOI 10.1021/acsami.8b20429
   Jiang PL, 2021, BIOACT MATER, V6, P1118, DOI 10.1016/j.bioactmat.2020.10.006
   Kang T, 2018, BIOMATERIALS, V164, P80, DOI 10.1016/j.biomaterials.2018.02.033
   Kelly CN, 2021, BIOMATERIALS, V279, DOI 10.1016/j.biomaterials.2021.121206
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   Kuang LJ, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202105383
   Kurnaravel V, 2019, APPL CATAL B ENVIRON, V244, P1021, DOI 10.1016/j.apcatb.2018.11.080
   Lee HJ, 2022, THERANOSTICS, V12, P105, DOI 10.7150/thno.63788
   Li K, 2020, BIOACT MATER, V5, P116, DOI 10.1016/j.bioactmat.2020.01.001
   Li K, 2019, ACS BIOMATER SCI ENG, V5, P2208, DOI 10.1021/acsbiomaterials.9b00073
   Li L, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807356
   Li MM, 2021, ADV MATER, V33, DOI 10.1002/adma.202104829
   Li M, 2019, ADV SCI, V6, DOI 10.1002/advs.201900599
   Li ZR, 2021, BIOACT MATER, V6, P4053, DOI 10.1016/j.bioactmat.2021.04.014
   Li Z, 2020, BRIT J PHARMACOL, V177, P5046, DOI 10.1111/bph.15169
   Liu Y, 2021, J HAZARD MATER, V414, DOI 10.1016/j.jhazmat.2021.125600
   Luo Q, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202110408
   Ma L, 2020, MATER TODAY, V36, P48, DOI 10.1016/j.mattod.2019.12.005
   Maier RA, 2020, CHEM MATER, V32, P4651, DOI 10.1021/acs.chemmater.0c01082
   Moncal KK, 2022, BIOMATERIALS, V281, DOI 10.1016/j.biomaterials.2021.121333
   Pan ZH, 2021, ACS NANO, V15, P12975, DOI 10.1021/acsnano.1c01817
   Perdew JP, 1997, PHYS REV LETT, V78, P1396, DOI 10.1103/PhysRevLett.77.3865
   Saputera WH, 2019, ACS CATAL, V9, P2674, DOI 10.1021/acscatal.8b04891
   Satale VV, 2021, INT J HYDROGEN ENERG, V46, P12715, DOI 10.1016/j.ijhydene.2021.01.142
   Siebert L, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202007555
   Su K, 2020, ACS NANO, V14, P2077, DOI 10.1021/acsnano.9b08686
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Tan L, 2018, ADV MATER, V30, DOI 10.1002/adma.201801808
   Tang HZ, 2022, ADV MATER, V34, DOI 10.1002/adma.202107300
   Tong LP, 2019, BIOMATERIALS, V193, P1, DOI 10.1016/j.biomaterials.2018.12.008
   Ullattil SG, 2018, CHEM ENG J, V343, P708, DOI 10.1016/j.cej.2018.01.069
   Um SH, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202005233
   Wang H, 2021, ADV MATER INTERFACES, V8, DOI 10.1002/admi.202001863
   Wang MF, 2018, ADV MATER, V30, DOI 10.1002/adma.201706747
   Wang Q, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202008906
   Wang YK, 2021, BIOACT MATER, V6, P1853, DOI 10.1016/j.bioactmat.2020.11.030
   Wu MQ, 2021, NANO TODAY, V37, DOI 10.1016/j.nantod.2021.101104
   Xiao Y, 2020, THERANOSTICS, V10, P1500, DOI 10.7150/thno.39471
   Xu C, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001183
   Xue Y, 2022, BIOACT MATER, V8, P1, DOI 10.1016/j.bioactmat.2021.06.029
   Xue YM, 2020, ACS NANO, V14, P442, DOI 10.1021/acsnano.9b06145
   Yang H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18891 x
   Yang MG, 2022, ADV MATER, V34, DOI 10.1002/adma.202106314
   Yang ZJ, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120534
   Yu Y, 2021, ACS NANO, V15, P10628, DOI 10.1021/acsnano.1c03424
   Yuan B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4704
   Yuan Z, 2019, BIOMATERIALS, V223, DOI 10.1016/j.biomaterials.2019.119479
   Zhang GN, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120634
   Zhang L, 2021, ACS APPL MATER INTER, V13, P28764, DOI 10.1021/acsami.1c04895
   Zhang Q, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202204182
   Zhang XD, 2021, NANO TODAY, V39, DOI 10.1016/j.nantod.2021.101196
   Zhao QM, 2020, MAT SCI ENG C MATER, V110, DOI 10.1016/j.msec.2020.110682
   Zhao R, 2020, THERANOSTICS, V10, P1572, DOI 10.7150/thno.40103
   Zhao R, 2019, NANOSCALE, V11, P2721, DOI 10.1039/c8nr09417a
   Zheng XL, 2021, ADV SCI, V8, DOI 10.1002/advs.202102741
NR 69
TC 29
Z9 29
U1 11
U2 122
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD NOV
PY 2022
VL 11
IS 22
AR 2200998
DI 10.1002/adhm.202200998
EA SEP 2022
PG 14
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA 6F9YE
UT WOS:000853955000001
PM 36064207
DA 2025 08 17
ER

PT J
AU Seo, W
   Lee, S
   Tran, PT
   Ngo, TQM
   Kim, O
   Le, TH
   Dang, NH
   Hwangbo, C
   Min, BS
   Lee, JH
AF Seo, Wonyoung
   Lee, Suhyun
   Phuong Thao Tran
   Thi Quynh Mai Ngo
   Kim, Okwha
   Thanh Huong Le
   Nguyen Hai Dang
   Hwangbo, Cheol
   Min, Byung Sun
   Lee, Jeong Hyung
TI 3 Hydroxyolean 12 en 27 oic Acids Inhibit RANKL Induced
   Osteoclastogenesis in Vitro and Inflammation Induced Bone Loss in Vivo
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE 3 hydroxyolean 12 en 27 oic acid; osteoclastogenesis; RANKL; c Fos;
   NFATc1
ID OLEANANE TYPE TRITERPENOIDS; ACERIPHYLLUM ROSSII; NATURAL PRODUCTS;
   DEFECTIVE INTERLEUKIN 1; DIFFERENTIATION; MECHANISMS; PROLIFERATION;
   OSTEOPETROSIS; MIGRATION; RECEPTOR
AB Olean 12 en 27 oic acids possess a variety of pharmacological effects. However, their effects and underlying mechanisms on osteoclastogenesis remain unclear. This study aimed to investigate the anti osteoclastogenic effects of five olean 12 en 27 oic acid derivatives including 3 alpha,23 isopropylidenedioxyolean 12 en 27 oic acid (AR 1), 3 oxoolean 12 en 27 oic acid (AR 2), 3 alpha hydroxyolean 12 en 27 oic acid (AR 3), 23 hydroxy 3 oxoolean 12 en 27 oic acid (AR 4), and aceriphyllic acid A (AR 5). Among the five olean 12 en 27 oic acid derivatives, 3 hydroxyolean 12 en 27 oic acid derivatives, AR 3 and AR 5, significantly inhibited receptor activator of nuclear factor kappa B ligand (RANKL) induced mature osteoclast formation by reducing the number of tartrate resistant acid phosphatase (TRAP) positive osteoclasts, F actin ring formation, and mineral resorption activity. AR 3 and AR 5 decreased RANKL induced expression levels of osteoclast specific marker genes such as c Src, TRAP, and cathepsin K (CtsK) as well as c Fos and nuclear factor of activated T cells cytoplasmic 1 (NFATc1). Mice treated with either AR 3 or AR 5 showed significant protection of the mice from lipopolysaccharide (LPS) induced bone destruction and osteoclast formation. In particular, AR 5 suppressed RANKL induced phosphorylation of JNK and ERK mitogen activated protein kinases (MAPKs). The results suggest that AR 3 and AR 5 attenuate osteoclast formation in vitro and in vivo by suppressing RANKL mediated MAPKs and NFATc1 signaling pathways and could potentially be lead compounds for the prevention or treatment of osteolytic bone diseases.
C1 [Seo, Wonyoung; Lee, Suhyun; Phuong Thao Tran; Kim, Okwha; Lee, Jeong Hyung] Kangwon Natl Univ, Dept Biochem, Chunchon 24341, Gangwon Do, South Korea.
   [Seo, Wonyoung; Lee, Suhyun; Phuong Thao Tran; Kim, Okwha; Lee, Jeong Hyung] Kangwon Natl Univ, Kangwon Inst Inclus Technol, Chunchon 24341, Gangwon Do, South Korea.
   [Thi Quynh Mai Ngo; Min, Byung Sun] Catholic Univ Daegu, Coll Pharm, Gyeongbuk 38430, South Korea.
   [Thanh Huong Le; Nguyen Hai Dang] Univ Sci & Technol Hanoi, Vietnam Acad Sci & Technol, 18 Hoang Quoc Viet, Hanoi 100000, Vietnam.
   [Hwangbo, Cheol] Gyeongsang Natl Univ, Coll Nat Sci, Div Appl Life Sci BK21 Plus, Div Life Sci,PMBBRC, Jinju 52828, South Korea.
C3 Kangwon National University; Kangwon National University; Catholic
   University of Daegu; Vietnam Academy of Science & Technology (VAST);
   University of Science & Technology of Hanoi (USTH); Gyeongsang National
   University
RP Lee, JH (通讯作者)，Kangwon Natl Univ, Dept Biochem, Chunchon 24341, Gangwon Do, South Korea.; Lee, JH (通讯作者)，Kangwon Natl Univ, Kangwon Inst Inclus Technol, Chunchon 24341, Gangwon Do, South Korea.
EM swy4262@naver.com; dltngus328@gmail.com; helytran@gmail.com;
   ngoquynhmai2011@gmail.com; kah3173@kangwon.ac.kr;
   le thanh.huong@usth.edu.vn; haidangnguyen@gmail.com; chwangbo@gnu.ac.kr;
   bsmin@cu.ac.kr; jhlee36@kangwon.ac.kr
OI Lee, Suhyun/0000 0003 0526 7030; Hwangbo, Cheol/0000 0001 6505 3080;
   Nguyen, Hai Dang/0000 0002 4470 8321; , Le Thanh
   Huong/0000 0002 7628 4674
FU National Research Foundation (NRF) of Korea [2018R1D1A1B07047187,
   2015M3A9A5031271]
FX This research was supported by grants from the National Research
   Foundation (NRF) of Korea (2018R1D1A1B07047187 and 2015M3A9A5031271).
CR An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Corbo F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01001
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Han JT, 2002, PLANTA MED, V68, P558, DOI 10.1055/s 2002 32565
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim JY, 2014, BONE, V60, P104, DOI 10.1016/j.bone.2013.12.013
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657
   Le TKV, 2009, J NAT PROD, V72, P1419, DOI 10.1021/np900273z
   Lee I, 2007, CHEM PHARM BULL, V55, P1376, DOI 10.1248/cpb.55.1376
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Min BS, 2008, PLANTA MED, V74, P726, DOI 10.1055/s 2008 1074534
   Muffler K, 2011, PROCESS BIOCHEM, V46, P1, DOI 10.1016/j.procbio.2010.07.015
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Tran PT, 2019, PHYTOMEDICINE, V55, P1, DOI 10.1016/j.phymed.2018.10.029
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Seo JH, 2015, PLANTA MED, V81, P228, DOI 10.1055/s 0034 1396242
   Sethi G, 2007, CHEM BIOL, V14, P738, DOI 10.1016/j.chembiol.2007.07.002
   Sheng HM, 2011, NAT PROD REP, V28, P543, DOI 10.1039/c0np00059k
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2007, J BIOL CHEM, V282, P18980, DOI 10.1074/jbc.M610938200
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Trang TTT, 2014, CHEM PHARM BULL, V62, P185, DOI 10.1248/cpb.c13 00664
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Xuan WH, 2017, CELL BIOCHEM FUNCT, V35, P171, DOI 10.1002/cbf.3260
   Yu WF, 2012, J BIOL CHEM, V287, P13694, DOI 10.1074/jbc.M112.355610
   Zhao DF, 2018, J PHARMACOL SCI, V137, P76, DOI 10.1016/j.jphs.2018.03.007
   Zheng CJ, 2010, J FOOD SCI, V75, pM78, DOI 10.1111/j.1750 3841.2009.01476.x
   Zheng CJ, 2008, J AGR FOOD CHEM, V56, P11752, DOI 10.1021/jf802832w
NR 48
TC 6
Z9 6
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2020
VL 21
IS 15
AR 5240
DI 10.3390/ijms21155240
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MZ5RO
UT WOS:000559181800001
PM 32718089
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tomazoni, SS
   Frigo, L
   Ferreira, TCD
   Casalechi, HL
   Teixeira, S
   de Almeida, P
   Muscara, MN
   Marcos, RL
   Serra, AJ
   de Carvalho, PDC
   Leal, ECP
AF Tomazoni, Shaiane Silva
   Frigo, Lucio
   dos Reis Ferreira, Tereza Cristina
   Casalechi, Heliodora Leao
   Teixeira, Simone
   de Almeida, Patricia
   Muscara, Marcelo Nicolas
   Marcos, Rodrigo Labat
   Serra, Andrey Jorge
   Camillo de Carvalho, Paulo de Tarso
   Pinto Leal Junior, Ernesto Cesar
TI Effects of photobiomodulation therapy and topical non steroidal
   anti inflammatory drug on skeletal muscle injury induced by contusion in
   rats part 2: biochemical aspects
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Photobiomodulation therapy; Low level laser therapy; Skeletal muscle
   injury; Contusion; Topical non steroidal anti inflammatory drug
ID LEVEL LASER THERAPY; MESSENGER RNA EXPRESSION; COLLAGENASE INDUCED
   TENDINITIS; EXPERIMENTAL MODEL; INFLAMMATORY MEDIATORS; ACHILLES
   TENDINITIS; SIGNALING PATHWAY; DOUBLE BLIND; 808 NM; EXERCISE
AB Muscle injuries trigger an inflammatory process, releasing important biochemical markers for tissue regeneration. The use of non steroidal anti inflammatory drugs (NSAIDs) is the treatment of choice to promote pain relief due to muscle injury. NSAIDs exhibit several adverse effects and their efficacy is questionable. Photobiomodulation therapy (PBMT) has been demonstrated to effectively modulate inflammation induced from musculoskeletal disorders and may be used as an alternative to NSAIDs. Here, we assessed and compared the effects of different doses of PBMT and topical NSAIDs on biochemical parameters during an acute inflammatory process triggered by a controlled model of contusion induced musculoskeletal injury in rats. Muscle injury was induced by trauma to the anterior tibial muscle of rats. After 1 h, rats were treated with PBMT (830 nm, continuous mode, 100mWof power, 35.71 W/cm(2); 1, 3, and 9 J; 10,30, and 90 s) or diclofenac sodium (1 g). Our results demonstrated that PBMT, 1 J (35.7 J/cm(2)), 3 J (107.1 J/cm(2)), and 9 J (321.4 J/cm(2)) reduced the expression of tumor necrosis factor alpha (TNF alpha) and cyclooxygenase 2 (COX 2) genes at all assessed times as compared to the injury and diclofenac groups (p < 0.05). The diclofenac group showed reduced levels of COX 2 only in relation to the injury group (p < 0.05). COX 2 protein expression remained unchanged with all therapies except with PBMT at a 3 J dose at 12 h (p < 0.05 compared to the injury group). In addition, PBMT (1, 3, and 9 J) effectively reduced levels of cytokines TNF alpha, interleukin (IL) 1 beta, and IL 6 at all assessed times as compared to the injury and diclofenac groups (p < 0.05). Thus, PBMTat a 3 J dose was more effective than other doses of PBMT and topical NSAIDs in the modulation of the inflammatory process caused by muscle contusion injuries.
C1 [Tomazoni, Shaiane Silva] Univ Cidade Sao Paulo UNICID, Masters Program Phys Therapy, Rua Cesario Galeno,448 475, BR 05508900 Sao Paulo, SP, Brazil.
   [Tomazoni, Shaiane Silva] Univ Cidade Sao Paulo UNICID, Doctoral Program Phys Therapy, Rua Cesario Galeno,448 475, BR 05508900 Sao Paulo, SP, Brazil.
   [Frigo, Lucio] Cruzeiro do Sul Univ UNICSUL, Biol Sci & Hlth Ctr, Sao Paulo, SP, Brazil.
   [dos Reis Ferreira, Tereza Cristina; Casalechi, Heliodora Leao; Pinto Leal Junior, Ernesto Cesar] Nove do Julho Univ UNINOVE, Lab Phototherapy Sports & Exercise, Sao Paulo, SP, Brazil.
   [dos Reis Ferreira, Tereza Cristina; Camillo de Carvalho, Paulo de Tarso; Pinto Leal Junior, Ernesto Cesar] Nove do Julho Univ UNINOVE, Postgrad Program Rehabil Sci, Sao Paulo, SP, Brazil.
   [Teixeira, Simone; Muscara, Marcelo Nicolas] Univ Sao Paulo, Dept Pharmacol, Inst Biomed Sci, Sao Paulo, SP, Brazil.
   [de Almeida, Patricia; Marcos, Rodrigo Labat; Serra, Andrey Jorge; Camillo de Carvalho, Paulo de Tarso] Nove do Julho Univ UNINOVE, Postgrad Program Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil.
C3 Universidade Cidade de Sao Paulo; Universidade Cidade de Sao Paulo;
   Universidade Cruzeiro do Sul; Universidade de Sao Paulo; Institute
   Biomed Science, University Sao Paulo
RP Tomazoni, SS (通讯作者)，Univ Cidade Sao Paulo UNICID, Masters Program Phys Therapy, Rua Cesario Galeno,448 475, BR 05508900 Sao Paulo, SP, Brazil.; Tomazoni, SS (通讯作者)，Univ Cidade Sao Paulo UNICID, Doctoral Program Phys Therapy, Rua Cesario Galeno,448 475, BR 05508900 Sao Paulo, SP, Brazil.
EM shaiane.tomazoni@gmail.com
RI ; Silva Tomazoni, Shaiane/H 9000 2016; Serra, Andrey/E 7460 2015;
   Leal Junior, Ernesto Cesar/H 8920 2016; Carvalho, Paulo/G 5333 2011;
   Muscara, Marcelo/F 3250 2012; de Almeida Mattos, Patricia/N 7857 2016;
   Frigo, Lucio/D 1708 2017; Tomazoni, Shaiane/H 9000 2016; Muscará,
   Marcelo/F 3250 2012; Teixeira, Simone/K 3991 2016; Marcos,
   Rodrigo/F 3524 2015
OI Leao Casalechi, Heliodora/0000 0003 1846 1844; Silva Tomazoni,
   Shaiane/0000 0002 0822 4864; de Almeida Mattos,
   Patricia/0000 0001 6738 094X; Serra, Andrey/0000 0002 5407 8183;
   Leal Junior, Ernesto Cesar/0000 0001 6393 7616; Muscara,
   Marcelo/0000 0002 8342 5586; Teixeira, Simone/0000 0002 8515 5030; 
FU FAPESP [2012/06832 5]; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [12/06832 5] Funding Source: FAPESP; Swedish Research
   Council [2012 06832] Funding Source: Swedish Research Council
FX The authors would like to thanks FAPESP for research grant to Lucio
   Frigo (grant number 2012/06832 5).
CR Albuquerque Pontes GM, 2015, LASER MED SCI, V30, P59, DOI 10.1007/s10103 014 1616 2
   Alves AN, 2016, LASER MED SCI, V31, P679, DOI 10.1007/s10103 016 1908 9
   Alves ACA, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4296
   Assis L, 2013, LASER MED SCI, V28, P947, DOI 10.1007/s10103 012 1183 3
   Basford JR, 1999, ARCH PHYS MED REHAB, V80, P647, DOI 10.1016/S0003 9993(99)90167 3
   Beiner JM, 2004, J AM ACAD ORTHOP SUR, V9, P227
   Bjordal JM, 2004, BMJ BRIT MED J, V329, P1317, DOI 10.1136/bmj.38273.626655.63
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   Casalechi HL, 2013, LASER MED SCI, V28, P989, DOI 10.1007/s10103 012 1189 x
   da Rosa AS, 2012, PHOTOCHEM PHOTOBIOL, V88, P161, DOI 10.1111/j.1751 1097.2011.01032.x
   Da Silva AA, 2013, J COSMET LASER THER, V15, P210, DOI 10.3109/14764172.2012.761345
   de Almeida P, 2014, LASER MED SCI, V29, P653, DOI 10.1007/s10103 013 1377 3
   de Almeida P, 2013, PHOTOCHEM PHOTOBIOL, V89, P501, DOI 10.1111/j.1751 1097.2012.01232.x
   de Almeida P, 2011, PHOTOCHEM PHOTOBIOL, V87, P1159, DOI 10.1111/j.1751 1097.2011.00968.x
   dos Santos SA, 2014, LASER MED SCI, V29, P1051, DOI 10.1007/s10103 013 1467 2
   Fukuda TY, 2010, LASER SURG MED, V42, P584, DOI 10.1002/lsm.20949
   Garrett WE, 1996, AM J SPORT MED, V24, pS2, DOI 10.1177/036354659602406S02
   Gur A, 2004, LASER SURG MED, V35, P229, DOI 10.1002/lsm.20082
   Heyneman CA, 2000, DRUGS, V60, P555, DOI 10.2165/00003495 200060030 00004
   JARVINEN MJ, 1993, SPORTS MED, V15, P78
   Kalimo H., 1997, Baillieres Clin Orthop, V2, P1
   Konstantinovic LM, 2010, PHOTOMED LASER SURG, V28, P553, DOI 10.1089/pho.2009.2576
   Kurosaka M, 2013, CELL PROLIFERAT, V46, P365, DOI 10.1111/cpr.12045
   Leal EC, 2011, LASER MED SCI, V26, P493, DOI 10.1007/s10103 010 0866 x
   Marcos RL, 2012, J ORTHOP RES, V30, P1945, DOI 10.1002/jor.22156
   Marcos RL, 2011, PHOTOCHEM PHOTOBIOL, V87, P1447, DOI 10.1111/j.1751 1097.2011.00999.x
   Musaro A., 2014, Advances in Biology, V2014, P1, DOI [10.1155/2014/612471, DOI 10.1155/2014/612471]
   Ostrowski K, 2000, EUR J APPL PHYSIOL, V83, P512, DOI 10.1007/s004210000312
   Ostrowski K, 1999, J PHYSIOL LONDON, V515, P287, DOI 10.1111/j.1469 7793.1999.287ad.x
   Pedersen BK, 2007, BIOCHEM SOC T, V35, P1295, DOI 10.1042/BST0351295
   Leal ECP, 2008, PHOTOMED LASER SURG, V26, P419, DOI 10.1089/pho.2007.2160
   Leal ECP, 2010, J ORTHOP SPORT PHYS, V40, P524, DOI 10.2519/jospt.2010.3294
   Leal ECP, 2009, LASER SURG MED, V41, P572, DOI 10.1002/lsm.20810
   Leal ECP, 2009, LASER MED SCI, V24, P425, DOI 10.1007/s10103 008 0592 9
   Leal ECP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089453
   Pires D, 2011, LASER MED SCI, V26, P85, DOI 10.1007/s10103 010 0811 z
   Ribeiro BG, 2015, LASER SURG MED, V47, P571, DOI 10.1002/lsm.22381
   Rizzi CF, 2006, LASER SURG MED, V38, P704, DOI 10.1002/lsm.20371
   Rodrigues NC, 2014, BRAZ J PHYS THER, V18, P395
   Laraia EMS, 2012, PHOTOCHEM PHOTOBIOL, V88, P1546, DOI 10.1111/j.1751 1097.2012.01179.x
   Sato K, 2003, MUSCLE NERVE, V28, P365, DOI 10.1002/mus.10436
   Servetto N, 2010, LASER SURG MED, V42, P577, DOI 10.1002/lsm.20910
   Tannenbaum H, 2006, J RHEUMATOL, V33, P140
   Tomazoni SS, 2017, LASER MED SCI, V32, P101, DOI 10.1007/s10103 016 2091 8
   Tomazoni SS, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.10.108001
   Wu J, 2013, NANOSCALE RES LETT, V8, P1, DOI 10.1186/1556 276X 8 5
NR 46
TC 26
Z9 27
U1 0
U2 10
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD NOV
PY 2017
VL 32
IS 8
BP 1879
EP 1887
DI 10.1007/s10103 017 2299 2
PG 9
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA FK6NK
UT WOS:000413620900020
PM 28795275
DA 2025 08 17
ER

PT J
AU Lee, AMC
   Bowen, JM
   Su, YW
   Plews, E
   Chung, R
   Keefe, DMK
   Xian, CJ
AF Lee, Alice M. C.
   Bowen, Joanne M.
   Su, Yu Wen
   Plews, Erin
   Chung, Rosa
   Keefe, Dorothy M. K.
   Xian, Cory J.
TI Individual or combination treatments with lapatinib and paclitaxel cause
   potential bone loss and bone marrow adiposity in rats
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone and bone marrow damage; breast cancer chemotherapy; ErbB1 and ErbB2
   dual inhibitor
ID EPIDERMAL GROWTH FACTOR; TYROSINE KINASE INHIBITOR; FACTOR RECEPTOR;
   BREAST CANCER; 1ST LINE TREATMENT; PLUS PACLITAXEL; EGF RECEPTOR;
   DOUBLE BLIND; CHEMOTHERAPY; EXPRESSION
AB Cancer treatments with cytotoxic drugs have been shown to cause bone loss. However, effects on bone are less clear for ErbB targeting tyrosine kinase inhibitors or their combination use with cytotoxic drugs. This study examined the effects of individual or combination treatments with breast cancer drugs lapatinib (a dual ErbB1/ErbB2 inhibitor) and paclitaxel (a microtubule stabilizing cytotoxic agent) on bone and bone marrow of rats. Wistar rats received lapatinib (240 mg/kg) daily, paclitaxel (12 mg/kg) weekly, or their combination for 4 weeks, and effects on bone/bone marrow were examined at the end of week 4. Microcomputed tomographical structural analyses showed a reduction in trabecular bone volume in tibia following the lapatinib, paclitaxel or their combination treatments (P < 0.05). Histomorphometry analyses revealed marked increases in bone marrow adipocyte contents in all treatment groups. Reverse transcription polymerase chain reaction gene expression studies with bone samples and cell culture studies with isolated bone marrow stromal cells showed that the all treatment groups displayed significantly reduced levels of osterix expression and osteogenic differentiation potential but increased expression levels of adipogenesis transcription factor peroxisome proliferator activated receptor gamma. In addition, these treatments suppressed the expression of Wnt10b and/or increased expression of Wnt antagonists (secreted frizzled related protein 1, Dickkopf related protein 1 and/or sclerostin). Furthermore, all treatment groups showed increased numbers of bone resorbing osteoclasts on trabecular bone surfaces, although only the lapatinib group displayed increased levels of osteoclastogenic signal (receptor activator of nuclear factor kappa Beta ligand/osteoclastogenesis inhibitor osteoprotegrin expression ratio) in the bones. Thus, inhibiting ErbB1 and ErbB2 by lapatinib or blocking cell division by paclitaxel or their combination causes significant trabecular bone loss and bone marrow adiposity involving a switch in osteogenesis/adipogenesis potential, altered expression of some major molecules of the Wnt/beta catenin signalling pathway, and increased recruitment of bone resorbing osteoclasts.
C1 [Lee, Alice M. C.; Su, Yu Wen; Chung, Rosa; Xian, Cory J.] Univ South Australia, UniSA Inst Canc Res, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
   [Bowen, Joanne M.; Plews, Erin] Univ Adelaide, Sch Med Sci, Physiol Discipline, Adelaide, SA, Australia.
   [Keefe, Dorothy M. K.] SA Hlth, SA Canc Clin Network, SA Canc Serv, Adelaide, SA, Australia.
   [Keefe, Dorothy M. K.] Univ Adelaide, Ctr Canc Med, Adelaide, SA, Australia.
C3 University of South Australia; University of Adelaide; SA Health
   Australia; University of Adelaide
RP Xian, CJ (通讯作者)，Univ South Australia, UniSA Inst Canc Res, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
EM cory.xian@unisa.edu.au
RI ; Su, Yu Wen/V 4948 2018; Xian, Cory/D 2646 2009; SU, Yu Wen/V 4948 2018
OI Chung, Rosa/0009 0000 2624 4191; Xian, Cory/0000 0002 8467 2845; SU,
   Yu Wen/0000 0002 2067 5270
FU National Health and Medical Research Council [1042105, 1010752,
   0508047]; Glaxo Smith Kline; Australian Research Council [LP120100519];
   Australian Research Council [LP120100519] Funding Source: Australian
   Research Council
FX National Health and Medical Research Council, Grant/Award Numbers:
   1042105, 1010752, 0508047; Glaxo Smith Kline, Grant/Award Number:
   Unrestricted educational grant; Australian Research Council, Grant/Award
   Number: LP120100519
CR Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014 5793(97)00412 2
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bowen JM, 2012, CANCER BIOL THER, V13, P1269, DOI 10.4161/cbt.21783
   Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521 1878(200008)22:8<697::AID BIES3>3.3.CO;2 T
   Chandra A, 2013, J BIOL CHEM, V288, P20488, DOI 10.1074/jbc.M112.447250
   Di Leo A, 2008, J CLIN ONCOL, V26, P5544, DOI 10.1200/JCO.2008.16.2578
   Din Omar S, 2008, Ther Clin Risk Manag, V4, P149
   Fan CM, 2017, BREAST CANCER RES TR, V165, P41, DOI 10.1007/s10549 017 4308 3
   Fan CM, 2016, J BONE MINER METAB, V34, P277, DOI 10.1007/s00774 015 0679 x
   Fan CM, 2014, J CHEMOTHERAPY, V26, P37, DOI 10.1179/1973947813Y.0000000108
   Georgiou KR, 2015, J CELL PHYSIOL, V230, P648, DOI 10.1002/jcp.24788
   Georgiou KR, 2012, BONE, V50, P1223, DOI 10.1016/j.bone.2012.03.027
   Georgiou KR, 2012, J CELL PHYSIOL, V227, P909, DOI 10.1002/jcp.22807
   Guan ZZ, 2013, J CLIN ONCOL, V31, P1947, DOI 10.1200/JCO.2011.40.5241
   Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015
   Hurvitz SA, 2015, LANCET ONCOL, V16, P816, DOI 10.1016/S1470 2045(15)00051 0
   Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734
   Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008 5472.CAN 05 1346
   LEE DC, 1995, PHARMACOL REV, V47, P51
   Lin TH, 2007, BONE, V41, P562, DOI 10.1016/j.bone.2007.06.017
   Linder M, 2018, CELL DEATH DIFFER, V25, P1094, DOI 10.1038/s41418 017 0054 7
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Nadhanan RR, 2012, AM J PHYSIOL ENDOC M, V302, pE1440, DOI 10.1152/ajpendo.00587.2011
   NG KW, 1983, CALCIFIED TISSUE INT, V35, P624, DOI 10.1007/BF02405105
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   Oh YL, 2015, J CANCER, V6, P82, DOI 10.7150/jca.10679
   OSHEROV N, 1993, J BIOL CHEM, V268, P11134
   Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073
   Pinkas Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967
   PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955 2235(92)90002 Y
   Qin L, 2005, J BIOL CHEM, V280, P3974, DOI 10.1074/jbc.M409807200
   Rusnak DW, 2001, MOL CANCER THER, V1, P85
   Ryan Q, 2008, ONCOLOGIST, V13, P1114, DOI 10.1634/theoncologist.2008 0816
   Sibilia M, 2003, DEVELOPMENT, V130, P4515, DOI 10.1242/dev.00664
   Smith BD, 2011, JNCI J NATL CANCER I, V103, P527, DOI 10.1093/jnci/djr073
   Su YW, 2017, ANN NY ACAD SCI, V1403, P109, DOI 10.1111/nyas.13380
   Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199
   te Winkel ML, 2014, BONE, V59, P223, DOI 10.1016/j.bone.2013.11.017
   Vaidya M, 2015, BONE, V81, P36, DOI 10.1016/j.bone.2015.06.012
   Voigtlaender Minna, 2018, Recent Results Cancer Res, V211, P19, DOI 10.1007/978 3 319 91442 8_2
   Wang K, 2004, J BIOL CHEM, V279, P53848, DOI 10.1074/jbc.M403114200
   Xian CJ, 2007, BONE, V41, P842, DOI 10.1016/j.bone.2007.07.021
   Xian CJ, 2007, ENDOCR REV, V28, P284, DOI 10.1210/er.2006 0049
   Xian CJ, 2007, CANCER BIOL THER, V6, P170, DOI 10.4161/cbt.6.2.3576
   Xian CJ, 2006, J CELL BIOCHEM, V99, P1688, DOI 10.1002/jcb.20889
   Yi T, 2008, J CELL PHYSIOL, V217, P409, DOI 10.1002/jcp.21511
   Zhang XR, 2011, J BONE MINER RES, V26, P2622, DOI 10.1002/jbmr.502
   Zhang XR, 2011, J BONE MINER RES, V26, P1022, DOI 10.1002/jbmr.295
   Zhou FH, 2004, BONE, V35, P1307, DOI 10.1016/j.bone.2004.09.014
   Zhu J, 2007, J BIOL CHEM, V282, P26656, DOI 10.1074/jbc.M705064200
   Zhu J, 2011, J CELL BIOCHEM, V112, P1749, DOI 10.1002/jcb.23094
NR 53
TC 5
Z9 5
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAR
PY 2019
VL 120
IS 3
BP 4180
EP 4191
DI 10.1002/jcb.27705
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HL1LP
UT WOS:000458459600150
PM 30260048
DA 2025 08 17
ER

PT J
AU Liu, WB
   Dong, SH
   Hu, WH
   Gao, M
   Li, T
   Ji, QB
   Yang, XQ
   Qi, DB
   Zhang, Z
   Song, ZL
   Liu, YJ
   Zhang, XS
AF Liu, Wei bo
   Dong, Su he
   Hu, Wen hao
   Gao, Meng
   Li, Teng
   Ji, Quan bo
   Yang, Xiao qing
   Qi, Deng bin
   Zhang, Zhen
   Song, Ze Long
   Liu, Yu jie
   Zhang, Xue song
TI A simple, universal and multifunctional template agent for personalized
   treatment of bone tumors
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Bone tumor; Osteosarcoma; Polydopamine; Photothermal therapy
ID PHOTOTHERMAL THERAPY; THERANOSTIC AGENT; DRUG DELIVERY; OSTEOSARCOMA;
   CHEMOTHERAPY; CABOZANTINIB; MULTICENTER; ABLATION; DESIGN
AB Bone tumors occur in bone or its accessory tissues. Benign bone tumors are easy to cure and have good prognosis, while malignant bone tumors develop rapidly and have poor and high mortality. So far, there is no satisfactory treatment method. Here, we designed a universal template vector for bone tumor therapy that simultaneously meets the needs of bone targeting, tumor killing, osteoclast suppression, and tumor imaging. The template is composed of a polydopamine (PDA) core and a multifunctional surface. PDA has excellent biosafety and photothermal performance. In this study, alendmnate sodium (ALN) is grafted to enable its general bone targeting function. PDA core can carry a variety of chemotherapy drugs, and the rich ALN group can carry a variety of metal ions with an imaging function. Therefore, more personalized treatment plans can be designed for different bone tumor patients. In addition, the PDA core enables photothermal therapy and enhanced chemotherapy. Through template drug Doxorubicin (DOX) and template imaging ion Fe (II), we systematically verified the therapeutic effect, imaging effect, and inhibition of bone dissolution of the agent on Osteosarcoma (OS), a primary malignant bone tumor, in vivo. In conclusion, our work provides a more general template carrier for the clinical treatment of bone tumors, through which personalized treatment of bone tumors can be achieved.
C1 [Liu, Wei bo; Hu, Wen hao; Li, Teng; Ji, Quan bo; Yang, Xiao qing; Qi, Deng bin; Zhang, Zhen; Song, Ze Long; Zhang, Xue song] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 4, Dept Orthopaed, 51 Fucheng Rd, Beijing 100048, Peoples R China.
   [Liu, Yu jie] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai 200001, Peoples R China.
   [Liu, Yu jie] Second Mil Med Univ, Changzheng Hosp, Spine Tumor Ctr, Shanghai 200001, Peoples R China.
   [Dong, Su he] PLA Rocket Force Characterist Med Ctr, Beijing 100088, Peoples R China.
   [Gao, Meng] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Naval Medical
   University; Naval Medical University; Nankai University
RP Zhang, XS (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Med Ctr 4, Dept Orthopaed, 51 Fucheng Rd, Beijing 100048, Peoples R China.; Liu, YJ (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai 200001, Peoples R China.; Liu, YJ (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Spine Tumor Ctr, Shanghai 200001, Peoples R China.
EM yujieliu16@163.com; zhangxuesong301@126.com
RI liu, yujie/R 9278 2016; Dong, sesar/GLT 7906 2022
OI liu, yujie/0000 0003 3994 4108; Ji, Quanbo/0000 0001 6212 6926; 
CR Chen K, 2020, BIOMATER SCI UK, V8, P4322, DOI 10.1039/d0bm00825g
   Chen YH, 2018, DALTON T, V47, P2435, DOI 10.1039/c7dt04080f
   Ekhtiari S, 2020, LANCET ONCOL, V21, P1021, DOI 10.1016/S1470 2045(20)30171 6
   Fabri Faja N, 2019, ANAL CHIM ACTA, V1077, P232, DOI 10.1016/j.aca.2019.05.038
   Fagioli F, 2020, LANCET ONCOL, V21, P331, DOI 10.1016/S1470 2045(20)30004 8
   Feng GX, 2020, CHEM SOC REV, V49, P8179, DOI 10.1039/d0cs00671h
   Gibson TM, 2018, LANCET ONCOL, V19, P1590, DOI 10.1016/S1470 2045(18)30537 0
   He SQ, 2018, CHEM SOC REV, V47, P4258, DOI 10.1039/c8cs00234g
   Heymann D, 2019, LANCET ONCOL, V20, P12, DOI 10.1016/S1470 2045(18)30821 0
   Italiano A, 2020, LANCET ONCOL, V21, P446, DOI [10.1016/51470 2045(19)30825 3, 10.1016/S1470 2045(19)30825 3]
   Kelley LM, 2020, J CLIN ONCOL, V38, P823, DOI 10.1200/JCO.19.00827
   Kleinerman E, 2016, LANCET ONCOL, V17, P1340, DOI 10.1016/S1470 2045(16)30270 4
   Li JW, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.637754
   Li X, 2021, BIOACT MATER, V6, P3473, DOI 10.1016/j.bioactmat.2021.03.021
   Li YY, 2021, J CONTROL RELEASE, V335, P59, DOI 10.1016/j.jconrel.2021.05.013
   Liao JF, 2021, BIOACT MATER, V6, P2221, DOI 10.1016/j.bioactmat.2021.01.006
   Lu JH, 2021, CHEM REC, V21, P781, DOI 10.1002/tcr.202000170
   Mamdani H, 2018, NEW ENGL J MED, V378, P1429, DOI 10.1056/NEJMicm1711874
   Pan SS, 2020, ADV SCI, V7, DOI 10.1002/advs.201901511
   Panwar N, 2019, CHEM REV, V119, P9559, DOI 10.1021/acs.chemrev.9b00099
   Piperno Neumann S, 2016, LANCET ONCOL, V17, P1070, DOI 10.1016/S1470 2045(16)30096 1
   Quadros M, 2021, MAT SCI ENG C MATER, V121, DOI 10.1016/j.msec.2021.111875
   Sahoo K, 2020, NANOTECHNOLOGY, V31, DOI 10.1088/1361 6528/ab7de5
   Sangnier AP, 2018, BEILSTEIN J NANOTECH, V9, P2947, DOI 10.3762/bjnano.9.273
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Son S, 2020, CHEM SOC REV, V49, P3244, DOI 10.1039/c9cs00648f
   Wang HF, 2022, BIOACT MATER, V7, P453, DOI 10.1016/j.bioactmat.2021.05.004
   Wang YT, 2018, BIOMATERIALS, V183, P10, DOI 10.1016/j.biomaterials.2018.08.033
   Wang YT, 2017, BIOMATERIALS, V114, P97, DOI 10.1016/j.biomaterials.2016.11.010
   Whelan JS, 2018, J CLIN ONCOL, V36, P188, DOI 10.1200/JCO.2017.75.1743
   Xi Y, 2021, NANOSCALE, V13, P5125, DOI 10.1039/d0nr08845e
   Xie ZJ, 2020, CHEM SOC REV, V49, P8065, DOI 10.1039/d0cs00215a
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Xu Z, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120647
   Xue S, 2021, BIOACT MATER, V6, P2372, DOI 10.1016/j.bioactmat.2021.01.017
   Yan Y, 2019, ACS APPL MATER INTER, V11, P160, DOI 10.1021/acsami.8b15827
   Yang B., 2018, ADV MATER, V30
   Yang DZ, 2021, ACS APPL MATER INTER, V13, P8909, DOI 10.1021/acsami.0c20202
   Yang Q., 2020, SMALL, V16
   Yang YQ, 2020, ACS NANO, V14, P2509, DOI 10.1021/acsnano.0c00043
   Zeng YY, 2020, BIOACT MATER, V5, P859, DOI 10.1016/j.bioactmat.2020.06.010
   Zhang LR, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00880 x
   Zhang YJ, 2019, ACCOUNTS CHEM RES, V52, P3164, DOI 10.1021/acs.accounts.9b00397
   Zheng QY, 2021, CHEM SOC REV, V50, P5086, DOI 10.1039/d1cs00056j
   Zhou LY, 2019, ACCOUNTS CHEM RES, V52, P3211, DOI 10.1021/acs.accounts.9b00427
   Zou Y, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb4696
NR 46
TC 14
Z9 14
U1 1
U2 87
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD JUN
PY 2022
VL 12
BP 292
EP 302
DI 10.1016/j.bioactmat.2021.10.27
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA ZL8XP
UT WOS:000763954500002
PM 35087969
DA 2025 08 17
ER

PT J
AU Liao, Z
   Nan, GX
   Yan, ZJ
   Zeng, LY
   Deng, YL
   Ye, JX
   Zhang, ZL
   Qiao, M
   Li, RF
   Denduluri, S
   Wang, J
   Wei, Q
   Geng, N
   Zhao, LG
   Lu, S
   Wang, X
   Zhou, GL
   Luu, HH
   Haydon, RC
   He, TC
   Wang, ZL
AF Liao, Zhan
   Nan, Guoxin
   Yan, Zhengjian
   Zeng, Liyi
   Deng, Youlin
   Ye, Jixing
   Zhang, Zhonglin
   Qiao, Min
   Li, Ruifang
   Denduluri, Sahitya
   Wang, Jing
   Wei, Qiang
   Geng, Nisha
   Zhao, Lianggong
   Lu, Shun
   Wang, Xin
   Zhou, Guolin
   Luu, Hue H.
   Haydon, Rex C.
   He, Tong Chuan
   Wang, Zhongliang
TI The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of
   Human Osteosarcoma Cells by Targeting Multiple Signal Pathways
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Anticancer agent; bone tumors; drug repurposing; niclosamide;
   osteosarcoma; sarcomas
ID SUPPRESSES TUMOR GROWTH; STEM CELLS; OSTEOGENIC DIFFERENTIATION;
   OSTEO/ODONTOBLASTIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION;
   PPAR GAMMA; CANCER; WNT; PROTEIN; EXPRESSION
AB Osteosarcoma (OS) is the most common primary malignant tumor of bone with a high propensity for lung metastasis. Despite significant advances in surgical techniques and chemotherapeutic regimens over the past few decades, there has been minimal improvement in OS patient survival. There is an urgent need to identify novel antitumor agents to treat human OS. Repurposing the clinically used drugs represents a rapid and effective approach to the development of new anticancer agents. The anthelmintic drug niclosamide has recently been identified as a potential anticancer agent in human cancers. Here, we investigate if niclosamide can be developed as an anti OS drug. We find that niclosamide can effectively inhibit OS cell proliferation and survival at low micromolar concentrations. Cell migration and wounding closure are significantly inhibited by niclosamide. Niclosamide induces cell apoptosis and inhibits cell cycle progression in OS cells. Analysis of niclosamide's effect on 11 cancer related signal pathway reporters reveals that three of them, the E2F1, AP1, and c Myc responsive reporters, are significantly inhibited. To a lesser extent, the HIF1 alpha, TCF/LEF, CREB, NF kappa B, Smad/TGF beta, and Rbpj/Notch pathway reporters are also inhibited, while the NFAT and Wnt/beta catenin reporters are not significantly affected by niclosamide treatment. We demonstrate that the expression of c Fos, c Jun. E2F1, and c Myc in OS cells is effectively inhibited by niclosamide. Furthermore, niclosamide is shown to effectively inhibit tumor growth in a mouse xenograft tumor model of human osteosarcoma cells. Taken together, these results strongly suggest that niclosamide may exert its anticancer activity in OS cells by targeting multiple signaling pathways. Future investigations should be directed to exploring the antitumor activity in clinically relevant OS models and ultimately in clinical trials.
C1 [Liao, Zhan; Nan, Guoxin; Yan, Zhengjian; Zeng, Liyi; Deng, Youlin; Ye, Jixing; Zhang, Zhonglin; Qiao, Min; Li, Ruifang; Denduluri, Sahitya; Wang, Jing; Wei, Qiang; Geng, Nisha; Zhao, Lianggong; Lu, Shun; Wang, Xin; Zhou, Guolin; Luu, Hue H.; Haydon, Rex C.; He, Tong Chuan; Wang, Zhongliang] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago Medical Center
RP Wang, ZL (通讯作者)，Chongqing Med Univ, Chongqing, Peoples R China.
EM tche@uchicago.edu; 4829855@163.com
RI GENG, NISHA/AAA 4646 2022; Lu, Shun/ABF 8341 2021; Wei,
   Qiang/HII 4390 2022; Ye, Jixing/JAX 5357 2023; wang,
   xinyi/JGE 0944 2023; GENG, NISHA/ABA 7419 2021
OI GENG, NISHA/0000 0002 9849 5296; 
FU National Institutes of Health [AT004418, AR50142, AR054381]; 973 Program
   of Ministry of Science and Technology (MOST) of China [2011CB707900];
   National Center for Advancing Translational Sciences (NCATS) of the
   National Institutes of Health [UL1 TR000430]
FX The reported work was supported in part by research grants from the
   National Institutes of Health (AT004418, AR50142, AR054381 to TCH, RCH
   and HHL), and the 973 Program of Ministry of Science and Technology
   (MOST) of China (#2011CB707900 to TCH). This work was also supported in
   part by The University of Chicago Core Facility Subsidy grant from the
   National Center for Advancing Translational Sciences (NCATS) of the
   National Institutes of Health through Grant UL1 TR000430.
CR Arend RC, 2014, GYNECOL ONCOL, V134, P112, DOI 10.1016/j.ygyno.2014.04.005
   Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124
   Bi Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1318, DOI 10.1159/000366340
   Bruland OS, 1997, EUR J CANCER, V33, P1725, DOI 10.1016/S0959 8049(97)00252 9
   Chen W, 2010, AM J PHYSIOL GASTR L, V299, pG293, DOI 10.1152/ajpgi.00005.2010
   Chen X, 2015, GENES DIS, V2, P96, DOI 10.1016/j.gendis.2014.12.001
   Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004
   Deng F., 2014, PLOS ONE, V9
   Fonseca BD, 2012, J BIOL CHEM, V287, P17530, DOI 10.1074/jbc.M112.359638
   Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936
   Gao JL, 2013, ONCOL REP, V30, P292, DOI 10.3892/or.2013.2438
   Garattini E, 2004, CURR PHARM DESIGN, V10, P433, DOI 10.2174/1381612043453351
   Gorlick R, 2003, CLIN CANCER RES, V9, P5442
   Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   He BC, 2011, INT J ONCOL, V38, P437, DOI 10.3892/ijo.2010.858
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478 3231.2009.02111.x
   Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008 5472.CAN 09 3950
   Jo A, 2014, GENES DIS, V1, P149, DOI 10.1016/j.gendis.2014.09.004
   Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000
   King M.L., 2014, ONCOGENE
   Lamplot J.D., 2015, CELL TRANSPLANT
   Lee SLO, 2014, BIOMED PHARMACOTHER, V68, P619, DOI 10.1016/j.biopha.2014.03.018
   Li M, 2013, INT J MED SCI, V10, P1035, DOI 10.7150/ijms.6639
   Li R., 2014, CURR CANC DRUG TARGE
   Li R, 2013, MOL CANCER THER, V12, P2200, DOI 10.1158/1535 7163.MCT 13 0095
   Li R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074670
   Li YH, 2014, CANCER LETT, V349, P8, DOI 10.1016/j.canlet.2014.04.003
   Li ZH, 2015, ONCOL REP, V33, P1763, DOI 10.3892/or.2015.3766
   Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078 0432.CCR 13 3296
   Londoño Joshi AI, 2014, MOL CANCER THER, V13, P800, DOI 10.1158/1535 7163.MCT 13 0555
   Lu W., 2011, PLOS ONE, V6
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999 008 0361 x
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luther G, 2011, CURR GENE THER, V11, P229
   Luther GA, 2013, CANCER LETT, V336, P222, DOI 10.1016/j.canlet.2013.05.002
   Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092 8674(95)90199 X
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Meyers PA, 1997, PEDIATR CLIN N AM, V44, P973, DOI 10.1016/S0031 3955(05)70540 X
   Mook RA, 2013, BIOORG MED CHEM LETT, V23, P2187, DOI 10.1016/j.bmcl.2013.01.101
   Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165 6147(00)01559 5
   Ono M, 2014, FERTIL STERIL, V101, P1441, DOI 10.1016/j.fertnstert.2014.01.017
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008 5472.CAN 10 3978
   Park BH, 2001, CURR OPIN ONCOL, V13, P78, DOI 10.1097/00001622 200101000 00015
   Rastegar F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014182
   Ren XM, 2010, ACS MED CHEM LETT, V1, P454, DOI 10.1021/ml100146z
   Sack U, 2011, JNCI J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190
   Sandberg AA, 2003, CANCER GENET CYTOGEN, V140, P1, DOI 10.1016/S0165 4608(02)00848 8
   Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585 009 9259 6
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Wagner ER, 2010, PPAR RES, V2010, DOI 10.1155/2010/956427
   Wang AM, 2009, J CELL BIOCHEM, V106, P682, DOI 10.1002/jcb.22065
   Wang JH, 2014, STEM CELLS DEV, V23, P1405, DOI 10.1089/scd.2013.0580
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097316
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093608
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang Y., 2013, Adv. Civ. Eng, V2013, P8, DOI DOI 10.1371/J0URNAL.P0NE.0081045
   Wen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094397
   Wieland A, 2013, CLIN CANCER RES, V19, P4124, DOI 10.1158/1078 0432.CCR 12 2895
   Wu N, 2014, GENE THER, V21, P629, DOI 10.1038/gt.2014.40
   Ye TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085887
   Yo YT, 2012, MOL CANCER THER, V11, P1703, DOI 10.1158/1535 7163.MCT 12 0002
   You S, 2014, MOL CANCER THER, V13, P606, DOI 10.1158/1535 7163.MCT 13 0608
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917
   Zhang YD, 2014, TECHNOLOGIES, V2, DOI 10.3390/technologies2040164
   Zhao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092908
   Zhu GH, 2009, DIFFERENTIATION, V78, P195, DOI 10.1016/j.diff.2009.06.001
NR 86
TC 73
Z9 78
U1 0
U2 18
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568 0096
EI 1873 5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PY 2015
VL 15
IS 8
BP 726
EP 738
DI 10.2174/1568009615666150629132157
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CS9SO
UT WOS:000362432200008
PM 26118906
DA 2025 08 17
ER

PT J
AU Wang, W
   Wang, B
AF Wang, Wei
   Wang, Bo
TI Isofraxidin Inhibits Receptor Activator of Nuclear Factor κB
   Ligand Induced Osteoclastogenesis in Bone Marrow Derived Macrophages
   Isolated from Sprague Dawley Rats by Regulating NF κB/NFATc1 and
   Akt/NFATc1 Signaling Pathways
SO CELL TRANSPLANTATION
LA English
DT Article
DE osteoporosis; isofraxidin; osteoclast formation; RANKL; NFATc1
AB Osteoporosis is a common bone disease that is characterized by decreased bone mass and fragility fractures. Isofraxidin is a hydroxy coumarin with several biological and pharmacological activities including an anti osteoarthritis effect. However, the role of isofraxidin in osteoporosis has not yet been investigated. In the present study, we used receptor activator of nuclear factor kappa B ligand (RANKL) to induce osteoclast formation in primary bone marrow macrophages (BMMs). Our results showed that RANKL treatment significantly increased tartrate resistant acid phosphatase (TRAP) activity, as well as the expression of osteoclastogenesis related markers including MMP 9, c Src, and cathepsin K at both mRNA and protein levels; however, these effects were inhibited by isofraxidin in BMMs. In addition, luciferase reporter assay demonstrated that isofraxidin treatment suppressed the RANKL induced an increase in nuclear factor of activated T cells cytoplasmic 1 (NFATc1) transcriptional activity. Besides, the decreased expression level of I kappa B alpha and increased levels of p p65, p I kappa B alpha, and p Akt in RANKL induced BMMs were attenuated by isofraxidin. Moreover, NFATc1 overexpression rescued the anti osteoclastogenic effect of isofraxidin with increased expression levels of MMP 9, c Src, and cathepsin K. Taken together, these findings indicated that isofraxidin inhibited RANKL induced osteoclast formation in BMMs via inhibiting the activation of NF kappa B/NFATc1 and Akt/NFATc1 signaling pathways. Thus, isofraxidin might be a therapeutic agent for the treatment of osteoporosis.
C1 [Wang, Wei; Wang, Bo] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthopaed, Tongji Med Coll, Wuhan 430030, Peoples R China.
C3 Huazhong University of Science & Technology
RP Wang, B (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthopaed, Tongji Med Coll, Wuhan 430030, Peoples R China.
EM wang_bow_b@163.com
CR Aoki M, 2017, CURR TOP MICROBIOL, V407, P153, DOI 10.1007/82_2017_6
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Bai YJ, 2011, J NAT MED TOKYO, V65, P417, DOI 10.1007/s11418 011 0509 y
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Chen GF, 2020, INFLAMMATION, V43, P712, DOI 10.1007/s10753 019 01158 z
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Guo BS, 2012, EXPERT REV ENDOCRINO, V7, P677, DOI [10.1586/EEM.12.63, 10.1586/eem.12.63]
   Jin JL, 2018, FOOD FUNCT, V9, P5641, DOI 10.1039/c8fo01445k
   Jin L, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106521
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lin J, 2018, INT IMMUNOPHARMACOL, V64, P238, DOI 10.1016/j.intimp.2018.09.003
   Liu L, 2015, IMMUNOBIOLOGY, V220, P406, DOI 10.1016/j.imbio.2014.10.007
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Majnooni MB, 2020, MOLECULES, V25, DOI 10.3390/molecules25092040
   Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev med 062913 051343
   McClung M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2167
   McClung Michael R, 2006, Curr Osteoporos Rep, V4, P28, DOI 10.1007/s11914 006 0012 7
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   Shen P, 2017, BIOMED PHARMACOTHER, V92, P78, DOI 10.1016/j.biopha.2017.05.065
   Sobacchi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00629
   Su XQ, 2019, J CELL BIOCHEM, V120, P13302, DOI 10.1002/jcb.28604
   Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641
   Yao ZQ, 2014, J BONE MINER RES, V29, P866, DOI 10.1002/jbmr.2108
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zhang H, 2018, MOL MED REP, V18, P407, DOI 10.3892/mmr.2018.8950
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 34
TC 6
Z9 6
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963 6897
EI 1555 3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PD FEB 10
PY 2021
VL 30
AR 0963689721990321
DI 10.1177/0963689721990321
PG 9
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA QI1ZE
UT WOS:000618772000001
PM 33573387
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sugahara, S
   Hanaoka, K
   Emori, T
   Takeshita, N
   Fujii, Y
   Nakano, M
   Suzuki, T
   Takahashi, J
   Nakamura, Y
AF Sugahara, Shingo
   Hanaoka, Kaori
   Emori, Takashi
   Takeshita, Nobuaki
   Fujii, Yasutomo
   Nakano, Masaki
   Suzuki, Takako
   Takahashi, Jun
   Nakamura, Yukio
TI Peficitinib improves bone fragility by recovering bone turnover
   imbalance in arthritic mice
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Arthritis; Osteoporosis; Osteoclast; osteoblast biology; Peficitinib;
   Bone density
ID FIBROBLAST LIKE SYNOVIOCYTES; TNF ALPHA; STRENGTH; DIFFERENTIATION;
   INFLAMMATION; MECHANISMS; DENSITY
AB Peficitinib, a pan JAK inhibitor, is known to suppress the activation of fibroblast like synoviocytes (FLSs) and thereby reduces joint inflammation associated with rheumatoid arthritis (RA). However, the effect on osteoporosis in RA remains to be elucidated. In this study, the effect of peficitinib or etanercept on joint inflammation, and consequently decreased bone mineral density (BMD) was evaluated in mice with collagen induced arthritis (CIA). Additionally, the effect on RANKL production from osteoblasts differentiated from the mesenchymal stem cells of RA patients was evaluated. Administration of peficitinib for established CIA ameliorated arthritis and improved BMD in the femoral metaphysis, but not in the femoral diaphysis. Conversely, etanercept suppressed an increase in synovial inflammatory markers but did not improve arthritic conditions or the reduction of BMD in either region. All elevated bone formation and bone resorption markers were decreased with peficitinib but only partially decreased with etanercept. Furthermore, production of RANKL by human osteoblasts was suppressed by peficitinib but enhanced by etanercept. Unlike etanercept, peficitinib is thought to increase BMD by ameliorating the high bone turnover associated with RA states, resulting in improvement of bone fragility. Our data provide evidence that peficitinib would be expected to show efficacy for osteoporosis associated with RA. (c) 2021 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY NC ND license (http://creativecommons.org/ licenses/by nc nd/4.0/).
C1 [Sugahara, Shingo; Hanaoka, Kaori; Emori, Takashi; Takeshita, Nobuaki; Fujii, Yasutomo] Astellas Pharma Inc, Drug Discovery Res, Tsukuba, Ibaraki, Japan.
   [Nakano, Masaki; Suzuki, Takako; Takahashi, Jun; Nakamura, Yukio] Shinshu Univ, Dept Orthopaed Surg, Sch Med, Matsumoto, Nagano, Japan.
C3 Astellas Pharmaceuticals; Shinshu University
RP Nakamura, Y (通讯作者)，Shinshu Univ, Dept Orthopaed Surg, Sch Med, Matsumoto, Nagano, Japan.
EM yxn14@shinshu u.ac.jp
FU Astellas Pharma Inc.   Astellas Pharma Inc.
FX This study was initiated and funded by Astellas Pharma Inc. The
   publication fee was also funded by Astellas Pharma Inc. The study
   sponsor was involved in all stages of the study, including manuscript
   development. All authors had full access to all study data and agreed to
   submit the manuscript for publication. No honorarium, grant, or other
   form of payment was provided to authors, with the exception of funding
   needed to perform their role in the study. All authors agreed to the
   provision of professional editorial support on behalf of the study
   sponsor.
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Caselli G, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1537 8
   Corrado A, 2015, CLIN EXP MED, V15, P277, DOI 10.1007/s10238 014 0307 4
   Emori T, 2020, EUR J PHARMACOL, V882, DOI 10.1016/j.ejphar.2020.173238
   Emori T, 2017, J IMMUNOL, V199, P3427, DOI 10.4049/jimmunol.1700941
   Epstein S, 2005, MAYO CLIN PROC, V80, P379, DOI 10.4065/80.3.379
   Erben RG, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00082
   Gropp KE, 2017, TOXICOL PATHOL, V45, P876, DOI 10.1177/0192623317735787
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Karonitsch T, 2018, RHEUMATOLOGY, V57, P572, DOI 10.1093/rheumatology/kex426
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kim KW, 2009, IMMUNOL LETT, V124, P9, DOI 10.1016/j.imlet.2009.02.006
   Kitanaga Y, 2020, RHEUMATOLOGY, V59, P1957, DOI 10.1093/rheumatology/kez526
   LaBranche TP, 2012, ARTHRITIS RHEUM US, V64, P3531, DOI 10.1002/art.34649
   Lloyd SAJ, 2008, CALCIFIED TISSUE INT, V82, P361, DOI 10.1007/s00223 008 9133 6
   Marupanthorn Kulisara, 2015, Journal of the Medical Association of Thailand, V98, pS34
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Miao Ping, 2018, Oncotarget, V9, P20366, DOI 10.18632/oncotarget.23917
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   O'Shea JJ, 2004, NAT REV DRUG DISCOV, V3, P555, DOI 10.1038/nrd1441
   Orsolini G, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104354
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00425
   Raterman HG, 2019, DRUG AGING, V36, P1061, DOI 10.1007/s40266 019 00714 4
   Saidenberg Kermanac'h N, 2004, BONE, V35, P1200, DOI 10.1016/j.bone.2004.07.004
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sugahara S, 2018, EUR J PHARMACOL, V833, P320, DOI 10.1016/j.ejphar.2018.06.021
   Tanaka Y, 2019, J BONE MINER METAB, V37, P2, DOI 10.1007/s00774 018 0965 5
   Toyoshima J, 2021, BRIT J CLIN PHARMACO, V87, P2014, DOI 10.1111/bcp.14605
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yoshida H, 2018, SCAND J RHEUMATOL, V47, P384, DOI 10.1080/03009742.2017.1416667
   Zerbini CAF, 2017, OSTEOPOROSIS INT, V28, P429, DOI 10.1007/s00198 016 3769 2
NR 34
TC 8
Z9 8
U1 0
U2 0
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD JAN
PY 2022
VL 148
IS 1
BP 134
EP 141
DI 10.1016/j.jphs.2021.10.006
EA NOV 2021
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XU1YA
UT WOS:000734068300017
PM 34924117
OA gold
DA 2025 08 17
ER

PT J
AU Xia, JL
   Wang, WY
   Jin, XX
   Zhao, J
   Chen, JY
   Li, N
   Xiao, SS
   Lin, DJ
   Song, ZY
AF Xia, Jianglong
   Wang, Wanying
   Jin, Xiaoxiong
   Zhao, Jing
   Chen, Jiaoyu
   Li, Ning
   Xiao, Shanshan
   Lin, Dongjun
   Song, Ziyuan
TI Effects of chain lengths and backbone chirality on the bone targeting
   ability of poly(glutamic acid)s
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID DRUG DELIVERY SYSTEM; BISPHOSPHONATES; OLIGOPEPTIDE; POLARIZATION;
   MECHANISMS; BINDING; DESIGN; GROWTH
AB Anionic synthetic polypeptides are promising candidates as standalone bone targeting drug carriers. Nevertheless, the structure property relationship of the bone targeting ability of polypeptides remains largely unexplored. Herein we report the optimization of the in vitro and in vivo bone targeting ability of poly(glutamic acid)s (PGAs) by altering their chain lengths and backbone chirality. PGA 100 mers exhibited higher hydroxyapatite affinity in vitro, but their rapid macrophage clearance limited their targeting ability. Shorter PGA was therefore favored in terms of in vivo bone targeting. Meanwhile, the backbone chirality showed less significant impact on the in vitro and in vivo targeting behavior. This study highlights the modulation of structural parameters on the bone targeting performance of anionic polypeptides, shedding light on the future design of polypeptide based carriers.
   The in vitro and in vivo bone targeting ability of poly(glutamic acid)s is highly dependent on their chain lengths rather than backbone chirality, with shorter polypeptides exhibiting a higher bone targeting effect.
C1 [Xia, Jianglong; Lin, Dongjun] Sun Yat sen Univ, Affiliated Hosp 7, Dept Haematol, Shenzhen 518107, Peoples R China.
   [Wang, Wanying; Jin, Xiaoxiong; Zhao, Jing; Chen, Jiaoyu; Li, Ning; Xiao, Shanshan; Song, Ziyuan] Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Jiangsu Key Lab Carbon Based Funct Mat & Devices, Suzhou 215123, Jiangsu, Peoples R China.
C3 Sun Yat Sen University; Soochow University   China
RP Lin, DJ (通讯作者)，Sun Yat sen Univ, Affiliated Hosp 7, Dept Haematol, Shenzhen 518107, Peoples R China.; Song, ZY (通讯作者)，Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Jiangsu Key Lab Carbon Based Funct Mat & Devices, Suzhou 215123, Jiangsu, Peoples R China.
EM lindongjun@163.com; zysong@suda.edu.cn
RI wang, wanying/NQE 7579 2025; xiao, shanshan/KBB 5719 2024; Song,
   Ziyuan/HDM 4995 2022
OI Song, Ziyuan/0000 0002 3165 3712
FU National Science Foundation of China [22101194]; Natural Science
   Foundation of Jiangsu Province [BK20210733]; Suzhou Municipal Science
   and Technology Bureau [ZXL2021447]; Shenzhen Science and Technology
   Program [JCYJ20230807110406013]; Collaborative Innovation Center of
   Suzhou Nano Science Technology; The 111 project; Suzhou Key Laboratory
   of Nanotechnology and Biomedicine; Joint International Research
   Laboratory of Carbon Based Functional Materials and Devices
FX This work was supported by the National Science Foundation of China
   (22101194), Natural Science Foundation of Jiangsu Province (BK20210733),
   Suzhou Municipal Science and Technology Bureau (ZXL2021447), Shenzhen
   Science and Technology Program (JCYJ20230807110406013), Collaborative
   Innovation Center of Suzhou Nano Science & Technology, the 111 project,
   Joint International Research Laboratory of Carbon Based Functional
   Materials and Devices, and Suzhou Key Laboratory of Nanotechnology and
   Biomedicine.
CR Adler A J, 1973, Methods Enzymol, V27, P675
   Aiman I. A. Q., 2014, AM J LIFE SCI, V2, P351
   Badasyan A, 2018, SOFT MATTER, V14, P4735, DOI 10.1039/c8sm00780b
   Badreldin M, 2023, PROG POLYM SCI, V147, DOI 10.1016/j.progpolymsci.2023.101752
   Bartl R., 2016, Bone Disorders : Biology, Diagnosis, Prevention, Therapy
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Chung WJ, 2011, LANGMUIR, V27, P7620, DOI 10.1021/la104757g
   Duanis Assaf T, 2022, LANGMUIR, V38, P968, DOI 10.1021/acs.langmuir.1c02293
   Evans BC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12906 y
   George A, 2008, CHEM REV, V108, P4670, DOI 10.1021/cr0782729
   Gustafson HH, 2015, NANO TODAY, V10, P487, DOI 10.1016/j.nantod.2015.06.006
   Han RJ, 2023, BIOMATER SCI UK, V11, P5218, DOI 10.1039/d3bm00532a
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kang EY, 2012, MACROMOLECULES, V45, P2007, DOI 10.1021/ma202809c
   Li CZ, 2022, ADV SCI, V9, DOI 10.1002/advs.202104134
   Li MM, 2023, NANO TODAY, V50, DOI 10.1016/j.nantod.2023.101838
   Li QY, 2023, MACROMOLECULES, V56, P7023, DOI 10.1021/acs.macromol.3c00704
   Lim CW, 2021, BIOMATER SCI UK, V9, P1660, DOI 10.1039/d0bm01473g
   Liu Y, 2021, ADV DRUG DELIVER REV, V171, P139, DOI 10.1016/j.addr.2020.12.007
   Lv SX, 2017, POLYM CHEM UK, V8, P1872, DOI 10.1039/c6py02230h
   Mammen Mathai, 1998, Angew Chem Int Ed Engl, V37, P2754, DOI 10.1002/(SICI)1521 3773(19981102)37:20<2754::AID ANIE2754>3.0.CO;2 3
   Mazo AR, 2020, CHEM SOC REV, V49, P4737, DOI 10.1039/c9cs00738e
   Melnyk T, 2020, ADV DRUG DELIVER REV, V160, P136, DOI 10.1016/j.addr.2020.10.007
   Méndez Ferrer S, 2020, NAT REV CANCER, V20, P285, DOI 10.1038/s41568 020 0245 2
   MILLER WG, 1968, BIOCHEMISTRY US, V7, P3925, DOI 10.1021/bi00851a021
   PIERCE WM, 1987, P SOC EXP BIOL MED, V186, P96
   Reichel Derek, 2019, Nanotheranostics, V3, P66, DOI 10.7150/ntno.30052
   Ren XX, 2022, CHEM ENG J, V446, DOI 10.1016/j.cej.2022.137133
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Samaniego R, 2014, J LEUKOCYTE BIOL, V95, P797, DOI 10.1189/jlb.0613345
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Seong S, 2023, BIOMATER SCI UK, V11, P2581, DOI 10.1039/d2bm02038f
   Soares AP, 2016, ENVIRON TOXICOL PHAR, V42, P212, DOI 10.1016/j.etap.2016.01.015
   Song ZY, 2019, P NATL ACAD SCI USA, V116, P10658, DOI 10.1073/pnas.1901442116
   Sun HL, 2019, BIOMACROMOLECULES, V20, P4299, DOI 10.1021/acs.biomac.9b01291
   Tang W, 2013, BIOMACROMOLECULES, V14, P3304, DOI 10.1021/bm400908c
   Tian ZR, 2022, ACS CENTRAL SCI, V8, P312, DOI 10.1021/acscentsci.1c01024
   Tian ZY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25689 y
   Ting G, 2022, BIOMATER SCI UK, V10, P1831, DOI 10.1039/d1bm01717a
   Tugyi R, 2005, P NATL ACAD SCI USA, V102, P413, DOI 10.1073/pnas.0407677102
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang K, 2024, BIOMATER SCI UK, V12, P1898, DOI 10.1039/d3bm01665j
   Wang WY, 2023, ACCOUNTS MATER RES, V4, P604, DOI 10.1021/accountsmr.3c00046
   Wu YM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07711 y
   Xia YC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20724 w
   Xu H, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01467 8
   Xu ZJ, 2018, J PHYS CHEM C, V122, P4372, DOI 10.1021/acs.jpcc.7b12142
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Zhang P, 2021, CHEM COMMUN, V57, P9489, DOI 10.1039/d1cc04053g
   Zhou X, 2021, NANO LETT, V21, P7998, DOI 10.1021/acs.nanolett.1c02150
   Zhou X, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120345
NR 53
TC 4
Z9 5
U1 10
U2 18
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD JUL 23
PY 2024
VL 12
IS 15
BP 3896
EP 3904
DI 10.1039/d4bm00437j
EA JUN 2024
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA ZH3Y5
UT WOS:001253429000001
PM 38913349
DA 2025 08 17
ER

PT J
AU Hofkens, W
   Grevers, LC
   Walgreen, B
   de Vries, TJ
   Leenen, PJM
   Everts, V
   Storm, G
   van den Berg, WB
   van Lent, PL
AF Hofkens, Wouter
   Grevers, Lilyanne C.
   Walgreen, Birgitte
   de Vries, Teun J.
   Leenen, Pieter J. M.
   Everts, Vincent
   Storm, Gert
   van den Berg, Wim B.
   van Lent, Peter L.
TI Intravenously delivered glucocorticoid liposomes inhibit osteoclast
   activity and bone erosion in murine antigen induced arthritis
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Rheumatoid arthritis; Glucocorticoids; Liposomes; Bone erosion;
   Osteoclasts
ID STERICALLY STABILIZED LIPOSOMES; RHEUMATOID ARTHRITIS; MACROPHAGES;
   EXPRESSION; INFLAMMATION; ACTIVATION; THERAPY; MARROW; CELLS
AB The objective of this study was to determine the effect of systemic delivery of prednisolone phosphate (PLP) encapsulated within long circulating 'stealth' liposomes on bone erosion and osteoclast activity during experimental antigen induced arthritis (AIA). Liposomal PLP strongly suppressed knee joint swelling. synovial infiltrate and bone erosion in antigen induced arthritis. The number of active osteoclasts was not only suppressed in bone lesions near inflamed synovium, but also within the trabecular bone of the tibia, suggesting a systemic suppression of osteoclast activation. Furthermore, liposomal PLP directly blocked osteoclast differentiation and bone resorption in vitro while it also suppressed expression of osteoclast differentiation factors M CSF and RANKL in the synovium. Targeting studies showed that liposomes are most efficiently phagocytosed by macrophages and early precursors of osteoclasts in the bone marrow rather than by mature osteoclasts, indicating a possible inhibition of osteoclast differentiation from an early stage. Conclusion: Liposomal glucocorticoid delivery rather than free PLP offers a more efficacious way to inhibit both inflammation and bone erosion in rheumatoid arthritis. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Hofkens, Wouter; Grevers, Lilyanne C.; Walgreen, Birgitte; van den Berg, Wim B.; van Lent, Peter L.] Radboud Univ Nijmegen, Med Ctr, Dept Rheumatol, NL 6525 ED Nijmegen, Netherlands.
   [de Vries, Teun J.; Everts, Vincent] Univ Amsterdam, Acad Ctr Dent Amsterdam ACTA, Dept Oral Cell Biol & Periodontol, NL 1012 WX Amsterdam, Netherlands.
   [Leenen, Pieter J. M.] Univ Med Ctr, Erasmus MC, Dept Immunol, Rotterdam, Netherlands.
   [Storm, Gert] Univ Utrecht, Utrecht Inst Pharmaceut Sci UIPS, Dept Pharmaceut, Utrecht, Netherlands.
   [de Vries, Teun J.; Everts, Vincent] Vrije Univ Amsterdam, Res Inst MOVE, Amsterdam, Netherlands.
C3 Radboud University Nijmegen; University of Amsterdam; Vrije Universiteit
   Amsterdam; Academic Center for Dentistry Amsterdam; Erasmus University
   Rotterdam; Erasmus MC; Utrecht University; Vrije Universiteit Amsterdam
RP van Lent, PL (通讯作者)，272 Radboud Univ Nijmegen, Med Ctr, Dept Rheumatol, POB 9101, NL 6500 HB Nijmegen, Netherlands.
EM p.vanlent@reuma.umcn.nl
RI Storm, Gerrit/O 8696 2016; van Lent, Peter/A 4047 2014; van den Berg,
   W.B./H 8010 2014; Leenen, Pieter/I 5839 2013
OI de Vries, Teun/0000 0001 6464 5172; Leenen, Pieter/0000 0001 9860 2920
CR Adamopoulos IE, 2006, J PATHOL, V208, P35, DOI 10.1002/path.1891
   ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165 6147(94)90314 X
   BARRERA P, 2008, ACR SCI M SAN FRANC
   BOERMAN OC, 1995, J NUCL MED, V36, P1639
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bugatti S, 2005, ARTHRITIS RHEUM US, V52, P3448, DOI 10.1002/art.21377
   Crommelin DJA, 1999, J CONTROL RELEASE, V62, P245, DOI 10.1016/S0168 3659(99)00044 9
   de Vries TJ, 2009, J LEUKOCYTE BIOL, V85, P919, DOI 10.1189/jlb.0708402
   GOEKOOPRUITERMA.YP, 2008, ARTHRITIS RHEUM S, pS126
   Goldring SR, 2003, CALCIFIED TISSUE INT, V73, P97, DOI 10.1007/s00223 002 1049 y
   Goldring SR, 2003, RHEUMATOLOGY, V42, P11, DOI 10.1093/rheumatology/keg327
   GRUBER MF, 1992, CELL IMMUNOL, V142, P361, DOI 10.1016/0008 8749(92)90297 3
   Hafström I, 2009, ANN RHEUM DIS, V68, P508, DOI 10.1136/ard.2008.087833
   Herman S, 2008, TRENDS MOL MED, V14, P245, DOI 10.1016/j.molmed.2008.04.001
   Hetland ML, 2008, ANN RHEUM DIS, V67, P815, DOI 10.1136/ard.2007.076307
   HUANG SK, 1992, CANCER RES, V52, P5135
   Islam S, 2008, MICROBIOL IMMUNOL, V52, P585, DOI 10.1111/j.1348 0421.2008.00076.x
   Jacobs JWG, 2006, ARTHRITIS RHEUM, V54, P1422, DOI 10.1002/art.21809
   JOHNSTONE SA, 2001, BIOCHIM BIOPHYS ACTA, V1, P25
   Kim HJ, 2007, ADV EXP MED BIOL, V602, P43
   KRUIJSEN MWM, 1983, BRIT J EXP PATHOL, V64, P298
   KRUIJSEN MWM, 1981, AGENTS ACTIONS, V11, P640, DOI 10.1007/BF01978775
   Lubberts E, 2002, ARTHRITIS RHEUM, V46, P3055, DOI 10.1002/art.10607
   Makrygiannakis D, 2006, ARTHRITIS RHEUM US, V54, P1463, DOI 10.1002/art.21767
   McDonough AK, 2008, CURR OPIN RHEUMATOL, V20, P131, DOI 10.1097/BOR.0b013e3282f51031
   Metselaar JM, 2004, ANN RHEUM DIS, V63, P348, DOI 10.1136/ard.2003.009944
   Metselaar JM, 2003, ARTHRITIS RHEUM US, V48, P2059, DOI 10.1002/art.11140
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Morand EF, 2007, CURR OPIN RHEUMATOL, V19, P302, DOI 10.1097/BOR.0b013e32805e87d0
   OELZNER P, 1990, CLIN IMMUNOL, V1, P79
   SCHALKWIJK J, 1985, BRIT J EXP PATHOL, V66, P435
   Schett G, 2008, ARTHRITIS RHEUM US, V58, P2936, DOI 10.1002/art.23951
   Schmidt J, 2003, BRAIN, V126, P1895, DOI 10.1093/brain/awg176
   SCHURIGT U, 2005, ARTHRITIS RES THER, V1, pR174
   Simon J, 2001, J AUTOIMMUN, V17, P127, DOI 10.1006/jaut.2001.0534
   Sou K, 2007, BIOMATERIALS, V28, P2655, DOI 10.1016/j.biomaterials.2007.01.041
   Thiele K, 2005, ARTHRIT RHEUM ARTHR, V53, P740, DOI 10.1002/art.21467
   Tunyogi Csapo M, 2008, ARTHRITIS RHEUM US, V58, P2397, DOI 10.1002/art.23653
   van der Voort R, 2005, ARTHRITIS RHEUM US, V52, P1381, DOI 10.1002/art.21004
   Wong PKK, 2001, J RHEUMATOL, V28, P2634
NR 40
TC 44
Z9 45
U1 0
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUN 30
PY 2011
VL 152
IS 3
BP 363
EP 369
DI 10.1016/j.jconrel.2011.03.001
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 791LK
UT WOS:000292666500005
PM 21396411
DA 2025 08 17
ER

PT J
AU Mortaz, E
   Redegeld, FA
   Nanne, BA
   Durismore, K
   Denenberg, A
   Wong, HR
   Nijkamp, FP
   Engels, F
AF Mortaz, E
   Redegeld, FA
   Nanne, BA
   Durismore, K
   Denenberg, A
   Wong, HR
   Nijkamp, FP
   Engels, F
TI Induction of HSP70 is dispensable for anti inflammatory action of heat
   shock or MAIDS in mast cells
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID KAPPA B ACTIVATION; FACTOR I; NUCLEAR TRANSLOCATION;
   RHEUMATOID ARTHRITIS; CYTOKINE PRODUCTION; PROTEIN INDUCTION; HUMAN
   MONOCYTES; INHIBITION; EXPRESSION; KINASE
AB Objective. It is well known that nonsteroidal anti inflammatory drugs (NSAIDs), such as acetylsalicylic acid, ibuprofen, and indomethacin, induce anti inflammatory effects through inhibition of cyclooxygenase enzyme activity. However, it has also been established that a variety of their anti inflammatory effects are independent of cyclooxygenase. In the search for alternative modes of action, it was found that NSAIDs share some cellular effects with heat shock treatment. This prompted us to investigate whether NSAIDs modulate production of proinflammatory cytokines by mast cells through the heat shock response.
   Materials and Methods. In mouse mast cells, derived from a culture of bone marrow cells of male BALB/cBy and null HSF 1( / ) mice, responsiveness to heat shock and NSAIDs was monitored by measuring tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL 6) production and signaling pathways.
   Results. In bone marrow derived mast cells (BMMC), we found that heat shock and a number of NSAIDs induced heat shock protein 70 (HSP70), which was closely paralleled with inhibition of IL 6 and TNF alpha production. Surprisingly, in BMMC from HSF 1( / ) mice, heat shock and selected NSAIDs were still able to suppress cytokine production in the absence of HSP70 induction.
   Conclusion. In this article, we provide evidence that inhibition of release of proinflammatory cytokines by NSAIDs and heat shock may be attributed to inhibition of the inhibitory nuclear factor kappa B (NF kappa B) kinase activity, extracellular signal regulated kinases 1/2, and p38 pathways, resulting in decreased transcriptional activity of the NF kappa B pathway. (c) 2006 International Society for Experimental Hematology. Published by Elsevier Inc.
C1 Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, NL 3508 TB Utrecht, Netherlands.
   Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA.
   Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA.
C3 Utrecht University; Cincinnati Children's Hospital Medical Center;
   Cincinnati Children's Hospital Medical Center; Cincinnati Children's
   Hospital Research Foundation
RP Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, POB 8002, NL 3508 TB Utrecht, Netherlands.
EM G.M.H.Engels@pharm.uu.nl
RI mortaz, esmael/G 7647 2017; Redegeld, Frank/O 6534 2016
OI Mortaz, Esmaeil/0000 0003 0250 087X; Engels, Ferdi/0000 0002 5761 9328;
   Wong, Hector/0000 0001 7989 1173
CR Amberger A, 1999, MOL MED, V5, P117, DOI 10.1007/BF03402146
   Boudreau RTM, 2004, J LEUKOCYTE BIOL, V76, P1075, DOI 10.1189/jlb.1003498
   Bradbury CM, 2001, CANCER RES, V61, P7689
   Derby E, 2001, IMMUNOL LETT, V78, P35, DOI 10.1016/S0165 2478(01)00226 7
   Din FVN, 2004, BRIT J CANCER, V91, P381, DOI 10.1038/sj.bjc.6601913
   DuBois RN, 1996, GASTROENTEROL CLIN N, V25, P773, DOI 10.1016/S0889 8553(05)70274 0
   Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724
   Galli SJ, 1996, NATURE, V381, P21, DOI 10.1038/381021a0
   Grossman BJ, 2002, BIOCHEM BIOPH RES CO, V297, P1264, DOI 10.1016/S0006 291X(02)02373 2
   Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003 4819 136 2 200201150 00016
   Hershko DD, 2002, J CELL BIOCHEM, V84, P687, DOI 10.1002/jcb.10083
   Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437
   Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325
   JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322
   Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200
   KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0
   LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207
   Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176
   LENTZ A, 2003, J ALLERGY CLIN IMMUN, V111, P1062
   Lorentz A, 2003, J ALLERGY CLIN IMMUN, V111, P1062, DOI 10.1067/mai.2003.1342
   Luo Fang, 2003, Zhonghua Er Ke Za Zhi, V41, P940
   Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200
   Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321
   Malhotra V, 2002, BIOCHEM BIOPH RES CO, V291, P453, DOI 10.1006/bbrc.2002.6470
   Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942
   Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood 2002 04 1154
   McCracken JD, 1996, J CLIN PHARMACOL, V36, P540, DOI 10.1002/j.1552 4604.1996.tb05043.x
   Mehta JL, 1998, CLIN CARDIOL, V21, P879, DOI 10.1002/clc.4960211204
   Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033
   Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0
   Palm Leis A, 2004, J BIOL CHEM, V279, P54905, DOI 10.1074/jbc.M407383200
   Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261
   Salminen WF Jr, 1998, J PHARMACOL EXP THER, V286, P519
   Schett G, 1998, J CLIN INVEST, V102, P302, DOI 10.1172/JCI2465
   Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200
   Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841
   Soncin F, 1996, BIOCHEM BIOPH RES CO, V229, P479, DOI 10.1006/bbrc.1996.1829
   Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723
   Toh ML, 2004, ARTHRITIS RHEUM US, V50, P3118, DOI 10.1002/art.20580
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092 8674(00)81433 6
   Vane JR, 2003, THROMB RES, V110, P255, DOI 10.1016/S0049 3848(03)00379 7
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Wong HR, 1997, J CLIN INVEST, V99, P2423, DOI 10.1172/JCI119425
   Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076
   Woolley DE, 2000, ARTHRITIS RES, V2, P65, DOI 10.1186/ar70
   Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943
   Yoo CG, 2000, J IMMUNOL, V164, P5416, DOI 10.4049/jimmunol.164.10.5416
   Zappulla JP, 2002, J NEUROIMMUNOL, V131, P5, DOI 10.1016/S0165 5728(02)00250 3
NR 48
TC 15
Z9 16
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0301 472X
EI 1873 2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD APR
PY 2006
VL 34
IS 4
BP 414
EP 423
DI 10.1016/j.exphem.2005.12.017
PG 10
WC Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Research & Experimental Medicine
GA 033HQ
UT WOS:000236838200003
PM 16569588
OA Bronze
DA 2025 08 17
ER

PT J
AU Yang, B
   Zhou, H
   Zhang, XD
   Liu, Z
   Fan, FY
   Sun, YM
AF Yang, Bing
   Zhou, Hui
   Zhang, Xiao Dong
   Liu, Zheng
   Fan, Fei Yue
   Sun, Yuan Ming
TI Effect of radiation on the expression of osteoclast marker genes in
   RAW264.7 cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE RAW264.7 cells; osteoclast; radiation
ID RESISTANT ACID PHOSPHATASE; DIFFERENTIATION; CALCITONIN; RECEPTOR; BONE;
   ACTIVATION; RANK; OSTEOPONTIN; IRRADIATION; SECRETION
AB Cancer radiation therapy can cause skeletal complications, such as osteopenia and osteoporosis. To understand the mechanism responsible for the skeletal complications, the expression profiles of osteoclast marker genes in RAW264.7 cells were observed. Osteoclast formation was established by RAW264.7 cells that were treated with the receptor activator of nuclear factor (NF) kappa B ligand (RANKL) and detected using immunochemistry and morphological observations. Quantitative real time polymerase chain reaction was used to assess the expression of a panel of osteoclast markers, including the receptor activator of NF kappa B (RANK), tartrate resistant acid phosphatase (TRAP), integrin beta 3 and the calcitonin receptor (CTR). RANKL induced osteoclasts were TRAP positive and multinucleated, and displayed a distinct morphology. RANK L induced osteoclast precursor cells had increased TRAP and RANK expression and decreased CTR expression compared to the control cells not treated with RANKL. RAW264.7 cells irradiated with 2 Gy gamma rays had upregulated integrin beta 3 and RANK expression and downregulated CTR expression compared to the control RAW264.7 cells. The effect of radiation on RANKL induced osteoclast differentiation enhanced the expression of CTR and inhibited the expression of RANK and TRAP. Therefore, radiation damage from 2 Gy gamma rays can promote the activities of osteoclast precursor cells, but not those of osteoclasts.
C1 [Yang, Bing; Zhang, Xiao Dong; Liu, Zheng; Fan, Fei Yue; Sun, Yuan Ming] Chinese Acad Med Sci, Inst Radiat Med, Tianjin Key Lab Mol Nucl Med, Tianjin 300192, Peoples R China.
   [Yang, Bing; Zhang, Xiao Dong; Liu, Zheng; Fan, Fei Yue; Sun, Yuan Ming] Peking Union Med Coll, Tianjin 300192, Peoples R China.
   [Zhou, Hui] Tianjin Med Univ, Sch Pharm, Tianjin 300070, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Radiation Medicine   CAMS; Chinese Academy of Medical
   Sciences   Peking Union Medical College; Peking Union Medical College;
   Tianjin Medical University
RP Sun, YM (通讯作者)，Chinese Acad Med Sci, Inst Radiat Med, Tianjin Key Lab Mol Nucl Med, Tianjin 300192, Peoples R China.
EM sym0702 dc@hotmail.com
RI fan, fan/KDO 5068 2024; Yang, Bing/G 7096 2019; Zhang,
   Xiaodong/F 4665 2015; Liu, Zheng/GVU 3695 2022
OI Zhang, Xiaodong/0000 0002 7212 0138; Liu, Zheng/0000 0003 4158 6768
FU National Nature Science Foundation of China [30970867]
FX This study was supported by grants from the National Nature Science
   Foundation of China (no. 30970867) (http://www.nsfc.gov.cn).
CR Andersson G, 2003, J BONE MINER RES, V18, P1912, DOI 10.1359/jbmr.2003.18.10.1912
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Banfi A, 2001, LEUKEMIA LYMPHOMA, V42, P863, DOI 10.3109/10428190109097705
   Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Cornish J, 2001, BONE, V29, P162, DOI 10.1016/S8756 3282(01)00494 X
   Cuetara BLV, 2006, IN VITRO CELL DEV AN, V42, P182, DOI 10.1290/0510075.1
   Darzy K H, 2005, J Endocrinol Invest, V28, P78
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Haynes DR, 2004, BIOMATERIALS, V25, P4877, DOI 10.1016/j.biomaterials.2004.01.003
   Hollberg K, 2005, J BONE MINER METAB, V23, P441, DOI 10.1007/s00774 005 0626 3
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hu DN, 2010, J ORTHOP RES, V28, P32, DOI 10.1002/jor.20955
   Ito M, 2005, AM J PHYSIOL CELL PH, V288, pC921, DOI 10.1152/ajpcell.00412.2004
   Kirstein B, 2006, J CELL BIOCHEM, V98, P1085, DOI 10.1002/jcb.20835
   LANGLANDS AO, 1977, CLIN RADIOL, V28, P93, DOI 10.1016/S0009 9260(77)80134 7
   LEE SK, 1995, ENDOCRINOLOGY, V136, P4572, DOI 10.1210/en.136.10.4572
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Makihira S, 2007, DENT MATER J, V26, P739, DOI 10.4012/dmj.26.739
   NICHOLSON GC, 1986, J CLIN INVEST, V78, P355, DOI 10.1172/JCI112584
   Quinn JMW, 1999, BONE, V25, P1, DOI 10.1016/S8756 3282(99)00094 0
   ROSS FP, 1993, J BIOL CHEM, V268, P9901
   Suter A, 2001, DEVELOPMENT, V128, P4899
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Walsh NC, 2003, GENE, V307, P111, DOI 10.1016/S0378 1119(03)00449 9
   Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002
   ZAIDI M, 1993, EXP PHYSIOL, V78, P721, DOI 10.1113/expphysiol.1993.sp003721
NR 29
TC 21
Z9 22
U1 0
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2012
VL 5
IS 4
BP 955
EP 958
DI 10.3892/mmr.2012.765
PG 4
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 906DC
UT WOS:000301324100013
PM 22294242
OA Green Published, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Meier, D
   Lodberg, A
   Gvozdenovic, A
   Pellegrini, G
   Neklyudova, O
   Born, W
   Fuchs, B
   Eijken, M
   Botter, SM
AF Meier, Daniela
   Lodberg, Andreas
   Gvozdenovic, Ana
   Pellegrini, Giovanni
   Neklyudova, Olga
   Born, Walter
   Fuchs, Bruno
   Eijken, Marco
   M. Botter, Sander
TI Inhibition of the activin receptor signaling pathway: A novel
   intervention against osteosarcoma
SO CANCER MEDICINE
LA English
DT Article
DE activin type II receptor; follistatin; osteosarcoma; pathological bone
   remodeling; zoledronic acid
ID ZOLEDRONIC ACID; CANCER CACHEXIA; LUNG METASTASIS; BISPHOSPHONATES;
   SURVIVAL; FOLLISTATIN; PROLONGS; BINDING
AB Osteosarcoma is a cancer of pathological bone remodeling with high mortality and severe comorbidity. New therapies are urgently needed. Activin A, a member of the transforming growth factor beta (TGF beta) superfamily, has been suggested to stimulate proliferation and invasion of osteosarcoma cells in vitro, thus representing a potential therapeutic target. In this study, inhibition of the activin receptor signaling pathway was explored as a therapy for osteosarcoma. In a murine intratibial osteosarcoma xenograft model, two types of inhibitors were tested: (a) a soluble activin type IIA decoy receptor (ActRIIA mFc), or (b) a modified variant of follistatin (FST Delta HBS hFc), either alone or in combination with a bisphosphonate. Both inhibitors reduced primary tumor development by nearly 50% compared to vehicle treatment. When ActRIIA mFc was combined with bisphosphonate, the effect on tumor size became even more pronounced (78% reduction vs. vehicle). Moreover, FST Delta HBS hFc increased body weight in the face of tumor progression (14% increase vs. vehicle), and ActRIIA mFc reduced the number of lung metastases when combined with bisphosphonate. The present study demonstrates a novel approach to treating osteosarcoma and encourages further investigation of inhibition of the activin receptor signaling pathway as an intervention against the disease.
C1 [Meier, Daniela; Gvozdenovic, Ana; Neklyudova, Olga; Born, Walter; Fuchs, Bruno; M. Botter, Sander] Balgrist Univ Hosp, Dept Orthoped, Zurich, Switzerland.
   [Lodberg, Andreas] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
   [Lodberg, Andreas] Aarhus Univ Hosp, Dept Pulm Med, Aarhus, Denmark.
   [Pellegrini, Giovanni] Univ Zurich, Inst Vet Pathol, Lab Anim Model Pathol, Zurich, Switzerland.
   [Eijken, Marco] Aarhus Univ Hosp, Dept Renal Med, Aarhus, Denmark.
   [Eijken, Marco] Aarhus Univ Hosp, Dept Clin Immunol, Aarhus, Denmark.
C3 University of Zurich; Aarhus University; Aarhus University; University
   of Zurich; Aarhus University; Aarhus University
RP Botter, SM (通讯作者)，Balgrist Campus AG, Swiss Ctr Musculoskeletal Biobanking, Lengghalde 5, CH 8008 Zurich, Switzerland.
EM sander.botter@balgristcampus.ch
RI ; pellegrini, giovanni/A 5122 2018; Lodberg, Andreas/ABB 2541 2021
OI Eijken, Marco/0000 0002 9043 3971; Botter, Sander/0000 0003 1695 1700;
   Lodberg, Andreas/0000 0001 9261 8753; Gvozdenovic,
   Ana/0000 0002 6013 0355; pellegrini, giovanni/0000 0001 9593 5578; 
FU Kinderkrebs Schweiz Foundation; Frode V. Nyegaard og Hustru's fond;
   Zurcher Krebsliga; University of Zurich; Danish Society of Respiratory
   Medicine; Schweizerischer Verein Balgrist; Osteoporoseforeningen; AP
   Moller Laegefonden [19 L 0041]; Dagmar Marshalls Fond; Highly
   Specialized Medicine for Musculoskeletal Oncology program of the Canton
   of Zurich; Johanna Wolf Foundation; Elsass Fonden [19 3 0531]
FX Kinderkrebs Schweiz Foundation; Frode V. Nyegaard og Hustru's fond;
   Zurcher Krebsliga; University of Zurich; Danish Society of Respiratory
   Medicine; Schweizerischer Verein Balgrist; Osteoporoseforeningen; AP
   Moller Laegefonden, Grant/Award Number: 19 L 0041; Dagmar Marshalls
   Fond; The Highly Specialized Medicine for Musculoskeletal Oncology
   program of the Canton of Zurich; Walter L. & Johanna Wolf Foundation;
   Elsass Fonden, Grant/Award Number: 19 3 0531
CR Aapro M, 2010, ONCOLOGIST, V15, P1147, DOI 10.1634/theoncologist.2007 0245
   Arlt MJE, 2012, JOVE J VIS EXP, DOI 10.3791/4162
   Arthur ST, 2016, J MED ECON, V19, P874, DOI 10.1080/13696998.2016.1181640
   Biswas AK, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a037416
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chantry AD, 2010, J BONE MINER RES, V25, P2357, DOI 10.1002/jbmr.142
   Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Hatakeyama S, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395 016 0098 2
   Horie N, 2007, BRIT J CANCER, V96, P255, DOI 10.1038/sj.bjc.6603548
   Kidd AC, 2019, CURR OPIN SUPPORT PA, V13, P316, DOI 10.1097/SPC.0000000000000465
   Klein MJ, 2006, AM J CLIN PATHOL, V125, P555, DOI 10.1309/UC6KQHLD9LV2KENN
   Koncarevic A, 2010, ENDOCRINOLOGY, V151, P4289, DOI 10.1210/en.2010 0134
   Kumar RMR, 2015, AM J CANCER RES, V5, P2156
   Labrinidis A, 2009, CLIN CANCER RES, V15, P3451, DOI 10.1158/1078 0432.CCR 08 1616
   Lareida A, 2019, J NEURO ONCOL, V145, P339, DOI 10.1007/s11060 019 03300 1
   Latres E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15153
   Liu W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10771
   Lodberg A, 2019, FASEB J, V33, P6001, DOI 10.1096/fj.201801969RR
   Lodberg A, 2018, BONE, V110, P326, DOI 10.1016/j.bone.2018.02.026
   Loomans HA, 2015, CANCERS, V7, P70, DOI 10.3390/cancers7010070
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Morianos I, 2019, J AUTOIMMUN, V104, DOI 10.1016/j.jaut.2019.102314
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   Paget S., 1889, Cancer Metastasis Rev, V133, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Piperno Neumann S, 2016, LANCET ONCOL, V17, P1070, DOI 10.1016/S1470 2045(16)30096 1
   Robl B, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046 016 0392 1
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Ryan AM, 2019, NUTRITION, V67 68, DOI 10.1016/j.nut.2019.06.020
   Sabile AA, 2012, J BONE MINER RES, V27, P58, DOI 10.1002/jbmr.535
   Sidis Y, 2005, ENDOCRINOLOGY, V146, P130, DOI 10.1210/en.2004 1041
   Susa Mira, 2004, J Transl Med, V2, P6, DOI 10.1186/1479 5876 2 6
   Takayama K, 2016, SUPPORT CARE CANCER, V24, P3473, DOI 10.1007/s00520 016 3156 8
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011
   Zhu JW, 2015, MOL MED REP, V11, P4501, DOI 10.3892/mmr.2015.3284
NR 41
TC 6
Z9 6
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2045 7634
J9 CANCER MED US
JI Cancer Med.
PD JAN
PY 2021
VL 10
IS 1
BP 286
EP 296
DI 10.1002/cam4.3581
EA NOV 2020
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA QB0TG
UT WOS:000588434300001
PM 33179858
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Avgoustou, P
   Jailani, ABA
   Desai, AJ
   Roberts, DJ
   Lilley, ER
   Stothard, GW
   Skerry, TM
   Richards, GO
AF Avgoustou, Paris
   Jailani, Ameera B. A.
   Desai, Aditya J.
   Roberts, David J.
   Lilley, Ewan R.
   Stothard, Grant W.
   Skerry, Timothy M.
   Richards, Gareth O.
TI Receptor activity modifying protein modulation of parathyroid hormone 1
   receptor function and signaling
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE parathyroid hormone receptor 1; parathyroid hormone; parathyroid
   hormone related protein; receptor activity modifying protein; biased
   agonism
ID INTERNATIONAL UNION; PEPTIDE; PTH; ADRENOMEDULLIN; CONFORMATIONS;
   PHARMACOLOGY; TRAFFICKING; SPECIFICITY; SELECTIVITY; ACTIVATION
AB Introduction Receptor activity modifying proteins (RAMPs) are known to modulate the pharmacology and function of several G protein coupled receptors (GPCRs), including the parathyroid hormone 1 receptor (PTH1R). However, the precise effects of different RAMPs on PTH1R signalling and trafficking remain poorly understood. This study investigated the impact of RAMP2 and RAMP3 on PTH1R function using a range of PTH and PTH related protein (PTHrP) derived ligands.Methods We employed FRET imaging to assess PTH1R interactions with RAMPs. Cell surface expression of PTH1R was evaluated in the presence of RAMPs. PTH1R mediated cAMP accumulation, beta arrestin recruitment, and calcium signalling were measured in response to various ligands. Antibody capture scintillation proximity assays were used to examine G protein activation patterns.Results PTH1R preferentially interacted with RAMP2 and, to a lesser extent, RAMP3, but not with RAMP1. RAMP3 co expression reduced cell surface expression of PTH1R. RAMP2 significantly enhanced PTH1R mediated signalling responses to PTH (1 34), PTHrP (1 34), PTH (1 84), and PTH (1 17) analogue ZP2307, while RAMP3 co expression attenuated or abolished these responses. Full length PTHrP analogues exhibited lower potency and efficacy than PTHrP (1 34) in activating PTH1R. RAMP2 increased the potency and/or efficacy of these analogues, whereas RAMP3 reduced these responses. RAMP2 differentially modulated G protein activation by PTH1R in a ligand dependent manner, with PTH (1 34) and PTHrP (1 34) inducing distinct patterns of G protein subtype activation.Discussion These findings highlight the complex role of RAMPs in regulating PTH1R signalling and trafficking, revealing differential effects of RAMP2 and RAMP3 on receptor function. The data suggest that targeting the PTH1R/RAMP2 complex may be a promising strategy for developing novel bone anabolic therapies by leveraging biased agonism and functional selectivity. Further research using physiologically relevant models is needed to elucidate the therapeutic potential of this approach.
C1 [Avgoustou, Paris; Jailani, Ameera B. A.; Desai, Aditya J.; Roberts, David J.; Lilley, Ewan R.; Stothard, Grant W.; Skerry, Timothy M.; Richards, Gareth O.] Univ Sheffield, Div Clin Med, Sheffield, England.
C3 University of Sheffield
RP Skerry, TM; Richards, GO (通讯作者)，Univ Sheffield, Div Clin Med, Sheffield, England.
EM t.skerry@sheffield.ac.uk; g.richards@sheffield.ac.uk
FU Biotechnology and Biological Sciences Research
   Council10.13039/501100000268 [117120, ZP2307, 1 108, 1 141]; BBSRC
FX The authors would like to thank the following for their assistance with
   these studies: BBSRC (Industrial Partnership Award, 117120) for funding
   and supporting these studies; Rasmus Just of Zealand Pharma for his
   generous gift of PTH (1 17), also known as ZP2307; and Professor Jack
   Martin from the University of Melbourne for his generous gift of the
   PTHrP peptides [PTHrP (1 108) and (1 141)] and critical review of this
   manuscript.
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Bailey RJ, 2007, BRIT J PHARMACOL, V151, P678, DOI 10.1038/sj.bjp.0707246
   Bohinc Brittany N., 2011, Endocrine Metabolic & Immune Disorders Drug Targets, V11, P112
   Bomberger JM, 2005, J BIOL CHEM, V280, P23926, DOI 10.1074/jbc.M501751200
   Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200
   Clemens TL, 2001, BRIT J PHARMACOL, V134, P1113, DOI 10.1038/sj.bjp.0704378
   Cosman F, 2022, OSTEOPOROSIS INT, V33, P1703, DOI 10.1007/s00198 022 06413 y
   Cussac D, 2004, EUR J PHARMACOL, V485, P111, DOI 10.1016/j.ejphar.2003.11.077
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Desai AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085237
   Feige JN, 2005, MICROSC RES TECHNIQ, V68, P51, DOI 10.1002/jemt.20215
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Gardella TJ, 2015, PHARMACOL REV, V67, P310, DOI 10.1124/pr.114.009464
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Gesty Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071
   Guise T A, 1996, Curr Opin Nephrol Hypertens, V5, P307, DOI 10.1097/00041552 199607000 00004
   Hachet Haas M, 2006, MICROSC RES TECHNIQ, V69, P941, DOI 10.1002/jemt.20376
   HAMMONDS RG, 1989, J BIOL CHEM, V264, P14806
   Harris M., 2021, BIORXIV, P436756, DOI [10.1101/2021.04.08.436756, DOI 10.1101/2021.04.08.436756]
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178
   Hay DL, 2016, BIOCHEM SOC T, V44, P568, DOI 10.1042/BST20150237
   Hay DL, 2016, ANNU REV PHARMACOL, V56, P469, DOI 10.1146/annurev pharmtox 010715 103120
   Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006 3495(02)75365 4
   Kadmiel M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181597
   Lan HX, 2009, MOL PHARMACOL, V75, P113, DOI 10.1124/mol.108.050534
   Lorenzen E, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw2778
   Luttrell LM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat7650
   Mackie DI, 2019, P NATL ACAD SCI USA, V116, P24093, DOI 10.1073/pnas.1905561116
   Martin TJ, 2016, PHYSIOL REV, V96, P831, DOI 10.1152/physrev.00031.2015
   McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666
   MIYAUCHI A, 1990, AM J PHYSIOL, V259, pF485, DOI 10.1152/ajprenal.1990.259.3.F485
   Morfis M, 2008, ENDOCRINOLOGY, V149, P5423, DOI 10.1210/en.2007 1735
   Neerup TSR, 2011, BONE, V48, P1319, DOI 10.1016/j.bone.2011.02.019
   Nemec K, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2122037119
   Peña KA, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102332
   Phelps E, 2005, CALCIFIED TISSUE INT, V77, P96, DOI 10.1007/s00223 004 0239 1
   Pickard BW, 2007, ENDOCRINOLOGY, V148, P2282, DOI 10.1210/en.2007 0157
   Pioszak AA, 2020, ADV PHARMACOL, V88, P115, DOI 10.1016/bs.apha.2020.01.001
   Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233
   Romero G, 2010, J BIOL CHEM, V285, P14756, DOI 10.1074/jbc.M110.102970
   Schlüter KD, 1999, NEWS PHYSIOL SCI, V14, P243
   Schwindinger WF, 1998, ENDOCRINE, V8, P201, DOI 10.1385/ENDO:8:2:201
   Sneddon WB, 2004, ENDOCRINOLOGY, V145, P2815, DOI 10.1210/en.2003 1185
   Sriram K, 2018, MOL PHARMACOL, V93, P251, DOI 10.1124/mol.117.111062
   Vilardaga JP, 2023, ENDOCR REV, V44, P474, DOI 10.1210/endrev/bnac032
   Wall MJ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 31652 2
   Wang B, 2007, J BIOL CHEM, V282, P36214, DOI 10.1074/jbc.M707263200
   Weston C, 2016, J BIOL CHEM, V291, P21925, DOI 10.1074/jbc.M116.751362
   Weston C, 2015, J BIOL CHEM, V290, P23009, DOI 10.1074/jbc.M114.624601
   Zhao LH, 2019, SCIENCE, V364, P148, DOI 10.1126/science.aav7942
NR 51
TC 0
Z9 0
U1 2
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 23
PY 2024
VL 15
AR 1455231
DI 10.3389/fphar.2024.1455231
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA H9R3K
UT WOS:001326727600001
PM 39376604
OA gold
DA 2025 08 17
ER

PT J
AU Ma, WJ
   Li, C
AF Ma, Wenjie
   Li, Chen
TI Enhancing postmenopausal osteoporosis: a study of KLF2 transcription
   factor secretion and PI3K Akt signaling pathway activation by PIK3CA in
   bone marrow mesenchymal stem cells
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE postmenopausal osteoporosis; osteoblast differentiation; WGCNA; GEO;
   Lasso regression analysis; PIK3CA; KLF2; PI3K Akt pathway
ID OSTEOGENIC DIFFERENTIATION
AB Introduction: Mesenchymal stem cells can develop into osteoblasts, making them a promising cell based osteoporosis treatment. Despite their therapeutic potential, their molecular processes are little known. Bioinformatics and experimental analysis were used to determine the molecular processes of bone marrow mesenchymal stem cell (BMSC) therapy for postmenopausal osteoporosis (PMO). Material and methods: We used weighted gene co expression network analysis (WGCNA) to isolate core gene sets from two GEO microarray datasets (GSE7158 and GSE56815). GeneCards found PMO related genes. GO, KEGG, Lasso regression, and ROC curve analysis refined our candidate genes. Using the GSE105145 dataset, we evaluated KLF2 expression in BMSCs and examined the link between KLF2 and PIK3CA using Pearson correlation analysis. We created a protein protein interaction network of essential genes involved in osteoblast differentiation and validated the functional roles of KLF2 and PIK3CA in BMSC osteoblast differentiation in vitro. Results: We created 6 co expression modules from 10 419 differentially expressed genes (DEGs). PIK3CA, the key gene in the PI3K Akt pathway, was among 197 PMO associated DEGs. KLF2 also induced PIK3CA transcription in PMO. BMSCs also expressed elevated KLF2. BMSC osteoblast differentiation involved the PI3K Akt pathway. In vitro, KLF2 increased PIK3CA transcription and activated the PI3K Akt pathway to differentiate BMSCs into osteoblasts. Conclusions: BMSCs release KLF2, which stimulates the PIK3CA dependent PI3K Akt pathway to treat PMO. Our findings illuminates the involvement of KLF2 and the PI3K Akt pathway in BMSC osteoblast development, which may lead to better PMO treatments.
C1 [Ma, Wenjie; Li, Chen] Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Endocrinol, Qingdao 266035, Peoples R China.
C3 Shandong University
RP Ma, WJ (通讯作者)，Shandong Univ, Qilu Hosp Qingdao, Cheeloo Coll Med, Dept Endocrinol, Qingdao 266035, Peoples R China.
EM lichenqd0108@126.com
RI Ma, Wen Jie/GPX 1080 2022
FX We acknowledge and appreciate our colleagues for their valuable efforts
   and comments on this study.
CR [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Bijelic Radojka, 2017, Med Arch, V71, P25, DOI 10.5455/medarh.2017.71.25 28
   Chen WK, 2020, FREE RADICAL BIO MED, V146, P92, DOI 10.1016/j.freeradbiomed.2019.10.412
   Cui HQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2723 6
   Deng YX, 2022, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.815245
   Ebert R, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 265
   Gong LL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.465
   He QT, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02623 z
   He XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01232 3
   Hou ZY, 2019, LAB INVEST, V99, P271, DOI 10.1038/s41374 018 0149 x
   Hu JH, 2017, BIOCHEM PHARMACOL, V136, P109, DOI 10.1016/j.bcp.2017.04.010
   Huang XF, 2021, CELL MOL IMMUNOL, V18, P969, DOI 10.1038/s41423 021 00660 5
   Jha P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112383
   Kim I, 2019, BMB REP, V52, P469, DOI 10.5483/BMBRep.2019.52.7.104
   Kong Y, 2019, EXP MOL PATHOL, V110, DOI 10.1016/j.yexmp.2019.104282
   Kou JQ, 2020, J CELL BIOCHEM, V121, P1216, DOI 10.1002/jcb.29355
   Lai K, 2015, J CLIN PATHOL, V68, P253, DOI 10.1136/jclinpath 2015 202885
   Li YH, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02316 7
   Liu BS, 2022, J HEALTHC ENG, V2022, DOI 10.1155/2022/5298892
   Luo HC, 2022, BRAIN RES, V1794, DOI 10.1016/j.brainres.2022.148042
   Luo ZW, 2019, NANOSCALE, V11, P20884, DOI 10.1039/c9nr02791b
   Malakoti F, 2022, BIOCHIMIE, V202, P56, DOI 10.1016/j.biochi.2022.08.008
   Migliorini F, 2021, EXPERT REV CLIN PHAR, V14, P105, DOI 10.1080/17512433.2021.1851192
   Migliorini F, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57101119
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02678 x
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02497 0
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02474 7
   Noronha Matos JB, 2016, J CELL PHYSIOL, V231, P1852, DOI 10.1002/jcp.25303
   Sako K, 2009, J BIOL CHEM, V284, P5592, DOI 10.1074/jbc.M806928200
   Shevroja E, 2021, ENDOCRINE, V74, P20, DOI 10.1007/s12020 021 02806 x
   Shi HL, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.819056
   Wang D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22987 3
   Wang HM, 2016, CYTOTECHNOLOGY, V68, P839, DOI 10.1007/s10616 014 9837 6
   Wu JC, 2021, BIOCHEM J, V478, P721, DOI 10.1042/BCJ20200314
   Xin Y, 2018, BIOMED PHARMACOTHER, V102, P1120, DOI 10.1016/j.biopha.2018.03.172
   Xu RY, 2021, THERANOSTICS, V11, P5491, DOI 10.7150/thno.55041
   Yuan X, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/5556653
   Zhang Y, 2020, J CELL PHYSIOL, V235, P5511, DOI 10.1002/jcp.29261
   Zhao FJ, 2021, AGING US, V13, P6945, DOI 10.18632/aging.202552
   Zheng HL, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03784 8
   Zhou Y, 2020, STEM CELLS, V38, P395, DOI 10.1002/stem.3120
   Zhou Y, 2014, IN VITRO CELL DEV AN, V50, P822, DOI 10.1007/s11626 014 9778 6
NR 42
TC 3
Z9 3
U1 5
U2 12
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA 2, POZNAN, 61 615, POLAND
SN 1734 1922
EI 1896 9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PY 2024
VL 20
IS 3
BP 918
EP 937
DI 10.5114/aoms/171785
PG 20
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA YB3X9
UT WOS:001265998100021
PM 39050179
OA gold
DA 2025 08 17
ER

PT J
AU Yang, F
   Lin, ZW
   Huang, TY
   Chen, TT
   Cui, J
   Li, MY
   Hua, YQ
AF Yang, F.
   Lin, Z. W.
   Huang, T. Y.
   Chen, T. T.
   Cui, J.
   Li, M. Y.
   Hua, Y. Q.
TI Ligustilide, a major bioactive component of Angelica sinensis,
   promotes bone formation via the GPR30/EGFR pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR; ZEBRAFISH MODELS;
   MC3T3 E1 CELLS; ESTROGEN; MECHANISMS; MARROW; TRANSACTIVATION;
   PROLIFERATION; OSTEOPOROSIS
AB Angelica sinensis (Oliv.) Diels is a widely used traditional Chinese herbal medicine in treating osteoporosis. Ligustilide (LIG) is the main component of A. sinensis and is considered to be the most effective biologically active ingredient in this plant. LIG has been found to have multiple pharmacological activities, such as anti atherosclerosis, neuroprotection, anticancer, anti inflammatory and analgesic. However, little is known regarding its anti osteoporotic effects. The aims of this study were to investigate any protective effect of LIG on bone formation. The results showed that LIG significantly ameliorated inhibition of bone formation in zebrafish caused by prednisolone. LIG promoted osteoblast differentiation, including that of the pre osteoblastic cell line MC3T3 E1 and bone marrow mesenchymal stem cells. LIG greatly improved the viability of MC3T3 E1 cells exposed to H2O2, attenuated H2O2 induced apoptosis and increased the expression of Bcl 2. Furthermore, LIG treatment lead to marked activation of phosphorylated EGFR and ERK1/2. These effects could be obviously inhibited by blocking GPR30 signaling with the specific inhibitor G15. Collectively, the results reveal that GPR30 is a positive switch for LIG to increase bone formation via regulation of EGFR, and these results provide evidence for the potential of LIG to treat osteoporosis.
C1 [Yang, F.; Lin, Z. W.; Huang, T. Y.; Chen, T. T.; Cui, J.; Li, M. Y.; Hua, Y. Q.] Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing 210023, Jiangsu, Peoples R China.
   [Hua, Y. Q.] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Nanjing 210023, Jiangsu, Peoples R China.
   [Yang, F.; Lin, Z. W.; Huang, T. Y.; Chen, T. T.; Cui, J.; Li, M. Y.; Hua, Y. Q.] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine
RP Hua, YQ (通讯作者)，Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing 210023, Jiangsu, Peoples R China.; Hua, YQ (通讯作者)，Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Nanjing 210023, Jiangsu, Peoples R China.; Hua, YQ (通讯作者)，Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210023, Jiangsu, Peoples R China.
EM hua_yq@njucm.edu.cn
RI hua, yq/G 4294 2011
FU National Natural Science Foundation of China [81473390, 30902014];
   Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources
   Industrialization [012092002001 7]; Open Project Program of Jiangsu Key
   Laboratory for Pharmacology and Safety Evaluation of Chinese Materia
   Medica [JKLPSE201818]; Project of the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD)
FX We thank Dr. L. Yu for zebrafish experimental technical support. This
   research was supported by grants from the National Natural Science
   Foundation of China (81473390, 30902014), the Jiangsu Collaborative
   Innovation Center of Chinese Medicinal Resources Industrialization (No.
   012092002001 7), the Open Project Program of Jiangsu Key Laboratory for
   Pharmacology and Safety Evaluation of Chinese Materia Medica (No.
   JKLPSE201818) and the Project of the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD).
CR Barrett Ruth, 2006, Biotechnology Journal, V1, P651, DOI 10.1002/biot.200600043
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Brann DW, 2007, STEROIDS, V72, P381, DOI 10.1016/j.steroids.2007.02.003
   Canalis E, 2003, CURR OPIN RHEUMATOL, V15, P454, DOI 10.1097/00002281 200307000 00013
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Chandra A, 2013, J BIOL CHEM, V288, P20488, DOI 10.1074/jbc.M112.447250
   Chaturantabut S, 2019, GASTROENTEROLOGY, V156, P1788, DOI 10.1053/j.gastro.2019.01.010
   Choi ES, 2018, PHYTOMEDICINE, V38, P12, DOI 10.1016/j.phymed.2017.09.022
   Choi KO, 2012, J MED FOOD, V15, P863, DOI 10.1089/jmf.2011.2047
   Crandall CJ, 2014, ANN INTERN MED, V161, P711, DOI 10.7326/M14 0317
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   Fu C, 2015, J CELL PHYSIOL, V230, P2184, DOI 10.1002/jcp.24947
   Geurtzen K, 2017, J BONE MINER RES, V32, P2476, DOI 10.1002/jbmr.3231
   Grimes DT, 2016, SCIENCE, V352, P1341, DOI 10.1126/science.aaf6419
   Hayes M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5777
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Jafari A, 2017, STEM CELL REP, V8, P373, DOI 10.1016/j.stemcr.2017.01.003
   Kang WB, 2015, J STEROID BIOCHEM, V154, P237, DOI 10.1016/j.jsbmb.2015.07.002
   Khan K, 2015, J NUTR BIOCHEM, V26, P1491, DOI 10.1016/j.jnutbio.2015.07.021
   Kong BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113242
   Li XB, 2018, CELL PHYSIOL BIOCHEM, V48, P2583, DOI 10.1159/000492701
   Linder M, 2018, CELL DEATH DIFFER, V25, P1094, DOI 10.1038/s41418 017 0054 7
   Liu Y, 2014, CELL STEM CELL, V15, P66, DOI 10.1016/j.stem.2014.03.005
   Long FY, 2018, EUR J PHARMACOL, V820, P198, DOI 10.1016/j.ejphar.2017.12.019
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Moriishi T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086629
   Noda Seino H, 2013, J ENDOCRINOL INVEST, V36, P21, DOI 10.3275/8301
   Oshina H, 2007, BONE, V41, P575, DOI 10.1016/j.bone.2007.06.022
   Panontin E, 2011, NEW ENGL J MED, V365, P673, DOI 10.1056/NEJMc1106933
   Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260
   Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Saito K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054853
   Shan PF, 2013, INT J ENDOCRINOL, V2013, DOI [10.1155/2013/753150, 10.1155/2013/952858]
   Shen GS, 2018, CELL PHYSIOL BIOCHEM, V50, P1916, DOI 10.1159/000494872
   Shi Y, 2014, INT IMMUNOPHARMACOL, V19, P358, DOI 10.1016/j.intimp.2014.02.007
   Sun XQ, 2018, MED SCI MONITOR, V24, P903, DOI 10.12659/MSM.908705
   Tu Kristie N, 2018, P T, V43, P92
   Wei WL, 2016, J ETHNOPHARMACOL, V190, P116, DOI 10.1016/j.jep.2016.05.023
   Weller ML, 2010, NAT MED, V16, P662, DOI 10.1038/nm.2145
   Wilson Carol, 2014, Nat Rev Endocrinol, V10, P3, DOI 10.1038/nrendo.2013.225
   Windahl SH, 2009, AM J PHYSIOL ENDOC M, V296, pE490, DOI 10.1152/ajpendo.90691.2008
   Yu Y, 2008, EXP BRAIN RES, V184, P307, DOI 10.1007/s00221 007 1100 3
   Zeboudj L, 2018, J AM COLL CARDIOL, V71, P160, DOI 10.1016/j.jacc.2017.10.084
   Zeng Q, 2015, J SEP SCI, V38, P4269, DOI 10.1002/jssc.201500862
   Zhang X, 2017, SCI REP UK, V7, DOI 10.1038/srep44552
   Zheng Zi Ran, 2014, Zhongguo Zhong Yao Za Zhi, V39, P3172
   Zuo Ai Hua, 2012, Zhongguo Zhong Yao Za Zhi, V37, P3350
   2018, J IMMUNOL RES, DOI DOI 10.1155/2018/6345857
NR 54
TC 43
Z9 59
U1 2
U2 42
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 6
PY 2019
VL 9
AR 6991
DI 10.1038/s41598 019 43518 7
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HW7PK
UT WOS:000466881600008
PM 31061445
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU De Boer, JP
   van Egmond, PW
   Helder, MN
   de Menezes, RX
   Cleton Jansen, AM
   Beliën, JAM
   Verheul, HMW
   van Royen, BJ
   Kaspers, GJJL
   van Beusechem, VW
AF De Boer, Jantine Posthuma
   van Egmond, Pim W.
   Helder, Marco N.
   de Menezes, Renee X.
   Cleton Jansen, Anne Marie
   Belien, Jeroen A. M.
   Verheul, Henk M. W.
   van Royen, Barend J.
   Kaspers, Gert Jan J. L.
   van Beusechem, Victor W.
TI Targeting JNK interacting protein 1 (JIP1) sensitises osteosarcoma to
   doxorubicin
SO ONCOTARGET
LA English
DT Article
DE osteosarcoma; functional genomics; siRNA; chemosensitisation; JIP1
ID HIGH GRADE OSTEOSARCOMA; HISTOLOGIC RESPONSE; THERAPEUTIC TARGETS;
   OSTEOGENIC SARCOMA; LUNG METASTASES; KINASE; CHEMOTHERAPY; APOPTOSIS;
   SCREEN; TUMOR
AB Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. Despite aggressive therapy, survival outcomes remain unsatisfactory, especially for patients with metastatic disease or patients with a poor chemotherapy response. Chemoresistance contributes to treatment failure. To increase the efficacy of conventional chemotherapy, essential survival pathways should be targeted concomitantly. Here, we performed a loss of function siRNA screen of the human kinome in SaOS 2 cells to identify critical survival kinases after doxorubicin treatment. Gene silencing of JNK interacting protein 1 (JIP1) elicited the most potent sensitisation to doxorubicin. This candidate was further explored as potential target for chemosensitisation in OS. A panel of OS cell lines and human primary osteoblasts was examined for sensitisation to doxorubicin using small molecule JIP1 inhibitor BI 78D3. JIP1 expression and JIP1 inhibitor effects on JNKsignalling were investigated by Western blot analysis. JIP1 expression in human OS tumours was assessed by immunohistochemistry on tissue micro arrays. BI 78D3 blocked JNK signalling and sensitised three out of four tested OS cell lines, but not healthy osteoblasts, to treatment with doxorubicin. Combination treatment increased the induction of apoptosis. JIP1 was found to be expressed in two thirds of human primary OS tissue samples. Patients with JIP1 positive tumours showed a trend to inferior overall survival. Collectively, JIP1 appears a clinically relevant novel target in OS to enhance the efficacy of doxorubicin treatment by means of RNA interference or pharmacological inhibition.
C1 [Verheul, Henk M. W.; van Beusechem, Victor W.] Vrije Univ Amsterdam Med Ctr, RIFOL, Dept Med Oncol, Amsterdam, Netherlands.
   [De Boer, Jantine Posthuma; Helder, Marco N.; van Royen, Barend J.] Vrije Univ Amsterdam Med Ctr, Dept Orthopaed Surg, Amsterdam, Netherlands.
   [van Egmond, Pim W.] MCA, Dept Surg, Amersfoort, Netherlands.
   [Helder, Marco N.; van Royen, Barend J.] STEGA, Res Inst MOVE, Amsterdam, Netherlands.
   [de Menezes, Renee X.] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
   [Cleton Jansen, Anne Marie] LUMC, Dept Pathol, Leiden, Netherlands.
   [Belien, Jeroen A. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije
   Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit
   Amsterdam; VU UNIVERSITY MEDICAL CENTER; Leiden University; Leiden
   University Medical Center (LUMC); Vrije Universiteit Amsterdam; VU
   UNIVERSITY MEDICAL CENTER
RP van Beusechem, VW (通讯作者)，Vrije Univ Amsterdam Med Ctr, RIFOL, Dept Med Oncol, Amsterdam, Netherlands.
EM vw.vanbeusechem@vumc.nl
RI van Royen, Barend/W 4864 2019; Kaspers, Gertjan/ABC 5334 2020; Belien,
   Jeroen/JCE 5492 2023; Menezes, Renee/L 2182 2019; Verheul,
   Henk/V 6462 2019
OI Kaspers, Gertjan/0000 0001 7716 8475; Belien,
   Jeroen/0000 0002 7160 5942; Verheul, Henk/0000 0001 5981 922X; 
FU Individualised Musculoskeletal Regeneration and Reconstruction Network
   (Danish Research Council), Aarhus, Denmark; VONK: VUmc Onderzoek naar
   Kinderkanker, Amsterdam, the Netherlands
FX JP is supported by the Individualised Musculoskeletal Regeneration and
   Reconstruction Network (Danish Research Council), Aarhus, Denmark; and
   by VONK: VUmc Onderzoek naar Kinderkanker, Amsterdam, the Netherlands.
   The RIFOL high throughput screening facility is supported by the
   Stichting VUmc CCA, Amsterdam, the Netherlands.
CR Altman DG., 1991, PRACTICAL STAT MED R
   Bacci G, 2001, CLIN ORTHOP RELAT R, P186
   Bacci G, 2008, J SURG ONCOL, V98, P415, DOI 10.1002/jso.21140
   Baumhoer D, 2011, ONCOTARGET, V2, P970
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Bielack SS, 2008, CURR TREAT OPTION ON, V9, P67, DOI 10.1007/s11864 008 0057 1
   Blanco S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001660
   Blay JY, 2007, ONKOLOGIE, V30, P226, DOI 10.1159/000101702
   Boutros M, 2006, GENOME BIOL, V7, DOI 10.1186/gb 2006 7 7 r66
   Chen Y, 2012, ONCOL LETT, V3, P1011, DOI 10.3892/ol.2012.604
   Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898 6568(01)00275 3
   Engström W, 2010, CELL PROLIFERAT, V43, P56, DOI 10.1111/j.1365 2184.2009.00654.x
   Gorlick R, 2003, CLIN CANCER RES, V9, P5442
   Gotink KJ, 2010, ANGIOGENESIS, V13, P1, DOI 10.1007/s10456 009 9160 6
   Graat HCA, 2007, MOL CANCER THER, V6, P1552, DOI 10.1158/1535 7163.MCT 06 0631
   Grant S, 2009, CELL MOL LIFE SCI, V66, P1163, DOI 10.1007/s00018 008 8539 7
   Huang GX, 2007, MOL CANCER THER, V6, P1610, DOI 10.1158/1535 7163.MCT 06 0580
   Hughes DPM, 2009, EXPERT OPIN DRUG DEL, V6, P1311, DOI 10.1517/17425240903280422
   Ikezoe T, 2004, BRIT J CANCER, V90, P2017, DOI 10.1038/sj.bjc.6601834
   Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130
   Jia SF, 1999, CLIN EXP METASTAS, V17, P501, DOI 10.1023/A:1006623001465
   Johnson SA, 2005, NAT METHODS, V2, P17, DOI 10.1038/NMETH731
   Kawabe T, 2004, MOL CANCER THER, V3, P513
   Kim JW, 2005, P NATL ACAD SCI USA, V102, P14308, DOI 10.1073/pnas.0501600102
   Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lewis IJ, 2007, JNCI J NATL CANCER I, V99, P112, DOI 10.1093/jnci/djk015
   Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262
   MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603
   Mullenders J, 2009, ONCOGENE, V28, P4409, DOI 10.1038/onc.2009.295
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Peterson D, 2010, CANCER RES, V70, P6325, DOI 10.1158/0008 5472.CAN 10 0015
   R Core Team, 2022, R: A language and environment for statistical computing
   ROSEN G, 1982, CANCER AM CANCER SOC, V49, P1221, DOI 10.1002/1097 0142(19820315)49:6<1221::AID CNCR2820490625>3.0.CO;2 E
   Saini V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041401
   Schlabach MR, 2008, SCIENCE, V319, P620, DOI 10.1126/science.1149200
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Scotlandi K, 2009, CURR CANCER DRUG TAR, V9, P843, DOI 10.2174/156800909789760410
   Senderowicz AM, 2000, JNCI J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502 e131
   Smeland S, 2004, ACTA ORTHOP SCAND, V75, P92, DOI 10.1080/00016470410001708380
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0 387 29362 0_23
   Stebbins JL, 2008, P NATL ACAD SCI USA, V105, P16809, DOI 10.1073/pnas.0805677105
   Swanton C, 2007, CELL CYCLE, V6, P2001, DOI 10.4161/cc.6.16.4538
   Vaishnav M, 2011, EXP CELL RES, V317, P1028, DOI 10.1016/j.yexcr.2011.01.011
   Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200
   Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697
   Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801
   Yamaguchi U, 2009, CANCER SCI, V100, P2268, DOI 10.1111/j.1349 7006.2009.01310.x
   Yang C, 2010, CARCINOGENESIS, V31, P552, DOI 10.1093/carcin/bgp330
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 54
TC 36
Z9 39
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD OCT
PY 2012
VL 3
IS 10
BP 1169
EP 1181
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 055JC
UT WOS:000312410800015
PM 23045411
DA 2025 08 17
ER

PT J
AU Sunyecz, JA
   Derman, R
AF Sunyecz, John A.
   Derman, Richard
TI Update on the use of bisphosphonates in the management of postmenopausal
   osteoporosis by obstetricians gynecologists
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Article
ID BONE MINERAL DENSITY; VITAMIN D SUPPLEMENTATION; MONTHLY ORAL
   IBANDRONATE; VERTEBRAL FRACTURE RISK; HIP FRACTURE; CALCIUM
   SUPPLEMENTATION; NONVERTEBRAL FRACTURES; STRONTIUM RANELATE;
   RANDOMIZED TRIAL; ELDERLY PEOPLE
AB Obstetricians gynecologists often have a special and long term relationship with their patients and are ideally placed to assess their fracture risk and to institute appropriate therapy for osteoporosis. Assessment of risk factors according to the World Health Organization and more recent guidelines (e.g., age, smoking history, previous fracture, parental fracture, corticosteroid use, weight) enables the clinician to target patients for testing of bone mineral density by techniques such as dual energy x ray absorptiometry at the proximal femur. The current therapy of choice is an oral bisphosphonate, which has proven efficacy in increasing bone mineral density, reducing bone tumover markers, and reducing fracture rates. Their main drawback is inconvenient dosing requirements, which necessitates taking the drug in the morning at least 30 minutes before the first meal or drink of the day;, this may contribute to poor adherence with therapy and suboptimal outcomes. The availability of daily or weekly (alendronate and risedronate) or monthly (ibandronate) bisphosphonates means that patients can have therapy at their preferred frequency, and along with education regarding lifestyle issues such as nutrition, exercise, smoking, and alcohol use, and measures to reduce tripping in the home, should reduce the prevalence of osteoporotic fractures.
   Target Audience: Obstetricians & Gynecologists, Family Physicians
   Learning Objectives: After completion of this article, the reader should be able to recall that there are high risk fracture patients, explain that Ob/Gyn physicians should target their diagnostic and treatment options to these patients, and state that there are ways that increase compliance to recommended bisphosphonates in addition to the recommended lifestyle changes.
C1 MenopauseRx Inc, Pittsburgh, PA USA.
   Univ Missouri, Sch Med, Kansas City, MO 64108 USA.
C3 University of Missouri System; University of Missouri Kansas City
RP Sunyecz, JA (通讯作者)，1142 Natl Pike Rd, Hopwood, PA 15445 USA.
EM sunyecz@mendpauserx.com
OI Derman, Richard/0000 0003 1148 1594
CR ADACHI K, 1990, ANN OTO RHINOL LARYN, V99, P738, DOI 10.1177/000348949009900914
   Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   [Anonymous], 1994, JAMA, V272, P1942
   [Anonymous], 2004, BON HLTH OST REP SUR
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2001, OSTEOPOROSIS INT, V12, P519, DOI 10.1007/s001980170072
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173
   Cauley JA, 2000, OSTEOPOROSIS INT, V11, P556, DOI 10.1007/s001980070075
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Cranney A, 2002, ENDOCR REV, V23, P540, DOI 10.1210/er.2001 6002
   Cummings SR, 1999, JAMA J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Derman Richard, 2004, Mo Med, V101, P54
   Dixon WG, 2005, RHEUMATOLOGY, V44, P642, DOI 10.1093/rheumatology/keh569
   Eastell R, 2005, J STEROID BIOCHEM, V95, P151, DOI 10.1016/j.jsbmb.2005.04.009
   Empana JP, 2004, J AM GERIATR SOC, V52, P685, DOI 10.1111/j.1532 5415.2004.52203.x
   Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532 5415.2000.tb02641.x
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   FIATARONE MA, 1990, JAMA J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029
   Gallagher JC, 2002, MENOPAUSE, V9, P84
   Going S, 2003, OSTEOPOROSIS INT, V14, P637, DOI 10.1007/s00198 003 1436 x
   Grant AM, 2005, LANCET, V365, P1621, DOI 10.1016/S0140 6736(05)63013 9
   Grauer A, 1995, EXP CLIN ENDOCR DIAB, V103, P345, DOI 10.1055/s 0029 1211376
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Heaney RP, 2001, J AM COLL NUTR, V20, P239, DOI 10.1080/07315724.2001.10719038
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218
   Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P475, DOI 10.1007/s00198 004 1698 y
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   KOTOWICZ MA, 1994, J BONE MINER RES, V9, P599
   Kroth Philip J, 2004, Am J Geriatr Pharmacother, V2, P112, DOI 10.1016/S1543 5946(04)90016 5
   Leib ES, 2004, J CLIN DENSITOM, V7, P1, DOI 10.1385/JCD:7:1:1
   Majumdar SR, 2005, ARCH INTERN MED, V165, P905, DOI 10.1001/archinte.165.8.905
   Melo Maico D, 2005, J Can Dent Assoc, V71, P111
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Miller PD, 2004, ARCH INTERN MED, V164, P1113, DOI 10.1001/archinte.164.10.1113
   Miller PD, 2005, J BONE MINER RES, V20, P1315, DOI 10.1359/JBMR.050313
   MUHLBAUER RC, 1991, J BONE MINER RES, V6, P1003
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003 4819 128 10 199805150 00001
   Papapoulos SE, 2003, INT J CLIN PRACT, V57, P417
   PREAMER A, 1999, MUSCULOSKELETAL COND, P182
   Purcell PM, 2005, MED J AUSTRALIA, V182, P417, DOI 10.5694/j.1326 5377.2005.tb06762.x
   Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   REGINSTER JY, 2005, INTRAVENOUS IBANDRON
   REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002 9343(99)80310 6
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Ringe JD, 2003, OSTEOPOROSIS INT, V14, P801, DOI 10.1007/s00198 003 1425 0
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Sunyecz JA, 2005, J WOMENS HEALTH, V14, P180, DOI 10.1089/jwh.2005.14.180
   Taggart H, 2002, MAYO CLIN PROC, V77, P262, DOI 10.4065/77.3.262
   Vik SA, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471 2474 6 7
   Wasnich RD, 2000, J CLIN ENDOCR METAB, V85, P231, DOI 10.1210/jc.85.1.231
   Watts NB, 2000, OBSTET GYNECOL SURV, V55, pS49, DOI 10.1097/00006254 200012001 00001
   *WHO, 1994, ASS FRACT RISK ITS A
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Zizic TM, 2004, AM FAM PHYSICIAN, V70, P1293
NR 76
TC 3
Z9 3
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029 7828
EI 1533 9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD JUN
PY 2007
VL 62
IS 6
BP 407
EP 416
DI 10.1097/01.ogx.0000266070.47052.52
PG 10
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 174BZ
UT WOS:000246917500004
PM 17511895
DA 2025 08 17
ER

PT J
AU Song, Y
   Jo, S
   Chung, JY
   Oh, Y
   Yoon, S
   Lee, YL
   Kim, SS
   Yang, JH
   Jang, K
   Yang, CS
   Kim, TH
   Kim, YH
AF Song, Yoonsung
   Jo, Sungsin
   Chung, Jee Young
   Oh, Younseo
   Yoon, Subin
   Lee, Young Lim
   Kim, Seong Su
   Yang, Jae Hyuk
   Jang, Kiseok
   Yang, Chul Su
   Kim, Tae Hwan
   Kim, Yong Hee
TI RNA interference mediated suppression of TNF α converting enzyme as an
   alternative anti TNF α therapy for rheumatoid arthritis
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Rheumatoid arthritis; TNF alpha converting enzyme; Gene therapy; Human
   primary synovial cells and osteoclast precursor
ID TUMOR NECROSIS FACTOR; BONE RESORPTION; SYNOVIAL FLUID; GENE DELIVERY;
   CYTOKINES; SERUM; INFLAMMATION; AUTOIMMUNE; OSTEOCLASTOGENESIS;
   DIFFERENTIATION
AB Excessive tumor necrosis factor alpha (TNF alpha) is associated with the pathogenesis of rheumatoid arthritis (RA). Approximately 90% of patients with RA, who have inadequate response to methotrexate, follow anti TNF alpha therapy as the first line immuno treatment. However, ineffective long term anti TNF alpha antibody cycling for 40% of non responders to anti TNF alpha antibodies is costly and associated with various side effects, which needs alternative mechanism of action therapies. In the present study, a novel strategy to down regulate TNF alpha level was developed by using an alternative method of suppressing TNF alpha converting enzyme (TACE), a transmembrane enzyme involved in cleaving and releasing bioactive soluble TNF alpha. TACE suppression can be an effective remedy to block the production of soluble TNF alpha, leading to an increased sensitivity to anti TNF alpha nonresponders. A disease site targeted RNA interference system was developed by forming non viral complex between shRNA against TACE (shTACE) and bone resorption site specific peptide carrier composed of aspartate repeating and arginine repeating sequences. The shTACE/peptide carrier complex alleviated arthritic symptoms in collagen induced arthritis (CIA) models by demonstrating enhanced anti inflammatory and anti osteoclastogenic effects. Similar results were obtained with human primary synovial cells and osteoclast precursor isolated from tissues and synovial fluids of RA patients. Taken together, the shTACE/targeting peptide complex provides a strong potential as an alternative anti TNF alpha therapeutic for RA treatment.
C1 [Song, Yoonsung; Chung, Jee Young; Kim, Seong Su; Kim, Yong Hee] Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Dept Bioengn, Seoul, South Korea.
   [Jo, Sungsin; Oh, Younseo; Yoon, Subin; Lee, Young Lim; Kim, Tae Hwan] Hanyang Univ, Inst Rheumatol Res, Seoul, South Korea.
   [Jo, Sungsin; Oh, Younseo; Yoon, Subin; Lee, Young Lim; Kim, Tae Hwan] Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul, South Korea.
   [Yang, Jae Hyuk] Hanyang Univ, Dept Orthopaed Surg, Guri Hosp, Guri, Gyeonggi Do, South Korea.
   [Jang, Kiseok] Hanyang Univ, Dept Pathol, Coll Med, Seoul, South Korea.
   [Yang, Chul Su] Hanyang Univ, Dept Mol & Life Sci, Ansan, Gyeonggi Do, South Korea.
C3 Hanyang University; Hanyang University; Hanyang University; Hanyang
   University; Hanyang University; Hanyang University
RP Kim, YH (通讯作者)，Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Dept Bioengn, Seoul, South Korea.; Kim, TH (通讯作者)，Hanyang Univ, Inst Rheumatol Res, Seoul, South Korea.
EM thkim@hanyang.ac.kr; yongheekim@hanyang.ac.kr
RI Yang, Chul Su/J 3833 2013; Jo, Sungsin/AAL 3659 2021; Kim,
   Tae Hwan/M 3962 2017
OI Yang, Chul Su/0000 0003 4918 961X; Jo, Sungsin/0000 0003 3034 5029
FU Korean Health Technology R&D Project through the Ministry of Health and
   Welfare [HI17C0888]; National Research Foundation of Korea
   [NRF 2016R1A2B4008606, NRF 2019R1A2C3008992, NRF 2019R1A2C2004214]; Bio
   & Medical Technology Development Program [NRF 2017M3A9F5029655]; Brain
   Korea 21 Plus Program [22A20130011095]
FX We would like to appreciate and Prof. Sang Cheol Bae (Hanyang University
   Hospital for Rheumatic Diseases) for providing the patient's sera with
   RA and Dr. Jinil Han (Gencurix, Korea) for analyzing and presenting GEO
   data. This research was partially supported by grants from the Korean
   Health Technology R&D Project through the Ministry of Health and Welfare
   (HI17C0888), the National Research Foundation of Korea
   (NRF 2016R1A2B4008606, NRF 2019R1A2C3008992, NRF 2019R1A2C2004214), Bio
   & Medical Technology Development Program (NRF 2017M3A9F5029655) and the
   Brain Korea 21 Plus Program (22A20130011095).
CR Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Alves JD, 2011, INT J CLIN PRACT, V65, P508, DOI 10.1111/j.1742 1241.2010.02612.x
   Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P968, DOI 10.1002/art.1780270902
   Catrina AI, 2002, RHEUMATOLOGY, V41, P484, DOI 10.1093/rheumatology/41.5.484
   Chung JY, 2017, MOL PHARMACEUT, V14, P3059, DOI 10.1021/acs.molpharmaceut.7b00282
   Colmegna I, 2012, CLIN PHARMACOL THER, V91, P607, DOI 10.1038/clpt.2011.325
   Colón AL, 2001, CYTOKINE, V16, P220, DOI 10.1006/cyto.2001.0969
   Dixon WG, 2010, ANN RHEUM DIS, V69, P522, DOI 10.1136/ard.2009.118935
   Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252
   Evans CH, 2018, NAT REV RHEUMATOL, V14, P381, DOI 10.1038/s41584 018 0009 5
   Evans CH, 2018, HUM GENE THER, V29, P2, DOI 10.1089/hum.2017.181
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Feng X, 2018, J DRUG TARGET, V26, P845, DOI 10.1080/1061186X.2018.1433680
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Firestein GS, 1999, J CLIN INVEST, V103, P3, DOI 10.1172/JCI5929
   Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473 3099(03)00545 0
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Green MJ, 2003, RHEUMATOLOGY, V42, P83, DOI 10.1093/rheumatology/keg037
   Jo S, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1582 3
   Klatzmann D, 2015, NAT REV IMMUNOL, V15, P283, DOI 10.1038/nri3823
   Kokkonen H, 2010, ARTHRITIS RHEUM US, V62, P383, DOI 10.1002/art.27186
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Leblond A, 2017, AUTOIMMUN REV, V16, P594, DOI 10.1016/j.autrev.2017.04.005
   Lee SJ, 2014, MOL THER, V22, P397, DOI 10.1038/mt.2013.245
   Liu F. L., 2013, TACE DEPENDENT AMPHI, V53, P260
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Moelants EAV, 2013, IMMUNOL CELL BIOL, V91, P393, DOI 10.1038/icb.2013.15
   Moss ML, 2008, NAT CLIN PRACT RHEUM, V4, P300, DOI 10.1038/ncprheum0797
   Moss ML, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9673537
   Nüesch E, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.d1165
   Ohta S, 2001, J RHEUMATOL, V28, P1756
   Patel IR, 1998, J IMMUNOL, V160, P4570
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Saito K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054853
   Song Y, 2016, J CONTROL RELEASE, V239, P231, DOI 10.1016/j.jconrel.2016.08.017
   Sung Y. K., SEMIN ARTHRITIS RHEU, P745
   Tchetverikov I, 2004, ANN RHEUM DIS, V63, P881, DOI 10.1136/ard.2003.013243
   TETTA C, 1990, ANN RHEUM DIS, V49, P665, DOI 10.1136/ard.49.9.665
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Won YW, 2014, NAT MATER, V13, P1157, DOI [10.1038/nmat4092, 10.1038/NMAT4092]
   Yang YH, 2011, P NATL ACAD SCI USA, V108, P12857, DOI 10.1073/pnas.1103569108
   You S, 2014, P NATL ACAD SCI USA, V111, P550, DOI 10.1073/pnas.1311239111
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 52
TC 22
Z9 23
U1 0
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 10
PY 2021
VL 330
BP 1300
EP 1312
DI 10.1016/j.jconrel.2020.11.041
EA FEB 2021
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA QT2ZE
UT WOS:000626459100097
PM 33242532
DA 2025 08 17
ER

PT J
AU Chao, K
   Katznelson, L
AF Chao, Kevin
   Katznelson, Laurence
TI Use of high dose oral bisphosphonate therapy for symptomatic fibrous
   dysplasia of the skull
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE alendronate; bisphosphonate; fibrous dysplasia; palliation; skull
ID INTRAVENOUS PAMIDRONATE; BONE; DISEASE
AB Fibrous dysplasia of the bone in adults is a rare anomaly of skeletal development caused by a defect in differentiation of osteoblasts. This condition is associated with bone pain, bone deformity, and an increased incidence of fracture. Involvement of the skull is associated with headache along with dysmorphic features. Until recently, the principal treatment has been resection or fracture repair, although the latter is often palliative at best. However, new insight into the molecular mechanism of fibrous dysplasia has led to the use of bisphosphonates to treat this disease.
   The authors examined the effects of high dose oral alendronate (40 mg daily) for 6 months on 3 adult patients with intractable headache due to fibrous dysplasia of the skull. Each patient had disease processes not amenable to surgery. The patients underwent clinical follow up at 1, 3, and 6 months. Their pain levels were documented at each visit by using a visual analog scale. All 3 patients demonstrated a significant decrease in pain levels and became independent of scheduled analgesics. Tumor bulk did not progress during this interval in any patient. Overall, alendronate was tolerated well, although in I patient it was discontinued early due to esophagitis. High dose oral bisphosphonate therapy is an alternative therapeutic option for the palliative treatment of patients with fibrous dysplagia of the skull.
C1 [Chao, Kevin; Katznelson, Laurence] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Katznelson, Laurence] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University
RP Katznelson, L (通讯作者)，875 Blake Wilbur Dr, Stanford, CA 94305 USA.
EM LKatznelson@stanford.edu
OI Katznelson, Laurence/0000 0001 8115 5714
CR Chappell NL, 2006, AM J HEALTH PROMOT, V21, P119, DOI 10.4278/0890 1171 21.2.119
   Chapurlat R, 2005, JOINT BONE SPINE, V72, P196, DOI 10.1016/j.jbspin.2004.08.001
   Chapurlat RD, 1997, J BONE MINER RES, V12, P1746, DOI 10.1359/jbmr.1997.12.10.1746
   Chapurlat RD, 2004, BONE, V35, P235, DOI 10.1016/j.bone.2004.03.004
   Colucci S, 1998, CALCIFIED TISSUE INT, V63, P230, DOI 10.1007/s002239900519
   Dolgitser Margarita, 2007, Manag Care Interface, V20, P33
   Dumont A S, 2001, Neurosurg Focus, V10, pE6
   Egner Höbarth S, 2007, ORTHOPADE, V36, P124, DOI 10.1007/s00132 007 1046 y
   Glorieux FH, 2006, J BONE MINER RES, V21, pP110, DOI 10.1359/JBMR.06S221
   Khadilkar V V, 2003, Indian Pediatr, V40, P894
   Kitagawa Y, 2004, J ORTHOP SCI, V9, P521, DOI 10.1007/s00776 004 0809 0
   Kumar S, 2004, Indian Pediatr, V41, P1069
   Lane JM, 2001, CLIN ORTHOP RELAT R, P6
   LIENS D, 1994, LANCET, V343, P953, DOI 10.1016/S0140 6736(94)90069 8
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   Parisi MS, 2003, BONE, V33, P582, DOI 10.1016/S8756 3282(03)00221 7
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Riminucci A, 2003, BONE, V33, P434, DOI 10.1016/S8756 3282(03)00064 4
   Riminucci M, 2006, J BONE MINER RES, V21, pP125, DOI 10.1359/JBMR.06S224
   SCHWARTZ DT, 1964, AM J MED SCI, V247, P1, DOI 10.1097/00000441 196401000 00001
   Stanton RP, 2006, J BONE MINER RES, V21, pP105, DOI 10.1359/JBMR.06S220
   Weinstein LS, 2006, J BONE MINER RES, V21, pP120, DOI 10.1359/JBMR.06S223
   Yamada Nobuko, 2006, Nihon Rinsho, VSuppl 2, P126
NR 23
TC 28
Z9 29
U1 0
U2 1
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022 3085
EI 1933 0693
J9 J NEUROSURG
JI J. Neurosurg.
PD NOV
PY 2008
VL 109
IS 5
BP 889
EP 892
DI 10.3171/JNS/2008/109/11/0889
PG 4
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Surgery
GA 364UY
UT WOS:000260362100014
PM 18976079
DA 2025 08 17
ER

PT J
AU Jiang, JW
   Jia, YW
   Lu, XY
   Zhang, T
   Zhao, KX
   Fu, ZY
   Pang, C
   Qian, Y
AF Jiang, Jiawei
   Jia, Yewei
   Lu, Xuanyuan
   Zhang, Tan
   Zhao, Kangxian
   Fu, Ziyuan
   Pang, Cong
   Qian, Yu
TI Vitexin suppresses RANKL induced osteoclastogenesis and prevents
   lipopolysaccharide (LPS) induced osteolysis
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE MAPK; osteoclast; osteolysis; therapeutics; vitexin
ID NF KAPPA B; RECEPTOR ACTIVATOR; UP REGULATION; BONE LOSS; IN VITRO;
   T CELLS; C FOS; DIFFERENTIATION; FUSION; P38
AB Osteolytic diseases are characterized by an increase in the number and/or activity of bone resorbing osteoclasts. Identification of natural compounds that can suppress osteoclast formation and function is crucial for the prevention and treatment of osteolytic diseases. Vitexin, a naturally derived flavonoid extracted from various medicinal plant species, demonstrates a broad range of pharmacological properties including anticancer and anti inflammatory effects. Here in this study, we showed that vitexin exerts antiosteoclastogenic effects by directly inhibiting receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation and bone resorption in vitro and protected against lipopolysaccharide (LPS) induced inflammatory osteolysis in vivo. Vitexin suppressed the early activation of ERK and p38 MAPK pathways in response to RANKL thereby attenuating the downstream induction of c Fos and NFATc1, and abrogating the expression of osteoclast marker genes. Collectively, these results provide evidence for the therapeutic application of vitexin in the treatment of osteoclast mediated bone lytic diseases.
C1 [Jiang, Jiawei; Jia, Yewei; Fu, Ziyuan; Qian, Yu] Zhejiang Univ, Shaoxing Hosp, Dept Orthopaed, Sch Med, 568 Zhongxing North Rd, Shaoxing 31200, Zhejiang, Peoples R China.
   [Jiang, Jiawei; Jia, Yewei; Lu, Xuanyuan; Zhang, Tan; Zhao, Kangxian; Fu, Ziyuan; Qian, Yu] Shaoxing Peoples Hosp, Dept Orthopaed, Shaoxing, Zhejiang, Peoples R China.
   [Jiang, Jiawei; Jia, Yewei; Fu, Ziyuan] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
   [Pang, Cong] Guangxi Med Univ, Dept Orthopaed, Affiliated Hosp 9, Beihai, Guangxi, Peoples R China.
C3 Zhejiang University; Zhejiang University; Guangxi Medical University
RP Qian, Y (通讯作者)，Zhejiang Univ, Shaoxing Hosp, Dept Orthopaed, Sch Med, 568 Zhongxing North Rd, Shaoxing 31200, Zhejiang, Peoples R China.
EM doctor120@hotmail.com
OI Jia, Yewei/0000 0001 5447 973X
FU Zhejiang Basic Public Welfare Research Project [LGF18H060010]; Projects
   of Medical and Health Technology Development Program in Zhejiang
   Province [2018KY824]; National Natural Science Foundation of China
   [81572126, 81871801]
FX Zhejiang Basic Public Welfare Research Project, Grant/Award Number:
   LGF18H060010; Projects of Medical and Health Technology Development
   Program in Zhejiang Province, Grant/Award Number: 2018KY824; National
   Natural Science Foundation of China, Grant/Award Numbers: No. 81572126,
   81871801
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bhardwaj M, 2015, LIFE SCI, V142, P36, DOI 10.1016/j.lfs.2015.10.012
   Borghi SM, 2013, J NAT PROD, V76, P1141, DOI 10.1021/np400222v
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chaweewannakorn W., JOURNAL OF CELLULAR, V234, P1745
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Fretz JA, 2008, MOL ENDOCRINOL, V22, P737, DOI 10.1210/me.2007 0333
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Rosa SIG, 2016, PHYTOMEDICINE, V23, P9, DOI 10.1016/j.phymed.2015.11.003
   He L., J CELLULAR PHYSL, V234, P4267
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jiang C, 2016, J CELL PHYSIOL, V231, P142, DOI 10.1002/jcp.25065
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li L, 2016, EUR J PHARMACOL, V777, P17, DOI 10.1016/j.ejphar.2016.02.057
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Song FM, 2018, J CELL PHYSIOL, V233, P1723, DOI 10.1002/jcp.26084
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Wei S, 2007, ADV ANAT PATHOL, V14, P42, DOI 10.1097/PAP.0b013e31802ef4f2
   Wiebe S H, 1996, Oral Dis, V2, P167
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yao J, 2015, J CELL PHYSIOL, V230, P1235, DOI 10.1002/jcp.24858
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zaveri TD, 2017, BIOMATERIALS, V115, P128, DOI 10.1016/j.biomaterials.2016.10.038
   Zhou J, 2013, ANTI CANCER DRUG, V24, P928, DOI 10.1097/CAD.0b013e328364e8d3
   Zhou YJ, 2009, CLIN CANCER RES, V15, P5161, DOI 10.1158/1078 0432.CCR 09 0661
   Zhu X, 2016, BIOCHEM PHARMACOL, V104, P118, DOI 10.1016/j.bcp.2016.02.013
NR 44
TC 14
Z9 17
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2019
VL 234
IS 10
BP 17549
EP 17560
DI 10.1002/jcp.28378
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA IH7ML
UT WOS:000474688200068
PM 30793311
DA 2025 08 17
ER

PT J
AU Zheng, H
   Wang, C
   He, JW
   Fu, WZ
   Zhang, ZL
AF Zheng, Hui
   Wang, Chun
   He, Jin Wei
   Fu, Wen Zhen
   Zhang, Zhen Lin
TI OPG, RANKL, and RANK gene polymorphisms and the
   bone mineral density response to alendronate therapy in postmenopausal
   Chinese women with osteoporosis or osteopenia
SO PHARMACOGENETICS AND GENOMICS
LA English
DT Article
ID RECEPTOR ACTIVATOR; CELL GROWTH; ASSOCIATION; BISPHOSPHONATES; PATHWAY;
   OSTEOCLASTOGENESIS; ETIDRONATE; RESORPTION; TNFRSF11A; TURNOVER
C1 [Zheng, Hui; Wang, Chun; He, Jin Wei; Fu, Wen Zhen; Zhang, Zhen Lin] Shanghai Jiao Tong Univ, Peoples Hosp 6, Metab Bone Dis & Genet Res Unit, Dept Osteoporosis & Bone Dis,Shanghai Key Clin Ct, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhang, ZL (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 6, Metab Bone Dis & Genet Res Unit, Dept Osteoporosis & Bone Dis,Shanghai Key Clin Ct, 600 Yi Shan Rd, Shanghai 200233, Peoples R China.
EM zzl2002@medmail.com.cn
RI Abbasi, Taufeeq/KHY 2325 2024; wang, chenchen/B 5838 2015
FU National Basic Research Program of China [2014CB942903]; National
   Natural Science Foundation of China [81070692, 81170803]; Frontier
   Technology Joint Research Program of the Shanghai municipal hospitals
   [SHDC 12013115]; Shanghai Leading Talents Award [051]; Shanghai
   Municipal Commission of Health and Family Planning [2014ZYJB0009];
   Science and Technology Commission of Chongqing municipality [CSTC2013jcy
   jC00009]; National Science and Technology Project [2011zx09307 001 02]
FX The study was supported by the National Basic Research Program of China
   (2014CB942903), the National Natural Science Foundation of China
   (81070692 and 81170803), the Frontier Technology Joint Research Program
   of the Shanghai municipal hospitals (SHDC 12013115), Shanghai Leading
   Talents Award (051), Shanghai Municipal Commission of Health and Family
   Planning (2014ZYJB0009), and the Science and Technology Commission of
   Chongqing municipality (CSTC2013jcy jC00009). The authors thank all the
   participants for their cooperation and the Drug Innovation Program of
   the National Science and Technology Project (2011zx09307 001 02).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bonnick SL, 2006, AM J MED, V119, p25S, DOI 10.1016/j.amjmed.2005.12.020
   Bonnick S, 2006, J CLIN ENDOCR METAB, V91, P2631, DOI 10.1210/jc.2005 2602
   Choi HJ, 2010, YONSEI MED J, V51, P231, DOI 10.3349/ymj.2010.51.2.231
   Crilly RG, 2000, OSTEOPOROSIS INT, V11, P607, DOI 10.1007/s001980070082
   Delmas PD, 2005, CURR OPIN RHEUMATOL, V17, P462
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gallagher JC, 2006, BONE, V39, P1268, DOI 10.1016/j.bone.2006.06.007
   Gao G, 2008, J CLIN DENSITOM, V11, P360, DOI 10.1016/j.jocd.2008.04.005
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hsu YH, 2006, HUM GENET, V118, P568, DOI 10.1007/s00439 005 0062 4
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Ke YH, 2009, ACTA PHARMACOL SIN, V30, P1204, DOI 10.1038/aps.2009.90
   Kim JG, 2007, MENOPAUSE, V14, P913, DOI 10.1097/gme.0b013e31802d976f
   Koh JM, 2007, OSTEOPOROSIS INT, V18, P323, DOI 10.1007/s00198 006 0244 5
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Marini F, 2008, CURR MED RES OPIN, V24, P2609, DOI [10.1185/03007990802352894, 10.1185/03007990802352894 ]
   Marini F, 2012, CURR OSTEOPOROS REP, V10, P221, DOI 10.1007/s11914 012 0110 7
   Nguyen TV, 2000, J BONE MINER RES, V15, P392, DOI 10.1359/jbmr.2000.15.3.392
   POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qureshi AM, 2002, CALCIFIED TISSUE INT, V70, P158, DOI 10.1007/s00223 001 1035 9
   Roshandel D, 2010, J BONE MINER RES, V25, P1830, DOI 10.1002/jbmr.78
   Seeman E, 2006, OSTEOPOROSIS INT, V17, P1577, DOI 10.1007/s00198 006 0160 8
   Styrkarsdottir U, 2008, NEW ENGL J MED, V358, P2355, DOI 10.1056/NEJMoa0801197
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Wang C, 2015, PHARMACOGENOMICS J, V15, P158, DOI 10.1038/tpj.2014.52
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhang ZL, 2005, ACTA PHARMACOL SIN, V26, P1111, DOI 10.1111/j.1745 7254.2005.00173.x
   Zhou PR, 2014, PHARMACOGENOMICS, V15, P821, DOI [10.2217/PGS.14.12, 10.2217/pgs.14.12]
   Zupan J, 2010, J STEROID BIOCHEM, V118, P102, DOI 10.1016/j.jsbmb.2009.10.013
NR 33
TC 18
Z9 19
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1744 6872
EI 1744 6880
J9 PHARMACOGENET GENOM
JI Pharmacogenet. Genomics
PD JAN
PY 2016
VL 26
IS 1
BP 12
EP 19
DI 10.1097/FPC.0000000000000181
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
   & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
   & Pharmacy
GA CY8XD
UT WOS:000366691100002
PM 26426211
DA 2025 08 17
ER

PT J
AU Marino, R
   Orlandi, F
   Arecco, F
   Gandolfo, S
   Pentenero, M
AF Marino, R.
   Orlandi, F.
   Arecco, F.
   Gandolfo, S.
   Pentenero, M.
TI Osteonecrosis of the jaw in a patient receiving cabozantinib
SO AUSTRALIAN DENTAL JOURNAL
LA English
DT Article
DE Antiangiogenic drugs; cabozantinib; medullary thyroid cancer;
   osteonecrosis of the jaw; VEGF inhibition
ID DRUG RELATED OSTEONECROSIS; AVASCULAR NECROSIS; BISPHOSPHONATES; CANCER;
   XL184; RET
AB Since the discovery of bisphosphonate related osteonecrosis of the jaw, there has been increasing evidence in recent years of osteonecrosis induced by drugs other than bisphosphonates, mainly agents with antiangiogenic and antiosteoclastic activity. Mandibular osteonecrosis was observed in a 51 year old female with medullary thyroid cancer receiving cabozantinib, a new tyrosine kinase inhibitor having antiangiogenic activity. The bone necrosis appeared after a dental extraction. The clinical, radiographic and histologic picture of a chronic non healing extraction socket was consistent with drug induced osteonecrosis of the jaw. Healing was achieved by segmental ostectomy. The osteonecrosis was likely associated with a vascular endothelial growth factor (VEGF) pathway inhibition, implying inhibition of angiogenesis and hampering of the local host defence mechanisms.
C1 [Marino, R.; Gandolfo, S.; Pentenero, M.] Univ Turin, Dept Oncol, Oral Med & Oral Oncol Unit, I 10124 Turin, Italy.
   [Orlandi, F.; Arecco, F.] Univ Turin, Dept Oncol, Endocrine Unit, I 10124 Turin, Italy.
C3 University of Turin; University of Turin
RP Gandolfo, S (通讯作者)，Dipartimento Oncol, Regione Gonzole 10, I 10043 Orbassano, TO, Italy.
EM sergio.gandolfo@unito.it
RI Gandolfo, Saviana/JTU 7271 2023; Pentenero, Monica/F 8797 2013
OI Pentenero, Monica/0000 0003 3972 1203
CR Bentzien F, 2013, THYROID, V23, P1569, DOI 10.1089/thy.2013.0137
   Carter GD, 2003, AUST DENT J, V48, P268
   Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659
   Haraldsdottir S, 2014, CURR OPIN ONCOL, V26, P36, DOI 10.1097/CCO.0000000000000029
   Hart CD, 2013, ONCOTARGETS THER, V6, P1, DOI 10.2147/OTT.S27671
   Lee SH, 2014, SUPPORT CARE CANCER, V22, P553, DOI 10.1007/s00520 013 2017 y
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mehrotra Bhoomi, 2006, Hematology Am Soc Hematol Educ Program, P356
   Mignogna MD, 2012, OR SURG OR MED OR PA, V113, P704, DOI 10.1016/j.oooo.2012.01.004
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Samadi AK, 2012, SURGERY, V152, P1238, DOI 10.1016/j.surg.2012.08.031
   Sivolella S, 2013, ANTICANCER RES, V33, P1793
   Traynor K, 2013, AM J HEALTH SYST PH, V70, P88, DOI 10.2146/news130005
   Troeltzsch M, 2012, J CAN DENT ASSOC, V78
   Viola D, 2013, FUTURE ONCOL, V9, P1083, DOI [10.2217/FON.13.128, 10.2217/fon.13.128]
   Yarom N, 2010, ORAL ONCOL, V46, pE1, DOI 10.1016/j.oraloncology.2009.10.004
NR 16
TC 37
Z9 39
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0045 0421
EI 1834 7819
J9 AUST DENT J
JI Aust. Dent. J.
PD DEC
PY 2015
VL 60
IS 4
BP 528
EP 531
DI 10.1111/adj.12254
PG 4
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA DA3JC
UT WOS:000367692000016
PM 25474298
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Lee, NJ
   Herzog, H
AF Lee, Nicola J.
   Herzog, Herbert
TI NPY regulation of bone remodelling
SO NEUROPEPTIDES
LA English
DT Article
ID ACTIVATED PROTEIN KINASE; NEUROPEPTIDE Y; PEPTIDE YY; IMMUNOREACTIVE
   NERVES; TYROSINE HYDROXYLASE; CYCLIC AMP; BETA CELL; RECEPTOR; MASS;
   EXPRESSION
AB Neuropeptide Y (NPY), a classic neuronal regulator of energy homeostasis, is now also known to be involved in the control of bone homeostasis. Of the five known Y receptors through which the NPY family of ligands signals, the Y1 and Y2 receptors have so far been implicated in the control of osteoblast activity and thus bone formation. Analysis of brain specific NPY overexpressing and Y receptor knockout models has revealed a powerful anabolic pathway likely involving hypothalamic Y2 receptors and osteoblastic Y1 receptors. Furthering our understanding of the mechanisms underlying the involvement of the NPY system in the control of bone could lead to the development of therapies to improve bone mass in patients with diseases such as osteoporosis. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Lee, Nicola J.; Herzog, Herbert] St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, Sydney, NSW 2010, Australia.
   [Herzog, Herbert] Univ New S Wales, Fac Med, Sydney, NSW, Australia.
C3 Garvan Institute of Medical Research; NSW Health; St Vincents Hospital
   Sydney; University of New South Wales Sydney
RP Herzog, H (通讯作者)，St Vincents Hosp, Garvan Inst Med Res, Neurosci Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.
EM h.herzog@garvan.org.au
RI Herzog, Herbert/B 8294 2008; Lee, Nicola/B 2038 2013
OI Herzog, Herbert/0000 0002 1713 1029; Lee, Nicola/0000 0001 7766 6095
CR AHMED M, 1993, SPINE, V18, P268, DOI 10.1097/00007632 199302000 00016
   Ahn JD, 2006, ENDOCRINOLOGY, V147, P3196, DOI 10.1210/en.2006 0281
   ALLISON S, 2008, J BONE MINER RES
   Allison SJ, 2006, J BIOL CHEM, V281, P23436, DOI 10.1074/jbc.M604839200
   Amano S, 2007, BBA GEN SUBJECTS, V1770, P966, DOI 10.1016/j.bbagen.2007.02.009
   Baldock PA, 2005, J BONE MINER RES, V20, P1851, DOI 10.1359/JBMR.050523
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200
   Baldock PA, 2006, J BONE MINER RES, V21, P1600, DOI 10.1359/JBMR.060705
   Baron R., 1999, PRIMER METABOLIC BON, P3
   BJURHOLM A, 1992, J BONE MINER RES, V7, P1011
   BJURHOLM A, 1988, ACTA PHYSIOL SCAND, V134, P451, DOI 10.1111/j.1748 1716.1988.tb08515.x
   BJURHOLM A, 1988, J AUTONOM NERV SYST, V25, P119, DOI 10.1016/0165 1838(88)90016 1
   Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166 2236(96)01057 0
   Cerdá Reverter JM, 2000, BIOCHEM CELL BIOL, V78, P371, DOI 10.1139/bcb 78 3 371
   Cho YR, 2004, BIOCHEM BIOPH RES CO, V314, P773, DOI 10.1016/j.bbrc.2003.12.170
   Cornish J, 1998, AM J PHYSIOL ENDOC M, V275, pE694, DOI 10.1152/ajpendo.1998.275.4.E694
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Duong L T, 2001, Rev Endocr Metab Disord, V2, P95, DOI 10.1023/A:1010063225902
   EKBLAD E, 1984, REGUL PEPTIDES, V8, P225, DOI 10.1016/0167 0115(84)90064 8
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Gehlert DR, 2004, NEUROPEPTIDES, V38, P135, DOI 10.1016/j.npep.2004.07.002
   GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758
   Gordeladze JO, 2003, J CELL BIOCHEM, V88, P706, DOI 10.1002/jcb.10385
   Gregor P, 1996, J BIOL CHEM, V271, P27776, DOI 10.1074/jbc.271.44.27776
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Henriksen DB, 2003, J BONE MINER RES, V18, P2180, DOI 10.1359/jbmr.2003.18.12.2180
   Herzog H, 1997, GENOMICS, V41, P315, DOI 10.1006/geno.1997.4684
   HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794
   HILL EL, 1991, CELL TISSUE RES, V264, P469, DOI 10.1007/BF00319037
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Ishizuka K, 2005, NEUROSCI LETT, V379, P47, DOI 10.1016/j.neulet.2004.12.046
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Keffel S, 1999, J PHARMACOL EXP THER, V291, P1172
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993
   Kuo LE, 2007, NAT MED, V13, P803, DOI 10.1038/nm1611
   LARHAMMAR D, 1993, COMP BIOCHEM PHYS C, V106, P743, DOI 10.1016/0742 8413(93)90236 E
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P477, DOI 10.1111/j.1748 1716.1982.tb07171.x
   LUNDBERG JM, 1985, BIOCHEM BIOPH RES CO, V133, P30, DOI 10.1016/0006 291X(85)91837 6
   Lundberg P, 2002, MICROSC RES TECHNIQ, V58, P98, DOI 10.1002/jemt.10124
   Lundberg P, 2007, J BIOL CHEM, V282, P19082, DOI 10.1074/jbc.M609629200
   Mackie K, 2008, MOL CELL ENDOCRINOL, V286, pS60, DOI 10.1016/j.mce.2008.01.022
   Mannon PJ, 2000, BIOCHEM J, V350, P655, DOI 10.1042/0264 6021:3500655
   Marks S., 2002, PRINCIPLES BONE BIOL, VSecond, P3, DOI DOI 10.1016/B978 012098652 1.50103 7
   Matsumoto M, 1996, J BIOL CHEM, V271, P27217, DOI 10.1074/jbc.271.44.27217
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Misra M, 2006, J CLIN ENDOCR METAB, V91, P1027, DOI 10.1210/jc.2005 1878
   Mori T, 1999, BIOCHEM BIOPH RES CO, V262, P418, DOI 10.1006/bbrc.1999.1220
   MOTULSKY HJ, 1988, AM J PHYSIOL, V255, pE880, DOI 10.1152/ajpendo.1988.255.6.E880
   Mundy G.R., 1999, PRIMER METABOLIC BON, P30, DOI DOI 10.1080/10255840802136150
   NAKAMURA M, 1995, J BIOL CHEM, V270, P30102, DOI 10.1074/jbc.270.50.30102
   Nie M, 1998, REGUL PEPTIDES, V75 6, P207, DOI 10.1016/S0167 0115(98)00070 6
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Rodan GA, 2003, CANCER, V97, P726, DOI 10.1002/cncr.11147
   Sainsbury A, 2003, MOL CELL BIOL, V23, P5225, DOI 10.1128/MCB.23.15.5225 5233.2003
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Sato S, 2007, NAT MED, V13, P1234, DOI 10.1038/nm1640
   Shih C, 1997, CLIN ORTHOP RELAT R, P335
   Sisask G, 1996, J AUTONOM NERV SYST, V59, P27, DOI 10.1016/0165 1838(95)00139 5
   Tabarowski Z, 1996, ACTA HISTOCHEM, V98, P453, DOI 10.1016/S0065 1281(96)80013 4
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435
   TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0
   TATEMOTO K, 1982, P NATL ACAD SCI BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485
   TEIXEIRA L, 2009, J CELL BIOCH
   Utz AL, 2008, BONE, V43, P135, DOI 10.1016/j.bone.2008.03.007
   van der Velde M, 2008, VITAM HORM, V77, P239, DOI 10.1016/S0083 6729(06)77010 8
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   Weinberg DH, 1996, J BIOL CHEM, V271, P16435, DOI 10.1074/jbc.271.28.16435
   Wortley KE, 2007, GASTROENTEROLOGY, V133, P1534, DOI 10.1053/j.gastro.2007.08.024
   XIONG ZG, 1995, PFLUG ARCH EUR J PHY, V431, P110, DOI 10.1007/BF00374383
   Yang KP, 2008, FASEB J, V22, P2452, DOI 10.1096/fj.07 100735
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 77
TC 66
Z9 89
U1 0
U2 11
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0143 4179
EI 1532 2785
J9 NEUROPEPTIDES
JI Neuropeptides
PD DEC
PY 2009
VL 43
IS 6
BP 457
EP 463
DI 10.1016/j.npep.2009.08.006
PG 7
WC Endocrinology & Metabolism; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 531KE
UT WOS:000272664000001
PM 19748118
DA 2025 08 17
ER

PT J
AU Vuong, T
   Peters, M
   Merrifield, A
   Firipis, M
   Belcher, J
   Elgebaly, Z
AF Vuong, Thu
   Peters, Matthew
   Merrifield, Alistair
   Firipis, Marnie
   Belcher, Josephine
   Elgebaly, Zain
TI Investigating the impact of a national educational program on patient
   adherence to osteoporosis medications
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE NPS MedicineWise osteoporosis program; Bisphosphonates; Denosumab
ID PERSISTENCE
AB Interrupted time series analysis (ITS) measured improvements in osteoporosis medication adherence after a national education program. The proportion of patients who were adherent to treatment increased following the program.IntroductionThe NPS MedicineWise osteoporosis program, implemented nationally in 2015 2016 in Australia, sought to improve adherence to osteoporosis medicines using evidence based multifaceted large scale educational interventions targeting general practitioners.MethodsWe undertook a retrospective, observational study using ITS analysis from 1 December 2011 to 31 December 2019 using a 10% sample of Pharmaceutical Benefits Scheme (PBS) dispensing data for 71,093 patients & GE; 45 years. The adherence measure was the percentage of patients with a proportion of days covered (PDC) & GE; 80%.ResultsThe program significantly increased adherence to osteoporosis medicines. After 12 months, the estimated adherence rate with the program was 48.4% (95% CI, 47.4 49.4%). Without the program, adherence would have fallen to 43.5% (95% CI, 42.5 44.5%). There was a further increase in adherence by the end of the study period (44 months after the program). Among patients prescribed denosumab only, despite a significant increase in adherence following the program, adherence rates were overall sub optimal (65.0% 12 months following the program).ConclusionsThe NPS MedicineWise osteoporosis program significantly increased osteoporosis medicine adherence. The program changed primary care prescriber behavior and improved treatment adherence. However, some patients had a period of treatment discontinuation, placing them at increased risk of fracture. A focused program emphasizing the importance of long term adherence with denosumab (including switching to bisphosphonates if treatment is discontinued) may be warranted to further improve the quality use of osteoporosis treatment in Australia.
C1 [Vuong, Thu; Peters, Matthew; Merrifield, Alistair; Firipis, Marnie; Belcher, Josephine; Elgebaly, Zain] NPS Med Wise, Level 7, 418A Elizabeth St, Surry Hills, NSW 2010, Australia.
RP Vuong, T (通讯作者)，NPS Med Wise, Level 7, 418A Elizabeth St, Surry Hills, NSW 2010, Australia.
EM huongthuhanoi@gmail.com
CR [Anonymous], 2015, J BRASILEIRO EC SA D
   [Anonymous], Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age
   Arnet I, 2014, INT J CLIN PHARM NET, V36, P192, DOI 10.1007/s11096 013 9891 8
   Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098
   Bijlsma MJ, 2016, PHARMACOEPIDEM DR S, V25, P325, DOI 10.1002/pds.3935
   Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524 4733.2007.00213.x
   Endocrinology Expert Group, 2014, THER GUID END VERS 5
   Fuksa L, 2015, CURR MED RES OPIN, V31, P1645, DOI 10.1185/03007995.2015.1065241
   Hiligsmann M, 2019, OSTEOPOROSIS INT, V30, P2155, DOI 10.1007/s00198 019 05104 5
   Hudson J, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874 019 0777 x
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Khosla S, 2017, J BONE MINER RES, V32, P424, DOI 10.1002/jbmr.3074
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   Lindsay BR, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657 016 0272 5
   Mellish Leigh, 2015, BMC Res Notes, V8, P634, DOI 10.1186/s13104 015 1616 8
   Naik Panvelkar P, 2020, BMC FAM PRACT, V21, DOI 10.1186/s12875 020 01103 2
   Nau DP, 2012, SPRINGFIELD VA PHARM, V6, P25
   Netelenbos JC, 2011, OSTEOPOROSIS INT, V22, P1537, DOI 10.1007/s00198 010 1372 5
   NPS MedicineWise, 2015, BON HLTH ACT PLAN US
   Pearson SA, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph182413345
   Pearson SA, 2015, PHARMACOEPIDEM DR S, V24, P447, DOI 10.1002/pds.3756
   Reginster JY., 2022, PATHYS PRINC PRACT G, V2, P972
   Sambrook Philip, 2006, Aust Fam Physician, V35, P135
   SAS Institute Inc, 2017, SASETS US GUID VERS
   Seeman E, 2007, OSTEOPOROSIS INT, V18, P711, DOI 10.1007/s00198 006 0294 8
   Seibel MJ, 2011, MED J AUSTRALIA, V195, P566, DOI 10.5694/mja11.11201
   Swart KMA, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875 018 0828 0
   Weekes LM, 2005, BRIT J CLIN PHARMACO, V59, P112, DOI 10.1111/j.1365 2125.2005.02231.x
   Weisenthal B, 2018, SEMINARS SPINE SURG
   Yeam CT, 2018, OSTEOPOROSIS INT, V29, P2623, DOI 10.1007/s00198 018 4759 3
NR 30
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD JUL 5
PY 2023
VL 18
IS 1
AR 90
DI 10.1007/s11657 023 01301 2
PG 10
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA L4IS0
UT WOS:001022917600001
PM 37405619
DA 2025 08 17
ER

PT J
AU Schmeel, LC
   Schmeel, FC
   Schmidt Wolf, IGH
AF Schmeel, Leonard Christopher
   Schmeel, Frederic Carsten
   Schmidt Wolf, Ingo G. H.
TI In Vitro Apoptosis Induction by Fenofibrate in Lymphoma and
   Multiple Myeloma
SO ANTICANCER RESEARCH
LA English
DT Article
DE Fenofibrate; apoptosis; multiple myeloma; lymphoma; therapy; Wnt
   signaling
ID WNT/BETA CATENIN PATHWAY; STEM CELL TRANSPLANTATION; BI FUNCTIONAL
   PEPTIDE; KILLER CIK CELLS; ETHACRYNIC ACID; WNT INHIBITORS; VIVO
   EFFICACY; BONE MARROW; GLIOBLASTOMA CELLS; CANCER
AB Background/Aim: Recent innovations in the treatment of multiple myeloma have enriched our therapeutic repertoire regarding the treatment of multiple myeloma during the last decades. However, despite today's therapies many multiple myeloma (MM) patients experience relapse of disease and eventually remain incurable. Wnt/beta catenin signaling has been demonstrated in lymphoma and MM, rendering related signaling molecules promising therapeutic targets. Fenofibrate, an extensively scrutinized and widely used drug for primary hypercholesterolemia or mixed dyslipidemia, has proven anticarcinogenic properties mediated by peroxisome proliferator activated receptor alpha (PPAR alpha) agonism, thereby also influencing WNT associated signaling molecules. Materials and Methods: The antitumor apoptotic effect of fenofibrate at doses ranging from 0.1 200 mu M was investigated on a total of seven human, two murine myeloma/lymphoma cell lines and two healthy control cell lines, as determined by 3'3 Dihexyloxacarbocyanine iodide (DiOC6) and propidium iodide (PI) staining in flow cytometry. Results: Fenofibrate significantly reduced viability due to apoptosis induction in all investigated myeloma and lymphoma cell lines in a dose dependent manner, whereas healthy control cells were less sensitive. Conclusion: Our results provide a rationale for future in vitro and in vivo studies with fenofibrate as a safe and well tolerated agent in MM and lymphoma treatment.
C1 [Schmeel, Leonard Christopher; Schmeel, Frederic Carsten] Univ Hosp Bonn, Dept Radiol & Radiat Oncol, Bonn, Germany.
   [Schmeel, Leonard Christopher; Schmeel, Frederic Carsten; Schmidt Wolf, Ingo G. H.] Univ Hosp Bonn, CIO, Med Clin & Policlin 3, Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Schmidt Wolf, IGH (通讯作者)，Univ Hosp Bonn, CIO, Sigmund Freud Str 25, D 53105 Bonn, Germany.
EM Ingo.Schmidt Wolf@ukbonn.de
OI Schmeel, Christopher/0000 0002 3901 4122; Schmeel,
   Frederic/0000 0003 0985 1517
CR Bringhen S, 2006, EXPERT OPIN INV DRUG, V15, P1565, DOI 10.1517/13543784.15.12.1565
   Butrym A, 2015, LEUKEMIA RES, V39, P1462, DOI 10.1016/j.leukres.2015.10.007
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Dutta Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood 2008 12 194290
   Fowler JA, 2012, CANCER RES, V72, P2183, DOI 10.1158/0008 5472.CAN 11 2067
   Gooding S, 2016, CURR OPIN PHARMACOL, V28, P43, DOI 10.1016/j.coph.2016.02.013
   Han DF, 2015, ONCOTARGET, V6, P26119, DOI 10.18632/oncotarget.4444
   Harousseau JL, 2009, NEW ENGL J MED, V360, P2645, DOI 10.1056/NEJMct0805626
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Howlader N., Natl Cancer Inst
   Kamihara Y, 2016, ONCOTARGET, V7, P64330, DOI 10.18632/oncotarget.11830
   Kim Y, 2012, LEUKEMIA RES, V36, P598, DOI 10.1016/j.leukres.2012.01.025
   Kim Y, 2011, IN VIVO, V25, P887
   Kim Y, 2011, ANTICANCER RES, V31, P725
   Kim Y, 2011, IN VIVO, V25, P99
   Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359
   Koller CM, 2013, ANTICANCER RES, V33, P2435
   Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746
   Li T, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 96
   Lu DS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008294
   Messina CS, 2017, ANTICANCER RES, V37, P555, DOI 10.21873/anticanres.11348
   Moreau P, 2006, BLOOD, V107, P397, DOI 10.1182/blood 2005 06 2573
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Panigrahy D, 2008, P NATL ACAD SCI USA, V105, P985, DOI 10.1073/pnas.0711281105
   Rades D, 2016, ANTICANCER RES, V36, P375
   ROBERTS WC, 1989, CARDIOLOGY, V76, P169, DOI 10.1159/000174488
   Rosiñol L, 2008, BLOOD, V112, P3591, DOI 10.1182/blood 2008 02 141598
   Schmeel FC, 2014, INT J MOL SCI, V15, P14632, DOI 10.3390/ijms150814632
   Schmeel FC, 2014, HEMATOL ONCOL, V32, P197, DOI 10.1002/hon.2122
   Schmeel LC, 2017, ANTICANCER RES, V37, P2289, DOI 10.21873/anticanres.11566
   Schmeel LC, 2016, ANTICANCER RES, V36, P3395
   Schmeel LC, 2015, ANTICANCER RES, V35, P5921
   Schmeel LC, 2015, J CANCER RES CLIN, V141, P839, DOI 10.1007/s00432 014 1864 3
   Schmeel LC, 2015, ANTICANCER RES, V35, P1369
   Schmeel LC, 2015, ANTICANCER RES, V35, P835
   Schmeel LC, 2013, ANTICANCER RES, V33, P4719
   Schmidt M, 2011, IN VIVO, V25, P325
   Schmidt M, 2009, BRIT J HAEMATOL, V144, P796, DOI 10.1111/j.1365 2141.2008.07503.x
   Su N, 2016, ONCOL LETT, V12, P4623, DOI 10.3892/ol.2016.5289
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   van Andel H, 2017, ONCOGENE, V36, P2105, DOI 10.1038/onc.2016.368
   van Andel H, 2017, P NATL ACAD SCI USA, V114, P376, DOI 10.1073/pnas.1618650114
   Von Schulz Hausmann SA, 2014, ANTICANCER RES, V34, P4101
   Wall I, 2014, ANTICANCER RES, V34, P5375
   Wilk A, 2012, CELL CYCLE, V11, P2660, DOI 10.4161/cc.21015
   Yamasaki D, 2011, EUR J CELL BIOL, V90, P657, DOI 10.1016/j.ejcb.2011.02.005
   Yang LPH, 2009, AM J CARDIOVASC DRUG, V9, P401, DOI 10.2165/11203920 000000000 00000
   Zak Z, 2010, LEUKEMIA, V24, P1476, DOI 10.1038/leu.2010.117
NR 50
TC 14
Z9 14
U1 0
U2 6
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUL
PY 2017
VL 37
IS 7
BP 3513
EP 3520
DI 10.21873/anticanres.11719
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FJ2OV
UT WOS:000412569900018
PM 28668840
OA Bronze
DA 2025 08 17
ER

PT J
AU Kanagawa, H
   Masuyama, R
   Morita, M
   Sato, Y
   Niki, Y
   Kobayashi, T
   Katsuyama, E
   Fujie, A
   Hao, W
   Tando, T
   Watanabe, R
   Miyamoto, K
   Morioka, H
   Matsumoto, M
   Toyama, Y
   Saya, H
   Miyamoto, T
AF Kanagawa, Hiroya
   Masuyama, Ritsuko
   Morita, Mayu
   Sato, Yuiko
   Niki, Yasuo
   Kobayashi, Tami
   Katsuyama, Eri
   Fujie, Atsuhiro
   Hao, Wu
   Tando, Toshimi
   Watanabe, Ryuichi
   Miyamoto, Kana
   Morioka, Hideo
   Matsumoto, Morio
   Toyama, Yoshiaki
   Saya, Hideyuki
   Miyamoto, Takeshi
TI Methotrexate inhibits osteoclastogenesis by decreasing RANKL induced
   calcium influx into osteoclast progenitors
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Methotrexate; Osteoclast; Differentiation; Calcium influx
ID BONE; CLODRONATE; RATS
AB The increasing number of osteoporosis patients is a pressing issue worldwide. Osteoporosis frequently causes fragility fractures, limiting activities of daily life and increasing mortality. Many osteoporosis patients take numerous medicines due to other health issues; thus, it would be preferable if a single medicine could ameliorate osteoporosis and other conditions. Here, we screened 96 randomly selected drugs targeting various diseases for their ability to inhibit differentiation of osteoclasts, which play a pivotal role in development of osteoporosis, and identified methotrexate (MTX), as a potential inhibitor. MTX is currently used to treat sarcomas or leukemic malignancies or auto inflammatory diseases such as rheumatoid arthritis (RA) through its anti proliferative and immunosuppressive activities; however, a direct effect on osteoclast differentiation has not been shown. Here, we report that osteoclast formation and expression of osteoclastic genes such as NFATc1 and DC STAMP, which are induced by the cytokine RANKL, are significantly inhibited by MTX. We found that RANKL dependent calcium (Ca) influx into osteoclast progenitors was significantly inhibited by MTX. RA patients often develop osteoporosis, and osteoclasts are reportedly required for joint destruction; thus, MTX treatment could have a beneficial effect on RA patients exhibiting high osteoclast activity by preventing both osteoporosis and joint destruction.
C1 [Kanagawa, Hiroya; Sato, Yuiko; Niki, Yasuo; Kobayashi, Tami; Katsuyama, Eri; Fujie, Atsuhiro; Hao, Wu; Tando, Toshimi; Watanabe, Ryuichi; Miyamoto, Kana; Morioka, Hideo; Matsumoto, Morio; Toyama, Yoshiaki; Miyamoto, Takeshi] Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Masuyama, Ritsuko] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, Nagasaki 8528588, Japan.
   [Sato, Yuiko] Keio Univ, Sch Med, Dept Musculoskeletal Reconstruct & Regenerat Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Morita, Mayu] Keio Univ, Sch Med, Dept Dent & Oral Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Saya, Hideyuki] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Miyamoto, Takeshi] Keio Univ, Sch Med, Dept Integrated Bone Metab & Immunol, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
C3 Keio University; Nagasaki University; Keio University; Keio University;
   Keio University; Keio University
RP Miyamoto, T (通讯作者)，Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.; Miyamoto, T (通讯作者)，Keio Univ, Sch Med, Dept Integrated Bone Metab & Immunol, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
EM miyamoto@z5.keio.jp
RI Saya, Hideyuki/J 4325 2013; hao, wu/HDM 1705 2022; Toyama,
   Yoshiaki/K 5743 2013
OI NIKI, YASUO/0000 0002 0197 5171; Saya, Hideyuki/0000 0001 6610 1902;
   Morita, Mayu/0009 0003 8092 0762
CR Aeberli D, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4180
   BLEYER WA, 1978, CANCER AM CANCER SOC, V41, P36, DOI 10.1002/1097 0142(197801)41:1<36::AID CNCR2820410108>3.0.CO;2 I
   Charles JF, 2012, J CLIN INVEST, V122, P4592, DOI 10.1172/JCI60920
   Cope Andrew P, 2008, Arthritis Res Ther, V10 Suppl 1, pS1, DOI 10.1186/ar2412
   Deodhar AA, 1996, BRIT J RHEUMATOL, V35, P309
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Hanayam R, 2009, INT J MOL MED, V23, P581, DOI 10.3892/ijmm_00000167
   JAFFE N, 1973, CANCER AM CANCER SOC, V31, P1367, DOI 10.1002/1097 0142(197306)31:6<1367::AID CNCR2820310611>3.0.CO;2 6
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   King TJ, 2012, AM J PATHOL, V181, P121, DOI 10.1016/j.ajpath.2012.03.037
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   KREMER JM, 1986, ARTHRITIS RHEUM US, V29, P822, DOI 10.1002/art.1780290702
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Masuyama R, 2012, J BONE MINER RES, V27, P1708, DOI 10.1002/jbmr.1629
   Mediero A, 2014, ARTHRITIS R IN PRESS
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Noh ALSM, 2011, LIFE SCI, V89, P159, DOI 10.1016/j.lfs.2011.05.009
   Oliver SJ, 2007, J RHEUMATOL, V34, P1802
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 25
TC 35
Z9 37
U1 0
U2 8
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD SEP
PY 2016
VL 34
IS 5
BP 526
EP 531
DI 10.1007/s00774 015 0702 2
PG 6
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA DV5AQ
UT WOS:000382938200005
PM 26202855
DA 2025 08 17
ER

PT J
AU Suominen, MI
   Fagerlund, KM
   Rissanen, JP
   Konkol, YM
   Morko, JP
   Peng, ZQ
   Alhoniemi, EJ
   Laine, SK
   Corey, E
   Mumberg, D
   Ziegelbauer, K
   Käkönen, SM
   Halleen, JM
   Vessella, RL
   Scholz, A
AF Suominen, Mari I.
   Fagerlund, Katja M.
   Rissanen, Jukka P.
   Konkol, Yvonne M.
   Morko, Jukka P.
   Peng, Zhiqi
   Alhoniemi, Esa J.
   Laine, Salla K.
   Corey, Eva
   Mumberg, Dominik
   Ziegelbauer, Karl
   Kakonen, Sanna Maria
   Halleen, Jussi M.
   Vessella, Robert L.
   Scholz, Arne
TI Radium 223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of
   Cancer Cells and Bone Microenvironment in Mouse Models
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID SKELETAL RELATED EVENTS; QUALITY OF LIFE; DOUBLE BLIND; ABIRATERONE
   ACETATE; SURVIVAL ANALYSIS; ZOLEDRONIC ACID; PLUS PREDNISONE;
   SIPULEUCEL T; OPEN LABEL; PLACEBO
AB Purpose: Radium 223 dichloride (radium 223, Xofigo), a targeted alpha therapy, is currently used for the treatment of patients with castration resistant prostate cancer (CRPC) with bone metastases. This study examines the mode of action and antitumor efficacy of radium 223 in two prostate cancer xenograft models.
   Experimental Design: Mice bearing intratibial LNCaP or LuCaP 58 tumors were randomized into groups (n = 12 17) based on lesion grade and/or serum PSA level and administered radium 223 (300 kBq/kg) or vehicle, twice at 4 week intervals. X rays and serum samples were obtained biweekly. Soft tissue tumors were observed macroscopically at sacrifice. Tibiae were analyzed by gamma counter, micro CT, autoradiography and histology.
   Results: Radium 223 inhibited tumor induced osteoblastic bone growth and protected normal bone architecture, leading to reduced bone volume in LNCaP and abiraterone resistant LuCaP 58 models. Furthermore, radium 223 resulted in lower PSA values and reduced total tissue and tumor areas, indicating that treatment constrains prostate cancer growth in bone. In addition, radium 223 suppressed abnormal bone metabolic activity as evidenced by decreased number of osteoblasts and osteoclasts and reduced level of the bone formation marker PINP. Mode of action studies revealed that radium 223 was deposited in the intratumoral bone matrix. DNA double strand breaks were induced in cancer cells within 24 hours after radium 223 treatment, and PSA levels were significantly lower 72 hours after treatment, providing further evidence of the antitumor effects.
   Conclusions: Taken together, radium 223 therapy exhibits a dual targeting mode of action that induces tumor cell death and suppresses tumor induced pathologic bone formation in tumor microenvironment of osseous CRPC growth in mice. (C) 2017 AACR.
C1 [Suominen, Mari I.; Fagerlund, Katja M.; Rissanen, Jukka P.; Konkol, Yvonne M.; Morko, Jukka P.; Peng, Zhiqi; Halleen, Jussi M.] Pharmatest Serv Ltd, Turku, Finland.
   [Alhoniemi, Esa J.] Avoltus Oy, Turku, Finland.
   [Laine, Salla K.; Kakonen, Sanna Maria] Aurexel Life Sci Ltd, Askainen, Finland.
   [Corey, Eva; Vessella, Robert L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
   [Mumberg, Dominik; Ziegelbauer, Karl; Scholz, Arne] Bayer AG, Div Pharmaceut, Drug Discovery, Therapeut Res Grp Oncol, Berlin, Germany.
   [Konkol, Yvonne M.; Kakonen, Sanna Maria] Univ Turku, Dept Cell Biol & Anat, Turku, Finland.
C3 Pharmatest Services; University of Washington; University of Washington
   Seattle; Bayer AG; University of Turku
RP Scholz, A (通讯作者)，Bayer AG, Mullerstr 178, D 13353 Berlin, Germany.
EM arne.scholz@bayer.com
RI ; Suominen, Mari/KHZ 4938 2024; Peng, zhiqi/GYU 3982 2022
OI Suominen, Mari/0000 0002 8760 6595; Kakonen,
   Sanna Maria/0000 0001 9393 6235; 
FU National Institutes of Health [NIHPO1 CA085859, NIHPO1 CA163227]; Bayer
   AG
FX The establishment of the LuCaP 58 PDX was supported by grants from the
   National Institutes of Health (to E. Corey, National Institutes of
   Health, NIHPO1 CA085859 and NIHPO1 CA163227). Bayer AG has paid
   Pharmatest Services Ltd. for the execution of the experiments. Editorial
   support was funded by Bayer AG.
CR Abou DS, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djv380
   Broder MS, 2015, SUPPORT CARE CANCER, V23, P237, DOI 10.1007/s00520 014 2437 3
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Clézardin P, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2835
   Corey E, 2002, PROSTATE, V52, P20, DOI 10.1002/pros.10091
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   De Vincentis G, 2016, CLIN GENITOURIN CANC, V14, pE529, DOI 10.1016/j.clgc.2016.04.014
   Fizazi K, 2014, LANCET ONCOL, V15, P1147, DOI 10.1016/S1470 2045(14)70303 1
   Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470 2045(12)70379 0
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Higano CS, 2009, CANCER AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429
   Hoskin P, 2014, LANCET ONCOL, V15, P1397, DOI 10.1016/S1470 2045(14)70474 7
   Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425
   Iuliani M, 2015, ONCOTARGET, V6, P12520, DOI 10.18632/oncotarget.3724
   Jayasekera J, 2014, PHARMACOECONOMICS, V32, P173, DOI 10.1007/s40273 013 0121 y
   Logothetis CJ, 2012, LANCET ONCOL, V13, P1210, DOI 10.1016/S1470 2045(12)70473 4
   Loriot Y, 2015, LANCET ONCOL, V16, P509, DOI 10.1016/S1470 2045(15)70113 0
   Malamas AS, 2016, ONCOTARGET, V7, P86937, DOI 10.18632/oncotarget.13520
   McNamara MA, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1390 y
   Nilsson S, 2013, CLIN GENITOURIN CANC, V11, P20, DOI 10.1016/j.clgc.2012.07.002
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Parker C, 2016, EUR UROL, V70, P875, DOI 10.1016/j.eururo.2016.06.002
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Pinheiro J, R CORE TEAM NLME LIN
   Redon CE, 2011, METHODS MOL BIOL, V682, P249, DOI 10.1007/978 1 60327 409 8_18
   Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470 2045(14)71205 7
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2016, LANCET ONCOL, V17, P1306, DOI 10.1016/S1470 2045(16)30173 5
   Sartor O, 2014, LANCET ONCOL, V15, P738, DOI 10.1016/S1470 2045(14)70183 4
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252
   Smith MR, 2015, ANN ONCOL, V26, P368, DOI 10.1093/annonc/mdu519
   Suominen MI, 2013, JNCI J NATL CANCER I, V105, P908, DOI 10.1093/jnci/djt116
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Todenhöfer T, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/838202
   Torre LA, 2015, CA CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vignani F, 2016, CANCER TREAT REV, V44, P61, DOI 10.1016/j.ctrv.2016.02.002
NR 39
TC 131
Z9 142
U1 2
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD AUG 1
PY 2017
VL 23
IS 15
BP 4335
EP 4346
DI 10.1158/1078 0432.CCR 16 2955
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FC2PL
UT WOS:000406680300038
PM 28364014
OA Green Submitted, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Öztürk, G
   Aydog, E
   Külcü, DG
AF Ozturk, Gulcan
   Aydog, Ece
   Geler Kulcu, Duygu
TI CONJUNCTIVITIS AS A RARE SIDE EFFECT OF RISEDRONATE: A CASE REPORT
SO TURKISH JOURNAL OF GERIATRICS TURK GERIATRI DERGISI
LA English
DT Article
DE Aged; Osteoporosis; Risedronate; Conjunctivitis
ID BISPHOSPHONATES; SCLERITIS
AB Osteoporosis is common metabolic bone disease in older people. Bisphosphonates is usually used in the management of osteoporosis. However, a small number of patients have been recognized to develop ocular inflammation due to administration of bisphosphonates. We report the case of risedronate induced conjunctivitis in a 68 year old woman. This was successfully treated with stopping risedronate. Applying Naranjo's adverse drug reaction probability scale, a causality assessment was made which categorized this reaction as probable with a score of 7. This case report reviews the literature on the ocular effects of risedronate and discusses a possible mechanism for the association. Although ocular adverse effects of bisphosphonates are rare, it may effect eyesight. Physical Medicine and Rehabilitation clinicians should be aware of ocular side effects in older patients because a delay in diagnosis may result in serious adverse outcomes.
C1 [Ozturk, Gulcan] Gebze Fatih State Hosp, Phys & Rehabil Clin, Kocaeli, Turkey.
   [Aydog, Ece] Yeditepe Univ, Phys & Rehabil Clin, Istanbul, Turkey.
   [Geler Kulcu, Duygu] Haydarpasa Numune Training & Res Hosp, Phys & Rehabil Clin, Istanbul, Turkey.
C3 Gebze Fatih State Hospital; Yeditepe University; Istanbul Haydarpasa
   Numune Training & Research Hospital; Istanbul Haydarpasa Sultan
   Abdulhamid Training & Research Hospital
RP Öztürk, G (通讯作者)，Gebze Fatih State Hosp, Phys & Rehabil Clin, Kocaeli, Turkey.
EM drgul_can@hotmail.com
RI Ozturk, Gulcan/HKM 6599 2023; Külcü, Duygu/GRX 8652 2022
CR [Anonymous], NZ MED J
   Aurich Barrera B, 2006, DRUG SAFETY, V29, P151, DOI 10.2165/00002018 200629020 00005
   Barrera BA, 2005, OSTEOPOROSIS INT, V16, P1989, DOI 10.1007/s00198 005 1986 1
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Fraunfelder FW, 2003, AM J OPHTHALMOL, V135, P219, DOI 10.1016/S0002 9394(02)01840 8
   Geneva II, 2013, JAMA OPHTHALMOL, V131, P249, DOI 10.1001/jamaophthalmol.2013.578
   Hemmati I, 2012, CLIN RHEUMATOL, V31, P1403, DOI 10.1007/s10067 012 2035 z
   McKague M, 2010, CAN FAM PHYSICIAN, V56, P1015
   Moorthy RS, 1998, SURV OPHTHALMOL, V42, P557, DOI 10.1016/S0039 6257(97)00130 6
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Or C, 2013, BRIT J OPHTHALMOL, V97, P1074, DOI 10.1136/bjophthalmol 2013 303355
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Pazianas M, 2013, J BONE MINER RES, V28, P455, DOI 10.1002/jbmr.1783
   Raja V, 2007, J POSTGRAD MED, V53, P274, DOI 10.4103/0022 3859.37525
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   Viñas G, 2002, MED CLIN BARCELONA, V118, P598, DOI 10.1016/S0025 7753(02)72464 0
   Vora MM, 2014, OPHTHAL PLAST RECONS, V30, pE84, DOI 10.1097/IOP.0b013e31829f3b46
NR 17
TC 1
Z9 1
U1 0
U2 0
PU GUNES KITABEVI LTD STI
PI ANKARA
PA M RAUF INAN SOK NO 3, ANKARA, SIHHIYE 06410, TURKEY
SN 1304 2947
EI 1307 9948
J9 TURK J GERIATR
JI Turk. J. Geriatr.
PY 2015
VL 18
IS 3
BP 251
EP 254
PG 4
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA DB1GY
UT WOS:000368257500011
DA 2025 08 17
ER

PT J
AU Zhang, WT
   Duan, N
   Zhang, Q
   Song, T
   Li, Z
   Zhang, CG
   Chen, X
   Wang, KZ
AF Zhang, Wentao
   Duan, Ning
   Zhang, Qian
   Song, Tao
   Li, Zhong
   Zhang, Caiguo
   Chen, Xun
   Wang, Kunzheng
TI DNA Methylation Mediated Down Regulation of miR 370 Regulates Cell
   Growth through Activation of the Wnt/β Catenin Signaling Pathway in
   Human Osteosarcoma Cells
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE miR 370; methylation; FOXM1; Wnt/beta Catenin; c Myc and Cyclin D1
ID GENE EXPRESSION; PROLIFERATION; CANCER; FOXM1; TRANSCRIPTION; PROMOTES;
   MICRORNA 370; PROTEINS; INVASION; COMPLEX
AB MicroRNA 370 (miR 370) has been observed to act as a tumor suppressor through the targeting of different proteins in a variety of tumors. Our previous study indicated that miR 370 was able to target forkhead box protein M1 (FOXM1) to inhibit cell growth and metastasis in human osteosarcoma cells. In this study, we reported that FOXM1 interacted with beta catenin in vitro and in vivo. Similar to FOXM1, critical components of the Wnt signaling pathway, including beta catenin, c Myc, and Cyclin D1, were also highly expressed in different human osteosarcoma cells lines. Pharmacological inhibition of FOXM1 or beta catenin but not of c Myc was associated with the increased expression of miR 370. Ectopic expression of miR 370 inhibited the downstream signaling of beta catenin. Moreover, osteosarcoma cells treated with 5 AZA 2' deoxycytidine (AZA), a DNA methylation inhibitor, exhibited increased levels of miR 370 and decreased levels of a catenin downstream targets, which resulted in inhibition of cell proliferation and colony formation ability. In conclusion, our results supported a model in which the DNA methylation mediated down regulation of miR 370 reduced its inhibitory effect on FOXM1, thereby promoting FOXM1 beta catenin interaction and activating the Wnt/beta Catenin signaling pathway in human osteosarcoma cells.
C1 [Zhang, Wentao; Wang, Kunzheng] Xi An Jiao Tong Univ, Dept Orthoped, Affiliated Hosp 2, Xian 710005, Shaanxi, Peoples R China.
   [Zhang, Wentao; Duan, Ning; Song, Tao; Li, Zhong; Chen, Xun] Xi An Jiao Tong Univ, Coll Med, Dept Orthopaed, Hong Hui Hosp, Xian 710054, Shaanxi, Peoples R China.
   [Zhang, Qian] Shaanxi Prov Tumor Hosp, Dept 2, Surg Room, Xian 710061, Shaanxi, Peoples R China.
   [Zhang, Caiguo] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; University of
   Colorado System; University of Colorado Anschutz Medical Campus
RP Wang, KZ (通讯作者)，Xi An Jiao Tong Univ, Dept Orthoped, Affiliated Hosp 2, Xian 710005, Shaanxi, Peoples R China.; Chen, X (通讯作者)，Xi An Jiao Tong Univ, Coll Med, Dept Orthopaed, Hong Hui Hosp, Xian 710054, Shaanxi, Peoples R China.; Zhang, CG (通讯作者)，Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA.
EM caiguo.zhang@ucdenver.edu; chenxun2008@yahoo.com;
   kunzhengwang@hotmail.com
RI Sohail, Yasir/JXN 9444 2024
CR Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chen X, 2016, J CANCER, V7, P1057, DOI 10.7150/jca.15061
   Chen YH, 2016, EMBO J, V35, P668, DOI 10.15252/embj.201592810
   Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684
   Duan N, 2015, INT J CLIN EXP PATHO, V8, P10250
   Durfee RA, 2016, RHEUMATOL THER, V3, P221, DOI 10.1007/s40744 016 0046 y
   Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008 5472.CAN 05 3138
   Kalinina OA, 2003, ONCOGENE, V22, P6266, DOI 10.1038/sj.onc.1206640
   Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008 5472.CAN 05 3003
   Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008 5472.CAN 15 3278
   Kobayashi Eisuke, 2012, Sarcoma, V2012, P359739, DOI 10.1155/2012/359739
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/B978 0 12 380866 0.60002 2, 10.1016/S0065 2660(10)70002 X]
   Lievens S, 2009, TRENDS BIOCHEM SCI, V34, P579, DOI 10.1016/j.tibs.2009.06.009
   Lv L, 2015, ONCOL LETT, V10, P907, DOI 10.3892/ol.2015.3336
   Ma RYM, 2010, METHODS MOL BIOL, V647, P113, DOI 10.1007/978 1 60761 738 9_6
   Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200
   Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Novello C, 2013, INT J ONCOL, V42, P667, DOI 10.3892/ijo.2012.1717
   Pei H, 2015, MOL CELL BIOCHEM, V400, P245, DOI 10.1007/s11010 014 2281 2
   Qu F, 2016, ONCOL LETT, V11, P1592, DOI 10.3892/ol.2015.4073
   Qu Y, 2016, TUMOR BIOL, V37, P5275, DOI 10.1007/s13277 015 4389 8
   Reddington JP, 2014, BIOESSAYS, V36, P134, DOI 10.1002/bies.201300130
   Saba R, 2016, INT J BREAST CANCER, V2016, DOI 10.1155/2016/9768183
   Sampson VB, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00069
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Ueda Y, 2014, DIGEST DIS SCI, V59, P2444, DOI 10.1007/s10620 014 3193 4
   Wang IC, 2012, MOL CELL BIOL, V32, P3838, DOI 10.1128/MCB.00355 12
   Wang W, 2016, ONCOL REP, V35, P1473, DOI 10.3892/or.2016.4542
   Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008 5472.CAN 07 1265
   Wierstra I, 2013, ADV CANCER RES, V118, P97, DOI 10.1016/B978 0 12 407173 5.00004 2
   Yamane K, 2016, SCI REP UK, V6, DOI 10.1038/srep30941
   Yin HX, 2016, SCI REP UK, V6, DOI 10.1038/srep18824
   Yuan F, 2015, MOL MED REP, V12, P4647, DOI 10.3892/mmr.2015.3921
   Zhang CG, 2010, PLANT CELL, V22, P2353, DOI 10.1105/tpc.110.073973
   Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016
   Zhang Y, 2014, P NATL ACAD SCI USA, V111, pE1695, DOI 10.1073/pnas.1405204111
NR 37
TC 37
Z9 42
U1 0
U2 6
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2017
VL 13
IS 5
BP 561
EP 573
DI 10.7150/ijbs.19032
PG 13
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA EV6SS
UT WOS:000401904400003
PM 28539830
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Inagaki, Y
   Kido, J
   Nishikawa, Y
   Kido, R
   Sakamoto, E
   Bando, M
   Naruishi, K
   Nagata, T
   Yumoto, H
AF Inagaki, Yuji
   Kido, Jun ichi
   Nishikawa, Yasufumi
   Kido, Rie
   Sakamoto, Eijiro
   Bando, Mika
   Naruishi, Koji
   Nagata, Toshihiko
   Yumoto, Hiromichi
TI Gan Lu Yin (Kanroin), Traditional Chinese Herbal Extracts, Reduces
   Osteoclast Differentiation In Vitro and Prevents Alveolar Bone
   Resorption in Rat Experimental Periodontitis
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE Gan Lu Yin; periodontitis; herbal medicine; osteoclastogenesis
AB Gan Lu Yin (GLY), a traditional Chinese herbal medicine, shows therapeutic effects on periodontitis, but that mechanism is not well known. This study aims to clarify the precise mechanism by investigating the inhibitory effects of GLY extracts on osteoclastogenesis in vitro and on bone resorption in periodontitis in vivo. RAW264.7 cells are cultured with soluble receptor activator of nuclear factor kappa B (sRANKL) and GLY extracts (0.01 1.0 mg/mL), and stained for tartrate resistant acid phosphatase (TRAP) to evaluate osteoclast differentiation. Experimental periodontitis is induced by placing a nylon ligature around the second maxillary molar in rats, and rats are administered GLY extracts (60 mg/kg) daily for 20 days. Their maxillae are collected on day 4 and 20, and the levels of alveolar bone resorption and osteoclast differentiation are estimated using micro computed tomography (CT) and histological analysis, respectively. In RAW264.7 cells, GLY extracts significantly inhibit sRANKL induced osteoclast differentiation at a concentration of more than 0.05 mg/mL. In experimental periodontitis, administering GLY extracts significantly decreases the number of TRAP positive osteoclasts in the alveolar bone on day 4, and significantly inhibits the ligature induced bone resorption on day 20. These results show that GLY extracts suppress bone resorption by inhibiting osteoclast differentiation in experimental periodontitis, suggesting that GLY extracts are potentially useful for oral care in periodontitis.
C1 [Inagaki, Yuji; Kido, Jun ichi; Nishikawa, Yasufumi; Kido, Rie; Sakamoto, Eijiro; Bando, Mika; Naruishi, Koji; Nagata, Toshihiko; Yumoto, Hiromichi] Tokushima Univ, Inst Biomed Sci, Dept Periodontol & Endodontol, Grad Sch, Tokushima 7708504, Japan.
C3 Tokushima University
RP Inagaki, Y (通讯作者)，Tokushima Univ, Inst Biomed Sci, Dept Periodontol & Endodontol, Grad Sch, Tokushima 7708504, Japan.
EM yinazo@tokushima u.ac.jp; kido.jun ichi@tokushima u.ac.jp;
   nishikawa.yasufumi@tokushima u.ac.jp; rie.kido@tokushima u.ac.jp;
   sakamoji@tokushima u.ac.jp; banchi@tokushima u.ac.jp;
   naruishi@tokushima u.ac.jp; nagata.toshihiko@tokushima u.ac.jp;
   yumoto@tokushima u.ac.jp
RI Sakamoto, Eijiro/AAD 3091 2021
OI Naruishi, Koji/0000 0002 7913 8488; Yumoto,
   Hiromichi/0000 0002 8659 9776
FU Japan Society for the Promotion of Science [16K11833]; Sunstar (Osaka,
   Japan); Grants in Aid for Scientific Research [16K11833] Funding Source:
   KAKEN
FX This study was supported in part by grants of the Grant in Aid for
   Scientific Research 16K11833 from the Japan Society for the Promotion of
   Science, and in part by research funds of Sunstar (Osaka, Japan).
CR An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Bartold PM, 2010, PERIODONTOL 2000, V53, P55, DOI 10.1111/j.1600 0757.2010.00347.x
   Cai X, 2008, J PERIODONTAL RES, V43, P14, DOI 10.1111/j.1600 0765.2007.00989.x
   Chien YC, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 137
   Martínez CC, 2017, PHARM BIOL, V55, P1992, DOI 10.1080/13880209.2017.1347188
   de Molon RS, 2018, MICROSC RES TECHNIQ, V81, P1412, DOI 10.1002/jemt.23101
   Eyre DR, 1997, SPINE, V22, p17S, DOI 10.1097/00007632 199712151 00004
   Fournier Larente J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148860
   Geng XL, 2015, EXP THER MED, V10, P1066, DOI 10.3892/etm.2015.2615
   Gokhale SR, 2013, BRIT DENT J, V214, P467, DOI 10.1038/sj.bdj.2013.432
   Hashimura S, 2020, BBA MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158698
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Ikeda Kyoji, 2014, J Bone Metab, V21, P163, DOI 10.11005/jbm.2014.21.3.163
   Isola G, 2021, J PERIODONTOL, V92, P896, DOI 10.1002/JPER.20 0242
   Isola G, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903 020 01258 5
   Jang S, 2010, PHYTOTHER RES, V24, P964, DOI 10.1002/ptr.3013
   Kim HJ, 2010, INT IMMUNOPHARMACOL, V10, P1440, DOI 10.1016/j.intimp.2010.08.017
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Kim YW, 2008, BRIT J PHARMACOL, V154, P165, DOI 10.1038/bjp.2008.79
   Ku SK, 2015, BMB REP, V48, P519, DOI 10.5483/BMBRep.2015.48.9.017
   Lee JW, 2010, BIOCHEM PHARMACOL, V80, P352, DOI 10.1016/j.bcp.2010.04.014
   Li ZK, 2018, CALCIFIED TISSUE INT, V103, P324, DOI 10.1007/s00223 018 0425 1
   Lin IH, 2006, J SEP SCI, V29, P172, DOI 10.1002/jssc.200500147
   Liu FC, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/684071
   Liu LH, 2017, IRAN J BASIC MED SCI, V20, P813, DOI 10.22038/IJBMS.2017.9017
   Luo W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051008
   Mao YJ, 2011, INT J MOL MED, V27, P669, DOI 10.3892/ijmm.2011.639
   Messora MR, 2016, ARCH ORAL BIOL, V66, P108, DOI 10.1016/j.archoralbio.2016.02.014
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Pan CH, 2010, J AGR FOOD CHEM, V58, P7685, DOI 10.1021/jf1002254
   Safiaghdam H, 2018, IRAN J BASIC MED SCI, V21, P978, DOI 10.22038/IJBMS.2018.31997.7690
   Seto H, 2008, J PERIODONTAL RES, V43, P261, DOI 10.1111/j.1600 0765.2007.01024.x
   Seto H, 2007, J PERIODONTAL RES, V42, P85, DOI 10.1111/j.1600 0765.2006.00919.x
   Surathu N, 2011, PERIODONTOL 2000, V56, P14, DOI 10.1111/j.1600 0757.2010.00369.x
   Takeda O, 2014, ARCH ORAL BIOL, V59, P1130, DOI 10.1016/j.archoralbio.2014.06.010
   Tokunaga K, 2011, J PERIODONTAL RES, V46, P655, DOI 10.1111/j.1600 0765.2011.01386.x
   Vargas Sanchez PK, 2017, J APPL ORAL SCI, V25, P490, DOI 10.1590/1678 7757 2016 0517
   Veilleux Marie Pier, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5020035
   Wada Mihara C, 2018, BIOMED PHARMACOTHER, V97, P765, DOI 10.1016/j.biopha.2017.10.165
   Wen X, 2016, ORAL DIS, V22, P109, DOI 10.1111/odi.12378
   Yagi M, 2006, J BONE MINER METAB, V24, P355, DOI 10.1007/s00774 006 0697 9
   Yang H, 2014, J PERIODONTAL RES, V49, P382, DOI 10.1111/jre.12117
   Yang JS, 2016, ENVIRON TOXICOL, V31, P1196, DOI 10.1002/tox.22127
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Yonezawa T, 2011, EUR J PHARMACOL, V650, P511, DOI 10.1016/j.ejphar.2010.10.048
   Zhang CC, 2014, J CELL PHYSIOL, V229, P1330, DOI 10.1002/jcp.24553
   Zhang Y, 2014, EXP THER MED, V7, P80, DOI 10.3892/etm.2013.1357
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zhao QX, 2009, BIOCHEM BIOPH RES CO, V380, P721, DOI 10.1016/j.bbrc.2009.01.139
   Zhou T, 2013, ACTA ODONTOL SCAND, V71, P349, DOI 10.3109/00016357.2012.682092
NR 53
TC 12
Z9 13
U1 3
U2 31
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2077 0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2021
VL 10
IS 3
AR 386
DI 10.3390/jcm10030386
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA QD1SF
UT WOS:000615306500001
PM 33498415
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xiao, LP
   Du, EX
   Homer Bouthiette, C
   Hurley, MM
AF Xiao, Liping
   Du, Erxia
   Homer Bouthiette, Collin
   Hurley, Marja M.
TI Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets
   in HMWFGF2 Tg Male Mice
SO ENDOCRINOLOGY
LA English
DT Article
ID FIBROBLAST GROWTH FACTOR; HIGH MOLECULAR WEIGHT; FACTOR RECEPTOR
   MUTATIONS; NON AUG CODONS; PHOSPHATE HOMEOSTASIS; TRANSGENIC MICE;
   BONE MARROW; IN VITRO; NUCLEAR LOCALIZATION; SKELETAL DISORDERS
AB Transgenic mice harboring high molecular weight fibroblast growth factor (FGF)2 isoforms (HMWTg) in osteoblast lineage cells phenocopy human X linked hypophosphatemic rickets (XLH) and Hyp murine model of XLH demonstrating increased FGF23/FGF receptor signaling and hypophosphatemic rickets. Because HMWFGF2 was upregulated in bones of Hyp mice and abnormal FGF receptor (FGFR) signaling is important in XLH, HMWTg mice were used to examine the effect of the FGFR inhibitor NVP BGJ398, now in clinical trials for cancer therapy, on hypophosphatemic rickets. Short term treatment with NVP BGJ398 rescued abnormal FGFR signaling and hypophosphatemia in HMWTg. Long term treatment with NVP BGJ398 normalized tail, tibia, and femur length. Four weeks NVP BGJ398 treatment significantly increased total body bone mineral density (BMD) and bone mineral content (BMC) in HMWTg mice; however, at 8 weeks, total body BMD and BMC was indistinguishable among groups. Micro computed tomography revealed decreased vertebral bone volume, trabecular number, and increased trabecular spacing, whereas femur trabecular tissue density was increased; however, NVP BGJ398 rescued defective cortical bone mineralization, increased thickness, reduced porosity, and increased endosteal perimeter and cortical tissue density in HMWTg. NVP BGJ398 improved femur cancellous bone, cortical bone structure, growth plate, and double labeling in cortical bone and also increased femur trabeculae double labeled surface, mineral apposition rate, bone formation rate, and osteoclast number and surface in HMWTg. The decreased NPT2a protein that is important for renal phosphate excretion was rescued by NVP BGJ398 treatment. We conclude that NVP BGJ398 partially rescued hypophosphatemic rickets in HMWTg. However, long term treatment with NVP BGJ398 further increased serum FGF23 that could exacerbate the mineralization defect.Long term inhibition of FGFR signaling with NVP BGJ398 partially rescued hypophosphatemic rickets in HMWTg male mice but further increased serum FGF23 that could exacerbate the mineralization defect.
C1 [Xiao, Liping; Du, Erxia; Homer Bouthiette, Collin; Hurley, Marja M.] Univ Connecticut, Sch Med, Dept Med, UConn Hlth, 263 Farmington Ave, Farmington, CT 06030 USA.
C3 University of Connecticut
RP Hurley, MM (通讯作者)，Univ Connecticut, Sch Med, Dept Med, UConn Hlth, 263 Farmington Ave, Farmington, CT 06030 USA.
EM hurley@uchc.edu
FU National Institutes of Health [DK098566]
FX This project was supported in part by National Institutes of Health
   Grant DK098566 (to M.M.H.). The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR A gene (PEX) with homologies to endopeptidases is mutated in patients with X linked hypophosphatemic, 1995, Nat Genet, V11, P130
   Arese M, 1999, MOL BIOL CELL, V10, P1429, DOI 10.1091/mbc.10.5.1429
   Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276
   Ben Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409
   Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   Bianchi A, 2016, OSTEOARTHR CARTILAGE, V24, P1961, DOI 10.1016/j.joca.2016.06.003
   COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861
   Dacic S, 2001, J BONE MINER RES, V16, P1228, DOI 10.1359/jbmr.2001.16.7.1228
   Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014 5793(00)01189 3
   DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959 437X(97)80152 9
   Du EX, 2016, J CELL BIOCHEM, V117, P1991, DOI 10.1002/jcb.25493
   Fan Y, 2016, FASEB J, V30, P428, DOI 10.1096/fj.15 278184
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146
   FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978
   GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo 124 3 1539
   Homer Bouthiette C, 2014, J BIOL CHEM, V289, P36303, DOI 10.1074/jbc.M114.619569
   Hurley MM., 2002, PRINCIPLES BONE BIOL, P825
   Imel EA, 2010, J CLIN ENDOCR METAB, V95, P1846, DOI 10.1210/jc.2009 1671
   Jiang ZS, 2007, J MOL CELL CARDIOL, V42, P222, DOI 10.1016/j.yjmcc.2006.09.002
   Kaipatur NR, 2008, J DENT RES, V87, P839, DOI 10.1177/154405910808700907
   Kawai M, 2013, J BIOL CHEM, V288, P2414, DOI 10.1074/jbc.M112.410043
   Komla Ebri D, 2016, J CLIN INVEST, V126, P1871, DOI 10.1172/JCI83926
   Larsson T, 2004, ENDOCRINOLOGY, V145, P3087, DOI 10.1210/en.2003 1768
   Liao SY, 2007, J MOL CELL CARDIOL, V42, P106, DOI 10.1016/j.yjmcc.2006.10.005
   Lorenz Depiereux B, 2006, NAT GENET, V38, P1248, DOI 10.1038/ng1868
   Ma X, 2007, J CELL PHYSIOL, V213, P690, DOI 10.1002/jcp.21139
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168 9525(00)89088 5
   Ohata Y, 2014, J BONE MINER RES, V29, P1627, DOI 10.1002/jbmr.2186
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Raimann A, 2013, CONNECT TISSUE RES, V54, P108, DOI 10.3109/03008207.2012.753879
   Rhee Y, 2011, BONE, V49, P636, DOI 10.1016/j.bone.2011.06.025
   Rowe PSN, 2004, CRIT REV ORAL BIOL M, V15, P264, DOI 10.1177/154411130401500503
   Rowe PSN, 2000, GENOMICS, V67, P54, DOI 10.1006/geno.2000.6235
   Shalhoub V, 2011, CALCIFIED TISSUE INT, V89, P140, DOI 10.1007/s00223 011 9501 5
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Sitara D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000154
   Sobue T, 2005, J CELL BIOCHEM, V95, P83, DOI 10.1002/jcb.20389
   Staines KA, 2013, J ENDOCRINOL, V219, pX1, DOI 10.1530/JOE 12 0143e
   Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248 4900(03)00033 9
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Wang JS, 1996, ACTA ORTHOP SCAND, V67, P229, DOI 10.3109/17453679608994678
   White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664
   Wöhrle S, 2013, J BONE MINER RES, V28, P899, DOI 10.1002/jbmr.1810
   Xiao L, 2003, J CELL BIOCHEM, V89, P1291, DOI 10.1002/jcb.10589
   Xiao LP, 2013, J BONE MINER RES, V28, P35, DOI 10.1002/jbmr.1721
   Xiao LP, 2010, BONE, V47, P360, DOI 10.1016/j.bone.2010.05.021
   Xiao LP, 2010, J BIOL CHEM, V285, P2834, DOI 10.1074/jbc.M109.030577
   Xiao LP, 2009, J BIOL CHEM, V284, P3170, DOI 10.1074/jbc.M804900200
   Yu PJ, 2007, J CELL BIOCHEM, V100, P1100, DOI 10.1002/jcb.21116
   Yu XJ, 2005, CYTOKINE GROWTH F R, V16, P221, DOI 10.1016/j.cytogfr.2005.01.002
   Zhang GX, 2004, ENDOCRINE, V24, P15, DOI 10.1385/ENDO:24:1:015
NR 54
TC 8
Z9 10
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD OCT
PY 2017
VL 158
IS 10
BP 3629
EP 3646
DI 10.1210/en.2016 1617
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FI9BO
UT WOS:000412298700048
PM 28938491
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Farrell, M
   Fairfield, H
   Costa, S
   D'Amico, A
   Falank, C
   Brooks, DJ
   Reagan, MR
AF Farrell, Mariah
   Fairfield, Heather
   Costa, Samantha
   D'Amico, Anastasia
   Falank, Carolyne
   Brooks, Daniel J.
   Reagan, Michaela R.
TI Sclerostin Neutralizing Antibody Treatment Rescues Negative Effects of
   Rosiglitazone on Mouse Bone Parameters
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANABOLICS; BONE HISTOMORPHOMETRY; BONE QCT; MCT; DXA; PRECLINICAL
   STUDIES; ROSIGLITAZONE; SCLEROSTIN
ID MARROW ADIPOSE TISSUE; INDUCE OSTEOCYTE APOPTOSIS; DIET INDUCED OBESITY;
   CORTICAL BONE; PARATHYROID HORMONE; MASS; THIAZOLIDINEDIONES;
   ADIPOCYTES; MICE; DIFFERENTIATION
AB Obesity, a growing pandemic, is a risk factor for many cancers and causes increased bone marrow adipose tissue (BMAT). in vitro studies and obese animal models suggest that BMAT contributes to cancer progression, but there is a lack of preclinical models to directly test BMAT's role in cancer. Overactivation of peroxisome proliferator activated receptor gamma (PPAR gamma) can skew bone formation and resorption rates, resulting in increased BMAT and trabecular bone loss. Thiazolidinediones (eg, rosiglitazone) are anti diabetic therapies that promote adipogenesis through PPAR gamma activation. We investigated if rosiglitazone increases BMAT in an immunocompromised model, commonly used in cancer research, and if these effects could be reversed by co administering a bone anabolic agent (sclerostin neutralizing antibody [Scl Ab]), which has been shown to inhibit adipogenesis, using DXA, mu CT, OsO4 mu CT, and dynamic histomorphometry. Four weeks of rosiglitazone in female SCID Beige mice (cohort 1) significantly decreased trabecular bone volume (BV/TV) by about one half, through increased osteoclast and suppressed osteoblast activity, and significantly increased BMAT. In cohort 2, mice were administered rosiglitazone +/  Scl Ab for 4 weeks, and then rosiglitazone was discontinued and Scl Ab or vehicle were continued for 6 weeks. Scl Ab significantly increased bone parameters (eg, BV/TV, N.Ob/B.Pm, and MS/BS) in both groups. Scl Ab also overcame many negative effects of rosiglitazone (eg, effects on trabecular bone parameters, increased mineralization lag time [MLT], and decreased bone formation rate [BFR]). Interestingly, Scl Ab significantly decreased rosiglitazone induced BMAT in the femur, mostly due to a reduction in adipocyte size, but had a much weaker effect on tibial BMAT. These data suggest targeting sclerostin can prevent rosiglitazone induced bone loss and reduce BM adiposity, in some, but not all BMAT locations. Collectively, our data demonstrate that rosiglitazone increases BMAT in SCID Beige mice, but concomitant changes in bone may confound its use to specifically determine BMAT's role in tumor models. (c) 2020 American Society for Bone and Mineral Research (ASBMR).
C1 [Farrell, Mariah; Fairfield, Heather; Costa, Samantha; D'Amico, Anastasia; Falank, Carolyne; Reagan, Michaela R.] Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA.
   [Farrell, Mariah; D'Amico, Anastasia; Reagan, Michaela R.] Univ Southern Maine, Biol Dept, Portland, ME USA.
   [Fairfield, Heather; Reagan, Michaela R.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Costa, Samantha; Reagan, Michaela R.] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME USA.
   [Brooks, Daniel J.] Massachusetts Gen Hosp, Ctr Skeletal Res, Boston, MA 02114 USA.
C3 Maine Medical Center; University of Maine System; University of Southern
   Maine; Tufts University; University of Maine System; University of Maine
   Orono; Harvard University; Harvard University Medical Affiliates;
   Massachusetts General Hospital
RP Reagan, MR (通讯作者)，Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.; Reagan, MR (通讯作者)，Ctr Translat Res, 81 Res Dr, Scarborough, ME 04074 USA.
EM mreagan@mmc.org
RI ; Reagan, Michaela/E 3549 2017
OI Reagan, Michaela/0000 0003 2884 6481; Costa,
   Samantha/0000 0001 5257 0898; 
FU NIH/National Institute of General Medical Sciences (NIGMS) [P20GM121301,
   P30GM106391, U54GM115516]; NIH/National Cancer Institute (NCI)
   [1R37CA245330 01A1]; Maine Medical Center Research Institute; American
   Cancer Society [IRG 16 191 33, 133077 RSG 19 037 01 LIB]; Massachusetts
   General Hospital (NIH/National Institute of Arthritis and
   Musculoskeletal and SkinDiseases [NIAMS]) [P30AR066261]; Massachusetts
   General Hospital Center for Skeletal Research (NIH) [P30AR075042];
   National Cancer Institute [R37CA245330] Funding Source: NIH RePORTER;
   National Institute of General Medical Sciences [P20GM121301] Funding
   Source: NIH RePORTER
FX This work was supported by grants from the NIH/National Institute of
   General Medical Sciences (NIGMS) (P20GM121301), P30GM106391,
   U54GM115516, and the NIH/National Cancer Institute (NCI)
   1R37CA245330 01A1. The authors' work is also supported by startup funds
   from the Maine Medical Center Research Institute and the American Cancer
   Society (Research Grant #IRG 16 191 33 and #133077 RSG 19 037 01 LIB).
   This work was also partially supported by a pilot grant from the
   Massachusetts General Hospital (NIH/National Institute of Arthritis and
   Musculoskeletal and SkinDiseases [NIAMS] P30AR066261). We thank Dr. Mary
   Bouxsein and Michael Bruce at the Massachusetts General Hospital Center
   for Skeletal Research (NIH P30AR075042) for mu CT and OsO<INF>4</INF> mu
   CT analysis and Drs. Marie Demay and Janaina Da Silva Martins for
   assisting with the OsteoMeasure analysis. We thank Peter Cardonna of the
   Histology and Imaging Core at the University of New England for imaging
   assistance. We thank Mereo for providing the Scl Ab. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH.
CR Ackert Bicknell CL, 2009, ENDOCRINOLOGY, V150, P1330, DOI 10.1210/en.2008 0936
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Amgen, 2019, EUR COMM APPR EVENIT
   Beason TS, 2013, ONCOLOGIST, V18, P1074, DOI 10.1634/theoncologist.2013 0015
   Beck GR, 2013, TRANSL RES, V161, P145, DOI 10.1016/j.trsl.2012.08.006
   Bornstein S, 2017, ENDOCRINOLOGY, V158, P3369, DOI 10.1210/en.2017 00299
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce RW, 2017, BONE, V101, P77, DOI 10.1016/j.bone.2017.04.005
   Bullwinkle EM, 2016, CANCER LETT, V380, P114, DOI 10.1016/j.canlet.2016.06.010
   Caers J, 2007, LEUKEMIA, V21, P1580, DOI 10.1038/sj.leu.2404658
   CAMPBELL HF, 2019, CL LYMPH MYELOM LE S, V19, pE88
   Cardinal M, 2020, CALCIFIED TISSUE INT, V106, P494, DOI 10.1007/s00223 019 00655 5
   Chandra A, 2017, J BONE MINER RES, V32, P360, DOI 10.1002/jbmr.2996
   Colucci S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.22
   Costa S, 2019, BONE, V123, P211, DOI 10.1016/j.bone.2019.03.038
   de Cobelli Ottavio, 2015, Urol Oncol, V33, DOI 10.1016/j.urolonc.2015.02.004
   Delgado Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Divakaruni AS, 2013, P NATL ACAD SCI USA, V110, P5422, DOI 10.1073/pnas.1303360110
   Engblom C, 2017, SCIENCE, V358, DOI 10.1126/science.aal5081
   Fairfield H, 2018, J CELL PHYSIOL, V233, P1156, DOI 10.1002/jcp.25976
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Farrell M, 2019, CL LYMPH MYELOM LEUK, V19, pE89, DOI 10.1016/j.clml.2019.09.145
   Huang QY, 2009, BONE, V45, P289, DOI 10.1016/j.bone.2009.03.676
   Kahn CR, 2000, J CLIN INVEST, V106, P1305, DOI 10.1172/JCI11705
   Kim SP, 2017, P NATL ACAD SCI USA, V114, pE11238, DOI 10.1073/pnas.1707876115
   Kumar S, 2013, J BONE MINER RES, V28, P1653, DOI 10.1002/jbmr.1918
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Liu C, 2015, SCI REP UK, V5, DOI 10.1038/srep09530
   Liu H, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau9087
   Liu P, 2017, NATURE, V546, P107, DOI 10.1038/nature22342
   Liu ZQ, 2015, ONCOTARGET, V6, P34329, DOI 10.18632/oncotarget.6020
   Lu WY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149543
   Lupi R, 2004, AM J PHYSIOL ENDOC M, V286, pE560, DOI 10.1152/ajpendo.00561.2002
   Lwin ST, 2015, LEUKEMIA, V29, P507, DOI 10.1038/leu.2014.295
   Mabilleau G, 2010, DIABETIC MED, V27, P925, DOI 10.1111/j.1464 5491.2010.03048.x
   Marinac CR, 2018, BRIT J CANCER, V118, P1013, DOI 10.1038/s41416 018 0010 4
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   Mieczkowska A, 2012, J BIOL CHEM, V287, P23517, DOI 10.1074/jbc.M111.324814
   Motyl KJ, 2015, ENDOCRINOLOGY, V156, P2374, DOI 10.1210/en.2015 1099
   National Osteoporosis Foundation, 2019, FDA APPR EVENITY ROM
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Picon Ruiz M, 2017, CA CANCER J CLIN, V67, P379, DOI 10.3322/caac.21405
   Reagan MR, 2016, NAT REV RHEUMATOL, V12, P154, DOI 10.1038/nrrheum.2015.160
   Reagan MR, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.119.119
   Reagan MR, 2015, BONE, V75, P161, DOI 10.1016/j.bone.2015.02.021
   Ren YS, 2016, MATRIX BIOL, V52 54, P151, DOI 10.1016/j.matbio.2015.12.009
   Scheller EL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8808
   Scheller EL, 2014, METHOD ENZYMOL, V537, P123, DOI 10.1016/B978 0 12 411619 1.00007 0
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, P587, DOI 10.1210/clinem/dgaa048
   Stechschulte LA, 2016, EBIOMEDICINE, V10, P174, DOI 10.1016/j.ebiom.2016.06.040
   Sulston RJ, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00128
   Tornvig L, 2001, CALCIFIED TISSUE INT, V69, P46, DOI 10.1007/s002230020018
   Veldhuis Vlug AG, 2018, J INTERN MED, V283, P121, DOI 10.1111/joim.12718
   Wang XT, 2014, LEUKEMIA RES, V38, P525, DOI 10.1016/j.leukres.2014.02.010
   Yerges LM, 2009, J BONE MINER RES, V24, P2039, DOI [10.1359/JBMR.090524, 10.1359/jbmr.090524]
   Zhao XF, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0085 4
NR 58
TC 8
Z9 8
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2021
VL 36
IS 1
BP 158
EP 169
DI 10.1002/jbmr.4170
EA SEP 2020
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PT4WF
UT WOS:000571979500001
PM 32845528
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Chen, JR
   Lai, YH
   Tsai, JJ
   Hsiao, CD
AF Chen, Jung Ren
   Lai, Yu Heng
   Tsai, Jhih Jie
   Hsiao, Chung Der
TI Live Fluorescent Staining Platform for Drug Screening and
   Mechanism Analysis in Zebrafish for Bone Mineralization
SO MOLECULES
LA English
DT Article
DE drug screening; bone mineralization; osteoclast; calcein; zebrafish
ID IN VITRO; OSTEOPOROSIS; ALENDRONATE; EMBRYOS
AB Currently, drug screening relies on cell based experiments or on animal models to confirm biological effects. The mammalian system is considered too time consuming, expensive and complex to perform high throughput drug screening. There is a gap between in vitro cell based models and the in vivo mammalian models. The zebrafish is an ideal model that could link preclinical toxicity screening with the drug development pipeline. Taking advantage of a highly conservative genomic, rapid development, large number of offspring, low cost and easy manipulation, zebrafish has been considered an excellent animal model for disease based drug screening. In this study, zebrafish embryos were incubated with small molecular compounds that potentially affected bone mineralization in microplates. Two compounds of alendronate and dorsomorphin were used as positive and negative controls, respectively. The level of osteogenic mineralization was measured and quantified by using ImageJ software with fluorescent calcein staining images. Among twenty four tested compounds from the kinase inhibitor library, we identified two compounds, pentamidine and BML 267, which showed increased embryonic mineralization; while six compounds, RWJ 60475, levamisole HCL, tetramisole HCL, fenvalerate, NSC 663284, and BML 267ester, were inhibitory to bone mineralization. In addition, real time quantitative PCR (RT qPCR) was performed to evaluate the biological pathways involved in bone metabolism at the molecular level. We confirmed that alendronate enhanced the level of bone mineralization by inhibiting osteoclast related genes. In summary, our research established a simple method to screen potential bone metabolic drugs and to perform mechanism analysis for bone mineralization in vivo.
C1 [Chen, Jung Ren] I Shou Univ, Coll Med, Dept Biol Sci & Technol, Kaohsiung 82445, Taiwan.
   [Lai, Yu Heng] Chinese Culture Univ, Dept Chem, Taipei 11114, Taiwan.
   [Tsai, Jhih Jie; Hsiao, Chung Der] Chung Yuan Christian Univ, Dept Biosci Technol, Chungli 32023, Taiwan.
   [Hsiao, Chung Der] Chung Yuan Christian Univ, Ctr Biomed Technol, Chungli 32023, Taiwan.
   [Hsiao, Chung Der] Chung Yuan Christian Univ, Ctr Nanotechnol, Chungli 32023, Taiwan.
C3 I Shou University; Chinese Culture University; Chung Yuan Christian
   University; Chung Yuan Christian University; Chung Yuan Christian
   University
RP Hsiao, CD (通讯作者)，Chung Yuan Christian Univ, Dept Biosci Technol, Chungli 32023, Taiwan.; Hsiao, CD (通讯作者)，Chung Yuan Christian Univ, Ctr Biomed Technol, Chungli 32023, Taiwan.; Hsiao, CD (通讯作者)，Chung Yuan Christian Univ, Ctr Nanotechnol, Chungli 32023, Taiwan.
EM jrchen@isu.edu.tw; lyh21@ulive.pccu.edu.tw; cdhsiao@yahoo.com.tw
RI ; Hsiao, Chung Der/W 4535 2019
OI Hsiao, Chung Der/0000 0002 6398 8672; 
FU Ministry of Science and Technology [MOST105 2313 B 033 001 MY3]
FX This work was funded by Ministry of Science and Technology (grant no.
   MOST105 2313 B 033 001 MY3) to C D Hsiao.
CR Akiyama H, 2005, P NATL ACAD SCI USA, V102, P14665, DOI 10.1073/pnas.0504750102
   Astashkina A, 2012, PHARMACOL THERAPEUT, V134, P82, DOI 10.1016/j.pharmthera.2012.01.001
   Benjamin RM, 2010, PUBLIC HEALTH REP, V125, P368, DOI 10.1177/003335491012500302
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Bradaschia Correa V, 2012, Eur J Histochem, V56, pe24, DOI 10.4081/ejh.2012.24
   Brey DM, 2011, BIOTECHNOL BIOENG, V108, P163, DOI 10.1002/bit.22925
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Drake MT, 2013, CURR OSTEOPOROS REP, V11, P163, DOI 10.1007/s11914 013 0154 3
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fisher S, 1999, NAT GENET, V23, P442, DOI 10.1038/70557
   Fleming A, 2005, J BIOMOL SCREEN, V10, P823, DOI 10.1177/1087057105279952
   Fleming A, 2004, DEVELOPMENT, V131, P873, DOI 10.1242/dev.00952
   Flores MV, 2004, GENE EXPR PATTERNS, V4, P573, DOI 10.1016/j.modgep.2004.01.016
   Heaney Robert P, 2003, Clin Med Res, V1, P93
   Hwang PP, 2013, PFLUG ARCH EUR J PHY, V465, P1233, DOI 10.1007/s00424 013 1269 1
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kashii M, 2008, J BONE MINER METAB, V26, P24, DOI 10.1007/s00774 007 0782 8
   Kim SN, 2012, AMINO ACIDS, V42, P1455, DOI 10.1007/s00726 011 0901 7
   Lazner F, 1999, HUM MOL GENET, V8, P1839, DOI 10.1093/hmg/8.10.1839
   Mabee PM, 2004, J MORPHOL, V261, P334, DOI 10.1002/jmor.10253
   Melton LJ, 2004, J BONE MINER RES, V19, P1055, DOI 10.1359/JBMR.040316
   Okamoto M, 2014, J TRANSPLANT, V2014, DOI 10.1155/2014/269613
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Pan TC, 2005, AM J PHYSIOL REG I, V289, pR1202, DOI 10.1152/ajpregu.00816.2004
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Spaink HP, 2013, METHODS, V62, P246, DOI 10.1016/j.ymeth.2013.06.002
   Suster Maximiliano L, 2009, Methods Mol Biol, V561, P41, DOI 10.1007/978 1 60327 019 9_3
   Tarasco M, 2017, COMP BIOCHEM PHYS C, V197, P45, DOI 10.1016/j.cbpc.2017.04.006
   TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092 8674(81)90037 4
   Vanoevelen J, 2011, FASEB J, V25, P3197, DOI 10.1096/fj.11 183145
   WESTERFIELD M, 1995, ZEBRAFISH BOOK GUIDE
   Yavropoulou MP, 2014, HORM INT J ENDOCRINO, V13, P24, DOI 10.1007/BF03401318
   Yoshioka T, 2013, J BONE MINER METAB, V31, P153, DOI 10.1007/s00774 012 0393 x
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
NR 39
TC 45
Z9 49
U1 0
U2 22
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD DEC
PY 2017
VL 22
IS 12
AR 2068
DI 10.3390/molecules22122068
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FR7IW
UT WOS:000419242400038
PM 29186901
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Taira, TM
   Ramos, ES Jr
   Melo, PH
   Costa Silva, CC
   Alteen, MG
   Vocadlo, DJ
   Dias, WB
   Cunha, FQ
   Alves, JC
   Soe, K
   Fukada, SY
AF Taira, T. M.
   Ramos Junior, E. S.
   Melo, P. H.
   Costa Silva, C. C.
   Alteen, M. G.
   Vocadlo, D. J.
   Dias, W. B.
   Cunha, F. Q.
   Alves Filho, J. C.
   Soe, K.
   Fukada, S. Y.
TI HBP/O GlcNAcylation Metabolic Axis Regulates Bone Resorption Outcome
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE OGT; osteoclast; bone resorption; NFATc1; cathepsin K; periapical
   periodontitis
ID OSTEOCLAST DIFFERENTIATION; N ACETYLGLUCOSAMINE; GLUCOSE METABOLISM;
   EXPRESSION; GLYCOSYLATION; INDUCTION; PROTEIN; NFAT2
AB Osteoclasts play a key role in the regulation of bone mass and are highly active metabolically. Here we show that a metabolic reprogramming toward the hexosamine biosynthetic pathway (HBP) is required not only for osteoclast differentiation but also to determine the bone resorption mode during physiological and pathological bone remodeling. We found that pharmacological inhibition of O GlcNAc transferase (OGT) significantly reduced protein O GlcNAcylation and osteoclast differentiation. Accordingly, genetic deletion of OGT also inhibited osteoclast formation and downregulated critical markers related to osteoclasts differentiation and function (NFATc1, alpha(v)integrin, cathepsin K). Indeed, cells treated with OSMI 1, an OGT inhibitor, also reduced nuclear translocation of NFATc1. Furthermore, the addition of exogenous N acetylglucosamine (GlcNAc) strongly increased osteoclast formation and demineralization ability. Strikingly, our data show for the first time that O GlcNAcylation facilitates an aggressive trench resorption mode in human cells. The incubation of osteoclasts with exogenous GlcNAc increases the percentage of erosion by trench while having no effect on pit resorption mode. Through time lapse recording, we documented that osteoclasts making trenches moving across the bone surface are sensitive to GlcNAcylation. Finally, osteoclast specific Ogt deficient mice show increased bone density and reduced inflammation induced bone loss during apical periodontitis model. We show that osteoclast specific Ogt deficient mice are less susceptible to develop bacterial induced periapical lesion. Consistent with this, Ogt deleted mice showed a decreased number of tartrate resistant acid phosphatase positive cells lining the apical periodontitis site. In summary, here we describe a hitherto undiscovered role of the HBP/O GlcNAcylation axis tuning resorption mode and dictating bone resorption outcome.
C1 [Taira, T. M.; Ramos Junior, E. S.; Costa Silva, C. C.; Fukada, S. Y.] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Biomol Sci, Ave Cafe SN, BR 14040903 Ribeirao Preto, Brazil.
   [Taira, T. M.] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Pediat, Prevent & Social Dent, Ribeirao Preto, Brazil.
   [Taira, T. M.; Cunha, F. Q.; Alves Filho, J. C.; Fukada, S. Y.] Univ Sao Paulo, Ctr Res Inflammatory Dis, Ribeirao Preto Med Sch, Ave Bandeirantes 3900,Casa 3, BR 14049900 Ribeirao Preto, Brazil.
   [Ramos Junior, E. S.] Augusta Univ, Dent Coll Georgia, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.
   [Melo, P. H.; Cunha, F. Q.; Alves Filho, J. C.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pharmacol, Ave Bandeirantes 3900, BR 14049900 Ribeirao Preto, Brazil.
   [Alteen, M. G.; Vocadlo, D. J.] Simon Fraser Univ, Dept Mol Biol & Biochem, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.
   [Dias, W. B.] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Lab Glicobiol Estrutural & Func, Inst Biofis Carlos Chagas Filho, Ave Carlos Chagas Filho 373, Rio De Janeiro, Brazil.
   [Soe, K.] Univ Southern Denmark, Dept Clin Res, Pathol Res Unit, Clin Cell Biol, DK 5230 Odense M, Denmark.
   [Soe, K.] Univ Southern Denmark, Dept Mol Med, Clin Cell Biol, DK 5230 Odense M, Denmark.
   [Soe, K.] Odense Univ Hosp, Dept Pathol, Clin Cell Biol, DK 5000 Odense C, Denmark.
C3 Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP);
   Universidade de Sao Paulo; Universidade de Sao Paulo; University System
   of Georgia; Augusta University; Universidade de Sao Paulo; Simon Fraser
   University; Universidade Federal do Rio de Janeiro; University of
   Southern Denmark; University of Southern Denmark; University of Southern
   Denmark; Odense University Hospital
RP Fukada, SY (通讯作者)，Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Biomol Sci Biol Sci Cell Biol, Ave Cafe,S N,Bloco S,Sala 90A, BR 14040903 Ribeirao Preto, SP, Brazil.
EM sfukada@usp.br
RI Dias, Wagner/B 1401 2016; Vocadlo, David/E 5508 2014; Alves Filho, Jose
   Carlos/B 5814 2008; Soe, Kent/N 3618 2017; Ramos Junior,
   Erivan/AAG 1396 2019; Fukada, Sandra/C 2314 2012
OI Vocadlo, David/0000 0001 6897 5558; Soe, Kent/0000 0001 7402 314X;
   Ramos Junior, Erivan/0000 0003 0228 4257; Dias,
   Wagner/0000 0002 8378 8846
CR Allison DF, 2012, P NATL ACAD SCI USA, V109, P16888, DOI 10.1073/pnas.1208468109
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bond MR, 2015, J CELL BIOL, V208, P869, DOI 10.1083/jcb.201501101
   Borggaard XG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165924
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Czupalla C, 2005, PROTEOMICS, V5, P3868, DOI 10.1002/pmic.200402059
   Facundo HT, 2012, AM J PHYSIOL HEART C, V302, pH2122, DOI 10.1152/ajpheart.00775.2011
   Fukada SY, 2008, J DENT RES, V87, P1155, DOI 10.1177/154405910808701207
   Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI 10.1038/NCHEMBIO.520
   Golks A, 2007, EMBO J, V26, P4368, DOI 10.1038/sj.emboj.7601845
   Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815
   Hart GW, 2019, J BIOL CHEM, V294, P2211, DOI 10.1074/jbc.AW119.003226
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kim MJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168888
   Koyama T, 2015, EXP CELL RES, V338, P194, DOI 10.1016/j.yexcr.2015.08.009
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Love D.C., 2005, SCI STKE, V2005, pr, DOI DOI 10.1126/STKE.3122005RE13
   Merrild DMH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.32
   Nagel AK, 2014, MOL CELL PROTEOMICS, V13, P3381, DOI 10.1074/mcp.M114.040691
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Ng AY, 2018, JBMR PLUS, V2, P328, DOI 10.1002/jbm4.10058
   O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680 1690.2004
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Soe K, 2017, J CELL SCI, V130, P2026, DOI 10.1242/jcs.202036
   Soe K, 2015, BONE, V73, P181, DOI 10.1016/j.bone.2014.12.010
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeuchi Tomoharu, 2016, Bone Rep, V5, P15, DOI 10.1016/j.bonr.2016.02.001
   Takeuchi T, 2017, BIOL PHARM BULL, V40, P352, DOI 10.1248/bpb.b16 00877
   Williams JP, 1997, BIOCHEM BIOPH RES CO, V235, P646, DOI 10.1006/bbrc.1997.6795
   Yang YR, 2012, AGING CELL, V11, P439, DOI 10.1111/j.1474 9726.2012.00801.x
   Zachara NE, 2018, FEBS LETT, V592, P3950, DOI 10.1002/1873 3468.13286
NR 36
TC 17
Z9 18
U1 1
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD APR
PY 2023
VL 102
IS 4
BP 440
EP 449
DI 10.1177/00220345221141043
EA FEB 2023
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 9Y5ZZ
UT WOS:000928256600001
PM 36749069
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Liu, X
   Qin, JQ
   Luo, Q
   Bi, Y
   Zhu, GH
   Jiang, W
   Kim, SH
   Li, M
   Su, YX
   Nan, GX
   Cui, J
   Zhang, WW
   Li, RD
   Chen, X
   Kong, YH
   Zhang, JY
   Wang, JH
   Rogers, MR
   Zhang, HY
   Shui, W
   Zhao, C
   Wang, N
   Liang, X
   Wu, NN
   He, YF
   Luu, HH
   Haydon, RC
   Shi, LL
   Li, TY
   He, TC
   Li, M
AF Liu, Xing
   Qin, Jiaqiang
   Luo, Qing
   Bi, Yang
   Zhu, Gaohui
   Jiang, Wei
   Kim, Stephanie H.
   Li, Mi
   Su, Yuxi
   Nan, Guoxin
   Cui, Jing
   Zhang, Wenwen
   Li, Ruidong
   Chen, Xiang
   Kong, Yuhan
   Zhang, Jiye
   Wang, Jinhua
   Rogers, Mary Rose
   Zhang, Hongyu
   Shui, Wei
   Zhao, Chen
   Wang, Ning
   Liang, Xi
   Wu, Ningning
   He, Yunfeng
   Luu, Hue H.
   Haydon, Rex C.
   Shi, Lewis L.
   Li, Tingyu
   He, Tong Chuan
   Li, Ming
TI Cross talk between EGF and BMP9 signalling pathways regulates the
   osteogenic differentiation of mesenchymal stem cells
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE BMP9 signalling; osteoblastic differentiation; EGF signalling;
   mesenchymal stem cells; osteogenic differentiation
ID EPIDERMAL GROWTH FACTOR; BONE MORPHOGENETIC PROTEINS; SUPPRESSES
   TUMOR GROWTH; FACTOR RECEPTOR; OSTEOBLAST DIFFERENTIATION; PLAYS; MICE;
   WNT; MECHANISMS; EXPANSION
AB Mesenchymal stem cells (MSCs) are multipotent progenitors, which give rise to several lineages, including bone, cartilage and fat. Epidermal growth factor (EGF) stimulates cell growth, proliferation and differentiation. EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface and stimulating the intrinsic protein tyrosine kinase activity of its receptor, which initiates a signal transduction cascade causing a variety of biochemical changes within the cell and regulating cell proliferation and differentiation. We have identified BMP9 as one of the most osteogenic BMPs in MSCs. In this study, we investigate if EGF signalling cross talks with BMP9 and regulates BMP9 induced osteogenic differentiation. We find that EGF potentiates BMP9 induced early and late osteogenic markers of MSCs in vitro, which can be effectively blunted by EGFR inhibitors Gefitinib and Erlotinib or receptor tyrosine kinase inhibitors AG 1478 and AG 494 in a dose  and time dependent manner. Furthermore, EGF significantly augments BMP9 induced bone formation in the cultured mouse foetal limb explants. In vivo stem cell implantation experiment reveals that exogenous expression of EGF in MSCs can effectively potentiate BMP9 induced ectopic bone formation, yielding larger and more mature bone masses. Interestingly, we find that, while EGF can induce BMP9 expression in MSCs, EGFR expression is directly up regulated by BMP9 through Smad1/5/8 signalling pathway. Thus, the cross talk between EGF and BMP9 signalling pathways in MSCs may underline their important roles in regulating osteogenic differentiation. Harnessing the synergy between BMP9 and EGF should be beneficial for enhancing osteogenesis in regenerative medicine.
C1 [Liu, Xing; Qin, Jiaqiang; Luo, Qing; Bi, Yang; Zhu, Gaohui; Li, Mi; Su, Yuxi; Nan, Guoxin; Li, Tingyu; He, Tong Chuan; Li, Ming] Chongqing Med Univ, Chinese Minist Educ, Key Lab Pediat, Stem Cell Biol & Therapy Lab, Chongqing 400014, Peoples R China.
   [Liu, Xing; Qin, Jiaqiang; Luo, Qing; Bi, Yang; Zhu, Gaohui; Li, Mi; Su, Yuxi; Nan, Guoxin; Li, Tingyu; He, Tong Chuan; Li, Ming] Chongqing Med Univ, Childrens Hosp, Dept Orthopaed Surg, Chongqing Bur Educ, Chongqing 400014, Peoples R China.
   [Qin, Jiaqiang; Luo, Qing; Bi, Yang; Zhu, Gaohui; Jiang, Wei; Kim, Stephanie H.; Li, Mi; Su, Yuxi; Nan, Guoxin; Cui, Jing; Zhang, Wenwen; Li, Ruidong; Chen, Xiang; Kong, Yuhan; Zhang, Jiye; Wang, Jinhua; Rogers, Mary Rose; Zhang, Hongyu; Shui, Wei; Zhao, Chen; Wang, Ning; Liang, Xi; Wu, Ningning; He, Yunfeng; Luu, Hue H.; Haydon, Rex C.; Shi, Lewis L.] Univ Chicago, Med Ctr, Dept Orthopaed Surg, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Cui, Jing; Zhang, Wenwen; Li, Ruidong; Kong, Yuhan; Zhang, Jiye; Wang, Jinhua; Zhang, Hongyu; Shui, Wei; Liang, Xi; Wu, Ningning; He, Yunfeng; He, Tong Chuan] Chongqing Med Univ, Dept Lab Med, Key Lab Diagnost Med, Minist Educ, Chongqing 400014, Peoples R China.
   [Cui, Jing; Zhang, Wenwen; Li, Ruidong; Kong, Yuhan; Zhang, Jiye; Wang, Jinhua; Zhang, Hongyu; Shui, Wei; Liang, Xi; Wu, Ningning; He, Yunfeng; He, Tong Chuan] Chongqing Med Univ, Affiliated Hosp, Chongqing 400014, Peoples R China.
   [Chen, Xiang] Fourth Mil Med Univ, Tangdu Hosp, Dept Orthopaed Surg, Xian 710032, Peoples R China.
   [Zhao, Chen; Wang, Ning] Third Mil Med Univ, Sch Lab Med, Chongqing, Peoples R China.
   [Zhao, Chen; Wang, Ning] Third Mil Med Univ, Affiliated Southwest Hosp, Chongqing, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; University
   of Chicago; University of Chicago Medical Center; Chongqing Medical
   University; Chongqing Medical University; Air Force Medical University;
   Army Medical University; Army Medical University
RP He, TC (通讯作者)，Chongqing Med Univ, Chinese Minist Educ, Key Lab Pediat, Stem Cell Biol & Therapy Lab, Chongqing 400014, Peoples R China.
EM tche@uchicago.edu; lm3180@163.com
RI he, yun/JMB 6362 2023; Chen, Xiangdong/KCX 7707 2024; Zhang,
   Jiye/LSJ 2675 2024
OI Chen, Xiang/0000 0001 7628 516X; 
FU Orthopaedic Research and Education Foundation; National Institutes of
   Health; Natural Science Foundation of China [81100309, 81001197,
   30973062, 81172545, 81272172]
FX We thank Dr. Chad Hanley of the Department of Radiology at The
   University of Chicago for his assistance and advice on mu CT scanning
   and imaging analysis. This study was supported in part by research
   grants from the Orthopaedic Research and Education Foundation (RCH and
   HHL), the National Institutes of Health (RCH, TCH and HHL), and the
   Natural Science Foundation of China (#81100309 to YB, #81001197 to YS,
   #30973062 and 81172545 to QL, and #81272172 to GN).
CR ANTOSZ ME, 1987, J BONE MINER RES, V2, P385
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254
   CANALIS E, 1979, ENDOCRINOLOGY, V104, P862, DOI 10.1210/endo 104 4 862
   Chan SY, 2000, J BIOL CHEM, V275, P38693, DOI 10.1074/jbc.M004189200
   Chen C, 2003, NAT BIOTECHNOL, V21, P294, DOI 10.1038/nbt795
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962
   David L, 2008, CIRC RES, V102, P914, DOI 10.1161/CIRCRESAHA.107.165530
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Fisher MC, 2007, DEV GROWTH DIFFER, V49, P503, DOI 10.1111/j.1440 169x.2007.00941.x
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kim JH, 2012, ANGIOGENESIS, V15, P497, DOI 10.1007/s10456 012 9277 x
   Krampera M, 2005, BLOOD, V106, P59, DOI 10.1182/blood 2004 09 3645
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   López Coviella I, 2000, SCIENCE, V289, P313, DOI 10.1126/science.289.5477.313
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luther G, 2011, CURR GENE THER, V11, P229
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   MARIE PJ, 1990, AM J PHYSIOL, V258, pE275, DOI 10.1152/ajpendo.1990.258.2.E275
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Ono M, 2006, CLIN CANCER RES, V12, P7242, DOI 10.1158/1078 0432.CCR 06 0646
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Rastegar Farbod, 2010, World J Stem Cells, V2, P67, DOI 10.4252/wjsc.v2.i4.67
   Rastegar F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014182
   Schneider MR, 2009, TRENDS ENDOCRIN MET, V20, P517, DOI 10.1016/j.tem.2009.06.008
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Sibilia M, 2003, DEVELOPMENT, V130, P4515, DOI 10.1242/dev.00664
   SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Tamama K, 2006, STEM CELLS, V24, P686, DOI 10.1634/stemcells.2005 0176
   Tamama K, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/795385
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919
   Wang K, 2004, J BIOL CHEM, V279, P53848, DOI 10.1074/jbc.M403114200
   Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309
   Zhang JW, 2005, DEV BIOL, V284, P1, DOI 10.1016/j.ydbio.2005.05.009
   Zhang W, 2010, PLOS ONE, V5
   Zhang XR, 2011, J BONE MINER RES, V26, P2622, DOI 10.1002/jbmr.502
   Zhang XR, 2011, J BONE MINER RES, V26, P1022, DOI 10.1002/jbmr.295
NR 61
TC 69
Z9 75
U1 0
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD SEP
PY 2013
VL 17
IS 9
BP 1160
EP 1172
DI 10.1111/jcmm.12097
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 224ZM
UT WOS:000324932100011
PM 23844832
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Carbone, EJ
   Rajpura, K
   Allen, BN
   Cheng, E
   Ulery, BD
   Lo, KWH
AF Carbone, Erica J.
   Rajpura, Komal
   Allen, Brittany N.
   Cheng, Emily
   Ulery, Bret D.
   Lo, Kevin W.  H.
TI Osteotropic nanoscale drug delivery systems based on small molecule
   bone targeting moieties
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Musculoskeletal tissue; Small molecules; Targeted drug delivery;
   Nanomedicine
ID PEG PLGA NANOPARTICLES; LOADED NANOPARTICLES; PARTICLE SIZE;
   OSTEOPOROSIS; BISPHOSPHONATES; ACID; CANCER; WOMEN; CARRIERS; SAFETY
AB Bone targeted drug delivery is an active research area because successful clinical applications of this technology can significantly advance the treatment of bone injuries and disorders. Molecules with bone targeting potential have been actively investigated as promising moieties in targeted drug delivery systems. In general, bone targetingmolecules are characterized by their high affinity for bone and their predisposition to persist in bone tissue for prolonged periods, while maintaining low systemic concentrations. Proteins, such as monoclonal antibodies, have shown promise as bone targeting molecules; however, they suffer fromseveral limitations including large molecular size, high production cost, and undesirable immune responses. Aviable alternative associated with significantly less side effects is the use of small molecule based targeting moieties. This review provides a summary of recent findings regarding small molecule compounds with bone targeting capacity, as well as nanoscale targeted drug delivery approaches employing these molecules. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Carbone, Erica J.; Rajpura, Komal; Lo, Kevin W.  H.] Univ Connecticut, Sch Med, Ctr Hlth, Inst Regenerat Engn, Farmington, CT 06030 USA.
   [Carbone, Erica J.; Rajpura, Komal; Lo, Kevin W.  H.] Univ Connecticut, Ctr Hlth, Sch Med, Raymond & Beverly Sackler Ctr Biomed Biol Phys &, Farmington, CT USA.
   [Carbone, Erica J.; Lo, Kevin W.  H.] Univ Connecticut, Ctr Hlth, Dept Med, Div Endocrinol,Sch Med, Farmington, CT USA.
   [Carbone, Erica J.; Lo, Kevin W.  H.] Univ Connecticut, Ctr Hlth, UConn Stem Cell Inst, Farmington, CT USA.
   [Allen, Brittany N.] Univ Missouri, Dept Bioengn, Columbia, MO USA.
   [Cheng, Emily; Ulery, Bret D.] Univ Missouri, Dept Chem Engn, Columbia, MO 65211 USA.
   [Lo, Kevin W.  H.] Univ Connecticut, Sch Engn, Dept Biomed Engn, Storrs, CT USA.
   [Rajpura, Komal; Lo, Kevin W.  H.] Univ Connecticut, Ctr Hlth, Connecticut Inst Clin & Translat Sci, Farmington, CT USA.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut; University of Connecticut; University of Missouri System;
   University of Missouri Columbia; University of Missouri System;
   University of Missouri Columbia; University of Connecticut; University
   of Connecticut
RP Lo, KWH (通讯作者)，Univ Connecticut, Sch Med, Ctr Hlth, Inst Regenerat Engn, Farmington, CT 06030 USA.
EM wlo@uchc.edu
RI Yang, Chi/JRY 4671 2023; Allen, Brittany/AAD 8587 2020
FU Raymond and Beverly Sackler Center for Biomedical, Biological, Physical
   and Engineering Sciences Foundation
FX We wish to thank all members of the Institute for Regenerative
   Engineering (IRE), past and present, and numerous colleagues and friends
   for their helpful discussions. We also thank the Raymond and Beverly
   Sackler Center for Biomedical, Biological, Physical and Engineering
   Sciences Foundation for their generous support of IRE.
CR Aoki K, 2012, ADV DRUG DELIVER REV, V64, P1220, DOI 10.1016/j.addr.2012.05.017
   Atteritano M, 2015, ENDOCRINE
   Benezra M, 2012, NEOPLASIA, V14, P1132, DOI 10.1593/neo.121750
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Body Jean Jacques, 2013, J Med Econ, V16, P539, DOI 10.3111/13696998.2013.774279
   Bolland MJ, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c3691
   Butoescu N, 2009, BIOMATERIALS, V30, P1772, DOI 10.1016/j.biomaterials.2008.12.017
   Carbone EJ, 2014, NANOMED NANOTECHNOL, V10, P1691, DOI 10.1016/j.nano.2014.05.013
   Casadei K, 2009, INT J WOMENS HEALTH, V1, P1
   Cenni E, 2008, BIOMATERIALS, V29, P1400, DOI 10.1016/j.biomaterials.2007.12.022
   Chen YC, 2013, J BIOMATER APPL, V27, P909, DOI 10.1177/0885328211429495
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cohen Sela E, 2009, J PHARM SCI US, V98, P1452, DOI 10.1002/jps.21527
   CONN J, 1974, AM J SURG, V128, P19, DOI 10.1016/0002 9610(74)90228 1
   de Miguel L, 2014, INT J PHARMACEUT, V460, P73, DOI 10.1016/j.ijpharm.2013.10.048
   Deng XY, 2014, CANCER TREAT REV, V40, P730, DOI 10.1016/j.ctrv.2014.04.003
   Dodson TB, 2015, ORAL MAXIL SURG CLIN, V27, P509, DOI 10.1016/j.coms.2015.06.003
   Engelke K, 2009, BONE, V45, P110, DOI 10.1016/j.bone.2009.03.669
   Enlow EM, 2011, NANO LETT, V11, P808, DOI 10.1021/nl104117p
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fu YC, 2014, ACTA BIOMATER, V10, P4583, DOI 10.1016/j.actbio.2014.07.015
   Fujiwara S, 2014, CLIN INTERV AGING, V9, P1879, DOI 10.2147/CIA.S70307
   Ganda K, 2014, OSTEOPOROSIS INT, V25, P1345, DOI 10.1007/s00198 013 2610 4
   Ghirardi A, 2015, CLIN PHARM, V70, P1129
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Gill KK, 2015, J DRUG TARGET, V23, P222, DOI 10.3109/1061186X.2014.997735
   Greenspan SL, 2015, JAMA INTERN MED, V175, P913, DOI 10.1001/jamainternmed.2015.0747
   Griffin MO, 2010, AM J PHYSIOL CELL PH, V299, pC539, DOI 10.1152/ajpcell.00047.2010
   Gu WY, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S44393
   Sillero MAG, 2009, BIOCHEM PHARMACOL, V78, P335, DOI 10.1016/j.bcp.2009.04.028
   Guo JW, 2011, BIOMATERIALS, V32, P8010, DOI 10.1016/j.biomaterials.2011.07.004
   Hagino H, 2014, CALCIFIED TISSUE INT, V95, P557, DOI 10.1007/s00223 014 9927 7
   Hough FS, 2014, SAMJ S AFR MED J, V104, P279, DOI 10.7196/SAMJ.7505
   Jain A, 2008, CRIT REV THER DRUG, V25, P403, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i5.10
   Jansen DR, 2009, J INORG BIOCHEM, V103, P1265, DOI 10.1016/j.jinorgbio.2009.07.007
   Ji W, 2012, ADV DRUG DELIVER REV, V64, P1152, DOI 10.1016/j.addr.2012.03.003
   Jiang T, 2014, INT J PHARMACEUT, V475, P547, DOI 10.1016/j.ijpharm.2014.08.067
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kamaly N, 2012, CHEM SOC REV, V41, P2971, DOI 10.1039/c2cs15344k
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Keum CG, 2011, INT J NANOMED, V6, P2225, DOI 10.2147/IJN.S24547
   Kinov P, 2012, INT J WOMENS HEALTH, V4, P167, DOI 10.2147/IJWH.S18209
   Kopecek J, 2000, EUR J PHARM BIOPHARM, V50, P61, DOI 10.1016/S0939 6411(00)00075 8
   KOPECEK J, 1973, J BIOMED MATER RES, V7, P179, DOI 10.1002/jbm.820070206
   Laurencin CT, 2014, DRUG DISCOV TODAY, V19, P794, DOI 10.1016/j.drudis.2014.01.012
   Lax R., 2010, PHARMANUFACTURING IN, P10
   Li YP, 2001, J CONTROL RELEASE, V71, P203, DOI 10.1016/S0168 3659(01)00218 8
   Liu J, 2012, J CONTROL RELEASE, V157, P398, DOI 10.1016/j.jconrel.2011.09.090
   Liu YT, 2010, BIOMATERIALS, V31, P9145, DOI 10.1016/j.biomaterials.2010.08.053
   Lo KWH, 2014, TRENDS BIOTECHNOL, V32, P74, DOI 10.1016/j.tibtech.2013.12.002
   Lo KWH, 2012, REGEN MED, V7, P535, DOI [10.2217/rme.12.33, 10.2217/RME.12.33]
   Lobo RA, 2014, CLIMACTERIC, V17, P540, DOI 10.3109/13697137.2014.933411
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Lu RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066128
   Makita K, 2015, J BONE MINER METAB, V33, P55, DOI 10.1007/s00774 013 0553 7
   Malugin A, 2006, MOL PHARMACEUT, V3, P351, DOI 10.1021/mp050065e
   McMillan J, 2011, PROG MOL BIOL TRANSL, V104, P563, DOI 10.1016/B978 0 12 416020 0.00014 0
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Misra R, 2009, NANOMEDICINE UK, V4, P519, DOI 10.2217/NNM.09.28
   Morton SW, 2014, ADV HEALTHC MATER, V3, P867, DOI 10.1002/adhm.201300465
   Murakami H, 2000, J CONTROL RELEASE, V67, P29, DOI 10.1016/S0168 3659(99)00288 6
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Ogawa K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084335
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Papapoulos SE, 1997, MEDICINA BUENOS AIRE, V57, P61
   Paulo S, 2014, ONCOL REV, V8, P44, DOI 10.4081/oncol.2014.254
   Payne JB, 2011, PHARMACOL RES, V63, P121, DOI 10.1016/j.phrs.2010.10.006
   Peroni A, 2008, J AM ACAD DERMATOL, V59, P125, DOI 10.1016/j.jaad.2008.03.009
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Petkovic H, 2006, MICROBIOL MOL BIOL R, V70, P704, DOI 10.1128/MMBR.00004 06
   Pignatello R, 2012, J FUNCT BIOMATER, V3, P79, DOI 10.3390/jfb3010079
   Pignatello R, 2009, NANOMEDICINE UK, V4, P161, DOI 10.2217/17435889.4.2.161
   Pillai RR, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/3/034114
   Pradhan R, 2013, J NANOSCI NANOTECHNO, V13, P5948, DOI 10.1166/jnn.2013.7735
   Prommer EE, 2009, J PALLIAT MED, V12, P1061, DOI 10.1089/jpm.2009.9936
   Quattrocchi E, 2004, CLIN THER, V26, P841, DOI 10.1016/S0149 2918(04)90128 2
   Reginster JY, 2015, OSTEOPOROSIS INT, V26, P1667, DOI 10.1007/s00198 015 3109 y
   Reid IR, 2015, J INTERN MED, V278, P354, DOI 10.1111/joim.12394
   Ríhová B, 2002, ADV DRUG DELIVER REV, V54, P653
   Ríhová B, 2001, MACROMOL SYMP, V172, P21, DOI 10.1002/1521 3900(200107)172:1<21::AID MASY21>3.0.CO;2 C
   Ríhová B, 2010, ADV DRUG DELIVER REV, V62, P184, DOI 10.1016/j.addr.2009.10.005
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Ross RD, 2011, J BIOMED MATER RES A, V99A, P58, DOI 10.1002/jbm.a.33165
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Sanders KM, 2010, JAMA J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   Sikon A, 2010, INT J WOMENS HEALTH, V2, P37
   Singh T, 2015, J DRUG TARGET, V23, P1, DOI 10.3109/1061186X.2014.950668
   Song XR, 2008, EUR J PHARM BIOPHARM, V69, P445, DOI 10.1016/j.ejpb.2008.01.013
   Song XR, 2008, INT J PHARMACEUT, V350, P320, DOI 10.1016/j.ijpharm.2007.08.034
   Sun L., 2013, Modern Chemistry Applications, V1, P1000
   Sun LM, 2014, J CLIN ENDOCR METAB, V99, P4259, DOI 10.1210/jc.2014 2239
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   Tewes F, 2007, EUR J PHARM BIOPHARM, V66, P488, DOI 10.1016/j.ejpb.2007.02.016
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Tosteson ANA, 2010, OSTEOPOROSIS INT, V21, P1769, DOI 10.1007/s00198 009 1133 5
   Tower RJ, 2014, J BONE MINER RES, V29, P1993, DOI 10.1002/jbmr.2224
   Tran TH, 2014, J NANOSCI NANOTECHNO, V14, P4820, DOI 10.1166/jnn.2014.8722
   Valentn S, 2009, CLIN COSMET INVESTI, V2, P129
   Vinay R, 2016, DRUG DELIV, V23, P21, DOI 10.3109/10717544.2014.913325
   Wang AZ, 2008, EXPERT OPIN BIOL TH, V8, P1063, DOI [10.1517/14712598.8.8.1063, 10.1517/14712598.8.8.1063 ]
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wells G, 2016, OSTEOPOROSIS INT, V27, P13, DOI 10.1007/s00198 015 3339 z
   Wen D, 2011, ORAL DIS, V17, P427, DOI 10.1111/j.1601 0825.2010.01772.x
   Wen ZY, 2011, J CONTROL RELEASE, V151, P131, DOI 10.1016/j.jconrel.2011.02.022
   Wijagkanalan W, 2011, FRONT BIOSCI LANDMRK, V16, P2970, DOI 10.2741/3892
   Willson TM, 1996, BIOORG MED CHEM LETT, V6, P1047, DOI 10.1016/0960 894X(96)00165 5
   Willson TM, 1996, BIOORG MED CHEM LETT, V6, P1043, DOI 10.1016/0960 894X(96)00164 3
   Woolf DK, 2014, ANN ONCOL
   WRONSKI TJ, 1988, ENDOCRINOLOGY, V123, P681, DOI 10.1210/endo 123 2 681
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 303
   Yu MK, 2012, THERANOSTICS, V2, P3, DOI 10.7150/thno.3463
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang XD, 2014, BIOMATERIALS, V35, P1932, DOI 10.1016/j.biomaterials.2013.10.034
   Zhao J, 2015, J BIOMAT SCI POLYM E, V26, P1067, DOI 10.1080/09205063.2015.1077919
   Zigoneanu IG, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957 4484/19/10/105606
NR 120
TC 58
Z9 62
U1 1
U2 76
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JAN
PY 2017
VL 13
IS 1
BP 37
EP 47
DI 10.1016/j.nano.2016.08.015
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA EO0HF
UT WOS:000396378200004
PM 27562211
DA 2025 08 17
ER

PT J
AU Lin, HN
   O'Connor, JP
AF Lin, Hsuan Ni
   O'Connor, J. Patrick
TI Osteoclast depletion with clodronate liposomes delays fracture healing
   in mice
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE fracture healing; bone regeneration; osteogenesis; osteoclasts;
   macrophages
ID ENDOCHONDRAL BONE FORMATION; ENDOTHELIAL GROWTH FACTOR; IN VIVO;
   MECHANICAL PROPERTIES; CATHEPSIN K; MACROPHAGES; RESORPTION; REPAIR;
   OSSIFICATION; CALLUS
AB Osteoclasts are abundant within the fracture callus and also localize at the chondro osseous junction. However, osteoclast functions during fracture healing are not well defined. Inhibition of osteoclast formation or resorptive activity impairs callus remodeling but does not prevent callus formation. Interestingly, though anti osteoclast therapies differentially affect resolution of callus cartilage into bone. Treatments that inhibit osteoclast formation or viability tend to impair callus cartilage resolution, while treatments that target inhibition of bone resorption generally do not affect callus cartilage resolution. Here, we tested whether depletion of osteoclasts by systemic treatment with clodronate liposomes would similarly impair callus cartilage resolution. ICR mice were treated by intraperitoneal injections of clodronate laden liposomes or control liposomes and subjected to closed femur fracture. Femurs were resected at multiple times after fracture and analyzed by radiography, histology, and mechanical testing to determine effects on healing. Clodronate liposome treatment did not prevent callus formation. However, radiographic scoring indicated that clodronate liposome treatment impaired healing. Clodronate liposome treatment significantly reduced callus osteoclast populations and delayed resolution of callus cartilage. Consistent with continued presence of callus cartilage, torsional mechanical testing found significant decreases in callus material properties after 28 days of healing. The results support a role for osteoclasts in the resolution of callus cartilage into bone. Whether the cartilage resolution role for osteoclasts is limited to simply resorbing cartilage at the chondro osseous junction or in promoting bone formation at the chondro osseous junction through another mechanism, perhaps similar to the reversal process in bone remodeling, will require further experimentation. (C) 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:1699 1706, 2017.
C1 [O'Connor, J. Patrick] Rutgers State Univ, Grad Sch Biomed Sci, Dept Orthopaed, 185 South Orange Ave, Newark, NJ 07103 USA.
   Rutgers State Univ, New Jersey Med Sch, 185 South Orange Ave, Newark, NJ 07103 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Newark; Rutgers University System; Rutgers University Newark;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences
RP O'Connor, JP (通讯作者)，Rutgers State Univ, Grad Sch Biomed Sci, Dept Orthopaed, 185 South Orange Ave, Newark, NJ 07103 USA.
EM oconnojp@njms.rutgers.edu
FU Department of Defense Congressionally Directed Medical Research Programs
   Peer Reviewed Orthopaedic Research Program [W81XWH 10 1 0944]
FX Grant sponsor: Department of Defense Congressionally Directed Medical
   Research Programs Peer Reviewed Orthopaedic Research Program; Grant
   number: W81XWH 10 1 0944.
CR Al Zube L, 2009, J ORTHOP RES, V27, P1074, DOI 10.1002/jor.20842
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Andersen TL, 2013, AM J PATHOL, V183, P235, DOI 10.1016/j.ajpath.2013.03.006
   Andreasen CM, 2015, BONE, V75, P32, DOI 10.1016/j.bone.2015.02.014
   ATHANASOU NA, 1990, J CLIN PATHOL, V43, P997, DOI 10.1136/jcp.43.12.997
   Behonick DJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001150
   Bergenstock M, 2005, J ORTHOP TRAUMA, V19, P717, DOI 10.1097/01.bot.0000184144.98071.5d
   Burnett SH, 2004, J LEUKOCYTE BIOL, V75, P612, DOI 10.1189/jlb.0903442
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Cho SW, 2014, P NATL ACAD SCI USA, V111, P1545, DOI 10.1073/pnas.1315153111
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Delos D, 2008, J ORTHOP RES, V26, P153, DOI 10.1002/jor.20469
   EKELAND A, 1981, ACTA ORTHOP SCAND, V52, P605, DOI 10.3109/17453678108992155
   ENGESAETER LB, 1978, ACTA ORTHOP SCAND, V49, P512, DOI 10.3109/17453677808993231
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736 0266(03)00011 1
   Gentile MA, 2014, BONE, V66, P72, DOI 10.1016/j.bone.2014.04.032
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Kamimura M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128210
   Kayal RA, 2007, J BONE MINER RES, V22, P560, DOI 10.1359/JBMR.070115
   Lin HN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088423
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925 4773(01)00601 3
   Manigrasso MB, 2004, J ORTHOP TRAUMA, V18, P687, DOI 10.1097/00005131 200411000 00006
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   Odgren PR, 2016, CONNECT TISSUE RES, V57, P161, DOI 10.3109/03008207.2016.1140752
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pennypacker BL, 2016, J ORTHOP RES, V34, P72, DOI 10.1002/jor.22982
   Raggatt LJ, 2014, AM J PATHOL, V184, P3192, DOI 10.1016/j.ajpath.2014.08.017
   Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood 2004 01 0041
   Russell RGG, 2015, CURR OPIN PHARMACOL, V22, P115, DOI 10.1016/j.coph.2015.05.005
   Sabokbar A, 1997, ANN RHEUM DIS, V56, P414, DOI 10.1136/ard.56.7.414
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735
   Soung DY, 2013, BONE, V55, P248, DOI 10.1016/j.bone.2013.02.010
   Tonna S, 2016, DEVELOPMENT, V143, P648, DOI 10.1242/dev.125625
   Touaitahuata H, 2014, DEV BIOL, V393, P57, DOI 10.1016/j.ydbio.2014.06.020
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   van Rooijen N, 2002, J LIPOSOME RES, V12, P81, DOI 10.1081/LPR 120004780
   van Rooijen N, 2003, METHOD ENZYMOL, V373, P3
   VANROOIJEN N, 1984, CELL TISSUE RES, V238, P355, DOI 10.1007/BF00217308
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   Vi L, 2015, J BONE MINER RES, V30, P1090, DOI 10.1002/jbmr.2422
   Wang BL, 2015, SCI REP UK, V5, DOI 10.1038/srep13667
   Wang BL, 2014, ARTHRITIS RHEUMATOL, V66, P107, DOI 10.1002/art.38195
   Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005
   Yu YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031771
NR 49
TC 33
Z9 36
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD AUG
PY 2017
VL 35
IS 8
BP 1699
EP 1706
DI 10.1002/jor.23440
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA FD0FY
UT WOS:000407216400014
PM 27653179
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lo, T
   Tsai, CF
   Shih, YRV
   Wang, YT
   Lu, SC
   Sung, TY
   Hsu, WL
   Chen, YJ
   Lee, OK
AF Lo, Ting
   Tsai, Chia Feng
   Shih, Yu Ru V.
   Wang, Yi Ting
   Lu, Sheng Chieh
   Sung, Ting Yi
   Hsu, Wen Lian
   Chen, Yu Ju
   Lee, Oscar K.
TI Phosphoproteomic Analysis of Human Mesenchymal Stromal Cells during
   Osteogenic Differentiation
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
ID STEM CELLS; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION;
   SIGNAL TRANSDUCTION; EXPRESSED PROTEINS; MYOSIN PHOSPHATASE;
   THYROID HORMONE; BINDING FACTOR; BONE FORMATION; KINASE
AB Human mesenchymal stromal cells (hMSCs) are promising candidates for cell therapy and tissue regeneration. Knowledge of the molecular mechanisms governing hMSC commitment into osteoblasts is critical to the development of therapeutic applications for human bone diseases. Because protein phosphorylation plays a critical role in signaling transduction network, the purpose of this study is to elucidate the phosphoproteomic changes in hMSCs during early osteogenic lineage commitment. hMSCs cultured in osteogenic induction medium for 0, 1, 3, and 7 days were analyzed by liquid chromatography tandem mass spectrometry (LC MS/MS). Surprisingly, we observed a dramatic loss of protein phosphorylation level after 1 day of osteogenic induction. Pathways analysis of these reduced phosphoproteins exhibited a high correlation with cell proliferation and protein synthesis pathways. During osteogenic differentiation, differentially expressed phosphoproteins demonstrated the dynamic alterations in cytoskeleton at the early stages of differentiation. The fidelity of our quantitative phosphoproteomic analyses were further confirmed by Western blot analyses, and the changes from protein expression or its phosphorylation level were distinguished. In addition, several ion channels and transcription factors with differentially expressed phosphorylation sites during osteogenic differentiation were identified and may serve as potentially unexplored transcriptional regulators of the osteogenic phenotype of hMSCs. Taken together, our results have demonstrated the dynamic changes in phosphoproteomic profiles of h.MSCs during osteogenic differentiation and unraveled potential candidates mediating the osteogenic commitment of hMSCs. The findings in this study may also shed light on the development of new therapeutic targets for metabolic bone diseases such as osteoporosis and osteomalacia.
C1 [Wang, Yi Ting; Chen, Yu Ju] Acad Sinica, Inst Chem, Taiwan Int Grad Program, Chem Biol & Mol Biophys Program, Taipei, Taiwan.
   [Tsai, Chia Feng; Wang, Yi Ting; Chen, Yu Ju] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Lu, Sheng Chieh; Sung, Ting Yi; Hsu, Wen Lian] Acad Sinica, Inst Informat Sci, Taipei, Taiwan.
   [Lee, Oscar K.] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan.
   [Lee, Oscar K.] Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, Taipei, Taiwan.
   [Lo, Ting; Shih, Yu Ru V.; Lee, Oscar K.] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Lee, Oscar K.] Natl Yang Ming Univ, Stem Cell Res Ctr, Taipei 112, Taiwan.
   [Tsai, Chia Feng; Chen, Yu Ju] Natl Taiwan Univ, Dept Chem, Taipei 10764, Taiwan.
   [Wang, Yi Ting] Natl Taiwan Univ, Inst Biochem Sci, Taipei, Taiwan.
C3 Academia Sinica   Taiwan; Academia Sinica   Taiwan; Academia Sinica  
   Taiwan; Taipei Veterans General Hospital; Taipei Veterans General
   Hospital; National Yang Ming Chiao Tung University; National Yang Ming
   Chiao Tung University; National Taiwan University; National Taiwan
   University
RP Chen, YJ (通讯作者)，Acad Sinica, Inst Chem, Taiwan Int Grad Program, Chem Biol & Mol Biophys Program, Taipei, Taiwan.
EM yjchen@chem.sinica.edu.tw; kslee@vghtpe.gov.tw
RI Hsu, Wen Lian/ABB 2851 2020; Sung, Ting Yi/AAQ 5413 2021; Wang,
   Yiting/S 2558 2017; Chen, Yu Ju/E 9481 2015; Lee, Oscar/MEK 9750 2025
OI Chen, Yu Ju/0000 0002 3178 6697; 
FU UST UCSD International Center of Excellence in Advanced Bioengineering;
   Taiwan National Science Council I RiCE [NSC 99 2911 I 009 101]; Taipei
   Veterans General Hospital [VGH100E1 010, VGH100C 056, VN100 05,
   VGH100D 003 2]; National Science Council, Taiwan [NSC100 2120 M 010 001,
   NSC100 2314 B 010 030 MY3, NSC100 2321 B 010 019, NSC99 3111 B 010 002,
   NSC98 2314 B 010 001 MY3, NSC 99 2911 I 010 501, NSC 99 3114 B 002 005];
   Ministry of Education, Aim for the Top University Plan
FX This work was supported in part by the UST UCSD International Center of
   Excellence in Advanced Bioengineering sponsored by the Taiwan National
   Science Council I RiCE Program under Grant Number:
   NSC 99 2911 I 009 101. The authors also acknowledge financial support
   from the Taipei Veterans General Hospital (VGH100E1 010, VGH100C 056,
   VN100 05, and VGH100D 003 2), the National Science Council, Taiwan
   (NSC100 2120 M 010 001, NSC100 2314 B 010 030 MY3,
   NSC100 2321 B 010 019, NSC99 3111 B 010 002, NSC98 2314 B 010 001 MY3,
   NSC 99 2911 I 010 501, and NSC 99 3114 B 002 005).This study was also
   supported by a grant from the Ministry of Education, Aim for the Top
   University Plan. We thank Dr. Shu Yu Lin for assistance with the
   LTQ Orbitrap XL hybrid mass spectrometry analyses from the common mass
   spectrometry facilities located at the Institute of Biological
   Chemistry, Academia Sinica.
CR Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Bassett JHD, 2003, TRENDS ENDOCRIN MET, V14, P356, DOI 10.1016/S1043 2760(03)00144 90
   Bassett JHD, 2003, MOL CELL ENDOCRINOL, V213, P1, DOI 10.1016/j.mce.2003.10.033
   Bennett KP, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 380
   Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440 1711.2000.00928.x
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22 4 625
   Bixby KA, 1999, NAT STRUCT BIOL, V6, P38
   Brill LM, 2009, CELL STEM CELL, V5, P204, DOI 10.1016/j.stem.2009.06.002
   Çelebi B, 2010, J PROTEOME RES, V9, P5217, DOI 10.1021/pr100506u
   Cheung BB, 2006, J BIOL CHEM, V281, P18246, DOI 10.1074/jbc.M600879200
   Cho T, 2002, NEUROREPORT, V13, P1447, DOI 10.1097/00001756 200208070 00020
   Choi YA, 2010, J PROTEOME RES, V9, P2946, DOI 10.1021/pr901110q
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Formigli L, 2007, J CELL PHYSIOL, V211, P296, DOI 10.1002/jcp.20936
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508 9516.2004
   GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311
   Han CL, 2008, MOL CELL PROTEOMICS, V7, P1983, DOI 10.1074/mcp.M800068 MCP200
   HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0
   Hasegawa T, 2000, BIOCHEM J, V347, P55, DOI 10.1042/0264 6021:3470055
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092 8674(95)90405 0
   Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Kim JS, 2008, BIOSCI BIOTECH BIOCH, V72, P2309, DOI 10.1271/bbb.80224
   Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245
   Kishiya M, 2008, J PHARMACOL SCI, V106, P404, DOI 10.1254/jphs.FP0072043
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood 2003 05 1670
   Liton P, 2006, MOL VIS, V12, P774
   Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092 8674(01)00623 7
   Marshall GM, 2010, ONCOGENE, V29, P6172, DOI 10.1038/onc.2010.340
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Meury T, 2010, MOL CELL BIOL, V30, P43, DOI 10.1128/MCB.00378 09
   Moreau A, 1998, MOL CELL BIOL, V18, P1312, DOI 10.1128/MCB.18.3.1312
   Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710 6718.2004
   Murányi A, 2005, FEBS LETT, V579, P6611, DOI 10.1016/j.febslet.2005.10.055
   Nishimura R, 2008, J BONE MINER METAB, V26, P203, DOI 10.1007/s00774 007 0824 2
   O'Connor RD, 2009, BONE, V45, P346, DOI 10.1016/j.bone.2009.04.251
   Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475
   Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030 MCP200
   Pan CP, 2009, MOL CELL PROTEOMICS, V8, P2796, DOI 10.1074/mcp.M900285 MCP200
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rajab A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000874
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   Ryu JM, 2010, J CELL PHYSIOL, V224, P59, DOI [10.1002/jcp.2209, 10.1002/jcp.22091]
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269
   Savitski MM, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.003830
   Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037
   Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03 1100fje
   Sottile V, 2003, CLONING STEM CELLS, V5, P149, DOI 10.1089/153623003322234759
   Sugiyama N, 2007, MOL CELL PROTEOMICS, V6, P1103, DOI 10.1074/mcp.T600060 MCP200
   Sun HJ, 2006, J ORTHOP RES, V24, P2059, DOI 10.1002/jor.20273
   Thingholm TE, 2008, J PROTEOME RES, V7, P3304, DOI 10.1021/pr800099y
   Thingholm TE, 2008, MOL CELL PROTEOMICS, V7, P661, DOI 10.1074/mcp.M700362 MCP200
   Tsai CF, 2008, J PROTEOME RES, V7, P4058, DOI 10.1021/pr800364d
   Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934
   Tsou CC, 2010, MOL CELL PROTEOMICS, V9, P131, DOI 10.1074/mcp.M900177 MCP200
   Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203
   van Kempen MJA, 2003, CELL PHYSIOL BIOCHEM, V13, P263, DOI 10.1159/000074541
   Wang YT, 2010, J PROTEOME RES, V9, P5582, DOI 10.1021/pr100394u
   WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16
   Xiao ZS, 2010, ANN NY ACAD SCI, V1192, P410, DOI 10.1111/j.1749 6632.2009.05239.x
   Zambelli A, 2005, CELL BIOL INT, V29, P647, DOI 10.1016/j.cellbi.2005.03.018
   Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 4 r28
   Zhang AX, 2007, MOL CELL BIOCHEM, V304, P167, DOI 10.1007/s11010 007 9497 3
   Zhang W., 2005, J BIOL CHEM
   Zhu Y, 2008, BBA GEN SUBJECTS, V1780, P128, DOI 10.1016/j.bbagen.2007.09.017
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 75
TC 15
Z9 16
U1 0
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535 3893
EI 1535 3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD FEB
PY 2012
VL 11
IS 2
BP 586
EP 598
DI 10.1021/pr200868p
PG 13
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 894WN
UT WOS:000300458300007
PM 22088210
DA 2025 08 17
ER

PT J
AU Qiu, Y
   Zhao, YY
   Long, ZM
   Song, AJ
   Huang, P
   Wang, KJ
   Xu, L
   Molloy, DP
   He, GQ
AF Qiu, Yu
   Zhao, Yueyang
   Long, Zhimin
   Song, Aijia
   Huang, Peng
   Wang, Kejian
   Xu, Ling
   Molloy, David Paul
   He, Guiqiong
TI Liquiritigenin promotes osteogenic differentiation and prevents bone
   loss via inducing auto lysosomal degradation and inhibiting apoptosis
SO GENES & DISEASES
LA English
DT Article
DE Auto lysosomal; Liquiritigenin; differentiation; degradation; Osteogenic
ID OSTEOBLAST DIFFERENTIATION; MC3T3 E1 CELLS; AUTOPHAGY; DISEASE; STRESS
AB Osteoporosis (OP) is a debilitating skeletal abnormality involving bone remodeling and bone cell homeostasis characterized by decreased bone strength and high fracture risk. A novel therapeutic intervention for OP by manipulating cellular autophagy apoptosis processes to promote skeletal homeostasis is presented. Protective effects of the naturally occurring plant extract Liquiritigenin (LG) were demonstrated in an ovariectomy (OVX) OP mouse model and preosteoblast MC3T3 E1 cells. Micro CT and histological staining assessments of skeletal phenotype were applied alongside detection of autophagy activity in osteocytes and MC3T3 E1 cells by transmission electron microscopy (TEM). The effects of LG on chloroquine (CQ)  and the apoptosis inducing TS treated osteogenic differentiations and status of lysosomes within MC3T3 E1 cells were analyzed by Neutral red, Alizarin red S and alkaline phosphatase (ALP) staining and Western blot assays. Treatment with LG prevented bone loss, increased osteogenic differentiation in vivo and in vitro, and inhibited osteoclast formation to some extent. TEM analyses revealed that LG can improve auto lysosomal degradation within osteocytes from OVX mice and MC3T3 E1 cells. The abnormal status of lysosomes associated with CQ and TS treatments was notably alleviated by LG which also reduced levels of apoptosis induced inhibition of osteogenic differentiation and averted abnormal osteogenic differentiation as a consequence of a blockage in autolysosome degradation. Overall, LG stimulates bone growth in OVX mice through increased osteogenic differentiation and regulation of autophagyapoptosis mechanisms, presenting an auspicious natural therapy for OP. 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY NC ND license (http://creativecommons.
C1 [Qiu, Yu; Xu, Ling] Chongqing Med Univ, Coll Stomatol, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing, Peoples R China.
   [Qiu, Yu; Zhao, Yueyang; Long, Zhimin; Wang, Kejian; He, Guiqiong] Chongqing Med Univ, Chongqing Key Lab Neurobiol, Chongqing 400016, Peoples R China.
   [Zhao, Yueyang; Long, Zhimin; Wang, Kejian; He, Guiqiong] Chongqing Med Univ, Dept Anat, Chongqing 400016, Peoples R China.
   [Song, Aijia; Huang, Peng] Chongqing Med Univ, Inst Life Sci, Lab Med Expt Technol, Chongqing 400016, Peoples R China.
   [Molloy, David Paul] Chongqing Med Univ, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China.
   [He, Guiqiong] Chongqing Med Univ, Chongqing Key Lab Neurobiol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
   [Xu, Ling] Chongqing Med Univ, Stomatol Hosp, Dept Prosthodont, 426 Songshibei Rd, Chongqing 401147, Peoples R China.
   [Molloy, David Paul] Chongqing Med Univ, Dept Biochem & Mol Biol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University; Chongqing Medical
   University; Chongqing Medical University; Chongqing Medical University;
   Chongqing Medical University
RP He, GQ (通讯作者)，Chongqing Med Univ, Chongqing Key Lab Neurobiol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.; Xu, L (通讯作者)，Chongqing Med Univ, Stomatol Hosp, Dept Prosthodont, 426 Songshibei Rd, Chongqing 401147, Peoples R China.; Molloy, DP (通讯作者)，Chongqing Med Univ, Dept Biochem & Mol Biol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM 500203@hospital.cqmu.edu.cn; 190495@cqmu.edu.cn; guiqionghe@cqmu.edu.cn
RI Qiu, Yu/IAQ 8265 2023; He, Guoqian/CAI 8663 2022; huang,
   peng/KBC 5715 2024; zhao, yueyang/LSJ 2770 2024; Wang,
   Kejian/AAC 7524 2020
OI He, guiqiong/0000 0002 8715 4576; 
FU National Natural Science Foundation of China [81671257, 81371221,
   CXQTP19019019034]; Innovation Research Group at Institutions of Higher
   Education in Chongqing, China; Program for Innovation Team Building at
   Institutions of Higher Education in Chongqing;  [31600825]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81671257, 81371221, 31600825) 81671257, 81371221, 31600825)
   Innovation Research Group at Institutions of Higher Education in
   Chongqing, China (No. CXQTP19019019034) Program for Innovation Team
   Building at Institutions of Higher Education in Chongqing in 2016.
CR Ansari MY, 2021, OSTEOARTHR CARTILAGE, V29, P100, DOI 10.1016/j.joca.2020.08.014
   Bae GD, 2018, BIOMED PHARMACOTHER, V101, P348, DOI 10.1016/j.biopha.2018.02.097
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Cao Y, 2019, BRIT J PHARMACOL, V176, P1282, DOI 10.1111/bph.14626
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Chiu YJ, 2018, AM J CHINESE MED, V46, P1535, DOI 10.1142/S0192415X18500799
   Choi EM, 2014, PHYTOTHER RES, V28, P880, DOI 10.1002/ptr.5071
   Choi EM, 2012, INT IMMUNOPHARMACOL, V12, P139, DOI 10.1016/j.intimp.2011.11.003
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556 018 0201 5
   Du YX, 2021, NEUROTOX RES, V39, P349, DOI 10.1007/s12640 020 00284 z
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Eskelinen Eeva Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962 8924(03)00005 9
   Fimia GM, 2010, CELL MOL LIFE SCI, V67, P1581, DOI 10.1007/s00018 010 0284 z
   Gomez Gutierrez JG, 2021, BIOTECH HISTOCHEM, V96, P302, DOI 10.1080/10520295.2020.1802065
   Gui X, 2019, NATURE, V567, P262, DOI 10.1038/s41586 019 1006 9
   Hocking LJ, 2012, J BONE MINER RES, V27, P1439, DOI 10.1002/jbmr.1668
   Hong D, 2010, EXP CELL RES, V316, P2291, DOI 10.1016/j.yexcr.2010.05.011
   Jaber FA, 2019, J CELL PHYSIOL, V234, P12105, DOI 10.1002/jcp.27071
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Klionsky DJ., 2021, P ADV NEUR INF PROC, V17, P1, DOI [DOI 10.1080/15548627.2020.1797280, 10.1080/15548627.2020.1797280]
   Lee JY, 2009, INT IMMUNOPHARMACOL, V9, P632, DOI 10.1016/j.intimp.2009.02.007
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lu JF, 2008, CANCER RES, V68, P9384, DOI 10.1158/0008 5472.CAN 08 2655
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   MELTON LJ, 1995, J BONE MINER RES, V10, P175
   Mialet Perez J, 2017, ESSAYS BIOCHEM, V61, P721, DOI 10.1042/EBC20170022
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002
   Moriishi T, 2016, J BONE MINER RES, V31, P1366, DOI 10.1002/jbmr.2808
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Mühlbauer RC, 2002, J BONE MINER RES, V17, P1230, DOI 10.1359/jbmr.2002.17.7.1230
   Myerowitz R, 2021, EBIOMEDICINE, V63, DOI 10.1016/j.ebiom.2020.103166
   New SA, 2000, AM J CLIN NUTR, V71, P142
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pasquier B, 2016, CELL MOL LIFE SCI, V73, P985, DOI 10.1007/s00018 015 2104 y
   PECK WA, 1993, AM J MED, V94, P646
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Qiu T, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0002 7
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sacks D, 2018, INT J STROKE, V13, P612, DOI [10.1177/1747493018778713, 10.1016/j.jvir.2017.11.026]
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Uchino K, 2015, PHYTOTHER RES, V29, P1714, DOI 10.1002/ptr.5416
   Walensky LD, 2019, NAT CHEM BIOL, V15, P657, DOI 10.1038/s41589 019 0306 6
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Wu JD, 2019, BONE, V121, P16, DOI 10.1016/j.bone.2018.12.019
   Wu XL, 2018, MOL CELLS, V41, P234, DOI 10.14348/molcells.2018.2340
   Xu X, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0005 4
   Yang EJ, 2013, NEUROTOXICOLOGY, V39, P114, DOI 10.1016/j.neuro.2013.08.012
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910 814
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
NR 59
TC 6
Z9 6
U1 5
U2 13
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
SN 2352 4820
EI 2352 3042
J9 GENES DIS
JI Genes Dis.
PD JAN
PY 2023
VL 10
IS 1
BP 284
EP 300
DI 10.1016/j.gendis.2021.06.008
PG 17
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA F7GM8
UT WOS:000983990100001
PM 37013063
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shar, A
   Aboutalebianaraki, N
   Misiti, K
   Li Sip, YY
   Zhai, L
   Razavi, M
AF Shar, Angela
   Aboutalebianaraki, Nadia
   Misiti, Kaylee
   Li Sip, Yuen Yee
   Zhai, Lei
   Razavi, Mehdi
TI A novel ultrasound mediated nanodroplet based gene delivery system for
   osteoporosis treatment
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Nanodroplet; siRNA delivery; Ultrasound; Osteoporosis; Targeting
ID INTENSITY PULSED ULTRASOUND; LEVEL LASER THERAPY; SIRNA; NANOBUBBLES;
   BIODEGRADATION; REPAIR; DRUG
AB This project aimed to develop, optimize, and test an ultrasound responsive targeted nanodroplet system for the delivery of osteoporosis related silencing gene Cathepsin K small interfering RNA (CTSK siRNA) for osteoporosis treatment. The nanodroplet (ND) is composed of a gas core made from perfluorocarbon, stabilized with albumin, encapsulated with CTSK siRNA, and embedded with alendronate (AL) for bone targeting (CTSK siRNA ND AL). Following the development, the responsiveness of CTSK siRNA ND AL to a therapeutic ultrasound probe was examined. The results of biocompatibility tests with human bone marrow derived mesenchymal stem cells proved no significant cell death (P > 0.05). When the CTSK siRNA ND AL was supplemented with human osteoclast precursors, they suppressed osteoclastogenesis. Thus, this project establishes the potential of nanotechnology and ultrasound to deliver genes into the osteoclasts. This research also presents a novel ultrasound responsive and targeted nanodroplet platform that can be used as a gene and drug delivery system for various diseases including cancer.(c) 2022 Elsevier Inc. All rights reserved.
C1 [Shar, Angela; Aboutalebianaraki, Nadia; Misiti, Kaylee; Razavi, Mehdi] Univ Cent Florida, Coll Med, Dept Internal Med, BiionixTM Bion Mat Implants & Interfaces Cluster, Orlando, FL 32816 USA.
   [Shar, Angela] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32816 USA.
   [Aboutalebianaraki, Nadia; Li Sip, Yuen Yee; Razavi, Mehdi] Univ Cent Florida, Dept Mat Sci & Engn, Orlando, FL 32816 USA.
   [Li Sip, Yuen Yee; Zhai, Lei] Univ Cent Florida, Nanosci Technol Ctr, Orlando, FL 32816 USA.
   [Zhai, Lei] Univ Cent Florida, Dept Chem, Orlando, FL 32816 USA.
C3 State University System of Florida; University of Central Florida; State
   University System of Florida; University of Central Florida; State
   University System of Florida; University of Central Florida; State
   University System of Florida; University of Central Florida; State
   University System of Florida; University of Central Florida
RP Razavi, M (通讯作者)，Univ Cent Florida, Coll Med, Dept Mat Sci & Engn, Dept Internal Med,BiionixTM Bion Mat Implants & I, Hlth Sci Campus Lake Nona, Orlando, FL 32816 USA.
EM Mehdi.Razavi@ucf.edu
RI Razavi, Mehdi/I 1151 2015
OI Razavi, Mehdi/0000 0002 3020 6187
FU UCF COMCECS Pilot Award; UCF Internal Medicine Seed Grant Award;
   Astronaut Scholarship; UCF Seed Funding: ER2, Shared Research Facility
   Usage Award; Life Gerontology Research Grant Program at UCF; Summer
   Undergraduate Research Fellowship (SURF) program at UCF; Honors
   Undergraduate Thesis Scholarship at UCF; Burnett Honors College Emerging
   Leader Scholarship at UCF; Judges' Choice Award from Student Scholar
   Symposium at UCF; Burnett Honors College Alvin Y. Wang Undergraduate
   Research Scholarship at UCF; Distinguished Undergraduate Researcher
   Award (DURA) at UCF
FX We acknowledge the support received from UCF COMCECS Pilot Award, UCF
   Internal Medicine Seed Grant Award, Astronaut Scholarship, UCF Seed
   Funding: ER2, Shared Research Facility Usage Award, Life Gerontology
   Research Grant Program at UCF, Summer Undergraduate Research Fellowship
   (SURF) program at UCF, Honors Undergraduate Thesis Scholarship at UCF,
   Burnett Honors College Emerging Leader Scholarship at UCF, Judges'
   Choice Award from Student Scholar Symposium at UCF, Burnett Honors
   College Alvin Y. Wang Undergraduate Research Scholarship at UCF, and
   Distinguished Undergraduate Researcher Award (DURA) at UCF.
CR Acar AH, 2016, ARCH ORAL BIOL, V61, P60, DOI 10.1016/j.archoralbio.2015.10.011
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bilecen DS, 2017, J BIOMAT SCI POLYM E, V28, P1859, DOI 10.1080/09205063.2017.1354675
   Blume SW, 2011, OSTEOPOROSIS INT, V22, P1835, DOI 10.1007/s00198 010 1419 7
   Chan CW, 2006, J ORTHOP RES, V24, P2072, DOI 10.1002/jor.20258
   Dong YZ, 2019, ADV DRUG DELIVER REV, V144, P133, DOI 10.1016/j.addr.2019.05.004
   Ferrara K, 2007, ANNU REV BIOMED ENG, V9, P415, DOI 10.1146/annurev.bioeng.8.061505.095852
   Gao K, 2009, MOL PHARMACEUT, V6, P651, DOI 10.1021/mp800134q
   GOLDBERG JA, 1991, NUCL MED COMMUN, V12, P57, DOI 10.1097/00006231 199101000 00007
   Hasuike A, 2011, ORAL SURG ORAL MED O, V111, pE12, DOI 10.1016/j.tripleo.2010.09.061
   Horie S, 2011, CANCER SCI, V102, P2082, DOI 10.1111/j.1349 7006.2011.02056.x
   Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
   Khan IA., 2020, Histology, Osteoclasts
   Khlebtsov BN, 2011, COLLOID J+, V73, P118, DOI 10.1134/S1061933X11010078
   Lirani Galvao AP, 2006, PHOTOMED LASER SURG, V24, P735, DOI 10.1089/pho.2006.24.735
   Liu G, 1997, OSTEOPOROSIS INT, V7, P564, DOI 10.1007/BF02652563
   Liu XL, 2016, J BIOMED RES, V30, P264, DOI 10.7555/JBR.30.20150110
   Lonza, HUMAN OSTEOCLAST PRE
   Mora Raimundo P, 2019, ACS NANO, V13, P5451, DOI 10.1021/acsnano.9b00241
   Nafee N, 2018, J DRUG TARGET, V26, P563, DOI 10.1080/1061186X.2017.1390670
   Negishi Y, 2008, J CONTROL RELEASE, V132, P124, DOI 10.1016/j.jconrel.2008.08.019
   Parsons JR, 2008, REV ENVIRON CONTAM T, V196, P53, DOI 10.1007/978 0 387 78444 1_2
   Petterson S, 2020, J PAIN RES, V13, DOI 10.2147/JPR.S247463
   Poolman RW, 2017, BMJ, P356
   Raemdonck K, 2008, ADV FUNCT MATER, V18, P993, DOI 10.1002/adfm.200701039
   Razavi M, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01897 z
   Razavi M, 2020, NANO LETT, V20, P7220, DOI 10.1021/acs.nanolett.0c02576
   Razavi M, 2020, ULTRASOUND MED BIOL, V46, P630, DOI 10.1016/j.ultrasmedbio.2019.11.016
   Razavi M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 49933 0
   Roberts BC, 2019, BONE, V127, P260, DOI 10.1016/j.bone.2019.06.024
   Roh YH, 2016, ANGEW CHEM INT EDIT, V55, P3347, DOI 10.1002/anie.201508978
   Sarett SM, 2015, J CONTROL RELEASE, V218, P94, DOI 10.1016/j.jconrel.2015.09.066
   Selinger CI, 2005, J CELL BIOCHEM, V96, P996, DOI 10.1002/jcb.20575
   Shim MS, 2008, BIOMACROMOLECULES, V9, P444, DOI 10.1021/bm7007313
   Song XJ, 2016, NANO LETT, V16, P6145, DOI 10.1021/acs.nanolett.6b02365
   Sun SJ, 2018, NANOSCALE, V10, P19945, DOI 10.1039/c8nr03074j
   Tardoski S, 2015, SCI REP UK, V5, DOI 10.1038/srep16354
   Tosteson ANA, 2008, OSTEOPOROSIS INT, V19, P437, DOI 10.1007/s00198 007 0550 6
   Tosteson ANA, 2008, AM J MANAG CARE, V14, P605
   Unger EC, 2001, PROG CARDIOVASC DIS, V44, P45, DOI 10.1053/pcad.2001.26443
   Urita A, 2013, J HAND SURG AM, V38A, P498, DOI 10.1016/j.jhsa.2012.11.032
   Wang P, 2016, NANOMED NANOTECHNOL, V12, P1139, DOI 10.1016/j.nano.2015.12.361
   Wang YW, 2013, THER DELIV, V4, P1239, DOI [10.4155/TDE.13.85, 10.4155/tde.13.85]
   Watson T, ULTRASOUND DOSE CALC
   Whitney NP, 2012, ULTRASOUND MED BIOL, V38, P1734, DOI 10.1016/j.ultrasmedbio.2012.06.002
   Xie Y, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0066 7
   Yin TH, 2013, BIOMATERIALS, V34, P4532, DOI 10.1016/j.biomaterials.2013.02.067
   Yin TH, 2012, INT J NANOMED, V7, P895, DOI 10.2147/IJN.S28830
   Zarnitsyn V, 2008, BIOPHYS J, V95, P4124, DOI 10.1529/biophysj.108.131664
   Zhang YF, 2016, SCI REP UK, V6, DOI 10.1038/srep26925
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
NR 51
TC 11
Z9 12
U1 1
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD APR
PY 2022
VL 41
AR 102530
DI 10.1016/j.nano.2022.102530
EA FEB 2022
PG 16
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA 0W9FT
UT WOS:000789325000003
PM 35104672
DA 2025 08 17
ER

PT J
AU Hou, MZ
   Deng, YG
   Lv, NN
   Wu, YB
   Zhu, YR
   Zhang, YJ
   Liu, Y
   Xia, XW
   Yu, CQ
   Yu, JF
   He, F
   Xu, Y
   Zhu, XS
AF Hou, Mingzhuang
   Deng, Yaoge
   Lv, Nanning
   Wu, Yubin
   Zhu, Yanrun
   Zhang, Yijian
   Liu, Yang
   Xia, Xiaowei
   Yu, Chenqi
   Yu, Jianfeng
   He, Fan
   Xu, Yong
   Zhu, Xuesong
TI Cyclic amplification of remodeling bone regeneration process via
   cerium energized spinning hydrogel biomembrane for rescuing osteoporotic
   bone defects
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Osteoporotic bone defect; Cerium; Spinning hydrogel membrane; Wnt
   pathway; Bone regeneration
ID NANOPARTICLES; FRAGILITY; THERAPY
AB The heightened activity of osteoclasts and diminished function of osteoblasts observed in individuals with osteoporosis present additional complexities in the management of critical bone defects. Consequently, an improved approach is urgently required to enhance bone regeneration in patients with osteoporosis. Our effective strategy involves the integration of hydrogels with spinning membrane technology, and accurately replicates the composition and structure of the native extracellular matrix found in periosteum tissues. Cerium, as a substitute for conventional protein growth factors, facilitates osteogenic differentiation and angiogenesis in stem cells, concurrently impeding bone resorption. In this study, we successfully synthesized a biomimetic electrospun hydrogel periosteum, grafted cerium ions onto the membrane via non covalently bound phosphate, and achieved cyclic amplification of bone regeneration. This approach represents a pioneering and efficient utilization of tissue engineered bionic periosteum to address osteoporotic bone defects.
C1 [Hou, Mingzhuang; Deng, Yaoge; Wu, Yubin; Zhu, Yanrun; Zhang, Yijian; Liu, Yang; Xia, Xiaowei; Yu, Chenqi; Yu, Jianfeng; He, Fan; Xu, Yong; Zhu, Xuesong] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Peoples R China.
   [Hou, Mingzhuang; Deng, Yaoge; Wu, Yubin; Zhu, Yanrun; Zhang, Yijian; Liu, Yang; Xia, Xiaowei; Yu, Chenqi; Yu, Jianfeng; He, Fan; Xu, Yong; Zhu, Xuesong] Soochow Univ, Orthopaed Inst, Suzhou Med Coll, Suzhou 215000, Peoples R China.
   [Lv, Nanning] Xuzhou Med Univ, Dept Orthoped Surg, Lianyungang Clin Coll, Lianyungang 222003, Peoples R China.
C3 Soochow University   China; Soochow University   China; Xuzhou Medical
   University
RP He, F; Xu, Y; Zhu, XS (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Peoples R China.; He, F; Xu, Y; Zhu, XS (通讯作者)，Soochow Univ, Orthopaed Inst, Suzhou Med Coll, Suzhou 215000, Peoples R China.
EM fanhe@suda.edu.cn; yxu1615@suda.edu.cn; zhuxs@suda.edu.cn
RI Zhang, Yijian/JTU 6960 2023; deng, yaoge/MZK 5928 2025; ZHU,
   XUESONG/AAI 1933 2020
FU National Natural Science Foundation of China [82072442, 82272494,
   82302664]; Natural Science Foundation of Jiangsu Province [BK20230494];
   Gusu Innovation and Entrepreneur Leading Talents project [ZXL2023204];
   National High level Young Talent Program [KS24700124]; Jiangsu
   Specially Appointed Professor Program [SR24700123]
FX This work was sup ported by the National Natural Science Foundation of
   China (82072442, 82272494 and 82302664) , the Natural Science Foundation
   of Jiangsu Province (BK20230494) , the Gusu Innovation and Entrepreneur
   Leading Talents project (ZXL2023204) , the National High level Young
   Talent Program (KS24700124) , Jiangsu Specially Appointed Professor
   Program (SR24700123) .
CR Alqahtani AM, 2023, POLYMERS BASEL, V15, DOI 10.3390/polym15163355
   Anginot A, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 37791 4
   Chen W, 2021, SMALL, V17, DOI 10.1002/smll.202104012
   Correa S, 2021, CHEM REV, V121, P11385, DOI 10.1021/acs.chemrev.0c01177
   Dang ZT, 2023, ADV MATER, V35, DOI 10.1002/adma.202306773
   Dou C, 2021, BIOACT MATER, V6, P4697, DOI 10.1016/j.bioactmat.2021.04.038
   Ehrnborg C, 2008, ASIAN J ANDROL, V10, P373, DOI 10.1111/j.1745 7262.2008.00403.x
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   He J, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202300395
   HEANEY RP, 1989, JAMA J AM MED ASSOC, V261, P2986, DOI 10.1001/jama.261.20.2986
   Hoit G., 2021, OTA international: the open access journal of orthopaedic trauma, V4, pe106
   Huang D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33006 4
   Huang K, 2024, CELL PROLIFERAT, V57, DOI 10.1111/cpr.13522
   Iolascon G, 2020, CLIN INTERV AGING, V15, P485, DOI 10.2147/CIA.S242038
   Janarthanan G, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0153 7
   Kelly RR, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00200
   Khan M, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12122117
   Koo S, 2023, NAT NANOTECHNOL, V18, DOI 10.1038/s41565 023 01523 y
   Kuddushi M, 2023, J MATER CHEM B, V11, P6201, DOI 10.1039/d3tb00639e
   Kushchayeva Y, 2022, J CLIN MED, V11, DOI 10.3390/jcm11247477
   Li CY, 2021, BIOL DIRECT, V16, DOI 10.1186/s13062 021 00310 w
   Li HX, 2020, J CELL BIOCHEM, V121, P1144, DOI 10.1002/jcb.29349
   Li JH, 2018, ADV SCI, V5, DOI 10.1002/advs.201700678
   Liu XF, 2023, BIOACT MATER, V27, P216, DOI 10.1016/j.bioactmat.2023.03.021
   Liu XK, 2021, MEMBRANES BASEL, V11, DOI 10.3390/membranes11100770
   Luo JC, 2023, BIOL TRACE ELEM RES, V201, P865, DOI 10.1007/s12011 022 03168 9
   Mauffrey C, 2015, J AM ACAD ORTHOP SUR, V23, P143, DOI 10.5435/JAAOS D 14 00018
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Müller WEG, 2022, DENT MATER, V38, P2014, DOI 10.1016/j.dental.2022.11.013
   Ng PY, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 36484 2
   Place DE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20807 8
   Ren SS, 2022, BIOACT MATER, V7, P242, DOI 10.1016/j.bioactmat.2021.05.037
   Rendina Ruedy E, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.932343
   Sabir PS, 2023, VET MED SCI, V9, P1726, DOI 10.1002/vms3.1190
   Singh KRB, 2020, RSC ADV, V10, P27194, DOI 10.1039/d0ra04736h
   Stefater JA, 2011, NATURE, V474, P511, DOI 10.1038/nature10085
   Wan QQ, 2022, ACS APPL MATER INTER, V14, P14103, DOI 10.1021/acsami.2c02079
   Wang LH, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.21106
   Wei F, 2023, BIOACT MATER, V21, P547, DOI 10.1016/j.bioactmat.2022.09.011
   Wu MR, 2017, P NATL ACAD SCI USA, V114, P10119, DOI 10.1073/pnas.1619294114
   Xiang JY, 2016, ACS APPL MATER INTER, V8, P4489, DOI 10.1021/acsami.6b00158
   Xu M., 2014, Circ Res, V346, P115
   Xu SX, 2022, BIOMATERIALS, V288, DOI 10.1016/j.biomaterials.2022.121751
   Xu Y, 2023, ACTA BIOMATER, V162, P211, DOI 10.1016/j.actbio.2023.03.015
   Yadav S, 2023, INT J BIOL MACROMOL, V246, DOI 10.1016/j.ijbiomac.2023.125673
   Ye XP, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1095711
   Ye YJ, 2023, TISSUE ENG REGEN MED, V20, P981, DOI 10.1007/s13770 023 00561 w
   Zhang MZ, 2023, ACS NANO, V17, P4433, DOI 10.1021/acsnano.2c09855
   Zhang XP, 2008, CLIN ORTHOP RELAT R, V466, P1777, DOI 10.1007/s11999 008 0312 6
   Zhang YJ, 2024, INNOVATION AMSTERDAM, V5, DOI 10.1016/j.xinn.2023.100542
   Zhang YS, 2017, SCIENCE, V356, DOI 10.1126/science.aaf3627
   Zhao QL, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201801027
   Zhao QL, 2018, ACS APPL MATER INTER, V10, P23583, DOI 10.1021/acsami.8b06205
   Zhou ZZ, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202302153
NR 54
TC 2
Z9 2
U1 14
U2 50
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD JUL 15
PY 2024
VL 492
AR 152262
DI 10.1016/j.cej.2024.152262
EA MAY 2024
PG 16
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA XU7M7
UT WOS:001264256100001
DA 2025 08 17
ER

PT J
AU Zhao, JJ
   Lin, JH
   Zhu, D
   Wang, XJ
   Brooks, D
   Chen, M
   Chu, ZB
   Takada, K
   Ciccarelli, B
   Admin, S
   Tao, JG
   Tai, YT
   Treon, S
   Pinkus, G
   Kuo, WP
   Hideshima, T
   Bouxsein, M
   Munshi, N
   Anderson, K
   Carrasco, R
AF Zhao, Jian Jun
   Lin, Jianhong
   Zhu, Di
   Wang, Xujun
   Brooks, Daniel
   Chen, Ming
   Chu, Zhang Bo
   Takada, Kohichi
   Ciccarelli, Bryan
   Admin, Samir
   Tao, Jianguo
   Tai, Yu Tzu
   Treon, Steven
   Pinkus, Geraldine
   Kuo, Winston Patrick
   Hideshima, Teru
   Bouxsein, Mary
   Munshi, Nikhil
   Anderson, Kenneth
   Carrasco, Ruben
TI miR 30 5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by
   Targeting the Oncogenic Wnt/β Catenin/BCL9 Pathway
SO CANCER RESEARCH
LA English
DT Article
ID MULTIPLE MYELOMA; IN VITRO; MOLECULAR ORIGINS; DOWN REGULATION;
   BETA CATENIN; STEM CELLS; EXPRESSION; CANCER; MICRORNAS; PROLIFERATION
AB Wnt/beta catenin signaling underlies the pathogenesis of a broad range of human cancers, including the deadly plasma cell cancer multiple myeloma. In this study, we report that downregulation of the tumor suppressor microRNA miR 30 5p is a frequent pathogenetic event in multiple myeloma. Evidence was developed that miR 30 5p downregulation occurs as a result of interaction between multiple myeloma cells and bone marrow stromal cells, which in turn enhances expression of BCL9, a transcriptional coactivator of the Wnt signaling pathway known to promote multiple myeloma cell proliferation, survival, migration, drug resistance, and formation of multiple myeloma cancer stem cells. The potential for clinical translation of strategies to re express miR 30 5p as a therapeutic approach was further encouraged by the capacity of miR 30c and miR 30 mix to reduce tumor burden and metastatic potential in vivo in three murine xenograft models of human multiple myeloma without adversely affecting associated bone disease. Together, our findings offer a preclinical rationale to explore miR 30 5p delivery as an effective therapeutic strategy to eradicate multiple myeloma cells in vivo. (C) 2014 AACR.
C1 [Zhao, Jian Jun; Lin, Jianhong; Zhu, Di; Chen, Ming; Chu, Zhang Bo; Takada, Kohichi; Ciccarelli, Bryan; Tai, Yu Tzu; Treon, Steven; Hideshima, Teru; Munshi, Nikhil; Anderson, Kenneth; Carrasco, Ruben] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Lin, Jianhong; Tai, Yu Tzu; Hideshima, Teru; Munshi, Nikhil; Anderson, Kenneth] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
   [Admin, Samir] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Pinkus, Geraldine; Carrasco, Ruben] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Kuo, Winston Patrick] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
   [Brooks, Daniel; Bouxsein, Mary] Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies, Boston, MA 02215 USA.
   [Tao, Jianguo] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
   [Wang, Xujun] Tongji Univ, Sch Life Sci & Technol, Jerome Lipper Multiple Myeloma Ctr, Shanghai 200092, Peoples R China.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard University; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute; Harvard University; Harvard
   T.H. Chan School of Public Health; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Harvard
   University; Harvard School of Dental Medicine; Harvard University;
   Harvard University Medical Affiliates; Beth Israel Deaconess Medical
   Center; H Lee Moffitt Cancer Center & Research Institute; Tongji
   University
RP Carrasco, R (通讯作者)，Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.
EM ruben_carrasco@dfci.harvard.edu
RI ; Wang, Jia Xin/KCJ 9455 2024; Anderson, Kenneth/ACP 5073 2022; Munshi,
   Nikhil/ABE 2338 2021; Lin, Jian Hong/AAX 9667 2021
OI wang, xujun/0000 0002 7152 611X; Zhao, Jianjun/0000 0003 3008 3655
FU Multiple Myeloma Research Foundation (MMRF); SPORE in Multiple Myeloma
   Career Development Award; China Scholarship Council (CSC); Harvard
   Catalyst, The Harvard Clinical and Translational Science Center; MMRF
   [1R01CA151391]
FX J. J. Zhao was supported by a Multiple Myeloma Research Foundation
   (MMRF) research fellow award. J. Lin was supported by a SPORE in
   Multiple Myeloma Career Development Award. Z. B. Chu was supported by a
   China Scholarship Council (CSC) award. W. P. Kuo was supported by
   Harvard Catalyst, The Harvard Clinical and Translational Science Center.
   K. Anderson is an American Cancer Society Clinical Research Professor.
   R. Carrasco is supported by an MMRF senior award and a 1R01CA151391.
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367
   Deka J, 2010, CANCER RES, V70, P6619, DOI 10.1158/0008 5472.CAN 10 0148
   Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101
   Di Martino MT, 2012, CLIN CANCER RES, V18, P6260, DOI 10.1158/1078 0432.CCR 12 1708
   Di Martino MT, 2013, ONCOTARGET, V4, P242, DOI 10.18632/oncotarget.820
   Dutta Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood 2008 12 194290
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Gu J, 2006, GENOME BIOL, V7, DOI 10.1186/gb 2006 7 5 r42
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Jia W, 2011, MOL CANCER RES, V9, P1732, DOI 10.1158/1541 7786.MCR 11 0245
   Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092 8674(02)00679 7
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kuehl WM, 2012, J CLIN INVEST, V122, P3456, DOI 10.1172/JCI61188
   Leone E, 2013, CLIN CANCER RES, V19, P2096, DOI 10.1158/1078 0432.CCR 12 3325
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lin J, 2011, LEUKEMIA, V25, P145, DOI 10.1038/leu.2010.230
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Mani M, 2009, CANCER RES, V69, P7577, DOI 10.1158/0008 5472.CAN 09 0773
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Martineza I, 2011, P NATL ACAD SCI USA, V108, P522, DOI 10.1073/pnas.1017346108
   Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005
   Polakis P, 2012, EMBO J, V31, P2737, DOI 10.1038/emboj.2012.126
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Rajkumar SV, 2011, AM J HEMATOL, V86, P57, DOI 10.1002/ajh.21913
   Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Sampietro J, 2006, MOL CELL, V24, P293, DOI 10.1016/j.molcel.2006.09.001
   Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tili Esmerina, 2007, Future Oncol, V3, P521, DOI 10.2217/14796694.3.5.521
   Townsley FM, 2004, NAT CELL BIOL, V6, P626, DOI 10.1038/ncb1141
   Walker BA, 2010, BLOOD, V116, pE56, DOI 10.1182/blood 2010 04 279596
   Willis TG, 1998, BLOOD, V91, P1873, DOI 10.1182/blood.V91.6.1873.1873_1873_1881
   Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
   Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood 2009 09 243147
   Zhou YM, 2010, P NATL ACAD SCI USA, V107, P7904, DOI 10.1073/pnas.0908441107
NR 45
TC 164
Z9 181
U1 0
U2 24
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2014
VL 74
IS 6
BP 1801
EP 1813
DI 10.1158/0008 5472.CAN 13 3311 T
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AE2OD
UT WOS:000333811700018
PM 24599134
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, YH
   Chen, W
   Hao, L
   McVicar, A
   Wu, JJ
   Gao, N
   Liu, YH
   Li, YP
AF Wang, Yuhui
   Chen, Wei
   Hao, Liang
   McVicar, Abigail
   Wu, Jinjin
   Gao, Ning
   Liu, Yuehua
   Li, Yi Ping
TI C1 Silencing Attenuates Inflammation and Alveolar Bone Resorption in
   Endodontic Disease
SO JOURNAL OF ENDODONTICS
LA English
DT Article
DE Atp6v1c1; RNA interference knockdown; gene therapy; gingival
   inflammation; oral bone resorption; periapical disease
ID OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; VACUOLAR ATPASE; PROTON
   PUMP; MOUSE MODEL; V ATPASE; CELLS; EXPRESSION; ATP6V1C1; SUBUNIT
AB Introduction: Endodontic disease, 1 of the most prevalent chronic infectious diseases worldwide, occurs when the dental pulp becomes infected and inflamed, leading to bone destruction around the tooth root, severe pain, and tooth loss. Although many studies have tried to develop therapies to alleviate the bone erosion and inflammation associated with endodontic disease, there is an urgent need for an effective treatment. Methods: In this study, we used a gene based therapy approach by administering recombinant adeno associated virus (AAV) mediated Atp6v1c1 knockdown to target both periapical bone resorption and inflammation in the mouse model of endodontic disease. Results: The results showed that Atp6v1c1 knockdown is simultaneously capable of reducing bone resorption by 70% through impaired osteoclast activation, inhibiting inflammation by decreasing T cell infiltration in the periapical lesion by 75%, and protecting the periodontal ligament from destruction caused by inflammation. Notably, AAV mediated gene therapy of Atp6v1c1 knockdown significantly reduced proinflammatory cytokine expression, including tumor necrosis factor alpha, interleukin 1 alpha, interleukin 17, interleukin 12, and interleukin 6 levels in periapical tissues caused by bacterial infection. Quantitative real time polymerase chain reaction revealed that Atp6v1c1 knockdown reduced osteoclast specific functional genes (ie, Ctsk) in periapical tissues. Conclusions: Our results showed that AAV mediated Atp6v1c1 knock down in periapical tissues slowed endodontic disease progression, prevented bone erosion, and alleviated inflammation in the periapical tissues and periodontal ligament potentially through regulation of toll like receptor signaling, indicating that targeting Atp6v1c1 may facilitate the design of novel therapeutic approaches to reduce inflammation and bone erosion in endodontic disease.
C1 [Wang, Yuhui] Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Sch & Hosp Stomatol, Dept Orthodont, Shanghai, Peoples R China.
   [Wang, Yuhui; Chen, Wei; Hao, Liang; McVicar, Abigail; Wu, Jinjin; Gao, Ning; Li, Yi Ping] Univ Alabama Birmingham, Dept Pathol, Sch Med, SHEL 810,1825 Univ Blvd, Birmingham, AL 35294 USA.
   [Liu, Yuehua] Fudan Univ, Shanghai Stomatol Hosp, Oral Biomed Engn Lab, 356 Beijing East Rd, Shanghai 20001, Peoples R China.
C3 Tongji University; University of Alabama System; University of Alabama
   Birmingham; Fudan University
RP Li, YP (通讯作者)，Univ Alabama Birmingham, Dept Pathol, Sch Med, SHEL 810,1825 Univ Blvd, Birmingham, AL 35294 USA.; Liu, YH (通讯作者)，Fudan Univ, Shanghai Stomatol Hosp, Oral Biomed Engn Lab, 356 Beijing East Rd, Shanghai 20001, Peoples R China.
EM joshua66@126.com; yipingli@uabmc.edu
RI ; gao, ning/KIE 2354 2024
OI Liu, Yuehua/0000 0003 3033 8873; Wu, Jinjin/0000 0003 0643 0899;
   McVicar, Abigail/0000 0001 5238 6564; 
FU National Institutes of Health [DE 028264, DE 023813, AR 070135,
   AG 056438]; National Nature Science Foundation of China [81470768]
FX Supported by the National Institutes of Health (grant nos. DE 028264 and
   DE 023813 to Y.P.L. and AR 070135 and AG 056438 to W.C.) and the
   National Nature Science Foundation of China (grant no. 81470768 to
   Y.L.).
CR Cintra LTA, 2014, CLIN ORAL INVEST, V18, P2123, DOI 10.1007/s00784 014 1192 7
   Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Feng SM, 2013, INT J BIOL SCI, V9, P853, DOI 10.7150/ijbs.6030
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Gao B, 2013, J DENT RES, V92, P180, DOI 10.1177/0022034512468757
   Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503
   Hirai K, 2019, J DENT RES, V98, P117, DOI 10.1177/0022034518796456
   Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964
   Huss M, 2009, J EXP BIOL, V212, P341, DOI 10.1242/jeb.024067
   Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200
   Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   LI YP, 1995, J BONE MINER RES, V10, P1197
   Ma JQ, 2013, INFECT IMMUN, V81, P1021, DOI 10.1128/IAI.00756 12
   Mabbott NA, 2011, IMMUNOLOGY, V133, P482, DOI 10.1111/j.1365 2567.2011.03461.x
   Nakashima T, 2009, J BONE MINER METAB, V27, P519, DOI 10.1007/s00774 009 0089 z
   Nilsson E, 2013, INT J DENT, V2013, DOI 10.1155/2013/929486
   Pérez Sayáns M, 2010, CANCER BIOL THER, V9, P1057, DOI 10.4161/cbt.9.12.11880
   Petzoldt AG, 2013, DIS MODEL MECH, V6, P689, DOI 10.1242/dmm.010660
   Rider D, 2016, ANAT REC, V299, P1281, DOI 10.1002/ar.23383
   Takayanagi H, 2010, ADV EXP MED BIOL, V658, P61, DOI 10.1007/978 1 4419 1050 9_7
   Wang Y, 2008, J BIOL CHEM, V283, P20696, DOI 10.1074/jbc.M803258200
   Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328
   Wu YL, 2008, AUTOIMMUNITY, V41, P183, DOI 10.1080/08916930701693180
   Yang S, 2013, BONE RES, V1, P260, DOI 10.4248/BR201303005
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Yuan FL, 2010, MOL BIOL REP, V37, P3561, DOI 10.1007/s11033 010 0004 7
   Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056
NR 30
TC 6
Z9 8
U1 1
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0099 2399
EI 1878 3554
J9 J ENDODONT
JI J. Endod.
PD JUL
PY 2019
VL 45
IS 7
BP 898
EP 906
DI 10.1016/j.joen.2019.02.024
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA II7ZP
UT WOS:000475410700010
PM 31104818
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Huang, JM
   Wang, Z
   Qi, GB
   Lai, Q
   Jiang, AL
   Zhang, YQ
   Chen, K
   Wang, XH
AF Huang, Jun Ming
   Wang, Zhe
   Qi, Guo Bin
   Lai, Qi
   Jiang, A lan
   Zhang, Yue Qi
   Chen, Kun
   Wang, Xiu Hui
TI Icaritin ameliorates RANKL mediated osteoclastogenesis and
   ovariectomy induced osteoporosis
SO AGING US
LA English
DT Article
DE icaritin; osteoclast; RANKL; osteoporosis; mitochondria
ID INDUCED BONE LOSS; DIFFERENTIATION; EPIDEMIOLOGY; PREVENTION
AB A rapidly aging society and longer life expectancy are causing osteoporosis to become a global epidemic. Over the last five decades, a number of drugs aimed at reducing bone resorption or restoring bone mass have been developed, but their efficacy and safety are limited. Icaritin (ICT) is a natural compound extracted from antiosteoporosis herb Epimedium spp. and has been shown to inhibit osteoclast differentiation. However, the molecular mechanism by which ICT weaken RANKL induced osteoclast differentiation has not been completely investigated. Here, we evaluated the anti osteoclastogenic effect of ICT in vitro and the potential drug candidate for treating osteoporosis in vivo. In vitro study, ICT was found to inhibit osteoclast formation and bone resorption function via downregulating transcription factors activated T cell cytoplasm 1 (NFATc1) and c fos, which further downregulate osteoclastogenesis specific gene. In addition, the enhanced mitochondrial mass and function required for osteoclast differentiation was mitigated by ICT. The histomorphological results from an in vivo study showed that ICT attenuated the bone loss associated with ovariectomy (OVX). Based on these results, we propose ICT as a promising new drug strategy for osteoporosis that inhibits osteoclast differentiation.
C1 [Huang, Jun Ming; Wang, Xiu Hui] Shanghai Univ Med & Hlth Sci, Dept Orthoped, Zhoupu Hosp, Shanghai, Peoples R China.
   [Huang, Jun Ming; Lai, Qi] Nanchang Univ, Orthoped Hosp, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Wang, Zhe; Qi, Guo Bin; Zhang, Yue Qi] Fudan Univ, Zhongshan Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Jiang, A lan] Nanchang Univ, Med Innovat Ctr, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Chen, Kun] Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Dept Orthoped, Hefei, Anhui, Peoples R China.
C3 Shanghai University of Medicine & Health Sciences; Nanchang University;
   Fudan University; Nanchang University; Chinese Academy of Sciences;
   University of Science & Technology of China, CAS
RP Wang, XH (通讯作者)，Shanghai Univ Med & Hlth Sci, Dept Orthoped, Zhoupu Hosp, Shanghai, Peoples R China.; Chen, K (通讯作者)，Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Dept Orthoped, Hefei, Anhui, Peoples R China.
EM chenkun1@ustc.edu.cn; wangxh@sumhs.edu.cn
RI Chen, Kun/AAG 9227 2021; Qi, Guobin/IXD 9658 2023; Wang,
   Xiuhui/O 5616 2019
FU National Natural Science Foundation of China [81871742, 82102538,
   82300994]; Jiangxi Provincial Natural Science Foundation
   [20232BAB216034]; Shanghai Sailing Program [21YF1405800]; Shanghai
   Pudong Science and Technology Development Funding [PKJ2020 Y44];
   Featured Clinical Discipline Project of Shanghai Pudong New District
   [Pwyts2021 03]
FX This work was sponsored by the National Natural Science Foundation of
   China (81871742, 82102538, 82300994), Jiangxi Provincial Natural Science
   Foundation (20232BAB216034), Shanghai Sailing Program (21YF1405800),
   Shanghai Pudong Science and Technology Development Funding (PKJ2020 Y44)
   and The Featured Clinical Discipline Project of Shanghai Pudong New
   District (Pwyts2021 03).
CR Adami G, 2022, THER ADV MUSCULOSKEL, V14, DOI 10.1177/1759720X221083541
   Aoki S, 2020, BIOCHEM BIOPH RES CO, V527, P874, DOI 10.1016/j.bbrc.2020.04.155
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Chen K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01046
   Gallagher JC, 2010, MATURITAS, V65, P301, DOI 10.1016/j.maturitas.2010.01.002
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hu XL, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1032614
   Huang JM, 2021, DRUG DES DEV THER, V15, P4811, DOI 10.2147/DDDT.S328238
   Huang JM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01016
   Huang JM, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/8085325
   Jalili C, 2020, OSTEOPOROSIS INT, V31, P1671, DOI 10.1007/s00198 020 05429 6
   Jordan KM, 2002, BEST PRACT RES CL RH, V16, P795, DOI 10.1053/berh.2002.0264
   Jung YY, 2019, CANCERS, V11, DOI 10.3390/cancers11010049
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kim SJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092554
   Kinov P, 2012, INT J WOMENS HEALTH, V4, P167, DOI 10.2147/IJWH.S18209
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Ma M, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.874952
   Mirza F, 2015, EUR J ENDOCRINOL, V173, pR131, DOI 10.1530/EJE 15 0118
   Nayak S, 2019, OSTEOPOROSIS INT, V30, P705, DOI 10.1007/s00198 018 4791 3
   Pinkerton JV, 2013, CLIN OBSTET GYNECOL, V56, P711, DOI 10.1097/GRF.0b013e3182a9fb02
   Qi GB, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1032866
   Qian Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01390
   Rendina Ruedy E, 2017, ENDOCRIN METAB CLIN, V46, P41, DOI 10.1016/j.ecl.2016.09.004
   Sarkar J, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05343 1
   Seo BJ, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101599
   Shen P, 2007, PHYTOCHEMISTRY, V68, P1448, DOI 10.1016/j.phytochem.2007.03.001
   Sun JH, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/483942
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Wong PI, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5982014
   Yang JG, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010132
   Yao XD, 2019, PHARMACOL RES, V139, P314, DOI 10.1016/j.phrs.2018.09.026
   Yong EL, 2021, PHYTOMEDICINE, V91, DOI 10.1016/j.phymed.2021.153680
NR 34
TC 5
Z9 6
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD OCT 15
PY 2023
VL 15
IS 19
BP 10220
EP 10235
PG 16
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA CN4K4
UT WOS:001125913100014
DA 2025 08 17
ER

PT J
AU Essex, AL
   Pin, F
   Huot, JR
   Bonewald, LF
   Plotkin, LI
   Bonetto, A
AF Essex, Alyson L.
   Pin, Fabrizio
   Huot, Joshua R.
   Bonewald, Lynda F.
   Plotkin, Lilian, I
   Bonetto, Andrea
TI Bisphosphonate Treatment Ameliorates Chemotherapy Induced Bone and
   Muscle Abnormalities in Young Mice
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE muscle; bone; cachexia; chemotherapy; bisphosphonates
ID CANCER RELATED FATIGUE; BREAST CANCER; SKELETAL MUSCLE; MINERAL DENSITY;
   TGF BETA; THERAPEUTIC TARGET; ZOLEDRONIC ACID; CACHEXIA; MASS;
   OSTEOPOROSIS
AB Chemotherapy is frequently accompanied by several side effects, including nausea, diarrhea, anorexia and fatigue. Evidence from ours and other groups suggests that chemotherapy can also play a major role in causing not only cachexia, but also bone loss. This complicates prognosis and survival among cancer patients, affects quality of life, and can increase morbidity and mortality rates. Recent findings suggest that soluble factors released from resorbing bone directly contribute to loss of muscle mass and function secondary to metastatic cancer. However, it remains unknown whether similar mechanisms also take place following treatments with anticancer drugs. In this study, we found that young male CD2F1 mice (8 week old) treated with the chemotherapeutic agent cisplatin (2.5 mg/kg) presented marked loss of muscle and bone mass. Myotubes exposed to bone conditioned medium from cisplatin treated mice showed severe atrophy ( 33%) suggesting a bone to muscle crosstalk. To test this hypothesis, mice were administered cisplatin in combination with an antiresorptive drug to determine if preservation of bone mass has an effect on muscle mass and strength following chemotherapy treatment. Mice received cisplatin alone or combined with zoledronic acid (ZA; 5 mu g/kg), a bisphosphonate routinely used for the treatment of osteoporosis. We found that cisplatin resulted in progressive loss of body weight ( 25%), in line with reduced fat ( 58%) and lean ( 17%) mass. As expected, microCT bone histomorphometry analysis revealed significant reduction in bone mass following administration of chemotherapy, in line with reduced trabecular bone volume (BV/TV) and number (Tb.N), as well as increased trabecular separation (Tb.Sp) in the distal femur. Conversely, trabecular bone was protected when cisplatin was administered in combination with ZA. Interestingly, while the animals exposed to chemotherapy presented significant muscle wasting ( 20% vs. vehicle treated mice), the administration of ZA in combination with cisplatin resulted in preservation of muscle mass (+12%) and strength (+42%). Altogether, these observations support our hypothesis of bone factors targeting muscle and suggest that pharmacological preservation of bone mass can benefit muscle mass and function following chemotherapy.
C1 [Essex, Alyson L.; Pin, Fabrizio; Bonewald, Lynda F.; Plotkin, Lilian, I; Bonetto, Andrea] Indiana Univ Sch Med, Dept Anat Cell Biol 8 Physiol, Indianapolis, IN 46202 USA.
   [Huot, Joshua R.; Bonetto, Andrea] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
   [Bonewald, Lynda F.; Plotkin, Lilian, I; Bonetto, Andrea] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
   [Bonewald, Lynda F.; Bonetto, Andrea] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN 46204 USA.
   [Bonewald, Lynda F.] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
   [Bonewald, Lynda F.; Bonetto, Andrea] Indiana Univ Sch Med, IUPUI Ctr Cachexia Res Innovat & Therapy, Indianapolis, IN 46202 USA.
   [Bonetto, Andrea] Indiana Univ Sch Med, Dept Otolaryngol Head & Neck Surg, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Indianapolis; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington
RP Bonetto, A (通讯作者)，Indiana Univ Sch Med, Dept Anat Cell Biol 8 Physiol, Indianapolis, IN 46202 USA.; Bonetto, A (通讯作者)，Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.; Bonetto, A (通讯作者)，Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.; Bonetto, A (通讯作者)，Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN 46204 USA.; Bonetto, A (通讯作者)，Indiana Univ Sch Med, IUPUI Ctr Cachexia Res Innovat & Therapy, Indianapolis, IN 46202 USA.; Bonetto, A (通讯作者)，Indiana Univ Sch Med, Dept Otolaryngol Head & Neck Surg, Indianapolis, IN 46202 USA.
EM abonetto@iu.edu
RI Bonetto, Andrea/MTA 9318 2025; Plotkin, Lilian/H 7188 2019; Bonewald,
   Lynda/Q 3638 2019
OI Plotkin, Lilian/0000 0002 9537 4544; ESSEX, ALYSON/0000 0001 7698 5342; 
FU Department of Surgery and the Department of Otolaryngology   Head & Neck
   Surgery at Indiana University; V Foundation for Cancer Research
   [V2017 021]; American Cancer Society [132013 RSG 18 010 01 CCG];
   Showalter Research Trust; T32 Institutional Training Grant from NIH
   [AR065971]
FX This study was supported by the Department of Surgery and the Department
   of Otolaryngology   Head & Neck Surgery at Indiana University, and by
   grants from the V Foundation for Cancer Research (V2017 021), the
   American Cancer Society (132013 RSG 18 010 01 CCG), and the Showalter
   Research Trust to AB. AE was supported by a T32 Institutional Training
   Grant from NIH (AR065971).
CR Abdul Ghani M, 2017, CELL RES, V27, P1195, DOI 10.1038/cr.2017.87
   Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   Agarwala S, 2019, ANN REHABIL MED ARM, V43, P314, DOI 10.5535/arm.2019.43.3.314
   Agri F, 2017, BMC SURG, V17, DOI 10.1186/s12893 017 0299 6
   Ahlberg K, 2003, LANCET, V362, P640, DOI 10.1016/S0140 6736(03)14186 4
   Anker MS, 2019, J CACHEXIA SARCOPENI, V10, P22, DOI 10.1002/jcsm.12402
   Antoun S, 2010, ANN ONCOL, V21, P1594, DOI 10.1093/annonc/mdp605
   Arthur ST, 2016, J MED ECON, V19, P874, DOI 10.1080/13696998.2016.1181640
   Baehr LM, 2011, J PHYSIOL LONDON, V589, P4759, DOI 10.1113/jphysiol.2011.212845
   Barreto R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15040 1
   Barreto R, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00472
   Barreto R, 2016, ONCOTARGET, V7, P43442, DOI 10.18632/oncotarget.9779
   BAYLINK DJ, 1983, NEW ENGL J MED, V309, P306, DOI 10.1056/NEJM198308043090509
   Body JJ, 2018, BMC UROL, V18, DOI 10.1186/s12894 018 0393 9
   Bonetto A., 2019, Basic and Applied Bone Biology, V2nd, P317, DOI [10.1016/B978 0 12 813259 3.00016 6, DOI 10.1016/B978 0 12 813259 3.00016 6]
   Bonetto A, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00679
   Bonetto A, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.101
   Bonewald L, 2019, BONE, V120, P212, DOI 10.1016/j.bone.2018.11.002
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Borsheim E, 2014, J BONE MINER RES, V29, P1369, DOI 10.1002/jbmr.2162
   Brotto M, 2015, BONE, V80, P109, DOI 10.1016/j.bone.2015.02.010
   Brown Sue A, 2007, Curr Osteoporos Rep, V5, P120
   Cameron DA, 2010, BREAST CANCER RES TR, V123, P805, DOI 10.1007/s10549 010 0899 7
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Chen JA, 2015, J CACHEXIA SARCOPENI, V6, P132, DOI 10.1002/jcsm.12023
   Chovanec M, 2017, ANN ONCOL, V28, P2670, DOI 10.1093/annonc/mdx360
   Clay H, 2016, DEV BIOL, V418, P157, DOI 10.1016/j.ydbio.2016.06.024
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Curt G A, 2000, Oncologist, V5, P353, DOI 10.1634/theoncologist.5 5 353
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Damrauer JS, 2018, EUR J TRANSL MYOL, V28, P139, DOI 10.4081/ejtm.2018.7590
   Davis HM, 2019, BONE, V124, P89, DOI 10.1016/j.bone.2019.04.012
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Dufresne SS, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478 018 0533 1
   Dufresne SS, 2016, AM J PHYSIOL CELL PH, V310, pC663, DOI 10.1152/ajpcell.00285.2015
   Ewelina B, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14440
   Fearon KCH, 2002, INT J CARDIOL, V85, P73, DOI 10.1016/S0167 5273(02)00235 8
   Fearon K, 2013, NAT REV CLIN ONCOL, V10, P90, DOI 10.1038/nrclinonc.2012.209
   Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470 2045(10)70218 7
   Finianos A, 2019, EXPERT OPIN PHARMACO, V20, P657, DOI 10.1080/14656566.2019.1574754
   FISHER DE, 1971, J BONE JOINT SURG AM, VA 53, P859, DOI 10.2106/00004623 197153050 00002
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   GAIL DB, 1990, AM REV RESPIR DIS, V142, P474
   GLAUS A, 1993, SUPPORT CARE CANCER, V1, P305, DOI 10.1007/BF00364968
   Goedendorp MM, 2012, CANCER AM CANCER SOC, V118, P3833, DOI 10.1002/cncr.26226
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Guttridge DC, 2015, NAT MED, V21, P1248, DOI 10.1038/nm.3988
   Hain B. A., 2019, JCSM RAPID COMMUN, V2, DOI DOI 10.1002/J.2617 1619.2019.TB00011.X31032492
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   Ho ATV, 2017, P NATL ACAD SCI USA, V114, P6675, DOI 10.1073/pnas.1705420114
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Huot JR, 2019, CANCERS, V11, DOI 10.3390/cancers11040571
   Jacobsen PB, 2007, CANCER, V110, P1851, DOI 10.1002/cncr.22993
   Karsenty G, 2012, NATURE, V481, P314, DOI 10.1038/nature10763
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Klimek MEB, 2010, BIOCHEM BIOPH RES CO, V391, P1548, DOI 10.1016/j.bbrc.2009.12.123
   Knobel H, 2001, J CLIN ONCOL, V19, P3226, DOI 10.1200/JCO.2001.19.13.3226
   Kubo T, 2008, CANCER AM CANCER SOC, V112, P2119, DOI 10.1002/cncr.23437
   Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03 0610com
   Levinger I, 2014, BONE, V64, P8, DOI 10.1016/j.bone.2014.03.008
   Lewiecki EM, 2010, THER ADV CHRONIC DIS, V1, P115, DOI 10.1177/2040622310374783
   Li T, 2010, INVEST OPHTH VIS SCI, V51, P2479, DOI 10.1167/iovs.09 4414
   Liu L, 2018, AM J PHYSIOL LUNG C, V315, pL609, DOI 10.1152/ajplung.00554.2017
   Luctkar Flude M, 2009, ONCOL NURS FORUM, V36, P194, DOI 10.1188/09.ONF.194 202
   Macherey S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006250.pub2
   Marques P, 2016, MINERVA ENDOCRINOL, V41, P78
   Meeske K, 2007, QUAL LIFE RES, V16, P947, DOI 10.1007/s11136 007 9215 3
   Mera P, 2016, MOL METAB, V5, P1042, DOI 10.1016/j.molmet.2016.07.002
   Mo Chenglin, 2012, Recent Pat Biotechnol, V6, P223
   Montazeri A, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477 7525 7 102
   Morse RT, 2019, HEAD NECK J SCI SPEC, V41, P2492, DOI 10.1002/hed.25717
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Neefjes ECW, 2017, J CACHEXIA SARCOPENI, V8, P623, DOI 10.1002/jcsm.12199
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Patrick Daniel L, 2004, J Natl Cancer Inst Monogr, P9
   Pin F, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00543
   Pin F, 2019, FASEB J, V33, P7778, DOI 10.1096/fj.201802799R
   Pin F, 2018, J CACHEXIA SARCOPENI, V9, P685, DOI 10.1002/jcsm.12311
   Porporato PE, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.3
   Prado CMM, 2011, CURR OPIN CLIN NUTR, V14, P250, DOI 10.1097/MCO.0b013e3283455d45
   Prue G, 2010, J PAIN SYMPTOM MANAG, V39, P197, DOI 10.1016/j.jpainsymman.2009.06.011
   Quach JM, 2015, J BONE MINER RES, V30, P886, DOI 10.1002/jbmr.2415
   Regan JN, 2017, CURR OSTEOPOROS REP, V15, P18, DOI 10.1007/s11914 017 0344 5
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Rudnicki MA, 2015, BONE, V80, P60, DOI 10.1016/j.bone.2015.02.009
   Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341
   Sartawi Z, 2017, PHARMACOL RES, V125, P232, DOI 10.1016/j.phrs.2017.08.013
   Sartori R, 2013, NAT GENET, V45, P1309, DOI 10.1038/ng.2772
   Sassoli C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108662
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shandala T, 2012, J CELL PHYSIOL, V227, P2889, DOI 10.1002/jcp.23034
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Stasi R, 2003, CANCER AM CANCER SOC, V98, P1786, DOI 10.1002/cncr.11742
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Touchberry CD, 2013, AM J PHYSIOL ENDOC M, V304, pE863, DOI 10.1152/ajpendo.00596.2012
   Uchiyama S, 2015, BONE, V75, P84, DOI 10.1016/j.bone.2015.02.018
   Vale CL, 2016, LANCET ONCOL, V17, P243, DOI 10.1016/S1470 2045(15)00489 1
   von Haehling S, 2014, J CACHEXIA SARCOPENI, V5, P261, DOI 10.1007/s13539 014 0164 8
   von Haehling S, 2010, J CACHEXIA SARCOPENI, V1, P1, DOI 10.1007/s13539 010 0002 6
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961
   Waning DL, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.59
   Wildemann B, 2007, J BIOMED MATER RES A, V81A, P437, DOI 10.1002/jbm.a.31085
   Willemse PM, 2014, J CLIN ENDOCR METAB, V99, P4101, DOI 10.1210/jc.2014 1722
   Yin RX, 2007, GROWTH FACTORS, V25, P286, DOI 10.1080/08977190701781289
   Yoon SH, 2016, NEUROMUSCULAR DISORD, V26, P73, DOI 10.1016/j.nmd.2015.09.015
NR 107
TC 40
Z9 41
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD NOV 19
PY 2019
VL 10
AR 809
DI 10.3389/fendo.2019.00809
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA JU0CJ
UT WOS:000501347600001
PM 31803146
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, YH
   Chung, CC
   Liu, YC
   Lai, WC
   Lin, ZS
   Chen, TM
   Li, LY
   Hung, MC
AF Chen, Ya Huey
   Chung, Chiao Chen
   Liu, Yu Chia
   Lai, Wei Chen
   Lin, Zong Shin
   Chen, Tsung Ming
   Li, Long Yuan
   Hung, Mien Chie
TI YY1 and HDAC9c transcriptionally regulate p38 mediated mesenchymal stem
   cell differentiation into osteoblasts
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Osteogenesis; mesenchymal stem cells; p38; HDAC9c; YY1
ID SKELETAL MYOGENESIS; SONIC HEDGEHOG; PROTEIN; PHOSPHORYLATION;
   EXPRESSION; RUNX2; BONE; MATURATION; OSTERIX; MAPKS
AB Mesenchymal stem cells (MSCs) have a high self renewal potential and can differentiate into various types of cells, including adipocytes, osteoblasts, and chondrocytes. Previously, we reported that the enhancer of zeste homolog 2 (EZH2), the catalytic component of the Polycomb repressive complex 2, and HDAC9c mediate the osteogenesis and adipogenesis of MSCs. In the current study, we identify the role of p38 in osteogenic differentiation from a MAPK antibody array screen and investigate the mechanisms underlying its transcriptional regulation. Our data show that YY1, a ubiquitously expressed transcription factor, and HDAC9c coordinate p38 transcriptional activity to promote its expression to facilitate the osteogenic potential of MSCs. Our results show that p38 mediates osteogenic differentiation, and this has significant implications in bone related diseases, bone tissue engineering, and regenerative medicine.
C1 [Chen, Ya Huey; Lin, Zong Shin; Hung, Mien Chie] China Med Univ, Coll Med, Grad Inst Biomed Sci, Taichung 40402, Taiwan.
   [Chen, Ya Huey; Chung, Chiao Chen; Liu, Yu Chia; Lai, Wei Chen; Li, Long Yuan; Hung, Mien Chie] China Med Univ Hosp, Ctr Mol Med, Taichung 40447, Taiwan.
   [Chen, Ya Huey; Li, Long Yuan; Hung, Mien Chie] China Med Univ, Canc Biol & Drug Discovery PhD Program, Taichung 40447, Taiwan.
   [Li, Long Yuan] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan.
   [Hung, Mien Chie] Asia Univ, Dept Biotechnol, Taichung 41354, Taiwan.
   [Hung, Mien Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Chen, Tsung Ming] Natl Kaohsiung Univ Sci & Technol, Dept & Grad Inst Aquaculture, Kaohsiung 81157, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; China Medical University Taiwan;
   National Chung Hsing University; Asia University Taiwan; University of
   Texas System; UTMD Anderson Cancer Center; National Kaohsiung University
   of Science & Technology
RP Li, LY (通讯作者)，Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan.; Hung, MC (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Chen, YH (通讯作者)，China Med Univ, Coll Med, 91 Hsuehshih Rd, Taichung 40402, Taiwan.
EM yahuey@mail.cmu.edu.tw; lyuan@dragon.nchu.edu.tw; mhung@mdanderson.org
RI Hung, Mien Chie/ABD 5911 2021
FU Ministry of Science and Technology [MOST 104 2320 B 039 047 MY3, MOST
   106 2320 B 039 047, MOST 104 2314 B 005 001, MOST 105 2320 B 005 009]
FX This work was supported in part by the following grants: the Ministry of
   Science and Technology (MOST 104 2320 B 039 047 MY3 and MOST
   106 2320 B 039 047 to Y. H.C. and MOST 104 2314 B 005 001 and MOST
   105 2320 B 005 009 to L.Y. Li.). The authors also appreciate Jennifer L.
   Hsu and Ian Crews for the critical reading and editing of the paper.
CR Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166
   Caplan AI, 2009, TISSUE ENG PART B RE, V15, P195, DOI [10.1089/ten.teb.2008.0515, 10.1089/ten.TEB.2008.0515]
   Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Chen YH, 2011, J BIOL CHEM, V286, P10671, DOI 10.1074/jbc.M110.199612
   D'Alimonte I, 2013, STEM CELL REV REP, V9, P642, DOI 10.1007/s12015 013 9436 5
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Barrantes IDB, 2011, P NATL ACAD SCI USA, V108, P12764, DOI 10.1073/pnas.1015013108
   Fontaine C, 2008, STEM CELLS, V26, P1037, DOI 10.1634/stemcells.2007 0974
   Freedman MS, 2010, MULT SCLER J, V16, P503, DOI 10.1177/1352458509359727
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Hah YS, 2013, MOL BIOL REP, V40, P4869, DOI 10.1007/s11033 013 2586 3
   Huang YF, 2012, J BONE MINER RES, V27, P1093, DOI 10.1002/jbmr.1548
   James AW, 2010, TISSUE ENG PT A, V16, P2605, DOI [10.1089/ten.tea.2010.0048, 10.1089/ten.TEA.2010.0048]
   James AW, 2012, STEM CELLS DEV, V21, P2170, DOI 10.1089/scd.2011.0461
   James AW, 2011, BIOCHEM BIOPH RES CO, V411, P126, DOI 10.1016/j.bbrc.2011.06.111
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140 6736(08)60690 X
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Neovius E, 2010, J PLAST RECONSTR AES, V63, P1615, DOI 10.1016/j.bjps.2009.06.003
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092 8674(00)82001 2
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Shi Y, 1997, BBA REV CANCER, V1332, pF49, DOI 10.1016/S0304 419X(96)00044 3
   Taipaleenmäki H, 2011, EXP CELL RES, V317, P745, DOI 10.1016/j.yexcr.2010.12.015
   Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408
   Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378 1119(99)00261 9
   Tolar J, 2010, STEM CELLS, V28, P1446, DOI 10.1002/stem.459
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006
   Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020 06
   Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845
   Yoo EJ, 2006, J BIOL CHEM, V281, P6608, DOI 10.1074/jbc.M508982200
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Zeitouni S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003396
   Zhou L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10026
NR 42
TC 14
Z9 14
U1 0
U2 2
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156 6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2018
VL 8
IS 3
BP 514
EP +
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GB5PY
UT WOS:000429119500013
PM 29637005
DA 2025 08 17
ER

PT J
AU Maurizi, A
   Capulli, M
   Curle, A
   Patel, R
   Ucci, A
   Côrtes, JA
   Oxford, H
   Lamandé, SR
   Bateman, JF
   Rucci, N
   Teti, A
AF Maurizi, Antonio
   Capulli, Mattia
   Curle, Annabel
   Patel, Rajvi
   Ucci, Argia
   Cortes, Juliana Alves
   Oxford, Harriet
   Lamande, Shireen R.
   Bateman, John F.
   Rucci, Nadia
   Teti, Anna
TI Extra skeletal manifestations in mice affected by Clcn7 dependent
   autosomal dominant osteopetrosis type 2 clinical and therapeutic
   implications
SO BONE RESEARCH
LA English
DT Article
ID ALBERS SCHONBERG DISEASE; REQUIRES OSTM1; THIOFLAVIN T; TGF BETA; CLC 7;
   MACROPHAGES; OSTEOCLASTS; ACTIVATION; PHENOTYPES; PATHOLOGY
AB Autosomal dominant osteopetrosis type 2 (ADO2) is a high density brittle bone disease characterized by bone pain, multiple fractures and skeletal related events, including nerve compression syndrome and hematological failure. We demonstrated that in mice carrying the heterozygous Clcn7(G213R) mutation, whose human mutant homolog CLCN7(G215R) affects patients, the clinical impacts of ADO2 extend beyond the skeleton, affecting several other organs. The hallmark of the extra skeletal alterations is a consistent perivascular fibrosis, associated with high numbers of macrophages and lymphoid infiltrates. Fragmented clinical information in a small cohort of patients confirms extra skeletal alterations consistent with a systemic disease, in line with the observation that the CLCN7 gene is expressed in many organs. ADO2 mice also show anxiety and depression and their brains exhibit not only perivascular fibrosis but also beta amyloid accumulation and astrogliosis, suggesting the involvement of the nervous system in the pathogenesis of the ADO2 extra skeletal alterations. Extra skeletal organs share a similar cellular pathology, confirmed also in vitro in bone marrow mononuclear cells and osteoclasts, characterized by an impairment of the exit pathway of the Clcn7 protein product, ClC7, through the Golgi, with consequent reduced ClC7 expression in late endosomes and lysosomes, associated with high vesicular pH and accumulation of autophagosome markers. Finally, an experimental siRNA therapy, previously proven to counteract the bone phenotype, also improves the extra skeletal alterations. These results could have important clinical implications, supporting the notion that a systematic evaluation of ADO2 patients for extra skeletal symptoms could help improve their diagnosis, clinical management, and therapeutic options.
C1 [Maurizi, Antonio; Capulli, Mattia; Curle, Annabel; Patel, Rajvi; Ucci, Argia; Cortes, Juliana Alves; Oxford, Harriet; Rucci, Nadia; Teti, Anna] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy.
   [Lamande, Shireen R.; Bateman, John F.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Lamande, Shireen R.; Bateman, John F.] Univ Melbourne, Melbourne, Vic, Australia.
C3 University of L'Aquila; Murdoch Children's Research Institute;
   University of Melbourne
RP Capulli, M (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy.
EM mattia.capulli@univaq.it
RI ; Capulli, Mattia/K 6604 2016; Ucci, Argia/ABH 2263 2021; Maurizi,
   Antonio/AAI 7728 2020
OI Curle, Annabel J/0000 0002 9105 1131; Maurizi,
   Antonio/0000 0002 7027 4694; Capulli, Mattia/0000 0003 0449 6720; Patel,
   Rajvi/0000 0002 5710 7867; Rucci, Nadia/0000 0002 1371 8252; Ucci,
   Argia/0000 0002 5191 5337; Lamande, Shireen/0000 0003 2938 2711; Teti,
   Anna Maria/0000 0002 5887 4419
FU Fondazione Telethon [GGP09018, GGP14014]; European Union
   [RUBICON H2020 MSCA RISE 2015_690850,
   SYBIL FP7 HEALTH 2013 INNOVATION 602300]; Progetti di Rilevante
   Interesse Nazionale (PRIN) [2015F3JHMB]
FX This work was supported by the Fondazione Telethon Grants GGP09018 and
   GGP14014, the European Union funded project
   SYBIL FP7 HEALTH 2013 INNOVATION 602300 and by the Progetti di Rilevante
   Interesse Nazionale (PRIN) grant 2015F3JHMB to A.T. A.M. and A.U. were
   recipients of Marie Curie fellowships from the European Union funded
   project RUBICON H2020 MSCA RISE 2015_690850 to A.T. We are indebted with
   Prof. Paul A. Gleeson, University of Melbourne Department of
   Biochemistry and Molecular Biology and Bio21 Molecular Science and
   Biotechnology Institute, for his advice in the Golgi studies, and with
   Dr. Rita Di Massimo for editing the paper.
CR Alam I, 2015, J BONE MINER RES, V30, P2005, DOI 10.1002/jbmr.2545
   Alam I, 2014, BONE, V59, P66, DOI 10.1016/j.bone.2013.10.021
   Albers Schonberg, 1904, Munch Med Wochenschr, V5, P365
   Arrant AE, 2013, BEHAV BRAIN RES, V256, P119, DOI 10.1016/j.bbr.2013.05.035
   Bénichou OD, 2000, BONE, V26, P87, DOI 10.1016/S8756 3282(99)00244 6
   Biancalana M, 2010, BBA PROTEINS PROTEOM, V1804, P1405, DOI 10.1016/j.bbapap.2010.04.001
   Biernacka A, 2011, GROWTH FACTORS, V29, P196, DOI 10.3109/08977194.2011.595714
   Bollerslev J, 2013, EUR J ENDOCRINOL, V169, pR39, DOI 10.1530/EJE 13 0136
   Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014 5793(95)01298 2
   Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286 4579(99)00250 6
   Caetano Lopes J, 2017, BONE, V105, P253, DOI 10.1016/j.bone.2017.09.007
   Cappariello A, 2016, HORM MOL BIOL CLIN I, V28, P5, DOI 10.1515/hmbci 2016 0009
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Capulli M, 2015, MOL THER NUCL ACIDS, V4, P1, DOI 10.1038/mtna.2015.21
   Chakraborty K, 2017, ELIFE, V6, DOI [10.7554/eLife.28862, 10.7554/elife.28862]
   Cleiren E, 2001, HUM MOL GENET, V10, P2861, DOI 10.1093/hmg/10.25.2861
   COHN ZA, 1963, J EXP MED, V118, P991, DOI 10.1084/jem.118.6.991
   David DJ, 2009, NEURON, V62, P479, DOI 10.1016/j.neuron.2009.04.017
   Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673
   Del Fattore A, 2008, BONE, V42, P19, DOI 10.1016/j.bone.2007.08.029
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166 4328(88)90157 X
   Ghavami S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.36
   Graves AR, 2008, NATURE, V453, P788, DOI 10.1038/nature06907
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hill B G, 1965, Med J Aust, V2, P365
   HIROYAMA Y, 1987, PEDIATR NEUROL, V3, P54, DOI 10.1016/0887 8994(87)90057 9
   Hsu HS, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14612 5
   Humphrey MB, 2005, IMMUNOL REV, V208, P50, DOI 10.1111/j.0105 2896.2005.00325.x
   Insel PA, 2012, BRIT J PHARMACOL, V166, P447, DOI 10.1111/j.1476 5381.2012.01847.x
   Kajiya H, 2009, PFLUG ARCH EUR J PHY, V458, P1049, DOI 10.1007/s00424 009 0689 4
   Kardash E, 2011, NAT PROTOC, V6, P1835, DOI 10.1038/nprot.2011.395
   Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576
   Kida Y., 2001, HISTOCHEM CELL BIOL, DOI [10.1007/s004180000245, DOI 10.1007/S004180000245]
   Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008 5472.CAN 08 4401
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   Lakatos HF, 2007, PPAR RES, V2007, DOI 10.1155/2007/71323
   Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535
   Lanz E., 1997, J FLUORESC, V7, P317, DOI DOI 10.1023/A:1022586127784
   Leisle L, 2011, EMBO J, V30, P2140, DOI 10.1038/emboj.2011.137
   Ludwig CF, 2013, J BIOL CHEM, V288, P28611, DOI 10.1074/jbc.M113.509364
   Martínez Gómez C, 2008, J ENVIRON MONITOR, V10, P490, DOI 10.1039/b800441m
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Maurizi A, 2018, BONE, V110, P343, DOI 10.1016/j.bone.2018.02.031
   Odaka C, 1999, J IMMUNOL, V163, P5346
   Pressey SNR, 2010, J NEUROPATH EXP NEUR, V69, P1228, DOI 10.1097/NEN.0b013e3181ffe742
   RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413
   Rodríguez Peña AB, 2005, J NEPHROL, V18, P341
   Rucci N, 2016, MATRIX BIOL, V52 54, P176, DOI 10.1016/j.matbio.2016.02.009
   Ruiz Ortega M, 2007, CARDIOVASC RES, V74, P196, DOI 10.1016/j.cardiores.2007.02.008
   Ryter SW, 2019, ANTIOXID REDOX SIGN, V30, P138, DOI 10.1089/ars.2018.7518
   Schulz P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012585
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Stauber T, 2010, J BIOL CHEM, V285, P34537, DOI 10.1074/jbc.M110.162545
   Steinberg BE, 2010, J CELL BIOL, V189, P1171, DOI 10.1083/jcb.200911083
   Teti A, 2017, BONE, V102, P50, DOI 10.1016/j.bone.2017.02.002
   Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116
   Waguespack SG, 2007, J CLIN ENDOCR METAB, V92, P771, DOI 10.1210/jc.2006 1986
   Wartosch L, 2009, FASEB J, V23, P4056, DOI 10.1096/fj.09 130880
   Weinert S, 2014, EMBO REP, V15, P784, DOI 10.15252/embr.201438553
   Weinert S, 2010, SCIENCE, V328, P1401, DOI 10.1126/science.1188072
   Whyte M. P., 2013, PRIMER METABOLIC BON, P769
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xue C, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.160696
NR 65
TC 13
Z9 13
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD JUN 11
PY 2019
VL 7
AR 17
DI 10.1038/s41413 019 0055 x
PG 15
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA IC6YU
UT WOS:000471119500001
PM 31231577
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Borsy, A
   Podani, J
   Stéger, V
   Balla, B
   Horváth, A
   Kósa, JP
   Gyurjan, I
   Molnár, A
   Szabolcsi, Z
   Szabó, L
   Jakó, E
   Zomborszky, Z
   Nagy, J
   Semsey, S
   Vellai, T
   Lakatos, P
   Orosz, L
AF Borsy, Adrienn
   Podani, Janos
   Steger, Viktor
   Balla, Bernadett
   Horvath, Arnold
   Kosa, Janos P.
   Gyurjan, Istvan, Jr.
   Molnar, Andrea
   Szabolcsi, Zoltan
   Szabo, Laszlo
   Jako, Eena
   Zomborszky, Zoltan
   Nagy, Janos
   Semsey, Szabolcs
   Vellai, Tibor
   Lakatos, Peter
   Orosz, Laszlo
TI Identifying novel genes involved in both deer physiological and human
   pathological osteoporosis
SO MOLECULAR GENETICS AND GENOMICS
LA English
DT Article
DE Bone metabolism; Interspecific microarray; Gene expression pattern;
   Real time PCR
ID ANTLER GROWTH; BONE MASS; LIMB DEVELOPMENT; COSTAL COMPACTA; EXPRESSION;
   MUTATIONS; BINDING; KINASE
AB Osteoporosis attacks 10% of the population worldwide. Humans or even the model animals of the disease cannot recover from porous bone. Regeneration in skeletal elements is the unique feature of our newly investigated osteoporosis model, the red deer (Cervus elaphus) stag. Cyclic physiological osteoporosis is a consequence of the annual antler cycle. This phenomenon raises the possibility to identify genes involved in the regulation of bone mineral density on the basis of comparative genomics between deer and human. We compare gene expression activity of osteoporotic and regenerating rib bone samples versus autumn dwell control in red deer by microarray hybridization. Identified genes were tested on human femoral bone tissue from non osteoporotic controls and patients affected with age related osteoporosis. Expression data were evaluated by Principal Components Analysis and Canonical Variates Analysis. Separation of patients into a normal and an affected group based on ten formerly known osteoporosis reference genes was significantly improved by expanding the data with newly identified genes. These genes include IGSF4, FABP3, FABP4, FKBP2, TIMP2, TMSB4X, TRIB, and members of the Wnt signaling. This study supports that extensive comparative genomic analyses, here deer and human, provide a novel approach to identify new targets for human diagnostics and therapy.
C1 [Borsy, Adrienn; Steger, Viktor; Gyurjan, Istvan, Jr.; Molnar, Andrea; Szabolcsi, Zoltan; Semsey, Szabolcs; Vellai, Tibor; Orosz, Laszlo] Eotvos Lorand Univ, Dept Genet, H 1117 Budapest, Hungary.
   [Borsy, Adrienn; Steger, Viktor; Szabolcsi, Zoltan; Szabo, Laszlo; Orosz, Laszlo] Agr Biotechnol Ctr, Inst Genet, H 2100 Godollo, Hungary.
   [Podani, Janos] Eotvos Lorand Univ, Dept Plant Taxon & Ecol, H 1117 Budapest, Hungary.
   [Borsy, Adrienn; Podani, Janos; Horvath, Arnold; Jako, Eena] Eotvos Lorand Univ, Reg Knowledge Ctr, Lorand Eotvos Univ eSci, H 1117 Budapest, Hungary.
   [Balla, Bernadett; Kosa, Janos P.; Lakatos, Peter] Semmelweis Univ, Dept Internal Med 1, H 1083 Budapest, Hungary.
   [Zomborszky, Zoltan] Univ Kaposvar, Dept Fish & Pet Anim Breeding, Fac Anim Sci, H 7400 Kaposvar, Hungary.
   [Nagy, Janos] Univ Kaposvar, Deer Farm Pannonian Equestrian Acad, H 7400 Kaposvar, Hungary.
C3 Eotvos Lorand University; Eotvos Lorand University; Eotvos Lorand
   University; Semmelweis University; Kaposvar University; Kaposvar
   University
RP Orosz, L (通讯作者)，Eotvos Lorand Univ, Dept Genet, Pazmany Peter S 1 C, H 1117 Budapest, Hungary.
EM orosz@abc.hu
RI Olsson, Stefan/H 2617 2014; Vellai, Tibor/AAG 2154 2020; Podani,
   Janos/G 3074 2014; Semsey, Szabolcs/L 6329 2013; Borsy,
   Adrienn/AAD 5595 2020
OI Steger, Viktor/0000 0002 9972 8602; Podani, Janos/0000 0002 1452 1486;
   Semsey, Szabolcs/0000 0002 4522 5495; 
FU OTKA [T032205, PD75496]; OTKANI [68218]; OM [0028/2001, 0320/2004]; NKFP
   [1A/007/2004]; Ministry of Health, Social and Family Affairs [454/2003];
   Janos Bolyai fellowship of the HAS
FX Thanks are due to Sankar Adhya (NIH, NCI, USA) for valuable advice and
   discussions. This work was supported by grants OTKA T032205 to L. O.,
   OTKANI 68218 to J.P.; OM 0028/2001 to L. O. and P. L., OM 0320/2004 to
   L. O., NKFP 1A/007/2004 to L. O., P. L. and T. V.; 454/2003 from the
   Ministry of Health, Social and Family Affairs to L. O., OTKA PD75496 to
   S. S., and by the Janos Bolyai fellowship of the HAS to S.S.
CR Balla B, 2008, CALCIFIED TISSUE INT, V82, P12, DOI 10.1007/s00223 007 9092 3
   BANKS WJ, 1968, ANAT REC, V162, P387, DOI 10.1002/ar.1091620401
   BANKS WJ, 1968, ANAT REC, V162, P399, DOI 10.1002/ar.1091620402
   Baxter BJ, 1999, ANAT REC, V256, P14, DOI 10.1002/(SICI)1097 0185(19990901)256:1<14::AID AR3>3.0.CO;2 A
   Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356
   BILEZIKIAN JP, 2000, PRINCIPLES BONE BIOL
   Bloom W, 1941, ANAT RECORD, V81, P443, DOI 10.1002/ar.1090810404
   Bock Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000
   CHAPMAN DI, 1975, MAMMAL REV, V5
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   GRIMMOND S, 1995, HUM GENET, V95, P455
   Gyurján I, 2007, MOL GENET GENOMICS, V277, P221, DOI 10.1007/s00438 006 0190 0
   Hecht J, 2007, GENE EXPR PATTERNS, V7, P102, DOI 10.1016/j.modgep.2006.05.014
   Johnson EB, 2005, HUM MOL GENET, V14, P3523, DOI 10.1093/hmg/ddi381
   Johnson EB, 2006, GENOMICS, V88, P600, DOI 10.1016/j.ygeno.2006.08.005
   Kamel HK, 2006, J MANAGE CARE PHARM, V12, pS4, DOI 10.18553/jmcp.2006.12.S6 A.S4
   Kamel HK, 2006, J MANAG CARE PHARM, V12, pS2, DOI 10.18553/jmcp.2006.12.S6 A.S2
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kiss Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934
   Levine AJ, 2006, CELL CYCLE, V5, P1069, DOI 10.4161/cc.5.10.2771
   MEADOWS SD, 1982, J WILDLIFE MANAGE, V46, P838, DOI 10.2307/3808588
   Molnár A, 2007, MOL GENET GENOMICS, V277, P237, DOI 10.1007/s00438 006 0193 x
   Mount JG, 2006, DEV DYNAM, V235, P1390, DOI 10.1002/dvdy.20742
   Podani J., 2001, SYNTAX 2000 USERS MA
   PODANI J, 2000, INTRO EXPLORATION MU
   Ralston SH, 2006, GENE DEV, V20, P2492, DOI 10.1101/gad.1449506
   Reddy S, 1998, J CELL PHYSIOL, V177, P636, DOI 10.1002/(SICI)1097 4652(199812)177:4<636::AID JCP14>3.0.CO;2 H
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Sambrook PN, 2000, CLIN EXP RHEUMATOL, V18, pS93
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   Simon Chazottes D, 2006, GENOMICS, V87, P673, DOI 10.1016/j.ygeno.2006.01.007
   Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383
   Stoick Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123
   Thorndike E. A., 1998, Frontiers in Bioscience, V3, pC17
   Turner A. Simon, 2001, European Cells & Materials, V1, P66
   Witthuhn BA, 2001, CYTOKINE, V14, P129, DOI 10.1006/cyto.2001.0864
NR 38
TC 32
Z9 35
U1 1
U2 23
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1617 4615
EI 1617 4623
J9 MOL GENET GENOMICS
JI Mol. Genet. Genomics
PD MAR
PY 2009
VL 281
IS 3
BP 301
EP 313
DI 10.1007/s00438 008 0413 7
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 411WT
UT WOS:000263684900006
PM 19107525
DA 2025 08 17
ER

PT J
AU Ran, QC
   Yu, YL
   Chen, WZ
   Shen, XK
   Mu, CY
   Yuan, Z
   Tao, BL
   Hu, Y
   Yang, WH
   Cai, KY
AF Ran, Qichun
   Yu, Yonglin
   Chen, Weizhen
   Shen, Xinkun
   Mu, Caiyun
   Yuan, Zhang
   Tao, Bailong
   Hu, Yan
   Yang, Weihu
   Cai, Kaiyong
TI Deferoxamine loaded titania nanotubes substrates regulate osteogenic and
   angiogenic differentiation of MSCs via activation of HIF 1α
   signaling
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Titania nanotube; Layer by layer assembly; Drug release; MSCs;
   Differentiation
ID MESENCHYMAL STEM CELLS; HYPOXIA INDUCIBLE FACTOR 1 ALPHA; TIO2
   NANOTUBES; CONTROLLED RELEASE; BONE REGENERATION; SURFACE
   FUNCTIONALIZATION; BIOMEDICAL APPLICATIONS; ANTIBACTERIAL ACTIVITY;
   ENHANCED ANGIOGENESIS; OSTEOBLAST ADHESION
AB To develop biomaterials for inducing osteogenic and angiogenic differentiation of mesenchymal stem cells (MSCs) is crucial for bone repair. In this study, we employed titania nanotubes (TNT) as drug nanoreservoirs to load deferoxamine (DFO), and then deposited chitosan (Chi) and gelatin (Gel) multilayer as coverage structure via layer by layer (LBL) assembly technique, resulting in TNT DFO LBL substrates. Scanning electron microscopy (SEM), atomic force microscopy (AFM), X ray photoelectron spectroscopy (XPS) and contact angle measurements were employed to characterize the physical and chemical properties of the substrates. The results proved the successful fabrication of multilayer coating on TNT array. DFO released from the TNT arrays in a sustained manner. The drug device combination titanium (Ti) substrates positively improved the adhesion, proliferation, osteogenic/angiogenic differentiation of MSCs and mediated the growth behavior of human umbilical vein endothelial cells (HUVECs). Moreover, the TNT DFO LBL substrates up regulated osteogenic and angiogenic differentiation related genes expression of MSCs by activating HIF 1 alpha signaling pathway. The approach presents here has a potential impact on the development of high quality Ti based orthopedic implants.
C1 [Ran, Qichun; Yu, Yonglin; Chen, Weizhen; Shen, Xinkun; Mu, Caiyun; Yuan, Zhang; Tao, Bailong; Hu, Yan; Yang, Weihu; Cai, Kaiyong] Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.
   [Cai, Kaiyong] Chongqing Collaborat Innovat Ctr Minimally Invas, Chongqing 400016, Peoples R China.
C3 Chongqing University
RP Yang, WH; Cai, KY (通讯作者)，Chongqing Univ, Coll Bioengn, Chongqing 400044, Peoples R China.
EM yangweihu@cqu.edu.cn; kaiyong_cai@cqu.edu.cn
RI ; Chen, Weizhen/JEZ 9613 2023; Tao, Bailong/AAR 1533 2021; Yu,
   Yonglin/B 6593 2019; Cai, Kaiyong/G 1233 2011
OI tao, bailong/0000 0001 8619 5029; Cai, Kaiyong/0000 0001 9029 680X;
   chen, Weizhen/0000 0001 5209 1934; 
FU National Key R&D Program of China [2016YFC1100300]; National Natural
   Science Foundation of China [21734002, 51673032, 31700827]; Innovation
   Team in University of Chongqing Municipal Government [OCIDX201601002];
   Fundamental Research Funds for the Central Universities
   [106112017CDJQJ238813]
FX This work was financially supported by National Key R&D Program of China
   (grant No. 2016YFC1100300), National Natural Science Foundation of China
   (21734002, 51673032, and 31700827), Innovation Team in University of
   Chongqing Municipal Government (OCIDX201601002), and Fundamental
   Research Funds for the Central Universities (106112017CDJQJ238813).
CR Alvarez MM, 2017, ACS NANO, V11, P5195, DOI 10.1021/acsnano.7b01493
   Badat M, 2015, BRIT J HAEMATOL, V171, P430, DOI 10.1111/bjh.13401
   Bose S, 2013, TRENDS BIOTECHNOL, V31, P594, DOI 10.1016/j.tibtech.2013.06.005
   Cai KY, 2002, J BIOMED MATER RES, V62, P283, DOI 10.1002/jbm.10067
   Chen H, 2016, ADV HEALTHC MATER, V5, P907, DOI 10.1002/adhm.201501018
   Chen WZ, 2017, BIOMATERIALS, V114, P82, DOI 10.1016/j.biomaterials.2016.10.055
   Dowling DP, 2011, J BIOMATER APPL, V26, P327, DOI 10.1177/0885328210372148
   Feng WC, 2016, MAT SCI ENG C MATER, V62, P105, DOI 10.1016/j.msec.2016.01.046
   Fu JH, 2005, BIOMATERIALS, V26, P6684, DOI 10.1016/j.biomaterials.2005.04.034
   Gong ZN, 2017, J MATER CHEM B, V5, P537, DOI 10.1039/c6tb02329k
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Gulati K, 2012, ACTA BIOMATER, V8, P449, DOI 10.1016/j.actbio.2011.09.004
   Hou YH, 2013, INT J NANOMED, V8, P3619, DOI 10.2147/IJN.S38992
   Hu Y, 2012, BIOMATERIALS, V33, P3515, DOI 10.1016/j.biomaterials.2012.01.040
   Hu Y, 2012, ACTA BIOMATER, V8, P439, DOI 10.1016/j.actbio.2011.10.021
   Huo KF, 2014, RSC ADV, V4, P17300, DOI 10.1039/c4ra01458h
   Jia P, 2016, J BIOMED MATER RES A, V104, P2515, DOI 10.1002/jbm.a.35793
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Khorasani AM, 2015, J BIOMATER TISS ENG, V5, P593, DOI 10.1166/JBT.2015.1361
   Kumeria T, 2015, COLLOID SURFACE B, V130, P255, DOI 10.1016/j.colsurfb.2015.04.021
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lai M, 2017, APPL SURF SCI, V396, P1741, DOI 10.1016/j.apsusc.2016.11.228
   Lai M, 2012, COLLOID SURFACE B, V97, P211, DOI 10.1016/j.colsurfb.2012.04.029
   Lai M, 2011, BIOMACROMOLECULES, V12, P1097, DOI 10.1021/bm1014365
   Li J, 2015, EXP BIOL MED, V240, P273, DOI 10.1177/1535370214553906
   Li Y, 2015, ACS APPL MATER INTER, V7, P5715, DOI 10.1021/acsami.5b00331
   Liu WW, 2016, NANOSCALE, V8, P15783, DOI 10.1039/c6nr04461a
   Lv J, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/3/035013
   Manokawinchoke J, 2016, TISSUE ENG REGEN MED, V13, P547, DOI 10.1007/s13770 016 9127 9
   Park HJ, 2016, BIOMACROMOLECULES, V17, P1939, DOI 10.1021/acs.biomac.5b01670
   Pina S, 2015, ADV MATER, V27, P1143, DOI 10.1002/adma.201403354
   Rahmany MB, 2013, ACTA BIOMATER, V9, P5431, DOI 10.1016/j.actbio.2012.11.019
   Rani VVD, 2012, ACTA BIOMATER, V8, P1976, DOI 10.1016/j.actbio.2012.01.021
   Riddle RC, 2009, J MOL MED, V87, P583, DOI 10.1007/s00109 009 0477 9
   Roy P, 2011, ANGEW CHEM INT EDIT, V50, P2904, DOI 10.1002/anie.201001374
   Saito T, 2014, ACTA BIOMATER, V10, P3641, DOI 10.1016/j.actbio.2014.04.021
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Scotti C, 2013, P NATL ACAD SCI USA, V110, P3997, DOI 10.1073/pnas.1220108110
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Shafiq M, 2016, BIOMATERIALS, V90, P85, DOI 10.1016/j.biomaterials.2016.03.020
   Shen XK, 2016, MATER DESIGN, V92, P1007, DOI 10.1016/j.matdes.2015.12.126
   Shen XK, 2014, ACS APPL MATER INTER, V6, P16426, DOI 10.1021/am5049338
   Shi MC, 2015, ACTA BIOMATER, V21, P178, DOI 10.1016/j.actbio.2015.04.019
   Sista S, 2013, MAT SCI ENG C MATER, V33, P1573, DOI 10.1016/j.msec.2012.12.063
   Smith GC, 2011, J CARDIOVASC MAGN R, V13, DOI 10.1186/1532 429X 13 34
   Stegen S, 2018, BONE, V115, P50, DOI 10.1016/j.bone.2017.08.022
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wang TT, 2017, ACS BIOMATER SCI ENG, V3, P816, DOI 10.1021/acsbiomaterials.7b00103
   Wei Q, 2014, ANGEW CHEM INT EDIT, V53, P8004, DOI 10.1002/anie.201400546
   Wittmer CR, 2007, BIOMATERIALS, V28, P851, DOI 10.1016/j.biomaterials.2006.09.037
   Xiang YM, 2018, MAT SCI ENG C MATER, V85, P214, DOI 10.1016/j.msec.2017.12.034
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yu WL, 2017, SCI REP UK, V7, DOI 10.1038/srep44129
   Yu YQ, 2017, ACTA BIOMATER, V49, P590, DOI 10.1016/j.actbio.2016.11.067
   Zhang KJ, 2017, MATER DESIGN, V130, P403, DOI 10.1016/j.matdes.2017.05.085
   Zhang XY, 2018, MAT SCI ENG C MATER, V82, P110, DOI 10.1016/j.msec.2017.08.061
   Zhang YL, 2016, MATER DESIGN, V92, P471, DOI 10.1016/j.matdes.2015.12.023
   Zhang Y, 2017, ACS APPL MATER INTER, V9, P9449, DOI 10.1021/acsami.7b00322
   Zhao LZ, 2013, BIOMATERIALS, V34, P19, DOI 10.1016/j.biomaterials.2012.09.041
   Zhao LZ, 2012, BIOMATERIALS, V33, P2629, DOI 10.1016/j.biomaterials.2011.12.024
NR 60
TC 51
Z9 52
U1 2
U2 107
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD OCT 1
PY 2018
VL 91
BP 44
EP 54
DI 10.1016/j.msec.2018.04.098
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA GR0GI
UT WOS:000442192000006
PM 30033275
DA 2025 08 17
ER

PT J
AU Aoki, K
   Matsunaga, S
   Ito, S
   Shibahara, T
   Nomura, T
   Matsuzaki, H
   Abe, S
   Yamaguchi, A
AF Aoki, Kazumitsu
   Matsunaga, Satoru
   Ito, Shinichirou
   Shibahara, Takahiko
   Nomura, Takeshi
   Matsuzaki, Hideo
   Abe, Shinichi
   Yamaguchi, Akira
TI Persistent bone resorption lacunae on necrotic bone distinguish
   bisphosphonate related osteonecrosis of jaw from denosumab related
   osteonecrosis
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Osteonecrosis of jaw; Bisphosphonate; BRONJ; Denosumab; Bone resorption
   lacunae
AB Background Bisphosphonate and denosumab are widely used for the treatment of osteoporosis and bone metastasis of cancer to prevent excessive bone resorption. Osteonecrosis of the jaw is a serious adverse effect of bisphosphonate or denosumab referred to as bisphosphonate related osteonecrosis of the jaw (BRONJ) or denosumab related osteonecrosis of the jaw (DRONJ), respectively. Since bisphosphonate and denosumab inhibit bone resorption by different mechanism, we evaluated whether these drug types result in different histopathological characteristics related to bone resorption. Materials and Methods We histopathologically investigated 10 cases of BRONJ, DRONJ, and suppurative osteomyelitis. Paraffin sections prepared from decalcified dissected jaw bones were used for histopathological observation, second harmonic generation imaging, and bone histomorphometry. The samples were also observed by a scanning electron microscope. Results Numerous bone resorption lacunae were observed on the necrotic bone surface in almost all cases of BRONJ; however, such resorption lacunae were limited in DRONJ and suppurative osteomyelitis. Prominent bone resorption lacunae were also confirmed by second harmonic generation imaging and scanning electron microscopy in BRONJ, but not in DRONJ or suppurative osteomyelitis. As determined by bone histomorphometry, the number of bone resorption lacunae and the length of the erosion surface of resorption lacunae were significantly higher in BRONJ group than in the DRONJ and suppurative osteomyelitis groups. These parameters were correlated between the necrotic bones and the vital bones in BRONJ. Conclusions Persistent bone resorption lacunae on the necrotic bone surface are unique to BRONJ, providing a basis for distinguishing BRONJ from DRONJ and OM in histopathological diagnosis.
C1 [Aoki, Kazumitsu; Matsunaga, Satoru; Abe, Shinichi] Tokyo Dent Coll, Dept Anat, Chiyoda Ku, 2 9 18 Kanda Misaki Cho, Tokyo 1010061, Japan.
   [Aoki, Kazumitsu; Matsuzaki, Hideo] Tokyo Metropolitan Bokutoh Hosp, Dept Dent & Oral Surg, Sumida Ku, 4 23 15 Kotobashi, Tokyo 1308675, Japan.
   [Matsunaga, Satoru; Nomura, Takeshi; Abe, Shinichi; Yamaguchi, Akira] Tokyo Dent Coll Res Branding Project, Chiyoda Ku, 2 9 18 Kanda Misaki Cho, Tokyo 1010061, Japan.
   [Ito, Shinichirou; Shibahara, Takahiko] Tokyo Dent Coll, Dept Oral & Maxillofacial Surg, Chiyoda Ku, 2 9 18 Kanda Misaki Cho, Tokyo 1010061, Japan.
   [Nomura, Takeshi] Ichikawa Gen Hosp, Tokyo Dent Coll, Dept Oral Oncol & Maxillofacial Surg, 5 11 13 Sugano, Ichikawa, Chiba 2728513, Japan.
   [Yamaguchi, Akira] Tokyo Dent Coll, Oral Hlth Sci Ctr, 2 9 18 Kanda Misaki Cho, Tokyo 1010061, Japan.
C3 Tokyo Dental College; Tokyo Dental College; Tokyo Dental College; Tokyo
   Dental College
RP Yamaguchi, A (通讯作者)，Tokyo Dent Coll Res Branding Project, Chiyoda Ku, 2 9 18 Kanda Misaki Cho, Tokyo 1010061, Japan.; Yamaguchi, A (通讯作者)，Tokyo Dent Coll, Oral Hlth Sci Ctr, 2 9 18 Kanda Misaki Cho, Tokyo 1010061, Japan.
EM akira@tdc.ac.jp
RI MATSUZAKI, HIDEO/AAE 5246 2020; Yamaguchi, Akira/AAD 1661 2021
OI Matsunaga, Satoru/0000 0001 7059 8413; 
FU grant for MEXT Private University Branding Project; Branding Project for
   Multidisciplinary Research Center for Jaw Disease Fund, Tokyo Dental
   College; Grants in Aid for Scientific Research [20H03894, 21K09961]
   Funding Source: KAKEN
FX This research was supported by a grant for MEXT Private University
   Branding Project, and Branding Project for Multidisciplinary Research
   Center for Jaw Disease Fund, Tokyo Dental College.
CR Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Cai GQ, 2018, J BONE MINER RES, V33, P773, DOI 10.1002/jbmr.3376
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Dempster DW, 2018, J CLIN ENDOCR METAB, V103, P2498, DOI 10.1210/jc.2017 02669
   Favia G, 2009, BONE, V45, P406, DOI 10.1016/j.bone.2009.05.008
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Franco Pretto E, 2014, OR SURG OR MED OR PA, V118, P408, DOI 10.1016/j.oooo.2014.04.017
   Gross C, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1230 8
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Hansen T, 2006, VIRCHOWS ARCH, V449, P448, DOI 10.1007/s00428 006 0261 y
   Hinson AM, 2014, INT J DENT, V2014, DOI 10.1155/2014/452737
   Hoefert S, 2017, J CRANIO MAXILL SURG, V45, P570, DOI 10.1016/j.jcms.2017.01.013
   Jain N, 2009, NAT REV RHEUMATOL, V5, P341, DOI 10.1038/nrrheum.2009.87
   Kim SM, 2017, OR SURG OR MED OR PA, V123, P220, DOI 10.1016/j.oooo.2016.09.225
   Koerdt S, 2014, J ORAL PATHOL MED, V43, P448, DOI 10.1111/jop.12156
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Loyson T, 2018, ACTA CLIN BELG, V73, P100, DOI 10.1080/17843286.2017.1348001
   Mamilos A, 2021, J ORAL PATHOL MED, V50, P76, DOI 10.1111/jop.13112
   Marx RE, 2012, INT J ORAL MAX SURG, V41, P283, DOI 10.1016/j.ijom.2011.12.016
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Matsushita Y, 2016, MOL CLIN ONCOL, V4, P191, DOI 10.3892/mco.2015.696
   McGowan K, 2018, ORAL DIS, V24, P527, DOI 10.1111/odi.12708
   Recker R R, 2004, Osteoporos Int, V15, P231, DOI 10.1007/s00198 003 1530 0
   Recknor C, 2013, OBSTET GYNECOL, V121, P1291, DOI 10.1097/AOG.0b013e318291718c
   Ren SM, 2005, ARCH HISTOL CYTOL, V68, P103, DOI 10.1679/aohc.68.103
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774 016 0810 7
   Yuan A, 2020, OR SURG OR MED OR PA, V129, P133, DOI 10.1016/j.oooo.2019.08.018
NR 31
TC 8
Z9 8
U1 0
U2 9
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD SEP
PY 2021
VL 39
IS 5
BP 737
EP 747
DI 10.1007/s00774 021 01223 4
EA APR 2021
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA UJ0UR
UT WOS:000638089300001
PM 33830351
DA 2025 08 17
ER

PT J
AU Xiao, HH
   Gao, QG
   Ho, MX
   Zhang, Y
   Wong, KC
   Dai, Y
   Yao, XS
   Wong, MS
AF Xiao, Hui Hui
   Gao, Quan Gui
   Ho, Ming Xian
   Zhang, Yan
   Wong, Ka Chun
   Dai, Yi
   Yao, Xin Sheng
   Wong, Man Sau
TI An 8 O 4′ norlignan exerts oestrogen like actions in osteoblastic
   cells via rapid nongenomic ER signaling pathway
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Phytoestrogen; Osteoblast; MAP kinase signaling pathway; 8 O 4 ' lignan;
   Sambucus willamsii Hance
ID SAMBUCUS WILLIAMSII HANCE; BONE LOSS; ICARIIN PROTECTS; LIGNANS;
   RECEPTOR; DIFFERENTIATION; PROLIFERATION; ANTIOXIDANT; FRACTIONS; MICE
AB Ethnopharmacological relevance: Sambucus williamsii Hance (SWH), which belongs to the Caprifoliaceae family distributed in various regions of China, Korea and Japan, has been used as a folk medicine for treatment of bone and joint diseases in China for thousands of years. In previous studies, SWH was shown to possess anti osteoporosis, healing fracture, anti inflammatory and analgesic activities. Our previous studies showed that SWH extract effectively suppressed ovariectomy induced increase in bone turnover and improved bone mineral density and bone biomechanical strength in rats as well as in mice. An 8 O 4' norlignan, (7R,8S) 1 (4 hydroxy 3 methoxyphenyl) 2 [4 (3 hydroxypropyl) 2 methoxyphenoxy] 1,3 propanediol (PPD) was previously isolated and identified as the bioactive ingredient in SWH. The present study aimed to characterize the bone protective effects as well as its mechanism of actions in osteoblasts.
   Materials and methods: Bone protective actions of PPD on different cells were determined by proliferation assay, alkaline phosphatase (ALP) activity assay, calcium deposition as well as real time reverse transcriptase polymerase chain reaction (RT PCR). In addition, estrogen receptor (ER) antagonist ICI182,780 and mitogen activated protein kinase kinase (MEK) inhibitor U0126 blocking assays, competitive ER radioligand binding assay, ERE dependent luciferase reporter assay and immunoblotting were used to determine if PPD activated ER and if the effects of PPD on osteoblastic functions were ER dependent.
   Results: PPD exerted anabolic effects in osteoblasts and its effects were abolished by co incubation with ICI182,780 or U0126. PPD induced mRNA expressions of Runx2, ALP, osteocalcin, and increased the ratio of osteoprotegerin/receptor activator of nuclear factor kappa B (OPG/RANKL). PPD failed to bind to either ER alpha or ER beta and did not activate ERE luciferase activity via ER. PPD induced the phosphorylation of extracellular regulated kinases (ERK) and its effect was completely abolished by U0126. It also induced the phosphorylation of ER alpha at serine 118.
   Conclusion: These data show that PPD is a bioactive compound in SWH that exerts oestrogen like actions in osteoblast like cells via ligand independent, estrogen response element (ERE) independent and mitogen activated protein (MAP) Kinase mediated rapid nongenomic ER signaling pathway. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Xiao, Hui Hui; Wong, Man Sau] Hong Kong Polytech Univ, Shenzhen Res Inst, State Key Lab Chinese Med & Mol Pharmacol Incubat, Shenzhen 518057, Peoples R China.
   [Xiao, Hui Hui; Gao, Quan Gui; Ho, Ming Xian; Zhang, Yan; Wong, Ka Chun; Wong, Man Sau] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
   [Zhang, Yan] Univ Shanghai Sci & Technol, Ctr Syst Biomed Sci, Shanghai 200093, Peoples R China.
   [Dai, Yi; Yao, Xin Sheng] Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China.
C3 Hong Kong Polytechnic University; Hong Kong Polytechnic University;
   University of Shanghai for Science & Technology; Jinan University
RP Wong, MS (通讯作者)，Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
EM tyaoxs@jnu.edu.cn; bcmswong@polyu.edu.hk
RI Wong, Man Sau/F 2059 2015; Dai, Yi/AAC 1336 2019; Wong,
   Ka Chun/L 7160 2019
OI Wong, Man Sau/0000 0002 0729 8618; 
FU State Key Laboratory of Chinese Medicine and Molecular Pharmacology
   (Incubation), Shenzhen; Central Research Fund of the Hong Kong
   Polytechnic University [GU324, GU256, GYM 47]; National Basic Research
   Program of China (973 program) [2012CB723506]; Shenzhen Key Laboratory
   Advancement Program; Shenzhen Basic Research Program
   [JCYJ20140819153305696, JCYJ20140819153305697]; National Natural Science
   Foundation of China [81202894, 81220108028]; National Major Scientific
   and Program of Introducing Talents of Discipline to Universities
   [B13038]
FX We thank the State Key Laboratory of Chinese Medicine and Molecular
   Pharmacology (Incubation), Shenzhen for its support. This work was
   supported by the Central Research Fund of the Hong Kong Polytechnic
   University (GU324, GU256, GYM 47), the National Basic Research Program
   of China (973 program, 2012CB723506), the Shenzhen Key Laboratory
   Advancement Program, the Shenzhen Basic Research Program
   (JCYJ20140819153305696, JCYJ20140819153305697), the National Natural
   Science Foundation of China (81202894, 81220108028) as well as the
   National Major Scientific and Program of Introducing Talents of
   Discipline to Universities (B13038).
CR Albertazzi P, 2008, MATURITAS, V61, P214, DOI 10.1016/j.maturitas.2008.11.017
   ARNOLDI A, 1985, J CHEM SOC PERK T 1, P2555, DOI 10.1039/p19850002555
   Bedell S, 2014, J STEROID BIOCHEM, V139, P225, DOI 10.1016/j.jsbmb.2012.12.004
   Björnström L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004 0486
   Caichompoo W, 2009, PHYTOTHER RES, V23, P289, DOI 10.1002/ptr.2585
   Chen WF, 2004, J CLIN ENDOCR METAB, V89, P2351, DOI 10.1210/jc.2003 032065
   Chin YW, 2008, J AGR FOOD CHEM, V56, P7759, DOI 10.1021/jf801792n
   COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843
   Cornish SM, 2009, APPL PHYSIOL NUTR ME, V34, P89, DOI 10.1139/H08 142
   Dodin S, 2005, J CLIN ENDOCR METAB, V90, P1390, DOI 10.1210/jc.2004 1148
   Fang H, 2001, CHEM RES TOXICOL, V14, P280, DOI 10.1021/tx000208y
   Feng RJ, 2013, CELL BIOCHEM BIOPHYS, V67, P189, DOI 10.1007/s12013 013 9533 8
   Fujimoto N, 2004, LIFE SCI, V74, P1417, DOI 10.1016/j.lfs.2003.08.012
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200
   Han H., 2013, China Pharm., V16, P482, DOI [10.3969/j.issn.1008 049X.2013.04.002, DOI 10.3969/J.ISSN.1008 049X.2013.04.002]
   Howell A, 2000, CANCER AM CANCER SOC, V89, P817, DOI 10.1002/1097 0142(20000815)89:4<817::AID CNCR14>3.3.CO;2 Y
   Jiang MM, 2009, PLANTA MED, V75, P340, DOI 10.1055/s 0028 1112212
   Jin JS, 2013, MOLECULES, V18, P1122, DOI 10.3390/molecules18011122
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Lau WS, 2009, BRIT J PHARMACOL, V156, P1136, DOI 10.1111/j.1476 5381.2009.00123.x
   Lee MK, 2007, BIOL PHARM BULL, V30, P814, DOI 10.1248/bpb.30.814
   Lee SU, 2009, PLANTA MED, V75, P152, DOI 10.1055/s 0028 1112197
   Macías FA, 2004, J AGR FOOD CHEM, V52, P6443, DOI 10.1021/jf048945d
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Nakajima K, 2010, BIOCHEM BIOPH RES CO, V395, P502, DOI 10.1016/j.bbrc.2010.04.041
   Tung NH, 2009, CHEM PHARM BULL, V57, P65, DOI 10.1248/cpb.57.65
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Penttinen Damdimopoulou PE, 2009, MOL NUTR FOOD RES, V53, P996, DOI 10.1002/mnfr.200800487
   Pianjing P, 2011, J AGR FOOD CHEM, V59, P212, DOI 10.1021/jf102006w
   Liao QC, 2007, ACTA PHARMACOL SIN, V28, P1597, DOI 10.1111/j.1745 7254.2007.00632.x
   RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85
   Sacco SM, 2014, APPL PHYSIOL NUTR ME, V39, P801, DOI 10.1139/apnm 2013 0417
   Sapir Koren R., 2011, IBMS BoneKEy, V8, P286, DOI [10.1138/20110516, DOI 10.1138/20110516]
   Sila Asna Monnipha, 2007, Kobe J Med Sci, V53, P25
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Wanachewin O, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 71
   Weitsman GE, 2006, CANCER RES, V66, P10162, DOI 10.1158/0008 5472.CAN 05 4111
   Xiao HH, 2014, J STEROID BIOCHEM, V144, P382, DOI 10.1016/j.jsbmb.2014.08.002
   Xiao HH, 2014, FITOTERAPIA, V94, P29, DOI 10.1016/j.fitote.2014.01.012
   Xiao HH, 2011, BRIT J NUTR, V106, P1802, DOI 10.1017/S0007114511002546
   Xie F, 2005, BIOL PHARM BULL, V28, P1879, DOI 10.1248/bpb.28.1879
   Yang XJ, 2007, J ASIAN NAT PROD RES, V9, P583, DOI 10.1080/10286020500530433
   Zhang R, 2014, J ETHNOPHARMACOL, V155, P104, DOI 10.1016/j.jep.2014.04.031
   Zhang Y, 2011, OSTEOPOROSIS INT, V22, P703, DOI 10.1007/s00198 010 1240 3
   Zhao M.J., 2010, CHIN J ETHNOMED ETHN, V14, P212
   Zhao You Xing, 2004, Acta Botanica Yunnanica, V26, P229
   Zheng CJ, 2014, FITOTERAPIA, V93, P31, DOI 10.1016/j.fitote.2013.12.006
   Zhong R.Q., 1985, CHIN J INTEGR TRADIT, V7, P408
NR 52
TC 13
Z9 15
U1 1
U2 30
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUL 21
PY 2015
VL 170
BP 39
EP 49
DI 10.1016/j.jep.2015.05.012
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA CL8SF
UT WOS:000357243700006
PM 25978953
DA 2025 08 17
ER

PT J
AU Jia, SH
   Zhou, J
   Fanelli, C
   Wee, YS
   Bonds, J
   Schneider, P
   Mues, G
   D'Souza, RN
AF Jia, Shihai
   Zhou, Jing
   Fanelli, Christopher
   Wee, Yinshen
   Bonds, John
   Schneider, Pascal
   Mues, Gabriele
   D'Souza, Rena N.
TI Small molecule Wnt agonists correct cleft palates in Pax9 mutant mice
   in utero
SO DEVELOPMENT
LA English
DT Article
DE Pax9; Wnt; Palatogenesis; Cleft palate; Mouse; Wnt agonist; Small
   molecule
ID NEURAL CREST; TRANSCRIPTIONAL REPRESSOR; TOOTH MORPHOGENESIS; SECONDARY
   PALATE; MSX1; DEFECTS; BMP4; ABNORMALITIES; OLIGODONTIA; EXPRESSION
AB Clefts of the palate and/or lip are among the most common human craniofacial malformations and involve multiple genetic and environmental factors. Defects can only be corrected surgically and require complex life long treatments. Our studies utilized the well characterized Pax9( / ) mouse model with a consistent cleft palate phenotype to test small molecule Wnt agonist therapies. We show that the absence of Pax9 alters the expression of Wnt pathway genes including Dkk1 and Dkk2, proven antagonists of Wnt signaling. The functional interactions between Pax9 and Dkk1 are shown by the genetic rescue of secondary palate clefts in Pax9( / )Dkk1(f/+); Wnt1Cre embryos. The controlled intravenous delivery of small molecule Wnt agonists (Dkk inhibitors) into pregnant Pax9(+/ ) mice restored Wnt signaling and led to the growth and fusion of palatal shelves, as marked by an increase in cell proliferation and osteogenesis in utero, while other organ defects were not corrected. This work underscores the importance of Pax9 dependent Wnt signaling in palatogenesis and suggests that this functional upstream molecular relationship can be exploited for the development of therapies for human cleft palates that arise from single gene disorders.
C1 [Jia, Shihai; Zhou, Jing; Fanelli, Christopher; Wee, Yinshen; D'Souza, Rena N.] Univ Utah, Sch Dent, Salt Lake City, UT 84112 USA.
   [Bonds, John; Mues, Gabriele] Texas A&M Univ, Coll Dent, Dept Biomed Sci, Dallas, TX 75246 USA.
   [Schneider, Pascal] Univ Lausanne, Dept Biochem, CH 1066 Epalinges, Switzerland.
   [D'Souza, Rena N.] Univ Utah, Sch Med, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA.
   [D'Souza, Rena N.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Texas A&M
   University System; University of Lausanne; Utah System of Higher
   Education; University of Utah; Utah System of Higher Education;
   University of Utah
RP D'Souza, RN (通讯作者)，Univ Utah, Sch Dent, Salt Lake City, UT 84112 USA.; D'Souza, RN (通讯作者)，Univ Utah, Sch Med, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA.; D'Souza, RN (通讯作者)，Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA.
EM rena.dsouza@hsc.utah.edu
RI Jia, Shihai/AAE 4204 2019
OI Schneider, Pascal/0000 0003 0677 9409; D'Souza, Rena/0000 0002 1505 5173
FU National Institutes of Health [DE019471, DE027255, DE019554,
   DE019471 ARRA, DE018380]; Swiss National Science Foundation
   (Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen
   Forschung)
FX The following grants from the National Institutes of Health have
   supported this research: DE019471, DE019471 ARRA supplement and DE027255
   to R.N.D., DE019554 to G.M., and a training stipend from DE018380
   (Principal Investigator R.N.D.) to J.B. P.S. is supported by grants from
   the Swiss National Science Foundation (Schweizerischer Nationalfonds zur
   Forderung der Wissenschaftlichen Forschung). Deposited in PMC for
   release after 12 months.
CR Almaidhan A, 2014, BMC DEV BIOL, V14, DOI 10.1186/1471 213X 14 3
   Baek JA, 2011, DEV BIOL, V350, P520, DOI 10.1016/j.ydbio.2010.12.028
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bohring A, 2009, AM J HUM GENET, V85, P97, DOI 10.1016/j.ajhg.2009.06.001
   Bragança J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200
   Brewer S, 2004, DEV BIOL, V267, P135, DOI 10.1016/j.ydbio.2003.10.039
   Byrd NA, 2005, DEV BIOL, V284, P233, DOI 10.1016/j.ydbio.2005.05.023
   Chen JQ, 2009, DEV BIOL, V334, P174, DOI 10.1016/j.ydbio.2009.07.015
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   DSOUZA RN, 1993, J BONE MINER RES, V8, P1127
   Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579
   Fuchs A, 2010, DEV DYNAM, V239, P2860, DOI 10.1002/dvdy.22421
   Fujitani Y, 1999, MOL CELL BIOL, V19, P8281
   Funato Noriko, 2015, World J Biol Chem, V6, P121, DOI 10.4331/wjbc.v6.i3.121
   GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092 8674(93)90619 2
   Goldenberg M, 2000, J DENT RES, V79, P1469, DOI 10.1177/00220345000790070701
   Greene RM, 2010, BIRTH DEFECTS RES C, V90, P133, DOI 10.1002/bdrc.20180
   Han J, 2009, DEVELOPMENT, V136, P4225, DOI 10.1242/dev.036723
   Hermes K, 2014, J INVEST DERMATOL, V134, P2985, DOI 10.1038/jid.2014.264
   Hilliard SA, 2005, J ANAT, V207, P655, DOI 10.1111/j.1469 7580.2005.00474.x
   Jia SH, 2016, DEV BIOL, V420, P110, DOI 10.1016/j.ydbio.2016.10.001
   Jia SH, 2013, DEVELOPMENT, V140, P423, DOI 10.1242/dev.081927
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   KIM S, 2017, JOVE J VIS EXP JUL, V125, DOI DOI 10.3791/56041
   Knight RD, 2005, DEVELOPMENT, V132, P3127, DOI 10.1242/dev.01879
   Kowalczyk C, 2011, J BIOL CHEM, V286, P30769, DOI 10.1074/jbc.M111.267997
   Lan Y, 2004, DEVELOPMENT, V131, P3207, DOI 10.1242/dev.01175
   Li C., 2017, J DENT RES
   Li XF, 2012, P NATL ACAD SCI USA, V109, P11402, DOI 10.1073/pnas.1205015109
   Lieven O, 2010, DEV BIOL, V340, P256, DOI 10.1016/j.ydbio.2010.01.037
   Liu KJ, 2007, NATURE, V446, P79, DOI 10.1038/nature05557
   Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100
   Mensah JK, 2004, J BIOL CHEM, V279, P5924, DOI 10.1074/jbc.M305648200
   Mossey PA, 2009, LANCET, V374, P1773, DOI 10.1016/S0140 6736(09)60695 4
   Mues G, 2014, AM J MED GENET A, V164, P2455, DOI 10.1002/ajmg.a.36520
   Nakatomi M, 2010, DEV BIOL, V340, P438, DOI 10.1016/j.ydbio.2010.01.031
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   O'Connell DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002414
   Pauws E, 2009, HUM MOL GENET, V18, P4171, DOI 10.1093/hmg/ddp368
   Pelletier JC, 2009, J MED CHEM, V52, P6962, DOI 10.1021/jm9014197
   Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494 348
   STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493 292
   Stockton DW, 2000, NAT GENET, V24, P18, DOI 10.1038/71634
   Tan K, 2003, J BIOL CHEM, V278, P20507, DOI 10.1074/jbc.M301994200
   van den Boogaard MJ, 2012, J MED GENET, V49, P327, DOI 10.1136/jmedgenet 2012 100750
   VELASCO MG, 1988, CLEFT PALATE J, V25, P171
   Zhang YD, 1999, DEV DYNAM, V215, P45, DOI 10.1002/(SICI)1097 0177(199905)215:1<45::AID DVDY5>3.0.CO;2 5
   Zhang ZY, 2002, DEVELOPMENT, V129, P4135
   Zhou J, 2013, DEVELOPMENT, V140, P4709, DOI 10.1242/dev.099028
   Zhou J, 2011, DEV BIOL, V353, P344, DOI 10.1016/j.ydbio.2011.03.012
NR 52
TC 51
Z9 64
U1 1
U2 24
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0950 1991
EI 1477 9129
J9 DEVELOPMENT
JI Development
PD OCT 15
PY 2017
VL 144
IS 20
BP 3819
EP 3828
DI 10.1242/dev.157750
PG 10
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA FJ9PP
UT WOS:000413111400017
PM 28893947
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Li, DW
   Zhou, J
   Zhang, MM
   Ma, YZ
   Yang, YY
   Han, X
   Wang, X
AF Li, Dawei
   Zhou, Jin
   Zhang, Mingming
   Ma, Yuanzheng
   Yang, Yanyu
   Han, Xue
   Wang, Xing
TI Long term delivery of alendronate through an injectable tetra PEG
   hydrogel to promote osteoporosis therapy
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID CROSS LINKING STRATEGY; BISPHOSPHONATES; CONSTRUCTION; FABRICATION;
   MECHANISM; CARRIERS; TOUGH; WOMEN
AB Pharmacotherapy for hypercalcemia, which is mainly caused by osteoporosis, is an effective method to regulate the in vivo calcium equilibrium. From this perspective, the development of a minimally invasive gelling system for the prolonged local delivery of bisphosphonates has practical significance in the clinical therapy of bone osteoporosis. Here, a biocompatible and injectable hydrogel based on a uniform tetra PEG network carrying a PEG modified alendronate (ALN) prodrug for the localized elution and long term sustained release of anti osteoporotic small molecule drugs is reported. The obtained ALN based tetra PEG hydrogels exhibit rapid gel formation and excellent injectability, thereby allowing for the easy injection and consequent adaptation of hydrogels into the bone defects with irregular shapes, which promotes the ALN based tetra PEG hydrogels with depot formulation capacity for governing the on demand release of ALN drugs and local reinforcement of bone osteoporosis at the implantation sites of animals. The findings imply that these injectable hydrogels mediate the optimized release of therapeutic cargoes and effectively promote in situ bone regeneration via minimally invasive procedures, which is effective for clinical osteoporosis therapy.
C1 [Li, Dawei; Zhou, Jin; Ma, Yuanzheng; Han, Xue] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 8, Beijing, Peoples R China.
   [Zhang, Mingming] PLA Strateg Support Force Characterist Med Ctr, Beijing, Peoples R China.
   [Yang, Yanyu] Zhengzhou Univ, Coll Sci & Engn, Zhengzhou, Henan, Peoples R China.
   [Wang, Xing] Chinese Acad Sci, Inst Chem, Beijing Natl Lab Mol Sci, Beijing, Peoples R China.
   [Wang, Xing] Univ Chinese Acad Sci, Beijing, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Zhengzhou University;
   Chinese Academy of Sciences; Institute of Chemistry, CAS; Chinese
   Academy of Sciences; University of Chinese Academy of Sciences, CAS
RP Han, X (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Med Ctr 8, Beijing, Peoples R China.; Yang, YY (通讯作者)，Zhengzhou Univ, Coll Sci & Engn, Zhengzhou, Henan, Peoples R China.; Wang, X (通讯作者)，Chinese Acad Sci, Inst Chem, Beijing Natl Lab Mol Sci, Beijing, Peoples R China.; Wang, X (通讯作者)，Univ Chinese Acad Sci, Beijing, Peoples R China.
EM beryl282004@sina.com; yyyang@zzu.edu.cn; wangxing@iccas.ac.cn
RI Zhang, Mingming/T 8374 2019; Li, Dawei/G 5195 2012
OI Yang, Yanyu/0000 0002 7707 5153; 
FU National Natural Science Foundation of China (NSFC) [81972081, 51973226,
   51803188]; Special Scientific Research Project of Military Health Care
   [17BJZ15]; Military Medical Science and Technology Youth Cultivation
   Project [20QNPY109]; Military Medical Youth Growth Program of PLA
   General Hospital [QNC19028]; Beijing Novel Program [Z181100006218059];
   China Postdoctoral Science Foundation [2019T120636, 2018M642783]
FX This work was supported by National Natural Science Foundation of China
   (NSFC, 81972081, 51973226 and 51803188), Special Scientific Research
   Project of Military Health Care (17BJZ15), Military Medical Science and
   Technology Youth Cultivation Project (20QNPY109), Military Medical Youth
   Growth Program of PLA General Hospital (QNC19028), the Beijing Novel
   Program (Z181100006218059) and the China Postdoctoral Science Foundation
   (2019T120636 and 2018M642783) for financial support.
CR Andersen CY, 2019, REPRODUCTION, V158, pF27, DOI 10.1530/REP 18 0635
   Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   Blank RD, 2019, FERTIL STERIL, V112, P782, DOI 10.1016/j.fertnstert.2019.09.038
   Bouten PJM, 2014, PROG POLYM SCI, V39, P1375, DOI 10.1016/j.progpolymsci.2014.02.001
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bu YZ, 2019, ADV MATER, V31, DOI 10.1002/adma.201901580
   Bu YZ, 2017, ACS APPL MATER INTER, V9, P2205, DOI 10.1021/acsami.6b15364
   Bu YZ, 2016, ACS APPL MATER INTER, V8, P12674, DOI 10.1021/acsami.6b03235
   Calvo Fernández T, 2010, EUR CELLS MATER, V20, P260
   Cao QC, 2018, CHINESE J POLYM SCI, V36, P8, DOI 10.1007/s10118 018 2061 7
   Chiu WY, 2020, OSTEOPOROSIS INT, V31, P193, DOI 10.1007/s00198 019 05127 y
   Choi WI, 2018, BIOMATER SCI UK, V6, P2627, DOI 10.1039/c8bm00524a
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Cramer JA, 2005, CURR MED RES OPIN, V21, P1453, DOI 10.1185/030079905X61875
   Dou XY, 2019, ACTA POLYM SIN, V50, P429, DOI 10.11777/j.issn1000 3304.2019.18263
   Dunn R, 2001, FERTIL STERIL, V75, P411, DOI 10.1016/S0015 0282(00)01677 0
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Henise J, 2015, BIOCONJUGATE CHEM, V26, P270, DOI 10.1021/bc5005476
   Hernandez AV, 2019, MATURITAS, V129, P12, DOI 10.1016/j.maturitas.2019.08.003
   Hoffmann P, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122178
   Huang D, 2019, J MATER CHEM B, V7, P2330, DOI 10.1039/c8tb02928h
   Kusamori K, 2010, J BONE MINER RES, V25, P2306, DOI 10.1002/jbmr.147
   Kuznik A, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172773
   Lee JH, 2013, MATER LETT, V105, P136, DOI 10.1016/j.matlet.2013.04.082
   Li Z, 2016, MACROMOLECULES, V49, P373, DOI 10.1021/acs.macromol.5b02359
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Macut D, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00681
   Miladi K, 2013, INT J PHARMACEUT, V445, P181, DOI 10.1016/j.ijpharm.2013.01.031
   Mukherjee D, 2018, DRUG DEV IND PHARM, V44, P1845, DOI 10.1080/03639045.2018.1503297
   Nafee N, 2018, J DRUG TARGET, V26, P563, DOI 10.1080/1061186X.2017.1390670
   Nam SH, 2012, BONE, V50, P149, DOI 10.1016/j.bone.2011.10.017
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Ogunwale AN, 2020, J BONE MINER RES, V35, P440, DOI 10.1002/jbmr.3916
   Qiao D, 2020, PUBLIC HEALTH, V180, P22, DOI 10.1016/j.puhe.2019.11.001
   Reid R, 2015, MACROMOLECULES, V48, P7359, DOI 10.1021/acs.macromol.5b01598
   Sam E. B., 2020, CURR OSTEOPOROS REP, V17, P527
   Shi R, 2019, J AM MED DIR ASSOC, V20, P1566, DOI 10.1016/j.jamda.2019.06.027
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Strampel W, 2007, DRUG SAFETY, V30, P755, DOI 10.2165/00002018 200730090 00003
   Sun GF, 2019, EUR POLYM J, V114, P338, DOI 10.1016/j.eurpolymj.2019.02.048
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang SJ, 2019, ADV MATER, V31, DOI 10.1002/adma.201904341
   Wang S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00174
   Wang X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05142 3
   Wang X, 2017, POLYM CHEM UK, V8, P3901, DOI 10.1039/c7py00698e
   Wang X, 2013, POLYM CHEM UK, V4, P4596, DOI 10.1039/c3py00811h
   Xu BB, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00247
   Xu HL, 2019, BIOMATER SCI UK, V7, P2582, DOI 10.1039/c9bm00341j
   Yang YY, 2018, ADV MATER, V30, DOI 10.1002/adma.201707071
   Yang YY, 2016, ADV MATER, V28, P7178, DOI 10.1002/adma.201601742
   Zacharis CK, 2008, J PHARMACEUT BIOMED, V48, P483, DOI 10.1016/j.jpba.2008.05.028
   Zhang KY, 2018, ADV SCI, V5, DOI 10.1002/advs.201800875
   Zhang YS, 2017, SCIENCE, V356, DOI 10.1126/science.aaf3627
   Zhang YF, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00682
   Zhu CX, 2019, CHEM ENG J, V369, P863, DOI 10.1016/j.cej.2019.03.169
NR 55
TC 52
Z9 54
U1 0
U2 99
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD JUN 7
PY 2020
VL 8
IS 11
BP 3138
EP 3146
DI 10.1039/d0bm00376j
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA LW8BT
UT WOS:000539368700011
PM 32352105
DA 2025 08 17
ER

PT J
AU Hannig, G
   Bernier, SG
   Hoyt, JG
   Doyle, B
   Clark, E
   Karp, RM
   Lorusso, J
   Westlin, WF
AF Hannig, Gerhard
   Bernier, Sylvie G.
   Hoyt, Jennifer G.
   Doyle, Beth
   Clark, Ed
   Karp, Russell M.
   Lorusso, Jeanine
   Westlin, William F.
TI Suppression of inflammation and structural damage in experimental
   arthritis through molecular targeted therapy with PPI 2458
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; MATRIX PROTEIN COMP; RHEUMATOID ARTHRITIS;
   ANGIOGENESIS INHIBITOR; OSTEOCLAST DIFFERENTIATION; PHASE I; METHIONINE
   AMINOPEPTIDASES; BONE RESORPTION; CARTILAGE; TNP 470
AB Objective. To determine the disease modifying activity and mechanism of action of the orally available methionine aminopeptidase type 2 inhibitor, [(1R) 1 carbamoyl 2 methyl propyll carbamic acid(3R,4S,5S,6R) 5 methoxy 4 [(2R,3R) 2 methyl 3 (3  methyl but 2 enyl) oxiranyl] 1 oxa spiro [2.5] oct 6 yl ester (PPI 2458), in a rat model of peptidoglycan polysaccharide (PG PS) induced arthritis.
   Methods. Arthritis was induced in rats by administration of PG PS, causing tarsal joint swelling and histopathologic changes characteristic of rheumatoid arthritis (RA). PPI 2458, a potent irreversible methionine aminopeptidase type 2 inhibitor, was administered orally every other day at 1, 5, or 10 mg/kg.
   Results. In an in vitro osteoclastogenesis model, PPI 2458 potently inhibited osteoclast differentiation and bone resorption. In the rat PG PS arthritis model, PPI 2458 afforded significant protection against established disease after therapeutic dosing. This in vivo activity of PPI 2458 was linked to the inhibition of methionine aminopeptidase type 2. Histopathologic assessment of affected joints showed improvement in processes of inflammation, bone resorption, and cartilage erosion, associated with significant improvement in all clinical indices. The protective effects of PPI 2458 against bone destruction in vivo, including the structural preservation of affected hind joints, correlated with improvements in bone histomorphometric markers, as determined by microfocal computed tomography and a significant decrease in systemic C telopeptide of type I collagen, suggesting decreased osteoclast activity in vivo. Moreover, PPI 2458 prevented cartilage erosion as shown by a significant decrease in systemic cartilage oligomeric matrix protein.
   Conclusion. The findings of this study suggest that PPI 2458 exerts disease modifying activity in experimental arthritis through its direct inhibition of several pathophysiologic processes of this disease. These results provide a rationale for assessing the potential of PPI 2458 as a novel RA therapy.
C1 Praecis Pharmaceut Inc, Waltham, MA 02451 USA.
RP Hannig, G (通讯作者)，Praecis Pharmaceut Inc, 830 Winter St, Waltham, MA 02451 USA.
EM Gerhard.Hannig@praecis.com
CR Anandarajah AP, 2006, J CELL BIOCHEM, V97, P226, DOI 10.1002/jcb.20674
   ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714
   Bernier SG, 2005, DRUG FUTURE, V30, P497, DOI 10.1358/dof.2005.030.05.895807
   Bernier SG, 2005, J CELL BIOCHEM, V95, P1191, DOI 10.1002/jcb.20493
   Bernier SG, 2004, P NATL ACAD SCI USA, V101, P10768, DOI 10.1073/pnas.0404105101
   Bhargava P, 1999, CLIN CANCER RES, V5, P1989
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bradshaw RA, 2002, ESSAYS BIOCHEM, V38, P65, DOI 10.1042/bse0380065
   Brahn E, 2001, ARTHRITIS RHEUM, V44, pS271
   Brahn E, 2003, ARTHRITIS RHEUM, V48, pS347
   Campagnuolo G, 2002, ARTHRITIS RHEUM US, V46, P1926, DOI 10.1002/art.10369
   Chen FH, 2005, J BIOL CHEM, V280, P32655, DOI 10.1074/jbc.M504778200
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Crnkic M, 2003, ARTHRITIS RES THER, V5, pR181, DOI 10.1186/ar760
   DATTA B, 1988, P NATL ACAD SCI USA, V85, P3324, DOI 10.1073/pnas.85.10.3324
   de Bandt M, 2000, ARTHRITIS RHEUM, V43, P2056
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Goldring SR, 2002, CURR OPIN RHEUMATOL, V14, P406, DOI 10.1097/00002281 200207000 00013
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074 5521(97)90198 8
   Hasegawa J, 2003, J RHEUMATOL, V30, P474
   Herrak P, 2004, ARTHRITIS RHEUM US, V50, P2327, DOI 10.1002/art.20384
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Koch AE, 1998, ARTHRITIS RHEUM US, V41, P951, DOI 10.1002/1529 0131(199806)41:6<951::AID ART2>3.0.CO;2 D
   Kudelka AP, 1997, CLIN CANCER RES, V3, P1501
   Kwoh CK, 2002, ARTHRITIS RHEUM US, V46, P328
   Lainer DT, 2005, EXPERT OPIN INV DRUG, V14, P1, DOI 10.1517/13543784.14.1.1
   Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140 6736(01)06075 5
   Lindqvist E, 2005, ANN RHEUM DIS, V64, P196, DOI 10.1136/ard.2003.019992
   Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324
   Logothetis CJ, 2001, CLIN CANCER RES, V7, P1198
   MANSSON B, 1995, J CLIN INVEST, V95, P1071, DOI 10.1172/JCI117753
   O'Dell JR, 2004, NEW ENGL J MED, V350, P2591, DOI 10.1056/NEJMra040226
   OBRYNE EM, 1991, AGENTS ACTIONS, V134, P239
   OLIVER SJ, 1994, CELL IMMUNOL, V157, P291, DOI 10.1006/cimm.1994.1223
   Osterman T, 1997, J PHARMACOL EXP THER, V280, P1001
   Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671
   PEACOCK DJ, 1992, J EXP MED, V175, P1135, DOI 10.1084/jem.175.4.1135
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099
   Sweeney SE, 2004, INT J BIOCHEM CELL B, V36, P372, DOI 10.1016/S1357 2725(03)00259 0
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wislowska M, 2005, CLIN RHEUMATOL, V24, P278, DOI 10.1007/s10067 004 1000 x
   Wu YL, 2005, ARTHRITIS RHEUM US, V52, P3257, DOI 10.1002/art.21354
   Yamane I, 2003, ARTHRITIS RHEUM, V48, P1732, DOI 10.1002/art.10987
NR 46
TC 23
Z9 26
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD FEB
PY 2007
VL 56
IS 3
BP 850
EP 860
DI 10.1002/art.22402
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 144XI
UT WOS:000244829400021
PM 17328059
DA 2025 08 17
ER

PT J
AU Xu, X
   Yan, YF
   Liu, ZC
   Qi, J
   Qian, ND
   Zhou, HB
   Zhou, Q
   Wang, TQ
   Huang, P
   Guo, L
   Jiang, M
   Deng, LF
AF Xu, Xing
   Yan, Yufei
   Liu, Zhuochao
   Qi, Jin
   Qian, Niandong
   Zhou, Hanbing
   Zhou, Qi
   Wang, Tianqi
   Huang, Ping
   Guo, Lei
   Jiang, Min
   Deng, Lianfu
TI The prevention of latanoprost on osteoclastgenesis in vitro and
   lipopolysaccharide induced murine calvaria osteolysis in vivo
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone resorption; latanoprost; lipopolysaccharide induced murine calvaria
   osteolysis; osteoclast
ID BONE RESORPTION; DRUG HOLIDAYS; PROSTAGLANDIN F2 ALPHA; ACTIVATION;
   RECEPTOR; DIFFERENTIATION; MECHANISMS; DISEASE; KIDNEY; NFAT2
AB Identification of agents that inhibit osteoclast formation and function is important for the treatment of osteolytic diseases which feature excessive osteoclast formation and bone resorption. Latanoprost (LTP), an analog of prostaglandin F2, is a medication which works to lower pressure inside the eyes. Prostaglandin F2 was reported to regulate bone metabolism, however, the effect of LTP in osteoclastogenesis is still unknown. Here, we found that LTP suppressed RANKL induced osteoclastogenesis in a dose dependent manner as illustrated by TRAP activity and TRAP staining. In addition, the osteoclast function was also reduced by LTP treatment, as indicated in less osteoclastic resorption pit areas. Furthermore, LTP inhibited the mRNA expressions of osteoclast marker genes such as TRAP and cathepsin K. In order to illustrate its molecular mechanism, we examined the changing of mRNA and protein levels of NFATc1 and c fos by LTP treatment, as well as the phosphorylation of ERK, AKT, JNK, and p38. The results suggested that LTP inhibited RANKL induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c fos/NFATc1 pathway. In agreement with in vitro results, using an in vivo lipopolysaccharide induced murine calvaria osteolysis mouse model, we found that administration of LTP was able to reverse the lipopolysaccharide induced bone loss. Together, these data demonstrated that LTP attenuated the bone loss in lipopolysaccharide induced murine calvaria osteolysis mice through inhibiting osteoclast formation and function. Our study thus provided the evidences that LTP was a potential treatment option against osteolytic bone diseases.
C1 [Xu, Xing; Yan, Yufei; Liu, Zhuochao; Qi, Jin; Qian, Niandong; Zhou, Hanbing; Zhou, Qi; Wang, Tianqi; Huang, Ping; Guo, Lei; Jiang, Min; Deng, Lianfu] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai Key Lab Bone & Joint Dis, Shanghai Inst Traumatol & Orthoped,Sch Med, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University
RP Jiang, M; Deng, LF (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai Key Lab Bone & Joint Dis, Shanghai Inst Traumatol & Orthoped,Sch Med, Shanghai 200025, Peoples R China.
EM jiangm263@163.com; lfdeng@msn.com
RI Zhou, Han/ISU 2803 2023; guo, leixin/HPF 6884 2023; Wang,
   Tianqi/KIC 1831 2024; Zhou, Qi/JGM 4026 2023
OI Jiang, Min/0000 0003 1530 6830; 
FU National Natural Science Foundation of China [81502902, 81703576];
   Municipal Health Bureau young scientific research foundation of Shanghai
   [20154Y0005, 20144Y0055]; Guangci Distinguished Young Scholars Training
   Program [GCQN 2017 B22, GCQN 2017 A16]; Committee of Science and
   Technology young scientific research foundation of Shanghai
   [16ZR1431900, 14ZR1437500]
FX Committee of Science and Technology young scientific research foundation
   of Shanghai, Grant numbers: 14ZR1437500, 16ZR1431900; Municipal Health
   Bureau young scientific research foundation of Shanghai, Grant numbers:
   20144Y0055, 20154Y0005; National Natural Science Foundation of China,
   Grant numbers: 81502902, 81703576; Guangci Distinguished Young Scholars
   Training Program, Grant number: GCQN 2017 A16, GCQN 2017 B22
CR Anagnostis P, 2015, CLIMACTERIC, V18, P32, DOI 10.3109/13697137.2015.1099092
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Goupil E, 2012, MOL ENDOCRINOL, V26, P1189, DOI 10.1210/me.2011 1245
   Halleen JM, 2006, CLIN LAB, V52, P499
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Kaludjerovic J, 2017, BONE, V100, P50, DOI 10.1016/j.bone.2017.02.006
   Kamon M, 2008, PROSTAG OTH LIPID M, V87, P26, DOI 10.1016/j.prostaglandins.2008.06.002
   Lv YD, 2015, EXP THER MED, V9, P143, DOI 10.3892/etm.2014.2071
   Makino S, 2007, SEMIN REPROD MED, V25, P60, DOI 10.1055/s 2006 956776
   Nasrallah R, 2007, CLIN SCI, V113, P297, DOI 10.1042/CS20070089
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Taketani Y, 2014, INVEST OPHTH VIS SCI, V55, P1269, DOI 10.1167/iovs.13 12589
   Tobinick EL, 2009, DRUG NEWS PERSPECT, V22, P119, DOI 10.1358/dnp.2009.22.2.1303818
   Trindade F, 2014, PROTEOM CLIN APPL, V8, P748, DOI 10.1002/prca.201400028
   Wang GH, 2013, DIABETOLOGIA, V56, P2702, DOI 10.1007/s00125 013 3032 8
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Xu X, 2016, EUR J MED CHEM, V123, P769, DOI 10.1016/j.ejmech.2016.08.004
   Yamamoto K, 2017, J NEUROCHEM, V140, P495, DOI 10.1111/jnc.13902
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   ZHENG MH, 1994, J CELL BIOCHEM, V54, P145, DOI 10.1002/jcb.240540203
NR 28
TC 5
Z9 5
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUN
PY 2018
VL 119
IS 6
BP 4680
EP 4691
DI 10.1002/jcb.26646
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GD7CP
UT WOS:000430667200042
PM 29274286
DA 2025 08 17
ER

PT J
AU Kats, A
   Gerasimcik, N
   Näreoja, T
   Nederberg, J
   Grenlöv, S
   Lagnöhed, E
   Desai, S
   Andersson, G
   Yucel Lindberg, T
AF Kats, Anna
   Gerasimcik, Natalija
   Nareoja, Tuomas
   Nederberg, Jonas
   Grenlov, Simon
   Lagnohed, Ekaterina
   Desai, Suchita
   Andersson, Goran
   Yucel Lindberg, Tulay
TI Aminothiazoles inhibit osteoclastogenesis and PGE2 production
   in LPS stimulated co cultures of periodontal ligament and RAW 264.7
   cells, and RANKL mediated osteoclastogenesis and bone resorption in
   PBMCs
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE aminothiazoles; bone resorption; human PBMCs; lipopolysaccharide;
   microsomal prostaglandin E synthase 1; osteoclastogenesis; osteoclasts;
   periodontal ligament cells; prostaglandin E 2; RAW 264.7 cells
ID NF KAPPA B; PROSTAGLANDIN E SYNTHASE 1; ANTIINFLAMMATORY DRUGS NSAIDS;
   RECEPTOR ACTIVATOR; COX 2 INHIBITORS; IN VITRO; EXPRESSION;
   CYCLOOXYGENASE 2; IDENTIFICATION; FIBROBLASTS
AB Inflammatory mediator prostaglandin E 2 (PGE(2)) contributes to bone resorption in several inflammatory conditions including periodontitis. The terminal enzyme, microsomal prostaglandin E synthase 1 (mPGES 1) regulating PGE(2) synthesis is a promising therapeutic target to reduce inflammatory bone loss. The aim of this study was to investigate effects of mPGES 1 inhibitors, aminothiazoles TH 848 and TH 644, on PGE(2) production and osteoclastogenesis in co cultures of periodontal ligament (PDL) and osteoclast progenitor cells RAW 264.7, stimulated by lipopolysaccharide (LPS), and bone resorption in RANKL mediated peripheral blood mononuclear cells (PBMCs). PDL and RAW 264.7 cells were cultured separately or co cultured and treated with LPS alone or in combination with aminothiazoles. Multinucleated cells stained positively for tartrate resistant acid phosphatase (TRAP) were scored as osteoclast like cells. Levels of PGE(2), osteoprotegerin (OPG) and interleukin 6, as well as mRNA expression of mPGES 1, OPG and RANKL were analysed in PDL cells. PBMCs were treated with RANKL alone or in combination with aminothiazoles. TRAP positive multinucleated cells were analysed and bone resorption was measured by the CTX I assay. Aminothiazoles reduced LPS stimulated osteoclast like cell formation both in co cultures and in RAW 264.7 cells. Additionally, aminothiazoles inhibited PGE(2) production in LPS stimulated cultures, but did not affect LPS induced mPGES 1, OPG or RANKL mRNA expression in PDL cells. In PBMCs, inhibitors decreased both osteoclast differentiation and bone resorption. In conclusion, aminothiazoles reduced the formation of osteoclast like cells and decreased the production of PGE(2) in co cultures as well as single cell cultures. Furthermore, these compounds inhibited RANKL induced bone resorption and differentiation of PBMCs, suggesting these inhibitors for future treatment of inflammatory bone loss such as periodontitis.
C1 [Kats, Anna; Gerasimcik, Natalija; Nederberg, Jonas; Grenlov, Simon; Lagnohed, Ekaterina; Yucel Lindberg, Tulay] Karolinska Inst, Div Periodontol, Dept Dent Med, Huddinge, Sweden.
   [Nareoja, Tuomas; Desai, Suchita; Andersson, Goran] Karolinska Univ Hosp, Karolinska Inst, Div Pathol, Dept Lab Med, Huddinge, Sweden.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska University
   Hospital
RP Yucel Lindberg, T (通讯作者)，Karolinska Inst, Div Periodontol, Dept Dent Med, Huddinge, Sweden.
EM tulay.lindberg@ki.se
RI ; Gerasimcik, Natalija/M 4350 2019; Nareoja, Tuomas/K 3800 2014;
   Näreoja, Tuomas/K 3800 2014
OI Yucel Lindberg, Tulay/0000 0003 0129 8809; Kats,
   Anna/0000 0003 3650 2195; Desai, Suchita/0000 0003 3173 5803;
   Gerasimcik, Natalija/0000 0001 9680 035X; Nareoja,
   Tuomas/0000 0002 2174 4434; 
FU Swedish Research Council; Swedish Patent Revenue Fund; Swedish Dental
   Society; Stockholm County Council; Karolinska Institutet; Loo and Hans
   Osterman foundation; Maud Kuistila Memorial foundation; Jane and Aatos
   Erkko foundation
FX This project was funded by grants from the Swedish Research Council
   (TYL, TN and GA); Swedish Patent Revenue Fund (TYL); the Swedish Dental
   Society (AK); the Stockholm County Council (TYL), Karolinska Institutet
   (AK and TYL), Loo and Hans Osterman foundation (TN), Maud Kuistila
   Memorial foundation (TN) and, Jane and Aatos Erkko foundation (TN).
CR Båge T, 2011, AM J PATHOL, V178, P1676, DOI 10.1016/j.ajpath.2010.12.048
   Bezerra MM, 2000, J PERIODONTOL, V71, P1009, DOI 10.1902/jop.2000.71.6.1009
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Bloemen V, 2010, J CELL PHYSIOL, V222, P565, DOI 10.1002/jcp.21971
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Cannon CP, 2012, SCIENCE, V336, P1386, DOI 10.1126/science.1224398
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Corso G, 2013, J CHEM INF MODEL, V53, P1804, DOI 10.1021/ci400180f
   Duarte WR, 1998, J DENT RES, V77, P1694, DOI 10.1177/00220345980770090501
   Funk CD, 2007, J CARDIOVASC PHARM, V50, P470, DOI 10.1097/FJC.0b013e318157f72d
   Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954
   Graham S, 2009, EXPERT OPIN INV DRUG, V18, P749, DOI [10.1517/13543780902893051 , 10.1517/13543780902893051]
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Hu Y, 2014, ORAL DIS, V20, P682, DOI 10.1111/odi.12189
   Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220
   Kaneko H, 2007, PROSTAG LEUKOTR ESS, V77, P181, DOI 10.1016/j.plefa.2007.09.002
   Karlstrom E, 2010, BIOCHEM BIOPH RES CO, V394, P593, DOI 10.1016/j.bbrc.2010.03.025
   Kats A, 2016, J CELL MOL MED, V20, P1128, DOI 10.1111/jcmm.12814
   Kats A, 2013, FASEB J, V27, P2328, DOI 10.1096/fj.12 214445
   Kobayashi Y, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.82
   Konermann A, 2012, INNATE IMMUN LONDON, V18, P745, DOI 10.1177/1753425912440598
   Lee HJ, 2008, J PHARM PHARMACOL, V60, P917, DOI 10.1211/jpp.60.7.0014
   Marchesan JT, 2011, ARCH ORAL BIOL, V56, P933, DOI 10.1016/j.archoralbio.2011.03.003
   McGettigan P, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001098
   Murakami M, 2002, PROSTAG OTH LIPID M, V68 9, P383, DOI 10.1016/S0090 6980(02)00043 6
   Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163 7827(03)00037 7
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Naruishi K, 2018, J CELL PHYSIOL, V233, P6393, DOI 10.1002/jcp.26521
   Nebel D, 2015, J PERIODONTAL RES, V50, P666, DOI 10.1111/jre.12249
   Nebel D, 2013, ACTA ODONTOL SCAND, V71, P892, DOI 10.3109/00016357.2012.734415
   Ng SC, 2010, CURR OPIN GASTROEN, V26, P611, DOI 10.1097/MOG.0b013e32833e91eb
   Noguchi K, 2007, PERIODONTOL 2000, V43, P85, DOI 10.1111/j.1600 0757.2006.00170.x
   Nukaga J, 2004, J PERIODONTOL, V75, P249, DOI 10.1902/jop.2004.75.2.249
   Park HJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030495
   Pawelzik SC, 2010, J BIOL CHEM, V285, P29254, DOI 10.1074/jbc.M110.114454
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Preshaw PM, 2002, J CLIN PERIODONTOL, V29, P15, DOI 10.1034/j.1600 051x.2002.290103.x
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Sampey AV, 2005, ARTHRITIS RES THER, V7, P114, DOI 10.1186/ar1748
   Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1
   Sokos D, 2015, J PERIODONTAL RES, V50, P152, DOI 10.1111/jre.12197
   Sostres C, 2010, BEST PRACT RES CL GA, V24, P121, DOI 10.1016/j.bpg.2009.11.005
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Strålberg F, 2013, FASEB J, V27, P2687, DOI 10.1096/fj.12 211748
   Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531
   Tominari T, 2017, FEBS OPEN BIO, V7, P1972, DOI 10.1002/2211 5463.12340
   WILLIAMS RC, 1989, J PERIODONTOL, V60, P485, DOI 10.1902/jop.1989.60.9.485
   Yen CA, 2008, J PERIODONTOL, V79, P104, DOI [10.1902/jop.2008.070271, 10.1902/jop.2008.070271 ]
NR 49
TC 11
Z9 12
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD FEB
PY 2019
VL 23
IS 2
BP 1152
EP 1163
DI 10.1111/jcmm.14015
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA HM8KM
UT WOS:000459729900041
PM 30506812
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Monajemi, M
   Fisk, S
   Pang, YCF
   Leung, J
   Menzies, SC
   Ben Othman, R
   Cai, B
   Kollmann, TR
   Rozmus, J
   Sly, LM
AF Monajemi, Mahdis
   Fisk, Shera
   Pang, Yvonne C. F.
   Leung, Jessica
   Menzies, Susan C.
   Ben Othman, Rym
   Cai, Bing
   Kollmann, Tobias R.
   Rozmus, Jacob
   Sly, Laura M.
TI Malt1 deficient mice develop osteoporosis independent of
   osteoclast intrinsic effects of Malt1 deficiency
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE combined immunodeficiency; macrophage colony stimulating factor;
   macrophages; Malt1; osteoclasts; osteoporosis; osteoprotegerin
ID NF KAPPA B; COLONY STIMULATING FACTOR; BETA GLUCAN RECEPTOR; T CELL;
   COMBINED IMMUNODEFICIENCY; PARACASPASE MALT1; PHARMACOLOGICAL
   INHIBITION; SIGNALING PATHWAY; PROTECTS MICE; DIFFERENTIATION
AB This study tested the hypothesis that mucosa associated lymphoid tissue 1 (Malt1) deficiency causes osteoporosis in mice by increasing osteoclastogenesis and osteoclast activity. A patient with combined immunodeficiency (CID) caused by MALT1 deficiency had low bone mineral density resulting in multiple low impact fractures that was corrected by hematopoietic stem cell transplant (HSCT). We have reported that Malt1 deficient M phi s, another myeloid cell type, are hyper responsive to inflammatory stimuli. Our objectives were to determine whether Malt1 deficient mice develop an osteoporosis like phenotype and whether it was caused by Malt1 deficiency in osteoclasts. We found that Malt1 deficient mice had low bone volume by 12 weeks of age, which was primarily associated with reduced trabecular bone. Malt1 protein is expressed and active in osteoclasts and is induced by receptor activator of NF kappa B ligand (RANKL) in preosteoclasts. Malt1 deficiency did not impact osteoclast differentiation or activity in vitro. However, Malt1 deficient (Malt1( / )) mice had more osteoclasts in vivo and had lower levels of serum osteoprotegerin (OPG), an endogenous inhibitor of osteoclastogenesis. Inhibition of Malt1 activity in M phi s induced MCSF production, required for osteoclastogenesis, and decreased OPG production in response to inflammatory stimuli. In vitro, MCSF increased and OPG inhibited osteoclastogenesis, but effects were not enhanced in Malt1 deficient osteoclasts. These data support the hypothesis that Malt1 deficient mice develop an osteoporotic phenotype with increased osteoclastogenesis in vivo, but suggest that this is caused by inflammation rather than an effect of Malt1 deficiency in osteoclasts.
C1 [Monajemi, Mahdis; Fisk, Shera; Pang, Yvonne C. F.; Leung, Jessica; Menzies, Susan C.; Sly, Laura M.] Univ British Columbia, Dept Pediat, Div Gastroenterol, Vancouver, BC, Canada.
   [Ben Othman, Rym; Cai, Bing] Univ British Columbia, Dept Pediat, Div Infect Dis, Vancouver, BC, Canada.
   [Kollmann, Tobias R.; Sly, Laura M.] Univ Western Australia, Telethon Kids Inst, Perth Childrens Hosp, Nedlands, WA, Australia.
   [Rozmus, Jacob] Univ British Columbia, Div Hematol & Oncol, BC Childrens Hosp Res Inst, Vancouver, BC, Canada.
C3 University of British Columbia; University of British Columbia;
   University of Western Australia; The Kids Research Institute Australia;
   Perth Childrens Hospital; University of British Columbia; BC Children's
   Hospital; BC Children's Hospital Research Institute
RP Sly, LM (通讯作者)，BC Childrens Hosp Res Inst, Room A5 142TRB,950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada.
EM laurasly@mail.ubc.ca
OI Kollmann, Tobias/0000 0003 2403 9762; , Jacob/0000 0003 4036 2105; Sly,
   Laura/0000 0002 1673 467X
FU Canadian Institutes of Health Research funded Transplantation Training
   Program Studentship; BC Children's Hospital research studentship; MITACS
   Accelerate Studentship; Canadian Association of Gastroenterology summer
   studentship; Michael Smith Foundation for Health Research; BC Children's
   Hospital Investigatorship; Canadian Institutes of Health Research (CIHR)
   [MOP 133607]
FX The authors would like to thank Dr. Margaret McKinnon, Dr. Stuart
   Turvey, and others involved in the exceptional clinical care of the
   person with MALT1 deficiency at BC Children's Hospital. The authors
   would also like to thank the Centre for High Throughput Phenogenomics
   for access to Micro CT. M.M. is the recipient of a Canadian Institutes
   of Health Research funded Transplantation Training Program Studentship,
   a BC Children's Hospital research studentship, and a MITACS Accelerate
   Studentship. JL is the recipient of a Canadian Association of
   Gastroenterology summer studentship. L.M.S. is the recipient of a
   Biomedical Scholar Award from the Michael Smith Foundation for Health
   Research and a BC Children's Hospital Investigatorship. This work was
   supported by an operating grant to L.M.S. from the Canadian Institutes
   of Health Research (CIHR; MOP 133607).
CR Baens M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103774
   Bardet M, 2018, IMMUNOL CELL BIOL, V96, P81, DOI 10.1111/imcb.1018
   Benlidayi IC, 2018, RHEUMATOL INT, V38, P1975, DOI 10.1007/s00296 018 4106 1
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Bornancin F, 2015, J IMMUNOL, V194, P3723, DOI 10.4049/jimmunol.1402254
   Boyce BF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02263
   Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470
   Brüstle A, 2012, J CLIN INVEST, V122, P4698, DOI 10.1172/JCI63528
   CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753 3322(94)90005 1
   Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561
   Cosman F, 2018, CURR OPIN RHEUMATOL, V30, P420, DOI 10.1097/BOR.0000000000000509
   de Vries TJ, 2009, J LEUKOCYTE BIOL, V85, P919, DOI 10.1189/jlb.0708402
   Dong W, 2006, J BIOL CHEM, V281, P26029, DOI 10.1074/jbc.M513057200
   FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo 127 5 2592
   Frans G, 2014, CRIT REV CL LAB SCI, V51, P112, DOI 10.3109/10408363.2014.881317
   Gaspar HB, 2014, J CLIN IMMUNOL, V34, P393, DOI 10.1007/s10875 014 0029 0
   Gewies A, 2014, CELL REP, V9, P1292, DOI 10.1016/j.celrep.2014.10.044
   Gobin K, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00083
   Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926
   Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108
   Hamdy NAT, 2007, CURR OPIN INVEST DR, V8, P299
   Holguin N, 2014, BONE, V65, P83, DOI 10.1016/j.bone.2014.05.006
   Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047
   Jaworski M, 2014, EMBO J, V33, P2765, DOI 10.15252/embj.201488987
   Klein T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9777
   KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LEE CH, 2017, SCI REP UK, V7
   Li M, 2018, SCI CHINA LIFE SCI, V61, P762, DOI 10.1007/s11427 017 9097 0
   Li Y, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.66
   Liu W, 2016, ONCOTARGET, V7, P30536, DOI 10.18632/oncotarget.8867
   Lu HY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02078
   Marino Silvia, 2014, Bonekey Rep, V3, P570, DOI 10.1038/bonekey.2014.65
   Matsumoto R, 2005, IMMUNITY, V23, P575, DOI 10.1016/j.immuni.2005.10.007
   Mc Guire C, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742 2094 11 124
   Mc Guire C, 2013, J IMMUNOL, V190, P2896, DOI 10.4049/jimmunol.1201351
   McKinnon ML, 2014, J ALLERGY CLIN IMMUN, V133, P1458, DOI 10.1016/j.jaci.2013.10.045
   Meloni L, 2018, MOLECULES, V23, DOI 10.3390/molecules23123144
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Monajemi M, 2018, J LEUKOCYTE BIOL, V104, P557, DOI 10.1002/JLB.3VMA0118 019R
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Nagel D, 2015, METHODS MOL BIOL, V1280, P239, DOI 10.1007/978 1 4939 2422 6_13
   Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002
   Paciolla M, 2015, GENES IMMUN, V16, P239, DOI 10.1038/gene.2015.3
   Puel A, 2004, CURR OPIN IMMUNOL, V16, P34, DOI 10.1016/j.coi.2003.11.013
   Punwani D, 2015, J CLIN IMMUNOL, V35, P135, DOI 10.1007/s10875 014 0125 1
   Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568
   Rozmus J, 2016, CLIN IMMUNOL, V168, P1, DOI 10.1016/j.clim.2016.04.011
   Ruefli Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769
   Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074 7613(03)00293 0
   Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092 8674(01)00189 1
   Shinohara H, 2007, J EXP MED, V204, P3285, DOI 10.1084/jem.20070379
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sly LM, 2009, BLOOD, V113, P2945, DOI 10.1182/blood 2008 06 166082
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876
   Tusche MW, 2009, J EXP MED, V206, P2671, DOI 10.1084/jem.20091802
   Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034
   Weisser SB, 2011, EUR J IMMUNOL, V41, P1742, DOI 10.1002/eji.201041105
   Wilcock A, 2018, J PAIN SYMPTOM MANAG, V56, P295, DOI 10.1016/j.jpainsymman.2018.05.021
   Yamada N, 2005, CYTOKINE, V31, P288, DOI 10.1016/j.cyto.2005.03.009
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yeo L, 2016, ANN RHEUM DIS, V75, P763, DOI 10.1136/annrheumdis 2014 206921
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Yoshitomi H, 2005, J EXP MED, V201, P949, DOI 10.1084/jem.20041758
   Yun TJ, 1998, J IMMUNOL, V161, P6113
NR 67
TC 9
Z9 11
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0741 5400
EI 1938 3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD OCT
PY 2019
VL 106
IS 4
SI SI
BP 863
EP 877
DI 10.1002/JLB.5VMA0219 054R
EA JUL 2019
PG 15
WC Cell Biology; Hematology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Immunology
GA IZ8IC
UT WOS:000476376200001
PM 31313375
DA 2025 08 17
ER

PT J
AU Tao, ZS
   Zhou, WS
   Xu, HG
   Yang, M
AF Tao, Zhou Shan
   Zhou, Wan Shu
   Xu, Hong Guang
   Yang, Min
TI Parathyroid hormone (1 34) can reverse the negative effect of valproic
   acid on the osseointegration of titanium rods in ovariectomized rats
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Osteoporosis; Osseointegration; Titanium implants; Parathyroid hormone
   (1 34); Valproic acid
AB Objective: The present work was aimed to evaluate the effect of valproic acid (VPA), Parathyroid hormone (1 34) (PTH)+VPA on Ti rods osseointegration in ovariectomized rats and further investigation of the possible mechanism.
   Methods: The MC3T3 E1 cells were co cultured with VPA, PTH + VPA and induced to osteogenesis, and the cell viability,mineralization ability were observed by MTT and ALP staining, Alizarin Red staining and Western blotting. Twelve weeks after bilateral ovariectomy, all animals were randomly divided into four groups: group OVX and VPA, PTH + VPA, and all the rats received Ti implants and animals belong to group VPA, PTH + VPA received valproic acid (300 mg/day), valproic acid (300 mg/day) plus Parathyroid hormone (1 34) every 3 days (60 mu g/kg), respectively, treatment until death at 12 weeks. Micro CT, histology, biomechanical testing, bone metabolism index and Reverse transcription quantitative polymerase chain reaction (RT qPCR) analysis were used to observe the therapeutic effect and explore the possible mechanism.
   Results: Results shown that VPA decreased new bone formation around the surface of titanium rods and push out force other than group OVX. Histology, Micro CT and biochemical analysis results showed combined application of systemic VPA showed harmful effects than OVX group on bone formation in osteopenia rats, with the worse effects on CTX 1, P1NP and microarchitecture as well as biomechanical parameters by down regulated gene expression of Runx2, OCN, Smad1, BMP 2 and OPG, while up regulated RANKL. However, after PTH treatment, the above indicators were significantly improved.
   Conclusions: The present study suggests that systemic use of VPA may bring harm to the stability of titanium implants in osteoporosis, PTH can reverse the negative effect of VPA on the osseointegration of titanium rods in ovariectomized rats.
   Translational potential of this article: According to our research, when patients with epilepsy have osteoporotic fractures, after joint replacement or internal fixation, continue to use sodium valproate for anti epileptic therapy, the possibility of postoperative loosening increases, again on the basis of It can be reversed with the anti osteoporosis drug parathyroid hormone (1 34).
C1 [Tao, Zhou Shan; Yang, Min] Yijishan Hosp, Wannan Med Coll, Affiliated Hosp 1, Dept Trauma Orthoped, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
   [Zhou, Wan Shu] Wannan Med Coll, Affiliated Hosp 2, Dept Geriatr, 123 Kangfu Rd, Wuhu 241000, Anhui, Peoples R China.
   [Xu, Hong Guang] Yijishan Hosp, Wannan Med Coll, Affiliated Hosp 1, Dept Spinal Orthoped, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
C3 Wannan Medical College; Wannan Medical College; Wannan Medical College
RP Tao, ZS (通讯作者)，Yijishan Hosp, Wannan Med Coll, Affiliated Hosp 1, Dept Trauma Orthoped, 2 Zhe Shan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
EM tzs19900327@126.com
RI Xu, Hong Guang/F 1731 2010
FU University Natural Science Research Project of Anhui Province (CN)
   [KJ2017A266]; Funding of "Peak"Training Program; "Panfeng"Innovation
   Team Project for Scientific Research of Yijishan Hospital, Wannan
   Medical College [GF2019G04, PF2019005, GF2019T02, PF2019007]; National
   Natural Science Foundation of China [82002322]; Wannan Medical College
   [YR201917]; Young and Middle aged Key Project of Wannan Medical College
   [WK2020ZF16]
FX This study was supported by a grant from the University Natural Science
   Research Project of Anhui Province (CN)(grant no. KJ2017A266), Funding
   of "Peak"Training Program and "Panfeng"Innovation Team Project for
   Scientific Research of Yijishan Hospital, Wannan Medical College (grant
   no. GF2019G04, PF2019005, GF2019T02 and PF2019007), National Natural
   Science Foundation of China(82002322), Talented Scholars of Wannan
   Medical College (YR201917) and Young and Middle aged Key Project of
   Wannan Medical College(WK2020ZF16).
CR [Anonymous], 2017, ORAL MAXILLOFAC SURG, V21, P247, DOI [10.1007/s10006 017 0624 3, DOI 10.1007/S10006 017 0624 3]
   Bouxsein ML, 2009, J BONE JOINT SURG AM, V91A, P1329, DOI 10.2106/JBJS.H.01030
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Ding LL, 2020, OSTEOPOROSIS INT, V31, P961, DOI 10.1007/s00198 019 05183 4
   Ecevit CG, 2004, PEDIATR NEUROL, V31, P279, DOI 10.1016/j.pediatrneurol.2004.03.021
   Fedorenko M, 2015, EPILEPSY BEHAV, V45, P217, DOI 10.1016/j.yebeh.2015.01.021
   Fu J, 2019, HORM METAB RES, V51, P511, DOI 10.1055/a 0963 0054
   Gabet Y, 2008, J BONE MINER RES, V23, P48, DOI 10.1359/JBMR.070901
   Huang D, 2020, CARBOHYD POLYM, V231, DOI 10.1016/j.carbpol.2019.115732
   Hwang D, 2007, IMPLANT DENT, V16, P13, DOI 10.1097/ID.0b013e31803276c8
   Jetté N, 2011, ARCH NEUROL CHICAGO, V68, P107, DOI 10.1001/archneurol.2010.341
   Khanna S, 2011, CNS NEUROL DISORD DR, V10, P361, DOI 10.2174/187152711794653797
   Khanna S, 2009, DRUG DISCOV TODAY, V14, P428, DOI 10.1016/j.drudis.2009.01.004
   Li H, 2018, BIOMED PHARMACOTHER, V103, P588, DOI 10.1016/j.biopha.2018.04.084
   Li YF, 2013, OSTEOPOROSIS INT, V24, P1063, DOI 10.1007/s00198 012 2258 5
   Li YF, 2010, BIOMATERIALS, V31, P9006, DOI 10.1016/j.biomaterials.2010.07.112
   Liu Y, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201165
   López Valverde N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072047
   Nikolaou VS, 2009, INJURY, V40, P663, DOI 10.1016/j.injury.2008.10.035
   Oki Y, 2017, J APPL ORAL SCI, V25, P498, DOI 10.1590/1678 7757 2016 0561
   Parveen B, 2018, BONE, V113, P57, DOI 10.1016/j.bone.2018.05.011
   Patel AA, 2020, PEDIATR NEUROL, V102, P49, DOI 10.1016/j.pediatrneurol.2019.06.020
   Siniscalchi Antonio, 2020, Psychopharmacol Bull, V50, P36
   Souverein PC, 2006, NEUROLOGY, V66, P1318, DOI 10.1212/01.wnl.0000210503.89488.88
   Takahashi E, 2017, BONE JOINT RES, V6, P351, DOI 10.1302/2046 3758.65.BJR 2017 0028.R1
   Tang CY, 2020, BIOCHEM J, V477, P2421, DOI 10.1042/BCJ20200036
   Tao ZS, 2019, J BIOMATER APPL, V34, P664, DOI 10.1177/0885328219863290
   Tao ZS, 2019, J BONE MINER METAB, V37, P1026, DOI 10.1007/s00774 019 01008 w
   Tao ZS, 2019, Z GERONTOL GERIATR, V52, P139, DOI 10.1007/s00391 018 1376 x
   Tao ZS, 2016, Z GERONTOL GERIATR, V49, P423, DOI 10.1007/s00391 015 0949 1
   Tao ZS, 2016, J BIOMATER APPL, V30, P952, DOI 10.1177/0885328215610898
   Tao ZS, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 015 5650 9
   Tao ZS, 2020, J BIOMATER APPL, V34, P1009, DOI 10.1177/0885328219889630
   Uezono M, 2013, J BIOMED MATER RES B, V101B, P1031, DOI 10.1002/jbm.b.32913
   Xu D, 2020, BIOMATER SCI UK, V8, P3286, DOI 10.1039/d0bm00443j
NR 35
TC 21
Z9 21
U1 1
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD MAR
PY 2021
VL 27
BP 67
EP 76
DI 10.1016/j.jot.2020.10.006
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA RJ3WF
UT WOS:000637527900011
PM 33437639
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cheng, BB
   Li, J
   Du, J
   Lv, X
   Weng, L
   Ling, CQ
AF Cheng, Binbin
   Li, Jun
   Du, Juan
   Lv, Xiang
   Weng, Li
   Ling, Changquan
TI Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF κB and
   MAPKs pathways
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Ginsenosides; Receptor activator of NF kappa B ligand;
   Osteoclastogenesis; Osteoporosis
ID HORMONE REPLACEMENT THERAPY; NECROSIS FACTOR RECEPTOR; C FOS; OSTEOBLAST
   DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; POSTMENOPAUSAL WOMEN;
   NUCLEAR FACTOR; KEY REGULATOR; BONE; LIGAND
AB Ginsenosides (GSS), the main active components of ginseng, have been reported possessing anti osteoporosis activity in ovariectomized rats. However, the active ingredient and the mechanisms underlying the anti osteoporosis activity of GSS have not been clearly elucidated. In the present study, we determined the effect of ginsenoside Rb1, a major component of ginsenosides, on receptor activator of NF kappa B ligand (RANKL) induced osteoclast formation. Ginsenoside Rb1 inhibited RANKL induced osteoclast differentiation from Raw264.7 cells without cytotoxicity. Ginsenoside Rb1 also inhibited RANKL induced TNF alpha, mRNA expression in Raw264.7 cells. Pretreatment with ginsenoside Rb1 significantly inhibited RANKL induced the gene expression of c Fos and nuclear factor of activated T cells c1 (NFATc1), which are two essential and crucial transcription factors for osteoclast formation. Rb1 inhibited RANKL induced nucleus translocation and activation of NF kappa B, the upstream factor of c Fos and NFATc1. Among the three well known mitogen activated protein kinases (MAPKs), Rb1 inhibited RANKL induced JNK and p38 phosphorylation, but not ERK1/2. Taken together, our data suggest that ginsenoside Rb1 is one of the effective components of GSS for the anti osteoporosis activity and can inhibit osteoclastogenesis by suppressing RANKL induced activation of both JNK and p38 MAPKs and NF kappa B pathways, and consequently down regulating the gene expression of c Fos and NFATc1 in osteoclast precursors. (C) 2012 Published by Elsevier Ltd.
C1 [Cheng, Binbin; Li, Jun; Du, Juan; Weng, Li; Ling, Changquan] Second Mil Med Univ, Dept Tradit Chinese Med, Changhai Hosp, Shanghai 200433, Peoples R China.
   [Lv, Xiang] Shanghai Municipal Hosp Tradit Chinese Med, Dept Oncol, Shanghai 200071, Peoples R China.
C3 Naval Medical University
RP Ling, CQ (通讯作者)，Second Mil Med Univ, Dept Tradit Chinese Med, Changhai Hosp, 168 Changhai Rd, Shanghai 200433, Peoples R China.
RI Cheng, Binbin/F 4684 2018; Li, Jun/N 3806 2014; Ling,
   Changquan/J 2108 2016
OI Cheng, Binbin/0000 0002 8321 130X; Ling, Changquan/0000 0002 0037 4059
FU National Nature Science Foundation of China [30730114, 81001672]
FX The work was supported by grants from National Nature Science Foundation
   of China (30730114 and 81001672). The authors declare that there is no
   conflict of interest that would prejudice the impartiality of this
   scientific work.
CR Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006 2952(99)00212 9
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Binbin C, 2009, HORM METAB RES, V41, P531, DOI 10.1055/s 0029 1216373
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cho JY, 2004, J CLIN ENDOCR METAB, V89, P3510, DOI 10.1210/jc.2003 031823
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092 8674(02)00699 2
   Cui L, 2001, ACTA PHARMACOL SIN, V22, P428
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Du J, 2011, J IMMUNOL, V187, P942, DOI 10.4049/jimmunol.1002579
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gong YS, 2006, J ASIAN NAT PROD RES, V8, P649, DOI 10.1080/10286020500246063
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092 8674(92)90592 Z
   Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kitazawa R, 1999, BBA GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167 4781(99)00032 9
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kuang Hong ying, 2008, Zhong Xi Yi Jie He Xue Bao, V6, P725, DOI 10.3736/jcim20080713
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Liang L, 2008, J PERIODONTOL, V79, P1745, DOI [10.1902/jop.2008.070437, 10.1902/jop.2008.070437 ]
   LIU CX, 1992, J ETHNOPHARMACOL, V36, P27, DOI 10.1016/0378 8741(92)90057 X
   Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Rauch A, 2011, FASEB J, V25, P1323, DOI 10.1096/fj.10 173393
   Robinson LJ, 2009, EXP CELL RES, V315, P1287, DOI 10.1016/j.yexcr.2009.01.014
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Taxel P, 2008, OSTEOPOROSIS INT, V19, P193, DOI 10.1007/s00198 007 0452 7
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vedi S, 1996, BONE, V19, P535, DOI 10.1016/S8756 3282(96)00227 X
   Vedi S, 2003, BONE, V33, P330, DOI 10.1016/S8756 3282(03)00114 5
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   You Yan li, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P762
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 49
TC 63
Z9 69
U1 4
U2 39
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278 6915
EI 1873 6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD MAY
PY 2012
VL 50
IS 5
BP 1610
EP 1615
DI 10.1016/j.fct.2012.02.019
PG 6
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Toxicology
GA 949JH
UT WOS:000304572000056
PM 22386813
DA 2025 08 17
ER

PT J
AU Yan, Y
   Gao, X
   Zhang, S
   Wang, YT
   Zhou, ZJ
   Xiao, JR
   Zhang, Q
   Cheng, YY
AF Yan, Yang
   Gao, Xin
   Zhang, Song
   Wang, Yitong
   Zhou, Zhengjie
   Xiao, Jianru
   Zhang, Qiang
   Cheng, Yiyun
TI A Carboxyl Terminated Dendrimer Enables Osteolytic Lesion Targeting and
   Photothermal Ablation of Malignant Bone Tumors
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE carboxyl terminated dendrimer; dendrimer encapsulated nanoparticles;
   bone targeting photothermal therapy; osteolysis
ID DRUG DELIVERY SYSTEM; OSTEOTROPIC PEPTIDE; ASPARTIC ACID; METASTASIS;
   CANCER; NANOPARTICLES; THERAPY; MICROENVIRONMENT; NANOMEDICINE;
   CONTRIBUTOR
AB Malignant bone tumor accompanied by tumor associated osteolysis remains a challenging task in clinical practice. Nanomedicines engineered with bone targeting ligands, such as alendronate and pamidronate, are developed for targeted delivery of therapeutic agents to bone tumors. However, these targeting strategies usually show relatively poor selectivity toward the healthy skeletons and the osteolytic lesions because of the high binding affinity of bisphosphonates with all the bone tissues. Here, we reported a carboxyl terminated dendrimer as the candidate to preferentially deliver therapeutic nanoparticles to the osteolytic lesions in a malignant bone tumor model. The high density of carboxyl groups on dendrimer surface endow the polymer with natural bone binding capability. The dendrimer encapsulated with platinum nanoparticle predominantly accumulates at the osteolytic lesions around bone tumors rather than at healthy bone tissues in vivo. The therapeutic experiments reveal that the dendrimer mediated photothermal therapy efficiently suppresses bone tumors and osteolysis, and the anionic polymer exhibits minimal cytotoxicity and hematologic toxicity. The results suggest that the carboxyl terminated dendrimer is a promising candidate for selective delivery of therapeutics to the osteolytic lesions and photothermal treatment of malignant bone tumors.
C1 [Yan, Yang; Zhang, Song; Wang, Yitong; Zhou, Zhengjie; Zhang, Qiang; Cheng, Yiyun] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Sch Life Sci, Shanghai 200241, Peoples R China.
   [Gao, Xin; Xiao, Jianru] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed Oncol, Shanghai 200003, Peoples R China.
C3 East China Normal University; Naval Medical University
RP Zhang, Q; Cheng, YY (通讯作者)，East China Normal Univ, Shanghai Key Lab Regulatory Biol, Sch Life Sci, Shanghai 200241, Peoples R China.
EM qzhang@bio.ecnu.edu.cn; yycheng@mail.ustc.edu.cn
RI Cheng, Jessica Yi Yun/MSZ 1589 2025
OI Zhou, Zhengjie/0000 0001 8329 6086
FU National Key Research and Development Program of China [2016YFC0902100];
   National Natural Science Foundation of China [21725402, 81671822]; SMSTC
   [17XD1401600]
FX We would like to thank the financial support from the National Key
   Research and Development Program of China (2016YFC0902100), the National
   Natural Science Foundation of China (21725402 and 81671822), and the
   SMSTC (17XD1401600) on this work.
CR Bansal G, 2005, ANGEW CHEM INT EDIT, V44, P3710, DOI 10.1002/anie.200500350
   Carbone EJ, 2017, J NANOSCI NANOTECHNO, V17, P1747, DOI 10.1166/jnn.2017.12855
   Chen Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13193
   Cheng YY, 2017, ACTA POLYM SIN, P1234, DOI 10.11777/j.issn1000 3304.2017.17095
   Cheng ZL, 2009, ADV FUNCT MATER, V19, P3753, DOI 10.1002/adfm.200901253
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Crooks RM, 2001, ACCOUNTS CHEM RES, V34, P181, DOI 10.1021/ar000110a
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Gittens SA, 2003, PHARMACEUT RES, V20, P978, DOI 10.1023/A:1024445903306
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Hirn S, 2011, EUR J PHARM BIOPHARM, V77, P407, DOI 10.1016/j.ejpb.2010.12.029
   Iafisco M, 2012, J INORG BIOCHEM, V117, P237, DOI 10.1016/j.jinorgbio.2012.06.004
   Jiang T, 2014, INT J PHARMACEUT, V475, P547, DOI 10.1016/j.ijpharm.2014.08.067
   Kannan RM, 2014, J INTERN MED, V276, P579, DOI 10.1111/joim.12280
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kollender Y, 2000, J UROLOGY, V164, P1505, DOI 10.1016/S0022 5347(05)67016 4
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   Lin Z, 2015, SCI REP UK, V5, DOI 10.1038/srep11709
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Morton SW, 2014, ADV HEALTHC MATER, V3, P867, DOI 10.1002/adhm.201300465
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nam J, 2009, J AM CHEM SOC, V131, P13639, DOI 10.1021/ja902062j
   POSNER AS, 1969, PHYSIOL REV, V49, P760, DOI 10.1152/physrev.1969.49.4.760
   Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Shanmugam V, 2014, CHEM SOC REV, V43, P6254, DOI 10.1039/c4cs00011k
   Silva SC, 2015, THER ADV MED ONCOL, V7, P219, DOI 10.1177/1758834015582178
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Wang CP, 2015, SMALL, V11, P2080, DOI 10.1002/smll.201403315
   Wang C, 2008, ANGEW CHEM INT EDIT, V47, P3588, DOI 10.1002/anie.200800073
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang XL, 2014, BIOMATER SCI UK, V2, P961, DOI [10.1039/c4bm00020j, 10.1039/C4BM00020J]
   Wang YT, 2017, BIOMATERIALS, V114, P97, DOI 10.1016/j.biomaterials.2016.11.010
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xia YN, 2011, ACCOUNTS CHEM RES, V44, P914, DOI 10.1021/ar200061q
   Xiao K, 2011, BIOMATERIALS, V32, P3435, DOI 10.1016/j.biomaterials.2011.01.021
   Yin Q, 2016, P NATL ACAD SCI USA, V113, pE4601, DOI 10.1073/pnas.1603316113
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang ZJ, 2013, ADV MATER, V25, P3869, DOI 10.1002/adma.201301890
   Zhou ZJ, 2016, ACS NANO, V10, P4863, DOI 10.1021/acsnano.6b02058
NR 48
TC 41
Z9 41
U1 1
U2 114
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JAN 9
PY 2019
VL 11
IS 1
BP 160
EP 168
DI 10.1021/acsami.8b15827
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA HH2PR
UT WOS:000455561200019
PM 30525391
DA 2025 08 17
ER

PT J
AU Scheiber, AL
   Wilkinson, KJ
   Suzuki, A
   Enomoto Iwamoto, M
   Kaito, T
   Cheah, KSE
   Iwamoto, M
   Leikin, S
   Otsuru, S
AF Scheiber, Amanda L.
   Wilkinson, Kevin J.
   Suzuki, Akiko
   Enomoto Iwamoto, Motomi
   Kaito, Takashi
   Cheah, Kathryn S. E.
   Iwamoto, Masahiro
   Leikin, Sergey
   Otsuru, Satoru
TI 4PBA reduces growth deficiency in osteogenesis imperfecta by enhancing
   transition of hypertrophic chondrocytes to osteoblasts
SO JCI INSIGHT
LA English
DT Article
ID ENDOPLASMIC RETICULUM STRESS; BETA CATENIN; MOUSE MODEL; PLATE
   CHONDROCYTES; SHORT CHILDREN; BONE GROWTH; ER STRESS; CELLS; CARTILAGE;
   RISEDRONATE
AB Short stature is a major skeletal phenotype in osteogenesis imperfecta (OI), a genetic disorder mainly caused by mutations in genes encoding type I collagen. However, the underlying mechanism is poorly understood, and no effective treatment is available. In OI mice that carry a G610C mutation in COL1A2, we previously found that mature hypertrophic chondrocytes (HCs) are exposed to cell stress due to accumulation of misfolded mutant type I procollagen in the endoplasmic reticulum (ER). By fate mapping analysis of HCs in G610C OI mice, we found that HCs stagnate in the growth plate, inhibiting translocation of HC descendants to the trabecular area and their differentiation to osteoblasts. Treatment with 4 phenylbutyric acid (4PBA), a chemical chaperone, restored HC ER structure and rescued this inhibition, resulting in enhanced longitudinal bone growth in G610C OI mice. Interestingly, the effects of 4PBA on ER dilation were limited in osteoblasts, and the bone fragility was not ameliorated. These results highlight the importance of targeting HCs to treat growth deficiency in OI. Our findings demonstrate that HC dysfunction induced by ER disruption plays a critical role in the pathogenesis of OI growth deficiency, which lays the foundation for developing new therapies for OI.
C1 [Scheiber, Amanda L.; Wilkinson, Kevin J.; Suzuki, Akiko; Enomoto Iwamoto, Motomi; Iwamoto, Masahiro; Otsuru, Satoru] Univ Maryland, Dept Orthopaed, Sch Med, 670 W Baltimore St HSF 3 Rm7173, Baltimore, MD 21201 USA.
   [Kaito, Takashi] Osaka Univ, Grad Sch Med, Dept Orthopaed Surg, Osaka, Japan.
   [Cheah, Kathryn S. E.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China.
   [Leikin, Sergey] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Phys Biochem, NIH, Bethesda, MD USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University of Osaka; University of Hong Kong; National Institutes of
   Health (NIH)   USA; NIH Eunice Kennedy Shriver National Institute of
   Child Health & Human Development (NICHD)
RP Otsuru, S (通讯作者)，Univ Maryland, Dept Orthopaed, Sch Med, 670 W Baltimore St HSF 3 Rm7173, Baltimore, MD 21201 USA.
EM sotsuru@som.umaryland.edu
RI Cheah, Kathryn Song Eng/C 4222 2009; Kaito, Takashi/AAJ 3892 2020;
   Otsuru, Satoru/HKN 3355 2023; Leikin, Sergey/A 5518 2008; Cheah,
   Kathryn/C 4222 2009
OI Cheah, Kathryn Song Eng/0000 0003 0802 8799; Wilkinson, Kevin
   J./0000 0002 5739 0017; 
FU University of Maryland, Baltimore; Maryland Stem Cell Research Fund
   (MSCRF) [2018 MSCRFD 4331]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases of the NIH [R01AR075733]; Division of
   Intramural Research, National Institute of Child Health and Human
   Development of NIH; Hong Kong Research Grants Council [T12 708/12N]
FX We thank the Animal Facility and Electron Microscopy Core Imaging
   Facility at the University of Maryland School of Medicine for providing
   their services, resources, and technical assistance. We also thank the
   Molec ular Genomics Core at the Eunice Kennedy Shriver National
   Institute of Child Health and Human Devel opment. This work was
   supported by the institutional funds from the University of Maryland,
   Baltimore, the Maryland Stem Cell Research Fund (MSCRF) Discovery Grant
   (2018 MSCRFD 4331) , and the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases of the NIH (R01AR075733) . This work
   was also supported by the Division of Intramural Research, National
   Institute of Child Health and Human Develop ment of NIH. KSEC is
   supported by the Hong Kong Research Grants Council project T12 708/12N.
CR Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   Barber LA, 2019, GENET MED, V21, P1233, DOI 10.1038/s41436 018 0307 y
   Besio R, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.038521
   Besio R, 2018, BBA MOL BASIS DIS, V1864, P1642, DOI 10.1016/j.bbadis.2018.02.002
   Bi XH, 2017, J BONE MINER RES, V32, P347, DOI 10.1002/jbmr.2997
   Bishop N, 2013, LANCET, V382, P1424, DOI 10.1016/S0140 6736(13)61091 0
   Bishop N, 2010, J BONE MINER RES, V25, P32, DOI 10.1359/jbmr.090712
   Bowen ME, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004364
   Cardinal M, 2020, CALCIFIED TISSUE INT, V106, P494, DOI 10.1007/s00223 019 00655 5
   Chan WCW, 2017, HUM MOL GENET, V26, P4572, DOI 10.1093/hmg/ddx339
   Chen ZJ, 2015, J BONE MINER RES, V30, P765, DOI 10.1002/jbmr.2409
   CHESSLER SD, 1993, J BIOL CHEM, V268, P18226
   Costa Mattioli M, 2020, SCIENCE, V368, P384, DOI 10.1126/science.aat5314
   Daley E, 2010, J BONE MINER RES, V25, P247, DOI 10.1359/jbmr.090720
   Dwan K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub3
   Engel J, 2005, TOP CURR CHEM, V247, P7, DOI 10.1007/b103818
   FARNUM CE, 1993, CALCIFIED TISSUE INT, V52, P110, DOI 10.1007/BF00308319
   Fass DM, 2011, ACS MED CHEM LETT, V2, P39, DOI 10.1021/ml1001954
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Forouhan M, 2018, HUM MOL GENET, V27, P3840, DOI 10.1093/hmg/ddy253
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gioia R, 2017, HUM MOL GENET, V26, P2897, DOI 10.1093/hmg/ddx171
   Gioia R, 2012, STEM CELLS, V30, P1465, DOI 10.1002/stem.1107
   Golovchenko S, 2013, BONE, V55, P102, DOI 10.1016/j.bone.2013.03.019
   Gorrell L, 2021, CELL MOL LIFE SCI, V78, P8283, DOI 10.1007/s00018 021 04017 z
   Grafe I, 2016, J BONE MINER RES, V31, P1030, DOI 10.1002/jbmr.2776
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Houben A, 2016, DEVELOPMENT, V143, P3826, DOI 10.1242/dev.137489
   Hoyer Kuhn H, 2016, J MUSCULOSKEL NEURON, V16, P24
   Hoyer Kuhn H, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023 014 0145 1
   Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101
   Jain M, 2019, GENET MED, V21, P275, DOI 10.1038/s41436 018 0045 1
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Karuppaiah K, 2016, DEVELOPMENT, V143, P1811, DOI 10.1242/dev.131722
   Kawamoto T, 2014, METHODS MOL BIOL, V1130, P149, DOI 10.1007/978 1 62703 989 5_11
   Kolb PS, 2015, INT J BIOCHEM CELL B, V61, P45, DOI 10.1016/j.biocel.2015.01.015
   KOOPS WJ, 1987, GROWTH, V51, P372
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Linz A, 2015, J BONE MINER RES, V30, P1481, DOI 10.1002/jbmr.2484
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Makareeva E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200264
   Makareeva E, 2011, TRENDS CELL BIOL, V21, P168, DOI 10.1016/j.tcb.2010.11.007
   MARINI JC, 1993, AM J MED GENET, V45, P261, DOI 10.1002/ajmg.1320450223
   MARINI JC, 1993, J CLIN ENDOCR METAB, V76, P251, DOI 10.1210/jc.76.1.251
   Marini JC, 2003, J BONE MINER RES, V18, P237, DOI 10.1359/jbmr.2003.18.2.237
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   Mirigian LS, 2016, J BONE MINER RES, V31, P1608, DOI 10.1002/jbmr.2824
   Mullan LA, 2017, J CLIN INVEST, V127, P3861, DOI 10.1172/JCI93094
   Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104
   Nishimura R, 2012, J BIOL CHEM, V287, P33179, DOI 10.1074/jbc.M111.337063
   Otsuru S, 2018, CYTOTHERAPY, V20, P62, DOI 10.1016/j.jcyt.2017.09.012
   Otsuru S, 2015, CYTOTHERAPY, V17, P262, DOI 10.1016/j.jcyt.2014.10.013
   Otsuru S, 2012, BLOOD, V120, P1933, DOI 10.1182/blood 2011 12 400085
   Pakos Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195
   Palomo T, 2015, J BONE MINER RES, V30, P2150, DOI 10.1002/jbmr.2567
   Patterson SE, 2014, DEV DYNAM, V243, P875, DOI [10.1002/DVDY.24131, 10.1002/dvdy.24131]
   Qiu T, 2015, J BONE MINER RES, V30, P309, DOI 10.1002/jbmr.2327
   Rajpar MH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000691
   Rauch F, 2009, J BONE MINER RES, V24, P1282, DOI [10.1359/jbmr.090213, 10.1359/JBMR.090213]
   SANGUINETTI C, 1990, J BONE JOINT SURG BR, V72, P475, DOI 10.1302/0301 620X.72B3.2187879
   Sarathchandra P, 2005, MICRON, V36, P715, DOI 10.1016/j.micron.2005.05.014
   Scheiber AL, 2019, BIOCHEM BIOPH RES CO, V509, P235, DOI 10.1016/j.bbrc.2018.12.111
   Sinder BP, 2015, BONE, V71, P115, DOI 10.1016/j.bone.2014.10.012
   Stoss H, 1985, Prog Clin Biol Res, V200, P343
   Tan ZJ, 2020, J BONE MINER RES, V35, P2444, DOI 10.1002/jbmr.4132
   Tsang KY, 2007, PLOS BIOL, V5, P568, DOI 10.1371/journal.pbio.0050044
   Tsang KY, 2019, CURR OPIN CELL BIOL, V61, P132, DOI 10.1016/j.ceb.2019.07.011
   Uveges TE, 2008, J BONE MINER RES, V23, P1983, DOI 10.1359/JBMR.080804
   Wang C, 2018, ELIFE, V7, DOI 10.7554/eLife.37673
   Wang WG, 2014, BIRTH DEFECTS RES C, V102, P37, DOI 10.1002/bdrc.21058
   Ward LM, 2011, J CLIN ENDOCR METAB, V96, P355, DOI 10.1210/jc.2010 0636
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yan B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11151
   Yang G, 2014, CELL RES, V24, P1266, DOI 10.1038/cr.2014.111
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Yao XM, 2013, ANN BIOMED ENG, V41, P1139, DOI 10.1007/s10439 013 0793 7
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
   Zieba J, 2020, J BONE MINER RES, V35, P1132, DOI 10.1002/jbmr.3979
NR 80
TC 27
Z9 28
U1 0
U2 3
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD FEB 8
PY 2022
VL 7
IS 3
AR e149636
DI 10.1172/jci.insight.149636
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA YX5TT
UT WOS:000754166000001
PM 34990412
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bermeo, S
   Al Saedi, A
   Vidal, C
   Khalil, M
   Pang, M
   Troen, BR
   Myers, D
   Duque, G
AF Bermeo, Sandra
   Al Saedi, Ahmed
   Vidal, Christopher
   Khalil, Mamdouh
   Pang, Manhui
   Troen, Bruce R.
   Myers, Damian
   Duque, Gustavo
TI Treatment with an inhibitor of fatty acid synthase attenuates bone loss
   in ovariectomized mice
SO BONE
LA English
DT Article
DE Cerulenin; Fatty acid synthase; Adipogenesis; Osteoblastogenesis;
   Osteoporosis
ID ADIPOSE TISSUE; MARROW FAT; CERULENIN; MECHANISMS; BROWN; LIPOTOXICITY;
   OSTEOPOROSIS; APOPTOSIS; OBESITY; DIET
AB Bone and fat cells have an antagonistic relationship. Adipocytes exert a toxic effect on bone cells in vitro through the secretion of fatty acids, which are synthesized by fatty acid synthase (FAS). Inhibition of FAS in vitro rescues osteoblasts from fat induced toxicity and cell death. In this study, we hypothesized that FAS inhibition would mitigate the loss of bone mass in ovariectomized (OVX) mice. We treated OVX C57BL/6 mice with cerulenin (a known inhibitor of FAS) for 6 weeks and compared their bone phenotype with vehicle treated controls. Cerulenin treated mice exhibited a significant decrease in body weight, triglycerides, leptin, and marrow and subcutaneous fat without changes in serum glucose or calciotropic hormones. These effects were associated with attenuation of bone loss and normalization of the bone phenotype in the cerulenin treated OVX group compared to the vehicle treated OVX group. Our results demonstrate that inhibition of FAS enhances bone formation, induces uncoupling between osteoblasts and osteoclasts, and favors mineralization, thus providing evidence that inhibition of FAS could constitute a new anabolic therapy for osteoporosis.
C1 [Bermeo, Sandra; Vidal, Christopher; Duque, Gustavo] Univ Sydney, Sydney Med Sch Nepean, Penrith, NSW 2750, Australia.
   [Bermeo, Sandra] Univ Simon Bolivar, Fac Ciencias Basicas & Biomed, Barranquilla, Colombia.
   [Al Saedi, Ahmed; Myers, Damian; Duque, Gustavo] Univ Melbourne, Australian Inst Musculoskeletal Sci AIMSS, 176 Furlong Rd, St Albans, Vic 3021, Australia.
   [Al Saedi, Ahmed; Myers, Damian; Duque, Gustavo] Western Hlth, 176 Furlong Rd, St Albans, Vic 3021, Australia.
   [Al Saedi, Ahmed; Myers, Damian; Duque, Gustavo] Univ Melbourne, Melbourne Med Sch, Dept Med, Western Hlth, St Albans, Vic 3021, Australia.
   [Khalil, Mamdouh] Univ Sydney, Sydney Med Sch Concord, ANZAC Res Inst, Concord, NSW 2137, Australia.
   [Pang, Manhui; Troen, Bruce R.] Univ Buffalo, Vet Affairs Western New York Healthcare Syst, Jacobs Sch Med & Biomed Sci, Div Geriatr & Palliat Med, Buffalo, NY USA.
   [Pang, Manhui; Troen, Bruce R.] Univ Buffalo, Vet Affairs Western New York Healthcare Syst, Res Serv, Buffalo, NY USA.
C3 University of Sydney; University of Melbourne; Australian Institute for
   Musculoskeletal Science; University of Melbourne; University of Sydney;
   ANZAC Research Institute; State University of New York (SUNY) System;
   University at Buffalo, SUNY; State University of New York (SUNY) System;
   University at Buffalo, SUNY
RP Duque, G (通讯作者)，Univ Melbourne, Australian Inst Musculoskeletal Sci AIMSS, 176 Furlong Rd, St Albans, Vic 3021, Australia.; Duque, G (通讯作者)，Western Hlth, 176 Furlong Rd, St Albans, Vic 3021, Australia.
EM gustavo.duque@unimelb.edu.au
RI Duque, Gustavo/HDO 1243 2022; Bermeo, Sandra/L 9886 2016; Troen,
   Bruce/ABB 4959 2021; Myers, Damian/L 5302 2013; Duque,
   Gustavo/G 6656 2015
OI Bermeo, Sandra/0000 0002 4524 5381; Myers, Damian/0000 0002 7569 9907;
   Troen, Bruce/0000 0002 3699 0021; Duque, Gustavo/0000 0001 8126 0637; Al
   Saedi, Ahmed/0000 0002 2479 5317
FU Australian National Health and Medical Research Council [NHMRC 632767];
   Australian Institute for Musculoskeletal Science (AIMSS); Nepean Medical
   Research Foundation; U.S. Department of Veterans Affairs (Merit Review);
   Indian Trail Foundation; Miami VAHS GRECC; Miami VAHS Research Service
FX This study was supported by grants from the Australian National Health
   and Medical Research Council (NHMRC 632767), the Australian Institute
   for Musculoskeletal Science (AIMSS), the Nepean Medical Research
   Foundation, the U.S. Department of Veterans Affairs (Merit Review), and
   the Indian Trail Foundation. Support was also received from the Miami
   VAHS GRECC and Research Service. M. Hernandez and M. Rodriguez provided
   technical assistance. The authors would like to thank Professor David
   Handelsman for his continuous support to this study.
CR Akter R, 2009, J BONE MINER RES, V24, P283, DOI 10.1359/JBMR.081010
   Ambrosi TH, 2017, J MOL MED, V95, P1291, DOI 10.1007/s00109 017 1604 7
   [Anonymous], 2005, STEDMANS LIPOTOXICIT, P2100
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cao JJ, 2010, ANN NY ACAD SCI, V1192, P292, DOI 10.1111/j.1749 6632.2009.05252.x
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Duque G, 2013, J BONE MINER RES, V28, P639, DOI 10.1002/jbmr.1782
   Duque G, 2011, BONE, V49, P412, DOI 10.1016/j.bone.2011.04.023
   Elbaz A, 2010, J CELL MOL MED, V14, P982, DOI 10.1111/j.1582 4934.2009.00751.x
   Fu DH, 2009, EUR J DRUG METAB PH, V34, P67
   Gunaratnam K, 2013, BIOL OPEN, V2, P1382, DOI 10.1242/bio.20136700
   Gunaratnam K, 2014, ENDOCRINOLOGY, V155, P108, DOI 10.1210/en.2013 1712
   Ho TS, 2007, BIOMED PHARMACOTHER, V61, P578, DOI 10.1016/j.biopha.2007.08.020
   Ikeda K, 2018, TRENDS ENDOCRIN MET, V29, P191, DOI 10.1016/j.tem.2018.01.001
   Jin YJ, 2004, ENDOCRINOLOGY, V145, P3197, DOI 10.1210/en.2004 0039
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim YM, 2010, J BIOL CHEM, V285, P29069, DOI 10.1074/jbc.M110.120386
   Krings A, 2012, BONE, V50, P546, DOI 10.1016/j.bone.2011.06.016
   Kühn MC, 2012, MOL CELL ENDOCRINOL, V349, P180, DOI 10.1016/j.mce.2011.10.018
   Lecka Czernik B, 2018, CURR OSTEOPOROS REP, V16, P123, DOI 10.1007/s11914 018 0426 z
   Li W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019313
   Liu ZL, 2012, MOL MED REP, V5, P326, DOI 10.3892/mmr.2011.661
   Ludgero Correia A, 2012, NUTRITION, V28, P316, DOI 10.1016/j.nut.2011.07.014
   Mobbs CV, 2002, NAT MED, V8, P335, DOI 10.1038/nm0402 335
   Murata S, 2010, CANCER SCI, V101, P1861, DOI 10.1111/j.1349 7006.2010.01596.x
   Nadal Casellas A, 2011, STEROIDS, V76, P1051, DOI 10.1016/j.steroids.2011.04.009
   Oh SR, 2010, J LIPID RES, V51, P892, DOI [10.1194/jlr.M800626 JLR200, 10.1194/jlr.M800626]
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pizer ES, 1998, CANCER RES, V58, P4611
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Ruan F, 2012, BIOSCIENCE REP, V32, P511, DOI 10.1042/BSR20110118
   Schmid B, 2005, BIOCHEM BIOPH RES CO, V328, P1073, DOI 10.1016/j.bbrc.2005.01.067
   Sepe A, 2011, GERONTOLOGY, V57, P66, DOI 10.1159/000279755
   Singh L, 2018, CURR OSTEOPOROS REP, V16, P130, DOI 10.1007/s11914 018 0427 y
   Smith SR, 2011, OBESITY, V19, P1796, DOI 10.1038/oby.2011.143
   Turner RT, 2013, J BONE MINER RES, V28, P22, DOI 10.1002/jbmr.1734
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Wu M, 2011, P NATL ACAD SCI USA, V108, P5378, DOI 10.1073/pnas.1002588108
NR 40
TC 20
Z9 22
U1 2
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2019
VL 122
BP 114
EP 122
DI 10.1016/j.bone.2019.02.017
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HT7UK
UT WOS:000464769700013
PM 30779961
DA 2025 08 17
ER

PT J
AU Clézardin, P
AF Clézardin, P
TI Anti tumour activity of zoledronic acid
SO CANCER TREATMENT REVIEWS
LA English
DT Article; Proceedings Paper
CT Satellite Symposium on Evidence and Experience   Zoledronic Acid in
   Cancer Induced Bone Disease
CY MAR 20 24, 2005
CL Davos, SWITZERLAND
DE zoledronic acid; bisphosphonates; anti tumour; cancer; angiogenesis;
   metastases; apoptosis
ID PROSTATE CANCER CELLS; MOUSE BREAST CANCER; DELTA T CELLS; IN VITRO;
   BISPHOSPHONATE IBANDRONATE; MULTIPLE MYELOMA; BONE METASTASIS;
   TUMOR CELLS; MICE; APOPTOSIS
AB Bisphosphonates are proven to be effective in the treatment of benign or malignant skeletal diseases characterized by enhanced osteoclastic bone resorption. Nitrogen containing bisphosphonates (N BPs) have also been demonstrated to exhibit direct anti tumour effects. They not only inhibit proliferation and induce apoptosis in cultured cancer cells, but additionally interfere with adhesion of cancer cells to the bone matrix and inhibit cell migration and invasion. These effects are potentiated when N BPs are combined with anticancer drugs like taxoids, doxorubicin or imatinib. Zotedronic acid is a highly potent N BP that has been particularly well investigated, preclinically and in clinical practice. Growing preclinical evidence shows that zoledronic acid also exhibits direct anti tumour activity. The overall effects on tumour cells appear to be mediated via diverse pathways, such as apoptosis, angiostasis, cell cell interactions and immunomodulation. The current insights and fronts of ongoing research are reviewed. Higher doses of zoledronic acid or more frequent applications than currently approved may be required to achieve clinically meaningful anti tumour effects. The future challenge is to focus on optimizing dosing regimens and drug combinations to maximize the anti tumour potential of zoledronic acid and to take advantage of the observed synergy with standard neoplastic agents. (C) 2005 Elsevier Ltd. All rights reserved.
C1 RTH Laennec, INSERM, U664, Fac Med, F 69372 Lyon 08, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Clézardin, P (通讯作者)，RTH Laennec, INSERM, U664, Fac Med, 7 11 Rue Guillaume Paradin, F 69372 Lyon 08, France.
EM clezardin@lyon.inserm.fr
RI Clezardin, Philippe/M 8071 2014
OI Clezardin, Philippe/0000 0003 0149 4463
CR Avcu F, 2005, EUR J HAEMATOL, V74, P496, DOI 10.1111/j.1600 0609.2005.00427.x
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Boissier S, 1997, CANCER RES, V57, P3890
   Brown JE, 2004, ENDOCR RELAT CANCER, V11, P207, DOI 10.1677/erc.0.0110207
   Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Cohen DM, 2004, METAB ENG, V6, P59, DOI 10.1016/j.ymben.2003.10.001
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fournier P, 2002, CANCER RES, V62, P6538
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hiraga T, 2003, INT J CANCER, V106, P973, DOI 10.1002/ijc.11330
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kim SJ, 2005, CANCER RES, V65, P3707, DOI 10.1158/0008 5472.CAN 04 3601
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Lee YP, 2002, CANCER RES, V62, P5564
   Mariani S, 2005, LEUKEMIA, V19, P664, DOI 10.1038/sj.leu.2403693
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Michigami T, 2002, BREAST CANCER RES TR, V75, P249, DOI 10.1023/A:1019905111666
   Mönkkönen H, 2004, BONE, V34, pS66
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Ramnath Nithya, 2004, Curr Oncol Rep, V6, P96, DOI 10.1007/s11912 004 0020 7
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Shipman CM, 2000, BRIT J HAEMATOL, V111, P283, DOI 10.1046/j.1365 2141.2000.02310.x
   Sohara Y, 2003, CANCER RES, V63, P3026
   Stearns ME, 1996, INVAS METAST, V16, P116
   Ulle' n A, 2003, P AN M AM SOC CLIN, V22, P432
   Vogt U, 2004, ONCOL REP, V12, P1109
   Walsh JP, 2004, MED J AUSTRALIA, V181, P262, DOI 10.5694/j.1326 5377.2004.tb06265.x
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yamagishi S, 2004, AM J PATHOL, V165, P1865, DOI 10.1016/S0002 9440(10)63239 7
   Yano S, 2003, CLIN CANCER RES, V9, P5380
NR 43
TC 53
Z9 62
U1 4
U2 10
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0305 7372
J9 CANCER TREAT REV
JI Cancer Treat. Rev.
PY 2005
VL 31
SU 3
BP S1
EP S8
DI 10.1016/j.ctrv.2005.09.002
PG 8
WC Oncology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 001TE
UT WOS:000234558600001
PM 16225995
DA 2025 08 17
ER

PT J
AU Cai, ZW
   Bai, L
   Li, QM
   Li, Y
   Cai, XX
   Lin, YF
AF Cai, Zhengwen
   Bai, Long
   Li, Qiumei
   Li, Yong
   Cai, Xiaoxiao
   Lin, Yunfeng
TI Gene Activating Framework Nucleic Acid Targeted Upregulating Sirtuin 1
   to Modulate Osteoimmune Microenvironment for Diabetic Osteoporosis
   Therapeutics
SO ACS NANO
LA English
DT Article
DE tetrahedral framework nucleic acid; small activatingRNA; sirtuin 1;
   osteoimmunology; diabeticosteoporosis; macrophage; osteoblast
ID MECHANISMS; MELLITUS; NAD(+); CELLS; BONE
AB Diabetic osteoporosis, a prevalent chronic complication of diabetes, is marked by reduced bone mass, increased bone fragility, and susceptibility to fractures. A significant cause of this condition is the disruption of osteoblastic homeostasis due to prolonged hyperglycemia, which impedes bone regeneration and remodeling. Despite its prevalence, no effective treatments specifically target diabetic osteoporosis. Recently, small activating RNA (saRNA) therapy has attracted attention for its targeting capacity, high efficacy, and minimal side effects. However, RNA's inherent properties, such as structural instability, susceptibility to degradation, and poor penetration, limit its applications. To address these limitations, a gene activating tetrahedral framework nucleic acid (tFNA) with sirtuin 1 (SIRT1) gene activation function is developed, termed Tsa. Tsa exhibits an RNA protecting effect and can effectively penetrate cell membranes to upregulate SIRT1 gene expression. At the histological level, Tsa treatment alleviates diabetic osteoporosis by increasing bone trabecular density and promoting new bone formation. At the cellular level, it switches macrophage polarization toward the anti inflammatory M2 phenotype while inhibiting the inflammatory M1 phenotype, creating a favorable bone immune microenvironment for osteoblasts. At the genetic level, Tsa activates SIRT1 expression, which deacetylates Acetyl p65 to block the NF kappa B pathway and restore the osteoimmune environment. Overall, this research demonstrates a nanodrug "Tsa", capable of activating SIRT1 and modulating the bone immune environment, thereby showcasing its immense potential for diabetic osteoporosis treatment.
C1 [Cai, Zhengwen; Bai, Long; Li, Yong; Cai, Xiaoxiao; Lin, Yunfeng] Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Cai, Zhengwen; Cai, Xiaoxiao; Lin, Yunfeng] Sichuan Prov Engn Res Ctr Oral Biomat, Chengdu 610041, Sichuan, Peoples R China.
   [Bai, Long; Li, Qiumei] Southwest Med Univ, Affiliated Stomatol Hosp, Dept Oral Implantol, Luzhou 646000, Peoples R China.
   [Lin, Yunfeng] Shanghai Jiao Tong Univ, Natl Ctr Translat Med, Shanghai 200240, Peoples R China.
C3 Sichuan University; Southwest Medical University; Shanghai Jiao Tong
   University
RP Lin, YF (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Lin, YF (通讯作者)，Sichuan Prov Engn Res Ctr Oral Biomat, Chengdu 610041, Sichuan, Peoples R China.; Lin, YF (通讯作者)，Shanghai Jiao Tong Univ, Natl Ctr Translat Med, Shanghai 200240, Peoples R China.
EM yunfenglin@scu.edu.cn
RI Cai, Zhengwen/JFS 3859 2023; Lin, Yunfeng/H 3393 2011; Cai,
   Xiaoxiao/C 4868 2018; Long, Bai/JDC 3687 2023
OI Lin, Yunfeng/0000 0003 1224 6561; Cai, Xiaoxiao/0000 0002 5654 7414;
   Cai, Zhengwen/0000 0001 9204 3398
FU Sichuan Provincial Science and Technology Support Program [82370929];
   National Natural Science Foundation of China [2022NSFSC0002]; Sichuan
   Science and Technology Program [2022JDTD0021]; Sichuan Province Youth
   Science and Technology Innovation Team [RD03202302, RCDWJS2024 1];
   Research and Develop Program, West China Hospital of Stomatology Sichuan
   University; State Key Laboratory of Oral Disease Research of Sichuan
   University
FX This study was supported by the National Natural Science Foundation of
   China (82370929), the Sichuan Science and Technology Program
   (2022NSFSC0002), the Sichuan Province Youth Science and Technology
   Innovation Team (2022JDTD0021), and Research and Develop Program, West
   China Hospital of Stomatology Sichuan University (RD03202302 and
   RCDWJS2024 1). The authors would like to thank to Liying Hao (State Key
   Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan
   University) for help in characterizing AFM and thank to my wife Zhongyu
   Jiang (Sichuan University) for help in schematics design and
   optimization. All animal experiments are approved by the Ethics
   Committee of the State Key Laboratory of Oral Disease Research of
   Sichuan University.
CR Anderson KA, 2014, CELL, V159, DOI 10.1016/j.cell.2014.10.045
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Bjornstad P, 2021, NEW ENGL J MED, V385, P416, DOI 10.1056/NEJMoa2100165
   Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93
   Cai ZW, 2023, ACS NANO, V17, P22668, DOI 10.1021/acsnano.3c06999
   Cantó C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chen XY, 2024, ADV MATER, V36, DOI 10.1002/adma.202406118
   Chen Y, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392 024 01736 0
   Chen Y, 2021, LIFE SCI, V269, DOI 10.1016/j.lfs.2021.119041
   Crooke ST, 2018, CELL METAB, V27, P714, DOI 10.1016/j.cmet.2018.03.004
   Ebeling PR, 2022, ENDOCR REV, V43, P240, DOI 10.1210/endrev/bnab028
   Escalona Garrido C, 2020, MOL METAB, V42, DOI 10.1016/j.molmet.2020.101097
   Ge YC, 2024, ADV SCI, V11, DOI 10.1002/advs.202308701
   He M, 2020, CELL METAB, V31, P580, DOI 10.1016/j.cmet.2020.01.009
   Huang W, 2012, ACTA PHARMACOL SIN, V33, P668, DOI 10.1038/aps.2011.189
   Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860
   Jiang XQ, 2024, ACS NANO, V18, P4269, DOI 10.1021/acsnano.3c09721
   Jin C, 2023, J AGR FOOD CHEM, P2745, DOI 10.1021/acs.jafc.2c05632
   Jin SE, 2024, ACTA BIOMATER, V177, P91, DOI 10.1016/j.actbio.2024.01.043
   Khosla S, 2021, NAT REV ENDOCRINOL, V17, P685, DOI 10.1038/s41574 021 00555 5
   Kingwell K, 2021, NAT REV DRUG DISCOV, V20, P573, DOI 10.1038/d41573 021 00127 2
   Li B, 2020, CELL MOL IMMUNOL, V17, P976, DOI 10.1038/s41423 019 0257 6
   Li HR, 2023, REDOX BIOL, V63, DOI 10.1016/j.redox.2023.102745
   Li JJ, 2022, ADV MATER, V34, DOI 10.1002/adma.202202513
   Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103
   Li SY, 2024, NAT ELECTRON, V7, P216, DOI 10.1038/s41928 024 01129 9
   Li SH, 2022, ADV MATER, V34, DOI 10.1002/adma.202204287
   Long J, 2023, ADV SCI, V10, DOI 10.1002/advs.202302539
   Ma YX, 2024, ACS NANO, V18, P5418, DOI 10.1021/acsnano.3c10213
   Meng X, 2016, NUCLEIC ACIDS RES, V44, P2274, DOI 10.1093/nar/gkw076
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Paunovska K, 2022, NAT REV GENET, V23, P265, DOI 10.1038/s41576 021 00439 4
   Portnoy V, 2016, CELL RES, V26, P320, DOI 10.1038/cr.2016.22
   Sheu A, 2022, TRENDS ENDOCRIN MET, V33, P333, DOI 10.1016/j.tem.2022.02.006
   Simic P, 2013, EMBO MOL MED, V5, P430, DOI 10.1002/emmm.201201606
   Srivastava RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00657
   Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014
   Sun H, 2022, DIABETES RES CLIN PR, V183, DOI 10.1016/j.diabres.2021.109119
   Teng Y, 2023, ACTA PHARM SIN B, V13, P2269, DOI 10.1016/j.apsb.2023.02.018
   Wang YL, 2023, BIOACT MATER, V28, P273, DOI 10.1016/j.bioactmat.2023.05.018
   Winkle M, 2021, NAT REV DRUG DISCOV, V20, P629, DOI 10.1038/s41573 021 00219 z
   Xourafa G, 2024, NAT REV ENDOCRINOL, V20, P27, DOI 10.1038/s41574 023 00898 1
   Yao L, 2025, ADV MATER, V37, DOI 10.1002/adma.202414336
   You YZ, 2023, BBA MOL BASIS DIS, V1869, DOI 10.1016/j.bbadis.2023.166815
   Yuan Q, 2018, INFLAMMATION, V41, P2149, DOI 10.1007/s10753 018 0858 8
   Zhang T, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202213401
   Zhang T, 2022, ADV MATER, DOI 10.1002/adma.202107820
   Zhang T, 2020, NAT PROTOC, V15, P2728, DOI 10.1038/s41596 020 0355 z
   Zheng Y, 2018, NAT REV ENDOCRINOL, V14, P88, DOI 10.1038/nrendo.2017.151
NR 50
TC 6
Z9 6
U1 31
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD DEC 17
PY 2024
VL 18
IS 52
BP 35214
EP 35229
DI 10.1021/acsnano.4c08727
EA DEC 2024
PG 16
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA Q8U2T
UT WOS:001379948500001
PM 39689347
DA 2025 08 17
ER

PT J
AU Li, M
   Yao, MY
   Wang, WD
   Wan, P
   Chu, X
   Zheng, YF
   Yang, K
   Zhang, Y
AF Li, Mei
   Yao, Mengyu
   Wang, Weidan
   Wan, Peng
   Chu, Xiao
   Zheng, Yufeng
   Yang, Ke
   Zhang, Yu
TI Nitrogen containing bisphosphonate loaded micro arc oxidation coating
   for biodegradable magnesium alloy pellets inhibits osteosarcoma through
   targeting of the mevalonate pathway
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Magnesium alloy pellets; Bisphosphonates coating; Osteosarcoma;
   Multicellular spheroids model; Mevalonate pathway
AB Osteosarcoma (OS) remains one of the most threatening primary malignant human tumors of the bone, especially in the first or second decade of life. Unfortunately, the clinical therapeutic efficacy has not substantially improved over the past four decades. Therefore, to achieve efficient tumor eradication, a new approach to prevent tumor recurrence is urgently needed. Here, we develop a new bisphosphonate (BP) loaded microarc oxidation (MAO) coated magnesium strontium (Mg Sr) alloy pellet that can inhibit OS, and we illuminate the cellular and molecular mechanisms of the inhibiting effect. To generate such pellets, nitrogen containing BP is chemically conjugated with a MAO coating on hollow Mg Sr alloys. We demonstrate that BP coated Mg pellet has multiple desired features for OS therapy through in vitro and in vivo studies. At the cellular level, BP coated Mg pellets not only induce apoptosis and necrosis, as well as antitumor invasion of OS cells in the two dimensional (2D) cell culture environment, but also damage the formation of multicellular tumor spheroids by OS cell lines in the three dimensional (3D) cell culture environment. At the in vivo level, BP coated Mg pellets can destroy tumors and prevent neoplasm recurrence via synergistic Mg degradation and drug release. It is further suggested that the superior inhibitory effect on OS of our pellet is achieved by inhibiting the mevalonate pathway at the molecular level. Hence, these results collectively show that the BP coated Mg pellet is a promising candidate for future applications in repairing defects after tumor removal in OS therapy.
   Statement of significance
   Osteosarcoma (OS) is prone to metastases and unfavorable prognosis and the clinical therapeutic efficacy has not substantially improved over the past four decades. It is of high demand in developing new materials that can not only repair the bone defects but also inhibit OS in the lesion location. To solve these problems, we design a hollow Mg Sr alloy pellet that is modificated with micro arc oxidation coating and then loaded with Bisphosphonates (BP). Our results of the in vitro and in vivo biological assays show the inhibition effects and the corresponding signal pathway of BP coated Mg pellets on OS. Our work illustrates the process and mechanism of the tumor therapeutic efficacy for a new biomaterial, which could expand our understanding the ultimate principle of biomaterials induced tumor therapy. (c) 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Li, Mei; Chu, Xiao; Zhang, Yu] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Res Ctr Med Sci, Dept Orthoped, Guangzhou 510080, Peoples R China.
   [Yao, Mengyu] South China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou 510006, Peoples R China.
   [Yao, Mengyu] South China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Peoples R China.
   [Wang, Weidan] Dalian Univ, Dept Orthopaed, Affiliated Zhongshan Hosp, Dalian 116001, Peoples R China.
   [Wan, Peng] Dongguan Univ Technol, Sch Mat Sci & Engn, Dongguan 523808, Peoples R China.
   [Zheng, Yufeng] Peking Univ, Coll Engn, Dept Mat Sci & Engn, Beijing 100871, Peoples R China.
   [Yang, Ke] Chinese Acad Sci, Inst Met Res, Shenyang 110016, Peoples R China.
C3 Guangdong Academy of Medical Sciences & Guangdong General Hospital;
   Southern Medical University   China; South China University of
   Technology; South China University of Technology; Dalian University;
   Dongguan University of Technology; Peking University; Chinese Academy of
   Sciences; Institute of Metal Research, CAS
RP Zhang, Y (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Res Ctr Med Sci, Dept Orthoped, Guangzhou 510080, Peoples R China.; Wan, P (通讯作者)，Dongguan Univ Technol, Sch Mat Sci & Engn, Dongguan 523808, Peoples R China.
EM wanpeng@dgut.edu.cn; luck_2001@126.com
RI ; Li, Mei/KRQ 7982 2024; YAN, Zheng Guang/HGC 8374 2022
OI Wang, Weidan/0000 0001 6051 4888; Li, Mei/0000 0002 9265 8541; Zheng,
   Y.F./0000 0002 7402 9979; 
FU Natural Science Foundation of Guangdong Province, China
   [2020A1515011447]; National Key Research Program of China
   [2017YFB0702604]; National Natural Science Foundation of China
   [31771038]; Scientific and Technological Projects of Guangzhou, China
   [202002030283]; DGUT [GC300501 082]
FX The authors gratefully acknowledge the financial support from the
   Natural Science Foundation of Guangdong Province, China (Grant No.
   2020A1515011447), the National Key Research Program of China (Grant No.
   2017YFB0702604), the National Natural Science Foundation of China (Grant
   No. 31771038), the Scientific and Technological Projects of Guangzhou,
   China (Grant No. 202002030283), and research start up funds of DGUT (No.
   GC300501 082). All animal experiments were approved and performed in
   compliance with the local ethics committee and Guangdong Provincial
   People's Hospital institutional guidelines.
CR Anwar MA, 2020, SEMIN CANCER BIOL, V64, P83, DOI 10.1016/j.semcancer.2019.05.018
   Coathup MJ, 2015, CLIN ORTHOP RELAT R, V473, P1505, DOI 10.1007/s11999 014 4116 6
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Dai XY, 2019, CANCER LETT, V442, P202, DOI 10.1016/j.canlet.2018.10.022
   Dowless M., CLIN CANC RES, V24, P6028
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Feng QH, 2019, ACS APPL MATER INTER, V11, P32729, DOI 10.1021/acsami.9b10948
   Gabizon A.A., 2019, SEMIN CANCER BIOL, P30396
   Göbel A, 2016, CANCER LETT, V375, P162, DOI 10.1016/j.canlet.2016.03.004
   Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465
   Grimer RJ, 2005, LANCET ONCOL, V6, P85, DOI 10.1016/S1470 2045(05)01734 1
   Grosset AA, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002847
   Han G, 2016, WORLD J SURG, V40, P2016, DOI 10.1007/s00268 016 3500 7
   Han JJ, 2016, MAT SCI ENG C MATER, V58, P799, DOI 10.1016/j.msec.2015.09.057
   Harnden K, 2015, J NATL COMPR CANC NE, V13, P480, DOI 10.6004/jnccn.2015.0061
   Henry KL, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aam8216
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097
   Kaymak I, 2020, CANCER RES, V80, P189, DOI 10.1158/0008 5472.CAN 19 0650
   Kögel D, 2020, CELLS BASEL, V9, DOI 10.3390/cells9030574
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Li C, 2016, MAT SCI ENG A STRUCT, V657, P347, DOI 10.1016/j.msea.2016.01.075
   Li CM, 2020, NAT REV MATER, V5, P61, DOI 10.1038/s41578 019 0150 z
   Li GY, 2018, ACTA BIOMATER, V65, P486, DOI 10.1016/j.actbio.2017.10.033
   Li M, 2018, ACTA BIOMATER, V77, P365, DOI 10.1016/j.actbio.2018.07.028
   Li M, 2014, J MATER SCI TECHNOL, V30, P888, DOI 10.1016/j.jmst.2014.04.010
   Li Y, 2019, ORTHOP SURG, V11, P451, DOI 10.1111/os.12483
   Ma HS, 2018, ACTA BIOMATER, V79, P37, DOI 10.1016/j.actbio.2018.08.026
   Mangat KS, 2011, EXPERT REV ANTICANC, V11, P205, DOI [10.1586/era.10.225, 10.1586/ERA.10.225]
   Moon SH, 2019, CELL, V176, P564, DOI 10.1016/j.cell.2018.11.011
   Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76
   Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013
   Ohba T, 2014, J BONE MINER RES, V29, P1431, DOI 10.1002/jbmr.2182
   Ory B, 2016, CLIN CANCER RES, V22, P2520, DOI 10.1158/1078 0432.CCR 15 1925
   Otto S, 2010, J ORAL MAXIL SURG, V68, P2837, DOI 10.1016/j.joms.2010.07.017
   Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138
   Palumbo BT, 2011, CANCER CONTROL, V18, P160, DOI 10.1177/107327481101800303
   Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6
   Pietrovito L, 2019, CURR CANCER DRUG TAR, V19, P807, DOI 10.2174/1568009619666190115142858
   Qiao H, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0008 9
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Roskoski R Jr, 2019, PHARMACOL RES, V139, P471, DOI 10.1016/j.phrs.2018.11.035
   Tang QL, 2017, EUR J PHARMACOL, V814, P169, DOI 10.1016/j.ejphar.2017.08.010
   Thierfelder S, 1996, KLIN MONATSBL AUGENH, V208, P243, DOI 10.1055/s 2008 1035204
   Vanderburgh J, 2020, ACS NANO, V14, P311, DOI 10.1021/acsnano.9b04571
   Veth R, 2003, LANCET ONCOL, V4, P343, DOI 10.1016/S1470 2045(03)01114 8
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   WILFLINGSEDER P, 1981, CHIR PLAST, V6, P105, DOI 10.1007/BF00289635
   Witte F, 2010, ACTA BIOMATER, V6, P1680, DOI 10.1016/j.actbio.2010.02.028
   Wu Q, 2018, NANOSCALE HORIZ, V3, DOI 10.1039/c8nh00113h
   Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070
   Zhang WJ, 2019, TRENDS CANCER, V5, P95, DOI 10.1016/j.trecan.2018.12.004
   Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162
   Zils K, 2013, ANN ONCOL, V24, P2190, DOI 10.1093/annonc/mdt154
NR 55
TC 22
Z9 25
U1 10
U2 97
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD FEB
PY 2021
VL 121
BP 682
EP 694
DI 10.1016/j.actbio.2020.11.019
EA JAN 2021
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA QB9XG
UT WOS:000614487800005
PM 33220487
DA 2025 08 17
ER

PT J
AU Figura, N
   Smith, J
   Yu, HHM
AF Figura, Nicholas
   Smith, Joshua
   Yu, Hsiang Hsuan Michael
TI Mechanisms of, and Adjuvants for, Bone Pain
SO HEMATOLOGY ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Metastatic; Bone; Pain; NGF; Bisphosphonate; RANKL inhibitor;
   Kyphoplasty; Vertebroplasty
ID NERVE GROWTH FACTOR; SPINAL CORD COMPRESSION; CANCER PAIN;
   BREAST CANCER; TUMOR GROWTH; RADIOFREQUENCY ABLATION;
   METASTATIC DISEASE; LOCAL INJECTION; SCORING SYSTEM; MURINE MODEL
AB Metastatic bone pain is a complex, poorly understood process. Understanding the unique mechanisms causing cancer induced bone pain may lead to potential therapeutic targets. This article discusses the effects of osteoclast overstimulation within the tumor microenvironment; the role of inflammatory factors at the tumor nociceptor interface; the development of structural instability, causing mechanical nerve damage; and, ultimately, the neuroplastic changes in the setting of sustained pain. Several adjuvant therapies are available to attenuate metastatic bone pain. This article discusses the role of pharmacologic therapies, surgery, kyphoplasty, vertebroplasty, and radiofrequency ablation.
C1 [Figura, Nicholas; Yu, Hsiang Hsuan Michael] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.
   [Smith, Joshua] H Lee Moffitt Canc Ctr & Res Inst, Dept Support Care Med, 12902 Magnolia Dr, Tampa, FL 33612 USA.
C3 H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer
   Center & Research Institute
RP Figura, N (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM nicholas.figura@moffitt.org
OI Yu, Hsiang Hsuan/0000 0002 0621 9519
CR Aaron AD, 1997, J BONE JOINT SURG AM, V79A, P917, DOI 10.2106/00004623 199706000 00018
   ALOE L, 1992, ARTHRITIS RHEUM, V35, P351, DOI 10.1002/art.1780350315
   Apfel SC, 2000, JAMA J AM MED ASSOC, V284, P2215, DOI 10.1001/jama.284.17.2215
   Astolfi A, 2001, EUR J CANCER, V37, P1719, DOI 10.1016/S0959 8049(01)00190 3
   BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166 2236(94)90149 X
   Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Conte PF, 1996, J CLIN ONCOL, V14, P2552, DOI 10.1200/JCO.1996.14.9.2552
   Davar G, 2001, PAIN MED, V2, P24, DOI 10.1046/j.1526 4637.2001.002001024.x
   Davidson B, 2004, LUNG CANCER, V44, P159, DOI 10.1016/j.lungcan.2003.11.014
   Davidson B, 2003, CLIN CANCER RES, V9, P2248
   de Wit R, 2001, PAIN, V91, P339, DOI 10.1016/S0304 3959(00)00455 3
   Dollé L, 2003, ONCOGENE, V22, P5592, DOI 10.1038/sj.onc.1206805
   Dupuy DE, 2010, CANCER AM CANCER SOC, V116, P989, DOI 10.1002/cncr.24837
   Dyck PJ, 1997, NEUROLOGY, V48, P501, DOI 10.1212/WNL.48.2.501
   Farooqui M, 2007, BRIT J CANCER, V97, P1523, DOI 10.1038/sj.bjc.6604057
   Fourney DR, 2003, J NEUROSURG, V98, P21, DOI 10.3171/spi.2003.98.1.0021
   Gabriel K, 2004, SEMIN NEUROL, V24, P375, DOI 10.1055/s 2004 861532
   Gatti D, 1999, DRUG AGING, V15, P285, DOI 10.2165/00002512 199915040 00004
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815 04.2005
   Goetz MP, 2004, J CLIN ONCOL, V22, P300, DOI 10.1200/JCO.2004.03.097
   Gokin AP, 2001, J NEUROSCI, V21, P5358, DOI 10.1523/JNEUROSCI.21 14 05358.2001
   Gordon Williams Richard M, 2007, Curr Opin Support Palliat Care, V1, P6, DOI 10.1097/SPC.0b013e328133f5e9
   Greenlee RT, 2000, CA CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326
   Halvorson KG, 2005, CANCER RES, V65, P9426, DOI 10.1158/0008 5472.CAN 05 0826
   Hefti FF, 2006, TRENDS PHARMACOL SCI, V27, P85, DOI 10.1016/j.tips.2005.12.001
   Hong J, 2004, J ORTHOP RES, V22, P479, DOI 10.1016/orthres.2003.09.006
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306 4522(00)00110 X
   Honore P, 2000, Prog Brain Res, V129, P357
   Honore P, 2000, Prog Brain Res, V129, P389
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019
   Katz N, 2011, PAIN, V152, P2248, DOI 10.1016/j.pain.2011.05.003
   Khodorova A, 2002, J NEUROSCI, V22, P7788
   Kirschstein T, 1999, J NEUROPHYSIOL, V82, P2853, DOI 10.1152/jn.1999.82.6.2853
   KRISHNAMURTHY GT, 1977, JAMA J AM MED ASSOC, V237, P2504, DOI 10.1001/jama.237.23.2504
   KRISHTAL OA, 1988, NEUROSCIENCE, V27, P995, DOI 10.1016/0306 4522(88)90203 5
   Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778
   Lopez Olivo MA, 2012, SUPPORT CARE CANCER, V20, P2985, DOI 10.1007/s00520 012 1563 z
   Mantyh PW, 2006, NAT REV NEUROSCI, V7, P797, DOI 10.1038/nrn1914
   Mantyh PW, 2011, ANESTHESIOLOGY, V115, P189, DOI 10.1097/ALN.0b013e31821b1ac5
   Masferrer JL, 2000, CANCER RES, V60, P1306
   McMahon SB, 1996, PHILOS T R SOC B, V351, P431, DOI 10.1098/rstb.1996.0039
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305 7372(98)90005 6
   Mercadante S, 2007, CURR OPIN ONCOL, V19, P308, DOI 10.1097/CCO.0b013e3281214400
   Meuser Thomas, 2001, Pain, V93, P247, DOI 10.1016/S0304 3959(01)00324 4
   MIRELS H, 1989, CLIN ORTHOP RELAT R, P256
   Moore BC, 2000, CURR MED CHEM, V7, P1131, DOI 10.2174/0929867003374273
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nelson JB, 2000, BJU INT, V85, P45, DOI 10.1046/j.1464 410X.2000.00063.x
   Nelson JB, 2008, CANCER AM CANCER SOC, V113, P2478, DOI 10.1002/cncr.23864
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140 6736(05)66954 1
   Peng XB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058361
   Pomonis JD, 2001, J NEUROSCI, V21, P999, DOI 10.1523/JNEUROSCI.21 03 00999.2001
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140 6736(99)01310 0
   Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896 6273(01)00547 5
   Price Nancy, 2004, Clin Lung Cancer, V5, P267
   Quang PN, 2010, PAIN, V149, P254, DOI 10.1016/j.pain.2010.02.009
   Ripamonti C, 1998, TUMORI J, V84, P442
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Seifert P, 2001, VIRCHOWS ARCH, V438, P228, DOI 10.1007/s004280000306
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   SIEGAL T, 1989, SPINE, V14, P223, DOI 10.1097/00007632 198902000 00015
   Singer HS, 1999, J NEURO ONCOL, V45, P1, DOI 10.1023/A:1006323523437
   Smith JS, 2011, SPINE, V36, P556, DOI 10.1097/BRS.0b013e3181eadd41
   Sopata M, 2015, PAIN, V156, P1703, DOI 10.1097/j.pain.0000000000000211
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896 6273(00)80564 4
   TUBIANAHULIN M, 1991, BONE, V12, pS9, DOI 10.1016/8756 3282(91)90059 R
   Urch CE, 2003, PAIN, V106, P347, DOI 10.1016/j.pain.2003.08.002
   Vasko MR, 1995, PROG BRAIN RES, V104, P367
   Wacnik PW, 2001, J NEUROSCI, V21, P9355, DOI 10.1523/JNEUROSCI.21 23 09355.2001
   WEIKERT DR, 1991, J BONE JOINT SURG BR, V73, P668, DOI 10.1302/0301 620X.73B4.2071657
   Wise JJ, 1999, SPINE, V24, P1943, DOI 10.1097/00007632 199909150 00014
   Wong R, 2002, Cochrane Database Syst Rev, pCD002068
NR 81
TC 16
Z9 20
U1 0
U2 12
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 8588
EI 1558 1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2018
VL 32
IS 3
BP 447
EP +
DI 10.1016/j.hoc.2018.01.006
PG 14
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA GI8DW
UT WOS:000434753000009
PM 29729780
DA 2025 08 17
ER

PT J
AU Dvorak, MM
   De Joussineau, C
   Carter, DH
   Pisitkun, T
   Knepper, MA
   Gamba, G
   Kemp, PJ
   Riccardi, D
AF Dvorak, Melita M.
   De Joussineau, Cyrille
   Carter, D. Howard
   Pisitkun, Trairak
   Knepper, Mark A.
   Gamba, Gerardo
   Kemp, Paul J.
   Riccardi, Daniela
TI Thiazide diuretics directly induce osteoblast differentiation and
   mineralized nodule formation by interacting with a sodium chloride
   co transporter in bone
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID RESORPTION IN VITRO; NA CL COTRANSPORTER; URINARY CALCIUM;
   HYDROCHLOROTHIAZIDE; CELLS; DENSITY; HYPERCALCIURIA; MECHANISMS;
   EXPRESSION; BINDING
AB Thiazide diuretics are used worldwide as a first choice drug for patients with uncomplicated hypertension. In addition to their anti hypertensive effect, thiazides increase bone mineral density and reduce the prevalence of fractures. Traditionally, these effects have been attributed to increased renal calcium reabsorption that occurs secondary to the inhibition of the thiazide sensitive sodium chloride cotransporter (NCC) in the distal tubule. The aim of the current study was to determine whether thiazides exert a direct bone forming effect independent of their renal action. We found that the osteoblasts of human and rat bone also express NCC, suggesting that these bone forming cells may be an additional target for thiazides. In vitro, NCC protein was virtually absent in proliferating human and fetal rat osteoblasts, whereas its expression dramatically increased during differentiation. Thiazides did not affect osteoblast proliferation, but directly stimulated the production of the osteoblast differentiation markers runtrelated transcription factor 2 (runx2) and osteopontin. Using overexpression/knockdown studies in fetal rat calvarial cells, we show that thiazides increase the formation of mineralized nodules, but loop diuretics do not. Overall, our study demonstrates that thiazides directly stimulate osteoblast differentiation and bone mineral formation independent of their effects in the kidney. Therefore, in addition to their use as anti hypertensive drugs, our results suggest that thiazides may find a role in the prevention and treatment of osteoporosis.
C1 Cardiff Univ, Sch Biosci, Cardiff CF10 3US, Wales.
   Cardiff Inst Tissue Engn & Repair, Cardiff, Wales.
   Univ Calif San Francisco, Dept Med, Endocrine Res Unit, San Francisco, CA 94143 USA.
   Univ Manchester, Tumer Dent Sch, Manchester M13 9PL, Lancs, England.
   NIH, NHLBI, Kidney & Electrolyte Metab Lab, Bethesda, MD 20892 USA.
   Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mol Physiol Unit, Mexico City 04510, DF, Mexico.
C3 Cardiff University; Cardiff University; University of California System;
   University of California San Francisco; University of Manchester;
   National Institutes of Health (NIH)   USA; NIH National Heart Lung &
   Blood Institute (NHLBI); Instituto Nacional de Ciencias Medicas y
   Nutricion Salvador Zubiran   Mexico; Universidad Nacional Autonoma de
   Mexico
RP Riccardi, D (通讯作者)，Cardiff Univ, Sch Biosci, Museum Ave, Cardiff CF10 3US, Wales.
EM riccardi@cardiff.ac.uk
RI ; Kemp, Paul/A 4634 2010; Gamba, Gerardo/P 4873 2016; Riccardi,
   Daniela/A 4674 2010; Knepper, Mark/AAF 8412 2020; de Joussineau,
   Cyrille/ITU 8428 2023
OI Pisitkun, Trairak/0000 0001 6677 2271; Kemp, Paul/0000 0003 2773 973X;
   Gamba, Gerardo/0000 0002 4378 9043; Riccardi,
   Daniela/0000 0002 7322 3163; 
FU Medical Research Council [G0600821] Funding Source: researchfish;
   Arthritis Research UK [16269] Funding Source: Medline; Medical Research
   Council [G0600821] Funding Source: Medline; Wellcome Trust [CRIG070159]
   Funding Source: Medline; Intramural NIH HHS [Z99 HL999999] Funding
   Source: Medline; MRC [G0600821] Funding Source: UKRI
CR ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203
   Aubin R, 1996, KIDNEY INT, V50, P1476, DOI 10.1038/ki.1996.461
   Barry ELR, 1997, AM J PHYSIOL CELL PH, V272, pC109, DOI 10.1152/ajpcell.1997.272.1.C109
   Biner HL, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134836
   BRICKMAN AS, 1972, J CLIN INVEST, V51, P945, DOI 10.1172/JCI106889
   Cruz DN, 2001, NEPHROL DIAL TRANSPL, V16, P691, DOI 10.1093/ndt/16.4.691 a
   DALLAS SL, 1994, J BIOL CHEM, V269, P6815
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Gamba G, 2005, PHYSIOL REV, V85, P423, DOI 10.1152/physrev.00011.2004
   GESEK FA, 1992, J CLIN INVEST, V90, P429, DOI 10.1172/JCI115878
   HALL TJ, 1994, CALCIFIED TISSUE INT, V55, P266, DOI 10.1007/BF00310404
   Hoover RS, 2003, J AM SOC NEPHROL, V14, P271, DOI 10.1097/01.ASN.0000043903.93452.D0
   JONES G, 1995, J BONE MINER RES, V10, P106
   Kamel HK, 2002, ANN INTERN MED, V136, P252, DOI 10.7326/0003 4819 136 3 200202050 00018
   Kim CH, 2000, METABOLISM, V49, P17, DOI 10.1016/S0026 0495(00)90563 8
   Kim GH, 1998, P NATL ACAD SCI USA, V95, P14552, DOI 10.1073/pnas.95.24.14552
   Kim GH, 1999, AM J PHYSIOL RENAL, V276, pF96, DOI 10.1152/ajprenal.1999.276.1.F96
   LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502
   Lalande A, 2001, J BONE MINER RES, V16, P361, DOI 10.1359/jbmr.2001.16.2.361
   Mayan H, 2002, J CLIN ENDOCR METAB, V87, P3248, DOI 10.1210/jc.87.7.3248
   Nicolet Barousse L, 2005, J BONE MINER RES, V20, P799, DOI 10.1359/JBMR.041238
   RAISZ LG, 1993, ENDOCRINOLOGY, V122, P1083
   VANDENBERG CJ, 1982, J CLIN ENDOCR METAB, V55, P23, DOI 10.1210/jcem 55 1 23
   WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605
NR 24
TC 98
Z9 116
U1 0
U2 7
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046 6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD SEP
PY 2007
VL 18
IS 9
BP 2509
EP 2516
DI 10.1681/ASN.2007030348
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 231YV
UT WOS:000250986000014
PM 17656470
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Mochmann, LH
   Bock, J
   Ortiz Tánchez, J
   Schlee, C
   Bohne, A
   Neumann, K
   Hofmann, WK
   Thiel, E
   Baldus, CD
AF Mochmann, L. H.
   Bock, J.
   Ortiz Tanchez, J.
   Schlee, C.
   Bohne, A.
   Neumann, K.
   Hofmann, W. K.
   Thiel, E.
   Baldus, C. D.
TI Genome wide screen reveals WNT11, a non canonical WNT gene, as a
   direct target of ETS transcription factor ERG
SO ONCOGENE
LA English
DT Article
DE ETS related gene (ERG); WNT11; acute leukemia; ERG target genes;
   6 bromoindirubin 3 oxime (BIO); morphological transformation
ID ACUTE MYELOID LEUKEMIA; EMBRYONIC STEM CELLS; T LYMPHOBLASTIC LEUKEMIA;
   PROSTATE CANCER; FAMILY; EXPRESSION; DIFFERENTIATION; TUMORIGENESIS;
   OVEREXPRESSION; TRANSFORMATION
AB E26 transforming sequence related gene (ERG) is a transcription factor involved in normal hematopoiesis and is dysregulated in leukemia. ERG mRNA overexpression was associated with poor prognosis in a subset of patients with T cell acute lymphoblastic leukemia (T ALL) and acute myeloid leukemia (AML). Herein, a genome wide screen of ERG target genes was conducted by chromatin immunoprecipitation on chip (ChIP chip) in Jurkat cells. In this screen, 342 significant annotated genes were derived from this global approach. Notably, ERG enriched targets included WNT signaling genes: WNT11, WNT2, WNT9A, CCND1 and FZD7. Furthermore, chromatin immunoprecipitation (ChIP) of normal and primary leukemia bone marrow material also confirmed WNT11 as a target of ERG in six of seven patient samples. A larger sampling of patient diagnostic material revealed that ERG and WNT11 mRNA were co expressed in 80% of AML (n = 30) and 40% in T ALL (n = 30) bone marrow samples. Small interfering RNA (siRNA) mediated knockdown of ERG confirmed down regulation of WNT11 transcripts. Conversely, in a tet on ERG inducible assay, WNT11 transcripts were co stimulated. A WNT pathway agonist, 6 bromoindirubin 3 oxime (BIO), was used to determine the effect of cell growth on the ERG inducible cells. The addition of BIO resulted in an ERG dependent proliferative growth advantage over ERG uninduced cells. Finally, ERG induction prompted morphological transformation whereby round unpolarized K562 cells developed elongated protrusions and became polarized. This morphological transformation could effectively be inhibited with BIO and with siRNA knockdown of WNT11. In conclusion, ERG transcriptional networks in leukemia converge on WNT signaling targets. Specifically, WNT11 emerged as a direct target of ERG. Potent ERG induction promoted morphological transformation through WNT11 signals. The findings in this study unravel new ERG directed molecular signals that may contribute to the resistance of current therapies in acute leukemia patients with poor prognosis characterized by high ERG mRNA expression. Oncogene (2011) 30, 2044 2056; doi:10.1038/onc.2010.582; published online 17 January 2011
C1 [Mochmann, L. H.; Bock, J.; Ortiz Tanchez, J.; Schlee, C.; Bohne, A.; Thiel, E.; Baldus, C. D.] Charite, Dept Hematol & Oncol, D 12203 Berlin, Germany.
   [Neumann, K.] Charite, Inst Biometr & Clin Epidemiol, Berlin, Germany.
   [Hofmann, W. K.] Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls
   University Heidelberg
RP Baldus, CD (通讯作者)，Charite, Dept Hematol & Oncol, Campus Benjamin Franklin,Hindenburgdamm 30, D 12203 Berlin, Germany.
EM claudia.baldus@charite.de
OI Mochmann, Liliana/0000 0002 6960 748X
FU Deutsche Krebshilfe (Max Eder Nachwuchsforderung)
FX This study was supported by a grant from the Deutsche Krebshilfe (Max
   Eder Nachwuchsforderung) to CDB. We thank Dr Martin Neumann (Department
   of Hematology and Oncology, Charite, Berlin, Germany) for his critical
   reading of the manuscript. We also thank Dr Anja Kuhl (Research Center
   ImmunoSciences, Charite, Berlin, Germany) for helpful advice and
   fluorescence microscopy assistance.
CR Anderson MK, 1999, DEVELOPMENT, V126, P3131
   Anton R, 2007, FEBS LETT, V581, P5247, DOI 10.1016/j.febslet.2007.10.012
   Baldus CD, 2004, P NATL ACAD SCI USA, V101, P3915, DOI 10.1073/pnas.0400272101
   Baldus CD, 2007, BRIT J HAEMATOL, V137, P387, DOI 10.1111/j.1365 2141.2007.06566.x
   Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580
   Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554
   Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854
   Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood 2007 08 105346
   Bohne A, 2009, LEUKEMIA RES, V33, P817, DOI 10.1016/j.leukres.2008.11.012
   Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141
   CHIANG J, 2009, P NATL ACAD SCI USA, V106, P3396
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Eisenberg CA, 1997, DEVELOPMENT, V124, P525
   Ellett F, 2009, MECH DEVELOP, V126, P220, DOI 10.1016/j.mod.2008.11.001
   Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636
   Flaherty MP, 2008, TRENDS CARDIOVAS MED, V18, P260, DOI 10.1016/j.tcm.2008.12.001
   GOMEZ JR, 2007, BLOOD, V109, P3462
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008 5472.CAN 10 0244
   Holmes T, 2008, STEM CELLS, V26, P1288, DOI 10.1634/stemcells.2007 0600
   Hu D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006640
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Iwamoto M, 2007, DEV BIOL, V305, P40, DOI 10.1016/j.ydbio.2007.01.037
   Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105
   Kong XT, 1997, BLOOD, V90, P1192
   Lai SL, 2009, CELL RES, V19, P532, DOI 10.1038/cr.2009.41
   LELINEK J, 2008, LEUKEMIA, V22, P1529
   Lin ZH, 2007, CANCER RES, V67, P5017, DOI 10.1158/0008 5472.CAN 06 3696
   Loughran SJ, 2008, NAT IMMUNOL, V9, P810, DOI 10.1038/ni.1617
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Marcucci G, 2005, J CLIN ONCOL, V23, P9234, DOI 10.1200/JCO.2005.03.6137
   MARTIN V, 2009, CANCER SCI, V3, P1
   Narod SA, 2008, BRIT J CANCER, V99, P847, DOI 10.1038/sj.bjc.6604558
   O'Neil J, 2007, ONCOGENE, V26, P6838, DOI 10.1038/sj.onc.1210766
   Rainis L, 2005, CANCER RES, V65, P7596, DOI 10.1158/0008 5472.CAN 05 0147
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Salek Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008 5472.CAN 09 0075
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076
   Shu JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008 5472.CAN 05 2629
   Singla DK, 2006, BIOCHEM BIOPH RES CO, V345, P789, DOI 10.1016/j.bbrc.2006.04.125
   Soda M, 2008, CELL SIGNAL, V20, P2317, DOI 10.1016/j.cellsig.2008.09.001
   SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294 146
   Stankiewicz MJ, 2009, BLOOD, V113, P3337, DOI 10.1182/blood 2008 08 174813
   Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679
   Uysal Onganer P, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 55
   Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106
   WU D, 2009, TREND BIOCH SCI, V722, P1
   Zhou WL, 2007, NAT GENET, V39, P1225, DOI 10.1038/ng2112
   Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008 5472.CAN 04 2704
NR 50
TC 32
Z9 35
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD APR
PY 2011
VL 30
IS 17
BP 2044
EP 2056
DI 10.1038/onc.2010.582
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 755YL
UT WOS:000289977400008
PM 21242973
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Xie, XX
   Chen, WW
   Xu, ML
   Chen, JC
   Yang, T
   Wang, CF
   Su, YG
   Zhao, JM
   Xu, JK
   Liu, Q
AF Xie, Xiaoxiao
   Chen, Weiwei
   Xu, Minglian
   Chen, Junchun
   Yang, Tao
   Wang, Chaofeng
   Su, Yuangang
   Zhao, Jinmin
   Xu, Jiake
   Liu, Qian
TI IKK/NF κB and ROS signal axes are involved in Tenacissoside H mediated
   inhibitory effects on LPS induced inflammatory osteolysis
SO CELL PROLIFERATION
LA English
DT Article
ID OXIDATIVE STRESS; BONE; OSTEOCLASTOGENESIS; DIFFERENTIATION; INJURY;
   MICE
AB Periodontal disease and arthroplasty prosthesis loosening and destabilization are both associated with osteolysis, which is predominantly caused by abnormal bone resorption triggered by pro inflammatory cytokines. Osteoclasts (OCs) are critical players in the process. Concerns regarding the long term efficacy and side effects of current frontline therapies, however, remain. Alternative therapies are still required. The aim of this work was to investigate the involvement of Tenacissoside H (TDH) in RANKL mediated OC differentiation, as well as inflammatory osteolysis and associated processes. In vitro, bone marrow derived macrophages (BMMs) cultured with RANKL and M CSF were used to detect TDH in the differentiation and function of OCs. Real time quantitative PCR was used to measure the expression of specific genes and inflammatory factors in OCs. Western blot was used to identify NFATc1, IKK, NF kappa B, MAPK pathway, and oxidative stress related components. Finally, an LPS mediated calvarial osteolysis mouse model was employed to explore TDH's role in inflammatory osteolysis. The results showed that in vivo TDH inhibited the differentiation and resorption functions of OCs and down regulated the transcription of osteoclast specific genes, as well as Il 1 beta, Il 6 and Tnf alpha. In addition, TDH inhibited the IKK and NF kappa B signalling pathways and down regulated the level of ROS. In vivo studies revealed that TDH improves the bone loss caused by LPS. TDH may be a new candidate or treatment for osteoclast associated inflammatory osteolytic disease.
C1 [Xie, Xiaoxiao; Chen, Weiwei; Xu, Minglian; Chen, Junchun; Yang, Tao; Wang, Chaofeng; Su, Yuangang; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Orthopaed Dept, Guangxi Key Lab Regenerat Med, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Xie, Xiaoxiao; Chen, Weiwei; Yang, Tao; Wang, Chaofeng; Liu, Qian] Guangxi Med Univ, Collaborat Innovat Ctr Regenerat Med & Med BioReso, Life Sci Inst, Nanning, Guangxi, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Xu, Jiake] Chinese Acad Sci, Shenzhen Inst Adv Technol, Fac Pharmaceut Sci, Shenzhen, Peoples R China.
   [Liu, Qian] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Orthopaed Dept, Affiliated Hosp 1, Nanning 530021, Guangxi, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
C3 Guangxi Medical University; Guangxi Medical University; University of
   Western Australia; Chinese Academy of Sciences; Shenzhen Institute of
   Advanced Technology, CAS; Guangxi Medical University; University of
   Western Australia
RP Liu, Q (通讯作者)，Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Orthopaed Dept, Affiliated Hosp 1, Nanning 530021, Guangxi, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
EM jiake.xu@uwa.edu.au; liuqian@gxmu.edu.cn
RI ; xie, xiaoxiao/KFA 9850 2024; zhao, jin/LBH 0351 2024; Su,
   Yuangang/KKU 6952 2024; Wang, Chaofeng/JKH 9328 2023
OI Wang, Chaofeng/0000 0002 2768 5009; Yang, Tao/0009 0002 6777 2649; Xu,
   Jiake/0000 0003 2021 8309; 
FU National Natural Science Foundation [81960405, 82260438]; Guangxi
   Science and Technology Base and Talent Special Project [AD19254003];
   Guangxi Natural Science Foundation [2023GXNSFDA026058, 2022GXNSFBA35492]
FX National Natural Science Foundation, Grant/Award Numbers: 81960405,
   82260438; Guangxi Science and Technology Base and Talent Special
   Project, Grant/Award Number: Guike AD19254003; Guangxi Natural Science
   Foundation, Grant/Award Numbers: 2023GXNSFDA026058, 2022GXNSFBA35492 &
   nbsp;
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Bjornson CRR, 2012, STEM CELLS, V30, P232, DOI 10.1002/stem.773
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen YY, 2021, MOL MED, V27, DOI 10.1186/s10020 021 00398 w
   Chu BX, 2020, J CELL MOL MED, V24, P14366, DOI 10.1111/jcmm.16055
   Comb WC, 2011, ONCOGENE, V30, P1727, DOI 10.1038/onc.2010.553
   Deng HD, 2017, ONCOTARGET, V8, P114428, DOI 10.18632/oncotarget.22826
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Fu XJ, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/282854
   Gillen J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020164
   Ha YJ, 2021, MAR DRUGS, V19, DOI 10.3390/md19030132
   He S, 2021, AGING US, V13, P5150, DOI 10.18632/aging.202434
   Hong ZS, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2824984
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jiang QL, 2018, GLOBALIZATION HEALTH, V14, DOI 10.1186/s12992 018 0408 z
   Kajiya Mikihito, 2010, J Oral Microbiol, V2, DOI 10.3402/jom.v2i0.5532
   Kaltschmidt B, 2022, FRONT MOL NEUROSCI, V15, DOI 10.3389/fnmol.2022.954541
   Kim J, 2021, MOLECULES, V26, DOI 10.3390/molecules26010035
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kwak SC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103164
   Lee Jong Hun, 2013, Pharmacol Ther, V137, P153, DOI 10.1016/j.pharmthera.2012.09.008
   Li BY, 2017, INT J MOL MED, V39, P1155, DOI 10.3892/ijmm.2017.2933
   Li JJ, 2018, FISH SHELLFISH IMMUN, V83, P205, DOI 10.1016/j.fsi.2018.09.032
   Li L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052303
   Lin JT, 2021, DOSE RESPONSE, V19, DOI 10.1177/15593258211011023
   Lin X, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.796227
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lv YN, 2019, BIOMED CHROMATOGR, V33, DOI 10.1002/bmc.4569
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Park HJ, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11050963
   Park HJ, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9070588
   Park HJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8982147
   Park Min KH, 2009, J IMMUNOL, V183, P2444, DOI 10.4049/jimmunol.0804165
   Putnam NE, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007744
   Qu ZC, 2022, J CELL MOL MED, V26, P4428, DOI 10.1111/jcmm.17467
   Sadgrove NJ, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02470
   Solorzano E, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23158258
   Wang TT, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13323
   Wei W, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12722
   Yang WL, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00151 3
   Yildirimturk S, 2016, J APPL ORAL SCI, V24, P239, DOI 10.1590/1678 775720150570
   Zhan YF, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01587
   Zhang R, 2021, CLIN EXP PHARMACOL P, V48, P757, DOI 10.1111/1440 1681.13398
   Zhang S, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.793012
   Zhao XL, 2021, J BONE MINER RES, V36, P591, DOI 10.1002/jbmr.4215
NR 46
TC 11
Z9 11
U1 2
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD JAN
PY 2024
VL 57
IS 1
AR e13535
DI 10.1111/cpr.13535
EA AUG 2023
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA EE1A3
UT WOS:001044294600001
PM 37551727
OA gold
DA 2025 08 17
ER

PT S
AU Neman, J
   Hambrecht, A
   Cadry, C
   Goodarzi, A
   Youssefzadeh, J
   Chen, MY
   Jandial, R
AF Neman, Josh
   Hambrecht, Amanda
   Cadry, Cherie
   Goodarzi, Amir
   Youssefzadeh, Jonathan
   Chen, Mike Y.
   Jandial, Rahul
BE Jandial, R
   Chen, MY
TI CLINICAL EFFICACY OF STEM CELL MEDIATED OSTEOGENESIS AND BIOCERAMICS FOR
   BONE TISSUE ENGINEERING
SO REGENERATIVE BIOLOGY OF THE SPINE AND SPINAL CORD
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
ID MORPHOGENETIC PROTEIN 2; GROWTH FACTOR; SIGNALING PATHWAYS;
   SPINAL FUSION; DIFFERENTIATION; REPAIR; EXPRESSION; OSTEOBLAST;
   SCAFFOLDS; MATRIX
AB Lower back pain is a common disorder that often requires bony spinal fusion for long term relief. Current arthrodesis procedures use bone grafts from autogenous bone, allogenic backed bone or synthetic materials. Autogenous bone grafts can result in donor site morbidity and pain at the donor site, while allogenic backed bone and synthetic materials have variable effectiveness. Given these limitations, researchers have focused on new treatments that will allow for safe and successful bone repair and regeneration. Mesenchymal stem cells (MSCs) have received attention for their ability to differentiate into osteoblasts, cells that synthesize the extracellular matrix and regulate matrix mineralization. Successful bone regeneration requires three elements: MSCs that serve as osteoblastic progenitors, osteoinductive growth factors and their pathways that promote development and differentiation of the cells as well as an osteoconductive scaffold that allows for the formation of a vascular network. Future treatments should strive to combine mesenchymal stem cells, cell seeded scaffolds and gene therapy to optimize the efficiency and safety of tissue repair and bone regeneration.
C1 [Neman, Josh; Chen, Mike Y.; Jandial, Rahul] City Hope Canc Ctr, Div Neurosurg, Los Angeles, CA 91010 USA.
   [Neman, Josh; Chen, Mike Y.; Jandial, Rahul] Beckman Res Inst, Los Angeles, CA USA.
   [Hambrecht, Amanda] New York Med Coll, New York, NY USA.
   [Cadry, Cherie] Univ Calif Irvine, Dept Publ Hlth Sci, Irvine, CA USA.
   [Goodarzi, Amir] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA.
   [Youssefzadeh, Jonathan] Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90024 USA.
C3 New York Medical College; University of California System; University of
   California Irvine; University of California System; University of
   California Davis; University of California System; University of
   California Los Angeles
RP Neman, J (通讯作者)，City Hope Canc Ctr, Div Neurosurg, Los Angeles, CA 91010 USA.
EM jneman@coh.org
RI goodarzi, Azadeh/Z 1736 2018
CR Aspenberg P, 2005, ACTA ORTHOP, V76, P741, DOI 10.1080/17453670510045318
   Balga R, 2006, BONE, V39, P325, DOI 10.1016/j.bone.2006.02.056
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74
   Betz VM, 2008, FRONT BIOSCI LANDMRK, V13, DOI 10.2741/2724
   BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309
   Braunecker J, 2004, INT J PHARMACEUT, V282, P19, DOI 10.1016/j.ijpharm.2003.08.020
   Bueno EM, 2009, NAT REV RHEUMATOL, V5, P685, DOI 10.1038/nrrheum.2009.228
   Butler DL, 2008, TISSUE ENG PT A, V14, P2089, DOI 10.1089/ten.tea.2007.0383
   Cancedda R, 2003, MATRIX BIOL, V22, P81, DOI 10.1016/S0945 053X(03)00012 X
   Carragee EJ, 2005, NEW ENGL J MED, V352, P1891, DOI 10.1056/NEJMcp042054
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Ciacci J, 2008, STEM CELLS CLONING, V1, P31
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Delécrin J, 2000, SPINE, V25, P563, DOI 10.1097/00007632 200003010 00006
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Deyo RA, 2004, NEW ENGL J MED, V350, P722, DOI 10.1056/NEJMsb031771
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Ebisawa T, 1999, J CELL SCI, V112, P3519
   EINHORN TA, 1995, J BONE MINER RES, V10, P1272
   El Tamer MK, 2009, J TISSUE ENG REGEN M, V3, P327, DOI 10.1002/term.173
   Fox JM, 2007, BRIT J HAEMATOL, V137, P491, DOI 10.1111/j.1365 2141.2007.06610.x
   Geiger F, 2005, J BONE MINER RES, V20, P2028, DOI 10.1359/JBMR.050701
   Gersbach CA, 2007, ANNU REV BIOMED ENG, V9, P87, DOI 10.1146/annurev.bioeng.9.060906.151949
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Gupta MK, 2003, WORLD J GASTROENTERO, V9, P1144, DOI 10.3748/wjg.v9.i6.1144
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210
   Hernigou P, 2005, J BONE JOINT SURG BR, V87B, P896, DOI 10.1302/0301 620X.87B7.16289
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Jane JA, 2002, MOL THER, V6, P464, DOI 10.1006/mthe.2002.0691
   Jorgensen NR, 2004, STEROIDS, V69, P219, DOI 10.1016/j.steroids.2003.12.005
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Kasper G, 2007, STEM CELLS, V25, P903, DOI 10.1634/stemcells.2006 0432
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P36, DOI 10.2106/JBJS.G.01260
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Kwan MD, 2008, HUM MOL GENET, V17, pR93, DOI 10.1093/hmg/ddn071
   LEE CK, 1984, SPINE, V9, P574, DOI 10.1097/00007632 198409000 00007
   Lee JY, 2006, CURR BIOL, V16, P1986, DOI 10.1016/j.cub.2006.08.090
   Li X, 2007, BIOCHEM BIOPH RES CO, V364, P187, DOI 10.1016/j.bbrc.2007.07.202
   Marcacci M, 2007, TISSUE ENG, V13, P947, DOI 10.1089/ten.2006.0271
   MIKOS AG, 1993, BIOTECHNOL BIOENG, V42, P716, DOI 10.1002/bit.260420606
   Miyazaki M, 2009, EUR SPINE J, V18, P783, DOI 10.1007/s00586 009 0924 x
   Murphy WL, 2005, BIOMATERIALS, V26, P303, DOI 10.1016/j.biomaterials.2004.02.034
   Oonishi H, 2000, J BIOMED MATER RES, V51, P37, DOI 10.1002/(SICI)1097 4636(200007)51:1<37::AID JBM6>3.0.CO;2 T
   Ortega N, 2004, TRENDS CELL BIOL, V14, P86, DOI 10.1016/j.tcb.2003.12.003
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Park KH, 2009, J BIOSCI BIOENG, V108, P530, DOI 10.1016/j.jbiosc.2009.05.021
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Potier E, 2007, TISSUE ENG, V13, P1325, DOI 10.1089/ten.2006.0325
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Richards M, 1999, J ORTHOP RES, V17, P900, DOI 10.1002/jor.1100170615
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Roy TD, 2003, J BIOMED MATER RES A, V66A, P283, DOI 10.1002/jbm.a.10582
   Russell JL, 1999, ORTHOPEDICS, V22, P524
   Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756 3282(98)00053 2
   Salasznyk RM, 2004, CELL COMMUN ADHES, V11, P137, DOI 10.1080/15419060500242836
   Salasznyk RM, 2004, J BIOMED BIOTECHNOL, P24, DOI 10.1155/S1110724304306017
   Salgado AJ, 2005, J MATER SCI MATER M, V16, P267, DOI 10.1007/s10856 005 6689 9
   Schwartz Z, 1996, J PERIODONTOL, V67, P918, DOI 10.1902/jop.1996.67.9.918
   Sheyn D, 2008, STEM CELLS, V26, P1056, DOI 10.1634/stemcells.2007 0858
   Sundelacruz S, 2009, SEMIN CELL DEV BIOL, V20, P646, DOI 10.1016/j.semcdb.2009.03.017
   Tasso R, 2009, CARCINOGENESIS, V30, P150, DOI 10.1093/carcin/bgn234
   Temenoff J. S., 2000, BONE ENG
   THOMSON RC, 1995, J BIOMAT SCI POLYM E, V7, P23, DOI 10.1163/156856295X00805
   Tolar J, 2007, STEM CELLS, V25, P371, DOI 10.1634/stemcells.2005 0620
   Ueda M, 2008, IMPLANT DENT, V17, P82, DOI 10.1097/ID.0b013e31815cd591
   Vacanti CA, 2001, NEW ENGL J MED, V344, P1511, DOI 10.1056/NEJM200105173442004
   Warnke PH, 2006, BIOMATERIALS, V27, P3163, DOI 10.1016/j.biomaterials.2006.01.050
   Wozniak MA, 2009, NAT REV MOL CELL BIO, V10, P34, DOI 10.1038/nrm2592
   Yang XBB, 2004, TISSUE ENG, V10, P1148, DOI 10.1089/ten.2004.10.1148
   Yaszemski M. J. O. J., 2000, BONE ENG
   Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315
NR 84
TC 9
Z9 11
U1 0
U2 17
PU SPRINGER VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D 14197 BERLIN, GERMANY
SN 0065 2598
EI 2214 8019
BN 978 1 4614 4089 5; 978 1 4614 4090 1
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2012
VL 760
BP 174
EP 187
D2 10.1007/978 1 4614 4090 1
PG 14
WC Medicine, Research & Experimental; Neurosciences
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Neurosciences & Neurology
GA BA2ST
UT WOS:000333849500011
PM 23281520
DA 2025 08 17
ER

PT J
AU Russell, RGG
AF Russell, RGG
TI Ibandronate: Pharmacology and preclinical studies
SO BONE
LA English
DT Article; Proceedings Paper
CT Ibandronate Satellite Symposium on Evoluation of Oral Ibandronate
CY JUN 25, 2005
CL Geneva, SWITZERLAND
DE bisphosphonate; ibandronate; once monthly; osteoporosis; postmenopausal;
   adherence
ID BONE MASS; BISPHOSPHONATE IBANDRONATE; IN VITRO; BIOMECHANICAL
   PROPERTIES; MOLECULAR INTERACTIONS; TISSUE CULTURE; INTERMITTENT;
   ALENDRONATE; MECHANISMS; RESORPTION
AB Over the past three decades, changes to the chemical structures of the bisphosphonates have resulted in progressive improvements in their antiresorptive potencies. Ibandronate is a potent, nitrogen containing bisphosphonate that possesses a tertiary nitrogen group On its R2 side chain and a hydroxyl group oil its R1 side chain, which together confer one of the highest antiresorptive potencies of all bisphosphonates. In common with other nitrogen containing bisphosphonates, ibandronate is a strong inhibitor of farnesyl pyrophosphate synthase, which probably accounts for its major effects on osteoclast activity. In addition, it binds strongly to hydroxyapatite. The pharmacological efficacy and safety of various continuous and intermittent regimens of ibandronate have been extensively investigated in experimental models of osteoporosis in several animal species.. including rats, dogs, and monkeys. In ovariectomized (OVX) rats, intermittent (dosing interval 2, 4, and 6 weeks) and Continuous ibandronate regimens provided equivalent results per total dose irrespective of the dosing regimen. Similar results were obtained in OVX dogs and monkeys. High doses of ibandronate many times those used therapeutically were well tolerated and did not impair bone quality or mineralization in rats. Moreover. bone mass, architecture, and strength were maintained or improved, and bone healing was not adversely affected in animal models, regardless of whether ibandronate was administered intermittently or daily. The findings from all these studies demonstrate the efficacy and safety of intermittent ibandronate regimens and support the development of such regimens for the clinical management of postmenopausal osteoporosis. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Oxford, Nuffield Dept Orthopaed Surg, Botnar Res Ctr, Oxford OX3 7LD, England.
   Univ Oxford, Inst Musculoskeletal Sci, Oxford OX3 7LD, England.
C3 University of Oxford; University of Oxford
RP Univ Oxford, Nuffield Dept Orthopaed Surg, Botnar Res Ctr, Oxford OX3 7LD, England.
EM graham.russell@ndos.ox.ac.uk
RI Russell, Robert Graham G/JEF 5877 2023; Russell, R/JEF 5877 2023
OI Russell, Robert Graham G/0000 0002 4136 1828; 
CR [Anonymous], 2000, NIH Consens Statement, V17, P1
   BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872
   Bauss F, 2002, J RHEUMATOL, V29, P990
   Bauss F, 2002, J RHEUMATOL, V29, P2200
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bauss Frieder, 2004, Journal of Pharmacological and Toxicological Methods, V50, P25, DOI 10.1016/j.vascn.2003.11.003
   BENEDICT JJ, 1990, S CEM CTR ET MAL OST, P7
   Body JJ, 2001, J MAMMARY GLAND BIOL, V6, P477, DOI 10.1023/A:1014795216669
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Devogelaer Jean Pierre, 2002, Treat Endocrinol, V1, P241, DOI 10.2165/00024677 200201040 00006
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino EH, 2005, J BONE MINER RES, V20, pS259
   Ebetino FH, 2005, J ORGANOMET CHEM, V690, P2679, DOI 10.1016/j.jorganchem.2005.03.005
   Ebetino Frank H., 1995, P139
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Geddes A D., 1994, Bone and Mineral Research, P265
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   GUY JA, 1993, CALCIFIED TISSUE INT, V53, P283, DOI 10.1007/BF01320915
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Kavanagh K, 2005, J BONE MINER RES, V20, pS95
   Kurth AHA, 2005, BONE, V37, P204, DOI 10.1016/j.bone.2004.12.017
   Lalla S, 1998, OSTEOPOROSIS INT, V8, P97, DOI 10.1007/BF02672503
   Lawson MA, 2005, J BONE MINER RES, V20, pS396
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Monier Faugere MC, 1999, J BONE MINER RES, V14, P1768, DOI 10.1359/jbmr.1999.14.10.1768
   MUHLBAUER RC, 1991, J BONE MINER RES, V6, P1003
   Müller R, 2004, J BONE MINER RES, V19, P1787, DOI 10.1359/JBMR.040809
   NANCOLLAS GH, 2005, IN PRESS BONE
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Riis BJ, 2001, J BONE MINER RES, V16, P1871, DOI 10.1359/jbmr.2001.16.10.1871
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   ROGERS MJ, 1994, BIOCHEM J, V303, P303, DOI 10.1042/bj3030303
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   RUSSELL RGG, 1970, CALC TISS RES, V6, P183, DOI 10.1007/BF02196199
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   Smith SY, 2003, BONE, V32, P45, DOI 10.1016/S8756 3282(02)00923 7
   TOOLAN BC, 1992, J BONE MINER RES, V7, P1399
   *US DHHS, 2004, BON HLTH OST REP SUR
   *US FDA, 1994, GUID PRECL CLIN EV A
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
NR 46
TC 19
Z9 19
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2006
VL 38
IS 4
SU 1
BP S7
EP S12
DI 10.1016/j.bone.2006.01.151
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 031NJ
UT WOS:000236711000003
PM 16531132
DA 2025 08 17
ER

PT J
AU Kushibiki, T
   Tu, YP
   Abu Yousif, AO
   Hasan, T
AF Kushibiki, Toshihiro
   Tu, Yupeng
   Abu Yousif, Adnan O.
   Hasan, Tayyaba
TI Photodynamic activation as a molecular switch to promote osteoblast cell
   differentiation via AP 1 activation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NF KAPPA B; MESENCHYMAL STEM CELLS; INDUCED PROTOPORPHYRIN IX; KINASE
   C THETA; TRANSCRIPTION FACTOR; BONE FORMATION; GROWTH FACTOR; ADIPOCYTE
   DIFFERENTIATION; DEATH PATHWAYS; THERAPY
AB In photodynamic therapy (PDT), cells are impregnated with a photosensitizing agent that is activated by light irradiation, thereby photochemically generating reactive oxygen species (ROS). The amounts of ROS produced depends on the PDT dose and the nature of the photosensitizer. Although high levels of ROS are cytotoxic, at physiological levels they play a key role as second messengers in cellular signaling pathways, pluripotency, and differentiation of stem cells. To investigate further the use of photochemically triggered manipulation of such pathways, we exposed mouse osteoblast precursor cells and rat primary mesenchymal stromal cells to low dose PDT. Our results demonstrate that low dose PDT can promote osteoblast differentiation via the activation of activator protein 1 (AP 1). Although PDT has been used primarily as an anti cancer therapy, the use of light as a photochemical "molecular switch" to promote differentiation should expand the utility of this method in basic research and clinical applications.
C1 [Kushibiki, Toshihiro; Tu, Yupeng; Abu Yousif, Adnan O.; Hasan, Tayyaba] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
   [Kushibiki, Toshihiro] Natl Def Med Coll, Dept Med Engn, Tokorozawa, Saitama 3598513, Japan.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School; National Defense Medical
   College   Japan
RP Hasan, T (通讯作者)，Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.
EM thasan@mgh.harvard.edu
RI ; Tu, Yupeng/AAD 3547 2020
OI Hasan, Tayyaba/0000 0003 0871 6057; Tu, Yupeng/0000 0002 8989 3241; 
FU National Cancer Institute of the National Institutes of Health
   [R01CA160998, P01CA084203]; Precursory Research for Embryonic Science
   and Technology (PRESTO) of the Japan Science and Technology Agency
   (JST); KAKENHI from Japan Society for the Promotion of Science (JSPS)
   [21687011, 25713009]; Grants in Aid for Scientific Research [25713009,
   21687011] Funding Source: KAKEN
FX This research was partially supported by the Precursory Research for
   Embryonic Science and Technology (PRESTO) of the Japan Science and
   Technology Agency (JST) and KAKENHI Grant Numbers 21687011 and 25713009
   from Japan Society for the Promotion of Science (JSPS). Research
   reported in this publication was supported by the National Cancer
   Institute of the National Institutes of Health under award numbers
   R01CA160998 and P01CA084203. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR AMSTAD P, 1990, B CANCER, V77, P501
   AMSTAD PA, 1992, CANCER RES, V52, P3952
   Ateghang B, 2006, J CELL SCI, V119, P1043, DOI 10.1242/jcs.02798
   BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842
   Berniakovich I, 2013, INT J MOL SCI, V14, P2119, DOI 10.3390/ijms14012119
   Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111
   Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470 2045(04)01529 3
   Buytaert E, 2007, BBA REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001
   Cárcamo Orive I, 2010, J BONE MINER RES, V25, P2115, DOI 10.1002/jbmr.120
   Celli JP, 2010, CHEM REV, V110, P2795, DOI 10.1021/cr900300p
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen Q, 2002, PHOTOCHEM PHOTOBIOL, V76, P197, DOI 10.1562/0031 8655(2002)076<0197:IOTRBM>2.0.CO;2
   Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Flaherty DM, 2002, J IMMUNOL, V168, P5675, DOI 10.4049/jimmunol.168.11.5675
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Ghaffari Tabrizi N, 1999, EUR J IMMUNOL, V29, P132
   Gollnick SO, 2001, PHOTOCHEM PHOTOBIOL, V73, P170, DOI 10.1562/0031 8655(2001)073<0170:AOTIGP>2.0.CO;2
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638
   HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092 8674(95)90404 2
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Holmström KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801
   Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211
   Huang Y., 2010, HDB PHOTONICS BIOMED, P161
   Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676
   Kanda Y, 2011, LIFE SCI, V89, P250, DOI 10.1016/j.lfs.2011.06.007
   Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414
   KICK G, 1995, CANCER RES, V55, P2373
   Kick G, 1996, BRIT J CANCER, V74, P30, DOI 10.1038/bjc.1996.311
   Lawrence Toby, 2009, Cold Spring Harb Perspect Biol, V1, pa001651, DOI 10.1101/cshperspect.a001651
   Lee SH, 2010, J CELL PHYSIOL, V222, P574, DOI 10.1002/jcp.21973
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   LENNON DP, 1995, EXP CELL RES, V219, P211, DOI 10.1006/excr.1995.1221
   Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137
   Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844
   Liu HJ, 2005, CIRC RES, V97, P967, DOI 10.1161/01.RES.0000188210.72062.10
   Liu WG, 2004, CANCER RES, V64, P6579, DOI 10.1158/0008 5472.CAN 04 1580
   Luther J, 2014, CELL DEATH DIFFER, V21, P655, DOI 10.1038/cdd.2013.198
   Maillet A, 2012, ANTIOXID REDOX SIGN, V16, P1285, DOI 10.1089/ars.2011.4434
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood 2004 07 2958
   Matroule JY, 2006, PHOTOCHEM PHOTOBIOL, V82, P1241, DOI 10.1562/2006 03 30 IR 862
   Ortel B, 1998, BRIT J CANCER, V77, P1744, DOI 10.1038/bjc.1998.292
   Palcy S, 2000, J BONE MINER RES, V15, P2352, DOI 10.1359/jbmr.2000.15.12.2352
   Piccoli Claudia, 2007, Ital J Biochem, V56, P295
   REGULA J, 1995, GUT, V36, P67, DOI 10.1136/gut.36.1.67
   Rizvi I, 2013, PHOTOCHEM PHOTOBIOL, V89, P942, DOI 10.1111/php.12065
   Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194
   Schmelter M, 2006, FASEB J, V20, P1182, DOI 10.1096/fj.05 4723fje
   Serena E, 2009, EXP CELL RES, V315, P3611, DOI 10.1016/j.yexcr.2009.08.015
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502 e131
   Tamama K, 2011, J CELL BIOCHEM, V112, P804, DOI 10.1002/jcb.22961
   Thannickal VJ, 2000, AM J PHYSIOL LUNG C, V279, pL1005
   Tseng WP, 2010, J CELL PHYSIOL, V223, P810, DOI 10.1002/jcp.22104
   Varum S, 2009, STEM CELL RES, V3, P142, DOI 10.1016/j.scr.2009.07.002
   Verma S, 2007, PHOTOCHEM PHOTOBIOL, V83, P996, DOI 10.1111/j.1751 1097.2007.00166.x
   Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902
   Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547
   Zhang YG, 2010, CONNECT TISSUE RES, V51, P14, DOI 10.3109/03008200902855891
   Ziello Jennifer E, 2007, Yale J Biol Med, V80, P51
NR 60
TC 37
Z9 43
U1 1
U2 21
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 17
PY 2015
VL 5
AR 13114
DI 10.1038/srep13114
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CO9VV
UT WOS:000359525200001
PM 26279470
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, WG
   Li, MJ
   Luo, M
   Shen, MK
   Xu, C
   Xu, GZ
   Chen, YK
   Xia, L
AF Wang, Wengang
   Li, Mingjun
   Luo, Ming
   Shen, Mingkui
   Xu, Chen
   Xu, Genzhong
   Chen, Yaokun
   Xia, Lei
TI Naringenin inhibits osteoclastogenesis through modulation of helper T
   cells secreted IL 4
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE IL 4; naringenin; osteoclast; RANKL; T cells
ID NF KAPPA B; BONE RESORPTION; RECEPTOR ACTIVATOR; IMMUNE RESPONSES;
   ACTINOMYCETEMCOMITANS; DIFFERENTIATION; SUPPRESSES; EXPRESSION; PATHWAY;
   SYSTEM
AB Naringenin (NAR) is a natural predominant flavanone and has a wide range of pharmacological activities. The aim of this study was to investigate the protective mechanisms of NAR on RANKL induced osteoclastogenesis and osteoclast bone resorption. T cells were divided into four groups under different concentrations of NAR (0, 25, 50, 100 mu M). CD4(+) T cell subsets in different groups were evaluated by flow cytometry. TRAP staining, pit formation assays and F actin ring immunofluorescent staining were performed. In addition, gene expression of osteoclast specific markers was analyzed by qPCR and Western blot. Our results showed that compared with the control group, there were relatively fewer Th1 and Th17 cells and more Th2 cells and Treg cells in the NAR groups. Besides, the number of TRAP positive multinucleated osteoclasts, the areas of bone resorption pits and the size and number of F actin rings were notably decreased in the bone marrow macrophages (BMMs) treated with T cell supernatant containing NAR. Moreover, NAR treatment dramatically reduced the expressions of cathepsin K, c Fos, DC STAMP, NFATc1, TRAP, and V ATPase d2 at mRNA and protein levels. However, these effects were abolished by adding a neutralizing antibody against IL 4. In conclusion, NAR suppressed RANKL induced osteoclastogenesis and osteoclast bone resorption by promoting the release of IL 4 from T cells.
C1 [Wang, Wengang; Luo, Ming; Shen, Mingkui; Xu, Chen; Xu, Genzhong; Chen, Yaokun; Xia, Lei] Zhengzhou Univ, Affiliated Hosp 1, Dept Orthopaed, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Li, Mingjun] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Henan, Peoples R China.
C3 Zhengzhou University; Zhengzhou University
RP Xia, L (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Orthopaed, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
EM xialei07@sohu.com
RI Li, Ming Jun/Z 5342 2019
FU Youth Foundation of the First Affiliated Hospital of Zhengzhou
   University
FX This study was supported by the Youth Foundation of the First Affiliated
   Hospital of Zhengzhou University.
CR Bettelli E, 2007, CURR OPIN IMMUNOL, V19, P652, DOI 10.1016/j.coi.2007.07.020
   BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0
   Bodet C, 2008, J PERIODONTAL RES, V43, P400, DOI 10.1111/j.1600 0765.2007.01055.x
   Bouvet Gerbettaz S, 2014, TISSUE ENG PT A, V20, P2950, DOI [10.1089/ten.tea.2013.0633, 10.1089/ten.TEA.2013.0633]
   Brincat P, 2012, CYTOM PART B CLIN CY, V82B, P245, DOI 10.1002/cyto.b.21021
   Cheng KW, 2009, CHEM RES TOXICOL, V22, P1483, DOI 10.1021/tx9001644
   Cui L, 2012, INT J MOL SCI, V13, P14251, DOI 10.3390/ijms131114251
   Geusens P, 2009, CLIN INTERV AGING, V4, P241
   Guo A, 2015, SCI REP UK, V5, DOI 10.1038/srep14046
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hwang SY, 2012, FASEB J, V26, P1484, DOI 10.1096/fj.11 194399
   Jayaraman J, 2011, FUND CLIN PHARMACOL, V25, P682, DOI 10.1111/j.1472 8206.2010.00899.x
   Kawaii S, 1999, J AGR FOOD CHEM, V47, P3565, DOI 10.1021/jf990153+
   Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kitaura H, 2003, IMMUNOL LETT, V88, P193, DOI 10.1016/S0165 2478(03)00082 8
   La VD, 2009, J PERIODONTAL RES, V44, P193, DOI 10.1111/j.1600 0765.2008.01107.x
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Li Y, 2010, MOL ORAL MICROBIOL, V25, P275, DOI 10.1111/j.2041 1014.2010.00576.x
   Lo YC, 2013, J IMMUNOL, V191, P5107, DOI 10.4049/jimmunol.1301433
   Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888
   Matsuzaki J, 2005, AUTOIMMUNITY, V38, P369, DOI 10.1080/08916930500124122
   Miceli TS, 2011, CLIN J ONCOL NURS, V15, P9, DOI 10.1188/11.S1.CJON.9 23
   Miller RE, 2007, J IMMUNOL, V179, P266, DOI 10.4049/jimmunol.179.1.266
   Ming LG, 2013, ENDOCRINOLOGY, V154, P1202, DOI 10.1210/en.2012 2086
   Moralès O, 2012, J IMMUNOTHER, V35, P254, DOI 10.1097/CJI.0b013e31824d72c5
   Mukherjee S, 2009, J BIOL CHEM, V284, P29391, DOI 10.1074/jbc.M109.005272
   Nakashima Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072033
   Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701
   Rifas L, 2009, ARTHRITIS RHEUM US, V60, P3324, DOI 10.1002/art.24877
   Sasaki K, 2009, J IMMUNOTHER, V32, P793, DOI 10.1097/CJI.0b013e3181acec1e
   Schira J, 2015, J CELL MOL MED, V19, P2842, DOI 10.1111/jcmm.12677
   Singh V, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471 2172 7 17
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Teng YTA, 1999, J PERIODONTAL RES, V34, P54, DOI 10.1111/j.1600 0765.1999.tb02222.x
   Thirukonda GJ, 2016, J BONE MINER METAB, V34, P395, DOI 10.1007/s00774 015 0683 1
   van Wijnen AJ, 2013, CURR OSTEOPOROS REP, V11, P72, DOI 10.1007/s11914 013 0143 6
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521 4141(200204)32:4<1090::AID IMMU1090>3.3.CO;2 G
   Wang WG, 2014, INT J MOL SCI, V15, P21913, DOI 10.3390/ijms151221913
   Weitzmann MN, 2000, BLOOD, V96, P1873, DOI 10.1182/blood.V96.5.1873.h8001873_1873_1878
   Yarilina A, 2011, P NATL ACAD SCI USA, V108, P1573, DOI 10.1073/pnas.1010030108
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
   Zhang MQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112350
   Zhao B, 2011, ARTHRITIS RES THER, V13, P1
   Zhu JF, 2015, CYTOKINE, V75, P14, DOI 10.1016/j.cyto.2015.05.010
   Ziegler SF, 2009, MICROBES INFECT, V11, P594, DOI 10.1016/j.micinf.2009.04.002
NR 50
TC 19
Z9 23
U1 1
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD FEB
PY 2018
VL 119
IS 2
BP 2084
EP 2093
DI 10.1002/jcb.26370
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FQ9UX
UT WOS:000418708300075
PM 28834554
DA 2025 08 17
ER

PT J
AU Liu, XS
   Guo, RR
   Huo, SC
   Chen, H
   Song, QX
   Jiang, G
   Yu, Y
   Huang, JL
   Xie, SW
   Gao, XL
   Lu, LJ
AF Liu, Xuesong
   Guo, Ruru
   Huo, Shicheng
   Chen, Huan
   Song, Qingxiang
   Jiang, Gan
   Yu, Ye
   Huang, Jialin
   Xie, Shaowei
   Gao, Xiaoling
   Lu, Liangjing
TI CaP based anti inflammatory HIF 1α siRNA encapsulating nanoparticle for
   rheumatoid arthritis therapy
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Rheumatoid arthritis; HIF 1 alpha; siRNA; Macrophage; Nanomedicine
ID NF KAPPA B; IMMUNE RESPONSE; HYPOXIA; INFLAMMATION; ANGIOGENESIS;
   MACROPHAGES; PHOSPHATE; DELIVERY; PROTEIN; CELLS
AB Rheumatoid arthritis (RA) is a common inflammatory disease and its treatment is largely limited by drug ineffectiveness or severe side effects. In RA progression, multiple signalling pathways, such as hypoxia inducible factor (HIF) 1 alpha, nuclear factor kappa B (NF kappa B), and mitogen activated protein kinase (MAPK) pathways, act synergistically to maintain the inflammatory response. To downregulate HIF 1 alpha, NF kappa B, and MAPK expression, we proposed HIF 1 alpha siRNA loaded calcium phosphate nanoparticles encapsulated in apolipoprotein E3 reconstituted high density lipoprotein (HIF CaP rHDL) for RA therapy. Here, we evaluated the potential of CaP rHDL nanoparticles in RA therapy using a murine macrophage line (RAW 264.7) and a collagen induced arthritis (CIA) mouse model. The CaP rHDL nanoparticles showed significant anti inflammatory effects along with HIF 1 alpha knockdown and NF kappa B and MAPK signalling pathway inhibition in lipopolysaccharide activated macrophages. Moreover, they inhibited receptor activator of NF kappa B ligand (RANKL) induced osteoclast formation. In CIA mice, their intravenous administration resulted in high accumulation at the arthritic joint sites, and HIF CaP rHDL effectively suppressed inflammatory cytokine secretion and relieved bone erosion, cartilage damage, and osteoclastogenesis. Thus, HIF CaP rHDL demonstrated great potential in RA precision therapy by inhibiting multiple inflammatory signalling pathways.
C1 [Liu, Xuesong; Guo, Ruru; Yu, Ye; Lu, Liangjing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
   [Chen, Huan; Song, Qingxiang; Jiang, Gan; Huang, Jialin; Gao, Xiaoling] Shanghai Jiao Tong Univ, Shanghai Univ Collaborat Innovat Ctr Translat Med, State Key Lab Oncogenes & Related Genes, Dept Pharmacol & Chem Biol,Sch Med, Shanghai 200025, Peoples R China.
   [Liu, Xuesong; Xie, Shaowei] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Ultrasound, 160 Pujian Rd, Shanghai 200127, Peoples R China.
   [Huo, Shicheng] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Bone & Joint Surg,Dept Orthoped, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University
RP Lu, LJ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.; Gao, XL (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Univ Collaborat Innovat Ctr Translat Med, State Key Lab Oncogenes & Related Genes, Dept Pharmacol & Chem Biol,Sch Med, Shanghai 200025, Peoples R China.
EM shellygao1@sjtu.edu.cn; lu_liangjing@163.com
RI ; Gao, xiao ling/GQI 2790 2022; Jiang, Gan/AAO 2173 2020; Huo,
   Shicheng/HGU 2326 2022; song, qingxiang/LKO 3054 2024; liu,
   xuesong/KBR 3450 2024
OI Huo, Shicheng/0000 0002 9047 8846; Gao, Xiaoling/0000 0001 6789 3059; 
FU National Key Research and Develop Program of China from the Ministry of
   Science and Technology [2017YFC0909002]; National Natural Science
   Foundation of China [81373209, 82001707, 81722043, 81973272, 81803089,
   81903582, 81801212, 92068111, 81901747]; Shanghai Sailing Program
   [20YF1425700, 18YF1413400]
FX This work was supported by the National Key Research and Develop Program
   of China (2017YFC0909002) grant from the Ministry of Science and
   Technology, National Natural Science Foundation of China (No. 81373209,
   82001707, 81722043, 81973272, 81803089, 81903582, 81801212, 92068111,
   81901747). Shanghai Sailing Program (20YF1425700 and 18YF1413400).
CR Agarwal SK, 2011, J MANAGE CARE PHARM, V17, pS14, DOI 10.18553/jmcp.2011.17.s9 b.S14
   Aldayel AM, 2018, J CONTROL RELEASE, V283, P280, DOI 10.1016/j.jconrel.2018.05.035
   Alghasham A, 2014, AUTOIMMUNITY, V47, P77, DOI 10.3109/08916934.2013.873413
   Ban HS, 2016, EXPERT OPIN THER PAT, V26, P309, DOI 10.1517/13543776.2016.1146252
   Bisso S, 2019, EUR J PHARM BIOPHARM, V142, P142, DOI 10.1016/j.ejpb.2019.06.013
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brouwer E, 2009, CLIN EXP RHEUMATOL, V27, P945
   Buch MH, 2007, RHEUMATOLOGY, V46, P1153, DOI 10.1093/rheumatology/kem075
   Catrysse L, 2017, TRENDS CELL BIOL, V27, P417, DOI 10.1016/j.tcb.2017.01.006
   Chen GJ, 2010, ARCH IMMUNOL THER EX, V58, P27, DOI 10.1007/s00005 009 0058 1
   Chen WH, 2015, CANCER LETT, V359, P65, DOI 10.1016/j.canlet.2014.12.052
   Chia WT, 2008, J FORMOS MED ASSOC, V107, P245, DOI 10.1016/S0929 6646(08)60143 6
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092 8674(03)00154 5
   Elshabrawy HA, 2015, ANGIOGENESIS, V18, P433, DOI 10.1007/s10456 015 9477 2
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Fotakis P, 2019, ARTERIOSCL THROM VAS, V39, pE253, DOI 10.1161/ATVBAHA.119.313253
   Frede S, 2006, BIOCHEM J, V396, P517, DOI 10.1042/BJ20051839
   Ghezzi B, 2020, MINERVA STOMATOL, V69, P87, DOI 10.23736/S0026 4970.20.04272 7
   Golledge J, 2010, ATHEROSCLEROSIS, V209, P487, DOI 10.1016/j.atherosclerosis.2009.09.027
   Hollander AP, 2001, ARTHRITIS RHEUM US, V44, P1540, DOI 10.1002/1529 0131(200107)44:7<1540::AID ART277>3.0.CO;2 7
   Hopkins RB, 2016, OSTEOPOROSIS INT, V27, P3023, DOI 10.1007/s00198 016 3631 6
   Hu FL, 2016, EUR J IMMUNOL, V46, P742, DOI 10.1002/eji.201545784
   Huang JL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15144
   Huang Y, 2018, ACTA BIOMATER, V66, P81, DOI 10.1016/j.actbio.2017.08.044
   Imtiyaz HZ, 2010, CURR TOP MICROBIOL, V345, P105, DOI 10.1007/82_2010_74
   Konisti S, 2012, NAT REV RHEUMATOL, V8, P153, DOI 10.1038/nrrheum.2011.205
   Kwoh CK, 2002, ARTHRITIS RHEUM US, V46, P328
   Lin N, 2016, J CLIN INVEST, V126, P3661, DOI 10.1172/JCI84426
   Liu Y, 2019, J CELL PHYSIOL, V234, P13832, DOI 10.1002/jcp.28063
   Lu Y, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800013
   LUNDOLESEN K, 1970, ARTHRITIS RHEUM US, V13, P769, DOI 10.1002/art.1780130606
   Marais AD, 2019, PATHOLOGY, V51, P165, DOI 10.1016/j.pathol.2018.11.002
   McMahon KM, 2014, EXPERT OPIN DRUG DEL, V11, P231, DOI 10.1517/17425247.2014.866089
   Meier FMP, 2013, IMMUNOTHERAPY UK, V5, P955, DOI 10.2217/imt.13.94
   Mostaghaci B, 2015, ACS APPL MATER INTER, V7, P5124, DOI 10.1021/am507193a
   Oliver KM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2575
   Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008
   Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Sun Y, 2017, ONCOL LETT, V13, P4849, DOI 10.3892/ol.2017.6045
   Taylor CT, 2009, ANN NY ACAD SCI, V1177, P178, DOI 10.1111/j.1749 6632.2009.05024.x
   Toita R, 2015, J MATER CHEM B, V3, P8738, DOI 10.1039/c5tb01679g
   Toms TE, 2012, J RHEUMATOL, V39, P218, DOI 10.3899/jrheum.110683
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Ye C, 2013, SCAND J RHEUMATOL, V42, P266, DOI 10.3109/03009742.2013.777779
   Yeung YT, 2018, CURR PHARM DESIGN, V24, P1449, DOI 10.2174/1381612824666180327165604
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
NR 52
TC 31
Z9 34
U1 5
U2 77
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR
PY 2022
VL 343
BP 314
EP 325
DI 10.1016/j.jconrel.2022.01.029
EA FEB 2022
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 0O3YT
UT WOS:000783465400003
PM 35085700
DA 2025 08 17
ER

PT J
AU Jeon, C
   Kim, D
   Kim, KM
   Lee, SH
   Lee, JH
   Kim, SH
   Kim, JS
   Kang, YM
   Jo, S
   Kim, TH
   Son, CN
AF Jeon, Chanhyeok
   Kim, Dongju
   Kim, Kyung Me
   Lee, Seung Hoon
   Lee, Ji Hyun
   Kim, Sang Hyon
   Kim, Jong Seo
   Kang, Young Mo
   Jo, Sungsin
   Kim, Tae Hwan
   Son, Chang Nam
TI Complement factor H related protein 5 alleviates joint inflammation and
   osteoclast differentiation by disrupting RANK JNK signaling in collagen
   antibody induced arthritis mouse model
SO CYTOKINE
LA English
DT Article
DE CFHR5; RANK JNK signaling; Inflammation; Arthritis; Osteoclasts
ID C REACTIVE PROTEIN; RHEUMATOID ARTHRITIS; INFLIXIMAB TREATMENT; PATHWAY
   ACTIVATION; SYSTEM; DESTRUCTION; THERAPY; DISEASE; BINDS; MICE
AB Background: Complement Factor H Related protein 5 (CFHR5) belongs to the factor H/CFHR family and regulates the complement system by modulating factor H's inhibitory activity against C3b. Despite its known role, the impact of CFHR5 on autoimmune arthritis and its relationship to pathophysiological changes in arthritis and bone loss remain unclear. This study aimed to assess the effect of CFHR5 on aggressive osteoclast activity and arthritis using a murine model of collagen antibody induced arthritis (CAIA). Methods: The effect of recombinant CFHR5 protein (rCFHR5) on arthritis were evaluated in CAIA. The mice were divided into three group and intraperitoneally treated with rCFHR5, methotrexate (MTX) as positive control or PBS as negative control. In the CAIA mouse model, the rCFHR5 treated group significantly reduced the incidence and clinical arthritis equivalent to the MTX group. Clinical arthritis scores, incidence and body weight were measured, and histological analysis of ankle joints was performed by Hematoxylin and Eosin (H&E) and Safranin O   Fast green (SOFG), Tartrate resistant acid phosphatase (TRAP) staining and Immunohistochemistry. Moreover, to investigate the rCFHR5 role, we isolated murine osteoclast precursor cells (OCPs) from each group, induced osteoclasts with M CSF and RANKL, and performed TRAP and F actin staining. To verify the mechanism, mRNA and protein analyses were performed in OCPs. Results: Histological examination of ankle joints revealed substantial reductions in synovial hyperplasia, bone marrow inflammation, bone erosion, cartilage destruction and TRAP positive cells in the rCFHR5 group compared to the vehicle group. The ankle joints of the rCFHR5 group showed markedly decreased expression of proinflammatory cytokines (TNF alpha, IL 1 beta and IL 6). Mechanically, treatment with rCFHR5 inhibited RANKLmediated osteoclast differentiation from OCPs and disrupted the RANK JNK signaling. These findings demonstrate that treatment with rCFHR5 attenuates joint inflammation and reduces osteoclast differentiation, indicating its potential anti inflammatory effect in autoimmune arthritis models.
C1 [Jeon, Chanhyeok; Kim, Dongju; Lee, Seung Hoon; Kim, Tae Hwan] Hanyang Univ Inst Rheumatol Res HYIRR, Seoul, South Korea.
   [Jeon, Chanhyeok; Kim, Dongju; Kim, Tae Hwan] Hanyang Univ, Grad Sch Biomed Sci & Engn, Deparment Translat Med, Seoul, South Korea.
   [Kim, Kyung Me; Lee, Ji Hyun; Son, Chang Nam] Eulji Univ, Uijeongbu Eulji Med Ctr, Sch Med, Dept Rheumatol, Uijongbu, South Korea.
   [Kim, Kyung Me; Lee, Ji Hyun; Son, Chang Nam] Eulji Univ, Eulji Rheumatol Res Inst, Uijongbu, South Korea.
   [Kim, Sang Hyon] Keimyung Univ, Sch Med, Dept Internal Med, Div Rheumatol, Daegu, South Korea.
   [Kim, Jong Seo] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea.
   [Kang, Young Mo] Preclina Inc, Incheon, South Korea.
   [Kang, Young Mo] Kyungpook Natl Univ Hosp, Dept Internal Med, Div Rheumatol, Daegu, South Korea.
   [Jo, Sungsin] Soonchunhyang Univ, Dept Biol, Asan, South Korea.
   [Kim, Tae Hwan] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, 222 1 Wangsimni Ro, Seoul 04763, South Korea.
C3 Hanyang University; Eulji University; Eulji University; Keimyung
   University; Seoul National University (SNU); Kyungpook National
   University (KNU); Kyungpook National University Hospital (KNUH);
   Soonchunhyang University; Hanyang University
RP Kim, TH (通讯作者)，Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, 222 1 Wangsimni Ro, Seoul 04763, South Korea.; Son, CN (通讯作者)，Eulji Univ, Uijeongbu Eulji Med Ctr, Sch Med, Dept Rheumatol, 712 Dongil Ro, Uijongbu 11759, Gyeonggi Do, South Korea.; Jo, S (通讯作者)，Soonchunhyang Univ, Coll Nat Sci, Dept Biol, 22 Soonchunhyang Ro, Asan 31538, Chungcheongnam, South Korea.
EM joejo0517@sch.ac.kr; thkim@hanyang.ac.kr; cnson@eulji.ac.kr
RI Li, Shaofu/O 2241 2019; Jo, Sungsin/AAL 3659 2021; Kim,
   Jong Seo/B 6478 2009
FU Soonchunhyang University Research Fund; Basic Science Research Program
   through the National Research Foundation of Korea [2021R1A6A1A03038899,
   2021R1A6A1A03039503, RS 2024 00351695]; Eulji University
   [2023 EMBRI UI0003]; Korea Basic Science Institute (National research
   Facilities and Equipment Center) grant  Ministry of Education
   [2022R1A6C101B794]
FX This work was supported by the Soonchunhyang University Research Fund,
   the Basic Science Research Program through the National Research
   Foundation of Korea (2021R1A6A1A03038899, 2021R1A6A1A03039503,
   RS 2024 00351695) , EMBRI Grants 2023 EMBRI UI0003 from Eulji
   University, and Korea Basic Science Institute (National research
   Facilities and Equipment Center) grant funded by the Ministry of
   Education (2022R1A6C101B794) .
CR Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Banda NK, 2007, J IMMUNOL, V179, P4101, DOI 10.4049/jimmunol.179.6.4101
   Banda NK, 2006, J IMMUNOL, V177, P1904, DOI 10.4049/jimmunol.177.3.1904
   Banda NK, 2012, J IMMUNOL, V188, P1469, DOI 10.4049/jimmunol.1102310
   Banda NK, 2009, J IMMUNOL, V183, P5928, DOI 10.4049/jimmunol.0901826
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Csincsi AI, 2017, J IMMUNOL, V199, P292, DOI 10.4049/jimmunol.1600483
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Durigutto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058696
   Familian A, 2005, ANN RHEUM DIS, V64, P1003, DOI 10.1136/ard.2004.029124
   Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140 6736(10)60670 8
   Hayer S, 2021, ANN RHEUM DIS, V80, P714, DOI 10.1136/annrheumdis 2020 219247
   Heesterbeek DAC, 2018, J INNATE IMMUN, V10, P455, DOI 10.1159/000491439
   Holers VM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01057
   Iglesias MJ, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 38383 y
   Jeon C, 2023, INT IMMUNOPHARMACOL, V118, DOI 10.1016/j.intimp.2023.110132
   Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074 7613(02)00275 3
   Jia YM, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04730 2
   Jo S, 2023, LIFE SCI, V334, DOI 10.1016/j.lfs.2023.122204
   Jo S, 2023, J RHEUMAT DIS, V30, P243, DOI 10.4078/jrd.2023.0024
   Jo S, 2023, J BONE MINER RES, V38, P300, DOI 10.1002/jbmr.4751
   Józsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Katschke KJ, 2007, J EXP MED, V204, P1319, DOI 10.1084/jem.20070432
   Krenn V, 2002, PATHOL RES PRACT, V198, P317, DOI 10.1078/0344 0338 5710261
   Lee JH, 2024, J MOL MED, V102, P571, DOI 10.1007/s00109 024 02428 6
   Lee S.H., 2024, Life Sci, V352
   Ling M, 2019, CLIN LAB MED, V39, P579, DOI 10.1016/j.cll.2019.07.006
   Loeven MA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.676662
   Macor P, 2012, ARTHRITIS RHEUM US, V64, P2559, DOI 10.1002/art.34430
   McRae JL, 2005, J IMMUNOL, V174, P6250, DOI 10.4049/jimmunol.174.10.6250
   Mehta G, 2015, J IMMUNOL, V194, P5446, DOI 10.4049/jimmunol.1403012
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Monteferrante G, 2007, MOL IMMUNOL, V44, P1704, DOI 10.1016/j.molimm.2006.08.004
   Möttönen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140 6736(98)08513 4
   Murphy B, 2002, AM J KIDNEY DIS, V39, P24, DOI 10.1053/ajkd.2002.29873
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Smolen JS, 2010, ANN RHEUM DIS, V69, P964, DOI 10.1136/ard.2009.126532
   WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955
   Weinberger A, 2003, ARTHRITIS RHEUM US, V48, P846, DOI 10.1002/art.10850
   Wijbrandts CA, 2008, ARTHRITIS RHEUM, V58, P3330, DOI 10.1002/art.23989
   Wouters D, 2006, ARTHRITIS RHEUM, V54, P1143, DOI 10.1002/art.21729
NR 42
TC 0
Z9 0
U1 1
U2 2
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 4666
EI 1096 0023
J9 CYTOKINE
JI Cytokine
PD DEC
PY 2024
VL 184
AR 156790
DI 10.1016/j.cyto.2024.156790
EA OCT 2024
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA K5K5S
UT WOS:001344261000001
PM 39461285
DA 2025 08 17
ER

PT J
AU Otero, JE
   Stevens, JW
   Malandra, AE
   Fredericks, DC
   Odgren, PR
   Buckwalter, JA
   Morcuende, J
AF Otero, Jesse E.
   Stevens, Jeff W.
   Malandra, Allison E.
   Fredericks, Douglas C.
   Odgren, Paul R.
   Buckwalter, Joseph A.
   Morcuende, Jose
TI Osteoclast Inhibition Impairs Chondrosarcoma Growth and Bone Destruction
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE chondrosarcoma; osteoclast; bisphosphonate; osteolysis
ID SWARM RAT CHONDROSARCOMA; ZOLEDRONIC ACID; TUMOR; CULTURES; PELVIS; GENE
AB Because Chondrosarcoma is resistant to available chemotherapy and radiation regimens, wide resection is the mainstay in treatment, which frequently results in high morbidity and which may not prevent local recurrence. There is a clear need for improved adjuvant treatment of this malignancy. We have observed the presence of osteoclasts in the microenvironment of chondrosarcoma in human pathological specimens. We utilized the Swarm rat chondrosarcoma (SRC) model to test the hypothesis that osteoclasts affect chondrosarcoma pathogenesis. We implanted SRC tumors in tibia of Sprague Dawley rats and analyzed bone histologically and radiographically for bone destruction and tumor growth. At three weeks, tumors invaded local bone causing cortical disruption and trabecular resorption. Bone destruction was accompanied by increased osteoclast number and resorbed bone surface. Treatment of rats with the zoledronic acid prevented cortical destruction, inhibited trabecular resorption, and resulted in decreased tumor volume in bone. To confirm that inhibition of osteoclasts per se, and not off target effects of drug, was responsible for the prevention of tumor growth and bone destruction, we implanted SRC into osteopetrotic rat tibia. SRC induced bone destruction and tumor growth were impaired in osteopetrotic bone compared with control bone. The results from our animal model demonstrate that osteoclasts contribute to chondrosarcoma mediated bone destruction and tumor growth and may represent a therapeutic target in particular chondrosarcoma patients. (c) 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:1562 1571, 2014.
C1 [Otero, Jesse E.; Buckwalter, Joseph A.; Morcuende, Jose] Univ Iowa, Dept Orthopaed Surg, Iowa City, IA 52242 USA.
   [Stevens, Jeff W.] Univ Iowa, Dept Internal Med, Sch Med, Iowa City, IA 52242 USA.
   [Malandra, Allison E.; Fredericks, Douglas C.] Univ Iowa, Dept Orthopaed Surg, Bone Healing Res Lab, Coralville, IA 52241 USA.
   [Odgren, Paul R.] Univ Massachusetts, Dept Cell & Dev Biol, Sch Med, North Worcester, MA 01655 USA.
   [Buckwalter, Joseph A.] Iowa City Vet Adm Med Ctr, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Massachusetts System; University of Massachusetts Worcester
RP Otero, JE (通讯作者)，Univ Iowa, Dept Orthopaed Surg, 200 Hawkins Dr,01051 JPP, Iowa City, IA 52242 USA.
EM jesse otero@uiowa.edu
OI Buckwalter, Joseph/0000 0003 4308 7583
FU Orthopaedic Research and Education Foundation Resident Clinician
   Scientist Training Grant
FX This work was funded through the Orthopaedic Research and Education
   Foundation Resident Clinician Scientist Training Grant
CR BREITKREUTZ D, 1979, CANCER RES, V39, P5093
   David E., 2011, Sarcoma, V2011, P1, DOI 10.1155/2011/932451
   Donati D, 2005, J BONE JOINT SURG BR, V87B, P1527, DOI 10.1302/0301 620X.87B11.16621
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gouin F, 2006, INT J CANCER, V119, P980, DOI 10.1002/ijc.21951
   Grimaud E, 2002, HISTOL HISTOPATHOL, V17, P1103, DOI 10.14670/HH 17.1103
   Hameed M, 2011, SEMIN DIAGN PATHOL, V28, P86, DOI 10.1053/j.semdp.2011.02.002
   Hamm CA, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 471
   HASCALL GK, 1981, ANAT RECORD, V200, P287, DOI 10.1002/ar.1092000307
   KENAN S, 1991, J ORTHOPAED RES, V9, P445, DOI 10.1002/jor.1100090317
   Kim Mi Jung, 2011, Sarcoma, V2011, DOI 10.1155/2011/405437
   KIMURA JH, 1979, J BIOL CHEM, V254, P2600
   Lee FY, 1999, J BONE JOINT SURG AM, V81A, P326, DOI 10.2106/00004623 199903000 00004
   MAIBENCO HC, 1967, CANCER RES, V27, P362
   Miot Noirault E, 2013, EJNMMI RES, V3, DOI 10.1186/2191 219X 3 40
   Morcuende Jose A, 2012, Iowa Orthop J, V32, P46
   Moussavi Harami F, 2006, BIOCHEM BIOPH RES CO, V346, P379, DOI 10.1016/j.bbrc.2006.05.158
   Murphey MD, 2003, RADIOGRAPHICS, V23, P1245, DOI 10.1148/rg.235035134
   Oji George S, 2007, Iowa Orthop J, V27, P9
   Pring ME, 2001, J BONE JOINT SURG AM, V83A, P1630, DOI 10.2106/00004623 200111000 00003
   PRITCHARD DJ, 1980, CANCER AM CANCER SOC, V45, P149, DOI 10.1002/1097 0142(19800101)45:1<149::AID CNCR2820450125>3.0.CO;2 A
   Sheth DS, 1996, CANCER, V78, P745, DOI 10.1002/(SICI)1097 0142(19960815)78:4<745::AID CNCR9>3.0.CO;2 D
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Van Wesenbeeck L, 2002, P NATL ACAD SCI USA, V99, P14303, DOI 10.1073/pnas.202332999
   Wardley A, 2005, BRIT J CANCER, V92, P1869, DOI 10.1038/sj.bjc.6602551
   Wirbel R J, 2000, Sarcoma, V4, P161, DOI 10.1080/13577140020025878
NR 28
TC 14
Z9 15
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD DEC
PY 2014
VL 32
IS 12
BP 1562
EP 1571
DI 10.1002/jor.22714
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA AR9FH
UT WOS:000343877500003
PM 25125336
DA 2025 08 17
ER

PT J
AU Sledge, GW
   Jotwani, AC
AF Sledge, George W., Jr.
   Jotwani, Aparna C.
TI Targeted Therapies in Early Stage Breast Cancer: Achievements and
   Promises
SO SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Breast cancer; Targeted therapy; HER2; Chemotherapy
ID ENDOTHELIAL GROWTH FACTOR; PACLITAXEL PLUS BEVACIZUMAB; GENE EXPRESSION;
   OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; ADJUVANT
   CHEMOTHERAPY; MONOCLONAL ANTIBODY; BONE METASTASES; TRASTUZUMAB;
   MECHANISMS
AB One of the most impressive changes in the therapeutic landscape of breast cancer in the past decade has been the advent of targeted therapies for specific subtypes. This article discusses the meaning of targeted therapy and examines the genomic basis for targeted therapy as it has emerged over the past decade. Human epidermal growth factor receptor 2 (HER2) targeted therapy, the principle example of targeted therapy to enter the adjuvant arena in the past decade, is described in depth. Novel targeted therapies under development, many currently being examined in the adjuvant setting, are also explored, including anti vascular endothelial growth factor therapy, poly (ADP ribose) polymerase (PARP) inhibition for triple negative breast cancers, and agents targeting site specific metastasis to the bone (receptor activator of NF kB [RANK] ligand inhibition). Chemotherapy, the epitome of nonspecific anticancer therapy, is in the process of becoming targeted therapy as understanding of breast cancer biology improves.
C1 [Sledge, George W., Jr.; Jotwani, Aparna C.] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis
RP Sledge, GW (通讯作者)，Indiana Univ, Simon Canc Ctr, RT 473,535 Barnhill Dr, Indianapolis, IN 46202 USA.
EM gsledge@iupui.edu
CR Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470 2045(09)70314 6
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Comen EA, 2010, ONCOLOGY NY, V24, P55
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320
   Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076
   Guise TA, 2009, GENE DEV, V23, P2117, DOI 10.1101/gad.1854909
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   HYNES NE, 1994, BBA REV CANCER, V1198, P165, DOI 10.1016/0304 419X(94)90012 4
   James JJ, 2003, BRIT J CANCER, V89, P660, DOI 10.1038/sj.bjc.6601198
   Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Konecny GE, 2004, CLIN CANCER RES, V10, P1706, DOI 10.1158/1078 0432.CCR 0951 3
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Linderholm B, 2004, EUR J CANCER, V40, P33, DOI 10.1016/S0959 8049(03)00673 7
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Martin SA, 2008, CURR OPIN GENET DEV, V18, P80, DOI 10.1016/j.gde.2008.01.016
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miles BJ, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.5077
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   OSHAUGHNESSY B, 2009, J CLIN ONCOL S, V27, pS18
   Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985
   PEGRAM M, 2006, BREAST CANC RES T S1, V100
   Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Piccart Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
   RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378 1119(94)00866 Q
   Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521 1878(199801)20:1<41::AID BIES7>3.0.CO;2 V
   Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roodman GD, 2001, J CLIN ONCOL, V19, P3562, DOI 10.1200/JCO.2001.19.15.3562
   Schneider BP, 2008, J CLIN ONCOL, V26, P4672, DOI 10.1200/JCO.2008.16.1612
   Schneider BP, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2250
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078 0432.CCR 08 1208
   Slamon D, 2009, 32 ANN SAN ANT BREAS
   SLAMON D, 2008, P AN M AM SOC CLIN, V16, P1016
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Sledge GW, 2005, J CLIN ONCOL, V23, P1614, DOI 10.1200/JCO.2005.01.016
   Sledge GW, 2002, CURR PROB CANCER, V26, P6, DOI 10.1016/S0147 0272(02)70005 6
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   STOPECK A, 2009, JOINT ECCO 15 34 ESM
   Tutt A, 2009, J CLIN ONCOL, V27
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 52
TC 3
Z9 3
U1 0
U2 8
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1055 3207
EI 1558 5042
J9 SURG ONCOL CLIN N AM
JI Surg. Oncol. Clin. N. Am.
PD JUL
PY 2010
VL 19
IS 3
BP 669
EP +
DI 10.1016/j.soc.2010.04.005
PG 12
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Surgery
GA 634RL
UT WOS:000280601200017
PM 20620934
DA 2025 08 17
ER

PT J
AU Lin, YF
   Wang, ZY
   Liu, SR
   Liu, JH
   Zhang, ZY
   Ouyang, YT
   Su, ZK
   Chen, D
   Guo, L
   Luo, T
AF Lin, Yifan
   Wang, Ziyan
   Liu, Shirong
   Liu, Jiaohong
   Zhang, Zhiyi
   Ouyang, Yuanting
   Su, Zhikang
   Chen, Ding
   Guo, Lvhua
   Luo, Tao
TI Roles of extracellular vesicles on macrophages in inflammatory bone
   diseases
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Extracellular vesicles; Macrophage; Inflammatory bone diseases;
   Periodontitis; Rheumatoid arthritis; Osteomyelitis
ID APOPTOTIC BODIES; DRUG DELIVERY; LUNG INJURY; EXOSOMES; CELLS;
   POLARIZATION; PERIODONTITIS; ARTHRITIS; CANCER; MICROPARTICLES
AB Inflammatory bone disease is a general term for a series of diseases caused by chronic inflammation, which leads to the destruction of bone homeostasis, that is, the osteolytic activity of osteoclasts increases, and the osteogenic activity of osteoblasts decreases, leading to osteolysis. Macrophages are innate immune cell with plasticity, and their polarization is related to inflammatory bone diseases. The dynamic balance of macrophages between the M1 phenotype and the M2 phenotype affects the occurrence and development of diseases. In recent years, an increasing number of studies have shown that extracellular vesicles existing in the extracellular environment can act on macrophages, affecting the progress of inflammatory diseases. This process is realized by influencing the physiological activity or functional activity of macrophages, inducing macrophages to secrete cytokines, and playing an anti inflammatory or pro inflammatory role. In addition, by modifying and editing extracellular vesicles, the potential of targeting macrophages can be used to provide new ideas for developing new drug carriers for inflammatory bone diseases.
C1 [Lin, Yifan; Wang, Ziyan; Liu, Shirong; Liu, Jiaohong; Zhang, Zhiyi; Ouyang, Yuanting; Su, Zhikang; Chen, Ding; Guo, Lvhua; Luo, Tao] Guangzhou Med Univ, Guangzhou, Guangdong, Peoples R China.
   [Lin, Yifan; Wang, Ziyan; Liu, Shirong; Liu, Jiaohong; Zhang, Zhiyi; Ouyang, Yuanting; Su, Zhikang; Chen, Ding; Guo, Lvhua; Luo, Tao] Guangzhou Med Univ, Guangdong Engn Res Ctr Oral Restorat & Reconstruct, Dept Prosthodont, Affiliated Stomatol Hosp,Guangzhou Key Lab Basic &, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou Medical University; Guangzhou Medical University
RP Guo, L; Luo, T (通讯作者)，Guangzhou Med Univ, Guangzhou, Guangdong, Peoples R China.; Guo, L; Luo, T (通讯作者)，Guangzhou Med Univ, Guangdong Engn Res Ctr Oral Restorat & Reconstruct, Dept Prosthodont, Affiliated Stomatol Hosp,Guangzhou Key Lab Basic &, Guangzhou, Guangdong, Peoples R China.
EM 2010686002@gzhmu.edu.cn; taoluocn@gmail.com
FU Guangdong Science and Technology Department [2021A0505030079]; Key
   Project of Science and Technology of Liwan District, Guangzhou City
   [2201006]
FX This study was supported by grants from Guangdong Science and Technology
   Department grant number 2021A0505030079; the Key Project of Science and
   Technology of Liwan District, Guangzhou City (No. 2201006).
CR Alghamdi M, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 021 04020 4
   Austin Williams S, 2021, FREE RADICAL BIO MED, V175, P80, DOI 10.1016/j.freeradbiomed.2021.08.235
   Bao LL, 2022, BIOACT MATER, V9, P183, DOI 10.1016/j.bioactmat.2021.08.008
   Boilard E, 2012, NAT REV RHEUMATOL, V8, P534, DOI 10.1038/nrrheum.2012.118
   Bonjoch L, 2016, J PATHOL, V240, P235, DOI 10.1002/path.4771
   Boutet MA, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102758
   Cabral J, 2018, ADV DRUG DELIVER REV, V129, P394, DOI 10.1016/j.addr.2018.01.018
   Cai MC, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106493
   Castegna A, 2020, PHARMACOL THERAPEUT, V210, DOI 10.1016/j.pharmthera.2020.107521
   Chang YJ, 2019, ARTERIOSCL THROM VAS, V39, P2492, DOI 10.1161/ATVBAHA.119.312707
   Chen HQ, 2022, TOXINS, V14, DOI 10.3390/toxins14070464
   Chen L, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1461505
   Chen XT, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01314 y
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Cheng LF, 2017, MOL THER, V25, P1665, DOI 10.1016/j.ymthe.2017.02.007
   Cloutier N, 2013, EMBO MOL MED, V5, P235, DOI 10.1002/emmm.201201846
   Cocozza F, 2020, CELL, V182, P262, DOI 10.1016/j.cell.2020.04.054
   Cosenza S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15376 8
   Dalirfardouei R, 2019, J TISSUE ENG REGEN M, V13, P555, DOI 10.1002/term.2799
   de Castilla PEM, 2021, ADV DRUG DELIVER REV, V175, DOI 10.1016/j.addr.2021.05.011
   de Couto G, 2019, ARTERIOSCL THROM VAS, V39, P2082, DOI 10.1161/ATVBAHA.119.313115
   Deng HM, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/7837837
   Deng HM, 2020, SHOCK, V54, P828, DOI 10.1097/SHK.0000000000001549
   Domenis R, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4814987
   Eken C, 2008, J IMMUNOL, V180, P817, DOI 10.4049/jimmunol.180.2.817
   Eken C, 2010, J BIOL CHEM, V285, P39914, DOI 10.1074/jbc.M110.126748
   Elsharkasy OM, 2020, ADV DRUG DELIVER REV, V159, P332, DOI 10.1016/j.addr.2020.04.004
   Gao WJ, 2021, PHARMACOL RES, V167, DOI 10.1016/j.phrs.2021.105563
   Gao YJ, 2021, EUR J MED CHEM, V213, DOI 10.1016/j.ejmech.2020.113056
   Gasser O, 2004, BLOOD, V104, P2543, DOI 10.1182/blood 2004 01 0361
   Ge XY, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12072
   Gimza BD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.638085
   Guo QQ, 2019, J HEPATOL, V71, P1193, DOI 10.1016/j.jhep.2019.07.019
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   He HL, 2017, J CONTROL RELEASE, V247, P106, DOI 10.1016/j.jconrel.2016.12.032
   Horwood NJ, 2016, CLIN REV ALLERG IMMU, V51, P79, DOI 10.1007/s12016 015 8519 2
   Hu YK, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6324912
   Huang YL, 2022, INT J NANOMED, V17, P799, DOI 10.2147/IJN.S350869
   Jahan N, 2022, ANTIBIOTICS BASEL, V11, DOI 10.3390/antibiotics11050542
   Jia YC, 2021, INT J BIOL SCI, V17, P549, DOI 10.7150/ijbs.54858
   Joswig AJ, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0503 8
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kang H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123843
   Kang MY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.878194
   Kavanagh N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00084 17
   Kim H, 2022, BIOMATERIALS, V286, DOI 10.1016/j.biomaterials.2022.121578
   Kim HY, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12157
   Kooijmans SAA, 2021, ADV DRUG DELIVER REV, V173, P252, DOI 10.1016/j.addr.2021.03.017
   Lai JL, 2022, J CONTROL RELEASE, V347, P27, DOI 10.1016/j.jconrel.2022.04.046
   Le Saux S, 2021, ADV DRUG DELIVER REV, V176, DOI 10.1016/j.addr.2021.113837
   Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Li H, 2022, J CONTROL RELEASE, V341, P16, DOI 10.1016/j.jconrel.2021.11.019
   Li JB, 2019, BIOCHEM BIOPH RES CO, V510, P565, DOI 10.1016/j.bbrc.2019.02.005
   Li JR, 2022, BURNS, V48, P1893, DOI 10.1016/j.burns.2021.12.010
   Li KL, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 021 01236 1
   Li Y, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 021 00152 2
   Liao CY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02980
   Lim GT, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12077
   Lin HB, 2022, J TRANSL MED, V20, DOI 10.1186/s12967 022 03487 4
   Liu C, 2021, ADV SCI, V8, DOI 10.1002/advs.202004433
   Liu J, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02014 w
   Liu L, 2021, TISSUE ENG PT A, V27, P962, DOI [10.1089/ten.tea.2020.0141, 10.1089/ten.TEA.2020.0141]
   Liu M, 2018, J DENT RES, V97, P859, DOI 10.1177/0022034518764411
   Lo Sicco C, 2017, STEM CELL TRANSL MED, V6, P1018, DOI 10.1002/sctm.16 0363
   Louiselle AE, 2021, TRANSL RES, V236, P109, DOI 10.1016/j.trsl.2021.05.006
   Lv LL, 2020, CELL DEATH DIFFER, V27, P210, DOI 10.1038/s41418 019 0349 y
   Ma JX, 2022, WIRES NANOMED NANOBI, V14, DOI 10.1002/wnan.1825
   Ma WT, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04117 5
   Mallik SB, 2018, J DIABETES COMPLICAT, V32, P524, DOI 10.1016/j.jdiacomp.2018.01.015
   Martin KE, 2021, ACTA BIOMATER, V133, P4, DOI 10.1016/j.actbio.2021.03.038
   Mayadas TN, 2014, ANNU REV PATHOL MECH, V9, P181, DOI 10.1146/annurev pathol 020712 164023
   Mentkowski KI, 2020, AM J PHYSIOL HEART C, V318, pH1447, DOI 10.1152/ajpheart.00155.2020
   Michalski MN, 2017, PHARMACOL THERAPEUT, V174, P43, DOI 10.1016/j.pharmthera.2017.02.017
   Missiakas D, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.621733
   Morrison TJ, 2017, AM J RESP CRIT CARE, V196, P1275, DOI 10.1164/rccm.201701 0170OC
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Naderi S, 2020, CURR ATHEROSCLER REP, V22, DOI 10.1007/s11883 020 00878 0
   Nakao Y, 2021, ACTA BIOMATER, V122, P306, DOI 10.1016/j.actbio.2020.12.046
   Nguyen MA, 2018, ARTERIOSCL THROM VAS, V38, P49, DOI 10.1161/ATVBAHA.117.309795
   Ni ZH, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0100 9
   Ni ZH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1739 2
   Ning HJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02591 4
   Pan WY, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0064 z
   Pan Y, 2019, J CLIN INVEST, V129, P834, DOI 10.1172/JCI123069
   Park J, 2019, THORAX, V74, P43, DOI 10.1136/thoraxjnl 2018 211576
   Patil M, 2021, CIRC RES, V129, P1006, DOI 10.1161/CIRCRESAHA.120.317900
   Phinney DG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9472
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Preshaw PM, 2012, DIABETOLOGIA, V55, P21, DOI 10.1007/s00125 011 2342 y
   Qiao SH, 2020, THERANOSTICS, V10, P11562, DOI 10.7150/thno.45459
   Rao NL, 2011, PLAST RECONSTR SURG, V127, p177S, DOI 10.1097/PRS.0b013e3182001f0f
   Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004
   Rhys HI, 2018, EBIOMEDICINE, V29, P60, DOI 10.1016/j.ebiom.2018.02.003
   Rowe SE, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00694 20
   Rowe SE, 2020, NAT MICROBIOL, V5, P282, DOI 10.1038/s41564 019 0627 y
   Sadrameli M, 2020, CURR OPIN NEUROL, V33, P230, DOI 10.1097/WCO.0000000000000797
   Sanz M, 2020, J CLIN PERIODONTOL, V47, P268, DOI [10.5334/gh.400, 10.1111/jcpe.13189]
   Schlundt C, 2021, ACTA BIOMATER, V133, P46, DOI 10.1016/j.actbio.2021.04.052
   Schmidt Bleek K, 2012, CELL TISSUE RES, V347, P567, DOI 10.1007/s00441 011 1205 7
   Shao HL, 2018, CHEM REV, V118, P1917, DOI 10.1021/acs.chemrev.7b00534
   Shen B, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1240301
   Sima C, 2013, PERIODONTOL 2000, V63, P80, DOI 10.1111/prd.12032
   Sun JY, 2022, FRONT CHEM, V10, DOI 10.3389/fchem.2022.863364
   Sun Y, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108576
   Takenaka M, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121160
   Tang DS, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.869207
   Tang DS, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.705472
   Tardito S, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102397
   Teng F, 2021, ADV SCI, V8, DOI 10.1002/advs.202003505
   Tran TH, 2015, CLIN IMMUNOL, V160, P46, DOI 10.1016/j.clim.2015.03.021
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Théry C, 2015, NATURE, V523, P161, DOI 10.1038/nature14626
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Tofiño Vian M, 2018, BIOCHEM PHARMACOL, V153, P134, DOI 10.1016/j.bcp.2018.02.004
   Trousil J, 2022, SMALL, V18, DOI 10.1002/smll.202201853
   Turpin D, 2016, AUTOIMMUN REV, V15, P174, DOI 10.1016/j.autrev.2015.11.004
   Udalova IA, 2016, NAT REV RHEUMATOL, V12, P472, DOI 10.1038/nrrheum.2016.91
   Wang JM, 2020, CRIT CARE MED, V48, pE599, DOI 10.1097/CCM.0000000000004315
   Wang R, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2019.106030
   Wang ZY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01310
   Wiklander OPB, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav8521
   Willis GR, 2018, AM J RESP CRIT CARE, V197, P104, DOI 10.1164/rccm.201705 0925OC
   Withrow J, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1178 8
   Woo CH, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1735249
   Wu Y, 2019, J CONTROL RELEASE, V316, P236, DOI 10.1016/j.jconrel.2019.10.043
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xia LJ, 2022, THERANOSTICS, V12, P2928, DOI 10.7150/thno.69533
   Xia YR, 2021, INFLAMMATION, V44, P2531, DOI 10.1007/s10753 021 01522 y
   Xu H, 2019, CLIN IMMUNOL, V205, P116, DOI 10.1016/j.clim.2019.06.006
   Xu XH, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01119 3
   Xu XB, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20180992
   Yan FL, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00675 6
   Yang JH, 2020, WORLD J STEM CELLS, V12, P688, DOI 10.4252/wjsc.v12.i7.688
   Yang SB, 2018, ACS APPL MATER INTER, V10, P14299, DOI 10.1021/acsami.7b15678
   Yang XH, 2021, J CONTROL RELEASE, V329, P454, DOI 10.1016/j.jconrel.2020.11.045
   Yang XH, 2018, INT J NANOMED, V13, P8095, DOI 10.2147/IJN.S179380
   Yang YH, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120390
   Ye QY, 2022, J PERIODONTOL, V93, P1738, DOI 10.1002/JPER.21 0657
   Yu B, 2016, SCI REP UK, V6, DOI 10.1038/srep34562
   Yu K, 2020, BONE JOINT RES, V9, P49, DOI 10.1302/2046 3758.92.BJR 2019 0131.R1
   Yuana Y, 2013, BLOOD REV, V27, P31, DOI 10.1016/j.blre.2012.12.002
   Zaborowska M, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121158
   Zelmer AR, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00227 8
   Zhang M, 2022, MATER TODAY BIO, V14, DOI 10.1016/j.mtbio.2022.100223
   Zhang MC, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03174 7
   Zhang SP, 2018, BIOMATERIALS, V156, P16, DOI 10.1016/j.biomaterials.2017.11.028
   Zhang X, 2021, ADV MATER, V33, DOI 10.1002/adma.202005709
   Zhang YL, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2021.107455
   Zhang Y, 2017, INT J NANOMED, V12, DOI 10.2147/IJN.S127715
   Zhao H, 2018, DIABETES, V67, P235, DOI 10.2337/db17 0356
   Zheng CX, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12109
   Zheng JM, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02039 1
   Zheng L, 2019, NANOMEDICINE UK, V14, P3193, DOI 10.2217/nnm 2018 0498
   Zhou M, 2022, J CONTROL RELEASE, V351, P394, DOI 10.1016/j.jconrel.2022.09.045
   Zou XY, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt428
NR 156
TC 5
Z9 5
U1 5
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JUN
PY 2024
VL 479
IS 6
BP 1401
EP 1414
DI 10.1007/s11010 023 04809 w
EA JUL 2023
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA XQ4N5
UT WOS:001026665100003
PM 37436653
DA 2025 08 17
ER

PT J
AU Li, YH
   Wu, ZZ
   Li, M
   Jia, XQ
   Yang, M
   Chen, MY
AF Li, Yinghong
   Wu, Zhengzhi
   Li, Ming
   Jia, Xiuqin
   Yang, Min
   Chen, Manyin
TI Gene expression in rat mesenchymal stem cells following treatment with
   natural cerebrolysin containing serum Validation of a whole genome
   microarray technique
SO NEURAL REGENERATION RESEARCH
LA English
DT Article
DE natural cerebrolysin; whole genome chip; mesenchymal stem cells; gene
   expression profile; Alzheimer's disease; neural regeneration;
   neurodegenerative disease
ID MARROW STROMAL CELLS; DIFFERENTIATE; DEFICIENT; DISEASE; MICE; SIZE
AB BACKGROUND: Natural cerebrolysin (NC), a Chinese herbal drug for the treatment of Alzheimer's disease (AD), induces mesenchymal stem cell (MSC) differentiation into neuron like cells, with low toxicity. But the mechanisms involved in NC effects on MSCs remain poorly understood.
   OBJECTIVE: We used a whole genome microarray technique to further investigate the molecular, genetic, and pharmacodynamic mechanisms of NC on MSC gene expression profiles.
   DESIGN, TIME AND SETTING: A parallel, controlled, in vitro experiment was performed at the First Affiliated Hospital of Shenzhen University, Shenzhen Institute of Integrated Chinese and Western Medicine, China, between September 2006 and October 2008.
   MATERIALS: NC was provided by Shenzhen Institute of Integrated Chinese and Western Medicine, China. It was predominantly composed of Renshen (Radix Ginseng), Tianma (Rhizoma Gastrodiae), and Yinxingye (Ginkgo Leaf) and prepared by conventional water extraction technology. Twelve adult, male, New Zealand rabbits were included, six of which underwent intragastric administration of NC extract for 1 month to create NC containing serum.
   METHODS: Bone marrow was collected from the tibia and femur of Sprague Dawley rats, aged 6 8 months old. Rat MSCs were isolated and purified by the whole bone marrow adherence method. After in vitro culture, MSCs from passage 4 were treated with NC containing serum for 48 hours, and total RNA was extracted. Gene expression in MSCs was analyzed using Affymetrix whole genome microarray analysis.
   MAIN OUTCOME MEASURES: Differentially expressed genes in NC serum treated MSCs.
   RESULTS: NC treated MSCs displayed 46 differentially expressed genes, 22 with upregulated expression (fold change > 2) and 24 with downregulated expression (fold change <  2). Differentially expressed genes participated in neuronal growth, differentiation, and function, cell growth, differentiation, proliferation, apoptosis, signal transduction, substance/energy metabolism, ion transport, and immune responses. NC treatment changed levels of transforming growth factor beta/bone morphogenetic proteins, Hedgehog, Bmp, and Wnt signaling pathways, which regulate nerve cell differentiation, development and function, as well as learning and memory; Ras, G protein coupled receptor signal pathways that are related to cell growth, proliferation, and apoptosis; and mitogen activated protein kinase kinase kinase signaling cascades.
   CONCLUSION: NC can regulate gene expression for many signal transduction pathways related to nerve cell differentiation, development and function, learning and memory function, as well as regulation of cell growth, differentiation, proliferation, or apoptosis to mediate the genetic effects of NC treatment on AD.
C1 [Li, Yinghong; Wu, Zhengzhi; Li, Ming; Jia, Xiuqin; Yang, Min; Chen, Manyin] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Inst Integrated Chinese & Western Med, Shenzhen 518035, Guangdong, Peoples R China.
C3 Shenzhen University
RP Wu, ZZ (通讯作者)，Shenzhen Univ, Affiliated Hosp 1, Shenzhen Inst Integrated Chinese & Western Med, Shenzhen 518035, Guangdong, Peoples R China.
EM zhengzhw@yahoo.com.cn
RI Li, Ying/U 4004 2017
FU Scientific and Technological Foundation of the National Administration
   of Traditional Chinese Medicine of China [02 03LP41]; Scientific and
   Technological Key Project of Guangdong Province [2006835630007]
FX Supported by: Scientific and Technological Foundation of the National
   Administration of Traditional Chinese Medicine of China, No. 02 03LP41;
   the Scientific and Technological Key Project of Guangdong Province, No.
   2006835630007
CR [Anonymous], 2005, Pharmacopoeia of thePeople's Republic of China
   [Anonymous], 2006, GUID SUGG CAR US LAB
   BIORKLUND A, 2000, NAT NEUROSCI, V3, P537
   Chai Li Hui, 2007, Sheng Wu Gong Cheng Xue Bao, V23, P252
   Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005
   CHEN Q, 2000, PHARM RES METHODOLOG
   Dong Xiao xian, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P51
   DONG YX, 2003, ZHONGHUA SHENJINGKE, V36, P355
   Holtz WA, 2005, ANTIOXID REDOX SIGN, V7, P639, DOI 10.1089/ars.2005.7.639
   Hosseinkhani H, 2006, BIOMED MATER, V1, P8, DOI 10.1088/1748 6041/1/1/002
   Jain KK, 2001, SCIENCE, V294, P621, DOI 10.1126/science.294.5542.621
   JIA YJ, 2002, ZHONGGUO BINGLI SHEN, V18, P247
   Kon E, 2000, J BIOMED MATER RES, V49, P328
   Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015
   LI YK, 1999, ZHONGYAO XINYAO YU L, V10, P95
   Lien WH, 2006, SCIENCE, V311, P1609, DOI 10.1126/science.1121449
   [刘金保 Liu Jinbao], 2003, [广东医学, Guangdong Medical Journal], V24, P466
   Newman MB, 2008, NEUROTHERAPEUTICS, V5, P237, DOI 10.1016/j.nurt.2008.02.004
   Nieto M, 2007, ONCOGENE, V26, P1673, DOI 10.1038/sj.onc.1209978
   Ovstebo R, 2008, INFECT IMMUN, V76, P2685, DOI 10.1128/IAI.01625 07
   PANG JP, 2005, ZHONGYAO YAOLI YU LI, V21, P9
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Sa Y.L., 2003, Acta Anatomica Sinica, V34, P514
   SA YL, 2002, ZHONGSHAN YIKE DAXUE, V23, P409
   Sanchez Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389
   Sensebé L, 2008, BIO MED MATER ENG, V18, pS3
   Seshareddy K, 2008, METHOD CELL BIOL, V86, P101, DOI 10.1016/S0091 679X(08)00006 X
   Singh S, 2008, STEM CELLS DEV, V17, P245, DOI 10.1089/scd.2007.0146
   Sotiropoulou Panagiota A., 2007, V407, P225, DOI 10.1007/978 1 59745 536 7_16
   Sugaya K, 2006, PANMINERVA MED, V48, P87
   WANG X, 2003, ZHONGCAOYAO, V34, P577
   Whittemore Scott R., 2008, V438, P375, DOI 10.1007/978 1 59745 133 8_29
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   WU ZZ, 2005, ZHONGGUO LINCHUANG K, V9, P178
   WU ZZ, 2007, ZHONGGUO ZHONGYIYAO, V14, P444
   WU ZZ, 2004, NEUROSCI BULL, V20, P167
   WU ZZ, 2007, SHENZHEN ZHONGXIYI J, V17, P278
   WU ZZ, 2005, ZHONGGUO LINCHUANG K, V9, P180
   WU ZZ, 2009, NEURAL REGEN RES, V4, P1
   WU ZZ, 1999, ZHONGGUO YIYAO XUEBA, V14, P18
   WU ZZ, 1998, ZHONGGUO ZHONGYIYAO, V5, P223
   XIA WJ, 2003, ZHONGGUO BINGLI SHEN, V19, P865
   XIA WJ, 2002, ZHONGGUO ZHONGXIYI J, V22, P921
   XIANG P, 2004, ZHONGGUO BINGLI SHEN, V20, P51
   XIANG P, 2001, CHINESE J PATHOPHYSI, V17, P385
   XIANG P, 2001, ZHONGSHAN YIKE DAXUE, V22, P321
   XIAO QZ, 2002, ZHONGSHAN YIKE DAXUE, V23, P405
   ZHAO TX, 2003, HUBEI ZHONGYI XUEYUA, V5, P45
NR 48
TC 1
Z9 1
U1 3
U2 17
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1673 5374
EI 1876 7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD MAR 30
PY 2010
VL 5
IS 6
BP 424
EP 432
DI 10.3969/j.issn.1673 5374.2010.06.004
PG 9
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA 582VE
UT WOS:000276627100004
DA 2025 08 17
ER

PT J
AU Rho, TW
   Lee, SY
   Han, SY
   Kim, JH
   Lee, KH
   Kim, DS
   Kwak, HB
   Kim, YK
AF Rho, Tae Won
   Lee, Seo Young
   Han, Sang Yong
   Kim, Ji Hoon
   Lee, Kyung Hee
   Kim, Dong Seon
   Kwak, Han Bok
   Kim, Yun Kyung
TI Glycyrrhizae Radix Inhibits Osteoclast Differentiation by Inhibiting
   c Fos Dependent NFATc1 Expression
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Glycyrrhizae Radix; Osteoporosis; Osteoclast Differentiation;
   c Fos Dependent NFATc1 Expression.
ID NF KAPPA B; BONE RESORPTION; NUCLEAR FACTOR; RANKL; ACTIVATION; CELLS;
   MECHANISMS; INDUCTION; MEDICINES; IMMUNE
AB Osteoporosis results from imbalance between new bone formation and bone resorption leading to bone loss and is especially troublesome for postmenopausal women who suffer from estrogen deficiency. The ability of new therapeutic agents to treat this bone disease with minimal side effects has been extensively reported on and is continuously being sought out by researchers in this field. Thus, the purpose of this study was to investigate a natural herb that was already being used as a new treatment for osteoporosis. Here we found that water extract of Glycyrrhizae radix (GR) inhibits receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation in a dose dependent manner without causing cytotoxicity. The mRNA expression of c Fos, nuclear factor of activated T cells cytoplasmic 1 (NFATc1), tartrate resistant acid phosphatase (TRAP), and osteoclast associated receptor (OSCAR) was considerably inhibited by GR treatment. GR inhibited RANKL mediated c Fos and NFATc1 expression in a dose dependent manner. GR inhibited the degradation of I kappa B in RANKL stimulated BMMs. However, GR mediated inhibition of osteoclast differentiation and osteoclast specific gene expression, including NFATc1, was reversed by ectopic expression of c Fos. Also, GR significantly inhibited osteoclast formation in mouse calvariae in the presence of IL 1 and prostaglandin E2 (PGE2). Taken together, these results suggest that GR inhibited osteoclast differentiation, raising the possibility that GR may serve as a useful drug for osteoporosis.
C1 [Rho, Tae Won; Lee, Seo Young; Han, Sang Yong; Kim, Ji Hoon; Kim, Yun Kyung] Wonkwang Univ, Dept Herbal Med, Coll Pharm, 460 Iksan Daero, Iksan, Jeonbuk, South Korea.
   [Han, Sang Yong; Kim, Ji Hoon; Lee, Kyung Hee; Kwak, Han Bok] Wonkwang Univ, Dept Herbal Resources, Profess Grad Sch Oriental Med, Plus Team BK21, 460 Iksan Daero, Iksan, Jeonbuk, South Korea.
   [Kim, Yun Kyung] Wonkwang Univ, Wonkwang Oriental Med Res Inst, 460 Iksan Daero, Iksan, Jeonbuk, South Korea.
   [Kim, Dong Seon] Korea Inst, Herbal Med Resources Grp, 1672 Yuseong Daero, Daejon, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University
RP Kim, YK (通讯作者)，Wonkwang Univ, Dept Herbal Med, Coll Pharm, 460 Iksan Daero, Iksan, Jeonbuk, South Korea.
EM hestia@wonkwang.ac.kr
RI Lee, Yoojin/AAB 9799 2022
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chambers TJ, 2000, J PATHOL, V192, P4
   Chen XW, 2011, CURR MED CHEM, V18, P3190, DOI 10.2174/092986711796391624
   Cheon YH, 2014, PHYTOTHER RES, V28, P586, DOI 10.1002/ptr.5034
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Fu YH, 2014, BBA GEN SUBJECTS, V1840, P1755, DOI 10.1016/j.bbagen.2014.01.024
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kamei J, 2003, EUR J PHARMACOL, V469, P159, DOI 10.1016/S0014 2999(03)01728 X
   Kao TC, 2014, J AGR FOOD CHEM, V62, P542, DOI 10.1021/jf404939f
   Karrasch T, 2008, INFLAMM BOWEL DIS, V14, P114, DOI 10.1002/ibd.20243
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kim YW, 2008, BRIT J PHARMACOL, V154, P165, DOI 10.1038/bjp.2008.79
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Ming LJ, 2013, NAT PROD COMMUN, V8, P415
   Miyata T, 2007, J PHARMACOL SCI, V103, P127, DOI 10.1254/jphs.CPJ06016X
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yazdi A, 2011, IRAN J PHARM RES, V10, P75
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
NR 35
TC 13
Z9 13
U1 0
U2 5
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2017
VL 45
IS 2
BP 283
EP 298
DI 10.1142/S0192415X17500185
PG 16
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA ES8YV
UT WOS:000399843700006
PM 28231743
DA 2025 08 17
ER

PT J
AU Seda, M
   Geerlings, M
   Lim, P
   Jeyabalan Srikaran, J
   Cichon, AC
   Scambler, PJ
   Beales, PL
   Hernandez Hernandez, V
   Stoker, AW
   Jenkins, D
AF Seda, Marian
   Geerlings, Maartje
   Lim, Peggy
   Jeyabalan Srikaran, Jeshmi
   Cichon, Ann Christin
   Scambler, Peter J.
   Beales, Philip L.
   Hernandez Hernandez, Victor
   Stoker, Andrew W.
   Jenkins, Dagan
TI An FDA Approved Drug Screen for Compounds Influencing Craniofacial
   Skeletal Development and Craniosynostosis
SO MOLECULAR SYNDROMOLOGY
LA English
DT Article
DE FDA approved drug screen; Neural crest stem/progenitor cells; Skeletal
   development
ID CREST MESODERM BOUNDARY; NEURAL CREST; CRANIOFRONTONASAL SYNDROME;
   RIBOSOME BIOGENESIS; SMALL MOLECULES; EFNB1 GENE; ZEBRAFISH; EXPRESSION;
   MUTATIONS; OSTEOARTHRITIS
AB Neural crest stem/progenitor cells (NCSCs) populate a variety of tissues, and their dysregulation is implicated in several human diseases including craniosynostosis and neuroblastoma. We hypothesised that small molecules that inhibit NCSC induction or differentiation may represent potential therapeutically relevant drugs in these disorders. We screened 640 FDA approved compounds currently in clinical use for other conditions to identify those which disrupt development of NCSC derived skeletal elements that form the zebrafish jaw. In the primary screen, we used heterozygous transgenic sox10: gfp zebrafish to directly visualise NCSC derived jaw cartilage. We noted partial toxicity of this transgene in relation to jaw patterning, suggesting that our primary screen was sensitised for NCSC defects, and we confirmed 10 novel, 4 previously reported, and 2 functional analogue drug hits in wild type embryos. Of these drugs, 9/14 and 7/14, respectively, are known to target pathways implicated in osteoarthritis pathogenesis or to cause reduced bone mineral density/increased fracture risk as side effects in patients treated for other conditions, suggesting that our screen enriched for pathways targeting skeletal tissue homeostasis. We selected one drug that inhibited NCSC induction and one drug that inhibits bone mineralisation for further detailed analyses which reflect our initial hypotheses. These drugs were leflunomide and cyclosporin A, respectively, and their functional analogues, teriflunomide and FK506 (tacrolimus). We identified their critical developmental windows of activity, showing that the severity of defects observed related to the timing, duration, and dose of treatment. While leflunomide has previously been shown to inhibit NCSC induction, we demonstrate additional later roles in cartilage remodelling. Both drugs altered expression of extracellular matrix metalloproteinases. As proof of concept, we also tested drug treatment of disease relevant mammalian cells. While leflunomide treatment inhibited the viability of several human NCSC derived neuroblastoma cell lines coincident with altered expression of genes involved in ribosome biogenesis and transcription, FK506 enhanced murine calvarial osteoblast differentiation and prevented fusion of the coronal suture in calvarial explants taken from Crouzon syndrome mice. (c) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Seda, Marian; Geerlings, Maartje; Lim, Peggy; Jeyabalan Srikaran, Jeshmi; Beales, Philip L.; Hernandez Hernandez, Victor; Jenkins, Dagan] UCL Inst Child Hlth, Genet & Genom Med, 30 Guilford St, London WC1N 1EH, England.
   [Cichon, Ann Christin; Scambler, Peter J.; Stoker, Andrew W.] UCL Inst Child Hlth, Dev Biol Programme, London, England.
   [Cichon, Ann Christin; Scambler, Peter J.; Stoker, Andrew W.] UCL Inst Child Hlth, Canc Programme, London, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London
RP Jenkins, D (通讯作者)，UCL Inst Child Hlth, Genet & Genom Med, 30 Guilford St, London WC1N 1EH, England.
EM d.jenkins@ucl.ac.uk
RI Stoker, andrew/AAX 1827 2020; Beales, Philip/C 7367 2009; Scambler,
   Peter/AAZ 6026 2020; Jenkins, Dagan/ISB 1573 2023; Geerlings,
   Maartje/P 8309 2015
OI Marian, Seda/0000 0002 5634 3585; Hernandez, Victor/0000 0002 4424 1848;
   Geerlings, Maartje/0000 0003 1164 3573; Jeyabalan Srikaran,
   Jeshmi/0000 0002 0195 8478
FU Medical Research Council New Investigator Research Grant [MR/L009978/1];
   Action Medical Research Project Grant [GN2595]; National Institute for
   Health Research Biomedical Research Centre at Great Ormond Street
   Hospital for Children NHS Foundation Trust; University College London;
   MRC [MR/L009978/1] Funding Source: UKRI; Action Medical Research;
   National Institute for Health Research [2595] Funding Source:
   researchfish; Great Ormond Street Hospital Childrens Charity [V2318]
   Funding Source: researchfish; Medical Research Council [MR/L009978/1]
   Funding Source: researchfish
FX This work was funded by a Medical Research Council New Investigator
   Research Grant (MR/L009978/1) and Action Medical Research Project Grant
   (GN2595) to D.J. This research was also supported by the National
   Institute for Health Research Biomedical Research Centre at Great Ormond
   Street Hospital for Children NHS Foundation Trust and University College
   London.
CR Åberg T, 2005, J HISTOCHEM CYTOCHEM, V53, P653, DOI 10.1369/jhc.4A6518.2005
   Ahi EP, 2016, PEERJ, V4, DOI 10.7717/peerj.1878
   Babbs C, 2011, HUM MUTAT, V32, P930, DOI 10.1002/humu.21521
   BATES RE, 1993, CRANIO, V11, P284, DOI 10.1080/08869634.1993.11677980
   Bay Jensen AC, 2013, MENOPAUSE, V20, P578, DOI 10.1097/GME.0b013e3182745993
   Beier F, 2014, OSTEOARTHR CARTILAGE, V22, P893, DOI 10.1016/j.joca.2014.04.011
   Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383
   Buckwalter Joseph A, 2005, Instr Course Lect, V54, P465
   Burleigh A, 2012, ARTHRITIS RHEUM US, V64, P2278, DOI 10.1002/art.34420
   Capellino S, 2014, ARTHRITIS RHEUMATOL, V66, P2685, DOI 10.1002/art.38746
   Carney TJ, 2006, DEVELOPMENT, V133, P4619, DOI 10.1242/dev.02668
   Cheng SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069051
   COHEN PS, 1995, CANCER RES, V55, P2380
   Cook D, 2014, NAT REV DRUG DISCOV, V13, P419, DOI 10.1038/nrd4309
   Davies MR, 2009, ARTHRITIS RHEUM US, V60, P1722, DOI 10.1002/art.24550
   Deckelbaum RA, 2012, DEVELOPMENT, V139, P1346, DOI 10.1242/dev.076729
   Dutton JR, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 105
   Eames BF, 2013, BMC DEV BIOL, V13, DOI 10.1186/1471 213X 13 23
   Eswarakumar VP, 2006, P NATL ACAD SCI USA, V103, P18603, DOI 10.1073/pnas.0609157103
   Gatsinzi T, 2012, J NEURO ONCOL, V109, P503, DOI 10.1007/s11060 012 0932 2
   Gut P, 2013, NAT CHEM BIOL, V9, P97, DOI [10.1038/NCHEMBIO.1136, 10.1038/nchembio.1136]
   Hehr U, 1999, MOL GENET METAB, V68, P139, DOI 10.1006/mgme.1999.2915
   Hikichi Y, 2009, BIOCHEM BIOPH RES CO, V386, P294, DOI 10.1016/j.bbrc.2009.06.052
   Ishizaki H, 2010, DIS MODEL MECH, V3, P639, DOI 10.1242/dmm.005769
   Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487
   Kaminuma Osamu, 2008, Inflamm Allergy Drug Targets, V7, P35, DOI 10.2174/187152808784165207
   Kaufman CK, 2016, SCIENCE, V351, DOI 10.1126/science.aad2197
   Keupp K, 2013, MOL GENET GENOM MED, V1, P223, DOI 10.1002/mgg3.28
   Kitambi SS, 2009, MECH DEVELOP, V126, P464, DOI 10.1016/j.mod.2009.01.002
   Kong YW, 2014, CHEM BIOL, V21, P488, DOI 10.1016/j.chembiol.2014.02.013
   Le XN, 2013, DEVELOPMENT, V140, P2354, DOI 10.1242/dev.088427
   Luo RS, 2001, DEV DYNAM, V220, P169, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1097>3.0.CO;2 1
   Mazziotti G, 2010, AM J MED, V123, P877, DOI 10.1016/j.amjmed.2010.02.028
   Merrill AE, 2006, HUM MOL GENET, V15, P1319, DOI 10.1093/hmg/ddl052
   Mitchell RE, 2013, OSTEOARTHR CARTILAGE, V21, P269, DOI 10.1016/j.joca.2012.11.004
   Mobasheri A, 2007, OSTEOARTHR CARTILAGE, V15, P1, DOI 10.1016/j.joca.2006.06.017
   Mork L, 2015, CURR TOP DEV BIOL, V115, P235, DOI 10.1016/bs.ctdb.2015.07.001
   Nagashimada M, 2012, J CLIN INVEST, V122, P3145, DOI 10.1172/JCI63401
   Namdaran P, 2012, J NEUROSCI, V32, P3516, DOI 10.1523/JNEUROSCI.3905 11.2012
   Ni TT, 2011, CHEM BIOL, V18, P1658, DOI 10.1016/j.chembiol.2011.09.015
   Nieminen P, 2011, AM J HUM GENET, V89, P67, DOI 10.1016/j.ajhg.2011.05.024
   North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883
   Paik EJ, 2010, ZEBRAFISH, V7, P61, DOI 10.1089/zeb.2009.0643
   Peal DS, 2011, CIRCULATION, V123, P23, DOI 10.1161/CIRCULATIONAHA.110.003731
   Peterson RT, 2004, NAT BIOTECHNOL, V22, P595, DOI 10.1038/nbt963
   Rennekamp AJ, 2015, CURR OPIN CHEM BIOL, V24, P58, DOI 10.1016/j.cbpa.2014.10.025
   Ridges S, 2012, BLOOD, V119, P5621, DOI 10.1182/blood 2011 12 398818
   Rihel J, 2010, SCIENCE, V327, P348, DOI 10.1126/science.1183090
   Rovira M, 2011, P NATL ACAD SCI USA, V108, P19264, DOI 10.1073/pnas.1113081108
   Schilling TF, 1997, DEVELOPMENT, V124, P2945
   Schwerd T, 2017, J EXP MED, V214, P2547, DOI 10.1084/jem.20161810
   Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535
   Sharif F, 2014, CELL J, V16, P211
   Stern HM, 2005, NAT CHEM BIOL, V1, P366, DOI 10.1038/nchembio749
   Takamatsu A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092699
   Trainor PA, 2014, BBA MOL BASIS DIS, V1842, P769, DOI 10.1016/j.bbadis.2013.11.010
   Twigg SRF, 2004, P NATL ACAD SCI USA, V101, P8652, DOI 10.1073/pnas.0402819101
   Twigg SRF, 2006, AM J HUM GENET, V78, P999, DOI 10.1086/504440
   Twigg SRF, 2015, AM J HUM GENET, V97, P359, DOI 10.1016/j.ajhg.2015.07.006
   Twigg SRF, 2013, HUM MOL GENET, V22, P1654, DOI 10.1093/hmg/ddt015
   Wang JX, 2009, J PATHOL, V219, P163, DOI 10.1002/path.2578
   White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882
   Wiley DS, 2017, METHOD CELL BIOL, V138, P651, DOI 10.1016/bs.mcb.2016.10.004
   Wilkie AOM, 2010, PEDIATRICS, V126, pE391, DOI 10.1542/peds.2009 3491
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yin YW, 2015, MOL GENET GENOMICS, V290, P513, DOI 10.1007/s00438 014 0940 3
   Yoo SA, 2007, ARTHRITIS RHEUM US, V56, P2299, DOI 10.1002/art.22731
   Zhu SJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071555, 10.1371/journal.pone.0067448]
NR 68
TC 11
Z9 11
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1661 8769
EI 1661 8777
J9 MOL SYNDROMOL
JI Mol. Syndromol.
PY 2019
VL 10
IS 1 2
BP 98
EP 114
DI 10.1159/000491567
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA HO5OG
UT WOS:000460977000009
PM 30976283
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Chen, L
   Yin, N
   Ding, Y
   Zhang, ML
   Li, M
   Zhong, JJ
   Feng, SM
AF Chen, Long
   Yin, Na
   Ding, Yi
   Zhang, Mei Lin
   Li, Min
   Zhong, Jin Jie
   Feng, Shu Mei
TI Effects of fluoride on the proliferation and activation of osteoblasts
   by regulating methylation of the DNA repair genes MGMT and MLH1
SO REGENERATIVE THERAPY
LA English
DT Article
DE NaF; Osteoblasts; MGMT; MLH1; Methylation; Skeletal fluorosis
AB Introduction: Fluoride can induce the proliferation and activation of osteoblasts, resulting in skeletal fluorosis progression; however, the specific mechanism is unclear.
   Methods: Cell proliferation was examined using the MTT assay. Flow cytometry was performed to detect the cell cycle distribution. Alkaline phosphatase (ALP) was calculated to evaluate bone formation and turnover. Gene methylation was examined using the MSP assay. mRNA and protein expression levels were assessed using qRT PCR and Western blot assays.
   Results: Low concentration NaF treatment promoted the cell cycle progression of osteoblasts to S phase, thus accelerating cell proliferation and activation in a concentration dependent manner. In addition, the methylation of the MGMT and MLH1 genes was increased, and their mRNA expression was reduced. Furthermore, the DNA methyltransferase inhibitor S AZA dC suppressed cell viability, cell number in Sphase, ALP activity and osteogenesis related protein levels in osteoblasts treated with low doses of NaF. Meanwhile, S AZA dC suppressed the increase in MGMT and MLH1 gene methylation in osteoblasts treated with low doses of NaF, leading to enhanced expression of MGMT and MLH1 mRNA.
   Conclusion: NaF treatment led to methylation of the DNA repair genes MGMT and MLH1 in osteoblasts, resulting in cell proliferation and activation and causing the development of skeletal fluorosis. (C) 2022, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
C1 [Chen, Long; Yin, Na] Xinjiang Med Univ, Funct Ctr, Sch Basic Med Sci, Urumqi 830011, Xinjiang, Peoples R China.
   [Ding, Yi; Li, Min; Feng, Shu Mei] Xinjiang Med Univ, Sch Basic Med Sci, Dept Histol & Embryol, 567 Shangde North Rd,Xuelianshan Campus, Urumqi 830011, Xinjiang, Peoples R China.
   [Zhang, Mei Lin] Urumqi Blood Ctr, Cilin Lab, Urumqi 830000, Xinjiang, Peoples R China.
   [Zhong, Jin Jie] Zhejiang Univ, Dept Basic Med Sci, Sch Med, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Xinjiang Medical University; Xinjiang Medical University; Zhejiang
   University
RP Feng, SM (通讯作者)，Xinjiang Med Univ, Sch Basic Med Sci, Dept Histol & Embryol, 567 Shangde North Rd,Xuelianshan Campus, Urumqi 830011, Xinjiang, Peoples R China.; Zhong, JJ (通讯作者)，Zhejiang Univ, Dept Basic Med Sci, Sch Med, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
EM 616504535@qq.com; 87391167@qq.com
RI ; Zhong, Jinjie/HGC 6822 2022
OI Ding, Yi/0000 0003 1356 6401; Zhong, Jinjie/0000 0002 7645 8400
FU Natural Science Foundation of Xinjiang Uygur Autonomous Region
   [2019D01C196]; National Natural Science Foundation of China [81660521];
   Autonomous Region's 13th Five Year Key Discipline Basic Medicine
FX This work was supported by Natural Science Foundation of Xinjiang Uygur
   Autonomous Region (2019D01C196), National Natural Science Foundation of
   China (81660521) and Autonomous Region's 13th Five Year Key
   Discipline Basic Medicine.
CR Alkam Y, 2013, HISTOPATHOLOGY, V63, P713, DOI 10.1111/his.12220
   Bocangel D, 2009, ANTICANCER RES, V29, P3741
   Brim H, 2008, MOL CANCER, V7, DOI 10.1186/1476 4598 7 68
   Chen Y, 2013, BIOCHEM BIOPH RES CO, V432, P116, DOI 10.1016/j.bbrc.2013.01.075
   Chu XF, 2005, CHIN J CLIN REHABIL, V9, P162
   Craig L, 2015, APPL GEOCHEM
   Everett ET, 2011, J DENT RES, V90, P552, DOI 10.1177/0022034510384626
   Nair M, 2011, BIOCHEM CELL BIOL, V89, P377, DOI 10.1139/O11 034
   Pan XL, 2020, CHEM BIOL INTERACT, V315, DOI 10.1016/j.cbi.2019.108875
   Pei JR, 2016, ENVIRON TOXICOL PHAR, V46, P241, DOI 10.1016/j.etap.2016.08.001
   PREUSS I, 1995, INT J CANCER, V61, P321, DOI 10.1002/ijc.2910610308
   Ren GX, 2011, BIOL TRACE ELEM RES, V144, P914, DOI 10.1007/s12011 011 9059 0
   Shouli Weimin, 2018, ENVIRON TOXICOL
   Wu CX, 2018, J TRACE ELEM MED BIO, V50, P223, DOI 10.1016/j.jtemb.2018.07.010
   Yang Jing, 2012, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V26, P984
   Zhao S, 2016, PEDIATR NEONATOL, V58
   Zheng C, 2009, CHIN J CLIN ONCOL
   Zhou YL, 2013, BIOL TRACE ELEM RES, V154, P448, DOI 10.1007/s12011 013 9752 2
NR 18
TC 3
Z9 3
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD MAR
PY 2022
VL 19
BP 107
EP 112
DI 10.1016/j.reth.2022.01.004
EA JAN 2022
PG 6
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA ZQ6MD
UT WOS:000767215900011
PM 35155723
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kowada, T
   Kikuta, J
   Kubo, A
   Ishii, M
   Maeda, H
   Mizukami, S
   Kikuchi, K
AF Kowada, Toshiyuki
   Kikuta, Junichi
   Kubo, Atsuko
   Ishii, Masaru
   Maeda, Hiroki
   Mizukami, Shin
   Kikuchi, Kazuya
TI In Vivo Fluorescence Imaging of Bone Resorbing Osteoclasts
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID BODIPY DYES; PROBES; RISEDRONATE; DESIGN; CELLS
AB Osteoclasts are giant polykaryons responsible for bone resorption. Because an enhancement or loss of osteoclast function leads to bone diseases such as osteoporosis and osteopetrosis, real time imaging of osteoclast activity in vivo can be of great help for the evaluation of drugs. Herein, pH activatable chemical probes BAp M and BAp E have been developed for the detection of bone resorbing osteoclasts in vivo. Their acid dissociation constants (pK(a)) were determined as 4.5 and 6.2 by fluorometry in various pH solutions. These plc values should be appropriate to perform selective imaging of bone resorbing osteoclasts, because synthesized probes Cannot fluoresce intrinsically at physiological pH and the pH in the resorption pit is lowered to about 4.5. Furthermore, BAp M and BAp E have a bisphosphonate Moiety that enabled the probes to localize. on bone tissues. The hydroxyapatite (HA) binding assay in vitro was, therefore, performed to confirm the tight binding of the probes to the bone tissues. Our probes showed :intense fluorescence at pH values but no fluorescence signal under physiological pH conditions on HA. Finally, we applied the probes to in vivo imaging of osteoclasts by using intravital two photon microscopy. As expected, the fluorescence signals of the probes were locally observed between; the osteoclasts and bone tissues, that is in resorption pits. These results indicate that our pH activatable probe g will prove to be a powerful tool for the selective detection of bone resorbing osteoclasts in vivo, because this is the first instance Where in vivo imaging has been conducted in a low pH region created by bone resorbing osteoclasts.
C1 [Kowada, Toshiyuki; Mizukami, Shin; Kikuchi, Kazuya] Osaka Univ, Immunol Frontier Res Ctr IFReC, Lab Chem Imaging Tech, Osaka, Japan.
   [Kikuta, Junichi; Kubo, Atsuko; Ishii, Masaru] Osaka Univ, Immunol Frontier Res Ctr IFReC, Lab Cellular Dynam, Osaka, Japan.
   [Kikuta, Junichi; Kubo, Atsuko; Ishii, Masaru] CREST, Japan Sci & Technol Agcy JST, Tokyo, Japan.
   [Maeda, Hiroki; Mizukami, Shin; Kikuchi, Kazuya] Osaka Univ, Grad Sch Engn, Dept Mat & Life Sci, Osaka, Japan.
C3 University of Osaka; University of Osaka; Japan Science & Technology
   Agency (JST); University of Osaka
RP Kikuchi, K (通讯作者)，Osaka Univ, Immunol Frontier Res Ctr IFReC, Lab Chem Imaging Tech, Osaka, Japan.
EM kkikuchi@mls.eng.osaka u.ac.jp
RI Kikuta, Junichi/HHS 8875 2022; Kowada, Toshiyuki/R 2716 2016; Kowada,
   Toshiyuki/JAO 0421 2023; Mizukami, Shin/AAE 2465 2019; Ishii,
   Masaru/D 2361 2009
OI Kowada, Toshiyuki/0000 0002 6623 6505; Mizukami,
   Shin/0000 0002 2292 8606; 
FU Japan Society for the Promotion of Science (JSPS); Ministry of
   Education, Culture, Sports, Science and Technology (MEXT) of Japan
   [22108519, 20675004]; Takeda Science Foundation; Mochida Memorial
   Foundation; Naito Foundation; Asahi Glass Foundation; Grants in Aid for
   Scientific Research [22689030, 22113007, 22108519, 20675004] Funding
   Source: KAKEN
FX This work was partially supported by the Japan Society for the Promotion
   of Science (JSPS) through its "Funding Program for World Leading
   Innovative R&D on Science and Technology (FIRST) Program" and by the
   Ministry of Education, Culture, Sports, Science and Technology (MEXT) of
   Japan (Grant No. 22108519 and 20675004). K.K. and M.I. express their
   special thanks for support from the Takeda Science Foundation and the
   Mochida Memorial Foundation. K.K. also thanks the Naito Foundation for
   financial support. K.K. and S.M. acknowledge the Asahi Glass Foundation
   for financial support.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Gabe Y, 2004, J AM CHEM SOC, V126, P3357, DOI 10.1021/ja037944j
   Giepmans BNG, 2006, SCIENCE, V312, P217, DOI 10.1126/science.1124618
   Han JY, 2010, CHEM REV, V110, P2709, DOI 10.1021/cr900249z
   Hinner MJ, 2010, CURR OPIN BIOTECH, V21, P766, DOI 10.1016/j.copbio.2010.09.011
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   KIKUTA J, UNPUB
   Kozloff KM, 2009, BONE, V44, P190, DOI 10.1016/j.bone.2008.10.036
   Loudet A, 2007, CHEM REV, V107, P4891, DOI 10.1021/cr078381n
   Marks KM, 2006, NAT METHODS, V3, P591, DOI 10.1038/NMETH906
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Sadhu KK, 2011, CHEMBIOCHEM, V12, P1299, DOI 10.1002/cbic.201100137
   Sunahara H, 2007, J AM CHEM SOC, V129, P5597, DOI 10.1021/ja068551y
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Ulrich G, 2008, ANGEW CHEM INT EDIT, V47, P1184, DOI 10.1002/anie.200702070
   Urano Y, 2009, NAT MED, V15, P104, DOI 10.1038/nm.1854
   Wang R, 2010, TRAC TREND ANAL CHEM, V29, P1004, DOI 10.1016/j.trac.2010.05.005
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
NR 21
TC 104
Z9 108
U1 0
U2 82
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002 7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD NOV 9
PY 2011
VL 133
IS 44
BP 17772
EP 17776
DI 10.1021/ja2064582
PG 5
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Chemistry
GA 838SJ
UT WOS:000296312200045
PM 21939210
DA 2025 08 17
ER

PT J
AU Le Goff, B
   Soltner, E
   Charrier, C
   Maugars, Y
   Rédini, F
   Heymann, D
   Berthelot, JM
AF Le Goff, Benoit
   Soltner, Elise
   Charrier, Celine
   Maugars, Yves
   Redini, Francoise
   Heymann, Dominique
   Berthelot, Jean Marie
TI A combination of methotrexate and zoledronic acid prevents bone erosions
   and systemic bone mass loss in collagen induced arthritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID LOW DOSE METHOTREXATE; ADJUVANT INDUCED ARTHRITIS; RANDOMIZED
   CONTROLLED TRIAL; EARLY RHEUMATOID ARTHRITIS; DOUBLE BLIND; MINERAL
   DENSITY; JOINT DAMAGE; SHORT TERM; RATS; BISPHOSPHONATES
AB Introduction Osteoclasts play a key role in the pathogenesis of bone erosion and systemic bone mass loss during rheumatoid arthritis (RA). In this study, we aimed to determine the effect of methotrexate (MTX) and zoledronic acid (ZA), used alone or in combination, on osteoclast mediated bone erosions and systemic bone mass loss in a rat model of collagen induced arthritis (CIA). We hypothesized that MTX and ZA could have an additive effect to prevent both bone erosion and systemic bone loss.
   Methods Arthritis was induced in 64 female Sprague Dawley rats. After the clinical onset of CIA, rats were assigned to treatment with MTX (1 mg/kg/week), ZA (100 mu g/kg twice weekly), both treatments at the same regimens, or vehicle. Arthritis score and paw thickness were recorded twice weekly. The rats were sacrificed on D28 and hind paws were removed for radiographic, histological and immunohistochemical analysis. The effects of treatments on osteoclastogenesis were determined by Tartrate resistant acid phosphatase (TRAP) staining. Micro CT of the tibia was carried out for histomorphometric analysis. Bone mass density was evaluated by densitometry.
   Results MTX significantly decreased the severity of CIA, whereas ZA slightly exacerbated it. When these two drugs were used in combination, MTX prevented the pro inflammatory effect of ZA. The combination of ZA with MTX was more effective than MTX alone for reducing structural joint damage with a dramatic decrease of osteoclasts' number in the eroded joints. However, MTX alone also significantly reduced the number of osteoclasts and the number of CD68+ mononuclear cells. ZA alone, or ZA with MTX, significantly increased the systemic bone mass density measured by densitometry and bone volume on histomorphometric analysis.
   Conclusions A combination of MTX and ZA prevented both bone erosion and systemic bone loss in a rat model of arthritis. Both treatments independently decreased the number of osteoclasts in the eroded joint. However, while MTX probably acts mainly through a decrease of inflammation, ZA has a direct effect on osteoclasts, allowing a dramatic down regulation of these cells in inflamed joints. These two different mechanisms of action provide support for the use of a combination of these two drugs to improve the prevention of structural joint damage in RA.
C1 [Le Goff, Benoit; Soltner, Elise; Charrier, Celine; Redini, Francoise; Heymann, Dominique; Berthelot, Jean Marie] INSERM, UMR S 957, F 44035 Nantes 1, France.
   [Le Goff, Benoit; Soltner, Elise; Charrier, Celine; Redini, Francoise; Heymann, Dominique; Berthelot, Jean Marie] Univ Nantes, Nantes Atlantique Univ, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, F 44035 Nantes 1, France.
   [Le Goff, Benoit; Soltner, Elise; Maugars, Yves; Heymann, Dominique; Berthelot, Jean Marie] Nantes Univ Hosp, Hotel Dieu, Rheumatol Unit, F 44093 Nantes 1, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Nantes Universite; Nantes Universite; CHU de Nantes
RP Le Goff, B (通讯作者)，INSERM, UMR S 957, 1 Rue Gaston Veil, F 44035 Nantes 1, France.
EM benlegoff@gmail.com
RI Le Goff, Benoit/K 8229 2015; REDINI, Francoise/K 7981 2015; Maugars,
   Yves/C 4026 2015; Charrier, Céline/K 9198 2015; Heymann,
   Dominique/AAC 6014 2019
OI Heymann, Dominique/0000 0001 7777 0669; 
FU French Rheumatology Society (Societe Francaise de Rhumatologie)
FX This study was supported by a grant from the French Rheumatology Society
   (Societe Francaise de Rhumatologie). Novartis Pharma provided the
   zoledronic acid. We also would like to thank Paul Pilet (Centre Commun
   de Microscopie Electronique, INSERM UMRS791) for technical support for
   the micro CT analysis.
CR Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   Chan ESL, 2002, ARTHRITIS RES, V4, P266, DOI 10.1186/ar419
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cranney AB, 2001, J RHEUMATOL, V28, P2395
   Cronstein BN, 2005, PHARMACOL REV, V57, P163, DOI 10.1124/pr.57.2.3
   Di Munno O, 2004, J RHEUMATOL, V31, P1305
   Eggelmeijer F, 1996, ARTHRITIS RHEUM, V39, P396, DOI 10.1002/art.1780390307
   ESSER RE, 1995, ARTHRITIS RHEUM, V38, P129, DOI 10.1002/art.1780380120
   Fan CM, 2009, BONE, V44, P61, DOI 10.1016/j.bone.2008.09.014
   Finckh A, 2006, ARTHRITIS RHEUM US, V54, P54, DOI 10.1002/art.21491
   Gasser JA, 2008, J BONE MINER RES, V23, P544, DOI 10.1359/JBMR.071207
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Harada H, 2004, INFLAMM RES, V53, P45, DOI 10.1007/s00011 003 1214 4
   Herrak P, 2004, ARTHRITIS RHEUM US, V50, P2327, DOI 10.1002/art.20384
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Jarrett SJ, 2006, ARTHRITIS RHEUM US, V54, P1410, DOI 10.1002/art.21824
   Lee CK, 2004, ARTHRITIS RHEUM US, V50, P3831, DOI 10.1002/art.20637
   MACCAGNO A, 1994, SCAND J RHEUMATOL, V23, P211, DOI 10.3109/03009749409103063
   MAY KP, 1994, ARTHRITIS RHEUM, V37, P201, DOI 10.1002/art.1780370208
   Minaur NJ, 2002, RHEUMATOLOGY, V41, P741, DOI 10.1093/rheumatology/41.7.741
   Morgan SL, 2001, J RHEUMATOL, V28, P1476
   Pettit AR, 2006, RHEUMATOLOGY, V45, P1068, DOI 10.1093/rheumatology/kel045
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   RAGAB AH, 1970, CANCER, V25, P580, DOI 10.1002/1097 0142(197003)25:3<580::AID CNCR2820250313>3.0.CO;2 M
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Reid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140 6736(09)60250 6
   Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood 2004 01 0041
   Romas E, 2005, BEST PRACT RES CL RH, V19, P1065, DOI 10.1016/j.berh.2005.06.008
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Sancho D, 2003, J CLIN INVEST, V112, P872, DOI 10.1172/JCI200319112
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2166
   SCHWARTZ AM, 1984, SKELETAL RADIOL, V11, P13, DOI 10.1007/BF00361126
   Sims NA, 2004, ARTHRITIS RHEUM US, V50, P2338, DOI 10.1002/art.20382
   Spadaro JA, 2006, J ORTHOP RES, V24, P936, DOI 10.1002/jor.20145
   Strand V, 1999, ARCH INTERN MED, V159, P2542, DOI 10.1001/archinte.159.21.2542
   Suzuki Y, 1997, J RHEUMATOL, V24, P1890
   Valleala H, 2003, J RHEUMATOL, V30, P468
   WHEELER DL, 1995, BONE, V16, P215, DOI 10.1016/8756 3282(94)00032 U
   Yilmaz L, 2001, RHEUMATOL INT, V20, P65, DOI 10.1007/s002960000080
   Yoshida M, 2005, J RHEUMATOL, V32, P787
NR 40
TC 49
Z9 50
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2009
VL 11
IS 6
AR R185
DI 10.1186/ar2877
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 604MC
UT WOS:000278282100025
PM 20003278
OA Green Accepted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Romero Prado, M
   Blázquez, C
   Rodríguez Navas, C
   Muñoz, J
   Guerrero, I
   Delgado Baeza, E
   García Ruiz, JP
AF Romero Prado, Marina
   Blazquez, Cristina
   Rodriguez Navas, Carmen
   Munoz, Jaime
   Guerrero, Isabel
   Delgado Baeza, Emilio
   Garcia Ruiz, Josefa P.
TI Functional characterization of human mesenchymal stem cells that
   maintain osteochondral fates
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Indian HH signaling; Runx2/AML3; bone marrow derived; mesenchymal stem
   cells; bone progenitor cells
ID INDIAN HEDGEHOG; BONE FORMATION; OSTEOBLAST DIFFERENTIATION;
   CLEIDOCRANIAL DYSPLASIA; GENE EXPRESSION; TGF BETA; MARROW; GROWTH;
   PROLIFERATION; TRANSCRIPTION
AB Adult stem cells are essential for tissue renewal, regeneration and repair, and their expansion in defined culture medium is on focus for regenerative medicine and genetic pathologies. The bone marrow has been shown to be very rich is pluripotent mesenchymal stem cells (MSCs) capable of forming bone, cartilage and also may give rise, to neurons and astrocytes in vivo and in vitro. MSCs can be isolated and expanded in culture, but human cells cannot be verified for a cartilage or a bone fate by transfer experiments. Accordingly, here we used different approaches to characterize hMSCs osteoblastic differentiation in vitro. hMSCs grown in culture in the presence of fetal bovine serum (FBS) expressed the bone specific transcription factor Runx2/AML3. When cells were incubated in osteoblastic differentiation medium, cells expressed transcripts belonging to the signaling of Indian HH PTHrP axis, GLI transcription factors, and bone target genes including osteopontin. The HH pathway proved to be functional since it induced cells to grow. Cells growing or differentiating to osteoblasts presented the Runx2/AML3 transcription factor, its partner CBFB, and Smad2/3 at the nuclei associated with the nuclear matrix. Furthermore, Runx2/AML3 was observed to co localize with SC35 to the nuclear intermediary filaments. These data support the notion that hMSCs isolated from human bone are or become bone progenitor cells upon culture. In the absence of FBS and in the presence of insulin or prolactin, cells show cytoskeletal organization and an AP 1 transcription site activity resembling proliferative osteochondrocytes while cells in the presence of dexamethasone and added prolactin or TGF beta resembled differentiated osteoblasts. These specific cellular conditions match those observed during endochondral bone formation.
C1 Univ Autonoma Madrid, Fac Ciencias, Dept Mol Biol, Ctr Biol Mol Severo Ochoa, E 28049 Madrid, Spain.
   Univ Autonoma Madrid, Hosp Univ La Paz, E 28049 Madrid, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC   Centro de
   Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid;
   Autonomous University of Madrid; Hospital Universitario La Paz
RP García Ruiz, JP (通讯作者)，Univ Autonoma Madrid, Fac Ciencias, Dept Mol Biol, Ctr Biol Mol Severo Ochoa, E 28049 Madrid, Spain.
EM pgarcia@cbm.uam.es
RI Rivera, Jaime/T 2118 2017; Guerrero, Isabel/K 2518 2014
OI , Jaime Munoz/0009 0001 5709 5050; Guerrero, Isabel/0000 0001 6761 1218
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   CAPLAN AI, 1987, BIOESSAYS, V6, P171, DOI 10.1002/bies.950060406
   Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001 0036
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   DUEY P, 1997, CELL, V89, P747
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0
   Guan Y, 2004, MOL ENDOCRINOL, V18, P214, DOI 10.1210/me.2003 0014
   Javed A, 2000, J CELL SCI, V113, P2221
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Karp SJ, 2000, DEVELOPMENT, V127, P543
   Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155
   Kitoh H, 2004, BONE, V35, P892, DOI 10.1016/j.bone.2004.06.013
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007
   Kosak ST, 2004, GENE DEV, V18, P1371, DOI 10.1101/gad.1209304
   Le Blanc K, 2005, TRANSPLANTATION, V79, P1607, DOI 10.1097/01.TP.0000159029.48678.93
   Lemischka IR, 2003, NATURE, V425, P778, DOI 10.1038/425778a
   Lennon DP, 1996, IN VITRO CELL DEV AN, V32, P602
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Massengale M, 2005, J EXP MED, V201, P1579, DOI 10.1084/jem.20050030
   Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950
   Moustakas A, 1999, J CELL SCI, V112, P1169
   Mullor JL, 1997, DEVELOPMENT, V124, P1227
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ogueta S, 2000, J ENDOCRINOL, V165, P321, DOI 10.1677/joe.0.1650321
   Ogueta S, 2002, MOL CELL ENDOCRINOL, V190, P51, DOI 10.1016/S0303 7207(02)00013 8
   Olazabal I, 2000, MOL ENDOCRINOL, V14, P564, DOI 10.1210/me.14.4.564
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Palcy S, 2000, J BONE MINER RES, V15, P2352, DOI 10.1359/jbmr.2000.15.12.2352
   Palma V, 2004, DEVELOPMENT, V131, P337, DOI 10.1242/dev.00930
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood 2003 08 2807
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Stein GS, 2004, J CELL BIOCHEM, V91, P287, DOI 10.1002/jcb.10777
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436
   Viereck V, 2002, J CELL BIOCHEM, V86, P348, DOI 10.1002/jcb.10220
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499
   Zaidi SK, 2003, P NATL ACAD SCI USA, V100, P14852, DOI 10.1073/pnas.2533076100
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zipori D, 2001, J LEUKOCYTE BIOL, V69, P867
NR 49
TC 33
Z9 43
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG 15
PY 2006
VL 98
IS 6
BP 1457
EP 1470
DI 10.1002/jcb.20778
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 069SZ
UT WOS:000239469800008
PM 16518860
DA 2025 08 17
ER

PT J
AU Qiao, H
   Wang, TY
   Yu, ZF
   Han, XG
   Liu, XQ
   Wang, YG
   Fan, QM
   Qin, A
   Tang, TT
AF Qiao, H.
   Wang, T y
   Yu, Z f
   Han, X g
   Liu, X q
   Wang, Y g
   Fan, Q m
   Qin, A.
   Tang, T t
TI 被撤回的出版物: Structural simulation of adenosine phosphate via plumbagin and
   zoledronic acid competitively targets JNK/Erk to synergistically
   attenuate osteoclastogenesis in a breast cancer model (Retracted
   Article)
SO CELL DEATH & DISEASE
LA English
DT Article; Retracted Publication
ID NF KAPPA B; IN VITRO; BONE METASTASIS; DOWN REGULATION; CELL GROWTH;
   HEPATITIS C; KINASE; INHIBITION; COMBINATION; ACTIVATION
AB The treatment of breast cancer induced osteolysis remains a challenge in clinical settings. Here, we explored the effect and mechanism of combined treatment with zoledronic acid (ZA) and plumbagin (PL), a widely investigated component derived from Plumbago zeylanica, against breast cancer induced osteoclastogenesis. We found that the combined treatment with PL and ZA suppressed cell viability of precursor osteoclasts and synergistically inhibited MDA MB 231 induced osteoclast formation (combination index = 0.28) with the abrogation of recombinant mouse receptor activator of nuclear factor kappa B ligand (RANKL) induced activation of NF kappa B/MAPK (nuclear factor kappa B/mitogen activated protein kinase) pathways. Molecular docking suggested a putative binding area within c Jun N terminal kinase/extracellular signal regulated kinase (JNK/Erk) protease active sites through the structural mimicking of adenosine phosphate (ANP) by the spatial combination of PL with ZA. A homogeneous time resolved fluorescence assay further illustrated the direct competitiveness of the dual drugs against ANP docking to phosphorylated JNK/Erk, contributing to the inhibited downstream expression of c Jun/c Fos/NFATc 1 (nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1). Then, in vivo testing demonstrated that the combined administration of PL and ZA attenuated breast cancer growth in the bone microenvironment. Additionally, these molecules prevented the destruction of proximal tibia, with significant reduction of tartrate resistant acid phosphatase (TRAcP) positive osteoclast cells and potentiation of apoptotic cancer cells, to a greater extent when combined than when the drugs were applied independently. Altogether, the combination treatment with PL and ZA could significantly and synergistically suppress osteoclastogenesis and inhibit tumorigenesis both in vitro and in vivo by simulating the spatial structure of ANP to inhibit competitively phosphorylation of c Jun N terminal kinase/extracellular signal regulated kinase (JNK/Erk).
C1 [Qiao, H.; Yu, Z f; Han, X g; Liu, X q; Wang, Y g; Fan, Q m; Qin, A.; Tang, T t] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants, Dept Orthopaed Surg,Sch Med, Zhizaoju Rd 639, Shanghai 20001, Peoples R China.
   [Wang, T y] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants, Dept Pharm,Sch Med, Shanghai 20001, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Qin, A; Tang, TT (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants, Dept Orthopaed Surg,Sch Med, Zhizaoju Rd 639, Shanghai 20001, Peoples R China.
EM dr_qinan@163.com; ttt@sjtu.edu.cn
RI Yu, Zhifeng/L 2248 2017; Qin, An/J 2518 2019; Tang, Tingting/B 1361 2013
OI Yu, Zhifeng/0000 0002 2224 8344; Tang, Tingting/0000 0002 1670 7452
FU National Natural Science Foundation of China [81172549, 81273777]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81172549 and 81273777). We thank Prof. Jiake Xu of
   the University of Western Australia for his kind gift of the human
   breast cancer cell line MDA MB 231SArfp.
CR Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Bhattacharya A, 2013, FEBS J, V280, P4585, DOI 10.1111/febs.12429
   Bi XH, 2013, BONE, V56, P454, DOI 10.1016/j.bone.2013.07.006
   Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chambers TJ, 2000, J PATHOL, V192, P4
   Checker R, 2009, INT IMMUNOPHARMACOL, V9, P949, DOI 10.1016/j.intimp.2009.03.022
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Chou TC, 2008, LEUKEMIA LYMPHOMA, V49, P2059, DOI 10.1080/10428190802353591
   De Cola A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.192
   Ding YX, 2005, J PHARM PHARMACOL, V57, P111, DOI 10.1211/0022357055119
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Guo H, 2014, J MED MICROBIOL, V63, P988, DOI 10.1099/jmm.0.073890 0
   Hope HR, 2009, J PHARMACOL EXP THER, V331, P882, DOI 10.1124/jpet.109.158329
   Horie N, 2007, BRIT J CANCER, V96, P255, DOI 10.1038/sj.bjc.6603548
   Hwang GH, 2015, EUR J PHARMACOL, V765, P384, DOI 10.1016/j.ejphar.2015.08.058
   Ibrahim T, 2013, INT J ONCOL, V42, P1263, DOI 10.3892/ijo.2013.1809
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Insalaco L, 2012, J CELL MOL MED, V16, P2186, DOI 10.1111/j.1582 4934.2012.01527.x
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Jia Y, 2006, ANAL BIOCHEM, V350, P268, DOI 10.1016/j.ab.2005.11.010
   Jia Y, 2005, ARCH BIOCHEM BIOPHYS, V441, P64, DOI 10.1016/j.abb.2005.06.020
   Jia Y, 2006, ANAL BIOCHEM, V356, P273, DOI 10.1016/j.ab.2006.05.006
   Khajuria DK, 2014, J ORTHOP SCI, V19, P646, DOI 10.1007/s00776 014 0557 8
   Khaw AK, 2015, MUTAT RES GEN TOX EN, V793, P86, DOI 10.1016/j.mrgentox.2015.06.004
   Kim HJ, 2007, MOL PHARMACOL, V72, P418, DOI 10.1124/mol.107.034173
   Klotz KN, 2016, N S ARCH PHARMACOL, V389, P349, DOI 10.1007/s00210 015 1197 z
   Kong YY, 2000, IMMUNOL TODAY, V21, P495, DOI 10.1016/S0167 5699(00)01718 7
   Lambrinoudaki I, 2006, ANN NY ACAD SCI, V1092, P397, DOI 10.1196/annals.1365.036
   Liu ZY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132459
   Lu SY, 2015, STRUCTURE, V23, P1725, DOI 10.1016/j.str.2015.06.027
   Luo KW, 2015, J CANCER RES CLIN, V141, P1025, DOI 10.1007/s00432 014 1882 1
   Mathew A, 2015, INT J CANCER, V137, P753, DOI 10.1002/ijc.28965
   Mathew A, 2014, NAT REV CLIN ONCOL, V11, P564, DOI 10.1038/nrclinonc.2014.152
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Menuki Kunitaka, 2015, Nihon Rinsho, V73, P1634
   Motawi TMK, 2015, CHEM BIOL INTERACT, V233, P147, DOI 10.1016/j.cbi.2015.03.028
   Ossipov DA, 2015, EXPERT OPIN DRUG DEL, V12, P1443, DOI 10.1517/17425247.2015.1021679
   Pham TNQ, 2004, J VIROL, V78, P5867, DOI 10.1128/JVI.78.11.5867 5874.2004
   Pham TNQ, 2008, GASTROENTEROLOGY, V134, P812, DOI 10.1053/j.gastro.2007.12.011
   Qiao H, 2015, ACTA PHARMACOL SIN, V36, P1085, DOI 10.1038/aps.2015.42
   Rabiller M, 2010, ARCH PHARM, V343, P193, DOI 10.1002/ardp.201000028
   Rana T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078043
   Rosborough BR, 2014, AM J TRANSPLANT, V14, P2173, DOI 10.1111/ajt.12799
   Rose AAN, 2006, B CANCER, V93, P931
   Schröder D, 2015, BIOCHEM PHARMACOL, V96, P143, DOI 10.1016/j.bcp.2015.05.004
   Simard JR, 2009, J AM CHEM SOC, V131, P13286, DOI 10.1021/ja902010p
   Singh T, 2015, J DRUG TARGET, V23, P1, DOI 10.3109/1061186X.2014.950668
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098 2795(199701)46:1<4::AID MRD2>3.0.CO;2 V
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Sumsakul W, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 15
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Thamake SI, 2012, BIOMATERIALS, V33, P7164, DOI 10.1016/j.biomaterials.2012.06.026
   Tong HJ, 2014, J ORTHOP TRANSL, V2, P157, DOI 10.1016/j.jot.2014.06.001
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang TY, 2014, FOOD CHEM TOXICOL, V64, P177, DOI 10.1016/j.fct.2013.11.027
   Yan CH, 2015, INT J CLIN EXP MED, V8, P14432
   Yan W, 2014, ACTA PHARMACOL SIN, V35, P124, DOI 10.1038/aps.2013.152
   Yan W, 2013, SCI REP UK, V3, DOI 10.1038/srep02376
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   Yu YF, 2014, ACTA BIOCH BIOPH SIN, V46, P792, DOI 10.1093/abbs/gmu069
   Zhai ZJ, 2014, BREAST CANCER RES TR, V144, P33, DOI 10.1007/s10549 014 2844 7
   Zhang HY, 2015, APOPTOSIS, V20, P50, DOI 10.1007/s10495 014 1066 0
   Zhang LY, 2015, ONCOTARGET, V6, P22918, DOI 10.18632/oncotarget.4382
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
   Zhou ZW, 2015, DRUG DES DEV THER, V9, P1511, DOI 10.2147/DDDT.S75976
   Zinonos I, 2009, MOL CANCER THER, V8, P2969, DOI 10.1158/1535 7163.MCT 09 0745
NR 72
TC 35
Z9 36
U1 1
U2 32
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB
PY 2016
VL 7
AR e2094
DI 10.1038/cddis.2016.11
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DG5FU
UT WOS:000372102400012
PM 26866274
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Peng, J
   Wang, H
   Liu, Z
   Xu, ZL
   Wang, MX
   Chen, QM
   Wu, ML
   Ren, XL
   Liang, QH
   Liu, FP
   Ban, B
AF Peng, Jing
   Wang, Hui
   Liu, Zhen
   Xu, Zhen Liang
   Wang, Mei Xia
   Chen, Qi Miao
   Wu, Ming Li
   Ren, Xiao Lei
   Liang, Qiu Hua
   Liu, Fu Peng
   Ban, Bo
TI Real world study of antiresorptive related osteonecrosis of jaw based on
   the US food and drug administration adverse event reporting system
   database
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE antiresorptive drugs; osteonecrosis of jaw; romosozumab; the US food and
   drug administration adverse event reporting system; database; signal
   processing
ID BISPHOSPHONATE RELATED OSTEONECROSIS; SIGNAL DETECTION
AB Objective: This study aims to explore the risk signals of osteonecrosis of the jaw induced by antiresorptive drugs and provide references for the clinical safety application.
   Method: According to the FDA's Adverse Event Reporting System (FAERS), from January 2004 to September 2021, we chose "Osteonecrosis of the jaw (10064658)" and "Exposed bone in jaw (10071014)" as preferred terms, "antiresorptive drugs" as the target drugs, and primary suspect drug as the drug role code in the dataset. We evaluated the association between drugs and adverse events by using reporting odds ratio (ROR) based on disproportionality analysis. We took the High Level Terms (HLT) of MedDRA (R) as the classification level of indications to calculate ROR to compare the signal difference of ONJ in different indications. In addition, patients with antiresorptive induced osteonecrosis of the jaw and the time of onset of the condition following different antiresorptive medications were collected for the study.
   Results: The FAERS contained 18,421 reports relating to jaw osteonecrosis from January 2004 to September 2021. A total of eight antiresorptive agents were included in the analysis. From high to low, the ROR of ONJ induced by antiresorptive agents (regardless of indication) is pamidronate (ROR = 494.8), zoledronic acid (ROR = 431.9), denosumab (ROR = 194.8), alendronate (ROR = 151.2), risedronate (ROR = 140.2), etidronic acid (ROR = 64.5), ibandronate (ROR = 40.8), and romosozumab (ROR = 6.4). HLT ROR values for "metabolic bone disorders" were the lowest for each drug, while HLT ROR values were high for "tumor related indications," including breast and nipple neoplasms malignant, plasma cell myelomas, and prostatic neoplasms malignant. The onset time for osteonecrosis of the jaw as median (01, 03), osteoporosis related indications, and the onset time for ONJ were 730 (368, 1268), 489.5 (236.3, 909.8), 722.5 (314, 1055), 761 (368, 1720), and 153 (50, 346) for zoledronic acid, denosumab, ibandronate, risedronate, and romosozumab, respectively. Cancer related indications: the onset time for ONJ were 680.5 (255.3, 1283), 488 (245, 851), and 696.5 (347, 1087) for zoledronic acid, denosumab, and pamidronate, respectively.
   Conclusion: When antiresorptive drugs are used for metastasis, they have the largest risk signal, followed by malignancy, and the smallest is osteoporosis. The onset time of ONJ may not be related to the indications. The onset time of ONJ for BPs was about 2 years, denosumab about 1.3 years, and romosozumab less than 1 year, which may be related to sequential treatment. When used according to the instructions, the risk of ONJ caused by denosumab was higher than that of zoledronic acid, regardless of the indication. Based on these findings, researchers will continue to monitor and identify risk factors.
C1 [Peng, Jing; Wang, Hui; Liu, Zhen; Wang, Mei Xia; Wu, Ming Li] Jining Med Univ, Affiliated Hosp, Dept Pharm, Jining, Shandong, Peoples R China.
   [Xu, Zhen Liang] Jining Med Univ, Affiliated Hosp, Pharm Intravenous Admixture Serv, Jining, Shandong, Peoples R China.
   [Chen, Qi Miao] Jining Haida Xingzhi Sch, High Sch Student, Grade 10, Jining, Shandong, Peoples R China.
   [Ren, Xiao Lei] Jining Med Univ, Affiliated Hosp, Data Ctr, Jining, Shandong, Peoples R China.
   [Liang, Qiu Hua; Liu, Fu Peng; Ban, Bo] Jining Med Univ, Affiliated Hosp, Dept Endocrinol, Jining, Shandong, Peoples R China.
C3 Jining Medical University; Jining Medical University; Jining Medical
   University; Jining Medical University
RP Wu, ML (通讯作者)，Jining Med Univ, Affiliated Hosp, Dept Pharm, Jining, Shandong, Peoples R China.; Ren, XL (通讯作者)，Jining Med Univ, Affiliated Hosp, Data Ctr, Jining, Shandong, Peoples R China.; Ban, B (通讯作者)，Jining Med Univ, Affiliated Hosp, Dept Endocrinol, Jining, Shandong, Peoples R China.
EM wumingli322@163.com; xiaolei.ren@qq.com; banbo2011@163.com
RI ; Chen, Qimiao/AAA 4659 2020; liu, zhen/KFS 0275 2024
OI Liu, Fupeng/0000 0003 3916 5833; Ren, Xiaolei/0009 0004 6191 3134
FU Young Research Foundation of Shandong Pharmaceutical Association
   [2022YXNS067]; Key research and development program of Jining; 
   [2021 03]
FX This research was partially supported by the Young Research Foundation
   of Shandong Pharmaceutical Association and Tianji Health Care (hlyy
   2021 03) and by the Key research and development program of Jining
   (2022YXNS067).
CR Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Almazrooa SA, 2009, J AM DENT ASSOC, V140, P864, DOI 10.14219/jada.archive.2009.0280
   Anastasilakis AD, 2022, J CLIN ENDOCR METAB, V107, P1441, DOI 10.1210/clinem/dgab888
   Boquete Castro A, 2016, CLIN ORAL IMPLAN RES, V27, P367, DOI 10.1111/clr.12556
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Crews Douglas E, 2006, J Physiol Anthropol, V25, P113, DOI 10.2114/jpa2.25.113
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Edwards BJ, 2008, J AM DENT ASSOC, V139, P1674, DOI 10.14219/jada.archive.2008.0110
   Ehrenstein V, 2021, CANCER AM CANCER SOC, V127, P4050, DOI 10.1002/cncr.33802
   European Medicines Agency, 2019, ROMOSOZUMAB EVENITY
   Everts Graber J, 2022, J BONE MINER RES, V37, P340, DOI 10.1002/jbmr.4472
   Food and Drug Administration, 2021, FDA ADVERSE EVENT RE
   Hadaya D, 2019, J BONE MINER RES, V34, P171, DOI 10.1002/jbmr.3581
   Hansen PJ, 2013, CLIN ORAL INVEST, V17, P1829, DOI 10.1007/s00784 012 0873 3
   Harpaz R, 2013, CLIN PHARMACOL THER, V93, P539, DOI 10.1038/clpt.2013.24
   Hauben Manfred, 2005, Expert Opin Drug Saf, V4, P929, DOI 10.1517/14740338.4.5.929
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kuroshima S, 2019, J ORAL BIOSCI, V61, P99, DOI 10.1016/j.job.2019.03.005
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati Cesar A., 2019, Journal of the National Cancer Institute Monographs, P107, DOI 10.1093/jncimonographs/lgz009
   Nakamura M, 2015, J PHARM HEALTH CARE, V1, DOI 10.1186/s40780 015 0035 2
   Paik J, 2020, DRUG AGING, V37, P845, DOI 10.1007/s40266 020 00793 8
   Pittman K, 2017, ASIA PAC J CLIN ONCO, V13, P266, DOI 10.1111/ajco.12517
   Sakaeda T, 2013, INT J MED SCI, V10, P796, DOI 10.7150/ijms.6048
   Uyanne Jettie, 2014, Dent Clin North Am, V58, P369, DOI 10.1016/j.cden.2013.12.006
   van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668
   Wang Y, 2009, OSTEOPOROSIS INT, V20, P1651, DOI 10.1007/s00198 009 0925 y
   Watts NB, 2008, SOUTH MED J, V101, P160, DOI 10.1097/SMJ.0b013e31816127d9
   Zhao B, 2021, J DIABETES INVEST, V12, P1400, DOI 10.1111/jdi.13481
NR 29
TC 19
Z9 19
U1 2
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 19
PY 2022
VL 13
AR 1017391
DI 10.3389/fphar.2022.1017391
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 5Z3UI
UT WOS:000879901000001
PM 36339548
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bernardini, C
   Saulnier, N
   Parrilla, C
   Pola, E
   Gambotto, A
   Michetti, F
   Robbins, PD
   Lattanzi, W
AF Bernardini, Camilla
   Saulnier, Nathalie
   Parrilla, Claudio
   Pola, Enrico
   Gambotto, Andrea
   Michetti, Fabrizio
   Robbins, Paul D.
   Lattanzi, Wanda
TI Early Transcriptional Events During Osteogenic Differentiation of Human
   Bone Marrow Stromal Cells Induced by Lim Mineralization Protein 3
SO GENE EXPRESSION
LA English
DT Article
DE Lim mineralization protein 3 (LMP3); Microarray; Osteogenesis;
   Mesechymal cells; Gene expression
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; GENE THERAPY;
   MORPHOGENETIC PROTEINS; TARGET GENE; I RECEPTOR; EXPRESSION; LMP 1;
   VIVO; CYCLE
AB Lim mineralization protein 3 (LMP3) induces osteoblast differentiation by regulating the expression and activity of certain molecules involved in the osteogenic cascade, including those belonging to the bone morphogenetic protein (BMP) family. The complete network of molecular events involved in LMP3 mediated osteogenesis is still unknown. The aim of this study was to analyze the genome wide gene expression profiles in human mesenchymal stem cells (hMSC) induced by exogenous LMP3 to mediate osteogenesis. For this purpose hMSC were transduced with a defective adenoviral vector expressing the human LMP3 gene and microarray analysis was performed 1 day post adenoviral transduction. Cells transduced with the vector backbone and untransduced cells were used as independent controls in the experiments. Microarray data were independently validated by means of real time PCR on selected transcripts. The statistical analysis of microarray data produced a list of 263 significantly (p < 0.01) differentially expressed transcripts. The biological interpretation of the results indicated, among the most noteworthy effects, the modulation of genes involved in the TGF beta 1 pathway: 88 genes coding for key regulators of the cell cycle regulatory machinery and 28 genes implicated in the regulation of cell proliferation along with the development of connective, muscular, and skeletal tissues. These results suggested that LMP3 could affect the fine balance between cell proliferation/differentiation of mesenchymal cells mostly by modulating the TGF beta 1 signaling pathway.
C1 [Bernardini, Camilla; Michetti, Fabrizio; Lattanzi, Wanda] Catholic Univ, Sch Med, Inst Anat & Cell Biol, I 00168 Rome, Italy.
   [Saulnier, Nathalie] Catholic Univ, Sch Med, Dept Internal Med, I 00168 Rome, Italy.
   [Parrilla, Claudio] Catholic Univ, Sch Med, Dept Otolaryngol, I 00168 Rome, Italy.
   [Pola, Enrico] Catholic Univ, Sch Med, Dept Orthoped, I 00168 Rome, Italy.
   [Gambotto, Andrea; Robbins, Paul D.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
   [Michetti, Fabrizio] Latium Musculo Skeletal Tissue Bank, Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Lattanzi, W (通讯作者)，Catholic Univ, Sch Med, Inst Anat & Cell Biol, Largo F Vito 1, I 00168 Rome, Italy.
EM wanda.lattanzi@rm.unicatt.it
RI Parrilla, Claudio/GRR 2439 2022; Lattanzi, Wanda/K 5978 2016; lattanzi,
   wanda/K 5978 2016
OI Saulnier, Nathalie/0000 0003 0159 8414; Parrilla,
   Claudio/0000 0001 5878 7668; lattanzi, wanda/0000 0003 3092 4936
FU Universita Cattolica del Sacro Cuore; Musculo Skeletal Tissue Bank of
   the Latium Region (Rome, IT)
FX This work was partially supported by the "Universita Cattolica del Sacro
   Cuore" and the Musculo Skeletal Tissue Bank of the Latium Region (Rome,
   IT).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Boden SD, 1998, SPINE, V23, P2486, DOI 10.1097/00007632 199812010 00003
   Boden SD, 1998, ENDOCRINOLOGY, V139, P5125, DOI 10.1210/en.139.12.5125
   Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201 365
   Bünger MH, 2003, CALCIFIED TISSUE INT, V73, P446, DOI 10.1007/s00223 002 2109 z
   Chalazonitis A, 2008, J COMP NEUROL, V509, P474, DOI 10.1002/cne.21770
   FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365 2184.1987.tb01309.x
   Granberg F, 2006, VIROLOGY, V353, P1, DOI 10.1016/j.virol.2006.06.019
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Haag J, 2007, EXP CELL RES, V313, P3386, DOI 10.1016/j.yexcr.2007.08.003
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Kitareewan S, 2008, INT J ONCOL, V33, P397, DOI 10.3892/ijo_00000021
   Lattanzi W, 2008, GENE THER, V15, P1330, DOI 10.1038/gt.2008.116
   Lattanzi W, 2007, J NEUROCHEM, V100, P1688, DOI 10.1111/j.1471 4159.2006.04331.x
   Liu JH, 1999, ONCOGENE, V18, P269, DOI 10.1038/sj.onc.1202263
   Liu YS, 2002, J BONE MINER RES, V17, P406, DOI 10.1359/jbmr.2002.17.3.406
   Luppen CA, 2003, J BIOL CHEM, V278, P44995, DOI 10.1074/jbc.M306730200
   Martinelli DC, 2007, CELL CYCLE, V6, P2650, DOI 10.4161/cc.6.21.4877
   Minamide A, 2003, J BONE JOINT SURG AM, V85A, P1030, DOI 10.2106/00004623 200306000 00007
   Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Neef R, 2002, CANCER RES, V62, P5920
   Parrilla C, 2010, HEAD NECK J SCI SPEC, V32, P310, DOI 10.1002/hed.21185
   PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pola E, 2004, GENE THER, V11, P683, DOI 10.1038/sj.gt.3302207
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Sangadala S, 2006, J BIOL CHEM, V281, P17212, DOI 10.1074/jbc.M511013200
   Saulnier N, 2009, EUR REV MED PHARMACO, V13, P71
   Sharov AA, 2006, P NATL ACAD SCI USA, V103, P18166, DOI 10.1073/pnas.0608899103
   Simon RaL A, 2006, TECHNICAL REPORTS NA
   Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200
   Strohbach C, 2008, J CELL BIOCHEM, V104, P1890, DOI 10.1002/jcb.21761
   Strohbach CA, 2008, CALCIFIED TISSUE INT, V83, P202, DOI 10.1007/s00223 008 9163 0
   Tamanini A, 2006, J VIROL, V80, P11241, DOI 10.1128/JVI.00721 06
   Tavares ALP, 2006, DEV DYNAM, V235, P1589, DOI 10.1002/dvdy.20771
   Toyoshima Y, 2004, J BIOL CHEM, V279, P25898, DOI 10.1074/jbc.M400661200
   TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242
   Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919
   Viggeswarapu M, 2001, J BONE JOINT SURG AM, V83A, P364, DOI 10.2106/00004623 200103000 00008
   Wilkinson L, 2003, J BIOL CHEM, V278, P34181, DOI 10.1074/jbc.M301247200
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Yoon ST, 2004, SPINE, V29, P2603, DOI 10.1097/01.brs.0000146103.94600.85
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Zandbergen F, 2005, BIOCHEM J, V392, P313, DOI 10.1042/BJ20050636
   Zhang Q, 2007, ARCH ORAL BIOL, V52, P720, DOI 10.1016/j.archoralbio.2007.02.005
NR 48
TC 15
Z9 17
U1 0
U2 6
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 1052 2166
EI 1555 3884
J9 GENE EXPRESSION
JI Gene Expr.
PY 2010
VL 15
IS 1
BP 27
EP 42
DI 10.3727/105221610X12819686555097
PG 16
WC Biotechnology & Applied Microbiology; Gastroenterology & Hepatology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Gastroenterology & Hepatology;
   Genetics & Heredity
GA 675NI
UT WOS:000283837000003
PM 21061915
OA Green Published
DA 2025 08 17
ER

PT J
AU Chiou, SS
   Wang, LT
   Huang, SB
   Chai, CY
   Wang, SN
   Liao, YM
   Lin, PC
   Liu, KY
   Hsu, SH
AF Chiou, Shyh Shin
   Wang, Li Ting
   Huang, Shih Bo
   Chai, Chee Yin
   Wang, Shen Nien
   Liao, Yu Mei
   Lin, Pei Chin
   Liu, Kwei Yan
   Hsu, Shih Hsien
TI Wntless (GPR177) expression correlates with poor prognosis in B cell
   precursor acute lymphoblastic leukemia via Wnt signaling
SO CARCINOGENESIS
LA English
DT Article
ID CHRONIC LYMPHOCYTIC LEUKEMIA; PROTEIN; SECRETION; PATHWAY; CANCER;
   DIFFERENTIATION; TUMORIGENESIS; ACTIVATION; CARCINOMA; SURVIVAL
AB B cell precursor acute lymphoblastic leukemia (BCP ALL) is the most common childhood leukemia, with a cure rate of 80%. Nevertheless, disease relapse is the most important prognostic factor for the disease outcome. We aimed to elucidate the role of Wnt secretion regulating protein, Wntless (Wls)/GPR177, on disease outcome in pediatric patients with BCP ALL, and assess its pathogenetic role in the regulation of the disease. Wls expression was characterized and correlated with Wnt pathway signaling in the bone marrow leukemia cells isolated from 44 pediatric patients with BCP ALL. The overexpression of Wls was detected in leukemia cells and was significantly correlated with the disease relapse and poor survival in the patients. The high expression of Wls also correlated with the Wnt expression and consequent downstream signaling activation, which was shown to provide essential proliferation, transformation and anti apoptotic activity during leukemogenesis. These results indicated that Wls played an essential role in disease relapse and poor survival in patients with BCP ALL. Therefore, Wls may provide a potential future therapeutic target, particularly for patients who do not respond to existing therapies and suffer relapse.
C1 [Chiou, Shyh Shin] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Pediat, Kaohsiung 807, Taiwan.
   [Chiou, Shyh Shin; Liao, Yu Mei; Lin, Pei Chin] Kaohsiung Med Univ Hosp, Dept Pediat, Div Hematol Oncol, Kaohsiung 807, Taiwan.
   [Wang, Li Ting; Huang, Shih Bo; Liu, Kwei Yan; Hsu, Shih Hsien] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Chai, Chee Yin] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Pathol, Kaohsiung 807, Taiwan.
   [Wang, Shen Nien] Fac Med Kaohsiung, Dept Surg, Kaohsiung 807, Taiwan.
   [Wang, Shen Nien] Kaohsiung Med Univ Hosp, Dept Surg, Div Hepatobiliary Surg, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University Hospital
RP Hsu, SH (通讯作者)，Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
EM jackhsu@kmu.edu.tw
RI ; Liao, Yu Chi/AAT 1357 2021; Huang, Shih Bo/AAO 9699 2021; Lin,
   Pei Chin/KIE 7988 2024; Chai, Chee Yin/D 5523 2009; Wang,
   Shen Nien/D 4853 2009
OI Hsu, Shih Hsien/0000 0003 2102 0505; Lin, Pei Chin/0000 0002 3371 3010;
   LIAO, YU MEI/0000 0001 9916 9356; Chai, Chee Yin/0000 0003 0486 9742;
   Wang, Li Ting/0000 0002 3335 8055; Huang, Shih Bo/0000 0002 1048 2344; 
FU National Science Council, Taiwan [KMUH100 0R20, KMUH100 0R21,
   NSC 102 2314 B 037 057 MY3, NSC 102 2320 B 037 032 MY3]
FX National Science Council, Taiwan (KMUH100 0R20, KMUH100 0R21,
   NSC 102 2314 B 037 057 MY3, NSC 102 2320 B 037 032 MY3).
CR Augustin I, 2012, EMBO MOL MED, V4, P38, DOI 10.1002/emmm.201100186
   Baba Y, 2005, IMMUNITY, V23, P599, DOI 10.1016/j.immuni.2005.10.009
   Bänziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049
   Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009
   Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141
   Bruggemann M, 2012, SEMIN ONCOL, V39, P47, DOI 10.1053/j.seminoncol.2011.11.009
   Cadigan KM, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002881
   Diller L, 2011, NEW ENGL J MED, V365, P1417, DOI 10.1056/NEJMcp1103645
   Eaton S, 2008, DEV CELL, V14, P4, DOI 10.1016/j.devcel.2007.12.014
   Fu J, 2009, P NATL ACAD SCI USA, V106, P18598, DOI 10.1073/pnas.0904894106
   Gandhirajan RK, 2010, CURR CANCER DRUG TAR, V10, P716
   Harterink M, 2011, NAT CELL BIOL, V13, P914, DOI 10.1038/ncb2281
   Hausmann G, 2007, NAT REV MOL CELL BIO, V8, P331, DOI 10.1038/nrm2141
   Hsu SH, 2005, CANCER RES, V65, P4041, DOI 10.1158/0008 5472.CAN 04 3658
   Hsu SH, 2013, CANCER RES, V73, P508, DOI 10.1158/0008 5472.CAN 12 2795
   Institute. N.C., SEER CANC STAT REV 1
   Khan NI, 2007, BRIT J HAEMATOL, V138, P338, DOI 10.1111/j.1365 2141.2007.06667.x
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Li HP, 2013, ONCOTARGET, V4, P2154, DOI 10.18632/oncotarget.1367
   Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015 007 0025 3
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Luis TC, 2009, BLOOD, V113, P546, DOI 10.1182/blood 2008 06 163774
   Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432 003 0431 0
   Nakano TA, 2012, BLOOD, V119, P4372, DOI 10.1182/blood 2011 10 367128
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Seaman MNJ, 2012, J CELL SCI, V125, P4693, DOI 10.1242/jcs.103440
   Sercan Z, 2009, TUMORI J, V95, P836, DOI 10.1177/030089160909500633
   Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034
   Wang LT, 2011, ONCOGENE, V30, P2921, DOI 10.1038/onc.2011.16
   Wang LT, 2012, KAOHSIUNG J MED SCI, V28, P355, DOI 10.1016/j.kjms.2012.02.001
   Yang PT, 2008, DEV CELL, V14, P140, DOI 10.1016/j.devcel.2007.12.004
NR 31
TC 19
Z9 21
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143 3334
EI 1460 2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2014
VL 35
IS 10
BP 2357
EP 2364
DI 10.1093/carcin/bgu166
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AU8EY
UT WOS:000345830400023
PM 25115440
OA Bronze
DA 2025 08 17
ER

PT J
AU Dohle, E
   Fuchs, S
   Kolbe, M
   Hofmann, A
   Schmidt, H
   Kirkpatrick, CJ
AF Dohle, Eva
   Fuchs, Sabine
   Kolbe, Marlen
   Hofmann, Alexander
   Schmidt, Harald
   Kirkpatrick, Charles James
TI Sonic Hedgehog Promotes Angiogenesis and Osteogenesis in a Coculture
   System Consisting of Primary Osteoblasts and Outgrowth Endothelial Cells
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID MESENCHYMAL STEM CELLS; HUMAN PERIPHERAL BLOOD; GROWTH FACTOR;
   OSTEOPROGENITOR PROLIFERATION; TIE2 RECEPTOR; DIFFERENTIATION;
   ANGIOPOIETIN 1; EXPRESSION; VASCULARIZATION; CONSTRUCTS
AB A number of previous studies documented the angiogenic potential of outgrowth endothelial cells in vitro and in vivo and provided evidence that therapeutic success could depend on coculture or coimplantation strategies. Thus, deeper insight into the molecular mechanisms underlying this pro angiogenic effect of cocultures might provide new translational options for tissue engineering and regenerative medicine. One promising signaling pathway in bone repair involved in neoangiogenesis and bone formation is the sonic hedgehog (Shh) pathway. In this article, we focus on the effect of Shh on the formation of microvessel like structures and osteoblastic differentiation in cocultures of primary osteoblasts and outgrowth endothelial cells. Already after 24 h of treatment, Shh leads to a massive increase in microvessel like structures compared with untreated cocultures. Increased formation of angiogenic structures seems to correlate with the upregulation of vascular endothelial growth factor or angiopoietins (Ang 1 and Ang 2) studied at both the mRNA and protein levels. In addition, treatment with cyclopamine, an inhibitor of hedgehog signaling, blocked the formation of microvessel like structures in the cocultures. However, exogenous Shh also resulted in the upregulation of several osteogenic differentiation markers in real time polymerase chain reaction, as well as in an increased mineralization and alkaline phosphatase activity. The present data highlight the central role of the Shh pathway in bone regeneration and vascularization. Further, Shh might have the potential to improve both angiogenesis and osteogenesis in clinical applications in the future.
C1 [Dohle, Eva; Fuchs, Sabine; Kolbe, Marlen; Kirkpatrick, Charles James] Johannes Gutenberg Univ Mainz, Inst Pathol, D 55101 Mainz, Germany.
   [Hofmann, Alexander] Johannes Gutenberg Univ Mainz, Dept Trauma Surg, D 55101 Mainz, Germany.
   [Schmidt, Harald] MetaPhysiol, Essenheim City, Germany.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz
RP Fuchs, S (通讯作者)，Johannes Gutenberg Univ Mainz, Inst Pathol, Langenbeckstr 1, D 55101 Mainz, Germany.
EM fuchss@uni mainz.de
RI ; Schmidt, Harald/E 8736 2014; Hofmann, Alexander/C 3943 2013
OI Kirkpatrick, Charles James/0000 0002 0088 418X; 
FU European commission [500283 2]; BMBF [0315033]
FX The authors would like to thank B. Pavic for her excellent technical
   assistance. This work was financially supported by grants from the
   European commission (EXPERTISSUES Contract number 500283 2) and BMBF,
   for German Chinese Young Investigator Group (grant number 0315033).
CR Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   Asai J, 2006, CIRCULATION, V113, P2413, DOI 10.1161/CIRCULATIONAHA.105.603167
   Au P, 2008, BLOOD, V111, P4551, DOI 10.1182/blood 2007 10 118273
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Choong CSN, 2006, TISSUE ENG, V12, P2521, DOI 10.1089/ten.2006.12.2521
   Elbjeirami WM, 2006, TISSUE ENG, V12, P381, DOI 10.1089/ten.2006.12.381
   FIETZ MJ, 1994, DEV S, V43, P43
   Fuchs S, 2007, TISSUE ENG, V13, P2577, DOI 10.1089/ten.2007.0022
   Fuchs S, 2006, CELL TISSUE RES, V326, P79, DOI 10.1007/s00441 006 0222 4
   Fuchs S, 2009, BIOMATERIALS, V30, P1329, DOI 10.1016/j.biomaterials.2008.11.028
   Fuchs S, 2009, BIOMATERIALS, V30, P526, DOI 10.1016/j.biomaterials.2008.09.058
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Guillotin B, 2008, BONE, V42, P1080, DOI 10.1016/j.bone.2008.01.025
   Gulati R, 2003, CIRC RES, V93, P1023, DOI 10.1161/01.RES.0000105569.77539.21
   Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200
   Heine P, 2009, NEUROREPORT, V20, P279, DOI 10.1097/WNR.0b013e32832000ae
   Hofmann A, 2003, J BIOMED MATER RES A, V67A, P191, DOI 10.1002/jbm.a.10594
   Horner A, 2001, BONE, V28, P65, DOI 10.1016/S8756 3282(00)00422 1
   Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06
   Jemtland R, 2003, BONE, V32, P611, DOI 10.1016/S8756 3282(03)00092 9
   Kasama T, 2007, TRANSL RES, V149, P265, DOI 10.1016/j.trsl.2006.12.007
   Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534 5807(02)00198 3
   Levenberg S, 2005, NAT BIOTECHNOL, V23, P879, DOI 10.1038/nbt1109
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   LIU F, 1994, DEV BIOL, V166, P220, DOI 10.1006/dbio.1994.1309
   MADOKA Y, 2008, CANCER SCI, V99, P1131
   Melero Martin JM, 2007, BLOOD, V109, P4761, DOI 10.1182/blood 2006 12 062471
   Nagase T, 2007, ANN NY ACAD SCI, V1101, P412, DOI 10.1196/annals.1389.029
   Nagase T, 2006, J CRANIOFAC SURG, V17, P736, DOI 10.1097/00001665 200607000 00026
   Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156
   Park JH, 2006, EXP CLIN ENDOCR DIAB, V114, P438, DOI 10.1055/s 2006 924400
   Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083
   Rasband, 1997, IMAGEJ
   Rouwkema J, 2006, TISSUE ENG, V12, P2685, DOI 10.1089/ten.2006.12.2685
   Sanz L, 2008, MICROVASC RES, V75, P308, DOI 10.1016/j.mvr.2007.11.007
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   Silva EA, 2008, P NATL ACAD SCI USA, V105, P14347, DOI 10.1073/pnas.0803873105
   Soleti R, 2009, CELL ADHES MIGR, V3, P293, DOI 10.4161/cam.3.3.9121
   Soleti R, 2009, CARCINOGENESIS, V30, P580, DOI 10.1093/carcin/bgp030
   Straface G, 2009, J CELL MOL MED, V13, P2424, DOI 10.1111/j.1582 4934.2008.00440.x
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092 8674(00)81813 9
   Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468
   Suzuki T, 2007, BIOCHEM BIOPH RES CO, V362, P1019, DOI 10.1016/j.bbrc.2007.08.099
   Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93
   Thomas M, 2009, ANGIOGENESIS, V12, P125, DOI 10.1007/s10456 009 9147 3
   Unger RE, 2007, BIOMATERIALS, V28, P3965, DOI 10.1016/j.biomaterials.2007.05.032
   Usami K, 2009, J BIOMED MATER RES A, V90A, P730, DOI 10.1002/jbm.a.32142
   van der Horst G, 2003, BONE, V33, P899, DOI 10.1016/j.bone.2003.07.004
   Veillette CJH, 2004, BONE, V34, P288, DOI 10.1016/j.bone.2003.10.009
   Villars F, 2002, AM J PHYSIOL CELL PH, V282, pC775, DOI 10.1152/ajpcell.00310.2001
   von Schroeder HP, 2003, BONE, V33, P673, DOI 10.1016/S8756 3282(03)00215 1
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Yuasa T, 2002, J CELL PHYSIOL, V193, P225, DOI 10.1002/jcp.10166
NR 53
TC 63
Z9 77
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD APR
PY 2010
VL 16
IS 4
BP 1235
EP 1246
DI 10.1089/ten.tea.2009.0493
PG 12
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 579GJ
UT WOS:000276356700012
PM 19886747
OA Green Published
DA 2025 08 17
ER

PT J
AU Both, T
   Zillikens, MC
   Schreuders Koedam, M
   Vis, M
   Lam, WK
   Weel, AEAM
   van Leeuwen, JPTM
   van Hagen, PM
   van der Eerden, BCJ
   van Daele, PLA
AF Both, Tim
   Zillikens, M. Carola
   Schreuders Koedam, Marijke
   Vis, Marijn
   Lam, Wai Kwan
   Weel, Angelique E. A. M.
   van Leeuwen, Johannes P. T. M.
   van Hagen, P. Martin
   van der Eerden, Bram C. J.
   van Daele, Paul L. A.
TI Hydroxychloroquine affects bone resorption both in vitro and in vivo
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE  CTx; bone mineral density; cholesterol; hydroxychloroquine; lysosomal
   membrane permeabilization; osteoclast
ID SYSTEMIC LUPUS ERYTHEMATOSUS; KAPPA B LIGAND; RECEPTOR ACTIVATOR;
   ANTIMALARIAL DRUGS; SJOGREN SYNDROME; MINERAL DENSITY; CHLOROQUINE;
   INHIBITION; MECHANISM; OSTEOCLASTOGENESIS
AB We recently showed that patients with primary Sjogren syndrome (pSS) have significantly higher bone mineral density (BMD) compared to healthy controls. The majority of those patients (69%) was using hydroxychloroquine (HCQ), which may have favorable effects on BMD. The aim of the study was to evaluate whether HCQ modulates osteoclast function. Osteoclasts were cultured from PBMC sorted monocytes for 14 days and treated with different HCQ doses (controls 1 and 5g/ml). TRAP staining and resorption assays were performed to evaluate osteoclast differentiation and activity, respectively. Staining with an acidification marker (acridine orange) was performed to evaluate intracellular pH at multiple timepoints. Additionally, a fluorescent cholesterol uptake assay was performed to evaluate cholesterol trafficking. Serum bone resorption marker  CTx was evaluated in rheumatoid arthritis patients. HCQ inhibits the formation of multinuclear osteoclasts and leads to decreased bone resorption. Continuous HCQ treatment significantly decreases intracellular pH and significantly enhanced cholesterol uptake in mature osteoclasts along with increased expression of the lowdensity lipoprotein receptor. Serum  CTx was significantly decreased after 6 months of HCQ treatment. In agreement with our clinical data, we demonstrate that HCQ suppresses bone resorption in vitro and decreases the resorption marker  CTx in vivo. We also showed that HCQ decreases the intracellular pH in mature osteoclasts and stimulates cholesterol uptake, suggesting that HCQ induces osteoclastic lysosomal membrane permeabilization (LMP) leading to decreased resorption without changes in apoptosis. We hypothesize that skeletal health of patients with increased risk of osteoporosis and fractures may benefit from HCQ by preventing BMD loss.
C1 [Both, Tim; van Hagen, P. Martin; van Daele, Paul L. A.] Erasmus MC, Div Clin Immunol, Dept Internal Med, Rotterdam, Netherlands.
   [Zillikens, M. Carola; Schreuders Koedam, Marijke; van Leeuwen, Johannes P. T. M.; van der Eerden, Bram C. J.] Erasmus MC, Dept Internal Med, Div Endocrinol, POB 2040 Room D 419, NL 3000 CA Rotterdam, Netherlands.
   [Vis, Marijn] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Vis, Marijn] Erasmus MC, Dept Rheumatol, Rotterdam, Netherlands.
   [Lam, Wai Kwan] St Franciscus Gasthuis, Dept Rheumatol, Rotterdam, Netherlands.
   [Weel, Angelique E. A. M.] Maasstad Hosp, Dept Rheumatol, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; Franciscus Gasthuis; Maasstad Hospital
RP van der Eerden, BCJ (通讯作者)，Erasmus MC, Dept Internal Med, Div Endocrinol, POB 2040 Room D 419, NL 3000 CA Rotterdam, Netherlands.
EM b.vandereerden@erasmusmc.nl
RI Weel, Angelique/O 1699 2016; van Leeuwen, Johannes/D 5015 2014; van der
   Eerden, Bram/I 7496 2012
OI van Daele, Paul/0000 0003 1832 337X; van Leeuwen,
   Johannes/0000 0002 2282 4006; van der Eerden, Bram/0000 0003 4403 6497;
   Weel  Koenders, Angelique/0000 0002 1831 5129
CR Both T, 2016, CALCIFIED TISSUE INT, V98, P573, DOI 10.1007/s00223 016 0112 z
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   Bruedigam Claudia, 2011, Curr Protoc Stem Cell Biol, VChapter 1, DOI 10.1002/9780470151808.sc01h03s17
   Clarke BL, 2010, RADIOL CLIN N AM, V48, P483, DOI 10.1016/j.rcl.2010.02.014
   de Jong PHP, 2013, ANN RHEUM DIS, V72, P1659, DOI 10.1136/annrheumdis 2012 202152
   Deng D, 2009, BBA BIOMEMBRANES, V1788, P470, DOI 10.1016/j.bbamem.2008.11.018
   ESDAILE JM, 1995, AM J MED, V98, P156
   FOUCHIER F, 1983, EUR J CELL BIOL, V30, P272
   FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049 0172(10)80012 5
   Fox RI, 1996, LUPUS, V5, pS31, DOI 10.1177/096120339600500108
   Gerstein HC, 2002, DIABETES RES CLIN PR, V55, P209, DOI 10.1016/S0168 8227(01)00325 4
   Hada N, 2012, BONE, V50, P226, DOI 10.1016/j.bone.2011.10.028
   HURST NP, 1987, ANN RHEUM DIS, V46, P750, DOI 10.1136/ard.46.10.750
   Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495 009 0452 5
   Jung HJ, 2010, ARTHRITIS RHEUM US, V62, P863, DOI 10.1002/art.27289
   Kerr G, 2014, ARTHRIT CARE RES, V66, P1619, DOI 10.1002/acr.22341
   Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702
   Lakshminarayanan S, 2001, J RHEUMATOL, V28, P102
   Lamphier M, 2014, MOL PHARMACOL, V85, P429, DOI 10.1124/mol.113.089821
   LANDEWE RBM, 1995, CLIN EXP IMMUNOL, V102, P144
   Lee CK, 2004, ARTHRITIS RHEUM US, V50, P3831, DOI 10.1002/art.20637
   Luegmayr E, 2004, CELL DEATH DIFFER, V11, pS108, DOI 10.1038/sj.cdd.4401399
   MATSUZAWA Y, 1980, J BIOL CHEM, V255, P5190
   Migkos MP, 2014, J RHEUMATOL, V41, P902, DOI 10.3899/jrheum.131156
   Mok C. C., 2005, Lupus, V14, P106, DOI 10.1191/0961203305lu2039oa
   Nilsson C, 2006, APOPTOSIS, V11, P1149, DOI 10.1007/s10495 006 7108 5
   Ochotny N, 2013, J CELL BIOCHEM, V114, P2823, DOI 10.1002/jcb.24630
   OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327
   Okahashi N, 1997, J BONE MINER RES, V12, P1116, DOI 10.1359/jbmr.1997.12.7.1116
   Ruiz Irastorza G, 2008, LUPUS, V17, P271, DOI 10.1177/0961203307086643
   SPERBER K, 1993, J RHEUMATOL, V20, P803
   TANENBAUM L, 1980, ARCH DERMATOL, V116, P587, DOI 10.1001/archderm.116.5.587
   van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
NR 34
TC 28
Z9 31
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2018
VL 233
IS 2
BP 1424
EP 1433
DI 10.1002/jcp.26028
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FL9RB
UT WOS:000414593500062
PM 28556961
DA 2025 08 17
ER

PT J
AU Xie, XD
   Hu, LC
   Mi, BB
   Panayi, AC
   Xue, H
   Hu, YQ
   Liu, GD
   Chen, L
   Yan, CC
   Zha, KK
   Lin, Z
   Zhou, W
   Gao, F
   Liu, GH
AF Xie, Xudong
   Hu, Liangcong
   Mi, Bobin
   Panayi, Adriana C.
   Xue, Hang
   Hu, Yiqiang
   Liu, Guodong
   Chen, Lang
   Yan, Chenchen
   Zha, Kangkang
   Lin, Ze
   Zhou, Wu
   Gao, Fei
   Liu, Guohui
TI SHIP1 Activator AQX 1125 Regulates Osteogenesis and Osteoclastogenesis
   Through PI3K/Akt and NF κb Signaling
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE AQX 1125; SHIP1; bone loss; osteoblast; osteoclast
ID BONE MASS; OSTEOPOROSIS; INDUCTION; EFFICACY; SKELETON
AB With the worldwide aging population, the prevalence of osteoporosis is on the rise, particularly the number of postmenopausal women with the condition. However, the various adverse side effects associated with the currently available treatment options underscore the need to develop novel therapies. In this study, we investigated the use of AQX 1125, a novel clinical stage activator of inositol phosphatase 1 (SHIP1), in ovariectomized (OVX) mice, identifying a protective role. We then found that the effect was likely due to increased osteogenesis and mineralization and decreased osteoclastogenesis caused by AQX 1125 in a time  and dose dependent manner. The effect against OVX induced bone loss was identified to be SHIP1 dependent as pretreatment of BMSCs and BMMs with SHIP1 RNAi could greatly diminish the osteoprotective effects. Furthermore, SHIP1 RNAi administration in vivo induced significant bone loss and decreased bone mass. Mechanistically, AQX 1125 upregulated the expression level and activity of SHIP1, followed upregulating the phosphorylation levels of PI3K and Akt to promote osteoblast related gene expressions, including Alp, cbfa1, Col1a1, and osteocalcin (OCN). NF kappa B signaling was also inhibited through suppression of the phosphorylation of I kappa B alpha and P65 induced by RANKL, resulting in diminished osteoclastogenesis. Taken together, our results demonstrate that AQX 1125 may be a promising candidate for preventing and treating bone loss.
C1 [Xie, Xudong; Hu, Liangcong; Mi, Bobin; Xue, Hang; Hu, Yiqiang; Chen, Lang; Yan, Chenchen; Zha, Kangkang; Lin, Ze; Zhou, Wu; Gao, Fei; Liu, Guohui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan, Peoples R China.
   [Xie, Xudong; Hu, Liangcong; Mi, Bobin; Xue, Hang; Hu, Yiqiang; Chen, Lang; Yan, Chenchen; Zha, Kangkang; Zhou, Wu; Gao, Fei; Liu, Guohui] Hubei Prov Key Lab Oral & Maxillofacial Dev & Rege, Wuhan, Peoples R China.
   [Panayi, Adriana C.] Brigham & Womens Hosp, Harvard Med Sch, Div Plast Surg, Boston, MA USA.
   [Liu, Guodong] Army Med Univ, Daping Hosp, Med Ctr Trauma & War Injuries, Chongqing, Peoples R China.
C3 Huazhong University of Science & Technology; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Harvard
   Medical School; Army Medical University
RP Zhou, W; Gao, F; Liu, GH (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan, Peoples R China.; Zhou, W; Gao, F; Liu, GH (通讯作者)，Hubei Prov Key Lab Oral & Maxillofacial Dev & Rege, Wuhan, Peoples R China.
EM 2016XH0120@hust.edu.cn; docgaofei@foxmail.com; liuguohui@hust.edu.cn
RI Yan, chenchen/HJY 0642 2023; Panayi, Adriana/AAF 1817 2020; Mi,
   Bobin/LTD 1938 2024; chou, wu/AAI 1145 2019; Liu, Guodong/C 5806 2011
OI Mi, Bobin/0000 0002 6994 4363; 
FU National Science Foundation of China [82002313, 82072444]; National Key
   Research & Development Program of China [2018YFC2001502,
   2018YFB1105705]; Hubei Province Key Laboratory of Oral and Maxillofacial
   Development and Regeneration [2020kqhm008]; Wuhan Union Hospital
   "Pharmaceutical Technology nursing" special fund [2019xhyn021]
FX This work was supported by the National Science Foundation of China (Nos
   82002313 and 82072444), the National Key Research & Development Program
   of China (Nos 2018YFC2001502 and 2018YFB1105705), the Hubei Province Key
   Laboratory of Oral and Maxillofacial Development and Regeneration (No.
   2020kqhm008), and the Wuhan Union Hospital "Pharmaceutical Technology
   nursing" special fund (No. 2019xhyn021).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Chen X, 2016, BONE, V93, P104, DOI 10.1016/j.bone.2016.09.016
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cross J, 2017, BRIT J PHARMACOL, V174, P3045, DOI 10.1111/bph.13934
   Desponts C, 2006, STEM CELLS DEV, V15, P641, DOI 10.1089/scd.2006.15.641
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Hazen AL, 2009, BLOOD, V113, P2924, DOI 10.1182/blood 2008 02 138008
   Iyer S, 2013, ANN NY ACAD SCI, V1280, P11, DOI 10.1111/nyas.12091
   Jakob F, 2015, UNFALLCHIRURG, V118, P925, DOI 10.1007/s00113 015 0085 9
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Knopp Sihota JA, 2013, BMC GERIATR, V13, DOI 10.1186/1471 2318 13 36
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Leali PT, 2009, CLIN CASES MINER BON, V6, P109
   Ling L, 2010, J BIOL CHEM, V285, P26233, DOI 10.1074/jbc.M110.122069
   Looker Anne C, 2012, NCHS Data Brief, P1
   Maupin KA, 2013, BONE RES, V1, DOI 10.4248/BR201301004
   Nickel JC, 2016, J UROLOGY, V196, P747, DOI 10.1016/j.juro.2016.03.003
   Peng QS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000500
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Seo BK, 2016, J ETHNOPHARMACOL, V193, P227, DOI 10.1016/j.jep.2016.07.022
   Stenton GR, 2013, BRIT J PHARMACOL, V168, P1519, DOI 10.1111/bph.12038
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wang YG, 2016, SCI REP UK, V6, DOI 10.1038/srep32771
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
NR 29
TC 9
Z9 11
U1 1
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD APR 4
PY 2022
VL 10
AR 826023
DI 10.3389/fcell.2022.826023
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA 0Y6NH
UT WOS:000790505100001
PM 35445030
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yong, JW
   von Bremen, J
   Ruiz Heiland, G
   Ruf, S
AF Yong, Jiawen
   von Bremen, Julia
   Ruiz Heiland, Gisela
   Ruf, Sabine
TI Adiponectin as Well as Compressive Forces Regulate in vitro
   β Catenin Expression on Cementoblasts via Mitogen Activated Protein
   Kinase Signaling Activation
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE adiponectin; MAPK pathway; &#946;  catenin; cementoblast; compression
ID WNT/BETA CATENIN; OSTEOBLAST DIFFERENTIATION; P38 MAPK; OSTEOGENIC
   DIFFERENTIATION; BONE FORMATION; STEM CELLS; APOPTOSIS; RECEPTOR;
   PATHWAY; INHIBITION
AB We aimed to investigate the molecular effect that adiponectin exerts on cementoblasts especially in the presence of compressive forces. OCCM 30 cells (M. Somerman, NIH, NIDCR, United States) were used. Real time reverse transcriptase polymerase chain reaction (RT PCR) and western blots were employed to verify if the mRNA and protein levels of adiponectin receptors (AdipoRs), mitogen activated protein kinase (MAPK), and beta catenin signaling were influenced by compressive forces or adiponectin. Moreover, siRNAs targeting P38 alpha, JNK1, ERK1, ERK2, and AdipoRs as well as pharmacological MAPK inhibition were performed. We found that compressive forces increase the expression of AdipoRs. Adiponectin and compression up regulate P38 alpha,JNK1, ERK1, and ERK2 as well as beta catenin gene expression. Western blots showed that co stimuli activate the MAPK and beta catenin signaling pathways. MAPK inhibition alters the compression induced beta catenin activation and the siRNAs targeting AdipoRs, P38 alpha, and JNK1, showing the interaction of single MAPK molecules and beta catenin signaling in response to compression or adiponectin. Silencing by a dominantly negative version of P38 alpha and JNK1 attenuates adiponectin induced TCF/LEF reporter activation. Together, we found that light compressive forces activate beta catenin and MAPK signaling pathways. Adiponectin regulates beta catenin signaling principally by inactivating the GSK 3 beta kinase activity. beta Catenin expression was partially inhibited by MAPK blockade, indicating that MAPK plays a crucial role regulating beta catenin during cementogenesis. Moreover, adiponectin modulates GSK 3 beta and beta catenin mostly through AdipoR1. P38 alpha is a key connector between beta catenin, TCF/LEF transcription, and MAPK signaling pathway.
C1 [Yong, Jiawen; von Bremen, Julia; Ruiz Heiland, Gisela; Ruf, Sabine] Justus Liebig Univ Giessen, Dept Orthodont, Fac Med, Giessen, Germany.
C3 Justus Liebig University Giessen
RP Yong, JW; Ruf, S (通讯作者)，Justus Liebig Univ Giessen, Dept Orthodont, Fac Med, Giessen, Germany.
EM Jiawen.Yong@dentist.med.uni giessen.de;
   sabine.ruf@dentist.med.uni giessen.de
RI Yong, Jiawen/AAD 6426 2022; Ruf, Sabine/CAI 6903 2022
OI Yong, Jiawen/0000 0002 3021 075X; 
FU China Scholarship Council (CSC)
FX We sincerely thank Prof. J. Deschner and Dr. M. Nokhbehsaim, Department
   of Periodontology, University of Bonn, Germany for facilitating the
   sending of OCCM 30 cells and Dr. P. Roemer, Department of Orthodontics,
   University of Regensburg, Germany, for his help in the establishment of
   the cell culture compression method in our laboratory. We thank Dr.
   Groeger for contributing to the manuscript correction. We also thank the
   China Scholarship Council (CSC) for the Ph.D. financial support.
CR Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854
   Bikkavilli Rama Kamesh, 2009, Commun Integr Biol, V2, P46
   Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137
   d'Apuzzo F, 2013, SCI WORLD J, DOI 10.1155/2013/105873
   Diercke K, 2014, J OROFAC ORTHOP, V75, P430, DOI 10.1007/s00056 014 0237 5
   Greenblatt MB, 2016, P NATL ACAD SCI USA, V113, pE1226, DOI 10.1073/pnas.1600813113
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101
   Kanas Robert J, 2011, Compend Contin Educ Dent, V32, pe38
   Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210
   Korb K, 2016, CLIN ORAL INVEST, V20, P2333, DOI 10.1007/s00784 016 1740 4
   Lim WH, 2014, AM J ORTHOD DENTOFAC, V146, P337, DOI 10.1016/j.ajodo.2014.05.027
   Lin YY, 2014, BONE, V64, P147, DOI 10.1016/j.bone.2014.03.051
   Matthews BG, 2016, J PERIODONTAL RES, V51, P304, DOI 10.1111/jre.12309
   Memmert S, 2019, CELL TISSUE RES, V378, P499, DOI 10.1007/s00441 019 03063 1
   Naot D, 2017, CALCIFIED TISSUE INT, V100, P486, DOI 10.1007/s00223 016 0216 5
   Nemoto E, 2009, BONE, V44, P805, DOI 10.1016/j.bone.2008.12.029
   Osaki LH, 2013, INT J MOL SCI, V14, P10143, DOI 10.3390/ijms140510143
   Proff P, 2014, J OROFAC ORTHOP, V75, P191, DOI 10.1007/s00056 014 0212 1
   Qiao LJ, 2011, MOL CELLS, V32, P437, DOI 10.1007/s10059 011 0107 6
   Sakisaka Y, 2016, BIOCHEM BIOPH RES CO, V478, P527, DOI 10.1016/j.bbrc.2016.07.076
   Sanchavanakit N, 2015, ARCH ORAL BIOL, V60, P1066, DOI 10.1016/j.archoralbio.2015.04.001
   Saygin NE, 2000, PERIODONTOL 2000, V24, P73, DOI 10.1034/j.1600 0757.2000.2240105.x
   SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746
   Shuqin Li, 2015, Hua Xi Kou Qiang Yi Xue Za Zhi, V33, P35
   Sindhavajiva PR, 2018, J CELL BIOCHEM, V119, P3474, DOI 10.1002/jcb.26519
   Sun YY, 2010, BIOFACTORS, V36, P179, DOI 10.1002/biof.83
   Thornton TM, 2008, SCIENCE, V320, P667, DOI 10.1126/science.1156037
   Thouverey C, 2016, J BONE MINER RES, V31, P985, DOI 10.1002/jbmr.2762
   Tilg H, 2005, EXPERT OPIN THER TAR, V9, P245, DOI 10.1517/14728222.9.2.245
   Wang PP, 2012, J ASIAN NAT PROD RES, V14, P897, DOI 10.1080/10286020.2012.702757
   Wang YY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03899 z
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yang HP, 2018, ORGANOGENESIS, V14, P36, DOI 10.1080/15476278.2018.1455010
   Yassir YA, 2021, EUR J ORTHODONT, V43, P442, DOI 10.1093/ejo/cjaa058
   Yong JW, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.585346
NR 37
TC 15
Z9 15
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD APR 28
PY 2021
VL 9
AR 645005
DI 10.3389/fcell.2021.645005
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA SA4XE
UT WOS:000649304700001
PM 33996803
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liang, HF
   Zhou, L
   Hu, ZC
   Ge, YX
   Zhang, TW
   Chen, Q
   Wang, B
   Lu, SY
   Ding, W
   Dong, J
   Xue, FF
   Jiang, LB
AF Liang, Haifeng
   Zhou, Lei
   Hu, Zhichao
   Ge, Yuxiang
   Zhang, Taiwei
   Chen, Qing
   Wang, Ben
   Lu, Shunyi
   Ding, Wang
   Dong, Jian
   Xue, Fengfeng
   Jiang, Libo
TI Siglec15 Checkpoint Blockade for Simultaneous Immunochemotherapy and
   Osteolysis Inhibition in Lung Adenocarcinoma Spinal Metastasis via a
   Hollow Nanoplatform
SO SMALL
LA English
DT Article
DE antiosteoclastogenesis; hollow MnO; (2); immune checkpoint blockade;
   lung adenocarcinoma spinal metastasis; RNA interference
ID UP CONVERSION NANOPARTICLES; BONE METASTASIS; TUMOR MICROENVIRONMENT;
   CANCER; OSTEOCLASTS; THERAPY; PEPTIDE; MECHANISMS; EXPRESSION; PROTEIN
AB Low responsiveness to anti programmed death 1/programmed death ligand 1 (anti PD 1/PD L1) for solid tumors indicates the presence of other immunosuppressive pathways. Siglec15, a newly discovered immune checkpoint, has been reported to repress immune responses in the tumor microenvironment (TME) and regulate osteoclast differentiation. However, the role of Siglec15 in the treatment for bone metastasis remains unclear. Herein, Siglec15 shows significantly higher expression in lung adenocarcinoma spinal metastasis (LUAD SM) than in para cancerous spinal tissues and primary LUAD. Subsequently, a TME responsive hollow MnO2 nanoplatform (H M) loaded with Siglec15 siRNA and cisplatin (H M@siS15/Cis) is developed, and the surface is modified with an aspartic acid octapeptide (Asp(8)), thus allowing H M to target spinal metastasis. High drug loading capacity, good biocompatibility, effective tumor accumulation, and efficient Siglec15 silencing are demonstrated. Furthermore, the nanoparticles could reverse immunosuppression caused by tumor cells and tumor associated macrophages (TAMs) and inhibit osteoclast differentiation via Siglec15 downregulation in vitro. In a LUAD SM mouse model, H M@siS15/Cis Asp(8) exhibits superior therapeutic efficacy via synergetic immunochemotherapy and osteolysis inhibition. Taken together, this single nanoplatform reveals the therapeutic potential of the new immune checkpoint Siglec15 in LUAD SM and provides a strategy to treat this disease.
C1 [Liang, Haifeng; Zhou, Lei; Zhang, Taiwei; Chen, Qing; Wang, Ben; Lu, Shunyi; Dong, Jian; Jiang, Libo] Fudan Univ, Zhongshan Hosp, Dept Orthopaed Surg, Shanghai 200032, Peoples R China.
   [Xue, Fengfeng] Shanghai Univ Med & Hlth Sci, Affiliated Zhoupu Hosp, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.
   [Liang, Haifeng; Zhou, Lei; Hu, Zhichao; Zhang, Taiwei; Chen, Qing; Wang, Ben; Dong, Jian; Jiang, Libo] Fudan Univ, Zhongshan Hosp, Ctr Canc, Shanghai 200032, Peoples R China.
   [Dong, Jian] Fudan Univ, Zhongshan Hosp, Wusong Branch, Dept Orthopaed Surg, Shanghai 200940, Peoples R China.
   [Ge, Yuxiang; Ding, Wang] Fudan Univ, Minhang Hosp, Dept Orthoped Surg, Shanghai 201100, Peoples R China.
C3 Fudan University; Shanghai University of Medicine & Health Sciences;
   Fudan University; Fudan University; Fudan University
RP Dong, J; Jiang, LB (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Orthopaed Surg, Shanghai 200032, Peoples R China.; Xue, FF (通讯作者)，Shanghai Univ Med & Hlth Sci, Affiliated Zhoupu Hosp, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.; Dong, J; Jiang, LB (通讯作者)，Fudan Univ, Zhongshan Hosp, Ctr Canc, Shanghai 200032, Peoples R China.; Dong, J (通讯作者)，Fudan Univ, Zhongshan Hosp, Wusong Branch, Dept Orthopaed Surg, Shanghai 200940, Peoples R China.
EM dong.jian@zs hospitcal.sh.cn; xueff@sumhs.edu.cn;
   jiang.libo@zs hospital.sh.cn
RI Xue, Fengfeng/I 4711 2016; lu, shunyi/IUP 2257 2023; Liang,
   Haifeng/NHQ 7694 2025
OI Lu, ShunYi/0009 0007 8045 5855
FU National Natural Science Foundation of China [81972508, 82172738,
   52103171]; Natural Science Foundation of Shanghai [21ZR1412300];
   "Technology Innovation Action Plan" of Shanghai Municipality
   [21S11902700]; Shanghai "Rising Stars of Medical Talent" Youth
   Development Program (Youth Medical Talents Specialist Program)
   [[2020]087]; Construction Project of Shanghai Key Laboratory of
   Molecular Imaging [18DZ2260400, KFKT 2022 05]; Shanghai Orthopaedic
   Clinical Medicine Research Center [21MC1930100]; Shanghai Talent
   Development Fund [2020067]
FX H.L., L.Z., Z.H., and Y.G. contributed equally to this work. This work
   was supported by the National Natural Science Foundation of China (Nos.
   81972508, 82172738, and 52103171), Natural Science Foundation of
   Shanghai (21ZR1412300), "Technology Innovation Action Plan" of Shanghai
   Municipality (21S11902700), Shanghai "Rising Stars of Medical Talent"
   Youth Development Program (Youth Medical Talents Specialist Program
   [2020]087), Shanghai Talent Development Fund (2020067), the Construction
   Project of Shanghai Key Laboratory of Molecular Imaging (18DZ2260400,
   KFKT 2022 05), and Shanghai Orthopaedic Clinical Medicine Research
   Center (21MC1930100).
CR Al Husaini H, 2009, J THORAC ONCOL, V4, P251, DOI 10.1097/JTO.0b013e31819518fc
   An G, 2016, BLOOD, V128, P1590, DOI 10.1182/blood 2016 03 707547
   [Anonymous], 2021, NAT COMMUN, DOI DOI 10.1038/S41467 021 24331 1
   Arbour KC, 2019, JAMA J AM MED ASSOC, V322, P764, DOI 10.1001/jama.2019.11058
   Cai MX, 2017, INT J NANOMED, V12, P7469, DOI 10.2147/IJN.S139775
   Chamseddine AN, 2022, PHARMACOL THERAPEUT, V231, DOI 10.1016/j.pharmthera.2021.107986
   Chao Y, 2018, NAT BIOMED ENG, V2, P611, DOI 10.1038/s41551 018 0262 6
   Chen HY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01088 9
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Ding BB, 2019, CHEM MATER, V31, P2651, DOI 10.1021/acs.chemmater.9b00893
   Fang TL, 2012, J NEUROSURG SPINE, V17, P271, DOI 10.3171/2012.7.SPINE111086
   Hao JQ, 2020, NEOPLASMA, V67, P1214, DOI 10.4149/neo_2020_200220N161
   Hiruma Y, 2011, BIOCHEM BIOPH RES CO, V409, P424, DOI 10.1016/j.bbrc.2011.05.015
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Hou L, 2022, ADV MATER, V34, DOI 10.1002/adma.202200389
   Huang KW, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax5032
   Huang LP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12771 9
   Huang YJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24564 0
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Kang FB, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104728
   Kwak G, 2017, ACS NANO, V11, P10135, DOI 10.1021/acsnano.7b04717
   Liang L., 2021, CHEM ENG J, V425, DOI DOI 10.1016/J.CEJ.2021.131451
   Liu JS, 2017, INT J NANOMED, V12, P3561, DOI 10.2147/IJN.S133787
   Ma QY, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12068
   Ma YQ, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120917
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159 8290.CD 20 0516
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Qin Y, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202104645
   Sato D, 2018, BONE, V116, P172, DOI 10.1016/j.bone.2018.07.026
   Shimizu T, 2015, BONE, V79, P65, DOI 10.1016/j.bone.2015.05.029
   Sun JW, 2021, CLIN CANCER RES, V27, P680, DOI 10.1158/1078 0432.CCR 19 2925
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Sznol M, 2013, CLIN CANCER RES, V19, P5542, DOI 10.1158/1078 0432.CCR 13 2234
   Tai YT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01822
   Thibault I, 2015, LANCET ONCOL, V16, pE595, DOI 10.1016/S1470 2045(15)00166 7
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang HL, 2020, TRANSL LUNG CANCER R, V9, DOI 10.21037/tlcr 20 1250
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591 019 0374 x
   Wang KT, 2021, THERANOSTICS, V11, P4770, DOI 10.7150/thno.54235
   Wang XL, 2014, BIOMATER SCI UK, V2, P961, DOI [10.1039/c4bm00020j, 10.1039/C4BM00020J]
   Wu SY, 2021, TRANSL LUNG CANCER R, V10, P439, DOI 10.21037/tlcr 20 835
   Xu J, 2017, ACS NANO, V11, P4463, DOI 10.1021/acsnano.7b00715
   Yang GB, 2018, NANO LETT, V18, P2475, DOI 10.1021/acs.nanolett.8b00040
   Yang GB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01050 0
   Zhang Y, 2016, JAMA ONCOL, V2, P1403, DOI 10.1001/jamaoncol.2016.2450
   Zhou J, 2018, SEMIN IMMUNOL, V35, P19, DOI 10.1016/j.smim.2017.12.004
   Zhou L., 2022, CHEM ENG J, V436
   Zhu WW, 2016, ADV FUNCT MATER, V26, P5490, DOI 10.1002/adfm.201600676
   Zhuang HJ, 2020, ACS APPL MATER INTER, V12, P38906, DOI 10.1021/acsami.0c08389
NR 52
TC 19
Z9 20
U1 13
U2 60
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD JUL
PY 2022
VL 18
IS 29
AR 2107787
DI 10.1002/smll.202107787
EA JUN 2022
PG 20
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 3E1VD
UT WOS:000815619300001
PM 35751455
DA 2025 08 17
ER

PT J
AU Rubin, J
   Murphy, TC
   Rahnert, J
   Song, H
   Nanes, MS
   Greenfield, EM
   Jo, H
   Fan, X
AF Rubin, J
   Murphy, TC
   Rahnert, J
   Song, H
   Nanes, MS
   Greenfield, EM
   Jo, H
   Fan, X
TI Mechanical inhibition of RANKL expression is regulated by H Ras GTPase
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID STRESS DEPENDENT ACTIVATION; FOCAL ADHESION KINASE; NITRIC OXIDE
   SYNTHASE; KAPPA B LIGAND; SHEAR STRESS; OSTEOCLAST DIFFERENTIATION;
   RECEPTOR ACTIVATOR; CELL SURFACE; IN VITRO; K RAS
AB Mechanical input is known to regulate bone remodeling, yet the molecular events involved in mechanical signal transduction are poorly understood. We here investigate proximal events leading to the ERK1/2 activation that is required for mechanical repression of RANKL (receptor activator of NF kappa B ligand) expression, the factor that controls local recruitment of osteoclasts. Using primary murine bone stromal cells we show that dynamic mechanical strain via substrate deformation activates Ras GTPase, in particular the H Ras isoform. Pharmacological inhibition of H Ras function prevents strain activation of H Ras as well as the downstream mechanical repression of RANKL. Furthermore, small interfering RNA silencing of H Ras, but not K Ras, abrogates mechanical strain repression of RANKL. H Ras specific inhibition of mechanorepression of RANKL was also demonstrated in a murine pre osteoblast cell line (CIMC 4). The requirement of cholesterol for H Ras activation was probed; cholesterol depletion of rafts using methyl beta cyclodextrin prevented mechanical H Ras activation. That the mechanical repression of RANKL requires activation of H Ras, a specific isoform of Ras GTP that is known to reside in the lipid raft microdomain, suggests that spatial arrangements are critical for generation of specific downstream events in response to mechanical signals. By partitioning signals this way, cells may be able to generate different downstream responses through seemingly similar signaling cascades.
C1 VAMC, Decatur, GA 30033 USA.
   Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
   Vet Affairs Med Ctr, Atlanta, GA 30033 USA.
   Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA.
   Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA.
C3 Emory University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Atlanta VA Health Care System; University System
   of Ohio; Case Western Reserve University; University System of Georgia;
   Georgia Institute of Technology
RP VAMC, 151,1670 Clairmont Rd, Decatur, GA 30033 USA.
EM janet.rubin@emory.edu
RI ; Jo, Hanjoong/L 6216 2019
OI Song Lee, Hannah/0009 0003 1360 2860; Jo, Hanjoong/0000 0003 1833 372X
FU NIAMS NIH HHS [AR 042360, R01 AR042360, R01 AR052014] Funding Source:
   Medline
CR Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955 0674(03)00016 4
   Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200
   Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535 6108(02)00122 8
   Carozzi AJ, 2002, J BIOL CHEM, V277, P17944, DOI 10.1074/jbc.M110879200
   Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525
   Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301 472X(02)00904 9
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Fan X, 2003, J BIOL CHEM, V278, P10232, DOI 10.1074/jbc.M209911200
   Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633
   Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105
   INOUE D, 2004, J BIOL CHEM, V279, P40805
   Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227
   JAMES GL, 1995, METHOD ENZYMOL, V255, P38
   JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096
   Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200
   Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395
   Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782
   Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960 9822(01)00582 6
   LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802
   Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455
   Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182
   Li YS, 1996, MOL CELL BIOL, V16, P5947
   Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009
   Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304
   Park H, 2000, AM J PHYSIOL HEART C, V278, pH1285, DOI 10.1152/ajpheart.2000.278.4.H1285
   Parton RG, 2001, METHOD ENZYMOL, V333, P172
   Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091
   Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050
   Ragab AA, 1998, J BONE MINER RES, V13, P970, DOI 10.1359/jbmr.1998.13.6.970
   Ragab AA, 2002, AM J PHYSIOL CELL PH, V283, pC679, DOI 10.1152/ajpcell.00421.2001
   Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323
   Rosen CJ, 2004, TRENDS ENDOCRIN MET, V15, P229, DOI 10.1016/j.tem.2004.05.005
   Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067
   Rubin J, 2002, J BONE MINER RES, V17, P1452, DOI 10.1359/jbmr.2002.17.8.1452
   Rubin J, 2000, AM J PHYSIOL CELL PH, V278, pC1126, DOI 10.1152/ajpcell.2000.278.6.C1126
   Rubin J, 1999, J ORTHOPAED RES, V17, P639, DOI 10.1002/jor.1100170504
   Rubin J, 2003, J BIOL CHEM, V278, P34018, DOI 10.1074/jbc.M302822200
   Rubin J, 1997, J CELL PHYSIOL, V170, P81, DOI 10.1002/(SICI)1097 4652(199701)170:1<81::AID JCP9>3.0.CO;2 H
   Tuschl Thomas, 2002, Mol Interv, V2, P158, DOI 10.1124/mi.2.3.158
   Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266
   Yang CM, 2004, J BIOL CHEM, V279, P22158, DOI 10.1074/jbc.M401343200
   Zhuang HM, 1996, BIOCHEM BIOPH RES CO, V229, P449, DOI 10.1006/bbrc.1996.1824
NR 42
TC 23
Z9 26
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 20
PY 2006
VL 281
IS 3
BP 1412
EP 1418
DI 10.1074/jbc.M508639200
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 002ZS
UT WOS:000234652000017
PM 16306046
OA hybrid
DA 2025 08 17
ER

PT J
AU Chen, C
   Li, YY
   Yu, XP
   Jiang, QL
   Xu, XH
   Yang, Q
   Qian, ZY
AF Chen, Can
   Li, Yiyan
   Yu, Xiaoping
   Jiang, Qinglin
   Xu, Xiaohong
   Yang, Qian
   Qian, Zhiyong
TI Bone targeting melphalan prodrug with tumor microenvironment
   sensitivity: Synthesis, in vitro and in vivo evaluation
SO CHINESE CHEMICAL LETTERS
LA English
DT Article
DE Bone targeted; Bisphosphonates; Melphalan; Tumor microenvironment
   sensitive; Prodrug
ID DELIVERY; MATRIX; NANOPARTICLES; BISPHOSPHONATES; HYDROXYAPATITE;
   ALENDRONATE; DOXORUBICIN; METASTASES; AGENTS; DRUGS
AB Bone tumor is a refractory neoplastic growth of tissue in bone. According to the unique environment and phys chemical characteristics of bone tissues, the chemotherapeutic agents are unlikely to prolong the survival of patients and often associated with systemic side effects. The bone targeting drug delivery via systemic administration may provide both better treatment efficacy and less frequent administration. In this study, we describe the synthesis, in vitro and in vivo evaluation of novel melphalan bisphosphonate hybrids, with a tumor microenvironment sensitive linkage, which could be enzymatic activation under tumor microenvironment conditions. We have also evaluated the in vitro targeting efficiency of these prodrugs via the affinity of hydroxyapatite (HA) and cellular proliferation. The in vivo distribution suggested the bisphosphonate conjugated prodrugs with high bone selectivity. (C) 2018 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.
C1 [Chen, Can] Chengdu Med Coll, Affiliated Hosp 1, Chengdu 610500, Sichuan, Peoples R China.
   [Li, Yiyan; Jiang, Qinglin; Xu, Xiaohong; Yang, Qian] Chengdu Med Coll, Sch Pharm, Coll Key Lab Sichuan Prov Specif Struct Small Mol, Chengdu 610500, Sichuan, Peoples R China.
   [Yu, Xiaoping] Chengdu Med Coll, Publ Hlth Dept, Chengdu 610500, Sichuan, Peoples R China.
   [Qian, Zhiyong] Sichuan Univ, West China Hosp, State Key Lab, Chengdu 610041, Sichuan, Peoples R China.
   [Qian, Zhiyong] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
C3 Chengdu Medical College; Chengdu Medical College; Chengdu Medical
   College; Sichuan University; Sichuan University
RP Xu, XH; Yang, Q (通讯作者)，Chengdu Med Coll, Sch Pharm, Coll Key Lab Sichuan Prov Specif Struct Small Mol, Chengdu 610500, Sichuan, Peoples R China.
EM xoxoho@163.com; yoyoyoung8293@gmail.com
RI Qian, Zhiyong/C 2706 2009; Qiao, Zhenhua/E 4081 2012; Yang,
   Qian/T 1065 2019
OI Yang, Qian/0000 0003 3243 3153; Jiang, Qinglin/0000 0002 4056 165X
FU National Natural Science Foundation of China [31600811, 81573154,
   81773432]; Application Fundamental Research Foundation of Sichuan
   Province Science and Technology Department, China [2016JY0157,
   2017JY0123]; Scientific Research Foundation of the Health and Family
   Planning Commission of Sichuan Province, China [17PJ556, 17PJ563]
FX This work was financially supported by the National Natural Science
   Foundation of China (Nos. 31600811, 81573154, 81773432), the Application
   Fundamental Research Foundation of Sichuan Province Science and
   Technology Department, China (Nos. 2016JY0157, 2017JY0123), and
   Scientific Research Foundation of the Health and Family Planning
   Commission of Sichuan Province, China (Nos. 17PJ556, 17PJ563).
CR Chau Y, 2004, BIOCONJUGATE CHEM, V15, P931, DOI 10.1021/bc0499174
   Clementi C, 2011, MOL PHARMACEUT, V8, P1063, DOI 10.1021/mp2001445
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Dai Z, 2016, J BIOMED NANOTECHNOL, V12, P1199, DOI 10.1166/jbn.2016.2249
   Gu WY, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S44393
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Kuang TR, 2016, CURR NANOSCI, V12, P38, DOI 10.2174/1573413711666150624170518
   Lai RH, 2014, CHINESE CHEM LETT, V25, P295, DOI 10.1016/j.cclet.2013.11.012
   Li QW, 2017, CHINESE CHEM LETT, V28, P1857, DOI 10.1016/j.cclet.2017.05.007
   NAKANO A, 1995, J NEUROSURG, V83, P298, DOI 10.3171/jns.1995.83.2.0298
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Schott H, 2011, BIOORGAN MED CHEM, V19, P3520, DOI 10.1016/j.bmc.2011.04.015
   Sun ZL, 2017, ACS APPL MATER INTER, V9, P40614, DOI 10.1021/acsami.7b11614
   Teotia AK, 2017, ACS APPL MATER INTER, V9, P6816, DOI 10.1021/acsami.6b14782
   Velasco CR, 2010, DRUG DISCOV TODAY, V15, P553, DOI 10.1016/j.drudis.2010.05.009
   Wang Q, 2017, J BIOMED NANOTECHNOL, V13, P911, DOI 10.1166/jbn.2017.2396
   Wang ZQ, 2014, CHINESE CHEM LETT, V25, P1545, DOI 10.1016/j.cclet.2014.06.021
   Wong R, 2002, Cochrane Database Syst Rev, pCD002068
   Yewle JN, 2011, BIOCONJUGATE CHEM, V22, P2496, DOI 10.1021/bc2003132
NR 19
TC 32
Z9 34
U1 0
U2 44
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1001 8417
EI 1878 5964
J9 CHINESE CHEM LETT
JI Chin. Chem. Lett.
PD NOV
PY 2018
VL 29
IS 11
BP 1609
EP 1612
DI 10.1016/j.cclet.2018.02.010
PG 4
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA GZ2TF
UT WOS:000449240600008
DA 2025 08 17
ER

PT J
AU Shockley, KR
   Rosen, CJ
   Churchill, GA
   Lecka Czernik, B
AF Shockley, K. R.
   Rosen, C. J.
   Churchill, G. A.
   Lecka Czernik, B.
TI PPARγ2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells
SO PPAR RESEARCH
LA English
DT Article
ID ACTIVATED RECEPTOR GAMMA; PPAR GAMMA; BONE MARROW; OSTEOBLAST
   DIFFERENTIATION; GENE EXPRESSION; SIDE POPULATION; ROSIGLITAZONE;
   TRANSCRIPTION; ADIPOCYTE; AGONIST
AB Bone formation and hematopoiesis are anatomically juxtaposed and share common regulatory mechanisms. Bone marrow mesenchymal stromal/stem cells (MSC) contain a compartment that provides progeny with bone forming osteoblasts and fat laden adipocytes as well as fibroblasts, chondrocytes, and muscle cells. In addition, marrow MSC provide an environment for support of hematopoiesis, including the development of bone resorbing osteoclasts. The PPAR gamma 2 nuclear receptor is an adipocyte specific transcription factor that controls marrow MSC lineage allocation toward adipocytes and osteoblasts. Increased expression of PPAR gamma 2 with aging correlates with changes in the MSC status in respect to both their intrinsic differentiation potential and production of signaling molecules that contribute to the formation of a specific marrow micro environment. Here, we investigated the effect of PPAR gamma 2 on MSC molecular signature in respect to the expression of gene markers associated exclusively with stem cell phenotype, as well as genes involved in the formation of a stem cell supporting marrow environment. We found that PPAR gamma 2 is a powerful modulator of stem cell related gene expression. In general, PPAR gamma 2 affects the expression of genes specific for the maintenance of stem cell phenotype, including LIF, LIF receptor, Kit ligand, SDF 1, Rex 1/Zfp42, and Oct 4. Moreover, the antidiabetic PPAR. agonist TZD rosiglitazone specifically affects the expression of "stemness" genes, including ABCG2, Egfr, and CD44. Our data indicate that aging and anti diabetic TZD therapy may affect mesenchymal stem cell phenotype through modulation of PPAR gamma 2 activity. These observations may have important therapeutic consequences and indicate a need for more detailed studies of PPAR gamma 2 role in stem cell biology. Copyright (C) 2007 K. R. Shockley et al.
C1 [Lecka Czernik, B.] Univ Toledo, Ctr Diabet & Endocrine Res, Dept Orthopaed Surg, Med Ctr, Toledo, OH 43614 USA.
   [Shockley, K. R.; Rosen, C. J.; Churchill, G. A.] Jackson Lab, Bar Harbor, ME 04609 USA.
C3 University System of Ohio; University of Toledo; Jackson Laboratory
RP Lecka Czernik, B (通讯作者)，Univ Toledo, Ctr Diabet & Endocrine Res, Dept Orthopaed Surg, Med Ctr, 3035 Arlington Ave,Mail Stop 1008, Toledo, OH 43614 USA.
EM Beata.LeckaCzernik@utoledo.edu
RI rosen, clifford/JOZ 3228 2023; Churchill, Gary/AAY 7496 2020
FU NIH/NIA [R01 AG17482, R01 AG028935]; American Diabetes Association
   [1 03 RA 46]; NIH/NHGRI [HG003968]
FX This work was supported by NIH/NIA under Grants no. R01 AG17482 and R01
   AG028935, and by the American Diabetes Association Research under Grant
   no. 1 03 RA 46 to BLC and by NIH/NHGRI Ruth L. Kirchstein Postdoctoral
   Fellowship HG003968 to KRS.
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Chen Y, 2006, BBA GENE STRUCT EXPR, V1759, P32, DOI 10.1016/j.bbaexp.2006.01.005
   Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254
   Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014 5793(98)01273 3
   Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779
   Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106
   GIMBLE JM, 1989, MOL CELL BIOL, V9, P4587, DOI 10.1128/MCB.9.11.4587
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   Gronthos S, 2007, TRENDS ENDOCRIN MET, V18, P108, DOI 10.1016/j.tem.2007.02.002
   Hirschmann Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101
   Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772
   Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004 0021
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lecka Czernik B, 2007, ENDOCRINOLOGY, V148, P903, DOI 10.1210/en.2006 1121
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Leclerc N, 2005, ARTHRITIS RHEUM US, V52, P929, DOI 10.1002/art.20872
   Li Y, 2002, MOL ENDOCRINOL, V16, P1040, DOI 10.1210/me.16.5.1040
   Mitchell JB, 2006, STEM CELLS, V24, P376, DOI 10.1634/stemcells.2005 0234
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Mongan NP, 2006, MOL CARCINOGEN, V45, P887, DOI 10.1002/mc.20186
   Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19 4 271
   Ramalho Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530
   Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357
   Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Schwartz AV, 2006, J CLIN ENDOCR METAB, V91, P3349, DOI 10.1210/jc.2005 2226
   Simmons DG, 2005, DEV BIOL, V284, P12, DOI 10.1016/j.ydbio.2005.05.010
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223 004 0224 8
   *SUP BIOSC CORP, 2006, OL GEARRAY MOUS STEM
   TAVASSOLI M, 1984, EXP HEMATOL, V12, P139
   TAVASSOLI M, 1989, HDB HEMATOPOIETIC MI, P157
   Voiculescu O, 2000, GENESIS, V26, P123, DOI 10.1002/(SICI)1526 968X(200002)26:2<123::AID GENE7>3.0.CO;2 O
   Wong RWC, 2003, CELL MOL LIFE SCI, V60, P113, DOI 10.1007/s000180300007
   Yamashita D, 2004, GENES CELLS, V9, P1017, DOI 10.1111/j.1365 2443.2004.00786.x
   Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200
   Zhang JZ, 2006, STEM CELLS, V24, P2661, DOI 10.1634/stemcells.2006 0017
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901 1028
   ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921
NR 49
TC 8
Z9 9
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 4757
EI 1687 4765
J9 PPAR RES
JI PPAR Res.
PY 2007
VL 2007
AR 81219
DI 10.1155/2007/81219
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA V14BY
UT WOS:000207711100001
PM 18288266
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Lin, B
   Huang, JF
   Liu, XW
   Ma, XT
   Liu, XL
   Lu, Y
   Zhou, Y
   Guo, FM
   Feng, TT
AF Lin, Bing
   Huang, Jun Fei
   Liu, Xiong Wei
   Ma, Xi Tao
   Liu, Xiong Li
   Lu, Yi
   Zhou, Ying
   Guo, Feng Min
   Feng, Ting Ting
TI Rapid, microwave accelerated synthesis and anti osteoporosis activities
   evaluation of Morusin scaffolds and Morusignin L scaffolds
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Morusin; Morusignin L; TRAP enzyme; Bone resorption; Anti osteoporosis
   activity
ID FUSED SPIROPYRROLIDINE OXINDOLES; POTENTIAL ANTICANCER AGENTS;
   OSTEOCLAST DIFFERENTIATION; BIOLOGICAL EVALUATION; HIGHLY EFFICIENT;
   IN VITRO; BONE; CONSTRUCTION; ISOFLAVONES; MECHANISMS
AB Described herein is a facile and efficient methodology toward the synthesis of Morusin scaffolds and Morusignin L scaffolds 4 9 and 12 via a novel three step approach (Michael addition or prenylation, cyclization and cyclization) and use a rapid, microwave accelerated cyclization as the key step. Furthermore, their biological activities have been preliminarily demonstrated by in vitro evaluation for anti osteoporosis activity. These Morusin, Morusignin L and newly synthesized compounds 5b, 6a, 8e, 8f greatly exhibited the highest potency, especially at the 10( 5) mol/L (P < 0.01), and had good in vitro anti osteoporosis activities using the commercially available standard drug Iprifiavone as a positive control. The mechanisms associated with anti osteoporosis effects of these compounds may be through the inhibition of TRAP enzyme activity and bone resorption in osteoclasts, and promotion effect of osteoblast proliferation in vitro. The results indicated that Morusin scaffolds and Morusignin L scaffolds may be useful leads for further anti osteoporosis activity screenings. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Lin, Bing; Huang, Jun Fei; Liu, Xiong Wei; Liu, Xiong Li; Lu, Yi; Zhou, Ying; Guo, Feng Min; Feng, Ting Ting] Guizhou Univ, Guizhou Engn Ctr Innovat Tradit Chinese Med & Eth, Guiyang 550025, Peoples R China.
   [Ma, Xi Tao] Chengdu Univ Tradit Chinese Med, Affiliated Hosp, Adverse Drug React Dept, Chengdu 610072, Peoples R China.
C3 Guizhou University; Chengdu University of Traditional Chinese Medicine
RP Liu, XL; Zhou, Y; Feng, TT (通讯作者)，Guizhou Univ, Guizhou Engn Ctr Innovat Tradit Chinese Med & Eth, Guiyang 550025, Peoples R China.
EM xlliu1@gzu.edu.cn; yzhou71@yeah.net; ttfeng@gzu.edu.cn
RI Ma, Xitao/GZL 5365 2022
OI Ma, Xi Tao/0000 0003 2790 4651
FU National Natural Science Foundations of China [81560563, 81660576,
   81603390]; Excellent creative talents of science and technology support
   plan in guizhou province colleges and universities [[(2015)491] Qian
   Jiao He KY Zi]; Guizhou chinese medicine and pharmaceutical engineering
   professional degree graduate student workstation UYSZ [JYSZ [2014]002];
   Major project of the graduate student education teaching reform [Qian
   Jiao Yan He JG Zi)[2016]06]; Science and technology major project of
   Guizhou province [Qian Ke He J Zhong Da Zi ([2015]6009 5]
FX We are grateful for the financial support from the National Natural
   Science Foundations of China (No. 81560563, No. 81660576 and No.
   81603390); Excellent creative talents of science and technology support
   plan in guizhou province colleges and universities ([(2015)491] Qian
   Jiao He KY Zi); Guizhou chinese medicine and pharmaceutical engineering
   professional degree graduate student workstation (JYSZ [2014]002); Major
   project of the graduate student education teaching reform (Qian Jiao Yan
   He JG Zi)[2016]06 and Science and technology major project of Guizhou
   province (Qian Ke He J Zhong Da Zi ([2015]6009 5).
CR Atmaca A, 2008, MENOPAUSE, V15, P748, DOI 10.1097/gme.0b013e31815c1e7f
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chiba H, 2003, J NUTR, V133, P1892, DOI 10.1093/jn/133.6.1892
   Elander N, 2000, CHEM SOC REV, V29, P239, DOI 10.1039/a901713e
   Feng TT, 2014, ORG BIOMOL CHEM, V12, P9366, DOI 10.1039/c4ob01523a
   Fukai T, 2003, FITOTERAPIA, V74, P720, DOI 10.1016/j.fitote.2003.07.004
   Karsenty G, 2012, ANNU REV PHYSIOL, V74, P87, DOI 10.1146/annurev physiol 020911 153233
   Kingston H.M., 1997, MICROWAVE ENHANCED C
   Kristensen HB, 2013, J BONE MINER RES, V28, P574, DOI 10.1002/jbmr.1760
   Liu H, [No title captured], Patent No. [CN101265250A, 101265250]
   Liu XL, 2016, TETRAHEDRON LETT, V57, P4411, DOI 10.1016/j.tetlet.2016.08.063
   Liu XL, 2016, TETRAHEDRON LETT, V57, P4113, DOI 10.1016/j.tetlet.2016.07.100
   Liu XL, 2016, TETRAHEDRON LETT, V57, P1385, DOI 10.1016/j.tetlet.2016.02.074
   Liu XL, 2015, ORG BIOMOL CHEM, V13, P601, DOI 10.1039/c4ob02103g
   Liu XL, 2013, ORG LETT, V15, P1246, DOI 10.1021/ol400183k
   Liu XW, 2016, TETRAHEDRON, V72, P1364, DOI 10.1016/j.tet.2016.01.029
   Loupy A., 2003, MICROWAVES ORGANIC S
   Migliaccio S, 2003, OSTEOPOROSIS INT, V14, P361, DOI 10.1007/s00198 002 1372 1
   Ming LG, 2013, ENDOCRINOLOGY, V154, P1202, DOI 10.1210/en.2012 2086
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Morito K, 2001, BIOL PHARM BULL, V24, P351, DOI 10.1248/bpb.24.351
   Özbas H, 2012, MOL BIOL REP, V39, P11289, DOI 10.1007/s11033 012 2038 5
   Rassi CM, 2002, J BONE MINER RES, V17, P630, DOI 10.1359/jbmr.2002.17.4.630
   Russell RGG, 2006, CURR OPIN RHEUMATOL, V18, pS3, DOI 10.1097/01.bor.0000229521.95384.7d
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Seijas JA, 2005, J ORG CHEM, V70, P2855, DOI 10.1021/jo048685z
   Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S
   Shi YQ, 2001, J NAT PROD, V64, P181, DOI 10.1021/np000317c
   Tseng TH, 2010, TETRAHEDRON, V66, P1335, DOI 10.1016/j.tet.2009.12.002
   Ullmann U, 2005, J Physiol Pharmacol, V56 Suppl 1, P79
   Yamagishi T, 2001, ENDOCRINOLOGY, V142, P3632, DOI 10.1210/en.142.8.3632
   Yang J, 2016, TETRAHEDRON, V72, P8523, DOI 10.1016/j.tet.2016.10.050
NR 32
TC 7
Z9 7
U1 1
U2 35
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 894X
EI 1464 3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 1
PY 2017
VL 27
IS 11
BP 2389
EP 2396
DI 10.1016/j.bmcl.2017.04.018
PG 8
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy; Chemistry
GA EV8IL
UT WOS:000402023800024
PM 28427808
DA 2025 08 17
ER

PT J
AU Leng, HF
   Zhang, HL
   Li, LS
   Zhang, SH
   Wang, YP
   Chavda, SJ
   Galas Filipowicz, D
   Lou, HT
   Ersek, A
   Morris, EV
   Sezgin, E
   Lee, YH
   Li, YS
   Lechuga Vieco, AV
   Tian, M
   Mi, JQ
   Yong, K
   Zhong, Q
   Edwards, CM
   Simon, AK
   Horwood, NJ
AF Leng, Houfu
   Zhang, Hanlin
   Li, Linsen
   Zhang, Shuhao
   Wang, Yanping
   Chavda, Selina J.
   Galas Filipowicz, Daria
   Lou, Hantao
   Ersek, Adel
   Morris, Emma V.
   Sezgin, Erdinc
   Lee, Yi Hsuan
   Li, Yunsen
   Lechuga Vieco, Ana Victoria
   Tian, Mei
   Mi, Jian Qing
   Yong, Kwee
   Zhong, Qing
   Edwards, Claire M.
   Simon, Anna Katharina
   Horwood, Nicole J.
TI Modulating glycosphingolipid metabolism and autophagy improves outcomes
   in pre clinical models of myeloma bone disease
SO NATURE COMMUNICATIONS
LA English
DT Article
ID FACTOR KAPPA B; RECEPTOR ACTIVATOR; OSTEOCLAST DIFFERENTIATION;
   SIGNAL TRANSDUCTION; MULTIPLE MYELOMA; INHIBITORS; VIRUS; TRIAL;
   HYDROXYCHLOROQUINE; OSTEOPROTEGERIN
AB Patients with multiple myeloma, an incurable malignancy of plasma cells, frequently develop osteolytic bone lesions that severely impact quality of life and clinical outcomes. Eliglustat, a U.S. Food and Drug Administration approved glucosylceramide synthase inhibitor, reduced osteoclast driven bone loss in preclinical in vivo models of myeloma. In combination with zoledronic acid, a bisphosphonate that treats myeloma bone disease, eliglustat provided further protection from bone loss. Autophagic degradation of TRAF3, a key step for osteoclast differentiation, was inhibited by eliglustat as evidenced by TRAF3 lysosomal and cytoplasmic accumulation. Eliglustat blocked autophagy by altering glycosphingolipid composition whilst restoration of missing glycosphingolipids rescued autophagy markers and TRAF3 degradation thus restoring osteoclastogenesis in bone marrow cells from myeloma patients. This work delineates both the mechanism by which glucosylceramide synthase inhibition prevents autophagic degradation of TRAF3 to reduce osteoclastogenesis as well as highlighting the clinical translational potential of eliglustat for the treatment of myeloma bone disease.
C1 [Leng, Houfu; Zhang, Hanlin; Zhang, Shuhao; Lee, Yi Hsuan; Lechuga Vieco, Ana Victoria; Simon, Anna Katharina; Horwood, Nicole J.] Univ Oxford, Kennedy Inst Rheumatol, Roosevelt Dr, Oxford OX3 7FY, England.
   [Li, Linsen; Zhong, Qing] Shanghai Jiao Tong Univ, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis, Chinese Minist Educ,Sch Med, Shanghai, Peoples R China.
   [Zhang, Shuhao] Carnegie Mellon Univ, Computat Biol Dept, Pittsburgh, PA 15217 USA.
   [Wang, Yanping; Li, Yunsen] Soochow Univ, Inst Biol Sci, Suzhou, Peoples R China.
   [Wang, Yanping; Li, Yunsen] Soochow Univ, Inst Med Sci, Suzhou, Peoples R China.
   [Chavda, Selina J.; Galas Filipowicz, Daria; Yong, Kwee] UCL, UCL Canc Inst, Dept Hematol, London, England.
   [Lou, Hantao] Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Med, Oxford OX3 7DQ, England.
   [Ersek, Adel; Lee, Yi Hsuan; Horwood, Nicole J.] Univ East Anglia, Norwich Med Sch, James Watson Rd, Norwich NR4 7UQ, Norfolk, England.
   [Morris, Emma V.; Edwards, Claire M.] Univ Oxford, Nuffield Dept Surg Sci, Botnar Res Ctr, Old Rd, Oxford OX3 7LD, England.
   [Sezgin, Erdinc] Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden.
   [Sezgin, Erdinc] MRC Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DS, England.
   [Tian, Mei] Fudan Univ, Human Phenome Inst, 825 Zhangheng Rd, Shanghai, Peoples R China.
   [Mi, Jian Qing] Shanghai Jiao Tong Univ, State Key Lab Med Genom, Natl Res Ctr Translat Med Shanghai, RuiJin Hosp,Shanghai Inst Hematol,Sch Med, Shanghai, Peoples R China.
   [Edwards, Claire M.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford OX3 7LD, England.
C3 University of Oxford; Kennedy Institute for Rheumatology; Shanghai Jiao
   Tong University; Carnegie Mellon University; Soochow University   China;
   Soochow University   China; University of London; University College
   London; Ludwig Institute for Cancer Research; University of Oxford;
   University of East Anglia; University of Oxford; Karolinska Institutet;
   Fudan University; Shanghai Jiao Tong University; Chinese Academy of
   Sciences; University of Oxford
RP Simon, AK; Horwood, NJ (通讯作者)，Univ Oxford, Kennedy Inst Rheumatol, Roosevelt Dr, Oxford OX3 7FY, England.; Horwood, NJ (通讯作者)，Univ East Anglia, Norwich Med Sch, James Watson Rd, Norwich NR4 7UQ, Norfolk, England.
EM katja.simon@imm.ox.ac.uk; n.horwood@uea.ac.uk
RI Zhong, Qing/GLT 4858 2022; Edwards, Claire/D 7114 2011; Sezgin,
   Erdinc/R 1980 2018; Horwood, Nicole/B 4351 2009; Simon,
   Anna/IAM 0780 2023
OI Zhong, Qing/0000 0001 6979 955X; Galas Filipowicz,
   Daria/0000 0002 4557 154X; Zhang, Hanlin/0000 0001 9353 6071; Leng,
   Houfu/0000 0002 4023 8588; Horwood, Nicole/0000 0002 6344 1677;
   Lechuga Vieco, Ana Victoria/0000 0001 5546 9752; Zhang,
   Shuhao/0000 0002 0301 5983
FU University of Oxford Medical and Life Sciences Translational Fund from
   Wellcome ISSF fund [MC_PC_17174, MC_PC_18059]; MRC confidence in
   concept; Wellcome Trust Fund [220784/Z/20/Z]; Versus Arthritis [20372];
   Genzyme grant [GZ 2015 11433]; NSFC [91754205, 91957204, 31771523];
   China Scholarship Council; China Scholarship Council Nuffield Department
   of Medicine Scholarship; Oxford Elysium Prize Fellowship; Blood Cancer
   UK [17012, 15026]; Knut and Alice Wallenberg Foundation; Swedish
   Research Council [2020 02682]; Wellcome Trust ISSF; European Molecular
   Biology Organization Postdoctoral Fellowship (EMBO) [ALTF115 2019];
   Wellcome Trust [220784/Z/20/Z] Funding Source: Wellcome Trust; MRC
   [MC_PC_18059] Funding Source: UKRI; UKRI [MC_PC_17174] Funding Source:
   UKRI; Versus Arthritis [20372] Funding Source: researchfish; Swedish
   Research Council [2020 02682] Funding Source: Swedish Research Council
FX We thank the patients who donated clinical samples used in this
   research. Zhenqiang Yao and AkramAyoub from Brendan Boyce's lab in
   University of Rochester Medical Center who provided scientific advice
   and prepared the TRAF3 KO mouse BM cells it is greatly appreciated. We
   thank Xiaoxia Liu and members from Qing Zhong's lab who helped with
   experiments. Confocal microscopy help from Christoffer Lagerholm, Senior
   Advanced Microscopy Manager in the Kennedy Institute of Rheumatology, is
   appreciated. Bin Xie, Pengjun Xi, and Jianqing Zheng from Kennedy
   Institute of Rheumatology, Zhu Liang from Target Discovery Institute,
   Jiahao Jiang and Jianwei Cui from Wellcome Centre for Human Genetics,
   University of Oxford; Jin Wang and Duohui Jing from Shanghai Ruijin
   Hospital; Ge Zhang from Hong Kong Baptist University all provided
   constructive comments. This work was supported by University of Oxford
   Medical and Life Sciences Translational Fund MC_PC_17174 and MC_PC_18059
   from Wellcome ISSF fund and the MRC confidence in concept to A.K.S. and
   H. Leng; Wellcome Trust Fund 220784/Z/20/Z to A.K.S.; Versus Arthritis
   grant 20372 to N.J.H. and A.E.; Genzyme grant GZ 2015 11433 to N.J.H.;
   NSFC grant 91754205, 91957204, and 31771523 to Q.Z.; China Scholarship
   Council to H. Leng; China Scholarship Council Nuffield Department of
   Medicine Scholarship and the Oxford Elysium Prize Fellowship to H.Z.;
   Blood Cancer UK 17012 and 15026 to C.M.E. and E.V.M.; Knut and Alice
   Wallenberg Foundation, Swedish Research Council (2020 02682) and
   Wellcome Trust ISSF to E.S.; European Molecular Biology Organization
   Postdoctoral Fellowship (EMBO) ALTF115 2019 to A.V.L.V.
CR Abian O, 2011, MOL PHARMACEUT, V8, P2390, DOI 10.1021/mp200313e
   Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   Ardila Osorio H, 2005, INT J CANCER, V113, P267, DOI 10.1002/ijc.20503
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   Ballabio A, 2020, NAT REV MOL CELL BIO, V21, P101, DOI 10.1038/s41580 019 0185 4
   Bedia C, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50761 5
   Belmatoug N, 2011, J INHERIT METAB DIS, V34, P991, DOI 10.1007/s10545 011 9368 7
   Boyce BF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02263
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Brown JE, 2012, NAT REV CLIN ONCOL, V9, P110, DOI 10.1038/nrclinonc.2011.197
   Chan ST, 2016, J VIROL, V90, P10928, DOI 10.1128/JVI.01365 16
   Chen WS, 2021, BIOMATER SCI UK, V9, P4922, DOI 10.1039/d1bm00691f
   Chicote J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.580343
   Chung YH, 2014, J CELL PHYSIOL, V229, P1963, DOI 10.1002/jcp.24646
   Clarke AJ, 2019, NAT REV IMMUNOL, V19, P170, DOI 10.1038/s41577 018 0095 2
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Diao JJ, 2015, NATURE, V520, P563, DOI 10.1038/nature14147
   Ersek A, 2015, J CLIN INVEST, V125, P2279, DOI 10.1172/JCI59987
   Ersek Adel, 2012, Front Endocrinol (Lausanne), V3, P106, DOI 10.3389/fendo.2012.00106
   Garcia Ruiz C, 2015, APOPTOSIS, V20, P607, DOI 10.1007/s10495 015 1092 6
   Gaudio A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103538
   Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242
   Ha H, 2003, J BIOL CHEM, V278, P18573, DOI 10.1074/jbc.M212626200
   Häcker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998
   Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298
   Hindi SM, 2016, J CLIN INVEST, V126, P151, DOI 10.1172/JCI81655
   Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007
   Kamath RS, 2014, SKELETAL RADIOL, V43, P1353, DOI 10.1007/s00256 014 1891 9
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khusbu FY, 2020, INT J BIOCHEM CELL B, V118, DOI 10.1016/j.biocel.2019.105644
   Kong XY, 2015, INT J BIOL SCI, V11, P1204, DOI 10.7150/ijbs.12296
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lee CK, 2004, ARTHRITIS RHEUM US, V50, P3831, DOI 10.1002/art.20637
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lwin ST, 2015, LEUKEMIA, V29, P507, DOI 10.1038/leu.2014.295
   Matarrese P, 2014, AUTOPHAGY, V10, P750, DOI 10.4161/auto.27959
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   Meckes DG, 2013, J VIROL, V87, P1301, DOI 10.1128/JVI.02519 12
   Morris EV, 2021, BEST PRACT RES CL EN, V35, DOI 10.1016/j.beem.2021.101541
   Muruganandan S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072277
   Nair S, 2016, NEW ENGL J MED, V374, P555, DOI 10.1056/NEJMoa1508808
   Newman AC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00859 z
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Pavlova EV, 2015, J PATHOL, V235, P113, DOI 10.1002/path.4452
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Poole RM, 2014, DRUGS, V74, P1829, DOI 10.1007/s40265 014 0296 3
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Rajkumar SV, 2010, MAYO CLIN PROC, V85, P945, DOI 10.4065/mcp.2010.0520
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rosenbloom BE, 2009, GENET MED, V11, P134, DOI 10.1097/GIM.0b013e318195e2b6
   Russell RGG, 2015, CURR OPIN PHARMACOL, V22, P115, DOI 10.1016/j.coph.2015.05.005
   Scheller EL, 2014, METHOD ENZYMOL, V537, P123, DOI 10.1016/B978 0 12 411619 1.00007 0
   Sezgin E, 2017, BIOPHYS J, V113, P1321, DOI 10.1016/j.bpj.2017.06.050
   Sezgin E, 2017, NAT REV MOL CELL BIO, V18, P361, DOI 10.1038/nrm.2017.16
   Sezgin E, 2015, CHEMPHYSCHEM, V16, P1387, DOI 10.1002/cphc.201402794
   Siegel RL, 2016, CA CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Vykoukal J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17645 z
   Wang C, 2016, PHARMACOL RES, V105, P164, DOI 10.1016/j.phrs.2016.01.028
   Wang Z, 2012, GLYCOBIOLOGY, V22, P930, DOI 10.1093/glycob/cws061
   Wei JS, 2009, AM J PATHOL, V174, P1891, DOI 10.2353/ajpath.2009.080680
   Wu YH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0760 0
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
   Zhang HL, 2019, MOL CELL, V76, P110, DOI 10.1016/j.molcel.2019.08.005
   Zhu J, 2014, LIVER INT, V34, P147, DOI 10.1111/liv.12265
   Zhu SP, 2016, J CELL BIOCHEM, V117, P1464, DOI 10.1002/jcb.25442
NR 70
TC 8
Z9 9
U1 1
U2 15
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC 22
PY 2022
VL 13
IS 1
AR 7868
DI 10.1038/s41467 022 35358 3
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA E0SR7
UT WOS:000972743600007
PM 36550101
OA Green Published, gold, Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Pal, S
   Porwal, K
   Rajak, S
   Sinha, RA
   Chattopadhyay, N
AF Pal, Subhashis
   Porwal, Konica
   Rajak, Sangam
   Sinha, Rohit A.
   Chattopadhyay, Naibedya
TI Selective dietary polyphenols induce differentiation of human
   osteoblasts by adiponectin receptor 1 mediated reprogramming of
   mitochondrial energy metabolism
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Adiponectin receptor; Mitochondrial biogenesis; EGCG; Resveretrol; Human
   osteoblast
ID BONE LOSS; OVARIECTOMIZED RATS; SIGNALING PATHWAY; RESVERATROL; AMPK;
   OSTEOPOROSIS; GENISTEIN; ADIPOR1; ASSOCIATION; ACTIVATION
AB Anabolic therapies for osteoporosis including dietary polyphenols promote osteoblast function by influencing its energy metabolism. Among the dietary polyphenols, the beneficial skeletal effects of genistein (an isoflavone), kaempferol (a flavone), resveratrol (RES, a stilbenoid) and epigallocatechin gallate (EGCG, a catechin) have been reported in preclinical studies. We studied the action mechanism of these nutraceuticals on osteoblast bioenergetics. All stimulated differentiation of human fetal osteoblasts (hFOB). However, only EGCG and RES stimulated mitochondrial parameters including basal and maximum respiration, spare respiratory capacity and ATP production (a measure of the activity of electron transport chain/ETC). Increases in these parameters were due to increased mitochondrial biogenesis and consequent upregulation of several mitochondrial proteins including those involved in ETC. Rotenone blocked the osteogenic effect of EGCG and RES suggesting the mediatory action of mitochondria. Both compounds rapidly activated AMPK, and dorsomorphin (an AMPK inhibitor) abolished ATP production stimulated by these compounds. Moreover, EGCG and RES upregulated the mitochondrial biogenesis factor, PGC 1 alpha which is downstream of AMPK activation, and silencing PGC 1 alpha blocked their stimulatory effects on ATP production and hFOB differentiation. Adiponectin receptor 1 (AdipoR1) is an upstream regulator of PGC 1 alpha, and both compounds increased the expression of AdipoR1 but not AdipoR2. Silencing AdipoRl blocked the upregulation of EGCG/RES induced PGC 1 alpha and hFOB differentiation. In rat calvarium, both compounds increased AdipoR1, PGC 1 alpha, and RunX2 (the osteoblast transcription factor) with a concomitant increase in mitochondrial copy number and ATP levels. We conclude that EGCG and RES display osteogenic effects by reprogramming osteoblastic bioenergetics by acting as the AdipoRl agonists.
C1 [Pal, Subhashis; Porwal, Konica; Chattopadhyay, Naibedya] CSIR Cent Drug Res Inst, Div Endocrinol, CSIR, Lucknow 226031, Uttar Pradesh, India.
   [Rajak, Sangam; Sinha, Rohit A.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow 226014, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Sanjay Gandhi Postgraduate
   Institute of Medical Sciences
RP Chattopadhyay, N (通讯作者)，CSIR Cent Drug Res Inst, Div Endocrinol, CSIR, Lucknow 226031, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI ; Sinha, Rohit/GXV 2427 2022; Chattopadhyay, Naibedya/AAQ 3213 2021;
   Pal, Subhashis/IXD 3635 2023
OI Pal, Subhashis/0000 0002 3916 5545; Chattopadhyay,
   Naibedya/0000 0003 2473 0246; Porwal, Konica/0000 0002 6447 4681; Rajak,
   Dr. Sangam/0000 0001 7529 6174
FU CSIR Nutraceutical Mission Project, Government of India [HCP0019 2.1];
   Science and Engineering Research Board [SRG/2019/000398]; Indian Council
   of Medical Research, Government of India [59/05/2019/ONLINE/BMS/TRM]
FX NC recieved funding from CSIR Nutraceutical Mission Project
   (HCP0019 2.1), Government of India. RAS is supported by the Science and
   Engineering Research Board (SRG/2019/000398) and Indian Council of
   Medical Research (59/05/2019/ONLINE/BMS/TRM), Government of India.
CR Adhikary S, 2018, NUTRITION, V53, P64, DOI 10.1016/j.nut.2017.12.003
   Aghaloo TL, 2007, J ORTHOP RES, V25, P1488, DOI 10.1002/jor.20437
   Bell S, 2015, J CLIN ENDOCR METAB, V100, P2763, DOI 10.1210/jc.2015 1845
   Chen CH, 2013, MENOPAUSE, V20, P687, DOI [10.1097/gme.0b013e31828244f0, 10.1097/GME.0b013e31828244f0]
   Cheng J, 2019, ARCH MED SCI, V15, P196, DOI 10.5114/aoms.2018.79937
   China SP, 2017, BONE, V105, P75, DOI 10.1016/j.bone.2017.08.005
   Dominy JE, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015008
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Esfahani M, 2015, IRAN J BASIC MED SCI, V18, P430
   Fanti P, 1998, OSTEOPOROSIS INT, V8, P274, DOI 10.1007/s001980050065
   Feng J, 2014, ACTA BIOCH BIOPH SIN, V46, P1024, DOI 10.1093/abbs/gmu103
   Guntur AR, 2018, J BONE MINER RES, V33, P1052, DOI 10.1002/jbmr.3390
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Guo DW, 2015, MOL MED REP, V12, P2098, DOI 10.3892/mmr.2015.3581
   Guo Y, 2011, ANN HUM GENET, V75, P569, DOI 10.1111/j.1469 1809.2011.00663.x
   Haghighatdoost F, 2017, J AM COLL NUTR, V36, P541, DOI 10.1080/07315724.2017.1333470
   Hall DT, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708307
   Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Ishimi Y, 1999, ENDOCRINOLOGY, V140, P1893, DOI 10.1210/en.140.4.1893
   Iwabu M, 2010, NATURE, V464, P1313, DOI 10.1038/nature08991
   Kang S, 2013, AUTOPHAGY, V9, P420, DOI 10.4161/auto.22920
   Khan MP, 2015, DIABETES, V64, P2609, DOI 10.2337/db14 1611
   Koh EH, 2007, DIABETES, V56, P2973, DOI 10.2337/db07 0510
   Lee SH, 2012, CALCIFIED TISSUE INT, V90, P404, DOI 10.1007/s00223 012 9584 7
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li YF, 2006, J BIOENERG BIOMEMBR, V38, P283, DOI 10.1007/s10863 006 9052 z
   Li YX, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204499
   Liu QQ, 2010, FASEB J, V24, P4229, DOI 10.1096/fj.10 159723
   Marin TL, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aaf7478
   Morabito N, 2002, J BONE MINER RES, V17, P1904, DOI 10.1359/jbmr.2002.17.10.1904
   Nakanishi A, 2017, J BIOL CHEM, V292, P19804, DOI 10.1074/jbc.M117.805085
   Nash LA, 2017, CRIT REV FOOD SCI, V57, P1603, DOI 10.1080/10408398.2014.1001019
   O'Brien AJ, 2015, BIOCHEM J, V469, P177, DOI 10.1042/BJ20150122
   Ornstrup MJ, 2014, J CLIN ENDOCR METAB, V99, P4720, DOI 10.1210/jc.2014 2799
   Pal S, 2019, BIOCHEM PHARMACOL, V164, P34, DOI 10.1016/j.bcp.2019.03.024
   Pal S, 2019, J ETHNOPHARMACOL, V235, P8, DOI 10.1016/j.jep.2019.01.029
   Park S, 2018, DIABETES METAB J, V42, P270, DOI 10.4093/dmj.2018.0101
   Pohjoismäki JLO, 2006, NUCLEIC ACIDS RES, V34, P5815, DOI 10.1093/nar/gkl703
   Qiao LP, 2012, DIABETES, V61, P1463, DOI 10.2337/db11 1475
   Quiros Pedro M, 2017, Curr Protoc Mouse Biol, V7, P47, DOI 10.1002/cpmo.21
   Sánchez de Diego C, 2019, ISCIENCE, V15, P79, DOI 10.1016/j.isci.2019.04.015
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Signes A, 2018, ESSAYS BIOCHEM, V62, P255, DOI 10.1042/EBC20170098
   Singh AK, 2014, DIABETES, V63, P3530, DOI 10.2337/db13 1619
   Song DW, 2014, INT J CLIN EXP MED, V7, P4183
   Sun YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063354
   Tou JC, 2015, ANN NY ACAD SCI, V1348, P75, DOI 10.1111/nyas.12840
   Varanasi SS, 1999, OSTEOPOROSIS INT, V10, P143, DOI 10.1007/s001980050209
   Wan ZX, 2014, OBESITY, V22, P730, DOI 10.1002/oby.20605
   Wang XW, 2017, EXP THER MED, V14, P5032, DOI 10.3892/etm.2017.5147
   Zhao HF, 2014, BRIT J NUTR, V111, P836, DOI 10.1017/S0007114513003115
NR 52
TC 16
Z9 17
U1 4
U2 19
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUL
PY 2020
VL 127
AR 110207
DI 10.1016/j.biopha.2020.110207
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA MC7WW
UT WOS:000543493200088
PM 32422565
OA gold
DA 2025 08 17
ER

PT J
AU Kusumbe, AP
   Ramasamy, SK
   Adams, RH
AF Kusumbe, Anjali P.
   Ramasamy, Saravana K.
   Adams, Ralf H.
TI Coupling of angiogenesis and osteogenesis by a specific vessel subtype
   in bone
SO NATURE
LA English
DT Article
ID HEMATOPOIETIC STEM CELLS; LINDAU TUMOR SUPPRESSOR; ENDOTHELIAL CELLS;
   FRACTURE REPAIR; VASCULAR CONTRIBUTION; ANGIOCRINE FACTORS;
   PLASMA MEMBRANE; TRABECULAR BONE; MARROW; HYPOXIA
AB The mammalian skeletal system harbours a hierarchical system of mesenchymal stem cells, osteoprogenitors and osteoblasts sustaining lifelong bone formation. Osteogenesis is indispensable for the homeostatic renewal of bone as well as regenerative fracture healing, but these processes frequently decline in ageing organisms, leading to loss of bone mass and increased fracture incidence. Evidence indicates that the growth of blood vessels in bone and osteogenesis are coupled, but relatively little is known about the underlying cellular and molecular mechanisms. Here we identify a new capillary subtype in the murine skeletal system with distinct morphological, molecular and functional properties. These vessels are found in specific locations, mediate growth of the bone vasculature, generate distinct metabolic and molecular microenvironments, maintain perivascular osteoprogenitors and couple angiogenesis to osteogenesis. The abundance of these vessels and associated osteoprogenitors was strongly reduced in bone from aged animals, and pharmacological reversal of this decline allowed the restoration of bone mass.
C1 [Kusumbe, Anjali P.; Ramasamy, Saravana K.; Adams, Ralf H.] Max Planck Inst Mol Biomed, Dept Tissue Morphogenesis, D 48149 Munster, Germany.
   [Adams, Ralf H.] Univ Munster, Fac Med, D 48149 Munster, Germany.
C3 Max Planck Society; University of Munster
RP Adams, RH (通讯作者)，Max Planck Inst Mol Biomed, Dept Tissue Morphogenesis, D 48149 Munster, Germany.
EM ralf.adams@mpi muenster.mpg.de
RI Adams, Ralf/AAE 9274 2019
OI Ramasamy, Saravana/0000 0003 2658 2945
FU Max Planck Society; University of Munster; DFG cluster of excellence
   'Cells in Motion'; European Research Council [AdG 339409 AngioBone]
FX We thank A. Medvinsky for kindly providing Flk1 GFP mice, M. Stehling
   for endothelial cell sorting and A. Borgscheiper for technical
   assistance. Funding was provided by the Max Planck Society, the
   University of Munster, the DFG cluster of excellence 'Cells in Motion'
   and the European Research Council (AdG 339409 AngioBone).
CR Bianco P, 2011, BLOOD, V117, P5281, DOI 10.1182/blood 2011 01 315069
   Boado RJ, 2002, J NEUROCHEM, V80, P552, DOI 10.1046/j.0022 3042.2001.00756.x
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791
   CROCK HV, 1965, J ANAT, V99, P77
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Ellis SL, 2011, BLOOD, V118, P1516, DOI 10.1182/blood 2010 08 303800
   Eshkar Oren I, 2009, DEVELOPMENT, V136, P1263, DOI 10.1242/dev.034199
   Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583
   Heaney RP, 1998, ENDOCRIN METAB CLIN, V27, P255, DOI 10.1016/S0889 8529(05)70004 9
   Helisch A, 2003, MICROCIRCULATION, V10, P83, DOI 10.1038/sj.mn.7800173
   Hooper AT, 2009, CELL STEM CELL, V4, P263, DOI 10.1016/j.stem.2009.01.006
   Jones DT, 2006, MOL CANCER THER, V5, P2193, DOI 10.1158/1535 7163.MCT 05 0443
   KATAOKA M, 1985, BLOOD, V65, P1163
   Kopp HG, 2005, PHYSIOLOGY, V20, P349, DOI 10.1152/physiol.00025.2005
   Kuznetsov SA, 2004, J CELL BIOL, V167, P1113, DOI 10.1083/jcb.200408079
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   Long MW, 2001, BLOOD CELL MOL DIS, V27, P677, DOI 10.1006/bcmd.2001.0431
   Losordo DW, 2001, ARTERIOSCL THROM VAS, V21, P6, DOI 10.1161/01.ATV.21.1.6
   Lu CY, 2008, J ORTHOP RES, V26, P1384, DOI 10.1002/jor.20667
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nombela Arrieta C, 2013, NAT CELL BIOL, V15, P533, DOI 10.1038/ncb2730
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603 677
   Red Horse K, 2007, DEV CELL, V12, P181, DOI 10.1016/j.devcel.2007.01.013
   Ribatti D, 2002, J HEMATOTH STEM CELL, V11, P81, DOI 10.1089/152581602753448559
   Rodríguez J, 2010, J CELL BIOL, V191, P967, DOI 10.1083/jcb.201004067
   Sale S, 2013, NAT CELL BIOL, V15, P451, DOI 10.1038/ncb2725
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   SKAWINA A, 1994, J ANAT, V185, P369
   SMITH DM, 1975, J CLIN INVEST, V56, P311, DOI 10.1172/JCI108095
   Swift MR, 2009, CIRC RES, V104, P576, DOI 10.1161/CIRCRESAHA.108.188805
   Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026
   Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298
   Tashiro Y, 2012, BLOOD, V119, P6382, DOI 10.1182/blood 2011 12 399659
   TRUETA J, 1953, J BONE JOINT SURG BR, V35, P442, DOI 10.1302/0301 620X.35B3.442
   TRUETA J, 1963, J BONE JOINT SURG BR, V45, P572, DOI 10.1302/0301 620X.45B3.572
   TRUETA J, 1960, J BONE JOINT SURG BR, V42, P97, DOI 10.1302/0301 620X.42B1.97
   Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200
   Wang L, 2013, EMBO J, V32, P219, DOI 10.1038/emboj.2012.308
   Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002
   Xu YL, 2010, J CELL BIOL, V188, P115, DOI 10.1083/jcb.200903137
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
   Zovein AC, 2008, CELL STEM CELL, V3, P625, DOI 10.1016/j.stem.2008.09.018
NR 50
TC 1571
Z9 1771
U1 43
U2 508
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028 0836
EI 1476 4687
J9 NATURE
JI Nature
PD MAR 20
PY 2014
VL 507
IS 7492
BP 323
EP +
DI 10.1038/nature13145
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AD1YG
UT WOS:000333029000026
PM 24646994
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sun, Y
   Wu, YX
   Zhang, P
   Peng, G
   Yu, SY
AF Sun, Yue
   Wu, Ying Xing
   Zhang, Peng
   Peng, Guang
   Yu, Shi Ying
TI Anti rheumatic drug iguratimod protects against cancer induced bone pain
   and bone destruction in a rat model
SO ONCOLOGY LETTERS
LA English
DT Article
DE bone metastasis; bone cancer pain; bone destruction; rat model;
   iguratimod; protection
ID NF KAPPA B; BREAST CANCER; DOUBLE BLIND; CLINICAL USE; MOUSE MODEL;
   MICROENVIRONMENT; METASTASIS; ACTIVATION; CYTOKINES; EFFICACY
AB The bone is one of the most common sites of metastasis in patients with cancer. Current treatments for bone metastases include bisphosphonates, denosumab, non steroidal anti inflammatory drugs and analgesics, but each of them has certain limitations. Cytokines and mediators released from various cells in the bone microenvironment may drive a vicious cycle of osteolytic bone metastases. Iguratimod (T 614), a novel disease modifying anti rheumatic drug, has demonstrated therapeutic effects by suppressing the production of inflammatory cytokines in rats and patients with rheumatoid arthritis. Therefore, the current study evaluated the hypothesis that iguratimod may protect against cancer induced bone pain and bone metastasis in a rat model. For this purpose, rats inoculated with Walker 256 cells were treated with iguratimod from days 11 17 post surgery. Mechanical paw withdrawal thresholds and expression levels of phosphorylated extracellular signal related kinase (pERK) and c Fos in the spinal cord were investigated to detect changes in bone pain. Bone destruction levels were detected using X rays, hematoxylin and eosin and tartrate resistant acid phosphatase staining. The results revealed that mechanical paw withdrawal thresholds and the expression levels of pERK and c Fos declined in a dose dependent manner in rats treated with iguratimod, and bone destruction severity was also reduced. These findings may provide important new insights into the treatment of bone metastasis symptoms.
C1 [Sun, Yue; Zhang, Peng; Yu, Shi Ying] Huazhong Univ Sci & Technol, Canc Ctr, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Rd, Wuhan 430030, Hubei, Peoples R China.
   [Wu, Ying Xing] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430030, Hubei, Peoples R China.
   [Peng, Guang] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; University of Texas System; UTMD Anderson Cancer
   Center
RP Yu, SY (通讯作者)，Huazhong Univ Sci & Technol, Canc Ctr, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Rd, Wuhan 430030, Hubei, Peoples R China.
EM syyu@tjh.tjmu.edu.cn
RI yu, shiying/MGB 6671 2025
FU National Natural Science Foundation of China [81372852]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 81372852). The authors would like to thank Dr Dai Shi
   and Dr Xuehai Guan (Department of Anesthesiology, Tongji Hospital,
   Wuhan, China) for their surgical and mechanical allodynia test
   suggestions. The authors would also like to thank Dr Qiaochu Fu
   (Department of Anesthesiology, Tongji Hospital) for her provision of the
   Walker 256 cells.
CR Aikawa Y, 2002, INFLAMM RES, V51, P188, DOI 10.1007/PL00000291
   Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026
   Ara T, 2009, CANCER RES, V69, P329, DOI 10.1158/0008 5472.CAN 08 0613
   Bloom AP, 2011, J PAIN, V12, P698, DOI 10.1016/j.jpain.2010.12.016
   Bussard KM, 2010, J CELL BIOCHEM, V111, P1138, DOI 10.1002/jcb.22799
   Clark AK, 2013, J PAIN RES, V6, P803, DOI 10.2147/JPR.S53660
   David Roodman G, 2003, CANCER S3, V97, pS733
   Doré Savard L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013774
   Du F, 2012, INT IMMUNOPHARMACOL, V13, P54, DOI 10.1016/j.intimp.2012.03.003
   Du F, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2554
   Ellis A, 2013, BRIT J ANAESTH, V111, P26, DOI 10.1093/bja/aet128
   Falk S, 2014, J CLIN ONCOL, V32, P1647, DOI 10.1200/JCO.2013.51.7219
   Gao Yong Jing, 2009, Open Pain J, V2, P11
   Guan XH, 2015, EXP NEUROL, V263, P39, DOI 10.1016/j.expneurol.2014.09.019
   Gui Q, 2013, CANCER BIOL THER, V14, P193, DOI 10.4161/cbt.23291
   Hara Masako, 2007, Mod Rheumatol, V17, P10
   Hara M, 2014, MOD RHEUMATOL, V24, P410, DOI 10.3109/14397595.2013.843756
   Holland PM, 2010, CANCER BIOL THER, V9, P539, DOI 10.4161/cbt.9.7.11266
   Jimenez Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749 6632.2009.05429.x
   Kane CM, 2015, BMJ BRIT MED J, V350, DOI 10.1136/bmj.h315
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Koo HJ, 2014, INT IMMUNOPHARMACOL, V22, P84, DOI 10.1016/j.intimp.2014.06.007
   Luo Q, 2013, J IMMUNOL, V191, P4969, DOI 10.4049/jimmunol.1300832
   Mantyh P, 2013, PAIN, V154, pS54, DOI 10.1016/j.pain.2013.07.044
   Mao Ying QL, 2006, BIOCHEM BIOPH RES CO, V345, P1292, DOI 10.1016/j.bbrc.2006.04.186
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304 3959(01)00437 7
   Okamura K, 2015, MOD RHEUMATOL, V25, P534, DOI 10.3109/14397595.2014.998361
   Okamura K, 2015, MOD RHEUMATOL, V25, P235, DOI 10.3109/14397595.2014.938401
   Paice JA, 2011, CA CANCER J CLIN, V61, P157, DOI 10.3322/caac.20112
   Pogatzki EM, 2003, ANESTHESIOLOGY, V99, P1023, DOI 10.1097/00000542 200310000 00041
   Roodman GD, 2012, CANCER METAST REV, V31, P569, DOI 10.1007/s10555 012 9372 x
   Siclari VA, 2006, CANCER METAST REV, V25, P621, DOI 10.1007/s10555 006 9023 1
   Sosnoski DM, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/160265
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Takiguchi S, 2014, INT J ONCOL, V44, P1316, DOI 10.3892/ijo.2014.2293
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Wang LN, 2011, MOL PAIN, V7, DOI 10.1186/1744 8069 7 48
   Wang XW, 2012, NEUROSCIENCE, V217, P172, DOI 10.1016/j.neuroscience.2012.04.065
   Xu B, 2014, EXP NEUROL, V255, P71, DOI 10.1016/j.expneurol.2014.02.019
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Yoneda T, 2011, BONE, V48, P100, DOI 10.1016/j.bone.2010.07.009
   Zinonos I, 2014, INT J ONCOL, V45, P532, DOI 10.3892/ijo.2014.2468
NR 43
TC 9
Z9 12
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUN
PY 2017
VL 13
IS 6
BP 4849
EP 4856
DI 10.3892/ol.2017.6045
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EY3XP
UT WOS:000403909200123
PM 28588731
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, WH
   Shi, W
   Wu, SH
   Kuss, M
   Jiang, XP
   Untrauer, JB
   Reid, S
   Duan, B
AF Zhang, Wenhai
   Shi, Wen
   Wu, Shaohua
   Kuss, Mitchell
   Jiang, Xiping
   Untrauer, Jason B.
   Reid, St Patrick
   Duan, Bin
TI 3D printed composite scaffolds with dual small molecule delivery for
   mandibular bone regeneration
SO BIOFABRICATION
LA English
DT Article
DE tissue engineering; vascularization; craniomaxillofacial reconstruction;
   Osteogenesis
ID MESENCHYMAL STEM CELLS; STRONTIUM RANELATE; GROWTH FACTOR; OSTEOBLAST
   DIFFERENTIATION; ENDOTHELIAL CELLS; RESVERATROL; FABRICATION;
   RESORPTION; RAT; HYDROXYAPATITE
AB Functional reconstruction of craniomaxillofacial defects is challenging, especially for the patients who suffer from traumatic injury, cranioplasty, and oncologic surgery. Three dimensional (3D) printing/bioprinting technologies provide a promising tool to fabricate bone tissue engineering constructs with complex architectures and bioactive components. In this study, we implemented multi material 3D printing to fabricate 3D printed PCL/hydrogel composite scaffolds loaded with dual bioactive small molecules (i.e. resveratrol and strontium ranelate). The incorporated small molecules are expected to target several types of bone cells. We systematically studied the scaffold morphologies and small molecule release profiles. We then investigated the effects of the released small molecules from the drug loaded scaffolds on the behavior and differentiation of mesenchymal stem cells (MSCs), monocyte derived osteoclasts, and endothelial cells. The 3D printed scaffolds, with and without small molecules, were further implanted into a rat model with a critical sized mandibular bone defect. We found that the bone scaffolds containing the dual small molecules had combinational advantages in enhancing angiogenesis and inhibiting osteoclast activities, and they synergistically promoted MSC osteogenic differentiation. The dual drug loaded scaffolds also significantly promotedin vivomandibular bone formation after 8 week implantation. This work presents a 3D printing strategy to fabricate engineered bone constructs, which can likely be used as off the shelf products to promote craniomaxillofacial regeneration.
C1 [Zhang, Wenhai] Tianjin Hosp, Hip Dept Orthoped 1, Tianjin 300211, Peoples R China.
   [Zhang, Wenhai; Shi, Wen; Wu, Shaohua; Kuss, Mitchell; Jiang, Xiping; Duan, Bin] Univ Nebraska Med Ctr, Mary & Dick Holland Regenerat Med Program, Omaha, NE 68198 USA.
   [Zhang, Wenhai; Shi, Wen; Wu, Shaohua; Kuss, Mitchell; Duan, Bin] Univ Nebraska Med Ctr, Dept Internal Med, Div Cardiol, Omaha, NE 68198 USA.
   [Wu, Shaohua] Qingdao Univ, Coll Text & Clothing, Qingdao, Peoples R China.
   [Wu, Shaohua] Qingdao Univ, Collaborat Innovat Ctr Marine Biomass Fibers, Qingdao, Peoples R China.
   [Jiang, Xiping] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Coll Med, Omaha, NE USA.
   [Untrauer, Jason B.] Univ Nebraska Med Ctr, Coll Med, Dept Surg, Div Oral & Maxillofacial Surg, Omaha, NE USA.
   [Reid, St Patrick] Univ Nebraska Med Ctr, Coll Med, Dept Pathol & Microbiol, Omaha, NE USA.
   [Duan, Bin] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE 68198 USA.
   [Duan, Bin] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center;
   Qingdao University; Qingdao University; University of Nebraska System;
   University of Nebraska Medical Center; University of Nebraska System;
   University of Nebraska Medical Center; University of Nebraska System;
   University of Nebraska Medical Center; University of Nebraska System;
   University of Nebraska Medical Center; University of Nebraska System;
   University of Nebraska Lincoln
RP Duan, B (通讯作者)，Univ Nebraska Med Ctr, Mary & Dick Holland Regenerat Med Program, Omaha, NE 68198 USA.; Duan, B (通讯作者)，Univ Nebraska Med Ctr, Dept Internal Med, Div Cardiol, Omaha, NE 68198 USA.; Duan, B (通讯作者)，Univ Nebraska Med Ctr, Dept Surg, Omaha, NE 68198 USA.; Duan, B (通讯作者)，Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA.
EM bin.duan@unmc.edu
RI ; Duan, Bin/A 1600 2013; Zhang, Wen Hai/D 4987 2016
OI Jiang, Xiping/0000 0002 9103 0891; Wu, Shaohua/0000 0002 7099 857X
FU Mary & Dick Holland Regenerative Medicine Program; University of
   Nebraska Collaboration Initiative Seed Grant; China Scholarship Council;
   Nebraska Research Initiative; Fred and Pamela Buffett Cancer Center
   Support Grant [P30CA036727]; Institutional Development Award (IDeA) from
   the NIGMS of the NIH [P30GM106397]; University of Nebraska Foundation;
   NIH [R01 AR073225, R21AI140026]
FX This work has been supported by Mary & Dick Holland Regenerative
   Medicine Program start up grant and pilot grant, Nebraska Research
   Initiative Funding, University of Nebraska Collaboration Initiative Seed
   Grant, NIH (R01 AR073225) to Dr. Bin Duan. NIH (R21AI140026) to Drs.
   Patrick Reid and Bin Duan. Xiping Jiang is partially supported by the
   China Scholarship Council. Support for the UNMC Advanced Microscopy Core
   Facility was provided by the Nebraska Research Initiative, the Fred and
   Pamela Buffett Cancer Center Support Grant (P30CA036727), and an
   Institutional Development Award (IDeA) from the NIGMS of the NIH
   (P30GM106397). The authors declare no competing financial interest. The
   Electron Microscopy Core Facility (EMCF) at UNMC is supported by state
   funds from the Nebraska Research Initiative and the University of
   Nebraska Foundation, and institutionally by the Office of the Vice
   Chancellor for Research.
CR Aldrich A, 2019, ACS APPL MATER INTER, V11, P12298, DOI 10.1021/acsami.9b00264
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   [Anonymous], J CELL MOL BIOL
   Aravamudhan A, 2013, CURR PHARM DESIGN, V19, P3420, DOI 10.2174/1381612811319190008
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Ashammakhi N, 2019, MATER TODAY BIO, V1, DOI 10.1016/j.mtbio.2019.100008
   Autefage H, 2019, BIOMATERIALS, V209, P152, DOI 10.1016/j.biomaterials.2019.03.035
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Barati D, 2016, J CONTROL RELEASE, V223, P126, DOI 10.1016/j.jconrel.2015.12.031
   Lino AB, 2019, ANN BIOMED ENG, V47, P902, DOI 10.1007/s10439 018 02183 z
   Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567
   Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH 19.189
   Boda SK, 2019, ACTA BIOMATER, V85, P282, DOI 10.1016/j.actbio.2018.12.051
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Silva GAB, 2018, J BONE MINER METAB, V36, P73, DOI 10.1007/s00774 017 0822 y
   Borrelli MR, 2020, J CRANIOFAC SURG, V31, P15, DOI 10.1097/SCS.0000000000005840
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Burg KJL, 2000, BIOMATERIALS, V21, P2347, DOI 10.1016/S0142 9612(00)00102 2
   Busse B, 2010, ACTA BIOMATER, V6, P4513, DOI 10.1016/j.actbio.2010.07.019
   Choi Y, 2019, AGING DIS, V10, P818, DOI 10.14336/AD.2018.0802
   Cook LM, 2019, ONCOGENE, V38, P6959, DOI 10.1038/s41388 019 0913 4
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Cui HT, 2016, ADV HEALTHC MATER, V5, P2174, DOI 10.1002/adhm.201600505
   Davison NL, 2014, BIOMATERIALS, V35, P7441, DOI 10.1016/j.biomaterials.2014.05.048
   De Witte TM, 2018, REGEN BIOMATER, V5, P197, DOI 10.1093/rb/rby013
   Feng C, 2017, ADV SCI, V4, DOI 10.1002/advs.201700401
   Fulda S, 2004, ONCOGENE, V23, P6702, DOI 10.1038/sj.onc.1207630
   Gaihre B, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8040049
   Gao XR, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578 018 0216 4
   Ghassemi T, 2018, ARCH BONE JT SURG AB, V6, P90
   Goonoo N, 2019, RSC ADV, V9, P18124, DOI 10.1039/c9ra02765c
   Gülçin I, 2010, INNOV FOOD SCI EMERG, V11, P210, DOI 10.1016/j.ifset.2009.07.002
   Guo XJ, 2018, ARTIF CELL NANOMED B, V46, pS629, DOI 10.1080/21691401.2018.1433188
   Guo XJ, 2016, INT J BIOL SCI, V12, P1511, DOI 10.7150/ijbs.16499
   Hu CX, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1412 9
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Ji YT, 2017, AM J TRANSL RES, V9, P2933
   Jia XS, 2017, ACTA BIOMATER, V53, P495, DOI 10.1016/j.actbio.2017.02.025
   Jiménez M, 2019, J MATER CHEM B, V7, P1974, DOI 10.1039/c8tb02738b
   Kuss MA, 2018, J BIOMED MATER RES B, V106, P1788, DOI 10.1002/jbm.b.33994
   LaFoya B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210607
   Li DZ, 2019, ACS BIOMATER SCI ENG, V5, P1440, DOI 10.1021/acsbiomaterials.8b01298
   Li Y, 2011, ACTA BIOMATER, V7, P751, DOI 10.1016/j.actbio.2010.09.008
   Lourenço AH, 2019, MAT SCI ENG C MATER, V99, P1289, DOI 10.1016/j.msec.2019.02.053
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   Maroulakos M, 2019, J DENT, V80, P1, DOI 10.1016/j.jdent.2018.11.004
   Matsuda Y, 2018, ORAL DIS, V24, P412, DOI 10.1111/odi.12785
   Mok SW, 2016, J ORTHOP TRANSL, V6, P42, DOI 10.1016/j.jot.2016.04.003
   Murgia D, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9030094
   Nair BP, 2016, COLLOID SURFACE B, V143, P423, DOI 10.1016/j.colsurfb.2016.03.033
   Nyberg EL, 2017, ANN BIOMED ENG, V45, P45, DOI 10.1007/s10439 016 1668 5
   Ornstrup MJ, 2016, CALCIFIED TISSUE INT, V99, P155, DOI 10.1007/s00223 016 0130 x
   Park JY, 2015, J MATER CHEM B, V3, P5415, DOI 10.1039/c5tb00637f
   Pati F, 2015, BIOMATERIALS, V37, P230, DOI 10.1016/j.biomaterials.2014.10.012
   Pilmane M, 2017, MAT SCI ENG C MATER, V78, P1222, DOI 10.1016/j.msec.2017.05.042
   Poornima B, 2017, CARBOHYD POLYM, V157, P1741, DOI 10.1016/j.carbpol.2016.11.056
   Prabha RD, 2019, MAT SCI ENG C MATER, V94, P509, DOI 10.1016/j.msec.2018.09.054
   Quade M, 2020, J BIOMED MATER RES B, V108, P174, DOI 10.1002/jbm.b.34376
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Roasa FV, 2018, CURR OPIN OTOLARYNGO, V26, P334, DOI 10.1097/MOO.0000000000000473
   Rutledge Katy E, 2016, J Nanomed Nanotechnol, V7
   Safaeinejad Z, 2018, EUR J MED CHEM, V155, P651, DOI 10.1016/j.ejmech.2018.06.037
   SALYER KE, 1987, CLIN PLAST SURG, V14, P27
   Segar CE, 2013, CURR PHARM DESIGN, V19, P3403, DOI 10.2174/1381612811319190007
   Shi W, 2020, CARBOHYD POLYM, V233, DOI 10.1016/j.carbpol.2019.115803
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Tian A, 2014, INT J ORAL MAX IMPL, V29, P1446, DOI 10.11607/jomi.3806
   Wang MO, 2015, ADV MATER, V27, P138, DOI 10.1002/adma.201403943
   Wang XX, 2016, MOL CELLS, V39, P418, DOI 10.14348/molcells.2016.2345
   Wang Y, 2018, ACS BIOMATER SCI ENG, V4, P4401, DOI 10.1021/acsbiomaterials.8b01277
   Wang Y, 2017, ACS BIOMATER SCI ENG, V3, P826, DOI 10.1021/acsbiomaterials.7b00101
   Wang ZH, 2017, ACS APPL MATER INTER, V9, P19541, DOI 10.1021/acsami.6b16573
   Wu SH, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa8fb8
   Wu SH, 2016, ACS APPL MATER INTER, V8, P16950, DOI 10.1021/acsami.6b05199
   Xue Y, 2009, BIOMED ENG ONLINE, V8, DOI 10.1186/1475 925X 8 34
   Yamaguchi M, 2012, MOL CELL BIOCHEM, V359, P399, DOI 10.1007/s11010 011 1034 8
   Yan FQ, 2018, EXP THER MED, V15, P1728, DOI 10.3892/etm.2017.5537
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Young S, 2009, TISSUE ENG PT A, V15, P2347, DOI 10.1089/ten.tea.2008.0510
   Yu XH, 2014, ADV FUNCT MATER, V24, P3082, DOI 10.1002/adfm.201302859
   Zaky SH, 2009, J DENT RES, V88, P1077, DOI 10.1177/0022034509349926
   Zhang WB, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a025775
   Zhao M, 2018, BRIT J PHARMACOL, V175, P4183, DOI 10.1111/bph.14477
   Zhu X, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0027081, 10.1371/journal.pone.0017783]
NR 84
TC 89
Z9 94
U1 8
U2 172
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1758 5082
EI 1758 5090
J9 BIOFABRICATION
JI Biofabrication
PD JUL
PY 2020
VL 12
IS 3
AR 035020
DI 10.1088/1758 5090/ab906e
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA MA8VD
UT WOS:000542187800001
PM 32369796
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, QQ
   Wang, HL
   Yan, HG
   Tian, HS
   Wang, YN
   Yu, W
   Dai, ZQ
   Chen, PF
   Liu, ZM
   Tang, RK
   Jiang, C
   Fan, SW
   Liu, X
   Lin, XF
AF Wang, Qingqing
   Wang, Haoli
   Yan, Huige
   Tian, Hongsen
   Wang, Yining
   Yu, Wei
   Dai, Zhanqiu
   Chen, Pengfei
   Liu, Zhaoming
   Tang, Ruikang
   Jiang, Chao
   Fan, Shunwu
   Liu, Xin
   Lin, Xianfeng
TI Suppression of osteoclast multinucleation via a posttranscriptional
   regulation based spatiotemporally selective delivery system
SO SCIENCE ADVANCES
LA English
DT Article
ID BONE RESORPTION; CELL MEMBRANE; DISEASE; FUSION; NANOPARTICLES;
   MODULATION; EXPRESSION; THERAPY; CD47; TIME
AB Redundancy of multinucleated osteoclasts, which results from the excessive fusion of mononucleated preosteoclasts (pOCs), leads to osteolytic diseases such as osteoporosis. Unfortunately, the currently available clinical drugs completely inhibit osteoclasts, thus interfering with normal physiological bone turnover. pOC specific regulation may be more suitable for maintaining bone homeostasis. Here, circBBS9, a previously unidentified circular RNA, was found to exert regulatory effects via the circBBS9/miR 423 3p/Traf6 axis in pOCs. To overcome the long standing challenge of spatiotemporal RNA delivery to cells, we constructed biomimetic nanoparticles to achieve the pOC specific targeted delivery of circBBS9. pOC membranes (POCMs) were extracted to camouflage cationic polymer for RNA interference with circBBS9 (POCM NPs@siRNA/shRNA(circBB59)) . POCM NPs endowed the nanocarriers with improved stability, accurate pOC targeting, fusogenic uptake, and reactive oxygen species responsive release. In summary, our findings may provide an alternative strategy for multinucleated cell related diseases that involves restriction of mononucleated cell multinucleation through a spatiotemporally selective delivery system.
C1 [Wang, Qingqing; Wang, Haoli; Yan, Huige; Tian, Hongsen; Wang, Yining; Yu, Wei; Dai, Zhanqiu; Chen, Pengfei; Jiang, Chao; Fan, Shunwu; Liu, Xin; Lin, Xianfeng] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Med Coll, Hangzhou 310016, Zhejiang, Peoples R China.
   [Wang, Qingqing; Wang, Haoli; Yan, Huige; Tian, Hongsen; Wang, Yining; Yu, Wei; Dai, Zhanqiu; Chen, Pengfei; Jiang, Chao; Fan, Shunwu; Liu, Xin; Lin, Xianfeng] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou 310016, Zhejiang, Peoples R China.
   [Liu, Zhaoming; Tang, Ruikang] Zhejiang Univ, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.
   [Liu, Zhaoming; Tang, Ruikang] Zhejiang Univ, Ctr Biomat & Biopathways, Hangzhou 310027, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University
RP Fan, SW; Liu, X; Lin, XF (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Med Coll, Hangzhou 310016, Zhejiang, Peoples R China.; Fan, SW; Liu, X; Lin, XF (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou 310016, Zhejiang, Peoples R China.
EM shunwu_fan@zju.edu.cn; xinliuzju@zju.edu.cn; xianfeng_lin@zju.edu.cn
RI Wang, Qingqing/E 7972 2014; Lin, Xianfeng/ABA 2917 2020; tian,
   hongsen/GLU 3656 2022
OI Tang, Ruikang/0000 0001 5277 7338; Chen, Pengfei/0000 0003 1484 2850;
   Wang, Haoli/0000 0003 0694 2341; hongsen, tian/0000 0002 9888 6617; Liu,
   Zhaoming/0000 0002 7564 6207; Dai, Zhanqiu/0000 0002 7408 7909
FU National Nature Science Fund of China [82072414, 82102313, 52003234];
   Natural Science Fund of Zhejiang Province [LQ21H060009, LY21H060002,
   LQ21E030007]; Innovative Talent Support Program Project of Zhejiang
   Provincial Health Commission [2021433298]; Public Projects of Zhejiang
   Province [LGF19H060013]; Zhejiang Provincial Program for the Cultivation
   of High Level Innovative Health Talents; Hangzhou Qianjiang
   Distinguished Expert
FX The study was supported by the National Nature Science Fund of China
   (grant nos. 82072414, 82102313, and 52003234), the Natural Science Fund
   of Zhejiang Province (grant nos. LQ21H060009, LY21H060002, and
   LQ21E030007), the Innovative Talent Support Program Project of Zhejiang
   Provincial Health Commission (grant no. 2021433298), the Public Projects
   of Zhejiang Province (LGF19H060013), the Zhejiang Provincial Program for
   the Cultivation of High Level Innovative Health Talents, and Hangzhou
   Qianjiang Distinguished Expert and Zhejiang Provincial Program for the
   Cultivation of High Level Innovative Health Talents.
CR Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Armamento Villareal R, 2006, NEW ENGL J MED, V355, P2048, DOI 10.1056/NEJMc062268
   Baum R, 2016, CLIN REV ALLERG IMMU, V51, P1, DOI 10.1007/s12016 015 8515 6
   Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637 016 0407 y
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Boissy P, 2002, ENDOCRINOLOGY, V143, P1913, DOI 10.1210/en.143.5.1913
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bracq L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00260
   Cai W, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131355
   Chambers TJ, 2010, ANN NY ACAD SCI, V1192, P19, DOI 10.1111/j.1749 6632.2009.05224.x
   Chen HY, 2020, ACTA BIOMATER, V112, P1, DOI 10.1016/j.actbio.2020.05.028
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chiu YH, 2012, J BONE MINER RES, V27, P79, DOI 10.1002/jbmr.531
   Dou C, 2018, ADV SCI, V5, DOI 10.1002/advs.201700578
   Dou C, 2016, SCI REP UK, V6, DOI 10.1038/srep21499
   Enuka Y, 2016, NUCLEIC ACIDS RES, V44, P1370, DOI 10.1093/nar/gkv1367
   Fang RH, 2018, ADV MATER, V30, DOI 10.1002/adma.201706759
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Grassi F, 2016, J BONE MINER RES, V31, P949, DOI 10.1002/jbmr.2757
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Gronthos S, 2007, TRENDS ENDOCRIN MET, V18, P108, DOI 10.1016/j.tem.2007.02.002
   Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200
   He AT, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00569 5
   He ZH, 2020, MAT SCI ENG C MATER, V106, DOI 10.1016/j.msec.2019.110298
   Helming L, 2007, IMMUNOBIOLOGY, V212, P785, DOI 10.1016/j.imbio.2007.09.012
   Herrtwich L, 2016, CELL, V167, P1264, DOI 10.1016/j.cell.2016.09.054
   Hu B, 2019, J GENE MED, V21, DOI 10.1002/jgm.3097
   Husch JFA, 2021, TISSUE ENG PART C ME, V27, P421, DOI [10.1089/ten.tec.2021.0122, 10.1089/ten.TEC.2021.0122]
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Khan AA, 2009, NAT BIOTECHNOL, V27, P549, DOI 10.1038/nbt.1543
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Kunisawa J, 2005, J CONTROL RELEASE, V105, P344, DOI 10.1016/j.jconrel.2005.03.020
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034
   Lim WA, 2017, CELL, V168, P724, DOI 10.1016/j.cell.2017.01.016
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Liu X, 2016, ADV MATER, V28, P1743, DOI 10.1002/adma.201504288
   Liu ZC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.594785
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Miao F, 2020, EUR REV MED PHARMACO, V24, P7580, DOI 10.26355/eurrev_202007_22256
   Moller AMJ, 2017, J CELL PHYSIOL, V232, P1396, DOI 10.1002/jcp.25633
   Nagasawa T, 2006, NAT REV IMMUNOL, V6, P107, DOI 10.1038/nri1780
   Pánczél A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.657935
   Podolnikova NP, 2019, J BIOL CHEM, V294, P7833, DOI 10.1074/jbc.RA118.006314
   Rao L, 2015, SMALL, V11, P6225, DOI 10.1002/smll.201502388
   Rebres RA, 2005, J CELL PHYSIOL, V205, P182, DOI 10.1002/jcp.20379
   Reid G, 2013, ANN ONCOL, V24, P3128, DOI 10.1093/annonc/mdt412
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   Song L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8417814
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Takito J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186629
   Trebec DP, 2007, J CELL BIOCHEM, V101, P205, DOI 10.1002/jcb.21171
   Tsiklauri L, 2018, OSTEOARTHR CARTILAGE, V26, P1225, DOI 10.1016/j.joca.2018.06.001
   Tsukasaki M, 2020, NAT METAB, V2, DOI 10.1038/s42255 020 00318 y
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Xiang JJ, 2018, ACS APPL MATER INTER, V10, P43352, DOI 10.1021/acsami.8b13291
   Yang R, 2019, MOL CANCER, V18, DOI 10.1186/s12943 018 0933 7
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
NR 60
TC 31
Z9 37
U1 8
U2 91
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375 2548
J9 SCI ADV
JI Sci. Adv.
PD JUL 1
PY 2022
VL 8
IS 26
AR eabn3333
DI 10.1126/sciadv.abn3333
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 2O3DR
UT WOS:000818943800012
PM 35767605
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Emori, H
   Iwai, S
   Ryu, K
   Amano, H
   Sambe, T
   Kobayashi, T
   Oguchi, T
   Ohura, K
   Oguchi, K
AF Emori, Haruka
   Iwai, Shinichi
   Ryu, Kakei
   Amano, Hitoshi
   Sambe, Takehiko
   Kobayashi, Takahiro
   Oguchi, Tatsunori
   Ohura, Kiyoshi
   Oguchi, Katsuji
TI A new method for measuring osteoclast formation by electrical impedance
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteoclast; Real time cell analyzing system; Cell morphology
ID COLONY STIMULATING FACTOR; BONE RESORPTION; DIFFERENTIATION;
   OSTEOPOROSIS
AB Osteoclasts are important target cells for osteoporosis treatment. Recently, a real time cell analysis (RTCA) system was developed to observe cell morphology and adhesion; however, the use of RTCA to study osteoclastogenesis has not been reported. Here, we investigated whether osteoclast formation could be monitored in real time using RTCA. The cell index determined via electrical impedance using RTCA, and the number of osteoclasts exhibited a significant positive correlation. RTCA was useful for determining the effect of ( ) epigallocatechin 3 gallate on the inhibition of bone resorption. We established a new method of measuring osteoclast formation in real time using RTCA. (C) 2015 Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Emori, Haruka; Ryu, Kakei; Sambe, Takehiko; Kobayashi, Takahiro; Oguchi, Tatsunori; Oguchi, Katsuji] Showa Univ, Sch Med, Dept Pharmacol, Shinagawa Ku, Tokyo 1428555, Japan.
   [Emori, Haruka] Showa Univ, Sch Med, Dept Orthopaed Surg, Shinagawa Ku, Tokyo 1428555, Japan.
   [Iwai, Shinichi] Showa Univ, Sch Pharm, Dept Healthcare & Regulatory Sci, Shinagawa Ku, Tokyo 1428555, Japan.
   [Amano, Hitoshi; Ohura, Kiyoshi] Osaka Dent Univ, Dept Pharmacol, Hirakata, Osaka 5731121, Japan.
C3 Showa University; Showa University; Showa University
RP Amano, H (通讯作者)，Osaka Dent Univ, Dept Pharmacol, 8 1 Kuzuhahanazono Cho, Hirakata, Osaka 5731121, Japan.
EM amano@cc.osaka dent.ac.jp
FU Ministry of Education, Culture, Sport, Science and Technology of Japan
   [25462899]; Grants in Aid for Scientific Research [25462899] Funding
   Source: KAKEN
FX This work was partly supported by a Grant in Aid for Scientific Research
   (25462899) from the Ministry of Education, Culture, Sport, Science and
   Technology of Japan.
CR Amano H, 1998, J BONE MINER RES, V13, P846, DOI 10.1359/jbmr.1998.13.5.846
   Balakrishna A, 2011, EUR J MED CHEM, V46, P1798, DOI 10.1016/j.ejmech.2011.02.038
   Daker M, 2012, CANCER CELL INT, V12, DOI 10.1186/1475 2867 12 34
   Eisenberg MC, 2011, P NATL ACAD SCI USA, V108, P20078, DOI 10.1073/pnas.1116327108
   Irie Y, 2014, SHOWA U J MED SCI, V26, P63
   Jonsson MKB, 2011, ASSAY DRUG DEV TECHN, V9, P589, DOI 10.1089/adt.2011.0396
   Lees RL, 1999, J BONE MINER RES, V14, P937, DOI 10.1359/jbmr.1999.14.6.937
   Limame R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046536
   Miller PD, 2006, REV ENDOCR METAB DIS, V7, P75, DOI 10.1007/s11154 006 9006 0
   Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   Ono T, 2013, SHOWA U J MED SCI, V25, P213
   Suzuki A, 2008, J PHARMACOL SCI, V106, P530, DOI 10.1254/jphs.FM0070218
   Woo JT, 2008, J PHARMACOL SCI, V106, P547, DOI 10.1254/jphs.FM0070288
   Yamaguchi M, 2011, INT J MOL MED, V28, P1049, DOI 10.3892/ijmm.2011.786
NR 15
TC 5
Z9 5
U1 0
U2 3
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD JUN
PY 2015
VL 128
IS 2
BP 87
EP 91
DI 10.1016/j.jphs.2015.05.002
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CM1WU
UT WOS:000357472000006
PM 26032840
OA gold
DA 2025 08 17
ER

PT J
AU Doh, KE
   Kang, JH
   Ting, Z
   Yim, MJ
   Choo, HYP
AF Doh, Kyung Eun
   Kang, Ju Hee
   Ting, Zheng
   Yim, Mijung
   Choo, Hea Young Park
TI Novel diether compounds inhibiting differentiation of osteoclasts
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article
DE Osteoporosis; Osteoclast; Differentiation; RANKL
ID KEY REGULATOR; C FOS; ACTIVATION; EXPRESSION; RECEPTOR; NFAT2
AB Osteoporosis is a disorder in which bone mass decreases and is responsible for many degenerative bone diseases. The excessive formation and activity of osteoclasts results in pathological disorders of the bone. Receptor Activator of Nuclear Factor kappa B Ligand (RANKL) is regarded as a key regulator of osteoclast activity and as a new therapeutic target for treating osteoporosis. Herein, we have synthesized several new small molecules and tested their inhibition activity on RANKL induced osteoclast formation. The active compounds 2c and 4d showed inhibitory activity against RANKL induced osteoclast differentiation (IC50 = 1.56 and 2.20 mu M, respectively). The most active compound 2c prevented LPS induced osteoclastogenesis in vivo. These data imply that the compound may be the potential candidate for a new therapeutic drug for treatment of bone resorption associated diseases.
C1 [Doh, Kyung Eun; Choo, Hea Young Park] Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea.
   [Doh, Kyung Eun; Choo, Hea Young Park] Ewha Womans Univ, Grad Sch Pharmaceut Sci, Seoul 120750, South Korea.
   [Kang, Ju Hee; Ting, Zheng; Yim, Mijung] Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea.
C3 Ewha Womans University; Ewha Womans University; Sookmyung Women's
   University
RP Choo, HYP (通讯作者)，Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea.; Choo, HYP (通讯作者)，Ewha Womans Univ, Grad Sch Pharmaceut Sci, Seoul 120750, South Korea.; Yim, MJ (通讯作者)，Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea.
EM myim@soomyung.ac.kr; hypark@ewha.ac.kr
RI ; Zheng, Ting/ITR 8293 2023; Kim, Se Ho/IUP 3256 2023
OI Zheng, Ting/0000 0001 7723 7653; 
FU Sookmyung Women's University [1 1303 0205]
FX This research was supported by the Sookmyung Women's University Research
   Grants (1 1303 0205).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Freimoser FM, 1999, APPL ENVIRON MICROB, V65, P3727
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hikiji H, 2009, P NATL ACAD SCI USA, V106, P21294, DOI 10.1073/pnas.0905209106
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Kim HJ, 2012, LIFE SCI, V91, P928, DOI 10.1016/j.lfs.2012.09.009
   Lee J, 2003, Patent, Patent No. [WO 2003040113, 2003040113]
   Lee J, 2006, Patent, Patent No. [WO 2006004368, 2006004368]
   Poole KES, 2006, BMJ BRIT MED J, V333, P1251, DOI 10.1136/bmj.39050.597350.47
   Sakae T, 2005, IMMUNOL REV, V208, P30
   Shinohara Masahiro, 2007, Curr Osteoporos Rep, V5, P67
   Song H, 2010, BIOORGAN MED CHEM, V18, P7580, DOI 10.1016/j.bmc.2010.08.047
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Suh H, 2003, Patent, Patent No. [WO 2003007947, 2003007947]
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wierzbicki M, 1998, ARZNEIMITTEL FORSCH, V48, P840
   Zerbini CAF, 2013, THER ADV MUSCULOSKEL, V5, P199, DOI 10.1177/1759720X13490860
NR 19
TC 3
Z9 3
U1 0
U2 5
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489 3 SUHCHO DONG, SUHCHO KU, SEOUL 137 071, SOUTH KOREA
SN 0253 6269
EI 1976 3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD FEB
PY 2016
VL 39
IS 2
BP 178
EP 190
DI 10.1007/s12272 015 0672 x
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DD9RP
UT WOS:000370263600005
PM 26670177
DA 2025 08 17
ER

PT J
AU Miraoui, H
   Oudina, K
   Petite, H
   Tanimoto, Y
   Moriyama, K
   Marie, PJ
AF Miraoui, Hichem
   Oudina, Karim
   Petite, Herve
   Tanimoto, Yukiho
   Moriyama, Keiji
   Marie, Pierre J.
TI Fibroblast Growth Factor Receptor 2 Promotes Osteogenic Differentiation
   in Mesenchymal Cells via ERK1/2 and Protein Kinase C Signaling
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; APERT SYNDROME; PHOSPHATIDYLINOSITOL
   3 KINASE; OSTEOBLASTIC DIFFERENTIATION; REGULATED KINASE; STROMAL CELLS;
   N CADHERIN; STEM CELLS; EXPRESSION; FGF
AB Mesenchymal stem cells (MSCs) are able to differentiate into several lineages including osteoblasts. The signaling mechanisms involved in the osteogenic differentiation of MSCs are however not fully understood. We investigated the role of fibroblast growth factor receptor 2 (FGFR2) in osteoblast committment and differentiation of murine mesenchymal C3H10T1/2 cells stably transfected with wild type (WT) or activated FGFR2 due to Apert S252W geneticmutation(MT). WTFGFR2 slightly increased, whereas MT FGFR2 strongly increased, FGFR2 tyrosine phosphorylation, indicating activation of the receptor. WT and MT FGFR2 increased C3H10T1/2 cell proliferation but not survival. Both WT and MT FGFR2 increased early and late osteoblast gene expression and matrix mineralization. Forced expression of WT and MT FGFR2 also increased osteoblast gene expression in MC3T3 E1 calvaria osteoblasts. In both cell types, MTFGFR2 was more effective than WTFGFR2. In contrast, WT and MTFGFR2 decreased adipocyte differentiation of C3H10T1/2 cells. WT and MT FGFR2 induced ERK1/2 but not JNK or PI3K/AKT phosphorylation. MT, but not WT, also increased protein kinase C (PKC) activity. Pharmacological inhibition of ERK1/2 prevented cell proliferation induced by WT and MT FGFR2. Using dominant negative ERK and PKC alpha vectors, we demonstrated that WT and MT FGFR2 promoted osteoblast gene expression through ERK1/2 and PKC alpha signaling, respectively. This study identifies FGFR2 as a novel regulatory molecule that promotes osteogenic differentiation in murine MSCs. The promoting effect of WT and MT FGFR2 is mediated by ERK1/2 and PKC alpha pathways that play essential and distinct roles in FGFR2 induced osteogenic differentiation of mesenchymal cells.
C1 [Marie, Pierre J.] Hop Lariboisiere, INSERM, U606, F 75475 Paris 10, France.
   [Miraoui, Hichem; Oudina, Karim; Petite, Herve; Marie, Pierre J.] Univ Paris 07, Paris 10, France.
   [Oudina, Karim; Petite, Herve] CNRS, UMR 7052, Paris 10, France.
   [Tanimoto, Yukiho; Moriyama, Keiji] Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Orthognath, Tokyo 1138549, Japan.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Universite
   Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS  
   Institute for Engineering & Systems Sciences (INSIS); Universite Paris
   Cite; Institute of Science Tokyo; Tokyo Medical & Dental University
   (TMDU)
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
RI Moriyama, Keiji/AAC 3193 2019; Petite, Herve/E 3478 2016
OI Moriyama, Keiji/0000 0003 0580 4510; 
CR Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097 4644(20010401)81:1<23::AID JCB1021>3.0.CO;2 H
   Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Aubin J.E., 2002, Principles of Bone Biology, V1, P59
   Baroni T, 2005, J CELL PHYSIOL, V202, P524, DOI 10.1002/jcp.20148
   Bensaïd W, 2003, BIOMATERIALS, V24, P2497, DOI 10.1016/S0142 9612(02)00618 X
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Chen L, 2003, BONE, V33, P169, DOI 10.1016/S8756 3282(03)00222 9
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   Debiais F, 2004, EXP CELL RES, V297, P235, DOI 10.1016/j.yexcr.2004.03.032
   Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097 4644(20010401)81:1<68::AID JCB1024>3.0.CO;2 S
   Eswarakumar VP, 2004, P NATL ACAD SCI USA, V101, P12555, DOI 10.1073/pnas.0405031101
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623
   Fragale A, 1999, AM J PATHOL, V154, P1465, DOI 10.1016/S0002 9440(10)65401 6
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gatesman A, 2004, MOL CELL BIOL, V24, P7578, DOI 10.1128/MCB.24.17.7578 7597.2004
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kaabeche K, 2004, J BIOL CHEM, V279, P36259, DOI 10.1074/jbc.M402469200
   Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188
   Kim BG, 2006, PROTEOMICS, V6, P1166, DOI 10.1002/pmic.200500289
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   LAUGHTON C, 1986, ANAL BIOCHEM, V156, P307, DOI 10.1016/0003 2697(86)90258 7
   Lemonnier J, 2001, AM J PATHOL, V158, P1833, DOI 10.1016/S0002 9440(10)64139 9
   Lemonnier J, 2001, J BONE MINER RES, V16, P832, DOI 10.1359/jbmr.2001.16.5.832
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Ling L, 2006, J CELL PHYSIOL, V209, P811, DOI 10.1002/jcp.20760
   Lomri A, 1998, J CLIN INVEST, V101, P1310
   Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007
   Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297
   Mansukhani A, 2005, J CELL BIOL, V168, P1065, DOI 10.1083/jcb.200409182
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456
   Mohammadi M, 1996, MOL CELL BIOL, V16, P977
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   Ng KW, 2007, STEM CELLS DEV, V16, P305, DOI 10.1089/scd.2006.0044
   Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   OWEN M, 2002, CELL SCI S, V10, P63
   PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Powers CJ, 2000, ENDOCR RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165
   Pratap J, 2003, CANCER RES, V63, P5357
   Pri Chen S, 1998, BONE, V23, P111, DOI 10.1016/S8756 3282(98)00087 8
   Pula G, 2005, J BIOL CHEM, V280, P7194, DOI 10.1074/jbc.M409212200
   Richardson JA, 2007, J CELL BIOCHEM, V100, P1131, DOI 10.1002/jcb.21112
   Rios H. F., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P325
   Rucci N, 2005, J CELL SCI, V118, P3263, DOI 10.1242/jcs.02436
   Shukla V, 2007, NAT GENET, V39, P1145, DOI 10.1038/ng2096
   Tang CH, 2007, J CELL PHYSIOL, V211, P45, DOI 10.1002/jcp.20896
   Tanimoto Y, 2004, J BIOL CHEM, V279, P45926, DOI 10.1074/jbc.M404824200
   Wang YL, 2005, DEVELOPMENT, V132, P3537, DOI 10.1242/dev.01914
   Wilkie AOM, 2002, AM J MED GENET, V112, P266, DOI 10.1002/ajmg.10775
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yin L, 2008, BONE, V42, P631, DOI 10.1016/j.bone.2007.11.019
NR 69
TC 137
Z9 146
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 20
PY 2009
VL 284
IS 8
BP 4897
EP 4904
DI 10.1074/jbc.M805432200
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 408DY
UT WOS:000263416600019
PM 19117954
OA hybrid
DA 2025 08 17
ER

PT J
AU Xia, Y
   Guo, Y
   Yang, ZK
   Chen, HM
   Ren, K
   Weir, MD
   Chow, LC
   Reynolds, MA
   Zhang, FM
   Gu, N
   Xu, HHK
AF Xia, Yang
   Guo, Yu
   Yang, Zukun
   Chen, Huimin
   Ren, Ke
   Weir, Michael D.
   Chow, Laurence C.
   Reynolds, Mark A.
   Zhang, Feimin
   Gu, Ning
   Xu, Hockin H. K.
TI Iron oxide nanoparticle calcium phosphate cement enhanced the osteogenic
   activities of stem cells through WNT/β catenin signaling
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Iron oxide nanoparticles; Calcium phosphate scaffold; Dental stem cells;
   Osteoinduction; Bone engineering
ID MAGNETIC NANOPARTICLES; BONE; DIFFERENTIATION; COMPOSITE; SCAFFOLDS;
   TOXICITY; CHITOSAN; COLLAGEN; RELEASE; PATHWAY
AB Calcium phosphate cement (CPC), functionalized with iron oxide nanoparticles (IONP), is of great promise to promote osteoinduction and new bone formation. In this work, the IONP powder was added into the CPC powder to fabricate CPC + IONP scaffolds and the effects of the novel composite on bone matrix formation and osteogenesis of human dental pulp stem cells (hDPSCs) were explored. A series of CPC + IONP magnetic scaffolds with different IONP contents (1%, 3% and 6%) were fabricated using 5% chitosan solution as the cement liquid. Western blotting and RT PCR were used to analyze the signaling pathway. The IONP incorporation substantially enhanced the performance of CPC + IONP, with increases in both mechanical strength and cellular activities. The IONP addition greatly promoted the osteogenesis of hDPSCs, elevating the ALP activity, the expression of osteogenic marker genes and bone matrix formation with 1.5 2 fold increases. The 3% IONP incorporation showed the most enhancement among all groups. Activation of the extracellular signal related kinases WNT/beta catenin in DPSCs was observed, and this activation was attenuated by the WNT inhibitor DKK1. The results indicated that the osteogenic behavior of hDPSCs was likely driven by CPC + IONP via the WNT signaling pathway. In conclusion, incorporate IONP into CPC scaffold remarkably enhanced the spreading, osteogenic differentiation and bone mineral synthesis of stem cell. Therefore, this method had great potential for bone tissue engineering. The novel CPC + IONP composite scaffolds with stem cells are promising to provide an innovative strategy to enhance bone regenerative therapies.
C1 [Xia, Yang; Guo, Yu; Yang, Zukun; Chen, Huimin; Zhang, Feimin] Nanjing Med Univ, Jiangsu Key Lab Oral Dis, Nanjing 210029, Jiangsu, Peoples R China.
   [Xia, Yang; Gu, Ning] Southeast Univ, Jiangsu Key Lab Biomat & Devices, Sch Biol Sci & Med Engn, Nanjing, Jiangsu, Peoples R China.
   [Xia, Yang; Weir, Michael D.; Reynolds, Mark A.; Xu, Hockin H. K.] Univ Maryland, Sch Dent, Dept Adv Oral Sci & Therapeut, Baltimore, MD 21201 USA.
   [Ren, Ke] Univ Maryland, Sch Dent, Dept Neural & Pain Sci, Baltimore, MD 21201 USA.
   [Chow, Laurence C.] NIST, Volpe Res Ctr, Amer Dent Assoc Fdn, Gaithersburg, MD 20899 USA.
   [Zhang, Feimin; Gu, Ning] Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Suzhou 215123, Jiangsu, Peoples R China.
   [Xu, Hockin H. K.] Univ Maryland, Sch Med, Ctr Stem Cell Biol & Regenerat Med, Baltimore, MD 21201 USA.
   [Xu, Hockin H. K.] Univ Maryland, Sch Med, Marlene & Stewart Greene Baum Canc Ctr, Baltimore, MD 21201 USA.
C3 Nanjing Medical University; Southeast University   China; University
   System of Maryland; University of Maryland Baltimore; University System
   of Maryland; University of Maryland Baltimore; National Institute of
   Standards & Technology (NIST)   USA; University System of Maryland;
   University of Maryland Baltimore; University System of Maryland;
   University of Maryland Baltimore
RP Zhang, FM (通讯作者)，Nanjing Med Univ, Jiangsu Key Lab Oral Dis, Nanjing 210029, Jiangsu, Peoples R China.; Gu, N (通讯作者)，Southeast Univ, Jiangsu Key Lab Biomat & Devices, Sch Biol Sci & Med Engn, Nanjing, Jiangsu, Peoples R China.; Xu, HHK (通讯作者)，Univ Maryland, Sch Dent, Dept Adv Oral Sci & Therapeut, Baltimore, MD 21201 USA.
EM fmzhang@njmu.edu.cn; guning@seu.edu.cn; hxu@umaryland.edu
RI ; guo, yu/KGM 7248 2024; 夏, 阳/HTS 0888 2023; Reynolds,
   Mark/AAO 9707 2021
OI Chow, Laurence/0000 0003 0651 2165; 
FU National Science Foundation of China [81771044]; National Key Research
   [2016YFA0201704/2016YFA0201700, 2017YFA0104301]; Jiangsu Provincial
   Medical Youth Talent [QNRC2016853]; Qing Lan Project, Southeast
   University Nanjing Medical University Cooperative Research Project
   [2242018K3DN16]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions [2018 87]; Collaborative Innovation Center of
   Suzhou Nano Science and Technology, University of Maryland Baltimore;
   University of Maryland School of Dentistry bridge fund
FX We thank Prof. Ashraf F. Fouad for providing the hDPSCs, Peng Wang for
   discussions, and Bo Chen for VSM examination. This study was supported
   by National Science Foundation of China (81771044), National Key
   Research (2016YFA0201704/2016YFA0201700, 2017YFA0104301), Jiangsu
   Provincial Medical Youth Talent (QNRC2016853), Qing Lan Project,
   Southeast University Nanjing Medical University Cooperative Research
   Project (2242018K3DN16), project funded by the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (2018 87),
   Collaborative Innovation Center of Suzhou Nano Science and Technology,
   University of Maryland Baltimore seed grant and University of Maryland
   School of Dentistry bridge fund.
CR Bock N, 2010, ACTA BIOMATER, V6, P786, DOI 10.1016/j.actbio.2009.09.017
   Chen B, 2016, MATER LETT, V170, P93, DOI 10.1016/j.matlet.2016.02.006
   Chen HM, 2018, ACS APPL MATER INTER, V10, P44279, DOI 10.1021/acsami.8b17427
   Chow LC, 2009, DENT MATER J, V28, P1
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   d'Aquino R, 2008, STEM CELL REV, V4, P21, DOI 10.1007/s12015 008 9013 5
   Felton C, 2014, DRUG METAB REV, V46, P142, DOI 10.3109/03602532.2013.876429
   Girelli D, 2018, INT J HEMATOL, V107, P16, DOI 10.1007/s12185 017 2373 3
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   He FP, 2013, COLLOID SURFACE B, V103, P209, DOI 10.1016/j.colsurfb.2012.10.018
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Hu HR, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0411 9
   Hu Y, 2018, CHEM SOC REV, V47, P1874, DOI 10.1039/c7cs00657h
   Huo MJ, 2014, FLUORIDE, V47, P320
   Kesmas S, 2010, ORAL SURG ORAL MED O, V110, pE24, DOI 10.1016/j.tripleo.2010.06.006
   Kim EC, 2015, BIOELECTROMAGNETICS, V36, P267, DOI 10.1002/bem.21903
   Li Y, 2018, CHEMPHYSCHEM, V19, P1965, DOI 10.1002/cphc.201701294
   Lindroos B, 2008, BIOCHEM BIOPH RES CO, V368, P329, DOI 10.1016/j.bbrc.2008.01.081
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Perez RA, 2015, RSC ADV, V5, P13411, DOI 10.1039/c4ra12640h
   Sharifi S, 2012, CHEM SOC REV, V41, P2323, DOI 10.1039/c1cs15188f
   Soenen SJH, 2010, NANOMEDICINE UK, V5, P1261, DOI [10.2217/nnm.10.106, 10.2217/NNM.10.106]
   Sun LM, 2007, J BIOMATER APPL, V21, P299, DOI 10.1177/0885328206063687
   Sverzut AT, 2015, CLIN ORAL IMPLAN RES, V26, P633, DOI 10.1111/clr.12346
   Tatullo M, 2015, J TISSUE ENG REGEN M, V9, P1205, DOI 10.1002/term.1899
   Tay ZW, 2018, ACS NANO, V12, P3699, DOI 10.1021/acsnano.8b00893
   Tian Q, 2016, PEERJ, V4, DOI 10.7717/peerj.2611
   Wan S, 2017, ADV MATER, V29, DOI 10.1002/adma.201700286
   Wang L, 2016, MAT SCI ENG C MATER, V69, P1125, DOI 10.1016/j.msec.2016.08.019
   Wang QW, 2017, NANO RES, V10, P626, DOI 10.1007/s12274 016 1322 4
   Wang QW, 2016, BIOMATERIALS, V86, P11, DOI 10.1016/j.biomaterials.2016.02.004
   Xia Y, 2019, MAT SCI ENG C MATER, V98, P30, DOI 10.1016/j.msec.2018.12.120
   Xia Y, 2018, BIOMATERIALS, V183, P151, DOI 10.1016/j.biomaterials.2018.08.040
   Xia Y, 2018, ARTIF CELL NANOMED B, V46, pS423, DOI 10.1080/21691401.2018.1428813
   Xia Y, 2018, NANOMED NANOTECHNOL, V14, P35, DOI 10.1016/j.nano.2017.08.014
   Xu HHK, 2002, J DENT RES, V81, P219, DOI 10.1177/154405910208100315
   Zeng XB, 2012, INT J NANOMED, V7, P3365, DOI 10.2147/IJN.S32264
   Zhang JT, 2014, ACTA BIOMATER, V10, P1035, DOI 10.1016/j.actbio.2013.11.001
   Zhang N, 2016, J DENT, V50, P51, DOI 10.1016/j.jdent.2016.05.001
   Zhou HZ, 2011, BIOMATERIALS, V32, P7503, DOI 10.1016/j.biomaterials.2011.06.045
   Zhou JH, 2018, NANOMED NANOTECHNOL, V14, P1719, DOI 10.1016/j.nano.2018.04.006
NR 41
TC 62
Z9 65
U1 2
U2 102
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD NOV
PY 2019
VL 104
AR 109955
DI 10.1016/j.msec.2019.109955
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA JA1HY
UT WOS:000487569300082
PM 31500064
DA 2025 08 17
ER

PT J
AU Siddiqi, A
   Payne, AGT
   Zafar, S
AF Siddiqi, Allauddin
   Payne, Alan G. T.
   Zafar, Sobia
TI Bisphosphonate induced osteonecrosis of the jaw: a medical enigma?
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND
   ENDODONTOLOGY
LA English
DT Article
ID RISK FACTORS; MULTIPLE MYELOMA; ORAL BISPHOSPHONATES; AVASCULAR
   NECROSIS; AMERICAN SOCIETY; BONE TURNOVER; PHOSSY JAW; CANCER;
   ASSOCIATION; ZOLEDRONATE
AB Bisphosphonates are used for the standard of care of patients with skeletal metastases and hypocalcemia of malignancy. Bisphosphonate induced osteonecrosis (BION) is a serious complication. Clinically, BION presents as an area of exposed alveolar bone that occurs spontaneously or becomes evident following an invasive surgical procedure such as extraction of a tooth, periodontal surgery, apicoectomy, or oral implant placement. The mechanism by which bisphosphonates cause osteonecrosis is uncertain. There are no controlled trials to show a direct cause effect relationship between bisphosphonates and osteonecrosis of the jaw.
   Oral bisphosphonate induced necrosis is a rare clinical entity, less frequent, less aggressive, more predictable, and more responsive to treatment than IV forms of bisphosphonate related osteonecrosis of the jaw. However, there have been reports of this complication with the less potent oral forms of bisphosphonates (0.007% to 0.01%). The morbidity of osteonecrosis of the jaw induced by IV bisphosphonates is significant, so prevention should receive prime importance. Patients should receive prophylactic dental examinations, and any necessary dental treatment before starting bisphosphonate therapy. Good communication among dentists, oral surgeons, physicians, and oncologists is of vital importance in providing care of these patients. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108: e1 e8)
C1 [Siddiqi, Allauddin; Payne, Alan G. T.] Univ Otago, Sch Dent, Sir John Walsh Res Inst, Oral Implantol Res Grp, Dunedin, New Zealand.
   [Zafar, Sobia] MMDC, Multan, Pakistan.
C3 University of Otago; Multan Medical & Dental College
RP Siddiqi, A (通讯作者)，Univ Otago, Sch Dent, Sir John Walsh Res Inst, Oral Implantol Res Grp, POB 647, Dunedin, New Zealand.
EM siddiqidr@gmail.com
RI ; Zafar, Sobia/AAT 4630 2021
OI SIDDIQI, ALLAUDDIN/0000 0001 5528 9153; Zafar,
   Sobia/0000 0001 5551 8147; 
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Abu Id MH, 2008, J CRANIO MAXILL SURG, V36, P95, DOI 10.1016/j.jcms.2007.06.008
   Adornato MC, 2007, J AM DENT ASSOC, V138, P971, DOI 10.14219/jada.archive.2007.0294
   *AM DENT ASS COUNC, 2006, J AM DENT ASSOC, V137, P1144
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bell BM, 2008, J ORAL MAXIL SURG, V66, P1022, DOI 10.1016/j.joms.2007.12.040
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Carter G, 2005, MED J AUSTRALIA, V182, P413, DOI 10.5694/j.1326 5377.2005.tb06761.x
   Chailurkit LO, 2001, CLIN CHEM, V47, P1083
   Chaudhry Ahmad N, 2007, Oral Maxillofac Surg Clin North Am, V19, P199, DOI 10.1016/j.coms.2007.01.005
   Ciantar M, 2007, BRIT J ORAL MAX SURG, V45, P507, DOI 10.1016/j.bjoms.2006.06.004
   Corso A, 2007, LEUKEMIA, V21, P1545, DOI 10.1038/sj.leu.2404682
   Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554
   Donoghue AM, 2005, MED J AUSTRALIA, V183, P163, DOI 10.5694/j.1326 5377.2005.tb06970.x
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Edwards BJ, 2008, J AM DENT ASSOC, V139, P1674, DOI 10.14219/jada.archive.2008.0110
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fugazzotto PA, 2007, J PERIODONTOL, V78, P1664, DOI 10.1902/jop.2007.060514
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hess LM, 2008, AM J MED, V121, P475, DOI 10.1016/j.amjmed.2008.01.047
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Hovi L, 1996, J PEDIAT HEMATOL ONC, V18, P90, DOI 10.1097/00043426 199602000 00018
   Jadu F, 2007, ANN ONCOL, V18, P2015, DOI 10.1093/annonc/mdm370
   Jeffcoat MK, 2006, INT J ORAL MAX IMPL, V21, P349
   Junquera L, 2008, J ORAL MAXIL SURG, V66, P1516, DOI 10.1016/j.joms.2008.02.012
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kos M., 2009, Biosci. Hypotheses, V2, P34, DOI [DOI 10.1016/J.BIHY.2008.08.004, 10.1016/j.bihy.2008.08.004]
   Kyrgidis A, 2008, J CLIN ONCOL, V26, P4634, DOI 10.1200/JCO.2008.16.2768
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   MARKOSE G, 2009, BRIT J ORAL MAXILLOF
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx RE, 2008, J ORAL MAXIL SURG, V66, P2356, DOI 10.1016/j.joms.2007.11.006
   Marx RobertE., 2007, Oral intravenous bisphosphonate induced osteonecrosis of the jaws. History, etiology, prevention
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   McClung MR, 2003, ENDOCRIN METAB CLIN, V32, P253, DOI 10.1016/S0889 8529(02)00079 8
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   MILES AEW, 1972, BRIT DENT J, V133, P203, DOI 10.1038/sj.bdj.4802906
   Otto S, 2009, J ORAL MAXIL SURG, V67, P589, DOI 10.1016/j.joms.2008.09.028
   Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P391, DOI 10.1016/j.joms.2003.11.003
   Polizzotto MN, 2006, BRIT J HAEMATOL, V132, P114, DOI 10.1111/j.1365 2141.2005.05833.x
   Purcell PM, 2005, MED J AUSTRALIA, V182, P417, DOI 10.5694/j.1326 5377.2005.tb06762.x
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Rizzoli R, 2008, BONE, V42, P841, DOI 10.1016/j.bone.2008.01.003
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Santini D, 2009, CRIT REV ONCOL HEMAT, V69, P83, DOI 10.1016/j.critrevonc.2008.07.008
   Sarasquete ME, 2008, BLOOD, V112, P2709, DOI 10.1182/blood 2008 04 147884
   Sawatari Yoh, 2007, Oral Maxillofac Surg Clin North Am, V19, P487, DOI 10.1016/j.coms.2007.07.003
   Sedghizadeh PP, 2008, J ORAL MAXIL SURG, V66, P767, DOI 10.1016/j.joms.2007.11.035
   Tarassoff P, 2003, J ORAL MAXIL SURG, V61, P1238, DOI 10.1016/j.joms.2003.09.001
   Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630
   Wang EP, 2007, J ORAL MAXIL SURG, V65, P1328, DOI 10.1016/j.joms.2007.03.006
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Wessel JH, 2008, J ORAL MAXIL SURG, V66, P625, DOI 10.1016/j.joms.2007.11.032
   Wutzl A, 2008, HEAD NECK J SCI SPEC, V30, P1224, DOI 10.1002/hed.20864
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
NR 67
TC 24
Z9 29
U1 1
U2 8
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1079 2104
EI 1528 395X
J9 ORAL SURG ORAL MED O
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
PD SEP
PY 2009
VL 108
IS 3
BP E1
EP E8
DI 10.1016/j.tripleo.2009.04.027
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 488PL
UT WOS:000269361900029
PM 19570696
DA 2025 08 17
ER

PT J
AU Sun, W
   Wang, YQ
   Yan, Q
   Lu, R
   Shi, B
AF Sun, Wei
   Wang, Yuan qin
   Yan, Qi
   Lu, Rui
   Shi, Bin
TI Effects of Er Zhi Wan on microarchitecture and regulation of
   Wnt/β catenin signaling pathway in alveolar bone of ovariectomized rats
SO JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY MEDICAL
   SCIENCES
LA English
DT Article
DE osteoporosis; Er Zhi Wan; alveolar bone; Wnt signaling pathway
ID CHINESE HERBAL PREPARATION; ESTROGEN DEFICIENCY; TRABECULAR BONE;
   IN VIVO; OSTEOPOROSIS; MASS; OSTEOBLASTOGENESIS; STRONTIUM; QUALITY;
   MARKERS
AB Recent studies have shown that Er Zhi Wan (EZW), a traditional Chinese medicine consisting of Herba Ecliptae (HE) and Fructus Ligustri Lucidi (FLL), had a definite antiosteoporotic effect on osteoporotic femur, but its effect on osteoporosis of alveolar bone remains unknown. In the present study, we investigated the effects of Er Zhi Wan (EZW) on the microarchitecture and the regulation of Wnt/beta catenin signaling pathway in the alveolar bone of ovariectomized rats. Thirty Sprague Dawley rats were randomly divided into three groups: sham operation group (sham, n=10), ovariectomy (OVX) group (n=10), and OVX with EZW treatment group (EZW group, n=10). From one week after ovariectomy, EZW (100 mg/mL) or vehicle (distilled water) was fed (1 mL/100 g) once per day for 12 weeks until the sacrifice of the rats. The body weights were measured weekly. After sacrifice, the sera and mandible were collected and routinely prepared for the measurement of alveolar trabecular microarchitecture, serum levels of E2, bone specific alkaline phosphatase (BALP) and tartrate resistant acid phosphatase 5b (TRAP5b), as well as mandibular mRNA expression of Wnt/beta catenin signaling pathway molecules wnt3a, low density lipoprotein receptor related protein 5 (LRP5), beta catenin and dickkopf homolog 1 (DKK1). The results showed that EZW treatment significantly prevented the body weight gain, degradation of alveolar trabecular microarchitecture and alveolar bone loss in the OVX rats. Furthermore, we observed that EZW could increase the serum levels of E2 and BALP, and decrease levels of serum TRAP5b in EZW group compared with vehicle group. In addition, RT PCR results revealed that EZW upregulated the expression levels of wnt3a, LRP5 and beta catenin, and reduced the expression of DKK1 in OVX rats. Taken together, our results suggested that EZW may have potential anti osteoporotic effects on osteoporotic alveolar bone by stimulating Wnt/LRP5/beta catenin signaling pathway.
C1 [Shi, Bin] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430079, Peoples R China.
   Wuhan Univ, Sch & Hosp Stomatol, Key Lab Oral Biomed Minist Educ KLOBM, Wuhan 430079, Peoples R China.
C3 Wuhan University; Wuhan University
RP Shi, B (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430079, Peoples R China.
EM Suzanne_whu@126.com; wang2118119@foxmail.com; shibin_dentist@foxmail.com
RI Sun, Weimiao/AAU 5390 2021; Lu, Rui/KCJ 8212 2024
FU National Natural Science Foundation of China [81170992]; Fundamental
   Research Funds for the Central Universities of Wuhan University
   [201130402020004]
FX This project was supported by grants from the National Natural Science
   Foundation of China (No. 81170992) and the Fundamental Research Funds
   for the Central Universities of Wuhan University (No. 201130402020004).
CR Ames MS, 2010, ARCH ORAL BIOL, V55, P599, DOI 10.1016/j.archoralbio.2010.05.011
   Birkenfeld L, 1999, MENOPAUSE, V6, P129
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Cavani F, 2012, J BONE MINER METAB, V30, P619, DOI 10.1007/s00774 012 0366 0
   Cheng M, 2011, J ETHNOPHARMACOL, V138, P279, DOI 10.1016/j.jep.2011.09.030
   Dervis E, 2005, ORAL SURG ORAL MED O, V100, P349, DOI 10.1016/j.tripleo.2005.04.010
   Eren E, 2005, INT J CLIN PRACT, V59, P46, DOI 10.1111/j.1742 1241.2005.00358.x
   Gilles JA, 1997, J ENDODONT, V23, P419, DOI 10.1016/S0099 2399(97)80294 4
   Hildebolt CF, 1997, DENTOMAXILLOFAC RAD, V26, P3, DOI 10.1038/sj.dmfr.4600226
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Huja SS, 2007, J DENT RES, V86, P237, DOI 10.1177/154405910708600308
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Li YF, 2012, CLIN ORAL IMPLAN RES, V23, P1038, DOI 10.1111/j.1600 0501.2011.02252.x
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Mc Donnell P, 2007, ANN BIOMED ENG, V35, P170, DOI 10.1007/s10439 006 9239 9
   Payne JB, 1999, OSTEOPOROSIS INT, V10, P34, DOI 10.1007/s001980050191
   Peng SL, 2010, J ORTHOP RES, V28, P1208, DOI 10.1002/jor.21127
   Prelevic G M, 2005, Minerva Endocrinol, V30, P27
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Stevenson JC, 2005, MATURITAS, V51, P113, DOI 10.1016/j.maturitas.2005.01.012
   Sugimoto M, 2013, BONE, V52, P181, DOI 10.1016/j.bone.2012.09.031
   Tanaka M, 2002, J PERIODONTAL RES, V37, P161, DOI 10.1034/j.1600 0765.2002.01601.x
   Tanaka M, 2003, ORAL SURG ORAL MED O, V95, P495, DOI 10.1067/moe.2003.135
   Xu H, 2012, J ETHNOPHARMACOL, V143, P109, DOI 10.1016/j.jep.2012.06.009
   Yang J, 2003, DENTOMAXILLOFAC RAD, V32, P247, DOI 10.1259/dmfr/12560890
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
NR 28
TC 16
Z9 19
U1 0
U2 36
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672 0733
EI 1993 1352
J9 J HUAZHONG U SCI MED
JI J. Huazhong Univ. Sci. Tech. Med.
PD FEB
PY 2014
VL 34
IS 1
BP 114
EP 119
DI 10.1007/s11596 014 1241 0
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AA3CZ
UT WOS:000330971800019
PM 24496689
DA 2025 08 17
ER

PT J
AU Yang, LY
   Liu, SY
   Mu, S
   Guo, R
   Zhou, L
   Fu, Q
AF Yang, Liyu
   Liu, Shengye
   Mu, Shuai
   Guo, Ran
   Zhou, Long
   Fu, Qin
TI Paeoniflorin Attenuates Dexamethasone Induced Apoptosis of Osteoblast
   Cells and Promotes Bone Formation via Regulating AKT/mTOR/Autophagy
   Signaling Pathway
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID AUTOPHAGY; INHIBITION; GLUCOCORTICOIDS; MODEL
AB Paeoniflorin, a natural product derived from Paeonia lactiflora, possesses diverse pharmacological activities such as anti inflammatory, antitumor, and antidiabetic effects. It has been reported for promoting osteoblastogenesis and inhibiting osteoclastogenesis. This study investigates the therapeutic effects of paeoniflorin in glucocorticoid induced osteoporosis (GIOP) in vitro and in vivo. MC3T3 E1 cells were incubated with dexamethasone (DEX; 200 mu M) and/or paeoniflorin (10 mu M), followed by the investigation of cell proliferation, differentiation, mineralization, apoptosis, and autophagy. The AKT activator SC79 was used for evaluating the involvement of the AKT/mTOR signaling pathway. After DEX pretreatments, paeoniflorin promoted osteoblast differentiation and mineralization characterized by increase in Runx2, ALP, beclin 1, and LC3 II/LC3 I ratio levels and a decrease in apoptosis. The autophagy promoting effects of paeoniflorin were reversed by SC79. C57BL/6 mice were given DEX (1 mg/kg) once daily and paeoniflorin (15 mg/kg) 48 hours for a total of 8 weeks followed by the investigation of histological changes, the trabecular bone microarchitecture, and the levels of bone turnover markers. The results showed that paeoniflorin increased alkaline phosphatase (ALP) activity and upregulated the expression of osteocalcin and beclin 1 but reduced the levels of Bax and C terminal telopeptide of type I collagen (CTX 1). Thus, paeoniflorin may alleviate DEX induced osteoporosis by promoting osteogenic differentiation and autophagy via inhibition of the AKT/mTOR signaling pathway.
C1 [Yang, Liyu; Liu, Shengye; Mu, Shuai; Guo, Ran; Zhou, Long; Fu, Qin] China Med Univ, Dept Orthoped, Shengjing Hosp, Shenyang 110003, Liaoning, Peoples R China.
C3 China Medical University
RP Fu, Q (通讯作者)，China Med Univ, Dept Orthoped, Shengjing Hosp, Shenyang 110003, Liaoning, Peoples R China.
EM fuqincmu@126.com
RI 杨, 立宇/GZM 5725 2022; Liu, Shengye/HKE 2627 2023
OI Yang, liyu/0000 0003 0497 1819
FU Guiding Plan of Scientific Research Foundation of Liaoning Province
   [2019 ZD 0761]; Scientific Research Project of Liaoning Provincial
   Department of Education [JC2019016]; 60 Talent Team Construction of
   Shengjing Hospital of China Medical University [M0452]
FX This study was supported by grants from the Guiding Plan of Scientific
   Research Foundation of Liaoning Province (No. 2019 ZD 0761), Scientific
   Research Project of Liaoning Provincial Department of Education
   (JC2019016), and 60 Talent Team Construction of Shengjing Hospital of
   China Medical University (M0452).
CR Bin Break MK, 2018, FITOTERAPIA, V125, P161, DOI 10.1016/j.fitote.2018.01.006
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Chen J, 2017, BIOMED PHARMACOTHER, V89, P1362, DOI 10.1016/j.biopha.2017.03.016
   Fan SL, 2018, LIFE SCI, V207, P205, DOI 10.1016/j.lfs.2018.06.006
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Gu XL, 2016, ONCOTARGET, V7, P65218, DOI 10.18632/oncotarget.11573
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Hwang PW, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44575 8
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Lin H, 2014, DRUG DES DEV THER, V8, P973, DOI 10.2147/DDDT.S65410
   Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312
   Ma YS, 2018, MOL MED REP, V17, P1633, DOI 10.3892/mmr.2017.8065
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Shen GY, 2018, CELL MOL LIFE SCI, V75, P2683, DOI 10.1007/s00018 018 2776 1
   Shi Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109566
   Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910 831
   Wang JY, 2017, SCI REP UK, V7, DOI 10.1038/srep44391
   Wang TT, 2020, APOPTOSIS, V25, P157, DOI 10.1007/s10495 020 01599 0
   Wang Y., 2018, ONCOTARGET, V9, p7372 7388, DOI DOI 10.18632/ONCOTARGET.23677
   Wang YM, 2018, BIOCHEM BIOPH RES CO, V498, P981, DOI 10.1016/j.bbrc.2018.03.093
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wen J, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104308
   Yang JL, 2018, BIOMED PHARMACOTHER, V103, P699, DOI 10.1016/j.biopha.2018.04.072
   Yang L, 2016, J MOL ENDOCRINOL, V56, P291, DOI 10.1530/JME 15 0267
   Zhang SK, 2018, MOL MED REP, V17, P4307, DOI 10.3892/mmr.2018.8461
   Zhou JY, 2017, MOL MED REP, V15, P3179, DOI 10.3892/mmr.2017.6371
   Zuo C, 2012, OSTEOPOROSIS INT, V23, P1653, DOI 10.1007/s00198 012 1909 x
NR 30
TC 25
Z9 32
U1 1
U2 15
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD APR 7
PY 2021
VL 2021
AR 6623464
DI 10.1155/2021/6623464
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA RP2ZY
UT WOS:000641603300004
PM 33880124
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mattazio, RR
   Noritomi, PY
   Silveira, ZC
AF Mattazio, Rafael R.
   Noritomi, Pedro Y.
   Silveira, Zilda C.
TI An In Silico Model for the Prediction of Changes in Mineral Density in
   Cortical Bone Remodeling
SO JOURNAL OF BIOMECHANICAL ENGINEERING TRANSACTIONS OF THE ASME
LA English
DT Article
ID OSTEOPOROTIC FRACTURES; PHYSICAL ACTIVITY; SERUM LEVELS;
   OSTEOPROTEGERIN; WOMEN; DIAGNOSIS; LIGAND; MEN; PATHOGENESIS; PREVENTION
AB An in silico model for the estimation of volumetric bone mineral density (vBMD) changes at a cortical bone site subjected to mechanobiological bone remodeling is proposed in this manuscript. Mechanisms of cell differentiation, receptor ligand binding, mechanical signaling, and resorption or deposition of bone matrix were considered, therefore providing a comprehensive description of mechanobiological bone remodeling in the bone microenvironment and enabling the analysis of temporal evolution of disease or therapy scenarios. The proposed model is composed by five modules, namely, bone cells populations, mechanobiology, volume fractions and porosity, mineral density, and structural stiffness. The model is an extension of other models found in the literature because equations for the obtaining of cortical vBMD and the binding of parathyroid hormone (PTH) to parathyroid hormone 1 receptor are included. The proposed model showed a satisfactory agreement with the solutions of other in silico models found in the literature. Simulations of walking and running exercise routines were performed for the evaluation of model capability regarding the control of the numerical error and prediction of vBMD. The computational method used to solve the case study controlled the relative numerical error by less than 1 x 10( 7) for approximately 1.7 x 10(6) time steps. The predicted values correlate with the concept of increasing BMD by vigorous physical activity; however, they contrast with the specific effect of physical activities on cortical vBMD.
C1 [Mattazio, Rafael R.; Silveira, Zilda C.] Univ Sao Paulo, Sao Carlos Sch Engn, 400 Trabalhador Sao Carlense Ave, BR 13566590 Sao Carlos, SP, Brazil.
   [Noritomi, Pedro Y.] Informat Technol Ctr Renato Archer, Three Dimens Technol, 143 6Km Dom Pedro I Highway SP 65, BR 13069901 Campinas, SP, Brazil.
C3 Universidade de Sao Paulo
RP Silveira, ZC (通讯作者)，Univ Sao Paulo, Sao Carlos Sch Engn, 400 Trabalhador Sao Carlense Ave, BR 13566590 Sao Carlos, SP, Brazil.
EM rahcor@protonmail.com; pedro.noritomi@cti.gov.br; silveira@sc.usp.br
RI Silveira, Zilda/T 3910 2019; Silveira, Zilda de Castro/T 3910 2019;
   Noritomi, Pedro/AAY 9174 2021
OI Silveira, Zilda de Castro/0000 0002 5040 0403; Noritomi,
   Pedro/0000 0001 7333 3445; 
CR [Anonymous], 2016, VALUE HEALTH, V19, P699
   [Anonymous], 2001, FOREIGN MED SCI SECT, V28, P29
   [Anonymous], J MIDWIFERY RES PRAC
   [Anonymous], 2008, SOLVING ORDINARY DIF
   [Anonymous], 2006, THISDAY NEWSPAP 1114, V11, P35
   [Anonymous], 2013, BMC PREGNANCY CHILDB, V13, P195
   Ashe MC, 2013, OSTEOPOROSIS INT, V24, P623, DOI 10.1007/s00198 012 2000 3
   ASHMAN RB, 1984, J BIOMECH, V17, P349, DOI 10.1016/0021 9290(84)90029 0
   Bousson V, 2000, RADIOLOGY, V217, P179, DOI 10.1148/radiology.217.1.r00se11179
   Burr DB, 1996, BONE, V18, P405, DOI 10.1016/8756 3282(96)00028 2
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   CARTER DR, 1987, J BIOMECH, V20, P785, DOI 10.1016/0021 9290(87)90058 3
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   CRISTY M, 1981, PHYS MED BIOL, V26, P389, DOI 10.1088/0031 9155/26/3/003
   DALSTRA M, 1995, J BIOMECH ENG T ASME, V117, P272, DOI 10.1115/1.2794181
   Dovio A, 2008, OSTEOPOROSIS INT, V19, P113, DOI 10.1007/s00198 007 0423 z
   Dowling NE., 2007, MECH BEHAV MAT ENG M, VThird
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Eriksen EF, 1999, J BONE MINER RES, V14, P1217, DOI 10.1359/jbmr.1999.14.7.1217
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Feldman S, 2012, MED SCI SPORT EXER, V44, P1580, DOI 10.1249/MSS.0b013e31824e10b6
   Franco N. M. B., 2007, Calculo Numerico, V1
   Grainger DJ, 1999, OSTEOPOROSIS INT, V9, P398, DOI 10.1007/s001980050163
   Granke M, 2011, BONE, V49, P1020, DOI 10.1016/j.bone.2011.08.002
   Guadalupe Grau A, 2009, SPORTS MED, V39, P439, DOI 10.2165/00007256 200939060 00002
   Guyton A. C., 2006, Textbook of medical physiology
   Hill AV, 1921, BIOCHEM J, V15, P577, DOI 10.1042/bj0150577
   Hou YC1, 2009, AM J PHYSIOL LUNG C, V296, pL288
   Huiskes R, 2000, J ANAT, V197, P145, DOI 10.1046/j.1469 7580.2000.19720145.x
   JAWORSKI ZFG, 1981, J ANAT, V133, P397
   KAHAN W, 1965, COMMUN ACM, V8, P40, DOI 10.1145/363707.363723
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Kanis JA, 2015, J BONE MINER RES, V30, P1747, DOI 10.1002/jbmr.2531
   Keaveny T.M., 2001, BONE MECH HDB
   Kurbel S, 2003, MED HYPOTHESES, V61, P346, DOI 10.1016/S0306 9877(03)00107 5
   L AR K DB L P C C., 1997, AM J MED, V103, p51S
   LaCroix AZ, 2013, BONE, V56, P474, DOI 10.1016/j.bone.2013.05.018
   LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lerner UH, 2004, CRIT REV ORAL BIOL M, V15, P64, DOI 10.1177/154411130401500202
   Lorentzon M, 2005, J BONE MINER RES, V20, P1936, DOI 10.1359/JBMR.050709
   Ma HQ, 2009, J BONE MINER RES, V24, P1427, DOI [10.1359/JBMR.090309, 10.1359/jbmr.090309]
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Martin RB., 1998, Skeletal tissue mechanics
   Mattazio R. R., 2016, THESIS
   Mazziotti G, 2005, J BONE MINER RES, V20, P480, DOI 10.1359/JBMR.041126
   Mercuri E. G. F., 2013, THESIS
   Milgrom C, 2000, J BONE JOINT SURG BR, V82B, P591, DOI 10.1302/0301 620X.82B4.9677
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Pescatello L. S., 2014, ACSMS GUIDELINES EXE
   Pinheiro MM, 2009, OSTEOPOROSIS INT, V20, P399, DOI 10.1007/s00198 008 0680 5
   Pinheiro MD, 2010, ARQ BRAS ENDOCRINOL, V54, P164, DOI 10.1590/S0004 27302010000200012
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Point Carbon, 2011, POINT CARBON, V6, P1
   Prendergast PJ, 1997, CLIN BIOMECH, V12, P343, DOI 10.1016/S0268 0033(97)00018 1
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Roesler C. R. M., 2004, 4 WORKSH INF APL SAU, P536
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Schmitt CP, 1998, J AM SOC NEPHROL, V9, P1832
   Schneeweis LA, 2005, J BIOL CHEM, V280, P41155, DOI 10.1074/jbc.M506366200
   Schulte FA, 2011, BONE, V49, P1166, DOI 10.1016/j.bone.2011.08.018
   Schurman L, 2013, MEDICINA BUENOS AIRE, V73, P55
   Seeman E, 2009, CRIT REV EUKAR GENE, V19, P219, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.40
   Servier Medical Art, 2015, END PPT
   Srinivasan A., 2011, Morbidity and Mortality Weekly Report, V60, P243, DOI 10.1016/j.annemergmed.2011.07.035
   Szulc P, 2001, J CLIN ENDOCR METAB, V86, P3162, DOI 10.1210/jc.86.7.3162
   TITUS L, 1991, J BONE MINER RES, V6, P631
   Todd JA, 2003, POSTGRAD MED J, V79, P320, DOI 10.1136/pmj.79.932.320
   Viceconti M, 2005, CLIN BIOMECH, V20, P451, DOI 10.1016/j.clinbiomech.2005.01.010
   Wachter NJ, 2002, BONE, V31, P90, DOI 10.1016/S8756 3282(02)00779 2
   WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932
   Wang XD, 2003, J ORTHOP RES, V21, P312, DOI 10.1016/S0736 0266(02)00157 2
   Wilks DC, 2009, BONE, V45, P91, DOI 10.1016/j.bone.2009.03.660
   Zhang SQ, 2009, ARCH BIOCHEM BIOPHYS, V487, P49, DOI 10.1016/j.abb.2009.04.008
NR 76
TC 3
Z9 3
U1 2
U2 10
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016 5990 USA
SN 0148 0731
EI 1528 8951
J9 J BIOMECH ENG T ASME
JI J. Biomech. Eng. Trans. ASME
PD JAN 1
PY 2020
VL 142
IS 1
AR 011008
DI 10.1115/1.4044094
PG 12
WC Biophysics; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Engineering
GA KZ0IR
UT WOS:000522956400012
PM 31233121
DA 2025 08 17
ER

PT J
AU D'Amelio, P
AF D'Amelio, Patrizia
TI The immune system and postmenopausal osteoporosis
SO IMMUNOLOGICAL INVESTIGATIONS
LA English
DT Article
DE B cells; cytokines; immune system; menopause; osteoclast; osteoporosis;
   T cells
ID KAPPA B LIGAND; TUMOR NECROSIS FACTOR; INDUCED BONE LOSS; LOSS IN VIVO;
   HORMONE REPLACEMENT THERAPY; MEMBRANE ESTROGEN RECEPTORS; CLASS II
   TRANSACTIVATOR; T CELL ACTIVATION; OSTEOCLAST FORMATION; TNF ALPHA
AB In the last decay investigators have paid attention to the relation between immune system, estrogen deficiency and bone loss; some of the pathways have been clarified whereas others remain an unexplained challenge. This review summarizes the evidence that links immune cells, estrogen loss, and osteoclast formation and activity.
C1 Univ Turin, Dept Med Sci, Gerontol Sect, I 10126 Turin, Italy.
C3 University of Turin
RP D'Amelio, P (通讯作者)，Univ Turin, Dept Med Sci, Gerontol Sect, Corso Bramante 88 90, I 10126 Turin, Italy.
EM patrizia.damelio@unito.it
RI ; D'AMELIO, PATRIZIA/K 3042 2016
OI D'AMELIO, PATRIZIA/0000 0002 4467 8337; 
CR Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018
   Adamopoulos IE, 2011, J IMMUNOL, V187, P951, DOI 10.4049/jimmunol.1003986
   Adamski J, 2004, MOL ENDOCRINOL, V18, P1963, DOI 10.1210/me.2004 0098
   Amelio PD, 2008, J BONE MINER RES, V23, P373, DOI 10.1359/JBMR.071031
   Anginot A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000585
   Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001
   Bedi B, 2010, ANN NY ACAD SCI, V1192, P215, DOI 10.1111/j.1749 6632.2009.05216.x
   Binder NB, 2013, ARTHRITIS RHEUM US, V65, P608, DOI 10.1002/art.37797
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Charatcharoenwitthaya N, 2007, J BONE MINER RES, V22, P724, DOI 10.1359/JBMR.070207
   Chen L, 2008, EUR J IMMUNOL, V38, P2845, DOI 10.1002/eji.200838192
   Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood 2004 02 0474
   D'Amelio P, 2011, OSTEOPOROSIS INT, V22, P2869, DOI 10.1007/s00198 010 1496 7
   D'Amelio P, 2010, OSTEOPOROSIS INT, V21, P1741, DOI 10.1007/s00198 009 1129 1
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   D'Amelio P, 2010, CALCIFIED TISSUE INT, V86, P463, DOI 10.1007/s00223 010 9362 3
   D'Amico L, 2013, ONCOL REP, V29, P1453, DOI 10.3892/or.2013.2280
   d'Elia HF, 2008, SCAND J IMMUNOL, V68, P661, DOI 10.1111/j.1365 3083.2008.02186.x
   Das Roy L, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2345
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Grcevic D, 2006, CLIN EXP IMMUNOL, V146, P146, DOI 10.1111/j.1365 2249.2006.03181.x
   Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600 065X.1996.tb00921.x
   Han X, 2009, ORAL MICROBIOL IMMUN, V24, P190, DOI 10.1111/j.1399 302X.2008.00494.x
   Han XZ, 2013, INFECT IMMUN, V81, P1502, DOI 10.1128/IAI.00043 13
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hu Y, 2013, INT ENDOD J, V46, P896, DOI 10.1111/iej.12077
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   Kawano Y, 2012, ONCOL REP, V27, P39, DOI 10.3892/or.2011.1491
   Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043 2760(01)00377 0
   Kim JH, 2010, CELL SIGNAL, V22, P1341, DOI 10.1016/j.cellsig.2010.05.001
   KOMSCHLIES KL, 1994, IMMUNOL SER, V61, P95
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kumru S, 2004, J REPROD IMMUNOL, V63, P31, DOI 10.1016/j.jri.2004.02.001
   Lee SK, 2006, J BONE MINER RES, V21, P1704, DOI 10.1359/JBMR.060726
   Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039 128X(01)00179 9
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Li Y, 2007, J CELL BIOCHEM, V100, P1370, DOI 10.1002/jcb.21121
   Lubberts E, 2005, ARTHRITIS RES THER, V7, P29, DOI 10.1186/ar1478
   Mackall CL, 2001, BLOOD, V97, P1491, DOI 10.1182/blood.V97.5.1491
   Mueller RB, 2005, ARTHRITIS RHEUM US, V52, P451, DOI 10.1002/art.20863
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Oostlander AE, 2012, J CELL BIOCHEM, V113, P260, DOI 10.1002/jcb.23352
   Porter VR, 2001, EXP GERONTOL, V36, P311, DOI 10.1016/S0531 5565(00)00195 9
   Quinn JMW, 2008, J IMMUNOL, V181, P5720, DOI 10.4049/jimmunol.181.8.5720
   Rifas L, 2009, ARTHRITIS RHEUM US, V60, P3324, DOI 10.1002/art.24877
   Roato I, 2004, FASEB J, V18, P228, DOI 10.1096/fj.04 1823fje
   Roato I, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000124
   Roato I, 2007, ANN NY ACAD SCI, V1117, P377, DOI 10.1196/annals.1402.002
   Roato I, 2010, BIOMATERIALS, V31, P7519, DOI 10.1016/j.biomaterials.2010.06.027
   Roato I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003627
   Rogers A, 2001, BONE, V29, P30, DOI 10.1016/S8756 3282(01)00468 9
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Ryan MR, 2005, P NATL ACAD SCI USA, V102, P16735, DOI 10.1073/pnas.0505168102
   Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083 6729(01)62006 5
   Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003 0023
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takahata M, 2012, ARTHRITIS RHEUM US, V64, P3649, DOI 10.1002/art.34639
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
   Wheater G, 2011, OSTEOPOROSIS INT, V22, P3067, DOI 10.1007/s00198 011 1607 0
   Wyzga N, 2004, BONE, V35, P614, DOI 10.1016/j.bone.2004.04.022
   Xue Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046740
   Yago T, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2297
   Yeo L, 2011, ANN RHEUM DIS, V70, P2022, DOI 10.1136/ard.2011.153312
   Yokoyama M, 2011, J PERIODONTAL RES, V46, P464, DOI 10.1111/j.1600 0765.2011.01362.x
   YOO ZB, 1995, J IMMUNOL, V155, P5483
   Yun TJ, 1998, J IMMUNOL, V161, P6113
   Zheng SX, 1997, MATURITAS, V26, P63, DOI 10.1016/S0378 5122(96)01080 8
NR 81
TC 22
Z9 22
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882 0139
EI 1532 4311
J9 IMMUNOL INVEST
JI Immunol. Invest.
PY 2013
VL 42
IS 7
BP 544
EP 554
DI 10.3109/08820139.2013.822764
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 216FV
UT WOS:000324268300005
PM 24004058
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Kong, LB
   Zhao, QP
   Wang, XD
   Zhu, JY
   Hao, DJ
   Yang, CF
AF Kong, Lingbo
   Zhao, Qinpeng
   Wang, Xiaodong
   Zhu, Jinyu
   Hao, Dingjun
   Yang, Chongfei
TI Angelica sinensis extract inhibits RANKL mediated osteoclastogenesis by
   down regulated the expression of NFATc1 in mouse bone marrow cells
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Angelica sinensis; Osteoclastogenesis; NFATc1; BMMs
ID ACTIVATED PROTEIN KINASE; NF KAPPA B; NUCLEAR FACTOR; C FOS; RECEPTOR
   ACTIVATOR; SIGNALING PATHWAYS; GENE EXPRESSION; AQUEOUS EXTRACT;
   RAW264.7 CELLS; DIFFERENTIATION
AB Background: Destructive erosion of bone or osteolysis is a major complication of inflammatory conditions such as rheumatoid arthritis (RA), periodontal disease, and periprosthetic osteolysis. Natural plant derived products have received recent attention as potential therapeutic and preventative drugs in human disease.
   Methods: The effect of Angelica sinensis (AS) extract on RANKL induced osteoclast differentiation was examined in this study. The osteoclast precursor cell line bone marrow macrophages (BMMs) was cultured and stimulated with RANKL followed by treatment with AS at several doses. Gene expression profiles of c Fos, c Jun, NFATc1, TRAP, and OSCAR were sequentially evaluated.
   Results: AS extract inhibited RANKL mediated osteoclast differentiation in BMMs in a dose dependent manner without any evidence of cytotoxicity. AS extract strongly inhibited p38, ERK, JNK, p65 phosphorylation and I kappa B degradation in RANKL stimulated BMMs. AS extract also inhibited the mRNA expression of c Fos, c Jun, NFATc1, TRAP, and OSCAR in RANKL treated BMMs. Moreover, RANKL induced c Fos, c Jun and NFATc1 protein expression was suppressed by AS extract.
   Conclusions: These results collectively suggested that AS extract demonstrated inhibitory effects on RANKL mediated osteoclast differentiation in bone marrow macrophages in vitro, indicating that AS may therefore serve as a useful drug in the prevention of bone loss.
C1 [Kong, Lingbo; Zhao, Qinpeng; Wang, Xiaodong; Hao, Dingjun] Xi An Jiao Tong Univ, Hong Hui Hosp, Coll Med, Xian 710054, Peoples R China.
   [Zhu, Jinyu; Yang, Chongfei] Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710054, Peoples R China.
C3 Xi'an Jiaotong University; Air Force Medical University
RP Hao, DJ (通讯作者)，Xi An Jiao Tong Univ, Hong Hui Hosp, Coll Med, Xian 710054, Peoples R China.
EM jinyuzhu@outlook.com; dhao.honghui@outlook.com
RI kong, lingbo/O 7491 2017
CR Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim YJ, 2005, J BIOL CHEM, V280, P21515, DOI 10.1074/jbc.M502230200
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Mohamed SGK, 2007, BONE, V41, P592, DOI 10.1016/j.bone.2007.05.016
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Su YW, 2011, INT IMMUNOPHARMACOL, V11, P1166, DOI 10.1016/j.intimp.2011.03.014
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang HC, 2006, J NUTR, V136, P360, DOI 10.1093/jn/136.2.360
   Yang CF, 2012, J SURG RES, V176, P476, DOI 10.1016/j.jss.2011.08.011
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 28
TC 26
Z9 28
U1 0
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD DEC 12
PY 2014
VL 14
AR 481
DI 10.1186/1472 6882 14 481
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA AX4AQ
UT WOS:000346877000002
PM 25496242
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, HY
   Zou, JL
   Luo, Y
   Chen, XP
   Zou, W
AF Wang, Hanyun
   Zou, Jiliang
   Luo, Ying
   Chen, Xinping
   Zou, Wei
TI HIV 1 infection and the hematopoietic microenvironment
SO AIDS REVIEWS
LA English
DT Article
DE HIV 1; Hematopoietic microenvironment; Hematopoietic stem cells; Bone
   marrow mesenchymal cells; HIV viral
ID MESENCHYMAL STROMAL CELLS; STEM CELLS; PROGENITOR CELLS; OSTEOBLAST
   FUNCTION; ENDOTHELIAL CELLS; GROWTH FACTOR; TAT PROTEIN; IN VITRO; BONE;
   SENESCENCE
AB HIV 1 infection causes abnormal hematopoiesis, which is the result of the interactions among HIV 1, hematopoietic stem cells (HSCs), and hematopoietic microenvironment. However, the underlying mechanisms of abnormal hematopoiesis in HIV infection are still not completely understood. Recent studies on hematopoietic microenvironment provide new insights on HIV 1 pathogenesis. Based on these studies, we summarized the detrimental influences of HIV, mainly HIV viral proteins Gag, Tat, Gp120, and Nef, on hematopoietic microenvironment. These viral proteins interfere with the development of HSCs and hematopoiesis by affecting mesenchymal stem cells, osteoblasts, endothelial cells, and related signaling factors within the microenvironment. At the same time, we introduced the research progress of targeted therapy for HIV viral proteins and tried to solve the hard to correct hematopoietic abnormalities after ART by combining targeted therapy with HIV viral proteins from the direction of hematopoietic microenvironment. Our manuscript will not only enhance our understanding of the pathogenesis of HIV infection from the root of blood cell development but also have important implications for the functional cure of HIV infection.
C1 [Wang, Hanyun; Zou, Jiliang] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Nanchang, Jiangxi, Peoples R China.
   [Luo, Ying; Zou, Wei] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Infect Dis, Nanchang, Jiangxi, Peoples R China.
   [Luo, Ying] Third Peoples Hosp Jiujiang, Dept Infect Dis, Jiujiang, Peoples R China.
   [Chen, Xinping] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Obstet & Gynecol, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University
RP Zou, W (通讯作者)，Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Infect Dis, Nanchang, Jiangxi, Peoples R China.; Chen, XP (通讯作者)，Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Obstet & Gynecol, Nanchang, Jiangxi, Peoples R China.
EM chenxpdr@163.com; ieeeif@hotmail.com
FU National Natural Science Foundation of China [82360391]; Jiangxi
   Department of Science and Technology [20202BAB206023]
FX This work was supported by the National Natural Science Foundation of
   China (grant No.: 82360391) , Jiangxi Department of Science and
   Technology (grant No.: 20202BAB206023) to Wei Zou.
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ambinder RF, 2019, BIOL BLOOD MARROW TR, V25, P2160, DOI 10.1016/j.bbmt.2019.06.033
   Aqil M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/492395
   Beaupere C, 2015, AGING CELL, V14, P534, DOI 10.1111/acel.12308
   Bonci D, 2004, BLOOD, V104, P3169, DOI 10.1182/blood 2003 11 3861
   Brothers TD, 2014, CURR OPIN HIV AIDS, V9, P412, DOI 10.1097/COH.0000000000000070
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Cafaro A, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25031704
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Chew N, 2014, J INT AIDS SOC, V17, P145, DOI 10.7448/IAS.17.4.19724
   Cotter EJ, 2007, AIDS RES HUM RETROV, V23, P1521, DOI 10.1089/aid.2007.0112
   Cotter EJ, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 33
   Davinelli S, 2014, BIOGERONTOLOGY, V15, P449, DOI 10.1007/s10522 014 9511 6
   de Jong W, 2019, VACCINES BASEL, V7, DOI 10.3390/vaccines7040209
   Deeks SG, 2002, MOL THER, V5, P788, DOI 10.1006/mthe.2002.0611
   Dinkins C, 2010, SEMIN CELL DEV BIOL, V21, P712, DOI 10.1016/j.semcdb.2010.04.004
   Dolan SE, 2006, J CLIN ENDOCR METAB, V91, P2938, DOI 10.1210/jc.2006 0127
   Dominkus PP, 2017, J NEUROVIROL, V23, P713, DOI 10.1007/s13365 017 0552 x
   Fakruddin JM, 2003, J BIOL CHEM, V278, P48251, DOI 10.1074/jbc.M304676200
   Fanales Belasio E, 2009, J IMMUNOL, V182, P2888, DOI 10.4049/jimmunol.0711406
   Fehrer C, 2005, EXP GERONTOL, V40, P926, DOI 10.1016/j.exger.2005.07.006
   Fei CM, 2014, EUR J HAEMATOL, V93, P476, DOI 10.1111/ejh.12385
   Gibellini D, 2005, NEW MICROBIOL, V28, P95
   Gibellini D, 2012, J CELL BIOCHEM, V113, P1132, DOI 10.1002/jcb.23446
   Gibellini D, 2010, BIOCHEM BIOPH RES CO, V401, P429, DOI 10.1016/j.bbrc.2010.09.071
   Gibellini D, 2007, J CELL PHYSIOL, V210, P315, DOI 10.1002/jcp.20815
   Johnson TP, 2013, P NATL ACAD SCI USA, V110, P13588, DOI 10.1073/pnas.1308673110
   Kast RE, 2002, NEUROIMMUNOMODULAT, V10, P85, DOI 10.1159/000065184
   Killian MS, 2012, AIDS RES THER, V9, DOI 10.1186/1742 6405 9 16
   Kuo LS, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742 4690 9 47
   Kyei GB, 2009, J CELL BIOL, V186, P255, DOI 10.1083/jcb.200903070
   Li YL, 2007, MED HYPOTHESES, V68, P169, DOI 10.1016/j.mehy.2006.06.006
   Ludwig A, 2014, CYTOTHERAPY, V16, P111, DOI 10.1016/j.jcyt.2013.07.007
   Manninen A, 1998, VIROLOGY, V250, P273, DOI 10.1006/viro.1998.9381
   McNamara RP, 2018, MBIO, V9, DOI 10.1128/mBio.02344 17
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Morini S, 2016, NEW MICROBIOL, V39, P13
   Muvarak N, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.1044713
   Nagasawa T, 2007, ADV EXP MED BIOL, V602, P69
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Park IW, 2001, BLOOD, V97, P352, DOI 10.1182/blood.V97.2.352
   Pelagiadis I, 2015, CELL BIOL INT, V39, P1099, DOI 10.1002/cbin.10483
   Powderly WG, 2002, J ACQ IMMUN DEF SYND, V29, pS28, DOI 10.1097/00126334 200202011 00005
   Prost S, 2008, J CLIN INVEST, V118, P1765, DOI 10.1172/JCI33037
   Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170
   Ruscetti FW, 2005, ONCOGENE, V24, P5751, DOI 10.1038/sj.onc.1208921
   Saribas AS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.467
   Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160
   Stone B, 2010, ARCH BIOCHEM BIOPHYS, V503, P66, DOI 10.1016/j.abb.2010.07.029
   Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518
   Ullrich CK, 2000, BLOOD, V96, P1438, DOI 10.1182/blood.V96.4.1438.h8001438_1438_1442
   Vanpouille C, 2024, J EXTRACELL VESICLES, V13, DOI 10.1002/jev2.12478
   Walker RE, 2000, BLOOD, V96, P467
   Wang MWH, 2004, J CLIN INVEST, V114, P206, DOI 10.1172/JCI200415797
   Wang XL, 2022, AIDS RES HUM RETROV, V38, P753, DOI [10.1089/aid.2022.0011, 10.1089/AID.2022.0011]
   Watkins RL, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742 4690 10 125
   Wilhelm E, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742 4690 9 62
   Yamashita A, 2006, FEBS LETT, V580, P4121, DOI 10.1016/j.febslet.2006.06.057
   Yamazaki S, 2006, EMBO J, V25, P3515, DOI 10.1038/sj.emboj.7601236
   Yamazaki S, 2009, BLOOD, V113, P1250, DOI 10.1182/blood 2008 04 146480
   Yano M, 2007, AIDS, V21, P911, DOI 10.1097/QAD.0b013e32810539f3
   Yuan YH, 2017, CELL BIOL INT, V41, P969, DOI 10.1002/cbin.10791
   Yuan YH, 2019, VIRUS RES, V273, DOI 10.1016/j.virusres.2019.197756
   Zauli G, 1996, PATHOBIOLOGY, V64, P53, DOI 10.1159/000164006
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
   Zhu B, 2014, ONCOGENE, V33, P5348, DOI 10.1038/onc.2013.477
   Zou W, 2021, AIDS, V35, P851, DOI 10.1097/QAD.0000000000002837
   Zou W, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742 4690 9 44
NR 70
TC 0
Z9 0
U1 0
U2 0
PU PERMANYER PUBL
PI BARCELONA
PA MALLORCA, 310, BARCELONA, 08037, SPAIN
SN 1139 6121
EI 1698 6997
J9 AIDS REV
JI Aids Rev.
PD SEP DEC
PY 2024
VL 26
IS 4
DI 10.24875/AIDSRev.24000015
PG 38
WC Immunology; Infectious Diseases
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases
GA 1AB4Q
UT WOS:001460101800001
PM 39970474
DA 2025 08 17
ER

PT J
AU Slone, WL
   Moses, BS
   Evans, R
   Piktel, D
   Martin, KH
   Petros, W
   Craig, M
   Gibson, LF
AF Slone, William L.
   Moses, Blake S.
   Evans, Rebecca
   Piktel, Debbie
   Martin, Karen H.
   Petros, William
   Craig, Michael
   Gibson, Laura F.
TI Modeling Chemotherapy Resistant Leukemia In Vitro
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 108; Leukemia; Chemotherapy; Microenvironment;
   Resistance; Niche; Marrow
ID ACUTE LYMPHOBLASTIC LEUKEMIA; MARROW STROMAL CELLS; SURVIVAL;
   MICROENVIRONMENT; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION;
   ADHESION; RELAPSE
AB It is well established that the bone marrow microenvironment provides a unique site of sanctuary for hematopoietic diseases that both initiate and progress in this site. The model presented in the current report utilizes human primary bone marrow stromal cells and osteoblasts as two representative cell types from the marrow niche that influence tumor cell phenotype. The in vitro co culture conditions described for human leukemic cells with these primary niche components support the generation of a chemoresistant subpopulation of tumor cells that can be efficiently recovered from culture for analysis by diverse techniques. A strict feeding schedule to prevent nutrient fluxes followed by gel type 10 cross linked dextran (G10) particles recovery of the population of tumor cells that have migrated beneath the adherent bone marrow stromal cells (BMSC) or osteoblasts (OB) generating a "phase dim" (PD) population of tumor cells, provides a consistent source of purified therapy resistant leukemic cells. This clinically relevant population of tumor cells can be evaluated by standard methods to investigate apoptotic, metabolic, and cell cycle regulatory pathways as well as providing a more rigorous target in which to test novel therapeutic strategies prior to pre clinical investigations targeted at minimal residual disease.
C1 [Slone, William L.; Moses, Blake S.; Evans, Rebecca; Piktel, Debbie; Martin, Karen H.; Petros, William; Craig, Michael; Gibson, Laura F.] W Virginia Univ, Sch Med, Alexander B Osborn Hematopoiet Malignancy & Trans, Mary Babb Randolph Canc Ctr,Robert C Byrd Hlth Sc, Morgantown, WV 26506 USA.
   [Martin, Karen H.] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Neurobiol & Anat, Morgantown, WV 26506 USA.
   [Gibson, Laura F.] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.
C3 West Virginia University; West Virginia University; West Virginia
   University
RP Gibson, LF (通讯作者)，W Virginia Univ, Sch Med, Alexander B Osborn Hematopoiet Malignancy & Trans, Mary Babb Randolph Canc Ctr,Robert C Byrd Hlth Sc, Morgantown, WV 26506 USA.
EM lgibson@hsc.wvu.edu
OI Martin, Karen/0000 0001 8916 4092; Moses, Blake/0000 0001 8045 3066
FU National Institutes of Health (NHLBI) [R01 HL056888]; National Cancer
   Institute (NCI) [RO1 CA134573NIH, P20GM103434]; WV CTR IDEA NIH [1U54
   GM104942]; Alexander B. Osborn Hematopoietic Malignancy and
   Transplantation Program; WV Research Trust Fund; West Virginia
   University Flow Cytometry Core Facility; NIH [S10 OD016165];
   Institutional Development Award (IDeA) from the NIH Institute of General
   Medical Sciences of the National Institutes of Health [CoBRE
   P30GM103488, INBRE P20GM103434]
FX Supported by National Institutes of Health (NHLBI) R01 HL056888 (LFG),
   National Cancer Institute (NCI) RO1 CA134573NIH (LFG), P30 GM103488
   (LFG), WV CTR IDEA NIH 1U54 GM104942, the Alexander B. Osborn
   Hematopoietic Malignancy and Transplantation Program, and the WV
   Research Trust Fund. We are grateful for the support of Dr. Kathy
   Brundage and the West Virginia University Flow Cytometry Core Facility,
   supported by NIH S10 OD016165 and the Institutional Development Award
   (IDeA) from the NIH Institute of General Medical Sciences of the
   National Institutes of Health (CoBRE P30GM103488 and INBRE P20GM103434).
CR Ayala F, 2009, LEUKEMIA, V23, P2233, DOI 10.1038/leu.2009.175
   Berniakovich I, 2013, INT J MOL SCI, V14, P2119, DOI 10.3390/ijms14012119
   Boyerinas B, 2013, BLOOD, V121, P4821, DOI 10.1182/blood 2012 12 475483
   Bradstock K, 1996, LEUKEMIA, V10, P813
   Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006 3495(01)75733 5
   Clutter SD, 2005, EXP HEMATOL, V33, P1192, DOI 10.1016/j.exphem.2005.06.022
   Coustan Smith E, 2000, BLOOD, V96, P2691, DOI 10.1182/blood.V96.8.2691
   Gaynon PS, 1998, CANCER, V82, P1387, DOI 10.1002/(SICI)1097 0142(19980401)82:7<1387::AID CNCR24>3.0.CO;2 1
   Hathcock KS., 2001, CURR PROTOC IMMUNOL
   Holzwarth C, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 11
   Jing DH, 2012, HAEMATOL HEMATOL J, V97, P331, DOI 10.3324/haematol.2011.050815
   Jing DH, 2010, HAEMATOL HEMATOL J, V95, P542, DOI 10.3324/haematol.2009.010736
   Kikuchi M, 2010, INT J HEMATOL, V92, P481, DOI 10.1007/s12185 010 0670 1
   Krause DS, 2013, CYTOM PART B CLIN CY, V84B, P7, DOI 10.1002/cyto.b.21066
   MANABE A, 1994, BLOOD, V83, P758
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Mudry RE, 2000, BLOOD, V96, P1926, DOI 10.1182/blood.V96.5.1926.h8001926_1926_1932
   Nguyen K, 2008, LEUKEMIA, V22, P2142, DOI 10.1038/leu.2008.251
   O'Leary H, 2010, CANCER MICROENVIRON, V3, P67, DOI 10.1007/s12307 010 0035 6
   Szczepanek J, 2011, ARCH IMMUNOL THER EX, V59, P61, DOI 10.1007/s00005 010 0110 1
   Tesfai Y, 2012, LEUKEMIA RES, V36, P299, DOI 10.1016/j.leukres.2011.08.001
   Wang L, 2005, LEUKEMIA, V19, P1486, DOI 10.1038/sj.leu.2403837
   Wang L, 2005, LEUKEMIA, V19, P344, DOI 10.1038/sj.leu.2403643
NR 23
TC 11
Z9 12
U1 0
U2 3
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD FEB
PY 2016
IS 108
AR e53645
DI 10.3791/53645
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DH0WF
UT WOS:000372504100051
PM 26891147
OA Green Published
DA 2025 08 17
ER

PT J
AU Majkowska, A
   Neves, M
   Antunes, I
   Bilewicz, A
AF Majkowska, Agnieszka
   Neves, Maria
   Antunes, Ines
   Bilewicz, Aleksander
TI Complexes of low energy beta emitters <SUP>47</SUP>Sc and
   <SUP>117</SUP>Lu with zoledronic acid for bone pain therapy
SO APPLIED RADIATION AND ISOTOPES
LA English
DT Article
DE Targeted radiotherapy; Bisphosphonates; Zoledronic acid
ID BISPHOSPHONATES; SM 153; RADIOPHARMACEUTICALS
AB Targeted radiopharmaceuticals have been mostly developed to visualize and/or treat oncologic diseases. In targeted radiotherapy radionuclide selection is a key issue, because the radionuclide should provide the appropriate radiation absorbed dose, matching the desirable biologic effect, but at the same time it should preclude irradiation of surrounding healthy tissues. Among the last generation of bisphosphonates with cyclic side chains, zoledronic acid is the most potent bisphosphonate, described till now, which inhibits bone resorption. In this paper, we describe the synthesis, properties and hydroxyapatite binding of zoledronic acid labeled with two low energy beta emitters, Sc 47 and Lu 177. Radiochemicals labeled with low energy electron emitters are preferred, because they deliver both a therapeutic dose to the bone and spare the bone marrow. Hydroxyapatite adsorption experiments have shown that the binding values obtained with complexes of zoledronic acid labeled with Sc 46 and Lu 177 are much higher than those of bisphosphonates labeled with Sm 153 and Ho 166. Hence, complexes of zoledronic acid with either Sc 46 or Lu 177 seems to be a promising radiopharmaceutical for bone pain therapy. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Majkowska, Agnieszka; Bilewicz, Aleksander] Inst Nucl Chem & Technol, PL 03195 Warsaw, Poland.
   [Neves, Maria; Antunes, Ines] Inst Technol & Nucl, P 2686953 Sacavem, Portugal.
C3 Institute of Nuclear Chemistry Technology; Universidade de Lisboa
RP Majkowska, A (通讯作者)，Inst Nucl Chem & Technol, Dorodna 16, PL 03195 Warsaw, Poland.
EM a.majkowska@ichtj.waw.pl
RI ; Bilewicz, Aleksander/HZM 2066 2023
OI Antunes, Ines/0000 0002 8003 5291; Majkowska Pilip,
   Agnieszka/0000 0001 9449 6411; Bilewicz, Aleksander/0000 0003 2490 3303
FU Marie Curie Action for the Transfer of Knowledge [MTKD CT 2004 509224];
   European Commission; Ministry of Science and Higher Education of Poland
   [N204 143 32/3547]; FCT Portuguese Foundation for Science and Technology
   [POCI/QUI/55508/2004]; Fundação para a Ciência e a Tecnologia
   [POCI/QUI/55508/2004] Funding Source: FCT
FX This work was carried out in the frame of Marie Curie Action for the
   Transfer of Knowledge, Contract no. MTKD CT 2004 509224, European
   Commission, and the Ministry of Science and Higher Education of Poland
   N204 143 32/3547, and FCT Portuguese Foundation for Science and
   Technology (FEDER and POCI/QUI/55508/2004). We would like to express our
   thanks to Novartis Pharma AG for zoledronic acid supply.
CR Bouchet LG, 2000, J NUCL MED, V41, P682
   FIRESTONE RB, 1996, TABLE ISOTOPES
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Louw WKA, 1996, NUCL MED BIOL, V23, P935, DOI 10.1016/S0969 8051(96)00117 5
   Marques F, 2006, J INORG BIOCHEM, V100, P270, DOI 10.1016/j.jinorgbio.2005.11.011
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Neves M, 2002, NUCL MED BIOL, V29, P329, DOI 10.1016/S0969 8051(01)00305 5
   Ogawa K, 2006, NUCL MED BIOL, V33, P513, DOI 10.1016/j.nucmedbio.2006.03.006
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Uehara T, 2007, NUCL MED BIOL, V34, P79, DOI 10.1016/j.nucmedbio.2006.10.001
   Zeevaart JR, 2001, J INORG BIOCHEM, V83, P57, DOI 10.1016/S0162 0134(00)00125 2
NR 12
TC 31
Z9 33
U1 0
U2 12
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0969 8043
J9 APPL RADIAT ISOTOPES
JI Appl. Radiat. Isot.
PD JAN
PY 2009
VL 67
IS 1
BP 11
EP 13
DI 10.1016/j.apradiso.2008.08.014
PG 3
WC Chemistry, Inorganic & Nuclear; Nuclear Science & Technology; Radiology,
   Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
GA 386CA
UT WOS:000261858700003
PM 18929490
DA 2025 08 17
ER

PT J
AU De Toni, F
   Racaud Sultan, C
   Chicanne, G
   Mansat De Mas, V
   Cariven, C
   Mesange, F
   Salles, JP
   Demur, C
   Allouche, M
   Payrastre, B
   Manenti, S
   Ysebaert, L
AF De Toni, F.
   Racaud Sultan, C.
   Chicanne, G.
   Mansat De Mas, V.
   Cariven, C.
   Mesange, F.
   Salles, J P
   Demur, C.
   Allouche, M.
   Payrastre, B.
   Manenti, S.
   Ysebaert, L.
TI A crosstalk between the Wnt and the adhesion dependent signaling
   pathways governs the chemosensitivity of acute myeloid leukemia
SO ONCOGENE
LA English
DT Article
DE leukemia; chemoresistance; adhesion; Wnt; GSK3 beta
ID GLYCOGEN SYNTHASE KINASE 3 BETA; NF KAPPA B; FRIZZLED RELATED PROTEIN 1;
   ACUTE MYELOGENOUS LEUKEMIA; TUMOR NECROSIS FACTOR; BETA CATENIN;
   STEM CELLS; DRUG RESISTANCE; CANCER CELLS; ACTIVATION
AB Relapses following chemotherapy are a major hindrance to patients' survival in acute myeloid leukemia (AML). To investigate the role of the hematopoietic niche in the chemoresistance of leukemic cells, we examined two pathways: one mediated by adhesion molecules/integrins, and the other by soluble factors of the morphogen Wnt pathway. In our study, both the adhesion of leukemic blasts to fibronectin and the addition of Wnt antagonists induced, independently, resistance of AML cells to daunorubicin in a cell survival assay. Using pharmacological inhibitors and siRNA, we showed that both resistance pathways required the activity of the glycogen synthase kinase 3 beta (GSK3 beta). Moreover, the AML cell protection downstream of GSK3 beta was mediated by NF kappa B. A link between the adhesion and the Wnt pathway was found, as adhesion of U937 on human osteoblasts, a component of the hematopoietic niche, triggered the secretion of the Wnt antagonist sFRP 1 and supported resistance to daunorubicin. The osteoblast conditioned medium could also confer chemoresistance to U937 cells cultured in suspension, and this cell protective effect was abrogated after depletion of sFRP 1. In the context of this potential double in vivo resistance, modulators of the common signal GSK3 beta and of its target NF kappa B could represent important novel therapeutic tools.
C1 CHU Purpan, INSERM, U563,CPTP, Dept Oncogenesis & Hematopoiet Cells,Hosp Purpan, F 31024 Toulouse 3, France.
   CHU Purpan, INSERM, Hematol Lab, Unite 563, F 31024 Toulouse 3, France.
   CHU Purpan, INSERM, IFR 30, Unite 563,Dept Lipoprot & Mediateurs Lipid, F 31024 Toulouse 3, France.
   CHU Purpan, INSERM, Serv Hematol Clin, Unite 563, F 31024 Toulouse 3, France.
C3 Universite de Toulouse; Universite Toulouse III   Paul Sabatier; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU de
   Toulouse; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Toulouse; Universite Toulouse III   Paul
   Sabatier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); CHU de Toulouse; Universite de Toulouse; Universite Toulouse
   III   Paul Sabatier
RP Racaud Sultan, C (通讯作者)，CHU Purpan, INSERM, U563,CPTP, Dept Oncogenesis & Hematopoiet Cells,Hosp Purpan, Pl Baylac, F 31024 Toulouse 3, France.
EM claire.racaud@toulouse.inserm.fr
RI Payrastre, Bernard/M 5295 2014; Chicanne, Gaëtan/M 5260 2014; De Mas,
   Véronique/P 2414 2014; Ysebaert, Loic/H 1554 2016; manenti,
   stephane/P 1518 2014; SALLES, Jean/K 2998 2014; Allouche,
   Michele/P 4865 2019
OI Chicanne, Gaetan/0000 0002 7081 2595; Racaud Sultan,
   Claire/0000 0002 6549 1088; , Bernard/0000 0002 8693 0190; manenti,
   stephane/0000 0002 4793 3196; 
CR Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136
   Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097 4547(20000701)61:1<21::AID JNR3>3.3.CO;2 Z
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982
   Czyz J, 2001, DIFFERENTIATION, V68, P167, DOI 10.1046/j.1432 0436.2001.680404.x
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200
   Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169
   Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729
   Ghosh JC, 2005, CLIN CANCER RES, V11, P4580, DOI 10.1158/1078 0432.CCR 04 2624
   Gradl D, 1999, MOL CELL BIOL, V19, P5576
   Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301
   Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599
   Han XZ, 2004, J BIOL CHEM, V279, P2832, DOI 10.1074/jbc.M308102200
   Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008 5472.CAN 03 1952
   Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574
   Hwang SG, 2002, LEUKEMIA RES, V26, P863, DOI 10.1016/S0145 2126(02)00018 8
   Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352 1359.2002
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491
   Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315
   Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200
   Liao XB, 2003, MOL CANCER THER, V2, P1215
   Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909
   Müller Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890 2904.2004
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008 5472.CAN 04 3642
   Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood 2003 08 2807
   Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008 5472.CAN 03 3005
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783
   Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083
   Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431
   Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yoganathan N, 2002, PHARMACOL THERAPEUT, V93, P233, DOI 10.1016/S0163 7258(02)00192 4
NR 39
TC 110
Z9 125
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD MAY 25
PY 2006
VL 25
IS 22
BP 3113
EP 3122
DI 10.1038/sj.onc.1209346
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 048MK
UT WOS:000237951000003
PM 16407823
OA Bronze
DA 2025 08 17
ER

PT J
AU Pal, S
   Mittapelly, N
   Husain, A
   Kushwaha, S
   Chattopadhyay, S
   Kumar, P
   Ramakrishna, E
   Kumar, S
   Maurya, R
   Sanyal, S
   Gayen, JR
   Mishra, PR
   Chattopadhyay, N
AF Pal, Subhashis
   Mittapelly, Naresh
   Husain, Athar
   Kushwaha, Sapana
   Chattopadhyay, Sourav
   Kumar, Padam
   Ramakrishna, Eppalapally
   Kumar, Sudhir
   Maurya, Rakesh
   Sanyal, Sabyasachi
   Gayen, Jiaur R.
   Mishra, Prabhat R.
   Chattopadhyay, Naibedya
TI A butanolic fraction from the standardized stem extract of Cassia
   occidentalis L delivered by a self emulsifying drug delivery system
   protects rats from glucocorticoid induced osteopenia and muscle atrophy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INDUCED OSTEOPOROSIS; OSTEOCYTE APOPTOSIS; BONE LOSS; OSTEOCLAST
   DIFFERENTIATION; BODY COMPOSITION; TRABECULAR BONE; RANKL; PROMOTES;
   TERIPARATIDE; ENHANCEMENT
AB We recently reported that a butanol soluble fraction from the stem of Cassia occidentalis (CSE Bu) consisting of osteogenic compounds mitigated methylprednisone (MP) induced osteopenia in rats, albeit failed to afford complete protection thus leaving a substantial scope for further improvement. To this aim, we prepared an oral formulation that was a lipid based self nano emulsifying drug delivery system (CSE BuF). The globule size of CSE BuF was in the range of 100 180nm of diluted emulsion and the zeta potential was  28 mV. CSE BuF enhanced the circulating levels of five osteogenic compounds compared to CSE Bu. CSE BuF (50mg/kg) promoted bone regeneration at the osteotomy site and completely prevented MP induced loss of bone mass and strength by concomitant osteogenic and anti resorptive mechanisms. The MP induced downregulations of miR29a (the positive regulator of the osteoblast transcription factor, Runx2) and miR17 and miR20a (the negative regulators of the osteoclastogenic cytokine RANKL) in bone was prevented by CSE BuF. In addition, CSE BuF protected rats from the MP induced sarcopenia and/or muscle atrophy by downregulating the skeletal muscle atrogenes, adverse changes in body weight and composition. CSE BuF did not impact the anti inflammatory effect of MP. Our preclinical study established CSE BuF as a prophylactic agent against MP induced osteopenia and muscle atrophy.
C1 [Pal, Subhashis; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Pal, Subhashis; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Ctr Res Anabol Skeletal Target Hlth & Illness AST, Lucknow 226031, Uttar Pradesh, India.
   [Mittapelly, Naresh; Mishra, Prabhat R.] CSIR CDRI, Div Pharmaceut, Lucknow 226031, Uttar Pradesh, India.
   [Husain, Athar; Gayen, Jiaur R.] CSIR CDRI, Div Pharmacokinet, Lucknow 226031, Uttar Pradesh, India.
   [Kushwaha, Sapana; Chattopadhyay, Sourav; Sanyal, Sabyasachi] CSIR CDRI, Div Biochem, Lucknow 226031, Uttar Pradesh, India.
   [Kumar, Padam; Ramakrishna, Eppalapally; Kumar, Sudhir; Maurya, Rakesh] CSIR CDRI, Div Med & Proc Chem, Lucknow 226031, Uttar Pradesh, India.
   [Chattopadhyay, Sourav; Sanyal, Sabyasachi] CSIR Cent Drug Res Inst Cam, AcSIR, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI); Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI); Council
   of Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI); Academy of Scientific & Innovative Research
   (AcSIR)
RP Chattopadhyay, N (通讯作者)，CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.; Chattopadhyay, N (通讯作者)，CSIR, Cent Drug Res Inst, Ctr Res Anabol Skeletal Target Hlth & Illness AST, Lucknow 226031, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI Chattopadhyay, Sourav/GQY 9508 2022; Naresh, Mittapelly/AGG 0376 2022;
   Husain, Dr. Athar/N 8788 2013; Kushwaha, Sapana/AAA 7852 2020; Kumar,
   Pradeep/GQA 7930 2022; Mishra, Prabhat/KHY 3664 2024; Sanyal,
   Sabyasachi/E 8034 2010; Pal, Subhashis/IXD 3635 2023; maurya,
   rakesh/AAV 7598 2021; Chattopadhyay, Naibedya/AAQ 3213 2021
OI Husain, Dr. Athar/0000 0002 1086 2339; Chattopadhyay,
   Sourav/0000 0003 0055 5818; Sanyal, Sabyasachi/0000 0002 8603 3828;
   Chattopadhyay, Naibedya/0000 0003 2473 0246; Gayen,
   Jiaur/0000 0001 7703 9307; Kushwaha, Sapana/0000 0001 8825 3034; Pal,
   Subhashis/0000 0002 3916 5545
CR Abu Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100
   Aqil F, 2013, CANCER LETT, V334, P133, DOI 10.1016/j.canlet.2013.02.032
   Arazzi M, 2017, G ITAL NEFROL, P34
   Ayroldi E, 2009, FASEB J, V23, P3649, DOI 10.1096/fj.09 134684
   Baker MS, 2015, INT J OBESITY, V39, P98, DOI 10.1038/ijo.2013.146
   Bereshchenko O, 2014, CELL REP, V7, P464, DOI 10.1016/j.celrep.2014.03.004
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Cabahug Zuckerman P, 2016, J BONE MINER RES, V31, P1356, DOI 10.1002/jbmr.2807
   Caplan A, 2017, J AM ACAD DERMATOL, V76, P1, DOI 10.1016/j.jaad.2016.01.062
   Chen XJ, 2017, ACTA BIOCH BIOPH SIN, V49, P867, DOI 10.1093/abbs/gmx087
   Cheruvu HS, 2018, J CHROMATOGR B, V1081, P80, DOI 10.1016/j.jchromb.2018.01.035
   China SP, 2017, BONE, V105, P75, DOI 10.1016/j.bone.2017.08.005
   Clayton SA, 2018, J BIOL CHEM, V293, P1865, DOI 10.1074/jbc.R117.000366
   Eastell R, 2010, BONE, V46, P929, DOI 10.1016/j.bone.2009.12.021
   Glüer CC, 2013, J BONE MINER RES, V28, P1355, DOI 10.1002/jbmr.1870
   Goto T, 2015, CYTOTECHNOLOGY, V67, P357, DOI 10.1007/s10616 014 9694 3
   Hara K, 2002, BONE, V31, P575, DOI 10.1016/S8756 3282(02)00874 8
   Jia JJ, 2011, FASEB J, V25, P3366, DOI 10.1096/fj.11 182519
   Khan K, 2013, OSTEOPOROSIS INT, V24, P1455, DOI 10.1007/s00198 012 2121 8
   Khan MP, 2013, PHYTOMEDICINE, V20, P1256, DOI 10.1016/j.phymed.2013.07.007
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Ko JY, 2015, BONE, V81, P80, DOI 10.1016/j.bone.2015.06.022
   Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914
   Langdahl BL, 2009, OSTEOPOROSIS INT, V20, P2095, DOI 10.1007/s00198 009 0917 y
   Losada BR, 2009, J CLIN DENSITOM, V12, P63, DOI 10.1016/j.jocd.2008.10.002
   Ma HD, 2012, DRUG DEV IND PHARM, V38, P1200, DOI 10.3109/03639045.2011.643897
   Mekjaruskul C, 2013, INT J PHARMACEUT, V445, P1, DOI 10.1016/j.ijpharm.2013.01.052
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Pal S, 2019, BIOCH PHARM
   Pal S, 2019, BIOCHEM PHARMACOL, V164, P34, DOI 10.1016/j.bcp.2019.03.024
   Pal S, 2019, J ETHNOPHARMACOL, V235, P8, DOI 10.1016/j.jep.2019.01.029
   Piemontese M, 2015, BONE, V75, P18, DOI 10.1016/j.bone.2015.02.005
   Plotkin LI, 2015, J BIOL CHEM, V290, P18934, DOI 10.1074/jbc.M115.642090
   Plotkin LI, 2007, J BIOL CHEM, V282, P24120, DOI 10.1074/jbc.M611435200
   Reginster JY, 2016, CURR OPIN CLIN NUTR, V19, P31, DOI 10.1097/MCO.0000000000000230
   Saag KG, 2016, ARTHRITIS RHEUMATOL, V68, P2122, DOI 10.1002/art.39726
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Sato AY, 2017, ENDOCRINOLOGY, V158, P664, DOI 10.1210/en.2016 1779
   Shi CG, 2014, BONE, V68, P67, DOI 10.1016/j.bone.2014.08.004
   Silva MGB, 2011, J ETHNOPHARMACOL, V136, P341, DOI 10.1016/j.jep.2011.04.070
   Singh AK, 2017, MOL CELL ENDOCRINOL, V439, P273, DOI 10.1016/j.mce.2016.09.013
   Singh Vibha, 2017, Natl J Maxillofac Surg, V8, P4, DOI 10.4103/0975 5950.208972
   Sokka T, 2007, ANN RHEUM DIS, V66, P1491, DOI 10.1136/ard.2006.069252
   Taicher GZ, 2003, ANAL BIOANAL CHEM, V377, P990, DOI 10.1007/s00216 003 2224 3
   Tang JL, 2008, DRUG DELIV, V15, P477, DOI [10.1080/10717540802039089, 10.1080/10717540802039089 ]
   Tripathi JK, 2015, BIOMATERIALS, V56, P92, DOI 10.1016/j.biomaterials.2015.03.046
   Vestergaard P, 2008, CALCIFIED TISSUE INT, V82, P249, DOI 10.1007/s00223 008 9124 7
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Whittier X, 2016, RHEUM DIS CLIN N AM, V42, P177, DOI 10.1016/j.rdc.2015.08.005
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Yadav JP, 2010, FITOTERAPIA, V81, P223, DOI 10.1016/j.fitote.2009.09.008
   Zhang L, 2015, DRUG DELIV, V22, P475, DOI 10.3109/10717544.2013.861659
   Zhao Y, 2010, INT J PHARMACEUT, V383, P170, DOI 10.1016/j.ijpharm.2009.08.035
NR 56
TC 21
Z9 25
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JAN 13
PY 2020
VL 10
IS 1
AR 195
DI 10.1038/s41598 019 56853 6
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA KI2DR
UT WOS:000511157800005
PM 31932603
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, RJ
   Zhang, WJ
   Ma, HL
   Zou, DH
   Zhang, ZY
   Wang, SY
AF Wang, Ruijie
   Zhang, Wenjie
   Ma, Hailong
   Zou, Duohong
   Zhang, Zhiyuan
   Wang, Shaoyi
TI Structural insights into the binding of zoledronic acid with RANKL
   via computational simulations
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE molecular simulation; BRONJ (bisphosphonate related osteonecrosis of the
   jaw); molecular docking; molecular dynamic (MD) analysis; surface plamon
   resonance
ID OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; MOLECULAR DOCKING;
   CRYSTAL STRUCTURE; BONE LOSS; BISPHOSPHONATES; OSTEONECROSIS;
   INHIBITION; AFFINITY; JAW
AB Zoledronic acid (ZOL) inhibits receptor activator of nuclear factor kappa B ligand (RANKL) and reduces bone turnover. This plays an important role in the development of bisphosphonate related osteonecrosis of the jaw (BRONJ). Previous reports have shown that ZOL binds to the enzyme farnesyl pyrophosphate synthase (FPPS) to block its activity. However, the mechanism of action of ZOL and its interaction with RANKL is still unclear. In this study, we confirmed that ZOL significantly suppressed the bone remodeling in ZOL treated rats, investigated whether ZOL could bind to RANKL and examined the interactions between these molecules at the atomic level. Surface plasmon resonance (SPR) assay was performed to validate that ZOL could directly bind to RANKL in a dose dependent manner, and the equilibrium constant was calculated (K D = 2.28 x 10( 4) M). Then, we used molecular docking simulation to predict the binding site and analyze the binding characteristics of ZOL and RANKL. Through molecular dynamics simulation, we confirmed the stable binding between ZOL and RANKL and observed their dynamic interactions over time. Binding free energy calculations and its decomposition were conducted to obtain the binding free energy  70.67 & PLUSMN; 2.62 kJ/mol for the RANKL ZOL complex. We identified the key residues of RANKL in the binding region, and these included Tyr217(A), Val277(A), Gly278(A), Val277(B), Gly278(B), and Tyr215(C). Taken together, our results demonstrated the direct interaction between ZOL and RANKL, indicating that the pharmacological action of ZOL might be closely related to RANKL. The design of novel small molecules targeting RANKL might reduce the occurrence of BRONJ.
C1 [Wang, Ruijie; Zou, Duohong; Wang, Shaoyi] Shanghai Jiao Tong Univ Sch Med, Shanghai Peoples Hosp 9, Dept Oral Surg, Shanghai, Peoples R China.
   [Wang, Ruijie; Zhang, Wenjie; Ma, Hailong; Zou, Duohong; Zhang, Zhiyuan; Wang, Shaoyi] Shanghai Jiao Tong Univ, Chinese Acad Med Sci, Coll Stomatol, Natl Ctr Stomatol,Shanghai Key Lab Stomatol,Res Un, Shanghai, Peoples R China.
   [Zhang, Wenjie] Shanghai Jiao Tong Univ Sch Med, Shanghai Peoples Hosp 9, Dept Prosthodont, Shanghai, Peoples R China.
   [Ma, Hailong; Zhang, Zhiyuan] Shanghai Jiao Tong Univ Sch Med, Shanghai Peoples Hosp 9, Dept Oral Maxillofacial Head & Neck Oncol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Medical Sciences   Peking Union Medical College; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University
RP Wang, SY (通讯作者)，Shanghai Jiao Tong Univ Sch Med, Shanghai Peoples Hosp 9, Dept Oral Surg, Shanghai, Peoples R China.; Zhang, ZY; Wang, SY (通讯作者)，Shanghai Jiao Tong Univ, Chinese Acad Med Sci, Coll Stomatol, Natl Ctr Stomatol,Shanghai Key Lab Stomatol,Res Un, Shanghai, Peoples R China.; Zhang, ZY (通讯作者)，Shanghai Jiao Tong Univ Sch Med, Shanghai Peoples Hosp 9, Dept Oral Maxillofacial Head & Neck Oncol, Shanghai, Peoples R China.
EM zhangzy1650@sh9hospital.org; wangshaoyi163@aliyun.com
RI Zhang, Wenjie/O 5336 2014; Wang, Ruijie/LKM 8204 2024
FU Science and Technology Commission of Shanghai Municipality; CAMS
   Innovation Fund for Medical Sciences (CIFMS); Shanghai Municipal Key
   Clinical Specialty; Shanghai Clinical Research Center for Oral Diseases;
    [19411962000];  [2019 I2M 5 037];  [shslczdzk01601];  [19MC1910600]
FX Funding The authors disclosed receipt of the following financial support
   for the research, authorship, and/or publication of this article: This
   study was supported in part by grants from Science and Technology
   Commission of Shanghai Municipality (Grant No. 19411962000). CAMS
   Innovation Fund for Medical Sciences (CIFMS) (Project No.
   2019 I2M 5 037); Shanghai Municipal Key Clinical Specialty
   (shslczdzk01601); Shanghai Clinical Research Center for Oral Diseases
   (19MC1910600).
CR Aguirre JI, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116184
   Allen MR, 2009, CELLS TISSUES ORGANS, V189, P289, DOI 10.1159/000151371
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Chypre M, 2017, CHEMMEDCHEM, V12, P1697, DOI 10.1002/cmdc.201700462
   De Vita S, 2019, J CHEM INF MODEL, V59, P4678, DOI 10.1021/acs.jcim.9b00428
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   El Bakri Y, 2021, APPL BIOCHEM BIOTECH, V193, P3602, DOI 10.1007/s12010 021 03615 8
   Febres Molina C, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13111840
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Gifre L, 2017, OSTEOPOROSIS INT, V28, P2707, DOI 10.1007/s00198 017 4090 4
   Giusti A, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000056
   Gulzar M, 2019, J BIOMOL STRUCT DYN, V37, P4327, DOI 10.1080/07391102.2018.1546621
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Huang XL, 2019, INT J MOL MED, V44, P582, DOI 10.3892/ijmm.2019.4207
   Ivankov DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006476
   Jimi E, 1999, J IMMUNOL, V163, P434
   Jones DH, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.suppl_2.ii32
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kimachi K, 2011, N S ARCH PHARMACOL, V383, P297, DOI 10.1007/s00210 010 0596 4
   Kumar A, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.898874
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Li MY, 2022, STEM CELL REV REP, V18, P378, DOI 10.1007/s12015 021 10241 8
   Liu H, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865 016 0183 7
   Lloyd SAJ, 2008, CALCIFIED TISSUE INT, V82, P361, DOI 10.1007/s00223 008 9133 6
   Luan XD, 2012, J IMMUNOL, V189, P245, DOI 10.4049/jimmunol.1103387
   McConkey BJ, 2003, P NATL ACAD SCI USA, V100, P3215, DOI 10.1073/pnas.0535768100
   Meng XY, 2011, CURR COMPUT AID DRUG, V7, P146
   Munasinghe A, 2017, J PHYS CHEM B, V121, P9141, DOI 10.1021/acs.jpcb.7b06687
   Nagaoka Y, 2015, J DENT RES, V94, P594, DOI 10.1177/0022034514564187
   Nagar PR, 2021, J MOL STRUCT, V1246, DOI 10.1016/j.molstruc.2021.131190
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nieto A, 2010, LANGMUIR, V26, P5038, DOI 10.1021/la904820k
   Ogunyemi OM, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.866719
   Ohno K, 2011, CURR MED CHEM, V18, P220, DOI 10.2174/092986711794088335
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Porkolab V, 2020, ORG BIOMOL CHEM, V18, P4763, DOI 10.1039/d0ob00781a
   Rastelli G, 2010, J COMPUT CHEM, V31, P797, DOI 10.1002/jcc.21372
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249 011 0700 9
   Soundia A, 2021, BONE, V148, DOI 10.1016/j.bone.2021.115945
   Stachnik A, 2014, P NATL ACAD SCI USA, V111, P17995, DOI 10.1073/pnas.1421422111
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Stroet M, 2018, J CHEM THEORY COMPUT, V14, P5834, DOI 10.1021/acs.jctc.8b00768
   Subramanian N, 2019, J CHEM INF MODEL, V59, P2287, DOI 10.1021/acs.jcim.8b00624
   Trang NM, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12020256
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang R J, 2021, Zhonghua Kou Qiang Yi Xue Za Zhi, V56, P679, DOI 10.3760/cma.j.cn112144 20200729 00441
   Wang SY, 2010, BONE, V46, P91, DOI 10.1016/j.bone.2009.09.008
   Wani TA, 2021, J MOL LIQ, V342, DOI 10.1016/j.molliq.2021.117542
   Watanabe J, 2020, J DENT RES, V99, P552, DOI 10.1177/0022034520906793
   Xiao Y, 2015, J DENT RES, V94, P1106, DOI 10.1177/0022034515586769
   Yan XH, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.668400
   Yang G, 2019, BONE, V124, P75, DOI 10.1016/j.bone.2019.04.010
   Yin FL, 2006, J AM CHEM SOC, V128, P3524, DOI 10.1021/ja0601639
   Zhang N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00325
   Zhou YQ, 2021, INT J MED SCI, V18, P2209, DOI 10.7150/ijms.56408
NR 59
TC 4
Z9 4
U1 1
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2296 889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD SEP 19
PY 2022
VL 9
AR 992473
DI 10.3389/fmolb.2022.992473
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 5C8RB
UT WOS:000864519800001
PM 36200071
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yi, O
   Lin, Y
   Hu, MY
   Hu, ST
   Su, ZL
   Liao, J
   Liu, B
   Liu, L
   Cai, X
AF Yi, Ouyang
   Lin, Ye
   Hu, Mingyue
   Hu, Shengtao
   Su, Zhaoli
   Liao, Jin
   Liu, Bin
   Liu, Liang
   Cai, Xiong
TI Lactate metabolism in rheumatoid arthritis: Pathogenic mechanisms and
   therapeutic intervention with natural compounds
SO PHYTOMEDICINE
LA English
DT Article
DE Rheumatoid arthritis; Hypoxic microenvironment; Lactate metabolism;
   Synovial fibroblasts; Natural compounds
ID FATTY ACID SYNTHESIS; INHIBITION; DEHYDROGENASE; ACTIVATION; EXPRESSION;
   TRANSPORT; TOXICITY; MCT4; DIFFERENTIATION; CYTOTOXICITY
AB Background: Rheumatoid arthritis (RA) is a common chronic and systemic autoimmune disease characterized by persistent inflammation and hyperplasia of the synovial membrane, the degradation of cartilage, and the erosion of bones in diarthrodial joints. The inflamed joints of patients with RA have been recognized to be a site of hypoxic microenvironment which results in an imbalance of lactate metabolism and the accumulation of lactate. Lactate is no longer considered solely a metabolic waste product of glycolysis, but also a combustion aid in the progression of RA from the early stages of inflammation to the late stages of bone destruction.Purpose: To review the pathogenic mechanisms of lactate metabolism in RA and investigate the potential of natural compounds for treating RA linked to the regulation of imbalance in lactate metabolism. Methods: Research advances in our understanding of lactate metabolism in the pathogenesis of RA and novel pharmacological approaches of natural compounds by targeting lactate metabolic signaling were comprehen sively reviewed and deeply discussed.Results: Lactate produced by RA synovial fibroblasts (RASFs) acts on targeted cells such as T cells, macrophages, dendritic cells and osteoclasts, and affects their differentiation, activation and function to accelerate the development of RA. Many natural compounds show therapeutic potential for RA by regulating glycolytic rate limiting enzymes to limit lactate production, and affecting monocarboxylate transporter and acetyl CoA carboxylase to inhibit lactate transport and conversion.Conclusion: Regulation of imbalance in lactate metabolism offers novel therapeutic approaches for RA, and natural compounds capable of targeting lactate metabolic signaling constitute potential candidates for devel opment of drugs RA.
C1 [Yi, Ouyang; Lin, Ye; Hu, Mingyue; Hu, Shengtao; Su, Zhaoli; Liao, Jin; Cai, Xiong] Hunan Univ Chinese Med, Inst Innovat & Appl Res Chinese Med, First Hosp, Changsha 410208, Hunan, Peoples R China.
   [Yi, Ouyang; Lin, Ye; Hu, Mingyue; Hu, Shengtao; Su, Zhaoli; Liao, Jin; Cai, Xiong] Hunan Univ Chinese Med, Dept Rheumatol, First Hosp, Changsha 410208, Hunan, Peoples R China.
   [Liu, Bin] Hunan Univ, Coll Biol, Changsha 410082, Hunan, Peoples R China.
   [Liu, Liang] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau 030027, Peoples R China.
C3 Hunan University of Chinese Medicine; Hunan University of Chinese
   Medicine; Hunan University; Macau University of Science & Technology
RP Cai, X (通讯作者)，Hunan Univ Chinese Med, Inst Innovat & Appl Res Chinese Med, First Hosp, Changsha 410208, Hunan, Peoples R China.; Cai, X (通讯作者)，Hunan Univ Chinese Med, Dept Rheumatol, First Hosp, Changsha 410208, Hunan, Peoples R China.; Liu, B (通讯作者)，Hunan Univ, Coll Biol, Changsha 410082, Hunan, Peoples R China.; Liu, L (通讯作者)，Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau 030027, Peoples R China.
FU Science and Technology Innovation Megaproject and Innovative Leading
   Talent Program of Hunan Science &Technology Department [2020SK1020, XKJ
   [2021]43 2021RC4035]; Hunan Furong Distinguished Scholar Program
   [XJT[2020]58]; Hunan Provincial 121 Training Project for Innovative
   Talents [XRSH [2019]192]; Chinese Academy of Engineering Academician
   Liang Liu's Workstation of Hunan University of Chinese Medicine (HNUCM)
   [XKXH[2020]34]; National First class Disciple Construction Project of
   Chinese Medicine of HNUCM [XXKZ[2018]3]
FX The work was funded by grants from the Science and Technology Innovation
   Megaproject and Innovative Leading Talent Program of Hunan Science
   &Technology Department (grant nos. 2020SK1020, XKJ [2021]43 2021RC4035),
   and was supported by the Hunan Furong Distinguished Scholar Program
   (grant no. XJT[2020]58), Hunan Provincial 121 Training Project for
   Innovative Talents (grant no. XRSH [2019]192), Chinese Academy of
   Engineering Academician Liang Liu's Workstation of Hunan University of
   Chinese Medicine (HNUCM) (grant no. XKXH[2020]34), and National
   First class Disciple Construction Project of Chinese Medicine of HNUCM
   (grant no. XXKZ[2018]3).
CR Bai JR, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110985
   Berod L, 2014, NAT MED, V20, P1327, DOI 10.1038/nm.3704
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown TP, 2020, ONCOGENE, V39, P3292, DOI 10.1038/s41388 020 1216 5
   Bustamante MF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1303 3
   Cabeza Cabrerizo M, 2021, ANNU REV IMMUNOL, V39, P131, DOI 10.1146/annurev immunol 061020 053707
   Chen MM, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12251
   Chen S, 2016, MOL MED REP, V14, P3389, DOI 10.3892/mmr.2016.5594
   Chen XW, 2011, CHEM BIOL INTERACT, V192, P161, DOI 10.1016/j.cbi.2011.03.016
   Cheng B., 2017, J CHROMATOGR B ANALY
   Cui ZL, 2022, IMMUNOL INVEST, V51, P1385, DOI 10.1080/08820139.2021.1948050
   Degboé Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00003
   Ding Peihui, 2009, Zhongguo Zhong Yao Za Zhi, V34, P1712
   Dutta P, 2013, CANCER RES, V73, P4190, DOI 10.1158/0008 5472.CAN 13 0465
   Elia I, 2019, NATURE, V568, P117, DOI 10.1038/s41586 019 0977 x
   Ernst J, 2017, MOL PSYCHIATR, V22, P113, DOI 10.1038/mp.2016.73
   FALCHUK KH, 1970, AM J MED, V49, P223, DOI 10.1016/S0002 9343(70)80078 X
   Fang SS, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114617
   Fujii W, 2015, ARTHRITIS RHEUMATOL, V67, P2888, DOI 10.1002/art.39270
   Funes SC, 2018, IMMUNOLOGY, V154, P186, DOI 10.1111/imm.12910
   Garcia Carbonell R, 2016, ARTHRITIS RHEUMATOL, V68, P1614, DOI 10.1002/art.39608
   Ghavre M, 2016, ANGEW CHEM INT EDIT, V55, P5642, DOI 10.1002/anie.201508227
   Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022
   Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood 2005 05 1795
   Gunnink LK, 2016, BIOCHIMIE, V125, P179, DOI 10.1016/j.biochi.2016.03.014
   Gupta P, 2016, EXP CELL RES, V347, P293, DOI 10.1016/j.yexcr.2016.08.008
   Haas R, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002202
   Han B, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/9398435
   He ZH, 2017, NAT IMMUNOL, V18, P1128, DOI 10.1038/ni.3832
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Huang ZL, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/2768444
   Hunkeler M, 2018, NATURE, V558, P470, DOI 10.1038/s41586 018 0201 4
   INABA K, 1985, SCIENCE, V229, P475, DOI 10.1126/science.3160115
   Jiang SQ, 2022, J ETHNOPHARMACOL, V288, DOI 10.1016/j.jep.2022.114993
   Jiang TT, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.785586
   Johar D, 2021, BIOFACTORS, V47, P713, DOI 10.1002/biof.1768
   Juel C, 1999, J PHYSIOL LONDON, V517, P633, DOI 10.1111/j.1469 7793.1999.0633s.x
   Kaushik DK, 2019, J CLIN INVEST, V129, P3277, DOI 10.1172/JCI124012
   Khajah MA, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.747001
   Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896
   Kittipaspallop W, 2018, EXP BIOL MED, V243, P1212, DOI 10.1177/1535370218819743
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107
   Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108
   Lemma S, 2017, BBA MOL BASIS DIS, V1863, P3254, DOI 10.1016/j.bbadis.2017.08.030
   Li C, 2020, JOINT BONE SPINE, V87, P425, DOI 10.1016/j.jbspin.2020.05.005
   Li J., SCI REP UK, V11, DOI [10.1038/s41598 021 97713, DOI 10.1038/S41598 021 97713]
   Li ZG, 2015, NAT REV RHEUMATOL, V11, P313, DOI 10.1038/nrrheum.2014.218
   Liang MG, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 02978 5
   Lin TF, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113831
   Lin YQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580593
   Liu J, 2020, J PHARM PHARMACOL, V72, P319, DOI 10.1111/jphp.13189
   Luo X, 2022, LIFE SCI, V291, DOI 10.1016/j.lfs.2021.120064
   Luz VB, 2018, TOXICON, V145, P56, DOI 10.1016/j.toxicon.2018.02.051
   Majumder S, 2019, NAT IMMUNOL, V20, P534, DOI 10.1038/s41590 019 0367 4
   Manning Fox J.E., 2000, J PHYSL, V285 293, P529
   Meredith D, 2002, CELL PHYSIOL BIOCHEM, V12, P227, DOI 10.1159/000066282
   Mikami M, 1999, BIOL PHARM BULL, V22, P674
   Minegishi H, 2013, ACS MED CHEM LETT, V4, P297, DOI 10.1021/ml3004632
   Mohseni M, 2021, PHYTOTHER RES, V35, P6862, DOI 10.1002/ptr.7273
   Morten KJ, 2013, J PATHOL, V229, P755, DOI 10.1002/path.4159
   Nasi A, 2013, J IMMUNOL, V191, P3090, DOI 10.4049/jimmunol.1300772
   Newton DA, 2021, RESP RES, V22, DOI 10.1186/s12931 021 01866 x
   Niu JX, 2019, NATURE, V573, P139, DOI 10.1038/s41586 019 1511 x
   O'Dell JR, 2004, NEW ENGL J MED, V350, P2591, DOI 10.1056/NEJMra040226
   Papakonstantinou E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062918
   Park J, 2018, NEURO ONCOLOGY, V20, P954, DOI 10.1093/neuonc/nox243
   Peng W, 2013, J ETHNOPHARMACOL, V148, P729, DOI 10.1016/j.jep.2013.05.007
   POSO H, 1980, LANCET, V1, P885
   Possemiers H, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009122
   Pucino V, 2019, CELL METAB, V30, P1055, DOI 10.1016/j.cmet.2019.10.004
   Rosafio K, 2014, GLIA, V62, P477, DOI 10.1002/glia.22618
   ROYER RE, 1986, J MED CHEM, V29, P1799, DOI 10.1021/jm00159a043
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shen Y, 2004, MOL CELL, V16, P881, DOI 10.1016/j.molcel.2004.11.034
   Shen Y, 2017, NAT IMMUNOL, V18, P1025, DOI 10.1038/ni.3808
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Song GH, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1865 3
   Souto Carneiro MM, 2020, ARTHRITIS RHEUMATOL, V72, P2050, DOI 10.1002/art.41420
   Strumillo J, 2018, BBA GEN SUBJECTS, V1862, P877, DOI 10.1016/j.bbagen.2017.12.017
   Sun Q, 2022, PHYTOMEDICINE, V94, DOI 10.1016/j.phymed.2021.153805
   Svensson RU, 2016, NAT MED, V22, P1108, DOI 10.1038/nm.4181
   Tang Y, 2019, J CELL PHYSIOL, V234, P11165, DOI 10.1002/jcp.27765
   Tardito S, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102397
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   THOMPSON PW, 1987, ANN RHEUM DIS, V46, P263, DOI 10.1136/ard.46.3.263
   Tiedemann K, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00435
   Udalova IA, 2016, NAT REV RHEUMATOL, V12, P472, DOI 10.1038/nrrheum.2016.91
   Urbanska K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092085
   Viola A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01462
   Wang L, 2020, DRUG DES DEV THER, V14, P4451, DOI 10.2147/DDDT.S266502
   Wasyluk W, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112412
   Weyand CM, 2017, NAT REV RHEUMATOL, V13, P1, DOI 10.1038/nrrheum.2017.49
   Xie Q., BIOMATER SCI UK, V9, P2991
   Xu DY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02919
   Xu DQ, 2020, NATURE, V580, P530, DOI 10.1038/s41586 020 2183 2
   Yang XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132695
   Yu Y, 2020, INT IMMUNOPHARMACOL, V87, DOI 10.1016/j.intimp.2020.106830
   Zhang CL, 2021, PHYTOMEDICINE, V93, DOI 10.1016/j.phymed.2021.153765
   Zhang JH, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389 020 0230 3
   Zheng TY, 2018, MOLECULES, V23, DOI 10.3390/molecules23061490
   Zheng ZG, 2021, AUTOPHAGY, V17, P1592, DOI 10.1080/15548627.2020.1757955
   Zou HY, 2021, PHYTOMEDICINE, V92, DOI 10.1016/j.phymed.2021.153736
NR 103
TC 30
Z9 32
U1 5
U2 75
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUN
PY 2022
VL 100
AR 154048
DI 10.1016/j.phymed.2022.154048
EA MAR 2022
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 1F4KS
UT WOS:000795138200002
PM 35316725
DA 2025 08 17
ER

PT J
AU Duggal, S
   Sharma, S
   Rai, N
   Chauhan, D
   Upadhyay, V
   Srivastava, S
   Porwal, K
   Kulkarni, C
   Trivedi, AK
   Gayen, JR
   Mishra, PR
   Chattopadhyay, N
   Pal, S
AF Duggal, Shivali
   Sharma, Shivani
   Rai, Nikhil
   Chauhan, Divya
   Upadhyay, Vishal
   Srivastava, Swati
   Porwal, Konica
   Kulkarni, Chirag
   Trivedi, Arun K.
   Gayen, Jiaur R.
   Mishra, Prabhat R.
   Chattopadhyay, Naibedya
   Pal, Subhashis
TI Anti Microbial Drug Metronidazole Promotes Fracture Healing: Enhancement
   in the Bone Regenerative Efficacy of the Drug by a Biodegradable
   Sustained Release In Situ Gel Formulation
SO BIOMEDICINES
LA English
DT Article
DE osteogenic; anti microbial drug; in situ gel formulation; osteoblast
   differentiation; fracture healing
ID IMIDAZOLE; NONUNION; PEPTIDE; SYSTEM
AB Nitroimidazoles comprise a class of broad spectrum anti microbial drugs with efficacy against parasites, mycobacteria, and anaerobic Gram positive and Gram negative bacteria. Among these drugs, metronidazole (MTZ) is commonly used with other antibiotics to prevent infection in open fractures. However, the effect of MTZ on bone remains understudied. In this paper, we evaluated six nitroimidazole drugs for their impact on osteoblast differentiation and identified MTZ as having the highest osteogenic effect. MTZ enhanced bone regeneration at the femur osteotomy site in osteopenic ovariectomized (OVX) rats at the human equivalent dose. Moreover, in OVX rats, MTZ significantly improved bone mass and strength and improved microarchitecture compared to the vehicle treated rats, which was likely achieved by an osteogenic mechanism attributed to the stimulation of the Wnt pathway in osteoblasts. To mitigate the reported neurological and genotoxic effects of MTZ, we designed an injectable sustained release in situ gel formulation of the drug that improved fracture healing efficacy by 3.5 fold compared to oral administration. This enhanced potency was achieved through a significant increase in the circulating half life and bioavailability of MTZ. We conclude that MTZ exhibits osteogenic effects, further accentuated by our sustained release delivery system, which holds promise for enhancing bone regeneration in open fractures.
C1 [Duggal, Shivali; Sharma, Shivani; Porwal, Konica; Kulkarni, Chirag; Chattopadhyay, Naibedya; Pal, Subhashis] CSIR Cent Drug Res Inst, Council Sci & Ind Res, Div Endocrinol, Lucknow 226031, India.
   [Sharma, Shivani; Rai, Nikhil; Chauhan, Divya; Upadhyay, Vishal; Kulkarni, Chirag; Trivedi, Arun K.; Chattopadhyay, Naibedya] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.
   [Rai, Nikhil; Chauhan, Divya; Gayen, Jiaur R.; Mishra, Prabhat R.] CSIR Cent Drug Res Inst, Div Pharmaceut & Pharmacokinet, Council Sci & Ind Res, Lucknow 226031, India.
   [Upadhyay, Vishal; Srivastava, Swati; Trivedi, Arun K.] CSIR Cent Drug Res Inst, Div Canc Biol, Council Sci & Ind Res, Lucknow 226031, India.
   [Pal, Subhashis] Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.
   [Pal, Subhashis] SRM Inst Sci & Technol SRM IST, SRM Med Coll Hosp & Res Ctr, Div Med Res, Kattankulathur 603203, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Academy of Scientific &
   Innovative Research (AcSIR); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI); Council
   of Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI); Emory University; SRM Institute of Science &
   Technology Chennai
RP Chattopadhyay, N; Pal, S (通讯作者)，CSIR Cent Drug Res Inst, Council Sci & Ind Res, Div Endocrinol, Lucknow 226031, India.; Chattopadhyay, N (通讯作者)，Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.; Pal, S (通讯作者)，Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.; Pal, S (通讯作者)，SRM Inst Sci & Technol SRM IST, SRM Med Coll Hosp & Res Ctr, Div Med Res, Kattankulathur 603203, India.
EM n_chattopadhyay@cdri.res.in; subhashis.pal@emory.edu
RI Chattopadhyay, Naibedya/AAF 2058 2019; Trivedi, Arun/W 1883 2019;
   Sharma, Dr Shivani/LRT 9327 2024; Mishra, Prabhat/KHY 3664 2024; Pal,
   Subhashis/IXD 3635 2023
OI Trivedi, Arun/0000 0002 6316 0947; Chattopadhyay,
   Naibedya/0000 0003 2473 0246; Pal, Subhashis/0000 0002 3916 5545; Gayen,
   Jiaur/0000 0001 7703 9307; 
FU Council of Scientific and Industrial Research, Government of India [MLP
   2035]
FX This research was funded by the Council of Scientific and Industrial
   Research (MLP 2035), Government of India. CDRI communication number for
   this article is 10827
CR Alsaeed OM, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.26731
   [Anonymous], Metronidazole (Oral Route) Proper Use Mayo Clinic
   Arya PN, 2024, WORLD J STEM CELLS, V16, DOI 10.4252/wjsc.v16.i2.102
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Barnhill AE, 2012, ANTIMICROB AGENTS CH, V56, P4046, DOI 10.1128/AAC.00678 12
   Bellei B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033021
   Beuttel E, 2019, MATERIALS, V12, DOI 10.3390/ma12071116
   Boyce BF, 2009, CRIT REV EUKAR GENE, V19, P171, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.10
   BRYER HP, 1995, J BONE MINER RES, V10, P132
   Chen TS, 2006, ASSAY DRUG DEV TECHN, V4, P387, DOI 10.1089/adt.2006.4.387
   Chu BY, 2016, SCI REP UK, V6, DOI 10.1038/srep34069
   Croes M, 2019, J ORTHOP RES, V37, P2067, DOI 10.1002/jor.24422
   Cui YT, 2022, MATER TODAY BIO, V16, DOI 10.1016/j.mtbio.2022.100409
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Dong X, 2016, ACS BIOMATER SCI ENG, V2, P2001, DOI 10.1021/acsbiomaterials.6b00403
   Flores MJ, 2022, J CLIN MED, V11, DOI 10.3390/jcm11247461
   Fraimow Henry S, 2009, Semin Plast Surg, V23, P90, DOI 10.1055/s 0029 1214161
   Garg A, 2024, INT J PHARMACEUT, V652, DOI 10.1016/j.ijpharm.2024.123819
   Gillespie WJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000244.pub2
   Golestani S, 2022, J KOR ASSOC ORAL MAX, V48, P94, DOI 10.5125/jkaoms.2022.48.2.94
   Hackl S, 2021, INJURY, V52, P3498, DOI 10.1016/j.injury.2021.08.014
   Haider Mahfood Ghaleb, 2013, Clujul Med, V86, P240
   Hall MM, 2011, PM&R, V3, P132, DOI 10.1016/j.pmrj.2010.10.003
   HEERSCHE JNM, 1981, PROSTAG OTH LIPID M, V21, P401, DOI 10.1016/0090 6980(81)90085 X
   Hellwinkel JE, 2022, J ORTHOP RES, V40, P541, DOI 10.1002/jor.25261
   Hosny KM, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030263
   Ihn HJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00367
   Ince A, 2007, INT ORTHOP, V31, P223, DOI 10.1007/s00264 006 0144 5
   Joiner DM, 2013, TRENDS ENDOCRIN MET, V24, P31, DOI 10.1016/j.tem.2012.10.003
   Khaing EM, 2022, GELS BASEL, V8, DOI 10.3390/gels8030169
   Kumar G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205154
   Le J. K., 2023, Metronidazole
   Leanza G, 2021, J BONE MINER RES, V36, P1403, DOI 10.1002/jbmr.4303
   Madan M, 2009, INDIAN J PHARM SCI, V71, P242, DOI 10.4103/0250 474X.56015
   Makaram NS, 2021, BONE JOINT OPEN, V2, P227, DOI 10.1302/2633 1462.24.BJO 2021 0012.R1
   Martinez V., Metronidazole PubMed
   Mircioiu C, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11030140
   Morgan S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236085
   Nelson AL, 2022, J TISSUE ENG REGEN M, V16, P961, DOI 10.1002/term.3349
   Pal S, 2024, CALCIFIED TISSUE INT, V114, P295, DOI 10.1007/s00223 023 01170 4
   Pal S, 2022, CALCIFIED TISSUE INT, V111, P196, DOI 10.1007/s00223 022 00979 9
   Pal S, 2021, EUR J PHARMACOL, V913, DOI 10.1016/j.ejphar.2021.174634
   Pal S, 2021, ACS APPL MATER INTER, V13, P17300, DOI 10.1021/acsami.1c01513
   Pal S, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 56853 6
   Pal S, 2019, CALCIFIED TISSUE INT, V105, P294, DOI 10.1007/s00223 019 00567 4
   Pal S, 2019, BIOCHEM PHARMACOL, V164, P34, DOI 10.1016/j.bcp.2019.03.024
   Pal S, 2019, J ETHNOPHARMACOL, V235, P8, DOI 10.1016/j.jep.2019.01.029
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Porwal K, 2017, J NUTR BIOCHEM, V44, P22, DOI 10.1016/j.jnutbio.2017.02.011
   Sherafudeen SP, 2015, RES PHARM SCI, V10, P466
   Stewart SK, 2019, MALAYS ORTHOP J, V13, P1, DOI 10.5704/MOJ.1907.001
   Terkawi MA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031786
   Tian Y, 2016, DRUG DELIV, V23, P2726, DOI 10.3109/10717544.2015.1061069
   Tripathi JK, 2015, BIOMATERIALS, V56, P92, DOI 10.1016/j.biomaterials.2015.03.046
   Warner AJ, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116377
NR 55
TC 1
Z9 1
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD JUL
PY 2024
VL 12
IS 7
AR 1603
DI 10.3390/biomedicines12071603
PG 23
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA ZQ0B9
UT WOS:001276632900001
PM 39062176
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Anitua, E
   Tejero, R
   Zalduendo, MM
   Orive, G
AF Anitua, Eduardo
   Tejero, Ricardo
   Zalduendo, Mari Mar
   Orive, Gorka
TI Plasma Rich in Growth Factors Promotes Bone Tissue Regeneration by
   Stimulating Proliferation, Migration, and Autocrine Secretion in Primary
   Human Osteoblasts
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE Blood platelets; bone and bones; intercellular signaling peptides and
   proteins; osteoblasts; platelet rich plasma; regeneration
ID MORPHOGENETIC PROTEIN 2; CHEMOTACTIC MIGRATION; FIBRIN MATRICES; DENTAL
   IMPLANTS; STEM CELLS; IN VITRO; MECHANISMS; PLATELETS; RESPONSES;
   MEDICINE
AB Background: Alveolar bone loss can be a major clinical concern affecting both functionality and esthetics. Osteoblasts are the main cells charged with the repair and regeneration of missing bone tissue. Plasma rich in growth factors (PRGF) allows delivery of a cocktail of proteins and growth factors that promote wound healing and tissue regeneration to the site of injury. This study tests the effect of this endogenous regenerative technology to stimulate alveolar osteoblast bone forming potential.
   Methods: Primary human osteoblasts were retrieved from alveolar bone of patients undergoing oral surgery. Cell proliferation was evaluated, and culture inserts and permeable transwell supports were used to assess cell migration and chemotaxis. The expression of differentiation markers was quantified by enzyme linked immunosorbent assay.
   Results: PRGF succeeded in increasing proliferation, migration, and chemotaxis of osteoblasts. Also, PRGF significantly enhanced the autocrine expression of two relevant proangiogenic factors, vascular endothelial growth factor and hepatocyte growth factor, and three markers of osteoblastic activity, procollagen I, osteocalcin, and alkaline phosphatase.
   Conclusion: The results indicate that PRGF can stimulate some of the biologic processes of the main cells responsible for bone regeneration and help support the positive clinical outcomes that have been reported with this technology.
C1 [Anitua, Eduardo; Tejero, Ricardo; Zalduendo, Mari Mar; Orive, Gorka] Inst Biotechnol, Vitoria, Spain.
   [Anitua, Eduardo] Eduardo Anitua Inst, Vitoria 10007, Spain.
RP Anitua, E (通讯作者)，Eduardo Anitua Inst, C Jose Maria Cagigal 19, Vitoria 10007, Spain.
EM eduardoanitua@eduardoanitua.com
RI Zalduendo, Mar/N 7896 2018; Tejero, Ricardo/N 7822 2018; ,
   Mar/N 7896 2018; Anitua, Eduardo/O 1154 2018
OI ORIVE, GORKA/0000 0002 0773 300X; , Mar/0000 0001 8458 6042; Anitua,
   Eduardo/0000 0002 8386 5303
FU Biotechnology Institute (BTI; Vitoria, Spain)
FX The study was funded by the Biotechnology Institute (BTI; Vitoria,
   Spain), which developed the PRGF Endoret system. Dr. Anitua is the
   scientific director, and Drs. Tejero, Zalduendo, and Orive are
   researchers at BTI. Dr. Anitua also has patents on PRGF Endoret
   technology.
CR Ahlmann E, 2002, J BONE JOINT SURG AM, V84A, P716, DOI 10.2106/00004623 200205000 00003
   Anitua E, 2006, J BIOMED MATER RES A, V77A, P285, DOI 10.1002/jbm.a.30585
   Anitua E, 2008, J CLIN PERIODONTOL, V35, P724, DOI 10.1111/j.1600 051X.2008.01248.x
   Anitua E, 2008, TRENDS PHARMACOL SCI, V29, P37, DOI 10.1016/j.tips.2007.10.010
   Anitua E, 2008, J BIOMED MATER RES B, V84B, P415, DOI 10.1002/jbm.b.30886
   Anitua E, 2007, BIOMATERIALS, V28, P4551, DOI 10.1016/j.biomaterials.2007.06.037
   Anitua E, 2012, J PERIODONTOL, V83, P1028, DOI 10.1902/jop.2011.110505
   Anitua E, 2012, J CONTROL RELEASE, V157, P29, DOI 10.1016/j.jconrel.2011.07.004
   Anitua E, 2011, J BIOMED MATER RES A, V97A, P536, DOI 10.1002/jbm.a.33053
   Anitua E, 2010, ADV DRUG DELIVER REV, V62, P741, DOI 10.1016/j.addr.2010.01.001
   Arisato T, 2003, J THROMB HAEMOST, V1, P2589, DOI 10.1046/j.1538 7836.2003.00475.x
   Bendinelli P, 2010, J CELL PHYSIOL, V225, P757, DOI 10.1002/jcp.22274
   Bunta AD, 2011, OSTEOPOROSIS INT, V22, pS477, DOI 10.1007/s00198 011 1704 0
   BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629
   Chen FM, 2010, BIOMATERIALS, V31, P7892, DOI 10.1016/j.biomaterials.2010.07.019
   Chen FM, 2010, BIOMATERIALS, V31, P6279, DOI 10.1016/j.biomaterials.2010.04.053
   de Gonzalo Calvo D, 2010, FREE RADICAL BIO MED, V49, P733, DOI 10.1016/j.freeradbiomed.2010.05.019
   Esposito M, 2006, INT J ORAL MAX IMPL, V21, P696
   Fiedler J, 2006, BIOCHEM BIOPH RES CO, V345, P1177, DOI 10.1016/j.bbrc.2006.05.034
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   Graziani F, 2006, CLIN ORAL IMPLAN RES, V17, P212, DOI 10.1111/j.1600 0501.2005.01203.x
   Gruber R, 2003, J ORTHOPAED RES, V21, P941, DOI 10.1016/S0736 0266(03)00053 6
   Gruber R, 2002, CLIN ORAL IMPLAN RES, V13, P529, DOI 10.1034/j.1600 0501.2002.130513.x
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   HUGHES FJ, 1992, BONE MINER, V19, P63, DOI 10.1016/0169 6009(92)90844 4
   Jayakumar P, 2010, P I MECH ENG H, V224, P1415, DOI 10.1243/09544119JEIM821
   KELLS AF, 1995, CONNECT TISSUE RES, V31, P117, DOI 10.3109/03008209509028399
   Kwan MD, 2008, HUM MOL GENET, V17, pR93, DOI 10.1093/hmg/ddn071
   Lepperdinger G, 2011, CURR OPIN IMMUNOL, V23, P518, DOI 10.1016/j.coi.2011.05.007
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lin Sylvia S, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P4358
   LIND M, 1995, APMIS, V103, P140, DOI 10.1111/j.1699 0463.1995.tb01089.x
   Lind M, 1996, BONE, V18, P53, DOI 10.1016/8756 3282(95)00423 8
   Lu HH, 2008, J BIOMED MATER RES A, V86A, P1128, DOI 10.1002/jbm.a.31740
   Lucarelli E, 2003, BIOMATERIALS, V24, P3095, DOI 10.1016/S0142 9612(03)00114 5
   Madeddu P, 2005, EXP PHYSIOL, V90, P315, DOI 10.1113/expphysiol.2004.028571
   MANN S, 2001, BIOMINERALIZATION PR, P89
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   Panetta NJ, 2010, CURR STEM CELL RES T, V5, P122
   Rendu F, 2001, PLATELETS, V12, P261, DOI 10.1080/09537100120068170
   Sánchez M, 2007, AM J SPORT MED, V35, P245, DOI 10.1177/0363546506294078
   Sanjabi S, 2009, CURR OPIN PHARMACOL, V9, P447, DOI 10.1016/j.coph.2009.04.008
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   Tare RS, 2010, P I MECH ENG H, V224, P1455, DOI 10.1243/09544119JEIM750
   Tojima H, 2012, HEPATOL INT, V6, P620, DOI 10.1007/s12072 011 9301 z
   Uggeri J, 2007, J PERIODONTOL, V78, P1985, DOI 10.1902/jop.2007.070116
   Verrier S, 2010, EUR CELLS MATER, V20, P403
   Woo EJ, 2012, J ORAL MAXIL SURG, V70, P765, DOI 10.1016/j.joms.2011.09.008
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
NR 49
TC 86
Z9 96
U1 0
U2 19
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611 2690 USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD AUG
PY 2013
VL 84
IS 8
BP 1180
EP 1190
DI 10.1902/jop.2012.120292
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 275NW
UT WOS:000328685100017
PM 23088531
DA 2025 08 17
ER

PT J
AU Naseri, Z
   Oskuee, RK
   Jaafari, MR
   Moghadam, MF
AF Naseri, Zahra
   Oskuee, Reza Kazemi
   Jaafari, Mahmoud Reza
   Moghadam, Mehdi Forouzandeh
TI Exosome mediated delivery of functionally active miRNA 142 3p inhibitor
   reduces tumorigenicity of breast cancer in vitro and in vivo
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE MSCs derived exosomes; tumor tropism; Wnt/beta catenin signaling
   pathway; breast cancer; LNA antimiR 142 3p
ID MESENCHYMAL STEM CELL; EXTRACELLULAR VESICLES; DRUG DELIVERY;
   BIODISTRIBUTION; MICRORNAS; THERAPEUTICS; MECHANISM; TRACKING; PROGRESS
AB Background: Exosomes, widely recognized natural nanovesicles, represent one of the recently discovered modes of intercellular communication due to their ability to transmit crucial cellular information that can be engineered to have robust delivery and targeting capacity. MiR 142 3p, one of the upregulated microRNAs (miRNAs) in many types of breast cancer, activates the canonical Wnt signaling pathway and transactivates the miR 150 expression, and results in the hyperproliferation of cancer cells in vitro and mammary glands in vivo.
   Materials and methods: In this study, we exploited the exosomes isolated from bone marrow derived mesenchymal stem cells (MSCs Exo) to deliver LNA (locked nucleic acid) modified anti miR 142 3p oligonucleotides to suppress the expression level of miR 142 3p and miR 150 in 4T1 and TUBO breast cancer cell lines.
   Results: The in vitro results showed that the MSCs Exo can efficiently deliver anti miR 142 3p to reduce the miR 142 3p and miR 150 levels and increase the transcription of the regulatory target genes, APC and P2X7R. We also evaluated in vivo distribution of the MSCs Exo in tumor bearing mice. The in vivo result indicated that MSCs Exo can penetrate the tumor site and are suitable nanovehicles to deliver the inhibitory oligonucleotides into the tumor tissues to downregulate the expression levels of miR 142 3p and miR 150.
   Conclusion: We showed that MSCs derived exosomes could be used as a feasible nanovehicle to deliver drug molecules like LNA anti miR 142 3p in both in vitro and in vivo studies.
C1 [Naseri, Zahra] Mashhad Univ Med Sci, Sch Med, Dept Med Biotechnol, Mashhad, Iran.
   [Oskuee, Reza Kazemi] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Iran.
   [Jaafari, Mahmoud Reza] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran.
   [Jaafari, Mahmoud Reza] Mashhad Univ Med Sci, Sch Pharm, Dept Pharmaceut Nanotechnol, POB 91775 1365, Mashhad, Iran.
   [Moghadam, Mehdi Forouzandeh] Tarbiat Modares Univ, Dept Med Biotechnol, Fac Med Sci, Jalal Ale Ahmad Highway,POB 14115 331, Tehran, Iran.
C3 Mashhad University of Medical Sciences; Mashhad University of Medical
   Sciences; Mashhad University of Medical Sciences; Mashhad University of
   Medical Sciences; Tarbiat Modares University
RP Jaafari, MR (通讯作者)，Mashhad Univ Med Sci, Sch Pharm, Dept Pharmaceut Nanotechnol, POB 91775 1365, Mashhad, Iran.; Moghadam, MF (通讯作者)，Tarbiat Modares Univ, Dept Med Biotechnol, Fac Med Sci, Jalal Ale Ahmad Highway,POB 14115 331, Tehran, Iran.
EM jafarimr@mums.ac.ir; foroz@modares.ac.ir
RI Oskuee, Reza/E 6336 2012; Forouzandeh Moghadam, Mehdi/JVP 1787 2024
OI Jaafari, Mahmoud Reza/0000 0003 3908 6828; 
FU Mashhad University of Medical Sciences; Tarbiat Modares University,
   Tehran [931289]; Cancer Research Center of Cancer Institute of Iran
   (Shams Cancer Charity) [37604 202 01 97]
FX This research was funded by Mashhad University of Medical Sciences and
   Tarbiat Modares University, Tehran (no. 931289), and a grant from Cancer
   Research Center of Cancer Institute of Iran (Shams Cancer Charity, grant
   no. 37604 202 01 97). We are grateful to our colleagues and PhD
   students, for their help and support during this work, in the Department
   of Medical Biotechnology, Faculty of Medical Sciences, at Tarbiat
   Modares University, Tehran.
CR Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005
   Alvarez Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Bala S, 2015, SCI REP UK, V5, DOI 10.1038/srep10721
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008
   Dai S, 2008, MOL THER, V16, P782, DOI 10.1038/mt.2008.1
   Grange C, 2014, INT J MOL MED, V33, P1055, DOI 10.3892/ijmm.2014.1663
   Greco SJ, 2012, THER DELIV, V3, P997, DOI 10.4155/TDE.12.69
   Greish K, 2010, METHODS MOL BIOL, V624, P25, DOI 10.1007/978 1 60761 609 2_3
   Hu TY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158432
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Johnsen KB, 2014, BBA REV CANCER, V1846, P75, DOI 10.1016/j.bbcan.2014.04.005
   Kim SH, 2007, J IMMUNOL, V179, P2242, DOI 10.4049/jimmunol.179.4.2242
   Kooijmans SAA, 2016, PHARMACOL RES, V111, P487, DOI 10.1016/j.phrs.2016.07.006
   Lai RC, 2015, SEMIN CELL DEV BIOL, V40, P82, DOI 10.1016/j.semcdb.2015.03.001
   Lakhal S, 2011, BIOESSAYS, V33, P737, DOI 10.1002/bies.201100076
   Lam P. Y. P, 2013, STEM CELL THERAPEUTI, P21, DOI [10.1002/9781118660423.ch3, DOI 10.1002/9781118660423.CH3]
   Lee HK, 2013, ONCOTARGET, V4, P346, DOI 10.18632/oncotarget.868
   Lee JK, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0084256, 10.1371/journal.pone.0066555]
   Liu YG, 2011, BIOCHEM BIOPH RES CO, V408, P259, DOI 10.1016/j.bbrc.2011.04.009
   Lötvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   McLellan AD, 2009, CRIT REV IMMUNOL, V29, P203, DOI 10.1615/CritRevImmunol.v29.i3.20
   Mead B, 2017, STEM CELL TRANSL MED, V6, P1273, DOI 10.1002/sctm.16 0428
   Momen Heravi F, 2014, NANOMED NANOTECHNOL, V10, P1517, DOI 10.1016/j.nano.2014.03.014
   Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641
   Munoz JL, 2013, MOL THER NUCL ACIDS, V2, DOI 10.1038/mtna.2013.60
   Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180
   Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44
   Ren JH, 2016, BIOMATER SCI UK, V4, P910, DOI 10.1039/c5bm00583c
   Smyth T, 2015, J CONTROL RELEASE, V199, P145, DOI 10.1016/j.jconrel.2014.12.013
   Sokolova V, 2011, COLLOID SURFACE B, V87, P146, DOI 10.1016/j.colsurfb.2011.05.013
   Stenvang Jan, 2012, Silence, V3, P1, DOI 10.1186/1758 907X 3 1
   Takahashi Y, 2013, J BIOTECHNOL, V165, P77, DOI 10.1016/j.jbiotec.2013.03.013
   Tan A, 2013, ADV DRUG DELIVER REV, V65, P357, DOI 10.1016/j.addr.2012.06.014
   Tian TA, 2010, J CELL BIOCHEM, V111, P488, DOI 10.1002/jcb.22733
   Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van Dommelen SM, 2012, J CONTROL RELEASE, V161, P635, DOI 10.1016/j.jconrel.2011.11.021
   Vlassov AV, 2012, BBA GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Wu XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079975
   Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001
   Yu B, 2014, INT J MOL SCI, V15, P4142, DOI 10.3390/ijms15034142
   Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020
   Zhang Y, 2013, J CONTROL RELEASE, V172, P962, DOI 10.1016/j.jconrel.2013.09.015
   Zhu L, 2014, WORLD J GASTROENTERO, V20, P6651, DOI 10.3748/wjg.v20.i21.6651
NR 45
TC 205
Z9 216
U1 2
U2 58
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2018
VL 13
BP 7727
EP 7747
DI 10.2147/IJN.S182384
PG 21
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA HB7JF
UT WOS:000451253100002
PM 30538455
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jiang, PF
   Zhang, PY
   Mukthavaram, R
   Nomura, N
   Pingle, SC
   Teng, DY
   Chien, S
   Guo, F
   Kesari, S
AF Jiang, Pengfei
   Zhang, Peiying
   Mukthavaram, Rajesh
   Nomura, Natsuko
   Pingle, Sandeep C.
   Teng, Dayu
   Chien, Shu
   Guo, Fang
   Kesari, Santosh
TI Anti cancer effects of nitrogen containing bisphosphonates on human
   cancer cells
SO ONCOTARGET
LA English
DT Article
DE glioblastoma; bisphosphonates; zoledronic acid; cancer therapy;
   autophagy
ID ZOLEDRONIC ACID; MEVALONATE PATHWAY; BONE METASTASES; BREAST CANCER;
   PROTEIN FARNESYLTRANSFERASE; RAB PRENYLATION; PROSTATE CANCER;
   LUNG CANCER; IN VITRO; GROWTH
AB Zoledronic acid, a potent nitrogen containing bisphosphonate (NBP), has been extensively used to limit bone turnover in a various diseases including tumors. Recent clinical studies have demonstrated direct anti cancer effects of zoledronic acid, in addition to its clinical benefits for skeletal related events. Here we investigated the effects of 4 clinically available NBPs on human tumor cell proliferation. Our data demonstrate a potent anti proliferative effect of zoledronic acid against glioblastoma (GBM) cell lines, breast cancer cells and GBM patient derived lines. Zoledronic acid also effectively inhibited GBM tumor growth in xenograft mouse models. Zoledronic acid strongly stimulated autophagy but not apoptotic signals in all tested cells. Only one intermediate product of cholesterols synthesis pathway, geranylgeranyl diphosphate (GGPP) rescued cells from the cytotoxic effects of zoledronic acid. To further investigate the effect of GGPP, we knocked down RABGGTA, which encodes a subunit of the Rabgeranylgeranyltransferase protein. This knockdown induced an effect similar to zoledronic acid in cancer cell lines. These data are promising and suggested a potential for zoledronic acid as an anti cancer agent, through its ablation of the function of Rab proteins.
C1 [Jiang, Pengfei; Mukthavaram, Rajesh; Nomura, Natsuko; Pingle, Sandeep C.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
   [Zhang, Peiying] Nanjing Univ Chinese Med, Southeast Univ, Xuzhou Clin Sch,Xuzhou Med Coll,Xuzhou Clin Med C, Dept Cardiol,Xuzhou Cent Hosp,Affiliated XuZhou H, Xuzhou 221009, Jiangsu, Peoples R China.
   [Teng, Dayu; Chien, Shu] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
   [Guo, Fang] Chinese Acad Sci, Shanghai Adv Res Inst, Key Lab Syst Biol, Shanghai 201210, Peoples R China.
   [Kesari, Santosh] John Wayne Canc Inst, Dept Translat Neurooncol & Neurotherapeut, Santa Monica, CA 90404 USA.
   [Kesari, Santosh] Providence St Johns Hlth Ctr, Pacific Neurosci Inst, Santa Monica, CA 90404 USA.
   [Teng, Dayu; Chien, Shu] Univ Calif San Diego, Inst Engn Med, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   Xuzhou Medical University; Nanjing University of Chinese Medicine;
   Southeast University   China; University of California System;
   University of California San Diego; Chinese Academy of Sciences;
   Shanghai Advanced Research Institute, CAS; John Wayne Cancer Institute;
   John Wayne Cancer Institute; University of California System; University
   of California San Diego
RP Jiang, PF (通讯作者)，Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
EM jiangpf1@gmail.com; kesaris@jwci.org
RI JIANG, PENGFEI/JCP 2151 2023; Guo, Fang/L 2273 2017; Kesari,
   Santosh/E 8461 2013
CR Almubarak Hussain, 2011, J Carcinog, V10, P2, DOI 10.4103/1477 3163.75723
   Alonso Curbelo D, 2014, CANCER CELL, V26, P61, DOI 10.1016/j.ccr.2014.04.030
   Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151
   Cimini E, 2011, INT J IMMUNOPATH PH, V24, P139, DOI 10.1177/039463201102400116
   Clendening JW, 2010, P NATL ACAD SCI USA, V107, P15051, DOI 10.1073/pnas.0910258107
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Costa L, 2011, CRIT REV ONCOL HEMAT, V77, pS31, DOI 10.1016/S1040 8428(11)70006 3
   de la Piedra C, 2013, BRIT J CANCER, V108, P2565, DOI 10.1038/bjc.2013.270
   De Marinis F, 2009, J THORAC ONCOL, V4, P1280, DOI 10.1097/JTO.0b013e3181b68e5a
   Deraeve C, 2012, J AM CHEM SOC, V134, P7384, DOI 10.1021/ja211305j
   Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697
   Dong WW, 2012, WORLD J GASTROENTERO, V18, P1806, DOI 10.3748/wjg.v18.i15.1806
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580
   El Oualid F, 2006, CURR MED CHEM, V13, P2385, DOI 10.2174/092986706777935078
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Guo RT, 2007, P NATL ACAD SCI USA, V104, P10022, DOI 10.1073/pnas.0702254104
   Holen I, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2769
   Huang HL, 2015, CANCER LETT, V362, P15, DOI 10.1016/j.canlet.2015.03.004
   Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795
   Jiang P, 2014, BRIT J CANCER, V111, P1562, DOI 10.1038/bjc.2014.431
   Jiang PF, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 13
   Kast RE, 2013, ONCOTARGET, V4, P502, DOI 10.18632/oncotarget.969
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103
   Lacerna L, 2003, SEMIN ONCOL, V30, P150, DOI 10.1053/j.seminoncol.2003.08.017
   Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289
   Lee MV, 2001, CANCER RES, V61, P2602
   Li Q, 2015, CANC TRANSL MED, V1, P176
   Marschalek N, 2015, J NEUROCHEM, V133, P153, DOI 10.1111/jnc.12959
   Massy ZA, 1999, KIDNEY INT, V56, pS80, DOI 10.1038/sj.ki.4495407
   No JH, 2012, P NATL ACAD SCI USA, V109, P4058, DOI 10.1073/pnas.1118215109
   Oades GM, 2002, PROSTATE CANCER P D, V5, P264, DOI 10.1038/sj.pcan.4500607
   OHIZUMI H, 1995, J BIOCHEM TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695
   Okamoto S, 2012, J THORAC ONCOL, V7, P873, DOI 10.1097/JTO.0b013e31824c7d43
   Rauthan M, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476 511X 10 243
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092 8674(91)90460 G
   Stenmark H, 2001, GENOME BIOL, V2
   Stigter EA, 2012, J MED CHEM, V55, P8330, DOI 10.1021/jm300624s
   Terry KL, 2006, BIOCHEMISTRY US, V45, P9746, DOI 10.1021/bi060295e
   Wang JS, 2008, MOL CANCER RES, V6, P372, DOI 10.1158/1541 7786.MCR 07 0162
   Wang QQ, 2015, MED ONCOL, V32, DOI 10.1007/s12032 014 0372 2
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   Zhang Q, 2002, HUM MOL GENET, V11, P697, DOI 10.1093/hmg/11.6.697
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 49
TC 19
Z9 21
U1 1
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 6
PY 2016
VL 7
IS 36
BP 57932
EP 57942
DI 10.18632/oncotarget.10773
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EB1YP
UT WOS:000387153200037
PM 27462771
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Harslof, T
   Langdahl, BL
AF Harslof, Torben
   Langdahl, Bente L.
TI New horizons in osteoporosis therapies
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID CATHEPSIN K INHIBITOR; BONE MINERAL DENSITY; PARATHYROID HORMONE;
   POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; TERIPARATIDE; ALENDRONATE;
   ODANACATIB; FRACTURES; ABALOPARATIDE
AB Efficient therapies are available for the treatment of osteoporosis, however, there are still unmet needs. Anti resorptive therapies only increase bone mineral density to a certain extent and reduce the risk of non vertebral fractures by 20%, only one anabolic option is available the effect of which levels off over time, and the evidence for combination therapy targeting both resorption and formation is limited. The current review will focus on emerging treatments of osteoporosis with the potential of enhanced anabolic effects (romosozumab and abaloparatide) or uncoupling of resorption and formation (odanacatib and romosozumab) as well as the effect of combination therapy.
C1 [Harslof, Torben; Langdahl, Bente L.] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Tage Hansens Gade 2, DK 8000 Aarhus C, Denmark.
C3 Aarhus University
RP Langdahl, BL (通讯作者)，Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Tage Hansens Gade 2, DK 8000 Aarhus C, Denmark.
EM bente.langdahl@aarhus.rm.dk
FU Amgen; UCB; Eli Lilly; Merck, Sharp Dohme; Novo Nordisk; Orkla Health
FX Torben Harslof has received lecturing fees from Amgen. Bente Langdahl
   serves on advisory boards for and has received lecturing fees from
   Amgen, UCB, Eli Lilly and Merck, Sharp & Dohme and has received research
   funding from Eli Lilly, Novo Nordisk and Orkla Health.
CR [Anonymous], ARCH OSTEOPOROS
   Atkins GJ, 2012, OSTEOPOROSIS INT, V23, P2067, DOI 10.1007/s00198 012 1915 z
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Culler M, 2001, J BONE MINER RES  S1, V16, pM460
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   Ferrari S, 2014, BEST PRACT RES CL EN, V28, P859, DOI 10.1016/j.beem.2014.08.002
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fitzpatrick L, 2015, J BONE MINER RES, P30
   Gasser J. A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P53
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941
   Kado DM, 1999, ARCH INTERN MED, V159, P1215, DOI 10.1001/archinte.159.11.1215
   Kannegaard PN, 2010, AGE AGEING, V39, P203, DOI 10.1093/ageing/afp221
   Langdahl BL, 2011, THER ADV MUSCULOSKEL, V3, P17, DOI 10.1177/1759720X10392105
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   McClung M, 2015, BONEKEY, P13
   McClung M, 2014, J BONE MINER RES, V29
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Miller P, 2015, BONEKEY, P13
   Nakamura T, 2014, OSTEOPOROSIS INT, V25, P367, DOI 10.1007/s00198 013 2398 2
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orwoll E, 2014, J BONE MINER RES, P339
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Walker MD, 2013, ENDOCRINE, V44, P237, DOI 10.1007/s12020 012 9819 4
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
NR 40
TC 29
Z9 34
U1 1
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2016
VL 28
BP 38
EP 42
DI 10.1016/j.coph.2016.02.012
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DM4QM
UT WOS:000376331800007
PM 26989807
DA 2025 08 17
ER

PT J
AU Rajnish, RK
   Elhence, A
   Jha, SS
   Dhanasekararaja, P
AF Rajnish, Rajesh Kumar
   Elhence, Abhay
   Jha, S. S.
   Dhanasekararaja, Palanisami
TI Pain Management in Osteoporosis
SO INDIAN JOURNAL OF ORTHOPAEDICS
LA English
DT Article
DE Osteoporosis; Fragility fracture; Osteoporotic fracture; Chronic pain;
   Osteoporotic pain treatment
ID BONE MINERAL DENSITY; VERTEBRAL COMPRESSION FRACTURES; POSTMENOPAUSAL
   WOMEN; STRONTIUM RANELATE; TREATING ACUTE; BACK PAIN; EFFICACY;
   CALCITONIN; RISK; REHABILITATION
AB The most prevalent metabolic bone disease, osteoporosis, is characterized by a decrease in bone mineral density and alterations to the bone's microstructure, both of which can result in fragility fractures. It affects a significant section of the population. Acute or chronic pain from these fractures is typical in elderly adults with other coexisting conditions. Since the antiresorptive medication only partially reduces pain, other analgesics are required for effective pain management. NSAIDs or selective COX 2 inhibitors can reduce acute pain, but persistent neuropathic pain is difficult to manage with these drugs. Opioids have their adverse effects and safety concerns, although they can be used to address acute or chronic pain. Hence, a multifaceted approach is to be implemented, including pharmacological and nonpharmacological therapy and surgical treatment in a selected number of cases. This chapter briefly describes the etiology of pain, its mechanism, and pain management in osteoporotic patients.
C1 [Rajnish, Rajesh Kumar; Elhence, Abhay] All India Inst Med Sci, Dept Orthopaed, Jodhpur, India.
   [Jha, S. S.] Harishchandra Inst Orthoped & Res, Patna, India.
   [Dhanasekararaja, Palanisami] Ganga Hosp, Dept Orthopaed, 313 Mettupalayam Rd, Coimbatore 641043, India.
C3 All India Institute of Medical Sciences (AIIMS) Jodhpur
RP Rajnish, RK (通讯作者)，All India Inst Med Sci, Dept Orthopaed, Jodhpur, India.
EM duktiraj@gmail.com; abhayelhence@gmail.com; drssjha@gmail.com;
   dhanasekararaja@gmail.com
RI Rajnish, Rajesh/AAX 4511 2020; ELHENCE, ABHAY/LEM 1584 2024; Rajnish,
   Rajesh kumar/AAX 4511 2020; Jha, Shiva Shankar/JQV 3316 2023
OI Rajnish, Rajesh kumar/0000 0002 2080 2612; 
CR Abdelaziz DM, 2015, BONE, V81, P400, DOI 10.1016/j.bone.2015.08.001
   Angin E, 2015, J BACK MUSCULOSKELET, V28, P849, DOI 10.3233/BMR 150604
   Bannuru RR, 2010, OSTEOARTHR CARTILAGE, V18, pS250, DOI 10.1016/S1063 4584(10)60585 7
   Bataille C, 2012, BONE, V50, P1162, DOI 10.1016/j.bone.2012.01.023
   Bautmans I, 2010, J REHABIL MED, V42, P129, DOI 10.2340/16501977 0486
   Benedetti MG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4840531
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140 6736(13)60900 9
   Bistolfi F, 2007, NEURORADIOL J, V20, P676, DOI 10.1177/197140090702000612
   BJURHOLM A, 1988, J AUTONOM NERV SYST, V25, P119, DOI 10.1016/0165 1838(88)90016 1
   Boucher E, 2020, CAN J EMERG MED, V22, P359, DOI 10.1017/cem.2019.490
   Cianferotti L, 2013, THER ADV MUSCULOSKEL, V5, P127, DOI 10.1177/1759720X13483187
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   DAVIDOVITCH Z, 1988, DENT CLIN N AM, V32, P411
   Deardorff WJ, 2022, JAMA INTERN MED, V182, P33, DOI 10.1001/jamainternmed.2021.6745
   Dursun N, 2001, INT J CLIN PRACT, V55, P505
   Ehde DM, 2014, AM PSYCHOL, V69, P153, DOI 10.1037/a0035747
   Eide PK, 2000, EUR J PAIN, V4, P5, DOI 10.1053/eujp.1999.0154
   Eimar H, 2013, J MUSCULOSKEL NEURON, V13, P124
   Endo N, 2017, J BONE MINER METAB, V35, P375, DOI 10.1007/s00774 016 0765 8
   Gregg EW, 1998, ANN INTERN MED, V129, P81, DOI 10.7326/0003 4819 129 2 199807150 00002
   He JY, 2011, AGEING RES REV, V10, P253, DOI 10.1016/j.arr.2011.01.002
   Hou YC, 2018, CLIN CHIM ACTA, V484, P179, DOI 10.1016/j.cca.2018.05.035
   Howe TE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000333, 10.1002/14651858.CD000333.pub2]
   Macías Hernández SI, 2015, REV INVEST CLIN, V67, P98
   Iwamoto J, 2005, AGING CLIN EXP RES, V17, P157
   Iwamoto J, 2011, OSTEOPOROSIS INT, V22, P2735, DOI 10.1007/s00198 010 1495 8
   Jimenez Andrade JM, 2012, NEUROBIOL AGING, V33, P921, DOI 10.1016/j.neurobiolaging.2010.08.008
   Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kanis JA, 2008, BONE, V42, P467, DOI 10.1016/j.bone.2007.11.001
   Karachalios TS, 2020, HIP INT, V30, P370, DOI 10.1177/1120700019883244
   Kaufman JM, 2013, J CLIN ENDOCR METAB, V98, P592, DOI 10.1210/jc.2012 3048
   Kim David H, 2006, Spine J, V6, P479, DOI 10.1016/j.spinee.2006.04.013
   Knopp JA, 2005, OSTEOPOROSIS INT, V16, P1281, DOI 10.1007/s00198 004 1798 8
   Knopp Sihota JA, 2012, OSTEOPOROSIS INT, V23, P17, DOI 10.1007/s00198 011 1676 0
   Koivisto K, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 64
   Kress HG, 2016, CURR MED RES OPIN, V32, P23, DOI 10.1185/03007995.2015.1100986
   Labianca R, 2012, CLIN DRUG INVEST, V32, P53, DOI 10.2165/11630080 000000000 00000
   Lange U, 2005, RHEUMATOL INT, V26, P99, DOI 10.1007/s00296 004 0528 z
   Lee CH, 2015, J ALTERN COMPLEM MED, V21, P754, DOI 10.1089/acm.2015.0119
   Lerner U. H., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P154
   Lolascon G, 2012, CLIN CASES MINER BON, V9, P161
   Negri AL, 2012, CLIN CASES MINER BON, V9, P166
   Maestú C, 2013, PAIN RES MANAG, V18, pE101, DOI 10.1155/2013/270183
   Manuele S, 2007, ARCH GERONTOL GERIAT, V44, P249, DOI 10.1016/j.archger.2007.01.034
   Mears SC, 2013, CURR GERIATR REP, V2, P99, DOI 10.1007/s13670 013 0044 7
   Mert T, 2017, BIOELECTROMAGNETICS, V38, P255, DOI 10.1002/bem.22038
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Nagae M, 2006, BONE, V39, P1107, DOI 10.1016/j.bone.2006.04.033
   Nevitt MC, 2006, OSTEOPOROSIS INT, V17, P273, DOI 10.1007/s00198 005 2013 2
   Ohtori S, 2010, J CLIN NEUROSCI, V17, P209, DOI 10.1016/j.jocn.2009.06.013
   ONeill TW, 1996, J BONE MINER RES, V11, P1010
   Oral A, 2013, EUR J PHYS REHAB MED, V49, P565
   Petranova T, 2014, BIOTECHNOL BIOTEC EQ, V28, P1127, DOI 10.1080/13102818.2014.967827
   Sanli I, 2020, EUR SPINE J, V29, P1553, DOI 10.1007/s00586 020 06391 x
   Scharla S, 2006, CURR MED RES OPIN, V22, P2393, DOI 10.1185/030079906X154097
   Schiller J, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657 016 0288 x
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   Sinaki M, 2005, OSTEOPOROSIS INT, V16, P1004, DOI 10.1007/s00198 004 1791 2
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tanna NK, 2022, OSTEOPORO SARCOPENIA, V8, P93, DOI 10.1016/j.afos.2022.09.003
   Tarantino U, 2013, AGING CLIN EXP RES, V25, pS93, DOI 10.1007/s40520 013 0097 7
   Tarantino U, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3213
   Vujasinovic Stupar N, 2010, SRP ARK CELOK LEK, V138, P56, DOI 10.2298/SARH1002056V
   Wells G, 1997, J RHEUMATOL, V24, P1230
   Yang J, 2020, J PAIN RES, V13, P411, DOI 10.2147/JPR.S244173
   Zylka MJ, 2005, NEURON, V45, P17, DOI 10.1016/j.neuron.2004.12.015
NR 68
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0019 5413
EI 1998 3727
J9 INDIAN J ORTHOP
JI Indian J. Orthop.
PD DEC
PY 2023
VL 57
IS SUPPL 1
SU 1
SI SI
BP 230
EP 236
DI 10.1007/s43465 023 01047 6
EA NOV 2023
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA HY4A3
UT WOS:001106048300002
PM 38107816
OA Green Published
DA 2025 08 17
ER

PT J
AU Döding, A
   Zimmermann, S
   Maghames, A
   Reimann, M
   Symmank, J
   Thürmer, M
   Gräler, MH
   Wolf, M
   Jacobs, C
   Koeberle, A
   Sigusch, B
   Schulze Späte, U
AF Doeding, Annika
   Zimmermann, Svenja
   Maghames, Ahmed
   Reimann, Michael
   Symmank, Judit
   Thuermer, Maria
   Graler, Markus H.
   Wolf, Michael
   Jacobs, Collin
   Koeberle, Andreas
   Sigusch, Bernd
   Schulze Spate, Ulrike
TI Immunometabolic capacities of nutritional fatty acids in regulation of
   inflammatory bone cell interaction and systemic impact of periodontal
   infection
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE bone remodeling; regeneration; lipids; inflammation; nutrition; bone
   loss; periodontal disease
ID STEAROYL COA DESATURASE 1; PALMITIC ACID; METABOLISM; ACCUMULATION;
   BIOMARKERS; DISEASE; OBESITY; STRESS; MICE
AB IntroductionNovel preventive strategies in periodontal disease target the bacterial induced inflammatory host response to reduce associated tissue destruction. Strategies focus on the modulation of tissue destroying inflammatory host response, particularly the reduction of inflammation and promotion of resolution. Thereby, nutrition is a potent immunometabolic non pharmacological intervention. Human studies have demonstrated the benefit of olive oil containing Mediterranean style diets (MDs), the main component of which being mono unsaturated fatty acid (FA) oleic acid (OA (C18:1)). Hence, nutritional OA strengthened the microarchitecture of alveolar trabecular bone and increased circulating pro resolving lipid mediators following bacterial inoculation with periodontal pathogen Porphyromonas gingivalis, contrary to saturated FA palmitic acid (PA (C16:0)), which is abundant in Western style diets. Additionally, the generalized distribution of inflammatory pathway mediators can occur in response to bacterial infection and compromise systemic tissue metabolism and bone homeostasis distant from the side of infection. Whether specific FA enriched nutrition and periodontal inoculation are factors in systemic pathology that can be immune modulatory targeted through dietary substitution is unknown and of clinical relevance.MethodsNormal weight C57BL/6 mice received OA or PA enriched diets (PA ED, OA ED, PA/OA ED) or a normal standard diet (n=12/group) for 16 weeks and were orally infected with P. gingivalis/placebo to induce periodontal disease. Using histomorphometry and LC MS/MS, systemic bone morphology, incorporated immunometabolic FA species, serological markers of bone metabolism, and stress response were determined in addition to bone cell inflammation and interaction in vitro.ResultsIn contrast to OA ED, PA ED reduced systemic bone microarchitecture paralleled by increased lipotoxic PA containing metabolite accumulation in bone. Substitution with OA reversed the bone destructive impact of PA, which was accompanied by reduced diacylglycerols (DAG) and saturated ceramide levels. Further, PA associated reduction in mineralization activity and concomitant pro inflammatory activation of primary osteoblasts were diminished in cultures where PA was replaced with OA, which impacted cellular interaction with osteoclasts. Additionally, PA ED increased osteoclast numbers in femurs in response to oral P. gingivalis infection, whereas OA ED reduced osteoclast occurrence, which was paralleled by serologically increased levels of the stress reducing lipokine PI(18:1/18:1).ConclusionOA substitution reverses the bone destructive and pro inflammatory effects of PA and eliminates incorporated lipotoxic PA metabolites. This supports Mediterranean style OA based diets as a preventive intervention to target the accumulation of PA associated lipotoxic metabolites and thereby supports systemic bone tissue resilience after oral bacterial P. gingivalis infection.
C1 [Doeding, Annika; Zimmermann, Svenja; Maghames, Ahmed; Reimann, Michael; Schulze Spate, Ulrike] Univ Hosp Jena, Dept Conservat Dent & Periodont, Sect Geriodont, Jena, Germany.
   [Symmank, Judit; Jacobs, Collin] Univ Hosp Jena, Dept Orthodont, Jena, Germany.
   [Thuermer, Maria; Koeberle, Andreas] Friedrich Schiller Univ Jena, Inst Pharm, Chair Pharmaceut & Med Chem, Jena, Germany.
   [Graler, Markus H.] Jena Univ Hosp, Ctr Mol Biomed CMB, Dept Anesthesiol & Intens Care Med, Jena, Germany.
   [Graler, Markus H.] Jena Univ Hosp, Ctr Sepsis Control & Care CSCC, Jena, Germany.
   [Wolf, Michael] Univ Hosp RWTH Aachen, Dept Orthodont, Aachen, Germany.
   [Koeberle, Andreas] Univ Innsbruck, Michael Popp Inst, Innsbruck, Austria.
   [Koeberle, Andreas] Univ Innsbruck, Ctr Mol Biosci Innsbruck CMBI, Innsbruck, Austria.
   [Sigusch, Bernd] Univ Hosp Jena, Dept Conservat Dent & Periodont, Jena, Germany.
C3 Friedrich Schiller University of Jena; Friedrich Schiller University of
   Jena; Friedrich Schiller University of Jena; Friedrich Schiller
   University of Jena; Friedrich Schiller University of Jena; RWTH Aachen
   University; RWTH Aachen University Hospital; University of Innsbruck;
   University of Innsbruck; Friedrich Schiller University of Jena
RP Schulze Späte, U (通讯作者)，Univ Hosp Jena, Dept Conservat Dent & Periodont, Sect Geriodont, Jena, Germany.
RI ; Jacobs, Collin/KMY 3514 2024; Koeberle, Andreas/ABC 5946 2021;
   Schulze Späte, Ulrike/K 6345 2018; Reimann, Michael/ADP 8460 2022;
   Gräler, Markus/ABH 1905 2021; Symmank, Judit/AAQ 7082 2021
OI Koeberle, Andreas/0000 0001 6269 5088; , Annika/0000 0003 2176 0722;
   Wolf, Michael/0000 0002 5882 3080; Symmank, Judit/0000 0001 9347 0172
FU The project was supported by the Interdisciplinary Center of Clinical
   Research of the Medical Faculty Jena (IZKF UKJ FF02), the German Federal
   Ministry of Education and Research (BMBF: 01EC1901B, Project 2),
   Foundation "Else Krouml;ner Fresenius Stiftung" [IZKF UKJ FF02];
   Interdisciplinary Center of Clinical Research of the Medical Faculty
   Jena [BMBF: 01EC1901B]; German Federal Ministry of Education and
   Research; Foundation "Else Krouml;ner Fresenius Stiftung" within the
   Graduate Program "Else Krouml;ner Promotionskolleg JSAM; Medical Faculty
   Jena (Doctoral Program) [512648189]; German Research Foundation; Open
   Access Publication Fund of the Thueringer Universitaets  und
   Landesbibliothek Jena
FX The project was supported by the Interdisciplinary Center of Clinical
   Research of the Medical Faculty Jena (IZKF UKJ FF02), the German Federal
   Ministry of Education and Research (BMBF: 01EC1901B, Project 2),
   Foundation "Else Kroener Fresenius Stiftung" within the Graduate Program
   "Else Kroener Promotionskolleg JSAM," Interdisciplinary Center of
   Clinical Research of the Medical Faculty Jena (Doctoral Program). We
   acknowledge support by the German Research Foundation Projekt Nr.
   512648189 and the Open Access Publication Fund of the Thueringer
   Universitaets & nbsp;und Landesbibliothek Jena.r The project was
   supported by the Interdisciplinary Center of Clinical Research of the
   Medical Faculty Jena (IZKF UKJ FF02), the German Federal Ministry of
   Education and Research (BMBF: 01EC1901B, Project 2), Foundation "Else
   Kroner Fresenius Stiftung" within the Graduate Program "Else Kroner
   Promotionskolleg JSAM," Interdisciplinary Center of Clinical Research of
   the Medical Faculty Jena (Doctoral Program). We acknowledge support by
   the German Research Foundation Projekt Nr. 512648189 and the Open Access
   Publication Fund of the Thueringer Universitaets  und Landesbibliothek
   Jena.
CR Abram M, 2000, MEDIAT INFLAMM, V9, P229, DOI 10.1080/09629350020025746
   Adamopoulos IE, 2018, CURR OPIN RHEUMATOL, V30, P59, DOI 10.1097/BOR.0000000000000449
   Alhassani AA, 2021, J CLIN PERIODONTOL, V48, P2, DOI 10.1111/jcpe.13380
   Alsahli A, 2016, CALCIFIED TISSUE INT, V98, P511, DOI 10.1007/s00223 015 0097 z
   Altun E, 2021, NUTRIENTS, V13, DOI 10.3390/nu13114167
   Alves CH, 2016, CLIN REV ALLERG IMMU, V51, P27, DOI 10.1007/s12016 015 8522 7
   Amend Sarah R, 2016, J Vis Exp, DOI 10.3791/53936
   Baker PJ, 2000, INFECT IMMUN, V68, P5864, DOI 10.1128/IAI.68.10.5864 5868.2000
   Bartha V, 2022, J CLIN PERIODONTOL, V49, P111, DOI 10.1111/jcpe.13576
   Baylin A, 2002, AM J CLIN NUTR, V76, P750, DOI 10.1093/ajcn/76.4.750
   Bekhite M, 2021, FREE RADICAL BIO MED, V167, P66, DOI 10.1016/j.freeradbiomed.2021.02.016
   Cai X, 2020, J PERIODONTAL RES, V55, P410, DOI 10.1111/jre.12725
   Cecoro G, 2020, MEDICINA LITHUANIA, V56, DOI 10.3390/medicina56060272
   Chapple ILC, 2018, J CLIN PERIODONTOL, V45, pS68, DOI 10.1111/jcpe.12940
   Clark JS, 2023, NUTRIENTS, V15, DOI 10.3390/nu15020366
   Clugston RD, 2011, J LIPID RES, V52, P2021, DOI 10.1194/jlr.M017368
   Cui YR, 2023, J PERIODONTOL, V94, P193, DOI 10.1002/JPER.22 0241
   Döding A, 2023, J CLIN PERIODONTOL, V50, P380, DOI 10.1111/jcpe.13751
   Dommisch H, 2018, PERIODONTOL 2000, V78, P129, DOI 10.1111/prd.12233
   Drosatos K, 2011, AM J PHYSIOL ENDOC M, V300, pE489, DOI 10.1152/ajpendo.00569.2010
   Drosatos Tampakaki Z, 2014, J BONE MINER RES, V29, P1183, DOI 10.1002/jbmr.2150
   du Sert NP, 2020, J CEREBR BLOOD F MET, V40, P1769, DOI [10.1186/s12917 020 02451 y, 10.1371/journal.pbio.3000410, 10.1177/0271678X20943823]
   El Kholy K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01300
   Fernandes J, 2020, NUTRITION, V69, DOI 10.1016/j.nut.2019.110559
   Forouhi NG, 2018, BMJ BRIT MED J, V361, DOI 10.1136/bmj.k2139
   Gillet C, 2015, ENDOCRINOLOGY, V156, P4081, DOI 10.1210/en.2015 1303
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Harmer D, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00788
   Huang YL, 2014, J BIOL CHEM, V289, P3001, DOI 10.1074/jbc.M113.524587
   Johnson CSC, 2021, ELIFE, V10, DOI 10.7554/eLife.68293
   Koeberle A, 2016, BBA MOL CELL BIOL L, V1861, P1719, DOI 10.1016/j.bbalip.2016.08.009
   Koeberle A, 2015, FASEB J, V29, P2439, DOI 10.1096/fj.14 268474
   Koeberle A, 2012, FASEB J, V26, P169, DOI 10.1096/fj.11 184879
   Korbecki J, 2019, INFLAMM RES, V68, P915, DOI 10.1007/s00011 019 01273 5
   Kruse AB, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 07989 5
   Li SY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.702661
   Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100
   Marruganti C, 2022, J PERIODONTOL, V93, P1218, DOI 10.1002/JPER.21 0643
   Martínez García M, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.709438
   Martinon P, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020197
   Muluke M, 2016, J DENT RES, V95, P223, DOI 10.1177/0022034515609882
   Phillips CM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081873
   Pinto RD, 2020, CURR PHARM DESIGN, V26, P2620, DOI 10.2174/1381612826666200403122600
   Rakian A, 2022, J DENT RES, V101, P1205, DOI 10.1177/00220345221090879
   Ramirez Tortosa MC, 2010, NUTR METAB CARDIOVAS, V20, P133, DOI 10.1016/j.numecd.2009.03.003
   Sanz M, 2020, J CLIN PERIODONTOL, V47, P4, DOI 10.1111/jcpe.13290
   Schulze Späte U, 2015, J CLIN ENDOCR METAB, V100, P2425, DOI 10.1210/jc.2014 4180
   Sergi D, 2020, NUTR NEUROSCI, V23, P321, DOI 10.1080/1028415X.2018.1501533
   Shively CA, 2019, OBESITY, V27, P777, DOI 10.1002/oby.22436
   Thürmer M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30374 9
   Tsigalou C, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8070201
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Varela López A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081202
   Wang CW, 2016, CURR OSTEOPOROS REP, V14, P284, DOI 10.1007/s11914 016 0330 3
   Woelber JP, 2019, J CLIN PERIODONTOL, V46, P481, DOI 10.1111/jcpe.13094
   Wolf TG, 2021, FRONT ORAL HEALTH, V2, DOI 10.3389/froh.2021.725460
   Zhang ZY, 2020, CURR MED SCI, V40, P753, DOI 10.1007/s11596 020 2243 8
NR 57
TC 5
Z9 5
U1 2
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 6
PY 2023
VL 14
AR 1213026
DI 10.3389/fimmu.2023.1213026
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA S7LU3
UT WOS:001072956100001
PM 37736098
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Park, MH
   Kim, S
   Cheon, J
   Lee, J
   Kim, BK
   Lee, SH
   Kong, C
   Kim, YY
   Kim, M
AF Park, Mi Hwa
   Kim, Seoyeon
   Cheon, Jihyeon
   Lee, Juyeong
   Kim, Bo Kyung
   Lee, Sang Hyeon
   Kong, Changsuk
   Kim, Yuck Yong
   Kim, Mihyang
TI Effects of Scytosiphon lomentaria on osteoblastic proliferation
   and differentiation of MC3T3 E1 cells
SO NUTRITION RESEARCH AND PRACTICE
LA English
DT Article
DE Scytosiphon lomentaria; MC3T3 E1 cell; differentiation; alkaline
   phosphatase; mineralization
ID IN VITRO; ALKALINE PHOSPHATASE; OSTEOCLAST DIFFERENTIATION; OXIDATIVE
   STRESS; BONE METABOLISM; OPG/RANKL RATIO; MINERALIZATION; EXPRESSION;
   OSTEOPOROSIS; MODEL
AB BACKGROUND/OBJECTIVES: Bone formation and bone resorption continuously occur in bone tissue to prevent the accumulation of old bone, this being called bone remodeling. Osteoblasts especially play a crucial role in bone formation through the differentiation and proliferation. Therefore, in this study, we investigated the effects of Scytosiphon lomentaria extract (SLE) on osteoblastic proliferation and differentiation in MC3T3 E1 cells.
   MATERIALS/METHODS: A cell proliferation assay, alkaline phosphatase (ALP) activity assay, alizarin red staining and protein expression analysis of osteoblastic genes were carried out to assess the osteoblastic proliferation and differentiation.
   RESULTS: The results indicated that treatment of SLE promoted the proliferation of MC3T3 E1 cells and improved ALP activity. And, SLE treatment significantly promoted mineralized nodule formation compared with control. In addition, cells treated with SLE significantly upregulated protein expression of ALP, type 1 collagen, bone morphogenetic protein 2, runt related transcription factor 2, osterix, and osteoprotegerin.
   CONCLUSIONS: The results demonstrate that SLE promote differentiation inducement and proliferation of osteoblasts and, therefore may help to elucidate the transcriptional mechanism of bone formation and possibly lead to the development of bone forming drugs.
C1 [Park, Mi Hwa; Kim, Seoyeon; Cheon, Jihyeon; Lee, Juyeong; Kim, Bo Kyung; Kong, Changsuk; Kim, Mihyang] Silla Univ, Dept Food & Nutr, Coll Med & Life Sci, 140 Baegyang Daero,700beon Gil, Busan 46958, South Korea.
   [Lee, Sang Hyeon] Silla Univ, Dept Pharmaceut Engn, Coll Med & Life Sci, Busan 46958, South Korea.
   [Kim, Yuck Yong] ISFOOD Co LTD, 7 Hoenggye Gil, Busan 46048, South Korea.
C3 Silla University; Silla University
RP Kim, M (通讯作者)，Silla Univ, Dept Food & Nutr, Coll Med & Life Sci, 140 Baegyang Daero,700beon Gil, Busan 46958, South Korea.
EM mihkim@silla.ac.kr
RI Kim, Kwang il/AAP 7315 2021
OI Park, Mi Hwa/0000 0002 3123 2870
FU Human Resource Training Program for Regional Innovation through the
   Ministry of Education; National Research Foundation of Korea
   [NRF 2013H1B8A2032201]
FX This work was supported by the Human Resource Training Program for
   Regional Innovation through the Ministry of Education and National
   Research Foundation of Korea (NRF 2013H1B8A2032201).
CR Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   Chandini SK, 2008, FOOD CHEM, V107, P707, DOI 10.1016/j.foodchem.2007.08.081
   Demirel Z, 2009, J SERB CHEM SOC, V74, P619, DOI 10.2298/JSC0906619D
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Glial W W., 1999, FOLIA MORPHOL WARSZ, V58, P155
   Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849
   HORIGUCHI Y, 1991, INFECT IMMUN, V59, P1112, DOI 10.1128/IAI.59.3.1112 1116.1991
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Huang WB, 2002, EXP CELL RES, V274, P226, DOI 10.1006/excr.2002.5483
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   Kühn MC, 2012, MOL CELL ENDOCRINOL, V349, P180, DOI 10.1016/j.mce.2011.10.018
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Li F, 2012, FITOTERAPIA, V83, P1443, DOI 10.1016/j.fitote.2012.08.008
   Liu ZP, 2005, J MED FOOD, V8, P14, DOI 10.1089/jmf.2005.8.14
   Michaëlsson K, 2005, ARCH INTERN MED, V165, P1825, DOI 10.1001/archinte.165.16.1825
   Musial Kinga, 2008, Pol Merkur Lekarski, V24 Suppl 4, P25
   NAKAMURA T, 1994, FISHERIES SCI, V60, P793, DOI 10.2331/fishsci.60.793
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Niu YB, 2012, OSTEOPOROSIS INT, V23, P2649, DOI 10.1007/s00198 012 1932 y
   O'Gorman DM, 2012, PHYTOTHER RES, V26, P375, DOI 10.1002/ptr.3561
   Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600 079X.2011.00875.x
   PECK WA, 1993, AM J MED, V94, P646
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Rassi CM, 2002, J BONE MINER RES, V17, P630, DOI 10.1359/jbmr.2002.17.4.630
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SLEMENDA CW, 1991, J BONE MINER RES, V6, P561
   TIETZ NW, 1983, CLIN CHEM, V29, P751
   WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439
   Yonezawa T, 2011, EUR J PHARMACOL, V650, P511, DOI 10.1016/j.ejphar.2010.10.048
   Yoon HJ, 2013, NUTR RES, V33, P1053, DOI 10.1016/j.nutres.2013.08.004
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
NR 35
TC 10
Z9 10
U1 0
U2 14
PU KOREAN NUTRITION SOC
PI SEOUL
PA 804 KST CTR, 635 4 YEOGSAM SONG KANGNAM KU, SEOUL, 135 703, SOUTH KOREA
SN 1976 1457
EI 2005 6168
J9 NUTR RES PRACT
JI Nutr. Res. Pract.
PD APR
PY 2016
VL 10
IS 2
BP 148
EP 153
DI 10.4162/nrp.2016.10.2.148
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA DI5QF
UT WOS:000373553000003
PM 27087897
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Zhang, WF
   Guo, C
   Yao, DB
   Lan, WQ
   Zhou, M
   Huang, ZH
   Kong, QQ
AF Zhang, Weifei
   Guo, Chuan
   Yao, Dengbo
   Lan, Weiqiang
   Zhou, Mi
   Huang, Zhangheng
   Kong, Qingquan
TI Effects and mechanisms of berberine loaded tetrahedral framework nucleic
   acids on osteoporosis
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID MESENCHYMAL STEM CELLS; DIFFERENTIATION
AB Osteoporosis is a disease that plagues the world, the complications of which, spinal fractures and hip fractures, seriously endanger the health of the elderly. At present, the main treatment for osteoporosis is anti osteoporosis drugs, some of which, however, have poor efficacy and side effects. Thus, the development of new drugs for the treatment of osteoporosis is of clinical significance. Berberine (BBR) has a good therapeutic effect on osteoporosis, but its poor solubility and instability limit its effect. Tetrahedral framework nucleic acids (tFNAs) are a novel nano drug delivery tool, and their good cell entry ability and stability make them an excellent carrier. Therefore, a new nanocomplex T BBR was synthesized by carrying BBR with tFNAs. Compared with BBR, T BBR showed better osteogenic and anti osteoporosis abilities in both in vivo and in vitro experiments, the mechanism of which was realized through the Wnt signaling pathway.
   A new nanocomplex T BBR was synthesized by carrying BBR with tFNAs. Compared with BBR, T BBR showed better osteogenic and anti osteoporosis abilities in both in vivo and in vitro experiments through the Wnt/beta catenin signaling pathway.
C1 [Zhang, Weifei; Guo, Chuan; Yao, Dengbo; Lan, Weiqiang; Kong, Qingquan] Sichuan Univ, West China Hosp, Orthoped Res Inst, Dept Orthoped Surg, Chengdu 610041, Sichuan, Peoples R China.
   [Zhou, Mi] Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Huang, Zhangheng] Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthopaed spine Surg, Wenzhou, Zhejiang, Peoples R China.
   [Kong, Qingquan] Hosp Chengdu Off Peoples Govt Tibetan Autonomous R, Dept Orthoped Surg, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Wenzhou Medical University
RP Kong, QQ (通讯作者)，Sichuan Univ, West China Hosp, Orthoped Res Inst, Dept Orthoped Surg, Chengdu 610041, Sichuan, Peoples R China.; Zhou, M (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Huang, ZH (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthopaed spine Surg, Wenzhou, Zhejiang, Peoples R China.; Kong, QQ (通讯作者)，Hosp Chengdu Off Peoples Govt Tibetan Autonomous R, Dept Orthoped Surg, Chengdu, Sichuan, Peoples R China.
EM zhoumi731@scu.edu.cn; hzh1319330149@sina.com; kqqspine@126.com
RI Huang, Zhangheng/HHD 0371 2022; zhang, weifei/AEG 8653 2022; Kong,
   qingquan/IXN 4311 2023
FU National Natural Science Foundation of China [82372447, 82202747];
   National Natural Science Foundation of China [XZ202201ZD0001G]; Science
   and Technology Major Project of Tibetan Autonomous Region of China
   [XZ202303ZY0007G, 1<middle dot>3<middle dot>]; Science and technology
   project of Tibet Autonomous Region [ZYJC21026, ZYJC21077]; West China
   Hospital, Sichuan University [2024HXBH160]; Postdoctor Research Fund of
   West China Hospital, Sichuan University
FX This work was supported by The National Natural Science Foundation of
   China (82372447, 82202747), Science and Technology Major Project of
   Tibetan Autonomous Region of China (XZ202201ZD0001G), Science and
   technology project of Tibet Autonomous Region (XZ202303ZY0007G),
   1<middle dot>3<middle dot>5 Project for Disciplines of Excellence, West
   China Hospital, Sichuan University (ZYJC21026, ZYJC21077). Postdoctor
   Research Fund of West China Hospital, Sichuan University, 2024HXBH160.
   Postdoctor Research Fund of West China Hospital, Sichuan University,
   2024HXBH160.
CR Adil M, 2017, BIOMED PHARMACOTHER, V94, P1010, DOI 10.1016/j.biopha.2017.08.001
   Bai L, 2024, ADV FUNCT MATER, V34, DOI 10.1002/adfm.202314789
   Bai L, 2023, CHEM ENG J, V472, DOI 10.1016/j.cej.2023.144978
   Chen QC, 2021, J BONE MINER METAB, V39, P748, DOI 10.1007/s00774 021 01225 2
   Clemence BF, 2024, POLYMERS BASEL, V16, DOI 10.3390/polym16162368
   Deng C, 2024, J COLLOID INTERF SCI, V671, P354, DOI 10.1016/j.jcis.2024.05.162
   Dong QF, 2022, ACAD RADIOL, V29, P1819, DOI 10.1016/j.acra.2022.02.020
   Gu SB, 2024, BONE, V185, DOI 10.1016/j.bone.2024.117114
   He XF, 2017, BOSNIAN J BASIC MED, V17, P295, DOI 10.17305/bjbms.2017.2596
   Hu J, 2020, ANALYST, V145, P6054, DOI 10.1039/d0an01212b
   Hu J, 2019, ACS NANO, V13, P7191, DOI 10.1021/acsnano.9b02679
   Jiang Q, 2024, J ORTHOP TRANSL, V47, P161, DOI 10.1016/j.jot.2024.06.005
   Kamei K, 2024, J BONE MINER RES, V39, P1340, DOI 10.1093/jbmr/zjae105
   Khotib J, 2023, J BIOMOL STRUCT DYN, V41, P10257, DOI 10.1080/07391102.2022.2148749
   Lagana M, 2024, EUR J CANCER, V208, DOI 10.1016/j.ejca.2024.114122
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee JY, 2024, J KOREAN MED SCI, V39, DOI 10.3346/jkms.2024.39.e175
   Li JJ, 2023, EXPERT OPIN DRUG DEL, V20, P1511, DOI 10.1080/17425247.2023.2276285
   Li MY, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1243820
   Li PX, 2024, CELL PROLIFERAT, V57, DOI 10.1111/cpr.13605
   Li Y, 2024, BONE RES, V12, DOI 10.1038/s41413 024 00319 7
   Lin YF, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00199 9
   Lyu X, 2024, ACS APPL MATER INTER, V16, P33192, DOI 10.1021/acsami.4c06460
   Mahmoud MA, 2024, J ENZYM INHIB MED CH, V39, DOI 10.1080/14756366.2024.2305856
   Majidzadeh H, 2020, COLLOID SURFACE B, V194, DOI 10.1016/j.colsurfb.2020.111188
   Marques C, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15092282
   Opejin A, 2024, SCI TOTAL ENVIRON, V950, DOI 10.1016/j.scitotenv.2024.175249
   Pang H, 2021, DRUG DES DEV THER, V15, P4795, DOI 10.2147/DDDT.S337215
   Prabhu KS, 2024, CELL DEATH DISCOV, V10, DOI 10.1038/s41420 024 01992 7
   Qiu XP, 2024, J NANOBIOTECHNOL, V22, DOI 10.1186/s12951 024 02546 w
   Rajwar A, 2022, ACS NANO, DOI 10.1021/acsnano.2c01382
   Salek A, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14091913
   Seeman NC, 1998, ANGEW CHEM INT EDIT, V37, P3220, DOI 10.1002/(SICI)1521 3773(19981217)37:23<3220::AID ANIE3220>3.0.CO;2 C
   Shi SR, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0077 4
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Tian T, 2023, NEONATOLOGY, V120, P441, DOI 10.1159/000530352
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang XC, 2024, INT J MOL MED, V54, DOI 10.3892/ijmm.2024.5385
   Xu H, 2024, ELIFE, V12, DOI 10.7554/eLife.89974
   Xu YD, 2024, J NANOBIOTECHNOL, V22, DOI 10.1186/s12951 024 02804 x
   Yang YT, 2024, BIOACT MATER, V39, P191, DOI 10.1016/j.bioactmat.2024.05.017
   Yue J, 2018, RSC ADV, V8, P40288, DOI 10.1039/c8ra07574c
   Zhang M, 2022, BIOACT MATER, V8, P368, DOI 10.1016/j.bioactmat.2021.06.003
   Zhang T, 2022, ADV MATER, DOI 10.1002/adma.202107820
   Zhang T, 2020, NAT PROTOC, V15, P2728, DOI 10.1038/s41596 020 0355 z
   Zhang WF, 2023, EUR J PHARMACOL, V950, DOI 10.1016/j.ejphar.2023.175753
   Zhang WF, 2022, MEMBRANES BASEL, V12, DOI 10.3390/membranes12030324
   Zhang Y., 2024, BONE
   Zhang YX, 2024, J BONE MINER RES, V39, P775, DOI 10.1093/jbmr/zjae042
   Zhao YX, 2023, SMALL, V19, DOI 10.1002/smll.202302326
   Zheng JH, 2025, J ADV RES, V69, P399, DOI 10.1016/j.jare.2024.03.021
NR 51
TC 1
Z9 1
U1 6
U2 16
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD OCT 23
PY 2024
VL 12
IS 41
BP 10705
EP 10718
DI 10.1039/d4tb01691b
EA SEP 2024
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA J7B2R
UT WOS:001319275900001
PM 39319556
DA 2025 08 17
ER

PT J
AU Sun, XD
   Zhang, RB
   Liu, M
   Chen, HG
   Chen, L
   Luo, FT
   Zhang, DL
   Huang, JL
   Li, FF
   Ni, ZH
   Qi, HB
   Su, N
   Jin, M
   Yang, J
   Tan, QY
   Du, XL
   Chen, B
   Huang, HY
   Chen, S
   Yin, LJ
   Xu, XL
   Deng, CX
   Luo, LF
   Xie, YL
   Chen, L
AF Sun, Xianding
   Zhang, Ruobin
   Liu, Mi
   Chen, Hangang
   Chen, Liang
   Luo, Fengtao
   Zhang, Dali
   Huang, Junlan
   Li, Fangfang
   Ni, Zhenhong
   Qi, Huabing
   Su, Nan
   Jin, Min
   Yang, Jing
   Tan, Qiaoyan
   Du, Xiaolan
   Chen, Bo
   Huang, Haiyang
   Chen, Shuai
   Yin, Liangjun
   Xu, Xiaoling
   Deng, Chuxia
   Luo, Lingfei
   Xie, Yangli
   Chen, Lin
TI Rmrp Mutation Disrupts Chondrogenesis and Bone Ossification in
   Zebrafish Model of Cartilage Hair Hypoplasia via Enhanced Wnt/β Catenin
   Signaling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CARTILAGE HAIR HYPOPLASIA; RMRP; ZEBRAFISH; SKELETAL DEVELOPMENT; WNT;
   Beta CATENIN
ID RNASE MRP RNA; MESSENGER RNA; BETA CATENIN; ENDORIBONUCLEASE;
   OSTEOBLAST; COMPONENT; PROMOTES; DISEASE; GROWTH; DIFFERENTIATION
AB Cartilage hair hypoplasia (CHH) is an autosomal recessive metaphyseal chondrodysplasia characterized by bone dysplasia and many other highly variable features. The gene responsible for CHH is the RNA component of the mitochondrial RNA processing endoribonuclease (RMRP) gene. Currently, the pathogenesis of osteochondrodysplasia and extraskeletal manifestations in CHH patients remains incompletely understood; in addition, there are no viable animal models for CHH. We generated an rmrp KO zebrafish model to study the developmental mechanisms of CHH. We found that rmrp is required for the patterning and shaping of pharyngeal arches. Rmrp mutation inhibits the intramembranous ossification of skull bones and promotes vertebrae ossification. The abnormalities of endochondral bone ossification are variable, depending on the degree of dysregulated chondrogenesis. Moreover, rmrp mutation inhibits cell proliferation and promotes apoptosis through dysregulating the expressions of cell cycle  and apoptosis related genes. We also demonstrate that rmrp mutation upregulates canonical Wnt/beta catenin signaling; the pharmacological inhibition of Wnt/beta catenin could partially alleviate the chondrodysplasia and increased vertebrae mineralization in rmrp mutants. Our study, by establishing a novel zebrafish model for CHH, partially reveals the underlying mechanism of CHH, hence deepening our understanding of the role of rmrp in skeleton development.
C1 [Sun, Xianding; Zhang, Ruobin; Liu, Mi; Chen, Hangang; Chen, Liang; Luo, Fengtao; Zhang, Dali; Huang, Junlan; Li, Fangfang; Ni, Zhenhong; Qi, Huabing; Su, Nan; Jin, Min; Yang, Jing; Tan, Qiaoyan; Du, Xiaolan; Chen, Bo; Huang, Haiyang; Chen, Shuai; Xie, Yangli; Chen, Lin] Army Med Univ, Lab Wound Repair & Rehabil, State Key Lab Trauma Burns & Combined Injury, Res Inst Surg,Daping Hosp,Trauma Ctr, Chongqing 400042, Peoples R China.
   [Yin, Liangjun] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthoped Surg, Chongqing 400010, Peoples R China.
   [Xu, Xiaoling; Deng, Chuxia] Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China.
   [Luo, Lingfei] Southwest Univ, Sch Life Sci, Key Lab Freshwater Fish Reprod & Dev, Lab Mol Dev Biol,Minist Educ, Chongqing 400715, Peoples R China.
C3 Army Medical University; Chongqing Medical University; University of
   Macau; Southwest University   China
RP Xie, YL; Chen, L (通讯作者)，Army Med Univ, Inst Surg Res, Daping Hosp, Ctr Trauma, Chongqing 400042, Peoples R China.
EM xieyangli841015@163.com; linchen70@163.com
RI ; Sun, Xianding/AAB 1267 2020; luo, ling/MIO 2796 2025; su,
   nan/GRS 5213 2022; Luo, Fengtao/E 1236 2017; Jin, Min/KFT 2653 2024; 谭,
   乔燕/HNQ 8742 2023; Xu, Xiaoling/JTT 9808 2023
OI Yin, Liang jun/0000 0002 9244 4965; zhenhong, ni/0000 0002 7464 4074; ,
   tan/0000 0002 8534 4763
FU National Natural Science Foundation of China [81772306, 81830075]
   Funding Source: Medline
CR Alexander C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004479
   Apschner A, 2011, METHOD CELL BIOL, V105, P239, DOI 10.1016/B978 0 12 381320 6.00010 2
   Bonafé L, 2005, PLOS GENET, V1, P444, DOI 10.1371/journal.pgen.0010047
   Chamberlain JR, 1998, GENE DEV, V12, P1678, DOI 10.1101/gad.12.11.1678
   CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460 2075.1987.tb04770.x
   Chang NN, 2013, CELL RES, V23, P465, DOI 10.1038/cr.2013.45
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Dale RM, 2011, DEV BIOL, V357, P518, DOI 10.1016/j.ydbio.2011.06.020
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Erickson R. P., 2016, EPSTEINS INBORN ERRO
   Fiedler IAK, 2018, J BONE MINER RES, V33, P1489, DOI 10.1002/jbmr.3445
   Gill T, 2004, MOL CELL BIOL, V24, P945, DOI 10.1128/MCB.24.3.945 953.2004
   Gistelinck C, 2016, J BONE MINER RES, V31, P1930, DOI 10.1002/jbmr.2977
   Glass RBJ, 1999, AM J MED GENET, V86, P312, DOI 10.1002/(SICI)1096 8628(19991008)86:4<312::AID AJMG2>3.0.CO;2 8
   Hammond Chrissy L, 2012, Front Endocrinol (Lausanne), V3, P91, DOI 10.3389/fendo.2012.00091
   Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0
   Hermanns P, 2005, HUM MOL GENET, V14, P3723, DOI 10.1093/hmg/ddi403
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jinn SW, 2005, DEVELOPMENT, V132, P5199, DOI 10.1242/dev.02087
   Kwan A, 2012, AM J MED GENET A, V158A, P2911, DOI 10.1002/ajmg.a.35604
   LEMERRER M, 1991, EUR J PEDIATR, V150, P847, DOI 10.1007/BF01955006
   Ling ITC, 2017, DEV BIOL, V421, P219, DOI 10.1016/j.ydbio.2016.11.016
   Lu HQ, 2013, DEV CELL, V24, P543, DOI 10.1016/j.devcel.2013.01.021
   Luderman LN, 2017, CURR TOP DEV BIOL, V124, P81, DOI 10.1016/bs.ctdb.2016.11.004
   Maida Y, 2009, NATURE, V461, P230, DOI 10.1038/nature08283
   MAKITIE O, 1992, PEDIATR RADIOL, V22, P434, DOI 10.1007/BF02013505
   Mäkitie O, 2001, J PEDIATR US, V138, P929, DOI 10.1067/mpd.2001.113632
   Makitie O., 1993, GeneReviews
   Martin AN, 2007, CELL RES, V17, P219, DOI 10.1038/sj.cr.7310120
   Nakashima E, 2007, AM J MED GENET A, V143A, P2675, DOI 10.1002/ajmg.a.32053
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Ofir Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031
   Park J, 2015, ONCOTARGET, V6, P34658, DOI 10.18632/oncotarget.5778
   Ridanpää M, 2002, EUR J HUM GENET, V10, P439, DOI 10.1038/sj.ejhg.5200824
   Ridanpää M, 2001, CELL, V104, P195, DOI 10.1016/S0092 8674(01)00205 7
   Riley P, 2015, J CHILD ORTHOP, V9, P145, DOI 10.1007/s11832 015 0646 z
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rogler LE, 2014, HUM MOL GENET, V23, P368, DOI 10.1093/hmg/ddt427
   Rosenbluh J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026270
   Sbisa E, 1996, J MOL EVOL, V43, P46, DOI 10.1007/BF02352299
   SCHMITT ME, 1993, FASEB J, V7, P208, DOI 10.1096/fasebj.7.1.7678563
   SCHMITT ME, 1992, GENE DEV, V6, P1975, DOI 10.1101/gad.6.10.1975
   SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935
   Steinbusch MMF, 2017, SCI REP UK, V7, DOI 10.1038/srep43558
   Thiel CT, 2007, AM J HUM GENET, V81, P519, DOI 10.1086/521034
   Thiel CT, 2005, AM J HUM GENET, V77, P795, DOI 10.1086/497708
   TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793
   van Karnebeek CDM, 2016, NAT GENET, V48, P777, DOI 10.1038/ng.3578
   Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558
   Weigele J, 2016, J ANAT, V229, P92, DOI 10.1111/joa.12480
   Westerfield M, 2007, ZEBRAFISH BOOK GUIDE
   Xu W, 2017, J BONE MINER RES, V32, P2194, DOI 10.1002/jbmr.3204
   Zhao L, 2003, MOL CANCER RES, V1, P195
NR 54
TC 18
Z9 20
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2019
VL 34
IS 11
BP 2101
EP 2116
DI 10.1002/jbmr.3820
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA JM2FN
UT WOS:000496036300014
PM 31237961
OA Bronze
DA 2025 08 17
ER

PT J
AU Dieudonné, FX
   Marion, A
   Marie, PJ
   Modrowski, D
AF Dieudonne, Francois Xavier
   Marion, Allison
   Marie, Pierre J.
   Modrowski, Dominique
TI Targeted inhibition of T cell factor activity promotes syndecan 2
   expression and sensitization to doxorubicin in osteosarcoma cells and
   bone tumors in mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE FOXO; ss CATENIN; SYNDECAN 2; OSTEOSARCOMA; CHEMOSENSITIVITY
ID BETA CATENIN; PROTEOGLYCAN SYNDECAN 2; PEDIATRIC OSTEOSARCOMA; INDUCED
   APOPTOSIS; CARCINOMA CELLS; CHEMOTHERAPY; RESISTANCE; FOXO;
   TRANSCRIPTION; SUPPRESSION
AB Alterations of Wnt signaling appear to be involved in the pathogenesis of osteosarcoma, presenting mutations of adenomatous polyposis coli (APC) and epigenetic downregulation of Wnt inhibitory factor 1. However, the precise role of Wnt effectors in the bone cancer progression remains unclear. We previously showed that Wnt/beta catenin/T cell factor (TCF) activation are responsible for the repression of syndecan 2, a key modulator of apoptosis and chemosensitivity in osteosarcoma cells, suggesting a role of Wnt signaling in chemoresistance. In this study, we investigated the functional relationship between syndecan 2, Wnt/beta catenin/TCF signaling and chemosensitivity in these cells. To this goal, we selected resistant osteosarcoma cells from sensitive human cell lines using repeated exposures to doxorubicin. In doxorubicin responsive but not in doxorubicin resistant derived cells syndecan 2 expression was upregulated by doxorubicin treatment. Moreover, syndecan 2 overexpression restored the sensitivity to doxorubicin in resistant derived cells. We found that syndecan 2 induction by doxorubicin is forkhead box protein O3A (Foxo3a) dependent. Foxo3a overexpression resulted in increased syndecan 2 expression in sensitive and resistant derived cells. Doxorubicin modulated Foxo3a binding on syndecan 2 gene promoter and induced Foxo dependent inhibition of Wnt/TCF activity. Conversely, beta catenin/TCF activation impaired syndecan 2 induction by doxorubicin, indicating that Wnt signaling is competing with the action of the cytotoxic drug. However, beta catenin was also found to be required for Foxo3a activity. Consistently, Dickkopf 1 (DKK1) and secreted frizzled related protein 1 (sFRP 1) altered doxorubicin action in sensitive cells, whereas inhibition of TCF activity strongly decreased cell viability and increased sensitivity to doxorubicin in sensitive and resistant cells. TCF inhibition also increased the effect of doxorubicin treatment in an orthotopic bone tumor model in mice. Altogether, these data provide evidence that the repression of syndecan 2 by Wnt/beta catenin/TCF signaling contributes to the resistance of osteosarcoma cells to doxorubicin and suggest that TCF inhibition may represent a novel therapeutic strategy in osteosarcoma. (c) 2012 American Society for Bone and Mineral Research.
C1 [Dieudonne, Francois Xavier; Marion, Allison; Marie, Pierre J.; Modrowski, Dominique] Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, F 75475 Paris 10, France.
   [Dieudonne, Francois Xavier; Marion, Allison; Marie, Pierre J.; Modrowski, Dominique] Univ Paris Diderot, UMR606, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Universite
   Paris Cite
RP Modrowski, D (通讯作者)，Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM dominique.modrowski@inserm.fr
RI Modrowski, Dominique/N 6578 2018
OI Modrowski, Dominique/0000 0003 1103 7127
FU European Calcified Tissue Society (ECTS); ARC; Ligue Nationale Contre le
   Cancer
FX FXD was supported by a PhD studentship from the European Calcified
   Tissue Society (ECTS). This work was supported by grants from ARC and
   the Ligue Nationale Contre le Cancer. We thank Dr. Miranda van Triest
   and Dr. Burgering (University Medical Center Utrecht, The Netherlands)
   for providing 6XDBE construct. We thank Prof. Paul J Coffer (University
   Medical Center Utrecht, The Netherlands) for the gift of Foxo3a
   expression plasmids. We thank Dr. Adrienne Anginot, Caroline Marty, and
   Alain Barbara for technical assistance with cytometry and histology and
   Dr. Zuzana Saidak for English correction of the manuscript. We thank
   Novartis (Switzerland) for the gift of PKF115 584.
CR Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Bodine PVN, 2008, CELL RES, V18, P248, DOI 10.1038/cr.2008.13
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113
   Dieudonné FX, 2010, CANCER RES, V70, P5399, DOI 10.1158/0008 5472.CAN 10 0090
   Doghman M, 2008, J CLIN ENDOCR METAB, V93, P3222, DOI 10.1210/jc.2008 0247
   Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083
   Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264 6021:3490629
   Gibbs C Parker Jr, 2002, Instr Course Lect, V51, P413
   Guo Y, 2008, CLIN ORTHOP RELAT R, V466, P2039, DOI 10.1007/s11999 008 0344 y
   Harisi R, 2007, CANCER BIOL THER, V6, P1240
   Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200
   Huang JW, 2005, BIOCHEM BIOPH RES CO, V330, P1087, DOI 10.1016/j.bbrc.2005.02.189
   Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547
   Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001
   Lin YL, 2007, J CELL BIOL, V177, P829, DOI 10.1083/jcb.200608121
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549 007 9867 2
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Modrowski D, 2005, BONE, V37, P180, DOI 10.1016/j.bone.2005.04.010
   Orosco A, 2007, CANCER RES, V67, P3708, DOI 10.1158/0008 5472.CAN 06 4164
   Orosco A, 2006, J CELL BIOCHEM, V98, P838, DOI 10.1002/jcb.20826
   Overholtzer M, 2003, P NATL ACAD SCI USA, V100, P11547, DOI 10.1073/pnas.1934852100
   Perona R, 2007, CLIN TRANSL ONCOL, V9, P625, DOI 10.1007/s12094 007 0115 3
   TABONE MD, 1994, J CLIN ONCOL, V12, P2614, DOI 10.1200/JCO.1994.12.12.2614
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Teixe T, 2008, MOL IMMUNOL, V45, P2905, DOI 10.1016/j.molimm.2008.01.033
   van der Vos KE, 2008, ONCOGENE, V27, P2289, DOI 10.1038/onc.2008.22
   Villena J, 2006, APOPTOSIS, V11, P2065, DOI 10.1007/s10495 006 0193 7
   Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030
   Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078 0432.CCR 08 0124
NR 37
TC 40
Z9 49
U1 1
U2 8
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD OCT
PY 2012
VL 27
IS 10
BP 2118
EP 2129
DI 10.1002/jbmr.1650
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 007ZB
UT WOS:000308925800009
PM 22550000
OA Bronze
DA 2025 08 17
ER

PT J
AU Xu, GY
   Zuo, GL
   Zhong, SH
   Zhang, W
AF Xu, Guangyu
   Zuo, Gaolei
   Zhong, Shihua
   Zhang, Wei
TI Synthesis and Hydroxyapatite Binding Activity of Bisphosphonate Statin
   Conjugates
SO LETTERS IN ORGANIC CHEMISTRY
LA English
DT Article
DE Statins; bisphosphonates; conjugate; bone targeting; hydroxyapatite
ID PRODRUGS; PREVENTION; INHIBITORS
AB To develop a methodology for delivering anabolic agents statins to bone, a bone targeting bisphosphonate was used as a carrier of drugs. Four statin bisphosphonate conjugates were synthesized and examined for their bone mineral affinity in vitro by hydroxyapatite absorption method. The conjugates showed high binding activity with HAP, implying the modified statins possess the potential of bone targeting property.
C1 [Xu, Guangyu; Zuo, Gaolei; Zhong, Shihua] Hunan Normal Univ, Coll Chem & Chem Engn, Changsha 410081, Hunan, Peoples R China.
   [Zhang, Wei] Hunan Normal Univ, Coll Med, Changsha 410081, Hunan, Peoples R China.
C3 Hunan Normal University; Hunan Normal University
RP Xu, GY (通讯作者)，Hunan Normal Univ, Coll Chem & Chem Engn, Changsha 410081, Hunan, Peoples R China.
EM gyxu@hunnu.edu.cn
FU National Natural Science Foundation of China [20602010]; Hunan
   Provincial Natural Science Foundation of China [06JJ50024]
FX We thank the National Natural Science Foundation of China (No. 20602010)
   and Hunan Provincial Natural Science Foundation of China (No. 06JJ50024)
   for financial support.
CR Bauss F, 1996, CALCIFIED TISSUE INT, V59, P168, DOI 10.1007/s002239900104
   Corsini A, 1999, PHARMACOL THERAPEUT, V84, P413, DOI 10.1016/S0163 7258(99)00045 5
   DEGENHARDT CR, 1986, J ORG CHEM, V51, P3488, DOI 10.1021/jo00368a017
   Erez R, 2008, BIOORG MED CHEM LETT, V18, P816, DOI 10.1016/j.bmcl.2007.11.029
   FLEISCH H, 1987, BONE, V8, pS23
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Gittens SA, 2005, ADV DRUG DELIVER REV, V57, P1011, DOI 10.1016/j.addr.2004.12.015
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Houghton TJ, 2008, J MED CHEM, V51, P6955, DOI 10.1021/jm801007z
   Jiang QL, 2008, LETT ORG CHEM, V5, P229, DOI 10.2174/157017808783955862
   Kantoci D, 1996, SYNTHETIC COMMUN, V26, P2037, DOI 10.1080/00397919608003560
   KARPEISKY M, Patent No. 6214812
   Lisic EC, 2001, NUCL MED BIOL, V28, P419, DOI 10.1016/S0969 8051(00)00205 5
   MCKENNA CE, 1977, TETRAHEDRON LETT, P155
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Overhand M, 1997, BIOORG MED CHEM LETT, V7, P2435, DOI 10.1016/S0960 894X(97)00448 4
   Reddy R, 2008, CHEMMEDCHEM, V3, P1863, DOI 10.1002/cmdc.200800255
   Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957
   STOKKER GE, 1986, J MED CHEM, V29, P170, DOI 10.1021/jm00152a002
   Winckler W, 1996, PHOSPHORUS SULFUR, V112, P137, DOI 10.1080/10426509608046357
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
NR 21
TC 2
Z9 2
U1 2
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570 1786
EI 1875 6255
J9 LETT ORG CHEM
JI Lett. Org. Chem.
PD JUL
PY 2009
VL 6
IS 5
BP 419
EP 423
DI 10.2174/157017809788681356
PG 5
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 473OY
UT WOS:000268218300017
DA 2025 08 17
ER

PT J
AU Chen, HW
   Fang, C
   Zhi, X
   Song, SJ
   Gu, YQ
   Chen, XF
   Cui, J
   Hu, Y
   Weng, WZ
   Zhou, QR
   Wang, YJ
   Wang, Y
   Jiang, H
   Li, XQ
   Cao, LH
   Chen, X
   Su, JC
AF Chen, Huiwen
   Fang, Chao
   Zhi, Xin
   Song, Shaojun
   Gu, Yanqiu
   Chen, Xiaofei
   Cui, Jin
   Hu, Yan
   Weng, Weizong
   Zhou, Qirong
   Wang, Yajun
   Wang, Yao
   Jiang, Hao
   Li, Xiaoqun
   Cao, Liehu
   Chen, Xiao
   Su, Jiacan
TI Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL
   signalling mediated TRAF6 and c Src recruitment and NF κB, MAPK and Akt
   pathways
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE c Src; neobavaisoflavone; osteoclastogenesis; osteoporosis; RANKL; TRAF6
ID FAMILY MEMBER; ACTIVATION; EXPRESSION; RECEPTOR; DIFFERENTIATION;
   OSTEOPETROSIS; OSTEOPOROSIS; APOPTOSIS; EXTRACT; COMPLEX
AB Psoralea corylifolia(P corylifolia) has been popularly applied in traditional Chinese medicine decoction for treating osteoporosis and promoting fracture healing since centuries ago. However, the bioactive natural components remain unknown. In this study, applying comprehensive two dimensional cell membrane chromatographic/C18 column/time of flight mass spectrometry (2D CMC/C18 column/TOFMS) system, neobavaisoflavone (NBIF), for the first time, was identified for the bioaffinity with RAW 264.7 cells membranes from the extracts ofP corylifolia. Here, we revealed that NBIF inhibited RANKL mediated osteoclastogenesis in bone marrow monocytes (BMMCs) and RAW264.7 cells dose dependently at the early stage. Moreover, NBIF inhibited osteoclasts function demonstrated by actin ring formation assay and pit formation assay. With regard to the underlying molecular mechanism, co immunoprecipitation showed that both the interactions of RANK with TRAF6 and with c Src were disrupted. In addition, NBIF inhibited the phosphorylation of P50, P65, I kappa B in NF kappa B pathway, ERK, JNK, P38 in MAPKs pathway, AKT in Akt pathway, accompanied with a blockade of calcium oscillation and inactivation of nuclear translocation of nuclear factor of activated T cells cytoplasmic 1 (NFATc1). In vivo, NBIF inhibited osteoclastogenesis, promoted osteogenesis and ameliorated bone loss in ovariectomized mice. In summary,P corylifolia derived NBIF inhibited RANKL mediated osteoclastogenesis by suppressing the recruitment of TRAF6 and c Src to RANK, inactivating NF kappa B, MAPKs, and Akt signalling pathways and inhibiting calcium oscillation and NFATc1 translocation. NBIF might serve as a promising candidate for the treatment of osteoclast associated osteopenic diseases.
C1 [Chen, Huiwen; Fang, Chao; Zhi, Xin; Song, Shaojun; Cui, Jin; Hu, Yan; Weng, Weizong; Zhou, Qirong; Wang, Yajun; Wang, Yao; Jiang, Hao; Li, Xiaoqun; Chen, Xiao; Su, Jiacan] Naval Mil Med Univ, Shanghai Changhai Hosp, Dept Orthoped Trauma, Shanghai, Peoples R China.
   [Zhi, Xin; Li, Xiaoqun] Naval Mil Med Univ, Basic Med Sch, Shanghai, Peoples R China.
   [Gu, Yanqiu] Shanghai 9th Peoples Hosp, Dept Pharm, Shanghai, Peoples R China.
   [Chen, Xiaofei] Second Mil Med Univ, Sch Pharm, Shanghai, Peoples R China.
   [Cao, Liehu] Shanghai Luodian Hosp, Dept Orthoped Trauma, Shanghai, Peoples R China.
   [Chen, Xiao] Fudan Univ, Dept Chem, Shanghai, Peoples R China.
   [Su, Jiacan] China South Korea Bioengn Ctr, Shanghai, Peoples R China.
C3 Naval Medical University; Naval Medical University; Naval Medical
   University; Fudan University
RP Chen, X; Su, JC (通讯作者)，Naval Mil Med Univ, Shanghai Changhai Hosp, Dept Orthoped Trauma, Shanghai, Peoples R China.; Cao, LH (通讯作者)，Shanghai Luodian Hosp, Dept Orthoped Trauma, Shanghai, Peoples R China.
EM caoliehu@126.com; sirchenxiao@126.com; drsujiacan@163.com
RI Chen, Huiwen/LZF 7424 2025; Hu, Yan/AFZ 8800 2022; Chen,
   Xiao/N 1298 2017; Su, Jiacan/N 7068 2019; Cui, Jin/HDL 7327 2022
OI Su, Jiacan/0000 0001 7080 263X
FU National Key Research and Development Plan [2018YFC2001500]; National
   Natural Science Foundation (NNSF) Key Research Program in Aging
   [91749204]; National Natural Science Foundation of China [81771491,
   81871099, 81501052]; Municipal Human Resources Development Program for
   Outstanding Leaders in Medical Disciplines in Shanghai [2017BR011];
   Science and Technology Support Project in Biomedical Field of Shanghai
   Science and Technology Innovation Plan [18431902300]; Shanghai Young
   Physician Supporting Program [2018.15]
FX National Key Research and Development Plan, Grant/Award Number:
   2018YFC2001500; National Natural Science Foundation (NNSF) Key Research
   Program in Aging, Grant/Award Number: 91749204; National Natural Science
   Foundation of China, Grant/Award Number: 81771491, 81871099 and
   81501052; Municipal Human Resources Development Program for Outstanding
   Leaders in Medical Disciplines in Shanghai, Grant/Award Number:
   2017BR011; Science and Technology Support Project in Biomedical Field of
   Shanghai Science and Technology Innovation Plan, Grant/Award Number:
   18431902300; Shanghai Young Physician Supporting Program, Grant/Award
   Number: 2018.15
CR Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200
   Boudot C, 2010, BONE, V46, P1416, DOI 10.1016/j.bone.2010.01.383
   Chen X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0035 6
   Chen X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00647
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Don MJ, 2012, PHYTOMEDICINE, V19, P551, DOI 10.1016/j.phymed.2012.01.006
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fumoto T, 2014, J BONE MINER RES, V29, P830, DOI 10.1002/jbmr.2096
   Gu YQ, 2020, ACTA PHARM SIN B, V10, P1856, DOI 10.1016/j.apsb.2020.01.019
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Jia D, 2016, J PHARMACEUT BIOMED, V118, P27, DOI 10.1016/j.jpba.2015.10.013
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Metavarayuth K, 2019, NANO LETT, V19, P8372, DOI 10.1021/acs.nanolett.9b02001
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Park JH, 2017, MOL CELLS, V40, P706
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Reid IR, 2008, SEMIN CELL DEV BIOL, V19, P473, DOI 10.1016/j.semcdb.2008.08.002
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Szliszka E, 2011, MOLECULES, V16, P3701, DOI 10.3390/molecules16053701
   Szliszka E, 2011, PHARMACOL REP, V63, P139, DOI 10.1016/S1734 1140(11)70408 X
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0
   Tsai MH, 2007, AM J CHINESE MED, V35, P669, DOI 10.1142/S0192415X07005168
   Walsh MC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004064
   Wang XY, 2018, J FOOD DRUG ANAL, V26, P823, DOI 10.1016/j.jfda.2017.11.010
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wong RWK, 2010, PHYTOTHER RES, V24, pS155, DOI 10.1002/ptr.3049
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Xiao GD, 2010, J CHROMATOGR A, V1217, P5470, DOI 10.1016/j.chroma.2010.06.041
   Xiao WM, 2016, FRONT ORAL BIOL, V18, P17, DOI 10.1159/000351896
   Zhi X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00022
NR 43
TC 53
Z9 59
U1 2
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD AUG
PY 2020
VL 24
IS 16
BP 9067
EP 9084
DI 10.1111/jcmm.15543
EA JUN 2020
PG 18
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA MX6GY
UT WOS:000548008900001
PM 32604472
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU López Herradón, A
   Fujikawa, R
   Gómez Marín, M
   Stedile Lovatel, JP
   Mulero, F
   Ardura, JA
   Ruiz, P
   Muñoz, I
   Esbrit, P
   Mahíllo Fernández, I
   Ortega de Mues, A
AF Lopez Herradon, A.
   Fujikawa, R.
   Gomez Marin, M.
   Stedile Lovatel, J. P.
   Mulero, F.
   Ardura, J. A.
   Ruiz, P.
   Munoz, I.
   Esbrit, P.
   Mahillo Fernandez, I.
   Ortega de Mues, A.
TI Impact of Chiropractic Manipulation on Bone and Skeletal Muscle of
   Ovariectomized Rats
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Chiropractic manipulation; Mechano growth factor (MGF); Osteoporotic
   bone; Skeletal muscle
ID MECHANO GROWTH FACTOR; FACTOR I; MODEL; ADAPTATION; EXPRESSION;
   DIFFERENTIATION; DISPLACEMENT; OSTEOBLASTS; THERAPY; PATHWAY
AB Evidence suggests that chiropractic manipulation might exert positive effects in osteoporotic patients. The aim of this study was to evaluate the effects of chiropractic manipulation on bone structure and skeletal muscle in rats with bone loss caused by ovariectomy (OVX). The 6 month old Sprague Dawley rats at 10 weeks following OVX or sham operation (Sh) did not suffer chiropractic manipulation (NM group) or were submitted to true chiropractic manipulation using the chiropractic adjusting instrument Activator V A (R) three times/week for 6 weeks as follows: Force 1 setting was applied onto the tibial tubercle of the rat right hind limb (TM group), whereas the corresponding left hind limb received a false manipulation (FM group) consisting of ActivatorV(A (R)) firing in the air and slightly touching the tibial tubercle. Bone mineral density (BMD) and bone mineral content (BMC) were determined in long bones and L3 L4 vertebrae in all rats. Femora and tibia were analyzed by mu CT. Mechano growth factor (MGF) was detected in long bones and soleus, quadriceps and tibial muscles by immunohistochemistry and Western blot. The decrease of BMD and BMC as well as trabecular bone impairment in the long bones of OVX rats vs Sh controls was partially reversed in the TM group versus FM or NM rats. This bone improvement by chiropractic manipulation was associated with an increased MGF expression in the quadriceps and the anterior tibial muscle in OVX rats. These findings support the notion that chiropractic manipulation can ameliorate osteoporotic bone at least partly by targeting skeletal muscle.
C1 [Lopez Herradon, A.; Fujikawa, R.; Gomez Marin, M.; Stedile Lovatel, J. P.; Ruiz, P.; Munoz, I.; Ortega de Mues, A.] Real Ctr Univ Escorial Maria Cristina, Madrid Coll Chiropract, 2 San Lorenzo de El Escorial, Madrid 28200, Spain.
   [Lopez Herradon, A.; Ardura, J. A.; Esbrit, P.] UAM, Fdn Jimenez Diaz, IIS, Lab Metabolismo Mineral & Oseo, Madrid, Spain.
   [Mulero, F.] CNIO, Unidad Imagen Mol, Madrid, Spain.
   [Mahillo Fernandez, I.] UAM, Fdn Jimenez Diaz, IIS, Unidad Epidemiol & Bioestadist, Madrid, Spain.
C3 Autonomous University of Madrid; Fundacion Jimenez Diaz; Centro Nacional
   de Investigaciones Oncologicas (CNIO); Fundacion Jimenez Diaz;
   Autonomous University of Madrid
RP Ortega de Mues, A (通讯作者)，Real Ctr Univ Escorial Maria Cristina, Madrid Coll Chiropract, 2 San Lorenzo de El Escorial, Madrid 28200, Spain.
EM aortega@rcumariacristina.com
RI ; Mulero, Francisca/M 3289 2014; Mulero, Francisca/R 2387 2019; Ardura,
   Juan/F 3378 2017; Mahillo Fernandez, Ignacio/T 2042 2018; Martinez,
   Fernando/E 8026 2016
OI Ortega De Mues, Arantxa/0000 0002 4730 0129; Mulero,
   Francisca/0000 0001 9584 4211; Ardura Rodriguez, Juan
   Antonio/0000 0002 2827 3364; Mahillo Fernandez,
   Ignacio/0000 0003 0558 6541; 
FU Spanish Chiropractic Association (AEQ); Fondation de Recherche
   Chiropratique du Quebec (Quebec, Canada)
FX This work was supported in part by grants from the Spanish Chiropractic
   Association (AEQ) and Fondation de Recherche Chiropratique du Quebec
   (Quebec, Canada).
CR Adams GR, 1998, EXERCISE SPORT SCI R, V26, P31
   Ahtiainen M, 2012, AGE, V34, P1249, DOI 10.1007/s11357 011 9298 1
   Bonewald LF, 2013, J BONE MINER RES, V28, P1857, DOI 10.1002/jbmr.1980
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brown JW, 2012, J THERM BIOL, V37, P309, DOI 10.1016/j.jtherbio.2011.09.006
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   Chapman Smith D, 2004, QUIROPRACTICA
   Colloca CJ, 2005, J MANIP PHYSIOL THER, V28, P414, DOI 10.1016/j.jmpt.2005.06.004
   Deng MY, 2011, INT ORTHOP, V35, P1099, DOI 10.1007/s00264 010 1141 2
   FUHR AW, 1986, J MANIP PHYSIOL THER, V9, P15
   Fuhr AW, 2009, ACTIVATOR METHODS
   Goldspink G, 2005, PHYSIOLOGY, V20, P232, DOI 10.1152/physiol.00004.2005
   Gonzalez JM, 2000, PRINCIPIOS MED INTER, V1, P1233
   Hamrick MW, 2010, J MUSCULOSKEL NEURON, V10, P64
   Hawk C, 2010, J MANIP PHYSIOL THER, V33, P464, DOI 10.1016/j.jmpt.2010.06.010
   Iwaniec UT, 2016, OSTEOPOROSIS INT, V27, P3091, DOI 10.1007/s00198 016 3634 3
   Jähn K, 2012, EUR CELLS MATER, V24, P197
   Jaspers RT, 2014, CLIN REV BONE MINER, V12, P27, DOI 10.1007/s12018 014 9156 7
   Johnson IP, 2008, MED HYPOTHESES, V71, P715, DOI 10.1016/j.mehy.2008.06.038
   Juffer P, 2012, AM J PHYSIOL ENDOC M, V302, pE389, DOI 10.1152/ajpendo.00320.2011
   Kaji Hiroshi, 2014, [Journal of Bone Metabolism, 대한골대사학회지], V21, P29
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kemmler W, 2012, OSTEOPOROSIS INT, V23, P1267, DOI 10.1007/s00198 011 1663 5
   Kennedy OD, 2009, J ANAT, V214, P729, DOI 10.1111/j.1469 7580.2009.01054.x
   Krane SM, 1998, PRINCIPLES INTERNAL, V2, P2557
   Kravchenko IV, 2011, ARCH BIOCHEM BIOPHYS, V507, P323, DOI 10.1016/j.abb.2010.12.028
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Liebschner MAK, 2014, ANN BIOMED ENG, V42, P2524, DOI 10.1007/s10439 014 1115 4
   Matheny RW, 2010, ENDOCRINOLOGY, V151, P865, DOI 10.1210/en.2009 1217
   Pedersen Bente Klarlund, 2011, J Exp Biol, V214, P337, DOI 10.1242/jeb.048074
   Pickar Joel G, 2002, Spine J, V2, P357, DOI 10.1016/S1529 9430(02)00400 X
   Portal Núñez S, 2010, FEBS LETT, V584, P3095, DOI 10.1016/j.febslet.2010.05.047
   Punkt K, 2004, ACTA HISTOCHEM, V106, P145, DOI 10.1016/j.acthis.2003.11.005
   Russell W. M. S., 1959, PRINCIPLES HUMANE EX, DOI [10.1038/1841675b0, DOI 10.1038/1841675B0]
   SMITH DB, 1989, J MANIP PHYSIOL THER, V12, P26
   Stock J.L., 1997, COMPLEMENT THER MED, V5, P36, DOI [10.1016/S0965 2299(97)80088 X, DOI 10.1016/S0965 2299(97)80088 X]
   Tang LL, 2006, ARCH ORAL BIOL, V51, P1080, DOI 10.1016/j.archoralbio.2006.06.009
   Trierweiler J, 2012, J MANIP PHYSIOL THER, V35, P18, DOI 10.1016/j.jmpt.2011.09.007
   Turner CH, 1998, BONE, V23, P399, DOI 10.1016/S8756 3282(98)00118 5
   TURNER RT, 1987, J BONE MINER RES, V2, P115
   Wang LC, 2001, J ANAT, V198, P295, DOI 10.1046/j.1469 7580.2001.19830295.x
   Wang LL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00266
   Woodhouse D., 2003, Clin. Chiropr., V6, P67, DOI [10.1016/S1479 2354(03)00020 8, DOI 10.1016/S1479 2354(03)00020 8]
   WRONSKI TJ, 1989, BONE, V10, P295, DOI 10.1016/8756 3282(89)90067 7
   Xin C, 2012, ARCH ORAL BIOL, V57, P720, DOI 10.1016/j.archoralbio.2011.11.016
NR 45
TC 5
Z9 5
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD NOV
PY 2017
VL 101
IS 5
BP 519
EP 529
DI 10.1007/s00223 017 0304 1
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FJ8KF
UT WOS:000413015300008
PM 28755011
DA 2025 08 17
ER

PT J
AU Dyer, MR
   Jing, ZH
   Duncan, K
   Godbe, J
   Shokeen, M
AF Dyer, Michael R.
   Jing, Zhenghan
   Duncan, Kathleen
   Godbe, Jacqueline
   Shokeen, Monica
TI Advancements in the development of radiopharmaceuticals for nuclear
   medicine applications in the treatment of bone metastases
SO NUCLEAR MEDICINE AND BIOLOGY
LA English
DT Article
DE Bone metastases; Nuclear medicine; Radionuclide; Radiopharmaceutical;
   Theranostics
ID REFRACTORY PROSTATE CANCER; RADIONUCLIDE THERAPY; NEUROENDOCRINE TUMOR;
   F 18 FDG PET/CT; RADIUM 223; TC 99M MDP; F 18 NAF; DISEASE;
   LU 177 PSMA 617; SCINTIGRAPHY
AB Bone metastases are a painful and complex condition that overwhelmingly impacts the prognosis and quality of life of cancer patients. Over the years, nuclear medicine has made remarkable progress in the diagnosis and management of bone metastases. This review aims to provide a comprehensive overview of the recent advancements in nuclear medicine for the diagnosis and management of bone metastases. Furthermore, the review explores the role of targeted radiopharmaceuticals in nuclear medicine for bone metastases, focusing on radiolabeled molecules that are designed to selectively target biomarkers associated with bone metastases, including osteocytes, osteoblasts, and metastatic cells. The applications of radionuclide based therapies, such as strontium89 (Sr 89) and radium 223 (Ra 223), are also discussed. This review also highlights the potential of theranostic approaches for bone metastases, enabling personalized treatment strategies based on individual patient characteristics. Importantly, the clinical applications and outcomes of nuclear medicine in osseous metastatic disease are discussed. This includes the assessment of treatment response, predictive and prognostic value of imaging biomarkers, and the impact of nuclear medicine on patient management and outcomes. The review identifies current challenges and future perspectives on the role of nuclear medicine in treating bone metastases. It addresses limitations in imaging resolution, radiotracer availability, radiation safety, and the need for standardized protocols. The review concludes by emphasizing the need for further research and advancements in imaging technology, radiopharmaceutical development, and integration of nuclear medicine with other treatment modalities. In summary, advancements in nuclear medicine have significantly improved the diagnosis and management of osseous metastatic disease and future developements in the integration of innovative imaging modalities, targeted radiopharmaceuticals, radionuclide production, theranostic approaches, and advanced image analysis techniques hold great promise in improving patient outcomes and enhancing personalized care for individuals with bone metastases.
C1 [Dyer, Michael R.; Jing, Zhenghan; Duncan, Kathleen; Godbe, Jacqueline; Shokeen, Monica] Washington Univ, Edward Mallinckrodt Inst Radiol, Sch Med, St Louis, MO 63110 USA.
   [Shokeen, Monica] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, Barnes Jewish Hosp, St Louis, MO 63110 USA.
   [Shokeen, Monica] Barnes Jewish Hosp, St Louis, MO 63110 USA.
   [Shokeen, Monica] Washington Univ St Louis, Dept Biomed Engn, St Louis, MO 63110 USA.
   [Shokeen, Monica] Washington Univ, Sch Med, Dept Med, St Louis, MO USA.
C3 Washington University (WUSTL); Barnes Jewish Hospital; Washington
   University (WUSTL); Siteman Cancer Center; Washington University
   (WUSTL); Barnes Jewish Hospital; Washington University (WUSTL);
   Washington University (WUSTL)
RP Shokeen, M (通讯作者)，Washington Univ, Edward Mallinckrodt Inst Radiol, Sch Med, St Louis, MO 63110 USA.
EM shokeenm@mir.wustl.edu
OI Duncan, Kathleen/0000 0001 8767 8372; Dyer, Michael/0009 0006 4824 5076
CR Casas EA, 2020, WORLD J GASTROENTERO, V26, P1513, DOI 10.3748/wjg.v26.i13.1513
   Akhtar M, 2019, ADV ANAT PATHOL, V26, P69, DOI 10.1097/PAP.0000000000000219
   Alavi Mehrosadat, 2015, World J Nucl Med, V14, P109, DOI 10.4103/1450 1147.157124
   Albertsson P, 2023, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.1076210
   Andreou C, 2022, NAT BIOMED ENG, V6, P527, DOI 10.1038/s41551 022 00891 5
   [Anonymous], 2006, DRUGS LACTATION DATA
   [Anonymous], 2023, Current and Resolved Drug Shortages and Discontinuations Reported to FDA
   Arnold C, 2022, NAT MED, V28, P606, DOI 10.1038/s41591 022 01759 6
   Askari E, 2021, CANCER BIOTHER RADIO, V36, P383, DOI 10.1089/cbr.2020.4323
   Badrising SK, 2022, PROSTATE CANCER P D, V25, P248, DOI 10.1038/s41391 021 00412 6
   Baldessari C, 2023, CANCERS, V15, DOI 10.3390/cancers15051518
   Balzer M, 2023, EJNMMI RADIOPHARM CH, V8, DOI 10.1186/s41181 023 00222 2
   Ban JZ, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112944
   Banerjee S, 2001, SEMIN NUCL MED, V31, P260, DOI 10.1053/snuc.2001.26205
   Banerjee SR, 2013, APPL RADIAT ISOTOPES, V76, P2, DOI 10.1016/j.apradiso.2013.01.039
   Bastawrous S, 2014, RADIOGRAPHICS, V34, P1295, DOI 10.1148/rg.345130061
   Basu S, 2014, J NUCL MED TECHNOL, V42, P296, DOI 10.2967/jnmt.114.139238
   Beijst C, 2017, J NUCL MED TECHNOL, V45, P272, DOI 10.2967/jnmt.117.190991
   Bodei L, 2022, NAT REV CLIN ONCOL, V19, P534, DOI 10.1038/s41571 022 00652 y
   Brito AE, 2020, SEMIN NUCL MED, V50, P177, DOI 10.1053/j.semnuclmed.2019.11.005
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   Carciona M, 1998, Aust N Z J Med, V28, P371
   Choi JY, 2018, NUCL MED MOLEC IMAG, V52, P200, DOI 10.1007/s13139 017 0509 2
   Ciovati G, 2020, SUPERCOND SCI TECH, V33, DOI 10.1088/1361 6668/ab8d98
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Cook GJR, 2020, J NUCL MED, V61, P799, DOI 10.2967/jnumed.119.234260
   Costa RP, 2019, CLIN TER, V170, pE1, DOI 10.7417/CT.2019.2100
   Crisan G, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23095023
   Cuneo KC, 2023, SURG ONCOL CLIN N AM, V32, P415, DOI 10.1016/j.soc.2023.02.002
   Dadgar H, 2022, WORLD J NUCL MED, V21, P1, DOI 10.1055/s 0042 1748154
   Das S, 2019, EXPERT REV GASTROENT, V13, P1023, DOI 10.1080/17474124.2019.1685381
   DELALOYE B, 1985, EUR J NUCL MED, V11, P182
   do Carmo SJC, 2020, EJNMMI RADIOPHARM CH, V5, DOI 10.1186/s41181 019 0088 x
   Eigqvist J, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00324
   Feng YT, 2021, NUCL MED BIOL, V100, P12, DOI 10.1016/j.nucmedbio.2021.05.007
   Fernández R, 2021, J NUCL MED, V62, P1126, DOI 10.2967/jnumed.120.255851
   Florimonte L, 2016, EUR J NUCL MED MOL I, V43, P1896, DOI 10.1007/s00259 016 3386 5
   Fortunati E, 2022, CURR TREAT OPTION ON, V23, P703, DOI 10.1007/s11864 022 00967 z
   Gavriilidis P, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12102335
   Gendi K, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064 016 3572 8
   Goldsmith SJ, 2020, SEMIN NUCL MED, V50, P87, DOI 10.1053/j.semnuclmed.2019.07.006
   Goud NS, 2020, EUR J MED CHEM, V187, DOI 10.1016/j.ejmech.2019.111979
   Groner D, 2020, J NUCL MED, V61
   Guérard F, 2013, CANCER BIOTHER RADIO, V28, P1, DOI 10.1089/cbr.2012.1292
   Guo X, 2018, CANCER MANAG RES, V10, P1639, DOI 10.2147/CMAR.S168579
   Gürsel IV, 2015, CHEM ENG J, V270, P468, DOI 10.1016/j.cej.2015.02.035
   Gutfilen B, 2018, DRUG DES DEV THER, V12, P3235, DOI 10.2147/DDDT.S170879
   Hao GY, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 82812 1
   Hennrich U, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15101292
   Hennrich U, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14080713
   Heskamp S, 2017, J NUCL MED, V58, P926, DOI 10.2967/jnumed.116.187021
   Hricak H, 2021, LANCET ONCOL, V22, pE136, DOI 10.1016/S1470 2045(20)30751 8
   Hsieh TC, 2021, J PERS MED, V11, DOI 10.3390/jpm11121248
   Huang XH, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14122705
   Jadvar H, 2012, CLIN NUCL MED, V37, P637, DOI 10.1097/RLU.0b013e318252d829
   James ND, 2016, JAMA ONCOL, V2, P493, DOI 10.1001/jamaoncol.2015.5570
   Jiang WL, 2020, J ORTHOP SURG HONG K, V28, DOI 10.1177/2309499020915989
   Kabunda J, 2021, CLIN NUCL MED, V46, P562, DOI 10.1097/RLU.0000000000003702
   Kasi PM, 2019, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00663
   Keinänen O, 2020, P NATL ACAD SCI USA, V117, P28316, DOI 10.1073/pnas.2009960117
   Kelly JM, 2020, MOL PHARMACEUT, V17, P1954, DOI 10.1021/acs.molpharmaceut.0c00060
   Kemble Jayson, 2023, Expert Rev Anticancer Ther, V23, P177, DOI 10.1080/14737140.2023.2173174
   Khawar A, 2019, ANN NUCL MED, V33, P404, DOI 10.1007/s12149 019 01348 7
   Khojasteh E, 2023, J BONE ONCOL, V40, DOI 10.1016/j.jbo.2023.100477
   Kim H, 2014, BRIT J CLIN PHARMACO, V77, P116, DOI 10.1111/bcp.12150
   Krasnovskaya OO, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24119154
   Kratochwil C, 2018, J NUCL MED, V59, P795, DOI 10.2967/jnumed.117.203539
   Kurt SK, 2016, CHEM ENG J, V284, P764, DOI 10.1016/j.cej.2015.08.099
   Lei L, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/6279826
   Li MS, 2020, CURR MED CHEM, V27, P7003, DOI 10.2174/0929867327999200727190423
   Lindegren S, 2020, CANCER BIOTHER RADIO, V35, P425, DOI 10.1089/cbr.2019.3055
   Ma J, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.796657
   Maisto C, 2022, MOLECULES, V27, DOI 10.3390/molecules27123862
   Manafi Farid R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082622
   Mangano AM, 2018, DIAGNOSTICS, V8, DOI 10.3390/diagnostics8010018
   Manzari MT, 2021, NAT REV MATER, V6, P351, DOI 10.1038/s41578 020 00269 6
   Martini P, 2019, MOLECULES, V24, DOI 10.3390/molecules24020334
   McNeil BL, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 37313 8
   McNeil BL, 2021, EJNMMI RADIOPHARM CH, V6, DOI 10.1186/s41181 021 00121 4
   Miller FH, 2021, RADIOGRAPHICS, V41, P1802, DOI 10.1148/rg.2021210014
   Morgenstern A, 2020, SEMIN NUCL MED, V50, P119, DOI 10.1053/j.semnuclmed.2020.02.003
   Morgenstern A, 2018, CURR RADIOPHARM, V11, P200, DOI 10.2174/1874471011666180502104524
   Mou LLA, 2022, MOLECULES, V27, DOI 10.3390/molecules27051501
   Murthy Ravi, 2008, Semin Intervent Radiol, V25, P48, DOI 10.1055/s 2008 1052306
   Nelson BJB, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010049
   Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470 2045(07)70147 X
   Nishikant D, 2007, J Nucl Med, V48, p142P
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Pain CD, 2022, EUR J NUCL MED MOL I, V49, P3098, DOI 10.1007/s00259 022 05746 4
   Papandrianos N, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10080532
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Parsi M, 2021, MED ONCOL, V38, DOI 10.1007/s12032 021 01537 3
   Patel CM, 2021, MOLECULES, V26, DOI 10.3390/molecules26082162
   PAUWELS EKJ, 1983, EUR J NUCL MED, V8, P118
   Pecher C, 1941, P SOC EXP BIOL MED, V46, P86
   Pfannkuchen N, 2018, CURR RADIOPHARM, V11, P223, DOI 10.2174/1874471011666180604083911
   Putzer D, 2009, J NUCL MED, V50, P1214, DOI 10.2967/jnumed.108.060236
   Radchenko Valery, 2021, J Nucl Med, V62, P1495, DOI 10.2967/jnumed.120.261016
   Ramnaraign B, 2023, ONCOLOGIST, V28, P392, DOI 10.1093/oncolo/oyac279
   Rathke H, 2018, J NUCL MED, V59, P1373, DOI 10.2967/jnumed.117.200220
   Ravi P, 2023, J NUCL MED, V64, P349, DOI 10.2967/jnumed.122.265194
   RAYUDU GVS, 1990, SEMIN NUCL MED, V20, P100, DOI 10.1016/S0001 2998(05)80163 1
   Rheinstein PH, 1998, AM FAM PHYSICIAN, V57, P2865
   Robertson AKH, 2018, CURR RADIOPHARM, V11, P156, DOI 10.2174/1874471011666180416161908
   ROBINSON RG, 1987, NUCL MED BIOL, V14, P219, DOI 10.1016/0883 2897(87)90045 6
   Rodnick ME, 2020, EJNMMI RADIOPHARM CH, V5, DOI 10.1186/s41181 020 00106 9
   Rold T, 2020, J NUCL MED, V61
   Rosenblat TL, 2022, CLIN CANCER RES, V28, P2030, DOI 10.1158/1078 0432.CCR 21 3712
   Sagandira CR, 2020, ARAB J CHEM, V13, P7886, DOI 10.1016/j.arabjc.2020.09.020
   Salih S, 2022, MOLECULES, V27, DOI 10.3390/molecules27165231
   Sartor O, 2021, NEW ENGL J MED, V385, P1091, DOI 10.1056/NEJMoa2107322
   Satapathy S, 2024, CLIN NUCL MED, V49, P131, DOI 10.1097/RLU.0000000000005000
   Sathekge M, 2023, EUR J NUCL MED MOL I, V50, P2210, DOI 10.1007/s00259 023 06165 9
   Seiler RL, 2012, ENVIRON HEALTH PERSP, V120, P1230, DOI 10.1289/ehp.1104607
   Sellier DLWAE, 2020, Design and development of a 3D printed back pressure regulator
   Serani F, 2023, CANCERS, V15, DOI 10.3390/cancers15082208
   Sgouros G, 2020, NAT REV DRUG DISCOV, V19, P589, DOI 10.1038/s41573 020 0073 9
   Sgouros G, 2019, J MED IMAGING RADIAT, V50, pS45, DOI 10.1016/j.jmir.2019.07.007
   Sharma S, 2017, Front Med, P4
   Solnes LB, 2021, SEMIN RADIAT ONCOL, V31, P83, DOI 10.1016/j.semradonc.2020.07.010
   Solodyannikova O I, 2022, Probl Radiac Med Radiobiol, V27, P131, DOI 10.33145/2304 8336 2022 27 131 137
   Starovoitova VN, 2014, APPL RADIAT ISOTOPES, V85, P39, DOI 10.1016/j.apradiso.2013.11.122
   Strosberg J, 2017, NEW ENGL J MED, V376, P125, DOI 10.1056/NEJMoa1607427
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Taheri M, 2018, NUKLEARMED NUCL MED, V57, P174, DOI 10.3413/Nukmed 0989 18 07
   Tarnawska Pierscinska M, 2011, NUCL MED REV, V14, P105, DOI 10.5603/NMR.2011.00024
   Terrisse S, 2020, JAMA ONCOL, V6, P206, DOI 10.1001/jamaoncol.2019.4097
   Thapa P, 2015, J NUCL MED, V56, P1513, DOI 10.2967/jnumed.115.155762
   Thokchom AK, 2022, INDIAN J NUCL MED, V37, P7, DOI 10.4103/ijnm.ijnm_115_21
   Van de Wiele Christophe, 2010, Curr Drug Discov Technol, V7, P247, DOI 10.2174/157016310793360701
   van der Zande K, 2021, CANCERS, V13, DOI 10.3390/cancers13174346
   Violet J, 2019, J NUCL MED, V60, P517, DOI 10.2967/jnumed.118.219352
   Waites LH, 2021, Tools for the Development and Applications of the IsoDAR Cyclotron, P550
   Wang JN, 2019, CLIN NUCL MED, V44, P431, DOI 10.1097/RLU.0000000000002575
   Wang QX, 2023, MOL PHARMACEUT, V20, P1788, DOI 10.1021/acs.molpharmaceut.2c00978
   Wang YW, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1027792
   Wang YW, 2022, MOLECULES, V27, DOI 10.3390/molecules27165294
   Wright CL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/481279
   Xu TT, 2023, CLIN NUCL MED, V48, P650, DOI 10.1097/RLU.0000000000004688
   Yadav MP, 2020, EJNMMI RES, V10, DOI 10.1186/s13550 020 00709 y
   Yong K, 2011, DALTON T, V40, P6068, DOI 10.1039/c0dt01387k
   Yordanova A, 2017, ONCOTARGETS THER, V10, P4821, DOI 10.2147/OTT.S140671
   Zacho HD, 2020, EJNMMI RES, V10, DOI 10.1186/s13550 020 00618 0
   Zenda S, 2014, INT J CLIN ONCOL, V19, P739, DOI 10.1007/s10147 013 0597 7
   Zhang WJ, 2019, TRENDS CANCER, V5, P95, DOI 10.1016/j.trecan.2018.12.004
   Zhang Y, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 20280 x
   Zhao G, 2022, AM J ROENTGENOL, V219, P386, DOI 10.2214/AJR.21.27323
NR 148
TC 8
Z9 9
U1 2
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0969 8051
EI 1872 9614
J9 NUCL MED BIOL
JI Nucl. Med. Biol.
PD MAR
PY 2024
VL 130
AR 108879
DI 10.1016/j.nucmedbio.2024.108879
EA FEB 2024
PG 15
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA LC0A4
UT WOS:001184450300001
PM 38340369
DA 2025 08 17
ER

PT J
AU Miki, Y
   Suzuki, T
   Hatori, M
   Igarashi, K
   Aisaki, K
   Kanno, J
   Nakamura, Y
   Uzuki, M
   Sawai, T
   Sasano, H
AF Miki, Yasuhiro
   Suzuki, Takashi
   Hatori, Masahito
   Igarashi, Katsuhide
   Aisaki, Ken ich
   Kanno, Jun
   Nakamura, Yasuhiro
   Uzuki, Miwa
   Sawai, Takashi
   Sasano, Hironobu
TI Effects of aromatase inhibitors on human osteoblast and osteoblast like
   cells: A possible androgenic bone protective effects induced by
   exemestane
SO BONE
LA English
DT Article
DE osteoblast; aromatase inhibitor; androgen; estrogen; exemestane
ID MINERAL DENSITY; BREAST CANCER; TGF BETA; EXPRESSION; RECEPTORS; MOUSE;
   DIFFERENTIATION; PROLIFERATION; TRANSSEXUALS; THERAPY
AB Effects of aromatase inhibitors (AIs) on the human skeletal system due to systemic estrogen depletion are becoming clinically important due to their increasing use as an adjuvant therapy in postmenopausal women with breast cancer. However, possible effects of AIs on human bone cells have remained largely unknown. We therefore studied effects of AIs including the steroidal AI, exemestane (EXE), and non steroidal AIs, Aromatase Inhibitor I (AI I) and aminoglutethimide (AGM), on a human osteoblast. We employed a human osteoblast cell line, hFOB, which maintains relatively physiological status of estrogen and androgen pathways of human osteoblasts, i.e., expression of aromatase, androgen receptor (AR), and estrogen receptor (ER) beta. We also employed osteoblast like cell lines, Saos 2 and MG 63 which expressed aromatase, AR, and ER alpha/beta in order to ftirther evaluate the mechanisms of effects of AIs on osteoblasts. There was a significant increment in the number of the cells following 72 h treatment with EXE in hFOB and Saos 2 but not in MG 63, in which the level of AR mRNA was lower than that in hFOB and Saos 2. Alkaline phosphatase activity was also increased by EXE treatment in hFOB and Saos 2. Pretreatment with the AR blocker, flutamide, partially inhibited the effect of EXE. AM exerted no effects on ostcoblast cell proliferation and AGM diminished the number of the cells. hFOB converted androstenedione into E2 and testosterone (TST). Both EXE and AM decreased E2 level and increased TST level. In a microarray analysis, gene profile patterns following treatment with EXE demonstrated similar patterns as with DHT but not with E2 treatment. The genes induced by EXE treatment were related to cell proliferation, differentiation which includes genes encoding cytoskeleton proteins. We also examined the expression levels of these genes using quantitative RT PCR in hFOB and Saos 2 treated with EXE and DHT and with/without flutamide. HOXD11 gene known as bone morphogenesis factor and ostcoblast growth related genes were induced by EXE treatment as well as DHT treatment in both hFOB and Saos 2. These results indicated that the steroidal aromatase inhibitor, EXE, stimulated hFOB cell proliferation via both AR dependent and independent pathways. (c) 2006 Elsevier Inc. All rights reserved.
C1 Tohoku Univ, Dept Pathol, Grad Sch Med, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   Tohoku Univ, Dept Orthoped Surg, Grad Sch Med, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   Natl Inst Hlth Sci, Div Toxicol, Biol Safety Res Ctr, Setagaya Ku, Tokyo 158, Japan.
   Iwate Med Univ, Dept Pathol, Morioka, Iwate, Japan.
C3 Tohoku University; Tohoku University; National Institute of Health
   Sciences   Japan; Iwate Medical University
RP Sasano, H (通讯作者)，Tohoku Univ, Dept Pathol, Grad Sch Med, Aoba Ku, 2 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM hsasano@patholo2.med.tohoku.ac.jp
RI Miki, Yasuhiro/AFQ 3410 2022
CR Abu EO, 1997, J CLIN ENDOCR METAB, V82, P3493, DOI 10.1210/jcem.82.10.4319
   Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309
   Boulet AM, 2004, DEVELOPMENT, V131, P299, DOI 10.1242/dev.00936
   Brum IS, 2005, J SOC GYNECOL INVEST, V12, P135, DOI 10.1016/j.jsgi.2004.11.003
   Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842
   Chen Q, 2004, HORM METAB RES, V36, P674, DOI 10.1055/s 2004 826013
   Chen QX, 2001, FEBS LETT, V491, P91, DOI 10.1016/S0014 5793(01)02160 3
   Chow LWC, 2003, J STEROID BIOCHEM, V86, P443, DOI 10.1016/S0960 0760(03)00355 8
   Coleman RE, 2005, BREAST CANCER RES TR, V94, pS233
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   *CTR DRUG EV RES, 1999, 20753 CTR DRUG EV RE
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601
   Goss PE, 2004, BONE, V34, P384, DOI 10.1016/j.bone.2003.11.006
   Goss PE, 2004, CLIN CANCER RES, V10, P5717, DOI 10.1158/1078 0432.CCR 04 0438
   Gutierrez J, 2006, J CELL PHYSIOL, V206, P58, DOI 10.1002/jcp.20428
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Ishizuka M, 2004, CLIN SCI, V106, P293, DOI 10.1042/CS20030317
   Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959 437X(03)00007 8
   Kanno J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471 2164 7 64
   KASPERK C, 1990, J CLIN ENDOCR METAB, V71, P1322, DOI 10.1210/jcem 71 5 1322
   KASPERK CH, 1989, ENDOCRINOLOGY, V124, P1576, DOI 10.1210/endo 124 3 1576
   Kellinsalmi M, 2005, BASIC CLIN PHARMACOL, V97, P382, DOI 10.1111/j.1742 7843.2005.pto_176.x
   Lester J, 2005, BRIT J CANCER, V93, pS16, DOI 10.1038/sj.bjc.6602691
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   Lonning PE, 1997, J STEROID BIOCHEM, V61, P151
   LONNING PE, 2005, J CLIN ONCOL, V23, P4847
   Lundberg P, 2001, ENDOCRINOLOGY, V142, P339, DOI 10.1210/en.142.1.339
   Miki Y, 2005, CANCER LETT, V220, P197, DOI 10.1016/j.canlet.2004.07.024
   Miki Y, 2002, J CLIN ENDOCR METAB, V87, P5760, DOI 10.1210/jc.2002 020670
   Miller W R, 2000, Clin Breast Cancer, V1 Suppl 1, pS9, DOI 10.3816/CBC.2000.s.002
   Omi M, 2005, DEV DYNAM, V233, P288, DOI 10.1002/dvdy.20353
   PUROHIT A, 1992, ENDOCRINOLOGY, V131, P2027, DOI 10.1210/en.131.4.2027
   Recanatini M, 2001, J MED CHEM, V44, P672, DOI 10.1021/jm000955s
   RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85
   RODAN GA, 2002, PRINCIPLES BONE BIOL, V1, P1275
   ROGERS J, 1969, NEW ENGL J MED, V280, P364, DOI 10.1056/NEJM196902132800705
   Ruetsche AG, 2005, OSTEOPOROSIS INT, V16, P791, DOI 10.1007/s00198 004 1754 7
   Sala A, 1999, J CELL PHYSIOL, V179, P245
   Sasano H, 1997, J BONE MINER RES, V12, P1416, DOI 10.1359/jbmr.1997.12.9.1416
   Sato T, 1996, J BONE MINER RES, V11, P392
   SCHWEIKERT HU, 1995, CLIN ENDOCRINOL, V43, P37, DOI 10.1111/j.1365 2265.1995.tb01890.x
   Suzuki T, 2001, J CLIN ENDOCR METAB, V86, P2250, DOI 10.1210/jc.86.5.2250
   TANAKA S, 1993, CALCIFIED TISSUE INT, V52, P107, DOI 10.1007/BF00308318
   Turner A, 2004, CLIN ENDOCRINOL, V61, P560, DOI 10.1111/j.1365 2265.2004.02125.x
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Vottero A, 1999, J CLIN ENDOCR METAB, V84, P1091, DOI 10.1210/jc.84.3.1091
   WINGATE L, 1984, J MED, V15, P243
   Wiren K e., 2002, Principles of Bone Biology, V1, P757
   Yamamoto M, 2003, BIOMATERIALS, V24, P4375, DOI 10.1016/S0142 9612(03)00337 5
NR 50
TC 43
Z9 52
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2007
VL 40
IS 4
BP 876
EP 887
DI 10.1016/j.bone.2006.11.029
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 153GI
UT WOS:000245419800010
PM 17254854
DA 2025 08 17
ER

PT J
AU Fan, CM
   Georgiou, KR
   McKinnon, RA
   Keefe, DMK
   Howe, PRC
   Xian, CJ
AF Fan, Chiaming
   Georgiou, Kristen R.
   McKinnon, Ross A.
   Keefe, Dorothy M. K.
   Howe, Peter R. C.
   Xian, Cory J.
TI Combination chemotherapy with cyclophosphamide, epirubicin and
   5 fluorouracil causes trabecular bone loss, bone marrow cell depletion
   and marrow adiposity in female rats
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Breast cancer chemotherapy; Bone loss; Marrow cellularity; Marrow
   adiposity; Osteoclast
ID EARLY BREAST CANCER; ADJUVANT CHEMOTHERAPY; ESTROGEN DEFICIENCY;
   OSTEOCLAST FORMATION; YOUNG RATS; METHOTREXATE; FLUOROURACIL; REGIMEN;
   WOMEN; SIZE
AB The introduction of anthracyclines to adjuvant chemotherapy has increased survival rates among breast cancer patients. Cyclophosphamide, epirubicin and 5 fluorouracil (CEF) combination therapy is now one of the preferred regimens for treating node positive breast cancer due to better survival with less toxicity involved. Despite the increasing use of CEF, its potential in causing adverse skeletal effects remains unclear. Using a mature female rat model mimicking the clinical setting, this study examined the effects of CEF treatment on bone and bone marrow in long bones. Following six cycles of CEF treatment (weekly intravenous injections of cyclophosphamide at 10 mg/kg, epirubicin at 2.5 mg/kg and 5 flurouracil at 10 mg/kg), a significant reduction in trabecular bone volume was observed at the metaphysis, which was associated with a reduced serum level of bone formation marker alkaline phosphatase (ALP), increased trends of osteoclast density and osteoclast area at the metaphysis, as well as an increased size of osteoclasts being formed from the bone marrow cells ex vivo. Moreover, a severe reduction of bone marrow cellularity was observed following CEF treatment, which was accompanied by an increase in marrow adipose tissue volume. This increase in marrow adiposity was associated with an expansion in adipocyte size but not in marrow adipocyte density. Overall, this study indicates that six cycles of CEF chemotherapy may induce some bone loss and severe bone marrow damage. Mechanisms for CEF induced bone/bone marrow pathologies and potential preventive strategies warrant further investigation.
C1 [Fan, Chiaming; Georgiou, Kristen R.; McKinnon, Ross A.; Keefe, Dorothy M. K.; Xian, Cory J.] Univ S Australia, Sch Pharm & Med Sci, City East Campus,GPO Box 2471, Adelaide, SA 5001, Australia.
   [Fan, Chiaming; Georgiou, Kristen R.; McKinnon, Ross A.; Keefe, Dorothy M. K.; Xian, Cory J.] Univ S Australia, Sansom Inst Hlth Res, City East Campus,GPO Box 2471, Adelaide, SA 5001, Australia.
   [McKinnon, Ross A.] Flinders Univ S Australia, Sch Med, Flinders Ctr Innovat Canc, Bedford Pk, SA 5042, Australia.
   [Keefe, Dorothy M. K.] SA Hlth, SA Canc Clin Network, SA Canc Serv, Adelaide, SA 5000, Australia.
   [Keefe, Dorothy M. K.] Univ Adelaide, Ctr Canc Med, Adelaide, SA 5000, Australia.
   [Howe, Peter R. C.] Univ Newcastle, Sch Biomed Sci & Pharm, Clin Nutr Res Ctr, Callaghan, NSW 2308, Australia.
C3 University of South Australia; University of South Australia; Flinders
   University South Australia; SA Health Australia; University of Adelaide;
   University of Newcastle
RP Xian, CJ (通讯作者)，Univ S Australia, Sch Pharm & Med Sci, City East Campus,GPO Box 2471, Adelaide, SA 5001, Australia.; Xian, CJ (通讯作者)，Univ S Australia, Sansom Inst Hlth Res, City East Campus,GPO Box 2471, Adelaide, SA 5001, Australia.
EM cory.xian@unisa.edu.au
RI ; Georgiou, Kristen/S 1483 2018; Georgiou, Kristen/F 4004 2013;
   McKinnon, Ross/B 9340 2009; Xian, Cory/D 2646 2009; Howe,
   Peter/A 5006 2008
OI Howe, Peter/0000 0001 6546 7742; McKinnon, Ross/0000 0002 3725 793X;
   Georgiou, Kristen/0000 0002 4740 0744; Xian, Cory/0000 0002 8467 2845; 
FU National Health Medical Research Council (NHMRC) of Australia;
   University of South Australia
FX This project was funded in parts by the National Health Medical Research
   Council (NHMRC) of Australia and the University of South Australia. CJ
   Xian is a senior research fellow of NHMRC Australia. The authors thank
   Dr. Alice Lee for the advice on serum ALP assay.
CR Ackland SP, 2001, J CLIN ONCOL, V19, P943, DOI 10.1200/JCO.2001.19.4.943
   Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   [Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD003142
   Berliere M, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 56
   Blogowski W, 2012, OBESITY, V20, P923, DOI 10.1038/oby.2011.398
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Burnell M, 2010, J CLIN ONCOL, V28, P77, DOI 10.1200/JCO.2009.22.1077
   Buttiglieri S, 2011, EXP HEMATOL, V39, P1171, DOI 10.1016/j.exphem.2011.08.009
   Erselcan T, 2000, BRIT J CANCER, V82, P777, DOI 10.1054/bjoc.1999.0998
   Fan CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046915
   Fan CM, 2009, BONE, V44, P61, DOI 10.1016/j.bone.2008.09.014
   Fujita K, 2012, NAT MED, V18, P589, DOI 10.1038/nm.2659
   Georgiou KR, 2012, AM J STEM CELLS, V1, P205
   Georgiou KR, 2012, BONE, V50, P1223, DOI 10.1016/j.bone.2012.03.027
   Glück S, 2005, ONCOLOGIST, V10, P780, DOI 10.1634/theoncologist.10 10 780
   Hui SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042668
   Jenkins Peter, 2010, J Oncol Pharm Pract, V16, P251, DOI 10.1177/1078155209351304
   Jonat W, 2002, J CLIN ONCOL, V20, P4628, DOI 10.1200/JCO.2002.05.042
   Jones LC, 2012, J BONE JOINT SURG BR, V94B, P60
   King TJ, 2012, AM J PATHOL, V181, P121, DOI 10.1016/j.ajpath.2012.03.037
   Kitajima M, 2007, MED MOL MORPHOL, V40, P150, DOI 10.1007/s00795 007 0367 6
   Laing K, 2008, CURR ONCOL, V15, P112
   Lee AMC, 2014, NUTRIENTS, V6, P5871, DOI 10.3390/nu6125871
   Lees RL, 2001, BONE, V28, P187, DOI 10.1016/S8756 3282(00)00433 6
   Martin M, 2003, ANN ONCOL, V14, P833, DOI 10.1093/annonc/mdg260
   MAUCH P, 1995, INT J RADIAT ONCOL, V31, P1319, DOI 10.1016/0360 3016(94)00430 S
   Miller KK, 1999, J CLIN ENDOCR METAB, V84, P1775, DOI 10.1210/jc.84.6.1775
   Miyanishi K, 2002, BONE, V30, P185, DOI 10.1016/S8756 3282(01)00663 9
   Muralikrishnan G, 2001, CANCER LETT, V169, P115, DOI 10.1016/S0304 3835(00)00700 X
   Murthy V, 2012, CANCER CONTROL, V19, P317, DOI 10.1177/107327481201900408
   Nadhanan RR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071592
   Nadhanan RR, 2012, AM J PHYSIOL ENDOC M, V302, pE1440, DOI 10.1152/ajpendo.00587.2011
   Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099
   Nurgalieva Z, 2011, MED ONCOL, V28, P716, DOI 10.1007/s12032 010 9512 5
   Pacifici R, 2008, CELL IMMUNOL, V252, P68, DOI 10.1016/j.cellimm.2007.06.008
   Ponnapakkam T, 2011, J ENDOCRINOL INVEST, V34, pE392, DOI 10.3275/7864
   Sen AK, 2010, Z NATURFORSCH C, V65, P211
   Shapiro CL, 2010, BREAST CANCER RES TR, V123, P815, DOI 10.1007/s10549 010 1099 1
   Shapiro CL, 2001, J CLIN ONCOL, V19, P3306, DOI 10.1200/JCO.2001.19.14.3306
   Shim K, 2008, DRUG SAFETY, V31, P359, DOI 10.2165/00002018 200831050 00001
   Subramaniam S., 1995, Indian Journal of Physiology and Pharmacology, V39, P263
   Tack DK, 2004, ONCOLOGY NY, V18, P1367
   VONWANGENHEIM KH, 1987, RADIAT ENVIRON BIOPH, V26, P163
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Xian CJ, 2004, BONE, V35, P739, DOI 10.1016/j.bone.2004.04.027
NR 45
TC 30
Z9 30
U1 0
U2 5
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2016
VL 34
IS 3
BP 277
EP 290
DI 10.1007/s00774 015 0679 x
PG 14
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA DJ9YE
UT WOS:000374568400004
PM 26056019
DA 2025 08 17
ER

PT J
AU Zhang, LW
   Zhang, L
   You, HJ
   Sun, SX
   Liao, ZR
   Zhao, G
   Chen, JQ
AF Zhang, Liwei
   Zhang, Lei
   You, Hongji
   Sun, Shengxuan
   Liao, Zirui
   Zhao, Gang
   Chen, Jianquan
TI Inhibition of osteoclastogenesis by histone deacetylase inhibitor
   Quisinostat protects mice against titanium particle induced bone loss
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Histone deacetylase inhibitor; Quisinostat; Osteoclastogenesis;
   Periprosthetic osteolysis; NF KB signaling
ID TOTAL JOINT ARTHROPLASTY; MESENCHYMAL STEM CELLS; KNEE REPLACEMENT;
   CONTROLLED TRIAL; TOTAL HIP; C FOS; SUPPRESSES; DIFFERENTIATION;
   OSTEOLYSIS; HDAC
AB Periprosthetic osteolysis (PPO) and subsequent aseptic loosening are major long term complications after total joint arthroplasty and have become the first causes for further revision surgery. Since PPO is primarily caused by excessive bone resorption stimulated by released wear particles, osteoclast targeted therapy is considered to be of great potential for PPO prevention and treatment. Accumulating evidences indicated that inhibition of histone deacetylases (HDACs) may represent a novel approach to suppress osteoclast differentiation. However, different inhibitors of HDACs were shown to exhibit distinct safety profiles and efficacy in inhibiting osteoclastogenesis. Quisinostat (Qst) is a hydroxamate based histone deacetylase inhibitor, and exerts potent anti cancer activity. However, its effect on osteoclastogenesis and its therapeutic potential in preventing PPO are still unclear. In this study, we found that Qst suppressed RANKL induced production of TRAP positive mature osteoclasts, expression of osteoclast specific genes, formation of F actin rings, and bone resorption activity at a nanomolar concentration as low as 2 nM in vitro. Furthermore, we found that as low as 30 mu g/kg of Qst was sufficient to exert preventive effect on titanium particle induced osteolysis in the murine calvarial osteolysis model. Mechanistically, we found that Qst suppressed osteoclastogenesis by interfering with NF KB and c Fos/NFATc1 pathways. Thus, our study revealed that Qst may serve as a potential therapeutic agent for prevention and treatment of PPO and other osteoclast mediated diseases.
C1 [Zhang, Liwei; Zhang, Lei; You, Hongji; Liao, Zirui; Chen, Jianquan] Soochow Univ, Orthoped Inst, Med Coll, Suzhou 215007, Jiangsu, Peoples R China.
   [Zhang, Liwei; Zhang, Lei; You, Hongji; Liao, Zirui; Chen, Jianquan] Soochow Univ, Dept Orthopaed, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.
   [Sun, Shengxuan] Soochow Univ, Dept Orthoped, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China.
   [Zhao, Gang] Soochow Univ, Dept Hand Surg, Wuxi Peoples Hosp 9, Wuxi 214062, Jiangsu, Peoples R China.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China; Soochow University   China
RP Chen, JQ (通讯作者)，Soochow Univ, Orthoped Inst, 708 Renmin Rd, Suzhou 215007, Jiangsu, Peoples R China.; Zhao, G (通讯作者)，Soochow Univ, Wuxi Peoples Hosp 9, 999 Liangxi Rd, Wuxi 214062, Jiangsu, Peoples R China.
EM zhaogangmd@suda.edu.cn; chenjianquan@suda.edu.cn
FU Experimental Animal Science Project of Zhejiang Province [2018C37123];
   Postgraduate Research & Practice Innovation Program of Jiangsu Province
   [KYCX20_2670]; Top Talent Support Program for young and middle aged
   people of Wuxi Heath Committee (2020)
FX This work was supported by Experimental Animal Science Project of
   Zhejiang Province (2018C37123 to Liwei Zhang), Postgraduate Research &
   Practice Innovation Program of Jiangsu Province (KYCX20_2670 to Liwei
   Zhang), and Top Talent Support Program for young and middle aged people
   of Wuxi Heath Committee (2020 to Gang Zhao).
CR Arts J, 2009, CLIN CANCER RES, V15, P6841, DOI 10.1158/1078 0432.CCR 09 0547
   Bhandari M, 2005, J BONE JOINT SURG AM, V87A, P293, DOI 10.2106/JBJS.D.01772
   Bradley EW, 2015, PHYSIOL REV, V95, P1359, DOI 10.1152/physrev.00004.2015
   Cantley MD, 2017, BONE, V95, P162, DOI 10.1016/j.bone.2016.11.028
   Cantley MD, 2011, J CELL PHYSIOL, V226, P3233, DOI 10.1002/jcp.22684
   Cantley MD, 2015, RHEUMATOLOGY, V54, P1713, DOI 10.1093/rheumatology/kev022
   Chen DS, 2012, INT J MOL MED, V30, P1417, DOI 10.3892/ijmm.2012.1145
   Chen GL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02004 y
   Chen JQ, 2015, J BONE MINER RES, V30, P369, DOI 10.1002/jbmr.2348
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Choo QY, 2010, RHEUMATOLOGY, V49, P1447, DOI 10.1093/rheumatology/keq108
   Daugaard H, 2011, CALCIFIED TISSUE INT, V88, P294, DOI 10.1007/s00223 010 9458 9
   Deleu S, 2009, LEUKEMIA, V23, P1894, DOI 10.1038/leu.2009.121
   Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963
   Faulkner B, 2019, MOLECULES, V24, DOI 10.3390/molecules24071355
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Haynes JA, 2016, J ARTHROPLASTY, V31, P622, DOI 10.1016/j.arth.2015.09.026
   Hazzalin CA, 2005, PLOS BIOL, V3, P2111, DOI 10.1371/journal.pbio.0030393
   Hsieh IN, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.133
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Imai Y, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85061
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kandahari AM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.14
   Kim HN, 2012, EUR J PHARMACOL, V691, P69, DOI 10.1016/j.ejphar.2012.07.034
   Kim HN, 2009, EUR J PHARMACOL, V623, P22, DOI 10.1016/j.ejphar.2009.09.025
   Ledin H, 2017, ACTA ORTHOP, V88, P255, DOI 10.1080/17453674.2017.1300746
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mandl LA, 2013, NAT REV RHEUMATOL, V9, P351, DOI 10.1038/nrrheum.2013.27
   McGee Lawrence ME, 2011, BONE, V48, P1117, DOI 10.1016/j.bone.2011.01.007
   Melak M, 2017, J CELL SCI, V130, P525, DOI 10.1242/jcs.189068
   Nakamura T, 2005, J IMMUNOL, V175, P5809, DOI 10.4049/jimmunol.175.9.5809
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Price AJ, 2018, LANCET, V392, P1672, DOI 10.1016/S0140 6736(18)32344 4
   Rahman MM, 2003, BLOOD, V101, P3451, DOI 10.1182/blood 2002 08 2622
   Sadoghi P, 2013, J ARTHROPLASTY, V28, P1329, DOI 10.1016/j.arth.2013.01.012
   Senn SM, 2010, EPILEPSIA, V51, P984, DOI 10.1111/j.1528 1167.2009.02516.x
   Shi M, 2018, OSTEOPOROSIS INT, V29, P1525, DOI 10.1007/s00198 018 4488 7
   Skou ST, 2015, NEW ENGL J MED, V373, P1597, DOI 10.1056/NEJMoa1505467
   Smith RL, 2014, CLIN ORTHOP RELAT R, V472, P3740, DOI 10.1007/s11999 014 3765 9
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Thiele K, 2015, J BONE JOINT SURG AM, V97A, P715, DOI 10.2106/JBJS.M.01534
   Toussirot É, 2010, JOINT BONE SPINE, V77, P395, DOI 10.1016/j.jbspin.2010.03.009
   van den Bosch T, 2017, EPIGENOMICS UK, V9, P1013, DOI 10.2217/epi 2017 0027
   Xu S, 2013, ACTA PHARMACOL SIN, V34, P699, DOI 10.1038/aps.2012.182
   Yang Y., J ORTHOP TRANSLAT, V26, P92
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Zhang LW, 2020, THERANOSTICS, V10, P6638, DOI 10.7150/thno.44793
NR 53
TC 7
Z9 7
U1 0
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 5
PY 2021
VL 904
AR 174176
DI 10.1016/j.ejphar.2021.174176
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SV3MH
UT WOS:000663726100005
PM 34004213
DA 2025 08 17
ER

PT J
AU Asagiri, M
   Hirai, T
   Kunigami, T
   Kamano, S
   Gober, HJ
   Okamoto, K
   Nishikawa, K
   Latz, E
   Golenbock, DT
   Aoki, K
   Ohya, K
   Imai, Y
   Morishita, Y
   Miyazono, K
   Kato, S
   Saftig, P
   Takayanagi, H
AF Asagiri, Masataka
   Hirai, Toshitake
   Kunigami, Toshihiro
   Kamano, Shunya
   Gober, Hans Juergen
   Okamoto, Kazuo
   Nishikawa, Keizo
   Latz, Eicke
   Golenbock, Douglas T.
   Aoki, Kazuhiro
   Ohya, Keiichi
   Imai, Yuuki
   Morishita, Yasuyuki
   Miyazono, Kohei
   Kato, Shigeaki
   Saftig, Paul
   Takayanagi, Hiroshi
TI Cathepsin K dependent Toll like receptor 9 signaling revealed in
   experimental arthritis
SO SCIENCE
LA English
DT Article
ID LYSOSOMAL CYSTEINE PROTEASES; ANTIGEN PRESENTATION; DENDRITIC CELLS;
   INNATE IMMUNITY; BONE LOSS; T CELLS; PYCNODYSOSTOSIS; AUTOIMMUNITY;
   ACTIVATION; ADJUVANTS
AB Cathepsin K was originally identified as an osteoclast  specific lysosomal protease, the inhibitor of which has been considered might have therapeutic potential. We show that inhibition of cathepsin K could potently suppress autoimmune inflammation of the joints as well as osteoclastic bone resorption in autoimmune arthritis. Furthermore, cathepsin K /  mice were resistant to experimental autoimmune encephalomyelitis. Pharmacological inhibition or targeted disruption of cathepsin K resulted in defective Toll  like receptor 9 signaling in dendritic cells in response to unmethylated CpG DNA, which in turn led to attenuated induction of T helper 17 cells, without affecting the antigen  presenting ability of dendritic cells. These results suggest that cathepsin K plays an important role in the immune system and may serve as a valid therapeutic target in autoimmune diseases.
C1 [Asagiri, Masataka; Hirai, Toshitake; Kunigami, Toshihiro; Kamano, Shunya; Gober, Hans Juergen; Okamoto, Kazuo; Nishikawa, Keizo; Takayanagi, Hiroshi] Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Tokyo 1138549, Japan.
   [Asagiri, Masataka; Takayanagi, Hiroshi] Tokyo Med & Dent Univ, Ctr Excellence Program Frontier Res Mol Destruct, Tokyo 1138549, Japan.
   [Aoki, Kazuhiro; Ohya, Keiichi] Tokyo Med & Dent Univ, Grad Sch, Pharmacol Sect, Dept Hard Tissue Engn, Tokyo 1138549, Japan.
   [Hirai, Toshitake; Kunigami, Toshihiro] Nippon Chemiphar Co Ltd, Saitama 3410005, Japan.
   [Kamano, Shunya] Juntendo Univ, Sch Med, Dept Orthopaed Surg, Tokyo 1138421, Japan.
   [Latz, Eicke; Golenbock, Douglas T.] Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA.
   [Imai, Yuuki; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.
   [Morishita, Yasuyuki; Miyazono, Kohei] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan.
   [Imai, Yuuki; Kato, Shigeaki] Japan Sci & Technol Agcy, Exploratory Res Adv Technol, Kawaguchi, Saitama 3320012, Japan.
   [Saftig, Paul] Univ Kiel, Inst Biochem, D 24098 Kiel, Germany.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Juntendo University; University of Massachusetts System; University of
   Massachusetts Worcester; University of Tokyo; University of Tokyo; Japan
   Science & Technology Agency (JST); University of Kiel
RP Takayanagi, H (通讯作者)，Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Tokyo 1138549, Japan.
EM taka.csi@tmd.ac.jp
RI AOKI, Kazuhiro/G 2258 2016; Saftig, Paul/A 7966 2010; Latz,
   Eicke/H 3951 2014; Imai, Yuuki/ABC 4687 2020
OI AOKI, Kazuhiro/0000 0001 6643 6315; Latz, Eicke/0000 0003 1488 5666; 
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Banchereau J, 2004, IMMUNITY, V20, P539, DOI 10.1016/S1074 7613(04)00108 6
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Holmdahl R, 2001, IMMUNOL REV, V184, P184, DOI 10.1034/j.1600 065x.2001.1840117.x
   Honey K, 2003, NAT REV IMMUNOL, V3, P472, DOI 10.1038/nri1110
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Latz E, 2007, NAT IMMUNOL, V8, P772, DOI 10.1038/ni1479
   Marshak Rothstein A, 2006, NAT REV IMMUNOL, V6, P823, DOI 10.1038/nri1957
   Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092 8674(01)00449 4
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Ochi S, 2007, P NATL ACAD SCI USA, V104, P11394, DOI 10.1073/pnas.0701971104
   Prinz M, 2006, J CLIN INVEST, V116, P456, DOI 10.1172/JCI26078
   Riese RJ, 1998, J CLIN INVEST, V101, P2351, DOI 10.1172/JCI1158
   Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Segal BM, 2000, J IMMUNOL, V164, P5683, DOI 10.4049/jimmunol.164.11.5683
   Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040
   Su SB, 2005, J IMMUNOL, V175, P6303, DOI 10.4049/jimmunol.175.10.6303
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
NR 25
TC 263
Z9 297
U1 0
U2 68
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036 8075
EI 1095 9203
J9 SCIENCE
JI Science
PD FEB 1
PY 2008
VL 319
IS 5863
BP 624
EP 627
DI 10.1126/science.1150110
PG 4
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 257AQ
UT WOS:000252772000042
PM 18239127
DA 2025 08 17
ER

PT J
AU Jiang, YK
   Tao, GY
   Guan, YZ
   Chen, SR
   He, YY
   Li, TC
   Zou, SJ
   Li, YY
AF Jiang, Yukun
   Tao, Guiyu
   Guan, Yuzhe
   Chen, Sirui
   He, Yuying
   Li, Tiancheng
   Zou, Shujuan
   Li, Yuyu
TI The role of ephrinB2 EphB4 signalling in bone remodelling during
   orthodontic tooth movement
SO ORTHODONTICS & CRANIOFACIAL RESEARCH
LA English
DT Article
DE alveolar bone remodelling; EphB4; ephrinB2; orthodontic tooth movement
ID LEVEL LASER THERAPY; EPHB4; DIFFERENTIATION; OSTEOBLASTS; MECHANISMS;
   RESORPTION; FORCES; MODEL
AB Objective The aim of this study was to investigate the role of ephrinB2 EphB4 signalling in alveolar bone remodelling on the tension side during orthodontic tooth movement (OTM). Materials and Methods An OTM model was established on sixty 8 week old male Wistar rats. They were randomly divided into the experimental group and the control group. The animals in the experimental group were administrated with subcutaneous injection of EphB4 inhibitor NVP BHG712 every other day, whereas the control group received only the vehicle. Samples containing the maxillary first molar and the surrounding bone were collected after 0, 3, 7, 14 and 21 days of tooth movement. Results EphrinB2 EphB4 signalling was actively expressed on the tension side during tooth movement. Micro CT analysis showed the distance of tooth movement in the experimental group was significantly greater than that of the control group (P < .05) with significantly increased trabecular separation (Tb. Sp) and decreased trabecular number (Tb. N) from day 14 to day 21. The number of osteoclasts significantly increased in the experimental group compared with the control group after 3 and 7 days of tooth movement (P < .05). The expressions of alkaline phosphatase (ALP) and osteopontin (OPN) were significantly reduced by inhibition of EphB4 (P < .05). Conclusion The inhibition of EphB4 suppressed bone formation and enhanced bone resorption activities on the tension side of tooth movement. The ephrinB2 EphB4 signalling might play an important role in alveolar bone remodelling during OTM.
C1 Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University
RP Li, YY (通讯作者)，Sichuan Univ, State Key Lab Oral Dis, West China Sch & Hosp Stomatol, 14,3rd Sect Renmin South Rd, Chengdu 610041, Peoples R China.; Li, YY (通讯作者)，Sichuan Univ, Natl Clin Res Ctr Oral Dis, West China Sch & Hosp Stomatol, 14,3rd Sect Renmin South Rd, Chengdu 610041, Peoples R China.; Li, YY (通讯作者)，Sichuan Univ, Dept Orthodont, West China Sch & Hosp Stomatol, 14,3rd Sect Renmin South Rd, Chengdu 610041, Peoples R China.
EM lyysunnysmell@163.com
RI Li, Yuyu/KFB 7000 2024; chen, sirui/ISB 6443 2023
FU National Natural Science Foundation of China; West China School/Hospital
   of Stomatology, Sichuan University; Sichuan University Postdoctoral
   Interdisciplinary Innovation Fund
FX National Natural Science Foundation of China; Research Funding from West
   China School/Hospital of Stomatology, Sichuan University; Sichuan
   University Postdoctoral Interdisciplinary Innovation Fund
CR Alikhani M, 2015, ORTHOD CRANIOFAC RES, V18, P8, DOI 10.1111/ocr.12090
   An JT, 2017, EXP THER MED, V13, P1793, DOI 10.3892/etm.2017.4186
   [Anonymous], 1997, Cell, V90, P403
   Arifin WN, 2017, MALAYS J MED SCI, V24, P101, DOI 10.21315/mjms2017.24.5.11
   Batra N, 2012, BBA BIOMEMBRANES, V1818, P1909, DOI 10.1016/j.bbamem.2011.09.018
   Taddei SRD, 2012, J BIOMECH, V45, P2729, DOI 10.1016/j.jbiomech.2012.09.006
   De Luca I, 2016, STEM CELL RES, V17, P248, DOI 10.1016/j.scr.2016.07.005
   Diercke K, 2011, J BIOL CHEM, V286, P37651, DOI 10.1074/jbc.M110.166900
   Gudhimella S, 2019, AM J ORTHOD DENTOFAC, V155, P254, DOI 10.1016/j.ajodo.2018.03.022
   Guo ZJ, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005124
   Guram G, 2018, CONTEMP CLIN DENT, V9, P105, DOI 10.4103/ccd.ccd_864_17
   Hemanth M, 2015, J Int Oral Health, V7, P114
   Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357 2725(02)00096 1
   Hou JH, 2014, KOREAN J ORTHOD, V44, P320, DOI 10.4041/kjod.2014.44.6.320
   Huang HM, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6531216
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Jiang LP, 2018, MOL MED REP, V17, P1499, DOI 10.3892/mmr.2017.8021
   Jin HM, 2019, J CELL MOL MED, V23, P522, DOI 10.1111/jcmm.13955
   Muñoz JJ, 2011, NEUROIMMUNOMODULAT, V18, P271, DOI 10.1159/000329490
   Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856
   Li F, 2013, AM J ORTHOD DENTOFAC, V144, P523, DOI 10.1016/j.ajodo.2013.05.010
   Li TC, 2021, J CELL PHYSIOL, V236, P2070, DOI 10.1002/jcp.29994
   Martin TJ, 2010, ADV EXP MED BIOL, V658, P51, DOI 10.1007/978 1 4419 1050 9_6
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Obi S, 2009, J APPL PHYSIOL, V106, P203, DOI 10.1152/japplphysiol.00197.2008
   Omidkhoda Maryam, 2018, J Dent (Shiraz), V19, P74
   Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662
   Suzuki SS, 2016, J BIOPHOTONICS, V9, P1222, DOI 10.1002/jbio.201600016
   Tsolakis AI, 2018, J MUSCULOSKEL NEURON, V18, P366
   Wang LM, 2018, J PERIODONTAL RES, V53, P66, DOI 10.1111/jre.12488
   Wise GE, 2008, J DENT RES, V87, P414, DOI 10.1177/154405910808700509
   Zhang RH, 2011, ANAT REC, V294, P406, DOI 10.1002/ar.21324
   Zhang ZD, 2019, MOL MED REP, V19, P3505, DOI 10.3892/mmr.2019.10051
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 34
TC 3
Z9 3
U1 0
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1601 6335
EI 1601 6343
J9 ORTHOD CRANIOFAC RES
JI Orthod. Craniofac. Res.
PD FEB
PY 2023
VL 26
IS 1
BP 107
EP 116
DI 10.1111/ocr.12591
EA JUN 2022
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 8C0CJ
UT WOS:000813357600001
PM 35621382
DA 2025 08 17
ER

PT J
AU Jeon, EJ
   Lee, DH
   Kim, YJ
   Ahn, J
   Kim, MJ
   Hwang, JT
   Hur, J
   Kim, M
   Jang, YJ
   Ha, TY
   Seo, DH
   Lee, JS
   Sung, MJ
   Jung, CH
AF Jeon, Eun Joo
   Lee, Da Hye
   Kim, Yang Ji
   Ahn, Jiyun
   Kim, Min Jung
   Hwang, Jin Taek
   Hur, Jinyoung
   Kim, Mina
   Jang, Young Jin
   Ha, Tae Youl
   Seo, Dong Hyun
   Lee, Jong Suk
   Sung, Mi Jeong
   Jung, Chang Hwa
TI Effects of yuja peel extract and its flavanones on osteopenia in
   ovariectomized rats and osteoblast differentiation
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE Flavanones; Osteoblastogenesis; Osteopenia; Ovariectomized; Yuja (Citrus
   junos Tanaka)
ID BONE LOSS; HESPERIDIN; YUZU; BIOAVAILABILITY; EXPRESSION; RESORPTION;
   TANAKA; SERUM; BMP 2; MICE
AB Scope: Yuja (Citrus junos Tanaka) possesses various health benefits, but its effects on bone health are unknown. In this study, the preventative effects of yuja peel ethanol extract (YPEE) on osteopenia were determined in ovariectomized (OVX) rats, and the mechanisms by which YPEE and its flavanones regulate osteoblastogenesis were examined in vitro.
   Methods and results: The effects of YPEE on osteoblastogenesis were investigated in MC3T3 E1 cells. YPEE promoted alkaline phosphatase (ALP) activity, mineralization, and the expression of osteoblast differentiation marker genes, such as ALP, runt related transcription factor 2 (Runx2), and osteocalcin. YPEE and its flavanones promoted osteoblast differentiation via BMP 2 mediated p38 and the Smad1/5/8 signaling pathway. YPEE supplementation significantly decreased body weight and increased uterine weight and bone mineral density in OVX rats. Based on a micro CT analysis of femurs, YPEE significantly attenuated osteopenia and increased trabecular volume fraction, trabecular separation, and trabecular number (p < 0.05).
   Conclusion: Dietary YPEE has a protective effect on OVX induced osteopenia. YPEE and its flavanones promote osteoblastogenesis via the activation of the BMP/p38/Smad/Runx2 pathways. These results extend our knowledge of the beneficial effects of YPEE and provide a basis for the development of novel therapies for osteoporosis.
C1 [Jeon, Eun Joo; Hwang, Jin Taek; Sung, Mi Jeong] Korea Food Res Inst, Res Grp Nutr & Diet, Seongnam, South Korea.
   [Lee, Da Hye; Kim, Yang Ji; Ahn, Jiyun; Kim, Min Jung; Hur, Jinyoung; Kim, Mina; Jang, Young Jin; Ha, Tae Youl; Jung, Chang Hwa] Korea Food Res Inst, Res Grp Metab Mech, Seongnam, South Korea.
   [Lee, Da Hye; Kim, Yang Ji; Ahn, Jiyun; Hwang, Jin Taek; Hur, Jinyoung; Ha, Tae Youl; Sung, Mi Jeong; Jung, Chang Hwa] Korea Univ Sci & Technol, Dept Food Biotechnol, Seongnam, South Korea.
   [Seo, Dong Hyun] Yonsei Univ, Dept Biomed Engn, Wonju, South Korea.
   [Lee, Jong Suk] Gyeonggi Inst Sci & Technol Promot, Dept Anal Support, Suwon, South Korea.
C3 Korea Food Research Institute (KFRI); Korea Food Research Institute
   (KFRI); Yonsei University
RP Sung, MJ (通讯作者)，Korea Food Res Inst, Res Grp Nutr & Diet, Seongnam, South Korea.; Jung, CH (通讯作者)，Korea Food Res Inst, Res Grp Metab Mech, Seongnam, South Korea.; Sung, MJ; Jung, CH (通讯作者)，Korea Univ Sci & Technol, Dept Food Biotechnol, Seongnam, South Korea.
EM chjung@kfri.re.kr
RI ; Jang, Young/AAT 1192 2020
OI Jang, Young Jin/0000 0003 0553 2498; 
FU Korea Food Research Institute of South Korea; National Research Council
   of Science & Technology (NST) grant by the Korea government (MSIP)
   [CAP 15 09 KIMS]
FX This study was supported by a grant from the Korea Food Research
   Institute of South Korea and National Research Council of Science &
   Technology (NST) grant by the Korea government (MSIP, No.
   CAP 15 09 KIMS).
CR Bartolozzi E, 2015, CLIN CASES MINER BON, V12, P111, DOI 10.11138/ccmbm/2015.12.2.111
   Carinci F, 2005, ARCH ORAL BIOL, V50, P481, DOI 10.1016/j.archoralbio.2004.11.006
   Chiba H, 2003, J NUTR, V133, P1892, DOI 10.1093/jn/133.6.1892
   Chung HJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 184
   Eshtiaghi R, 2010, MATURITAS, V65, P262, DOI 10.1016/j.maturitas.2009.11.004
   Fan JF, 2015, MOL MED REP, V12, P4759, DOI 10.3892/mmr.2015.3996
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Habauzit V, 2011, BONE, V49, P1108, DOI 10.1016/j.bone.2011.07.030
   Habauzit V, 2009, BRIT J NUTR, V102, P976, DOI 10.1017/S0007114509338830
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hirata M, 2009, J HEALTH SCI, V55, P463, DOI 10.1248/jhs.55.463
   Hirota R, 2010, J FOOD SCI, V75, pH87, DOI 10.1111/j.1750 3841.2010.01541.x
   Horcajada MN, 2008, J APPL PHYSIOL, V104, P648, DOI 10.1152/japplphysiol.00441.2007
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359 6101(00)00030 7
   Hosking DJ, 1998, CLIN THER, V20, P933, DOI 10.1016/S0149 2918(98)80075 1
   Kim SH, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/921012
   Kim TH, 2015, BIOMOL THER, V23, P149, DOI 10.4062/biomolther.2015.011
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Lee D. H., 2016, J FUNCT FOODS, V16, P484
   Li NH, 2013, J ORTHOP SCI, V18, P478, DOI 10.1007/s00776 013 0362 9
   MCELROY JF, 1987, PHYSIOL BEHAV, V39, P361, DOI 10.1016/0031 9384(87)90235 6
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Nie QX, 2017, CRIT REV FOOD SCI, V57, P2432, DOI 10.1080/10408398.2015.1077194
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Peterson JJ, 2006, J FOOD COMPOS ANAL, V19, pS74, DOI 10.1016/j.jfca.2005.12.009
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Roudsari JM, 2012, CASP J INTERN MED, V3, P478
   Shen CL, 2012, NUTR RES, V32, P897, DOI 10.1016/j.nutres.2012.09.018
   Sieber C, 2009, CYTOKINE GROWTH F R, V20, P343, DOI 10.1016/j.cytogfr.2009.10.007
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Trzeciakiewicz A, 2010, J NUTR BIOCHEM, V21, P424, DOI 10.1016/j.jnutbio.2009.01.017
   Trzeciakiewicz A, 2010, J AGR FOOD CHEM, V58, P668, DOI 10.1021/jf902680n
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Wong RWK, 2006, BIOMATERIALS, V27, P1824, DOI 10.1016/j.biomaterials.2005.11.009
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325
   Yang GB, 2014, J CELL PHYSIOL, V229, P943, DOI 10.1002/jcp.24525
   Yang HJ, 2013, J NUTR, V143, P1093, DOI 10.3945/jn.112.173401
   Yoo KM, 2004, J AGR FOOD CHEM, V52, P5907, DOI 10.1021/jf0498158
   You MK, 2015, NUTR RES PRACT, V9, P459, DOI 10.4162/nrp.2015.9.5.459
NR 40
TC 15
Z9 15
U1 0
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1613 4125
EI 1613 4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD DEC
PY 2016
VL 60
IS 12
BP 2587
EP 2601
DI 10.1002/mnfr.201600257
PG 15
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA EJ3ZV
UT WOS:000393156600006
PM 27506630
DA 2025 08 17
ER

PT J
AU Lan, Q
   Xiao, X
   Bi, XT
   Gu, YC
   Ai, YL
AF Lan, Qian
   Xiao, Xin
   Bi, Xueting
   Gu, Yangcong
   Ai, Yilong
TI Effects of periodontal ligament stem cell derived exosomes on
   osteoblastic proliferation, migration, differentiation, apoptosis, and
   signaling pathways
SO ORAL DISEASES
LA English
DT Article
DE apoptosis; exosomes; migration; periodontal disease; periodontal
   ligament stem cells; proliferation
ID THERAPY; COMMUNICATION; REGENERATION; METASTASIS; BIOLOGY
AB Objective Periodontitis is characterized by alveolar bone injury and absorption, with high incidence and poor treatment effect. Proliferation, migration, differentiation and apoptosis of osteoblasts are identified as key factors during the regeneration of alveolar bone tissue processes. Periodontal ligament stem cells (PDLSCs) have been proved to be a possible candidate for the treatment of periodontitis due to its multiple advantages, such as increasing the regenerative capacity of bone tissue. However, the effect of exosomes derived from PDLSCs (PDLSC Exo) on osteoblasts remains to be further studied. Methods and Materials In this work, cell proliferation, migration, osteogenic differentiation, and H2O2 induced apoptosis were detected after cells were exposed to PDLSC Exo by CCK 8, scratch wound assay, alizarin red S and alkaline phosphatase staining, real time PCR, flow cytometry, tunel assay, and so on. Moreover, the activation of PI3K/AKT and MEK/ERK signaling pathways was evaluated by western blotting. Results We found that PDLSC Exo are capable of promoting hFOB1.19 cell proliferation, migration and osteogenic differentiation, inhibiting H2O2 induced apoptosis, and activating the PI3K/AKT and MEK/ERK signaling pathways. Conclusion These results suggest that PDLSC Exo may be a promising therapeutic for osteoblastic damage.
C1 [Lan, Qian; Xiao, Xin; Bi, Xueting] Foshan Univ, Foshan Stomatol Hosp, Dept Periodont, Foshan, Guangdong, Peoples R China.
   [Lan, Qian; Xiao, Xin; Bi, Xueting; Gu, Yangcong; Ai, Yilong] Foshan Univ, Sch Med, Foshan, Guangdong, Peoples R China.
   [Gu, Yangcong] Foshan Univ, Foshan Stomatol Hosp, Dept Maxillofacial Surg, Foshan, Guangdong, Peoples R China.
   [Ai, Yilong] Foshan Univ, Foshan Stomatol Hosp, Dept Orthodont, Foshan, Guangdong, Peoples R China.
C3 Foshan University; Foshan University; Foshan University; Foshan
   University
RP Lan, Q (通讯作者)，Foshan Univ, Foshan Stomatol Hosp, Dept Periodont, Foshan, Guangdong, Peoples R China.; Lan, Q; Ai, YL (通讯作者)，Foshan Univ, Sch Med, Foshan, Guangdong, Peoples R China.; Ai, YL (通讯作者)，Foshan Univ, Foshan Stomatol Hosp, Dept Orthodont, Foshan, Guangdong, Peoples R China.
EM maggielan@126.com; aiyilong@126.com
RI ; 兰, 倩/HTL 8188 2023
OI Qian, Lan/0000 0002 2010 6836; 
FU Foshan Engineering Technology Research Center [2120001008692]
FX Foshan Engineering Technology Research Center, Grant/Award Number:
   2120001008692
CR Bright R, 2015, J PERIODONTAL RES, V50, P160, DOI 10.1111/jre.12205
   He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945
   Huang L, 2013, INVEST OPHTH VIS SCI, V54, P3965, DOI 10.1167/iovs.13 11910
   Ibrahim A, 2016, ANNU REV PHYSIOL, V78, P67, DOI 10.1146/annurev physiol 021115 104929
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Lai RC, 2015, SEMIN CELL DEV BIOL, V40, P82, DOI 10.1016/j.semcdb.2015.03.001
   Li Q, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01938 7
   Liu J, 2020, J DENT, V92, DOI 10.1016/j.jdent.2019.103259
   Lv PY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01815 3
   Ma T, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3290372
   Ma YM, 2020, AM J TRANSL RES, V12, P3895
   Maeda H, 2020, WORLD J STEM CELLS, V12, P1023, DOI 10.4252/wjsc.v12.i9.1023
   Milane L, 2015, J CONTROL RELEASE, V219, P278, DOI 10.1016/j.jconrel.2015.06.029
   Monsel A, 2016, EXPERT OPIN BIOL TH, V16, P859, DOI 10.1517/14712598.2016.1170804
   Morsczeck C, 2018, EXPERT OPIN BIOL TH, V18, P187, DOI 10.1080/14712598.2018.1402004
   Nagata M, 2017, TISSUE ENG PT A, V23, P367, DOI [10.1089/ten.tea.2016.0274, 10.1089/ten.TEA.2016.0274]
   Nuñez J, 2019, PERIODONTOL 2000, V79, P107, DOI 10.1111/prd.12250
   Tang YY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02138 7
   Tavelli L, 2020, J PERIODONTOL, V91, P147, DOI 10.1002/JPER.19 0352
   Tomokiyo A, 2019, STEM CELLS DEV, V28, P974, DOI 10.1089/scd.2019.0031
   Trubiani O, 2019, STEM CELLS DEV, V28, P995, DOI 10.1089/scd.2019.0025
   Trzyna A, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11060878
   Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011
   Wu HY, 2021, J PHARMACOL SCI, V147, P143, DOI 10.1016/j.jphs.2021.06.008
   Zhou XN, 2020, CANCER SCI, V111, P3100, DOI 10.1111/cas.14563
   Yu M, 2017, J PERIODONTOL, V88, pE159, DOI 10.1902/jop.2017.170016
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
   Zhang L, 2019, BBA REV CANCER, V1871, P455, DOI 10.1016/j.bbcan.2019.04.004
   Zhang Y, 2020, INT J NANOMED, V15, P6917, DOI 10.2147/IJN.S264498
   Zhang ZY, 2021, J LEUKOCYTE BIOL, V110, P565, DOI 10.1002/JLB.4MR0421 750R
NR 30
TC 19
Z9 20
U1 4
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1354 523X
EI 1601 0825
J9 ORAL DIS
JI Oral Dis.
PD MAR
PY 2024
VL 30
IS 2
BP 710
EP 718
DI 10.1111/odi.14375
EA SEP 2022
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA KE2C8
UT WOS:000860308500001
PM 36076350
DA 2025 08 17
ER

PT J
AU Lee, JM
   Park, H
   Noh, ALSM
   Kang, JH
   Chen, L
   Zheng, T
   Lee, J
   Ji, SY
   Jang, CY
   Shin, CS
   Ha, H
   Lee, ZH
   Park, HY
   Lee, DS
   Yim, M
AF Lee, Jung Min
   Park, Hyojung
   Noh, A. Long Sae Mi
   Kang, Ju Hee
   Chen, Ling
   Zheng, Ting
   Lee, Juhyun
   Ji, Sun Young
   Jang, Chang Young
   Shin, Chan Soo
   Ha, Hyunil
   Lee, Zang Hee
   Park, Hea Young
   Lee, Dong Seok
   Yim, Mijung
TI 5 Lipoxygenase Mediates RANKL Induced Osteoclast Formation via the
   Cysteinyl Leukotriene Receptor 1
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NECROSIS FACTOR RECEPTOR; GENE EXPRESSION; BONE RESORPTION; B 4
   RECEPTOR; IN VITRO; T CELLS; DIFFERENTIATION; INHIBITION; TRANCE; LIGAND
AB 5 Lipoxygenase (5 LO) catalyzes the formation of two major groups of leukotrienes, leukotriene B4 and cysteinyl leukotrienes (CysLTs), and it has been implicated as a promising drug target to treat various inflammatory diseases. However, its role in osteoclastogenesis has not been investigated. In this study, we used mouse bone marrow derived macrophages (BMMs) to show that 5 LO inhibitor suppresses RANKL induced osteoclast formation. Inhibition of 5 LO was associated with impaired activation of multiple signaling events downstream of RANK, including ERK and p38 phosphorylation, and I kappa B degradation, followed by a decrease in NFATc1 expression. Ectopic overexpression of a constitutively active form of NFATc1 partly rescued the antiosteoclastogenic effect of 5 LO inhibitor. The knockdown of 5 LO in BMMs also resulted in a significant reduction in RANKL induced osteoclast formation, accompanied by decreased expression of NFATc1. Similar effects were shown with CysLT receptor (CysLTR)1/2 antagonist and small RNA for CysLTR1 in BMMs, indicating the involvement of CysLT and CysLTR1 in 5 LO mediated osteoclastogenesis. Finally, 5 LO inhibitor suppressed LPS induced osteoclast formation and bone loss in the in vivo mouse experiments, suggesting a potential therapeutic strategy for treating diseases involving bone destruction. Taken together, the results of this study demonstrate that 5 LO is a key mediator of RANKL induced osteoclast formation and possibly a novel therapeutic target for bone resorption diseases. The Journal of Immunology, 2012, 189: 5284 5292.
C1 [Lee, Jung Min; Park, Hyojung; Noh, A. Long Sae Mi; Kang, Ju Hee; Chen, Ling; Zheng, Ting; Lee, Juhyun; Ji, Sun Young; Jang, Chang Young; Yim, Mijung] Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea.
   [Shin, Chan Soo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea.
   [Ha, Hyunil; Lee, Zang Hee] Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, Seoul 110749, South Korea.
   [Park, Hea Young] Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea.
   [Lee, Dong Seok] Kyungpook Natl Univ, Coll Nat Sci, Taegu 702701, South Korea.
C3 Sookmyung Women's University; Seoul National University (SNU); Seoul
   National University (SNU); Ewha Womans University; Kyungpook National
   University (KNU)
RP Yim, M (通讯作者)，Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea.
EM myim@sookmyung.ac.kr
RI Shin, Chan/I 7320 2012; Zheng, Ting/ITR 8293 2023; Lee,
   Jung Min/L 8227 2016; Kim, Se Ho/IUP 3256 2023
OI Zheng, Ting/0000 0001 7723 7653; Lee, Dong Seok/0000 0001 6348 8937; 
FU National Research Foundation of Korea [2012 0000684, 2011 0030700,
   2012 0004319]; Ministry of Education, Science and Technology
FX This work was supported by the Science Research Center program
   (2012 0000684), the Medical Research Center program (2011 0030700), and
   the Basic Science Research program (2012 0004319) through National
   Research Foundation of Korea grants funded by the Ministry of Education,
   Science and Technology to M.Y.
CR Berger W, 2007, INT J CLIN PRACT, V61, P663, DOI 10.1111/j.1742 1241.2007.01320.x
   Bonewald LF, 1997, ADV EXP MED BIOL, V433, P299
   Capra V, 2003, PROSTAG OTH LIPID M, V71, P235, DOI 10.1016/S1098 8823(03)00045 5
   CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891
   Cottrell JA, 2009, J BONE JOINT SURG AM, V91A, P2653, DOI 10.2106/JBJS.H.01844
   Diamant Z, 2009, EXPERT REV CLIN IMMU, V5, P639, DOI 10.1586/ECI.09.62
   Evans JF, 2002, PROSTAG OTH LIPID M, V68 9, P587, DOI 10.1016/S0090 6980(02)00057 6
   Garcia C, 1996, J BONE MINER RES, V11, P1619
   Ha H, 2006, J IMMUNOL, V176, P111, DOI 10.4049/jimmunol.176.1.111
   Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200
   Hikiji H, 2009, P NATL ACAD SCI USA, V106, P21294, DOI 10.1073/pnas.0905209106
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Lee J, 2006, BLOOD, V107, P2686, DOI 10.1182/blood 2005 07 2798
   Lynch KR, 1999, NATURE, V399, P789
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Mehta M, 2010, BONE, V47, P219, DOI 10.1016/j.bone.2010.05.029
   Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Murphy RC, 2007, BIOCHEM J, V405, P379, DOI 10.1042/BJ20070289
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Peters Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   Rådmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178
   Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359 6101(03)00027 3
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Yagi M, 2007, J BONE MINER RES, V22, P992, DOI 10.1359/JBMR.070401
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421
   Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506
   Young RN, 1999, EUR J MED CHEM, V34, P671, DOI 10.1016/S0223 5234(99)00225 1
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 36
TC 27
Z9 28
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 2012
VL 189
IS 11
BP 5284
EP 5292
DI 10.4049/jimmunol.1003738
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 039ZJ
UT WOS:000311287600025
PM 23109727
DA 2025 08 17
ER

PT J
AU Han, B
   Wei, SP
   Zhang, XC
   Li, H
   Li, Y
   Li, RX
   Li, K
   Zhang, XZ
AF Han, Biao
   Wei, Shu Ping
   Zhang, Xin Chang
   Li, Hao
   Li, Yu
   Li, Rui Xin
   Li, Kairen
   Zhang, Xi Zheng
TI Effects of constrained dynamic loading, CKIP 1 gene knockout and
   combination stimulations on bone loss caused by mechanical unloading
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE mechanical unloading; bone loss; constrained dynamic loading; CKIP 1
   knockout; bone formation; bone resorption
ID OSTEOBLAST DIFFERENTIATION; TARGETING CKIP 1; DELIVERY SYSTEM;
   OSTEOPOROSIS; PROTEIN; CELLS; SPACEFLIGHT; OSTEOPROTEGERIN;
   OSTEOCLASTOGENESIS; PROLIFERATION
AB Mechanical stimulation plays an important role in maintaining the growth and normal function of the skeletal system. Mechanical unloading occurs, for example, in astronauts spending long periods of time in space or in patients on prolonged bed rest, and causes a rapid loss of bone mass. Casein kinase 2 interacting protein 1 (CKIP 1) is a novel negative bone regulation factor that has been demonstrated to reduce bone loss and enhance bone formation. The aim of this study was to investigate the effect of constrained dynamic loading (Loading) in combination with CKIP 1 gene knockout (KO) on unloading induced bone loss in tail suspension mice. The blood serum metabolism index [alkaline phosphatase (ALP) activity and osteocalcin (OCN) levels], tibia mechanical behavior (including bone trabecular microstructure parameters and tibia biomechanical properties), osteoblast related gene expression [ALP, OCN, collagen I and bone morphogenetic protein 2 and osteoprotegerin (OPG)] and osteoclast related gene expression [receptor activators of NF kB ligand (RANKL)] were measured. The results demonstrated that mice experienced a loss of bone mass after four weeks of tail suspension compared with a wild type group. The mechanical properties, microarchitecture and mRNA expression were significantly increased in mice after Loading + KO treatment (P<0.05). Furthermore, compared with loading or KO alone, the ratio of OPG/RANKL was increased in the combined treatment group. The combined effect of Loading + KO was greater than that observed with loading or KO alone (P<0.05). The present study demonstrates that Loading + KO can counter unloading induced bone loss, and combining the two treatments has an additive effect. These results indicate that combined therapy could be a novel strategy for the clinical treatment of disuse osteoporosis associated with space travel or bed rest.
C1 [Han, Biao; Wei, Shu Ping; Li, Hao; Li, Rui Xin; Li, Kairen; Zhang, Xi Zheng] Acad Mil Med Sci, Tianjin Inst Med Equipment, Dept Biomed Engn & Med Technol, 106 Wandong Rd, Tianjin 300161, Peoples R China.
   [Zhang, Xin Chang; Li, Yu] Logist Coll Peoples Armed Police Forces, Dept Clin Med, Tianjin 300162, Peoples R China.
C3 Academy of Military Medical Sciences   China
RP Zhang, XZ (通讯作者)，Acad Mil Med Sci, Tianjin Inst Med Equipment, Dept Biomed Engn & Med Technol, 106 Wandong Rd, Tianjin 300161, Peoples R China.
EM z84656716@yaoo.com
RI Zhang, Xinchang/HOH 1114 2023; biao, han/GRX 8847 2022; Li,
   Hao/HKO 5710 2023
FU National Natural Science Foundation of China [31370942, 11432016]
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 31370942 and 11432016).
CR Allen DL, 2009, J APPL PHYSIOL, V106, P582, DOI 10.1152/japplphysiol.90780.2008
   Baas D, 2012, J CELL SCI, V125, P3790, DOI 10.1242/jcs.101048
   Barger Lux M Janet, 2002, Top Magn Reson Imaging, V13, P297
   Barry PL, 2001, GOOD VIBRATIONS NEW
   Cicciù M, 2017, J CRANIOFAC SURG, V28, P592, DOI 10.1097/SCS.0000000000003595
   Crucian B, 2009, J LEUKOCYTE BIOL, V86, P1017, DOI 10.1189/jlb.0709500
   Ferrari Lacraz S, 2011, OSTEOPOROSIS INT, V22, P435, DOI 10.1007/s00198 010 1326 y
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Frost HM, 1997, BONE, V20, P385, DOI 10.1016/S8756 3282(97)00019 7
   Goodship AE, 1998, ACTA ASTRONAUT, V43, P65, DOI 10.1016/S0094 5765(98)00144 1
   Guo BS, 2014, BONE, V59, P76, DOI 10.1016/j.bone.2013.11.007
   Guo Y, 2012, BIOMED ENG ONLINE, V11, DOI 10.1186/1475 925X 11 80
   Hatton DC, 2002, J APPL PHYSIOL, V92, P3, DOI 10.1152/jappl.2002.92.1.3
   Herford AS, 2010, J CRANIOFAC SURG, V21, P1970, DOI 10.1097/SCS.0b013e3181f502fa
   Herford AS, 2016, INT J CLIN EXP MED, V9, P17187
   HILLAM RA, 1995, J BONE MINER RES, V10, P683
   Jansen JHW, 2010, J ORTHOP RES, V28, P390, DOI 10.1002/jor.20991
   Jaul E, 2009, J AM GERIATR SOC, V57, P1318, DOI 10.1111/j.1532 5415.2009.02334.x
   Judex S, 2009, ORTHOD CRANIOFAC RES, V12, P94, DOI 10.1111/j.1601 6343.2009.01442.x
   Kaspar D, 2002, J BIOMECH, V35, P873, DOI 10.1016/S0021 9290(02)00058 1
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kühn MC, 2012, MOL CELL ENDOCRINOL, V349, P180, DOI 10.1016/j.mce.2011.10.018
   Landis WJ, 2000, J BONE MINER RES, V15, P1099, DOI 10.1359/jbmr.2000.15.6.1099
   Li H, 2013, J BIOMECH, V46, P1242, DOI 10.1016/j.jbiomech.2013.02.016
   Li J, 2017, BONE, V97, P2, DOI 10.1016/j.bone.2016.12.009
   Liu L, 2012, ACTA BIOCH BIOPH SIN, V44, P669, DOI 10.1093/abbs/gms049
   Liu QL, 2018, MOL MED REP, V17, P4797, DOI 10.3892/mmr.2018.8416
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   NASA, 2012, STRONG BON FEW REN S
   Nie J, 2013, AGEING RES REV, V12, P276, DOI 10.1016/j.arr.2012.07.002
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Olsten MEK, 2005, MOL CELL BIOCHEM, V274, P115, DOI 10.1007/s11010 005 3072 6
   Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Song DH, 2003, J BIOL CHEM, V278, P24018, DOI 10.1074/jbc.M212260200
   Stürmer EK, 2006, J BONE MINER RES, V21, P89, DOI 10.1359/JBMR.050913
   Sun LW, 2014, INT J SPORTS MED, V35, P615, DOI 10.1055/s 0033 1358468
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Tavella S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033179
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140 6736(00)02217 0
   Wang LA, 2010, CELL PHYSIOL BIOCHEM, V26, P1093, DOI 10.1159/000323987
   Wang QS, 2018, J ORTHOP RES, V36, P1415, DOI 10.1002/jor.23777
   Wang QS, 2015, BIOMED ENG ONLINE, V14, DOI 10.1186/s12938 015 0039 z
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang YY, 2012, BONE, V50, P409, DOI 10.1016/j.bone.2011.07.012
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yu HC, 2010, J BONE MINER RES, V25, P1128, DOI 10.1002/jbmr.9
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang L, 2017, ACS APPL MATER INTER, V9, P34722, DOI 10.1021/acsami.7b12079
   Zhang XC, 2016, PROG BIOPHYS MOL BIO, V122, P140, DOI 10.1016/j.pbiomolbio.2016.09.007
   Zhou ZC, 2017, OR SURG OR MED OR PA, V123, pE1, DOI 10.1016/j.oooo.2016.07.013
NR 55
TC 9
Z9 11
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD AUG
PY 2018
VL 18
IS 2
BP 2506
EP 2514
DI 10.3892/mmr.2018.9222
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GP1NU
UT WOS:000440583800154
PM 29956799
OA Bronze
DA 2025 08 17
ER

PT J
AU Guo, J
   Yang, D
   Okamura, H
   Teramachi, J
   Ochiai, K
   Qiu, L
   Haneji, T
AF Guo, J.
   Yang, D.
   Okamura, H.
   Teramachi, J.
   Ochiai, K.
   Qiu, L.
   Haneji, T.
TI Calcium Hydroxide Suppresses Porphyromonas endodontalis
   Lipopolysaccharide induced Bone Destruction
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE nuclear factor of activated T cell cytoplasmic 1; tumor necrosis
   factor alpha; osteoclasts; osteoblasts; bone resorption; interleukin 6
ID NF KAPPA B; TNF ALPHA; OSTEOBLAST; DIFFERENTIATION; GINGIVALIS;
   ACTIVATION; RANKL; CELLS
AB Porphyromonas endodontalis and its main virulence factor, lipopolysaccharide (LPS), are associated with the development of periapical diseases and alveolar bone loss. Calcium hydroxide is commonly used for endodontic therapy. However, the effects of calcium hydroxide on the virulence of P. endodontalis LPS and the mechanism of P. endodontalis LPS induced bone destruction are not clear. Calcium hydroxide rescued the P. endodontalis LPS suppressed viability of MC3T3 E1 cells and activity of nuclear factor kappa B (NF kappa B) in these cells, resulting in the reduced expression of interleukin 6 and tumor necrosis factor alpha. In addition, calcium hydroxide inhibited P. endodontalis LPS induced osteoclastogenesis by decreasing the activities of NF kappa B, p38, and ERK1/2 and the expression of nuclear factor of activated T cell cytoplasmic 1 in RAW264.7 cells. Calcium hydroxide also rescued the P. endodontalis LPS induced osteoclastogenesis and bone destruction in mouse calvaria. Taken together, our present results indicate that calcium hydroxide suppressed bone destruction by attenuating the virulence of P. endodontalis LPS on bone cells.
C1 [Guo, J.; Yang, D.; Qiu, L.] China Med Univ, Sch Stomatol, Dept Endodont, Shenyang 110002, Peoples R China.
   [Yang, D.; Okamura, H.; Teramachi, J.; Haneji, T.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Histol & Oral Histol, Kuramoto, Tokushima 7708504, Japan.
   [Ochiai, K.] Nippon Vet & Life Sci Univ, Sch Vet Nursing & Technol, Dept Basic Sci, Fac Vet Sci, Musashino, Tokyo 1808602, Japan.
C3 China Medical University; Tokushima University; Nippon Veterinary & Life
   Science University
RP Qiu, L (通讯作者)，China Med Univ, Sch Stomatol, Dept Endodont, Shenyang 110002, Peoples R China.
EM drqlh@yahoo.com; tat hane@tokushima u.ac.jp
RI ; Okamura, Hirohiko/I 5917 2019; Guo, Jiajie/KQU 7744 2024
OI Okamura, Hirohiko/0000 0002 3254 5238; Guo, Jiajie/0000 0002 4116 6512;
   OCHIAI, Kazuhiko/0000 0002 5736 0598; 
FU Science and Technology Foundation of Liaoning Province [2011225020];
   Ministry of Education, Science, Sports, and Culture of Japan [21592330,
   23592703]; Ichiro Kanehara Foundation; Takeda Science Foundation;
   Grants in Aid for Scientific Research [23592703, 21592330, 26462786,
   25462859] Funding Source: KAKEN
FX We thank Ms. E. Sasaki for her skillful technical assistance. This study
   was supported by grants from the Science and Technology Foundation of
   Liaoning Province (2011225020), the Grant in Aid for Scientific Research
   from the Ministry of Education, Science, Sports, and Culture of Japan
   (21592330 and 23592703), the Ichiro Kanehara Foundation, and Takeda
   Science Foundation. The authors declare no potential conflicts of
   interest with respect to the authorship and/or publication of this
   article.
CR Assed S, 1996, ENDOD DENT TRAUMATOL, V12, P66
   Axmann R, 2009, ARTHRITIS RHEUM US, V60, P2747, DOI 10.1002/art.24781
   Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891
   Bonsignore LA, 2013, BONE, V52, P93, DOI 10.1016/j.bone.2012.09.011
   Buck RA, 2001, J ENDODONT, V27, P325, DOI 10.1097/00004770 200105000 00003
   Chang J, 2005, J DENT RES, V84, P994, DOI 10.1177/154405910508401105
   Farhad A, 2005, INT DENT J, V55, P293, DOI 10.1111/j.1875 595X.2005.tb00326.x
   Gao LN, 2013, J ETHNOPHARMACOL, V149, P772, DOI 10.1016/j.jep.2013.07.039
   Henderson JC, 2013, JOVE J VIS EXP, DOI 10.3791/50623
   Hong CY, 2004, J ORAL PATHOL MED, V33, P162, DOI 10.1111/j.0904 2512.2004.00045.x
   Inada M, 2006, J IMMUNOL, V177, P1879, DOI 10.4049/jimmunol.177.3.1879
   Jiang J, 2003, ORAL SURG ORAL MED O, V95, P348, DOI 10.1067/moe.2003.18
   Khan AA, 2008, J ENDODONT, V34, P1360, DOI 10.1016/j.joen.2008.08.020
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   KOGA T, 1985, INFECT IMMUN, V47, P638, DOI 10.1128/IAI.47.3.638 647.1985
   Kukita A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038500
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Matsushita K, 1999, J ENDODONT, V25, P795, DOI 10.1016/S0099 2399(99)80299 4
   Montagner F, 2012, J ENDODONT, V38, P158, DOI 10.1016/j.joen.2011.09.029
   Narita H, 2010, ACTA BIOMATER, V6, P586, DOI 10.1016/j.actbio.2009.08.005
   Quinn JMW, 2000, J BONE MINER RES, V15, P1459, DOI 10.1359/jbmr.2000.15.8.1459
   Roberts HC, 2008, EUR J ORAL SCI, V116, P207, DOI 10.1111/j.1600 0722.2008.00535.x
   Rogers JE, 2007, J PERIODONTOL, V78, P550, DOI 10.1902/jop.2007.060321
   SAFAVI KE, 1993, J ENDODONT, V19, P76, DOI 10.1016/S0099 2399(06)81199 4
   Siqueira JF, 1999, INT ENDOD J, V32, P361, DOI 10.1046/j.1365 2591.1999.00275.x
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tang Y, 2011, J ENDODONT, V37, P1653, DOI 10.1016/j.joen.2011.08.015
   Tomazinho LF, 2007, ORAL SURG ORAL MED O, V103, P285, DOI 10.1016/j.tripleo.2006.05.010
   Wittgow W C Jr, 1975, J Endod, V1, P168, DOI 10.1016/S0099 2399(75)80115 4
   Yang Di, 2009, Shanghai Kou Qiang Yi Xue, V18, P194
NR 31
TC 27
Z9 33
U1 0
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD MAY
PY 2014
VL 93
IS 5
BP 508
EP 513
DI 10.1177/0022034514526886
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AE8PZ
UT WOS:000334265100012
PM 24603641
DA 2025 08 17
ER

PT J
AU Wang, FF
   Yang, PM
   Wan, TH
   Liu, C
   Zhu, YJ
   Chen, XZ
   Liu, HY
AF Wang, Feifei
   Yang, Peiming
   Wan, Tianhao
   Liu, Cong
   Zhu, Yujuan
   Chen, Xuzhuo
   Liu, Huanyan
TI Osthole Inhibits M1 Macrophage Polarization and Attenuates Osteolysis in
   a Mouse Skull Model
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID NF KAPPA B; BONE; OSTEOCLASTOGENESIS; DIFFERENTIATION; INFLAMMATION;
   MATURATION
AB Excessive bone resorption due to increased inflammatory factors is a common feature of inflammatory lytic bone diseases. This group of diseases is effectively treated with drugs. In recent years, many studies have reported that traditional Chinese medicine herbs have substantial effects on inflammation, osteoclast differentiation and maturation, and bone destruction. Herein, we investigated the effects of osthole (OST) on lipopolysaccharide  (LPS ) induced macrophage polarization, inflammatory responses, and osteolysis. In vitro, we used immunofluorescence and quantitative real time polymerase chain reaction assays to confirm whether bone marrow derived macrophages showed an increased expression of inflammatory factors, such as interleukin 6, iNOS, CCR7, and CD86, in the presence of LPS. However, we found that such expression was suppressed and that the M2 macrophage expression increased in the presence of OST. OST reduced LPS  and RANKL induced intracellular reactive oxygen species production in the bone marrow derived macrophages. Further, it potently suppressed osteoclast differentiation and osteoclast specific gene expression by suppressing the P38/MAPK and NF kappa B pathways. Consistent with the in vitro observations, OST greatly ameliorated LPS induced bone resorption and modulated the ratio of macrophages at the site of osteolysis. Taken together, OST has great potential for use in the management of osteolytic diseases.
C1 [Wang, Feifei; Liu, Cong; Liu, Huanyan] Qingdao Univ, Affiliated Taian City Cent Hosp, Tai An 271000, Shandong, Peoples R China.
   [Yang, Peiming] Xuzhou Cent Hosp, Dept Stomatol, Xuzhou 221000, Jiangsu, Peoples R China.
   [Wan, Tianhao] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200011, Peoples R China.
   [Zhu, Yujuan] Taian Second Hosp Tradit Chinese Med, Dept Stomatol, Tai An 271000, Shandong, Peoples R China.
   [Chen, Xuzhuo] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Oral Surg, Shanghai Key Lab Stomatol,Coll Stomatol,Sch Med, 639 Zhi Zao Ju Rd, Shanghai 200011, Peoples R China.
C3 Qingdao University; Shanghai Jiao Tong University; Shanghai Jiao Tong
   University
RP Liu, HY (通讯作者)，Qingdao Univ, Affiliated Taian City Cent Hosp, Tai An 271000, Shandong, Peoples R China.; Chen, XZ (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Oral Surg, Shanghai Key Lab Stomatol,Coll Stomatol,Sch Med, 639 Zhi Zao Ju Rd, Shanghai 200011, Peoples R China.
EM 1848308168@qq.com; yangpm187@163.com; 1161654235@qq.com;
   976187593@qq.com; zhuyujuan1012@163.com; cxzzxcaa@126.com;
   2307222877@qq.com
RI Chen, Xuzhuo/ACC 3813 2022; 王, 菲菲/R 1936 2019; Zhu, Yujuan/KFB 2912 2024
OI Liu, Huanyan/0000 0001 5302 3618; chen, xuzhuo/0000 0002 1276 1662; 
FU Digaoda Program of Shanghai Education Commission [20152226]; Industrial
   Support Fund of Huangpu District [XK2020013]; Shanghai Shenkang Project
   [SHDC2020CR3060B]; Faculty of Medicine, Shanghai Jiao Tong University
   [1420Y503]
FX This study was supported by the Digaoda Program of Shanghai Education
   Commission (No. 20152226), the Industrial Support Fund of Huangpu
   District (No. XK2020013), the Shanghai Shenkang Project
   (SHDC2020CR3060B), and the Faculty of Medicine, Shanghai Jiao Tong
   University (No. 1420Y503).
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Charles JF, 2014, CURR OSTEOPOROS REP, V12, P1, DOI 10.1007/s11914 014 0195 2
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen XW, 2019, J CELL PHYSIOL, V234, P20944, DOI 10.1002/jcp.28699
   Chiang CY, 2017, CELL MOL IMMUNOL, V14, P935, DOI 10.1038/cmi.2017.71
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   De Vries TJ, 2015, J CELL PHYSIOL, V230, P210, DOI 10.1002/jcp.24702
   García Arroyo FE, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052431
   Hao YG, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04111 0
   Hu Y, 2019, FREE RADICAL BIO MED, V145, P146, DOI 10.1016/j.freeradbiomed.2019.09.024
   Jennes ME, 2021, ANTIBIOTICS BASEL, V10, DOI 10.3390/antibiotics10111350
   Jie ZW, 2019, FASEB J, V33, P4236, DOI 10.1096/fj.201801977R
   Kavanagh N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00084 17
   Li J, 2013, J PHARMACEUT BIOMED, V74, P156, DOI 10.1016/j.jpba.2012.10.018
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Lu JS, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02512 z
   Lu XG, 2017, BIOMED PHARMACOTHER, V88, P102, DOI 10.1016/j.biopha.2017.01.041
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   McGreevy C, 2011, THER ADV DRUG SAF, V2, P159, DOI 10.1177/2042098611411012
   Ming LG, 2011, PHARMACOLOGY, V88, P33, DOI 10.1159/000328776
   Moretti S, 2015, J DENT RES, V94, P1267, DOI 10.1177/0022034515591790
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Pradeep AR, 2015, J INVESTIG CLIN DENT, V6, P170, DOI 10.1111/jicd.12091
   Shu Goukei, 2006, Mod Rheumatol, V16, P343
   Sun AJR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183693
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Van Raemdonck K, 2020, CELL MOL LIFE SCI, V77, P1387, DOI 10.1007/s00018 019 03235 w
   Wang BT, 2018, J PHARMACOL SCI, V137, P290, DOI 10.1016/j.jphs.2018.07.007
   Wang Y, 2017, INT IMMUNOPHARMACOL, V50, P345, DOI 10.1016/j.intimp.2017.07.019
   Wei S, 2008, PATHOL RES PRACT, V204, P695, DOI 10.1016/j.prp.2008.07.002
   Yang J, 2020, CHEM BIOL INTERACT, V316, DOI 10.1016/j.cbi.2019.108934
   Yu PJ, 2020, INT J BIOL MACROMOL, V165, P1634, DOI 10.1016/j.ijbiomac.2020.10.016
   Zhao QJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00637
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Zheng L, 2019, FASEB J, V33, P7667, DOI 10.1096/fj.201802364RR
   Zhou F, 2019, ACTA PHARM SIN B, V9, P973, DOI 10.1016/j.apsb.2019.01.015
   Zhou LN, 2019, ORAL DIS, V25, P265, DOI 10.1111/odi.12983
NR 37
TC 10
Z9 14
U1 1
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1942 0900
EI 1942 0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD JAN 12
PY 2023
VL 2023
AR 2975193
DI 10.1155/2023/2975193
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 8E7KG
UT WOS:000919146900001
PM 36686380
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Chen, ZX
   Zhang, C
   Hong, HS
   Xu, WB
   Sha, M
   Ding, ZQ
AF Chen, Zhangxin
   Zhang, Cong
   Hong, Haisen
   Xu, Wenbin
   Sha, Mo
   Ding, Zhenqi
TI Potential alternative drug treatment for bone giant cell tumor
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE bone giant cell tumor; fracture healing; potential genes; potential
   drugs; drug treatment
ID INTERACTION NETWORKS; DIAGNOSTIC TOOL; CATHEPSIN K
AB Background: Bone giant cell tumor (BGCT) is one of the world's major disease types of locally aggressive bone tumors. In recent years, denosumab treatment has been introduced before curettage surgery. However, the current therapeutic was practical only sometimes, given the local recurrence effects after discontinuation of denosumab. Due to the complex nature of BGCT, this study aims to use bioinformatics to identify potential genes and drugs associated with BGCT.Methods: The genes that integrate BGCT and fracture healing were determined by text mining. The gene was obtained from the pubmed2ensembl website. We filtered out common genes for the function, and signal pathway enrichment analyses were implemented. The protein protein interaction (PPI) networks and the hub genes were screened by MCODE built in Cytoscape software. Lastly, the confirmed genes were queried in the Drug Gene Interaction Database to determine potential genes and drugs.Results: Our study finally identified 123 common specific genes in bone giant cell tumors and fracture healing text mining concepts. The GO enrichment analysis finally analyzed 115 characteristic genes in BP, CC, and MF. We selected 10 KEGG pathways and identified 68 characteristic genes. We performed protein protein interaction analysis (PPI) on 68 selected genes and finally identified seven central genes. In this study, these seven genes were substituted into drug gene interactions, and there were 15 antineoplastic drugs, 1 anti involving drug, and 1 anti influenza drug.Conclusion: The 7 genes (including ANGPT2, COL1A1, COL1A2, CTSK, FGFR1, NTRK2, and PDGFB) and 17 drugs, which have not been used in BGCT, but 6 of them approved by the FDA for other diseases, could be potential genes and drugs, respectively, to improve BGCT treatment. In addition, the correlation study and analysis of potential drugs through genes provide great opportunities to promote the repositioning of drugs and the study of pharmacology in the pharmaceutical industry.
C1 [Chen, Zhangxin; Zhang, Cong; Hong, Haisen; Sha, Mo; Ding, Zhenqi] Xiamen Univ, Hosp 909, Sch Med, Dept Orthoped, Zhangzhou, Peoples R China.
   [Zhang, Cong; Xu, Wenbin; Sha, Mo; Ding, Zhenqi] Xiamen Univ, Sch Med, Xiamen, Peoples R China.
   [Xu, Wenbin] Xiamen Univ, Dept Orthoped, Affiliated Hosp 1, Xiamen, Peoples R China.
C3 Xiamen University; Xiamen University; Xiamen University
RP Sha, M; Ding, ZQ (通讯作者)，Xiamen Univ, Hosp 909, Sch Med, Dept Orthoped, Zhangzhou, Peoples R China.; Sha, M; Ding, ZQ (通讯作者)，Xiamen Univ, Sch Med, Xiamen, Peoples R China.
EM shamo5@163.com; dzqi@xmu.edu.cn
FU Military logistics research program of China [CNJ16C013]
FX Funding This project was supported and funded by the Military logistics
   research program of China (CNJ16C013).
CR Algawahmed H., 2010, Sarcoma, V2010, P586090, DOI 10.1155/2010/586090
   Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432 008 0370 x
   Baran J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024716
   Mallick AB, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912 021 01047 5
   Chen T, 2021, ANN DIAGN PATHOL, V54, DOI 10.1016/j.anndiagpath.2021.151800
   Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Gatalica Z, 2019, MODERN PATHOL, V32, P147, DOI 10.1038/s41379 018 0118 3
   Hartmann Wolfgang, 2021, Surg Pathol Clin, V14, P695, DOI 10.1016/j.path.2021.06.010
   Hasenfratz M, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85319 x
   Kivioja AH, 2008, ACTA ORTHOP, V79, P86, DOI 10.1080/17453670710014815
   Knochentumoren A, 2008, J BONE JOINT SURG AM, V90A, P1060, DOI 10.2106/JBJS.D.02771
   Li HY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.580605
   Li N, 2018, INT J CLIN EXP PATHO, V11, P4052
   Lindeman JHN, 2004, AM J PATHOL, V165, P593, DOI 10.1016/S0002 9440(10)63323 8
   Luengo Alonso G, 2019, ARCH ORTHOP TRAUM SU, V139, P1339, DOI 10.1007/s00402 019 03167 x
   Montgomery C, 2019, J KNEE SURG, V32, P331, DOI 10.1055/s 0038 1675815
   Nishina T, 2018, INVEST NEW DRUG, V36, P424, DOI 10.1007/s10637 017 0514 4
   Pathan M, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1321455
   Perera TPS, 2017, MOL CANCER THER, V16, P1010, DOI 10.1158/1535 7163.MCT 16 0589
   Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS 21 02 118
   Sano K, 2020, J ORTHOP SURG HONG K, V28, DOI 10.1177/2309499020929786
   Stroup GB, 2001, J BONE MINER RES, V16, P1739, DOI 10.1359/jbmr.2001.16.10.1739
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Traub F, 2016, EUR J CANCER, V59, P1, DOI 10.1016/j.ejca.2016.01.006
   Tsukamoto S, 2020, CLIN ORTHOP RELAT R, V478, P1076, DOI 10.1097/CORR.0000000000001074
   Wagner AH, 2016, NUCLEIC ACIDS RES, V44, pD1036, DOI 10.1093/nar/gkv1165
   Zhu Q S, 1994, Zhonghua Bing Li Xue Za Zhi, V23, P162
NR 30
TC 2
Z9 2
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JUN 13
PY 2023
VL 11
AR 1193217
DI 10.3389/fcell.2023.1193217
PG 11
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA K7GD7
UT WOS:001018078600001
PM 37384251
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fan, SQ
   Pan, HD
   Huang, JX
   Lei, ZQ
   Liu, JF
AF Fan, Siqi
   Pan, Haida
   Huang, Jiaxing
   Lei, Zhiqiang
   Liu, Jinfu
TI Hyperoside exerts osteoprotective effect on dexamethasone induced
   osteoblasts by targeting NADPH Oxidase 4 (NOX4) to inhibit the reactive
   oxygen species (ROS) accumulation and activate c Jun N terminal kinase
   (JNK) pathway
SO BIOENGINEERED
LA English
DT Article
DE Hyperoside; NADPH oxidase 4; osteoblast; osteonecrosis of the femoral
   head
ID FEMORAL HEAD; OSTEONECROSIS
AB Hyperoside (Hyp) is a flavonoid active compound deriving from Chinese herbal medicines. Increasing studies have implicated that Hyp may serve as a predominant promoting factor in osteoblast differentiation. This paper investigates whether Hyp could relieve glucocorticoid induced osteonecrosis of the femoral head (GONFH) via promoting osteoblast survival and differentiation as well as to uncover its potential mechanism. GONFH cell model was induced by treating MC3T3 E1 cells with dexamethasone (DEX). The viability, apoptosis, and osteogenic differentiation of DEX induced cells with the presence or absence of Hyp were assessed by CCK 8, Tunel, ALP assay, and ARS staining, respectively. The NADPH Oxidase 4 (NOX4) overexpression was performed by transfection with overexpression vector. Besides, western blot was used to determine the levels of apoptosis , osteogenic differentiation , and c Jun N terminal kinase (JNK) signaling related proteins. It was noticed that Hyp caused no significant effects on the viability of MC3T3 E1 cells without any treatment but significantly enhanced the viability of DEX induced cells. Besides, Hyp inhibited the apoptosis in DEX induced cells but enhanced ALP activity and calcium nodule formation. Additionally, Hyp declined NOX4 expression in DEX induced cells. However, NOX4 overexpression partially reversed the impacts of Hyp on DEX exposed MC3T3 E1 cells. Finally, Hyp suppressed the activation of ROS/JNK pathway in DEX induced cells, which was then counteracted by NOX4 overexpression. In conclusion, Hyp could promote the survival and differentiation of DEX induced osteoblasts by targeting NOX4 to inhibit the ROS/JNK pathway. These results provide evidence for the application of Hyp in treating GONFH.
C1 [Fan, Siqi; Liu, Jinfu] Guangxi Univ Chinese Med, Dept Orthoped & Traumatol, Affiliated Hosp 1, Nanning, Peoples R China.
   [Pan, Haida] Guangxi Univ Tradit Chinese Med, Res Student Acad, Nanning, Peoples R China.
   [Huang, Jiaxing] Yulin Orthoped Hosp Chinese & Western Med, Yulin, Peoples R China.
   [Lei, Zhiqiang] Guangxi Univ Chinese Med, Emergency Dept, Affiliated Hosp 1, Nanning, Peoples R China.
C3 Guangxi University of Chinese Medicine; Guangxi University of Chinese
   Medicine; Guangxi University of Chinese Medicine
RP Liu, JF (通讯作者)，Guangxi Univ Chinese Med, Affiliated Hosp 1, 327 Xianhu Ave, Nanning 530000, Guangxi, Peoples R China.
EM liujinfu413@163.com
RI Fan, Siqi/JRY 1339 2023; Huang, Jiaxing/HZH 3850 2023
FU project of improving the basic scientific research ability of young and
   middle aged teachers in Guangxi universities [2022KY0282];
   hospital level scientific research project of the First Affiliated
   Hospital of Guangxi University of Traditional Chinese Medicine
   [2020QN008]
FX 1. The project of improving the basic scientific research ability of
   young and middle aged teachers in Guangxi uni versities (2022KY0282).
   The hospital level scientific research project of the First Affiliated
   Hospital of Guangxi University of Traditional Chinese Medicine
   (2020QN008).
CR Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Chen YQ, 2018, BIOMED PHARMACOTHER, V107, P1175, DOI 10.1016/j.biopha.2018.08.069
   Choi EM, 2013, J APPL TOXICOL, V33, P190, DOI 10.1002/jat.1733
   Deng S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01787
   Fan ZQ, 2021, ORTHOP SURG, V13, P2145, DOI 10.1111/os.13127
   FARNSWOR.NR, 1968, J PHARM SCI US, V57, P1059, DOI 10.1002/jps.2600570641
   Huang CK, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00431
   Huang JZ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.550955
   Jang HO, 2007, NAT PROD RES, V21, P787, DOI 10.1080/14786410601133475
   Kim J, 2015, J MED FOOD, V18, P446, DOI 10.1089/jmf.2014.3215
   Kuang MJ, 2019, CHEM BIOL INTERACT, V304, P97, DOI 10.1016/j.cbi.2019.03.008
   Li SY, 2005, J AGR FOOD CHEM, V53, P32, DOI 10.1021/jf0484780
   Liu ZY, 2005, BIOMED PHARMACOTHER, V59, P481, DOI 10.1016/j.biopha.2005.06.009
   Peng PJ, 2021, FEBS OPEN BIO, V11, P312, DOI 10.1002/2211 5463.13037
   Qiu JX, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010131
   Suzuki M, 2015, FREE RADICAL BIO MED, V89, P369, DOI 10.1016/j.freeradbiomed.2015.08.015
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Wang XY, 2020, EUR J PHARMACOL, V880, DOI 10.1016/j.ejphar.2020.173212
   Wei AW, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117735
   Wong RWK, 2006, J ORAL MAXIL SURG, V64, P828, DOI 10.1016/j.joms.2006.01.017
   Wu XJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8140595
   Xu T, 2020, FEBS OPEN BIO, V10, P1843, DOI 10.1002/2211 5463.12937
   Yan ZJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01195
   Zalavras CG, 2014, J AM ACAD ORTHOP SUR, V22, P455, DOI 10.5435/JAAOS 22 07 455
   Zhan JD, 2020, FOOD FUNCT, V11, P7830, DOI [10.1039/d0fo00837k, 10.1039/D0FO00837K]
   Zhang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098973
NR 28
TC 4
Z9 6
U1 1
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165 5979
EI 2165 5987
J9 BIOENGINEERED
JI Bioengineered
PD APR 1
PY 2022
VL 13
IS 4
BP 8657
EP 8666
DI 10.1080/21655979.2022.2054499
PG 10
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA ZZ2MV
UT WOS:000773110000001
PM 35331079
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, BL
   Guo, HH
   Geng, TX
   Sun, KN
   Zhang, L
   Lu, ZD
   Jin, QH
AF Wang, Bolun
   Guo, Haohui
   Geng, Tianxiang
   Sun, Kening
   Zhang, Liang
   Lu, Zhidong
   Jin, Qunhua
TI The effect of strontium ranelate on titanium particle induced
   periprosthetic osteolysis regulated by WNT/β caten n signaling in
   vivo and in vitro
SO BIOSCIENCE REPORTS
LA English
DT Article
ID TOTAL KNEE ARTHROPLASTY; POLYETHYLENE PARTICLES; IMMUNE RESPONSE;
   LONG TERM; BONE; OSTEOBLASTS; WEAR; DIFFERENTIATION; MACROPHAGES;
   OSTEOCLASTOGENESIS
AB Aseptic loosening following periprosthetic osteolysis is the primary complication that limits the lifetime of total joint arthroplasty (TJA). The wear particles trigger a chronic inflammation response in the periprosthetic tissue and turn over the bone balance to bone resorption. The present study aimed to investigate the possible effect and mechanism of strontium ranelate (SR), a clinically safe drug for osteoporosis, on particle induced periprosthetic osteolysis. Thirty six female C57BL/6j mice underwent tibial Ti nail implantation to establish an animal model of aseptic loosening. After 12 weeks, micro CT results showed that strontium ranelate could inhibit periprosthetic bone resorption. in vitro, Ti particles were used to stimulate RAW264.7 cell line to collect conditioned medium, and co culture MC3T3 E1 cell line with conditioned medium to establish a cell model of aseptic loosening. The results of alkaline phosphatase (ALP) detection, immunofluorescence, and flow cytometry demonstrated that strontium ranelate could regulate the expression of OPG/RANKL, promote differentiation and mineralization, and inhibit apoptosis in osteoblasts. Moreover, we revealed that SR's exerted its therapeutic effect by down regulating sclerostin, thereby activating the Wnt/beta catenin signal pathway. Therefore, this research suggests that strontium ranelate could be a potential drug or the prevention and treatment of particle induced aseptic loosening post TJA.
C1 [Wang, Bolun; Geng, Tianxiang] Ningxia Med Univ, Dept Orthoped Surg, 1160 Shengli St, Yinchuan 750004, Ningxia, Peoples R China.
   [Guo, Haohui; Sun, Kening; Zhang, Liang; Lu, Zhidong; Jin, Qunhua] Ningxia Med Univ, Gen Hosp, Dept Orthoped, 804 Shengli St, Yinchuan 750004, Ningxia, Peoples R China.
C3 Ningxia Medical University; Ningxia Medical University
RP Jin, QH (通讯作者)，Ningxia Med Univ, Gen Hosp, Dept Orthoped, 804 Shengli St, Yinchuan 750004, Ningxia, Peoples R China.
EM jinqunhua0951@gmail.com
RI ; Sun, kening/LYO 6367 2024; Geng, Tianxiang/JXY 0418 2024
OI Geng, Tianxiang/0000 0002 9636 3257; Jin, Qunhua/0000 0002 5409 1986;
   Jin, Qunhua/0000 0001 7616 3357
FU Advantage Discipline Group Program of Ningxia Medical University
   [XY201423]; National Nature Science Foundation of China [81460333,
   81660373]
FX This work was supported by the Advantage Discipline Group Program of
   Ningxia Medical University [grant number XY201423] and the National
   Nature Science Foundation of China [grant numbers 81460333 and
   81660373].
CR Abrahamsen B, 2014, OSTEOPOROSIS INT, V25, P757, DOI 10.1007/s00198 013 2469 4
   Anderl W, 2016, KNEE SURG SPORT TR A, V24, P102, DOI 10.1007/s00167 014 3345 2
   Atkins GJ, 2011, WORLD J ORTHOP, V2, P93, DOI 10.5312/wjo.v2.i10.93
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Barman J, 2018, CURR PHARM BIOTECHNO, V19, P644, DOI 10.2174/1389201019666180821093239
   Baud'huin M, 2013, CYTOKINE GROWTH F R, V24, P401, DOI 10.1016/j.cytogfr.2013.06.001
   Berry DJ, 2002, J BONE JOINT SURG AM, V84A, P171, DOI 10.2106/00004623 200202000 00002
   Blum JS, 2001, J CELL BIOCHEM, V80, P532, DOI 10.1002/1097 4644(20010315)80:4<532::AID JCB1007>3.0.CO;2 B
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Bu YM, 2018, CONNECT TISSUE RES, V59, P534, DOI 10.1080/03008207.2017.1413362
   Chen WS, 2017, BIOMATERIALS, V143, P46, DOI 10.1016/j.biomaterials.2017.07.028
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Fraser JF, 2015, J KNEE SURG, V28, P139, DOI 10.1055/s 0034 1398375
   Gallo J, 2013, ACTA BIOMATER, V9, P8046, DOI 10.1016/j.actbio.2013.05.005
   Geoffroy V, 2011, OSTEOPOROSIS INT, V22, P289, DOI 10.1007/s00198 010 1193 6
   Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015
   Goldhahn J, 2012, CALCIFIED TISSUE INT, V90, P343, DOI 10.1007/s00223 012 9587 4
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Granchi D, 2004, BIOMATERIALS, V25, P4037, DOI 10.1016/j.biomaterials.2003.10.100
   Hallab NJ, 2009, BULL HOSP JT DIS, V67, P182
   Hamdy NAT, 2009, RHEUMATOLOGY, V48, pIV9, DOI 10.1093/rheumatology/kep274
   Hanada R, 2011, J MOL MED, V89, P647, DOI 10.1007/s00109 011 0749 z
   He YQ, 2014, J BIOMED SEMANT, V5, DOI 10.1186/2041 1480 5 29
   Henderson WR, 2010, P NATL ACAD SCI USA, V107, P14309, DOI 10.1073/pnas.1001520107
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Jähn K, 2012, EUR CELLS MATER, V24, P197
   Kurtz SM, 2009, CLIN ORTHOP RELAT R, V467, P2606, DOI 10.1007/s11999 009 0834 6
   KurtzS, 2007, Journal of Bone and Joint Surgery89, P780, DOI DOI 10.2106/JBJS.F.00222
   Lee SS, 2012, BIOMATERIALS, V33, P4251, DOI 10.1016/j.biomaterials.2012.03.005
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Li YF, 2012, BIOCHEM BIOPH RES CO, V418, P725, DOI 10.1016/j.bbrc.2012.01.088
   Liu JM, 2009, BONE, V45, P460, DOI 10.1016/j.bone.2009.05.014
   Liu X, 2014, ACTA BIOMATER, V10, P4912, DOI 10.1016/j.actbio.2014.07.025
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lochner K, 2011, INT J MOL MED, V28, P1055, DOI 10.3892/ijmm.2011.778
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Marie PJ, 2006, CURR OPIN RHEUMATOL, V18, pS11, DOI 10.1097/01.bor.0000229522.89546.7b
   Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Millan Jose Luis, 2006, Purinergic Signal, V2, P335, DOI 10.1007/s11302 005 5435 6
   Miyamoto S, 2015, ACTA BIOMATER, V12, P216, DOI 10.1016/j.actbio.2014.10.038
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Odland AN, 2011, CLIN ORTHOP RELAT R, V469, P41, DOI 10.1007/s11999 010 1429 y
   Osborne V, 2010, DRUG SAFETY, V33, P579, DOI 10.2165/11533770 000000000 00000
   Pérez Sayáns M, 2010, ORAL SURG ORAL MED O, V109, P679, DOI 10.1016/j.tripleo.2009.10.042
   Petit A, 2006, J MATER SCI MATER M, V17, P667, DOI 10.1007/s10856 006 9230 x
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Ryu DJ, 2020, MATERIALS, V13, DOI 10.3390/ma13020472
   Schwartz AM, 2020, J ARTHROPLASTY, V35, pS79, DOI 10.1016/j.arth.2020.02.030
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   St Pierre CA, 2010, J ORTHOP RES, V28, P1418, DOI 10.1002/jor.21149
   Streit MR, 2013, CLIN ORTHOP RELAT R, V471, P3262, DOI 10.1007/s11999 013 3033 4
   USE OF LABORATORY A, 2011, National Academies Press (US) Copyright 1990 by the National Academy of Sciences
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   Vidal C, 2013, BIOCHIMIE, V95, P793, DOI 10.1016/j.biochi.2012.11.008
   Wang XJ, 2016, BIOMATERIALS, V83, P127, DOI 10.1016/j.biomaterials.2016.01.012
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Xing M, 2019, ACTA BIOMATER, V91, P294, DOI 10.1016/j.actbio.2019.05.003
   Yang SY, 2007, J ORTHOP RES, V25, P603, DOI 10.1002/jor.20342
   Zhang HW, 2010, CELL SIGNAL, V22, P1753, DOI 10.1016/j.cellsig.2010.06.016
   Zhang JH, 2014, ACTA BIOMATER, V10, P2269, DOI 10.1016/j.actbio.2014.01.001
NR 70
TC 9
Z9 9
U1 1
U2 19
PU PORTLAND PRESS LTD
PI LONDON
PA 1ST FLR, 10 QUEEN STREET PLACE, LONDON, ENGLAND
SN 0144 8463
EI 1573 4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JAN
PY 2021
VL 41
IS 1
AR BSR20203003
DI 10.1042/BSR20203003
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA QX1ND
UT WOS:000629114800045
PM 33443286
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mezban, SA
   Fox, SW
AF Mezban, Safaa Al Thamiree
   Fox, Simon William
TI Genistein and coumestrol reduce MCF 7 breast cancer cell viability and
   inhibit markers of preferential metastasis, bone matrix attachment and
   tumor induced osteoclastogenesis
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Skeletal metastasis; Osteoclastogenesis; Bone adhesion; Phytoestrogens
ID PROSTATE CANCER; MOUSE MODEL; PHYTOESTROGENS; PREVENTION; MDA MB 231;
   EXPRESSION; MIGRATION
AB The propensity of breast cancer to preferentially metastasize to the skeleton is well known. Once established in bone metastatic breast cancers have a poor prognosis due to their ability to promote extensive bone loss which augments tumor burden. Unfortunately, current anti resorptive therapies for skeletal metastasis are typically prescribed after secondary tumors have formed and are palliative in nature. One group of compounds with the potential to reduce both tumor burden and osteolysis are phytoestrogens (PE), but the mechanisms mediating a beneficial effect are unclear. Therefore, the current study examined the effect of genistein and coumestrol alone or in combination on breast cancer cell number, expression of mediators of preferential skeletal metastasis, bone matrix attachment and tumor induced osteoclast formation. Results showed that genistein and coumestrol significantly reduced viable cell number in an estrogen receptor dependent manner (p < 0.05), whereas combinations of PE had no effect. In addition, genistein and coumestrol significantly reduced expression of genes driving epithelial to mesenchymal transition (snail), bone attachment (CXCR4 and integrin alpha V) and osteolysis (PTHrP and TNF alpha). In keeping with this genistein and coumestrol significantly suppressed attachment of breast cancer cells to bone matrix and inhibited tumor and RANKL induced osteoclast formation. Our data suggests that phytoestrogens not only decrease breast cancer cell viability but also antagonize essential tumor bone interactions that establish and drive the progression of skeletal metastasis.
C1 [Mezban, Safaa Al Thamiree; Fox, Simon William] Univ Plymouth, Fac Hlth, Sch Biomed Sci, Plymouth, Devon, England.
   [Fox, Simon William] Univ Plymouth, Room B407 Portland Sq, Plymouth PL4 8AA, Devon, England.
C3 University of Plymouth; University of Plymouth
RP Fox, SW (通讯作者)，Univ Plymouth, Room B407 Portland Sq, Plymouth PL4 8AA, Devon, England.
EM Simon.fox@plymouth.ac.uk
RI ; fox, simon/D 8119 2014
OI Fox, Simon/0000 0002 4862 5363; 
FU Iraqi Cultural Attache? [1332]
FX Funding This work was partly funded by the Iraqi Cultural Attache?
   (Grant number 1332) .
CR Alonso V, 2009, LIFE SCI, V85, P421, DOI 10.1016/j.lfs.2009.07.005
   Bergonzini C, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.863850
   Bhattarai G, 2017, J BIOMED MATER RES A, V105, P2510, DOI 10.1002/jbm.a.36109
   Bilal I, 2014, WORLD J CLIN ONCOL, V5, P705, DOI 10.5306/wjco.v5.i4.705
   Boutas I, 2022, IN VIVO, V36, P556, DOI 10.21873/invivo.12737
   BURSTONE MS, 1958, JNCI J NATL CANCER I, V21, P523
   Cayetano Salazar L, 2021, PHYTOTHER RES, V35, P4092, DOI 10.1002/ptr.7072
   Choi EJ, 2013, MOL MED REP, V7, P781, DOI 10.3892/mmr.2013.1283
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Danciu C, 2013, NAT PROD COMMUN, V8, P343
   Ganguly SS, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00364
   Hatono M, 2021, BREAST CANCER RES TR, V185, P307, DOI 10.1007/s10549 020 05957 z
   Hwang KA, 2015, NUTR CANCER, V67, P796, DOI 10.1080/01635581.2015.1040516
   Kabala Dzik A, 2018, CELL MOL BIOL, V64, P1, DOI 10.14715/cmb/2018.64.8.1
   Krazeisen A, 2001, MOL CELL ENDOCRINOL, V171, P151, DOI 10.1016/S0303 7207(00)00422 6
   Kuchuk I, 2013, J BONE ONCOL, V2, P137, DOI 10.1016/j.jbo.2013.09.001
   Kyro C, 2015, BREAST CANCER RES TR, V154, P389, DOI 10.1007/s10549 015 3595 9
   La Verde N, 2021, CLIN BREAST CANCER, V21, pE489, DOI 10.1016/j.clbc.2020.11.001
   Lim W, 2017, J CELL PHYSIOL, V232, P862, DOI 10.1002/jcp.25494
   Martínez Montemayor MM, 2010, CLIN EXP METASTAS, V27, P465, DOI 10.1007/s10585 010 9336 x
   McDonald MM, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10539
   Mezencev R, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2274 5
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Pan W, 2005, J CELL BIOCHEM, V94, P307, DOI 10.1002/jcb.20308
   Pantano F, 2021, ONCOGENE, V40, P1284, DOI 10.1038/s41388 020 01603 6
   Park S, 2023, NUTRIENTS, V15, DOI 10.3390/nu15040954
   Sharif PS, 2011, AGE, V33, P421, DOI 10.1007/s11357 010 9180 6
   Sharifi Rad J, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3268136
   Sottnik JL, 2013, CLIN EXP METASTAS, V30, P569, DOI 10.1007/s10585 012 9561 6
   Torre LA, 2015, CA CANCER J CLIN, V65, P108, DOI [DOI 10.3322/caac.20115, 10.3322/caac.21262]
   Tu YB, 2021, PHARMACOL RES, V169, DOI 10.1016/j.phrs.2021.105615
   Xie Q, 2014, GENE CHROMOSOME CANC, V53, P422, DOI 10.1002/gcc.22154
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Zhang LL, 2008, ACTA PHARMACOL SIN, V29, P1060, DOI 10.1111/j.1745 7254.2008.00831.x
   Zhang Q, 2017, INT J FOOD SCI NUTR, V68, P28, DOI 10.1080/09637486.2016.1216525
   Zhang YY, 2010, ENVIRON TOXICOL PHAR, V30, P37, DOI 10.1016/j.etap.2010.03.016
   Zhang YF, 2010, CANCER LETT, V292, P1, DOI 10.1016/j.canlet.2009.11.003
   Zhou R, 2014, HORM METAB RES, V46, P753, DOI 10.1055/s 0034 1376977
NR 39
TC 13
Z9 13
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003 9861
EI 1096 0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD MAY 15
PY 2023
VL 740
AR 109583
DI 10.1016/j.abb.2023.109583
EA MAR 2023
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA D1LT0
UT WOS:000966412500001
PM 36967033
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Nie, P
   Li, Y
   Suo, HR
   Jiang, N
   Yu, DD
   Fang, B
AF Nie, Ping
   Li, Yao
   Suo, Hairui
   Jiang, Ning
   Yu, Dedong
   Fang, Bing
TI Dasatinib Promotes Chondrogenic Differentiation of Human Mesenchymal
   Stem Cells via the Src/Hippo YAP Signaling Pathway
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE mesenchymal stem cells; dasatinib; chondrocytes; osteoblasts;
   Src/Hippo YAP signaling
ID TYROSINE PHOSPHORYLATION; ARTICULAR CARTILAGE; OSTEOARTHRITIS;
   PROLIFERATION; GLUCOSAMINE; PHENOTYPE; YAP/TAZ; MATRIX; REPAIR; CUES
AB Mesenchymal stem cells (MSCs) are progenitors of chondrocytes and could be used as a potential therapy for cartilage defects in diarthrodial joints. However, promoting chondrogenic differentiation of MSCs remains a daunting challenge. As a small molecular drug, dasatinib can promote MSC differentiation, although the exact mechanisms of chondrogenic differentiation are unclear. In this study, the differentiation of MSCs into osteoblasts, adipocytes, and chondrocytes was assessed by the protein and mRNA levels of osteoblast  and chondrocyte related proteins using western blotting and real time polymerase chain reaction, respectively. MSCs were induced to differentiate into chondrocytes or osteoblasts with or without dasatinib in vitro. The effects of dasatinib on cartilage regeneration were also assessed in vivo in a rabbit model of full thickness cartilage defects using methacrylate gelatin hydrogel as scaffolds. Dasatinib promoted chondrogenic differentiation and inhibited osteogenic differentiation of MSCs. Furthermore, dasatinib significantly inhibited the expression of YAP and TAZ and the phosphorylation of Src, but it enhanced serine phosphorylation of YAP during the chondrogenic differentiation of MSCs in vitro. Inhibition of the Hippo pathway using XMU MP 1 dramatically suppressed the serine phosphorylation of YAP and chondrogenic differentiation of MSCs. Moreover, we confirmed that the sustained release of dasatinib from the hydrogel promoted rabbit cartilage repair. The results demonstrated that dasatinib might promote chondrogenic differentiation of MSCs via the Src/Hippo YAP signaling pathway and that hydrogel sustained release dasatinib had a certain effect on the repair of cartilage defects.
C1 [Nie, Ping; Jiang, Ning] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Oral & Craniomaxillofacial Surg, Coll Stomatol,Ctr Craniofacial Orthodont,Sch Med, Shanghai 200011, Peoples R China.
   [Fang, Bing] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Coll Stomatol, Dept Orthodont,Sch Med, Shanghai 200011, Peoples R China.
   [Yu, Dedong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Coll Stomatol, Dent Ctr 2,Sch Med, Shanghai 201999, Peoples R China.
   [Nie, Ping; Jiang, Ning; Yu, Dedong; Fang, Bing] Natl Clin Res Ctr Oral Dis, Shanghai Key Lab Stomatol, Shanghai 200011, Peoples R China.
   [Nie, Ping; Jiang, Ning; Yu, Dedong; Fang, Bing] Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China.
   [Li, Yao] Shanghai Jiao Tong Univ, Sch Mat Sci & Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
   [Suo, Hairui] Hangzhou Dianzi Univ, Sch Automat, Hangzhou 310018, Zhejiang, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Hangzhou Dianzi
   University
RP Fang, B (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Coll Stomatol, Dept Orthodont,Sch Med, Shanghai 200011, Peoples R China.; Yu, DD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Coll Stomatol, Dent Ctr 2,Sch Med, Shanghai 201999, Peoples R China.; Yu, DD; Fang, B (通讯作者)，Natl Clin Res Ctr Oral Dis, Shanghai Key Lab Stomatol, Shanghai 200011, Peoples R China.; Yu, DD; Fang, B (通讯作者)，Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China.
EM yudedong@alumni.sjtu.edu.cn; fangbing@sjtu.edu.cn
RI Nie, Ping/T 2767 2017
FU National Natural Science Foundation of China [51605289];
   Interdisciplinary Program of Shanghai Jiao Tong University [YG2017QN11,
   YG2017QN12]
FX The study is supported by the National Natural Science Foundation of
   China (grant no. 51605289) and the Interdisciplinary Program of Shanghai
   Jiao Tong University (project no. YG2017QN11, YG2017QN12).
CR Aleksander Konert E, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0016 y
   Bai Y, 2018, FASEB J, V32, P4573, DOI [10.1096/fj.201701411R, 10.1096/fj.201701411r]
   Borriello A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028555
   Boufker HI, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 298
   Buckwalter JA, 1998, AAOS INSTR COURS LEC, V47, P487
   Bursell L, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2308
   Deng YJ, 2016, CELL REP, V14, P2224, DOI 10.1016/j.celrep.2016.02.021
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Eslaminejad MB, 2014, IRAN J MED SCI, V39, P107
   Fan FQ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2304
   Garcia Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034914
   Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416
   Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500
   Hao J, 2014, CELL SIGNAL, V26, P186, DOI 10.1016/j.cellsig.2013.11.006
   Hong WJ, 2012, SEMIN CELL DEV BIOL, V23, P785, DOI 10.1016/j.semcdb.2012.05.004
   Hyunchul C, 2017, AM J SPORT MED, V45, P2774, DOI 10.1177/0363546517716641
   Johnson K, 2012, SCIENCE, V336, P717, DOI 10.1126/science.1215157
   Jönsson S, 2010, LEUKEMIA, V24, P1357, DOI 10.1038/leu.2010.84
   Karystinou A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0639 9
   Keating GM, 2017, DRUGS, V77, P85, DOI 10.1007/s40265 016 0677 x
   KRAJEWSKAWLODARCZY, 2018, INT J MOL SCI, V19, DOI DOI 10.3390/IJMS19020623
   Lee AS, 2013, GENE, V527, P440, DOI 10.1016/j.gene.2013.05.069
   Lee YC, 2010, ONCOGENE, V29, P3196, DOI 10.1038/onc.2010.73
   Li JM, 2019, FASEB J, V33, P6378, DOI 10.1096/fj.201802187R
   Mobasheri A, 2016, ANN PHYS REHABIL MED, V59, P333, DOI 10.1016/j.rehab.2016.07.004
   Nichol JW, 2010, BIOMATERIALS, V31, P5536, DOI 10.1016/j.biomaterials.2010.03.064
   O'Driscoll SW, 2001, TISSUE ENG, V7, P313, DOI 10.1089/10763270152044170
   Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974
   Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148
   Shi Q, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00143
   Si Y, 2017, CANCER RES, V77, P4868, DOI 10.1158/0008 5472.CAN 17 0391
   Suo HR, 2016, BIOMED CHROMATOGR, V30, P169, DOI 10.1002/bmc.3533
   Suo HR, 2015, J BIOMATER APPL, V29, P977, DOI 10.1177/0885328214551009
   Van den Borne MPJ, 2007, OSTEOARTHR CARTILAGE, V15, P1397, DOI 10.1016/j.joca.2007.05.005
   Wang LT, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929 016 0289 5
   Yano F, 2014, ANN RHEUM DIS, V73, P2062, DOI 10.1136/annrheumdis 2014 205672
   Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073
   Zhang Q, 2018, CURR STEM CELL RES T, V13, P576, DOI 10.2174/1574888X13666180102121455
   Zhang YQ, 2010, CLIN GERIATR MED, V26, P355, DOI [10.1016/j.rdc.2012.10.004, 10.1016/j.cger.2010.03.001]
   Zhong WL, 2013, J MOL HISTOL, V44, P587, DOI 10.1007/s10735 013 9502 y
NR 41
TC 17
Z9 19
U1 2
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD OCT
PY 2019
VL 5
IS 10
BP 5255
EP 5265
DI 10.1021/acsbiomaterials.9b00618
PG 21
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA JE4JG
UT WOS:000490658800035
PM 33455230
DA 2025 08 17
ER

PT J
AU Spinelli, FR
   Colbert, RA
   Gadina, M
AF Spinelli, Francesca Romana
   Colbert, Robert A.
   Gadina, Massimo
TI JAK1: Number one in the family; number one in inflammation?
SO RHEUMATOLOGY
LA English
DT Article
DE cytokines; signal transduction; JAK kinases; JAK inhibitors; rheumatoid
   arthritis; spondyloarthritis; spondyloarthropathies; inflammation
ID RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS;
   INTERFERON RESPONSE; ONCOSTATIN M; TNF ALPHA; TOFACITINIB; METHOTREXATE;
   FIBROBLAST; EXPRESSION
AB Several cytokines involved in inflammatory pathologies signal via the Janus kinase signal transducer and activator of transcription pathway. Four JAKs are known: JAK1, JAK2, JAK3 and TYK2. The specific activation of JAKs and STATs determines the biological effects of each cytokine. JAK1 is involved in the signalling of 'gamma c' receptor cytokines (IL 2, IL 4, IL 7, IL 9, IL 15 and IL 21), pro inflammatory cytokines including IL 6, as well as IFN. The critical position of JAK1 downstream of these cytokines suggests that JAK1 selective inhibitors are comparable to non selective ones, without the unwanted consequences of JAK2  or JAK3 blockade. JAK inhibition has led to a better understanding of the biology of synovial inflammation and bone homeostasis. Moreover, the efficacy of non selective JAK inhibitors and novel JAK1 selective drugs in RA supports a role for JAK1 in its pathogenesis. JAK1 selective drugs are also showing promise in axial spondyloarthritis, suggesting that they may target additional regulatory pathways that impact cytokines such as TNF and IL 17A, which do not use JAKs. Additionally, evidence now supports a JAK1 predominance in the signalling of IL 6 and oncostatin M, and indirectly, of TNF in synovial fibroblasts, macrophages and endothelial cells. Notably, bone homeostasis is also dependent on cytokines relying on JAK1 signalling to promote receptor activator of NF kappa B ligand expression in osteoblasts and T cells, contributing to osteoclastogenesis. Here, the contribution of JAK1 over other kinases is unclear. While beneficial effects of JAK inhibitors on bone erosion are supported by preclinical and clinical data, effects on new bone formation in axial spondyloarthritis requires additional study.
C1 [Spinelli, Francesca Romana] Sapienza Univ Roma, Dipartimento Sci Clin Internist Anestesiol & Card, Rome, Italy.
   [Colbert, Robert A.] NIAMSD, Pediat Translat Res Branch, NIH, Bethesda, MD 20892 USA.
   [Gadina, Massimo] NIAMSD, Translat Immunol Sect, NIH, Bethesda, MD 20892 USA.
C3 Sapienza University Rome; National Institutes of Health (NIH)   USA; NIH
   National Institute of Arthritis & Musculoskeletal & Skin Diseases
   (NIAMS); National Institutes of Health (NIH)   USA; NIH National
   Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)
RP Gadina, M (通讯作者)，NIAMSD, Translat Immunol Sect, NIH, Bethesda, MD 20892 USA.
EM gadinama@mail.nih.gov
RI Spinelli, Francesca/AAM 7061 2020
OI Spinelli, Francesca Romana/0000 0003 1969 2097
FU Gilead; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases [ZIDAR041180] Funding Source: NIH RePORTER
FX This paper was published as part of a supplement supported by an
   educational grant from Gilead.
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Albacker LA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176181
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P710, DOI 10.1136/annrheumdis 2012 202698
   Biggioggero M, 2019, DRUGS CONTEXT, V8, P1
   Bonelli M, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 019 0267 6
   Bottini N, 2013, NAT REV RHEUMATOL, V9, P24, DOI 10.1038/nrrheum.2012.190
   Boyle DL, 2015, ANN RHEUM DIS, V74, P1311, DOI 10.1136/annrheumdis 2014 206028
   Braun J, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1911 1
   Choy EH, 2019, RHEUMATOLOGY, V58, P953, DOI 10.1093/rheumatology/key339
   Cohen SB, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen 2020 001395
   Diller M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00541
   Eletto D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13992
   Fiocco U, 2015, J RHEUMATOL, V42, P48, DOI 10.3899/jrheum.150636
   Fleischmann R, 2017, ARTHRITIS RHEUMATOL, V69, P506, DOI 10.1002/art.39953
   Gao W, 2016, ANN RHEUM DIS, V75, P311, DOI 10.1136/annrheumdis 2014 207201
   Genovese MC, 2020, LANCET RHEUMATOL, V2, pE347, DOI 10.1016/S2665 9913(20)30032 1
   Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668
   GRATACOS J, 1994, BRIT J RHEUMATOL, V33, P927
   Gruber CN, 2020, IMMUNITY, V53, P672, DOI 10.1016/j.immuni.2020.07.006
   Hanlon MM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02056
   Haroon N, 2013, ARTHRITIS RHEUM US, V65, P2645, DOI 10.1002/art.38070
   Isomäki P, 2015, RHEUMATOLOGY, V54, P1103, DOI 10.1093/rheumatology/keu430
   Jo S, 2020, RHEUMATOLOGY, DOI [10.1093/rheumatology/keaa846, DOI 10.1093/rheumatology/keaa846]
   Kleppe M, 2017, CELL STEM CELL, V21, P489, DOI 10.1016/j.stem.2017.08.011
   Lee EB, 2014, NEW ENGL J MED, V370, P2377, DOI 10.1056/NEJMoa1310476
   Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293
   Maksymowych WP, 2020, ANN RHEUM DIS, V79, P417, DOI 10.1136/annrheumdis 2020 eular.2553
   Maksymowych WP, 2018, RHEUMATOLOGY, V57, P1390, DOI 10.1093/rheumatology/key104
   Merola JF, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen 2018 000656
   Migita K, 2013, CLIN EXP IMMUNOL, V174, P356, DOI 10.1111/cei.12190
   Miller DM, 1998, J EXP MED, V187, P675, DOI 10.1084/jem.187.5.675
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Najm A, 2020, ARTHRITIS RHEUMATOL, V72, P2030, DOI 10.1002/art.41441
   O'Shea JJ, 2013, NEW ENGL J MED, V368, P161, DOI 10.1056/NEJMra1202117
   Ren JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024496
   Ren Y, 2013, SCI REP UK, V3, DOI 10.1038/srep03042
   Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092 8674(00)81166 6
   Rosengren S, 2012, ANN RHEUM DIS, V71, P440, DOI 10.1136/ard.2011.150284
   Sieper J, 2014, ANN RHEUM DIS, V73, P95, DOI 10.1136/annrheumdis 2013 203559
   Sims NA, 2020, EXP MOL MED, V52, P1185
   Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254 003 0013 1
   Tarrant JM, 2020, RHEUMATOL THER, V7, P173, DOI 10.1007/s40744 019 00192 5
   Taylor PC, 2019, RHEUMATOLOGY, V58, P17, DOI 10.1093/rheumatology/key225
   THOMA B, 1994, J BIOL CHEM, V269, P6215
   van der Heijde D, 2019, LANCET, V394, P2108, DOI 10.1016/S0140 6736(19)32534 6
   van der Heijde D, 2019, J RHEUMATOL, V46, P1089, DOI 10.3899/jrheum.180971
   van der Heijde D, 2018, LANCET, V392, P2378, DOI 10.1016/S0140 6736(18)32463 2
   van der Heijde D, 2017, ANN RHEUM DIS, V76, P1340, DOI 10.1136/annrheumdis 2016 210322
   van der Heijde D, 2013, ARTHRITIS RHEUM US, V65, P559, DOI 10.1002/art.37816
   Venkatesh D, 2013, IMMUNITY, V38, P1025, DOI 10.1016/j.immuni.2013.01.012
   Waldmann TA, 2017, ANNU REV IMMUNOL, V35, P533, DOI 10.1146/annurev immunol 110416 120628
   Wu YX, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.6
   Yarilina A, 2008, NAT IMMUNOL, V9, P378, DOI 10.1038/ni1576
   Yarilina A, 2012, ARTHRITIS RHEUM US, V64, P3856, DOI 10.1002/art.37691
NR 54
TC 41
Z9 41
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
EI 1462 0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD MAY
PY 2021
VL 60
SU 2
BP II3
EP II10
DI 10.1093/rheumatology/keab024
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA SN3VU
UT WOS:000658222100002
PM 33950229
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Wang, KP
   Wu, ZL
   Gong, CY
   Zhao, GH
   Zhang, HH
AF Wang, Keping
   Wu, Zuolong
   Gong, Chaoyang
   Zhao, Guanghai
   Zhang, Haihong
TI TGF β1 Inhibits Osteoclast Differentiation and Abnormal Angiogenesis in
   Intervertebral Disc Degeneration: Evidence from RNA Sequencing and
   Animal Studies
SO ORTHOPAEDIC SURGERY
LA English
DT Article
DE Angiogenesis; Bone homeostasis; Cartilage endplate; Intervertebral disc
   degeneration; Osteoclast differentiation; TGF beta 1; Transcriptome
   sequencing
ID MESENCHYMAL STEM CELLS; NUCLEUS PULPOSUS; TRANSFORMING
   GROWTH FACTOR BETA 1; IN VIVO; OSTEOGENESIS; EXPRESSION; TRANSITION;
   MIGRATION; APOPTOSIS; ALGINATE
AB Objective Mechanisms involved in developing intervertebral disc degeneration (IDD) are poorly understood, thus making developing effective therapies difficult. This study aimed to suggest a possible molecular mechanism, based on transcriptome sequencing identified transforming growth factor (TGF beta), underlying the effects on bone homeostasis in IDD.Methods A mouse model for IDD was established. Transcriptome sequencing of nucleus pulposus tissue from mice (n = 3) identified differentially expressed mRNAs and key genes impacting bone homeostasis. A protein protein interaction network pinpointed core genes. GO and KEGG analysis revealed gene functions. Expression levels of TGF beta 1, tartrate resistant acid phosphatase (TRAP), and cathepsin K (CTSK) were measured. Micro CT evaluated vertebral structures and vascular imaging. Western Blot measured expression levels of Vegf, Opn, MMP3, and MMP13. Safranin O Fast Green and TRAP staining were performed on intervertebral discs and endplates.Results Transcriptomic analysis found 1790 differentially expressed mRNAs in IDD mice. Twenty eight genes related to bone homeostasis in IDD were identified. TGF beta 1 was confirmed as the core gene. GO and KEGG showed TGF beta 1 regulates osteoclast markers like CTSK and TRAP through pathways including NF kappa B and MAPK. Experimental validation revealed lower TGF beta 1 expression in IDD mice than controls, and increased TRAP and CTSK expression. Micro CT showed decreased bone mass and intervertebral disc space in IDD mice. Vascular imaging showed increased vascular volume in IDD cartilaginous endplates. Western blot displayed increased VEGF and OPN levels, but decreased MMP3 and MMP13 in IDD mice. Safranin O fast green staining revealed severe IDD degeneration. However, TGF beta 1 injection improved bone parameters in IDD mice. In vitro experiments confirmed TGF beta 1 inhibits bone marrow macrophages differentiation into osteoclasts.Conclusion From our data, we conclude that TGF beta 1 repressed osteoclast differentiation and aberrant bone associated angiogenesis in cartilage endplates (EPs) to alleviate IDD, which may be instrumental for the therapeutic targeting of IDD.
C1 [Wang, Keping; Wu, Zuolong; Gong, Chaoyang; Zhao, Guanghai; Zhang, Haihong] Lanzhou Univ, Second Hosp, Dept Orthoped, Lanzhou, Peoples R China.
   [Wang, Keping; Wu, Zuolong; Gong, Chaoyang; Zhao, Guanghai; Zhang, Haihong] Key Lab Orthoped Dis Gansu Prov, Lanzhou 730000, Gansu, Peoples R China.
   [Wang, Keping; Wu, Zuolong; Gong, Chaoyang; Zhao, Guanghai; Zhang, Haihong] Lanzhou Univ, Lanzhou, Peoples R China.
   [Zhang, Haihong] Lanzhou Univ, Second Hosp, Dept Orthoped, 82 Cuiyingmen, Lanzhou 730000, Peoples R China.
C3 Lanzhou University; Lanzhou University; Lanzhou University
RP Zhang, HH (通讯作者)，Lanzhou Univ, Second Hosp, Dept Orthoped, 82 Cuiyingmen, Lanzhou 730000, Peoples R China.
EM zhanghaihongldey@163.com
RI Wang, Keping/KVA 9146 2024
FU Scientific Research Program of Gansu Provincial Department of Health
FX No Statement Available
CR Ao X, 2019, CLIN ORTHOP RELAT R, V477, P1492, DOI 10.1097/CORR.0000000000000712
   Ban ZF, 2019, ONCOL REP, V41, P3270, DOI 10.3892/or.2019.7123
   Bian Q, 2016, SCI REP UK, V6, DOI 10.1038/srep27093
   BORN GVR, 1989, SEMIN THROMB HEMOST, V15, P140, DOI 10.1055/s 2007 1002696
   Cai F, 2017, DNA CELL BIOL, V36, P143, DOI 10.1089/dna.2016.3230
   Chen Q, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.913979
   Chen S, 2019, OSTEOARTHR CARTILAGE, V27, P1109, DOI 10.1016/j.joca.2019.05.005
   Chen WH, 2006, J CELL PHYSIOL, V209, P744, DOI 10.1002/jcp.20765
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   DALLAS SL, 1994, J BIOL CHEM, V269, P6815
   Ding F, 2013, APOPTOSIS, V18, P777, DOI 10.1007/s10495 013 0839 1
   Duvall CL, 2004, AM J PHYSIOL HEART C, V287, pH302, DOI 10.1152/ajpheart.00928.2003
   Good SR, 2009, J IMMUNOL, V183, P3839, DOI 10.4049/jimmunol.0901411
   Gruber HE, 1997, EXP CELL RES, V235, P13, DOI 10.1006/excr.1997.3647
   Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Kim J, 2022, VIRUSES BASEL, V14, DOI 10.3390/v14050859
   Kirnaz S, 2022, WORLD NEUROSURG, V157, P264, DOI 10.1016/j.wneu.2021.09.066
   Kos Natasa, 2019, Med Arch, V73, P421, DOI 10.5455/medarh.2019.73.421 424
   KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Laffosse JM, 2010, J ORTHOP RES, V28, P1229, DOI 10.1002/jor.21137
   Lai A, 2016, SPINE J, V16, P420, DOI 10.1016/j.spinee.2015.11.019
   Li HX, 2020, LIFE SCI, V263, DOI 10.1016/j.lfs.2020.118567
   Liang N, 2017, INT J ONCOL, V51, P213, DOI 10.3892/ijo.2017.4004
   Liu FZ, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/4062813
   Liu Q, 2019, SPINE, V44, pE510, DOI 10.1097/BRS.0000000000002904
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Masuda Koichi, 2004, Spine J, V4, p330S, DOI 10.1016/j.spinee.2004.07.028
   Ndaw VS, 2017, J IMMUNOL, V199, P866, DOI 10.4049/jimmunol.1601983
   Nerlich AG, 2005, EUR SPINE J, V14, P17, DOI 10.1007/s00586 004 0745 x
   Nishida K, 1999, SPINE, V24, P2419, DOI 10.1097/00007632 199912010 00002
   Pattison ST, 2001, CELL BIOL INT, V25, P679, DOI 10.1006/cbir.2000.0718
   Pistell PJ, 2010, NEUROSCIENCE, V166, P61, DOI 10.1016/j.neuroscience.2009.12.029
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Sessler T, 2013, PHARMACOL THERAPEUT, V140, P186, DOI 10.1016/j.pharmthera.2013.06.009
   Stelzer G., 2016, CURR PROTOC BIOINFOR, V54, p1.30.31, DOI [10.1002/cpbi.5, DOI 10.1002/CPBI.5]
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tang Y, 2020, THERANOSTICS, V10, P2229, DOI 10.7150/thno.40559
   Tsuji T, 2007, SPINE, V32, P849, DOI 10.1097/01.brs.0000259804.39881.62
   Vergroesen PPA, 2015, OSTEOARTHR CARTILAGE, V23, P1057, DOI 10.1016/j.joca.2015.03.028
   Von Forell GA, 2014, J BIOMECH ENG T ASME, V136, DOI 10.1115/1.4027301
   Walsh AJL, 2004, SPINE, V29, P156, DOI 10.1097/01.BRS.0000107231.67854.9F
   Wang SL, 2013, EXP THER MED, V6, P1522, DOI 10.3892/etm.2013.1348
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Xia C, 2019, FREE RADICAL BIO MED, V143, P1, DOI 10.1016/j.freeradbiomed.2019.07.026
   Xia W, 2018, ORTHOP SURG, V10, P134, DOI 10.1111/os.12377
   Xiao ZF, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1701 1
   Yang HL, 2016, J CELL MOL MED, V20, P1542, DOI 10.1111/jcmm.12847
   Yang HL, 2015, SCI REP UK, V5, DOI 10.1038/srep13254
   Yang HL, 2010, SPINE J, V10, P802, DOI 10.1016/j.spinee.2010.06.019
   Zhang J, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.136
   Zhao HY, 2017, MOL CELLS, V40, P211, DOI 10.14348/molcells.2017.2303
   Zou SB, 2016, PHARMACOL REP, V68, P7, DOI 10.1016/j.pharep.2015.06.004
NR 54
TC 3
Z9 3
U1 3
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1757 7853
EI 1757 7861
J9 ORTHOP SURG
JI Orthop. Surg.
PD JAN
PY 2024
VL 16
IS 1
BP 167
EP 182
DI 10.1111/os.13912
EA NOV 2023
PG 16
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA EK7X1
UT WOS:001120042600001
PM 38014468
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xu, XY
   Luo, HY
   Chen, Q
   Wang, ZK
   Chen, XX
   Li, XP
   Chen, H
   Wang, M
   Xu, YY
   Dai, M
   Wang, JW
   Huang, XK
   Wu, B
   Li, YP
AF Xu, Xiaoyu
   Luo, Hongyu
   Chen, Qian
   Wang, Zikang
   Chen, Xixuan
   Li, Xiaping
   Chen, Huan
   Wang, Miao
   Xu, Yingyue
   Dai, Min
   Wang, Jianwei
   Huang, Xuekuan
   Wu, Bin
   Li, Yanping
TI Detecting potential mechanism of vitamin D in treating rheumatoid
   arthritis based on network pharmacology and molecular docking
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE vitamin D; rheumatoid arthritis; network pharmacology; molecular
   docking; diagnostic marker or target
ID TNF SUPERFAMILY; KAPPA B; OSTEOCLASTS; APOPTOSIS; CASPASE 3; ALBUMIN;
   MEMBERS
AB Aim: Vitamin D plays a vital role in Rheumatoid arthritis (RA). However, the mechanism of vitamin D and rheumatism is still unclear. Therefore, a strategy based on network pharmacology and molecular docking was used to explore the mechanism of vitamin D and RA.Methods: The targets of RA were obtained from the GeneCards database and Therapeutic Targets Database, and the targets of vitamin D were obtained from the Drugbank database and STITCH database. Next, overlapping genes were identified by Venny, and further Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and molecular docking analyses were performed.Results: A total of 1,139 targets of RA and 201 targets of vitamin D were obtained. A total of 76 overlapping genes were identified by Venny. The enrichment analysis showed that cell proliferation, immune response, and apoptotic process were the critical biological processes of vitamin D in treating RA. Antifolate resistance, osteoclast differentiation, and the nuclear factor kappa B (NF  kappa B) signalling pathway are fundamental mechanisms of vitamin D in treating RA. According to further molecular docking, ALB, TNF, CASP3, and TP53 may be important punctuation points or diagnostic markers for future RA treatment.Conclusion: By analysing overlapping genes of diseases and drugs, this study confirmed that ALB, TNF, CASP3, and TP53 may be essential markers or diagnostic markers for future RA treatment.
C1 [Xu, Xiaoyu; Luo, Hongyu; Chen, Qian; Wang, Zikang; Chen, Xixuan; Li, Xiaping; Chen, Huan; Wang, Jianwei; Huang, Xuekuan; Wu, Bin; Li, Yanping] Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing, Peoples R China.
   [Xu, Xiaoyu; Wang, Miao; Xu, Yingyue; Dai, Min; Wu, Bin; Li, Yanping] Chongqing Hosp Tradit Chinese Med, Dept Rheumatol, Chongqing, Peoples R China.
   [Luo, Hongyu; Wang, Jianwei; Huang, Xuekuan] Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing Key Lab Tradit Chinese Med Prevent & Cur, Chongqing, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Wang, JW; Huang, XK; Wu, B; Li, YP (通讯作者)，Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing, Peoples R China.; Wu, B; Li, YP (通讯作者)，Chongqing Hosp Tradit Chinese Med, Dept Rheumatol, Chongqing, Peoples R China.; Wang, JW; Huang, XK (通讯作者)，Chongqing Med Univ, Coll Tradit Chinese Med, Chongqing Key Lab Tradit Chinese Med Prevent & Cur, Chongqing, Peoples R China.
EM wuubinn@126.com; wangjianwei@cqmu.edu.cn; xkhuang2002@cqmu.edu.cn;
   840051779@qq.com
RI ; chen, zhiping/IST 6333 2023; Wu, Bin/AAA 9378 2019
OI CHEN, Qian/0009 0005 1528 1006; 
FU Youth Fund of National Natural Science Foundation of China [82104848];
   Natural Science Foundation of Chong Qing Postdoctoral Science Foundation
   [cstc2019jcyj bshX0044]; Natural Science Foundation of Chongqing, China
   [cstc2020jcyj msxmX0404]; Chongqing Municipal Health Commission [20];
   Project of Chongqing Hospital of Traditional Chinese Medicine
   [cqzyymzygzs 001]; Xinglin scholar hospital project of Chengdu
   University of Traditional Chinese Medicine [YYZX2020056]
FX This work was supported by the Youth Fund of National Natural Science
   Foundation of China (No: 82104848) and the Natural Science Foundation of
   Chong Qing Postdoctoral Science Foundation (cstc2019jcyj bshX0044), the
   Natural Science Foundation of Chongqing, China (cstc2020jcyj msxmX0404),
   Chongqing Municipal Health Commission (Chongqing Traditional Chinese
   Medicine (2020) No. 20), Project of Chongqing Hospital of Traditional
   Chinese Medicine (cqzyymzygzs 001), and the Xinglin scholar hospital
   project of Chengdu University of Traditional Chinese Medicine
   (YYZX2020056).
CR Asadi M, 2022, BIOTECHNOL APPL BIOC, V69, P1633, DOI 10.1002/bab.2233
   Baum R, 2016, CLIN REV ALLERG IMMU, V51, P1, DOI 10.1007/s12016 015 8515 6
   Bergström B, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1554 7
   Cao X, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.793888
   Cardoso I, 2022, NUTRIENTS, V14, DOI 10.3390/nu14030447
   Chang JJ, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 96152 7
   Chen SS, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22695
   Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148
   Croft M, 2012, TRENDS IMMUNOL, V33, P144, DOI 10.1016/j.it.2011.10.004
   Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526
   Dehkordi MH, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.840023
   El Banna HS, 2020, EXPERT REV CLIN IMMU, V16, P847, DOI 10.1080/1744666X.2020.1805317
   Fan WQ, 2021, INFLAMMATION, V44, P1803, DOI 10.1007/s10753 021 01459 2
   Fernández Villa D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20204996
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Gansmo LB, 2021, GENE, V793, DOI 10.1016/j.gene.2021.145747
   Gu X, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.300
   Hahn J, 2022, BMJ BRIT MED J, V376, DOI 10.1136/bmj 2021 066452
   He LG, 2014, ACTA PHARMACOL SIN, V35, P203, DOI 10.1038/aps.2013.139
   He YJ, 2020, CLIN CHIM ACTA, V500, P149, DOI 10.1016/j.cca.2019.10.009
   Hegarty RSM, 2021, ARTHRIT CARE RES, V73, P1282, DOI 10.1002/acr.24224
   Hsin KY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083922
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kaltschmidt C, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082042
   Kizilirmak C, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.886127
   Kuhn M, 2010, NUCLEIC ACIDS RES, V38, pD552, DOI 10.1093/nar/gkp937
   Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068
   Lei Q, 2022, TALANTA, V240, DOI 10.1016/j.talanta.2021.123198
   Li X, 2022, COMPUT BIOL MED, V144, DOI 10.1016/j.compbiomed.2022.105389
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   Maiuolo J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010081
   Masoumi M, 2021, INFLAMMATION, V44, P466, DOI 10.1007/s10753 020 01371 1
   Millier MJ, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02748 3
   Mormile I, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.685214
   Mouterde G, 2020, J RHEUMATOL, V47, P1624, DOI 10.3899/jrheum.190795
   Nawaz H, 2021, CLIN RHEUMATOL, V40, P1767, DOI 10.1007/s10067 020 05438 0
   Nogales C, 2022, TRENDS PHARMACOL SCI, V43, P136, DOI 10.1016/j.tips.2021.11.004
   Nowakowska Plaza A, 2014, SCAND J RHEUMATOL, V43, P17, DOI 10.3109/03009742.2013.811537
   Okamoto Takashi, 2006, Endocrine Metabolic & Immune Disorders Drug Targets, V6, P359
   Pinzi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184331
   Pirooznia M, 2007, BIOINFORMATION, V1, P420, DOI 10.6026/97320630001420
   Piva R, 2006, ANN NY ACAD SCI, V1091, P509, DOI 10.1196/annals.1378.092
   Piva R, 2009, ANN NY ACAD SCI, V1171, P448, DOI 10.1111/j.1749 6632.2009.04906.x
   Reina Bueno M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18095042
   Ren BD, 2019, APOPTOSIS, V24, P892, DOI 10.1007/s10495 019 01567 3
   Ru JL, 2019, INT J RHEUM DIS, V22, P608, DOI 10.1111/1756 185X.13397
   Safran M, 2010, DATABASE OXFORD, DOI 10.1093/database/baq020
   Sahebari M, 2016, BIOL TRACE ELEM RES, V171, P237, DOI 10.1007/s12011 015 0501 6
   Seeliger Daniel, 2010, J Comput Aided Mol Des, V24, P417, DOI 10.1007/s10822 010 9352 6
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Szekanecz Z, 2021, NAT REV RHEUMATOL, V17, P585, DOI 10.1038/s41584 021 00652 9
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Szymczyk KH, 2006, J CELL PHYSIOL, V209, P836, DOI 10.1002/jcp.20770
   Tag HM, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906 015 0744 y
   Taghadosi M, 2021, IMMUNOL RES, V69, P225, DOI 10.1007/s12026 021 09202 7
   Trenkmann M, 2010, CLIN REV ALLERG IMMU, V39, P10, DOI 10.1007/s12016 009 8166 6
   Venetsanopoulou AI, 2022, EXPERT REV CLIN IMMU, V18, P923, DOI 10.1080/1744666X.2022.2106970
   Verma S, 2021, MOL CELL BIOCHEM, V476, P4351, DOI 10.1007/s11010 021 04245 8
   Wang DS, 2021, PHARMACOL RES, V171, DOI 10.1016/j.phrs.2021.105496
   Wang L, 2021, J INTERF CYTOK RES, V41, P347, DOI 10.1089/jir.2021.0044
   Wang Q, 2021, CLIN EXP RHEUMATOL, V39, P829, DOI 10.55563/clinexprheumatol/y562nj
   Wang YJ, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110519
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wysocki T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042366
   Yan HH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.789334
   Zhai ZQ, 2022, ARTHRITIS RHEUMATOL, V74, P427, DOI 10.1002/art.41963
   Zhang L, 2019, MED SCI MONITOR, V25, P7709, DOI 10.12659/MSM.919935
   Zhang TP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.731565
   Zhao JA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.790122
   Zheng ZH, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.849050
NR 70
TC 3
Z9 3
U1 0
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 30
PY 2022
VL 13
AR 1047061
DI 10.3389/fphar.2022.1047061
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 7B1JK
UT WOS:000898898500001
PM 36532774
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tatara, MR
   Krupski, W
   Majer Dziedzic, B
AF Tatara, Marcin R.
   Krupski, Witold
   Majer Dziedzic, Barbara
TI Bone mineral density changes of lumbar spine and femur in osteoporotic
   patient treated with bisphosphonates and
   beta hydroxy beta methylbutyrate (HMB)
SO MEDICINE
LA English
DT Article
DE beta hydroxy beta methylbutyrate; bisphosphonates; bone mineral density;
   dual energy X ray absorptiometry; osteoporosis; quantitative computed
   tomography
ID POSTMENOPAUSAL OSTEOPOROSIS; INTRAVENOUS PAMIDRONATE; SKELETAL
   DEVELOPMENT; ORAL ALENDRONATE; ZOLEDRONIC ACID; PREVENTION; STRENGTH;
   IBANDRONATE; MECHANISMS; DIAGNOSIS
AB Rationale: Currently available approaches to osteoporosis treatment include applicationof antiresorptive and anabolic agents influencing bone tissuemetabolism. The aim of the study was to present bone mineral density (BMD) changes of lumbar spine in osteoporotic patient treated with bisphosphonates such as ibandronic acid and pamidronic acid, and beta hydroxy beta methylbutyrate (HMB).
   Patient concerns: BMD and volumetric BMD (vBMD) of lumbar spine were measured during the 6 year observation period with the use of dual energy X ray absorptiometry (DEXA) and quantitative computed tomography (QCT).
   Diagnoses: The described case report of osteoporotic patient with family history of severe osteoporosis has shown sitedependent response of bone tissue to antiosteoporotic treatment with bisphosphonates.
   Interventions and outcomes: Twenty five month treatment with ibandronic acid improved proximal femur BMD with relatively poor effects on lumbar spine BMD. Over 15 month therapy with pamidronic acid was effective to improve lumbar spine BMD, while in the proximal femur the treatment was not effective. A total of 61 week long oral administration with calcium salt of HMB improved vBMD of lumbar spine in the trabecular and cortical bone compartments when monitored by QCT. Positive effects of nearly 2.5 year HMB treatment on BMD of lumbar spine and femur in the patient were also confirmed using DEXA method.
   Lessons: The results obtained indicate that HMB may be applied for the effective treatment of osteoporosis in humans. Further studies on wider human population are recommended to evaluate mechanisms influencing bone tissue metabolism by HMB.
C1 [Tatara, Marcin R.] Univ Life Sci Lublin, Dept Anim Physiol, Fac Vet Med, Ul Akad 12, PL 20950 Lublin, Poland.
   [Tatara, Marcin R.; Krupski, Witold] Med Univ Lublin, Dept Radiol 2, Ul Staszica 16, Lublin, Poland.
   [Majer Dziedzic, Barbara] Univ Life Sci Lublin, Dept Microbiol, Fac Vet Med, Ul Akad 12, Lublin, Poland.
C3 University of Life Sciences in Lublin; Medical University of Lublin;
   University of Life Sciences in Lublin
RP Tatara, MR (通讯作者)，Univ Life Sci Lublin, Dept Anim Physiol, Fac Vet Med, Ul Akad 12, PL 20950 Lublin, Poland.
EM matatar99@gazeta.pl
RI Tatara, Marcin/AAF 9786 2020
OI Tatara, Marcin/0000 0003 2211 874X
CR Albright F, 1941, J AMER MED ASSOC, V116, P2465, DOI 10.1001/jama.1941.02820220007002
   [Anonymous], 2000, NIH Consens Statement, V17, P1
   Bienko M, 2006, MED WETER, V62, P963
   Brumsen C, 2002, J BONE MINER RES, V17, P1057, DOI 10.1359/jbmr.2002.17.6.1057
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Cummings SR, 2002, JAMA J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Czerwinski Edward, 2007, Ortop Traumatol Rehabil, V9, P337
   Demontiero O, 2009, CLIN INTERV AGING, V4, P153
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Heijckmann AC, 2002, NETH J MED, V60, P315
   Hou YJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001007
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Krupski W, 2011, J PRECILN CLIN RES, V5, P60
   Krupski W, 2007, POLISH J ENV STUD, V16, P290
   Lochmüller EM, 2002, BONE, V31, P77, DOI 10.1016/S8756 3282(02)00792 5
   Marcora S, 2005, CLIN NUTR, V24, P442, DOI 10.1016/j.clnu.2005.01.006
   McKiernan FE, 2011, OSTEOPOROSIS INT, V22, P1069, DOI 10.1007/s00198 010 1307 1
   Nissen SL, 1997, NUTR BIOCH, V8, P300
   PECK WA, 1993, AM J MED, V94, P646
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   REID IR, 1994, J CLIN ENDOCR METAB, V79, P1595, DOI 10.1210/jc.79.6.1595
   Riis BJ, 2001, J BONE MINER RES, V16, P1871, DOI 10.1359/jbmr.2001.16.10.1871
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Russell RGG, 2007, BONE, V40, pS21, DOI 10.1016/j.bone.2007.03.002
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Spence MM, 2010, ANN PHARMACOTHER, V44, P1384, DOI 10.1345/aph.1P152
   Szczesniak KA, 2015, J ANIM PHYSIOL AN N, V99, P405, DOI 10.1111/jpn.12234
   Tatara MR, 2016, HUM HEALT HANDB, V13, P129, DOI 10.3920/978 90 8686 823 0_7
   Tatara MR, 2009, J ANIM PHYSIOL AN N, V93, P669, DOI 10.1111/j.1439 0396.2008.00854.x
   Tatara MR, 2008, NUTRITION, V24, P753, DOI 10.1016/j.nut.2008.03.009
   Tatara MR, 2008, EXP PHYSIOL, V93, P763, DOI 10.1113/expphysiol.2007.041145
   Tatara MR, 2007, BONE, V40, P1615, DOI 10.1016/j.bone.2007.02.018
   Tatara MR, 2012, NUTR METAB, V9, DOI 10.1186/1743 7075 9 39
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Vis M, 2005, OSTEOPOROSIS INT, V16, P1432, DOI 10.1007/s00198 005 1862 z
   Williams JZ, 2002, ANN SURG, V236, P369, DOI 10.1097/00000658 200209000 00013
NR 37
TC 4
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT
PY 2017
VL 96
IS 41
AR e8178
DI 10.1097/MD.0000000000008178
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA FO2VJ
UT WOS:000416652600011
PM 29019883
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Paíno, T
   Garcia Gomez, A
   González Méndez, L
   San Segundo, L
   Hernández García, S
   López Iglesias, AA
   Algarín, EM
   Martín Sánchez, M
   Corbacho, D
   Ortiz de Solorzano, C
   Corchete, LA
   Gutiérrez, NC
   Maetos, MV
   Garayoa, M
   Ocio, EM
AF Paino, Teresa
   Garcia Gomez, Antonio
   Gonzalez Mendez, Lorena
   San Segundo, Laura
   Hernandez Garcia, Susana
   Lopez Iglesias, Ana Alicia
   Algarin, Esperanza M.
   Martin Sanchez, Montserrat
   Corbacho, David
   Ortiz de Solorzano, Carlos
   Corchete, Luis A.
   Gutierrez, Norma C.
   Maetos, Maria Victoria
   Garayoa, Mercedes
   Ocio, Enrique M.
TI The Novel Pan PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma
   and Bone Protective Effects, and Potently Synergizes with Current
   Standards of Care
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MULTIPLE MYELOMA; CELL CYCLE; ACTIVATION; MECHANISMS; SURVIVAL; REVEALS;
   BAD; TRANSCRIPTION; CYTOTOXICITY; PROGRESSION
AB Purpose: PIM kinases are a family of serine/threonine kinases recently proposed as therapeutic targets in oncology. In the present work, we have investigated the effects of the novel pan PIM kinase inhibitor, PIM447, on myeloma cells and myeloma associated bone disease using different preclinical models.
   Experimental Design: In vitro/ex vivo cytotoxicity of PIM447 was evaluated on myeloma cell lines and patient samples. Synergistic combinations with standard treatments were analyzed with Calcusyn Software. PIM447 effects on bone cells were assessed on osteogenic and osteoclastogenic cultures. The mechanisms of PIM447 were explored by immunoblotting, qPCR, and immunofluorescence. A murine model of disseminated multiple myeloma was employed for in vivo studies.
   Results: PIM447 is cytotoxic for myeloma cells due to cell cycle disruption and induction of apoptosis mediated by a decrease in phospho Bad (Ser112) and c Myc levels and the inhibition of mTORC1 pathway. Importantly, PIM447 demonstrates a very strong synergy with different standard treatments such as bortezomib + dexamethasone (combination index, CI = 0.002), lenalidomide + dexamethasone (CI = 0.065), and pomalidomide dexamethasone (CI = 0.077). PIM447 also inhibits in vitro osteoclast formation and resorption, downregulates key molecules involved in these processes, and partially disrupts the F actin ring, while increasing osteoblast activity and mineralization. Finally, PIM447 significantly reduced the tumor burden and prevented tumor associated bone loss in a disseminated murine model of human myeloma.
   Conclusions: Our results demonstrate dual antitumoral and bone protective effects of PIM447. This fact, together with the very strong synergy exhibited with standard of care treatments, supports the future clinical development of this drug in multiple myeloma. (C) 2016 AACR.
C1 [Paino, Teresa; Garcia Gomez, Antonio; Gonzalez Mendez, Lorena; San Segundo, Laura; Hernandez Garcia, Susana; Lopez Iglesias, Ana Alicia; Algarin, Esperanza M.; Martin Sanchez, Montserrat; Corchete, Luis A.; Gutierrez, Norma C.; Maetos, Maria Victoria; Garayoa, Mercedes; Ocio, Enrique M.] Univ Salamanca, CSIC, IBMCC, Ctr Invest Canc, Salamanca, Spain.
   [Paino, Teresa; Garcia Gomez, Antonio; Gonzalez Mendez, Lorena; San Segundo, Laura; Hernandez Garcia, Susana; Lopez Iglesias, Ana Alicia; Algarin, Esperanza M.; Martin Sanchez, Montserrat; Corchete, Luis A.; Gutierrez, Norma C.; Maetos, Maria Victoria; Garayoa, Mercedes; Ocio, Enrique M.] Complejo Asistencial Univ Salamanca IBSAL, Salamanca, Spain.
   [Corbacho, David; Ortiz de Solorzano, Carlos] Univ Navarra, Program Solid Tumors & Biomarkers, CIMA, Pamplona, Spain.
   [Corbacho, David; Ortiz de Solorzano, Carlos] Navarras Hlth Res Inst IDISNA, Pamplona, Spain.
C3 University of Salamanca; Consejo Superior de Investigaciones Cientificas
   (CSIC); CSIC USAL   Instituto de Biologia Molecular y Celular del Cancer
   de Salamanca (IBMCC); University of Navarra
RP Ocio, EM (通讯作者)，Hosp Univ Salamanca, Paseo San Vicente 58 182, Salamanca 37007, Spain.
EM emocio@usal.es
RI Garayoa, Mercedes/O 6039 2017; Ortiz de Solorzano, Carlos/G 3278 2010;
   Pachon, Esperanza/AAL 1745 2020; San Segundo, Laura/E 6441 2018;
   Corchete Sanchez, Luis Antonio/D 1336 2018; Corchete Sánchez, Luis
   Antonio/D 1336 2018; San Segundo, Laura/E 6441 2018; Ortiz de Solorzano,
   Carlos/G 3278 2010
OI Garayoa, Mercedes/0000 0003 2194 2841; Ortiz de Solorzano,
   Carlos/0000 0001 8720 0205; San Segundo, Laura/0000 0003 2391 5935;
   Corchete Sanchez, Luis Antonio/0000 0003 4577 8599; Gutierrez,
   Norma/0000 0001 5834 9510; Ocio, Enrique M./0000 0002 5765 0085; Garcia,
   Antonio/0000 0003 0527 7351; Algarin Pachon, Esperanza
   Macarena/0000 0002 5112 341X
FU RTICC Hematology Group [RD12/0036/0058]; Spanish FIS [PI11/01465,
   PI15/02156]; FEDER Funds; Ministerio de Economia y Competitividad
   [DPI2012 38090 C03 02, DPI2015 64221 C2 2]; AECC [GCB120981SAN]; Junta
   de Castilla y Leon; Consejerias de Sanidad [GRS 862/A/13, GRS 1175/A/15,
   BIO/SA05/14]; Consejerias de Educacion [FIC335U14]; Centro en Red de
   Medicina Regenerativa y Terapia Celular de Castilla y Leon
FX This work was supported by funding from the RTICC Hematology Group
   (RD12/0036/0058), Spanish FIS (PI11/01465 and PI15/02156) and FEDER
   Funds, Ministerio de Economia y Competitividad grants
   DPI2012 38090 C03 02 and DPI2015 64221 C2 2, AECC (GCB120981SAN), Junta
   de Castilla y Leon, Consejerias de Sanidad (GRS 862/A/13, GRS 1175/A/15
   and BIO/SA05/14) y Educacion (FIC335U14) and the Centro en Red de
   Medicina Regenerativa y Terapia Celular de Castilla y Leon.
CR Abe M, 2011, INT J HEMATOL, V94, P334, DOI 10.1007/s12185 011 0949 x
   Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050
   Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273
   Asano J, 2011, LEUKEMIA, V25, P1182, DOI 10.1038/leu.2011.60
   Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691 702.2001
   Blanco Aparicio C, 2013, BIOCHEM PHARMACOL, V85, P629, DOI 10.1016/j.bcp.2012.09.018
   Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321
   Burger MT, 2015, J MED CHEM, V58, P8373, DOI 10.1021/acs.jmedchem.5b01275
   Cervantes Gomez Fabiola, 2013, Clin Lymphoma Myeloma Leuk, V13 Suppl 2, pS317, DOI 10.1016/j.clml.2013.05.019
   Chen LS, 2011, BLOOD, V118, P693, DOI 10.1182/blood 2010 12 323022
   Chen LS, 2009, BLOOD, V114, P4150, DOI 10.1182/blood 2009 03 212852
   Chiles TC, 2004, J IMMUNOL, V173, P2901, DOI 10.4049/jimmunol.173.5.2901
   Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood 2002 01 0008
   Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260
   Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   Garcia PD, 2014, CLIN CANCER RES, V20, P1834, DOI 10.1158/1078 0432.CCR 13 2062
   Garcia Gomez A, 2014, CLIN CANCER RES, V20, P1542, DOI 10.1158/1078 0432.CCR 13 1657
   Garcia Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034914
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hiasa M, 2015, LEUKEMIA, V29, P207, DOI 10.1038/leu.2014.147
   Hurchla MA, 2013, LEUKEMIA, V27, P430, DOI 10.1038/leu.2012.183
   Keeton EK, 2014, BLOOD, V123, P905, DOI 10.1182/blood 2013 04 495366
   Kim K, 2010, J IMMUNOL, V185, P7460, DOI 10.4049/jimmunol.1000885
   Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313
   Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood 2007 10 116129
   López Corral L, 2014, HAEMATOLOGICA, V99, P1365, DOI 10.3324/haematol.2013.087809
   Lu J, 2013, BLOOD, V122, P1610, DOI 10.1182/blood 2013 01 481457
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Maiso P, 2006, CANCER RES, V66, P5781, DOI 10.1158/0008 5472.CAN 05 4186
   Meja K, 2014, BRIT J HAEMATOL, V167, P69, DOI 10.1111/bjh.13013
   Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102 459b
   Ocio EM, 2014, LEUKEMIA, V28, P525, DOI 10.1038/leu.2013.350
   Ocio EM, 2009, BLOOD, V113, P3781, DOI 10.1182/blood 2008 09 177774
   OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612
   Paíno T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092378
   PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197
   Raab MS, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.301.301
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Röllig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140 6736(14)60493 1
   Sonmez M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756 9966 27 11
   VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460 2075.1995.tb07251.x
   Yaccoby S, 2010, BRIT J HAEMATOL, V149, P311, DOI 10.1111/j.1365 2141.2010.08141.x
   Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200
   Yang QS, 2012, BLOOD, V120, P3491, DOI 10.1182/blood 2012 02 412643
   Zhang Y, 2008, ONCOGENE, V27, P4809, DOI 10.1038/onc.2008.123
NR 46
TC 46
Z9 49
U1 1
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 1
PY 2017
VL 23
IS 1
BP 225
EP 238
DI 10.1158/1078 0432.CCR 16 0230
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EK4DC
UT WOS:000393876300026
PM 27440267
OA Green Accepted, Green Submitted, Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Weitzmann, MN
   Ha, SW
   Vikulina, T
   Roser Page, S
   Lee, JK
   Beck, GR
AF Weitzmann, M. Neale
   Ha, Shin Woo
   Vikulina, Tatyana
   Roser Page, Susanne
   Lee, Jin Kyu
   Beck, George R., Jr.
TI Bioactive silica nanoparticles reverse age associated bone loss in mice
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Silica nanoparticles; Osteoporosis; Bone formation; Aging; Toxicity
ID IN VIVO; KAPPA B; OSTEOPOROSIS; FRACTURES; POSTMENOPAUSAL; CYTOTOXICITY;
   OSTEOBLASTS; MECHANISMS; EXPRESSION; GUIDELINES
AB We recently reported that in vitro, engineered 50 nm spherical silica nanoparticles promote the differentiation and activity of bone building osteoblasts but suppress bone resorbing osteoclasts. Furthermore, these nanoparticles promote bone accretion in young mice in vivo. We have now investigated the capacity of these nanoparticles to reverse bone loss in aged mice, a model of human senile osteoporosis. Aged mice received nanoparticles weekly and bone mineral density (BMD), bone structure, and bone turnover were quantified. Our data revealed a significant increase in BMD, bone volume, and biochemical markers of bone formation. Biochemical and histological examinations failed to identify any abnormalities caused by nanoparticle administration. Our studies demonstrate that silica nanoparticles effectively blunt and reverse age associated bone loss in mice by a mechanism involving promotion of bone formation. The data suggest that osteogenic silica nanoparticles may be a safe and effective therapeutic for counteracting age associated bone loss. From the Clinical Editor: Osteoporosis poses a significant problem in the society. Based on their previous in vitro findings, the authors' group investigated the effects of spherical silica nanoparticles in reversing bone loss in a mouse model of osteoporosis. The results showed that intra peritoneal injections of silica nanoparticles could increase bone mineral density, with little observed toxic side effects. This novel method may prove important in future therapy for combating osteoporosis. Published by Elsevier Inc.
C1 [Weitzmann, M. Neale; Roser Page, Susanne; Beck, George R., Jr.] Vet Affairs Med Ctr, Atlanta Dept, Decatur, GA 30033 USA.
   [Weitzmann, M. Neale; Ha, Shin Woo; Vikulina, Tatyana; Roser Page, Susanne; Beck, George R., Jr.] Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.
   [Weitzmann, M. Neale; Beck, George R., Jr.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
   [Lee, Jin Kyu] Seoul Natl Univ, Dept Chem, Seoul, South Korea.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Emory University; Emory University; Seoul National University (SNU)
RP Weitzmann, MN (通讯作者)，Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu; george.beck@emory.edu
RI Beck, George/AAO 2117 2020
FU NIAMS [AR056090, AR059364, AR053607]; Georgia Research Alliance
   [GRA.VL12.C2]; Center for Pediatric Nanomedicine [RC159 G3]; Emory
   University; Department of Biomedical Engineering at Georgia Institute of
   Technology; Children's Healthcare of Atlanta, Atlanta, GA, USA;
   Biomedical Laboratory Research & Development Service of the VA Office of
   Research and Development [5I01BX000105]; NIA [AG040013]; Biomedical
   Laboratory Research & Development Service Award from the VA Office of
   Research and Development [I01BX002363]; NCI [CA136716]
FX This study was supported in part by grants from NIAMS (AR056090), the
   Georgia Research Alliance (GRA.VL12.C2) and the Center for Pediatric
   Nanomedicine (RC159 G3) sponsored by Emory University, the Department of
   Biomedical Engineering at Georgia Institute of Technology, and
   Children's Healthcare of Atlanta, Atlanta, GA, USA to M.N. Weitzmann and
   G.R. Beck Jr. M.N. Weitzmann is also supported in part by funding from
   the Biomedical Laboratory Research & Development Service of the VA
   Office of Research and Development (5I01BX000105) and by grants AR059364
   and AR053607 from NIAMS and AG040013 from NIA. G.R. Beck Jr. is also
   supported by a Biomedical Laboratory Research & Development Service
   Award Number I01BX002363 from the VA Office of Research and Development
   and in part by a grant from the NCI (CA136716). The content of this
   manuscript is solely the responsibility of the authors and does not
   represent the official views of the Department of Veterans Affairs, the
   National Institutes of Health, or the United States Government.
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Bass E, 2007, ANN EPIDEMIOL, V17, P514, DOI 10.1016/j.annepidem.2006.12.004
   Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756 3282(96)00047 6
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Flurkey K, 2007, The mouse in biomedical research, DOI DOI 10.1016/B978 012369454 6/50074 1
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Ha SW, 2014, TOXICOL IN VITRO, V28, P354, DOI 10.1016/j.tiv.2013.12.001
   Ha SW, 2013, SOFT MATER, V11, P195, DOI 10.1080/1539445X.2012.617641
   Ha SW, 2009, CHEM COMMUN, P2881, DOI 10.1039/b902195g
   Halloran BP, 2002, J BONE MINER RES, V17, P1044, DOI 10.1359/jbmr.2002.17.6.1044
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kates SL, 2007, INJURY, V38, P17, DOI 10.1016/j.injury.2007.08.007
   Kim JS, 2006, TOXICOL SCI, V89, P338, DOI 10.1093/toxsci/kfj027
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Magdolenova Z, 2014, NANOTOXICOLOGY, V8, P233, DOI 10.3109/17435390.2013.773464
   MANOLAGAS SC, 1995, INT J IMMUNOPHARMACO, V17, P109, DOI 10.1016/0192 0561(94)00089 7
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   McLean AJ, 2004, PHARMACOL REV, V56, P163, DOI 10.1124/pr.56.2.4
   Napierska D, 2009, SMALL, V5, P846, DOI 10.1002/smll.200800461
   Sahoo SK, 2007, NANOMED NANOTECHNOL, V3, P20, DOI 10.1016/j.nano.2006.11.008
   Salvioli S, 2006, CURR PHARM DESIGN, V12, P3161, DOI 10.2174/138161206777947470
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Streckfus CF, 1999, GERONTOLOGY, V45, P110, DOI 10.1159/000022072
   Sundberg JP, 2011, PATHOBIOL AGING AGE, V1, DOI 10.3402/pba.v1i0.7179
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Yoon TJ, 2006, SMALL, V2, P209, DOI [10.1002/smll.200500360, 10.1002/511111.200500360]
NR 36
TC 38
Z9 38
U1 0
U2 44
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD MAY
PY 2015
VL 11
IS 4
BP 959
EP 967
DI 10.1016/j.nano.2015.01.013
PG 9
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA CI2FD
UT WOS:000354559600017
PM 25680544
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Miller, K
   Clementi, C
   Polyak, D
   Eldar Boock, A
   Benayoun, L
   Barshack, I
   Shaked, Y
   Pasut, G
   Satchi Fainaro, R
AF Miller, Keren
   Clementi, Chiara
   Polyak, Dina
   Eldar Boock, Anat
   Benayoun, Liat
   Barshack, Iris
   Shaked, Yuval
   Pasut, Gianfranco
   Satchi Fainaro, Ronit
TI Poly(ethylene glycol) paclitaxel alendronate self assembled micelles for
   the targeted treatment of breast cancer bone metastases
SO BIOMATERIALS
LA English
DT Article
DE Angiogenesis; Polymer therapeutics; Dendrimers; Bone targeting; PEG;
   Alendronate
ID DRUG DELIVERY SYSTEMS; MACROMOLECULAR THERAPEUTICS; PROSTATE CANCER;
   HIGH RISK; PACLITAXEL; ANGIOGENESIS; ALENDRONATE; ANTICANCER; AGENTS;
   BISPHOSPHONATES
AB Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases. Growing evidence suggests that low dose taxanes and bisphosphonates possess anti angiogenic properties. However, PTX is water insoluble and toxic, even if administered at anti angiogenic dosing schedule. Polymer conjugation of PTX will increase water solubility and improve its pharmacokinetic profile directing it to the tumor site. We further propose to combine it with ALN for active bone targeting. We conjugated ALN and PTX with poly(ethylene glycol) (PEG) forming self assembled micelles where PTX molecules are located at the inner core and the water soluble ALN molecules at the outer shell. PTX PEG ALN micelles exhibited similar in vitro cytotoxic and anti angiogenic activity as the free drugs. Biodistribution analysis demonstrated preferential tumor accumulation of FITC labeled PTX PEG ALN micelles. Pharmacokinetic studies revealed longer tip of the conjugate than free PTX. PTX PEG ALN micelles achieved improved efficacy and safety profiles over free PTX in syngeneic and xenogeneic mouse models of mCherry infected mammary adenocarcinoma in the tibia, as monitored intravitally non invasively by a fluorescence imaging system. The described data warrants the potential use of PTX PEG ALN as bone targeted anticancer and anti angiogenic therapy for breast cancer bone metastases. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Miller, Keren; Polyak, Dina; Eldar Boock, Anat; Satchi Fainaro, Ronit] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL 69978 Tel Aviv, Israel.
   [Clementi, Chiara; Pasut, Gianfranco] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I 35131 Padua, Italy.
   [Benayoun, Liat; Shaked, Yuval] Technion Israel Inst Technol, Rappaport Fac Med, Dept Mol Pharmacol, IL 31096 Haifa, Israel.
   [Barshack, Iris] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL 69978 Tel Aviv, Israel.
   [Barshack, Iris] Chaim Sheba Med Ctr, Dept Pathol, IL 52621 Ramat Gan, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; University of Padua;
   Technion Israel Institute of Technology; Rappaport Faculty of Medicine;
   Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Chaim Sheba Medical Center
RP Satchi Fainaro, R (通讯作者)，Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL 69978 Tel Aviv, Israel.
EM ronitsf@post.tau.ac.il
RI ; Satchi Fainaro, Ronit/F 9137 2011; Pasut, Gianfranco/I 5944 2012
OI Barshack, Iris/0000 0001 8216 8963; Satchi Fainaro,
   Ronit/0000 0002 7360 7837; Pasut, Gianfranco/0000 0002 8754 0899
FU Chief Scientist Office of the Ministry of Health, Israel [5145 300000];
   ISRAEL SCIENCE FOUNDATION [1309/10]; United States Israel Binational
   Science Foundation (BSF), Swiss Bridge Award [2007347]; Israel Cancer
   Research Fund (ICRF) (RSF); Italian Ministry of Education University and
   Research (MIUR) [60A04 3953/10]; Marian Gertner Institute for Medical
   Nanosystems; Cancer Biology Research Center; ISF under EU; Marie Curie
   under EU; Fine Student Education Foundation; Jacobs Student Education
   Foundation; Israel Student Education Foundation
FX This study was supported (in part) by grant no. 5145 300000 from the
   Chief Scientist Office of the Ministry of Health, Israel, by THE ISRAEL
   SCIENCE FOUNDATION (grant No. 1309/10), Grant No. 2007347 given by the
   United States Israel Binational Science Foundation (BSF), Swiss Bridge
   Award, The Israel Cancer Research Fund (ICRF) (RSF) and by The Italian
   Ministry of Education University and Research (MIUR; grant No.
   60A04 3953/10) (GP). We are grateful to the Marian Gertner Institute for
   Medical Nanosystems and The Cancer Biology Research Center for a Ph.D.
   fellowship (KM, AEB). This work was also supported by ISF and Marie
   Curie (under the FP7 EU program) given to YS. LB is supported by Fine,
   Jacobs and Israel Student Education Foundation studentships.
CR ARBUCK SG, 1994, HEMATOL ONCOL CLIN N, V8, P121, DOI 10.1016/S0889 8588(18)30191 6
   Bender JLG, 2008, J CLIN ONCOL, V26, P399, DOI 10.1200/JCO.2007.11.9230
   Bertolini F, 2006, NAT REV CANCER, V6, P833, DOI 10.1039/nrc1971
   Bertolini F, 2009, BBA REV CANCER, V1796, P27, DOI 10.1016/j.bbcan.2009.04.003
   Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Cetnar JP, 2008, UROLOGY, V71, P942, DOI 10.1016/j.urology.2007.11.117
   Clementi C, 2011, MOL PHARMACEUT, V8, P1063, DOI 10.1021/mp2001445
   Colleoni M, 2000, J CLIN ONCOL, V18, P3925, DOI 10.1200/JCO.2000.18.23.3925
   Dellapasqua S, 2008, J CLIN ONCOL, V26, P4899, DOI 10.1200/JCO.2008.17.4789
   Demicheli R, 2001, BRIT J CANCER, V85, P490, DOI 10.1054/bjoc.2001.1969
   Duncan R, 2007, BIOCHEM SOC T, V35, P56, DOI 10.1042/BST0350056
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Fournier P, 2002, CANCER RES, V62, P6538
   Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959 8049(01)00171 X
   HANSEN E, 1995, ARCH SURG CHICAGO, V130, P387
   Hennenfent KL, 2006, ANN ONCOL, V17, P735, DOI 10.1093/annonc/mdj100
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Horwitz Susan Band, 1993, Journal of the National Cancer Institute Monographs, V0, P55
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168 3659(99)00248 5
   Mancuso P, 2006, BLOOD, V108, P452, DOI 10.1182/blood 2005 11 4570
   Miller K, 2011, MOL PHARMACEUT, V8, P1052, DOI 10.1021/mp200083n
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Parkin DM, 2005, CA CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pasquier E, 2004, MOL CANCER THER, V3, P1301
   Pasut G, 2009, ADV DRUG DELIVER REV, V61, P1177, DOI 10.1016/j.addr.2009.02.010
   Pasut G, 2009, J MED CHEM, V52, P6499, DOI 10.1021/jm900804m
   Sanfilippo NJ, 2008, J CLIN ONCOL, V26, P2973, DOI 10.1200/JCO.2007.14.4105
   Santucci L, 2007, ANTI CANCER DRUG, V18, P1081, DOI 10.1097/CAD.0b013e3281db8322
   Satchi Fainaro R, 2002, J DRUG TARGET, V10, P529, DOI 10.1080/1061186021000051062
   Segal E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005233
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023
   Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang JY, 2003, ANTI CANCER DRUG, V14, P13, DOI 10.1097/00001813 200301000 00003
   WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101
   WEISS RB, 1990, J CLIN ONCOL, V8, P1263, DOI 10.1200/JCO.1990.8.7.1263
   Yoneda T, 2000, J Orthop Sci, V5, P75, DOI 10.1007/s007760050012
NR 42
TC 75
Z9 82
U1 2
U2 143
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2013
VL 34
IS 15
BP 3795
EP 3806
DI 10.1016/j.biomaterials.2013.01.052
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 120KH
UT WOS:000317168700007
PM 23434349
DA 2025 08 17
ER

PT J
AU Zheng, HY
   Feng, HT
   Zhang, WZ
   Han, YT
   Zhao, WW
AF Zheng, Haoyi
   Feng, Haitao
   Zhang, Wenzhong
   Han, Yantao
   Zhao, Wenwen
TI Targeting autophagy by natural product Ursolic acid for prevention and
   treatment of osteoporosis
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Osteoporosis; Ursolic acid; Autophagy; Osteoclast
ID NF KAPPA B; CANCER CELLS; C FOS; OSTEOCLASTOGENESIS; EXPRESSION;
   APOPTOSIS; INVASION; KINASE; DEATH; MAPKS
AB With the growth of the aging population, osteoporosis is becoming a global health problem. Ursolic acid (UA) is an active ingredient existed in a variety of foods and nature plants and owns plenty of pharmacological effects especially in treating metabolic disease. Our predication from network pharmacology hinted that UA has potential for ameliorating osteoporosis. Firstly through in vivo experiment, we confirmed that UA administration obviously protected against ovariectomy (OVX) induced osteoporosis in rats by improving microarchitectural deterioration of trabecular bone (P < 0.001), decreasing numbers of TRAP positive osteoclast in vertebra (P < 0.001), as well as decreasing serum osteoclast specific cytokines release (P < 0.001). Besides, UA ameliorated kidney damage secondary to OVX induced osteoporosis by ameliorating glomerular atrophy, decreasing BUN and creatinine levels in OVX rats. In vitro, UA noticeably decreased osteoclastic special marker proteins c Fos and NFATc1 expressions (P < 0.001) in response to RANKL stimulation in macrophagy. Importantly, autophagy pathway was activated in the process of osteoclast differentiation and blocked by UA pretreatment. Furthermore, autophagy inhibitors suppressed osteoclast differentiation (P < 0.001). Collectively, UA may ameliorate osteoporosis by suppressing osteoclast differentiation mediated by autophagy. Our research provides scientific support for UA treating osteoporosis and offers an optimal dose for daily intake of UA safely to prevent bone diseases.
C1 [Zheng, Haoyi; Han, Yantao; Zhao, Wenwen] Qingdao Univ, Med Coll, 308 Ningxia Rd, Qingdao 266021, Shandong, Peoples R China.
   [Feng, Haitao] Kyushu Univ, Fac Engn, Dept Appl Chem, Fukuoka, Japan.
   [Zhang, Wenzhong] Qingdao Univ, Dept Cardiol, Affiliated Hosp, Qingdao 266000, Shandong, Peoples R China.
C3 Qingdao University; Kyushu University; Qingdao University
RP Zhao, WW (通讯作者)，Qingdao Univ, Med Coll, 308 Ningxia Rd, Qingdao 266021, Shandong, Peoples R China.
EM daisy@qdu.edu.cn
FU National Natural Science Foundation of China [81803766]; Key Research
   and Discovery Program of Shandong Province [2019GSF107072]; Natural
   Science Foundation of Shandong Province [ZR2018BH036]; China
   Postdoctoral Science Foundation [2019M652336]
FX This study was supported by the National Natural Science Foundation of
   China (81803766), the Key Research and Discovery Program of Shandong
   Province (2019GSF107072), the Natural Science Foundation of Shandong
   Province (ZR2018BH036) and China Postdoctoral Science Foundation
   (2019M652336).
CR Abe F, 2002, BIOL PHARM BULL, V25, P1485, DOI 10.1248/bpb.25.1485
   Afrose S., 2020, DRUG DISCOV TODAY, VS1359 6446, P30299, DOI [10.1016/j.drudis.2020.07, DOI 10.1016/J.DRUDIS.2020.07]
   Ali SA, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01769
   Aljubran SA, 2014, ALLERGY, V69, P1429, DOI 10.1111/all.12438
   Anghan H, 2018, INDIAN J CRIT CARE M, V22, P718, DOI 10.4103/ijccm.IJCCM_468_17
   Bahrami SA, 2016, BIOMED PHARMACOTHER, V82, P8, DOI 10.1016/j.biopha.2016.04.047
   Barron RL, 2020, OSTEOPOROSIS INT, V31, P2103, DOI 10.1007/s00198 020 05294 3
   Bedogni G, 2020, CURR OPIN LIPIDOL, V31, P27, DOI 10.1097/MOL.0000000000000652
   Chen WJ, 2019, OSTEOPOROSIS INT, V30, P807, DOI 10.1007/s00198 018 4789 x
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Darba J, 2015, CLINICOECONOMIC OUTC, V7, P105, DOI 10.2147/CEOR.S78349
   Deng S, 2019, CANCER AM CANCER SOC, V125, P1228, DOI 10.1002/cncr.31978
   Dobosz A., 2020, FARM POL, V76, P344, DOI 10.32383/farmpol/
   Farah BL, 2020, MOL GENET METAB, V129, P3, DOI 10.1016/j.ymgme.2019.11.005
   Feng X, 2014, CALCIFIED TISSUE INT, V94, P433, DOI 10.1007/s00223 013 9825 4
   Fontanay S, 2008, J ETHNOPHARMACOL, V120, P272, DOI 10.1016/j.jep.2008.09.001
   Fu FS, 2019, J CELL PHYSIOL, V234, P11951, DOI 10.1002/jcp.27888
   Gurusamy N, 2010, CARDIOVASC RES, V86, P103, DOI 10.1093/cvr/cvp384
   Habtemariam S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8512048
   Han J, 2012, AUTOPHAGY, V8, P812, DOI 10.4161/auto.19471
   Hsu RK, 2020, CLIN KIDNEY J, V13, P55, DOI 10.1093/ckj/sfz057
   Nguyen HN, 2018, ATHEROSCLEROSIS, V275, P333, DOI 10.1016/j.atherosclerosis.2018.06.882
   Khwaza V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165920
   Kim JC, 2018, KOREAN J PHYSIOL PHA, V22, P427, DOI 10.4196/kjpp.2018.22.4.427
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Leng SL, 2013, INT J CANCER, V133, P2781, DOI 10.1002/ijc.28301
   Liao YX, 2019, INT J ONCOL, V55, P1213, DOI 10.3892/ijo.2019.4902
   Lin R, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00620
   Lin TK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196713
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Manu KA, 2008, INT IMMUNOPHARMACOL, V8, P974, DOI 10.1016/j.intimp.2008.02.013
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Meng YQ, 2020, J ASIAN NAT PROD RES, V22, P359, DOI 10.1080/10286020.2019.1571488
   Orgah JO, 2020, PHARMACOL RES, V153, DOI 10.1016/j.phrs.2020.104654
   Pampel F, 2013, CONTEMP SOCIOL, V42, P246, DOI 10.1177/0094306113477381w
   Pitaloka DAE, 2020, INFECT DIS REP, V12, P5, DOI 10.4081/idr.2020.8717
   Rashid S, 2013, EUR J MED CHEM, V66, P238, DOI 10.1016/j.ejmech.2013.05.029
   Ryter Stefan W, 2010, Proc Am Thorac Soc, V7, P40, DOI 10.1513/pats.200909 100JS
   Salmon J W, 1976, J Allied Health, V5, P5
   Shapiro IM, 2014, AUTOPHAGY, V10, P7, DOI 10.4161/auto.26679
   Shen GY, 2018, CELL MOL LIFE SCI, V75, P2683, DOI 10.1007/s00018 018 2776 1
   Siveen KS, 2014, ONCOTARGET, V5, P634, DOI 10.18632/oncotarget.1596
   Starling S, 2019, NAT REV ENDOCRINOL, V15, P438, DOI 10.1038/s41574 019 0223 5
   Steinkamp Fenske Katja, 2007, Atherosclerosis, V195, pe104, DOI 10.1016/j.atherosclerosis.2007.03.028
   Tan H, 2019, J AGR FOOD CHEM, V67, P3333, DOI 10.1021/acs.jafc.8b06954
   Thummuri D, 2019, J CELL PHYSIOL, V234, P443, DOI 10.1002/jcp.26575
   Tohmé MJ, 2019, INT J ANTIMICROB AG, V54, P601, DOI 10.1016/j.ijantimicag.2019.07.015
   Vindis C, 2015, BRIT J PHARMACOL, V172, P2167, DOI 10.1111/bph.13052
   Voigt N, 2019, CARDIOVASC RES, V115, pE91, DOI 10.1093/cvr/cvz124
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Wang QQ, 2019, J CELL MOL MED, V23, P380, DOI 10.1111/jcmm.13942
   Wang YH, 2019, AUTOPHAGY, V15, P886, DOI 10.1080/15548627.2019.1569912
   Wang ZH, 2020, CELL BIOCHEM FUNCT, V38, P792, DOI 10.1002/cbf.3548
   Wooltorton E, 2006, CAN MED ASSOC J, V175, P147, DOI 10.1503/cmaj.060781
   Wu HZ, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 0682 2
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Xu XH, 2016, INT IMMUNOPHARMACOL, V34, P212, DOI 10.1016/j.intimp.2016.03.001
   Yeh CT, 2010, MOL NUTR FOOD RES, V54, P1285, DOI 10.1002/mnfr.200900414
   Yin M, 2020, CANCER MED US, V9, P247, DOI 10.1002/cam4.2678
   Zhan QP, 2020, FOOD FUNCT, V11, P7048, DOI [10.1039/d0fo00884b, 10.1039/D0FO00884B]
   Zhao J, 2019, CYTOKINE, V123, DOI 10.1016/j.cyto.2019.05.013
   Zheng L, 2019, FASEB J, V33, P7667, DOI 10.1096/fj.201802364RR
   Zhu Y, 2019, AGING US, V11, P1089, DOI 10.18632/aging.101766
NR 63
TC 36
Z9 39
U1 3
U2 34
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0041 008X
EI 1096 0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD DEC 15
PY 2020
VL 409
AR 115271
DI 10.1016/j.taap.2020.115271
PG 11
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA PG1MH
UT WOS:000599506200005
PM 33065153
DA 2025 08 17
ER

PT J
AU Kim, M
   Lin, TC
   Arora, T
   Zhao, H
   Balasubramanian, A
   Stad, RK
   O'Kelly, J
   Spangler, L
   Bradbury, BD
   Curtis, JR
AF Kim, Min
   Lin, Tzu Chieh
   Arora, Tarun
   Zhao, Hong
   Balasubramanian, Akhila
   Stad, Robert Kees
   O'Kelly, James
   Spangler, Leslie
   Bradbury, Brian D. D.
   Curtis, Jeffrey R. R.
TI Comparability of Osteoporosis Treatment Groups Among Female Medicare
   Beneficiaries in the United States
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE THERAPEUTICS ANTIRESORPTIVES; FRACTURE PREVENTION; EPIDEMIOLOGY;
   STATISTICAL METHODS DISEASES; DISORDERS OF/RELATED TO BONE OSTEOPOROSIS
ID NEGATIVE CONTROL OUTCOMES; FRACTURE RISK REDUCTION; POSTMENOPAUSAL
   WOMEN; ZOLEDRONIC ACID; CLINICAL TRIALS; META REGRESSION; DENOSUMAB;
   THERAPIES; PREVENTION; DENSITY
AB It is often difficult to obtain valid estimates of comparative treatment effectiveness and safety owing to differences across patient populations taking different medications in the real world. One approach for assessing comparability between treatment groups in effectiveness studies is to use negative control outcomes (NCOs). NCOs share similar sources of bias with the primary outcomes but have no plausible causal relationship to the treatment of interest. Observing differences in the risk of NCOs thus provides evidence for residual confounding between groups. This retrospective study assessed the comparability of postmenopausal women, treated with osteoporosis medications with various mechanisms of action such as denosumab (receptor activator of nuclear factor kappa B ligand [RANKL] inhibitor), zoledronic acid (bisphosphonate derivative), or oral bisphosphonates including alendronate. Administrative claims data were extracted from the US Centers for Medicare and Medicaid Services' Chronic Condition Warehouse database (May 2010 December 2016). Propensity scores were used to match denosumab patients 1:1 to comparators. Four nonfracture NCOs and three early fracture NCOs (before substantial biologic effects of treatment would be expected) were assessed over 1 year and 3 month follow up periods, respectively. According to comparability decision rules established a priori, patients initiating denosumab were comparable to those initiating zoledronic acid or alendronate, irrespective of prior osteoporosis treatment experience. Among new users, new switchers, and in the historical fracture subgroup, no meaningful differences were observed in the cumulative incidence of the seven NCOs comparing denosumab to zoledronic acid. This empirical examination can assist in the selection of appropriate comparator groups for future comparability research using real world data. (c) 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Kim, Min; Lin, Tzu Chieh; Balasubramanian, Akhila; Stad, Robert Kees; Spangler, Leslie; Bradbury, Brian D. D.] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA USA.
   [Arora, Tarun; Zhao, Hong; Curtis, Jeffrey R. R.] Univ Alabama Birmingham, Birmingham, AL USA.
   [O'Kelly, James] Amgen Ltd, Ctr Observat Res, Uxbridge, England.
   [Curtis, Jeffrey R. R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL USA.
   [Kim, Min] Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
C3 Amgen; University of Alabama System; University of Alabama Birmingham;
   Amgen; Amgen Limited; University of Alabama System; University of
   Alabama Birmingham; Amgen
RP Kim, M (通讯作者)，Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM mkim08@amgen.com
RI Arora, Tarun/I 6808 2019; Curtis, Jeffrey/I 6723 2015
FU Amgen Inc
FX This study was funded by Amgen Inc. The funding source was involved in
   the study design and statistical analysis of the data. Writing
   assistance was provided by K. Miles, PhD (BioScience Communications),
   funded by Amgen Inc.
CR Amidei CB, 2021, JAMA J AM MED ASSOC, V325, P1640, DOI 10.1001/jama.2021.4001
   Arnold BF, 2016, JAMA J AM MED ASSOC, V316, P2597, DOI 10.1001/jama.2016.17700
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Barrionuevo P, 2019, J CLIN ENDOCR METAB, V104, P1623, DOI 10.1210/jc.2019 00192
   Baum Ulrike, 2021, Euro Surveill, V26, DOI 10.2807/1560 7917.ES.2021.26.36.2100054
   Beeri MS, 2020, LANCET DIABETES ENDO, V8, P736, DOI 10.1016/S2213 8587(20)30267 9
   Behanova M, 2019, CALCIFIED TISSUE INT, V105, P630, DOI 10.1007/s00223 019 00611 3
   Bergmann PJM, 2019, J BONE MINER RES, V34, P1976, DOI [10.1002/jbmr.3835, 10.1002/jbmr.3641]
   Black DM, 2020, LANCET DIABETES ENDO, V8, P672, DOI 10.1016/S2213 8587(20)30159 5
   Blank RD, 1999, J CLIN DENSITOM, V2, P435, DOI 10.1016/S1094 6950(06)60409 5
   Bolognese MA, 2013, J CLIN DENSITOM, V16, P147, DOI 10.1016/j.jocd.2012.02.006
   bonehealthandosteoporosis, 2019, NEW REP BURD OST HIG
   Brookhart MA, 2010, MED CARE, V48, pS114, DOI 10.1097/MLR.0b013e3181dbebe3
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Cheng LI, 2015, J MANAG CARE SPEC PH, V21, P824, DOI 10.18553/jmcp.2015.21.9.824
   Choi NK, 2017, J BONE MINER RES, V32, P611, DOI 10.1002/jbmr.3019
   Clemens KK, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00796 3
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Darbà J, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889 015 1684 7
   Durden E, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0316 5
   Eastell R, 2022, J BONE MINER RES, V37, P29, DOI 10.1002/jbmr.4433
   Hansen D, 2021, MED COST OSTEOPOROTI
   Jeremiah MP, 2015, AM FAM PHYSICIAN, V92, P261
   Lai FH, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.702261
   Lash TL, 2014, INT J EPIDEMIOL, V43, P1969, DOI 10.1093/ije/dyu149
   Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb
   McGrail S., 2020, ANAL CLAIMS DATA SHO
   McGrath LJ, 2020, PHARMACOEPIDEM DR S, V29, P854, DOI 10.1002/pds.5037
   McGrath LJ., 2021, 37 INT SOC PHARMACOE
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P3163, DOI 10.1210/jc.2016 1801
   Modi A, 2017, OSTEOPOROSIS INT, V28, P1355, DOI 10.1007/s00198 016 3886 y
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Pedersen AB, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2416
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Shi X, 2020, CURR EPIDEMIOL REP, V7, P190, DOI 10.1007/s40471 020 00243 4
   Suissa S, 2017, PHARMACOEPIDEM DR S, V26, P459, DOI 10.1002/pds.4107
   Williams SA, 2021, ANN PHARMACOTHER, V55, P821, DOI 10.1177/1060028020970518
   Wright NC, 2019, J BONE MINER RES, V34, P1798, DOI 10.1002/jbmr.3807
   Yun H, 2015, CLIN EXP RHEUMATOL, V33, P302
   Yusuf AA, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0439 3
   Zullo AR, 2021, OSTEOPOROSIS INT, V32, P565, DOI 10.1007/s00198 020 05732 2
NR 42
TC 6
Z9 6
U1 2
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2023
VL 38
IS 6
BP 829
EP 840
DI 10.1002/jbmr.4817
EA MAY 2023
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA O8NP8
UT WOS:000984888100001
PM 37088886
OA hybrid
DA 2025 08 17
ER

PT J
AU Zahn, G
   Baukmann, HA
   Wu, J
   Jordan, J
   Birkenfeld, AL
   Dirckx, N
   Schmidt, MF
AF Zahn, Grit
   Baukmann, Hannes A.
   Wu, Jasmine
   Jordan, Jens
   Birkenfeld, Andreas L.
   Dirckx, Naomi
   Schmidt, Marco F.
TI Targeting Longevity Gene SLC13A5: A Novel Approach to Prevent
   Age Related Bone Fragility and Osteoporosis
SO METABOLITES
LA English
DT Article
DE mINDY; citrate; citrate transporter; NaCT; osteoporosis; Mendelian
   randomization; drug development
ID PLASMA CITRATE; MOUSE MODEL; NACT; TRANSPORTER; ASSOCIATION; MUTATIONS;
   INSULIN
AB Reduced expression of the plasma membrane citrate transporter SLC13A5, also known as INDY, has been linked to increased longevity and mitigated age related cardiovascular and metabolic diseases. Citrate, a vital component of the tricarboxylic acid cycle, constitutes 1 5% of bone weight, binding to mineral apatite surfaces. Our previous research highlighted osteoblasts' specialized metabolic pathway facilitated by SLC13A5 regulating citrate uptake, production, and deposition within bones. Disrupting this pathway impairs bone mineralization in young mice. New Mendelian randomization analysis using UK Biobank data indicated that SNPs linked to reduced SLC13A5 function lowered osteoporosis risk. Comparative studies of young (10 weeks) and middle aged (52 weeks) osteocalcin cre driven osteoblast specific Slc13a5 knockout mice (Slc13a5(cKO)) showed a sexual dimorphism: while middle aged females exhibited improved elasticity, middle aged males demonstrated enhanced bone strength due to reduced SLC13A5 function. These findings suggest reduced SLC13A5 function could attenuate age related bone fragility, advocating for SLC13A5 inhibition as a potential osteoporosis treatment.
C1 [Zahn, Grit] Eternygen GmbH, Westhafenstr 1, D 13353 Berlin, Germany.
   [Baukmann, Hannes A.; Schmidt, Marco F.] biotxai GmbH, Muhlenberg 11, D 14476 Potsdam, Germany.
   [Wu, Jasmine; Dirckx, Naomi] Univ Maryland Baltimore, Sch Med, Dept Orthopaed, Baltimore, MD 21201 USA.
   [Jordan, Jens] Inst Aerosp Med, German Aerosp Ctr DLR, D 51147 Cologne, Germany.
   [Birkenfeld, Andreas L.] Eberhard Karls Univ Tubingen, Univ Hosp Tubingen, Dept Diabetol Endocrinol & Nephrol, Internal Med 4, D 72074 Tubingen, Germany.
   [Birkenfeld, Andreas L.] Eberhard Karls Univ Tubingen, Inst Diabet Res & Metab Dis IDM, German Ctr Diabet Res DZD, Helmholtz Ctr Munich, D 72074 Tubingen, Germany.
   [Birkenfeld, Andreas L.] Kings Coll London, Dept Diabet Life Sci & Med, Cardiovasc Med & Sci, London WC2R 2LS, England.
C3 University System of Maryland; University of Maryland Baltimore;
   Helmholtz Association; German Aerospace Centre (DLR); Eberhard Karls
   University of Tubingen; Eberhard Karls University Hospital; Eberhard
   Karls University of Tubingen; Helmholtz Association; Helmholtz Center
   Munich   German Research Center for Environmental Health; German Center
   for Diabetes Research (DZD); University of London; King's College London
RP Zahn, G (通讯作者)，Eternygen GmbH, Westhafenstr 1, D 13353 Berlin, Germany.
EM g.zahn@eternygen.com; jens.jordan@dlr.de; ms@biotx.ai
RI Birkenfeld, Andreas/U 3954 2019
OI Birkenfeld, Andreas/0000 0003 1407 9023
FU Eternygen GmbH
FX No Statement Available
CR Bainbridge MN, 2017, MOL GENET METAB, V121, P314, DOI 10.1016/j.ymgme.2017.06.009
   Baukmann HA, 2022, medRxiv, DOI [10.1101/2021.05.18.21256584, 10.1101/2021.05.18.21256584, DOI 10.1101/2021.05.18.21256584]
   Birkenfeld AL, 2011, CELL METAB, V14, P184, DOI 10.1016/j.cmet.2011.06.009
   Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221
   Brent MB, 2023, PHARMACOL THERAPEUT, V244, DOI 10.1016/j.pharmthera.2023.108383
   Brown TL, 2021, METABOLITES, V11, DOI 10.3390/metabo11110746
   Burgess S, 2023, AM J HUM GENET, V110, P195, DOI 10.1016/j.ajhg.2022.12.017
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586 018 0579 z
   Chen HD, 2018, BONE, V114, P189, DOI 10.1016/j.bone.2018.06.014
   Costello Leslie C, 2018, J Liver Res Disord Ther, V4, P114, DOI 10.15406/jlrdt.2018.04.00112
   Costello Leslie C, 2012, Open Bone J, V4, DOI 10.2174/1876525401204010027
   Dewulf JP, 2019, ANN NEUROL, V85, P385, DOI 10.1002/ana.25412
   Dickens F, 1941, BIOCHEM J, V35, P1011, DOI 10.1042/bj0351011
   Dirckx N, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2212178119
   Fernandez Fuente G, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003 023 05311 1
   Gill D., 2023, medRxiv, DOI [10.1101/2023.08.29.23294760, DOI 10.1101/2023.08.29.23294760]
   Gill Dipender, 2021, Wellcome Open Res, V6, P16, DOI 10.12688/wellcomeopenres.16544.1
   Gopal E, 2015, J PHARMACOL EXP THER, V353, P17, DOI 10.1124/jpet.114.221523
   Granchi D, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112576
   Hardies K, 2015, BRAIN, V138, DOI 10.1093/brain/awv263
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Henke C, 2020, NEUROBIOL DIS, V143, DOI 10.1016/j.nbd.2020.105018
   Ho HTB, 2007, KIDNEY INT, V72, P63, DOI 10.1038/sj.ki.5002258
   Hsu WB, 2018, BONE JOINT RES, V7, P601, DOI 10.1302/2046 3758.711.BJR 2018 0075.R2
   Huard K, 2015, SCI REP UK, V5, DOI 10.1038/srep17391
   Imai K, 2004, J AM STAT ASSOC, V99, P854, DOI 10.1198/016214504000001187
   Inoue K, 2004, BIOCHEM J, V378, P949, DOI 10.1042/BJ20031261
   Inoue K, 2002, J BIOL CHEM, V277, P39469, DOI 10.1074/jbc.M207072200
   Irizarry AR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175465
   Kar SP, 2019, INT J EPIDEMIOL, V48, P1727, DOI 10.1093/ije/dyz047
   KATAN MB, 1986, LANCET, V1, P507
   Kopel JJ, 2021, BIOCHEM J, V478, P463, DOI 10.1042/BCJ20200877
   Li Z, 2016, CPT PHARMACOMET SYST, V5, P132, DOI 10.1002/psp4.12062
   Ma CY, 2018, P NATL ACAD SCI USA, V115, pE11741, DOI 10.1073/pnas.1813000115
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Mishra D, 2021, FRONT AGING LAUSANNE, V2, DOI 10.3389/fragi.2021.782162
   Moffatt P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105290
   Nethander M, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100776
   Orho Melander M, 2018, INT J EPIDEMIOL, V47, P495, DOI 10.1093/ije/dyx237
   Pan BJ, 2022, OSTEOPOROSIS INT, V33, P2275, DOI 10.1007/s00198 022 06459 y
   Pesta D, 2022, METABOLITES, V12, DOI 10.3390/metabo12030244
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137
   Stoecker WV, 2017, J BONE MINER RES, V32, P1386, DOI 10.1002/jbmr.3145
   Tang YC, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 14548 5
   Thevenon J, 2014, AM J HUM GENET, V95, P113, DOI 10.1016/j.ajhg.2014.06.006
   Thrailkill KM, 2017, BONE, V94, P141, DOI 10.1016/j.bone.2016.10.026
   Trajanoska K, 2018, BMJ BRIT MED J, V362, DOI 10.1136/bmj.k3225
   von Loeffelholz C, 2017, HEPATOLOGY, V66, P616, DOI 10.1002/hep.29089
   Wang QL, 2021, NATURE, V597, P527, DOI 10.1038/s41586 021 03855 y
   Willmes DM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.136083
   Yilmaz H, 2014, Endocr Regul, V48, P25
   Yu XY, 2015, ARCH GERONTOL GERIAT, V61, P76, DOI 10.1016/j.archger.2015.03.011
   Zahn G, 2022, METABOLITES, V12, DOI 10.3390/metabo12080732
   Zhai TY, 2022, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.825448
   Zhu H, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000032125
NR 57
TC 3
Z9 3
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 1989
J9 METABOLITES
JI Metabolites
PD DEC
PY 2023
VL 13
IS 12
AR 1186
DI 10.3390/metabo13121186
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA DZ8D3
UT WOS:001136001400001
PM 38132868
OA gold, Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Kumar, M
   Kumar, R
   Kumar, S
AF Kumar, Manjeet
   Kumar, Rajesh
   Kumar, Sandeep
TI Nanomaterial reinforced composite for biomedical implants applications:
   a mini review
SO BIOINSPIRED BIOMIMETIC AND NANOBIOMATERIALS
LA English
DT Article
ID INCREASED OSTEOBLAST FUNCTIONS; IN VITRO; ORTHOPEDIC IMPLANTS;
   MECHANICAL PROPERTIES; OXIDATIVE STRESS; DRUG DELIVERY; PORE SIZE;
   INORGANIC NANOPARTICLES; CELLULOSE NANOWHISKERS; DECREASED FIBROBLAST
AB There is heavy demand for suitable implant materials with improved mechanical and biological properties. Classically, the demand was catered by conventional materials like metals, alloys, and polymer based materials. Recently, nanomaterial reinforced composites have played a significant role in replacing conventional materials due to their excellent properties such as biocompatibility, bioactivity, high strength to weight ratio, long life, corrosion & wear resistance, and tailor ability. Herein, we composed a systematic focus review on the role of nanoparticles in the form of composite materials for the advancements in orthopedic implants. Several nano materials based reinforcements have been reviewed with various matrix materials, including metals, alloys, ceramics, composites, and polymers for biomedical implant applications. Moreover, the improved biological properties, mechanical properties, and other functionalities like infection resistance, drug delivery at the target, sensing, and detection of bone diseases, and corrosion & wear resistance are elaborated. At last, a particular focus has been given to the un resolved challenges in orthopedic implant development.
C1 [Kumar, Manjeet; Kumar, Rajesh] Panjab Univ, Dept Mech Engn, UIET, Sect 25, Chandigarh, India.
   [Kumar, Sandeep] Guru Jambheshwar Univ, Dept Bio & Nanotechnol, Hisar, India.
C3 Panjab University; Guru Jambheshwar University of Science & Technology
RP Kumar, M (通讯作者)，Panjab Univ, Dept Mech Engn, UIET, Sect 25, Chandigarh, India.
EM dangi.manjeet@yahoo.com
RI ; Kumar, Rajesh/G 1408 2014
OI KUMAR, RAJESH/0000 0002 7284 2309; 
CR Abdel Salam FS, 2020, INT J PHARMACEUT, V580, DOI 10.1016/j.ijpharm.2020.119213
   Aguirre JD, 2009, J AM CHEM SOC, V131, P11353, DOI 10.1021/ja9021717
   Ahirwar H, 2020, COATINGS, V10, DOI 10.3390/coatings10030264
   Almasi D, 2016, INT J BIOMATER, V2016, DOI 10.1155/2016/8202653
   Aninwene GE, 2013, INT J NANOMED, V8, P1197, DOI 10.2147/IJN.S40300
   [Anonymous], 2006, NSTI NAN C TRAD SHOW
   Arora M, 2013, WORLD J ORTHOP, V4, P67, DOI 10.5312/wjo.v4.i2.67
   Auclair Daigle C, 2005, J BIOMED MATER RES A, V73A, P398, DOI 10.1002/jbm.a.30284
   Avouris P, 2003, P IEEE, V91, P1772, DOI 10.1109/JPROC.2003.818338
   Balasundaram G, 2007, MACROMOL BIOSCI, V7, P635, DOI 10.1002/mabi.200600270
   Bauer S, 2013, PROG MATER SCI, V58, P261, DOI 10.1016/j.pmatsci.2012.09.001
   Bhong SY, 2019, SN APPL SCI, V1, DOI 10.1007/s42452 018 0082 z
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Briggs EP, 2004, J MATER SCI MATER M, V15, P1021, DOI 10.1023/B:JMSM.0000042688.33507.12
   Brooker RobertJ., 2009, Genetics: analysis principles
   Brunner TJ, 2006, ENVIRON SCI TECHNOL, V40, P4374, DOI 10.1021/es052069i
   Burny F, 2000, MED ENG PHYS, V22, P469, DOI 10.1016/S1350 4533(00)00062 X
   Cai YR, 2007, CHEM MATER, V19, P3081, DOI 10.1021/cm070298t
   Carter DR, 1998, CLIN ORTHOP RELAT R, pS41
   Castiglioni S, 2017, NANOMATERIALS BASEL, V7, DOI 10.3390/nano7060124
   Castiglioni S, 2015, TOXICOL LETT, V237, P237, DOI 10.1016/j.toxlet.2015.06.1707
   Castiglioni Sara, 2014, World J Biol Chem, V5, P457, DOI 10.4331/wjbc.v5.i4.457
   Cecchinato R, 2020, EUR SPINE J, V29, P57, DOI 10.1007/s00586 019 06282 w
   Chen G, 2016, EBARA MBT BN, P77, DOI [10.1016/B978 0 323 37127 8.00006 6, DOI 10.1016/B978 0 323 37127 8.00006 6]
   Chennell P, 2013, INT J PHARMACEUT, V455, P298, DOI 10.1016/j.ijpharm.2013.07.014
   Chun AL, 2007, NANOTECHNOLOGY IN BIOLOGY AND MEDICINE: METHODS, DEVICES, AND APPLICATIONS
   Curodeau A, 2000, J BIOMED MATER RES, V53, P525, DOI 10.1002/1097 4636(200009)53:5<525::AID JBM12>3.0.CO;2 1
   Dash R, 2013, CARBOHYD POLYM, V91, P638, DOI 10.1016/j.carbpol.2012.08.080
   De Silva RT, 2017, INT J BIOMATER, V2017, DOI 10.1155/2017/1391298
   Di Leo CV, 2019, SCRIPTA MATER, V166, P149, DOI 10.1016/j.scriptamat.2019.03.019
   Eliaz N., 2012, Degradation of Implant Materials
   Eschbach L, 2000, Injury, V31 Suppl 4, P22
   Fekete Z, 2017, SENSOR ACTUAT B CHEM, V243, P1214, DOI 10.1016/j.snb.2016.12.096
   Frank IW, 2007, J VAC SCI TECHNOL B, V25, P2558, DOI 10.1116/1.2789446
   Gouma P., 2009, Nanomaterials for Chemical Sensors and Biotechnology
   Gupta AK, 2005, BIOMATERIALS, V26, P1565, DOI 10.1016/j.biomaterials.2004.05.022
   Harrison BS, 2007, BIOMATERIALS, V28, P344, DOI 10.1016/j.biomaterials.2006.07.044
   Hasan A, 2018, INT J BIOL MACROMOL, V111, P923, DOI 10.1016/j.ijbiomac.2018.01.089
   Hetrick EM, 2006, CHEM SOC REV, V35, P780, DOI 10.1039/b515219b
   Holtorf HL, 2005, J BIOMED MATER RES A, V74A, P171, DOI 10.1002/jbm.a.30330
   Huang HH, 2004, SCRIPTA MATER, V51, P1017, DOI 10.1016/j.scriptamat.2004.08.017
   Huang L, 2019, J MECH BEHAV BIOMED, V90, P604, DOI 10.1016/j.jmbbm.2018.11.002
   Itoh S, 2006, BIOMATERIALS, V27, P5572, DOI 10.1016/j.biomaterials.2006.07.007
   Jakhmola A, 2012, ADV HEALTHC MATER, V1, P413, DOI 10.1002/adhm.201200032
   Kádár E, 2010, ANAL BIOANAL CHEM, V396, P657, DOI 10.1007/s00216 009 3191 0
   Kalita SJ, 2007, MAT SCI ENG C BIO S, V27, P441, DOI 10.1016/j.msec.2006.05.018
   Kay S, 2002, TISSUE ENG, V8, P753, DOI 10.1089/10763270260424114
   Kikuchi M, 2001, BIOMATERIALS, V22, P1705, DOI 10.1016/S0142 9612(00)00305 7
   Kim JS, 2007, NANOMED NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   Kiran ASK, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8100860
   Korkin A, 2010, NANOSTRUCT SCI TECHN, P1, DOI 10.1007/978 1 4419 7454 9
   KUHNE JH, 1994, ACTA ORTHOP SCAND, V65, P246, DOI 10.3109/17453679408995448
   Kumar M, 2019, ADV MECHATRON MECH E, P1, DOI 10.4018/978 1 5225 5445 5.ch001
   Kumar S, 2020, MAT SCI ENG C MATER, V106, DOI 10.1016/j.msec.2019.110154
   Kumta PN, 2005, ACTA BIOMATER, V1, P65, DOI 10.1016/j.actbio.2004.09.008
   Landsiedel R, 2010, NANOTOXICOLOGY, V4, P364, DOI 10.3109/17435390.2010.506694
   Lanone S, 2006, CURR MOL MED, V6, P651, DOI 10.2174/156652406778195026
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Lee C, 2008, SCIENCE, V321, P385, DOI 10.1126/science.1157996
   LeGeros RZ, 2008, CHEM REV, V108, P4742, DOI 10.1021/cr800427g
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Li M, 2018, BIOACT MATER, V3, P1, DOI 10.1016/j.bioactmat.2018.01.001
   Li N, 2010, NANOSCALE RES LETT, V5, P108, DOI 10.1007/s11671 009 9451 2
   Li Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5697250
   Liao CZ, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10010124
   Liu H, 2007, BIOMATERIALS, V28, P354, DOI 10.1016/j.biomaterials.2006.08.049
   Liu H, 2006, J BIOMED MATER RES A, V78A, P798, DOI 10.1002/jbm.a.30734
   Logeart Avramoglou D, 2005, J CELL MOL MED, V9, P72, DOI 10.1111/j.1582 4934.2005.tb00338.x
   Long M, 1998, BIOMATERIALS, V19, P1621, DOI 10.1016/S0142 9612(97)00146 4
   Mahmoud D, 2017, J MANUF MATER PROC, V1, DOI 10.3390/jmmp1020013
   Maitra A, 2005, EXPERT REV MOL DIAGN, V5, P893, DOI 10.1586/14737159.5.6.893
   Manjrekar S, 2018, ORTHOPEDIC DEVICES M, V2026, P2018
   MARTENS M, 1983, J BIOMECH, V16, P971, DOI 10.1016/0021 9290(83)90098 2
   Mauricio MR, 2015, CARBOHYD POLYM, V115, P715, DOI 10.1016/j.carbpol.2014.07.063
   Mazaheri M, 2015, INT J NANOMED, V10, P6039, DOI 10.2147/IJN.S73737
   McHale G, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.036102
   Michael FM, 2016, MAT SCI ENG C MATER, V67, P792, DOI 10.1016/j.msec.2016.05.037
   Miller DC, 2004, BIOMATERIALS, V25, P53, DOI 10.1016/S0142 9612(03)00471 X
   Mishnaevsky L, 2014, MAT SCI ENG R, V81, P1, DOI 10.1016/j.mser.2014.04.002
   Mohammadi H, 2020, CERAM INT, V46, P4335, DOI 10.1016/j.ceramint.2019.10.156
   Morgan EF, 2018, ANNU REV BIOMED ENG, V20, P119, DOI [10.1146/annurev bioeng 062117 121139, 10.1146/annurev bioeng 062117121139]
   Morouço P, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1596157
   Na HB, 2009, ADV MATER, V21, P2133, DOI 10.1002/adma.200802366
   Nalwa H.S., 2009, NANOMATERIALS ENERGY
   Navaei A, 2019, BIOMATER SCI UK, V7, P585, DOI 10.1039/c8bm01050a
   Niinomi M, 2011, INT J BIOMATER, V2011, DOI 10.1155/2011/836587
   Oesterling E, 2008, TOXICOL LETT, V178, P160, DOI 10.1016/j.toxlet.2008.03.011
   Ogasawara T, 2011, COMPOS SCI TECHNOL, V71, P73, DOI 10.1016/j.compscitech.2010.10.001
   Orlovskii VP, 2002, INORG MATER+, V38, P973, DOI 10.1023/A:1020585800572
   Palka K, 2018, ADV ENG MATER, V20, DOI 10.1002/adem.201700648
   Papageorgiou I, 2007, BIOMATERIALS, V28, P2946, DOI 10.1016/j.biomaterials.2007.02.034
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939 6411(00)00090 4
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Pisanic TR, 2007, BIOMATERIALS, V28, P2572, DOI 10.1016/j.biomaterials.2007.01.043
   Pizzoferrato A, 2002, INTEGRATED BIOMATERIALS SCIENCE, P735, DOI 10.1007/0 306 47583 9_26
   Price RL, 2003, BIOMATERIALS, V24, P1877, DOI 10.1016/S0142 9612(02)00609 9
   PublicationsPublications UN.UN2017, 2017, WORLD POP AG 2015
   Puértolas JA, 2019, CARBON, V141, P107, DOI 10.1016/j.carbon.2018.09.036
   Rai MK, 2012, J APPL MICROBIOL, V112, P841, DOI 10.1111/j.1365 2672.2012.05253.x
   Rajzer I, 2020, J MATER SCI, V55, P4030, DOI 10.1007/s10853 019 04298 7
   Ramesh N, 2018, J BIOMED MATER RES B, V106, P2046, DOI 10.1002/jbm.b.33950
   Rehman H, 2018, INT J SURG, V56, P294, DOI 10.1016/j.ijsu.2018.06.019
   Rony L., 2018, Morphologie, V102, P231, DOI 10.1016/j.morpho.2018.09.003
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Saji Viswanathan S., 2010, International Journal of Nano and Biomaterials, V3, P119, DOI 10.1504/IJNBM.2010.037801
   Sarao TPS, 2012, METALL MATER TRANS A, V43A, P4365, DOI 10.1007/s11661 012 1175 8
   Serra G, 2013, MAT SCI ENG C MATER, V33, P4197, DOI 10.1016/j.msec.2013.06.012
   Sharma BB, 2020, CRIT REV SOLID STATE, V45, P134, DOI 10.1080/10408436.2019.1582003
   Shirwaiker RA, 2013, WIRES NANOMED NANOBI, V5, P191, DOI 10.1002/wnan.1201
   Smith IO, 2009, WIRES NANOMED NANOBI, V1, P226, DOI 10.1002/wnan.26
   Smith LL, 2007, INT J NANOMED, V2, P383
   Soleimani M, 2020, MATER RES EXPRESS, V7, DOI 10.1088/2053 1591/ab62fa
   Streicher R, RESISTANCE ALUMINA M
   Supronowicz PR, 2002, J BIOMED MATER RES, V59, P499, DOI 10.1002/jbm.10015
   Tappa K, 2019, J FUNCT BIOMATER, V10, DOI 10.3390/jfb10020017
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   Thapa A, 2003, J BIOMED MATER RES A, V67A, P1374, DOI 10.1002/jbm.a.20037
   THOMAS KA, 1985, J BIOMED MATER RES, V19, P875, DOI 10.1002/jbm.820190802
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   Tran P, 2008, INT J NANOMED, V3, P391
   Tran PA, 2009, J MATER CHEM, V19, P2653, DOI 10.1039/b814334j
   Tsaousi A, 2010, MUTAT RES GEN TOX EN, V697, P1, DOI 10.1016/j.mrgentox.2010.01.012
   Tsuruga E, 1997, J BIOCHEM TOKYO, V121, P317
   Vance RJ, 2004, BIOMATERIALS, V25, P2095, DOI 10.1016/j.biomaterials.2003.08.064
   Veljovic D, 2009, CERAM INT, V35, P1407, DOI 10.1016/j.ceramint.2008.07.007
   Venugopal JR, 2008, ARTIF ORGANS, V32, P388, DOI 10.1111/j.1525 1594.2008.00557.x
   Vinogradov SV, 2002, ADV DRUG DELIVER REV, V54, P135, DOI 10.1016/S0169 409X(01)00245 9
   Volkmer E, 2008, TISSUE ENG PT A, V14, P1331, DOI 10.1089/ten.tea.2007.0231
   Wang W, 2011, ANN ACAD MED SINGAP, V40, P237
   Washburn NR, 2004, BIOMATERIALS, V25, P1215, DOI 10.1016/j.biomaterials.2003.08.043
   Watari F, 2008, J CERAM SOC JPN, V116, P1, DOI 10.2109/jcersj2.116.1
   Webster T.J., 2001, ADV CHEM ENG, V27, P125
   Webster TJ, 2005, BIOMATERIALS, V26, P953, DOI 10.1016/j.biomaterials.2004.03.040
   Webster TJ, 2004, BIOMATERIALS, V25, P4731, DOI 10.1016/j.biomaterials.2003.12.002
   Weng H, 2004, J BIOMAT SCI POLYM E, V15, P1167, DOI 10.1163/1568562041753106
   Wilde G., 2009, NANOSTRUCT MATER, V1
   Wu CT, 2008, ACTA BIOMATER, V4, P569, DOI 10.1016/j.actbio.2007.11.005
   Wu SL, 2014, MAT SCI ENG R, V80, P1, DOI 10.1016/j.mser.2014.04.001
   Wu XT, 2018, J INT MED RES, V46, P368, DOI 10.1177/0300060517715529
   Xin L, 2015, HUM EXP TOXICOL, V34, P315, DOI 10.1177/0960327114538988
   Xu AX, 2015, MAT SCI ENG C MATER, V48, P592, DOI 10.1016/j.msec.2014.12.061
   Yan FK, 2012, ACTA MATER, V60, P1059, DOI 10.1016/j.actamat.2011.11.009
   Yan JH, 2018, INT J NANOMED, V13, P3425, DOI 10.2147/IJN.S160030
   Yang L., 2017, MRS BULL, V42
   Yang L., 2015, NANOTECHNOLOGY ENHAN, P1, DOI DOI 10.1016/B978 0 85709 844 3.00001 X
   Yang L, 2011, ADV ENG MATER, V13, pB197, DOI 10.1002/adem.201080140
   Yang L, 2009, EXPERT OPIN DRUG DEL, V6, P851, DOI 10.1517/17425240903044935
   Ye W, 2009, ELECTROCHIM ACTA, V54, P1339, DOI 10.1016/j.electacta.2008.08.073
   Ye YY, 2010, TOXICOL IN VITRO, V24, P751, DOI 10.1016/j.tiv.2010.01.001
   Ye YY, 2010, ENVIRON TOXICOL PHAR, V29, P131, DOI 10.1016/j.etap.2009.12.002
   Yeong KCB, 1999, MATER LETT, V38, P208, DOI 10.1016/S0167 577X(98)00160 8
   Yin H, 2010, LANGMUIR, V26, P15399, DOI 10.1021/la101033n
   Yin HM, 2019, APPL SURF SCI, V481, P987, DOI 10.1016/j.apsusc.2019.03.193
   Yuan YG, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030569
   Zeltinger J, 2001, TISSUE ENG, V7, P557, DOI 10.1089/107632701753213183
   Zhang LJ, 2009, NANO TODAY, V4, P66, DOI 10.1016/j.nantod.2008.10.014
   Zhang YZ, 2008, BIOMATERIALS, V29, P4314, DOI 10.1016/j.biomaterials.2008.07.038
   ZhangZhangX ShenW, 2016, INTINTJ MOLSCIREV J, V17
   Zhou H, 2011, ACTA BIOMATER, V7, P2769, DOI 10.1016/j.actbio.2011.03.019
   Zhou X, MATER CHEM FRONT
   Zhu K, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201605352
   Ziech D, 2010, CHEM BIOL INTERACT, V188, P334, DOI 10.1016/j.cbi.2010.07.010
   Zielinska A, 2020, MOLECULES, V25, DOI 10.3390/molecules25163731
NR 163
TC 2
Z9 2
U1 2
U2 9
PU EMERALD GROUP PUBLISHING LTD
PI Leeds
PA Floor 5, Northspring 21 23 Wellington Street, Leeds, W YORKSHIRE,
   ENGLAND
SN 2045 9858
EI 2045 9866
J9 BIOINSPIR BIOMIM NAN
JI Bioinspired Biomim. Nanobiomat.
PD MAY 27
PY 2022
VL 11
IS 2
BP 34
EP 55
DI 10.1680/jbibn.21.00061
EA MAY 2022
PG 22
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 5I6HG
UT WOS:000809354300001
DA 2025 08 17
ER

PT J
AU Li, H
   Wang, J
   Sun, QW
   Chen, G
   Sun, SN
   Ma, XM
   Qiu, HW
   Liu, XR
   Xu, LY
   Liu, M
AF Li, Hui
   Wang, Jing
   Sun, Qiwen
   Chen, Gang
   Sun, Shengnan
   Ma, Xuemei
   Qiu, Haiwen
   Liu, Xuerong
   Xu, Liangyi
   Liu, Mei
TI Jatrorrhizine Hydrochloride Suppresses RANKL Induced Osteoclastogenesis
   and Protects against Wear Particle Induced Osteolysis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE jatrorrhizine hydrochloride; osteoclast formation; bone resorption; wear
   particle induced osteolysis; MAPK signaling pathway
ID BISPHOSPHONATE THERAPY; TITANIUM PARTICLES; BONE FORMATION; TOTAL HIP;
   POLYETHYLENE; EXTRACT; OSTEOPOROSIS; ACTIVATION; BIOLOGY
AB Wear particle induced aseptic prosthetic loosening is a major complication associated with total joint arthroplasty (TJA). A growing body of evidence suggests that receptor activator of nuclear factor  B ligand (RANKL) stimulated osteoclastogenesis and bone resorption are responsible for peri implant loosening. Thus, agents which attenuate excessive osteoclast differentiation and function have been considered to offer therapeutic potential for prolonging the life of TJA implants. Jatrorrhizine hydrochloride (JH), a major protoberberine alkaloid isolated from the traditional Chinese herb Coptis chinensis, has been reported to have antimicrobial, antitumor, and antihypercholesterolemic and neuroprotective activities. However, its effects on osteoclast biology remain unknown. Here, we found that JH inhibited RANKL induced osteoclast formation and bone resorption in vitro and exerted protection against titanium (Ti) particle induced osteolysis in vivo. Biochemical analysis demonstrated that JH suppressed RANKL induced activation of MAPKs (p38 and ERK) which down regulated the production of NFATc1 and NFATc1 regulated osteoclastic marker genes, such as TRAP, CTR and CTSK. Collectively, our findings suggest that JH may be a promising anti osteoclastogenesis agent for treating periprosthetic osteolysis or other osteoclast related osteolytic diseases.
C1 [Li, Hui; Wang, Jing; Sun, Qiwen; Chen, Gang; Sun, Shengnan; Ma, Xuemei; Qiu, Haiwen; Liu, Xuerong; Xu, Liangyi; Liu, Mei] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Jiangsu, Peoples R China.
C3 Nanjing Normal University
RP Liu, M (通讯作者)，Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Jiangsu, Peoples R China.
EM 15050527874@163.com; njskywj@163.com; sunqiwen123@163.com;
   m18852005775@163.com; alyssia_s@163.com; njnumaxuemei@163.com;
   15895937858@163.com; 13852240843@163.com; 15651792179@163.com;
   liumei@njnu.edu.cn
RI Sun, shengnan/MTB 2852 2025
FU National Natural Science Foundation of China [31870895, 31171135];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD); Top notch Academic Programs Project of Jiangsu
   Higher Education Institutions (TAPP)
FX This study was supported by National Natural Science Foundation of China
   (Grant No. 31870895; 31171135), the Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD) and
   Top notch Academic Programs Project of Jiangsu Higher Education
   Institutions (TAPP).
CR Ang ESM, 2012, J CELL BIOCHEM, V113, P946, DOI 10.1002/jcb.23423
   Chao J, 2013, INT J MOL SCI, V14, P2928, DOI 10.3390/ijms14022928
   Córdova LA, 2015, ACTA BIOMATER, V13, P150, DOI 10.1016/j.actbio.2014.10.042
   David JP, 1999, J BONE MINER RES, V14, pS149
   [付燕 Fu Yan], 2005, [中草药, Chinese Traditional and Herbal Drugs], V36, P548
   Gallo J, 2014, ACTA BIOMATER, V10, P2354, DOI 10.1016/j.actbio.2014.02.003
   Gannon SC, 2013, J CELL PHYSIOL, V228, P1098, DOI 10.1002/jcp.24259
   Harris WH, 2001, CLIN ORTHOP RELAT R, P66
   Hiligsmann M, 2013, EXPERT REV PHARM OUT, V13, P19, DOI [10.1586/erp.12.76, 10.1586/ERP.12.76]
   Hirakawa K, 1996, J BIOMED MATER RES, V31, P257, DOI 10.1002/(SICI)1097 4636(199606)31:2<257::AID JBM13>3.0.CO;2 I
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jiang YP, 2013, ACTA ORTHOP BELG, V79, P1
   Kaar SG, 2001, J ORTHOPAED RES, V19, P171, DOI 10.1016/S0736 0266(00)00033 4
   Kang Ju Hee, 2016, J Bone Metab, V23, P207, DOI 10.11005/jbm.2016.23.4.207
   Kanno Y, 2014, J BIOL CHEM, V289, P15154, DOI 10.1074/jbc.A110.152181
   Lin CC, 2004, CLIN EXP PHARMACOL P, V31, P65, DOI 10.1111/j.1440 1681.2004.03951.x
   Liu M, 2015, AM J PATHOL, V185, P2653, DOI 10.1016/j.ajpath.2015.06.017
   Liu RF, 2013, ANTI CANCER DRUG, V24, P667, DOI 10.1097/CAD.0b013e328361ab28
   Marx RE, 2014, INT J ORAL MAX IMPL, V29, pE37, DOI 10.11607/jomi.te40
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Olof S., 2016, BMC MUSCULOSKEL DIS, V17, P1
   Park JH, 2017, MOL CELLS, V40, P706
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Qiu HW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051514
   Slobodníková L, 2004, PHYTOTHER RES, V18, P674, DOI 10.1002/ptr.1517
   Soysa N.S., 2016, J MED DENT SCI, V59, P65
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Taki N, 2005, J ORTHOP RES, V23, P376, DOI 10.1016/j.orthres.2004.08.023
   Verron E, 2014, DRUG DISCOV TODAY, V19, P312, DOI 10.1016/j.drudis.2013.08.010
   Volleková A, 2003, PHYTOTHER RES, V17, P834, DOI 10.1002/ptr.1256
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Waddell J, 2005, CLIN ORTHOP RELAT R, P170, DOI 10.1097/01.blo.0000155079.29604.d4
   Wedemeyer C, 2005, BIOMATERIALS, V26, P3719, DOI 10.1016/j.biomaterials.2004.09.026
   Weinstein RS, 2009, NEW ENGL J MED, V360, P1677
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Xiao F, 2015, EXP CELL RES, V330, P91, DOI 10.1016/j.yexcr.2014.07.005
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yamazaki T, 2012, BONE, V51, P882, DOI 10.1016/j.bone.2012.08.115
   Yang WW, 2016, MOL MED REP, V14, P3277, DOI 10.3892/mmr.2016.5634
NR 43
TC 21
Z9 22
U1 0
U2 15
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2018
VL 19
IS 11
AR 3698
DI 10.3390/ijms19113698
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HC0ZM
UT WOS:000451528500413
PM 30469456
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Jones, IC
   Carnagarin, R
   Armstrong, J
   Lin, DPL
   Baxter Holland, M
   Elahy, M
   Dass, CR
AF Jones, Isobel C. C.
   Carnagarin, Revathy
   Armstrong, Jo
   Lin, Daphne P. L.
   Baxter Holland, Mia
   Elahy, Mina
   Dass, Crispin R. R.
TI Pigment Epithelium Derived Factor: Inhibition of Phosphorylation of
   Insulin Receptor (IR)/IR Substrate (IRS), Osteogeneration from
   Adipocytes, and Increased Levels Due to Doxorubicin Exposure
SO PHARMACEUTICS
LA English
DT Article
DE PEDF; metabolism; insulin; differentiation; doxorubicin
ID FACTOR PEDF; NADPH OXIDASE; IN VIVO; CELLS; WHITE; ANGIOGENESIS;
   METABOLISM; GLUCOSE; OBESITY; DIFFERENTIATION
AB Objectives: Pigment epithelium derived factor (PEDF) has been recently linked to insulin resistance and is capable of differentiating myocytes to bone. We examined in more detail the intricate signalling of the insulin pathway influenced by PEDF in skeletal myocytes. We tested whether this serpin is also capable of generating de novo bone from adipocytes in vitro and in vivo, and how the anticancer drug doxorubicin links with PEDF and cellular metabolism. Methods and key findings: We demonstrate that PEDF can inhibit phosphorylation of insulin receptor (IR) and insulin receptor substrate (IRS) in skeletal myocytes. PEDF constitutively activates p42/44 MAPK/Erk, but paradoxically does not affect mitogenic signalling. PEDF did not perturb either mitochondrial activity or proliferation in cells representing mesenchymal stem cells, cardiomyocytes, and skeletal myocytes and adipocytes. PEDF induced transdifferentiation of adipocytes to osteoblasts, promoting bone formation in cultured adipocytes in vitro and gelfoam fatpad implants in vivo. Bone formation in white adipose tissue (WAT) was better than in brown adipose tissue (BAT). The frontline anticancer drug doxorubicin increased levels of PEDF in a human breast cancer cell line, mirroring the in vivo finding where cardiac muscle tissue was stained increasingly for PEDF as the dose of doxorubicin increased in mice. PEDF also increased levels of reactive oxygen species (ROS) and glutathione (GSH) in the breast cancer cell line. Conclusions: PEDF may be used to regenerate bone from adipose tissue in cases of trauma such as fractures or bone cancers. The increased presence of PEDF in doxorubicin treated tumour cells need further exploration, and could be useful therapeutically in future. The safety of PEDF administration in vivo was further demonstrated in this study.
C1 [Jones, Isobel C. C.; Dass, Crispin R. R.] Curtin Univ, Curtin Med Sch, Bentley, WA 6102, Australia.
   [Jones, Isobel C. C.] Univ Notre Dame, Sch Med, Fremantle, WA 6160, Australia.
   [Carnagarin, Revathy] Univ Western Australia, Royal Perth Hosp Unit, Fac Med, Dobney Hypertens Ctr, Perth, WA 6009, Australia.
   [Carnagarin, Revathy; Armstrong, Jo; Lin, Daphne P. L.; Dass, Crispin R. R.] Curtin Univ, Sch Pharm, Bentley, WA 6102, Australia.
   [Baxter Holland, Mia; Elahy, Mina; Dass, Crispin R. R.] Curtin Univ, Sch Pharm & Biomed Sci, Bentley, WA 6102, Australia.
   [Elahy, Mina] Univ New South Wales, Sch Med Sci, Kensington, NSW 2052, Australia.
   [Dass, Crispin R. R.] Curtin Univ, Curtin Hlth Innovat Res Inst, Bentley, WA 6102, Australia.
C3 Curtin University; The University of Notre Dame Australia; East
   Metropolitan Health Service; Royal Perth Hospital; University of Western
   Australia; Curtin University; Curtin University; University of New South
   Wales Sydney; Curtin University
RP Dass, CR (通讯作者)，Curtin Univ, Curtin Med Sch, Bentley, WA 6102, Australia.; Dass, CR (通讯作者)，Curtin Univ, Sch Pharm, Bentley, WA 6102, Australia.; Dass, CR (通讯作者)，Curtin Univ, Sch Pharm & Biomed Sci, Bentley, WA 6102, Australia.; Dass, CR (通讯作者)，Curtin Univ, Curtin Hlth Innovat Res Inst, Bentley, WA 6102, Australia.
EM crispin.dass@curtin.edu.au
OI Jones, Isobel/0000 0001 9778 1381; Carnagarin,
   Revathy/0000 0003 4714 0206; Dass, Crispin/0000 0001 7087 7957
CR Abooshahab R, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15020543
   Achkar IW, 2020, METABOLITES, V10, DOI 10.3390/metabo10070268
   Borg ML, 2011, DIABETES, V60, P1458, DOI 10.2337/db10 0845
   Bråkenhielm E, 2004, CIRC RES, V94, P1579, DOI 10.1161/01.RES.0000132745.76882.70
   Branco AF, 2012, CARDIOVASC TOXICOL, V12, P326, DOI 10.1007/s12012 012 9177 8
   Burgers TA, 2013, BONE, V54, P244, DOI 10.1016/j.bone.2013.02.022
   Cao Y, 2007, J CLIN INVEST, V117, P2362, DOI 10.1172/JCI32239
   Cao YH, 2010, NAT REV DRUG DISCOV, V9, P107, DOI 10.1038/nrd3055
   Carnagarin R, 2018, MOL CELL ENDOCRINOL, V472, P159, DOI 10.1016/j.mce.2017.12.008
   Carnagarin R, 2016, INT J BIOCHEM CELL B, V78, P229, DOI 10.1016/j.biocel.2016.06.013
   Carnagarin R, 2016, MOL CELL ENDOCRINOL, V422, P115, DOI 10.1016/j.mce.2015.12.010
   Chen WW, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.961761
   Chen YN, 2016, MOL CELL ENDOCRINOL, V426, P50, DOI 10.1016/j.mce.2016.02.004
   Crowe S, 2009, CELL METAB, V10, P40, DOI 10.1016/j.cmet.2009.06.001
   Dai CH, 2013, DIABETES, V62, P4144, DOI 10.2337/db12 1657
   Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870
   Ek ETH, 2007, J ORTHOP RES, V25, P1671, DOI 10.1002/jor.20434
   Ek ETH, 2007, CLIN EXP METASTAS, V24, P93, DOI 10.1007/s10585 007 9062 1
   Elahy M, 2018, CURR DRUG TARGETS, V19, P467, DOI 10.2174/1389450116666151001112455
   Farhane Z, 2017, J BIOPHOTONICS, V10, P151, DOI 10.1002/jbio.201600019
   Feldmann HM, 2009, CELL METAB, V9, P203, DOI 10.1016/j.cmet.2008.12.014
   Gattu AK, 2013, FASEB J, V27, P4384, DOI 10.1096/fj.13 232900
   Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776
   Huang B, 2019, INT J MOL MED, V43, P1979, DOI 10.3892/ijmm.2019.4132
   Jones IC, 2022, J PHARM PHARMACOL, V74, P1677, DOI 10.1093/jpp/rgac063
   Klaus S, 1997, BIOESSAYS, V19, P215, DOI 10.1002/bies.950190307
   Lee RX, 2016, PHARMAZIE, V71, P382, DOI 10.1691/ph.2016.6010
   Lemma S, 2017, BBA MOL BASIS DIS, V1863, P3254, DOI 10.1016/j.bbadis.2017.08.030
   Li F, 2015, J CELL PHYSIOL, V230, P1243, DOI 10.1002/jcp.24859
   Montanari T, 2017, OBES REV, V18, P495, DOI 10.1111/obr.12520
   Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911
   Qian SW, 2013, P NATL ACAD SCI USA, V110, pE798, DOI 10.1073/pnas.1215236110
   Riccillo FL, 2012, TISSUE CELL, V44, P101, DOI 10.1016/j.tice.2011.12.002
   Rodeheffer MS, 2008, CELL, V135, P240, DOI 10.1016/j.cell.2008.09.036
   Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799
   STONE RL, 1990, DIFFERENTIATION, V45, P119, DOI 10.1111/j.1432 0436.1990.tb00465.x
   Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359
   Tacar O, 2015, J PHARM PHARMACOL, V67, P231, DOI 10.1111/jphp.12324
   Tam J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004974
   Tan ML, 2014, BIOMATERIALS, V35, P7828, DOI 10.1016/j.biomaterials.2014.05.087
   Tan ML, 2010, BIOCHEM BIOPH RES CO, V398, P613, DOI 10.1016/j.bbrc.2010.05.098
   Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232
   Tsuruhisa S, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.12890
   Unser AM, 2015, BIOTECHNOL ADV, V33, P962, DOI 10.1016/j.biotechadv.2015.07.005
   Walenta S, 2000, CANCER RES, V60, P916
   Wang QH, 2009, ISLETS, V1, P95, DOI 10.4161/isl.1.2.9263
   Wei YZ, 2019, BONE, V124, P103, DOI 10.1016/j.bone.2019.04.014
   Yagihashi S, 2017, J DIABETES INVEST, V8, P413, DOI 10.1111/jdi.12590
   Yamagishi S, 2005, CELL TISSUE RES, V320, P437, DOI 10.1007/s00441 005 1094 8
   Yamauchi T, 1996, MOL CELL BIOL, V16, P3074
   Zhu Hong, 2016, React Oxyg Species (Apex), V1, P189
NR 51
TC 5
Z9 5
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD JUL
PY 2023
VL 15
IS 7
AR 1960
DI 10.3390/pharmaceutics15071960
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA N4JY9
UT WOS:001036706700001
PM 37514146
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Campbell, GM
   Tiwati, S
   Picke, AK
   Hofbauer, C
   Rauner, M
   Morlock, MM
   Hofbauer, LC
   Glüer, CC
AF Campbell, G. M.
   Tiwati, S.
   Picke, A.  K.
   Hofbauer, C.
   Rauner, M.
   Morlock, M. M.
   Hofbauer, L. C.
   Glueer, C.  C.
TI Effects of insulin therapy on porosity, non enzymatic glycation and
   mechanical competence in the bone of rats with type 2 diabetes mellitus
SO BONE
LA English
DT Article
DE Insulin; Biomechanics; Diabetes; Collagen; Non enzymatic glycation;
   Preclinical studies
ID END PRODUCTS; HIGH GLUCOSE; OSTEOCLAST DIFFERENTIATION; DEFECT
   REGENERATION; PARATHYROID HORMONE; CORTICAL POROSITY; HIP FRACTURE;
   CROSS LINKS; MASS; CELLS
AB Type 2 diabetes mellitus increases skeletal fragility; however, the contributing mechanisms and optimal treatment strategies remain unclear. We studied the effects of diabetes and insulin therapy on non enzymatic glycation (NEG), cortical porosity (Ct.Po) and biomechanics of the bone tissue in Zucker Diabetic Fatty (ZDF) rats. Eleven week old ZDF diabetic and non diabetic rats were given insulin to achieve glycaemic control or vehicle seven days per week over twelve weeks (insulin dose adapted individually 0.5 international units (IU) at week 1 to 13.0 IU at week 12). The right femora were excised, micro CT scanned, and tested in 3 point bending to measure biomechanics. NEG of the midshaft was determined from bulk fluorescence.
   Diabetes led to increased NEG (+ 50.1%, p = 0.001) and Ct.Po (+ 22.9%, p = 0.004), as well as to reduced mechanical competence (max. stress:  14.2%, p = 0.041, toughness:  29.7%, p = 0.016) in the bone tissue. NEG and Ct.Po both correlated positively to serum glucose (NEG: R 2 = 0.41, p < 0.001, Ct.Po: R 2 = 034, p = 0.003) and HbA1c (NEG: R 2 = 0.42, p < 0.001, Ct.Po: R 2 = 0.28, p = 0.008) levels, while NEG correlated negatively with bone biomechanics (elastic modulus: R 2 = 0.21, p = 0.023, yield stress: R 2 = 0.17, p = 0.047). Twelve weeks of insulin therapy had no significant effect on NEG or Ct.Po, and was unable to improve the mechanical competence of the bone tissue.
   A reduction of mechanical competence was observed in the bone tissue of the diabetic rats, which was explained in part by increased collagen NEG. Twelve weeks of insulin therapy did not alter NEG, Ct.Po or bone biomechanics. However, significant correlations between NEG and serum glucose and HbA1c were observed, both of which were reduced with insulin therapy. This suggests that a longer duration of insulin therapy may be required to reduce the NEG of the bone collagen and restore the mechanical competence of diabetic bone. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Campbell, G. M.; Tiwati, S.; Glueer, C.  C.] Univ Hosp Schleswig Holstein, Dept Radiol & Neurol, Sect Biomed Imaging, Campus Kiel, Kiel, Germany.
   [Campbell, G. M.; Morlock, M. M.] TUHH Hamburg Univ Technol, Inst Biomech, Denickestr 15, D 21073 Hamburg, Germany.
   [Picke, A.  K.; Rauner, M.; Hofbauer, L. C.] Tech Univ Dresden, Med Ctr, Dept Med 3, Dresden, Germany.
   [Hofbauer, C.] Tech Univ Dresden, Med Ctr, Dept Orthoped, Dresden, Germany.
   [Hofbauer, L. C.] Ctr Regenerat Therapies Dresden, Dresden, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; Hamburg
   University of Technology; Technische Universitat Dresden; Technische
   Universitat Dresden; Technische Universitat Dresden
RP Campbell, GM (通讯作者)，TUHH Hamburg Univ Technol, Inst Biomech, Denickestr 15, D 21073 Hamburg, Germany.
EM graeme.campbell@tuhh.de
RI Bloch, Michael/O 7845 2017; Glüer, Claus Christian/C 9752 2010; Rauner,
   Martina/A 1665 2015; Hofbauer, Lorenz/G 2490 2010; Hofbauer, Lorenz
   C./G 2490 2010; Tiwari, Sanjay/Q 1853 2016; Campbell,
   Graeme/JPX 2238 2023
OI Morlock, Michael/0000 0002 5330 2454; Rauner,
   Martina/0000 0002 4067 6799; Hofbauer, Lorenz C./0000 0002 8691 8423;
   Tiwari, Sanjay/0000 0002 3804 3300; 
FU Deutsche Forschungsgemeinschaft (DFG) through Forschergruppe 1586
   SKELMET [GL 289/9 1]; state of Schleswig Holstein; European Union
   ERDF European Regional Development Fund (MOIN CC, Zukunftsprogramm
   Wirtschaft)
FX The authors are grateful to Gabriele Mielke and Kay Sellenschloh from
   the TUHH for their assistance with the sample preparation and operation
   of the mechanical testing. Financial support was provided by the
   Deutsche Forschungsgemeinschaft (DFG) through the Forschergruppe 1586
   SKELMET (GL 289/9 1) (LCH and CCG) and Transregio 67, project B2 (CH,
   LCH) and by the research grant from the state of Schleswig Holstein and
   the European Union ERDF European Regional Development Fund (MOIN CC,
   Zukunftsprogramm Wirtschaft). Authors' roles: study design: GMC, CH, LCH
   and CCG. Study conduct: GMC and ST. Data collection: GMC, GH and ST.
   Data analysis: GMC. Data interpretation: GMC, ST, CH, AKP, MR, GH, MMM,
   LCH and CCG. Drafting manuscript: GMC. Revising manuscript content: GMC,
   ST, CH, AKP, MR, GH, MMM, LCH and CCG. Approval of final version of
   manuscript: GMC, ST, CH, AKP, MR, GH, MMM, LCH and CCG. GMC takes
   responsibility for the integrity of the data analysis.
CR Buie HR, 2007, BONE, V41, P505, DOI 10.1016/j.bone.2007.07.007
   Burghardt AJ, 2010, J CLIN ENDOCR METAB, V95, P5045, DOI 10.1210/jc.2010 0226
   Campbell EJ, 2015, EXPERT OPIN BIOL TH, V15, P119, DOI 10.1517/14712598.2015.977249
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Cunha JS, 2014, CELL TISSUE RES, V358, P249, DOI 10.1007/s00441 014 1913 x
   Dempster DW, 2003, CLIN GERIATR MED, V19, P259, DOI 10.1016/S0749 0690(02)00098 8
   Dong XN, 2011, BONE, V49, P174, DOI 10.1016/j.bone.2011.04.009
   Fajardo RJ, 2014, J BONE MINER RES, V29, P1025, DOI 10.1002/jbmr.2210
   Forsén L, 1999, DIABETOLOGIA, V42, P920, DOI 10.1007/s001250051248
   Hamann C, 2014, ENDOCRINOLOGY, V155, P1197, DOI 10.1210/en.2013 1960
   Hamann C, 2013, J BONE MINER RES, V28, P627, DOI 10.1002/jbmr.1803
   Hamann C, 2011, AM J PHYSIOL ENDOC M, V301, pE1220, DOI 10.1152/ajpendo.00378.2011
   HOUGH S, 1981, ENDOCRINOLOGY, V108, P2228, DOI 10.1210/endo 108 6 2228
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Levinger I, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12700
   Liu ZD, 2007, ACTA ORTHOP, V78, P46, DOI 10.1080/17453670610013411
   McCarthy AD, 1999, ACTA DIABETOL, V36, P45, DOI 10.1007/s005920050144
   Mercer N, 2007, MOL CELL BIOCHEM, V306, P87, DOI 10.1007/s11010 007 9557 8
   Miyata T, 1997, J AM SOC NEPHROL, V8, P260
   Monami M, 2008, DIABETES CARE, V31, P199, DOI 10.2337/dc07 1736
   Napoli N, 2014, DIABETOLOGIA, V57, P2057, DOI 10.1007/s00125 014 3289 6
   Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192
   Odetti P, 2005, ANN NY ACAD SCI, V1043, P710, DOI 10.1196/annals.1333.082
   Ogawa N, 2007, HORM METAB RES, V39, P871, DOI 10.1055/s 2007 991157
   Paccou J., 2015, CALCIF TISSUE INT
   Pastor MMC, 2000, OSTEOPOROSIS INT, V11, P455, DOI 10.1007/s001980070114
   Patsch JM, 2013, J BONE MINER RES, V28, P313, DOI 10.1002/jbmr.1763
   Picke AK, 2016, BONE, V82, P108, DOI 10.1016/j.bone.2015.06.001
   Reinwald S, 2009, AM J PHYSIOL ENDOC M, V296, pE765, DOI 10.1152/ajpendo.90937.2008
   Ritchie RO, 2008, BONE, V43, P798, DOI 10.1016/j.bone.2008.04.027
   Saito M, 2006, OSTEOPOROSIS INT, V17, P1514, DOI 10.1007/s00198 006 0155 5
   Saito M, 2006, OSTEOPOROSIS INT, V17, P986, DOI 10.1007/s00198 006 0087 0
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Schwartz AV, 2001, J CLIN ENDOCR METAB, V86, P32, DOI 10.1210/jc.86.1.32
   SELL DR, 1989, CONNECT TISSUE RES, V19, P77, DOI 10.3109/03008208909016816
   Suzuki K, 2003, BONE, V33, P108, DOI 10.1016/S8756 3282(03)00169 8
   Tanaka KI, 2015, BIOCHEM BIOPH RES CO, V461, P193, DOI 10.1016/j.bbrc.2015.02.091
   Tang SY, 2007, BONE, V40, P1144, DOI 10.1016/j.bone.2006.12.056
   Tang SY, 2011, J BIOMECH, V44, P330, DOI 10.1016/j.jbiomech.2010.10.016
   Tang SY, 2010, BONE, V46, P148, DOI 10.1016/j.bone.2009.09.003
   Thrailkill KM, 2005, AM J PHYSIOL ENDOC M, V289, pE735, DOI 10.1152/ajpendo.00159.2005
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Vashishth D, 2001, BONE, V28, P195, DOI 10.1016/S8756 3282(00)00434 8
   Williams JP, 1997, BIOCHEM BIOPH RES CO, V235, P646, DOI 10.1006/bbrc.1997.6795
   Xu J, 2015, MOL MED REP, V11, P865, DOI 10.3892/mmr.2014.2807
NR 46
TC 11
Z9 13
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2016
VL 91
BP 186
EP 193
DI 10.1016/j.bone.2016.08.003
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DU7YX
UT WOS:000382431600020
PM 27497735
DA 2025 08 17
ER

PT J
AU Maresova, KB
   Franek, T
   Vondracek, T
   Stepan, JJ
AF Maresova, Kristyna Brabnikova
   Franek, Tomas
   Vondracek, Tomas
   Stepan, Jan J.
TI A comparison of the acute effects of calcium and strontium ranelate on
   the serum marker of bone resorption
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE bone markers; calcium; collagen type I; strontium ranelate
ID SENSING RECEPTOR; I COLLAGEN; OSTEOPOROSIS; TELOPEPTIDES; OSTEOCLASTS;
   CROSSLAPS; WOMEN
AB Background: To investigate the mechanism by which strontium ranelate (SrR) inhibits the bone resorption, this study compared the effects of SrR and calcium on parathyroid hormone (PTH) and the biochemical marker of bone resorption (serum type I collagen cross linked C telopepticle, beta CTX).
   Methods: In 10 healthy young subjects, after overnight fasting, 1000 mg of elemental calcium and 2000 mg of SrR containing 600 mg Sr2+ were administered consecutively with a 1 week washout period. During the control period no drug was given. Fasting blood samples were drawn at baseline and throughout the next 5 h period.
   Results: After the ingestion of either calcium or SrR, there was a significant increase in serum calcium and strontium concentrations, and a decrease in serum beta CTX and intact PTH concentrations as compared to the baseline values (p<0.05). In the fasting subjects, no significant differences in the variable were found as compared to the baseline values.
   Conclusions: The decrease in PTH and the marker of bone resorption observed after the SrR administration is comparable to the decrease observed after the calcium administration in young adults.
C1 [Maresova, Kristyna Brabnikova; Vondracek, Tomas; Stepan, Jan J.] Charles Univ Prague, Inst Rheumatol, Fac Med 1, Prague, Czech Republic.
   [Franek, Tomas] Charles Univ Prague, Univ Hosp Motol, Dept Clin Biochem & Pathobiochem, Fac Med 2, Prague, Czech Republic.
C3 Institute of Rheumatology; Charles University Prague; Motol University
   Hospital; Charles University Prague
RP Maresova, KB (通讯作者)，Charles Univ Prague, Inst Rheumatol, Fac Med 1, Prague, Czech Republic.
EM maresova.kristyna@seznam.cz
RI Stepan, Jan/A 7280 2013
OI Stepan, Jan/0000 0003 1541 8306
FU MZd CR [000 237280]
FX The study was fully supported by the grant MZd CR 000 237280.
CR Brown EM, 2003, OSTEOPOROSIS INT, V14, pS25, DOI 10.1007/s00198 002 1343 6
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   Coulombe J, 2004, BIOCHEM BIOPH RES CO, V323, P1184, DOI 10.1016/j.bbrc.2004.08.209
   Fabrik I, 2009, ELECTROANAL, V21, P650, DOI 10.1002/elan.200804431
   Guillemant J, 2000, AM J NEPHROL, V20, P48, DOI 10.1159/000013555
   Guillemant JA, 2003, CLIN CHIM ACTA, V337, P35, DOI 10.1016/S0009 8981(03)00293 6
   Huang Y, 2007, J BIOL CHEM, V282, P19000, DOI 10.1074/jbc.M701096200
   Hurtel Lemaire AS, 2009, J BIOL CHEM, V284, P575, DOI 10.1074/jbc.M801668200
   Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   MOONGA BS, 1990, J PHYSIOL LONDON, V429, P29, DOI 10.1113/jphysiol.1990.sp018242
   Rosenquist C, 1998, CLIN CHEM, V44, P2281
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   Zikan V., 2001, Nutritional aspects of osteoporosis, P131
   Zikán V, 2001, CALCIFIED TISSUE INT, V68, P352, DOI 10.1007/s00223 001 0010 9
NR 15
TC 3
Z9 3
U1 0
U2 7
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D 10785 BERLIN, GERMANY
SN 1434 6621
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PY 2012
VL 50
IS 2
BP 333
EP 335
DI 10.1515/CCLM.2011.781
PG 3
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Medical Laboratory Technology
GA 914ZB
UT WOS:000301991300018
PM 22080821
DA 2025 08 17
ER

PT J
AU Chava, S
   Chennakesavulu, S
   Gayatri, MB
   Reddy, ABM
AF Chava, Suresh
   Chennakesavulu, S.
   Gayatri, Meher B.
   Reddy, Aramati B. M.
TI A novel phosphorylation by AMP activated kinase regulates RUNX2 from
   ubiquitination in osteogenesis over adipogenesis
SO CELL DEATH & DISEASE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; PPAR GAMMA; ENERGY
   SENSOR; BONE; OSTEOCLASTOGENESIS; DEGRADATION; MECHANISMS; STRESS
AB Mesenchymal stem cells (MSCs) function as progenitors to a variety of cell types. The reported association between osteogenic and adipogenic commitment during differentiation is due to the regulation of key transcription factors in the signaling pathways. However, the process of adipogenesis at the expense of osteogenic phenotype during metabolic stress is still unclear. In this study, we showed for the first time that RUNX2 is a novel substrate of AMP activated kinase (AMPK), which directly phosphorylates at serine 118 residue in the DNA binding domain of RUNX2. Our results in in vitro MSC lineage differentiation models confirmed that active AMPK and RUNX2 S118 phosphorylation are preferentially associated with osteogenic commitment, whereas the lack of this phosphorylation leads to adipogenesis. This interplay is regulated by the ubiquitination of non phosphorylated RUNX2 S118, which is evident in the dominant mutant RUNX2 S118D. Pharmacological activation of AMPK by metformin significantly abrogated the loss of RUNX2 S118 phosphorylation and protected from tunicamycin induced endoplasmic reticulum stress, high glucose induced in vitro adipogenesis and streptozotocin induced in vivo bone adiposity and bone phenotype. In conclusion, results from this study demonstrated that RUNX2 is a direct target of AMPK which simplified the outlook towards several complex mechanisms that are currently established concerning cellular metabolism and pathogenesis.
C1 [Chava, Suresh; Chennakesavulu, S.; Gayatri, Meher B.; Reddy, Aramati B. M.] Univ Hyderabad, Sch Life Sci, Dept Anim Biol, Hyderabad 500046, Telangana, India.
C3 University of Hyderabad
RP Reddy, ABM (通讯作者)，Univ Hyderabad, Sch Life Sci, Dept Anim Biol, Hyderabad 500046, Telangana, India.
EM abmsl@uohyd.ernet.in
RI Chava, Suresh/AEC 9388 2022; Bolisetti, meher/JZT 8974 2024; Sugali,
   Chenna Kesavulu/JTU 3163 2023
OI Chava, Suresh/0000 0002 9360 5249; Reddy, Aramati Bindu
   Madhava/0000 0002 9069 0310; SUGALI, CHENNA KESAVULU/0000 0002 6523 7688
FU University of Hyderabad through UPE II; DST FIST; PURSE; RGYI;
   Department of Biotechnology, Government of India; CSIR
FX The laboratory was partly supported by the University of Hyderabad
   through institutional funding from UPE II, DST FIST, PURSE, and
   acknowledges the funding from RGYI, RNAi task force from the Department
   of Biotechnology, Government of India. S. C., B. M. G. and S. C.
   acknowledge CSIR for student fellowship. The authors thank Prasanth
   Mitreya, MNR Dental College and Professor UmaKrishnan, SASTRA
   University, for mu CT image analysis and Bandapalli OR, Munugalavadla V
   and Nagaraju GP for critical comments.
CR Adhami M, 2011, CELLS TISSUES ORGANS, V194, P232, DOI 10.1159/000324763
   Aguiari P, 2008, P NATL ACAD SCI USA, V105, P1226, DOI 10.1073/pnas.0711402105
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Anjana RM, 2011, DIABETOLOGIA, V54, P3022, DOI 10.1007/s00125 011 2291 5
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen SC, 2017, MOL CELL ENDOCRINOL, V440, P57, DOI 10.1016/j.mce.2016.11.011
   Chen T, 2015, BIOCHEM BIOPH RES CO, V461, P237, DOI 10.1016/j.bbrc.2015.03.168
   D'Souza DR, 2009, J BIOL CHEM, V284, P17947, DOI 10.1074/jbc.M109.002378
   Demmer RT, 2013, AM J EPIDEMIOL, V178, P1106, DOI 10.1093/aje/kwt088
   McCarthy AD, 2016, WORLD J DIABETES, V7, P122, DOI 10.4239/wjd.v7.i6.122
   Fu XJ, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0400 6
   Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032
   Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Huang YF, 2012, J BONE MINER RES, V27, P1093, DOI 10.1002/jbmr.1548
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Jang WG, 2011, BIOCHEM BIOPH RES CO, V404, P1004, DOI 10.1016/j.bbrc.2010.12.099
   Jeyabalan J, 2012, J ENDOCRINOL, V212, P277, DOI 10.1530/JOE 11 0306
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Li XN, 2008, J CELL BIOL, V181, P959, DOI 10.1083/jcb.200711044
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72
   Nakatani Y, 2005, J BIOL CHEM, V280, P847, DOI 10.1074/jbc.M411860200
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pladzyk A, 2006, INVEST OPHTH VIS SCI, V47, P5395, DOI 10.1167/iovs.06 0469
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Rajgopal A, 2007, J CELL BIOCHEM, V100, P1509, DOI 10.1002/jcb.21137
   Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097 2765(00)80211 7
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   Savopoulos C, 2011, HIPPOKRATIA, V15, P18
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Shen R, 2006, J BIOL CHEM, V281, P16347, DOI 10.1074/jbc.M603439200
   Shimazu J, 2016, CELL REP, V15, P27, DOI 10.1016/j.celrep.2016.03.003
   Shu L, 2013, J BONE MINER RES, V28, P1925, DOI 10.1002/jbmr.1938
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Thacker G, 2016, BBA MOL CELL RES, V1863, P510, DOI 10.1016/j.bbamcr.2016.01.010
   Veldhuis Vlug AG, 2017, METABOLISM, V67, P106, DOI 10.1016/j.metabol.2016.11.013
   WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582
   Wang P, 2018, J TISSUE ENG REGEN M, V12, P437, DOI 10.1002/term.2470
   Wang YG, 2016, SCI REP UK, V6, DOI 10.1038/srep32771
   Wang YG, 2016, CELL SIGNAL, V28, P1270, DOI 10.1016/j.cellsig.2016.06.004
   Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo reports/kvf193
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
NR 51
TC 56
Z9 59
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL 9
PY 2018
VL 9
AR 754
DI 10.1038/s41419 018 0791 7
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GM7KZ
UT WOS:000438367000002
PM 29988028
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shi, YY
   Li, YQ
   Xie, X
   Zhou, YT
   Zhang, Q
   Yu, JL
   Li, P
   Mi, N
   Li, F
AF Shi, Yuan Yuan
   Li, Ying Qi
   Xie, Xiang
   Zhou, Yu Ting
   Zhang, Qian
   Yu, Jia Lin
   Li, Ping
   Mi, Na
   Li, Fei
TI Homotherapy for heteropathy active components and mechanisms of
   Qiang Huo Sheng Shi decoction for treatment of rheumatoid arthritis and
   osteoarthritis
SO COMPUTATIONAL BIOLOGY AND CHEMISTRY
LA English
DT Article
DE Qiang Huo Sheng Shi decoction; Rheumatoid arthritis; Osteoarthritis;
   Network pharmacology; Homotherapy for heteropathy
ID NETWORK PHARMACOLOGY APPROACH; TRADITIONAL CHINESE MEDICINE; GENE;
   POLYMORPHISMS; INFLAMMATION; PATHWAYS; UPDATE; MICE
AB Qiang Huo Sheng Shi decoction (QHSSD), a classic traditional Chinese herbal formula, which has been reported to be effective in rheumatoid arthritis (RA) and osteoarthritis (OA). However, the concurrent targeting mechanism of how the aforementioned formula is valid in the two distinct diseases OA and RA, which represents the homotherapy for heteropathy principle in traditional Chinese medicine (TCM), have not yet been clarified. In the present study, network pharmacology was adopted to analyze the potential molecular mechanism, and therapeutic effective components of QHSSD on both OA and RA. A total of 153 active ingredients in QHSSD were identified, 142 of which associated with 59 potential targets for the two diseases were identified. By constructing the protein protein interaction network and the compound target disease network, 72 compounds and 10 proteins were obtained as the hub targets of QHSSD against OA and RA. The hub genes of ESR1, PTGS2, PPARG, IL1B, TNF, MMP2, IL6, CYP3A4, MAPK8, and ALB were mainly involved in osteoclast differentiation, the NF kappa B and TNF signaling pathways. Moreover, molecular docking results showed that the screened active compounds had a high affinity for the hub genes. This study provides new insight into the molecular mechanisms behind how QHSSD presents homotherapy for hetempathy therapeutic efficacy in both OA and RA. For the first time, a two disease model was linked with a TCM formula using network pharmacology to identify the key active components and understand the common mechanisms of its multi pathway regulation. This study will inspire more innovative and important studies on the modern research of TCM formulas.
C1 [Shi, Yuan Yuan; Zhou, Yu Ting; Li, Fei] Xinjiang Med Univ, Coll Pharm, Urumqi 830011, Peoples R China.
   [Shi, Yuan Yuan; Li, Ying Qi; Zhang, Qian; Yu, Jia Lin; Li, Ping; Li, Fei] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China.
   [Xie, Xiang; Mi, Na] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi 830011, Peoples R China.
   [Li, Fei] China Pharmaceut Univ, Jiangsu Key Lab Druggabil Biopharmaceut, Nanjing 210009, Peoples R China.
C3 Xinjiang Medical University; China Pharmaceutical University; Xinjiang
   Medical University; China Pharmaceutical University
RP Li, F (通讯作者)，Xinjiang Med Univ, Coll Pharm, Urumqi 830011, Peoples R China.; Li, P (通讯作者)，China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China.; Mi, N (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 1, Urumqi 830011, Peoples R China.
EM liping2004@126.com; mina2a@163.com; lifeicpu@163.com
RI xie, xiang/AAG 2128 2021; mi, na/JSK 4322 2023
OI Mi, Na/0000 0003 3090 197X; 
FU National Key R&D Program of China [2019YFC1711000]; National Natural
   Science Foundation of China [81873185, 81860773]; Natural Science
   Foundation of Jiangsu province [BK20181327]; Xinjiang Science Fund for
   Distinguished Young Scholar Project [2018Q003]
FX This study was supported by grants from the National Key R&D Program of
   China (2019YFC1711000), National Natural Science Foundation of China
   (No. 81873185, and No. 81860773), Natural Science Foundation of Jiangsu
   province (No. BK20181327), Xinjiang Science Fund for Distinguished Young
   Scholar Project (No. 2018Q003).
CR Anitha P, 2016, GENE, V575, P253, DOI 10.1016/j.gene.2015.08.068
   [Anonymous], 2017, TREATMENT OSTEOARTHR
   Azietaku JT, 2017, J ETHNOPHARMACOL, V202, P241, DOI 10.1016/j.jep.2017.03.022
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Charles Janice, 2013, Aust Fam Physician, V42, P765
   Choudhary N, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 46715 6
   Deng JL, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00695
   Devaraj E, 2020, N S ARCH PHARMACOL, V393, P1067, DOI 10.1007/s00210 020 01810 8
   Feunang YD, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321 016 0174 y
   Gan DH, 2019, MED SCI MONITOR, V25, P5700, DOI 10.12659/MSM.915170
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   Goel A, 2015, MOL CELL ENDOCRINOL, V411, P155, DOI 10.1016/j.mce.2015.04.023
   Gong BJ, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/2735050
   Gong R, 2019, BIOMED RES INT UK, V2019, DOI 10.1155/2019/1907906
   Guo W, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01185
   Hong JI, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020533
   Jahanban Esfahlan R, 2018, BRIT J PHARMACOL, V175, P3230, DOI 10.1111/bph.13898
   Kapoor T, 2018, RHEUM DIS CLIN N AM, V44, P571, DOI 10.1016/j.rdc.2018.06.008
   Karakaya S, 2020, SAUDI PHARM J, V28, P1, DOI 10.1016/j.jsps.2019.11.001
   Kim KA, 2014, MOL NUTR FOOD RES, V58, P963, DOI 10.1002/mnfr.201300433
   Kitanaka T, 2017, SCI REP UK, V7, DOI 10.1038/srep39914
   Lee NY, 2017, J CELL BIOCHEM, V118, P3993, DOI 10.1002/jcb.26055
   Lei LJ, 2019, J NAT MED TOKYO, V73, P1, DOI 10.1007/s11418 018 1245 3
   Lequerré T, 2019, JOINT BONE SPINE, V86, P151, DOI 10.1016/j.jbspin.2018.03.018
   Li C, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/5196302
   Li F, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 56050 5
   Li HY, 2018, MED SCI MONITOR, V24, P5668, DOI 10.12659/MSM.908756
   Li N, 2010, DEVELOPMENT, V137, P389, DOI 10.1242/dev.044164
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Li Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5486403
   Lin J, 2018, MOL MED REP, V18, P5594, DOI 10.3892/mmr.2018.9575
   Liu JJ, 2019, MED SCI MONITOR, V25, P7735, DOI 10.12659/MSM.919768
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Lü SW, 2015, J ETHNOPHARMACOL, V176, P177, DOI 10.1016/j.jep.2015.10.010
   Ma HC, 2015, INT J CLIN EXP MED, V8, P13446
   Ma JH, 2019, J ETHNOPHARMACOL, V231, P152, DOI 10.1016/j.jep.2018.10.040
   Meng ZQ, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/4637839
   Pawlik A, 2012, PHARMACOL REP, V64, P185, DOI 10.1016/S1734 1140(12)70745 4
   Ramírez Pelayo C, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01937
   Rawla Prashanth, 2019, Reumatologia (Warsaw), V57, P27, DOI 10.5114/reum.2019.83236
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Scherer HU, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102400
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Smith JF, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00080
   Tai J, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/7631365
   Truhlar DG, 2007, J COMPUT CHEM, V28, P73, DOI 10.1002/jcc.20529
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Xia BJ, 2014, CALCIFIED TISSUE INT, V95, P495, DOI 10.1007/s00223 014 9917 9
   Xiong YY, 2019, J CELL BIOCHEM, V120, P12461, DOI 10.1002/jcb.28513
   Xu XX, 2018, DRUG DES DEV THER, V12, P967, DOI 10.2147/DDDT.S161904
   Yang SH, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01629
   Yang X, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/8957245
   Yao Y, 2013, J ETHNOPHARMACOL, V150, P619, DOI 10.1016/j.jep.2013.09.018
   Yokota Kazuhiro, 2017, Nihon Rinsho Meneki Gakkai Kaishi, V40, P367, DOI 10.2177/jsci.40.367
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang JY, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68224 7
   Zhao Xiao Ping, 2017, Zhongguo Zhong Yao Za Zhi, V42, P4905, DOI 10.19540/j.cnki.cjcmm.2017.0217
   Zhou W, 2016, SCI REP UK, V6, DOI 10.1038/srep36985
NR 59
TC 8
Z9 8
U1 4
U2 49
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1476 9271
EI 1476 928X
J9 COMPUT BIOL CHEM
JI Comput. Biol. Chem.
PD DEC
PY 2020
VL 89
AR 107397
DI 10.1016/j.compbiolchem.2020.107397
PG 14
WC Biology; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Computer Science
GA PH6UK
UT WOS:000600544900010
PM 33035753
DA 2025 08 17
ER

PT J
AU Kim, JG
   Sharma, AR
   Lee, YH
   Chatterjee, S
   Choi, YJ
   Rajvansh, R
   Chakraborty, C
   Lee, SS
AF Kim, Jae Gyu
   Sharma, Ashish Ranjan
   Lee, Yeon Hee
   Chatterjee, Srijan
   Choi, Yean Jung
   Rajvansh, Roshani
   Chakraborty, Chiranjib
   Lee, Sang Soo
TI Therapeutic Potential of Quercetin as an Antioxidant for
   Bone Muscle Tendon Regeneration and Aging
SO AGING AND DISEASE
LA English
DT Article
DE Quercetin; Bioflavonoid; Oxidative stress; Musculoskeletal aging
ID NF KAPPA B; ACTIVATED PROTEIN KINASE; OSTEOBLAST DIFFERENTIATION;
   MITOCHONDRIAL BIOGENESIS; INDUCED INFLAMMATION; FLAVONOID QUERCETIN;
   SIGNALING PATHWAY; NATURAL PRODUCTS; CELLS; EXPRESSION
AB Quercetin (QC), a naturally occurring bioflavonoid found in various fruits and vegetables, possesses many potential health benefits, primarily attributed to its robust antioxidant properties. The generation of oxidative stress in bone cells is a key modulator of their physiological behavior. Moreover, oxidative stress status influences the pathophysiology of mineralized tissues. Increasing scientific evidence demonstrates that manipulating the redox balance in bone cells might be an effective technique for developing bone disease therapies. The QC antioxidant abilities in skeletal muscle significantly enhance muscle regeneration and reduce muscle atrophy. In addition, QC has been shown to have protective effects against oxidative stress, inflammation, apoptosis, and matrix degradation in tendons, helping to maintain the structural integrity and functionality of tendons. Thus, the antioxidant properties of QC might be crucial for addressing age related musculoskeletal disorders like osteoporosis, sarcopenia, and tendonrelated inflammatory conditions. Understanding how QC influences redox signaling pathways involved in musculoskeletal disorders, including their effect on bone, muscle, and tendon differentiation, might provide insights into the diverse advantages of QC in promoting tissue regeneration and preventing cellular damage. Therefore, this study reviewed the intricate relationship among oxidative stress, inflammation, and tissue repair, affected by the antioxidative abilities of QC, in age related musculoskeletal tissues to improve the overall health of bones, muscles, and tendons of the skeletal system. Also, reviewing the ongoing clinical trials of QC for musculoskeletal systems is encouraging. Given the positive effect of QC on musculoskeletal health, further scientific investigations and controlled human intervention studies are necessary to explore the therapeutic potential to its optimum strength.
C1 [Kim, Jae Gyu; Sharma, Ashish Ranjan; Lee, Yeon Hee; Chatterjee, Srijan; Choi, Yean Jung; Chakraborty, Chiranjib; Lee, Sang Soo] Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chunchon Si 24252, Gangwon Do, South Korea.
   [Choi, Yean Jung] Sahmyook Univ, Dept Food & Nutr, Seoul 01795, South Korea.
   [Chakraborty, Chiranjib] Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India.
C3 Hallym University; Sahmyook University
RP Lee, SS (通讯作者)，Hallym Univ, Chuncheon Sacred Heart Hosp, Inst Skeletal Aging & Orthoped Surg, Chunchon Si 24252, Gangwon Do, South Korea.
EM 123sslee@gmail.com
RI Lee, Sang Soo/LTD 5070 2024; Sharma, Ashish/W 4816 2019; Chakraborty,
   Chiranjib/J 4847 2013
OI Chatterjee, Srijan/0000 0002 8282 8324; 
FU Hallym University Research Fund; Basic Science Research Program through
   the National Research Foundation of Korea (NRF)   Ministry of Education
   [NRF 2020R1C1C1008694, NRF 2020R1I1A3074575, RS 2023 272748]; The
   "Regional Innovation Strategy (RIS) " through the NRF   Ministry of
   Education (MOE) [2022RIS 005]
FX This study was supported by the Hallym University Research Fund, the
   Basic Science Research Program through the National Research Foundation
   of Korea (NRF) funded by the Ministry of Education NRF 2020R1C1C1008694,
   NRF 2020R1I1A3074575 & RS 2023 272748) , and "Regional Innovation
   Strategy (RIS)" through the NRF funded by the Ministry of Education
   (MOE) (2022RIS 005) .For figures, some artworks were adapted from
   Servier Medical Art., licensed under a Creative Commons Attribution 4.0
   Unported License (https://creativecommons.org/licenses/by/4.0/)
CR Aditya NP, 2014, LWT FOOD SCI TECHNOL, V59, P115, DOI 10.1016/j.lwt.2014.04.058
   Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Aghababaei F, 2023, PHARMACEUTICALS BASE, V16, DOI 10.3390/ph16071020
   Ali IHA, 2014, BRIT J PHARMACOL, V171, P3620, DOI 10.1111/bph.12724
   Alway SE, 2015, J APPL PHYSIOL, V118, P319, DOI 10.1152/japplphysiol.00674.2014
   Anand David Alexander Victor, 2016, Pharmacogn Rev, V10, P84, DOI 10.4103/0973 7847.194044
   Andres S, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700447
   Babosova R, 2018, J MICROB BIOTEC FOOD, V7, P469, DOI 10.15414/jmbfs.2018.7.5.469 472
   Babosova R, 2016, ACTA VET SCAND, V58, DOI 10.1186/s13028 016 0225 4
   Bansal T, 2008, LIFE SCI, V83, P250, DOI 10.1016/j.lfs.2008.06.007
   Basaran E, 2022, EUR J PHARM SCI, V172, DOI 10.1016/j.ejps.2022.106153
   Granado Serrano AB, 2012, NUTR CANCER, V64, P588, DOI 10.1080/01635581.2012.661513
   Bell KE, 2016, J FRALITY AGING, V5, P33, DOI 10.14283/jfa.2016.78
   Bentzinger CF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008342
   Bian W, 2021, BMC COMPLEMENT MED, V21, DOI 10.1186/s12906 021 03418 8
   Bijlsma AY, 2012, AGEING RES REV, V11, P320, DOI 10.1016/j.arr.2012.01.001
   Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389
   Bosco F, 2021, PHARMACOL RES, V165, DOI 10.1016/j.phrs.2021.105427
   Braun KF, 2011, THESCIENTIFICWORLDJO, V11, P2348, DOI 10.1100/2011/471426
   Cai WT, 2018, DRUG DES DEV THER, V12, P4149, DOI 10.2147/DDDT.S185618
   Cancer IAfRo, 2012, AG CLASS IARC MON, V1 106
   Cao H, 2019, EXP THER MED, V18, P2451, DOI 10.3892/etm.2019.7851
   Caron AZ, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 185
   Casado Díaz A, 2016, J NUTR BIOCHEM, V32, P151, DOI 10.1016/j.jnutbio.2016.03.005
   Challoumas Dimitris, 2020, Fac Rev, V9, P16, DOI 10.12703/b/9 16
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JY, 2013, J BIOMED SCI, V20, DOI 10.1186/1423 0127 20 95
   Choi EM, 2012, EXP TOXICOL PATHOL, V64, P211, DOI 10.1016/j.etp.2010.08.008
   Choi JUA, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.770143
   Chow YY, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8293921
   Chuang CH, 2019, CHEM BIOL INTERACT, V306, P54, DOI 10.1016/j.cbi.2019.04.006
   Chung Hoe Jeong, 2022, Hip Pelvis, V34, P150, DOI 10.5371/hp.2022.34.3.150
   Cruz Jentoft AJ, 2019, LANCET, V393, P2636, DOI 10.1016/S0140 6736(19)31138 9
   Curcio M, 2012, J FUNCT BIOMATER, V3, DOI 10.3390/jfb3020269
   D'Andrea G, 2015, FITOTERAPIA, V106, P256, DOI 10.1016/j.fitote.2015.09.018
   Dabeek WM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102288
   Date AA, 2011, MOL PHARMACEUT, V8, P716, DOI 10.1021/mp100305h
   Davis JM, 2009, AM J PHYSIOL REG I, V296, pR1071, DOI 10.1152/ajpregu.90925.2008
   Davis TA, 2009, CURR OPIN CLIN NUTR, V12, P78, DOI 10.1097/MCO.0b013e32831cef9f
   Mota KSD, 2009, MOLECULES, V14, P979, DOI 10.3390/molecules14030979
   Dehghani F, 2023, CLIN NUTR ESPEN, V56, P73, DOI 10.1016/j.clnesp.2023.04.019
   Deng TT, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1338951
   Derakhshanian H, 2013, CAN J PHYSIOL PHARM, V91, P380, DOI 10.1139/cjpp 2012 0190
   Deshmukh Prashant, 2017, Biophys Rev, V9, P41, DOI 10.1007/s12551 016 0244 4
   Dey M, 2020, COLLOID SURFACE B, V196, DOI 10.1016/j.colsurfb.2020.111341
   Ding KX, 2023, REV BRAS FARMACOGN, V33, P502, DOI 10.1007/s43450 022 00347 6
   Ditsios K, 2003, J ORTHOPAED RES, V21, P990, DOI 10.1016/S0736 0266(03)00112 8
   Duan CX, 2022, CRYST GROWTH DES, V22, P4885, DOI 10.1021/acs.cgd.2c00370
   Durmaz Bekir, 2023, J Oral Biol Craniofac Res, V13, P22, DOI 10.1016/j.jobcr.2022.10.008
   Eid HM, 2010, MOL NUTR FOOD RES, V54, P991, DOI 10.1002/mnfr.200900218
   Ellingson AJ, 2022, EUR CELLS MATER, V43, P130, DOI 10.22203/eCM.v043a11
   Erlund I, 2000, EUR J CLIN PHARMACOL, V56, P545, DOI 10.1007/s002280000197
   Evans WJ, 2010, AM J CLIN NUTR, V91, p1123S, DOI 10.3945/ajcn.2010.28608A
   Fatemi MJ, 2018, ANN PLAS SURG, V80, P171, DOI 10.1097/SAP.0000000000001169
   Fatokun AA, 2015, NAT PROD RES, V29, P1127, DOI 10.1080/14786419.2014.980252
   Fayed HA, 2019, EUR J PHARMACOL, V865, DOI 10.1016/j.ejphar.2019.172785
   Fleming Braden C, 2005, Curr Opin Orthop, V16, P354, DOI 10.1097/01.bco.0000176423.07865.d2
   Forte L, 2017, J BIOMED MATER RES A, V105, P3293, DOI 10.1002/jbm.a.36192
   Forte L, 2016, ACTA BIOMATER, V32, P298, DOI 10.1016/j.actbio.2015.12.013
   Frisbee JC, 2019, J APPL PHYSIOL, V126, P626, DOI 10.1152/japplphysiol.00751.2018
   Gao L, 2011, INT J PHARMACEUT, V404, P231, DOI 10.1016/j.ijpharm.2010.11.009
   Giannouli M, 2018, MATER TODAY PROC, V5, P15998, DOI 10.1016/j.matpr.2018.05.044
   Gilley AD, 2017, CARBOHYD POLYM, V157, P86, DOI 10.1016/j.carbpol.2016.09.067
   Górniak I, 2019, PHYTOCHEM REV, V18, P241, DOI 10.1007/s11101 018 9591 z
   Gros J, 2005, NATURE, V435, P954, DOI 10.1038/nature03572
   Guerquin MJ, 2013, J CLIN INVEST, V123, P3564, DOI 10.1172/JCI67521
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Guo R, 2022, EPIGENETICS INSIGHTS, V15, DOI 10.1177/25168657211064232
   Guo Y, 2015, J NUTR BIOCHEM, V26, P201, DOI 10.1016/j.jnutbio.2014.10.008
   Guo Y, 2013, MOL NUTR FOOD RES, V57, P896, DOI 10.1002/mnfr.201200619
   Han J, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.813057
   Han MK, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp 2018 000392
   Hassan JK, 2018, ADV PHARMACOL PHARM, V6, P43, DOI 10.13189/app.2018.060202
   Hayeshi R, 2006, EUR J PHARM SCI, V29, P70, DOI 10.1016/j.ejps.2006.05.009
   Heiman Erick, 2022, Hip Pelvis, V34, P69, DOI 10.5371/hp.2022.34.2.69
   Heinz SA, 2010, PHARMACOL RES, V62, P237, DOI 10.1016/j.phrs.2010.05.001
   Hemdan DII, 2009, J MED INVESTIG, V56, P26, DOI 10.2152/jmi.56.26
   Hour TC, 2022, NUTRIENTS, V14, DOI 10.3390/nu14194106
   Hsu CL, 2006, MOL NUTR FOOD RES, V50, P1072, DOI 10.1002/mnfr.200600040
   Hsu TH, 2023, PLOS ONE, V18, DOI 10.1371/journal.pone.0291462
   Huang J, 2020, LWT FOOD SCI TECHNOL, V117, DOI 10.1016/j.lwt.2019.108615
   Huang L, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12010044
   Huang YJ, 2018, CELL PHYSIOL BIOCHEM, V49, P758, DOI 10.1159/000493040
   Hutcheson DA, 2009, GENE DEV, V23, P997, DOI 10.1101/gad.1769009
   Ishikawa Y, 2000, KIDNEY INT, V58, P1078, DOI 10.1046/j.1523 1755.2000.00265.x
   Janssen I, 2010, APPL PHYSIOL NUTR ME, V35, P707, DOI 10.1139/H10 067
   Jelinsky SA, 2011, J ORTHOP RES, V29, P1604, DOI 10.1002/jor.21427
   Jung ChangHwa Jung ChangHwa, 2013, Phytotherapy Research, V27, P139, DOI 10.1002/ptr.4687
   Jung WJ, 2004, BIOFACTORS, V21, P113, DOI 10.1002/biof.552210122
   Khan A, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01383
   Kim C, 2020, J MED FOOD, V23, P29, DOI 10.1089/jmf.2019.4426
   Kim DS, 2007, J CELL BIOCHEM, V101, P790, DOI 10.1002/jcb.21233
   Kim HR, 2019, J MED FOOD, V22, P152, DOI 10.1089/jmf.2018.4259
   Kim J, 2023, NUTRIENTS, V15, DOI 10.3390/nu15112625
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim Y, 2018, J MED FOOD, V21, P551
   Kobets T, 2022, FOODS, V11, DOI 10.3390/foods11182828
   Koshinaka K, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030729
   Lan DM, 2022, J MOL ENDOCRINOL, V69, P401, DOI 10.1530/JME 22 0086
   Le NH, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/834294
   Lee H, 2018, J PERIODONTAL RES, V53, P801, DOI 10.1111/jre.12569
   Lee J, 2012, J AGR FOOD CHEM, V60, P3874, DOI 10.1021/jf3001857
   Lee T, 2020, FOOD HYDROCOLLOID, V108, DOI 10.1016/j.foodhyd.2020.106086
   Legrand A, 2017, J HAND SURG AM, V42, P722, DOI 10.1016/j.jhsa.2017.06.013
   Lesjak M, 2018, J FUNCT FOODS, V40, P68, DOI 10.1016/j.jff.2017.10.047
   Li HW, 2021, DRUG DELIV, V28, P1226, DOI 10.1080/10717544.2021.1927244
   Li HL, 2009, J CONTROL RELEASE, V133, P238, DOI 10.1016/j.jconrel.2008.10.002
   Li KQ, 2019, J CELL PHYSIOL, V234, P18017, DOI 10.1002/jcp.28433
   Li SS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.717065
   Li Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030167
   Li YZ, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.1013449
   Li ZW, 2018, INT J CLIN EXP PATHO, V11, P5149
   Liang D, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1186712
   Liang Y, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03618 2
   Lipman K, 2018, DRUG DES DEV THER, V12, P591, DOI 10.2147/DDDT.S154660
   Liu K, 2020, CARBOHYD POLYM, V236, DOI 10.1016/j.carbpol.2020.116009
   Lojk J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910840
   Lui PPY, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23073571
   Manning CN, 2014, J ORTHOP RES, V32, P645, DOI 10.1002/jor.22575
   Mariee AD, 2012, PHARM BIOL, V50, P1019, DOI 10.3109/13880209.2012.655424
   Martinez Canton M, 2023, NUTRIENTS, V15, DOI 10.3390/nu15132848
   Martínez Flórez S, 2005, J NUTR, V135, P1359, DOI 10.1093/jn/135.6.1359
   Messer JG, 2016, J CELL PHYSIOL, V231, P2779, DOI 10.1002/jcp.25392
   Messer JG, 2015, J CELL BIOCHEM, V116, P1857, DOI 10.1002/jcb.25141
   Minode M, 2022, ADV POWDER TECHNOL, V33, DOI 10.1016/j.apt.2022.103582
   Mirza MA, 2023, PHARMACEUTICALS BASE, V16, DOI 10.3390/ph16111631
   Mohos V, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082306
   Moon HJ, 2013, J FOOD SCI, V78, pH785, DOI 10.1111/1750 3841.12116
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Mukai R, 2016, J NUTR BIOCHEM, V31, P67, DOI 10.1016/j.jnutbio.2016.02.001
   Mukai R, 2010, J NAT PROD, V73, P1708, DOI 10.1021/np100240y
   Mukund K, 2020, WIRES SYST BIOL MED, V12, DOI 10.1002/wsbm.1462
   Munguía L, 2022, J MED FOOD, V25, P465
   Murase T, 2008, AM J PHYSIOL REG I, V295, pR281, DOI 10.1152/ajpregu.00880.2007
   Nelson F, 2006, OSTEOARTHR CARTILAGE, V14, P114, DOI 10.1016/j.joca.2005.08.005
   Nikawa T, 2021, MOLECULES, V26, DOI 10.3390/molecules26164887
   Noshadi N, 2024, J FUNCT FOODS, V116, DOI 10.1016/j.jff.2024.106175
   Nourissat G, 2015, NAT REV RHEUMATOL, V11, P223, DOI 10.1038/nrrheum.2015.26
   Oh JH, 2019, ASIAN J PHARM SCI, V14, P621, DOI 10.1016/j.ajps.2018.12.003
   Otsuka Y, 2019, BIOCHEM BIOPHYS REP, V18, DOI 10.1016/j.bbrep.2019.100618
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41
   Pang XG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4178021
   Papiez MA, 2008, FOOD CHEM TOXICOL, V46, P3053, DOI 10.1016/j.fct.2008.06.006
   Park JY, 2016, BIOMOL THER, V24, P610, DOI 10.4062/biomolther.2016.026
   Parmar K., 2018, Orthopaedics and Trauma, V32, P241, DOI [10.1016/j.mporth.2018.05.008, DOI 10.1016/J.MPORTH.2018.05.008]
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Pizzino G., 2017, OXID MED CELL LONGEV, DOI [10.1155/2017/8416763, DOI 10.1155/2017/8416763]
   Powers SK, 2016, MED SCI SPORT EXER, V48, P2307, DOI 10.1249/MSS.0000000000000975
   Qaseem A, 2017, ANN INTERN MED, V166, P818, DOI 10.7326/M15 1361
   Qiu L, 2018, BIOMED PHARMACOTHER, V103, P1585, DOI 10.1016/j.biopha.2018.05.003
   Qu ZH, 2021, J NUTR BIOCHEM, V93, DOI 10.1016/j.jnutbio.2021.108619
   Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594
   Rezbarikova P, 2023, GEN PHYSIOL BIOPHYS, V42, P457, DOI 10.4149/gpb_2023020
   Ribbans WJ, 2022, LIFE BASEL, V12, DOI 10.3390/life12050663
   Rivera L, 2008, OBESITY, V16, P2081, DOI 10.1038/oby.2008.315
   Rosenberg IH, 1997, J NUTR, V127, pS990, DOI 10.1093/jn/127.5.990S
   Ruangsuriya J, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 02892 w
   Sakuma K, 2017, PFLUG ARCH EUR J PHY, V469, P573, DOI 10.1007/s00424 016 1933 3
   Sambasivan R, 2007, SEMIN CELL DEV BIOL, V18, P870, DOI 10.1016/j.semcdb.2007.09.013
   Sartori R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20123 1
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Schmalbruch H, 2000, MUSCLE NERVE, V23, P617, DOI 10.1002/(SICI)1097 4598(200004)23:4<617::AID MUS22>3.0.CO;2 Y
   Schoenfeld BJ, 2012, J STRENGTH COND RES, V26, P1441, DOI 10.1519/JSC.0b013e31824f207e
   Scott A, 2020, BRIT J SPORT MED, V54, P260, DOI 10.1136/bjsports 2019 100885
   Scott A, 2011, J ORTHOP RES, V29, P289, DOI 10.1002/jor.21220
   Semis HS, 2022, AM J SPORT MED, V50, P486, DOI 10.1177/03635465211059821
   Seo MJ, 2015, J NUTR BIOCHEM, V26, P1308, DOI 10.1016/j.jnutbio.2015.06.005
   Shao Y, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1479571
   Sharma AR, 2024, AGING DIS, V15, P1619, DOI 10.14336/AD.2023.00903
   Sharma AR, 2023, NUTRIENTS, V15, DOI 10.3390/nu15040919
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Sharma P, 2005, J BONE JOINT SURG AM, V87A, P187, DOI 10.2106/JBJS.D.01850
   Sheng YH, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1144878
   Shi XB, 2020, PHARM DEV TECHNOL, V25, P472, DOI 10.1080/10837450.2019.1709502
   Shoskes DA, 1999, UROLOGY, V54, P960, DOI 10.1016/S0090 4295(99)00358 1
   Siddiqui JA, 2011, MENOPAUSE, V18, P198, DOI 10.1097/gme.0b013e3181e84e67
   Soare A, 2014, AGING US, V6, P149
   Song JE, 2020, J BIOMED MATER RES A, V108, P784, DOI 10.1002/jbm.a.36857
   Tang BL, 2016, MOL CELLS, V39, P87, DOI 10.14348/molcells.2016.2318
   Tang J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7039802
   Tang SM, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109604
   Tsai CF, 2022, NUTRIENTS, V14, DOI 10.3390/nu14010067
   Tsuji M, 2009, J BONE MINER METAB, V27, P673, DOI 10.1007/s00774 009 0088 0
   Tu WJ, 2019, AGING DIS, V10, P637, DOI 10.14336/AD.2018.0513
   Tungmunnithum Duangjai, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030093
   van Kappel EC, 2017, BRIT J PHARMACOL, V174, P4575, DOI 10.1111/bph.13922
   Velázquez KT, 2014, J NUTR, V144, P868, DOI 10.3945/jn.113.188367
   Wang XJ, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20171056
   Wang XC, 2014, MOL MED REP, V10, P3320, DOI 10.3892/mmr.2014.2633
   Wang YH, 2004, LIFE SCI, V74, P1191, DOI 10.1016/j.lfs.2003.06.044
   Watanabe K, 2023, J INT SOC SPORT NUTR, V20, DOI 10.1080/15502783.2023.2265140
   Wattel A, 2004, J CELL BIOCHEM, V92, P285, DOI 10.1002/jcb.20071
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Wolffram S, 2002, J NUTR, V132, P630, DOI 10.1093/jn/132.4.630
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Wu C, 2023, NUTRIENTS, V15, DOI 10.3390/nu15183897
   Wu SH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082171
   Xiao JC, 2023, LIFE SCI, V322, DOI 10.1016/j.lfs.2022.121326
   Xing WM, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04321 1
   Xu B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200367
   Xu D, 2019, MOLECULES, V24, DOI 10.3390/molecules24061123
   Yamaguchi M, 2007, MOL CELL BIOCHEM, V303, P83, DOI 10.1007/s11010 007 9458 x
   Yamaguchi M, 2011, INT J MOL MED, V28, P521, DOI 10.3892/ijmm.2011.749
   Yoo Jun Il, 2022, Hip Pelvis, V34, P1, DOI 10.5371/hp.2022.34.1.1
   Yoshikawa T, 2022, BMC MUSCULOSKEL DIS, V23, DOI 10.1186/s12891 022 05513 4
   Yoshino M, 2015, J NUTR BIOCHEM, V26, P1193, DOI 10.1016/j.jnutbio.2015.05.010
   Yuan Z, 2018, AM J TRANSL RES, V10, P4313
   Yurteri A, 2023, JOINT DIS RELAT SURG, V34, P365, DOI 10.52312/jdrs.2023.870
   Zhang N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00325
   Zhang ZJ, 2020, INT J PHARMACEUT, V585, DOI 10.1016/j.ijpharm.2020.119500
   Zhang ZJ, 2019, CRYST GROWTH DES, V19, P3851, DOI 10.1021/acs.cgd.9b00294
   Zhou YN, 2017, J MATER CHEM B, V5, P612, DOI 10.1039/c6tb02312f
   Zhou YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129605
   Zhu CX, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.938526
NR 214
TC 9
Z9 9
U1 7
U2 18
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152 5250
J9 AGING DIS
JI Aging Dis.
PD JUN
PY 2025
VL 16
IS 3
BP 1414
EP 1437
DI 10.14336/AD.2024.0282
EA JUL 2024
PG 24
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 3EY6R
UT WOS:001267433700001
PM 39012676
OA gold
DA 2025 08 17
ER

PT J
AU Ma, AB
   Shang, HY
   Song, YJ
   Chen, B
   You, YP
   Han, W
   Zhang, X
   Zhang, WY
   Li, Y
   Li, CY
AF Ma, Aobo
   Shang, Haiyan
   Song, Yunjia
   Chen, Bo
   You, Yapeng
   Han, Wen
   Zhang, Xu
   Zhang, Wenyi
   Li, Ying
   Li, Changyi
TI Icariin Functionalized Coating on TiO2 Nanotubes Surface to
   Improve Osteoblast Activity In Vitro and Osteogenesis Ability In Vivo
SO COATINGS
LA English
DT Article
DE icariin; TiO2 nanotubes; PLGA coatings; controlled release; titanium;
   surface modification; osteogenesis
ID IMPLANT SURFACES; BONE; SCAFFOLD; DIFFERENTIATION; PROLIFERATION;
   OSTEOPOROSIS; MECHANISMS; ARRAYS; CELLS
AB Surface modification of titanium is encouraged to facilitate early osseointegration in dental and orthopedic fields. Icariin is the main active constituents of Herba Epimedii, which has good bone promoting ability. We established an icariin functionalized coating composed of icariin and poly (lactic co glycolic acid) (PLGA) on TiO2 nanotubes surface (NT ICA PLGA) to promote osteoblast cell activity and early osseointegration. Surface topography, wettability and drug release pattern of the established NT ICA PLGA surface were characterized by scanning electron microscopy (SEM), contact angle test and drug release test. MC3T3 E1 osteoblast cell activity tests were performed using SEM, immunofluorescent staining, cell counting kit 8 and alkaline phosphatase assays. The osteogenic effects of different surfaces were observed using a rat model. Surface characterization proved the successful fabrication of the icariin functionalized coating on the TiO2 nanotube structure, with increased wettability. The NT ICA PLGA substrate showed sustained release of icariin until two weeks. Osteoblast cells grown on the NT ICA PLGA substrate displayed improved cell adhesion, proliferation and differentiation ability than the control Ti surface. The in vivo experiment also revealed superior bone forming ability on the NT ICA PLGA surface, compared to the pure Ti control. These results imply that the developed NT ICA PLGA substrate has a promising future use as functionalized coating for implant surface modification.
C1 [Ma, Aobo; Shang, Haiyan; Song, Yunjia; Chen, Bo; You, Yapeng; Han, Wen; Zhang, Xu; Zhang, Wenyi; Li, Ying; Li, Changyi] Tianjin Med Univ, Sch Dent, Tianjin 300070, Peoples R China.
C3 Tianjin Medical University
RP Li, Y; Li, CY (通讯作者)，Tianjin Med Univ, Sch Dent, Tianjin 300070, Peoples R China.
EM maaobo@tmu.edu.cn; shanghaiyan@tmu.edu.cn; songyunjia@tmu.edu.cn;
   chenbo@tmu.edu.cn; youyapeng@tmu.edu.cn; hanwen@tmu.edu.cn;
   zhangxu@tmu.edu.cn; zhangwenyi@tmu.edu.cn; yingli@tmu.edu.cn;
   lichangyi@tmu.edu.cn
RI ; Li, Ying/R 2373 2018; Li, Changyi/GVS 6654 2022; chen,
   bo/AAC 7188 2022
OI Ma, Aobo/0000 0003 3151 7523; Li, Ying/0000 0003 2314 9599; 
FU National Natural Science Foundation of China [81870809, 81500886,
   31470920]; Tianjin Natural Science Foundation [16JCYBJC28700]; Natural
   Science Foundation of Hebei Province of China [E2017202032]
FX This study was supported by grants from National Natural Science
   Foundation of China (Nos. 81870809, 81500886, 31470920), Tianjin Natural
   Science Foundation (No. 16JCYBJC28700) and Natural Science Foundation of
   Hebei Province of China (No. E2017202032).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169 409X(97)00048 3
   Aw MS, 2014, BIOMATER SCI UK, V2, P10, DOI 10.1039/c3bm60196j
   Calciolari E, 2018, J PERIODONTAL RES, V53, P598, DOI 10.1111/jre.12550
   Cheng Y, 2018, J MATER CHEM B, V6, P1862, DOI 10.1039/c8tb00149a
   Ehrenfest DMD, 2010, TRENDS BIOTECHNOL, V28, P198, DOI 10.1016/j.tibtech.2009.12.003
   Ercan B, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/29/295102
   Feng RJ, 2013, CELL BIOCHEM BIOPHYS, V67, P189, DOI 10.1007/s12013 013 9533 8
   Gentile P, 2014, INT J MOL SCI, V15, P3640, DOI 10.3390/ijms15033640
   Kankala RK, 2018, MATERIALS, V11, DOI 10.3390/ma11081390
   Khudhair D, 2016, MAT SCI ENG C MATER, V59, P1125, DOI 10.1016/j.msec.2015.10.042
   Kulkarni M, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957 4484/26/6/062002
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Lai YX, 2018, BIOMATERIALS, V153, P1, DOI 10.1016/j.biomaterials.2017.10.025
   Liu H, 2017, MAT SCI ENG C MATER, V79, P399, DOI 10.1016/j.msec.2017.05.077
   Liu YJ, 2017, CELL PHYSIOL BIOCHEM, V41, P1605, DOI 10.1159/000470896
   Losic D, 2015, EXPERT OPIN DRUG DEL, V12, P103, DOI 10.1517/17425247.2014.945418
   Losic D, 2009, EXPERT OPIN DRUG DEL, V6, P1363, DOI 10.1517/17425240903300857
   Offermanns V, 2018, INT J NANOMED, V13, P2189, DOI 10.2147/IJN.S161061
   Qin L, 2015, BIOMATERIALS, V59, P125, DOI 10.1016/j.biomaterials.2015.04.038
   Rani VVD, 2012, ACTA BIOMATER, V8, P1976, DOI 10.1016/j.actbio.2012.01.021
   Reiter T, 2019, BIOACT MATER, V4, P1, DOI 10.1016/j.bioactmat.2018.10.001
   Roy P, 2011, ANGEW CHEM INT EDIT, V50, P2904, DOI 10.1002/anie.201001374
   Schmitt B, 2003, DIFFERENTIATION, V71, P567, DOI 10.1111/j.1432 0436.2003.07109003.x
   Shan LJ, 2019, MATERIALS, V12, DOI 10.3390/ma12050815
   Song YY, 2009, J AM CHEM SOC, V131, P4230, DOI 10.1021/ja810130h
   Stan MS, 2015, J BIOMED MATER RES A, V103, P48, DOI 10.1002/jbm.a.35148
   Sun SJ, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6138 1
   Sun XD, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951 019 0447 5
   von Wilmowsky C, 2012, CLIN ORAL IMPLAN RES, V23, P359, DOI 10.1111/j.1600 0501.2010.02139.x
   Vyatskikh A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03071 9
   Wang Q, 2017, INT J NANOMED, V12, DOI 10.2147/IJN.S117498
   Wang ZC, 2018, MOL MED REP, V17, P8237, DOI 10.3892/mmr.2018.8913
   Wu P, 2006, BIOMATERIALS, V27, P2450, DOI 10.1016/j.biomaterials.2005.11.031
   Wu T, 2009, CHINESE SCI BULL, V54, P2953, DOI 10.1007/s11434 009 0250 z
   Yang JR, 2018, ACTA BIOMATER, V74, P156, DOI 10.1016/j.actbio.2018.05.005
   Yin LH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07759 8
   Yu WQ, 2010, J BIOMED MATER RES A, V94A, P1012, DOI 10.1002/jbm.a.32687
   Yu WQ, 2015, COLLOID SURFACE B, V136, P779, DOI 10.1016/j.colsurfb.2015.10.019
   Zhang X, 2014, PHYTOTHER RES, V28, P498, DOI 10.1002/ptr.5027
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
NR 41
TC 20
Z9 20
U1 0
U2 49
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 2079 6412
J9 COATINGS
JI Coatings
PD MAY
PY 2019
VL 9
IS 5
AR 327
DI 10.3390/coatings9050327
PG 17
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science; Physics
GA IN6SG
UT WOS:000478810800047
OA gold
DA 2025 08 17
ER

PT J
AU Shin, HR
   Bae, HS
   Kim, BS
   Yoon, HI
   Cho, YD
   Kim, WJ
   Choi, KY
   Lee, YS
   Woo, KM
   Baek, JH
   Ryoo, HM
AF Shin, H. R.
   Bae, H. S.
   Kim, B. S.
   Yoon, H., I
   Cho, Y. D.
   Kim, W. J.
   Choi, K. Y.
   Lee, Y. S.
   Woo, K. M.
   Baek, J. H.
   Ryoo, H. M.
TI PIN1 is a new therapeutic target of craniosynostosis
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID FACTOR RECEPTOR 2 FGFR2; PROLYL ISOMERASE PIN1; HUMAN APERT SYNDROME;
   OSTEOBLAST DIFFERENTIATION; BONE DEVELOPMENT; S252W MUTATION; MOUSE
   MODELS; CELL CYCLE; IN VIVO; GROWTH
AB Gain of function mutations in fibroblast growth factor receptors (FGFRs) cause congenital skeletal anomalies, including craniosynostosis (CS), which is characterized by the premature closure of craniofacial sutures. Apert syndrome (AS) is one of the severest forms of CS, and the only treatment is surgical expansion of prematurely fused sutures in infants. Previously, we demonstrated that the prolyl isomerase peptidyl prolyl cis trans isomerase interacting 1 (PIN1) plays a critical role in mediating FGFR signaling and that Pin1(+/ ) mice exhibit delayed closure of cranial sutures. In this study, using both genetic and pharmacological approaches, we tested whether PIN1 modulation could be used as a therapeutic regimen against AS. In the genetic approach, we crossbred Fgfr2(S252W/+), a mouse model of AS, and Pin(1+/ ) mice. Downregulation of Pin1 gene dosage attenuated premature cranial suture closure and other phenotypes of AS in Fgfr2(S252W/+) mutant mice. In the pharmacological approach, we intraperitoneally administered juglone, a PIN1 enzyme inhibitor, to pregnant Fgfr2(S252W/+) mutant mice and found that this treatment successfully interrupted fetal development of AS phenotypes. Primary cultured osteoblasts from Fgfr2(S252W/+) mutant mice expressed high levels of FGFR2 downstream target genes, but this phenotype was attenuated by PIN1 inhibition. Post translational stabilization and activation of Runt related transcription factor 2 (RUNX2) in Fgfr2(S252W/+) osteoblasts were also attenuated by PIN1 inhibition. Based on these observations, we conclude that PIN1 enzyme activity is important for FGFR2 induced RUNX2 activation and craniofacial suture morphogenesis. Moreover, these findings highlight that juglone or other PIN1 inhibitors represent viable alternatives to surgical intervention for treatment of CS and other hyperostotic diseases.
C1 [Shin, H. R.; Bae, H. S.; Kim, B. S.; Yoon, H., I; Cho, Y. D.; Kim, W. J.; Lee, Y. S.; Woo, K. M.; Baek, J. H.; Ryoo, H. M.] Seoul Natl Univ, Sch Dent, Dept Mol Genet & Dent Pharmacol & Therapeut, BK21 Program, Seoul 08826, South Korea.
   [Shin, H. R.; Bae, H. S.; Kim, B. S.; Yoon, H., I; Cho, Y. D.; Kim, W. J.; Lee, Y. S.; Woo, K. M.; Baek, J. H.; Ryoo, H. M.] Seoul Natl Univ, Dent Res Inst, Seoul 08826, South Korea.
   [Cho, Y. D.] Seoul Natl Univ, Sch Dent, Dept Periodontol, Seoul 110749, South Korea.
   [Choi, K. Y.] Kyungpook Natl Univ, Sch Med, Dept Plast & Reconstruct Surg, Daegu 41566, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Kyungpook National University (KNU)
RP Ryoo, HM (通讯作者)，Seoul Natl Univ, Sch Dent, Dept Mol Genet & Dent Pharmacol, Room 404,Bldg 86,1 Kwanak Ro, Seoul 08826, South Korea.
EM hmryoo@snu.ac.kr
RI Cho, Young Dan/AAR 4573 2021; Woo, Kyung/A 2793 2009; Ryoo,
   Hyun Mo/D 5839 2012; Baek, Jeong Hwa/A 8628 2012
OI Ryoo, Hyun Mo/0000 0001 6769 8341; 
FU General Researcher Program of the National Research Foundation of Korea
   [NRF 2014R1A2A2A01004865, NRF 2017R1A2B3011778]
FX General Researcher Program of the National Research Foundation of Korea
   (NRF 2014R1A2A2A01004865, NRF 2017R1A2B3011778).
CR Aithal KB, 2012, INTEGR CANCER THER, V11, P68, DOI 10.1177/1534735411403477
   Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475
   Avci E, 2016, GENE, V588, P74, DOI 10.1016/j.gene.2016.05.001
   Bae H. S., 2017, J BONE MINER RES
   Bagheri Fam S, 2015, HUM MOL GENET, V24, P6699, DOI 10.1093/hmg/ddv374
   Chao SH, 2001, NUCLEIC ACIDS RES, V29, P767, DOI 10.1093/nar/29.3.767
   Chen L, 2003, BONE, V33, P169, DOI 10.1016/S8756 3282(03)00222 9
   Chen LJ, 2005, XENOBIOTICA, V35, P1019, DOI 10.1080/00498250500356621
   Chen P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087311
   Cho Y, 2015, J DENT RES, V94, P491, DOI 10.1177/0022034514566432
   Cho YD, 2016, J CELL PHYSIOL, V231, P1484, DOI 10.1002/jcp.25183
   Clendenning DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036789
   Cowan CM, 2003, J BIOL CHEM, V278, P32005, DOI 10.1074/jbc.M304698200
   Deckelbaum RA, 2006, DEVELOPMENT, V133, P63, DOI 10.1242/dev.02171
   Derderian Christopher, 2012, Semin Plast Surg, V26, P64, DOI 10.1055/s 0032 1320064
   Du XL, 2010, J ANAT, V217, P97, DOI 10.1111/j.1469 7580.2010.01248.x
   Faedo A, 2010, J NEUROSCI, V30, P4015, DOI 10.1523/JNEUROSCI.0307 10.2010
   Fakhry A, 2005, BONE, V36, P254, DOI 10.1016/j.bone.2004.10.003
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736
   Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200
   Grande MA, 1997, J CELL SCI, V110, P1781
   Hennig L, 1998, BIOCHEMISTRY US, V37, P5953, DOI 10.1021/bi973162p
   Heuzé Y, 2014, BONE, V63, P101, DOI 10.1016/j.bone.2014.03.003
   Holmes G, 2009, DEV BIOL, V328, P273, DOI 10.1016/j.ydbio.2009.01.026
   Hsu T, 2001, NAT CELL BIOL, V3, P538, DOI 10.1038/35078508
   Iborra FJ, 1996, EXP CELL RES, V229, P167, DOI 10.1006/excr.1996.0355
   Ibrahimi OA, 2004, HUM MOL GENET, V13, P2313, DOI 10.1093/hmg/ddh235
   Islam R., 2016, J CELL PHYSL
   Islam R, 2017, J CELL PHYSIOL, V232, P2339, DOI 10.1002/jcp.25442
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jeong HG, 2009, J IMMUNOL, V183, P6689, DOI 10.4049/jimmunol.0901431
   Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487
   Jin SW, 2016, J KOREAN NEUROSURG S, V59, P192, DOI 10.3340/jkns.2016.59.3.192
   Johnson D, 2011, EUR J HUM GENET, V19, P369, DOI 10.1038/ejhg.2010.235
   Kim HJ, 2004, J CELL BIOCHEM, V91, P1239, DOI 10.1002/jcb.20038
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kim W. J., 2016, J CELL PHYSL
   Kim WJ, 2017, J CELL PHYSIOL, V232, P2798, DOI 10.1002/jcp.25673
   Koca TT, 2016, NORTH CLIN ISTANB, V3, P135, DOI 10.14744/nci.2015.30602
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860
   Lee YC, 2017, SCI REP UK, V7, DOI 10.1038/srep43220
   Maga AM, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00092
   Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955 0674(98)80007 0
   Miura T, 2009, J ANAT, V215, P642, DOI 10.1111/j.1469 7580.2009.01148.x
   Morriss Kay GM, 2005, J ANAT, V207, P637, DOI 10.1111/j.1469 7580.2005.00475.x
   Nakamura K, 2012, MOL CELL BIOL, V32, P2966, DOI 10.1128/MCB.05688 11
   Park MH, 2001, J BONE MINER RES, V16, P885, DOI 10.1359/jbmr.2001.16.5.885
   Park OJ, 2010, J BIOL CHEM, V285, P3568, DOI 10.1074/jbc.M109.055053
   PARK WJ, 1995, AM J HUM GENET, V57, P321
   Perrine SMM, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00369
   Phupong Vorapong, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P977
   Purushothaman R, 2011, BIRTH DEFECTS RES A, V91, P603, DOI 10.1002/bdra.20811
   Quarto N, 2006, TISSUE ENG, V12, P1405, DOI 10.1089/ten.2006.12.1405
   Quarto N, 2009, CELLS TISSUES ORGANS, V190, P158, DOI 10.1159/000202789
   Reese S, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755 1536 3 1
   Rice David P, 2008, Front Oral Biol, V12, pxi
   Robin NH., 1993, Genereviews((r))
   Ruan MZC, 2016, MOL THER METH CLIN D, V3, DOI 10.1038/mtm.2016.8
   Ruan MZC, 2013, ARTHRITIS RHEUM US, V65, P388, DOI 10.1002/art.37766
   Saling SC, 2011, TOXICOL APPL PHARM, V257, P319, DOI 10.1016/j.taap.2011.09.004
   Shin HR, 2016, J BIOL CHEM, V291, P5555, DOI 10.1074/jbc.M115.698563
   Shukla V, 2007, NAT GENET, V39, P1145, DOI 10.1038/ng2096
   Slaney SF, 1996, AM J HUM GENET, V58, P923
   Smith TG, 2005, DEVELOPMENT, V132, P1305, DOI 10.1242/dev.01699
   Su N, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.3
   Szentirmay MN, 2000, NUCLEIC ACIDS RES, V28, P2019, DOI 10.1093/nar/28.10.2019
   Tanimoto Y, 2004, J BIOL CHEM, V279, P45926, DOI 10.1074/jbc.M404824200
   Tanimoto Y, 2012, J BIOL CHEM, V287, P21429, DOI 10.1074/jbc.M112.362145
   Teven CM, 2014, GENES DIS, V1, P199, DOI 10.1016/j.gendis.2014.09.005
   Twigg SRF, 2015, AM J HUM GENET, V97, P359, DOI 10.1016/j.ajhg.2015.07.006
   Wang YL, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 22
   Wang YL, 2005, DEVELOPMENT, V132, P3537, DOI 10.1242/dev.01914
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Yang F, 2008, BONE, V43, P55, DOI 10.1016/j.bone.2008.02.008
   Yin L, 2008, BONE, V42, P631, DOI 10.1016/j.bone.2007.11.019
   Yoon WJ, 2015, J CELL PHYSIOL, V230, P640, DOI 10.1002/jcp.24787
   Yoon WJ, 2014, J BIOL CHEM, V289, P8828, DOI 10.1074/jbc.M113.516237
   Yoon WJ, 2013, J CELL PHYSIOL, V228, P2377, DOI 10.1002/jcp.24403
   Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536
   Zhang Wei, 2015, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V31, P186
NR 83
TC 18
Z9 20
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964 6906
EI 1460 2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV
PY 2018
VL 27
IS 22
BP 3827
EP 3839
DI 10.1093/hmg/ddy252
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA HD4YT
UT WOS:000452535200001
PM 30007339
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Marsell, R
   Sisask, G
   Nilsson, Y
   Sundgren Andersson, AK
   Andersson, U
   Larsson, S
   Nilsson, O
   Ljunggren, Ö
   Jonsson, KB
AF Marsell, Richard
   Sisask, Gregor
   Nilsson, Yvonne
   Sundgren Andersson, Anna K.
   Andersson, Ulf
   Larsson, Sune
   Nilsson, Olle
   Ljunggren, Osten
   Jonsson, Kenneth B.
TI GSK 3 inhibition by an orally active small molecule increases bone mass
   in rats
SO BONE
LA English
DT Article
DE GSK 3; Osteoporosis; BMD; Wnt; beta Catenin; Bone formation
ID LRP5 GENE; MICE; DIFFERENTIATION; OSTEOPOROSIS; OSTEOBLAST;
   METAANALYSIS; MUTATIONS; FRACTURES; THERAPIES; PROTEINS
AB Glycogen synthase kinase 3 beta (GSK 3 beta) actions are central in the canonical Wnt pathway, important in many biological processes and a potential drug target for treating several diseases. It is appreciated that a balanced Wnt canonical signaling is crucial for the maintenance of normal bone mass. In this study we investigated the effects of a potent orally active GSK 3 inhibitor, AZD2858, on bone mass in rats.
   Treatment (1 mu M) of human osteoblast cells with AZD2858 in vitro increased beta catenin levels after a short period of time. In rats, oral AZD2858 treatment caused a dose dependent increase in trabecular bone mass compared to control after a two week treatment with a maximum effect at a dose of 20 mg/kg once daily (total BMC: 172% of control; p<0.001). A small but significant effect was also seen at cortical sites (total BMC: 111% of control; p<0.001). Biomechanical testing demonstrated an increase in both vertebral compression strength at a dose of 20 mg/kg once daily (Load at failure: 370% of control, p<0.001) and diaphyseal strength of femora subjected to a three point bending test (Load at failure: 115% of control; p<0.01). Furthermore, histomorphometry showed a dramatic increase in bone formation indices, and serum markers of both bone formation (Osteocalcin, 146% of control: p<0.001) and resorption (CTX, 189% of control; p<0.001) were elevated.
   Our conclusion is that a GSK 3 inhibitor drug may prove effective as an anabolic strategy in the treatment of diseases characterized by low bone mass, since AZD2858 has extensive bone building effects at predominantly trabecular sites. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Marsell, Richard; Sisask, Gregor; Larsson, Sune; Nilsson, Olle; Jonsson, Kenneth B.] Univ Uppsala Hosp, Dept Surg Sci, SE 75185 Uppsala, Sweden.
   [Nilsson, Yvonne; Sundgren Andersson, Anna K.] AstraZeneca R&D Sodertalje, SE 15185 Sodertalje, Sweden.
   [Andersson, Ulf] AstraZeneca R&D, Toxicol Sci, Global Safety Assessment, SE 43183 Molndal, Sweden.
   [Ljunggren, Osten] Uppsala Univ, Dept Med Sci, SE 75185 Uppsala, Sweden.
C3 Uppsala University; Uppsala University Hospital; AstraZeneca;
   AstraZeneca; Uppsala University
RP Jonsson, KB (通讯作者)，Univ Uppsala Hosp, Dept Surg Sci, SE 75185 Uppsala, Sweden.
EM Richard.Marsell@surgsci.uu.se; Gregor.Sisask@akademiska.se;
   yvonne.nilsson@astrazeneca.com; anna.sundgren andersson@astrazeneca.com;
   ulf.andersson@astrazeneca.com; Sune.Larsson@surgsci.uu.se;
   Olle.Nilsson@surgsci.uu.se; Osten.Ljunggren@medsci.uu.se;
   Kenneth.Jonsson@surgsci.uu.se
RI , kenneth/GPF 8006 2022; Sundgren, Anna/AAJ 4180 2020
FU AstraZeneca; Stiftelsen Konsul Thure Karlssons Minne; Uppsala University
FX The study was financed by AstraZeneca and by research grants from
   Stiftelsen Konsul Thure Karlssons Minne. The study was also supported by
   Uppsala University.
CR Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Bhat RV, 2004, J NEUROCHEM, V89, P1313, DOI 10.1111/j.1471 4159.2004.02422.x
   Boonen S, 2005, OSTEOPOROSIS INT, V16, P1291, DOI 10.1007/s00198 005 1945 x
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Grisanti M, 2006, ASBMR ANN M PHIL US
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064 006 9128 5
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   McCombs JS, 2004, MATURITAS, V48, P271, DOI 10.1016/j.maturitas.2004.02.005
   Moon RT., 2005, Sci STKE
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Mussmann R, 2007, J BIOL CHEM, V282, P12030, DOI 10.1074/jbc.M609637200
   NAKAMURA K, 1985, ANAL BIOCHEM, V148, P311, DOI 10.1016/0003 2697(85)90234 9
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P45, DOI 10.1007/s00198 006 0204 0
   Wang FS, 2007, BONE, V40, P485, DOI 10.1016/j.bone.2006.09.004
NR 30
TC 60
Z9 69
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD MAR
PY 2012
VL 50
IS 3
BP 619
EP 627
DI 10.1016/j.bone.2011.11.007
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 897KR
UT WOS:000300650100006
PM 22142634
DA 2025 08 17
ER

PT J
AU Shymanskyi, I
   Lisakovska, O
   Mazanova, A
   Labudzynskyi, D
   Veliky, M
AF Shymanskyi, Ihor
   Lisakovska, Olha
   Mazanova, Anna
   Labudzynskyi, Dmytro
   Veliky, Mykola
TI Vitamin D3 Modulates Impaired Crosstalk Between RANK and
   Glucocorticoid Receptor Signaling in Bone Marrow Cells After Chronic
   Prednisolone Administration
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE prednisolone; osteoporosis; vitamin D; vitamin D receptor;
   glucocorticoid receptor; RANKL/RANK/osteoprotegerin axis; nuclear factor
   kappa B; osteoclastogenesis
ID NF KAPPA B; INDUCED OSTEOPOROSIS; 1,25 DIHYDROXYVITAMIN D 3; OSTEOCLAST
   PRECURSORS; GENE EXPRESSION; MECHANISMS; DIFFERENTIATION;
   OSTEOPROTEGERIN; ACTIVATION; BIOLOGY
AB The effectiveness of vitamin D 3 (cholecalciferol) in counteracting the side effects of glucocorticoid (GC) therapy has been demonstrated previously. Abnormalities in systemic hormonal and local (cytokine) regulation of bone marrow (BM) cells may underlie GC induced imbalance between osteosynthesis and bone resorption. The cytokine system receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) is considered as an integrating link in the NF kappa B mediated interaction of various cells involved in maintaining osteoblastic osteoclastic balance, which makes it a pharmacological target for regulation and correction of the bone remodeling process. We studied GC induced impairments of the RANKL/RANK/OPG axis in BM cells depending on vitamin D bioavailability and whether these changes were mediated by glucocorticoid (GR) and/or vitamin D (VDR) receptors. Female Wistar rats administered with prednisolone (5 mg/kg b.w., 30 days) showed a decrease in the GR protein level and the number of GR positive BM cells. GC caused a marked elevation of RANKL and RANK levels in BM, while OPG decreased. Flow cytometry data indicated GC elicited increase in the number of circulating RANK positive osteoclast precursors (OCPs) in BM, peripheral blood, and spleen. In full accordance with the data that the interaction of RANKL RANK leads to transcriptional activation of NF kappa B and subsequent differentiation of osteoclasts, we found an increase in the level of phosphorylated p65 subunit of NF kappa B with a simultaneous decrease in the NF kappa B inhibitor (I kappa B) level. These changes were accompanied by vitamin D insufficiency and downregulated expression of CYP27B1 and VDR, which are responsible for synthesis and hormonal signaling of 1,25(OH)(2)D. Notably, we observed VDR and RANK co localization in OCPs. Cholecalciferol co administration (1,000 IU/kg b.w., 30 days) with prednisolone resulted in elevated GR synthesis in BM. Cholecalciferol prevented prednisolone elicited disturbances of the RANKL/RANK/OPG, which correlated with improved bioavailability and vitamin D signaling through VDR. This caused the lowering of phosphoNF kappa B p65 level and inhibiting NF kappa B translocation to the nucleus that could reduce the circulating OCPs pool in BM, peripheral blood, and spleen. Our findings suggest that prednisolone induced abnormalities in GR and RANKL/RANK/OPG signaling pathways are associated with the impairments of vitamin D auto/paracrine system in BM cells and can be ameliorated by cholecalciferol supplementation.
C1 [Shymanskyi, Ihor; Lisakovska, Olha; Mazanova, Anna; Labudzynskyi, Dmytro; Veliky, Mykola] Natl Acad Sci Ukraine, Palladin Inst Biochem, Dept Biochem Vitamins & Coenzymes, Kiev, Ukraine.
C3 National Academy of Sciences Ukraine; Palladin Institute of Biochemistry
   of NASU
RP Shymanskyi, I (通讯作者)，Natl Acad Sci Ukraine, Palladin Inst Biochem, Dept Biochem Vitamins & Coenzymes, Kiev, Ukraine.
EM ihorshym@gmail.com
RI Lisakovska, Olha/ABE 5999 2020; Veliky, Mykola/AAC 5644 2019; Mazanova,
   Anna/D 3319 2017; Labudzynskyi, Dmytro/NHP 7591 2025; Labudzynskyi,
   Dmytro/JLM 0765 2023
OI Veliky, Mykola/0000 0002 8125 308X; Shymanskyi,
   Ihor/0000 0002 1507 8906; Lisakovska, Olha/0000 0002 5844 1453;
   Mazanova, Anna/0000 0002 3211 5094; Labudzynskyi,
   Dmytro/0000 0003 4389 6049
FU research grant of the interdisciplinary program "Molecular and cellular
   biotechnology for medicine" of the National Academy of Sciences of
   Ukraine [32]
FX This work was supported by a research grant of the interdisciplinary
   program "Molecular and cellular biotechnology for medicine" (No. 32) of
   the National Academy of Sciences of Ukraine.
CR Bikle DD, 2012, CURR OSTEOPOROS REP, V10, P151, DOI 10.1007/s11914 012 0098 z
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   Briot K, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2014 000014
   Cheng Q, 2011, NUCLEIC ACIDS RES, V39, P9605, DOI 10.1093/nar/gkr656
   Cohen Lahav M, 2006, NEPHROL DIAL TRANSPL, V21, P889, DOI 10.1093/ndt/gfi254
   Cruz Topete D, 2015, NEUROIMMUNOMODULAT, V22, P20, DOI 10.1159/000362724
   Ferreira GB, 2012, J PROTEOME RES, V11, P941, DOI 10.1021/pr200724e
   Fierro FA, 2017, STEM CELLS, V35, P1461, DOI 10.1002/stem.2625
   Fraser LA, 2009, THER ADV MUSCULOSKEL, V1, P71, DOI 10.1177/1759720X09343729
   Geusens P, 2012, THER ADV MUSCULOSKEL, V4, P225, DOI 10.1177/1759720X12438080
   Gu JH, 2015, J STEROID BIOCHEM, V152, P25, DOI 10.1016/j.jsbmb.2015.04.003
   Haussler MR, 2011, BEST PRACT RES CL EN, V25, P543, DOI 10.1016/j.beem.2011.05.010
   Hidalgo AA, 2010, J STEROID BIOCHEM, V121, P372, DOI 10.1016/j.jsbmb.2010.03.081
   Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jungblut Melanie, 2008, J Vis Exp, DOI 10.3791/1029
   Jusu S, 2018, ENDOCRINOLOGY, V159, P1303, DOI 10.1210/en.2017 03098
   Kai M, 2009, FEBS LETT, V583, P3265, DOI 10.1016/j.febslet.2009.09.017
   Kim HJ, 2010, BMB REP, V43, P524, DOI 10.5483/BMBRep.2010.43.8.524
   Kim S, 2006, MOL CELL BIOL, V26, P6469, DOI 10.1128/MCB.00353 06
   Kim YH, 2006, ARCH PHARM RES, V29, P691, DOI 10.1007/BF02968254
   Kohli Sarvraj Singh, 2011, Indian J Endocrinol Metab, V15, P175, DOI 10.4103/2230 8210.83401
   Kondo T, 2008, J CELL BIOCHEM, V103, P335, DOI 10.1002/jcb.21414
   Löwenberg M, 2008, STEROIDS, V73, P1025, DOI 10.1016/j.steroids.2007.12.002
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Nakamichi Y, 2012, P NATL ACAD SCI USA, V109, P10006, DOI 10.1073/pnas.1207361109
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007
   Pike JW, 2010, ENDOCRIN METAB CLIN, V39, P255, DOI 10.1016/j.ecl.2010.02.007
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Shi CG, 2014, BONE, V68, P67, DOI 10.1016/j.bone.2014.08.004
   Shymanskyi IO, 2017, B SUSTAVY POZVONOCHN, V7, P93, DOI [10.22141/2224 1507.7.3.2017.116863, DOI 10.22141/2224 1507.7.3.2017.116863]
   Spath L, 2017, SCI REP UK, V7, DOI 10.1038/srep40370
   Stahn C, 2008, NAT CLIN PRACT RHEUM, V4, P525, DOI 10.1038/ncprheum0898
   Takahashi Naoyuki, 2014, Bonekey Rep, V3, P495, DOI 10.1038/bonekey.2013.229
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Widén C, 2003, BIOCHEM J, V373, P211, DOI 10.1042/BJ20030175
   Wu AC, 2012, AM J RESP CRIT CARE, V186, P508, DOI 10.1164/rccm.201202 0351OC
   Zofkova I, 2017, PHYSIOL RES, V66, pS341, DOI 10.33549/physiolres.933720
NR 46
TC 19
Z9 21
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JUN 7
PY 2018
VL 9
AR 303
DI 10.3389/fendo.2018.00303
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GI5EH
UT WOS:000434393300001
PM 29930537
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Nakano, A
   Miki, H
   Nakamura, S
   Harada, T
   Oda, A
   Amou, H
   Fujii, S
   Kagawa, K
   Takeuchi, K
   Ozaki, S
   Matsumoto, T
   Abe, M
AF Nakano, Ayako
   Miki, Hirokazu
   Nakamura, Shingen
   Harada, Takeshi
   Oda, Asuka
   Amou, Hiroe
   Fujii, Shiro
   Kagawa, Kumiko
   Takeuchi, Kyoko
   Ozaki, Shuji
   Matsumoto, Toshio
   Abe, Masahiro
TI Up regulation of hexokinaseII in myeloma cells: targeting myeloma cells
   with 3 bromopyruvate
SO JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
LA English
DT Article
DE Multiple myeloma; Gycolysis; Hexokinase II; 3 bromopyruvate; Osteoclast
ID OSTEOBLAST DIFFERENTIATION; OSTEOLYTIC LESIONS; GLUCOSE CATABOLISM; ABC
   TRANSPORTERS; BONE DISEASE; CANCER CELLS; PROTEIN; GLYCOLYSIS;
   RESISTANCE; INHIBITOR
AB Hexokinase II (HKII), a key enzyme of glycolysis, is widely over expressed in cancer cells. However, HKII levels and its roles in ATP production and ATP dependent cellular process have not been well studied in hematopoietic malignant cells including multiple myeloma (MM) cells. We demonstrate herein that HKII is constitutively over expressed in MM cells. 3 bromopyruvate (3BrPA), an inhibitor of HKII, promptly and substantially suppresses ATP production and induces cell death in MM cells. Interestingly, cocultures with osteoclasts (OCs) but not bone marrow stromal cells (BMSCs) enhanced the phosphorylation of Akt along with an increase in HKII levels and lactate production in MM cells. The enhancement of HKII levels and lactate production in MM cells by OCs were mostly abrogated by the PI3K inhibitor LY294002, suggesting activation of glycolysis in MM cells by OCs via the PI3K Akt HKII pathway. Although BMSCs and OCs stimulate MM cell growth and survival, 3BrPA induces cell death in MM cells even in cocultures with OCs as well as BMSCs. Furthermore, 3BrPA was able to diminish ATP dependent ABC transporter activity to restore drug retention in MM cells in the presence of OCs. These results may underpin possible clinical application of 3BrPA in patients with MM.
C1 [Nakano, Ayako; Miki, Hirokazu; Nakamura, Shingen; Harada, Takeshi; Oda, Asuka; Amou, Hiroe; Fujii, Shiro; Kagawa, Kumiko; Matsumoto, Toshio; Abe, Masahiro] Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan.
   [Takeuchi, Kyoko] Tokushima Univ Hosp, Div Transfus Med, Tokushima, Japan.
   [Ozaki, Shuji] Tokushima Prefectural Hosp, Div Internal Med, Tokushima, Japan.
C3 Tokushima University; Tokushima University
RP Abe, M (通讯作者)，Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM masabe@clin.med.tokushima u.ac.jp
RI Nakamura, Shingen/GPX 5438 2022; Abe, Masahiro/AAJ 3032 2021
FU National Cancer Center Research and Development; Grants in Aid for
   Scientific Research [23591390] Funding Source: KAKEN
FX This work was supported in part by Grants in aid for Scientific Research
   (C) to M.A., and National Cancer Center Research and Development Fund to
   M.A. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228
   Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Abe M, 2011, INT J HEMATOL, V94, P334, DOI 10.1007/s12185 011 0949 x
   Asano J, 2011, LEUKEMIA, V25, P1182, DOI 10.1038/leu.2011.60
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Chen Z, 2009, BBA BIOENERGETICS, V1787, P553, DOI 10.1016/j.bbabio.2009.03.003
   Cheng L, 2011, EXPERT REV ANTICANC, V11, P1131, DOI [10.1586/era.11.82, 10.1586/ERA.11.82]
   Choi SJ, 2000, BLOOD, V96, P671
   de Figueiredo Pontes LL, 2008, CYTOM PART B CLIN CY, V74B, P163, DOI 10.1002/cyto.b.20403
   Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911 009 9109 9
   Draoui N, 2011, DIS MODEL MECH, V4, P727, DOI 10.1242/dmm.007724
   Ehrlich LA, 2005, BLOOD, V106, P1407, DOI 10.1182/blood 2005 03 1080
   Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789
   Ge Y, 2006, BRIT J HAEMATOL, V133, P83, DOI 10.1111/j.1365 2141.2006.05976.x
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901
   Hiasa M, 2009, BLOOD, V114, P4517, DOI 10.1182/blood 2009 04 215020
   Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI 10.2217/FON.09.145
   Kim W, 2007, MOL CANCER THER, V6, P2554, DOI 10.1158/1535 7163.MCT 07 0115
   Ko YH, 2001, CANCER LETT, V173, P83, DOI 10.1016/S0304 3835(01)00667 X
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev cellbio 092910 154237
   Mahindra A, 2010, BLOOD REV, V24, pS5, DOI 10.1016/S0268 960X(10)70003 5
   Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603
   Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006
   MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918
   Nakano A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027222
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863 007 9094 x
   Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P1, DOI 10.1007/s10863 007 9070 5
   Roodman GD, 2010, J BONE MINER METAB, V28, P244, DOI 10.1007/s00774 009 0154 7
   SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014 5793(91)81102 E
   Standal T, 2007, BLOOD, V109, P3024, DOI 10.1182/blood 2006 07 034884
   Stiles BL, 2009, ADV DRUG DELIVER REV, V61, P1276, DOI 10.1016/j.addr.2009.07.017
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470
   Yaccoby S, 2008, LEUKEMIA, V22, P406, DOI 10.1038/sj.leu.2405048
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Yaccoby S, 2010, BRIT J HAEMATOL, V149, P311, DOI 10.1111/j.1365 2141.2010.08141.x
   Zhang XD, 2006, ANTICANCER RES, V26, P3561
NR 42
TC 44
Z9 51
U1 1
U2 23
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0145 479X
EI 1573 6881
J9 J BIOENERG BIOMEMBR
JI J. Bioenerg. Biomembr.
PD FEB
PY 2012
VL 44
IS 1
BP 31
EP 38
DI 10.1007/s10863 012 9412 9
PG 8
WC Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Cell Biology
GA 913AF
UT WOS:000301843000004
PM 22298254
DA 2025 08 17
ER

PT J
AU Konstantinou, E
   Zagoriti, Z
   Pyriochou, A
   Poulas, K
AF Konstantinou, Evangelia
   Zagoriti, Zoi
   Pyriochou, Anastasia
   Poulas, Konstantinos
TI Microcurrent Stimulation Triggers MAPK Signaling and TGF β1 Release in
   Fibroblast and Osteoblast Like Cell Lines
SO CELLS
LA English
DT Article
DE electrical stimulation; fibroblasts; osteoblast like cells; signaling
   pathways
ID ELECTRICAL STIMULATION; WOUND REPAIR; FIELDS; ANGIOGENESIS; IMPAIRMENT;
   EXPRESSION; THERAPY; PATHWAY
AB Wound healing constitutes an essential process for all organisms and involves a sequence of three phases. The disruption or elongation of any of these phases can lead to a chronic or non healing wound. Electrical stimulation accelerates wound healing by mimicking the current that is generated in the skin after any injury. Here, we sought to identify the molecular mechanisms involved in the healing process following in vitro microcurrent stimulation a type of electrotherapy. Our results concluded that microcurrents promote cell proliferation and migration in an ERK 1/2  or p38 dependent way. Furthermore, microcurrents induce the secretion of transforming growth factor beta 1 (TGF beta 1) in fibroblasts and osteoblast like cells. Interestingly, transcriptomic analysis uncovered that microcurrents enhance the transcriptional activation of genes implicated in Hedgehog, TGF beta 1 and MAPK signaling pathways. Overall, our results demonstrate that microcurrents may enhance wound closure through a combination of signal transductions, via MAPK's phosphorylation, and the transcriptional activation of specific genes involved in the healing process. These mechanisms should be further examined in vivo, in order to verify the beneficial effects of microcurrents in wound or fracture healing.
C1 [Konstantinou, Evangelia; Zagoriti, Zoi; Pyriochou, Anastasia; Poulas, Konstantinos] Univ Patras, Dept Pharm, Lab Mol Biol & Immunol, Rion 26504, Greece.
C3 University of Patras
RP Poulas, K (通讯作者)，Univ Patras, Dept Pharm, Lab Mol Biol & Immunol, Rion 26504, Greece.
EM ekonstan@upatras.gr; zoizag@upatras.gr; apyriohou@upatras.gr;
   kpoulas@upatras.gr
RI Poulas, Konstantinos/L 4874 2018
OI Poulas, Konstantinos/0000 0002 5397 1543
FU project "Synthetic Biology: From omics technologies to genomic
   engineering (OMIC ENGINE)"   Operational Programme "Competitiveness,
   Entrepreneurship and Innovation" (NSRF 2014 2020) [MIS 5002636];
   European Union (European Regional Development Fund); Hellenic Foundation
   for Research and Innovation
FX This work was supported by the project "Synthetic Biology: From omics
   technologies to genomic engineering (OMIC ENGINE)" (MIS 5002636) which
   is implemented under the Action "Reinforcement of the Research and
   Innovation Infrastructure", funded by the Operational Programme
   "Competitiveness, Entrepreneurship and Innovation" (NSRF 2014 2020) and
   co financed by Greece and the European Union (European Regional
   Development Fund). E.K. was funded by 1st PhD fellowship from Hellenic
   Foundation for Research and Innovation.
CR Aaron RK, 2004, CLIN ORTHOP RELAT R, P21, DOI 10.1097/01.blo.0000118699.26862.41
   Arvaniti E, 2016, SCI REP UK, V6, DOI 10.1038/srep26235
   Bayat M, 2006, J REHABIL RES DEV, V43, P219, DOI 10.1682/JRRD.2005.05.0089
   Castana O, 2013, INT J LOW EXTR WOUND, V12, P18, DOI 10.1177/1534734613476517
   Ciombor Deborah McK, 2005, Foot Ankle Clin, V10, P579, DOI 10.1016/j.fcl.2005.06.006
   Cooper L, 2005, GENOME BIOL, V6
   Crignis E.D., 2020, bioRxiv, DOI 10.1101/568147
   Gonzalez ACD, 2016, AN BRAS DERMATOL, V91, P614
   desJardins Park HE, 2018, REGEN MED, V13, P491, DOI 10.2217/rme 2018 0073
   Di Mauro C, 2017, BRIT J CANCER, V116, P1425, DOI 10.1038/bjc.2017.116
   Diegelmann RF, 2004, FRONT BIOSCI LANDMRK, V9, P283, DOI 10.2741/1184
   dos Santos Silva MA, 2017, EXP BIOL MED, V242, P358, DOI 10.1177/1535370216675066
   Driskell RR, 2013, NATURE, V504, P277, DOI 10.1038/nature12783
   Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337
   Falanga V, 2005, LANCET, V366, P1736, DOI 10.1016/S0140 6736(05)67700 8
   FOULDS IS, 1983, BRIT J DERMATOL, V109, P515, DOI 10.1111/j.1365 2133.1983.tb07673.x
   GENTZKOW GD, 1993, J DERMATOL SURG ONC, V19, P753, DOI 10.1111/j.1524 4725.1993.tb00420.x
   Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125
   Harrington Christina A, 2009, J Ocul Biol Dis Infor, V2, P243
   Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481
   Hunckler J, 2017, J MULTIDISCIP HEALTH, V10, DOI 10.2147/JMDH.S127207
   Isseroff RR, 2012, ADV WOUND CARE, V1, P238, DOI 10.1089/wound.2011.0351
   Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037
   Karagianni P, 2020, CELL REP, V30, P1319, DOI 10.1016/j.celrep.2020.01.006
   Lagoumintzis G, 2019, BIOSENSORS BASEL, V9, DOI 10.3390/bios9030107
   Laurendeau I, 2010, MOL MED, V16, P262, DOI 10.2119/molmed.2010.00005
   Le H, 2008, WOUND REPAIR REGEN, V16, P768, DOI 10.1111/j.1524 475X.2008.00430.x
   Lee BY, 2007, ADV THER, V24, P1202, DOI 10.1007/BF02877766
   Lohmann CH, 2000, J ORTHOP RES, V18, P637, DOI 10.1002/jor.1100180417
   McCaig CD, 2009, J CELL SCI, V122, P4267, DOI 10.1242/jcs.023564
   Medicherla S, 2009, DIABET METAB SYND OB, V2, P91
   Messerli MA, 2011, BIOL BULL US, V221, P79, DOI 10.1086/BBLv221n1p79
   Moulos P, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.73
   Moulos P, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1273
   Nishimura KY, 1996, J CELL SCI, V109, P199
   Olczyk Pawel, 2014, Biomed Res Int, V2014, P747584, DOI 10.1155/2014/747584
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Pinter M, 2013, UNITED EUR GASTROENT, V1, P265, DOI 10.1177/2050640613496605
   Pucihar G, 2001, BIOELECTROCHEMISTRY, V54, P107, DOI 10.1016/S1567 5394(01)00117 7
   Ramadhinara A, 2013, ADV SKIN WOUND CARE, V26, P1, DOI 10.1097/01.ASW.0000425942.32993.e9
   Reid B, 2014, ADV WOUND CARE, V3, P184, DOI 10.1089/wound.2013.0442
   Reinke JM, 2012, EUR SURG RES, V49, P35, DOI 10.1159/000339613
   Shaw TJ, 2009, J CELL SCI, V122, P3209, DOI 10.1242/jcs.031187
   Sheikh AQ, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0548
   dos Santos MPS, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41540 3
   Sun YS, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5289041
   Taghian T, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0153
   Todd I, 2001, ATLA ALTERN LAB ANIM, V29, P693, DOI 10.1177/026119290102900611
   Ud Din S, 2014, HEALTHCARE BASEL, V2, P445, DOI 10.3390/healthcare2040445
   Ud Din S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124502
   Wang ET, 2003, INVEST OPHTH VIS SCI, V44, P244, DOI 10.1167/iovs.02 0456
   Wirsing PG, 2015, INT WOUND J, V12, P693, DOI 10.1111/iwj.12204
   Zhao M, 2004, J CELL SCI, V117, P397, DOI 10.1242/jcs.00868
   Zhao M, 2006, NATURE, V442, P457, DOI 10.1038/nature04925
   Zhu ZX, 2017, EXP CELL RES, V355, P83, DOI 10.1016/j.yexcr.2017.03.054
NR 56
TC 25
Z9 25
U1 5
U2 41
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD SEP
PY 2020
VL 9
IS 9
AR 1924
DI 10.3390/cells9091924
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA OD9VX
UT WOS:000580192900001
PM 32825091
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Anastasilakis, AD
   Papachatzopoulos, S
   Makras, P
   Gkiomisi, A
   Nikolakopoulos, P
   Polyzos, SA
   Ntenti, C
   Ballaouri, I
   Gerou, S
   Tsachouridou, O
   Papatheodorou, A
   Aliazis, K
   Fermanoglou, S
   Bisbinas, I
   Yavropoulou, MP
AF Anastasilakis, Athanasios D.
   Papachatzopoulos, Stergios
   Makras, Polyzois
   Gkiomisi, Athina
   Nikolakopoulos, Panagiotis
   Polyzos, Stergios A.
   Ntenti, Charikleia
   Ballaouri, Iris
   Gerou, Spyridon
   Tsachouridou, Olga
   Papatheodorou, Athanasios
   Aliazis, Konstantinos
   Fermanoglou, Sofia
   Bisbinas, Ilias
   Yavropoulou, Maria P.
TI The effect of pharmacological cessation and restoration of menstrual
   cycle on bone metabolism in premenopausal women with endometriosis
SO BONE
LA English
DT Article
DE Menstrual cessation; GnRH analog; Bone mineral density; Bone turnover
   markers; Sclerostin; Circulating miRNA
ID HORMONE AGONIST THERAPY; MINERAL DENSITY; GNRH AGONIST; SYMPTOMATIC
   ENDOMETRIOSIS; OSTEOBLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN;
   ESTROGEN DEFICIENCY; OVARIAN SUPPRESSION; SCLEROSTIN LEVELS; NAFARELIN
AB Introduction: GnRH analogs induce bone loss. We aimed to investigate the effects of goserelin induced menstrual cessation (MC) and subsequent menstrual restoration (MR) on bone metabolism (BM).
   Methods: In this prospective cohort study, premenopausal women (PMW) with histologically verified endometriosis (n = 21) received goserelin monthly for 6 months (6 m) resulting in MC and were followed up for another 6 m after MR (12 m). Age  and BMI matched healthy PMW (n = 20) served as controls for bone mineral density (BMD) measurements. The primary endpoint was changes in lumbar spine (LS) BMD at 6 m and 12 m; Secondary endpoints were changes in femoral neck (FN) BMD, bone turnover markers (P1NP and CTx), sclerostin, and expression of bone related circulating microRNAs (miRNAs) at 6 m and 12 m.
   Results: Goserelin induced MC reduced LS  and FN BMD at 6 m (both p < 0.001). From 6 m to 12 m, LS BMD increased (p < 0.001) but remained below baseline values (p = 0.012), whereas FN BMD remained stable (p = 1.000). CTx and P1NP levels increased at 6 m (both p < 0.001) and decreased at 12 m (p < 0.001 and p = 0.013, respectively), while CTx (p = 1.000) alone and not P1NP (p = 0.020) returned to baseline. Sclerostin levels did not change. Relative expression of miRNAs targeting RUNX 2 and beta catenin was significantly downregulated at 6 m compared to baseline (p < 0.001), while the expression of miRNAs targeting osteoblast and osteoclast function at both directions demonstrated a robust increase (up to 400fold) at 12 m (p < 0.001).
   Conclusions: Six months of goserelin induced MC lead to significant bone loss associated with increased bone turnover and changes in the expression of bone related miRNAs, changes that are only partially reversed at 6 m after MR.
C1 [Anastasilakis, Athanasios D.] 424 Gen Mil Hosp, Dept Endocrinol, Thessaloniki, Greece.
   [Papachatzopoulos, Stergios; Gkiomisi, Athina; Nikolakopoulos, Panagiotis] 424 Gen Mil Hosp, Dept Obstet & Gynaecol, Thessaloniki, Greece.
   [Makras, Polyzois; Papatheodorou, Athanasios; Aliazis, Konstantinos] 251 Hellen Air Force & VA Gen Hosp, Dept Endocrinol & Diabet, Dept Med Res, Athens, Greece.
   [Polyzos, Stergios A.; Ntenti, Charikleia] Aristotle Univ Thessaloniki, Sch Med, Lab Pharmacol 1, Thessaloniki, Greece.
   [Ballaouri, Iris; Gerou, Spyridon] Anal Labs, Thessaloniki, Greece.
   [Tsachouridou, Olga] AHEPA Hosp, Dept Internal Med 1, Thessaloniki, Greece.
   [Fermanoglou, Sofia] 424 Gen Mil Hosp, Dept Orthopaed 1, Thessaloniki, Greece.
   [Bisbinas, Ilias] AHEPA Hosp, Dept Clin Densitometry, Thessaloniki, Greece.
   [Yavropoulou, Maria P.] Natl & Kapodistrian Univ Athens, Med Sch, Dept Propaedeut & Internal Med 1, Endocrinol Unit, Athens, Greece.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki; Ahepa University Hospital; Aristotle University of
   Thessaloniki; Ahepa University Hospital; National & Kapodistrian
   University of Athens
RP Anastasilakis, AD (通讯作者)，Ring Rd,564 29 N Efkarpia, Thessaloniki, Greece.
EM a.anastasilakis@gmail.com
RI Polyzos, Stergios/H 2844 2019; Anastasilakis, Athanasios/AAF 7669 2020;
   Ntenti, Charikleia/AAK 8600 2021; Nikolakopoulos,
   Panagiotis/J 7684 2019; Makras, Polyzois/AAF 5871 2020; Yavropoulou,
   Maria/AAW 8768 2020
OI Anastasilakis, Athanasios/0000 0002 9624 6296; Aliazis,
   Konstantinos/0000 0003 1954 7914; Ntenti, Charikleia/0000 0003 3769 9903
CR Adamson GD, 1997, AM J OBSTET GYNECOL, V177, P1413, DOI 10.1016/S0002 9378(97)70084 X
   ADASHI EY, 1994, HUM REPROD, V9, P1380, DOI 10.1093/oxfordjournals.humrep.a138715
   Agarwal SK, 2002, J REPROD MED, V47, P530
   Anastasilakis AD, 2018, J CLIN ENDOCR METAB, V103, P1206, DOI 10.1210/jc.2017 02406
   Andreyko J L, 1987, Obstet Gynecol Surv, V42, P1
   Arfat Y, 2018, MOL THER NUCL ACIDS, V11, P323, DOI 10.1016/j.omtn.2017.11.009
   BIANCHI S, 1995, CALCIFIED TISSUE INT, V57, P78, DOI 10.1007/BF00299002
   Borderie D, 1998, CALCIFIED TISSUE INT, V62, P21, DOI 10.1007/s002239900388
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   COMPSTON JE, 1995, BONE, V16, P261, DOI 10.1016/8756 3282(94)00038 2
   Dai Y, 2021, J CELL BIOCHEM, V122, P1251, DOI 10.1002/jcb.29497
   DAMEWOOD MD, 1989, FERTIL STERIL, V52, P596
   DEVOGELAER JP, 1987, LANCET, V1, P1498
   Dmowski WP, 1996, FERTIL STERIL, V66, P929, DOI 10.1016/S0015 0282(16)58685 3
   DODIN S, 1991, OBSTET GYNECOL, V77, P410
   Fernandez H, 2004, HUM REPROD, V19, P1465, DOI 10.1093/humrep/deh250
   Fujita K, 2014, J CLIN ENDOCR METAB, V99, pE81, DOI 10.1210/jc.2013 3249
   GOLAN A, 1989, FERTIL STERIL, V52, P406
   Hamdy Ronald C, 2002, J Clin Densitom, V5 Suppl, pS11, DOI 10.1385/JCD:5:3S:S11
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P701, DOI 10.1210/jcem 67 4 701
   Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243
   Kennedy S, 2005, HUM REPROD, V20, P2698, DOI 10.1093/humrep/dei135
   Khosla S, 2005, J CLIN ENDOCR METAB, V90, P5096, DOI 10.1210/jc.2005 0396
   KLIBANSKI A, 1988, J CLIN ENDOCR METAB, V67, P124, DOI 10.1210/jcem 67 1 124
   KURABAYASHI T, 1993, J ENDOCRINOL, V138, P115, DOI 10.1677/joe.0.1380115
   LEATHER AT, 1993, OBSTET GYNECOL, V81, P104
   Lee Y, 2013, BONE, V56, P383, DOI 10.1016/j.bone.2013.07.007
   Li Y, 2015, MOL THER, V23, P1349, DOI 10.1038/mt.2015.101
   Lupoli G, 1997, J ENDOCRINOL INVEST, V20, P493, DOI 10.1007/BF03348007
   Makita K, 2005, J BONE MINER METAB, V23, P389, DOI 10.1007/s00774 005 0618 3
   Matsuo H, 2004, FERTIL STERIL, V81, P149, DOI 10.1016/j.fertnstert.2003.05.022
   MATTA WHM, 1989, BRIT J OBSTET GYNAEC, V96, P200, DOI 10.1111/j.1471 0528.1989.tb01663.x
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   NENCIONI T, 1991, GYNECOL ENDOCRINOL, V5, P49, DOI 10.3109/09513599109049941
   NEWHALLPERRY K, 1995, AM J OBSTET GYNECOL, V173, P824, DOI 10.1016/0002 9378(95)90348 8
   ORWOLL ES, 1994, AM J OBSTET GYNECOL, V171, P1221, DOI 10.1016/0002 9378(94)90136 8
   Paoletti AM, 1996, FERTIL STERIL, V65, P707, DOI 10.1016/S0015 0282(16)58200 4
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   RITTMASTER RS, 1988, J CLIN ENDOCR METAB, V67, P651, DOI 10.1210/jcem 67 4 651
   ROCK JA, 1993, OBSTET GYNECOL, V82, P198
   Sagsveen M., 2003, COCHRANE DB SYST REV
   SCHARLA SH, 1990, J CLIN ENDOCR METAB, V70, P1055, DOI 10.1210/jcem 70 4 1055
   SCIALLI AR, 1993, FERTIL STERIL, V59, P674
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Simberg N, 1996, J CLIN ENDOCR METAB, V81, P646, DOI 10.1210/jc.81.2.646
   STEVENSON JC, 1989, HORM RES, V32, P161, DOI 10.1159/000181335
   SURREY ES, 1992, J CLIN ENDOCR METAB, V75, P558, DOI 10.1210/jc.75.2.558
   Szulc P, 2017, OSTEOPOROSIS INT, V28, P2541, DOI 10.1007/s00198 017 4082 4
   Taga M, 1996, ACTA OBSTET GYN SCAN, V75, P162, DOI 10.3109/00016349609033310
   TUMMON IS, 1988, FERTIL STERIL, V49, P792
   UEMURA T, 1994, FERTIL STERIL, V62, P246
   WAIBELTREBER S, 1989, HUM REPROD, V4, P384, DOI 10.1093/oxfordjournals.humrep.a136912
   Wang SL, 2020, MOL MED REP, V21, P1125, DOI 10.3892/mmr.2020.10938
   WHEELER JM, 1993, AM J OBSTET GYNECOL, V169, P26, DOI 10.1016/0002 9378(93)90126 4
   WHITEHOUSE RW, 1990, CLIN ENDOCRINOL, V33, P365, DOI 10.1111/j.1365 2265.1990.tb00501.x
   Yavropoulou MP, 2018, J MUSCULOSKEL NEURON, V18, P18
   Yavropoulou M.P., 2020, J CLIN ENDOCR METAB, V105, DOI DOI 10.1210/clinem/dgaa368
   Yavropoulou MP, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8120601
   Yavropoulou MP, 2017, EUR J ENDOCRINOL, V176, P169, DOI 10.1530/EJE 16 0583
   Zondervan KT, 2020, NEW ENGL J MED, V382, P1244, DOI 10.1056/NEJMra1810764
NR 63
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2022
VL 158
AR 116354
DI 10.1016/j.bone.2022.116354
EA FEB 2022
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZZ8ZQ
UT WOS:000773553300007
PM 35150909
DA 2025 08 17
ER

PT J
AU Sun, YL
   Chen, ZH
   Li, DJ
   Zhao, F
   Ma, XL
   Shang, P
   Yang, TM
   Qian, AR
AF Sun, Yu long
   Chen, Zhi hao
   Li, Di jie
   Zhao, Fan
   Ma, Xiao li
   Shang, Peng
   Yang, Tuanming
   Qian, Airong
TI Neuropeptide FF Inhibits LPS Mediated Osteoclast Differentiation of
   RAW264.7 Cells
SO PROTEIN AND PEPTIDE LETTERS
LA English
DT Article
DE Bone resorption; LPS; Neuropeptide FF; NPFFR2; Osteoclast; RF9
ID TUMOR NECROSIS FACTOR; NF KAPPA B; NITRIC OXIDE; NPFF RECEPTORS;
   OSTEOPROTEGERIN LIGAND; TRANSCRIPTION FACTOR; MORPHINE ANALGESIA;
   BONE RESORPTION; PEPTIDES; LIPOPOLYSACCHARIDE
AB Neuropeptide FF (NPFF) has been implicated in many physiological processes. Previously, we have reported that NPFF modulates the viability and nitric oxide (NO) production of RAW264.7 macrophages. In this study, we investigated the influence of NPFF on lipopolysaccharide (LPS) mediated osteoclast formation of RAW264.7 cells. Our results suggest that, NPFF dose dependently (1 nM, 10 nM and 100 nM) inhibited osteoclast formation, TRAP enzyme activity and bone resorption in osteoclasts induced by LPS respectively. Moreover, LPS provoked NO release was also inhibited by NPFF treatment, indicating a NO dependent pathway is mainly involved. Furthermore, the alterations of osteoclast marker genes were also assessed including TRAP, Cathepsin K, MMP 9, NFATc1 and Runx2. NPFF downregulated LPS caused gene augmentations of TRAP, Cathepsin K and MMP 9, whereas showed no influences on NFATc1 and Runx2. In addition, NPFF receptor 2 (NPFFR2) mRNA expression was also augmented in response to NPFF treatment, hinting the involvement of NPFFR2 pathway. It should be mentioned that RF9 (1 mu M), a reported pharmacological inhibitor for NPFF receptors, exerted NPFF like agonist properties as to attenuate osteoclastogenesis. Collectively, our findings provide new evidence for the in vitro activity of NPFF on osteoclasts, which may be helpful to extend the scope of NPFF functions.
C1 [Sun, Yu long; Chen, Zhi hao; Li, Di jie; Zhao, Fan; Ma, Xiao li; Shang, Peng; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Inst Special Environm Biophys, Key Lab Space Biosci & Biotechnol, Xian 710072, Peoples R China.
   [Yang, Tuanming] Xi An Jiao Tong Univ, Hong Hui Hosp, Coll Med, Xian 710054, Shaan Xi Provin, Peoples R China.
C3 Northwestern Polytechnical University; Xi'an Jiaotong University
RP Yang, TM (通讯作者)，Xi An Jiao Tong Univ, Hong Hui Hosp, Coll Med, South Door Slightly Friendship Rd 555, Xian 710054, Shaan Xi Provin, Peoples R China.
EM doctoryangtm@163.com; qianair@nwpu.edu.cn
RI Sun, Yulong/E 6722 2010; Li, Dijie/KVB 3667 2024; yulong,
   sun/E 6722 2010; Chen, Zhihao/ACK 3514 2022; chen, zhihao/GXM 3816 2022
OI Sun, Yulong/0000 0002 6811 5926; Chen, Zhihao/0000 0003 0128 1409; 
FU National Natural Science Foundation of China [81401553]; China
   Postdoctoral Science Foundation [2014M552492]; Fundamental Research
   Funds for the Central Universities [3102014JKY15010]; 973 Program
   [2011CB710903]
FX We are grateful to the anonymous reviewers for their constructive
   criticisms and suggestions. This work was supported by grants from the
   National Natural Science Foundation of China (No. 81401553), the China
   Postdoctoral Science Foundation (No. 2014M552492), the Fundamental
   Research Funds for the Central Universities (No. 3102014JKY15010), and
   the 973 Program (No. 2011CB710903).
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Akhtar J, 2012, INT J PHARMACEUT, V434, P429, DOI 10.1016/j.ijpharm.2012.06.012
   Änkö ML, 2006, J NEUROCHEM, V96, P573, DOI 10.1111/j.1471 4159.2005.03581.x
   Bonini JA, 2000, J BIOL CHEM, V275, P39324, DOI 10.1074/jbc.M004385200
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Caraty A, 2012, J NEUROENDOCRINOL, V24, P725, DOI 10.1111/j.1365 2826.2012.02283.x
   Elhabazi K, 2013, NEUROPHARMACOLOGY, V75, P164, DOI 10.1016/j.neuropharm.2013.07.012
   Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200
   Fang Q, 2005, PEPTIDES, V26, P791, DOI 10.1016/j.peptides.2004.12.009
   Fang Q, 2008, REGUL PEPTIDES, V147, P45, DOI 10.1016/j.regpep.2007.12.007
   Fang Q, 2010, PEPTIDES, V31, P683, DOI 10.1016/j.peptides.2009.11.003
   Findeisen M, 2012, J MED CHEM, V55, P6124, DOI 10.1021/jm300535s
   Fukusumi S, 2006, PEPTIDES, V27, P1073, DOI 10.1016/j.peptides.2005.06.031
   Gaubert G, 2009, J MED CHEM, V52, P6511, DOI 10.1021/jm9011998
   GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jhamandas J. H., 2013, FRONTIERS ENDOCRINOL, DOI [10.3389/fendo.2013.00008, DOI 10.3389/FEND0.2013.00008]
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kotani M, 2001, BRIT J PHARMACOL, V133, P138, DOI 10.1038/sj.bjp.0704038
   Kotlinska JH, 2012, PEPTIDES, V33, P156, DOI 10.1016/j.peptides.2011.12.002
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lameh J, 2010, J PHARMACOL EXP THER, V334, P244, DOI 10.1124/jpet.109.164384
   LECRON JC, 1992, J NEUROIMMUNOL, V38, P1, DOI 10.1016/0165 5728(92)90084 X
   Li SF, 2014, BONE, V61, P164, DOI 10.1016/j.bone.2014.01.010
   Lian JB, 2013, J BONE MINER RES, V28, P2060, DOI 10.1002/jbmr.2076
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200
   Maletínská L, 2013, BRAIN RES, V1498, P33, DOI 10.1016/j.brainres.2012.12.037
   Malin DH, 1996, PEPTIDES, V17, P615, DOI 10.1016/0196 9781(96)00035 6
   Martínez Ruiz A, 2011, FREE RADICAL BIO MED, V51, P17, DOI 10.1016/j.freeradbiomed.2011.04.010
   MINAULT M, 1995, PEPTIDES, V16, P105, DOI 10.1016/0196 9781(94)00159 4
   Moulédous L, 2010, BIOFACTORS, V36, P423, DOI 10.1002/biof.116
   Moulédous L, 2010, NEUROPEPTIDES, V44, P453, DOI 10.1016/j.npep.2010.05.003
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Narita K, 2010, TRAFFIC, V11, P287, DOI 10.1111/j.1600 0854.2009.01016.x
   Nichols SP, 2012, ADV DRUG DELIVER REV, V64, P1177, DOI 10.1016/j.addr.2012.03.002
   Nilforoushan D, 2009, NITRIC OXIDE BIOL CH, V21, P27, DOI 10.1016/j.niox.2009.04.002
   Nystedt JM, 2004, NEUROBIOL DIS, V16, P254, DOI 10.1016/j.nbd.2004.02.001
   Odkhuu E, 2015, INNATE IMMUN LONDON, V21, P194, DOI 10.1177/1753425914524242
   Park EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027739
   Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014 5793(97)00557 7
   Pineda R, 2010, ENDOCRINOLOGY, V151, P1902, DOI 10.1210/en.2009 1259
   Saito TH, 2010, J NEUROPHYSIOL, V104, P3518, DOI 10.1152/jn.01027.2009
   Sakuma Y, 2000, J BONE MINER RES, V15, P218, DOI 10.1359/jbmr.2000.15.2.218
   Shanmugarajan S, 2010, ENDOCRINOLOGY, V151, P4389, DOI 10.1210/en.2010 0244
   Simonin F, 2006, P NATL ACAD SCI USA, V103, P466, DOI 10.1073/pnas.0502090103
   Sun YL, 2014, PROTEIN PEPTIDE LETT, V21, P490, DOI 10.2174/0929866520666131125094445
   Sun YL, 2013, PEPTIDES, V47, P124, DOI 10.1016/j.peptides.2013.07.003
   Sun YL, 2012, PEPTIDES, V38, P110, DOI 10.1016/j.peptides.2012.08.019
   Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Vilim FS, 1999, MOL PHARMACOL, V55, P804
   Wimalawansa SJ, 2010, ANN NY ACAD SCI, V1192, P391, DOI 10.1111/j.1749 6632.2009.05230.x
   Yang HYT, 2008, NEUROPEPTIDES, V42, P1, DOI 10.1016/j.npep.2007.06.004
   YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757
   Yang HYT, 2003, NEUROSCIENCE, V118, P179, DOI 10.1016/S0306 4522(02)00931 4
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zajac JM, 2000, PEPTIDES, V21, P1209, DOI 10.1016/S0196 9781(00)00261 8
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 68
TC 4
Z9 4
U1 0
U2 29
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929 8665
EI 1875 5305
J9 PROTEIN PEPTIDE LETT
JI Protein Pept. Lett.
PY 2015
VL 22
IS 3
BP 270
EP 284
DI 10.2174/0929866522666150115113428
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CC6NY
UT WOS:000350483400010
PM 25619121
DA 2025 08 17
ER

PT J
AU Hou, QK
   Huang, YQ
   Liu, YM
   Luo, YW
   Wang, B
   Deng, RD
   Zhang, SX
   Liu, FB
   Chen, DF
AF Hou, Qiuke
   Huang, Yongquan
   Liu, Yamei
   Luo, Yiwen
   Wang, Bin
   Deng, Rudong
   Zhang, Saixia
   Liu, Fengbin
   Chen, Dongfeng
TI Profiling the miRNA mRNA lncRNA interaction network in MSC osteoblast
   differentiation induced by (+) cholesten 3 one
SO BMC GENOMICS
LA English
DT Article
DE (+) cholesten 3 one; Osteoblastic differentiation; Mesenchymal stem
   cells; miRNA mRNA lncRNA
ID MESENCHYMAL STEM CELLS; MULTIPLE MYELOMA PATIENTS; MARROW STROMAL CELLS;
   LONG NONCODING RNAS; OSTEOGENIC DIFFERENTIATION; SIGNALING PATHWAY;
   EXPRESSION; PROLIFERATION; OVEREXPRESSION; REVEALS
AB BackgroundOur previous study showed that (+) cholesten 3 one (CN) has the potential to induce the osteoblastic differentiation of mesenchymal stem cells (MSCs). However, the roles of CN in targeting miRNA mRNA lncRNA interactions to regulate osteoblast differentiation remain poorly understood.ResultsA total of 77 miRNAs (36 upregulated and 41 downregulated) and 295 lncRNAs (281 upregulated and 14 downregulated) were significantly differentially expressed during CN induced MSC osteogenic differentiation. Bioinformatic analysis identified that several pathways may play vital roles in MSC osteogenic differentiation, such as the vitamin D receptor signalling, TNF signalling, PI3K Akt signalling, calcium signalling, and mineral absorption pathways. Further bioinformatic analysis revealed 16 core genes, including 6 mRNAs (Vdr, Mgp, Fabp3, Fst, Cd38, and Col1a1), 5 miRNAs (miR 483, miR 298, miR 361, miR 92b and miR 155) and 5 lncRNAs (NR_046246.1, NR_046239.1, XR_086062.1, XR_145872.1 and XR_146737.1), that may play important roles in regulating the CN induced osteogenic differentiation of MSCs. Verified by the luciferase reporter, AR S, qRT PCR and western blot assays, we identified one miRNA (miR 298) that may enhance the osteogenic differentiation potential of MSCs via the vitamin D receptor signalling pathway.ConclusionsThis study revealed the global expression profile of miRNAs and lncRNAs involved in the Chinese medicine active ingredient CN induced osteoblast differentiation of MSCs for the first time and provided a foundation for future investigations of miRNA mRNA lncRNA interaction networks to completely illuminate the regulatory role of CN in MSC osteoblast differentiation.
C1 [Hou, Qiuke; Deng, Rudong; Zhang, Saixia; Chen, Dongfeng] Guangzhou Univ Chinese Med, Res Ctr Integrat Med, Dept Anat, Guangzhou 510000, Guangdong, Peoples R China.
   [Hou, Qiuke; Liu, Fengbin] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510000, Guangdong, Peoples R China.
   [Huang, Yongquan] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Orthopaed, Guangzhou 510000, Guangdong, Peoples R China.
   [Liu, Yamei] Guangzhou Univ Chinese Med, Dept Diag Tradit Chinese Med, Guangzhou 510000, Guangdong, Peoples R China.
   [Luo, Yiwen; Wang, Bin] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Dept Trauma, Guangzhou 510000, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Chen, DF (通讯作者)，Guangzhou Univ Chinese Med, Res Ctr Integrat Med, Dept Anat, Guangzhou 510000, Guangdong, Peoples R China.
EM cdf27212@21cn.com
RI ; liu, jiawen/F 2634 2012
OI Liu, Yamei/0000 0002 0770 8381; Chen, Dongfeng/0000 0003 1263 2374
FU Natural Science Foundation of Guangdong Province [2017A030312009]; China
   Postdoctoral Science Foundation [2017 M612641]; Guangdong Provincial
   Traditional Chinese Medicine Research Project [20181095, 20182043]
FX This study was supported by the Natural Science Foundation of Guangdong
   Province (no. 2017A030312009), the China Postdoctoral Science Foundation
   (no. 2017 M612641) and the Guangdong Provincial Traditional Chinese
   Medicine Research Project (no. 20181095, no. 20182043).
CR Bai F, 2018, J CRANIOFAC SURG
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bu YM, 2018, CONNECT TISSUE RES, V59, P534, DOI 10.1080/03008207.2017.1413362
   Burke M, 2017, J STRUCT BIOL, V199, P153, DOI 10.1016/j.jsb.2017.06.008
   Casero D, 2015, NAT IMMUNOL, V16, P1282, DOI 10.1038/ni.3299
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Cui M, 2015, SCI REP UK, V5, DOI 10.1038/srep16455
   De Ugarte L, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0149 2
   Deng P, 2016, STEM CELL REP, V6, P456, DOI 10.1016/j.stemcr.2016.02.006
   Doroudi M, 2014, STEROIDS, V81, P81, DOI 10.1016/j.steroids.2013.10.019
   Gajos Michniewicz A, 2012, J BONE MINER METAB, V30, P426, DOI 10.1007/s00774 011 0347 8
   Gao XR, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578 018 0216 4
   Gothelf Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0692 1
   Gu Y, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1893520
   Guo J, 2017, ONCOTARGET, V8, P55405, DOI 10.18632/oncotarget.19265
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Harimoto K, 2012, DENT MATER J, V31, P674, DOI 10.4012/dmj.2012 075
   Heilmeier U, 2016, J BONE MINER RES, V31, P2173, DOI 10.1002/jbmr.2897
   Horikiri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076785
   Hou QK, 2017, EXP THER MED, V13, P1841, DOI 10.3892/etm.2017.4200
   Hou QK, 2017, AM J TRANSL RES, V9, P4963
   Hu ZB, 2015, SCI REP UK, V5, DOI 10.1038/srep18655
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Kaneto CM, 2014, BMC MED GENET, V15, DOI 10.1186/1471 2350 15 45
   Kang JM, 2012, ACTA BIOMATER, V8, P1759, DOI 10.1016/j.actbio.2012.01.005
   Kim BJ, 2018, J CLIN INVEST, V128, P1429, DOI 10.1172/JCI91086
   Le MH, 2016, J DENT RES, V95, P423, DOI 10.1177/0022034515622443
   Lee S, 2016, CELL, V164, P69, DOI 10.1016/j.cell.2015.12.017
   Li R, 2012, ARCH ORAL BIOL, V57, P1408, DOI 10.1016/j.archoralbio.2012.07.005
   Lu XL, 2012, J BONE MINER RES, V27, P563, DOI 10.1002/jbmr.1474
   Luo S, 2016, CELL STEM CELL, V18, P637, DOI 10.1016/j.stem.2016.01.024
   Luo X, 2013, CELL PROLIFERAT, V46, P436, DOI 10.1111/cpr.12038
   Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104
   Misawa A, 2018, CALCIF TISSUE INT
   Morsczeck C, 2017, MOL CELL BIOCHEM, V428, P79, DOI 10.1007/s11010 016 2918 4
   MYERS EW, 1989, B MATH BIOL, V51, P5, DOI 10.1007/BF02458834
   Necsulea A, 2014, NATURE, V505, P635, DOI 10.1038/nature12943
   O'Hara SP, 2009, GASTROENTEROLOGY, V136, P17, DOI 10.1053/j.gastro.2008.11.028
   Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001
   Pierroz DD, 2012, J BONE MINER RES, V27, P1252, DOI 10.1002/jbmr.1594
   Serrano JC, 2018, J MECH BEHAV BIOMED, V77, P250, DOI 10.1016/j.jmbbm.2017.09.018
   Simann M, 2017, J CELL BIOCHEM, V118, P263, DOI 10.1002/jcb.25631
   Solberg LB, 2015, HISTOCHEM CELL BIOL, V143, P195, DOI 10.1007/s00418 014 1272 4
   Suh JS, 2013, BIOMATERIALS, V34, P4347, DOI 10.1016/j.biomaterials.2013.02.039
   Sun GW, 2015, BIOSCI BIOTECH BIOCH, V79, P1232, DOI 10.1080/09168451.2014.1003128
   Tang ZY, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0406 8
   Uchihashi K, 2013, BONE, V52, P102, DOI 10.1016/j.bone.2012.09.001
   Wang SN, 2014, EXP CELL RES, V323, P56, DOI 10.1016/j.yexcr.2014.02.015
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Wu Q, 2015, J CELL MOL MED, V19, P2874, DOI 10.1111/jcmm.12681
   Wu Q, 2018, EXP THER MED, V15, P173, DOI 10.3892/etm.2017.5356
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006
   Yang XC, 2018, INT J MOL MED, V41, P1536, DOI 10.3892/ijmm.2018.3363
   Yu GY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7130653
   Zenata O, 2017, ONCOTARGET, V8, P35390, DOI 10.18632/oncotarget.15697
   Zhang W, 2016, SCI REP UK, V6, DOI 10.1038/srep27622
   Zhang WY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0485 6
   Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221
   Zhou ML, 2014, ENDOCRINE, V45, P302, DOI 10.1007/s12020 013 9986 y
   Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989
   Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017
NR 64
TC 23
Z9 27
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2164
J9 BMC GENOMICS
JI BMC Genomics
PD OCT 29
PY 2018
VL 19
AR 783
DI 10.1186/s12864 018 5155 2
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA GY6WR
UT WOS:000448739500002
PM 30373531
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Surowiec, RK
   Battle, LF
   Ward, FS
   Schlecht, SH
   Khoury, BM
   Robbins, C
   Wojtys, EM
   Caird, MS
   Kozloff, KM
AF Surowiec, Rachel K.
   Battle, Lauren F.
   Ward, Ferrous S.
   Schlecht, Stephen H.
   Khoury, Basma M.
   Robbins, Christopher
   Wojtys, Edward M.
   Caird, Michelle S.
   Kozloff, Kenneth M.
TI A xenograft model to evaluate the bone forming effects of sclerostin
   antibody in human bone derived from pediatric osteogenesis imperfecta
   patients
SO BONE
LA English
DT Article
DE Anabolic therapy; Xenograft model; Osteogenesis imperfecta; Sclerostin
   antibody; Immunohistochemistry; Micro computed tomography; Bone
   formation
ID BRTL/+ MOUSE MODEL; POSTMENOPAUSAL WOMEN; CELL PROLIFERATION;
   CLINICAL TRIAL; IMPROVES; MASS; CHILDREN; TERIPARATIDE; MECHANISMS;
   BLOSOZUMAB
AB Osteogenesis imperfecta (OI) is a rare and severe skeletal dysplasia marked by low bone mass and poor bone quality which is especially burdensome during childhood. Since clinical trials for pediatric OI are difficult, there is a widespread reliance on genetically modified murine models to understand the skeletal effects of emerging therapeutics. However a common model does not yet exist to understand how patient specific genotype may influence treatment efficacy. Recently, sclerostin antibody (SclAb) has been introduced as a novel putative anabolic therapy for diseases of low bone mass, but effects in pediatric patients remain unexplored. In this study, we aim to establish a direct xenograft approach using OI patient derived bone isolates which retain patientspecific genetic defects and cells residing in their intrinsic extracellular environment to evaluate the boneforming effects of SclAb as a bridge to clinical trials.
   OI and age matched non OI patient bone typically discarded as surgical waste during corrective orthopaedic procedures were collected, trimmed and implanted subcutaneously (s.c.) on the dorsal surface of 4 6 week athymic mice. A subset of implanted mice were evaluated at short (1 week), intermediate (4 week), and long term (12 week) durations to assess bone cell survival and presence of donor bone cells in order to determine an appropriate treatment duration. Remaining implanted mice were randomly assigned to a two or four week SclAb treated (25 mg/kg s.c. 2QW) or untreated control group. Immunohistochemistry determined osteocyte and osteoblast donor/host relationship, TRAP staining quantified osteoclast activity, and TUNEL assay was used to understand rates of bone cell apoptosis at each implantation timepoint. Longitudinal changes of in vivo mu CT outcomes and dynamic histomorphometry were used to assess treatment response and ex vivo mu CT and dynamic histomorphometry of host femora served as a positive internal control to confirm a bone forming response to SclAb.
   Human derived osteocytes and lining cells were present up to 12 weeks post implantation with nominal cell apoptosis in the implant. Sclerostin expression remained donor derived throughout the study. Osterix expression was primarily donor derived in treated implants and shifted in favor of the host when implants remained untreated. mu CT measures of BMD, TMD, BV/TV and BV increased with treatment but response was variable and impacted by bone implant morphology (trabecular, cortical) which was corroborated by histomorphometry. There was no statistical difference between treated and untreated osteoclast number in the implants. Host femora confirmed a systemic bone forming effect of SclAb.
   Findings support use of the xenograft model using solid bone isolates to explore the effects of novel bone targeted therapies. These findings will impact our understanding of SclAb therapy in pediatric OI tissue through establishing the efficacy of this treatment in human cells prior to extension to the clinic.
C1 [Surowiec, Rachel K.; Battle, Lauren F.; Ward, Ferrous S.; Schlecht, Stephen H.; Khoury, Basma M.; Robbins, Christopher; Wojtys, Edward M.; Caird, Michelle S.; Kozloff, Kenneth M.] Univ Michigan, Dept Orthopaed Surg, Ann Arbor, MI 48109 USA.
   [Surowiec, Rachel K.; Ward, Ferrous S.; Kozloff, Kenneth M.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Schlecht, Stephen H.] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Kozloff, KM (通讯作者)，Univ Michigan, Orthopaed Res Labs, 2015 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.
EM kenkoz@umich.edu
RI Surowiec, Rachel/LFU 6479 2024; Schlecht, Stephen/AAE 2347 2020
OI , Christopher B Robbins/0009 0000 1117 8814; Surowiec,
   Rachel/0000 0001 7614 4412
FU National Science Foundation [1256260 DGE]; National Institutes of Health
   [NIH AR062522, NIH AR075197, MICHR NIH/NCATSUL1TR000433, NIH AR069620,
   NIH S10 OD017979, NIH AR070903]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [P30AR069620] Funding Source: NIH
   RePORTER
FX This material is based upon work supported by the National Science
   Foundation Graduate Research Fellowship Program under Grant No. 1256260
   DGE (RKS), and the National Institutes of Health under NIH AR062522, NIH
   AR075197, MICHR NIH/NCATSUL1TR000433, NIH AR069620, NIH S10 OD017979,
   and NIH AR070903.
CR [Anonymous], J BONE MINER RES
   [Anonymous], JBMR PLUS
   [Anonymous], [No title captured]
   [Anonymous], SKELETAL HETEROGENEI
   Aparicio S, 2015, NAT REV CANCER, V15, P311, DOI 10.1038/nrc3944
   Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dwan K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub3
   Feldman AT, 2014, METHODS MOL BIOL, V1180, P31, DOI 10.1007/978 1 4939 1050 2_3
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Genant HK, 2017, J BONE MINER RES, V32, P181, DOI 10.1002/jbmr.2932
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Graeff C, 2015, BONE, V81, P364, DOI 10.1016/j.bone.2015.07.036
   Grafe I, 2016, J BONE MINER RES, V31, P1030, DOI 10.1002/jbmr.2776
   Hald JD, 2015, J BONE MINER RES, V30, P929, DOI 10.1002/jbmr.2410
   Hauge E, 1999, BONE, V25, P389, DOI 10.1016/S8756 3282(99)00194 5
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Holdsworth G, 2018, BONE, V107, P93, DOI 10.1016/j.bone.2017.11.003
   Hoyer Kuhn H, 2016, J MUSCULOSKEL NEURON, V16, P24
   Irie K, 2008, J HISTOCHEM CYTOCHEM, V56, P561, DOI 10.1369/jhc.2008.950527
   Jacobsen CM, 2014, J BONE MINER RES, V29, P2297, DOI 10.1002/jbmr.2198
   Kang H, 2017, TRANSL RES, V181, P27, DOI 10.1016/j.trsl.2016.11.005
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   KEMBER NF, 1960, J BONE JOINT SURG BR, V42, P824, DOI 10.1302/0301 620X.42B4.824
   Land C, 2007, BONE, V40, P638, DOI 10.1016/j.bone.2006.10.010
   Li GW, 2018, ACTA PAEDIATR, V107, P534, DOI 10.1111/apa.14154
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marini JC, 2003, J BONE MINER RES, V18, P237, DOI 10.1359/jbmr.2003.18.2.237
   Marini JC, 2007, HUM MUTAT, V28, P209, DOI 10.1002/humu.20429
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   McClung MR, 2014, NEW ENGL J MED, V370, P1664, DOI 10.1056/NEJMc1402396
   MCCULLOCH CAG, 1988, ANAT RECORD, V222, P128, DOI 10.1002/ar.1092220204
   Morton CL, 2007, NAT PROTOC, V2, P247, DOI 10.1038/nprot.2007.25
   NAKAHARA H, 1991, J ORTHOP RES, V9, P465, DOI 10.1002/jor.1100090402
   OHGUSHI H, 1989, ACTA ORTHOP SCAND, V60, P334, DOI 10.3109/17453678909149289
   Olvera D, 2018, J BONE MINER RES, V33, P1272, DOI 10.1002/jbmr.3421
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Orwoll ES, 2014, J CLIN INVEST, V124, P491, DOI 10.1172/JCI71101
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   OWEN M, 1963, J CELL BIOL, V19, P33, DOI 10.1083/jcb.19.1.33
   Parfitt AM, 2004, BONE, V35, P1, DOI 10.1016/j.bone.2004.03.022
   Pettway GJ, 2005, BONE, V36, P959, DOI 10.1016/j.bone.2005.02.015
   Pettway Glenda J., 2008, V455, P101, DOI 10.1007/978 1 59745 104 8_7
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Recknor CP, 2015, J BONE MINER RES, V30, P1717, DOI 10.1002/jbmr.2489
   Reyes C, 2016, J CELL BIOCHEM, V117, P20, DOI 10.1002/jcb.25266
   Roschger A, 2014, BONE, V66, P182, DOI 10.1016/j.bone.2014.06.015
   Schlecht SH, 2012, AM J PHYS ANTHROPOL, V149, P599, DOI 10.1002/ajpa.22150
   Schneider A, 2003, J ORTHOP RES, V21, P859, DOI 10.1016/S0736 0266(03)00042 1
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sinder BP, 2014, OSTEOPOROSIS INT, V25, P2097, DOI 10.1007/s00198 014 2737 y
   Sinder BP, 2015, BONE, V71, P115, DOI 10.1016/j.bone.2014.10.012
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Spatz JM, 2013, J BONE MINER RES, V28, P865, DOI 10.1002/jbmr.1807
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Van Dijk FS, 2014, AM J MED GENET A, V164, P1470, DOI 10.1002/ajmg.a.36545
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   YOUNG RW, 1962, J CELL BIOL, V14, P357, DOI 10.1083/jcb.14.3.357
   Zacharin M, 2002, J PEDIATR ENDOCR MET, V15, P163
NR 63
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2020
VL 130
AR 115118
DI 10.1016/j.bone.2019.115118
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA JW8UD
UT WOS:000503321100026
PM 31678490
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Deng, ZT
   Wang, ZH
   Jin, JW
   Wang, Y
   Bao, NR
   Gao, Q
   Zhao, JN
AF Deng, Zhantao
   Wang, Zhenheng
   Jin, Jiewen
   Wang, Yong
   Bao, Nirong
   Gao, Qian
   Zhao, Jianning
TI SIRT1 protects osteoblasts against particle induced inflammatory
   responses and apoptosis in aseptic prosthesis loosening
SO ACTA BIOMATERIALIA
LA English
DT Article
DE SIRT1; Osteoblast; Inflammatory responses; Apoptosis; Osteolysis;
   Aseptic loosening
ID FOXO TRANSCRIPTION FACTORS; PARTICULATE WEAR DEBRIS; PERIPROSTHETIC
   OSTEOLYSIS; TITANIUM PARTICLES; DEACETYLASE SIRT1; BONE FORMATION;
   TNF ALPHA; KAPPA B; AUTOPHAGY; P53
AB We hypothesized that SIRT1 downregulation in osteoblasts induced by wear particles was one of the reasons for particle induced osteolysis (PIO) in total joint arthroplasty failure. In the present study, the expression of SIRT1 was examined in osteoblasts treated with TiAl6V4 particles (Ties) and CoCrMo particles (Cops) from materials used in prosthetics and specimens from PIO animal models. To address whether SIRT1 downregulation triggers inflammatory responses and apoptosis in osteoblasts, the effect of a SIRT1 activator, resveratrol on the expression of inflammatory cytokines and apoptosis in particle treated osteoblasts was tested. The results demonstrated that SIRT1 expression was significantly down regulated in particle treated osteoblasts and PIO animal models. Both pharmacological activation and overexpression of SIRT1 dramatically reduced the particle induced expression of inflammatory cytokines and osteoblast apoptosis through NE kappa B and p53 signaling, respectively. Furthermore, in PIO animal models, resveratrol significantly reduced the severity of osteolysis. Collectively, the results of the present study indicated that SIRT1 plays a vital role in the pathogenesis of aseptic loosening, and further treatment targeted at SIRT1 possibly lead to novel approaches for prevention of aseptic prosthesis loosening.
   Statement of Significance
   Aseptic loosening is the most common cause of total hip arthroplasty (THA) and total knee arthroplasty (TKA) failure and revision surgery. However, there is still no effective therapeutic target in the clinical treatment. Besides, the underlying mechanism of aseptic loosening is largely unknown. The result of our study indicated that SIRTI has the ability to effectively regulate the wear particle induced inflammatory responses, apoptosis, osteolysis in particle stimulated osteoblasts and particle induced osteolysis animal models. Our study provides a potential target for the prevention and treatment of aseptic loosening and further investigated the underlying mechanism of aseptic loosening, which may make contribution to decrease the incidence of THA and TKA failure in the clinical practice. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Deng, Zhantao; Wang, Zhenheng; Bao, Nirong; Zhao, Jianning] Nanjing Univ, Sch Med, Jinling Hosp, Dept Orthoped, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China.
   [Deng, Zhantao; Jin, Jiewen; Wang, Yong; Gao, Qian] Nanjing Univ, Ctr Translat Med, Sch Med, Nanjing, Jiangsu, Peoples R China.
   [Deng, Zhantao; Jin, Jiewen; Wang, Yong; Gao, Qian] Nanjing Univ, Jiangsu Key Lab Mol Med, Sch Med, 22 Hankou Rd, Nanjing 210002, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University
RP Bao, NR; Zhao, JN (通讯作者)，Nanjing Univ, Sch Med, Jinling Hosp, Dept Orthoped, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China.; Gao, Q (通讯作者)，Nanjing Univ, Jiangsu Key Lab Mol Med, Sch Med, 22 Hankou Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM dengzhantao_med@163.com; wangzhenheng1987@163.com; 18757851015@163.com;
   yongwang@nju.edu.cn; bnrbnr@sina.com; qian_gao@nju.edu.cn;
   zhaojianning.0207@163.com
FU National Natural Science Foundation of China [81572111, 81501925];
   Clinical Science and Technology Project Foundation of Jiangsu Province
   [BL2012002]; Scientific Research Project of Nanjing [201402007]; Natural
   Science Foundation of Jiangsu Province [BK20161385]
FX This study was supported by the National Natural Science Foundation of
   China (81572111), Clinical Science and Technology Project Foundation of
   Jiangsu Province (BL2012002), Scientific Research Project of Nanjing
   (201402007) and Natural Science Foundation of Jiangsu Province
   (BK20161385), National Natural Science Foundation of China (81501925).
CR Armour KE, 1999, J BONE MINER RES, V14, P2137, DOI 10.1359/jbmr.1999.14.12.2137
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Berdichevsky A, 2006, CELL CYCLE, V5, P2588, DOI 10.4161/cc.5.22.3513
   Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616
   Burnell AM, 2005, EXP GERONTOL, V40, P850, DOI 10.1016/j.exger.2005.09.006
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen RM, 2005, J ORTHOP RES, V23, P462, DOI 10.1016/j.orthres.2004.08.011
   Cheng YD, 2013, EUR J PHARMACOL, V715, P219, DOI 10.1016/j.ejphar.2013.05.017
   Cherian JJ, 2015, CLIN ORTHOP RELAT R, V473, P2700, DOI 10.1007/s11999 015 4220 2
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Daitoku H, 2007, J BIOCHEM, V141, P769, DOI 10.1093/jb/mvm104
   Dong L, 2008, J ORTHOP RES, V26, P1114, DOI 10.1002/jor.20607
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Fehring KA, 2015, ORTHOP CLIN N AM, V46, P185, DOI 10.1016/j.ocl.2014.11.001
   Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Fritz EA, 2006, J BIOMED MATER RES A, V77A, P192, DOI 10.1002/jbm.a.30609
   Fujii J, 2011, HIP INT, V21, P231, DOI 10.5301/HIP.2011.7977
   Gallo J, 2013, ACTA BIOMATER, V9, P8046, DOI 10.1016/j.actbio.2013.05.005
   Gallo J, 2013, INNATE IMMUN LONDON, V19, P213, DOI 10.1177/1753425912451779
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Goodman SB, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0962
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   Haigis MC, 2010, ANNU REV PATHOL MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250
   Haleem Smith H, 2012, J ORTHOP RES, V30, P853, DOI 10.1002/jor.22002
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Hwang JW, 2010, ARCH BIOCHEM BIOPHYS, V500, P203, DOI 10.1016/j.abb.2010.05.013
   Ingham E, 2000, P I MECH ENG H, V214, P21, DOI 10.1243/0954411001535219
   Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092 8674(00)81698 0
   Jeong JK, 2013, NEUROBIOL AGING, V34, P146, DOI 10.1016/j.neurobiolaging.2012.04.002
   Jiang YP, 2013, J BIOMED MATER RES A, V101, P2817, DOI 10.1002/jbm.a.34595
   Jiang YP, 2013, ACTA ORTHOP BELG, V79, P1
   Keurentjes JC, 2014, J BONE JOINT SURG AM, V96A, P79, DOI 10.2106/JBJS.N.00397
   Kim HN, 2015, MOL ENDOCRINOL, V29, P1498, DOI 10.1210/me.2015 1133
   Kitada M., 2011, EXP DIABESITY RES, V2011, P59
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   LEE JM, 1992, J BONE JOINT SURG BR, V74, P380, DOI 10.1302/0301 620X.74B3.1587882
   Li CG, 2009, J MOL CELL BIOL, V1, P37, DOI 10.1093/jmcb/mjp002
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Lisi R. D., 2007, CELL METAB, V6, P458
   Liu GJ, 2015, SHOCK VIB, V2015, DOI 10.1155/2015/583862
   Liu Guo Yin, 2013, Zhongguo Gu Shang, V26, P791
   Lochner K, 2011, INT J MOL MED, V28, P1055, DOI 10.3892/ijmm.2011.778
   Mammucari C, 2008, AUTOPHAGY, V4, P524, DOI 10.4161/auto.5905
   Meléndez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140
   Nine MJ, 2014, MATERIALS, V7, P980, DOI 10.3390/ma7020980
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Okafor CC, 2006, J ORTHOP RES, V24, P461, DOI 10.1002/jor.20075
   Pang WJ, 2013, EXP CELL RES, V319, P670, DOI 10.1016/j.yexcr.2012.12.025
   Pioletti DP, 1999, J BIOMED MATER RES, V46, P399, DOI 10.1002/(SICI)1097 4636(19990905)46:3<399::AID JBM13>3.0.CO;2 B
   Powell MJ, 2011, CANCER RES, V71, P964, DOI 10.1158/0008 5472.CAN 10 3172
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Queally JM, 2009, J ORTHOP RES, V27, P855, DOI 10.1002/jor.20837
   Salminen A, 2009, CELL SIGNAL, V21, P1356, DOI 10.1016/j.cellsig.2009.02.014
   Schmid G, 2007, J CELL BIOCHEM, V101, P1355, DOI 10.1002/jcb.21383
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   SHANBHAG AS, 1994, J BONE JOINT SURG BR, V76B, P60, DOI 10.1302/0301 620X.76B1.8300684
   Stern ST, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743 8977 9 20
   Takeda Watanabe A, 2012, BIOCHEM BIOPH RES CO, V427, P191, DOI 10.1016/j.bbrc.2012.09.042
   Takei H, 2000, J BIOMED MATER RES, V52, P382, DOI 10.1002/1097 4636(200011)52:2<382::AID JBM19>3.0.CO;2 V
   Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702
   Tavernarakis N, 2008, AUTOPHAGY, V4, P870, DOI 10.4161/auto.6730
   Tlsty TD, 2002, CANCER CELL, V2, P2, DOI 10.1016/S1535 6108(02)00088 0
   VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723
   Vermes C, 2001, J BONE JOINT SURG AM, V83A, P201, DOI 10.2106/00004623 200102000 00007
   Vermes C, 2000, J BONE MINER RES, V15, P1756, DOI 10.1359/jbmr.2000.15.9.1756
   Wang R, 2013, BIOMATERIALS, V34, P2611, DOI 10.1016/j.biomaterials.2013.01.025
   Wang Z, 2015, PLOS ONE, V10
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Wang ZH, 2015, ACTA BIOMATER, V24, P352, DOI 10.1016/j.actbio.2015.06.024
   Wei Sirtl, 2012, ACTA PHARMACOL SIN, V33, P668
   Wooley PH, 2004, GENE THER, V11, P402, DOI 10.1038/sj.gt.3302202
   Wu YY, 2008, CANCER LETT, V271, P231, DOI 10.1016/j.canlet.2008.06.006
   Wu YC, 2011, NEUROSIGNALS, V19, P163, DOI 10.1159/000328516
   Xue YB, 2012, AM J PHYSIOL ENDOC M, V302, pE841, DOI 10.1152/ajpendo.00599.2011
   Yao JL, 1997, J BONE JOINT SURG AM, V79A, P107, DOI 10.2106/00004623 199701000 00011
   Yong  Bo Y. U., 2013, J HAZARD MATER, V221, P5239
   Zabirnyk O, 2007, AUTOPHAGY, V3, P278, DOI 10.4161/auto.3916
   Zhang K, 2015, J BIOMED MATER RES A, V103, P358, DOI 10.1002/jbm.a.35176
   Zhang Y., 2015, NATURE, V2, P308
   Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004
NR 85
TC 51
Z9 57
U1 2
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD FEB
PY 2017
VL 49
BP 541
EP 554
DI 10.1016/j.actbio.2016.11.051
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA EK6UU
UT WOS:000394062100044
PM 27890623
DA 2025 08 17
ER

PT J
AU Tian, JQ
   Song, DD
   Peng, YJ
   Zhang, J
   Ma, L
   Chen, Z
   Liang, LY
   Zhang, ZT
   Yun, X
   Zhang, L
AF Tian, Jiaqi
   Song, Dandan
   Peng, Yanjie
   Zhang, Jing
   Ma, Lan
   Chen, Zhen
   Liang, Liyang
   Zhang, Zitong
   Yun, Xiang
   Zhang, Lin
TI Silica induced macrophage pyroptosis propels pulmonary fibrosis through
   coordinated activation of relaxin and osteoclast differentiation
   signaling to reprogram fibroblasts
SO ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
LA English
DT Article
DE Silica nanoparticle; Pulmonary fibrosis; Macrophage; Fibroblast;
   Pyroptosis; Transdifferentiation
ID LUNG EPITHELIAL CELLS; NANOPARTICLES; CYTOTOXICITY; SIZE
AB Silica nanoparticle (SiNP) exposure induces severe pulmonary inflammation and fibrosis, but the pathogenesis remains unclear, and effective therapies are currently lacking. To explore the mechanism underlying SiNPsinduced pulmonary fibrosis, we constructed in vivo silica exposure animal models and in vitro models of silicainduced macrophage pyroptosis and fibroblast transdifferentiation. We found that SiNP exposure elicits upregulation of pulmonary proteins associated with pyroptosis, including NLRP3, ASC, IL 1 beta, and GSDMD, while the immunofluorescence staining co  localized NLRP3 and GSDMD with macrophage  specific biomarker F4/80 in silica  exposed lung tissues. However, the NLRP3 inhibitor MCC950 and classical anti  fibrosis drug pirfenidone (PFD) were found to be able to alleviate silica  induced collagen deposition in the lungs. In in vitro studies, we exposed the fibroblast to a conditioned medium from silica  induced pyroptotic macrophages and found enhanced expression of alpha SMA, suggesting increased transdifferentiation of fibroblast to myofibroblast. In line with in vivo studies, the combined treatment of MCC950 and PFD was demonstrated to inhibit the expression of alpha SMA and attenuate fibroblast transdifferentiation. Mechanistically, we adopted high throughput RNA sequencing on fibroblast with different treatments and found activated signaling of relaxin and osteoclast differentiation pathways, where the expression of the dysregulated genes in these two pathways was examined and found to be consistently altered both in vitro and in vivo. Collectively, our study demonstrates that SiNP exposure induces macrophage pyroptosis, which subsequently causes fibroblast transdifferentiation to myofibroblasts, in which the relaxin and osteoclast differentiation signaling pathways play crucial roles. These findings may provide valuable references for developing new therapies for pulmonary fibrosis.
C1 [Tian, Jiaqi; Song, Dandan; Peng, Yanjie; Ma, Lan; Chen, Zhen; Zhang, Zitong; Zhang, Lin] Qingdao Univ, Shandong Prov Maternal & Child Hlth Care Hosp, Clin Med Res Ctr Women & Children Dis, Key Lab Birth Regulat & Control Technol Natl Hlth, Jinan 250001, Peoples R China.
   [Tian, Jiaqi; Song, Dandan; Peng, Yanjie; Ma, Lan; Chen, Zhen; Zhang, Zitong; Zhang, Lin] Key Lab Birth Defect Prevent & Genet Med Shandong, Jinan 250001, Peoples R China.
   [Zhang, Jing] Dept Publ Hlth, Zhue Town Hlth Clin, Dezhou 253000, Peoples R China.
   [Liang, Liyang] Tangshan Gongren Hosp, Dept Surg Oncol, Tangshan 063000, Peoples R China.
   [Zhang, Zitong] Qingdao Univ, Sch Publ Hlth, Qingdao 266071, Peoples R China.
   [Yun, Xiang] North China Univ Sci & Technol, Sch Publ Hlth, Tangshan 063210, Peoples R China.
   [Zhang, Lin] Qingdao Univ, Shandong Prov Maternal & Child Hlth Care Hosp, Clin Med Res Ctr Women & Children Dis, Jinan 250001, Peoples R China.
C3 Qingdao University; Qingdao University; North China University of
   Science & Technology; Qingdao University
RP Zhang, L (通讯作者)，Qingdao Univ, Shandong Prov Maternal & Child Hlth Care Hosp, Clin Med Res Ctr Women & Children Dis, Jinan 250001, Peoples R China.
EM zhanglin8901@163.com
RI chen, zhen/KYR 5096 2024; Song, Dandan/ACL 2677 2022; zhang,
   ivy/IQR 7724 2023
FU National Natural Science Foundation of China [82003405]; Natural Science
   Foundation of Shandong [ZR2020QH290]; China Postdoctoral Science
   Foundation [2023M742579]
FX This work was financially supported by the National Natural Science
   Foundation of China (82003405), the Natural Science Foundation of
   Shandong (ZR2020QH290), and the China Postdoctoral Science Foundation
   (2023M742579). The funders had no role in study design, data collection,
   interpretation, or the decision to submit the work for publication.
CR Adamcakova J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084162
   Bolourani S, 2021, J MOL MED, V99, P1373, DOI 10.1007/s00109 021 02113 y
   Cao ZJ, 2022, ACTA PHARMACOL SIN, V43, P908, DOI 10.1038/s41401 021 00706 4
   Chanda D, 2019, MOL ASPECTS MED, V65, P56, DOI 10.1016/j.mam.2018.08.004
   Chen FT, 2022, RENAL FAILURE, V44, P513, DOI 10.1080/0886022X.2022.2044351
   Chen JS, 2023, BONE, V169, DOI 10.1016/j.bone.2023.116680
   Chen LJ, 2018, NANOMEDICINE UK, V13, P1939, DOI 10.2217/nnm 2018 0076
   Doolina MT, 2021, MOL BIOL CELL, V32, DOI 10.1091/mbc.E20 08 0536
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Fennen M, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1187 7
   Hindman B, 2019, ARCH TOXICOL, V93, P887, DOI 10.1007/s00204 019 02411 y
   Hoy RF, 2020, ALLERGY, V75, P2805, DOI 10.1111/all.14202
   Hozayen WG, 2019, BIOMED PHARMACOTHER, V109, P2527, DOI 10.1016/j.biopha.2018.11.093
   Li JX, 2021, ENVIRON INT, V152, DOI 10.1016/j.envint.2021.106497
   Li N, 2023, INT J RADIAT BIOL, DOI 10.1080/09553002.2023.2263550
   Li XF, 2013, INT IMMUNOPHARMACOL, V17, P537, DOI 10.1016/j.intimp.2013.07.020
   Ma L, 2022, J INFLAMM RES, V15, P4537, DOI 10.2147/JIR.S371536
   Ng HH, 2019, MOL CELL ENDOCRINOL, V487, P59, DOI 10.1016/j.mce.2019.01.015
   Samuel CS, 2017, BRIT J PHARMACOL, V174, P962, DOI 10.1111/bph.13529
   Savin IA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232314959
   Sayan M, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989 016 0162 4
   Scherer MD, 2019, SCI TOTAL ENVIRON, V660, P459, DOI 10.1016/j.scitotenv.2018.12.444
   Song MY, 2022, ACTA PHARM SIN B, V12, P1213, DOI 10.1016/j.apsb.2021.10.006
   Sun WQ, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00329 5
   Tao HH, 2023, ECOTOX ENVIRON SAFE, V249, DOI 10.1016/j.ecoenv.2022.114359
   Tian JQ, 2021, SCI TOTAL ENVIRON, V762, DOI 10.1016/j.scitotenv.2020.143152
   Wu YL, 2022, MILITARY MED RES, V9, DOI 10.1186/s40779 022 00404 0
   Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807
   Xia QY, 2019, INT J NANOMED, V14, P6957, DOI 10.2147/IJN.S214008
   Yin HY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.874459
   Yin HY, 2021, J HAZARD MATER, V412, DOI 10.1016/j.jhazmat.2021.125234
   Zhang J, 2022, ENVIRON TOXICOL, V37, P2235, DOI 10.1002/tox.23590
   Zhang L, 2023, ECOTOX ENVIRON SAFE, V258, DOI 10.1016/j.ecoenv.2023.114975
   Zhang WJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.643149
   Zhang X, 2021, NANOTOXICOLOGY, V15, P588, DOI 10.1080/17435390.2021.1905098
   Zhang YL, 2022, J HAZARD MATER, V432, DOI 10.1016/j.jhazmat.2022.128655
   Zhao XY, 2021, CHEMOSPHERE, V275, DOI 10.1016/j.chemosphere.2021.129969
NR 37
TC 11
Z9 12
U1 2
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0147 6513
EI 1090 2414
J9 ECOTOX ENVIRON SAFE
JI Ecotox. Environ. Safe.
PD MAR 15
PY 2024
VL 273
AR 116106
DI 10.1016/j.ecoenv.2024.116106
EA FEB 2024
PG 11
WC Environmental Sciences; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Environmental Sciences & Ecology; Toxicology
GA NK2W0
UT WOS:001200291900001
PM 38377782
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, X
   Yang, M
   Lin, L
   Chen, P
   Ma, KT
   Zhou, CY
   Ao, YF
AF Zhang, X.
   Yang, M.
   Lin, L.
   Chen, P.
   Ma, K. T.
   Zhou, C. Y.
   Ao, Y. F.
TI Runx2 overexpression enhances osteoblastic differentiation and
   mineralization in adipose  : derived stem cells in vitro and
   in vivo
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE adipose derived stem cells; Runx2; gene therapy; differentiation;
   osteogenesis
ID BONE MORPHOGENETIC PROTEIN 2; GENE THERAPY; TRANSCRIPTION FACTOR;
   STROMAL CELLS; TISSUE; REGENERATION; RUNX2/CBFA1; EXPRESSION; MODEL
AB Like bone marrow stromal cells, adipose tissue derived stem cells (ADSCs) possess multilineage potential, a capacity for self renewal and long term viability. To confirm whether ADSCs represent a promising source of cells for gene enhanced bone tissue engineering, the osteogenic potential of ADSCs under the control of certain osteoinductive genes has been evaluated. Runx2, a transcription factor at the downstream end of bone morphogenetic protein (BMP) signaling pathways, is essential for osteoblast differentiation and bone formation. In this study we used adenovirus vector to deliver Runx2 to ADSCs and then examined the enhancement of osteogenic activity. Overexpression of Runx2 inhibited adipogenesis, as demonstrated by suppression of LPL and PPAR gamma expression at the mRNA level and reduced lipid droplet formation. Moreover, ADSCs transduced with AdRunx2 underwent rapid and marked osteoblast differentiation as determined by osteoblastic gene expression, alkaline phosphatase activity and mineral deposition. Additionally, histological examination revealed that implantation of Runx2 modified ADSCs could induce mineral deposition and bone like tissue formation in vivo. These results confirmed, firstly, the ability of Runx2 to promote osteogenesis and cell differentiation and, secondly, the competence of ADSCs as target cells for bone tissue engineering. Our work demonstrates a potential new approach for bone repair using Runx2 modified ADSCs for bone tissue engineering.
C1 Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China.
   Wannan Med Coll, Yijishan Hosp, Dept Orthoped, Wuhu 241001, Peoples R China.
   Peking Univ, Hosp 3, Dept Sports Med, Beijing 100083, Peoples R China.
C3 Peking University; Wannan Medical College; Peking University
RP Zhou, CY (通讯作者)，Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China.
EM chunyanzhou@bjmu.edu.cn; yingfang.ao@vip.sina.com
RI Zhou, Chunyan/H 1529 2016
CR Blum JS, 2003, HUM GENE THER, V14, P1689, DOI 10.1089/104303403322611719
   Breitbart AS, 1999, ANN PLAS SURG, V42, P488, DOI 10.1097/00000637 199905000 00005
   Bruder SP, 1998, CLIN ORTHOP RELAT R, pS247
   Byers BA, 2002, J BONE MINER RES, V17, P1931, DOI 10.1359/jbmr.2002.17.11.1931
   Chen XM, 2001, EMBO REP, V2, P68, DOI 10.1093/embo reports/kve005
   Conget PA, 2000, EXP HEMATOL, V28, P382, DOI 10.1016/S0301 472X(00)00134 X
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Edwards PC, 2005, GENE THER, V12, P75, DOI 10.1038/sj.gt.3302386
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P1425, DOI 10.2106/00004623 200308000 00002
   Franceschi RT, 2004, CELLS TISSUES ORGANS, V176, P95, DOI 10.1159/000075031
   Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509
   Gazit D, 1999, J GENE MED, V1, P121, DOI 10.1002/(SICI)1521 2254(199903/04)1:2<121::AID JGM26>3.0.CO;2 J
   Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222 6233.2002
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   Hannallah David, 2003, Instr Course Lect, V52, P753
   Hidaka C, 2002, ORTHOP CLIN N AM, V33, P439, DOI 10.1016/S0030 5898(01)00018 9
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kang SK, 2003, EXP NEUROL, V183, P355, DOI 10.1016/S0014 4886(03)00089 X
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890 199704270 00003
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Mason JM, 2000, CLIN ORTHOP RELAT R, pS171
   Seeherman HJ, 2004, J BONE JOINT SURG AM, V86A, P1961, DOI 10.2106/00004623 200409000 00015
   Starr AJ, 2003, J BONE JOINT SURG AM, V85A, P2049, DOI 10.2106/00004623 200310000 00027
   Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092 8674(04)00208 9
   WINNARD RG, 1995, J BONE MINER RES, V10, P1969
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 29
TC 151
Z9 176
U1 0
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD SEP
PY 2006
VL 79
IS 3
BP 169
EP 178
DI 10.1007/s00223 006 0083 6
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 087AC
UT WOS:000240713600006
PM 16969589
DA 2025 08 17
ER

PT J
AU Sun, XW
   Xie, Z
   Ma, Y
   Pan, X
   Wang, JY
   Chen, ZJ
   Shi, PH
AF Sun, Xuewu
   Xie, Ziang
   Ma, Yan
   Pan, Xin
   Wang, Jiying
   Chen, Zhijun
   Shi, Peihua
TI TGF β inhibits osteogenesis by upregulating the expression of ubiquitin
   ligase SMURF1 via MAPK ERK signaling
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE alkaline phosphatase; bone morphogenic protein; extracellular
   signal regulated kinase; osteogenic differentiation; RUNX2
ID ACTIVATED PROTEIN KINASE; BONE MORPHOGENETIC PROTEIN 2; OSTEOBLAST
   DIFFERENTIATION; TRANSFORMING GROWTH FACTOR BETA 1; IN VITRO;
   OSTEOPOROSIS; DEGRADATION; CELLS; MINERALIZATION; REPRESSION
AB High incidence of osteoporotic fractures emphasizes the necessity of developing effective measures to promote osteogenesis. In our study, we investigated a possible role of MAPK ERK signaling in the TGF beta mediated osteoblastic differentiation. Our results indicated that TGF beta activated the MAPK ERK pathway and inhibited osteogenesis in mesenchymal pluripotent cell line, C3H10T1/2, and preosteoblastic cell line, MC3T3 cells. And the downregulation of MAPK ERK signaling using pharmacological inhibitor U0126 and RNA interference rescued osteoblast differentiation suppressed by TGF beta, which was confirmed by Alkaline phosphatase (ALP) staining and alizarrn red staining, and the enhanced expression of osteogenesic markers. Western blotting analysis indicated that TGF beta induced protein expression of E3 ubiquitin protein ligase SMURF1, which contributed to the degradation of RUNX2 and SMAD1 as evidenced by SMURF1 inhibition using RNA interference and proteasome inhibitor MG132. Moreover, we observed that the expression of SMURF1 was decreased, while that of SMAD1 and RUNX2 increased by MAPK ERK inhibitor U0126 in TGF beta treated differentiating preosteoblasts, suggesting that MAPK ERK regulated the transcription of osteogenesis related genes. Furthermore, a synergistic effect between U0126 and bone morphogenic protein (BMP) 2 on osteoblast differentiation and bone formation was observed both in cell cultures and experimental animals. In conclusion, our results revealed that TGF beta inhibited osteoblastic differentiation by inducing the MAPK ERK pathway which upregulated the expression of ubiquitin ligase SMURF1 and resulted in reduced presence of osteogenic proteins. In addition, the potentiation of BMP 2 on osteogenic activity by ERK1/2 inhibitor U0126 suggests that it may have potential clinical utility for promoting osteogenesis in bone fracture repair.
C1 [Sun, Xuewu; Xie, Ziang; Ma, Yan; Pan, Xin; Wang, Jiying; Chen, Zhijun; Shi, Peihua] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed, Coll Med, Hangzhou 310016, Zhejiang, Peoples R China.
   [Sun, Xuewu; Xie, Ziang; Ma, Yan; Pan, Xin; Wang, Jiying; Chen, Zhijun; Shi, Peihua] Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Chen, ZJ; Shi, PH (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed, Coll Med, Hangzhou 310016, Zhejiang, Peoples R China.
EM nju_chen@163.com; awushiye@163.com
RI Wang, Yijun/GXW 1763 2022
OI Shi, Peihua/0000 0002 2063 0419
FU National Natural Science Foundation of China [81372006, 81672208,
   81601925, 81601924, 81501912, 81472064, 81401821]
FX National Natural Science Foundation of China, Grant numbers: 81372006,
   81672208, 81601925, 81601924, 81501912, 81472064, 81401821
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Chen J, 2014, J CELL PHYSIOL, V229, P1647, DOI 10.1002/jcp.24610
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432 0436.1999.6420067.x
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Heberden C, 1998, GEN PHARMACOL VASC S, V30, P145, DOI 10.1016/S0306 3623(97)00271 1
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Holm TM, 2011, SCIENCE, V332, P358, DOI 10.1126/science.1192149
   Huang YH, 2015, 2015 12TH WEB INFORMATION SYSTEM AND APPLICATION CONFERENCE (WISA), P3, DOI [10.1109/WISA.2015.16, 10.1109/PPC.2015.7296864]
   Hug BA, 2004, CELL, V119, P448, DOI 10.1016/j.cell.2004.10.023
   Jackson RD, 2014, SEMIN REPROD MED, V32, P454, DOI 10.1055/s 0034 1384629
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348
   Kwok S, 2009, J CELL BIOCHEM, V106, P161, DOI 10.1002/jcb.21991
   Lee HL, 2014, EXP CELL RES, V323, P276, DOI 10.1016/j.yexcr.2014.03.004
   Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210
   Nanes MS, 2009, FERTIL STERIL, V92, P403, DOI 10.1016/j.fertnstert.2009.05.049
   Park OJ, 2010, J BIOL CHEM, V285, P3568, DOI 10.1074/jbc.M109.055053
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Ritt DA, 2016, MOL CELL, V64, P875, DOI 10.1016/j.molcel.2016.10.029
   Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006
   Schindeler A, 2006, J BONE MINER RES, V21, P1331, DOI 10.1359/JBMR.060603
   Simann M., 2016, J CELL BIOCHEM, V118, P263
   Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   Tasadduq R., 2016, J CELLULAR PHYSL, V232, P540
   van Zoelen EJ, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0375 3
   Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445
   Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Zhang R, 2016, AM J TRANSL RES, V8, P2783
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhao YX, 2012, ADV DIFFER EQU NY, P1, DOI 10.1186/1687 1847 2012 15
NR 36
TC 45
Z9 51
U1 0
U2 42
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JAN
PY 2018
VL 233
IS 1
BP 596
EP 606
DI 10.1002/jcp.25920
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FI3BF
UT WOS:000411829600051
PM 28322449
DA 2025 08 17
ER

PT J
AU Hwang, YH
   Ha, H
   Kim, R
   Cho, CW
   Song, YR
   Hong, HD
   Kim, T
AF Hwang, Youn Hwan
   Ha, Hyunil
   Kim, Rajeong
   Cho, Chang Won
   Song, Young Ran
   Hong, Hee Do
   Kim, Taesoo
TI Protective effects of a polysaccharide BLE0 isolated from barley leaf on
   bone loss in ovariectomized mice
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Polysaccharides; Barley leaf; Osteoporosis; Ovariectomy; Osteoclast
   differentiation
ID OSTEOCLAST DIFFERENTIATION; NFATC1; OSTEOPROTEGERIN; ACTIVATION;
   EXPRESSION; INDUCTION; PATHWAYS; LEAVES
AB Potent anti osteoporotic drugs have been developed over the past decades; however, the substantial need for treatments that can effectively and safely manage osteoporosis remains unmet. Barley leaf derived products are one of best functional foods that can be used as nutritional supplements and detoxifiers in humans and are beneficial in improving bone disease. However, little information is available regarding the anti osteoporotic effects of polysaccharides as the main component of barley leaf. This study aimed to clarify the beneficial effects of barley leaf (BLE0) polysaccharides on bone loss in ovariectomized mice and osteoclast differentiation in bone marrow derived macrophages. BLE0 remarkably inhibited receptor activator of the nuclear factor KB ligand (RANKL) induced osteoclast differentiation in a dose dependent manner. It also blocked RANKL induced activation of osteoclastogenic signals including ERK and p38 and the expression of nuclear factor of activated T cells cytoplasmic 1, as a master regulator of osteodast differentiation, leading to decreased expression of osteoclastspecific marker genes such as Atp6v0d2, DC STAMP and cathepsin K. Micro computed tomography revealed that a seven week oral administration of BLE0 dramatically improved ovariectomy induced trabecular bone loss. Anti osteoporotic effects were confirmed using morphometric analysis. Taken together, BLED is a bioactive polysaccharide; it mitigates estrogen deficiency induced bone loss by directly inhibiting osteoclast differentiation. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Hwang, Youn Hwan; Ha, Hyunil; Kim, Rajeong; Kim, Taesoo] Korea Inst Oriental Med, Herbal Med Res Div, Daejeon 34054, South Korea.
   [Cho, Chang Won; Song, Young Ran; Hong, Hee Do] Korea Food Res Inst, Wanju Gun 55365, Jeollabuk Do, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Korea Food Research
   Institute (KFRI)
RP Kim, T (通讯作者)，Korea Inst Oriental Med, Herbal Med Res Div, Daejeon 34054, South Korea.; Hong, HD (通讯作者)，Korea Food Res Inst, Wanju Gun 55365, Jeollabuk Do, South Korea.
EM honghd@kfri.re.kr; xotn91@kiom.re.kr
RI ; Cho, Chang Won/GPF 4456 2022; Hwang, Youn Hwan/AAU 9373 2021
OI Cho, Chang Won/0000 0003 0496 8046; 
FU Main Research Program of the Korea Food Research Institute (KFRI)  
   Ministry of Science and ICT [E0164700]; Korea Institute of Oriental
   Medicine, Republic of Korea [K18221, P18070]; Austrian Science Fund
   (FWF) [P18070] Funding Source: Austrian Science Fund (FWF)
FX This work was supported by the Main Research Program (E0164700) of the
   Korea Food Research Institute (KFRI) funded by the Ministry of Science
   and ICT, and the grants [Grant no. K18221, P18070] from the Korea
   Institute of Oriental Medicine, Republic of Korea.
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   [Anonymous], EVIDENCE BASED COMPL
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003 2697(73)90377 1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1038/168167a0
   Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859
   Ha H, 2014, MOLECULES, V19, P3940, DOI 10.3390/molecules19043940
   Ha H, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/852648
   Hagiwara Y, 2001, J JPN SOC FOOD SCI, V48, P712
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Jakubas Przewlocka J, 2005, CLIN EXP RHEUMATOL, V23, P385
   KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003 2697(78)90260 9
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim H, 2017, CARBOHYD POLYM, V157, P282, DOI 10.1016/j.carbpol.2016.09.056
   Kim H, 2016, INT J BIOL MACROMOL, V87, P308, DOI 10.1016/j.ijbiomac.2016.02.072
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lahouar L, 2015, AM J CHINESE MED, V43, P1311, DOI 10.1142/S0192415X15500743
   Liu H, 2016, BONE JOINT RES, V5, P253, DOI 10.1302/2046 3758.56.2000565
   Liu Y., 2014, COCHRANE DB SYST REV, V6
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Naylor K, 2012, NAT REV RHEUMATOL, V8, P379, DOI 10.1038/nrrheum.2012.86
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Shetty Sahana, 2016, Indian J Endocrinol Metab, V20, P846
   Song L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8417814
   Song YR, 2018, INT J BIOL MACROMOL, V116, P1089, DOI 10.1016/j.ijbiomac.2018.05.132
   Sophocleous Antonia, 2014, Bonekey Rep, V3, P614, DOI 10.1038/bonekey.2014.109
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tanaka S, 2007, AM J NEPHROL, V27, P466, DOI 10.1159/000106484
   Tu Kristie N, 2018, P T, V43, P92
   Wang XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118184
   Wong KC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050530
   Wright LE, 2008, J BONE MINER RES, V23, P1296, DOI 10.1359/JBMR.080309
   Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630
   Zeng Y., 2018, OXID MED CELL LONGEV, V2018
NR 41
TC 18
Z9 19
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD FEB 15
PY 2019
VL 123
BP 314
EP 321
DI 10.1016/j.ijbiomac.2018.11.075
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA HI9FG
UT WOS:000456760100037
PM 30439432
DA 2025 08 17
ER

PT J
AU Zhang, Q
   Hu, SJ
   Wu, JJ
   Sun, P
   Zhang, QL
   Wang, Y
   Zhao, QM
   Han, T
   Qin, LP
   Zhang, QY
AF Zhang, Qi
   Hu, Sijing
   Wu, Jianjun
   Sun, Peng
   Zhang, Quanlong
   Wang, Yang
   Zhao, Qiming
   Han, Ting
   Qin, Luping
   Zhang, Qiaoyan
TI Nystose attenuates bone loss and promotes BMSCs differentiation to
   osteoblasts through BMP and Wnt/? catenin pathway in ovariectomized mice
SO FOOD SCIENCE AND HUMAN WELLNESS
LA English
DT Article
DE Nystose; Bone marrow mesenchymal stem cell; Osteoblast; Adipocyte; BMP
   pathway; Wnt; ? catenin pathway
ID OSTEOPOROSIS; INULIN; CELLS
AB Increasing the osteogenic differentiation ability and decreasing the adipogenic differentiation ability of bone marrow mesenchymal stem cells (BMSCs) is a potential strategy for the treatment of osteoporosis (OP). Naturally derived oligosaccharides have shown signifi cant anti osteoporotic effects. Nystose (NST), an oligosaccharide, was isolated from the roots of Morinda officinalis How. (MO). The aim of the present study was to investigate the effects of NST on bone loss in ovariectomized mice, and explore the underlying mechanism of NST in promoting differentiation of BMSCs to osteoblasts. Administration of NST (40, 80 and 160 mg/kg) and the positive control of estradiol valerate (0.2 mg/kg) for 8 weeks significantly prevented bone loss induced by ovariectomy (OVX), increased the bone mass density (BMD), improved the bone microarchitecture and reduced urine calcium and deoxypyridinoline (DPD) in ovariectomized mice, while inhibited the increase of body weight without significantly affecting the uterus weight. Furthermore, we found that NST increased osteogenic differentiation, inhibited adipogenic differentiation of BMSCs in vitro, and upregulated the expression of the key proteins of BMP and Wnt/fl catenin pathways. In addition, Noggin and Dickkopf related protein 1 (DKK 1) reversed the effect of NST on osteogenic differentiation and expression of the key proteins in BMP and Wnt/ fl catenin pathway. The luciferase activities and the molecular docking analysis further supported the mechanism of NST. In conclusion, these results indicating that NST can be clinically used as a potential alternative medicine for the prevention and treatment of postmenopausal osteoporosis.(c) 2023 Beijing Academy of Food Sciences. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Zhang, Qi; Hu, Sijing; Wu, Jianjun; Sun, Peng; Zhang, Quanlong; Zhao, Qiming; Qin, Luping; Zhang, Qiaoyan] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Peoples R China.
   [Wang, Yang] Zhejiang Tradit Chinese Med & Hlth Ind Grp Co Ltd, Hangzhou 310016, Peoples R China.
   [Han, Ting; Qin, Luping; Zhang, Qiaoyan] Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
C3 Zhejiang Chinese Medical University; Naval Medical University
RP Qin, LP; Zhang, QY (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Peoples R China.; Han, T; Qin, LP; Zhang, QY (通讯作者)，Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
EM Than927@163.com; lpqin@zcmu.edu.cn; zqy1965@163.com
RI wu, jianjun/MHQ 7575 2025
FU National Natural Science Foundation of China [81973534, U1505226]
FX We appreciate the technical support from the Public Platform of Medical
   Research Center, Academy of Chinese Medical Science, Zhejiang Chinese
   Medical University. The project was sponsored by the National Natural
   Science Foundation of China (81973534, U1505226). The funding body did
   not have any influence on the design of the study and collection,
   analysis, and interpretation of data and in writing the manuscript.
CR Abdallah BM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929 019 0544 7
   Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Apolinar Valiente R, 2021, FOOD CHEM, V342, DOI 10.1016/j.foodchem.2020.128330
   Apolinário AC, 2017, IND CROP PROD, V108, P355, DOI 10.1016/j.indcrop.2017.06.045
   Bali V, 2015, CRIT REV FOOD SCI, V55, P1475, DOI 10.1080/10408398.2012.694084
   Cha XX, 2019, CARBOHYD POLYM, V216, P97, DOI 10.1016/j.carbpol.2019.03.016
   Chai S, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.153063
   Chen M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02239 3
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chi LD, 2020, PHYTOMEDICINE, V67, DOI 10.1016/j.phymed.2019.153157
   Hong GJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010203
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Kamiya N, 2011, BIOFACTORS, V37, P75, DOI 10.1002/biof.139
   Karadeniz F, 2020, PHYTOMEDICINE, V71, DOI 10.1016/j.phymed.2020.153225
   Kim D, 2019, INT J BIOL MACROMOL, V134, P749, DOI 10.1016/j.ijbiomac.2019.04.184
   Kim MH, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153397
   L.L.C. Schrodinger,, 2017, PYMOL MOL GRAPHICS S
   Li H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.675503
   LIU JH, 1993, CARBOHYD RES, V245, P11, DOI 10.1016/0008 6215(93)80056 K
   Macías I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051653
   Manandhar S, 2020, PHYTOMEDICINE, V76, DOI 10.1016/j.phymed.2020.153243
   Mira Pascual L, 2020, CALCIFIED TISSUE INT, V106, P194, DOI 10.1007/s00223 019 00618 w
   Niramitchainon C, 2020, J PERIODONTOL, V91, P1264, DOI 10.1002/JPER.19 0580
   Okada H, 2010, CARBOHYD RES, V345, P414, DOI 10.1016/j.carres.2009.12.003
   Parida S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102519
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Ruiz Aceituno L, 2017, J AGR FOOD CHEM, V65, P10505, DOI 10.1021/acs.jafc.7b03092
   Schrodinger, 2017, MAESTR VERS 11 0
   Seok JW, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154250
   Singh SP, 2017, APPL BIOCHEM BIOTECH, V183, P613, DOI 10.1007/s12010 017 2605 2
   Stauffer F, 2016, BIOORG MED CHEM LETT, V26, P2065, DOI 10.1016/j.bmcl.2016.02.074
   Sun X, 2020, J CELL MOL MED, V24, P3692, DOI 10.1111/jcmm.15072
   Tanabe K, 2019, J AGR FOOD CHEM, V67, P867, DOI 10.1021/acs.jafc.8b05164
   TIMMERMANS JW, 1993, CARBOHYD RES, V243, P379, DOI 10.1016/0008 6215(93)87041 P
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Wang HD, 2015, ACUPUNCT MED, V33, P465, DOI 10.1136/acupmed 2014 010743
   Wang L, 2016, J TRADIT CHIN MED, V36, P332
   Yan CY, 2019, INT J BIOL MACROMOL, V133, P446, DOI 10.1016/j.ijbiomac.2019.04.084
   Yan CY, 2019, CARBOHYD POLYM, V210, P110, DOI 10.1016/j.carbpol.2019.01.026
   Yang X, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00412
   Yang ZM, 2011, CARBOHYD POLYM, V83, P1997, DOI 10.1016/j.carbpol.2010.11.006
   Yodthong T, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020190
   Yu AXD, 2020, FASEB J, V34, P4311, DOI 10.1096/fj.201902319RRR
   Zhang JH, 2018, J ETHNOPHARMACOL, V213, P230, DOI 10.1016/j.jep.2017.10.028
   Zhao J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054645
   Zheng H, 2020, INT J BIOL MACROMOL, V156, P1135, DOI 10.1016/j.ijbiomac.2019.11.145
   Zhou T, 2019, REDOX REP, V24, P62, DOI 10.1080/13510002.2019.1658376
NR 48
TC 7
Z9 7
U1 5
U2 70
PU TSINGHUA UNIV PRESS
PI BEIJING
PA B605D, XUE YAN BUILDING, BEIJING, 100084, PEOPLES R CHINA
EI 2213 4530
J9 FOOD SCI HUM WELL
JI Food Sci. Human Wellness
PD MAR
PY 2023
VL 12
IS 2
BP 634
EP 646
DI 10.1016/j.fshw.2022.07.066
PG 13
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA 5A0LN
UT WOS:000862588300001
OA gold
DA 2025 08 17
ER

PT J
AU Wang, FJ
   Tu, PF
   Zeng, KW
   Jiang, Y
AF Wang, Fujiang
   Tu, Pengfei
   Zeng, Kewu
   Jiang, Yong
TI Total glycosides and polysaccharides of Cistanche deserticola
   prevent osteoporosis by activating Wnt/β catenin signaling pathway in
   SAMP6 mice
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Cistanche deserticola; Osteoporosis; Total glycosides; Polysaccharides;
   Wnt/beta catenin pathway
ID NF KAPPA B; DIFFERENTIATED OSTEOBLASTS; BONE FORMATION;
   OSTEOCLASTOGENESIS; INHIBITION; EXPRESSION
AB Ethnopharmacological relevance: Traditional Chinese medicine Cistanche deserticola Y. C. Ma has effect of "tonifying kidney and strengthening bone". However, the specific active extracts of C. deserticola and mechanisms for treatment of osteoporotic are not clear.
   Aim of the study: We wanted to identify the effective component extracts of C. deserticola for the treatment of osteoporosis and the potential mechanisms.
   Materials and methods: Our group researched the extracts of C. deserticola with anti osteoporotic activity, including total glycosides (TGs), polysaccharides (PSs), and oligosaccharides (OSs) in senescence accelerated mouse prone 6 (SAMP6) mice. The Goldner's Trichrome, Van Gieson's (VG), Safranin O Fast Green staining and Von Kossa staining were performed to investigate the bone structure formation and calcium deposits. Serum was collected for detecting biochemical markers. Bone micro architecture was detected by micro CT. Expressions of bone morphogenetic protein 2 (BMP 2), osteocalcin (OCN), osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), p glycogen synthetase kinase 3 beta (p GSK 3 beta), and p beta catenin were analyzed by western blotting and immunohistochemistry.
   Results: TGs and PSs ameliorated bone histopathological damages, promoted the formation of new bone, collagenous fiber, and chondrocytes, and accelerated the calcium deposits. Moreover, they remarkable altered the biomarkers of bone turnover and effectively ameliorated bone microarchitecture. The further mechanisms study showed that TGs and PSs significantly decreased the expressions of RANKL, p beta catenin, as well as up regulated the expression of BMP 2, OCN, OPG, and p GSK 3 beta (Ser9).
   Conclusion: The findings of this study suggest that TGs and PSs can promote osteoblastogenic bone formation and improve bone microstructure damage in SAMP6 mice, and their therapeutic effect on osteoporosis is via activating Wnt/beta catenin signaling pathway.
C1 [Wang, Fujiang; Tu, Pengfei; Zeng, Kewu; Jiang, Yong] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Wang, Fujiang] Jiangsu Suzhong Pharmaceut Res Inst Co Ltd, Nanjing 210000, Jiangsu, Peoples R China.
C3 Peking University
RP Zeng, KW; Jiang, Y (通讯作者)，Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM ZKW@bjmu.edu.cn; yongjiang@bjmu.edu.cn
RI Ke wu, Zeng/U 6930 2019; WANG, FUJIANG/AAI 1901 2020; Tu, Peng
   Fei/E 2089 2018
FU National Key Research and Development Project [2017YFC1702400]; National
   Natural Science Foundation of China [81773932]; National Key Technology
   R&D Program "New Drug Innovation" of China [2018ZX09711001 008 003]
FX This study was supported by the National Key Research and Development
   Project (2017YFC1702400) , the National Natural Science Foundation of
   China (81773932) and the National Key Technology R&D Program "New Drug
   Innovation" of China (2018ZX09711001 008 003) .
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Canalis E, 2009, J CELL BIOCHEM, V108, P769, DOI 10.1002/jcb.22322
   Chen Y., 2020, J ETHNOPHARMACOL, V257, P1
   Gang X., 2018, JILIN XUE XUE BAO, V44, P68
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Han Z., 2015, MODERN CHINESE MED, V17, P19
   Huo J., 2016, Genetics and Molecular Research, V15, P15049169
   Hwang YH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070901
   Jing H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0231 0
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li F, 2013, PHYTOMEDICINE, V20, P549, DOI 10.1016/j.phymed.2013.01.001
   Li Rui yan, 2019, Journal of Chinese Pharmaceutical Sciences, V28, P537, DOI 10.5246/jcps.2019.08.051
   Li TM, 2012, J PHARM PHARMACOL, V64, P897, DOI 10.1111/j.2042 7158.2012.01483.x
   Liang HD, 2013, MOL BIOL REP, V40, P757, DOI 10.1007/s11033 012 2065 2
   Liu JJ, 2018, PHYTOMEDICINE, V42, P43, DOI 10.1016/j.phymed.2018.03.020
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   National Pharmacopoeia Committee, 2020, PHARMACOPOEIA PEOPLE, P140
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Shi Z., 2019, MOD CHIN MED, V32, P1, DOI [10.13313/j.issn.1673 4890.20190320006, DOI 10.13313/J.ISSN.1673 4890.20190320006]
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Song DZ, 2018, J CELL PHYSIOL, V233, P9674, DOI 10.1002/jcp.26882
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Wang FJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00236
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Xu XX, 2017, MOLECULES, V22, DOI 10.3390/molecules22020197
   Ye CY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12752
   Zhang B, 2019, FRONT PHARMACOL
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
NR 32
TC 36
Z9 42
U1 6
U2 94
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAY 10
PY 2021
VL 271
AR 113899
DI 10.1016/j.jep.2021.113899
EA FEB 2021
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA QR6YT
UT WOS:000625362800007
PM 33549763
DA 2025 08 17
ER

PT J
AU Zhong, ZY
   Qian, Z
   Zhang, X
   Chen, FC
   Ni, S
   Kang, ZR
   Zhang, FX
   Li, DJ
   Yu, BQ
AF Zhong, Zeyuan
   Qian, Zhi
   Zhang, Xu
   Chen, Fancheng
   Ni, Shuo
   Kang, Zhanrong
   Zhang, Fangxue
   Li, Dejian
   Yu, Baoqing
TI Tetrandrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting
   RANKL Induced Osteoclastogenesis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE postmenopausal osteoporosis; tetrandrine; osteoclasts; differentiation;
   OVX mice
ID ALKALOID TETRANDRINE; OSTEOPOROSIS; INSIGHTS; IMMUNE; DIFFERENTIATION;
   MECHANISMS; TURNOVER; ESTROGEN; THERAPY; GROWTH
AB Postmenopausal osteoporosis (PMOP) is a metabolic bone disease characterized by decreased bone density and strength due to the imbalance between osteogenesis and osteoclastogenesis. Postmenopausal estrogen withdrawal increases proinflammatory cytokines and increases the serum level of Receptor activator of NF kB ligand (RANKL)/Osteoprotegerin (OPG), which then leads to the overactivation of osteoclastogenesis. Tetrandrine, a bis benzylisoquinoline alkaloid, has been widely used in the treatment of rheumatoid arthritis clinically in China. Here, we demonstrate that tetrandrine significantly prevented ovariectomy induced bone loss and inhibited RANKL induced osteoclastogenesis. In vivo, we found that intraperitoneal injection of tetrandrine (30 mg/kg) every other day markedly reduced bone loss in ovariectomized mice and the serum levels of TRAcp5b, TNF a, IL 6, CTX I, and RANKL/OPG were significantly decreased. In vitro, we found that tetrandrine significantly inhibited osteoclast differentiation in bone marrow monocytes (BMMs) and RAW264.7 cells according to the results of osteoclastogenesis related gene expression, tartrate resistant acid phosphatase (TRAP) staining and actin ring formation as well as bone resorption assay. Mechanistically, tetrandrine inhibited RANKL induced osteoclastogenesis by suppressing NF kB, Ca2(+), PI3K/AKT, and MAPKs signaling pathways. Taken together, our findings suggest that tetrandrine suppresses osteoclastogenesis through modulation of multiple pathways and has potential value as a therapeutic agent for PMOP, especially for those suffering from RA and PMOP at the same time.
C1 [Zhong, Zeyuan; Qian, Zhi; Zhang, Xu; Ni, Shuo; Kang, Zhanrong; Zhang, Fangxue; Li, Dejian; Yu, Baoqing] Fudan Univ, Shanghai Pudong Hosp, Dept Orthoped, Pudong Med Ctr, Shanghai, Peoples R China.
   [Chen, Fancheng] Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China.
C3 Fudan University; Fudan University
RP Li, DJ; Yu, BQ (通讯作者)，Fudan Univ, Shanghai Pudong Hosp, Dept Orthoped, Pudong Med Ctr, Shanghai, Peoples R China.
EM lidejian880820@163.com; doctorybq@163.com
RI Qian, Zhimin/P 1823 2018; Li, Dejian/ABG 3740 2021
OI Qian, Zhi/0000 0003 3265 7560; Zhong, Zeyuan/0000 0001 6990 8648; 
FU National Natural Science Foundation of China [81971753]; Outstanding
   Clinical Discipline Project of Shanghai Pudong [PWYgy2018 09]; key
   Disciplines Group Construction Project of Pudong Health Bureau of
   Shanghai [PWZxq2017 11]; Program for Outstanding Leader of Shanghai
   [046]
FX This work was supported by the National Natural Science Foundation of
   China (81971753), The Outstanding Clinical Discipline Project of
   Shanghai Pudong (Grant No. PWYgy2018 09), The key Disciplines Group
   Construction Project of Pudong Health Bureau of Shanghai (PWZxq2017 11),
   Program for Outstanding Leader of Shanghai (046).
CR Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0040 9
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Croft M, 2017, NAT REV RHEUMATOL, V13, P217, DOI 10.1038/nrrheum.2017.22
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Farr JN, 2015, NAT REV ENDOCRINOL, V11, P513, DOI 10.1038/nrendo.2015.89
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Gartlehner G, 2017, JAMA J AM MED ASSOC, V318, P2234, DOI 10.1001/jama.2017.16952
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Ho LJ, 2004, BRIT J PHARMACOL, V143, P919, DOI 10.1038/sj.bjp.0706000
   Jia YG, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1286 2
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Liu C, 2018, EUR J MED CHEM, V145, P661, DOI 10.1016/j.ejmech.2018.01.022
   Liu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8949
   Liu T, 2017, BRIT J PHARMACOL, V174, P4308, DOI 10.1111/bph.14031
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mei LF, 2015, BRIT J PHARMACOL, V172, P2232, DOI 10.1111/bph.13045
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Sapir Koren R, 2017, BONE, V103, P102, DOI 10.1016/j.bone.2017.06.020
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takito J, 2017, BIOL OPEN, V6, P1104, DOI 10.1242/bio.025460
   Wang G, 2004, TRENDS PHARMACOL SCI, V25, P120, DOI 10.1016/j.tips.2004.01.009
   Watts NB, 2014, NAT REV ENDOCRINOL, V10, P412, DOI 10.1038/nrendo.2014.55
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Yu M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0779 2
NR 34
TC 34
Z9 37
U1 0
U2 38
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 10
PY 2020
VL 10
AR 1530
DI 10.3389/fphar.2019.01530
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA KF4ZW
UT WOS:000509253100001
PM 31998129
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yantsen, YS
   Olzhayev, F
   Umbayev, B
   Tsoy, A
   Hortelano, G
   Tokay, T
   Murata, H
   Russell, A
   Askarova, S
AF Yantsen, Yuliya Safarova
   Olzhayev, Farkhad
   Umbayev, Bauyrzhan
   Tsoy, Andrey
   Hortelano, Gonzalo
   Tokay, Tursonjan
   Murata, Hironobu
   Russell, Alan
   Askarova, Sholpan
TI Mesenchymal Stem Cells Coated with Synthetic Bone Targeting Polymers
   Enhance Osteoporotic Bone Fracture Regeneration
SO BIOENGINEERING BASEL
LA English
DT Article
DE osteoporosis; bone fracture; mesenchymal stem cells; targeted cell
   delivery
AB Osteoporosis is a progressive skeletal disease characterized by reduced bone density leading to bone fragility and an elevated risk of bone fractures. In osteoporotic conditions, decrease in bone density happens due to the augmented osteoclastic activity and the reduced number of osteoblast progenitor cells (mesenchymal stem cells, MSCs). We investigated a new method of cell therapy with membrane engineered MSCs to restore the osteoblast progenitor pool and to inhibit osteoclastic activity in the fractured osteoporotic bones. The primary active sites of the polymer are the N hydroxysuccinimide and bisphosphonate groups that allow the polymer to covalently bind to the MSCs' plasma membrane, target hydroxyapatite molecules on the bone surface and inhibit osteolysis. The therapeutic utility of the membrane engineered MSCs was investigated in female rats with induced estrogen dependent osteoporosis and ulnar fractures. The analysis of the bone density dynamics showed a 27.4% and 21.5% increase in bone density at 4 and 24 weeks after the osteotomy of the ulna in animals that received four transplantations of polymer modified MSCs. The results of the intravital observations were confirmed by the post mortem analysis of histological slices of the fracture zones. Therefore, this combined approach that involves polymer and cell transplantation shows promise and warrants further bio safety and clinical exploration.
C1 [Yantsen, Yuliya Safarova; Olzhayev, Farkhad; Umbayev, Bauyrzhan; Tsoy, Andrey; Askarova, Sholpan] Nazarbayev Univ, Lab Bioengn & Regenerat Med, Natl Lab Astana, Nur Sultan 010000, Kazakhstan.
   [Yantsen, Yuliya Safarova] Nazarbayev Univ, Sch Engn & Digital Sci, Nur Sultan 010000, Kazakhstan.
   [Hortelano, Gonzalo; Tokay, Tursonjan] Nazarbayev Univ, Sch Sci & Humanities, Nur Sultan 010000, Kazakhstan.
   [Murata, Hironobu; Russell, Alan] Carnegie Mellon Univ, Dept Chem Engn, Pittsburgh, PA 15213 USA.
C3 Nazarbayev University; Nazarbayev University; Nazarbayev University;
   Carnegie Mellon University
RP Askarova, S (通讯作者)，Nazarbayev Univ, Lab Bioengn & Regenerat Med, Natl Lab Astana, Nur Sultan 010000, Kazakhstan.
EM yantsen@nu.edu.kz; folzhayev@nu.edu.kz; bauyrzhan.umbayev@nu.edu.kz;
   andrey.tsoy@nu.edu.kz; gonzalo.hortelano@nu.edu.kz;
   tursonjan.tokay@nu.edu.kz; hiromura@andrew.cmu.edu; alanrussell@cmu.edu;
   shaskarova@nu.edu.kz
RI tokay, tursonjan/D 2457 2016; Safarova (Yantsen), Yuliya/AAL 7843 2020;
   Umbayev, Bauyrzhan/AAR 1900 2020; Askarova, Sholpan/P 1091 2017;
   Olzhayev, Farkhad/P 2121 2015
OI Safarova (Yantsen), Yuliya/0000 0003 0695 0413; Umbayev,
   Bauyrzhan/0000 0002 0286 7252; Tokay, Tursonjan/0000 0003 2219 3301;
   Murata, Hironobu/0000 0001 9040 214X; Askarova,
   Sholpan/0000 0001 6161 1671; 
FU Ministry of Education and Science of the Republic of Kazakhstan
   [0118PK01040]; CRP grant of Nazarbayev University [091019CRP2113]
FX This work was funded by the Grant of the Ministry of Education and
   Science of the Republic of Kazakhstan No. 0118PK01040 and the CRP grant
   of Nazarbayev University No. 091019CRP2113.
CR An SH, 2012, DENT MATER, V28, P1221, DOI 10.1016/j.dental.2012.09.001
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Chen L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153120
   Cheung WH, 2016, INJURY, V47, pS21, DOI 10.1016/S0020 1383(16)47004 X
   Cho SW, 2009, MOL THER, V17, P1979, DOI 10.1038/mt.2009.153
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   D'Souza S, 2014, BIOMATERIALS, V35, P9447, DOI 10.1016/j.biomaterials.2014.07.041
   Funk JR, 2000, J ORTHOP RES, V18, P126, DOI 10.1002/jor.1100180118
   Giannoudis P, 2007, INJURY, V38, pS90, DOI 10.1016/j.injury.2007.02.014
   GRUNDNES O, 1992, ACTA ORTHOP SCAND, V63, P487, DOI 10.3109/17453679209154720
   Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Huang S, 2015, CELL TRANSPLANT, V24, P2643, DOI 10.3727/096368915X687219
   James R, 2011, FRONT MATER SCI, V5, P342, DOI 10.1007/s11706 011 0151 3
   Jeon OH, 2016, DRUG DELIV TRANSL RE, V6, P105, DOI 10.1007/s13346 015 0266 7
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kamrani RS, 2013, J ORTHOP SCI, V18, P563, DOI 10.1007/s00776 013 0395 0
   Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187
   Kiernan J, 2016, STEM CELL TRANSL MED, V5, P683, DOI 10.5966/sctm.2015 0231
   Kubo T, 1999, J STEROID BIOCHEM, V68, P197, DOI 10.1016/S0960 0760(99)00032 1
   Leibacher J, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 015 0271 2
   Mathavan N, 2015, CALCIFIED TISSUE INT, V97, P134, DOI 10.1007/s00223 015 9991 7
   McCann RM, 2008, J ORTHOP RES, V26, P384, DOI 10.1002/jor.20505
   Mills LA, 2012, J BONE JOINT SURG BR, V94B, P865, DOI 10.1302/0301 620X.94B7.27370
   Nakase T, 2009, ARCH ORTHOP TRAUM SU, V129, P1539, DOI 10.1007/s00402 009 0914 9
   Namkung Matthai H, 2001, BONE, V28, P80, DOI 10.1016/S8756 3282(00)00414 2
   Pesce V, 2009, CLIN CASES MINER BON, V6, P131
   Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763
   Sackstein R, 2008, NAT MED, V14, P181, DOI 10.1038/nm1703
   Singh J, 2015, CURR STEM CELL RES T, V10, P37
   Tasso R, 2013, STEM CELLS DEV, V22, P3178, DOI 10.1089/scd.2013.0313
   Teitelbaum SL, 2010, CELL STEM CELL, V7, P553, DOI 10.1016/j.stem.2010.10.004
   Tevlin R, 2014, JOVE J VIS EXP, DOI 10.3791/52056
   Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001155.pub2
   Yamada Y, 2003, J CRANIO MAXILL SURG, V31, P27, DOI 10.1016/S1010 5182(02)00143 9
   Yao W, 2015, BONE, V70, P62, DOI 10.1016/j.bone.2014.07.026
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhang Linxia, 2010, J Vis Exp, DOI 10.3791/1852
NR 39
TC 3
Z9 3
U1 1
U2 18
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2306 5354
J9 BIOENGINEERING BASEL
JI Bioengineering Basel
PD DEC
PY 2020
VL 7
IS 4
AR 125
DI 10.3390/bioengineering7040125
PG 16
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA PJ0BY
UT WOS:000601446200001
PM 33053753
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Miyama, A
   Ebina, K
   Hirao, M
   Okamura, G
   Etani, Y
   Takami, K
   Goshima, A
   Miura, T
   Oyama, S
   Kanamoto, T
   Yoshikawa, H
   Nakata, K
AF Miyama, Akira
   Ebina, Kosuke
   Hirao, Makoto
   Okamura, Gensuke
   Etani, Yuki
   Takami, Kenji
   Goshima, Atsushi
   Miura, Taihei
   Oyama, Shohei
   Kanamoto, Takashi
   Yoshikawa, Hideki
   Nakata, Ken
TI Effects of iguratimod on glucocorticoid induced disorder of bone
   metabolism in vitro
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Glucocorticoid induced osteoporosis; Iguratimod; Osteoblast; Osteoclast;
   Osteocyte
AB Introduction Glucocorticoids are widely used to treat various diseases including rheumatoid arthritis (RA); however, one of the most frequent and severe adverse effects is glucocorticoid induced osteoporosis (GIOP). Iguratimod (IGU) is a novel conventional synthetic disease modifying anti rheumatic drug developed in Japan. The aim of this study is to investigate the effects of IGU on glucocorticoid induced disorder of bone metabolism in vitro. Materials and methods In osteoclastogenesis of mouse bone marrow derived cells, tartrate resistant acid phosphatase staining, resorption pit assay, western blotting, real time polymerase chain reaction (PCR), and mRNA sequencing were performed. In osteoblastogenesis of MC3T3 E1 cells, alkaline phosphatase (ALP) staining and activity, alizarin red staining, and mRNA sequencing were performed, and real time PCR and western blotting were conducted in MC3T3 E1 cells and murine osteocyte like cell line MLO Y4 cells. Results IGU significantly suppressed a dexamethasone induced increase in osteoclasts, differentiation, and bone resorption activity by inhibition of the receptor activator of the nuclear factor kappa B (RANK)/tumor necrosis factor receptor (TNFR) associated factor 6 (TRAF6)/nuclear factor kappa B (NF kappa B) p52 pathway. In MC3T3 E1 cells, IGU significantly upregulated dexamethasone induced downregulation of ALP activity, bone mineralization, and osteoblast related gene and protein expression. In MLO Y4 cells, IGU significantly upregulated dexamethasone induced downregulation of the gene expression of ALP and osteocalcin, and also downregulated receptor activator of NF kappa B ligand (RANKL)/osteoprotegerin gene expression ratio without dexamethasone. Conclusion These results suggest that IGU may improve glucocorticoid induced disorder of bone metabolism and may exhibit positive effects against GIOP associated with RA.
C1 [Miyama, Akira; Hirao, Makoto; Etani, Yuki; Takami, Kenji; Goshima, Atsushi; Miura, Taihei] Osaka Univ, Dept Orthopaed Surg, Grad Sch Med, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
   [Ebina, Kosuke; Oyama, Shohei] Osaka Univ, Dept Musculoskeletal Regenerat Med, Grad Sch Med, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
   [Okamura, Gensuke] Osaka Rosai Hosp, Dept Orthopaed Surg, Kita Ku, 1179 3 Nagasone Cho, Sakai, Osaka 5918025, Japan.
   [Kanamoto, Takashi; Nakata, Ken] Osaka Univ, Dept Hlth & Sport Sci, Grad Sch Med, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
   [Yoshikawa, Hideki] Toyonaka City Hosp, Dept Orthopaed Surg, 4 14 1 Shibaharacho, Toyonaka, Osaka 5608565, Japan.
C3 University of Osaka; University of Osaka; Osaka Rosai Hospital;
   University of Osaka
RP Ebina, K (通讯作者)，Osaka Univ, Dept Musculoskeletal Regenerat Med, Grad Sch Med, 2 2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM k ebina@umin.ac.jp
RI Takami, Kenji/ABG 3188 2020; Ebina, Kosuke/AAH 6171 2019
OI Etani, Yuki/0000 0001 5741 5969; Ebina, Kosuke/0000 0002 2426 1024
FU Grants in Aid for Scientific Research [21K16708, 20K09460] Funding
   Source: KAKEN
CR Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Du F, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2554
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gan K, 2016, INT IMMUNOPHARMACOL, V35, P294, DOI 10.1016/j.intimp.2016.03.038
   Hansen KE, 2014, SEMIN ARTHRITIS RHEU, V44, P47, DOI 10.1016/j.semarthrit.2014.02.002
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kohno M, 2001, J RHEUMATOL, V28, P2591
   Kuriyama K, 2002, BIOCHEM BIOPH RES CO, V299, P903, DOI 10.1016/S0006 291X(02)02754 7
   Li CH, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107219
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Naganathan V, 2000, ARCH INTERN MED, V160, P2917, DOI 10.1001/archinte.160.19.2917
   Noguchi T, 2017, OSTEOPOROSIS INT, V28, P1063, DOI 10.1007/s00198 016 3830 1
   Okada H, 2019, J BONE MINER RES, V34, P1744, DOI 10.1002/jbmr.3754
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis 2016 210715
   Song JL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4901591
   Suematsu Ayako, 2007, Mod Rheumatol, V17, P17
   Tanaka K, 2003, RHEUMATOLOGY, V42, P1365, DOI 10.1093/rheumatology/keg381
   Tanaka T, 2018, J BONE MINER METAB, V36, P519, DOI 10.1007/s00774 017 0868 x
   Wei Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/214683
   Wu YX, 2017, MOL MED REP, V16, P8200, DOI 10.3892/mmr.2017.7648
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yu CQ, 2017, MOL MED REP, V15, P543, DOI 10.3892/mmr.2016.6047
   Zhu L, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903432
NR 30
TC 4
Z9 6
U1 0
U2 6
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JUL
PY 2021
VL 39
IS 4
BP 639
EP 648
DI 10.1007/s00774 021 01206 5
EA FEB 2021
PG 10
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA TG4FX
UT WOS:000616436700001
PM 33564917
OA Green Published
DA 2025 08 17
ER

PT J
AU Hrnjak, AR
   Vuksanovic, M
   Dimkovic, N
   Djurovic, A
   Petronijevic, N
   Petronijevic, M
AF Hrnjak, Aleksandra Rakocevic
   Vuksanovic, Miljenka
   Dimkovic, Nada
   Djurovic, Aleksandar
   Petronijevic, Natasa
   Petronijevic, Milan
TI The effects of extreme low frequency pulsed electromagnetic field on
   bone mineral density and incidence of fractures in patients with end  
   stage renal disease on dialysis   three year follow up study
SO VOJNOSANITETSKI PREGLED
LA English
DT Article
DE kidney failure; chronic; renal dialysis; electromagnetic fields; bone
   density; fractures; bones; incidence; treatment outcome
ID BIOCHEMICAL MARKERS; HEMODIALYSIS; RISK; ASSOCIATION; MORTALITY;
   OUTCOMES; MASS
AB Background/Aim. A variety of physical therapy options has been developed for the treatment of musculoskeletal disorders including those characterized with low bone mineral density (BMD). Extreme low frequency pulsed electromagnetic field (ELF PEMF) can accelerate bone formation. Patients with end stage of renal disease (ESRD) are predisposed to high incidence of fractures due to bone disorder with multifactorial pathogenesis. Vitamin D, calcium supplements, antiresorptive and anabolic drugs in those patients have changed pharmacodynamics and pharmacokinetics and have minimal or limited effects. The aim of this study was to assess the effectiveness of longterm ELF PEMF therapy applied in concordance with physical exercise on bone mass, incidence of new bone fractures and parathyroid hormone concentrations in ESRD patients on dialysis. Methods. In this 3 year prospective clinical trial, 151 patients with ESRD on dialysis program were subjected to treatment with ELF PEMF (18 Hz, 2 mT) applied during 40 min after 10 consecutive dialysis procedures, 4 times through one year (120 treatments in total during three years) together with kinesitherapy (study group) or only with kinesitherapy (control group) on the voluntary basis. Results. Total of 124 patients have completed the study. In the study group (n = 54), regardless of sex, significant improvements of BMD, T score and Z score on both lumbar spine and femoral neck were achieved after 3 year treatment with ELF PEMF. In the control group (n = 70), significant decreases of BMD, T score and Z score as well as the higher incidence of new bone fractures were recorded. Conclusion. ELF PEMF could be a convenient and safe non pharmacological therapeutic strategy for fracture prevention in nephrology practices.
C1 [Hrnjak, Aleksandra Rakocevic] Univ Med Ctr Zvezdara, Ctr Phys Med & Rehabil, Belgrade, Serbia.
   [Vuksanovic, Miljenka; Dimkovic, Nada] Univ Med Ctr Zvezdara, Clin Internal Med, Belgrade, Serbia.
   [Djurovic, Aleksandar] Mil Med Acad, Clin Phys Med & Rehabil, Belgrade, Serbia.
   [Petronijevic, Milan] Mil Med Acad, Clin Rheumatol & Clin Immunol, Belgrade, Serbia.
   [Djurovic, Aleksandar; Petronijevic, Milan] Univ Def, Med Fac, Mil Med Acad, Belgrade, Serbia.
   [Petronijevic, Natasa] Univ Belgrade, Sch Med, Inst Med & Clin Biochem, Belgrade, Serbia.
C3 University of Belgrade
RP Petronijevic, M (通讯作者)，Univ Def, Fac Med, Mil Med Acad, Clin Rheumatol & Clin Immunol, Crnotravska 17, Belgrade 11000, Serbia.
EM milanpetronijevic@yahoo.com
OI Petronijevic, Natasa/0000 0002 4338 1953; Vuksanovic,
   Miljanka/0000 0002 1512 479X
CR BASSETT CAL, 1977, CLIN ORTHOP RELAT R, P128
   BASSETT CAL, 1989, CRIT REV BIOMED ENG, V17, P451
   Beaubrun AC, 2013, J AM SOC NEPHROL, V24, P1461, DOI 10.1681/ASN.2012090916
   Bragin DE, INCREASES MICROVASCU
   Chen YJ, 2014, OSTEOPOROSIS INT, V25, P1513, DOI 10.1007/s00198 014 2632 6
   Disthabanchong S, 2014, BLOOD PURIFICAT, V37, P33, DOI 10.1159/000357639
   Giannakopoulos XK, 2011, INT UROL NEPHROL, V43, P955, DOI 10.1007/s11255 011 9944 7
   Goto T, 2010, J ORTHOP SCI, V15, P661, DOI 10.1007/s00776 010 1510 0
   Hug K, 2012, BIOELECTROMAGNETICS, V33, P95, DOI 10.1002/bem.20703
   Iimori S, 2012, NEPHROL DIAL TRANSPL, V27, P345, DOI 10.1093/ndt/gfr317
   Jamal SA, 2012, OSTEOPOROSIS INT, V23, P1191, DOI 10.1007/s00198 011 1781 0
   Jing D, 2014, J BONE MINER RES, V29, P2250, DOI 10.1002/jbmr.2260
   Jing D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079377
   Kohno K, 2009, CALCIFIED TISSUE INT, V84, P180, DOI 10.1007/s00223 008 9206 6
   Luo F, 2012, ORTHOPEDICS, V35, pE526, DOI 10.3928/01477447 20120327 11
   Matsubara K, 2008, BLOOD PURIFICAT, V26, P284, DOI 10.1159/000126925
   OCONNOR BT, 1984, LANCET, V2, P171
   Panaput T, 2014, BLOOD PURIFICAT, V38, P253, DOI 10.1159/000368885
   Park SH, 2013, J NEPHROL, V26, P485, DOI 10.5301/jn.5000185
   Pieber K, 2010, J REHABIL MED, V42, P289, DOI 10.2340/16501977 0554
   Rajabi AH, 2015, ACTA BIOMATER, V24, P12, DOI 10.1016/j.actbio.2015.07.010
   Rodríguez García M, 2009, NEPHROL DIAL TRANSPL, V24, P239, DOI 10.1093/ndt/gfn466
   Salam SN, 2014, AM J KIDNEY DIS, V63, P1049, DOI 10.1053/j.ajkd.2013.12.016
   Schnoke M, 2007, J ORTHOP RES, V25, P933, DOI 10.1002/jor.20373
   Shen WW, 2010, BIOELECTROMAGNETICS, V31, P113, DOI 10.1002/bem.20535
   Shupak N. M., 2003, Radio Science Bulletin, P9
   Stevens PE, 2013, ANN INTERN MED, V158, P825, DOI 10.7326/0003 4819 158 11 201306040 00007
   Ureña P, 2003, NEPHROL DIAL TRANSPL, V18, P2325, DOI 10.1093/ndt/gfg403
   Vincenzi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065561
   von der Recke P, 1999, AM J MED, V106, P273, DOI 10.1016/S0002 9343(99)00028 5
   Wagner J, 2014, NEPHROL DIAL TRANSPL, V29, P146, DOI 10.1093/ndt/gft352
   Wang Q, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 271
   West SL, 2010, BMC NEPHROL, V11, DOI 10.1186/1471 2369 11 17
NR 33
TC 1
Z9 1
U1 0
U2 5
PU MILITARY MEDICAL ACAD INI
PI BELGRADE
PA CRNOTRAVSKA 17, PO BOX 33 35, BELGRADE, 11040, SERBIA
SN 0042 8450
EI 2406 0720
J9 VOJNOSANIT PREGL
JI Vojnosanit. Pregl.
PY 2018
VL 75
IS 3
BP 273
EP 280
DI 10.2298/VSP160617212R
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA GB8EO
UT WOS:000429308400006
OA gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Binder, NB
   Puchner, A
   Niederreiter, B
   Hayer, S
   Leiss, H
   Blüml, S
   Kreindl, R
   Smolen, JS
   Redlich, K
AF Binder, Nikolaus B.
   Puchner, Antonia
   Niederreiter, Birgit
   Hayer, Silvia
   Leiss, Harald
   Blueml, Stephan
   Kreindl, Roman
   Smolen, Josef S.
   Redlich, Kurt
TI Tumor necrosis factorinhibiting therapy preferentially targets bone
   destruction but not synovial inflammation in a tumor necrosis
   factordriven model of rheumatoid arthritis
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID ACUTE PHASE REACTANTS; KAPPA B LIGAND; FACTOR ALPHA; OSTEOCLAST
   DIFFERENTIATION; PLUS METHOTREXATE; PHYSICAL DISABILITY; RECEPTOR
   ACTIVATOR; JOINT DESTRUCTION; TRANSGENIC MICE; DAMAGE
AB Objective To investigate how tumor necrosis factor (TNF)inhibiting therapy affects bone destruction and inflammation in a TNF driven mouse model of rheumatoid arthritis. Methods In order to evaluate the influence of TNF on osteoclastogenesis in vitro, different concentrations of TNF were added to spleen cellderived monocytes in the absence or presence of different concentrations of RANKL. In addition, the effects of TNF inhibition on osteoclast precursors as well as local bone destruction in vivo were assessed by treating TNF transgenic mice with different doses of adalimumab. Results TNF stimulated osteoclastogenesis mainly by increasing the number of osteoclast precursor cells in vitro. This TNF effect was independent of the presence of RANKL. In the hTNF transgenic mouse model of destructive arthritis, low dose TNF inhibiting therapy with adalimumab had no effect on synovial inflammation but significantly inhibited local bone destruction and the generation of osteoclasts. This inhibition was accompanied by a reduction in the number of c Fmspositive osteoclast precursor cells in the bone marrow and a reduction of the osteoclast precursor pools in the blood and inflamed synovial membrane of hTNF transgenic mice. Conclusion Low dose TNF inhibiting therapy significantly reduces bone erosions by reducing the number of circulating and joint invading osteoclast precursors. This effect is uncoupled from its antiinflammatory action.
C1 [Binder, Nikolaus B.; Puchner, Antonia; Niederreiter, Birgit; Hayer, Silvia; Leiss, Harald; Blueml, Stephan; Kreindl, Roman; Smolen, Josef S.; Redlich, Kurt] Med Univ Vienna, A 1090 Vienna, Austria.
   [Binder, Nikolaus B.] Hosp Special Surg, New York, NY 10021 USA.
C3 Medical University of Vienna
RP Redlich, K (通讯作者)，Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, Wahringer Gurtel 18 20, A 1090 Vienna, Austria.
EM kurt.redlich@meduniwien.ac.at
RI ; Smolen, Josef/ADI 7087 2022
OI Bluml, Stephan/0000 0002 2758 4400; Hayer, Silvia/0000 0003 1334 5668; 
FU European Community Seventh Framework Programme (project Masterswitch)
   [HEALTH F2 2008 223404]; Abbott Immunology
FX Supported by the European Community Seventh Framework Programme (project
   Masterswitch: HEALTH F2 2008 223404) and in part by a grant from Abbott
   Immunology.
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Aletaha D, 2005, ARTHRITIS RES THER, V7, pR796, DOI 10.1186/ar1740
   Axmann R, 2009, ARTHRITIS RHEUM US, V60, P2747, DOI 10.1002/art.24781
   Blüml S, 2010, ARTHRITIS RHEUM US, V62, P1608, DOI 10.1002/art.27399
   Chiu YG, ARTHRITIS RES THER, V12, pR14
   Crotti TN, 2002, ANN RHEUM DIS, V61, P1047, DOI 10.1136/ard.61.12.1047
   Eferl R, 2008, P NATL ACAD SCI USA, V105, P10525, DOI 10.1073/pnas.0801414105
   Emery P, 2009, J RHEUMATOL, V36, P1429, DOI 10.3899/jrheum.081018
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Feldmann M, 2008, IMMUNOL REV, V223, P7, DOI 10.1111/j.1600 065X.2008.00626.x
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Hayer S, 2005, J EXP MED, V201, P903, DOI 10.1084/jem.20040852
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Klarenbeek NB, 2010, ANN RHEUM DIS, V69, P2107, DOI 10.1136/ard.2010.131201
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Landewé R, 2006, ARTHRITIS RHEUM US, V54, P3119, DOI 10.1002/art.22143
   Leonard JP, 2012, BLOOD, V119, P4597, DOI 10.1182/blood 2011 10 388298
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Partsch G, 1997, J RHEUMATOL, V24, P518
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   SAXNE T, 1985, LANCET, V2, P127
   Smolen JS, 2012, ANN RHEUM DIS, V71, P687, DOI 10.1136/annrheumdis 2011 200395
   Smolen JS, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2418
   Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   VANDERHEIJDE DMFM, 1992, BRIT J RHEUMATOL, V31, P519
   VANLEEUWEN MA, 1994, J RHEUMATOL, V21, P425
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Weinblatt ME, 2003, ARTHRITIS RHEUM US, V48, P35, DOI 10.1002/art.10697
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Ziolkowska M, 2002, ARTHRITIS RHEUM US, V46, P1744, DOI 10.1002/art.10388
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
   Zwerina J, 2007, P NATL ACAD SCI USA, V104, P11742, DOI 10.1073/pnas.0610812104
NR 38
TC 49
Z9 64
U1 0
U2 6
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD MAR
PY 2013
VL 65
IS 3
BP 608
EP 617
DI 10.1002/art.37797
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 097CU
UT WOS:000315452400009
PM 23280418
DA 2025 08 17
ER

PT J
AU Yao, J
   Li, J
   Zhou, L
   Cheng, JW
   Chim, SM
   Zhang, G
   Quinn, JMW
   Tickner, J
   Zhao, JM
   Xu, JK
AF Yao, Jun
   Li, Jia
   Zhou, Lin
   Cheng, Jianwen
   Chim, Shek Man
   Zhang, Ge
   Quinn, Julian M. W.
   Tickner, Jennifer
   Zhao, Jinmin
   Xu, Jiake
TI Protein Kinase C Inhibitor, GF109203X Attenuates Osteoclastogenesis,
   Bone Resorption and RANKL Induced NF κB and NFAT Activity
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID TUMOR NECROSIS FACTOR; OSTEOPROTEGERIN LIGAND; SELECTIVE INHIBITOR;
   PHORBOL ESTER; PKC ISOFORMS; CANCER CELLS; DIFFERENTIATION; ACTIVATION;
   TRANSCRIPTION; PROMOTER
AB Osteolytic bone diseases are characterized by excessive osteoclast formation and activation. Protein kinase C (PKC) dependent pathways regulate cell growth, differentiation and apoptosis in many cellular systems, and have been implicated in cancer development and osteoclast formation. A number of PKC inhibitors with anti cancer properties have been developed, but whether they might also influence osteolysis (a common complication of bone invading cancers) is unclear. We studied the effects of the PKC inhibitor compound, GF109203X on osteoclast formation and activity, processes driven by receptor activator of NFB ligand (RANKL). We found that GF109203X strongly and dose dependently suppresses osteoclastogenesis and osteoclast activity in RANKL treated primary mouse bone marrow cells. Consistent with this GF109203X reduced expression of key osteoclastic genes, including cathepsin K, calcitonin receptor, tartrate resistant acid phosphatase (TRAP) and the proton pump subunit V ATPase d2 in RANKL treated primary mouse bone marrow cells. Expression of these proteins is dependent upon RANKL induced NF B and NFAT transcription factor actions; both were reduced in osteoclast progenitor populations by GF109203X treatment, notably NFATc1 levels. Furthermore, we showed that GF109203X inhibits RANKL induced calcium oscillation. Together, this study shows GF109203X may block osteoclast functions, suggesting that pharmacological blockade of PKC dependent pathways has therapeutic potential in osteolytic diseases. J. Cell. Physiol. 230: 1235 1242, 2015. (c) 2014 Wiley Periodicals, Inc., A Wiley Company
C1 [Yao, Jun; Li, Jia; Cheng, Jianwen; Zhao, Jinmin; Xu, Jiake] Guangxi Med Univ, Dept Orthopaed Surg, Res Ctr Regenerat Med, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Yao, Jun; Zhou, Lin; Cheng, Jianwen; Chim, Shek Man; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia.
   [Li, Jia] Guangxi Med Univ, Dept Pathol, Res Ctr Regenerat Med, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Zhang, Ge] Hong Kong Baptist Univ, Inst Adv Translat Med Bone & Joint Dis, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
   [Quinn, Julian M. W.] Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia.
   [Quinn, Julian M. W.] MIMR PHI Inst, Clayton, Vic, Australia.
C3 Guangxi Medical University; University of Western Australia; Guangxi
   Medical University; Hong Kong Baptist University; Garvan Institute of
   Medical Research; Prince Henry's Institute of Medical Research
RP Zhao, JM (通讯作者)，Guangxi Med Univ, Dept Orthopaed Surg, Res Ctr Regenerat Med, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning, Guangxi, Peoples R China.
EM zhaojingmin@126.com; jiake.xu@uwa.edu.au
RI ; Tickner, Jennifer/H 5965 2014; zhao, jin/LBH 0351 2024; Zhang,
   Ge/N 4150 2013; ZHANG, Ge/N 4150 2013; Chim, Shek/AAK 6809 2020
OI Zhao, Jinmin/0000 0002 1047 8820; Tickner, Jennifer/0000 0002 5020 0671;
   Xu, Jiake/0000 0003 2021 8309; ZHANG, Ge/0000 0002 7807 7695; 
FU National Natural Science Foundation of China (NSFC) [81228013]
FX Contract grant sponsor: National Natural Science Foundation of China
   (NSFC); Contract grant number: 81228013.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Catley MC, 2004, J BIOL CHEM, V279, P18457, DOI 10.1074/jbc.M400765200
   Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344
   DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968 0004(94)90038 8
   Diaz Meco MT, 2012, IMMUNOL REV, V246, P154, DOI 10.1111/j.1600 065X.2012.01093.x
   El Fitori J, 2007, CANCER AM CANCER SOC, V110, P1457, DOI 10.1002/cncr.22931
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454
   HEIKKILA J, 1993, BIOCHEM BIOPH RES CO, V197, P1185, DOI 10.1006/bbrc.1993.2602
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jimi E, 1999, J IMMUNOL, V163, P434
   Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898 6568(97)00121 6
   Khor EC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070815
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092 8674(86)90874 3
   Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440 1711.1999.00815.x
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Larsen EC, 2000, J IMMUNOL, V165, P2809, DOI 10.4049/jimmunol.165.5.2809
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lee SW, 2003, BONE, V32, P217, DOI 10.1016/S8756 3282(02)00976 6
   Lin WW, 1998, BRIT J PHARMACOL, V125, P1601, DOI 10.1038/sj.bjp.0702219
   Liu Q, 2013, BIOCHEM PHARMACOL, V86, P1775, DOI 10.1016/j.bcp.2013.09.017
   Moonga BS, 1998, EXP PHYSIOL, V83, P717, DOI 10.1113/expphysiol.1998.sp004153
   Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272
   NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960 9822(95)00191 6
   NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651
   Sipma H, 1996, BRIT J PHARMACOL, V119, P730, DOI 10.1111/j.1476 5381.1996.tb15733.x
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Tekle C, 2008, BRIT J CANCER, V99, P750, DOI 10.1038/sj.bjc.6604566
   TOULLEC D, 1991, J BIOL CHEM, V266, P15771
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Wu J, 2010, INVEST NEW DRUG, V28, P268, DOI 10.1007/s10637 009 9242 8
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
NR 39
TC 22
Z9 23
U1 1
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2015
VL 230
IS 6
BP 1235
EP 1242
DI 10.1002/jcp.24858
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA CC4EK
UT WOS:000350303400008
PM 25363829
DA 2025 08 17
ER

PT J
AU Salman, S
   Kumbasar, S
   Hacimuftuoglu, A
   Ozturk, B
   Seven, B
   Polat, B
   Gundogdu, C
   Demirci, E
   Yildirim, K
   Akcay, F
   Uslu, T
   Daloglu, FT
   Suleyman, H
AF Salman, Suleyman
   Kumbasar, Serkan
   Hacimuftuoglu, Ahmet
   Ozturk, Berna
   Seven, Bedri
   Polat, Beyzagul
   Gundogdu, Cemal
   Demirci, Elif
   Yildirim, Kadir
   Akcay, Fatih
   Uslu, Turan
   Daloglu, Ferrah Tuncel
   Suleyman, Halis
TI The effect of metyrosine/prednisolone combination to
   oophorectomy induced osteoporosis
SO IRANIAN JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article
DE Osteoporosis; Metyrosine; Methylprednisolon; Alendronate; Ovariectomy
ID ANTIULCER EFFECT MECHANISM; BONE DENSITY; ADRENERGIC RECEPTORS;
   POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; ELDERLY WOMEN; RATS;
   ESTROGEN; HORMONE; CYCLOOXYGENASE 2
AB Background: Osteoporosis is a chronic disease characterized by a decrease in bone mineral density (BMD) and corruption of the microarchitectural structure of bone tissue.
   Objective: It was investigated whether methylprednisolone had a favorable effect on osteoporotic bone tissue in Oophorectomy induced osteoporotic rats whose endogenous adrenaline levels are suppresed with metyrosine.
   Materials and Methods: Bone Mineral Density, number of osteoblast osteoclast, bone osteocalcin levels and alkaline phosphatase (ALP) measurements were performed. Obtained results were compared with that of alendronate.
   Results: Oophorectomy induced osteoporosis was exacerbated by methylprednisolone. Alentronate prevented ovariectomised induced osteoporis, but it couldn't prevent methylprednisolone +ovariectomised induced osteoporosis in rats.
   Conclusion: Combined treatment with methylprednisolon and metyrosine was the best treatment for preventing osteoporosis but metyrosine alone couldn't prevent osteoporosis in ovariectomised rats.
C1 [Hacimuftuoglu, Ahmet; Ozturk, Berna; Polat, Beyzagul; Suleyman, Halis] Ataturk Univ, Fac Med, Dept Pharmacol, Erzurum, Turkey.
   [Salman, Suleyman; Kumbasar, Serkan] Igdir Natl Hosp, Dept Obstet & Gynecol, Igdir, Turkey.
   [Seven, Bedri] Ataturk Univ, Fac Med, Dept Nucl Med, Erzurum, Turkey.
   [Gundogdu, Cemal; Demirci, Elif; Daloglu, Ferrah Tuncel] Ataturk Univ, Fac Med, Dept Pathol, Erzurum, Turkey.
   [Yildirim, Kadir] Ataturk Univ, Fac Med, Dept Phys Med & Rehabil, Erzurum, Turkey.
   [Akcay, Fatih] Ataturk Univ, Fac Med, Dept Biochem, Erzurum, Turkey.
   [Uslu, Turan] Fatih Sultan Mehmet Educ & Res Hosp, Dept Phys Med & Rehabil, Istanbul, Turkey.
C3 Ataturk University; Igdir State Hospital; Ataturk University; Ataturk
   University; Ataturk University; Ataturk University; Fatih Sultan Mehmet
   Training & Research Hospital
RP Suleyman, H (通讯作者)，Ataturk Univ, Fac Med, Dept Pharmacol, Erzurum, Turkey.
EM suleyman@atauni.edu.tr
RI ; seven, bedri/K 1029 2015; kumbasar, serkan/GWV 5707 2022; AKCAY,
   Fatih/AAG 7735 2019; salman, süleyman/JJY 1475 2023; Öztürk Karagöz,
   Berna/A 2919 2019; Hacimuftuoglu, Ahmet/U 9109 2018; polat,
   beyzagul/G 6010 2012
OI OZTURK KARAGOZ, BERNA/0000 0001 7187 1557; Seven,
   Bedri/0000 0002 2645 7661; Gundogdu, Cemal/0000 0003 2857 923X;
   Hacimuftuoglu, Ahmet/0000 0002 9658 3313; 
CR Adachi JD, 2000, SEMIN ARTHRITIS RHEU, V29, P228, DOI 10.1016/S0049 0172(00)80011 6
   Albayrak A, 2010, PHARMACOL REP, V62, P113, DOI 10.1016/S1734 1140(10)70248 6
   Andreassen H, 1997, SCAND J GASTROENTERO, V32, P1247, DOI 10.3109/00365529709028155
   Bezerra MM, 2000, J PERIODONTOL, V71, P1009, DOI 10.1902/jop.2000.71.6.1009
   Birdwood G, 1996, UNDERSTANDING OSTEOP, P37
   Biyikli NK, 2004, PEDIATR NEPHROL, V19, P869, DOI 10.1007/s00467 004 1537 6
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Borekci B, 2009, GYNECOL ENDOCRINOL, V25, P264, DOI 10.1080/09513590802630104
   BUCKWALTER JA, 1995, J BONE JOINT SURG AM, V77A, P1256, DOI 10.2106/00004623 199508000 00019
   Eastell R, 1996, OSTEOPOROSIS INT, V6, P3, DOI 10.1007/BF01625232
   Ettinger B, 1998, J CLIN ENDOCR METAB, V83, P2239, DOI 10.1210/jc.83.7.2239
   FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601
   Fleisch H, 2001, OSTEOPOROSIS, P449
   GARNERO P, 1996, CALCIFIED TISSUE INT, V59, P2
   Genant HK, 1996, J BONE MINER RES, V11, P707
   Gilbert SM, 2005, CURR OPIN UROL, V15, P23, DOI 10.1097/00042307 200501000 00006
   Hoffman BB, 2009, GOODMAN GILMANS PHAR, P845
   KELLY P, 1969, GASTROENTEROLOGY, V56, P24
   Mano Tadaaki, 2010, Acta Physiol Hung, V97, P354, DOI 10.1556/APhysiol.97.2010.4.8
   McCormick RK, 2007, ALTERN MED REV, V12, P113
   Morton RS, 2001, J PERIODONTOL, V72, P461, DOI 10.1902/jop.2001.72.4.461
   Mosekilde L, 2008, CLIN ENDOCRINOL, V69, P1, DOI 10.1111/j.1365 2265.2007.03162.x
   Nancy EL., 2006, AM J OBSTET GYNECOL, V194, P3
   Nar A, 2009, GYNECOL ENDOCRINOL, V25, P773, DOI 10.3109/09513590903159532
   Papakitsou EF, 2004, MATURITAS, V47, P185, DOI 10.1016/S0378 5122(03)00282 2
   Reid IR, 2000, BEST PRACT RES CL EN, V14, P279, DOI 10.1053/beem.2000.0074
   Rosen CJ, 2000, CLIN LAB MED, V20, P455
   Seibel MJ, 2003, ENDOCRIN METAB CLIN, V32, P83, DOI 10.1016/S0889 8529(02)00077 4
   STEWART AF, 1985, ANN INTERN MED, V102, P776, DOI 10.7326/0003 4819 102 6 776
   Suleyman H, 2009, J PHYSIOL PHARMACOL, V60, P129
   Suleyman H, 2007, N S ARCH PHARMACOL, V375, P189, DOI 10.1007/s00210 007 0151 0
   TAKEUCHI K, 1989, GASTROENTEROLOGY, V97, P284, DOI 10.1016/0016 5085(89)90063 2
   Tekin Y, 2005, TURK KLIN BIYOKIMYA, V3, P73
   Tiras MB, 2000, HUM REPROD, V15, P2087, DOI 10.1093/humrep/15.10.2087
   van Staa T, 2001, BONE MINER RES, V15, P993
   Vytrisalova M, 2007, MATURITAS, V56, P21, DOI 10.1016/j.maturitas.2006.05.005
NR 36
TC 7
Z9 7
U1 0
U2 11
PU SHAHID SADOUGHI UNIV MEDICAL SCIENCES YAZD
PI YAZD
PA RESEARCH & CLINICAL CENTER FOR INFERTILITY, PO BOX 89195 999, YAZD,
   00000, IRAN
SN 1680 6433
J9 IRAN J REPROD MED
JI Iran. J. Reprod. Med.
PD JUL
PY 2012
VL 10
IS 4
BP 363
EP 372
PG 10
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 994XZ
UT WOS:000307969500011
PM 25246899
DA 2025 08 17
ER

PT J
AU Wang, ZX
   Yin, XY
   Zhuang, CY
   Wu, K
   Wang, HR
   Shao, ZZ
   Tian, B
   Lin, H
AF Wang, Zixiang
   Yin, Xueyang
   Zhuang, Chenyang
   Wu, Kang
   Wang, Huiren
   Shao, Zhengzhong
   Tian, Bo
   Lin, Hong
TI Injectable Regenerated Silk Fibroin Micro/Nanosphere with Enhanced
   Permeability and Stability for Osteoarthritis Therapy
SO SMALL
LA English
DT Article
DE isoliquiritin; micro/nanosphere; osteoarthritis; phenylboronic acid;
   regenerated silk fibroin
ID SUBCHONDRAL BONE; RAT MODEL; ISOLIQUIRITIN; NANOPARTICLES; ACID; PH;
   CARTILAGE; STRENGTH; DELIVERY
AB In the therapy of early stage osteoarthritis, to accomplish full infiltration of subchondral bone and cartilage, and to target osteoclast and chondrocyte simultaneously remain challenges in biomaterials design. Herein, a novel hierarchical drug delivery system is introduced, with micrometer scale outer layer spheres composed of regenerated silk fibroin, characterized by connected porous structure through the n butanol and regenerated silk fibroin combined emulsion route and freezing method. The design effectively resists clearance from the joint cavity, ensuring stable delivery and prolonged residence time within the joint space. Additionally, the system incorporates phenylboronic acid enriched silk fibroin nanoparticles, stabilized through chemical cross linking, which encapsulate isoliquiritin derived from Glycyrrhiza uralensis. These nanoparticles facilitate complete penetration of the cartilage extracellular matrix, exhibit pH responsive behavior, neutralize reactive oxygen species, and enable controlled drug release, thereby enhancing therapeutic efficacy. The in vitro and in vivo experiments both demonstrate that the composite micro/nanospheres not only inhibit osteoclastogenesis with bone loss in subchondral bone and osteophyte formation, but also mitigate chondrocytes apoptosis, reduce oxidative stress associated with cartilage degeneration, and ameliorate neuropathic hyperalgesia, with the underlying mechanisms being elucidated. The study indicates that such an injectable strategy combining organic biomaterials with Chinese medicine holds substantial promise for the treatment of early osteoarthritis.
   A micro/nano drug delivery system with micrometer sized outer layer spheres of regenerated silk fibroin is conducted, resisting the cavity clearance effect and realizing the stable conveyance and enduring residence time in the knee joint. The embedded phenylboronic acid rich regenerated silk fibroin nanoparticles carrying isoliquiritin achieve the full penetration of cartilage extracellular matrix, pH responsiveness, reactive oxygen species obliteration, and drug release control. image
C1 [Wang, Zixiang; Yin, Xueyang; Zhuang, Chenyang; Wu, Kang; Wang, Huiren; Shao, Zhengzhong; Tian, Bo; Lin, Hong] Fudan Univ, Zhongshan Hosp, Dept Orthoped, State Key Lab Mol Engn Polymers,Lab Adv Mat, Shanghai 200032, Peoples R China.
   [Wang, Zixiang; Yin, Xueyang; Zhuang, Chenyang; Wu, Kang; Wang, Huiren; Shao, Zhengzhong; Tian, Bo; Lin, Hong] Fudan Univ, Dept Macromol Sci, Shanghai 200032, Peoples R China.
   [Zhuang, Chenyang; Lin, Hong] Fudan Univ, Shanghai Geriatr Med Ctr, Dept Orthoped, Shanghai 201100, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Shao, ZZ; Tian, B; Lin, H (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Orthoped, State Key Lab Mol Engn Polymers,Lab Adv Mat, Shanghai 200032, Peoples R China.; Shao, ZZ; Tian, B; Lin, H (通讯作者)，Fudan Univ, Dept Macromol Sci, Shanghai 200032, Peoples R China.; Lin, H (通讯作者)，Fudan Univ, Shanghai Geriatr Med Ctr, Dept Orthoped, Shanghai 201100, Peoples R China.
EM zzshao@fudan.edu.cn; tian.bo@zs hospital.sh.cn;
   lin.hong1@zs hospital.sh.cn
RI Zhang, Renyuan/E 3914 2015; Wu, Kang/GQZ 8327 2022
FU National Natural Science Foundation of China [21935002]; Natural Science
   Foundation of Shanghai Municipality [21ZR1455800]; Shanghai Pujiang
   Program [22PJD010]; Three Year Initiative Plan for Strengthening Public
   Health System Construction in Shanghai [GWV 10.2 XD11]; Figdraw
FX Z.W., X.Y., and C.Z. contributed equally to this work. This study was
   supported by the National Natural Science Foundation of China (Grant
   number: 21935002), the Natural Science Foundation of Shanghai
   Municipality (Grant Number: 21ZR1455800), the Shanghai Pujiang Program
   (Grant Number: 22PJD010), and the Three Year Initiative Plan for
   Strengthening Public Health System Construction in Shanghai (Grant
   number: GWV 10.2 XD11). All animal experiments were performed with the
   approval of the Animal Ethical Committee of Zhongshan Hospital, Fudan
   University. Part of the materials in the scheme was supported by
   Figdraw.
CR Amin HH, 2017, COLLOID SURFACE B, V159, P571, DOI 10.1016/j.colsurfb.2017.08.014
   Barton NJ, 2007, J NEUROSCI METH, V163, P67, DOI 10.1016/j.jneumeth.2007.02.012
   Bian Y., 2023, WENG ADV SCI, V10
   Bolduc JA, 2019, FREE RADICAL BIO MED, V132, P73, DOI 10.1016/j.freeradbiomed.2018.08.038
   Bruno MC, 2022, ACS NANO, V16, P19665, DOI 10.1021/acsnano.2c06393
   Cadahía JP, 2019, MEDCHEMCOMM, V10, P1531, DOI 10.1039/c9md00169g
   Cao ZB, 2007, SOFT MATTER, V3, P910, DOI 10.1039/b703139d
   Cao ZB, 2013, MAT SCI ENG C MATER, V33, P3522, DOI 10.1016/j.msec.2013.04.045
   Chan PMB, 2015, J ORTHOP TRANSL, V3, P71, DOI 10.1016/j.jot.2015.02.002
   Chen L., 2023, ADV FUNCT MATER, V33
   Collins JA, 2016, J BIOL CHEM, V291, P6641, DOI 10.1074/jbc.M115.693523
   Deng CJ, 2023, ACS NANO, V17, P21690, DOI 10.1021/acsnano.3c06909
   Deshpande R, 2022, ACS BIOMATER SCI ENG, V8, P1226, DOI 10.1021/acsbiomaterials.1c01103
   Fang H, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21184 5
   Soares DCF, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110695
   Foo CWP, 2006, APPL PHYS A MATER, V82, P223, DOI 10.1007/s00339 005 3426 7
   Formica FA, 2019, J CONTROL RELEASE, V295, P118, DOI 10.1016/j.jconrel.2018.12.025
   Grässel S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246156
   Gu ZH, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202212561
   Guo CC, 2020, APPL PHYS REV, V7, DOI 10.1063/1.5091442
   He WB, 2022, EXPLORATION PRC, V2, DOI 10.1002/EXP.20210093
   Hosseinzadeh H, 2015, PHYTOTHER RES, V29, P1868, DOI 10.1002/ptr.5487
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Kim J, 2010, OSTEOARTHR CARTILAGE, V18, P424, DOI 10.1016/j.joca.2009.09.008
   Kong YF, 2021, APPL MATER TODAY, V24, DOI 10.1016/j.apmt.2021.101090
   Lee S, 2018, ACS APPL MATER INTER, V10, P40378, DOI 10.1021/acsami.8b08254
   Li XX, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100883
   Li Y, 2022, J NAT FIBERS, V19, P10979, DOI 10.1080/15440478.2021.2002785
   Liu YY, 2019, DRUG DES DEV THER, V13, P3735, DOI 10.2147/DDDT.S213088
   Liu Y, 2023, RHEUMATOLOGY, V62, P1436, DOI 10.1093/rheumatology/keac539
   Liu ZY, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003 023 04738 w
   Löfvall H, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1564 5
   Lu TY, 2021, ACS APPL MATER INTER, V13, P38074, DOI 10.1021/acsami.1c10160
   Luo JC, 2021, N S ARCH PHARMACOL, V394, P1991, DOI 10.1007/s00210 021 02131 0
   Numata K, 2017, BIOMACROMOLECULES, V18, P1937, DOI 10.1021/acs.biomac.7b00376
   Ohyama Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191192
   Pei ZY, 2022, FRONT MED LAUSANNE, V9, DOI 10.3389/fmed.2022.873739
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Pu PD, 2021, Z ORTHOP UNFALLCHIR, V159, P54, DOI 10.1055/a 1019 8117
   Ren PL, 2021, CALCIFIED TISSUE INT, V109, P179, DOI 10.1007/s00223 021 00834 3
   Saha A, 2019, ACS APPL NANO MATER, V2, P3671, DOI 10.1021/acsanm.9b00607
   Shao ZZ, 2002, NATURE, V418, P741, DOI 10.1038/418741a
   Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805
   Song CC, 2013, ACS MACRO LETT, V2, P273, DOI 10.1021/mz4000392
   Sun N, 2019, J MATER SCI, V54, P3319, DOI 10.1007/s10853 018 3022 9
   Tian Y, 2014, ADV MATER, V26, P7393, DOI 10.1002/adma.201403562
   Upadhyay S, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112690
   Wang Y, 2015, ARTHRITIS RHEUMATOL, V67, P2141, DOI 10.1002/art.39182
   Wu M, 2018, J MATER CHEM B, V6, P1179, DOI 10.1039/c7tb03113k
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Yan Y, 2023, ADV SCI, V10, DOI 10.1002/advs.202207490
   Yu C, 2020, EUR J PHARMACOL, V881, DOI 10.1016/j.ejphar.2020.173184
   Zhang K, 2020, CHEM EUR J, V26, P10564, DOI 10.1002/chem.202001372
   Zheng GD, 2021, ACS OMEGA, V6, P8672, DOI 10.1021/acsomega.1c00606
   Zhou L, 2013, POLYMER, V54, P5035, DOI 10.1016/j.polymer.2013.07.002
   Zhou YZ, 2017, FOOD FUNCT, V8, P1235, DOI [10.1039/c6fo01503d, 10.1039/C6FO01503D]
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Zhuang CY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.762543
   Zong Lujie, 2022, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V36, P908, DOI 10.7507/1002 1892.202203033
NR 59
TC 9
Z9 9
U1 30
U2 73
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD NOV
PY 2024
VL 20
IS 46
DI 10.1002/smll.202405049
EA AUG 2024
PG 18
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA M7T8Y
UT WOS:001283371300001
PM 39101301
DA 2025 08 17
ER

PT J
AU Carbone, C
   Piro, G
   Gaianigo, N
   Ligorio, F
   Santoro, R
   Merz, V
   Simionato, F
   Zecchetto, C
   Falco, G
   Conti, G
   Kamga, PT
   Krampera, M
   Di Nicolantonio, F
   De Franceschi, L
   Scarpa, A
   Tortora, G
   Melisi, D
AF Carbone, C.
   Piro, G.
   Gaianigo, N.
   Ligorio, F.
   Santoro, R.
   Merz, V.
   Simionato, F.
   Zecchetto, C.
   Falco, G.
   Conti, G.
   Kamga, P. T.
   Krampera, M.
   Di Nicolantonio, F.
   De Franceschi, L.
   Scarpa, A.
   Tortora, G.
   Melisi, D.
TI Adipocytes sustain pancreatic cancer progression through a non canonical
   WNT paracrine network inducing ROR2 nuclear shuttling
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
ID BODY MASS INDEX; STEM CELLS; OBESITY; RESISTANCE; RISK;
   MICROENVIRONMENT; ADENOCARCINOMA; METAANALYSIS; EXPRESSION; THERAPY
AB BACKGROUND: Solid epidemiological evidences connect obesity with incidence, stage and survival in pancreatic cancer. However, the underlying mechanistic basis linking adipocytes to pancreatic cancer progression remain largely elusive. We hypothesized that factors secreted by adipocytes could be responsible for epithelial to mesenchymal transition (EMT) induction and, in turn, a more aggressive phenotype in models of pancreatic preneoplastic lesions.
   METHODS: We studied the role of factors secreted by two adipogenic model systems from primary human bone marrow stromal cells (hBMSCs) in an in vitro experimental cell transformation model system of human pancreatic ductal epithelial (HPDE) cell stably expressing activated KRAS (HPDE/KRAS),
   RESULTS: We measured a significant induction of EMT and aggressiveness in HPDE and HPDE/KRAS cell lines when cultured with medium conditioned by fully differentiated adipocytes (ADIPOCM) if compared with the same cells cultured with medium conditioned by hBMSC (hBMSCCM) from two different healthy donors. Several genes coding for soluble modulators of the non canonical WNT signaling pathway, including FRZB, SFRP2, RSPO1, WNT5A and 5B were significantly overexpressed in fully differentiated adipocytes than in their respective in hBMSC. ADIPOCM induced the overexpression and the nuclear translocation of the Frizzled family member receptor tyrosine kinase like orphan receptor (Ror) 2 in HPDE and HPDE/KRAS cells. Vantictumab, an anti Frizzled monoclonal antibody, reduced ROR2 nuclear translocation and in turn the EMT and aggressiveness in HPDE and HPDE/KRAS cells.
   CONCLUSIONS: We demonstrated that adipocytes could induce EMT and aggressiveness in models of pancreatic preneoplastic lesions by orchestrating a complex paracrine signaling of soluble modulators of the non canonical WNT signaling pathway that determine, in turn, the activation and nuclear translocation of ROR2. This signaling pathway could represent a novel target for pancreatic cancer chemoprevention. Most importantly, these factors could serve as novel biomarkers to select a risk population among obese subjects for screening and, thus, early diagnosis of pancreatic cancer.
C1 [Carbone, C.; Piro, G.; Gaianigo, N.; Ligorio, F.; Santoro, R.; Melisi, D.] Univ Verona, Dept Med, Digest Mol Clin Oncol Res Unit, Verona, Italy.
   [Piro, G.; Tortora, G.] Univ Verona, Dept Med, Lab Oncol & Mol Therapy, Verona, Italy.
   [Merz, V.; Simionato, F.; Zecchetto, C.; Tortora, G.; Melisi, D.] Azienda Osped Univ Integrata, Dept Med, Med Oncol Unit, Verona, Italy.
   [Falco, G.] Univ Naples Federico II, Dept Biol, Naples, Italy.
   [Conti, G.] Univ Verona, Neusosci Biomed & Movement Dept, Anat & Histol Div, Verona, Italy.
   [Kamga, P. T.; Krampera, M.] Univ Verona, Dept Med, Sect Hematol, Verona, Italy.
   [Di Nicolantonio, F.] Univ Turin, Dept Oncol, Candiolo, Italy.
   [Di Nicolantonio, F.] IRCCS, FPO, Candiolo Canc Inst, Candiolo, Italy.
   [De Franceschi, L.] Univ Verona, AOUI, Dept Med, Verona, Italy.
   [Carbone, C.; Piro, G.; Scarpa, A.] Univ Verona, ARC Net Res Ctr, Verona, Italy.
   [Carbone, C.; Piro, G.; Scarpa, A.] Univ Verona, Dept Pathol & Diagnost, Verona, Italy.
C3 University of Verona; University of Verona; University of Verona;
   Azienda Ospedaliera Universitaria Integrata Verona; University of Naples
   Federico II; University of Verona; University of Verona; University of
   Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of
   Verona; Azienda Ospedaliera Universitaria Integrata Verona; University
   of Verona; University of Verona
RP Melisi, D (通讯作者)，Univ Verona, AOUI Verona Policlin GB Rossi, Dept Med, Digest Mol Clin Oncol Unit,Sect Med Oncol, Piazzale LA Scuro 10, I 37134 Verona, Italy.
EM davide.melisi@univr.it
RI Ligorio, Francesca/MYR 1543 2025; Merz, Valeria/AAC 6495 2022; Santoro,
   Raffaela/B 1152 2013; Tortora, Giampaolo/AAA 1252 2019; Piro,
   Geny/R 5563 2019; DE FRANCESCHI, Lucia/AAB 8652 2022; KRAMPERA,
   MAURO/K 5596 2018; scarpa, aldo/K 6832 2016; Melisi, Davide/K 7947 2016;
   TAKAM KAMGA, Paul/AAR 6469 2020; Scarpa, Aldo/K 6832 2016; Di
   Nicolantonio, Federica/A 2503 2011; Carbone, Carmine/L 1009 2016
OI Tortora, Giampaolo/0000 0002 1378 4962; Melisi,
   Davide/0000 0002 4031 7585; Takam Kamga, Paul/0000 0002 8586 1381;
   Scarpa, Aldo/0000 0003 1678 739X; Ligorio,
   Francesca/0000 0003 3313 4120; Merz, Valeria/0000 0002 2120 1923; Di
   Nicolantonio, Federica/0000 0001 9618 2010; falco,
   geppino/0000 0001 6193 7233; Carbone, Carmine/0000 0001 5168 747X;
   KRAMPERA, Mauro/0000 0002 7280 2040
FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [19111, 18599];
   Basic Research Project through the University of Verona; Nastro Viola
   patients' association
FX Part of the work was performed at the Laboratorio Universitario di
   Ricerca Medica (LURM) Research Center, University of Verona. We thank Dr
   Marzia Di Chio at the Department of Diagnostic and Public Health,
   University of Verona for technical execution of immunofluorescence
   analyses. This work was supported by the Investigator grant no. 19111 to
   DM and no. 18599 to GT through the Associazione Italiana per la Ricerca
   sul Cancro (AIRC), by the Basic Research Project 2015 through the
   University of Verona to DM, and by the Nastro Viola patients'
   association donations to DM.
CR Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Carbone C, 2017, CLIN CANCER RES, V23, P4312, DOI 10.1158/1078 0432.CCR 16 3153
   Carbone C, 2015, ONCOTARGET, V6, P13822, DOI 10.18632/oncotarget.2635
   Dawson DW, 2013, CANCER PREV RES, V6, P1064, DOI 10.1158/1940 6207.CAPR 13 0065
   Debebe Z, 2015, PHARMACOL THERAPEUT, V150, P143, DOI 10.1016/j.pharmthera.2015.01.010
   Di Trapani M, 2013, STEM CELLS DEV, V22, P2990, DOI 10.1089/scd.2013.0204
   GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092 8674(74)90116 0
   Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710
   Himbert C, 2017, CANCER PREV RES, V10, P494, DOI 10.1158/1940 6207.CAPR 16 0322
   Ho HYH, 2012, P NATL ACAD SCI USA, V109, P4044, DOI 10.1073/pnas.1200421109
   Huang JF, 2015, SCI REP UK, V5, DOI 10.1038/srep12991
   Hugo ER, 2006, ENDOCRINOLOGY, V147, P306, DOI 10.1210/en.2005 0989
   Incio J, 2016, CANCER DISCOV, V6, P852, DOI 10.1158/2159 8290.CD 15 1177
   Larsson SC, 2007, INT J CANCER, V120, P1993, DOI 10.1002/ijc.22535
   Melisi D, 2014, CURR PHARM DESIGN, V20, P6660, DOI 10.2174/1381612820666140826154327
   Melisi D, 2013, CURR OPIN PHARMACOL, V13, P536, DOI 10.1016/j.coph.2013.06.012
   Melisi D, 2012, CURR DRUG TARGETS, V13, P729, DOI 10.2174/138945012800564130
   Melisi D, 2009, CLIN CANCER RES, V15, P6367, DOI 10.1158/1078 0432.CCR 09 0910
   Michaud DS, 2001, JAMA J AM MED ASSOC, V286, P921, DOI 10.1001/jama.286.8.921
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Duong MN, 2017, ONCOTARGET, V8, P57622, DOI 10.18632/oncotarget.18038
   Park J, 2011, ENDOCR REV, V32, P550, DOI 10.1210/er.2010 0030
   Piro G, 2015, BRIT J CANCER, V113, P878, DOI 10.1038/bjc.2015.283
   Piro G, 2016, CLIN CANCER RES, V22, P6164, DOI 10.1158/1078 0432.CCR 16 0178
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pozza ED, 2015, INT J ONCOL, V46, P1099, DOI 10.3892/ijo.2014.2796
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140 6736(08)60269 X
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Rosen ED, 2014, CELL, V156, P20, DOI 10.1016/j.cell.2013.12.012
   Sbarbati A, 2010, EUR J HISTOCHEM, V54, P226, DOI 10.4081/ejh.2010.e48
   Smith DC, 2013, MOL CANCER THER, V12, DOI 10.1158/1535 7163.TARG 13 B24
   Tseng HC, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 48
   Vaccaro V, 2015, WORLD J GASTROENTERO, V21, P4788, DOI 10.3748/wjg.v21.i16.4788
   Vaccaro V, 2011, EXPERT OPIN THER TAR, V15, P1183, DOI 10.1517/14728222.2011.607438
   Vucenik I, 2012, ANN NY ACAD SCI, V1271, P37, DOI 10.1111/j.1749 6632.2012.06750.x
   Yuan C, 2013, J CLIN ONCOL, V31, P4229, DOI 10.1200/JCO.2013.51.7532
   Zoico E, 2016, ONCOTARGET, V7, P20223, DOI 10.18632/oncotarget.7936
NR 37
TC 32
Z9 34
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307 0565
EI 1476 5497
J9 INT J OBESITY
JI Int. J. Obes.
PD MAR
PY 2018
VL 42
IS 3
BP 334
EP 343
DI 10.1038/ijo.2017.285
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA GB1XL
UT WOS:000428844600008
PM 29151594
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Sanchez, CP
   He, YZ
AF Sanchez, Cheryl P.
   He, Yu Zhu
TI Bone growth during rapamycin therapy in young rats
SO BMC PEDIATRICS
LA English
DT Article
ID ADVANCED SECONDARY HYPERPARATHYROIDISM; MAMMALIAN TARGET; RENAL FAILURE;
   HORMONE; KINASE; IMMUNOSUPPRESSANT; DIFFERENTIATION; PROLIFERATION;
   CALCITRIOL; CARTILAGE
AB Background: Rapamycin is an effective immunosuppressant widely used to maintain the renal allograft in pediatric patients. Linear growth may be adversely affected in young children since rapamycin has potent anti proliferative and anti angiogenic properties.
   Methods: Weanling three week old rats were given rapamycin at 2.5 mg/kg daily by gavage for 2 or 4 weeks and compared to a Control group given equivalent amount of saline. Morphometric measurements and biochemical determinations for serum calcium, phosphate, iPTH, urea nitrogen, creatinine and insulin growth factor I (IGF I) were obtained. Histomorphometric analysis of the growth plate cartilage, in situ hybridization experiments and immunohistochemical studies for various proteins were performed to evaluate for chondrocyte proliferation, chondrocyte differentiation and chondro/osteoclastic resorption.
   Results: At the end of the 2 weeks, body and tibia length measurements were shorter after rapamycin therapy associated with an enlargement of the hypertrophic zone in the growth plate cartilage. There was a decrease in chondrocyte proliferation assessed by histone 4 and mammalian target of rapamycin (mTOR) expression. A reduction in parathyroid hormone/parathyroid hormone related peptide (PTH/PTHrP) and an increase in Indian hedgehog (Ihh) expression may explain in part, the increase number of hypertrophic chondrocytes. The number of TRAP positive multinucleated chondro/osteoclasts declined in the chondro osseous junction with a decrease in the receptor activator of nuclear factor kappa beta ligand (RANKL) and vascular endothelial growth factor (VEGF) expression. Although body and tibial length remained short after 4 weeks of rapamycin, changes in the expression of chondrocyte proliferation, chondrocyte differentiation and chondro/osteoclastic resorption which were significant after 2 weeks of rapamycin improved at the end of 4 weeks.
   Conclusion: When given to young rats, 2 weeks of rapamycin significantly decreased endochondral bone growth. No catch up growth was demonstrated at the end of 4 weeks, although markers of chondrocyte proliferation and differentiation improved. Clinical studies need to be done to evaluate these changes in growing children.
C1 [Sanchez, Cheryl P.; He, Yu Zhu] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Sanchez, CP (通讯作者)，Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI 53706 USA.
EM cpsanchez@pediatrics.wisc.edu; yhe@wisc.edu
RI He, Yuzhu/KWT 8961 2024; Sanchez, Cheryl/AAF 6973 2020
FU Southern Wisconsin National Kidney Foundation; NIH/NIDDK [DK 56688 01];
   Department of Pediatrics, University of Wisconsin School of Medicine &
   Public Health, Madison, Wisconsin, USA
FX This paper was supported in part by the Southern Wisconsin National
   Kidney Foundation Affiliate Grant, NIH/NIDDK Grant No. DK 56688 01 and
   by the research funds from the Department of Pediatrics, University of
   Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA.
CR Alvarez Garcia O, 2007, PEDIATR NEPHROL, V22, P954, DOI 10.1007/s00467 007 0456 8
   AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611
   Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200
   Dias VC, 1998, DIGEST DIS SCI, V43, P2227, DOI 10.1023/A:1026610404647
   El Hashemite N, 2003, CANCER RES, V63, P5173
   Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424
   Jacenko O, 2002, AM J PATHOL, V160, P2019, DOI 10.1016/S0002 9440(10)61152 2
   JOFFE I, 1993, CALCIFIED TISSUE INT, V53, P45, DOI 10.1007/BF01352014
   KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277
   Karp SJ, 2000, DEVELOPMENT, V127, P543
   LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531
   MacLean HE, 2004, J CLIN INVEST, V113, P1334, DOI 10.1172/JCI200421252
   Manegold PC, 2008, CLIN CANCER RES, V14, P892, DOI 10.1158/1078 0432.CCR 07 0955
   Ogawa T, 1998, BIOCHEM BIOPH RES CO, V249, P226, DOI 10.1006/bbrc.1998.9118
   ROMERO DF, 1995, J BONE MINER RES, V10, P760
   Sanchez CP, 2007, KIDNEY INT, V72, P582, DOI 10.1038/sj.ki.5002375
   Sanchez CP, 1998, KIDNEY INT, V54, P1879, DOI 10.1046/j.1523 1755.1998.00199.x
   Sanchez CP, 2004, KIDNEY INT, V65, P1740, DOI 10.1111/j.1523 1755.2004.00577.x
   Sanchez CP, 2002, BONE, V30, P692, DOI 10.1016/S8756 3282(02)00696 8
   SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Tremblay F, 2005, ENDOCRINOLOGY, V146, P1328, DOI 10.1210/en.2004 0777
   Wang Y, 2007, IUBMB LIFE, V59, P717, DOI 10.1080/15216540701646484
   Wilsman NJ, 1996, J ORTHOP RES, V14, P927, DOI 10.1002/jor.1100140613
NR 26
TC 51
Z9 55
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD JAN 13
PY 2009
VL 9
AR 3
DI 10.1186/1471 2431 9 3
PG 13
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA 421HL
UT WOS:000264349900001
PM 19144108
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Galvano, A
   Gristina, V
   Scaturro, D
   Russo, TDB
   Tomasello, S
   Vitagliani, F
   Carità, F
   La Mantia, M
   Fulfaro, F
   Bazan, V
   Mauro, GL
   Russo, A
AF Galvano, Antonio
   Gristina, Valerio
   Scaturro, Dalila
   Bazan Russo, Tancredi Didier
   Tomasello, Sofia
   Vitagliani, Fabio
   Carita, Federica
   La Mantia, Maria
   Fulfaro, Fabio
   Bazan, Viviana
   Mauro, Giulia Letizia
   Russo, Antonio
TI The role of bone modifying agents for secondary osteoporosis prevention
   and pain control in post menopausal osteopenic breast cancer patients
   undergoing adjuvant aromatase inhibitors
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE alendronate; denosumab; secondary osteoporosis; pain control; breast
   cancer; aromatase inhibitors (AIS)
ID CLINICAL EFFICACY; BISPHOSPHONATES; DENOSUMAB; ALENDRONATE; WOMEN; CARE
AB IntroductionHormonal therapy (HT) blocks the hormone mediated growth signal dramatically reducing estrogenic levels with aromatase inhibitors (AIs) becoming a crucial component of the treatment mainstay in patients with early breast cancer (BC). Postmenopausal BC patients receiving HT present with a significant risk of secondary osteoporosis with AIs further reducing estrogen levels and ultimately leading to an accelerated rate of bone resorption and thus decreased bone mineral density (BMD). This was an observational retrospective clinical study that consecutively enrolled early BC patients with osteopenia to compare the impact of alendronate versus denosumab on secondary osteoporosis prevention and pain control.MethodsWe identified two groups of patients treated with denosumab 60 mg by subcutaneous injection once every six months or alendronate 70 mg orally once a week. All the patients underwent a baseline physiatric evaluation (T0) and underwent a follow up visit after 18 months (T1) together with femoral and vertebral Dual Energy X ray Absorptiometry (DEXA) exam evaluating T Score marks. From September 2015 to December 2019 a total of 50 early (stage I III) BC patients were considered eligible and consecutively enrolled in our study if they met pre specified inclusion criteria.ResultsIn the entire observed population, the addition of treatment with alendronate or denosumab led to a significant T score improvement at the lumbar spine level ( 1.92 vs  1.52, p=0.03), with a comparable contribution from alendronate ( 1.60 vs  1.45, p=0.07) and denosumab ( 2.26 vs  1.58, p=0.07). Regarding the femoral region, neither alendronate ( 0.98 vs  1.07, p=0.23) nor denosumab ( 1.39 vs  1.34, p=0.81) were able to produce any statistically relevant effect. However, concerning pain control, BMAs had a significant impact on reducing NRS scoresin the general population (T1 3.94 vs. baseline 4.32, p=0.007), with a likelyspecific contribution from alendronate (T1 3.52 vs. baseline 3.88, p=0.004) compared to denosumab (T1 4.36 vs baseline 4.76, p=0.12), without any differences in analgesic therapy assumption over time (p=0.93).DiscussionBoth alendronate and denosumab significantly contributed to preventing secondary osteoporosis in early BC patients with low BMD undergoing AIs, mostly at the lumbar spine level. Moreover, alendronate seemed to significantly impact pain control in such patients further supporting alendronate as a cost effective option in this frail setting, although BMAs particularities should be carefully considered on an individual basis according to specific clinical contexts.
C1 [Galvano, Antonio; Gristina, Valerio; Scaturro, Dalila; Bazan Russo, Tancredi Didier; Carita, Federica; La Mantia, Maria; Fulfaro, Fabio; Mauro, Giulia Letizia; Russo, Antonio] Univ Palermo, Dept Surg Oncol & Oral Sci, Palermo, Italy.
   [Tomasello, Sofia] Univ Verona, Neuromotor & Cognit Rehabil Res Ctr, Phys & Rehabil Med Sect, Dept Neurosci Biomed & Movement Sci, Verona, Italy.
   [Vitagliani, Fabio] Univ Catania, Dept Biomed Sci BIOMED, Catania, Italy.
   [Bazan, Viviana] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost BIND, Palermo, Italy.
C3 University of Palermo; University of Verona; University of Catania;
   University of Palermo
RP Russo, A (通讯作者)，Univ Palermo, Dept Surg Oncol & Oral Sci, Palermo, Italy.
EM antonio.russo@usa.net
RI Russo, Antonio/JBJ 3134 2023; Galvano, Antonio/K 7810 2016; scaturro,
   dalila/AAR 4452 2020; GRISTINA, VALERIO/AAC 1601 2019; La Mantia,
   Maria/AAC 6018 2022
CR Abdel Rahman O, 2016, EXPERT REV ANTICANC, V16, P885, DOI 10.1080/14737140.2016.1192466
   Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   Anastasilakis AD, 2018, EUR J ENDOCRINOL, V179, pR31, DOI 10.1530/EJE 18 0056
   Bae K, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen 2019 033461
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bassatne A, 2022, METABOLISM, V128, DOI 10.1016/j.metabol.2021.154962
   Bock O., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P144
   Brazill JM, 2019, J BONE MINER RES, V34, P1393, DOI 10.1002/jbmr.3822
   Breast Cancer Study Group Along Yangtze River, 2022, Precis Cancer Med, V5, P33, DOI [10.21037/pcm 22 57, DOI 10.21037/PCM 22 57]
   Burstein HJ, 2019, J CLIN ONCOL, V37, P423, DOI 10.1200/JCO.18.01160
   Chen Z, 2009, OSTEOPOROSIS INT, V20, P527, DOI 10.1007/s00198 008 0721 0
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   De Luca R, 2018, DRUG DES DEV THER, V12, P1769, DOI 10.2147/DDDT.S165851
   de Sire A, 2022, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.829875
   Galvano A, 2020, CANCERS, V12, DOI 10.3390/cancers12030534
   Hadji P, 2016, ANN ONCOL, V27, P379, DOI 10.1093/annonc/mdv617
   Kalder M, 2014, BREAST CARE, V9, P312, DOI 10.1159/000368843
   Lin T, 2012, INT J CLIN PRACT, V66, P399, DOI 10.1111/j.1742 1241.2011.02806.x
   Listì A, 2019, TRANSL CANCER RES, V8, pS55, DOI 10.21037/tcr.2018.10.04
   Miyashita H, 2020, BREAST CANCER RES TR, V181, P279, DOI 10.1007/s10549 020 05640 3
   Porta Sales J, 2017, PALLIATIVE MED, V31, P5, DOI 10.1177/0269216316639793
   Porter I, 2021, J BONE ONCOL, V31, DOI 10.1016/j.jbo.2021.100402
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Sawka AM, 2005, J OBSTET GYNAECOL CA, V27, P759, DOI 10.1016/S1701 2163(16)30727 7
   Siegel RL, 2023, CA CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
   Tolia M, 2014, ANTICANCER RES, V34, P23
   Vardy J, 2014, J CLIN ONCOL, V32, P1677, DOI 10.1200/JCO.2013.52.8356
   von Moos R, 2017, EUR J CANCER, V71, P80, DOI 10.1016/j.ejca.2016.10.021
   White M, 2020, ARTHRITIS RHEUMATOL, V72
NR 29
TC 4
Z9 4
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD NOV 21
PY 2023
VL 14
AR 1297950
DI 10.3389/fendo.2023.1297950
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA Z9PI6
UT WOS:001115323400001
PM 38075057
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, W
   Li, S
   Xu, LJ
   Jiang, ML
   Li, XY
   Zhang, Y
   Tighe, S
   Zhu, YT
   Li, GG
AF Wang, Wei
   Li, Shen
   Xu, Lingjuan
   Jiang, Menglin
   Li, Xinyu
   Zhang, Yuan
   Tighe, Sean
   Zhu, Yingting
   Li, Guigang
TI Differential Gene Expression between Limbal Niche Progenitors and Bone
   Marrow Derived Mesenchymal Stem Cells
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Gene expression; gene chip; LNC; BMMSC
ID CORNEAL SURFACE; RECONSTRUCTION; EPITHELIUM; EXPANSION; THERAPY
AB Purpose: To compare the difference in gene expression between human limbal niche cells (LNC) and bone marrow derived mesenchymal stem cells (BMMSC).
   Methods: LNC were isolated by collagenase and expanded in modified embryonic stem cell medium (MESCM) on a Matrigel coated plastic plate. Cell diameters were measured with Image J software. Relative gene expression levels between LNC and BMMSC were compared using Affymetrix Human Primer View Gene Expression Array. A subset of differentially expressed genes was verified by RT qPCR. The protein level of LAMA1 and COL4A1 was confirmed by Western blot and immunostaining.
   Results: The average diameter of LNC was 10.2 +/  2.4 mu m, which was significantly smaller than that of BMMSC (14 +/  3.4 mu m) (p<0.0001). Expression of 20,432 genes was examined by Gene Expression Array, among which expression of 349 genes in LNC was 10 fold or higher than that of BMMSC and expression of 8 genes in LNC was 100 fold or higher than that of BMMSC, while expression of 3 genes in BMMSC was 100 fold higher than that of LNC. GO analysis and pathway analysis showed that the differentially expressed genes were mainly enriched in the extracellular matrix receptor interaction pathway and Wnt signaling pathway. In addition, RT qPCR results demonstrated that the expression of CD73, CD90, CD105, PDGFR beta, Vimentin, SCF, KIT (CD117), COL14A1, LAMA2, THBS2, FZD1, BMP2 and CXCL12 genes in LNC were at least 2 folds higher than BMMSC. The protein level of LAMA1 was higher but the protein level of COL4A1 was lower in LNC than that in BMMSC.
   Conclusion: LNC exhibit differential gene expression from BMMSC in the extracellular matrix (ECM) receptor interaction pathway and Wnt signaling pathway, suggesting that LNC have their unique signaling pathways to support limbal stem cell niches.
C1 [Wang, Wei; Li, Shen; Xu, Lingjuan; Jiang, Menglin; Li, Xinyu; Li, Guigang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Ophthalmol, Wuhan 430030, Hubei, Peoples R China.
   [Zhang, Yuan; Tighe, Sean; Zhu, Yingting] Tissue Tech Inc, Miami, FL 33126 USA.
C3 Huazhong University of Science & Technology
RP Li, GG (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Ophthalmol, Wuhan 430030, Hubei, Peoples R China.
EM guigli@163.com
RI ; Chen, Zhongshan/JMQ 9642 2023
OI Zhu, Yingting/0000 0002 3332 9713; 
FU National Natural Science Foundation of China [81200661, 81470606,
   81570819]; Nature Science Foundation of Hubei Province [2014CFB973]; Top
   Ten Translational Medical Research Projects from Tongji Hospital
   [2016ZHYX20]; Training Project of Young medical Pioneers in Wuhan City
   [2015whzqnyxggrc10]
FX Supported by National Natural Science Foundation of China (No. 81200661,
   81470606, 81570819), Nature Science Foundation of Hubei Province (No.
   2014CFB973), Top Ten Translational Medical Research Projects from Tongji
   Hospital (No.2016ZHYX20) and Training Project of Young medical Pioneers
   in Wuhan City (No.2015whzqnyxggrc10).
CR Acar U, 2015, OPHTHALMIC RES, V53, P82, DOI 10.1159/000368659
   Cejka C, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5843809
   Chen SY, 2015, STEM CELLS
   Chen SY, 2011, TISSUE ENG PART C ME, V17, P537, DOI [10.1089/ten.tec.2010.0609, 10.1089/ten.TEC.2010.0609]
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Demirayak B, 2016, EXP EYE RES, V151, P227, DOI 10.1016/j.exer.2016.08.011
   Deng CL, 2017, WOUND REPAIR REGEN, V25, P923, DOI 10.1111/wrr.12602
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Guo P, 2018, J CELL MOL MED, V22, P3315, DOI 10.1111/jcmm.13635
   Han B, 2014, STEM CELL RES, V12, P562, DOI 10.1016/j.scr.2014.01.003
   Jiang TS, 2010, MOL VIS, V16, P1304
   Katikireddy KR, 2014, STEM CELLS, V32, P717, DOI 10.1002/stem.1541
   Li GG, 2012, INVEST OPHTH VIS SCI, V53, P5686, DOI 10.1167/iovs.12 10300
   Li GG, 2012, INVEST OPHTH VIS SCI, V53, P3357, DOI 10.1167/iovs.11 9414
   Li GG, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24862 6
   Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794
   Li RJ, 2011, J CONTROL RELEASE, V149, P281, DOI 10.1016/j.jconrel.2010.10.019
   Li W, 2007, CELL RES, V17, P26, DOI 10.1038/sj.cr.7310137
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Liu HS, 2012, J CELL MOL MED, V16, P1114, DOI 10.1111/j.1582 4934.2011.01418.x
   Ma YL, 2006, STEM CELLS, V24, P315, DOI 10.1634/stemcells.2005 0046
   Oberauer R, 2010, MOL CELL BIOCHEM, V343, P257, DOI 10.1007/s11010 010 0521 7
   Pathak M, 2016, EXP EYE RES, V153, P122, DOI 10.1016/j.exer.2016.09.012
   Ratajczak MZ, 2012, AGING US, V4, P235, DOI 10.18632/aging.100449
   Rohaina CM, 2014, TRANSL RES, V163, P200, DOI 10.1016/j.trsl.2013.11.004
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Tseng SCG, 2010, CURR MOL MED, V10, P841
   Twal WO, 2001, J CELL SCI, V114, P4587
   Xie HT, 2012, INVEST OPHTH VIS SCI, V53, P279, DOI 10.1167/iovs.11 8441
   Yao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030842
   Ye J, 2006, EYE, V20, P482, DOI 10.1038/sj.eye.6701913
NR 32
TC 10
Z9 10
U1 1
U2 20
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2020
VL 17
IS 4
BP 549
EP 557
DI 10.7150/ijms.40881
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA KN5BF
UT WOS:000514851600015
PM 32174786
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jahnke, W
   Henry, C
AF Jahnke, Wolfgang
   Henry, Chrystele
TI An in vitro Assay to Measure Targeted Drug Delivery to Bone Mineral
SO CHEMMEDCHEM
LA English
DT Article
DE adsorption; bone; drug delivery; hydroxyapatite; NMR spectroscopy
ID SRC TYROSINE KINASE; BISPHOSPHONATE ACTIONS; BINDING AFFINITIES;
   CLINICAL EFFICACY; RATIONAL DESIGN; HYDROXYAPATITE; OSTEOPOROSIS;
   DISCOVERY; NMR; INHIBITION
AB Targeted delivery of drugs to their site of action is a promising strategy to decrease adverse effects and enhance efficacy, but successful applications of this strategy have been scarce. Human bone is a tissue with unique properties due to its high hydroxyapatite mineral content. However, with the exception, of bisphosphonates, bone mineral has not been targeted in a successful clinical application of drugs that act on bone, such as anti resorptive or bone anabolic agents. Herein we present an NMR based in vitro assay to measure binding affinities of small molecules to hydroxyapatite (HAP) or bone powder. 1 Binding was shown to be specific and competitive, and the assay can be carried out in a direct binding format or in competition mode. A selection of clinically relevant bisphosphonates was ranked by their binding affinity for HAP. The binding affinity decreases in the order: pamidronate > alendronate > zoledronate > risedronate > ibandronate. The differences in binding affinities span a factor of 2.1 between pamidronate and ibandronate, consistent with previous studies. The rank order is very similar with bone powder, although the binding capacity of bone powder is smaller and binding kinetics are slower. A zoledronate derivative that lacks the central hydroxy group binds to HAP with 2.3 fold weaker affinity than zoledronate itself. Any small molecule can be analyzed for its binding to HAP or bone powder, and the binding of common bone staining agents such as alizarin and its derivatives was confirmed in the new assay. This assay supports a strategy for targeted delivery of drugs to bone by attaching a bone affinity tag to the active drug substance.
C1 [Jahnke, Wolfgang; Henry, Chrystele] Novartis Inst Biomed Res, Ctr Prote Chem, CH 4002 Basel, Switzerland.
C3 Novartis
RP Jahnke, W (通讯作者)，Novartis Inst Biomed Res, Ctr Prote Chem, CH 4002 Basel, Switzerland.
EM wolfgang.jahnke@novartis.com
CR Christiansen C, 2003, OSTEOPOROSIS INT, V14, pS38
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Erez R, 2008, BIOORG MED CHEM LETT, V18, P816, DOI 10.1016/j.bmcl.2007.11.029
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Henneman ZJ, 2008, J BIOMED MATER RES A, V85A, P993, DOI 10.1002/jbm.a.31599
   Hirabayashi H, 2001, PHARM RES DORDR, V18, P646, DOI 10.1023/A:1011033326980
   [黄文才 Huang Wencai], 2003, [中国药物化学杂志, Chinese Journal of Medicinal Chemistry], V13, P138
   Jahnke W, 2007, J BIOMOL NMR, V39, P87, DOI 10.1007/s10858 007 9183 5
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Li JJ, 2007, J MED CHEM, V50, P3015, DOI 10.1021/jm070312d
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Mukherjee S, 2009, J AM CHEM SOC, V131, P8374, DOI 10.1021/ja902895p
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Papapoulos SE, 2006, BONE, V38, P613, DOI 10.1016/j.bone.2006.01.141
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Rucci N, 2008, ANTI CANCER AGENT ME, V8, P342, DOI 10.2174/187152008783961905
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schuffenhauer A, 2005, CURR TOP MED CHEM, V5, P751, DOI 10.2174/1568026054637700
   Seo SI, 2008, CLIN CANCER RES, V14, P6198, DOI 10.1158/1078 0432.CCR 08 1023
   Shakespeare W, 2000, P NATL ACAD SCI USA, V97, P9373, DOI 10.1073/pnas.97.17.9373
   Shakespeare WC, 2003, CURR OPIN DRUG DISC, V6, P729
   Stepensky D, 2003, CLIN PHARMACOKINET, V42, P863, DOI 10.2165/00003088 200342100 00001
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   VANBEEK E, 1994, J BONE MINER RES, V9, P1875, DOI 10.1002/jbmr.5650091206
   Wang Y, 2006, CHINESE CHEM LETT, V17, P310
   Wang YH, 2003, BIOORG MED CHEM LETT, V13, P3067, DOI 10.1016/S0960 894X(03)00648 6
   Wright JEI, 2004, ADV EXP MED BIOL, V553, P139
   Xu LH, 2005, CHINESE CHEM LETT, V16, P1434
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhang X., 2009, ANGEW CHEM, V121, P6819
   Zhang XL, 2009, ANGEW CHEM INT EDIT, V48, P6691, DOI 10.1002/anie.200902591
NR 42
TC 45
Z9 56
U1 0
U2 29
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860 7179
EI 1860 7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD MAY
PY 2010
VL 5
IS 5
BP 770
EP 776
DI 10.1002/cmdc.201000016
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 596ZP
UT WOS:000277725100016
PM 20209564
DA 2025 08 17
ER

PT J
AU Sugamori, Y
   Mise Omata, S
   Maeda, C
   Aoki, S
   Tabata, Y
   Murali, R
   Yasuda, H
   Udagawa, N
   Suzuki, H
   Honma, M
   Aoki, K
AF Sugamori, Yasutaka
   Mise Omata, Setsuko
   Maeda, Chizuko
   Aoki, Shigeki
   Tabata, Yasuhiko
   Murali, Ramachandran
   Yasuda, Hisataka
   Udagawa, Nobuyuki
   Suzuki, Hiroshi
   Honma, Masashi
   Aoki, Kazuhiro
TI Peptide drugs accelerate BMP 2 induced calvarial bone regeneration and
   stimulate osteoblast differentiation through mTORC1 signaling
SO BIOESSAYS
LA English
DT Article
DE BMP 2; bone regeneration; histomorphometry; mTORC1; osteoblast
   differentiation; peptide therapeutics; rapamycin
ID RECEPTOR ACTIVATOR; RANKL; GROWTH; PEPTIDOMIMETICS; RESORPTION; BINDING;
   CELLS; MODEL
AB Both W9 and OP3 4 were known to bind the receptor activator of NF B ligand (RANKL), inhibiting osteoclastogenesis. Recently, both peptides were shown to stimulate osteoblast differentiation; however, the mechanism underlying the activity of these peptides remains to be clarified. A primary osteoblast culture showed that rapamycin, an mTORC1 inhibitor, which was recently demonstrated to be an important serine/threonine kinase for bone formation, inhibited the peptide induced alkaline phosphatase activity. Furthermore, both peptides promoted the phosphorylation of Akt and S6K1, an upstream molecule of mTORC1 and the effector molecule of mTORC1, respectively. In the in vivo calvarial defect model, W9 and OP3 4 accelerated BMP 2 induced bone formation to a similar extent, which was confirmed by histomorphometric analyses using fluorescence images of undecalcified sections. Our data suggest that these RANKL binding peptides could stimulate the mTORC1 activity, which might play a role in the acceleration of BMP 2 induced bone regeneration by the RANKL binding peptides.
C1 [Sugamori, Yasutaka; Mise Omata, Setsuko; Maeda, Chizuko; Aoki, Kazuhiro] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Biomatrix Pharmacol, Tokyo, Japan.
   [Aoki, Shigeki; Suzuki, Hiroshi; Honma, Masashi] Univ Tokyo, Tokyo Univ Hosp, Dept Pharm, Fac Med, Tokyo, Japan.
   [Tabata, Yasuhiko] Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Field Tissue Engn, Kyoto, Japan.
   [Murali, Ramachandran] Cedars Sinai Med Ctr, Dept Biomed Sci, Div Immunol Res, Los Angeles, CA 90048 USA.
   [Yasuda, Hisataka] Oriental Yeast Co Ltd, Nagahama Inst Biochem Sci, Shiga, Japan.
   [Udagawa, Nobuyuki] Matsumoto Dent Univ, Dept Biochem, Nagano, Japan.
   [Honma, Masashi] Univ Tokyo, Tokyo Univ Hosp, Dept Pharmacol & Pharmacokinet, Fac Med, Tokyo, Japan.
   [Aoki, Shigeki] Chiba Univ, Grad Sch Pharmaceut Sci, Lab Biopharmaceut, Chiba, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   University of Tokyo; Kyoto University; Cedars Sinai Medical Center;
   Oriental Yeast Co., Ltd.; Matsumoto Dental University; University of
   Tokyo; Chiba University
RP Aoki, K (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Biomatrix Pharmacol, Tokyo, Japan.
EM kazu.hpha@tmd.ac.jp
RI AOKI, Kazuhiro/G 2258 2016; Aoki, Shigeki/ABB 2942 2020
OI AOKI, Kazuhiro/0000 0001 6643 6315; Yasuda,
   Hisataka/0000 0003 3511 609X; Biresaw, Samuel
   Shiferaw/0000 0001 5508 8511; Aoki, Shigeki/0000 0003 2821 0651; Murali,
   Ramachandran/0000 0002 8384 2793
FU JSPS KAKENHI [25293377, 23659867]; Grants in Aid for Scientific Research
   [23659867, 16K09867, 25293377] Funding Source: KAKEN
FX The authors are grateful to the lab members of the Pharmacology section
   in Tokyo Medical and Dental University and their families for their
   participation and contributions. We also thank to Mr. Makoto Matsui
   (Institute for Frontier Medical Sciences, Kyoto University; the present
   affiliation is Polymer Chemistry Division, Chemical Resources
   Laboratory, Tokyo Institute of Technology) for synthesizing gelatin
   hydrogel. This study was supported by grants in aid to K.A. from JSPS
   KAKENHI (nos. 25293377 and 23659867).
CR Al Mamun MA, 2013, J ORAL BIOSCI, V55, P217, DOI 10.1010/j.job.2013.06.008
   Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Aoki K, 2012, ADV DRUG DELIVER REV, V64, P1220, DOI 10.1016/j.addr.2012.05.017
   Aoki S, 2010, J BONE MINER RES, V25, P1907, DOI 10.1002/jbmr.89
   Carreira AC, 2014, J DENT RES, V93, P335, DOI 10.1177/0022034513518561
   Cheng J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115339
   Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   Furuya Y, 2013, J BIOL CHEM, V288, P5562, DOI 10.1074/jbc.M112.426080
   Han PP, 2015, J BONE MINER RES, V30, P1160, DOI 10.1002/jbmr.2445
   Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008 5472.CAN 06 1287
   Henriksen K, 2014, CALCIFIED TISSUE INT, V94, P88, DOI 10.1007/s00223 013 9741 7
   Honma M, 2013, J BONE MINER RES, V28, P1936, DOI 10.1002/jbmr.1941
   Im Jin Young, 2013, Lab Anim Res, V29, P196, DOI 10.5625/lar.2013.29.4.196
   Kariya Y, 2009, J BONE MINER RES, V24, P1741, DOI [10.1359/JBMR.090409, 10.1359/jbmr.090409]
   Kato G, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0753 8
   Khan AA, 2013, J ORAL BIOSCI, V55, P47, DOI 10.1016/j.job.2012.12.005
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Kubota K, 2002, BONE, V31, P465, DOI 10.1016/S8756 3282(02)00852 9
   Kuroshima S, 2013, J DENT RES, V92, P553, DOI 10.1177/0022034513487558
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Nakamura Y, 2005, BONE, V36, P399, DOI 10.1016/j.bone.2004.11.010
   Recker RR, 1983, BONE HISTOMORPHOMETR, V23
   Rodgers JT, 2014, NATURE, V510, P393, DOI 10.1038/nature13255
   Rodríguez Carballo E, 2011, J BONE MINER RES, V26, P718, DOI 10.1002/jbmr.260
   Saito H, 2007, ARTHRITIS RHEUM US, V56, P1164, DOI 10.1002/art.22495
   Sims NA, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0861 5
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Suzuki N, 2016, BIOMECH MODEL MECHAN, V15, P1091, DOI 10.1007/s10237 015 0746 1
   Tachi K, 2011, TISSUE ENG PT A, V17, P597, DOI [10.1089/ten.tea.2010.0094, 10.1089/ten.TEA.2010.0094]
   Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197 1266
   Woo EJ, 2013, CLIN ORTHOP RELAT R, V471, P1707, DOI 10.1007/s11999 012 2684 x
   Ye JH, 2011, BIOMATERIALS, V32, P5065, DOI 10.1016/j.biomaterials.2011.03.053
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Yun JI, 2010, J CLIN PERIODONTOL, V37, P419, DOI 10.1111/j.1600 051X.2010.01547.x
NR 36
TC 24
Z9 26
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0265 9247
EI 1521 1878
J9 BIOESSAYS
JI Bioessays
PD AUG
PY 2016
VL 38
IS 8
BP 717
EP 725
DI 10.1002/bies.201600104
PG 9
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA DR6YO
UT WOS:000380047400003
PM 27345003
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Yuan, FL
   Li, X
   Lu, WG
   Li, CW
   Li, JP
   Wang, Y
AF Yuan, Feng Lai
   Li, Xia
   Lu, Wei Guo
   Li, Cheng Wan
   Li, Jian Ping
   Wang, Yu
TI The vacuolar ATPase in bone cells: a potential therapeutic target in
   osteoporosis
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE V ATPases; Osteoclast; Osteoporosis; V ATPases inhibitors
ID MEDIATED EXTRACELLULAR ACIDIFICATION; INFANTILE MALIGNANT OSTEOPETROSIS;
   OSTEOCLAST V ATPASE; ACTIN BINDING SITE; H+ ATPASE; PROTON PUMP;
   B SUBUNIT; SELECTIVE INHIBITION; ACCESSORY SUBUNIT; A3 SUBUNIT
AB The vacuolar ATPase (V ATPase) is a multi subunit enzyme that couples ATP hydrolysis to proton pumping across membranes. Recently, there is increasing evidence that V ATPase may contribute to the pathogenesis of bone resorption disorders due to it is predominantly expressed in osteoclasts also function in bone resorption making it a good candidate in a therapeutic target for osteoporosis. Osteoclasts are capable of generating an acidic microenvironment necessary for bone resorption by utilizing V ATPases to pump protons into the resorption lacuna. In addition, it has been shown that therapeutic interventions have been proposed that specifically target inhibition of the osteoclast proton pump. Modulation of osteoclastic V ATPase activity has been considered to be a suitable therapy for the treatment of osteoporosis. All theses findings suggest that V ATPase have important biological effects in bone resorption that might be a promising therapeutic target for osteoporosis. In this review, we will briefly discuss the biological features of osteoporosis and summarize recent advances on the role of V ATPase in the pathogenesis and treatment of osteoporosis.
C1 [Yuan, Feng Lai; Li, Xia; Lu, Wei Guo; Li, Cheng Wan; Li, Jian Ping; Wang, Yu] Nantong Univ, Hosp 3, Wuxi 214041, Jiangsu, Peoples R China.
C3 Nantong University
RP Li, X (通讯作者)，Nantong Univ, Hosp 3, Wuxi 214041, Jiangsu, Peoples R China.
EM bjjq88@163.com; lixia.ahmu.cn@163.com
RI li, xia/HHZ 7468 2022
FU China National Science Foundation [30901526]
FX This work was supported by the China National Science Foundation grants
   No. 30901526.
CR BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220
   BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Blake Palmer KG, 2007, GENE, V393, P94, DOI 10.1016/j.gene.2007.01.020
   Chen SH, 2004, J BIOL CHEM, V279, P7988, DOI 10.1074/jbc.M305351200
   Cipriano DJ, 2008, BBA BIOENERGETICS, V1777, P599, DOI 10.1016/j.bbabio.2008.03.013
   Da Silva N, 2007, AM J PHYSIOL CELL PH, V293, pC199, DOI 10.1152/ajpcell.00596.2006
   Drory O, 2006, PHYSIOLOGY, V21, P317, DOI 10.1152/physiol.00017.2006
   Farina C, 2002, CURR PHARM DESIGN, V8, P2033, DOI 10.2174/1381612023393369
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Francis MJO, 2002, INT J BIOCHEM CELL B, V34, P459, DOI 10.1016/S1357 2725(01)00142 X
   Geyer M, 2002, MOL BIOL CELL, V13, P2045, DOI 10.1091/mbc.02 02 0026
   GRAF R, 1994, J BIOL CHEM, V269, P3767
   GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037
   HALL TJ, 1994, CELL BIOL INT, V18, P189, DOI 10.1006/cbir.1994.1060
   HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004
   Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200
   Hu YW, 2005, FEBS LETT, V579, P4937, DOI 10.1016/j.febslet.2005.07.078
   Imai Senga Y, 2002, GENE, V289, P7, DOI 10.1016/S0378 1119(02)00542 5
   Inoue T, 2005, J BIOENERG BIOMEMBR, V37, P393, DOI 10.1007/s10863 005 9478 8
   Jefferies KC, 2008, ARCH BIOCHEM BIOPHYS, V476, P33, DOI 10.1016/j.abb.2008.03.025
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   Laitala Leinonen T, 1999, J CELL SCI, V112, P3657
   Laitala Leinonen T, 1999, ANTISENSE NUCLEIC A, V9, P155, DOI 10.1089/oli.1.1999.9.155
   Lee BS, 1996, AM J PHYSIOL CELL PH, V270, pC382, DOI 10.1152/ajpcell.1996.270.1.C382
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Manolson MF, 2003, J BIOL CHEM, V278, P49271, DOI 10.1074/jbc.M309914200
   Marie PJ, 2009, OSTEOPOROSIS INT, V20, P1037, DOI 10.1007/s00198 009 0856 7
   Mattson NP, 1997, J BONE MINER RES, V12, P753, DOI 10.1359/jbmr.1997.12.5.753
   Mattsson JP, 1996, BBA BIOMEMBRANES, V1280, P98, DOI 10.1016/0005 2736(95)00285 5
   Michigami T, 2002, BONE, V30, P436, DOI 10.1016/S8756 3282(01)00684 6
   Muench SP, 2009, J MOL BIOL, V386, P989, DOI 10.1016/j.jmb.2009.01.014
   Nadler G, 1998, BIOORG MED CHEM LETT, V8, P3621, DOI 10.1016/S0960 894X(98)00660 X
   NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497
   Niikura K, 2005, J BONE MINER RES, V20, P1579, DOI 10.1359/JBMR.050517
   Niikura K, 2006, DRUG NEWS PERSPECT, V19, P139, DOI 10.1358/dnp.2006.19.3.977442
   Okumura S, 2006, BONE, V39, P684, DOI 10.1016/j.bone.2006.04.010
   Pérez Sayáns M, 2009, INT J ONCOL, V34, P1513, DOI 10.3892/ijo_00000280
   Qi J, 2007, J BIOENERG BIOMEMBR, V39, P423, DOI 10.1007/s10863 007 9116 8
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Schoonderwoert VTG, 2002, MOL MEMBR BIOL, V19, P67, DOI 10.1080/09687680110112910
   Smith AN, 2005, J AM SOC NEPHROL, V16, P1245, DOI 10.1681/ASN.2004090761
   Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767
   Sorensen MG, 2007, J BONE MINER RES, V22, P1640, DOI 10.1359/JBMR.070613
   Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200
   SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006 291X(90)91709 2
   SUNDQUIST K, 1993, BONE MINER, V20, P17, DOI 10.1016/S0169 6009(08)80034 7
   SUPEK F, 1994, J BIOL CHEM, V269, P24102
   Supekova L, 1996, J EXP BIOL, V199, P1147
   VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305
   Visentin L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145
   Wang Y, 2007, J BIOL CHEM, V282, P34058, DOI 10.1074/jbc.M704331200
   Wang YR, 2004, J BIOL CHEM, V279, P44628, DOI 10.1074/jbc.M407345200
   Xiao YT, 2008, INT J BIOCHEM CELL B, V40, P2002, DOI 10.1016/j.biocel.2007.08.006
   Xu J, 2007, HISTOL HISTOPATHOL, V22, P443, DOI 10.14670/HH 22.443
   Xu J, 2003, J CELL BIOCHEM, V88, P1256, DOI 10.1002/jcb.10477
   Yao GF, 2007, BIOCHEM BIOPH RES CO, V357, P821, DOI 10.1016/j.bbrc.2007.04.082
   Yesim F, 2001, MOL VIS, V7, P234
   Zhang ZY, 2008, J BIOL CHEM, V283, P35983, DOI 10.1074/jbc.M805345200
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 60
TC 28
Z9 33
U1 0
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 4851
EI 1573 4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD OCT
PY 2010
VL 37
IS 7
BP 3561
EP 3566
DI 10.1007/s11033 010 0004 7
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 652ES
UT WOS:000281985400069
PM 20182803
DA 2025 08 17
ER

PT J
AU Matsunaga, A
   Takami, M
   Irié, T
   Mishima, K
   Inagaki, K
   Kamijo, R
AF Matsunaga, Akihiro
   Takami, Masamichi
   Irie, Tarou
   Mishima, Kenji
   Inagaki, Katsunori
   Kamijo, Ryutaro
TI Microscopic study on resorption of β tricalcium phosphate materials by
   osteoclasts
SO CYTOTECHNOLOGY
LA English
DT Article
DE Osteoclasts; beta Tricalcium phosphate (beta TCP); Actin; Electron
   microscopy; Cytoskeleton
ID BONE RESORPTION; POLARIZATION
AB Sintered compounds prepared with beta tricalcium phosphate (beta TCP) are commonly used as biocompatible materials for bone regenerative medicine. Although implanted beta TCP is gradually replaced with new bone after resorption by osteoclasts, exactly how osteoclasts resorb beta TCP is not well understood. To elucidate this mechanism, we analyzed the structure of beta TCP discs on which mouse mature osteoclasts were cultured using scanning electron microscopy. We found that beta TCP was resorbed by mature osteoclasts on one side of each disc, as evidenced by the formation of multiple spine like crystals at the exposed areas. Because osteoclasts secrete acid to resorb bone minerals, we mimicked this acidification by dipping beta TCP slices into HCl solution (pH 2.0). However, no spine like crystals appeared even though the size of each beta TCP particle was reduced. On dentin slices, osteoclasts formed clear actin rings, which are cytoskeletal structures characteristic of bone resorbing osteoclasts. No clear actin rings were observed in osteoclasts cultured on beta TCP slices, although small actin dots were observed. Analysis by transmission electron microscopy showed that osteoclasts attached to beta TCP particles. These results suggest that osteoclasts resorb beta TCP particles independently of clear actin ring formation.
C1 [Matsunaga, Akihiro; Takami, Masamichi; Kamijo, Ryutaro] Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan.
   [Matsunaga, Akihiro; Inagaki, Katsunori] Showa Univ, Sch Med, Dept Orthopediat, Shinagawa Ku, Tokyo 1428555, Japan.
   [Takami, Masamichi] Showa Univ, Sch Dent, Dept Dent Pharmacol, Shinagawa Ku, Tokyo 1428555, Japan.
   [Irie, Tarou; Mishima, Kenji] Showa Univ, Sch Dent, Div Pathol, Dept Oral Diagnost Sci,Shinagawa Ku, Tokyo 1428555, Japan.
C3 Showa University; Showa University; Showa University; Showa University
RP Takami, M (通讯作者)，Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428555, Japan.
EM takami@dent.showa u.ac.jp
OI Takami, Masamichi/0000 0002 4506 3975
FU Grants in Aid for Scientific Research [24659830, 25462875, 26293398]
   Funding Source: KAKEN
CR BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Chazono M, 2004, J BIOMED MATER RES A, V70A, P542, DOI 10.1002/jbm.a.30094
   INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013
   Linovitz RJ, 2002, ORTHOPEDICS, V25, pS585
   Liu Bin, 2012, Orthop Surg, V4, P139, DOI 10.1111/j.1757 7861.2012.00189.x
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   Nakamura I, 1996, CELL TISSUE RES, V286, P507, DOI 10.1007/s004410050720
   Nakamura I, 1996, J BONE MINER RES, V11, P1873
   Ogose A, 2002, J BIOMED MATER RES, V63, P601, DOI 10.1002/jbm.10380
   Sagawa H, 2010, ARTIF ORGANS, V34, P491, DOI 10.1111/j.1525 1594.2009.00912.x
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   SASAKI T, 1995, BONE, V16, P9, DOI 10.1016/S8756 3282(94)00001 8
   Suzuki H, 1996, ENDOCRINOLOGY, V137, P4685, DOI 10.1210/en.137.11.4685
NR 13
TC 10
Z9 10
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920 9069
EI 1573 0778
J9 CYTOTECHNOLOGY
JI Cytotechnology
PD AUG
PY 2015
VL 67
IS 4
SI SI
BP 727
EP 732
DI 10.1007/s10616 015 9854 0
PG 6
WC Biotechnology & Applied Microbiology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Cell Biology
GA CK8XN
UT WOS:000356523500016
PM 25672942
OA Green Published
DA 2025 08 17
ER

PT J
AU Laurent, M
   Gielen, E
   Claessens, F
   Boonen, S
   Vanderschueren, D
AF Laurent, Michael
   Gielen, Evelien
   Claessens, Frank
   Boonen, Steven
   Vanderschueren, Dirk
TI Osteoporosis in older men: Recent advances in pathophysiology and
   treatment
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE osteoporosis; osteoporotic fractures; male; bone mineral density;
   ageing; androgens; oestrogens; testosterone; hypogonadism; peak bone
   mass; dual energy X ray absorptiometry; bisphosphonates; denosumab;
   teriparatide; strontium ranelate
ID BONE MINERAL DENSITY; HORMONE BINDING GLOBULIN; LATE ONSET HYPOGONADISM;
   MIDDLE AGED MEN; FRACTURE RISK; ELDERLY MEN; HIP FRACTURE; ANDROGEN
   RECEPTOR; VITAMIN D; ULTRASOUND PARAMETERS
AB Osteoporosis remains underrecognized and undertreated but more so in men, adding considerably to fracture burden and costs. Fracture related morbidity and mortality is higher in men, partly due to greater frailty. Improved peak bone mass, geometry and turn over contribute to lower fracture incidence in men. Bioavailable androgens and oestrogens regulate these aspects of musculoskeletal sexual dimorphism, yet the direct cellular and molecular targets of sex steroids in bone remain incompletely understood. Screening with clinical risk factors and dual energy X ray absorptiometry are advised in men from age 70 (or 50 with additional risk factors). We now have compelling evidence that osteoporosis drugs are equally effective in men and women, not only to increase bone density but also to prevent osteoporotic fractures. The use of testosterone or selective androgen receptor modulators for osteoporosis, sarcopenia, frailty and falls in men with late onset hypogonadism requires further investigation. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Laurent, Michael; Gielen, Evelien; Boonen, Steven; Vanderschueren, Dirk] Univ Hosp Leuven, B 3000 Louvain, Belgium.
   [Laurent, Michael; Gielen, Evelien; Boonen, Steven; Vanderschueren, Dirk] Katholieke Univ Leuven, Dept Clin & Expt Med, B 3000 Louvain, Belgium.
   [Laurent, Michael; Claessens, Frank] Katholieke Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, B 3000 Louvain, Belgium.
   [Boonen, Steven; Vanderschueren, Dirk] Univ Hosp Leuven, Ctr Metab Bone Dis, B 3000 Louvain, Belgium.
C3 KU Leuven; University Hospital Leuven; KU Leuven; KU Leuven; KU Leuven;
   University Hospital Leuven
RP Laurent, M (通讯作者)，Univ Hosp Leuven, Herestr 49, B 3000 Louvain, Belgium.
EM michael.laurent@med.kuleuven.be; evelien.gielen@uzleuven.be;
   frank.claessens@med.kuleuven.be; dirk.vanderschueren@uzleuven.be
RI Gielen, Evelien/L 6604 2018; Laurent, Michaël/D 5748 2011; Claessens,
   Frank/M 8565 2016; Laurent, Michael/D 5748 2011
OI Gielen, Evelien/0000 0002 8985 1201; Claessens,
   Frank/0000 0002 8676 7709; Laurent, Michael/0000 0001 9681 8330;
   vanderschueren, dirk/0000 0003 1395 0104
FU Research Foundation Flanders [G.0858.11N, G.0684.12N, G.0488.08,
   G.0565.12N]; Catholic University Leuven [OT 09 035]
FX M. Laurent is a research fellow of the Research Foundation Flanders.
   This work was supported by the Research Foundation Flanders via grants
   G.0858.11N and G.0684.12N to F. Claessens, and grants G.0488.08 and
   G.0565.12N to S. Boonen. D. Vanderschueren is supported by grant
   OT 09 035 from the Catholic University Leuven.
CR Adler RA, 2011, MATURITAS, V68, P143, DOI 10.1016/j.maturitas.2010.11.003
   Alibhai SMH, 2012, JAMA J AM MED ASSOC, V307, P255, DOI 10.1001/jama.2011.2022
   Aversa A, 2012, AGING MALE, V15, P96, DOI 10.3109/13685538.2011.631230
   Barrett Connor E, 2012, J BONE MINER RES, V27, P2306, DOI 10.1002/jbmr.1697
   Barrett Connor E, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1069
   Basaria S, 2010, NEW ENGL J MED, V363, P109, DOI 10.1056/NEJMoa1000485
   Bauer DC, 2009, J BONE MINER RES, V24, P2032, DOI [10.1359/jbmr.090526, 10.1359/JBMR.090526]
   Blaizot S, 2012, OSTEOPOROSIS INT, V23, P2785, DOI 10.1007/s00198 012 1906 0
   Bolland MJ, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.d2040
   Bondo L, 2013, OSTEOPOROSIS INT, V24, P245, DOI 10.1007/s00198 012 2024 8
   Boonen S, 2007, J CLIN ENDOCR METAB, V92, P1415, DOI 10.1210/jc.2006 1404
   Boonen S, 2012, NEW ENGL J MED, V367, P1714, DOI 10.1056/NEJMoa1204061
   Boonen S, 2012, BONE, V51, P383, DOI 10.1016/j.bone.2012.06.016
   Boonen S, 2012, J BONE MINER RES, V27, P963, DOI 10.1002/jbmr.1570
   Boonen S, 2011, J AM GERIATR SOC, V59, P2084, DOI 10.1111/j.1532 5415.2011.03666.x
   Boonen S, 2011, EUR J ENDOCRINOL, V165, P977, DOI 10.1530/EJE 11 0353
   Bours SPG, 2011, J CLIN ENDOCR METAB, V96, P1360, DOI 10.1210/jc.2010 2135
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Burnett Bowie SAM, 2009, J CLIN ENDOCR METAB, V94, P4785, DOI 10.1210/jc.2009 0739
   Byberg L, 2012, J BONE MINER RES, V27, P797, DOI 10.1002/jbmr.1498
   Callewaert F, 2010, J ENDOCRINOL, V207, P127, DOI 10.1677/JOE 10 0209
   Cauley JA, 2010, J CLIN ENDOCR METAB, V95, P4314, DOI 10.1210/jc.2009 2635
   Cawthon PM, 2012, J BONE MINER RES, V27, P2179, DOI 10.1002/jbmr.1671
   Center JR, 2007, JAMA J AM MED ASSOC, V297, P387, DOI 10.1001/jama.297.4.387
   Center JR, 2011, J CLIN ENDOCR METAB, V96, P1006, DOI 10.1210/jc.2010 2730
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Cooper C, 2011, OSTEOPOROSIS INT, V22, P1277, DOI 10.1007/s00198 011 1601 6
   Dalton JT, 2011, J CACHEXIA SARCOPENI, V2, P153, DOI 10.1007/s13539 011 0034 6
   Dawson Hughes B, 2012, OSTEOPOROSIS INT, V23, P811, DOI 10.1007/s00198 011 1694 y
   Eriksson AL, 2006, J CLIN ENDOCR METAB, V91, P5029, DOI 10.1210/jc.2006 0679
   Gielen E, 2012, CALCIFIED TISSUE INT, V91, P161, DOI 10.1007/s00223 012 9622 5
   Gielen E, 2011, BEST PRACT RES CL EN, V25, P321, DOI 10.1016/j.beem.2010.08.012
   Gómez Cabello A, 2012, SPORTS MED, V42, P301, DOI 10.2165/11597670 000000000 00000
   Greenspan SL, 2013, J BONE MINER RES, V28, P325, DOI 10.1002/jbmr.1771
   Gunter K, 2008, J BONE MINER RES, V23, P986, DOI 10.1359/JBMR.071201
   Haentjens P, 2004, J BONE MINER RES, V19, P1933, DOI 10.1359/JBMR.040917
   Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003 4819 152 6 201003160 00008
   Han TS, 2008, EUR J ENDOCRINOL, V159, P179, DOI 10.1530/EJE 08 0166
   Huhtaniemi IT, 2009, J CLIN ENDOCR METAB, V94, P277, DOI 10.1210/jc.2008 0848
   Idan A, 2010, ANN INTERN MED, V153, P621, DOI 10.7326/0003 4819 153 10 201011160 00004
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198 012 1964 3
   Kaufman JM, 2013, J CLIN ENDOCR METAB, V98, P592, DOI 10.1210/jc.2012 3048
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   Kirmani S, 2009, J BONE MINER RES, V24, P1033, DOI [10.1359/JBMR.081255, 10.1359/jbmr.081255]
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lapauw B, 2009, J CLIN ENDOCR METAB, V94, P4300, DOI 10.1210/jc.2009 0568
   LeBlanc ES, 2009, J CLIN ENDOCR METAB, V94, P3337, DOI 10.1210/jc.2009 0206
   LeBrasseur NK, 2012, J BONE MINER RES, V27, P2159, DOI 10.1002/jbmr.1666
   Lee DM, 2012, EUR J ENDOCRINOL, V166, P77, DOI 10.1530/EJE 11 0743
   Leslie WD, 2012, CAN MED ASSOC J, V184, P290, DOI 10.1503/cmaj.111158
   Limer KL, 2009, J BONE MINER RES, V24, P314, DOI [10.1359/jbmr.080912, 10.1359/JBMR.080912]
   Lippuner K, 2009, OSTEOPOROSIS INT, V20, P1131, DOI 10.1007/s00198 008 0779 8
   Liu CT, 2012, J BONE MINER RES, V27, P2051, DOI 10.1002/jbmr.1679
   Looker AC, 2012, OSTEOPOROSIS INT, V23, P771, DOI 10.1007/s00198 011 1623 0
   Lorentzon M, 2007, J CLIN ENDOCR METAB, V92, P497, DOI 10.1210/jc.2006 1294
   Lynn HS, 2008, OSTEOPOROSIS INT, V19, P1087, DOI 10.1007/s00198 007 0553 3
   Majumdar SR, 2012, J CLIN ENDOCR METAB, V97, P1236, DOI 10.1210/jc.2011 2645
   Meier C, 2005, J BONE MINER RES, V20, P579, DOI 10.1359/JBMR.041207
   Meier C, 2004, J CLIN ENDOCR METAB, V89, P3033, DOI 10.1210/jc.2003 031992
   Meier C, 2008, ARCH INTERN MED, V168, P47, DOI 10.1001/archinternmed.2007.2
   Mellström D, 2008, J BONE MINER RES, V23, P1552, DOI 10.1359/JBMR.080518
   Mellström D, 2006, J BONE MINER RES, V21, P529, DOI 10.1359/JBMR.060110
   Fernández Balsells MM, 2010, J CLIN ENDOCR METAB, V95, P2560, DOI 10.1210/jc.2009 2575
   Nair KS, 2006, NEW ENGL J MED, V355, P1647, DOI 10.1056/NEJMoa054629
   Nguyen ND, 2007, J BONE MINER RES, V22, P781, DOI 10.1359/JBMR.070315
   Nordström P, 2011, CALCIFIED TISSUE INT, V89, P203, DOI 10.1007/s00223 011 9507 z
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Nurmi Lüthje I, 2011, J BONE MINER RES, V26, P1845, DOI 10.1002/jbmr.375
   Orwoll E, 2012, J BONE MINER RES, V27, pS6
   Orwoll E, 2012, J CLIN ENDOCR METAB, V97, P3161, DOI 10.1210/jc.2012 1569
   Pye SR, 2010, CALCIFIED TISSUE INT, V86, P211, DOI 10.1007/s00223 009 9330 y
   Ryan CS, 2011, OSTEOPOROSIS INT, V22, P1845, DOI 10.1007/s00198 010 1421 0
   Sandhu SK, 2010, OSTEOPOROSIS INT, V21, P863, DOI 10.1007/s00198 009 1026 7
   Sawka AM, 2006, J CLIN DENSITOM, V9, P413, DOI 10.1016/j.jocd.2006.07.004
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Sinnesael M, 2012, J BONE MINER RES, V27, P2535, DOI 10.1002/jbmr.1713
   Smith MR, 2004, J CLIN ONCOL, V22, P2546, DOI 10.1200/JCO.2004.01.174
   Srinivasan B, 2012, OSTEOPOROSIS INT, V23, P155, DOI 10.1007/s00198 011 1822 8
   Szulc P, 2008, ANN RHEUM DIS, V67, P1249, DOI 10.1136/ard.2007.077941
   Szulc P, 2007, OSTEOPOROSIS INT, V18, P1451, DOI 10.1007/s00198 007 0407 z
   Szulc P, 2006, BONE, V38, P595, DOI 10.1016/j.bone.2005.09.004
   Szulc P, 2011, CALCIFIED TISSUE INT, V89, P303, DOI 10.1007/s00223 011 9519 8
   Szulc P, 2011, J BONE MINER RES, V26, P1358, DOI 10.1002/jbmr.319
   Szulc P, 2010, J BONE MINER RES, V25, P1446, DOI 10.1002/jbmr.13
   Tajar A, 2012, J CLIN ENDOCR METAB, V97, P1508, DOI 10.1210/jc.2011 2513
   Tarride JE, 2012, J BONE MINER RES, V27, P1830, DOI 10.1002/jbmr.1615
   Tracz MJ, 2006, J CLIN ENDOCR METAB, V91, P2011, DOI 10.1210/jc.2006 0036
   Van Caenegem E, 2012, J CLIN ENDOCR METAB, V97, P2503, DOI 10.1210/jc.2012 1187
   Vanbillemont G, 2010, J CLIN ENDOCR METAB, V95, P1579, DOI 10.1210/jc.2009 2189
   Vanderschueren D, 2010, OSTEOPOROSIS INT, V21, P1331, DOI 10.1007/s00198 009 1144 2
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Verschueren S, 2013, OSTEOPOROSIS INT, V24, P87, DOI 10.1007/s00198 012 2057 z
   von Friesendorff M, 2011, J AM GERIATR SOC, V59, P806, DOI 10.1111/j.1532 5415.2011.03399.x
   Wang X, 2012, J BONE MINER RES, V27, P808, DOI 10.1002/jbmr.1539
   Ward KA, 2011, OSTEOPOROSIS INT, V22, P1513, DOI 10.1007/s00198 010 1437 5
   Watts NB, 2012, J CLIN ENDOCR METAB, V97, P1802, DOI 10.1210/jc.2011 3045
   Wiren KM, 2012, BONE, V51, P835, DOI 10.1016/j.bone.2012.08.111
   Yang L, 2012, J BONE MINER RES, V27, P2314, DOI 10.1002/jbmr.1693
   Yu E, 2012, J BONE MINER RES, V27, pS66
NR 101
TC 34
Z9 37
U1 0
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD AUG
PY 2013
VL 27
IS 4
BP 527
EP 539
DI 10.1016/j.beem.2013.04.010
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 231BE
UT WOS:000325387200006
PM 24054929
DA 2025 08 17
ER

PT J
AU Song, Y
   Guo, NH
   Zi, FM
   Zheng, JF
   Cheng, J
AF Song, Yuan
   Guo, Ninghong
   Zi, Fuming
   Zheng, Jifu
   Cheng, Jing
TI lncRNA H19 plays a role in multiple myeloma via interacting with
   hnRNPA2B1 to stabilize BET proteins by targeting osteoclasts and
   osteoblasts
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Multiple myeloma; Osteolysis; Osteogenesis; H19; Exosomes; BET proteins
ID BONE MARROW; NONCODING RNAS; EXOSOMES; CELLS
AB Background: Multiple myeloma (MM), characterized with bone marrow microenvironment disorder, accounts for about 20% of hematological cancer deaths globally. Tissue extracellular communication, especially extracellular vesicles, has been defined as important mediator among cell to cell cross talk. Our previous study revealed an elevated level of H19 in MM, whereas, its role in MM exosomes in the development of osteolysis remains largely unknown. Method: MM exosomes referring to 5TGM1 cells were isolated and characterized using transmission electron microscopy (TEM), nanoparticle tracking and western blot analysis. The biological effects of blocking H19 were examined on osteolysis in vivo of C57Bl6/KalwRij mice, as well as on the osteoclast differentiation in vitro of RAW264.7 cells, by the application of TRAP, either with osteogenic differentiation in vitro of bone marrow mesenchymal stem cells (BMSCs), by the detection of alkaline phosphatase (ALP), alizarin red dye staining (ARS). The targeted relationships among H19/hnRNPA2B1/BET proteins were validated through RNA immunoprecipitation (RIP) and RNA pull down assays. Results: 5TGM1 cells derived exosomes lacking H19 dramatically blocked osteolysis and boosted osteogeneis in C57Bl6/KalwRij mice, either with osteoclastic differentiation of RAW264.7 cells and osteogenic differentiation of BMSCs, thereby enhancing their resorptive activity. Physically, H19 interacted with hnRNPA2B1 by preferentially adhering to it and enhancing its nuclear cytoplasmic translocation. Further mechanistic research validated that H19 promoted the stabilization of BET proteins through hnRNA2B1 to be involved in osteoclast differentiation for contributing to MM progression. Conclusion: Altogether, our findings suggest that H19, serving as an essential role for exosomes in the bone marrow environment, might be a viable diagnostic and therapeutic target for MM therapy.
C1 [Song, Yuan; Guo, Ninghong; Zi, Fuming; Zheng, Jifu; Cheng, Jing] Nanchang Univ, Dept Hematol, Affiliated Hosp 2, 1 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University
RP Cheng, J (通讯作者)，Nanchang Univ, Dept Hematol, Affiliated Hosp 2, 1 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China.
EM jingcheng1056@163.com
FU National Natural Science Foundation of China [82060027]
FX This work was supported by National Natural Science Foundation of China
   (82060027) .
CR Adams BD, 2017, J CLIN INVEST, V127, P761, DOI 10.1172/JCI84424
   Boriachek K, 2018, SMALL, V14, DOI 10.1002/smll.201702153
   Boyiadzis M, 2017, LEUKEMIA, V31, P1259, DOI 10.1038/leu.2017.91
   Braicu C, 2015, CELL DEATH DIFFER, V22, P34, DOI 10.1038/cdd.2014.130
   Chen TZ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.608815
   García Sánchez D, 2023, WORLD J STEM CELLS, V15, P421, DOI 10.4252/wjsc.v15.i5.421
   Garrett IR, 1997, BONE, V20, P515, DOI 10.1016/S8756 3282(97)00056 2
   Goodarzi H, 2012, NATURE, V485, P264, DOI 10.1038/nature11013
   He J, 2012, CANCER RES, V72, P6393, DOI 10.1158/0008 5472.CAN 12 2664
   Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018 017 2595 9
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hu WL, 2018, NAT CELL BIOL, V20, P492, DOI 10.1038/s41556 018 0066 7
   Huang Z, 2021, HEPATOLOGY, V74, P214, DOI 10.1002/hep.31673
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Jiang FJ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045 021 01066 6
   Jiang HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.258
   Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113
   Li MZ, 2019, J CANCER, V10, P6154, DOI 10.7150/jca.31752
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Liu R, 2022, THERANOSTICS, V12, P7760, DOI 10.7150/thno.76852
   Moloudizargari M, 2019, BLOOD REV, V38, DOI 10.1016/j.blre.2019.100595
   Pan YF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1219 0
   Panaroni C, 2017, CURR OSTEOPOROS REP, V15, P483, DOI 10.1007/s11914 017 0397 5
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Peperstraete E, 2020, CANCERS, V12, DOI 10.3390/cancers12071730
   RADL J, 1988, AM J PATHOL, V132, P593
   Radl J, 1999, PATHOL BIOL, V47, P109
   Raimondo S, 2020, NON CODING RNA, V6, DOI 10.3390/ncrna6030030
   Ren C, 2016, METHOD ENZYMOL, V573, P321, DOI 10.1016/bs.mie.2016.01.018
   Sharp A, 2016, CLIN CANCER RES, V22, P4280, DOI 10.1158/1078 0432.CCR 16 1137
   Siegel R.L., 2020, CA CANCER J CLIN, V70, P7
   Smits G, 2008, NAT GENET, V40, P971, DOI 10.1038/ng.168
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Thery Clotilde, 2011, F1000 Biol Rep, V3, P15, DOI 10.3410/B3 15
   van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307
   Yáñez Mó M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066
   Yang J, 2021, INT J BIOL SCI, V17, P3188, DOI 10.7150/ijbs.62573
   Yu LJ, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12056
   Yuan XX, 2021, THERANOSTICS, V11, P1429, DOI 10.7150/thno.45351
   Zhang YH, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046 020 01619 6
   Zhao SL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00991 2
   Zheng JF, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00382 19
   Zhou XS, 2020, J VIROL, V94, DOI 10.1128/JVI.00367 20
   Zhuang JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048871
NR 44
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC 5
PY 2024
VL 142
AR 113080
DI 10.1016/j.intimp.2024.113080
EA SEP 2024
PN B
PG 12
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA G6T6Q
UT WOS:001317943300001
PM 39288624
DA 2025 08 17
ER

PT J
AU Satterwhite, J
   Heathman, M
   Miller, PD
   Marín, F
   Glass, EV
   Dobnig, H
AF Satterwhite, Julie
   Heathman, Michael
   Miller, Paul D.
   Marin, Fernando
   Glass, Emmett V.
   Dobnig, Harald
TI Pharmacokinetics of Teriparatide (rhPTH[1 34]) and Calcium
   Pharmacodynamics in Postmenopausal Women with Osteoporosis
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Anabolic agent; Osteoporosis therapy; Peptide hormone; Parathyroid
   hormone; Teriparatide pharmacokinetics; Calcium pharmacodynamics
ID BONE MINERAL DENSITY; PARATHYROID HORMONE; PERIPHERAL METABOLISM;
   ALENDRONATE; RATS
AB Teriparatide (rhPTH[1 34]) affects calcium metabolism in a pattern consistent with the known actions of endogenous parathyroid hormone (PTH). This report describes the pharmacokinetics and resulting serum calcium response to teriparatide in postmenopausal women with osteoporosis. Pharmacokinetic samples for this analysis were obtained from 360 women who participated in the Fracture Prevention Trial. Postmenopausal women with osteoporosis received daily subcutaneous injections of either teriparatide 20 mu g (4.86 mu mol) or placebo, median 21 months' treatment. Serum teriparatide and calcium concentrations were measured throughout the study. An indirect response model was developed to describe the pharmacokinetic pharmacodynamic relationship between teriparatide concentrations and serum calcium response. The pharmacokinetics of teriparatide were characterized by rapid absorption (maximum concentration achieved within 30 min) and rapid elimination (half life of 1 h), resulting in a total duration of exposure to the peptide of approximately 4 h. Teriparatide transiently increased serum calcium, with the maximum effect observed at approximately 4.25 h (median increase 0.4 mg/dl [0.1 mmol/l]). Calcium concentrations returned to predose levels by 16 24 h after each dose. Persistent hypercalcemia was not observed; one teriparatide 20 mu g treated patient had a predose serum calcium value above the normal range but < 11.0 mg/dl (2.75 mmol/l). Following once daily subcutaneous administration, teriparatide produces a modest but transient increase in serum calcium, consistent with the known effects of endogenous PTH on mineral metabolism. The excursion in serum calcium is brief, due to the short length of time that teriparatide concentrations are elevated.
C1 [Dobnig, Harald] Med Univ Graz, Div Endocrinol & Nucl Med, Dept Internal Med, A 8036 Graz, Austria.
   [Satterwhite, Julie; Heathman, Michael; Glass, Emmett V.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.
   [Miller, Paul D.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA.
   [Miller, Paul D.] Colorado Ctr Bone Res, Lakewood, CO USA.
   [Marin, Fernando] Eli Lilly & Co, Lilly Res Ctr, Windlesham, Surrey, England.
C3 Medical University of Graz; Eli Lilly; Lilly Research Laboratories;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado Denver; Colorado Center For Bone
   Research; Eli Lilly; Lilly Research Laboratories
RP Dobnig, H (通讯作者)，Med Univ Graz, Div Endocrinol & Nucl Med, Dept Internal Med, Auenbruggerpl 15, A 8036 Graz, Austria.
EM harald.dobnig@meduni graz.at
RI Marin, Fernando/K 7666 2019
FU Eli Lilly and Company; Roche; Novartis; Nycomed; Procter Gamble; Sanofi
   Aventis; Merck Co.; Amgen; Lilly Research Laboratories; Eli Lilly and
   Company, Indianapolis, IN
FX J. Satterwhite, M. Heathman, and F. Marin are full time employees of Eli
   Lilly and Company. E. Glass was an employee of Eli Lilly and Company
   during the preparation of this manuscript and is now an employee of
   Amgen. H. Dobnig received lecture fees from Eli Lilly and Company,
   Roche, Novartis, Nycomed, and Servier. P. Miller has received scientific
   grants from Procter & Gamble, Sanofi Aventis, Roche, Eli Lilly and
   Company, Merck & Co., Novartis, and Amgen. P. Miller is on the
   speaker/advisory boards and consultant for Procter & Gamble, Sanofi
   Aventis, Merck & Co., Eli Lilly and Company, Amgen, NPS Pharmaceuticals,
   Novartis, Roche, and GlaxoSmithKline. This study was funded by Lilly
   Research Laboratories, Eli Lilly and Company, Indianapolis, IN.
   Editorial assistance was provided by Gail P. Dalsky, PhD, an employee of
   Eli Lilly and Company.
CR Beal SL., 2006, NONMEM users guides
   BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371
   Daugaard H, 1996, DAN MED BULL, V43, P203
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   *E LILL CO, 2009, TER RHPTH 1 34 FORT
   *EPAR, 2007, PREOT PROD INF
   *EPAR, 2009, FORST PROD INF
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   GOLTZMAN D, 1986, RECENT PROG HORM RES, V42, P665
   Goltzman D, 2008, ARCH BIOCHEM BIOPHYS, V473, P218, DOI 10.1016/j.abb.2008.03.003
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   HABENER JF, 1984, PHYSIOL REV, V64, P985, DOI 10.1152/physrev.1984.64.3.985
   Kronenberg HM., 2001, The Parathyroids, VSecond, P17
   Lewin E, 1995, Curr Opin Nephrol Hypertens, V4, P324, DOI 10.1097/00041552 199507000 00007
   LUDDEN TM, 1988, J CLIN PHARMACOL, V28, P1059, DOI 10.1002/j.1552 4604.1988.tb05714.x
   MARTIN KJ, 1979, NEW ENGL J MED, V301, P1092, DOI 10.1056/NEJM197911153012005
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Miller PD, 2007, J CLIN ENDOCR METAB, V92, P3535, DOI 10.1210/jc.2006 2439
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Schwietert HR, 1997, CLIN PHARMACOL THER, V61, P360, DOI 10.1016/S0009 9236(97)90169 7
   Sheiner LB, 2000, ANNU REV PHARMACOL, V40, P67, DOI 10.1146/annurev.pharmtox.40.1.67
   Yano Y, 2001, J PHARMACOKINET PHAR, V28, P171, DOI 10.1023/A:1011555016423
   2007, RHPTH 1 84 PREOTACT
NR 25
TC 78
Z9 89
U1 1
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD DEC
PY 2010
VL 87
IS 6
BP 485
EP 492
DI 10.1007/s00223 010 9424 6
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 679JT
UT WOS:000284158400002
PM 20953593
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Tournis, S
   Dede, AD
AF Tournis, Symeon
   Dede, Anastasia D.
TI Osteogenesis imperfecta   A clinical update
SO METABOLISM CLINICAL AND EXPERIMENTAL
LA English
DT Article
DE Collagen; Bone fragility; Blue sclerae; Atypical fracture; Zebra sign
ID SCLEROSTIN ANTIBODY TREATMENT; INTRAVENOUS BISPHOSPHONATE TREATMENT;
   GENOTYPE PHENOTYPE CORRELATIONS; VITAMIN D SUPPLEMENTATION; BRTL/+ MOUSE
   MODEL; TERIPARATIDE TREATMENT; DELETION MUTATION; ZOLEDRONIC ACID;
   MUSCLE FUNCTION; WNT1 MUTATIONS
AB Osteogenesis imperfecta ((DI) is the most common inherited form of bone fragility and includes a heterogenous group of genetic disorders which most commonly result from defects associated with type 1 collagen. 85% 90% of cases are inherited in an autosomal dominant manner and are caused by mutations in the COL1A1 and COL1A2 genes, leading to quantitative or qualitative defects in type 1 collagen. In the last decade, defects in several other proteins involved in the normal processing of type 1 collagen have been described. Recent advances in genetics have called for reconsideration of the classification of OI, however, most recent classifications align with the classic clinical classification by Sillence. The hallmark of the disease is bone fragility but other tissues are also affected. Intravenous bisphosphonates (BPs) are the most widely used intervention, having significant favorable effects regarding areal bone mineral density (BMD) and vertebral reshaping following fractures in growing children. BPs have a modest effect in long bone fracture incidence, their effects in adults with OI concerns only BMD, while there are reports of subtrochanteric fractures resembling atypical femoral fractures. Other therapies showing promising results include denosumab, teriparatide, sclerostin inhibition, combination therapy with antiresorptive and anabolic drugs and TGF beta inhibition. Gene targeting approaches are under evaluation. More research is needed to delineate the best therapeutic approach in this heterogeneous disease. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Tournis, Symeon; Dede, Anastasia D.] Univ Athens, KAT Hosp, Lab Res Musculoskeletal Syst Th Garofalidis, 10 Athinas Str, Athens 14561, Greece.
   [Dede, Anastasia D.] Chelsea & Westminster Hosp, Dept Endocrinol & Diabet, London, England.
C3 National & Kapodistrian University of Athens; Imperial College London
RP Tournis, S (通讯作者)，Univ Athens, KAT Hosp, Lab Res Musculoskeletal Syst Th Garofalidis, 10 Athinas Str, Athens 14561, Greece.
EM stoumis@med.uoa.gr
OI TOURNIS, SYMEON/0000 0002 8301 324X
CR Albert C, 2014, BONE, V66, P121, DOI 10.1016/j.bone.2014.05.022
   Amor IMB, 2013, J BONE MINER RES, V28, P2001
   Anam EA, 2015, J BONE MINER RES, V30, P1362, DOI 10.1002/jbmr.2486
   Anastasilakis AD, 2017, J BONE MINER RES
   ANDERSEN PE, 1989, CLIN GENET, V36, P250
   Arponen H, 2015, J NEUROSURG PEDIATR, V15, P313, DOI 10.3171/2014.11.PEDS14113
   Arponen H, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 428
   Arponen H, 2012, J BONE MINER RES, V27, P1142, DOI 10.1002/jbmr.1555
   Asharani PV, 2012, AM J HUM GENET, V90, P661, DOI 10.1016/j.ajhg.2012.02.026
   Ashournia H, 2015, INT J CARDIOL, V196, P149, DOI 10.1016/j.ijcard.2015.06.001
   Åström E, 2002, ARCH DIS CHILD, V86, P356, DOI 10.1136/adc.86.5.356
   Barnes AM, 2012, HUM MUTAT, V33, P1589, DOI 10.1002/humu.22139
   Barnes AM, 2006, NEW ENGL J MED, V355, P2757, DOI 10.1056/NEJMoa063804
   Barron MJ, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750 1172 3 31
   Becker J, 2011, AM J HUM GENET, V88, P362, DOI 10.1016/j.ajhg.2011.01.015
   Bhatt RN, 2014, AUST DENT J, V59, P9, DOI 10.1111/adj.12140
   Biggin A, 2014, HORM RES PAEDIAT, V81, P204, DOI 10.1159/000355111
   Bishop N, 2016, J BONE MINER RES, V31, P699, DOI 10.1002/jbmr.2835
   Bishop N, 2013, LANCET, V382, P1424, DOI 10.1016/S0140 6736(13)61091 0
   Bonafe L, 2015, AM J MED GENET A, V167, P2869, DOI 10.1002/ajmg.a.37365
   Brizola E, 2014, PEDIATR PHYS THER, V26, P245, DOI 10.1097/PEP.0000000000000042
   Cabral WA, 2007, NAT GENET, V39, P359, DOI 10.1038/ng1968
   Carmel AS, 2012, OSTEOPOROSIS INT, V23, P2479, DOI 10.1007/s00198 011 1868 7
   Cheung MS, 2011, J BONE MINER RES, V26, P405, DOI 10.1002/jbmr.220
   Cho TJ, 2012, AM J HUM GENET, V91, P343, DOI 10.1016/j.ajhg.2012.06.005
   Christiansen HE, 2010, AM J HUM GENET, V86, P389, DOI 10.1016/j.ajhg.2010.01.034
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Dwan K, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub3
   Edouard T, 2011, J CLIN ENDOCR METAB, V96, P3193, DOI 10.1210/jc.2011 1480
   Engelbert RH, 2004, ARCH PHYS MED REHAB, V85, P772, DOI 10.1016/j.apmr.2003.08.085
   Etxebarria Foronda I, 2015, CLIN CASES MINER BON, V12, P278, DOI 10.11138/ccmbm/2015.12.3.278
   Folkestad L, 2016, J BONE MINER RES, V31, P2159, DOI 10.1002/jbmr.2895
   Folkestad L, 2016, INT J CARDIOL, V225, P250, DOI 10.1016/j.ijcard.2016.09.107
   Folkestad L, 2012, J BONE MINER RES, V27, P1405, DOI 10.1002/jbmr.1592
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Garbes L, 2015, AM J HUM GENET, V96, P432, DOI 10.1016/j.ajhg.2015.01.002
   Gatti D, 2013, CALCIFIED TISSUE INT, V93, P448, DOI 10.1007/s00223 013 9770 2
   George S, 2015, J CLIN ENDOCR METAB, V100, P4163, DOI 10.1210/jc.2015 2680
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Grafe I, 2016, J BONE MINER RES, V31, P1030, DOI 10.1002/jbmr.2776
   Ha Vinh R, 2004, AM J MED GENET A, V131A, P115, DOI 10.1002/ajmg.a.30231
   Hald JD, 2015, J BONE MINER RES, V30, P929, DOI 10.1002/jbmr.2410
   Hegazy A, 2016, J PEDIATR ORTHOPED, V36, P757, DOI 10.1097/BPO.0000000000000552
   Hegde V, 2016, OSTEOPOROSIS INT, V27, P861, DOI 10.1007/s00198 015 3331 7
   Hennedige Anusha Adeline, 2013, J Oral Maxillofac Res, V4, pe1, DOI 10.5037/jomr.2013.4401
   Högler W, 2017, J CLIN ENDOCR METAB, V102, P2734, DOI 10.1210/jc.2017 00275
   Holm J, 2014, ENDOCR PRACT, V20, pE187, DOI 10.4158/EP14141.CR
   Homan EP, 2011, J BONE MINER RES, V26, P2798, DOI 10.1002/jbmr.487
   Hoyer Kuhn H, 2016, J MUSCULOSKEL NEURON, V16, P24
   Hoyer Kuhn H, 2014, J MUSCULOSKEL NEURON, V14, P445
   Hoyer Kuhn H, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023 014 0145 1
   Imbert L, 2014, BONE, V65, P18, DOI 10.1016/j.bone.2014.04.030
   Jacobsen CM, 2014, J BONE MINER RES, V29, P2297, DOI 10.1002/jbmr.2198
   Kelley BP, 2011, J BONE MINER RES, V26, P666, DOI 10.1002/jbmr.250
   Kuurila K, 2002, ANN OTO RHINOL LARYN, V111, P939, DOI 10.1177/000348940211101014
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Lapunzina P, 2010, AM J HUM GENET, V87, P110, DOI 10.1016/j.ajhg.2010.05.016
   Lim J, 2017, BONE
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Lindahl K, 2015, EUR J HUM GENET, V23, P1042, DOI 10.1038/ejhg.2015.81
   Lindahl K, 2014, EUR J ENDOCRINOL, V171, pR79, DOI 10.1530/EJE 14 0017
   Majorana A, 2010, INT J PAEDIATR DENT, V20, P112, DOI 10.1111/j.1365 263X.2010.01033.x
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Malfait F, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 78
   Manolopoulos KN, 2013, J CLIN ENDOCR METAB, V98, P871, DOI 10.1210/jc.2012 4195
   Marom R, 2016, AM J MED GENET C, V9999C, P1
   Martínez Glez V, 2012, HUM MUTAT, V33, P343, DOI 10.1002/humu.21647
   McAllion SJ, 1996, J CLIN PATHOL, V49, P627, DOI 10.1136/jcp.49.8.627
   McKiernan FE, 2005, OSTEOPOROSIS INT, V16, P1698, DOI 10.1007/s00198 005 1905 5
   Meier RPH, 2012, ACTA ORTHOP, V83, P548, DOI 10.3109/17453674.2012.729183
   Morello R, 2006, CELL, V127, P291, DOI 10.1016/j.cell.2006.08.039
   O'Connell AC, 1999, ORAL SURG ORAL MED O, V87, P189, DOI 10.1016/S1079 2104(99)70272 6
   Orwoll ES, 2014, J CLIN INVEST, V124, P491, DOI 10.1172/JCI71101
   Palomo T, 2015, J BONE MINER RES, V30, P2150, DOI 10.1002/jbmr.2567
   PATERSON CR, 1984, NEW ENGL J MED, V310, P1694, DOI 10.1056/NEJM198406283102602
   PEDERSEN U, 1984, SCAND AUDIOL, V13, P67, DOI 10.3109/01050398409043042
   Peris P, 2012, BONE, V51, P54, DOI 10.1016/j.bone.2012.03.026
   Plante L, 2016, BONE, V86, P36, DOI 10.1016/j.bone.2016.02.013
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Rauch F, 2007, BONE, V40, P821, DOI 10.1016/j.bone.2006.11.020
   Rijks EBG, 2015, HORM RES PAEDIAT, V84, P26, DOI 10.1159/000381713
   Roschger A, 2014, BONE, V66, P182, DOI 10.1016/j.bone.2014.06.015
   Rubinato E, 2014, GENE, V545, P290, DOI 10.1016/j.gene.2014.05.028
   Sato A, 2016, BONE, V86, P53, DOI 10.1016/j.bone.2016.02.018
   Schwarze U, 2013, HUM MOL GENET, V22, P1, DOI 10.1093/hmg/dds371
   Semler O, 2012, J MUSCULOSKEL NEURON, V12, P183
   Semler O, 2012, AM J HUM GENET, V91, P349, DOI 10.1016/j.ajhg.2012.06.011
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   SILLENCE D, 1993, AM J MED GENET, V45, P183, DOI 10.1002/ajmg.1320450207
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   SILLENCE DO, 1994, PEDIATR RADIOL, V24, P427, DOI 10.1007/BF02011910
   Sinder BP, 2014, OSTEOPOROSIS INT, V25, P2097, DOI 10.1007/s00198 014 2737 y
   Sinder BP, 2015, BONE, V71, P115, DOI 10.1016/j.bone.2014.10.012
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   STOLL C, 1989, CLIN GENET, V35, P88
   Swinnen FKR, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750 1172 6 88
   Trejo P, 2016, OSTEOPOROSIS INT, V27, P3427, DOI 10.1007/s00198 016 3723 3
   Puig Hervás MT, 2012, HUM MUTAT, V33, P1444, DOI 10.1002/humu.22133
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   van Dijk FS, 2009, AM J HUM GENET, V85, P521, DOI 10.1016/j.ajhg.2009.09.001
   Vasanwala RF, 2016, J BONE MINER RES, V31, P1449, DOI 10.1002/jbmr.2805
   Veilleux LN, 2014, J CLIN ENDOCR METAB, V99, pE356, DOI 10.1210/jc.2013 3209
   Volodarsky M, 2013, HUM MUTAT, V34, P582, DOI 10.1002/humu.22274
   Vuorimies I, 2017, J CLIN ENDOCR METAB, V102, P1333, DOI 10.1210/jc.2016 3745
   Vuorimies I, 2017, BONE, V94, P29, DOI 10.1016/j.bone.2016.10.004
   Ward LM, 2016, OSTEOPOROSIS INT, V27, P2147, DOI 10.1007/s00198 016 3515 9
   Ward LM, 2011, J CLIN ENDOCR METAB, V96, P355, DOI 10.1210/jc.2010 0636
   Weaver CM, 2016, OSTEOPOROSIS INT, V27, P367, DOI 10.1007/s00198 015 3386 5
   Zhang H, 2017, OSTEOPOROSIS INT, V28, P1473, DOI 10.1007/s00198 016 3866 2
NR 111
TC 99
Z9 118
U1 0
U2 20
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0026 0495
EI 1532 8600
J9 METABOLISM
JI Metab. Clin. Exp.
PD MAR
PY 2018
VL 80
BP 27
EP 37
DI 10.1016/j.metabol.2017.06.001
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FY0XE
UT WOS:000426535200004
PM 28625337
DA 2025 08 17
ER

PT J
AU Wang, ZQ
   Feng, X
   Zhang, GR
   Li, HY
   Zhou, F
   Xie, YX
   Li, TJ
   Zhao, CZ
   Luo, WX
   Xiong, Y
   Wu, YY
AF Wang, Zhanqi
   Feng, Xuan
   Zhang, Guorui
   Li, Haiyun
   Zhou, Feng
   Xie, Yaxin
   Li, Tianjiao
   Zhao, Chengzhi
   Luo, Wenxin
   Xiong, Yi
   Wu, Yingying
TI Artesunate ameliorates ligature induced periodontitis by attenuating
   NLRP3 inflammasome mediated osteoclastogenesis and enhancing osteogenic
   differentiation
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Artesunate; Osteoclasts; NLRP3; Inflammasomes; Periodontitis;
   Osteoblasts
ID BONE RESORPTION; KAPPA B; INHIBITION; ACTIVATION; ADULTS
AB Periodontitis, arguably the greatest common infective chronic inflammatory disease, is characterized by an imbalance of the host immune system and excessive osteoclastogenesis activity with severe alveolar bone loss. Nevertheless, in consideration of the harmful effects of repeated treatment, more sensible intervention drugs for periodontitis need to be developed. Artesunate (ART), derived from Artemisia annua L., has shown remarkable pharmacokinetic and clinical value, as well as anti inflammatory and immunomodulatory effects in various immune and chronic diseases due to its endoperoxide group. However, the role of ART in mediating periodontitis induced alveolar bone resorption has not been examined. In this study, ART treatment effectively ameliorated ligature induced periodontitis via attenuating osteoclast formation in a dose dependent manner. Mechanistically, RNA seq revealed that ART dramatically reduced the enrichment of NLRP3 inflammasomerelated genes. Concordant with our study, MCC950, a specific inhibitor of NLRP3 inflammasome, also greatly restrained osteoclastogenesis, suggesting that ART suppressed osteoclast formation by blocking NLRP3 inflammasome activation. In addition to regulating osteoclastogenesis, ART significantly enhanced osteogenic differentiation by alleviating the expression of cytokines in inflammatory conditions. Our data shed light on the probably potential mechanism of ART treatment for the intervention of periodontitis.
C1 [Wang, Zhanqi; Feng, Xuan; Zhang, Guorui; Li, Haiyun; Zhou, Feng; Luo, Wenxin; Xiong, Yi; Wu, Yingying] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Wang, Zhanqi; Li, Haiyun; Zhou, Feng; Xiong, Yi; Wu, Yingying] Sichuan Univ, West China Hosp Stomatol, Dept Oral Implantol, Chengdu, Peoples R China.
   [Xie, Yaxin] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Orthodont,State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Li, Tianjiao; Zhao, Chengzhi] Sichuan Univ, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Li, Tianjiao; Zhao, Chengzhi] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Oral & Maxillofacial Surg, Chengdu, Peoples R China.
   [Wu, Yingying] Sichuan Univ, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, 14 3 Sect,Renmin Nan Rd, Chengdu 610041, Peoples R China.
   [Wu, Yingying] Sichuan Univ, West China Hosp Stomatol, Dept Oral Implantol, 14 3 Sect,Renmin Nan Rd, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University; Sichuan University; Sichuan University; Sichuan University
RP Wu, YY (通讯作者)，Sichuan Univ, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, 14 3 Sect,Renmin Nan Rd, Chengdu 610041, Peoples R China.; Wu, YY (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Oral Implantol, 14 3 Sect,Renmin Nan Rd, Chengdu 610041, Peoples R China.
EM yywdentist@163.com
RI ; Xie, Yaxin/KEH 4726 2024; XIONG, Yi/HGU 1217 2022; Zhong,
   Qihuang/JDW 5049 2023
OI Luo, Wenxin/0009 0008 9233 8848; Wang, Zhanqi/0000 0002 5907 9134; 
FU National Natural Science Foundation of China [81970966, 82001084];
   Natural Science Foundation of Sichuan Province [2023NSFSC0574,
   2023NSFSC1513]
FX Funding This work was supported by the National Natural Science
   Foundation of China (No. 81970966 and 82001084) , and by the Natural
   Science Foundation of Sichuan Province (No. 2023NSFSC0574 and
   2023NSFSC1513) .
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Bartold PM, 2018, PERIODONTOL 2000, V78, P7, DOI 10.1111/prd.12237
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Chen YY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12973
   Cheng FF, 2015, INT J MOL SCI, V16, P18956, DOI 10.3390/ijms160818956
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   de Veerdonk FLV, 2011, TRENDS IMMUNOL, V32, P110, DOI 10.1016/j.it.2011.01.003
   Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520
   Feng XC, 2020, PHARMACOL THERAPEUT, V216, DOI 10.1016/j.pharmthera.2020.107650
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hathaway Schrader JD, 2021, PERIODONTOL 2000, V86, P157, DOI 10.1111/prd.12368
   Kawahara Y, 2020, J DENT RES, V99, P830, DOI 10.1177/0022034520913250
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Lalla E, 2011, NAT REV ENDOCRINOL, V7, P738, DOI 10.1038/nrendo.2011.106
   Li X, 2019, ACTA BIOMATER, V94, P627, DOI 10.1016/j.actbio.2019.06.023
   Liu CJ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29633 6
   Newton PN, 2006, EUR J CLIN PHARMACOL, V62, P1003, DOI 10.1007/s00228 006 0203 2
   Pan WY, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0064 z
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Robaszkiewicz A, 2016, SCI REP UK, V6, DOI 10.1038/srep21131
   Sims NA, 1996, CALCIFIED TISSUE INT, V59, P121, DOI 10.1007/s002239900098
   Slots J, 2020, PERIODONTOL 2000, V83, P272, DOI 10.1111/prd.12325
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   STERRETT JD, 1986, J CLIN PERIODONTOL, V13, P258, DOI 10.1111/j.1600 051X.1986.tb02220.x
   Su XH, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111382
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577 019 0165 0
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tiwari MK, 2020, MED RES REV, V40, P1220, DOI 10.1002/med.21657
   Wang C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.58
   Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907
   Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06898 4
   Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014
   Zeng XZ, 2020, ACTA PHARMACOL SIN, V41, P229, DOI 10.1038/s41401 019 0289 6
   Zhang J, 2020, ENVIRON TOXICOL PHAR, V76, DOI 10.1016/j.etap.2020.103358
   Zhang J, 2020, J CLIN PERIODONTOL, V47, P451, DOI 10.1111/jcpe.13258
   Zhao CJ, 2017, BIOMED PHARMACOTHER, V96, P410, DOI 10.1016/j.biopha.2017.10.018
   Zhu XB, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.03.40
NR 40
TC 10
Z9 12
U1 4
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2023
VL 123
AR 110749
DI 10.1016/j.intimp.2023.110749
EA JUL 2023
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA P6RC1
UT WOS:001051918100001
PM 37531830
DA 2025 08 17
ER

PT J
AU Anderson, K
   Ismaila, N
   Flynn, PJ
   Halabi, S
   Jagannath, S
   Ogaily, MS
   Omel, J
   Raje, N
   Roodman, GD
   Yee, GC
   Kyle, RA
AF Anderson, Kenneth
   Ismaila, Nofisat
   Flynn, Patrick J.
   Halabi, Susan
   Jagannath, Sundar
   Ogaily, Mohammed S.
   Omel, Jim
   Raje, Noopur
   Roodman, G. David
   Yee, Gary C.
   Kyle, Robert A.
TI Role of Bone Modifying Agents in Multiple Myeloma: American Society of
   Clinical Oncology Clinical Practice Guideline Update
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID ZOLEDRONIC ACID; BISPHOSPHONATE THERAPY; CELL TRANSPLANTATION;
   SYSTEMATIC REVIEWS; TRIAL; OSTEONECROSIS; JAW; DENOSUMAB; IX;
   COMPLICATIONS
AB PurposeTo update guideline recommendations on the role of bone modifying agents in multiple myeloma.MethodsAn update panel conducted a targeted systematic literature review by searching PubMed and the Cochrane Library for randomized controlled trials, systematic reviews, meta analyses, clinical practice guidelines, and observational studies.ResultsThirty five relevant studies were identified, and updated evidence supports the current recommendations.RecommendationsFor patients with active symptomatic multiple myeloma that requires systemic therapy with or without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is recommended. Denosumab has shown to be noninferior to zoledronic acid for the prevention of skeletal related events and provides an alternative. Fewer adverse events related to renal toxicity have been noted with denosumab compared with zoledronic acid and may be preferred in this setting. The update panel recommends that clinicians consider reducing the initial pamidronate dose in patients with preexisting renal impairment. Zoledronic acid has not been studied in patients with severe renal impairment and is not recommended in this setting. The update panel suggests that bone modifying treatment continue for up to 2 years. Less frequent dosing has been evaluated and should be considered in patients with responsive or stable disease. Continuous use is at the discretion of the treating physician and the risk of ongoing skeletal morbidity. Retreatment should be initiated at the time of disease relapse. The update panel discusses measures regarding osteonecrosis of the jaw. Additional information is available at www.asco.org/hematologic malignancies guidelines and www.asco.org/guidelineswiki. (C) 2018 by American Society of Clinical Oncology
C1 [Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Raje, Noopur] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Ismaila, Nofisat] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA.
   [Flynn, Patrick J.] Minnesota Oncol, Woodbury, NY USA.
   [Kyle, Robert A.] Mayo Clin, Rochester, MN USA.
   [Halabi, Susan] Duke Univ, Med Ctr, Durham, NC USA.
   [Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA.
   [Ogaily, Mohammed S.] Beuamont Ctr Hematol & Oncol Downriver, Brownstown, MI USA.
   [Omel, Jim] Educ & Advocacy, Grand Isl, NE USA.
   [Yee, Gary C.] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Roodman, G. David] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; American Society of Clinical
   Oncology; Mayo Clinic; Duke University; Icahn School of Medicine at
   Mount Sinai; University of Nebraska System; University of Nebraska
   Medical Center; Indiana University System; Indiana University
   Bloomington
RP Anderson, K (通讯作者)，Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA.
RI ; Yee, Gary/KBC 0317 2024; Ismaila, Nofisat/HGC 3899 2022; Halabi,
   Susan/AFL 7973 2022; Anderson, Kenneth/ACP 5073 2022; Kyle,
   Robert/AIC 6889 2022
OI Halabi, Susan/0000 0003 4135 2777; 
CR Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   Berenson JR, 2008, CLIN CANCER RES, V14, P6289, DOI 10.1158/1078 0432.CCR 08 0666
   Berenson JR, 2011, AM J HEMATOL, V86, P25, DOI 10.1002/ajh.21912
   Bower JE, 2014, J CLIN ONCOL, V32, P1840, DOI 10.1200/JCO.2013.53.4495
   Centers for Medicare & Medicaid Services, 2 QUART 2017 MED PAY
   D'Arena G, 2011, LEUKEMIA LYMPHOMA, V52, P771, DOI 10.3109/10428194.2011.553000
   Delforge M, 2011, EUR J HAEMATOL, V86, P372, DOI 10.1111/j.1600 0609.2011.01599.x
   Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554
   Ferrell BR, 2017, J CLIN ONCOL, V35, P96, DOI 10.1200/JCO.2016.70.1474
   Gabbert TI, 2015, J CANCER RES CLIN, V141, P749, DOI 10.1007/s00432 014 1853 6
   García Sanz R, 2015, HAEMATOLOGICA, V100, P1207, DOI 10.3324/haematol.2015.128439
   Geng CJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen 2014 007258
   Gilligan T, 2017, J CLIN ONCOL, V35, P3618, DOI 10.1200/JCO.2017.75.2311
   Gimsing P, 2010, LANCET ONCOL, V11, P973, DOI 10.1016/S1470 2045(10)70198 4
   Hageman K, 2013, ANN PHARMACOTHER, V47, P1069, DOI 10.1345/aph.1R776
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Jackson GH, 2014, BRIT J HAEMATOL, V166, P109, DOI 10.1111/bjh.12861
   Jung TI, 2010, J CANCER RES CLIN, V136, P363, DOI 10.1007/s00432 009 0662 9
   Kumar A, 2011, ACTA HAEMATOL BASEL, V125, P8, DOI 10.1159/000318880
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Laroche M, 2012, EUR J HAEMATOL, V88, P388, DOI 10.1111/j.1600 0609.2012.01751.x
   Mhaskar R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003188.pub2
   Morgan GJ, 2012, BLOOD, V119, P5374, DOI 10.1182/blood 2011 11 392522
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Musto P, 2008, CANCER AM CANCER SOC, V113, P1588, DOI 10.1002/cncr.23783
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Patel CG, 2014, CLIN CANCER RES, V20, P3955, DOI 10.1158/1078 0432.CCR 14 0434
   Peng Fengping, 2015, Zhonghua Yi Xue Za Zhi, V95, P3436
   Raje N, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2015.96
   Raje N, LANCET ONCO IN PRESS
   Raje N, 2016, CLIN CANCER RES, V22, P1378, DOI 10.1158/1078 0432.CCR 15 1864
   Raje NS, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.8005
   Shojania KG, 2007, ANN INTERN MED, V147, P224, DOI 10.7326/0003 4819 147 4 200708210 00179
   Spencer Andrew, 2008, BMC Clin Pharmacol, V8, P2, DOI 10.1186/1472 6904 8 2
   Tatekoshi Ayumi, 2014, Rinsho Ketsueki, V55, P2271
   Terpos E, 2014, LEUKEMIA, V28, P928, DOI 10.1038/leu.2013.267
   Thumbigere Math V, 2012, AM J CLIN ONCOL CANC, V35, P386, DOI 10.1097/COC.0b013e3182155fcb
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Van den Wyngaert T, 2013, SUPPORT CARE CANCER, V21, P3483, DOI 10.1007/s00520 013 1934 0
   Varadarajan P, 2012, SUPPORT CARE CANCER, V20, P2969, DOI 10.1007/s00520 012 1429 4
   Vij R, 2009, AM J HEMATOL, V84, P650, DOI 10.1002/ajh.21509
   Weide R, 2010, J CANCER RES THER, V6, P31, DOI 10.4103/0973 1482.63570
NR 43
TC 80
Z9 82
U1 0
U2 14
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732 183X
EI 1527 7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 10
PY 2018
VL 36
IS 8
BP 812
EP +
DI 10.1200/JCO.2017.76.6402
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FY9FU
UT WOS:000427171900012
PM 29341831
DA 2025 08 17
ER

PT J
AU Tsourdi, E
   Rachner, TD
   Gruber, M
   Hamann, C
   Ziemssen, T
   Hofbauer, LC
AF Tsourdi, Elena
   Rachner, Tilman D.
   Gruber, Matthias
   Hamann, Christine
   Ziemssen, Tjalf
   Hofbauer, Lorenz C.
TI Seizures Associated with Zoledronic Acid for Osteoporosis
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID BONE; BISPHOSPHONATES; FRACTURES
AB Context: Bisphosphonates represent potent antiresorptive drugs that are established for therapy of patients with benign and malignant bone diseases. Zoledronic acid is an iv aminobisphosphonate that is administered annually against osteoporosis. Because of its potency and the parenteral route of administration, zoledronic acid is an alternative to oral bisphosphonates, in particular in elderly patients with multiple comorbidities. The most common side effects include an acute phase reaction and mild and transient hypocalcemia.
   Objective: Here, we report three cases of seizures that developed after the administration of zoledronic acid.
   Methods: We review case histories and laboratory results of three patients with seizures associated with the administration of zoledronic acid. We discuss their course and comorbidities in the context of the published literature.
   Results: All three patients were elderly persons with multiple comorbidities, including neurological diseases, that required parenteral bisphosphonates for severe osteoporosis with concurrent contraindications for oral bisphosphonates.
   Conclusion: We analyze potential mechanisms underlying these seizures in association with zoledronic acid exposure and discuss potential strategies to minimize this risk. (J Clin Endocrinol Metab 96: 1955 1959, 2011)
C1 [Tsourdi, Elena; Rachner, Tilman D.; Gruber, Matthias; Hamann, Christine; Hofbauer, Lorenz C.] Tech Univ Med Ctr, Div Endocrinol Diabet & Bone Dis, Dept Med 3, D 01307 Dresden, Germany.
   [Ziemssen, Tjalf] Tech Univ Med Ctr, Div Neurol, D 01307 Dresden, Germany.
   [Hofbauer, Lorenz C.] Ctr Regenerat Therapies, D 01307 Dresden, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden;
   Technische Universitat Dresden
RP Hofbauer, LC (通讯作者)，Tech Univ Med Ctr, Div Endocrinol Diabet & Bone Dis, Dept Med 3, Fetscherstr 74, D 01307 Dresden, Germany.
EM lorenz.hofbauer@uniklinikum dresden.de
RI Tsourdi, Elena/W 9970 2019; Hofbauer, Lorenz C./G 2490 2010; Ziemssen,
   Tjalf/J 2017 2019; Hofbauer, Lorenz/G 2490 2010
OI Hofbauer, Lorenz C./0000 0002 8691 8423; Ziemssen,
   Tjalf/0000 0001 8799 8202
FU Deutsche Forschungsgemeinschaft [HO 1875/8 1, HO 1875/12 1, HO
   1875/13 1]
FX The research program of L.C.H. is supported by Deutsche
   Forschungsgemeinschaft grants HO 1875/8 1, HO 1875/12 1, and HO
   1875/13 1. This manuscript contains parts of the medical thesis from E.
   T. at Dresden Technical University Medical School.
CR Ali II, 2004, EPILEPSY BEHAV, V5, P296, DOI 10.1016/j.yebeh.2004.02.005
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   Clowes JA, 2005, J BONE MINER RES, V20, P1497, DOI 10.1359/JBMR.050524
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Dubé CM, 2009, BRAIN DEV JPN, V31, P366, DOI 10.1016/j.braindev.2008.11.010
   HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528 1157.1991.tb04675.x
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Maclsaac RJ, 2002, J ROY SOC MED, V95, P615, DOI 10.1258/jrsm.95.12.615
   Navarro M, 2007, J PALLIAT MED, V10, P1226, DOI 10.1089/jpm.2007.0113
   Reid DM, 2009, LANCET, V373, P1253, DOI 10.1016/S0140 6736(09)60250 6
NR 11
TC 15
Z9 15
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0021 972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUL
PY 2011
VL 96
IS 7
BP 1955
EP 1959
DI 10.1210/jc.2011 0418
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 788OO
UT WOS:000292454500028
PM 21508139
OA Bronze
DA 2025 08 17
ER

PT J
AU Fan, M
   Yan, JX
   Tan, HP
   Ben, DD
   He, QL
   Huang, ZW
   Hu, XH
AF Fan, Ming
   Yan, Jingxuan
   Tan, Huaping
   Ben, Dandan
   He, Qiuling
   Huang, Zhongwei
   Hu, Xiaohong
TI Nanostructured Gel Scaffolds for Osteogenesis through Biological
   Assembly of Biopolymers via Specific Nucleobase Pairing
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE cell growth factor; gel scaffold; nanostructure; osteogenesis; tissue
   engineering
ID FIBROBLAST GROWTH FACTOR; CONTROLLED RELEASE; CELL AGGREGATION;
   DRUG DELIVERY; HYDROGEL; HEPARIN; DIFFERENTIATION; MATRICES; SYSTEMS;
   NANOPARTICLES
AB Biopolymer based gel scaffolds have great potential in the field of tissue regenerative medicine. In this work, a nanostructured biopolymer gel scaffold via specific pairing of functionalized nucleobases was developed for specifically targeted drug delivery and in vitro osteogenesis. The biopolymer gel system was established by the Watson Crick base pairing between thymine and adenine via the hydrogen bonding. As gel scaffold precursors, opposite charged polysaccharide derivatives, e. g. quaternized cellulose and heparin, could be additionally crosslinked by extra electrostatic interactions. The potential application of this gel scaffold in bone tissue engineering was confirmed by encapsulation behavior of osteoblasts. In combination with cell growth factor, e. g. bone morphogenetic protein, the nanostructured gel scaffold exhibited beneficial effects on osteoblast activity and differentiation, which suggested a promising future for local treatment of pathologies involving bone loss.
C1 [Fan, Ming; Yan, Jingxuan; Tan, Huaping; Ben, Dandan; He, Qiuling; Huang, Zhongwei] Nanjing Univ Sci & Technol, Sch Mat Sci & Engn, Nanjing 210094, Jiangsu, Peoples R China.
   [Hu, Xiaohong] Jinling Inst Technol, Sch Mat Engn, Nanjing 211169, Jiangsu, Peoples R China.
C3 Nanjing University of Science & Technology; Jinling Institute of
   Technology
RP Tan, HP (通讯作者)，Nanjing Univ Sci & Technol, Sch Mat Sci & Engn, Nanjing 210094, Jiangsu, Peoples R China.
EM hptan@njust.edu.cn; huxiaohong07@163.com
RI zhongwei, Huang/AAC 8450 2021; Ben, Dandan/AAR 5314 2020
FU National Natural Science Foundation of China [51103071, 51103066];
   Natural Science Foundation of Jiangsu Province [BK2011714]; Zijin
   Intelligent Program of NJUST
FX This study is financially supported by National Natural Science
   Foundation of China (51103071, 51103066), Natural Science Foundation of
   Jiangsu Province (BK2011714), and Zijin Intelligent Program of NJUST.
CR Anderson DG, 2004, SCIENCE, V305, P1923, DOI 10.1126/science.1099987
   Chinen N, 2003, J BIOMED MATER RES A, V67A, P61, DOI 10.1002/jbm.a.10061
   DeForest CA, 2009, NAT MATER, V8, P659, DOI [10.1038/NMAT2473, 10.1038/nmat2473]
   Estroff LA, 2004, CHEM REV, V104, P1201, DOI 10.1021/cr0302049
   Hudalla GA, 2011, ADV MATER, V23, P5415, DOI 10.1002/adma.201103046
   Kost J, 2001, ADV DRUG DELIVER REV, V46, P125, DOI 10.1016/S0169 409X(00)00136 8
   Kretlow JD, 2007, ADV DRUG DELIVER REV, V59, P263, DOI 10.1016/j.addr.2007.03.013
   Lee KY, 2003, ADV MATER, V15, P1828, DOI 10.1002/adma.200305406
   Lutolf MP, 2003, ADV MATER, V15, P888, DOI 10.1002/adma.200304621
   Mahler A, 2006, ADV MATER, V18, P1365, DOI 10.1002/adma.200501765
   Manna U, 2009, BIOMACROMOLECULES, V10, P2632, DOI 10.1021/bm9005535
   Morishita M, 2002, J CONTROL RELEASE, V81, P25, DOI 10.1016/S0168 3659(02)00019 6
   Schenning APHJ, 2005, CHEM COMMUN, P3245, DOI 10.1039/b501804h
   Sekine J, 2011, ADV MATER, V23, P4788, DOI 10.1002/adma.201102151
   Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783
   Smith AM, 2008, ADV MATER, V20, P37, DOI 10.1002/adma.200701221
   Song YB, 2012, J MATER CHEM, V22, P2512, DOI 10.1039/c1jm13735b
   Song YB, 2010, BIOCONJUGATE CHEM, V21, P1271, DOI 10.1021/bc100068f
   Tan HP, 2008, POLYM ADVAN TECHNOL, V19, P15, DOI 10.1002/pat.962
   Tan HP, 2013, CHEM COMMUN, V49, P11554, DOI 10.1039/c3cc47101b
   Tan HP, 2012, MACROMOL RAPID COMM, V33, P2015, DOI 10.1002/marc.201200360
   Tan HP, 2012, CHEM COMMUN, V48, P10289, DOI 10.1039/c2cc35449g
   Tan HP, 2012, MACROMOL BIOSCI, V12, P621, DOI 10.1002/mabi.201100502
   Tan HP, 2011, MACROMOL RAPID COMM, V32, P905, DOI 10.1002/marc.201100125
   Tan HP, 2011, J TISSUE ENG REGEN M, V5, P790, DOI 10.1002/term.378
   Tan HP, 2010, MACROMOL BIOSCI, V10, P156, DOI 10.1002/mabi.200900160
   Tan HP, 2009, BIOMATERIALS, V30, P6844, DOI 10.1016/j.biomaterials.2009.08.058
   Tan HP, 2009, BIOMATERIALS, V30, P2499, DOI 10.1016/j.biomaterials.2008.12.080
   Vermonden T, 2012, CHEM REV, V112, P2853, DOI 10.1021/cr200157d
   Wang DA, 2007, NAT MATER, V6, P385, DOI 10.1038/nmat1890
   Wang QG, 2007, ANGEW CHEM INT EDIT, V46, P4285, DOI 10.1002/anie.200700404
   Wissink MJB, 2001, BIOMATERIALS, V22, P2291, DOI 10.1016/S0142 9612(00)00418 X
   Xu X, 2011, ACTA BIOMATER, V7, P3050, DOI 10.1016/j.actbio.2011.04.018
   Zhang JX, 2010, ACS NANO, V4, P1049, DOI 10.1021/nn901213a
   Zhao YN, 2009, J AM CHEM SOC, V131, P8398, DOI 10.1021/ja901831u
NR 35
TC 12
Z9 14
U1 0
U2 62
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D 69469 WEINHEIM, GERMANY
SN 1616 5187
EI 1616 5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD NOV
PY 2014
VL 14
IS 11
BP 1521
EP 1527
DI 10.1002/mabi.201400320
PG 7
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA AT2FT
UT WOS:000344749200002
PM 25181443
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhu, B
   Xue, F
   Zhang, CQ
   Li, GY
AF Zhu, Bin
   Xue, Feng
   Zhang, Changqing
   Li, Guangyi
TI Ginkgolide B promotes osteoblast differentiation via activation of
   canonical Wnt signalling and alleviates osteoporosis through a bone
   anabolic way
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone anabolic way; Ginkgolide B; osteoblast; osteoporosis;
   Wnt/ss catenin signalling
ID BETA CATENIN; LINING CELLS; PROLIFERATION; PREVENTION; MANAGEMENT;
   FRACTURES; DISEASE; UPDATE
AB Osteoporosis has become a worldwide problem as the population ages. Although many advances have been made in the treatment of osteoporosis in the past few years, the outcome are sometimes disturbing because of the adverse effects of these treatments. Further studies are still needed to identify novel alternate agents to improve the therapeutic effect. Ginkgolide B (GB), a derivative of Ginkgo biloba leaves, has numerous pharmacological effects, including anticancer and anti inflammation activities. However, the effect of GB on the regulation of osteoblast activity and bone formation effect has not yet been investigated. In this study, we showed the in vitro and in vivo effects of GB on osteoblast differentiation and bone formation. We found that GB promotes osteoblast differentiation of Bone Mesenchymal Stem Cells (BMSCs) and MC3T3 E1 cells in vitro in a Wnt/ss catenin dependent manner. In an in vivo study, we constructed a cranial defect model in rats and treated with GB. Histomorphometric and histological analyses confirmed that the usage of GB significantly promotes bone formation. Further study on ovariectomy (OVX) rats demonstrated that GB is capable of alleviating ovariectomy induced bone loss by enhancing osteoblast activity. Our findings indicate that GB is a potential therapeutic agent of osteoporosis through an anabolic way in bone.
C1 [Zhu, Bin; Xue, Feng; Zhang, Changqing; Li, Guangyi] Shanghai Jiao Tong Univ, Dept Orthopaed, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhang, CQ; Li, GY (通讯作者)，Shanghai Jiao Tong Univ, Dept Orthopaed, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM zhangcq@sjtu.edu.cn; guangyi.li@shsmu.edu.cn
OI zhang, changqing/0000 0002 7408 4126
FU National Natural Science Foundation of China [81702181]; Shanghai
   Pujiang Talent Program [16PJ1408100]
FX National Natural Science Foundation of China, Grant/Award Number:
   81702181; Shanghai Pujiang Talent Program, Grant/Award Number:
   16PJ1408100
CR Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   Altundag K, 2017, J BUON, V22, P1603
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Brauer CA, 2009, JAMA J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cauley JA, 2017, CURR OPIN RHEUMATOL, V29, P150, DOI 10.1097/BOR.0000000000000365
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137
   Chen K, 2017, COMPUT INTEL NEUROSC, V2017, DOI 10.1155/2017/4629534
   Dawson Hughes B, 2010, OSTEOPOROSIS INT, V21, P41, DOI 10.1007/s00198 009 1034 7
   Debruyne DN, 2018, ONCOGENE, V37, P241, DOI 10.1038/onc.2017.323
   Gambacciani M, 2014, PANMINERVA MED, V56, P115
   Gao CX, 2014, J BIOL CHEM, V289, P7099, DOI 10.1074/jbc.M113.532606
   Gennari L, 2016, EXPERT OPIN PHARMACO, V17, P1141, DOI 10.1080/14656566.2016.1176147
   Ghosh Swarupa, 2014, Nanomedicine, V9, P441, DOI [10.2217/nnm.13.56, 10.2217/nnm.14.4]
   Grabowski P, 2015, ENDOCR DEV, V28, P33, DOI 10.1159/000380991
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Higuchi T, 2018, OR SURG OR MED OR PA, V125, P547, DOI 10.1016/j.oooo.2018.02.010
   Hindi SM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01866 w
   Hu HJ, 2018, ADV CLIN EXP MED, V27, P913, DOI 10.17219/acem/70414
   Hua J, 2017, BIOMED PHARMACOTHER, V96, P792, DOI 10.1016/j.biopha.2017.10.050
   Iyer S, 2013, J CLIN INVEST, V123, P3409, DOI 10.1172/JCI68049
   Jiang W, 2014, INTEGR CANCER THER, V13, pNP10, DOI 10.1177/1534735411433833
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kushwaha P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.350
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Li MY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32960 8
   Lymperi S, 2011, BLOOD, V117, P1540, DOI 10.1182/blood 2010 05 282855
   Matic I, 2016, STEM CELLS, V34, P2930, DOI 10.1002/stem.2474
   Miller S.C., 1989, SCANNING MICROSCOPY, V3, P60
   MILLER SC, 1989, SCANNING MICROSCOPY, V3, P953
   Montagnani A, 2014, WORLD J ORTHOP, V5, P247, DOI 10.5312/wjo.v5.i3.247
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Rudnicki MA, 2015, BONE, V80, P60, DOI 10.1016/j.bone.2015.02.009
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sun L, 2015, INT J CLIN EXP PATHO, V8, P432
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Titorencu I, 2014, CELL TISSUE RES, V355, P23, DOI 10.1007/s00441 013 1750 3
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   Wu SY, 2013, GENOME MED, V5, DOI 10.1186/gm448
   Yao B, 2017, ONCOTARGET, V8, P13846, DOI 10.18632/oncotarget.14647
   Yarom N, 2018, OR SURG OR MED OR PA, V125, P27, DOI 10.1016/j.oooo.2017.09.014
   Zhang Y, 2018, Front. Microbiol, V9, P1
   Zheng PD, 2018, NEURAL REGEN RES, V13, P1204, DOI 10.4103/1673 5374.232476
   Zhou XL, 2017, CANCER RES, V77, P6589, DOI 10.1158/0008 5472.CAN 17 0219
NR 51
TC 32
Z9 33
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD AUG
PY 2019
VL 23
IS 8
BP 5782
EP 5793
DI 10.1111/jcmm.14503
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA IR6EN
UT WOS:000481532600083
PM 31225702
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU González Suárez, E
AF Gonzalez Suarez, Eva
TI RANKL inhibition: a promising novel strategy for breast cancer treatment
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE RANK; RANKL; Osteoprotegerin; Progesterone; Her2/neu; Mammary gland
   development
ID MAMMARY GLAND DEVELOPMENT; KAPPA B LIGAND; STEM CELL; RECEPTOR
   ACTIVATOR; PROSTATE CANCER; BONE METASTASES; OSTEOCLAST DIFFERENTIATION;
   EPITHELIAL PROLIFERATION; FACTOR OSTEOPROTEGERIN; TRANSGENIC MICE
AB The cytokine RANKL and its receptor RANK, key proteins in bone remodelling and bone metastasis, are essential for mammary gland development in mice. RANK absence or overexpression results in a lactation defect and a non functional mammary gland. RANKL signalling mediates progesterone induced proliferation and expansion of the stem cell compartment in the mouse mammary gland. RANK overexpressing mammary epithelial acini show hallmarks of transformation in a RANKL dependent manner. Complementary gain  and loss of function approaches (RANK transgenic and knock out mouse models and pharmacological RANKL inhibition) define a direct contribution of this pathway to progestin driven mammary cancer. Moreover, decreased RANKL signalling attenuates preneoplasic lesions and lung metastasis in the spontaneous model of mammary tumorigenesis MMTV neu, suggesting that RANK pathway promotes mammary tumorigenesis and metastasis in a wider tumour spectrum and beyond its established role in bone metastasis. In this review, we summarise the role of the RANKL pathway in mammary gland development, breast cancer and metastasis, and discuss the potential application of RANKL inhibition for breast cancer treatment.
C1 Hosp Llobregat, Bellvitge Inst Biomed Res IDIBELL, Canc Epigenet & Biol Program PEBC, Transformat & Metastasis Grp, ES 08908 Barcelona, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of
   Barcelona
RP González Suárez, E (通讯作者)，Hosp Llobregat, Bellvitge Inst Biomed Res IDIBELL, Canc Epigenet & Biol Program PEBC, Transformat & Metastasis Grp, Avda Gran Via LHosp,199 203, ES 08908 Barcelona, Spain.
EM egsuarez@idibell.cat
RI Gonzalez Suarez, Eva/L 6298 2014
OI Gonzalez Suarez, Eva/0000 0003 0858 8171
FU Spanish Ministry [SAF2008 01975]; AECC Catalunya; Concern Foundation
FX The laboratory of Eva Gonzalez Suarez is supported by grants from the
   Spanish Ministry SAF2008 01975, AECC Catalunya and the Concern
   Foundation. I thank Purificacion Munoz Moruno, Cristina Munoz Pinedo,
   Ander Urruticoechea and Irene Ferrer for critical reading of the
   manuscript.
CR Al Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Asselin Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Beleut M, 2010, P NATL ACAD SCI USA, V107, P2989, DOI 10.1073/pnas.0915148107
   Bhatia P, 2005, CLIN CANCER RES, V11, P162
   Body JJ, 2010, J BONE MINER RES, V25, P440, DOI 10.1359/jbmr.090810
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Canon J, 2010, BONE, V46, P1613, DOI 10.1016/j.bone.2010.03.001
   Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092 8674(01)00599 2
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen G, 2006, CANCER AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978
   Chlebowski RT, 2003, JAMA J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243
   Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911 005 2542 5
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Fernandez Valdivia R, 2008, ENDOCRINOLOGY, V149, P6236, DOI 10.1210/en.2008 0768
   Fernandez Valdivia R, 2009, DEV BIOL, V328, P127, DOI 10.1016/j.ydbio.2009.01.019
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Gonzalez Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298 06
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Hanada R, 2010, BIOL CHEM, V391, P1365, DOI 10.1515/BC.2010.149
   Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559
   Holland PM, 2010, CANCER BIOL THER, V9, P539, DOI 10.4161/cbt.9.7.11266
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115
   Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471 2164 9 591
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Leibbrandt A, 2010, ADV EXP MED BIOL, V658, P77, DOI 10.1007/978 1 4419 1050 9_9
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Lin SX, 2010, NAT REV ENDOCRINOL, V6, P485, DOI 10.1038/nrendo.2010.92
   Lindeman GJ, 2010, ASIA PAC J CLIN ONCO, V6, P89, DOI 10.1111/j.1743 7563.2010.01279.x
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656
   Mikami S, 2009, J PATHOL, V218, P530, DOI 10.1002/path.2567
   Miller RE, 2008, MOL CANCER THER, V7, P2160, DOI 10.1158/1535 7163.MCT 08 0046
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Mukherjee A, 2010, FASEB J, V24, P4408, DOI 10.1096/fj.10 157982
   Mulac Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Rakha EA, 2009, CLIN CANCER RES, V15, P2302, DOI 10.1158/1078 0432.CCR 08 2132
   Santini D, 2011, J CELL PHYSIOL, V226, P780, DOI 10.1002/jcp.22402
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065
   Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371
   Srivastava S, 2003, J BIOL CHEM, V278, P46171, DOI 10.1074/jbc.M308545200
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264 6021:3460561
   Virk MS, 2011, BONE, V48, P578, DOI 10.1016/j.bone.2010.11.003
   Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
NR 60
TC 27
Z9 28
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1699 048X
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD APR
PY 2011
VL 13
IS 4
BP 222
EP 228
DI 10.1007/s12094 011 0646 5
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 753SP
UT WOS:000289800300004
PM 21493182
DA 2025 08 17
ER

PT J
AU Oh, Y
   Ahn, CB
   Cho, WH
   Yoon, NY
   Je, JY
AF Oh, Yunok
   Ahn, Chang Bum
   Cho, Won Ho
   Yoon, Na Young
   Je, Jae Young
TI Anti Osteoporotic Effects of Antioxidant Peptides PIISVYWK and FSVVPSPK
   fromMytilus edulison Ovariectomized Mice
SO ANTIOXIDANTS
LA English
DT Article
DE osteoporosis; osteoblasts; alkaline phosphatase; bone mineral density;
   bioactive peptide
ID OSTEOBLAST DIFFERENTIATION; PROTEIN; PURIFICATION; CELLS; HYDROLYSATE;
   ACTIVATION
AB Numerous amounts of evidence suggest that bioactive peptides with diverse physiological activities can be nutraceuticals or potential drug candidates. In this study, blue mussel derived antioxidant peptides PIISVYWK and FSVVPSPK were subjected to evaluate their osteogenic effect in mouse bone marrow mesenchymal stem cells (mBMMSCs) followed by anin vivoanti osteoporotic effect. Treatment of PIISVYWK and FSVVPSPK on mBMMSCs stimulated alkaline phosphatase activity and calcification. Western blot results revealed that PIISVYWK and FSVVPSPK increased the expression of bone morphogenetic protein 2/4 (BMP 2/4) followed by upregulating p Smad1/5, type I collagen, and transcription factors including Runx2 and osterix in mBMMSCs. Two peptides also activated the phosphorylation of MAPKs (p p38, p ERK, and p JNK). Treatment of MAPK inhibitors significantly inhibited the BMP signaling pathway, indicating that PIISVYWK and FSVVPSPK stimulated osteoblast differentiation of mBMMSCs through the MAPK dependent BMP signaling pathway. The anti osteoporotic effect of PIISVYWK and FSVVPSPK in ovariectomized (OVX) mice was investigated. Treatment of PIISVYWK and FSVVPSPK for ten weeks showed a notable anti osteoporotic effect in OVX mice via increasing bone mineral density and other bone parameters compared to OVX mice without peptides. Serum analysis also showed that treatment of PIISVYWK and FSVVPSPK completely reduced osteocalcin and ALP (alkAline phosphatase) activity. Taken together, these results suggest that PIISVYWK and FSVVPSPK could be health promoting functional food ingredients against osteoporosis.
C1 [Oh, Yunok] Pukyong Natl Univ, Inst Marine Life Sci, Busan 48613, South Korea.
   [Ahn, Chang Bum] Chonnam Natl Univ, Div Food & Nutr, Gwangju 61186, South Korea.
   [Cho, Won Ho] Pusan Natl Univ, Pusan Natl Univ Hosp, Med Res Inst, Dept Neurosurg,Sch Med, Busan 49241, South Korea.
   [Yoon, Na Young] Natl Fisheries Res & Dev Inst, Food & Safety Div, Busan 46083, South Korea.
   [Je, Jae Young] Pukyong Natl Univ, Dept Marine Bio Convergence Sci, Busan 48547, South Korea.
C3 Pukyong National University; Chonnam National University; Pusan National
   University; Pusan National University Hospital; Pukyong National
   University
RP Je, JY (通讯作者)，Pukyong Natl Univ, Dept Marine Bio Convergence Sci, Busan 48547, South Korea.
EM si565@daum.net; a321@jnu.ac.kr; mdcwh@naver.com; dbssud@korea.kr;
   jjy1915@pknu.ac.kr
OI Je, Jae Young/0000 0002 4800 0566
FU National Institute of Fisheries Science [NIFS/R2020053]
FX National Institute of Fisheries Science (NIFS/R2020053).
CR Canpolat S, 2010, J PHYSIOL BIOCHEM, V66, P23, DOI 10.1007/s13105 010 0008 8
   Cheung RCF, 2015, MAR DRUGS, V13, P4006, DOI 10.3390/md13074006
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Guillerminet F, 2012, OSTEOPOROSIS INT, V23, P1909, DOI 10.1007/s00198 011 1788 6
   Han JF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181175
   Hata K, 2007, J BIOMED MATER RES A, V81A, P446, DOI 10.1002/jbm.a.31086
   Hyung JH, 2018, FOOD CHEM, V242, P156, DOI 10.1016/j.foodchem.2017.09.043
   Hyung JH, 2016, RSC ADV, V6, P29365, DOI 10.1039/c6ra00898d
   Jin JE, 2018, PROCESS BIOCHEM, V72, P170, DOI 10.1016/j.procbio.2018.06.001
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kim HK, 2012, BIOMATERIALS, V33, P7057, DOI 10.1016/j.biomaterials.2012.06.036
   Kim SS, 2018, FOOD BIOSCI, V25, P128, DOI 10.1016/j.fbio.2018.08.010
   Lee JS, 2018, STEM CELL RES, V26, P28, DOI 10.1016/j.scr.2017.11.016
   Min SK, 2018, CELL DEATH DIFFER, V25, P268, DOI 10.1038/cdd.2017.153
   Mundy G.R., 1999, BONE REMODELLING ITS
   O'Grady S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 36496 9
   Oh Y, 2019, NUTR CANCER, V71, P118, DOI 10.1080/01635581.2018.1540717
   Oh Y, 2019, MAR DRUGS, V17, DOI 10.3390/md17020135
   Oh Y, 2018, BIOMED PHARMACOTHER, V108, P103, DOI 10.1016/j.biopha.2018.08.143
   Park SY, 2016, J FUNCT FOODS, V20, P88, DOI 10.1016/j.jff.2015.10.023
   Pengjam Y, 2016, BIOMOL THER, V24, P123, DOI 10.4062/biomolther.2015.106
   Reddi S, 2016, J NUTR BIOCHEM, V38, P134, DOI 10.1016/j.jnutbio.2016.08.003
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sable R, 2017, MAR DRUGS, V15, DOI 10.3390/md15040124
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Udenigwe CC, 2012, J FOOD SCI, V77, pR11, DOI 10.1111/j.1750 3841.2011.02455.x
   Wanachewin O, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 71
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Yang J., 2014, Food Science and Human Wellness, V3, P127, DOI DOI 10.1016/J.FSHW.2014.12.002
   Yoon KH, 2012, J KOREAN NEUROSURG S, V51, P323, DOI 10.3340/jkns.2012.51.6.323
NR 31
TC 23
Z9 26
U1 4
U2 53
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3921
J9 ANTIOXIDANTS BASEL
JI Antioxidants
PD SEP
PY 2020
VL 9
IS 9
AR 866
DI 10.3390/antiox9090866
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA OE7TN
UT WOS:000580728600001
PM 32942523
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kang, JH
   Lim, H
   Lee, DS
   Yim, M
AF Kang, Ju Hee
   Lim, Hyungsik
   Lee, Dong Seok
   Yim, Mijung
TI Montelukast inhibits RANKL induced osteoclast formation and bone loss
   via CysLTR1 and P2Y12
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE montelukast; cysteinyl leukotriene receptor 1 antagonist; P2Y12;
   osteoclast; nuclear factor B ligand; nuclear factor of activated T cells
   1; bone loss
ID CYSTEINYL LEUKOTRIENES; ALLERGIC RHINITIS; DIFFERENTIATION; RECEPTOR;
   DISEASE; ASTHMA; ACTIVATION; RESORPTION; FAMILIES; EFFICACY
AB Osteoclasts (OCs) are resorptive cells responsible for bone erosion in diseases, including osteoporosis, periodontitis and rheumatoid arthritis. Montelukast is a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist clinically used for the treatment of asthma. In the present study, the role of CysLTR1 on OC formation and bone loss was investigated using montelukast. Montelukast inhibited receptor activator of nuclear factor B ligand (RANKL) induced OC formation in cultures of mouse bone marrow macrophages. Additionally, montelukast suppressed actin ring formation and bone resorption activity of differentiated OCs. The inhibitory effect of montelukast was associated with impaired activation of extracellular signal regulated kinase, AKT serine/threonine kinase, and/or phospholipase C2 signaling pathways downstream of RANK, followed by decreased expression of nuclear factor of activated T cells c1. Notably, OC formation was efficiently restored by addition of adenosine diphosphate, a P2Y12 agonist, as well as by addition of CysLT. Furthermore, similar to montelukast, P2Y12 blockade by a pharmacological inhibitor or siRNAs suppressed OC differentiation. These data indicate the involvement of the P2Y12 receptor in the inhibitory effect of montelukast on osteoclastogenesis. In vivo, montelukast significantly inhibited inflammation induced osteoclastogenesis in the calvarial model. Montelukast also served a protective role in a murine ovariectomy (OVX)  and unloading induced bone loss model. Altogether, these results confirmed that the CysLTR1 antagonist exerted an inhibitory effect on OC formation in vitro and in vivo. It may be useful for the treatment of bone diseases associated with excessive bone resorption.
C1 [Kang, Ju Hee; Yim, Mijung] Sookmyung Womens Univ, Coll Pharm, 52 Hyochangwongil, Seoul 140742, South Korea.
   [Kang, Ju Hee; Yim, Mijung] Sookmyung Womens Univ, Res Inst Pharmaceut Sci, 52 Hyochangwongil, Seoul 140742, South Korea.
   [Lim, Hyungsik] CUNY Hunter Coll, Dept Phys, New York, NY 10065 USA.
   [Lee, Dong Seok] Kyungpook Natl Univ, Plus KNU Creat BioRes Grp BK21, Dept Nat Sci, Sch Life Sci,Coll Nat Sci, Daegu 41566, South Korea.
C3 Sookmyung Women's University; Sookmyung Women's University; City
   University of New York (CUNY) System; Hunter College (CUNY); Kyungpook
   National University (KNU)
RP Yim, M (通讯作者)，Sookmyung Womens Univ, Coll Pharm, 52 Hyochangwongil, Seoul 140742, South Korea.; Yim, M (通讯作者)，Sookmyung Womens Univ, Res Inst Pharmaceut Sci, 52 Hyochangwongil, Seoul 140742, South Korea.
EM myim@sm.ac.kr
RI ; Kim, Se Ho/IUP 3256 2023
OI Lee, Dong Seok/0000 0001 6348 8937; 
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [HI14C24470000]; National Research Foundation of Korea
   (NRF); Ministry of Science, ICT and Future Planning (MSIP)
   [NRF 2014M1A3A3A02034917, NRF 2016R1A2B4011636]
FX The present study was supported by grants from the Korean Health
   Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
   (grant no. HI14C24470000) and from the National Research Foundation of
   Korea (NRF), funded by Ministry of Science, ICT and Future Planning
   (MSIP; grant nos. NRF 2014M1A3A3A02034917 and NRF 2016R1A2B4011636).
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Di Capite J, 2009, FASEB J, V23, P894, DOI 10.1096/fj.08 118935
   Faccio R, 2010, ANN NY ACAD SCI, V1192, P124, DOI 10.1111/j.1749 6632.2009.05217.x
   Ferron M, 2011, CELL METAB, V14, P466, DOI 10.1016/j.cmet.2011.08.013
   Finsterer J, 2013, CURR TOP MED CHEM, V13, P2386, DOI 10.2174/15680266113136660166
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   Ha H, 2006, J IMMUNOL, V176, P111, DOI 10.4049/jimmunol.176.1.111
   Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003
   Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nayak A, 2004, EXPERT OPIN PHARMACO, V5, P679, DOI 10.1517/eoph.5.3.679.27358
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nonaka Y, 2005, BIOCHEM BIOPH RES CO, V337, P281, DOI 10.1016/j.bbrc.2005.09.052
   Paggiaro P, 2011, THER ADV CHRONIC DIS, V2, P47, DOI 10.1177/2040622310383343
   Riccioni G, 2007, CURR MED CHEM, V14, P1966
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Theron AJ, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/608930
   Tintinger GR, 2010, THESCIENTIFICWORLDJO, V10, P2403, DOI 10.1100/tsw.2010.229
   Virchow JC, 2006, RESP MED, V100, P1952, DOI 10.1016/j.rmed.2006.02.026
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959 437X(00)00228 8
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 31
TC 26
Z9 27
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD AUG
PY 2018
VL 18
IS 2
BP 2387
EP 2398
DI 10.3892/mmr.2018.9179
PG 12
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GP1NU
UT WOS:000440583800140
PM 29916540
OA Bronze
DA 2025 08 17
ER

PT J
AU Mbalaviele, G
   Anderson, G
   Jones, A
   De Ciechi, P
   Settle, S
   Mnich, S
   Thiede, M
   Abu Amer, Y
   Portanova, J
   Monahan, J
AF Mbalaviele, Gabriel
   Anderson, Gary
   Jones, Amy
   De Ciechi, Pamela
   Settle, Steve
   Mnich, Steve
   Thiede, Mark
   Abu Amer, Yousef
   Portanova, Joseph
   Monahan, Joseph
TI Inhibition of p38 mitogen activated protein kinase prevents inflammatory
   bone destruction
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID NF KAPPA B; MICROPHTHALMIA TRANSCRIPTION FACTOR; RECEPTOR ACTIVATOR;
   JOINT DESTRUCTION; KEY REGULATOR; OSTEOCLASTOGENESIS; EXPRESSION;
   ARTHRITIS; PATHWAYS; TARGET
AB Mitogen  activated protein kinase (MAPK) pathways are implicated in joint destruction in rheumatoid arthritis (RA) by modulating the production and functions of inflammatory cytokines. Although p38 MAPK (p38) participates in signaling cascades leading to osteolysis in arthritis, the mechanisms of its action in this process remain incompletely understood. Here, we found that the osteoclast (Ocl) precursors expressed p38 alpha, but not p38 beta, p38 delta, and p38 gamma isoforms. Treatment of these cells with receptor activator of nuclear factor (NF) kappa B ligand (RANKL) resulted in p38 activation. Importantly, Ocl development induced lby RANKL or RANKL and tumor necrosis factor (TNF) alpha was blocked with the novel p38 inhibitor 4 (3 (4 chlorophenyl)5 (1 methylpiperidin 4 yl) 1H pyrazol 4 yl)pyrimidine (SC 409). To validate in vitro data, p38 role was further investigated in streptococcal cell wall (SCW) induced arthritis in rats. We found that SCW induced joint swelling and bone destruction were attenuated by SC 409. Mechanistically, the data show that SCW stimulated DNA binding activity of the transcription factor myocyte enhancing factor 2 C, which is downstream of p38, was inhibited by SC 409. In addition, SC  409 inhibited SCW stimulated expression of numerous factors, including TNF alpha, interleukin 1 beta, and RANKL. Although c Jun NH2 terminal kinase and NF kappa B pathways were activated in vitro by RANKL and in vivo by SCW, SC 409 had no significant effect on these pathways. In conclusion, our data show that p38 modulates the production and signaling of cytokines, thus providing a mechanism of the bone sparing effect of SC 409 in rat arthritis. These data present SC 409 as a novel potent p38 inhibitor and suggest that p38 based therapies may be beneficial in preventing bone loss associated with RA.
C1 Pfizer Inc, Dept Inflammat, St Louis, MO USA.
   Washington Univ, Sch Med, Dept Orthoped, St Louis, MO USA.
   Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO USA.
C3 Pfizer; Pfizer USA; Washington University (WUSTL); Washington University
   (WUSTL)
RP Mbalaviele, G (通讯作者)，Pfizer Inc, 700 Chesterfield Pkway W,Mail Stop AA5G, Chesterfield, MO 63017 USA.
EM gabriel.mbalaviele@pfizer.com
OI Reeves, Amy/0000 0002 1430 2224
CR Badger AM, 2000, ARTHRITIS RHEUM, V43, P175, DOI 10.1002/1529 0131(200001)43:1<175::AID ANR22>3.0.CO;2 S
   Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298
   BRAHN E, 1991, CLIN ORTHOP RELAT R, P42
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   Darnay BG, 1997, FEBS LETT, V406, P101, DOI 10.1016/S0014 5793(97)00251 2
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014
   Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Han ZN, 1998, AUTOIMMUNITY, V28, P197, DOI 10.3109/08916939808995367
   Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466
   HOM JT, 1991, AGENTS ACTIONS, V33, P300, DOI 10.1007/BF01986577
   Komine M, 2001, BONE, V28, P474, DOI 10.1016/S8756 3282(01)00420 3
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082
   Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P295
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   MBALAVIELE G, 1995, J CLIN INVEST, V95, P2757, DOI 10.1172/JCI117979
   Merrell M, 2003, BREAST CANCER RES TR, V81, P231, DOI 10.1023/A:1026126430905
   Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   MUNDY GR, 1995, OSTEOPOROSIS, P302
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Wada Y, 2006, INT IMMUNOPHARMACOL, V6, P144, DOI 10.1016/j.intimp.2005.07.009
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Wolfe F, 2001, Curr Rheumatol Rep, V3, P46, DOI 10.1007/s11926 001 0050 1
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
NR 40
TC 70
Z9 81
U1 0
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUN
PY 2006
VL 317
IS 3
BP 1044
EP 1053
DI 10.1124/jpet.105.100362
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 044AE
UT WOS:000237643600015
PM 16501068
DA 2025 08 17
ER

PT J
AU Hong, S
   Lazerka, N
   Jeon, BJ
   Kim, JD
   Erdenebileg, S
   Nho, CW
   Yoo, G
AF Hong, Soyeon
   Lazerka, Nadzeya
   Jeon, Byeong Jun
   Kim, Jeong Do
   Erdenebileg, Saruul
   Nho, Chu Won
   Yoo, Gyhye
TI Osteogenic Effects of the Diospyros lotus L. Leaf Extract on
   MC3T3 E1 Pre Osteoblasts and Ovariectomized Mice via BMP2/4 and TGF β
   Pathways
SO NUTRIENTS
LA English
DT Article
DE osteoporosis; Diospyros lotus leaf extract (DLE); osteoblast
   differentiation; bone morphogenic protein 2/4 (BMP2/4); transforming
   growth factor beta (TGF beta)
ID MYRICETIN; OSTEOPOROSIS; PREVENTION
AB Osteoporosis, a disease defined by the primary bone strength due to a low bone mineral density, is a bone disorder associated with increased mortality in the older adult population. Osteoporosis is mainly treated via hormone replacement therapy, bisphosphates, and anti bone resorption agents. However, these agents exert severe side effects, necessitating the development of novel therapeutic agents. Many studies are focusing on osteogenic agents as they increase the bone density, which is essential for osteoporosis treatment. Here, we aimed to investigate the effects of Diospyros lotus L. leaf extract (DLE) and its components on osteoporosis in MC3T3 E1 pre osteoblasts and ovariectomized mice and to elucidate the underlying related pathways. DLE enhanced the differentiation of MC3T3 E1 pre osteoblasts, with a 1.5 fold elevation in ALP activity, and increased the levels of osteogenic molecules, RUNX family transcription factor 2, and osterix. This alteration resulted from the activation of bone morphogenic protein 2/4 (BMP2/4) and transformation of growth factor beta (TGF beta) pathways. In ovariectomized mice, DLE suppressed the decrease in bone mineral density by 50% and improved the expression of other bone markers, which was confirmed by the 3 similar to 40 fold increase in osteogenic proteins and mRNA expression levels in bone marrow cells. The three major compounds identified in DLE exhibited osteogenic and estrogenic activities with their aglycones, as previously reported. Among the major compounds, myricitrin alone was not as strong as whole DLE with all its constituents. The osteogenic activity of DLE was partially suppressed by the inhibitor of estrogen signaling, indicating that the estrogenic activity of DLE participated in its osteogenic activity. Overall, DLE suppresses osteoporosis by inducing osteoblast differentiation.
C1 [Hong, Soyeon; Lazerka, Nadzeya; Jeon, Byeong Jun; Kim, Jeong Do; Erdenebileg, Saruul; Nho, Chu Won; Yoo, Gyhye] Korea Inst Sci & Technol KIST, Gangneung Inst Nat Prod, Smart Farm Res Ctr, Kangnung 25451, South Korea.
   [Lazerka, Nadzeya; Erdenebileg, Saruul; Nho, Chu Won; Yoo, Gyhye] Univ Sci & Technol UST, KIST Sch, Div Nat Prod Appl Sci, Seoul 02792, South Korea.
C3 Korea Institute of Science & Technology (KIST); Korea Institute of
   Science & Technology (KIST); University of Science & Technology (UST)
RP Yoo, G (通讯作者)，Korea Inst Sci & Technol KIST, Gangneung Inst Nat Prod, Smart Farm Res Ctr, Kangnung 25451, South Korea.; Yoo, G (通讯作者)，Univ Sci & Technol UST, KIST Sch, Div Nat Prod Appl Sci, Seoul 02792, South Korea.
EM hongsso@kist.re.kr; nadzeya.lazerka@kist.re.kr;
   jeonbyeongjun@kist.re.kr; kimjeongdo@kist.re.kr; 619008@kist.re.kr;
   cwnho@kist.re.kr; loshell@kist.re.kr
OI Hong, Soyeon/0009 0007 8309 6042
FU Korea Institute of Science and Technology
FX No Statement Available
CR Barlas N, 2014, TOXICOL LETT, V226, P35, DOI 10.1016/j.toxlet.2014.01.030
   Campbell Graeme M, 2014, Bonekey Rep, V3, P564, DOI 10.1038/bonekey.2014.59
   Che DN, 2019, FOOD SCI BIOTECHNOL, V28, P1207, DOI 10.1007/s10068 018 00551 y
   Cho BO, 2017, BIOMED PHARMACOTHER, V95, P264, DOI 10.1016/j.biopha.2017.07.159
   Cho BO, 2016, BIOSCI BIOTECH BIOCH, V80, P1520, DOI 10.1080/09168451.2016.1171697
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Fan SL, 2018, LIFE SCI, V207, P205, DOI 10.1016/j.lfs.2018.06.006
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hong S, 2022, J NUTR BIOCHEM, V101, DOI 10.1016/j.jnutbio.2021.108900
   Hong S, 2021, PHYTOMEDICINE, V84, DOI 10.1016/j.phymed.2021.153517
   Jeon JH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103120
   Kim YH, 2017, J AGR FOOD CHEM, V65, P836, DOI 10.1021/acs.jafc.6b05160
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Moreira AC, 2014, J STEROID BIOCHEM, V143, P61, DOI 10.1016/j.jsbmb.2014.01.016
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rauf A, 2016, NAT PROD RES, V30, P1205, DOI 10.1080/14786419.2015.1046381
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Uddin G, 2014, PHYTOMEDICINE, V21, P954, DOI 10.1016/j.phymed.2014.03.001
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Wong SK, 2019, DRUG DES DEV THER, V13, P3497, DOI 10.2147/DDDT.S227738
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xi YH, 2022, J PHARM SCI US, V111, P2341, DOI 10.1016/j.xphs.2022.03.014
   Xu X, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.46
   Yin H, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13685
NR 33
TC 0
Z9 0
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD APR
PY 2024
VL 16
IS 8
AR 1247
DI 10.3390/nu16081247
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA OZ4A7
UT WOS:001211074200001
PM 38674937
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Guo, CJ
   Yang, K
   Yan, YF
   Yan, DM
   Cheng, YF
   Yan, XM
   Qian, ND
   Zhou, Q
   Chen, B
   Jiang, M
   Zhou, HB
   Li, CW
   Wang, F
   Qi, J
   Xu, XY
   Deng, LF
AF Guo, Changjun
   Yang, Kai
   Yan, Yufei
   Yan, Dongming
   Cheng, Yifan
   Yan, Xueming
   Qian, Niandong
   Zhou, Qi
   Chen, Bo
   Jiang, Min
   Zhou, Hanbing
   Li, Changwei
   Wang, Fei
   Qi, Jin
   Xu, Xiangyang
   Deng, Lianfu
TI SF deferoxamine, a bone seeking angiogenic drug, prevents bone loss in
   estrogen deficient mice
SO BONE
LA English
DT Article
DE Deferoxamine; Osteoporosis; Bone seeking; Angiogenesis; HIF
ID HYPOXIA INDUCIBLE FACTOR; MARROW PERFUSION; MINERAL DENSITY; PATHWAY;
   OSTEOGENESIS; ACTIVATION; EXPRESSION; INHIBITORS; TOXICITY; THERAPY
AB Deferoxamine (DFO) possesses a good chelating capability and is therefore used for the clinical treatment of ion deposition diseases. Increasing evidence shows that DFO can inhibit the activity of proline hydroxylase (PHD) by chelating iron, resulting in hypoxia induced factor (HIF) signaling activation and angiogenesis promotion. However, clinical evidence indicates that a high concentration of DFO could be biotoxic due to its enrichment in related organs. Thus, we established a new compound by conjugating DFO with the bone seeking agent iminodiacetic acid (IDA); the new agent is called SF DFO, and we verified its promotion of HIF activation and tube formation in vivo. After confirming the bone seeking property of SF DFO in the femur and vertebra of both male and female mice and comparing it to that of DFO, we analyzed the protective effect of DFO and SF DFO in an ovariectomized (OVX) mouse model. The serum CTX I level revealed no influence of DFO and SF DFO on osteoclast activity, but the blood vessels and osteoblasts in the metaphysis were more abundant after SF DFO treatment, which resulted in a greater protective effect against trabecular bone loss compared to the DFO group. Additionally, the cortical parameters and bone strength performance were identical between the DFO and SF DFO groups. However, the diffuse inflammatory response in the liver and spleen that occurred after DFO injection was not observed in the SF DFO group. Thus, with reduced biotoxicity and an equivalent bone seeking capability, SF DFO may be a better choice for the prevention of vascular degradation induced osteoporosis.
C1 [Guo, Changjun; Yang, Kai; Yan, Yufei; Yan, Xueming; Qian, Niandong; Zhou, Qi; Chen, Bo; Jiang, Min; Zhou, Hanbing; Li, Changwei; Wang, Fei; Qi, Jin; Deng, Lianfu] Shanghai Jiao Tong Univ, Shanghai Key Lab Prevent & Treatment Bone & Joint, Shanghai Inst Traumatol & Orthoped, Ruijin Hosp,Sch Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
   [Guo, Changjun; Xu, Xiangyang] Shanghai Jiao Tong Univ, Rui Jin North Hosp, Sch Med, Dept Orthoped, 999 Xiwang Rd, Shanghai 201801, Peoples R China.
   [Xu, Xiangyang] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Orthoped, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
   [Yan, Dongming; Cheng, Yifan] Natl Shanghai Ctr New Drug Safety Evaluat & Res, 199 Guoshoujing Rd, Shanghai 201203, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Qi, J; Deng, LF (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Key Lab Prevent & Treatment Bone & Joint, Shanghai Inst Traumatol & Orthoped, Ruijin Hosp,Sch Med, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.; Xu, XY (通讯作者)，Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Orthoped, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China.
EM jinjin838@hotmail.com; xu664531@hotmail.com; lf_deng@126.com
RI ; Zhou, Han/ISU 2803 2023; Zhou, Qi/JTT 3417 2023; Li,
   Changwei/JWQ 0219 2024; Wang, Fei/ABE 3386 2021; guo,
   changjun/GWV 9962 2022; Yang, Kai/JQW 2039 2023
OI guo, changjun/0000 0003 4151 5150; Changwei, Li/0000 0001 9324 4685;
   Yang, Kai/0000 0002 5544 7817
FU National Natural Science Foundation of China [81572099, 81702108,
   81700778]; Shanghai Science and Technology Commission of Jiading
   District [JDKW 2017 W10]; Shanghai Municipal Commission of Health and
   Family Planning [201440411, 20184Y0108]
FX We would like to thank Guowei Ni in Shanghai Institute of Pharmaceutical
   Industry for pharmaceutical technic supports. This work was supported by
   the National Natural Science Foundation of China (81572099, 81702108,
   81700778), Shanghai Science and Technology Commission of Jiading
   District (JDKW 2017 W10) and Shanghai Municipal Commission of Health and
   Family Planning (201440411, 20184Y0108).
CR Bauss F, 1996, CALCIFIED TISSUE INT, V59, P168, DOI 10.1007/s002239900104
   Brittenham GM, 2011, NEW ENGL J MED, V364, P146, DOI 10.1056/NEJMct1004810
   Cappellini Maria D, 2009, Hemoglobin, V33 Suppl 1, pS58, DOI 10.3109/03630260903346924
   Chan YL, 2001, J ULTRAS MED, V20, P723
   Chen SH, 2005, J PEDIAT HEMATOL ONC, V27, P651, DOI 10.1097/01.mph.0000194019.95096.b6
   COHEN A, 1990, J PEDIATR US, V117, P326, DOI 10.1016/S0022 3476(05)80556 6
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050 1738(00)00074 8
   Griffith JF, 2005, RADIOLOGY, V236, P945, DOI 10.1148/radiol.2363041425
   He GD, 2014, ASIA PAC J CLIN NUTR, V23, P174, DOI 10.6133/apjcn.2014.23.1.14
   Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253
   Kang H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01312
   Kontoghiorghes GJ, 2003, LANCET, V361, P184, DOI 10.1016/S0140 6736(03)12225 8
   Kumfu S, 2016, LIFE SCI, V150, P15, DOI 10.1016/j.lfs.2016.02.082
   Lin JC, 1999, OSTEOPOROSIS INT, V9, P516
   LUCARELLI G, 1995, NEW ENGL J MED, V332, P271
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440
   Myllyharju J, 2013, BIOL CHEM, V394, P435, DOI 10.1515/hsz 2012 0328
   Nagle DG, 2006, CURR PHARM DESIGN, V12, P2673, DOI 10.2174/138161206777698783
   OLIVIERI NF, 1986, NEW ENGL J MED, V314, P869, DOI 10.1056/NEJM198604033141402
   Park JH, 2002, MOL CELL ENDOCRINOL, V192, P197, DOI 10.1016/S0303 7207(02)00036 9
   PIERCE WM, 1987, P SOC EXP BIOL MED, V186, P96
   Shen X, 2009, J ORTHOP RES, V27, P1298, DOI 10.1002/jor.20886
   Shih TTF, 2004, RADIOLOGY, V233, P121, DOI 10.1148/radiol.2331031509
   Syed Farhan A, 2010, Curr Osteoporos Rep, V8, P235, DOI 10.1007/s11914 010 0035 y
   Takeyama M, 2008, BRIT J HAEMATOL, V142, P962, DOI 10.1111/j.1365 2141.2008.07289.x
   Thirunavukkarasu M, 2013, INT J CARDIOL, V168, P2474, DOI 10.1016/j.ijcard.2013.03.005
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang YXJ, 2009, BONE, V45, P711, DOI 10.1016/j.bone.2009.06.016
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Zhao Q, 2013, CALCIFIED TISSUE INT, V93, P172, DOI 10.1007/s00223 013 9739 1
   Zhao Q, 2012, BONE, V50, P763, DOI 10.1016/j.bone.2011.12.003
NR 35
TC 26
Z9 28
U1 2
U2 63
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2019
VL 120
BP 156
EP 165
DI 10.1016/j.bone.2018.10.025
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HL1PP
UT WOS:000458471700019
PM 30385424
DA 2025 08 17
ER

PT J
AU Lee, CH
   Bae, SJ
   Kim, M
AF Lee, Chang Hoon
   Bae, Su Jeong
   Kim, Miok
TI Mucosa associated lymphoid tissue lymphoma translocation 1 as a novel
   therapeutic target for rheumatoid arthritis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID KAPPA B ACTIVATION; PARACASPASE MALT1; CLEAVAGE; BONE; OSTEOIMMUNOLOGY;
   THERAPIES; IMMUNE; ALPHA; CELLS
AB Emerging evidence suggests that mucosa associated lymphoid tissue lymphoma translocation 1 (MALT1) is a key regulator of inflammatory diseases; however, the pathological role of MALT1 in rheumatoid arthritis (RA) is not well understood. Consequently, this protein has not been therapeutically targeted for the treatment of RA. MALT1 plays a role in the paracaspase pathway, has proteolytic activity and is involved in the regulation of inflammatory responses. In this study, we found that the MALT1 targeting inhibitory small molecule, MALT1 selective inhibitor 2 chloro N [4 [5 (3,4 dichlorophenyl) 3 (2 methoxyethoxy) 1H 1,2,4 triazol 1 yl] phenylacetamide (MI 2) strongly suppresses the differentiation of monocytes into osteoclasts in the absence or presence of the inflammatory cytokine tumour necrosis factor a. Furthermore, MI 2 ameliorates pathologic bone erosion and synovitis in an in vivo mouse model of collagen induced arthritis. Mechanistically, MI 2 blocked expression of the master osteoclast regulator nuclear factor of activated T cells 1 (NFATc1) by inhibiting nuclear factor kappa,B (NF kappa.B), which is a critical regulator of NFATc1. These findings highlight the important regulatory role of MALT1 in the NF .B NFATc1 signalling axis during osteoclastogenesis and suggest that targeting MALT1 is a promising treatment option for rheumatoid arthritis.
C1 [Lee, Chang Hoon; Bae, Su Jeong; Kim, Miok] Korea Res Inst Chem Technol, Ctr Drug Discovery Technol, Bio & Drug Discovery Div, Daejeon, South Korea.
   [Lee, Chang Hoon; Bae, Su Jeong; Kim, Miok] Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon, South Korea.
C3 Korea Research Institute of Chemical Technology (KRICT); Korea Research
   Institute of Bioscience & Biotechnology (KRIBB)
RP Lee, CH (通讯作者)，Korea Res Inst Chem Technol, Ctr Drug Discovery Technol, Bio & Drug Discovery Div, Daejeon, South Korea.; Lee, CH (通讯作者)，Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon, South Korea.
EM Lee2014@krict.re.kr
OI Lee, Chang Hoon/0000 0001 8953 9069
FU National Research Council of Science & Technology (NST) of the Korean
   government (MSIP) [CRC 15 02 KRIBB]
FX This work was supported by a grant from the National Research Council of
   Science & Technology (NST) of the Korean government (MSIP; grant no.
   CRC 15 02 KRIBB).
CR Afonina IS, 2015, FEBS J, V282, P3286, DOI 10.1111/febs.13325
   Brustle A, 2015, CELL DEATH DIFFER
   Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561
   Deng GM, 2000, ARTHRITIS RHEUM US, V43, P2283, DOI 10.1002/1529 0131(200010)43:10<2283::AID ANR16>3.0.CO;2 9
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Fontan L, 2012, CANCER CELL, V22, P812, DOI 10.1016/j.ccr.2012.11.003
   Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108
   Kaneko K, 2016, ARTHRITIS RHEUMATOL, V68, P521, DOI 10.1002/art.39414
   Klein T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9777
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Lipsky PE, 2008, NAT CLIN PRACT RHEUM, V4, P111, DOI 10.1038/ncprheum0764
   Prieto Potin I, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0664 5
   Rashidian A, 2016, INFLAMMOPHARMACOLOGY, V24, P109, DOI 10.1007/s10787 016 0263 6
   Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Scott David L, 2010, Lancet, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Shiozawa S, 2011, ARCH IMMUNOL THER EX, V59, P89, DOI 10.1007/s00005 011 0116 3
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140 6736(07)60784 3
   Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85
   Strand V, 2007, NAT REV DRUG DISCOV, V6, P75, DOI 10.1038/nrd2196
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034
   Weissmann G, 2006, BULL HOSP JT DIS, V64, P12
   WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784
   Yu JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127083
NR 26
TC 28
Z9 29
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 19
PY 2017
VL 7
AR 11889
DI 10.1038/s41598 017 12349 9
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FH4XG
UT WOS:000411165100066
PM 28928392
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, L
   Hu, SL
   Xie, J
   Yan, DY
   Weng, SJ
   Tang, JH
   Wang, BZ
   Xie, ZJ
   Wu, ZY
   Yang, L
AF Chen, Liang
   Hu, Sun Li
   Xie, Jun
   Yan, De Yi
   Weng, She Ji
   Tang, Jia Hao
   Wang, Bing Zhang
   Xie, Zhong Jie
   Wu, Zong Yi
   Yang, Lei
TI Proanthocyanidins Mediated Nrf2 Activation Ameliorates
   Glucocorticoid Induced Oxidative Stress and Mitochondrial Dysfunction in
   Osteoblasts
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID PREVALENCE; APOPTOSIS; AUTOPHAGY; SUPPRESS; PATHWAY; BONE
AB The widespread use of therapeutic glucocorticoids has increased the frequency of glucocorticoid induced osteoporosis (GIOP). One of the potential pathological processes of GIOP is an increased level of oxidative stress and mitochondrial dysfunction, which eventually leads to osteoblast apoptosis. Proanthocyanidins (PAC) are plant derived antioxidants that have therapeutic potential against GIOP. In our study, a low dose of PAC was nontoxic to healthy osteoblasts and restored osteogenic function in dexamethasone  (Dex ) treated osteoblasts by suppressing oxidative stress, mitochondrial dysfunction, and apoptosis. Mechanistically, PAC neutralized Dex induced damage in the osteoblasts by activating the Nrf2 pathway, since silencing Nrf2 partly eliminated the protective effects of PAC. Furthermore, PAC injection restored bone mass and promoted the expression of Nrf2 in the distal femur of Dex treated osteoporotic rats. In summary, PAC protect osteoblasts against Dex induced oxidative stress and mitochondrial dysfunction via the Nrf2 pathway activation and may be a promising drug for treating GIOP.
C1 [Chen, Liang; Hu, Sun Li; Xie, Jun; Yan, De Yi; Weng, She Ji; Tang, Jia Hao; Wang, Bing Zhang; Xie, Zhong Jie; Wu, Zong Yi; Yang, Lei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou 325000, Peoples R China.
   [Chen, Liang; Hu, Sun Li; Xie, Jun; Yan, De Yi; Weng, She Ji; Tang, Jia Hao; Wang, Bing Zhang; Xie, Zhong Jie; Wu, Zong Yi; Yang, Lei] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Peoples R China.
   [Chen, Liang; Hu, Sun Li; Xie, Jun; Yan, De Yi; Tang, Jia Hao; Wang, Bing Zhang; Yang, Lei] Key Lab Orthopaed Zhejiang Prov, Wenzhou 325000, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Yang, L (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou 325000, Peoples R China.; Yang, L (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Peoples R China.
EM wyey_yl@hotmail.com
OI Yang, Lei/0000 0002 9473 8625
FU Science and Technology Department of Zhejiang Province [2016C37122];
   National Natural Science Foundation of China [81772348]
FX This study was funded by a research grant of the Science and Technology
   Department of Zhejiang Province (Grant No. 2016C37122) and the National
   Natural Science Foundation of China (Grant No. 81772348).
CR Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Bhogal RH, 2012, AUTOPHAGY, V8, P545, DOI 10.4161/auto.19012
   Castellani R, 2002, J NEUROSCI RES, V70, P357, DOI 10.1002/jnr.10389
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Fardet L, 2011, RHEUMATOLOGY, V50, P1982, DOI 10.1093/rheumatology/ker017
   Han DD, 2019, FREE RADICAL BIO MED, V137, P1, DOI 10.1016/j.freeradbiomed.2019.04.014
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   Hsu E, 2017, CURR OPIN ENDOCRINOL, V24, P411, DOI 10.1097/MED.0000000000000368
   Ibáñez L, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/726590
   Kang H, 2016, OSTEOPOROSIS INT, V27, P1493, DOI 10.1007/s00198 015 3381 x
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kumar H, 2014, NAT PROD REP, V31, P109, DOI 10.1039/c3np70065h
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Liu BY, 2018, J NUTR BIOCHEM, V52, P115, DOI 10.1016/j.jnutbio.2017.09.025
   Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212
   Nandakumar V, 2008, CANCER LETT, V269, P378, DOI 10.1016/j.canlet.2008.03.049
   Niture SK, 2010, TOXICOL APPL PHARM, V244, P37, DOI 10.1016/j.taap.2009.06.009
   Ouyang ZX, 2018, ONCOTARGET, V9, P1868, DOI 10.18632/oncotarget.22930
   Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796
   Rajput S.A., 2019, TOXINS, V11
   Rizzoli R, 2017, NAT REV RHEUMATOL, V13, P635, DOI 10.1038/nrrheum.2017.141
   Rodríguez Pérez C, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102435
   Schäcke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163 7258(02)00297 8
   Shen GY, 2018, CELL MOL LIFE SCI, V75, P2683, DOI 10.1007/s00018 018 2776 1
   Shi XJ, 2010, TOXICOL SCI, V115, P391, DOI 10.1093/toxsci/kfq066
   Sun QR, 2019, AGING US, V11, P4107, DOI 10.18632/aging.102041
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Turrens JF, 2003, J PHYSIOL LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Xu MC, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8549035
   Xu WN, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00922
   Xu Y, 2020, NANO LETT, V20, P2558, DOI 10.1021/acs.nanolett.9b05340
   Yun SJ, 2020, J TRACE ELEM MED BIO, V57, P83, DOI 10.1016/j.jtemb.2019.126407
   Zhao CC, 2014, J BIOL CHEM, V289, P17020, DOI 10.1074/jbc.M114.563114
   Zhen YF, 2014, J CELL PHYSIOL, V229, P1475, DOI 10.1002/jcp.24589
NR 37
TC 38
Z9 45
U1 1
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942 0900
EI 1942 0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD SEP 25
PY 2020
VL 2020
AR 9102012
DI 10.1155/2020/9102012
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA OB2PF
UT WOS:000578315000001
PM 33062149
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, FZ
   Xie, JL
   Wang, GL
   Zhang, G
   Yang, HL
AF Zhang, Fuzhan
   Xie, Jile
   Wang, Genlin
   Zhang, Ge
   Yang, Huilin
TI Anti osteoporosis activity of Sanguinarine in preosteoblast MC3T3 E1
   cells and an ovariectomized rat model
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE AMPK; osteoportosis; Sanguinarine
ID OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAYS; BONE RESORPTION;
   KAPPA B; ACTIVATION; KINASE; CANCER; MINERALIZATION; MODULATION;
   INHIBITOR
AB Sanguinarine, a benzophenanthridine alkaloid, has been previously demonstrated to exert antimicrobial, anti inflammatory, and anti tumor activities. A previous study has identified Sanguinarine as a potential drug candidate for osteoporosis treatment by computational bioinformatics analysis. This study further evaluated the effects of Sanguinarine on the differentiation of murine preosteoblast MC3T3 E1 cells and its anti osteoporosis activity in an ovarietomized rat model. Sanguinarine treatment (0.25, 0.5, 1, and 2 mu m) of MC3T3 E1 cells significantly increased alkaline phosphatase (ALP) activity and the phoshporalyation of AMP activated protein kinase subunit (AMPK), but did not affect cell proliferation. The induction effects of Sanguinarine treatment (2 mu m) on ALP activity, AMPK phosphorylation, Smad1 phosphorylation, and the expression of three osteoblast differentiation regulators (bone morphogenetic protein 2 [BMP2], osterix [OSX], and osteoprotegerin [OPG]) were partially reversed by Compound C treatment. More importantly, Sanguinarine treatment promoted bone tissue growth in an ovariectomized (OVX) osteoporosis rat model as evaluated by histological examination, micro CT analysis, and serum parameter detection. In conclusion, these results indicate that Sanguinarine induces the differentiation of MC3T3 E1 cells through the activation of the AMPK/Smad1 signaling pathway. Sanguinarine can stimulate bone growth in vivo and may be an effective drug for osteoporosis treatment.
C1 [Zhang, Fuzhan; Xie, Jile; Wang, Genlin; Zhang, Ge; Yang, Huilin] Soochow Univ, Dept Orthopaed Surg, Affiliated Hosp 1, 899 Pinghai Rd, Suzhou 215006, Jiangsu, Peoples R China.
C3 Soochow University   China
RP Wang, GL (通讯作者)，Soochow Univ, Dept Orthopaed Surg, Affiliated Hosp 1, 899 Pinghai Rd, Suzhou 215006, Jiangsu, Peoples R China.
EM wglsci@126.com
RI Xie, Jile/HCJ 0620 2022; Zhang, Ge/HRC 8248 2023
FU Natural Sciences Foundation of China [81271960]
FX The Natural Sciences Foundation of China, Grant number: 81271960
CR Adhami VM, 2004, MOL CANCER THER, V3, P933
   Ahmad N, 2000, CLIN CANCER RES, V6, P1524
   Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129
   Choi J, 2011, BIOCHEM BIOPH RES CO, V413, P259, DOI 10.1016/j.bbrc.2011.08.081
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   GODOWSKI K C, 1989, Journal of Clinical Dentistry, V1, P96
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hughes FJ, 2006, PERIODONTOL 2000, V41, P48, DOI 10.1111/j.1600 0757.2006.00161.x
   Jang WG, 2011, BIOCHEM BIOPH RES CO, V404, P1004, DOI 10.1016/j.bbrc.2010.12.099
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kim DY, 2012, FITOTERAPIA, V83, P215, DOI 10.1016/j.fitote.2011.10.017
   Kling JM, 2014, J WOMENS HEALTH, V23, P563, DOI 10.1089/jwh.2013.4611
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Niu XF, 2012, EUR J PHARMACOL, V689, P262, DOI 10.1016/j.ejphar.2012.05.039
   Pica F, 2012, ANTI CANCER DRUG, V23, P32, DOI 10.1097/CAD.0b013e32834a0c8e
   Shaarawy M, 2001, SCAND J CLIN LAB INV, V61, P513
   Sun M, 2012, PROSTATE, V72, P82, DOI 10.1002/pros.21409
   TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006 291X(91)90490 X
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
   Xue LM, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/490843
   Yavropoulou MP, 2010, EXPERT REV ENDOCRINO, V5, P711, DOI 10.1586/EEM.10.48
   Yu GY, 2013, EUR J MED RES, V18, DOI 10.1186/2047 783X 18 5
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhao Y, 2007, BIOMATERIALS, V28, P3063, DOI 10.1016/j.biomaterials.2007.03.003
NR 29
TC 36
Z9 42
U1 1
U2 69
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2018
VL 233
IS 6
BP 4626
EP 4633
DI 10.1002/jcp.26187
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FX6JP
UT WOS:000426190900020
PM 28926099
DA 2025 08 17
ER

PT J
AU Van Poznak, C
   Somerfield, MR
   Barlow, WE
   Biermann, JS
   Bosserman, LD
   Clemons, MJ
   Dhesy Thind, SK
   Dillmon, MS
   Eisen, A
   Frank, ES
   Jagsi, R
   Jimenez, R
   Theriault, RL
   Vandenberg, TA
   Yee, GC
   Moy, B
AF Van Poznak, Catherine
   Somerfield, Mark R.
   Barlow, William E.
   Biermann, J. Sybil
   Bosserman, Linda D.
   Clemons, Mark J.
   Dhesy Thind, Sukhbinder K.
   Dillmon, Melissa S.
   Eisen, Andrea
   Frank, Elizabeth S.
   Jagsi, Reshma
   Jimenez, Rachel
   Theriault, Richard L.
   Vandenberg, Theodore A.
   Yee, Gary C.
   Moy, Beverly
TI Role of Bone Modifying Agents in Metastatic Breast Cancer: An American
   Society of Clinical Oncology Cancer Care Ontario Focused Guideline
   Update
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID ZOLEDRONIC ACID; DOUBLE BLIND; PHASE III; TRIAL; BISPHOSPHONATES;
   DENOSUMAB; STANDARD; COMPLICATIONS; MANAGEMENT; EFFICACY
AB PurposeTo update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain.MethodsA joint ASCO CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies.ResultsThe Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta analysis of studies of de escalation of BMAs, and two randomized trials of BMAs in control of pain secondary to bone metastases.RecommendationsPatients with breast cancer who have evidence of bone metastases should be treated with BMAs. Options include denosumab, 120 mg subcutaneously, every 4 weeks; pamidronate, 90 mg intravenously, every 3 to 4 weeks; or zoledronic acid, 4 mg intravenously every 12 weeks or every 3 to 4 weeks. The analgesic effects of BMAs are modest, and they should not be used alone for bone pain. The Update Committee recommends that the current standard of care for supportive care and pain managementanalgesia, adjunct therapies, radiotherapy, surgery, systemic anticancer therapy, and referral to supportive care and pain managementbe applied. Evidence is insufficient to support the use of one BMA over another. Additional information is available at www.asco.org/breast cancer guidelines and www.asco.org/guidelineswiki.
C1 [Van Poznak, Catherine; Biermann, J. Sybil; Jagsi, Reshma] Univ Michigan, Ann Arbor, MI 48109 USA.
   [Somerfield, Mark R.] Amer Soc Clin Oncol, Alexandria, VA USA.
   [Barlow, William E.] Canc Res & Biostat, Seattle, WA USA.
   [Bosserman, Linda D.] City Hope Natl Med Ctr, Duarte, CA USA.
   [Clemons, Mark J.] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada.
   [Dhesy Thind, Sukhbinder K.] Juravinski Hosp & Canc Ctr, Hamilton, ON, Canada.
   [Eisen, Andrea; Vandenberg, Theodore A.] London Reg Canc Program, London, ON, Canada.
   [Dillmon, Melissa S.] Harbin Clin, Rome, GA USA.
   [Frank, Elizabeth S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Jimenez, Rachel; Moy, Beverly] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Theriault, Richard L.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Yee, Gary C.] Univ Nebraska Med Ctr, Omaha, NE USA.
C3 University of Michigan System; University of Michigan; American Society
   of Clinical Oncology; Cancer Research & Biostatistics; City of Hope;
   University of Ottawa; Ottawa Hospital Research Institute; McMaster
   University; Western University (University of Western Ontario);
   University Western Ontario Hospital; Harvard University; Harvard
   University Medical Affiliates; Dana Farber Cancer Institute; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital; University of Texas System; UTMD Anderson Cancer Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Van Poznak, C (通讯作者)，Amer Soc Clin Oncol, 2318 Mill Rd,Ste 800, Alexandria, VA 22314 USA.
EM guidelines@asco.org
RI ; Yee, Gary/KBC 0317 2024
OI Dhesy Thind, Sukhbinder/0000 0002 6377 4703; Eisen,
   Andrea/0000 0001 8037 9556; 
CR Ahn SG, 2013, YONSEI MED J, V54, P1168, DOI 10.3349/ymj.2013.54.5.1168
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   [Anonymous], J CLIN ONCOL
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Dusetzina SB, 2014, J CLIN ONCOL, V32, P306, DOI 10.1200/JCO.2013.52.9123
   Ferrell BR, 2017, J CLIN ONCOL, V35, P96, DOI 10.1200/JCO.2016.70.1474
   Giordano SH, 2008, ONCOLOGIST, V13, P494, DOI 10.1634/theoncologist.2007 0200
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Ibrahim MFK, 2015, ANN ONCOL, V26, P2205, DOI 10.1093/annonc/mdv284
   Major PP, 2002, AM J CLIN ONCOL CANC, V25, pS10, DOI 10.1097/00000421 200212001 00003
   Martin M, 2012, CLIN CANCER RES, V18, P4841, DOI 10.1158/1078 0432.CCR 11 3310
   Meropol NJ, 2009, J CLIN ONCOL, V27, P3868, DOI 10.1200/JCO.2009.23.1183
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Rosen LS, 2001, CANCER J, V7, P377
   Runowicz CD, 2016, J CLIN ONCOL, V34, P611, DOI 10.1200/JCO.2015.64.3809
   Shojania KG, 2007, ANN INTERN MED, V147, P224, DOI 10.7326/0003 4819 147 4 200708210 00179
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Streeter SB, 2011, J ONCOL PRACT, V7, p46S, DOI 10.1200/JOP.2011.000316
   Van Poznak CH, 2011, J ONCOL PRACT, V7, P117, DOI 10.1200/JOP.2011.000212
NR 22
TC 129
Z9 131
U1 0
U2 13
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732 183X
EI 1527 7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 10
PY 2017
VL 35
IS 35
BP 3978
EP +
DI 10.1200/JCO.2017.75.4614
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FP4CV
UT WOS:000417565500012
PM 29035643
DA 2025 08 17
ER

PT J
AU Boonen, S
   Rosenberg, E
   Claessens, F
   Vanderschueren, D
   Papapoulos, S
AF Boonen, Steven
   Rosenberg, Elizabeth
   Claessens, Frank
   Vanderschueren, Dirk
   Papapoulos, Socrates
TI Inhibition of Cathepsin K for Treatment of Osteoporosis
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Cathepsin K inhibition; Osteoporosis
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; RESORPTION; TURNOVER;
   EFFICACY; ONO 5334; PYCNODYSOSTOSIS; OSTEOPETROSIS; DEGRADATION;
   OSTEOCLASTS
AB Cathepsin K is the protease that is primarily responsible for the degradation of bone matrix by osteoclasts. Inhibitors of cathepsin K are in development for treatment of osteoporosis. Currently available antiresorptive drugs interfere with osteoclast function. They inhibit both bone resorption and formation, due to the coupling between these processes. Cathepsin K inhibitors, conversely, target the resorption process itself and may not interfere with osteoclast stimulation of bone formation. In fact, when cathepsin K is absent or inhibited in mice, rabbits, or monkeys, bone formation is maintained or increased. In humans, inhibition of cathepsin K is associated with sustained reductions in bone resorption markers but with smaller and transient reductions in bone formation markers. The usefulness of cathepsin K inhibitors in osteoporosis is now being examined in phase 2 and phase 3 clinical trials of postmenopausal osteoporotic women.
C1 [Boonen, Steven] Leuven Univ, Div Geriatr Med, B 3000 Leuven, Belgium.
   [Boonen, Steven] Ctr Metab Bone Dis, B 3000 Leuven, Belgium.
   [Rosenberg, Elizabeth] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA.
   [Claessens, Frank] Leuven Univ, Dept Mol Cell Biol, B 3000 Leuven, Belgium.
   [Vanderschueren, Dirk] Leuven Univ, Dept Androl & Endocrinol, B 3000 Leuven, Belgium.
   [Papapoulos, Socrates] Leiden Univ, Med Ctr, Leiden, Netherlands.
C3 KU Leuven; Merck & Company; KU Leuven; KU Leuven; Leiden University  
   Excl LUMC; Leiden University; Leiden University Medical Center (LUMC)
RP Boonen, S (通讯作者)，Leuven Univ, Div Geriatr Med, UZ Leuven Campus Gasthuisberg,Herestr 49, B 3000 Leuven, Belgium.
EM steven.boonen@uzleuven.be; elizabeth.rosenberg@Merck.com;
   frank.claessens@med.kuleuven.be; dirk.vanderschueren@uzleuven.be;
   S.E.Papapoulos@lumc.nl
RI Claessens, Frank/M 8565 2016
OI Claessens, Frank/0000 0002 8676 7709; vanderschueren,
   dirk/0000 0003 1395 0104
CR Adami S, 2006, J BONE MINER RES, V21, pS24
   Binkley N, 2011, AM SOC BON MIN RES S
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bone H, 2010, END SOC M SAN DIEG C
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Cusick T, 2011, J BONE MINE IN PRESS
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Eastell R, 2011, J BONE MINER RES
   Eastell R, 2011, J BONE MINER RES, V26, P1303, DOI 10.1002/jbmr.341
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Fuller K, 2008, BONE, V42, P200, DOI 10.1016/j.bone.2007.09.044
   Gallagher JC, 2002, J CLIN ENDOCR METAB, V87, P4914, DOI 10.1210/jc.2002 020727
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Henriksen K, 2009, BONE, V44, P1026, DOI 10.1016/j.bone.2009.03.671
   Ho N, 1999, J BONE MINER RES, V14, P1649, DOI 10.1359/jbmr.1999.14.10.1649
   Jerome C, 2011, OSTEOPOROS INT
   Karsdal MA, 2007, J BONE MINER RES, V22, P487, DOI 10.1359/JBMR.070109
   Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444
   Lecaille F, 2008, BIOCHIMIE, V90, P208, DOI 10.1016/j.biochi.2007.08.011
   Li CY, 2006, J BONE MINER RES, V21, P865, DOI 10.1359/JBMR.060313
   Masarachia PJ, 2011, J BONE MINE IN PRESS
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Mayhew PM, 2005, LANCET, V366, P129, DOI 10.1016/S0140 6736(05)66870 5
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Ochi Y, 2011, BONE, V48, pS72, DOI 10.1016/j.bone.2011.03.079
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Peroni A, 2008, J AM ACAD DERMATOL, V59, P125, DOI 10.1016/j.jaad.2008.03.009
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Runger TM, 2011, J AM ACAD DERMATOL, DOI [10.1016/j.jaad2010.11.033, DOI 10.1016/J.JAAD2010.11.033]
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Schilling AF, 2007, OSTEOPOROSIS INT, V18, P659, DOI 10.1007/s00198 006 0311 y
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Stakkestad JA, 2008, CLIN RHEUMATOL, V27, P955, DOI 10.1007/s10067 007 0824 6
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Stroup GB, 2009, CALCIFIED TISSUE INT, V85, P344, DOI 10.1007/s00223 009 9279 x
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Yamada H, 2011, BONE, V48, pS221, DOI 10.1016/j.bone.2011.03.515
   Yamada H, 2010, EUR CAL TISS INT GLA
   Yamashita DS, 2006, J MED CHEM, V49, P1597, DOI 10.1021/jm050915u
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 53
TC 91
Z9 102
U1 2
U2 29
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1544 1873
EI 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD MAR
PY 2012
VL 10
IS 1
BP 73
EP 79
DI 10.1007/s11914 011 0085 9
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA V35YR
UT WOS:000209181500011
PM 22228398
DA 2025 08 17
ER

PT J
AU Zhou, XF
   Moussa, FM
   Mankoci, S
   Ustriyana, P
   Zhang, NL
   Abdelmagid, S
   Molenda, J
   Murphy, WL
   Safadi, FF
   Sahai, N
AF Zhou, Xianfeng
   Moussa, Fouad M.
   Mankoci, Steven
   Ustriyana, Putu
   Zhang, Nianli
   Abdelmagid, Samir
   Molenda, Jim
   Murphy, William L.
   Safadi, Fayez F.
   Sahai, Nita
TI Orthosilicic acid, Si(OH)4, stimulates osteoblast
   differentiation in vitro by upregulating miR 146a to antagonize
   NF κB activation
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Silicic acid; Osteoblastic differentiation; Osteoclastic
   differentiation; microRNA; NF kappa B
ID MESENCHYMAL STEM CELLS; SILICON SUBSTITUTED HYDROXYAPATITE; BONE MINERAL
   DENSITY; OSTEOGENIC DIFFERENTIATION; TRICALCIUM PHOSPHATE; MESOPOROUS
   MATERIALS; IMPLANT INTERFACE; RATS; VIVO; NANOPARTICLES
AB Accumulating evidence over the last 40 years suggests that silicate from dietary as well as silicate containing biomaterials is beneficial to bone formation. However, the exact biological role(s) of silicate on bone cells are still unclear and controversial. Here, we report that orthosilicic acid (Si(OH)(4)) stimulated human mesenchymal stem cells (hMSCs) osteoblastic differentiation in vitro. To elucidate the possible molecular mechanisms, differential microRNA microarray analysis was used to show that Si(OH)(4) significantly up regulated microRNA 146a (miR 146a) expression during hMSC osteogenic differentiation. Si (OH)(4) induced miR 146a expression profiling was further validated by quantitative RT PCR (qRT PCR), which indicated miR 146a was up regulated during the late stages of hMSC osteogenic differentiation. Inhibition of miR 146a function by anti miR 146a suppressed osteogenic differentiation of MC3T3 preosteoblasts, whereas Si(OH)(4) treatment promoted osteoblast specific genes transcription, alkaline phosphatase (ALP) production, and mineralization. Furthermore, luciferase reporter assay, Western blotting, enzyme linked immunosorbent assay (ELISA), and immunofluorescence showed that Si(OH)(4) decreased TNFoc induced activation of NF kappa B, a signal transduction pathway that inhibits osteoblastic bone formation, through the known miR 146a negative feedback loop. Our studies established a mechanism for Si (OH)(4) to promote osteogenesis by antagonizing NF kappa B activation via miR 146a, which might be interesting to guide the design of osteo inductive biomaterials for treatments of bone defects in humans.
   Statement of Significance
   Accumulating evidence over 40 years suggests that silicate is beneficial to bone formation. However, the biological role(s) of silicate on bone cells are still unclear and controversial. Here, we report that Si(OH)(4), the simplest form of silicate, can stimulate human mesenchymal stem cells osteoblastic differentiation. We identified that miR 146a is the expression signature in bone cells treated with Si(OH)(4). Further analysis of miR 146a in bone cells reveals that Si(OH)(4) upregulates miR 146a to antagonize the activation of NF kappa B. Si(OH)(4) was also shown to deactivate the same NF kappa B pathway to suppress osteoclast formation. Our findings are important to the development of third generation cell  and gene affecting biomaterials, and suggest silicate and miR 146a can be used as pharmaceuticals for bone fracture prevention and therapy. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Zhou, Xianfeng; Mankoci, Steven; Ustriyana, Putu; Sahai, Nita] Univ Akron, Dept Polymer Sci, Akron, OH 44325 USA.
   [Moussa, Fouad M.; Abdelmagid, Samir; Safadi, Fayez F.] Northeast Ohio Med Univ, Dept Anat & Neurobiol, Rootstown, OH USA.
   [Safadi, Fayez F.] Kent State Univ, Biomed Sci Grad Program, Kent, OH 44242 USA.
   [Zhang, Nianli] Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   [Molenda, Jim; Murphy, William L.] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53705 USA.
   [Molenda, Jim; Murphy, William L.] Univ Wisconsin, Dept Orthopaed & Rehabil, Madison, WI 53705 USA.
   [Sahai, Nita] Univ Akron, Integrated Biosci Program, Akron, OH 44325 USA.
   [Sahai, Nita] Univ Akron, Dept Geol, Akron, OH 44325 USA.
C3 University System of Ohio; University of Akron; University System of
   Ohio; Northeast Ohio Medical University (NEOMED); University System of
   Ohio; Kent State University; Kent State University Kent; Kent State
   University Salem; University of Michigan System; University of Michigan;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University System of Ohio; University of Akron; University System of
   Ohio; University of Akron
RP Zhou, XF; Sahai, N (通讯作者)，Univ Akron, Dept Polymer Sci, Akron, OH 44325 USA.
EM xianfeng@uakron.edu; sahai@uakron.edu
RI Safadi, Fayez/AAU 8699 2021; Zhou, Xianfeng/B 6957 2013; Murphy,
   William/I 4096 2014
OI Ustriyana, Putu/0000 0001 9804 3081; Zhou, Xianfeng/0000 0002 1408 3180;
   Murphy, William/0000 0001 5577 7739; 
FU NSF DMR grant [0906817]; University of Akron; Ohio Research Scholar
   Program; Direct For Mathematical & Physical Scien; Division Of Materials
   Research [0906817] Funding Source: National Science Foundation
FX We are grateful to Dr. Kan He, Department of Pathology, University of
   Pittsburgh School of Medicine, for excellent technical assistance and
   helpful discussion. Mr. Weilong Zhao in University of Akron is
   gratefully thanked for assistance with illustration of the mechanism.
   The Gene Expression and Genotyping Facility at Case Western Reserve
   University are acknowledged for the help with microRNA microarray and
   data analysis. NF kappa B Luc plasmid is the gift from Dr. Thomas in
   Kent State University. Financial support was provided by NSF DMR
   (0906817) grant and start up funds from University of Akron, and Ohio
   Research Scholar Program to Dr. Nita Sahai, PI.
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   BEERTSEN W, 1992, J CLIN INVEST, V89, P1974, DOI 10.1172/JCI115805
   BHATTACHARYYA P, 1980, P NATL ACAD SCI BIOL, V77, P6386, DOI 10.1073/pnas.77.11.6386
   Bohner M, 2009, BIOMATERIALS, V30, P6403, DOI 10.1016/j.biomaterials.2009.08.007
   CARLISLE EM, 1972, SCIENCE, V178, P619, DOI 10.1126/science.178.4061.619
   CARLISLE EM, 1970, SCIENCE, V167, P279, DOI 10.1126/science.167.3916.279
   CASEY WH, 1993, NATURE, V366, P253, DOI 10.1038/366253a0
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   CLARK AE, 1976, J BIOMED MATER RES, V10, P161, DOI 10.1002/jbm.820100202
   De Aza PN, 2004, BIOMATERIALS, V25, P1983, DOI 10.1016/j.biomaterials.2003.08.036
   De Aza PN, 2000, BIOMATERIALS, V21, P1735, DOI 10.1016/S0142 9612(00)00058 2
   DeAza PN, 1997, BIOMATERIALS, V18, P1285, DOI 10.1016/S0142 9612(97)00063 X
   DeLong RK, 2009, BIOMATERIALS, V30, P6451, DOI 10.1016/j.biomaterials.2009.07.067
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Gaharwar AK, 2013, ADV MATER, V25, P3329, DOI 10.1002/adma.201300584
   Gibson IR, 2002, J AM CERAM SOC, V85, P2771, DOI 10.1111/j.1151 2916.2002.tb00527.x
   Gibson IR, 1999, J BIOMED MATER RES, V44, P422, DOI 10.1002/(SICI)1097 4636(19990315)44:4<422::AID JBM8>3.0.CO;2 #
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hench L L, 1988, Ann N Y Acad Sci, V523, P54, DOI 10.1111/j.1749 6632.1988.tb38500.x
   Hench L.L., 1971, Journal of Biomedical Materials Research Symposium, V36, P117, DOI DOI 10.1002/JBM.820050611
   Hench LL, 2009, J EUR CERAM SOC, V29, P1257, DOI 10.1016/j.jeurceramsoc.2008.08.002
   Hench LL, 2000, MATER RES INNOV, V3, P313, DOI 10.1007/s100190000055
   Hobert O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651
   HOTT M, 1993, CALCIFIED TISSUE INT, V53, P174, DOI 10.1007/BF01321834
   Huang DM, 2005, FASEB J, V19, P2014, DOI 10.1096/fj.05 4288fje
   ILER RK, 1979, CHEM SILICA SOLUBILI
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Izquierdo Barba I, 2005, SOLID STATE SCI, V7, P983, DOI 10.1016/j.solidstatesciences.2005.04.003
   Jugdaohsingh R, 2007, J NUTR HEALTH AGING, V11, P99
   Jugdaohsingh R, 2004, J BONE MINER RES, V19, P297, DOI 10.1359/JBMR.0301225
   Jugdaohsingh R, 2008, BONE, V43, P596, DOI 10.1016/j.bone.2008.04.014
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   LI R, 1991, J APPL BIOMATER, V2, P231, DOI 10.1002/jab.770020403
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Calvo Guirado JL, 2015, CLIN ORAL IMPLAN RES, V26, P891, DOI 10.1111/clr.12413
   Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007
   Mladenovic Z, 2014, ACTA BIOMATER, V10, P406, DOI 10.1016/j.actbio.2013.08.039
   Nielsen FH, 2004, J TRACE ELEM EXP MED, V17, P137, DOI 10.1002/jtra.20004
   Nuttelman CR, 2006, BIOMATERIALS, V27, P1377, DOI 10.1016/j.biomaterials.2005.08.014
   OHURA K, 1992, J MATER SCI MATER M, V3, P95, DOI 10.1007/BF00705275
   Pietak AM, 2007, BIOMATERIALS, V28, P4023, DOI 10.1016/j.biomaterials.2007.05.003
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Porter AE, 2004, BIOMATERIALS, V25, P3303, DOI 10.1016/j.biomaterials.2003.10.006
   Porter AE, 2003, BIOMATERIALS, V24, P4609, DOI 10.1016/S0142 9612(03)00355 7
   Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198
   Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756 3282(02)00950 X
   Reilly GC, 2007, BIOMATERIALS, V28, P4091, DOI 10.1016/j.biomaterials.2007.05.038
   Sayer M, 2003, BIOMATERIALS, V24, P369, DOI 10.1016/S0142 9612(02)00327 7
   Schröder HC, 2004, BIOCHEM J, V381, P665, DOI 10.1042/BJ20040463
   SCHWARZ K, 1972, NATURE, V239, P333, DOI 10.1038/239333a0
   Selvamani SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103624
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tossell JA, 2000, GEOCHIM COSMOCHIM AC, V64, P4097, DOI 10.1016/S0016 7037(00)00497 X
   Vallet Regí M, 1999, J BIOMED MATER RES, V46, P560
   Vallet Regí MA, 2006, J MATER CHEM, V16, P26, DOI 10.1039/b509744d
   Vimalraj S, 2013, CURR ISSUES MOL BIOL, V15, P7
   Wiens M, 2010, BIOMATERIALS, V31, P7716, DOI 10.1016/j.biomaterials.2010.07.002
   Xynos ID, 2000, CALCIFIED TISSUE INT, V67, P321, DOI 10.1007/s002230001134
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Zhang NL, 2013, BIOMATER SCI UK, V1, P1101, DOI 10.1039/c3bm60034c
   Zhang NL, 2010, BIOMATERIALS, V31, P7653, DOI 10.1016/j.biomaterials.2010.06.043
   Zou S, 2009, J BIOMED MATER RES B, V90B, P123, DOI 10.1002/jbm.b.31262
NR 72
TC 72
Z9 78
U1 1
U2 74
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUL 15
PY 2016
VL 39
BP 192
EP 202
DI 10.1016/j.actbio.2016.05.007
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DQ1NA
UT WOS:000378966500018
PM 27163405
DA 2025 08 17
ER

PT J
AU Alves, RDAM
   Eijken, M
   van de Peppel, J
   van Leeuwen, JPTM
AF Alves, Rodrigo D. A. M.
   Eijken, Marco
   van de Peppel, Jeroen
   van Leeuwen, Johannes P. T. M.
TI Calcifying vascular smooth muscle cells and osteoblasts: independent
   cell types exhibiting extracellular matrix and biomineralization related
   mimicries
SO BMC GENOMICS
LA English
DT Article
DE Calcifying; Vascular smooth muscle cells; Osteoblasts; Gene expression;
   Extracellular matrix; Biomineralization
ID UP REGULATION; BONE MINERALIZATION; DEFICIENT MICE; GLA PROTEIN;
   CROSS TALK; IN VITRO; CALCIFICATION; EXPRESSION; DIFFERENTIATION;
   GLUCOCORTICOIDS
AB Background: Ectopic vascular calcifications represent a major clinical problem associated with cardiovascular disease and mortality. However, the mechanisms underlying pathological vascular calcifications are largely unknown hampering the development of therapies to tackle this life threatening medical condition.
   Results: In order to gain insight into the genes and mechanisms driving this pathological calcification process we analyzed the transcriptional profile of calcifying vascular smooth muscle cells (C VSMCs). These profiles were compared to differentiating osteoblasts, cells that constitute their physiological calcification counterparts in the body. Overall the transcriptional program of C VSMC and osteoblasts did not overlap. Several genes, some of them relevant for bone formation, were distinctly modulated by C VSMCs which did not necessarily lose their smooth muscle cell markers while calcifying. Bioinformatics gene clustering and correlation analysis disclosed limited bone related mechanisms being shared by two cell types. Extracellular matrix (ECM) and biomineralization genes represented common denominators between pathological vascular and physiological bone calcifications. These genes constitute the strongest link between these cells and represent potential drivers for their shared end point phenotype.
   Conclusions: The analyses support the hypothesis that VSMC trans differentiate into C VSMCs keeping their own identity while using mechanisms that osteoblasts use to mineralize. The data provide novel insights into groups of genes and biological processes shared in MSC and VSMC osteogenic differentiation. The distinct gene regulation between C VSMC and osteoblasts might hold clues to find cell specific pathway modulations, opening the possibility to tackle undesired vascular calcifications without disturbing physiologic bone formation and vice versa.
C1 [Alves, Rodrigo D. A. M.; Eijken, Marco; van de Peppel, Jeroen; van Leeuwen, Johannes P. T. M.] Erasmus MC, Dept Internal Med, NL 3015 CN Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC
RP van Leeuwen, JPTM (通讯作者)，Erasmus MC, Dept Internal Med, Wytemaweg 80, NL 3015 CN Rotterdam, Netherlands.
EM j.vanleeuwen@erasmusmc.nl
RI van Leeuwen, Johannes/D 5015 2014; van de Peppel, Jeroen/K 6683 2019
OI van Leeuwen, Johannes/0000 0002 2282 4006; van de peppel,
   jeroen/0000 0002 6524 727X; Eijken, Marco/0000 0002 9043 3971
FU ECTS Postdoctoral Fellowship; NWO ZON [91206069]; Erasmus Medical
   Center, Rotterdam, The Netherlands
FX This work was supported an ECTS Postdoctoral Fellowship award granted to
   M. Eijken in 2008, NWO ZON (contract grant #91206069) and the Erasmus
   Medical Center, Rotterdam, The Netherlands. The authors gratefully
   acknowledge Marijke Koedam and Tanja Strini for the technical assistance
   provided with cell culture experiments and Bram van der Eerden for
   support with editing the references.
CR Alves RDAM, 2010, J PROTEOME RES, V9, P4688, DOI 10.1021/pr100400d
   BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391
   Chen NX, 2008, J BONE MINER RES, V23, P1798, DOI 10.1359/JBMR.080604
   Davies MR, 2003, J AM SOC NEPHROL, V14, P1559, DOI 10.1097/01.ASN.0000068404.57780.DD
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   Dhore CR, 2001, ARTERIOSCL THROM VAS, V21, P1998, DOI 10.1161/hq1201.100229
   Dorai H, 2000, J CELL PHYSIOL, V184, P37, DOI 10.1002/(SICI)1097 4652(200007)184:1<37::AID JCP4>3.0.CO;2 M
   Drabek K, 2011, J BONE MINER RES, V26, P2045, DOI 10.1002/jbmr.435
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   EATON RH, 1968, ENZYMOLOGIA, V35, P168
   Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034
   Eijken M, 2005, MOL ENDOCRINOL, V19, P621, DOI 10.1210/me.2004 0212
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Engelbrecht Y, 2003, ENDOCRINOLOGY, V144, P412, DOI 10.1210/en.2002 220769
   Fessing MY, 2010, J INVEST DERMATOL, V130, P398, DOI 10.1038/jid.2009.259
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Hruska KA, 2005, CIRC RES, V97, P105, DOI 10.1161/01.RES.00000175571.53833.6c
   Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236
   Lomashvili KA, 2004, J AM SOC NEPHROL, V15, P1392, DOI 10.1097/01.ASN.0000128955.83129.9C
   LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   Mochida Y, 2009, MATRIX BIOL, V28, P44, DOI 10.1016/j.matbio.2008.11.003
   Moe SM, 2005, KIDNEY INT, V67, P2295, DOI 10.1111/j.1523 1755.2005.00333.x
   Monzack EL, 2011, J HEART VALVE DIS, V20, P449
   Morikawa M, 2011, NUCLEIC ACIDS RES, V39, P8712, DOI 10.1093/nar/gkr572
   Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205
   Nakashima A, 2005, J BIOL CHEM, V280, P37660, DOI 10.1074/jbc.M504612200
   Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003
   Pahl MV, 2010, CLIN J AM SOC NEPHRO, V5, P56, DOI 10.2215/CJN.03390509
   Parhami F, 2001, CIRC RES, V88, P954, DOI 10.1161/hh0901.090975
   Pasco JA, 2001, J CLIN ENDOCR METAB, V86, P1884, DOI 10.1210/jc.86.5.1884
   Persy V, 2009, TRENDS MOL MED, V15, P405, DOI 10.1016/j.molmed.2009.07.001
   Pevsner Fischer M, 2011, STEM CELL REV REP, V7, P560, DOI 10.1007/s12015 011 9229 7
   Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097 4644(19991201)75:3<424::AID JCB8>3.0.CO;2 8
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506 500
   Rekhter MD, 1993, AM J PATHOL
   Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   SCHLUESENER HJ, 1995, ATHEROSCLEROSIS, V113, P153, DOI 10.1016/0021 9150(94)05438 O
   Shanahan CM, 1999, CIRCULATION, V100, P2168, DOI 10.1161/01.CIR.100.21.2168
   Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Speer MY, 2002, J EXP MED, V196, P1047, DOI 10.1084/jem.20020911
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Theocharis AD, 2006, J BIOL CHEM, V281, P35116, DOI 10.1074/jbc.M601061200
   Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074 7696(08)61987 7
   Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427
   Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465
   WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205
   Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315
   Yeung KY, 2001, BIOINFORMATICS, V17, P309, DOI 10.1093/bioinformatics/17.4.309
NR 54
TC 77
Z9 85
U1 1
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2164
J9 BMC GENOMICS
JI BMC Genomics
PD NOV 7
PY 2014
VL 15
AR 965
DI 10.1186/1471 2164 15 965
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AU7OY
UT WOS:000345791100001
PM 25380738
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fan, YS
   Li, Q
   Hamdan, N
   Bian, YF
   Zhuang, S
   Fan, K
   Liu, ZJ
AF Fan, Ying Sai
   Li, Qin
   Hamdan, Nawras
   Bian, Yi Fei
   Zhuang, Shen
   Fan, Kai
   Liu, Zhong Jie
TI Tetrahydroxystilbene Glucoside Regulates Proliferation, Differentiation,
   and OPG/RANKL/M CSF Expression in MC3T3 E1 Cells via the PI3K/Akt
   Pathway
SO MOLECULES
LA English
DT Article
DE tetrahydroxystilbene glucoside; osteoblast; PI3K/Akt; herbal medicine;
   osteoporosis
ID OSTEOBLAST DIFFERENTIATION; MECHANISMS; AKT1; MICE
AB Tetrahydroxystilbene glucoside (TSG) is a unique component of the bone reinforcing herb Radix Polygoni Multiflori Preparata (RPMP). It has the ability to promote bone formation and protect osteoblasts. However, the underlying mechanism remains unclear. To better understand its biological function, we determined TSG's effect on murine pre osteoblastic MC3T3 E1 cells by the MTT assay, flow cytometry, FQ PCR, Western blot, and ELISA. The results showed that TSG caused an elevation of the MC3T3 E1 cell number, the number of cells in the S phase, and the mRNA levels of the runt related transcription factor 2 (Runx2), osterix (Osx), and collagen type I alpha 1 (Col1a1). In addition, the osteoprotegerin (OPG) mRNA level was up regulated, while the nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor (M CSF) mRNA levels were down regulated by TSG. Furthermore, TSG activated the phosphoinosmde 3 kinase/protein kinase B (also known as PI3K/Akt) pathway, and blocking this pathway by the inhibitor LY 294002 could impair TSG's functions in relation to the MC3T3 E1 cells. In conclusion, TSG could activate the PI3K/Akt pathway and thus promote MC3T3 E1 cell proliferation and differentiation, and influence OPG/RANKL/M CSF expression. TSG merits further investigation as a potential therapeutic agent for osteoporosis treatment.
C1 [Fan, Ying Sai; Hamdan, Nawras; Bian, Yi Fei; Zhuang, Shen; Fan, Kai; Liu, Zhong Jie] China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.
   [Li, Qin] Hebei Univ Engn, Coll Life Sci & Food Engn, Handan 056038, Peoples R China.
C3 China Agricultural University; Hebei University of Engineering
RP Liu, ZJ (通讯作者)，China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.
EM funinside@cau.edu.cn; liqin_00753@outlook.com;
   nawras_hamdan@hotmail.com; bianshuais@163.com; zhuangshenzs@163.com;
   dirtyfan@sina.com; liuzhongjiecau@163.com
RI Li, QIn/GXA 1934 2022; Bian, Yifei/HSG 0798 2023
FU National Natural Science Foundation of China [31702283]
FX This research was funded by National Natural Science Foundation of China
   [31702283].
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   [Anonymous], 2000, NIH Consens Statement, V17, P1
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247
   Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901
   Chen XF, 2017, PHARMACOLOGY, V99, P153, DOI 10.1159/000452672
   Chinese pharmacopoeia commission, 2012, PHARMACOPOEIA PEOPLE, P122
   Choi YH, 2011, BIOCHEM BIOPH RES CO, V411, P637, DOI 10.1016/j.bbrc.2011.07.009
   Cohen Solal KA, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0404 3
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377
   Ju DH, 2014, FRONT MED PRC, V8, P389, DOI 10.1007/s11684 014 0362 y
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Komori T, 2010, J CELL BIOCHEM, V87, P1
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li Q, 2015, PAK VET J, V35, P414
   Li Q, 2015, J ETHNOPHARMACOL, V170, P88, DOI 10.1016/j.jep.2015.05.013
   Lin C. Y., 2018, INT ENDOD J
   Liu ZH, 2015, IMPLANT DENT, V24, P83, DOI 10.1097/ID.0000000000000196
   Mackie E. J, 2013, INT J BIOCHEM CELL B, V35, P1301
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Qin R, 2011, TOXICOL LETT, V202, P1, DOI 10.1016/j.toxlet.2011.01.001
   Rao S, 2018, TRENDS CELL BIOL, V28, P213, DOI 10.1016/j.tcb.2017.11.001
   Tsai PW, 2018, MOLECULES, V23, DOI 10.3390/molecules23030571
   Vasudevan KM, 2011, CURR TOP MICROBIOL, V347, P105, DOI 10.1007/82_2010_66
   Wang ZQ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/356260
   Wu JJ, 2017, EUR J PHARMACOL, V811, P21, DOI 10.1016/j.ejphar.2017.05.037
   Zhang JK, 2012, EUR J PHARMACOL, V689, P31, DOI 10.1016/j.ejphar.2012.05.045
   Zheng YY, 2017, EXP THER MED, V14, P2845, DOI 10.3892/etm.2017.4915
NR 32
TC 27
Z9 30
U1 0
U2 28
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2018
VL 23
IS 9
AR 2306
DI 10.3390/molecules23092306
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GW9YP
UT WOS:000447365100217
PM 30201908
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Farbod, K
   Diba, M
   Zinkevich, T
   Schmidt, S
   Harrington, MJ
   Kentgens, APM
   Leeuwenburgh, SCG
AF Farbod, Kambiz
   Diba, Mani
   Zinkevich, Tatiana
   Schmidt, Stephan
   Harrington, Matthew J.
   Kentgens, Arno P. M.
   Leeuwenburgh, Sander C. G.
TI Gelatin Nanoparticles with Enhanced Affinity for Calcium Phosphate
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE bisphosphonates; bone specific; conjugation; gelatin nanoparticles;
   targeted delivery
ID TARGETED DRUG DELIVERY; IN VIVO; CONTROLLED RELEASE; MAGNETIC
   MICROSPHERES; DICLOFENAC SODIUM; TITANIUM IMPLANTS; GENE DELIVERY; BONE;
   SYSTEM; POLYMER
AB Gelatin nanoparticles can be tuned with respect to their drug loading efficiency, degradation rate, and release kinetics, which renders these drug carriers highly suitable for a wide variety of biomedical applications. The ease of functionalization has rendered gelatin an interesting candidate material to introduce specific motifs for selective targeting to specific organs, but gelatin nanoparticles have not yet been modified to increase their affinity to mineralized tissue. By means of conjugating bone targeting alendronate to biocompatible gelatin nanoparticles, a simple method is developed for the preparation of gelatin nanoparticles which exhibit strong affinity to mineralized surfaces. It has been shown that the degree of alendronate functionalization can be tuned by controlling the glutaraldehyde crosslinking density, the molar ratio between alendronate and glutaraldehyde, as well as the pH of the conjugation reaction. Moreover, it has been shown that the affinity of gelatin nanoparticles to calcium phosphate increases considerably upon functionalization with alendronate. In summary, gelatin nanoparticles have been developed, which exhibit great potential for use in bone specific drug delivery and regenerative medicine.
C1 [Farbod, Kambiz; Diba, Mani; Leeuwenburgh, Sander C. G.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Biomat, Philips van Leydenlaan 25, NL 6525 EX Nijmegen, Netherlands.
   [Zinkevich, Tatiana; Kentgens, Arno P. M.] Radboud Univ Nijmegen, Inst Mol & Mat, Dept Solid State NMR, Heyendaalseweg 135, NL 6525 AJ Nijmegen, Netherlands.
   [Schmidt, Stephan] Univ Leipzig, Fac Biosci Pharm & Psychol, Inst Biochem, Biophys Chem Grp, D 04103 Leipzig, Germany.
   [Schmidt, Stephan] Univ Dusseldorf, Inst Organ & Macromol Chem, Univ Str 1, D 40225 Dusseldorf, Germany.
   [Harrington, Matthew J.] Max Planck Inst Colloids & Interfaces, Dept Biomat, D 14424 Potsdam, Germany.
C3 Philips; Radboud University Nijmegen; Radboud University Nijmegen;
   Leipzig University; Heinrich Heine University Dusseldorf; Max Planck
   Society
RP Leeuwenburgh, SCG (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Biomat, Philips van Leydenlaan 25, NL 6525 EX Nijmegen, Netherlands.
EM sander.leeuwenburgh@radboudumc.nl
RI Leeuwenburgh, S.C.G./L 4483 2015; Diba, Mani/V 3209 2019; Schmidt,
   Stephan/B 8393 2013; Farbod, Kambiz/A 4907 2016; Kentgens,
   Arno/D 8170 2012; Leeuwenburgh, Sander/L 4483 2015
OI Diba, Mani/0000 0002 5291 3712; Farbod, Kambiz/0000 0003 4451 6183;
   Schmidt, Stephan/0000 0002 4357 304X; Kentgens,
   Arno/0000 0001 5893 4488; Leeuwenburgh, Sander/0000 0003 1471 6133
FU NIRM, Netherlands Institute for Regenerative Medicine and AgentschapNL
   (IOP Self Healing Materials) [SHM012014]; MPI Potsdam [ICSHM2013];
   TA COAST program
FX The authors are grateful for the support from funding NIRM, Netherlands
   Institute for Regenerative Medicine and AgentschapNL (IOP Self Healing
   Materials, Project no. SHM012014). M.D. would like to acknowledge the
   travel award from the ICSHM2013 conference supporting the research stay
   at the MPI Potsdam. T.Z. would like to acknowledge the support from
   funding TA COAST program. The Netherlands Organisation for Scientific
   Research (NWO) is acknowledged for support of the solid state NMR
   facility for advanced materials science. Furthermore, the authors would
   like to thank Vincent M. Cuijpers, Martijn Martens, Paul Tinnemans,
   Fereshteh Pashaei Kamali and Alexey Klymov for their practical
   assistance.
CR Alghamdi HS, 2013, BIOMATERIALS, V34, P3747, DOI 10.1016/j.biomaterials.2013.02.033
   Anande NM, 2008, INT J PHARMACEUT, V359, P182, DOI 10.1016/j.ijpharm.2008.04.009
   Bajpai AK, 2006, J MATER SCI MATER M, V17, P345, DOI 10.1007/s10856 006 8235 9
   BENNETT AE, 1995, J CHEM PHYS, V103, P6951, DOI 10.1063/1.470372
   Boanini E, 2011, J COLLOID INTERF SCI, V362, P594, DOI 10.1016/j.jcis.2011.06.061
   Bourquin C, 2008, J IMMUNOL, V181, P2990, DOI 10.4049/jimmunol.181.5.2990
   Brzoska M, 2004, BIOCHEM BIOPH RES CO, V318, P562, DOI 10.1016/j.bbrc.2004.04.067
   BUBNIS WA, 1992, ANAL BIOCHEM, V207, P129, DOI 10.1016/0003 2697(92)90513 7
   Cascone MG, 2002, J MATER SCI MATER M, V13, P523, DOI 10.1023/A:1014791327253
   Chen HY, 2012, BIOCONJUGATE CHEM, V23, P1915, DOI 10.1021/bc3003088
   Chen JP, 2011, J PHARM SCI US, V100, P655, DOI 10.1002/jps.22309
   Ding D, 2011, EUR J PHARM BIOPHARM, V79, P142, DOI 10.1016/j.ejpb.2011.01.008
   Doi N, 2012, J BIOMAT SCI POLYM E, V23, P991, DOI 10.1163/092050611X568214
   Dorkoosh FA, 2004, J CONTROL RELEASE, V99, P199, DOI 10.1016/j.jconrel.2004.06.012
   Elzoghby AO, 2013, J CONTROL RELEASE, V172, P1075, DOI 10.1016/j.jconrel.2013.09.019
   Ethirajan A, 2008, ADV FUNCT MATER, V18, P2221, DOI 10.1002/adfm.200800048
   Farbod K, 2014, TISSUE ENG PART B RE, V20, P173, DOI [10.1089/ten.TEB.2013.0221, 10.1089/ten.teb.2013.0221]
   Goldenstedt C, 2008, ULTRASON SONOCHEM, V15, P808, DOI 10.1016/j.ultsonch.2007.10.005
   GREGORIADIS G, 1993, DRUGS, V45, P15, DOI 10.2165/00003495 199345010 00003
   Gupta AK, 2004, J CONTROL RELEASE, V95, P197, DOI 10.1016/j.jconrel.2003.11.006
   Heller DA, 2013, ADV MATER, V25, P1449, DOI 10.1002/adma.201202881
   Hermanson GT, 2008, BIOCONJUGATE TECHNIQUES, 2ND EDITION, P1, DOI 10.1016/B978 0 12 370501 3.00001 1
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Ironside MS, 2010, EUR J PHARM BIOPHARM, V76, P120, DOI 10.1016/j.ejpb.2010.05.013
   Kale RN, 2010, J YOUNG PHARM, V2, P90, DOI 10.4103/0975 1483.62223
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007 007 0045 1
   Lawlor C, 2011, MOL PHARMACEUT, V8, P1100, DOI 10.1021/mp1004178
   Lee SJ, 2013, J CONTROL RELEASE, V172, P358, DOI 10.1016/j.jconrel.2013.09.002
   Li JK, 1998, J MICROENCAPSUL, V15, P163, DOI 10.3109/02652049809006846
   Li MY, 2006, BIOMATERIALS, V27, P2705, DOI 10.1016/j.biomaterials.2005.11.037
   Liu J, 2007, BIOMATERIALS, V28, P3236, DOI 10.1016/j.biomaterials.2007.03.022
   Liu J, 2009, CANCER RES, V69, P1174, DOI 10.1158/0008 5472.CAN 08 1753
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Mundada AS, 2006, DRUG DEV IND PHARM, V32, P443, DOI 10.1080/03639040500534101
   Nejadnik MR, 2014, BIOMATERIALS, V35, P6918, DOI 10.1016/j.biomaterials.2014.05.003
   Nejadnik MR, 2012, J BIOMED MATER RES A, V100A, P1316, DOI 10.1002/jbm.a.34071
   Rajan M, 2013, INT J PHARMACEUT, V453, P514, DOI 10.1016/j.ijpharm.2013.06.030
   Santoro M, 2014, J CONTROL RELEASE, V190, P210, DOI 10.1016/j.jconrel.2014.04.014
   Saravanan M, 2004, INT J PHARM, V283, P71, DOI 10.1016/j.ijpharm.2004.06.023
   Saravanan M, 2008, J DRUG TARGET, V16, P366, DOI [10.1080/10611860802046224, 10.1080/10611860802046224 ]
   Selkirk SM, 2002, GENE THER, V9, P432, DOI 10.1038/sj.gt.3301643
   Song J, 2014, THER DELIV, V5, P943, DOI [10.4155/tde.14.42, 10.4155/TDE.14.42]
   Sze DY, 2006, J VASC INTERV RADIOL, V17, P163, DOI 10.1097/01.RVI.0000183192.01135.B1
   Tabata Y, 1998, ADV DRUG DELIVER REV, V31, P287, DOI 10.1016/S0169 409X(97)00125 7
   Thakor D, 2007, MOL THER, V15, P2124, DOI 10.1038/sj.mt.6300256
   Tseng CL, 2009, BIOMATERIALS, V30, P3476, DOI 10.1016/j.biomaterials.2009.03.010
   Wang H., 2011, TISSUE ENG PART B RE, V18, P24
   Wang HA, 2014, ACTA BIOMATER, V10, P508, DOI 10.1016/j.actbio.2013.08.036
   Wang HN, 2013, J CONTROL RELEASE, V166, P172, DOI 10.1016/j.jconrel.2012.12.015
   Wang HA, 2011, ADV MATER, V23, pH119, DOI 10.1002/adma.201003908
   Wolke JGC, 2003, BIOMATERIALS, V24, P2623, DOI 10.1016/S0142 9612(03)00067 X
   Wu DC, 2008, J PHARM PHARM SCI, V11, P32, DOI 10.18433/J3988J
   Yang F, 2009, DRUG DEV IND PHARM, V35, P639, DOI 10.1080/03639040802512243
   Yoshinari M, 1997, J BIOMED MATER RES, V37, P60, DOI 10.1002/(SICI)1097 4636(199710)37:1<60::AID JBM8>3.0.CO;2 H
   Young S, 2005, J CONTROL RELEASE, V109, P256, DOI 10.1016/j.jconrel.2005.09.023
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 56
TC 19
Z9 21
U1 6
U2 80
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 5187
EI 1616 5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD MAY
PY 2016
VL 16
IS 5
BP 717
EP 729
DI 10.1002/mabi.201500414
PG 13
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA DM0XT
UT WOS:000376070000009
PM 26773715
OA Green Published
DA 2025 08 17
ER

PT J
AU Al Waeli, H
   Nicolau, B
   Stone, L
   Abu Nada, L
   Gao, Q
   Abdallah, MN
   Abdulkader, E
   Suzuki, M
   Mansour, A
   Al Subaie, A
   Tamimi, F
AF Al Waeli, H.
   Nicolau, B.
   Stone, L.
   Abu Nada, L.
   Gao, Q.
   Abdallah, M. N.
   Abdulkader, E.
   Suzuki, M.
   Mansour, A.
   Al Subaie, A.
   Tamimi, F.
TI Chronotherapy of Non Steroidal Anti Inflammatory Drugs May Enhance
   Postoperative Recovery
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MIGRATION INHIBITORY FACTOR; RESOLVING LIPID MEDIATORS;
   NECROSIS FACTOR ALPHA; CIRCADIAN CLOCK; INFLAMMATORY RESPONSE;
   DIURNAL VARIATION; BONE METABOLISM; GENE EXPRESSION; PAIN MANAGEMENT;
   GROWTH FACTOR
AB Postoperative pain relief is crucial for full recovery. With the ongoing opioid epidemic and the insufficient effect of acetaminophen on severe pain; non steroidal anti inflammatory drugs (NSAIDs) are heavily used to alleviate this pain. However, NSAIDs are known to inhibit postoperative healing of connective tissues by inhibiting prostaglandin signaling. Pain intensity, inflammatory mediators associated with wound healing and the pharmacological action of NSAIDs vary throughout the day due to the circadian rhythm regulated by the clock genes. According to this rhythm, most of wound healing mediators and connective tissue formation occurs during the resting phase, while pain, inflammation and tissue resorption occur during the active period of the day. Here we show, in a murine tibia fracture surgical model, that NSAIDs are most effective in managing postoperative pain, healing and recovery when drug administration is limited to the active phase of the circadian rhythm. Limiting NSAID treatment to the active phase of the circadian rhythm resulted in overexpression of circadian clock genes, such as Period 2 (Per2) at the healing callus, and increased serum levels of anti inflammatory cytokines interleukin 13 (IL 13), interleukin 4 (IL 4) and vascular endothelial growth factor. By contrast, NSAID administration during the resting phase resulted in severe bone healing impairment.
C1 [Al Waeli, H.; Nicolau, B.; Abdulkader, E.] McGill Univ, Fac Dent, 2001 Ave McGill Coll Suite 500, Montreal, PQ H3A 1G1, Canada.
   [Stone, L.; Abu Nada, L.; Gao, Q.; Suzuki, M.; Mansour, A.; Al Subaie, A.; Tamimi, F.] McGill Univ, Fac Dent, Strathcona Anat & Dent Bldg, Montreal, PQ H3A 0C7, Canada.
   [Abdallah, M. N.] Univ Toronto, Fac Dent, 124 Edward St, Toronto, ON M5G 1G, Canada.
C3 McGill University; McGill University; University of Toronto
RP Tamimi, F (通讯作者)，McGill Univ, Fac Dent, Strathcona Anat & Dent Bldg, Montreal, PQ H3A 0C7, Canada.
EM faleh.tamimimarino@mcgill.ca
RI Abdallah, Mohamed Nur/D 9303 2017; Mansour, Alaa/AAA 3227 2020; Abu
   Nada, Lina/GQB 4434 2022; Stone, Lyman/KUD 8092 2024; Gao,
   Qiman/JOK 7671 2023
OI Abdallah, Mohamed Nur/0000 0003 1179 6270; Gao,
   Qiman/0000 0003 2771 1147; 
FU Canada Research Chair program for Translational Cranofacial Research;
   Natural Sciences and Engineering Research Council of Canada (NSERC)
   Discovery program; Alpha Omega foundation; Quebec Network for Bone and
   Oral Health Research (RSBO); Fonds de Recherche du Quebec Sante (FRQS)
FX The authors would like to acknowldge financial support from the Canada
   Research Chair program for Translational Cranofacial Research (F.T), the
   Natural Sciences and Engineering Research Council of Canada (NSERC)
   Discovery program (F.T), the Alpha Omega foundation (H.A), the Quebec
   Network for Bone and Oral Health Research (RSBO) and the Fonds de
   Recherche du Quebec Sante (FRQS). We also thank the Bone Biology Lab,
   McGill University for providing the space and the scan to perform the CT
   scan images. Also, we thank the McGill Quebec Genome Center for their
   help with the gene expression analysis experiment.
CR Abu Nada L, 2018, J CLIN PERIODONTOL, V45, P1485, DOI 10.1111/jcpe.13015
   Al Subaie AE, 2016, J CLIN PERIODONTOL, V43, P1160, DOI 10.1111/jcpe.12632
   Alves CJ, 2016, BONE, V85, P107, DOI 10.1016/j.bone.2016.01.026
   Alzahrani MM, 2016, CLIN ORTHOP RELAT R, V474, P1294, DOI 10.1007/s11999 015 4640 z
   Arvidson NG, 1997, ANN RHEUM DIS, V56, P27, DOI 10.1136/ard.56.1.27
   Bastidas Coral AP, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1318256
   Bergese Sergio, 2016, Evid Based Med, V21, P24, DOI 10.1136/ebmed 2015 110278
   Bergmann A, 2008, EUR J ORAL SCI, V116, P18, DOI 10.1111/j.1600 0722.2007.00502.x
   Bhatwadekar AD, 2013, DIABETES, V62, P273, DOI 10.2337/db12 0172
   Bissinger O, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1241 2
   Bruguerolle B, 2007, ADV DRUG DELIVER REV, V59, P883, DOI 10.1016/j.addr.2006.06.001
   Bueno JSS, 2006, GENETICS, V174, P945, DOI 10.1534/genetics.106.057281
   Cao Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0200 4
   Curtis AM, 2014, IMMUNITY, V40, P178, DOI 10.1016/j.immuni.2014.02.002
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Druzd D, 2017, IMMUNITY, V46, P120, DOI 10.1016/j.immuni.2016.12.011
   Dudek M, 2014, BIOCHEM J, V463, P1, DOI 10.1042/BJ20140700
   Edderkaoui B, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00039
   Eimar H, 2016, BONE, V84, P131, DOI 10.1016/j.bone.2015.12.009
   EINHORN TA, 1995, J BONE MINER RES, V10, P1272
   Fujihara Y, 2014, BONE, V61, P1, DOI 10.1016/j.bone.2013.12.026
   Gaber T, 2005, ANN RHEUM DIS, V64, P971, DOI 10.1136/ard.2004.031641
   Gerstenfeld LC, 2001, CELLS TISSUES ORGANS, V169, P285, DOI 10.1159/000047893
   Gerstenfeld Louis C, 2004, Expert Opin Drug Saf, V3, P131, DOI 10.1517/14740338.3.2.131
   Gibon E, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0300 9
   Gohlmann H.a. T. W, 2013, GENE EXPRESSION STUD, P79
   Goodman SB, 2007, J BIOMED MATER RES A, V81A, P310, DOI 10.1002/jbm.a.30983
   Guo B, 2015, OSTEOARTHR CARTILAGE, V23, P1981, DOI 10.1016/j.joca.2015.02.020
   HANSSON LI, 1974, ACTA ORTHOP SCAND, V45, P499, DOI 10.3109/17453677408989173
   Hollmann MW, 2019, LANCET, V393, P1483, DOI 10.1016/S0140 6736(19)30854 2
   Iimura T, 2012, J BONE MINER METAB, V30, P254, DOI 10.1007/s00774 011 0295 3
   Ivaska KK, 2005, CLIN CHEM, V51, P618, DOI 10.1373/clinchem.2004.043901
   Jorgensen LN, 2003, APMIS, V111, P9
   Kaiser K, 2018, N S ARCH PHARMACOL, V391, P523, DOI 10.1007/s00210 018 1483 7
   Kasahara T, 2010, P NATL ACAD SCI USA, V107, P6412, DOI 10.1073/pnas.0914399107
   Keller M, 2009, P NATL ACAD SCI USA, V106, P21407, DOI 10.1073/pnas.0906361106
   Kim SH, 2013, BBA MOL BASIS DIS, V1832, P1969, DOI 10.1016/j.bbadis.2013.06.010
   King A, 2014, ADV WOUND CARE, V3, P315, DOI 10.1089/wound.2013.0461
   Klein M, 2012, DAN MED J, V59
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Koyanagi S, 2003, CANCER RES, V63, P7277
   Kunimoto T, 2016, SCI REP UK, V6, DOI 10.1038/srep22409
   LABRECQUE G, 1995, PHARMACOL THERAPEUT, V66, P285, DOI 10.1016/0163 7258(94)00082 E
   Labrecque N, 2015, J BIOL RHYTHM, V30, P277, DOI 10.1177/0748730415577723
   Lau K H William, 2014, J Bone Metab, V21, P169, DOI 10.11005/jbm.2014.21.3.169
   Lemmer B, 2007, ADV DRUG DELIVER REV, V59, P825, DOI 10.1016/j.addr.2007.08.001
   Lévi F, 2002, CHRONOBIOL INT, V19, P1, DOI 10.1081/CBI 120002676
   LEVI F, 1985, CLIN PHARMACOL THER, V37, P77, DOI 10.1038/clpt.1985.15
   Lévi F, 2011, EXPERT OPIN DRUG DEL, V8, P1535, DOI 10.1517/17425247.2011.618184
   Liggett JL, 2014, CANCER LETT, V346, P217, DOI 10.1016/j.canlet.2014.01.021
   Lin HN, 2016, J ORTHOP RES, V34, P1883, DOI 10.1002/jor.23213
   Linder M, 2018, CELL DEATH DIFFER, V25, P1094, DOI 10.1038/s41418 017 0054 7
   Liu JG, 2006, INFECT IMMUN, V74, P4750, DOI 10.1128/IAI.00287 06
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Macias MP, 2001, J CLIN INVEST, V107, P949, DOI 10.1172/JCI11232
   Markoulli M, 2012, INVEST OPHTH VIS SCI, V53, P1479, DOI 10.1167/iovs.11 8365
   Maronde E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011527
   Mathiesen O, 2014, ACTA ANAESTH SCAND, V58, P1182, DOI 10.1111/aas.12380
   Matsumiya LC, 2012, J AM ASSOC LAB ANIM, V51, P42
   Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092
   Morrison BW, 1999, CLIN THER, V21, P943, DOI 10.1016/S0149 2918(99)80016 2
   Mountziaris PM, 2008, TISSUE ENG PART B RE, V14, P179, DOI 10.1089/ten.teb.2008.0038
   Na YR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063451
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Nakamura Y, 2016, J ALLERGY CLIN IMMUN, V137, P1226, DOI 10.1016/j.jaci.2015.08.052
   Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871
   O'Connor J Patrick, 2014, Bonekey Rep, V3, P517, DOI 10.1038/bonekey.2014.12
   Onodera S, 2004, HISTOCHEM CELL BIOL, V121, P209, DOI 10.1007/s00418 004 0624 x
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Petrovsky N, 2003, IMMUNOL CELL BIOL, V81, P137, DOI 10.1046/j.0818 9641.2002.01148.x
   Pozzi A, 2011, ANN STOMATOL, V2, P3
   Scheiermann C, 2013, NAT REV IMMUNOL, V13, P190, DOI 10.1038/nri3386
   Scheiermann C, 2012, IMMUNITY, V37, P290, DOI 10.1016/j.immuni.2012.05.021
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Schmidt Bleek K, 2015, TISSUE ENG PART B RE, V21, P354, DOI [10.1089/ten.teb.2014.0677, 10.1089/ten.TEB.2014.0677]
   Schmidt Bleek K, 2014, J TISSUE ENG REGEN M, V8, P120, DOI 10.1002/term.1505
   Schmidt Bleek K, 2012, CELL TISSUE RES, V347, P567, DOI 10.1007/s00441 011 1205 7
   Serhan CN, 2015, SEMIN IMMUNOL, V27, P200, DOI 10.1016/j.smim.2015.03.004
   Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
   Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276
   Spiro AS, 2010, J ORTHOP RES, V28, P785, DOI 10.1002/jor.21044
   Su B, 2013, J APPL PHYSIOL, V115, P892, DOI 10.1152/japplphysiol.00053.2013
   Sulli G, 2018, TRENDS PHARMACOL SCI, V39, P812, DOI 10.1016/j.tips.2018.07.003
   Swanson CM, 2018, METABOLISM, V84, P28, DOI 10.1016/j.metabol.2017.12.002
   Tajima K, 2010, J ORTHOP RES, V28, P937, DOI 10.1002/jor.21086
   Tao WW, 2015, SCI REP UK, V5, DOI 10.1038/srep15212
   Tétreault P, 2011, PHYSIOL BEHAV, V104, P495, DOI 10.1016/j.physbeh.2011.05.015
   Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229
   Tim CR, 2016, J PHOTOCH PHOTOBIO B, V154, P8, DOI 10.1016/j.jphotobiol.2015.10.028
   To H, 2011, CHRONOBIOL INT, V28, P267, DOI 10.3109/07420528.2011.553017
   Utvåg SE, 2010, J INVEST SURG, V23, P257, DOI 10.3109/08941939.2010.481009
   Vermeren M, 2017, MAMM GENOME, V28, P498, DOI 10.1007/s00335 017 9718 3
   Vgontzas AN, 2005, NEUROIMMUNOMODULAT, V12, P131, DOI 10.1159/000084844
   Xu YQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044237
   Yang XM, 2009, J BIOCHEM, V145, P289, DOI 10.1093/jb/mvn167
   Yasuda M, 2013, J PAIN RES, V6, P161, DOI 10.2147/JPR.S41527
   Yoshitake R, 2017, VET J, V221, P38, DOI 10.1016/j.tvjl.2017.02.001
   YOUNG MRI, 1995, CHRONOBIOL INT, V12, P19, DOI 10.3109/07420529509064496
   Zhang MJ, 2011, J BONE MINER RES, V26, P792, DOI 10.1002/jbmr.272
   Zhang XR, 2011, J BONE MINER RES, V26, P1022, DOI 10.1002/jbmr.295
   Zhao ZG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118299
   Zura R, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.2775
NR 102
TC 26
Z9 27
U1 2
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JAN 16
PY 2020
VL 10
IS 1
AR 468
DI 10.1038/s41598 019 57215 y
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA MO3XA
UT WOS:000551461800019
PM 31949183
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, YX
   Wang, Q
   Xu, QH
   Li, JR
   Zhao, FC
AF Wang, Yuxin
   Wang, Quan
   Xu, Qianhui
   Li, Jiarui
   Zhao, Fengchao
TI Single cell RNA sequencing analysis dissected the osteo immunology
   microenvironment and revealed key regulators in osteoporosis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Single cell RNA sequencing; Osteoclast; Osteoporosis; Immune cell;
   Cell cell communication
ID BONE; EXPRESSION; GENE; DIFFERENTIATION; RECONSTRUCTION; ACTIVATION;
   RESISTIN; PROTEIN; SYSTEM; MODEL
AB Osteoporotic fractures become increasingly common in postmenopausal women over age 55 years and men after age 65 years, bringing about substantial bone associated morbidities, and augmented mortality and health care costs. Advanced researches have led to a more accurate assessment of osteoporosis (OP) and have broadened the range of therapeutic approaches available to prevent osteoporotic fractures. Single cell RNA sequencing (scRNA seq) analysis is an evolutionary method that quantifies the majority of transcripts in individual cells at isoform resolution, paving the way for more detailed analyses of gene regulation in biology and medicine. We have extracted 19,102 cells and 4097 dynamical genes with significant expression changes. Several new subtypes of macrophages and differentially over expressed genes were discovered in the trajectory of osteoclasts formation. The zinc finger protein 36, C3H type like 1 (ZFP36L1) and defensin alpha 3 (DEFA3) were identified as novel bone metabolism related genes. RETN CAP1 was newly found to be involved in the interaction between osteo clasts and immunocytes, indicating that osteo immunology microenvironment substantially contributed to the pathology of osteoporosis or osteopenia. In this research, we have performed Single cell RNA sequencing analysis to display the trajectory of osteoclast formation and reveal the possible gene targets and signaling pathways that probably play an important role in osteoporosis.
C1 [Wang, Yuxin; Wang, Quan; Li, Jiarui; Zhao, Fengchao] Zhejiang Univ Sch Med, Affiliated Hosp 1, Dept Orthopaed Surg, Hangzhou 310003, Peoples R China.
   [Xu, Qianhui] Fudan Univ, Zhongshan Hosp, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
   [Zhao, Fengchao] Zhejiang Univ Sch Med, Affiliated Hosp 1, Dept Orthopaed Surg, 79 Qingchun Rd, Hangzhou 310003, Peoples R China.
C3 Fudan University
RP Zhao, FC (通讯作者)，Zhejiang Univ Sch Med, Affiliated Hosp 1, Dept Orthopaed Surg, 79 Qingchun Rd, Hangzhou 310003, Peoples R China.
EM zhaofengchao@zju.edu.cn
FU Zhejiang Provincial Natural Science Foundation of China [LGF22H060003]
FX Acknowledgements This research was supported by Zhejiang Provincial
   Natural Science Foundation of China under Grant No. LGF22H060003.
CR Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]
   Bai HB, 2019, J BIOCHEM, V166, P475, DOI 10.1093/jb/mvz060
   Boudin E, 2017, EUR J ENDOCRINOL, V177, pR69, DOI 10.1530/EJE 16 0990
   Bullwinkel J, 2006, J CELL PHYSIOL, V206, P624, DOI 10.1002/jcp.20494
   Carrión M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174091
   Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood 2004 02 0474
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   Gillespie MT, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2141
   Grcevic D, 2023, BONE, V168, DOI 10.1016/j.bone.2021.116296
   Hao H, 2003, BLOOD, V101, P4551, DOI 10.1182/blood 2002 10 3174
   Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590 019 0526 7
   HATTNER R, 1965, NATURE, V206, P489, DOI 10.1038/206489a0
   Ho XD, 2017, EXP BIOL MED, V242, P1802, DOI 10.1177/1535370217736512
   Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21246 9
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kaur K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 76702 1
   Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990
   Lu XQ, 2019, MED SCI MONITOR, V25, P9524, DOI 10.12659/MSM.918333
   Luecken MD, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188746
   Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76
   PECK WA, 1993, AM J MED, V94, P646
   Qiu X, 2021, AGING US, V13, P15595, DOI 10.18632/aging.203124
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rahmanzadeh R, 2007, CELL PROLIFERAT, V40, P422, DOI 10.1111/j.1365 2184.2007.00433.x
   Samanna V, 2007, J CELL PHYSIOL, V213, P710, DOI 10.1002/jcp.21137
   Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192
   Silswal N, 2005, BIOCHEM BIOPH RES CO, V334, P1092, DOI 10.1016/j.bbrc.2005.06.202
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Stubbington MJT, 2017, SCIENCE, V358, P58, DOI 10.1126/science.aan6828
   Thommesein L, 2006, J CELL BIOCHEM, V99, P824, DOI 10.1002/jcb.20915
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Verma R, 2014, J EXP MED, V211, P1715, DOI 10.1084/jem.20130624
   Xu QH, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00663 1
   Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Yoshida H, 2013, P NATL ACAD SCI USA, V110, P5612, DOI 10.1073/pnas.1215432110
NR 39
TC 20
Z9 22
U1 11
U2 61
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC
PY 2022
VL 113
AR 109302
DI 10.1016/j.intimp.2022.109302
EA OCT 2022
PN A
PG 15
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 8T9MQ
UT WOS:000929577300003
PM 36257255
DA 2025 08 17
ER

PT J
AU Kaji, H
   Naito, J
   Sowa, H
   Sugimoto, T
   Chihara, K
AF Kaji, H.
   Naito, J.
   Sowa, H.
   Sugimoto, T.
   Chihara, K.
TI Serum soluble factors induce the proliferation, alkaline phosphatase
   activity and transforming growth factor β signal in osteoblastic cells
   in the patient with hepatitis C associated osteosclerosis
SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
LA English
DT Article
DE osteosclerosis TGF beta; osteoblast; Smad3
ID CAMURATI ENGELMANN DISEASE; INTRAVENOUS DRUG ABUSE; BONE FORMATION;
   DIFFUSE OSTEOSCLEROSIS; ACQUIRED OSTEOSCLEROSIS; BLOOD TRANSFUSION;
   MUTATIONS; SYSTEM; GROWTH FACTOR BETA 1; MINERALIZATION
AB Hepatitis C associated osteosclerosis (HCAO) is a rare syndrome characterized by severe, acquired, generalized osteosclerosis and hyperostosis in adults who are infected with the hepatitis C virus. However, the detail of the pathogenesis of HCAO is still unknown. We examined the effects of serum of the HCAO patient on the proliferation, alkaline phosphatase (ALP) activity and transforming growth factor (TGF) beta Smad signaling in mouse osteoblastic cells. The patient was compatible with HCAO, characterized by high bone mass, bone thickening and bone pain with normal lamelar bone. The serum from the HCAO patient increased the levels of TGF beta and Smad3 expression in osteoblastic MC3T3 E1 cells, compared with the control subject. Moreover, the serum from the HCAO patient significantly augmented TGF beta induced transcriptional activity with luciferase assay using 3TP Lux with a Smad3 specific responsive element. In addition, the serum from the HCAO patient significantly stimulated the MTT intensity, the level of proliferating cell nuclear antigen expression, a proliferation marker, and ALP activity in MC3T3 E1 cells, compared with that from the control subject. In conclusion, the present study indicated that the serum from the HCAO patient stimulated TGF beta Smad signaling, as well as the proliferation and ALP activity in osteoblastic cells. Some soluble factors other than parathyroid hormone might be related to the pathogenesis of HCAO.
C1 Kobe Univ, Grad Sch Med, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   Shimane Univ, Div Endocrinol Metab & Hematol Oncol, Sch Med, Shimane, Japan.
C3 Kobe University; Shimane University
RP Kaji, H (通讯作者)，Kobe Univ, Grad Sch Med, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med,Chuo Ku, 7 5 2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM hiroshik@med.kobe u.ac.jp
RI Kaji, Hiroshi/AAI 5628 2020
CR BECK LS, 1993, J BONE MINER RES, V8, P753
   BEYER HS, 1990, J BONE MINER RES, V5, P1257
   Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754
   Diamond T, 1996, BONE, V19, P679, DOI 10.1016/S8756 3282(96)00304 3
   Hassoun AAK, 1997, AM J MED, V103, P70, DOI 10.1016/S0002 9343(97)00139 3
   Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563
   Janssens K, 2006, J MED GENET, V43, P1, DOI 10.1136/jmg.2005.033522
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Janssens K, 2003, J BIOL CHEM, V278, P7718, DOI 10.1074/jbc.M208857200
   JEACH RJ, 2001, J CLIN ENDOCR METAB, V86, P24
   JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo 126 2 1014
   JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195
   Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098
   Khosla S, 1998, J CLIN INVEST, V101, P2165, DOI 10.1172/JCI1111
   Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128
   Manganelli P, 2005, CLIN RHEUMATOL, V24, P296, DOI 10.1007/s10067 004 1031 3
   Massagué J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745
   Massagué J, 2000, GENE DEV, V14, P627
   NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo 124 6 2991
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   ROSEN D, 1994, BONE, V15, P355, DOI 10.1016/8756 3282(94)90300 X
   Shaker JL, 1998, J CLIN ENDOCR METAB, V83, P93, DOI 10.1210/jc.83.1.93
   Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190
   Sowa H, 2003, J BIOL CHEM, V278, P52240, DOI 10.1074/jbc.M302566200
   Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200
   SPARKES RS, 1972, J MED GENET, V9, P73, DOI 10.1136/jmg.9.1.73
   VILLAREAL DT, 1992, AM J MED, V93, P371, DOI 10.1016/0002 9343(92)90165 8
   Whyte MP, 1996, J BONE MINER RES, V11, P554
   Whyte MP, 1997, AM J MED, V102, P219, DOI 10.1016/S0002 9343(97)89507 1
NR 30
TC 10
Z9 10
U1 0
U2 1
PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
PI STUTTGART
PA RUEDIGERSTR 14, D 70469 STUTTGART, GERMANY
SN 0947 7349
EI 1439 3646
J9 EXP CLIN ENDOCR DIAB
JI Exp. Clin. Endocrinol. Diabet.
PD NOV
PY 2006
VL 114
IS 10
BP 599
EP 604
DI 10.1055/s 2006 924399
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 121VW
UT WOS:000243186100011
PM 17177144
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ng, YH
   Gino, PD
   Lingaraj, K
   Das De, S
AF Ng, Y. H.
   Gino, P. D.
   Lingaraj, K.
   Das De, S.
TI Femoral shaft fractures in the elderly   Role of prior bisphosphonate
   therapy
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Alendronate; Bisphosphonates; Femoral shaft fracture; Insufficiency
   fracture; Elderly; Low impact; Radiographic features; Prodromal pain;
   Treatment protocol
ID SUPPRESSED BONE TURNOVER; PARATHYROID HORMONE 1 34; ALENDRONATE THERAPY;
   POSTMENOPAUSAL WOMEN; INSUFFICIENCY FRACTURES; ACCUMULATES MICRODAMAGE;
   RANDOMIZED TRIAL; CORTICAL BONE; DOG RIB; OSTEOPOROSIS
AB Introduction: There is a recent surge in interest on bisphosphonate related femoral fractures. Most studies have examined subtrochanteric fractures in patients on long term bisphosphonates. This study evaluates the characteristics of low impact femoral shaft fractures in elderly patients on long term alendronate.
   Materials and methods: All patients above 60 years old admitted to the National University Hospital for femoral shaft fracture from January 2003 to January 2007 were retrospectively analysed. Of the 55 patients included, 7 had prior alendronate therapy and were examined in detail.
   Results: All 7 patients on prior alendronate therapy sustained their fractures by low impact or atraumatic mechanisms of injury. 5 of these 7 patients exhibited a characteristic fracture pattern of thickened lateral cortices at the proximal fracture fragment (p < 0.05) and all 7 patients had either transverse or short oblique fractures. Notably, none of the 7 patients had bone mineral density scans prior to their fractures. One patient was started on alendronate after a vertebral compression fracture, whilst the other 6 patients were started on alendronate without any clear clinical indication. All 7 patients reported prodromal thigh pain 3 weeks to 2 years prior to the fracture.
   Conclusions: Low impact femoral shaft fractures in elderly patients on long term alendronate therapy represent a new entity of insufficiency fractures, with characteristic low impact modes of injury and fracture patterns on radiograph. Prodromal thigh pain is a warning sign for impending fracture in this group of patients and should be evaluated closely. Teriparatide is a possible alternative to alendronate following such a fracture though more long term clinical studies are required. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Ng, Y. H.; Gino, P. D.; Lingaraj, K.; Das De, S.] Natl Univ Singapore Hosp, Dept Orthopaed Surg, Singapore 119074, Singapore.
C3 National University of Singapore
RP Ng, YH (通讯作者)，Natl Univ Singapore Hosp, Dept Orthopaed Surg, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.
EM honggg_85@hotmail.com
CR Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   BOSTMAN O, 1989, J TRAUMA, V29, P639
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Capeci CM, 2009, J BONE JOINT SURG AM, V91A, P2556, DOI 10.2106/JBJS.H.01774
   Das De S, 2010, J BONE JOINT SURG BR, V92B, P679, DOI 10.1302/0301 620X.92B5.22941
   Dobnig H, 2009, J BONE MINER RES, V24, P1998, DOI [10.1359/JBMR.090527, 10.1359/jbmr.090527]
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   Goddard Maria S, 2009, Orthopedics, V32, DOI 10.3928/01477447 20090624 27
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Jobke B, 2009, CONNECT TISSUE RES, V50, P46, DOI 10.1080/03008200802412462
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   Komatsubara S, 2004, J BONE MINER RES, V19, P999, DOI 10.1359/JBMR.040126
   Komatsubara S, 2003, J BONE MINER RES, V18, P512, DOI 10.1359/jbmr.2003.18.3.512
   Kootstra G :., 1973, Femoral shaft fractures in adults. A study of 329 consecutive cases with a statistical analysis of different methods of treatment
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   Lin JH, 1999, INT J CLIN PRACT, P18
   Mashiba T, 2005, J BONE MINER METAB, V23, P36, DOI 10.1007/BF03026321
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   MCKENNA MJ, 1987, BONE, V8, P71, DOI 10.1016/8756 3282(87)90073 1
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   MOONEY V, 1984, FRACTURES ADULTS, V2, P1357
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Pazianas M, 2008, OSTEOPOROSIS INT, V19, P773, DOI 10.1007/s00198 007 0502 1
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Salminen ST, 2000, CLIN ORTHOP RELAT R, P241
   STEPAN JJ, 2010, OSTEOPOROS INT
   Stock JL, 1997, AM J MED, V103, P291, DOI 10.1016/S0002 9343(97)00130 7
   Tang SY, 2009, OSTEOPOROSIS INT, V20, P887, DOI 10.1007/s00198 008 0754 4
   Tashjian AH, 2002, J BONE MINER RES, V17, P1151, DOI 10.1359/jbmr.2002.17.7.1151
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
NR 37
TC 8
Z9 8
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
J9 INJURY
JI Injury Int. J. Care Inj.
PD JUL
PY 2011
VL 42
IS 7
BP 702
EP 706
DI 10.1016/j.injury.2010.12.019
PG 5
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 772OL
UT WOS:000291243100015
PM 21316051
DA 2025 08 17
ER

EF